PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Markova, SV; Golz, S; Frank, LA; Kalthof, B; Vysotski, ES				Markova, SV; Golz, S; Frank, LA; Kalthof, B; Vysotski, ES			Cloning and expression of cDNA for a luciferase from the marine copepod Metridia longa - A novel secreted bioluminescent reporter enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VARGULA-HILGENDORFII LUCIFERASE; GREEN FLUORESCENT PROTEIN; GENE-EXPRESSION; FIREFLY LUCIFERASE; PROMOTER ACTIVITY; MAMMALIAN-CELLS; RECEPTOR; CANCER; PHOTOPROTEINS; LUMINESCENCE	Metridia longa is a marine copepod from which a blue bioluminescence originates as a secretion from epidermal glands in response to various stimuli. We demonstrate that Metridia luciferase is specific for coelenterazine to produce blue light (lambda(max)=480 nm). Using an expression cDNA library and functional screening, we cloned and sequenced the cDNA encoding the Metridia luciferase. The cDNA is an 897-bp fragment with a 656-bp open reading frame, which encodes a 219-amino acid polypeptide with a molecular weight of 23,885. The polypeptide contains an N-terminal signal peptide of 17 amino acid residues for secretion. On expression of the Metridia luciferase gene in mammalian Chinese hamster ovary cells the luciferase is detected in the culture medium confirming the existence of a naturally occurring signal peptide for secretion in the cloned luciferase. The novel secreted luciferase was tested in a practical assay application in which the activity of A2a and NPY2 G-protein-coupled receptors was detected. These results clearly suggest that the secreted Metridia luciferase is well suited as a reporter for monitoring gene expression and, in particular, for the development of novel ultra-high throughput screening technologies.	Russian Acad Sci, Siberian Branch, Inst Biophys, Photobiol Lab, Krasnoyarsk 660036, Russia; Bayer AG, Pharma Res Mol Screening Technol, D-42096 Wuppertal, Germany	Russian Academy of Sciences; Krasnoyarsk Science Center of the Siberian Branch of the Russian Academy of Sciences; Biophysics Institute, Siberian Branch, Russian Academy of Sciences; Bayer AG	Vysotski, ES (corresponding author), Russian Acad Sci, Siberian Branch, Inst Biophys, Photobiol Lab, Krasnoyarsk 660036, Russia.	vys@bmb.uga.edu	Markova, Svetlana V./AAT-7574-2020; Frank, Ludmila A/P-8560-2015; Vysotski, Eugene/I-1761-2013	Markova, Svetlana V./0000-0001-5702-1193; Vysotski, Eugene/0000-0002-5884-3081				Ando S, 2002, MOL CELL ENDOCRINOL, V193, P121, DOI 10.1016/S0303-7207(02)00105-3; Bevis BJ, 2002, NAT BIOTECHNOL, V20, P83, DOI 10.1038/nbt0102-83; Bhaumik S, 2002, P NATL ACAD SCI USA, V99, P377, DOI 10.1073/pnas.012611099; Bi XJ, 2002, J BIOTECHNOL, V93, P231, DOI 10.1016/S0168-1656(01)00400-X; Broussard DR, 2002, J VIROL, V76, P2087, DOI 10.1128/jvi.76.5.2087-2099.2002; CAMPBELL AK, 1990, MAR BIOL, V104, P219, DOI 10.1007/BF01313261; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARKE GL, 1962, J MAR BIOL ASSOC UK, V42, P541, DOI 10.1017/S0025315400054254; Duisit G, 2002, MOL THER, V6, P446, DOI 10.1006/mthe.2002.0690; Evstigneev PV., 1990, BIOLUMINESCENCE MARI; GANDELMAN O, 1994, J BIOLUM CHEMILUM, V9, P363, DOI 10.1002/bio.1170090603; Hough RB, 2002, P NATL ACAD SCI USA, V99, P8145, DOI 10.1073/pnas.122231099; ILLARIONOV BA, 1992, DOKL AKAD NAUK+, V326, P911; INOUYE S, 1992, P NATL ACAD SCI USA, V89, P9584, DOI 10.1073/pnas.89.20.9584; Inouye S, 2000, FEBS LETT, V481, P19, DOI 10.1016/S0014-5793(00)01963-3; JOHNSON CH, 1995, SCIENCE, V269, P1863, DOI 10.1126/science.7569925; JOHNSON GL, 1989, ENDOCR REV, V10, P317, DOI 10.1210/edrv-10-3-317; KONDO T, 1993, P NATL ACAD SCI USA, V90, P5672, DOI 10.1073/pnas.90.12.5672; Kostrouchova M, 2002, P NATL ACAD SCI USA, V99, P9254, DOI 10.1073/pnas.112213799; Langer I, 2001, CELL CALCIUM, V30, P229, DOI 10.1054/ceca.2001.0230; LEMBERT N, 1995, BIOCHEM J, V305, P929, DOI 10.1042/bj3050929; Liu JX, 2000, LUMINESCENCE, V15, P45, DOI 10.1002/(SICI)1522-7243(200001/02)15:1<45::AID-BIO553>3.0.CO;2-E; Liu S, 2001, J BIOTECHNOL, V87, P1, DOI 10.1016/S0168-1656(00)00421-1; Liu Y, 2000, PLASMID, V44, P250, DOI 10.1006/plas.2000.1486; LORENZ WW, 1991, P NATL ACAD SCI USA, V88, P4438, DOI 10.1073/pnas.88.10.4438; Markova SV, 2002, BIOCHEMISTRY-US, V41, P2227, DOI 10.1021/bi0117910; MILLAR AJ, 1992, PLANT CELL, V4, P1075, DOI 10.1105/tpc.4.9.1075; Radford JC, 2002, J BIOL CHEM, V277, P38810, DOI 10.1074/jbc.M203694200; Ronen M, 2002, P NATL ACAD SCI USA, V99, P10555, DOI 10.1073/pnas.152046799; Tanahashi Y, 2001, ANAL BIOCHEM, V289, P260, DOI 10.1006/abio.2000.4932; THOMPSON EM, 1990, GENE, V96, P257, DOI 10.1016/0378-1119(90)90261-O; THOMPSON EM, 1995, P NATL ACAD SCI USA, V92, P1317, DOI 10.1073/pnas.92.5.1317; THOMPSON EM, 1989, P NATL ACAD SCI USA, V86, P6567, DOI 10.1073/pnas.86.17.6567; TSUJI FI, 1995, PHOTOCHEM PHOTOBIOL, V62, P657, DOI 10.1111/j.1751-1097.1995.tb08713.x; Yoon K, 2000, MOL CELL ENDOCRINOL, V162, P211, DOI 10.1016/S0303-7207(99)00261-0; Yoshida R, 1998, BIOCHEM BIOPH RES CO, V242, P659, DOI 10.1006/bbrc.1997.8045	37	110	129	1	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	2004	279	5					3212	3217		10.1074/jbc.M309639200	http://dx.doi.org/10.1074/jbc.M309639200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	766MF	14583604	hybrid			2022-12-27	WOS:000188379600011
J	Baumgrass, R; Zhang, YX; Erdmann, F; Thiel, A; Weiwad, M; Radbruch, A; Fischer, G				Baumgrass, R; Zhang, YX; Erdmann, F; Thiel, A; Weiwad, M; Radbruch, A; Fischer, G			Substitution in position 3 of cyclosporin A abolishes the cyclophilin-mediated gain-of-function mechanism but not immunosuppression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCINEURIN PHOSPHATASE-ACTIVITY; PROLYL CIS/TRANS ISOMERASES; TRANSCRIPTION FACTOR NFAT1; X-RAY-STRUCTURE; CELLULAR-REGULATION; ENZYME-INHIBITION; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; IMMUNOPHILIN; COMPLEXES	Binary complex formation between the immunosuppressive drug cyclosporin A (CsA) and cyclophilin 18 is the prerequisite for the ability of CsA to inhibit the protein phosphatase activity of calcineurin, a central mediator of antigen-receptor signaling. We show here that several CsA derivatives substituted in position 3 can inhibit calcineurin without prior formation of a complex with cyclophilin 18. [Methylsarcosine(3)] CsA was shown to inhibit calcineurin, either in its free form with an IC50 value of 10 muM, or in its complex form with cyclophilin 18 with an IC50 of 500 nM. [Dimethylaminoethylthiosarcosine(3)] CsA ([Dat-Sar(3)] CsA) was found to inhibit calcineurin on its own, with an IC50 value of 1.0 muM, but was not able to inhibit calcineurin after forming the [Dat-Sar(3)] CsA-cyclophilin 18 binary complex. Despite their different inhibitory properties, both CsA and [Dat-Sar(3)] CsA suppressed T cell proliferation and cytokine production mainly through blocking NFAT activation and interleukin-2 gene expression. Furthermore, to demonstrate that [Dat-Sar(3)] CsA can inhibit calcineurin in a cyclophilin-independent manner in vivo, we tested its effect in a Saccharomyces cerevisiae strain (Delta12), in which all the 12 cyclophilins and FKBPs were deleted. [Dat-Sar(3)] CsA, but not CsA, bypassed the requirement for cellular cyclophilins and caused growth inhibition in the salt-stressed Delta12 strain.	Max Planck Res Unit Enzymol Prot Folding, D-06120 Halle An Der Saale, Germany; Deutsch Rheuma Forschungszentrum Berlin, D-10117 Berlin, Germany	Max Planck Society; Deutsches Rheuma-Forschungszentrum (DRFZ)	Fischer, G (corresponding author), Max Planck Res Unit Enzymol Prot Folding, Weinbergweg 22, D-06120 Halle An Der Saale, Germany.	fischer@enzyme-halle.mpg.de	Thiel, Andreas/F-1539-2013; Erdmann, Frank/AAF-1091-2021	Erdmann, Frank/0000-0001-5261-0984; Baumgrass, Ria/0000-0002-3289-1608; Thiel, Andreas/0000-0002-5515-4002; Radbruch, Andreas/0000-0001-5753-0000				Aramburu J, 1999, SCIENCE, V285, P2129, DOI 10.1126/science.285.5436.2129; Barford D, 1996, TRENDS BIOCHEM SCI, V21, P407, DOI 10.1016/S0968-0004(96)10060-8; Batiuk TD, 1997, J CLIN INVEST, V100, P1894, DOI 10.1172/JCI119719; Baumgrass R, 2001, J BIOL CHEM, V276, P47914, DOI 10.1074/jbc.M103273200; BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; BREUDER T, 1994, P NATL ACAD SCI USA, V91, P5372, DOI 10.1073/pnas.91.12.5372; Bueno OF, 2002, P NATL ACAD SCI USA, V99, P9398, DOI 10.1073/pnas.152665399; Cardenas Maria E., 1994, Perspectives in Drug Discovery and Design, V2, P103, DOI 10.1007/BF02171739; Creighton T. E., 1993, PROTEINS STRUCTURES; CUMME GA, 1986, BIOMED BIOCHIM ACTA, V45, P961; Dolinski K, 1997, P NATL ACAD SCI USA, V94, P13093, DOI 10.1073/pnas.94.24.13093; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; FISCHER G, 1994, ANGEW CHEM INT EDIT, V33, P1415, DOI 10.1002/anie.199414151; Fox DS, 2002, BIOESSAYS, V24, P894, DOI 10.1002/bies.10157; Gautschi M, 2002, P NATL ACAD SCI USA, V99, P4209, DOI 10.1073/pnas.062048599; GRIFFITH JP, 1995, CELL, V82, P507, DOI 10.1016/0092-8674(95)90439-5; Hemenway Charles S., 1999, Cell Biochemistry and Biophysics, V30, P115, DOI 10.1007/BF02737887; HU MK, 1995, J MED CHEM, V38, P4164, DOI 10.1021/jm00021a005; Huai Q, 2002, P NATL ACAD SCI USA, V99, P12037, DOI 10.1073/pnas.192206699; Jin L, 2002, P NATL ACAD SCI USA, V99, P13522, DOI 10.1073/pnas.212504399; Keleti T., 1986, BASIC ENZYME KINETIC; KESSLER H, 1990, HELV CHIM ACTA, V73, P1818, DOI 10.1002/hlca.19900730703; KISSINGER CR, 1995, NATURE, V378, P641, DOI 10.1038/378641a0; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU J, 1992, BIOCHEMISTRY-US, V31, P3896, DOI 10.1021/bi00131a002; Loh C, 1996, J BIOL CHEM, V271, P10884, DOI 10.1074/jbc.271.18.10884; MIKOL V, 1993, J MOL BIOL, V234, P1119, DOI 10.1006/jmbi.1993.1664; MILAN D, 1994, CELL, V79, P437, DOI 10.1016/0092-8674(94)90253-4; MILTENYI S, 1990, CYTOMETRY, V11, P231, DOI 10.1002/cyto.990110203; Mondragon A, 1997, BIOCHEMISTRY-US, V36, P4934, DOI 10.1021/bi9631935; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; NELSON PA, 1993, J IMMUNOL, V150, P2139; Okamura H, 2000, MOL CELL, V6, P539, DOI 10.1016/S1097-2765(00)00053-8; PELECH S, 1985, EUR J BIOCHEM, V148, P245, DOI 10.1111/j.1432-1033.1985.tb08832.x; Puech J, 1998, J ENZYM INHIB, V14, P27, DOI 10.3109/14756369809036544; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Richter A, 1999, J EXP MED, V190, P1439, DOI 10.1084/jem.190.10.1439; Schreiber SL, 1998, BIOORGAN MED CHEM, V6, P1127, DOI 10.1016/S0968-0896(98)00126-6; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SEEBACH D, 1993, HELV CHIM ACTA, V76, P1564, DOI 10.1002/hlca.19930760415; SIGAL NH, 1991, J EXP MED, V173, P619, DOI 10.1084/jem.173.3.619; SWANSON SKH, 1992, P NATL ACAD SCI USA, V89, P3741, DOI 10.1073/pnas.89.9.3741; Thiel A, 1999, ARTHRITIS RES, V1, P25, DOI 10.1186/ar7; Tradler T, 1997, FEBS LETT, V407, P184, DOI 10.1016/S0014-5793(97)00345-1; TUNG HYL, 1985, EUR J BIOCHEM, V148, P253, DOI 10.1111/j.1432-1033.1985.tb08833.x; WAELKENS E, 1984, BIOCHEM BIOPH RES CO, V120, P397, DOI 10.1016/0006-291X(84)91267-1; WENGER RM, 1994, FEBS LETT, V340, P255, DOI 10.1016/0014-5793(94)80149-5; Zenke G, 2001, J IMMUNOL, V166, P7165, DOI 10.4049/jimmunol.166.12.7165; Zhang W, 1996, J EXP MED, V183, P413, DOI 10.1084/jem.183.2.413; Zhu J, 2000, CELL MOL LIFE SCI, V57, P411, DOI 10.1007/PL00000703	50	32	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	2004	279	4					2470	2479		10.1074/jbc.M304754200	http://dx.doi.org/10.1074/jbc.M304754200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	764MU	14583619	hybrid			2022-12-27	WOS:000188211300018
J	Figge, A; Lammert, F; Paigen, B; Henkel, A; Matern, S; Korstanje, R; Shneider, BL; Chen, F; Stoltenberg, E; Spatz, K; Hoda, F; Cohen, DE; Green, RM				Figge, A; Lammert, F; Paigen, B; Henkel, A; Matern, S; Korstanje, R; Shneider, BL; Chen, F; Stoltenberg, E; Spatz, K; Hoda, F; Cohen, DE; Green, RM			Hepatic overexpression of murine Abcb11 increases hepatobiliary lipid secretion and reduces hepatic steatosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHOLESTEROL CHOLELITHIASIS; LITH GENES; PHENOTYPIC CHARACTERIZATION; DETERMINE SUSCEPTIBILITY; INBRED MICE; FEEDBACK-REGULATION; GALLSTONE FORMATION; MOLECULAR-CLONING; NUCLEAR RECEPTORS; DEOXYCHOLIC-ACID	Abcb11 encodes for the liver bile salt export pump, which is rate-limiting for hepatobiliary bile salt secretion. We employed transthyretin-Abcb11 and BAC-Abcb11 transgenes to develop mice overexpressing the bile salt export pump in the liver. The mice manifest increases in bile flow and biliary secretion of bile salts, phosphatidylcholine, and cholesterol. Hepatic gene expression of cholesterol 7alpha-hydroxylase and ileal expression of the apical sodium bile salt transporter are markedly reduced, whereas gene expression of targets of the nuclear bile salt receptor FXR ( ileal lipid-binding protein, short heterodimer partner (SHP) is increased. Because these changes in gene expression are associated with an increased overall hydrophobicity of the bile salt pool and a 4-fold increase of the FXR ligand taurodeoxycholate, they reflect bile salt-mediated regulation of FXR and SHP target genes. Despite the increased biliary secretion of bile salts, fecal bile salt excretion is unchanged, suggestive of an enhanced enterohepatic cycling of bile salts. Abcb11 transgenic mice fed a lithogenic ( high cholesterol/fat/cholic acid) diet display markedly reduced hepatic steatosis compared with wild-type controls. We conclude that mice overexpressing Abcb11 display an increase in biliary bile salt secretion and taurodeoxycholate content, which is associated with FXR/SHP-mediated changes in hepatic and ileal gene expression. Because these mice are resistant to hepatic lipid accumulation, regulation of Abcb11 may be important for the pathogenesis and treatment of steatohepatitis.	Northwestern Univ, Feinberg Sch Med, Dept Med, Div Hepatol, Chicago, IL 60611 USA; Univ Aachen, Univ Hosp Aachen, Dept Med 3, D-52074 Aachen, Germany; Jackson Lab, Bar Harbor, ME 04609 USA; Mt Sinai Sch Med, New York, NY USA; Yeshiva Univ Albert Einstein Coll Med, Bronx, NY 10461 USA; Chicago Vet Affairs Med Ctr, Lakeside Div, Chicago, IL USA	Northwestern University; Feinberg School of Medicine; RWTH Aachen University; RWTH Aachen University Hospital; Jackson Laboratory; Icahn School of Medicine at Mount Sinai; Yeshiva University; Albert Einstein College of Medicine	Green, RM (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Med, Div Hepatol, Searle 10-555,303 E Chicago Ave, Chicago, IL 60611 USA.	r-green2@northwestern.edu			NICHD NIH HHS [R01 HD40027] Funding Source: Medline; NIDDK NIH HHS [R01 DK59580, DK48873, DK56626] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD040027] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048873, R29DK048873, R01DK059580, R37DK048873, R01DK056626] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Apstein MD, 1996, EUR J CLIN INVEST, V26, P343, DOI 10.1046/j.1365-2362.1996.148287.x; Arden SD, 1999, DIABETES, V48, P531, DOI 10.2337/diabetes.48.3.531; Bouchard G, 1999, MAMM GENOME, V10, P1070, DOI 10.1007/s003359901163; Carey Martin C., 1994, P719; Chen F, 2003, J BIOL CHEM, V278, P19909, DOI 10.1074/jbc.M207903200; Chiang JYL, 2000, J BIOL CHEM, V275, P10918, DOI 10.1074/jbc.275.15.10918; CHILDS S, 1995, CANCER RES, V55, P2029; Davis-Hayman SR, 2002, MOL BIOCHEM PARASIT, V122, P1, DOI 10.1016/S0166-6851(02)00063-4; Fickert P, 2001, GASTROENTEROLOGY, V121, P170, DOI 10.1053/gast.2001.25542; Fuchs M, 2001, HEPATOLOGY, V33, P1451, DOI 10.1053/jhep.2001.24373; Gerloff T, 1998, J BIOL CHEM, V273, P10046, DOI 10.1074/jbc.273.16.10046; Goodwin B, 2000, MOL CELL, V6, P517, DOI 10.1016/S1097-2765(00)00051-4; Green RM, 2000, HEPATOLOGY, V32, p390A; Green RM, 2000, GENE, V241, P117, DOI 10.1016/S0378-1119(99)00460-6; HAMMES A, 2000, PRACT APPROACH SER, V217, P217; Haque M, 2002, BEST PRACT RES CL GA, V16, P709, DOI 10.1053/bega.2002.0325; Harrison Stephen A, 2002, Semin Gastrointest Dis, V13, P3; HAY DW, 1993, J LIPID RES, V34, P759; HEUMAN DM, 1989, J LIPID RES, V30, P719; HODA F, 2003, IN PRESS J MEMBR BIO; Hussaini SH, 1995, HEPATOLOGY, V22, P1735, DOI 10.1016/0270-9139(95)90199-X; Koivusalo M, 2001, J LIPID RES, V42, P663; Kok T, 2003, J BIOL CHEM, V278, P41930, DOI 10.1074/jbc.M306309200; Kozarsky KF, 1997, NATURE, V387, P414, DOI 10.1038/387414a0; Lammert F, 1997, HEPATOLOGY, V26, P920; Lammert F, 2002, HEPATOLOGY, V36, P1145, DOI 10.1053/jhep.2002.36821; Lammert F, 1999, J LIPID RES, V40, P2080; LAMMERT F, 2001, HEPATOBILIARY TRANSP, P78; Lu TT, 2000, MOL CELL, V6, P507, DOI 10.1016/S1097-2765(00)00050-2; MARCUS SN, 1988, GUT, V29, P522, DOI 10.1136/gut.29.4.522; Meier PJ, 2002, ANNU REV PHYSIOL, V64, P635, DOI 10.1146/annurev.physiol.64.082201.100300; NISHINA PM, 1993, LIPIDS, V28, P599, DOI 10.1007/BF02536053; Paigen B, 2000, PHYSIOL GENOMICS, V4, P59, DOI 10.1152/physiolgenomics.2000.4.1.59; Paigen B., 2002, GENETIC BASIS COMMON, P298; PAULETZKI JG, 1995, HEPATOLOGY, V22, P325, DOI 10.1016/0270-9139(95)90387-9; Repa JJ, 2000, ANNU REV CELL DEV BI, V16, P459, DOI 10.1146/annurev.cellbio.16.1.459; Repa JJ, 2002, J BIOL CHEM, V277, P18793, DOI 10.1074/jbc.M109927200; Sehayek E, 2003, J LIPID RES, V44, P1605, DOI 10.1194/jlr.M200488-JLR200; SHEFFER S, 1970, J LIPID RES, V11, P404; Strautnieks SS, 1998, NAT GENET, V20, P233, DOI 10.1038/3034; Trauner M, 2003, PHYSIOL REV, V83, P633, DOI 10.1152/physrev.00027.2002; TROTMAN BW, 1977, GASTROENTEROLOGY, V72, P495; Vlahcevic ZR, 1999, GASTROENTEROL CLIN N, V28, P1, DOI 10.1016/S0889-8553(05)70041-8; Wang DQH, 1999, J LIPID RES, V40, P2066; Wang DQH, 1997, J LIPID RES, V38, P1395; Wang HB, 1999, MOL CELL, V3, P543, DOI 10.1016/S1097-2765(00)80348-2; Wang RX, 2001, P NATL ACAD SCI USA, V98, P2011, DOI 10.1073/pnas.031465498; Wittenburg H, 2003, GASTROENTEROLOGY, V125, P868, DOI 10.1016/S0016-5085(03)01053-9; Younossi ZM, 2002, HEPATOLOGY, V35, P746, DOI 10.1053/jhep.2002.32483; Yu LQ, 2002, J CLIN INVEST, V110, P671, DOI [10.1172/JCI200216001, 10.1172/JCI0216001]	50	75	88	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	2004	279	4					2790	2799		10.1074/jbc.M307363200	http://dx.doi.org/10.1074/jbc.M307363200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	764MU	14570929	hybrid			2022-12-27	WOS:000188211300057
J	Allard, STM; Cleland, WW; Holden, HM				Allard, STM; Cleland, WW; Holden, HM			High resolution x-ray structure of dTDP-glucose 4,6-dehydratase from Streptomyces venezuelae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UDP-GALACTOSE 4-EPIMERASE; ESCHERICHIA-COLI; MACROMOLECULAR STRUCTURES; POLYKETIDE LIBRARIES; PROTEIN STRUCTURES; DIFFRACTION DATA; ACTIVE-SITE; MECHANISM; OXIDOREDUCTASE; GLYCOSYLATION	Desosamine is a 3-(dimethylamino)-3,4,6-trideoxyhexose found in some macrolide antibiotics. In Streptomyces venezuelae, there are seven genes required for the biosynthesis of this unusual sugar. One of the genes, desIV, codes for a dTDP-glucose 4,6-dehydratase, which is referred to as DesIV. The reaction mechanisms for these types of dehydratases are quite complicated with proton abstraction from the sugar 4'-hydroxyl group and hydride transfer to NAD(+), proton abstraction at C-5, and elimination of the hydroxyl group at C-6 of the sugar, and finally return of a proton to C-5 and a hydride from NADH to C-6. Here we describe the cloning, overexpression, and purification, and high resolution x-ray crystallographic analysis to 1.44 Angstrom of wild-type DesIV complexed with dTDP. Additionally, for this study, a double site-directed mutant protein (D128N/E129Q) was prepared, crystallized as a complex with NAD(+) and the substrate dTDP-glucose and its structure determined to 1.35 Angstrom resolution. In DesIV, the phenolate group of Tyr(151) and O-gamma of Thr(127) lie at 2.7 and 2.6 Angstrom, respectively from the 4'-hydroxyl group of the dTDP-glucose substrate. The side chain of Asp(128) is in the correct position to function as a general acid for proton donation to the 6'-hydroxyl group while the side chain of Glu(129) is ideally situated to serve as the general base for proton abstraction at C-5. This investigation provides further detailed information for understanding the exquisite chemistry that occurs in these remarkable enzymes.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Holden, HM (corresponding author), Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA.	Hazel_Holden@biochem.wisc.edu			NIDDK NIH HHS [DK 47814] Funding Source: Medline; NIGMS NIH HHS [GM 18938] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047814, R56DK047814] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM018938, R01GM018938] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allard STM, 2002, STRUCTURE, V10, P81, DOI 10.1016/S0969-2126(01)00694-3; Allard STM, 2001, J MOL BIOL, V307, P283, DOI 10.1006/jmbi.2000.4470; Beis K, 2003, J AM CHEM SOC, V125, P11872, DOI 10.1021/ja035796r; Charnock SJ, 2002, P NATL ACAD SCI USA, V99, P12067, DOI 10.1073/pnas.182431199; Chen S, 2001, GENE, V263, P255, DOI 10.1016/S0378-1119(00)00560-6; Duax WL, 2000, VITAM HORM, V58, P121, DOI 10.1016/S0083-6729(00)58023-6; Duax WL, 1996, CURR OPIN STRUC BIOL, V6, P813, DOI 10.1016/S0959-440X(96)80012-1; GABRIEL O, 1968, J BIOL CHEM, V243, P1479; Gerratana B, 2001, BIOCHEMISTRY-US, V40, P9187, DOI 10.1021/bi0108249; Gross JW, 2000, BIOCHEMISTRY-US, V39, P13633, DOI 10.1021/bi001963d; Gross JW, 2001, BIOCHEMISTRY-US, V40, P12497, DOI 10.1021/bi011138c; Hansen JL, 2002, MOL CELL, V10, P117, DOI 10.1016/S1097-2765(02)00570-1; Hegeman AD, 2002, BIOCHEMISTRY-US, V41, P2797, DOI 10.1021/bi011748c; Hegeman AD, 2001, BIOCHEMISTRY-US, V40, P6598, DOI 10.1021/bi010441a; JORNVALL H, 1995, BIOCHEMISTRY-US, V34, P6003, DOI 10.1021/bi00018a001; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P67, DOI 10.1107/S0021889887009737; Kallberg Y, 2002, EUR J BIOCHEM, V269, P4409, DOI 10.1046/j.1432-1033.2002.03130.x; Khosla C, 1996, TRENDS BIOTECHNOL, V14, P335, DOI 10.1016/0167-7799(96)10046-9; KLEYWEGT GJ, 1994, ACTA CRYSTALLOGR D, V50, P178, DOI 10.1107/S0907444993011333; KLEYWEGT GJ, 1993, ESF CCP4 NEWSLETTER, V29, P26; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; MARCH J, 1985, ADV ORG CHEM, P218; MELO A, 1968, J BIOL CHEM, V243, P1467; Mendez C, 2001, TRENDS BIOTECHNOL, V19, P449, DOI 10.1016/S0167-7799(01)01765-6; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; OKAZAKI R, 1962, J BIOL CHEM, V237, P3014; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Roussel A, 1990, ACTA CRYSTALLOGR A, V46, pC66; SAMBOROK J, 2001, MOL CLONING LAB MANU; SNIPES CE, 1977, J BIOL CHEM, V252, P8113; Tang L, 2001, CHEM BIOL, V8, P547, DOI 10.1016/S1074-5521(01)00032-1; Thoden JB, 1996, BIOCHEMISTRY-US, V35, P5137, DOI 10.1021/bi9601114; Thoden JB, 1998, BIOCHEMISTRY-US, V37, P11469, DOI 10.1021/bi9808969; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; WeymouthWilson AC, 1997, NAT PROD REP, V14, P99, DOI 10.1039/np9971400099; Xue YQ, 1998, P NATL ACAD SCI USA, V95, P12111, DOI 10.1073/pnas.95.21.12111	39	38	39	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 16	2004	279	3					2211	2220		10.1074/jbc.M310134200	http://dx.doi.org/10.1074/jbc.M310134200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	762WT	14570895	hybrid			2022-12-27	WOS:000188005700078
J	Gibson, RP; Tarling, CA; Roberts, S; Withers, SG; Davies, GJ				Gibson, RP; Tarling, CA; Roberts, S; Withers, SG; Davies, GJ			The donor subsite of trehalose-6-phosphate synthase - Binary complexes with UDP-glucose and UDP-2-deoxy-2-fluoro-glucose at 2 angstrom resolution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; CATALYTIC MECHANISM; ESCHERICHIA-COLI; CORYNEBACTERIUM-GLUTAMICUM; SACCHAROMYCES-CEREVISIAE; BETA-GLUCOSYLTRANSFERASE; GLYCOGEN-PHOSPHORYLASE; NEISSERIA-MENINGITIDIS; TREHALOSE ACCUMULATION; GLYCOSIDE HYDROLASES	Trehalose is an unusual non-reducing disaccharide that plays a variety of biological roles, from food storage to cellular protection from environmental stresses such as desiccation, pressure, heat-shock, extreme cold, and oxygen radicals. It is also an integral component of the cell-wall glycolipids of mycobacteria. The primary enzymatic route to trehalose first involves the transfer of glucose from a UDP-glucose donor to glucose-6-phosphate to form alpha,alpha-1,1 trehalose-6-phosphate. This reaction, in which the configurations of two glycosidic bonds are set simultaneously, is catalyzed by the glycosyltransferase trehalose-6-phosphate synthase ( OtsA), which acts with retention of the anomeric configuration of the UDP-sugar donor. The classification of activated sugar-dependent glycosyltransferases into approximately 70 distinct families based upon amino acid sequence similarities places OtsA in glycosyltransferase family 20 (see afmb.cnrs-mrs.fr/CAZY/). The recent 2.4 Angstrom structure of Escherichia coli OtsA revealed a two-domain enzyme with catalysis occurring at the interface of the twin beta/alpha/beta domains. Here we present the 2.0 Angstrom structures of the E. coli OtsA in complex with either UDP-Glc or the non-transferable analogue UDP-2-deoxy-2-fluoroglucose. Both complexes unveil the donor subsite interactions, confirming a strong similarity to glycogen phosphorylases, and reveal substantial conformational differences to the previously reported complex with UDP and glucose 6-phosphate. Both the relative orientation of the two domains and substantial ( up to 10 Angstrom) movements of an N-terminal loop ( residues 9 - 22) characterize the more open "relaxed" conformation of the binary UDP-sugar complexes reported here.	Univ York, Dept Chem, Struct Biol Lab, York YO10 5YW, N Yorkshire, England; Univ British Columbia, Dept Chem, Vancouver, BC V6T 1Z1, Canada	University of York - UK; University of British Columbia	Davies, GJ (corresponding author), Univ York, Dept Chem, Struct Biol Lab, York YO10 5YW, N Yorkshire, England.	davies@ysbl.york.ac.uk	Davies, Gideon J/A-9042-2011	Davies, Gideon J/0000-0002-7343-776X	Biotechnology and Biological Sciences Research Council [B20376] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; Benaroudj N, 2001, J BIOL CHEM, V276, P24261, DOI 10.1074/jbc.M101487200; Boix E, 2002, J BIOL CHEM, V277, P28310, DOI 10.1074/jbc.M202631200; Bourne Y, 2001, CURR OPIN STRUC BIOL, V11, P593, DOI 10.1016/S0959-440X(00)00253-0; Charnock SJ, 1999, BIOCHEMISTRY-US, V38, P6380, DOI 10.1021/bi990270y; Chatterjee D, 1997, CURR OPIN CHEM BIOL, V1, P579, DOI 10.1016/S1367-5931(97)80055-5; Chen QF, 2002, J BIOL CHEM, V277, P3274, DOI 10.1074/jbc.M109479200; Coutinho PM, 2003, J MOL BIOL, V328, P307, DOI 10.1016/S0022-2836(03)00307-3; CROWE JH, 1984, SCIENCE, V223, P701, DOI 10.1126/science.223.4637.701; D'Alfonso L, 2003, EUR J BIOCHEM, V270, P2497, DOI 10.1046/j.1432-1033.2003.03621.x; DAVIES G, 1997, COMPREHENSIVE BIOL C, V1, P119; Davies GJ, 2001, NAT STRUCT BIOL, V8, P98, DOI 10.1038/84198; De Smet KAL, 2000, MICROBIOL-UK, V146, P199, DOI 10.1099/00221287-146-1-199; Eastmond PJ, 2003, CURR OPIN PLANT BIOL, V6, P231, DOI 10.1016/S1369-5266(03)00037-2; Elbein AD, 2003, GLYCOBIOLOGY, V13, p17R, DOI 10.1093/glycob/cwg047; Esnouf R. M., 1997, J MOL GRAPHICS, V15, P133; Foster AJ, 2003, EMBO J, V22, P225, DOI 10.1093/emboj/cdg018; Garg AK, 2002, P NATL ACAD SCI USA, V99, P15898, DOI 10.1073/pnas.252637799; Gastinel LN, 2001, EMBO J, V20, P638, DOI 10.1093/emboj/20.4.638; Gibson RP, 2002, ACTA CRYSTALLOGR D, V58, P349, DOI 10.1107/S090744490102056X; Gibson RP, 2002, CHEM BIOL, V9, P1337, DOI 10.1016/S1074-5521(02)00292-2; Ha S, 2000, PROTEIN SCI, V9, P1045, DOI 10.1110/ps.9.6.1045; Iwahashi H, 2003, EXTREMOPHILES, V7, P291, DOI 10.1007/s00792-003-0322-y; KLEYWEGT GJ, 1994, ESF CCP4 NEWSLETTER, V31, P9; LEWIS ES, 1952, J AM CHEM SOC, V74, P308, DOI 10.1021/ja01122a005; Ly HD, 2002, BIOCHEMISTRY-US, V41, P5075, DOI 10.1021/bi012031s; MARTIN JL, 1990, BIOCHEMISTRY-US, V29, P10745, DOI 10.1021/bi00500a005; Morera S, 1999, J MOL BIOL, V292, P717, DOI 10.1006/jmbi.1999.3094; Mulichak AM, 2003, P NATL ACAD SCI USA, V100, P9238, DOI 10.1073/pnas.1233577100; Mulichak AM, 2001, STRUCTURE, V9, P547, DOI 10.1016/S0969-2126(01)00616-5; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Namchuk MN, 1995, BIOCHEMISTRY-US, V34, P16194, DOI 10.1021/bi00049a035; Navaza J, 1997, METHOD ENZYMOL, V276, P581, DOI 10.1016/S0076-6879(97)76079-8; Notenboom V, 1998, NAT STRUCT BIOL, V5, P812, DOI 10.1038/1852; Ortner J, 1999, J CARBOHYD CHEM, V18, P297, DOI 10.1080/07328309908543997; Pereira ED, 2003, CELL STRESS CHAPERON, V8, P120; Persson K, 2001, NAT STRUCT BIOL, V8, P166, DOI 10.1038/84168; Porchia AC, 1999, PLANT SCI, V149, P43, DOI 10.1016/S0168-9452(99)00142-9; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Ronning DR, 2000, NAT STRUCT BIOL, V7, P141; Sahara T, 2002, J BIOL CHEM, V277, P50015, DOI 10.1074/jbc.M209258200; Schluepmann H, 2003, P NATL ACAD SCI USA, V100, P6849, DOI 10.1073/pnas.1132018100; Singer MA, 1998, TRENDS BIOTECHNOL, V16, P460, DOI 10.1016/S0167-7799(98)01251-7; SINNOTT ML, 1980, J AM CHEM SOC, V102, P2026, DOI 10.1021/ja00526a043; Stick RV, 2002, MONATSH CHEM, V133, P541, DOI 10.1007/s007060200027; Sussich F, 2001, CARBOHYD RES, V334, P165, DOI 10.1016/S0008-6215(01)00189-6; Tarbouriech N, 2001, J MOL BIOL, V314, P655, DOI 10.1006/jmbi.2001.5159; Tews I, 1996, NAT STRUCT BIOL, V3, P638, DOI 10.1038/nsb0796-638; Tzvetkov M, 2003, MICROBIOL-SGM, V149, P1659, DOI 10.1099/mic.0.26205-0; Unligil UM, 2000, EMBO J, V19, P5269, DOI 10.1093/emboj/19.20.5269; Unligil UM, 2000, CURR OPIN STRUC BIOL, V10, P510, DOI 10.1016/S0959-440X(00)00124-X; Vocadlo DJ, 2001, NATURE, V412, P835, DOI 10.1038/35090602; VRIELINK A, 1994, EMBO J, V13, P3413, DOI 10.1002/j.1460-2075.1994.tb06646.x; Welsh DT, 1999, FEMS MICROBIOL LETT, V174, P57, DOI 10.1016/S0378-1097(99)00122-6; WITHERS SG, 1981, BIOCHEMISTRY-US, V20, P1748, DOI 10.1021/bi00510a007; Withers SG, 2002, CHEM BIOL, V9, P1270, DOI 10.1016/S1074-5521(02)00291-0; WITHERS SG, 1986, CARBOHYD RES, V154, P127, DOI 10.1016/S0008-6215(00)90028-4; Wittmann V, 1997, J ORG CHEM, V62, P2144, DOI 10.1021/jo9620066; Wolf A, 2003, MOL MICROBIOL, V49, P1119, DOI 10.1046/j.1365-2958.2003.03625.x; Zaragoza O, 1998, J BACTERIOL, V180, P3809, DOI 10.1128/JB.180.15.3809-3815.1998	60	94	98	2	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 16	2004	279	3					1950	1955		10.1074/jbc.M307643200	http://dx.doi.org/10.1074/jbc.M307643200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	762WT	14570926	hybrid			2022-12-27	WOS:000188005700049
J	Mulcahy, ER; Bessen, RA				Mulcahy, ER; Bessen, RA			Strain-specific kinetics of prion protein formation in vitro and in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMISSIBLE MINK ENCEPHALOPATHY; FOLLICULAR DENDRITIC CELLS; CREUTZFELDT-JAKOB-DISEASE; SCRAPIE; CONVERSION; CONFORMATIONS; MODEL; AGENT; BRAIN; MICE	The molecular basis of prion strain diversity is proposed to be encoded by distinct conformations of the abnormal scrapie isoform of the prion protein ( PrPSc). PrPSc formation for the hyper (HY) and drowsy (DY) strains of the transmissible mink encephalopathy (TME) agent was investigated using the cell-free PrP conversion reaction to determine the role of distinct PrPSc conformations in the rate of in vitro conversion of cellular PrP into protease-resistant PrP. PrP conversion increased at an exponential rate for both TME strains until peak levels were reached at 72 - 96 h of reaction time. The amount and rate of PrP conversion for HY TME was greater than those for DY TME between 48 h and the peak level of PrP conversion. Between 96 and 120 h, there was a negative rate of PrP conversion; and between 120 and 168 h, the net rate of HY and DY PrP conversion approached zero. These findings suggest that PrP conversion can occur in three distinct stages: an elongation phase, a depolymerization phase, and a steady-state phase. Strain-specific properties between the TME strains were identified only during the elongation phase. The steady-state phase could be disrupted by the addition of PrPSc to, or by sonication of, the cell-free PrP conversion reaction. These treatments resulted in an increase in the amount of PrP conversion that was equal to or greater than that found during the peak level of PrP conversion for both TME strains, indicating that the steady-state phase was in dynamic equilibrium. In a related study, the rate of accumulation of HY and DY PrPSc in hamster brain exhibited a strain-specific pattern that had similarities to the strain-specific PrP conversion reaction during the elongation phase. These results suggest that strain-specific conformations of PrPSc have the ability to influence the rate of additional PrPSc formation from cellular PrP both in vitro and in vivo.	Creighton Univ, Dept Med Microbiol & Immunol, Omaha, NE 68178 USA	Creighton University	Bessen, RA (corresponding author), Montana State Univ, Dept Vet Mol Biol, POB 173610, Bozeman, MT 59717 USA.	rbessen@montana.edu			NINDS NIH HHS [NS 37914-05] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS037914] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bartz JC, 2002, J VIROL, V76, P5759, DOI 10.1128/JVI.76.11.5759-5768.2002; BESSEN RA, 1994, J VIROL, V68, P7859, DOI 10.1128/JVI.68.12.7859-7868.1994; BESSEN RA, 1992, J GEN VIROL, V73, P329, DOI 10.1099/0022-1317-73-2-329; BESSEN RA, 1992, J VIROL, V66, P2096, DOI 10.1128/JVI.66.4.2096-2101.1992; BESSEN RA, 1995, NATURE, V375, P698, DOI 10.1038/375698a0; BOLTON DC, 1991, J GEN VIROL, V72, P2905, DOI 10.1099/0022-1317-72-12-2905; BOLTON DC, 1988, CIBA F SYMP, V135, P164; Callahan NA, 2001, J BIOL CHEM, V276, P28022, DOI 10.1074/jbc.M103629200; Caughey B, 1998, J BIOL CHEM, V273, P32230, DOI 10.1074/jbc.273.48.32230; Caughey B, 1995, CHEM BIOL, V2, P807, DOI 10.1016/1074-5521(95)90087-X; CAUGHEY BW, 1991, BIOCHEMISTRY-US, V30, P7672, DOI 10.1021/bi00245a003; Chabry J, 1999, J VIROL, V73, P6245, DOI 10.1128/JVI.73.8.6245-6250.1999; Collinge J, 1996, NATURE, V383, P685, DOI 10.1038/383685a0; GAJDUSEK DC, 1988, J NEUROIMMUNOL, V20, P95; GRIFFITH JS, 1967, NATURE, V215, P1043, DOI 10.1038/2151043a0; Jackson GS, 1999, SCIENCE, V283, P1935, DOI 10.1126/science.283.5409.1935; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; KITAMOTO T, 1991, J VIROL, V65, P6292, DOI 10.1128/JVI.65.11.6292-6295.1991; KOCISKO DA, 1994, NATURE, V370, P471, DOI 10.1038/370471a0; MCBRIDE PA, 1992, J PATHOL, V168, P413, DOI 10.1002/path.1711680412; MERZ PA, 1981, ACTA NEUROPATHOL, V54, P63, DOI 10.1007/BF00691333; MEYER RK, 1986, P NATL ACAD SCI USA, V83, P2310, DOI 10.1073/pnas.83.8.2310; MONARI L, 1994, P NATL ACAD SCI USA, V91, P2839, DOI 10.1073/pnas.91.7.2839; Naiki H, 1996, LAB INVEST, V74, P374; NAIKI H, 1991, LAB INVEST, V65, P104; *NAT RES COUNC, 1996, GUID CAR US LAB; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; Parchi P, 1997, NATURE, V386, P232, DOI 10.1038/386232a0; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; PRUSINER SB, 1983, CELL, V35, P349, DOI 10.1016/0092-8674(83)90168-X; Saborio GP, 2001, NATURE, V411, P810, DOI 10.1038/35081095; Torrent J, 2003, BIOCHEMISTRY-US, V42, P1318, DOI 10.1021/bi0269916	33	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 16	2004	279	3					1643	1649		10.1074/jbc.M307844200	http://dx.doi.org/10.1074/jbc.M307844200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	762WT	14573620	hybrid			2022-12-27	WOS:000188005700012
J	Davies, CC; Mason, J; Wakelam, MJO; Young, LS; Eliopoulos, AG				Davies, CC; Mason, J; Wakelam, MJO; Young, LS; Eliopoulos, AG			Inhibition of phosphatidylinositol 3-kinase- and ERK MAPK-regulated protein synthesis reveals the pro-apoptotic properties of CD40 ligation in carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S6 KINASE; TRANSLATION INITIATION; EPITHELIAL-CELLS; FAS LIGAND; HYPER-IGM; B-CELLS; ACTIVATION; DEATH; PHOSPHORYLATION; INDUCTION	CD40, a member of the tumor necrosis factor receptor superfamily, is frequently expressed in carcinomas where its stimulation results in induction of apoptosis when de novo protein synthesis is inhibited. The requirement of protein synthesis inhibition for efficient killing suggests that CD40 transduces potent survival signals capable of suppressing its pro-apoptotic effects. We have found that inhibition of CD40 signaling on the phosphatidylinositol 3-kinase (PI3K) and ERK MAPK but not on the p38 MAPK axis disrupts this balance and sensitizes carcinoma cells to CD40-mediated cell death. The CD40-mediated PI3K and ERK activities were found to converge on the regulation of protein synthesis in carcinoma cells via a pathway involving the activation of p90 ribosomal S6 kinase (p90Rsk) and p70S6 kinases, upstream of the translation elongation factor eEF2. In addition, CD40 ligation was found to mediate a PI3K- and mammalian target of rapamycin (mTOR)-dependent phosphorylation of 4E-BP1 and its subsequent dissociation from the mRNA cap-binding protein eIF4E as well as an ERK-dependent phosphorylation of eIF4E, thus promoting translation initiation. Concomitantly, the antiapoptotic protein cFLIP was found to be induced in CD40 ligand-stimulated carcinoma cells in a PI3K-, ERK-, and mammalian target of rapamycin (mTOR)-dependent manner and down-regulation of cFLIPS expression sensitized to CD40-mediated carcinoma cell death. These data underline the significance of the PI3K and ERK pathways in controlling the balance between CD40-mediated survival and death signals through the regulation of the protein synthesis machinery. Pharmacological agents that target this machinery or its upstream kinases could, therefore, be exploited for CD40-based tumor therapy.	Univ Birmingham, Sch Med, Canc Res United Kingdom Inst Canc Studies, Birmingham B15 2TA, W Midlands, England; Univ Birmingham, Sch Med, MRC, Ctr Immune Regulat, Birmingham B15 2TA, W Midlands, England	University of Birmingham; University of Birmingham	Eliopoulos, AG (corresponding author), Univ Birmingham, Sch Med, Canc Res United Kingdom Inst Canc Studies, Birmingham B15 2TA, W Midlands, England.		Young, Lawrence S/B-7213-2009; ELIOPOULOS, ARISTIDES/ABI-6632-2020; ELIOPOULOS, ARISTIDES/R-9449-2018	Young, Lawrence S/0000-0003-3919-4298; ELIOPOULOS, ARISTIDES/0000-0002-6403-6761; ELIOPOULOS, ARISTIDES/0000-0002-6403-6761; Davies, Clare/0000-0003-3097-1791; Wakelam, Michael/0000-0003-4059-9276				Afford SC, 1999, J EXP MED, V189, P441, DOI 10.1084/jem.189.2.441; Baker MP, 1998, BLOOD, V92, P2830, DOI 10.1182/blood.V92.8.2830.420k10_2830_2843; Berberich I, 1996, EMBO J, V15, P92, DOI 10.1002/j.1460-2075.1996.tb00337.x; CALLARD RE, 1993, IMMUNOL TODAY, V14, P559, DOI 10.1016/0167-5699(93)90188-Q; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Deregibus MC, 2003, J BIOL CHEM, V278, P18008, DOI 10.1074/jbc.M300711200; Djerbi M, 2001, SCAND J IMMUNOL, V54, P180, DOI 10.1046/j.1365-3083.2001.00941.x; Dufner A, 1999, EXP CELL RES, V253, P100, DOI 10.1006/excr.1999.4683; Eliopoulos AG, 2003, EMBO J, V22, P3855, DOI 10.1093/emboj/cdg386; Eliopoulos AG, 2000, MOL CELL BIOL, V20, P5503, DOI 10.1128/MCB.20.15.5503-5515.2000; Eliopoulos AG, 2002, EMBO J, V21, P4831, DOI 10.1093/emboj/cdf478; Eliopoulos AG, 1996, ONCOGENE, V13, P2243; Fulda S, 2000, CANCER RES, V60, P3947; FUNAKOSHI S, 1994, BLOOD, V83, P2787, DOI 10.1182/blood.V83.10.2787.2787; Ghamande S, 2001, CANCER RES, V61, P7556; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; GORDON J, 1995, BLOOD REV, V9, P53, DOI 10.1016/0268-960X(95)90040-3; Grell M, 1999, EMBO J, V18, P3034, DOI 10.1093/emboj/18.11.3034; Gulbins E, 1996, J IMMUNOL, V157, P2844; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; Hayward AR, 1997, J IMMUNOL, V158, P977; Hennino A, 2001, J EXP MED, V193, P447, DOI 10.1084/jem.193.4.447; Herbert TP, 2000, J BIOL CHEM, V275, P11249, DOI 10.1074/jbc.275.15.11249; Hess S, 1996, J EXP MED, V183, P159, DOI 10.1084/jem.183.1.159; Hinton HJ, 1999, J IMMUNOL, V162, P7002; Hirano A, 1999, BLOOD, V93, P2999; Kashiwada M, 1998, J EXP MED, V187, P237, DOI 10.1084/jem.187.2.237; Kennedy SG, 1999, MOL CELL BIOL, V19, P5800; Kirchhoff S, 2000, J IMMUNOL, V165, P6293, DOI 10.4049/jimmunol.165.11.6293; Knox PG, 2003, J IMMUNOL, V170, P677, DOI 10.4049/jimmunol.170.2.677; Kreuz S, 2001, MOL CELL BIOL, V21, P3964, DOI 10.1128/MCB.21.12.3964-3973.2001; Lizcano JM, 2000, BIOCHEM J, V349, P547, DOI 10.1042/bj3490547; Panka DJ, 2001, J BIOL CHEM, V276, P6893, DOI 10.1074/jbc.C000569200; Papadaki HA, 2003, BLOOD, V101, P2591, DOI 10.1182/blood-2002-09-2898; Patel NA, 2001, J BIOL CHEM, V276, P22648, DOI 10.1074/jbc.M101260200; Perez D, 2003, J VIROL, V77, P2651, DOI 10.1128/JVI.77.4.2651-2662.2003; Polunovsky VA, 1996, MOL CELL BIOL, V16, P6573; REN CL, 1994, J EXP MED, V179, P673, DOI 10.1084/jem.179.2.673; Sakata N, 1995, J BIOL CHEM, V270, P30823, DOI 10.1074/jbc.270.51.30823; Tee AR, 2000, ONCOGENE, V19, P3021, DOI 10.1038/sj.onc.1203622; Tran SEF, 2001, J BIOL CHEM, V276, P16484, DOI 10.1074/jbc.M010384200; van Kooten C, 2000, J LEUKOCYTE BIOL, V67, P2, DOI 10.1002/jlb.67.1.2; Vonderheide RH, 2001, J CLIN ONCOL, V19, P3280, DOI 10.1200/JCO.2001.19.13.3280; Wang XM, 2001, EMBO J, V20, P4370, DOI 10.1093/emboj/20.16.4370; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; Weng QP, 1998, J BIOL CHEM, V273, P16621, DOI 10.1074/jbc.273.26.16621; Wilson KF, 2000, J BIOL CHEM, V275, P37307, DOI 10.1074/jbc.C000482200; Young LS, 1998, IMMUNOL TODAY, V19, P502, DOI 10.1016/S0167-5699(98)01340-1	50	65	74	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 9	2004	279	2					1010	1019		10.1074/jbc.M303820200	http://dx.doi.org/10.1074/jbc.M303820200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	759DJ	14581487	hybrid			2022-12-27	WOS:000187722800024
J	Nakamura, T; Unda, F; de-Vega, S; Vilaxa, A; Fukumoto, S; Yamada, KM; Yamada, Y				Nakamura, T; Unda, F; de-Vega, S; Vilaxa, A; Fukumoto, S; Yamada, KM; Yamada, Y			The Kruppel-like factor epiprofin is expressed by epithelium of developing teeth, hair follicles, and limb buds and promotes cell proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR SP1; FAMILY; GROWTH; IDENTIFICATION; PROTEINS; ELEMENT; REGION; GENE; KLF4	We identified a cDNA clone for epiprofin, which is preferentially expressed in teeth, by differential hybridization using DNA microarrays from an embryonic day 19.5 mouse molar cDNA library. Sequence analysis revealed that this cDNA encodes a member of the Kruppel-like factor family containing three characteristic C2H2-type zinc finger motifs. The full-length cDNA was obtained by the 5' Cap capture method. Except for its 5'-terminal sequence, the epiprofin mRNA sequence is almost identical to the predicted sequence of Kruppel-like factor 14/Sp6 ( specificity protein 6), which was previously identified in expressed sequence tag data bases and GenBank(TM) by an Sp1 zinc finger DNA-binding domain search (Scohy, S., Gabant, P., Van Reeth, T., Hertveldt, V., Dreze, P. L., Van Vooren, P., Riviere, M., Szpirer, J., and Szpirer, C. (2000) Genomics 70, 93 - 101). This sequence difference is due to differences in the assignment of the location of exon 1. In situ hybridization revealed that epiprofin mRNA is expressed by proliferating dental epithelium, differentiated odontoblast, and also hair follicle matrix epithelium. In addition, whole mount in situ hybridization showed transient expression of epiprofin mRNA in cells of the apical ectodermal ridge in developing limbs and the posterior neuropore. Transfection of an epiprofin expression vector revealed that this molecule is localized in the nucleus and promotes cell proliferation. Thus, epiprofin is a highly cell- and tissue-specific nuclear protein expressed primarily by proliferating epithelial cells of teeth, hair follicles, and limbs that may function in the development of these tissues by regulating cell growth.	NIDCR, Craniofacial Dev Biol & Regenerat Branch, NIH, Bethesda, MD 20892 USA; Univ Basque Country, Fac Med & Dent, Dept Cell Biol & Histol, Leioa 48490, Spain; Univ Tarapaca, Dept Biol & Salud, Arica, Chile	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); University of Basque Country; Universidad de Tarapaca	Yamada, Y (corresponding author), NIDCR, Craniofacial Dev Biol & Regenerat Branch, NIH, Bldg 30,Rm 405,30 Convent Dr, Bethesda, MD 20892 USA.	yoshi.yamada@nih.gov	de Vega, Susana/AAH-4775-2020; Nakamura, Takashi/A-8931-2012; Nakamura, Takashi/P-7796-2016; Unda, Fernando/AAF-9128-2019	Nakamura, Takashi/0000-0001-9904-1037; Nakamura, Takashi/0000-0001-9904-1037; Yamada, Kenneth/0000-0003-1512-6805; Fukumoto, Satoshi/0000-0002-5046-6891				Aberg T, 1997, DEV DYNAM, V210, P383, DOI 10.1002/(SICI)1097-0177(199712)210:4<383::AID-AJA3>3.0.CO;2-C; ANDERSON KP, 1995, MOL CELL BIOL, V15, P5957; Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; Bouwman P, 2000, EMBO J, V19, P655, DOI 10.1093/emboj/19.4.655; Chen XM, 2001, J BIOL CHEM, V276, P30423, DOI 10.1074/jbc.M101194200; COHN SA, 1957, AM J ANAT, V101, P295, DOI 10.1002/aja.1001010205; Dang DT, 2002, NUCLEIC ACIDS RES, V30, P2736, DOI 10.1093/nar/gkf400; Dang DT, 2001, ONCOGENE, V20, P4884, DOI 10.1038/sj.onc.1204645; HIROTA S, 1992, MOL BRAIN RES, V15, P47, DOI 10.1016/0169-328X(92)90150-A; IMATAKA H, 1992, EMBO J, V11, P3663, DOI 10.1002/j.1460-2075.1992.tb05451.x; Jaubert J, 2003, DEVELOPMENT, V130, P2767, DOI 10.1242/dev.00477; Jernvall J, 2000, MECH DEVELOP, V92, P19, DOI 10.1016/S0925-4773(99)00322-6; Kaczynski J, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-2-206; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LEBLOND CP, 1979, J DENT RES, V58, P950, DOI 10.1177/00220345790580024901; Marin M, 1997, CELL, V89, P619, DOI 10.1016/S0092-8674(00)80243-3; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/s0092-8674(01)00622-5; Nieto MA, 1996, METHOD CELL BIOL, V51, P219, DOI 10.1016/S0091-679X(08)60630-5; Philipsen S, 1999, NUCLEIC ACIDS RES, V27, P2991, DOI 10.1093/nar/27.15.2991; SAMBROOK J, 1989, EXTRACTION PURIFICAT; Scohy S, 2000, GENOMICS, V70, P93, DOI 10.1006/geno.2000.6362; Segre JA, 1999, NAT GENET, V22, P356, DOI 10.1038/11926; Shalon D, 1996, GENOME RES, V6, P639, DOI 10.1101/gr.6.7.639; Smith CE, 1998, CRIT REV ORAL BIOL M, V9, P128, DOI 10.1177/10454411980090020101; Sun RG, 2001, J BIOL CHEM, V276, P6897, DOI 10.1074/jbc.C000870200; Supp DM, 1996, DEV BIOL, V176, P284, DOI 10.1006/dbio.1996.0134; Sur I, 2002, EUR J CELL BIOL, V81, P323, DOI 10.1078/0171-9335-00257; TURNER CA, 1994, CELL, V77, P297, DOI 10.1016/0092-8674(94)90321-2; WARSHAWSKY H, 1974, ANAT RECORD, V179, P423, DOI 10.1002/ar.1091790403; Yoon HS, 2003, J BIOL CHEM, V278, P2101, DOI 10.1074/jbc.M211027200; Zhang ZP, 2003, NUCLEIC ACIDS RES, V31, P2196, DOI 10.1093/nar/gkg310	33	70	71	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 2	2004	279	1					626	634		10.1074/jbc.M307502200	http://dx.doi.org/10.1074/jbc.M307502200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	757GU	14551215	hybrid			2022-12-27	WOS:000187555300076
J	Rickman, C; Meunier, FA; Binz, T; Davletov, B				Rickman, C; Meunier, FA; Binz, T; Davletov, B			High affinity interaction of syntaxin and SNAP-25 on the plasma membrane is abolished by botulinum toxin E	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMAFFIN CELL; EXOCYTOSIS; FUSION; SNARE; COMPLEX; NEUROTOXINS; SYNAPTOBREVIN; VESICLES; DYNAMICS; RELEASE	The release of hormones and neurotransmitters requires the fusion of cargo-containing vesicles with the plasma membrane. This process of exocytosis relies on three SNARE proteins, namely syntaxin and SNAP-25 on the target plasma membrane and synaptobrevin on the vesicular membrane. In this study we examined the molecular assembly pathway that leads to formation of the fusogenic SNARE complex. We now show that the plasma membrane syntaxin and SNAP-25 interact with high affinity and equimolar stoichiometry to form a stable dimer on the pathway to the ternary SNARE complex. In bovine chromaffin cells, syntaxin and SNAP-25 colocalize in defined clusters that average 700 nm in diameter and cover 10% of the plasma membrane. Removal of the C terminus of SNAP-25 by botulinum neurotoxin E, a known neuroparalytic agent, dissociates the target SNARE dimer in vitro and disrupts the SNARE clustering in vivo. Together, our data uncover formation of stable syntaxin/SNAP-25 dimers as a central principle of the SNARE assembly pathway underlying regulated exocytosis.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England; Hannover Med Sch, Dept Biophys Chem, D-30625 Hannover, Germany; Hannover Med Sch, Dept Biochem, D-30625 Hannover, Germany	MRC Laboratory Molecular Biology; Hannover Medical School; Hannover Medical School	Davletov, B (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.		Davletov, Bazbek/ABA-8569-2021; Meunier, Frederic A/C-8161-2009	Meunier, Frederic A/0000-0001-6400-1107; Rickman, Colin/0000-0001-8938-524X; Davletov, Bazbek/0000-0003-4658-3275				Bader MF, 2002, ANN NY ACAD SCI, V971, P178, DOI 10.1111/j.1749-6632.2002.tb04461.x; BINZ T, 1994, J BIOL CHEM, V269, P1617; Burgoyne RD, 2003, PHYSIOL REV, V83, P581, DOI 10.1152/physrev.00031.2002; CHAPMAN ER, 1994, J BIOL CHEM, V269, P27427; Chen YA, 1999, CELL, V97, P165, DOI 10.1016/S0092-8674(00)80727-8; Chen YA, 2001, NEURON, V30, P161, DOI 10.1016/S0896-6273(01)00270-7; Duncan RR, 2003, NATURE, V422, P176, DOI 10.1038/nature01389; Fasshauer D, 2002, NAT STRUCT BIOL, V9, P144, DOI 10.1038/nsb750; Fasshauer D, 1997, J BIOL CHEM, V272, P4582, DOI 10.1074/jbc.272.7.4582; GARCIA EP, 1995, J CELL BIOL, V129, P105, DOI 10.1083/jcb.129.1.105; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; Hu K, 2002, NATURE, V415, P646, DOI 10.1038/415646a; JACOBSSON G, 1994, P NATL ACAD SCI USA, V91, P12487, DOI 10.1073/pnas.91.26.12487; Koh TW, 2003, TRENDS NEUROSCI, V26, P413, DOI 10.1016/S0166-2236(03)00195-4; Lang T, 2002, J CELL BIOL, V158, P751, DOI 10.1083/jcb.200203088; Lang T, 2001, EMBO J, V20, P2202, DOI 10.1093/emboj/20.9.2202; Meunier FA, 2003, MOL CELL NEUROSCI, V22, P454, DOI 10.1016/S1044-7431(02)00016-7; Oheim M, 1999, EUR BIOPHYS J BIOPHY, V28, P91, DOI 10.1007/s002490050188; Plattner H, 1997, J CELL BIOL, V139, P1709, DOI 10.1083/jcb.139.7.1709; Schiavo G, 2000, PHYSIOL REV, V80, P717, DOI 10.1152/physrev.2000.80.2.717; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Steinberg TH, 1996, ANAL BIOCHEM, V239, P223, DOI 10.1006/abio.1996.0319; Sudhof TC, 2001, SYNAPSES, P177; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; VITALE ML, 1995, NEURON, V14, P353, DOI 10.1016/0896-6273(95)90291-0; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Whiteheart SW, 2001, INT REV CYTOL, V207, P71; Xu T, 1998, NAT NEUROSCI, V1, P192, DOI 10.1038/642; Zenisek D, 2000, NATURE, V406, P849, DOI 10.1038/35022500	29	74	76	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	2004	279	1					644	651		10.1074/jbc.M310879200	http://dx.doi.org/10.1074/jbc.M310879200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	757GU	14551199	hybrid			2022-12-27	WOS:000187555300078
J	Helfand, MS; Bethel, CR; Hujer, AM; Hujer, KM; Anderson, VE; Bonomo, RA				Helfand, MS; Bethel, CR; Hujer, AM; Hujer, KM; Anderson, VE; Bonomo, RA			Understanding resistance to beta-lactams and beta-lactamase inhibitors in the SHV beta-lactamase - Lessons from the mutagenesis of Ser-130	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; ESCHERICHIA-COLI; CLAVULANIC ACID; CLINICAL ISOLATE; VARIANT; ENZYME; INACTIVATION; ARGININE-244; TAZOBACTAM; SEQUENCE	Bacterial resistance to beta-lactam/beta-lactamase inhibitor combinations by single amino acid mutations in class A beta-lactamases threatens our most potent clinical antibiotics. In TEM-1 and SHV-1, the common class A beta-lactamases, alterations at Ser-130 confer resistance to inactivation by the beta-lactamase inhibitors, clavulanic acid, and tazobactam. By using site-saturation mutagenesis, we sought to determine the amino acid substitutions at Ser-130 in SHV-1 beta-lactamase that result in resistance to these inhibitors. Antibiotic susceptibility testing revealed that ampicillin and ampicillin/clavulanic acid resistance was observed only for the S130G beta-lactamase expressed in Escherichia coli. Kinetic analysis of the S130G beta-lactamase demonstrated a significant elevation in apparent Km and a reduction in k(cat)/K-m for ampicillin. Marked increases in the dissociation constant for the preacylation complex, K-I, of clavulanic acid (SHV-1, 0.14 muM; S130G, 46.5 muM) and tazobactam (SHV-1, 0.07 muM; S130G, 4.2 muM) were observed. In contrast, the k(inact)s of S130G and SHV-1 differed by only 17% for clavulanic acid and 40% for tazobactam. Progressive inactivation studies showed that the inhibitor to enzyme ratios required to inactivate SHV-1 and S130G were similar. Our observations demonstrate that enzymatic activity is preserved despite amino acid substitutions that significantly alter the apparent affinity of the active site for beta-lactams and beta-lactamase inhibitors. These results underscore the mechanistic versatility of class A beta-lactamases and have implications for the design of novel beta-lactamase inhibitors.	Louis Stokes Cleveland Dept Vet Affairs Med Ctr, Infect Dis Sect, Res Serv, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center; Case Western Reserve University	Bonomo, RA (corresponding author), Louis Stokes Cleveland Dept Vet Affairs Med Ctr, Infect Dis Sect, Res Serv, 10701 East Blvd, Cleveland, OH 44106 USA.		Anderson, Vernon/W-2673-2019	Anderson, Vernon Emmett/0000-0002-1699-7621				Bermudes H, 1999, ANTIMICROB AGENTS CH, V43, P1657, DOI 10.1128/AAC.43.7.1657; Brown RPA, 1996, BIOCHEMISTRY-US, V35, P12421, DOI 10.1021/bi961044g; Fersht A., 1984, ENZYME STRUCTURE MEC; Fowler RA, 2003, CHEST, V123, P835, DOI 10.1378/chest.123.3.835; GALLENI M, 1995, BIOCHEM PHARMACOL, V49, P1171, DOI 10.1016/0006-2952(94)00502-D; GORBACH SL, 1994, INTENS CARE MED, V20, P27; Guillaume G, 1997, J BIOL CHEM, V272, P5438, DOI 10.1074/jbc.272.9.5438; Helfand Marion S., 2003, Current Drug Targets - Infectious Disorders, V3, P9, DOI 10.2174/1568005033342181; Helfand MS, 2002, J BIOL CHEM, V277, P47719, DOI 10.1074/jbc.M207271200; Hujer AM, 2002, ANTIMICROB AGENTS CH, V46, P3971, DOI 10.1128/AAC.46.12.3971-3977.2002; Hujer AM, 2002, J CLIN MICROBIOL, V40, P1947, DOI 10.1128/JCM.40.6.1947-1957.2002; Hujer AM, 2001, BBA-PROTEIN STRUCT M, V1547, P37, DOI 10.1016/S0167-4838(01)00164-9; IMTIAZ U, 1994, BIOCHEMISTRY-US, V33, P5728, DOI 10.1021/bi00185a009; IMTIAZ U, 1993, J AM CHEM SOC, V115, P4435, DOI 10.1021/ja00064a003; JACOB F, 1990, BIOCHEM J, V271, P399, DOI 10.1042/bj2710399; JUTEAU JM, 1992, PROTEIN ENG, V5, P693, DOI 10.1093/protein/5.7.693; Kuzin AP, 1999, BIOCHEMISTRY-US, V38, P5720, DOI 10.1021/bi990136d; Kuzin AP, 2001, BIOCHEMISTRY-US, V40, P1861, DOI 10.1021/bi0022745; Lin S, 1998, BIOCHEM J, V333, P395, DOI 10.1042/bj3330395; Meroueh SO, 2002, J AM CHEM SOC, V124, P9422, DOI 10.1021/ja026547q; Prinarakis EE, 1997, ANTIMICROB AGENTS CH, V41, P838, DOI 10.1128/AAC.41.4.838; Rice LB, 2000, ANTIMICROB AGENTS CH, V44, P362, DOI 10.1128/AAC.44.2.362-367.2000; STRYNADKA NCJ, 1992, NATURE, V359, P700, DOI 10.1038/359700a0; Swaren P, 1999, BIOCHEMISTRY-US, V38, P9570, DOI 10.1021/bi990758z; Vakulenko SB, 1998, ANTIMICROB AGENTS CH, V42, P1542, DOI 10.1128/AAC.42.7.1542; Wang XJ, 2002, J BIOL CHEM, V277, P32149, DOI 10.1074/jbc.M204212200; WILSON SE, 1995, AM J SURG, V169, pS21; ZAFARALLA G, 1992, BIOCHEMISTRY-US, V31, P3847, DOI 10.1021/bi00130a016	28	50	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52724	52729		10.1074/jbc.M306059200	http://dx.doi.org/10.1074/jbc.M306059200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14534312	hybrid			2022-12-27	WOS:000187480700090
J	Kocher, O; Yesilaltay, A; Cirovic, C; Pal, R; Rigotti, A; Krieger, M				Kocher, O; Yesilaltay, A; Cirovic, C; Pal, R; Rigotti, A; Krieger, M			Targeted disruption of the PDZK1 gene in mice causes tissue-specific depletion of the high density lipoprotein receptor scavenger receptor class B type I and altered lipoprotein metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AUTOSOMAL RECESSIVE HYPERCHOLESTEROLEMIA; DOMAIN-CONTAINING PROTEIN; SR-BI; LIPID-METABOLISM; HUMAN CARCINOMAS; ADAPTER PROTEIN; DOWN-REGULATION; LDL RECEPTOR; IDENTIFICATION; EXPRESSION	PDZK1, a multi-PDZ domain containing adaptor protein, interacts with various membrane proteins, including the high density lipoprotein (HDL) receptor scavenger receptor class B type I (SR-BI). Here we show that PDZK1 controls in a tissue-specific and post-transcriptional fashion the expression of SR-BI in vivo. SR-BI protein expression in PDZK1 knock-out (KO) mice was reduced by 95% in the liver, 50% in the proximal intestine, and not affected in steroidogenic organs (adrenal, ovary, and testis). Thus, PDZK1 joins a growing list of adaptors that control tissue-specific activity of cell surface receptors. Hepatic expression of SR-BII, a minor splice variant with an alternative C-terminal cytoplasmic domain, was not affected in PDZK1 KO mice, suggesting that binding of PDZK1 to SR-BI is required for controlling hepatic SR-BI expression. The loss of hepatic SR-BI was the likely cause of the elevation in plasma total and HDL cholesterol and the increase in HDL particle size in PDZK1 KO mice, phenotypes similar to those observed in SR-BI KO mice. PDZK1 KO mice differed from SR-BI KO mice in that the ratio of unesterified to total plasma cholesterol was normal, females were fertile, and cholesteryl ester stores in steroidogenic organs were essentially unaffected. These differences may be due to nearly normal extrahepatic expression of SR-BI in PDZK1 KO mice. The PDZK1-dependent regulation of hepatic SR-BI and, thus, lipoprotein metabolism supports the proposal that this adaptor may represent a new target for therapeutic intervention in cardiovascular disease.	Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA; MIT, Dept Biol, Cambridge, MA 02139 USA; Pontificia Univ Catolica Chile, Fac Med, Dept Gastroenterol, Santiago, Chile	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Massachusetts Institute of Technology (MIT); Pontificia Universidad Catolica de Chile	Kocher, O (corresponding author), Beth Israel Deaconess Med Ctr, Dept Pathol, 330 Brookline Ave, Boston, MA 02215 USA.		Krieger, Marco/AAE-8611-2020		FOGARTY INTERNATIONAL CENTER [R03TW006153] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL066105, R01HL064737] Funding Source: NIH RePORTER; FIC NIH HHS [TW006153] Funding Source: Medline; NHLBI NIH HHS [HL66105, HL64737] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; Arai T, 1999, P NATL ACAD SCI USA, V96, P12050, DOI 10.1073/pnas.96.21.12050; Braun A, 2003, P NATL ACAD SCI USA, V100, P7283, DOI 10.1073/pnas.1237725100; Braun A, 2002, CIRC RES, V90, P270, DOI 10.1161/hh0302.104462; BROWN MS, 1986, SCIENCE, V232, P33; Garcia CK, 2001, SCIENCE, V292, P1394, DOI 10.1126/science.1060458; Gentzsch M, 2003, J BIOL CHEM, V278, P6440, DOI 10.1074/jbc.M211050200; Gisler SM, 2001, J BIOL CHEM, V276, P9206, DOI 10.1074/jbc.M008745200; GLASS C, 1983, P NATL ACAD SCI-BIOL, V80, P5435, DOI 10.1073/pnas.80.17.5435; GLOMSET JA, 1968, J LIPID RES, V9, P155; Gu XJ, 2000, J BIOL CHEM, V275, P29993, DOI 10.1074/jbc.275.39.29993; He GC, 2002, J BIOL CHEM, V277, P44044, DOI 10.1074/jbc.M208539200; Hung AY, 2002, J BIOL CHEM, V277, P5699, DOI 10.1074/jbc.R100065200; Ikemoto M, 2000, P NATL ACAD SCI USA, V97, P6538, DOI 10.1073/pnas.100114397; Ji Y, 1997, J BIOL CHEM, V272, P20982, DOI 10.1074/jbc.272.34.20982; Kocher O, 1998, LAB INVEST, V78, P117; Kocher O, 2003, MOL CELL BIOL, V23, P1175, DOI 10.1128/MCB.23.4.1175-1180.2003; Kocher O, 1996, AM J PATHOL, V149, P493; Kocher O, 1999, LAB INVEST, V79, P1161; Kocher O, 1995, CLIN CANCER RES, V1, P1209; Krieger M, 1999, CURR OPIN LIPIDOL, V10, P491, DOI 10.1097/00041433-199912000-00003; Krieger M, 1999, ANNU REV BIOCHEM, V68, P523, DOI 10.1146/annurev.biochem.68.1.523; Landschulz KT, 1996, J CLIN INVEST, V98, P984, DOI 10.1172/JCI118883; Liang KH, 1999, KIDNEY INT, V56, P621, DOI 10.1046/j.1523-1755.1999.00585.x; Mardones P, 2003, J BIOL CHEM, V278, P7884, DOI 10.1074/jbc.M211627200; Miettinen HE, 2001, J CLIN INVEST, V108, P1717, DOI 10.1172/JCI13288; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Rigotti A, 2003, ENDOCR REV, V24, P357, DOI 10.1210/er.2001-0037; Rigotti A, 1997, P NATL ACAD SCI USA, V94, P12610, DOI 10.1073/pnas.94.23.12610; Rigotti A, 1996, J BIOL CHEM, V271, P33545, DOI 10.1074/jbc.271.52.33545; Silver DL, 2003, J BIOL CHEM, V278, P28528, DOI 10.1074/jbc.M304109200; Silver DL, 2002, J BIOL CHEM, V277, P34042, DOI 10.1074/jbc.M206584200; STEIN Y, 1983, BIOCHIM BIOPHYS ACTA, V752, P98, DOI 10.1016/0005-2760(83)90237-0; Trigatti B, 1999, P NATL ACAD SCI USA, V96, P9322, DOI 10.1073/pnas.96.16.9322; Van Eck M, 2003, J BIOL CHEM, V278, P23699, DOI 10.1074/jbc.M211233200; Voshol PJ, 2001, BIOCHEM J, V356, P317, DOI 10.1042/0264-6021:3560317; Wang SS, 2000, CELL, V103, P169, DOI 10.1016/S0092-8674(00)00096-9; Webb NR, 1998, J BIOL CHEM, V273, P15241, DOI 10.1074/jbc.273.24.15241; Webb NR, 1997, J LIPID RES, V38, P1490; Wilund KR, 2002, HUM MOL GENET, V11, P3019, DOI 10.1093/hmg/11.24.3019; Witt W, 2000, J LIPID RES, V41, P2009; Zuliani G, 1999, ARTERIOSCL THROM VAS, V19, P802, DOI 10.1161/01.ATV.19.3.802	42	141	146	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52820	52825		10.1074/jbc.M310482200	http://dx.doi.org/10.1074/jbc.M310482200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14551195	hybrid			2022-12-27	WOS:000187480700101
J	Lee, DJ; Busby, SJW; Lloyd, GS				Lee, DJ; Busby, SJW; Lloyd, GS			Exploitation of a chemical nuclease to investigate the location and orientation of the Escherichia coli RNA polymerase alpha subunit C-terminal domains at simple promoters that are activated by cyclic AMP receptor protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION ACTIVATION; DEPENDENT PROMOTERS; CONTACT DOMAIN; MINOR-GROOVE; DNA-BINDING; CAMP-CRP; ELEMENT; COMPLEX; DETERMINANTS; ORGANIZATION	The C-terminal domain of the alpha subunit (alphaCTD) of bacterial RNA polymerase plays an important role in promoter recognition. It is known that alphaCTD binds to the DNA minor groove at different locations at different promoters via a surface-exposed determinant, the 265 determinant. Here we describe experiments that permit us to determine the location and orientation of binding of alphaCTD at any promoter. In these experiments, a DNA cleavage reagent is attached to specific locations on opposite faces of the RNA polymerase alpha subunit. After incorporation of the tagged alpha subunits into holo-RNA polymerase, patterns of DNA cleavage due to the reagent are determined in open complexes. The locations of DNA cleavage due to the reagent attached at different positions allow the position and orientation of alphaCTD to be deduced. Here we present data from experiments with simple Escherichia coli promoters that are activated by the cyclic AMP receptor protein.	Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England	University of Birmingham	Lloyd, GS (corresponding author), Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England.	G.S.Lloyd@bham.ac.uk	Busby, Stephen/C-2712-2015	Busby, Stephen/0000-0003-2148-1758; Lee, David/0000-0003-2395-351X; Lloyd, Georgina/0000-0002-8104-4878				Belyaeva TA, 1996, NUCLEIC ACIDS RES, V24, P2243, DOI 10.1093/nar/24.12.2243; Benoff B, 2002, SCIENCE, V297, P1562, DOI 10.1126/science.1076376; BLATTER EE, 1994, CELL, V78, P889, DOI 10.1016/S0092-8674(94)90682-3; Boucher PE, 2003, MOL CELL, V11, P163, DOI 10.1016/S1097-2765(03)00007-8; BUCKLE M, 1992, EMBO J, V11, P2619, DOI 10.1002/j.1460-2075.1992.tb05327.x; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; Busby S, 1999, J MOL BIOL, V293, P199, DOI 10.1006/jmbi.1999.3161; Chen H, 2003, MOL CELL, V11, P1621, DOI 10.1016/S1097-2765(03)00201-6; EBRIGHT RH, 1995, CURR OPIN GENET DEV, V5, P197, DOI 10.1016/0959-437X(95)80008-5; Ebright RH, 2000, J MOL BIOL, V304, P687, DOI 10.1006/jmbi.2000.4309; Eichenberger P, 1996, BIOCHEMISTRY-US, V35, P15302, DOI 10.1021/bi961377d; Gaal T, 1996, GENE DEV, V10, P16, DOI 10.1101/gad.10.1.16; GASTON K, 1990, CELL, V62, P733, DOI 10.1016/0092-8674(90)90118-X; Gourse RL, 2000, MOL MICROBIOL, V37, P687, DOI 10.1046/j.1365-2958.2000.01972.x; Greiner DP, 1997, BIOCONJUGATE CHEM, V8, P44, DOI 10.1021/bc9600731; Gross CA, 1998, COLD SPRING HARB SYM, V63, P141, DOI 10.1101/sqb.1998.63.141; IGARASHI K, 1991, CELL, V65, P1015, DOI 10.1016/0092-8674(91)90553-B; JEON YH, 1995, SCIENCE, V270, P1495, DOI 10.1126/science.270.5241.1495; Jeon YH, 1997, J MOL BIOL, V267, P953, DOI 10.1006/jmbi.1997.0902; Jessee J., 1986, FOCUS, V8, P9; KOLB A, 1995, NUCLEIC ACIDS RES, V23, P819, DOI 10.1093/nar/23.5.819; KOLB A, 1993, ANNU REV BIOCHEM, V62, P749, DOI 10.1146/annurev.bi.62.070193.003533; KOLB A, 1993, NUCLEIC ACIDS RES, V21, P319, DOI 10.1093/nar/21.2.319; Law EC, 1999, BIOCHEM J, V337, P415, DOI 10.1042/0264-6021:3370415; Lee DJ, 2000, MOL MICROBIOL, V37, P1032, DOI 10.1046/j.1365-2958.2000.02086.x; Lloyd GS, 2002, GENE DEV, V16, P2557, DOI 10.1101/gad.237502; Murakami K, 1997, P NATL ACAD SCI USA, V94, P11274, DOI 10.1073/pnas.94.21.11274; Murakami K, 1997, P NATL ACAD SCI USA, V94, P1709, DOI 10.1073/pnas.94.5.1709; Naryshkin N, 2000, CELL, V101, P601, DOI 10.1016/S0092-8674(00)80872-7; Ozoline ON, 2000, J BIOL CHEM, V275, P1119, DOI 10.1074/jbc.275.2.1119; Ozoline ON, 2001, NUCLEIC ACIDS RES, V29, P4909, DOI 10.1093/nar/29.24.4909; Rhodius VA, 1998, CURR OPIN MICROBIOL, V1, P152, DOI 10.1016/S1369-5274(98)80005-2; Ross W, 2003, GENE DEV, V17, P1293, DOI 10.1101/gad.1079403; Ross W, 2001, GENE DEV, V15, P491, DOI 10.1101/gad.870001; Savery NJ, 1998, EMBO J, V17, P3439, DOI 10.1093/emboj/17.12.3439; Savery NJ, 2002, J BACTERIOL, V184, P2273, DOI 10.1128/JB.184.8.2273-2280.2002; TANG H, 1994, GENE DEV, V8, P3058, DOI 10.1101/gad.8.24.3058; TANG H, 1995, P NATL ACAD SCI USA, V92, P4902, DOI 10.1073/pnas.92.11.4902; Yasuno K, 2001, J MOL BIOL, V306, P213, DOI 10.1006/jmbi.2000.4369	39	18	18	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52944	52952		10.1074/jbc.M308300200	http://dx.doi.org/10.1074/jbc.M308300200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14530288	hybrid			2022-12-27	WOS:000187480700117
J	Izaguirre, G; Zhang, WQ; Swanson, R; Bedsted, T; Olson, ST				Izaguirre, G; Zhang, WQ; Swanson, R; Bedsted, T; Olson, ST			Localization of an antithrombin exosite that promotes rapid inhibition of factors Xa and IXa dependent on heparin activation of the serpin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REACTIVE CENTER LOOP; CONFORMATIONAL-CHANGE; BETA-ANTITHROMBIN; BINDING EXOSITE; BASIC RESIDUES; AUTOLYSIS LOOP; HIGH-AFFINITY; THROMBIN; MECHANISM; PENTASACCHARIDE	We have previously shown that exosites in antithrombin outside the P6-P3' reactive loop region become available upon heparin activation to promote rapid inhibition of the target proteases, factor Xa and factor IXa. To identify these exosites, we prepared six antithrombin-alpha(1)-proteinase inhibitor chimeras in which antithrombin residues 224-286 and 310-322 that circumscribe a region surrounding the reactive loop on the inhibitor surface were replaced in 10-16-residue segments with the homologous segments of alpha(1)-proteinase inhibitor. All chimeras bound heparin with a high affinity similar to wild-type, underwent heparin-induced fluorescence changes indicative of normal conformational activation, and were able to form SDS-stable complexes with thrombin, factor Xa, and factor IXa and inhibit these proteases with stoichiometries minimally altered from those of wild-type antithrombin. With only one exception, conformational activation of the chimeras with a heparin pentasaccharide resulted in normal similar to 100-300-fold enhancements in reactivity with factor Xa and factor IXa. The exception was the chimera in which residues 246-258 were replaced, corresponding to strand 3 of beta-sheet C, which showed little or no enhancement of its reactivity with these proteases following pentasaccharide activation. By contrast, all chimeras including the strand 3C chimera showed essentially wild-type reactivities with thrombin after pentasaccharide activation as well as normal full-length heparin enhancements in reactivity with all proteases due to heparin bridging. These findings suggest that antithrombin exosites responsible for enhancing the rates of factor Xa and factor IXa inhibition in the conformationally activated inhibitor lie in strand 3 of beta-sheet C of the serpin.	Univ Illinois, Ctr Mol Biol Oral Dis, Coll Dent, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Olson, ST (corresponding author), Univ Illinois, Ctr Mol Biol Oral Dis, Coll Dent, Rm 530E Dent M-C 860,801 S Paulina St, Chicago, IL 60612 USA.				NHLBI NIH HHS [P01-HL-64013, R01-HL-39888] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL064013, R01HL039888] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arocas V, 2001, J BIOL CHEM, V276, P43809, DOI 10.1074/jbc.M105294200; Backovic M, 2002, J PROTEOME RES, V1, P367, DOI 10.1021/pr025515z; Baglin TP, 2002, P NATL ACAD SCI USA, V99, P11079, DOI 10.1073/pnas.162232399; Bedsted T, 2003, BIOCHEMISTRY-US, V42, P8143, DOI 10.1021/bi034363y; Bjork I, 1997, ADV EXP MED BIOL, V425, P17; Chen VC, 2000, J BIOL CHEM, V275, P40371, DOI 10.1074/jbc.M005691200; CHOAY J, 1983, BIOCHEM BIOPH RES CO, V116, P492, DOI 10.1016/0006-291X(83)90550-8; Chuang YJ, 2001, J BIOL CHEM, V276, P14961, DOI 10.1074/jbc.M011550200; Chuang YJ, 2001, BIOCHEMISTRY-US, V40, P6670, DOI 10.1021/bi002933d; Elliott PR, 1998, J MOL BIOL, V275, P419, DOI 10.1006/jmbi.1997.1458; ERSDALBADJU E, 1995, BIOCHEM J, V310, P323, DOI 10.1042/bj3100323; Futamura A, 2001, BIOCHEMISTRY-US, V40, P6680, DOI 10.1021/bi0029346; GAN ZR, 1994, J BIOL CHEM, V269, P1301; Gettins PGW, 2002, CHEM REV, V102, P4751, DOI 10.1021/cr010170+; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Huntington JA, 2003, J THROMB HAEMOST, V1, P1535, DOI 10.1046/j.1538-7836.2003.00305.x; Huntington JA, 2000, NATURE, V407, P923, DOI 10.1038/35038119; Irving JA, 2000, GENOME RES, V10, P1845, DOI 10.1101/gr.GR-1478R; Ishiguro K, 2000, J CLIN INVEST, V106, P873, DOI 10.1172/JCI10489; Jairajpuri MA, 2003, J BIOL CHEM, V278, P15941, DOI 10.1074/jbc.M212319200; Jairajpuri MA, 2002, J BIOL CHEM, V277, P24460, DOI 10.1074/jbc.M203127200; Jin L, 1997, P NATL ACAD SCI USA, V94, P14683, DOI 10.1073/pnas.94.26.14683; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lapatto R, 1997, EMBO J, V16, P5151, DOI 10.1093/emboj/16.17.5151; Manithody C, 2002, BIOCHEMISTRY-US, V41, P6780, DOI 10.1021/bi0255367; MARCUM JA, 1986, J BIOL CHEM, V261, P7507; McCoy AJ, 2003, J MOL BIOL, V326, P823, DOI 10.1016/S0022-2836(02)01382-7; MILETICH JP, 1980, ANAL BIOCHEM, V105, P304, DOI 10.1016/0003-2697(80)90462-5; NORDENMAN B, 1977, EUR J BIOCHEM, V78, P195, DOI 10.1111/j.1432-1033.1977.tb11730.x; OLSON ST, 1992, J BIOL CHEM, V267, P12528; OLSON ST, 1991, J BIOL CHEM, V266, P6353; Olson ST, 2002, TRENDS CARDIOVAS MED, V12, P331, DOI 10.1016/S1050-1738(02)00183-4; Olson ST, 2002, TRENDS CARDIOVAS MED, V12, P198, DOI 10.1016/S1050-1738(02)00160-3; OLSON ST, 1993, METHOD ENZYMOL, V222, P525; Olson ST, 2001, BIOCHEMISTRY-US, V40, P11742, DOI 10.1021/bi0107290; OWEN W G, 1973, Thrombosis Research, V3, P705, DOI 10.1016/0049-3848(73)90017-0; PICARD V, 1995, BIOCHEMISTRY-US, V34, P8433, DOI 10.1021/bi00026a026; Pike RN, 1997, J BIOL CHEM, V272, P19652, DOI 10.1074/jbc.272.32.19652; Quinsey NS, 2002, J BIOL CHEM, V277, P15971, DOI 10.1074/jbc.M108131200; Rezaie AR, 1998, J BIOL CHEM, V273, P16824, DOI 10.1074/jbc.273.27.16824; Rezaie AR, 2000, J BIOL CHEM, V275, P3320, DOI 10.1074/jbc.275.5.3320; SHEEHAN JP, 1994, P NATL ACAD SCI USA, V91, P5518, DOI 10.1073/pnas.91.12.5518; Skinner R, 1997, J MOL BIOL, V266, P601, DOI 10.1006/jmbi.1996.0798; Stratikos E, 1999, P NATL ACAD SCI USA, V96, P4808, DOI 10.1073/pnas.96.9.4808; THUNBERG L, 1982, CARBOHYD RES, V100, P393, DOI 10.1016/S0008-6215(00)81050-2; Turk B, 1997, BIOCHEMISTRY-US, V36, P6682, DOI 10.1021/bi9702492; TURKO IV, 1993, FEBS LETT, V335, P9, DOI 10.1016/0014-5793(93)80429-X; vanBoven HH, 1997, SEMIN HEMATOL, V34, P188; VANDEERLIN VMD, 1991, J BIOL CHEM, V266, P20223; Wei AZ, 1998, J MOL BIOL, V283, P147, DOI 10.1006/jmbi.1998.2069; Yang LK, 2003, J BIOL CHEM, V278, P25032, DOI 10.1074/jbc.M302174200; Yang LK, 2002, J BIOL CHEM, V277, P50756, DOI 10.1074/jbc.M208485200	52	39	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51433	51440		10.1074/jbc.M309266200	http://dx.doi.org/10.1074/jbc.M309266200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14532267	hybrid			2022-12-27	WOS:000187206300072
J	Renshaw, SA; Dempsey, CE; Barnes, FA; Bagstaff, SM; Dower, SK; Bingle, CD; Whyte, MKB				Renshaw, SA; Dempsey, CE; Barnes, FA; Bagstaff, SM; Dower, SK; Bingle, CD; Whyte, MKB			Three novel bid proteins generated by alternative splicing of the human bid gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; BCL-2 FAMILY; CYTOCHROME-C; BONE-MARROW; BH3 DOMAIN; APOPTOSIS; CLEAVAGE; MITOCHONDRIA; MEMBER; LINE	Bid, a BH3-only Bcl-2 protein, is activated by proteolytic cleavage exposing the BH3 domain, which then induces apoptosis by interacting with pro-apoptotic Bcl-2 family proteins (e.g. Bax and Bak) at the mitochondrial surface. The arrangement of domains within Bid suggested that Bid function might be regulated in part by alternative splicing. We have determined the gene structure of human Bid and identified a number of novel exons. We have also demonstrated endogenous mRNA and protein expression for three novel isoforms of Bid, generated using these exons. Bid(S) contains the N-terminal regulatory domains of Bid without the BH3 domain; Bid(EL) corresponds to full-length Bid with additional N-terminal sequence; and Bid(ES) contains only the Bid sequence downstream of the BH3 domain. Expression of these isoforms is regulated during granulocyte maturation. In functional studies Bid(EL) induces apoptosis, whereas BidS abrogates the pro-apoptotic effects of truncated Bid and inhibits Fas-mediated apoptosis. Bid(ES) induces apoptosis but is also able to partially inhibit the pro-apoptotic effects of truncated Bid. These three novel endogenously expressed isoforms of Bid are distinct in their expression, their cellular localization, and their effects upon cellular apoptosis. Differential expression of these novel Bid isoforms may regulate the function of Bid following cleavage and thus influence the fate of cells exposed to a range of pro-apoptotic stimuli.	Univ Sheffield, Royal Hallamshire Hosp, Div Gen Med, Acad Unit Resp Med,Sect Funct Gen, Sheffield S10 2JF, S Yorkshire, England; Univ Sheffield, Royal Hallamshire Hosp, Div Gen Med, Acad Unit Cell Biol,Sect Funct Gen, Sheffield S10 2JF, S Yorkshire, England	University of Sheffield; University of Sheffield	Whyte, MKB (corresponding author), Univ Sheffield, Royal Hallamshire Hosp, Div Gen Med, Acad Unit Resp Med,Sect Funct Gen, Glossop Rd, Sheffield S10 2JF, S Yorkshire, England.	m.k.whyte@sheffield.ac.uk	Renshaw, Steve/E-6192-2010; Whyte, Moira/E-6210-2010	Renshaw, Steve/0000-0003-1790-1641; dower, steve/0000-0002-4675-4225; Bingle, Colin/0000-0002-5405-6988				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Ausubel F.M., 1992, SHORT PROTOCOLS MOL; Bae J, 2000, J BIOL CHEM, V275, P25255, DOI 10.1074/jbc.M909826199; Bingle CD, 2000, J BIOL CHEM, V275, P22136, DOI 10.1074/jbc.M909572199; Bjerregaard MD, 2003, BLOOD, V101, P4322, DOI 10.1182/blood-2002-03-0835; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Cain K, 2000, J BIOL CHEM, V275, P6067, DOI 10.1074/jbc.275.9.6067; Cazzola M, 2000, BLOOD, V95, P3280, DOI 10.1182/blood.V95.11.3280.011k41_3280_3288; Chou JJ, 1999, CELL, V96, P615, DOI 10.1016/S0092-8674(00)80572-3; Cowland JB, 1999, J IMMUNOL METHODS, V232, P191, DOI 10.1016/S0022-1759(99)00176-3; Desagher S, 2001, MOL CELL, V8, P601, DOI 10.1016/S1097-2765(01)00335-5; Esposti MD, 2003, CELL DEATH DIFFER, V10, P1300, DOI 10.1038/sj.cdd.4401306; Fujita N, 1998, ONCOGENE, V17, P1295, DOI 10.1038/sj.onc.1202065; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Grinberg M, 2002, J BIOL CHEM, V277, P12237, DOI 10.1074/jbc.M104893200; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hsu YT, 1997, J BIOL CHEM, V272, P13829, DOI 10.1074/jbc.272.21.13829; Hsu YT, 1998, J BIOL CHEM, V273, P10777, DOI 10.1074/jbc.273.17.10777; Itoh M, 2000, ORAL ONCOL, V36, P277, DOI 10.1016/S1368-8375(00)00010-5; Jiang ZH, 1999, P SOC EXP BIOL MED, V220, P64, DOI 10.1046/j.1525-1373.1999.d01-11.x; Kirsch DG, 1999, J BIOL CHEM, V274, P21155, DOI 10.1074/jbc.274.30.21155; Korsmeyer SJ, 1999, CANCER RES, V59, p1693S; Kudla G, 2000, J BIOL CHEM, V275, P22713, DOI 10.1074/jbc.M003807200; LANOTTE M, 1991, BLOOD, V77, P1080; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Lutter M, 2000, NAT CELL BIOL, V2, P754, DOI 10.1038/35036395; Lutter M, 2001, BMC CELL BIOL, V2, DOI 10.1186/1471-2121-2-22; McDonnell JM, 1999, CELL, V96, P625, DOI 10.1016/S0092-8674(00)80573-5; Morris DR, 2000, MOL CELL BIOL, V20, P8635, DOI 10.1128/MCB.20.23.8635-8642.2000; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; Plesnila N, 2001, P NATL ACAD SCI USA, V98, P15318, DOI 10.1073/pnas.261323298; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Renshaw SA, 2000, J LEUKOCYTE BIOL, V67, P662, DOI 10.1002/jlb.67.5.662; Renshaw SA, 2003, J IMMUNOL, V170, P1027, DOI 10.4049/jimmunol.170.2.1027; RUCHAUD S, 1994, P NATL ACAD SCI USA, V91, P8428, DOI 10.1073/pnas.91.18.8428; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Savill J, 2000, NATURE, V407, P784, DOI 10.1038/35037722; Sax JK, 2002, NAT CELL BIOL, V4, P842, DOI 10.1038/ncb866; Stoka V, 2001, J BIOL CHEM, V276, P3149, DOI 10.1074/jbc.M008944200; STRAUSBERG R, 2002, MAMMALIAN GENE COLLE; Tan KO, 1999, J BIOL CHEM, V274, P23687, DOI 10.1074/jbc.274.34.23687; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Wang QMJ, 1999, J BIOL CHEM, V274, P37233, DOI 10.1074/jbc.274.52.37233; Wood DE, 2000, EXP CELL RES, V256, P375, DOI 10.1006/excr.2000.4859; Xie ZH, 1998, BIOCHEMISTRY-US, V37, P6410, DOI 10.1021/bi973052i; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730; Zha JP, 2000, SCIENCE, V290, P1761, DOI 10.1126/science.290.5497.1761; Zinkel SS, 2003, GENE DEV, V17, P229, DOI 10.1101/gad.1045603	52	30	32	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	2004	279	4					2846	2855		10.1074/jbc.M309769200	http://dx.doi.org/10.1074/jbc.M309769200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	764MU	14583606	hybrid			2022-12-27	WOS:000188211300064
J	Rosado, JA; Redondo, PC; Salido, GM; Gomez-Arteta, E; Sage, SO; Pariente, JA				Rosado, JA; Redondo, PC; Salido, GM; Gomez-Arteta, E; Sage, SO; Pariente, JA			Hydrogen peroxide generation induces pp60(src) activation in human platelets - Evidence for the involvement of this pathway in store-mediated calcium entry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; CA2+ ENTRY; TYROSINE KINASES; REDOX REGULATION; BLOOD-PLATELETS; SRC; ACTIN; RECEPTOR; CELLS; PHOSPHORYLATION	Reactive oxygen species, such as H2O2, have been recognized as intracellular messengers involved in several cell functions. Here we report the activation of the tyrosine kinase pp60(src) by H2O2, a mechanism required for the activation of store-mediated Ca2+ entry ( SMCE) in human platelets. Treatment of platelets with H2O2 resulted in a time- and concentration-dependent activation of pp60(src). Incubation with GF 109203X, a protein kinase C (PKC) inhibitor, prevented H2O2-induced pp60(src) activation. In contrast, dimethyl-BAPTA loading did not affect this response, suggesting that activation of pp60(src) by H2O2 is independent of increases in [Ca2+](i). Cytochalasin D, an inhibitor of actin polymerization, significantly reduced H2O2-induced pp60src activation. We found that platelet stimulation with thapsigargin (TG) plus ionomycin (Iono) or thrombin induced rapid H2O2 production, a mechanism independent of elevations in [Ca2+](i). Treatment of platelets with catalase attenuated TG plus Iono- and thrombin-induced activation of pp60(src). In addition, catalase as well as the pp60(src) inhibitor, PP1, reduced both the activation of SMCE and the coupling between the hTrp1 and the IP3R type II without having any effect on the maintenance of SMCE. Consistent with the role of PKC in the activation of pp60(src) by H2O2, the PKC inhibitors GF 109202X and Ro-31-8220 were found to reduced SMCE in platelets. This study suggests that platelet activation with TG plus Iono or thrombin is associated with H2O2 production, which acts as a second messenger by stimulating pp60(src) by a PKC-dependent pathway and is involved in the activation of SMCE in these cells.	Univ Extremadura, Fac Vet Sci, Dept Physiol, Caceres 10071, Spain; Hosp San Pedro Alcantara, Caceres 10005, Spain; Univ Cambridge, Dept Physiol, Cambridge CB2 3EG, England	Universidad de Extremadura; University of Cambridge	Rosado, JA (corresponding author), Univ Extremadura, Fac Vet Sci, Dept Physiol, POB 643, Caceres 10071, Spain.	jarosado@unex.es	Rosado, Juan A/H-3488-2015; Liberal, Pedro C Redondo/F-4592-2016; Salido, Gines M/A-4292-2009	Rosado, Juan A/0000-0002-9749-2325; Liberal, Pedro C Redondo/0000-0002-2067-2627; Salido, Gines M/0000-0002-8687-2445; Sage, Stewart/0000-0001-8578-3558; PARIENTE, JOSE ANTONIO/0000-0002-9094-9943				Abe J, 1997, J BIOL CHEM, V272, P20389, DOI 10.1074/jbc.272.33.20389; Alioua A, 2002, P NATL ACAD SCI USA, V99, P14560, DOI 10.1073/pnas.222348099; Atmane N, 2003, J BIOL CHEM, V278, P35086, DOI 10.1074/jbc.M303813200; Babnigg G, 1997, J BIOL CHEM, V272, P29434, DOI 10.1074/jbc.272.47.29434; Bertagnolli ME, 1999, BIOCHEM BIOPH RES CO, V260, P790, DOI 10.1006/bbrc.1999.0985; Bjorge JD, 1996, BIOCHEM CELL BIOL, V74, P477, DOI 10.1139/o96-052; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P9; CLARK EA, 1994, TRENDS BIOCHEM SCI, V19, P464, DOI 10.1016/0968-0004(94)90131-7; CLARK EA, 1993, MOL CELL BIOL, V13, P1863, DOI 10.1128/MCB.13.3.1863; Diaz A, 2001, FREE RADICAL BIO MED, V31, P1323, DOI 10.1016/S0891-5849(01)00637-2; Diver JM, 2001, CELL CALCIUM, V30, P323, DOI 10.1054/ceca.2001.0239; DONI MG, 1994, BIOCHEM J, V303, P599, DOI 10.1042/bj3030599; Esposito F, 2003, J BIOL CHEM, V278, P20828, DOI 10.1074/jbc.M211841200; FAVERO TG, 1995, J BIOL CHEM, V270, P25557, DOI 10.1074/jbc.270.43.25557; Finkel T, 1998, CURR OPIN CELL BIOL, V10, P248, DOI 10.1016/S0955-0674(98)80147-6; FOX JEB, 1981, NATURE, V292, P650, DOI 10.1038/292650a0; Frame MC, 2002, NAT REV MOL CELL BIO, V3, P233, DOI 10.1038/nrm779; Frank GD, 2000, BIOCHEM BIOPH RES CO, V270, P761, DOI 10.1006/bbrc.2000.2505; GOLDEN A, 1989, P NATL ACAD SCI USA, V86, P901, DOI 10.1073/pnas.86.3.901; GonzalezRubio M, 1996, KIDNEY INT, V50, P164, DOI 10.1038/ki.1996.299; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hu QH, 1998, CIRCULATION, V97, P268, DOI 10.1161/01.CIR.97.3.268; KIMURA T, 1995, ENDOCRINOLOGY, V136, P116, DOI 10.1210/en.136.1.116; KOOY MV, 1993, BRIT J HAEMATOL, V83, P253; Korzets A, 1999, J LAB CLIN MED, V133, P362, DOI 10.1016/S0022-2143(99)90067-7; Krippeit-Drews P, 1999, J PHYSIOL-LONDON, V514, P471, DOI 10.1111/j.1469-7793.1999.471ae.x; KRIPPEITDREWS P, 1995, BIOCHEM BIOPH RES CO, V209, P139, DOI 10.1006/bbrc.1995.1481; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDGREN E, 1995, ONCOGENE, V10, P2027; LIEBENHOFF U, 1994, CELL MOL BIOL, V40, P645; Luo YQ, 1998, J BIOL CHEM, V273, P3756, DOI 10.1074/jbc.273.6.3756; ODA A, 1992, J BIOL CHEM, V267, P20075; OSUSKY M, 1995, J BIOL CHEM, V270, P25729, DOI 10.1074/jbc.270.43.25729; Pariente JA, 2001, J MEMBRANE BIOL, V179, P27, DOI 10.1007/s002320010034; Patterson RL, 1999, CELL, V98, P487, DOI 10.1016/S0092-8674(00)81977-7; PETERSEN CCH, 1994, J BIOL CHEM, V269, P32246; Pignatelli P, 1998, BLOOD, V91, P484, DOI 10.1182/blood.V91.2.484.484_484_490; Ping PP, 1999, CIRC RES, V85, P542, DOI 10.1161/01.RES.85.6.542; Putney JW, 2001, J CELL SCI, V114, P2223; Redondo PC, 2003, BIOCHEM J, V370, P255, DOI 10.1042/BJ20021505; REDONDO PC, 2004, IN PRESS BIOCH PHARM; RINK TJ, 1990, ANNU REV PHYSIOL, V52, P431, DOI 10.1146/annurev.ph.52.030190.002243; Rosado JA, 2000, BIOCHEM J, V351, P429, DOI 10.1042/0264-6021:3510429; Rosado JA, 2000, J BIOL CHEM, V275, P7527, DOI 10.1074/jbc.275.11.7527; Rosado JA, 2000, BIOCHEM J, V350, P631, DOI 10.1042/0264-6021:3500631; Rosado JA, 2000, BIOCHEM J, V347, P183, DOI 10.1042/0264-6021:3470183; Rosado JA, 2002, J BIOL CHEM, V277, P42157, DOI 10.1074/jbc.M207320200; Rosado JA, 2001, BIOCHEM J, V356, P191, DOI 10.1042/0264-6021:3560191; Rosado JA, 2001, AM J PHYSIOL-CELL PH, V280, pC1636, DOI 10.1152/ajpcell.2001.280.6.C1636; Rosado JA, 2000, J PHYSIOL-LONDON, V529, P159, DOI 10.1111/j.1469-7793.2000.00159.x; SAGE SO, 1990, BIOCHEM J, V265, P675, DOI 10.1042/bj2650675; Salmeen A, 2003, NATURE, V423, P769, DOI 10.1038/nature01680; Seno T, 2001, THROMB RES, V103, P399, DOI 10.1016/S0049-3848(01)00341-3; Stenberg PE, 1997, BLOOD, V89, P2384, DOI 10.1182/blood.V89.7.2384; THASTRUP O, 1989, AGENTS ACTIONS, V27, P17, DOI 10.1007/BF02222186; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Waltenberger J, 1999, CIRC RES, V85, P12; Wang XT, 2001, J BIOL CHEM, V276, P28364, DOI 10.1074/jbc.M102693200; Xie Q, 2002, J BIOL CHEM, V277, P16559, DOI 10.1074/jbc.M109518200; Yada T, 2003, CIRCULATION, V107, P1040, DOI 10.1161/01.CIR.0000050145.25589.65; Yao Y, 1999, CELL, V98, P475, DOI 10.1016/S0092-8674(00)81976-5; Yu XM, 1999, P NATL ACAD SCI USA, V96, P7697, DOI 10.1073/pnas.96.14.7697; Zhang YQ, 2003, J BIOL CHEM, V278, P10417, DOI 10.1074/jbc.M211044200	63	117	120	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 16	2004	279	3					1665	1675		10.1074/jbc.M307963200	http://dx.doi.org/10.1074/jbc.M307963200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	762WT	14581479	hybrid			2022-12-27	WOS:000188005700015
J	Dhami, R; Schuchman, EH				Dhami, R; Schuchman, EH			Mannose 6-phosphate receptor-mediated uptake is defective in acid sphingomyelinase-deficient macrophages - Implications for Niemann-Pick disease enzyme replacement therapy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSOSOMAL-ENZYMES; MUCOPOLYSACCHARIDOSIS-VII; BETA-GLUCURONIDASE; GAUCHERS-DISEASE; FABRY-DISEASE; MODEL; GLUCOCEREBROSIDASE; BINDING; CELLS; MICE	Progressive accumulation of lipid-laden macrophages is a hallmark of the acid sphingomyelinase (ASM)-deficient forms of Niemann-Pick disease (i.e. Types A and B NPD). To investigate the mechanisms underlying enzyme replacement therapy for this disorder, we studied the uptake of recombinant, human ASM (rhASM) by alveolar macrophages from ASM knock-out (ASMKO) mice. The recombinant enzyme used for these studies was produced in Chinese hamster ovary cells and contained complex type, N-linked oligosaccharides. Binding of radiolabeled, rhASM to the ASMKO macrophages was enhanced as compared with normal macrophages, consistent with their larger size and increased surface area. However, internalization of the enzyme by the ASMKO cells was markedly reduced when compared with normal cells. Studies using receptor-specific ligands to inhibit enzyme uptake revealed that in normal cells rhASM was taken up by a combination of mannose and mannose 6-phosphate receptors (MR and M6PR, respectively), whereas in the ASMKO cells the M6PR had a minimal role in rhASM uptake. Expression of M6PR mRNA was normal in the ASMKO cells, although Western blotting revealed more receptors in these cells when compared with normal. We therefore hypothesized that lipid accumulation in ASMKO macrophages led to abnormalities in M6PR trafficking and/or degradation, resulting in reduced enzyme uptake. Consistent with this hypothesis, we also found that, when rhASM was modified to expose terminal mannose residues and target mannose receptors, the uptake of this modified enzyme form by ASMKO cells was similar to10-fold greater when compared with the "complex" type rhASM. These findings have important implications for NPD enzyme replacement therapy, particularly in the lung.	CUNY Mt Sinai Sch Med, Dept Human Genet, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Carl C Icahn Inst Gene Therapy & Mol Med, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Schuchman, EH (corresponding author), CUNY Mt Sinai Sch Med, Dept Human Genet, Box 14-98,1425 Madison Ave,Rm 14-98, New York, NY 10029 USA.	Edward.Schuchman@mssm.edu			NICHD NIH HHS [R01-HD-28607] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD028607] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BARTON NW, 1991, NEW ENGL J MED, V324, P1464, DOI 10.1056/NEJM199105233242104; BLUM JS, 1991, CARBOHYD RES, V213, P145, DOI 10.1016/S0008-6215(00)90605-0; BRADY RO, 1974, NEW ENGL J MED, V291, P989, DOI 10.1056/NEJM197411072911901; BRADY RO, 1973, NEW ENGL J MED, V289, P9, DOI 10.1056/NEJM197307052890103; BRAULKE T, 1987, J CELL BIOL, V104, P1735, DOI 10.1083/jcb.104.6.1735; DEDUVE C, 1966, ANNU REV PHYSIOL, V28, P435, DOI 10.1146/annurev.ph.28.030166.002251; Desnick RJ, 2001, J INHERIT METAB DIS, V24, P251, DOI 10.1023/A:1010331404448; DESNICK RJ, 1979, P NATL ACAD SCI USA, V76, P5326, DOI 10.1073/pnas.76.10.5326; Dhami R, 2001, LAB INVEST, V81, P987, DOI 10.1038/labinvest.3780311; DIMENT S, 1983, BIOCHIM BIOPHYS ACTA, V762, P165, DOI 10.1016/0167-4889(83)90068-X; Ferlinz K, 1997, EUR J BIOCHEM, V243, P511, DOI 10.1111/j.1432-1033.1997.511_1a.x; Fuller M, 1998, BBA-MOL BASIS DIS, V1406, P283, DOI 10.1016/S0925-4439(98)00011-8; GINSEL LA, 1991, CELL BIOL INT REP, V15, P1167, DOI 10.1016/0309-1651(91)90088-Z; HARRIS N, 1992, BLOOD, V80, P2363; He XX, 1999, BBA-PROTEIN STRUCT M, V1432, P251, DOI 10.1016/S0167-4838(99)00069-2; He XX, 2003, ANAL BIOCHEM, V314, P116, DOI 10.1016/S0003-2697(02)00629-2; HORINOUCHI K, 1995, NAT GENET, V10, P288, DOI 10.1038/ng0795-288; Ioannou YA, 2001, AM J HUM GENET, V68, P14, DOI 10.1086/316953; Kakkis ED, 2001, NEW ENGL J MED, V344, P182, DOI 10.1056/NEJM200101183440304; KERY V, 1992, ARCH BIOCHEM BIOPHYS, V298, P49, DOI 10.1016/0003-9861(92)90092-B; Lane KB, 1998, J LEUKOCYTE BIOL, V64, P345, DOI 10.1002/jlb.64.3.345; Minai OA, 2000, RESP MED, V94, P1241, DOI 10.1053/rmed.2000.0942; Miranda SRP, 2000, FASEB J, V14, P1988, DOI 10.1096/fj.00-0014com; MURRAY GJ, 1987, METHOD ENZYMOL, V149, P25; Neufeld E F, 1980, Birth Defects Orig Artic Ser, V16, P77; Sands MS, 2001, J BIOL CHEM, V276, P43160, DOI 10.1074/jbc.M107778200; SATO Y, 1993, J CLIN INVEST, V91, P1909, DOI 10.1172/JCI116409; SCHREIBER S, 1993, J IMMUNOL, V151, P4973; Schuchman EH, 2001, METABOLIC MOL BASES, V3, P3589; SCOTT CD, 1987, ENDOCRINOLOGY, V120, P1; SHEPHERD VL, 1984, J BIOL CHEM, V259, P2257; Sly W S, 1978, Prog Clin Biol Res, V23, P547; STAHL P, 1980, CELL, V19, P207, DOI 10.1016/0092-8674(80)90402-X; Stahl PD, 1998, CURR OPIN IMMUNOL, V10, P50, DOI 10.1016/S0952-7915(98)80031-9; Van den Hout H, 2000, LANCET, V356, P397, DOI 10.1016/S0140-6736(00)02533-2; Vogler C, 2001, PEDIATR DEVEL PATHOL, V4, P421, DOI 10.1007/s10024001-0079-1; Volders P, 2002, AM J MED GENET, V109, P42, DOI 10.1002/ajmg.10278; Wraith JE, 2001, J INHERIT METAB DIS, V24, P245, DOI 10.1023/A:1010379320378	38	57	64	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 9	2004	279	2					1526	1532		10.1074/jbc.M309465200	http://dx.doi.org/10.1074/jbc.M309465200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	759DJ	14557264	hybrid			2022-12-27	WOS:000187722800084
J	Ehrenman, K; Yang, G; Hong, WP; Gao, T; Jang, WH; Brock, DA; Hatton, RD; Shoemaker, JD; Gomer, RH				Ehrenman, K; Yang, G; Hong, WP; Gao, T; Jang, WH; Brock, DA; Hatton, RD; Shoemaker, JD; Gomer, RH			Disruption of aldehyde reductase increases group size in Dictyostelium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUMBER-COUNTING FACTOR; DENSITY-SENSING FACTOR; CELL-CELL ADHESION; ENZYME-MEDIATED INTEGRATION; GENE-EXPRESSION; SIGNAL-TRANSDUCTION; MOLECULE GP80; SLIME-MOLD; DISCOIDEUM; PROTEIN	Developing Dictyostelium cells form structures containing similar to20,000 cells. The size regulation mechanism involves a secreted counting factor (CF) repressing cytosolic glucose levels. Glucose or a glucose metabolite affects cell-cell adhesion and motility; these in turn affect whether a group stays together, loses cells, or even breaks up. NADPH-coupled aldehyde reductase reduces a wide variety of aldehydes to the corresponding alcohols, including converting glucose to sorbitol. The levels of this enzyme previously appeared to be regulated by CF. We find that disrupting alrA, the gene encoding aldehyde reductase, results in the loss of alrA mRNA and AlrA protein and a decrease in the ability of cell lysates to reduce both glyceraldehyde and glucose in an NADPH-coupled reaction. Counterintuitively, alrA- cells grow normally and have decreased glucose levels compared with parental cells. The alrA- cells form long unbroken streams and huge groups. Expression of AlrA in alrA- cells causes cells to form normal fruiting bodies, indicating that AlrA affects group size. alrA(-) cells have normal adhesion but a reduced motility, and computer simulations suggest that this could indeed result in the formation of large groups. alrA(-) cells secrete low levels of countin and CF50, two components of CF, and this could partially account for why alrA(-) cells form large groups. alrA(-) cells are responsive to CF and are partially responsive to recombinant countin and CF50, suggesting that disrupting alrA inhibits but does not completely block the CF signal transduction pathway. Gas chromatography/mass spectroscopy indicates that the concentrations of several metabolites are altered in alrA(-) cells, suggesting that the Dictyostelium aldehyde reductase affects several metabolic pathways in addition to converting glucose to sorbitol. Together, our data suggest that disrupting alrA affects CF secretion, causes many effects on cellular metabolism, and has a major effect on group size.	Rice Univ, Howard Hughes Med Inst, Houston, TX 77005 USA; Rice Univ, Dept Biochem & Cell Biol, Houston, TX 77005 USA; St Louis Univ, Dept Biochem & Mol Biol, Metab Screening Lab, St Louis, MO 63104 USA	Howard Hughes Medical Institute; Rice University; Rice University; Saint Louis University	Gomer, RH (corresponding author), Rice Univ, Howard Hughes Med Inst, MS-140,6100 S Main St, Houston, TX 77005 USA.	richard@bioc.rice.edu		Hatton, Roberta/0000-0001-8268-874X; Gomer, Richard/0000-0003-2361-4307; Jang, Wonhee/0000-0003-2470-8137				ADACHI H, 1995, BIOCHEM BIOPH RES CO, V208, P1181, DOI 10.1006/bbrc.1995.1458; ADACHI H, 1994, BIOCHEM BIOPH RES CO, V205, P1808, DOI 10.1006/bbrc.1994.2880; Aida K, 2000, BIOCHEM BIOPH RES CO, V277, P281, DOI 10.1006/bbrc.2000.3648; Allan D, 2000, MECH DEVELOP, V94, P271, DOI 10.1016/S0925-4773(00)00293-8; Barski OA, 1999, GENOMICS, V60, P188, DOI 10.1006/geno.1999.5915; BOHREN KM, 1989, J BIOL CHEM, V264, P9547; Brazill DT, 1998, J BIOL CHEM, V273, P8161, DOI 10.1074/jbc.273.14.8161; Brock DA, 1996, DEVELOPMENT, V122, P2569; Brock DA, 1999, GENE DEV, V13, P1960, DOI 10.1101/gad.13.15.1960; Brock DA, 2002, DEVELOPMENT, V129, P3657; Buczynski G, 1997, MOL BIOL CELL, V8, P1343, DOI 10.1091/mbc.8.7.1343; BUSH J, 1994, J CELL SCI, V107, P2801; CHARLESWORTH MC, 1975, EUR J BIOCHEM, V54, P307, DOI 10.1111/j.1432-1033.1975.tb04141.x; Clarke M, 1995, EXPERIENTIA, V51, P1124, DOI 10.1007/BF01944730; Cooper ME, 2001, DIABETOLOGIA, V44, P1957, DOI 10.1007/s001250100000; Day SJ, 2000, DEVELOPMENT, V127, P2977; Deery WJ, 1999, J BIOL CHEM, V274, P34476, DOI 10.1074/jbc.274.48.34476; DESBARATS L, 1994, J CELL SCI, V107, P1705; DEVREOTES P, 1989, SCIENCE, V245, P1054, DOI 10.1126/science.2672337; DUNLOP M, 2000, KIDNEY INT S, V77, P3; ECKERT BS, 1977, J CELL BIOL, V72, P339, DOI 10.1083/jcb.72.2.339; ElKabbani O, 1997, PROTEINS, V29, P186, DOI 10.1002/(SICI)1097-0134(199710)29:2<186::AID-PROT6>3.0.CO;2-B; Ellis EM, 2002, FEMS MICROBIOL LETT, V216, P123, DOI 10.1111/j.1574-6968.2002.tb11425.x; FIRTEL RA, 1995, GENE DEV, V9, P1427, DOI 10.1101/gad.9.12.1427; FLYNN TG, 1995, ADV EXP MED BIOL, V372, P193; Gabbay K H, 1975, Methods Enzymol, V41, P159; Gao T, 2002, J BIOL CHEM, V277, P32596, DOI 10.1074/jbc.M203075200; GARROD DR, 1972, J EMBRYOL EXP MORPH, V28, P463; GERST JE, 1992, P NATL ACAD SCI USA, V89, P4338, DOI 10.1073/pnas.89.10.4338; GOMER RH, 1991, DEVELOPMENT, V112, P269; Gomer RH, 2001, NAT REV MOL CELL BIO, V2, P48, DOI 10.1038/35048058; GONZALEZYANES B, 1992, J BIOL CHEM, V267, P9595; Haldane J. B. S., 1928, POSSIBLE WORLDS OTHE, P20; Harris E, 2002, J CELL SCI, V115, P3703, DOI 10.1242/jcs.00050; Ho HTB, 2000, MOL CELL BIOL, V20, P5840, DOI 10.1128/MCB.20.16.5840-5846.2000; JAIN R, 1994, J BIOL CHEM, V269, P9128; JAIN R, 1992, GENE DEV, V6, P390, DOI 10.1101/gad.6.3.390; Jang W, 2002, J BIOL CHEM, V277, P39202, DOI 10.1074/jbc.M205635200; Jez JM, 1997, BIOCHEM J, V326, P625, DOI 10.1042/bj3260625; KAMBOJ RK, 1990, CELL REGUL, V1, P715, DOI 10.1091/mbc.1.10.715; Kessin R.H., 2001, DICTYOSTELIUM EVOLUT; KNECHT DA, 1987, DEV BIOL, V121, P277, DOI 10.1016/0012-1606(87)90160-6; KUSPA A, 1992, P NATL ACAD SCI USA, V89, P8803, DOI 10.1073/pnas.89.18.8803; Kuwayama H, 1996, SCIENCE, V271, P207, DOI 10.1126/science.271.5246.207; Lee H, 1998, YEAST, V14, P977, DOI 10.1002/(SICI)1097-0061(199808)14:11<977::AID-YEA302>3.0.CO;2-J; LOOMIS WF, 1988, DEV GENET, V9, P549, DOI 10.1002/dvg.1020090431; LOOMIS WF, 1993, CURR TOP DEV BIOL, V28, P1, DOI 10.1016/S0070-2153(08)60208-2; Loomis WF., 1975, DICTYOSTELIUM DISCOI; MANN SKO, 1988, DEV GENET, V9, P337, DOI 10.1002/dvg.1020090415; MANSTEIN DJ, 1995, GENE, V162, P129, DOI 10.1016/0378-1119(95)00351-6; McNew JA, 2000, NATURE, V407, P153, DOI 10.1038/35025000; MEHDY MC, 1985, MOL CELL BIOL, V5, P705, DOI 10.1128/MCB.5.4.705; MEIER UT, 1992, CELL, V70, P127; MULLERTAUBENBERGER A, 1989, J BIOL CHEM, V264, P5319; Newell PC, 1995, BIOSCIENCE REP, V15, P445, DOI 10.1007/BF01204348; Potter CJ, 2001, CURR OPIN GENET DEV, V11, P279, DOI 10.1016/S0959-437X(00)00191-X; PRICE MG, 1993, J BIOL CHEM, V268, P21800; Ramana KV, 2002, J BIOL CHEM, V277, P32063, DOI 10.1074/jbc.M202126200; Roisin-Bouffay C, 2000, MOL CELL, V6, P953, DOI 10.1016/S1097-2765(05)00082-1; ROONEY EK, 1994, CELL CALCIUM, V16, P509, DOI 10.1016/0143-4160(94)90081-7; SCHAAP P, 1991, MICROBIAL CELL CELL, P147; SHAFFER BM, 1958, Q J MICROSC SCI, V98, P393; SHOEMAKER JD, 1991, J CHROMATOGR-BIOMED, V562, P125, DOI 10.1016/0378-4347(91)80571-S; Siu C.-H., 1997, DICTYOSTELIUM CELL D, P111; SIU CH, 1990, DEV GENET, V11, P377, DOI 10.1002/dvg.1020110509; SIU CH, 1988, BIOCHIM BIOPHYS ACTA, V968, P283, DOI 10.1016/0167-4889(88)90019-5; SONNEMANN J, 1991, J BIOL CHEM, V266, P23091; Spann TP, 1996, P NATL ACAD SCI USA, V93, P5003, DOI 10.1073/pnas.93.10.5003; Srinivasan S, 1999, J BIOL CHEM, V274, P35823, DOI 10.1074/jbc.274.50.35823; SUTOH K, 1993, PLASMID, V30, P150, DOI 10.1006/plas.1993.1042; Tang L, 2002, P NATL ACAD SCI USA, V99, P1371, DOI 10.1073/pnas.022516099; Tang L, 2001, J BIOL CHEM, V276, P27663, DOI 10.1074/jbc.M102205200; Tapparo A, 1999, BIOCHIMIE, V81, P943, DOI 10.1016/S0300-9084(99)00225-4; TROLL H, 1992, J BIOL CHEM, V267, P21072; TROLL H, 1993, J BIOL CHEM, V268, P25469; VARNUM B, 1985, J CELL BIOL, V101, P1, DOI 10.1083/jcb.101.1.1; YUEN IS, 1995, J CELL BIOL, V129, P1251, DOI 10.1083/jcb.129.5.1251; YUEN IS, 1994, J THEOR BIOL, V167, P273, DOI 10.1006/jtbi.1994.1069	78	18	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 9	2004	279	2					837	847		10.1074/jbc.M310539200	http://dx.doi.org/10.1074/jbc.M310539200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	759DJ	14551196	hybrid			2022-12-27	WOS:000187722800005
J	Jiang, BB; Xu, SQ; Hou, XY; Pimentel, DR; Brecher, P; Cohen, RA				Jiang, BB; Xu, SQ; Hou, XY; Pimentel, DR; Brecher, P; Cohen, RA			Temporal control of NF-kappa B activation by ERK differentially regulates interleukin-1 beta-induced gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; CELL-ADHESION MOLECULE-1; SMOOTH-MUSCLE-CELLS; PERSISTENT ACTIVATION; TRANSCRIPTION FACTOR; INDUCTION; BETA; INHIBITOR; PROMOTER; ALPHA	In cultured rat vascular smooth muscle cells, sustained activation of ERK is required for interleukin-1beta to persistently activate NF-kappaB. Without ERK activation, interleukin-1beta induces only acute and transient NF-kappaB activation. The present study examined whether the temporal control of NF-kappaB activation by ERK could differentially regulate the expression of NF-kappaB-dependent genes, including inducible nitric oxide synthase ( iNOS), cyclooxygenase-2 (COX-2), vascular cell adhesion molecule-1 (VCAM-1), and manganese-containing superoxide dismutase (Mn-SOD). Treatment of vascular smooth muscle cells with interleukin-1beta induced the expression of iNOS, COX-2, VCAM-1, and Mn-SOD in a time-dependent manner, but with different patterns. Either PD98059 or U0126, selective inhibitors of MEK, or overexpression of a dominant negative MEK-1 inhibited interleukin-1beta-induced ERK activation and the expression of iNOS and COX-2 but had essentially no effect on the expression of VCAM-1 and Mn-SOD. The expression of these genes was inhibited when NF-kappaB activation was down-regulated by MG132, a proteasome inhibitor, or by overexpression of an I-kappaBalpha mutant that prevented both the transient and the persistent activation of NF-kappaB. Inhibition of ERK did not affect interleukin-1beta-induced I-kappaBalpha phosphorylation and degradation but attenuated I-kappaBbeta degradation. Thus, although NF-kappaB activation was essential for interleukin-1beta induction of each of the proteins studied, gene expression was differentially regulated by ERK and by the duration of NF-kappaB activation. These results reveal a novel functional role for ERK as an important temporal regulator of NF-kappaB activation and NF-kappaB-dependent gene expression.	Boston Univ, Sch Med, Dept Med,Vasc Biol Unit, Whitaker Cardiovasc Inst, Boston, MA 02118 USA	Boston University	Jiang, BB (corresponding author), Boston Univ, Sch Med, Dept Med,Vasc Biol Unit, Whitaker Cardiovasc Inst, Boston, MA 02118 USA.			/0000-0002-1070-6408; Pimentel, David/0000-0002-0537-7195; Brecher, Peter/0000-0002-9347-6643	NHLBI NIH HHS [HL-55620] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055620] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Chen F, 1999, CLIN CHEM, V45, P7; Cheshire JL, 1997, MOL CELL BIOL, V17, P6746, DOI 10.1128/MCB.17.11.6746; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; Heitmeier MR, 1999, J BIOL CHEM, V274, P29266, DOI 10.1074/jbc.274.41.29266; Hoffmann A, 2002, SCIENCE, V298, P1241, DOI 10.1126/science.1071914; IADEMARCO MF, 1992, J BIOL CHEM, V267, P16323; Jiang BB, 1999, HYPERTENSION, V34, P574, DOI 10.1161/01.HYP.34.4.574; Jiang BB, 2000, HYPERTENSION, V35, P914, DOI 10.1161/01.HYP.35.4.914; Jiang BB, 2002, ARTERIOSCL THROM VAS, V22, P1811, DOI 10.1161/01.ATV.0000037679.60584.3F; Jiang BB, 2001, ARTERIOSCL THROM VAS, V21, P1915, DOI 10.1161/hq1201.099424; Jobin C, 2000, AM J PHYSIOL-CELL PH, V278, pC451, DOI 10.1152/ajpcell.2000.278.3.C451; KHACHIGIAN LM, 1995, BIOCHEM BIOPH RES CO, V206, P462, DOI 10.1006/bbrc.1995.1065; Lawrence T, 2001, NAT MED, V7, P1291, DOI 10.1038/nm1201-1291; LEBAIL O, 1993, EMBO J, V12, P5043, DOI 10.1002/j.1460-2075.1993.tb06197.x; Malek S, 2001, J BIOL CHEM, V276, P45225, DOI 10.1074/jbc.M105865200; May MJ, 1999, SCIENCE, V284, P271, DOI 10.1126/science.284.5412.271; NEISH AS, 1992, J EXP MED, V176, P1583, DOI 10.1084/jem.176.6.1583; Phelps CB, 2000, J BIOL CHEM, V275, P29840, DOI 10.1074/jbc.M004899200; SPINK J, 1995, J BIOL CHEM, V270, P29541, DOI 10.1074/jbc.270.49.29541; Suyang H, 1996, MOL CELL BIOL, V16, P5444; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; XIE QW, 1994, J BIOL CHEM, V269, P4705; Zhang HF, 2000, BRIT J PHARMACOL, V130, P270, DOI 10.1038/sj.bjp.0703284	26	159	164	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 9	2004	279	2					1323	1329		10.1074/jbc.M307521200	http://dx.doi.org/10.1074/jbc.M307521200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	759DJ	14581482	hybrid			2022-12-27	WOS:000187722800059
J	Fang, J; Sullivan, M; McCutchan, TF				Fang, J; Sullivan, M; McCutchan, TF			The effects of glucose concentration on the reciprocal regulation of rRNA promoters in Plasmodium falciparum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRINGENT CONTROL; ESCHERICHIA-COLI; MALARIA PARASITE; DNA; GENE; SEQUENCES; DISTINCT; YEAST; AMPLIFICATION; TRANSCRIPTION	The developmental progression of Plasmodium falciparum is remarkably sensitive to glucose concentration. We have investigated the effects of glucose concentration on the parasite development cycle as reflected by changes of ribosomal RNA ( rRNA) transcription. We showed that glucose starvation differentially affects transcriptional control of the rRNA genes by sharply repressing transcription from those loci involved with asexual development of the parasite while up-regulating transcription at those loci involved with sexual development of the parasite. Temperature change also effects regulation of transcription. We found that the effects of temperature and glucose were synergistic. We identified and compared the upstream region of the transcription start sites of each gene. These putative promoter structures are considerably different from one another and contain structures remarkably similar to rRNA control elements in other organisms.	NIAID, Mol Biol Sect, Lab Malaria & Vector Res, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	McCutchan, TF (corresponding author), NIAID, Mol Biol Sect, Lab Malaria & Vector Res, NIH, Bethesda, MD 20892 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000208, ZIAAI000208] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bayele HK, 2000, J BIOL CHEM, V275, P14217, DOI 10.1074/jbc.275.19.14217; Biggar SR, 2001, EMBO J, V20, P3167, DOI 10.1093/emboj/20.12.3167; CONCONI A, 1989, CELL, V57, P753, DOI 10.1016/0092-8674(89)90790-3; DAME JB, 1983, MOL BIOCHEM PARASIT, V8, P263, DOI 10.1016/0166-6851(83)90048-8; DAS BS, 1988, T ROY SOC TROP MED H, V82, P197, DOI 10.1016/0035-9203(88)90407-5; DEBOER HA, 1979, CELL, V17, P201, DOI 10.1016/0092-8674(79)90308-8; Fang J, 2002, NATURE, V418, P742, DOI 10.1038/418742a; Forsberg H, 2001, CURR GENET, V40, P91, DOI 10.1007/s002940100244; Gorner W, 2002, EMBO J, V21, P135, DOI 10.1093/emboj/21.1.135; GUNDERSON JH, 1987, SCIENCE, V238, P933, DOI 10.1126/science.3672135; Hayward RE, 2000, MOL MICROBIOL, V35, P6, DOI 10.1046/j.1365-2958.2000.01730.x; Hayward RE, 2000, MOL BIOCHEM PARASIT, V107, P227, DOI 10.1016/S0166-6851(00)00191-2; JOSAITIS CA, 1995, P NATL ACAD SCI USA, V92, P1117, DOI 10.1073/pnas.92.4.1117; LAMOND AI, 1985, CELL, V41, P6, DOI 10.1016/0092-8674(85)90050-9; LANGSLEY G, 1983, NUCLEIC ACIDS RES, V11, P8703, DOI 10.1093/nar/11.24.8703; LI J, 1994, EXP PARASITOL, V78, P437, DOI 10.1006/expr.1994.1051; Li J, 1997, J MOL BIOL, V269, P203, DOI 10.1006/jmbi.1997.1038; MACK SR, 1979, J PARASITOL, V65, P217, DOI 10.2307/3280149; MCCUTCHAN TF, 1988, MOL BIOCHEM PARASIT, V28, P63, DOI 10.1016/0166-6851(88)90181-8; Okazaki N, 1998, MOL CELL BIOL, V18, P887, DOI 10.1128/MCB.18.2.887; Rogers MJ, 1996, RNA, V2, P134; ROGERS MJ, 1995, J MOL BIOL, V254, P881; Sambrook J., 1989, MOL CLONING; Santoro R, 2001, MOL CELL, V8, P719, DOI 10.1016/S1097-2765(01)00317-3; Su XZ, 1996, NUCLEIC ACIDS RES, V24, P1574, DOI 10.1093/nar/24.8.1574; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; TRAVERS AA, 1980, J BACTERIOL, V141, P973, DOI 10.1128/JB.141.2.973-976.1980; TRIGLIA T, 1988, NUCLEIC ACIDS RES, V16, P8186, DOI 10.1093/nar/16.16.8186; Velichutina IV, 1998, RNA, V4, P594, DOI 10.1017/S1355838298980049; WARNER JR, 1978, NATURE, V275, P338, DOI 10.1038/275338a0; WATERS AP, 1995, MOL BIOCHEM PARASIT, V72, P227, DOI 10.1016/0166-6851(94)00077-Z; WHITE NJ, 1992, ADV PARASIT, V31, P83, DOI 10.1016/S0065-308X(08)60021-4; ZACHARIAS M, 1989, EMBO J, V8, P3357, DOI 10.1002/j.1460-2075.1989.tb08498.x; ZACHARIAS M, 1991, BIOCHIMIE, V73, P699, DOI 10.1016/0300-9084(91)90050-B	34	29	29	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	2004	279	1					720	725		10.1074/jbc.M308284200	http://dx.doi.org/10.1074/jbc.M308284200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	757GU	14570919	hybrid			2022-12-27	WOS:000187555300086
J	Lemonnier, J; Ghayor, C; Guicheux, J; Caverzasio, J				Lemonnier, J; Ghayor, C; Guicheux, J; Caverzasio, J			Protein kinase C-independent activation of protein kinase D is involved in BMP-2-induced activation of stress mitogen-activated protein kinases JNK and p38 and osteoblastic cell differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE MORPHOGENETIC PROTEIN-2; PLECKSTRIN HOMOLOGY DOMAIN; TYROSINE PHOSPHORYLATION; ALKALINE-PHOSPHATASE; SIGNAL-TRANSDUCTION; MOLECULAR-CLONING; LOOP SER(744); INTACT-CELLS; FAMILY; MU	An important role for JNK* and p38 has recently been discovered in the differentiating effect of bone morphogenetic protein 2 (BMP-2) on osteoblastic cells. In this study, we investigated the molecular mechanism by which BMP-2 activates JNK and p38 in MC3T3-E1 osteoblastic cells. Activation of JNK and p38 induced by BMP-2 was blocked by the protein kinase C/protein kinase D (PKC/PKD) inhibitor Go6976 but not by the related compound, Go6983, a selective inhibitor of conventional PKCs. Associated with this inhibitory effect of Go6976, BMP-2 induced a selective and a dose-dependent Ser(916) phosphorylation/activation of PKD, which was also blocked by Go6976. In contrast to the recently described PKC-dependent molecular mechanism involved in activation of PKD by G protein-coupled receptor agonists, BMP-2 did not induce a phosphorylation of PKD on Ser(744/748). To further document an implication of PKD in activation of JNK and p38 induced by BMP-2, we constructed MC3T3-E1 cells stably expressing PKD antisense oligonucleotide (AS-PKD). In AS-PKD clones having low PKD levels, activation of JNK and p38 by BMP-2, but not of Smad1/5, was markedly impaired compared with empty vector transfected (V-PKD) cells. Analysis of osteoblastic cell differentiation in AS-PKD compared with V-PKD cells showed that mRNA and protein expressions of alkaline phosphatase and osteocalcin induced by BMP-2 were markedly reduced in AS-PKD. In conclusion, results presented in this study indicate that BMP-2 can induce activation of PKD in osteoblastic cells by a PKC-independent mechanism and that this kinase is involved in activation of JNK and p38 induced by BMP-2. Thus, this pathway, in addition to Smads, appears to be essential for the effect of BMP-2 on osteoblastic cell differentiation.	Univ Hosp Geneva, Dept Geriatr, Div Bone Dis, CH-1211 Geneva 14, Switzerland	University of Geneva	Caverzasio, J (corresponding author), Univ Hosp Geneva, Dept Geriatr, Div Bone Dis, CH-1211 Geneva 14, Switzerland.	Joseph.Caverzasio@medecine.unige.ch	guicheux, Jerome/F-7767-2013	guicheux, Jerome/0000-0003-2754-3024; Ghayor, Chafik/0000-0002-3016-3412				Caverzasio J, 1997, J BONE MINER RES, V12, P1975, DOI 10.1359/jbmr.1997.12.12.1975; Endo K, 2000, J BIOL CHEM, V275, P18476, DOI 10.1074/jbc.M002266200; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; Gazzerro E, 1998, J CLIN INVEST, V102, P2106, DOI 10.1172/JCI3459; Ghosh-Choudhury N, 2002, J BIOL CHEM, V277, P33361, DOI 10.1074/jbc.M205053200; Gschwendt M, 1996, FEBS LETT, V392, P77, DOI 10.1016/0014-5793(96)00785-5; Gschwendt M, 1997, J BIOL CHEM, V272, P20742, DOI 10.1074/jbc.272.33.20742; Guicheux J, 2003, J BONE MINER RES, V18, P2060, DOI 10.1359/jbmr.2003.18.11.2060; HAENDLER B, 1987, EMBO J, V6, P947, DOI 10.1002/j.1460-2075.1987.tb04843.x; HAKEDA Y, 1987, ENDOCRINOLOGY, V121, P1966, DOI 10.1210/endo-121-6-1966; Hay E, 1999, J CELL BIOCHEM, V72, P81, DOI 10.1002/(SICI)1097-4644(19990101)72:1<81::AID-JCB9>3.0.CO;2-N; Hay E, 2001, J BIOL CHEM, V276, P29028, DOI 10.1074/jbc.M011265200; Hayashi A, 1999, BBA-MOL CELL RES, V1450, P99, DOI 10.1016/S0167-4889(99)00040-3; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; HUGHES FJ, 1995, ENDOCRINOLOGY, V136, P2671, DOI 10.1210/en.136.6.2671; Ikegame M, 2001, J BONE MINER RES, V16, P24, DOI 10.1359/jbmr.2001.16.1.24; IWASAKI S, 1995, J BIOL CHEM, V270, P5476, DOI 10.1074/jbc.270.10.5476; Jamora C, 1999, CELL, V98, P59, DOI 10.1016/S0092-8674(00)80606-6; JOHANNES FJ, 1994, J BIOL CHEM, V269, P6140; Johannes FJ, 1998, EUR J BIOCHEM, V257, P47, DOI 10.1046/j.1432-1327.1998.2570047.x; Kretzschmar M, 1997, GENE DEV, V11, P984, DOI 10.1101/gad.11.8.984; Liberati NT, 1999, P NATL ACAD SCI USA, V96, P4844, DOI 10.1073/pnas.96.9.4844; Matthews SA, 1997, J BIOL CHEM, V272, P20245, DOI 10.1074/jbc.272.32.20245; Nishimura R, 1998, J BIOL CHEM, V273, P1872, DOI 10.1074/jbc.273.4.1872; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; Prestle J, 1996, J CELL BIOL, V134, P1401, DOI 10.1083/jcb.134.6.1401; Rey O, 2001, J BIOL CHEM, V276, P32616, DOI 10.1074/jbc.M101649200; Rykx A, 2003, FEBS LETT, V546, P81, DOI 10.1016/S0014-5793(03)00487-3; Sano Y, 1999, J BIOL CHEM, V274, P8949, DOI 10.1074/jbc.274.13.8949; Schmitt JM, 1999, J ORTHOPAED RES, V17, P269, DOI 10.1002/jor.1100170217; Storz P, 2003, J BIOL CHEM, V278, P17969, DOI 10.1074/jbc.M213224200; Sturany S, 2001, J BIOL CHEM, V276, P3310, DOI 10.1074/jbc.M008719200; Suzuki A, 1998, BONE, V23, P197, DOI 10.1016/S8756-3282(98)00099-4; THIEDE MA, 1988, P NATL ACAD SCI USA, V85, P319, DOI 10.1073/pnas.85.2.319; Toker Alex, 1998, Frontiers in Bioscience, V3, pD1134; VALVERDE AM, 1994, P NATL ACAD SCI USA, V91, P8572, DOI 10.1073/pnas.91.18.8572; Van Lint J, 2002, INT J BIOCHEM CELL B, V34, P577, DOI 10.1016/S1357-2725(01)00163-7; Van Lint J, 2002, TRENDS CELL BIOL, V12, P193, DOI 10.1016/S0962-8924(02)02262-6; Vertommen D, 2000, J BIOL CHEM, V275, P19567, DOI 10.1074/jbc.M001357200; Waldron RT, 2001, J BIOL CHEM, V276, P32606, DOI 10.1074/jbc.M101648200; Waldron RT, 1999, ELECTROPHORESIS, V20, P382, DOI 10.1002/(SICI)1522-2683(19990201)20:2<382::AID-ELPS382>3.0.CO;2-N; Waldron RT, 2003, J BIOL CHEM, V278, P154, DOI 10.1074/jbc.M208075200; YAMAGUCHI A, 1995, SEMIN CELL BIOL, V6, P165, DOI 10.1006/scel.1995.0023; Yamamoto N, 1997, BIOCHEM BIOPH RES CO, V238, P574, DOI 10.1006/bbrc.1997.7325; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zugaza JL, 1996, EMBO J, V15, P6220, DOI 10.1002/j.1460-2075.1996.tb01012.x	47	114	120	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 2	2004	279	1					259	264		10.1074/jbc.M308665200	http://dx.doi.org/10.1074/jbc.M308665200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	757GU	14573624	hybrid			2022-12-27	WOS:000187555300032
J	Ahuja, U; Thony-Meyer, L				Ahuja, U; Thony-Meyer, L			Dynamic features of a heme delivery system for cytochrome c maturation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI K-12; N-OXIDE REDUCTASE; CHAPERONE CCME; MUTATIONAL ANALYSIS; BIOGENESIS; BACTERIA; GENE; PATHWAY; PROTEIN; IDENTIFICATION	In Escherichia coli, heme is delivered to cytochrome c in a process involving eight proteins encoded by the ccmABCDEFGH operon. Heme is transferred to the periplasmic heme chaperone CcmE by CcmC and from there to apocytochrome c. The role of CcmC was investigated by random as well as site-directed mutagenesis. Important amino acids were all located in periplasmic domains of the CcmC protein that has six membrane-spanning helices. Besides the tryptophan-rich motif and two conserved histidines, new residues were identified as functionally important. Mutants G111S and H184Y had a clear defect in CcmC-CcmE interaction, did not transfer heme to CcmE, and lacked c-type cytochromes. Conversely, mutants D47N, R55P, and S176Y were affected neither in interaction with nor in delivery of heme to CcmE but produced less than 10% c-type cytochromes. A strain carrying a CcmCE fusion had a similar phenotype, suggesting that CcmC is important not only for heme transfer to CcmE but also for its delivery to cytochrome c. Co-immunoprecipitation of CcmC with CcmF was not detectable although CcmE co-precipitated individually with CcmC and CcmF. This contradicts the idea of CcmCEF supercomplex formation. Our results favor a model that predicts CcmE to shuttle between CcmC and CcmF for heme delivery.	ETH, Inst Mikrobiol, CH-8092 Zurich, Switzerland	ETH Zurich	Thony-Meyer, L (corresponding author), ETH, Inst Mikrobiol, Schmelzbergstr 7, CH-8092 Zurich, Switzerland.		Ahuja, Umesh/ABC-2954-2020					BONNEFOY V, 1994, ANTON LEEUW INT J G, V66, P47, DOI 10.1007/BF00871632; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; CHOE M, 1993, J BACTERIOL, V175, P1165, DOI 10.1128/JB.175.4.1165-1172.1993; Cole J, 1996, FEMS MICROBIOL LETT, V136, P1; FABIANEK RA, 1999, THESIS EIDGENOSSISCH; Gaballa A, 1998, MOL MICROBIOL, V30, P547, DOI 10.1046/j.1365-2958.1998.01085.x; Gaballa A, 1996, MOL MICROBIOL, V21, P777, DOI 10.1046/j.1365-2958.1996.391399.x; Gennis R. B., 1996, ESCHERICHIA COLI SAL, P217; Goldman BS, 1997, J MOL BIOL, V268, P724, DOI 10.1006/jmbi.1997.0992; Goldman BS, 1998, P NATL ACAD SCI USA, V95, P5003, DOI 10.1073/pnas.95.9.5003; Gon S, 2000, J BACTERIOL, V182, P5779, DOI 10.1128/JB.182.20.5779-5786.2000; Greener A., 1994, STRATEGIES, V7, P32; Grove J, 1996, MOL MICROBIOL, V19, P467, DOI 10.1046/j.1365-2958.1996.383914.x; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; IOBBINIVOL C, 1994, FEMS MICROBIOL LETT, V119, P89, DOI 10.1016/0378-1097(94)90397-2; Kranz R, 1998, MOL MICROBIOL, V29, P383, DOI 10.1046/j.1365-2958.1998.00869.x; MEISSNER PS, 1987, P NATL ACAD SCI USA, V84, P4171, DOI 10.1073/pnas.84.12.4171; Miller J. H., 1992, SHORT COURSE BACTERI, P263; Oresnik IJ, 2001, MOL MICROBIOL, V40, P323, DOI 10.1046/j.1365-2958.2001.02391.x; Page MD, 1998, TRENDS BIOCHEM SCI, V23, P103, DOI 10.1016/S0968-0004(98)01173-6; Page MD, 1999, MICROBIOL-UK, V145, P3047, DOI 10.1099/00221287-145-11-3047; Pommier J, 1998, J BIOL CHEM, V273, P16615, DOI 10.1074/jbc.273.26.16615; RABIN RS, 1993, J BACTERIOL, V175, P3259, DOI 10.1128/jb.175.11.3259-3268.1993; Ren Q, 2002, J BIOL CHEM, V277, P7657, DOI 10.1074/jbc.M110979200; Ren Q, 2001, J BIOL CHEM, V276, P32591, DOI 10.1074/jbc.M103058200; SAMBASIVARAO D, 1991, J BACTERIOL, V173, P5935, DOI 10.1128/jb.173.19.5935-5943.1991; Schulz H, 1998, SCIENCE, V281, P1197, DOI 10.1126/science.281.5380.1197; Schulz H, 1999, P NATL ACAD SCI USA, V96, P6462, DOI 10.1073/pnas.96.11.6462; Schulz H, 2000, MOL MICROBIOL, V37, P1379, DOI 10.1046/j.1365-2958.2000.02083.x; Tanapongpipat S, 1998, BIOCHEM J, V334, P355, DOI 10.1042/bj3340355; Thony-Meyer L, 2000, BBA-BIOENERGETICS, V1459, P316, DOI 10.1016/S0005-2728(00)00167-5; THONYMEYER L, 1995, J BACTERIOL, V177, P4321; ThonyMeyer L, 1996, EUR J BIOCHEM, V235, P754, DOI 10.1111/j.1432-1033.1996.00754.x; ThonyMeyer L, 1997, MICROBIOL MOL BIOL R, V61, P337; THONYMEYER L, 1994, MOL MICROBIOL, V12, P1, DOI 10.1111/j.1365-2958.1994.tb00988.x; ThroneHolst M, 1997, FEBS LETT, V410, P351, DOI 10.1016/S0014-5793(97)00656-X; Tusnady GE, 1998, J MOL BIOL, V283, P489, DOI 10.1006/jmbi.1998.2107; Viswanathan VK, 2002, INFECT IMMUN, V70, P1842, DOI 10.1128/IAI.70.4.1842-1852.2002; Xie ZY, 1998, BBA-BIOENERGETICS, V1365, P309, DOI 10.1016/S0005-2728(98)00085-1; Xie ZY, 1996, J BIOL CHEM, V271, P4632	40	27	28	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52061	52070		10.1074/jbc.M310077200	http://dx.doi.org/10.1074/jbc.M310077200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14532274	hybrid			2022-12-27	WOS:000187480700012
J	Al-Shawi, MK; Polar, MK; Omote, H; Figler, RA				Al-Shawi, MK; Polar, MK; Omote, H; Figler, RA			Transition state analysis of the coupling of drug transport to ATP hydrolysis by P-glycoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; MULTIDRUG-RESISTANCE PROTEIN; NUCLEOTIDE-BINDING DOMAINS; CATALYTIC CYCLE; ABC TRANSPORTERS; ESCHERICHIA-COLI; CYSTIC-FIBROSIS; DIFFERENTIAL IMMUNOREACTIVITY; CONFORMATIONAL-CHANGES; PEPTIDE-BINDING	ATPase activity associated with P-glycoprotein (Pgp) is characterized by three drug-dependent phases: basal (no drug), drug-activated, and drug-inhibited. To understand the communication between drug-binding sites and ATP hydrolytic sites, we performed steady-state thermodynamic analyses of ATP hydrolysis in the presence and absence of transport substrates. We used purified human Pgp (ABCB1, MDR1) expressed in Saccharomyces cerevisiae (Figler, R. A., Omote, H., Nakamoto, R. K., and Al-Shawi, M. K. (2000) Arch. Biochem. Biophys. 376, 34-46) as well as Chinese hamster Pgp (PGP1). Between 23 and 35 degreesC, we obtained linear Arrhenius relationships for the turnover rate of hydrolysis of saturating MgATP in the presence of saturating drug concentrations (k(cat)), from which we calculated the intrinsic enthalpic, entropic, and free energy terms for the rate-limiting transition states. Linearity of the Arrhenius plots indicated that the same rate-limiting step was being measured over the temperature range employed. Using linear free energy analysis, two distinct transition states were found: one associated with uncoupled basal activity and the other with coupled drug transport activity. We concluded that basal ATPase activity associated with Pgp is not a consequence of transport of an endogenous lipid or other endogenous substrates. Rather, it is an intrinsic mechanistic property of the enzyme. We also found that rapidly transported substrates bound tighter to the transition state and required fewer conformational alterations by the enzyme to achieve the coupling transition state. The overall rate-limiting step of Pgp during transport is a carrier reorientation step. Furthermore, Pgp is optimized to transport drugs out of cells at high rates at the expense of coupling efficiency. The drug inhibition phase was associated with low affinity drug-binding sites. These results are consistent with an expanded version of the alternating catalytic site drug transport model (Senior, A. E., Al-Shawi, M. K., and Urbatsch, I. L. (1995) FEBS Lett. 377, 285-289). A new kinetic model of drug transport is presented.	Univ Virginia Hlth Syst, Dept Mol Physiol & Biol Phys, Charlottesville, VA 22908 USA	University of Virginia	Al-Shawi, MK (corresponding author), Univ Virginia Hlth Syst, Dept Mol Physiol & Biol Phys, POB 800736, Charlottesville, VA 22908 USA.		OMOTE, Hiroshi/B-1635-2011		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052502] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM52502] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aleksandrov AA, 2000, J PHYSIOL-LONDON, V528, P259, DOI 10.1111/j.1469-7793.2000.00259.x; Aleksandrov L, 2002, J BIOL CHEM, V277, P15419, DOI 10.1074/jbc.M111713200; AlShawi MK, 1997, J BIOL CHEM, V272, P2300; ALSHAWI MK, 1993, J BIOL CHEM, V268, P4197; ALSHAWI MK, 1988, J BIOL CHEM, V263, P19640; AlShawi MK, 1997, BIOCHEMISTRY-US, V36, P12961, DOI 10.1021/bi971478r; Ambudkar SV, 1999, ANNU REV PHARMACOL, V39, P361, DOI 10.1146/annurev.pharmtox.39.1.361; Autry JM, 1997, J BIOL CHEM, V272, P15872, DOI 10.1074/jbc.272.25.15872; Borgnia MJ, 1996, J BIOL CHEM, V271, P3163, DOI 10.1074/jbc.271.6.3163; BOTTS J, 1953, T FARADAY SOC, V49, P696, DOI 10.1039/tf9534900696; BUDAVARI S, 1996, MERCK INDEX, P1173; Buxbaum E, 1999, EUR J BIOCHEM, V265, P54, DOI 10.1046/j.1432-1327.1999.00643.x; Chang G, 2001, SCIENCE, V293, P1793, DOI 10.1126/science.293.5536.1793; CHOW DC, 1995, J EXP BIOL, V198, P1; Davidson AL, 2002, J BACTERIOL, V184, P1225, DOI 10.1128/JB.184.5.1225-1233.2002; Dey S, 1999, BIOCHEMISTRY-US, V38, P6630, DOI 10.1021/bi983038l; Dey S, 1997, P NATL ACAD SCI USA, V94, P10594, DOI 10.1073/pnas.94.20.10594; DOIGE CA, 1993, BIOCHIM BIOPHYS ACTA, V1146, P65, DOI 10.1016/0005-2736(93)90339-2; Druley TE, 2001, BIOCHEMISTRY-US, V40, P4312, DOI 10.1021/bi001371v; Exner O., 1973, PROG PHYS ORG CHEM, V10, P411; Eytan GD, 1996, J BIOL CHEM, V271, P12897, DOI 10.1074/jbc.271.22.12897; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; Figler RA, 2000, ARCH BIOCHEM BIOPHYS, V376, P34, DOI 10.1006/abbi.2000.1712; Gao M, 2000, J BIOL CHEM, V275, P13098, DOI 10.1074/jbc.275.17.13098; Garrigos M, 1997, EUR J BIOCHEM, V244, P664, DOI 10.1111/j.1432-1033.1997.00664.x; Garrigues A, 2002, MOL PHARMACOL, V62, P1288, DOI 10.1124/mol.62.6.1288; Garrigues A, 2002, P NATL ACAD SCI USA, V99, P10347, DOI 10.1073/pnas.162366399; Gorbulev S, 2001, P NATL ACAD SCI USA, V98, P3732, DOI 10.1073/pnas.061467898; Gottesman MM, 2001, J BIOENERG BIOMEMBR, V33, P453, DOI 10.1023/A:1012866803188; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; Gruol DJ, 2002, MOL PHARMACOL, V62, P1238, DOI 10.1124/mol.62.5.1238; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Holland IB, 1999, J MOL BIOL, V293, P381, DOI 10.1006/jmbi.1999.2993; Hou YX, 2000, J BIOL CHEM, V275, P20280, DOI 10.1074/jbc.M001109200; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; KAPLAN RS, 1985, ANAL BIOCHEM, V150, P97, DOI 10.1016/0003-2697(85)90445-2; Kerr KM, 2001, J BIOL CHEM, V276, P8657, DOI 10.1074/jbc.M010044200; KLINGENBERG M, 1975, CIBA F S, V31, P105; KNOLL W, 1975, Journal of Membrane Biology, V25, P249, DOI 10.1007/BF01868578; Krupka RM, 1999, J MEMBRANE BIOL, V172, P129, DOI 10.1007/s002329900591; Lerner-Marmarosh N, 1999, J BIOL CHEM, V274, P34711, DOI 10.1074/jbc.274.49.34711; Litman T, 1997, BBA-MOL BASIS DIS, V1361, P147, DOI 10.1016/S0925-4439(97)00025-2; Litman T, 1997, BBA-MOL BASIS DIS, V1361, P169, DOI 10.1016/S0925-4439(97)00027-6; Litman T, 1997, BBA-MOL BASIS DIS, V1361, P159, DOI 10.1016/S0925-4439(97)00026-4; Loo TW, 1999, J BIOL CHEM, V274, P35388, DOI 10.1074/jbc.274.50.35388; Loo TW, 1997, J BIOL CHEM, V272, P20986, DOI 10.1074/jbc.272.34.20986; Loo TW, 2002, P NATL ACAD SCI USA, V99, P3511, DOI 10.1073/pnas.022049799; Lu PH, 2001, EUR J BIOCHEM, V268, P1687, DOI 10.1046/j.1432-1033.2001.02041.x; Martin C, 2001, BIOCHEMISTRY-US, V40, P15733, DOI 10.1021/bi011211z; Mechetner EB, 1997, P NATL ACAD SCI USA, V94, P12908, DOI 10.1073/pnas.94.24.12908; Nakamoto RK, 1999, ANNU REV BIOPH BIOM, V28, P205, DOI 10.1146/annurev.biophys.28.1.205; Omote H, 2002, J BIOL CHEM, V277, P45688, DOI 10.1074/jbc.M206479200; OMOTE H, 2003, BIOCHEMISTRY; Orlowski S, 1998, Cancer Biochem Biophys, V16, P85; POST RL, 1965, J BIOL CHEM, V240, P1437; Qu Q, 2003, BIOCHEMISTRY-US, V42, P1345, DOI 10.1021/bi0267745; Qu Q, 2003, BIOCHEMISTRY-US, V42, P1170, DOI 10.1021/bi026555j; Romsicki Y, 1997, BIOCHEMISTRY-US, V36, P9807, DOI 10.1021/bi963120l; Romsicki Y, 1998, EUR J BIOCHEM, V256, P170, DOI 10.1046/j.1432-1327.1998.2560170.x; Romsicki Y, 2001, BIOCHEMISTRY-US, V40, P6937, DOI 10.1021/bi0024456; Rosenberg MF, 2003, J BIOL CHEM, V278, P8294, DOI 10.1074/jbc.M211758200; Rosenberg MF, 2001, EMBO J, V20, P5615, DOI 10.1093/emboj/20.20.5615; Sauna ZE, 2001, J BIOL CHEM, V276, P21199, DOI 10.1074/jbc.M100886200; Sauna ZE, 2001, J BIOL CHEM, V276, P11653, DOI 10.1074/jbc.M011294200; Seelig A, 2000, INT J CLIN PHARM TH, V38, P111; SENIOR AE, 1995, J BIOENERG BIOMEMBR, V27, P31, DOI 10.1007/BF02110328; Senior AE, 1995, FEBS LETT, V377, P285, DOI 10.1016/0014-5793(95)01345-8; Senior AE, 1998, METHOD ENZYMOL, V292, P514; Shapiro AB, 1997, EUR J BIOCHEM, V250, P130, DOI 10.1111/j.1432-1033.1997.00130.x; Shapiro AB, 1999, EUR J BIOCHEM, V259, P841, DOI 10.1046/j.1432-1327.1999.00098.x; Sharom FJ, 1997, J MEMBRANE BIOL, V160, P161, DOI 10.1007/s002329900305; Sharom FJ, 1998, BIOCHEM J, V333, P621, DOI 10.1042/bj3330621; Sonveaux N, 1999, J BIOL CHEM, V274, P17649, DOI 10.1074/jbc.274.25.17649; Urbatsch IL, 2003, J BIOL CHEM, V278, P23171, DOI 10.1074/jbc.M301957200; URBATSCH IL, 1994, BIOCHEMISTRY-US, V33, P7069, DOI 10.1021/bi00189a008; URBATSCH IL, 1995, ARCH BIOCHEM BIOPHYS, V316, P135, DOI 10.1006/abbi.1995.1020; VANVELDHOVEN PP, 1987, ANAL BIOCHEM, V161, P45, DOI 10.1016/0003-2697(87)90649-X; Velazquez-Campoy A, 2000, BIOCHEMISTRY-US, V39, P2201, DOI 10.1021/bi992399d; WATTERSON JG, 1975, EUR J BIOCHEM, V56, P79, DOI 10.1111/j.1432-1033.1975.tb02209.x	79	136	144	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52629	52640		10.1074/jbc.M308175200	http://dx.doi.org/10.1074/jbc.M308175200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14551217	hybrid			2022-12-27	WOS:000187480700081
J	Allen, JWA; Barker, PD; Ferguson, SJ				Allen, JWA; Barker, PD; Ferguson, SJ			A cytochrome b(562) variant with a c-type cytochrome CXXCH heme-binding motif as a probe of the Escherichia coli cytochrome c maturation system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISULFIDE OXIDOREDUCTASES DSBA; DEPENDENT NITRITE REDUCTION; IN-VITRO FORMATION; HYDROGENOBACTER-THERMOPHILUS; RHODOBACTER-CAPSULATUS; BOND FORMATION; CYCA GENE; BIOGENESIS; PROTEIN; EXPRESSION	Cytochrome b(562) is a periplasmic Escherichia coli protein; previous work has shown that heme can be attached covalently in vivo as a consequence of introduction of one or two cysteines into the heme-binding pocket. A heterogeneous mixture of products was obtained, and it was not established whether the covalent bond formation was catalyzed or spontaneous. Here, we show that coexpression from plasmids of a variant of cytochrome b(562) containing a CXXCH heme-binding motif with the E. coli cytochrome c maturation (Ccm) proteins results in an essentially homogeneous product that is a correctly matured c-type cytochrome. Formation of the holocytochrome was accompanied by substantial production of its apo form, in which, for the protein as isolated, there is a disulfide bond between the two cysteines in the CXXCH motif. Following addition of heme to reduced CXXCH apoprotein, spontaneous covalent addition of heme to polypeptide occurred in vitro. Strikingly, the spectral properties were very similar to those of the material obtained from cells in which presumed uncatalyzed addition of heme (i.e. in the absence of Ccm) had been observed. The major product from uncatalyzed heme attachment was an incorrectly matured cytochrome with the heme rotated by 180degrees relative to its normal orientation. The contrast between Ccm-dependent and Ccm-independent covalent attachment of heme indicates that the Ccm apparatus presents heme to the protein only in the orientation that results in formation of the correct product and also that heme does not become covalently attached to the apocytochrome b562 CXXCH variant without being handled by the Ccm system in the periplasm. The CXXCH variant of cytochrome b562 was also expressed in E. coli strains deficient in the periplasmic reductant DsbD or oxidant DsbA. In the DsbA(-) strain under aerobic conditions, c-type cytochromes were made abundantly and correctly when the Ccm proteins were expressed. This contrasts with previous reports indicating that DsbA is essential for cytochrome c biogenesis in E. coli.	Univ Oxford, Dept Biochem, Oxford OX1 3QU, England; Univ Cambridge, Dept Chem, Cambridge CB2 1EW, England; Univ Cambridge, Ctr Prot Engn, Cambridge CB2 1EW, England	University of Oxford; University of Cambridge; University of Cambridge	Ferguson, SJ (corresponding author), Univ Oxford, Dept Biochem, S Parks Rd, Oxford OX1 3QU, England.	stuart.ferguson@bioch.ox.ac.uk			Biotechnology and Biological Sciences Research Council [B19947] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Allen JWA, 2003, BIOCHEM J, V375, P721, DOI 10.1042/BJ20030752; Allen JWA, 2003, PHILOS T ROY SOC B, V358, P255, DOI 10.1098/rstb.2002.1192; Allen JWA, 2002, J BIOL CHEM, V277, P33559, DOI 10.1074/jbc.M204963200; Arnesano F, 1999, BIOCHEMISTRY-US, V38, P8657, DOI 10.1021/bi982785f; Arslan E, 1998, BIOCHEM BIOPH RES CO, V251, P744, DOI 10.1006/bbrc.1998.9549; Bamford VA, 2002, BIOCHEMISTRY-US, V41, P2921, DOI 10.1021/bi015765d; BARDWELL JCA, 1991, CELL, V67, P581, DOI 10.1016/0092-8674(91)90532-4; Barker PD, 1999, STRUCTURE, V7, pR281, DOI 10.1016/S0969-2126(00)88334-3; Barker PD, 2001, EUR J BIOCHEM, V268, P4468, DOI 10.1046/j.1432-1327.2001.02369.x; BARKER PD, 1995, BIOCHEMISTRY-US, V34, P15191, DOI 10.1021/bi00046a027; Barker PD, 1996, BIOCHEMISTRY-US, V35, P13627, DOI 10.1021/bi961128p; Bartsch R. G., 1971, METHODS ENZYMOL, V23, P344, DOI [10.1016/S0076-6879(71)23110-4, DOI 10.1016/S0076-6879(71)23110-4]; Daltrop O, 2003, J BIOL CHEM, V278, P24308, DOI 10.1074/jbc.M301967200; Daltrop O, 2003, J BIOL CHEM, V278, P4404, DOI 10.1074/jbc.M211124200; Daltrop O, 2002, P NATL ACAD SCI USA, V99, P7872, DOI 10.1073/pnas.132259099; Deshmukh M, 2000, MOL MICROBIOL, V35, P123, DOI 10.1046/j.1365-2958.2000.01683.x; Deshmukh M, 2003, J BACTERIOL, V185, P3361, DOI 10.1128/JB.185.11.3361-3372.2003; Fabianek RA, 2000, FEMS MICROBIOL REV, V24, P303, DOI 10.1111/j.1574-6976.2000.tb00544.x; FENG YQ, 1994, NAT STRUCT BIOL, V1, P30, DOI 10.1038/nsb0194-30; HAMADA K, 1995, J MOL BIOL, V247, P947, DOI 10.1006/jmbi.1995.0192; HUSSAIN H, 1994, MOL MICROBIOL, V12, P153, DOI 10.1111/j.1365-2958.1994.tb01004.x; IOBBINIVOL C, 1994, FEMS MICROBIOL LETT, V119, P89, DOI 10.1016/0378-1097(94)90397-2; ITAGAKI E, 1966, J BIOL CHEM, V241, P3687; Karan EF, 2002, J BIOL INORG CHEM, V7, P260, DOI 10.1007/s007750100292; KARIM A, 1993, BIO-TECHNOL, V11, P612, DOI 10.1038/nbt0593-612; Keightley JA, 1998, J BIOL CHEM, V273, P12006, DOI 10.1074/jbc.273.20.12006; Kellogg JA, 2002, BBA-PROTEINS PROTEOM, V1601, P215, DOI 10.1016/S1570-9639(02)00471-5; Kranz R, 1998, MOL MICROBIOL, V29, P383, DOI 10.1046/j.1365-2958.1998.00869.x; MATHEWS FS, 1979, J BIOL CHEM, V254, P1699; McRee DE, 2001, J BIOL CHEM, V276, P6537, DOI 10.1074/jbc.M008421200; METHERINGHAM R, 1995, ARCH MICROBIOL, V164, P301, DOI 10.1007/BF02529965; Metheringham R, 1996, MOL GEN GENET, V253, P95; Moore G. R., 1990, CYTOCHROMES C EVOLUT; MOORE GR, 1982, EUR J BIOCHEM, V123, P73, DOI 10.1111/j.1432-1033.1982.tb06500.x; NICHOLLS DG, 2002, BIOENERGETICS, P140; NIKKILA H, 1991, EUR J BIOCHEM, V202, P309, DOI 10.1111/j.1432-1033.1991.tb16377.x; Page MD, 1998, TRENDS BIOCHEM SCI, V23, P103, DOI 10.1016/S0968-0004(98)01173-6; Pettigrew G.W., 1987, CYTOCHROMES C BIOL A; PETTIGREW GW, 1975, BIOCHEM J, V147, P291, DOI 10.1042/bj1470291; Rai DK, 2003, ANAL CHEM, V75, P1978, DOI 10.1021/ac026228h; Reid E, 2001, BIOCHEM J, V355, P51, DOI 10.1042/0264-6021:3550051; Rice JK, 1999, BIOCHEMISTRY-US, V38, P16847, DOI 10.1021/bi990880y; RIDDLES PW, 1983, METHOD ENZYMOL, V91, P49; SAMBONGI Y, 1994, FEBS LETT, V340, P65, DOI 10.1016/0014-5793(94)80174-6; SAMBONGI Y, 1994, FEBS LETT, V353, P235, DOI 10.1016/0014-5793(94)01053-6; SAMBONGI Y, 1994, FEBS LETT, V344, P207, DOI 10.1016/0014-5793(94)00399-8; Sambongi Y, 1996, FEBS LETT, V398, P265, DOI 10.1016/S0014-5793(96)01256-2; Sanders C, 2000, BBA-BIOENERGETICS, V1459, P131, DOI 10.1016/S0005-2728(00)00122-5; Spielewoy N, 2001, J BIOL CHEM, V276, P5491, DOI 10.1074/jbc.M008853200; Thony-Meyer L, 2000, BBA-BIOENERGETICS, V1459, P316, DOI 10.1016/S0005-2728(00)00167-5; THONYMEYER L, 1995, J BACTERIOL, V177, P4321; Tomlinson EJ, 2000, P NATL ACAD SCI USA, V97, P5156, DOI 10.1073/pnas.090089397; WU JZ, 1991, BIOCHEMISTRY-US, V30, P2156, DOI 10.1021/bi00222a020	53	50	53	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52075	52083		10.1074/jbc.M307196200	http://dx.doi.org/10.1074/jbc.M307196200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14534316	hybrid			2022-12-27	WOS:000187480700014
J	Gobel, C; Feussner, I; Rosahl, S				Gobel, C; Feussner, I; Rosahl, S			Lipid peroxidation during the hypersensitive response in potato in the absence of 9-lipoxygenases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; INDUCE APOPTOSIS; LIPOXYGENASE; EXPRESSION; PLANTS; LEAVES; ACID; TOBACCO; HYDROPEROXIDES; PROTOPLASTS	Hypersensitive cell death is an important defense reaction of plants to pathogen infection and is accompanied by lipid peroxidation processes. These may occur non-enzymatically by the action of reactive oxygen species or may be catalyzed by enzymes such as alpha-dioxygenases, lipoxygenases, or peroxidases. Correlative data showing increases in 9-lipoxygenase products in hypersensitively reacting cells have so far suggested that a large part of lipid peroxidation is mediated by a specific set of 9-lipoxygenases. To address the significance of 9-lipoxygenases for this type of pathogen response in potato, RNA interference constructs of a specific pathogen-induced potato 9-lipoxygenase were transferred to potato plants. Significantly reduced 9-lipoxygenase transcript levels were observed in transgenic plants after pathogen treatment. In addition, 9-lipoxygenase activity was hardly detectable, and levels of 9-lipoxygenase-derived oxylipins were reduced up to 12-fold after pathogen infection. In contrast to wild type plants, high levels of non-enzymatically as well as 13-lipoxygenase-derived oxylipins were present in 9-lipoxygenase-deficient plants. From this we conclude that during the normal hypersensitive response in potato, lipid peroxidation may occur as a controlled and directed process that is facilitated by the action of a specific 9-lipoxygenase. If 9-lipoxygenase-mediated formation of hydroperoxides is repressed, autoxidative lipid peroxidation processes and 13-lipoxygenase-mediated oxylipins synthesis become prominent. The unaltered timing and extent of necrosis formation suggests that the origin of lipid hydroperoxides does not influence pathogen-induced cell death in potato.	Inst Plant Biochem, Dept Stress & Dev Biol, D-06120 Halle Saale, Germany; Univ Gottingen, Albert von Haller Inst Plant Sci, Dept Plant Biochem, D-37077 Gottingen, Germany	Leibniz Institut fur Pflanzenbiochemie; University of Gottingen	Rosahl, S (corresponding author), Inst Plant Biochem, Dept Stress & Dev Biol, Weinberg 3, D-06120 Halle Saale, Germany.		Feussner, Ivo/H-9320-2013	Feussner, Ivo/0000-0002-9888-7003				Berger S, 2001, BBA-MOL CELL BIOL L, V1533, P266, DOI 10.1016/S1388-1981(01)00161-5; COHEN Y, 1993, PHYTOPATHOLOGY, V83, P1054, DOI 10.1094/Phyto-83-1054; FELTKAMP D, 1995, PLANT SCI, V109, P57, DOI 10.1016/0168-9452(95)04154-M; Feussner I, 2002, ANNU REV PLANT BIOL, V53, P275, DOI 10.1146/annurev.arplant.53.100301.135248; FEUSSNER I, 1995, P NATL ACAD SCI USA, V92, P11849, DOI 10.1073/pnas.92.25.11849; Fidantsef AL, 1998, PHYSIOL PLANTARUM, V102, P257, DOI 10.1034/j.1399-3054.1998.1020214.x; GATZ C, 1992, PLANT J, V2, P397, DOI 10.1046/j.1365-313X.1992.t01-37-00999.x; GEERTS A, 1994, PLANT PHYSIOL, V105, P269, DOI 10.1104/pp.105.1.269; Gobel C, 2002, BBA-MOL CELL BIOL L, V1584, P55, DOI 10.1016/S1388-1981(02)00268-8; Gobel C, 2001, J BIOL CHEM, V276, P6267, DOI 10.1074/jbc.M008606200; Heath MC, 2000, PLANT MOL BIOL, V44, P321, DOI 10.1023/A:1026592509060; Jalloul A, 2002, PLANT J, V32, P1, DOI 10.1046/j.1365-313X.2002.01393.x; KNIGHT V, 1995, PLANT PHYSIOL, V108, P101; Knight VI, 2001, PHYSIOL MOL PLANT P, V59, P277, DOI 10.1006/pmpp.2001.0366; KOCH E, 1990, PLANT CELL, V2, P437, DOI 10.1105/tpc.2.5.437; Kolomiets MV, 2000, PLANT PHYSIOL, V124, P1121, DOI 10.1104/pp.124.3.1121; Leon J, 2001, J EXP BOT, V52, P1, DOI 10.1093/jexbot/52.354.1; MACCARRONE M, 1995, BBA-LIPID LIPID MET, V1259, P1, DOI 10.1016/0005-2760(95)00153-4; Maccarrone M, 2000, EUR J BIOCHEM, V267, P5078, DOI 10.1046/j.1432-1327.2000.01564.x; Maccarrone M, 2001, CELL DEATH DIFFER, V8, P776, DOI 10.1038/sj.cdd.4400908; OHTA H, 1990, PLANT CELL PHYSIOL, V31, P1117; Rance I, 1998, P NATL ACAD SCI USA, V95, P6554, DOI 10.1073/pnas.95.11.6554; RICKER KE, 1994, PHYSIOL MOL PLANT P, V44, P65, DOI 10.1016/S0885-5765(05)80095-5; Rosahl S, 1996, Z NATURFORSCH C, V51, P123; Royo J, 1996, J BIOL CHEM, V271, P21012, DOI 10.1074/jbc.271.35.21012; Rusterucci C, 1999, J BIOL CHEM, V274, P36446, DOI 10.1074/jbc.274.51.36446; Rusterucci C, 1996, PLANT PHYSIOL, V111, P885, DOI 10.1104/pp.111.3.885; SANDSTROM PA, 1994, J BIOL CHEM, V269, P798; SANDSTROM PA, 1995, FEBS LETT, V365, P66, DOI 10.1016/0014-5793(95)00443-D; Schnurr K, 1996, FREE RADICAL BIO MED, V20, P11, DOI 10.1016/0891-5849(95)02012-8; Shureiqi I, 2003, P NATL ACAD SCI USA, V100, P9968, DOI 10.1073/pnas.1631086100; ThordalChristensen H, 1997, PLANT J, V11, P1187, DOI 10.1046/j.1365-313X.1997.11061187.x; van Leyen K, 1998, NATURE, V395, P392, DOI 10.1038/26500; Veronesi C, 1996, PLANT PHYSIOL, V112, P997, DOI 10.1104/pp.112.3.997; Viehweger K, 2002, PLANT CELL, V14, P1509, DOI 10.1105/tpc.002329; Wasternack C, 2002, PROG NUCLEIC ACID RE, V72, P165, DOI 10.1016/S0079-6603(02)72070-9; Weber H, 1999, PLANT CELL, V11, P485, DOI 10.1105/tpc.11.3.485; Weichert H, 1999, FEBS LETT, V464, P133, DOI 10.1016/S0014-5793(99)01697-X	38	90	96	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52834	52840		10.1074/jbc.M310833200	http://dx.doi.org/10.1074/jbc.M310833200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14551198	hybrid			2022-12-27	WOS:000187480700103
J	Jung, YW; Lippard, SJ				Jung, YW; Lippard, SJ			Multiple states of stalled T7 RNA polymerase at DNA lesions generated by platinum anticancer agents	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRINSIC TRANSCRIPT CLEAVAGE; NUCLEOTIDE EXCISION-REPAIR; CISPLATIN ADDUCTS; II TRANSCRIPTION; CROSS-LINKS; ELONGATION; COMPLEXES; BINDING; RECOGNITION; DIMER	Transcription inhibition by DNA adducts of cisplatin is considered to be one of the major routes by which this anticancer drug kills cancer cells. Stalled RNA polymerases at platinum-DNA lesions evoke various cellular responses such as nucleotide excision repair, polymerase degradation, and apoptosis. T7 RNA polymerase and site-specifically platinated DNA templates immobilized on a solid support were used to study stalled transcription elongation complexes. In vitro transcription studies were performed in both a promoter-dependent and - independent manner. An elongation complex is strongly blocked by cisplatin 1,2-intrastrand d(GpG) and 1,3-intrastrand d( GpTpG) cross-links located on the template strand. Polymerase action is inhibited at multiple sites in the vicinity of the platinum lesion, the nature of which can be altered by the choice and concentration of NTPs. The {(1R, 2R-diaminocyclohexane) Pt}(2+) DNA adducts formed by oxaliplatin, which carries a stereochemically more demanding spectator ligand than the ammine groups in cisplatin, also strongly block the polymerase with measurable differences compared with cis-{(NH3)(2)Pt}(2+) lesions. Elongation complexes stopped at sites of platinum damage were isolated and characterized. The stalled polymerase can be dissociated from the DNA by subsequent polymerases initiated from the same template. We also discovered that a polymerase stalled at the platinum-DNA lesion can resume transcription after the platinum adduct is chemically removed from the template.	MIT, Dept Chem, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Lippard, SJ (corresponding author), MIT, Dept Chem, Cambridge, MA 02139 USA.	lippard@lippard.mit.edu	Jung, Yongwon/G-7634-2012		NATIONAL CANCER INSTITUTE [R01CA034992, R37CA034992] Funding Source: NIH RePORTER; NCI NIH HHS [CA 34992] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAUER W, 1978, BIOCHEMISTRY-US, V17, P1060, DOI 10.1021/bi00599a019; Cline SD, 2003, NAT REV MOL CELL BIO, V4, P361, DOI 10.1038/nrm1101; CORDA Y, 1991, BIOCHEMISTRY-US, V30, P222, DOI 10.1021/bi00215a032; Cullinane C, 1999, BIOCHEMISTRY-US, V38, P6204, DOI 10.1021/bi982685+; Dundr M, 2002, SCIENCE, V298, P1623, DOI 10.1126/science.1076164; Epshtein V, 2003, EMBO J, V22, P4719, DOI 10.1093/emboj/cdg452; Epshtein V, 2003, SCIENCE, V300, P801, DOI 10.1126/science.1083219; Erie DA, 2002, BBA-GENE STRUCT EXPR, V1577, P224, DOI 10.1016/S0167-4781(02)00454-2; Foster JE, 2001, CELL, V106, P243, DOI 10.1016/S0092-8674(01)00420-2; Hara R, 1999, J BIOL CHEM, V274, P24779, DOI 10.1074/jbc.274.35.24779; He B, 1997, PROTEIN EXPRES PURIF, V9, P142, DOI 10.1006/prep.1996.0663; Hoogstraten D, 2002, MOL CELL, V10, P1163, DOI 10.1016/S1097-2765(02)00709-8; Jamieson ER, 1999, CHEM REV, V99, P2467, DOI 10.1021/cr980421n; Jordan P, 1998, NUCLEIC ACIDS RES, V26, P2831, DOI 10.1093/nar/26.12.2831; Kartalou M, 2001, MUTAT RES-FUND MOL M, V478, P1, DOI 10.1016/s0027-5107(01)00142-7; Kimura H, 2002, J CELL BIOL, V159, P777, DOI 10.1083/jcb.200206019; Kireeva ML, 2002, MOL CELL, V9, P541, DOI 10.1016/S1097-2765(02)00472-0; Lee KB, 2002, P NATL ACAD SCI USA, V99, P4239, DOI 10.1073/pnas.072068399; LEMAIRE MA, 1991, P NATL ACAD SCI USA, V88, P1982, DOI 10.1073/pnas.88.5.1982; LIPPARD SJ, 1983, BIOCHEMISTRY-US, V22, P5165, DOI 10.1021/bi00291a016; MELLO JA, 1995, BIOCHEMISTRY-US, V34, P14783, DOI 10.1021/bi00045a020; ORLOVA M, 1995, P NATL ACAD SCI USA, V92, P4596, DOI 10.1073/pnas.92.10.4596; Park JS, 2002, CELL, V109, P757, DOI 10.1016/S0092-8674(02)00769-9; Perlow RA, 2002, J MOL BIOL, V321, P29, DOI 10.1016/S0022-2836(02)00593-4; Sastry SS, 1997, J BIOL CHEM, V272, P8644, DOI 10.1074/jbc.272.13.8644; Selby CP, 1997, NUCLEIC ACIDS RES, V25, P787, DOI 10.1093/nar/25.4.787; SELBY CP, 1993, SCIENCE, V260, P53, DOI 10.1126/science.8465200; SELBY CP, 1990, J BIOL CHEM, V265, P21330; SHI YB, 1987, NUCLEIC ACIDS RES, V15, P6843, DOI 10.1093/nar/15.17.6843; SHI YB, 1988, J MOL BIOL, V199, P277, DOI 10.1016/0022-2836(88)90314-2; Svejstrup JQ, 2003, J CELL SCI, V116, P447, DOI 10.1242/jcs.00271; Tahirov TH, 2002, NATURE, V420, P43, DOI 10.1038/nature01129; TAKAHARA PM, 1995, NATURE, V377, P649, DOI 10.1038/377649a0; Temiakov D, 2002, J BIOL CHEM, V277, P47035, DOI 10.1074/jbc.M208923200; Tornaletti S, 2001, J BIOL CHEM, V276, P45367, DOI 10.1074/jbc.M105282200; Tornaletti S, 2003, J BIOL CHEM, V278, P35791, DOI 10.1074/jbc.M305394200; Tornaletti S, 1999, J BIOL CHEM, V274, P24124, DOI 10.1074/jbc.274.34.24124; van den Boom V, 2002, BIOESSAYS, V24, P780, DOI 10.1002/bies.10150; VANGARDEREN CJ, 1994, EUR J BIOCHEM, V225, P1169; von Hippel PH, 2002, BIOPHYS CHEM, V101, P401, DOI 10.1016/S0301-4622(02)00160-6; Wang D, 2003, BIOCHEMISTRY-US, V42, P6747, DOI 10.1021/bi034264k; Wei M, 2001, J BIOL CHEM, V276, P38774, DOI 10.1074/jbc.M106374200; Weilbaecher RG, 2003, J BIOL CHEM, V278, P24189, DOI 10.1074/jbc.M211197200; WHITEHALL SK, 1994, J BIOL CHEM, V269, P2299; Yang LY, 2003, ONCOL REP, V10, P1489; Yin YW, 2002, SCIENCE, V298, P1387, DOI 10.1126/science.1077464; ZAMBLE DB, 1999, 30 YEARS CISPLATIN C, P73; Zlatanova J, 1998, FASEB J, V12, P791, DOI 10.1096/fasebj.12.10.791	48	27	28	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52084	52092		10.1074/jbc.M310120200	http://dx.doi.org/10.1074/jbc.M310120200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14534300	hybrid			2022-12-27	WOS:000187480700015
J	Viswanathan, P; Venkaiah, B; Kumar, MS; Rasheedi, S; Vrati, S; Bashyam, MD; Hasnain, SE				Viswanathan, P; Venkaiah, B; Kumar, MS; Rasheedi, S; Vrati, S; Bashyam, MD; Hasnain, SE			The homologous region sequence (hr1) of Autographa californica multinucleocapsid polyhedrosis virus can enhance transcription from non-baculoviral promoters in mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							30-KDA PROTEIN-BINDING; GENE-EXPRESSION; HOST FACTOR; RECOMBINANT BACULOVIRUSES; DNA; ELEMENTS; VECTORS; INSECT; SV40; INITIATOR	The Autographa californica multinucleocapsid polyhedrosis virus homologous region sequence hr1 enhances transcription from the viral polyhedrin promoter in Spodoptera frugiperda insect cells and independently functions as an origin of replication (ori) sequence. The binding of the host nuclear protein, hr1-binding protein (hr1-BP), is crucial for the enhancer activity (Habib, S., Pandey, S., Chatterji, U., Burma, S., Ahmad, R., Jain, A., and Hasnain, S. E. (1996) DNA Cell Biol. 15, 737-747 and Habib, S., and Hasnain, S. E. (1996) J. Biol. Chem. 271, 28250-28258). We demonstrate that hr1 can also enhance transcription from non-baculoviral promoters like cytomegalovirus and hsp70 in mammalian cells but does not support ori activity in these cells. Unlike insect cells, hr1 can also function in mammalian cells as an enhancer when present in trans. hr1 DNA sequence binds with high affinity and specificity to nuclear factors in the mammalian cells. The insect hr1-BP- and the hr1-BP-like proteins from mammalian cells (mhr1-BP) have different properties with respect to ion requirements, DNA groove binding, and molecular size. When mammalian cells are infected with a recombinant baculovirus containing two promoters, the baculovirus polyhedrin and Drosophila hsp70 gene promoter, the hsp70 gene promoter alone is active in these cells, and this activity is further enhanced by the presence of an additional hr1 in the recombinant virus. hr1 may thus also have a role in baculovirus-mediated gene delivery in mammalian cells.	Ctr DNA Fingerprinting & Diagnost, Cellular & Mol Biol Lab, Hyderabad 500076, Andhra Pradesh, India; Natl Inst Immunol, New Delhi 110067, India; Jawaharlal Nehru Ctr Adv Sci Res, Bangalore 560064, Karnataka, India	Department of Biotechnology (DBT) India; Centre for DNA Fingerprinting & Diagnostics (CDFD); Department of Biotechnology (DBT) India; National Institute of Immunology (NII); Department of Science & Technology (India); Jawaharlal Nehru Center for Advanced Scientific Research (JNCASR)	Hasnain, SE (corresponding author), Ctr DNA Fingerprinting & Diagnost, Cellular & Mol Biol Lab, Hyderabad 500076, Andhra Pradesh, India.		HASNAIN, SEYED/C-1492-2009	Hasnain, Seyed/0000-0002-2967-0791; Murugapiran, Senthil/0000-0002-6952-4713				AYERS MD, 1994, VIROLOGY, V202, P586; BANERJI J, 1981, CELL, V27, P299, DOI 10.1016/0092-8674(81)90413-X; BOWERS WJ, 1992, J VIROL, V66, P6578, DOI 10.1128/JVI.66.11.6578-6586.1992; Boyce FM, 1996, P NATL ACAD SCI USA, V93, P2348, DOI 10.1073/pnas.93.6.2348; BURMA S, 1994, J BIOL CHEM, V269, P2750; CARSON DD, 1991, J VIROL, V65, P945, DOI 10.1128/JVI.65.2.945-951.1991; Chatterji U, 1996, GENE, V171, P209, DOI 10.1016/0378-1119(96)00188-6; Chen JL, 2002, P NATL ACAD SCI USA, V99, P3723, DOI 10.1073/pnas.062447999; Condreay JP, 1999, P NATL ACAD SCI USA, V96, P127, DOI 10.1073/pnas.96.1.127; DEVILLIERS J, 1982, NUCLEIC ACIDS RES, V10, P7965, DOI 10.1093/nar/10.24.7965; DUNAWAY M, 1989, NATURE, V341, P657, DOI 10.1038/341657a0; Ghosh S, 2002, MOL THER, V6, P5, DOI 10.1006/mthe.2000.0643; Ghosh S, 1998, J VIROL, V72, P7484, DOI 10.1128/JVI.72.9.7484-7493.1998; GUARINO LA, 1986, J VIROL, V60, P224, DOI 10.1128/JVI.60.1.224-229.1986; GUARINO LA, 1986, J VIROL, V60, P215, DOI 10.1128/JVI.60.1.215-223.1986; Habib S, 1996, J BIOL CHEM, V271, P28250, DOI 10.1074/jbc.271.45.28250; Habib S, 1996, DNA CELL BIOL, V15, P737, DOI 10.1089/dna.1996.15.737; Habib S, 2000, J VIROL, V74, P5182, DOI 10.1128/JVI.74.11.5182-5189.2000; Hasnain SE, 1997, GENE, V190, P113, DOI 10.1016/S0378-1119(96)00827-X; Hasnain SE, 1996, METHOD ENZYMOL, V274, P20; HASNAIN SE, 1999, Patent No. 5965393; HOFMANN C, 1995, P NATL ACAD SCI USA, V92, P10099, DOI 10.1073/pnas.92.22.10099; Huser Andreas, 2003, Am J Pharmacogenomics, V3, P53; Jain A, 1996, EUR J BIOCHEM, V239, P384, DOI 10.1111/j.1432-1033.1996.0384u.x; Jarvis DL, 2003, VIROLOGY, V310, P1, DOI 10.1016/S0042-6822(03)00120-X; KNEBEL D, 1987, VIRUS RES, V4, P317; Kost TA, 1999, CURR OPIN BIOTECH, V10, P428, DOI 10.1016/S0958-1669(99)00005-1; Kost TA, 2002, TRENDS BIOTECHNOL, V20, P173, DOI 10.1016/S0167-7799(01)01911-4; LAIMINS LA, 1982, P NATL ACAD SCI-BIOL, V79, P6453, DOI 10.1073/pnas.79.21.6453; Lo HR, 2002, J BIOL CHEM, V277, P5256, DOI 10.1074/jbc.M108895200; MOREAU P, 1981, NUCLEIC ACIDS RES, V9, P6047, DOI 10.1093/nar/9.22.6047; Morris JR, 1998, P NATL ACAD SCI USA, V95, P10740, DOI 10.1073/pnas.95.18.10740; MUKHERJEE B, 1995, J BIOL CHEM, V270, P4405, DOI 10.1074/jbc.270.9.4405; Ramachandran A, 2001, CURR SCI INDIA, V81, P998; Ramachandran A, 2001, J BIOL CHEM, V276, P23440, DOI 10.1074/jbc.M101537200; Rasmussen C, 1996, VIROLOGY, V224, P235, DOI 10.1006/viro.1996.0525	36	37	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52564	52571		10.1074/jbc.M309351200	http://dx.doi.org/10.1074/jbc.M309351200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14570875	hybrid			2022-12-27	WOS:000187480700074
J	Mould, AP; Barton, SJ; Askari, JA; Craig, SE; Humphries, MJ				Mould, AP; Barton, SJ; Askari, JA; Craig, SE; Humphries, MJ			Role of ADMIDAS cation-binding site in ligand recognition by integrin alpha(5)beta(1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I-DOMAIN; A-DOMAIN; EXTRACELLULAR SEGMENT; MONOCLONAL-ANTIBODY; CRYSTAL-STRUCTURE; BETA(2) SUBUNIT; ACTIVATION; MECHANISM; SEQUENCE; CA2+	Integrin-ligand interactions are regulated in a complex manner by divalent cations, and multiple cation-binding sites are found in both alpha and beta integrin subunits. A key cation-binding site that lies in the beta subunit A-domain is known as the metal-ion dependent adhesion site (MIDAS). Recent x-ray crystal structures of integrin alpha(V)beta(3) have identified a novel cation binding site in this domain, known as the ADMIDAS (adjacent to MIDAS). The role of this novel site in ligand recognition has yet to be elucidated. Using the interaction between alpha(5)beta(1) and fibronectin as a model system, we show that mutation of residues that form the ADMIDAS site inhibits ligand binding but this effect can be partially rescued by the use of activating monoclonal antibodies. The ADMIDAS mutants had decreased expression of activation epitopes recognized by 12G10, 15/7, and HUTS-4, suggesting that the ADMIDAS is important for stabilizing the active conformation of the integrin. Consistent with this suggestion, the ADMIDAS mutations markedly increased the dissociation rate of the integrin-fibronectin complex. Mutation of the ADMIDAS residues also reduced the allosteric inhibition of Mn2+-supported ligand binding by Ca2+, suggesting that the ADMIDAS is a Ca2+-binding site involved in the inhibition of Mn2+-supported ligand binding. Mutations of the ADMIDAS site also perturbed transduction of a conformational change from the MIDAS through the C-terminal helix region of the betaA domain to the underlying hybrid domain, implying an important role for this site in receptor signaling.	Univ Manchester, Sch Biol Sci, Wellcome Trust Ctr Cell Matrix Res, Manchester M13 9PT, Lancs, England	University of Manchester	Mould, AP (corresponding author), Univ Manchester, Sch Biol Sci, Wellcome Trust Ctr Cell Matrix Res, 2-205 Stopford Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.			Humphries, Martin/0000-0002-4331-6967; Mould, Paul/0000-0003-0076-6228				BAJT ML, 1994, J BIOL CHEM, V269, P20913; BELGOVA N, 2002, NAT STRUCT BIOL, V9, P282; Brower DL, 1997, P NATL ACAD SCI USA, V94, P9182, DOI 10.1073/pnas.94.17.9182; Burrows L, 1999, BIOCHEM J, V344, P527, DOI 10.1042/0264-6021:3440527; Chen LL, 1999, J BIOL CHEM, V274, P13167, DOI 10.1074/jbc.274.19.13167; Chen LL, 2001, J BIOL CHEM, V276, P36520, DOI 10.1074/jbc.M106216200; Chigaev A, 2001, J BIOL CHEM, V276, P48670, DOI 10.1074/jbc.M103194200; Coe APF, 2001, J BIOL CHEM, V276, P35854, DOI 10.1074/jbc.M103639200; DRANSFIELD I, 1992, J CELL BIOL, V116, P219, DOI 10.1083/jcb.116.1.219; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Hu DD, 1996, J BIOL CHEM, V271, P21745, DOI 10.1074/jbc.271.36.21745; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Kamata T, 2002, J IMMUNOL, V168, P2296, DOI 10.4049/jimmunol.168.5.2296; Labadia ME, 1998, J IMMUNOL, V161, P836; Lee JO, 1995, STRUCTURE, V3, P1333, DOI 10.1016/S0969-2126(01)00271-4; Liddington RC, 2002, J CELL BIOL, V158, P833, DOI 10.1083/jcb.200206011; MOULD AP, 1995, J BIOL CHEM, V270, P26270, DOI 10.1074/jbc.270.44.26270; Mould AP, 2003, J BIOL CHEM, V278, P17028, DOI 10.1074/jbc.M213139200; Mould AP, 2002, J BIOL CHEM, V277, P19800, DOI 10.1074/jbc.M201571200; Mould AP, 1997, J BIOL CHEM, V272, P17283, DOI 10.1074/jbc.272.28.17283; MOULD AP, 1995, FEBS LETT, V363, P118, DOI 10.1016/0014-5793(95)00301-O; Ridgway JBB, 1996, PROTEIN ENG, V9, P617, DOI 10.1093/protein/9.7.617; SMITH JW, 1994, J BIOL CHEM, V269, P960; Springer TA, 2000, CELL, V102, P275, DOI 10.1016/S0092-8674(00)00033-7; Takagi J, 2002, CELL, V110, P599, DOI 10.1016/S0092-8674(02)00935-2; Takagi J, 2003, EMBO J, V22, P4607, DOI 10.1093/emboj/cdg445; Takagi J, 2002, IMMUNOL REV, V186, P141, DOI 10.1034/j.1600-065X.2002.18613.x; Vinogradova O, 2002, CELL, V110, P587, DOI 10.1016/S0092-8674(02)00906-6; Whittaker CA, 2002, MOL BIOL CELL, V13, P3369, DOI 10.1091/mbc.E02-05-0259; Xiong JP, 2001, SCIENCE, V294, P339, DOI 10.1126/science.1064535; Xiong JP, 2002, SCIENCE, V296, P151, DOI 10.1126/science.1069040; Xiong YM, 2001, J BIOL CHEM, V276, P19340, DOI 10.1074/jbc.M008903200	32	77	79	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51622	51629		10.1074/jbc.M306655200	http://dx.doi.org/10.1074/jbc.M306655200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14532288	hybrid			2022-12-27	WOS:000187206300096
J	Becker, L; Cook, PM; Wright, TG; Koschinsky, ML				Becker, L; Cook, PM; Wright, TG; Koschinsky, ML			Quantitative evaluation of the contribution of weak lysine-binding sites present within apolipoprotein(a) kringle IV types 6-8 to lipoprotein(a) assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONCOVALENT ASSOCIATION; IDENTIFICATION; PLASMINOGEN; MUTAGENESIS; SEQUENCES; MEDIATE; RESIDUE; TYPE-7; APO(A); LP(A)	During lipoprotein(a) (Lp(a)) assembly, non-covalent interactions between apolipoprotein(a) (apo(a)) and low density lipoprotein precede specific disulfide bond formation. Studies have shown that the non-covalent step involves an interaction between the weak lysine-binding sites (WLBS) present within each of apo(a) kringle IV types 6, 7, and 8 (KIV6-8), and two lysine residues (Lys(680) and Lys(690)) within the NH2 terminus of the apolipoprotein B-100 (apoB) component of low density lipoprotein. In the present study, we introduced single point mutations (E56G) into each of the WLBS present in apo(a) KIV6-8 and expressed these mutations in the context of a 17-kringle (17K) recombinant apo(a) variant. Single mutations that disrupt the WLBS in KIV6, KIV7, and KIV8, as well as mutants that disrupt the WLBS in both KIV6 and KIV7, or both KIV7 and KIV8, were assessed for their ability to form non-covalent and covalent Lp(a) complexes. Our results demonstrate that both apo(a) KIV7 and KIV8, but not KIV6, are required for maximally efficient non-covalent and covalent Lp(a) assembly. Single mutations in the WLBS of KIV7 or KIV8 resulted in a 3-fold decrease in the affinity of 17K recombinant apo(a) for apoB, and a 20% reduction in the rate of covalent Lp(a) formation. Tandem mutations in the WLBS in both KIV7 and KIV8 resulted in a 13-fold reduction in the binding affinity between apo(a) and apoB, and a 75% reduction in the rate of the covalent step of Lp(a) formation. We also showed that KIV7 and KIV8 specifically bind with high affinity to apoB-derived peptides containing Lys690 or Lys680, respectively. Taken together, our data demonstrate that specific interactions between apo(a) KIV7 and KIV8 and Lys680 and Lys690 in apoB mediate a high affinity non-covalent interaction between apo(a) and low density lipoprotein, which dictates the efficiency of covalent Lp(a) formation.	Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada	Queens University - Canada	Koschinsky, ML (corresponding author), Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada.	mk11@post.queensu.ca		Koschinsky, Marlys/0000-0002-2643-2288				Becker L, 2003, J BIOL CHEM, V278, P14074, DOI 10.1074/jbc.M212855200; Becker L, 2001, J BIOL CHEM, V276, P36155, DOI 10.1074/jbc.M104789200; BRUNNER C, 1993, P NATL ACAD SCI USA, V90, P11643, DOI 10.1073/pnas.90.24.11643; CALLOW MJ, 1995, J BIOL CHEM, V270, P23914, DOI 10.1074/jbc.270.41.23914; ERNST A, 1995, J BIOL CHEM, V270, P6227, DOI 10.1074/jbc.270.11.6227; FODOR SPA, 1989, J AM CHEM SOC, V111, P5509, DOI 10.1021/ja00197a001; FRANK S, 1995, ARTERIOSCL THROM VAS, V15, P1774, DOI 10.1161/01.ATV.15.10.1774; FRANK S, 1994, BIOCHEM J, V304, P27, DOI 10.1042/bj3040027; Gabel BR, 1998, ARTERIOSCL THROM VAS, V18, P1738, DOI 10.1161/01.ATV.18.11.1738; Gabel BR, 1996, ARTERIOSCL THROM VAS, V16, P1559, DOI 10.1161/01.ATV.16.12.1559; Gabel BR, 1998, BIOCHEMISTRY-US, V37, P7892, DOI 10.1021/bi973186w; KOSCHINSKY ML, 1991, BIOCHEMISTRY-US, V30, P5044, DOI 10.1021/bi00234a029; KOSCHINSKY ML, 1993, J BIOL CHEM, V268, P19819; LACKNER C, 1993, HUM MOL GENET, V2, P933, DOI 10.1093/hmg/2.7.933; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Maderegger B, 2002, BIOCHEMISTRY-US, V41, P660, DOI 10.1021/bi011430k; Marcovina S M, 1999, Curr Cardiol Rep, V1, P105, DOI 10.1007/s11886-999-0067-z; Marcovina Santica M, 2002, Semin Vasc Med, V2, P335, DOI 10.1055/s-2002-35404; McCormick SPA, 1997, J BIOL CHEM, V272, P23616, DOI 10.1074/jbc.272.38.23616; MCCORMICK SPA, 1995, P NATL ACAD SCI USA, V92, P10147, DOI 10.1073/pnas.92.22.10147; MCLEAN JW, 1987, NATURE, V330, P132, DOI 10.1038/330132a0; Rahman MN, 2002, BIOCHEMISTRY-US, V41, P1149, DOI 10.1021/bi010964i; Sangrar W, 1997, BIOCHEMISTRY-US, V36, P10353, DOI 10.1021/bi962433d; Sharp RJ, 2003, ARTERIOSCL THROM VAS, V23, P502, DOI 10.1161/01.ATV.0000055741.13940.15; TRIEU VN, 1995, J BIOL CHEM, V270, P15471, DOI 10.1074/jbc.270.26.15471; Trieu VN, 1998, BIOCHEM BIOPH RES CO, V251, P356, DOI 10.1006/bbrc.1998.9478; VANDERHOEK YY, 1993, HUM MOL GENET, V2, P361, DOI 10.1093/hmg/2.4.361; Ye QL, 2001, PROTEIN SCI, V10, P1124, DOI 10.1110/ps.01701	28	26	30	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	2004	279	4					2679	2688		10.1074/jbc.M309414200	http://dx.doi.org/10.1074/jbc.M309414200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	764MU	14581473	hybrid			2022-12-27	WOS:000188211300044
J	Okuwaki, M; Verreault, A				Okuwaki, M; Verreault, A			Maintenance DNA methylation of nucleosome core particles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT HUMAN DNA; BASE EXCISION-REPAIR; MOUSE H19 GENE; CYTOSINE-5 METHYLTRANSFERASES; CHROMATIN STRUCTURE; MAMMALIAN NUCLEI; HISTONE OCTAMER; CPG ISLANDS; DE-NOVO; REPLICATION	The enzyme responsible for maintenance methylation of CpG dinucleotides in vertebrates is DNMT1. The presence of DNMT1 in DNA replication foci raises the issue of whether this enzyme needs to gain access to nascent DNA before its packaging into nucleosomes, which occurs very rapidly behind the replication fork. Using nucleosomes positioned along the 5 S rRNA gene, we find that DNMT1 is able to methylate a number of CpG sites even when the DNA major groove is oriented toward the histone surface. However, we also find that the ability of DNMT1 to methylate nucleosomal sites is highly dependent on the nature of the DNA substrate. Although nucleosomes containing the Air promoter are refractory to methylation irrespective of target cytosine location, nucleosomes reconstituted onto the H19 imprinting control region are more accessible. These results argue that although DNMT1 is intrinsically capable of methylating some DNA sequences even after their packaging into nucleosomes, this is not the case for at least a fraction of DNA sequences whose function is regulated by DNA methylation.	Canc Res UK, Clare Hall Labs, London Res Inst, S Mimms EN6 3LD, Herts, England	Cancer Research UK	Verreault, A (corresponding author), Canc Res UK, Clare Hall Labs, London Res Inst, S Mimms EN6 3LD, Herts, England.	alain.verreault@cancer.org.uk	Okuwaki, Mitsuru/R-3038-2019	Okuwaki, Mitsuru/0000-0003-2118-442X				Anderson JD, 2002, MOL CELL BIOL, V22, P7147, DOI 10.1128/MCB.22.20.7147-7157.2002; ANTEQUERA F, 1990, CELL, V62, P503, DOI 10.1016/0092-8674(90)90015-7; Aoki A, 2001, NUCLEIC ACIDS RES, V29, P3506, DOI 10.1093/nar/29.17.3506; Araujo FD, 1998, MOL CELL BIOL, V18, P3475, DOI 10.1128/MCB.18.6.3475; Bacolla A, 1999, J BIOL CHEM, V274, P33011, DOI 10.1074/jbc.274.46.33011; Baylin SB, 2002, SEMIN CANCER BIOL, V12, P331, DOI 10.1016/S1044-579X(02)00053-6; Beard BC, 2003, P NATL ACAD SCI USA, V100, P7465, DOI 10.1073/pnas.1330328100; BEARD C, 1995, GENE DEV, V9, P2325, DOI 10.1101/gad.9.19.2325; Bell AC, 2000, NATURE, V405, P482, DOI 10.1038/35013100; Chandler SP, 1999, BIOCHEMISTRY-US, V38, P7008, DOI 10.1021/bi990224y; Cheng XD, 2001, NUCLEIC ACIDS RES, V29, P3784, DOI 10.1093/nar/29.18.3784; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; Davey CA, 2002, J MOL BIOL, V319, P1097, DOI 10.1016/S0022-2836(02)00386-8; Dennis K, 2001, GENE DEV, V15, P2940, DOI 10.1101/gad.929101; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Flaus A, 1996, P NATL ACAD SCI USA, V93, P1370, DOI 10.1073/pnas.93.4.1370; Haaf T, 2000, CYTOGENET CELL GENET, V91, P113, DOI 10.1159/000056830; Hamiche A, 1999, CELL, V97, P833, DOI 10.1016/S0092-8674(00)80796-5; Hark AT, 2000, NATURE, V405, P486, DOI 10.1038/35013106; Iida T, 2002, GENES CELLS, V7, P997, DOI 10.1046/j.1365-2443.2002.00584.x; Krawitz DC, 2002, MOL CELL BIOL, V22, P614, DOI 10.1128/MCB.22.2.614-625.2002; LEONHARDT H, 1992, CELL, V71, P865, DOI 10.1016/0092-8674(92)90561-P; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0; Liang GG, 2002, MOL CELL BIOL, V22, P480, DOI 10.1128/MCB.22.2.480-491.2002; Liu YL, 1998, NUCLEIC ACIDS RES, V26, P1038, DOI 10.1093/nar/26.4.1038; Lowary PT, 1998, J MOL BIOL, V276, P19, DOI 10.1006/jmbi.1997.1494; Maga G, 2003, J CELL SCI, V116, P3051, DOI 10.1242/jcs.00653; Moggs JG, 2000, MOL CELL BIOL, V20, P1206, DOI 10.1128/MCB.20.4.1206-1218.2000; NAN XS, 1993, NUCLEIC ACIDS RES, V21, P4886, DOI 10.1093/nar/21.21.4886; Nilsen H, 2002, EMBO J, V21, P5943, DOI 10.1093/emboj/cdf581; Okano M, 1998, NAT GENET, V19, P219, DOI 10.1038/890; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; POLACH KJ, 1995, J MOL BIOL, V254, P130, DOI 10.1006/jmbi.1995.0606; Pradhan S, 1999, J BIOL CHEM, V274, P33002, DOI 10.1074/jbc.274.46.33002; Rein T, 1999, J BIOL CHEM, V274, P25792, DOI 10.1074/jbc.274.36.25792; Richmond TJ, 2003, NATURE, V423, P145, DOI 10.1038/nature01595; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; Santoro R, 2002, NAT GENET, V32, P393, DOI 10.1038/ng1010; Shibahara K, 1999, CELL, V96, P575, DOI 10.1016/S0092-8674(00)80661-3; SIMON RH, 1979, NUCLEIC ACIDS RES, V6, P689, DOI 10.1093/nar/6.2.689; Sleutels F, 2002, NATURE, V415, P810, DOI 10.1038/415810a; Sleutels F, 2003, EMBO J, V22, P3696, DOI 10.1093/emboj/cdg341; SOGO JM, 1986, J MOL BIOL, V189, P189, DOI 10.1016/0022-2836(86)90390-6; Stancheva I, 2000, GENE DEV, V14, P313; Steger DJ, 1997, METHODS, V12, P276, DOI 10.1006/meth.1997.0479; STOGER R, 1993, CELL, V73, P61, DOI 10.1016/0092-8674(93)90160-R; TAZI J, 1990, CELL, V60, P909, DOI 10.1016/0092-8674(90)90339-G; TREMBLAY KD, 1995, NAT GENET, V9, P407, DOI 10.1038/ng0495-407; Tremblay KD, 1997, MOL CELL BIOL, V17, P4322, DOI 10.1128/MCB.17.8.4322; Walsh CP, 1998, NAT GENET, V20, P116, DOI 10.1038/2413; WOODCOCK DM, 1986, EXP CELL RES, V166, P103, DOI 10.1016/0014-4827(86)90511-2; Zhang ZG, 2000, NATURE, V408, P221, DOI 10.1038/35041601	53	39	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	2004	279	4					2904	2912		10.1074/jbc.M310111200	http://dx.doi.org/10.1074/jbc.M310111200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	764MU	14578347	hybrid			2022-12-27	WOS:000188211300070
J	Gambelli, F; Di, P; Niu, XM; Friedman, M; Hammond, T; Riches, DWH; Ortiz, LA				Gambelli, F; Di, P; Niu, XM; Friedman, M; Hammond, T; Riches, DWH; Ortiz, LA			Phosphorylation of tumor necrosis factor receptor 1 (p55) protects macrophages from silica-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; TNF-ALPHA; IN-VITRO; CD120A P55; SIGNAL-TRANSDUCTION; PULMONARY FIBROSIS; MOUSE MACROPHAGES; MAP KINASE; CELL-DEATH; ACTIVATION	Macrophages play a fundamental role in silicosis in part by removing silica particles and producing inflammatory mediators in response to silica. Tumor necrosis factor alpha (TNFalpha) is a prominent mediator in silicosis. Silica induction of apoptosis in macrophages might be mediated by TNFalpha. However, TNFalpha also activates signal transduction pathways (NF-kappaB and AP-1) that rescue cells from apoptosis. Therefore, we studied the TNFalpha-mediated mechanisms that confer macrophage protection against the pro-apoptotic effects of silica. We will show that exposure to silica induced TNFalpha production by RAW 264.7 cells, but not by IC-21. Silica-induced activation of NF-kappaB and AP-1 was only observed in RAW 264.7 macrophages. ERK activation in response to silica exposure was only observed in RAW 264.7 macrophages, whereas activation of p38 phosphorylation was predominantly observed in IC-21 macrophages. No changes in JNK activity were observed in either cell line in response to silica exposure. Silica induced apoptosis in both macrophage cell lines, but the induction of apoptosis was significantly larger in IC-21 cells. Protection against apoptosis in RAW 264.7 cells in response to silica was mediated by enhanced NF-kappaB activation and ERK-mediated phosphorylation of the p55 TNFalpha receptor. Inhibition of these two protective mechanisms by specific pharmacological inhibitors or transfection of dominant negative mutants that inhibit IkappaBalpha or ERK phosphorylation significantly increased silica-induced apoptosis in RAW 264.7 macrophages. These data suggest that NF-kappaB activation and ERK-mediated phosphorylation of the p55 TNF receptor are important cell survival mechanisms in the macrophage response to silica exposure.	Univ Pittsburgh, Dept Environm & Occupat Hlth, Div Occupat Med, Pittsburgh, PA 15261 USA; Tulane Hlth Sci Ctr, Dept Med, Sect Pulm Crit Care & Environm Med, New Orleans, LA 70112 USA; Tulane Hlth Sci Ctr, Dept Med, Nephrol Sect, New Orleans, LA 70112 USA; Natl Jewish Med & Res Ctr, Dept Pediat, Cell Biol Program, Denver, CO 80206 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Tulane University; Tulane University; National Jewish Health	Ortiz, LA (corresponding author), Univ Pittsburgh, Grad Sch Publ Hlth, Dept Environm & Occupat Hlth, Div Environm & Occupat Med, A731 Crabtree Hall,130 De Soto St, Pittsburgh, PA 15261 USA.	lao1@pitt.edu	ortiz, luis a/H-9851-2013; Di, Yuanpu Peter/H-4191-2016	ortiz, luis a/0000-0003-4510-7066; Di, Yuanpu Peter/0000-0003-2028-2087	NHLBI NIH HHS [HL 68628, HL 55549, HL 65326] Funding Source: Medline; NIEHS NIH HHS [ES 10859-01A1, ES 08663, K22 ES011033] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065326, R01HL055549, R01HL068628] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES010859, R01ES008663] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Albrecht C, 2002, TOXICOL APPL PHARM, V184, P37, DOI 10.1006/taap.2002.9500; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; Bazzoni F, 1996, NEW ENGL J MED, V334, P1717, DOI 10.1056/NEJM199606273342607; BERNSTEIN LR, 1994, J BIOL CHEM, V269, P9401; BEUTLER B, 1994, SCIENCE, V264, P667, DOI 10.1126/science.8171316; BOULTON TG, 1991, BIOCHEMISTRY-US, V30, P278, DOI 10.1021/bi00215a038; Bradley JR, 2001, ONCOGENE, V20, P6482, DOI 10.1038/sj.onc.1204788; Chan ED, 1997, P NATL ACAD SCI USA, V94, P13169, DOI 10.1073/pnas.94.24.13169; Claudio E, 1996, EXP CELL RES, V224, P63, DOI 10.1006/excr.1996.0111; CLAUDIO E, 1995, AM J RESP CELL MOL, V13, P547, DOI 10.1165/ajrcmb.13.5.7576690; Corbett EL, 2002, AM J RESP CRIT CARE, V165, P690, DOI 10.1164/ajrccm.165.5.2010050; Cottin V, 1999, J BIOL CHEM, V274, P32975, DOI 10.1074/jbc.274.46.32975; Cottin V, 2001, J BIOL CHEM, V276, P17252, DOI 10.1074/jbc.M010681200; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Darnay BG, 1997, J LEUKOCYTE BIOL, V61, P559, DOI 10.1002/jlb.61.5.559; DAVIS GS, 1986, LUNG, V164, P139, DOI 10.1007/BF02713638; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Ding M, 1999, J BIOL CHEM, V274, P30611, DOI 10.1074/jbc.274.43.30611; Fox T, 1998, PROTEIN SCI, V7, P2249, DOI 10.1002/pro.5560071102; Holian A, 1997, ENVIRON HEALTH PERSP, V105, P1139, DOI 10.2307/3433522; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Hubbard AK, 2002, AM J PHYSIOL-LUNG C, V282, pL968, DOI 10.1152/ajplung.00327.2001; Iimuro Y, 1998, J CLIN INVEST, V101, P802, DOI 10.1172/JCI483; Iyer R, 1996, TOXICOL APPL PHARM, V141, P84, DOI 10.1006/taap.1996.0263; IYER R, 1997, AM J PHYSIOL, V273, P760; Janssen-Heininger YMW, 1999, AM J RESP CELL MOL, V20, P942, DOI 10.1165/ajrcmb.20.5.3452; Jobin C, 1998, J IMMUNOL, V160, P410; Kaltschmidt B, 2000, EUR J BIOCHEM, V267, P3828, DOI 10.1046/j.1432-1327.2000.01421.x; Lim Y, 1999, TOXICOL LETT, V108, P335, DOI 10.1016/S0378-4274(99)00107-1; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Mossman BT, 1998, AM J RESP CRIT CARE, V157, P1666, DOI 10.1164/ajrccm.157.5.9707141; Oberdorster G., 1994, Annals of Occupational Hygiene, V38, P421; OBERDORSTER G, 1994, ANN OCCUP HYG, V38, P601, DOI 10.1093/annhyg/38.4.601; OHTSUKA Y, 1995, AM J RESP CRIT CARE, V152, P2144, DOI 10.1164/ajrccm.152.6.8520788; Ortiz LA, 1998, AM J PHYSIOL-LUNG C, V275, pL1208, DOI 10.1152/ajplung.1998.275.6.L1208; Ortiz LA, 1999, AM J RESP CELL MOL, V20, P825, DOI 10.1165/ajrcmb.20.4.3193; Ortiz LA, 2001, AM J RESP CRIT CARE, V163, P244, DOI 10.1164/ajrccm.163.1.2002123; Pagliari LJ, 2000, MOL CELL BIOL, V20, P8855, DOI 10.1128/MCB.20.23.8855-8865.2000; PENNICA D, 1985, P NATL ACAD SCI USA, V82, P6060, DOI 10.1073/pnas.82.18.6060; Pierce JW, 1997, J BIOL CHEM, V272, P21096, DOI 10.1074/jbc.272.34.21096; PIGUET PF, 1994, EUR RESPIR J, V7, P515, DOI 10.1183/09031936.94.07030515; PIGUET PF, 1990, NATURE, V344, P245, DOI 10.1038/344245a0; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; SARIH M, 1993, J LEUKOCYTE BIOL, V54, P407, DOI 10.1002/jlb.54.5.407; Shukla A, 2001, CANCER RES, V61, P1791; Takahashi Y, 2002, AM J PHYSIOL-GASTR L, V283, pG1175, DOI 10.1152/ajpgi.00515.2001; Tewari M, 1996, CURR OPIN GENET DEV, V6, P39, DOI 10.1016/S0959-437X(96)90008-8; Van Antwerp DJ, 1998, TRENDS CELL BIOL, V8, P107, DOI 10.1016/S0962-8924(97)01215-4; Van Linden AA, 2000, J BIOL CHEM, V275, P6996, DOI 10.1074/jbc.275.10.6996; Wajant H, 2001, CELL SIGNAL, V13, P389, DOI 10.1016/S0898-6568(01)00160-7; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Winston BW, 1997, J IMMUNOL, V159, P4491; WINSTON BW, 1995, P NATL ACAD SCI USA, V92, P1614, DOI 10.1073/pnas.92.5.1614; Yucesoy B, 2001, TOXICOL APPL PHARM, V172, P75, DOI 10.1006/taap.2001.9124	59	23	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 16	2004	279	3					2020	2029		10.1074/jbc.M309763200	http://dx.doi.org/10.1074/jbc.M309763200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	762WT	14570868	hybrid			2022-12-27	WOS:000188005700056
J	Hansen, T; Wendorff, D; Schonheit, P				Hansen, T; Wendorff, D; Schonheit, P			Bifunctional Phosphoglucose/Phosphomannose isomerases from the archaea Aeropyrum pernix and Thermoplasma acidophilum constitute a novel enzyme family within the phosphoglucose isomerase superfamily	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIUM THERMOTOGA-MARITIMA; PROTEIN SECONDARY STRUCTURE; CRYSTAL-STRUCTURE; GLUCOSE-6-PHOSPHATE ISOMERASE; PYROCOCCUS-FURIOSUS; CUPIN SUPERFAMILY; GLUCOSEPHOSPHATE ISOMERASE; PHOSPHOMANNOSE ISOMERASE; CONFORMATIONAL-CHANGES; GLYCOLYTIC ENZYME	The hyperthermophilic crenarchaeon Aeropyrum pernix contains phosphoglucose isomerase (PGI) activity. However, obvious homologs with significant identity to known PGIs could not be identified in the sequenced genome of this organism. The PGI activity from A. pernix was purified and characterized. Kinetic analysis revealed that, unlike all known PGIs, the enzyme catalyzed reversible isomerization not only of glucose 6-phosphate but also of epimeric mannose 6-phosphate at similar catalytic efficiency, thus defining the protein as bifunctional phosphoglucose/phosphomannose isomerase (PGI/PMI). The gene pgi/pmi encoding PGI/PMI (open reading frame APE0768) was identified by matrix-assisted laser desorption ionization time-of-flight analyses; the gene was overexpressed in Escherichia coli as functional PGI/PMI. Putative PGI/PMI homologs were identified in several (hyper) thermophilic archaea and two bacteria. The homolog from Thermoplasma acidophilum (Ta1419) was overexpressed in E. coli, and the recombinant enzyme was characterized as bifunctional PGI/PMI. PGI/PMIs showed low sequence identity to the PGI superfamily and formed a distinct phylogenetic cluster. However, secondary structure predictions and the presence of several conserved amino acids potentially involved in catalysis indicate some structural and functional similarity to the PGI superfamily. Thus, we propose that bifunctional PGI/PMI constitutes a novel protein family within the PGI superfamily.	Univ Kiel, Inst Allgemeine Mikrobiol, D-24118 Kiel, Germany	University of Kiel	Schonheit, P (corresponding author), Univ Kiel, Inst Allgemeine Mikrobiol, Bot Garten 1-9, D-24118 Kiel, Germany.	peter.schoenheit@ifam.uni-kiel.de						ACHARI A, 1981, PHILOS T ROY SOC B, V293, P145, DOI 10.1098/rstb.1981.0068; Arsenieva D, 2002, J MOL BIOL, V323, P77, DOI 10.1016/S0022-2836(02)00892-6; Arsenieva D, 2002, P NATL ACAD SCI USA, V99, P5872, DOI 10.1073/pnas.052131799; Bateman A, 2000, NUCLEIC ACIDS RES, V28, P263, DOI 10.1093/nar/28.1.263; Berrisford JM, 2003, J BIOL CHEM, V278, P33290, DOI 10.1074/jbc.M305170200; Boriss H, 2001, BIOCHIMIE, V83, P979, DOI 10.1016/S0300-9084(01)01328-1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHARLES D, 1980, MOL CELL BIOCHEM, V29, P11; Chou CC, 2000, J BIOL CHEM, V275, P23154, DOI 10.1074/jbc.M002017200; Concepcion JL, 1999, COMP BIOCHEM PHYS B, V122, P211, DOI 10.1016/S0305-0491(99)00002-4; Cordeiro AT, 2003, BBA-PROTEINS PROTEOM, V1645, P117, DOI 10.1016/S1570-9639(02)00464-8; Davies C, 2003, ACTA CRYSTALLOGR D, V59, P1111, DOI 10.1107/S0907444903007352; Davies C, 2003, ACTA CRYSTALLOGR D, V59, P453, DOI 10.1107/S0907444902023387; Davies C, 2002, PROTEINS, V49, P577, DOI 10.1002/prot.10255; DELEAGE G, 1993, COMPUT APPL BIOSCI, V9, P197; Dunwell JM, 2001, TRENDS BIOCHEM SCI, V26, P740, DOI 10.1016/S0968-0004(01)01981-8; Dunwell JM, 2000, MICROBIOL MOL BIOL R, V64, P153, DOI 10.1128/MMBR.64.1.153-179.2000; FROMAN BE, 1989, MOL GEN GENET, V217, P126, DOI 10.1007/BF00330951; Gracy R W, 1975, Methods Enzymol, V41, P392; Hansen T, 2002, FEMS MICROBIOL LETT, V216, P249, DOI 10.1016/S0378-1097(02)01021-2; Hansen T, 2002, J BACTERIOL, V184, P5955, DOI 10.1128/JB.184.21.5955-5965.2002; Hansen T, 2001, ARCH MICROBIOL, V177, P62, DOI 10.1007/s00203-001-0359-1; Hansen T, 1999, ARCH BIOCHEM BIOPHYS, V363, P135, DOI 10.1006/abbi.1998.1072; Hansen T, 2001, J BACTERIOL, V183, P3428, DOI 10.1128/JB.183.11.3428-3435.2001; Henze K, 2001, GENE, V281, P123, DOI 10.1016/S0378-1119(01)00773-9; HESMAN TL, 1991, J BACTERIOL, V173, P3215, DOI 10.1128/JB.173.10.3215-3223.1991; Hizukuri S, 1975, Methods Enzymol, V41, P388; Jeffery CJ, 2000, BIOCHEMISTRY-US, V39, P955, DOI 10.1021/bi991604m; Jeffery CJ, 2001, BIOCHEMISTRY-US, V40, P1560, DOI 10.1021/bi0018483; Jeong JJ, 2003, FEBS LETT, V535, P200, DOI 10.1016/S0014-5793(02)03900-5; Johnsen U, 2003, J BIOL CHEM, V278, P25417, DOI 10.1074/jbc.M210288200; KAWARABAYASI Y, 1999, DNA RES, V6, P142; KINDLER B, 1997, THESIS U HANNOVER; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee JH, 2001, BIOCHEMISTRY-US, V40, P7799, DOI 10.1021/bi002916o; LOWE SL, 1975, J BIOL CHEM, V250, P94; MURAMATSU N, 1971, ARCH BIOCHEM BIOPHYS, V144, P245, DOI 10.1016/0003-9861(71)90475-9; Nimtz M, 1999, EUR J BIOCHEM, V265, P703, DOI 10.1046/j.1432-1327.1999.00766.x; NOLTMANN EA, 1972, ENZYMES; Nomura M, 1997, ARCH BIOCHEM BIOPHYS, V341, P315, DOI 10.1006/abbi.1997.9959; Nowitzki U, 1998, GENE, V214, P205, DOI 10.1016/S0378-1119(98)00229-7; NYAME K, 1994, MOL BIOCHEM PARASIT, V67, P269, DOI 10.1016/0166-6851(94)00139-1; Otte S, 2001, FEMS MICROBIOL LETT, V194, P221, DOI 10.1016/S0378-1097(00)00534-6; PRADHAN PG, 1980, BIOCHIM BIOPHYS ACTA, V615, P465, DOI 10.1016/0005-2744(80)90512-4; Read J, 2001, J MOL BIOL, V309, P447, DOI 10.1006/jmbi.2001.4680; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; Ruepp A, 2000, NATURE, V407, P508, DOI 10.1038/35035069; Ruijter GJG, 1999, BIOCHIMIE, V81, P267, DOI 10.1016/S0300-9084(99)80061-3; Sako Y, 1996, INT J SYST BACTERIOL, V46, P1070, DOI 10.1099/00207713-46-4-1070; SALAS M, 1965, J BIOL CHEM, V240, P561; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMIDT M, 1992, GENE, V122, P35, DOI 10.1016/0378-1119(92)90029-O; SCHONHEIT P, 1995, WORLD J MICROB BIOT, V11, P26, DOI 10.1007/BF00339135; SCHREYER R, 1980, ARCH MICROBIOL, V127, P289, DOI 10.1007/BF00427206; SEEHOLZER SH, 1993, P NATL ACAD SCI USA, V90, P1237, DOI 10.1073/pnas.90.4.1237; SMITH DJ, 1995, YEAST, V11, P301, DOI 10.1002/yea.320110402; SUN AQ, 1990, ARCH BIOCHEM BIOPHYS, V283, P120, DOI 10.1016/0003-9861(90)90621-5; TAKAMA M, 1980, J BIOCHEM, V87, P1821, DOI 10.1093/oxfordjournals.jbchem.a132927; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Verhees CH, 2001, J BIOL CHEM, V276, P40926, DOI 10.1074/jbc.M104603200	61	39	43	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 16	2004	279	3					2262	2272		10.1074/jbc.M309849200	http://dx.doi.org/10.1074/jbc.M309849200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	762WT	14551194	hybrid			2022-12-27	WOS:000188005700083
J	Lamontagne, B; Abou Elela, S				Lamontagne, B; Abou Elela, S			Evaluation of the RNA determinants for bacterial and yeast RNase III binding and cleavage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; RIBONUCLEASE-III; SCHIZOSACCHAROMYCES-POMBE; SUBSTRATE RECOGNITION; PAC1 RIBONUCLEASE; HUMAN DICER; DOMAIN; RNT1P; PURIFICATION; MECHANISM	Bacterial double-stranded RNA-specific RNase III recognizes the A-form of an RNA helix with little sequence specificity. In contrast, baker yeast RNase III (Rnt1p) selectively recognizes NGNN tetraloops even when they are attached to a B-form DNA helix. To comprehend the general mechanism of RNase III substrate recognition, we mapped the Rnt1p binding signal and directly compared its substrate specificity to that of both Escherichia coli RNase III and fission yeast RNase III (PacI). Rnt1p bound but did not cleave long RNA duplexes without NGNN tetraloops, whereas RNase III indiscriminately cleaved all RNA duplexes. PacI cleaved RNA duplexes with some preferences for NGNN-capped RNA stems under physiological conditions. Hydroxyl radical footprints indicate that Rnt1p specifically interacts with the NGNN tetraloop and its surrounding nucleotides. In contrast, Rnt1p interaction with GAAA-capped hairpins was weak and largely unspecific. Certain duality of substrate recognition was exhibited by PacI but not by bacterial RNase III. E. coli RNase III recognized RNA duplexes longer than 11 bp with little specificity, and no specific features were required for cleavage. On the other hand, PacI cleaved long, but not short, RNA duplexes with little sequence specificity. PacI cleavage of RNA stems shorter than 27 bp was dependent on the presence of an UU-UC internal loop two nucleotides upstream of the cleavage site. These observations suggest that yeast RNase IIIs have two recognition mechanisms, one that uses specific structural features and another that recognizes general features of the A-form RNA helix.	Univ Sherbrooke, Fac Med, Dept Microbiol & Infectiol, Grp ARN RNA Grp, Sherbrooke, PQ J1H 5N4, Canada	University of Sherbrooke	Abou Elela, S (corresponding author), Univ Sherbrooke, Fac Med, Dept Microbiol & Infectiol, Grp ARN RNA Grp, Sherbrooke, PQ J1H 5N4, Canada.	Sherif.Abou.Elela@USherbrooke.ca						AbouElela S, 1996, CELL, V85, P115, DOI 10.1016/S0092-8674(00)81087-9; Banerjee D, 2002, BIOESSAYS, V24, P119, DOI 10.1002/bies.10046; Blaszczyk J, 2001, STRUCTURE, V9, P1225, DOI 10.1016/S0969-2126(01)00685-2; Chanfreau C, 2000, P NATL ACAD SCI USA, V97, P3142, DOI 10.1073/pnas.070043997; Chanfreau G, 1997, GENE DEV, V11, P2741, DOI 10.1101/gad.11.20.2741; CHELLADURAI BS, 1991, NUCLEIC ACIDS RES, V19, P1759, DOI 10.1093/nar/19.8.1759; Conrad C, 2002, INT J BIOCHEM CELL B, V34, P116, DOI 10.1016/S1357-2725(01)00112-1; Grishok A, 2002, ADV GENET, V46, P339; IINO Y, 1991, EMBO J, V10, P221, DOI 10.1002/j.1460-2075.1991.tb07939.x; Kelly SM, 2000, CURR PROTEIN PEPT SC, V1, P349, DOI 10.2174/1389203003381315; Lamontagne B, 2003, J MOL BIOL, V327, P985, DOI 10.1016/S0022-2836(03)00231-6; Lamontagne B, 2001, Curr Issues Mol Biol, V3, P71; Lamontagne B, 2000, MOL CELL BIOL, V20, P1104, DOI 10.1128/MCB.20.4.1104-1115.2000; Lamontagne B, 2001, METHOD ENZYMOL, V342, P159, DOI 10.1016/S0076-6879(01)42543-2; Lebars I, 2001, EMBO J, V20, P7250, DOI 10.1093/emboj/20.24.7250; Li HL, 1996, EMBO J, V15, P1421, DOI 10.1002/j.1460-2075.1996.tb00484.x; Nagel R, 2000, RNA, V6, P1142, DOI 10.1017/S1355838200000431; Nicholson AW, 1999, FEMS MICROBIOL REV, V23, P371, DOI 10.1016/S0168-6445(99)00013-3; Nicholson AW, 1996, PROG NUCLEIC ACID RE, V52, P1, DOI 10.1016/S0079-6603(08)60963-0; Provost P, 2002, EMBO J, V21, P5864, DOI 10.1093/emboj/cdf578; Ramos A, 2000, EMBO J, V19, P997, DOI 10.1093/emboj/19.5.997; Rotondo G, 1996, NUCLEIC ACIDS RES, V24, P2377, DOI 10.1093/nar/24.12.2377; Rotondo G, 1997, RNA, V3, P1182; Saunders LR, 2003, FASEB J, V17, P961, DOI 10.1096/fj.02-0958rev; Sollner-Webb B, 2001, METHOD ENZYMOL, V342, P378, DOI 10.1016/S0076-6879(01)42560-2; Spasov K, 2002, MOL CELL, V9, P433, DOI 10.1016/S1097-2765(02)00461-6; Sun WM, 2001, BIOCHEMISTRY-US, V40, P14976, DOI 10.1021/bi011570u; Tremblay A, 2002, MOL CELL BIOL, V22, P4792, DOI 10.1128/MCB.22.13.4792-4802.2002; Zhang HD, 2002, EMBO J, V21, P5875, DOI 10.1093/emboj/cdf582; Zhang KJ, 1997, P NATL ACAD SCI USA, V94, P13437, DOI 10.1073/pnas.94.25.13437; Zhou DW, 1999, RNA, V5, P1083, DOI 10.1017/S1355838299990726	31	45	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 16	2004	279	3					2231	2241		10.1074/jbc.M309324200	http://dx.doi.org/10.1074/jbc.M309324200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	762WT	14581474	hybrid			2022-12-27	WOS:000188005700080
J	Yamakawa, H; Katou, S; Seo, S; Mitsuhara, I; Kamada, H; Ohashi, Y				Yamakawa, H; Katou, S; Seo, S; Mitsuhara, I; Kamada, H; Ohashi, Y			Plant MAPK phosphatase interacts with calmodulins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; DISEASE RESISTANCE; NEGATIVE REGULATOR; BINDING PROTEINS; OXIDATIVE BURST; NAD KINASE; CELL-DEATH; TOBACCO; ARABIDOPSIS; RESPONSES	A mitogen-activated protein kinase (MAPK) phosphatase gene, designated NtMKP1, was isolated as a candidate gene for a calmodulin (CaM)-binding protein from tobacco. NtMKP1 protein has four characteristic domains conserved among plant MAPK phosphatases reported so far, namely a dual specificity protein phosphatase catalytic domain, gelsolin-like domain, putative CaM-binding domain (CaMBD), and serine-rich region, indicating that NtMKP1 is the ortholog of Arabidopsis MKP1. The bacterially expressed NtMKP1 protein physically interacted with three plant-specific types of CaM in an overlay assay with labeled CaMs, showing high affinity to NtCaM1 and NtCaM3 but lower affinity to NtCaM13. The peptide for the putative CaMBD bound both NtCaM1 and NtCaM3 significantly but bound NtCaM13 only slightly. Moreover, CaM overlay assays with mutated CaMBDs revealed that Trp(440) and Leu(443) in the middle of the basic amphiphilic alpha-helix motif (amino acids 436-453) are critical for binding CaM. In comparison with the transient accumulation of a wound-induced MAPK, WIPK transcript, a prolonged activation of NtMKP1 expression was found in response to wounding and tobacco mosaic virus-induced hypersensitive reaction. In transgenic tobacco plants overexpressing NtMKP1, wound-induced activation of SIPK, salicylic acid-induced MAPK, and WIPK was inhibited. These results suggest that plant CaMs are involved in these stress-activated MAPK cascades via NtMKP1.	Natl Inst Agrobiol Sci, Dept Plant Physiol, Tsukuba, Ibaraki 3058602, Japan; Program Promot Basic Res Act Innovat Biosci, Minato Ku, Tokyo 1050001, Japan; Univ Tsukuba, Inst Biol Sci, Tsukuba 3058572, Japan	National Institute of Agrobiological Sciences - Japan; University of Tsukuba	Ohashi, Y (corresponding author), Natl Inst Agrobiol Sci, Dept Plant Physiol, Kannondai 2-1-2, Tsukuba, Ibaraki 3058602, Japan.			Seo, Shigemi/0000-0003-4940-288X				ANTHONY FA, 1986, ANAL BIOCHEM, V155, P103, DOI 10.1016/0003-2697(86)90232-0; ARAZI T, 1995, PLANT PHYSIOL, V108, P551, DOI 10.1104/pp.108.2.551; Asai T, 2002, NATURE, V415, P977, DOI 10.1038/415977a; Bogre L, 1997, PLANT CELL, V9, P75, DOI 10.1105/tpc.9.1.75; ERICKSONVIITANEN S, 1987, METHOD ENZYMOL, V139, P455; Grant M, 2000, PLANT J, V23, P441, DOI 10.1046/j.1365-313x.2000.00804.x; Gupta R, 1998, PLANT J, V16, P581, DOI 10.1046/j.1365-313x.1998.00327.x; HARMON AC, 1984, ANAL BIOCHEM, V141, P168, DOI 10.1016/0003-2697(84)90441-X; Heo WD, 1999, P NATL ACAD SCI USA, V96, P766, DOI 10.1073/pnas.96.2.766; HORSCH RB, 1985, SCIENCE, V227, P1229, DOI 10.1126/science.227.4691.1229; Ichimura K, 2002, TRENDS PLANT SCI, V7, P301, DOI 10.1016/S1360-1385(02)02302-6; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; Jin HL, 2003, PLANT J, V33, P719, DOI 10.1046/j.1365-313X.2003.01664.x; KINGSTON RE, 1996, CURRENT PROTOCOLS MO; KLEE CB, 1982, ADV PROTEIN CHEM, V35, P213, DOI 10.1016/S0065-3233(08)60470-2; KNIGHT MR, 1991, NATURE, V352, P524, DOI 10.1038/352524a0; Kumar VB, 1999, ANAL BIOCHEM, V269, P17, DOI 10.1006/abio.1999.4013; Lebrun-Garcia A, 1998, PLANT J, V15, P773, DOI 10.1046/j.1365-313X.1998.00269.x; Lee SH, 2000, BIOCHEM J, V350, P299, DOI 10.1042/0264-6021:3500299; Liao BR, 1995, METHOD CELL BIOL, V49, P487, DOI 10.1016/S0091-679X(08)61475-2; Meskiene I, 1998, P NATL ACAD SCI USA, V95, P1938, DOI 10.1073/pnas.95.4.1938; Meskiene I, 2003, J BIOL CHEM, V278, P18945, DOI 10.1074/jbc.M300878200; MUTO S, 1977, PLANT PHYSIOL, V59, P55, DOI 10.1104/pp.59.1.55; NURNBERGER T, 1994, CELL, V78, P449, DOI 10.1016/0092-8674(94)90423-5; Ohtsubo N, 1999, PLANT CELL PHYSIOL, V40, P808, DOI 10.1093/oxfordjournals.pcp.a029609; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; Park HJ, 1998, PLANT CELL PHYSIOL, V39, P1218, DOI 10.1093/oxfordjournals.pcp.a029323; Piedras P, 1998, MOL PLANT MICROBE IN, V11, P1155, DOI 10.1094/MPMI.1998.11.12.1155; Reddy VS, 2002, J BIOL CHEM, V277, P9840, DOI 10.1074/jbc.M111626200; Sanders D, 1999, PLANT CELL, V11, P691, DOI 10.1105/tpc.11.4.691; Seo S, 1999, PLANT CELL, V11, P289, DOI 10.1105/tpc.11.2.289; SEO S, 1995, SCIENCE, V270, P1988, DOI 10.1126/science.270.5244.1988; SHEN WJ, 1989, NUCLEIC ACIDS RES, V17, P8385, DOI 10.1093/nar/17.20.8385; Ulm R, 2002, EMBO J, V21, P6483, DOI 10.1093/emboj/cdf646; Ulm R, 2001, GENE DEV, V15, P699, DOI 10.1101/gad.192601; USAMI S, 1995, P NATL ACAD SCI USA, V92, P8660, DOI 10.1073/pnas.92.19.8660; Yamakawa H, 2001, EUR J BIOCHEM, V268, P3916, DOI 10.1046/j.1432-1327.2001.02301.x; Yang KY, 2001, P NATL ACAD SCI USA, V98, P741, DOI 10.1073/pnas.98.2.741	38	54	60	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 9	2004	279	2					928	936		10.1074/jbc.M310277200	http://dx.doi.org/10.1074/jbc.M310277200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	759DJ	14573600	hybrid			2022-12-27	WOS:000187722800015
J	Davis, ME; Grumbach, IM; Fukai, T; Cutchins, A; Harrison, DG				Davis, ME; Grumbach, IM; Fukai, T; Cutchins, A; Harrison, DG			Shear stress regulates endothelial nitric-oxide synthase promoter activity through nuclear factor kappa B binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; CELLS TRANSDUCE; C-SRC; EXPRESSION; TRANSCRIPTION; ACTIVATION; KINASE; PATHWAY; FLOW; INHIBITION	We have previously demonstrated that shear stress increases transcription of the endothelial nitric-oxide synthase ( eNOS) by a pathway involving activation of the tyrosine kinase c-Src and extracellular signal-related kinase 1/2 (ERK1/2). In the present study sought to determine the events downstream of this pathway. Shear stress activated a human eNOS promoter chloramphenicol acetyl-CoA transferase chimeric construct in a time-dependent fashion, and this could be prevented by inhibition of the c-Src and MEK1/2. Studies using electromobility shift assays, promoter deletions, and promoter mutations revealed that shear activation of the eNOS promoter was due to binding of nuclear factor kappaB subunits p50 and p65 to a GAGACC sequence -990 to -984 base pairs upstream of the eNOS transcription start site. Shear induced nuclear translocation of p50 and p65, and activation of the eNOS promoter by shear could be prevented by co-transfection with a dominant negative I kappa Balpha. Exposure of endothelial cells to shear resulted in Ikappa kinase phosphorylation, and this was blocked by the MEK1/2 inhibitor PD98059 and the cSrc inhibitor PP1, suggesting these signaling molecules are upstream of NFkappaB activation. These experiments indicate that shear stress increases eNOS transcription by NFkappaB activation and p50/p65 binding to a GAGACC sequence present of the human eNOS promoter. While NFkappaB activation is generally viewed as a proinflammatory stimulus, the current data indicate that its transient activation by shear may increase expression of eNOS, which via production of nitric oxide could convey anti-inflammatory and anti-atherosclerotic properties.	Emory Univ, Div Cardiol, Atlanta, GA 30322 USA; Emory Univ, Mol & Syst Pharmacol Program, Atlanta, GA 30322 USA; Vet Affairs Med Ctr, Decatur, GA 30033 USA	Emory University; Emory University; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Harrison, DG (corresponding author), Emory Univ, Div Cardiol, 1639 Pierce Dr,WMB 319, Atlanta, GA 30322 USA.	dharr02@emory.edu		Grumbach, Isabella/0000-0002-2285-3157	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059248, P01HL058000] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL59248, HL390006, HL58000] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Cieslik K, 2001, J BIOL CHEM, V276, P1211, DOI 10.1074/jbc.M005305200; Davis ME, 2003, AM J PHYSIOL-HEART C, V284, pH1449, DOI 10.1152/ajpheart.00918.2002; Davis ME, 2001, CIRC RES, V89, P1073, DOI 10.1161/hh2301.100806; DelaTorre A, 1997, BIOCHEM BIOPH RES CO, V238, P703, DOI 10.1006/bbrc.1997.7279; DEWEY CF, 1981, J BIOMECH ENG-T ASME, V103, P177, DOI 10.1115/1.3138276; Dhawan P, 2002, J BIOL CHEM, V277, P7920, DOI 10.1074/jbc.M112210200; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Drummond GR, 2000, CIRC RES, V86, P347, DOI 10.1161/01.RES.86.3.347; Fleming I, 1999, CARDIOVASC RES, V43, P532, DOI 10.1016/S0008-6363(99)00094-2; GLAGOV S, 1994, CIRCULATION, V89, P2888, DOI 10.1161/01.CIR.89.6.2888; Hajra L, 2000, P NATL ACAD SCI USA, V97, P9052, DOI 10.1073/pnas.97.16.9052; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; HSIEH HJ, 1993, J CELL PHYSIOL, V154, P143, DOI 10.1002/jcp.1041540118; Ishida T, 1997, ANN NY ACAD SCI, V811, P12, DOI 10.1111/j.1749-6632.1997.tb51984.x; Ishida T, 1996, CIRC RES, V79, P310, DOI 10.1161/01.RES.79.2.310; KU DN, 1985, ARTERIOSCLEROSIS, V5, P293, DOI 10.1161/01.ATV.5.3.293; LAN QX, 1994, BIOCHEM BIOPH RES CO, V201, P950, DOI 10.1006/bbrc.1994.1794; Malek AM, 1999, BIOCHEM BIOPH RES CO, V254, P231, DOI 10.1006/bbrc.1998.9921; Miyauchi T, 2003, J APPL PHYSIOL, V94, P60, DOI 10.1152/japplphysiol.00269.2002; NISHIDA K, 1992, J CLIN INVEST, V90, P2092, DOI 10.1172/JCI116092; PENG HB, 1995, J BIOL CHEM, V270, P14214, DOI 10.1074/jbc.270.23.14214; READ MA, 1994, J EXP MED, V179, P503, DOI 10.1084/jem.179.2.503; RESNICK N, 1993, P NATL ACAD SCI USA, V90, P4591, DOI 10.1073/pnas.90.10.4591; Richmond A, 2002, NAT REV IMMUNOL, V2, P664, DOI 10.1038/nri887; Silacci P, 2000, NITRIC OXIDE-BIOL CH, V4, P47, DOI 10.1006/niox.2000.0271; Topper JN, 1996, P NATL ACAD SCI USA, V93, P10417, DOI 10.1073/pnas.93.19.10417; Traub O, 1998, ARTERIOSCL THROM VAS, V18, P677, DOI 10.1161/01.ATV.18.5.677; VENEMA RC, 1994, BBA-GENE STRUCT EXPR, V1218, P413, DOI 10.1016/0167-4781(94)90195-3; Yamamoto Yumi, 2001, Current Molecular Medicine (Hilversum), V1, P287; Yu SM, 1997, BIOCHEM J, V328, P363; ZHANG R, 1995, J BIOL CHEM, V270, P15320, DOI 10.1074/jbc.270.25.15320	32	152	164	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 2	2004	279	1					163	168		10.1074/jbc.M307528200	http://dx.doi.org/10.1074/jbc.M307528200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	757GU	14570928	hybrid			2022-12-27	WOS:000187555300020
J	Gaudreault, SB; Chabot, C; Gratton, JP; Poirier, J				Gaudreault, SB; Chabot, C; Gratton, JP; Poirier, J			The caveolin scaffolding domain modifies 2-amino-3-hydroxy-5-methyl-4-isoxazole propionate receptor binding properties by inhibiting phospholipase A(2) activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; RAT-BRAIN SYNAPTONEUROSOMES; H-3 AMPA BINDING; ARACHIDONIC-ACID; GLUTAMATE RECEPTORS; BROMOPHENACYL BROMIDE; PLASMA-MEMBRANE; GENE FAMILY; IN-VIVO; EXPRESSION	Activation of the enzyme phospholipase (PLA(2)) has been proposed to be part of the molecular mechanism involved in the alteration of 2-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA) glutamate receptor responsiveness during long term changes in synaptic plasticity (long term potentiation). This study assesses the effect of the caveolin-1 scaffolding domain (CSD) on the activity of the regulatory enzyme PLA(2). Caveolin-1 is a 22-kDa cholesterol-binding membrane protein known to inhibit the activity of most of its interacting partners. Our results show that the calcium-dependent cytosolic form of PLA(2) (cPLA(2)) and caveolin-1 co-localized in mouse primary hippocampal neuron cultures and that they were co-immunoprecipitated from mouse hippocampal homogenates. A peptide corresponding to the scaffolding domain of caveolin-1 (Cav-(82-101)) dramatically inhibited cPLA(2) activity in purified hippocampal synaptoneurosomes. Activation of endogenous PLA(2) activity with KCl or melittin increased the binding of [H-3] AMPA to its receptor. This effect was almost completely abolished by the addition of the CSD peptide to these preparations. Moreover, we demonstrated that the inhibitory action of the CSD peptide on AMPA receptor binding properties is specific (because a scrambled version of this peptide failed to have any effect) and that it is mediated by an inhibition of PLA(2) enzymatic activity (because the CSD peptide failed to have an effect in membrane preparations lacking endogenous PLA(2) activity). These results raised the possibility that caveolin-1, via the inhibition of cPLA(2) enzymatic activity, may interfere with synaptic facilitation and long term potentiation formation in the hippocampus.	McGill Ctr Studies Aging, Verdun, PQ H4H 1R3, Canada; McGill Univ, Dept Neurol & Neurosurg, Douglas Hosp Res Ctr, Montreal, PQ H4A 2B4, Canada; Inst Rech Clin Montreal, Montreal, PQ H2W 1R7, Canada	McGill University; McGill University; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal	Poirier, J (corresponding author), McGill Ctr Studies Aging, 6825 Blvd LaSalle, Verdun, PQ H4H 1R3, Canada.			Gratton, Jean-Philippe/0000-0001-9877-8520				BERNARD J, 1994, HIPPOCAMPUS, V4, P447, DOI 10.1002/hipo.450040407; BERNARD J, 1993, BRAIN RES, V628, P340, DOI 10.1016/0006-8993(93)90977-U; BERNARD J, 1992, J NEUROCHEM, V58, P387, DOI 10.1111/j.1471-4159.1992.tb09323.x; BERNARD J, 1995, BRAIN RES, V671, P195, DOI 10.1016/0006-8993(94)01313-7; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; CATANIA MV, 1993, J NEUROCHEM, V60, P236, DOI 10.1111/j.1471-4159.1993.tb05843.x; Chabot C, 1996, DEV BRAIN RES, V93, P70, DOI 10.1016/0165-3806(96)00021-1; Chabot C, 1998, HIPPOCAMPUS, V8, P299, DOI 10.1002/(SICI)1098-1063(1998)8:3<299::AID-HIPO11>3.0.CO;2-W; CLARK JD, 1995, J LIPID MEDIAT CELL, V12, P83, DOI 10.1016/0929-7855(95)00012-F; CRUICKSHANK AM, 1994, FEBS LETT, V339, P168, DOI 10.1016/0014-5793(94)80408-7; DAVIES SN, 1989, NATURE, V338, P500, DOI 10.1038/338500a0; DUMUIS A, 1988, NATURE, V336, P68, DOI 10.1038/336068a0; DUMUIS A, 1993, MOL PHARMACOL, V43, P976; FAROOQUI AA, 1994, J NEUROSCI RES, V38, P6, DOI 10.1002/jnr.490380103; Farooqui AA, 1997, J NEUROCHEM, V69, P889; FIEDLER K, 1993, BIOCHEMISTRY-US, V32, P6365, DOI 10.1021/bi00076a009; GAUDREAULT SB, 2003, NEUROBIOL AGING; Gratton JP, 2000, J BIOL CHEM, V275, P22268, DOI 10.1074/jbc.M001644200; GRONICH JH, 1988, J BIOL CHEM, V263, P16645; HOLLINGSWORTH EB, 1985, J NEUROSCI, V5, P2240; KAUER JA, 1988, NEURON, V1, P911, DOI 10.1016/0896-6273(88)90148-1; Kawabe J, 2001, MOL CELL ENDOCRINOL, V176, P91, DOI 10.1016/S0303-7207(01)00472-5; KURZCHALIA TV, 1992, J CELL BIOL, V118, P1003, DOI 10.1083/jcb.118.5.1003; Li SW, 1996, J BIOL CHEM, V271, P28647, DOI 10.1074/jbc.271.45.28647; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; LYNCH MA, 1989, NEUROSCIENCE, V30, P693, DOI 10.1016/0306-4522(89)90162-0; MAREN S, 1993, P NATL ACAD SCI USA, V90, P9654, DOI 10.1073/pnas.90.20.9654; MASSICOTTE G, 1990, BRAIN RES, V537, P49, DOI 10.1016/0006-8993(90)90338-C; MASSICOTTE G, 1990, MOL PHARMACOL, V37, P278; MASSICOTTE G, 1991, P NATL ACAD SCI USA, V88, P1893, DOI 10.1073/pnas.88.5.1893; Massicotte G, 2000, CELL MOL LIFE SCI, V57, P1542, DOI 10.1007/PL00000639; MITCHELL JB, 1992, NEUROSCIENCE, V48, P631, DOI 10.1016/0306-4522(92)90407-S; Murakami M, 2000, BBA-MOL CELL BIOL L, V1488, P159, DOI 10.1016/S1388-1981(00)00118-9; Murakami M, 1999, J BIOL CHEM, V274, P29927, DOI 10.1074/jbc.274.42.29927; Nayak A, 1998, NATURE, V394, P680, DOI 10.1038/29305; Oka N, 1997, J BIOL CHEM, V272, P33416, DOI 10.1074/jbc.272.52.33416; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Park WY, 2000, J BIOL CHEM, V275, P20847, DOI 10.1074/jbc.M908162199; Parton RG, 1997, J CELL BIOL, V136, P137, DOI 10.1083/jcb.136.1.137; Pike LJ, 2002, BIOCHEMISTRY-US, V41, P2075, DOI 10.1021/bi0156557; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; Scherer PE, 1997, J BIOL CHEM, V272, P29337, DOI 10.1074/jbc.272.46.29337; Scherer PE, 1996, P NATL ACAD SCI USA, V93, P131, DOI 10.1073/pnas.93.1.131; SCHERER PE, 1994, J CELL BIOL, V127, P1233, DOI 10.1083/jcb.127.5.1233; Schievella AR, 1995, J BIOL CHEM, V270, P30749, DOI 10.1074/jbc.270.51.30749; SEVERS NJ, 1988, J CELL SCI, V90, P341; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; Song KS, 1996, J BIOL CHEM, V271, P15160, DOI 10.1074/jbc.271.25.15160; Suzuki T, 2001, MOL BRAIN RES, V89, P20, DOI 10.1016/S0169-328X(01)00051-1; Tang ZL, 1996, J BIOL CHEM, V271, P2255, DOI 10.1074/jbc.271.4.2255; VERITY MA, 1994, J NEUROCHEM, V62, P705; WILLIAMS JH, 1989, NEUROSCI LETT, V107, P301, DOI 10.1016/0304-3940(89)90835-5	53	42	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	2004	279	1					356	362		10.1074/jbc.M304777200	http://dx.doi.org/10.1074/jbc.M304777200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	757GU	14561756	hybrid			2022-12-27	WOS:000187555300043
J	Lu, ZCJ; Markham, GD				Lu, ZCJ; Markham, GD			Catalytic properties of the archaeal S-adenosylmethionine decarboxylase from Methanococcus jannaschii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT HISTIDINE-DECARBOXYLASE; ESCHERICHIA-COLI; PUTRESCINE STIMULATION; ESTER INTERMEDIATE; PYRUVOYL ENZYMES; RAT-LIVER; MECHANISM; PYRUVATE; IDENTIFICATION; INACTIVATION	S-Adenosylmethionine decarboxylase (AdoMetDC) is a pyruvoyl cofactor-dependent enzyme that participates in polyamine biosynthesis. AdoMetDC from the Archaea Methanococcus jannaschii is a prototype for a recently discovered class that is not homologous to the eucaryotic enzymes or to a distinct group of microbial enzymes. M. jannaschii AdoMetDC has a K-m of 95 muM and the turnover number (k(cat)) of 0.0075 s(-1) at pH 7.5 and 22degreesC. The turnover number increased similar to38-fold at a more physiological temperature of 80degreesC. AdoMetDC was inactivated by treatment with the imine reductant NaCNBH3 only in the presence of substrate. Mass spectrometry of the inactivated protein showed modification solely of the pyruvoyl-containing subunit, with a mass increase corresponding to reduction of a Schiff base adduct with decarboxylated AdoMet. The presteady state time course of the AdoMetDC reaction revealed a burst of product formation; thus, a step after CO2 formation is rate-limiting in turnover. Comparable D2O kinetic isotope effects of were seen on the first turnover (1.9) and on k(cat)/K-m (1.6); there was not a significant D2O isotope effect on k(cat), suggesting that product release is rate-limiting in turnover. The pH dependence of the steady state rate showed participation of acid and basic groups with pK values of 5.3 and 8.2 for kcat and 6.5 and 8.3 for k(cat)/K-m, respectively. The competitive inhibitor methylglyoxal bis(guanylhydrazone) binds at a single site per (alphabeta) heterodimer. UV spectroscopic studies show that methylglyoxal bis(guanylhydrazone) binds as the dication with a 23 muM dissociation constant. Studies with substrate analogs show a high specificity for AdoMet.	Fox Chase Canc Ctr, Inst Canc Res, Philadelphia, PA 19111 USA	Fox Chase Cancer Center	Markham, GD (corresponding author), Fox Chase Canc Ctr, Inst Canc Res, 333 Cottman Ave, Philadelphia, PA 19111 USA.				NATIONAL CANCER INSTITUTE [P30CA006927] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031186] Funding Source: NIH RePORTER; NCI NIH HHS [CA06927] Funding Source: Medline; NIGMS NIH HHS [GM31186] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABELL LM, 1988, BIOCHEMISTRY-US, V27, P5933, DOI 10.1021/bi00416a017; ABELL LM, 1988, BIOCHEMISTRY-US, V27, P5927, DOI 10.1021/bi00416a016; ALLEN RR, 1981, J BIOL CHEM, V256, P3233; ANTON DL, 1987, J BIOL CHEM, V262, P2817; ANTON DL, 1987, BIOCHEMISTRY-US, V26, P6444, DOI 10.1021/bi00394a022; Bach RD, 1996, J ORG CHEM, V61, P6346, DOI 10.1021/jo960356m; BAIOCCHI F, 1963, J MED CHEM, V6, P431, DOI 10.1021/jm00340a020; Bennett EM, 2002, BIOCHEMISTRY-US, V41, P14509, DOI 10.1021/bi026710u; Boyer P.D., 1990, ENZYMES, V19, P99; Bulaj G, 1998, BIOCHEMISTRY-US, V37, P8965, DOI 10.1021/bi973101r; CLELAND WW, 1967, ADV ENZYMOL RAMB, V29, P1; Cohen SS, 1988, GUIDE POLYAMINES; COHN MS, 1977, J BIOL CHEM, V252, P8212; DEMETRIOU AA, 1978, J BIOL CHEM, V253, P1684; DIAZ E, 1991, BIOCHEMISTRY-US, V30, P4078, DOI 10.1021/bi00230a037; Ekstrom JL, 1999, STRUCTURE, V7, P583, DOI 10.1016/S0969-2126(99)80074-4; Ekstrom JL, 2001, BIOCHEMISTRY-US, V40, P9495, DOI 10.1021/bi010736o; Gallivan JP, 1999, P NATL ACAD SCI USA, V96, P9459, DOI 10.1073/pnas.96.17.9459; *GEN COMP GROUP, 1999, PEPTIDESORT VERS 10; Graham DE, 2002, J BIOL CHEM, V277, P23500, DOI 10.1074/jbc.M203467200; HACKERT ML, 1997, COMPREHENSIVE BIOCH, V2, P201; HAMILTON WC, 1968, ACTA CRYSTALL B-STRU, VB 24, P1147, DOI 10.1107/S0567740868003882; JANNE J, 1985, ADV ENZYME REGUL, V24, P125, DOI 10.1016/0065-2571(85)90073-1; Kashiwagi K, 1988, Adv Exp Med Biol, V250, P73; Kim AD, 2000, J BACTERIOL, V182, P6667, DOI 10.1128/JB.182.23.6667-6672.2000; Kinch LN, 2000, BIOCHEMISTRY-US, V39, P3336, DOI 10.1021/bi991493r; KUO DJ, 1985, BIOCHEMISTRY-US, V24, P3947, DOI 10.1021/bi00336a022; Li YF, 2001, P NATL ACAD SCI USA, V98, P10578, DOI 10.1073/pnas.181341198; MARKHAM GD, 1982, J BIOL CHEM, V257, P2063; MARTON LJ, 1995, ANNU REV PHARMACOL, V35, P55, DOI 10.1146/annurev.pa.35.040195.000415; MUDD SH, 1966, BIOCHEMISTRY-US, V5, P1653, DOI 10.1021/bi00869a030; Noren CJ, 2000, ANGEW CHEM INT EDIT, V39, P450; PEGG AE, 1974, BIOCHEM J, V141, P581, DOI 10.1042/bj1410581; Ramjee MK, 1997, BIOCHEM J, V323, P661, DOI 10.1042/bj3230661; RECSEI PA, 1984, ANNU REV BIOCHEM, V53, P357, DOI 10.1146/annurev.bi.53.070184.002041; REGENASS U, 1994, CANCER RES, V54, P3210; SCHOWEN KB, 1982, METHOD ENZYMOL, V87, P551; Sekowska A, 2000, MOL MICROBIOL, V36, P1135, DOI 10.1046/j.1365-2958.2000.01930.x; SOMERO GN, 1995, ANNU REV PHYSIOL, V57, P43, DOI 10.1146/annurev.ph.57.030195.000355; STANEK J, 1993, J MED CHEM, V36, P2168, DOI 10.1021/jm00067a014; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; TABOR CW, 1984, ADV ENZYMOL RAMB, V56, P251; TEKWANI BL, 1992, BIOCHEM PHARMACOL, V44, P905, DOI 10.1016/0006-2952(92)90122-Y; Tolbert WD, 2001, BIOCHEMISTRY-US, V40, P9484, DOI 10.1021/bi010735w; Toney MD, 2001, BIOCHEMISTRY-US, V40, P1378, DOI 10.1021/bi0012383; VANPOELJE PD, 1990, ANNU REV BIOCHEM, V59, P29, DOI 10.1146/annurev.bi.59.070190.000333; WICKNER RB, 1970, J BIOL CHEM, V245, P2132; WILLIAMSASHMAN HG, 1972, BIOCHEM BIOPH RES CO, V46, P288, DOI 10.1016/0006-291X(72)90661-4; Xiong HS, 1999, J BIOL CHEM, V274, P35059, DOI 10.1074/jbc.274.49.35059; Xiong HS, 1999, BIOCHEMISTRY-US, V38, P2462, DOI 10.1021/bi9825201	50	7	8	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	2004	279	1					265	273		10.1074/jbc.M308793200	http://dx.doi.org/10.1074/jbc.M308793200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	757GU	14573607	hybrid			2022-12-27	WOS:000187555300033
J	Zhang, HB; Liu, XH; Zhang, K; Chen, CK; Frederick, JM; Prestwich, GD; Baehr, W				Zhang, HB; Liu, XH; Zhang, K; Chen, CK; Frederick, JM; Prestwich, GD; Baehr, W			Photoreceptor cGMP phosphodiesterase delta subunit (PDE delta) functions as a prenyl-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-GMP PHOSPHODIESTERASE; PIGMENTOSA GTPASE REGULATOR; ROD OUTER SEGMENTS; MEMBRANE ASSOCIATION; CATALYTIC SUBUNITS; HRG4 UNC119; RAB GTPASES; EXPRESSION; RPGR; INTERACTS	Bovine PDEdelta was originally copurified with rod cGMP phosphodiesterase (PDE) and shown to interact with prenylated, carboxymethylated C-terminal Cys residues. Other studies showed that PDEdelta can interact with several small GTPases including Rab13, Ras, Rap, and Rho6, all of which are prenylated, as well as the N-terminal portion of retinitis pigmentosa GTPase regulator and Arl2/Arl3, which are not prenylated. We show by immunocytochemistry with a PDEdelta-specific antibody that PDEdelta is present in rods and cones. We find by yeast two-hybrid screening with a PDEdelta bait that it can interact with farnesylated rhodopsin kinase (GRK1) and that prenylation is essential for this interaction. In vitro binding assays indicate that both recombinant farnesylated GRK1 and geranylgeranylated GRK7 co-precipitate with a glutathione S-transferase-PDEdelta fusion protein. Using fluorescence resonance energy transfer techniques exploiting the intrinsic tryptophan fluorescence of PDEdelta and dansylated prenyl cysteines as fluorescent ligands, we show that PDEdelta specifically binds geranylgeranyl and farnesyl moieties with a K-d of 19.06 and 0.70 muM, respectively. Our experiments establish that PDEdelta functions as a prenyl-binding protein interacting with multiple prenylated proteins.	Univ Utah, Hlth Sci Ctr, Moran Eye Ctr, Dept Neurobiol & Anat, Salt Lake City, UT 84112 USA; Univ Utah, Dept Med Chem, Salt Lake City, UT 84112 USA; Univ Utah, Dept Human Genet, Salt Lake City, UT 84112 USA; Univ Utah, Dept Ophthalmol & Visual Sci, Salt Lake City, UT 84112 USA; Univ Utah, Dept Biol, Salt Lake City, UT 84112 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Baehr, W (corresponding author), Univ Utah, Hlth Sci Ctr, Moran Eye Ctr, Dept Neurobiol & Anat, 75 N Med Dr, Salt Lake City, UT 84112 USA.		Zhang, Kang/Y-2740-2019; Zhang, Houbin/A-8887-2012	Zhang, Kang/0000-0002-4549-1697; Zhang, Houbin/0000-0002-2968-7454	NEI NIH HHS [R01EY08123, EY013811] Funding Source: Medline; NIGMS NIH HHS [GM44836] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY013811, R01EY008123, R56EY013811] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044836] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANANT JS, 1992, J BIOL CHEM, V267, P687; BAEHR W, 1979, J BIOL CHEM, V254, P1669; BEAVO JA, 1995, PHYSIOL REV, V75, P725, DOI 10.1152/physrev.1995.75.4.725; Chavrier P, 1999, CURR OPIN CELL BIOL, V11, P466, DOI 10.1016/S0955-0674(99)80067-2; Chen CK, 2001, MOL VIS, V7, P305; Cook TA, 2000, BIOCHEMISTRY-US, V39, P13516, DOI 10.1021/bi001070l; Cook TA, 2001, J BIOL CHEM, V276, P5248, DOI 10.1074/jbc.M004690200; DETERRE P, 1988, P NATL ACAD SCI USA, V85, P2424, DOI 10.1073/pnas.85.8.2424; Florio SK, 1996, J BIOL CHEM, V271, P24036, DOI 10.1074/jbc.271.39.24036; FUNG BKK, 1990, BIOCHEMISTRY-US, V29, P2657, DOI 10.1021/bi00463a006; GILLESPIE PG, 1989, J BIOL CHEM, V264, P12187; Hammer JA, 2002, CURR OPIN CELL BIOL, V14, P69, DOI 10.1016/S0955-0674(01)00296-4; Hanzal-Bayer M, 2002, EMBO J, V21, P2095, DOI 10.1093/emboj/21.9.2095; Higashide T, 1999, GENOMICS, V57, P446, DOI 10.1006/geno.1999.5791; Hillig RC, 2000, STRUCTURE, V8, P1239, DOI 10.1016/S0969-2126(00)00531-1; Hisatomi O, 1998, FEBS LETT, V424, P159, DOI 10.1016/S0014-5793(98)00162-8; Jacobson SG, 1997, INVEST OPHTH VIS SCI, V38, P1983; Kobayashi A, 2003, FEBS LETT, V534, P26, DOI 10.1016/S0014-5793(02)03766-3; Li N, 1998, FEBS LETT, V440, P454, DOI 10.1016/S0014-5793(98)01501-4; Linari M, 1999, P NATL ACAD SCI USA, V96, P1315, DOI 10.1073/pnas.96.4.1315; Linari M, 1999, FEBS LETT, V458, P55, DOI 10.1016/S0014-5793(99)01117-5; Liu XH, 2002, J AM CHEM SOC, V124, P20, DOI 10.1021/ja0119144; Marzesco AM, 1998, J BIOL CHEM, V273, P22340, DOI 10.1074/jbc.273.35.22340; Mondal MS, 2000, BIOCHEMISTRY-US, V39, P406, DOI 10.1021/bi991856n; Nancy V, 2002, J BIOL CHEM, V277, P15076, DOI 10.1074/jbc.M109983200; Polans A, 1996, TRENDS NEUROSCI, V19, P547, DOI 10.1016/S0166-2236(96)10059-X; QIN N, 1992, J BIOL CHEM, V267, P8458; QIN N, 1994, J BIOL CHEM, V269, P3265; Swaroop A, 1988, GENOMICS, V2, P37, DOI 10.1016/0888-7543(88)90107-3; Weiss E R, 1998, Mol Vis, V4, P27; Yan D, 1998, J BIOL CHEM, V273, P19656, DOI 10.1074/jbc.273.31.19656; Zhang HB, 2003, INVEST OPHTH VIS SCI, V44, P2858, DOI 10.1167/iovs.03-0072; Zhao Y, 2003, P NATL ACAD SCI USA, V100, P3965, DOI 10.1073/pnas.0637349100	33	99	103	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	2004	279	1					407	413		10.1074/jbc.M306559200	http://dx.doi.org/10.1074/jbc.M306559200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	757GU	14561760	hybrid			2022-12-27	WOS:000187555300049
J	Hirao, M; Posakony, J; Nelson, M; Hruby, H; Jung, MF; Simon, JA; Bedalov, A				Hirao, M; Posakony, J; Nelson, M; Hruby, H; Jung, MF; Simon, JA; Bedalov, A			Identification of selective inhibitors of NAD(+)-dependent deacetylases using phenotypic screens in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NAD-DEPENDENT DEACETYLASE; PROTEIN-KINASE INHIBITORS; SACCHAROMYCES-CEREVISIAE; HISTONE DEACETYLASE; SIR2-LIKE PROTEINS; SIR2; FAMILY; P53; MECHANISM; HST1	Sir2 and Hst1 are NAD(+)-dependent deacetylases involved in transcriptional repression in yeast. The two enzymes are highly homologous yet have different sensitivity to the small-molecule inhibitor splitomicin (compound 1) (Bedalov, A., Gatbonton, T., Irvine, W. P., Gottschling, D. E., and Simon, J. A. (2001) Proc. Natl. Acad. Sci. U. S. A. 98, 15113-15118). We have now defined a critical amino acid residue within a small helical module of Hst1 that confers relative resistance to splitomicin. Parallel cell-based screens of 100 splitomicin analogues led to the identification of compounds that exhibit a higher degree of selectivity toward Sir2 or Hst1. A series of compounds based on a splitomicin derivative, dehydrosplitomicin (compound 2), effectively phenocopied a yeast strain that lacked Hst1 deacetylase while having no effect on the silencing activities of Sir2. In addition, we identified a compound with improved selectivity for Sir2. Selectivity was affirmed using whole-genome DNA microarray analysis. This study underscores the power of phenotypic screens in the development and characterization of selective inhibitors of enzyme functions.	Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98109 USA; Fred Hutchinson Canc Res Ctr, Div Human Biol, Seattle, WA 98109 USA; Univ Washington, Program Biomol Struct & Design, Seattle, WA 98195 USA; Univ Munster, Dept Pharmaceut & Med Chem, D-48149 Munster, Germany	Fred Hutchinson Cancer Center; Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; University of Munster	Bedalov, A (corresponding author), Fred Hutchinson Canc Res Ctr, Div Clin Res, 1100 Fairview Ave N,Mailstop D2-100, Seattle, WA 98109 USA.	abedalov@fhcrc.org	Jung, Manfred/Q-8029-2016	Jung, Manfred/0000-0002-6361-7716; Hirao, Maki/0000-0001-7148-9278	NCI NIH HHS [CA78746] Funding Source: Medline; NHLBI NIH HHS [HL04211] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078746] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL004211] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Armstrong CM, 2002, MOL BIOL CELL, V13, P1427, DOI 10.1091/mbc.01-10-0482; Avalos JL, 2002, MOL CELL, V10, P523, DOI 10.1016/S1097-2765(02)00628-7; Bain J, 2003, BIOCHEM J, V371, P199, DOI 10.1042/BJ20021535; Bedalov A, 2003, MOL CELL BIOL, V23, P7044, DOI 10.1128/MCB.23.19.7044-7054.2003; Bedalov A, 2001, P NATL ACAD SCI USA, V98, P15113, DOI 10.1073/pnas.261574398; Bereshchenko OR, 2002, NAT GENET, V32, P606, DOI 10.1038/ng1018; Bernstein BE, 2000, P NATL ACAD SCI USA, V97, P13708, DOI 10.1073/pnas.250477697; Brachmann CB, 1998, YEAST, V14, P115; BRACHMANN CB, 1995, GENE DEV, V9, P2888, DOI 10.1101/gad.9.23.2888; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; BUCK SW, 1995, GENE DEV, V9, P370, DOI 10.1101/gad.9.3.370; Chang JH, 2002, J BIOL CHEM, V277, P34489, DOI 10.1074/jbc.M205460200; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; DeLano W.L, PYMOL MOL GRAPHICS S; Deryshire MK, 1996, YEAST, V12, P631; Finnin MS, 2001, NAT STRUCT BIOL, V8, P621, DOI 10.1038/89668; Frye RA, 2000, BIOCHEM BIOPH RES CO, V273, P793, DOI 10.1006/bbrc.2000.3000; Garcia SN, 2002, GENETICS, V162, P721; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; Gray NS, 1998, SCIENCE, V281, P533, DOI 10.1126/science.281.5376.533; Hughes TR, 2000, CELL, V102, P109, DOI 10.1016/S0092-8674(00)00015-5; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Jackson AD, 2002, J BIOL CHEM, V277, P18535, DOI 10.1074/jbc.M200671200; Landry J, 2000, BIOCHEM BIOPH RES CO, V278, P685, DOI 10.1006/bbrc.2000.3854; Landry J, 2000, P NATL ACAD SCI USA, V97, P5807, DOI 10.1073/pnas.110148297; Langley E, 2002, EMBO J, V21, P2383, DOI 10.1093/emboj/21.10.2383; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Marton MJ, 1998, NAT MED, V4, P1293, DOI 10.1038/3282; McCord R, 2003, MOL CELL BIOL, V23, P2009, DOI 10.1128/MCB.23.6.2009-2016.2003; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Min JR, 2001, CELL, V105, P269, DOI 10.1016/S0092-8674(01)00317-8; Moazed D, 2001, CURR OPIN CELL BIOL, V13, P232, DOI 10.1016/S0955-0674(00)00202-7; Norman TC, 1999, SCIENCE, V285, P591, DOI 10.1126/science.285.5427.591; North BJ, 2003, MOL CELL, V11, P437, DOI 10.1016/S1097-2765(03)00038-8; Perrod S, 2001, EMBO J, V20, P197, DOI 10.1093/emboj/20.1.197; Rusche LN, 2003, ANNU REV BIOCHEM, V72, P481, DOI 10.1146/annurev.biochem.72.121801.161547; Rusche LN, 2001, GENE DEV, V15, P955; Sauve AA, 2001, BIOCHEMISTRY-US, V40, P15456, DOI 10.1021/bi011858j; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; SIKORSKI RS, 1989, GENETICS, V122, P19; Smith JS, 2000, P NATL ACAD SCI USA, V97, P6658, DOI 10.1073/pnas.97.12.6658; Smith JS, 2002, METHOD ENZYMOL, V353, P282; Starai VJ, 2002, SCIENCE, V298, P2390, DOI 10.1126/science.1077650; Sutton A, 2001, MOL CELL BIOL, V21, P3514, DOI 10.1128/MCB.21.10.3514-3522.2001; Tanner KG, 2000, P NATL ACAD SCI USA, V97, P14178, DOI 10.1073/pnas.250422697; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; VOJTEK AB, 1995, METHOD ENZYMOL, V255, P331; Xie JX, 1999, EMBO J, V18, P6448, DOI 10.1093/emboj/18.22.6448	48	70	75	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52773	52782		10.1074/jbc.M308966200	http://dx.doi.org/10.1074/jbc.M308966200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14534292	hybrid			2022-12-27	WOS:000187480700096
J	Phetsuksiri, B; Jackson, M; Scherman, H; McNeil, M; Besra, GS; Baulard, AR; Slayden, RA; DeBarber, AE; Barry, CE; Baird, MS; Crick, DC; Brennan, PJ				Phetsuksiri, B; Jackson, M; Scherman, H; McNeil, M; Besra, GS; Baulard, AR; Slayden, RA; DeBarber, AE; Barry, CE; Baird, MS; Crick, DC; Brennan, PJ			Unique mechanism of action of the thiourea drug isoxyl on Mycobacterium tuberculosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID; POSITIONAL DISTRIBUTION; COFACTOR REQUIREMENTS; THERMAL ADAPTATION; STEAROYL-COENZYME; TUBERCLE-BACILLI; BIOSYNTHESIS; INHIBITION; DESATURATION; CHEMISTRY	The thiourea isoxyl (thiocarlide; 4,4'-diisoamyloxydiphenylthiourea) is known to be an effective anti-tuberculosis drug, active against a range of multidrug-resistant strains of Mycobacterium tuberculosis and has been used clinically. Little was known of its mode of action. We now demonstrate that isoxyl results in a dose-dependent decrease in the synthesis of oleic and, consequently, tuberculostearic acid in M. tuberculosis with complete inhibition at 3 mug/ml. Synthesis of mycolic acid was also affected. The anti-bacterial effect of isoxyl was partially reversed by supplementing growth medium with oleic acid. The specificity of this inhibition pointed to a Delta9-stearoyl desaturase as the drug target. Development of a cell-free assay for Delta9-desaturase activity allowed direct demonstration of the inhibition of oleic acid synthesis by isoxyl. Interestingly, sterculic acid, a known inhibitor of Delta9-desaturases, emulated the effect of isoxyl on oleic acid synthesis but did not affect mycolic acid synthesis, demonstrating the lack of a relationship between the two effects of the drug. The three putative fatty acid desaturases in the M. tuberculosis genome, desA1, desA2, and desA3, were cloned and expressed in Mycobacterium bovis BCG. Cell-free assays and whole cell labeling demonstrated increased Delta9-desaturase activity and oleic acid synthesis only in the desA3-overexpressing strain and an increase in the minimal inhibitory concentration for isoxyl, indicating that DesA3 is the target of the drug. These results validate membrane-bound Delta9-desaturase, DesA3, as a new therapeutic target, and the thioureas as anti-tuberculosis drugs worthy of further development.	Colorado State Univ, Dept Microbiol Pathol & Immunol, Ft Collins, CO 80523 USA; NIAID, NIH, Rockville, MD 20852 USA; Univ Wales, Dept Chem, Bangor LL57 2UW, Gwynedd, Wales	Colorado State University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Bangor University	Brennan, PJ (corresponding author), Colorado State Univ, Dept Microbiol Pathol & Immunol, Ft Collins, CO 80523 USA.	Patrick.Brennan@ColoState.edu	Baird, Mark/A-2470-2009; Slayden, Richard/O-8626-2016; Baulard, Alain R/E-6830-2017; Slayden, Richard/AAV-2582-2021; Barry, Clifton E/ABE-7992-2020; Crick, Dean/H-8251-2017; Barry, III, Clifton/H-3839-2012; McNeil, Michael/G-3325-2019; Jackson, Mary/D-5345-2017	Baird, Mark/0000-0001-5340-8745; Slayden, Richard/0000-0001-6857-7277; Baulard, Alain R/0000-0002-0150-5241; Slayden, Richard/0000-0001-6857-7277; Barry, Clifton E/0000-0002-2927-270X; Crick, Dean/0000-0001-9281-7058; Barry, III, Clifton/0000-0002-2927-270X; Jackson, Mary/0000-0002-9212-0258; Besra, Gurdyal/0000-0002-5605-0395	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI018357, R37AI018357, Z01AI000734, P01AI046393, U19AI038087, Z01AI000783, R22AI018357] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AKAMATSU Y, 1970, J BIOL CHEM, V245, P701; Anderson RJ, 1929, J BIOL CHEM, V83, P169; ANDRIANAIVORAFEHIVOLA AA, 1994, OLEAGINEUX, V49, P177; Barry CE, 2000, BIOCHEM PHARMACOL, V59, P221, DOI 10.1016/S0006-2952(99)00253-1; Barry CE, 1998, PROG LIPID RES, V37, P143, DOI 10.1016/S0163-7827(98)00008-3; Baulard AR, 2000, J BIOL CHEM, V275, P28326; Besra GS, 1997, J BIOL CHEM, V272, P18460, DOI 10.1074/jbc.272.29.18460; Camacho LR, 1999, MOL MICROBIOL, V34, P257, DOI 10.1046/j.1365-2958.1999.01593.x; CAMPBELL IM, 1969, J LIPID RES, V10, P593; Carson J, 1950, J AM CHEM SOC, V72, P4837, DOI [10.1021/ja01166a531, DOI 10.1021/JA01166A531]; Chou S, 1996, J CLIN MICROBIOL, V34, P1317, DOI 10.1128/JCM.34.5.1317-1320.1996; Chou S, 1998, J CLIN MICROBIOL, V36, P577, DOI 10.1128/JCM.36.2.577-579.1998; COHN ML, 1968, AM REV RESPIR DIS, V98, P295; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Cox JS, 1999, NATURE, V402, P79, DOI 10.1038/47042; DeBarber AE, 2000, P NATL ACAD SCI USA, V97, P9677, DOI 10.1073/pnas.97.17.9677; DUNPHY PJ, 1967, BIOCHIM BIOPHYS ACTA, V136, P136, DOI 10.1016/0304-4165(67)90329-7; Dye C, 2002, SCIENCE, V295, P2042, DOI 10.1126/science.1063814; Espinal MA, 2003, TUBERCULOSIS, V83, P44, DOI 10.1016/S1472-9792(02)00058-6; EVANS JE, 1983, BIOCHIM BIOPHYS ACTA, V752, P346, DOI 10.1016/0005-2760(83)90133-9; FULCO AJ, 1962, BIOCHIM BIOPHYS ACTA, V63, P545, DOI 10.1016/0006-3002(62)90130-0; FULCO AJ, 1964, J BIOL CHEM, V239, P993; GINGER LG, 1945, J BIOL CHEM, V157, P203; HAZEL JR, 1995, ANNU REV PHYSIOL, V57, P19, DOI 10.1146/annurev.ph.57.030195.000315; HOUSLAY MD, 1983, CURR TOP MEMBR TRANS, V18, P179; Jackson M, 2000, J BIOL CHEM, V275, P30092, DOI 10.1074/jbc.M004658200; JEFFCOAT R, 1977, LIPIDS, V12, P480, DOI 10.1007/BF02535446; JOHNSON AR, 1967, NATURE, V214, P1244, DOI 10.1038/2141244a0; KANEDA T, 1963, J BIOL CHEM, V238, P1229; KASHIWABARA Y, 1973, J BIOCHEM, V74, P405, DOI 10.1093/oxfordjournals.jbchem.a130260; KASHIWABARA Y, 1975, J BIOCHEM, V78, P803, DOI 10.1093/oxfordjournals.jbchem.a130969; KREMER L, 1995, J BACTERIOL, V177, P642, DOI 10.1128/jb.177.3.642-653.1995; LAMBELIN G, 1970, ANTIBIOT CHEMOTHER, V16, P84; LENNARZ WJ, 1962, J BIOL CHEM, V237, P664; Los DA, 1998, BBA-LIPID LIPID MET, V1394, P3, DOI 10.1016/S0005-2760(98)00091-5; MORRIS LJ, 1966, J LIPID RES, V7, P717; Obukowicz MG, 1998, J PHARMACOL EXP THER, V287, P157; OKUYAMA H, 1967, J BIOCHEM-TOKYO, V61, P732, DOI 10.1093/oxfordjournals.jbchem.a128607; Phetsuksiri B, 1999, ANTIMICROB AGENTS CH, V43, P1042, DOI 10.1128/AAC.43.5.1042; Quintana J, 1998, TETRAHEDRON, V54, P10187, DOI 10.1016/S0040-4020(98)00611-5; Ratledge C., 1982, BIOL MYCOBACTERIA, P53; RUSSELL NJ, 1984, TRENDS BIOCHEM SCI, V9, P108, DOI 10.1016/0968-0004(84)90106-3; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sauton B, 1912, CR HEBD ACAD SCI, V155, P860; SHANKLIN J, 1994, BIOCHEMISTRY-US, V33, P12787, DOI 10.1021/bi00209a009; STOVER CK, 1991, NATURE, V351, P456, DOI 10.1038/351456a0; STUBBS CD, 1984, BIOCHIM BIOPHYS ACTA, V779, P89, DOI 10.1016/0304-4157(84)90005-4; Titscher R, 1966, Prax Pneumol, V20, P202; URBANCIK B, 1970, ANTIBIOT CHEMOTHER, V16, P117; Urbancik B, 1966, Tubercle, V47, P283, DOI 10.1016/S0041-3879(66)80007-7; WALKER RW, 1970, LIPIDS, V5, P684, DOI 10.1007/BF02531435; *WHO, 2002, WHOCDSTB2002296WHOHI; Winder F. G., 1982, The biology of the mycobacteria. Volume 1, P353; WINDER F G, 1970, Journal of General Microbiology, V63, P41; WINDER FG, 1971, J GEN MICROBIOL, V66, P379, DOI 10.1099/00221287-66-3-379; YAJKO DM, 1995, J CLIN MICROBIOL, V33, P2324, DOI 10.1128/JCM.33.9.2324-2327.1995	56	130	149	0	13	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					53123	53130		10.1074/jbc.M311209200	http://dx.doi.org/10.1074/jbc.M311209200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14559907	Green Accepted, hybrid			2022-12-27	WOS:000187480700137
J	Priest, JW; Mehlert, A; Arrowood, MJ; Riggs, MW; Ferguson, MAJ				Priest, JW; Mehlert, A; Arrowood, MJ; Riggs, MW; Ferguson, MAJ			Characterization of a low molecular weight glycolipid antigen from Cryptosporidium parvum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMODIUM-FALCIPARUM GLYCOSYLPHOSPHATIDYLINOSITOLS; NEUTRALIZATION-SENSITIVE EPITOPES; IMMUNOGLOBULIN-G ANTIBODIES; ENZYME-IMMUNOASSAY; DRINKING-WATER; OUTBREAK; INFECTION; ANCHORS; CARBOHYDRATE; TRYPANOSOMA	Cryptosporidium parvum, an Apicomplexan parasite of the mammalian gut epithelium, causes a diarrheal illness in a wide range of hosts and is transmitted by contamination of food or water with oocyst-laden feces from an infected animal. We have identified a glycosyl-inositol phospholipid from the sporozoite stage of the parasite that is frequently recognized by serum antibodies from human cryptosporidiosis patients. The humoral immune response is dominated by IgG(1) subclass antibodies but can also include IgA and IgM antibodies. The glycosylinositol phospholipids were purified by butanol extraction of a Triton X-114-soluble fraction followed by octyl-Sepharose column chromatography and preparative high performance TLC and were shown to include at least 5 species. By using mass spectrometry and radiolabeled neutral glycan analysis, we found that the structure of the dominant glycosylinositol phospholipid antigen contained a C18:0 lyso-acylglycerol, a C16:0-acylated inositol, and an unsubstituted mannose(3)-glucosamine glycan core. Other diacyl species were also identified, most notably a series of glycosylinositol phospholipids having an acyl-linked C20:0 to C28:0 lipid on the inositol ring. Less abundant species having three acyl-linked fatty acids and species with an additional 1-3 hexoses linked to the mannose core were also observed. We are currently working to determine the role that these glycolipids may play in the development of disease and in the clearance of infection.	Ctr Dis Control & Prevent, Div Parasit Dis, Atlanta, GA 30341 USA; Univ Dundee, Div Biol Chem & Mol Microbiol, Dundee DD1 4HN, Scotland; Univ Arizona, Dept Vet Sci & Microbiol, Tucson, AZ 85721 USA; Atlanta Res & Educ Fdn, Decatur, GA 30033 USA	Centers for Disease Control & Prevention - USA; University of Dundee; University of Arizona	Priest, JW (corresponding author), Ctr Dis Control & Prevent, Div Parasit Dis, 4770 Buford Hwy NE, Atlanta, GA 30341 USA.	jpriest@cdc.gov	Ferguson, Michael A. J./F-7829-2010; Riggs, Michael/W-6518-2019	Ferguson, Michael A. J./0000-0003-1321-8714; 				ARROWOOD MJ, 1987, J PARASITOL, V73, P314, DOI 10.2307/3282084; BJORNEBY JM, 1990, J IMMUNOL, V145, P298; Boutlis CS, 2003, J INFECT DIS, V187, P862, DOI 10.1086/367897; *CDC, 1998, MMWR-MORBID MORTAL W, V47, P856; Chappell CL, 1996, J INFECT DIS, V173, P232, DOI 10.1093/infdis/173.1.232; Chen XM, 2002, NEW ENGL J MED, V346, P1723, DOI 10.1056/NEJMra013170; de Souza JB, 2002, INFECT IMMUN, V70, P5045, DOI 10.1128/IAI.70.9.5045-5051.2002; Dillingham RA, 2002, MICROBES INFECT, V4, P1059, DOI 10.1016/S1286-4579(02)01630-1; Dworkin MS, 1996, J INFECT DIS, V174, P1372, DOI 10.1093/infdis/174.6.1372; Ferguson MAJ, 1999, J CELL SCI, V112, P2799; FERGUSON MAJ, 1992, BIOCHEM J, V284, P297, DOI 10.1042/bj2840297; FERGUSON MAJ, 1994, GLYCOBIOLOGY PRACTIC, P349; Fontaine T, 2003, GLYCOBIOLOGY, V13, P169, DOI 10.1093/glycob/cwg004; Goldstein ST, 1996, ANN INTERN MED, V124, P459, DOI 10.7326/0003-4819-124-5-199603010-00001; HAYES EB, 1989, NEW ENGL J MED, V320, P1372, DOI 10.1056/NEJM198905253202103; Isaac-Renton J, 1999, AM J TROP MED HYG, V60, P578, DOI 10.4269/ajtmh.1999.60.578; JURANEK DD, 1995, CLIN INFECT DIS, V21, pS57, DOI 10.1093/clinids/21.Supplement_1.S57; KO YG, 1995, ANAL BIOCHEM, V224, P166, DOI 10.1006/abio.1995.1024; KORICH DG, 1990, APPL ENVIRON MICROB, V56, P1423, DOI 10.1128/AEM.56.5.1423-1428.1990; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee Sherline H, 2002, MMWR Surveill Summ, V51, P1; MacKenzie WR, 1995, EPIDEMIOL INFECT, V115, P545, DOI 10.1017/S0950268800058714; MACKENZIE WR, 1994, NEW ENGL J MED, V331, P161, DOI 10.1056/NEJM199407213310304; MCCONVILLE MJ, 1993, J BIOL CHEM, V268, P15595; McDonald AC, 2001, J INFECT DIS, V183, P1373, DOI 10.1086/319862; MEAD JR, 1988, J PARASITOL, V74, P135, DOI 10.2307/3282489; Morgan UM, 1997, J PARASITOL, V83, P825, DOI 10.2307/3284275; MOSS DM, 1993, AM J TROP MED HYG, V49, P393, DOI 10.4269/ajtmh.1993.49.393; Moss DM, 1998, AM J TROP MED HYG, V58, P110, DOI 10.4269/ajtmh.1998.58.110; Moss DM, 1998, J INFECT DIS, V178, P827, DOI 10.1086/515377; Naik RS, 2000, J EXP MED, V192, P1563, DOI 10.1084/jem.192.11.1563; Pozio E, 1997, J INFECT DIS, V176, P969, DOI 10.1086/516498; Priest JW, 1999, J CLIN MICROBIOL, V37, P1385, DOI 10.1128/JCM.37.5.1385-1392.1999; Priest JW, 2000, MOL BIOCHEM PARASIT, V106, P261, DOI 10.1016/S0166-6851(99)00223-6; Priest JW, 2001, CLIN DIAGN LAB IMMUN, V8, P415, DOI 10.1128/CDLI.8.2.415-423.2001; Priest JW, 2001, MOL BIOCHEM PARASIT, V113, P117, DOI 10.1016/S0166-6851(00)00386-8; REPERANT JM, 1994, VET PARASITOL, V55, P1, DOI 10.1016/0304-4017(94)90051-5; RIGGS MW, 1989, J IMMUNOL, V143, P1340; Riggs MW, 1999, INFECT IMMUN, V67, P1317, DOI 10.1128/IAI.67.3.1317-1322.1999; Ropert C, 2000, CURR OPIN MICROBIOL, V3, P395, DOI 10.1016/S1369-5274(00)00111-9; SCHNEIDER P, 1993, ANAL BIOCHEM, V210, P106, DOI 10.1006/abio.1993.1158; Schofield L, 2002, NATURE, V418, P785, DOI 10.1038/nature00937; Tachado SD, 1997, P NATL ACAD SCI USA, V94, P4022, DOI 10.1073/pnas.94.8.4022; Treumann A, 1998, METH MOL B, V76, P213; Treumann A, 1997, J MOL BIOL, V269, P529, DOI 10.1006/jmbi.1997.1066; WOODWARD MP, 1985, J IMMUNOL METHODS, V78, P143, DOI 10.1016/0022-1759(85)90337-0	46	20	22	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52212	52222		10.1074/jbc.M306835200	http://dx.doi.org/10.1074/jbc.M306835200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14557271	hybrid			2022-12-27	WOS:000187480700030
J	Soundar, S; Park, JH; Huh, TL; Colman, RF				Soundar, S; Park, JH; Huh, TL; Colman, RF			Evaluation by mutagenesis of the importance of 3 arginines in alpha, beta, and gamma subunits of human NAD-dependent isocitrate dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALLOSTERIC ADP SITE; PIG-HEART; AFFINITY LABEL; BINDING-SITES; 2-(4-BROMO-2,3-DIOXOBUTYLTHIO)ADENOSINE 5'-DIPHOSPHATE; CRYSTAL-STRUCTURE; TARGET PEPTIDES; PORCINE HEART; IDENTIFICATION; SUBSTRATE	Mammalian NAD-dependent isocitrate dehydrogenase is an allosteric enzyme, activated by ADP and composed of 3 distinct subunits in the ratio 2alpha:1beta:1gamma. Based on the crystal structure of NADP-dependent isocitrate dehydrogenases from Escherichia coli, Bacillus subtilis, and pig heart, and a comparison of their amino acid sequences, alpha-Arg(88), beta-Arg(99), and beta-Arg(97) of human NAD-dependent isocitrate dehydrogenase were chosen as candidates for mutagenesis to test their roles in catalytic activity and ADP activation. A plasmid harboring cDNA that encodes alpha, beta, and gamma subunits of the human isocitrate dehydrogenase (Kim, Y. O., Koh, H. J., Kim, S. H., Jo, S. H., Huh, J. W., Jeong, K. S., Lee, I. J., Song, B. J., and Huh, T. L. ( 1999) J. Biol. Chem. 274, 36866 36875) was used to express the enzyme in isocitrate dehydrogenase-deficient E. coli. Wild type (WT) and mutant enzymes ( each containing 2 normal subunits plus a mutant subunit with alpha-R88Q, beta-R99Q, or gamma-R97Q) were purified to homogeneity yielding enzymes with 2alpha:1beta:1gamma subunit composition and a native molecular mass of 315 kDa. Specific activities of 22, 14, and 2 mumol of NADH/ min/mg were measured, respectively, for WT, beta-R99Q, and gamma-R97Q enzymes. In contrast, mutant enzymes with normal beta and gamma subunits and alpha-R88Q mutant subunit has no detectable activity, demonstrating that, although beta-Arg(99) and gamma-Arg(97) contribute to activity, alpha-Arg(88) is essential for catalysis. For WT enzyme, the Km for isocitrate is 2.2 mM, decreasing to 0.3 mM with added ADP. In contrast, for beta-R99Q and gamma-R97Q enzymes, the K-m for isocitrate is the same in the absence or presence of ADP, although all the enzymes bind ADP. These results suggest that beta-Arg(99) and gamma-Arg(97) are needed for normal ADP activation. In addition, the gamma-R97Q enzyme has a K-m for NAD 10 times that of WT enzyme. This study indicates that a normal alpha subunit is required for catalytic activity and alpha-Arg(88) likely participates in the isocitrate site, whereas the beta and gamma subunits have roles in the nucleotide functions of this allosteric enzyme.	Univ Delaware, Dept Chem & Biochem, Newark, DE 19716 USA; Kyungpook Natl Univ, Dept Genet Engn, Taegu 702701, South Korea	University of Delaware; Kyungpook National University	Colman, RF (corresponding author), Univ Delaware, Dept Chem & Biochem, Newark, DE 19716 USA.				NHLBI NIH HHS [R01 HL67774] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067774] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BLACKSHEAR PJ, 1984, METHOD ENZYMOL, V104, P237; Ceccarelli C, 2002, J BIOL CHEM, V277, P43454, DOI 10.1074/jbc.M207306200; Chen HY, 1998, BIOCHEMISTRY-US, V37, P6541, DOI 10.1021/bi973032g; COHEN PF, 1972, BIOCHEMISTRY-US, V11, P1501, DOI 10.1021/bi00758a027; COHEN PF, 1971, BIOCHIM BIOPHYS ACTA, V242, P325, DOI 10.1016/0005-2744(71)90224-5; CUPP JR, 1993, BIOCHEMISTRY-US, V32, P9323, DOI 10.1021/bi00087a010; EHRLICH RS, 1983, J BIOL CHEM, V258, P7079; EHRLICH RS, 1981, J BIOL CHEM, V256, P1276; EHRLICH RS, 1982, J BIOL CHEM, V257, P4769; EHRLICH RS, 1981, J BIOL CHEM, V256, P560; Endrizzi J, 1996, ACTA CRYSTALLOGR D, V52, P1024, DOI 10.1107/S0907444996006154; GIORGIO NA, 1970, J BIOL CHEM, V245, P5469; HUANG Y, 1986, J BIOL CHEM, V261, P14100; HUANG YC, 1989, J BIOL CHEM, V264, P12208; HUANG YC, 1990, BIOCHEMISTRY-US, V29, P8266, DOI 10.1021/bi00488a010; Huang YC, 1997, ARCH BIOCHEM BIOPHYS, V348, P207, DOI 10.1006/abbi.1997.0392; HURLEY JH, 1989, P NATL ACAD SCI USA, V86, P8635, DOI 10.1073/pnas.86.22.8635; HURLEY JH, 1991, BIOCHEMISTRY-US, V30, P8671, DOI 10.1021/bi00099a026; KIM YO, 1995, BIOCHEM J, V308, P63, DOI 10.1042/bj3080063; Kim YO, 1999, J BIOL CHEM, V274, P36866, DOI 10.1074/jbc.274.52.36866; KUMAR A, 1994, ARCH BIOCHEM BIOPHYS, V308, P357, DOI 10.1006/abbi.1994.1051; Lin AP, 2003, J BIOL CHEM, V278, P12864, DOI 10.1074/jbc.M300154200; Panisko EA, 2001, J BIOL CHEM, V276, P1204, DOI 10.1074/jbc.M005056200; RAMACHANDRAN N, 1980, J BIOL CHEM, V255, P8859; RAMACHANDRAN N, 1978, P NATL ACAD SCI USA, V75, P252, DOI 10.1073/pnas.75.1.252; Singh SK, 2001, J BIOL CHEM, V276, P26154, DOI 10.1074/jbc.M101191200; SOUNDAR S, 1993, J BIOL CHEM, V268, P5264; Soundar S, 2002, FASEB J, V16, pA536; Soundar S, 2000, J BIOL CHEM, V275, P5606, DOI 10.1074/jbc.275.8.5606; STODDARD BL, 1993, BIOCHEMISTRY-US, V32, P9310, DOI 10.1021/bi00087a008; TAO BY, 1994, PCR TECHNOLOGY CURRE, P71; Warburg O., 1942, BIOCHEM Z, V310, P384	32	25	25	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52146	52153		10.1074/jbc.M306178200	http://dx.doi.org/10.1074/jbc.M306178200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14555658	hybrid			2022-12-27	WOS:000187480700022
J	Zhang, SP; Liu, JX; Dragunow, M; Cooper, GJS				Zhang, SP; Liu, JX; Dragunow, M; Cooper, GJS			Fibrillogenic amylin evokes islet beta-cell apoptosis through linked activation of a caspase cascade and JNK1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYPE-2 DIABETES-MELLITUS; AMYLOID FIBRIL FORMATION; FAS-MEDIATED APOPTOSIS; GENE-RELATED PEPTIDE; TRANSGENIC MICE; FULL-LENGTH; POLYPEPTIDE; KINASE; EXPRESSION; INSULIN	Fibrillogenic human amylin elicits pancreatic beta-cell apoptosis that may contribute to development of type-2 diabetes. Here, we demonstrated that activation of a caspase cascade is necessary for induction of apoptosis by fibrillogenic amylin variants in two pancreatic beta-cell lines. Human amylin, as well as truncated (8-37)human amylin, evoked sequential activation of caspases-8 and -3, and apoptosis, whereas non-beta-sheet forming and non-fibrillogenic homologs, such as [(25,28,29)triprolyl]human amylin, did not, implying that the beta-sheet conformer is required for human amylin-induced caspase activation. Significant inhibition of apoptosis was evoked by a selective caspase-1 inhibitor, indicating that caspase-1 is also essential for activation of the caspase cascade. Furthermore, we showed that specific jnk1 antisense oligonucleotides, which suppress phospho-JNK1 expression, effectively decreased human amylin-induced activation of c-Jun. Studies of the interplay between the caspase cascade and the JNK pathway showed that both apoptosis and caspase-3 activation were suppressed by treatment with a JNK inhibitor and by transfection of antisense jnk1 oligonucleotides or antisense-c-jun, whereas a selective inhibitor of caspases-1 and -3 prevented apoptosis but not c-Jun activation. Thus, the JNK1 activation preceded activation of caspases-1 and -3. However, selective JNK inhibition had no effect on caspase-8 activation, and selective caspase-8 inhibition only partially suppressed apoptosis and c-Jun activation, indicating that caspase-8 may partially act upstream of the JNK pathway. Our studies demonstrate a functional interaction of a caspase cascade and JNK1. Fibrillogenic amylin can evoke a JNK1-mediated apoptotic pathway, which is partially dependent and partially independent of caspase-8, and in which caspase-3 acts as a common downstream effector.	Univ Auckland, Sch Biol Sci, Fac Sci, Auckland 1, New Zealand; Univ Auckland, Fac Med & Hlth Sci, Dept Pharmacol & Clin Pharmacol, Auckland 1, New Zealand	University of Auckland; University of Auckland	Cooper, GJS (corresponding author), Univ Auckland, Sch Biol Sci, Fac Sci, 3 Symonds St,Level 4-1,Private Bag 92019, Auckland 1, New Zealand.		Cooper, Garth JS/I-3201-2015	Cooper, Garth JS/0000-0001-5241-3163; Zhang, Shaoping/0000-0003-2969-7043				Bai JZ, 1999, BIOCHEM J, V343, P53, DOI 10.1042/0264-6021:3430053; Bonny C, 2001, DIABETES, V50, P77, DOI 10.2337/diabetes.50.1.77; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; CLARK A, 1987, LANCET, V2, P231; COOPER GJS, 1989, BIOCHIM BIOPHYS ACTA, V1014, P247, DOI 10.1016/0167-4889(89)90220-6; COOPER GJS, 1994, ENDOCR REV, V15, P163, DOI 10.1210/er.15.2.163; COOPER GJS, 1987, P NATL ACAD SCI USA, V84, P8628, DOI 10.1073/pnas.84.23.8628; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; Fineman M, 2000, DIABETES, V49, pA106; Fineman MS, 2002, METABOLISM, V51, P636, DOI 10.1053/meta.2002.32022; Goldsbury C, 2000, J STRUCT BIOL, V130, P352, DOI 10.1006/jsbi.2000.4268; Goldsbury C, 1999, J MOL BIOL, V285, P33, DOI 10.1006/jmbi.1998.2299; Goldsbury CS, 1997, J STRUCT BIOL, V119, P17, DOI 10.1006/jsbi.1997.3858; Green J, 2003, J MOL BIOL, V326, P1147, DOI 10.1016/S0022-2836(02)01377-3; GUELI N, 1987, J EXP CLIN CANC RES, V6, P281; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; Hettiarachchi M, 1997, AM J PHYSIOL-ENDOC M, V273, pE859, DOI 10.1152/ajpendo.1997.273.5.E859; Hoppener JWM, 2000, NEW ENGL J MED, V343, P411; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Jaikaran ETAS, 2001, J MOL BIOL, V308, P515, DOI 10.1006/jmbi.2001.4593; Janciauskiene S, 2000, BIOCHEM BIOPH RES CO, V267, P619, DOI 10.1006/bbrc.1999.1989; Janes S, 1996, DIABETES, V45, P865; Janson J, 1996, P NATL ACAD SCI USA, V93, P7283, DOI 10.1073/pnas.93.14.7283; Janson J, 1999, DIABETES, V48, P491, DOI 10.2337/diabetes.48.3.491; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; Kahn SE, 1999, DIABETES, V48, P241, DOI 10.2337/diabetes.48.2.241; Kapurniotu A, 2001, BIOPOLYMERS, V60, P438, DOI 10.1002/1097-0282(2001)60:6<438::AID-BIP10182>3.0.CO;2-A; Kumagae Y, 1999, MOL BRAIN RES, V67, P10, DOI 10.1016/S0169-328X(99)00013-3; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Longthorne VL, 1997, EMBO J, V16, P3805, DOI 10.1093/emboj/16.13.3805; LORENZO A, 1994, NATURE, V368, P756, DOI 10.1038/368756a0; Mazor Y, 2002, J MOL BIOL, V322, P1013, DOI 10.1016/S0022-2836(02)00887-2; Mirzabekov TA, 1996, J BIOL CHEM, V271, P1988, DOI 10.1074/jbc.271.4.1988; MOORE CX, 1991, BIOCHEM BIOPH RES CO, V179, P1, DOI 10.1016/0006-291X(91)91325-7; Nilsson MR, 1999, J MOL BIOL, V294, P1375, DOI 10.1006/jmbi.1999.3286; OGAWA A, 1990, J CLIN INVEST, V85, P973, DOI 10.1172/JCI114528; Ohtsuka T, 2002, J BIOL CHEM, V277, P29294, DOI 10.1074/jbc.M203342200; Poyner D, 1995, TRENDS PHARMACOL SCI, V16, P424, DOI 10.1016/S0165-6147(00)89093-8; ROBERTS AN, 1989, P NATL ACAD SCI USA, V86, P9662, DOI 10.1073/pnas.86.24.9662; Saafi EL, 2001, CELL BIOL INT, V25, P339, DOI 10.1006/cbir.2000.0643; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; Soeller WC, 1998, DIABETES, V47, P743, DOI 10.2337/diabetes.47.5.743; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; Tenidis K, 2000, J MOL BIOL, V295, P1055, DOI 10.1006/jmbi.1999.3422; THOMPSON CB, 1995, SCIENCE, V267, P1455; Thompson RG, 1997, DIABETIC MED, V14, P547, DOI 10.1002/(SICI)1096-9136(199707)14:7<547::AID-DIA390>3.0.CO;2-U; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; van Hulst KL, 1999, EUR J ENDOCRINOL, V140, P69, DOI 10.1530/eje.0.1400069; VAUX DL, 1993, P NATL ACAD SCI USA, V90, P786, DOI 10.1073/pnas.90.3.786; Verchere CB, 1996, P NATL ACAD SCI USA, V93, P3492, DOI 10.1073/pnas.93.8.3492; Villunger A, 2000, J IMMUNOL, V165, P1337, DOI 10.4049/jimmunol.165.3.1337; WATANABEFUKUNAG.R, 1992, NATURE, V356, P317; WESTERMARK P, 1990, P NATL ACAD SCI USA, V87, P5036, DOI 10.1073/pnas.87.13.5036; Weyer C, 2001, CURR PHARM DESIGN, V7, P1353, DOI 10.2174/1381612013397357; Yamada K, 1999, DIABETES, V48, P478, DOI 10.2337/diabetes.48.3.478; Zhang SP, 2002, J MOL BIOL, V324, P271, DOI 10.1016/S0022-2836(02)01044-6; Zhang SP, 1999, FEBS LETT, V455, P315, DOI 10.1016/S0014-5793(99)00894-7	60	93	96	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52810	52819		10.1074/jbc.M308244200	http://dx.doi.org/10.1074/jbc.M308244200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14532296	hybrid			2022-12-27	WOS:000187480700100
J	Putkey, JA; Kleerekoper, Q; Gaertner, TR; Waxham, MN				Putkey, JA; Kleerekoper, Q; Gaertner, TR; Waxham, MN			A new role for IQ motif proteins in regulating calmodulin function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING; CA2+ BINDING; KINASE-II; PEPTIDES; DISSOCIATION; NEUROMODULIN; COMPLEXES; CHANNEL; SIGNAL; SITE	IQ motifs are found in diverse families of calmodulin (CaM)-binding proteins. Some of these, like PEP-19 and RC3, are highly abundant in neuronal tissues, but being devoid of catalytic activity, their biological roles are not understood. We hypothesized that these IQ motif proteins might have unique effects on the Ca2+ binding properties of CaM, since they bind to CaM in the presence or absence of Ca2+. Here we show that PEP-19 accelerates by 40 to 50-fold both the slow association and dissociation of Ca2+ from the C-domain of free CaM, and we identify the sites of interaction between CaM and PEP-19 using NMR. Importantly, we demonstrate that PEP-19 can also increase the rate of dissociation of Ca2+ from CaM when bound to intact CaM-dependent protein kinase II. Thus, PEP-19, and presumably similar members of the IQ family of proteins, has the potential to alter the Ca2+-binding dynamics of free CaM and CaM that is bound to other target proteins. Since Ca2+ binding to the C-domain of CaM is the rate-limiting step for activation of CaM-dependent enzymes, the data reveal a new concept of importance in understanding the temporal dynamics of Ca2+-dependent cell signaling.	Univ Texas, Sch Med, Dept Biochem & Mol Biol, Houston, TX 77030 USA; Univ Texas, Sch Med, Dept Neurobiol & Anat, Houston, TX 77030 USA	University of Texas System; University of Texas System	Putkey, JA (corresponding author), Univ Texas, Sch Med, Dept Biochem & Mol Biol, Houston, TX 77030 USA.	John.Putkey@uth.tmc.edu		Waxham, M. Neal/0000-0003-4801-1190	NHLBI NIH HHS [HL45724] Funding Source: Medline; NINDS NIH HHS [NS26086] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045724] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS026086, R56NS026086] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALEXANDER KA, 1987, J BIOL CHEM, V262, P6108; BAUDIER J, 1991, J BIOL CHEM, V266, P229; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; Bootman MD, 2001, J CELL SCI, V114, P2213; BRITO RMM, 1991, BIOCHEMISTRY-US, V30, P10236, DOI 10.1021/bi00106a023; Brown SE, 1997, J BIOL CHEM, V272, P3389, DOI 10.1074/jbc.272.6.3389; Chou JJ, 2001, NAT STRUCT BIOL, V8, P990, DOI 10.1038/nsb1101-990; DeMaria CD, 2001, NATURE, V411, P484, DOI 10.1038/35078091; Dolmetsch RE, 2001, SCIENCE, V294, P333, DOI 10.1126/science.1063395; Franks KM, 2002, BIOESSAYS, V24, P1130, DOI 10.1002/bies.10193; Gerendasy D, 1999, J NEUROSCI RES, V58, P107, DOI 10.1002/(SICI)1097-4547(19991001)58:1<107::AID-JNR11>3.0.CO;2-G; GERENDASY DD, 1994, J BIOL CHEM, V269, P22420; Hoeflich KP, 2002, CELL, V108, P739, DOI 10.1016/S0092-8674(02)00682-7; Hudmon A, 2002, ANNU REV BIOCHEM, V71, P473, DOI 10.1146/annurev.biochem.71.110601.135410; IKURA M, 1990, BIOCHEMISTRY-US, V29, P4659, DOI 10.1021/bi00471a022; Johnson JD, 1996, J BIOL CHEM, V271, P761, DOI 10.1074/jbc.271.2.761; Lee A, 1999, NATURE, V399, P155, DOI 10.1038/20194; LINSE S, 1991, J BIOL CHEM, V266, P8050; LIU YC, 1990, TRENDS PHARMACOL SCI, V11, P107; Mouton J, 2001, J BIOL CHEM, V276, P22359, DOI 10.1074/jbc.M100755200; OLWIN BB, 1985, BIOCHEMISTRY-US, V24, P8081, DOI 10.1021/bi00348a037; Pate P, 2000, J BIOL CHEM, V275, P39786, DOI 10.1074/jbc.M007158200; Peersen OB, 1997, PROTEIN SCI, V6, P794; Persechini A, 1996, J BIOL CHEM, V271, P62, DOI 10.1074/jbc.271.1.62; Putkey JA, 1996, J BIOL CHEM, V271, P29619, DOI 10.1074/jbc.271.47.29619; Sabatini BL, 2002, NEURON, V33, P439, DOI 10.1016/S0896-6273(02)00573-1; Slemmon JR, 2000, MOL NEUROBIOL, V22, P99, DOI 10.1385/MN:22:1-3:099; Waxham MN, 1998, J BIOL CHEM, V273, P17579, DOI 10.1074/jbc.273.28.17579	28	81	82	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					49667	49670		10.1074/jbc.C300372200	http://dx.doi.org/10.1074/jbc.C300372200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	14551202	hybrid			2022-12-27	WOS:000187068200003
J	Scheuring, S; Francia, F; Busselez, J; Melandri, BA; Rigaud, JL; Levy, D				Scheuring, S; Francia, F; Busselez, J; Melandri, BA; Rigaud, JL; Levy, D			Structural role of PufX in the dimerization of the photosynthetic core complex of Rhodobacter sphaeroides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-HARVESTING COMPLEX; RESOLUTION AFM TOPOGRAPHS; 2-DIMENSIONAL CRYSTALLIZATION; RHODOPSEUDOMONAS-VIRIDIS; RHODOSPIRILLUM-RUBRUM; CRYSTAL-STRUCTURE; PROJECTION MAP; PROTEIN; APPARATUS; UNIT	Monomeric and dimeric PufX-containing core complexes have been purified from membranes of wild-type Rhodobacter sphaeroides. Reconstitution of both samples by detergent removal in the presence of lipids leads to the formation of two-dimensional crystals constituted of dimeric core complexes. Two-dimensional crystals were further analyzed by cryoelectron microscopy and atomic force microscopy. A projection map at 26-Angstrom resolution reveals that core complexes assemble in an "S"-shaped dimeric complex. Each core complex is composed of one reaction center, 12 light-harvesting 1 alpha/beta-heterodimers, and one PufX protein. The light-harvesting 1 assemblies are open with a gap of density of similar to30-Angstrom width and surround oriented reaction centers. A maximum density is found at the dimer junction. Based on the projection map, a model is proposed, in which the two PufX proteins are located at the dimer junction, consistent with the finding of dimerization of monomeric core complexes upon reconstitution. This localization of PufX in the core complex implies that PufX is the structural key for the dimer complex formation rather than a channel-forming protein for the exchange of ubiquinone/ubiquinol between the reaction center and the cytochrome bc1 complex.	Inst Curie, CNRS, UMR 168, F-75231 Paris 05, France; CEA, LRC, F-75231 Paris 05, France; Univ Bologna, Dept Biol, Biochem & Biophys Lab, I-40126 Bologna, Italy	Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); UDICE-French Research Universities; PSL Research University Paris; Sorbonne Universite; UNICANCER; Institut Curie; CEA; University of Bologna	Levy, D (corresponding author), Inst Curie, CNRS, UMR 168, 11 Rue Pierre & Marie Curie, F-75231 Paris 05, France.	daniel.levy@curie.fr	Scheuring, Simon/L-9843-2018	Scheuring, Simon/0000-0003-3534-069X; FRANCIA, FRANCESCO/0000-0003-2888-0938; levy, daniel/0000-0002-8949-4072				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARZ WP, 1995, BIOCHEMISTRY-US, V34, P15248, DOI 10.1021/bi00046a033; Chami M, 2001, J STRUCT BIOL, V133, P64, DOI 10.1006/jsbi.2001.4344; CHEN YR, 1994, BIOCHEMISTRY-US, V33, P495; Crofts AR, 2000, TRENDS MICROBIOL, V8, P107, DOI 10.1016/S0966-842X(99)01695-9; Crowther RA, 1996, J STRUCT BIOL, V116, P9, DOI 10.1006/jsbi.1996.0003; DEISENHOFER J, 1985, NATURE, V318, P618, DOI 10.1038/318618a0; ENGELHARDT H, 1986, P NATL ACAD SCI USA, V83, P8972, DOI 10.1073/pnas.83.23.8972; FARCHAUS JW, 1992, EMBO J, V11, P2779, DOI 10.1002/j.1460-2075.1992.tb05345.x; Francia F, 1999, BIOCHEMISTRY-US, V38, P6834, DOI 10.1021/bi982891h; Francia F, 2002, EUR J BIOCHEM, V269, P1877, DOI 10.1046/j.1432-1033.2002.02834.x; Frese RN, 2000, P NATL ACAD SCI USA, V97, P5197, DOI 10.1073/pnas.090083797; Hu XC, 2002, Q REV BIOPHYS, V35, P1, DOI 10.1017/S0033583501003754; Ikeda-Yamasaki I, 1998, FEBS LETT, V425, P505, DOI 10.1016/S0014-5793(98)00300-7; Jamieson SJ, 2002, EMBO J, V21, P3927, DOI 10.1093/emboj/cdf410; Jungas C, 1999, EMBO J, V18, P534, DOI 10.1093/emboj/18.3.534; KARRASCH S, 1995, EMBO J, V14, P631, DOI 10.1002/j.1460-2075.1995.tb07041.x; Koepke J, 1996, STRUCTURE, V4, P581, DOI 10.1016/S0969-2126(96)00063-9; Levy D, 1999, J STRUCT BIOL, V127, P44, DOI 10.1006/jsbi.1999.4155; LILBURN TG, 1992, BIOCHIM BIOPHYS ACTA, V1100, P160; Loach PA, 2000, P NATL ACAD SCI USA, V97, P5016, DOI 10.1073/pnas.97.10.5016; MCDERMOTT G, 1995, NATURE, V374, P517, DOI 10.1038/374517a0; MCGLYNN P, 1994, FEBS LETT, V349, P349, DOI 10.1016/0014-5793(94)00701-2; MECKENSTOCK RU, 1994, BIOL CHEM H-S, V375, P429, DOI 10.1515/bchm3.1994.375.7.429; MILLER KR, 1982, NATURE, V300, P53, DOI 10.1038/300053a0; Parkes-Loach PS, 2001, BIOCHEMISTRY-US, V40, P5593, DOI 10.1021/bi002580i; Pugh RJ, 1998, BBA-BIOENERGETICS, V1366, P301, DOI 10.1016/S0005-2728(98)00131-5; Recchia PA, 1998, BIOCHEMISTRY-US, V37, P11055, DOI 10.1021/bi980657l; RIGAUD J, 2000, BIOCHIM BIOPHYS ACTA, V23, P112; Rigaud JL, 1998, EUR BIOPHYS J BIOPHY, V27, P305, DOI 10.1007/s002490050138; ROST B, 1994, COMPUT APPL BIOSCI, V10, P53; SCHABERT FA, 1994, BIOPHYS J, V67, P2394, DOI 10.1016/S0006-3495(94)80726-X; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Scheuring S, 2003, P NATL ACAD SCI USA, V100, P1690, DOI 10.1073/pnas.0437992100; Scheuring S, 2003, J MOL BIOL, V325, P569, DOI 10.1016/S0022-2836(02)01241-X; Scheuring S, 1999, EMBO J, V18, P4981, DOI 10.1093/emboj/18.18.4981; Scheuring S, 2001, EMBO J, V20, P3029, DOI 10.1093/emboj/20.12.3029; Stahlberg H, 1998, J MOL BIOL, V282, P819, DOI 10.1006/jmbi.1998.1975; STARK W, 1984, EMBO J, V3, P777, DOI 10.1002/j.1460-2075.1984.tb01884.x; VALPUESTA JM, 1994, J MOL BIOL, V240, P281, DOI 10.1006/jmbi.1994.1445; Vermeglio A, 1999, TRENDS MICROBIOL, V7, P435, DOI 10.1016/S0966-842X(99)01625-X; Walz T, 1998, J MOL BIOL, V282, P833, DOI 10.1006/jmbi.1998.2050; Walz T, 1997, J MOL BIOL, V265, P107, DOI 10.1006/jmbi.1996.0714; Westerhuis WHJ, 2002, BIOCHEMISTRY-US, V41, P8698, DOI 10.1021/bi011663b; Xia D, 1997, SCIENCE, V277, P60, DOI 10.1126/science.277.5322.60	46	104	110	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	2004	279	5					3620	3626		10.1074/jbc.M310050200	http://dx.doi.org/10.1074/jbc.M310050200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	766MF	14581468	hybrid			2022-12-27	WOS:000188379600060
J	Grimshaw, SJ; Mott, HR; Stott, KM; Nielsen, PR; Evetts, KA; Hopkins, LJ; Nietlispach, D; Owen, D				Grimshaw, SJ; Mott, HR; Stott, KM; Nielsen, PR; Evetts, KA; Hopkins, LJ; Nietlispach, D; Owen, D			Structure of the sterile alpha motif (SAM) domain of the Saccharomyces cerevisiae mitogen-activated protein kinase pathway-modulating protein STE50 and analysis of its interaction with the STE11 SAM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCHIZOSACCHAROMYCES-POMBE; SIGNAL-TRANSDUCTION; RESPONSE PATHWAY; CHEMICAL-SHIFT; RECEPTOR; YEAST; ASSOCIATION; BYR2; IDENTIFICATION; HOMOLOGY	The sterile alpha motif (SAM) is a 65-70-amino acid domain found in over 300 proteins that are involved in either signal transduction or transcriptional activation and repression. SAM domains have been shown to mediate both homodimerization and heterodimerization and in some cases oligomerization. Here, we present the solution structure of the SAM domain of the Saccharomyces cerevisiae protein, Ste50p. Ste50p functions as a modulator of the mitogen-activated protein kinase (MAPK) cascades in S. cerevisiae, which control mating, pseudohyphal growth, and osmo-tolerance. This is the first example of the structure of a SAM domain from a MAPK module protein. We have studied the associative behavior of Ste50p SAM in solution and shown that it is monomeric. We have examined the SAM domain from Ste11p, the MAPK kinase kinase that associates with Ste50p in vivo, and shown that it forms dimers with a self-association K-d of similar to 0.5 mM. We have also analyzed the interaction of Ste50p SAM with Ste11p SAM and the effects of mutations at Val-37, Asp-38, Pro-71, Leu-73, Leu-75, and Met-99 of STE50 on the heterodimerization properties of Ste50p SAM. We have found that L73A and L75A abrogate the Ste50p interaction with Ste11p, and we compare these data with the known interaction sites defined for other SAM domain interactions.	Univ Cambridge, Dept Biochem, Cambridge CB2 1GA, England	University of Cambridge	Owen, D (corresponding author), Univ Cambridge, Dept Biochem, 80 Tennis Court Rd, Cambridge CB2 1GA, England.	do@bioc.cam.ac.uk	Mott, Helen/AAV-3873-2020	Mott, Helen/0000-0002-7890-7097; Nietlispach, Daniel/0000-0003-4364-9291; Stott, Katherine/0000-0002-4014-1188				Banuett F, 1998, MICROBIOL MOL BIOL R, V62, P249, DOI 10.1128/MMBR.62.2.249-274.1998; Barr MM, 1996, MOL CELL BIOL, V16, P5597; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; Behlke J, 2001, EUR BIOPHYS J BIOPHY, V30, P411, DOI 10.1007/s002490100164; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chi SW, 1999, EMBO J, V18, P4438, DOI 10.1093/emboj/18.16.4438; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; Hock B, 1998, P NATL ACAD SCI USA, V95, P9779, DOI 10.1073/pnas.95.17.9779; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; Kim CA, 2002, NAT STRUCT BIOL, V9, P453, DOI 10.1038/nsb802; Kim CA, 2001, EMBO J, V20, P4173, DOI 10.1093/emboj/20.15.4173; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRAULIS PJ, 1994, BIOCHEMISTRY-US, V33, P3515, DOI 10.1021/bi00178a008; Kyba M, 1998, DEV GENET, V22, P74, DOI 10.1002/(SICI)1520-6408(1998)22:1<74::AID-DVG8>3.3.CO;2-V; Linge JP, 2001, METHOD ENZYMOL, V339, P71, DOI 10.1016/S0076-6879(01)39310-2; MARSH L, 1991, ANNU REV CELL BIOL, V7, P699, DOI 10.1146/annurev.cellbio.7.1.699; McGrath JA, 2001, HUM MOL GENET, V10, P221, DOI 10.1093/hmg/10.3.221; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Pervushin K, 1997, P NATL ACAD SCI USA, V94, P12366, DOI 10.1073/pnas.94.23.12366; PONTING CP, 1995, PROTEIN SCI, V4, P1928, DOI 10.1002/pro.5560040927; Posas F, 1998, MOL CELL BIOL, V18, P5788, DOI 10.1128/MCB.18.10.5788; RAD MR, 1992, MOL GEN GENET, V236, P145; Rad MR, 1998, MOL GEN GENET, V259, P29, DOI 10.1007/s004380050785; Ramachander R, 2002, J BIOL CHEM, V277, P39585, DOI 10.1074/jbc.M207273200; Ramezani-Rad M, 2003, CURR GENET, V43, P161, DOI 10.1007/s00294-003-0383-6; Schultz J, 1997, PROTEIN SCI, V6, P249; SERRAPAGES C, 1995, EMBO J, V14, P2827, DOI 10.1002/j.1460-2075.1995.tb07282.x; Slupsky CM, 1998, P NATL ACAD SCI USA, V95, P12129, DOI 10.1073/pnas.95.21.12129; Smalla M, 1999, PROTEIN SCI, V8, P1954, DOI 10.1110/ps.8.10.1954; Stapleton D, 1999, NAT STRUCT BIOL, V6, P44; Stein E, 1996, J BIOL CHEM, V271, P23588, DOI 10.1074/jbc.271.38.23588; Stein E, 1998, GENE DEV, V12, P667, DOI 10.1101/gad.12.5.667; Thanos CD, 1999, PROTEIN SCI, V8, P1708, DOI 10.1110/ps.8.8.1708; Thanos CD, 1999, SCIENCE, V283, P833, DOI 10.1126/science.283.5403.833; Thanos CD, 1999, J BIOL CHEM, V274, P37301, DOI 10.1074/jbc.274.52.37301; Tu H, 1997, MOL CELL BIOL, V17, P5876, DOI 10.1128/MCB.17.10.5876; Wang WK, 2001, ACTA CRYSTALLOGR D, V57, P545, DOI 10.1107/S0907444901002529; Wu CL, 1999, MOL BIOL CELL, V10, P2425, DOI 10.1091/mbc.10.7.2425; Xu G, 1996, MOL MICROBIOL, V20, P773, DOI 10.1111/j.1365-2958.1996.tb02516.x	39	36	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 16	2004	279	3					2192	2201		10.1074/jbc.M305605200	http://dx.doi.org/10.1074/jbc.M305605200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	762WT	14573615	hybrid			2022-12-27	WOS:000188005700076
J	Naka, K; Tachibana, A; Ikeda, K; Motoyama, N				Naka, K; Tachibana, A; Ikeda, K; Motoyama, N			Stress-induced premature senescence in hTERT-expressing ataxia telangiectasia fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE; OXIDATIVE STRESS; G(1) ARREST; CELL-CYCLE; C-MYC; REPLICATIVE SENESCENCE; TELOMERASE ACTIVITY; SHORTENS TELOMERES; IONIZING-RADIATION; SIGNALING PATHWAY	In addition to replicative senescence, normal diploid fibroblasts undergo stress-induced premature senescence (SIPS) in response to DNA damage caused by oxidative stress or ionizing radiation (IR). SIPS is not prevented by telomere elongation, indicating that, unlike replicative senescence, it is triggered by nonspecific genome-wide DNA damage rather than by telomere shortening. ATM, the product of the gene mutated in individuals with ataxia telangiectasia (AT), plays a central role in cell cycle arrest in response to DNA damage. Whether ATM also mediates signaling that leads to SIPS was investigated with the use of normal and AT fibroblasts stably transfected with an expression vector for the catalytic subunit of human telomerase (hTERT). Expression of hTERT in AT fibroblasts resulted in telomere elongation and prevented premature replicative senescence, but it did not rescue the defect in G(1) checkpoint activation or the hypersensitivity of the cells to IR. Despite these remaining defects in the DNA damage response, hTERT-expressing AT fibroblasts exhibited characteristics of senescence on exposure to IR or H2O2 in such a manner that triggers SIPS in normal fibroblasts. These characteristics included the adoption of an enlarged and flattened morphology, positive staining for senescence-associated beta-galactosidase activity, termination of DNA synthesis, and accumulation of p53, p21(WAF1), and p16(INK4A). The phosphorylation of p38 mitogen-activated protein kinase ( p38 MAPK), which mediates signaling that leads to senescence, was also detected in both IR- or H2O2-treated AT and normal fibroblasts expressing hTERT. These results suggest that the ATM-dependent signaling pathway triggered by DNA damage is dispensable for activation of p38 MAPK and SIPS in response to IR or oxidative stress.	Natl Inst Longev Sci, Dept Geriatr Res, Morioka, Obu 4748522, Japan; Kyoto Univ, Ctr Radiat Biol, Sakyo Ku, Kyoto 6068501, Japan	Kyoto University	Motoyama, N (corresponding author), Natl Inst Longev Sci, Dept Geriatr Res, 36-3 Gengo, Morioka, Obu 4748522, Japan.	motoyama@nils.go.jp	Naka, Kazuhito/X-3756-2019; Tachibana, Akira/G-1529-2010	Naka, Kazuhito/0000-0001-6646-6004; Tachibana, Akira/0000-0002-2357-9276				ANDERSON CW, 2003, HDB CELL SIGNALING, P237; Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Barzilai A, 2002, DNA REPAIR, V1, P3, DOI 10.1016/S1568-7864(01)00007-6; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Brancho D, 2003, GENE DEV, V17, P1969, DOI 10.1101/gad.1107303; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Bulavin DV, 2002, NAT GENET, V31, P210, DOI 10.1038/ng894; Chan SWL, 2003, MOL CELL, V11, P1379, DOI 10.1016/S1097-2765(03)00174-6; Chehab NH, 2000, GENE DEV, V14, P278; Chen QM, 1998, BIOCHEM J, V332, P43, DOI 10.1042/bj3320043; Chen QM, 2001, EXP CELL RES, V265, P294, DOI 10.1006/excr.2001.5182; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Dumont P, 2000, FREE RADICAL BIO MED, V28, P361, DOI 10.1016/S0891-5849(99)00249-X; Ejima Y, 1998, HUM GENET, V102, P403, DOI 10.1007/s004390050712; Gorbunova V, 2002, J BIOL CHEM, V277, P38540, DOI 10.1074/jbc.M202671200; Hai T, 1999, GENE EXPRESSION, V7, P321; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Hirao A, 2002, MOL CELL BIOL, V22, P6521, DOI 10.1128/MCB.22.18.6521-6532.2002; Iwasa H, 2003, GENES CELLS, V8, P131, DOI 10.1046/j.1365-2443.2003.00620.x; Kang YB, 2003, MOL CELL, V11, P915, DOI 10.1016/S1097-2765(03)00109-6; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Khanna KK, 2001, CELL DEATH DIFFER, V8, P1052, DOI 10.1038/sj.cdd.4400874; Kim GY, 2002, J BIOL CHEM, V277, P29792, DOI 10.1074/jbc.M201299200; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Kool J, 2003, ONCOGENE, V22, P4235, DOI 10.1038/sj.onc.1206611; Kowalik TF, 1998, CELL GROWTH DIFFER, V9, P113; Lavin MF, 1997, ANNU REV IMMUNOL, V15, P177, DOI 10.1146/annurev.immunol.15.1.177; MEDRANO EE, 1995, CANCER RES, V55, P4047; Melchionna R, 2000, NAT CELL BIOL, V2, P762, DOI 10.1038/35036406; Metcalfe JA, 1996, NAT GENET, V13, P350, DOI 10.1038/ng0796-350; MEYN MS, 1995, CANCER RES, V55, P5991; Morgan SE, 1997, ADV CANCER RES, V71, P1, DOI 10.1016/S0065-230X(08)60095-0; Nakamura H, 2002, J RADIAT RES, V43, P167, DOI 10.1269/jrr.43.167; Ogryzko VV, 1996, MOL CELL BIOL, V16, P5210; Oh CW, 2001, RADIAT RES, V156, P232, DOI 10.1667/0033-7587(2001)156[0232:IOASLP]2.0.CO;2; Ohtani N, 2001, NATURE, V409, P1067, DOI 10.1038/35059131; PANDITA TK, 1995, CYTOGENET CELL GENET, V71, P86, DOI 10.1159/000134069; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Ranganathan V, 2001, CURR BIOL, V11, P962, DOI 10.1016/S0960-9822(01)00267-6; Rogoff HA, 2002, MOL CELL BIOL, V22, P5308, DOI 10.1128/MCB.22.15.5308-5318.2002; Sanchez-Prieto R, 2000, CANCER RES, V60, P2464; Sedgwick R, 1991, HDB CLIN NEUROLOGY, P347; Serra V, 2003, J BIOL CHEM, V278, P6824, DOI 10.1074/jbc.M207939200; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Serrano M, 2001, CURR OPIN CELL BIOL, V13, P748, DOI 10.1016/S0955-0674(00)00278-7; Shackelford RE, 2001, J BIOL CHEM, V276, P21951, DOI 10.1074/jbc.M011303200; Shay JW, 2001, SCIENCE, V291, P839, DOI 10.1126/science.1058546; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; SHILOH Y, 1995, EUR J HUM GENET, V3, P116; Takai H, 2002, EMBO J, V21, P5195, DOI 10.1093/emboj/cdf506; Takai H, 2003, CURR BIOL, V13, P1549, DOI 10.1016/S0960-9822(03)00542-6; Tanaka H, 2002, MOL CELL, V9, P1017, DOI 10.1016/S1097-2765(02)00522-1; TAYLOR AMR, 1975, NATURE, V258, P427, DOI 10.1038/258427a0; Toussaint O, 2000, EXP GERONTOL, V35, P927, DOI 10.1016/S0531-5565(00)00180-7; Vafa O, 2002, MOL CELL, V9, P1031, DOI 10.1016/S1097-2765(02)00520-8; von Zglinicki T, 2002, TRENDS BIOCHEM SCI, V27, P339, DOI 10.1016/S0968-0004(02)02110-2; von Zglinicki T, 2003, NAT BIOTECHNOL, V21, P229, DOI 10.1038/nbt0303-229b; VONZGLINICKI T, 1995, EXP CELL RES, V220, P186, DOI 10.1006/excr.1995.1305; Wang WP, 2002, MOL CELL BIOL, V22, P3389, DOI 10.1128/MCB.22.10.3389-3403.2002; Wong KK, 2003, NATURE, V421, P643, DOI 10.1038/nature01385; Wood LD, 2001, ONCOGENE, V20, P278, DOI 10.1038/sj.onc.1204072; Wyllie FS, 2000, NAT GENET, V24, P16, DOI 10.1038/71630; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997	68	62	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 16	2004	279	3					2030	2037		10.1074/jbc.M309457200	http://dx.doi.org/10.1074/jbc.M309457200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	762WT	14570874	hybrid			2022-12-27	WOS:000188005700057
J	van der Laan, M; Nouwen, N; Driessen, AJM				van der Laan, M; Nouwen, N; Driessen, AJM			SecYEG proteoliposomes catalyze the Delta psi-dependent membrane insertion of FtsQ	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL RECOGNITION PARTICLE; COLI INNER MEMBRANE; ESCHERICHIA-COLI; PROTEIN TRANSLOCATION; BACTERIAL PROTEIN; CHARGED RESIDUES; TRIGGER FACTOR; NASCENT FTSQ; M13 PROCOAT; YIDC	In Escherichia coli, the insertion of most inner membrane proteins is mediated by the Sec translocase. Ribosome-bound nascent chains of Sec-dependent inner membrane proteins are targeted to the SecYEG complex via the signal recognition particle pathway. We now demonstrate that the signal recognition particle-dependent co-translational membrane targeting and membrane insertion of FtsQ can be reconstituted with proteoliposomes containing purified SecYEG. SecA and a transmembrane electrical potential are essential for the translocation of the large periplasmic domain of FtsQ, whereas co-reconstituted YidC has an inhibitory effect. These data demonstrate that membrane protein insertion can be reconstituted with a minimal set of purified Sec components.	Univ Groningen, Dept Microbiol, NL-9751 NN Haren, Netherlands; Univ Groningen, Inst Biotechnol, NL-9751 NN Haren, Netherlands	University of Groningen; University of Groningen	Driessen, AJM (corresponding author), Univ Groningen, Dept Microbiol, Kerklaan 30, NL-9751 NN Haren, Netherlands.	a.j.m.driessen@biol.rug.nl	Driessen, Arnold J.M./D-1876-2012	Driessen, Arnold J.M./0000-0001-9258-9104; van der Laan, Martin/0000-0003-0789-9912				AKIMARU J, 1991, P NATL ACAD SCI USA, V88, P6545, DOI 10.1073/pnas.88.15.6545; ANDERSSON H, 1994, EMBO J, V13, P2267, DOI 10.1002/j.1460-2075.1994.tb06508.x; ANDERSSON H, 1993, EMBO J, V12, P683, DOI 10.1002/j.1460-2075.1993.tb05702.x; BANEYX F, 1990, J BACTERIOL, V172, P491, DOI 10.1128/JB.172.1.491-494.1990; Beck K, 2001, EMBO REP, V2, P709, DOI 10.1093/embo-reports/kve154; BRUNDAGE L, 1990, CELL, V62, P649, DOI 10.1016/0092-8674(90)90111-Q; Buddelmeijer N, 1998, J BACTERIOL, V180, P6107; CABELLI RJ, 1988, CELL, V55, P683, DOI 10.1016/0092-8674(88)90227-9; CAO GQ, 1995, EMBO J, V14, P866, DOI 10.1002/j.1460-2075.1995.tb07068.x; Chen MY, 2003, J BIOL CHEM, V278, P23295, DOI 10.1074/jbc.M301008200; de Gier JW, 2001, MOL MICROBIOL, V40, P314, DOI 10.1046/j.1365-2958.2001.02392.x; de Keyzer J, 2002, FEBS LETT, V510, P17, DOI 10.1016/S0014-5793(01)03213-6; DEVRIJE T, 1987, BIOCHIM BIOPHYS ACTA, V900, P63, DOI 10.1016/0005-2736(87)90278-1; Duong F, 1999, EMBO J, V18, P3263, DOI 10.1093/emboj/18.12.3263; Herskovits AA, 2000, MOL MICROBIOL, V38, P927, DOI 10.1046/j.1365-2958.2000.02198.x; Herskovits AA, 2001, EMBO REP, V2, P1040, DOI 10.1093/embo-reports/kve226; Houben ENG, 2000, FEBS LETT, V476, P229, DOI 10.1016/S0014-5793(00)01735-X; Kiefer D, 1999, EMBO J, V18, P6299, DOI 10.1093/emboj/18.22.6299; Koch HG, 2000, J CELL BIOL, V150, P689, DOI 10.1083/jcb.150.3.689; Koch HG, 2002, J BIOL CHEM, V277, P5715, DOI 10.1074/jbc.C100683200; Kuhn A, 2003, TRENDS CELL BIOL, V13, P510, DOI 10.1016/j.tcb.2003.08.005; KUSTERS R, 1992, FEBS LETT, V308, P97, DOI 10.1016/0014-5793(92)81060-Y; LEE JI, 1992, J BIOL CHEM, V267, P938; LUIRINK J, 1994, EMBO J, V13, P2289, DOI 10.1002/j.1460-2075.1994.tb06511.x; Manting EH, 2000, EMBO J, V19, P852, DOI 10.1093/emboj/19.5.852; Manting EH, 2000, MOL MICROBIOL, V37, P226, DOI 10.1046/j.1365-2958.2000.01980.x; Matsumoto G, 1998, P NATL ACAD SCI USA, V95, P13567, DOI 10.1073/pnas.95.23.13567; Montoya G, 1997, PROTEINS, V28, P285, DOI 10.1002/(SICI)1097-0134(199706)28:2<285::AID-PROT15>3.0.CO;2-E; Neumann-Haefelin C, 2000, EMBO J, V19, P6419, DOI 10.1093/emboj/19.23.6419; Nishiyama KI, 1996, CELL, V85, P71, DOI 10.1016/S0092-8674(00)81083-1; Nouwen N, 1996, P NATL ACAD SCI USA, V93, P5953, DOI 10.1073/pnas.93.12.5953; Nouwen N, 2001, FEBS LETT, V508, P103, DOI 10.1016/S0014-5793(01)03033-2; Samuelson JC, 2000, NATURE, V406, P637, DOI 10.1038/35020586; Samuelson JC, 2001, J BIOL CHEM, V276, P34847, DOI 10.1074/jbc.M105793200; Scotti PA, 2000, EMBO J, V19, P542, DOI 10.1093/emboj/19.4.542; Scotti PA, 1999, J BIOL CHEM, V274, P29883, DOI 10.1074/jbc.274.42.29883; Urbanus ML, 2002, J BIOL CHEM, V277, P12718, DOI 10.1074/jbc.M200311200; Urbanus ML, 2001, EMBO REP, V2, P524, DOI 10.1093/embo-reports/kve108; Valent QA, 1997, MOL MICROBIOL, V25, P53, DOI 10.1046/j.1365-2958.1997.4431808.x; VALENT QA, 1995, EMBO J, V14, P5494, DOI 10.1002/j.1460-2075.1995.tb00236.x; Valent QA, 1998, EMBO J, V17, P2504, DOI 10.1093/emboj/17.9.2504; van der Does C, 2000, J BIOL CHEM, V275, P2472, DOI 10.1074/jbc.275.4.2472; van der Laan M, 2003, P NATL ACAD SCI USA, V100, P5801, DOI 10.1073/pnas.0636761100; van der Laan M, 2001, EMBO REP, V2, P519, DOI 10.1093/embo-reports/kve106; Yi L, 2003, BIOCHEMISTRY-US, V42, P10537, DOI 10.1021/bi034309h	45	48	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 16	2004	279	3					1659	1664		10.1074/jbc.M306527200	http://dx.doi.org/10.1074/jbc.M306527200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	762WT	14578344	hybrid, Green Published			2022-12-27	WOS:000188005700014
J	Bigelow, RLH; Chari, NS; Unden, AB; Spurgers, KB; Lee, SJ; Roop, DR; Toftgard, R; McDonnell, TJ				Bigelow, RLH; Chari, NS; Unden, AB; Spurgers, KB; Lee, SJ; Roop, DR; Toftgard, R; McDonnell, TJ			Transcriptional regulation of bcl-2 mediated by the sonic hedgehog signaling pathway through gli-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASAL-CELL CARCINOMA; GENE-EXPRESSION; PROTEIN; ACTIVATION; MICE; SKIN; INDUCTION; DEATH; PROMOTER; FAMILY	Basal cell carcinomas (BCCs) express high levels of the antiapoptotic proto-oncogene, bcl-2, and we have shown that bcl-2 contributes to the malignant phenotype in a transgenic mouse model. The basis of bcl-2 transcriptional regulation in keratinocytes is unknown. The sonic hedgehog (SHH) signaling pathway is frequently altered in BCCs. Mediators of shh signaling include the downstream transactivator, gli-1, and transrepressor, gli-3. Seven candidate gli binding sites were identified in the bcl-2 promoter. Cotransfection of increasing amounts of gli-1 in keratinoycytes resulted in a corresponding dose-dependent increase in bcl-2 promoter luciferase activity. Gli-1 was also able to up-regulate endogenous bcl-2. Gli-3 cotransfection resulted in no significant changes in bcl-2 promoter activity compared with control. Gli-3 has been demonstrated to be proteolytically processed into an N-terminal repressive form that can inhibit downstream transactivation by gli-1. Gli-3 mutants possessing only the N-terminal region or the C-terminal region were made and used in luciferase assays. The N terminus of gli-3 inhibited gli-1 transactivation of the bcl-2 promoter. Gel shift analysis and luciferase assays demonstrated that gli binding site 4 ( - 428 to - 420), is important for gli transcriptional regulation. Skin samples from transgenic mice expressing an RU486 gli-1 transgene exhibited significantly higher levels of endogenous bcl-2 protein in epidermal keratinocytes as assessed by immunoblotting and immunohistochemistry. Together, these findings provide consistent evidence that gli proteins can transcriptionally regulate the bcl-2 promoter and that gli-3 can inhibit transactivation by gli-1. These studies further suggest that one consequence of the deregulation of shh signaling in BCC is the up-regulation of bcl-2.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA; Karolinska Inst, Novum, Dept Biosci, SE-14157 Huddinge, Sweden; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Dermatol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; Karolinska Institutet; Baylor College of Medicine; Baylor College of Medicine	McDonnell, TJ (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, 1515 Holcombe Blvd,Box 89, Houston, TX 77030 USA.	tmcdonne@mdanderson.org			NATIONAL CANCER INSTITUTE [P01CA078778, R44CA067559, P01CA068233, R43CA067559] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR047898] Funding Source: NIH RePORTER; NCI NIH HHS [T32 CA 67559, P01 CA 78778, P01 CA 68233] Funding Source: Medline; NIAMS NIH HHS [AR 47898-02/05] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Altaba ARI, 1999, TRENDS GENET, V15, P418, DOI 10.1016/S0168-9525(99)01840-5; Aszterbaum M, 1999, NAT MED, V5, P1285, DOI 10.1038/15242; Britto JM, 2000, BIOESSAYS, V22, P499, DOI 10.1002/(SICI)1521-1878(200006)22:6<499::AID-BIES1>3.0.CO;2-F; CHEN HM, 1995, MOL CELL BIOL, V15, P3840; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; Chiang C, 1999, DEV BIOL, V205, P1, DOI 10.1006/dbio.1998.9103; Chuong CM, 1996, J INVEST DERMATOL, V107, P639, DOI 10.1111/1523-1747.ep12584254; Dahmane N, 1997, NATURE, V389, P876, DOI 10.1038/39918; Dai P, 1999, J BIOL CHEM, V274, P8143, DOI 10.1074/jbc.274.12.8143; Delehedde M, 2001, J INVEST DERMATOL, V116, P366, DOI 10.1046/j.1523-1747.2001.01260.x; Delehedde M, 1999, CANCER, V85, P1514, DOI 10.1002/(SICI)1097-0142(19990401)85:7<1514::AID-CNCR12>3.3.CO;2-H; Gailani MR, 1997, JNCI-J NATL CANCER I, V89, P1103, DOI 10.1093/jnci/89.15.1103; Gailani MR, 1996, J NATL CANCER I, V88, P349, DOI 10.1093/jnci/88.6.349; Ghali L, 1999, J INVEST DERMATOL, V113, P595, DOI 10.1046/j.1523-1747.1999.00729.x; Green J, 1998, BRIT J DERMATOL, V139, P911; Hewitt SM, 1997, ANTICANCER RES, V17, P3211; HEWITT SM, 1995, CANCER RES, V55, P5386; Ingham PW, 1998, EMBO J, V17, P3505, DOI 10.1093/emboj/17.13.3505; Kallassy M, 1997, CANCER RES, V57, P4731; KINZLER KW, 1990, MOL CELL BIOL, V10, P634, DOI 10.1128/MCB.10.2.634; Krajewski S, 1997, AM J PATHOL, V150, P805; LAVKER RM, 1993, J INVEST DERMATOL, V101, pS16, DOI 10.1111/1523-1747.ep12362556; Litingtung Y, 1998, NAT GENET, V20, P58, DOI 10.1038/1717; Mayo MW, 1999, EMBO J, V18, P3990, DOI 10.1093/emboj/18.14.3990; McDonnell TJ, 1996, EXPERIENTIA, V52, P1008, DOI 10.1007/BF01920110; MILLER SJ, 1991, J AM ACAD DERMATOL, V24, P1, DOI 10.1016/0190-9622(91)70001-I; Nilsson M, 2000, P NATL ACAD SCI USA, V97, P3438, DOI 10.1073/pnas.050467397; Oro AE, 1997, SCIENCE, V276, P817, DOI 10.1126/science.276.5313.817; Rodriguez-Villanueva J, 1998, ONCOGENE, V16, P853, DOI 10.1038/sj.onc.1201610; RODRIGUEZVILLANUEVA J, 1995, PATHOL RES PRACT, V191, P391, DOI 10.1016/S0344-0338(11)80724-7; Romero F, 1999, EMBO J, V18, P3419, DOI 10.1093/emboj/18.12.3419; RUPPERT JM, 1990, MOL CELL BIOL, V10, P5408, DOI 10.1128/MCB.10.10.5408; Sasaki H, 1997, DEVELOPMENT, V124, P1313; Sasaki H, 1999, DEVELOPMENT, V126, P3915; Sato N, 1999, J CLIN INVEST, V104, P855, DOI 10.1172/JCI7691; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; Smith MD, 1998, J BIOL CHEM, V273, P16715, DOI 10.1074/jbc.273.27.16715; STENN KS, 1994, J INVEST DERMATOL, V103, P107, DOI 10.1111/1523-1747.ep12391844; Wang ZD, 1999, VIROLOGY, V257, P502, DOI 10.1006/viro.1999.9688; Weed M, 1997, MATRIX BIOL, V16, P53, DOI 10.1016/S0945-053X(97)90072-X; Wicking C, 1997, AM J HUM GENET, V60, P21; Xie JW, 1998, NATURE, V391, P90, DOI 10.1038/34201; Yoon JW, 2002, J BIOL CHEM, V277, P5548, DOI 10.1074/jbc.M105708200; Yoon JW, 1998, J BIOL CHEM, V273, P3496, DOI 10.1074/jbc.273.6.3496; YOUNG RL, 1993, MOL CELL BIOL, V13, P3686, DOI 10.1128/MCB.13.6.3686	45	189	196	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 9	2004	279	2					1197	1205		10.1074/jbc.M310589200	http://dx.doi.org/10.1074/jbc.M310589200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	759DJ	14555646	hybrid			2022-12-27	WOS:000187722800045
J	Fliegmann, J; Mithofer, A; Wanner, G; Ebel, J				Fliegmann, J; Mithofer, A; Wanner, G; Ebel, J			An ancient enzyme domain hidden in the putative beta-glucan elicitor receptor of soybean may play an active part in the perception of pathogen-associated molecular patterns during broad host resistance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-AFFINITY BINDING; BETA-1,3-GLUCAN RECOGNITION PROTEIN; GLYCINE-MAX L; GLUCOSIDE ELICITOR; PHYTOALEXIN ACCUMULATION; DEFENSE RESPONSES; INNATE IMMUNITY; PURIFICATION; GENE; SEQUENCE	A successful defense against potential pathogens requires that a host organism is able to discriminate between self and nonself structures. Soybean (Glycine max L.) exploits a specific molecular pattern, a 1,6-beta-linked and 1,3-beta-branched heptaglucoside (HG), present in cell walls of the oomycetal pathogen Phytophthora sojae, as a signal compound eliciting the onset of defense reactions. The specific and high affinity HG-binding site is contained in the beta-glucan-binding protein (GBP), which in turn is part of a proposed receptor complex. The ability to perceive and respond to Phytophthora cell wall-derived beta-glucan elicitors is exclusive to plants that belong to the Fabaceae. However, we propose that the presence of the GBP is essential, but not sufficient for beta-glucan elicitor-dependent disease resistance because genes encoding GBP-related proteins can be retrieved from many plant species. Furthermore, we show that the GBP is composed of two different carbohydrate-active protein domains, one containing the beta-glucan-binding site, and the other related to glucan endoglucosidases of fungal origin. The glucan hydrolase displays most likely an endo-specific mode of action, cleaving only 1,3-beta-D-glucosidic linkages of oligoglucosides consisting of at least four moieties. Thus, the intrinsic endo-1,3-beta-glucanase activity of the GBP is perfectly suited during initial contact with Phytophthora to release oligoglucoside fragments enriched in motifs that constitute ligands for the high affinity binding site present in the same protein. The concept of innate immunity in plants receives substantial support by this highly sophisticated system using ancient enzyme modules as an active part of the recognition mechanism.	Univ Munich, Dept Biol Bot 1, D-80638 Munich, Germany; MPI Chem Okol, D-07745 Jena, Germany	University of Munich	Fliegmann, J (corresponding author), Univ Munich, Dept Biol Bot 1, Menzinger Str 67, D-80638 Munich, Germany.	judith.fliegmann@lmu.de		Fliegmann, Judith/0000-0003-1021-8006				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AYERS AR, 1976, PLANT PHYSIOL, V57, P766, DOI 10.1104/pp.57.5.766; Baladron V, 2002, EUKARYOT CELL, V1, P774, DOI 10.1128/EC.1.5.774-786.2002; Bhagwat AA, 1999, PLANT PHYSIOL, V119, P1057, DOI 10.1104/pp.119.3.1057; Bogdanove AJ, 2002, PLANT MOL BIOL, V50, P981, DOI 10.1023/A:1021263027600; BOLLER T, 1995, ANNU REV PLANT PHYS, V46, P189, DOI 10.1146/annurev.arplant.46.1.189; Brunner F, 1998, PLANT J, V14, P225, DOI 10.1046/j.1365-313X.1998.00116.x; CHEONG JJ, 1991, PLANT CELL, V3, P127, DOI 10.1105/tpc.3.2.127; CHEONG JJ, 1991, PLANT CELL, V3, P137, DOI 10.1105/tpc.3.2.137; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; Cosio EG, 1996, PLANTA, V200, P92, DOI 10.1007/BF00196654; COSIO EG, 1990, FEBS LETT, V271, P223, DOI 10.1016/0014-5793(90)80411-B; Cote F, 2000, PLANTA, V211, P596, DOI 10.1007/s004250000325; Dangl JL, 2001, NATURE, V411, P826, DOI 10.1038/35081161; Ebel J, 1998, PLANTA, V206, P335, DOI 10.1007/s004250050409; Ebel J, 1998, BIOESSAYS, V20, P569, DOI 10.1002/(SICI)1521-1878(199807)20:7&lt;569::AID-BIES8&gt;3.0.CO;2-F; EBEL J, 1997, MYCOTA PLANT RELAT A, V5, P85; Felix G, 2003, J BIOL CHEM, V278, P6201, DOI 10.1074/jbc.M209880200; Fontaine T, 1997, EUR J BIOCHEM, V243, P315, DOI 10.1111/j.1432-1033.1997.0315a.x; FREY T, 1993, PHYTOCHEMISTRY, V32, P543, DOI 10.1016/S0031-9422(00)95134-3; Girardin SE, 2002, TRENDS MICROBIOL, V10, P193, DOI 10.1016/S0966-842X(02)02334-X; Gomez-Gomez L, 2002, TRENDS PLANT SCI, V7, P251, DOI 10.1016/S1360-1385(02)02261-6; Gomez-Gomez L, 2000, MOL CELL, V5, P1003, DOI 10.1016/S1097-2765(00)80265-8; Goubet F, 2002, ANAL BIOCHEM, V300, P53, DOI 10.1006/abio.2001.5444; Hahn MG, 1996, ANNU REV PHYTOPATHOL, V34, P387, DOI 10.1146/annurev.phyto.34.1.387; Hall A., 1999, NUCL ACIDS S SERIES, V41, P95, DOI [citeulike-article-id:691774, DOI 10.1021/BK-1999-0734.CH008]; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; JANEWAY CA, 1989, COLD SPRING HARB SYM, V54, P1; Jin W, 1999, GENETICS, V153, P445; KEEN NT, 1983, PLANT PHYSIOL, V71, P460, DOI 10.1104/pp.71.3.460; Kim YS, 2000, J BIOL CHEM, V275, P32721, DOI 10.1074/jbc.M003934200; Klarzynski O, 2000, PLANT PHYSIOL, V124, P1027, DOI 10.1104/pp.124.3.1027; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Ma CC, 2000, J BIOL CHEM, V275, P7505, DOI 10.1074/jbc.275.11.7505; Martin GB, 1999, CURR OPIN PLANT BIOL, V2, P273, DOI 10.1016/S1369-5266(99)80049-1; Medzhitov R, 1997, CELL, V91, P295, DOI 10.1016/S0092-8674(00)80412-2; Mithofer A, 1999, FEBS LETT, V458, P129, DOI 10.1016/S0014-5793(99)01126-6; Mithofer A, 1996, PLANTA, V199, P270, DOI 10.1007/BF00196568; Mithofer A, 2000, BIOL CHEM, V381, P705, DOI 10.1515/BC.2000.091; Mithofer A, 1996, FEBS LETT, V381, P203, DOI 10.1016/0014-5793(96)00126-3; Mithofer A, 1999, BBA-BIOMEMBRANES, V1418, P127, DOI 10.1016/S0005-2736(99)00010-3; Montesano M, 2003, MOL PLANT PATHOL, V4, P73, DOI 10.1046/j.1364-3703.2003.00150.x; Mouyna I, 2002, MED MYCOL, V40, P455, DOI 10.1080/mmy.40.5.455.464; Nakabayashi M, 1998, J FERMENT BIOENG, V85, P459, DOI 10.1016/S0922-338X(98)80062-7; Nurnberger T, 2001, TRENDS PLANT SCI, V6, P372, DOI 10.1016/S1360-1385(01)02019-2; Nurnberger T, 2002, CURR OPIN PLANT BIOL, V5, P318, DOI 10.1016/S1369-5266(02)00265-0; O'Reilly D.R., 1994, BACULOVIRUS EXPRESSI; Ochiai M, 2000, J BIOL CHEM, V275, P4995, DOI 10.1074/jbc.275.7.4995; OKINAKA Y, 1995, PLANT PHYSIOL, V109, P839, DOI 10.1104/pp.109.3.839; Parker JE, 2003, TRENDS PLANT SCI, V8, P245, DOI 10.1016/S1360-1385(03)00105-5; Richter TE, 2000, PLANT MOL BIOL, V42, P195, DOI 10.1023/A:1006388223475; SHARP JK, 1984, J BIOL CHEM, V259, P1312; SHEN SH, 1991, J BIOL CHEM, V266, P1058; SPURR AR, 1969, J ULTRA MOL STRUCT R, V26, P31, DOI 10.1016/S0022-5320(69)90033-1; STASKAWICZ BJ, 1995, SCIENCE, V268, P661, DOI 10.1126/science.7732374; Tyler BM, 2002, ANNU REV PHYTOPATHOL, V40, P137, DOI 10.1146/annurev.phyto.40.120601.125310; Umemoto N, 1997, P NATL ACAD SCI USA, V94, P1029, DOI 10.1073/pnas.94.3.1029; van der Biezen EA, 1998, TRENDS BIOCHEM SCI, V23, P454, DOI 10.1016/S0968-0004(98)01311-5; WAFFENSCHMIDT S, 1987, ANAL BIOCHEM, V165, P337, DOI 10.1016/0003-2697(87)90278-8; Yamaguchi T, 2000, PLANT CELL, V12, P817, DOI 10.1105/tpc.12.5.817; Yang YO, 1997, GENE DEV, V11, P1621, DOI 10.1101/gad.11.13.1621	62	116	126	0	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 9	2004	279	2					1132	1140		10.1074/jbc.M308552200	http://dx.doi.org/10.1074/jbc.M308552200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	759DJ	14578352	hybrid			2022-12-27	WOS:000187722800037
J	Aoki, K; Nakamura, T; Matsuda, M				Aoki, K; Nakamura, T; Matsuda, M			Spatio-temporal regulation of Rac1 and Cdc42 activity during nerve growth factor-induced neurite outgrowth in PC12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; RHO-GTPASES; PHOSPHATIDYLINOSITOL 3-KINASE; RAS; POLARITY; SYSTEM; FAMILY; KINASE; DIFFERENTIATION; PHOSPHORYLATION	Neurite outgrowth is an important process in the formation of neuronal networks. It is widely accepted that Rac1 and Cdc42, members of the Rho GTPase family, positively regulate neurite extension through reorganization of the actin cytoskeleton; however, it remains largely unknown when and where Rac1 and Cdc42 are activated during neuritogenesis. This study visualized the spatio-temporal regulation of Rac1 and Cdc42 activities during nerve growth factor ( NGF)-induced neurite outgrowth in living PC12 cells by using probes based on the principle of fluorescence resonance energy transfer ( FRET). Immediately after the addition of NGF, Rac1 and Cdc42 were transiently activated in broad areas of the cell periphery; a repetitive activation and inactivation cycle was then observed at the motile tips of protrusions. This localized activation, which was more evident in PC12 cells treated with NGF for more than 24 h, might facilitate neurite extension, because the expression of constitutively active mutants of Rac1 and Cdc42 abrogated NGF-induced neurite outgrowth. FRET imaging also delineated a difference between the localization of activated Rac1 and that of Cdc42 within the neurite tips. Experiments with dominant-negative mutants suggested that Rac1 and Cdc42 were activated by a common guanine nucleotide exchange factor(s) in an early stage of the activation phase. Therefore, the difference between Rac1- and Cdc42-activated areas possibly came from the differential localization between Rac1- specific GTPase-activation proteins ( GAPs) and Cdc42-specific GAPs. It was concluded that the localized activation of Rac1 and Cdc42 was caused by both guanine nucleotide exchange factors and GAPs, and was important for neurite extension.	Osaka Univ, Microbial Dis Res Inst, Dept Tumor Virol, Suita, Osaka 5650871, Japan	Osaka University	Nakamura, T (corresponding author), Osaka Univ, Microbial Dis Res Inst, Dept Tumor Virol, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.		Aoki, Kazuhiro/I-5483-2019; Aoki, Kazuhiro/B-5777-2013	Aoki, Kazuhiro/0000-0001-7263-1555; Aoki, Kazuhiro/0000-0001-7263-1555; Matsuda, Michiyuki/0000-0002-5876-9969				Banzai Y, 2000, J BIOL CHEM, V275, P11987, DOI 10.1074/jbc.275.16.11987; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Chen XQ, 1999, J BIOL CHEM, V274, P19901, DOI 10.1074/jbc.274.28.19901; Daniels RH, 1998, EMBO J, V17, P754, DOI 10.1093/emboj/17.3.754; GORDONWEEKS RR, 2000, NEURONAL GROWTH CONE; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Itoh RE, 2002, MOL CELL BIOL, V22, P6582, DOI 10.1128/MCB.22.18.6582-6591.2002; Jackson TR, 1996, J CELL SCI, V109, P289; Kaplan DR, 2000, CURR OPIN NEUROBIOL, V10, P381, DOI 10.1016/S0959-4388(00)00092-1; Katoh H, 2000, MOL CELL BIOL, V20, P7378, DOI 10.1128/MCB.20.19.7378-7387.2000; Kobayashi M, 1997, J BIOL CHEM, V272, P16089, DOI 10.1074/jbc.272.26.16089; Lamarche-Vane N, 1998, J BIOL CHEM, V273, P29172, DOI 10.1074/jbc.273.44.29172; Luo LQ, 2000, NAT REV NEUROSCI, V1, P173, DOI 10.1038/35044547; Markus A, 2002, CURR OPIN NEUROBIOL, V12, P523, DOI 10.1016/S0959-4388(02)00372-0; Michaelson D, 2001, J CELL BIOL, V152, P111, DOI 10.1083/jcb.152.1.111; Miki H, 1998, NATURE, V391, P93, DOI 10.1038/34208; Mochizuki N, 2001, NATURE, V411, P1065, DOI 10.1038/35082594; Moon SY, 2003, TRENDS CELL BIOL, V13, P13, DOI 10.1016/S0962-8924(02)00004-1; Mueller BK, 1999, ANNU REV NEUROSCI, V22, P351, DOI 10.1146/annurev.neuro.22.1.351; Nakamura T, 2002, MOL CELL BIOL, V22, P8721, DOI 10.1128/MCB.22.24.8721-8734.2002; Nakayama H, 2001, J NEUROCHEM, V79, P489, DOI 10.1046/j.1471-4159.2001.00602.x; Nusser N, 2002, J BIOL CHEM, V277, P35840, DOI 10.1074/jbc.M203617200; Ohba Y, 2003, EMBO J, V22, P859, DOI 10.1093/emboj/cdg087; Ono Y, 2000, ONCOGENE, V19, P3050, DOI 10.1038/sj.onc.1203631; Patapoutian A, 2001, CURR OPIN NEUROBIOL, V11, P272, DOI 10.1016/S0959-4388(00)00208-7; Sarner S, 2000, MOL CELL BIOL, V20, P158, DOI 10.1128/MCB.20.1.158-172.2000; Sasaki T, 1998, BIOCHEM BIOPH RES CO, V245, P641, DOI 10.1006/bbrc.1998.8253; Schmidt A, 2002, GENE DEV, V16, P1587, DOI 10.1101/gad.1003302; Shi SH, 2003, CELL, V112, P63, DOI 10.1016/S0092-8674(02)01249-7; Svoboda K, 1998, NAT NEUROSCI, V1, P93, DOI 10.1038/339; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; VAN AL, 1997, GENE DEV, V11, P2295; van Leeuwen FN, 1999, NAT CELL BIOL, V1, P242, DOI 10.1038/12068; Wang F, 2002, NAT CELL BIOL, V4, P513, DOI 10.1038/ncb810; Weiner OD, 2002, NAT CELL BIOL, V4, P509, DOI 10.1038/ncb811; Yamaguchi Y, 2001, J BIOL CHEM, V276, P18977, DOI 10.1074/jbc.M100254200; Yasui H, 2001, J BIOL CHEM, V276, P15298, DOI 10.1074/jbc.M008546200; Yoshizaki H, 2003, J CELL BIOL, V162, P223, DOI 10.1083/jcb.200212049	39	126	130	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	2004	279	1					713	719		10.1074/jbc.M306382200	http://dx.doi.org/10.1074/jbc.M306382200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	757GU	14570905	hybrid			2022-12-27	WOS:000187555300085
J	Quevillon-Cheruel, S; Leulliot, N; Meyer, P; Graille, M; Bremang, M; Blondeau, K; Sorel, I; Poupon, A; Janin, J; van Tilbeurgh, H				Quevillon-Cheruel, S; Leulliot, N; Meyer, P; Graille, M; Bremang, M; Blondeau, K; Sorel, I; Poupon, A; Janin, J; van Tilbeurgh, H			Crystal structure of the bifunctional chorismate synthase from Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHIKIMATE PATHWAY; FLAVIN REDUCTASE; SUBSTRATE; SEQUENCE; BINDING; ENZYMES; SITE	Chorismate synthase (EC 4.2.3.5), the seventh enzyme in the shikimate pathway, catalyzes the transformation of 5-enolpyruvylshikimate 3-phosphate ( EPSP) to chorismate, which is the last common precursor in the biosynthesis of numerous aromatic compounds in bacteria, fungi, and plants. The chorismate synthase reaction involves a 1,4-trans-elimination of phosphoric acid from EPSP and has an absolute requirement for reduced FMN as a cofactor. We have determined the three-dimensional x-ray structure of the yeast chorismate synthase from selenomethionine-labeled crystals at 2.2-Angstrom resolution. The structure shows a novel betaalphabetaalpha fold consisting of an alternate tight packing of two alpha-helical and two beta-sheet layers, showing no resemblance to any documented protein structure. The molecule is arranged as a tight tetramer with D2 symmetry, in accordance with its quaternary structure in solution. Electron density is missing for 23% of the amino acids, spread over sequence regions that in the three-dimensional structure converge on the surface of the protein. Many totally conserved residues are contained within these regions, and they probably form a structured but mobile domain that closes over a cleft upon substrate binding and catalysis. This hypothesis is supported by previously published spectroscopic measurements implying that the enzyme undergoes considerable structural changes upon binding of both FMN and EPSP.	Univ Paris 11, CNRS, UMR 8619, Inst Biochim & Biophys Mol & Cellulaire, F-91405 Orsay, France; CNRS, UPR 9063, Lab Enzymol & Biochim Struct, F-91198 Gif Sur Yvette, France; Univ Paris 11, CNRS, UMR 8621, Inst Genet & Microbiol, F-91405 Orsay, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	van Tilbeurgh, H (corresponding author), Univ Paris 11, CNRS, UMR 8619, Inst Biochim & Biophys Mol & Cellulaire, Batiment 430, F-91405 Orsay, France.	herman@lebs.cnrs-gif.fr	GRAILLE, Marc/D-3242-2014; Meyer, Philippe/AAC-6038-2019; Janin, Joel/I-2958-2012; Leulliot, Nicolas/AAA-7160-2019	GRAILLE, Marc/0000-0002-7853-5852; Meyer, Philippe/0000-0002-6220-0679; Leulliot, Nicolas/0000-0003-0283-4298; Bremang, Michael/0000-0003-1386-7351; Poupon, Anne/0000-0003-0617-0935				Ahn HJ, 2003, ACTA CRYSTALLOGR D, V59, P569, DOI 10.1107/S090744490300009X; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BAKER PJ, 1992, J MOL BIOL, V228, P662, DOI 10.1016/0022-2836(92)90848-E; BENTLEY R, 1990, CRIT REV BIOCHEM MOL, V25, P307, DOI 10.3109/10409239009090615; Bornemann S, 1996, BIOCHEMISTRY-US, V35, P9907, DOI 10.1021/bi952958q; Braun M, 1996, PLANTA, V200, P64, DOI 10.1007/BF00196650; Carugo O, 1997, PROTEINS, V28, P29, DOI 10.1002/(SICI)1097-0134(199705)28:1<29::AID-PROT3>3.3.CO;2-C; Fitzpatrick T, 2001, MOL MICROBIOL, V40, P65, DOI 10.1046/j.1365-2958.2001.02366.x; GOUET P, 1995, J MOL BIOL, V249, P933, DOI 10.1006/jmbi.1995.0350; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; HENDRICKSON WA, 1990, EMBO J, V9, P1665, DOI 10.1002/j.1460-2075.1990.tb08287.x; HENSTRAND JM, 1995, J BIOL CHEM, V270, P20447, DOI 10.1074/jbc.270.35.20447; Henstrand JM, 1996, MOL MICROBIOL, V22, P859, DOI 10.1046/j.1365-2958.1996.01534.x; HENSTRAND JM, 1995, PLANT PHYSIOL, V108, P1127, DOI 10.1104/pp.108.3.1127; HILL RK, 1969, J AM CHEM SOC, V91, P5893, DOI 10.1021/ja01049a045; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Lo Conte L, 1999, J MOL BIOL, V285, P2177; Macheroux P, 1996, BIOCHEMISTRY-US, V35, P1643, DOI 10.1021/bi951705u; Macheroux P, 1998, BIOCHEM J, V335, P319, DOI 10.1042/bj3350319; Macheroux P, 1996, J BIOL CHEM, V271, P25850, DOI 10.1074/jbc.271.42.25850; Mesecar AD, 1997, SCIENCE, V277, P202, DOI 10.1126/science.277.5323.202; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; RAY MVL, 1993, BIO-TECHNOL, V11, P64, DOI 10.1038/nbt0193-64; Roberts F, 1998, NATURE, V393, P801, DOI 10.1038/31723; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; WELCH GR, 1974, ARCH BIOCHEM BIOPHYS, V165, P505, DOI 10.1016/0003-9861(74)90276-8; Westhead DR, 1998, TRENDS BIOCHEM SCI, V23, P35, DOI 10.1016/S0968-0004(97)01161-4; WHITE PJ, 1988, BIOCHEM J, V251, P313, DOI 10.1042/bj2510313; WILSON DK, 1992, SCIENCE, V257, P81, DOI 10.1126/science.1621098; XIONG JP, 1994, NAT STRUCT BIOL, V1, P695, DOI 10.1038/nsb1094-695	32	25	28	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 2	2004	279	1					619	625		10.1074/jbc.M310380200	http://dx.doi.org/10.1074/jbc.M310380200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	757GU	14573601	hybrid, Green Published			2022-12-27	WOS:000187555300075
J	Kuttner-Kondo, LA; Dybvig, MP; Mitchell, LM; Muqim, N; Atkinson, JP; Medof, ME; Hourcade, DE				Kuttner-Kondo, LA; Dybvig, MP; Mitchell, LM; Muqim, N; Atkinson, JP; Medof, ME; Hourcade, DE			A corresponding tyrosine residue in the C2/factor B type A domain is a hot spot in the decay acceleration of the complement C3 convertases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; ACQUIRED IMMUNE-RESPONSE; C4B BINDING-SITE; COMPONENT C2; FACTOR-H; PROTEIN INTERFACES; ACTIVE-SITES; FACTOR DAF; AFFINITY; RECEPTOR	The cleavage of C3 by the C3 convertases (C3bBb and C4b2a) determines whether complement activation proceeds. Dissociation ( decay acceleration) of these central enzymes by the regulators decay-accelerating factor (DAF), complement receptor 1 (CR1), factor H, and C4-binding protein (C4BP) controls their function. In a previous investigation, we obtained evidence implicating the alpha4/5 region of the type A domain of Bb (especially Tyr(338)) in decay acceleration of C3bBb and proposed this site as a potential interaction point with DAF and long homologous repeat A of CR1. Because portions of only two DAF complement control protein domains (CCPs), CCP2 and CCP3, are necessary to mediate its decay of the CP C3 convertase (as opposed to portions of at least three CCPs in all other cases, e. g. CCPs 1-3 of CR1), DAF/C4b2a provides the simplest structural model for this reaction. Therefore, we examined the importance of the C2 alpha4/5 site on decay acceleration of C4b2a. Functional C4b2a complexes made with the C2 Y327A mutant, the C2 homolog to factor B Y338A, were highly resistant to DAF, C4BP, and long homologous repeat A of CR1, whereas C2 substitutions in two nearby residues (N324A and L328A) resulted in partial resistance. Our new findings indicate that the alpha4/5 region of C2a is critical to decay acceleration mediated by DAF, C4BP, and CR1 and suggest that decay acceleration of C4b2a and C3bBb requires interaction of the convertase alpha4/5 region with a CCP2/CCP3 site of DAF or structurally homologous sites of CR1 and C4BP.	Washington Univ, Sch Med, Div Rheumatol, Dept Med, St Louis, MO 63110 USA; Case Western Reserve Univ, Inst Pathol, Cleveland, OH 44106 USA	Washington University (WUSTL); Case Western Reserve University	Hourcade, DE (corresponding author), Washington Univ, Sch Med, Div Rheumatol, Dept Med, 660 S Euclid Ave,Box 8045, St Louis, MO 63110 USA.			Atkinson, John/0000-0002-2514-3441				Ahearn JM, 1998, HUMAN COMPLEMENT SYS, P167; BENTLEY DR, 1986, BIOCHEM J, V239, P339, DOI 10.1042/bj2390339; Blom AM, 2001, J BIOL CHEM, V276, P27136, DOI 10.1074/jbc.M102445200; Bogan AA, 1998, J MOL BIOL, V280, P1, DOI 10.1006/jmbi.1998.1843; Brodbeck WG, 1996, J IMMUNOL, V156, P2528; Brodbeck WG, 2000, IMMUNOLOGY, V101, P104, DOI 10.1046/j.1365-2567.2000.00086.x; Carroll MC, 1998, CURR OPIN IMMUNOL, V10, P36; Clackson T, 1998, J MOL BIOL, V277, P1111, DOI 10.1006/jmbi.1998.1669; EMBER JA, 1998, HUMAN COMPLEMENT SYS, P241; Fearon DT, 1996, SCIENCE, V272, P50, DOI 10.1126/science.272.5258.50; Hinshelwood J, 1999, J MOL BIOL, V294, P587, DOI 10.1006/jmbi.1999.3223; HORIUCHI T, 1991, J IMMUNOL, V147, P584; Hourcade DE, 1999, J IMMUNOL, V162, P2906; HOURCADE DE, 1995, J BIOL CHEM, V270, P19716, DOI 10.1074/jbc.270.34.19716; Hourcade DE, 2002, J BIOL CHEM, V277, P1107, DOI 10.1074/jbc.M109322200; Hu ZJ, 2000, PROTEINS, V39, P331, DOI 10.1002/(SICI)1097-0134(20000601)39:4<331::AID-PROT60>3.0.CO;2-A; HUANG XQ, 1991, ADV APPL MATH, V12, P337, DOI 10.1016/0196-8858(91)90017-D; KINOSHITA T, 1986, J IMMUNOL, V136, P3390; KRYCH M, 1994, J BIOL CHEM, V269, P13273; Krych-Goldberg M, 1999, J BIOL CHEM, V274, P31160, DOI 10.1074/jbc.274.44.31160; Kuhn S, 1996, EUR J IMMUNOL, V26, P2383, DOI 10.1002/eji.1830261017; Kuttner-Kondo LA, 2001, J IMMUNOL, V167, P2164, DOI 10.4049/jimmunol.167.4.2164; KuttnerKondo L, 1996, PROTEIN ENG, V9, P1143, DOI 10.1093/protein/9.12.1143; KUTTNERKONDO LA, 2002, INT IMMUNOPHARMACOL, V2, P1275; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; Liszewski M.K., 1998, HUMAN COMPLEMENT SYS, P149; MOLE JE, 1984, J BIOL CHEM, V259, P3407; Nielsen CH, 2000, IMMUNOLOGY, V100, P4, DOI 10.1046/j.1365-2567.2000.00009.x; OGLESBY TJ, 1988, J IMMUNOL, V141, P926; PANGBURN MK, 1986, J IMMUNOL, V136, P2216; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Tsukamoto H, 1996, J IMMUNOL, V156, P4901; Uhrinova S, 2003, P NATL ACAD SCI USA, V100, P4718, DOI 10.1073/pnas.0730844100; Volanakis JE, 1998, HUMAN COMPLEMENT SYS, V20, P9, DOI DOI 10.1201/B14212-3; Williams P, 2003, J BIOL CHEM, V278, P10691, DOI 10.1074/jbc.M212561200	35	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52386	52391		10.1074/jbc.M304620200	http://dx.doi.org/10.1074/jbc.M304620200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14561755	hybrid			2022-12-27	WOS:000187480700050
J	Sever, N; Song, BL; Yabe, D; Goldstein, JL; Brown, MS; DeBose-Boyd, RA				Sever, N; Song, BL; Yabe, D; Goldstein, JL; Brown, MS; DeBose-Boyd, RA			Insig-dependent ubiquitination and degradation of mammalian 3-hydroxy-3-methylglutaryl-CoA reductase stimulated by sterols and geranylgeraniol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A REDUCTASE; CLEAVAGE-ACTIVATING PROTEIN; HMG-COA REDUCTASE; ELEMENT-BINDING PROTEINS; ENDOPLASMIC-RETICULUM; REGULATED DEGRADATION; MESSENGER-RNA; IN-VIVO; ACCELERATED DEGRADATION; MEMBRANE-PROTEIN	The endoplasmic reticulum enzyme 3-hydroxy-3-methylglutaryl-CoA reductase produces mevalonate, which is converted to sterols and to other products, including geranylgeraniol groups attached to proteins. The enzyme is known to be ubiquitinated and rapidly degraded when sterols and nonsterol end products of mevalonate metabolism accumulate in cells. Here, we use RNA interference to show that sterol-accelerated ubiquitination of reductase requires Insig-1 and Insig-2, membrane-bound proteins of the endoplasmic reticulum that were shown previously to accelerate degradation of reductase when overexpressed by transfection. Alanine substitution experiments reveal that binding of reductase to Insigs and subsequent ubiquitination require the tetrapeptide sequence YIYF in the second membrane-spanning helix of reductase. The YIYF peptide is also found in the sterol-sensing domain of SCAP, another protein that binds to Insigs in a sterol-stimulated fashion. When lysine 248 of reductase is substituted with arginine, Insig binding persists, but the reductase is no longer ubiquitinated and degradation is markedly slowed. Lysine 248 is predicted to lie immediately adjacent to a membrane-spanning helix, suggesting that a membrane-bound ubiquitin transferase is responsible. Finally, we show that Insig-dependent, sterol-stimulated degradation of reductase is further accelerated when cells are also supplied with the 20-carbon isoprenoid geranylgeraniol, but not the 15-carbon farnesol, raising the possibility that the nonsterol potentiator of reductase regulation is a geranylgeranylated protein.	Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Goldstein, JL (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75390 USA.		Yabe, Daisuke/J-6682-2014	Yabe, Daisuke/0000-0002-5334-7687; Song, Bao-Liang/0000-0002-6397-5935	NHLBI NIH HHS [HL70441, HL20948] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948, K01HL070441] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Brown MS, 1999, P NATL ACAD SCI USA, V96, P11041, DOI 10.1073/pnas.96.20.11041; BROWN MS, 1980, J LIPID RES, V21, P505; CORRELL CC, 1994, J BIOL CHEM, V269, P633; CORRELL CC, 1994, J BIOL CHEM, V269, P17390; Crick DC, 1997, BIOCHEM BIOPH RES CO, V237, P483, DOI 10.1006/bbrc.1997.7145; DeBose-Boyd RA, 1999, CELL, V99, P703, DOI 10.1016/S0092-8674(00)81668-2; Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3; GARCIA CK, 1994, CELL, V76, P865, DOI 10.1016/0092-8674(94)90361-1; Gardner RG, 2001, MOL CELL BIOL, V21, P4276, DOI 10.1128/MCB.21.13.4276-4291.2001; Gardner RG, 1999, J BIOL CHEM, V274, P31671, DOI 10.1074/jbc.274.44.31671; GIL G, 1985, CELL, V41, P249, DOI 10.1016/0092-8674(85)90078-9; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; Hampton RY, 2002, CURR OPIN CELL BIOL, V14, P476, DOI 10.1016/S0955-0674(02)00358-7; Hampton RY, 1996, MOL BIOL CELL, V7, P2029, DOI 10.1091/mbc.7.12.2029; HORIE M, 1990, J BIOL CHEM, V265, P18075; Hua XX, 1996, CELL, V87, P415, DOI 10.1016/S0092-8674(00)81362-8; INOUE S, 1992, J BIOL CHEM, V267, P9080; KIM CM, 1992, J BIOL CHEM, V267, P23113; Kuwabara PE, 2002, TRENDS GENET, V18, P193, DOI 10.1016/S0168-9525(02)02640-9; Liang GS, 2002, J BIOL CHEM, V277, P9520, DOI 10.1074/jbc.M111421200; LISCUM L, 1985, J BIOL CHEM, V260, P522; LISCUM L, 1983, J BIOL CHEM, V258, P8450; LUSKEY KL, 1985, J BIOL CHEM, V260, P271; Meigs TE, 1996, J BIOL CHEM, V271, P7916, DOI 10.1074/jbc.271.14.7916; Mimnaugh EG, 1999, ELECTROPHORESIS, V20, P418, DOI 10.1002/(SICI)1522-2683(19990201)20:2<418::AID-ELPS418>3.0.CO;2-N; Moon YA, 2003, J BIOL CHEM, V278, P7335, DOI 10.1074/jbc.M211684200; NAKANISHI M, 1988, J BIOL CHEM, V263, P8929; Nohturfft A, 2000, CELL, V102, P315, DOI 10.1016/S0092-8674(00)00037-4; Nohturfft A, 1998, P NATL ACAD SCI USA, V95, P12848, DOI 10.1073/pnas.95.22.12848; Nohturfft A, 1996, P NATL ACAD SCI USA, V93, P13709, DOI 10.1073/pnas.93.24.13709; Ravid T, 2000, J BIOL CHEM, V275, P35840, DOI 10.1074/jbc.M004793200; Rawson RB, 1999, J BIOL CHEM, V274, P28549, DOI 10.1074/jbc.274.40.28549; ROITELMAN J, 1992, J CELL BIOL, V117, P959, DOI 10.1083/jcb.117.5.959; ROITELMAN J, 1992, J BIOL CHEM, V267, P25264; SATO R, 1993, P NATL ACAD SCI USA, V90, P9261, DOI 10.1073/pnas.90.20.9261; Seabra MC, 2002, TRENDS MOL MED, V8, P23, DOI 10.1016/S1471-4914(01)02227-4; Sever N, 2003, MOL CELL, V11, P25, DOI 10.1016/S1097-2765(02)00822-5; SKALNIK DG, 1988, J BIOL CHEM, V263, P6836; Yabe D, 2002, P NATL ACAD SCI USA, V99, P12753, DOI 10.1073/pnas.162488899; YAMAMOTO T, 1984, CELL, V39, P27, DOI 10.1016/0092-8674(84)90188-0; Yang T, 2002, CELL, V110, P489, DOI 10.1016/S0092-8674(02)00872-3; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325	44	227	242	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52479	52490		10.1074/jbc.M310053200	http://dx.doi.org/10.1074/jbc.M310053200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14563840	hybrid			2022-12-27	WOS:000187480700062
J	Higurashi, M; Ohtsuki, T; Inase, A; Kusumoto, R; Masutani, C; Hanaoka, F; Iwai, S				Higurashi, M; Ohtsuki, T; Inase, A; Kusumoto, R; Masutani, C; Hanaoka, F; Iwai, S			Identification and characterization of an intermediate in the alkali degradation of (6-4) photoproduct-containing DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLOBUTANE PYRIMIDINE DIMERS; NUCLEOTIDE EXCISION-REPAIR; TRANS-SYN-I; ESCHERICHIA-COLI; MAMMALIAN-CELLS; ABASIC SITES; UV-LIGHT; CIS-SYN; DAMAGE; OLIGONUCLEOTIDES	The (6-4) photoproduct formed by ultraviolet light is known as an alkali-labile DNA lesion. Strand breaks occur at (6-4) photoproducts when UV-irradiated DNA is treated with hot alkali. We have analyzed the degradation reaction of this photoproduct under alkaline conditions using synthetic oligonucleotides. A tetramer, d(GT(6-4) TC), was prepared, and its degradation in 50 mM KOH at 60 degreesC was monitored by high performance liquid chromatography. A single peak with a UV absorption spectrum similar to that of the starting material was detected after the reaction, and this compound was regarded as an intermediate before the strand break. The formation of this intermediate was compared with intermediates from the degradation of other alkali-labile lesions such as the abasic site, thymine glycol, and 5,6-dihydrothymine. The results strongly suggested that the first step of the alkali degradation of the (6- 4) photoproduct was the hydrolysis between the N3 and C4 positions of the 5'-pyrimidine component. Analyses by NMR spectroscopy and mass spectrometry supported the chemical structure of this product. Assays of the complex formation with XPC . HR23B and the translesion synthesis by DNA polymerase eta revealed that the biochemical properties are indistinguishable between the intact and hydrolyzed photoproducts.	Univ Tokyo, Dept Chem & Biotechnol, Bunkyo Ku, Tokyo 1138656, Japan; Univ Tokyo, Dept Integrated Biosci, Grad Sch Frontier Biosci, Chiba 2778562, Japan; Japan Sci & Technol Corp, Grad Sch Frontier Biosci, Osaka 5650871, Japan; Japan Sci & Technol Corp, Core Res Evolut Sci & Technol, Osaka 5650871, Japan; Osaka Univ, Div Chem, Grad Sch Engn Sci, Osaka 5608531, Japan	University of Tokyo; University of Tokyo; Japan Science & Technology Agency (JST); Japan Science & Technology Agency (JST); Osaka University	Iwai, S (corresponding author), Osaka Univ, Div Chem, Grad Sch Engn Sci, 1-3 Machikaneyama, Osaka 5608531, Japan.		OHTSUKI, Takashi/B-1471-2011; Masutani, Chikahide/I-6160-2014	OHTSUKI, Takashi/0000-0002-3183-5305; Masutani, Chikahide/0000-0002-8600-8227				Aso M, 1999, J AM CHEM SOC, V121, P9023, DOI 10.1021/ja991574a; BAILLET S, 1995, TETRAHEDRON LETT, V36, P8981, DOI 10.1016/0040-4039(95)01950-M; Dubey I, 2001, NUCLEOS NUCLEOT NUCL, V20, P1463, DOI 10.1081/NCN-100105241; FRANKLIN WA, 1982, J BIOL CHEM, V257, P13535; Horsfall MJ, 1997, J BACTERIOL, V179, P2835, DOI 10.1128/jb.179.9.2835-2839.1997; IDE H, 1987, BIOCHEMISTRY-US, V26, P964, DOI 10.1021/bi00377a042; IDE H, 1991, J BIOL CHEM, V266, P1469; IDE H, 1985, NUCLEIC ACIDS RES, V13, P8035, DOI 10.1093/nar/13.22.8035; Iwai S, 2000, ANGEW CHEM INT EDIT, V39, P3874, DOI 10.1002/1521-3773(20001103)39:21<3874::AID-ANIE3874>3.0.CO;2-O; Iwai S, 2001, CHEM-EUR J, V7, P4343, DOI 10.1002/1521-3765(20011015)7:20<4343::AID-CHEM4343>3.0.CO;2-H; Iwai S, 1996, J AM CHEM SOC, V118, P7642, DOI 10.1021/ja9603158; Kamiya H, 1998, NUCLEIC ACIDS RES, V26, P2611, DOI 10.1093/nar/26.11.2611; Klungland A, 1999, MOL CELL, V3, P33, DOI 10.1016/S1097-2765(00)80172-0; LECLERC JE, 1991, P NATL ACAD SCI USA, V88, P9685, DOI 10.1073/pnas.88.21.9685; LEMAIRE DGE, 1993, BIOCHEMISTRY-US, V32, P2525, DOI 10.1021/bi00061a009; Lhomme J, 1999, BIOPOLYMERS, V52, P65, DOI 10.1002/1097-0282(1999)52:2<65::AID-BIP1>3.0.CO;2-U; LIPPKE JA, 1981, P NATL ACAD SCI-BIOL, V78, P3388, DOI 10.1073/pnas.78.6.3388; Masutani C, 2000, EMBO J, V19, P3100, DOI 10.1093/emboj/19.12.3100; Masutani C, 1999, EMBO J, V18, P3491, DOI 10.1093/emboj/18.12.3491; MAZUMDER A, 1991, BIOCHEMISTRY-US, V30, P1119, DOI 10.1021/bi00218a033; MCHUGH PJ, 1995, NUCLEIC ACIDS RES, V23, P1664, DOI 10.1093/nar/23.10.1664; Peng W, 1996, BIOCHEMISTRY-US, V35, P10172, DOI 10.1021/bi960001x; PFEIFER GP, 1991, P NATL ACAD SCI USA, V88, P1374, DOI 10.1073/pnas.88.4.1374; Pfeifer GP, 1997, METHODS, V11, P189, DOI 10.1006/meth.1996.0405; Ravanat JL, 2001, J PHOTOCH PHOTOBIO B, V63, P88, DOI 10.1016/S1011-1344(01)00206-8; SMITH CA, 1993, J BIOL CHEM, V268, P11143; Smith CA, 1996, BIOCHEMISTRY-US, V35, P4146, DOI 10.1021/bi951975c; Sugasawa K, 1998, MOL CELL, V2, P223, DOI 10.1016/S1097-2765(00)80132-X; Sugasawa K, 2001, GENE DEV, V15, P507, DOI 10.1101/gad.866301; TORNALETTI S, 1995, J MOL BIOL, V249, P714, DOI 10.1006/jmbi.1995.0331; Tu YQ, 1998, J MOL BIOL, V284, P297, DOI 10.1006/jmbi.1998.2176; Wood RD, 1997, J BIOL CHEM, V272, P23465, DOI 10.1074/jbc.272.38.23465; Yoon JH, 2000, J MOL BIOL, V299, P681, DOI 10.1006/jmbi.2000.3771; You YH, 2001, J BIOL CHEM, V276, P44688, DOI 10.1074/jbc.M107696200	34	13	13	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51968	51973		10.1074/jbc.M307186200	http://dx.doi.org/10.1074/jbc.M307186200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14534315	hybrid			2022-12-27	WOS:000187206300133
J	Oppegard, LM; Hillestad, M; McCarthy, RT; Pai, RD; Connell, GJ				Oppegard, LM; Hillestad, M; McCarthy, RT; Pai, RD; Connell, GJ			Cis-acting elements stimulating kinetoplastid guide RNA-directed editing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B MESSENGER-RNA; TRYPANOSOMA-BRUCEI; LEISHMANIA-TARENTOLAE; IN-VITRO; DIRECT VISUALIZATION; URIDINE INSERTION; SEQUENCE; MOLECULES; PROTEINS; IDENTIFICATION	The coding sequence of several mitochondrial mRNAs of the kinetoplastid protozoa is created through the insertion and deletion of specific uridylates. The editing reactions are required to be highly specific in order to ensure that functional open reading frames are created in edited mRNAs and that potentially deleterious modification of normally nonedited sequence does not occur. Selection-amplification and mutagenesis were previously used to identify the optimal sequence requirements for in vitro editing. There is, however, a minority of natural editing sites with suboptimal sequence. Several cis-acting elements, obtained from an in vitro selection, are described here that are able to compensate for a suboptimal editing site. An A + U sequence element within the 5'-untranslated region of cytochrome b mRNA from Leishmania tarentolae is also demonstrated to function as a cis-acting guide RNA and is postulated to compensate for a suboptimal editing site in vivo. Two proteins within an enriched editing extract are UV-cross-linked to two different in vitro selected editing substrates more efficiently than poorly edited RNAs. The results suggest that these proteins contribute to the specificity of the editing reaction.	Univ Minnesota, Sch Med, Dept Pharmacol, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Connell, GJ (corresponding author), Univ Minnesota, Sch Med, Dept Pharmacol, 6-120 Jackson Hall,321 Church St SE, Minneapolis, MN 55455 USA.	gconnell@lenti.med.umn.edu						BLUM B, 1990, CELL, V60, P189, DOI 10.1016/0092-8674(90)90735-W; BRALY P, 1974, J PROTOZOOL, V21, P782, DOI 10.1111/j.1550-7408.1974.tb03752.x; Bringaud F, 1997, MOL CELL BIOL, V17, P3915, DOI 10.1128/MCB.17.7.3915; Brown LM, 1999, J BIOL CHEM, V274, P6295, DOI 10.1074/jbc.274.10.6295; Burgess MLK, 2000, RNA, V6, P1492, DOI 10.1017/S1355838200000066; Byrne EM, 1996, EMBO J, V15, P6758, DOI 10.1002/j.1460-2075.1996.tb01065.x; Connell GJ, 1997, J BIOL CHEM, V272, P4212, DOI 10.1074/jbc.272.7.4212; Cruz-Reyes J, 2001, MOL CELL BIOL, V21, P884, DOI 10.1128/MCB.21.3.884-892.2001; CruzReyes J, 1996, P NATL ACAD SCI USA, V93, P8901, DOI 10.1073/pnas.93.17.8901; Drozdz M, 2002, EMBO J, V21, P1791, DOI 10.1093/emboj/21.7.1791; ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0; Ernst NL, 2003, MOL CELL, V11, P1525, DOI 10.1016/S1097-2765(03)00185-0; GOLD L, 1995, ANNU REV BIOCHEM, V64, P763, DOI 10.1146/annurev.bi.64.070195.003555; Huang CE, 2002, MOL CELL BIOL, V22, P3194, DOI 10.1128/MCB.22.9.3194-3203.2002; Igo RP, 2002, MOL CELL BIOL, V22, P1567, DOI 10.1128/MCB.22.5.1567-1576.2002; Kabb AL, 2001, NUCLEIC ACIDS RES, V29, P2575, DOI 10.1093/nar/29.12.2575; Kable ML, 1996, SCIENCE, V273, P1189, DOI 10.1126/science.273.5279.1189; KOLLER J, 1994, NUCLEIC ACIDS RES, V22, P1988, DOI 10.1093/nar/22.11.1988; KROL A, 1989, METHOD ENZYMOL, V180, P212; LEEGWATER P, 1995, EUR J BIOCHEM, V227, P780, DOI 10.1111/j.1432-1033.1995.tb20201.x; MASLOV DA, 1992, CELL, V70, P459, DOI 10.1016/0092-8674(92)90170-H; McManus MT, 2001, RNA, V7, P167, DOI 10.1017/S1355838201002072; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; Oppegard LM, 2000, J BIOL CHEM, V275, P33911, DOI 10.1074/jbc.M003002200; Oppegard LM, 2002, INT J PARASITOL, V32, P859, DOI 10.1016/S0020-7519(02)00015-2; Pai RD, 2003, RNA, V9, P469, DOI 10.1261/rna.2175703; Panigrahi AK, 2001, MOL CELL BIOL, V21, P6833, DOI 10.1128/MCB.21.20.6833-6840.2001; Rusche LN, 2001, MOL CELL BIOL, V21, P979, DOI 10.1128/MCB.21.4.979-989.2001; Schnaufer A, 2001, SCIENCE, V291, P2159, DOI 10.1126/science.1058655; Seiwert SD, 1996, CELL, V84, P831, DOI 10.1016/S0092-8674(00)81062-4; THIEMANN OH, 1994, EMBO J, V13, P5689, DOI 10.1002/j.1460-2075.1994.tb06907.x; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	33	3	3	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51167	51175		10.1074/jbc.M307997200	http://dx.doi.org/10.1074/jbc.M307997200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14532294	hybrid			2022-12-27	WOS:000187206300042
J	Pfeiffer, M; Kirscht, S; Stumm, R; Koch, T; Wu, DF; Laugsch, M; Schroder, H; Hollt, V; Schulz, S				Pfeiffer, M; Kirscht, S; Stumm, R; Koch, T; Wu, DF; Laugsch, M; Schroder, H; Hollt, V; Schulz, S			Heterodimerization of substance P and mu-opioid receptors regulates receptor trafficking and resensitization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; BETA-ARRESTIN; MICE LACKING; SPINAL-CORD; OLIGOMERIZATION; SUBTYPES; INTERNALIZATION; MORPHINE; NK1; HOMODIMERIZATION	The mu-opioid receptor (MOR1) and the substance P receptor (NK1) coexist and functionally interact in nociceptive brain regions; however, a molecular basis for this interaction has not been established. Using coimmunoprecipitation and bioluminescence resonance energy transfer (BRET), we show that MOR1 and NK1 can form heterodimers in HEK 293 cells coexpressing the two receptors. Although NK1-MOR1 heterodimerization did not substantially change the ligand binding and signaling properties of these receptors, it dramatically altered their internalization and resensitization profile. Exposure of the NK1-MOR1 heterodimer to the MOR1-selective ligand [D-Ala(2), Me-Phe(4), Gly(5)-ol] enkephalin (DAMGO) promoted cross-phosphorylation and cointernalization of the NK1 receptor. Conversely, exposure of the NK1-MOR1 heterodimer to the NK1-selective ligand substance P (SP) promoted cross-phosphorylation and cointernalization of the MOR1 receptor. In cells expressing MOR1 alone, beta-arrestin directs the receptors to clathrin-coated pits, but does not internalize with the receptor. In cells expressing NK1 alone, beta-arrestin internalizes with the receptor into endosomes. Interestingly, in cells coexpressing MOR1 and NK1 both DAMGO and SP induced the recruitment of beta-arrestin to the plasma membrane and cointernalization of NK1-MOR1 heterodimers with beta-arrestin into the same endosomal compartment. Consequently, resensitization of MOR1-dependent receptor functions was severely delayed in coexpressing cells as compared with cells expressing MOR1 alone. Together, our findings indicate that MOR1 by virtue of its physical interaction with NK1 is sequestered via an endocytotic pathway with delayed recycling and resensitization kinetics.	Otto von Guericke Univ, Dept Pharmacol & Toxicol, D-39120 Magdeburg, Germany	Otto von Guericke University	Schulz, S (corresponding author), Otto von Guericke Univ, Dept Pharmacol & Toxicol, Leipziger Str 44, D-39120 Magdeburg, Germany.	Stefan.Schulz@Medizin.Uni-Magdeburg.de	Schulz, Stefan/A-6928-2017; Laugsch, Magdalena/AAH-8170-2021	Schulz, Stefan/0000-0002-5997-8885; 				Aicher SA, 2000, J NEUROSCI, V20, P4345; Aicher SA, 2000, SYNAPSE, V36, P12, DOI 10.1002/(SICI)1098-2396(200004)36:1<12::AID-SYN2>3.0.CO;2-E; Angers S, 2000, P NATL ACAD SCI USA, V97, P3684, DOI 10.1073/pnas.060590697; Angers S, 2001, LIFE SCI, V68, P2243, DOI 10.1016/S0024-3205(01)01012-8; Angers S, 2002, ANNU REV PHARMACOL, V42, P409, DOI 10.1146/annurev.pharmtox.42.091701.082314; Barak LS, 1999, J BIOL CHEM, V274, P7565, DOI 10.1074/jbc.274.11.7565; Bouvier M, 2001, NAT REV NEUROSCI, V2, P274, DOI 10.1038/35067575; Devi LA, 2001, TRENDS PHARMACOL SCI, V22, P532, DOI 10.1016/S0165-6147(00)01799-5; Foran SE, 2000, P NATL ACAD SCI USA, V97, P7621, DOI 10.1073/pnas.130181897; George SR, 2002, NAT REV DRUG DISCOV, V1, P808, DOI 10.1038/nrd913; Gouldson PR, 2000, NEUROPSYCHOPHARMACOL, V23, pS60, DOI 10.1016/S0893-133X(00)00153-6; Hanyaloglu AC, 2002, J BIOL CHEM, V277, P50422, DOI 10.1074/jbc.M209340200; Herrero JF, 2000, PROG NEUROBIOL, V61, P169, DOI 10.1016/S0301-0082(99)00051-9; Jasmin L, 2002, P NATL ACAD SCI USA, V99, P1029, DOI 10.1073/pnas.012598599; Jones KA, 1998, NATURE, V396, P674, DOI 10.1038/25348; Kaupmann K, 1998, NATURE, V396, P683, DOI 10.1038/25360; Koch T, 2001, J BIOL CHEM, V276, P31408, DOI 10.1074/jbc.M100305200; Koch T, 1998, J BIOL CHEM, V273, P13652, DOI 10.1074/jbc.273.22.13652; Kuner R, 1999, SCIENCE, V283, P74, DOI 10.1126/science.283.5398.74; Luttrell LM, 2002, J CELL SCI, V115, P455; Max M, 2001, NAT GENET, V28, P58, DOI 10.1038/88270; McConalogue K, 1999, J BIOL CHEM, V274, P16257, DOI 10.1074/jbc.274.23.16257; Mercier JF, 2002, J BIOL CHEM, V277, P44925, DOI 10.1074/jbc.M205767200; Milligan G, 2001, J CELL SCI, V114, P1265; Murtra P, 2000, NATURE, V405, P180, DOI 10.1038/35012069; Oakley RH, 2001, J BIOL CHEM, V276, P19452, DOI 10.1074/jbc.M101450200; Oakley RH, 1999, J BIOL CHEM, V274, P32248, DOI 10.1074/jbc.274.45.32248; Oakley RH, 2000, J BIOL CHEM, V275, P17201, DOI 10.1074/jbc.M910348199; Pfeiffer M, 2001, J BIOL CHEM, V276, P14027, DOI 10.1074/jbc.M006084200; Pfeiffer M, 2002, J BIOL CHEM, V277, P19762, DOI 10.1074/jbc.M110373200; Ramsay D, 2002, BIOCHEM J, V365, P429, DOI 10.1042/BJ20020251; Ripley TL, 2002, NEUROPHARMACOLOGY, V43, P1258, DOI 10.1016/S0028-3908(02)00295-2; Schulz S, 1998, NEUROSCIENCE, V82, P613; Spike RC, 2002, EUR J NEUROSCI, V15, P1306, DOI 10.1046/j.1460-9568.2002.01969.x; Stumm RK, 2002, J NEUROSCI, V22, P5865; Terrillon S, 2003, MOL ENDOCRINOL, V17, P677, DOI 10.1210/me.2002-0222; Tohgo A, 2003, J BIOL CHEM, V278, P6258, DOI 10.1074/jbc.M212231200; White JH, 1998, NATURE, V396, P679, DOI 10.1038/25354; Zhang J, 1998, P NATL ACAD SCI USA, V95, P7157, DOI 10.1073/pnas.95.12.7157	39	114	121	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51630	51637		10.1074/jbc.M307095200	http://dx.doi.org/10.1074/jbc.M307095200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14532289	hybrid			2022-12-27	WOS:000187206300097
J	Woo, HA; Kang, SW; Kim, HK; Yang, KS; Chae, HZ; Rhee, SG				Woo, HA; Kang, SW; Kim, HK; Yang, KS; Chae, HZ; Rhee, SG			Reversible oxidation of the active site cysteine of peroxiredoxins to cysteine sulfinic acid - Immunoblot detection with antibodies specific for the hyperoxidized cysteine-containing sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THIOL-SPECIFIC ANTIOXIDANT; MAMMALIAN PEROXIREDOXIN; 2-CYS PEROXIREDOXIN; CRYSTAL-STRUCTURE; THIOREDOXIN; PROTEIN; FAMILY; OVEROXIDATION; INACTIVATION; REDUCTASE	We previously suggested that oxidation of the active site cysteine of peroxiredoxin (Prx) I or Prx II to cysteine sulfinic acid in H2O2-treated cells is reversible (Woo, H. A., Chae, H. Z., Hwang, S. C., Yang, K.- S., Kang, S. W., Kim, K., and Rhee, S. G. (2003) Science 300, 653-656). In contrast, it was recently proposed that sulfinylation of Prx II, but not that of Prx I or Prx III, is reversible (Chevallet, M., Wagner, E., Luche, S., van Dorssealaer, A., Leize-Wagner, E., and Rabilloud, T. (2003) J. Biol. Chem. 278, 37146 - 37153). The detection of sulfinylated proteins in both of these previous studies relied on complex proteomics analysis. We now describe a simple immunoblot assay for the detection of sulfinylated Prx enzymes that is based on antibodies produced in response to a sulfonylated peptide modeled on the conserved active site sequence. These antibodies recognized both sulfinic and sulfonic forms of Prx equally well and allowed the detection of sulfinylated Prx enzymes in H2O2-treated cells with high sensitivity and specificity. With the use of these antibodies, we demonstrated that not only the cytosolic enzymes Prx I and Prx II but also the mitochondrial enzyme Prx III undergo reversible sulfinylation. The generation of antibodies specific for sulfonylated peptides should provide insight into protein function similar to that achieved with antibodies to peptides containing phosphoserine or phosphothreonine.	NHLBI, Lab Cell Signaling, NIH, Bethesda, MD 20892 USA; Ewha Womans Univ, Ctr Cell Signaling Res, Seoul 120750, South Korea; Ewha Womans Univ, Div Mol Life Sci, Seoul 120750, South Korea; Labfrontier Life Sci Inst, Suwon 442766, Kyunngi Do, South Korea	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Ewha Womans University; Ewha Womans University	Rhee, SG (corresponding author), NHLBI, Lab Cell Signaling, NIH, Bldg 50,Rm 3523,South Dr,MSC 8015, Bethesda, MD 20892 USA.		Woo, Hyun Ae/AAT-9586-2021					CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7017, DOI 10.1073/pnas.91.15.7017; CHAE HZ, 1994, J BIOL CHEM, V269, P27670; Chae HZ, 1999, DIABETES RES CLIN PR, V45, P101, DOI 10.1016/S0168-8227(99)00037-6; CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7022, DOI 10.1073/pnas.91.15.7022; Chang TS, 2002, J BIOL CHEM, V277, P25370, DOI 10.1074/jbc.M110432200; Chevallet M, 2003, J BIOL CHEM, V278, P37146, DOI 10.1074/jbc.M305161200; Georgiou G, 2003, SCIENCE, V300, P592, DOI 10.1126/science.1084976; Hamann M, 2002, METHOD ENZYMOL, V348, P146, DOI 10.1016/S0076-6879(02)48634-X; Hirotsu S, 1999, P NATL ACAD SCI USA, V96, P12333, DOI 10.1073/pnas.96.22.12333; Hofmann B, 2002, BIOL CHEM, V383, P347, DOI 10.1515/BC.2002.040; Jin DY, 1997, J BIOL CHEM, V272, P30952, DOI 10.1074/jbc.272.49.30952; Kang SW, 1998, J BIOL CHEM, V273, P6297, DOI 10.1074/jbc.273.11.6297; Matsumoto A, 1999, FEBS LETT, V443, P246, DOI 10.1016/S0014-5793(98)01736-0; Neumann CA, 2003, NATURE, V424, P561, DOI 10.1038/nature01819; Rabilloud T, 2002, J BIOL CHEM, V277, P19396, DOI 10.1074/jbc.M106585200; Rhee SG, 2001, IUBMB LIFE, V52, P35, DOI 10.1080/15216540252774748; Schroder E, 2000, STRUCTURE, V8, P605, DOI 10.1016/S0969-2126(00)00147-7; WATABE S, 1994, J BIOCHEM, V115, P648, DOI 10.1093/oxfordjournals.jbchem.a124390; Woo HA, 2003, SCIENCE, V300, P653, DOI 10.1126/science.1080273; Wood ZA, 2003, SCIENCE, V300, P650, DOI 10.1126/science.1080405; Yang KS, 2002, J BIOL CHEM, V277, P38029, DOI 10.1074/jbc.M206626200	21	190	195	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					47361	47364		10.1074/jbc.C300428200	http://dx.doi.org/10.1074/jbc.C300428200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	14559909	hybrid			2022-12-27	WOS:000186731400003
J	Ohana, E; Segal, D; Palty, R; Dien, TT; Moran, A; Sensi, SL; Weiss, JH; Hershfinkel, M; Sekler, I				Ohana, E; Segal, D; Palty, R; Dien, TT; Moran, A; Sensi, SL; Weiss, JH; Hershfinkel, M; Sekler, I			A sodium zinc exchange mechanism is mediating extrusion of zinc in mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASIC CALCIUM-PHOSPHATE; PROTEIN-KINASE-C; SYNAPTICALLY-RELEASED ZINC; INTRACELLULAR FREE ZINC; RAT-BRAIN; HUMAN FIBROBLASTS; CORTICAL-NEURONS; MOLECULAR-MECHANISM; CRYSTALS; ZN2+	Zinc influx, driven by a steep inward electrochemical gradient, plays a fundamental role in zinc signaling and in pathophysiologies linked to intracellular accumulation of toxic zinc. Yet, the cellular transport mechanisms that actively generate or maintain the transmembrane gradients are not well understood. We monitored Na+-dependent Zn2+ transport in HEK293 cells and cortical neurons, using fluorescent imaging. Treatment of the HEK293 cells with CaPO4 precipitates induced Na+-dependent Zn2+ extrusion, against a 500-fold transmembrane zinc gradient, or zinc influx upon reversal of Na+ gradient, thus indicating that Na+/Zn2+ exchange is catalyzing active Zn2+ transport. Depletion of intracellular ATP did not inhibit the Na+-dependent Zn2+ extrusion, consistent with a mechanism involving a secondary active transporter. Inhibitors of the Na+/Ca2+ exchanger failed to inhibit Na+-dependent Zn2+ efflux. In addition, zinc transport was unchanged in HEK293 cells heterologously expressing functional cardiac or neuronal Na+/Ca2+ exchangers, thus indicating that the Na+/Zn2+ exchange activity is not mediated by the Na+/Ca2+ exchanger. Sodium-dependent zinc exchange, facilitating the removal of intracellular zinc, was also monitored in neurons. To our knowledge, the Na+/Zn2+ exchanger described here is the first example of a mammalian transport mechanism capable of Na+-dependent active extrusion of zinc. Such mechanism is likely to play an important role, not only in generating the transmembrane zinc gradients, but also in protecting cells from the potentially toxic effects of permeation of this ion.	Ben Gurion Univ Negev, Fac Hlth Sci, Dept Physiol, IL-84105 Beer Sheva, Israel; Ben Gurion Univ Negev, Fac Hlth Sci, Dept Morphol, IL-84105 Beer Sheva, Israel; Univ Calif Irvine, Dept Neurol, Irvine, CA 92697 USA; Univ G DAnnunzio, Dept Neurol, CESI Ctr Res Aging, I-66013 Chieti, Italy	Ben Gurion University; Ben Gurion University; University of California System; University of California Irvine; G d'Annunzio University of Chieti-Pescara	Moran, A (corresponding author), Ben Gurion Univ Negev, Fac Hlth Sci, Dept Physiol, POB 653, IL-84105 Beer Sheva, Israel.	arie@bgumail.bgu.ac.il; sekler@bgumail.bgu.ac.il	Sensi, Stefano L./J-3164-2016; Ohana, Ehud/ABB-3060-2020; Palty, Raz/HCH-3978-2022; weiss, john/B-4283-2008; ohana, ehud/C-3077-2014; Sensi, Stefano L./O-1335-2019; Hershfinkel, Michal/F-1548-2012; MORAN, ARIE/F-1210-2012	Sensi, Stefano L./0000-0002-0710-2574; weiss, john/0000-0001-9323-7813; Sensi, Stefano L./0000-0002-0710-2574; Hershfinkel, Michal/0000-0003-1652-1989; Ohana, Ehud/0000-0001-8598-4042	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030884] Funding Source: NIH RePORTER; NIA NIH HHS [AG00919, AG00836] Funding Source: Medline; NINDS NIH HHS [NS30884] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ATAR D, 1995, J BIOL CHEM, V270, P2473, DOI 10.1074/jbc.270.6.2473; Bai G, 2001, OSTEOARTHR CARTILAGE, V9, P416, DOI 10.1053/joca.2000.0407; Blaustein MP, 1999, PHYSIOL REV, V79, P763, DOI 10.1152/physrev.1999.79.3.763; Canzoniero LMT, 1997, NEUROBIOL DIS, V4, P275, DOI 10.1006/nbdi.1997.0160; Cheung HS, 1996, BBA-MOL BASIS DIS, V1315, P105, DOI 10.1016/0925-4439(95)00106-9; Choi DW, 1998, ANNU REV NEUROSCI, V21, P347, DOI 10.1146/annurev.neuro.21.1.347; Colvin RA, 1998, NEUROREPORT, V9, P3091, DOI 10.1097/00001756-199809140-00032; Colvin RA, 2000, NEUROCHEM INT, V36, P539, DOI 10.1016/S0197-0186(99)00127-8; Costello LC, 1999, J BIOL CHEM, V274, P17499, DOI 10.1074/jbc.274.25.17499; Cousins RJ, 2000, J NUTR, V130, p1384S, DOI 10.1093/jn/130.5.1384S; DEHAYE JP, 1995, J TRACE ELEM MED BIO, V9, P94, DOI 10.1016/S0946-672X(11)80017-9; Despa S, 2002, J PHYSIOL-LONDON, V539, P133, DOI 10.1113/jphysiol.2001.012940; Diarra A, 2001, AM J PHYSIOL-CELL PH, V280, pC1623, DOI 10.1152/ajpcell.2001.280.6.C1623; FREDERICKSON CJ, 1989, BRAIN RES, V480, P317, DOI 10.1016/0006-8993(89)90199-6; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Gutser UT, 1998, NEUROPHARMACOLOGY, V37, P1139, DOI 10.1016/S0028-3908(98)00114-2; Hershfinkel M, 2001, P NATL ACAD SCI USA, V98, P11749, DOI 10.1073/pnas.201193398; Kasir J, 1999, J BIOL CHEM, V274, P24873, DOI 10.1074/jbc.274.35.24873; Kim AH, 2000, BRAIN RES, V886, P99, DOI 10.1016/S0006-8993(00)02944-9; Kim BJ, 2000, DIABETES, V49, P367, DOI 10.2337/diabetes.49.3.367; Koh JY, 1996, SCIENCE, V272, P1013, DOI 10.1126/science.272.5264.1013; Li Y, 2001, J NEUROSCI, V21, P8015, DOI 10.1523/JNEUROSCI.21-20-08015.2001; McCarthy GM, 1998, J BIOL CHEM, V273, P35161, DOI 10.1074/jbc.273.52.35161; McCarthy GM, 2001, ANN RHEUM DIS, V60, P399, DOI 10.1136/ard.60.4.399; Outten CE, 2001, SCIENCE, V292, P2488, DOI 10.1126/science.1060331; PALMITER RD, 1995, EMBO J, V14, P639, DOI 10.1002/j.1460-2075.1995.tb07042.x; Philipson KD, 2000, ANNU REV PHYSIOL, V62, P111, DOI 10.1146/annurev.physiol.62.1.111; Pozos TC, 1996, MOL CELL BIOL, V16, P3730; Reuben PM, 2002, J BIOL CHEM, V277, P15190, DOI 10.1074/jbc.M200278200; SEKLER I, 1995, J BIOL CHEM, V270, P28751, DOI 10.1074/jbc.270.48.28751; Sensi SL, 2003, CELL CALCIUM, V34, P281, DOI 10.1016/S0143-4160(03)00122-2; Sensi SL, 2003, P NATL ACAD SCI USA, V100, P6157, DOI 10.1073/pnas.1031598100; Sensi SL, 1997, J NEUROSCI, V17, P9554; Sensi SL, 2002, NEUROBIOL DIS, V10, P100, DOI 10.1006/nbdi.2002.0493; Sensi SL, 1999, P NATL ACAD SCI USA, V96, P2414, DOI 10.1073/pnas.96.5.2414; Shaul O, 1999, EMBO J, V18, P3973, DOI 10.1093/emboj/18.14.3973; Sheline CT, 2000, J NEUROSCI, V20, P3139, DOI 10.1523/JNEUROSCI.20-09-03139.2000; Suh SW, 2000, BRAIN RES, V852, P268, DOI 10.1016/S0006-8993(99)02095-8; Sun YB, 2002, J BIOL CHEM, V277, P1544, DOI 10.1074/jbc.M100567200; VALLEE BL, 1993, PHYSIOL REV, V73, P79, DOI 10.2466/pr0.1993.73.1.79; Vogt K, 2000, NEURON, V26, P187, DOI 10.1016/S0896-6273(00)81149-6; Wang YH, 2001, AM J PHYSIOL-CELL PH, V281, pC1667, DOI 10.1152/ajpcell.2001.281.5.C1667; Weiss JH, 2000, TRENDS PHARMACOL SCI, V21, P395, DOI 10.1016/S0165-6147(00)01541-8; Yin H z, 1994, Neurobiol Dis, V1, P43, DOI 10.1006/nbdi.1994.0006; Zeng XR, 2003, CELLS TISSUES ORGANS, V174, P63, DOI 10.1159/000070575	46	55	56	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					4278	4284		10.1074/jbc.M309229200	http://dx.doi.org/10.1074/jbc.M309229200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14581475	hybrid			2022-12-27	WOS:000188554300045
J	Stover, AG; Correia, JD; Evans, JT; Cluff, CW; Elliott, MW; Jeffery, EW; Johnson, DA; Lacy, MJ; Baldridge, JR; Probst, P; Ulevitch, RJ; Persing, DH; Hershberg, RM				Stover, AG; Correia, JD; Evans, JT; Cluff, CW; Elliott, MW; Jeffery, EW; Johnson, DA; Lacy, MJ; Baldridge, JR; Probst, P; Ulevitch, RJ; Persing, DH; Hershberg, RM			Structure-activity relationship of synthetic Toll-like receptor 4 agonists	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOLL-LIKE RECEPTOR-4; NECROSIS-FACTOR-ALPHA; LIPID-A; CELL ACTIVATION; GENE-EXPRESSION; IMMUNE CELLS; LIPOPOLYSACCHARIDE; TLR4; ENDOTOXIN; PROTEIN	Important questions remain regarding the impact of variations in the structure of the lipid A portion of lipopolysaccharide on activation of cells via the Toll-like receptor 4 complex. We have studied a series of synthetic lipid A mimetic compounds known as aminoalkyl glucosaminide phosphates in which the length of the secondary acyl chain has been systematically varied. Using transcriptional profiling of human monocytes and responses of Toll-like receptor 4 complex cell transfectants, we demonstrate a clear dependence of length on secondary acyl chain on Toll-like receptor 4 activation. Compounds with secondary acyl chains less than eight carbons in length have dramatically reduced activity, and substitutions of the left-sided secondary acyl chain had the most important effect on the Toll-like receptor 4 agonist activity of these molecules. The structure-function relationships of these compounds assessed via the induction of chemokines and cytokines following in vivo administration closely mirrored those seen with cell-based studies. This novel set of synthetic lipid A mimetics will be useful for Toll-like receptor 4-based investigations and may have clinical utility as stand-alone immunomodulators.	Corixa Corp, Seattle, WA 98104 USA; Corixa Corp, Hamilton, MT 59840 USA; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Infect Dis Res Inst, Seattle, WA 98104 USA	Corixa; Corixa; Scripps Research Institute	Persing, DH (corresponding author), Corixa Corp, 1124 Columbia St,Suite 200, Seattle, WA 98104 USA.	persing@corixa.com	Ulevitch, Richard J/Q-3393-2017	Evans, Jay T./0000-0001-6602-0272				BAKER PJ, 1992, INFECT IMMUN, V60, P2694, DOI 10.1128/IAI.60.7.2694-2701.1992; Bauer S, 2001, P NATL ACAD SCI USA, V98, P9237, DOI 10.1073/pnas.161293498; Bishop RE, 2000, EMBO J, V19, P5071, DOI 10.1093/emboj/19.19.5071; Brandenburg K, 2002, BIOPHYS J, V83, P322, DOI 10.1016/S0006-3495(02)75172-2; Chuang TH, 2001, BBA-GENE STRUCT EXPR, V1518, P157, DOI 10.1016/S0167-4781(00)00289-X; Correia JD, 2002, J BIOL CHEM, V277, P1845, DOI 10.1074/jbc.M109910200; Correia JD, 2001, J BIOL CHEM, V276, P21129, DOI 10.1074/jbc.M009164200; EBERWINE J, 1992, P NATL ACAD SCI USA, V89, P3010, DOI 10.1073/pnas.89.7.3010; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Flo TH, 2002, J BIOL CHEM, V277, P35489, DOI 10.1074/jbc.M201366200; Guo L, 1998, CELL, V95, P189, DOI 10.1016/S0092-8674(00)81750-X; Hajjar AM, 2002, NAT IMMUNOL, V3, P354, DOI 10.1038/ni777; Hegde P, 2000, BIOTECHNIQUES, V29, P548, DOI 10.2144/00293bi01; Hemmi H, 2002, NAT IMMUNOL, V3, P196, DOI 10.1038/ni758; Johnson DA, 1999, BIOORG MED CHEM LETT, V9, P2273, DOI 10.1016/S0960-894X(99)00374-1; Krieg AM, 2000, VACCINE, V19, P618, DOI 10.1016/S0264-410X(00)00249-8; LEE JD, 1993, P NATL ACAD SCI USA, V90, P9930, DOI 10.1073/pnas.90.21.9930; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; Luo L, 1999, NAT MED, V5, P117, DOI 10.1038/4806; Martin M, 2003, INFECT IMMUN, V71, P2498, DOI 10.1128/IAI.71.5.2498-2507.2003; Mujumdar SR, 1996, BIOCONJUGATE CHEM, V7, P356, DOI 10.1021/bc960021b; Mullarkey M, 2003, J PHARMACOL EXP THER, V304, P1093, DOI 10.1124/jpet.102.044487; Persing DH, 2002, TRENDS MICROBIOL, V10, pS32, DOI 10.1016/S0966-842X(02)02426-5; Poltorak A, 2000, P NATL ACAD SCI USA, V97, P2163, DOI 10.1073/pnas.040565397; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Probst P, 1997, EUR J IMMUNOL, V27, P2634, DOI 10.1002/eji.1830271024; Rock FL, 1998, P NATL ACAD SCI USA, V95, P588, DOI 10.1073/pnas.95.2.588; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Takeuchi O, 1999, GENE, V231, P59, DOI 10.1016/S0378-1119(99)00098-0; Tamai R, 2003, IMMUNOLOGY, V110, P66, DOI 10.1046/j.1365-2567.2003.01709.x; TOBIAS PS, 1993, IMMUNOBIOLOGY, V187, P227, DOI 10.1016/S0171-2985(11)80341-4; VANGELDER RN, 1990, P NATL ACAD SCI USA, V87, P1663, DOI 10.1073/pnas.87.5.1663; Visintin A, 2001, P NATL ACAD SCI USA, V98, P12156, DOI 10.1073/pnas.211445098; XING Z, 1994, AM J RESP CELL MOL, V10, P148, DOI 10.1165/ajrcmb.10.2.8110470; Yang SH, 2001, INFECT IMMUN, V69, P2025, DOI 10.1128/IAI.69.4.2025-2030.2001	36	124	146	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					4440	4449		10.1074/jbc.M310760200	http://dx.doi.org/10.1074/jbc.M310760200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14570885	hybrid			2022-12-27	WOS:000188554300063
J	Han, XZ; Amar, S				Han, XZ; Amar, S			Secreted frizzled-related protein 1 (SFRP1) protects fibroblasts from ceramide-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERIODONTAL-LIGAMENT FIBROBLASTS; CELL-DEATH; BCL-2; EXPRESSION; ACTIVATION; GROWTH; P53; OVEREXPRESSION; GENES; MECHANISMS	Secreted frizzled-related proteins (SFRPs) are soluble proteins that have highly restricted tissue distribution. Although not fully understood, a role of SFRP1 in the regulation of apoptosis has been suggested. Our previous study disclosed a much greater level of SFRP1 expression in periodontal ligament fibroblasts (PDLFs), which have been suggested to maintain a reduced level of apoptosis compared with gingival fibroblasts. We have tested the role of SFRP1 in the regulation of fibroblast apoptosis both in vitro and in vivo. Our data showed that SFRP1 was significantly up-regulated in cultured human PDLFs during ceramide-induced apoptosis. In vivo study demonstrated an increased SFRP1 expression in mice periodontal ligament during force-induced apoptosis. While inhibition of endogenous SFRP1 increased the percentage of cell death in cultured human PDLFs, exogenous SFRP1 substantially reduced apoptosis in cultured human gingival fibroblasts, which do not maintain a high level of endogenous SFRP1 expression. The effect of SFRP1 on apoptosis was linked to the regulation of several apoptosis-related genes, including p53, caspase-3, caspase-9, and BCL-2-interacting killer (BIK). Furthermore our results indicated that the addition of exogenous SFRP1 could reduce the level of apoptosis in dermal fibroblasts in vivo, and this effect was also linked to the regulation of similar apoptosis-related genes as observed in in vitro studies. Collectively our results suggest that the constitutive up-regulation of SFRP1 could be an adaptive cell survival mechanism inherent to functionally specialized fibroblasts, and the addition of SFRP1 may contribute to the inhibition of apoptosis in fibroblast-related cells.	Boston Univ, Goldman Sch Grad Dent, Dept Periodontol & Oral Biol, Boston, MA 02118 USA	Boston University	Amar, S (corresponding author), Boston Univ, Goldman Sch Grad Dent, Dept Periodontol & Oral Biol, 700 Albany St,W-201E, Boston, MA 02118 USA.	samar@bu.edu		Amar, Salomon/0000-0002-0017-5930	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE012482] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE12482] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Bafico A, 1999, J BIOL CHEM, V274, P16180, DOI 10.1074/jbc.274.23.16180; Balciunaite G, 2002, NAT IMMUNOL, V3, P1102, DOI 10.1038/ni850; Bennett CN, 2002, J BIOL CHEM, V277, P30998, DOI 10.1074/jbc.M204527200; BOYD JM, 1995, ONCOGENE, V11, P1921; Bradley L, 2000, DEV BIOL, V227, P118, DOI 10.1006/dbio.2000.9873; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Dahan M, 2001, J CLIN PERIODONTOL, V28, P128, DOI 10.1034/j.1600-051x.2001.028002128.x; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Dufourcq P, 2002, CIRCULATION, V106, P3097, DOI 10.1161/01.CIR.0000039342.85015.5C; Fang L, 2001, EMBO J, V20, P1931, DOI 10.1093/emboj/20.8.1931; Fukuhara K, 2002, J CLIN ENDOCR METAB, V87, P1729, DOI 10.1210/jc.87.4.1729; Gazit A, 1999, ONCOGENE, V18, P5959, DOI 10.1038/sj.onc.1202985; Germain M, 2002, J BIOL CHEM, V277, P18053, DOI 10.1074/jbc.M201235200; Gillissen B, 2003, EMBO J, V22, P3580, DOI 10.1093/emboj/cdg343; Golstein P, 1997, SCIENCE, V275, P1081, DOI 10.1126/science.275.5303.1081; Guenal I, 1997, ONCOGENE, V15, P347, DOI 10.1038/sj.onc.1201182; Han X, 2003, J DENT RES, V82, P454, DOI 10.1177/154405910308200610; Han X, 2002, J DENT RES, V81, P399, DOI 10.1177/154405910208100609; Hargrave KM, 2002, OBES RES, V10, P1284, DOI 10.1038/oby.2002.174; Hatai T, 2001, ORAL DIS, V7, P287, DOI 10.1034/j.1601-0825.2001.00663.x; HavemosePoulsen A, 1997, CRIT REV ORAL BIOL M, V8, P217, DOI 10.1177/10454411970080020801; Howard PS, 1998, J PERIODONTAL RES, V33, P500; Hu ED, 1998, BIOCHEM BIOPH RES CO, V247, P287, DOI 10.1006/bbrc.1998.8784; Ibrado AM, 1996, CANCER RES, V56, P4743; Ijiri K, 2002, J RHEUMATOL, V29, P2266; Imai K, 2002, CHEST, V121, p7S, DOI 10.1378/chest.121.3_suppl.7S; Jelaska A, 1998, J CELL PHYSIOL, V175, P19, DOI 10.1002/(SICI)1097-4652(199804)175:1<19::AID-JCP3>3.0.CO;2-F; Kainulainen T, 2002, J BIOL CHEM, V277, P21998, DOI 10.1074/jbc.M200715200; Kitanaka C, 1997, ONCOGENE, V15, P1763, DOI 10.1038/sj.onc.1201349; KORSMEYER SJ, 1993, SEMIN CANCER BIOL, V4, P327; Le HT, 2003, J BIOL CHEM, V278, P21136, DOI 10.1074/jbc.M300588200; Lee SW, 2000, P NATL ACAD SCI USA, V97, P8302, DOI 10.1073/pnas.150024397; Lekic P, 1996, ANAT REC, V245, P327; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li L, 2002, INFECT IMMUN, V70, P3915, DOI 10.1128/IAI.70.7.3915-3922.2002; Melkonyan HS, 1997, P NATL ACAD SCI USA, V94, P13636, DOI 10.1073/pnas.94.25.13636; MIYASHITA T, 1995, CELL, V80, P293; Murakami S, 1999, J PERIODONTAL RES, V34, P425, DOI 10.1111/j.1600-0765.1999.tb02277.x; Phipps RP, 1997, J PERIODONTAL RES, V32, P159, DOI 10.1111/j.1600-0765.1997.tb01398.x; Rana MW, 2001, AM J ORTHOD DENTOFAC, V119, P516, DOI 10.1067/mod.2001.113654; Rincheval V, 2002, BIOCHEM BIOPH RES CO, V298, P282, DOI 10.1016/S0006-291X(02)02454-3; Roth W, 2000, ONCOGENE, V19, P4210, DOI 10.1038/sj.onc.1203783; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Sculean A, 1999, J CLIN PERIODONTOL, V26, P318, DOI 10.1034/j.1600-051X.1999.260510.x; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Uren A, 2000, J BIOL CHEM, V275, P4374, DOI 10.1074/jbc.275.6.4374; van Gijn ME, 2001, EXP CELL RES, V265, P46, DOI 10.1006/excr.2001.5174; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Yang J, 2001, J BIOL CHEM, V276, P27129, DOI 10.1074/jbc.M100729200; Yoshino K, 2001, MECH DEVELOP, V102, P45, DOI 10.1016/S0925-4773(01)00282-9	51	40	45	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	2004	279	4					2832	2840		10.1074/jbc.M308102200	http://dx.doi.org/10.1074/jbc.M308102200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	764MU	14581477	hybrid			2022-12-27	WOS:000188211300062
J	Kessl, JJ; Hill, P; Lange, BB; Meshnick, SR; Meunier, B; Trumpower, BL				Kessl, JJ; Hill, P; Lange, BB; Meshnick, SR; Meunier, B; Trumpower, BL			Molecular basis for atovaquone resistance in Pneumocystis jirovecii modeled in the cytochrome bc(1) complex of Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BC(1) COMPLEX; MUTATIONAL ANALYSIS; ANTIMALARIAL-DRUGS; CARINII-PNEUMONIA; B MUTATIONS; C REDUCTASE; IN-VITRO; PENTAMIDINE; 566C80; HYDROXYNAPHTHOQUINONE	Atovaquone is a substituted hydroxynaphthoquinone that is widely used to prevent and clear Plasmodium falciparum malaria and Pneumocystis jirovecii pneumonia. Atovaquone inhibits respiration in target organisms by specifically binding to the ubiquinol oxidation site at center P of the cytochrome bc(1) complex. The failure of atovaquone treatment and mortality of patients with malaria and P. jirovecii pneumonia has been linked to the appearance of mutations in the cytochrome b gene. To better understand the molecular basis of atovaquone resistance, we have introduced seven of the mutations from atovaquone-resistant P. jirovecii into the cytochrome b gene of Saccharomyces cerevisiae and thus obtained cytochrome bc1 complexes resistant to inhibition by atovaquone. In these enzymes, the IC(50) for atovaquone increases from 25 nM for the enzyme from wild-type yeast to > 500 nM for some of the mutated enzymes. Modeling of the changes in cytochrome b structure and atovaquone binding with the mutated bc1 complexes provides the first quantitative explanation for the molecular basis of atovaquone resistance.	Dartmouth Coll Sch Med, Dept Biochem, Hanover, NH 03755 USA; UCL, Wolfson Inst Biomed Res, London WC1E 6BT, England; Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA	Dartmouth College; University of London; University College London; University of North Carolina; University of North Carolina Chapel Hill	Trumpower, BL (corresponding author), Dartmouth Coll Sch Med, Dept Biochem, 7200 Vail, Hanover, NH 03755 USA.	Trumpower@Dartmouth.edu	Kessl, Jacques/J-6073-2015; Kessl, Jacques/AAV-2526-2021	Meunier, Brigitte/0000-0002-6988-4663	NIAID NIH HHS [AI46966] Funding Source: Medline; NIGMS NIH HHS [GM20379] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI046966] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM020379, R01GM020379] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARAUJO FG, 1991, ANTIMICROB AGENTS CH, V35, P293, DOI 10.1128/AAC.35.2.293; Bonnefoy N, 2001, METHOD CELL BIOL, V65, P381, DOI 10.1016/S0091-679X(01)65022-2; Bruns TD, 1992, MOL PHYLOGENET EVOL, V1, P231, DOI 10.1016/1055-7903(92)90020-H; Butow R A, 1996, Methods Enzymol, V264, P265, DOI 10.1016/S0076-6879(96)64026-9; Chan C, 1999, J INFECT DIS, V180, P369, DOI 10.1086/314893; CUSHION MT, 1994, LUNG BIOL HLTH DIS, V69, P123; Darrouzet E, 2003, BIOCHEMISTRY-US, V42, P1499, DOI 10.1021/bi026656h; DIRAGO JP, 1989, J BIOL CHEM, V264, P14543; El-Sadr WM, 1998, NEW ENGL J MED, V339, P1889, DOI 10.1056/NEJM199812243392604; FOX TD, 1988, P NATL ACAD SCI USA, V85, P7288, DOI 10.1073/pnas.85.19.7288; FRY M, 1992, BIOCHEM PHARMACOL, V43, P1545, DOI 10.1016/0006-2952(92)90213-3; Gutierrez-Cirlos EB, 2002, J BIOL CHEM, V277, P1195, DOI 10.1074/jbc.M109097200; GUTTERIDGE WE, 1989, J ROY SOC MED, V82, P63; GUTTERIDGE WE, 1991, J PROTOZOOL, V38, P141; HATFIELD C, 1991, J PROTOZOOL, V38, pS70; Hill P, 2003, ANTIMICROB AGENTS CH, V47, P2725, DOI 10.1128/AAC.47.9.2725-2731.2003; HOWELL N, 1988, J MOL BIOL, V203, P607, DOI 10.1016/0022-2836(88)90195-7; HUDSON AT, 1991, DRUG EXP CLIN RES, V17, P427; HUGHES WT, 1995, J INFECT DIS, V172, P1042, DOI 10.1093/infdis/172.4.1042; HUGHES WT, 1990, ANTIMICROB AGENTS CH, V34, P225, DOI 10.1128/AAC.34.2.225; Hunte C, 2000, STRUCTURE, V8, P669, DOI 10.1016/S0969-2126(00)00152-0; Kazanjian P, 2001, J INFECT DIS, V183, P819, DOI 10.1086/318835; Kessl JJ, 2003, J BIOL CHEM, V278, P31312, DOI 10.1074/jbc.M304042200; Korsinczky M, 2000, ANTIMICROB AGENTS CH, V44, P2100, DOI 10.1128/AAC.44.8.2100-2108.2000; LJUNGDAHL O, 1987, BIOCHIM BIOPHYS ACTA, V891, P227; LJUNGDAHL PO, 1989, J BIOL CHEM, V264, P3723; Looareesuwan S, 1996, AM J TROP MED HYG, V54, P62, DOI 10.4269/ajtmh.1996.54.62; LUDEWIG G, 1994, ANTIMICROB AGENTS CH, V38, P1123, DOI 10.1128/AAC.38.5.1123; LUDEWIG G, 1994, ANTIMICROB AGENTS CH, V38, P2850, DOI 10.1128/AAC.38.12.2850; OHNISHI T, 1988, EUR J BIOCHEM, V176, P385, DOI 10.1111/j.1432-1033.1988.tb14293.x; Palsdottir H, 2003, J BIOL CHEM, V278, P31303, DOI 10.1074/jbc.M302195200; Schwobel B, 2003, MALARIA J, V2, DOI 10.1186/1475-2875-2-5; Snyder CH, 1999, J BIOL CHEM, V274, P31209, DOI 10.1074/jbc.274.44.31209; Srivastava IK, 1999, ANTIMICROB AGENTS CH, V43, P1334, DOI 10.1128/AAC.43.6.1334; Walker DJ, 1998, J INFECT DIS, V178, P1767, DOI 10.1086/314509; WENDEL WB, 1946, FED PROC, V5, P406	36	55	59	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 23	2004	279	4					2817	2824		10.1074/jbc.M309984200	http://dx.doi.org/10.1074/jbc.M309984200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	764MU	14576156	hybrid			2022-12-27	WOS:000188211300060
J	Simizu, S; Ishida, K; Wierzba, MK; Osada, H				Simizu, S; Ishida, K; Wierzba, MK; Osada, H			Secretion of heparanase protein is regulated by glycosylation in human tumor cell lines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							QUALITY-CONTROL; MAMMALIAN HEPARANASE; EXPRESSION; CLONING; SULFATE; ENZYME; BIOSYNTHESIS; ANGIOGENESIS; INVOLVEMENT; METASTASIS	The endo-beta-D-glucuronidase, heparanase, is capable of specifically degrading heparan sulfate, and this activity is associated with the metastatic potential of tumor cells. The predicted amino acid sequence of heparanase includes six putative N-glycosylation sites; however, the precise biochemical role of glycosylated heparanase remains unknown. In this study, we examined the link between glycosylation and the function of heparanase in human tumor cell lines. Heparanase protein was glycosylated at six Asn residues in human tumor cell lines. Treatment with a glycosylation inhibitor demonstrated that glycosylation was not required for the activity of heparanase. However, glycosylation affected the kinetics of endoplasmic reticulum-to-Golgi transport and of secretion of the enzyme.	RIKEN, Antiobiot Lab, Wako, Saitama 3510198, Japan; Saitama Univ, Grad Sch Sci & Engn, Saitama 3388570, Japan	RIKEN; Saitama University	Osada, H (corresponding author), RIKEN, Antiobiot Lab, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.	osadah@riken.jp	Osada, Hiroyuki/N-4305-2014; Osada, Hiroyuki/AAY-6254-2020	Simizu, Siro/0000-0003-2949-2427				ATSUMI S, 1993, CANCER RES, V53, P4896; Bame KJ, 2001, GLYCOBIOLOGY, V11, p91R, DOI 10.1093/glycob/11.6.91R; Bironaite D, 2000, TUMOR BIOL, V21, P165, DOI 10.1159/000030123; Blott EJ, 2002, NAT REV MOL CELL BIO, V3, P122, DOI 10.1038/nrm732; Brockhausen I, 1999, BBA-GEN SUBJECTS, V1473, P67, DOI 10.1016/S0304-4165(99)00170-1; Cabral CM, 2001, TRENDS BIOCHEM SCI, V26, P619, DOI 10.1016/S0968-0004(01)01942-9; Comer FI, 2000, J BIOL CHEM, V275, P29179, DOI 10.1074/jbc.R000010200; Correia JD, 2002, J BIOL CHEM, V277, P1845, DOI 10.1074/jbc.M109910200; Dempsey LA, 2000, TRENDS BIOCHEM SCI, V25, P349, DOI 10.1016/S0968-0004(00)01619-4; DEVOUGE MW, 1994, INT J CANCER, V56, P286, DOI 10.1002/ijc.2910560224; Drickamer K, 1998, TRENDS BIOCHEM SCI, V23, P321, DOI 10.1016/S0968-0004(98)01246-8; Dwek RA, 2002, NAT REV DRUG DISCOV, V1, P65, DOI 10.1038/nrd708; El-Assal ON, 2001, CLIN CANCER RES, V7, P1299; Esko JD, 2002, ANNU REV BIOCHEM, V71, P435, DOI 10.1146/annurev.biochem.71.110601.135458; Fairbanks MB, 1999, J BIOL CHEM, V274, P29587, DOI 10.1074/jbc.274.42.29587; Fujiwara T, 1998, J BIOL CHEM, V273, P3068, DOI 10.1074/jbc.273.5.3068; Goldshmidt O, 2002, P NATL ACAD SCI USA, V99, P10031, DOI 10.1073/pnas.152070599; Goldshmidt O, 2002, EXP CELL RES, V281, P50, DOI 10.1006/excr.2002.5651; Goldshmidt O, 2001, J BIOL CHEM, V276, P29178, DOI 10.1074/jbc.M102462200; Helenius A, 2001, SCIENCE, V291, P2364, DOI 10.1126/science.291.5512.2364; Hileman RE, 1998, BIOESSAYS, V20, P156, DOI 10.1002/(SICI)1521-1878(199802)20:2<156::AID-BIES8>3.3.CO;2-#; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hulett MD, 2000, BIOCHEMISTRY-US, V39, P15659, DOI 10.1021/bi002080p; Hulett MD, 1999, NAT MED, V5, P803, DOI 10.1038/10525; HUTCHISON KA, 1992, J BIOL CHEM, V267, P13952; Kadowaki T, 2000, J BIOL CHEM, V275, P25577, DOI 10.1074/jbc.M003521200; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; Koliopanos A, 2001, CANCER RES, V61, P4655; Kussie PH, 1999, BIOCHEM BIOPH RES CO, V261, P183, DOI 10.1006/bbrc.1999.0962; Lehrman MA, 2001, J BIOL CHEM, V276, P8623, DOI 10.1074/jbc.R100002200; MAREEL MM, 1985, CLIN EXP METASTAS, V3, P197, DOI 10.1007/BF01786763; Mikami S, 2001, JPN J CANCER RES, V92, P1062, DOI 10.1111/j.1349-7006.2001.tb01061.x; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; Naim HY, 1999, J BIOL CHEM, V274, P17961, DOI 10.1074/jbc.274.25.17961; NAKAJIMA M, 1983, SCIENCE, V220, P611, DOI 10.1126/science.6220468; Parish CR, 2001, BBA-REV CANCER, V1471, pM99, DOI 10.1016/S0304-419X(01)00017-8; PILI R, 1995, CANCER RES, V55, P2920; Rochefort H, 1996, ENZYME PROTEIN, V49, P106, DOI 10.1159/000468620; Sasisekharan R, 2002, NAT REV CANCER, V2, P521, DOI 10.1038/nrc842; Simizu S, 2000, NAT CELL BIOL, V2, P852, DOI 10.1038/35041102; Simizu S, 1996, CANCER RES, V56, P4978; Simizu S, 2003, CANCER LETT, V193, P83, DOI 10.1016/S0304-3835(02)00719-X; SLOANE BF, 1994, J CELL SCI, V107, P373; Spiro RG, 2000, J BIOL CHEM, V275, P35657, DOI 10.1074/jbc.R000022200; Toyoshima M, 1999, J BIOL CHEM, V274, P24153, DOI 10.1074/jbc.274.34.24153; Turnbull J, 2001, TRENDS CELL BIOL, V11, P75, DOI 10.1016/S0962-8924(00)01897-3; Uno F, 2001, CANCER RES, V61, P7855; Vlodavsky I, 2001, J CLIN INVEST, V108, P341, DOI 10.1172/JCI200113662; Vlodavsky I, 1999, NAT MED, V5, P793, DOI 10.1038/10518; YE SQ, 1992, J BIOL CHEM, V267, P21961	50	57	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	2004	279	4					2697	2703		10.1074/jbc.M300541200	http://dx.doi.org/10.1074/jbc.M300541200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	764MU	14573609	hybrid			2022-12-27	WOS:000188211300046
J	Cheng, J; Wang, H; Guggino, WB				Cheng, J; Wang, H; Guggino, WB			Modulation of mature cystic fibrosis transmembrane regulator protein by the PDZ domain protein CAL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONDUCTANCE REGULATOR; GOLGI PROTEIN; CFTR; RECEPTOR; BINDING; IDENTIFICATION; PROTEASOME; FAMILY; GENE; INTERNALIZATION	We have previously identified the cystic fibrosis transmembrane regulator (CFTR)-interacting protein CAL and demonstrated that CAL modulates CFTR plasma membrane expression by retaining CFTR within the cell. Here, we report that in addition to regulating membrane expression, CAL also regulates the expression of mature CFTR. The co-expression of hemagglutinin-tagged or Myc-tagged CAL with green fluorescent protein (GFP)-CFTR in COS-7 cells causes a dose-dependent reduction in mature GFP-CFTR, independent of its tags. Bafilomycin A1, a lysosomal proton pump inhibitor, increases mature GFP-CFTR, confirming previous reports of lysosomal degradation of mature CFTR. Importantly, bafilomycin A1 reverses CAL-mediated CFTR degradation. The proteasome inhibitor, MG132, on the other hand, does not reverse the effect of CAL. CAL has no effect on CFTR maturation, suggesting that it exerts its effects on mature CFTR. Co-expression of CAL enhances the degradation of CFTR. We showed previously that CAL reduces the half-life of CFTR at the cell surface. Here we show that expression of dominant-negative dynamin 2 K44A, a large GTPase inhibitor that is known to inhibit clathrin-mediated endocytosis and vesicle formation in the Golgi, increases cell surface CFTR as measured by surface biotinylation. More importantly, dynamin 2 K44A also restores cell surface CFTR in CAL-overexpressing cells and partially blocks the CAL-mediated degradation of mature CFTR. These data suggest a model in which CAL retains CFTR in the cell and targets CFTR for degradation.	Johns Hopkins Univ, Sch Med, Dept Physiol, Baltimore, MD 21205 USA	Johns Hopkins University	Guggino, WB (corresponding author), Johns Hopkins Univ, Sch Med, Dept Physiol, Baltimore, MD 21205 USA.	wguggino@bs.jhmi.edu			NHLBI NIH HHS [HL 47122] Funding Source: Medline; NIDDK NIH HHS [DK 48977] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047122] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK048977] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Benharouga M, 2001, J CELL BIOL, V153, P957, DOI 10.1083/jcb.153.5.957; Benharouga Mohamed, 2002, Methods Mol Med, V70, P229; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; Bradbury NA, 1999, AM J PHYSIOL-LUNG C, V276, pL659, DOI 10.1152/ajplung.1999.276.4.L659; Cao H, 2000, J CELL SCI, V113, P1993; Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; Charest A, 2001, J BIOL CHEM, V276, P29456, DOI 10.1074/jbc.M104137200; Cheng J, 2002, J BIOL CHEM, V277, P3520, DOI 10.1074/jbc.M110177200; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; Gentzsch M, 2003, J BIOL CHEM, V278, P6440, DOI 10.1074/jbc.M211050200; Hall RA, 1998, P NATL ACAD SCI USA, V95, P8496, DOI 10.1073/pnas.95.15.8496; Hassel B, 2003, J BIOL CHEM, V278, P40136, DOI 10.1074/jbc.M305577200; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; KOPITO RR, 1999, PHYSIOL REV, V79, P167; Lukacs GL, 1997, BIOCHEM J, V328, P353; McNiven MA, 2000, TRENDS BIOCHEM SCI, V25, P115, DOI 10.1016/S0968-0004(99)01538-8; Moyer BD, 1998, J BIOL CHEM, V273, P21759, DOI 10.1074/jbc.273.34.21759; Naren AP, 2003, P NATL ACAD SCI USA, V100, P342, DOI 10.1073/pnas.0135434100; Neudauer CL, 2001, BIOCHEM BIOPH RES CO, V280, P541, DOI 10.1006/bbrc.2000.4160; Pier GB, 1997, P NATL ACAD SCI USA, V94, P12088, DOI 10.1073/pnas.94.22.12088; Raghuram V, 2001, P NATL ACAD SCI USA, V98, P1300, DOI 10.1073/pnas.031538898; RIORDAN JR, 1989, SCIENCE, V245, P1066; Rosenstein BJ, 2002, PEDIATR PULM, V33, P83, DOI 10.1002/ppul.10053; Sans N, 2003, NAT CELL BIOL, V5, P520, DOI 10.1038/ncb990; SCHWIEBERT EM, 1999, PHYSL REV S, V79, P145; Sheppard DN, 1999, PHYSIOL REV, V79, P23; Short DB, 1998, J BIOL CHEM, V273, P19797, DOI 10.1074/jbc.273.31.19797; STUTTS MJ, 1995, SCIENCE, V269, P847, DOI 10.1126/science.7543698; Sun F, 2000, J BIOL CHEM, V275, P29539, DOI 10.1074/jbc.M004961200; Swiatecka-Urban A, 2002, J BIOL CHEM, V277, P40099, DOI 10.1074/jbc.M206964200; Wang SS, 1998, FEBS LETT, V427, P103, DOI 10.1016/S0014-5793(98)00402-5; Wang SS, 2000, CELL, V103, P169, DOI 10.1016/S0092-8674(00)00096-9; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Weixel KM, 2001, PFLUG ARCH EUR J PHY, V443, pS70; Yao RJ, 2002, P NATL ACAD SCI USA, V99, P11211, DOI 10.1073/pnas.162027899; Yao RJ, 2001, BIOCHEM BIOPH RES CO, V286, P771, DOI 10.1006/bbrc.2001.5430; Yue ZY, 2002, NEURON, V35, P921, DOI 10.1016/S0896-6273(02)00861-9	40	99	100	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 16	2004	279	3					1892	1898		10.1074/jbc.M308640200	http://dx.doi.org/10.1074/jbc.M308640200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	762WT	14570915	hybrid			2022-12-27	WOS:000188005700042
J	Manion, MK; O'Neill, JW; Giedt, CD; Kim, KM; Zhang, KYZ; Hockenbery, DM				Manion, MK; O'Neill, JW; Giedt, CD; Kim, KM; Zhang, KYZ; Hockenbery, DM			Bcl-X-L mutations suppress cellular sensitivity to antimycin A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BCL-X(L); APOPTOSIS; IDENTIFICATION; INHIBITORS; LYSOZYME; LIGAND; DOMAIN; CORE	Cells expressing high levels of the BCL-X-L anti-apoptotic protein are preferentially killed by the mitochondrial inhibitor antimycin A ( AA). Computational modeling predicts a binding site for AA in the extended hydrophobic groove on BCL-X-L, previously identified as an interface for dimerization to BAX and related proapoptotic proteins. Here, we identify BCL-X-L hydrophobic groove mutants with normal cellular anti-apoptotic function but suppressed sensitivity to AA. The LD50 of AA for cells expressing BCL-X-L mutants directly correlates with the measured in vitro dissociation constants for AA binding. These results indicate that BCL-X-L is a principal target mediating AA cytotoxicity.	Fred Hutchinson Canc Res Ctr, Div Human Biol, Seattle, WA 98109 USA; Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98109 USA	Fred Hutchinson Cancer Center; Fred Hutchinson Cancer Center	Hockenbery, DM (corresponding author), Fred Hutchinson Canc Res Ctr, Div Human Biol, Seattle, WA 98109 USA.	dhockenb@fhcrc.org	Zhang, Kam Y. J./B-3552-2012	Zhang, Kam Y. J./0000-0002-9282-8045	NATIONAL CANCER INSTITUTE [U01CA091310, T32CA080416] Funding Source: NIH RePORTER; NCI NIH HHS [T32 CA 80416, 5U01 CA 91310] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baldwin E, 1996, J MOL BIOL, V259, P542, DOI 10.1006/jmbi.1996.0338; Brenner C, 2000, ONCOGENE, V19, P329, DOI 10.1038/sj.onc.1203298; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Degterev A, 2001, NAT CELL BIOL, V3, P173, DOI 10.1038/35055085; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Heiden MGV, 2001, J BIOL CHEM, V276, P19414, DOI 10.1074/jbc.M101590200; Holinger EP, 1999, J BIOL CHEM, V274, P13298, DOI 10.1074/jbc.274.19.13298; Kim KM, 2001, BIOCHEMISTRY-US, V40, P4911, DOI 10.1021/bi002368e; Kissinger CR, 1999, ACTA CRYSTALLOGR D, V55, P484, DOI 10.1107/S0907444998012517; LAKOWICZ JR, 1999, PRINCIPLES FLUORESCE, P308; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lugovskoy AA, 2002, J AM CHEM SOC, V124, P1234, DOI 10.1021/ja011239y; MAYER LD, 1986, BIOCHIM BIOPHYS ACTA, V858, P161, DOI 10.1016/0005-2736(86)90302-0; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Minn AJ, 1999, EMBO J, V18, P632, DOI 10.1093/emboj/18.3.632; Ottilie S, 1997, J BIOL CHEM, V272, P30866, DOI 10.1074/jbc.272.49.30866; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; Singh J., 1992, ATLAS PROTEIN SIDE C, VII; Singh J., 1992, ATLAS PROTEIN SIDE C, VI; STEWART JCM, 1980, ANAL BIOCHEM, V104, P10, DOI 10.1016/0003-2697(80)90269-9; Tzung SP, 2001, NAT CELL BIOL, V3, P183, DOI 10.1038/35055095; Vander Heiden MG, 2000, P NATL ACAD SCI USA, V97, P4666, DOI 10.1073/pnas.090082297; Vander Heiden MG, 1999, MOL CELL, V3, P159; Xu JA, 1998, PROTEIN SCI, V7, P158, DOI 10.1002/pro.5560070117	26	77	83	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 16	2004	279	3					2159	2165		10.1074/jbc.M306021200	http://dx.doi.org/10.1074/jbc.M306021200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	762WT	14534311	hybrid			2022-12-27	WOS:000188005700072
J	Friedrich, KL; Giese, KC; Buan, NR; Vierling, E				Friedrich, KL; Giese, KC; Buan, NR; Vierling, E			Interactions between small heat shock protein subunits and substrate in small heat shock protein-substrate complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-A-CRYSTALLIN; MOLECULAR CHAPERONE ACTIVITY; HYDROPHOBIC SURFACES; DENATURED PROTEINS; OLIGOMER FORMATION; ESCHERICHIA-COLI; ENERGY-TRANSFER; IN-VITRO; EXCHANGE; EXPRESSION	Small heat shock proteins (sHSPs) are dynamic oligomeric proteins that bind unfolding proteins and protect them from irreversible aggregation. This binding results in the formation of sHSP-substrate complexes from which substrate can later be refolded. Interactions between sHSP and substrate in sHSP-substrate complexes and the mechanism by which substrate is transferred to ATP-dependent chaperones for refolding are poorly defined. We have established C-terminal affinity-tagged sHSPs from a eukaryote ( pea HSP18.1) and a prokaryote ( Synechocystis HSP16.6) as tools to investigate these issues. We demonstrate that sHSP subunit exchange for HSP18.1 and HSP16.6 is temperature-dependent and rapid at the optimal growth temperature for the organism of origin. Increasing the ratio of sHSP to substrate during substrate denaturation decreased sHSP-substrate complex size, and accordingly, addition of substrate to pre-formed sHSP-substrate complexes increased complex size. However, the size of pre-formed sHSP-substrate complexes could not be reduced by addition of more sHSP, and substrate could not be observed to transfer to added sHSP, although added sHSP subunits continued to exchange with subunits in sHSP-substrate complexes. Thus, although some number of sHSP subunits within complexes remain dynamic and may be important for complex structure/solubility, association of substrate with the sHSP does not appear to be similarly dynamic. These observations are consistent with a model in which ATP-dependent chaperones associate directly with sHSP-bound substrate to initiate refolding.	Univ Arizona, Dept Biochem & Mol Biophys, Tucson, AZ 85721 USA	University of Arizona	Vierling, E (corresponding author), Univ Arizona, Dept Biochem & Mol Biophys, 1007 E Lowell St, Tucson, AZ 85721 USA.			Vierling, Elizabeth/0000-0002-0066-4881	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042762] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM42762] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andley UP, 1996, J BIOL CHEM, V271, P31973, DOI 10.1074/jbc.271.50.31973; Bova MP, 2000, J BIOL CHEM, V275, P1035, DOI 10.1074/jbc.275.2.1035; Bova MP, 2002, J BIOL CHEM, V277, P38468, DOI 10.1074/jbc.M205594200; Bova MP, 1997, J BIOL CHEM, V272, P29511, DOI 10.1074/jbc.272.47.29511; Carver JA, 1999, PROG RETIN EYE RES, V18, P431, DOI 10.1016/S1350-9462(98)00027-5; DAS KP, 1995, FEBS LETT, V369, P321, DOI 10.1016/0014-5793(95)00775-5; de Jong WW, 1998, INT J BIOL MACROMOL, V22, P151, DOI 10.1016/S0141-8130(98)00013-0; Derham BK, 1999, PROG RETIN EYE RES, V18, P463, DOI 10.1016/S1350-9462(98)00030-5; Ehrnsperger M, 1997, EMBO J, V16, P221, DOI 10.1093/emboj/16.2.221; Giese KC, 2002, J BIOL CHEM, V277, P46310, DOI 10.1074/jbc.M208926200; GROENEN PJTA, 1994, EUR J BIOCHEM, V225, P1, DOI 10.1111/j.1432-1033.1994.00001.x; Gu LX, 2002, J MOL BIOL, V319, P517, DOI 10.1016/S0022-2836(02)00311-X; Haslbeck M, 1999, EMBO J, V18, P6744, DOI 10.1093/emboj/18.23.6744; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; JAKOB U, 1993, J BIOL CHEM, V268, P1517; Kim KK, 1998, NATURE, V394, P595, DOI 10.1038/29106; Lee GJ, 2000, PLANT PHYSIOL, V122, P189, DOI 10.1104/pp.122.1.189; Lee GJ, 1998, METHOD ENZYMOL, V290, P350, DOI 10.1016/S0076-6879(98)90031-3; LEE GJ, 1995, J BIOL CHEM, V270, P10432, DOI 10.1074/jbc.270.18.10432; Lee GJ, 1997, EMBO J, V16, P659, DOI 10.1093/emboj/16.3.659; Leroux MR, 1997, J BIOL CHEM, V272, P24646, DOI 10.1074/jbc.272.39.24646; Lindner RA, 2000, EUR J BIOCHEM, V267, P1923, DOI 10.1046/j.1432-1327.2000.01188.x; MERCK KB, 1992, BIOCHIM BIOPHYS ACTA, V1130, P267, DOI 10.1016/0167-4781(92)90439-7; Mogk A, 2003, J BIOL CHEM, V278, P31033, DOI 10.1074/jbc.M303587200; Neal R, 2001, BIOCHEM BIOPH RES CO, V280, P14, DOI 10.1006/bbrc.2000.4092; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; PLESOFSKYVIG N, 1995, P NATL ACAD SCI USA, V92, P5032, DOI 10.1073/pnas.92.11.5032; RAMAN B, 1994, J BIOL CHEM, V269, P27264; RAO PV, 1993, BIOCHEM BIOPH RES CO, V190, P786, DOI 10.1006/bbrc.1993.1118; Shearstone JR, 1999, J BIOL CHEM, V274, P9937, DOI 10.1074/jbc.274.15.9937; Sobott F, 2002, J BIOL CHEM, V277, P38921, DOI 10.1074/jbc.M206060200; Stromer T, 2003, J BIOL CHEM, V278, P18015, DOI 10.1074/jbc.M301640200; Studer S, 2000, J BIOL CHEM, V275, P37212, DOI 10.1074/jbc.M004701200; Sun TX, 1998, FEBS LETT, V430, P401, DOI 10.1016/S0014-5793(98)00707-8; Torok Z, 2001, P NATL ACAD SCI USA, V98, P3098, DOI 10.1073/pnas.051619498; Van Montfort R, 2002, ADV PROTEIN CHEM, V59, P105; van Montfort RLM, 2001, NAT STRUCT BIOL, V8, P1025, DOI 10.1038/nsb722; Veinger L, 1998, J BIOL CHEM, V273, P11032, DOI 10.1074/jbc.273.18.11032; Wang KY, 2000, EUR J BIOCHEM, V267, P4705, DOI 10.1046/j.1432-1327.2000.01521.x; Yang HM, 1999, PROTEIN SCI, V8, P174	40	87	100	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 9	2004	279	2					1080	1089		10.1074/jbc.M311104200	http://dx.doi.org/10.1074/jbc.M311104200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	759DJ	14573605	hybrid, Green Published			2022-12-27	WOS:000187722800031
J	Horowitz, JC; Lee, DY; Waghray, M; Keshamouni, VG; Thomas, PE; Zhang, HM; Cui, ZB; Thannickal, VJ				Horowitz, JC; Lee, DY; Waghray, M; Keshamouni, VG; Thomas, PE; Zhang, HM; Cui, ZB; Thannickal, VJ			Activation of the pro-survival phosphatidylinositol 3-kinase/AKT pathway by transforming growth factor-beta 1 in mesenchymal cells is mediated by p38 MAPK-dependent induction of an autocrine growth factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN LUNG FIBROBLASTS; FOCAL ADHESION KINASE; FACTOR TYPE-BETA; PROTEIN-KINASE; TRANSFORMING GROWTH-FACTOR-BETA-1; GRANULATION-TISSUE; EXTRACELLULAR-MATRIX; SYSTEMIC-SCLEROSIS; APOPTOSIS; EXPRESSION	Transforming growth factor-beta1 (TGF-beta1) is a multifunctional cytokine involved in differentiation, growth, and survival of mesenchymal cells while inhibiting growth/ survival of most other cell types. The mechanism(s) of pro-survival signaling by TGF-beta1 in mesenchymal cells is unclear. In this report, we demonstrate that TGF-beta1 protects against serum deprivation-induced apoptosis of mesenchymal cells isolated from patients with acute lung injury and of normal human fetal lung fibroblasts (IMR-90). TGF-beta receptor(s)-activated signaling in these cells involves rapid activation of the Smad and p38 MAPK pathways within minutes of TGF-beta1 treatment followed by a more delayed activation of the pro-survival phosphatidylinositol 3-kinase-protein kinase B (PKB)/Akt pathway. Pharmacological inhibition of p38 MAPK with SB203580 or expression of a p38 kinase-deficient mutant protein inhibits TGF-beta1-induced PKB/Akt phosphorylation. Conditioned medium from TGF-beta1-treated cells rapidly induces PKB/Akt activation in an SB203580- and suramin-sensitive manner, suggesting p38 MAPK-dependent production of a secreted growth factor that activates this pro-survival pathway by an autocrine/paracrine mechanism. Inhibition of the phosphatidylinositol 3-kinase-PKB/ Akt pathway blocks TGF-beta1-induced resistance to apoptosis. These results demonstrate the activation of a novel TGF-beta1-activated pro-survival/anti-apoptotic signaling pathway in mesenchymal cells/fibroblasts that may explain cell-specific actions of TGF-beta1 and provide mechanistic insights into its pro-fibrotic and tumor-promoting effects.	Univ Michigan, Div Pulm & Crit Care Med, Med Ctr, Dept Med, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Thannickal, VJ (corresponding author), Univ Michigan, Div Pulm & Crit Care Med, Med Ctr, Dept Med, 6301 MSRB III,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.		Horowitz, Jeffrey/AAY-7238-2021	Horowitz, Jeffrey/0000-0002-1505-2837; Keshamouni, Venkateshwar/0000-0003-1947-791X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL074024, R01HL067967] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL-67967, P50 HL-74021, R01 HL067967, P50 HL074024] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bakin AV, 2000, J BIOL CHEM, V275, P36803, DOI 10.1074/jbc.M005912200; Bakin AV, 2002, J CELL SCI, V115, P3193; Bhowmick NA, 2001, J BIOL CHEM, V276, P46707, DOI 10.1074/jbc.M106176200; Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807; BORDER WA, 1992, J CLIN INVEST, V90, P1, DOI 10.1172/JCI115821; BORDER WA, 1994, NEW ENGL J MED, V331, P1286; Brazil DP, 2002, CELL, V111, P293, DOI 10.1016/S0092-8674(02)01083-8; Brown TL, 1999, J BIOL CHEM, V274, P23256, DOI 10.1074/jbc.274.33.23256; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; Chen RH, 1998, ONCOGENE, V17, P1959, DOI 10.1038/sj.onc.1202111; Dai CS, 2003, J BIOL CHEM, V278, P12537, DOI 10.1074/jbc.M300777200; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; DESMOULIERE A, 1993, J CELL BIOL, V122, P103, DOI 10.1083/jcb.122.1.103; DESMOULIERE A, 1995, AM J PATHOL, V146, P56; Edlund S, 2003, MOL BIOL CELL, V14, P529, DOI 10.1091/mbc.02-03-0037; Esposito F, 2003, J BIOL CHEM, V278, P20828, DOI 10.1074/jbc.M211841200; Finlay GA, 2000, J BIOL CHEM, V275, P27650; Frankfurt OS, 2001, J IMMUNOL METHODS, V253, P133, DOI 10.1016/S0022-1759(01)00387-8; Ge BX, 2003, J BIOL CHEM, V278, P2286, DOI 10.1074/jbc.M210918200; Gooch JL, 2001, J BIOL CHEM, V276, P42492, DOI 10.1074/jbc.M102994200; Grande JP, 1997, P SOC EXP BIOL MED, V214, P27; Grinnell F, 1999, EXP CELL RES, V248, P608, DOI 10.1006/excr.1999.4440; Hanafusa H, 1999, J BIOL CHEM, V274, P27161, DOI 10.1074/jbc.274.38.27161; IGNOTZ RA, 1986, J BIOL CHEM, V261, P4337; JANIN A, 1990, CLIN EXP RHEUMATOL, V8, P237; Jelaska A, 2000, ARTHRITIS RHEUM-US, V43, P2230, DOI 10.1002/1529-0131(200010)43:10<2230::AID-ANR10>3.0.CO;2-8; Kim G, 2002, ARTHRITIS RHEUM-US, V46, P1504, DOI 10.1002/art.10314; LEOF EB, 1986, P NATL ACAD SCI USA, V83, P2453, DOI 10.1073/pnas.83.8.2453; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Nicolas FJ, 2003, J BIOL CHEM, V278, P3251, DOI 10.1074/jbc.M209019200; Nomura M, 2001, J BIOL CHEM, V276, P46624, DOI 10.1074/jbc.M107897200; POSTLETHWAITE AE, 1987, J EXP MED, V165, P251, DOI 10.1084/jem.165.1.251; ROBERTS AB, 1986, P NATL ACAD SCI USA, V83, P4167, DOI 10.1073/pnas.83.12.4167; Robertson G, 2001, UASGCP REP, V2001, P43; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; Shibuya H, 1996, SCIENCE, V272, P1179, DOI 10.1126/science.272.5265.1179; Song K, 2003, J BIOL CHEM, V278, P38342, DOI 10.1074/jbc.M304583200; Tamura M, 1999, J BIOL CHEM, V274, P20693, DOI 10.1074/jbc.274.29.20693; Thannickal VJ, 1998, J BIOL CHEM, V273, P23611, DOI 10.1074/jbc.273.36.23611; Thannickal VJ, 1995, J BIOL CHEM, V270, P30334, DOI 10.1074/jbc.270.51.30334; Thannickal VJ, 1998, BIOCHEM BIOPH RES CO, V251, P437, DOI 10.1006/bbrc.1998.9443; Thannickal VJ, 2003, J BIOL CHEM, V278, P12384, DOI 10.1074/jbc.M208544200; Tomasek JJ, 2002, NAT REV MOL CELL BIO, V3, P349, DOI 10.1038/nrm809; Valdes F, 2002, MOL CANCER RES, V1, P68; WAHL SM, 1987, P NATL ACAD SCI USA, V84, P5788, DOI 10.1073/pnas.84.16.5788; Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806; White ES, 2003, J PATHOL, V201, P343, DOI 10.1002/path.1446; Yamaguchi K, 1999, EMBO J, V18, P179, DOI 10.1093/emboj/18.1.179; Yu L, 2002, EMBO J, V21, P3749, DOI 10.1093/emboj/cdf366; Zhang HY, 1999, AM J RESP CELL MOL, V21, P658, DOI 10.1165/ajrcmb.21.6.3720	52	198	215	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 9	2004	279	2					1359	1367		10.1074/jbc.M306248200	http://dx.doi.org/10.1074/jbc.M306248200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	759DJ	14576166	Green Accepted, hybrid			2022-12-27	WOS:000187722800064
J	Iverson, SL; Enoksson, M; Gogvadze, V; Ott, M; Orrenius, S				Iverson, SL; Enoksson, M; Gogvadze, V; Ott, M; Orrenius, S			Cardiolipin is not required for Bax-mediated cytochrome c release from yeast mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID-PEROXIDATION; PERMEABILITY TRANSITION; RESPIRATORY-CHAIN; INDUCED APOPTOSIS; RAT-HEART; MEMBRANE; PROTEIN; PHOSPHOLIPIDS; EXPRESSION; OXIDASE	Cardiolipin (CL) is an inner mitochondrial membrane phospholipid that contributes to optimal mitochondrial function and is gaining widespread attention in studies of mitochondria-mediated apoptosis. Divergent hypotheses describing the role of CL in cytochrome c release and apoptosis have evolved. We addressed this controversy directly by comparing the spontaneous- and Bax-mediated cytochrome c release from mitochondria isolated from two strains of Saccharomyces cerevisiae: one lacking CL-synthase and therefore CL (DeltaCRD1) and the other, its corresponding wild type (WT). We demonstrated by liquid chromatography-mass spectrometry that the main yeast CL species [( 16: 1) 2( 18: 1) 2] differs in fatty acid composition from mammalian CL [( 18: 2) 4], and we verified the absence of the yeast CL species in the DeltaCRD1 strain. We also demonstrated that the mitochondrial association of Bax and the resulting cytochrome c release is not dependent on the CL content of the yeast mitochondrial membranes. Bax inserted equally into both WT and DeltaCRD1 mitochondrial membranes under conditions that lead to the release of cytochrome c from both strains of yeast mitochondria. Furthermore, using models of synthetic liposomes and isolated yeast mitochondria, we found that cytochrome c was bound more "loosely" to the CL-deficient systems compared with when CL is present. These data challenge recent studies implicating that CL is required for Bax-mediated pore formation leading to the release of proteins from the mitochondrial intermembrane space. In contrast, they support our recently proposed two-step mechanism of cytochrome c release, which suggests that CL is required for binding cytochrome c to the inner mitochondrial membrane.	Karolinska Inst, Div Toxicol, Inst Environm Med, SE-17177 Stockholm, Sweden	Karolinska Institutet	Orrenius, S (corresponding author), Karolinska Inst, Div Toxicol, Inst Environm Med, Box 210, SE-17177 Stockholm, Sweden.	sten.orrenius@imm.ki.se	Gogvadze, Vladimir/A-4392-2014	Ott, Martin/0000-0001-6367-3091				Asumendi A, 2002, BRIT J CANCER, V86, P1951, DOI 10.1038/sj.bjc.6600356; Atlante A, 2000, J BIOL CHEM, V275, P37159, DOI 10.1074/jbc.M002361200; Buser CA, 1998, METH MOL B, V84, P267; DAUM G, 1982, J BIOL CHEM, V257, P3028; Epand RF, 2002, BIOCHEM J, V367, P849, DOI 10.1042/BJ20020986; Epand RF, 2002, BIOCHEM BIOPH RES CO, V298, P744, DOI 10.1016/S0006-291X(02)02544-5; Fleury C, 2002, BIOSCIENCE REP, V22, P59, DOI 10.1023/A:1016013123094; Giaever G, 2002, NATURE, V418, P387, DOI 10.1038/nature00935; Gogvadze V, 2001, J BIOL CHEM, V276, P19066, DOI 10.1074/jbc.M100614200; Jiang F, 1999, MOL MICROBIOL, V31, P373, DOI 10.1046/j.1365-2958.1999.01181.x; Jiang F, 2000, J BIOL CHEM, V275, P22387, DOI 10.1074/jbc.M909868199; Kirkland RA, 2002, NEUROSCIENCE, V115, P587, DOI 10.1016/S0306-4522(02)00512-2; Koshkin V, 2002, BIOCHEM J, V364, P317, DOI 10.1042/bj3640317; Koshkin V, 2000, BIOCHEM J, V347, P687, DOI 10.1042/0264-6021:3470687; Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X; Manon S, 1997, FEBS LETT, V415, P29, DOI 10.1016/S0014-5793(97)01087-9; Montessuit S, 1999, PROTEIN EXPRES PURIF, V15, P202, DOI 10.1006/prep.1998.1010; Mutter T, 2000, BIOCHEM J, V346, P403, DOI 10.1042/0264-6021:3460403; Nomura K, 2000, BIOCHEM J, V351, P183, DOI 10.1042/0264-6021:3510183; Ostrander DB, 2001, J BIOL CHEM, V276, P38061; Ott M, 2002, P NATL ACAD SCI USA, V99, P1259, DOI 10.1073/pnas.241655498; Paradies G, 1997, FEBS LETT, V406, P136, DOI 10.1016/S0014-5793(97)00264-0; Petrosillo G, 2001, FEBS LETT, V509, P435, DOI 10.1016/S0014-5793(01)03206-9; Piccotti L, 2002, J BIOL CHEM, V277, P12075, DOI 10.1074/jbc.M200029200; Priault M, 1999, EUR J BIOCHEM, V260, P684, DOI 10.1046/j.1432-1327.1999.00198.x; Roucou X, 2002, BIOCHEM J, V368, P915, DOI 10.1042/BJ20020972; Santos AC, 1998, FREE RADICAL BIO MED, V24, P1455, DOI 10.1016/S0891-5849(98)00003-3; Schagger H, 2002, BBA-BIOENERGETICS, V1555, P154, DOI 10.1016/S0005-2728(02)00271-2; Schlame M, 2000, PROG LIPID RES, V39, P257, DOI 10.1016/S0163-7827(00)00005-9; Shidoji Y, 1999, BIOCHEM BIOPH RES CO, V264, P343, DOI 10.1006/bbrc.1999.1410; Spickett CM, 2001, BIOCHEM J, V355, P449, DOI 10.1042/0264-6021:3550449; Tafani M, 2002, J BIOL CHEM, V277, P10073, DOI 10.1074/jbc.M111350200; Tuominen EKJ, 2002, J BIOL CHEM, V277, P8822, DOI 10.1074/jbc.M200056200; Ushmorov A, 1999, BLOOD, V93, P2342, DOI 10.1182/blood.V93.7.2342.407k09_2342_2352; vanKlompenburg W, 1997, EMBO J, V16, P4261, DOI 10.1093/emboj/16.14.4261; YAFFE MP, 1991, METHOD ENZYMOL, V194, P627; Zhang M, 2002, J BIOL CHEM, V277, P43553, DOI 10.1074/jbc.C200551200	37	72	74	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 9	2004	279	2					1100	1107		10.1074/jbc.M305020200	http://dx.doi.org/10.1074/jbc.M305020200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	759DJ	14551208	hybrid			2022-12-27	WOS:000187722800033
J	Krzywda, S; Brzozowski, AM; Higashitsuji, H; Fujita, J; Welchman, R; Dawson, S; Mayer, RJ; Wilkinson, AJ				Krzywda, S; Brzozowski, AM; Higashitsuji, H; Fujita, J; Welchman, R; Dawson, S; Mayer, RJ; Wilkinson, AJ			The crystal structure of gankyrin, an oncoprotein found in complexes with cyclin-dependent kinase 4, a 19 S proteasomal ATPase regulator, and the tumor suppressors Rb and p53	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANKYRIN-REPEAT PROTEIN; HEPATOCELLULAR-CARCINOMA; PROTEASOME; INTERACTS; CRYSTALLIZATION; P16(INK4A); REFINEMENT; UBIQUITIN; INSIGHTS; KINASE	Gankyrin is a 25-kDa hepatocellular carcinoma-associated protein that mediates protein-protein interactions in cell cycle control and protein degradation. It has been reported to form complexes with cyclin-dependent kinase 4, retinoblastoma protein, the S6b ATPase subunit of the 19 S regulator of the 26 S proteasome, and Mdm2, an E3 ubiquitin ligase involved in p53 degradation. It is the first protein described to bind both to the 26 S proteasome and to proteins in other complexes containing cyclin-dependent kinase(s) and p53 ubiquitylating activities, thus providing a mechanism for delivering cell cycle regulating machinery and ubiquitylated substrates to the proteasome for degradation. Gankyrin contains a 33-residue motif known as the ankyrin repeat that occurs five and a half to six times in the sequence. As a step toward understanding gankyrin interactions with its protein partners we have determined its three-dimensional crystal structure to 2.0-Angstrom resolution. It reveals that the entire 226-residue gankyrin polypeptide folds into seven ankyrin repeat elements. The ankyrin repeats, consisting of an antiparallel beta-hairpin followed by a perpendicularly oriented helix-loop-helix, pack side-by-side, creating an extended curved structure with a groove running across the long concave surface. Comparison with the structures of other ankyrin repeat proteins suggests that interactions with partner proteins are mediated by residues situated on this concave surface.	Univ York, Struct Biol Lab, York YO10 5YW, N Yorkshire, England; Univ Nottingham, Lab Intracellular Proteolysis, Sch Biomed Sci, Nottingham NG7 2UH, England; Queens Med Ctr, Sch Med, Nottingham NG7 2UH, England; Kyoto Univ, Fac Med, Dept Clin Mol Biol, Sakyo Ku, Kyoto 6068507, Japan	University of York - UK; University of Nottingham; University of Nottingham; Kyoto University	Brzozowski, AM (corresponding author), Univ York, Struct Biol Lab, York YO10 5YW, N Yorkshire, England.			Krzywda, Szymon/0000-0002-1216-3187; Wilkinson, Anthony/0000-0003-4577-9479				Adachi N, 2002, ACTA CRYSTALLOGR D, V58, P859, DOI 10.1107/S0907444902004808; Batchelor AH, 1998, SCIENCE, V279, P1037, DOI 10.1126/science.279.5353.1037; Dawson S, 2002, J BIOL CHEM, V277, P10893, DOI 10.1074/jbc.M107313200; Fu XY, 2002, WORLD J GASTROENTERO, V8, P638, DOI 10.3748/wjg.v8.i4.638; Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001; Higashitsuji H, 2000, NAT MED, V6, P96, DOI 10.1038/71600; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; Huxford T, 1998, CELL, V95, P759, DOI 10.1016/S0092-8674(00)81699-2; Kohl A, 2003, P NATL ACAD SCI USA, V100, P1700, DOI 10.1073/pnas.0337680100; Krzywda S, 2003, ACTA CRYSTALLOGR D, V59, P1294, DOI 10.1107/S0907444903009892; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lee JO, 1998, NATURE, V391, P859, DOI 10.1038/36038; Li JN, 2002, BIOCHEMISTRY-US, V41, P3977, DOI 10.1021/bi011550s; Muratani M, 2003, NAT REV MOL CELL BIO, V4, P192, DOI 10.1038/nrm1049; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nagao T, 2003, J BIOL CHEM, V278, P10668, DOI 10.1074/jbc.M206104200; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Ogura T, 2001, GENES CELLS, V6, P575, DOI 10.1046/j.1365-2443.2001.00447.x; Park TJ, 2001, MOL CARCINOGEN, V30, P138, DOI 10.1002/mc.1022; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Russo AA, 1998, NATURE, V395, P237, DOI 10.1038/26155; Sedgwick SG, 1999, TRENDS BIOCHEM SCI, V24, P311, DOI 10.1016/S0968-0004(99)01426-7; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009	24	70	78	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 9	2004	279	2					1541	1545		10.1074/jbc.M310265200	http://dx.doi.org/10.1074/jbc.M310265200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	759DJ	14573599	hybrid			2022-12-27	WOS:000187722800086
J	Fang, LW; Tai, TS; Yu, WN; Liao, F; Lai, MZ				Fang, LW; Tai, TS; Yu, WN; Liao, F; Lai, MZ			Phosphatidylinositide 3-kinase priming couples c-FLIP to T cell activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMINANT INTERFERING MUTANT; PROTEIN-KINASE; MEDIATED APOPTOSIS; INHIBITORY PROTEIN; SIGNALING MECHANISMS; DEATH; PROLIFERATION; CASPASE-8; RECEPTOR; FADD	Cellular FLICE (FADD-like interleukin-1-beta-converting enzyme)-inhibitory protein (c-FLIP) inhibits death receptor-induced apoptosis by binding to FADD ( Fas-associated death domain protein) and pro-caspase-8. cFLIP has also been shown to transmit activation signals and to enhance interleukin (IL)-2 production. However, c-FLIP-mediated T cell activation is difficult to detect in most cells. We found that in DO11.10 T cells, c-FLIP expression led to inhibition of IL-2 production, in contrast to the readily detectable c-FLIP-induced activation in Jurkat cells. A direct comparison revealed that distinct signal pathways were regulated by c-FLIP in Jurkat cells and DO11.10 cells. We investigated whether constitutively activated phosphatidylinositide 3-kinase (PI3K) in Jurkat cells stimulated c-FLIP. Inhibition of PI3K in Jurkat cells abrogated a c-FLIP-mediated increase in IL-2 production. In addition, c-FLIP coordinated with active PI3K for ERK activation. Furthermore, introduction of PTEN back into Jurkat cells eliminated the stimulatory effect of c-FLIP on IL-2 production and ERK activation. Our results suggest that priming with PI3K promotes the coupling of c-FLIP to T cell activation.	Acad Sinica, Inst Mol Biol, Taipei 11529, Taiwan; Natl Def Med Ctr, Grad Inst Life Sci, Taipei 11472, Taiwan; Natl Taiwan Univ, Grad Inst Immunol, Taipei 10002, Taiwan; Acad Sinica, Inst Biomed Sci, Taipei 11529, Taiwan	Academia Sinica - Taiwan; National Defense Medical Center; National Taiwan University; Academia Sinica - Taiwan	Lai, MZ (corresponding author), Acad Sinica, Inst Mol Biol, Taipei 11529, Taiwan.		Lai, Ming-Zong/AAA-4408-2021; Liao, Fang/S-7021-2018	Lai, Ming-Zong/0000-0002-3237-4803				Alam A, 1999, J EXP MED, V190, P1879, DOI 10.1084/jem.190.12.1879; AlberolaIla J, 1997, ANNU REV IMMUNOL, V15, P125, DOI 10.1146/annurev.immunol.15.1.125; Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Astoul E, 2001, TRENDS IMMUNOL, V22, P490, DOI 10.1016/S1471-4906(01)01973-1; Boissonnas A, 2002, EUR J IMMUNOL, V32, P3007, DOI 10.1002/1521-4141(2002010)32:10<3007::AID-IMMU3007>3.0.CO;2-9; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; Budd RC, 2002, J CLIN INVEST, V109, P437, DOI 10.1172/JC1200215077; Chang DW, 2002, EMBO J, V21, P3704, DOI 10.1093/emboj/cdf356; Chun HJ, 2002, NATURE, V419, P395, DOI 10.1038/nature01063; Costa GL, 2000, J IMMUNOL, V164, P3581, DOI 10.4049/jimmunol.164.7.3581; CROOKS MEC, 1995, MOL CELL BIOL, V15, P6820; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; Djerbi M, 1999, J EXP MED, V190, P1025, DOI 10.1084/jem.190.7.1025; Goltsev YV, 1997, J BIOL CHEM, V272, P19641, DOI 10.1074/jbc.272.32.19641; Hsu SC, 1999, J BIOL CHEM, V274, P25769, DOI 10.1074/jbc.274.36.25769; Hu SM, 1997, J BIOL CHEM, V272, P17255, DOI 10.1074/jbc.272.28.17255; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; JAIN J, 1995, CURR OPIN IMMUNOL, V7, P333, DOI 10.1016/0952-7915(95)80107-3; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; Kataoka T, 2000, CURR BIOL, V10, P640, DOI 10.1016/S0960-9822(00)00512-1; Kennedy NJ, 1999, J EXP MED, V190, P1891, DOI 10.1084/jem.190.12.1891; Krueger A, 2001, MOL CELL BIOL, V21, P8247, DOI 10.1128/MCB.21.24.8247-8254.2001; Lens SMA, 2002, MOL CELL BIOL, V22, P5419, DOI 10.1128/MCB.22.15.5419-5433.2002; Lewis RS, 2001, ANNU REV IMMUNOL, V19, P497, DOI 10.1146/annurev.immunol.19.1.497; Mack A, 2002, EUR J IMMUNOL, V32, P1986, DOI 10.1002/1521-4141(200207)32:7<1986::AID-IMMU1986>3.0.CO;2-#; Matsuda S, 1998, J BIOL CHEM, V273, P12378, DOI 10.1074/jbc.273.20.12378; Medema JP, 1999, J EXP MED, V190, P1033, DOI 10.1084/jem.190.7.1033; Micheau O, 2002, J BIOL CHEM, V277, P45162, DOI 10.1074/jbc.M206882200; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Newton K, 2003, GENE DEV, V17, P819, DOI 10.1101/gad.1077403; Newton K, 1998, EMBO J, V17, P706, DOI 10.1093/emboj/17.3.706; Newton K, 2001, CURR BIOL, V11, P273, DOI 10.1016/S0960-9822(01)00067-7; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; Salmena L, 2003, GENE DEV, V17, P883, DOI 10.1101/gad.1063703; Scaffidi C, 1999, J BIOL CHEM, V274, P1541, DOI 10.1074/jbc.274.3.1541; Shu HB, 1997, IMMUNITY, V6, P751, DOI 10.1016/S1074-7613(00)80450-1; Srinivasula SM, 1997, J BIOL CHEM, V272, P18542, DOI 10.1074/jbc.272.30.18542; Thome M, 2001, NAT REV IMMUNOL, V1, P50, DOI 10.1038/35095508; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; TRUITT KE, 1995, J IMMUNOL, V155, P4702; Wajant H, 2002, SCIENCE, V296, P1635, DOI 10.1126/science.1071553; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; Walsh CM, 1998, IMMUNITY, V8, P439, DOI 10.1016/S1074-7613(00)80549-X; Ward SG, 1996, IMMUNOL TODAY, V17, P187, DOI 10.1016/0167-5699(96)80618-9; Yeh JH, 1998, J EXP MED, V188, P1795, DOI 10.1084/jem.188.10.1795; Yu CT, 2001, J IMMUNOL, V166, P284, DOI 10.4049/jimmunol.166.1.284; Zhang J, 1999, J IMMUNOL, V162, P3819; Zhang JK, 1998, NATURE, V392, P296, DOI 10.1038/32681; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	50	28	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	2004	279	1					13	18		10.1074/jbc.M303860200	http://dx.doi.org/10.1074/jbc.M303860200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	757GU	14578361	hybrid			2022-12-27	WOS:000187555300002
J	Skaar, EP; Gaspar, AH; Schneewind, O				Skaar, EP; Gaspar, AH; Schneewind, O			IsdG and IsdI, heme-degrading enzymes in the cytoplasm of Staphylococcus aureus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXYGENASE HMU O; GRAM-NEGATIVE BACTERIA; CORYNEBACTERIUM-DIPHTHERIAE; COUPLED OXIDATION; PORPHYROMONAS-GINGIVALIS; SURFACE PROTEIN; OUTER-MEMBRANE; IRON; HEMOGLOBIN; IDENTIFICATION	Staphylococcus aureus requires iron for growth and utilizes heme as a source of iron during infection. Staphylococcal surface proteins capture hemoglobin, release heme from hemoglobin and transport this compound across the cell wall envelope and plasma membrane into the bacterial cytoplasm. Here we show that Staphylococcus aureus isdG and isdI encode cytoplasmic proteins with heme binding properties. IsdG and IsdI cleave the tetrapyrrol ring structure of heme in the presence of NADPH cytochrome P450 reductase, thereby releasing iron. Further, IsdI complements the heme utilization deficiency of a Corynebacterium ulcerans heme oxygenase mutant, demonstrating in vivo activity of this enzyme. Although Staphylococcus epidermidis, Listeria monocytogenes, and Bacillus anthracis encode homologues of IsdG and IsdI, these proteins are not found in other bacteria or mammals. Thus, it appears that bacterial pathogens evolved different strategies to retrieve iron from scavenged heme molecules and that staphylococcal IsdG and IsdI represent examples of bacterial heme-oxygenases.	Univ Chicago, Comm Microbiol, Chicago, IL 60637 USA	University of Chicago	Schneewind, O (corresponding author), Univ Chicago, Comm Microbiol, 920 E 58th St, Chicago, IL 60637 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038897, R01AI052474] Funding Source: NIH RePORTER; NIAID NIH HHS [AI52474, AI38897] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ankri S, 1996, PLASMID, V35, P62, DOI 10.1006/plas.1996.0007; Avila L, 2003, J AM CHEM SOC, V125, P4103, DOI 10.1021/ja029311v; Bateman A, 2002, NUCLEIC ACIDS RES, V30, P276, DOI 10.1093/nar/30.1.276; BRAUN V, 1991, BIOL MET, V4, P14, DOI 10.1007/BF01135552; Bridges K, 1995, BLOOD PRINCIPLES PRA; BULLEN JJ, 1981, REV INFECT DIS, V3, P1127; BULLEN JJ, 1999, IRON INFECT MOL PHYS, P87; Chipperfield JR, 2000, BIOMETALS, V13, P165, DOI 10.1023/A:1009227206890; Chu GC, 1999, J BIOL CHEM, V274, P21319, DOI 10.1074/jbc.274.30.21319; Chu GC, 1999, J BIOL CHEM, V274, P24490, DOI 10.1074/jbc.274.35.24490; Chu GC, 2000, J BIOL CHEM, V275, P17494, DOI 10.1074/jbc.M000830200; Cope LD, 1998, INFECT IMMUN, V66, P4511; Crusats J, 1998, J ORG CHEM, V63, P602, DOI 10.1021/jo9714728; DeCarlo AA, 1999, J BACTERIOL, V181, P3784, DOI 10.1128/JB.181.12.3784-3791.1999; Drazek ES, 2000, MOL MICROBIOL, V36, P68, DOI 10.1046/j.1365-2958.2000.01818.x; Dryla A, 2003, MOL MICROBIOL, V49, P37, DOI 10.1046/j.1365-2958.2003.03542.x; Escolar L, 1999, J BACTERIOL, V181, P6223, DOI 10.1128/JB.181.20.6223-6229.1999; FALK JE, 1963, CHEM BIOCH PORPHYRIN, P9; Genco CA, 2001, MOL MICROBIOL, V39, P1, DOI 10.1046/j.1365-2958.2001.02231.x; ITOMAKI M, 1995, ARCH BIOCHEM BIOPHYS, V317, P253, DOI 10.1006/abbi.1995.1160; Kalish H, 2003, J AM CHEM SOC, V125, P4674, DOI 10.1021/ja021253q; Lei BF, 2002, INFECT IMMUN, V70, P4494, DOI 10.1128/IAI.70.8.4494-4500.2002; Letoffe S, 1999, MOL MICROBIOL, V33, P546, DOI 10.1046/j.1365-2958.1999.01499.x; Lewis JP, 1999, J BACTERIOL, V181, P4905, DOI 10.1128/JB.181.16.4905-4913.1999; Lewis LA, 1998, J BACTERIOL, V180, P6043, DOI 10.1128/JB.180.22.6043-6047.1998; Maines MD, 1997, ANNU REV PHARMACOL, V37, P517, DOI 10.1146/annurev.pharmtox.37.1.517; MAINES MD, 1986, J BIOL CHEM, V261, P411; Mazmanian SK, 2002, P NATL ACAD SCI USA, V99, P2293, DOI 10.1073/pnas.032523999; Mazmanian SK, 2003, SCIENCE, V299, P906, DOI 10.1126/science.1081147; OCARRA P, 1975, PORPHYRINS METALLOPO, P130; Olczak T, 2001, J BACTERIOL, V183, P5599, DOI 10.1128/JB.183.19.5599-5608.2001; Orenstein A, 1997, FEMS IMMUNOL MED MIC, V19, P307, DOI 10.1016/S0928-8244(97)00097-7; Panchenko MV, 2000, AM J PHYSIOL-CELL PH, V278, pC92, DOI 10.1152/ajpcell.2000.278.1.C92; Poss KD, 1997, P NATL ACAD SCI USA, V94, P10925, DOI 10.1073/pnas.94.20.10925; Ratliff M, 2001, J BACTERIOL, V183, P6394, DOI 10.1128/JB.183.21.6394-6403.2001; Rice JK, 1999, BIOCHEMISTRY-US, V38, P16847, DOI 10.1021/bi990880y; Sakamoto H, 2000, J INORG BIOCHEM, V82, P113, DOI 10.1016/S0162-0134(00)00149-5; Sambrook J., 2002, MOL CLONING LAB MANU; Schmitt MP, 1997, J BACTERIOL, V179, P838, DOI 10.1128/jb.179.3.838-845.1997; Sciara G, 2003, EMBO J, V22, P205, DOI 10.1093/emboj/cdg031; Sigman JA, 2001, J AM CHEM SOC, V123, P6945, DOI 10.1021/ja015776u; Stojiljkovic I, 1996, J BACTERIOL, V178, P4670, DOI 10.1128/jb.178.15.4670-4678.1996; Stojiljkovic I, 2001, EXPERT OPIN INV DRUG, V10, P309, DOI 10.1517/13543784.10.2.309; Tenhunen R, 1969, Trans Assoc Am Physicians, V82, P363; VAUGHAN L, 1990, RES MICROBIOL, V141, P941, DOI 10.1016/0923-2508(90)90133-B; Wandersman C, 2000, CURR OPIN MICROBIOL, V3, P215, DOI 10.1016/S1369-5274(00)00078-3; Wilks A, 2000, J BIOL CHEM, V275, P11686, DOI 10.1074/jbc.275.16.11686; Wilks A, 1996, BIOCHEMISTRY-US, V35, P930, DOI 10.1021/bi952405f; WILKS A, 1995, BIOCHEMISTRY-US, V34, P4421, DOI 10.1021/bi00013a034; Wilks A, 1998, J BIOL CHEM, V273, P837, DOI 10.1074/jbc.273.2.837; WILKS A, 1994, J BIOL CHEM, V269, P29553; Wu JM, 2002, BRAIN RES, V953, P45, DOI 10.1016/S0006-8993(02)03268-7; Yet SF, 2001, CIRC RES, V89, P168, DOI 10.1161/hh1401.093314; YOSHIDA T, 1978, J BIOL CHEM, V253, P8479; Zhu WM, 2000, J BACTERIOL, V182, P6783, DOI 10.1128/JB.182.23.6783-6790.2000	55	215	230	2	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	2004	279	1					436	443		10.1074/jbc.M307952200	http://dx.doi.org/10.1074/jbc.M307952200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	757GU	14570922	hybrid			2022-12-27	WOS:000187555300053
J	Wang, LM; Zhang, Q; Zhang, Q; Zhu, W; He, C; Lu, CL; Ding, DF; Chen, ZY				Wang, LM; Zhang, Q; Zhang, Q; Zhu, W; He, C; Lu, CL; Ding, DF; Chen, ZY			Identification of the key amino acids of glial cell line-derived neurotrophic factor family receptor alpha 1 involved in its biological function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE; RET RECEPTOR; GDNF; BINDING; PROTEIN; NEURTURIN; SURVIVAL; GFR-ALPHA-1; SPECIFICITY; ACTIVATION	Glial cell line-derived neurotrophic factor (GDNF) plays a critical role in neurodevelopment and survival of midbrain dopaminergic and spinal motor neurons in vitro and in vivo. The biological actions of GDNF are mediated by a two-receptor complex consisting of a glycosylphosphatidylinositol-linked cell surface molecule, the GDNF family receptor alpha1 (GFRalpha1), and receptor protein tyrosine kinase Ret. Although structural analysis of GDNF has been extensively examined, less is known about the structural basis of GFRalpha1 function. In this study, based on evolutionary trace method and relative solvent accessibility prediction of residues, a set of trace residues that are solvent-accessible was selected for site-directed mutagenesis. A series of GFRalpha1 mutations was made, and PC12 cell lines stably expressing different GFRalpha1 mutants were generated. According to the survival and differentiation responses of these stable PC12 cells upon GDNF stimulation and the GDNF-GFRalpha1-Ret interaction assay, residues (NN153)-N-152, Arg(259), and (SNS318)-S-316 in the GFRalpha1 central region were found to be critical for GFRalpha1 binding to GDNF and eliciting downstream signal transduction. The single mutation R259A in the GFRalpha1 molecule simultaneously lost its binding ability to GDNF and Ret. However N152A/N153A or S316A/N317A/S318A mutation in the GFRalpha1 molecule still retained the ability to bind with Ret. These findings suggest that distinct structural elements in GFRalpha1 may be involved in binding to GDNF and Ret.	Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, Key Lab Proteom, Shanghai 200031, Peoples R China; Second Mil Med Univ, Dept Neurobiol, Shanghai 200433, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Naval Medical University	Ding, DF (corresponding author), Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, Key Lab Proteom, 320 Yue Yang Rd Shanghai, Shanghai 200031, Peoples R China.	dingdafu@server.shcnc.ac.cn; zheyu_chen@hotmail.com	Zhang, Qing/A-3565-2010					Airaksinen MS, 1999, MOL CELL NEUROSCI, V13, P313, DOI 10.1006/mcne.1999.0754; Armon A, 2001, J MOL BIOL, V307, P447, DOI 10.1006/jmbi.2000.4474; Baloh RH, 2000, J BIOL CHEM, V275, P3412, DOI 10.1074/jbc.275.5.3412; Baloh RH, 1998, NEURON, V21, P1291, DOI 10.1016/S0896-6273(00)80649-2; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chen ZY, 2000, BIOCHEM BIOPH RES CO, V268, P692, DOI 10.1006/bbrc.2000.2196; Chen ZY, 2000, BIOCHEM BIOPH RES CO, V273, P902, DOI 10.1006/bbrc.2000.3046; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; DIKIC I, 1994, CURR BIOL, V4, P702, DOI 10.1016/S0960-9822(00)00155-X; Durbec P, 1996, NATURE, V381, P789, DOI 10.1038/381789a0; Eigenbrot C, 1997, NAT STRUCT BIOL, V4, P435, DOI 10.1038/nsb0697-435; Eketjall S, 1999, EMBO J, V18, P5901, DOI 10.1093/emboj/18.21.5901; Grondin R, 1998, J NEUROL, V245, pP35, DOI 10.1007/PL00007744; HENDERSON CE, 1994, SCIENCE, V266, P1062, DOI 10.1126/science.7973664; Horger BA, 1998, J NEUROSCI, V18, P4929; IBANEZ CF, 1992, CELL, V69, P329, DOI 10.1016/0092-8674(92)90413-7; Jeanmougin F, 1998, TRENDS BIOCHEM SCI, V23, P403, DOI 10.1016/S0968-0004(98)01285-7; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; Klein RD, 1997, NATURE, V387, P717, DOI 10.1038/42722; Kotzbauer PT, 1996, NATURE, V384, P467, DOI 10.1038/384467a0; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Landgraf R, 1999, PROTEIN ENG, V12, P943, DOI 10.1093/protein/12.11.943; Lichtarge O, 1996, J MOL BIOL, V257, P342, DOI 10.1006/jmbi.1996.0167; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; Meng XJ, 2000, SCIENCE, V287, P1489, DOI 10.1126/science.287.5457.1489; Milbrandt J, 1998, NEURON, V20, P245, DOI 10.1016/S0896-6273(00)80453-5; Miyamoto M, 2000, CELL TRANSPLANT, V9, P681, DOI 10.1177/096368970000900514; NIELSEN FC, 1988, BIOCHEM BIOPH RES CO, V154, P1018, DOI 10.1016/0006-291X(88)90241-0; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; RYDEN M, 1995, EMBO J, V14, P1979, DOI 10.1002/j.1460-2075.1995.tb07190.x; Sariola H, 1997, CURR OPIN CELL BIOL, V9, P877, DOI 10.1016/S0955-0674(97)80091-9; Scott RP, 2001, J BIOL CHEM, V276, P1450, DOI 10.1074/jbc.M006157200; Sweeney KJ, 2000, MECH DEVELOP, V92, P263, DOI 10.1016/S0925-4773(00)00242-2; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; Trupp M, 1996, NATURE, V381, P785, DOI 10.1038/381785a0; Vallee RB, 2001, TRENDS CELL BIOL, V11, P155, DOI 10.1016/S0962-8924(01)01956-0; Vega QC, 1996, P NATL ACAD SCI USA, V93, P10657, DOI 10.1073/pnas.93.20.10657; Wang LM, 2003, PROTEIN PEPTIDE LETT, V10, P61, DOI 10.2174/0929866033408318; Worby CA, 1996, J BIOL CHEM, V271, P23619, DOI 10.1074/jbc.271.39.23619	39	17	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 2	2004	279	1					109	116		10.1074/jbc.M306287200	http://dx.doi.org/10.1074/jbc.M306287200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	757GU	14563851	hybrid			2022-12-27	WOS:000187555300014
J	Brasse-Lagnel, C; Fairand, A; Lavoinne, A; Husson, A				Brasse-Lagnel, C; Fairand, A; Lavoinne, A; Husson, A			Glutamine stimulates argininosuccinate synthetase gene expression through cytosolic O-glycosylation of Sp1 in Caco-2 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSING RESPONSE PATHWAY; AMINO-ACID DEPRIVATION; MESSENGER-RNA LEVELS; HEXOSAMINE BIOSYNTHESIS; TRANSCRIPTION; BINDING; GLUCOSE; ACTIVATION; INDUCTION; PROMOTER	Glutamine stimulates the expression of the argininosuccinate synthetase (ASS) gene at both the level of enzyme activity and mRNA in Caco-2 cells. Searching to identify the pathway involved, we observed that (i) the stimulating effect of glutamine was totally mimicked by glucosamine addition, and (ii) its effect but not that of glucosamine was totally blocked by 6-diazo-5-oxo-L-norleucine (DON), an inhibitor of amidotransferases, suggesting that the metabolism of glutamine to glucosamine 6-phosphate was required. Moreover, run-on assays revealed that glucosamine was acting at a transcriptional level. Because three functional GC boxes were identified on the ASS gene promoter (Anderson, G.M., and Freytag, S.O. (1991) Mol. Cell Biol. 11, 1935-1943), the potential involvement of Sp1 family members was studied. Electrophoretic mobility shift assays using either the Sp1 consensus sequence or an appropriate fragment of the ASS promoter sequence as a probe demonstrated that both glutamine and glucosamine increased Sp1 DNA binding. Immunoprecipitation-Western blot experiments demonstrated that both compounds increased O-glycosylation of Sp1 leading to its translocation into nucleus. Again, the effect of glutamine on Sp1 was inhibited by the addition of DON but not of glucosamine. Taken together, the results clearly demonstrate that the metabolism of glutamine through the hexosamine pathway leads to the cytosolic O-glycosylation of Sp1, which, in turn, translocates into nucleus and stimulates the ASS gene transcription. Collectively, the results constitute the first demonstration of a functional relationship between a regulating signal (glutamine), a transcription factor (Sp1), and the transcription of the ASS gene.	Univ Rouen, Fac Med Pharm Rouen, Inst Federat Rech Multidisciplinaires Peptides, ADEN EA 3324,Grp Appareil Digest Environm & Nutr, F-76183 Rouen, France	Universite de Rouen Normandie	Husson, A (corresponding author), Univ Rouen, Fac Med Pharm Rouen, Inst Federat Rech Multidisciplinaires Peptides, ADEN EA 3324,Grp Appareil Digest Environm & Nutr, 22 Blvd Gambetta, F-76183 Rouen, France.	annie.husson@univ-rouen.fr		Brasse-Lagnel, carole/0000-0003-4370-2865				Abcouwer SF, 1999, J BIOL CHEM, V274, P28645, DOI 10.1074/jbc.274.40.28645; Abcouwer SF, 2002, INVEST OPHTH VIS SCI, V43, P2791; ANDERSON GM, 1991, MOL CELL BIOL, V11, P1935, DOI 10.1128/MCB.11.4.1935; BELLON G, 1995, BBA-MOL CELL RES, V1268, P311, DOI 10.1016/0167-4889(95)00093-8; Black AR, 1999, J BIOL CHEM, V274, P1207, DOI 10.1074/jbc.274.3.1207; Bourgeois P, 1997, EUR J BIOCHEM, V249, P669, DOI 10.1111/j.1432-1033.1997.t01-1-00669.x; BRADFORD MM, 1972, ANAL BIOCHEM, V71, P248; Bruhat A, 2000, MOL CELL BIOL, V20, P7192, DOI 10.1128/MCB.20.19.7192-7204.2000; Bruhat A, 2002, J BIOL CHEM, V277, P48107, DOI 10.1074/jbc.M206149200; CAI JW, 1991, FEBS LETT, V288, P229, DOI 10.1016/0014-5793(91)81041-6; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Coeffier M, 2002, CYTOKINE, V18, P92, DOI 10.1006/cyto.2002.1027; Comer FI, 1999, BBA-GEN SUBJECTS, V1473, P161, DOI 10.1016/S0304-4165(99)00176-2; Doble MA, 2002, J GASTROINTEST SURG, V6, P387, DOI 10.1016/S1091-255X(01)00049-X; Du XL, 2000, P NATL ACAD SCI USA, V97, P12222, DOI 10.1073/pnas.97.22.12222; Fafournoux P, 2000, BIOCHEM J, V351, P1, DOI 10.1042/0264-6021:3510001; Goldberg HJ, 2000, DIABETES, V49, P863, DOI 10.2337/diabetes.49.5.863; Han I, 1997, MOL CELL BIOL, V17, P2550, DOI 10.1128/MCB.17.5.2550; Husson A, 2003, EUR J BIOCHEM, V270, P1887, DOI 10.1046/j.1432-1033.2003.03559.x; Husson A, 1996, FEBS LETT, V394, P353, DOI 10.1016/0014-5793(96)00985-4; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; KANDIL HM, 1995, AM J PHYSIOL-GASTR L, V269, pG591, DOI 10.1152/ajpgi.1995.269.4.G591; KILBERG MS, 1994, FASEB J, V8, P13, DOI 10.1096/fasebj.8.1.8299885; Lavoinne A, 1996, EUR J BIOCHEM, V242, P537, DOI 10.1111/j.1432-1033.1996.0537r.x; Leung-Pineda V, 2002, J BIOL CHEM, V277, P16585, DOI 10.1074/jbc.M110972200; Li LY, 1995, CELL MOL BIOL RES, V41, P361; Majumdar G, 2003, AM J PHYSIOL-ENDOC M, V285, pE584, DOI 10.1152/ajpendo.00140.2003; MARSHALL S, 1991, J BIOL CHEM, V266, P4706; Marten NW, 1999, BBA-GENE STRUCT EXPR, V1447, P160, DOI 10.1016/S0167-4781(99)00165-7; MCLEAN P, 1965, BIOCHEM J, V94, P422, DOI 10.1042/bj0940422; Meisse D, 1999, CLIN NUTR, V18, P111, DOI 10.1016/S0261-5614(99)80061-2; Quillard M, 1996, EUR J BIOCHEM, V236, P56, DOI 10.1111/j.1432-1033.1996.00056.x; Rhoads JM, 1997, AM J PHYSIOL-GASTR L, V272, pG943, DOI 10.1152/ajpgi.1997.272.5.G943; Roos MD, 1997, MOL CELL BIOL, V17, P6472, DOI 10.1128/MCB.17.11.6472; Rumberger JM, 2003, J BIOL CHEM, V278, P28547, DOI 10.1074/jbc.M302793200; Sayeski PP, 1996, J BIOL CHEM, V271, P15237, DOI 10.1074/jbc.271.25.15237; Siu F, 2001, J BIOL CHEM, V276, P48100, DOI 10.1074/jbc.M109533200; Siu F, 2002, J BIOL CHEM, V277, P24120, DOI 10.1074/jbc.M201959200; SU TS, 1981, J BIOL CHEM, V256, P1826; THEODOROPOULOS PA, 1992, FEBS LETT, V311, P241, DOI 10.1016/0014-5793(92)81111-X; VANNICE JL, 1984, P NATL ACAD SCI-BIOL, V81, P4241, DOI 10.1073/pnas.81.14.4241; Wells L, 2003, FEBS LETT, V546, P154, DOI 10.1016/S0014-5793(03)00641-0; Yang XY, 2001, P NATL ACAD SCI USA, V98, P6611, DOI 10.1073/pnas.111099998; Yassad A, 1997, FEBS LETT, V413, P81, DOI 10.1016/S0014-5793(97)00881-8; Ye XB, 2002, J BIOL CHEM, V277, P31863, DOI 10.1074/jbc.M205544200; Zhang PL, 2002, ENDOCRINOLOGY, V143, P99, DOI 10.1210/en.143.1.99	47	56	58	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52504	52510		10.1074/jbc.M306752200	http://dx.doi.org/10.1074/jbc.M306752200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14570901	hybrid			2022-12-27	WOS:000187480700065
J	Brophy, PD; Lang, KM; Dressler, GR				Brophy, PD; Lang, KM; Dressler, GR			The secreted frizzled related protein 2 (SFRP2) gene is a target of the Pax2 transcription factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METANEPHRIC MESENCHYME; URETERAL BUD; EPITHELIAL TRANSFORMATION; BRANCHING MORPHOGENESIS; DEVELOPING KIDNEY; EXPRESSION; ACTIVATION; CHROMATIN; WNT-4; DIFFERENTIATION	Despite their essential role in vertebrate development, the function of Pax proteins in gene regulation is not well understood. To identify potential genes regulated by the Pax2 protein, we screened embryonic kidney cells transformed with Pax2-expressing retroviruses for genes activated in response to Pax2 expression. In this system, the gene encoding the secreted frizzled related protein, Sfrp2, was strongly activated in all Pax2b-expressing cells. This activation of Sfrp2 expression correlated with changes in chromatin structure at the Sfrp2 locus, particularly in and around regions of Pax2 binding. Although the amount of Pax2-dependent transactivation was low in transient assays, the data suggests that local alterations of chromatin structure by Pax proteins can greatly enhance expression when presented in the right cellular context.	Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Pediat, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Dressler, GR (corresponding author), Univ Michigan, Dept Pathol, 1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.				NIDDK NIH HHS [DK54723, DK54740] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054723, R01DK054740] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bouchard M, 2002, GENE DEV, V16, P2958, DOI 10.1101/gad.240102; Brophy PD, 2001, DEVELOPMENT, V128, P4747; Cai Y, 2003, EMBO J, V22, P5522, DOI 10.1093/emboj/cdg536; Cai Y, 2002, J BIOL CHEM, V277, P1217, DOI 10.1074/jbc.M109663200; Chi N, 2002, TRENDS GENET, V18, P41, DOI 10.1016/S0168-9525(01)02594-X; Cirillo LA, 2002, MOL CELL, V9, P279, DOI 10.1016/S1097-2765(02)00459-8; Daniel L, 2001, HUM PATHOL, V32, P282, DOI 10.1053/hupa.2001.22753; Dehbi M, 1996, ONCOGENE, V13, P447; Dudley AT, 1999, GENE DEV, V13, P1601, DOI 10.1101/gad.13.12.1601; GNARRA JR, 1995, CANCER RES, V55, P4092; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Karavanova ID, 1996, DEVELOPMENT, V122, P4159; Khoubehi B, 2001, J UROLOGY, V165, P2115, DOI 10.1016/S0022-5347(05)66304-5; Kispert A, 1998, DEVELOPMENT, V125, P4225; Ladher RK, 2000, DEV BIOL, V218, P183, DOI 10.1006/dbio.1999.9586; Lechner MS, 1996, J BIOL CHEM, V271, P21088, DOI 10.1074/jbc.271.35.21088; Lee CS, 2000, DEVELOPMENT, V127, P109; Leimeister C, 1998, MECH DEVELOP, V75, P29, DOI 10.1016/S0925-4773(98)00072-0; Lescher B, 1998, DEV DYNAM, V213, P440, DOI 10.1002/(SICI)1097-0177(199812)213:4<440::AID-AJA9>3.0.CO;2-6; LUO G, 1995, GENE DEV, V9, P2808, DOI 10.1101/gad.9.22.2808; Mazal PR, 2002, NEW ENGL J MED, V347, P653, DOI 10.1056/NEJMoa013413; McConnell MJ, 1997, ONCOGENE, V14, P2689, DOI 10.1038/sj.onc.1201114; Miyazaki Y, 2000, J CLIN INVEST, V105, P863, DOI 10.1172/JCI8256; Ostrom L, 2000, DEV BIOL, V219, P250, DOI 10.1006/dbio.2000.9618; Phelps DE, 1996, J BIOL CHEM, V271, P7978, DOI 10.1074/jbc.271.14.7978; Plisov SY, 2001, DEVELOPMENT, V128, P1045; Pohl M, 2000, AM J PHYSIOL-RENAL, V279, pF891, DOI 10.1152/ajprenal.2000.279.5.F891; Qiao J, 2001, MECH DEVELOP, V109, P123, DOI 10.1016/S0925-4773(01)00592-5; Raatikainen-Ahokas A, 2000, DEV DYNAM, V217, P146, DOI 10.1002/(SICI)1097-0177(200002)217:2<146::AID-DVDY2>3.3.CO;2-9; SANYANUSIN P, 1995, HUM MOL GENET, V4, P2183, DOI 10.1093/hmg/4.11.2183; STARK K, 1994, NATURE, V372, P679, DOI 10.1038/372679a0; Torres M, 1995, DEVELOPMENT, V121, P4057; Vassetzky Y, 2000, GENE DEV, V14, P1541; Weston CR, 2003, GENE DEV, V17, P1271, DOI 10.1101/gad.1087303; Winyard PJD, 1996, J CLIN INVEST, V98, P451, DOI 10.1172/JCI118811; Yoshino K, 2001, MECH DEVELOP, V102, P45, DOI 10.1016/S0925-4773(01)00282-9	36	30	30	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52401	52405		10.1074/jbc.M305614200	http://dx.doi.org/10.1074/jbc.M305614200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14561758	hybrid			2022-12-27	WOS:000187480700052
J	Rong, R; Ahn, JY; Chen, P; Suh, PG; Ye, KQ				Rong, R; Ahn, JY; Chen, P; Suh, PG; Ye, KQ			Phospholipase activity of phospholipase C-gamma 1 is required for nerve growth factor-regulated MAP kinase signaling cascade in PC12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCHANGE FACTOR; SH3 DOMAIN; C-GAMMA; B-RAF; MEDIATED ACTIVATION; PROTEIN-KINASE; NUCLEAR GTPASE; DNA-SYNTHESIS; C-GAMMA-1; PLC-GAMMA-1	Phospholipase C-gamma1( PLC-gamma1) hydrolyzes phosphatidylinositol 4,5-bisphosphate to the second messengers inositol 1,4,5-trisphosphate and diacylglycerol (DAG). PLC-gamma1 is implicated in a variety of cellular signalings and processes including mitogenesis and calcium entry. However, numerous studies demonstrate that the lipase activity is not required for PLC-gamma1 to mediate these events. Here, we report that the phospholipase activity of PLC-gamma1 plays an essential role in nerve growth factor (NGF)-triggered Raf/MEK/MAPK pathway activation in PC12 cells. Employing PC12 cells stably transfected with an inducible form of wild-type PLC-gamma1 or lipase inactive PLC-gamma1 with histidine 335 mutated into glutamine in the catalytic domain, we show that NGF provokes robust activation of MAP kinase in wild-type but not in lipase inactive cells. Both Ras/C-Raf/MEK1 and Rap1/B-Raf/MEK1 pathways are intact in the wild-type cells. By contrast, these signaling cascades are diminished in the mutant cells. Pretreatment with cell permeable DAG analog 1-oleyl-2-acetylglycerol rescues the MAP kinase pathway activation in the mutant cells. These observations indicate that the lipase activity of PLC-gamma1 mediates NGF-regulated MAPK signaling upstream of Ras/Rap1 activation probably through second messenger DAG-activated Ras and Rap-GEFs.	Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30322 USA; Pohang Univ Sci & Technol, Dept Life Sci, Div Mol Life Sci, Pohang 790784, South Korea	Emory University; Pohang University of Science & Technology (POSTECH)	Ye, KQ (corresponding author), Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30322 USA.		Suh, Pann-Ghill/F-3610-2010					CEN H, 1993, MOL CELL BIOL, V13, P7718, DOI 10.1128/MCB.13.12.7718; Corbit KC, 1999, MOL CELL BIOL, V19, P4209; Ebinu JO, 1998, SCIENCE, V280, P1082, DOI 10.1126/science.280.5366.1082; Fam NP, 1997, MOL CELL BIOL, V17, P1396, DOI 10.1128/MCB.17.3.1396; FARNSWORTH CL, 1995, NATURE, V376, P524, DOI 10.1038/376524a0; Finkbeiner S, 1996, NEURON, V16, P233, DOI 10.1016/S0896-6273(00)80040-9; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; GOLDSCHMIDTCLERMONT PJ, 1991, SCIENCE, V251, P1231, DOI 10.1126/science.1848725; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Grewal SS, 1999, CURR OPIN NEUROBIOL, V9, P544, DOI 10.1016/S0959-4388(99)00010-0; Gurd JW, 1997, J NEUROCHEM, V69, P623; HUANG JT, 1995, J BIOL CHEM, V270, P5065, DOI 10.1074/jbc.270.10.5065; HUANG PS, 1995, FEBS LETT, V358, P287, DOI 10.1016/0014-5793(94)01453-8; Jaiswal RK, 1996, J BIOL CHEM, V271, P23626, DOI 10.1074/jbc.271.39.23626; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; Ji QS, 1997, P NATL ACAD SCI USA, V94, P2999, DOI 10.1073/pnas.94.7.2999; Kao SC, 2001, J BIOL CHEM, V276, P18169, DOI 10.1074/jbc.M008870200; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; Kim MJ, 2000, BIOCHEMISTRY-US, V39, P8674, DOI 10.1021/bi992558t; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MUSLIN AJ, 1993, MOL CELL BIOL, V13, P4197, DOI 10.1128/MCB.13.7.4197; OBERMEIER A, 1994, EMBO J, V13, P1585, DOI 10.1002/j.1460-2075.1994.tb06421.x; OSHIMA M, 1991, J BIOL CHEM, V266, P23753; Patterson RL, 2002, CELL, V111, P529, DOI 10.1016/S0092-8674(02)01045-0; Pei ZD, 1997, ARCH BIOCHEM BIOPHYS, V345, P103, DOI 10.1006/abbi.1997.0245; Scholler JK, 2000, EUR J IMMUNOL, V30, P2378, DOI 10.1002/1521-4141(2000)30:8<2378::AID-IMMU2378>3.0.CO;2-E; SMITH MR, 1994, P NATL ACAD SCI USA, V91, P6554, DOI 10.1073/pnas.91.14.6554; SMITH MR, 1990, SCIENCE, V247, P1074, DOI 10.1126/science.2408147; SMITH MR, 1989, P NATL ACAD SCI USA, V86, P3659, DOI 10.1073/pnas.86.10.3659; Smith MR, 1996, BIOCHEM BIOPH RES CO, V222, P186, DOI 10.1006/bbrc.1996.0719; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; STEPHENS RM, 1992, MOL CELL BIOL, V12, P3733, DOI 10.1128/MCB.12.9.3733; SULTZMAN L, 1991, MOL CELL BIOL, V11, P2018, DOI 10.1128/MCB.11.4.2018; Thackeray JR, 1998, DEVELOPMENT, V125, P5033; Yablonski D, 2001, MOL CELL BIOL, V21, P4208, DOI 10.1128/MCB.21.13.4208-4218.2001; Ye KQ, 2000, CELL, V103, P919, DOI 10.1016/S0092-8674(00)00195-1; Ye KQ, 2002, NATURE, V415, P541, DOI 10.1038/415541a; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; Zapf-Colby A, 1999, ONCOGENE, V18, P4908, DOI 10.1038/sj.onc.1202861	41	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52497	52503		10.1074/jbc.M306744200	http://dx.doi.org/10.1074/jbc.M306744200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14570902	hybrid			2022-12-27	WOS:000187480700064
J	Stuven, E; Porat, A; Shimron, F; Fass, E; Kaloyanova, D; Brugger, B; Wieland, FT; Elazar, Z; Helms, JB				Stuven, E; Porat, A; Shimron, F; Fass, E; Kaloyanova, D; Brugger, B; Wieland, FT; Elazar, Z; Helms, JB			Intra-Golgi protein transport depends on a cholesterol balance in the lipid membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROTRIMERIC G-PROTEINS; GPI-ANCHORED PROTEINS; COPI-COATED VESICLES; PLASMA-MEMBRANE; ENRICHED MICRODOMAINS; BIOLOGICAL-MEMBRANES; EPITHELIAL-CELLS; BREFELDIN-A; RAFTS; COMPLEX	Transport of proteins between intracellular membrane compartments is mediated by a protein machinery that regulates the budding and fusion processes of individual transport steps. Although the core proteins of both processes are defined at great detail, much less is known about the involvement of lipids. Here we report that changing the cellular balance of cholesterol resulted in changes of the morphology of the Golgi apparatus, accompanied by an inhibition of protein transport. By using a well characterized cell-free intra-Golgi transport assay, these observations were further investigated, and it was found that the transport reaction is sensitive to small changes in the cholesterol content of Golgi membranes. Addition as well as removal of cholesterol (10 +/- 6%) to Golgi membranes by use of methyl-beta-cyclodextrin specifically inhibited the intra-Golgi transport assay. Transport inhibition occurred at the fusion step. Modulation of the cholesterol content changed the lipid raft partitioning of phosphatidylcholine and heterotrimeric G proteins, but not of other (non) lipid raft proteins and lipids. We suggest that the cholesterol balance in Golgi membranes plays an essential role in intra-Golgi protein transport and needs to be carefully regulated to maintain the structural and functional organization of the Golgi apparatus.	Univ Utrecht, Dept Biochem & Cell Biol, NL-3508 TD Utrecht, Netherlands; Univ Heidelberg, Biochem Zentrum Heidelberg, D-69120 Heidelberg, Germany; Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel	Utrecht University; Ruprecht Karls University Heidelberg; Weizmann Institute of Science	Helms, JB (corresponding author), Univ Utrecht, Dept Biochem & Cell Biol, POB 80176, NL-3508 TD Utrecht, Netherlands.							ALBERTS AW, 1980, P NATL ACAD SCI-BIOL, V77, P3957, DOI 10.1073/pnas.77.7.3957; Anderson RGW, 2002, SCIENCE, V296, P1821, DOI 10.1126/science.1068886; Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; Bremser M, 1999, CELL, V96, P495, DOI 10.1016/S0092-8674(00)80654-6; BRETSCHER MS, 1993, SCIENCE, V261, P1280, DOI 10.1126/science.8362242; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Brown DA, 1998, J MEMBRANE BIOL, V164, P103, DOI 10.1007/s002329900397; Brugger B, 2000, J CELL BIOL, V151, P507, DOI 10.1083/jcb.151.3.507; Chamberlain LH, 2001, P NATL ACAD SCI USA, V98, P5619, DOI 10.1073/pnas.091502398; Chatterjee S, 2001, EMBO J, V20, P1583, DOI 10.1093/emboj/20.7.1583; Cluett EB, 1996, J CELL SCI, V109, P2121; COXEY RA, 1993, J LIPID RES, V34, P1165; Drevot P, 2002, EMBO J, V21, P1899, DOI 10.1093/emboj/21.8.1899; Eberle HB, 2002, J CELL SCI, V115, P827; ELAZAR Z, 1994, J CELL BIOL, V124, P415, DOI 10.1083/jcb.124.4.415; Fielding CJ, 1997, J LIPID RES, V38, P1503; Gkantiragas I, 2001, MOL BIOL CELL, V12, P1819, DOI 10.1091/mbc.12.6.1819; Grimmer S, 2000, MOL BIOL CELL, V11, P4205, DOI 10.1091/mbc.11.12.4205; Hannan LA, 1996, J CELL BIOL, V133, P1265, DOI 10.1083/jcb.133.6.1265; Hansen GH, 2000, J BIOL CHEM, V275, P5136, DOI 10.1074/jbc.275.7.5136; Heino S, 2000, P NATL ACAD SCI USA, V97, P8375, DOI 10.1073/pnas.140218797; Helms JB, 1998, J BIOL CHEM, V273, P15203, DOI 10.1074/jbc.273.24.15203; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; Jamora C, 1997, CELL, V91, P617, DOI 10.1016/S0092-8674(00)80449-3; Janes PW, 2000, SEMIN IMMUNOL, V12, P23, DOI 10.1006/smim.2000.0204; Kato M, 2001, EMBO J, V20, P4035, DOI 10.1093/emboj/20.15.4035; Keller P, 1998, J CELL BIOL, V140, P1357, DOI 10.1083/jcb.140.6.1357; KILSDONK EPC, 1995, J BIOL CHEM, V270, P17250, DOI 10.1074/jbc.270.29.17250; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KLEIN U, 1995, BIOCHEMISTRY-US, V34, P13784, DOI 10.1021/bi00042a009; Kobayashi T, 1998, SEMIN CELL DEV BIOL, V9, P517, DOI 10.1006/scdb.1998.0257; Lafont F, 1999, P NATL ACAD SCI USA, V96, P3734, DOI 10.1073/pnas.96.7.3734; Lang T, 2001, EMBO J, V20, P2202, DOI 10.1093/emboj/20.9.2202; Langlet C, 2000, CURR OPIN IMMUNOL, V12, P250, DOI 10.1016/S0952-7915(00)00084-4; Ledesma MD, 1998, P NATL ACAD SCI USA, V95, P3966, DOI 10.1073/pnas.95.7.3966; LEVINE YK, 1971, NATURE-NEW BIOL, V230, P69, DOI 10.1038/newbio230069a0; Lipardi C, 2000, MOL BIOL CELL, V11, P531, DOI 10.1091/mbc.11.2.531; Liscum L, 1999, BBA-MOL CELL BIOL L, V1438, P19, DOI 10.1016/S1388-1981(99)00043-8; Mayor S, 1998, EMBO J, V17, P4626, DOI 10.1093/emboj/17.16.4626; MELANCON P, 1987, CELL, V51, P1053, DOI 10.1016/0092-8674(87)90591-5; Mukherjee S, 1999, J CELL BIOL, V144, P1271, DOI 10.1083/jcb.144.6.1271; Nagahama M, 1996, J CELL BIOL, V133, P507, DOI 10.1083/jcb.133.3.507; Nakamura N, 1997, CELL, V89, P445, DOI 10.1016/S0092-8674(00)80225-1; NEUMANN D, 1993, J BIOL CHEM, V268, P13639; NEZIL FA, 1992, BIOPHYS J, V61, P1176, DOI 10.1016/S0006-3495(92)81926-4; OHTANI Y, 1989, EUR J BIOCHEM, V186, P17, DOI 10.1111/j.1432-1033.1989.tb15171.x; ORCI L, 1981, P NATL ACAD SCI-BIOL, V78, P293, DOI 10.1073/pnas.78.1.293; ORCI L, 1991, CELL, V64, P1183; PAGANO RE, 1989, J CELL BIOL, V109, P2067, DOI 10.1083/jcb.109.5.2067; PFANNER N, 1990, J CELL BIOL, V110, P955, DOI 10.1083/jcb.110.4.955; Porat A, 2000, J BIOL CHEM, V275, P14457, DOI 10.1074/jbc.275.19.14457; Rabouille C, 1998, CELL, V92, P603, DOI 10.1016/S0092-8674(00)81128-9; Rodal SK, 1999, MOL BIOL CELL, V10, P961, DOI 10.1091/mbc.10.4.961; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Sandhoff R, 1999, J LIPID RES, V40, P126; Scales SJ, 1997, CELL, V90, P1137, DOI 10.1016/S0092-8674(00)80379-7; Scheiffele P, 1999, J BIOL CHEM, V274, P2038, DOI 10.1074/jbc.274.4.2038; Shima DT, 1997, J CELL BIOL, V137, P1211, DOI 10.1083/jcb.137.6.1211; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SIMONS K, 1988, BIOCHEMISTRY-US, V27, P6197, DOI 10.1021/bi00417a001; TAYLOR TC, 1994, MOL BIOL CELL, V5, P237, DOI 10.1091/mbc.5.2.237; Thiele C, 2000, NAT CELL BIOL, V2, P42, DOI 10.1038/71366; Uittenbogaard A, 1998, J BIOL CHEM, V273, P6525, DOI 10.1074/jbc.273.11.6525; URBANI L, 1990, J BIOL CHEM, V265, P1919; VAN MEER G, 1988, J CELL BIOCHEM, V36, P51, DOI 10.1002/jcb.240360106; VAN MEER G, 1989, ANNU REV CELL BIOL, V5, P247, DOI 10.1146/annurev.cellbio.5.1.247; van Meer G, 1998, TRENDS CELL BIOL, V8, P29, DOI 10.1016/S0962-8924(97)01196-3; Wang YZ, 2000, TRAFFIC, V1, P952, DOI 10.1034/j.1600-0854.2000.011205.x; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Yamaguchi T, 1997, J BIOL CHEM, V272, P25260, DOI 10.1074/jbc.272.40.25260; Yang T, 2002, CELL, V110, P489, DOI 10.1016/S0092-8674(02)00872-3	75	38	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					53112	53122		10.1074/jbc.M300402200	http://dx.doi.org/10.1074/jbc.M300402200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14561753	hybrid			2022-12-27	WOS:000187480700136
J	Choe, JY; Nelson, SW; Arienti, KL; Axe, FU; Collins, TL; Jones, TK; Kimmich, RDA; Newman, MJ; Norvell, K; Ripka, WC; Romano, SJ; Short, KM; Slee, DH; Fromm, HJ; Honzatko, RB				Choe, JY; Nelson, SW; Arienti, KL; Axe, FU; Collins, TL; Jones, TK; Kimmich, RDA; Newman, MJ; Norvell, K; Ripka, WC; Romano, SJ; Short, KM; Slee, DH; Fromm, HJ; Honzatko, RB			Inhibition of fructose-1,6-bisphosphatase by a new class of allosteric effectors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT PORCINE FRUCTOSE-1,6-BISPHOSPHATASE; RABBIT LIVER FRUCTOSE-1,6-BISPHOSPHATASE; FRUCTOSE 1,6-BISPHOSPHATASE; STRUCTURE REFINEMENT; AMP COOPERATIVITY; PRODUCT COMPLEXES; CRYSTAL-STRUCTURE; DYNAMIC LOOP; 2,6-BISPHOSPHATE; MECHANISM	A highly constrained pseudo-tetrapeptide (OC252-324) further defines a new allosteric binding site located near the center of fructose-1,6-bisphosphatase. In a crystal structure, pairs of inhibitory molecules bind to opposite faces of the enzyme tetramer. Each ligand molecule is in contact with three of four subunits of the tetramer, hydrogen bonding with the side chain of Asp(187) and the backbone carbonyl of residue 71, and electrostatically interacting with the backbone carbonyl of residue 51. The ligated complex adopts a quaternary structure between the canonical R- and T-states of fructose-1,6-bisphosphatase, and yet a dynamic loop essential for catalysis (residues 52-72) is in a conformation identical to that of the T-state enzyme. Inhibition by the pseudo-tetrapeptide is cooperative (Hill coefficient of 2), synergistic with both AMP and fructose 2,6-bisphosphate, noncompetitive with respect to Mg2+, and uncompetitive with respect to fructose 1,6-bisphosphate. The ligand dramatically lowers the concentration at which substrate inhibition dominates the kinetics of fructose-1,6-bisphosphatase. Elevated substrate concentrations employed in kinetic screens may have facilitated the discovery of this uncompetitive inhibitor. Moreover, the inhibitor could mimic an unknown natural effector of fructose-1,6-bisphosphatase, as it interacts strongly with a conserved residue of undetermined functional significance.	Iowa State Univ, Dept Biochem Biophys & Mol Biol, Ames, IA 50011 USA; Ontogen Corp, Carlsbad, CA 92009 USA	Iowa State University	Honzatko, RB (corresponding author), Iowa State Univ, Dept Biochem Biophys & Mol Biol, Ames, IA 50011 USA.		Short, Kieran/O-4476-2019	Short, Kieran/0000-0001-9137-008X	NIDDK NIH HHS [R43-DK57342-01, R44 DK57342-02] Funding Source: Medline; NINDS NIH HHS [NS 10546] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R44DK057342, R43DK057342] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS010546, R56NS010546] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BENKOVIC SJ, 1982, ADV ENZYMOL RAMB, V53, P45; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Choe JY, 2000, BIOCHEMISTRY-US, V39, P8565, DOI 10.1021/bi000574g; Choe JY, 1998, BIOCHEMISTRY-US, V37, P11441, DOI 10.1021/bi981112u; Choe JY, 2003, J BIOL CHEM, V278, P16008, DOI 10.1074/jbc.M212394200; Choe JY, 2003, J BIOL CHEM, V278, P16015, DOI 10.1074/jbc.M212395200; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; HOWARD AJ, 1985, METHOD ENZYMOL, V114, P452; KE H, 1990, J MOL BIOL, V212, P513, DOI 10.1016/0022-2836(90)90329-K; KE HM, 1991, P NATL ACAD SCI USA, V88, P2989, DOI 10.1073/pnas.88.8.2989; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kuzmic P, 1996, ANAL BIOCHEM, V237, P260, DOI 10.1006/abio.1996.0238; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LAWSON JWR, 1976, GLUCONEOGENESIS ITS, P481; LIU F, 1988, J BIOL CHEM, V263, P9122; LU G, 1997, J BIOL CHEM, V297, P5076; Lu GQ, 1996, PROTEIN SCI, V5, P2333, DOI 10.1002/pro.5560051120; MACGREGOR JS, 1980, P NATL ACAD SCI-BIOL, V77, P3889, DOI 10.1073/pnas.77.7.3889; MCGRANE MM, 1983, J BIOL CHEM, V258, P445; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; MOORHEAD GBG, 1994, ARCH BIOCHEM BIOPHYS, V312, P326, DOI 10.1006/abbi.1994.1316; Nelson SW, 2001, J BIOL CHEM, V276, P6119, DOI 10.1074/jbc.M009485200; Nelson SW, 2000, BIOCHEMISTRY-US, V39, P11100, DOI 10.1021/bi000609c; NIMMO HG, 1975, EUR J BIOCHEM, V58, P567, DOI 10.1111/j.1432-1033.1975.tb02407.x; Okar DA, 1999, BIOFACTORS, V10, P1, DOI 10.1002/biof.5520100101; PILKIS SJ, 1981, J BIOL CHEM, V256, P3619; PILKIS SJ, 1988, ANNU REV BIOCHEM, V57, P755, DOI 10.1146/annurev.bi.57.070188.003543; PONTREMOLI S, 1983, BIOCHEM SOC T, V11, P241; Rakus D, 2000, BIOCHEM BIOPH RES CO, V275, P611, DOI 10.1006/bbrc.2000.3308; SCHEFFLER JE, 1986, BIOCHEMISTRY-US, V25, P6659, DOI 10.1021/bi00369a050; Shyur LF, 1997, J BIOL CHEM, V272, P26295, DOI 10.1074/jbc.272.42.26295; STONE SR, 1980, BIOCHEMISTRY-US, V19, P620, DOI 10.1021/bi00545a003; TEJWANI GA, 1983, ADV ENZYMOL RAMB, V54, P121; Van Schaftingen E., 1987, ADV ENZYMOL RELAT AR, V59, P45; Wen J, 2001, PHOTOCHEM PHOTOBIOL, V74, P679, DOI 10.1562/0031-8655(2001)074<0679:EOTIPF>2.0.CO;2; Wright SW, 2002, J MED CHEM, V45, P3865, DOI 10.1021/jm010496a; XUE YF, 1994, P NATL ACAD SCI USA, V91, P12482, DOI 10.1073/pnas.91.26.12482; ZHANG YP, 1994, J MOL BIOL, V244, P609, DOI 10.1006/jmbi.1994.1755	40	36	37	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51176	51183		10.1074/jbc.M308396200	http://dx.doi.org/10.1074/jbc.M308396200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14530289	hybrid			2022-12-27	WOS:000187206300043
J	Kulkarni, AA; Haworth, IS; Uchiyama, T; Lee, VHL				Kulkarni, AA; Haworth, IS; Uchiyama, T; Lee, VHL			Analysis of transmembrane segment 7 of the dipeptide transporter hPepT1 by cysteine-scanning mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUT1 GLUCOSE-TRANSPORTER; BRUSH-BORDER MEMBRANE; BINDING-SITE CREVICE; DOPAMINE D2 RECEPTOR; PEPTIDE TRANSPORTER; GLYCYLSARCOSINE TRANSPORT; OLIGOPEPTIDE TRANSPORTER; SPANNING SEGMENT; ACTIVE-TRANSPORT; IDENTIFICATION	To investigate the involvement of transmembrane segment 7 (TMS7) of hPepT1 in forming the putative central aqueous channel through which the substrate traverses, we individually mutated each of the 21 amino acids in TMS7 to a cysteine and analyzed the mutated transporters using the scanning cysteine accessibility method. Y287C- and M292C-hPepT1 did not express at the plasma membrane. Out of the remaining 19 transporters, three (F293C-, L296C-, and F297C-hPepT1) showed negligible glycyl-sarcosine (gly-sar) uptake activity and may play an important role in defining the overall hPepT1 structure. K278C-hPepT1 showed similar to40% activity and the 15 other transporters exhibited more than 50% gly-sar uptake when compared with wild type (WT)-hPepT1. Gly-sar uptake for the 16 active transporters containing cysteine mutations was then measured in the presence of 2.5 mM 2-aminoethyl methanethiosulfonate hydrobromide (MTSEA) or 1 mM [2-(trimethylammonium) ethyl] methanethiosulfonate bromide (MTSET). Gly-sar uptake was significantly inhibited for each of the 16 single cysteine mutants in the presence of 2.5 mM MTSEA. In contrast, significant inhibition of uptake was only observed for K278C-, M279C-, V280C-, T281C-, M284C-, L286C-, P291C-, and D298C-hPepT1 in the presence of 1 mM MTSET. MTSET modification of R282C-hPepT1 resulted in a significant increase in gly-sar uptake. To investigate this further, we mutated WT-hPepT1 to R282A-, R282E-, and R282K-hPepT1. R282E-hPepT1 showed a 43% reduction in uptake activity, whereas R282A- and R282K-hPepT1 had activities comparable with WT-hPepT1, suggesting a role for the Arg-282 positive charge in substrate translocation. Most of the amino acids that were MTSET-sensitive upon cysteine mutation, including R282C, are located toward the intracellular end of TMS7. Hence, our results suggest that TMS7 of hPepT1 is relatively solvent-accessible along most of its length but that the intracellular end of the transmembrane domain is particularly so. From a structure-function perspective, we speculate that the extracellular end of TMS7 may shift following substrate binding, providing the basis for channel opening and substrate translocation.	Univ So Calif, Sch Pharm, Dept Pharmaceut Sci, Los Angeles, CA 90089 USA; Univ So Calif, Sch Pharm, Dept Ophthalmol, Los Angeles, CA 90089 USA	University of Southern California; University of Southern California	Haworth, IS (corresponding author), Univ So Calif, Sch Pharm, Dept Pharmaceut Sci, 1985 Zonal Ave, Los Angeles, CA 90089 USA.	ihaworth@usc.edu	Lee, Vincent HL/A-9439-2008	Lee, Vincent HL/0000-0001-7708-6269	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK048522] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059297] Funding Source: NIH RePORTER; NIDDK NIH HHS [IP30 DK48522] Funding Source: Medline; NIGMS NIH HHS [GM59297] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anand BS, 2003, J PHARMACOL EXP THER, V304, P781, DOI 10.1124/jpet.102.044313; Anand BS, 2002, EXPERT OPIN BIOL TH, V2, P607, DOI 10.1517/14712598.2.6.607; Bockman DE, 1997, INT J PANCREATOL, V22, P221; Bolger MB, 1998, J PHARM SCI-US, V87, P1286, DOI 10.1021/js980090u; Doring F, 1996, J PHYSIOL-LONDON, V497, P773; Fei YJ, 1998, BIOCHEM BIOPH RES CO, V246, P39, DOI 10.1006/bbrc.1998.8566; Fu DY, 1996, BIOCHEMISTRY-US, V35, P11278, DOI 10.1021/bi960928x; GANAPATHY V, 1984, J BIOL CHEM, V259, P8954; Han HK, 1998, PHARMACEUT RES, V15, P1154, DOI 10.1023/A:1011919319810; Hruz PW, 1999, J BIOL CHEM, V274, P36176, DOI 10.1074/jbc.274.51.36176; INUI KI, 1992, J PHARMACOL EXP THER, V260, P482; Javitch JA, 2000, BIOCHEMISTRY-US, V39, P12190, DOI 10.1021/bi001069m; JAVITCH JA, 1994, P NATL ACAD SCI USA, V91, P10355, DOI 10.1073/pnas.91.22.10355; Kulkarni AA, 2003, BIOCHEM BIOPH RES CO, V306, P177, DOI 10.1016/S0006-291X(03)00926-4; LU Q, 1995, SCIENCE, V268, P304, DOI 10.1126/science.7716526; MADDEN DR, 1993, CELL, V75, P693, DOI 10.1016/0092-8674(93)90490-H; Martinez MN, 2002, J CLIN PHARMACOL, V42, P620, DOI 10.1177/00970002042006005; Mueckler M, 1999, J BIOL CHEM, V274, P10923, DOI 10.1074/jbc.274.16.10923; Mueckler M, 2002, J BIOL CHEM, V277, P3498, DOI 10.1074/jbc.M109157200; PerezGarcia MT, 1996, P NATL ACAD SCI USA, V93, P300, DOI 10.1073/pnas.93.1.300; RONG LA, 1995, J BIOL CHEM, V270, P6456, DOI 10.1074/jbc.270.12.6456; SAHINTOTH M, 1993, PROTEIN SCI, V2, P1024, DOI 10.1002/pro.5560020615; Slotboom DJ, 2001, J BIOL CHEM, V276, P10775, DOI 10.1074/jbc.M011064200; Temple CS, 1998, J BIOL CHEM, V273, P20, DOI 10.1074/jbc.273.1.20; Terada T, 2000, PHARM RES-DORDR, V17, P15, DOI 10.1023/A:1007554105597; Thamotharan M, 1997, J BIOL CHEM, V272, P11786, DOI 10.1074/jbc.272.18.11786; THWAITES DT, 1994, BRIT J PHARMACOL, V113, P1050, DOI 10.1111/j.1476-5381.1994.tb17099.x; TSUJI A, 1987, BIOCHEM PHARMACOL, V36, P565, DOI 10.1016/0006-2952(87)90369-8; TSUJI A, 1990, PHARMACEUT RES, V7, P308, DOI 10.1023/A:1015894617027; Yeung AK, 1998, BIOCHEM BIOPH RES CO, V250, P103, DOI 10.1006/bbrc.1998.9283; Zhang EY, 2002, DRUG METAB REV, V34, P709, DOI 10.1081/DMR-120015692; Zhang EY, 2002, ADV DRUG DELIVER REV, V54, P329, DOI 10.1016/S0169-409X(02)00007-8; Zhou XD, 2000, BBA-BIOMEMBRANES, V1466, P372, DOI 10.1016/S0005-2736(00)00201-7	33	33	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51833	51840		10.1074/jbc.M308356200	http://dx.doi.org/10.1074/jbc.M308356200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14532279	hybrid			2022-12-27	WOS:000187206300119
J	Noronha, EJ; Sterling, KH; Calame, KL				Noronha, EJ; Sterling, KH; Calame, KL			Increased expression of Bcl-xL and c-Myc is associated with transformation by Abelson murine leukemia virus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ABL TYROSINE KINASE; WILD-TYPE P53; V-ABL; TELOMERASE ACTIVITY; GENE AMPLIFICATION; IN-VIVO; APOPTOSIS; CELLS; ONCOGENE; TRANSCRIPTION	Transformation mediated by the v- Abl oncoprotein, a tyrosine kinase encoded by the Abelson murine leukemia virus, is a multi- step process requiring genetic alterations in addition to expression of v- Abl. Loss of p53 or p19ARF was previously shown to be required for Abelson murine leukemia virus transformation of primary mouse embryonic fibroblasts ( MEFs). By comparing gene expression patterns in primary p53(-/-) MEFs acutely infected with the v- Abl retrovirus, v- Abl- transformed MEF clones, and v- Abl- transformed MEF clones treated with Abl kinase inhibitor STI 571, we have identified additional genetic alterations associated with v-Abl transformation. Bcl- xL mRNA was elevated in three of five v- Abl- transformed MEF clones. In addition, elevated expression of c- Myc mRNA, caused either by c- myc gene amplification or by enhanced signaling via STAT3, was observed in five v- Abl- transformed MEF clones. The data suggest that increases in cell survival associated with Bcl- xL and increases in cell growth associated with c- Myc facilitate the transformation process dependent on constitutive mitogenic signaling by v- Abl.	Columbia Univ Coll Phys & Surg, Dept Microbiol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Biochem & Mol Biophys, New York, NY 10032 USA	Columbia University; Columbia University	Calame, KL (corresponding author), Columbia Univ Coll Phys & Surg, Dept Microbiol, 701 W 168th St, New York, NY 10032 USA.	klc1@columbia.edu						Banerjee A, 1998, J IMMUNOL, V161, P4611; Buchdunger E, 1996, CANCER RES, V56, P100; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; Chen Q, 1997, ONCOGENE, V15, P2249, DOI 10.1038/sj.onc.1201371; COLLEDGE WH, 1989, ONCOGENE, V4, P753; Cong F, 1999, ONCOGENE, V18, P7731, DOI 10.1038/sj.onc.1203290; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Coutts M, 2000, ONCOGENE, V19, P801, DOI 10.1038/sj.onc.1203398; Danial NN, 2000, ONCOGENE, V19, P2523, DOI 10.1038/sj.onc.1203484; DANIAL NN, 1995, SCIENCE, V269, P1875, DOI 10.1126/science.7569929; DePinho RA, 2000, NATURE, V408, P248, DOI 10.1038/35041694; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; ENGELMAN A, 1990, J VIROL, V64, P4242, DOI 10.1128/JVI.64.9.4242-4251.1990; Fukasawa K, 1997, ONCOGENE, V15, P1295, DOI 10.1038/sj.onc.1201482; GOFF SP, 1985, P SOC EXP BIOL MED, V179, P403; GREEN PL, 1989, J VIROL, V63, P1989, DOI 10.1128/JVI.63.5.1989-1994.1989; GREEN PL, 1987, J VIROL, V61, P2192, DOI 10.1128/JVI.61.7.2192-2197.1987; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Hackett JA, 2002, ONCOGENE, V21, P619, DOI 10.1038/sj.onc.1205061; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hilbert DM, 1996, IMMUNITY, V5, P81, DOI 10.1016/S1074-7613(00)80312-X; Hoffman B, 2002, ONCOGENE, V21, P3414, DOI 10.1038/sj.onc.1205400; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kim NW, 1997, NUCLEIC ACIDS RES, V25, P2595, DOI 10.1093/nar/25.13.2595; Kiuchi N, 1999, J EXP MED, V189, P63, DOI 10.1084/jem.189.1.63; Lin Y, 1997, SCIENCE, V276, P596, DOI 10.1126/science.276.5312.596; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; NEPVEU A, 1985, NATURE, V317, P440, DOI 10.1038/317440a0; Packham G, 1998, GENE DEV, V12, P2475, DOI 10.1101/gad.12.16.2475; Pelengaris S, 2002, NAT REV CANCER, V2, P764, DOI 10.1038/nrc904; Radfar A, 1998, P NATL ACAD SCI USA, V95, P13194, DOI 10.1073/pnas.95.22.13194; ROSENBERG N, 1988, ADV VIRUS RES, V35, P39; SAMBROOK J, 1989, MOL CLONING, V2, P9; SAWYERS CL, 1992, CELL, V70, P901, DOI 10.1016/0092-8674(92)90241-4; Shore SK, 2002, ONCOGENE, V21, P8568, DOI 10.1038/sj.onc.1206084; Traver D, 1998, IMMUNITY, V9, P47, DOI 10.1016/S1074-7613(00)80587-7; Unnikrishnan I, 1999, MOL CELL BIOL, V19, P4825, DOI 10.1128/mcb.19.7.4825; WHITLOCK CA, 1983, MOL CELL BIOL, V3, P596, DOI 10.1128/MCB.3.4.596; Wu KJ, 1999, NAT GENET, V21, P220, DOI 10.1038/6010; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; Zou XM, 1999, J BIOL CHEM, V274, P18141, DOI 10.1074/jbc.274.26.18141; Zou XM, 1997, GENE DEV, V11, P654, DOI 10.1101/gad.11.5.654; Zou XM, 2000, MOL CELL BIOL, V20, P628, DOI 10.1128/MCB.20.2.628-633.2000	45	8	8	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					50915	50922		10.1074/jbc.M306629200	http://dx.doi.org/10.1074/jbc.M306629200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14559912	hybrid			2022-12-27	WOS:000187206300012
J	Povsic, TJ; Kohout, TA; Lefkowitz, RJ				Povsic, TJ; Kohout, TA; Lefkowitz, RJ			beta-arrestin1 mediates insulin-like growth factor 1 (IGF-1) activation of phosphatidylinositol 3-kinase (PI3K) and anti-apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-I RECEPTOR; SMOOTH-MUSCLE-CELLS; PROTEIN-KINASE-B; TYROSINE KINASE; BETA-ARRESTINS; PHOSPHOINOSITIDE 3-KINASE; GROWTH-FACTOR-1 RECEPTOR; SIGNAL-TRANSDUCTION; INSULIN; GROWTH	beta-arrestins (1 and 2) are widely expressed cytosolic proteins that play central roles in G protein-coupled receptor signaling. beta-arrestin1 is also recruited to the insulin-like growth factor 1 (IGF-1) receptor, a receptor tyrosine kinase, upon agonist binding. Here we report that, in response to IGF-1 stimulation, beta-arrestin1 mediates activation of phosphatidylinositol 3-kinase in a pathway that leads to the subsequent activation of Akt and anti-apoptosis. This process is independent of both G(i) and ERK activity. The pathway fails in mouse embryo fibroblasts lacking both beta-arrestins and is restored by stable transfection of beta-arrestin1. Remarkably, this pathway is insensitive to chemical inhibition of IGF-1 receptor tyrosine kinase activity. These results suggest that, in addition to their roles in G protein-coupled receptor signaling, beta-arrestins couple the IGF-1 receptor tyrosine kinase to the phosphatidylinositol 3-kinase system and suggest that this mechanism is operative independently of the tyrosine kinase activity of the receptor.	Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Med & Biochem, Durham, NC 27710 USA; Duke Univ, Med Ctr, Div Cardiol, Durham, NC 27710 USA; Neurocrine Biosci Inc, San Diego, CA 92121 USA	Duke University; Howard Hughes Medical Institute; Duke University; Neurocrine Biosciences	Lefkowitz, RJ (corresponding author), Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Med & Biochem, Box 3821, Durham, NC 27710 USA.	lefko001@receptor-biol.duke.edu	Lefkowitz, Robert/AAW-2649-2021		NHLBI NIH HHS [HL 07101, HL 70631, HL 16037] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL070631, R37HL016037, R01HL016037, T32HL007101] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adams TE, 2000, CELL MOL LIFE SCI, V57, P1050, DOI 10.1007/PL00000744; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; ATTRAMADAL H, 1992, J BIOL CHEM, V267, P17882; BALTENSPERGER K, 1994, J BIOL CHEM, V269, P28937; Butler AA, 1998, COMP BIOCHEM PHYS B, V121, P19, DOI 10.1016/S0305-0491(98)10106-2; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; Chen RY, 2001, J BIOL CHEM, V276, P31858, DOI 10.1074/jbc.C100271200; Conus NM, 2002, J BIOL CHEM, V277, P38021, DOI 10.1074/jbc.M203387200; Czech MP, 1999, J BIOL CHEM, V274, P1865, DOI 10.1074/jbc.274.4.1865; Dalle S, 2001, J BIOL CHEM, V276, P15688, DOI 10.1074/jbc.M010884200; Du J, 1996, BIOCHEM BIOPH RES CO, V218, P934, DOI 10.1006/bbrc.1996.0165; Fruman DA, 2002, SEMIN IMMUNOL, V14, P7, DOI 10.1006/smim.2001.0337; Goel R, 2002, J BIOL CHEM, V277, P18640, DOI 10.1074/jbc.M108995200; Haugh JM, 2000, J CELL BIOL, V151, P1269, DOI 10.1083/jcb.151.6.1269; Jiang TY, 2003, J BIOL CHEM, V278, P15789, DOI 10.1074/jbc.M212525200; Katso R, 2001, ANNU REV CELL DEV BI, V17, P615, DOI 10.1146/annurev.cellbio.17.1.615; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Keummerle JF, 2001, J BIOL CHEM, V276, P7187, DOI 10.1074/jbc.M011145200; Kozma SC, 2002, BIOESSAYS, V24, P65, DOI 10.1002/bies.10031; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Lin FT, 1998, J BIOL CHEM, V273, P31640, DOI 10.1074/jbc.273.48.31640; LUTTRELL LM, 1995, J BIOL CHEM, V270, P16495, DOI 10.1074/jbc.270.28.16495; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; Martin TFJ, 1998, ANNU REV CELL DEV BI, V14, P231, DOI 10.1146/annurev.cellbio.14.1.231; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; McDonald PH, 2001, CELL SIGNAL, V13, P683, DOI 10.1016/S0898-6568(01)00203-0; Meier R, 1999, J RECEPT SIGNAL TR R, V19, P121, DOI 10.3109/10799899909036639; Miller WE, 2000, J BIOL CHEM, V275, P11312, DOI 10.1074/jbc.275.15.11312; Miller WE, 2001, CURR OPIN CELL BIOL, V13, P139, DOI 10.1016/S0955-0674(00)00190-3; Perry SJ, 2002, SCIENCE, V298, P834, DOI 10.1126/science.1074683; Phillips-Mason PJ, 2002, ANN NY ACAD SCI, V973, P142, DOI 10.1111/j.1749-6632.2002.tb04623.x; Pierce KL, 2001, ONCOGENE, V20, P1532, DOI 10.1038/sj.onc.1204184; RAO GN, 1995, J BIOL CHEM, V270, P27871, DOI 10.1074/jbc.270.46.27871; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; Valentinis B, 2001, J CLIN PATHOL-MOL PA, V54, P133, DOI 10.1136/mp.54.3.133; Watton SJ, 1999, CURR BIOL, V9, P433, DOI 10.1016/S0960-9822(99)80192-4	36	137	140	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51334	51339		10.1074/jbc.M309968200	http://dx.doi.org/10.1074/jbc.M309968200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14534298	hybrid			2022-12-27	WOS:000187206300061
J	Hays, FA; Watson, J; Ho, PS				Hays, FA; Watson, J; Ho, PS			Caution! DNA crossing: crystal structures of Holliday junctions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							SEQUENCE; DYNAMICS; GEOMETRY; COMPLEX; DOMAIN; MODEL		Oregon State Univ, Dept Biochem & Biophys, Corvallis, OR 97331 USA	Oregon State University	Ho, PS (corresponding author), Oregon State Univ, Dept Biochem & Biophys, ALS 2011, Corvallis, OR 97331 USA.	hops@onid.orst.edu	Ho, Pui/AAF-8838-2020; Ho, Pui S/F-6186-2014	Ho, Pui/0000-0002-8082-4311; Ho, Pui S/0000-0002-8082-4311; Watson, Jeffrey/0000-0002-6939-0137	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000210] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062957] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES00210] Funding Source: Medline; NIGMS NIH HHS [R01 GM062957-02, R1GM62957A, R01 GM062957] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aymami J, 2002, ACTA CRYSTALLOGR D, V58, P310, DOI 10.1107/S0907444901018959; BERMAN HM, 1992, BIOPHYS J, V63, P751, DOI 10.1016/S0006-3495(92)81649-1; Carlstrom G, 1996, BIOCHEMISTRY-US, V35, P3534, DOI 10.1021/bi952571n; Chen Y, 2000, MOL CELL, V6, P885, DOI 10.1016/S1097-2765(05)00088-2; CLEGG RM, 1994, BIOPHYS J, V66, P99, DOI 10.1016/S0006-3495(94)80765-9; CLEGG RM, 1992, BIOCHEMISTRY-US, V31, P4846, DOI 10.1021/bi00135a016; COOPER JP, 1987, J MOL BIOL, V198, P711, DOI 10.1016/0022-2836(87)90212-9; COOPER JP, 1989, P NATL ACAD SCI USA, V86, P7336, DOI 10.1073/pnas.86.19.7336; Cox MM, 2000, NATURE, V404, P37, DOI 10.1038/35003501; Declais AC, 2003, EMBO J, V22, P1398, DOI 10.1093/emboj/cdg132; DICKERSON RE, 1999, OXFORD HDB NUCL ACID, P145; Dickman MJ, 2002, EUR J BIOCHEM, V269, P5492, DOI 10.1046/j.1432-1033.2002.03250.x; DUCKETT DR, 1988, CELL, V55, P79, DOI 10.1016/0092-8674(88)90011-6; Eichman BF, 2000, P NATL ACAD SCI USA, V97, P3971, DOI 10.1073/pnas.97.8.3971; Eichman BF, 2002, J MOL BIOL, V320, P1037, DOI 10.1016/S0022-2836(02)00540-5; Eichman BF, 2001, J MOL BIOL, V308, P15, DOI 10.1006/jmbi.2001.4567; GOODSELL DS, 1995, BIOCHEMISTRY-US, V34, P1022, DOI 10.1021/bi00003a037; Gopaul DN, 1998, EMBO J, V17, P4175, DOI 10.1093/emboj/17.14.4175; Grainger RJ, 1998, BIOCHEMISTRY-US, V37, P23, DOI 10.1021/bi9721492; Guo F, 1997, NATURE, V389, P40, DOI 10.1038/37925; Haber JE, 2001, CELL, V107, P551, DOI 10.1016/S0092-8674(01)00593-1; Hargreaves D, 1998, NAT STRUCT BIOL, V5, P441, DOI 10.1038/nsb0698-441; Hays FA, 2003, BIOCHEMISTRY-US, V42, P9586, DOI 10.1021/bi0346603; HEINEMANN U, 1989, J MOL BIOL, V210, P369, DOI 10.1016/0022-2836(89)90337-9; Ho PS, 2001, CURR OPIN STRUC BIOL, V11, P302, DOI 10.1016/S0959-440X(00)00219-0; HOLLIDAY R, 1964, GENET RES, V5, P282, DOI 10.1017/S0016672300001233; Kato M, 2003, BIOPHYS J, V85, P402, DOI 10.1016/S0006-3495(03)74484-1; Lilley DMJ, 2000, Q REV BIOPHYS, V33, P109, DOI 10.1017/S0033583500003590; Lilley DMJ, 2001, NAT REV MOL CELL BIO, V2, P433, DOI 10.1038/35073057x; Mao CD, 1999, J AM CHEM SOC, V121, P5437, DOI 10.1021/ja9900398; McKinney SA, 2003, NAT STRUCT BIOL, V10, P93, DOI 10.1038/nsb883; Miick SM, 1997, P NATL ACAD SCI USA, V94, P9080, DOI 10.1073/pnas.94.17.9080; MURCHIE AIH, 1989, NATURE, V341, P763, DOI 10.1038/341763a0; Nowakowski J, 2000, J MOL BIOL, V300, P93, DOI 10.1006/jmbi.2000.3826; Nowakowski J, 1999, NAT STRUCT BIOL, V6, P151; NUNESDUBY SE, 1987, CELL, V50, P779, DOI 10.1016/0092-8674(87)90336-9; Ortiz-Lombardia M, 1999, NAT STRUCT BIOL, V6, P913; PANYUTIN IG, 1994, P NATL ACAD SCI USA, V91, P2021, DOI 10.1073/pnas.91.6.2021; PANYUTIN IG, 1995, EMBO J, V14, P1819, DOI 10.1002/j.1460-2075.1995.tb07170.x; Raaijmakers H, 1999, EMBO J, V18, P1447, DOI 10.1093/emboj/18.6.1447; Sha RJ, 2000, CHEM BIOL, V7, P743, DOI 10.1016/S1074-5521(00)00024-7; Sha RJ, 2002, BIOCHEMISTRY-US, V41, P5950, DOI 10.1021/bi020001z; Shlyakhtenko LS, 1998, J MOL BIOL, V280, P61, DOI 10.1006/jmbi.1998.1855; Subramaniam S, 2003, J MOL BIOL, V329, P423, DOI 10.1016/S0022-2836(03)00469-8; Thorpe JH, 2003, J MOL BIOL, V327, P97, DOI 10.1016/S0022-2836(03)00088-3; Thorpe JH, 2002, ACTA CRYSTALLOGR D, V58, P567, DOI 10.1107/S0907444902001555; Vargason JM, 2002, J BIOL CHEM, V277, P21041, DOI 10.1074/jbc.M201357200; VONKITZING E, 1990, NUCLEIC ACIDS RES, V18, P2671, DOI 10.1093/nar/18.9.2671; Wood AA, 1997, J MOL BIOL, V269, P827, DOI 10.1006/jmbi.1997.1089	49	35	35	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					49663	49666		10.1074/jbc.R300033200	http://dx.doi.org/10.1074/jbc.R300033200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	14563836	hybrid			2022-12-27	WOS:000187068200002
J	Di Sole, F; Cerull, R; Babich, V; Quinones, H; Gisler, SM; Biber, J; Murer, H; Burckhardt, G; Helmle-Kolb, C; Moe, OW				Di Sole, F; Cerull, R; Babich, V; Quinones, H; Gisler, SM; Biber, J; Murer, H; Burckhardt, G; Helmle-Kolb, C; Moe, OW			Acute regulation of Na/H exchanger NHE3 by adenosine A(1) receptors is mediated by calcineurin homologous protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BORDER NA+/H+ EXCHANGER; PARATHYROID-HORMONE; ACUTE INHIBITION; CA2+-DEPENDENT INHIBITION; CA2+-BINDING PROTEIN; PROXIMAL TUBULE; APICAL MEMBRANE; CELL-DEATH; KINASE-A; KIDNEY	Adenosine is an autacoid that regulates renal Na+ transport. Activation of adenosine A(1) receptor (A(1)R) by N-6-cyclopentidyladenosine (CPA) inhibits the Na+/H+ exchanger 3 (NHE3) via phospholipase C/Ca2+/protein kinase C (PKC) signaling pathway. Mutation of PKC phosphorylation sites on NHE3 does not affected regulation of NHE3 by CPA, but amino acid residues 462 and 552 are essential for A(1)R-dependent control of NHE3 activity. One binding partner of the NHE family is calcineurin homologous protein (CHP). We tested the role of NHE3-CHP interaction in mediating CPA-induced inhibition of NHE3 in opossum kidney (OK) and Xenopus laevis uroepithelial (A6) cells. Both native and transfected NHE3 and CHP are present in the same immunocomplex by co-immunoprecipitation. CPA (10(-6) M) increases CHP-NHE3 interaction by 30-60% (native and transfected proteins). Direct CHP-NHE3 interaction is evident by yeast two-hybrid assay (bait, NHE3(C terminus); prey, CHP); the minimal interacting region is localized to the juxtamembrane region of NHE3(C terminus) (amino acids 462-552 of opossum NHE3). The yeast data were confirmed in OK cells where truncated NHE3 (NHE3(Delta552)) still shows CPA-stimulated CHP interaction. Overexpression of the polypeptide from the CHP binding region (NHE3(462-552)) interferes with the ability of CPA to inhibit NHE3 activity and to increase CHP-NHE3(Full-length) interaction. Reduction of native CHP expression by small interference RNA abolishes the ability of CPA to inhibit NHE3 activity. We conclude that CHP-NHE3 interaction is regulated by A(1)R activation and this interaction is a necessary and integral part of the signaling pathway between adenosine and NHE3.	Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Ctr Mineral Metab & Clin Res, Dallas, TX 75390 USA; Vet Affairs Med Ctr, Med Serv, Dallas, TX 75216 USA; Univ Gottingen, Dept Physiol & Pathophysiol, D-37073 Gottingen, Germany; Univ Zurich, Inst Physiol, CH-8057 Zurich, Switzerland	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Gottingen; University of Zurich	Di Sole, F (corresponding author), Univ Texas, SW Med Ctr, Dept Internal Med, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	Francesca.DiSole@UTsouthwestern.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048482, T32DK007257] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01-DK-54392, T32 DK07257-2031, R01-DK-48482] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; AMEMIYA M, 1995, KIDNEY INT, V48, P1206, DOI 10.1038/ki.1995.404; Barroso MR, 1996, J BIOL CHEM, V271, P10183, DOI 10.1074/jbc.271.17.10183; BIEMESDERFER D, 1993, AM J PHYSIOL, V265, pF736, DOI 10.1152/ajprenal.1993.265.5.F736; BLOND DM, 1964, BIOCHEM J, V92, P158, DOI 10.1042/bj0920158; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; Burckhardt G, 2002, J NEPHROL, V15, pS3; Casavola V, 1997, MOL PHARMACOL, V51, P516; Choi JY, 2000, J CLIN INVEST, V105, P1141, DOI 10.1172/JCI9260; Chow CW, 1999, J BIOL CHEM, V274, P37551, DOI 10.1074/jbc.274.53.37551; COLE NB, 1995, CURR OPIN CELL BIOL, V7, P55, DOI 10.1016/0955-0674(95)80045-X; Collazo R, 2000, J BIOL CHEM, V275, P31601, DOI 10.1074/jbc.M000600200; Counillon L, 2000, J BIOL CHEM, V275, P1, DOI 10.1074/jbc.275.1.1; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; Di Sole F, 2003, J AM SOC NEPHROL, V14, P1720, DOI 10.1097/01.ASN.0000072743.97583.DB; Di Sole F, 2002, J PHYSIOL-LONDON, V541, P529, DOI 10.1113/jphysiol.2001.013438; Di Sole F, 1999, J PHYSIOL-LONDON, V515, P829, DOI 10.1111/j.1469-7793.1999.829ab.x; DINOUR D, 1993, EXP NEPHROL, V1, P152; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fan LZ, 1999, J BIOL CHEM, V274, P11289, DOI 10.1074/jbc.274.16.11289; Gietz RD, 1995, METHOD MOL CELL BIOL, V5, P255; Gisler SM, 2001, J BIOL CHEM, V276, P9206, DOI 10.1074/jbc.M008745200; Goyal S, 2003, AM J PHYSIOL-RENAL, V284, pF467, DOI 10.1152/ajprenal.00352.2002; Gundersen GG, 1999, CURR OPIN CELL BIOL, V11, P81, DOI 10.1016/S0955-0674(99)80010-6; HELMLEKOLB C, 1990, PFLUG ARCH EUR J PHY, V415, P461, DOI 10.1007/BF00373624; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; Hu MC, 2001, J BIOL CHEM, V276, P26906, DOI 10.1074/jbc.M011338200; Inoue H, 2003, BIOL PHARM BULL, V26, P148, DOI 10.1248/bpb.26.148; INOUE H, 1990, GENE, V96, P23, DOI 10.1016/0378-1119(90)90336-P; Jackson EK, 2002, AM J PHYSIOL-RENAL, V283, pF41, DOI 10.1152/ajprenal.00232.2001; Jackson EK, 2001, AM J PHYSIOL-RENAL, V281, pF597, DOI 10.1152/ajprenal.2001.281.4.F597; Kaiser SM, 1999, DRUG DISCOV TODAY, V4, P542, DOI 10.1016/S1359-6446(99)01421-X; KIIL F, 1980, INT J BIOCHEM, V12, P245, DOI 10.1016/0020-711X(80)90079-8; Kim JH, 2002, J BIOL CHEM, V277, P23714, DOI 10.1074/jbc.M200835200; KRAYERPAWLOWSKA D, 1991, J MEMBRANE BIOL, V120, P173, DOI 10.1007/BF01872400; Kurashima K, 1999, J BIOL CHEM, V274, P29843, DOI 10.1074/jbc.274.42.29843; Kurashima K, 1997, J BIOL CHEM, V272, P28672, DOI 10.1074/jbc.272.45.28672; Lee-Kwon W, 2003, AM J PHYSIOL-CELL PH, V285, pC1527, DOI 10.1152/ajpcell.00017.2003; Lin X, 1996, P NATL ACAD SCI USA, V93, P12631, DOI 10.1073/pnas.93.22.12631; Lin X, 1999, J BIOL CHEM, V274, P36125, DOI 10.1074/jbc.274.51.36125; Lorenz JN, 1999, AM J PHYSIOL-RENAL, V277, pF447, DOI 10.1152/ajprenal.1999.277.3.F447; Matsumoto M, 2001, J BIOCHEM, V130, P217, DOI 10.1093/oxfordjournals.jbchem.a002975; Meyer T, 1999, NAT CELL BIOL, V1, pE93, DOI 10.1038/12090; Minkoff C, 1999, CURR OPIN NEPHROL HY, V8, P603, DOI 10.1097/00041552-199909000-00012; Moe OW, 1999, J AM SOC NEPHROL, V10, P2412; Nakamura N, 2002, J BIOCHEM, V132, P483, DOI 10.1093/oxfordjournals.jbchem.a003246; Numata M, 1998, J BIOL CHEM, V273, P6951, DOI 10.1074/jbc.273.12.6951; Okusa MD, 2002, AM J PHYSIOL-RENAL, V282, pF10, DOI 10.1152/ajprenal.2002.282.1.F10; Orlowski J, 1997, J BIOL CHEM, V272, P22373, DOI 10.1074/jbc.272.36.22373; OSTENSEN J, 1989, ACTA PHYSIOL SCAND, V137, P189, DOI 10.1111/j.1748-1716.1989.tb08738.x; Pang TX, 2002, J BIOL CHEM, V277, P43771, DOI 10.1074/jbc.M208313200; Pang TX, 2001, J BIOL CHEM, V276, P17367, DOI 10.1074/jbc.M100296200; Peng Y, 2001, AM J PHYSIOL-RENAL, V280, pF34, DOI 10.1152/ajprenal.2001.280.1.F34; Poulsen SA, 1998, BIOORGAN MED CHEM, V6, P619, DOI 10.1016/S0968-0896(98)00038-8; PRESTON AS, 1988, AM J PHYSIOL, V255, pC661, DOI 10.1152/ajpcell.1988.255.5.C661; Rose MD., 1990, METHODS YEAST GENETI; SPIELMAN WS, 1991, HYPERTENSION, V17, P117, DOI 10.1161/01.HYP.17.2.117; Timm S, 1999, MOL BIOL CELL, V10, P3473, DOI 10.1091/mbc.10.10.3473; ULLRICH SJ, 1986, P NATL ACAD SCI USA, V83, P3121, DOI 10.1073/pnas.83.10.3121; VERREY F, 1994, J MEMBRANE BIOL, V138, P65; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Wakabayashi S, 1997, PHYSIOL REV, V77, P51, DOI 10.1152/physrev.1997.77.1.51; Wang T, 2001, AM J PHYSIOL-RENAL, V281, pF1117, DOI 10.1152/ajprenal.2001.281.6.F1117; Welch WJ, 2002, CURR OPIN PHARMACOL, V2, P165, DOI 10.1016/S1471-4892(02)00134-0; Wiederkehr MR, 2001, KIDNEY INT, V59, P197, DOI 10.1046/j.1523-1755.2001.00480.x; Wiederkehr MR, 1999, AM J PHYSIOL-CELL PH, V276, pC1205, DOI 10.1152/ajpcell.1999.276.5.C1205; Wu MS, 1996, J BIOL CHEM, V271, P32749, DOI 10.1074/jbc.271.51.32749; Yip JW, 1997, J BIOL CHEM, V272, P18473, DOI 10.1074/jbc.272.29.18473; Yun CHC, 1997, P NATL ACAD SCI USA, V94, P3010, DOI 10.1073/pnas.94.7.3010; Yun CHC, 1998, J BIOL CHEM, V273, P25856, DOI 10.1074/jbc.273.40.25856; Zhao H, 1999, J BIOL CHEM, V274, P3978, DOI 10.1074/jbc.274.7.3978	71	38	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	2004	279	4					2962	2974		10.1074/jbc.M306838200	http://dx.doi.org/10.1074/jbc.M306838200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	764MU	14570899	hybrid, Green Accepted			2022-12-27	WOS:000188211300077
J	Zeng, GF; Pypaert, M; Slayman, CL				Zeng, GF; Pypaert, M; Slayman, CL			Epitope tagging of the yeast K+ carrier TRK2p demonstrates folding that is consistent with a channel-like structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFFINITY POTASSIUM UPTAKE; XENOPUS-LAEVIS OOCYTES; ALKALI METAL CATIONS; SACCHAROMYCES-CEREVISIAE; ENDOPLASMIC-RETICULUM; ESCHERICHIA-COLI; CELL-SURFACE; CHEMICAL CHAPERONES; LACTOSE PERMEASE; TRANSPORTER HKT1	TRK family proteins, which mediate the concentrative uptake of potassium by plant cells, fungi, and bacteria, resemble primitive potassium channels in sequence and have recently been proposed actually to fold like potassium channels in a 4-MPM motif (Durell, S. R., and Guy, H. R. (1999) Biophys. J. 77, 789-807), instead of like conventional substrate porters in the 12-TM motif (Gaber, R. F., Styles, C. A., and Fink, G. R. ( 1988) Mol. Cell. Biol. 8, 2848 - 2859). The known fungal members of this family possess a very long hydrophilic loop, positioned intracellularly in the K+-channel model and extracellularly in the substrate porter model. This and two shorter hydrophilic segments have been tested as topological markers for the true folding pattern of TRK proteins using Saccharomyces cerevisiae Trk2p. Hemagglutinin epitope tags were inserted into all three segments, and the enhanced green fluorescent protein (EGFP) was fused to the C terminus of Trk2p. The gene constructs were expressed from a high copy plasmid, and sidedness of the tags was determined by native fluorescence (EGFP), indirect immunofluorescence, and immunoelectron microscopy. Both the long-loop tag and the C-terminal EGFP fusion allowed abundant protein to reach the plasma membrane and support normal yeast growth. In all determinations, the long-loop tag was localized to the inner surface of the yeast cell plasma membrane, thus strongly supporting the channel-like folding model. Additional observations showed (i) membrane-associated Trk2p to lie in proteolipid rafts; (ii) significant tagged protein, expressed from the plasmid, to be sequestered in cytoplasmic vesicular-tubular clusters; and (iii) suppression of such clusters by yeast growth in 5-10% glycerol. This chaperone-like effect may assist other membrane proteins (overexpressed or heterologously expressed) to function within the yeast plasma membrane.	Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Ctr Cell & Mol Imaging, New Haven, CT 06520 USA	Yale University; Yale University	Slayman, CL (corresponding author), Yale Univ, Sch Med, Dept Cellular & Mol Physiol, 333 Cedar St, New Haven, CT 06520 USA.	clifford.slayman@yale.edu		Slayman, Clifford/0000-0002-3029-2054	NIGMS NIH HHS [GM-60696] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060696] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abramson J, 2003, SCIENCE, V301, P610, DOI 10.1126/science.1088196; ALTENDORF K, 1992, ANN NY ACAD SCI, V671, P228, DOI 10.1111/j.1749-6632.1992.tb43799.x; ARMSTRONG WM, 1967, J GEN PHYSIOL, V50, P967, DOI 10.1085/jgp.50.4.967; ARMSTRONG WM, 1964, J GEN PHYSIOL, V48, P61, DOI 10.1085/jgp.48.1.61; Arriza JL, 1997, P NATL ACAD SCI USA, V94, P4155, DOI 10.1073/pnas.94.8.4155; Artigas P, 2003, P NATL ACAD SCI USA, V100, P501, DOI 10.1073/pnas.0135849100; Bagnat M, 2000, P NATL ACAD SCI USA, V97, P3254, DOI 10.1073/pnas.060034697; Bagnat M, 2002, P NATL ACAD SCI USA, V99, P14183, DOI 10.1073/pnas.172517799; BALCH WE, 1994, CELL, V76, P841, DOI 10.1016/0092-8674(94)90359-X; Bannykh SI, 1996, J CELL BIOL, V135, P19, DOI 10.1083/jcb.135.1.19; Bednarek SY, 1995, CELL, V83, P1183, DOI 10.1016/0092-8674(95)90144-2; BIEMANS R, 1992, DNA CELL BIOL, V11, P621, DOI 10.1089/dna.1992.11.621; Bihler H, 2002, BBA-BIOMEMBRANES, V1558, P109, DOI 10.1016/S0005-2736(01)00414-X; BLATT MR, 1987, J MEMBRANE BIOL, V98, P169, DOI 10.1007/BF01872129; BLATT MR, 1987, P NATL ACAD SCI USA, V84, P2737, DOI 10.1073/pnas.84.9.2737; BONE Q, 1971, J CELL BIOL, V49, P571, DOI 10.1083/jcb.49.3.571; BORSTPAUWELS GWFH, 1981, BIOCHIM BIOPHYS ACTA, V650, P88, DOI 10.1016/0304-4157(81)90002-2; Bourot S, 2000, J BIOL CHEM, V275, P1050, DOI 10.1074/jbc.275.2.1050; Boyd J, 2003, J MEMBRANE BIOL, V195, P109, DOI 10.1007/s00232-003-2049-1; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Cheong KH, 1999, P NATL ACAD SCI USA, V96, P6241, DOI 10.1073/pnas.96.11.6241; DERKS WJG, 1980, BIOCHIM BIOPHYS ACTA, V596, P381, DOI 10.1016/0005-2736(80)90125-X; Diamant S, 2001, J BIOL CHEM, V276, P39586, DOI 10.1074/jbc.M103081200; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Durell SR, 2000, BIOPHYS J, V78, P188, DOI 10.1016/S0006-3495(00)76584-2; Durell SR, 1999, BIOPHYS J, V77, P775, DOI 10.1016/S0006-3495(99)76931-6; Durell SR, 1999, BIOPHYS J, V77, P789, DOI 10.1016/S0006-3495(99)76932-8; DURELL SR, 1998, 11 INT WORKSH PLANT; Ferreira T, 2002, J BIOL CHEM, V277, P21027, DOI 10.1074/jbc.M112281200; Figler RA, 2000, ARCH BIOCHEM BIOPHYS, V376, P34, DOI 10.1006/abbi.2000.1712; GABER RF, 1988, MOL CELL BIOL, V8, P2848, DOI 10.1128/MCB.8.7.2848; Garnier C, 1996, MOL MICROBIOL, V21, P1061, DOI 10.1046/j.1365-2958.1996.621430.x; GONG X, 2001, P NATL ACAD SCI USA, V98, P9401; GRIFFITHS G, 1993, FINE STRUCTURE IMMUN; Grunewald M, 2000, J BIOL CHEM, V275, P9684, DOI 10.1074/jbc.275.13.9684; HANSEN UP, 1983, J MEMBRANE BIOL, V75, P141, DOI 10.1007/BF01995634; Harder T, 1998, J CELL BIOL, V141, P929, DOI 10.1083/jcb.141.4.929; Haro R, 2003, BBA-BIOMEMBRANES, V1613, P1, DOI 10.1016/S0005-2736(03)00132-9; Haro R, 2002, BBA-BIOMEMBRANES, V1564, P114, DOI 10.1016/S0005-2736(02)00408-X; HEDRICH R, 1989, ANNU REV PLANT PHYS, V40, P539, DOI 10.1146/annurev.pp.40.060189.002543; Huang YF, 2003, SCIENCE, V301, P616, DOI 10.1126/science.1087619; Jan LY, 1997, ANNU REV NEUROSCI, V20, P91, DOI 10.1146/annurev.neuro.20.1.91; JARDETZK.O, 1966, NATURE, V211, P969, DOI 10.1038/211969a0; Kaback HR, 1997, P NATL ACAD SCI USA, V94, P5539, DOI 10.1073/pnas.94.11.5539; Kato Y, 2001, P NATL ACAD SCI USA, V98, P6488, DOI 10.1073/pnas.101556598; Kettner C, 2003, BIOPHYS J, V85, P3730, DOI 10.1016/S0006-3495(03)74789-4; KO CH, 1991, MOL CELL BIOL, V11, P4266, DOI 10.1128/MCB.11.8.4266; LAUGER P, 1980, J MEMBRANE BIOL, V57, P163, DOI 10.1007/BF01869585; Liu WH, 2000, J BIOL CHEM, V275, P27924; Maathuis FJM, 1996, PHYSIOL PLANTARUM, V96, P158, DOI 10.1111/j.1399-3054.1996.tb00197.x; Maser P, 2002, P NATL ACAD SCI USA, V99, P6428, DOI 10.1073/pnas.082123799; MCCULLOCH SR, 1990, J MEMBRANE BIOL, V115, P129, DOI 10.1007/BF01869452; ORCI L, 1994, P NATL ACAD SCI USA, V91, P11924, DOI 10.1073/pnas.91.25.11924; RODRIGUEZNAVARRO A, 1986, J GEN PHYSIOL, V87, P649, DOI 10.1085/jgp.87.5.649; RUBIO F, 1995, SCIENCE, V270, P1660, DOI 10.1126/science.270.5242.1660; SCHACHTMAN DP, 1994, NATURE, V370, P655, DOI 10.1038/370655a0; SENTENAC H, 1992, SCIENCE, V256, P663, DOI 10.1126/science.1585180; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Singer MA, 1998, MOL CELL, V1, P639, DOI 10.1016/S1097-2765(00)80064-7; SLAYMAN CL, 1987, J BIOENERG BIOMEMBR, V19, P1; SLAYMAN CL, 1985, BIOCHEM SOC SYMP, P11; Slotboom DJ, 1999, P NATL ACAD SCI USA, V96, P14282, DOI 10.1073/pnas.96.25.14282; SMITH FA, 1989, J MEMBRANE BIOL, V108, P125, DOI 10.1007/BF01871024; STUMPE G, 1996, TRANSPORT PROCESSES, P473; Tholema N, 1999, FEBS LETT, V450, P217, DOI 10.1016/S0014-5793(99)00504-9; Uozumi N, 2000, PLANT PHYSIOL, V122, P1249, DOI 10.1104/pp.122.4.1249; VILLALBA JM, 1992, J BIOL CHEM, V267, P12341; WADLICHE JI, 1995, NEURON, V15, P721; Weber WM, 1999, BBA-BIOMEMBRANES, V1421, P213, DOI 10.1016/S0005-2736(99)00135-2; WRIGHT R, 1988, J CELL BIOL, V107, P101, DOI 10.1083/jcb.107.1.101	71	28	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	2004	279	4					3003	3013		10.1074/jbc.M309760200	http://dx.doi.org/10.1074/jbc.M309760200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	764MU	14570869	hybrid			2022-12-27	WOS:000188211300081
J	Garrity, JD; Carenbauer, AL; Herron, LR; Crowder, MW				Garrity, JD; Carenbauer, AL; Herron, LR; Crowder, MW			Metal binding Asp-120 in metallo-beta-lactamase L1 from Stenotrophomonas maltophilia plays a crucial role in catalysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRAM-NEGATIVE BACTERIA; ACTIVE-SITE SERINE; BACTEROIDES-FRAGILIS; CRYSTAL-STRUCTURE; PSEUDOMONAS-MALTOPHILIA; SEQUENCE-ANALYSIS; SOLVENT ISOTOPE; MECHANISM; INHIBITION; PURIFICATION	Metallo-beta-lactamase L1 from Stenotrophomonas maltophilia is a dinuclear Zn(II) enzyme that contains a metal-binding aspartic acid in a position to potentially play an important role in catalysis. The presence of this metal-binding aspartic acid appears to be common to most dinuclear, metal-containing, hydrolytic enzymes; particularly those with a beta-lactamase fold. In an effort to probe the catalytic and metal-binding role of Asp-120 in L1, three site-directed mutants (D120C, D120N, and D120S) were prepared and characterized using metal analyses, circular dichroism spectroscopy, and pre-steady-state and steady-state kinetics. The D120C, D120N, and D120S mutants were shown to bind 1.6+/-0.2, 1.8+/-0.2, and 1.1+/-0.2 mol of Zn(II) per monomer, respectively. The mutants exhibited 10- to 1000-fold drops in k(cat) values as compared with wild-type L1, and a general trend of activity, wild-type>D120N>D120C and D120S, was observed for all substrates tested. Solvent isotope and pH dependence studies indicate one or more protons in flight, with pK(a) values outside the range of pH 5-10 (except D120N), during a rate-limiting step for all the enzymes. These data demonstrate that Asp-120 is crucial for L1 to bind its full complement of Zn( II) and subsequently for proper substrate binding to the enzyme. This work also confirms that Asp-120 plays a significant role in catalysis, presumably via hydrogen bonding with water, assisting in formation of the bridging hydroxide/water, and a rate-limiting proton transfer in the hydrolysis reaction.	Miami Univ, Dept Chem & Biochem, Oxford, OH 45056 USA	Miami University	Crowder, MW (corresponding author), Miami Univ, Dept Chem & Biochem, 112 Hughes Hall, Oxford, OH 45056 USA.	crowdemw@muohio.edu	Herron, Lissa/C-7780-2013	Herron, Lissa/0000-0001-9961-4421	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI040052] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R15GM040052] Funding Source: NIH RePORTER; NIAID NIH HHS [AI40052] Funding Source: Medline; NIGMS NIH HHS [GM40052] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arakawa Y, 2000, J CLIN MICROBIOL, V38, P40; Auld DS, 1997, STRUCT BOND, V89, P29; Bernstein NJ, 1999, BIOCHEMISTRY-US, V38, P10499, DOI 10.1021/bi990428e; Bertini I., 1994, BIOINORG CHEM, P37; Bienvenue DL, 2002, J BIOL INORG CHEM, V7, P129, DOI 10.1007/s007750100280; Bounaga S, 2001, BIOORGAN MED CHEM, V9, P503, DOI 10.1016/S0968-0896(00)00257-1; Bounaga S, 1998, BIOCHEM J, V331, P703, DOI 10.1042/bj3310703; Bush K, 1998, ADV EXP MED BIOL, V456, P71; Bush K, 1998, CLIN INFECT DIS, V27, pS48, DOI 10.1086/514922; BUSH K, 1995, ANTIMICROB AGENTS CH, V39, P1211, DOI 10.1128/AAC.39.6.1211; Bush K, 2001, CLIN INFECT DIS, V32, P1085, DOI 10.1086/319610; Carenbauer AL, 2002, BMC BIOCHEM, V3; Carfi A, 1997, ACTA CRYSTALLOGR D, V53, P485, DOI 10.1107/S0907444997000966; Caselli E, 2000, CHEM BIOL, V49, P1; Concha NO, 1996, STRUCTURE, V4, P823, DOI 10.1016/S0969-2126(96)00089-5; Crowder MW, 1998, ANTIMICROB AGENTS CH, V42, P921, DOI 10.1128/AAC.42.4.921; Crowder MW, 2001, J BIOL INORG CHEM, V6, P91, DOI 10.1007/s007750000173; Crowder MW, 1999, RRD ANTIMICROB AG  1, V3, P105; Daiyasu H, 2001, FEBS LETT, V503, P1, DOI 10.1016/S0014-5793(01)02686-2; Diaz N, 2000, J AM CHEM SOC, V122, P4197, DOI 10.1021/ja994462s; Eberhardt C, 2003, J BACTERIOL, V185, P3726, DOI 10.1128/JB.185.13.3726-3734.2003; FELICI A, 1995, ANTIMICROB AGENTS CH, V39, P1300, DOI 10.1128/AAC.39.6.1300; Galleni M, 2001, ANTIMICROB AGENTS CH, V45, P660, DOI 10.1128/AAC.45.3.660-663.2001; Hammond GG, 1999, FEMS MICROBIOL LETT, V179, P289, DOI 10.1111/j.1574-6968.1999.tb08740.x; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; KHARDORI N, 1990, REV INFECT DIS, V12, P997; Knox JR, 1996, CHEM BIOL, V3, P937, DOI 10.1016/S1074-5521(96)90182-9; Kotra Lakshmi P., 1999, Archivum Immunologiae et Therapiae Experimentalis, V47, P211; Lee NLS, 2001, JAMA-J AM MED ASSOC, V285, P386, DOI 10.1001/jama.285.4.386; Levy SB, 1998, SCI AM, V278, P46, DOI 10.1038/scientificamerican0398-46; Liu CL, 2002, J INORG BIOCHEM, V88, P77, DOI 10.1016/S0162-0134(01)00337-3; MARTIN BL, 1994, BBA-PROTEIN STRUCT M, V1206, P136, DOI 10.1016/0167-4838(94)90082-5; McManus-Munoz S, 1999, BIOCHEMISTRY-US, V38, P1547, DOI 10.1021/bi9826512; METT H, 1988, REV INFECT DIS, V10, P765; MUDER RR, 1987, ARCH INTERN MED, V147, P1672, DOI 10.1001/archinte.147.9.1672; Nagano R, 1999, ANTIMICROB AGENTS CH, V43, P2497, DOI 10.1128/AAC.43.10.2497; NEU HC, 1992, SCIENCE, V257, P1064, DOI 10.1126/science.257.5073.1064; Olsen L, 2003, J PHYS CHEM B, V107, P2366, DOI 10.1021/jp0275950; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; PAYNE DJ, 1993, J MED MICROBIOL, V39, P93, DOI 10.1099/00222615-39-2-93; Payne DJ, 1997, FEMS MICROBIOL LETT, V157, P171, DOI 10.1016/S0378-1097(97)00472-2; Payne DJ, 1997, ANTIMICROB AGENTS CH, V41, P135, DOI 10.1128/AAC.41.1.135; Prosperi-Meys C, 1999, FEBS LETT, V443, P109, DOI 10.1016/S0014-5793(98)01689-5; Rice LB, 2000, DRUG RESIST UPDATE, V3, P178, DOI 10.1054/drup.2000.0144; Salsbury FR, 2001, PROTEINS, V44, P448, DOI 10.1002/prot.1110; SCHOWEN KB, 1982, METHOD ENZYMOL, V87, P551; Siemann S, 2002, ANTIMICROB AGENTS CH, V46, P2450, DOI 10.1128/AAC.46.8.2450-2457.2002; Spencer J, 2001, J BIOL CHEM, V276, P33638, DOI 10.1074/jbc.M105550200; Strater N, 1996, ANGEW CHEM INT EDIT, V35, P2024, DOI 10.1002/anie.199620241; STRATER N, 1995, SCIENCE, V268, P1489, DOI 10.1126/science.7770774; Suarez D, 2001, J AM CHEM SOC, V123, P3759, DOI 10.1021/ja003796a; Therrien C, 2000, FEMS MICROBIOL REV, V24, P251, DOI 10.1111/j.1574-6976.2000.tb00541.x; Toney JH, 2001, J BIOL CHEM, V276, P31913, DOI 10.1074/jbc.M104742200; Toney JH, 1999, BIOORG MED CHEM LETT, V9, P2741, DOI 10.1016/S0960-894X(99)00458-8; Ullah JH, 1998, J MOL BIOL, V284, P125, DOI 10.1006/jmbi.1998.2148; Uppenberg J, 1999, J MOL BIOL, V290, P201, DOI 10.1006/jmbi.1999.2896; VENKATASUBBAN KS, 1984, CRC CR REV BIOCH MOL, V17, P1, DOI 10.3109/10409238409110268; VILLARINO ME, 1992, INFECT CONT HOSP EP, V13, P201, DOI 10.1086/646510; WALSH TR, 1994, BBA-GENE STRUCT EXPR, V1218, P199, DOI 10.1016/0167-4781(94)90011-6; Walsh TR, 1997, ANTIMICROB AGENTS CH, V41, P1460, DOI 10.1128/AAC.41.7.1460; Walter MW, 1999, BIOORG CHEM, V27, P35, DOI 10.1006/bioo.1998.1111; Wang ZG, 1998, J AM CHEM SOC, V120, P10788, DOI 10.1021/ja982621m; Wang ZG, 1999, BIOCHEMISTRY-US, V38, P10013, DOI 10.1021/bi990356r; Wang ZG, 1998, J BIOL CHEM, V273, P22402, DOI 10.1074/jbc.273.35.22402; Wang ZG, 1999, CURR OPIN CHEM BIOL, V3, P614, DOI 10.1016/S1367-5931(99)00017-4; Williams NH, 1999, J AM CHEM SOC, V121, P3341, DOI 10.1021/ja9827797; Williamson B, 1999, J DIGIT IMAGING, V12, P1, DOI 10.1007/BF03168740; Wommer S, 2002, J BIOL CHEM, V277, P24142, DOI 10.1074/jbc.M202467200; Yanchak MP, 2000, BIOCHEMISTRY-US, V39, P11330, DOI 10.1021/bi0010524; Yang KW, 1999, ARCH BIOCHEM BIOPHYS, V368, P1, DOI 10.1006/abbi.1999.1293	70	60	62	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 9	2004	279	2					920	927		10.1074/jbc.M309852200	http://dx.doi.org/10.1074/jbc.M309852200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	759DJ	14573595	hybrid			2022-12-27	WOS:000187722800014
J	Iwano, T; Tachibana, M; Reth, M; Shinkai, Y				Iwano, T; Tachibana, M; Reth, M; Shinkai, Y			Importance of TRF1 for functional telomere structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN; LENGTH; MOUSE; END; REGULATOR; BINDING	Telomeres are comprised of telomeric DNA sequences and associated binding molecules. Their structure functions to protect the ends of linear chromosomes and ensure chromosomal stability. One of the mammalian telomere-binding factors, TRF1, localizes telomeres by binding to double-stranded telomeric DNA arrays. Because the overexpression of wild-type and dominant-negative TRF1 induces progressive telomere shortening and elongation in human cells, respectively, a proposed major role of TRF1 is that of a negative regulator of telomere length. Here we report another crucial function of TRF1 in telomeres. In conditional mouse TRF1 null mutant embryonic stem cells, TRF1 deletion induced growth defect and chromosomal instability. Although no clear telomere shortening or elongation was observed in short term cultured TRF1-deficient cells, abnormal telomere signals were observed, and TRF1-interacting telomere-binding factor, TIN2, lost telomeric association. Furthermore, another double-stranded telomeric DNA-binding factor, TRF2, also showed decreased telomeric association. Importantly, end-to-end fusions with detectable telomere signals at fusion points accumulated in TRF1-deficient cells. These results strongly suggest that TRF1 interacts with other telomere-binding molecules and integrates into the functional telomere structure.	Kyoto Univ, Expt Res Ctr Infect Dis, Inst Virus Res, Kyoto 6068507, Japan; Kyoto Univ, Dept Mol & Cellular Biol, Grad Sch Biostudies, Kyoto 6068507, Japan; Univ Freiburg, Dept Mol Immunol, D-79108 Freiburg, Germany; Max Planck Inst Immunobiol, D-79108 Freiburg, Germany	Kyoto University; Kyoto University; University of Freiburg; Max Planck Society	Shinkai, Y (corresponding author), Kyoto Univ, Expt Res Ctr Infect Dis, Inst Virus Res, Kawara Cho, Kyoto 6068507, Japan.	yshinkai@virus.kyoto-u.ac.jp	Shinkai, Yoichi/N-3909-2014	Shinkai, Yoichi/0000-0002-6051-2484				Baumann P, 2001, SCIENCE, V292, P1171, DOI 10.1126/science.1060036; Bianchi A, 1997, EMBO J, V16, P1785, DOI 10.1093/emboj/16.7.1785; Blackburn EH, 2000, NATURE, V408, P53, DOI 10.1038/35040500; Blackburn EH, 2001, CELL, V106, P661, DOI 10.1016/S0092-8674(01)00492-5; Broccoli D, 1997, HUM MOL GENET, V6, P69, DOI 10.1093/hmg/6.1.69; Broccoli D, 1997, NAT GENET, V17, P231, DOI 10.1038/ng1097-231; CHONG L, 1995, SCIENCE, V270, P1663, DOI 10.1126/science.270.5242.1663; Cook BD, 2002, MOL CELL BIOL, V22, P332, DOI 10.1128/MCB.22.1.332-342.2002; DELANGE T, 1995, TELOMERES, P265; Griffith J, 1998, J MOL BIOL, V278, P79, DOI 10.1006/jmbi.1998.1686; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; HARLEY CB, 1995, TELOMERES, P247; Hsu HL, 2000, GENE DEV, V14, P2807, DOI 10.1101/gad.844000; KANEGAE Y, 1995, NUCLEIC ACIDS RES, V23, P3816, DOI 10.1093/nar/23.19.3816; Karlseder J, 1999, SCIENCE, V283, P1321, DOI 10.1126/science.283.5406.1321; Karlseder J, 2003, MOL CELL BIOL, V23, P6533, DOI 10.1128/MCB.23.18.6533-6541.2003; Karlseder J, 2002, SCIENCE, V295, P2446, DOI 10.1126/science.1069523; Kim SH, 1999, NAT GENET, V23, P405, DOI 10.1038/70508; Loayza D, 2003, NATURE, V423, P1013, DOI 10.1038/nature01688; Masutomi K, 2003, CELL, V114, P241, DOI 10.1016/S0092-8674(03)00550-6; McClintock B, 1941, GENETICS, V26, P234; MULLER HJ, 1938, COLLECTING NET, V13, P183; OLOVNIKOV AM, 1973, J THEOR BIOL, V41, P181, DOI 10.1016/0022-5193(73)90198-7; Smith S, 2000, CURR BIOL, V10, P1299, DOI 10.1016/S0960-9822(00)00752-1; Smogorzewska A, 2000, MOL CELL BIOL, V20, P1659, DOI 10.1128/MCB.20.5.1659-1668.2000; Smogorzewska A, 2002, EMBO J, V21, P4338, DOI 10.1093/emboj/cdf433; Stansel RM, 2001, EMBO J, V20, P5532; Stewart SA, 2003, NAT GENET, V33, P492, DOI 10.1038/ng1127; Tachibana M, 2002, GENE DEV, V16, P1779, DOI 10.1101/gad.989402; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; vanSteensel B, 1997, NATURE, V385, P740, DOI 10.1038/385740a0; Zhang Y, 1996, NUCLEIC ACIDS RES, V24, P543, DOI 10.1093/nar/24.4.543; Zhou XZ, 2001, CELL, V107, P347, DOI 10.1016/S0092-8674(01)00538-4; Zijlmans JMJM, 1997, P NATL ACAD SCI USA, V94, P7423, DOI 10.1073/pnas.94.14.7423	34	90	102	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 9	2004	279	2					1442	1448		10.1074/jbc.M309138200	http://dx.doi.org/10.1074/jbc.M309138200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	759DJ	14559908	hybrid			2022-12-27	WOS:000187722800074
J	Larsson, SL; Skogsberg, J; Bjorkegren, J				Larsson, SL; Skogsberg, J; Bjorkegren, J			The low density lipoprotein receptor prevents secretion of dense ApoB100-containing lipoproteins from the liver	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIGLYCERIDE TRANSFER PROTEIN; APOLIPOPROTEIN-B SECRETION; APO-B; ABETALIPOPROTEINEMIA GENE; EMBRYONIC LETHALITY; RICH LIPOPROTEINS; MCA-RH7777 CELLS; KNOCKOUT MICE; LDL RECEPTOR; CORE LIPIDS	The assembly and secretion of very low density lipoproteins (VLDL) require microsomal triglyceride transfer protein (MTP). Recent evidence also suggests a role for the low density lipoprotein (LDL) receptor in this process. However, the relative importance of MTP in the two steps of VLDL assembly and the specific role of the LDL receptor still remain unclear. To further investigate the role of MTP and the LDL receptor in VLDL assembly, we bred mice harboring "floxed" Mttp alleles (Mttp(flox/flox)) and a Cre transgene on a low-density lipoprotein receptor-deficient background to generate mice with double deficiency in the liver (Ldlr(-/-) Mttp(Delta/Delta)). In contrast to the plasma of Ldlr(+/+) Mttp(Delta/Delta) mice, the plasma of Ldlr(-/-) Mttp(Delta/Delta) mice contained apoB100. Accordingly, Ldlr(-/-) Mttp(Delta/Delta) but not Ldlr(+/+) Mttp(Delta/Delta) hepatocytes secreted apoB100-containing lipoprotein particles. The secreted lipoproteins were of LDL and HDL sizes but no VLDL-sized lipoproteins could be detected. These findings indicate that hepatic LDL receptors function as "gatekeepers" targeting dense apoB100-containing lipoproteins for degradation. In addition, these results suggest that very low levels of MTP are insufficient to mediate the second step but sufficient for the first step of VLDL assembly.	Karolinska Hosp, Karolinska Inst, King Gustaf V Res Inst, Atherosclerosis Res Unit, S-17176 Stockholm, Sweden	Karolinska Institutet; Karolinska University Hospital	Bjorkegren, J (corresponding author), Karolinska Hosp, Karolinska Inst, King Gustaf V Res Inst, Atherosclerosis Res Unit, S-17176 Stockholm, Sweden.							Bakillah A, 2000, BIOCHEMISTRY-US, V39, P4892, DOI 10.1021/bi9924009; Bjorkegren J, 2001, J BIOL CHEM, V276, P38511, DOI 10.1074/jbc.M106839200; Bradbury P, 1999, J BIOL CHEM, V274, P3159, DOI 10.1074/jbc.274.5.3159; Carlson K, 1973, J Clin Pathol Suppl (Assoc Clin Pathol), V5, P32; Chang BHJ, 1999, J BIOL CHEM, V274, P6051, DOI 10.1074/jbc.274.10.6051; ENDO A, 1992, J LIPID RES, V33, P1569; FARESE RV, 1995, P NATL ACAD SCI USA, V92, P1774, DOI 10.1073/pnas.92.5.1774; Gillian-Daniel DL, 2002, P NATL ACAD SCI USA, V99, P4337, DOI 10.1073/pnas.072557199; Gordon DA, 2000, BBA-MOL CELL BIOL L, V1486, P72, DOI 10.1016/S1388-1981(00)00049-4; GORDON DA, 1994, P NATL ACAD SCI USA, V91, P7628, DOI 10.1073/pnas.91.16.7628; Gordon DA, 1997, CURR OPIN LIPIDOL, V8, P131, DOI 10.1097/00041433-199706000-00002; Gordon DA, 1996, J BIOL CHEM, V271, P33047, DOI 10.1074/jbc.271.51.33047; Gregg Richard E., 1994, Current Opinion in Lipidology, V5, P81, DOI 10.1097/00041433-199404000-00003; HOEG JM, 1990, J LIPID RES, V31, P1761; Hussain MM, 1997, BIOCHEMISTRY-US, V36, P13060, DOI 10.1021/bi971395a; ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663; KARPE F, 1994, J LIPID RES, V35, P1311; Kim E, 1998, J CLIN INVEST, V101, P1468; Kulinski A, 2002, J BIOL CHEM, V277, P31516, DOI 10.1074/jbc.M202015200; LEIPER JM, 1994, J BIOL CHEM, V269, P21951; Leung GK, 2000, J BIOL CHEM, V275, P7515, DOI 10.1074/jbc.275.11.7515; Levy E, 2002, J BIOL CHEM, V277, P16470, DOI 10.1074/jbc.M102385200; Levy E, 1996, HEPATOLOGY, V23, P848, DOI 10.1002/hep.510230428; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MA PTS, 1986, P NATL ACAD SCI USA, V83, P8370, DOI 10.1073/pnas.83.21.8370; Marks DL, 1999, J BIOL CHEM, V274, P451, DOI 10.1074/jbc.274.1.451; Millar JS, 2002, ARTERIOSCL THROM VAS, V22, P989, DOI 10.1161/01.ATV.0000018304.30943.06; Pan MH, 2002, J BIOL CHEM, V277, P4413, DOI 10.1074/jbc.M107460200; Raabe M, 1999, J CLIN INVEST, V103, P1287, DOI 10.1172/JCI6576; Raabe M, 1998, P NATL ACAD SCI USA, V95, P8686, DOI 10.1073/pnas.95.15.8686; Rajewsky K, 1996, J CLIN INVEST, V98, P600, DOI 10.1172/JCI118828; Rustaeus S, 1998, J BIOL CHEM, V273, P5196, DOI 10.1074/jbc.273.9.5196; Schuster H, 2002, ATHEROSCLEROSIS SUPP, V2, P27, DOI 10.1016/S1567-5688(01)00019-8; Segrest JP, 1999, J LIPID RES, V40, P1401; Sellers JA, 2001, J LIPID RES, V42, P1897; Shelness GS, 2001, CURR OPIN LIPIDOL, V12, P151, DOI 10.1097/00041433-200104000-00008; Twisk J, 2000, J CLIN INVEST, V105, P521, DOI 10.1172/JCI8623; Veniant MM, 2000, J CLIN INVEST, V106, P1501, DOI 10.1172/JCI10695; Wang YW, 1999, J BIOL CHEM, V274, P27793, DOI 10.1074/jbc.274.39.27793; WILLIAMS KJ, 1990, J BIOL CHEM, V265, P16741	40	48	53	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 9	2004	279	2					831	836		10.1074/jbc.M303057200	http://dx.doi.org/10.1074/jbc.M303057200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	759DJ	14583618	hybrid			2022-12-27	WOS:000187722800004
J	Wang, H; Hill, K; Perry, SE				Wang, H; Hill, K; Perry, SE			An Arabidopsis RNA lariat debranching enzyme is essential for embryogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL NUCLEOLAR RNAS; EMBRYO DEVELOPMENT; LEAFY COTYLEDON1; CELL-DIVISION; GENE; SUSPENSOR; MUTANT; EXPRESSION; THALIANA; ENCODES	An embryo-defective mutant of Arabidopsis thaliana was isolated that arrests development at a variety of stages, from as early as the globular stage of embryogenesis to as late as formation of an abnormal bent cotyledon stage embryo. Defects in the suspensor, a normally transient structure derived from the fertilized egg, were often associated with the arrested embryo. The lesion was within a gene encoding a protein with domains characteristic of lariat debranching enzymes, which has been named AtDBR1 (for (A) under bar rabidopsis (t) under bar haliana (D) under bare (b) under bar ranching enzyme (1) under bar). Cleavage of the 2'-5'-phosphodiester bond found in excised intron lariats ("debranching") is essential for turnover of intronic sequences as well as generation of some small nucleolar RNAs. The mutation within AtDBR1 was confirmed by complementation as being responsible for the embryo-lethal phenotype, and the activity of the encoded protein in cleavage of 2'-5'-phosphodiester bonds was verified using an in vitro debranching assay.	Univ Kentucky, Dept Agron, Lexington, KY 40546 USA	University of Kentucky	Perry, SE (corresponding author), Univ Kentucky, Dept Agron, 1405 Vet Dr,307 Plant Sci Bldg, Lexington, KY 40546 USA.		Perry, Sharyn/M-9177-2013; Hill, Kristine/ABG-1386-2020	Perry, Sharyn/0000-0002-3011-8240; Hill, Kristine/0000-0002-3429-5818				Aoyama T, 1997, PLANT J, V11, P605, DOI 10.1046/j.1365-313X.1997.11030605.x; Aravind L, 1998, NUCLEIC ACIDS RES, V26, P3746, DOI 10.1093/nar/26.16.3746; Barneche F, 2000, J BIOL CHEM, V275, P27212; Brown JWS, 2003, TRENDS PLANT SCI, V8, P42, DOI 10.1016/S1360-1385(02)00007-9; Busch M, 1996, MOL GEN GENET, V250, P681, DOI 10.1007/BF02172979; CHAPMAN KB, 1991, CELL, V65, P483, DOI 10.1016/0092-8674(91)90466-C; Chen CL, 2003, NUCLEIC ACIDS RES, V31, P2601, DOI 10.1093/nar/gkg373; Clark TA, 2002, SCIENCE, V296, P907, DOI 10.1126/science.1069415; Danin-Kreiselman M, 2003, MOL CELL, V11, P1279, DOI 10.1016/S1097-2765(03)00137-0; Girke T, 2000, PLANT PHYSIOL, V124, P1570, DOI 10.1104/pp.124.4.1570; Golden TA, 2002, PLANT PHYSIOL, V130, P808, DOI 10.1104/pp.003491; Jacobsen SE, 1999, DEVELOPMENT, V126, P5231; KELLER W, 1984, CELL, V39, P423, DOI 10.1016/0092-8674(84)90449-5; Kim HC, 2001, MOL CELLS, V11, P198; Kim JW, 2000, NUCLEIC ACIDS RES, V28, P3666, DOI 10.1093/nar/28.18.3666; Kiss T, 2002, CELL, V109, P145, DOI 10.1016/S0092-8674(02)00718-3; Kiss T, 2001, EMBO J, V20, P3617, DOI 10.1093/emboj/20.14.3617; LIM D, 1989, CELL, V56, P891, DOI 10.1016/0092-8674(89)90693-4; LIU YG, 1995, PLANT J, V8, P457, DOI 10.1046/j.1365-313X.1995.08030457.x; Lotan T, 1998, CELL, V93, P1195, DOI 10.1016/S0092-8674(00)81463-4; McElver J, 2000, PLANT CELL, V12, P1379, DOI 10.1105/tpc.12.8.1379; McElver J, 2001, GENETICS, V159, P1751; MEINKE DW, 1995, ANNU REV PLANT PHYS, V46, P369, DOI 10.1146/annurev.pp.46.060195.002101; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; Nam K, 1997, MOL CELL BIOL, V17, P809, DOI 10.1128/MCB.17.2.809; NAM KB, 1994, J BIOL CHEM, V269, P20613; Ooi SL, 2001, METHOD ENZYMOL, V342, P233, DOI 10.1016/S0076-6879(01)42548-1; Petfalski E, 1998, MOL CELL BIOL, V18, P1181, DOI 10.1128/MCB.18.3.1181; Piano F, 2002, CURR BIOL, V12, P1959, DOI 10.1016/S0960-9822(02)01301-5; PICKETT FB, 1995, PLANT CELL, V7, P1347, DOI 10.1105/tpc.7.9.1347; SCHWARTZ BW, 1994, DEVELOPMENT, V120, P3235; SHEVELL DE, 1994, CELL, V77, P1051, DOI 10.1016/0092-8674(94)90444-8; Stone SL, 2001, P NATL ACAD SCI USA, V98, P11806, DOI 10.1073/pnas.201413498; The Arabidopsis Genome Initiative, 2000, NATURE, V408, P796; Tzafrir I, 2003, NUCLEIC ACIDS RES, V31, P90, DOI 10.1093/nar/gkg028; VERNON DM, 1994, DEV BIOL, V165, P566, DOI 10.1006/dbio.1994.1276; Vernon DM, 2001, AM J BOT, V88, P570, DOI 10.2307/2657055; Wang H, 2002, PLANT J, V32, P831, DOI 10.1046/j.1365-313X.2002.01455.x; WEST MAL, 1994, PLANT CELL, V6, P1731, DOI 10.1105/tpc.6.12.1731; WEST MAL, 1993, PLANT CELL, V5, P1361, DOI 10.1105/tpc.5.10.1361; White JA, 2000, PLANT PHYSIOL, V124, P1582, DOI 10.1104/pp.124.4.1582; Wilkins Thea A., 1996, P21; YADEGARI R, 1994, PLANT CELL, V6, P1713, DOI 10.1105/tpc.6.12.1713; YEUNG EC, 1993, PLANT CELL, V5, P1371, DOI 10.1105/tpc.5.10.1371; Zhang JZ, 1997, P NATL ACAD SCI USA, V94, P7349, DOI 10.1073/pnas.94.14.7349	45	205	213	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 9	2004	279	2					1468	1473		10.1074/jbc.M309106200	http://dx.doi.org/10.1074/jbc.M309106200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	759DJ	14570879	hybrid			2022-12-27	WOS:000187722800077
J	Wu, KH; Tai, PC				Wu, KH; Tai, PC			Cys(32) and His(105) are the critical residues for the calcium-dependent cysteine proteolytic activity of CvaB, an ATP-binding cassette transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; ABC TRANSPORTERS; EXPORT SYSTEM; CYSTIC-FIBROSIS; M-CALPAIN; SECRETION; PROTEASE; DOMAIN; SITE	CvaB, a member of the ATP-binding cassette transporter superfamily, is the central membrane transporter of the colicin V secretion system in Escherichia coli. Cys(32) and His(105) in the N-terminal domain of CvaB were identified as critical residues for both colicin V secretion and cysteine proteolytic activity. By inhibiting degradation with N-ethylmaleimide and a mixture of protease inhibitors, a stable wild-type N-terminal domain (which showed cysteine protease activity when activated) was purified. Such protease activity was Ca2+- and concentration-dependent and could be inhibited by antipain, N-ethylmaleimide, EDTA, and EGTA. At low concentrations, the Ca2+ analogs Tb3+ and La3+ (but not Fe3+) significantly enhanced proteolytic activity, suggesting that the size of the cations is important for activity. Together with comparisons of the sequences of members of the cysteine protease family, these results indicate that Cys(32) and His(105) are the critical residues in the CvaB N-terminal domain for the calcium-dependent cysteine protease activity and secretion of colicin V.	Georgia State Univ, Dept Biol, Atlanta, GA 30303 USA	University System of Georgia; Georgia State University	Tai, PC (corresponding author), Georgia State Univ, Dept Biol, 402 Kell Hall,24 Peachtree Ctr Ave, Atlanta, GA 30303 USA.	biopct@langate.gsu.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034766] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM34766] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALIVERTI A, 1991, EUR J BIOCHEM, V198, P21, DOI 10.1111/j.1432-1033.1991.tb15981.x; BARRETT AJ, 1994, METHOD ENZYMOL, V244, P1; BLIGHT MA, 1994, TRENDS BIOTECHNOL, V12, P450, DOI 10.1016/0167-7799(94)90020-5; Bobadilla JL, 2002, HUM MUTAT, V19, P575, DOI 10.1002/humu.10041; Boyer AE, 1998, J BACTERIOL, V180, P1662, DOI 10.1128/JB.180.7.1662-1672.1998; Carafoli E, 1998, BIOCHEM BIOPH RES CO, V247, P193, DOI 10.1006/bbrc.1998.8378; Chen M, 2000, BIOCHEM BIOPH RES CO, V273, P170, DOI 10.1006/bbrc.2000.2919; DEAN M, 1995, CURR OPIN GENET DEV, V5, P779, DOI 10.1016/0959-437X(95)80011-S; Decottignies A, 1997, NAT GENET, V15, P137, DOI 10.1038/ng0297-137; DELANEY SJ, 1991, P NATL ACAD SCI USA, V88, P7214, DOI 10.1073/pnas.88.16.7214; Diederichs K, 2000, EMBO J, V19, P5951, DOI 10.1093/emboj/19.22.5951; Ehrmann M, 1998, MOL MICROBIOL, V29, P685, DOI 10.1046/j.1365-2958.1998.00915.x; FATH MJ, 1994, BIOCHEMISTRY-US, V33, P6911, DOI 10.1021/bi00188a021; FATH MJ, 1993, MICROBIOL REV, V57, P995, DOI 10.1128/MMBR.57.4.995-1017.1993; FELMLEE T, 1985, J BACTERIOL, V163, P94, DOI 10.1128/JB.163.1.94-105.1985; Gafni J, 2002, J NEUROSCI, V22, P4842, DOI 10.1523/JNEUROSCI.22-12-04842.2002; GILSON L, 1987, J BACTERIOL, V169, P2466, DOI 10.1128/jb.169.6.2466-2470.1987; GILSON L, 1990, EMBO J, V9, P3875, DOI 10.1002/j.1460-2075.1990.tb07606.x; Glading A, 2002, TRENDS CELL BIOL, V12, P46, DOI 10.1016/S0962-8924(01)02179-1; Greger R, 2001, PFLUG ARCH EUR J PHY, V443, pS3; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; Harlow E., 1988, ANTIBODIES LAB MANUA; Hata S, 2001, FEBS LETT, V501, P111, DOI 10.1016/S0014-5793(01)02611-4; HAVARSTEIN LS, 1995, MOL MICROBIOL, V16, P229, DOI 10.1111/j.1365-2958.1995.tb02295.x; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Holland IB, 1999, J MOL BIOL, V293, P381, DOI 10.1006/jmbi.1999.2993; HORROCKS WDW, 1993, METHOD ENZYMOL, V226, P495, DOI 10.1016/0076-6879(93)26023-3; Hung LW, 1998, NATURE, V396, P703, DOI 10.1038/25393; HUSAIN SS, 1968, BIOCHEM J, V108, P855, DOI 10.1042/bj1080855; Hwang J, 1997, J BACTERIOL, V179, P689, DOI 10.1128/jb.179.3.689-696.1997; James R, 1992, BACTERIOCINS MICROCI; Jones PM, 2002, P NATL ACAD SCI USA, V99, P12639, DOI 10.1073/pnas.152439599; Kontani M, 1996, INFECT IMMUN, V64, P756, DOI 10.1128/IAI.64.3.756-762.1996; Kulkarni S, 2002, J BIOL CHEM, V277, P24435, DOI 10.1074/jbc.M203457200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lin GD, 1997, NAT STRUCT BIOL, V4, P539, DOI 10.1038/nsb0797-539; Linton KJ, 1998, MOL MICROBIOL, V28, P5, DOI 10.1046/j.1365-2958.1998.00764.x; MENARD R, 1991, BIOCHEMISTRY-US, V30, P8924, DOI 10.1021/bi00101a002; Menshikova EV, 2000, J BIOL CHEM, V275, P36775, DOI 10.1074/jbc.C000367200; Moldoveanu T, 2002, CELL, V108, P649, DOI 10.1016/S0092-8674(02)00659-1; Pal GP, 2001, J BIOL CHEM, V276, P47233, DOI 10.1074/jbc.M105149200; Perry DK, 1997, J BIOL CHEM, V272, P18530, DOI 10.1074/jbc.272.30.18530; Rank KB, 2001, PROTEIN EXPRES PURIF, V22, P258, DOI 10.1006/prep.2001.1433; Reverter D, 2001, TRENDS CARDIOVAS MED, V11, P222, DOI 10.1016/S1050-1738(01)00112-8; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Shaw CF, 1997, J BIOL INORG CHEM, V2, P65, DOI 10.1007/s007750050107; SKVIRSKY RC, 1991, METHOD CELL BIOL, V34, P205; Someya Y, 2002, J VIROL, V76, P5949, DOI 10.1128/JVI.76.12.5949-5958.2002; Stennicke HR, 1997, J BIOL CHEM, V272, P25719, DOI 10.1074/jbc.272.41.25719; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; Tzeng WP, 2002, J VIROL, V76, P3189, DOI 10.1128/JVI.76.7.3189-3201.2002; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; Zhong XT, 1998, J BACTERIOL, V180, P1347, DOI 10.1128/JB.180.6.1347-1353.1998; Zhong XT, 1996, J BIOL CHEM, V271, P28057, DOI 10.1074/jbc.271.45.28057	54	41	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 9	2004	279	2					901	909		10.1074/jbc.M308296200	http://dx.doi.org/10.1074/jbc.M308296200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	759DJ	14570918	hybrid			2022-12-27	WOS:000187722800012
J	Abe-Dohmae, S; Ikeda, Y; Matsuo, M; Hayashi, M; Okuhira, K; Ueda, K; Yokoyama, S				Abe-Dohmae, S; Ikeda, Y; Matsuo, M; Hayashi, M; Okuhira, K; Ueda, K; Yokoyama, S			Human ABCA7 supports apolipoprotein-mediated release of cellular cholesterol and phospholipid to generate high density lipoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP-BINDING CASSETTE; TANGIER-DISEASE; A-I; GENOMIC ORGANIZATION; TRANSPORTER A1; EXTRACELLULAR DOMAIN; ABCG1 ABC8; EFFLUX; DEFICIENCY; MUTATIONS	Apolipoprotein-mediated release of cellular cholesterol and phospholipids was induced in HEK293 cells by expressing human ATP-binding cassette transporter A7 (ABCA7) and ABC transporter A1 (ABCA1) proteins, whether transient or stable, to generate cholesterol-rich high density lipoprotein (HDL). Green fluorescent protein (GFP) attached at their C termini did not influence the lipid release reactions. Transfected ABCA7-GFP induced apolipoprotein-mediated assembly of cholesterol-containing HDL also in L929 cells, which otherwise generate only cholesterol-deficient HDL with their endogenous ABCA1. Time-dependent release of cholesterol and phospholipid by apolipoprotein A ( apoA)-I was parallel both with ABCA1 and with ABCA7 when highly expressed in HEK293 cells, but dose-dependent profiles of lipid release on apoA-I and apoA-II were somewhat different between ABCA1 and ABCA7. Analyses of the stable clones with ABCA1-GFP (293/2c) and ABCA7-GFP (293/6c) by using the same vector indicated some differences in regulation of their activities by protein kinase modulators. Dibutyryl cyclic AMP increased ABCA1-GFP and the release of cholesterol and phospholipid in 293/2c but increased neither ABCA7-GFP nor the lipid release in 293/6c. Expression of ABCA1-GFP- and apoA-I-mediated lipid release were enhanced in parallel by phorbol 12-myristate 13-acetate (PMA) in 293/2c cells. In contrast, the same treatment of 293/6c increased ABCA7-GFP, but apoA-I-mediated lipid release was significantly suppressed. Despite these different responses to PMA, all of the effects of PMA were reversed by a specific protein kinase C inhibitor Go6976, suggesting that the changes were in fact due to protein kinase C activation. A thiol protease inhibitor, N-acetyl-Leu-Leu-norleucinal, increased the protein levels of ABCA1-GFP in 293/2c and ABCA7-GFP in 293/6c, indicating their common degradation pathway. The data indicated that human ABCA7 would compensate the function of ABCA1 for release of cell cholesterol in a certain condition(s), but post-transcriptional regulation of their activity is different.	Nagoya City Univ, Grad Sch Med Sci, Nagoya, Aichi 4678601, Japan; Kyoto Univ, Grad Sch Agr, Div Appl Life Sci, Lab Cellular Biochem, Kyoto 6068502, Japan	Nagoya City University; Kyoto University	Yokoyama, S (corresponding author), Nagoya City Univ, Grad Sch Med Sci, Nagoya, Aichi 4678601, Japan.			Ueda, Kazumitsu/0000-0003-2980-6078				Abe-Dohmae S, 2000, BIOCHEMISTRY-US, V39, P11092, DOI 10.1021/bi0008175; Arakawa R, 2002, J BIOL CHEM, V277, P22426, DOI 10.1074/jbc.M202996200; Assmann G, 2001, METABOLIC MOL BASES, P2937; Becq F, 1997, J BIOL CHEM, V272, P2695, DOI 10.1074/jbc.272.5.2695; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Broccardo C, 2001, CYTOGENET CELL GENET, V92, P264, DOI 10.1159/000056914; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Christiansen-Weber TA, 2000, AM J PATHOL, V157, P1017, DOI 10.1016/S0002-9440(10)64614-7; FRANCIS GA, 1995, J CLIN INVEST, V96, P78, DOI 10.1172/JCI118082; Haidar B, 2002, J LIPID RES, V43, P2087, DOI 10.1194/jlr.M200235-JLR200; HARA H, 1991, J BIOL CHEM, V266, P3080; Kaminski WE, 2000, BIOCHEM BIOPH RES CO, V278, P782, DOI 10.1006/bbrc.2000.3880; Kishimoto T, 2002, CLIN BIOCHEM, V35, P411, DOI 10.1016/S0009-9120(02)00327-2; Klucken J, 2000, P NATL ACAD SCI USA, V97, P817, DOI 10.1073/pnas.97.2.817; Kojima K, 2001, BBA-MOL CELL BIOL L, V1532, P173, DOI 10.1016/S1388-1981(01)00124-X; Lorkowski S, 2001, BIOCHEM BIOPH RES CO, V283, P821, DOI 10.1006/bbrc.2001.4863; Marcil M, 1999, LANCET, V354, P1341, DOI 10.1016/S0140-6736(99)07026-9; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; McNeish J, 2000, P NATL ACAD SCI USA, V97, P4245, DOI 10.1073/pnas.97.8.4245; Oram JF, 2000, J BIOL CHEM, V275, P34508, DOI 10.1074/jbc.M006738200; Orso E, 2000, NAT GENET, V24, P192, DOI 10.1038/72869; Remaley AT, 1997, ARTERIOSCL THROM VAS, V17, P1813, DOI 10.1161/01.ATV.17.9.1813; Remaley AT, 1999, P NATL ACAD SCI USA, V96, P12685, DOI 10.1073/pnas.96.22.12685; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; Santamarina-Fojo S, 2000, P NATL ACAD SCI USA, V97, P7987, DOI 10.1073/pnas.97.14.7987; Sasaki M, 2003, BIOCHEM BIOPH RES CO, V304, P777, DOI 10.1016/S0006-291X(03)00659-4; See RH, 2002, J BIOL CHEM, V277, P41835, DOI 10.1074/jbc.M204923200; Smith JD, 1996, J BIOL CHEM, V271, P30647, DOI 10.1074/jbc.271.48.30647; TAJIMA S, 1983, J BIOL CHEM, V258, P73; Tanaka AR, 2001, BIOCHEM BIOPH RES CO, V283, P1019, DOI 10.1006/bbrc.2001.4891; Tanaka AR, 2003, J BIOL CHEM, V278, P8815, DOI 10.1074/jbc.M206885200; Wang N, 2003, J BIOL CHEM, V278, P42906, DOI 10.1074/jbc.M307831200; Wang N, 2003, J CLIN INVEST, V111, P99, DOI 10.1172/JCI200316808; Wang N, 2001, J BIOL CHEM, V276, P23742, DOI 10.1074/jbc.M102348200; Yamauchi Y, 2003, J BIOL CHEM, V278, P47890, DOI 10.1074/jbc.M306258200; Yamauchi Y, 2002, BBA-MOL CELL BIOL L, V1585, P1, DOI 10.1016/S1388-1981(02)00304-9; YOKOYAMA S, 1982, J BIOCHEM, V91, P1267, DOI 10.1093/oxfordjournals.jbchem.a133811	37	145	153	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	2004	279	1					604	611		10.1074/jbc.M309888200	http://dx.doi.org/10.1074/jbc.M309888200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	757GU	14570867	hybrid			2022-12-27	WOS:000187555300073
J	Aizawa, K; Suzuki, T; Kada, N; Ishihara, A; Kawai-Kowase, K; Matsumura, T; Sasaki, K; Munemasa, Y; Manabe, I; Kurabayashi, M; Collins, T; Nagai, R				Aizawa, K; Suzuki, T; Kada, N; Ishihara, A; Kawai-Kowase, K; Matsumura, T; Sasaki, K; Munemasa, Y; Manabe, I; Kurabayashi, M; Collins, T; Nagai, R			Regulation of platelet-derived growth factor-A chain by Kruppel-like factor 5 - New pathway of cooperative activation with nuclear factor-kappa B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL ACTIVATION; DEFICIENT MICE; 3 FINGERS; ATHEROSCLEROSIS; PROMOTER; CELLS; PDGF; GENE; DISEASE; BINDING	The transcription factor Kruppel-like factor 5 (KLF5) and its genetically downstream target gene platelet-derived growth factor-A (PDGF-A) chain are key factors in regulation of cardiovascular remodeling in response to stress. We show that KLF5 mediates a novel distinct delayed persistent induction of PDGF-A chain in response to the model agonist, phorbol ester, through a cis-element previously shown to mediate phorbol ester induction on to PDGF-A chain through the early growth response factor (Egr-1). Interestingly, the nuclear factor-kappaB (NF-kappaB) p50 subunit further cooperatively activates PDGF-A chain through protein-protein interaction with KLF5 but not Egr-1. RNA interference analysis confirmed that KLF5 and p50 are important for induction of PDGF-A chain. Collectively, we identify a novel regulatory pathway in which PDGF-A chain gene expression, under the control of KLF5, is cooperatively activated by the NF-kappaB p50 subunit and a pathophysiological stimulus.	Univ Tokyo, Grad Sch Med, Dept Cardiovasc Med, Bunkyo Ku, Tokyo 1138655, Japan; Univ Tokyo, Dept Clin Bioinformat, Bunkyo Ku, Tokyo 1138655, Japan; Gunma Univ, Grad Sch Med, Dept Med & Biol Sci, Gunma 3718511, Japan; Harvard Univ, Sch Med, Childrens Hosp, Dept Pathol, Boston, MA 02115 USA	University of Tokyo; University of Tokyo; Gunma University; Harvard University; Boston Children's Hospital; Harvard Medical School	Suzuki, T (corresponding author), Univ Tokyo, Grad Sch Med, Dept Cardiovasc Med & Clin Bioinformat, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.		Manabe, Ichiro/AAE-5105-2021; Manabe, Ichiro/E-1529-2014	Suzuki, Toru/0000-0002-8371-664X				Bieker JJ, 2001, J BIOL CHEM, V276, P34355, DOI 10.1074/jbc.R100043200; Carmeliet P, 2000, J PATHOL, V190, P387; Collins T, 2001, J CLIN INVEST, V107, P255, DOI 10.1172/JCI10373; Conkright MD, 1999, NUCLEIC ACIDS RES, V27, P1263, DOI 10.1093/nar/27.5.1263; FORSBERG K, 1993, P NATL ACAD SCI USA, V90, P393, DOI 10.1073/pnas.90.2.393; Hehner SP, 1999, J IMMUNOL, V163, P5617; Karlsson L, 2000, DEVELOPMENT, V127, P3457; Kawai-Kowase K, 1999, CIRC RES, V85, P787, DOI 10.1161/01.RES.85.9.787; KHACHIGIAN LM, 1995, J BIOL CHEM, V270, P27679, DOI 10.1074/jbc.270.46.27679; Khachigian LM, 1997, CIRC RES, V81, P457, DOI 10.1161/01.RES.81.4.457; KUNSCH C, 1993, MOL CELL BIOL, V13, P6137, DOI 10.1128/MCB.13.10.6137; Libby P, 2002, NATURE, V420, P868, DOI 10.1161/ATVBAHA.108.179705; Lindahl P, 1997, SCIENCE, V277, P242, DOI 10.1126/science.277.5323.242; Manabe I, 2001, CIRC RES, V88, P1127, DOI 10.1161/hh1101.091339; Philipsen S, 1999, NUCLEIC ACIDS RES, V27, P2991, DOI 10.1093/nar/27.15.2991; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Shi HP, 1999, NUCLEIC ACIDS RES, V27, P4807, DOI 10.1093/nar/27.24.4807; Shindo T, 2002, NAT MED, V8, P856, DOI 10.1038/nm738; Sun RG, 2001, J BIOL CHEM, V276, P6897, DOI 10.1074/jbc.C000870200; Suzuki T, 2000, GENES CELLS, V5, P29, DOI 10.1046/j.1365-2443.2000.00302.x	21	78	81	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	2004	279	1					70	76		10.1074/jbc.M306621200	http://dx.doi.org/10.1074/jbc.M306621200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	757GU	14573617	hybrid			2022-12-27	WOS:000187555300009
J	Qiu, QS; Guo, Y; Quintero, FJ; Pardo, JM; Schumaker, KS; Zhu, JK				Qiu, QS; Guo, Y; Quintero, FJ; Pardo, JM; Schumaker, KS; Zhu, JK			Regulation of vacuolar Na+/H+ exchange in Arabidopsis thaliana by the salt-overly-sensitive (SOS) pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSLOCATING INORGANIC PYROPHOSPHATASE; MEMBRANE H+-ATPASE; PLASMA-MEMBRANE; TONOPLAST VESICLES; PROTEIN-KINASE; SODIUM-TRANSPORT; GENETIC-ANALYSIS; STORAGE TISSUE; BETA-VULGARIS; RED BEET	For plants growing in highly saline environments, accumulation of sodium in the cell cytoplasm leads to disruption of metabolic processes and reduced growth. Maintaining low levels of cytoplasmic sodium requires the coordinate regulation of transport proteins on numerous cellular membranes. Our previous studies have linked components of the Salt-Overly-Sensitive pathway (SOS1-3) to salt tolerance in Arabidopsis thaliana and demonstrated that the activity of the plasma membrane Na+/H+ exchanger (SOS1) is regulated by SOS2 (a protein kinase) and SOS3 ( a calcium-binding protein). Current studies were undertaken to determine if the Na+/H+ exchanger in the vacuolar membrane ( tonoplast) of Arabidopsis is also a target for the SOS regulatory pathway. Characterization of tonoplast Na+/H+ exchange demonstrated that it represents activity originating from the AtNHX proteins since it could be inhibited by 5-(N-methyl-N-isobutyl) amiloride and by anti-NHX1 antibodies. Transport activity was selective for sodium (apparent K-m = 31 mM) and electroneutral ( one sodium ion for each proton). When compared with tonoplast Na+/H+-exchange activity in wild type, activity was significantly higher, greatly reduced, and unchanged in sos1, sos2, and sos3, respectively. Activated SOS2 protein added in vitro increased tonoplast Na+/ H+-exchange activity in vesicles isolated from sos2 but did not have any effect on activity in vesicles isolated from wild type, sos1, or sos3. These results demonstrate that (i) the tonoplast Na+/H+ exchanger in Arabidopsis is a target of the SOS regulatory pathway, (ii) there are branches to the SOS pathway, and (iii) there may be coordinate regulation of the exchangers in the tonoplast and plasma membrane.	Univ Arizona, Dept Plant Sci, Tucson, AZ 85721 USA; CSIC, Inst Recursos Nat & Agrobiol, E-41080 Seville, Spain	University of Arizona; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Recursos Naturales y Agrobiologia de Sevilla (IRNAS)	Schumaker, KS (corresponding author), Univ Arizona, Dept Plant Sci, Tucson, AZ 85721 USA.		Zhu, Jian-Kang/F-7658-2011; Quintero, Francisco J./AAG-2924-2019; Pardo, Jose M/AAB-5866-2022; Guo, Yan/X-1245-2019; Pardo, Jose M./B-4652-2009; Quintero, Francisco J/C-3086-2014	Zhu, Jian-Kang/0000-0001-5134-731X; Quintero, Francisco J./0000-0001-8718-2975; Pardo, Jose M/0000-0003-4510-8624; Pardo, Jose M./0000-0003-4510-8624; Quintero, Francisco J/0000-0001-8718-2975	NIGMS NIH HHS [R01GM59138] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059138] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Apse MP, 1999, SCIENCE, V285, P1256, DOI 10.1126/science.285.5431.1256; BENNETT AB, 1983, J MEMBRANE BIOL, V71, P95, DOI 10.1007/BF01870678; Blumwald E, 2000, CURR OPIN CELL BIOL, V12, P431, DOI 10.1016/S0955-0674(00)00112-5; BLUMWALD E, 1985, PLANT PHYSIOL, V78, P163, DOI 10.1104/pp.78.1.163; Blumwald E, 2000, BBA-BIOMEMBRANES, V1465, P140, DOI 10.1016/S0005-2736(00)00135-8; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHENG NH, 2003, J BIOL CHEM; Darley CP, 2000, BIOCHEM J, V351, P241, DOI 10.1042/0264-6021:3510241; Drozdowicz YM, 2000, PLANT PHYSIOL, V123, P353, DOI 10.1104/pp.123.1.353; GALLAGHER SR, 1982, PLANT PHYSIOL, V70, P1335, DOI 10.1104/pp.70.5.1335; Gaxiola RA, 1999, P NATL ACAD SCI USA, V96, P1480, DOI 10.1073/pnas.96.4.1480; GINNINI JL, 1987, PLANT PHYSIOL, V84, P613; GordonWeeks R, 1997, PLANT PHYSIOL, V114, P901, DOI 10.1104/pp.114.3.901; Guo Y, 2001, PLANT CELL, V13, P1383, DOI 10.1105/tpc.13.6.1383; Halfter U, 2000, P NATL ACAD SCI USA, V97, P3735, DOI 10.1073/pnas.040577697; Hasegawa M, 2000, TRENDS PLANT SCI, V5, P317, DOI 10.1016/S1360-1385(00)01692-7; Hasegawa PM, 2000, ANNU REV PLANT PHYS, V51, P463, DOI 10.1146/annurev.arplant.51.1.463; KAESTNER KH, 1987, PLANT PHYSIOL, V83, P483, DOI 10.1104/pp.83.3.483; Liu JP, 2000, P NATL ACAD SCI USA, V97, P3730, DOI 10.1073/pnas.060034197; Liu JP, 1998, SCIENCE, V280, P1943, DOI 10.1126/science.280.5371.1943; Parks GE, 2002, J EXP BOT, V53, P1055, DOI 10.1093/jexbot/53.371.1055; POOLE RJ, 1984, PLANT PHYSIOL, V74, P549, DOI 10.1104/pp.74.3.549; Qiu QS, 1999, J PLANT PHYSIOL, V154, P628, DOI 10.1016/S0176-1617(99)80237-5; Qiu QS, 1998, AUST J PLANT PHYSIOL, V25, P923, DOI 10.1071/PP98036; Qiu QS, 2003, PLANT PHYSIOL, V132, P1041, DOI 10.1104/pp.102.010421; Qiu QS, 2002, P NATL ACAD SCI USA, V99, P8436, DOI 10.1073/pnas.122224699; Quintero FJ, 2002, P NATL ACAD SCI USA, V99, P9061, DOI 10.1073/pnas.132092099; Quintero FJ, 2000, FEBS LETT, V471, P224, DOI 10.1016/S0014-5793(00)01412-5; REA PA, 1985, PLANT PHYSIOL, V77, P46, DOI 10.1104/pp.77.1.46; Schachtman D, 1999, TRENDS PLANT SCI, V4, P281, DOI 10.1016/S1360-1385(99)01428-4; Shi HZ, 2000, P NATL ACAD SCI USA, V97, P6896, DOI 10.1073/pnas.120170197; Shi HZ, 2002, PLANT CELL, V14, P465, DOI 10.1105/tpc.010371; STANLEY KK, 1984, EMBO J, V3, P1329; Venema K, 2002, J BIOL CHEM, V277, P2413, DOI 10.1074/jbc.M105043200; Wu SJ, 1996, PLANT CELL, V8, P617, DOI 10.1105/tpc.8.4.617; Yokoi S, 2002, PLANT J, V30, P529, DOI 10.1046/j.1365-313X.2002.01309.x; Zhang HX, 2001, NAT BIOTECHNOL, V19, P765, DOI 10.1038/90824; Zhang HX, 2001, P NATL ACAD SCI USA, V98, P12832, DOI 10.1073/pnas.231476498; Zhu JK, 2000, PLANT PHYSIOL, V124, P941, DOI 10.1104/pp.124.3.941; Zhu JK, 1998, PLANT CELL, V10, P1181, DOI 10.1105/tpc.10.7.1181	40	261	295	7	92	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	2004	279	1					207	215		10.1074/jbc.M307982200	http://dx.doi.org/10.1074/jbc.M307982200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	757GU	14570921	hybrid			2022-12-27	WOS:000187555300025
J	Tokumitsu, H; Hatano, N; Inuzuka, H; Ishikawa, Y; Uyeda, TQP; Smith, JL; Kobayashi, R				Tokumitsu, H; Hatano, N; Inuzuka, H; Ishikawa, Y; Uyeda, TQP; Smith, JL; Kobayashi, R			Regulatory mechanism of Dictyostelium myosin light chain kinase A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE MYOSIN; MOTOR DOMAIN; MLCK-A; PROTEIN; PHOSPHORYLATION; IDENTIFICATION; ACTIVATION; CALMODULIN; EXPRESSION; REQUIREMENTS	In this study, we examined the activation mechanism of Dictyostelium myosin light chain kinase A (MLCK-A) using constitutively active Ca2+/calmodulin-dependent protein kinase kinase as a surrogate MLCK-A kinase. MLCK-A was phosphorylated at Thr(166) by constitutively active Ca2+/calmodulin-dependent protein kinase kinase, resulting in an similar to 140-fold increase in catalytic activity, using intact Dictyostelium myosin II. Recombinant Dictyostelium myosin II regulatory light chain and Kemptamide were also readily phosphorylated by activated MLCK-A. Mass spectrometry analysis revealed that MLCK-A expressed by Escherichia coli was autophosphorylated at Thr(289) and that, subsequent to Thr(166) phosphorylation, MLCK-A also underwent a slow rate of autophosphorylation at multiple Ser residues. Using site-directed mutagenesis, we show that autophosphorylation at Thr(289) is required for efficient phosphorylation and activation by an upstream kinase. By performing enzyme kinetics analysis on a series of MLCK-A truncation mutants, we found that residues 283 - 288 function as an autoinhibitory domain and that autoinhibition is fully relieved by Thr(166) phosphorylation. Simple removal of this region resulted in a significant increase in the k(cat) of MLCK-A; however, it did not generate maximum enzymatic activity. Together with the results of our kinetic analysis of the enzymes, these findings demonstrate that Thr(166) phosphorylation of MLCK-A by an upstream kinase subsequent to autophosphorylation at Thr289 results in generation of maximum MLCK-A activity through both release of an autoinhibitory domain from its catalytic core and a further increase (15-19-fold) in the kcat of the enzyme.	Kagawa Med Univ, Dept Signal Transduct Sci, Miki, Kagawa 7610793, Japan; Kagawa Med Univ, Dept Cell Physiol, Miki, Kagawa 7610793, Japan; Natl Inst Adv Ind Sci & Technol, Gene Discovery Res Ctr, Tsukuba, Ibaraki 3058562, Japan; Boston Biomed Res Inst, Watertown, MA 02472 USA	Kagawa University; Kagawa University; National Institute of Advanced Industrial Science & Technology (AIST); Boston Biomedical Research Institute	Tokumitsu, H (corresponding author), Kagawa Univ, Fac Med, Dept Signal Transduct Sci, 1750-1 Miki Cho, Miki, Kagawa 7610793, Japan.	tokumit@kms.ac.jp	Hatano, Naoya/F-6147-2011; Tokumitsu, Hiroshi/M-3978-2015	Tokumitsu, Hiroshi/0000-0002-2193-6794				Bosgraaf L, 2002, EMBO J, V21, P4560, DOI 10.1093/emboj/cdf438; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bresnick AR, 1999, CURR OPIN CELL BIOL, V11, P26, DOI 10.1016/S0955-0674(99)80004-0; Corcoran EE, 2001, J BIOL CHEM, V276, P2975, DOI 10.1074/jbc.R000027200; Eto K, 1999, J BIOL CHEM, V274, P22556, DOI 10.1074/jbc.274.32.22556; Goldberg JM, 2002, P NATL ACAD SCI USA, V99, P6749, DOI 10.1073/pnas.102167299; GRIFFITH LM, 1987, J CELL BIOL, V104, P1309, DOI 10.1083/jcb.104.5.1309; HARIBABU B, 1995, EMBO J, V14, P3679, DOI 10.1002/j.1460-2075.1995.tb00037.x; HARTSHORNE DJ, 1987, PHYSL GASTROINTESTIN, V2, P423; Joseph JD, 2000, J BIOL CHEM, V275, P38230, DOI 10.1074/jbc.M006422200; KAMM KE, 1985, ANNU REV PHARMACOL, V25, P593, DOI 10.1146/annurev.pharmtox.25.1.593; Kamm KE, 2001, J BIOL CHEM, V276, P4527, DOI 10.1074/jbc.R000028200; KEMP BE, 1985, J BIOL CHEM, V260, P3355; Liu X, 1998, P NATL ACAD SCI USA, V95, P14124, DOI 10.1073/pnas.95.24.14124; Matsushita M, 1998, J BIOL CHEM, V273, P21473, DOI 10.1074/jbc.273.34.21473; NAKIELNY S, 1992, EMBO J, V11, P2123, DOI 10.1002/j.1460-2075.1992.tb05271.x; OSTROW BD, 1994, J CELL BIOL, V127, P1945, DOI 10.1083/jcb.127.6.1945; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; RUPPEL KM, 1994, J BIOL CHEM, V269, P18773; Sellers JR, 1991, CURR OPIN CELL BIOL, V3, P98, DOI 10.1016/0955-0674(91)90171-T; SELLERS JR, 1985, CURR TOP CELL REGUL, V27, P51; Silveira LA, 1998, P NATL ACAD SCI USA, V95, P13000, DOI 10.1073/pnas.95.22.13000; Smith JL, 1996, P NATL ACAD SCI USA, V93, P12321, DOI 10.1073/pnas.93.22.12321; Smith JL, 1996, EMBO J, V15, P6075, DOI 10.1002/j.1460-2075.1996.tb00996.x; Soderling TR, 1999, TRENDS BIOCHEM SCI, V24, P232, DOI 10.1016/S0968-0004(99)01383-3; TAN JL, 1990, J BIOL CHEM, V265, P13818; TAN JL, 1992, ANNU REV BIOCHEM, V61, P721, DOI 10.1146/annurev.bi.61.070192.003445; TAN JL, 1991, J BIOL CHEM, V266, P16044; Tokumitsu H, 2000, J BIOL CHEM, V275, P20090, DOI 10.1074/jbc.M002193200; Tokumitsu H, 1999, J BIOL CHEM, V274, P15803, DOI 10.1074/jbc.274.22.15803; Tokumitsu H, 1996, J BIOL CHEM, V271, P5617, DOI 10.1074/jbc.271.10.5617; TOKUMITSU H, 1994, J BIOL CHEM, V269, P28640; Tokumitsu H, 2001, BIOCHEMISTRY-US, V40, P13925, DOI 10.1021/bi010863k; TOKUMITSU H, 1995, J BIOL CHEM, V270, P19320, DOI 10.1074/jbc.270.33.19320; Uyeda TQP, 1996, P NATL ACAD SCI USA, V93, P4459, DOI 10.1073/pnas.93.9.4459	35	5	5	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 2	2004	279	1					42	50		10.1074/jbc.M309621200	http://dx.doi.org/10.1074/jbc.M309621200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	757GU	14570871	hybrid			2022-12-27	WOS:000187555300006
J	Yoshimura, T; Sagami, I; Sasakura, Y; Shimizu, T				Yoshimura, T; Sagami, I; Sasakura, Y; Shimizu, T			Relationships between heme incorporation, tetramer formation, and catalysis of a heme-regulated phosphodiesterase from Escherichia coli - A study of deletion and site-directed mutants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIRECT OXYGEN SENSOR; LIGAND DISCRIMINATION; RESONANCE RAMAN; PAS KINASE; DOMAIN; MECHANISM; PROTEIN; BINDING; HEMOGLOBIN	The heme-regulated phosphodiesterase (PDE) from Escherichia coli (Ec DOS) is a tetrameric protein composed of an N-terminal sensor domain (amino acids 1-201) containing two PAS domains (PAS-A, amino acids 21-84, and PAS-B, amino acids 144-201) and a C-terminal catalytic domain ( amino acids 336-799). Heme is bound to the PAS-A domain, and the redox state of the heme iron regulates PDE activity. In our experiments, a H77A mutation and deletion of the PAS-B domain resulted in the loss of heme binding affinity to PAS-A. However, both mutant proteins were still tetrameric and more active than the full-length wild-type enzyme (140% activity compared with full-length wild type), suggesting that heme binding is not essential for catalysis. An N-terminal truncated mutant (DeltaN147, amino acids 148-807) containing no PAS-A domain or heme displayed 160% activity compared with full-length wildtype protein, confirming that the heme-bound PAS-A domain is not required for catalytic activity. An analysis of C-terminal truncated mutants led to mapping of the regions responsible for tetramer formation and revealed PDE activity in tetrameric proteins only. Mutations at a putative metal-ion binding site (His-590, His-594) totally abolished PDE activity, suggesting that binding of Mg2+ to the site is essential for catalysis. Interestingly, the addition of the isolated PAS-A domain in the Fe2+ form to the full-length wild-type protein markedly enhanced PDE activity (>5-fold). This activation is probably because of structural changes in the catalytic site as a result of interactions between the isolated PAS-A domain and that of the holoenzyme.	Tohoku Univ, Inst Multidisciplinary Res Adv Mat, Aoba Ku, Sendai, Miyagi 9808577, Japan	Tohoku University	Shimizu, T (corresponding author), Tohoku Univ, Inst Multidisciplinary Res Adv Mat, Aoba Ku, 2-1-1 Katahira, Sendai, Miyagi 9808577, Japan.	shimizu@tagen.tohoku.ac.jp						Ackers GK, 2002, P NATL ACAD SCI USA, V99, P9777, DOI 10.1073/pnas.152225999; Amezcua CA, 2002, STRUCTURE, V10, P1349, DOI 10.1016/S0969-2126(02)00857-2; Aono S, 2002, J BIOL CHEM, V277, P13528, DOI 10.1074/jbc.M112256200; Ceci P, 2002, J BIOL CHEM, V277, P6929, DOI 10.1074/jbc.M107422200; Chan MK, 2001, CURR OPIN CHEM BIOL, V5, P216, DOI 10.1016/S1367-5931(00)00193-9; Conti M, 2000, PROG NUCLEIC ACID RE, V63, P1; Delgado-Nixon VM, 2000, BIOCHEMISTRY-US, V39, P2685, DOI 10.1021/bi991911s; Gilles-Gonzalez MA, 2001, IUBMB LIFE, V51, P165, DOI 10.1080/152165401753544232; Hao B, 2002, BIOCHEMISTRY-US, V41, P12952, DOI 10.1021/bi020144l; Jain R, 2003, J BIOL INORG CHEM, V8, P1, DOI 10.1007/s00775-002-0405-8; Lee ME, 2002, FEBS LETT, V530, P53, DOI 10.1016/S0014-5793(02)03396-3; Martin E, 2003, P NATL ACAD SCI USA, V100, P9208, DOI 10.1073/pnas.1633590100; Rutter J, 2002, SCIENCE, V298, P1567, DOI 10.1126/science.1080001; Rutter J, 2001, P NATL ACAD SCI USA, V98, P8991, DOI 10.1073/pnas.161284798; Sasakura Y, 2002, J BIOL CHEM, V277, P23821, DOI 10.1074/jbc.M202738200; Sato A, 2002, J BIOL CHEM, V277, P32650, DOI 10.1074/jbc.M204559200; Sung BJ, 2003, NATURE, V425, P98, DOI 10.1038/nature01914; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; Xu RX, 2000, SCIENCE, V288, P1822, DOI 10.1126/science.288.5472.1822	19	31	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					53105	53111		10.1074/jbc.M304408200	http://dx.doi.org/10.1074/jbc.M304408200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14551206	hybrid			2022-12-27	WOS:000187480700135
J	Fukuda, T; Chen, K; Shi, XH; Wu, CY				Fukuda, T; Chen, K; Shi, XH; Wu, CY			PINCH-1 is an obligate partner of integrin-linked kinase (ILK) functioning in cell shape modulation, motility, and survival	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION PROTEIN; EXTRACELLULAR-MATRIX; PROTEASOME INHIBITORS; SIGNAL-TRANSDUCTION; BINDING PROTEIN; LIM PROTEIN; DOMAIN; EXPRESSION; FIBRONECTIN; SITES	PINCH-1 is a widely expressed focal adhesion protein that forms a ternary complex with integrin-linked kinase (ILK) and CH-ILKBP/actopaxin/alpha-parvin (abbreviated as alpha-parvin herein). We have used RNA interference, a powerful approach of reverse genetics, to investigate the functions of PINCH-1 and ILK in human cells. We report here the following. First, PINCH-1 and ILK, but not alpha-parvin, are essential for prompt cell spreading and motility. Second, PINCH-1 and ILK, like alpha-parvin, are crucial for cell survival. Third, PINCH-1 and ILK are required for optimal activating phosphorylation of PKB/Akt, an important signaling intermediate of the survival pathway. Whereas depletion of ILK reduced Ser(473) phosphorylation but not Thr(308) phosphorylation of PKB/Akt, depletion of PINCH-1 reduced both the Ser(473) and Thr(308) phosphorylation of PKB/Akt. Fourth, PINCH-1 and ILK function in the survival pathway not only upstream but also downstream (or in parallel) of protein kinase B (PKB)/Akt. Fifth, PINCH-1, ILK and to a less extent alpha-parvin are mutually dependent in maintenance of their protein, but not mRNA, levels. The coordinated down-regulation of PINCH-1, ILK, and alpha-parvin proteins is mediated at least in part by proteasomes. Finally, increased expression of PINCH-2, an ILK-binding protein that is structurally related to PINCH-1, prevented the down-regulation of ILK and alpha-parvin induced by the loss of PINCH-1 but failed to restore the survival signaling or cell shape modulation. These results provide new insights into the functions of PINCH proteins in regulation of ILK and alpha-parvin and control of cell behavior.	Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Wu, CY (corresponding author), Univ Pittsburgh, Dept Pathol, 707B Scaife Hall,3550 Terrace St, Pittsburgh, PA 15261 USA.	carywu@pitt.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054639] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065188] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK54639] Funding Source: Medline; NIGMS NIH HHS [GM65188] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; BAUER JS, 1992, J CELL BIOL, V116, P477, DOI 10.1083/jcb.116.2.477; Braun A, 2003, EXP CELL RES, V284, P239, DOI 10.1016/S0014-4827(02)00039-3; Brazil DP, 2001, TRENDS BIOCHEM SCI, V26, P657, DOI 10.1016/S0968-0004(01)01958-2; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Chung DH, 1998, VIRCHOWS ARCH, V433, P113, DOI 10.1007/s004280050225; Clark KA, 2003, DEVELOPMENT, V130, P2611, DOI 10.1242/dev.00492; Cordes N, 2002, INT J RADIAT BIOL, V78, P347, DOI 10.1080/09553000110117340; Cruet-Hennequart S, 2003, ONCOGENE, V22, P1688, DOI 10.1038/sj.onc.1206347; Di-Poi N, 2002, MOL CELL, V10, P721, DOI 10.1016/S1097-2765(02)00646-9; Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3; Fan XM, 2001, INT J CANCER, V93, P481, DOI 10.1002/ijc.1373; Fukuda T, 2003, J CELL BIOL, V160, P1001, DOI 10.1083/jcb.200212113; Geiger B, 2001, NAT REV MOL CELL BIO, V2, P793, DOI 10.1038/35099066; Graff JR, 2001, CLIN CANCER RES, V7, P1987; Grashoff C, 2003, EMBO REP, V4, P432, DOI 10.1038/sj.embor.embor801; Guo L, 2002, FASEB J, V16, P1298, DOI 10.1096/fj.02-0089fje; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a; Hobert O, 1999, J CELL BIOL, V144, P45, DOI 10.1083/jcb.144.1.45; Howe A, 1998, CURR OPIN CELL BIOL, V10, P220, DOI 10.1016/S0955-0674(98)80144-0; Hudson DF, 2002, TRENDS CELL BIOL, V12, P281, DOI 10.1016/S0962-8924(02)02281-X; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Ito R, 2003, VIRCHOWS ARCH, V442, P118, DOI 10.1007/s00428-002-0718-6; KOMORIYA A, 1991, J BIOL CHEM, V266, P15075; Lawlor MA, 2001, J CELL SCI, V114, P2903; Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4; Li FG, 1999, J CELL SCI, V112, P4589; Lin XY, 2003, CURR BIOL, V13, P922, DOI 10.1016/S0960-9822(03)00372-5; Mackinnon AC, 2002, CURR BIOL, V12, P787, DOI 10.1016/S0960-9822(02)00810-2; Marotta A, 2001, ONCOGENE, V20, P6250, DOI 10.1038/sj.onc.1204791; MICHELSEN JW, 1993, P NATL ACAD SCI USA, V90, P4404, DOI 10.1073/pnas.90.10.4404; Naujokat C, 2000, EUR J HAEMATOL, V65, P221, DOI 10.1034/j.1600-0609.2000.065004221.x; Nikolopoulos SN, 2000, J CELL BIOL, V151, P1435, DOI 10.1083/jcb.151.7.1435; Nikolopoulos SN, 2001, J BIOL CHEM, V276, P23499, DOI 10.1074/jbc.M102163200; Olski TM, 2001, J CELL SCI, V114, P525; REARDEN A, 1994, BIOCHEM BIOPH RES CO, V201, P1124, DOI 10.1006/bbrc.1994.1822; Richardson A, 1997, MOL CELL BIOL, V17, P6906, DOI 10.1128/MCB.17.12.6906; Sakai T, 2003, GENE DEV, V17, P926, DOI 10.1101/gad.255603; SCHMEICHEL KL, 1994, CELL, V79, P211, DOI 10.1016/0092-8674(94)90191-0; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Troussard AA, 2003, J BIOL CHEM, V278, P22374, DOI 10.1074/jbc.M303083200; Tu YZ, 2001, J CELL BIOL, V153, P585, DOI 10.1083/jcb.153.3.585; Tu YZ, 1999, MOL CELL BIOL, V19, P2425; Velyvis A, 2001, J BIOL CHEM, V276, P4932, DOI 10.1074/jbc.M007632200; Webb DJ, 2002, NAT CELL BIOL, V4, pE97, DOI 10.1038/ncb0402-e97; White DE, 2001, ONCOGENE, V20, P7064, DOI 10.1038/sj.onc.1204910; WU CY, 1995, J CELL SCI, V108, P821; Wu CY, 1999, J CELL SCI, V112, P4485; Wu CY, 2001, J CELL BIOL, V155, P505, DOI 10.1083/jcb.200108077; Wu CY, 1998, J BIOL CHEM, V273, P528, DOI 10.1074/jbc.273.1.528; Yamaji S, 2001, J CELL BIOL, V153, P1251, DOI 10.1083/jcb.153.6.1251; Zamir E, 2001, J CELL SCI, V114, P3583; Zervas CG, 2001, J CELL BIOL, V152, P1007, DOI 10.1083/jcb.152.5.1007; Zhan Y, 2002, J BIOL CHEM, V277, P4512, DOI 10.1074/jbc.M109520200; Zhang YJ, 2002, J CELL SCI, V115, P4777, DOI 10.1242/jcs.00166; Zhang YJ, 2002, J BIOL CHEM, V277, P38328, DOI 10.1074/jbc.M205576200	59	165	173	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51324	51333		10.1074/jbc.M309122200	http://dx.doi.org/10.1074/jbc.M309122200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14551191	hybrid			2022-12-27	WOS:000187206300060
J	Perez-Sala, D; Cernuda-Morollon, E; Canada, FJ				Perez-Sala, D; Cernuda-Morollon, E; Canada, FJ			Molecular basis for the direct inhibition of AP-1 DNA binding by 15-deoxy-Delta(12,14)-prostaglandin J(2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED RECEPTOR-GAMMA; NF-KAPPA-B; NITRIC-OXIDE; CYCLOPENTENONE PROSTAGLANDINS; CYCLOOXYGENASE-2 EXPRESSION; DEPENDENT REPRESSION; POTENTIAL INDUCERS; REDOX REGULATION; PROTEIN-KINASE; APOPTOSIS	Cyclopentenone prostaglandins may interfere with cellular functions by multiple mechanisms. The cyclopentenone 15-deoxy-Delta(12,14)-prostaglandin J(2) (15d- PGJ(2)) has been reported to inhibit the activity of the transcription factor AP-1 in several experimental settings. We have explored the possibility of a direct interaction of 15d- PGJ(2) with AP-1 proteins. Here we show that 15d-PGJ(2) covalently modifies c-Jun and directly inhibits the DNA binding activity of AP-1. The modification of c-Jun occurs both in vitro and in intact cells as detected by labeling with biotinylated 15d- PGJ(2) and mass spectrometry analysis. Attachment of the cyclopentenone prostaglandin occurs at cysteine 269, which is located in the c-Jun DNA binding domain. In addition, 15d- PGJ(2) can promote the oligomerization of a fraction of c-Jun through the formation of intermolecular disulfide bonds or 15d-PGJ(2)-bonded dimers. Our results identify a novel site of interaction of 15d- PGJ(2) with the AP-1 activation pathway that may contribute to the complex effects of cyclopentenone prostaglandins on the cellular response to pro-inflammatory agents. They also show the first evidence for the induction of protein cross-linking by 15d- PGJ(2).	CSIC, Dept Estructura & Func Prot, Ctr Invest Biol, Madrid 28040, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB)	Perez-Sala, D (corresponding author), CSIC, Dept Estructura & Func Prot, Ctr Invest Biol, Ramiro Maeztui 9, Madrid 28040, Spain.	dperezsala@cib.csic.es	Perez-Sala, Dolores/L-5969-2014; Cañada, Francisco J./D-5837-2014	Perez-Sala, Dolores/0000-0003-0600-665X; Cañada, Francisco J./0000-0003-4462-1469				ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ATSMON J, 1990, BIOCHEMISTRY-US, V29, P3760, DOI 10.1021/bi00467a023; BANNISTER AJ, 1991, ONCOGENE, V6, P1243; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; Boyault S, 2001, FEBS LETT, V501, P24, DOI 10.1016/S0014-5793(01)02614-X; Castrillo A, 2000, MOL CELL BIOL, V20, P1692, DOI 10.1128/MCB.20.5.1692-1698.2000; Castrillo A, 2003, MOL CELL BIOL, V23, P1196, DOI 10.1128/MCB.23.4.1196-1208.2003; Cernuda-Morollon E, 2002, J AM SOC NEPHROL, V13, P2223, DOI 10.1097/01.ASN.0000025786.87646.B1; Cernuda-Morollon E, 2001, J BIOL CHEM, V276, P35530, DOI 10.1074/jbc.M104518200; Clay CE, 2001, J BIOL CHEM, V276, P47131, DOI 10.1074/jbc.C100339200; Cox B, 2002, BBA-MOL CELL BIOL L, V1584, P37, DOI 10.1016/S1388-1981(02)00267-6; Cuzzocrea S, 2002, MOL PHARMACOL, V61, P997, DOI 10.1124/mol.61.5.997; Davies SS, 2002, FASEB J, V16, P715, DOI 10.1096/fj.01-0696fje; Delerive P, 1999, CIRC RES, V85, P394, DOI 10.1161/01.RES.85.5.394; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; Diaz-Cazorla M, 1999, J AM SOC NEPHROL, V10, P943; Fahmi H, 2001, ARTHRITIS RHEUM, V44, P595, DOI 10.1002/1529-0131(200103)44:3<595::AID-ANR108>3.3.CO;2-#; Filomeni G, 2002, BIOCHEM PHARMACOL, V64, P1057, DOI 10.1016/S0006-2952(02)01176-0; Gilroy DW, 1999, NAT MED, V5, P698, DOI 10.1038/9550; GLOVER JNM, 1995, NATURE, V373, P257, DOI 10.1038/373257a0; Hortelano S, 2000, J IMMUNOL, V165, P6525, DOI 10.4049/jimmunol.165.11.6525; Jung KM, 2003, MOL PHARMACOL, V63, P607, DOI 10.1124/mol.63.3.607; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Kawamoto Y, 2000, J BIOL CHEM, V275, P11291, DOI 10.1074/jbc.275.15.11291; Klatt P, 1999, J BIOL CHEM, V274, P15857, DOI 10.1074/jbc.274.22.15857; Klatt P, 1999, FASEB J, V13, P1481, DOI 10.1096/fasebj.13.12.1481; Kondo M, 2002, P NATL ACAD SCI USA, V99, P7367, DOI 10.1073/pnas.112212599; Kondo M, 2001, J BIOL CHEM, V276, P12076, DOI 10.1074/jbc.M009630200; Li LY, 2001, J BIOL CHEM, V276, P38152; Li M, 2000, MOL CELL BIOL, V20, P4699, DOI 10.1128/MCB.20.13.4699-4707.2000; Maggi LB, 2000, DIABETES, V49, P346, DOI 10.2337/diabetes.49.3.346; Moos PJ, 2003, J BIOL CHEM, V278, P745, DOI 10.1074/jbc.M211134200; NARUMIYA S, 1987, J PHARMACOL EXP THER, V242, P306; NOYORI R, 1993, SCIENCE, V259, P44, DOI 10.1126/science.8418493; Oliva JL, 2003, P NATL ACAD SCI USA, V100, P4772, DOI 10.1073/pnas.0735842100; Reilly CM, 2000, J IMMUNOL, V164, P1498, DOI 10.4049/jimmunol.164.3.1498; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Rossi A, 2000, NATURE, V403, P103, DOI 10.1038/47520; Sawano H, 2002, KIDNEY INT, V61, P1957, DOI 10.1046/j.1523-1755.2002.00351.x; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Shibata T, 2002, J BIOL CHEM, V277, P10459, DOI 10.1074/jbc.M110314200; Shibata T, 2003, J BIOL CHEM, V278, P26046, DOI 10.1074/jbc.M303690200; Simonin MA, 2002, AM J PHYSIOL-CELL PH, V282, pC125, DOI 10.1152/ajpcell.2002.282.1.C125; Straus DS, 2000, P NATL ACAD SCI USA, V97, P4844, DOI 10.1073/pnas.97.9.4844; Straus DS, 2001, MED RES REV, V21, P185, DOI 10.1002/med.1006; Subbaramaiah K, 2001, J BIOL CHEM, V276, P12440, DOI 10.1074/jbc.M007237200; Tsubouchi Y, 2001, BIOCHEM BIOPH RES CO, V283, P750, DOI 10.1006/bbrc.2001.4847; Wang CG, 2001, MOL CELL BIOL, V21, P3057, DOI 10.1128/MCB.21.9.3057-3070.2001	48	130	135	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51251	51260		10.1074/jbc.M309409200	http://dx.doi.org/10.1074/jbc.M309409200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14532268	hybrid, Green Published			2022-12-27	WOS:000187206300051
J	Fan, KQ; Wei, P; Feng, Q; Chen, SD; Huang, CK; Ma, L; Lai, B; Pei, JF; Liu, Y; Chen, JG; Lai, LH				Fan, KQ; Wei, P; Feng, Q; Chen, SD; Huang, CK; Ma, L; Lai, B; Pei, JF; Liu, Y; Chen, JG; Lai, LH			Biosynthesis, purification, and substrate specificity of severe acute respiratory syndrome coronavirus 3C-like proteinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHINOVIRUS 3C PROTEASE; STRUCTURE-BASED DESIGN; BIOLOGICAL EVALUATION; MAIN PROTEINASE; 2-PYRIDONE-CONTAINING PEPTIDOMIMETICS; AMINO-ACIDS; INHIBITORS; SARS; REVEALS; FOLD	The 3C-like proteinase of severe acute respiratory syndrome (SARS) coronavirus has been proposed to be a key target for structural-based drug design against SARS. In order to understand the active form and the substrate specificity of the enzyme, we have cloned, expressed, and purified SARS 3C-like proteinase. Analytic gel filtration shows a mixture of monomer and dimer at a protein concentration of 4 mg/ml and mostly monomer at 0.2 mg/ml, which correspond to the concentration used in the enzyme assays. The linear decrease of the enzymatic-specific activity with the decrease of enzyme concentration revealed that only the dimeric form is active and the dimeric interface could be targeted for structural-based drug design against SARS 3C-like proteinase. By using a high pressure liquid chromatography assay, SARS 3C-like proteinase was shown to cut the 11 peptides covering all of the 11 cleavage sites on the viral polyprotein with different efficiency. The two peptides corresponding to the two self-cleavage sites are the two with highest cleavage efficiency, whereas peptides with non-canonical residues at P2 or P1' positions react slower. The P2 position of the substrates seems to favor large hydrophobic residues. Secondary structure studies for the peptide substrates revealed that substrates with more beta-sheetlike structure tend to react fast. This study provides a basic understanding of the enzyme catalysis and a full substrate specificity spectrum for SARS 3C-like proteinase, which are helpful for structural-based inhibitor design against SARS and other coronavirus.	Peking Univ, Coll Chem, State Key Lab Struct Chem Stable & Unstable Speci, Beijing 100871, Peoples R China; Peking Univ, Coll Life Sci, Dept Cell Biol & Genet, Beijing 100871, Peoples R China; Peking Univ, Ctr Theoret Biol, Beijing 100871, Peoples R China	Peking University; Peking University; Peking University	Lai, LH (corresponding author), Peking Univ, Coll Chem, State Key Lab Struct Chem Stable & Unstable Speci, Beijing 100871, Peoples R China.	lhlai@pku.edu.cn	Fan, Keqiang/E-5366-2012; Pei, Jianfeng/U-9790-2019; CHEN, SIDI/D-8284-2016	Fan, Keqiang/0000-0003-2420-1889; Pei, Jianfeng/0000-0002-8482-1185; CHEN, SIDI/0000-0002-3819-5005				Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658; Anand K, 2002, EMBO J, V21, P3213, DOI 10.1093/emboj/cdf327; Chou KC, 2003, BIOCHEM BIOPH RES CO, V308, P148, DOI 10.1016/S0006-291X(03)01342-1; CORDINGLEY MG, 1990, J BIOL CHEM, V265, P9062; Dragovich PS, 2002, BIOORG MED CHEM LETT, V12, P733, DOI 10.1016/S0960-894X(02)00008-2; Dragovich PS, 2002, J MED CHEM, V45, P1607, DOI 10.1021/jm010469k; Dragovich PS, 2000, BIOORG MED CHEM LETT, V10, P45, DOI 10.1016/S0960-894X(99)00587-9; Dragovich PS, 1999, BIOORG MED CHEM LETT, V9, P2189, DOI 10.1016/S0960-894X(99)00368-6; Dragovich PS, 1999, J MED CHEM, V42, P1213, DOI 10.1021/jm9805384; Dragovich PS, 1999, J MED CHEM, V42, P1203, DOI 10.1021/jm980537b; Dragovich PS, 1998, J MED CHEM, V41, P2819, DOI 10.1021/jm9800696; Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747; FIELDS GB, 1990, INT J PEPT PROT RES, V35, P161, DOI 10.1111/j.1399-3011.1990.tb00939.x; Hegyi A, 2002, J GEN VIROL, V83, P595, DOI 10.1099/0022-1317-83-3-595; JOHNSON WC, 1988, ANNU REV BIOPHYS BIO, V17, P145, DOI 10.1146/annurev.bb.17.060188.001045; Liu Shiyong, 2003, Beijing Da Xue Xue Bao Yi Xue Ban, V35 Suppl, P62; Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953; MATTHEWS DA, 1994, CELL, V77, P761, DOI 10.1016/0092-8674(94)90059-0; Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952; Seipelt J, 1999, VIRUS RES, V62, P159, DOI 10.1016/S0168-1702(99)00043-X; Xiong B, 2003, ACTA PHARMACOL SIN, V24, P497; Ziebuhr J, 1997, J VIROL, V71, P3992, DOI 10.1128/JVI.71.5.3992-3997.1997; ZIEBUHR J, 1995, J VIROL, V69, P4331, DOI 10.1128/JVI.69.7.4331-4338.1995	24	238	256	2	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 16	2004	279	3					1637	1642		10.1074/jbc.M310875200	http://dx.doi.org/10.1074/jbc.M310875200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	762WT	14561748	hybrid, Green Published			2022-12-27	WOS:000188005700011
J	Liu, YL; Burch-Smith, T; Schiff, M; Feng, SH; Dinesh-Kumar, SP				Liu, YL; Burch-Smith, T; Schiff, M; Feng, SH; Dinesh-Kumar, SP			Molecular chaperone Hsp90 associates with resistance protein n and its signaling proteins SGT1 and Rar1 to modulate an innate immune response in plants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCF UBIQUITIN-LIGASE; DISEASE RESISTANCE; MEDIATED RESISTANCE; ESSENTIAL COMPONENT; COP9 SIGNALOSOME; GENE-N; TOLL; ARABIDOPSIS; MAINTENANCE; CAPACITOR	SGT1 and Rar1 are important signaling components of resistance (R) gene-mediated plant innate immune responses. Here we report that SGT1 and Rar1 associate with the molecular chaperone Hsp90. In addition, we show that Hsp90 associates with the resistance protein N that confers resistance to tobacco mosaic virus. This suggests that Hsp90-SGT1-Rar1 and R proteins might exist in one complex. Suppression of Hsp90 in Nicotiana benthamiana plants shows that it plays an important role in plant growth and development. In addition, Hsp90 suppression in NN plants compromises N-mediated resistance to tobacco mosaic virus. Our results reveal a new role for SGT1- and Rar1-associated chaperone machinery in R gene-mediated defense signaling.	Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA	Yale University	Dinesh-Kumar, SP (corresponding author), Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA.	savithramma.dinesh-kumar@yale.edu	Schiff, Manuel/G-3596-2017; Liu, Yule/E-5700-2010	Schiff, Manuel/0000-0001-8272-232X; Liu, Yule/0000-0002-4423-6045	NIGMS NIH HHS [R01 GM 62625] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062625] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Austin MJ, 2002, SCIENCE, V295, P2077, DOI 10.1126/science.1067747; Azevedo C, 2002, SCIENCE, V295, P2073, DOI 10.1126/science.1067554; Bandholtz L, 2003, CELL MOL LIFE SCI, V60, P422, DOI 10.1007/s000180300035; Caplan Avrom J., 2003, EMBO Reports, V4, P126, DOI 10.1038/sj.embor.embor742; Chinkers M, 2001, TRENDS ENDOCRIN MET, V12, P28, DOI 10.1016/S1043-2760(00)00335-0; Dangl JL, 2001, NATURE, V411, P826, DOI 10.1038/35081161; FINLEY RL, 1996, GENE PROBES PRACTICA, P169; FLOR HH, 1971, ANNU REV PHYTOPATHOL, V9, P275, DOI 10.1146/annurev.py.09.090171.001423; Garcia-Ranea JA, 2002, FEBS LETT, V529, P162, DOI 10.1016/S0014-5793(02)03321-5; Hammond-Kosack KE, 2003, CURR OPIN BIOTECH, V14, P177, DOI 10.1016/S0958-1669(03)00035-1; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Imai J, 2003, EMBO J, V22, P3557, DOI 10.1093/emboj/cdg349; Kanzaki H, 2003, MOL PLANT PATHOL, V4, P383, DOI [10.1046/j.1364-3703.2003.00186.x, 10.1046/J.1364-3703.2003.00186.X]; Kitagawa K, 1999, MOL CELL, V4, P21, DOI 10.1016/S1097-2765(00)80184-7; Krishna P, 1997, PLANT MOL BIOL, V33, P457, DOI 10.1023/A:1005709308096; Krishna P, 2001, CELL STRESS CHAPERON, V6, P238, DOI 10.1379/1466-1268(2001)006<0238:THFOPI>2.0.CO;2; Liu Y, 2002, PLANT CELL, V14, P1483, DOI 10.1105/tpc.002493; Liu YL, 2002, PLANT J, V30, P415, DOI 10.1046/j.1365-313X.2002.01297.x; Lyapina S, 2001, SCIENCE, V292, P1382, DOI 10.1126/science.1059780; Matsuzawa S, 2001, MOL CELL, V7, P915, DOI 10.1016/S1097-2765(01)00242-8; Medzhitov R, 2000, TRENDS MICROBIOL, V8, P452, DOI 10.1016/S0966-842X(00)01845-X; Pearl LH, 2002, ADV PROTEIN CHEM, V59, P157; Peart JR, 2002, P NATL ACAD SCI USA, V99, P10865, DOI 10.1073/pnas.152330599; Picard D, 2002, CELL MOL LIFE SCI, V59, P1640, DOI 10.1007/PL00012491; Pratt WB, 1999, CELL SIGNAL, V11, P839, DOI 10.1016/S0898-6568(99)00064-9; Queitsch C, 2002, NATURE, V417, P618, DOI 10.1038/nature749; Randow F, 2001, NAT CELL BIOL, V3, P891, DOI 10.1038/ncb1001-891; Richter K, 2001, J CELL PHYSIOL, V188, P281, DOI 10.1002/jcp.1131; Ruiz MT, 1998, PLANT CELL, V10, P937, DOI 10.1105/tpc.10.6.937; Rutherford SL, 1998, NATURE, V396, P336, DOI 10.1038/24550; Shirasu K, 1999, CELL, V99, P355, DOI 10.1016/S0092-8674(00)81522-6; Stemmann O, 2002, P NATL ACAD SCI USA, V99, P8585, DOI 10.1073/pnas.082223899; Takahashi A, 2003, P NATL ACAD SCI USA, V100, P11777, DOI 10.1073/pnas.2033934100; Vabulas RM, 2002, CURR TOP MICROBIOL, V270, P169; Vabulas RM, 2002, J BIOL CHEM, V277, P20847, DOI 10.1074/jbc.M200425200; Wei N, 1999, TRENDS GENET, V15, P98, DOI 10.1016/S0168-9525(98)01670-9; WHITHAM S, 1994, CELL, V78, P1101, DOI 10.1016/0092-8674(94)90283-6; Young JC, 2001, J CELL BIOL, V154, P267, DOI 10.1083/jcb.200104079; Zhang SQ, 1998, P NATL ACAD SCI USA, V95, P7433, DOI 10.1073/pnas.95.13.7433; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a	40	259	278	3	32	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 16	2004	279	3					2101	2108		10.1074/jbc.M310029200	http://dx.doi.org/10.1074/jbc.M310029200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	762WT	14583611	hybrid			2022-12-27	WOS:000188005700066
J	Mohanty, BK; Bastia, D				Mohanty, BK; Bastia, D			Binding of the replication terminator protein Fob1p to the Ter sites of yeast causes polar fork arrest	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-I; RIBOSOMAL DNA-REPLICATION; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; FISSION YEAST; BLOCK PROTEIN; RECOMBINATION; TRANSCRIPTION; RDNA; HELICASE	Fob1p protein has been implicated in the termination of replication forks at the two tandem termini present in the non-transcribed spacer region located between the sequences encoding the 35 S and the 5 S RNAs of Saccharomyces cerevisiae. However, the biochemistry and mode of action of this protein were previously unknown. We have purified the Fob1p protein to near-homogeneity, and we developed a novel technique to show that it binds specifically to the Ter1 and Ter2 sequences. Interestingly, the two sequences share no detectable homology. We present two lines of evidence showing that the interaction of the Fob1p with the Ter sites causes replication termination. First, a mutant of FOB1, L104S that significantly reduced the binding of the mutant form of the protein to the tandem Ter sites, also failed to promote replication termination in vivo. The mutant did not diminish nucleolar transport, and interaction of the mutant form of Fob1p with itself and with another protein encoded in the locus YDR026C suggested that the mutation did not cause global misfolding of the protein. Second, DNA site mutations in the Ter sequences that separately and specifically abolished replication fork arrest at Ter1 or Ter2 also eliminated sequence-specific binding of the Fob1p to the two sites. The work presented here definitively established Ter DNA-Fob1p interaction as an important step in fork arrest.	Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA	Medical University of South Carolina	Bastia, D (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA.	bastia@musc.edu						Bastia D., 1996, DNA REPLICATION EUKA, P177; Benguria A, 2003, NUCLEIC ACIDS RES, V31, P893, DOI 10.1093/nar/gkg188; BREWER BJ, 1987, CELL, V51, P463, DOI 10.1016/0092-8674(87)90642-8; BREWER BJ, 1992, CELL, V71, P267, DOI 10.1016/0092-8674(92)90355-G; Codlin S, 2003, EMBO J, V22, P3431, DOI 10.1093/emboj/cdg330; Dalgaard JZ, 2000, CELL, V102, P745, DOI 10.1016/S0092-8674(00)00063-5; Dalgaard LZ, 1999, NATURE, V400, P181, DOI 10.1038/22139; Davey MJ, 2003, J BIOL CHEM, V278, P4491, DOI 10.1074/jbc.M210511200; Defossez PA, 1999, MOL CELL, V3, P447, DOI 10.1016/S1097-2765(00)80472-4; Dlakic M, 2002, PROTEIN SCI, V11, P1274, DOI 10.1110/ps.4470102; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Gadal O, 2002, EMBO J, V21, P5498, DOI 10.1093/emboj/cdf539; HUANG GS, 1995, GENETICS, V141, P845; Imai S, 2000, COLD SPRING HARB SYM, V65, P297, DOI 10.1101/sqb.2000.65.297; Ito T, 2001, P NATL ACAD SCI USA, V98, P4569, DOI 10.1073/pnas.061034498; Ivessa AS, 2000, CELL, V100, P479, DOI 10.1016/S0092-8674(00)80683-2; James P, 1996, GENETICS, V144, P1425; Johzuka K, 2002, GENES CELLS, V7, P99, DOI 10.1046/j.1356-9597.2001.00508.x; Kaplan DL, 2003, J BIOL CHEM, V278, P49171, DOI 10.1074/jbc.M308074200; KEIL RL, 1984, CELL, V39, P377, DOI 10.1016/0092-8674(84)90016-3; KHATRI GS, 1989, CELL, V59, P667, DOI 10.1016/0092-8674(89)90012-3; Kobayashi T, 1998, GENE DEV, V12, P3821, DOI 10.1101/gad.12.24.3821; Kobayashi T, 1996, GENES CELLS, V1, P465, DOI 10.1046/j.1365-2443.1996.d01-256.x; Labib K, 2000, SCIENCE, V288, P1643, DOI 10.1126/science.288.5471.1643; Labib K, 2001, MOL BIOL CELL, V12, P3658, DOI 10.1091/mbc.12.11.3658; Landry J, 2000, P NATL ACAD SCI USA, V97, P5807, DOI 10.1073/pnas.110148297; LEE EH, 1989, P NATL ACAD SCI USA, V86, P9104, DOI 10.1073/pnas.86.23.9104; Lee JK, 2001, P NATL ACAD SCI USA, V98, P54, DOI 10.1073/pnas.98.1.54; LIN YH, 1991, GENETICS, V127, P31; LINSKENS MHK, 1988, MOL CELL BIOL, V8, P4927, DOI 10.1128/MCB.8.11.4927; LITTLE RD, 1993, MOL CELL BIOL, V13, P6600, DOI 10.1128/MCB.13.10.6600; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Lopez-Estrano C, 1999, PLANT MOL BIOL, V40, P99, DOI 10.1023/A:1026405311132; Lopez-Estrano C, 1998, J MOL BIOL, V277, P249, DOI 10.1006/jmbi.1997.1607; Min JR, 2001, CELL, V105, P269, DOI 10.1016/S0092-8674(01)00317-8; Mohanty BK, 1996, EMBO J, V15, P2530, DOI 10.1002/j.1460-2075.1996.tb00610.x; Mulugu S, 2001, P NATL ACAD SCI USA, V98, P9569, DOI 10.1073/pnas.171065898; Puig O, 2001, METHODS, V24, P218, DOI 10.1006/meth.2001.1183; Rothstein R, 2000, GENE DEV, V14, P1; Sanchez JA, 1998, EXP CELL RES, V238, P220, DOI 10.1006/excr.1997.3835; Schwacha A, 2001, MOL CELL, V8, P1093, DOI 10.1016/S1097-2765(01)00389-6; Takeuchi Y, 2003, GENE DEV, V17, P1497, DOI 10.1101/gad.1085403; Tanner KG, 2000, P NATL ACAD SCI USA, V97, P14178, DOI 10.1073/pnas.250422697; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; VOELKELMEIMAN K, 1987, CELL, V48, P1071, DOI 10.1016/0092-8674(87)90714-8; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; Ward TR, 2000, MOL CELL BIOL, V20, P4948, DOI 10.1128/MCB.20.13.4948-4957.2000; WIESENDANGER B, 1994, NUCLEIC ACIDS RES, V22, P5038, DOI 10.1093/nar/22.23.5038; ZEHFUS BR, 1990, GENETICS, V126, P41; Zhang XD, 2000, MOL CELL, V6, P1473, DOI 10.1016/S1097-2765(00)00143-X	50	48	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 16	2004	279	3					1932	1941		10.1074/jbc.M309078200	http://dx.doi.org/10.1074/jbc.M309078200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	762WT	14576157	hybrid			2022-12-27	WOS:000188005700047
J	Besnard-Guerin, C; Belaidouni, N; Lassot, I; Segeral, E; Jobart, A; Marchal, C; Benarous, R				Besnard-Guerin, C; Belaidouni, N; Lassot, I; Segeral, E; Jobart, A; Marchal, C; Benarous, R			HIV-1 Vpu sequesters beta-transducin repeat-containing protein (beta TrCP) in the cytoplasm and provokes the accumulation of beta-catenin and other SCF beta TrCP substrates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I-KAPPA-B; F-BOX PROTEIN; P105 REQUIRES PHOSPHORYLATION; SIGNAL-INDUCED UBIQUITINATION; THYMOCYTE DEVELOPMENT; AXIS FORMATION; TCF COMPLEX; DEGRADATION; LIGASE; ACTIVATION	The human immunodeficiency virus type 1 Vpu protein acts as an adaptor for the proteasomal degradation of CD4 by recruiting CD4 and beta-transducin repeat-containing protein (betaTrCP), the receptor component of the multisubunit SCF-betaTrCP E3 ubiquitin ligase complex. We showed that the expression of a Vpu-green fluorescent fusion protein prevented the proteosomal degradation of betaTrCP substrates such as beta-catenin, IkappaBalpha, and ATF4, which are normally directly targeted to the proteasome for degradation. beta-Catenin was translocated into the nucleus, whereas the tumor necrosis factor-induced nuclear translocation of NFkappaB was impaired. beta-Catenin was also up-regulated in cells producing Vpu+ human immunodeficiency virus type 1 but not in cells producing Vpu-deficient viruses. The overexpression of ATF4 also provoked accumulation of beta-catenin, but to a lower level than that resulting from the expression of Vpu. Finally, the expression of Vpu induces the exclusion of betaTrCP from the nucleus. These data suggest that Vpu is a strong competitive inhibitor of betaTrCP that impairs the degradation of SCF-betaTrCP substrates as long as Vpu has an intact phosphorylation motif and can bind to betaTrCP.	Univ Paris 05, Inst Cochin, Dept Infect Dis, CNRS,UMR 8104,INSERM,U567, F-75014 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Benarous, R (corresponding author), Univ Paris 05, Inst Cochin, Dept Infect Dis, CNRS,UMR 8104,INSERM,U567, 27 Rue Faubourg St Jacques, F-75014 Paris, France.		Besnard-Guerin, Corinne/J-3985-2017; Lassot, Irena/O-3208-2017	Lassot, Irena/0000-0001-7059-7963				Akari H, 2001, J EXP MED, V194, P1299, DOI 10.1084/jem.194.9.1299; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BOUR S, 1995, J VIROL, V69, P1510, DOI 10.1128/JVI.69.3.1510-1520.1995; Bour S, 2001, J BIOL CHEM, V276, P15920, DOI 10.1074/jbc.M010533200; Casella CR, 1999, J VIROL, V73, P92, DOI 10.1128/JVI.73.1.92-100.1999; Davis M, 2002, GENE DEV, V16, P439, DOI 10.1101/gad.218702; Fong A, 2002, J BIOL CHEM, V277, P22111, DOI 10.1074/jbc.C200151200; Fuchs SY, 1999, ONCOGENE, V18, P2039, DOI 10.1038/sj.onc.1202760; Fujimuro M, 2003, NAT MED, V9, P300, DOI 10.1038/nm829; Gounari F, 2001, NAT IMMUNOL, V2, P863, DOI 10.1038/ni0901-863; Hampton RY, 2002, CURR OPIN CELL BIOL, V14, P476, DOI 10.1016/S0955-0674(02)00358-7; Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8; Ioannidis V, 2001, NAT IMMUNOL, V2, P691, DOI 10.1038/90623; Kitagawa M, 1999, EMBO J, V18, P2401, DOI 10.1093/emboj/18.9.2401; KLIMKAIT T, 1990, J VIROL, V64, P621, DOI 10.1128/JVI.64.2.621-629.1990; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Kramps T, 2002, CELL, V109, P47, DOI 10.1016/S0092-8674(02)00679-7; Kroll M, 1999, J BIOL CHEM, V274, P7941, DOI 10.1074/jbc.274.12.7941; Lagna G, 1999, MECH DEVELOP, V80, P101, DOI 10.1016/S0925-4773(98)00208-1; Lang V, 2003, MOL CELL BIOL, V23, P402, DOI 10.1128/MCB.23.1.402-413.2003; Lassot I, 2001, MOL CELL BIOL, V21, P2192, DOI 10.1128/MCB.21.6.2192-2202.2001; Latres E, 1999, ONCOGENE, V18, P849, DOI 10.1038/sj.onc.1202653; Levesque K, 2003, J BIOL CHEM, V278, P28346, DOI 10.1074/jbc.M300327200; Liu CM, 1999, P NATL ACAD SCI USA, V96, P6273, DOI 10.1073/pnas.96.11.6273; Maniatis T, 1999, GENE DEV, V13, P505, DOI 10.1101/gad.13.5.505; Margottin F, 1996, VIROLOGY, V223, P381, DOI 10.1006/viro.1996.0491; Margottin F, 1998, MOL CELL, V1, P565, DOI 10.1016/S1097-2765(00)80056-8; Miller JR, 1996, GENE DEV, V10, P2527, DOI 10.1101/gad.10.20.2527; Orian A, 2000, EMBO J, V19, P2580, DOI 10.1093/emboj/19.11.2580; Parker DS, 2002, DEVELOPMENT, V129, P2565; Sadot E, 2000, ONCOGENE, V19, P1992, DOI 10.1038/sj.onc.1203519; SCHUBERT U, 1994, J VIROL, V68, P2260, DOI 10.1128/JVI.68.4.2260-2271.1994; SCHUBERT U, 1995, J VIROL, V69, P7699, DOI 10.1128/JVI.69.12.7699-7711.1995; Schubert U, 1996, J VIROL, V70, P809, DOI 10.1128/JVI.70.2.809-819.1996; Spencer E, 1999, GENE DEV, V13, P284, DOI 10.1101/gad.13.3.284; Staal FJT, 2001, EUR J IMMUNOL, V31, P285, DOI 10.1002/1521-4141(200101)31:1<285::AID-IMMU285>3.3.CO;2-4; Stephens EB, 2002, VIROLOGY, V293, P252, DOI 10.1006/viro.2001.1244; STREBEL K, 1989, J VIROL, V63, P3784, DOI 10.1128/JVI.63.9.3784-3791.1989; Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074-7613(00)80042-4; van Noort M, 2002, DEV BIOL, V244, P1, DOI 10.1006/dbio.2001.0566; Willert K, 1998, CURR OPIN GENET DEV, V8, P95, DOI 10.1016/S0959-437X(98)80068-3; WILLEY RL, 1992, J VIROL, V66, P226, DOI 10.1128/JVI.66.1.226-234.1992; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Wu C, 1999, J BIOL CHEM, V274, P29591, DOI 10.1074/jbc.274.42.29591; Yaron A, 1998, NATURE, V396, P590, DOI 10.1038/25159	45	67	69	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	2004	279	1					788	795		10.1074/jbc.M308068200	http://dx.doi.org/10.1074/jbc.M308068200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	757GU	14561767	hybrid			2022-12-27	WOS:000187555300094
J	Higuchi, H; Grambihler, A; Canbay, A; Bronk, SF; Gores, GJ				Higuchi, H; Grambihler, A; Canbay, A; Bronk, SF; Gores, GJ			Bile acids up-regulate death receptor 5/TRAIL-receptor 2 expression via a c-Jun N-terminal kinase-dependent pathway involving Sp1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED APOPTOSIS; NUCLEAR RECEPTOR; GENE-EXPRESSION; TRANSCRIPTION FACTORS; KILLER/DR5 GENE; RAT HEPATOCYTES; MAP KINASES; DNA-DAMAGE; FAS LIGAND; C/EBP-BETA	Bile acids up-regulate death receptor 5 (DR5)/TRAIL-receptor 2 (TRAIL-R2) expression thereby sensitizing hepatocytes to TRAIL-mediated apoptosis. However, the precise mechanism by which bile acids enhance DR5/ TRAIL-R2 expression is unknown. Although several bile acids enhanced DR5/ TRAIL-R2 expression, deoxycholic acid (DCA) was the most potent. DCA stimulated JNK activation and the JNK inhibitor SP600125 blocked DCA-induced DR5/ TRAIL-R2 mRNA and protein expression. Reporter gene analysis identified a 5'-flanking region containing two Sp1 binding sites within the DR5/ TRAIL-R2 promoter as bile acid responsive. Sp1 binding to one of the two sites was enhanced by DCA treatment as evaluated by electrophoretic mobility shift assays and chromatin immunoprecipitation studies. JNK inhibition with SP600125 also blocked binding of Sp1 to the DR5/ TRAIL-R2 promoter. Finally, point mutations of the Sp1 binding site attenuated promoter activity. In conclusion, Sp1 is a bile acid-responsive transcription factor that mediates DR5/ TRAIL-R2 gene expression downstream of JNK.	Mayo Med Sch Clin & Fdn, Div Gastroenterol & Hepatol, Rochester, MN 55905 USA	Mayo Clinic	Gores, GJ (corresponding author), Mayo Med Sch Clin & Fdn, Div Gastroenterol & Hepatol, 200 1st St SW, Rochester, MN 55905 USA.	gores.gregory@mayo.edu	Canbay, Ali/AAL-9620-2020	Canbay, Ali/0000-0001-6069-7899	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK041876, R01DK041876, R37DK041876] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK41876] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bernstein H, 1999, TOXICOL LETT, V108, P37, DOI 10.1016/S0378-4274(99)00113-7; Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; Blaine SA, 2001, J BIOL CHEM, V276, P42737, DOI 10.1074/jbc.M107773200; Botelho FM, 1998, J BIOL CHEM, V273, P5211, DOI 10.1074/jbc.273.9.5211; Bouwman P, 2002, MOL CELL ENDOCRINOL, V195, P27, DOI 10.1016/S0303-7207(02)00221-6; Briz O, 2000, INT J CANCER, V88, P287, DOI 10.1002/1097-0215(20001015)88:2<287::AID-IJC22>3.0.CO;2-U; Brodin G, 2000, J BIOL CHEM, V275, P29023, DOI 10.1074/jbc.M002815200; Choi YH, 2001, INT J ONCOL, V18, P979; Crenesse D, 2000, HEPATOLOGY, V32, P1029, DOI 10.1053/jhep.2000.19065; Czaja MJ, 2003, AM J PHYSIOL-GASTR L, V284, pG875, DOI 10.1152/ajpgi.00549.2002; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Faris M, 1998, J IMMUNOL, V160, P134; Grambihler A, 2003, J BIOL CHEM, V278, P26831, DOI 10.1074/jbc.M303229200; GREIM H, 1972, GASTROENTEROLOGY, V63, P846; Gumpricht E, 2002, J BIOL CHEM, V277, P25823, DOI 10.1074/jbc.M112305200; Gupta S, 2001, J BIOL CHEM, V276, P15816, DOI 10.1074/jbc.M010878200; Haidweger E, 2001, J MOL BIOL, V306, P201, DOI 10.1006/jmbi.2000.4406; Han I, 1998, J CELL BIOCHEM, V68, P50, DOI 10.1002/(SICI)1097-4644(19980101)68:1<50::AID-JCB5>3.0.CO;2-V; Higuchi H, 2003, AM J PHYSIOL-GASTR L, V284, pG734, DOI 10.1152/ajpgi.00491.2002; Higuchi H, 2003, J BIOL CHEM, V278, P454, DOI 10.1074/jbc.M209387200; Higuchi H, 2002, J PHARMACOL EXP THER, V303, P461, DOI 10.1124/jpet.102.040030; Higuchi H, 2001, J BIOL CHEM, V276, P38610, DOI 10.1074/jbc.M105300200; Holt JA, 2003, GENE DEV, V17, P1581, DOI 10.1101/gad.1083503; Ichikawa K, 2001, NAT MED, V7, P954, DOI 10.1038/91000; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; KRAMER B, 1995, J BIOL CHEM, V270, P6577; Kummer JL, 1997, J BIOL CHEM, V272, P20490, DOI 10.1074/jbc.272.33.20490; Makishima M, 2002, SCIENCE, V296, P1313, DOI 10.1126/science.1070477; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; Meng RD, 2001, EXP CELL RES, V262, P154, DOI 10.1006/excr.2000.5073; Miura T, 2001, J BIOL CHEM, V276, P47371, DOI 10.1074/jbc.M107098200; MOLL T, 1995, J BIOL CHEM, V270, P3849, DOI 10.1074/jbc.270.8.3849; MURATA Y, 1994, J BIOL CHEM, V269, P20674; Parks DJ, 1999, SCIENCE, V284, P1365, DOI 10.1126/science.284.5418.1365; PATEL T, 1995, HEPATOLOGY, V21, P1725, DOI 10.1002/hep.1840210635; Pellicciari R, 2002, J MED CHEM, V45, P3569, DOI 10.1021/jm025529g; Pircher PC, 2003, J BIOL CHEM, V278, P27703, DOI 10.1074/jbc.M302128200; Qiao D, 2001, CARCINOGENESIS, V22, P35, DOI 10.1093/carcin/22.1.35; Qiao DH, 2002, BBA-MOL CELL BIOL L, V1583, P108, DOI 10.1016/S1388-1981(02)00190-7; Qiao L, 2003, MOL CELL BIOL, V23, P3052, DOI 10.1128/MCB.23.9.3052-3066.2003; Qiao L, 2002, HEPATOLOGY, V36, P39, DOI 10.1053/jhep.2002.33899; Qiao L, 2001, MOL BIOL CELL, V12, P2629, DOI 10.1091/mbc.12.9.2629; Rafty LA, 2001, NUCLEIC ACIDS RES, V29, P1027, DOI 10.1093/nar/29.5.1027; Ravi R, 2001, NAT CELL BIOL, V3, P409, DOI 10.1038/35070096; Rodrigues CMP, 1998, J CLIN INVEST, V101, P2790, DOI 10.1172/JCI1325; Rust C, 2000, J BIOL CHEM, V275, P20210, DOI 10.1074/jbc.M909992199; Samson SLA, 2002, J MOL ENDOCRINOL, V29, P265, DOI 10.1677/jme.0.0290265; Sheikh MS, 1998, CANCER RES, V58, P1593; Shetty S, 2002, APOPTOSIS, V7, P413, DOI 10.1023/A:1020031023947; Srivastava S, 1998, J CLIN INVEST, V102, P1850, DOI 10.1172/JCI4561; Staudinger JL, 2001, P NATL ACAD SCI USA, V98, P3369, DOI 10.1073/pnas.051551698; Stefano F, 2002, GASTROENTEROLOGY, V122, pA444; Takimoto R, 2000, ONCOGENE, V19, P1735, DOI 10.1038/sj.onc.1203489; Tanaka T, 2000, J MOL CELL CARDIOL, V32, P1955, DOI 10.1006/jmcc.2000.1228; Wang HB, 1999, MOL CELL, V3, P543, DOI 10.1016/S1097-2765(00)80348-2; Wu GS, 2000, ADV EXP MED BIOL, V465, P143; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xie W, 2001, P NATL ACAD SCI USA, V98, P3375, DOI 10.1073/pnas.051014398; Yoshida T, 2001, FEBS LETT, V507, P381, DOI 10.1016/S0014-5793(01)02947-7; Zagariya A, 1998, MOL CELL BIOL, V18, P2815, DOI 10.1128/MCB.18.5.2815	62	113	116	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 2	2004	279	1					51	60		10.1074/jbc.M309476200	http://dx.doi.org/10.1074/jbc.M309476200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	757GU	14561739	hybrid			2022-12-27	WOS:000187555300007
J	Sowden, MP; Lehmann, DM; Lin, XY; Smith, CO; Smith, HC				Sowden, MP; Lehmann, DM; Lin, XY; Smith, CO; Smith, HC			Identification of novel alternative splice variants of APOBEC-1 complementation factor with different capacities to support apolipoprotein B mRNA editing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRACT BINDING-PROTEIN; CATALYTIC SUBUNIT; MOORING SEQUENCE; CYTIDINE DEAMINASE; MOLECULAR-CLONING; DEVELOPMENTAL REGULATION; ESCHERICHIA-COLI; GRY-RBP; ENZYME; DOMAINS	Two novel mRNA transcripts have been identified that result from species- and tissue-specific, alternative polyadenylation and splicing of the pre-mRNA encoding the apolipoprotein B ( apoB) editing catalytic subunit 1 (APOBEC-1) complementation factor (ACF) family of related proteins. The alternatively processed mRNAs encode 43- and 45-kDa proteins that are components of the previously identified p44 cluster of apoB RNA binding, editosomal proteins. Recombinant ACF45 displaced ACF64 and ACF43 in mooring sequence RNA binding but did not demonstrate strong binding to APOBEC-1. In contrast, ACF43 bound strongly to APOBEC-1 but demonstrated weak binding to mooring sequence RNA. Consequently ACF45/43 complemented APOBEC-1 in apoB mRNA editing with less efficiency than full-length ACF64. These data, together with the finding that all ACF variants were co-expressed in rat liver nuclei ( the site of apoB mRNA editing), suggested that ACF variants might compete with one another for APOBEC-1 and apoB mRNA binding and thereby contribute to the regulation of apoB mRNA editing. In support for this hypothesis, the ratio of nuclear ACF65/64 to ACF45/43 decreased when hepatic editing was inhibited by fasting and increased when editing was re-stimulated by refeeding. These findings suggested a new model for the regulation of apoB mRNA editing in which the catalytic potential of editosomes is modulated at the level of their assembly by alterations in the relative abundance of multiple related RNA-binding auxiliary proteins and the expression level of APOBEC-1.	Univ Rochester, Dept Biochem & Biophys, Rochester, NY 14642 USA; Univ Rochester, Dept Pathol & Lab Med, Rochester, NY 14642 USA; Univ Rochester, Environm Hlth Sci Ctr, Rochester, NY 14642 USA; Univ Rochester, James P Wilmot Canc Ctr, Rochester, NY 14642 USA	University of Rochester; University of Rochester; University of Rochester; University of Rochester	Smith, HC (corresponding author), Univ Rochester, Dept Biochem & Biophys, 601 Elmwood Ave, Rochester, NY 14642 USA.	harold_smith@urmc.rochester.edu		Lehmann, David/0000-0003-0174-344X; Smith, Harold/0000-0001-6257-6791	NIDDK NIH HHS [DK43739] Funding Source: Medline; NIEHS NIH HHS [5T32 ES07026] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043739] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007026] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Anant S, 2001, J BIOL CHEM, V276, P47338, DOI 10.1074/jbc.M104911200; Anant S, 2001, CURR OPIN LIPIDOL, V12, P159, DOI 10.1097/00041433-200104000-00009; Anant S, 2001, AM J PHYSIOL-CELL PH, V281, pC1904, DOI 10.1152/ajpcell.2001.281.6.C1904; BACKUS JW, 1991, NUCLEIC ACIDS RES, V19, P6781, DOI 10.1093/nar/19.24.6781; Bass BL, 2002, ANNU REV BIOCHEM, V71, P817, DOI 10.1146/annurev.biochem.71.110601.135501; BAUM CL, 1990, J BIOL CHEM, V265, P19263; Blanc V, 2001, J BIOL CHEM, V276, P46386, DOI 10.1074/jbc.M107654200; Blanc V, 2001, J BIOL CHEM, V276, P10272, DOI 10.1074/jbc.M006435200; BLANC V, 2003, J BIOL CHEM; Carstens RP, 2000, MOL CELL BIOL, V20, P7388, DOI 10.1128/MCB.20.19.7388-7400.2000; CHAN L, 1992, J BIOL CHEM, V267, P25621; Charlet-B N, 2002, MOL CELL, V9, P649, DOI 10.1016/S1097-2765(02)00479-3; CHEN SH, 1987, SCIENCE, V238, P363, DOI 10.1126/science.3659919; Chester A, 2003, EMBO J, V22, P3971, DOI 10.1093/emboj/cdg369; Chou MY, 2000, MOL CELL, V5, P949, DOI 10.1016/S1097-2765(00)80260-9; Dance GSC, 2002, J BIOL CHEM, V277, P12703, DOI 10.1074/jbc.M111337200; Dance GSC, 2000, NUCLEIC ACIDS RES, V28, P424, DOI 10.1093/nar/28.2.424; Dance GSC, 2001, NUCLEIC ACIDS RES, V29, P1772, DOI 10.1093/nar/29.8.1772; FUNAHASHI T, 1995, J LIPID RES, V36, P414; Galloway CA, 2003, BIOTECHNIQUES, V34, P524, DOI 10.2144/03343st04; Giangreco A, 2001, BIOCHEM BIOPH RES CO, V289, P1162, DOI 10.1006/bbrc.2001.6082; GIANNONI F, 1995, J LIPID RES, V36, P1664; GREEVE J, 1993, J LIPID RES, V34, P1367; Greeve J, 1998, BIOL CHEM, V379, P1063, DOI 10.1515/bchm.1998.379.8-9.1063; HARRIS SG, 1993, J BIOL CHEM, V268, P7382; Hastings ML, 2001, CURR OPIN CELL BIOL, V13, P302, DOI 10.1016/S0955-0674(00)00212-X; Henderson JO, 2001, BBA-GENE STRUCT EXPR, V1522, P22, DOI 10.1016/S0167-4781(01)00295-0; Kendrick JS, 2001, BIOCHEM J, V356, P821, DOI 10.1042/0264-6021:3560821; Ladd AN, 2002, GENOME BIOL, V3; LASKI FA, 1986, CELL, V44, P7, DOI 10.1016/0092-8674(86)90480-0; LAU PP, 1995, J LIPID RES, V36, P2069; Lau PP, 1997, J BIOL CHEM, V272, P1452, DOI 10.1074/jbc.272.3.1452; Lau PP, 2001, BIOCHEM BIOPH RES CO, V282, P977, DOI 10.1006/bbrc.2001.4679; Lau PP, 2001, J BIOL CHEM, V276, P46445, DOI 10.1074/jbc.M109215200; Lellek H, 2000, J BIOL CHEM, V275, P19848, DOI 10.1074/jbc.M001786200; Lopez AJ, 1998, ANNU REV GENET, V32, P279, DOI 10.1146/annurev.genet.32.1.279; Maas S, 2000, BIOESSAYS, V22, P790, DOI 10.1002/1521-1878(200009)22:9<790::AID-BIES4>3.0.CO;2-0; Mehta A, 2000, MOL CELL BIOL, V20, P1846, DOI 10.1128/MCB.20.5.1846-1854.2000; Mehta A, 2002, RNA, V8, P69, DOI 10.1017/S1355838202015649; Min HS, 1997, GENE DEV, V11, P1023, DOI 10.1101/gad.11.8.1023; Mukhopadhyay D, 2003, ENDOCRINOLOGY, V144, P711, DOI 10.1210/en.2002-220741; Mukhopadhyay D, 2002, AM J HUM GENET, V70, P38, DOI 10.1086/337952; NAVARATNAM N, 1993, P NATL ACAD SCI USA, V90, P222, DOI 10.1073/pnas.90.1.222; NAVARATNAM N, 1993, J BIOL CHEM, V268, P20709; Navaratnam N, 1998, J MOL BIOL, V275, P695, DOI 10.1006/jmbi.1997.1506; Oka K, 1997, J BIOL CHEM, V272, P1456, DOI 10.1074/jbc.272.39.24387; Phung TL, 1996, METABOLISM, V45, P1056, DOI 10.1016/S0026-0495(96)90001-3; POWELL LM, 1987, CELL, V50, P831, DOI 10.1016/0092-8674(87)90510-1; Rueter SM, 1999, NATURE, V399, P75, DOI 10.1038/19992; SHAH RR, 1991, J BIOL CHEM, V266, P16301; Skuse GR, 1996, NUCLEIC ACIDS RES, V24, P478, DOI 10.1093/nar/24.3.478; Smith CWJ, 2000, TRENDS BIOCHEM SCI, V25, P381, DOI 10.1016/S0968-0004(00)01604-2; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; Smith HC, 1998, METHODS, V15, P27, DOI 10.1006/meth.1998.0603; SMITH HC, 1991, P NATL ACAD SCI USA, V88, P1489, DOI 10.1073/pnas.88.4.1489; Sowden M, 1996, J BIOL CHEM, V271, P3011, DOI 10.1074/jbc.271.6.3011; Sowden MP, 2002, J CELL SCI, V115, P1027; Sowden MP, 1998, NUCLEIC ACIDS RES, V26, P1644, DOI 10.1093/nar/26.7.1644; Sowden MP, 2001, BIOCHEM J, V359, P697, DOI 10.1042/0264-6021:3590697; Stamm S, 2002, HUM MOL GENET, V11, P2409, DOI 10.1093/hmg/11.20.2409; Steinburg MF, 1999, BIOCHEM BIOPH RES CO, V263, P81, DOI 10.1006/bbrc.1999.1329; TENG BB, 1993, SCIENCE, V260, P1816, DOI 10.1126/science.8511591; THORNGATE FE, 1994, P NATL ACAD SCI USA, V91, P5392, DOI 10.1073/pnas.91.12.5392; Van Mater D, 1998, BIOCHEM BIOPH RES CO, V252, P334, DOI 10.1006/bbrc.1998.9647; von Wronski MA, 1998, METABOLISM, V47, P869, DOI 10.1016/S0026-0495(98)90128-7; Wagner EJ, 2002, MOL CELL, V10, P943, DOI 10.1016/S1097-2765(02)00645-7; Wagner EJ, 2001, MOL CELL BIOL, V21, P3281, DOI 10.1128/MCB.21.10.3281-3288.2001; Wedekind JE, 2003, TRENDS GENET, V19, P207, DOI 10.1016/S0168-9525(03)00054-4; Yamanaka S, 1997, GENE DEV, V11, P321, DOI 10.1101/gad.11.3.321; Yang Y, 1997, J BIOL CHEM, V272, P27700, DOI 10.1074/jbc.272.44.27700; Yang Y, 1997, P NATL ACAD SCI USA, V94, P13075, DOI 10.1073/pnas.94.24.13075; Yang Y, 2001, EXP CELL RES, V267, P153, DOI 10.1006/excr.2001.5255; Yang Y, 2000, J BIOL CHEM, V275, P22663, DOI 10.1074/jbc.M910406199; Zhao J, 1999, MICROBIOL MOL BIOL R, V63, P405, DOI 10.1128/MMBR.63.2.405-445.1999	74	20	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 2	2004	279	1					197	206		10.1074/jbc.M307920200	http://dx.doi.org/10.1074/jbc.M307920200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	757GU	14570923	hybrid			2022-12-27	WOS:000187555300024
J	Diks, SH; Hardwick, JC; Diab, RM; van Santen, MM; Versteeg, HH; van Deventer, SJH; Richel, DJ; Peppelenbosch, MP				Diks, SH; Hardwick, JC; Diab, RM; van Santen, MM; Versteeg, HH; van Deventer, SJH; Richel, DJ; Peppelenbosch, MP			Activation of the canonical beta-catenin pathway by histamine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; SYNTHASE KINASE 3-BETA; ADENOMATOUS POLYPOSIS; COLORECTAL-CANCER; MEDIATED TRANSCRIPTION; THYMOCYTE DEVELOPMENT; GROWTH-FACTOR; COLON-CANCER; HELA-CELLS; IN-VITRO	Histamine signaling is a principal regulator in a variety of pathophysiological processes including inflammation, gastric acid secretion, neurotransmission, and tumor growth. We report that histamine stimulation causes transactivation of a T cell factor/beta-catenin-responsive construct in HeLa cells and in the SW-480 colon cell line, whereas histamine did not effect transactivation of a construct containing the mutated response construct FOP. On the protein level, histamine treatment increases phosphorylation of glycogen synthase kinase 3-beta in HeLa cells, murine macrophages, and DLD-1, HT-29, and SW-480 colon cell lines. Furthermore, histamine also decreases the phosphorylated beta-catenin content in HeLa cells and murine macrophages. Finally, pharmacological inhibitors of the histamine H1 receptor counteracted histamine-induced T cell factor/beta-catenin-responsive construct transactivation and the dephosphorylation of beta-catenin in HeLa cells and in macrophages. We conclude that the canonical beta-catenin pathway acts downstream of the histamine receptor H1 in a variety of cell types. The observation that inflammatory molecules, like histamine, activate the beta-catenin pathway may provide a molecular explanation for a possible link between inflammation and cancer.	Univ Amsterdam, Acad Med Ctr, Lab Expt Internal Med, NL-1105 AZ Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam	Diks, SH (corresponding author), Univ Amsterdam, Acad Med Ctr, Lab Expt Internal Med, G2-130,Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.		Versteeg, Henri/G-1783-2018; Hardwick, James/J-4862-2013	Versteeg, Henri/0000-0003-4294-175X; Hardwick, James/0000-0002-9575-5099; Peppelenbosch, Maikel/0000-0001-9112-6028				Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; ADAMS WJ, 1994, GUT, V35, P1632, DOI 10.1136/gut.35.11.1632; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; ARIASMONTANO JA, 1993, EUR J PHARM-MOLEC PH, V245, P291, DOI 10.1016/0922-4106(93)90110-U; ARRANG JM, 1983, NATURE, V302, P832, DOI 10.1038/302832a0; ASH ASF, 1966, BRIT J PHARM CHEMOTH, V27, P427, DOI 10.1111/j.1476-5381.1966.tb01674.x; Bakker Remko A, 2002, Clin Allergy Immunol, V17, P27; Barker N, 2000, ADV CANCER RES, V77, P1; Baron JA, 2000, ANNU REV MED, V51, P511, DOI 10.1146/annurev.med.51.1.511; Baulida J, 1999, BIOCHEM J, V344, P565, DOI 10.1042/0264-6021:3440565; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Bienz M, 1999, CURR OPIN GENET DEV, V9, P595, DOI 10.1016/S0959-437X(99)00016-7; BLACK JW, 1972, NATURE, V236, P385, DOI 10.1038/236385a0; BRONSTEIN I, 1994, BIOTECHNIQUES, V17, P172; Cooper HS, 2000, CARCINOGENESIS, V21, P757, DOI 10.1093/carcin/21.4.757; CRICCO GP, 1994, AGENTS ACTIONS, V43, P17, DOI 10.1007/BF02005757; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Debruyne P, 1999, ACTA GASTRO-ENT BELG, V62, P393; Ding VW, 2000, J BIOL CHEM, V275, P32475, DOI 10.1074/jbc.M005342200; DUBOIS RN, 1995, GASTROENTEROLOGY, V108, P1310, DOI 10.1016/0016-5085(95)90235-X; Elenkov IJ, 1998, J IMMUNOL, V161, P2586; Farr GH, 2000, J CELL BIOL, V148, P691, DOI 10.1083/jcb.148.4.691; Frame S, 2001, MOL CELL, V7, P1321, DOI 10.1016/S1097-2765(01)00253-2; Fujino H, 2001, J BIOL CHEM, V276, P12489, DOI 10.1074/jbc.C100039200; Goss KH, 2000, J CLIN ONCOL, V18, P1967, DOI 10.1200/JCO.2000.18.9.1967; Gounari F, 2001, NAT IMMUNOL, V2, P863, DOI 10.1038/ni0901-863; Grimes CA, 2001, PROG NEUROBIOL, V65, P391, DOI 10.1016/S0301-0082(01)00011-9; HAZAMA A, 1985, BIOCHIM BIOPHYS ACTA, V845, P249, DOI 10.1016/0167-4889(85)90183-1; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; HILL SJ, 1990, PHARMACOL REV, V42, P45; Jacoby RF, 2000, CANCER RES, V60, P5040; Jonsson M, 2000, EUR J CANCER, V36, P242, DOI 10.1016/S0959-8049(99)00276-2; KAHLSON G, 1968, PHYSIOL REV, V48, P155, DOI 10.1152/physrev.1968.48.1.155; Kelly MD, 1999, CANCER, V85, P1658, DOI 10.1002/(SICI)1097-0142(19990415)85:8<1658::AID-CNCR3>3.0.CO;2-Q; Lawson JA, 1996, BRIT J CANCER, V73, P872, DOI 10.1038/bjc.1996.155; LEURS R, 1995, PHARMACOL THERAPEUT, V66, P413, DOI 10.1016/0163-7258(95)00006-3; Li L, 1999, EMBO J, V18, P4233, DOI 10.1093/emboj/18.15.4233; Liu CL, 2001, MOL PHARMACOL, V59, P420, DOI 10.1124/mol.59.3.420; Liu T, 2001, SCIENCE, V292, P1718, DOI 10.1126/science.1060100; Meigs TE, 2001, P NATL ACAD SCI USA, V98, P519, DOI 10.1073/pnas.021350998; Michaelson JS, 2001, ONCOGENE, V20, P5093, DOI 10.1038/sj.onc.1204586; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Nakamura T, 2000, BIOCHEM BIOPH RES CO, V279, P615, DOI 10.1006/bbrc.2000.4008; Nusse R, 1997, CELL, V89, P321, DOI 10.1016/S0092-8674(00)80210-X; OSSIPOVA O, 2003, NAT CELL BIO; Ota S, 2000, ACTA PHARMACOL SIN, V21, P391; Polakis P, 1999, CURR OPIN GENET DEV, V9, P15, DOI 10.1016/S0959-437X(99)80003-3; POLAKIS P, 1997, BIOCHIM BIOPHYS ACTA, V1332, P127; ROSZKOWSKI W, 1977, SCIENCE, V195, P683, DOI 10.1126/science.190677; Seeling JM, 1999, SCIENCE, V283, P2089, DOI 10.1126/science.283.5410.2089; Slusarski DC, 1997, NATURE, V390, P410, DOI 10.1038/37138; Srivastava AK, 1998, MOL CELL BIOCHEM, V182, P135, DOI 10.1023/A:1006857527588; Staal FJT, 2001, EUR J IMMUNOL, V31, P285, DOI 10.1002/1521-4141(200101)31:1<285::AID-IMMU285>3.3.CO;2-4; Strul H, 2000, ISR MED ASSOC J, V2, P695; Takahashi K, 2001, BIOCHEM BIOPH RES CO, V281, P1113, DOI 10.1006/bbrc.2001.4487; Thors B, 2003, ATHEROSCLEROSIS, V168, P245, DOI 10.1016/S0021-9150(03)00127-8; TILLY BC, 1990, J CELL BIOL, V110, P1211, DOI 10.1083/jcb.110.4.1211; TILLY BC, 1990, BIOCHEM J, V266, P235, DOI 10.1042/bj2660235; Tucker EL, 2000, HISTOL HISTOPATHOL, V15, P251, DOI 10.14670/HH-15.251; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; Waltzer L, 1999, CANCER METAST REV, V18, P231, DOI 10.1023/A:1006321324190; Werle E, 1936, BIOCHEM Z, V288, P292; Yuan HD, 1999, J BIOL CHEM, V274, P30419, DOI 10.1074/jbc.274.43.30419	64	19	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52491	52496		10.1074/jbc.M310712200	http://dx.doi.org/10.1074/jbc.M310712200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14563838	hybrid			2022-12-27	WOS:000187480700063
J	Haruta, N; Yu, XN; Yang, SX; Egelman, EH; Cox, MM				Haruta, N; Yu, XN; Yang, SX; Egelman, EH; Cox, MM			A DNA pairing-enhanced conformation of bacterial RecA proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; ATP-GAMMA-S; EXTREMELY RADIATION-RESISTANT; ESCHERICHIA-COLI; DEINOCOCCUS-RADIODURANS; HETERODUPLEX FORMATION; HELICAL FILAMENTS; NUCLEOSIDE TRIPHOSPHATE; BRANCH MIGRATION; BINDING PROTEIN	The RecA proteins of Escherichia coli (Ec) and Deinococcus radiodurans (Dr) both promote a DNA strand exchange reaction involving two duplex DNAs. The four-strand exchange reaction promoted by the DrRecA protein is similar to that promoted by EcRecA, except that key parts of the reaction are inhibited by Ec single-stranded DNA-binding protein (SSB). In the absence of SSB, the initiation of strand exchange is greatly enhanced by dsDNA-ssDNA junctions at the ends of DNA gaps. This same trend is seen with the EcRecA protein. The results lead to an expansion of published hypotheses for the pathway for RecA-mediated DNA pairing, in which the slow first order step (observed in several studies) involves a structural transition to a state we designate P. The P state is identical to the state found when RecA is bound to double-stranded (ds) DNA. The structural state present when the RecA protein is bound to single-stranded (ss) DNA is designated A. The DNA pairing model in turn facilitates an articulation of three additional conclusions arising from the present work. 1) When a segment of a RecA filament bound to ssDNA is forced into the P state (as RecA bound to the ssDNA immediately adjacent to dsDNA-ssDNA junction), the segment becomes "pairing enhanced." 2) The unusual DNA pairing properties of the D. radiodurans RecA protein can be explained by postulating this protein has a more stringent requirement to initiate DNA strand exchange from the P state. 3) RecA filaments bound to dsDNA (P state) have directly observable structural changes relative to RecA filaments bound to ssDNA (A state), involving the C-terminal domain.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA; Univ Virginia, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA	University of Wisconsin System; University of Wisconsin Madison; University of Virginia	Cox, MM (corresponding author), Univ Wisconsin, Dept Biochem, 433 Babcock Dr, Madison, WI 53706 USA.	cox@biochem.wisc.edu	yang, shixin/B-4015-2010; Egelman, Edward H/A-2488-2009	yang, shixin/0000-0002-3639-7818; Egelman, Edward/0000-0003-4844-5212; Haruta, Nami/0000-0002-4232-9635	NIGMS NIH HHS [GM35269, GM32335] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032335, R01GM035269] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arenson TA, 1999, J MOL BIOL, V288, P391, DOI 10.1006/jmbi.1999.2705; Battista JR, 1999, TRENDS MICROBIOL, V7, P362, DOI 10.1016/S0966-842X(99)01566-8; Bazemore LR, 1997, J BIOL CHEM, V272, P14672, DOI 10.1074/jbc.272.23.14672; Bazemore LR, 1997, P NATL ACAD SCI USA, V94, P11863, DOI 10.1073/pnas.94.22.11863; Bedale WA, 1996, J BIOL CHEM, V271, P5725, DOI 10.1074/jbc.271.10.5725; BENEDICT RC, 1988, J BIOL CHEM, V263, P15513; CHOW SA, 1992, J MOL BIOL, V223, P79, DOI 10.1016/0022-2836(92)90717-X; CONLEY EC, 1990, J BIOL CHEM, V265, P10156; Cox MM, 2003, ANNU REV MICROBIOL, V57, P551, DOI 10.1146/annurev.micro.57.030502.090953; COX MM, 1981, P NATL ACAD SCI-BIOL, V78, P6018, DOI 10.1073/pnas.78.10.6018; COX MM, 1999, PROG NUCL ACID RES M, V63, P310; CRAIG NL, 1981, J BIOL CHEM, V256, P8039; DALY MJ, 1994, J BACTERIOL, V176, P3508, DOI 10.1128/JB.176.12.3508-3517.1994; EGELMAN EH, 1988, J MOL BIOL, V200, P329, DOI 10.1016/0022-2836(88)90245-8; EGELMAN EH, 1986, J MOL BIOL, V191, P677, DOI 10.1016/0022-2836(86)90453-5; Egelman EH, 2000, ULTRAMICROSCOPY, V85, P225, DOI 10.1016/S0304-3991(00)00062-0; EGELMAN EH, 1989, SCIENCE, V245, P404, DOI 10.1126/science.2667137; Eggler AL, 2003, J BIOL CHEM, V278, P16389, DOI 10.1074/jbc.M212920200; Ferreira AC, 1997, INT J SYST BACTERIOL, V47, P939, DOI 10.1099/00207713-47-4-939; FLORY J, 1984, P NATL ACAD SCI-BIOL, V81, P7026, DOI 10.1073/pnas.81.22.7026; Gupta RC, 1999, MOL CELL, V4, P705, DOI 10.1016/S1097-2765(00)80381-0; HONIGBERG SM, 1985, J BIOL CHEM, V260, P1845; JAIN SK, 1994, J BIOL CHEM, V269, P20653; KAHN R, 1981, P NATL ACAD SCI-BIOL, V78, P4786, DOI 10.1073/pnas.78.8.4786; KIM JI, 1992, J BIOL CHEM, V267, P16444; Kim JI, 2002, P NATL ACAD SCI USA, V99, P7917, DOI 10.1073/pnas.122218499; KIM JI, 1992, J BIOL CHEM, V267, P16438; Kim JI, 2002, J BACTERIOL, V184, P1649, DOI 10.1128/JB.184.6.1649-1660.2002; KOWALCZYKOWSKI SC, 1987, J MOL BIOL, V193, P97, DOI 10.1016/0022-2836(87)90630-9; KOWALCZYKOWSKI SC, 1991, BIOCHIMIE, V73, P289, DOI 10.1016/0300-9084(91)90216-N; KOWALCZYKOWSKI SC, 1995, P NATL ACAD SCI USA, V92, P3478, DOI 10.1073/pnas.92.8.3478; LAVERY PE, 1992, J BIOL CHEM, V267, P9315; LEE JW, 1990, BIOCHEMISTRY-US, V29, P7677, DOI 10.1021/bi00485a017; LEE JW, 1990, BIOCHEMISTRY-US, V29, P7666, DOI 10.1021/bi00485a016; Lin JY, 1999, SCIENCE, V285, P1558, DOI 10.1126/science.285.5433.1558; LINDSLEY JE, 1990, J BIOL CHEM, V265, P10164; LITTLE JW, 1991, BIOCHIMIE, V73, P411, DOI 10.1016/0300-9084(91)90108-D; LITTLE JW, 1980, P NATL ACAD SCI-BIOL, V77, P3225, DOI 10.1073/pnas.77.6.3225; LOHMAN TM, 1985, J BIOL CHEM, V260, P3594; Lusetti SL, 2002, ANNU REV BIOCHEM, V71, P71, DOI 10.1146/annurev.biochem.71.083101.133940; Lusetti SL, 2003, J BIOL CHEM, V278, P16381, DOI 10.1074/jbc.M212916200; Lusetti SL, 2003, J BIOL CHEM, V278, P16372, DOI 10.1074/jbc.M212917200; Makarova KS, 2001, MICROBIOL MOL BIOL R, V65, P44, DOI 10.1128/MMBR.65.1.44-79.2001; MENETSKI JP, 1990, P NATL ACAD SCI USA, V87, P21, DOI 10.1073/pnas.87.1.21; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MINTON KW, 1994, MOL MICROBIOL, V13, P9, DOI 10.1111/j.1365-2958.1994.tb00397.x; Minton KW, 1996, MUTAT RES-DNA REPAIR, V363, P1, DOI 10.1016/0921-8777(95)00014-3; MUNIYAPPA K, 1984, P NATL ACAD SCI-BIOL, V81, P2757, DOI 10.1073/pnas.81.9.2757; NEUENDORF SK, 1986, J BIOL CHEM, V261, P8276; Nishinaka T, 1997, P NATL ACAD SCI USA, V94, P6623, DOI 10.1073/pnas.94.13.6623; REHRAUER WM, 1993, J BIOL CHEM, V268, P1292; SCHUTTE BC, 1987, BIOCHEMISTRY-US, V26, P5616, DOI 10.1021/bi00392a006; Shan Q, 1997, J BIOL CHEM, V272, P11063; Shan Q, 1998, MOL CELL, V1, P309, DOI 10.1016/S1097-2765(00)80031-3; Shan Q, 1996, J BIOL CHEM, V271, P5712, DOI 10.1074/jbc.271.10.5712; Shan Q, 1996, J MOL BIOL, V257, P756, DOI 10.1006/jmbi.1996.0200; STASIAK A, 1988, J MOL BIOL, V202, P659, DOI 10.1016/0022-2836(88)90293-8; Stole E, 1997, BIOCHEMISTRY-US, V36, P3483, DOI 10.1021/bi962881l; STOLE E, 1994, J BIOL CHEM, V269, P7919; STOLE E, 1995, J BIOL CHEM, V270, P20322, DOI 10.1074/jbc.270.35.20322; TAKAHASHI M, 1989, EUR J BIOCHEM, V183, P617, DOI 10.1111/j.1432-1033.1989.tb21091.x; TATEISHI S, 1992, J MOL BIOL, V223, P115, DOI 10.1016/0022-2836(92)90720-5; ULLSPERGER CJ, 1995, BIOCHEMISTRY-US, V34, P10859, DOI 10.1021/bi00034a019; VanLoock MS, 2003, STRUCTURE, V11, P187, DOI 10.1016/S0969-2126(03)00003-0; WEST SC, 1982, MOL GEN GENET, V187, P209, DOI 10.1007/BF00331119; WEST SC, 1984, CELL, V37, P683, DOI 10.1016/0092-8674(84)90401-X; WEST SC, 1981, P NATL ACAD SCI-BIOL, V78, P6149, DOI 10.1073/pnas.78.10.6149; WEST SC, 1982, MOL GEN GENET, V186, P333, DOI 10.1007/BF00729451; YANCEYWRONA JE, 1995, CURR BIOL, V5, P1149, DOI 10.1016/S0960-9822(95)00231-4; Yang SX, 2001, J MOL BIOL, V314, P1077, DOI 10.1006/jmbi.2000.5213; YU X, 1992, J MOL BIOL, V225, P193, DOI 10.1016/0022-2836(92)91036-O; YU X, 1992, J MOL BIOL, V227, P334, DOI 10.1016/0022-2836(92)90702-L; Yu X, 2001, P NATL ACAD SCI USA, V98, P8419, DOI 10.1073/pnas.111005398	73	36	39	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52710	52723		10.1074/jbc.M308563200	http://dx.doi.org/10.1074/jbc.M308563200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14530291	hybrid			2022-12-27	WOS:000187480700089
J	Monick, MM; Yarovinsky, TO; Powers, LS; Butler, NS; Carter, AB; Gudmundsson, G; Hunninghake, GW				Monick, MM; Yarovinsky, TO; Powers, LS; Butler, NS; Carter, AB; Gudmundsson, G; Hunninghake, GW			Respiratory syncytial virus up-regulates TLR4 and sensitizes airway epithelial cells to endotoxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALVEOLAR MACROPHAGES; TOLL-LIKE RECEPTOR-4; INDUCED LUNG INFLAMMATION; INNATE IMMUNITY; LIPOPOLYSACCHARIDE EXPOSURE; SIGNAL-TRANSDUCTION; SCHOOL-AGE; KAPPA-B; RECOGNITION; ACTIVATION	Airway epithelial cells are unresponsive to endotoxin (lipopolysaccharide (LPS)) exposure under normal conditions. This study demonstrates that respiratory syncytial virus (RSV) infection results in increased sensitivity to this environmental exposure. Infection with RSV results in increased expression of Toll-like receptor (TLR) 4 mRNA, protein, and increased TLR4 membrane localization. This permits significantly enhanced LPS binding to the epithelial monolayer that is blocked by disruption of the Golgi. The increased TLR4 results in an LPS-induced inflammatory response as demonstrated by increased mitogen-activated protein (MAP) kinase activity, IL-8 production, and tumor necrosis factor alpha production. RSV infection also allowed for tumor necrosis factor alpha production subsequent to TLR4 cross-linking with an immobilized antibody. These data suggest that RSV infection sensitizes airway epithelium to a subsequent environmental exposure (LPS) by altered expression and membrane localization of TLR4. The increased interaction between airway epithelial cells and LPS has the potential to profoundly alter airway inflammation.	Univ Iowa, Roy J & Lucille A Carver Coll Med, Iowa City, IA 52240 USA; Natl Univ Hosp Reykjavik, Dept Med, IS-101 Reykjavik, Iceland; Vet Affairs Med Ctr, Iowa City, IA 52240 USA	University of Iowa; Landspitali National University Hospital; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System	Monick, MM (corresponding author), Univ Iowa, Roy J & Lucille A Carver Coll Med, Div Pulm Crit Care & Occupat Med, Rm 100,EMRB, Iowa City, IA 52242 USA.	martha-monick@uiowa.edu	Gudmundsson, Gunnar/F-1974-2013	Gudmundsson, Gunnar/0000-0002-7251-8322; Butler, Noah/0000-0002-1429-0796	NCRR NIH HHS [RR00059] Funding Source: Medline; NHLBI NIH HHS [HL-60316, HL-03860, HL073967-01] Funding Source: Medline; NIEHS NIH HHS [ES-09607] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000059] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL060316, R01HL073967] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES009607] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Abreu MT, 2002, J BIOL CHEM, V277, P20431, DOI 10.1074/jbc.M110333200; Abreu MT, 2001, J IMMUNOL, V167, P1609, DOI 10.4049/jimmunol.167.3.1609; Baldwin TA, 2002, J BIOL CHEM, V277, P50333, DOI 10.1074/jbc.M209075200; Barton GM, 2002, CURR TOP MICROBIOL, V270, P81; Becker S, 2002, AM J RESP CELL MOL, V27, P611, DOI 10.1165/rcmb.4868; Beutler B, 2000, CURR OPIN MICROBIOL, V3, P23, DOI 10.1016/S1369-5274(99)00046-6; Beutler B, 2001, BIOCHEM SOC T, V29, P853, DOI 10.1042/0300-5127:0290853; Beutler B, 2003, NAT REV IMMUNOL, V3, P169, DOI 10.1038/nri1004; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Chen WZ, 2000, EXP LUNG RES, V26, P13, DOI 10.1080/019021400269934; DICKENS LE, 1984, J VIROL, V52, P364, DOI 10.1128/JVI.52.2.364-369.1984; Eigen H, 1999, J PEDIATR-US, V135, pS1; Eisenbarth SC, 2002, J EXP MED, V196, P1645, DOI 10.1084/jem.20021340; Haeberle HA, 2002, J INFECT DIS, V186, P1199, DOI 10.1086/344644; Haynes LM, 2001, J VIROL, V75, P10730, DOI 10.1128/JVI.75.22.10730-10737.2001; Holla AD, 2002, CURR OPIN ALLERGY CL, V2, P141, DOI 10.1097/00130832-200204000-00010; Illi S, 2001, BMJ-BRIT MED J, V322, P390, DOI 10.1136/bmj.322.7283.390; Jagielo PJ, 1996, AM J PHYSIOL-LUNG C, V270, pL1052, DOI 10.1152/ajplung.1996.270.6.L1052; Jagielo PJ, 1998, AM J PHYSIOL-LUNG C, V274, pL26, DOI 10.1152/ajplung.1998.274.1.L26; Joseph TD, 2001, J BIOL CHEM, V276, P47136, DOI 10.1074/jbc.M102030200; Karp Philip H, 2002, Methods Mol Biol, V188, P115; Kline JN, 2000, J APPL PHYSIOL, V89, P1172, DOI 10.1152/jappl.2000.89.3.1172; Kurt-Jones EA, 2000, NAT IMMUNOL, V1, P398, DOI 10.1038/80833; Latz E, 2002, J BIOL CHEM, V277, P47834, DOI 10.1074/jbc.M207873200; Lau Susanne, 2002, Paediatr Respir Rev, V3, P265, DOI 10.1016/S1526-0542(02)00189-6; Levy BT, 1997, J FAM PRACTICE, V45, P473; Means TK, 2000, LIFE SCI, V68, P241, DOI 10.1016/S0024-3205(00)00939-5; Medzhitov R, 2000, TRENDS MICROBIOL, V8, P452, DOI 10.1016/S0966-842X(00)01845-X; Medzhitov R, 2003, CURR OPIN IMMUNOL, V15, P2, DOI 10.1016/S0952-7915(02)00019-5; Medzhitov R, 2001, NAT REV IMMUNOL, V1, P135, DOI 10.1038/35100529; Melmed G, 2003, J IMMUNOL, V170, P1406, DOI 10.4049/jimmunol.170.3.1406; Monick MM, 1999, J BIOL CHEM, V274, P18075, DOI 10.1074/jbc.274.25.18075; Monick MM, 2002, AM J PHYSIOL-LUNG C, V283, pL390, DOI 10.1152/ajplung.00437.2001; Monick MM, 2002, J BIOL CHEM, V277, P32992, DOI 10.1074/jbc.M203218200; Monick MM, 2001, J IMMUNOL, V166, P4713, DOI 10.4049/jimmunol.166.7.4713; Monick MM, 2003, J IMMUNOL, V171, P2625, DOI 10.4049/jimmunol.171.5.2625; Monick MM, 1999, J IMMUNOL, V162, P3005; Mukaida N, 2003, AM J PHYSIOL-LUNG C, V284, pL566, DOI 10.1152/ajplung.00233.2002; Nagai Y, 2002, NAT IMMUNOL, V3, P667, DOI 10.1038/ni809; Nyunoya T, 2003, J BIOL CHEM, V278, P36099, DOI 10.1074/jbc.M304370200; Sengler C, 2001, RESP RES, V3; Soukup JM, 2001, TOXICOL APPL PHARM, V171, P20, DOI 10.1006/taap.2000.9096; Stein R, 1999, LANCET, V354, P541, DOI 10.1016/S0140-6736(98)10321-5; Stephens R, 2002, CURR OPIN ALLERGY CL, V2, P31, DOI 10.1097/00130832-200202000-00006; Suzuki M, 2003, INFECT IMMUN, V71, P3503, DOI 10.1128/IAI.71.6.3503-3511.2003; Thomas KW, 2002, J BIOL CHEM, V277, P492, DOI 10.1074/jbc.M108107200; Tsutsumi-Ishii Y, 2003, J IMMUNOL, V170, P4226, DOI 10.4049/jimmunol.170.8.4226; Vernooy JHJ, 2002, AM J RESP CELL MOL, V26, P152, DOI 10.1165/ajrcmb.26.1.4652; Welliver RC, 1999, J PEDIATR-US, V135, pS14; Zabner J, 2003, AM J PHYSIOL-LUNG C, V284, pL844, DOI 10.1152/ajplung.00355.2002	51	212	235	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					53035	53044		10.1074/jbc.M308093200	http://dx.doi.org/10.1074/jbc.M308093200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14565959	hybrid			2022-12-27	WOS:000187480700127
J	Zhang, XM; Wang, XT; Yue, HW; Leung, SW; Thibodeau, PH; Thomas, PJ; Guggino, SE				Zhang, XM; Wang, XT; Yue, HW; Leung, SW; Thibodeau, PH; Thomas, PJ; Guggino, SE			Organic solutes rescue the functional defect in Delta F508 cystic fibrosis transmembrane conductance regulator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHYLENETETRAHYDROFOLATE REDUCTASE DEFICIENCY; NEPHROGENIC DIABETES-INSIPIDUS; CELL-SURFACE EXPRESSION; PROTEIN STABILIZATION; CHEMICAL CHAPERONES; EPITHELIAL-CELLS; ION-CHANNEL; CFTR; BETAINE; STABILITY	The most common defect in cystic fibrosis, deletion of phenylalanine from position 508 of the cystic fibrosis transmembrane conductance regulator (DeltaF508 CFTR), decreases the trafficking of this protein to the cell surface membrane. Previous studies have shown that low temperature and high concentrations of glycerol or trimethylamine N-oxide can partially counteract the processing defect of DeltaF508 CFTR. The present study investigates whether physiologically relevant concentrations of organic solutes, accumulated by cotransporter proteins, can rescue the misprocessing of DeltaF508 CFTR. Myoinositol alone or myoinositol, betaine, and taurine given sequentially increased the processing of core-glycosylated, endoplasmic reticulum-arrested DeltaF508 CFTR into the fully glycosylated form of CFTR in IB3 cells or NIH 3T3 cells stably expressing DeltaF508 CFTR. Pulse-chase experiments using transiently transfected COS7 cells demonstrated that organic solutes also increased the processing of the core-glycosylated form of green fluorescent protein-DeltaF508 CFTR. Moreover, the prolonged half-life of the complex-glycosylated form of GFP-DeltaF508 CFTR suggests that this treatment stabilized the mature form of the protein. In vitro studies of purified NBD1 stability and aggregation showed that myoinositol stabilized both the DeltaF508 and wild type CFTR and inhibited DeltaF508 misfolding. Most significantly, treatment of CF bronchial airway cells with these transportable organic solutes restores cAMP-stimulated single channel activity of both CFTR and outwardly rectifying chloride channel in the cell surface membrane and also restores a forskolin-stimulated macroscopic Cl-36(-) efflux. We conclude that organic solutes can repair CFTR functions by enhancing the processing of DeltaF508 CFTR to the plasma membrane by stabilizing the complex-glycosylated form of DeltaF508 CFTR.	Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Physiol, Baltimore, MD 21205 USA; Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75235 USA	Johns Hopkins University; Johns Hopkins University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Guggino, SE (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, Rm 929,Ross Bldg,720 Rutland Ave, Baltimore, MD 21205 USA.	sguggino@jhmi.edu	Thomas, Philip J/F-7115-2012; Leung, Steve W/E-5624-2011	Leung, Steve W/0000-0003-2832-2258; Thibodeau, Patrick/0000-0002-6790-144X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK049835, R01DK049835] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK49835] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abdelmalek MF, 2001, AM J GASTROENTEROL, V96, P2711; BACK JF, 1979, BIOCHEMISTRY-US, V18, P5191, DOI 10.1021/bi00590a025; Barak AJ, 1997, ALCOHOL CLIN EXP RES, V21, P1100, DOI 10.1097/00000374-199709000-00024; Barak AJ, 1996, ALCOHOL, V13, P395, DOI 10.1016/0741-8329(96)00030-4; Bedwell DM, 1997, NAT MED, V3, P1280, DOI 10.1038/nm1197-1280; BORDEN LA, 1995, J NEUROCHEM, V64, P977; Brown CR, 1996, CELL STRESS CHAPERON, V1, P117, DOI 10.1379/1466-1268(1996)001<0117:CCCTMP>2.3.CO;2; BURG MB, 1995, AM J PHYSIOL-RENAL, V268, pF983, DOI 10.1152/ajprenal.1995.268.6.F983; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; Collins KD, 1997, BIOPHYS J, V72, P65, DOI 10.1016/S0006-3495(97)78647-8; DALEMANS W, 1991, NATURE, V354, P526, DOI 10.1038/354526a0; DARLING PB, 1985, PEDIATR RES, V19, P578, DOI 10.1203/00006450-198506000-00015; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; DENNING GM, 1992, J CELL BIOL, V118, P551, DOI 10.1083/jcb.118.3.551; Dobson CM, 1999, TRENDS BIOCHEM SCI, V24, P329, DOI 10.1016/S0968-0004(99)01445-0; DRUMM ML, 1991, SCIENCE, V254, P1797, DOI 10.1126/science.1722350; EGAN M, 1992, NATURE, V358, P581, DOI 10.1038/358581a0; EGAN ME, 1995, AM J PHYSIOL-CELL PH, V268, pC243, DOI 10.1152/ajpcell.1995.268.1.C243; Foster BA, 1999, SCIENCE, V286, P2507, DOI 10.1126/science.286.5449.2507; Gao L, 1999, AM J PHYSIOL-LUNG C, V277, pL113, DOI 10.1152/ajplung.1999.277.1.L113; GEKKO K, 1990, J BIOCHEM-TOKYO, V107, P572, DOI 10.1093/oxfordjournals.jbchem.a123088; GEKKO K, 1981, J BIOCHEM-TOKYO, V90, P1633, DOI 10.1093/oxfordjournals.jbchem.a133638; GORDON RE, 1986, AM J PATHOL, V125, P585; GORDON RE, 1992, ADV EXP MED BIOL, V315, P319; GREGORY RJ, 1990, NATURE, V347, P382, DOI 10.1038/347382a0; HAMOSH A, 1992, HUM MOL GENET, V1, P542, DOI 10.1093/hmg/1.7.542; HAWORTH JC, 1993, AM J MED GENET, V45, P572, DOI 10.1002/ajmg.1320450510; HOLME E, 1989, ARCH DIS CHILD, V64, P1061, DOI 10.1136/adc.64.7.1061; HUXTABLE RJ, 1992, PHYSIOL REV, V72, P101, DOI 10.1152/physrev.1992.72.1.101; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; KARTNER N, 1992, NAT GENET, V1, P321, DOI 10.1038/ng0892-321; KENDLER BS, 1989, PREV MED, V18, P79, DOI 10.1016/0091-7435(89)90056-X; Morello JP, 2000, J CLIN INVEST, V105, P887, DOI 10.1172/JCI8688; Moyer BD, 1998, J BIOL CHEM, V273, P21759, DOI 10.1074/jbc.273.34.21759; NAKANISHI T, 1989, P NATL ACAD SCI USA, V86, P6002, DOI 10.1073/pnas.86.15.6002; Peter K, 2002, J BIOL CHEM, V277, P49952, DOI 10.1074/jbc.M209275200; Qu BH, 1996, J BIOL CHEM, V271, P7261, DOI 10.1074/jbc.271.13.7261; Qu BH, 1997, J BIOL CHEM, V272, P15739, DOI 10.1074/jbc.272.25.15739; Rajesh D, 2003, J BIOL CHEM, V278, P35968, DOI 10.1074/jbc.M303280200; RASOLA A, 1995, FEBS LETT, V373, P229, DOI 10.1016/0014-5793(95)01052-G; ROUM JH, 1993, J APPL PHYSIOL, V75, P2419, DOI 10.1152/jappl.1993.75.6.2419; Sato S, 1996, J BIOL CHEM, V271, P635, DOI 10.1074/jbc.271.2.635; Sato S, 1998, J BIOL CHEM, V273, P7189, DOI 10.1074/jbc.273.13.7189; Schwiebert EM, 1998, P NATL ACAD SCI USA, V95, P2674, DOI 10.1073/pnas.95.5.2674; SCHWIEBERT EM, 1999, PHYSL REV S, V79, P145; Sharma M, 2001, J BIOL CHEM, V276, P8942, DOI 10.1074/jbc.M009172200; Sheppard DN, 1999, PHYSIOL REV, V79, P23; SONE M, 1993, AM J PHYSIOL, V264, pF722, DOI 10.1152/ajprenal.1993.264.4.F722; Soto C, 2001, FEBS LETT, V498, P204, DOI 10.1016/S0014-5793(01)02486-3; Tamarappoo BK, 1998, J CLIN INVEST, V101, P2257, DOI 10.1172/JCI2303; Tamarappoo BK, 1999, J BIOL CHEM, V274, P34825, DOI 10.1074/jbc.274.49.34825; TAYLOR LS, 1995, BBA-PROTEIN STRUCT M, V1253, P39, DOI 10.1016/0167-4838(95)00142-H; THOMAS PJ, 1995, TRENDS BIOCHEM SCI, V20, P456, DOI 10.1016/S0968-0004(00)89100-8; van der Vliet A, 2000, Curr Opin Pulm Med, V6, P533, DOI 10.1097/00063198-200011000-00013; Wang AJ, 1997, BIOCHEMISTRY-US, V36, P9101, DOI 10.1021/bi970247h; WARD CL, 1994, J BIOL CHEM, V269, P25710; WHITESIDE CI, 1991, AM J PHYSIOL, V260, pF138, DOI 10.1152/ajprenal.1991.260.1.F138; Wimmer R, 1997, J BIOTECHNOL, V55, P85, DOI 10.1016/S0168-1656(97)00061-8; Yue HW, 2000, J BIOL CHEM, V275, P10030, DOI 10.1074/jbc.275.14.10030	59	73	73	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51232	51242		10.1074/jbc.M309076200	http://dx.doi.org/10.1074/jbc.M309076200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14532265	hybrid			2022-12-27	WOS:000187206300049
J	Covo, S; Blanco, L; Livneh, Z				Covo, S; Blanco, L; Livneh, Z			Lesion bypass by human DNA polymerase mu reveals a template-dependent, sequence-independent nucleotidyl transferase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL NUCLEAR ANTIGEN; YEAST REV1 PROTEIN; TRANSLESION REPLICATION; POL-MU; ABASIC SITES; ESCHERICHIA-COLI; DCMP TRANSFERASE; APURINIC SITES; BETA; DELTA	DNA polymerase mu(pol mu), which is related to terminal deoxynucleotidyl transferase and DNA polymerase beta, is thought to be involved in non-homologous end joining and V(D) J recombination. Pol mu is induced by ionizing radiation and exhibits low fidelity. Analysis of translesion replication by purified human pol mu revealed that it bypasses a synthetic abasic site with high efficiency, using primarily a misalignment mechanism. It can also replicate across two tandem abasic sites, using the same mechanism. Pol mu extends primers whose 3'-terminal nucleotides are located opposite the abasic site. Most remarkably, this extension occurs via a mode of nucleotidyl transferase activity, which does not depend on the sequence of the template. This is not due to simple terminal nucleotidyl transferase activity, because pol mu is unable to add dNTPs to an oligo(dT)(29) primer or to a blunt end duplex oligonucleotide under standard conditions. Thus, pol mu is a dual mode DNA-synthesizing enzyme, which can act as either a classical DNA polymerase or as a non-canonical, template-dependent, but sequence-independent nucleotidyl transferase. To our knowledge, this is the first report on a DNA-synthesizing enzyme with such properties. These activities may be required for its function in non-homologous end joining in the processing of DNA ends prior to ligation.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel; Univ Autonoma Madrid, CSIC, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain	Weizmann Institute of Science; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Livneh, Z (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.		Covo, Shay/GRJ-0608-2022; Blanco, Luis/I-1848-2015					Aoufouchi S, 2000, NUCLEIC ACIDS RES, V28, P3684, DOI 10.1093/nar/28.18.3684; Avkin S, 2002, P NATL ACAD SCI USA, V99, P3764, DOI 10.1073/pnas.062038699; Bertocci B, 2003, IMMUNITY, V19, P203, DOI 10.1016/S1074-7613(03)00203-6; Bertocci B, 2002, J IMMUNOL, V168, P3702, DOI 10.4049/jimmunol.168.8.3702; Daube SS, 2000, BIOCHEMISTRY-US, V39, P397, DOI 10.1021/bi991443m; Daube SS, 2000, BIOCHEMISTRY-US, V39, P348, DOI 10.1021/bi9917784; Dominguez O, 2000, EMBO J, V19, P1731, DOI 10.1093/emboj/19.7.1731; Duvauchelle JB, 2002, NUCLEIC ACIDS RES, V30, P2061, DOI 10.1093/nar/30.9.2061; Efrati E, 1997, J BIOL CHEM, V272, P2559; Friedberg ECW GC, 1995, DNA REPAIR MUTAGENES, P19; Haracska L, 2002, J BIOL CHEM, V277, P15546, DOI 10.1074/jbc.M112146200; Haracska L, 2001, GENE DEV, V15, P945, DOI 10.1101/gad.882301; Haracska L, 2001, J BIOL CHEM, V276, P6861, DOI 10.1074/jbc.M008021200; Havener JM, 2003, BIOCHEMISTRY-US, V42, P1777, DOI 10.1021/bi0270079; HEVRONI D, 1988, P NATL ACAD SCI USA, V85, P5046, DOI 10.1073/pnas.85.14.5046; Kobayashi S, 2002, J BIOL CHEM, V277, P34198, DOI 10.1074/jbc.M204826200; Kornberg A., 1991, DNA REPLICATION; Lin WS, 1999, NUCLEIC ACIDS RES, V27, P4468, DOI 10.1093/nar/27.22.4468; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; Maga G, 2002, J BIOL CHEM, V277, P48434, DOI 10.1074/jbc.M206889200; Mahajan KN, 2002, MOL CELL BIOL, V22, P5194, DOI 10.1128/MCB.22.14.5194-5202.2002; Maor-Shoshani A, 2003, DNA REPAIR, V2, P1227, DOI 10.1016/S1568-7864(03)00142-3; Masuda Y, 2002, J BIOL CHEM, V277, P3040, DOI 10.1074/jbc.M110149200; McElhinny SAN, 2003, MOL CELL BIOL, V23, P2309, DOI 10.1128/MCB.23.7.2309-2315.2003; Mozzherin DJ, 1997, P NATL ACAD SCI USA, V94, P6126, DOI 10.1073/pnas.94.12.6126; Nelson JR, 1996, NATURE, V382, P729, DOI 10.1038/382729a0; PazElizur T, 1997, BIOCHEMISTRY-US, V36, P1766, DOI 10.1021/bi9621324; PazElizur T, 1996, J BIOL CHEM, V271, P24662, DOI 10.1074/jbc.271.40.24662; Ruiz JF, 2003, NUCLEIC ACIDS RES, V31, P4441, DOI 10.1093/nar/gkg637; SAGHER D, 1983, BIOCHEMISTRY-US, V22, P4518, DOI 10.1021/bi00288a026; SCHAAPER RM, 1983, P NATL ACAD SCI-BIOL, V80, P487, DOI 10.1073/pnas.80.2.487; TAKESHITA M, 1987, J BIOL CHEM, V262, P10171; Tomer G, 1998, P NATL ACAD SCI USA, V95, P14106, DOI 10.1073/pnas.95.24.14106; Zhang YB, 2002, J BIOL CHEM, V277, P44582, DOI 10.1074/jbc.M207297200; Zhang YB, 2002, NUCLEIC ACIDS RES, V30, P1630, DOI 10.1093/nar/30.7.1630; Zhang YB, 2001, MOL CELL BIOL, V21, P7995, DOI 10.1128/MCB.21.23.7995-8006.2001	36	44	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 9	2004	279	2					859	865		10.1074/jbc.M310447200	http://dx.doi.org/10.1074/jbc.M310447200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	759DJ	14581466	hybrid			2022-12-27	WOS:000187722800007
J	Nantermet, PV; Xu, J; Yu, YJ; Hodor, P; Holder, D; Adamski, S; Gentile, MA; Kimmel, DB; Harada, S; Gerhold, D; Freedman, LP; Ray, WJ				Nantermet, PV; Xu, J; Yu, YJ; Hodor, P; Holder, D; Adamski, S; Gentile, MA; Kimmel, DB; Harada, S; Gerhold, D; Freedman, LP; Ray, WJ			Identification of genetic pathways activated by the androgen receptor during the induction of proliferation in the ventral prostate gland	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-AMIDATING MONOOXYGENASE; EPITHELIAL-CELL PROLIFERATION; GROWTH-FACTOR-BETA; PROTEIN-KINASE; BINDING-PROTEIN; CANCER-CELLS; NEUROENDOCRINE DIFFERENTIATION; PYRUVATE-DEHYDROGENASE; TYROSINE KINASE; GOLGI STRUCTURE	The androgen receptor (AR), when complexed with 5alpha-dihydrotestosterone (DHT), supports the survival and proliferation of prostate cells, a process critical for normal development, benign prostatic hypertrophy, and tumorigenesis. However, the androgen-responsive genetic pathways that control prostate cell division and differentiation are largely unknown. To identify such pathways, we examined gene expression in the ventral prostate 6 and 24 h after DHT administration to androgen-depleted rats. 234 transcripts were expressed significantly differently from controls ( p < 0.05) at both time points and were subjected to extensive data mining. Functional clustering of the data reveals that the majority of these genes can be classified as participating in induction of secretory activity, metabolic activation, and intracellular signaling/signal transduction, indicating that AR rapidly modulates the expression of genes involved in proliferation and differentiation in the prostate. Notably AR represses the expression of several key cell cycle inhibitors, while modulating members of the wnt and notch signaling pathways, multiple growth factors, and peptide hormone signaling systems, and genes involved in MAP kinase and calcium signaling. Analysis of these data also suggested that p53 activity is negatively regulated by AR activation even though p53 RNA was unchanged. Experiments in LNCaP prostate cancer cells reveal that AR inhibits p53 protein accumulation in the nucleus, providing a post-transcriptional mechanism by which androgens control prostate cell growth and survival. In summary these data provide a comprehensive view of the earliest events in AR-mediated prostate cell proliferation in vivo, and suggest that nuclear exclusion of p53 is a critical step in prostate growth.	Merck Res Labs, Dept Mol Endocrinol & Bone Biol, West Point, PA 19486 USA; Merck Res Labs, Dept Lab Sci & Invest Toxicol, West Point, PA 19486 USA; Merck Res Labs, Dept Mol Profiling, West Point, PA 19486 USA; Merck Res Labs, Dept Biometr Res, West Point, PA 19486 USA	Merck & Company; Merck & Company; Merck & Company; Merck & Company	Ray, WJ (corresponding author), Merck Res Labs, Dept Mol Endocrinol & Bone Biol, POB 4,WP26A1000, West Point, PA 19486 USA.	james_ray@merck.com	Ray, William J/E-9834-2016	Ray, William/0000-0002-4491-167X; Gerhold, David/0000-0001-5739-730X				Abate-Shen C, 2000, GENE DEV, V14, P2410, DOI 10.1101/gad.819500; Abrahamsson PA, 1999, ENDOCR-RELAT CANCER, V6, P503, DOI 10.1677/erc.0.0060503; Alam MR, 1997, J BIOL CHEM, V272, P12667, DOI 10.1074/jbc.272.19.12667; Alarcon-Vargas D, 2002, CARCINOGENESIS, V23, P541, DOI 10.1093/carcin/23.4.541; ARUNAKARAN J, 1992, Indian Journal of Experimental Biology, V30, P8; Ashcroft M, 1999, ONCOGENE, V18, P7637, DOI 10.1038/sj.onc.1203012; Bai GE, 1998, J ANDROL, V19, P127; Bamforth SD, 2001, NAT GENET, V29, P469, DOI 10.1038/ng768; Bateman A, 1998, J ENDOCRINOL, V158, P145, DOI 10.1677/joe.0.1580145; Bhattacharya S, 1999, GENE DEV, V13, P64, DOI 10.1101/gad.13.1.64; Bonkhoff H, 2001, ANN ONCOL, V12, pS141, DOI 10.1093/annonc/12.suppl_2.S141; BRADBURY AF, 1991, TRENDS BIOCHEM SCI, V16, P112, DOI 10.1016/0968-0004(91)90044-V; Brantley DM, 2002, ONCOGENE, V21, P7011, DOI 10.1038/sj.onc.1205679; Bruchovsky N, 1975, Vitam Horm, V33, P61; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Burchardt M, 2001, PROSTATE, V48, P225, DOI 10.1002/pros.1101; Chen LH, 1998, J BIOL CHEM, V273, P33524, DOI 10.1074/jbc.273.50.33524; Chesire DR, 2002, ONCOGENE, V21, P2679, DOI 10.1038/sj.onc.1205352; Chi HB, 2000, MOL CELL BIOL, V20, P6496, DOI 10.1128/MCB.20.17.6496-6507.2000; CHUNG LWK, 1995, CANCER SURV, V23, P33; CLAESSENS F, 1989, BIOCHEM BIOPH RES CO, V164, P833, DOI 10.1016/0006-291X(89)91534-9; COFFEY DS, 1968, MOL PHARMACOL, V4, P580; COSTELLO LC, 1993, HORM METAB RES, V25, P268, DOI 10.1055/s-2007-1002094; Costello LC, 2002, HORM METAB RES, V34, P417, DOI 10.1055/s-2002-33598; Coulthard MG, 2001, GROWTH FACTORS, V18, P303, DOI 10.3109/08977190109029118; Culig Z, 1996, PROSTATE, V28, P392, DOI 10.1002/(SICI)1097-0045(199606)28:6<392::AID-PROS9>3.0.CO;2-C; CUNHA GR, 1995, WORLD J UROL, V13, P264; De Strooper B, 2001, J CELL BIOL, V152, pF17, DOI 10.1083/jcb.152.4.F17; Dhanasekaran SM, 2001, NATURE, V412, P822, DOI 10.1038/35090585; Dierick H, 1999, CURR TOP DEV BIOL, V43, P153, DOI 10.1016/S0070-2153(08)60381-6; DiGiovanni J, 2000, P NATL ACAD SCI USA, V97, P3455, DOI 10.1073/pnas.97.7.3455; Donald CD, 2001, ANTICANCER RES, V21, P3739; Donoviel DB, 1998, MECH DEVELOP, V78, P203, DOI 10.1016/S0925-4773(98)00146-4; EKLOV S, 1993, CANCER RES, V53, P3193; EVANS GS, 1987, PROSTATE, V11, P339, DOI 10.1002/pros.2990110406; Feng ZW, 1998, ONCOGENE, V17, P2593, DOI 10.1038/sj.onc.1202195; FISCHER TV, 1976, IN VITRO CELL DEV B, V12, P382, DOI 10.1007/BF02796316; Franck-Lissbrant I, 1998, ENDOCRINOLOGY, V139, P451, DOI 10.1210/en.139.2.451; FRICK J, 1991, INFECTION, V19, pS115, DOI 10.1007/BF01643679; Fujimoto N, 2001, UROLOGY, V58, P289, DOI 10.1016/S0090-4295(01)01117-7; Gelmann EP, 2002, J CLIN ONCOL, V20, P3001, DOI 10.1200/JCO.2002.10.018; Gimm O, 2001, J CLIN ENDOCR METAB, V86, P1801, DOI 10.1210/jc.86.4.1801; Gioeli D, 2002, J BIOL CHEM, V277, P29304, DOI 10.1074/jbc.M204131200; Gioeli D, 1999, CANCER RES, V59, P279; HARKONEN P, 1981, J STEROID BIOCHEM, V14, P1075, DOI 10.1016/0022-4731(81)90219-3; He ZH, 1999, CANCER RES, V59, P3222; Heemers H, 2001, MOL ENDOCRINOL, V15, P1817, DOI 10.1210/me.15.10.1817; Hengstschlager M, 1999, MUTAT RES-REV MUTAT, V436, P1, DOI 10.1016/S1383-5742(98)00022-2; HOLDER D, 2001, P AM STAT ASS STAT A; ISAACS WB, 1991, CANCER RES, V51, P4716; Jenkin L, 1999, J ANDROL, V20, P80; Jimenez N, 2001, INT J CANCER, V94, P28, DOI 10.1002/ijc.1436; JUNGBLUT T, 1989, UROL INT, V44, P352, DOI 10.1159/000281539; Kampa M, 1997, EUR J PHARMACOL, V335, P255, DOI 10.1016/S0014-2999(97)01213-2; Kang HY, 2002, J BIOL CHEM, V277, P43749, DOI 10.1074/jbc.M205603200; Kopan R, 1996, CURR OPIN NEUROBIOL, V6, P594, DOI 10.1016/S0959-4388(96)80090-0; Kops GJPL, 2002, MOL CELL BIOL, V22, P2025, DOI 10.1128/MCB.22.7.2025-2036.2002; Kravets FG, 2000, PROSTATE, V43, P169, DOI 10.1002/(SICI)1097-0045(20000515)43:3<169::AID-PROS2>3.0.CO;2-D; Kwabi-Addo B, 2001, P NATL ACAD SCI USA, V98, P11563, DOI 10.1073/pnas.201167798; Leav I, 1996, LAB INVEST, V75, P361; Lee C, 1999, PROSTATE, V39, P285; Legrand G, 2001, J BIOL CHEM, V276, P47608, DOI 10.1074/jbc.M107011200; Leite KRM, 2001, MODERN PATHOL, V14, P428, DOI 10.1038/modpathol.3880330; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Lobaccaro JM, 1999, ENDOCRINOLOGY, V140, P350, DOI 10.1210/en.140.1.350; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; Lu L, 2001, J CELL SCI, V114, P4543; Marker PC, 2003, DEV BIOL, V253, P165, DOI 10.1016/S0012-1606(02)00031-3; MARTI A, 1994, ONCOGENE, V9, P1213; Mathupala SP, 1997, J BIOL CHEM, V272, P22776, DOI 10.1074/jbc.272.36.22776; Miao H, 2001, NAT CELL BIOL, V3, P527, DOI 10.1038/35074604; Nair P, 1997, J BIOL CHEM, V272, P20131, DOI 10.1074/jbc.272.32.20131; Nicholson H D, 1996, Rev Reprod, V1, P69; Osman I, 1999, CLIN CANCER RES, V5, P2082; Pang ST, 2002, ENDOCRINOLOGY, V143, P4897, DOI 10.1210/en.2002-220327; Papandreou CN, 1998, NAT MED, V4, P50, DOI 10.1038/nm0198-050; Parrinello S, 2001, J BIOL CHEM, V276, P39213, DOI 10.1074/jbc.M104473200; Puthenveedu MA, 2001, J CELL BIOL, V155, P227, DOI 10.1083/jcb.200105005; Raman V, 2000, NATURE, V405, P974, DOI 10.1038/35016125; RAVENNA L, 1995, PROSTATE, V26, P290, DOI 10.1002/pros.2990260604; REDDY PRK, 1976, MOL CELL ENDOCRINOL, V5, P23, DOI 10.1016/0303-7207(76)90067-8; RENNIE PS, 1993, MOL ENDOCRINOL, V7, P23, DOI 10.1210/me.7.1.23; RIEGMAN PHJ, 1991, MOL ENDOCRINOL, V5, P1921, DOI 10.1210/mend-5-12-1921; SCHOONES R, 1972, Journal of Surgical Oncology, V4, P169, DOI 10.1002/jso.2930040302; Schug J., 1997, CBILTR19971001 U PEN; Shen RQ, 2000, MOL CELL ENDOCRINOL, V170, P131, DOI 10.1016/S0303-7207(00)00326-9; Shenk JL, 2001, J BIOL CHEM, V276, P38472, DOI 10.1074/jbc.M103652200; Shou JY, 2001, CANCER RES, V61, P7291; Singh G, 1999, J CELL PHYSIOL, V180, P431, DOI 10.1002/(SICI)1097-4652(199909)180:3<431::AID-JCP14>3.0.CO;2-O; Straume O, 2002, AM J PATHOL, V160, P1009, DOI 10.1016/S0002-9440(10)64922-X; Sun H, 2002, BMC NEUROSCI, V3, DOI 10.1186/1471-2202-3-11; Swinnen JV, 1998, J STEROID BIOCHEM, V65, P191, DOI 10.1016/S0960-0760(97)00187-8; THOMPSON SA, 1978, ANAT RECORD, V191, P31, DOI 10.1002/ar.1091910104; VELDSCHOLTE J, 1990, BIOCHEM BIOPH RES CO, V173, P534, DOI 10.1016/S0006-291X(05)80067-1; Verrijdt G, 1999, MOL ENDOCRINOL, V13, P1558, DOI 10.1210/me.13.9.1558; Walden PD, 1998, EXP CELL RES, V245, P19, DOI 10.1006/excr.1998.4237; Waltregny D, 2001, MOL ENDOCRINOL, V15, P765, DOI 10.1210/me.15.5.765; Xia XF, 2001, P NATL ACAD SCI USA, V98, P10863, DOI 10.1073/pnas.191284198; Yang FJ, 2002, J BIOL CHEM, V277, P11336, DOI 10.1074/jbc.M111962200; Zebedee Z, 2001, ONCOGENE, V20, P8317, DOI 10.1038/sj.onc.1205092	100	90	94	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 9	2004	279	2					1310	1322		10.1074/jbc.M310206200	http://dx.doi.org/10.1074/jbc.M310206200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	759DJ	14576152	hybrid			2022-12-27	WOS:000187722800058
J	Danon, A; Rotari, VI; Gordon, A; Mailhac, N; Gallois, P				Danon, A; Rotari, VI; Gordon, A; Mailhac, N; Gallois, P			Ultraviolet-C overexposure induces programmed cell death in Arabidopsis, which is mediated by caspase-like activities and which can be suppressed by caspase inhibitors, p35 and Defender against Apoptotic Death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BAX INHIBITOR-1; MAMMALIAN OLIGOSACCHARYLTRANSFERASE; SIGNAL-TRANSDUCTION; DISEASE RESISTANCE; BACULOVIRUS P35; SALICYLIC-ACID; PLANT HOMOLOG; PROTEASE; DAD1; GENE	Plants, animals, and several branches of unicellular eukaryotes use programmed cell death (PCD) for defense or developmental mechanisms. This argues for a common ancestral apoptotic system in eukaryotes. However, at the molecular level, very few regulatory proteins or protein domains have been identified as conserved across all eukaryotic PCD forms. A very important goal is to determine which molecular components may be used in the execution of PCD in plants, which have been conserved during evolution, and which are plant-specific. Using Arabidopsis thaliana, we have shown that UV radiation can induce apoptosis-like changes at the cellular level and that a UV experimental system is relevant to the study of PCD in plants. We report here that UV induction of PCD required light and that a protease cleaving the caspase substrate Asp-Glu-Val- Asp ( DEVDase activity) was induced within 30 min and peaked at 1 h. This DEVDase appears to be related to animal caspases at the biochemical level, being insensitive to broad-range cysteine protease inhibitors. In addition, caspase-1 and caspase-3 inhibitors and the pan-caspase inhibitor p35 were able to suppress DNA fragmentation and cell death. These results suggest that a YVADase activity and an inducible DEVDase activity possibly mediate DNA fragmentation during plant PCD induced by UV overexposure. We also report that At-DAD1 and At-DAD2, the two A. thaliana homologs of Defender against Apoptotic Death-1, could suppress the onset of DNA fragmentation in A. thaliana, supporting an involvement of the endoplasmic reticulum in this form of the plant PCD pathway.	Univ Perpignan, Lab Genome & Dev Plantes, CNRS, UMR 5096, F-66860 Perpignan, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite Perpignan Via Domitia	Gallois, P (corresponding author), Univ Manchester, Sch Biol Sci, 3-614 Stopford Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.		Danon, Antoine/A-6058-2009; Danon, Antoine/F-7790-2018	Danon, Antoine/0000-0001-6311-6076; GALLOIS, Patrick/0000-0002-6305-2807				Asai T, 2000, PLANT CELL, V12, P1823, DOI 10.1105/tpc.12.10.1823; Bertin J, 1996, J VIROL, V70, P6251, DOI 10.1128/JVI.70.9.6251-6259.1996; Bolduc N, 2003, PLANTA, V216, P377, DOI 10.1007/s00425-002-0879-1; Brewster JL, 2000, GENESIS, V26, P271, DOI 10.1002/(SICI)1526-968X(200004)26:4<271::AID-GENE90>3.0.CO;2-E; Brodersen P, 2002, GENE DEV, V16, P490, DOI 10.1101/gad.218202; BUMP NJ, 1995, SCIENCE, V269, P1885, DOI 10.1126/science.7569933; Danon A, 1998, FEBS LETT, V437, P131, DOI 10.1016/S0014-5793(98)01208-3; DANON A, 2000, PLANT PHYSIOL BIOCH, V38, P1; del Pozo O, 1998, CURR BIOL, V8, P1129, DOI 10.1016/S0960-9822(98)70469-5; Delorme VGR, 2000, PLANT PHYSIOL, V123, P917, DOI 10.1104/pp.123.3.917; Devic M, 1996, PLANT J, V9, P205, DOI 10.1046/j.1365-313X.1996.09020205.x; Gallois P, 1995, Methods Mol Biol, V55, P89; Gallois P, 1997, PLANT J, V11, P1325, DOI 10.1046/j.1365-313X.1997.11061325.x; Gray J, 2002, PLANT PHYSIOL, V130, P1894, DOI 10.1104/pp.008441; Hansen G, 2000, MOL PLANT MICROBE IN, V13, P649, DOI 10.1094/MPMI.2000.13.6.649; Hoeberichts FA, 2003, BIOESSAYS, V25, P47, DOI 10.1002/bies.10175; Hull G, 1996, PLANT SCI, V120, P153, DOI 10.1016/S0168-9452(96)04496-2; Jansen MAK, 1998, TRENDS PLANT SCI, V3, P131, DOI 10.1016/S1360-1385(98)01215-1; Kawai M, 1999, FEBS LETT, V464, P143, DOI 10.1016/S0014-5793(99)01695-6; Kawai-Yamada M, 2001, P NATL ACAD SCI USA, V98, P12295, DOI 10.1073/pnas.211423998; Kelleher DJ, 1997, P NATL ACAD SCI USA, V94, P4994, DOI 10.1073/pnas.94.10.4994; Kinoshita T, 1999, PLANT J, V19, P43, DOI 10.1046/j.1365-313X.1999.00497.x; Korthout HAAJ, 2000, FEBS LETT, V475, P139, DOI 10.1016/S0014-5793(00)01643-4; Kulms D, 2000, PHOTODERMATOL PHOTO, V16, P195, DOI 10.1034/j.1600-0781.2000.160501.x; Lam E, 1999, CURR OPIN PLANT BIOL, V2, P502, DOI 10.1016/S1369-5266(99)00026-6; Lam E, 2000, PLANT MOL BIOL, V44, P417, DOI 10.1023/A:1026509012695; Leborgne-Castel N, 1999, PLANT CELL, V11, P459, DOI 10.1105/tpc.11.3.459; Lincoln JE, 2002, P NATL ACAD SCI USA, V99, P15217, DOI 10.1073/pnas.232579799; Makishima T, 2000, J BIOCHEM-TOKYO, V128, P399, DOI 10.1093/oxfordjournals.jbchem.a022767; Matsumura H, 2003, PLANT J, V33, P425, DOI 10.1046/j.1365-313X.2003.01639.x; McDowell JM, 2000, TRENDS BIOCHEM SCI, V25, P79, DOI 10.1016/S0968-0004(99)01532-7; Minami A, 1995, PLANT CELL PHYSIOL, V36, P1599; Mullineaux P, 2002, CURR OPIN PLANT BIOL, V5, P43, DOI 10.1016/S1369-5266(01)00226-6; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; NAKASHIMA T, 1993, MOL CELL BIOL, V13, P6367, DOI 10.1128/MCB.13.10.6367; Nawrath C, 2002, PLANT CELL, V14, P275, DOI 10.1105/tpc.010376; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Nishii K, 1999, GENES CELLS, V4, P243, DOI 10.1046/j.1365-2443.1999.00256.x; Pennell RI, 1997, PLANT CELL, V9, P1157, DOI 10.1105/tpc.9.7.1157; Rotari VI, 2001, BIOL CHEM, V382, P953, DOI 10.1515/BC.2001.119; Rusterucci C, 2001, PLANT CELL, V13, P2211, DOI 10.1105/tpc.13.10.2211; Sanchez P, 2000, PLANT J, V21, P393, DOI 10.1046/j.1365-313x.2000.00690.x; Scorrano L, 2003, SCIENCE, V300, P135, DOI 10.1126/science.1081208; Solomon M, 1999, PLANT CELL, V11, P431, DOI 10.1105/tpc.11.3.431; Stennicke HR, 2000, METHOD ENZYMOL, V322, P91; SUGIMOTO A, 1995, EMBO J, V14, P4434, DOI 10.1002/j.1460-2075.1995.tb00122.x; Sun YL, 1999, FEBS LETT, V462, P317, DOI 10.1016/S0014-5793(99)01539-2; THORNBERRY NA, 1994, METHOD ENZYMOL, V244, P615; Tian RH, 2000, FEBS LETT, V474, P11, DOI 10.1016/S0014-5793(00)01561-1; Uren AG, 2000, MOL CELL, V6, P961, DOI 10.1016/S1097-2765(05)00086-9; Wildermuth MC, 2001, NATURE, V414, P562, DOI 10.1038/35107108; Woltering EJ, 2002, PLANT PHYSIOL, V130, P1764, DOI 10.1104/pp.006338	53	182	206	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	2004	279	1					779	787		10.1074/jbc.M304468200	http://dx.doi.org/10.1074/jbc.M304468200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	757GU	14573611	Green Published, hybrid			2022-12-27	WOS:000187555300093
J	Gobert, AP; Bambou, JC; Werts, C; Balloy, V; Chignard, M; Moran, AP; Ferrero, RL				Gobert, AP; Bambou, JC; Werts, C; Balloy, V; Chignard, M; Moran, AP; Ferrero, RL			Helicobacter pylori heat shock protein 60 mediates interleukin-6 production by macrophages via a Toll-like receptor (TLR)-2-, TLR-4-, and myeloid differentiation factor 88-independent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; CYTOKINE MESSENGER-RNA; NITRIC-OXIDE SYNTHASE; TUMOR-NECROSIS-FACTOR; MURINE MACROPHAGES; GASTRIC-CANCER; CUTTING EDGE; PROTECTIVE IMMUNITY; ENDOTHELIAL-CELLS; FACTOR-ALPHA	Helicobacter pylori has been reported to induce interleukin-6 (IL-6) production in monocytes/macrophages and in chronically inflamed gastric tissues. The mechanism by which H. pylori induces IL-6 production in macrophages, however, has not been investigated. To identify the H. pylori factor responsible for this activity, we fractionated soluble proteins from H. pylori strain 26695 by ion exchange and size exclusion chromatography and screened the fractions for IL-6-inducing activity on RAW 264.7 macrophages. A single protein was purified and identified by mass spectrometry as H. pylori heat shock protein 60 (HSP60). Consistent with the observed IL-6-inducing activity of H. pylori HSP60, soluble protein extracts of H. pylori 26695 and SS1 strains that were depleted of this protein by affinity chromatography had dramatically reduced IL-6-inducing activities. The immunopurified HSP60 stimulated IL-6 production in macrophages. When stimulated with H. pylori HSP60 or intact bacteria, peritoneal macrophages from mice deficient in Toll-like receptor (TLR)-2, TLR-4, TLR2/TLR-4, and myeloid differentiation factor 88 produced the same amount of IL-6 than macrophages from wildtype mice, demonstrating the independence of H. pylori HSP60 responses from these signaling molecules. H. pylori HSP60-induced IL-6 mRNA expression, and NF-kappaB activation in RAW 264.7 cells was abrogated in the presence of MG-132, a proteasome inhibitor. In contrast, inhibitors of protein kinase A or C, mitogen-activated protein kinase kinase, and phosphoinositide 3-kinase had no effect on IL-6 mRNA levels. This study demonstrates the induction of innate immune responses by H. pylori HSP60, thereby implicating this highly conserved protein in the pathophysiology of chronic gastritis.	Inst Pasteur, UPBM, F-75724 Paris 15, France; Inst Pasteur, Unite Bacteriol Mol & Med, F-75724 Paris, France; Inst Pasteur, Unite Def Innee & Inflammat, INSERM, F-75724 Paris 15, France; Natl Univ Ireland Univ Coll Galway, Dept Microbiol, IRL, Galway, Ireland	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Ollscoil na Gaillimhe-University of Galway	Ferrero, RL (corresponding author), Inst Pasteur, UPBM, 28 Rue Dr Roux, F-75724 Paris 15, France.		Balloy, Viviane/B-8551-2014; WERTS, Catherine/AAD-5447-2020; Chignard, Michel/B-4351-2008; Gobert, Alain P/AHB-1368-2022; Ferrero, Richard/U-1332-2017	Balloy, Viviane/0000-0001-9093-9676; WERTS, Catherine/0000-0003-3079-5476; Chignard, Michel/0000-0003-3810-6575; Ferrero, Richard/0000-0001-6817-6211				Akira S, 2003, J INFECT DIS, V187, pS356, DOI 10.1086/374749; Aliprantis AO, 1999, SCIENCE, V285, P736, DOI 10.1126/science.285.5428.736; Asea A, 2002, J BIOL CHEM, V277, P15028, DOI 10.1074/jbc.M200497200; Backhed F, 2003, J INFECT DIS, V187, P829; BIRKHOLZ S, 1993, FEMS IMMUNOL MED MIC, V6, P317, DOI 10.1111/j.1574-695X.1993.tb00344.x; BLANDER SJ, 1993, J CLIN INVEST, V91, P717, DOI 10.1172/JCI116253; Bulut Y, 2002, J IMMUNOL, V168, P1435, DOI 10.4049/jimmunol.168.3.1435; CRABTREE JE, 1991, GUT, V32, P1473, DOI 10.1136/gut.32.12.1473; Curfs JHAJ, 1997, CLIN MICROBIOL REV, V10, P742, DOI 10.1128/CMR.10.4.742; FERRERO RL, 1994, INFECT IMMUN, V62, P4981, DOI 10.1128/IAI.62.11.4981-4989.1994; FERRERO RL, 1995, P NATL ACAD SCI USA, V92, P6499, DOI 10.1073/pnas.92.14.6499; Fu SD, 1999, GASTROENTEROLOGY, V116, P1319, DOI 10.1016/S0016-5085(99)70496-8; Gao BC, 2003, J BIOL CHEM, V278, P22523, DOI 10.1074/jbc.M303161200; Gao BC, 2003, J BIOL CHEM, V278, P174, DOI 10.1074/jbc.M208742200; GIONCHETTI P, 1994, AM J GASTROENTEROL, V89, P883; Girardin SE, 2003, SCIENCE, V300, P1584, DOI 10.1126/science.1084677; Gobert AP, 1998, INFECT IMMUN, V66, P4068; Gobert AP, 2002, J IMMUNOL, V168, P6002, DOI 10.4049/jimmunol.168.12.6002; Habich C, 2003, FEBS LETT, V533, P105, DOI 10.1016/S0014-5793(02)03772-9; Habich C, 2002, J IMMUNOL, V168, P569, DOI 10.4049/jimmunol.168.2.569; Hansen PS, 1999, APMIS, V107, P1117, DOI 10.1111/j.1699-0463.1999.tb01517.x; Harris PR, 2000, J INFECT DIS, V181, P783, DOI 10.1086/315257; Harris PR, 1998, J INFECT DIS, V178, P1516, DOI 10.1086/314426; Innocenti M, 2002, INFECT IMMUN, V70, P4581, DOI 10.1128/IAI.70.8.4581-4590.2002; Kamiya S, 1998, J CLIN GASTROENTEROL, V27, pS35, DOI 10.1097/00004836-199800001-00007; Kol A, 2000, J IMMUNOL, V164, P13, DOI 10.4049/jimmunol.164.1.13; Kol A, 1999, J CLIN INVEST, V103, P571, DOI 10.1172/JCI5310; KOPF M, 1994, NATURE, V368, P339, DOI 10.1038/368339a0; LABIGNE A, 1991, J BACTERIOL, V173, P1920, DOI 10.1128/jb.173.6.1920-1931.1991; Lee A, 1997, GASTROENTEROLOGY, V112, P1386, DOI 10.1016/S0016-5085(97)70155-0; Ley C, 2001, GASTROENTEROLOGY, V120, P324; Long KH, 2003, J IMMUNOL, V170, P487, DOI 10.4049/jimmunol.170.1.487; Maeda S, 2001, J BIOL CHEM, V276, P44856, DOI 10.1074/jbc.M105381200; MAI UEH, 1991, J CLIN INVEST, V87, P894, DOI 10.1172/JCI115095; MORAN AP, 1992, J BACTERIOL, V174, P1370, DOI 10.1128/jb.174.4.1370-1377.1992; Phadnis SH, 1996, INFECT IMMUN, V64, P905, DOI 10.1128/IAI.64.3.905-912.1996; RETZLAFF C, 1994, INFECT IMMUN, V62, P5689, DOI 10.1128/IAI.62.12.5689-5693.1994; SARTOR RB, 1994, GASTROENTEROLOGY, V106, P533, DOI 10.1016/0016-5085(94)90614-9; Segal ED, 1997, P NATL ACAD SCI USA, V94, P7595, DOI 10.1073/pnas.94.14.7595; Takeuchi O, 2000, J IMMUNOL, V165, P5392, DOI 10.4049/jimmunol.165.10.5392; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; Vabulas RM, 2002, J BIOL CHEM, V277, P15107, DOI 10.1074/jbc.M111204200; Vabulas RM, 2001, J BIOL CHEM, V276, P31332, DOI 10.1074/jbc.M103217200; Vanet A, 1998, INFECT IMMUN, V66, P1023, DOI 10.1128/IAI.66.3.1023-1027.1998; Wilson KT, 1996, GASTROENTEROLOGY, V111, P1524, DOI 10.1016/S0016-5085(96)70014-8; Wu CW, 1996, AM J GASTROENTEROL, V91, P1417; Yamaoka Y, 2002, GASTROENTEROLOGY, V123, P1992, DOI 10.1053/gast.2002.37074; Yamaoka Y, 1996, GASTROENTEROLOGY, V110, P1744, DOI 10.1053/gast.1996.v110.pm8964399	48	134	142	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	2004	279	1					245	250		10.1074/jbc.M307858200	http://dx.doi.org/10.1074/jbc.M307858200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	757GU	14573621	hybrid			2022-12-27	WOS:000187555300030
J	Im, JS; Yu, KOA; Illarionov, PA; LeClair, KP; Storey, JR; Kennedy, MW; Besra, GS; Porcelli, SA				Im, JS; Yu, KOA; Illarionov, PA; LeClair, KP; Storey, JR; Kennedy, MW; Besra, GS; Porcelli, SA			Direct measurement of antigen binding properties of CD1 proteins using fluorescent lipid probes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL RECOGNITION; MOLECULAR RECOGNITION; LIPOGLYCAN ANTIGENS; GLYCOLIPIDS; EXPRESSION; MOUSE; RESPONSES; ACTIVATION; INFECTION; ANGSTROM	CD1 proteins are antigen-presenting molecules that bind foreign and self-lipids and stimulate specific T cell responses. In the current study, we investigated ligand binding by CD1 proteins by developing a fluorescent probe binding approach using soluble recombinant human CD1 proteins. To increase stability and yield, soluble group 1 CD1 (CD1b and CD1c) and group 2 CD1 (CD1d) proteins were produced as single chain secreted CD1 proteins in which beta(2)-microglobulin was fused to the N termini of the CD1 heavy chains by a flexible peptide linker sequence. Analysis of ligand binding properties of single chain secreted CD1 proteins by using fluorescent lipid probes indicated significant differences in ligand preference and in pH dependence of binding by group 1 versus group 2 CD1 proteins. Whereas group 1 CD1 isoforms (CD1b and CD1c) show stronger binding of nitrobenzoxadiazole (NBD)-labeled dialkyl-based ligands (phosphatidylcholine, sphingomyelin, and ceramide), group 2 CD1 (CD1d) proteins were stronger binders of small hydrophobic probes such as 1-anilinonaphthalene-8-sulfonic acid and 4,4'-dianilino-1,1'-naphthyl-5,5'-disulfonic acid. Competition studies indicated that binding of fluorescent lipid probes involved association of the probe with the hydrophobic ligand binding groove of CD1 proteins. Analysis of selected alanine substitution mutants of human CD1b known to inhibit antigen presentation showed that NBD-labeled lipid probe binding could be used to distinguish mutations that interfere with ligand binding from those that affect T cell receptor docking. Our findings provide further evidence for the functional specialization of different CD1 isoforms and demonstrate the value of the fluorescent lipid probe binding method for assisting structure-based studies of CD1 function.	Yeshiva Univ Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA; Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England; Antigen Inc, Lexington, MA 02421 USA; Univ Glasgow, Inst Biomed & Life Sci, Div Environm & Evolutionary Biol, Glasgow G12 8QQ, Lanark, Scotland	Yeshiva University; Albert Einstein College of Medicine; University of Birmingham; Agenus Inc; University of Glasgow	Porcelli, SA (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Microbiol & Immunol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.			Besra, Gurdyal/0000-0002-5605-0395	NIAID NIH HHS [N01 AI-75320] Funding Source: Medline; PHS HHS [48933, 45889] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI075320] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Angenieux C, 2000, J BIOL CHEM, V275, P37757, DOI 10.1074/jbc.M007082200; Bauer A, 1997, EUR J IMMUNOL, V27, P1366, DOI 10.1002/eji.1830270611; Beckman EM, 1996, J IMMUNOL, V157, P2795; BEEKMAN EM, 1994, NATURE, V372, P691, DOI 10.1038/372691a0; BEHAR SM, 1995, J EXP MED, V182, P2007, DOI 10.1084/jem.182.6.2007; Benlagha K, 2000, J EXP MED, V191, P1895, DOI 10.1084/jem.191.11.1895; Briken V, 2000, J EXP MED, V192, P281, DOI 10.1084/jem.192.2.281; Cohen CJ, 2003, J IMMUNOL METHODS, V277, P39, DOI 10.1016/S0022-1759(03)00110-8; Dutronc Y, 2002, TISSUE ANTIGENS, V60, P337, DOI 10.1034/j.1399-0039.2002.600501.x; Ernst WA, 1998, IMMUNITY, V8, P331, DOI 10.1016/S1074-7613(00)80538-5; FAVALORO EJ, 1986, DIS MARKERS, V4, P261; Gadola SD, 2002, NAT IMMUNOL, V3, P721, DOI 10.1038/ni821; Geho DH, 2000, J IMMUNOL, V165, P1272, DOI 10.4049/jimmunol.165.3.1272; Grant EP, 1999, J EXP MED, V189, P195, DOI 10.1084/jem.189.1.195; Gumperz JE, 2000, IMMUNITY, V12, P211, DOI 10.1016/S1074-7613(00)80174-0; Hiromatsu K, 2002, J IMMUNOL, V169, P330, DOI 10.4049/jimmunol.169.1.330; Huttinger R, 1999, INT IMMUNOL, V11, P1615, DOI 10.1093/intimm/11.10.1615; Illes Z, 2000, J IMMUNOL, V164, P4375, DOI 10.4049/jimmunol.164.8.4375; Jackman RM, 1998, IMMUNITY, V8, P341, DOI 10.1016/S1074-7613(00)80539-7; Joyce S, 1998, SCIENCE, V279, P1541, DOI 10.1126/science.279.5356.1541; Kamada N, 2001, INT IMMUNOL, V13, P853, DOI 10.1093/intimm/13.7.853; Kawano T, 1997, SCIENCE, V278, P1626, DOI 10.1126/science.278.5343.1626; LeVine H, 2002, ARCH BIOCHEM BIOPHYS, V404, P106; Martsev SP, 2002, BIOCHEMISTRY-US, V41, P3389, DOI 10.1021/bi015894u; Melian A, 2000, J IMMUNOL, V165, P4494, DOI 10.4049/jimmunol.165.8.4494; Moody DB, 2000, NATURE, V404, P884, DOI 10.1038/35009119; Moody DB, 1997, SCIENCE, V278, P283, DOI 10.1126/science.278.5336.283; Naidenko OV, 1999, J EXP MED, V190, P1069, DOI 10.1084/jem.190.8.1069; Niazi KR, 2002, NAT IMMUNOL, V3, P703, DOI 10.1038/ni0802-703; Niazi KR, 2001, J IMMUNOL, V166, P2562, DOI 10.4049/jimmunol.166.4.2562; Oehler L, 1998, J EXP MED, V187, P1019, DOI 10.1084/jem.187.7.1019; Oishi Y, 2001, J RHEUMATOL, V28, P275; OLIVE D, 1984, IMMUNOGENETICS, V20, P253, DOI 10.1007/BF00364207; Park SH, 2000, NATURE, V406, P788, DOI 10.1038/35021233; Porcelli SA, 1999, ANNU REV IMMUNOL, V17, P297, DOI 10.1146/annurev.immunol.17.1.297; Rosat JP, 1999, J IMMUNOL, V162, P366; Shamshiev A, 2002, J EXP MED, V195, P1013, DOI 10.1084/jem.20011963; Shamshiev A, 1999, EUR J IMMUNOL, V29, P1667, DOI 10.1002/(SICI)1521-4141(199905)29:05<1667::AID-IMMU1667>3.0.CO;2-U; SIELING PA, 1995, SCIENCE, V269, P227, DOI 10.1126/science.7542404; Spada FM, 1998, J EXP MED, V188, P1529, DOI 10.1084/jem.188.8.1529; Spada FM, 2000, EUR J IMMUNOL, V30, P3468, DOI 10.1002/1521-4141(2000012)30:12<3468::AID-IMMU3468>3.0.CO;2-C; Sugita M, 2000, P NATL ACAD SCI USA, V97, P8445, DOI 10.1073/pnas.150236797; Wilson SB, 1998, NATURE, V391, P177, DOI 10.1038/34419; Zajonc DM, 2003, NAT IMMUNOL, V4, P808, DOI 10.1038/ni948	44	38	45	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	2004	279	1					299	310		10.1074/jbc.M308803200	http://dx.doi.org/10.1074/jbc.M308803200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	757GU	14551186	hybrid			2022-12-27	WOS:000187555300037
J	Schwantner, A; Dingley, AJ; Ozbek, S; Rose-John, S; Grotzinger, J				Schwantner, A; Dingley, AJ; Ozbek, S; Rose-John, S; Grotzinger, J			Direct determination of the interleukin-6 binding epitope of the interleukin-6 receptor by NMR spectroscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN SECONDARY STRUCTURE; CHEMICAL-SHIFT INDEX; TERMINAL DOMAIN; LIGAND-BINDING; IL-6 RECEPTOR; GP130; COMPLEX; IDENTIFICATION; ASSOCIATION; MECHANISMS	All cytokines belonging to the interleukin-6 (IL-6)type family of cytokines utilize receptors that have a modular build of several immunoglobulin- like and fibronectin type III-like domains. Characteristic of these receptors is a cytokine receptor homology region consisting of two such fibronectin domains defined by a set of four conserved cysteines and a tryptophan-serine-X-tryptophanserine sequence motif. On target cells, interleukin-6 first binds to its specific receptor and subsequently to a homodimer of the signal transducer protein gp130. The interleukin-6 receptor consists of three extracellular domains. The N-terminal immunoglobulin-like domain is not involved in ligand binding, whereas the third membrane proximal fibronectin-like domain accounts for more than 90% of the binding energy to IL-6. Here, the key residues of this fibronectin-like domain involved in the interaction with IL-6 are described. Chemical shift mapping data with N-15-labeled IL-6R-D3 and unlabeled IL-6 coupled with recent structural data clearly reveal the epitope within the IL-6R-D3 responsible for mediating the high affinity interaction with its cognate cytokine.	Univ Kiel, Inst Biochem, D-24118 Kiel, Germany; UCL, Dept Biochem & Mol Biol, London WC1E 6BT, England; Univ Basel, Bioctr, Dept Biophys Chem, CH-4056 Basel, Switzerland	University of Kiel; University of London; University College London; University of Basel	Grotzinger, J (corresponding author), Univ Kiel, Inst Biochem, Olshaussenstr 40, D-24118 Kiel, Germany.	jgroetzinger@biochem.uni-kiel.de	Dingley, Andrew/G-6427-2013; Özbek, Suat/D-3701-2014; Rose-John, Stefan/A-7998-2010	Dingley, Andrew/0000-0002-6838-5803; Rose-John, Stefan/0000-0002-7519-3279; Ozbek, Suat/0000-0003-2569-3942				Arai K, 1997, MOL CELLS, V7, P1; ARCONE R, 1993, EUR J BIOCHEM, V211, P347, DOI 10.1111/j.1432-1033.1993.tb19904.x; Boulanger MJ, 2003, SCIENCE, V300, P2101, DOI 10.1126/science.1083901; Chow DC, 2001, SCIENCE, V291, P2150, DOI 10.1126/science.1058308; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Giese B, 2003, J BIOL CHEM, V278, P39205, DOI 10.1074/jbc.M303347200; Grotzinger J, 1997, PROTEINS, V27, P96; Grotzinger J, 2002, BBA-MOL CELL RES, V1592, P215, DOI 10.1016/S0167-4889(02)00316-6; Heinrich PC, 2003, BIOCHEM J, V374, P1, DOI 10.1042/BJ20030407; Horsten U, 1997, J BIOL CHEM, V272, P23748, DOI 10.1074/jbc.272.38.23748; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Jones SA, 2002, BBA-MOL CELL RES, V1592, P251, DOI 10.1016/S0167-4889(02)00319-1; Kalai M, 1997, BLOOD, V89, P1319, DOI 10.1182/blood.V89.4.1319; Kernebeck T, 1999, PROTEIN SCI, V8, P5; Man D, 2003, J BIOL CHEM, V278, P23285, DOI 10.1074/jbc.M301976200; Ozbek S, 1998, J BIOL CHEM, V273, P21374, DOI 10.1074/jbc.273.33.21374; Schleinkofer K, 2001, J MOL BIOL, V306, P263, DOI 10.1006/jmbi.2000.4387; Schuster B, 2003, J BIOL CHEM, V278, P9528, DOI 10.1074/jbc.M210044200; Somers W, 1997, EMBO J, V16, P989, DOI 10.1093/emboj/16.5.989; SPRANG SR, 1993, CURR OPIN STRUC BIOL, V3, P815, DOI 10.1016/0959-440X(93)90144-A; Taga T, 1997, ANNU REV IMMUNOL, V15, P797, DOI 10.1146/annurev.immunol.15.1.797; Varghese JN, 2002, P NATL ACAD SCI USA, V99, P15959, DOI 10.1073/pnas.232432399; WISHART DS, 1994, J BIOMOL NMR, V4, P171; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; Xu GY, 1997, J MOL BIOL, V268, P468, DOI 10.1006/jmbi.1997.0933; Yamasaki K, 1997, NAT STRUCT BIOL, V4, P498, DOI 10.1038/nsb0697-498; YAWATA H, 1993, EMBO J, V12, P1705, DOI 10.1002/j.1460-2075.1993.tb05815.x	28	10	16	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 2	2004	279	1					571	576		10.1074/jbc.M311019200	http://dx.doi.org/10.1074/jbc.M311019200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	757GU	14557255	hybrid			2022-12-27	WOS:000187555300069
J	Wong, W; Schlichter, LC				Wong, W; Schlichter, LC			Differential recruitment of Kv1.4 and Kv4.2 to lipid rafts by PSD-95	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESISTANT MEMBRANE RAFTS; RAT HIPPOCAMPAL-NEURONS; OUTWARD K+ CURRENT; POTASSIUM CHANNEL; TYROSINE PHOSPHORYLATION; CLUSTERING INTERACTIONS; DEPENDENT RECRUITMENT; SIGNALING COMPLEX; PLASMA-MEMBRANE; PROTEIN	The activity of voltage-gated potassium (Kv) channels, and consequently their influence on cellular functions, can be substantially altered by phosphorylation. Several protein kinases that modulate Kv channel activity are found in membrane subdomains known as lipid rafts, which are thought to organize signaling complexes in the cell. Thus, we asked whether Kv1.4 and Kv4.2, two channels with critical roles in excitable cells, are found in lipid rafts. Acylation can target proteins to raft regions; however, Kv channels are not acylated, and therefore, a different mechanism must exist to bring them into these membrane subdomains. Because both Kv1.4 and Kv4.2 interact with postsynaptic density protein 95 ( PSD-95), which is acylated ( specifically, palmitoylated), we examined whether PSD-95 can recruit these channels to lipid rafts. We found that a portion of Kv1.4 and Kv4.2 protein in rat brain membranes is raft-associated. Lipid raft patching and immunostaining confirmed that some Kv4.2 is in Thy-1-containing rafts in rat hippocampal neurons. Using a heterologous expression system, we determined that palmitoylation of PSD-95 was crucial to its localization to lipid rafts. We then assessed the contribution of PSD-95 to the raft association of these channels. Co-expression of PSD-95 increased the amount of Kv1.4, but not Kv4.2, in lipid rafts. Deleting the PSD-95 binding motif of Kv1.4 eliminated this recruitment, as did substituting a palmitoylation-deficient PSD-95 mutant. This work represents the first evidence that PSD-95 binding can recruit Kv channels into lipid rafts, a process that could facilitate interactions with the protein kinases that affect channel activity.	Toronto Western Res Inst, Univ Hlth Network, Div Cellular & Mol Biol, Toronto, ON M5T 2S8, Canada; Univ Toronto, Dept Pharmacol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Physiol, Toronto, ON M5S 1A8, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto	Schlichter, LC (corresponding author), Toronto Western Hosp, MC9-415,399 Bathurst St, Toronto, ON M5T 2S8, Canada.	schlicht@uhnres.utoronto.ca						Aarts LHJ, 1999, MOL CELL NEUROSCI, V14, P85, DOI 10.1006/mcne.1999.0775; Adams JP, 2000, J NEUROCHEM, V75, P2277, DOI 10.1046/j.1471-4159.2000.0752277.x; Alonso G, 1997, NEUROSCIENCE, V77, P617; An WF, 2000, NATURE, V403, P553, DOI 10.1038/35000592; Anderson AE, 2000, J BIOL CHEM, V275, P5337, DOI 10.1074/jbc.275.8.5337; Anderson HA, 2000, NAT IMMUNOL, V1, P156, DOI 10.1038/77842; Arni S, 1998, J BIOL CHEM, V273, P28478, DOI 10.1074/jbc.273.43.28478; Arnold DB, 1999, NEURON, V23, P149, DOI 10.1016/S0896-6273(00)80761-8; BANKER G, 1998, CULTURING NERVE CELL; Bi K, 2001, NAT IMMUNOL, V2, P556, DOI 10.1038/88765; Brewer GJ, 1999, EXP NEUROL, V159, P237, DOI 10.1006/exnr.1999.7123; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Burke NA, 1999, J GEN PHYSIOL, V113, P71, DOI 10.1085/jgp.113.1.71; Cerny J, 1996, EUR J IMMUNOL, V26, P2335, DOI 10.1002/eji.1830261010; Cheng PC, 1999, J EXP MED, V190, P1549, DOI 10.1084/jem.190.11.1549; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; Colledge M, 2000, NEURON, V27, P107, DOI 10.1016/S0896-6273(00)00013-1; Cooper EC, 1998, J NEUROSCI, V18, P965; Debanne D, 1997, NATURE, V389, P286, DOI 10.1038/38502; DESOUZA S, 2002, SCI STKE, pE45; DOTTI CG, 1991, NATURE, V349, P158, DOI 10.1038/349158a0; Drobnik W, 2002, TRAFFIC, V3, P268, DOI 10.1034/j.1600-0854.2002.030404.x; El-Husseini AE, 2001, J BIOL CHEM, V276, P44984, DOI 10.1074/jbc.M103049200; El-Husseini AE, 2002, CELL, V108, P849, DOI 10.1016/S0092-8674(02)00683-9; Fallon L, 2002, J BIOL CHEM, V277, P486, DOI 10.1074/jbc.M109806200; FIELD KA, 1995, P NATL ACAD SCI USA, V92, P9201, DOI 10.1073/pnas.92.20.9201; FRA AM, 1994, J BIOL CHEM, V269, P30745; Furuchi T, 1998, J BIOL CHEM, V273, P21099, DOI 10.1074/jbc.273.33.21099; Gomez-Mouton C, 2001, P NATL ACAD SCI USA, V98, P9642, DOI 10.1073/pnas.171160298; Harder T, 1998, J CELL BIOL, V141, P929, DOI 10.1083/jcb.141.4.929; Hering H, 2003, J NEUROSCI, V23, P3262; Hiltbold EM, 2003, J IMMUNOL, V170, P1329, DOI 10.4049/jimmunol.170.3.1329; Hiol A, 2003, J BIOL CHEM, V278, P19301, DOI 10.1074/jbc.M210123200; Hoffman DA, 1998, J NEUROSCI, V18, P3521; Hsueh YP, 1999, J BIOL CHEM, V274, P532, DOI 10.1074/jbc.274.1.532; JACKSON MB, 1991, P NATL ACAD SCI USA, V88, P380, DOI 10.1073/pnas.88.2.380; Janes PW, 1999, J CELL BIOL, V147, P447, DOI 10.1083/jcb.147.2.447; Jones OT, 1997, J NEUROSCI, V17, P6152; Jugloff DGM, 2000, J BIOL CHEM, V275, P1357, DOI 10.1074/jbc.275.2.1357; Kim E, 1996, NEUROPHARMACOLOGY, V35, P993, DOI 10.1016/0028-3908(96)00093-7; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; Laux T, 2000, J CELL BIOL, V149, P1455, DOI 10.1083/jcb.149.7.1455; Ledesma MD, 1998, P NATL ACAD SCI USA, V95, P3966, DOI 10.1073/pnas.95.7.3966; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; Lue RA, 1996, J CELL BIOL, V135, P1125, DOI 10.1083/jcb.135.4.1125; LUE RA, 1994, P NATL ACAD SCI USA, V91, P9818, DOI 10.1073/pnas.91.21.9818; Ma L, 2003, J NEUROSCI, V23, P3164; MALETICSAVATIC M, 1995, J NEUROSCI, V15, P3840; Martens JR, 2000, J BIOL CHEM, V275, P7443, DOI 10.1074/jbc.275.11.7443; Martens JR, 2001, J BIOL CHEM, V276, P8409, DOI 10.1074/jbc.M009948200; McCabe JB, 2001, MOL BIOL CELL, V12, P3601, DOI 10.1091/mbc.12.11.3601; Melkonian KA, 1999, J BIOL CHEM, V274, P3910, DOI 10.1074/jbc.274.6.3910; Mineo C, 1998, J CELL BIOL, V141, P601, DOI 10.1083/jcb.141.3.601; MULLER BM, 1995, J NEUROSCI, V15, P2354, DOI 10.1523/JNEUROSCI.15-03-02354.1995; MURRAY KT, 1994, CIRC RES, V75, P999, DOI 10.1161/01.RES.75.6.999; Nadal MS, 2003, NEURON, V37, P449, DOI 10.1016/S0896-6273(02)01185-6; Nakamura TY, 1997, AM J PHYSIOL-HEART C, V273, pH1775, DOI 10.1152/ajpheart.1997.273.4.H1775; Nishiyama A, 2001, AM J PHYSIOL-HEART C, V281, pH1800, DOI 10.1152/ajpheart.2001.281.4.H1800; Nitabach MN, 2001, P NATL ACAD SCI USA, V98, P705, DOI 10.1073/pnas.031446198; Nix SL, 2000, J BIOL CHEM, V275, P41192, DOI 10.1074/jbc.M002078200; NORMAN AW, 1972, J BIOL CHEM, V247, P1918; Ostermeyer AG, 1999, J BIOL CHEM, V274, P34459, DOI 10.1074/jbc.274.48.34459; Peretz A, 1999, J PHYSIOL-LONDON, V519, P373, DOI 10.1111/j.1469-7793.1999.0373m.x; Perez AS, 1998, NEUROSCI LETT, V258, P121, DOI 10.1016/S0304-3940(98)00846-5; Perez-Garcia MT, 1999, J GEN PHYSIOL, V113, P897, DOI 10.1085/jgp.113.6.897; Pesanova Z, 1999, FEBS LETT, V464, P35, DOI 10.1016/S0014-5793(99)01666-X; Petrecca K, 2000, J NEUROSCI, V20, P8736; Pralle A, 2000, J CELL BIOL, V148, P997, DOI 10.1083/jcb.148.5.997; Reuver SM, 1998, J CELL SCI, V111, P1071; Roper K, 2000, NAT CELL BIOL, V2, P582, DOI 10.1038/35023524; Rybin VO, 2000, J BIOL CHEM, V275, P41447, DOI 10.1074/jbc.M006951200; Saeki K, 2003, EMBO J, V22, P3015, DOI 10.1093/emboj/cdg293; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; Schuck S, 2003, P NATL ACAD SCI USA, V100, P5795, DOI 10.1073/pnas.0631579100; Schutz GJ, 2000, EMBO J, V19, P892, DOI 10.1093/emboj/19.5.892; SHENG M, 1992, NEURON, V9, P271, DOI 10.1016/0896-6273(92)90166-B; Slimane TA, 2003, MOL BIOL CELL, V14, P611, DOI 10.1091/mbc.E02-08-0528; Stauffer TP, 1997, J CELL BIOL, V139, P1447, DOI 10.1083/jcb.139.6.1447; Takeuchi S, 2000, J MOL CELL CARDIOL, V32, P1361, DOI 10.1006/jmcc.2000.1172; Tanimura N, 2003, J CELL BIOL, V160, P125, DOI 10.1083/jcb.200207096; Tavalin SJ, 2002, J NEUROSCI, V22, P3044, DOI 10.1523/JNEUROSCI.22-08-03044.2002; Tezuka T, 1999, P NATL ACAD SCI USA, V96, P435, DOI 10.1073/pnas.96.2.435; Vainio S, 2002, EMBO REP, V3, P95, DOI 10.1093/embo-reports/kvf010; van Ijzendoorn SCD, 1999, MOL BIOL CELL, V10, P3449, DOI 10.1091/mbc.10.10.3449; Varma R, 1998, NATURE, V394, P798, DOI 10.1038/29563; Watzl C, 2003, J EXP MED, V197, P77, DOI 10.1084/jem.20020427; Wickenden AD, 1999, AM J PHYSIOL-HEART C, V276, pH1599, DOI 10.1152/ajpheart.1999.276.5.H1599; Wong W, 2002, J BIOL CHEM, V277, P20423, DOI 10.1074/jbc.M109412200; Wong W, 2000, MOL BIOL CELL, V11, p222A; Wu CB, 1997, J BIOL CHEM, V272, P3554, DOI 10.1074/jbc.272.6.3554; Wu HJ, 1998, J CELL SCI, V111, P2365; Xavier R, 1998, IMMUNITY, V8, P723, DOI 10.1016/S1074-7613(00)80577-4; Yamashita T, 2000, CIRCULATION, V101, P2007, DOI 10.1161/01.CIR.101.16.2007; Zhang M, 2001, CIRC RES, V88, P1012, DOI 10.1161/hh1001.090839; Zhang WG, 1998, IMMUNITY, V9, P239, DOI 10.1016/S1074-7613(00)80606-8; [No title captured]	97	89	93	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 2	2004	279	1					444	452		10.1074/jbc.M304675200	http://dx.doi.org/10.1074/jbc.M304675200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	757GU	14559911	hybrid			2022-12-27	WOS:000187555300054
J	Caivano, M; Rodriguez, C; Cohen, P; Alemany, S				Caivano, M; Rodriguez, C; Cohen, P; Alemany, S			15-deoxy-Delta(12,14)-prostaglandin J(2) regulates endogenous cot MAPK kinase kinase 1 activity induced by lipopolysaccharide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; T-CELLS; TYROSINE PHOSPHORYLATION; GENE-EXPRESSION; RECEPTOR-GAMMA; INFLAMMATORY CYTOKINES; MACROPHAGE ACTIVATION; SIGNAL-TRANSDUCTION; RAW264 MACROPHAGES; NF-KAPPA-B1 P105	Cot is a MAPK kinase kinase that has been implicated in cellular activation and proliferation. Here, we show that the addition of lipopolysaccharide (LPS) to RAW264 macrophages induces a 10-fold increase of endogenous Cot activity, measured as MAPK kinase kinase 1 activity. Taxol, but not phorbol 12-myristate 13-acetate (PMA), induces a similar activation of Cot. A tyrosine kinase activity is involved in Cot activation by LPS. 15-Deoxy-Delta(12,14)-prostaglandin J(2), but not rosiglitazone, blocks Cot activation by LPS. Furthermore, 15-deoxyDelta(12,14)- prostaglandin J(2) also inhibited the LPS-induced Cot in vitro. However, 15-deoxy-Delta(12,14-)prostaglandin J(2) does not inhibit MAPK kinase 1 or ERK1/ERK2 activation/ phosphorylation induced by PMA and mediated by c-Raf. Considering these data, we propose that the inhibition of LPS-induced Cot activation is one mechanism by which 15-deoxy-Delta(12,14)-prostaglandin J(2) acts as an anti-inflammatory.	Univ Autonoma Madrid, Fac Med, CSIC, Inst Invest Biomed, E-28029 Madrid, Spain; Univ Dundee, Sch Life Sci, Phosphorylat Unit, Med Res Council Prot, Dundee DD1 5EH, Scotland	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); University of Dundee	Alemany, S (corresponding author), Univ Autonoma Madrid, Fac Med, CSIC, Inst Invest Biomed, Arturo Duperier 4, E-28029 Madrid, Spain.		Alemany, Susana/J-6307-2014	Alemany, Susana/0000-0002-4089-7620				ALESSI DR, 1995, METHOD ENZYMOL, V255, P279; Alleva DG, 2002, J LEUKOCYTE BIOL, V71, P677; Andonegui G, 2002, J IMMUNOL, V169, P2111, DOI 10.4049/jimmunol.169.4.2111; ARDITI M, 1995, J IMMUNOL, V155, P3994; Ballester A, 1998, J BIOL CHEM, V273, P14099, DOI 10.1074/jbc.273.23.14099; Ballester A, 1997, J IMMUNOL, V159, P1613; Beinke S, 2003, MOL CELL BIOL, V23, P4739, DOI 10.1128/MCB.23.14.4739-4752.2003; Belich MP, 1999, NATURE, V397, P363, DOI 10.1038/16946; Caivano M, 2000, J IMMUNOL, V164, P3018, DOI 10.4049/jimmunol.164.6.3018; Caivano M, 1998, FEBS LETT, V429, P249, DOI 10.1016/S0014-5793(98)00578-X; Castrillo A, 2001, J EXP MED, V194, P1231, DOI 10.1084/jem.194.9.1231; Ceci JD, 1997, GENE DEV, V11, P688, DOI 10.1101/gad.11.6.688; Chakravortty D, 2001, J IMMUNOL, V166, P2011, DOI 10.4049/jimmunol.166.3.2011; Chen SC, 2001, J BIOL CHEM, V276, P9631, DOI 10.1074/jbc.M008414200; Chiariello M, 2000, MOL CELL BIOL, V20, P1747, DOI 10.1128/MCB.20.5.1747-1758.2000; de Gregorio R, 2001, J BIOL CHEM, V276, P27003, DOI 10.1074/jbc.M100885200; Dumitru CD, 2000, CELL, V103, P1071, DOI 10.1016/S0092-8674(00)00210-5; Eliopoulos AG, 2002, J VIROL, V76, P4567, DOI 10.1128/JVI.76.9.4567-4579.2002; GEPPERT TD, 1994, MOL MED, V1, P93; Gilroy DW, 1999, NAT MED, V5, P698, DOI 10.1038/9550; Guthridge CJ, 1997, MOL CELL BIOL, V17, P1118, DOI 10.1128/MCB.17.3.1118; Hagemann D, 1999, ONCOGENE, V18, P1391, DOI 10.1038/sj.onc.1202431; Heumann D, 1998, CURR OPIN MICROBIOL, V1, P49, DOI 10.1016/S1369-5274(98)80142-2; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; Kane LP, 2002, MOL CELL BIOL, V22, P5962, DOI 10.1128/MCB.22.16.5962-5974.2002; Kawasaki K, 2003, J IMMUNOL, V170, P413, DOI 10.4049/jimmunol.170.1.413; Lin X, 1999, IMMUNITY, V10, P271, DOI 10.1016/S1074-7613(00)80027-8; Luo SF, 2000, BRIT J PHARMACOL, V130, P1799, DOI 10.1038/sj.bjp.0703489; Mak TW, 2002, NATURE, V418, P835, DOI 10.1038/418835a; MAKRIS A, 1993, J VIROL, V67, P1286, DOI 10.1128/JVI.67.3.1286-1291.1993; MIYOSHI J, 1991, MOL CELL BIOL, V11, P4088, DOI 10.1128/MCB.11.8.4088; Moon SK, 2002, BBA-MOL CELL RES, V1590, P41, DOI 10.1016/S0167-4889(02)00196-9; Moos PJ, 1999, J IMMUNOL, V162, P467; OBRIEN JM, 1995, J IMMUNOL, V154, P4113; PATRIOTIS C, 1994, P NATL ACAD SCI USA, V91, P9755, DOI 10.1073/pnas.91.21.9755; PATRIOTIS C, 1993, P NATL ACAD SCI USA, V90, P2251, DOI 10.1073/pnas.90.6.2251; REIMANN T, 1994, J IMMUNOL, V153, P5740; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Salmeron A, 1996, EMBO J, V15, P817, DOI 10.1002/j.1460-2075.1996.tb00417.x; Sanchez-Gongora E, 2000, J BIOL CHEM, V275, P31379, DOI 10.1074/jbc.M000382200; Schletter J, 1995, ARCH MICROBIOL, V164, P383, DOI 10.1007/BF02529735; Schoonjans K, 1997, CURR OPIN LIPIDOL, V8, P159, DOI 10.1097/00041433-199706000-00006; Sourvinos G, 1999, ONCOGENE, V18, P4968, DOI 10.1038/sj.onc.1202891; Straus DS, 2000, P NATL ACAD SCI USA, V97, P4844, DOI 10.1073/pnas.97.9.4844; Straus DS, 2001, MED RES REV, V21, P185, DOI 10.1002/med.1006; Su CG, 1999, J CLIN INVEST, V104, P383, DOI 10.1172/JCI7145; Thieringer R, 2000, J IMMUNOL, V164, P1046, DOI 10.4049/jimmunol.164.2.1046; Tsatsanis C, 1998, P NATL ACAD SCI USA, V95, P3827, DOI 10.1073/pnas.95.7.3827; Ulevitch RJ, 1999, CURR OPIN IMMUNOL, V11, P19, DOI 10.1016/S0952-7915(99)80004-1; Valledor AF, 2000, J BIOL CHEM, V275, P7403, DOI 10.1074/jbc.275.10.7403; van der Bruggen T, 1999, INFECT IMMUN, V67, P3824, DOI 10.1128/IAI.67.8.3824-3829.1999; Velasco-Sampayo A, 2001, J IMMUNOL, V166, P6084, DOI 10.4049/jimmunol.166.10.6084; Waterfield MR, 2003, MOL CELL, V11, P685, DOI 10.1016/S1097-2765(03)00070-4; Weber SM, 2002, J IMMUNOL, V168, P5303, DOI 10.4049/jimmunol.168.10.5303; WEINSTEIN SL, 1992, J BIOL CHEM, V267, P14955; WEINSTEIN SL, 1991, P NATL ACAD SCI USA, V88, P4148, DOI 10.1073/pnas.88.10.4148	56	27	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52124	52130		10.1074/jbc.M306583200	http://dx.doi.org/10.1074/jbc.M306583200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14557273	hybrid			2022-12-27	WOS:000187480700019
J	Serero, A; Giglione, C; Sardini, A; Martinez-Sanz, J; Meinnel, T				Serero, A; Giglione, C; Sardini, A; Martinez-Sanz, J; Meinnel, T			An unusual peptide deformylase features in the human mitochondrial N-terminal methionine excision pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE-SITE; NEW-GENERATION; ACTINONIN; AMINOPEPTIDASE; INHIBITORS; REQUIRES; UNIVERSALITY; RESISTANCE; PROTEINS; STRAINS	Dedicated machinery for N-terminal methionine excision (NME) was recently identified in plant organelles and shown to be essential in plastids. We report here the existence of mitochondrial NME in mammals, as shown by the identification of cDNAs encoding specific peptide deformylases (PDFs) and new methionine aminopeptidases (MAP1D). We cloned the two full-length human cDNAs and showed that the N-terminal domains of the encoded enzymes were specifically involved in targeting to mitochondria. In contrast to mitochondrial MAP1D, the human PDF sequence differed from that of known PDFs in several key features. We characterized the human PDF fully in vivo and in vitro. Comparison of the processed human enzyme with the plant mitochondrial PDF1A, to which it is phylogenetically related, showed that the human enzyme had an extra N-terminal domain involved in both mitochondrial targeting and enzyme stability. Mammalian PDFs also display non-random substitutions in the conserved motifs important for activity. Human PDF site-directed mutagenesis variants were studied and compared with the corresponding plant PDF1A variants. We found that amino acid substitutions in human PDF specifically altered its catalytic site, resulting in an enzyme intermediate between bacterial PDF1Bs and plant PDF1As. Because (i) human PDF was found to be active both in vitro and in vivo, (ii) the entire machinery is conserved and expressed in most animals, (iii) the mitochondrial genome expresses substrates for these enzymes, and (iv) mRNA synthesis is regulated, we conclude that animal mitochondria have a functional NME machinery that can be regulated.	CNRS, UPR 2355, Inst Sci Vegetal, Prot Maturat Grp, F-91198 Gif Sur Yvette, France; Imperial Coll Sch Med, MRC, Ctr Clin Sci, London W12 0NN, England	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Imperial College London	Meinnel, T (corresponding author), CNRS, UPR 2355, Inst Sci Vegetal, Prot Maturat Grp, Batiment 23,1 Ave Terrasse, F-91198 Gif Sur Yvette, France.	meinnel@isv.cnrs-gif.fr	Meinnel, Thierry/B-9813-2016	Meinnel, Thierry/0000-0001-5642-8637; Giglione, Carmela/0000-0002-7475-1558				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Boisson B, 2003, J BIOL CHEM, V278, P43418, DOI 10.1074/jbc.M307321200; Bracchi-Ricard V, 2001, ARCH BIOCHEM BIOPHYS, V396, P162, DOI 10.1006/abbi.2001.2631; Bradshaw RA, 1998, TRENDS BIOCHEM SCI, V23, P263, DOI 10.1016/S0968-0004(98)01227-4; Brown JR, 2003, NAT REV GENET, V4, P121, DOI 10.1038/nrg1000; Chen DZ, 2000, BIOCHEMISTRY-US, V39, P1256, DOI 10.1021/bi992245y; Clements JM, 2001, ANTIMICROB AGENTS CH, V45, P563, DOI 10.1128/AAC.45.2.563-570.2001; DARDEL F, 1994, COMPUT APPL BIOSCI, V10, P273; Dardel F, 1998, J MOL BIOL, V280, P501, DOI 10.1006/jmbi.1998.1882; Davies SJ, 2003, BIOORG MED CHEM LETT, V13, P2715, DOI 10.1016/S0960-894X(03)00533-X; Giglione C, 2003, EMBO J, V22, P13, DOI 10.1093/emboj/cdg007; Giglione C, 2001, TRENDS PLANT SCI, V6, P566, DOI 10.1016/S1360-1385(01)02151-3; Giglione C, 2001, Expert Opin Ther Targets, V5, P41, DOI 10.1517/14728222.5.1.41; Giglione C, 2000, MOL MICROBIOL, V36, P1197, DOI 10.1046/j.1365-2958.2000.01908.x; Giglione C, 2000, EMBO J, V19, P5916, DOI 10.1093/emboj/19.21.5916; Groche D, 1998, BIOCHEM BIOPH RES CO, V246, P342, DOI 10.1006/bbrc.1998.8616; Grujic M, 2002, CANCER LETT, V182, P113, DOI 10.1016/S0304-3835(02)00086-1; Guilloteau JP, 2002, J MOL BIOL, V320, P951, DOI 10.1016/S0022-2836(02)00549-1; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; Jeanmougin F, 1998, TRENDS BIOCHEM SCI, V23, P403, DOI 10.1016/S0968-0004(98)01285-7; Keeling PJ, 1996, TRENDS BIOCHEM SCI, V21, P285; KOZAK M, 1983, MICROBIOL REV, V47, P1; Kumar A, 2002, STRUCTURE, V10, P357, DOI 10.1016/S0969-2126(02)00719-0; Lang BF, 1999, ANNU REV GENET, V33, P351, DOI 10.1146/annurev.genet.33.1.351; Lazennec C, 1997, ANAL BIOCHEM, V244, P180, DOI 10.1006/abio.1996.9910; Legros F, 2002, MOL BIOL CELL, V13, P4343, DOI 10.1091/mbc.E02-06-0330; Lowther WT, 2002, CHEM REV, V102, P4581, DOI 10.1021/cr0101757; Margolis P, 2001, ANTIMICROB AGENTS CH, V45, P2432, DOI 10.1128/AAC.45.9.2432-2435.2001; MAZEL D, 1994, EMBO J, V13, P914, DOI 10.1002/j.1460-2075.1994.tb06335.x; MEINNEL T, 1995, J BACTERIOL, V177, P1883, DOI 10.1128/jb.177.7.1883-1887.1995; MEINNEL T, 1995, J MOL BIOL, V254, P175, DOI 10.1006/jmbi.1995.0609; MEINNEL T, 1988, NUCLEIC ACIDS RES, V16, P8095, DOI 10.1093/nar/16.16.8095; Meinnel T, 1996, FEBS LETT, V385, P91, DOI 10.1016/0014-5793(96)00357-2; Meinnel T, 1999, BIOCHEMISTRY-US, V38, P4287, DOI 10.1021/bi982622r; Meinnel T, 1997, J MOL BIOL, V267, P749, DOI 10.1006/jmbi.1997.0904; MEINNEL T, 1993, BIOCHIMIE, V75, P1061, DOI 10.1016/0300-9084(93)90005-D; MEINNEL T, 1994, J BACTERIOL, V176, P7387, DOI 10.1128/JB.176.23.7387-7390.1994; Meinnel T, 2000, PARASITOL TODAY, V16, P165, DOI 10.1016/S0169-4758(99)01627-0; Miesel L, 2003, NAT REV GENET, V4, P442, DOI 10.1038/nrg1086; Nguyen KT, 2003, BIOCHEMISTRY-US, V42, P9952, DOI 10.1021/bi0346446; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; Polevoda B, 2003, J MOL BIOL, V325, P595, DOI 10.1016/S0022-2836(02)01269-X; Ragusa S, 1999, J MOL BIOL, V289, P1445, DOI 10.1006/jmbi.1999.2832; Ragusa S, 1998, J MOL BIOL, V280, P515, DOI 10.1006/jmbi.1998.1883; Rajagopalan PTR, 2000, BIOCHEMISTRY-US, V39, P779, DOI 10.1021/bi9919899; Rajagopalan PTR, 1997, J AM CHEM SOC, V119, P12418, DOI 10.1021/ja9734096; Rajagopalan PTR, 1998, J BIOL CHEM, V273, P22305, DOI 10.1074/jbc.273.35.22305; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Rost B, 1996, PROTEIN SCI, V5, P1704, DOI 10.1002/pro.5560050824; Serero A, 2001, J MOL BIOL, V314, P695, DOI 10.1006/jmbi.2001.5175; SHARP PM, 1987, NUCLEIC ACIDS RES, V15, P1281, DOI 10.1093/nar/15.3.1281; SINGER M, 1989, MICROBIOL REV, V53, P1; Solbiati J, 1999, J MOL BIOL, V290, P607, DOI 10.1006/jmbi.1999.2913; Sulavik MC, 2001, ANTIMICROB AGENTS CH, V45, P1126, DOI 10.1128/AAC.45.4.1126-1136.2001; Vetro JA, 2002, J CELL BIOCHEM, V85, P678, DOI 10.1002/jcb.10161; Waller AS, 2002, CURR OPIN DRUG DI DE, V5, P785; Wiesner J, 2001, TRENDS PARASITOL, V17, P7, DOI 10.1016/S1471-4922(00)01735-9; Xia D, 1997, SCIENCE, V277, P60, DOI 10.1126/science.277.5322.60; Xu Y, 1998, CLIN CANCER RES, V4, P171; Yan Z, 2003, J BIOL CHEM, V278, P8826, DOI 10.1074/jbc.M209879200; Yuan ZY, 2001, DRUG DISCOV TODAY, V6, P954, DOI 10.1016/S1359-6446(01)01925-0	61	109	120	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52953	52963		10.1074/jbc.M309770200	http://dx.doi.org/10.1074/jbc.M309770200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14532271	hybrid			2022-12-27	WOS:000187480700118
J	Cirman, T; Oresic, K; Mazovec, GD; Turk, V; Reed, JC; Myers, RM; Salvesen, GS; Turk, B				Cirman, T; Oresic, K; Mazovec, GD; Turk, V; Reed, JC; Myers, RM; Salvesen, GS; Turk, B			Selective disruption of lysosomes in HeLa cells triggers apoptosis mediated by cleavage of bid by multiple papain-like lysosomal cathepsins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUCINE METHYL-ESTER; CYTOCHROME-C RELEASE; MYOCLONUS EPILEPSY EPM1; TUMOR-NECROSIS-FACTOR; BCL-2 FAMILY MEMBERS; OR-DEATH DECISIONS; CYSTEINE PROTEASES; OXIDATIVE STRESS; HEPATOCYTE APOPTOSIS; ESCHERICHIA-COLI	Increasing evidence suggests that lysosomal proteases are actively involved in apoptosis. Using HeLa cells as the model system, we show that selective lysosome disruption with L-leucyl-L-leucine methyl ester results in apoptosis, characterized by translocation of lysosomal proteases into the cytosol and by the cleavage of a proapoptotic Bcl-2-family member Bid. Apoptosis and Bid cleavage, but not translocation of lysosomal proteases to the cytosol, could be prevented by 15 muM L-trans-epoxysuccinyl(OEt)-Leu-3-methylbutylamide, an inhibitor of papain-like cysteine proteases. Incubation of cells with 15 muM N-benzoyloxycarbonyl-VAD-fluoromethyl ketone prevented apoptosis but not Bid cleavage, suggesting that cathepsin-mediated apoptosis in this system is caspase-dependent. In vitro experiments performed at neutral pH showed that papain-like cathepsins B, H, L, S, and K cleave Bid predominantly at Arg(65) or Arg(71). No Bid cleavage was observed with cathepsins C and X or the aspartic protease cathepsin D. Incubation of full-length Bid treated with cathepsins B, H, L, and S resulted in rapid cytochrome c release from isolated mitochondria. Thus, Bid may be an important mediator of apoptosis induced by lysosomal disruption.	Jozef Stefan Inst, Dept Biochem & Mol Biol, Ljubljana 1000, Slovenia; Burnham Inst, La Jolla, CA 92037 USA; Stanford Univ, Dept Genet, Sch Med, Stanford, CA 94305 USA	Slovenian Academy of Sciences & Arts (SASA); Jozef Stefan Institute; Sanford Burnham Prebys Medical Discovery Institute; Stanford University	Turk, B (corresponding author), Jozef Stefan Inst, Dept Biochem & Mol Biol, Jamova 39, Ljubljana 1000, Slovenia.	boris.turk@ijs.si		Turk, Boris/0000-0002-9007-5764	NIGMS NIH HHS [GM60554] Funding Source: Medline; NINDS NIH HHS [NS37878] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060554] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037878] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adams JM, 2001, TRENDS BIOCHEM SCI, V26, P61, DOI 10.1016/S0968-0004(00)01740-0; Adrain C, 2001, TRENDS BIOCHEM SCI, V26, P390, DOI 10.1016/S0968-0004(01)01844-8; Antunes F, 2001, BIOCHEM J, V356, P549, DOI 10.1042/0264-6021:3560549; Barlic-Maganja D, 1998, BIOL CHEM, V379, P1449; Bidere N, 2003, J BIOL CHEM, V278, P31401, DOI 10.1074/jbc.M301911200; Borner C, 2003, MOL IMMUNOL, V39, P615, DOI 10.1016/S0161-5890(02)00252-3; Boya P, 2003, J EXP MED, V197, P1323, DOI 10.1084/jem.20021952; Brunk UT, 1999, REDOX REP, V4, P3, DOI 10.1179/135100099101534675; Brunk UT, 1997, FREE RADICAL BIO MED, V23, P616, DOI 10.1016/S0891-5849(97)00007-5; Bursch W, 2001, CELL DEATH DIFFER, V8, P569, DOI 10.1038/sj.cdd.4400852; Chen M, 2001, J BIOL CHEM, V276, P30724, DOI 10.1074/jbc.M103701200; Chou JJ, 1999, CELL, V96, P615, DOI 10.1016/S0092-8674(00)80572-3; Cuervo AM, 2000, EXP GERONTOL, V35, P119, DOI 10.1016/S0531-5565(00)00075-9; D'Alessio KJ, 1999, PROTEIN EXPRES PURIF, V15, P213, DOI 10.1006/prep.1998.1013; Dolenc I, 1996, FEBS LETT, V392, P277, DOI 10.1016/0014-5793(96)00828-9; Ferri KF, 2001, NAT CELL BIOL, V3, pE255, DOI 10.1038/ncb1101-e255; Foghsgaard L, 2001, J CELL BIOL, V153, P999, DOI 10.1083/jcb.153.5.999; Gil-Parrado S, 2002, J BIOL CHEM, V277, P27217, DOI 10.1074/jbc.M202945200; Gray J, 2001, J BIOL CHEM, V276, P32750, DOI 10.1074/jbc.M103150200; Guicciardi ME, 2000, J CLIN INVEST, V106, P1127, DOI 10.1172/JCI9914; Guicciardi ME, 2001, AM J PATHOL, V159, P2045, DOI 10.1016/S0002-9440(10)63056-8; Guncar G, 1998, STRUCTURE, V6, P51; Hampton MB, 1997, FEBS LETT, V414, P552, DOI 10.1016/S0014-5793(97)01068-5; Harris JL, 2000, P NATL ACAD SCI USA, V97, P7754, DOI 10.1073/pnas.140132697; Heibein JA, 2000, J EXP MED, V192, P1391, DOI 10.1084/jem.192.10.1391; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Houseweart MK, 2003, CELL DEATH DIFFER, V10, P1329, DOI 10.1038/sj.cdd.4401309; Houseweart MK, 2003, J NEUROBIOL, V56, P315, DOI 10.1002/neu.10253; Kagedal K, 2001, BIOCHEM J, V359, P335, DOI 10.1042/0264-6021:3590335; KIRSCHKE H, 1989, BIOCHEM J, V264, P467, DOI 10.1042/bj2640467; Kirschke H, 1995, PROTEIN PROFILE, V2, P1587; Klemencic I, 2000, EUR J BIOCHEM, V267, P5404, DOI 10.1046/j.1432-1327.2000.01592.x; Kobayashi Y, 2000, BIOCHEM BIOPH RES CO, V272, P687, DOI 10.1006/bbrc.2000.2836; KUHELJ R, 1995, EUR J BIOCHEM, V229, P533, DOI 10.1111/j.1432-1033.1995.0533k.x; Leist M, 2001, NAT REV MOL CELL BIO, V2, P589, DOI 10.1038/35085008; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li W, 2000, FEBS LETT, V470, P35, DOI 10.1016/S0014-5793(00)01286-2; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Mandic A, 2002, MOL CELL BIOL, V22, P3003, DOI 10.1128/MCB.22.9.3003-3013.2002; Mason R W, 1996, Subcell Biochem, V27, P159; McDonnell JM, 1999, CELL, V96, P625, DOI 10.1016/S0092-8674(00)80573-5; Mehta DP, 1996, J BIOL CHEM, V271, P10897, DOI 10.1074/jbc.271.18.10897; NIKAWA T, 1992, EUR J BIOCHEM, V204, P381, DOI 10.1111/j.1432-1033.1992.tb16647.x; OLLINGER K, 1995, FREE RADICAL BIO MED, V19, P565, DOI 10.1016/0891-5849(95)00062-3; Ott M, 2002, P NATL ACAD SCI USA, V99, P1259, DOI 10.1073/pnas.241655498; Pennacchio LA, 1998, NAT GENET, V20, P251, DOI 10.1038/3059; Reiners JJ, 2002, CELL DEATH DIFFER, V9, P934, DOI 10.1038/sj.cdd.4401048; Roberg K, 1998, AM J PATHOL, V152, P1151; Roberg K, 2002, AM J PATHOL, V161, P89, DOI 10.1016/S0002-9440(10)64160-0; Rozman-Pungercar J, 2003, CELL DEATH DIFFER, V10, P881, DOI 10.1038/sj.cdd.4401247; Schendel SL, 1999, J BIOL CHEM, V274, P21932, DOI 10.1074/jbc.274.31.21932; Schotte P, 1998, BIOCHEM BIOPH RES CO, V251, P379, DOI 10.1006/bbrc.1998.9425; Stennicke HR, 2000, BIOCHEM J, V350, P563, DOI 10.1042/0264-6021:3500563; Stennicke HR, 1997, J BIOL CHEM, V272, P25719, DOI 10.1074/jbc.272.41.25719; Stoka V, 2001, J BIOL CHEM, V276, P3149, DOI 10.1074/jbc.M008944200; STORRIE B, 1990, METHOD ENZYMOL, V182, P203; Sutton VR, 2000, J EXP MED, V192, P1403, DOI 10.1084/jem.192.10.1403; THIELE DL, 1992, J IMMUNOL, V148, P3950; THIELE DL, 1990, P NATL ACAD SCI USA, V87, P83, DOI 10.1073/pnas.87.1.83; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; Turk B, 2000, BBA-PROTEIN STRUCT M, V1477, P98, DOI 10.1016/S0167-4838(99)00263-0; TURK B, 1994, BIOCHEMISTRY-US, V33, P14800, DOI 10.1021/bi00253a019; TURK B, 1993, BIOCHEMISTRY-US, V32, P375, DOI 10.1021/bi00052a046; Turk B, 2002, CURR PHARM DESIGN, V8, P1623, DOI 10.2174/1381612023394124; Turk B, 2002, BIOL CHEM, V383, P1035, DOI 10.1515/BC.2002.112; Turk B, 1997, BIOL CHEM, V378, P141; Turk B., 1998, HDB PROTEOLYTIC ENZY, P631; Turk D, 1998, BIOL CHEM, V379, P137, DOI 10.1515/bchm.1998.379.2.137; Turk V, 2001, EMBO J, V20, P4629, DOI 10.1093/emboj/20.17.4629; Uchimoto T, 1999, APOPTOSIS, V4, P357, DOI 10.1023/A:1009695221038; Yamashima T, 2000, PROG NEUROBIOL, V62, P273, DOI 10.1016/S0301-0082(00)00006-X	71	379	400	3	35	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	2004	279	5					3578	3587		10.1074/jbc.M308347200	http://dx.doi.org/10.1074/jbc.M308347200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	766MF	14581476	hybrid			2022-12-27	WOS:000188379600055
J	Lindvall, H; Nevsten, P; Strom, K; Wallenberg, R; Sundler, F; Langin, D; Winzell, MSR; Holm, C				Lindvall, H; Nevsten, P; Strom, K; Wallenberg, R; Sundler, F; Langin, D; Winzell, MSR; Holm, C			A novel hormone-sensitive lipase isoform expressed in pancreatic beta-cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-SECRETION; ADIPOSE-TISSUE; RAT ISLETS; GLUCOSE; GENE; SEQUENCE; ORGANIZATION; STIMULATION; ADIPOCYTES; LIPOLYSIS	Hormone-sensitive lipase (HSL) is a key enzyme in fatty acid mobilization in many cell types. Two isoforms of HSL are known to date, namely HSLadi (84 kDa in rat) and HSLtes (130 kDa in rat). These are encoded by the same gene, with exons 1-9 encoding the parts that are common to both and an additional 5'-exon encoding the additional amino acids in HSLtes. HSL of various tissues, among these the islet of Langerhans, is larger than HSLadi, but not as large as HSLtes, indicating that there may be other 5'-coding exons. Here we describe the molecular basis for a novel 89-kDa HSL isoform that is expressed in beta-cells, adipocytes, adrenal glands, and ovaries in the rat and that is encoded by exons 1-9 and exon A, which is spliced to exon 1 and thereby introducing an upstream start codon. The additional 5'-base pairs encode a 43-amino acid peptide, which is highly positively charged. Conglomerates of HSL molecules are in close association with the secretory granules of the beta-cell, as determined by immunoelectron microscopy with antibodies targeting two separate regions of HSL. We have also determined that the human genomic sequence upstream of exon A has promoter activity in INS-1 cells as well as glucose sensing capability, mediating an increase in expression at high glucose concentration. The minimal promoter is present within 170 bp from the transcriptional start site and maximal glucose responsiveness is conferred by sequence within 850 bp from the transcriptional start site.	Lund Univ, Biomed Ctr, Dept Cell & Mol Biol, Sect Mol Signaling, SE-22184 Lund, Sweden; Lund Univ, Natl Ctr High Resolut Electron Microscopy, SE-22184 Lund, Sweden; Lund Univ, Dept Physiol Sci, SE-22184 Lund, Sweden; Lund Univ, Dept Med, SE-22184 Lund, Sweden; Univ Toulouse 3, Ctr Hosp Univ Toulouse, Inst Louis Bugnard, INSERM,U586,Unite Rech Obes, F-31403 Toulouse, France	Lund University; Lund University; Lund University; Lund University; CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Lindvall, H (corresponding author), Lund Univ, Biomed Ctr, Dept Cell & Mol Biol, Sect Mol Signaling, C11, SE-22184 Lund, Sweden.	hakan.lindvall@medkem.lu.se	Wallenberg, Reine/H-5405-2011	Wallenberg, Reine/0000-0002-0850-0398; Langin, Dominique/0000-0002-2669-7825				Anthonsen MW, 1998, J BIOL CHEM, V273, P215, DOI 10.1074/jbc.273.1.215; Botion LM, 1999, DIABETES, V48, P1691, DOI 10.2337/diabetes.48.9.1691; Branstrom R, 1998, J BIOL CHEM, V273, P31395, DOI 10.1074/jbc.273.47.31395; Brasaemle DL, 2000, BBA-MOL CELL BIOL L, V1483, P251, DOI 10.1016/S1388-1981(99)00179-1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Corkey BE, 2000, J NUTR, V130, p299S, DOI 10.1093/jn/130.2.299S; Deeney JT, 2000, J BIOL CHEM, V275, P9363, DOI 10.1074/jbc.275.13.9363; Dobbins RL, 1998, J CLIN INVEST, V101, P2370, DOI 10.1172/JCI1813; ELKS ML, 1993, ENDOCRINOLOGY, V133, P208, DOI 10.1210/en.133.1.208; Flamez D, 2002, DIABETES, V51, P2018, DOI 10.2337/diabetes.51.7.2018; Geng XH, 2003, DIABETES, V52, P767, DOI 10.2337/diabetes.52.3.767; Grober J, 1997, BIOCHEM J, V328, P453, DOI 10.1042/bj3280453; Grober J, 2003, J BIOL CHEM, V278, P6510, DOI 10.1074/jbc.M208513200; Holm C, 2000, ANNU REV NUTR, V20, P365, DOI 10.1146/annurev.nutr.20.1.365; HOLM C, 1987, BIOCHEM BIOPH RES CO, V148, P99, DOI 10.1016/0006-291X(87)91081-3; HOLM C, 1988, SCIENCE, V241, P1503, DOI 10.1126/science.3420405; Holst LS, 1996, GENOMICS, V35, P441, DOI 10.1006/geno.1996.0383; KHOO JC, 1993, J LIPID RES, V34, P1969; Koyama K, 1997, DIABETES, V46, P1276, DOI 10.2337/diabetes.46.8.1276; LANGIN D, 1993, P NATL ACAD SCI USA, V90, P4897, DOI 10.1073/pnas.90.11.4897; Laurin NN, 2000, MAMM GENOME, V11, P972, DOI 10.1007/s003350010185; LI ZG, 1994, GENOMICS, V24, P259, DOI 10.1006/geno.1994.1614; Mairal A, 2002, BIOCHEM BIOPH RES CO, V291, P286, DOI 10.1006/bbrc.2002.6427; Mantovani R, 1998, NUCLEIC ACIDS RES, V26, P1135, DOI 10.1093/nar/26.5.1135; Mulder H, 2003, J BIOL CHEM, V278, P36380, DOI 10.1074/jbc.M213032200; Mulder H, 1999, DIABETES, V48, P228, DOI 10.2337/diabetes.48.1.228; Osterlund T, 1996, BIOCHEM J, V319, P411, DOI 10.1042/bj3190411; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Raclot T, 1998, BIOCHEM BIOPH RES CO, V245, P510, DOI 10.1006/bbrc.1998.8469; SAKO Y, 1990, ENDOCRINOLOGY, V127, P1580, DOI 10.1210/endo-127-4-1580; Shen WJ, 1999, P NATL ACAD SCI USA, V96, P5528, DOI 10.1073/pnas.96.10.5528; Smale ST, 1997, BBA-GENE STRUCT EXPR, V1351, P73, DOI 10.1016/S0167-4781(96)00206-0; SMITH F, 2002, DIABETES, V51, P293; Winzell MS, 2001, DIABETES, V50, P2225, DOI 10.2337/diabetes.50.10.2225	34	31	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 30	2004	279	5					3828	3836		10.1074/jbc.M311365200	http://dx.doi.org/10.1074/jbc.M311365200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	766MF	14576146	hybrid			2022-12-27	WOS:000188379600085
J	Ano, S; Pereira, R; Pironin, M; Lesault, I; Milley, C; Lebigot, I; Quang, CT; Ghysdael, J				Ano, S; Pereira, R; Pironin, M; Lesault, I; Milley, C; Lebigot, I; Quang, CT; Ghysdael, J			Erythroblast transformation by FLI-1 depends upon its specific DNA binding and transcriptional activation properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULV-INDUCED ERYTHROLEUKEMIAS; RNA-POLYMERASE-II; ETS-DOMAIN; ERYTHROPOIETIN RECEPTOR; FUSION PROTEIN; EWING SARCOMA; F-MULV; LINEAGE COMMITMENT; COMPLEX-FORMATION; TERNARY COMPLEX	FLI-1 is a transcriptional regulator of the ETS family of proteins. Insertional activation at the FLI-1 locus is an early event in F-murine leukemia virus-induced erythroleukemia. Consistent with its essential role in erythroid transformation, enforced expression of FLI-1 in primary erythroblasts strongly impairs the response of these cells to erythropoietin (Epo), a cytokine essential to erythropoiesis. We show here that point mutations in the ETS domain that abolished FLI-1 binding to specific DNA elements (ETS-binding sites) suppressed the ability of FLI-1 to transform erythroblasts. The exchange of the entire ETS domain (DNA binding domain) of FLI-1 for that of PU.1 changed the DNA binding specificity of FLI-1 for that of PU.1 and impaired FLI-1 transforming properties. In contrast, ETS domain swapping mutants that maintained the DNA binding specificity of FLI-1 did not affect the ability of FLI-1 to transform erythroblasts. Deletion and swapping mutants that failed to inhibit the DNA binding activity of FLI-1 but impaired its transcriptional activation properties were also transformation-defective. Taken together, these results show that both the ability of FLI-1 to inhibit Epo-induced differentiation of erythroblasts and to confer enhanced cell survival in the absence of Epo critically depend upon FLI-1 ETS-binding site-dependent transcriptional activation properties.	Inst Curie, CNRS, UMR 146, F-91405 Orsay, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Ghysdael, J (corresponding author), Inst Curie, CNRS, UMR 146, Ctr Univ,Bat 110, F-91405 Orsay, France.	Jacques.Ghysdael@curie.u-psud.fr	GHYSDAEL, Jacques/F-3377-2013; QUANG, christine TRAN/G-7508-2016					Arvand A, 2001, CANCER RES, V61, P5311; BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; Batchelor AH, 1998, SCIENCE, V279, P1037, DOI 10.1126/science.279.5353.1037; Behre G, 1999, J BIOL CHEM, V274, P4939, DOI 10.1074/jbc.274.8.4939; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; Bertolotti A, 1996, EMBO J, V15, P5022, DOI 10.1002/j.1460-2075.1996.tb00882.x; BRAUN BS, 1995, MOL CELL BIOL, V15, P4623; Chansky HA, 2001, CANCER RES, V61, P3586; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Czuwara-Ladykowska J, 2001, J BIOL CHEM, V276, P20839, DOI 10.1074/jbc.M010133200; Dalgleish P, 2000, NUCLEIC ACIDS RES, V28, P560, DOI 10.1093/nar/28.2.560; Darby TG, 1997, ONCOGENE, V15, P3067, DOI 10.1038/sj.onc.1201503; Dauphinot L, 2001, ONCOGENE, V20, P3258, DOI 10.1038/sj.onc.1204437; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; Escalante CR, 2002, MOL CELL, V10, P1097, DOI 10.1016/S1097-2765(02)00703-7; Fukuma M, 2003, ONCOGENE, V22, P1, DOI 10.1038/sj.onc.1206055; Garvie CW, 2001, MOL CELL, V8, P1267, DOI 10.1016/S1097-2765(01)00410-5; GEGONNE A, 1993, EMBO J, V12, P1169, DOI 10.1002/j.1460-2075.1993.tb05758.x; Hahm KB, 1999, NAT GENET, V23, P222, DOI 10.1038/13854; Hahn SL, 1997, ONCOGENE, V15, P1489, DOI 10.1038/sj.onc.1201301; Hassler M, 2001, EMBO J, V20, P3018, DOI 10.1093/emboj/20.12.3018; HOWARD JC, 1993, ONCOGENE, V8, P2721; Howard JC, 1996, ONCOGENE, V12, P1405; Howard JC, 2001, ONCOGENE, V20, P2291, DOI 10.1038/sj.onc.1204348; Jaishankar S, 1999, ONCOGENE, V18, P5592, DOI 10.1038/sj.onc.1202940; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KNIGHT J, 1988, GENE DEV, V2, P247, DOI 10.1101/gad.2.2.247; Knoop LL, 2000, J BIOL CHEM, V275, P24865, DOI 10.1074/jbc.M001661200; Kodandapani R, 1996, NATURE, V380, P456, DOI 10.1038/380456a0; LEBIGOT I, 2003, IN PRESS BLOOD; Lesault I, 2002, EMBO J, V21, P694, DOI 10.1093/emboj/21.4.694; LIANG H, 1994, NAT STRUCT BIOL, V1, P871, DOI 10.1038/nsb1294-871; Lin CS, 1996, GENE DEV, V10, P154, DOI 10.1101/gad.10.2.154; Lopez R, 1999, J BIOL CHEM, V274, P30132, DOI 10.1074/jbc.274.42.30132; MAO XH, 1994, J BIOL CHEM, V269, P18216; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; Mo Y, 1998, MOL CELL, V2, P201, DOI 10.1016/S1097-2765(00)80130-6; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; Nerlov C, 1998, GENE DEV, V12, P2403, DOI 10.1101/gad.12.15.2403; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; OHNO T, 1993, CANCER RES, V53, P5859; Pereira R, 1999, ONCOGENE, V18, P1597, DOI 10.1038/sj.onc.1202534; Quang CT, 1997, EMBO J, V16, P5639, DOI 10.1093/emboj/16.18.5639; RABAULT B, 1994, J BIOL CHEM, V269, P28143; RAO VN, 1993, ONCOGENE, V8, P2167; RAYGALLET D, 1995, ONCOGENE, V11, P303; Reddy VA, 2002, BLOOD, V100, P483, DOI 10.1182/blood.V100.2.483; Rekhtman N, 1999, GENE DEV, V13, P1398, DOI 10.1101/gad.13.11.1398; Shore P, 1996, MOL CELL BIOL, V16, P3338; Starck J, 1999, MOL CELL BIOL, V19, P121; Starck J, 2003, MOL CELL BIOL, V23, P1390, DOI 10.1128/MCB.23.4.1390-1402.2003; Tamir A, 1999, MOL CELL BIOL, V19, P4452; Truong AHL, 2000, ONCOGENE, V19, P6482, DOI 10.1038/sj.onc.1204042; Welford SM, 2001, J BIOL CHEM, V276, P41977, DOI 10.1074/jbc.M106757200; Whyatt D, 2002, EMBO REP, V3, P130, DOI 10.1093/embo-reports/kvf033; WOODS DB, 1992, NUCLEIC ACIDS RES, V20, P699, DOI 10.1093/nar/20.4.699; WU H, 1995, CELL, V83, P59, DOI 10.1016/0092-8674(95)90234-1; Yang L, 2000, J BIOL CHEM, V275, P37612, DOI 10.1074/jbc.M005739200; ZHANG LQ, 1993, ONCOGENE, V8, P1621; Zhang P, 1999, P NATL ACAD SCI USA, V96, P8705, DOI 10.1073/pnas.96.15.8705; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x; Zwerner JP, 2001, ONCOGENE, V20, P626, DOI 10.1038/sj.onc.1204133	62	9	10	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	2004	279	4					2993	3002		10.1074/jbc.M303816200	http://dx.doi.org/10.1074/jbc.M303816200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	764MU	14570912	hybrid			2022-12-27	WOS:000188211300080
J	Hwa, V; Little, B; Kofoed, EM; Rosenfeld, RG				Hwa, V; Little, B; Kofoed, EM; Rosenfeld, RG			Transcriptional regulation of insulin-like growth factor-I by interferon-gamma requires STAT-5b	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; GENE-EXPRESSION; IFN-GAMMA; IGF-I; C2C12 MYOBLASTS; STAT5B; CELLS; GH; ACTIVATION; RECEPTOR	Insulin-like growth factor (IGF)-I, a growth factor important for cell proliferation, cellular differentiation, and multiple metabolic functions, is regulated in vivo by growth factors and cytokines, but the mechanism(s) of regulation at the cellular level is not well understood. We now demonstrate, employing primary human dermal fibroblasts (CF), that the multipotent cytokine, interferon-gamma (IFN-gamma), can up-regulate IGF-I mRNA expression and that this regulation occurs via activation of the signal transducer and activator of transcription-5b (STAT-5b) pathway. IFN-gamma (100 units/ml) treatment of CF cells resulted in a preferential, time-dependent activation of STAT-5b, although both STAT-5a and STAT-5b isoforms are present. The activated STAT-5b translocated to the nucleus within 30 min of treatment and induced an increase in IGF-I mRNA of 6 +/- 1.0-fold, 3 h post-treatment, with a further increase to 8 +/- 1.7-fold at 5 h. In contrast, IFN-gamma treatment of primary human dermal fibroblasts with a nonfunctional STAT-5b (PF cells) resulted in activation of only STAT-5a and an increase of the IGF-I mRNA level of 1.7 +/- 0.6-fold, 5 h post-treatment. The IFN-gamma-induced regulation of the interferon regulatory factor-1 gene, whose expression is dependent on activated STAT-1, was the same between CF and PF cells. In summary, our results provide evidence of the following in human primary dermal fibroblasts: ( a) IFN-gamma preferentially activates STAT-5b, but, in the absence of a functional STAT-5b, STAT-5a is activated; (b) IFN-gamma time-dependently up-regulates IGF-I mRNA expression; ( c) the regulation of IGF-I requires an active STAT-5b, and activated STAT-5a cannot substitute for an inactive STAT-5b; and (d) STAT-5b has an essential role in the transcriptional up-regulation of IGF-I.	Oregon Hlth & Sci Univ, Dept Pediat, Portland, OR 97239 USA; Lucile Packard Fdn Childrens Hlth, Palo Alto, CA 94304 USA; Stanford Univ, Stanford, CA 94305 USA	Oregon Health & Science University; Stanford University	Hwa, V (corresponding author), Oregon Hlth & Sci Univ, Dept Pediat, NRC5,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.	hwav@ohsu.edu			NATIONAL CANCER INSTITUTE [R01CA058110] Funding Source: NIH RePORTER; NCI NIH HHS [CA58110] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anwar A, 2002, CIRCULATION, V105, P1220, DOI 10.1161/hc1002.105187; ARKINS S, 1995, MOL ENDOCRINOL, V9, P350, DOI 10.1210/me.9.3.350; Chacko MS, 2002, ENDOCRINOLOGY, V143, P525, DOI 10.1210/en.143.2.525; Davey HW, 2001, ENDOCRINOLOGY, V142, P3836, DOI 10.1210/en.142.9.3836; FARRAR MA, 1993, ANNU REV IMMUNOL, V11, P571, DOI 10.1146/annurev.iy.11.040193.003035; Fernandez-Celemin L, 2002, AM J PHYSIOL-ENDOC M, V283, pE1279, DOI 10.1152/ajpendo.00054.2002; Frost RA, 2003, ENDOCRINOLOGY, V144, P1770, DOI 10.1210/en.2002-220808; Frost RA, 2002, ENDOCRINOLOGY, V143, P492, DOI 10.1210/en.143.2.492; Gil MP, 2001, P NATL ACAD SCI USA, V98, P6680, DOI 10.1073/pnas.111163898; Glazebrook H, 1998, J VASC RES, V35, P143, DOI 10.1159/000025577; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; GREENLUND AC, 1995, IMMUNITY, V2, P677, DOI 10.1016/1074-7613(95)90012-8; Hoeck J, 2001, J IMMUNOL, V166, P4507, DOI 10.4049/jimmunol.166.7.4507; Kofoed EM, 2003, NEW ENGL J MED, V349, P1139, DOI 10.1056/NEJMoa022926; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; Li XX, 1996, J BIOL CHEM, V271, P5790, DOI 10.1074/jbc.271.10.5790; Meinke A, 1996, MOL CELL BIOL, V16, P6937; Miura H, 2000, ARCH DERMATOL RES, V292, P590, DOI 10.1007/s004030000188; Ramana CV, 2002, TRENDS IMMUNOL, V23, P96, DOI 10.1016/S1471-4906(01)02118-4; Ramana CV, 2000, EMBO J, V19, P263, DOI 10.1093/emboj/19.2.263; Ramana CV, 2001, P NATL ACAD SCI USA, V98, P6674, DOI 10.1073/pnas.111164198; Sadowski CL, 2001, ENDOCRINOLOGY, V142, P3890, DOI 10.1210/en.142.9.3890; Sambrook J., 2002, MOL CLONING LAB MANU; Silva CM, 2002, ENDOCRINOLOGY, V143, P2610, DOI 10.1210/en.143.7.2610; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; Thissen JP, 1997, ENDOCRINOLOGY, V138, P1078, DOI 10.1210/en.138.3.1078; Udy GB, 1997, P NATL ACAD SCI USA, V94, P7239, DOI 10.1073/pnas.94.14.7239; Wilson EM, 2001, J CLIN ENDOCR METAB, V86, P4504, DOI 10.1210/jc.86.9.4504; Woelfle J, 2003, J BIOL CHEM, V278, P22696, DOI 10.1074/jbc.M301362200; Woldman I, 2001, J BIOL CHEM, V276, P45722, DOI 10.1074/jbc.M105320200; Woods KA, 1996, NEW ENGL J MED, V335, P1363, DOI 10.1056/NEJM199610313351805; Wynes MW, 2003, J IMMUNOL, V171, P3550, DOI 10.4049/jimmunol.171.7.3550	33	44	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 23	2004	279	4					2728	2736		10.1074/jbc.M310495200	http://dx.doi.org/10.1074/jbc.M310495200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	764MU	14570891	hybrid			2022-12-27	WOS:000188211300050
J	Sarangapani, KK; Yago, T; Klopocki, AG; Lawrence, MB; Fieger, CB; Rosen, SD; McEver, RP; Zhu, C				Sarangapani, KK; Yago, T; Klopocki, AG; Lawrence, MB; Fieger, CB; Rosen, SD; McEver, RP; Zhu, C			Low force decelerates L-selectin dissociation from P-selectin glycoprotein ligand-1 and endoglycan	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE SULFATION; LEUKOCYTE ADHESION; CELL-ADHESION; BONDS; BINDING; IDENTIFICATION; DIMERIZATION; THRESHOLD; KINETICS; GLYCOSULFOPEPTIDES	Selectin-ligand interactions mediate the tethering and rolling of circulating leukocytes on vascular surfaces during inflammation and immune surveillance. To support rolling, these interactions are thought to have rapid off-rates that increase slowly as wall shear stress increases. However, the increase of off-rate with force, an intuitive characteristic named slip bonds, is at odds with a shear threshold requirement for selectin-mediated cell rolling. As shear drops below the threshold, fewer cells roll and those that do roll less stably and with higher velocity. We recently demonstrated a low force regime where the off-rate of P-selectin interacting with P-selectin glycoprotein ligand-1 (PSGL-1) decreased with increasing force. This counter-intuitive characteristic, named catch bonds, might partially explain the shear threshold phenomenon. Because L-selectin-mediated cell rolling exhibits a much more pronounced shear threshold, we used atomic force microscopy and flow chamber experiments to determine off-rates of L-selectin interacting with their physiological ligands and with an antibody. Catch bonds were observed at low forces for L-selectin-PSGL-1 interactions coinciding with the shear threshold range, whereas slip bonds were observed at higher forces. These catch-slip transitional bonds were also observed for L-selectin interacting with endoglycan, a newly identified PSGL-1-like ligand. By contrast, only slip bonds were observed for L-selectin- antibody interactions. These findings suggest that catch bonds contribute to the shear threshold for rolling and are a common characteristic of selectin-ligand interactions.	Oklahoma Med Res Fdn, Cardiovasc Biol Res Program, Oklahoma City, OK 73104 USA; Georgia Inst Technol, Coulter Dept Biomed Engn, Atlanta, GA 30332 USA; Georgia Inst Technol, George W Woodruff Sch Mech Engn, Atlanta, GA 30332 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Oklahoma Ctr Med Glycobiol, Oklahoma City, OK 73104 USA; Univ Virginia, Sch Med, Dept Biomed Engn, Charlottesville, VA 22908 USA; Univ Virginia, Sch Engn & Appl Sci, Charlottesville, VA 22908 USA; Univ Calif San Francisco, Dept Anat, Program Immunol, San Francisco, CA 94143 USA	Oklahoma Medical Research Foundation; University System of Georgia; Georgia Institute of Technology; University System of Georgia; Georgia Institute of Technology; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Virginia; University of Virginia; University of California System; University of California San Francisco	Zhu, C (corresponding author), Oklahoma Med Res Fdn, Cardiovasc Biol Res Program, 825 NE 13th St, Oklahoma City, OK 73104 USA.	cheng.zhu@me.gatech.edu	Zhu, Cheng/A-5724-2011	Rosen, Steven/0000-0002-6245-701X	NHLBI NIH HHS [HL 054614, HL 65631] Funding Source: Medline; NIAID NIH HHS [AI 44902] Funding Source: Medline; NIGMS NIH HHS [R37 GM 23547, GM 57411] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054614, R01HL065631, R29HL054614] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI044902, R01AI044902] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057411, R37GM023547] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alon R, 1998, P NATL ACAD SCI USA, V95, P11631, DOI 10.1073/pnas.95.20.11631; Alon R, 1997, J CELL BIOL, V138, P1169, DOI 10.1083/jcb.138.5.1169; ALON R, 1995, NATURE, V374, P539, DOI 10.1038/374539a0; Barkalow FJ, 2000, BLOOD, V96, P3070; BELL GI, 1978, SCIENCE, V200, P618, DOI 10.1126/science.347575; Chang KC, 1999, BIOPHYS J, V76, P1280, DOI 10.1016/S0006-3495(99)77291-7; Chen SQ, 1999, J CELL BIOL, V144, P185, DOI 10.1083/jcb.144.1.185; Chen SQ, 2001, P NATL ACAD SCI USA, V98, P950, DOI 10.1073/pnas.98.3.950; DEMBO M, 1988, PROC R SOC SER B-BIO, V234, P55, DOI 10.1098/rspb.1988.0038; Dembo M., 1994, LECT MATH LIFE SCI, V24, P51; DUSTIN ML, 1989, J EXP MED, V169, P503, DOI 10.1084/jem.169.2.503; Dwir O, 2002, J BIOL CHEM, V277, P21130, DOI 10.1074/jbc.M201999200; Dwir O, 2001, J CELL BIOL, V155, P145, DOI 10.1083/jcb.200103042; Epperson TR, 2000, J BIOL CHEM, V275, P7839, DOI 10.1074/jbc.275.11.7839; Evans E, 2001, P NATL ACAD SCI USA, V98, P3784, DOI 10.1073/pnas.061324998; Fieger CB, 2003, J BIOL CHEM, V278, P27390, DOI 10.1074/jbc.M304204200; Finger EB, 1996, NATURE, V379, P266, DOI 10.1038/379266a0; KISHIMOTO TK, 1990, P NATL ACAD SCI USA, V87, P2244, DOI 10.1073/pnas.87.6.2244; Lawrence MB, 1997, J CELL BIOL, V136, P717, DOI 10.1083/jcb.136.3.717; Leppanen A, 2003, J BIOL CHEM, V278, P26391, DOI 10.1074/jbc.M303551200; Leppanen A, 1999, J BIOL CHEM, V274, P24838, DOI 10.1074/jbc.274.35.24838; Leppanen A, 2000, J BIOL CHEM, V275, P39569, DOI 10.1074/jbc.M005005200; Li FG, 1996, J BIOL CHEM, V271, P6342, DOI 10.1074/jbc.271.11.6342; Marshall BT, 2003, NATURE, V423, P190, DOI 10.1038/nature01605; MCCONNELL HM, 1986, BIOCHIM BIOPHYS ACTA, V864, P95, DOI 10.1016/0304-4157(86)90016-X; McEver RP, 2001, THROMB HAEMOSTASIS, V86, P746; McEver RP, 2002, CURR OPIN CELL BIOL, V14, P581, DOI 10.1016/S0955-0674(02)00367-8; MOORE KL, 1992, J CELL BIOL, V118, P445, DOI 10.1083/jcb.118.2.445; MOORE KL, 1995, J CELL BIOL, V128, P661, DOI 10.1083/jcb.128.4.661; Pierres A, 1996, P NATL ACAD SCI USA, V93, P15114, DOI 10.1073/pnas.93.26.15114; Ramachandran V, 1999, P NATL ACAD SCI USA, V96, P13771, DOI 10.1073/pnas.96.24.13771; Ramachandran V, 2001, P NATL ACAD SCI USA, V98, P10166, DOI 10.1073/pnas.171248098; Sassetti C, 2000, J BIOL CHEM, V275, P9001, DOI 10.1074/jbc.275.12.9001; SIMMONS DL, 1993, CELLULAR INTERACTION, P93; Smith MJ, 1999, BIOPHYS J, V77, P3371, DOI 10.1016/S0006-3495(99)77169-9; Snapp KR, 1998, BLOOD, V91, P154, DOI 10.1182/blood.V91.1.154.154_154_164; Somers WS, 2000, CELL, V103, P467, DOI 10.1016/S0092-8674(00)00138-0; USHIYAMA S, 1993, J BIOL CHEM, V268, P15229; Vestweber D, 1999, PHYSIOL REV, V79, P181, DOI 10.1152/physrev.1999.79.1.181; Wong JY, 1999, BIOPHYS J, V77, P1445, DOI 10.1016/S0006-3495(99)76992-4; Yago T, 2002, J CELL BIOL, V158, P787, DOI 10.1083/jcb.200204041; Zhao YH, 2001, BIOPHYS J, V80, P1124, DOI 10.1016/S0006-3495(01)76090-0	43	206	213	2	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 16	2004	279	3					2291	2298		10.1074/jbc.M310396200	http://dx.doi.org/10.1074/jbc.M310396200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	762WT	14573602	hybrid			2022-12-27	WOS:000188005700086
J	Burcelin, R; Uldry, M; Foretz, M; Perrin, C; Dacosta, A; Nenniger-Tosato, M; Seydoux, J; Cotecchia, S; Thorens, B				Burcelin, R; Uldry, M; Foretz, M; Perrin, C; Dacosta, A; Nenniger-Tosato, M; Seydoux, J; Cotecchia, S; Thorens, B			Impaired glucose homeostasis in mice lacking the alpha(1b)-adrenergic receptor subtype	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROPEPTIDE-Y; NORMAL RATS; VENTROMEDIAL HYPOTHALAMUS; GENE-EXPRESSION; ADIPOSE-TISSUE; GLYCOGEN-METABOLISM; INSULIN-RECEPTOR; LEPTIN ACTION; B-CELLS; LIVER	To assess the role of the alpha(1b)-adrenergic receptor (AR) in glucose homeostasis, we investigated glucose metabolism in knockout mice deficient of this receptor subtype (alpha(1b)-AR(-/-)). Mutant mice had normal blood glucose and insulin levels, but elevated leptin concentrations in the fed state. During the transition to fasting, glucose and insulin blood concentrations remained markedly elevated for at least 6 h and returned to control levels after 24 h whereas leptin levels remained high at all times. Hyperinsulinemia in the post-absorptive phase was normalized by atropine or methylatropine indicating an elevated parasympathetic activity on the pancreatic beta cells, which was associated with increased levels of hypothalamic NPY mRNA. Euglycemic clamps at both low and high insulin infusion rates revealed whole body insulin resistance with reduced muscle glycogen synthesis and impaired suppression of endogenous glucose production at the low insulin infusion rate. The liver glycogen stores were 2-fold higher in the fed state in the alpha(1b)-AR(-/-) compared with control mice, but were mobilized at the same rate during the fed to fast transition or following glucagon injections. Finally, high fat feeding for one month increased glucose intolerance and body weight in the alpha(1b)-AR(-/-), but not in control mice. Altogether, our results indicate that in the absence of the alpha(1b)-AR the expression of hypotalamic NPY and the parasympathetic nervous activity are both increased resulting in hyperinsulinemia and insulin resistance as well as favoring obesity and glucose intolerance development during high fat feeding.	Univ Lausanne, Inst Pharmacol & Toxicol, CH-1005 Lausanne, Switzerland; Univ Lausanne, Inst Physiol, CH-1005 Lausanne, Switzerland; Hop Rangueil, UPS, CNRS, UMR 5018, F-31403 Toulouse, France; Ctr Med Univ Geneva, Dept Physiol, CH-1211 Geneva, Switzerland	University of Lausanne; University of Lausanne; Centre National de la Recherche Scientifique (CNRS); CHU de Toulouse; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; University of Geneva	Thorens, B (corresponding author), Univ Lausanne, Inst Pharmacol & Toxicol, 27 Rue Bugnon, CH-1005 Lausanne, Switzerland.	Bernard.Thorens@ipharm.unil.ch	burcelin, remy/M-6013-2014; FORETZ, Marc/O-7334-2017	FORETZ, Marc/0000-0001-7017-9032				Acosta-Martinez M, 1999, NEUROCHEM INT, V35, P383, DOI 10.1016/S0197-0186(99)00077-7; Angel I, 1996, ENDOCRINOLOGY, V137, P2022, DOI 10.1210/en.137.5.2022; BILLINGTON CJ, 1991, AM J PHYSIOL, V260, pR321, DOI 10.1152/ajpregu.1991.260.2.R321; Bollen M, 1998, BIOCHEM J, V336, P19, DOI 10.1042/bj3360019; BRODDE O, 1999, PHARMACOL REV, V51, P561; Burcelin M, 2002, AM J PHYSIOL-ENDOC M, V282, pE834, DOI 10.1152/ajpendo.00332.2001; Burcelin R, 1999, METABOLISM, V48, P252, DOI 10.1016/S0026-0495(99)90043-4; Burcelin R, 2000, J BIOL CHEM, V275, P10930, DOI 10.1074/jbc.275.15.10930; Cavalli A, 1997, P NATL ACAD SCI USA, V94, P11589, DOI 10.1073/pnas.94.21.11589; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Dallaporta M, 1999, NEUROREPORT, V10, P2657, DOI 10.1097/00001756-199908200-00040; DUNNING BE, 1991, ADV EXP MED BIOL, V291, P107; Duplain H, 2001, CIRCULATION, V104, P342, DOI 10.1161/01.CIR.104.3.342; DUVAL N, 1991, ADV BIOSCI, V82, P25; EXTON JH, 1981, ADV CYCL NUCL RES<D>, V14, P491; FAIN J, 1981, J LIPID RES, V24, P945; Fraley GS, 2003, ENDOCRINOLOGY, V144, P75, DOI 10.1210/en.2002-220659; GARVEY WT, 1985, J CLIN INVEST, V76, P22, DOI 10.1172/JCI111950; Graham RM, 1996, CIRC RES, V78, P737, DOI 10.1161/01.RES.78.5.737; Hardie LJ, 1996, HORM METAB RES, V28, P685, DOI 10.1055/s-2007-979878; HENQUIN JC, 1988, ENDOCRINOLOGY, V122, P2134, DOI 10.1210/endo-122-5-2134; HIMMI T, 1988, PHYSIOL BEHAV, V44, P347, DOI 10.1016/0031-9384(88)90036-4; KAHN CR, 1988, J CLIN INVEST, V82, P1151, DOI 10.1172/JCI113711; Kalra SP, 1999, ENDOCR REV, V20, P68, DOI 10.1210/er.20.1.68; Kamohara S, 1997, NATURE, V389, P374, DOI 10.1038/38717; Minokoshi Y, 1999, DIABETES, V48, P287, DOI 10.2337/diabetes.48.2.287; MINOKOSHI Y, 1994, BRAIN RES, V649, P343, DOI 10.1016/0006-8993(94)91085-5; Moore MC, 1996, NUTRITION, V12, P282, DOI 10.1016/S0899-9007(97)85073-4; Moore MC, 1996, REPROD NUTR DEV, V36, P399, DOI 10.1051/rnd:19960406; Moore MC, 1996, AM J PHYSIOL-ENDOC M, V271, pE215, DOI 10.1152/ajpendo.1996.271.2.E215; PIERRET P, 1994, J PHYSIOLOGY-PARIS, V88, P89, DOI 10.1016/0928-4257(94)90095-7; Rapacciuolo A, 2001, J AM COLL CARDIOL, V38, P876, DOI 10.1016/S0735-1097(01)01433-4; Sainsbury A, 1996, DIABETOLOGIA, V39, P353; Sainsbury A, 1997, DIABETOLOGIA, V40, P1269, DOI 10.1007/s001250050820; SANTOS RM, 1989, FEBS LETT, V249, P411, DOI 10.1016/0014-5793(89)80669-6; SCHUIT FC, 1986, SCIENCE, V232, P875, DOI 10.1126/science.2871625; Schwartz MW, 1996, J CLIN INVEST, V98, P1101, DOI 10.1172/JCI118891; Schwartz MW, 2000, NATURE, V404, P661, DOI 10.1038/35007534; Schwartz MW, 1996, DIABETES, V45, P531, DOI 10.2337/diabetes.45.4.531; SIMPSON PC, 1990, J VASCULAR MED BIOL, V2, P236; Small CJ, 2003, INT J OBESITY, V27, P530, DOI 10.1038/sj.ijo.0802253; Stumpel F, 1997, FEBS LETT, V406, P119, DOI 10.1016/S0014-5793(97)00254-8; Takahashi A, 1997, METABOLISM, V46, P897, DOI 10.1016/S0026-0495(97)90076-7; Viollet B, 2003, J CLIN INVEST, V111, P91, DOI 10.1172/JCI200316567; Yamada M, 2001, NATURE, V410, P207, DOI 10.1038/35065604; YAMAGUCHI N, 1992, CAN J PHYSIOL PHARM, V70, P167, DOI 10.1139/y92-024; ZARJEVSKI N, 1994, DIABETES, V43, P764, DOI 10.2337/diabetes.43.6.764; ZARJEVSKI N, 1993, ENDOCRINOLOGY, V133, P1753, DOI 10.1210/en.133.4.1753	48	42	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 9	2004	279	2					1108	1115		10.1074/jbc.M307788200	http://dx.doi.org/10.1074/jbc.M307788200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	759DJ	14581480	hybrid			2022-12-27	WOS:000187722800034
J	Chen, ZL; Dillon, GH; Huang, RQ				Chen, ZL; Dillon, GH; Huang, RQ			Molecular determinants of proton modulation of glycine receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GABA-ACTIVATED CURRENT; EXTRACELLULAR PH; ZINC INHIBITION; BINDING-SITES; SUBUNIT; CHANNEL; SENSITIVITY; DOMAIN; ZN2+; IDENTIFICATION	Extracellular pH regulates glycine receptors through an unknown mechanism. Here we demonstrate that acidic pH remarkably inhibited glycine-activated whole-cell currents in recombinant glycine alpha1 and alpha1beta receptors transiently expressed in human embryonic kidney 293 cells. The proton effect was voltage-independent and pharmacologically competed with glycine receptor agonist glycine and antagonist strychnine. Using site-directed mutagenesis, we have identified an N-terminal domain that is essential for proton-induced inhibition of glycine current. In alpha1 homomers, removal of the hydroxyl group by mutation of residue Thr-112 to Ala or Phe abolished inhibition of glycine currents by acidification. In contrast, mutation of Thr-112 to another hydroxylated residue (Tyr) produced receptors that retained partial proton sensitivity. In alpha1beta heteromers, a single mutation of the beta subunit T135A, which is homologous to alpha1 Thr-112, reduced proton sensitivity, whereas the double mutation alpha1(T112A)beta(T135A) almost completely eliminated the proton sensitivity. In addition, the mutation alpha1 H109A greatly reduced sensitivity to protons in homomeric alpha1 receptors. The results demonstrate that extracellular pH can regulate the function of glycine alpha1 and alpha1beta receptors. An extracellular domain consisting of Thr-112 and His-109 at the alpha1 subunit and Thr-135 at the beta subunit plays a critical role in determining proton modulation of glycine receptor function.	Univ N Texas, Hlth Sci Ctr, Dept Pharmacol & Neurosci, Ft Worth, TX 76107 USA	University of North Texas System; University of North Texas Health Science Center	Huang, RQ (corresponding author), Univ N Texas, Hlth Sci Ctr, Dept Pharmacol & Neurosci, Ft Worth, TX 76107 USA.	rhuang@hsc.unt.edu			NIEHS NIH HHS [ES07904] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES007904, R29ES007904] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Baron A, 2001, J BIOL CHEM, V276, P35361, DOI 10.1074/jbc.M105208200; CHESLER M, 1992, TRENDS NEUROSCI, V15, P396, DOI 10.1016/0166-2236(92)90191-A; Clarke CE, 2000, J PHYSIOL-LONDON, V523, P697, DOI 10.1111/j.1469-7793.2000.00697.x; Clements JD, 1996, TRENDS NEUROSCI, V19, P163, DOI 10.1016/S0166-2236(96)10024-2; DAUMAS P, 1993, J GEN PHYSIOL, V101, P27, DOI 10.1085/jgp.101.1.27; FABER DS, 1988, P NATL ACAD SCI USA, V85, P8708, DOI 10.1073/pnas.85.22.8708; Flint AC, 1998, NEURON, V20, P43, DOI 10.1016/S0896-6273(00)80433-X; Han NLR, 2001, J NEUROCHEM, V79, P636, DOI 10.1046/j.1471-4159.2001.00601.x; Harvey RJ, 1999, J PHYSIOL-LONDON, V520, P53, DOI 10.1111/j.1469-7793.1999.00053.x; Huang RQ, 1999, J NEUROPHYSIOL, V82, P1233, DOI 10.1152/jn.1999.82.3.1233; Krishek BJ, 1996, J PHYSIOL-LONDON, V492, P431, DOI 10.1113/jphysiol.1996.sp021319; LANGOSCH D, 1988, P NATL ACAD SCI USA, V85, P7394, DOI 10.1073/pnas.85.19.7394; Laube B, 2000, J PHYSIOL-LONDON, V522, P215, DOI 10.1111/j.1469-7793.2000.t01-1-00215.x; Laube B, 2002, TRENDS PHARMACOL SCI, V23, P519, DOI 10.1016/S0165-6147(02)02138-7; Legendre P, 2001, CELL MOL LIFE SCI, V58, P760, DOI 10.1007/PL00000899; LI L, 1992, CELL MOL NEUROBIOL, V12, P83, DOI 10.1007/BF00713363; Low CM, 2003, MOL PHARMACOL, V63, P1212, DOI 10.1124/mol.63.6.1212; Low CM, 2000, P NATL ACAD SCI USA, V97, P11062, DOI 10.1073/pnas.180307497; Nevin ST, 2003, J BIOL CHEM, V278, P28985, DOI 10.1074/jbc.M300097200; ONEIL MJ, 2001, MERCK INDEX, V13, P8941; Piao HL, 2001, J BIOL CHEM, V276, P36673, DOI 10.1074/jbc.M106123200; PRIBILLA I, 1992, EMBO J, V11, P4305, DOI 10.1002/j.1460-2075.1992.tb05529.x; Qu ZQ, 1999, J BIOL CHEM, V274, P13783, DOI 10.1074/jbc.274.20.13783; RAJENDRA S, 1995, EMBO J, V14, P2987, DOI 10.1002/j.1460-2075.1995.tb07301.x; Rampon C, 1996, NEUROSCIENCE, V75, P737, DOI 10.1016/0306-4522(96)00278-3; SCHMIEDEN V, 1993, SCIENCE, V262, P256, DOI 10.1126/science.8211147; Schmieden V, 1999, MOL PHARMACOL, V56, P464, DOI 10.1124/mol.56.3.464; Siesjo BK, 1996, ADV NEUROL, V71, P209; Singer JH, 1998, J NEUROPHYSIOL, V80, P2608, DOI 10.1152/jn.1998.80.5.2608; TANG CM, 1990, P NATL ACAD SCI USA, V87, P6445, DOI 10.1073/pnas.87.16.6445; Tombaugh GC, 1996, J PHYSIOL-LONDON, V493, P719, DOI 10.1113/jphysiol.1996.sp021417; TRAYNELIS SF, 1990, NATURE, V345, P347, DOI 10.1038/345347a0; Vafa B, 1999, J NEUROCHEM, V73, P2158; VANDENBERG RJ, 1992, P NATL ACAD SCI USA, V89, P1765, DOI 10.1073/pnas.89.5.1765; VANDENBERG RJ, 1992, NEURON, V9, P491, DOI 10.1016/0896-6273(92)90186-H; VONHANWEHR R, 1986, J NEUROCHEM, V46, P331; Wegelius K, 1996, NEUROREPORT, V7, P2005, DOI 10.1097/00001756-199608120-00030; YOUNG AB, 1981, MOL PHARM, V10, P790; Zhai J, 1998, PFLUG ARCH EUR J PHY, V435, P539, DOI 10.1007/s004240050550; Zong XG, 2001, J BIOL CHEM, V276, P6313, DOI 10.1074/jbc.M010326200	40	32	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 9	2004	279	2					876	883		10.1074/jbc.M307684200	http://dx.doi.org/10.1074/jbc.M307684200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	759DJ	14563849	hybrid			2022-12-27	WOS:000187722800009
J	Brooks, DR; Appleford, PJ; Murray, L; Isaac, RE				Brooks, DR; Appleford, PJ; Murray, L; Isaac, RE			An essential role in molting and morphogenesis of Caenorhabditis elegans for ACN-1, a novel member of the angiotensin-converting enzyme family that lacks a metallopeptidase active site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DROSOPHILA-MELANOGASTER; C-ELEGANS; EXPRESSION ANALYSIS; GENE-EXPRESSION; BLOOD-PRESSURE; CELL FUSIONS; RECEPTOR; HOMOLOG; PREDICTION; DHR3	Genome sequence analyses predict many proteins that are structurally related to proteases but lack catalytic residues, thus making functional assignment difficult. We show that one of these proteins (ACN-1), a unique multi-domain angiotensin-converting enzyme (ACE)-like protein from Caenorhabditis elegans, is essential for larval development and adult morphogenesis. Green fluorescent protein-tagged ACN-1 is expressed in hypodermal cells, the developing vulva, and the ray papillae of the male tail. The hypodermal expression of acn-1 appears to be controlled by nhr-23 and nhr-25, two nuclear hormone receptors known to regulate molting in C. elegans. acn-1(RNAi) causes arrest of larval development because of a molting defect, a protruding vulva in adult hermaphrodites, severely disrupted alae, and an incomplete seam syncytium. Adult males also have multiple tail defects. The failure of the larval seam cells to undergo normal cell fusion is the likely reason for the severe disruption of the adult alae. We propose that alteration of the ancestral ACE during evolution, by loss of the metallopeptidase active site and the addition of new protein modules, has provided opportunities for novel molecular interactions important for post-embryonic development in nematodes.	Univ Leeds, Fac Biol Sci, Leeds LS2 9JT, W Yorkshire, England	University of Leeds	Isaac, RE (corresponding author), Univ Leeds, Fac Biol Sci, Miall Bldg, Leeds LS2 9JT, W Yorkshire, England.	r.e.isaac@leeds.ac.uk						Aguinaldo AMA, 1997, NATURE, V387, P489, DOI 10.1038/387489a0; Asahina M, 2000, GENES CELLS, V5, P711, DOI 10.1046/j.1365-2443.2000.00361.x; Coates D, 2000, BIOCHEMISTRY-US, V39, P8963, DOI 10.1021/bi000593q; CORVOL P, 1995, METHOD ENZYMOL, V248, P283; Crackower MA, 2002, NATURE, V417, P822, DOI 10.1038/nature00786; Donoghue M, 2000, CIRC RES, V87, pE1, DOI 10.1161/01.res.87.5.e1; Eisenhaber B, 1999, J MOL BIOL, V292, P741, DOI 10.1006/jmbi.1999.3069; EMMONS SW, 1997, C ELEGANS, V2, P295; Esther CR, 1996, LAB INVEST, V74, P953; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; FITCH DHA, 1995, DEV BIOL, V170, P564, DOI 10.1006/dbio.1995.1237; Fraser AG, 2000, NATURE, V408, P325, DOI 10.1038/35042517; Gissendanner CR, 2000, DEV BIOL, V221, P259, DOI 10.1006/dbio.2000.9679; Hansen JE, 1998, GLYCOCONJUGATE J, V15, P115, DOI 10.1023/A:1006960004440; Hobert O, 2002, BIOTECHNIQUES, V32, P728, DOI 10.2144/02324bm01; Houard X, 1998, EUR J BIOCHEM, V257, P599, DOI 10.1046/j.1432-1327.1998.2570599.x; Huang X, 2003, DEVELOPMENT, V130, P3147, DOI 10.1242/dev.00518; Hurst D, 2003, DEV BIOL, V254, P238, DOI 10.1016/S0012-1606(02)00082-9; Isaac RE, 2000, BIOCHEM SOC T, V28, P460, DOI 10.1042/0300-5127:0280460; KOELLE MR, 1992, P NATL ACAD SCI USA, V89, P6167, DOI 10.1073/pnas.89.13.6167; Kostrouchova M, 1998, DEVELOPMENT, V125, P1617; Kostrouchova M, 2001, P NATL ACAD SCI USA, V98, P7360, DOI 10.1073/pnas.131171898; KREGE JH, 1995, NATURE, V375, P146, DOI 10.1038/375146a0; Lam G, 1999, DEV BIOL, V212, P204, DOI 10.1006/dbio.1999.9343; Lam GT, 1997, DEVELOPMENT, V124, P1757; Lee Donald L., 2002, P171; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Mohler WA, 1998, CURR BIOL, V8, P1087, DOI 10.1016/S0960-9822(98)70447-6; Natesh R, 2003, NATURE, V421, P551, DOI 10.1038/nature01370; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; PODBILEWICZ B, 1994, DEV BIOL, V161, P408, DOI 10.1006/dbio.1994.1041; Puente XS, 2003, NAT REV GENET, V4, P544, DOI 10.1038/nrg1111; Rawlings ND, 2002, NUCLEIC ACIDS RES, V30, P343, DOI 10.1093/nar/30.1.343; RIDDLE LD, 1997, C ELEGANS, V2, P739; Simmer F, 2002, CURR BIOL, V12, P1317, DOI 10.1016/S0960-9822(02)01041-2; SINGH RN, 1978, NEMATOLOGICA, V24, P63, DOI 10.1163/187529278X00074; Siviter RJ, 2002, PEPTIDES, V23, P2025, DOI 10.1016/S0196-9781(02)00190-0; Sluder AE, 1999, GENOME RES, V9, P103; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; Tabara H, 1996, NUCLEIC ACIDS RES, V24, P2119, DOI 10.1093/nar/24.11.2119; Tipnis SR, 2000, J BIOL CHEM, V275, P33238, DOI 10.1074/jbc.M002615200; Turner AJ, 2002, TRENDS PHARMACOL SCI, V23, P177, DOI 10.1016/S0165-6147(00)01994-5; Vargas JD, 2002, MECH DEVELOP, V117, P289, DOI 10.1016/S0925-4773(02)00182-X; Wang J, 2003, DEVELOPMENT, V130, P1621, DOI 10.1242/dev.00363; White J., 1988, NEMATODE CAENORHABDI, V17, P81; Williams TA, 1996, BIOCHEM J, V318, P125, DOI 10.1042/bj3180125	46	53	59	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52340	52346		10.1074/jbc.M308858200	http://dx.doi.org/10.1074/jbc.M308858200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14559923	hybrid			2022-12-27	WOS:000187480700044
J	Musson, JA; Walker, N; Flick-Smith, H; Williamson, ED; Robinson, JH				Musson, JA; Walker, N; Flick-Smith, H; Williamson, ED; Robinson, JH			Differential processing of CD4 T-cell epitopes from the protective antigen of Bacillus anthracis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIABLE STREPTOCOCCUS-PYOGENES; CLASS-II MOLECULES; DENDRITIC CELLS; SALMONELLA-TYPHIMURIUM; ENDOCYTIC COMPARTMENT; LYSOSOMAL PROTEINASES; DEPENDENT PROCESS; EDEMA FACTORS; LETHAL TOXIN; M5 PROTEIN	We have mapped CD4+ T-cell epitopes located in three domains of the recombinant protective antigen of Bacillus anthracis. Mouse T-cell hybridomas specific for these epitopes were generated to study the mechanisms of proteolytic processing of recombinant protective antigen for antigen presentation by bone marrow-derived macrophages. Overall, epitopes differed considerably in their processing requirements. In particular, the kinetics of presentation, ranging from 15 (fast) to 120 min (slow), suggested sequential liberation of epitopes during proteolytic processing of the intact PA molecule. Pretreatment of macrophages with ammonium chloride or inhibitors of the major enzyme families showed that T-cell responses to an epitope presented with fast kinetics were unaffected by raising endosomal pH or inhibiting cysteine or aspartic proteinases, suggesting presentation independent of lysosomal processing. In contrast, responses to epitopes presented with slower kinetics were dependent on low pH and the activity of cysteine or aspartic proteinases indicating a requirement for lysosomal processing. In addition, responses to all epitopes, whether their presentation was dependent on low pH or not, were prevented by treatment of macrophages with broad spectrum serine proteinase inhibitors. Thus, our data are consistent with a model of sequential antigen processing within the endosomal system, beginning with a pre-processing step mediated by serine or metalloproteinases prior to further processing by lysosomal enzymes. Rapidly presented epitopes seemed to require only limited proteolysis at earlier stages of endocytosis, whereas the majority of epitopes required more extensive processing by neutral proteinases followed by lysosomal enzymes.	Univ Newcastle Upon Tyne, Fac Med Sci, Musculoskeletal Res Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Def Sci & Technol Lab, Salisbury SP4 0JQ, Wilts, England	Newcastle University - UK; Defence Science & Technology Laboratory	Robinson, JH (corresponding author), Univ Newcastle Upon Tyne, Fac Med Sci, Musculoskeletal Res Grp, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.		Williamson, Ethel Diane/AAQ-8878-2020					Abrami L, 2003, J CELL BIOL, V160, P321, DOI 10.1083/jcb.200211018; Accapezzato D, 1998, J IMMUNOL, V160, P5262; Agrawal A, 2003, NATURE, V424, P329, DOI 10.1038/nature01794; Amoscato AA, 1998, J IMMUNOL, V161, P4023; Antoniou AN, 2000, IMMUNITY, V12, P391, DOI 10.1016/S1074-7613(00)80191-0; APLIN RT, 1992, J CHEM SOC CHEM COMM, P1650, DOI 10.1039/c39920001650; Baillie L, 2001, J APPL MICROBIOL, V91, P609, DOI 10.1046/j.1365-2672.2001.01498.x; Barnard JP, 1999, INFECT IMMUN, V67, P562, DOI 10.1128/IAI.67.2.562-567.1999; Beauregard KE, 2000, CELL MICROBIOL, V2, P251, DOI 10.1046/j.1462-5822.2000.00052.x; BOND JS, 1987, ANNU REV BIOCHEM, V56, P333, DOI 10.1146/annurev.bi.56.070187.002001; Bradley KA, 2001, NATURE, V414, P225, DOI 10.1038/n35101999; Carrasco-Marin E, 1998, IMMUNOLOGY, V95, P314; Conte MP, 1996, J MED MICROBIOL, V44, P418, DOI 10.1099/00222615-44-6-418; COULSON NM, 1994, VACCINE, V12, P1395, DOI 10.1016/0264-410X(94)90148-1; Cunningham K, 2002, P NATL ACAD SCI USA, V99, P7049, DOI 10.1073/pnas.062160399; Delvig AA, 1998, J IMMUNOL, V160, P5267; Delvig AA, 1998, J BIOL CHEM, V273, P3291, DOI 10.1074/jbc.273.6.3291; EISENLOHR LC, 1988, J IMMUNOL, V141, P1870; FernandezBorja M, 1996, INT IMMUNOL, V8, P625, DOI 10.1093/intimm/8.5.625; FISCHER HG, 1988, EUR J IMMUNOL, V18, P1151, DOI 10.1002/eji.1830180802; Flick-Smith HC, 2002, INFECT IMMUN, V70, P1653, DOI 10.1128/IAI.70.3.1653-1656.2002; FRIEDLANDER AM, 1986, J BIOL CHEM, V261, P7123; Griffin JP, 1997, J IMMUNOL, V158, P1523; HARPER JW, 1985, BIOCHEMISTRY-US, V24, P1831, DOI 10.1021/bi00329a005; Ishidoh K, 2002, BIOL CHEM, V383, P1827, DOI 10.1515/BC.2002.206; Jensen P E, 1995, Semin Immunol, V7, P347, DOI 10.1006/smim.1995.0039; JENSEN PE, 1993, J IMMUNOL, V150, P3347; Lacy DB, 2002, J BIOL CHEM, V277, P3006, DOI 10.1074/jbc.M109997200; Lennon-Dumenil AM, 2002, CURR OPIN IMMUNOL, V14, P15, DOI 10.1016/S0952-7915(01)00293-X; Leppla S. H., 1995, Bacterial toxins and virulence factors in disease., P543; Maric M, 2001, SCIENCE, V294, P1361, DOI 10.1126/science.1065500; McBride B, 1998, VACCINE, V16, P810, DOI 10.1016/S0264-410X(97)00268-5; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; Mogridge J, 2002, P NATL ACAD SCI USA, V99, P7045, DOI 10.1073/pnas.052160199; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; Musson JA, 2002, EUR J IMMUNOL, V32, P2664, DOI 10.1002/1521-4141(200209)32:9<2664::AID-IMMU2664>3.0.CO;2-N; Nakagawa TY, 1999, IMMUNOL REV, V172, P121, DOI 10.1111/j.1600-065X.1999.tb01361.x; Petosa C, 1997, NATURE, V385, P833, DOI 10.1038/385833a0; PETOSA C, 1996, PROTEIN TOXIN STRUCT, P97; Pieters J, 2000, ADV IMMUNOL, V75, P159, DOI 10.1016/S0065-2776(00)75004-8; PURI J, 1988, J IMMUNOL, V141, P3313; Quin SJ, 2001, EUR J IMMUNOL, V31, P72, DOI 10.1002/1521-4141(200101)31:1&lt;72::AID-IMMU72&gt;3.0.CO;2-Z; Riese RJ, 2000, CURR OPIN IMMUNOL, V12, P107, DOI 10.1016/S0952-7915(99)00058-8; Robinson JH, 2002, IMMUNOLOGY, V105, P252, DOI 10.1046/j.0019-2805.2001.01358.x; Santambrogio L, 1999, P NATL ACAD SCI USA, V96, P15056, DOI 10.1073/pnas.96.26.15056; Sellman BR, 2001, J BIOL CHEM, V276, P8371, DOI 10.1074/jbc.M008309200; Sellman BR, 2001, SCIENCE, V292, P695, DOI 10.1126/science.109563; SERVCARZ EE, 2003, NAT REV IMMUNOL, V3, P621; SHIMONKEVITZ R, 1984, J IMMUNOL, V133, P2067; Singh Y, 1998, INFECT IMMUN, V66, P3447, DOI 10.1128/IAI.66.7.3447-3448.1998; Sinnathamby G, 2003, J IMMUNOL, V170, P3504, DOI 10.4049/jimmunol.170.7.3504; TAKAHASHI H, 1989, J IMMUNOL, V142, P2221; TAMAI M, 1986, J PHARMACOBIO-DYNAM, V9, P672, DOI 10.1248/bpb1978.9.672; TAN FL, 1993, J BIOL CHEM, V268, P16631; Unanue ER, 2002, IMMUNOL REV, V185, P86, DOI 10.1034/j.1600-065X.2002.18510.x; van der Merwe PA, 2003, ANNU REV IMMUNOL, V21, P659, DOI 10.1146/annurev.immunol.21.120601.141036; Villadangos JA, 2000, IMMUNITY, V12, P233, DOI 10.1016/S1074-7613(00)80176-4; Villadangos JA, 1997, J EXP MED, V186, P549, DOI 10.1084/jem.186.4.549; von Delwig A, 2003, EUR J IMMUNOL, V33, P2353, DOI 10.1002/eji.200323559; Watts C, 2001, CURR OPIN IMMUNOL, V13, P26, DOI 10.1016/S0952-7915(00)00177-1	60	27	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52425	52431		10.1074/jbc.M309034200	http://dx.doi.org/10.1074/jbc.M309034200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14561737	hybrid			2022-12-27	WOS:000187480700055
J	Pearce, LL; Bominaar, EL; Hill, BC; Peterson, J				Pearce, LL; Bominaar, EL; Hill, BC; Peterson, J			Reversal of cyanide inhibition of cytochrome c oxidase by the auxiliary substrate nitric oxide - An endogenous antidote to cyanide poisoning?	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-PARAMAGNETIC-RES; MITOCHONDRIAL RESPIRATION; PHOTO-DISSOCIATION; CIRCULAR-DICHROISM; BINUCLEAR CENTER; ACTIVE-SITE; MECHANISM; A3; SYNTHASE; OXYGEN	Nitric oxide ( NO) is shown to overcome the cyanide inhibition of cytochrome c oxidase in the presence of excess ferrocytochrome c and oxygen. Addition of NO to the partially reduced cyanide-inhibited form of the bovine enzyme is shown by electron paramagnetic resonance spectroscopy to result in substitution of cyanide at ferriheme a(3) by NO with reduction of the heme. The resulting nitrosylferroheme a(3) is a 5-coordinate structure, the proximal bond to histidine having been broken. NO does not simply act as a reversibly bound competitive inhibitor but is an auxiliary substrate consumed in a catalytic cycle along with ferrocytochrome c and oxygen. The implications of this observation with regard to estimates of steady-state NO levels in vivo is discussed. Given the multiple sources of NO available to mitochondria, the present results appear to explain in part some of the curious biomedical observations reported by other laboratories; for example, the kidneys of cyanide poisoning victims surprisingly exhibit no significant irreversible damage, and lethal doses of potassium cyanide are able to inhibit cytochrome c oxidase activity by only similar to50% in brain mitochondria.	Univ Pittsburgh, Pittsburgh, PA 15260 USA; Carnegie Mellon Univ, Pittsburgh, PA 15213 USA; Queens Univ, Kingston, ON K7L 3N6, Canada	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Carnegie Mellon University; Queens University - Canada	Peterson, J (corresponding author), Mellon Inst, Box 170,4400 5th Ave, Pittsburgh, PA 15213 USA.	jamesp@andrew.cmu.edu		Pearce, Linda/0000-0002-0940-965X; Peterson, James/0000-0002-7300-5887				Andersson ME, 1999, FEBS LETT, V449, P17, DOI 10.1016/S0014-5793(99)00376-2; Babcock GT, 1999, P NATL ACAD SCI USA, V96, P12971, DOI 10.1073/pnas.96.23.12971; BAKER GM, 1987, J BIOL CHEM, V262, P595; Bartsch R. G., 1971, METHODS ENZYMOL, V23, P344, DOI [10.1016/S0076-6879(71)23110-4, DOI 10.1016/S0076-6879(71)23110-4]; BOELENS R, 1982, BIOCHIM BIOPHYS ACTA, V679, P84, DOI 10.1016/0005-2728(82)90258-4; BORAK J, 1995, J OCCUP ENVIRON MED, V37, P793, DOI 10.1097/00043764-199507000-00004; Boveris A, 1999, METHOD ENZYMOL, V301, P188; BOVERIS A, 2000, NITRIC OXIDE BIOL PA, P355; Brookes P, 2002, FREE RADICAL BIO MED, V32, P370, DOI 10.1016/S0891-5849(01)00805-X; Brown GC, 1999, BIOCHEM SOC SYMP, V66, P17, DOI 10.1042/bss0660017; Brown GC, 2001, BBA-BIOENERGETICS, V1504, P46, DOI 10.1016/S0005-2728(00)00238-3; BRUDVIG GW, 1980, BIOCHEMISTRY-US, V19, P5275, DOI 10.1021/bi00564a020; Brunori M, 1999, CELL MOL LIFE SCI, V56, P549, DOI 10.1007/s000180050452; Cooper CE, 1997, FEBS LETT, V414, P281, DOI 10.1016/S0014-5793(97)01009-0; Cooper CE, 2002, TRENDS BIOCHEM SCI, V27, P33, DOI 10.1016/S0968-0004(01)02035-7; EGLINTON DG, 1980, BIOCHEM J, V191, P319, DOI 10.1042/bj1910319; Ghafourifar P, 1997, FEBS LETT, V418, P291, DOI 10.1016/S0014-5793(97)01397-5; GIBSON QH, 1965, J BIOL CHEM, V240, P915; Giuffre A, 1998, J BIOL CHEM, V273, P32475, DOI 10.1074/jbc.273.49.32475; Giuffre A, 2002, J BIOL CHEM, V277, P22402, DOI 10.1074/jbc.M201514200; Giuffre A, 2000, BIOCHEMISTRY-US, V39, P15446, DOI 10.1021/bi000447k; HILL BC, 1983, BIOCHEM J, V215, P57, DOI 10.1042/bj2150057; JOHNSON MK, 1981, BIOCHEM J, V193, P699, DOI 10.1042/bj1930699; Kanai AJ, 2001, P NATL ACAD SCI USA, V98, P14126, DOI 10.1073/pnas.241380298; LABIANCA DA, 1979, J CHEM EDUC, V56, P788, DOI 10.1021/ed056p788; Pearce LL, 1999, J BIOL CHEM, V274, P35763, DOI 10.1074/jbc.274.50.35763; Pearce LL, 2002, J BIOL CHEM, V277, P13556, DOI 10.1074/jbc.M109838200; PETERSON J, 2001, IN PRESS AM J PHYSL; PETTERSEN JC, 1993, J APPL TOXICOL, V13, P9, DOI 10.1002/jat.2550130104; PITT BR, 1979, ARCH ENVIRON HEALTH, V34, P354, DOI 10.1080/00039896.1979.10667431; Proshlyakov DA, 2000, SCIENCE, V290, P1588, DOI 10.1126/science.290.5496.1588; Puig JM, 1996, TRANSPLANT INT, V9, P87, DOI 10.1111/j.1432-2277.1996.tb00859.x; Ragan MT, 1987, MITOCHONDRIA PRACTIC, P79; Ravishankar DK, 1998, CLIN TRANSPLANT, V12, P142; Sarti P, 2000, BIOCHEM BIOPH RES CO, V274, P183, DOI 10.1006/bbrc.2000.3117; Sarti P, 2003, FREE RADICAL BIO MED, V34, P509, DOI 10.1016/S0891-5849(02)01326-6; SCHEIDT WR, 1975, J AM CHEM SOC, V97, P17, DOI 10.1021/ja00834a005; Siedow JN, 2000, BBA-BIOENERGETICS, V1459, P432, DOI 10.1016/S0005-2728(00)00181-X; SINJORGO KMC, 1987, BIOCHIM BIOPHYS ACTA, V893, P251, DOI 10.1016/0005-2728(87)90046-6; Soulimane T, 2000, EMBO J, V19, P1766, DOI 10.1093/emboj/19.8.1766; SPAULDING LD, 1975, J AM CHEM SOC, V97, P2517, DOI 10.1021/ja00842a032; STEVENS TH, 1981, J BIOL CHEM, V256, P1069; STEVENS TH, 1979, P NATL ACAD SCI USA, V76, P3320, DOI 10.1073/pnas.76.7.3320; STEVENS TH, 1979, FEBS LETT, V97, P314, DOI 10.1016/0014-5793(79)80110-6; Szibor M, 2001, ANTIOXID REDOX SIGN, V3, P515, DOI 10.1089/15230860152409149; Tatoyan A, 1998, J BIOL CHEM, V273, P11044, DOI 10.1074/jbc.273.18.11044; THOMSON AJ, 1985, J INORG BIOCHEM, V23, P187, DOI 10.1016/0162-0134(85)85025-X; Torres J, 1998, J BIOENERG BIOMEMBR, V30, P63, DOI 10.1023/A:1020559528124; Torres J, 2000, FEBS LETT, V475, P263, DOI 10.1016/S0014-5793(00)01682-3; TORRES J, 1995, BIOCHEM J, V312, P169, DOI 10.1042/bj3120169; VANGELDER BF, 1966, BIOCHIM BIOPHYS ACTA, V118, P36, DOI 10.1016/S0926-6593(66)80142-X; Villani G, 2001, METHOD CELL BIOL, V65, P119, DOI 10.1016/S0091-679X(01)65007-6; WAYLAND BB, 1973, J CHEM SOC CHEM COMM, P897, DOI 10.1039/c39730000897; Wittenberg JB, 2003, J EXP BIOL, V206, P2011, DOI 10.1242/jeb.00243; YONETANI T, 1966, BIOCHEM PREP, V11, P14; YOSHIDA S, 1980, J BIOCHEM-TOKYO, V88, P1623, DOI 10.1093/oxfordjournals.jbchem.a133138; YOSHIMURA T, 1986, INORG CHIM A-BIOINOR, V125, pL27, DOI 10.1016/S0020-1693(00)84708-8; YOSHIMURA T, 1978, B CHEM SOC JPN, V51, P1237, DOI 10.1246/bcsj.51.1237	58	70	72	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52139	52145		10.1074/jbc.M310359200	http://dx.doi.org/10.1074/jbc.M310359200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14534303	hybrid			2022-12-27	WOS:000187480700021
J	Luciano, RL; Wilson, AC				Luciano, RL; Wilson, AC			HCF-1 functions as a coactivator for the zinc finger protein Krox20	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HERPES-SIMPLEX-VIRUS; HOST-CELL FACTOR; VP16 ACCESSORY PROTEIN; TRANSCRIPTIONAL ACTIVATION; VP16-INDUCED COMPLEX; TERMINAL SUBUNIT; C1 FACTOR; BINDING; FAMILY; DOMAIN	HCF-1 is a transcriptional cofactor required for activation of herpes simplex virus immediate-early genes by VP16 as well as less clearly defined roles in cell proliferation, cytokinesis, and spliceosome formation. It is expressed as a large precursor that undergoes proteolysis to yield two subunits that remain stably associated. VP16 uses a degenerate 4-amino acid sequence, known as the HCF-binding motif, to bind to a six-bladed beta-propeller domain at the N terminus of HCF-1. Functional HCF-binding motifs are also found in LZIP and Zhangfei, two cellular bZIP transcription factors of unknown function. Here we show that the HCF-binding motif occurs in a wide spectrum of DNA-binding proteins and transcriptional cofactors. Three well characterized examples were further analyzed for their ability to use HCF-1 as a coactivator. Krox20, a zinc finger transcription factor required for Schwann cell differentiation, and E2F4, a cell cycle regulator, showed a strong requirement for functional HCF-1 to activate transcription. In contrast, activation by estrogen receptor-alpha did not display HCF dependence. In Krox20, the HCF-binding motif lies within the N-terminal activation domain and mutation of this sequence diminishes both transactivation and association with the HCF-1 beta-propeller. The activation domain in the C-terminal subunit of HCF-1 contributes to activation by Krox20, possibly through recruitment of p300. These results suggest that HCF-1 is recruited by many different classes of cellular transcription factors and is therefore likely to be required for a variety of cellular processes including cell cycle progression and development.	NYU, Sch Med, Dept Microbiol, New York, NY 10016 USA; NYU, Sch Med, Inst Canc, New York, NY 10016 USA	New York University; New York University	Wilson, AC (corresponding author), NYU, Sch Med, Dept Microbiol, 550 1st Ave, New York, NY 10016 USA.	angus.wilson@med.nyu.edu	Wilson, Angus C/AAA-8153-2019	Wilson, Angus C/0000-0002-5016-4164	NIAID NIH HHS [AI07180-21, T32 AI007180] Funding Source: Medline; NIGMS NIH HHS [GM61139, R01 GM061139] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007180] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061139] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ajuh P, 2002, EMBO J, V21, P6590, DOI 10.1093/emboj/cdf652; Biesiada E, 1996, J BIOL CHEM, V271, P18576, DOI 10.1074/jbc.271.31.18576; Chan HM, 2001, J CELL SCI, V114, P2363; Coulthard VH, 2003, J BIOL CHEM, V278, P10942, DOI 10.1074/jbc.M212950200; FRATTINI A, 1994, GENOMICS, V23, P30, DOI 10.1006/geno.1994.1455; Freiman RN, 1997, GENE DEV, V11, P3122, DOI 10.1101/gad.11.23.3122; Gattiker A, 2002, PROTEOMICS, V2, P1435, DOI 10.1002/1615-9861(200210)2:10<1435::AID-PROT1435>3.0.CO;2-9; Goto H, 1997, GENE DEV, V11, P726, DOI 10.1101/gad.11.6.726; Gunther M, 2000, MOL CELL BIOCHEM, V210, P131, DOI 10.1023/A:1007177623283; Heery DM, 2001, J BIOL CHEM, V276, P6695, DOI 10.1074/jbc.M009404200; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Jessen KR, 2002, J ANAT, V200, P367, DOI 10.1046/j.1469-7580.2002.00046.x; Kristie TM, 1999, P NATL ACAD SCI USA, V96, P1229, DOI 10.1073/pnas.96.4.1229; KRISTIE TM, 1995, J BIOL CHEM, V270, P4387, DOI 10.1074/jbc.270.9.4387; La Boissiere S, 1999, EMBO J, V18, P480; LaBoissiere S, 1997, MOL CELL BIOL, V17, P7108, DOI 10.1128/MCB.17.12.7108; Lai JS, 1997, MOL CELL BIOL, V17, P3937, DOI 10.1128/MCB.17.7.3937; Lin JD, 2002, J BIOL CHEM, V277, P1645, DOI 10.1074/jbc.C100631200; Lu R, 1997, MOL CELL BIOL, V17, P5117, DOI 10.1128/MCB.17.9.5117; Lu R, 2000, NUCLEIC ACIDS RES, V28, P2446, DOI 10.1093/nar/28.12.2446; Lu R, 1998, J VIROL, V72, P6291, DOI 10.1128/JVI.72.8.6291-6297.1998; Luciano RL, 2000, P NATL ACAD SCI USA, V97, P10757, DOI 10.1073/pnas.190062797; Luciano RL, 2002, P NATL ACAD SCI USA, V99, P13403, DOI 10.1073/pnas.202200399; Mahajan SS, 2002, J BIOL CHEM, V277, P44292, DOI 10.1074/jbc.M205440200; McDonnell DP, 2002, SCIENCE, V296, P1642, DOI 10.1126/science.1071884; Naar AM, 2001, ANNU REV BIOCHEM, V70, P475, DOI 10.1146/annurev.biochem.70.1.475; Nagarajan R, 2001, NEURON, V30, P355, DOI 10.1016/S0896-6273(01)00282-3; OHARE P, 1993, SEMIN VIROL, V4, P145, DOI 10.1006/smvy.1993.1010; Piluso D, 2002, J BIOL CHEM, V277, P46799, DOI 10.1074/jbc.M206226200; Rayman JB, 2002, GENE DEV, V16, P933, DOI 10.1101/gad.969202; Reilly PT, 2002, EXP CELL RES, V277, P119, DOI 10.1006/excr.2002.5551; Reilly PT, 2002, MOL CELL BIOL, V22, P6767, DOI 10.1128/MCB.22.19.6767-6778.2002; RUSSO MW, 1993, MOL CELL BIOL, V13, P6858, DOI 10.1128/MCB.13.11.6858; Scarr RB, 2002, ONCOGENE, V21, P5245, DOI 10.1038/sj.onc.1205647; SCHNEIDERMAUNOURY S, 1993, CELL, V75, P1199, DOI 10.1016/0092-8674(93)90329-O; Sevetson BR, 2000, J BIOL CHEM, V275, P9749, DOI 10.1074/jbc.275.13.9749; Shibata F, 1991, GROWTH FACTORS, V4, P277, DOI 10.3109/08977199109043913; Simmen KA, 1997, J VIROL, V71, P3886, DOI 10.1128/JVI.71.5.3886-3894.1997; Su LF, 2001, J BIOL CHEM, V276, P3231, DOI 10.1074/jbc.M005547200; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; Svaren J, 1998, EMBO J, V17, P6010, DOI 10.1093/emboj/17.20.6010; SWIATEK PJ, 1993, GENE DEV, V7, P2071, DOI 10.1101/gad.7.11.2071; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Venken K, 2002, NEUROGENETICS, V4, P37, DOI 10.1007/s10048-001-0124-2; VESQUE C, 1992, NUCLEIC ACIDS RES, V20, P2485, DOI 10.1093/nar/20.10.2485; Vogel JL, 2000, EMBO J, V19, P683, DOI 10.1093/emboj/19.4.683; Wang DW, 2000, MOL CELL BIOL, V20, P3417, DOI 10.1128/MCB.20.10.3417-3424.2000; Warner LE, 1999, HUM MOL GENET, V8, P1245, DOI 10.1093/hmg/8.7.1245; Wilson AC, 2000, MOL CELL BIOL, V20, P6721, DOI 10.1128/MCB.20.18.6721-6730.2000; WILSON AC, 1995, GENE DEV, V9, P2445, DOI 10.1101/gad.9.20.2445; Wilson AC, 1997, MOL CELL BIOL, V17, P6139, DOI 10.1128/MCB.17.10.6139; WILSON AC, 1993, CELL, V74, P115, DOI 10.1016/0092-8674(93)90299-6; WU TJ, 1994, MOL CELL BIOL, V14, P3484, DOI 10.1128/MCB.14.5.3484; Wysocka J, 2003, TRENDS BIOCHEM SCI, V28, P294, DOI 10.1016/S0968-0004(03)00088-4; Wysocka J, 2003, GENE DEV, V17, P896, DOI 10.1101/gad.252103; Wysocka J, 2001, MOL CELL BIOL, V21, P3820, DOI 10.1128/MCB.21.11.3820-3829.2001; XU M, 1994, MOL CELL BIOL, V14, P8420, DOI 10.1128/MCB.14.12.8420	58	50	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51116	51124		10.1074/jbc.M303470200	http://dx.doi.org/10.1074/jbc.M303470200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14532282	hybrid, Green Accepted			2022-12-27	WOS:000187206300036
J	Sandu, C; Chiribau, CB; Brandsch, R				Sandu, C; Chiribau, CB; Brandsch, R			Characterization of HdnoR, the transcriptional repressor of the 6-hydroxy-D-nicotine oxidase gene of Arthrobacter nicotinovorans pAO1, and its DNA-binding activity in response to L- and D-nicotine derivatives	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D-6-HYDROXYNICOTINE OXIDASE; PURIFICATION; OPERATOR; SYSTEM; IDENTIFICATION; DEGRADATION; SPECIFICITY; INDUCTION; REGULATOR; MECHANISM	Utilization of L-nicotine as growth substrate by Arthrobacter nicotinovorans pAO1 starts with hydroxylation of the pyridine ring at C6. Next, the pyrrolidine ring is oxidized by 6-hydroxy-L-nicotine oxidase, which acts strictly stereo-specific on the L-enantiomer. Surprisingly, L-nicotine also induces the synthesis of a 6-hydroxy-D-nicotine-specific oxidase in the bacteria. Genes of nicotine-degrading enzymes are located on the catabolic plasmid pAO1. The pAO1 sequence revealed that the 6-hydroxy-D-nicotine oxidase gene is flanked by two open reading frames with a similarity to amino acid permeases and a divergently transcribed open reading frame with a similarity to proteins of the tetracycline repressor TetR family. Reverse transcription PCR and primer extension analysis of RNA transcripts isolated from A. nicotinovorans pAO1 indicated that the 6-hydroxy-D-nicotine oxidase gene represents a transcriptional unit. DNA electromobility shift assays established that the purified TetR-similar protein represents the 6-hydroxy-D-nicotine oxidase gene repressor HdnoR and binds to the 6-hydroxy-D-nicotine oxidase gene operator with a K-d of 21 nM. The enantiomers 6-hydroxy-D- and 6-hydroxy-L-nicotine acted in vitro as inducers. In vivo analysis of 6-hydroxy-D- nicotine oxidase gene transcripts from bacteria grown with L- and D-nicotine confirmed this conclusion. The poor discrimination by HdnoR between the 6-hydroxy-L- and 6-hydroxy-D- nicotine enantiomers explains the presence of the 6-hydroxy-D-nicotine-specific enzyme in bacteria grown on L-nicotine.	Univ Freiburg, Inst Biochem & Mol Biol, D-79104 Freiburg, Germany	University of Freiburg	Brandsch, R (corresponding author), Univ Freiburg, Inst Biochem & Mol Biol, Hermann Herder Str 7, D-79104 Freiburg, Germany.		Sandu, Cristinel/A-3063-2008					Baitsch D, 2001, J BACTERIOL, V183, P5262, DOI 10.1128/JB.183.18.5262-5267.2001; BERNAUER H, 1992, MOL MICROBIOL, V6, P1809, DOI 10.1111/j.1365-2958.1992.tb01353.x; BERTHOLD H, 1992, PROTEIN EXPRES PURIF, V3, P50, DOI 10.1016/1046-5928(92)90055-2; BRANDSCH R, 1984, ARCH MICROBIOL, V138, P15, DOI 10.1007/BF00425400; BRUHMULLER M, 1972, EUR J BIOCHEM, V29, P143, DOI 10.1111/j.1432-1033.1972.tb01968.x; DECKER K, 1972, Z NATURFORSCH PT B, VB 27, P1072; DECKER K, 1967, EUR J BIOCHEM, V3, P132, DOI 10.1111/j.1432-1033.1967.tb19507.x; DECKER K, 1965, BIOCHIM BIOPHYS ACTA, V105, P313, DOI 10.1016/S0926-6593(65)80155-2; EBERWEIN H, 1961, H-S Z PHYSIOL CHEM, V323, P236, DOI 10.1515/bchm2.1961.323.1.236; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GLOGER M, 1969, Z NATURFORSCH PT B, VB 24, P1016; Grkovic S, 2001, J BACTERIOL, V183, P7102, DOI 10.1128/JB.183.24.7102-7109.2001; HINRICHS W, 1994, SCIENCE, V264, P418, DOI 10.1126/science.8153629; HOCHSTEIN LI, 1959, J BIOL CHEM, V234, P156; Igloi GL, 2003, J BACTERIOL, V185, P1976, DOI 10.1128/JB.185.6.1976-1986.2003; KISAKI T, 1961, ARCH BIOCHEM BIOPHYS, V92, P351, DOI 10.1016/0003-9861(61)90360-5; KODAMA Y, 1992, INT J SYST BACTERIOL, V42, P234, DOI 10.1099/00207713-42-2-234; MAUCH L, 1990, MOL GEN GENET, V221, P427, DOI 10.1007/BF00259408; Mesnard F, 2001, PLANT SCI, V161, P1011, DOI 10.1016/S0168-9452(01)00509-X; NWOSU CG, 1988, XENOBIOTICA, V18, P1361, DOI 10.3109/00498258809042260; Orth P, 2000, NAT STRUCT BIOL, V7, P215; Recchi C, 2003, J BIOL CHEM, V278, P33763, DOI 10.1074/jbc.M305963200	22	24	27	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51307	51315		10.1074/jbc.M307797200	http://dx.doi.org/10.1074/jbc.M307797200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14534317	hybrid			2022-12-27	WOS:000187206300058
J	Wu, JM; Xiao, L; Cheng, XK; Cui, LX; Wu, NH; Shen, YF				Wu, JM; Xiao, L; Cheng, XK; Cui, LX; Wu, NH; Shen, YF			PKC epsilon is a unique regulator for hsp90 beta gene in heat shock response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; SIGNAL-TRANSDUCTION; EXPRESSION; INHIBITION; ISOENZYMES; PROMOTER; SEQUENCE; HSP70	An early event in cellular heat shock response is the transmittance of stress signals from the cell surface into the nuclei, resulting in the induction of heat shock proteins (Hsps). Protein kinase C (PKC) has been implicated as a key player in transducing stress signals. However, mechanism(s) by which PKC regulates heat shock-induced events remains largely unknown. Here we present data that pan-PKC inhibitor GF109203X, but not classic PKC inhibitor Go6976, specifically repressed heat shock-induced accumulation of mRNA as well as promoter activity of hsp90beta, but not hsp90alpha, in Jurkat cells. Subcellular fractionation studies revealed that heat shock exclusively induced PKC-epsilon membrane translocation. Consistently, expression of a constitutively active PKC-epsilon(A159E) resulted in an enhanced promoter activity of hsp90beta upon heat shock, whereas a dominant-negative PKC-epsilon(K437R) abolished this effect. In contrast, constitutively active-PKC-alpha or dominant-negative-PKC-alpha had no effects on heat shock induction of the gene. The effect of PKC-epsilon on hsp90beta expression seems to be stimuli-specific, as phorbol myristate acetate-mediated hsp90beta expression was PKC-epsilon-independent. We conclude that PKC-epsilon is specifically required in the signaling pathway leading to the induction of hsp90beta gene in response to heat shock.	Chinese Acad Med Sci, Inst Basic Med Sci, Natl Lab Med Mol Biol, Beijing 100005, Peoples R China; Peking Union Med Coll, Beijing 100005, Peoples R China; Univ Florida, Shands Canc Ctr, Gainesville, FL 32610 USA; Univ Florida, Dept Anat & Cell Biol, Gainesville, FL 32610 USA	Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Basic Medical Sciences - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; State University System of Florida; University of Florida; State University System of Florida; University of Florida	Xiao, L (corresponding author), Chinese Acad Med Sci, Inst Basic Med Sci, Natl Lab Med Mol Biol, 5 Dongdan Santiao, Beijing 100005, Peoples R China.	lxiao@ufl.edu; yfshen@imicams.ac.cn			NCI NIH HHS [R01-CA88815] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA088815] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEERE HM, 2001, SCI STKE; Blagosklonny MV, 2002, LEUKEMIA, V16, P455, DOI 10.1038/sj.leu.2402415; Caplan AJ, 1999, TRENDS CELL BIOL, V9, P262, DOI 10.1016/S0962-8924(99)01580-9; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; Dempsey EC, 2000, AM J PHYSIOL-LUNG C, V279, pL429, DOI 10.1152/ajplung.2000.279.3.L429; Ding L, 2002, J BIOL CHEM, V277, P35305, DOI 10.1074/jbc.M201460200; Elefant F, 1999, MOL BIOL CELL, V10, P2101, DOI 10.1091/mbc.10.7.2101; HICKEY E, 1989, MOL CELL BIOL, V9, P2615, DOI 10.1128/MCB.9.6.2615; Holmberg CI, 1998, J CELL SCI, V111, P3357; Hostein I, 2001, CANCER RES, V61, P4003; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; JACQUIERSARLIN MR, 1995, J BIOL CHEM, V270, P14094, DOI 10.1074/jbc.270.23.14094; KOIDE H, 1992, P NATL ACAD SCI USA, V89, P1149, DOI 10.1073/pnas.89.4.1149; LANG W, 2003, IN PRESS CELL SIGNAL; LeHoux JG, 2001, J BIOL CHEM, V276, P8021, DOI 10.1074/jbc.M009495200; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; Mayer MP, 1999, CURR BIOL, V9, pR322, DOI 10.1016/S0960-9822(99)80203-6; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; Mo ZC, 2002, PROG NAT SCI, V12, P742; Newton AC, 2001, CHEM REV, V101, P2353, DOI 10.1021/cr0002801; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; Nollen EAA, 2002, J CELL SCI, V115, P2809; PARSELL DA, 1993, ANNU REV GENET, V27, P437, DOI 10.1146/annurev.ge.27.120193.002253; Pearl LH, 2000, CURR OPIN STRUC BIOL, V10, P46, DOI 10.1016/S0959-440X(99)00047-0; REBBE NF, 1987, GENE, V53, P235, DOI 10.1016/0378-1119(87)90012-6; RITZ MF, 1993, RECEPTOR, V3, P311; SAMBROOK J, 2000, MOL CLONING LAB MANU; Shen Y F, 1986, J Cell Physiol Suppl, V4, P35; Shen YF, 1997, FEBS LETT, V413, P92, DOI 10.1016/S0014-5793(97)00883-1; SHEN YF, 1999, ADV MED MOL BIOL, V2, P205; Slepko N, 1999, J NEUROSCI RES, V57, P33, DOI 10.1002/(SICI)1097-4547(19990701)57:1<33::AID-JNR4>3.0.CO;2-6; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; WANG YF, 1995, THESIS PEKING UNION; Wang YL, 1996, CHINESE SCI BULL, V41, P1730; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; Xiao L, 2000, CANCER RES, V60, P400; XU Y, 1993, P NATL ACAD SCI USA, V90, P7074, DOI 10.1073/pnas.90.15.7074; Young JC, 2001, J CELL BIOL, V154, P267, DOI 10.1083/jcb.200104079; Zhang SL, 1999, FEBS LETT, V444, P130, DOI 10.1016/S0014-5793(99)00044-7	42	25	27	3	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51143	51149		10.1074/jbc.M305537200	http://dx.doi.org/10.1074/jbc.M305537200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14532285	hybrid			2022-12-27	WOS:000187206300039
J	Chi, YQ; Senyuk, V; Chakraborty, S; Nucifora, G				Chi, YQ; Senyuk, V; Chakraborty, S; Nucifora, G			EVI1 promotes cell proliferation by interacting with BRG1 and blocking the repression of BRG1 on E2F1 activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMATIN REMODELING COMPLEX; ACUTE MYELOGENOUS LEUKEMIAS; ZINC-FINGER PROTEIN; SWI/SNF COMPLEX; TRANSCRIPTIONAL ACTIVATION; RETINOBLASTOMA PROTEIN; GROWTH-REGULATION; MYELOID-LEUKEMIA; GENE-EXPRESSION; BINDING-SITE	EVI1 is a complex protein required for embryogenesis and inappropriately expressed in many types of human myeloid leukemia. Earlier we showed that the forced expression of EVI1 in murine hematopoietic precursor cells leads to their abnormal differentiation and increased proliferation. In this report, we show that EVI1 physically interacts with BRG1 and its functional homolog BRM in mammalian cells. We found that the C terminus of EVI1 interacts strongly with BRG1 and that the central and C-terminal regions of BRG1 are involved in EVI1-BRG1 interaction. Using reporter gene assays, we demonstrate that EVI1 activates the E2F1 promoter in NIH3T3 cells but not in BRG1-negative SW13 cells. Ectopic expression of BRG1 is able to repress the E2F1 promoter in vector-transfected SW13 cells but not in EVI1-transfected SW13 cells. Finally, we show that EVI1 up-regulates cell proliferation in BRG1-positive 32Dcl3 cells but not in BRG1-negative SW13 cells. Taken together, these data support the hypothesis that the interaction with BRG1 is important for up-regulation of cell-growth by EVI1.	Univ Chicago, Dept Pathol, Chicago, IL 60637 USA; Univ Chicago, Ctr Canc, Chicago, IL 60637 USA	University of Chicago; University of Chicago	Nucifora, G (corresponding author), Univ Chicago, Dept Pathol, Mol Biol Res Bldg,M-C 737,900 S Ashland Ave, Chicago, IL 60637 USA.	nucifora@uic.edu			NCI NIH HHS [CA72675, CA67189] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA067189, R29CA067189, R01CA072675] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bartek J, 1997, EXP CELL RES, V237, P1, DOI 10.1006/excr.1997.3776; Bochar DA, 2000, CELL, V102, P257, DOI 10.1016/S0092-8674(00)00030-1; Brockmann D, 2001, GENE, V277, P111, DOI 10.1016/S0378-1119(01)00703-X; Brown RC, 2002, MOL CELL BIOL, V22, P161, DOI 10.1128/MCB.22.1.161-170.2002; Chakraborty S, 2001, J BIOL CHEM, V276, P44936, DOI 10.1074/jbc.M106733200; Cheng SWG, 1999, NAT GENET, V22, P102, DOI 10.1038/8811; Chi TH, 2002, NATURE, V418, P195, DOI 10.1038/nature00876; de la Serna IL, 2001, NAT GENET, V27, P187, DOI 10.1038/84826; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; DiRenzo J, 2000, MOL CELL BIOL, V20, P7541, DOI 10.1128/MCB.20.20.7541-7549.2000; DOBROWOLSKI SF, 1994, ONCOGENE, V9, P2605; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; FATTAEY AR, 1993, MOL CELL BIOL, V13, P7267, DOI 10.1128/MCB.13.12.7267; FICHELSON S, 1992, LEUKEMIA, V6, P93; Fryer CJ, 1998, NATURE, V393, P88, DOI 10.1038/30032; Hebbar PB, 2003, MOL CELL BIOL, V23, P887, DOI 10.1128/MCB.23.3.887-898.2003; Ishizaki J, 1996, NAT MED, V2, P1386, DOI 10.1038/nm1296-1386; JENKINS RB, 1989, CANCER GENET CYTOGEN, V39, P167, DOI 10.1016/0165-4608(89)90182-9; Karlseder J, 1996, MOL CELL BIOL, V16, P1659; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; Kingston RE, 1999, GENE DEV, V13, P2339, DOI 10.1101/gad.13.18.2339; Kowenz-Leutz E, 1999, MOL CELL, V4, P735, DOI 10.1016/S1097-2765(00)80384-6; KREIDER BL, 1993, P NATL ACAD SCI USA, V90, P6454, DOI 10.1073/pnas.90.14.6454; Kurokawa M, 1998, NATURE, V394, P92, DOI 10.1038/27945; Lee CH, 1999, P NATL ACAD SCI USA, V96, P12311, DOI 10.1073/pnas.96.22.12311; MATSUGI T, 1990, MOL CELL BIOL, V10, P1259, DOI 10.1128/MCB.10.3.1259; MEANS AL, 1992, MOL CELL BIOL, V12, P1054, DOI 10.1128/MCB.12.3.1054; MORISHITA K, 1992, P NATL ACAD SCI USA, V89, P3937, DOI 10.1073/pnas.89.9.3937; MORISHITA K, 1988, CELL, V54, P831, DOI 10.1016/S0092-8674(88)91175-0; MUCENSKI ML, 1988, MOL CELL BIOL, V8, P301, DOI 10.1128/MCB.8.1.301; MUCHARDT C, 1995, NUCLEIC ACIDS RES, V23, P1127, DOI 10.1093/nar/23.7.1127; Muchardt C, 1996, EMBO J, V15, P3394, DOI 10.1002/j.1460-2075.1996.tb00705.x; Muchardt C, 1999, J MOL BIOL, V293, P187, DOI 10.1006/jmbi.1999.2999; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; Nevins JR, 1997, J CELL PHYSIOL, V173, P233, DOI 10.1002/(SICI)1097-4652(199711)173:2<233::AID-JCP27>3.0.CO;2-F; Nielsen AL, 2002, EMBO J, V21, P5797, DOI 10.1093/emboj/cdf560; OGRIS E, 1993, J VIROL, V67, P1765, DOI 10.1128/JVI.67.4.1765-1771.1993; Pattenden SG, 2002, EMBO J, V21, P1978, DOI 10.1093/emboj/21.8.1978; PEARSON BE, 1991, MOL CELL BIOL, V11, P2081, DOI 10.1128/MCB.11.4.2081; PERKINS AS, 1991, DEVELOPMENT, V111, P479; Phelan ML, 1999, MOL CELL, V3, P247, DOI 10.1016/S1097-2765(00)80315-9; RANDAZZO FM, 1994, DEV BIOL, V161, P229, DOI 10.1006/dbio.1994.1023; Reyes JC, 1997, J CELL BIOL, V137, P263, DOI 10.1083/jcb.137.2.263; Sambrook J, 1989, MOL CLONING LABORATO, V9, P16; Senyuk V, 2002, ONCOGENE, V21, P3232, DOI 10.1038/sj.onc.1205436; Sif S, 2001, GENE DEV, V15, P603, DOI 10.1101/gad.872801; Sitailo S, 1999, LEUKEMIA, V13, P1639, DOI 10.1038/sj.leu.2401585; Slansky JE, 1996, BIOESSAYS, V18, P55, DOI 10.1002/bies.950180111; Sood R, 1999, LEUKEMIA, V13, P348, DOI 10.1038/sj.leu.2401360; Strobeck MW, 2001, J BIOL CHEM, V276, P9273, DOI 10.1074/jbc.M009747200; Strober BE, 1996, MOL CELL BIOL, V16, P1576; SUZUKAWA K, 1994, BLOOD, V84, P2681; Trouche D, 1997, P NATL ACAD SCI USA, V94, P11268, DOI 10.1073/pnas.94.21.11268; Underhill C, 2000, J BIOL CHEM, V275, P40463, DOI 10.1074/jbc.M007864200; Varga-Weisz P, 2001, ONCOGENE, V20, P3076, DOI 10.1038/sj.onc.1204332; Vignali M, 2000, MOL CELL BIOL, V20, P1899, DOI 10.1128/MCB.20.6.1899-1910.2000; WADE M, 1992, MOL CELL BIOL, V12, P4364, DOI 10.1128/MCB.12.10.4364; Wang WD, 1996, EMBO J, V15, P5370, DOI 10.1002/j.1460-2075.1996.tb00921.x; Wang WD, 1996, GENE DEV, V10, P2117, DOI 10.1101/gad.10.17.2117; Yeh JH, 2002, NUCLEIC ACIDS RES, V30, P1944, DOI 10.1093/nar/30.9.1944	61	33	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					49806	49811		10.1074/jbc.M309645200	http://dx.doi.org/10.1074/jbc.M309645200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	14555651	hybrid			2022-12-27	WOS:000187068200021
J	Hussein, SM; Duff, EK; Sirard, C				Hussein, SM; Duff, EK; Sirard, C			Smad4 and beta-catenin co-activators functionally interact with lymphoid-enhancing factor to regulate graded expression of Msx2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; EMBRYONIC STEM-CELLS; NEURAL CREST MIGRATION; GENE-EXPRESSION; TRANSCRIPTIONAL ACTIVATION; CHICK-EMBRYO; DNA-BINDING; WNT; XENOPUS; INDUCTION	Recent in vivo evidence suggests that Wnt signaling plays a central role in determining the fate of stem cells in the ectoderm and in the neural crest by modulating bone morphogenetic protein (BMP) levels, which, in turn, influence Msx gene expression. However, the molecular mechanism regulating the expression of the Msx genes as key regulators of cell fate has not been elucidated. Here we show in murine embryonic stem cells that BMP-dependent activation of Msx2 is mediated via the cooperative binding of Smad4 at two Smad binding elements and of lymphoid enhancing factor (Lef1) at two Lef1/TCF binding sites. Lef1 can synergize with Smad4 and Smad1 to activate Msx2 promoter, and this transcriptional complex is assembled on the endogenous promoter in response to BMP2. The Wnt/beta-catenin signaling pathway can activate Msx2 via the binding of Lef1 to its promoter and synergizes with BMP2 to activate Msx2 expression, possibly via enhanced recruitment of the p300/cAMP-response element-binding protein-binding protein co-factor. Interestingly, the Wnt/beta-catenin- dependent activation of Msx2 was defective in Smad4-deficient embryonic stem cells or when Smad binding elements were mutated but persisted in the presence of various BMP antagonists, indicating that Smad4 was involved in transducing the Wnt/beta-catenin signals in the absence of a BMP autocrine loop. A chromatin immunoprecipitation analysis revealed that endogenous Smad4, but not Smad1, was part of the Lef1 transcriptional complex in response to beta-catenin activation, dismissing any implication of BMP signaling in this response. We propose that Wnt signaling pathway could dictate cell fate not only by modulating BMP levels but also by directly regulating cooperatively BMP-target genes.	McGill Univ, Montreal Neurol Inst, Brain Tumor Res Ctr, Montreal, PQ H3A 2B4, Canada	McGill University	Sirard, C (corresponding author), 3801 Univ St, Montreal, PQ H3A 2B4, Canada.							Attisano L, 2000, CURR OPIN CELL BIOL, V12, P235, DOI 10.1016/S0955-0674(99)00081-2; Attisano L, 1998, CURR OPIN CELL BIOL, V10, P188, DOI 10.1016/S0955-0674(98)80141-5; Beanan MJ, 2000, MECH DEVELOP, V91, P227, DOI 10.1016/S0925-4773(99)00303-2; Boyd KE, 1999, MOL CELL BIOL, V19, P8393; DAVIDSON D, 1995, TRENDS GENET, V11, P405, DOI 10.1016/S0168-9525(00)89124-6; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; DICKINSON ME, 1995, DEVELOPMENT, V121, P2099; Drapkin Paola T, 2002, BMC Developmental Biology, V2, P1; Eckner R, 1996, BIOL CHEM, V377, P685; EGAN C, 1988, MOL CELL BIOL, V8, P3955, DOI 10.1128/MCB.8.9.3955; Ellies DL, 2000, DEVELOPMENT, V127, P5285; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Fischer L, 2002, J BIOL CHEM, V277, P30870, DOI 10.1074/jbc.M109330200; Garcia-Castro MI, 2002, SCIENCE, V297, P848, DOI 10.1126/science.1070824; Goldman PS, 1997, RECENT PROG HORM RES, V52, P103; GRAHAM A, 1994, NATURE, V372, P684, DOI 10.1038/372684a0; Hecht A, 2000, EMBO J, V19, P1839, DOI 10.1093/emboj/19.8.1839; Hogan BLM, 1996, CURR OPIN GENET DEV, V6, P432, DOI 10.1016/S0959-437X(96)80064-5; Hollnagel A, 1999, J BIOL CHEM, V274, P19838, DOI 10.1074/jbc.274.28.19838; HOLLYDAY M, 1995, MECH DEVELOP, V52, P9, DOI 10.1016/0925-4773(95)00385-E; Hoppler S, 1998, MECH DEVELOP, V71, P119, DOI 10.1016/S0925-4773(98)00004-5; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Janknecht R, 1996, CURR BIOL, V6, P951, DOI 10.1016/S0960-9822(02)00636-X; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Kim JS, 2002, CANCER RES, V62, P2744; Korinek V, 1998, MOL CELL BIOL, V18, P1248, DOI 10.1128/MCB.18.3.1248; Labbe E, 2000, P NATL ACAD SCI USA, V97, P8358, DOI 10.1073/pnas.150152697; Lako M, 2001, MECH DEVELOP, V103, P49, DOI 10.1016/S0925-4773(01)00331-8; Maden M, 1997, DEVELOPMENT, V124, P2799; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; Millar JBA, 2002, GENOME BIOL, V3; Nishita M, 2000, NATURE, V403, P781, DOI 10.1038/35001602; Odelberg SJ, 2000, CELL, V103, P1099, DOI 10.1016/S0092-8674(00)00212-9; Park GT, 2002, NUCLEIC ACIDS RES, V30, P515, DOI 10.1093/nar/30.2.515; Pearson KL, 1999, BBA-GENE STRUCT EXPR, V1489, P354, DOI 10.1016/S0167-4781(99)00166-9; Pierreux CE, 2000, MOL CELL BIOL, V20, P9041, DOI 10.1128/MCB.20.23.9041-9054.2000; Pouponnot C, 1998, J BIOL CHEM, V273, P22865, DOI 10.1074/jbc.273.36.22865; SASAI Y, 1995, NATURE, V376, P333, DOI 10.1038/376333a0; Sela-Donenfeld D, 1999, DEVELOPMENT, V126, P4749; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; Sirard C, 2000, J BIOL CHEM, V275, P2063, DOI 10.1074/jbc.275.3.2063; Sirard C, 1998, GENE DEV, V12, P107, DOI 10.1101/gad.12.1.107; Suzuki A, 1997, DEVELOPMENT, V124, P3037; Takahashi K, 1998, DEVELOPMENT, V125, P1627; Takahashi K, 2001, DEV DYNAM, V222, P252, DOI 10.1002/dvdy.1185; Takemaru KI, 2000, J CELL BIOL, V149, P249, DOI 10.1083/jcb.149.2.249; Theil T, 2002, DEVELOPMENT, V129, P3045; Thompson-Jaeger S, 2000, MOL CELL BIOCHEM, V208, P63, DOI 10.1023/A:1007069317131; Timmer JR, 2002, DEVELOPMENT, V129, P2459; Trainor PA, 2002, DEVELOPMENT, V129, P433; Tropepe V, 2001, NEURON, V30, P65, DOI 10.1016/S0896-6273(01)00263-X; Vindevoghel L, 1998, J BIOL CHEM, V273, P13053, DOI 10.1074/jbc.273.21.13053; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; Wilson PA, 1997, DEVELOPMENT, V124, P3177; Wilson SI, 2001, NATURE, V411, P325, DOI 10.1038/35077115; Wingender E, 2000, NUCLEIC ACIDS RES, V28, P316, DOI 10.1093/nar/28.1.316; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; WOLOSHIN P, 1995, CELL, V82, P611, DOI 10.1016/0092-8674(95)90033-0; Wotton D, 1999, CELL, V97, P29, DOI 10.1016/S0092-8674(00)80712-6; Wrana JL, 1998, MINER ELECTROL METAB, V24, P120, DOI 10.1159/000057359; Xiao Z, 2003, ONCOGENE, V22, P1057, DOI 10.1038/sj.onc.1206212; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4; Yeo CY, 1999, J BIOL CHEM, V274, P26584, DOI 10.1074/jbc.274.37.26584; Yingling JM, 1997, MOL CELL BIOL, V17, P7019, DOI 10.1128/MCB.17.12.7019; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1	67	169	175	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					48805	48814		10.1074/jbc.M305472200	http://dx.doi.org/10.1074/jbc.M305472200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	14551209	hybrid			2022-12-27	WOS:000186829000037
J	Dame, C; Sola, MC; Lim, KC; Leach, KM; Fandrey, J; Ma, Y; Knopfle, G; Engel, JD; Bungert, J				Dame, C; Sola, MC; Lim, KC; Leach, KM; Fandrey, J; Ma, Y; Knopfle, G; Engel, JD; Bungert, J			Hepatic erythropoietin gene regulation by GATA-4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR GATA-1; MESSENGER-RNA EXPRESSION; CENTRAL-NERVOUS-SYSTEM; TRANSGENIC MICE; ERYTHROID-DIFFERENTIATION; CELL-LINES; HEMATOPOIETIC DEFECT; NEGATIVE REGULATION; BINDING-PROTEIN; FETAL LIVER	Erythropoietin production switches from fetal liver to adult kidney during development. GATA transcription factors 2 and 3 could be involved in modulating this switch, because they were shown to negatively regulate erythropoietin gene transcription through a promoter proximal GATA site. Herein, we analyzed the role of several GATA factors in the regulation of the erythropoietin gene in human liver and in hepatoma cells. Although GATA-3 expression in hepatocytes increases during human development, erythropoietin mRNA accumulation is unaltered in mutant mice lacking GATA-3. We found that GATA-2, -3, -4, and -6 are all expressed in human hepatocytes and that GATA-4 exhibits the most prominent Epo promoter binding activity in vitro and in vivo. Inhibition of GATA-4 expression by RNA interference leads to a dramatic reduction in Epo gene transcription in Hep3B cells. Moreover, GATA-4 expression is high and limited to hepatocytes in the fetal liver, whereas GATA-4 expression in the adult liver is low and restricted to epithelial cells surrounding the biliary ducts. Thus, GATA-4 is critical for transcription of the Epo gene in hepatocytes and may contribute to the switch in the site of Epo gene expression from the fetal liver to the adult kidney.	Univ Florida, Dept Biochem & Mol Biol, Gainesville, FL 32610 USA; Univ Florida, Div Neonatol, Gainesville, FL 32610 USA; Univ Michigan, Dept Cell & Dev Biol, Ann Arbor, MI 48109 USA; Univ Essen Gesamthsch, Inst Physiol, D-45147 Essen, Germany; Univ Bonn, Dept Pathol, D-53127 Bonn, Germany	State University System of Florida; University of Florida; State University System of Florida; University of Florida; University of Michigan System; University of Michigan; University of Duisburg Essen; University of Bonn	Bungert, J (corresponding author), Univ Florida, Dept Biochem & Mol Biol, POB 100245, Gainesville, FL 32610 USA.	jbungert@college.med.ufl.edu	Fandrey, Joachim/AAA-3524-2021	Fandrey, Joachim/0000-0001-9585-0531	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052356] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK52356] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AIRD WC, 1994, J BIOL CHEM, V269, P883; ARCECI RJ, 1993, MOL CELL BIOL, V13, P2235, DOI 10.1128/MCB.13.4.2235; Bai YQ, 2000, MOL CARCINOGEN, V28, P184, DOI 10.1002/1098-2744(200007)28:3<184::AID-MC7>3.0.CO;2-6; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BLANCHARD KL, 1992, MOL CELL BIOL, V12, P5373, DOI 10.1128/MCB.12.12.5373; Blobel GA, 1998, P NATL ACAD SCI USA, V95, P2061, DOI 10.1073/pnas.95.5.2061; BONDURANT MC, 1991, SEMIN HEMATOL, V28, P20; Bossard P, 1998, DEVELOPMENT, V125, P4909; Charron F, 1999, MOL CELL BIOL, V19, P4355; Cirillo LA, 2002, MOL CELL, V9, P279, DOI 10.1016/S1097-2765(02)00459-8; Dame C, 1998, BLOOD, V92, P3218, DOI 10.1182/blood.V92.9.3218; Dame C, 2002, BRIT J HAEMATOL, V119, P510, DOI 10.1046/j.1365-2141.2002.03816.x; Ebert BL, 1998, MOL CELL BIOL, V18, P4089, DOI 10.1128/MCB.18.7.4089; Ebert BL, 1999, BLOOD, V94, P1864; ECKHARDT KU, 1992, J CLIN INVEST, V89, P753; FLAKE AW, 1987, BLOOD, V70, P542; GEORGE KM, 1994, DEVELOPMENT, V120, P2673; GOLDBERG MA, 1987, P NATL ACAD SCI USA, V84, P7972, DOI 10.1073/pnas.84.22.7972; Hendriks RW, 1999, EUR J IMMUNOL, V29, P1912, DOI 10.1002/(SICI)1521-4141(199906)29:06<1912::AID-IMMU1912>3.3.CO;2-4; IMAGAWA S, 1994, J BIOL CHEM, V269, P9038; Imagawa S, 2002, INT J HEMATOL, V75, P376, DOI 10.1007/BF02982127; Imagawa S, 1997, BLOOD, V89, P1430, DOI 10.1182/blood.V89.4.1430; ITO E, 1993, NATURE, V362, P466, DOI 10.1038/362466a0; Kang SHL, 2002, NUCLEIC ACIDS RES, V30; Kiekhaefer CM, 2002, P NATL ACAD SCI USA, V99, P14309, DOI 10.1073/pnas.212389499; Klemcke HG, 2001, ANIM REPROD SCI, V66, P93, DOI 10.1016/S0378-4320(01)00084-7; Kochling J, 1998, BRIT J HAEMATOL, V103, P960; La Ferla K, 2002, FASEB J, V16, P1811, DOI 10.1096/fj.02-0168fje; Laitinen MPE, 2000, J CLIN ENDOCR METAB, V85, P3476, DOI 10.1210/jc.85.9.3476; Lakshmanan G, 1999, MOL CELL BIOL, V19, P1558; LAVERRIERE AC, 1994, J BIOL CHEM, V269, P23177; Leach KM, 2003, NUCLEIC ACIDS RES, V31, P1292, DOI 10.1093/nar/gkg209; Leach KM, 2001, MOL CELL BIOL, V21, P2629, DOI 10.1128/MCB.21.8.2629-2640.2001; LEONARD M, 1993, BLOOD, V82, P1071; Letting DL, 2003, MOL CELL BIOL, V23, P1334, DOI 10.1128/MCB.23.4.1334-1340.2003; LIM GB, 1994, BLOOD, V84, P460; Lim KC, 2000, NAT GENET, V25, P209, DOI 10.1038/76080; LIN FK, 1985, P NATL ACAD SCI USA, V82, P7580, DOI 10.1073/pnas.82.22.7580; Lowry JA, 2000, J MOL EVOL, V50, P103, DOI 10.1007/s002399910012; Ma GT, 1997, DEVELOPMENT, V124, P907; MADAN A, 1995, BLOOD, V85, P2735; Masuda S, 1999, INT J HEMATOL, V70, P1; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; Moritz KM, 1997, AM J PHYSIOL-REG I, V273, pR1829, DOI 10.1152/ajpregu.1997.273.6.R1829; Morrisey EE, 1996, DEV BIOL, V177, P309, DOI 10.1006/dbio.1996.0165; Morrisey EE, 1998, GENE DEV, V12, P3579, DOI 10.1101/gad.12.22.3579; Nardelli J, 1999, DEV BIOL, V210, P305, DOI 10.1006/dbio.1999.9278; Nemer G, 2003, DEV BIOL, V254, P131, DOI 10.1016/S0012-1606(02)00026-X; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Ozawa Y, 2001, BLOOD, V98, P2116, DOI 10.1182/blood.V98.7.2116; PANDOLFI PP, 1995, NAT GENET, V11, P40, DOI 10.1038/ng0995-40; PESCHLE C, 1975, LIFE SCI, V17, P1325, DOI 10.1016/0024-3205(75)90146-0; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; PUGH CW, 1994, BBA-GENE STRUCT EXPR, V1217, P297, DOI 10.1016/0167-4781(94)90289-5; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; SEMENZA GL, 1990, MOL CELL BIOL, V10, P930, DOI 10.1128/MCB.10.3.930; SEMENZA GL, 1991, P NATL ACAD SCI USA, V88, P8725, DOI 10.1073/pnas.88.19.8725; Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599; TAN CC, 1992, AM J PHYSIOL, V263, P474; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; van Doorninck J H, 1999, J Neurosci, V19, pRC12; WEISS MJ, 1995, EXP HEMATOL, V23, P99; ZANJANI ED, 1977, J LAB CLIN MED, V89, P640; Zhou YH, 2000, DEVELOPMENT, V127, P3829; Zhou YH, 1998, EMBO J, V17, P6689, DOI 10.1093/emboj/17.22.6689	65	71	79	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	2004	279	4					2955	2961		10.1074/jbc.M310404200	http://dx.doi.org/10.1074/jbc.M310404200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	764MU	14583613	hybrid			2022-12-27	WOS:000188211300076
J	Golan, G; Shallom, D; Teplitsky, A; Zaide, G; Shulami, S; Baasov, T; Stojanoff, V; Thompson, A; Shoham, Y; Shoham, G				Golan, G; Shallom, D; Teplitsky, A; Zaide, G; Shulami, S; Baasov, T; Stojanoff, V; Thompson, A; Shoham, Y; Shoham, G			Crystal structures of Geobacillus stearothermophilus alpha-glucuronidase complexed with its substrate and products - Mechanistic implications	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOSYL-ENZYME INTERMEDIATE; DETAILED KINETIC-ANALYSIS; ACTIVE-SITE; ASPERGILLUS-NIGER; ENDOPOLYGALACTURONASE II; L-ARABINOFURANOSIDASE; ANGSTROM RESOLUTION; ASSISTED CATALYSIS; BETA-XYLOSIDASE; MOLECULAR-BASIS	alpha-Glucuronidases cleave the alpha-1,2-glycosidic bond between 4-O-methyl-D-glucuronic acid and short xylooligomers as part of the hemicellulose degradation system. To date, all of the alpha-glucuronidases are classified as family 67 glycosidases, which catalyze the hydrolysis via the investing mechanism. Here we describe several high resolution crystal structures of the alpha-glucuronidase (AguA) from Geobacillus stearothermophilus, in complex with its substrate and products. In the complex of AguA with the intact substrate, the 4-O-methyl-D-glucuronic acid sugar ring is distorted into a half-chair conformation, which is closer to the planar conformation required for the oxocarbenium ion-like transition state structure. In the active site, a water molecule is coordinated between two carboxylic acids, in an appropriate position to act as a nucleophile. From the structural data it is likely that two carboxylic acids, Asp(364) and Glu(392), activate together the nucleophilic water molecule. The loop carrying the catalytic general acid Glu(285) cannot be resolved in some of the structures but could be visualized in its "open" and "closed" (catalytic) conformations in other structures. The protonated state of Glu(285) is presumably stabilized by its proximity to the negative charge of the substrate, representing a new variation of substrate-assisted catalysis mechanism.	Technion Israel Inst Technol, Dept Food Engn & Biotechnol, IL-32000 Haifa, Israel; Hebrew Univ Jerusalem, Dept Inorgan Chem, IL-91904 Jerusalem, Israel; Hebrew Univ Jerusalem, Lab Struct Chem & Biol, IL-91904 Jerusalem, Israel; Technion Israel Inst Technol, Inst Catalysis Sci & Technol, IL-32000 Haifa, Israel; Technion Israel Inst Technol, Dept Chem, IL-32000 Haifa, Israel; European Synchrotron Radiat Facil, F-38043 Grenoble, France	Technion Israel Institute of Technology; Hebrew University of Jerusalem; Hebrew University of Jerusalem; Technion Israel Institute of Technology; Technion Israel Institute of Technology; European Synchrotron Radiation Facility (ESRF)	Shoham, Y (corresponding author), Technion Israel Inst Technol, Dept Food Engn & Biotechnol, IL-32000 Haifa, Israel.	yshoham@tx.technion.ac.il; gil2@vms.huji.ac.il	Baasov, Timor/L-5173-2019; stojanoff, vivian/I-7290-2012; Shoham, Yuval/M-4409-2013	Baasov, Timor/0000-0002-1427-2619; stojanoff, vivian/0000-0002-6650-512X; 				Alzari PM, 1996, STRUCTURE, V4, P265, DOI 10.1016/S0969-2126(96)00031-7; Armand S, 2000, J BIOL CHEM, V275, P691, DOI 10.1074/jbc.275.1.691; Biely P, 1997, J BIOTECHNOL, V57, P151, DOI 10.1016/S0168-1656(97)00096-5; Biely P, 2000, BBA-GEN SUBJECTS, V1474, P360, DOI 10.1016/S0304-4165(00)00029-5; Bourne Y, 2001, CURR OPIN STRUC BIOL, V11, P593, DOI 10.1016/S0959-440X(00)00253-0; Bravman T, 2003, BIOCHEMISTRY-US, V42, P10528, DOI 10.1021/bi034505o; Bravman T, 2001, FEBS LETT, V495, P115, DOI 10.1016/S0014-5793(01)02371-7; BRONNENMEIER K, 1995, MICROBIOL-SGM, V141, P2033, DOI 10.1099/13500872-141-9-2033; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Dall'Acqua W, 2000, PROTEIN SCI, V9, P1; DAVIES G, 1995, STRUCTURE, V3, P853, DOI 10.1016/S0969-2126(01)00220-9; Davies G. J., 1998, INCOMPREHENSIVE BIOL, P119; Davies GJ, 2003, BIOCHEM SOC T, V31, P523, DOI 10.1042/BST0310523; Dominguez R, 1996, J MOL BIOL, V257, P1042, DOI 10.1006/jmbi.1996.0222; Fierobe HP, 1998, BIOCHEMISTRY-US, V37, P3743, DOI 10.1021/bi972231x; GAT O, 1994, APPL ENVIRON MICROB, V60, P1889, DOI 10.1128/AEM.60.6.1889-1896.1994; GILEAD S, 1995, APPL ENVIRON MICROB, V61, P170, DOI 10.1128/AEM.61.1.170-174.1995; Guerin DMA, 2002, J MOL BIOL, V316, P1061, DOI 10.1006/jmbi.2001.5404; Hendrickson WA, 1997, METHOD ENZYMOL, V276, P494, DOI 10.1016/S0076-6879(97)76074-9; Holm L, 1998, NUCLEIC ACIDS RES, V26, P316, DOI 10.1093/nar/26.1.316; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Joshi MD, 2001, BIOCHEMISTRY-US, V40, P10115, DOI 10.1021/bi0105429; Koivula A, 2002, J AM CHEM SOC, V124, P10015, DOI 10.1021/ja012659q; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; Ly HD, 1999, ANNU REV BIOCHEM, V68, P487, DOI 10.1146/annurev.biochem.68.1.487; Mark BL, 2001, J BIOL CHEM, V276, P10330, DOI 10.1074/jbc.M011067200; MCCARTER JD, 1994, CURR OPIN STRUC BIOL, V4, P885, DOI 10.1016/0959-440X(94)90271-2; McIntosh LP, 1996, BIOCHEMISTRY-US, V35, P9958, DOI 10.1021/bi9613234; Mechaly A, 2000, J BIOTECHNOL, V78, P83, DOI 10.1016/S0168-1656(99)00226-6; Milner Y., 1967, CARBOHYD RES, V4, P359, DOI DOI 10.1016/S0008-6215(00)80191-3; Nagy T, 2003, J BIOL CHEM, V278, P20286, DOI 10.1074/jbc.M302205200; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Nurizzo D, 2002, STRUCTURE, V10, P547, DOI 10.1016/S0969-2126(02)00742-6; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pickersgill R, 1998, J BIOL CHEM, V273, P24660, DOI 10.1074/jbc.273.38.24660; Ramasubbu N, 2003, J MOL BIOL, V325, P1061, DOI 10.1016/S0022-2836(02)01326-8; Sabini E, 1999, CHEM BIOL, V6, P483, DOI 10.1016/S1074-5521(99)80066-0; Schwarz WH, 2001, APPL MICROBIOL BIOT, V56, P634, DOI 10.1007/s002530100710; Shallom D, 2003, CURR OPIN MICROBIOL, V6, P219, DOI 10.1016/S1369-5274(03)00056-0; Shallom D, 2002, J BIOL CHEM, V277, P43667, DOI 10.1074/jbc.M208285200; Shimizu T, 2002, BIOCHEMISTRY-US, V41, P6651, DOI 10.1021/bi025541a; Shoham Y, 1999, TRENDS MICROBIOL, V7, P275, DOI 10.1016/S0966-842X(99)01533-4; Shulami S, 1999, J BACTERIOL, V181, P3695, DOI 10.1128/JB.181.12.3695-3704.1999; Sidhu G, 1999, BIOCHEMISTRY-US, V38, P5346, DOI 10.1021/bi982946f; SINNOTT ML, 1990, CHEM REV, V90, P1171, DOI 10.1021/cr00105a006; Steinbacher S, 1997, J MOL BIOL, V267, P865, DOI 10.1006/jmbi.1997.0922; Tenkanen M, 2000, J BIOTECHNOL, V78, P149, DOI 10.1016/S0168-1656(99)00240-0; Teplitsky A, 1999, ACTA CRYSTALLOGR D, V55, P869, DOI 10.1107/S0907444998012918; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P1872, DOI 10.1107/S090744499901029X; Tews I, 1996, NAT STRUCT BIOL, V3, P638, DOI 10.1038/nsb0796-638; UCHIDA H, 1992, BIOSCI BIOTECH BIOCH, V56, P1608, DOI 10.1271/bbb.56.1608; van Santen Y, 1999, J BIOL CHEM, V274, P30474, DOI 10.1074/jbc.274.43.30474; Varrot A, 1999, BIOCHEMISTRY-US, V38, P8884, DOI 10.1021/bi9903998; Varrot A, 2003, CHEM COMMUN, P946, DOI 10.1039/b301592k; Vasella A, 2002, CURR OPIN CHEM BIOL, V6, P619, DOI 10.1016/S1367-5931(02)00380-0; Wicki J, 2002, METHOD ENZYMOL, V354, P84; Wolfenden R, 1998, J AM CHEM SOC, V120, P6814, DOI 10.1021/ja9813055; WOOD TM, 1995, APPL MICROBIOL BIOT, V43, P893, DOI [10.1007/BF02431925, 10.1007/s002530050502]; Zaide G, 2001, EUR J BIOCHEM, V268, P3006, DOI 10.1046/j.1432-1327.2001.02193.x; Zechel DL, 2000, ACCOUNTS CHEM RES, V33, P11, DOI 10.1021/ar970172+	61	55	58	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	2004	279	4					3014	3024		10.1074/jbc.M310098200	http://dx.doi.org/10.1074/jbc.M310098200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	764MU	14573597	hybrid			2022-12-27	WOS:000188211300082
J	Pang, SS; Duggleby, RG; Schowen, RL; Guddat, LW				Pang, SS; Duggleby, RG; Schowen, RL; Guddat, LW			The crystal structures of Klebsiella pneumoniae acetolactate synthase with enzyme-bound cofactor and with an unusual intermediate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; DIPHOSPHATE-DEPENDENT ENZYME; MOBILIS PYRUVATE DECARBOXYLASE; ACETOHYDROXY ACID SYNTHASE; THIAMIN DIPHOSPHATE; AEROBACTER-AEROGENES; ZYMOMONAS-MOBILIS; ESCHERICHIA-COLI; FORMING ENZYME; ANGSTROM RESOLUTION	Acetohydroxyacid synthase (AHAS) and acetolactate synthase (ALS) are thiamine diphosphate (ThDP)-dependent enzymes that catalyze the decarboxylation of pyruvate to give a cofactor-bound hydroxyethyl group, which is transferred to a second molecule of pyruvate to give 2-acetolactate. AHAS is found in plants, fungi, and bacteria, is involved in the biosynthesis of the branched-chain amino acids, and contains non-catalytic FAD. ALS is found only in some bacteria, is a catabolic enzyme required for the butanediol fermentation, and does not contain FAD. Here we report the 2.3-Angstrom crystal structure of Klebsiella pneumoniae ALS. The overall structure is similar to AHAS except for a groove that accommodates FAD in AHAS, which is filled with amino acid side chains in ALS. The ThDP cofactor has an unusual conformation that is unprecedented among the 26 known three-dimensional structures of nine ThDP-dependent enzymes, including AHAS. This conformation suggests a novel mechanism for ALS. A second structure, at 2.0 Angstrom, is described in which the enzyme is trapped halfway through the catalytic cycle so that it contains the hydroxyethyl intermediate bound to ThDP. The cofactor has a tricyclic structure that has not been observed previously in any ThDP-dependent enzyme, although similar structures are well known for free thiamine. This structure is consistent with our proposed mechanism and probably results from an intramolecular proton transfer within a tricyclic carbanion that is the true reaction intermediate. Modeling of the second molecule of pyruvate into the active site of the enzyme with the bound intermediate is consistent with the stereochemistry and specificity of ALS.	Univ Queensland, Dept Biochem & Mol Biol, Brisbane, Qld 4072, Australia; Univ Kansas, Dept Chem, Lawrence, KS 66045 USA	University of Queensland; University of Kansas	Duggleby, RG (corresponding author), Univ Queensland, Dept Biochem & Mol Biol, Brisbane, Qld 4072, Australia.	Ronald.Duggleby@mailbox.uq.edu.au	Guddat, Luke/AAI-2930-2021	Guddat, Luke/0000-0002-8204-8408				Arjunan P, 1996, J MOL BIOL, V256, P590, DOI 10.1006/jmbi.1996.0111; Bar-Ilan A, 2001, BIOCHEMISTRY-US, V40, P11946, DOI 10.1021/bi0104524; BARGER G, 1935, CHEM BER, V68, P2257; Bornemann S, 2002, NAT PROD REP, V19, P761, DOI 10.1039/b108916c; Bowen TL, 1997, GENE, V188, P77, DOI 10.1016/S0378-1119(96)00779-2; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Candy JM, 1996, BIOCHEM J, V315, P745, DOI 10.1042/bj3150745; CANDY JM, 1994, BIOCHEM J, V300, P7, DOI 10.1042/bj3000007; Candy JM, 1998, BBA-PROTEIN STRUCT M, V1385, P323, DOI 10.1016/S0167-4838(98)00077-6; Chabriere E, 2001, SCIENCE, V294, P2559, DOI 10.1126/science.1066198; CHANG YY, 1988, J BACTERIOL, V170, P3937, DOI 10.1128/jb.170.9.3937-3945.1988; Dobritzsch D, 1998, J BIOL CHEM, V273, P20196, DOI 10.1074/jbc.273.32.20196; DOUGHTY MB, 1985, J CHEM SOC CHEM COMM, P454, DOI 10.1039/c39850000454; Dreveny I, 2001, STRUCTURE, V9, P803, DOI 10.1016/S0969-2126(01)00639-6; Duggleby RG, 2000, J BIOCHEM MOL BIOL, V33, P1; DYDA F, 1993, BIOCHEMISTRY-US, V32, P6165, DOI 10.1021/bi00075a008; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; Fang R, 1998, FEBS LETT, V437, P273, DOI 10.1016/S0014-5793(98)01249-6; Fiedler E, 2002, P NATL ACAD SCI USA, V99, P591, DOI 10.1073/pnas.022510999; Garcia-Sevilla F, 2000, BIOSYSTEMS, V54, P151, DOI 10.1016/S0303-2647(99)00071-4; GOLLOP N, 1989, BIOCHEMISTRY-US, V28, P6310, DOI 10.1021/bi00441a024; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; Graupner M, 2000, J BACTERIOL, V182, P4862, DOI 10.1128/JB.182.17.4862-4867.2000; Hasson MS, 1998, BIOCHEMISTRY-US, V37, P9918, DOI 10.1021/bi973047e; HAWKINS CF, 1989, FEBS LETT, V255, P77, DOI 10.1016/0014-5793(89)81064-6; Hill CM, 1997, BIOCHEM J, V327, P891, DOI 10.1042/bj3270891; HOLTZCLAW WD, 1975, J BACTERIOL, V121, P917, DOI 10.1128/JB.121.3.917-922.1975; HUSEBY NE, 1971, EUR J BIOCHEM, V20, P209, DOI 10.1111/j.1432-1033.1971.tb01381.x; HUSEBY NE, 1971, EUR J BIOCHEM, V20, P215, DOI 10.1111/j.1432-1033.1971.tb01382.x; Ibdah M, 1996, BIOCHEMISTRY-US, V35, P16282, DOI 10.1021/bi961588i; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kern D, 1997, SCIENCE, V275, P67, DOI 10.1126/science.275.5296.67; KillenbergJabs M, 1997, BIOCHEMISTRY-US, V36, P1900, DOI 10.1021/bi961341l; KLUGER R, 1987, CHEM REV, V87, P863, DOI 10.1021/cr00081a001; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lehtio L, 2002, ACTA CRYSTALLOGR D, V58, P2209, DOI 10.1107/S0907444902016402; LINDQVIST Y, 1992, EMBO J, V11, P2373, DOI 10.1002/j.1460-2075.1992.tb05301.x; MAIER GD, 1957, J AM CHEM SOC, V79, P4386, DOI 10.1021/ja01573a040; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MULLER YA, 1994, J MOL BIOL, V237, P315, DOI 10.1006/jmbi.1994.1233; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NIXON PF, 1992, BIOCHEM PHARMACOL, V44, P177, DOI 10.1016/0006-2952(92)90053-L; Osborne A, 2000, J BIOL CHEM, V275, P35825, DOI 10.1074/jbc.M005796200; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pang SS, 2002, J MOL BIOL, V317, P249, DOI 10.1006/jmbi.2001.5419; Pang SS, 2002, ACTA CRYSTALLOGR D, V58, P1237, DOI 10.1107/S0907444902008132; Pang SS, 2003, J BIOL CHEM, V278, P7639, DOI 10.1074/jbc.M211648200; PENG HL, 1992, GENE, V117, P125, DOI 10.1016/0378-1119(92)90500-O; PLETCHER J, 1972, J AM CHEM SOC, V94, P3998, DOI 10.1021/ja00766a058; Schellenberger A, 1997, METHOD ENZYMOL, V279, P131; Schutz A, 2003, EUR J BIOCHEM, V270, P2312, DOI 10.1046/j.1432-1033.2003.03601.x; STORMER FC, 1968, J BIOL CHEM, V243, P3735; STORMER FC, 1967, J BIOL CHEM, V242, P1756; SYLVESTER SR, 1979, BIOCHEMISTRY-US, V18, P4529, DOI 10.1021/bi00588a011; Tittmann K, 2003, BIOCHEMISTRY-US, V42, P7885, DOI 10.1021/bi034465o; Todd AE, 2002, TRENDS BIOCHEM SCI, V27, P419, DOI 10.1016/S0968-0004(02)02158-8; VARGO D, 1981, J BIOL CHEM, V256, P6027; Wajant H, 1996, BIOL CHEM, V377, P611; WASHABAUGH MW, 1993, BIOORG CHEM, V21, P170, DOI 10.1006/bioo.1993.1016; WIKNER C, 1994, J BIOL CHEM, V269, P32144; Zoltewicz JA, 1997, J ORG CHEM, V62, P6760, DOI 10.1021/jo970782n; ZOLTEWICZ JA, 1994, BIOORG CHEM, V22, P1, DOI 10.1006/bioo.1994.1001	62	65	79	1	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 16	2004	279	3					2242	2253		10.1074/jbc.M304038200	http://dx.doi.org/10.1074/jbc.M304038200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	762WT	14557277	hybrid			2022-12-27	WOS:000188005700081
J	Yanagida, M; Hayano, T; Yamauchi, Y; Shinkawa, T; Natsume, T; Isobe, T; Takahashi, N				Yanagida, M; Hayano, T; Yamauchi, Y; Shinkawa, T; Natsume, T; Isobe, T; Takahashi, N			Human fibrillarin forms a sub-complex with splicing factor 2-associated p32, protein arginine methyltransferases, and tubulins alpha 3 and beta 1 that is independent of its association with preribosomal ribonucleoprotein complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL NUCLEOLAR RNA; RIBOSOMAL-RNA; PROTEOMIC CHARACTERIZATION; MUTATIONAL ANALYSIS; MOLECULAR-CLONING; IN-VITRO; METHYLATION; YEAST; SMN; U3	Fibrillarin (FIB, Nop1p in yeast) is an RNA methyltransferase found not only in the fibrillar region of the nucleolus but also in Cajal bodies. FIB is essential for efficient processing of preribosomal RNA during ribosome biogenesis, although its precise function in this process and its role in Cajal bodies remain uncertain. Here, we demonstrate that the human FIB N-terminal glycine- and arginine-rich domain ( residues 1 - 77) and its spacer region 1 ( 78 - 132) interact with splicing factor 2-associated p32 (SF2A-p32) and that the FIB methyltransferase-like domain ( 133 - 321) interacts with protein-arginine methyltransferase 5 (PRMT5, Janus kinase-binding protein 1). We also show that these proteins associate with several additional proteins, including PRMT1, tubulin alpha3, and tubulin beta1 to form a sub-complex that is principally independent of the association of FIB with preribosomal ribonucleoprotein complexes that co-immunoprecipitate with the sub-complex in human cells expressing FLAG-tagged FIB. Based on the physical association of FIB with SF2A-p32 and PRMTs, as well as the other reported results, we propose that FIB may coordinate both RNA and protein methylation during the processes of ribosome biogenesis in the nucleolus and RNA editing such as small nuclear ( nucleolar) ribonucleoprotein biogenesis in Cajal bodies.	Tokyo Univ Agr & Technol, United Grad Sch Agr, Dept Appl Biol Sci, Fuchu, Tokyo 1838509, Japan; Tokyo Univ Agr & Technol, United Grad Sch Agr, Dept Biotechnol, Fuchu, Tokyo 1838509, Japan; Minist Educ Culture Sports Sci & Technol Japan, Pioneer Res Genome Frontier, Integrated Prote Syst Project, Tokyo, Japan; Tokyo Metropolitan Univ, Grad Sch Sci, Biochem Lab, Tokyo 1920397, Japan; Natl Inst Adv Ind Sci & Technol, Biol Informat Res Ctr, Kohtoh Ku, Tokyo 1350064, Japan	Tokyo University of Agriculture & Technology; Tokyo University of Agriculture & Technology; Tokyo Metropolitan University; National Institute of Advanced Industrial Science & Technology (AIST)	Takahashi, N (corresponding author), Tokyo Univ Agr & Technol, United Grad Sch Agr, Dept Appl Biol Sci, 3-5-8 Saiwai Cho, Fuchu, Tokyo 1838509, Japan.	ntakahas@cc.tuat.ac.jp	Natsume, Tohru/M-7627-2018; Isobe, Toshiaki/Q-9279-2017; TAKAHASHI, Nobuhiro/G-1129-2013	Natsume, Tohru/0000-0002-1510-2582; 				Andersen JS, 2002, CURR BIOL, V12, P1, DOI 10.1016/S0960-9822(01)00650-9; ARIS JP, 1991, P NATL ACAD SCI USA, V88, P931, DOI 10.1073/pnas.88.3.931; BASERGA SJ, 1991, EMBO J, V10, P2645, DOI 10.1002/j.1460-2075.1991.tb07807.x; Boisvert FM, 2002, J CELL BIOL, V159, P957, DOI 10.1083/jcb.200207028; David E, 1997, MOL BIOL CELL, V8, P1051, DOI 10.1091/mbc.8.6.1051; EICHLER DC, 1994, PROG NUCLEIC ACID RE, V49, P197; Friesen WJ, 2001, MOL CELL BIOL, V21, P8289, DOI 10.1128/MCB.21.24.8289-8300.2001; Fujiyama S, 2002, J BIOL CHEM, V277, P23773, DOI 10.1074/jbc.M201181200; Gary JD, 1998, PROG NUCLEIC ACID RE, V61, P65, DOI 10.1016/S0079-6603(08)60825-9; GOLDFARB DS, 1986, NATURE, V322, P641, DOI 10.1038/322641a0; Hayano T, 2003, J BIOL CHEM, V278, P34309, DOI 10.1074/jbc.M304304200; HENRIQUEZ R, 1990, J BIOL CHEM, V265, P2209; HOFER L, 1991, J VIROL, V65, P3379, DOI 10.1128/JVI.65.6.3379-3383.1991; JANSEN RP, 1991, J CELL BIOL, V113, P715, DOI 10.1083/jcb.113.4.715; Jones KW, 2001, J BIOL CHEM, V276, P38645, DOI 10.1074/jbc.M106161200; KissLaszlo Z, 1996, CELL, V85, P1077, DOI 10.1016/S0092-8674(00)81308-2; LAPEYRE B, 1990, MOL CELL BIOL, V10, P430, DOI 10.1128/MCB.10.1.430; LISCHWE MA, 1985, J BIOL CHEM, V260, P14304; LISCHWE MA, 1985, BIOCHEMISTRY-US, V24, P6025, DOI 10.1021/bi00343a001; Natsume T, 2002, ANAL CHEM, V74, P4725, DOI 10.1021/ac020018n; Nicol SM, 2000, EXP CELL RES, V257, P272, DOI 10.1006/excr.2000.4886; Niewmierzycka A, 1999, J BIOL CHEM, V274, P814, DOI 10.1074/jbc.274.2.814; Nissan TA, 2002, EMBO J, V21, P5539, DOI 10.1093/emboj/cdf547; Omer AD, 2002, P NATL ACAD SCI USA, V99, P5289, DOI 10.1073/pnas.082101999; Pellizzoni L, 2002, SCIENCE, V298, P1775, DOI 10.1126/science.1074962; Petersen-Mahrt SK, 1999, EMBO J, V18, P1014, DOI 10.1093/emboj/18.4.1014; Pintard L, 2000, MOL CELL BIOL, V20, P1370, DOI 10.1128/MCB.20.4.1370-1381.2000; Scherl A, 2002, MOL BIOL CELL, V13, P4100, DOI 10.1091/mbc.E02-05-0271; SCHIMMANG T, 1989, EMBO J, V8, P4015, DOI 10.1002/j.1460-2075.1989.tb08584.x; Smith CM, 1997, CELL, V89, P669, DOI 10.1016/S0092-8674(00)80247-0; Snaar S, 2000, J CELL BIOL, V151, P653, DOI 10.1083/jcb.151.3.653; Spector DL, 2001, J CELL SCI, V114, P2891; Takahashi N, 2003, MASS SPECTROM REV, V22, P287, DOI 10.1002/mas.10057; TOLLERVEY D, 1993, CELL, V72, P443, DOI 10.1016/0092-8674(93)90120-F; TURLEY SJ, 1993, BIOCHIM BIOPHYS ACTA, V1216, P119, DOI 10.1016/0167-4781(93)90046-G; TYC K, 1989, EMBO J, V8, P3113, DOI 10.1002/j.1460-2075.1989.tb08463.x; Tycowski KT, 1996, P NATL ACAD SCI USA, V93, P14480, DOI 10.1073/pnas.93.25.14480; Wang HM, 2000, EMBO J, V19, P317, DOI 10.1093/emboj/19.3.317; Warner JR, 1990, CURR OPIN CELL BIOL, V2, P521, DOI 10.1016/0955-0674(90)90137-4; Wehner KA, 2002, BRAIN RES, V945, P160, DOI 10.1016/S0006-8993(02)02750-6; Whitehead SE, 2002, J BIOL CHEM, V277, P48087, DOI 10.1074/jbc.M204551200; Yanagida M, 2001, PROTEOMICS, V1, P1390, DOI 10.1002/1615-9861(200111)1:11<1390::AID-PROT1390>3.0.CO;2-Z	42	57	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 16	2004	279	3					1607	1614		10.1074/jbc.M305604200	http://dx.doi.org/10.1074/jbc.M305604200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	762WT	14583623	hybrid			2022-12-27	WOS:000188005700007
J	Li, KW; Hornshaw, MP; Van der Schors, RC; Watson, R; Tate, S; Casetta, B; Jimenez, CR; Gouwenberg, Y; Gundelfinger, ED; Smalla, KH; Smit, AB				Li, KW; Hornshaw, MP; Van der Schors, RC; Watson, R; Tate, S; Casetta, B; Jimenez, CR; Gouwenberg, Y; Gundelfinger, ED; Smalla, KH; Smit, AB			Proteomics analysis of rat brain postsynaptic density - Implications of the diverse protein functional groups for the integration of synaptic physiology	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; AMPA RECEPTOR TRAFFICKING; DOMAIN-CONTAINING PROTEIN; HEAT-SHOCK PROTEINS; E3 UBIQUITIN LIGASE; DENDRITIC SPINES; ACTIN-FILAMENTS; NMDA RECEPTOR; ELONGATION FACTOR-1-ALPHA; MOLECULAR-ORGANIZATION	The postsynaptic density contains multiple protein complexes that together relay the presynaptic neurotransmitter input to the activation of the postsynaptic neuron. In the present study we took two independent proteome approaches for the characterization of the protein complement of the postsynaptic density, namely 1) two-dimensional gel electrophoresis separation of proteins in conjunction with mass spectrometry to identify the tryptic peptides of the protein spots and 2) isolation of the trypsin-digested sample that was labeled with isotope-coded affinity tag, followed by liquid chromatography-tandem mass spectrometry for the partial separation and identification of the peptides, respectively. Functional grouping of the identified proteins indicates that the postsynaptic density is a structurally and functionally complex organelle that may be involved in a broad range of synaptic activities. These proteins include the receptors and ion channels for glutamate neurotransmission, proteins for maintenance and modulation of synaptic architecture, sorting and trafficking of membrane proteins, generation of anaerobic energy, scaffolding and signaling, local protein synthesis, and correct protein folding and breakdown of synaptic proteins. Together, these results imply that the postsynaptic density may have the ability to function (semi-)autonomously and may direct various cellular functions in order to integrate synaptic physiology.	Vrije Univ Amsterdam, Fac Earth & Life Sci, Neurosci Res Inst, Dept Mol & Cellular Neurobiol, NL-1081 HV Amsterdam, Netherlands; Appl Biosyst Inc, Warrington WA3 7QH, Cheshire, England; Applera Italia, Appl Biosyst, I-20052 Monza, Italy; Leibniz Inst Neurobiol, Dept Neurochem & Mol Biol, D-39118 Magdeburg, Germany; FAN GmbH, D-39120 Magdeburg, Germany	Vrije Universiteit Amsterdam; Thermo Fisher Scientific; Applied Biosystems; Thermo Fisher Scientific; Applied Biosystems; Leibniz Institut fur Neurobiologie (LIN)	Li, KW (corresponding author), Vrije Univ Amsterdam, Fac Earth & Life Sci, Neurosci Res Inst, Dept Mol & Cellular Neurobiol, Boelelaan 1085, NL-1081 HV Amsterdam, Netherlands.		Smit, August B/E-8410-2011; Jimenez, Connie/AAI-3763-2020; Smalla, Dr. Karl-Heinz/C-3950-2012	Smalla, Dr. Karl-Heinz/0000-0002-0269-0311; tate, stephen/0000-0001-5508-0819; li, ka wan/0000-0001-6983-5055; Jimenez, Connie R/0000-0002-3103-4508				Allison DW, 2000, J NEUROSCI, V20, P4545, DOI 10.1523/JNEUROSCI.20-12-04545.2000; Ames A, 2000, BRAIN RES REV, V34, P42, DOI 10.1016/S0165-0173(00)00038-2; Bader GD, 2002, NAT BIOTECHNOL, V20, P991, DOI 10.1038/nbt1002-991; Ballinger CA, 1999, MOL CELL BIOL, V19, P4535; BENFENATI F, 1992, NATURE, V359, P417, DOI 10.1038/359417a0; Blanpied TA, 2002, NEURON, V36, P435, DOI 10.1016/S0896-6273(02)00979-0; Bockmann J, 2002, J NEUROCHEM, V83, P1013, DOI 10.1046/j.1471-4159.2002.01204.x; Burbea M, 2002, NEURON, V35, P107, DOI 10.1016/S0896-6273(02)00749-3; Burette A, 2002, J NEUROSCI, V22, P8961; CARLIN RK, 1980, J CELL BIOL, V86, P831, DOI 10.1083/jcb.86.3.831; Chang JS, 2002, J BIOL CHEM, V277, P19697, DOI 10.1074/jbc.M111206200; CHAPMAN AP, 1994, NEUROSCI LETT, V168, P238, DOI 10.1016/0304-3940(94)90459-6; Chew CS, 2000, J CELL SCI, V113, P2035; Chin LS, 2002, J BIOL CHEM, V277, P35071, DOI 10.1074/jbc.M203300200; Cooper JA, 2000, CURR OPIN CELL BIOL, V12, P97, DOI 10.1016/S0955-0674(99)00062-9; Costa RM, 2001, NAT GENET, V27, P399, DOI 10.1038/86898; Cronshaw JA, 2002, J CELL BIOL, V158, P915, DOI 10.1083/jcb.200206106; DAVIS JQ, 1994, J BIOL CHEM, V269, P27163; De Vries L, 1998, P NATL ACAD SCI USA, V95, P12340, DOI 10.1073/pnas.95.21.12340; Deneka M, 2002, NAT CELL BIOL, V4, pE33, DOI 10.1038/ncb0202-e33; Di Cunto F, 2003, BRAIN RES BULL, V60, P319, DOI 10.1016/S0361-9230(03)00058-3; Dityatev A, 2003, NAT REV NEUROSCI, V4, P456, DOI 10.1038/nrn1115; Dresbach T, 2001, CELL MOL LIFE SCI, V58, P94, DOI 10.1007/PL00000781; Ehlers MD, 2003, NAT NEUROSCI, V6, P231, DOI 10.1038/nn1013; El-Husseini AE, 2002, CELL, V108, P849, DOI 10.1016/S0092-8674(02)00683-9; Garner CC, 2000, TRENDS CELL BIOL, V10, P274, DOI 10.1016/S0962-8924(00)01783-9; Gerke V, 2002, PHYSIOL REV, V82, P331, DOI 10.1152/physrev.00030.2001; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Goda Y, 2002, NEURON, V35, P1, DOI 10.1016/S0896-6273(02)00765-1; Griffin TJ, 2001, ANAL CHEM, V73, P978, DOI 10.1021/ac001169y; Gygi SP, 1999, NAT BIOTECHNOL, V17, P994, DOI 10.1038/13690; Halpain S, 1998, J NEUROSCI, V18, P9835; Hansen KC, 2003, MOL CELL PROTEOMICS, V2, P299, DOI 10.1074/mcp.M300021-MCP200; Hsieh JC, 1999, NATURE, V398, P431, DOI 10.1038/18899; Huang YS, 2002, EMBO J, V21, P2139, DOI 10.1093/emboj/21.9.2139; Huntley GW, 2002, CELL, V108, P1, DOI 10.1016/S0092-8674(01)00631-6; Husi H, 2000, NAT NEUROSCI, V3, P661, DOI 10.1038/76615; HUSI H, 2002, FENS FOR 2002 PAR; Ishimoto T, 2002, BBA-GENE STRUCT EXPR, V1579, P189, DOI 10.1016/S0167-4781(02)00538-9; Janmey PA, 1998, PHYSIOL REV, V78, P763, DOI 10.1152/physrev.1998.78.3.763; Jiang JH, 2001, J BIOL CHEM, V276, P42938, DOI 10.1074/jbc.M101968200; Jimenez CR, 2002, J NEUROCHEM, V81, P735, DOI 10.1046/j.1471-4159.2002.00873.x; Jordan JD, 2000, CELL, V103, P193, DOI 10.1016/S0092-8674(00)00112-4; Kaech S, 2001, P NATL ACAD SCI USA, V98, P7086, DOI 10.1073/pnas.111146798; KAUR KJ, 1994, J BIOL CHEM, V269, P23045; Kennedy MB, 2000, SCIENCE, V290, P750, DOI 10.1126/science.290.5492.750; Kessels MM, 2002, EMBO J, V21, P6083, DOI 10.1093/emboj/cdf604; Kim JH, 2003, J NEUROSCI, V23, P1119; Kinoshita M, 2002, DEV CELL, V3, P791, DOI 10.1016/S1534-5807(02)00366-0; Koller A, 2002, P NATL ACAD SCI USA, V99, P11969, DOI 10.1073/pnas.172183199; Komiyama NH, 2002, J NEUROSCI, V22, P9721; Langnaese K, 1996, MOL BRAIN RES, V42, P118, DOI 10.1016/S0169-328X(96)00147-7; Lee HK, 2002, J NEUROCHEM, V81, P1338, DOI 10.1046/j.1471-4159.2002.00937.x; Lee SH, 2002, NEURON, V36, P661, DOI 10.1016/S0896-6273(02)01024-3; Lei SB, 2001, J NEUROSCI, V21, P8464, DOI 10.1523/JNEUROSCI.21-21-08464.2001; Lim IA, 2002, J BIOL CHEM, V277, P21697, DOI 10.1074/jbc.M112339200; Lippe R, 2001, MOL BIOL CELL, V12, P2219, DOI 10.1091/mbc.12.7.2219; Lisman JE, 2001, NEURON, V31, P191, DOI 10.1016/S0896-6273(01)00364-6; Llorca O, 2001, EMBO J, V20, P4065, DOI 10.1093/emboj/20.15.4065; Malinow R, 2002, ANNU REV NEUROSCI, V25, P103, DOI 10.1146/annurev.neuro.25.112701.142758; Matus A, 2000, SCIENCE, V290, P754, DOI 10.1126/science.290.5492.754; McClatchy DB, 2002, J BIOL CHEM, V277, P29268, DOI 10.1074/jbc.M203081200; McGee AW, 2003, CURR OPIN NEUROBIOL, V13, P111, DOI 10.1016/S0959-4388(03)00008-4; Miller S, 2002, NEURON, V36, P507, DOI 10.1016/S0896-6273(02)00978-9; Murphey RK, 2002, NEURON, V36, P5, DOI 10.1016/S0896-6273(02)00943-1; Nagle GT, 2001, EUR J BIOCHEM, V268, P1213, DOI 10.1046/j.1432-1327.2001.01972.x; Nimchinsky EA, 2002, ANNU REV PHYSIOL, V64, P313, DOI 10.1146/annurev.physiol.64.081501.160008; Ostroff LE, 2002, NEURON, V35, P535, DOI 10.1016/S0896-6273(02)00785-7; Packard M, 2002, CELL, V111, P319, DOI 10.1016/S0092-8674(02)01047-4; Pomies P, 1997, J CELL BIOL, V139, P157, DOI 10.1083/jcb.139.1.157; Sheng M, 2001, P NATL ACAD SCI USA, V98, P7058, DOI 10.1073/pnas.111146298; Soderling TR, 2000, TRENDS NEUROSCI, V23, P75, DOI 10.1016/S0166-2236(99)01490-3; Spacek J, 1997, J NEUROSCI, V17, P190, DOI 10.1523/JNEUROSCI.17-01-00190.1997; Star EN, 2002, NAT NEUROSCI, V5, P239, DOI 10.1038/nn811; Suzuki T, 1999, BRAIN RES, V816, P99, DOI 10.1016/S0006-8993(98)01083-X; Suzuki T, 1997, NEUROREPORT, V8, P2931, DOI 10.1097/00001756-199709080-00025; Takahashi H, 2003, J NEUROSCI, V23, P6586; Takayama S, 1999, J BIOL CHEM, V274, P781, DOI 10.1074/jbc.274.2.781; Takenawa T, 2001, J CELL SCI, V114, P1801; Tao WA, 2003, CURR OPIN BIOTECH, V14, P110, DOI 10.1016/S0958-1669(02)00018-6; Terry-Lorenzo RT, 2002, J BIOL CHEM, V277, P27716, DOI 10.1074/jbc.M203365200; Walikonis RS, 2000, J NEUROSCI, V20, P4069; WALSH MJ, 1992, J NEUROCHEM, V59, P667, DOI 10.1111/j.1471-4159.1992.tb09421.x; Weber A, 1999, J BIOL CHEM, V274, P34637, DOI 10.1074/jbc.274.49.34637; Worby CA, 2002, NAT REV MOL CELL BIO, V3, P919, DOI 10.1038/nrm974; WU K, 1986, J NEUROCHEM, V46, P831, DOI 10.1111/j.1471-4159.1986.tb13047.x; Wu K, 1997, P NATL ACAD SCI USA, V94, P13273, DOI 10.1073/pnas.94.24.13273; Wyneken U, 2001, NEUROSCIENCE, V102, P65, DOI 10.1016/S0306-4522(00)00469-3; Xiao B, 2000, CURR OPIN NEUROBIOL, V10, P370, DOI 10.1016/S0959-4388(00)00087-8; Xu WP, 2002, P NATL ACAD SCI USA, V99, P12847, DOI 10.1073/pnas.202365899; Yuasa K, 2001, EUR J BIOCHEM, V268, P4440, DOI 10.1046/j.1432-1327.2001.02366.x; Yunoue S, 2003, J BIOL CHEM, V278, P26958, DOI 10.1074/jbc.M209413200; Yuste R, 2001, ANNU REV NEUROSCI, V24, P1071, DOI 10.1146/annurev.neuro.24.1.1071; Zhang WD, 1999, J NEUROSCI, V19, P96, DOI 10.1523/JNEUROSCI.19-01-00096.1999; Zhang WD, 2000, HIPPOCAMPUS, V10, P512, DOI 10.1002/1098-1063(2000)10:5<512::AID-HIPO2>3.0.CO;2-M; Zhou ZL, 2002, NATURE, V419, P182, DOI 10.1038/nature01031; Ziff EB, 1997, NEURON, V19, P1163, DOI 10.1016/S0896-6273(00)80409-2	97	213	225	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 9	2004	279	2					987	1002		10.1074/jbc.M303116200	http://dx.doi.org/10.1074/jbc.M303116200			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	759DJ	14532281	hybrid, Green Published			2022-12-27	WOS:000187722800022
J	Meehan, WJ; Samant, RS; Hopper, JE; Carrozza, MJ; Shevde, LA; Workman, JL; Eckert, KA; Verderame, MF; Welch, DR				Meehan, WJ; Samant, RS; Hopper, JE; Carrozza, MJ; Shevde, LA; Workman, JL; Eckert, KA; Verderame, MF; Welch, DR			Breast cancer metastasis suppressor 1 (BRMS1) forms complexes with retinoblastoma-binding protein 1 (RBP1) and the mSin3 histone deacetylase complex and represses transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE MAMMARY-TUMOR; N-COR; EPIGENETIC REGULATION; COREPRESSOR COMPLEX; INTEGRAL COMPONENT; GENE; INHIBITORS; CELLS; YEAST; MTA1	Breast cancer metastasis suppressor 1 (BRMS1) suppresses metastasis of multiple human and murine cancer cells without inhibiting tumorigenicity. By yeast two-hybrid and co-immunoprecipitation, BRMS1 interacts with retinoblastoma binding protein 1 and at least seven members of the mSin3 histone deacetylase (HDAC) complex in human breast and melanoma cell lines. BRMS1 co-immunoprecipitates enzymatically active HDAC proteins and represses transcription when recruited to a Gal4 promoter in vivo. BRMS1 exists in large mSin3 complex(es) of similar to1.4-1.9 MDa, but also forms smaller complexes with HDAC1. Deletion analyses show that the carboxyl-terminal 42 amino acids of BRMS1 are not critical for interaction with much of the mSin3 complex and that BRMS1 appears to have more than one binding point to the complex. These results further show that BRMS1 may participate in transcriptional regulation via interaction with the mSin3.HDAC complex and suggest a novel mechanism by which BRMS1 might suppress cancer metastasis.	Penn State Univ, Coll Med, Dept Pathol, Jake Gittlen Canc Res Inst, Hershey, PA 17033 USA; Penn State Univ, Coll Med, Dept Biochem, Hershey, PA 17033 USA; Penn State Univ, Coll Med, Dept Med, Hershey, PA 17033 USA; Stowers Inst Med Res, Kansas City, MO 64110 USA; Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Natl Fdn Canc Res, Ctr Metastasis Res, Birmingham, AL 35294 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Stowers Institute for Medical Research; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Welch, DR (corresponding author), Univ Alabama Birmingham, Dept Pathol, 1670 Univ Blvd,Volker Hall G-038, Birmingham, AL 35294 USA.	dwelch@path.uab.edu	Welch, Danny R/B-7310-2009	Welch, Danny R/0000-0002-1951-4947; , William/0000-0003-2481-8985; Verderame, Michael F./0000-0001-7046-0879	NCI NIH HHS [R01-CA88728, P50-CA89019] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA089019] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahringer J, 2000, TRENDS GENET, V16, P351, DOI 10.1016/S0168-9525(00)02066-7; Alland L, 2002, MOL CELL BIOL, V22, P2743, DOI 10.1128/MCB.22.8.2743-2750.2002; Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; ASLAKSON CJ, 1992, CANCER RES, V52, P1399; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; Berger SL, 2002, CURR OPIN GENET DEV, V12, P142, DOI 10.1016/S0959-437X(02)00279-4; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321; FATTAEY AR, 1993, ONCOGENE, V8, P3149; Fu TM, 1996, VIROLOGY, V222, P269, DOI 10.1006/viro.1996.0419; Hartsough MT, 2001, CANCER RES, V61, P2320; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; Hunter KW, 2001, CANCER RES, V61, P8866; Johnstone RW, 2002, NAT REV DRUG DISCOV, V1, P287, DOI 10.1038/nrd772; Kelly WK, 2002, EXPERT OPIN INV DRUG, V11, P1695, DOI 10.1517/13543784.11.12.1695; KIERSTEAD TD, 1993, J VIROL, V67, P1817, DOI 10.1128/JVI.67.4.1817-1829.1993; Knoepfler PS, 1999, CELL, V99, P447, DOI 10.1016/S0092-8674(00)81531-7; Kolle D, 1998, METHODS, V15, P323, DOI 10.1006/meth.1998.0636; Kumar R, 2002, NATURE, V418, P654, DOI 10.1038/nature00889; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Laherty CD, 1998, MOL CELL, V2, P33, DOI 10.1016/S1097-2765(00)80111-2; Lai A, 2001, MOL CELL BIOL, V21, P2918, DOI 10.1128/MCB.21.8.2918-2932.2001; Laj A, 1999, MOL CELL BIOL, V19, P6632; Lechner T, 2000, J BIOL CHEM, V275, P40961, DOI 10.1074/jbc.M005730200; Li JW, 2002, GENE DEV, V16, P687, DOI 10.1101/gad.962502; Li YH, 2002, P NATL ACAD SCI USA, V99, P16462, DOI 10.1073/pnas.162371699; LIOTTA LA, 1993, CANC PRINCIPLES PRAC, P134; Marks PA, 2001, NAT REV CANCER, V1, P194, DOI 10.1038/35106079; MILLER BE, 1980, CANCER RES, V40, P3977; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Ng HH, 2000, TRENDS BIOCHEM SCI, V25, P121; Nicolson GL, 2003, CLIN EXP METASTAS, V20, P19, DOI 10.1023/A:1022534217769; Paget S, 1989, LANCET, V8, P98, DOI [DOI 10.1016/S0140-6736(00)49915-0, 10.1016/S0140-6736(00)49915-0]; Samant RS, 2002, INT J CANCER, V97, P15, DOI 10.1002/ijc.1569; Samant RS, 2001, CLIN EXP METASTAS, V18, P683, DOI 10.1023/A:1013124725690; Saunders MM, 2001, CANCER RES, V61, P1765; Sekita N, 2001, JPN J CANCER RES, V92, P947, DOI 10.1111/j.1349-7006.2001.tb01185.x; Seraj MJ, 2000, CANCER RES, V60, P2764; Shevde LA, 2003, CANCER LETT, V198, P1, DOI 10.1016/S0304-3835(03)00304-5; Shevde LA, 2002, EXP CELL RES, V273, P229, DOI 10.1006/excr.2001.5452; Steeg PS, 2003, NAT REV CANCER, V3, P55, DOI 10.1038/nrc967; TOH Y, 1994, J BIOL CHEM, V269, P22958; TRAINER DL, 1988, CLIN EXP METASTAS, V6, P185, DOI 10.1007/BF01782479; VAN AL, 1993, P NATL ACAD SCI USA, V90, P6213; Vigushin DM, 2002, ANTI-CANCER DRUG, V13, P1, DOI 10.1097/00001813-200201000-00001; Welch DR, 1998, ENDOCR-RELAT CANCER, V5, P155, DOI 10.1677/erc.0.0050155; WELCH DR, 1994, ONCOGENE, V9, P255; Xue YT, 1998, MOL CELL, V2, P851, DOI 10.1016/S1097-2765(00)80299-3; Yoshida BA, 2000, JNCI-J NATL CANCER I, V92, P1717, DOI 10.1093/jnci/92.21.1717; Zhang Y, 1997, CELL, V89, P357, DOI 10.1016/S0092-8674(00)80216-0; Zhang Y, 1998, MOL CELL, V1, P1021, DOI 10.1016/S1097-2765(00)80102-1	54	138	151	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 9	2004	279	2					1562	1569		10.1074/jbc.M307969200	http://dx.doi.org/10.1074/jbc.M307969200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	759DJ	14581478	hybrid			2022-12-27	WOS:000187722800089
J	Qin, LY; Liu, YX; Wang, TG; Wei, SJ; Block, ML; Wilson, B; Liu, B; Hong, JS				Qin, LY; Liu, YX; Wang, TG; Wei, SJ; Block, ML; Wilson, B; Liu, B; Hong, JS			NADPH oxidase mediates lipopolysaccharide-induced neurotoxicity and proinflammatory gene expression in activated microglia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; NITRIC-OXIDE; RESPIRATORY BURST; DOPAMINERGIC NEUROTOXICITY; MESENCEPHALIC NEURONS; SIGNAL-TRANSDUCTION; ALZHEIMERS-DISEASE; TETRAZOLIUM SALT; PARKINSONS; DEGENERATION	Parkinson's disease is characterized by the progressive degeneration of dopaminergic neurons in the substantia nigra. We have previously reported that lipopolysaccharide (LPS)-induced degeneration of dopaminergic neurons is mediated by the release of proinflammatory factors from activated microglia. Here, we report the pivotal role of NADPH oxidase in inflammation-mediated neurotoxicity, where the LPS-induced loss of nigral dopaminergic neurons in vivo was significantly less pronounced in NADPH oxidase-deficient ( PHOX-/-) mice when compared with control (PHOX+/+) mice. Dopaminergic neurons in primary mensencephalic neuron-glia cultures from PHOX+/+ mice were significantly more sensitive to LPS- induced neurotoxicity in vitro when compared with PHOX-/- mice. Further, PHOX+/+ neuron-glia cultures chemically depleted of microglia failed to show dopaminergic neurotoxicity with the addition of LPS. Neuron-enriched cultures from both PHOX+/+ mice and PHOX-/- mice also failed to show any direct LPS- induced dopaminergic neurotoxicity. However, the addition of PHOX+/+ microglia to neuron-enriched cultures from either strain resulted in reinstatement of LPS- induced dopaminergic neurotoxicity, supporting the role of microglia as the primary source of NADPH oxidase-generated insult and neurotoxicity. Immunostaining for F4/80 in mensencephalic neuron-glia cultures revealed that PHOX-/- microglia failed to show activated morphology at 10 h, suggesting an important role of reactive oxygen species (ROS) generated from NADPH oxidase in the early activation of microglia. LPS also failed to elicit extracellular superoxide and produced low levels of intracellular ROS in microglia-enriched cultures from PHOX-/- mice. Gene expression and release of tumor necrosis factor alpha was much lower in PHOX-/- mice than in control PHOX-/- mice. Together, these results demonstrate the dual neurotoxic functions of microglial NADPH oxidase: 1) the production of extracellular ROS that is toxic to dopamine neurons and 2) the amplification of proinflammatory gene expression and associated neurotoxicity.	NIEHS, Neuropharmacol Sect, Lab Pharmacol & Chem, Res Triangle Pk, NC 27709 USA; NIEHS, Natl Ctr Toxicogenom, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Qin, LY (corresponding author), NIEHS, Neuropharmacol Sect, Lab Pharmacol & Chem, MD F1-01,POB 12233, Res Triangle Pk, NC 27709 USA.	Hong3@niehs.nih.gov	liu, Bin/A-7695-2009; Hong, Jau-shyong/F-1920-2019	Hong, Jau-shyong/0000-0002-3056-8401; Block, Michelle/0000-0001-8303-7914; Wei, Sung Jen/0000-0002-9810-9041				Aloisi F, 1999, ADV EXP MED BIOL, V468, P123; Bhat NR, 1998, J NEUROSCI, V18, P1633; BOJE KM, 1992, BRAIN RES, V587, P250, DOI 10.1016/0006-8993(92)91004-X; BOULET I, 1992, ONCOGENE, V7, P703; CHAO CC, 1995, CRIT REV NEUROBIOL, V9, P189; Chen CC, 1998, J BIOL CHEM, V273, P19424, DOI 10.1074/jbc.273.31.19424; Cicchetti F, 2002, EUR J NEUROSCI, V15, P991, DOI 10.1046/j.1460-9568.2002.01938.x; Combs CK, 2000, J NEUROSCI, V20, P558, DOI 10.1523/JNEUROSCI.20-02-00558.2000; Combs CK, 1999, J NEUROSCI, V19, P928; DICKSON DW, 1993, GLIA, V7, P75, DOI 10.1002/glia.440070113; Forman HJ, 2002, AM J RESP CRIT CARE, V166, pS4, DOI 10.1164/rccm.2206007; Franklin K. B., 1997, MOUSE BRAIN STEREOTA; Gao HM, 2003, FASEB J, V17, DOI 10.1096/fj.03-0109fje; Gao HM, 2003, J NEUROSCI, V23, P6181; Gao HM, 2003, J NEUROSCI, V23, P1228, DOI 10.1523/JNEUROSCI.23-04-01228.2003; Gao HM, 2002, J NEUROCHEM, V81, P1285, DOI 10.1046/j.1471-4159.2002.00928.x; GLASS GA, 1986, J BIOL CHEM, V261, P3247; GOLDMAN R, 1992, FEBS LETT, V309, P190, DOI 10.1016/0014-5793(92)81092-Z; Green SP, 2001, J CEREBR BLOOD F MET, V21, P374, DOI 10.1097/00004647-200104000-00006; Guyton KZ, 1996, CANCER RES, V56, P3480; Hsu HY, 2002, J BIOL CHEM, V277, P22131, DOI 10.1074/jbc.M111883200; Iravani MM, 2002, NEUROSCIENCE, V110, P49, DOI 10.1016/S0306-4522(01)00562-0; Jeohn GH, 2002, ANN NY ACAD SCI, V962, P347, DOI 10.1111/j.1749-6632.2002.tb04079.x; Kang JH, 2001, NEUROREPORT, V12, P1449, DOI 10.1097/00001756-200105250-00030; Kim WG, 2000, J NEUROSCI, V20, P6309, DOI 10.1523/JNEUROSCI.20-16-06309.2000; Konishi H, 1997, P NATL ACAD SCI USA, V94, P11233, DOI 10.1073/pnas.94.21.11233; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Li YB, 1998, BIOCHEM BIOPH RES CO, V253, P295, DOI 10.1006/bbrc.1998.9729; LIPTON SA, 1994, DEV NEUROSCI-BASEL, V16, P145, DOI 10.1159/000112101; Liu B, 2000, NEUROSCIENCE, V97, P749, DOI 10.1016/S0306-4522(00)00057-9; Liu B, 2003, METH MOLEC MED, V79, P387; Liu B, 2003, J PHARMACOL EXP THER, V304, P1, DOI 10.1124/jpet.102.035048; Liu B, 2002, ANN NY ACAD SCI, V962, P318, DOI 10.1111/j.1749-6632.2002.tb04077.x; Liu B, 2001, J NEUROCHEM, V77, P182, DOI 10.1046/j.1471-4159.2001.t01-1-00216.x; LOEFFLER DA, 1994, CLIN NEUROPHARMACOL, V17, P370, DOI 10.1097/00002826-199408000-00009; McDonald DR, 1997, J NEUROSCI, V17, P2284; MCGEER PL, 1988, NEUROLOGY, V38, P1285, DOI 10.1212/WNL.38.8.1285; MEDA L, 1995, NATURE, V374, P647, DOI 10.1038/374647a0; Peskin AV, 2000, CLIN CHIM ACTA, V293, P157, DOI 10.1016/S0009-8981(99)00246-6; Qin LY, 2002, J NEUROCHEM, V83, P973, DOI 10.1046/j.1471-4159.2002.01210.x; Sanlioglu S, 2001, J BIOL CHEM, V276, P30188, DOI 10.1074/jbc.M102061200; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; Schumann RR, 1998, GLIA, V22, P295, DOI 10.1002/(SICI)1098-1136(199803)22:3<295::AID-GLIA8>3.0.CO;2-4; SHERMAN MP, 1992, MED HYPOTHESES, V39, P143, DOI 10.1016/0306-9877(92)90175-C; Sriram K, 2002, FASEB J, V16, P1474, DOI 10.1096/fj.02-0216fje; Tan AS, 2000, J IMMUNOL METHODS, V238, P59, DOI 10.1016/S0022-1759(00)00156-3; Ueda S, 2002, ANTIOXID REDOX SIGN, V4, P405, DOI 10.1089/15230860260196209; Walker NJ, 2001, J BIOCHEM MOL TOXIC, V15, P121, DOI 10.1002/jbt.8; Wu DC, 2003, P NATL ACAD SCI USA, V100, P6145, DOI 10.1073/pnas.0937239100; YOUDIM MBH, 1994, ANN NY ACAD SCI, V738, P64	50	475	495	1	33	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 9	2004	279	2					1415	1421		10.1074/jbc.M307657200	http://dx.doi.org/10.1074/jbc.M307657200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	759DJ	14578353	hybrid			2022-12-27	WOS:000187722800071
J	Campbell, JD; Koike, K; Moreau, C; Sansom, MSP; Deeley, RG; Cole, SPC				Campbell, JD; Koike, K; Moreau, C; Sansom, MSP; Deeley, RG; Cole, SPC			Molecular modeling correctly predicts the functional importance of Phe(594) in transmembrane Helix 11 of the multidrug resistance protein, MRP1 (ABCC1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING DOMAINS; HUMAN P-GLYCOPROTEIN; ATP-BINDING; CLOSED CONFORMATION; ELECTRON-MICROSCOPY; ESCHERICHIA-COLI; TRANSPORTER; TRYPTOPHAN; MSBA; MRP1/ABCC1	The human ATP-binding cassette (ABC) transporter, multidrug resistance protein 1 (MRP1/ABCC1), confers resistance to a broad range of anti-cancer agents and transports a variety of organic anions. At present, essentially no structural data exists for MRP1 that might be used to elucidate its mechanism of transport. Consequently, we have applied a modeling strategy incorporating crystal and indirect structural data from other ABC transporters to construct a model of the transmembrane domains of the core region of MRP1 that includes the amino acid side chains. Three conserved Trp residues and one non-conserved Tyr residue, shown previously to be of functional importance ( Koike, K., Oleschuk, C. J., Haimeur, A., Olsen, S. L., Deeley, R. G., and Cole, S. P. C. ( 2002) J. Biol. Chem. 277, 49495 - 49503), were found to line the "pore" in our model proximal to the membrane cytosol interface. A fifth aromatic residue (Phe(594)) was identified that, with the Trp and Tyr residues, completed a ring or "basket" of aromatic amino acids and, accordingly, we postulated that it would also be of functional importance. To test this idea, MRP1-Phe(594) mutants were expressed in human embryonic kidney cells, and their properties were examined using membrane vesicles. Substitution of Phe594 with Ala substantially reduced or eliminated the transport of five organic anion substrates by MRP1 and abrogated the binding of leukotriene C-4. On the other hand, the conservatively substituted F594W and F594Y mutants remained transport competent, although significant substrate- and substitution-specific changes were observed. These studies provide some structural insight into a possible substrate binding/transport site of MRP1 at the beginning of a putative substrate translocation pathway and demonstrate the usefulness of modeling for directing structure-function analyses of this transporter.	Univ Oxford, Dept Biochem, Lab Mol Biophys, Oxford OX1 3QU, England	University of Oxford	Cole, SPC (corresponding author), Queens Univ, Canc Res Labs, 3rd Floor,Botterell Hall, Kingston, ON K7L 3N6, Canada.	coles@post.queensu.ca	Deeley, Roger/J-4828-2012; MOREAU, Christophe/AAC-7912-2020; Cole, Susan P.C./I-6389-2017; MOREAU, Christophe J/D-3736-2009	MOREAU, Christophe/0000-0002-5463-9593; Cole, Susan P.C./0000-0001-6571-6884; MOREAU, Christophe J/0000-0002-5463-9593	Biotechnology and Biological Sciences Research Council [BEP17032, BBS/B/16011, B19456] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bakos E, 1998, J BIOL CHEM, V273, P32167, DOI 10.1074/jbc.273.48.32167; Chang G, 2001, SCIENCE, V293, P1793, DOI 10.1126/science.293.5536.1793; Chang G, 2003, J MOL BIOL, V330, P419, DOI 10.1016/S0022-2836(03)00587-4; CHAY TR, 1983, BIOPHYS J, V42, P181, DOI 10.1016/S0006-3495(83)84384-7; Cserzo M, 1997, PROTEIN ENG, V10, P673, DOI 10.1093/protein/10.6.673; Fetsch EE, 2002, P NATL ACAD SCI USA, V99, P9685, DOI 10.1073/pnas.152204499; Gao M, 2000, J BIOL CHEM, V275, P13098, DOI 10.1074/jbc.275.17.13098; Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706; Hipfner DR, 1996, CANCER RES, V56, P3307; Hofmann K., 1993, BIOL CHEM H-S, V374, P166, DOI DOI 10.1515/BCHM3.1993.374.1-6.143; Hou YX, 2002, J BIOL CHEM, V277, P5110, DOI 10.1074/jbc.M107133200; Ito K, 2001, J BIOL CHEM, V276, P15616, DOI 10.1074/jbc.M011246200; Koike K, 2002, J BIOL CHEM, V277, P49495, DOI 10.1074/jbc.M206896200; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lee JY, 2002, J BIOL CHEM, V277, P40125, DOI 10.1074/jbc.M206871200; Leslie EM, 2001, TOXICOLOGY, V167, P3, DOI 10.1016/S0300-483X(01)00454-1; Leslie EM, 2003, DRUG METAB DISPOS, V31, P11, DOI 10.1124/dmd.31.1.11; Lindahl E, 2001, J MOL MODEL, V7, P306, DOI 10.1007/s008940100045; Locher KP, 2002, SCIENCE, V296, P1091, DOI 10.1126/science.1071142; Loe DW, 1996, J BIOL CHEM, V271, P9675, DOI 10.1074/jbc.271.16.9675; Loo TW, 2000, J BIOL CHEM, V275, P5253, DOI 10.1074/jbc.275.8.5253; Loo TW, 2002, J BIOL CHEM, V277, P41303, DOI 10.1074/jbc.C200484200; Loo TW, 2001, J BIOL CHEM, V276, P36877, DOI 10.1074/jbc.C100467200; Qu Q, 2001, BIOCHEMISTRY-US, V40, P1413, DOI 10.1021/bi002035h; Rosenberg MF, 2003, J BIOL CHEM, V278, P8294, DOI 10.1074/jbc.M211758200; Rosenberg MF, 2001, EMBO J, V20, P5615, DOI 10.1093/emboj/20.20.5615; Rosenberg MF, 2001, J BIOL CHEM, V276, P16076, DOI 10.1074/jbc.M100176200; Rosenberg MF, 1997, J BIOL CHEM, V272, P10685; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Seigneuret M, 2003, J BIOL CHEM, V278, P30115, DOI 10.1074/jbc.M302443200; Senior AE, 1998, BIOCHEMISTRY-US, V37, P831, DOI 10.1021/bi9719962; Smith PC, 2002, MOL CELL, V10, P139, DOI 10.1016/S1097-2765(02)00576-2; Stenham DR, 2003, FASEB J, V17, P2287, DOI 10.1096/fj.03-0107fje; Tang YJ, 2002, J BIOL CHEM, V277, P39880, DOI 10.1074/jbc.M206582200; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tusnady GE, 2001, BIOINFORMATICS, V17, P849, DOI 10.1093/bioinformatics/17.9.849; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; Zhang DW, 2001, J BIOL CHEM, V276, P13231, DOI 10.1074/jbc.M010008200	39	68	68	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	2004	279	1					463	468		10.1074/jbc.M310711200	http://dx.doi.org/10.1074/jbc.M310711200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	757GU	14561746	hybrid			2022-12-27	WOS:000187555300056
J	Ohuchi, SJ; Ikawa, Y; Shiraishi, H; Inoue, T				Ohuchi, SJ; Ikawa, Y; Shiraishi, H; Inoue, T			Artificial modules for enhancing rate constants of a group I intron ribozyme without a P4-P6 core element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPLICE-SITE; PHOSPHOROTHIOATE; CATALYSIS; VITRO	In this paper we report newly selected artificial modules that enhance the k(cat) values comparable with or higher than those of the wild-type ribozyme with broad substrate specificity. The elements required for the catalysis of Group I intron ribozymes are concentrated in the P3-P7 domain of their core region, which consists of two conserved helical domains, P4-P6 and P3-P7. Previously, we reported the in vitro selection of artificial modules residing at the peripheral region of a mutant Group I ribozyme lacking P4-P6. We found that derivatives of the ribozyme containing the modules performed the reversal of the first step of the self-splicing reaction efficiently by using their affinity to the substrate RNA, although their kcat values and substrate specificity were uninfluenced and limited, respectively. The results show that it is possible to add a variety of new domains at the peripheral region that play a role comparable with that of the conserved P4-P6 domain.	Kyoto Univ, Grad Sch Sci, Kyoto 6068502, Japan; Kyoto Univ, Grad Sch Biostudies, Kyoto 6068502, Japan	Kyoto University; Kyoto University	Inoue, T (corresponding author), Kyoto Univ, Grad Sch Sci, Kyoto 6068502, Japan.	tan@kuchem.kyoto-u.ac.jp	Shiraishi, Hideaki/GZH-2798-2022; Ikawa, Yoshiya/G-8759-2016	Ikawa, Yoshiya/0000-0002-6814-0443; Shiraishi, Hideaki/0000-0002-3490-9269				Berens C, 1998, CHEM BIOL, V5, P163, DOI 10.1016/S1074-5521(98)90061-8; CECH TR, 1990, ANNU REV BIOCHEM, V59, P543, DOI 10.1146/annurev.bi.59.070190.002551; CECH TR, 1998, RNA WORLD, V2, P321; CELANDER DW, 2000, CURRENT PROTOCOLS NU; CHRISTIAN EL, 1993, BIOCHEMISTRY-US, V32, P4475, DOI 10.1021/bi00068a001; CHRISTIAN EL, 1992, J MOL BIOL, V228, P743, DOI 10.1016/0022-2836(92)90861-D; DOUDNA JA, 1989, NATURE, V339, P519, DOI 10.1038/339519a0; Golden BL, 1998, SCIENCE, V282, P259, DOI 10.1126/science.282.5387.259; GREEN R, 1992, SCIENCE, V258, P1910, DOI 10.1126/science.1470913; GREEN R, 1990, NATURE, V347, P406, DOI 10.1038/347406a0; HEUER TS, 1991, P NATL ACAD SCI USA, V88, P11105, DOI 10.1073/pnas.88.24.11105; Ikawa Y, 2000, NAT STRUCT BIOL, V7, P1032; Ikawa Y, 2001, GENES CELLS, V6, P411, DOI 10.1046/j.1365-2443.2001.00437.x; JAEGER L, 1996, CATALYTIC RNA, P33; KAY PS, 1987, NATURE, V327, P343, DOI 10.1038/327343a0; Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700; MICHEL F, 1990, J MOL BIOL, V216, P585, DOI 10.1016/0022-2836(90)90386-Z; Ohuchi SJ, 2002, NUCLEIC ACIDS RES, V30, P3473, DOI 10.1093/nar/gkf453; Ortoleva-Donnelly L, 1998, RNA, V4, P498, DOI 10.1017/S1355838298980086; Pichler A, 2002, J BIOL CHEM, V277, P17987, DOI 10.1074/jbc.M111798200; PICHLER A, 2000, RIBOZYME BIOCH BIOTE, P7; Streicher B, 1996, EMBO J, V15, P2556, DOI 10.1002/j.1460-2075.1996.tb00613.x; Strobel SA, 1999, CHEM BIOL, V6, P153, DOI 10.1016/S1074-5521(99)89007-3; SUH E, 1992, NUCLEIC ACIDS RES, V20, P6303, DOI 10.1093/nar/20.23.6303; Szewczak AA, 2002, BIOCHEMISTRY-US, V41, P2516, DOI 10.1021/bi011973u; WARING RB, 1989, NUCLEIC ACIDS RES, V17, P10281, DOI 10.1093/nar/17.24.10281; Zuker M, 1999, NATO ASI 3 HIGH TECH, V70, P11	27	9	11	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 2	2004	279	1					540	546		10.1074/jbc.M305499200	http://dx.doi.org/10.1074/jbc.M305499200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	757GU	14573613	hybrid			2022-12-27	WOS:000187555300065
J	Roy, R; Meier, B; McAinsh, AD; Feldmann, HM; Jackson, SP				Roy, R; Meier, B; McAinsh, AD; Feldmann, HM; Jackson, SP			Separation-of-function mutants of yeast Ku80 reveal a Yku80p-Sir4p interaction involved in telomeric silencing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; DOUBLE-STRAND BREAKS; SACCHAROMYCES-CEREVISIAE; DNA-REPAIR; LENGTH REGULATION; SIR PROTEINS; BINDING; HETEROCHROMATIN; HOMOLOG; MAINTENANCE	The Saccharomyces cerevisiae Ku heterodimer comprising Yku70p and Yku80p is involved in telomere maintenance and DNA repair by the pathway of nonhomologous end joining. It is also a key regulator of transcriptional silencing of genes placed in close proximity to telomeres. Here, we describe the identification of separation-of-function mutants of Yku80p that exhibit defects in silencing but not DNA repair and show that these mutations map to an evolutionarily conserved domain within Yku80p. Furthermore, we reveal that Yku80p interacts with the silent information regulator protein Sir4p and that this interaction is mediated by the N-terminal 200 amino acid residues of Sir4p. Notably, this interaction also requires the region of Yku80p that contains the sites of the silencing defective mutations. Finally, we show that these mutations impair the Yku80p-Sir4p interaction and recruitment of Sir3p to telomeric regions in vivo. Taken together with other data, these findings indicate that the Yku80p-Sir4p interaction plays a vital role in the assembly of telomeric heterochromatin.	Univ Munich, Inst Biochem, D-81377 Munich, Germany; Univ Cambridge, Wellcome Trust Canc Res UK Inst Canc & Dev Biol, Cambridge CB2 1QR, England; Univ Cambridge, Dept Zool, Cambridge CB2 1QR, England	University of Munich; University of Cambridge; University of Cambridge	Feldmann, HM (corresponding author), Univ Munich, Inst Biochem, Feodor Lynen Str 25, D-81377 Munich, Germany.		Jackson, Stephen Philip/R-4548-2019; McAinsh, Andrew/C-6438-2012; Dry, Kate/I-2328-2014	Jackson, Stephen Philip/0000-0001-9317-7937; McAinsh, Andrew/0000-0001-6808-0711; Meier, Bettina/0000-0002-9227-6519				APARICIO OM, 1991, CELL, V66, P1279, DOI 10.1016/0092-8674(91)90049-5; AUSBEL FM, 1991, CURRENT PROTOCOLS MO; Boulton SJ, 1996, NUCLEIC ACIDS RES, V24, P4639, DOI 10.1093/nar/24.23.4639; Boulton SJ, 1996, EMBO J, V15, P5093, DOI 10.1002/j.1460-2075.1996.tb00890.x; Boulton SJ, 1998, EMBO J, V17, P1819, DOI 10.1093/emboj/17.6.1819; BRENT R, 1985, CELL, V43, P729, DOI 10.1016/0092-8674(85)90246-6; Critchlow SE, 1998, TRENDS BIOCHEM SCI, V23, P394, DOI 10.1016/S0968-0004(98)01284-5; Dionne I, 1996, P NATL ACAD SCI USA, V93, P13902, DOI 10.1073/pnas.93.24.13902; Dionne I, 1998, NUCLEIC ACIDS RES, V26, P5365, DOI 10.1093/nar/26.23.5365; Dynan WS, 1998, NUCLEIC ACIDS RES, V26, P1551, DOI 10.1093/nar/26.7.1551; FELDMANN H, 1993, J BIOL CHEM, V268, P12895; Feldmann H, 1996, J BIOL CHEM, V271, P27765, DOI 10.1074/jbc.271.44.27765; Gell D, 1999, NUCLEIC ACIDS RES, V27, P3494, DOI 10.1093/nar/27.17.3494; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; Grandin N, 2000, MOL CELL BIOL, V20, P8397, DOI 10.1128/MCB.20.22.8397-8408.2000; HARDY CFJ, 1992, GENE DEV, V6, P801, DOI 10.1101/gad.6.5.801; HECHT A, 1995, CELL, V80, P583, DOI 10.1016/0092-8674(95)90512-X; Hecht A, 1996, NATURE, V383, P92, DOI 10.1038/383092a0; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Laroche T, 1998, CURR BIOL, V8, P653, DOI 10.1016/S0960-9822(98)70252-0; Luo KH, 2002, GENE DEV, V16, P1528, DOI 10.1101/gad.988802; Martin SG, 1999, CELL, V97, P621, DOI 10.1016/S0092-8674(00)80773-4; Meier B, 2001, MOL CELL BIOL, V21, P4233, DOI 10.1128/MCB.21.13.4233-4245.2001; Mishra K, 1999, CURR BIOL, V9, P1123, DOI 10.1016/S0960-9822(99)80483-7; Moazed D, 1997, P NATL ACAD SCI USA, V94, P2186, DOI 10.1073/pnas.94.6.2186; MORETTI P, 1994, GENE DEV, V8, P2257, DOI 10.1101/gad.8.19.2257; MUHLRAD D, 1992, YEAST, V8, P79, DOI 10.1002/yea.320080202; Nugent CI, 1998, CURR BIOL, V8, P657, DOI 10.1016/S0960-9822(98)70253-2; Peterson SE, 2001, NAT GENET, V27, P64, DOI 10.1038/83778; Porter SE, 1996, NUCLEIC ACIDS RES, V24, P582, DOI 10.1093/nar/24.4.582; Rouse J, 2002, MOL CELL, V9, P857, DOI 10.1016/S1097-2765(02)00507-5; Sherman F, 1979, METHODS YEAST GENETI; SHORE D, 1995, TELOMERES; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; Smith JS, 2000, P NATL ACAD SCI USA, V97, P6658, DOI 10.1073/pnas.97.12.6658; StrahlBolsinger S, 1997, GENE DEV, V11, P83, DOI 10.1101/gad.11.1.83; SWENSON DH, 1980, CARCINOGENESIS, V1, P931, DOI 10.1093/carcin/1.11.931; Tsukamoto Y, 1997, NATURE, V388, P900, DOI 10.1038/42288; Walker JR, 2001, NATURE, V412, P607, DOI 10.1038/35088000; Wang JS, 1998, J BIOL CHEM, V273, P842, DOI 10.1074/jbc.273.2.842; Wu XT, 1996, MOL CELL BIOL, V16, P5186; [No title captured]	44	71	75	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	2004	279	1					86	94		10.1074/jbc.M306841200	http://dx.doi.org/10.1074/jbc.M306841200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	757GU	14551211	hybrid			2022-12-27	WOS:000187555300011
J	Storici, P; De Biase, D; Bossa, F; Bruno, S; Mozzarelli, A; Peneff, C; Silverman, RB; Schirmer, T				Storici, P; De Biase, D; Bossa, F; Bruno, S; Mozzarelli, A; Peneff, C; Silverman, RB; Schirmer, T			Structures of gamma-aminobutyric acid (GABA) aminotransferase, a pyridoxal 5 '-phosphate, and [2Fe-2S] cluster-containing enzyme, complexed with gamma-ethynyl-GABA and with the antiepilepsy drug vigabatrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRAIN 4-AMINOBUTYRATE AMINOTRANSFERASE; CRYSTAL-STRUCTURE; ACTIVE-SITE; CATALYTIC INHIBITOR; RESTRICTED ANALOG; ACETYLENIC GABA; INACTIVATION; TRANSAMINASE; MECHANISM; SYNTHASE	gamma-Aminobutyric acid aminotransferase (GABA-AT) is a pyridoxal 5'-phosphate-dependent enzyme responsible for the degradation of the inhibitory neurotransmitter GABA. GABA-AT is a validated target for antiepilepsy drugs because its selective inhibition raises GABA concentrations in brain. The antiepilepsy drug, gamma-vinyl-GABA (vigabatrin) has been investigated in the past by various biochemical methods and resulted in several proposals for its mechanisms of inactivation. In this study we solved and compared the crystal structures of pig liver GABA-AT in its native form (to 2.3-Angstrom resolution) and in complex with vigabatrin as well as with the close analogue gamma-ethynyl-GABA (to 2.3 and 2.8 Angstrom, respectively). Both inactivators form a covalent ternary adduct with the active site Lys329 and the pyridoxal 5'-phosphate (PLP) cofactor. The crystal structures provide direct support for specific inactivation mechanisms proposed earlier on the basis of radiolabeling experiments. The reactivity of GABA-AT crystals with the two GABA analogues was also investigated by polarized absorption microspectrophotometry. The spectral data are discussed in relation to the proposed mechanism. Intriguingly, all three structures revealed a [2Fe-2S] cluster of yet unknown function at the center of the dimeric molecule in the vicinity of the PLP cofactors.	Univ Basel, Biozentrum, Div Biol Struct, CH-4056 Basel, Switzerland; Univ Roma La Sapienza, Dept Biochem Sci A Rossi Fanelli, I-00185 Rome, Italy; Univ Roma La Sapienza, Ctr Eccellenza Biol & Med Mol, I-00185 Rome, Italy; Univ Parma, Dept Biochem & Mol Biol, I-43100 Parma, Italy; Univ Parma, Natl Inst Phys Matter, I-43100 Parma, Italy; Northwestern Univ, Dept Chem, Evanston, IL 60208 USA; Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA; Northwestern Univ, Drug Discovery Program, Evanston, IL 60208 USA	University of Basel; Sapienza University Rome; Sapienza University Rome; University of Parma; Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale per la Fisica della Materia (INFM-CNR); University of Parma; Northwestern University; Northwestern University; Northwestern University	Silverman, RB (corresponding author), Univ Basel, Biozentrum, Div Biol Struct, Klingelbergstr 50-70, CH-4056 Basel, Switzerland.	Agman@chem.northwestern.edu; tilman.schirmer@unibas.ch	storici, paola/ABB-3831-2021; storici, paola/GRJ-7559-2022; Messier, Claude/A-2322-2008; Mozzarelli, Andrea/C-3615-2014; De Biase, Daniela/H-3678-2019; Bruno, Stefano/A-4582-2011	storici, paola/0000-0002-2590-3332; storici, paola/0000-0002-2590-3332; Messier, Claude/0000-0002-4791-1763; Mozzarelli, Andrea/0000-0003-3762-0062; De Biase, Daniela/0000-0003-3536-9927; Bruno, Stefano/0000-0002-7890-2472	NINDS NIH HHS [NS15703] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS015703] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AOYAGI T, 1990, CHEM PHARM BULL, V38, P1748; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BAKAY RAE, 1981, BRAIN RES, V206, P387, DOI 10.1016/0006-8993(81)90539-4; BAXTER CF, 1958, J BIOL CHEM, V233, P1135; BEART PM, 1971, NATURE-NEW BIOL, V234, P80, DOI 10.1038/newbio234080a0; Beinert H, 1999, CURR OPIN CHEM BIOL, V3, P152, DOI 10.1016/S1367-5931(99)80027-1; Beinert H, 1997, SCIENCE, V277, P653, DOI 10.1126/science.277.5326.653; BREHM L, 1972, ACTA CHEM SCAND, V26, P1298, DOI 10.3891/acta.chem.scand.26-1298; BURKE JR, 1991, J AM CHEM SOC, V113, P9329, DOI 10.1021/ja00024a042; BUTTERWORTH J, 1983, J NEUROCHEM, V41, P440, DOI 10.1111/j.1471-4159.1983.tb04761.x; Chen DW, 2001, BIOCHEMISTRY-US, V40, P596, DOI 10.1021/bi002265w; Choi S, 2002, J AM CHEM SOC, V124, P1620, DOI 10.1021/ja011968d; CHURCHICH JE, 1981, J BIOL CHEM, V256, P1101; CLARK PA, 1993, J AM CHEM SOC, V115, P1894, DOI 10.1021/ja00058a039; COOPER AJL, 1985, METHOD ENZYMOL, V113, P80; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; DEBIASE D, 1992, EUR J BIOCHEM, V208, P351; DEBIASE D, 1991, J BIOL CHEM, V266, P20056; Dewey SL, 1998, SYNAPSE, V30, P119, DOI 10.1002/(SICI)1098-2396(199810)30:2<119::AID-SYN1>3.0.CO;2-F; FAEDER EJ, 1970, BIOCHEMISTRY-US, V9, P4043, DOI 10.1021/bi00823a003; FOWLER LJ, 1972, BIOCHEM J, V130, P569, DOI 10.1042/bj1300569; FU WG, 1994, BIOCHEMISTRY-US, V33, P13455, DOI 10.1021/bi00249a034; GALE D, 1989, INT ECON REV, V30, P3, DOI 10.2307/2526545; Gidal BE, 1999, ANN PHARMACOTHER, V33, P1277, DOI 10.1345/aph.18376; GUNNE LM, 1984, NATURE, V309, P347, DOI 10.1038/309347a0; HOFRICHTER J, 1976, ANNU REV BIOPHYS BIO, V5, P511, DOI 10.1146/annurev.bb.05.060176.002455; JOHN RA, 1984, BIOCHEM SOC T, V12, P430, DOI 10.1042/bst0120430; JOHN RA, 1979, BIOCHEM J, V177, P721, DOI 10.1042/bj1770721; JOHN RA, 1976, BIOCHEM J, V155, P645, DOI 10.1042/bj1550645; JOHNSTON GA, 1975, J NEUROCHEM, V24, P157, DOI 10.1111/j.1471-4159.1975.tb07642.x; JOHNSTON GAR, 1977, J PHARM PHARMACOL, V29, P240, DOI 10.1111/j.2042-7158.1977.tb11297.x; JUNG MJ, 1977, J NEUROCHEM, V28, P717, DOI 10.1111/j.1471-4159.1977.tb10618.x; JUNG MJ, 1975, BIOCHEM BIOPH RES CO, V67, P301, DOI 10.1016/0006-291X(75)90316-2; Kalviainen R, 2001, CNS DRUGS, V15, P217; KARLSSON A, 1974, BIOCHEM PHARMACOL, V23, P3053, DOI 10.1016/0006-2952(74)90281-0; KING TE, 1967, METHOD ENZYMOL, V10, P631; KROGSGAARDLARSEN P, 1977, NATURE, V268, P53, DOI 10.1038/268053a0; KWON OS, 1992, J BIOL CHEM, V267, P7215; LIPPERT B, 1980, BRAIN RES BULL, V5, P375, DOI 10.1016/0361-9230(80)90060-X; LIPPERT B, 1977, EUR J BIOCHEM, V74, P441, DOI 10.1111/j.1432-1033.1977.tb11410.x; Lloyd KG, 1981, NEUROTRANSMITTERS SE, P325; LOSCHER W, 1986, BIOCHEM PHARMACOL, V35, P3176, DOI 10.1016/0006-2952(86)90408-9; LOSCHER W, 1982, NEUROPHARMACOLOGY, V21, P803, DOI 10.1016/0028-3908(82)90068-5; McGeer E. G., 1983, GLUTAMINE GLUTAMATE, P3; McNamara J.O, 1996, PHARM BASIS THERAPEU, P461; MCPHALEN CA, 1992, J MOL BIOL, V225, P495, DOI 10.1016/0022-2836(92)90935-D; Mehta PK, 2000, ADV ENZYMOL RAMB, V74, P129; METCALF BW, 1979, BIOCHEM PHARMACOL, V28, P1705, DOI 10.1016/0006-2952(79)90529-X; MOZZARELLI A, 1989, J BIOL CHEM, V264, P15774; Mozzarelli A, 1996, ANNU REV BIOPH BIOM, V25, P343; Mozzarelli A, 2001, ADVANCED FUNCTIONAL MOLECULES AND POLYMERS, VOL 4, P55; NANAVATI SM, 1991, J AM CHEM SOC, V113, P9341, DOI 10.1021/ja00024a043; NANAVATI SM, 1989, J MED CHEM, V32, P2413, DOI 10.1021/jm00131a001; NISHINO N, 1988, JPN J PHARMACOL, V48, P331, DOI 10.1254/jjp.48.331; Ollagnier-de-Choudens S, 2002, BIOCHEMISTRY-US, V41, P9145, DOI 10.1021/bi0122011; Paul V, 2000, BRAIN RES BULL, V51, P43, DOI 10.1016/S0361-9230(99)00206-3; Phillips RS, 2002, J BIOL CHEM, V277, P21592, DOI 10.1074/jbc.M200216200; RANDO RR, 1977, BIOCHEM BIOPH RES CO, V76, P1276, DOI 10.1016/0006-291X(77)90993-7; ROGAWSKI MA, 1990, PHARMACOL REV, V42, P223; SCHON F, 1974, BRAIN RES, V66, P289, DOI 10.1016/0006-8993(74)90147-4; Shen BW, 1998, J MOL BIOL, V277, P81, DOI 10.1006/jmbi.1997.1583; Silverman R.B., 2002, ORGANIC CHEM ENZYME, V2nd; SILVERMAN RB, 1995, METHOD ENZYMOL, V249, P240; STOOKEY LL, 1970, ANAL CHEM, V42, P779, DOI 10.1021/ac60289a016; Storici P, 1999, BIOCHEMISTRY-US, V38, P8628, DOI 10.1021/bi990478j; TONEY MD, 1993, SCIENCE, V261, P756, DOI 10.1126/science.8342040; Weyand M, 1999, BIOCHEMISTRY-US, V38, P16469, DOI 10.1021/bi9920533; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736	68	116	124	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 2	2004	279	1					363	373		10.1074/jbc.M305884200	http://dx.doi.org/10.1074/jbc.M305884200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	757GU	14534310	hybrid			2022-12-27	WOS:000187555300044
J	Wang, XH; Chen, LY; Maures, TJ; Herrington, J; Carter-Su, C				Wang, XH; Chen, LY; Maures, TJ; Herrington, J; Carter-Su, C			SH2-B is a positive regulator of nerve growth factor-mediated activation of the Akt/forkhead pathway in PC12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; FORKHEAD TRANSCRIPTION FACTOR; GLYCOGEN-SYNTHASE KINASE-3-BETA; FACTOR-I RECEPTOR; NF-KAPPA-B; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL-TRANSDUCTION; SYMPATHETIC NEURONS; FACTOR WITHDRAWAL; INSULIN-RECEPTOR	To gain insight into the mechanism by which the adapter protein SH2-B promotes nerve growth factor (NGF)-mediated neuronal differentiation and survival, the effect of SH2-B on the serine/threonine kinase Akt/ protein kinase B and downstream effector proteins was examined. PC12 cells stably overexpressing SH2-Bbeta, which exhibit enhanced NGF-induced neuronal differentiation compared with control cells, showed enhanced and prolonged NGF-induced phosphorylation of Akt on Ser(473) and Akt enzymatic activity. Surprisingly, NGF-induced phosphorylation of Akt on Ser473 and Akt activity were not altered in cells overexpressing SH2Bbeta(R555E) with a defective SH2 domain, despite the ability of the overexpressed SH2-Bbeta(R555E) to block NGF-induced differentiation. Consistent with SH2-Bbeta enhancing the activity of Akt, cells overexpressing SH2-Bbeta but not SH2-Bbeta(R555E) exhibited increased and/or prolonged phosphorylation of the pro-apoptotic Akt effector proteins, glycogen synthase kinase-3, and forkhead transcription factors, FKHRL1/FOXO3 and FKHR/FOXO1. Immunolocalization studies indicated that, although ectopically expressed FKHR was primarily concentrated in the cytoplasm of control cells and cells transiently overexpressing SH2-Bbeta, it was concentrated in the nucleus of cells transiently overexpressing SH2-Bbeta (R555E). Similarly, SH2-Bbeta stimulated the accumulation of FKHR in the cytoplasm of 293T and COS-7 cells, whereas SH2-Bbeta(R555E) enhanced its accumulation in the nucleus. In PC12 cells stably expressing forms of SH2-Bbeta, SH2-Bbeta mimicked the ability of NGF to promote redistribution of FKHR to the cytoplasm whereas SH2-Bbeta(R555E) blocked this effect of NGF. Taken together, these data indicate that SH2- B is a positive regulator of NGF-mediated activation of the Akt/ Forkhead pathway.	Univ Michigan, Sch Med, Dept Mol & Integrat Physiol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Program Mol & Cellular Biol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Carter-Su, C (corresponding author), Univ Michigan, Sch Med, Dept Mol & Integrat Physiol, Ann Arbor, MI 48109 USA.			Huang, Guojin/0000-0001-7020-5528	NIDDK NIH HHS [R01 DK054222, R01-DK54222, P60-DK20572] Funding Source: Medline; NIGMS NIH HHS [T32 GM007315, GM-07315] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054222, P60DK020572] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007315] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Bartlett SE, 1997, BRAIN RES, V761, P257, DOI 10.1016/S0006-8993(97)00329-6; BATISTATOU A, 1993, J CELL BIOL, V122, P523, DOI 10.1083/jcb.122.3.523; Bhat RV, 2000, P NATL ACAD SCI USA, V97, P11074, DOI 10.1073/pnas.190297597; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; Borkhardt A, 1997, ONCOGENE, V14, P195, DOI 10.1038/sj.onc.1200814; Brunet A, 2002, J CELL BIOL, V156, P817, DOI 10.1083/jcb.200112059; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Crowder RJ, 2000, J BIOL CHEM, V275, P34266, DOI 10.1074/jbc.M006160200; Crowder RJ, 1998, J NEUROSCI, V18, P2933; D'Mello SR, 1997, J NEUROSCI, V17, P1548; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DECKWERTH TL, 1993, J CELL BIOL, V123, P1207, DOI 10.1083/jcb.123.5.1207; del Peso L, 1999, ONCOGENE, V18, P7328, DOI 10.1038/sj.onc.1203159; DEL PL, 1997, SCIENCE, V278, P687; Dijkers PF, 2000, MOL CELL BIOL, V20, P9138, DOI 10.1128/MCB.20.24.9138-9148.2000; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; ESTEVEZ AG, 1995, J NEUROCHEM, V65, P1543; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; Hetman M, 1999, J BIOL CHEM, V274, P22569, DOI 10.1074/jbc.274.32.22569; Hillion J, 1997, BLOOD, V90, P3714, DOI 10.1182/blood.V90.9.3714; HUANG XM, 1995, P NATL ACAD SCI USA, V92, P11618, DOI 10.1073/pnas.92.25.11618; Kaplan DR, 1997, CURR OPIN CELL BIOL, V9, P213, DOI 10.1016/S0955-0674(97)80065-8; Klesse LJ, 1999, ONCOGENE, V18, P2055, DOI 10.1038/sj.onc.1202524; Klippel A, 1996, MOL CELL BIOL, V16, P4117; Kops GJPL, 1999, J MOL MED-JMM, V77, P656, DOI 10.1007/s001099900050; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Kruman I, 1998, J NEUROSCI RES, V51, P293, DOI 10.1002/(SICI)1097-4547(19980201)51:3<293::AID-JNR3>3.0.CO;2-B; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319; LINDENBOIM L, 1995, J NEUROCHEM, V64, P1054; Markus A, 2002, NEURON, V35, P65, DOI 10.1016/S0896-6273(02)00752-3; Mazzoni IE, 1999, J NEUROSCI, V19, P9716; Miller TM, 1997, J BIOL CHEM, V272, P9847; NAKAJIMA M, 1994, NEUROSCI LETT, V176, P161, DOI 10.1016/0304-3940(94)90072-8; Nelms K, 1999, MAMM GENOME, V10, P1160, DOI 10.1007/s003359901183; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; OSBORNE MA, 1995, BIO-TECHNOL, V13, P1474, DOI 10.1038/nbt1295-1474; Ozes ON, 1999, NATURE, V401, P82; Pap M, 1998, J BIOL CHEM, V273, P19929, DOI 10.1074/jbc.273.32.19929; Qian XZ, 2001, MOL CELL BIOL, V21, P1613, DOI 10.1128/MCB.21.5.1613-1620.2001; Qian XZ, 1998, NEURON, V21, P1017, DOI 10.1016/S0896-6273(00)80620-0; Rena G, 2002, EMBO J, V21, P2263, DOI 10.1093/emboj/21.9.2263; Riedel H, 1997, J BIOCHEM-TOKYO, V122, P1105; Riedel H, 2000, ONCOGENE, V19, P39, DOI 10.1038/sj.onc.1203253; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Rui LY, 1999, J BIOL CHEM, V274, P10590, DOI 10.1074/jbc.274.15.10590; Rui LY, 1999, J BIOL CHEM, V274, P26485, DOI 10.1074/jbc.274.37.26485; Rui LY, 1998, J BIOL CHEM, V273, P21239, DOI 10.1074/jbc.273.33.21239; Rui LY, 1997, MOL CELL BIOL, V17, P6633, DOI 10.1128/MCB.17.11.6633; RUKENSTEIN A, 1991, J NEUROSCI, V11, P2552; Sanchez S, 2001, J NEUROCHEM, V78, P468, DOI 10.1046/j.1471-4159.2001.00453.x; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; Troy CM, 1997, J NEUROSCI, V17, P1911; Vaillant AR, 1999, J CELL BIOL, V146, P955, DOI 10.1083/jcb.146.5.955; Wadia JS, 1998, J NEUROSCI, V18, P932; Wang J, 1998, J BIOL CHEM, V273, P3136, DOI 10.1074/jbc.273.6.3136; WOOD KW, 1993, P NATL ACAD SCI USA, V90, P5016, DOI 10.1073/pnas.90.11.5016; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; Wooten MW, 2000, MOL CELL BIOL, V20, P4494, DOI 10.1128/MCB.20.13.4494-4504.2000; Yamaguchi H, 2001, ONCOGENE, V20, P7779, DOI 10.1038/sj.onc.1204984; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Yokouchi M, 1997, ONCOGENE, V15, P7, DOI 10.1038/sj.onc.1201163; Yousaf N, 2001, J BIOL CHEM, V276, P40940, DOI 10.1074/jbc.M104191200; Zhang ZH, 1998, NATURE, V395, P698, DOI 10.1038/27208; Zheng WH, 2000, J BIOL CHEM, V275, P39152, DOI 10.1074/jbc.M002417200	75	45	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	2004	279	1					133	141		10.1074/jbc.M310040200	http://dx.doi.org/10.1074/jbc.M310040200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	757GU	14565960	hybrid			2022-12-27	WOS:000187555300017
J	Naider, F; Ding, FX; VerBerkmoes, NC; Arshava, B; Becker, JM				Naider, F; Ding, FX; VerBerkmoes, NC; Arshava, B; Becker, JM			Synthesis and biophysical characterization of a multidomain peptide from a Saccharomyces cerevisiae G protein-coupled receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-FACTOR RECEPTOR; TRANSMEMBRANE SEGMENTS; POLYPEPTIDE FRAGMENTS; PHEROMONE RECEPTOR; DOMAIN; RHODOPSIN; LIGATION; ORIENTATION; EXPRESSION; SEQUENCE	We attached peptides corresponding to the seventh transmembrane domain (TMD7) of the alpha-mating factor receptor (Ste2p) of Saccharomyces cerevisiae to a hydrophilic, 40-residue fragment of the carboxyl terminus of this G protein-coupled receptor. Peptides corresponding to (a) the 40-residue portion of the carboxyl tail (T-40), (b) the tail plus a part of TMD7 (M7-12-T40), and (c) to the tail plus the full TMD7 (M7-24-T40) were chemically synthesized and purified. The molecular mass and primary sequence of these peptides were confirmed by mass spectrometry and tandem mass spectrometry procedures. Circular dichroism (CD) revealed that T-40 was disordered in phosphate buffer and in the presence of 1,2-dimyristoyl-sn-glycero-3-phosphocholine/1,2-dimyristoylsn-glycero-3-[phospho-racemic-(1-glycerol)] bilayers. In contrast, M7-12-T40 and M7-24-T40 peptides were partially helical in the presence of vesicles, and difference CD spectroscopy showed that the transmembrane regions of these peptides were 42 and 94% helical, respectively. CD analysis also demonstrated that M7-24-T40 retained its secondary structure in the presence of 1-palmitoyl-2-hydroxy-sn-glycero-3-[phospho-racemic(1-glycerol)] micelles at 0.5 mM concentration. Thus, the tail and the transmembrane domain of the multidomain 64-amino acid residue peptide manifest individual conformational preferences. Measurement of tryptophan fluorescence indicated that the transmembrane domain integrated into bilayers in a manner similar to that expected for this region in the native state of the receptor. This study demonstrated that the tail of Ste2p can be used as a hydrophilic template to study transmembrane domain structure using techniques such as CD and NMR spectroscopy.	CUNY Coll Staten Isl, Dept Chem, Staten Isl, NY 10314 USA; CUNY, Inst Macromol Assemblies, Staten Isl, NY 10314 USA; CUNY Grad Sch & Univ Ctr, PhD Program Biochem & Chem, New York, NY 10016 USA; Univ Tennessee, Oak Ridge Natl Lab, Grad Sch Genome Sci & Technol, Oak Ridge, TN 37830 USA; Oak Ridge Natl Lab, Organ & Biol Mass Spectrometry Grp, Oak Ridge, TN 37831 USA; Univ Tennessee, Dept Microbiol, Knoxville, TN 37996 USA	City University of New York (CUNY) System; College of Staten Island (CUNY); City University of New York (CUNY) System; City University of New York (CUNY) System; City University of New York (CUNY) Graduate School; United States Department of Energy (DOE); Oak Ridge National Laboratory; University of Tennessee System; University of Tennessee Knoxville; United States Department of Energy (DOE); Oak Ridge National Laboratory; University of Tennessee System; University of Tennessee Knoxville	Naider, F (corresponding author), CUNY Coll Staten Isl, Dept Chem, Staten Isl, NY 10314 USA.	naider@postbox.csi.cuny.edu			NIGMS NIH HHS [GM22087, GM22086] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R56GM022087, R56GM022086, R01GM022086, R01GM022087] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Albert AD, 2000, METHOD ENZYMOL, V315, P107; Arshava B, 1998, BIOPOLYMERS, V46, P343, DOI 10.1002/(SICI)1097-0282(199811)46:6<343::AID-BIP1>3.0.CO;2-L; BURKHOLDER AC, 1985, NUCLEIC ACIDS RES, V13, P8463, DOI 10.1093/nar/13.23.8463; Chen QJ, 1996, MOL CELL BIOL, V16, P247; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; Dawson PE, 2000, ANNU REV BIOCHEM, V69, P923, DOI 10.1146/annurev.biochem.69.1.923; de Planque MRR, 2001, BIOCHEMISTRY-US, V40, P5000, DOI 10.1021/bi000804r; Deber CM, 1999, J PEPT RES, V54, P200, DOI 10.1034/j.1399-3011.1999.00118.x; Ding FX, 2002, J BIOL CHEM, V277, P14483, DOI 10.1074/jbc.M111382200; Ding FX, 2001, BIOCHEMISTRY-US, V40, P8945, DOI 10.1021/bi010394m; Dohlman HG, 2002, ANNU REV PHYSIOL, V64, P129, DOI 10.1146/annurev.physiol.64.081701.133448; Dowell SJ, 2001, DRUG DISCOV TODAY, V6, P884, DOI 10.1016/S1359-6446(01)01936-5; Hicke L, 1996, CELL, V84, P277, DOI 10.1016/S0092-8674(00)80982-4; Konopka JB, 1996, P NATL ACAD SCI USA, V93, P6764, DOI 10.1073/pnas.93.13.6764; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Marti T, 1998, J BIOL CHEM, V273, P9312, DOI 10.1074/jbc.273.15.9312; Martin NP, 1999, BIOCHEMISTRY-US, V38, P682, DOI 10.1021/bi982062w; Melnyk RA, 2001, BIOCHEMISTRY-US, V40, P11106, DOI 10.1021/bi010642e; Muir TW, 1998, P NATL ACAD SCI USA, V95, P6705, DOI 10.1073/pnas.95.12.6705; Naider F, 2001, BIOPOLYMERS, V60, P334, DOI 10.1002/1097-0282(2001)60:5<334::AID-BIP10175>3.0.CO;2-K; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; REDDY AP, 1994, BIOPOLYMERS, V34, P679, DOI 10.1002/bip.360340510; RENEKE JE, 1988, CELL, V55, P221, DOI 10.1016/0092-8674(88)90045-1; Ridge KD, 1996, J BIOL CHEM, V271, P7860, DOI 10.1074/jbc.271.13.7860; Tam JP, 2001, BIOPOLYMERS, V60, P194, DOI 10.1002/1097-0282(2001)60:3<194::AID-BIP10031>3.0.CO;2-8; Therien AG, 2002, PROTEIN EXPRES PURIF, V25, P81, DOI 10.1006/prep.2001.1612; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; WU CSC, 1981, BIOCHEMISTRY-US, V20, P566, DOI 10.1021/bi00506a019; Xie HB, 2000, BIOCHEMISTRY-US, V39, P15462, DOI 10.1021/bi001432p; Zhou FX, 2001, P NATL ACAD SCI USA, V98, P2250, DOI 10.1073/pnas.041593698	31	12	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52537	52545		10.1074/jbc.M309467200	http://dx.doi.org/10.1074/jbc.M309467200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14570873	hybrid			2022-12-27	WOS:000187480700070
J	Purcarea, C; Ahuja, A; Lu, T; Kovari, L; Guy, HI; Evans, DR				Purcarea, C; Ahuja, A; Lu, T; Kovari, L; Guy, HI; Evans, DR			Aquifex aeolicus aspartate transcarbamoylase, an enzyme specialized for the efficient utilization of unstable carbamoyl phosphate at elevated temperature	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; ALLOSTERIC TRANSITION; REGULATORY PROPERTIES; PYROCOCCUS-ABYSSI; DOMAIN CLOSURE; PROTEINS; SYNTHETASE; PYRIMIDINE; CATALYSIS; MECHANISM	Aquifex aeolicus, an organism that flourishes at 95degreesC, is one of the most thermophilic eubacteria thus far described. The A. aeolicus pyrB gene encoding aspartate transcarbamoylase (ATCase) was cloned, overexpressed in Escherichia coli, and purified by affinity chromatography to a homogeneous form that could be crystallized. Chemical cross-linking and size exclusion chromatography showed that the protein was a homotrimer of 34-kDa catalytic chains. The activity of A. aeolicus ATCase increased dramatically with increasing temperature due to an increase in k(cat) with little change in the Km for the substrates, carbamoyl phosphate and aspartate. The Km for both substrates was 30-40-fold lower than the corresponding values for the homologous E. coli ATCase catalytic subunit. Although rapidly degraded at high temperature, the carbamoyl phosphate generated in situ by A. aeolicus carbamoyl phosphate synthetase (CPSase) was channeled to ATCase. The transient time for carbamoyl aspartate formation was 26 s, compared with the much longer transient times observed when A. aeolicus CPSase was coupled to E. coli ATCase. Several other approaches provided strong evidence for channeling and transient complex formation between A. aeolicus ATCase and CPSase. The high affinity for substrates combined with channeling ensures the efficient transfer of carbamoyl phosphate from the active site of CPSase to that of ATCase, thus preserving it from degradation and preventing the formation of toxic cyanate.	Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, Detroit, MI 48201 USA	Wayne State University	Evans, DR (corresponding author), Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, 540 E Canfield St, Detroit, MI 48201 USA.	devans@cmb.biosci.wayne.edu		Purcarea, Cristina/0000-0001-5784-8545	NIGMS NIH HHS [GM47399] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ackers G K, 1970, Adv Protein Chem, V24, P343, DOI 10.1016/S0065-3233(08)60245-4; AGIUS L, 1997, CHANNELING INTERMEDI, V9; Ahuja A, 2001, J BIOL CHEM, V276, P45694, DOI 10.1074/jbc.M106382200; ALLEN CM, 1964, BIOCHEMISTRY-US, V3, P1238, DOI 10.1021/bi00897a010; ANDERSON PM, 1990, FEMS MICROBIOL LETT, V87, P247, DOI 10.1016/0378-1097(90)90462-Y; BRABSON JS, 1985, METHOD ENZYMOL, V113, P627; Chaudhuri BN, 2001, STRUCTURE, V9, P987, DOI 10.1016/S0969-2126(01)00661-X; COLLINS KD, 1971, J BIOL CHEM, V246, P6599; CROKAERT R, 1958, B SOC CHIM BIOL, V40, P1093; DAVIES GE, 1970, P NATL ACAD SCI USA, V66, P651, DOI 10.1073/pnas.66.3.651; Deckert G, 1998, NATURE, V392, P353, DOI 10.1038/32831; DEMBOWSKI NJ, 1990, BIOCHEMISTRY-US, V29, P3716, DOI 10.1021/bi00467a018; EASTERBY JS, 1984, BIOCHEM J, V219, P843, DOI 10.1042/bj2190843; Geck MK, 1999, BIOCHEMISTRY-US, V38, P8032, DOI 10.1021/bi983029c; GREENWELL P, 1973, J BIOL CHEM, V248, P5994; Hack ES, 2000, J BIOL CHEM, V275, P15820, DOI 10.1074/jbc.M909220199; HYDE CC, 1988, J BIOL CHEM, V263, P17857; Irvine HS, 1997, EUR J BIOCHEM, V247, P1063, DOI 10.1111/j.1432-1033.1997.01063.x; Jin L, 1999, PROTEINS, V37, P729, DOI 10.1002/(SICI)1097-0134(19991201)37:4<729::AID-PROT21>3.0.CO;2-F; KANTROWITZ ER, 1988, SCIENCE, V241, P669, DOI 10.1126/science.3041592; KANTROWITZ ER, 1990, TRENDS BIOCHEM SCI, V15, P53, DOI 10.1016/0968-0004(90)90176-C; Kim JH, 1996, J BIOL CHEM, V271, P15549, DOI 10.1074/jbc.271.26.15549; Kim R, 1998, BIOTECHNOL LETT, V20, P207, DOI 10.1023/A:1005305330517; LADJIMI MM, 1988, BIOCHEMISTRY-US, V27, P268, DOI 10.1021/bi00401a041; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIPSCOMB WN, 1994, ADV ENZYMOL RAMB, V68, P67; MOODY MF, 1979, J MOL BIOL, V133, P517, DOI 10.1016/0022-2836(79)90405-4; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; OROSZ F, 1987, BIOCHIM BIOPHYS ACTA, V915, P53, DOI 10.1016/0167-4838(87)90124-5; OVADI J, 1995, CELL ARCHITECTURE ME, P1093; PASTRALANDIS SC, 1981, ANAL BIOCHEM, V118, P358, DOI 10.1016/0003-2697(81)90594-7; PRESCOTT LM, 1969, ANAL BIOCHEM, V32, P408, DOI 10.1016/S0003-2697(69)80008-4; Purcarea C, 1999, J BIOL CHEM, V274, P6122, DOI 10.1074/jbc.274.10.6122; PURCAREA C, 1994, MICROBIOL-SGM, V140, P1967, DOI 10.1099/13500872-140-8-1967; REYSENBACH AL, 1994, APPL ENVIRON MICROB, V60, P2113, DOI 10.1128/AEM.60.6.2113-2119.1994; SALI A, 1995, PROTEINS, V23, P318, DOI 10.1002/prot.340230306; SCHURR MJ, 1995, J BACTERIOL, V177, P1751, DOI 10.1128/jb.177.7.1751-1759.1995; Serre V, 1999, J BIOL CHEM, V274, P23794, DOI 10.1074/jbc.274.34.23794; SETCHELL WA, 1993, SCIENCE, V17, P934; STEVENS RC, 1990, BIOCHEMISTRY-US, V29, P7691, DOI 10.1021/bi00485a019; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; Thoden JB, 1997, BIOCHEMISTRY-US, V36, P6305, DOI 10.1021/bi970503q; VandeCasteele M, 1997, J BACTERIOL, V179, P3470, DOI 10.1128/jb.179.11.3470-3481.1997; VANDECASTEELE M, 1990, J GEN MICROBIOL, V136, P1177, DOI 10.1099/00221287-136-7-1177; Vickrey JF, 2002, J BIOL CHEM, V277, P24490, DOI 10.1074/jbc.M200009200; WEDLER FC, 1974, ARCH BIOCHEM BIOPHYS, V163, P57, DOI 10.1016/0003-9861(74)90454-8; WILEY DC, 1968, NATURE, V218, P1119, DOI 10.1038/2181119a0	47	29	30	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52924	52934		10.1074/jbc.M309383200	http://dx.doi.org/10.1074/jbc.M309383200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14534296	hybrid			2022-12-27	WOS:000187480700115
J	Puxeddu, E; Mitsutake, N; Knauf, JA; Moretti, S; Kim, HW; Seta, KA; Brockman, D; Myatt, L; Millhorn, DE; Fagin, JA				Puxeddu, E; Mitsutake, N; Knauf, JA; Moretti, S; Kim, HW; Seta, KA; Brockman, D; Myatt, L; Millhorn, DE; Fagin, JA			Microsomal prostaglandin E-2 synthase-1 is induced by conditional expression of RET/PTC in thyroid PCCL3 cells through the activation of the MEK-ERK pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLOOXYGENASE-2 MESSENGER-RNA; ARACHIDONIC-ACID METABOLISM; UP-REGULATION; COLORECTAL ADENOMAS; INTESTINAL POLYPOSIS; PAPILLARY CARCINOMAS; RANDOMIZED-TRIAL; GENE-EXPRESSION; PROTEIN-KINASE; DOCKING SITE	RET/PTC rearrangements are believed to be tumor-initiating events in papillary thyroid carcinomas. We identified microsomal prostaglandin E-2 synthase-1 (mPGES-1) as a RET/PTC-inducible gene through subtraction hybridization cloning and expression profiling with custom microarrays. The inducible prostaglandin E-2 (PGE(2)) biosynthetic enzymes cyclooxygenase-2 (COX-2) and mPGES-1 are up-regulated in many cancers. COX-2 is overexpressed in thyroid malignancies compared with benign nodules and normal thyroid tissues. Eicosanoids may promote tumorigenesis through effects on tumor cell growth, immune surveillance, and angiogenesis. Conditional RET/PTC1 or RET/PTC3 expression in PCCL3 thyroid cells markedly induced mPGES-1 and COX-2. PGE(2) was the principal prostanoid and up-regulated ( by similar to60-fold), whereas hydroxyeicosatetraenoic acid metabolites were decreased, consistent with shunting of prostanoid biosynthesis toward PGE(2) by coactivation of the two enzymes. RET/PTC activated mPGES-1 gene transcription. Based on experiments with kinase inhibitors, with PCCL3 cell lines with doxycycline-inducible expression of RET/PTC mutants with substitutions of critical tyrosine residues in the kinase domain, and lines with inducible expression of activated mutants of H-RAS and MEK1, RET/PTC was found to regulate mPGES-1 through Shc-RAS-MEK-ERK. These data show a direct relationship between activation of a tyrosine kinase receptor oncogene and regulation of PGE(2) biosynthesis. As enzymes involved in prostanoid biosynthesis can be targeted with pharmacological inhibitors, these findings may have therapeutic implications.	Univ Cincinnati, Coll Med, Div Endocrinol & Metab, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Genome Sci, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Obstet & Gynecol, Cincinnati, OH 45267 USA; Univ Perugia, Dipartimento Med Interna, I-06126 Perugia, Italy	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University of Perugia	Fagin, JA (corresponding author), Univ Cincinnati, Coll Med, Div Endocrinol & Metab, POB 670547, Cincinnati, OH 45267 USA.	james.fagin@uc.edu	Mitsutake, Norisato/U-9626-2018; Puxeddu, Efisio/I-8188-2012	Mitsutake, Norisato/0000-0002-2744-8046; Knauf, Jeffrey/0000-0003-4456-8792	NATIONAL CANCER INSTITUTE [R01CA050706, R29CA050706] Funding Source: NIH RePORTER; NCI NIH HHS [CA50706] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arighi E, 1997, ONCOGENE, V14, P773, DOI 10.1038/sj.onc.1200896; Asai N, 1996, J BIOL CHEM, V271, P17644, DOI 10.1074/jbc.271.30.17644; Baron JA, 2003, NEW ENGL J MED, V348, P891, DOI 10.1056/NEJMoa021735; Bongarzone I, 1996, J CLIN ENDOCR METAB, V81, P2006, DOI 10.1210/jc.81.5.2006; Borrello MG, 1996, MOL CELL BIOL, V16, P2151; Chen XX, 2002, CARCINOGENESIS, V23, P2095, DOI 10.1093/carcin/23.12.2095; Chulada PC, 2000, CANCER RES, V60, P4705; Claveau D, 2003, J IMMUNOL, V170, P4738, DOI 10.4049/jimmunol.170.9.4738; Cornetta AJ, 2002, LARYNGOSCOPE, V112, P238, DOI 10.1097/00005537-200202000-00008; Durick K, 1998, MOL CELL BIOL, V18, P2298, DOI 10.1128/MCB.18.4.2298; DURICK K, 1995, J BIOL CHEM, V270, P24642, DOI 10.1074/jbc.270.42.24642; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; Faour WH, 2001, J BIOL CHEM, V276, P31720, DOI 10.1074/jbc.M104036200; Fitzpatrick FA, 2001, J CLIN INVEST, V107, P1347, DOI 10.1172/JCI13241; Fournier T, 1997, J BIOL CHEM, V272, P31065, DOI 10.1074/jbc.272.49.31065; FUGAZZOLA L, 1995, CANCER RES, V55, P5617; Gross GA, 1998, P NATL ACAD SCI USA, V95, P11875, DOI 10.1073/pnas.95.20.11875; Grubbs CJ, 2000, CANCER RES, V60, P5599; Han R, 2002, J BIOL CHEM, V277, P36897, DOI 10.1074/jbc.M206949200; Han R, 2002, J BIOL CHEM, V277, P16355, DOI 10.1074/jbc.M111246200; Harris RE, 2000, CANCER RES, V60, P2101; ITO T, 1993, CANCER RES, V53, P2940; Jabbour HN, 2001, BRIT J CANCER, V85, P1023; Jhiang SM, 1996, ENDOCRINOLOGY, V137, P375, DOI 10.1210/en.137.1.375; Kamei D, 2003, J BIOL CHEM, V278, P19396, DOI 10.1074/jbc.M213290200; Kimura ET, 2003, CANCER RES, V63, P1454; Klugbauer S, 1995, ONCOGENE, V11, P2459; Knauf JA, 2003, ONCOGENE, V22, P4406, DOI 10.1038/sj.onc.1206602; Koki A, 2002, ADV EXP MED BIOL, V507, P177; LANGENBACH R, 1995, CELL, V83, P483, DOI 10.1016/0092-8674(95)90126-4; Mancini JA, 2001, J BIOL CHEM, V276, P4469, DOI 10.1074/jbc.M006865200; Monick MM, 2002, J BIOL CHEM, V277, P32992, DOI 10.1074/jbc.M203218200; Murakami M, 2003, J BIOL CHEM, V278, P37937, DOI 10.1074/jbc.M305108200; Murakami M, 1997, J BIOL CHEM, V272, P19891, DOI 10.1074/jbc.272.32.19891; Murakami M, 2000, J BIOL CHEM, V275, P32783, DOI 10.1074/jbc.M003505200; Murakami M, 1997, CRIT REV IMMUNOL, V17, P225, DOI 10.1615/CritRevImmunol.v17.i3-4.10; Nikiforov YE, 1999, ONCOGENE, V18, P6330, DOI 10.1038/sj.onc.1203019; Nikiforov YE, 1997, CANCER RES, V57, P1690; Nikiforova MN, 2000, SCIENCE, V290, P138, DOI 10.1126/science.290.5489.138; Nithipatikom K, 2003, J CHROMATOGR B, V785, P135, DOI 10.1016/S1570-0232(02)00906-6; Nose F, 2002, AM J CLIN PATHOL, V117, P546; Oshima M, 2001, CANCER RES, V61, P1733; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Powell DJ, 1998, CANCER RES, V58, P5523; Reddy BS, 2000, CANCER RES, V60, P293; ROSE MP, 1990, PROSTAG LEUKOTR ESS, V39, P303, DOI 10.1016/0952-3278(90)90010-I; Saavedra HI, 2000, ONCOGENE, V19, P3948, DOI 10.1038/sj.onc.1203723; Sandler RS, 2003, NEW ENGL J MED, V348, P883, DOI 10.1056/NEJMoa021633; Santoro M, 2002, ANN NY ACAD SCI, V963, P116, DOI 10.1111/j.1749-6632.2002.tb04102.x; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Sheng HM, 2001, CANCER RES, V61, P2670; Shirokawa JM, 2000, MOL ENDOCRINOL, V14, P1725, DOI 10.1210/me.14.11.1725; Shitashige M, 1998, BBA-LIPID LIPID MET, V1389, P57, DOI 10.1016/S0005-2760(97)00129-X; Smith WL, 2001, J CLIN INVEST, V107, P1491, DOI 10.1172/JCI13271; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; Soares P, 2003, ONCOGENE, V22, P4578, DOI 10.1038/sj.onc.1206706; Specht MC, 2002, J CLIN ENDOCR METAB, V87, P358, DOI 10.1210/jc.87.1.358; Sugg SL, 1998, J CLIN ENDOCR METAB, V83, P4116, DOI 10.1210/jc.83.11.4116; TAHARA K, 1991, J BIOL CHEM, V266, P440; Tanikawa N, 2002, BIOCHEM BIOPH RES CO, V291, P884, DOI 10.1006/bbrc.2002.6531; Tanioka T, 2000, J BIOL CHEM, V275, P32775, DOI 10.1074/jbc.M003504200; Thoren S, 2000, EUR J BIOCHEM, V267, P6428, DOI 10.1046/j.1432-1327.2000.01735.x; Tjandrawinata RR, 1997, ADV EXP MED BIOL, V407, P163; Tong Q, 1997, J BIOL CHEM, V272, P9043; Vadlamudi R, 1999, ONCOGENE, V18, P305, DOI 10.1038/sj.onc.1202307; VIGLIETTO G, 1995, ONCOGENE, V11, P1207; Wang JW, 2003, MOL ENDOCRINOL, V17, P1425, DOI 10.1210/me.2003-0041; Yoshimatsu K, 2001, CLIN CANCER RES, V7, P3971; Yoshimatsu K, 2001, CLIN CANCER RES, V7, P2669; Zweifel BS, 2002, CANCER RES, V62, P6706	70	27	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52131	52138		10.1074/jbc.M306003200	http://dx.doi.org/10.1074/jbc.M306003200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14555660	hybrid			2022-12-27	WOS:000187480700020
J	Towbin, H; Bair, KW; DeCaprio, JA; Eck, MJ; Kim, S; Kinder, FR; Morollo, A; Mueller, DR; Schindler, P; Song, HK; van Oostrum, J; Versace, RW; Voshol, H; Wood, J; Zabludoff, S; Phillips, PE				Towbin, H; Bair, KW; DeCaprio, JA; Eck, MJ; Kim, S; Kinder, FR; Morollo, A; Mueller, DR; Schindler, P; Song, HK; van Oostrum, J; Versace, RW; Voshol, H; Wood, J; Zabludoff, S; Phillips, PE			Proteomics-based target identification - Bengamides as a new class of methionine aminopeptidase inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SELECTIVE-INHIBITION; 67-KDA POLYPEPTIDE; IN-VIVO; PROTEIN; FUMAGILLIN; ANGIOGENESIS; ISOFORMS; PHOSPHORYLATION; OVALICIN; ANALOGS	LAF389 is a synthetic analogue of bengamides, a class of marine natural products that produce inhibitory effects on tumor growth in vitro and in vivo. A proteomics-based approach has been used to identify signaling pathways affected by bengamides. LAF389 treatment of cells resulted in altered mobility of a subset of proteins on two-dimensional gel electrophoresis. Detailed analysis of one of the proteins, 14-3-3gamma, showed that bengamide treatment resulted in retention of the amino-terminal methionine, suggesting that bengamides directly or indirectly inhibited methionine aminopeptidases (MetAps). Both known MetAps are inhibited by LAF389. Short interfering RNA suppression of MetAp2 also altered amino-terminal processing of 14-3-3gamma. A high resolution structure of human MetAp2 co-crystallized with a bengamide shows that the compound binds in a manner that mimics peptide substrates. Additionally, the structure reveals that three key hydroxyl groups on the inhibitor coordinate the di-cobalt center in the enzyme active site.	Novartis Pharma AG, CH-4036 Basel, Switzerland; Novartis Pharmaceut, E Hanover, NJ 07936 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Novartis; Novartis; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School	Towbin, H (corresponding author), Novartis Pharma AG, Lichstr 35, CH-4036 Basel, Switzerland.	harry.towbin@pharma.novartis.com; penny.phillips@pharma.novartis.com	Song, Hyun Kyu/D-6763-2016	Song, Hyun Kyu/0000-0001-5684-4059				Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chen SP, 2002, ARCH BIOCHEM BIOPHYS, V398, P87, DOI 10.1006/abbi.2001.2675; DATTA B, 1989, J BIOL CHEM, V264, P20620; DATTA B, 1988, P NATL ACAD SCI USA, V85, P3324, DOI 10.1073/pnas.85.10.3324; Dubois T, 1997, J BIOL CHEM, V272, P28882, DOI 10.1074/jbc.272.46.28882; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Endo H, 2002, J BIOL CHEM, V277, P26396, DOI 10.1074/jbc.M202244200; Griffith EC, 1998, P NATL ACAD SCI USA, V95, P15183, DOI 10.1073/pnas.95.26.15183; Griffith EC, 1997, CHEM BIOL, V4, P461, DOI 10.1016/S1074-5521(97)90198-8; INGBER D, 1990, NATURE, V348, P555, DOI 10.1038/348555a0; Jones TA, 1997, METHOD ENZYMOL, V277, P173, DOI 10.1016/S0076-6879(97)77012-5; Kinder FR, 2001, J MED CHEM, V44, P3692; Kinder FR, 2001, J ORG CHEM, V66, P2118; Li X, 1996, BIOCHEM BIOPH RES CO, V227, P152, DOI 10.1006/bbrc.1996.1482; LI X, 1995, BBA-GENE STRUCT EXPR, V1260, P333, DOI 10.1016/0167-4781(94)00227-T; Li X, 1995, P NATL ACAD SCI USA, V92, P12357, DOI 10.1073/pnas.92.26.12357; Liu SP, 1998, SCIENCE, V282, P1324, DOI 10.1126/science.282.5392.1324; Liu WF, 2001, ACTA BIOCH BIOPH SIN, V33, P719; Lowther WT, 2000, BBA-PROTEIN STRUCT M, V1477, P157, DOI 10.1016/S0167-4838(99)00271-X; Lowther WT, 1999, BIOCHEMISTRY-US, V38, P7678, DOI 10.1021/bi990684r; MARTIN H, 1993, FEBS LETT, V331, P296, DOI 10.1016/0014-5793(93)80356-Y; Megidish T, 1998, J BIOL CHEM, V273, P21834, DOI 10.1074/jbc.273.34.21834; Muller DR, 1999, J MASS SPECTROM, V34, P336, DOI 10.1002/(SICI)1096-9888(199904)34:4<336::AID-JMS765>3.0.CO;2-U; Nagase T, 1995, DNA Res, V2, P37, DOI 10.1093/dnares/2.1.37; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; QUINOA E, 1986, J ORG CHEM, V51, P4494, DOI 10.1021/jo00373a036; Rabilloud T, 1997, ELECTROPHORESIS, V18, P307, DOI 10.1002/elps.1150180303; Sin N, 1997, P NATL ACAD SCI USA, V94, P6099, DOI 10.1073/pnas.94.12.6099; SUDA H, 1976, ARCH BIOCHEM BIOPHYS, V177, P196, DOI 10.1016/0003-9861(76)90429-X; Thale Z, 2001, J ORG CHEM, V66, P1733, DOI 10.1021/jo001380+; Towbin H, 2001, ELECTROPHORESIS, V22, P1887, DOI 10.1002/1522-2683(200106)22:10<1887::AID-ELPS1887>3.0.CO;2-Q; Turk BE, 1999, CHEM BIOL, V6, P823, DOI 10.1016/S1074-5521(99)80129-X; Tzivion G, 2001, ONCOGENE, V20, P6331, DOI 10.1038/sj.onc.1204777; Varshavsky A, 1996, P NATL ACAD SCI USA, V93, P12142, DOI 10.1073/pnas.93.22.12142; Wang JY, 2000, J CELL BIOCHEM, V77, P465, DOI 10.1002/(SICI)1097-4644(20000601)77:3<465::AID-JCB11>3.3.CO;2-D; WU SY, 1993, J BIOL CHEM, V268, P10796; Yoshida T, 1998, CANCER RES, V58, P3751	37	128	143	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52964	52971		10.1074/jbc.M309039200	http://dx.doi.org/10.1074/jbc.M309039200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14534293	hybrid			2022-12-27	WOS:000187480700119
J	Heermann, R; Altendorf, K; Jung, K				Heermann, R; Altendorf, K; Jung, K			The N-terminal input domain of the sensor kinase KdpD of Escherichia coli stabilizes the interaction between the cognate response regulator KdpE and the corresponding DNA-binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYL PHOSPHATE; TURGOR SENSOR; POTASSIUM-TRANSPORT; KDPABC OPERON; EXPRESSION; PROTEINS; PROMOTER; SYSTEM; PHOSPHORYLATION; ACTIVATION	The sensor kinase/response regulator system KdpD/KdpE of Escherichia coli regulates expression of the kdpFABC operon, which encodes the high affinity K+ transport system KdpFABC. The membrane-bound sensor kinase KdpD consists of an N-terminal input domain (comprising a large cytoplasmic domain and four transmembrane domains) and a cytoplasmic C-terminal transmitter domain. Here we show that the cytoplasmic N-terminal domain of KdpD (KdpD/1-395) alone supports semi-constitutive kdpFABC expression, which becomes dependent on the extracellular K+ concentration under K+-limiting growth conditions. However, it should be noted that the non-phosphorylatable derivative KdpD/H673Q or the absence of KdpD abolishes kdpFABC expression completely. KdpD/1-395 mediated kdpFABC expression requires the corresponding response regulator KdpE with an intact phosphorylation site. Experiments with an Escherichia coli mutant unable to synthesize acetyl phosphate as well as transposon mutagenesis suggest that KdpE is phosphorylated in vivo by low molecular weight phosphodonors in the absence of the full-length sensor kinase. Various biochemical approaches provide first evidence that kdpFABC expression mediated by KdpD/1-395 is due to a stabilizing effect of this domain on the binding of KdpEsimilar toP to its corresponding DNA-binding site. Such a stabilizing effect of a sensor kinase domain on the DNA-protein interaction of the cognate response regulator has never been observed before for any other sensor kinase. It describes a new mechanism in bacterial two-component signal transduction.	Univ Osnabruck, Fachbereich Biol Chem, Abt Mikrobiol, D-49069 Osnabruck, Germany; Tech Univ Darmstadt, Inst Mikrobiol & Genet, D-64287 Darmstadt, Germany	University Osnabruck; Technical University of Darmstadt	Jung, K (corresponding author), Univ Osnabruck, Fachbereich Biol Chem, Abt Mikrobiol, D-49069 Osnabruck, Germany.	jung@bio.tu-darmstadt.de	Heermann, Ralf/CAF-8609-2022; Heermann, Ralf/E-1793-2013	Heermann, Ralf/0000-0003-0631-6156				ALTENDORF K, 1996, BIOMEMBR, V5, P403; Ballal A, 2002, ARCH MICROBIOL, V178, P141, DOI 10.1007/s00203-002-0435-1; Bouche S, 1998, MOL MICROBIOL, V27, P787, DOI 10.1046/j.1365-2958.1998.00725.x; Chamnongpol S, 2000, J MOL BIOL, V300, P291, DOI 10.1006/jmbi.2000.3848; CHANG YY, 1994, MOL MICROBIOL, V11, P1019, DOI 10.1111/j.1365-2958.1994.tb00380.x; EPSTEIN W, 1971, J BACTERIOL, V108, P639, DOI 10.1128/JB.108.2.639-644.1971; EPSTEIN W, 1992, ACTA PHYSIOL SCAND, V146, P193; FENG JL, 1992, J BACTERIOL, V174, P6061, DOI 10.1128/JB.174.19.6061-6070.1992; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; Heermann R, 2003, MOL MICROBIOL, V47, P839, DOI 10.1046/j.1365-2958.2003.03348.x; Heermann R, 2000, J BIOL CHEM, V275, P17080, DOI 10.1074/jbc.M000093200; Heermann R, 1998, BBA-BIOMEMBRANES, V1415, P114, DOI 10.1016/S0005-2736(98)00181-3; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Jung K, 1998, J BIOL CHEM, V273, P17406, DOI 10.1074/jbc.273.28.17406; Jung K, 1997, J BIOL CHEM, V272, P10847; Jung K, 2001, J BIOL CHEM, V276, P40896, DOI 10.1074/jbc.M107871200; Jung K, 1998, BBA-BIOMEMBRANES, V1372, P311, DOI 10.1016/S0005-2736(98)00070-4; Jung K, 1998, J BIOL CHEM, V273, P26415, DOI 10.1074/jbc.273.41.26415; Kaneko T, 1996, DNA Res, V3, P109; KLECKNER N, 1991, METHOD ENZYMOL, V204, P139; KOLLMANN R, 1993, BIOCHIM BIOPHYS ACTA, V1143, P62, DOI 10.1016/0005-2728(93)90216-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAIMINS LA, 1981, P NATL ACAD SCI-BIOL, V78, P464, DOI 10.1073/pnas.78.1.464; LEDER P, 1977, SCIENCE, V196, P175, DOI 10.1126/science.322278; LUCASSEN M, 1998, THESIS U OSNBRUCK; LUKAT GS, 1992, P NATL ACAD SCI USA, V89, P718, DOI 10.1073/pnas.89.2.718; Matsubara M, 1999, BIOSCI BIOTECH BIOCH, V63, P408, DOI 10.1271/bbb.63.408; MCCLEARY WR, 1994, J BIOL CHEM, V269, P31567; Miller JH., 1992, SHORT COURSE BACTERI, P72; NAKASHIMA K, 1993, MOL MICROBIOL, V7, P109, DOI 10.1111/j.1365-2958.1993.tb01102.x; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; POLAREK JW, 1988, METHOD ENZYMOL, V157, P655; Puppe W, 1996, J BIOL CHEM, V271, P25027, DOI 10.1074/jbc.271.40.25027; Sardesai AA, 2001, J BACTERIOL, V183, P86, DOI 10.1128/JB.183.1.86-93.2001; SEKIMIZU K, 1994, CHEM PHYS LIPIDS, V73, P223, DOI 10.1016/0009-3084(94)90183-X; STADTMAN ER, 1957, METHOD ENZYMOL, V3, P228, DOI 10.1016/S0076-6879(57)03379-0; Steyn AJC, 2003, MOL MICROBIOL, V47, P1074, DOI 10.1046/j.1365-2958.2003.03356.x; SUGIURA A, 1993, BIOSCI BIOTECH BIOCH, V57, P356, DOI 10.1271/bbb.57.356; SUGIURA A, 1992, MOL MICROBIOL, V6, P1769, DOI 10.1111/j.1365-2958.1992.tb01349.x; SUGIURA A, 1994, MOL MICROBIOL, V14, P929, DOI 10.1111/j.1365-2958.1994.tb01328.x; Sun JZ, 1996, BIOCHEMISTRY-US, V35, P990, DOI 10.1021/bi952166w; WALDERHAUG MO, 1992, J BACTERIOL, V174, P2152, DOI 10.1128/JB.174.7.2152-2159.1992; White O, 1999, SCIENCE, V286, P1571, DOI 10.1126/science.286.5444.1571; Wright JS, 2000, J BACTERIOL, V182, P6279, DOI 10.1128/JB.182.22.6279-6286.2000; Wright JS, 2001, J BACTERIOL, V183, P3149, DOI 10.1128/JB.183.10.3149-3159.2001; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZIMMANN P, 1995, J BIOL CHEM, V270, P28282	48	34	35	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51277	51284		10.1074/jbc.M303801200	http://dx.doi.org/10.1074/jbc.M303801200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14534307	hybrid			2022-12-27	WOS:000187206300054
J	Inagaki, T; Suzuki, S; Miyamoto, T; Takeda, T; Yamashita, K; Komatsu, A; Yamauchi, K; Hashizume, K				Inagaki, T; Suzuki, S; Miyamoto, T; Takeda, T; Yamashita, K; Komatsu, A; Yamauchi, K; Hashizume, K			The retinoic acid-responsive proline-rich protein is identified in promyeloleukemic HL-60 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; GENE-EXPRESSION; DIFFERENTIATION; RECEPTOR; ALPHA; INDUCTION; RXR	To identify new genes that retinoic acid activates, we employed an mRNA differential display technique and screened for genes that are differentially expressed in promyeloleukemic HL-60 cells incubated in the presence of all-trans-retinoic acid ( ATRA) compared with the absence of ATRA. We cloned the coding region of a retinoic acid-induced gene from a human thymus library, which was the mRNA encoding the 666-amino acid human homologue of mouse proline-rich protein 76. We have designated it RARP1 ( retinoic acid response proline-rich protein 1). Transcription of an similar to 2.4-kbp mRNA occurred mainly in organs with immune functions, such as thymus, spleen, and peripheral leukocytes. Cycloheximide blocked the ATRA-induced expression. In megakaryocyte-like human erythroleukemia HEL cells, the amount of RARP1 mRNA was high, but it was low in human T-lymphoblastoid Jurkat cells. A specific antibody against RARP1 recognized a 110-kDa protein, which accumulates after incubation of HL-60 cells with ATRA. In immunohistochemical experiments, strong RARP1 staining was observed in the megakaryocytes of bone marrow and spleen, and heterogeneous stain was seen in thymus. Transcriptional studies showed that RARP1 expression impaired the transactivation through activator protein1 and serum response-element in all cell lines we checked, whereas it did not affect the transactivation through cAMP-response element in the same cell lines. Further analysis demonstrated that proline-rich regions of RARP1 are the functional regions regulated for suppression of activator protein1 transactivation. These data suggest that ATRA-inducible RARP1 selectively affects signal transduction and may contribute to myeloid and megakaryocytic differentiation.	Shinshu Univ, Grad Sch, Dept Aging Med & Geriatr, Inst Aging & Adaptat,Div Med, Nagano 3908621, Japan	Shinshu University	Suzuki, S (corresponding author), Shinshu Univ, Grad Sch, Dept Aging Med & Geriatr, Inst Aging & Adaptat,Div Med, 3-1-1 Asahi, Nagano 3908621, Japan.		Inagaki, Takeshi/J-8802-2013	Inagaki, Takeshi/0000-0003-1711-8286				ANN DK, 1992, J BIOL CHEM, V267, P699; Battle TE, 2001, EUR J CELL BIOL, V80, P59, DOI 10.1078/0171-9335-00141; BRADFORD PG, 1992, J BIOL CHEM, V267, P20959; Breitman T R, 1986, Prog Clin Biol Res, V226, P215; BREITMAN TR, 1980, P NATL ACAD SCI-BIOL, V77, P2936, DOI 10.1073/pnas.77.5.2936; Chacko G, 1998, J BIOL CHEM, V273, P19840, DOI 10.1074/jbc.273.31.19840; DEVALIA V, 1992, BLOOD, V80, P68; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; HSU HC, 1993, LEUKEMIA, V7, P458; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; KATAGIRI K, 1991, J IMMUNOL, V146, P701; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; Liu TX, 2000, BLOOD, V96, P1496, DOI 10.1182/blood.V96.4.1496.h8001496_1496_1504; LOTAN R, 1980, BIOCHIM BIOPHYS ACTA, V605, P33, DOI 10.1016/0304-419X(80)90021-9; Mori JI, 2002, ENDOCRINOLOGY, V143, P1538, DOI 10.1210/en.143.4.1538; Ohtsuki T, 1997, BIOCHEM BIOPH RES CO, V230, P81, DOI 10.1006/bbrc.1996.5887; Pessin Jeffrey E., 1999, Endocrine Journal, V46, pS11, DOI 10.1507/endocrj.46.Suppl_S11; PFAHL M, 1994, VITAM HORM, V49, P327; SARASTE M, 1995, CURR OPIN STRUC BIOL, V5, P403, DOI 10.1016/0959-440X(95)80104-9; Suzuki S, 2003, EUR J ENDOCRINOL, V148, P259, DOI 10.1530/eje.0.1480259; YAMAUCHI K, 1994, MOL CELL BIOL, V14, P4427, DOI 10.1128/MCB.14.7.4427	21	10	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51685	51692		10.1074/jbc.M308016200	http://dx.doi.org/10.1074/jbc.M308016200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14530287	hybrid			2022-12-27	WOS:000187206300103
J	Baronas-Lowell, D; Lauer-Fields, JL; Fields, GB				Baronas-Lowell, D; Lauer-Fields, JL; Fields, GB			Induction of endothelial cell activation by a triple helical alpha(2)beta(1) integrin ligand, derived from type I collagen alpha 1(I)496-507	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERCELLULAR-ADHESION MOLECULE-1; MEDIATED SIGNAL-TRANSDUCTION; PEPTIDE-AMPHIPHILES; GENE-EXPRESSION; E-SELECTIN; INTERSTITIAL COLLAGENS; LEUKOCYTE ADHESION; CANCER PATIENTS; BINDING-SITES; GER SEQUENCE	Endothelial cell activation involves the elevated expression of cell adhesion molecules, chemoattractants, chemokines, and cytokines. These expression profiles may be regulated by integrin-mediated cell signaling pathways. In the current study, an alpha(2)beta(1) integrin triple helical peptide ligand derived from type I collagen residues alpha1(I) 496-507 was examined for induction of human aortic endothelial cell (HAEC) activation. In addition, a "miniextracellular matrix" composed of a mixture of the alpha1(I) 496-507 ligand and a second, alpha-helical ligand incorporating the endothelial cell proliferating region of SPARC (secreted protein acidic and rich in cysteine) was studied for induction of HAEC activation. Following HAEC adhesion to alpha1(I) 496-507, mRNA expression of E-selectin-1, vascular and intercellular cell adhesion molecules-1, and monocytic chemoattractant protein-1 was stimulated, whereas that of endothelin-1 was inhibited. Enzyme-linked immunosorbent assay analysis demonstrated that E-selectin-1 and monocytic chemoattractant protein-1 expression was also stimulated, whereas endothelin-1 protein expression diminished. Engagement of the alpha(2)beta(1) integrin initiated a HAEC response similar to that of tumor necrosis factor-alpha-induced HAECs but was not sufficient to induce an inflammatory response. Addition of the SPARC(119-122) region had only a slight effect on HAEC activation. Other cell-extracellular matrix interactions appear to be required to elicit an inflammatory response. The alpha(2)beta(1) integrin specific triple helical peptide ligand described herein represents a more general in vitro model system by which gene expression and protein production profiles induced by binding to a single cellular receptor type can be quantified.	Florida Atlantic Univ, Dept Chem & Biochem, Boca Raton, FL 33431 USA	State University System of Florida; Florida Atlantic University	Fields, GB (corresponding author), Florida Atlantic Univ, Dept Chem & Biochem, 777 Glades Rd, Boca Raton, FL 33431 USA.				NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB000289] Funding Source: NIH RePORTER; NIBIB NIH HHS [EB00289] Funding Source: Medline	NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))		Alexiou D, 2003, AM J GASTROENTEROL, V98, P478, DOI 10.1016/S0002-9270(02)05927-0; Alexiou D, 2001, EUR J CANCER, V37, P2392, DOI 10.1016/S0959-8049(01)00318-5; BEVILACQUA MP, 1987, P NATL ACAD SCI USA, V84, P9238, DOI 10.1073/pnas.84.24.9238; Bianco-Peled H, 2001, LANGMUIR, V17, P6931, DOI 10.1021/la990383i; Brekken RA, 2000, MATRIX BIOL, V19, P569, DOI 10.1016/S0945-053X(00)00105-0; Brivanlou AH, 2002, SCIENCE, V295, P813, DOI 10.1126/science.1066355; Camper L, 1998, J BIOL CHEM, V273, P20383, DOI 10.1074/jbc.273.32.20383; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; COLE WG, 1994, PROG NUCLEIC ACID RE, V47, P29, DOI 10.1016/S0079-6603(08)60249-4; de Fougerolles AR, 2000, J CLIN INVEST, V105, P721, DOI 10.1172/JCI7911; DEFILIPPI P, 1994, CELL ADHES COMMUN, V2, P75, DOI 10.3109/15419069409014203; DEFILIPPI P, 1991, J CELL BIOL, V114, P855, DOI 10.1083/jcb.114.4.855; Di Lullo GA, 2002, J BIOL CHEM, V277, P4223, DOI 10.1074/jbc.M110709200; Dillow AK, 2001, BIOMATERIALS, V22, P1493, DOI 10.1016/S0142-9612(00)00304-5; Dori Y, 2000, J BIOMED MATER RES, V50, P75, DOI 10.1002/(SICI)1097-4636(200004)50:1<75::AID-JBM11>3.0.CO;2-A; Emsley J, 2000, CELL, V101, P47, DOI 10.1016/S0092-8674(00)80622-4; Fields GB, 1995, CONNECT TISSUE RES, V31, P235, DOI 10.3109/03008209509010815; Fields GB, 1998, BIOPOLYMERS, V47, P143, DOI 10.1002/(SICI)1097-0282(1998)47:2<143::AID-BIP3>3.0.CO;2-U; Forns P, 2000, BIOPOLYMERS, V54, P531, DOI 10.1002/1097-0282(200012)54:7<531::AID-BIP60>3.0.CO;2-X; FUNK SE, 1993, J CELL PHYSIOL, V154, P53, DOI 10.1002/jcp.1041540108; GEARING AJH, 1993, IMMUNOL TODAY, V14, P506, DOI 10.1016/0167-5699(93)90267-O; Gibbons GH, 1996, SCIENCE, V272, P689, DOI 10.1126/science.272.5262.689; Goebeler M, 1999, BLOOD, V93, P857, DOI 10.1182/blood.V93.3.857.403k03_857_865; Gonzalez-Amaro R, 1998, DRUGS, V56, P977, DOI 10.2165/00003495-199856060-00003; Haas TL, 1998, J BIOL CHEM, V273, P3604, DOI 10.1074/jbc.273.6.3604; Harari OA, 1999, J IMMUNOL, V163, P6860; HARLAN JM, 1985, BLOOD, V65, P513; Heino J, 2000, MATRIX BIOL, V19, P319, DOI 10.1016/S0945-053X(00)00076-7; Hubbard AK, 2000, FREE RADICAL BIO MED, V28, P1379, DOI 10.1016/S0891-5849(00)00223-9; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Khachigian LM, 1996, SCIENCE, V271, P1427, DOI 10.1126/science.271.5254.1427; Knight CG, 2000, J BIOL CHEM, V275, P35, DOI 10.1074/jbc.275.1.35; Knight CG, 1998, J BIOL CHEM, V273, P33287, DOI 10.1074/jbc.273.50.33287; KOSEKI N, 1994, CELL ADHES COMMUN, V1, P355, DOI 10.3109/15419069409097266; Koyama H, 1996, CELL, V87, P1069, DOI 10.1016/S0092-8674(00)81801-2; KRAMER RH, 1989, J BIOL CHEM, V264, P4684; Kuhn K, 1994, Trends Cell Biol, V4, P256, DOI 10.1016/0962-8924(94)90124-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lafont A, 1999, CIRCULATION, V100, P1109, DOI 10.1161/01.CIR.100.10.1109; Lafrenie RM, 1996, J CELL BIOCHEM, V61, P543, DOI 10.1002/(SICI)1097-4644(19960616)61:4<543::AID-JCB7>3.0.CO;2-O; LANE TF, 1994, J CELL BIOL, V125, P929, DOI 10.1083/jcb.125.4.929; Lauer JL, 1998, BIOCHEMISTRY-US, V37, P5279, DOI 10.1021/bi972958l; Lauer-Fields JL, 2003, J BIOL CHEM, V278, P18140, DOI 10.1074/jbc.M211330200; Lauer-Fields JL, 2003, J BIOL CHEM, V278, P14321, DOI 10.1074/jbc.M212246200; LOBB RR, 1999, GUIDEBOOK EXTRACELLU, P380; Malkar NB, 2003, BIOMACROMOLECULES, V4, P518, DOI 10.1021/bm0256597; Malkar NB, 2002, BIOCHEMISTRY-US, V41, P6054, DOI 10.1021/bi012071w; Mantovani A, 1997, IMMUNOL TODAY, V18, P231, DOI 10.1016/S0167-5699(97)81662-3; Mombouli JV, 1999, J MOL CELL CARDIOL, V31, P61, DOI 10.1006/jmcc.1998.0844; Naito S, 2002, BIOCHEM BIOPH RES CO, V291, P130, DOI 10.1006/bbrc.2002.6418; NEWMAN W, 1993, J IMMUNOL, V150, P644; Nguyen M, 2000, INT J BIOCHEM CELL B, V32, P621, DOI 10.1016/S1357-2725(00)00013-3; Noble KE, 1996, EUR J IMMUNOL, V26, P2944, DOI 10.1002/eji.1830261221; OSBORN L, 1990, CELL, V62, P3, DOI 10.1016/0092-8674(90)90230-C; Pakalns T, 1999, BIOMATERIALS, V20, P2265, DOI 10.1016/S0142-9612(99)00157-X; Pober JS, 2002, ARTHRITIS RES THER, V4, pS109, DOI 10.1186/ar576; Stupack DG, 2002, J CELL SCI, V115, P3729, DOI 10.1242/jcs.00071; Sweeney SM, 1998, P NATL ACAD SCI USA, V95, P7275, DOI 10.1073/pnas.95.13.7275; Sweeney SM, 2003, J BIOL CHEM, V278, P30516, DOI 10.1074/jbc.M304237200; Tiger CF, 2001, DEV BIOL, V237, P116, DOI 10.1006/dbio.2001.0363; van der Flier A, 2001, CELL TISSUE RES, V305, P285, DOI 10.1007/s004410100417; Velling T, 1999, J BIOL CHEM, V274, P25735, DOI 10.1074/jbc.274.36.25735; Vogel WF, 2001, EUR J DERMATOL, V11, P506; Werle M, 2002, CARDIOVASC RES, V56, P284, DOI 10.1016/S0008-6363(02)00600-4; Xu JH, 1998, J CELL BIOL, V140, P709, DOI 10.1083/jcb.140.3.709; Xu Y, 2000, J BIOL CHEM, V275, P38981, DOI 10.1074/jbc.M007668200; Yu YC, 1997, METHOD ENZYMOL, V289, P571; Zhang WM, 2003, J BIOL CHEM, V278, P7270, DOI 10.1074/jbc.M210313200	68	17	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 9	2004	279	2					952	962		10.1074/jbc.M305989200	http://dx.doi.org/10.1074/jbc.M305989200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	759DJ	14581484	hybrid			2022-12-27	WOS:000187722800018
J	Steiglitz, BM; Ayala, M; Narayanan, K; George, A; Greenspan, DS				Steiglitz, BM; Ayala, M; Narayanan, K; George, A; Greenspan, DS			Bone morphogenetic protein-1/tolloid-like proteinases process dentin matrix protein-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROCOLLAGEN C-PROTEINASE; COLLAGEN; GENE; EXPRESSION; METALLOPROTEINASES; IDENTIFICATION; MINERALIZATION; CLEAVAGE; BIGLYCAN; FAMILY	Bone morphogenetic protein-1 (BMP-1)/Tolloid-like metalloproteinases play key roles in formation of mammalian extracellular matrix (ECM), through the biosynthetic conversion of precursor proteins into their mature functional forms. These proteinases probably play a further role in formation of bone through activation of transforming growth factor beta-like BMPs. Dentin matrix protein-1 (DMP1), deposited into the ECM during assembly and involved in initiating mineralization of bones and teeth, is thought to undergo proteolysis in vivo to generate functional cleavage fragments found in extracts of mineralized tissues. Here, we have generated recombinant DMP1 and demonstrate that it is cleaved, to varying extents, by all four mammalian BMP-1/Tolloid-like proteinases, to generate fragments similar in size to those previously isolated from bone. Consistent with possible roles for the BMP-1/Tolloid-like proteinases in the physiological processing of DMP1, NH2-terminal sequences of products generated by BMP-1 cleavage of DMP1 match those predicted from processing at the predicted DMP1 site that shows greatest cross-species conservation of sequences. Moreover, fibroblasts derived from mouse embryos homozygous null for genes encoding three of the four mammalian BMP1/Tolloid-like proteinases appear to be deficient in processing of DMP1. Thus, a further role for BMP-1-Tolloid-like proteinases in formation of mineralized tissues is indicated, via proteolytic processing of DMP1.	Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI 53706 USA; Univ Wisconsin, Dept Biomol Chem, Madison, WI 53706 USA; Univ Illinois, Dept Oral Biol, Chicago, IL 60612 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Greenspan, DS (corresponding author), Univ Wisconsin, Dept Pathol & Lab Med, 1300 Univ Ave, Madison, WI 53706 USA.	dsgreens@wisc.edu	Narayanan, Karthikeyan/D-1957-2010	Narayanan, Karthikeyan/0000-0001-5136-2296; Greenspan, Daniel/0000-0001-8096-7446; GEORGE, ANNE/0000-0002-9008-7642; Ayala, Melvin/0000-0002-8669-1046	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR047746, R56AR047746] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063471, T32GM007215] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR47746] Funding Source: Medline; NIGMS NIH HHS [T32 GM07215, GM63471] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amano S, 2000, J BIOL CHEM, V275, P22728, DOI 10.1074/jbc.M002345200; BIRK DE, 1990, J CELL SCI, V95, P649; Blader P, 1997, SCIENCE, V278, P1937, DOI 10.1126/science.278.5345.1937; Boileau G, 2001, BIOCHEM J, V355, P707, DOI 10.1042/bj3550707; BOND JS, 1995, PROTEIN SCI, V4, P1247, DOI 10.1002/pro.5560040701; Butler WT, 1998, EUR J ORAL SCI, V106, P204, DOI 10.1111/j.1600-0722.1998.tb02177.x; Campos M, 2003, BIOCHEM J, V373, P271, DOI 10.1042/BJ20030287; Corsi A, 2002, J BONE MINER RES, V17, P1180, DOI 10.1359/jbmr.2002.17.7.1180; Dahl T, 1998, J STRUCT BIOL, V123, P162, DOI 10.1006/jsbi.1998.4025; Feng JQ, 2002, J BONE MINER RES, V17, P1822, DOI 10.1359/jbmr.2002.17.10.1822; Fratzl P, 1996, J CLIN INVEST, V97, P396, DOI 10.1172/JCI118428; FUJISAWA R, 1992, CALCIFIED TISSUE INT, V51, P438; FUKAGAWA M, 1994, DEV BIOL, V163, P175, DOI 10.1006/dbio.1994.1133; GEORGE A, 1993, J BIOL CHEM, V268, P12624; He G, 2003, NAT MATER, V2, P552, DOI 10.1038/nmat945; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Hunter GK, 1996, BIOCHEM J, V317, P59, DOI 10.1042/bj3170059; Imamura Y, 1998, J BIOL CHEM, V273, P27511, DOI 10.1074/jbc.273.42.27511; Karsenty G, 1998, DEV GENET, V22, P301, DOI 10.1002/(SICI)1520-6408(1998)22:4&lt;301::AID-DVG1&gt;3.0.CO;2-A; Kessler E, 1996, SCIENCE, V271, P360, DOI 10.1126/science.271.5247.360; Kurisu K, 1997, Oral Dis, V3, P223; Li SW, 1996, P NATL ACAD SCI USA, V93, P5127, DOI 10.1073/pnas.93.10.5127; MENDLER M, 1989, J CELL BIOL, V108, P191, DOI 10.1083/jcb.108.1.191; Pappano WN, 2003, MOL CELL BIOL, V23, P4428, DOI 10.1128/MCB.23.13.4428-4438.2003; Phillips CL, 2000, BONE, V27, P219, DOI 10.1016/S8756-3282(00)00311-2; Piccolo S, 1997, CELL, V91, P407, DOI 10.1016/S0092-8674(00)80424-9; Qin C, 2002, J DENT RES, V81, P392, DOI 10.1177/154405910208100607; Qin CL, 2001, EUR J ORAL SCI, V109, P133, DOI 10.1034/j.1600-0722.2001.00001.x; Qin CL, 2003, J BIOL CHEM, V278, P34700, DOI 10.1074/jbc.M305315200; Qin CL, 2001, J BIOL CHEM, V276, P904, DOI 10.1074/jbc.M006271200; Quarles LD, 2003, AM J PHYSIOL-ENDOC M, V285, pE1, DOI 10.1152/ajpendo.00016.2003; Rattenholl A, 2002, J BIOL CHEM, V277, P26372, DOI 10.1074/jbc.M203247200; Scott IC, 1999, DEV BIOL, V213, P283, DOI 10.1006/dbio.1999.9383; Scott IC, 2000, J BIOL CHEM, V275, P30504, DOI 10.1074/jbc.M004846200; Septier D, 2001, CALCIFIED TISSUE INT, V69, P38, DOI 10.1007/s002230020047; Sreenath T, 2003, J BIOL CHEM, V278, P24874, DOI 10.1074/jbc.M303908200; Srinivasan R, 1999, CONNECT TISSUE RES, V40, P251, DOI 10.3109/03008209909000703; Steiglitz BM, 2002, J BIOL CHEM, V277, P49820, DOI 10.1074/jbc.M209891200; STETLERSTEVENSON WG, 1983, BIOCHEMISTRY-US, V22, P4326, DOI 10.1021/bi00287a025; Suzuki N, 1996, DEVELOPMENT, V122, P3587; Thotakura SR, 2000, J DENT RES, V79, P835, DOI 10.1177/00220345000790030901; Toyosawa S, 1999, GENE, V234, P307, DOI 10.1016/S0378-1119(99)00195-X; Toyosawa S, 2000, J MOL EVOL, V50, P31, DOI 10.1007/s002399910004; Unsold C, 2002, J BIOL CHEM, V277, P5596, DOI 10.1074/jbc.M110003200; Uzel MI, 2001, J BIOL CHEM, V276, P22537, DOI 10.1074/jbc.M102352200; Van Den Bussche RA, 2003, MOL PHYLOGENET EVOL, V26, P89, DOI 10.1016/S1055-7903(02)00297-X; VEIS A, 1993, J BONE MINER RES, V8, pS493; Veitch DP, 2003, J BIOL CHEM, V278, P15661, DOI 10.1074/jbc.M210588200; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; Xu TS, 1998, NAT GENET, V20, P78, DOI 10.1038/1746; Zhang XH, 2001, NAT GENET, V27, P151, DOI 10.1038/84765	51	117	121	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 9	2004	279	2					980	986		10.1074/jbc.M310179200	http://dx.doi.org/10.1074/jbc.M310179200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	759DJ	14578349	hybrid			2022-12-27	WOS:000187722800021
J	Eriksen, KW; Sommer, VH; Woetmann, A; Rasmussen, AB; Brender, C; Svejgaard, A; Skov, S; Geisler, C; Odum, N				Eriksen, KW; Sommer, VH; Woetmann, A; Rasmussen, AB; Brender, C; Svejgaard, A; Skov, S; Geisler, C; Odum, N			Bi-phasic effect of interferon (IFN)-alpha - IFN-alpha up- and down-regulates interleukin-4 signaling in human T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; HUMAN MONOCYTES; CROSS-TALK; MYCOSIS-FUNGOIDES; II INTERFERONS; IL-4 RECEPTOR; GAMMA; STAT6; ACTIVATION; INDUCTION	Interferon (IFN)-alpha/beta is produced by virally infected cells and is believed to play an important role in early phases of the innate immune response. In addition, IFN-alpha/beta inhibits interleukin ( IL)-4 signaling in B cells and monocytes, suggesting that IFN-alpha/beta (like IFN-gamma) is a Th1 cytokine. Here, we study cross-talk between IFN-alpha and IL-4 in human T cells. As expected, stimulation with IFN-alpha for 12 - 24 h inhibits IL-4 signaling. Surprisingly, however, IFN-alpha has the opposite effect on IL-4 signaling at earlier time points (up to 6 h). Thus, IFN-alpha enhances IL-4-mediated STAT6 activation in both CD4+ and CD8+ human T cells. The effect is specific because (i) another interferon, IFN-gamma, does not enhance IL-4-mediated STAT6 activation, (ii) IFN-alpha-mediated STAT1 and STAT2 activation is not modulated by IL-4, and (iii) activation of Janus kinases is not enhanced or prolonged by simultaneous stimulation with IFN-alpha and IL-4. Moreover, costimulation results in a selective increased STAT6/ STAT2 association and an association between IFNAR/ IL-4R components, suggesting that the IFNAR provides an additional STAT6 docking site via STAT2, leading to a more efficient dimerization/activation of STAT6 only. The co-stimulatory effect on STAT6 activation correlates with a cooperative increase in nuclear translocation, DNA binding, transcriptional activity, and mRNA expression of STAT6 target genes (IL-4Ralpha and IL-15Ralpha). In conclusion, we provide evidence that IFN-alpha both up- and down-regulates IL-4-mediated STAT6 signaling and thereby regulates the sensitivity to IL-4 in human T lymphocytes. Thus, our findings suggest that IFN-alpha has a complex regulatory role in adaptive immunity, which is different from the "classical" Th1 profile of IFN-gamma.	Univ Copenhagen, Inst Med Microbiol & Immunol, DK-2200 Copenhagen, Denmark; Univ Copenhagen, Inst Mol Biol, DK-2200 Copenhagen, Denmark; Natl Univ Hosp, Dept Clin Immunol, DK-2200 Copenhagen, Denmark	University of Copenhagen; University of Copenhagen	Odum, N (corresponding author), Univ Copenhagen, Inst Med Microbiol & Immunol, Panum 22-5-34,Blegdamsvej 3C, DK-2200 Copenhagen, Denmark.		Woetmann, Anders/AAJ-3171-2020; Geisler, Carsten/A-7056-2012	Geisler, Carsten/0000-0002-8472-0771; Woetmann, Anders/0000-0002-3008-735X; Skov, Soren/0000-0003-0732-0026				ALDERSON MR, 1994, CYTOKINE, V6, P407, DOI 10.1016/1043-4666(94)90065-5; Brender C, 2001, EXP CLIN IMMUNOGENET, V18, P80, DOI 10.1159/000049186; BRINKMANN V, 1993, J EXP MED, V178, P1655, DOI 10.1084/jem.178.5.1655; Crespo A, 2000, BIOCHEM J, V349, P99, DOI 10.1042/0264-6021:3490099; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DELESPESSE G, 1989, J IMMUNOL, V142, P134; DENOROY MC, 1990, MOL IMMUNOL, V27, P129, DOI 10.1016/0161-5890(90)90107-B; Dickensheets HL, 1999, J LEUKOCYTE BIOL, V65, P307, DOI 10.1002/jlb.65.3.307; Dickensheets HL, 1999, P NATL ACAD SCI USA, V96, P10800, DOI 10.1073/pnas.96.19.10800; Eriksen KW, 2001, EXP CLIN IMMUNOGENET, V18, P233, DOI 10.1159/000049202; Eriksen KW, 2001, LEUKEMIA, V15, P787, DOI 10.1038/sj.leu.2402093; GAROTTA G, 1986, BIOCHEM BIOPH RES CO, V140, P948, DOI 10.1016/0006-291X(86)90727-8; GEISLER C, 1990, J IMMUNOL, V145, P1761; Gupta S, 1999, J IMMUNOL, V163, P3834; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; KALTOFT K, 1992, IN VITRO CELL DEV-AN, V28A, P161; KALTOFT K, 1994, DERMATOL CLIN, V12, P295, DOI 10.1016/S0733-8635(18)30176-1; Kaplan MH, 1996, IMMUNITY, V4, P313, DOI 10.1016/S1074-7613(00)80439-2; KOPF M, 1993, NATURE, V362, P245, DOI 10.1038/362245a0; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; Mikita T, 1996, MOL CELL BIOL, V16, P5811; Mitani Y, 2001, GENES CELLS, V6, P631, DOI 10.1046/j.1365-2443.2001.00448.x; Nelms K, 1999, ANNU REV IMMUNOL, V17, P701, DOI 10.1146/annurev.immunol.17.1.701; Nielsen M, 1997, P NATL ACAD SCI USA, V94, P6764, DOI 10.1073/pnas.94.13.6764; NIELSEN M, 1994, EXP CLIN IMMUNOGENET, V11, P23; OShea JJ, 1997, IMMUNITY, V7, P1, DOI 10.1016/S1074-7613(00)80505-1; Paludan SR, 1998, SCAND J IMMUNOL, V48, P459; PAUL WE, 1999, FUNDAMENTAL IMMUNOLO, P879; PENE J, 1988, P NATL ACAD SCI USA, V85, P6880, DOI 10.1073/pnas.85.18.6880; Pestka Sidney, 1997, Seminars in Oncology, V24, P18; PUNNONEN J, 1993, ALLERGY, V48, P189, DOI 10.1111/j.1398-9995.1993.tb00712.x; QUELLE FW, 1995, MOL CELL BIOL, V15, P3336; Rogge L, 1998, J IMMUNOL, V161, P6567; So EY, 2000, J IMMUNOL, V165, P5472, DOI 10.4049/jimmunol.165.10.5472; Takaoka A, 2000, SCIENCE, V288, P2357, DOI 10.1126/science.288.5475.2357; TE VA, 1990, J IMMUNOL, V144, P3052; Venkataraman C, 1999, J IMMUNOL, V162, P4053; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WALLACH D, 1983, CELL IMMUNOL, V75, P390, DOI 10.1016/0008-8749(83)90337-4; Wang Q, 2000, BLOOD, V96, P2093; Woetmann A, 2003, J BIOL CHEM, V278, P2787, DOI 10.1074/jbc.M210196200	42	14	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	2004	279	1					169	176		10.1074/jbc.M310472200	http://dx.doi.org/10.1074/jbc.M310472200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	757GU	14559900	hybrid			2022-12-27	WOS:000187555300021
J	Lee, JW; Blanco, L; Zhou, T; Garcia-Diaz, M; Bebenek, K; Kunkel, TA; Wang, ZG; Povirk, LF				Lee, JW; Blanco, L; Zhou, T; Garcia-Diaz, M; Bebenek, K; Kunkel, TA; Wang, ZG; Povirk, LF			Implication of DNA polymerase lambda in alignment-based gap filling for nonhomologous DNA end joining in human nuclear extracts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRAND BREAK; DEPENDENT PROTEIN-KINASE; CELL-FREE-EXTRACTS; MU POL-MU; IN-VITRO; LIGASE-IV; 3'-PHOSPHOGLYCOLATE TERMINI; MAMMALIAN CHROMOSOME; IONIZING-RADIATION; CATALYTIC SUBUNIT	Accurate repair of free radical-mediated DNA double-strand breaks by the nonhomologous end joining pathway requires replacement of fragmented nucleotides in the aligned ends by a gap-filling DNA polymerase. Nuclear extracts of human HeLa cells, supplemented with recombinant XRCC4-DNA ligase IV complex (XRCC4/ligase IV), were capable of accurately rejoining model double-strand break substrates with a 1- or 2-base gap, and the gap-filling step was dependent on XRCC4/ligase IV. To determine what polymerase was responsible for gap filling, end joining was examined in the presence of polyclonal antibodies against each of two prime candidate enzymes, DNA polymerases mu and lambda, both of which were present in the extracts. For a DNA substrate with partially complementary 3' overhangs and a 2-base gap, antibodies to polymerase lambda completely eliminated both gap filling and accurate end joining, whereas antibodies to polymerase mu had little effect. Immunodepletion of polymerase lambda, but not polymerase mu, likewise blocked both gap filling and end joining, and both functions could be restored by addition of recombinant polymerase lambda. Recombinant polymerase mu, and a truncated polymerase lambda lacking the Brca1 C-terminal domain, were at least 10-fold less active in restoring gap filling to the immunodepleted extracts, and polymerase beta was completely inactive. The results suggest that polymerase lambda is the primary gap-filling polymerase for accurate nonhomologous end joining, and that the Brca1 C-terminal domain is required for this activity.	Virginia Commonwealth Univ, Dept Pharmacol & Toxicol, Richmond, VA 23298 USA; Univ Autonoma Madrid, CSIC, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain; NIEHS, Genet Mol Lab, Dept Hlth & Human Serv, Res Triangle Pk, NC 27709 USA; NIEHS, Struct Biol Lab, Dept Hlth & Human Serv, Res Triangle Pk, NC 27709 USA; Univ Kentucky, Grad Ctr Toxicol, Lexington, KY 40536 USA	Virginia Commonwealth University; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of Kentucky	Povirk, LF (corresponding author), Virginia Commonwealth Univ, Dept Pharmacol & Toxicol, POB 980230, Richmond, VA 23298 USA.		Kunkel, Thomas A./D-5088-2019; Blanco, Luis/I-1848-2015	Kunkel, Thomas A./0000-0002-9900-1788; 	NATIONAL CANCER INSTITUTE [R01CA040615] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES065070, ZIAES065070] Funding Source: NIH RePORTER; NCI NIH HHS [CA40615] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aoufouchi S, 2000, NUCLEIC ACIDS RES, V28, P3684, DOI 10.1093/nar/28.18.3684; Baumann P, 1998, P NATL ACAD SCI USA, V95, P14066, DOI 10.1073/pnas.95.24.14066; Bebenek K, 2003, J BIOL CHEM, V278, P34685, DOI 10.1074/jbc.M305705200; Bennett RAO, 1996, INT J RADIAT BIOL, V70, P623; Bertocci B, 2002, J IMMUNOL, V168, P3702, DOI 10.4049/jimmunol.168.8.3702; Blaisdell JO, 2001, P NATL ACAD SCI USA, V98, P7426, DOI 10.1073/pnas.131077798; Chan DW, 2002, GENE DEV, V16, P2333, DOI 10.1101/gad.1015202; Chen S, 2001, J BIOL CHEM, V276, P24323, DOI 10.1074/jbc.M010544200; Daza P, 1996, BIOL CHEM, V377, P775, DOI 10.1515/bchm3.1996.377.12.775; DeFazio LG, 2002, EMBO J, V21, P3192, DOI 10.1093/emboj/cdf299; Dominguez O, 2000, EMBO J, V19, P1731, DOI 10.1093/emboj/19.7.1731; Douglas P, 2002, BIOCHEM J, V368, P243, DOI 10.1042/BJ20020973; Feldmann E, 2000, NUCLEIC ACIDS RES, V28, P2585, DOI 10.1093/nar/28.13.2585; Garcia-Diaz M, 2002, J BIOL CHEM, V277, P13184, DOI 10.1074/jbc.M111601200; Garcia-Diaz M, 2000, J MOL BIOL, V301, P851, DOI 10.1006/jmbi.2000.4005; Gu XY, 1998, BIOCHEMISTRY-US, V37, P9827, DOI 10.1021/bi980198o; Huang JR, 2002, NUCLEIC ACIDS RES, V30, P667, DOI 10.1093/nar/30.3.667; Huyton T, 2000, MUTAT RES-DNA REPAIR, V460, P319, DOI 10.1016/S0921-8777(00)00034-3; Inamdar KV, 2002, J BIOL CHEM, V277, P27162, DOI 10.1074/jbc.M204688200; Junop MS, 2000, EMBO J, V19, P5962, DOI 10.1093/emboj/19.22.5962; Lee JW, 2003, CANCER RES, V63, P22; LUKACSOVICH T, 1994, NUCLEIC ACIDS RES, V22, P5649, DOI 10.1093/nar/22.25.5649; Ma YM, 2002, CELL, V108, P781, DOI 10.1016/S0092-8674(02)00671-2; Mahajan KN, 2002, MOL CELL BIOL, V22, P5194, DOI 10.1128/MCB.22.14.5194-5202.2002; Pastwa E, 2001, NUCLEIC ACIDS RES, V29, part. no., DOI 10.1093/nar/29.16.e78; Pelletier H, 1996, BIOCHEMISTRY-US, V35, P12742, DOI 10.1021/bi952955d; PFEIFFER P, 1994, MOL CELL BIOL, V14, P888, DOI 10.1128/MCB.14.2.888; PHILLIPS JW, 1994, MOL CELL BIOL, V14, P5794, DOI 10.1128/MCB.14.9.5794; ROTH DB, 1986, MOL CELL BIOL, V6, P4295, DOI 10.1128/MCB.6.12.4295; ROUET P, 1994, MOL CELL BIOL, V14, P8096, DOI 10.1128/MCB.14.12.8096; Ruiz JF, 2001, PHILOS T R SOC B, V356, P99, DOI 10.1098/rstb.2000.0754; Sibanda BL, 2001, NAT STRUCT BIOL, V8, P1015, DOI 10.1038/nsb725; Sutherland BM, 2000, P NATL ACAD SCI USA, V97, P103, DOI 10.1073/pnas.97.1.103; THODE S, 1990, CELL, V60, P921, DOI 10.1016/0092-8674(90)90340-K; Tian KG, 2002, DNA REPAIR, V1, P1039, DOI 10.1016/S1568-7864(02)00163-5; Tseng HM, 2002, J BIOL CHEM, V277, P45630, DOI 10.1074/jbc.M206861200; Valerie K, 2003, ONCOGENE, V22, P5792, DOI 10.1038/sj.onc.1206679; Walker JR, 2001, NATURE, V412, P607, DOI 10.1038/35088000; Zhang YB, 2001, MOL CELL BIOL, V21, P7995, DOI 10.1128/MCB.21.23.7995-8006.2001	39	178	183	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	2004	279	1					805	811		10.1074/jbc.M307913200	http://dx.doi.org/10.1074/jbc.M307913200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	757GU	14561766	hybrid			2022-12-27	WOS:000187555300096
J	Leemhuis, J; Boutillier, S; Barth, H; Feuerstein, TJ; Brock, C; Nurnberg, B; Aktories, K; Meyer, DK				Leemhuis, J; Boutillier, S; Barth, H; Feuerstein, TJ; Brock, C; Nurnberg, B; Aktories, K; Meyer, DK			Rho GTPases and phosphoinositide 3-kinase organize formation of branched dendrites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; G-BETA-GAMMA; INDUCED NEURITE RETRACTION; BINDING PROTEIN-RHO; CYCLIC-AMP; PHOSPHATIDYLINOSITOL 3-KINASE; PC12 CELLS; IN-VIVO; HIPPOCAMPAL-NEURONS; DISTINCT ASPECTS	Neurons receive information from other neurons via their dendritic tree. Dendrites and their branches result from alternating outgrowth and retraction. The Rho GTPases Rac and Cdc42 (cell division cycle 42) facilitate the outgrowth of branches, whereas Rho attenuates it. The mechanism of neurite retraction is unknown. Because the adenylyl cyclase activator forskolin causes numerous branched extensions in NG108-15 cells, we have investigated the underlying mechanism in this cell line. In additional studies, we used cultured hippocampal neurons in which forskolin induces branched dendrites. In both cell types, forskolin enhanced the activity of Cdc42, but not that of Rac, although both GTPases were necessary for the formation of branched extensions. Time lapse microscopy showed that forskolin did not increase the rate of addition of new extensions or branches, but it reduced the rate of the retraction so that more branched extensions persisted. Inhibition of phosphoinositide 3-kinase activity by wortmannin or LY294002 also reduced the rate of retraction and thus facilitated dendritic arborization. Forskolin diminished the activity of phosphoinositide 3-kinases. Inhibitors of phosphoinositide 3-kinases not only reduced the retraction but also the addition of new dendrites and branches. This reduction was no longer present when Rho kinase was simultaneously inactivated, suggesting an interaction of phosphoinositide 3-kinases and Rho kinase. The present results show a central role of phosphoinositide 3-kinases in dendrite formation. In neuronal cells, increased levels of cAMP can support dendritic arborization by modulating the activity of the lipid kinase.	Univ Freiburg, Inst Expt & Klin Pharmakol & Toxikol, Zentrum Neurowissensch, D-79104 Freiburg, Germany; Univ Freiburg, Neurol Klin, D-79104 Freiburg, Germany; Klinikum Univ Dusseldorf, Inst Biochem & Mol Biol 2, D-40225 Dusseldorf, Germany	University of Freiburg; University of Freiburg; Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf Hospital	Meyer, DK (corresponding author), Univ Freiburg, Inst Expt & Klin Pharmakol & Toxikol, Zentrum Neurowissensch, Albert Str 23, D-79104 Freiburg, Germany.	Dieter.Meyer@pharmakol.uni-freiburg.de	Aktories, Klaus/CAJ-5682-2022	Aktories, Klaus/0000-0002-5397-0436; Nurnberg, Bernd/0000-0002-5995-6555				Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; Atwal JK, 2000, NEURON, V27, P265, DOI 10.1016/S0896-6273(00)00035-0; Balla T, 2000, TRENDS PHARMACOL SCI, V21, P238, DOI 10.1016/S0165-6147(00)01500-5; Barth H, 1998, INFECT IMMUN, V66, P1364, DOI 10.1128/IAI.66.4.1364-1369.1998; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; Bito H, 2000, NEURON, V26, P431, DOI 10.1016/S0896-6273(00)81175-7; Bradke F, 1999, SCIENCE, V283, P1931, DOI 10.1126/science.283.5409.1931; Brock C, 2003, J CELL BIOL, V160, P89, DOI 10.1083/jcb.200210115; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Cass LA, 1999, MOL CELL BIOL, V19, P5882; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; Dong JM, 1998, J BIOL CHEM, V273, P22554, DOI 10.1074/jbc.273.35.22554; Feoktistov I, 2000, MOL PHARMACOL, V58, P903, DOI 10.1124/mol.58.5.903; Fiala JC, 1998, J NEUROSCI, V18, P8900; Goldberg JL, 2002, NEURON, V33, P689, DOI 10.1016/S0896-6273(02)00602-5; GUNNING PW, 1981, J CELL BIOL, V89, P240, DOI 10.1083/jcb.89.2.240; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hernandez-Deviez DJ, 2002, NAT NEUROSCI, V5, P623, DOI 10.1038/nn865; Higuchi H, 2003, EMBO J, V22, P1790, DOI 10.1093/emboj/cdg177; JALINK K, 1994, J CELL BIOL, V126, P801, DOI 10.1083/jcb.126.3.801; JUST I, 1995, NATURE, V375, P500, DOI 10.1038/375500a0; Kim S, 2001, J BIOL CHEM, V276, P12864, DOI 10.1074/jbc.M001492200; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; KIMURA K, 1994, J BIOL CHEM, V269, P18961; Kobayashi M, 1997, J BIOL CHEM, V272, P16089, DOI 10.1074/jbc.272.26.16089; Kohrmann M, 1999, J NEUROSCI RES, V58, P831; Lang P, 1996, EMBO J, V15, P510, DOI 10.1002/j.1460-2075.1996.tb00383.x; Laudanna C, 1997, J BIOL CHEM, V272, P24141, DOI 10.1074/jbc.272.39.24141; Leemhuis J, 2002, J PHARMACOL EXP THER, V300, P1000, DOI 10.1124/jpet.300.3.1000; Leopoldt D, 1998, J BIOL CHEM, V273, P7024, DOI 10.1074/jbc.273.12.7024; Li Z, 2002, NEURON, V33, P741, DOI 10.1016/S0896-6273(02)00621-9; Li Z, 2000, NAT NEUROSCI, V3, P217, DOI 10.1038/72920; Luo LQ, 2000, NAT REV NEUROSCI, V1, P173, DOI 10.1038/35044547; Maier U, 1999, J BIOL CHEM, V274, P29311, DOI 10.1074/jbc.274.41.29311; MARKHAM JA, 1986, DEV BRAIN RES, V27, P263, DOI 10.1016/0165-3806(86)90253-1; Markus A, 2002, NEURON, V35, P65, DOI 10.1016/S0896-6273(02)00752-3; Mei FC, 2002, J BIOL CHEM, V277, P11497, DOI 10.1074/jbc.M110856200; Ming GL, 1997, NEURON, V19, P1225, DOI 10.1016/S0896-6273(00)80414-6; MONFAR M, 1995, MOL CELL BIOL, V15, P326, DOI 10.1128/MCB.15.1.326; Mueller BK, 1999, ANNU REV NEUROSCI, V22, P351, DOI 10.1146/annurev.neuro.22.1.351; Neumann H, 2002, J NEUROSCI, V22, P854, DOI 10.1523/JNEUROSCI.22-03-00854.2002; Nusser N, 2002, J BIOL CHEM, V277, P35840, DOI 10.1074/jbc.M203617200; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Reif K, 1996, CURR BIOL, V6, P1445, DOI 10.1016/S0960-9822(96)00749-X; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Ridley AJ, 2001, FEBS LETT, V498, P168, DOI 10.1016/S0014-5793(01)02481-4; Sarner S, 2000, MOL CELL BIOL, V20, P158, DOI 10.1128/MCB.20.1.158-172.2000; Schmidt G, 1997, NATURE, V387, P725, DOI 10.1038/42735; Scott EK, 2003, J NEUROSCI, V23, P3118; SEKINE A, 1989, J BIOL CHEM, V264, P8602; Shi SH, 2003, CELL, V112, P63, DOI 10.1016/S0092-8674(02)01249-7; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; Suvarna NU, 2002, J PHARMACOL EXP THER, V302, P249, DOI 10.1124/jpet.302.1.249; Tigyi G, 1996, J NEUROCHEM, V66, P549; Tsuji T, 2002, J CELL BIOL, V157, P819, DOI 10.1083/jcb.200112107; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; Vanhaesebroeck B, 1999, EXP CELL RES, V253, P239, DOI 10.1006/excr.1999.4701; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Wahl S, 2000, J CELL BIOL, V149, P263, DOI 10.1083/jcb.149.2.263; WEEKS BS, 1991, J CELL PHYSIOL, V147, P62, DOI 10.1002/jcp.1041470109; Wong WT, 2000, J NEUROSCI, V20, P5024; Wu GY, 1998, SCIENCE, V279, P222, DOI 10.1126/science.279.5348.222; Yamaguchi Y, 2001, J BIOL CHEM, V276, P18977, DOI 10.1074/jbc.M100254200; Yang H, 2002, AM J PHYSIOL-REG I, V283, pR107, DOI 10.1152/ajpregu.00611.2001; Yuan XB, 2003, NAT CELL BIOL, V5, P38, DOI 10.1038/ncb895; ZHENG Y, 1994, J BIOL CHEM, V269, P18727	70	49	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 2	2004	279	1					585	596		10.1074/jbc.M307066200	http://dx.doi.org/10.1074/jbc.M307066200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	757GU	14578357	hybrid			2022-12-27	WOS:000187555300071
J	Alikhani, MI; Alikhani, ZB; He, HB; Liu, RK; Popek, BI; Graves, DT				Alikhani, MI; Alikhani, ZB; He, HB; Liu, RK; Popek, BI; Graves, DT			Lipopolysaccharides indirectly stimulate apoptosis and global induction of apoptotic genes in fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; TNF-ALPHA; OSTEOCLAST FORMATION; CELL-DEATH; INFLAMMATION; ACTIVATION; INHIBITION; PATHWAYS; CYTOKINES; MECHANISMS	Following Gram-negative bacterial infection there is a reduction in matrix-producing cells. The goal of the present study was to examine the apoptotic effects of lipopolysaccharide (LPS) on fibroblastic cells and to investigate the role that the host response plays in this reaction. This was accomplished in vivo by subcutaneous inoculation of LPS in wild type and TNFR1(-/-)R2(-/-) mice. The direct effects of LPS on fibroblast apoptosis was studied in vitro with normal diploid human fibroblasts. The results indicate that LPS in vivo induces apoptosis of fibroblasts. By RNA profiling we demonstrated that LPS stimulates global expression of apoptotic genes and down-regulates anti-apoptotic genes. Fluorometric studies demonstrated that LPS in vivo significantly increased caspase-8 and caspase-3 activity and by use of specific inhibitors, the activation of caspase-3 was shown to be initiated by caspase-8 with no contribution from caspase-9. In vitro studies demonstrated that LPS did not induce apoptosis of fibroblasts, whereas tumor necrosis factor (TNF) did. In addition, the pattern of apoptotic gene expression induced by TNF in vitro was nearly identical to that induced by LPS in vivo, as measured by RNase protection assay. Moreover, pre-treatment of cells with TNF greatly enhanced apoptosis induced by a second stimulation with TNF 24 h later, suggesting that the global induction of proapoptotic genes was functionally significant. Thus, LPS acts to modulate the expression of a large number of genes that favor apoptosis of fibroblastic cells that is dependent upon activation of caspase-8 and is largely mediated by TNF.	Boston Univ, Sch Dent Med, Dept Periodontol & Oral Biol, Boston, MA 02118 USA	Boston University	Graves, DT (corresponding author), Boston Univ, Sch Dent Med, Dept Periodontol & Oral Biol, Boston, MA 02118 USA.	dgraves@bu.edu			NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R23DE007559, R01DE007559] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE07559] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Akgul C, 2001, FEBS LETT, V487, P318, DOI 10.1016/S0014-5793(00)02324-3; BRENNAN FM, 1990, EUR J IMMUNOL, V20, P2141, DOI 10.1002/eji.1830200938; Buck M, 1996, AM J PATHOL, V149, P195; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Deaciuc IV, 2001, ALCOHOL CLIN EXP RES, V25, P935; DEGROOTE MA, 1995, CLIN INFECT DIS, V21, pS162, DOI 10.1093/clinids/21.Supplement_2.S162; FAHEY TJ, 1995, J SURG RES, V58, P759, DOI 10.1006/jsre.1995.1120; Fang FC, 1997, J CLIN INVEST, V99, P2818, DOI 10.1172/JCI119473; Feterowski C, 2001, EUR J IMMUNOL, V31, P1268, DOI 10.1002/1521-4141(200104)31:4<1268::AID-IMMU1268>3.0.CO;2-C; GERMAIN L, 1994, J SURG RES, V57, P268, DOI 10.1006/jsre.1994.1143; GOLDRING M B, 1991, Critical Reviews in Eukaryotic Gene Expression, V1, P301; Goyal A, 2002, AM J RESP CELL MOL, V26, P224, DOI 10.1165/ajrcmb.26.2.4640; Graves DT, 2001, J DENT RES, V80, P1875, DOI 10.1177/00220345010800100301; Graves DT, 1999, CLIN INFECT DIS, V28, P482, DOI 10.1086/515178; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; HACHIYA O, 1995, MICROBIOL IMMUNOL, V39, P715, DOI 10.1111/j.1348-0421.1995.tb03247.x; Hasegawa Chikako, 2000, Medical Electron Microscopy, V33, P82, DOI 10.1007/s007950070006; Henderson B, 1996, IMMUNOPHARMACOLOGY, V35, P1, DOI 10.1016/0162-3109(96)00144-0; Hull C, 2002, J IMMUNOL, V169, P2611, DOI 10.4049/jimmunol.169.5.2611; Kawahara T, 2001, AM J PHYSIOL-GASTR L, V281, pG726; Kitaura H, 2002, J IMMUNOL, V169, P4732, DOI 10.4049/jimmunol.169.9.4732; Koizumi K, 2003, INVEST OPHTH VIS SCI, V44, P2184, DOI 10.1167/iovs.02-0589; Koteish A, 2002, J BIOL CHEM, V277, P13037, DOI 10.1074/jbc.M101632200; Koulouri O, 1999, J CLIN PERIODONTOL, V26, P552, DOI 10.1034/j.1600-051X.1999.260810.x; Lakics V, 1998, J IMMUNOL, V161, P2490; Leonis NA, 2002, HEPATOLOGY, V36, P1053, DOI 10.1053/jhep.2002.36822; Li HL, 2002, AM J PHYSIOL-HEART C, V283, pH461, DOI 10.1152/ajpheart.00701.2001; Libby P, 2002, NATURE, V420, P868, DOI 10.1161/ATVBAHA.108.179705; Mahalingam S, 1999, IMMUNOL CELL BIOL, V77, P469, DOI 10.1046/j.1440-1711.1999.00858.x; MANGAN DF, 1991, INFECT IMMUN, V59, P3267, DOI 10.1128/IAI.59.9.3267-3272.1991; Manhart N, 2000, SHOCK, V14, P478, DOI 10.1097/00024382-200014040-00010; Matsukawa A, 1998, INFLAMM RES, V47, pS137; McDonald TE, 2000, AM J PHYSIOL-HEART C, V279, pH2053; Munshi N, 2002, J IMMUNOL, V168, P5860, DOI 10.4049/jimmunol.168.11.5860; Nakama T, 2001, HEPATOLOGY, V33, P1441, DOI 10.1053/jhep.2001.24561; Nathan C, 2002, NATURE, V420, P846, DOI 10.1038/nature01320; Okuyama H, 2003, HEPATOLOGY, V37, P1015, DOI 10.1053/jhep.2003.50203; PAI CH, 1986, INFECT IMMUN, V51, P16, DOI 10.1128/IAI.51.1.16-23.1986; Pinkoski MJ, 2002, J BIOL CHEM, V277, P42380, DOI 10.1074/jbc.M208167200; PRICOLO VE, 1990, J SURG RES, V48, P534, DOI 10.1016/0022-4804(90)90226-R; REGAN MC, 1991, J SURG RES, V50, P442, DOI 10.1016/0022-4804(91)90022-E; Sears CL, 1996, MICROBIOL REV, V60, P167, DOI 10.1128/MMBR.60.1.167-215.1996; Soler C, 2001, J BIOL CHEM, V276, P30043, DOI 10.1074/jbc.M101807200; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Tonetti MS, 1998, INFECT IMMUN, V66, P5190, DOI 10.1128/IAI.66.11.5190-5195.1998; TRACEY KJ, 1993, ANNU REV CELL BIOL, V9, P317, DOI 10.1146/annurev.cb.09.110193.001533; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; WANG SD, 1994, J IMMUNOL, V152, P5014; WARD PA, 1988, FREE RADICAL BIO MED, V5, P403, DOI 10.1016/0891-5849(88)90114-1; WOOD DD, 1983, ARTHRITIS RHEUM, V26, P975, DOI 10.1002/art.1780260806; Xaus J, 2000, BLOOD, V95, P3823; Yamamoto Y, 2001, J CLIN INVEST, V107, P135, DOI 10.1172/JCI11914; Yin XM, 2000, J MOL MED-JMM, V78, P203, DOI 10.1007/s001090000099; ZAPPA U, 1992, J PERIODONTOL, V63, P748, DOI 10.1902/jop.1992.63.9.748	55	47	50	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52901	52908		10.1074/jbc.M307638200	http://dx.doi.org/10.1074/jbc.M307638200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14551216	hybrid			2022-12-27	WOS:000187480700111
J	Chen, PF; Wu, KK				Chen, PF; Wu, KK			Structural elements contribute to the calcium/calmodulin dependence on enzyme activation in human endothelial nitric-oxide synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AUTOINHIBITORY CONTROL ELEMENT; ELECTRON FLOW-THROUGH; CALMODULIN-BINDING; CATALYTIC-ACTIVITY; BIDOMAIN STRUCTURE; CRYSTAL-STRUCTURE; NO SYNTHASE; PHOSPHORYLATION; CELLS; REDUCTASE	Two regions, located at residues 594-606/614-645 and residues 1165-1178, are present in the reductase domain of human endothelial nitric-oxide synthase (eNOS) but absent in its counterpart, inducible nitric-oxide synthase (iNOS). We previously demonstrated that removing residues 594-606/614-645 resulted in an enzyme (Delta45) containing an intrinsic calmodulin (CaM) purified from an Sf9/baculovirus expression system (Chen, P.-F., and Wu, K. K. (2000) J. Biol. Chem. 275, 13155-13163). Here we have further elucidated the differential requirement of Ca2+/CaM for enzyme activation between eNOS and iNOS by either deletion of residues 1165-1178 (Delta14) or combined deletions of residues 594-606/614-645 and 1165-1178(Delta45/Delta14) from eNOS to mimic iNOS. We measured the catalytic rates using purified proteins completely free of CaM. Steady-state analysis indicated that the Delta45 supported NO synthesis in the absence of CaM at 60% of the rate in its presence, consistent with our prior result that CaM-bound Delta45 retained 60% of its activity in the presence of 10 mM EGTA. Mutant Delta14 displayed a 1.5-fold reduction of EC50 for Ca2+/CaM-dependence in L-citrulline formation, and a 2-4-fold increase in the rates of NO synthesis, NADPH oxidation, and cytochrome c reduction relative to the wild type. The basal rates of double mutant Delta45/Delta14 in NO production, NADPH oxidation, and cytochrome c reduction were 3-fold greater than those of CaM-stimulated wild-type eNOS. Interestingly, all three activities of Delta45/Delta14 were suppressed rather than enhanced by Ca2+/CaM, indicating a complete Ca2+/CaM independence for those reactions. The results suggest that the Ca2+/CaM-dependent catalytic activity of eNOS appears to be conferred mainly by these two structural elements, and the interdomain electron transfer from reductase to oxygenase domain does not require Ca2+/CaM when eNOS lacks these two segments.	Univ Texas, Hlth Sci Ctr, Dept Internal Med, Sch Med,Div Hematol, Houston, TX 77225 USA; Univ Texas, Hlth Sci Ctr, Vasc Biol Res Ctr, Houston, TX 77225 USA	University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston	Chen, PF (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Internal Med, Sch Med,Div Hematol, 6431 Fannin,POB 20708, Houston, TX 77225 USA.	pei-feng.chen@uth.tmc.edu			NHLBI NIH HHS [HL-50675] Funding Source: Medline; NINDS NIH HHS [NS-23327] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050675] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS023327] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABUSOUD HM, 1993, P NATL ACAD SCI USA, V90, P10769, DOI 10.1073/pnas.90.22.10769; ABUSOUD HM, 1994, J BIOL CHEM, V269, P32047; Adak S, 2002, P NATL ACAD SCI USA, V99, P13516, DOI 10.1073/pnas.192283399; Adak S, 2001, J BIOL CHEM, V276, P1244, DOI 10.1074/jbc.M006857200; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; Chen PF, 2000, J BIOL CHEM, V275, P13155, DOI 10.1074/jbc.275.17.13155; Chen PF, 1997, J BIOL CHEM, V272, P6114, DOI 10.1074/jbc.272.10.6114; Chen PF, 1996, J BIOL CHEM, V271, P14631, DOI 10.1074/jbc.271.24.14631; CHO HJ, 1992, J EXP MED, V176, P599, DOI 10.1084/jem.176.2.599; Crane BR, 1998, SCIENCE, V279, P2121, DOI 10.1126/science.279.5359.2121; Daff S, 1999, J BIOL CHEM, V274, P30589, DOI 10.1074/jbc.274.43.30589; Dimmeler S, 2000, FEBS LETT, V477, P258, DOI 10.1016/S0014-5793(00)01657-4; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Fischmann TO, 1999, NAT STRUCT BIOL, V6, P233, DOI 10.1038/6675; FORSTERMANN U, 1991, BIOCHEM PHARMACOL, V42, P1849, DOI 10.1016/0006-2952(91)90581-O; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P3491, DOI 10.1073/pnas.90.8.3491; GHOSH DK, 1995, BIOCHEMISTRY-US, V34, P801, DOI 10.1021/bi00003a013; Harris MB, 2001, J BIOL CHEM, V276, P16587, DOI 10.1074/jbc.M100229200; Haynes MP, 2000, CIRC RES, V87, P677, DOI 10.1161/01.RES.87.8.677; Hisamoto K, 2001, J BIOL CHEM, V276, P3459, DOI 10.1074/jbc.M005036200; Igarashi J, 2001, J BIOL CHEM, V276, P12420, DOI 10.1074/jbc.M008375200; JANSSENS SP, 1992, J BIOL CHEM, V267, P14519; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lane P, 2002, J BIOL CHEM, V277, P19087, DOI 10.1074/jbc.M200258200; MARLETTA MA, 1993, J BIOL CHEM, V268, P12231; McCabe TJ, 2000, J BIOL CHEM, V275, P6123, DOI 10.1074/jbc.275.9.6123; MCMILLAN K, 1992, P NATL ACAD SCI USA, V89, P11141, DOI 10.1073/pnas.89.23.11141; Montagnani M, 2001, J BIOL CHEM, V276, P30392, DOI 10.1074/jbc.M103702200; Montgomery HJ, 2000, J BIOL CHEM, V275, P5052, DOI 10.1074/jbc.275.7.5052; MURPHY ME, 1994, METHOD ENZYMOL, V233, P240; NAKANE M, 1993, FEBS LETT, V316, P175, DOI 10.1016/0014-5793(93)81210-Q; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; Nishida CR, 1999, J BIOL CHEM, V274, P14692, DOI 10.1074/jbc.274.21.14692; Nishida CR, 1998, J BIOL CHEM, V273, P5566, DOI 10.1074/jbc.273.10.5566; POLLOCK JS, 1991, P NATL ACAD SCI USA, V88, P10480, DOI 10.1073/pnas.88.23.10480; Raman CS, 1998, CELL, V95, P939, DOI 10.1016/S0092-8674(00)81718-3; Roman LJ, 2000, J BIOL CHEM, V275, P29225, DOI 10.1074/jbc.M004766200; Roman LJ, 2000, J BIOL CHEM, V275, P21914, DOI 10.1074/jbc.M002449200; Roman LJ, 2003, J BIOL CHEM, V278, P25700, DOI 10.1074/jbc.M212309200; Ruan J, 1996, J BIOL CHEM, V271, P22679, DOI 10.1074/jbc.271.37.22679; Salerno JC, 1997, J BIOL CHEM, V272, P29769, DOI 10.1074/jbc.272.47.29769; SHEPHARD EA, 1992, ARCH BIOCHEM BIOPHYS, V294, P168, DOI 10.1016/0003-9861(92)90152-M; SHETA EA, 1994, J BIOL CHEM, V269, P15147; STUEHR DJ, 1992, ADV ENZYMOL, V65, P287; VERMILION JL, 1978, J BIOL CHEM, V253, P8812; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522; Zhang J, 2001, J BIOL CHEM, V276, P37506, DOI 10.1074/jbc.M105503200	50	28	33	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52392	52400		10.1074/jbc.M305469200	http://dx.doi.org/10.1074/jbc.M305469200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14561757	hybrid			2022-12-27	WOS:000187480700051
J	Piechotta, K; Garbarini, N; England, R; Delpire, E				Piechotta, K; Garbarini, N; England, R; Delpire, E			Characterization of the interaction of the stress kinase SPAK with the Na+-K+-2Cl(-) cotransporter in the nervous system - Evidence for a scaffolding role of the kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K-CL COTRANSPORTER; CHLORIDE COTRANSPORT; GENE; CELLS; EXPRESSION; APOPTOSIS; PROTEIN; HYPERTENSION; OTOFERLIN; TERMINUS	Activity of heterologously expressed NKCC1 was analyzed under basal and activated conditions in the presence and absence of binding of Ste20-related proline-alanine-rich kinase (SPAK). Mutant NKCC1 that lacks the ability to bind to this kinase showed K+ transport function identical to wild-type NKCC1. Thus, preventing the binding of the kinase to the cotransporter does not affect cotransporter function. In contrast, several experiments suggest a possible role for SPAK as a scaffolding protein. First, Western blot analysis revealed the presence, and in some tissues abundance, of truncated forms of SPAK and OSR1 in which the kinase domains are affected and thus lack kinase activity. Second, a yeast two-hybrid screen of proteins that interact with the regulatory (binding) domain of SPAK identified several proteins all involved in cellular stress pathways. Third, p38, one of the three major MAPKs, can be coimmunoprecipitated with SPAK and with NKCC1 in an activity-dependent manner. The amount of p38 coimmunoprecipitated with the kinase and the cotransporter significantly decreases upon cellular stress, whereas the interaction of the kinase with NKCC1 remains unchanged. These findings suggest that cation-chloride cotransporters might act as "sensors" for cellular stress, and SPAK, by interacting with the cotransporter, serves as an intermediate in the response to cellular stress.	Vanderbilt Univ, Med Ctr, Dept Anesthesiol, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Ctr Mol Neurosci, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Delpire, E (corresponding author), T-4202 Med Ctr N, Nashville, TN 37232 USA.	eric.delpire@vanderbilt.edu		Garbarini, Nicole/0000-0001-9593-8074	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS036758] Funding Source: NIH RePORTER; NINDS NIH HHS [NS36758] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Alvarez-Leefmans FJ, 2001, NEUROSCIENCE, V104, P569, DOI 10.1016/S0306-4522(01)00091-4; Christofidou-Solomidou M, 2002, LUNG, V180, P91, DOI 10.1007/s004080000084; Dan I, 2001, TRENDS CELL BIOL, V11, P220, DOI 10.1016/S0962-8924(01)01980-8; Darman RB, 2002, J BIOL CHEM, V277, P37542, DOI 10.1074/jbc.M206293200; Darman RB, 2001, J BIOL CHEM, V276, P34359, DOI 10.1074/jbc.C100368200; Delpire E, 2002, ANNU REV PHYSIOL, V64, P803, DOI 10.1146/annurev.physiol.64.081501.155847; Dowd BFX, 2003, J BIOL CHEM, V278, P27347, DOI 10.1074/jbc.M301899200; Flatman PW, 1999, J PHYSIOL-LONDON, V519, P143, DOI 10.1111/j.1469-7793.1999.0143o.x; HEBERT SC, IN PRESS PFLUEGERS A; James P, 1996, GENETICS, V144, P1425; Johnston AM, 2000, ONCOGENE, V19, P4290, DOI 10.1038/sj.onc.1203784; Kaplan MR, 1996, J CLIN INVEST, V98, P723, DOI 10.1172/JCI118844; Kaplan MR, 1996, ANNU REV PHYSIOL, V58, P649, DOI 10.1146/annurev.ph.58.030196.003245; Kim JA, 2001, EUR J PHARMACOL, V433, P1, DOI 10.1016/S0014-2999(01)01420-0; Kojima R, 1996, J BIOL CHEM, V271, P12327, DOI 10.1074/jbc.271.21.12327; Koya RC, 2000, J BIOL CHEM, V275, P15343, DOI 10.1074/jbc.275.20.15343; LAUF PK, 1992, AM J PHYSIOL, V263, pC917, DOI 10.1152/ajpcell.1992.263.5.C917; Leiserson WM, 2000, NEURON, V28, P793, DOI 10.1016/S0896-6273(00)00154-9; Loffing J, 1996, KIDNEY INT, V50, P1180, DOI 10.1038/ki.1996.426; Lu J, 1999, J NEUROBIOL, V39, P558, DOI 10.1002/(SICI)1097-4695(19990615)39:4<558::AID-NEU9>3.0.CO;2-5; Monti J, 2003, HYPERTENSION, V41, P938, DOI 10.1161/01.HYP.0000063147.92433.7D; Panet R, 2000, J CELL PHYSIOL, V182, P109, DOI 10.1002/(SICI)1097-4652(200001)182:1<109::AID-JCP12>3.0.CO;2-A; Pearson MM, 2001, NEUROSCIENCE, V103, P481, DOI 10.1016/S0306-4522(00)00567-4; Piechotta K, 2002, J BIOL CHEM, V277, P50812, DOI 10.1074/jbc.M208108200; Plotkin MD, 1997, AM J PHYSIOL-CELL PH, V272, pC173, DOI 10.1152/ajpcell.1997.272.1.C173; Russell JM, 2000, PHYSIOL REV, V80, P211, DOI 10.1152/physrev.2000.80.1.211; Santos BC, 1998, AM J PHYSIOL-RENAL, V274, pF1054, DOI 10.1152/ajprenal.1998.274.6.F1054; Shen MR, 2001, P NATL ACAD SCI USA, V98, P14714, DOI 10.1073/pnas.251388798; Strange K, 2000, AM J PHYSIOL-CELL PH, V279, pC860, DOI 10.1152/ajpcell.2000.279.3.C860; Sun D, 1997, AM J PHYSIOL-CELL PH, V272, pC1829, DOI 10.1152/ajpcell.1997.272.6.C1829; Tamari M, 1999, J HUM GENET, V44, P116, DOI 10.1007/s100380050121; Tomomura M, 2003, MOL BRAIN RES, V112, P103, DOI 10.1016/S0169-328X(03)00054-8; Topper JN, 1997, J CLIN INVEST, V99, P2941, DOI 10.1172/JCI119489; Ushiro H, 1998, ARCH BIOCHEM BIOPHYS, V355, P233, DOI 10.1006/abbi.1998.0736; Varga R, 2003, J MED GENET, V40, P45, DOI 10.1136/jmg.40.1.45; Wilson FH, 2003, P NATL ACAD SCI USA, V100, P680, DOI 10.1073/pnas.242735399; Wu Q, 1998, AM J PHYSIOL-CELL PH, V275, pC1565, DOI 10.1152/ajpcell.1998.275.6.C1565; Yasunaga S, 1999, NAT GENET, V21, P363, DOI 10.1038/7693	38	175	176	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52848	52856		10.1074/jbc.M309436200	http://dx.doi.org/10.1074/jbc.M309436200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14563843	hybrid			2022-12-27	WOS:000187480700105
J	De Freitas, JM; Kim, JH; Poynton, H; Su, T; Wintz, H; Fox, T; Holman, P; Loguinov, A; Keles, S; van der Laan, M; Vulpe, C				De Freitas, JM; Kim, JH; Poynton, H; Su, T; Wintz, H; Fox, T; Holman, P; Loguinov, A; Keles, S; van der Laan, M; Vulpe, C			Exploratory and confirmatory gene expression profiling of mac1 Delta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FRATAXIN-DEFICIENT STRAIN; AFFINITY IRON UPTAKE; SACCHAROMYCES-CEREVISIAE; COPPER UPTAKE; RHIZOBIUM-LEGUMINOSARUM; SIDEROPHORE-IRON; PLASMA-MEMBRANE; PROTEIN AKR1P; YEAST GENES; TRANSPORT	Exploratory outlier identification methods and confirmatory gene expression studies showed induction of the iron regulon in Saccharomyces cerevisiae lacking Mac1p, a copper-responsive transcription factor. The Aft1p/Aft2p binding motif was the most discriminating motif between up- and down-regulated genes, and we identified new genes potentially regulated by Aft1p/ Aft2p. In addition, multiple genes encoding proteins containing Fe-S clusters were down-regulated suggesting metabolic reorganization to conserve iron in mac1Delta. Null mutants of each of the differentially expressed genes were characterized for copper- or iron-related phenotypes. New or additional support for a role in copper and iron homeostasis is provided in this study for the gene products of AKR1, MRS4, PCA1, SSU1, TIS11, YBR047W, YHL035C, YHR045W, YLR047C, YLR126C, and YTP1.	Univ Calif Berkeley, Dept Nutr Sci & Toxicol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Div Biostat, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley	Vulpe, C (corresponding author), Univ Calif Berkeley, Dept Nutr Sci & Toxicol, Berkeley, CA 94720 USA.	vulpe@uclink4.berkeley.edu	Poynton, Helen/AAT-2831-2021; Vulpe, Chris/AAF-9170-2020	Poynton, Helen/0000-0003-2663-9841; Vulpe, Chris/0000-0001-5134-8929				ASKWITH C, 1994, CELL, V76, P403, DOI 10.1016/0092-8674(94)90346-8; Askwith CC, 1996, MOL MICROBIOL, V20, P27, DOI 10.1111/j.1365-2958.1996.tb02485.x; Blaiseau PL, 2001, J BIOL CHEM, V276, P34221, DOI 10.1074/jbc.M104987200; BOSSIER P, 1993, J BIOL CHEM, V268, P23640; BURNS N, 1994, GENE DEV, V8, P1087, DOI 10.1101/gad.8.9.1087; Casas C, 1997, YEAST, V13, P621, DOI 10.1002/(SICI)1097-0061(19970615)13:7<621::AID-YEA121>3.0.CO;2-U; De Freitas J, 2003, BIOMETALS, V16, P185, DOI 10.1023/A:1020771000746; Eide DJ, 2000, ADV MICROB PHYSIOL, V43, P1, DOI 10.1016/S0065-2911(00)43001-8; Feng Y, 2000, MOL CELL BIOL, V20, P5350, DOI 10.1128/MCB.20.14.5350-5359.2000; Finegold AA, 1996, J BIOL CHEM, V271, P31021, DOI 10.1074/jbc.271.49.31021; Foury F, 2002, J BIOL CHEM, V277, P24475, DOI 10.1074/jbc.M111789200; Foury F, 2001, J BIOL CHEM, V276, P7762, DOI 10.1074/jbc.M005804200; Georgatsou E, 1999, YEAST, V15, P573, DOI 10.1002/(SICI)1097-0061(199905)15:7<573::AID-YEA404>3.3.CO;2-Z; Georgatsou E, 1997, J BIOL CHEM, V272, P13786, DOI 10.1074/jbc.272.21.13786; Givan SA, 1997, MOL BIOL CELL, V8, P1317, DOI 10.1091/mbc.8.7.1317; Gross C, 2000, J BIOL CHEM, V275, P32310, DOI 10.1074/jbc.M005946200; Hassett R, 2000, BIOCHEM J, V351, P477, DOI 10.1042/0264-6021:3510477; HIRATA D, 1994, MOL GEN GENET, V242, P250, DOI 10.1007/BF00280413; Hughes TR, 2000, CELL, V102, P109, DOI 10.1016/S0092-8674(00)00015-5; KAMPFENKEL K, 1995, J BIOL CHEM, V270, P28479, DOI 10.1074/jbc.270.47.28479; Kooperberg C, 2001, GENET EPIDEMIOL, V21, pS626, DOI 10.1002/gepi.2001.21.s1.s626; Koppenol WH, 2001, REDOX REP, V6, P229, DOI 10.1179/135100001101536373; Labbe S, 1997, J BIOL CHEM, V272, P15951, DOI 10.1074/jbc.272.25.15951; LESUISSE E, 1992, J GEN MICROBIOL, V138, P85, DOI 10.1099/00221287-138-1-85; LESUISSE E, 1995, MICROBIOL-UK, V141, P2937, DOI 10.1099/13500872-141-11-2937; Li LT, 2001, J BIOL CHEM, V276, P29515, DOI 10.1074/jbc.M103944200; Lin SJ, 1997, J BIOL CHEM, V272, P9215; Liochev SI, 1999, IUBMB LIFE, V48, P157, DOI 10.1080/152165499307161; LOGUINOV AV, 2003, IN PRESS GENOME BIOL; Lyons TJ, 2000, P NATL ACAD SCI USA, V97, P7957, DOI 10.1073/pnas.97.14.7957; MacDiarmid CW, 2000, EMBO J, V19, P2845, DOI 10.1093/emboj/19.12.2845; Martins LJ, 1998, J BIOL CHEM, V273, P23716, DOI 10.1074/jbc.273.37.23716; Pandolfo D, 1996, YEAST, V12, P1071; Pena MMO, 1999, J NUTR, V129, P1251, DOI 10.1093/jn/129.7.1251; Protchenko O, 2001, J BIOL CHEM, V276, P49244, DOI 10.1074/jbc.M109220200; RAD MR, 1994, YEAST, V10, P1217, DOI 10.1002/yea.320100910; RIOUX CR, 1986, ARCH BIOCHEM BIOPHYS, V248, P175, DOI 10.1016/0003-9861(86)90414-5; RIOUX CR, 1986, ARCH BIOCHEM BIOPHYS, V248, P183, DOI 10.1016/0003-9861(86)90415-7; Roth AF, 2002, J CELL BIOL, V159, P23, DOI 10.1083/jcb.200206120; Rutherford JC, 2003, J BIOL CHEM, V278, P27636, DOI 10.1074/jbc.M300076200; Rutherford JC, 2001, P NATL ACAD SCI USA, V98, P14322, DOI 10.1073/pnas.261381198; Spizzo T, 1997, MOL GEN GENET, V256, P547; Stearman R, 1996, SCIENCE, V271, P1552, DOI 10.1126/science.271.5255.1552; Szczypka MS, 1997, YEAST, V13, P1423, DOI 10.1002/(SICI)1097-0061(199712)13:15<1423::AID-YEA190>3.3.CO;2-3; Valentine JS, 1997, SCIENCE, V278, P817, DOI 10.1126/science.278.5339.817; van Helden J, 1998, J MOL BIOL, V281, P827, DOI 10.1006/jmbi.1998.1947; Waters BM, 2002, J BIOL CHEM, V277, P33749, DOI 10.1074/jbc.M206214200; West RW, 1996, GENE, V169, P119, DOI 10.1016/0378-1119(95)00774-1; YAMAGUCHIIWAI Y, 1995, EMBO J, V14, P1231, DOI 10.1002/j.1460-2075.1995.tb07106.x; YamaguchiIwai Y, 1997, J BIOL CHEM, V272, P17711, DOI 10.1074/jbc.272.28.17711; YamaguchiIwai Y, 1996, EMBO J, V15, P3377, DOI 10.1002/j.1460-2075.1996.tb00703.x; Yuan DS, 1997, J BIOL CHEM, V272, P25787, DOI 10.1074/jbc.272.41.25787; YUAN DS, 1995, P NATL ACAD SCI USA, V92, P2632, DOI 10.1073/pnas.92.7.2632; Yun CW, 2000, J BIOL CHEM, V275, P16354, DOI 10.1074/jbc.M001456200; Yun CW, 2000, J BIOL CHEM, V275, P10709, DOI 10.1074/jbc.275.14.10709; Yun CW, 2001, J BIOL CHEM, V276, P10218, DOI 10.1074/jbc.M010065200	56	33	38	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					4450	4458		10.1074/jbc.M212308200	http://dx.doi.org/10.1074/jbc.M212308200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14534306	hybrid			2022-12-27	WOS:000188554300064
J	Senogles, SE; Heimert, TL; Odife, ER; Quasney, MW				Senogles, SE; Heimert, TL; Odife, ER; Quasney, MW			A region of the third intracellular loop of the short form of the D2 dopamine receptor dictates G(i) coupling specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENYLATE-CYCLASE; PITUITARY-CELLS; MESSENGER-RNA; G-PROTEINS; RAT-BRAIN; INHIBITION; ACTIVATION; EXPRESSION; BINDING; SITE	The D2 dopamine receptor has two isoforms, the short form (D2s receptor) and the long form (D2l receptor), which differ by the presence of a 29-amino acid insert in the third cytoplasmic loop. Both the D2s and D2l receptors have been shown to couple to members of the Galpha(i) family of G proteins, but whether each isoform couples to specific Galpha(i) protein(s) remains controversial. In previous studies using Galpha(i) mutants resistant to modification by pertussis toxin (Galpha(i)PT), we demonstrated that the D2s receptor couples selectively to Galpha(i2)PT and that the D2l receptor couples selectively to Galpha(i3)PT (Senogles, S. E. ( 1994) J. Biol. Chem. 269, 23120 - 23127). In this study, two point mutations of the D2s receptor were created by random mutagenesis (R233G and A234T). The two mutant D2s receptors demonstrated pharmacological characteristics comparable with those of the wildtype D2s receptor, with similar agonist and antagonist binding affinities. We used human embryonic kidney 293 cells stably transfected with Galpha(i1)PT, Galpha(i2)PT, or Galpha(i3)PT to measure agonist-mediated inhibition of forskolin-stimulated cAMP accumulation before and after pertussis toxin treatment. The two mutant D2s receptors demonstrated a change in G(i) coupling specificity compared with the wild-type D2s receptor. Whereas the wild-type D2s receptor coupled predominantly to Galpha(i2)PT, mutant R233G coupled preferentially to Galpha(i3)PT, and mutant A234T coupled preferentially to Galpha(i1)PT. These results suggest that this region of the third cytoplasmic loop is crucial for determining G(i) protein coupling specificity.	Univ Tennessee, Ctr Hlth Sci, Dept Mol Sci, Coll Med, Memphis, TN 38163 USA; St Jude Childrens Res Hosp, Lebonheur Childrens Med Ctr, Dept Pediat, Memphis, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center; St Jude Children's Research Hospital	Senogles, SE (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Mol Sci, Coll Med, 858 Madison Ave,Suite G01, Memphis, TN 38163 USA.	ssenogles@utmem.edu			NINDS NIH HHS [NS 28811] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS028811, R01NS028811] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUNZOW JR, 1988, NATURE, V336, P783, DOI 10.1038/336783a0; BURNSTEIN ES, 1996, J BIOL CHEM, V271, P2882; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DALTOSO R, 1998, EMBO J, V13, P4025; EINHORN LC, 1991, J NEUROSCI, V11, P3727; Frishman D, 1997, PROTEINS, V27, P329, DOI 10.1002/(SICI)1097-0134(199703)27:3<329::AID-PROT1>3.0.CO;2-8; Ghahremani MH, 1999, J BIOL CHEM, V274, P9238, DOI 10.1074/jbc.274.14.9238; GIANNATTASIO G, 1981, LIFE SCI, V28, P1605, DOI 10.1016/0024-3205(81)90315-5; GRANDY DK, 1989, P NATL ACAD SCI USA, V86, P9762, DOI 10.1073/pnas.86.24.9762; Grunewald S, 1996, BIOCHEMISTRY-US, V35, P15162, DOI 10.1021/bi960757w; Jiang MS, 2001, P NATL ACAD SCI USA, V98, P3577, DOI 10.1073/pnas.051632598; Khan ZU, 1998, P NATL ACAD SCI USA, V95, P7731, DOI 10.1073/pnas.95.13.7731; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU YF, 1994, J BIOL CHEM, V269, P13880; LLEDO PM, 1992, NEURON, V8, P455, DOI 10.1016/0896-6273(92)90273-G; MANSOUR A, 1990, J NEUROSCI, V10, P2587; MCDONALD WM, 1984, MOL CELL ENDOCRINOL, V36, P201, DOI 10.1016/0303-7207(84)90037-6; Missale C, 1998, PHYSIOL REV, V78, P189, DOI 10.1152/physrev.1998.78.1.189; MONTMAYEUR JP, 1993, MOL ENDOCRINOL, V7, P161, DOI 10.1210/me.7.2.161; ODOWD BF, 1988, J BIOL CHEM, V263, P15985; OHara CM, 1996, J PHARMACOL EXP THER, V278, P354; OMALLEY KL, 1990, BIOCHEMISTRY-US, V29, P1367, DOI 10.1021/bi00458a003; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SENOGLES SE, 1994, J BIOL CHEM, V269, P23120; SENOGLES SE, 1995, MOL CELLULAR MECH NE, P103; STRADER CD, 1987, J BIOL CHEM, V262, P16439; TAUSSIG R, 1992, NEURON, V8, P799, DOI 10.1016/0896-6273(92)90100-R; Usiello A, 2000, NATURE, V408, P199, DOI 10.1038/35041572; Wang YY, 2000, J NEUROSCI, V20, P8305, DOI 10.1523/JNEUROSCI.20-22-08305.2000; Watts VJ, 1998, J NEUROSCI, V18, P8692; WEINER DM, 1989, FEBS LETT, V253, P207, DOI 10.1016/0014-5793(89)80960-3	32	37	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 16	2004	279	3					1601	1606		10.1074/jbc.M309792200	http://dx.doi.org/10.1074/jbc.M309792200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	762WT	14581469	hybrid			2022-12-27	WOS:000188005700006
J	Slavik, JM; Lim, DG; Burakoff, SJ; Hafler, DA				Slavik, JM; Lim, DG; Burakoff, SJ; Hafler, DA			Rapamycin-resistant proliferation of CD8+T cells correlates with p27(kip1) down-regulation and bcl-x(L) induction, and is prevented by an inhibitor of phosphoinositide 3-kinase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT KINASE INHIBITOR; P70 S6 KINASE; T-LYMPHOCYTES; PROTEIN-KINASE; CYCLOSPORINE-A; MESSENGER-RNA; CYTOCHROME-C; GROWTH; EXPRESSION; ACTIVATION	Rapamycin inhibits the proliferation of many mammalian cell types, including lymphocytes, making the compound useful as an immunosuppressant. Rapamycin has also been a useful tool for studying signaling mechanisms regulating cellular proliferation. However, the effects of rapamycin remain poorly understood, and the precise mechanisms of clinical action remain elusive. Previously, we found that, depending on the strength of the signal delivered to the T cell via both the T cell receptor and the costimulatory molecule CD28, CD8+ T cells are capable of rapamycin-resistant proliferation. Here, we have further elucidated the mechanism of rapamycin-resistant proliferation of human CD8+ T cells. Under conditions where rapamycin inhibited proliferation, p27(kip1) down-regulation was prevented, whereas under conditions resulting in rapamycin-resistant proliferation, p27(kip1) was down-regulated. Further, T cell receptor/CD28-dependent induction of bcl-x(L) expression was not inhibited by rapamycin, which correlated with both rapamycin-resistant proliferation and increased cell survival. Moreover, an inhibitor of phosphoinositide 3-kinase activity was able to eliminate rapamycin-resistant proliferation of freshly isolated CD8+ human cells, strongly suggesting that phosphoinositide 3-kinase activity was required for the rapamycin-resistant proliferation of CD8+ T cells. The selective immunosuppressive effect of rapamycin in human CD8+ T cell populations could be predictive of a selective effect allowing cytotoxic responses during microbial infections where there are strong strengths of signals associated with high affinity T cell receptors and strong costimulatory second signals. In contrast, the weaker autoimmune and perhaps allogeneic responses can be selectively inhibited by the actions of rapamycin.	Brigham & Womens Hosp, Ctr Neurol Dis, Lab Mol Immunol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; NYU, Dept Med, New York, NY 10016 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; New York University	Slavik, JM (corresponding author), Brigham & Womens Hosp, Ctr Neurol Dis, Lab Mol Immunol, 77 Ave Louis Pasteur, Boston, MA 02115 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI039671, R01AI044447] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024247] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI44447-01, P01 AI39671] Funding Source: Medline; NINDS NIH HHS [R01 NS24247] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abraham RT, 1996, ANNU REV IMMUNOL, V14, P483, DOI 10.1146/annurev.immunol.14.1.483; Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; AJCHENBAUM F, 1993, J BIOL CHEM, V268, P4113; Beretta L, 1996, EMBO J, V15, P658, DOI 10.1002/j.1460-2075.1996.tb00398.x; BOISE LH, 1995, IMMUNITY, V3, P87, DOI 10.1016/1074-7613(95)90161-2; Brunn GJ, 1996, EMBO J, V15, P5256, DOI 10.1002/j.1460-2075.1996.tb00911.x; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; Calastretti A, 2001, EUR J CANCER, V37, P2121, DOI 10.1016/S0959-8049(01)00256-8; CALVO V, 1992, P NATL ACAD SCI USA, V89, P7571, DOI 10.1073/pnas.89.16.7571; Chen CM, 2001, J BIOL CHEM, V276, P38518, DOI 10.1074/jbc.M105702200; Dennis PB, 1999, CURR OPIN GENET DEV, V9, P49, DOI 10.1016/S0959-437X(99)80007-0; Dumont F J, 1996, Life Sci, V58, P373; FRUMAN DA, 1992, P NATL ACAD SCI USA, V89, P3686, DOI 10.1073/pnas.89.9.3686; Fujita N, 2002, J BIOL CHEM, V277, P28706, DOI 10.1074/jbc.M203668200; GAKOUI A, 1999, SCIENCE, V285, P221; Gesbert F, 2000, J BIOL CHEM, V275, P39223, DOI 10.1074/jbc.M007291200; Gingras AC, 1998, GENE DEV, V12, P502, DOI 10.1101/gad.12.4.502; Gonzalez-Garcia A, 2002, J BIOL CHEM, V277, P1500, DOI 10.1074/jbc.M103808200; GRAVES LM, 1995, P NATL ACAD SCI USA, V92, P7222, DOI 10.1073/pnas.92.16.7222; Grumont RJ, 2002, MOL CELL, V10, P1283, DOI 10.1016/S1097-2765(02)00779-7; Hashemolhosseini S, 1998, J BIOL CHEM, V273, P14424, DOI 10.1074/jbc.273.23.14424; Hemenway Charles S., 1999, Cell Biochemistry and Biophysics, V30, P115, DOI 10.1007/BF02737887; Hosoi H, 1998, MOL PHARMACOL, V54, P815, DOI 10.1124/mol.54.5.815; Kawamata S, 1998, BLOOD, V91, P561, DOI 10.1182/blood.V91.2.561.561_561_569; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Lim DG, 2000, J IMMUNOL, V165, P6214, DOI 10.4049/jimmunol.165.11.6214; Luo Y, 1996, MOL CELL BIOL, V16, P6744; LYONS AB, 1994, J IMMUNOL METHODS, V171, P131, DOI 10.1016/0022-1759(94)90236-4; Martin KA, 2001, J BIOL CHEM, V276, P7884, DOI 10.1074/jbc.M006969200; MIYAZAKI T, 1995, CELL, V81, P223, DOI 10.1016/0092-8674(95)90332-1; Monks CRF, 1998, NATURE, V395, P82, DOI 10.1038/25764; MORICE WG, 1993, J BIOL CHEM, V268, P22737; Nelsen CJ, 2003, J BIOL CHEM, V278, P3656, DOI 10.1074/jbc.M209374200; Nguyen H, 1999, MOL CELL BIOL, V19, P1190; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; OLASHAW N, 2002, SCI STKE; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Pavletich NP, 1999, J MOL BIOL, V287, P821, DOI 10.1006/jmbi.1999.2640; Plas DR, 2001, J BIOL CHEM, V276, P12041, DOI 10.1074/jbc.M010551200; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; Raught B, 2001, P NATL ACAD SCI USA, V98, P7037, DOI 10.1073/pnas.121145898; Rohde J, 2001, J BIOL CHEM, V276, P9583, DOI 10.1074/jbc.R000034200; Saunders RN, 2001, KIDNEY INT, V59, P3, DOI 10.1046/j.1523-1755.2001.00460.x; Shapiro AMJ, 2000, NEW ENGL J MED, V343, P230, DOI 10.1056/NEJM200007273430401; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Slavik JM, 2001, J IMMUNOL, V166, P3201, DOI 10.4049/jimmunol.166.5.3201; Takuwa N, 1999, MOL CELL BIOL, V19, P1346; TURNER JM, 1993, INT IMMUNOL, V5, P1199, DOI 10.1093/intimm/5.10.1199; Windhagen A, 1998, J NEUROIMMUNOL, V91, P1, DOI 10.1016/S0165-5728(98)00086-1; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129	50	32	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 9	2004	279	2					910	919		10.1074/jbc.M209733200	http://dx.doi.org/10.1074/jbc.M209733200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	759DJ	14573608	hybrid			2022-12-27	WOS:000187722800013
J	Choi, JM; Park, EY; Kim, JH; Chang, SK; Cho, YJ				Choi, JM; Park, EY; Kim, JH; Chang, SK; Cho, YJ			Probing the functional importance of the hexameric ring structure of RNase PH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; POLYNUCLEOTIDE PHOSPHORYLASE; CRYSTAL-STRUCTURE; ANGSTROM RESOLUTION; MATURATION; PRECURSORS; PROTEINS; PATHWAYS; INVITRO; SYSTEM	RNase PH is a phosphate-dependent exoribonuclease that catalyzes the removal of nucleotides at the 3' end of the tRNA precursor, leading to the release of nucleoside diphosphate, and generates the CCA end during the maturation process. The 1.9-Angstrom crystal structures of the apo and the phosphate-bound forms of RNase PH from Pseudomonas aeruginosa reveal a monomeric RNase PH with an alpha/beta-fold tightly associated into a hexameric ring structure in the form of a trimer of dimers. A five ion pair network, Glu-63-Arg-74-Asp-116-Arg-77-Asp-118 and an ion-pair Glu-26-Arg-69 that are positioned symmetrically in the trimerization interface play critical roles in the formation of a hexameric ring. Single or double mutations of Arg-69, Arg-74, or Arg-77 in these ion pairs leads to the dissociation of the RNase PH hexamer into dimers without perturbing the overall monomeric structure. The dissociated RNase PH dimer completely lost its binding affinity and catalytic activity against a precursor tRNA. Our structural and mutational analyses of RNase PH demonstrate that the hexameric ring formation is a critical feature for the function of members of the RNase PH family.	Pohang Univ Sci & Technol, Ctr Struct Biol, Natl Creat Res Initiat, Pohang 790784, Kyungbook, South Korea; Pohang Univ Sci & Technol, Dept Life Sci, Pohang 790784, Kyungbook, South Korea	Pohang University of Science & Technology (POSTECH); Pohang University of Science & Technology (POSTECH)	Cho, YJ (corresponding author), Pohang Univ Sci & Technol, Ctr Struct Biol, Natl Creat Res Initiat, Hyo Ja Dong,San31, Pohang 790784, Kyungbook, South Korea.			Choi, Jung Min/0000-0003-2450-3916				Ambros V, 2003, CELL, V113, P673, DOI 10.1016/S0092-8674(03)00428-8; Bateman A, 2000, NUCLEIC ACIDS RES, V28, P263, DOI 10.1093/nar/28.1.263; BIKOFF EK, 1975, J BIOL CHEM, V271, P1048; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CUDNY H, 1988, J BIOL CHEM, V263, P1518; DEUTSCHER MP, 1988, P NATL ACAD SCI USA, V85, P4710, DOI 10.1073/pnas.85.13.4710; DEUTSCHER MP, 1993, NUCLEASES, P377; Deutscher Murray P., 1995, P51; DONOVAN WP, 1986, P NATL ACAD SCI USA, V83, P120, DOI 10.1073/pnas.83.1.120; Frank DN, 1998, ANNU REV BIOCHEM, V67, P153, DOI 10.1146/annurev.biochem.67.1.153; HENDSCH ZS, 1994, PROTEIN SCI, V3, P211; Ishii R, 2003, J BIOL CHEM, V278, P32397, DOI 10.1074/jbc.M300639200; Jarrige AC, 2002, J MOL BIOL, V321, P397, DOI 10.1016/S0022-2836(02)00645-9; KELLY KO, 1992, J BIOL CHEM, V267, P17153; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Li ZW, 1998, P NATL ACAD SCI USA, V95, P2856, DOI 10.1073/pnas.95.6.2856; Li ZW, 1996, CELL, V86, P503, DOI 10.1016/S0092-8674(00)80123-3; Lim JH, 1997, J MOL BIOL, V270, P259, DOI 10.1006/jmbi.1997.1105; MORI M, 2001, EMBO REP, V2, P17; OST KA, 1990, BIOCHIMIE, V72, P813, DOI 10.1016/0300-9084(90)90190-R; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Rees DC, 2001, METHOD ENZYMOL, V334, P423; SACK JS, 1988, J MOL GRAPHICS, V6, P224, DOI 10.1016/S0263-7855(98)80040-4; Schurer H, 2001, BIOL CHEM, V382, P1147, DOI 10.1515/BC.2001.144; SEKIYA T, 1979, J BIOL CHEM, V254, P5802; Shi HJ, 2000, RNA, V6, P1091, DOI 10.1017/S1355838200000364; Symmons MF, 2000, STRUCTURE, V8, P1215, DOI 10.1016/S0969-2126(00)00521-9; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; YIP KSP, 1995, STRUCTURE, V3, P1147, DOI 10.1016/S0969-2126(01)00251-9	29	22	23	3	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	2004	279	1					755	764		10.1074/jbc.M309628200	http://dx.doi.org/10.1074/jbc.M309628200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	757GU	14573594	hybrid			2022-12-27	WOS:000187555300090
J	Hillig, RC; Hulsmeyer, M; Saenger, W; Welfle, K; Misselwitz, R; Welfle, H; Kozerski, C; Volz, A; Uchanska-Ziegler, B; Ziegler, A				Hillig, RC; Hulsmeyer, M; Saenger, W; Welfle, K; Misselwitz, R; Welfle, H; Kozerski, C; Volz, A; Uchanska-Ziegler, B; Ziegler, A			Thermodynamic and structural analysis of peptide- and allele-dependent properties of two HLA-B27 subtypes exhibiting differential disease association	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-I; T-CELL-RECEPTOR; CRYSTAL-STRUCTURE; ANKYLOSING-SPONDYLITIS; 3-DIMENSIONAL STRUCTURE; HISTOCOMPATIBILITY ANTIGEN; IMMUNODOMINANT PEPTIDE; RESOLUTION STRUCTURE; ANGSTROM RESOLUTION; COMPLEX	Selected HLA-B27 subtypes are associated with spondyloarthropathies, but the underlying mechanism is not understood. To explain this association in molecular terms, a comparison of peptide-dependent dynamic and structural properties of the differentially disease-associated subtypes HLA-B*2705 and HLA-B*2709 was carried out. These molecules differ only by a single amino acid at the floor of the peptide binding groove. The thermostabilities of a series of HLA-B27 molecules complexed with nonameric and decameric peptides were determined and revealed substantial differences depending on the subtype as well as the residues at the termini of the peptides. In addition we present the crystal structure of the B*2709 subtype complexed with a decameric peptide. This structure provides an explanation for the preference of HLA-B27 for a peptide with an N-terminal arginine as secondary anchor and the lack of preference for tyrosine as peptide C terminus in B*2709. The data show that differences in thermodynamic properties between peptide-complexed HLA-B27 subtypes are correlated with a variety of structural properties.	Free Univ Berlin, Inst Kristallog, D-14195 Berlin, Germany; Humboldt Univ, Charite, Inst Immungenet, D-14050 Berlin, Germany; Max Delbruck Ctr Mol Med, D-13092 Berlin, Germany	Free University of Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Saenger, W (corresponding author), Free Univ Berlin, Inst Kristallog, Takustr 6, D-14195 Berlin, Germany.	saenger@chemie.fu-berlin.de; welfle@mdc-berlin.de; andreas.ziegler@charite.de						Achour A, 1998, IMMUNITY, V9, P199, DOI 10.1016/S1074-7613(00)80602-0; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Binz AK, 2003, BIOCHEMISTRY-US, V42, P4954, DOI 10.1021/bi034077m; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BOUVIER M, 1994, SCIENCE, V265, P398, DOI 10.1126/science.8023162; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Colbert RA, 2000, MOL MED TODAY, V6, P224, DOI 10.1016/S1357-4310(00)01699-3; DAMATO M, 1995, EUR J IMMUNOL, V25, P3199, DOI 10.1002/eji.1830251133; Dangoria NS, 2002, J BIOL CHEM, V277, P23459, DOI 10.1074/jbc.M110336200; Dedier S, 2000, J BIOL CHEM, V275, P27055; Fiorillo MT, 1997, EUR J IMMUNOL, V27, P368, DOI 10.1002/eji.1830270205; FREMONT DH, 1992, SCIENCE, V257, P919, DOI 10.1126/science.1323877; Gakamsky DM, 2000, BIOCHEMISTRY-US, V39, P11163, DOI 10.1021/bi000763z; Gakamsky DM, 1996, BIOCHEMISTRY-US, V35, P14841, DOI 10.1021/bi961707u; Gakamsky DM, 1999, BIOPHYS J, V76, P1552, DOI 10.1016/S0006-3495(99)77314-5; Ghendler Y, 1998, P NATL ACAD SCI USA, V95, P10061, DOI 10.1073/pnas.95.17.10061; Griffin TA, 1997, J IMMUNOL, V159, P4887; Hennecke J, 2000, EMBO J, V19, P5611, DOI 10.1093/emboj/19.21.5611; Hillig RC, 2001, J MOL BIOL, V310, P1167, DOI 10.1006/jmbi.2001.4816; Hulsmeyer M, 2002, J BIOL CHEM, V277, P47844, DOI 10.1074/jbc.M206392200; Kern PS, 1998, IMMUNITY, V9, P519, DOI 10.1016/S1074-7613(00)80635-4; Khan MA, 2002, ANN INTERN MED, V136, P896, DOI 10.7326/0003-4819-136-12-200206180-00011; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lamas JR, 1999, ARTHRITIS RHEUM-US, V42, P1975, DOI 10.1002/1529-0131(199909)42:9<1975::AID-ANR25>3.0.CO;2-V; Li HM, 1998, J MOL BIOL, V283, P179, DOI 10.1006/jmbi.1998.2091; Li YL, 2000, J MOL BIOL, V304, P177, DOI 10.1006/jmbi.2000.4198; Li YL, 2001, IMMUNITY, V14, P93, DOI 10.1016/S1074-7613(01)00092-9; Lopez-Larrea C, 2002, ARTHRITIS RHEUM-US, V46, P2968, DOI 10.1002/art.10584; MADDEN DR, 1992, CELL, V70, P1035, DOI 10.1016/0092-8674(92)90252-8; MADDEN DR, 1995, ANNU REV IMMUNOL, V13, P587, DOI 10.1146/annurev.iy.13.040195.003103; MATSUMURA M, 1992, SCIENCE, V257, P927, DOI 10.1126/science.1323878; MCLACHLAN AD, 1982, ACTA CRYSTALLOGR A, V38, P871, DOI 10.1107/S0567739482001806; Menssen R, 1999, J MOL BIOL, V285, P645, DOI 10.1006/jmbi.1998.2363; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Minasov G, 2002, J AM CHEM SOC, V124, P5333, DOI 10.1021/ja0259640; Mullen MM, 2002, MOL CELL, V9, P375, DOI 10.1016/S1097-2765(02)00465-3; Murshudov GN, 1999, ACTA CRYSTALLOGR D, V55, P247, DOI 10.1107/S090744499801405X; Navaza J, 1997, METHOD ENZYMOL, V276, P581, DOI 10.1016/S0076-6879(97)76079-8; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pace C. N., 1997, PROTEIN STRUCTURE PR, V2, P299; Pamer E, 1998, ANNU REV IMMUNOL, V16, P323, DOI 10.1146/annurev.immunol.16.1.323; Privalov P L, 1986, Methods Enzymol, V131, P4; Privalov P L, 1979, Adv Protein Chem, V33, P167, DOI 10.1016/S0065-3233(08)60460-X; RAMMENSEE HG, 1995, IMMUNOGENETICS, V41, P178, DOI 10.1007/BF00172063; Ramos M, 2002, J BIOL CHEM, V277, P28749, DOI 10.1074/jbc.M204155200; Ramos M, 2002, TISSUE ANTIGENS, V60, P191, DOI 10.1034/j.1399-0039.2002.600301.x; Reinelt S, 2001, J BIOL CHEM, V276, P18472, DOI 10.1074/jbc.M101282200; ROGNAN D, 1994, BIOCHEMISTRY-US, V33, P11476, DOI 10.1021/bi00204a009; Rudolph MG, 2002, ANNU REV BIOPH BIOM, V31, P121, DOI 10.1146/annurev.biophys.31.082901.134423; Rudolph MG, 2001, IMMUNITY, V14, P231, DOI 10.1016/S1074-7613(01)00105-4; Sanner MF, 1996, BIOPOLYMERS, V38, P305, DOI 10.1002/(SICI)1097-0282(199603)38:3<305::AID-BIP4>3.3.CO;2-8; SAPER MA, 1991, J MOL BIOL, V219, P277, DOI 10.1016/0022-2836(91)90567-P; Sieper J, 2002, ANN RHEUM DIS, V61, P8; Speir JA, 1999, IMMUNITY, V10, P51, DOI 10.1016/S1074-7613(00)80006-0; Strong RK, 2003, J BIOL CHEM, V278, P5082, DOI 10.1074/jbc.M208268200; Sundberg EJ, 2002, J MOL BIOL, V319, P449, DOI 10.1016/S0022-2836(02)00370-4; Tormo J, 1999, NATURE, V402, P623, DOI 10.1038/45170; Uchanska-Ziegler B, 2003, TRENDS IMMUNOL, V24, P73, DOI 10.1016/S1471-4906(02)00028-5; UCHANSKAZIEGLER B, 2003, HLA 2002 IMMUNOBIOLO; Umezawa Y, 1998, BIOORGAN MED CHEM, V6, P2507, DOI 10.1016/S0968-0896(98)80024-2; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; Weiss MS, 2001, TRENDS BIOCHEM SCI, V26, P521, DOI 10.1016/S0968-0004(01)01935-1; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736; ZHANG WG, 1992, P NATL ACAD SCI USA, V89, P8403, DOI 10.1073/pnas.89.17.8403	64	56	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 2	2004	279	1					652	663		10.1074/jbc.M307457200	http://dx.doi.org/10.1074/jbc.M307457200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	757GU	14555655	hybrid			2022-12-27	WOS:000187555300079
J	Meyer, RD; Singh, AJ; Rahimi, N				Meyer, RD; Singh, AJ; Rahimi, N			The carboxyl terminus controls ligand-dependent activation of VEGFR-2 and its signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASE; JUXTAMEMBRANE REGION; CRYSTAL-STRUCTURE; GROWTH; DOMAIN; AUTOPHOSPHORYLATION; PHOSPHORYLATION; PROTEIN; LOOP; AUTOINHIBITION	Vascular endothelial growth factor receptor-2 (VEGFR-2/FLK-1) is a receptor tyrosine kinase whose activation stimulates angiogenesis. We recently generated a chimeric VEGFR-2 in which the extracellular domain of VEGFR-2 was replaced with the extracellular domain of human colony stimulating factor-1 receptor and expressed in endothelial cells. To study the contribution of the carboxyl terminus to activation of VEGFR-2, we created a panel of truncated receptors in which the carboxyl terminus of VEGFR-2 was progressively deleted. Removal of the entire carboxyl terminus eliminated activation of VEGFR-2, its ability to activate signaling proteins, and its ability to stimulate cell proliferation. The carboxyl terminus-deleted VEGFR- 2 exhibited impaired ligand-dependent down-regulation and inhibited the activation of wild-type receptor in a dominant-negative fashion. Furthermore, introducing the carboxyl terminus of another receptor, i.e., VEGFR- 1, restored the ligand-dependent activation of the carboxyl terminus-deleted VEGFR- 2 and its ability to stimulate cell proliferation. Our findings suggest that the carboxyl terminus of VEGFR- 2 plays a critical role in VEGFR- 2 activation, its ability to activate signaling proteins, and its ability to induce biological responses. The presence of at least 57 amino acids at the carboxyl terminus of VEGFR- 2 are required for VEGFR- 2 activation. Thus, we propose that the carboxyl terminus is required for activation of VEGFR- 2, and absence of the carboxyl terminus renders VEGFR- 2 inactive.	Boston Univ, Sch Med, Dept Ophthalmol & Biochem, Boston, MA 02118 USA	Boston University	Rahimi, N (corresponding author), Boston Univ, Sch Med, Dept Ophthalmol & Biochem, 715 Albany St,Rm L921, Boston, MA 02118 USA.	nrahimi@bu.edu		Rahimi, Nader/0000-0002-6745-1725	NEI NIH HHS [R03 EY013706, EY 0137061, R01 EY012997, EY012997] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY012997, R03EY013706] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AKIYAMA T, 1991, MOL CELL BIOL, V11, P833, DOI 10.1128/MCB.11.2.833; Bardelli A, 1999, J BIOL CHEM, V274, P29274, DOI 10.1074/jbc.274.41.29274; Binns KL, 2000, MOL CELL BIOL, V20, P4791, DOI 10.1128/MCB.20.13.4791-4805.2000; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Chang PM, 2003, MOL CELL BIOL, V23, P3067, DOI 10.1128/MCB.23.9.3067-3078.2003; Cunningham ME, 1997, J BIOL CHEM, V272, P10957; Cunningham ME, 1998, EMBO J, V17, P7282, DOI 10.1093/emboj/17.24.7282; Dayanir V, 2001, J BIOL CHEM, V276, P17686, DOI 10.1074/jbc.M009128200; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; Dougher M, 1999, ONCOGENE, V18, P1619, DOI 10.1038/sj.onc.1202478; Favelyukis S, 2001, NAT STRUCT BIOL, V8, P1058, DOI 10.1038/nsb721; Gruenberg J, 2001, NAT REV MOL CELL BIO, V2, P721, DOI 10.1038/35096054; Herbst R, 2000, EMBO J, V19, P67, DOI 10.1038/sj.emboj.7592228b; Hubbard SR, 2002, FRONT BIOSCI, V7, pD330, DOI 10.2741/hubbard; Hubbard SR, 1999, NAT STRUCT BIOL, V6, P711, DOI 10.1038/11468; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; Hubbard SR, 1998, J BIOL CHEM, V273, P11987, DOI 10.1074/jbc.273.20.11987; McTigue MA, 1999, STRUCT FOLD DES, V7, P319, DOI 10.1016/S0969-2126(99)80042-2; Meyer RD, 2003, J BIOL CHEM, V278, P16347, DOI 10.1074/jbc.M300259200; Meyer RD, 2002, J BIOL CHEM, V277, P27081, DOI 10.1074/jbc.M110544200; Millauer B, 1996, CANCER RES, V56, P1615; Mohammadi M, 1996, CELL, V86, P577, DOI 10.1016/S0092-8674(00)80131-2; Niu XL, 2002, J BIOL CHEM, V277, P31768, DOI 10.1074/jbc.M203995200; OHTSUKA M, 1990, MOL CELL BIOL, V10, P1664, DOI 10.1128/MCB.10.4.1664; Ory DS, 1996, P NATL ACAD SCI USA, V93, P11400, DOI 10.1073/pnas.93.21.11400; Rahimi N, 2000, J BIOL CHEM, V275, P16986, DOI 10.1074/jbc.M000528200; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; SEEDORF K, 1991, J BIOL CHEM, V266, P12424; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Shewchuk LM, 2000, STRUCTURE, V8, P1105, DOI 10.1016/S0969-2126(00)00516-5; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; Sorkin A, 2002, NAT REV MOL CELL BIO, V3, P600, DOI 10.1038/nrm883; Till JH, 2001, J BIOL CHEM, V276, P10049, DOI 10.1074/jbc.M010161200; WALTON GM, 1990, J BIOL CHEM, V265, P1750; WEDEGAERTNER PB, 1992, ARCH BIOCHEM BIOPHYS, V292, P273, DOI 10.1016/0003-9861(92)90079-C; WOOLFORD J, 1988, CELL, V55, P965, DOI 10.1016/0092-8674(88)90242-5	36	21	22	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 2	2004	279	1					735	742		10.1074/jbc.M305575200	http://dx.doi.org/10.1074/jbc.M305575200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	757GU	14573614	hybrid, Green Accepted			2022-12-27	WOS:000187555300088
J	Johnson, EC; Bohn, LM; Barak, LS; Birse, RT; Nassel, DR; Caron, MG; Taghert, PH				Johnson, EC; Bohn, LM; Barak, LS; Birse, RT; Nassel, DR; Caron, MG; Taghert, PH			Identification of Drosophila neuropeptide receptors by G protein-coupled receptors-beta-arrestin2 interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ARRESTIN; FUNCTIONAL EXPRESSION; MOLECULAR-CLONING; BETA(2)-ADRENERGIC RECEPTOR; DIFFERENTIAL REGULATION; FMRFAMIDE RECEPTOR; OPIOID RECEPTORS; MELANOGASTER; DESENSITIZATION; PEPTIDES	Activation of G protein-coupled receptors ( GPCR) leads to the recruitment of beta-arrestins. By tagging the beta-arrestin molecule with a green fluorescent protein, we can visualize the activation of GPCRs in living cells. We have used this approach to de-orphan and study 11 GPCRs for neuropeptide receptors in Drosophila melanogaster. Here we verify the identities of ligands for several recently de-orphaned receptors, including the receptors for the Drosophila neuropeptides proctolin (CG6986), neuropeptide F (CG1147), corazonin (CG10698), dFMRF-amide (CG2114), and allatostatin C (CG7285 and CG13702). We also de-orphan CG6515 and CG7887 by showing these two suspected tachykinin receptor family members respond specifically to a Drosophila tachykinin neuropeptide. Additionally, the translocation assay was used to de-orphan three Drosophila receptors. We show that CG14484, encoding a receptor related to vertebrate bombesin receptors, responds specifically to allatostatin B. Furthermore, the pair of paralogous receptors CG8985 and CG13803 responds specifically to the FMRF-amide-related peptide dromyosuppressin. To corroborate the findings on orphan receptors obtained by the translocation assay, we show that dromyosuppressin also stimulated GTPgammaS binding and inhibited cAMP by CG8985 and CG13803. Together these observations demonstrate the beta-arrestin-green fluorescent protein translocation assay is an important tool in the repertoire of strategies for ligand identification of novel G protein-coupled receptors.	Washington Univ, Sch Med, Dept Anat & Neurobiol, St Louis, MO 63110 USA; Duke Univ, Dept Cell Biol, Durham, NC 27710 USA; Stockholm Univ, Howard Hughes Med Inst, SE-10691 Stockholm, Sweden; Stockholm Univ, Dept Zool, SE-10691 Stockholm, Sweden	Washington University (WUSTL); Duke University; Stockholm University; Stockholm University	Caron, MG (corresponding author), Washington Univ, Sch Med, Dept Anat & Neurobiol, St Louis, MO 63110 USA.	m.caron@cellbio.duke.edu; taghertp@pcg.wustl.edu	Gimenez, Luis E Diaz/D-9291-2011; Bohn, Laura/A-4412-2008; Bohn, Laura M/A-7483-2014	Bohn, Laura M/0000-0002-6474-8179	NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH067122] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS019576] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [K01DA014600] Funding Source: NIH RePORTER; NIDA NIH HHS [DA14600] Funding Source: Medline; NIMH NIH HHS [MH067122] Funding Source: Medline; NINDS NIH HHS [NS27149, NS19576] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Barak LS, 2003, ASSAY DRUG DEV TECHN, V1, P409, DOI 10.1089/154065803322163722; Barak LS, 1999, J BIOL CHEM, V274, P7565, DOI 10.1074/jbc.274.11.7565; Barak LS, 1997, J BIOL CHEM, V272, P27497, DOI 10.1074/jbc.272.44.27497; Barak LS, 2001, P NATL ACAD SCI USA, V98, P93, DOI 10.1073/pnas.011303698; Birgul N, 1999, EMBO J, V18, P5892, DOI 10.1093/emboj/18.21.5892; Brody T, 2000, J CELL BIOL, V150, pF83, DOI 10.1083/jcb.150.2.F83; Broeck JV, 2001, PEPTIDES, V22, P241, DOI 10.1016/S0196-9781(00)00376-4; CASSILL JA, 1991, P NATL ACAD SCI USA, V88, P11067, DOI 10.1073/pnas.88.24.11067; Cazzamali G, 2002, BIOCHEM BIOPH RES CO, V298, P31, DOI 10.1016/S0006-291X(02)02398-7; Cazzamali G, 2002, P NATL ACAD SCI USA, V99, P12073, DOI 10.1073/pnas.192442799; Egerod K, 2003, P NATL ACAD SCI USA, V100, P9808, DOI 10.1073/pnas.1632197100; Garczynski SF, 2002, PEPTIDES, V23, P773, DOI 10.1016/S0196-9781(01)00647-7; Hearn MG, 2002, P NATL ACAD SCI USA, V99, P14554, DOI 10.1073/pnas.202498299; Hewes RS, 1998, J NEUROSCI, V18, P7138; Hewes RS, 2001, GENOME RES, V11, P1126, DOI 10.1101/gr.169901; Johnson E, 2000, J INSECT PHYSIOL, V46, P1229, DOI 10.1016/S0022-1910(00)00043-3; Johnson EC, 2003, P NATL ACAD SCI USA, V100, P6198, DOI 10.1073/pnas.1030108100; Keith DE, 1996, J BIOL CHEM, V271, P19021, DOI 10.1074/jbc.271.32.19021; Kim KM, 2001, J BIOL CHEM, V276, P37409, DOI 10.1074/jbc.M106728200; Kohout TA, 2003, MOL PHARMACOL, V63, P9, DOI 10.1124/mol.63.1.9; Kreienkamp HJ, 2002, J BIOL CHEM, V277, P39937, DOI 10.1074/jbc.M206931200; Larsen MJ, 2001, BIOCHEM BIOPH RES CO, V286, P895, DOI 10.1006/bbrc.2001.5476; LI XJ, 1991, EMBO J, V10, P3221, DOI 10.1002/j.1460-2075.1991.tb04885.x; Meeusen T, 2002, P NATL ACAD SCI USA, V99, P15363, DOI 10.1073/pnas.252339599; MONNIER D, 1992, J BIOL CHEM, V267, P1298; NICHOLS R, 1992, J MOL NEUROSCI, V3, P213, DOI 10.1007/BF03380141; Oakley RH, 2002, ASSAY DRUG DEV TECHN, V1, P21, DOI 10.1089/154065802761001275; Oakley RH, 2001, J BIOL CHEM, V276, P19452, DOI 10.1074/jbc.M101450200; Park Y, 2002, P NATL ACAD SCI USA, V99, P11423, DOI 10.1073/pnas.162276199; Roman G, 2000, GENETICS, V155, P1281; Siviter RJ, 2000, J BIOL CHEM, V275, P23273, DOI 10.1074/jbc.M002875200; Staubli F, 2002, P NATL ACAD SCI USA, V99, P3446, DOI 10.1073/pnas.052556499; Taghert PH, 2003, ADV GENET, V49, P1, DOI 10.1016/S0065-2660(03)01001-0; Tohgo A, 2003, J BIOL CHEM, V278, P6258, DOI 10.1074/jbc.M212231200; Torfs H, 2001, ARCH INSECT BIOCHEM, V48, P39, DOI 10.1002/arch.1056; Walker JKL, 1999, J BIOL CHEM, V274, P31515, DOI 10.1074/jbc.274.44.31515; Whistler JL, 1998, P NATL ACAD SCI USA, V95, P9914, DOI 10.1073/pnas.95.17.9914; Wilbanks AM, 2002, BIOCHEMISTRY-US, V41, P11981, DOI 10.1021/bi020275m; Zhang J, 1998, P NATL ACAD SCI USA, V95, P7157, DOI 10.1073/pnas.95.12.7157; Zhang J, 1997, J BIOL CHEM, V272, P27005, DOI 10.1074/jbc.272.43.27005	41	90	93	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52172	52178		10.1074/jbc.M306756200	http://dx.doi.org/10.1074/jbc.M306756200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14555656	hybrid			2022-12-27	WOS:000187480700025
J	Shen, X; Woodgate, R; Goodman, MF				Shen, X; Woodgate, R; Goodman, MF			Escherichia coli DNA polymerase V subunit exchange - A post-SOS mechanism to curtail error-prone DNA synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UMUD MUTAGENESIS PROTEIN; RECA PROTEIN; ULTRAVIOLET-LIGHT; BIOCHEMICAL BASIS; CLEAVAGE; PURIFICATION; DEFICIENT; MUTATIONS; COMPLEX; MUTANTS	DNA polymerase V consisting of a heterotrimer composed of one molecule of UmuC and two molecules of UmuD' (UmuD'C-2) is responsible for SOS damage-induced mutagenesis in Escherichia coli. Here we show that although the UmuD'C-2 complex remains intact through multiple chromatographic steps, excess UmuD, the precursor to UmuD', displaces UmuD' from UmuD'C-2 by forming a UmuDD' heterodimer, while UmuC concomitantly aggregates as an insoluble precipitate. Although soluble UmuD'C-2 is readily detected when the two genes are co-transcribed and translated in vitro, soluble UmuD(2)C or UmuDD'C are not detected. The subunit exchange between UmuD'C-2 and UmuD offers a biological means to inactivate error-prone polymerase V following translesion synthesis, thus preventing mutations from occurring on undamaged DNA.	Univ So Calif, Dept Chem & Biol Sci, Hedco Mol Biol Labs, Los Angeles, CA 90089 USA; NICHD, Sect DNA Replicat Repair & Mutagenesis, NIH, Bethesda, MD 20892 USA	University of Southern California; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Goodman, MF (corresponding author), Univ So Calif, Dept Biol Sci, SHS Rm 172,Univ Pk, Los Angeles, CA 90089 USA.			Woodgate, Roger/0000-0001-5581-4616	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM021422, R01GM021422] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM42554, GM21422] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAGG A, 1981, P NATL ACAD SCI-BIOL, V78, P5749, DOI 10.1073/pnas.78.9.5749; BATTISTA JR, 1990, P NATL ACAD SCI USA, V87, P7190, DOI 10.1073/pnas.87.18.7190; BROWDER LW, 1992, ANAL BIOCHEM, V204, P85, DOI 10.1016/0003-2697(92)90143-U; Bruck I, 1996, J BIOL CHEM, V271, P10767, DOI 10.1074/jbc.271.18.10767; BURCKHARDT SE, 1988, P NATL ACAD SCI USA, V85, P1811, DOI 10.1073/pnas.85.6.1811; Courcelle J, 2001, GENETICS, V158, P41; COX MM, 1981, P NATL ACAD SCI-BIOL, V78, P3433, DOI 10.1073/pnas.78.6.3433; ECHOLS H, 1990, MUTAT RES, V236, P301, DOI 10.1016/0921-8777(90)90013-U; Fernandez de Henestrosa AR, 2000, MOL MICROBIOL, V35, P1560, DOI 10.1046/j.1365-2958.2000.01826.x; Frank EG, 1996, J BACTERIOL, V178, P3550, DOI 10.1128/jb.178.12.3550-3556.1996; FRANK EG, 1993, P NATL ACAD SCI USA, V90, P8169, DOI 10.1073/pnas.90.17.8169; Frank EG, 1996, P NATL ACAD SCI USA, V93, P10291, DOI 10.1073/pnas.93.19.10291; Friedberg E.C., 1995, DNA REPAIR MUTAGENES, P407; Gonzalez M, 2000, EMBO J, V19, P5251, DOI 10.1093/emboj/19.19.5251; Gonzalez M, 1998, GENE DEV, V12, P3889, DOI 10.1101/gad.12.24.3889; Goodman MF, 2002, ANNU REV BIOCHEM, V71, P17, DOI 10.1146/annurev.biochem.71.083101.124707; Goodman MF, 2000, COLD SPRING HARB SYM, V65, P31, DOI 10.1101/sqb.2000.65.31; KALINICH JF, 1992, ANAL BIOCHEM, V205, P208, DOI 10.1016/0003-2697(92)90425-7; KATO T, 1977, MOL GEN GENET, V156, P121, DOI 10.1007/BF00283484; KOCH WH, 1992, MOL GEN GENET, V233, P443, DOI 10.1007/BF00265442; McDonald JP, 1998, J MOL BIOL, V282, P721, DOI 10.1006/jmbi.1998.2044; NOHMI T, 1988, P NATL ACAD SCI USA, V85, P1816, DOI 10.1073/pnas.85.6.1816; PETIT MA, 1994, J BIOL CHEM, V269, P23824; Pham P, 2001, NATURE, V409, P366, DOI 10.1038/35053116; Radman M., 1975, MOL MECHANISMS REPAI, P355; Reuven NB, 1999, J BIOL CHEM, V274, P31763, DOI 10.1074/jbc.274.45.31763; SHINAGAWA H, 1988, P NATL ACAD SCI USA, V85, P1806, DOI 10.1073/pnas.85.6.1806; STEINBORN G, 1978, MOL GEN GENET, V165, P87, DOI 10.1007/BF00270380; Sutton MD, 2001, J BACTERIOL, V183, P1215, DOI 10.1128/JB.183.4.1215-1224.2001; Tang MJ, 2000, NATURE, V404, P1014, DOI 10.1038/35010020; Tang MJ, 1999, P NATL ACAD SCI USA, V96, P8919, DOI 10.1073/pnas.96.16.8919; Tang MJ, 1998, P NATL ACAD SCI USA, V95, P9755, DOI 10.1073/pnas.95.17.9755; WITKIN EM, 1975, GENETICS, V79, P199; WOODGATE R, 1989, P NATL ACAD SCI USA, V86, P7301, DOI 10.1073/pnas.86.19.7301	34	19	19	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52546	52550		10.1074/jbc.M310127200	http://dx.doi.org/10.1074/jbc.M310127200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14573598	hybrid			2022-12-27	WOS:000187480700071
J	Koenderink, JB; Geibel, S; Grabsch, E; De Pont, JJHHM; Bamberg, E; Friedrich, T				Koenderink, JB; Geibel, S; Grabsch, E; De Pont, JJHHM; Bamberg, E; Friedrich, T			Electrophysiological analysis of the mutated Na,K-ATPase cation binding pocket	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							5TH TRANSMEMBRANE SEGMENT; NA+-K+ PUMP; ALPHA-SUBUNIT; VOLTAGE-DEPENDENCE; XENOPUS-OOCYTES; NA/K PUMP; RENAL NA,K-ATPASE; ATP-CONCENTRATION; NA,K PUMP; COORDINATING RESIDUES	Na, K-ATPase mediates net electrogenic transport by extruding three Na+ ions and importing two K+ ions across the plasma membrane during each reaction cycle. We mutated putative cation coordinating amino acids in transmembrane hairpin M5-M6 of rat Na, K-ATPase: Asp(776) (Gln, Asp, Ala), Glu(779) (Asp, Gln, Ala), Asp(804) (Glu, Asn, Ala), and Asp(808) (Glu, Asn, Ala). Electrogenic cation transport properties of these 12 mutants were analyzed in two-electrode voltage-clamp experiments on Xenopus laevis oocytes by measuring the voltage dependence of K+-stimulated stationary currents and pre-steady-state currents under electrogenic Na+/Na+ exchange conditions. Whereas mutants D804N, D804A, and D808A hardly showed any Na+/K+ pump currents, the other constructs could be classified according to the [K+] and voltage dependence of their stationary currents; mutants N776A and E779Q behaved similarly to the wild-type enzyme. Mutants E779D, E779A, D808E, and D808N had in common a decreased apparent affinity for extracellular K+. Mutants N776Q, N776D, and D804E showed large deviations from the wild-type behavior; the currents generated by mutant N776D showed weaker voltage dependence, and the current-voltage curves of mutants N776Q and D804E exhibited a negative slope. The apparent rate constants determined from transient Na+/Na+ exchange currents are rather voltage-independent and at potentials above -60 mV faster than the wild type. Thus, the characteristic voltage-dependent increase of the rate constants at hyperpolarizing potentials is almost absent in these mutants. Accordingly, dislocating the carboxamide or carboxyl group of Asn(776) and Asp(804), respectively, decreases the extracellular Na+ affinity.	Univ Nijmegen, Dept Biochem 160, Med Ctr, NL-6500 HB Nijmegen, Netherlands; Max Planck Inst Biophys, Dept Biophys Chem, D-60439 Frankfurt, Germany	Radboud University Nijmegen; Max Planck Society	Koenderink, JB (corresponding author), Univ Nijmegen, Dept Biochem 160, Med Ctr, POB 9101, NL-6500 HB Nijmegen, Netherlands.	J.Koenderink@ncmls.kun.nl	Friedrich, Thomas/AAA-3418-2022; Koenderink, Jan/N-3578-2014					ANDERSEN JP, 1995, FEBS LETT, V359, P101, DOI 10.1016/0014-5793(95)00019-6; Arguello JM, 1999, ARCH BIOCHEM BIOPHYS, V364, P254, DOI 10.1006/abbi.1999.1124; Arguello JM, 1996, J BIOL CHEM, V271, P24610, DOI 10.1074/jbc.271.40.24610; BAHINSKI A, 1988, P NATL ACAD SCI USA, V85, P3412, DOI 10.1073/pnas.85.10.3412; Beguin P, 2000, MOL BIOL CELL, V11, P1657, DOI 10.1091/mbc.11.5.1657; CLELAND WW, 1989, BIOCHIM BIOPHYS ACTA, V1000, P209; DEWEER P, 1990, NA K PUMP CURRENT GE; FENDLER K, 1985, EMBO J, V4, P3079, DOI 10.1002/j.1460-2075.1985.tb04048.x; Friedrich T, 1997, BIOPHYS J, V73, P186, DOI 10.1016/S0006-3495(97)78059-7; Friedrich T, 1996, BIOPHYS J, V71, P2486, DOI 10.1016/S0006-3495(96)79442-0; GEERING K, 1989, AM J PHYSIOL, V257, pC851, DOI 10.1152/ajpcell.1989.257.5.C851; Geibel S, 2003, P NATL ACAD SCI USA, V100, P964, DOI 10.1073/pnas.0337336100; HILGEMANN DW, 1994, SCIENCE, V263, P1429, DOI 10.1126/science.8128223; Hilgemann DW, 1997, ANN NY ACAD SCI, V834, P260, DOI 10.1111/j.1749-6632.1997.tb52257.x; Holmgren M, 2000, NATURE, V403, P898, DOI 10.1038/35002599; HOLMGREN M, 1994, BIOPHYS J, V66, P912, DOI 10.1016/S0006-3495(94)80867-7; JENCKS WP, 1989, METHOD ENZYMOL, V171, P145; Jorgensen PL, 2003, ANNU REV PHYSIOL, V65, P817, DOI 10.1146/annurev.physiol.65.092101.142558; Jorgensen PL, 2001, BBA-BIOENERGETICS, V1505, P57, DOI 10.1016/S0005-2728(00)00277-2; Kamsteeg EJ, 2001, BIOCHEM BIOPH RES CO, V282, P683, DOI 10.1006/bbrc.2001.4629; Kaplan JH, 2002, ANNU REV BIOCHEM, V71, P511, DOI 10.1146/annurev.biochem.71.102201.141218; Koenderink JB, 2000, P NATL ACAD SCI USA, V97, P11209, DOI 10.1073/pnas.200109597; Koenderink JB, 2000, BIOCHEMISTRY-US, V39, P9959, DOI 10.1021/bi0001168; Koster JC, 1996, J BIOL CHEM, V271, P2413, DOI 10.1074/jbc.271.5.2413; Kuntzweiler TA, 1996, J BIOL CHEM, V271, P29682, DOI 10.1074/jbc.271.47.29682; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAFAIRE AV, 1986, J MEMBRANE BIOL, V91, P43, DOI 10.1007/BF01870213; LAUGER P, 1979, BIOCHIM BIOPHYS ACTA, V552, P143, DOI 10.1016/0005-2736(79)90253-0; Lauger P., 1991, ELECTROGENIC ION PUM; Lorenz L, 1996, P NATL ACAD SCI USA, V93, P13362, DOI 10.1073/pnas.93.23.13362; MacLennan DH, 1997, J BIOL CHEM, V272, P28815, DOI 10.1074/jbc.272.46.28815; NAGEL G, 1987, BIOCHIM BIOPHYS ACTA, V901, P239, DOI 10.1016/0005-2736(87)90120-9; NAKAO M, 1986, NATURE, V323, P628, DOI 10.1038/323628a0; Nielsen JM, 1998, BIOCHEMISTRY-US, V37, P1961, DOI 10.1021/bi972524q; Ogawa H, 2002, P NATL ACAD SCI USA, V99, P15977, DOI 10.1073/pnas.202622299; Pedersen PA, 1998, BIOCHEMISTRY-US, V37, P17818, DOI 10.1021/bi981898w; Pedersen PA, 1997, FEBS LETT, V400, P206, DOI 10.1016/S0014-5793(96)01381-6; Peluffo RD, 1997, J PHYSIOL-LONDON, V501, P33, DOI 10.1111/j.1469-7793.1997.033bo.x; Peluffo RD, 2000, J GEN PHYSIOL, V116, P47, DOI 10.1085/jgp.116.1.47; Peluffo RD, 2000, J GEN PHYSIOL, V116, P61, DOI 10.1085/jgp.116.1.61; RAKOWSKI RF, 1991, J MEMBRANE BIOL, V121, P177, DOI 10.1007/BF01870531; RAKOWSKI RF, 1993, J GEN PHYSIOL, V101, P117, DOI 10.1085/jgp.101.1.117; RAKOWSKI RF, 1988, J MEMBRANE BIOL, V106, P173, DOI 10.1007/BF01871399; SACHS JR, 1980, J PHYSIOL-LONDON, V302, P219; SAGAR A, 1994, J GEN PHYSIOL, V103, P869, DOI 10.1085/jgp.103.5.869; SCHWARZ W, 1988, BIOCHIM BIOPHYS ACTA, V945, P167, DOI 10.1016/0005-2736(88)90479-8; STURMER W, 1989, J MEMBRANE BIOL, V110, P67, DOI 10.1007/BF01870994; THOMAS RC, 1972, PHYSIOL REV, V52, P563, DOI 10.1152/physrev.1972.52.3.563; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; VanHuysse JW, 1996, FEBS LETT, V389, P179, DOI 10.1016/0014-5793(96)00578-9; Vasilets LA, 1998, BBA-BIOMEMBRANES, V1368, P137, DOI 10.1016/S0005-2736(97)00195-8; VILSEN B, 1995, BIOCHEMISTRY-US, V34, P1455, DOI 10.1021/bi00004a041; Wang XY, 1996, J PHYSIOL-LONDON, V491, P579, DOI 10.1113/jphysiol.1996.sp021241; Zillikens S, 2000, BBA-BIOMEMBRANES, V1509, P155, DOI 10.1016/S0005-2736(00)00289-3	55	51	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51213	51222		10.1074/jbc.M306384200	http://dx.doi.org/10.1074/jbc.M306384200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14532287	hybrid, Green Published			2022-12-27	WOS:000187206300047
J	Wang, Z; Garabedian, MJ				Wang, Z; Garabedian, MJ			Modulation of glucocorticoid receptor transcriptional activation, phosphorylation, and growth inhibition by p27(Kip1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE ARREST; CDK INHIBITOR; MULTIPLE FUNCTIONS; MICE LACKING; P27; PROTEIN; CANCER; DIFFERENTIATION; EXPRESSION; SURVIVAL	The cyclin- dependent kinase inhibitor p27(Kip1) is frequently inactivated in human cancers. Glucocorticoids, acting through the glucocorticoid receptor ( GR), are frequently used to treat certain malignancies and are growth inhibitive, but the relationship between GR activity and p27 status has not been explored. We have therefore examined GR- dependent transcriptional activation, receptor phosphorylation, and glucocorticoid-dependent growth inhibition in p27- deficient ( p27(-/-)) murine embryonic fibroblasts ( MEFs). We find that GR transcriptional enhancement as well as receptor phosphorylation at two putative cyclin- dependent kinase sites are elevated in p27(-/-) MEFs, relative to control cells. This increased GR transcriptional activation appears to be mediated through the GR N terminus, and coexpression of the GR N- terminal coactivator, DRIP150, further enhanced GR- dependent transcriptional activation. Furthermore, p27(-/-) MEFs are partially resistant to the growth inhibitory effects of glucocorticoids. Thus, p27 appears to be an important element in the GR transcription and growth inhibitory responses.	NYU, Sch Med, Inst Canc, Dept Microbiol, New York, NY 10016 USA; NYU, Sch Med, Inst Canc, Dept Urol, New York, NY 10016 USA	New York University; New York University	Garabedian, MJ (corresponding author), NYU, Sch Med, Inst Canc, Dept Microbiol, 550 1St Ave, New York, NY 10016 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050836] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 50836] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALMLOF T, 1995, J BIOL CHEM, V270, P17535, DOI 10.1074/jbc.270.29.17535; Blain SW, 2003, CANCER CELL, V3, P111, DOI 10.1016/S1535-6108(03)00026-6; Bloom J, 2003, SEMIN CANCER BIOL, V13, P41, DOI 10.1016/S1044-579X(02)00098-6; BODWELL JE, 1995, J STEROID BIOCHEM, V52, P135, DOI 10.1016/0960-0760(94)00157-H; Bodwell JE, 1998, J STEROID BIOCHEM, V65, P91, DOI 10.1016/S0960-0760(97)00185-4; Catzavelos C, 1999, CANCER RES, V59, P684; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; Drissi H, 1999, CANCER RES, V59, P3705; Durand B, 1998, CURR BIOL, V8, P431, DOI 10.1016/S0960-9822(98)70177-0; Hittelman AB, 1999, EMBO J, V18, P5380, DOI 10.1093/emboj/18.19.5380; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Krstic MD, 1997, MOL CELL BIOL, V17, P3947, DOI 10.1128/MCB.17.7.3947; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; MASON SA, 1993, J BIOL CHEM, V268, P21501; MINER JN, 1991, TRENDS BIOCHEM SCI, V16, P423, DOI 10.1016/0968-0004(91)90168-U; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; ORTI E, 1989, J STEROID BIOCHEM, V34, P85, DOI 10.1016/0022-4731(89)90069-1; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Ramalingam A, 1997, MOL ENDOCRINOL, V11, P577, DOI 10.1210/me.11.5.577; Reichardt HM, 1998, CELL, V93, P531, DOI 10.1016/S0092-8674(00)81183-6; Reichardt HM, 2000, MOL CELL BIOL, V20, P9009, DOI 10.1128/MCB.20.23.9009-9017.2000; Roca R, 2003, P NATL ACAD SCI USA, V100, P3113, DOI 10.1073/pnas.0634912100; Rogatsky I, 1999, MOL CELL BIOL, V19, P5036; Rogatsky I, 1997, MOL CELL BIOL, V17, P3181, DOI 10.1128/MCB.17.6.3181; Sgambato A, 2000, J CELL PHYSIOL, V183, P18, DOI 10.1002/(SICI)1097-4652(200004)183:1<18::AID-JCP3>3.0.CO;2-S; Slingerland J, 2000, J CELL PHYSIOL, V183, P10, DOI 10.1002/(SICI)1097-4652(200004)183:1<10::AID-JCP2>3.0.CO;2-I; Tan P, 1997, CANCER RES, V57, P1259; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Wang Z, 2002, J BIOL CHEM, V277, P26573, DOI 10.1074/jbc.M110530200; Webster JC, 1997, J BIOL CHEM, V272, P9287; Yamamoto K R, 1995, Harvey Lect, V91, P1; Yang RM, 1998, J UROLOGY, V159, P941, DOI 10.1016/S0022-5347(01)63776-5	32	33	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					50897	50901		10.1074/jbc.M310297200	http://dx.doi.org/10.1074/jbc.M310297200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14534302	hybrid			2022-12-27	WOS:000187206300009
J	Lee, MH; Osaki, T; Lee, JY; Baek, MJ; Zhang, R; Park, JW; Kawabata, S; Soderhall, K; Lee, BL				Lee, MH; Osaki, T; Lee, JY; Baek, MJ; Zhang, R; Park, JW; Kawabata, S; Soderhall, K; Lee, BL			Peptidoglycan recognition proteins involved in 1,3-beta-D-glucan-dependent prophenoloxidase activation system of insect	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRO-PHENOL-OXIDASE; FRESH-WATER CRAYFISH; PATTERN-RECOGNITION; SERINE-PROTEASE; COLEOPTERAN INSECT; MANDUCA-SEXTA; SILKWORM; CDNA; TOLL; PHENOLOXIDASE	The prophenoloxidase (proPO) cascade is a major innate immune response in invertebrates, which is triggered into its active form by elicitors, such as lipopolysaccharide, peptidoglycan, and 1,3-beta-D-glucan. A key question of the proPO system is how pattern recognition proteins recognize pathogenic microbes and subsequently activate the system. To investigate the biological function of 1,3-beta-D-glucan pattern recognition protein in the proPO cascade system, we isolated eight different 1,3-beta-D-glucan-binding proteins from the hemolymph of large beetle (Holotrichia diomphalia) larvae by using 1,3-beta-D-glucan immobilized column. Among them, a 20- and 17-kDa protein ( referred to as Hd-PGRP-1 and Hd-PGRP-2) show high sequence identity with the short forms of peptidoglycan recognition proteins (PGRPs-S) from human and Drosophila melanogaster. To be able to characterize the biochemical properties of these two proteins, we expressed them in Drosophila S2 cells. Hd-PGRP-1 and Hd-PGRP-2 were found to specifically bind both 1,3-beta-D-glucan and peptidoglycan. By BIAcore analysis, the minimal 1,3-beta-D-glucan structure required for binding to Hd-PGRP-1 was found to be laminaritetraose. Hd-PGRP-1 increased serine protease activity upon binding to 1,3-beta-D-glucan and subsequently induced the phenoloxidase activity in the presence of both 1,3-beta-D-glucan and Ca2+, but no phenoloxidase activity was elicited under the same conditions in the presence of peptidoglycan and Ca2+. These results demonstrate that Hd-PGRP-1 can serve as a receptor for 1,3-beta-D-glucan in the insect proPO activation system.	Pusan Natl Univ, Coll Pharm, Pusan 609735, South Korea; Kyushu Univ, Fac Sci, Dept Biol, Fukuoka 8128581, Japan; Uppsala Univ, Evolutionary Biol Ctr, Dept Comparat Physiol, SE-75236 Uppsala, Sweden	Pusan National University; Kyushu University; Uppsala University	Lee, BL (corresponding author), Pusan Natl Univ, Coll Pharm, Jangjeon Dong, Pusan 609735, South Korea.	brlee@pusan.ac.kr	Baek, Moo-Jun/W-1736-2019	Baek, Moo-Jun/0000-0003-3567-6687; Osaki, Tsukasa/0000-0002-9487-3253				Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; ASHIDA M, 1983, BIOCHEM BIOPH RES CO, V113, P562, DOI 10.1016/0006-291X(83)91762-X; ASHIDA M, 1990, EUR J BIOCHEM, V188, P507, DOI 10.1111/j.1432-1033.1990.tb15429.x; Ashida Masaaki, 1998, P135; CHENG XD, 1994, P NATL ACAD SCI USA, V91, P4034, DOI 10.1073/pnas.91.9.4034; Choe KM, 2002, SCIENCE, V296, P359, DOI 10.1126/science.1070216; De Gregorio E, 2002, DEV CELL, V3, P581, DOI 10.1016/S1534-5807(02)00267-8; Gillespie JP, 1997, ANNU REV ENTOMOL, V42, P611, DOI 10.1146/annurev.ento.42.1.611; Gottar M, 2002, NATURE, V416, P640, DOI 10.1038/nature734; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; Hultmark D, 2003, CURR OPIN IMMUNOL, V15, P12, DOI 10.1016/S0952-7915(02)00005-5; Hyuk T, 1997, MOL CELLS, V7, P90; Jiang HB, 2003, J BIOL CHEM, V278, P3552, DOI 10.1074/jbc.M205743200; Jiang HB, 1998, P NATL ACAD SCI USA, V95, P12220, DOI 10.1073/pnas.95.21.12220; Kang DW, 1998, P NATL ACAD SCI USA, V95, P10078, DOI 10.1073/pnas.95.17.10078; Kim MS, 2003, NAT IMMUNOL, V4, P787, DOI 10.1038/ni952; Kim MS, 2002, J BIOL CHEM, V277, P39999, DOI 10.1074/jbc.M205508200; Kwon TH, 2000, EUR J BIOCHEM, V267, P6188, DOI 10.1046/j.1432-1327.2000.01695.x; Lee KY, 2002, EUR J BIOCHEM, V269, P4375, DOI 10.1046/j.1432-1033.2002.03155.x; Lee SY, 2000, J BIOL CHEM, V275, P1337, DOI 10.1074/jbc.275.2.1337; Lee SY, 1998, EUR J BIOCHEM, V254, P50, DOI 10.1046/j.1432-1327.1998.2540050.x; Lee SY, 1998, EUR J BIOCHEM, V257, P615, DOI 10.1046/j.1432-1327.1998.2570615.x; LEGENDRE N, 1988, BIOTECHNIQUES, V6, P154; LEONARD C, 1985, INSECT BIOCHEM, V15, P803, DOI 10.1016/0020-1790(85)90109-X; Levashina EA, 1999, SCIENCE, V285, P1917, DOI 10.1126/science.285.5435.1917; Ligoxygakis P, 2002, EMBO J, V21, P6330, DOI 10.1093/emboj/cdf661; Liu C, 2001, J BIOL CHEM, V276, P34686, DOI 10.1074/jbc.M105566200; Ma CC, 2000, J BIOL CHEM, V275, P7505, DOI 10.1074/jbc.275.11.7505; MCCAULEY R, 1973, MOL CELL BIOCHEM, V1, P73, DOI 10.1007/BF01659940; Medzhitov R, 2002, SCIENCE, V296, P298, DOI 10.1126/science.1068883; Mellroth P, 2003, J BIOL CHEM, V278, P7059, DOI 10.1074/jbc.M208900200; Michel T, 2001, NATURE, V414, P756, DOI 10.1038/414756a; Ochiai M, 1999, J BIOL CHEM, V274, P11854, DOI 10.1074/jbc.274.17.11854; Ochiai M, 2000, J BIOL CHEM, V275, P4995, DOI 10.1074/jbc.275.7.4995; Ramet M, 2002, NATURE, V416, P644, DOI 10.1038/nature735; RAO P, 1989, ANAL BIOCHEM, V181, P18, DOI 10.1016/0003-2697(89)90387-4; Rehman A, 2001, CYTOKINE, V13, P8, DOI 10.1006/cyto.2000.0800; ROSENTHAL RS, 1994, METHOD ENZYMOL, V235, P253; Satoh D, 1999, J BIOL CHEM, V274, P7441, DOI 10.1074/jbc.274.11.7441; SGARAMELLA V, 1972, J MOL BIOL, V72, P427, DOI 10.1016/0022-2836(72)90155-6; SODERHALL K, 1979, CAN J MICROBIOL, V25, P406, DOI 10.1139/m79-062; Soderhall K, 1998, CURR OPIN IMMUNOL, V10, P23, DOI 10.1016/S0952-7915(98)80026-5; Sugumaran M, 2001, ADV EXP MED BIOL, V484, P289; Takaki Y, 2002, J BIOL CHEM, V277, P14281, DOI 10.1074/jbc.M200177200; Takeda K, 2003, CELL MICROBIOL, V5, P143, DOI 10.1046/j.1462-5822.2003.00264.x; Takehana A, 2002, P NATL ACAD SCI USA, V99, P13705, DOI 10.1073/pnas.212301199; Tydell CC, 2002, J BIOL CHEM, V277, P19658, DOI 10.1074/jbc.M200659200; Wang RG, 2001, EUR J BIOCHEM, V268, P895, DOI 10.1046/j.1432-1327.2001.01945.x; Werner T, 2003, J BIOL CHEM, V278, P26319, DOI 10.1074/jbc.C300184200; Werner T, 2000, P NATL ACAD SCI USA, V97, P13772, DOI 10.1073/pnas.97.25.13772; Yoshida H, 1996, J BIOL CHEM, V271, P13854, DOI 10.1074/jbc.271.23.13854; Zhang R, 2003, J BIOL CHEM, V278, P42072, DOI 10.1074/jbc.M307475200	53	85	91	0	14	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	2004	279	5					3218	3227		10.1074/jbc.M309821200	http://dx.doi.org/10.1074/jbc.M309821200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	766MF	14583608	hybrid			2022-12-27	WOS:000188379600012
J	Beck, DO; Bukys, MA; Singh, LS; Szabo, KA; Kalafatis, M				Beck, DO; Bukys, MA; Singh, LS; Szabo, KA; Kalafatis, M			The contribution of amino acid region Asp(695)-Tyr(698) of factor V to procofactor activation and factor Va function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-COAGULATION FACTOR; ANION-BINDING EXOSITE; FACTOR-XA; PROTHROMBINASE COMPLEX; HEAVY-CHAIN; PROTEIN-C; MACROMOLECULAR SUBSTRATE; PROEXOSITE-I; ACTIVE-SITE; ANTICOAGULANT ACTIVITY	There is strong evidence that a functionally important cluster of amino acids is located on the COOH-terminal portion of the heavy chain of factor Va, between amino acid residues 680 and 709. To ascertain the importance of this region for cofactor activity, we have synthesized five overlapping peptides representing this amino acid stretch (10 amino acids each, HC1-HC5) and tested them for inhibition of prothrombinase assembly and function. Two peptides, HC3 (spanning amino acid region 690 699) and HC4 (containing amino acid residues 695-704), were found to be potent inhibitors of prothrombinase activity with IC50 values of similar to12 and similar to10 muM, respectively. The two peptides were unable to interfere with the binding of factor Va to active site fluorescently labeled Glu-Gly-Arg human factor Xa, and kinetic analyses showed that HC3 and HC4 are competitive inhibitors of prothrombinase with respect to prothrombin with K-i values of similar to6.3 and similar to5.3 muM, respectively. These data suggest that the peptides inhibit prothrombinase because they interfere with the incorporation of prothrombin into prothrombinase. The shared amino acid motif between HC3 and HC4 is composed of Asp(695)-Tyr-Asp- Tyr-Gln(699) (DYDYQ). A pentapeptide with this sequence inhibited both prothrombinase function with an IC50 of 1.6 muM (with a K-D for prothrombin of 850 nM), and activation of factor V by thrombin. Peptides HC3, HC4, and DYDYQ were also found to interact with immobilized thrombin. A recombinant factor V molecule with the mutations Asp(695) --> Lys, Tyr(696) --> Phe, Asp(697) --> Lys, and Tyr(698) --> Phe (factor V-2K2F) was partially resistant to activation by thrombin but could be readily activated by RVV-V activator (factor Va(RVV)(2K2F)) and factor Xa ( factor Va(Xa)(2K2F)). Factor Va(RVV)(2K2F) and factor Va(Xa)(2K2F) had impaired cofactor activity within prothrombinase in a system using purified reagents. Our data demonstrate for the first time that amino acid sequence 695 698 of factor Va heavy chain is important for procofactor activation and is required for optimum prothrombinase function. These data provide functional evidence for an essential and productive contribution of factor Va to the activity of prothrombinase.	Cleveland State Univ, Dept Chem, Cleveland, OH 44115 USA; Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Cardiol, Cleveland, OH 44195 USA	University System of Ohio; Cleveland State University; Cleveland Clinic Foundation	Kalafatis, M (corresponding author), Cleveland State Univ, Dept Chem, 2121 Euclid Ave,Campus Locat Sci Bldg SR370, Cleveland, OH 44115 USA.	m.kalafatis@csuohio.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL034575, R01HL034575] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL34575] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anderson PJ, 2000, J BIOL CHEM, V275, P16428, DOI 10.1074/jbc.M001254200; Anderson PJ, 2000, J BIOL CHEM, V275, P16435, DOI 10.1074/jbc.M001255200; ARMSTRONG SA, 1990, J BIOL CHEM, V265, P6210; BAKKER HM, 1994, J BIOL CHEM, V269, P20662; Banner DW, 1996, NATURE, V380, P41, DOI 10.1038/380041a0; BARENHOLZ Y, 1977, BIOCHEMISTRY-US, V16, P2806, DOI 10.1021/bi00631a035; Betz A, 1998, J BIOL CHEM, V273, P10709, DOI 10.1074/jbc.273.17.10709; Bianchini EP, 2002, J BIOL CHEM, V277, P20527, DOI 10.1074/jbc.M201139200; Blostein MD, 2000, J BIOL CHEM, V275, P38120, DOI 10.1074/jbc.M007174200; Boskovic DS, 2000, J BIOL CHEM, V275, P38561, DOI 10.1074/jbc.M006637200; BOSKOVIC DS, 1990, J BIOL CHEM, V265, P10497; Boskovic DS, 2001, J BIOL CHEM, V276, P28686, DOI 10.1074/jbc.M101813200; Buddai SK, 2002, J BIOL CHEM, V277, P26689, DOI 10.1074/jbc.M202507200; CAMIRE RM, 1998, BIOCHEMISTRY-US, V37, P20527; Chen L, 2003, J BIOL CHEM, V278, P27564, DOI 10.1074/jbc.M302707200; Dharmawardana KR, 1999, J BIOL CHEM, V274, P18635, DOI 10.1074/jbc.274.26.18635; Dharmawardana KR, 1998, BIOCHEMISTRY-US, V37, P13143, DOI 10.1021/bi9812165; Esmon CT, 1996, J BIOL CHEM, V271, P13882, DOI 10.1074/jbc.271.23.13882; Fuentes-Prior P, 2000, NATURE, V404, P518, DOI 10.1038/35006683; Gomori G, 1942, J LAB CLIN MED, V27, P955; Grimm DR, 2001, CELL MOL LIFE SCI, V58, P148, DOI 10.1007/PL00000775; GUINTO ER, 1984, J BIOL CHEM, V259, P3986; GUINTO ER, 1992, J BIOL CHEM, V267, P2971; HOFSTEENGE J, 1986, BIOCHEM J, V237, P243, DOI 10.1042/bj2370243; HOFSTEENGE J, 1988, BIOCHEMISTRY-US, V27, P2144, DOI 10.1021/bi00406a049; HORTIN GL, 1989, J BIOL CHEM, V264, P13979; HORTIN GL, 1991, J BIOL CHEM, V266, P6866; HORTIN GL, 1990, BLOOD, V76, P946; HUTTNER WB, 1988, ANNU REV PHYSIOL, V50, P363, DOI 10.1146/annurev.ph.50.030188.002051; Huttner WB, 1988, MODERN CELL BIOL, V6, P97; JENNY RJ, 1987, P NATL ACAD SCI USA, V84, P4846, DOI 10.1073/pnas.84.14.4846; Kalafatis M, 1996, BLOOD, V87, P4695, DOI 10.1182/blood.V87.11.4695.bloodjournal87114695; KALAFATIS M, 1993, J BIOL CHEM, V268, P27246; Kalafatis M, 2003, J BIOL CHEM, V278, P33550, DOI 10.1074/jbc.M303153200; Kalafatis M, 2002, BIOCHEMISTRY-US, V41, P12715, DOI 10.1021/bi026208+; KALAFATIS M, 1994, BIOCHEMISTRY-US, V33, P6538, DOI 10.1021/bi00187a022; KALAFATIS M, 1995, J BIOL CHEM, V270, P4053, DOI 10.1074/jbc.270.8.4053; Kalafatis M, 2001, J BIOL CHEM, V276, P18614, DOI 10.1074/jbc.M007134200; KALAFATIS M, 1994, J BIOL CHEM, V269, P31869; Kalafatis M, 1997, CRIT REV EUKAR GENE, V7, P241, DOI 10.1615/CritRevEukarGeneExpr.v7.i3.40; KANE WH, 1981, J BIOL CHEM, V256, P1002; KATZMANN JA, 1981, P NATL ACAD SCI-BIOL, V78, P162, DOI 10.1073/pnas.78.1.162; KRISHNASWAMY S, 1990, J BIOL CHEM, V265, P3708; Krishnaswamy S, 1997, BIOCHEMISTRY-US, V36, P3319, DOI 10.1021/bi9623993; KRISHNASWAMY S, 1988, J BIOL CHEM, V263, P3823; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN WH, 1992, J BIOL CHEM, V267, P2876; LIU LW, 1991, J BIOL CHEM, V266, P16977; LUCKOW EA, 1989, BIOCHEMISTRY-US, V28, P2348, DOI 10.1021/bi00431a055; Mann KG, 2003, BLOOD, V101, P20, DOI 10.1182/blood-2002-01-0290; Mann KG, 1997, J BIOL CHEM, V272, P20678, DOI 10.1074/jbc.272.33.20678; MARAGANORE JM, 1989, J BIOL CHEM, V264, P8692; MARQUETTE KA, 1995, BLOOD, V86, P3026; MICHNICK DA, 1994, J BIOL CHEM, V269, P20095; MONKOVIC DD, 1990, BIOCHEMISTRY-US, V29, P1118, DOI 10.1021/bi00457a004; Monteiro RQ, 2002, THROMB HAEMOSTASIS, V87, P288; Myles T, 2001, J BIOL CHEM, V276, P25143, DOI 10.1074/jbc.M011324200; NESHEIM ME, 1979, BIOCHEMISTRY-US, V18, P996, DOI 10.1021/bi00573a010; NESHEIM ME, 1981, METHOD ENZYMOL, V80, P249; NESHEIM ME, 1984, J BIOL CHEM, V259, P3187; NESHEIM ME, 1979, J BIOL CHEM, V254, P952; NIEHRS C, 1990, EMBO J, V9, P35, DOI 10.1002/j.1460-2075.1990.tb08077.x; Orcutt SJ, 2002, J BIOL CHEM, V277, P46191, DOI 10.1074/jbc.M208677200; Parry MAA, 1998, NAT STRUCT BIOL, V5, P917, DOI 10.1038/2359; Pineda AO, 2002, J BIOL CHEM, V277, P32015, DOI 10.1074/jbc.M205009200; PITTMAN DD, 1994, BIOCHEMISTRY-US, V33, P6952, DOI 10.1021/bi00188a026; Rose T, 2002, J BIOL CHEM, V277, P18875, DOI 10.1074/jbc.M110977200; ROSING J, 1995, J BIOL CHEM, V270, P27852, DOI 10.1074/jbc.270.46.27852; SHEEHAN JP, 1993, J BIOL CHEM, V268, P3639; Singh LS, 2003, J BIOL CHEM, V278, P28335, DOI 10.1074/jbc.M300233200; STONE SR, 1994, BIOCHEMISTRY-US, V33, P7731, DOI 10.1021/bi00190a028; STONE SR, 1987, BIOCHEMISTRY-US, V26, P4617, DOI 10.1021/bi00389a004; SUZUKI K, 1982, J BIOL CHEM, V257, P6556; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSIANG M, 1995, J BIOL CHEM, V270, P16854, DOI 10.1074/jbc.270.28.16854; vantVeer C, 1997, J BIOL CHEM, V272, P20721, DOI 10.1074/jbc.272.33.20721; vantVeer C, 1997, J BIOL CHEM, V272, P7983, DOI 10.1074/jbc.272.12.7983; Verhamme IM, 2002, J BIOL CHEM, V277, P6788, DOI 10.1074/jbc.M110257200; VIJAYALAKSHMI J, 1994, PROTEIN SCI, V3, P2254, DOI 10.1002/pro.5560031211; WALKER RK, 1994, J BIOL CHEM, V269, P27441; Wilkens M, 2002, J BIOL CHEM, V277, P9366, DOI 10.1074/jbc.M110848200; WU QY, 1994, J BIOL CHEM, V269, P3725; Yang TL, 1998, BLOOD, V91, P4593, DOI 10.1182/blood.V91.12.4593.412a02_4593_4599	83	40	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	2004	279	4					3084	3095		10.1074/jbc.M306850200	http://dx.doi.org/10.1074/jbc.M306850200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	764MU	14559913	Green Published, hybrid			2022-12-27	WOS:000188211300090
J	Apaja, PM; Harju, KT; Aatsinki, JT; Petaja-Repo, UE; Rajaniemi, HJ				Apaja, PM; Harju, KT; Aatsinki, JT; Petaja-Repo, UE; Rajaniemi, HJ			Identification and structural characterization of the neuronal luteinizing hormone receptor associated with sensory systems	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; LUTROPIN-CHORIOGONADOTROPIN RECEPTOR; MESSENGER-RIBONUCLEIC-ACID; GONADOTROPIN RECEPTORS; THYROTROPIN RECEPTORS; STEROIDOGENIC ENZYMES; BINDING DOMAINS; GENE-EXPRESSION; LEYDIG-CELLS; RAT TESTIS	The luteinizing hormone receptor (LHR) is a G protein-coupled receptor involved in regulation of ovarian and testicular functions. Here we show that the receptor is present also in specific areas of the peripheral and central nervous system and may thus have a broader functional role than has been anticipated. Full-length LHR mRNA and two receptor protein species of M-r 90,000 and 73,000, representing mature and precursor forms, respectively, were expressed in adult and developing rat nervous tissue, starting at fetal day 14.5. The receptor was capable of ligand binding because it was purified by ligand affinity chromatography, and human chorionic gonadotropin and LH were able to displace I-125-labeled human chorionic gonadotropin binding to fetal head membranes in a dose-dependent manner. Finally, two 5'-flanking sequences (similar to2 and 4 kb) of the rat LHR gene were shown to direct expression of the lacZ reporter to specific areas of the peripheral and central nervous system in fetal and adult transgenic mice, especially to structures associated with sensory, memory, reproductive behavior, and autonomic functions. Importantly, the transgene activity was confined to neurons and colocalized with the cytochrome P450 side chain cleavage enzyme. Taken together, these results indicate that the neuronal LHR is a functional protein, implicating a role in neuronal development and function, possibly by means of regulating synthesis of neurosteroids.	Univ Oulu, Dept Anat & Cell Biol, FIN-90014 Oulu, Finland; Univ Oulu, Bioctr Oulu, FIN-90014 Oulu, Finland; Univ Oulu, Dept Pediat, FIN-90014 Oulu, Finland; Univ Oulu, Dept Dent, FIN-90014 Oulu, Finland	University of Oulu; University of Oulu; University of Oulu; University of Oulu	Petaja-Repo, UE (corresponding author), Univ Oulu, Dept Anat & Cell Biol, POB 5000, FIN-90014 Oulu, Finland.	Ulla.Petaja-Repo@oulu.fi; Hannu.Rajaniemi@oulu.fi	Petäjä-Repo, Ulla/AAV-6115-2021	Apaja, Pirjo/0000-0002-1622-2332				AATSINKI JT, 1994, BIOTECHNIQUES, V16, P282; AATSINKI JT, 1992, MOL CELL ENDOCRINOL, V84, P127, DOI 10.1016/0303-7207(92)90079-L; AlHader AA, 1997, BIOL REPROD, V56, P501, DOI 10.1095/biolreprod56.2.501; AlHader AA, 1997, BIOL REPROD, V56, P1071, DOI 10.1095/biolreprod56.5.1071; Ascoli M, 2002, ENDOCR REV, V23, P141, DOI 10.1210/er.23.2.141; BACICH DJ, 1994, ENDOCRINOLOGY, V135, P735, DOI 10.1210/en.135.2.735; Beau I, 1997, J BIOL CHEM, V272, P5241, DOI 10.1074/jbc.272.8.5241; COMPAGNONE NA, 1995, ENDOCRINOLOGY, V136, P2689, DOI 10.1210/en.136.6.2689; Derecka K, 1999, J REPROD FERTIL, V115, P365, DOI 10.1530/jrf.0.1150365; Gether U, 2000, ENDOCR REV, V21, P90, DOI 10.1210/er.21.1.90; Hamalainen T, 1999, ENDOCRINOLOGY, V140, P5322, DOI 10.1210/en.140.11.5322; HANLEY T, 1991, BIOTECHNIQUES, V10, P56; Hermey G, 1999, BIOCHEM BIOPH RES CO, V254, P273, DOI 10.1006/bbrc.1998.9882; HIPKIN RW, 1992, MOL ENDOCRINOL, V6, P2210, DOI 10.1210/me.6.12.2210; Hogan B, 1994, MANIPULATING MOUSE E; Hsu SY, 1998, MOL ENDOCRINOL, V12, P1830, DOI 10.1210/me.12.12.1830; Hsu SY, 2002, SCIENCE, V295, P671, DOI 10.1126/science.1065654; Hsu SY, 2000, MOL ENDOCRINOL, V14, P1257, DOI 10.1210/me.14.8.1257; JI I, 1994, ENDOCR J, P279; Ji TH, 1998, J BIOL CHEM, V273, P17299, DOI 10.1074/jbc.273.28.17299; Jiang XL, 1995, STRUCTURE, V3, P1341, DOI 10.1016/S0969-2126(01)00272-6; Kajava AV, 1998, J MOL BIOL, V277, P519, DOI 10.1006/jmbi.1998.1643; KEINANEN KP, 1987, J BIOL CHEM, V262, P7920; King SR, 2002, J NEUROSCI, V22, P10613; LEGOASCOGNE C, 1987, SCIENCE, V237, P1212, DOI 10.1126/science.3306919; LEI ZM, 1993, ENDOCRINOLOGY, V132, P2262, DOI 10.1210/en.132.5.2262; MALEY F, 1989, ANAL BIOCHEM, V180, P195, DOI 10.1016/0003-2697(89)90115-2; McDonald T, 1998, BIOCHEM BIOPH RES CO, V247, P266, DOI 10.1006/bbrc.1998.8774; MCFARLAND KC, 1989, SCIENCE, V245, P494, DOI 10.1126/science.2502842; Mellon SH, 2001, BRAIN RES REV, V37, P3, DOI 10.1016/S0165-0173(01)00109-6; Mensah-Nyagan AG, 1999, PHARMACOL REV, V51, P63; NELSON S, 1994, ENDOCRINOLOGY, V135, P1729, DOI 10.1210/en.135.5.1729; Petaja-Repo UE, 2000, J BIOL CHEM, V275, P13727, DOI 10.1074/jbc.275.18.13727; PIERCE JG, 1981, ANNU REV BIOCHEM, V50, P465, DOI 10.1146/annurev.bi.50.070181.002341; PIETILA EM, 1996, J PHYSIOL PHARMACOL, V47, P5; RAO CV, 1993, J CLIN ENDOCR METAB, V77, P1706, DOI 10.1210/jc.77.6.1706; RESHEF E, 1990, J CLIN ENDOCR METAB, V70, P421, DOI 10.1210/jcem-70-2-421; ROCHE PC, 1989, J BIOL CHEM, V264, P4636; SAEZ JM, 1994, ENDOCR REV, V15, P574, DOI 10.1210/er.15.5.574; SEGALOFF DL, 1993, ENDOCR REV, V14, P324, DOI 10.1210/er.14.3.324; SOKKA T, 1992, ENDOCRINOLOGY, V130, P1738, DOI 10.1210/en.130.3.1738; TSAIMORRIS CH, 1990, J BIOL CHEM, V265, P19385; TSAIMORRIS CH, 1994, J BIOL CHEM, V269, P15868; Vannier B, 1996, BIOCHEMISTRY-US, V35, P1358, DOI 10.1021/bi952290f; VASSART G, 1992, ENDOCR REV, V13, P596, DOI 10.1210/er.13.3.596; VOUTILAINEN R, 1988, DNA-J MOLEC CELL BIO, V7, P9, DOI 10.1089/dna.1988.7.9; VOUTILAINEN R, 1986, J CLIN ENDOCR METAB, V63, P202, DOI 10.1210/jcem-63-1-202; WANG HY, 1991, ENDOCRINOLOGY, V129, P133, DOI 10.1210/endo-129-1-133; WARREN DW, 1984, ENDOCRINOLOGY, V114, P470, DOI 10.1210/endo-114-2-470; ZHANG FP, 1994, ENDOCRINOLOGY, V134, P2206, DOI 10.1210/en.134.5.2206; ZHANG QY, 1989, P NATL ACAD SCI USA, V86, P8294, DOI 10.1073/pnas.86.21.8294; Zheng ML, 2001, BIOL REPROD, V64, P179, DOI 10.1093/biolreprod/64.1.179	52	60	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 16	2004	279	3					1899	1906		10.1074/jbc.M311395200	http://dx.doi.org/10.1074/jbc.M311395200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	762WT	14581462	Green Published, hybrid			2022-12-27	WOS:000188005700043
J	Floquet, N; Pasco, S; Ramont, L; Derreumaux, P; Laronze, JY; Nuzillard, JM; Maquart, FX; Alix, AJP; Monboisse, JC				Floquet, N; Pasco, S; Ramont, L; Derreumaux, P; Laronze, JY; Nuzillard, JM; Maquart, FX; Alix, AJP; Monboisse, JC			The antitumor properties of the alpha 3(IV)-(185-203) peptide from the NC1 domain of type IV collagen (tumstatin) are conformation-dependent	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN SECONDARY STRUCTURE; MATRIX METALLOPROTEINASES; BASEMENT-MEMBRANE; NONCOLLAGENOUS DOMAINS; EXTRACELLULAR-MATRIX; TUMOR-GROWTH; CHAIN; ACTIVATION; CELLS; MELANOMA	Tumor progression may be controlled by various fragments derived from noncollagenous 1 (NC1) C-terminal domains of type IV collagen. We demonstrated previously that a peptide sequence from the NC1 domain of the alpha3(IV) collagen chain inhibits the in vitro expression of matrix metalloproteinases in human melanoma cells through RGD-independent binding to alpha(v)beta(3) integrin. In the present paper, we demonstrate that in a mouse melanoma model, the NC1 alpha3(IV)-(185 - 203) peptide inhibits in vivo tumor growth in a conformation-dependent manner. The decrease of tumor growth is the result of an inhibition of cell proliferation and a decrease of cell invasive properties by down-regulation of proteolytic cascades, mainly matrix metalloproteinases and the plasminogen activation system. A shorter peptide comprising the seven N-terminal residues 185 - 191 (CNYYSNS) shares the same inhibitory profile. The three-dimensional structures of the CNYYSNS and NC1 alpha3(IV)-(185 - 203) peptides show a beta-turn at the YSNS ( 188 - 191) sequence level, which is crucial for biological activity. As well, the homologous MNYYSNS heptapeptide keeps the beta-turn and the inhibitory activity. In contrast, the DNYYSNS heptapeptide, which does not form the beta-turn at the YSNS level, is devoid of inhibitory activity. Structural studies indicate a strong structure-function relationship of the peptides and point to the YSNS turn as necessary for biological activity. These peptides could act as potent and specific antitumor antagonists of alpha(v)beta(3) integrin in melanoma progression.	Univ Reims, Lab Spect & Biomol Struct, EA 3305, F-51095 Reims, France; Univ Reims, Lab Med Biochem & Mol Biol, CNRS, Format Rech Evolut 2534, F-51095 Reims, France; Univ Reims, Inst Federat Rech Biomol 53, CNRS, Unite Mixte Rech 6013, F-51095 Reims, France; Univ Aix Marseille 2, CNRS, Unite Propre Rech 2589, F-13402 Marseille, France; Univ Paris 07, CNRS, Unite Propre Rech 9080, Lab Theoret Biochem, F-75005 Paris, France	Universite de Reims Champagne-Ardenne; Centre National de la Recherche Scientifique (CNRS); Universite de Reims Champagne-Ardenne; Centre National de la Recherche Scientifique (CNRS); Universite de Reims Champagne-Ardenne; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite	Monboisse, JC (corresponding author), Fac Med, CNRS, FRE 2534, Lab Med Biochem & Mol Biol, 51 Rue Cognacq Jay, F-51095 Reims, France.	jc.monboisse@univ-reims.fr	Floquet, Nicolas/A-5996-2009; Derreumaux, Philippe/E-9036-2019	Brassart-Pasco, Sylvie/0000-0002-1340-7868; Nuzillard, Jean-Marc/0000-0002-5120-2556				Alix AJP, 1997, NATO ADV SCI I E-APP, V342, P121; Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; Borza DB, 2002, J BIOL CHEM, V277, P40075, DOI 10.1074/jbc.M207769200; Bouifraden S, 1999, AMINO ACIDS, V16, P345, DOI 10.1007/BF01388176; Boutaud A, 2000, J BIOL CHEM, V275, P30716, DOI 10.1074/jbc.M004569200; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Colorado PC, 2000, CANCER RES, V60, P2520; Derreumaux P, 1997, J CHEM PHYS, V107, P1941, DOI 10.1063/1.474546; Deryugina EI, 2001, EXP CELL RES, V263, P209, DOI 10.1006/excr.2000.5118; deVries TJ, 1996, MELANOMA RES, V6, P79, DOI 10.1097/00008390-199604000-00001; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Fawzi A, 2000, CELL SIGNAL, V12, P327, DOI 10.1016/S0898-6568(00)00074-7; GIBRAT JF, 1987, J MOL BIOL, V198, P425, DOI 10.1016/0022-2836(87)90292-0; Han J, 1997, J BIOL CHEM, V272, P20395, DOI 10.1074/jbc.272.33.20395; Hofmann UB, 2000, J INVEST DERMATOL, V115, P337, DOI 10.1046/j.1523-1747.2000.00068.x; HORNEBECK W, 2002, SEMIN CANCER BIOL, V439, P1; HUDSON BG, 1993, J BIOL CHEM, V268, P26033; Huet E, 2002, CLIN EXP METASTAS, V19, P107, DOI 10.1023/A:1014547324918; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; Kamphaus GD, 2000, J BIOL CHEM, V275, P1209, DOI 10.1074/jbc.275.2.1209; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; LINDBLOM A, 1996, EXTRACELLULAR MATRIX, V1, P132; MacKerell AD, 1998, J PHYS CHEM B, V102, P3586, DOI 10.1021/jp973084f; Maeshima Y, 2000, J BIOL CHEM, V275, P23745, DOI 10.1074/jbc.C000186200; Maeshima Y, 2000, J BIOL CHEM, V275, P21340, DOI 10.1074/jbc.M001956200; Marneros AG, 2001, MATRIX BIOL, V20, P337, DOI 10.1016/S0945-053X(01)00151-2; MONBOISSE JC, 1994, J BIOL CHEM, V269, P25475; Netzer KO, 1998, PROTEIN SCI, V7, P1340, DOI 10.1002/pro.5560070610; Ohuchi E, 1997, J BIOL CHEM, V272, P2446, DOI 10.1074/jbc.272.4.2446; Ortega N, 2002, J CELL SCI, V115, P4201, DOI 10.1242/jcs.00106; Pasco S, 2000, CANCER RES, V60, P467; Pasco S, 2000, J BIOL CHEM, V275, P32999, DOI 10.1074/jbc.M005235200; Petitclerc E, 2000, J BIOL CHEM, V275, P8051, DOI 10.1074/jbc.275.11.8051; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; Seiki M, 2002, CURR OPIN CELL BIOL, V14, P624, DOI 10.1016/S0955-0674(02)00363-0; Shahan TA, 1999, CONNECT TISSUE RES, V40, P221, DOI 10.3109/03008209909005285; Shahan TA, 1999, CANCER RES, V59, P4584; SSAKI T, 2000, J MOL BIOL, V301, P1179; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545; Than ME, 2002, P NATL ACAD SCI USA, V99, P6607, DOI 10.1073/pnas.062183499; Vihinen P, 2002, INT J CANCER, V99, P157, DOI 10.1002/ijc.10329; Wald M, 2001, CANCER CHEMOTH PHARM, V47, pS16, DOI 10.1007/s002800170004	44	59	76	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 16	2004	279	3					2091	2100		10.1074/jbc.M307736200	http://dx.doi.org/10.1074/jbc.M307736200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	762WT	14583633	hybrid			2022-12-27	WOS:000188005700065
J	Fluhrer, R; Friedlein, A; Haass, C; Walter, J				Fluhrer, R; Friedlein, A; Haass, C; Walter, J			Phosphorylation of presenilin 1 at the caspase recognition site regulates its proteolytic processing and the progression of apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; FAMILIAL ALZHEIMERS-DISEASE; CAPACITATIVE CALCIUM-ENTRY; GAMMA-SECRETASE CLEAVAGE; C-TERMINAL FRAGMENT; BETA-CATENIN; IN-VIVO; ENDOPLASMIC-RETICULUM; NEURONAL APOPTOSIS; EARLY-ONSET	The Alzheimer's disease-associated presenilin (PS) 1 is intimately involved in gamma-secretase cleavage of beta-amyloid precursor protein and other proteins. In addition, PS1 plays a role in beta-catenin signaling and in the regulation of apoptosis. Here we demonstrate that phosphorylation of PS1 is regulated by two independent signaling pathways involving protein kinase (PK) A and PKC and that both kinases can directly phosphorylate the large hydrophilic domain of PS1 in vitro and in cultured cells. A phosphorylation site at serine residue 346 was identified that is selectively phosphorylated by PKC but not by PKA. This site is localized within a recognition motif for caspases, and phosphorylation strongly inhibits proteolytic processing of PS1 by caspase activity during apoptosis. Moreover, PS1 phosphorylation reduces the progression of apoptosis. Our data indicate that phosphorylation/ dephosphorylation at the caspase recognition site provides a mechanism to reversibly regulate properties of PS1 in apoptosis.	Univ Bonn, Dept Neurol, D-53127 Bonn, Germany; F Hoffmann La Roche & Co Ltd, Roche Ctr Med Gen, CH-4070 Basel, Switzerland; Univ Munich, Dept Biochem, D-80336 Munich, Germany	University of Bonn; Roche Holding; University of Munich	Walter, J (corresponding author), Univ Bonn, Dept Neurol, Siegmund Freud Str 25, D-53127 Bonn, Germany.	Jochen.Walter@ukb.uni-bonn.de	Fluhrer, Regina/F-2642-2011; Walter, Jochen/B-3677-2014; Wang, Caihong/T-5837-2019	Wang, Caihong/0000-0002-6808-3709; Walter, Jochen/0000-0002-4678-2912				Alper O, 1999, ONCOGENE, V18, P4999, DOI 10.1038/sj.onc.1202830; Annaert WG, 2001, NEURON, V32, P579, DOI 10.1016/S0896-6273(01)00512-8; Araki W, 2001, J NEUROCHEM, V79, P1161, DOI 10.1046/j.1471-4159.2001.00638.x; Baki L, 2001, P NATL ACAD SCI USA, V98, P2381, DOI 10.1073/pnas.041603398; Barkett M, 1997, J BIOL CHEM, V272, P29419, DOI 10.1074/jbc.272.47.29419; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Capell A, 1998, J BIOL CHEM, V273, P3205, DOI 10.1074/jbc.273.6.3205; Choi EK, 2001, J BIOL CHEM, V276, P19197, DOI 10.1074/jbc.M008597200; Cross TG, 2000, EXP CELL RES, V256, P34, DOI 10.1006/excr.2000.4836; da Costa CA, 2002, P NATL ACAD SCI USA, V99, P4043, DOI 10.1073/pnas.062059899; Desagher S, 2001, MOL CELL, V8, P601, DOI 10.1016/S1097-2765(01)00335-5; ELSTEIN KH, 1994, EXP CELL RES, V211, P322, DOI 10.1006/excr.1994.1094; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; Franklin RA, 2000, LEUKEMIA, V14, P2019, DOI 10.1038/sj.leu.2401967; Georgakopoulos A, 1999, MOL CELL, V4, P893, DOI 10.1016/S1097-2765(00)80219-1; Grunberg J, 1998, BIOCHEMISTRY-US, V37, P2263, DOI 10.1021/bi972106l; Gu YJ, 2003, J BIOL CHEM, V278, P7374, DOI 10.1074/jbc.M209499200; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; Haass C, 2002, TRENDS CELL BIOL, V12, P556, DOI 10.1016/S0962-8924(02)02394-2; Herreman A, 2000, NAT CELL BIOL, V2, P461, DOI 10.1038/35017105; JAATTELA M, 1995, ONCOGENE, V10, P2297; Janicki S, 1997, J CELL BIOL, V139, P485, DOI 10.1083/jcb.139.2.485; Kaether C, 2002, J CELL BIOL, V158, P551, DOI 10.1083/jcb.200201123; Kang DE, 2002, CELL, V110, P751, DOI 10.1016/S0092-8674(02)00970-4; Killick R, 2001, J BIOL CHEM, V276, P48554, DOI 10.1074/jbc.M108332200; Kim TW, 1997, SCIENCE, V277, P373, DOI 10.1126/science.277.5324.373; Kirschenbaum F, 2001, J BIOL CHEM, V276, P7366, DOI 10.1074/jbc.M004697200; Lau KF, 2002, MOL CELL NEUROSCI, V20, P13, DOI 10.1006/mcne.2002.1108; Leissring MA, 2000, J CELL BIOL, V149, P793, DOI 10.1083/jcb.149.4.793; Loetscher H, 1997, J BIOL CHEM, V272, P20655, DOI 10.1074/jbc.272.33.20655; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; Mathews PM, 2000, MOL MED, V6, P878, DOI 10.1007/BF03401825; Mattson MP, 2000, NAT REV MOL CELL BIO, V1, P120, DOI 10.1038/35040009; Mattson MP, 1997, PHYSIOL REV, V77, P1081, DOI 10.1152/physrev.1997.77.4.1081; Mattson MP, 1998, J NEUROCHEM, V70, P1; Naruse S, 1998, NEURON, V21, P1213, DOI 10.1016/S0896-6273(00)80637-6; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Roperch JP, 1998, NAT MED, V4, P835, DOI 10.1038/nm0798-835; Ruvolo PP, 1998, J BIOL CHEM, V273, P25436, DOI 10.1074/jbc.273.39.25436; Saura CA, 2000, J BIOL CHEM, V275, P17136, DOI 10.1074/jbc.M909624199; Seeger M, 1997, P NATL ACAD SCI USA, V94, P5090, DOI 10.1073/pnas.94.10.5090; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Soriano S, 2001, J CELL BIOL, V152, P785, DOI 10.1083/jcb.152.4.785; Steiner H, 2000, NAT REV MOL CELL BIO, V1, P217, DOI 10.1038/35043065; Steiner H, 2002, J BIOL CHEM, V277, P39062, DOI 10.1074/jbc.C200469200; Steiner H, 1999, J BIOL CHEM, V274, P28669, DOI 10.1074/jbc.274.40.28669; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Vito P, 1997, J BIOL CHEM, V272, P28315, DOI 10.1074/jbc.272.45.28315; Vito P, 1996, SCIENCE, V271, P521, DOI 10.1126/science.271.5248.521; Walter J, 1998, BIOCHEMISTRY-US, V37, P5961, DOI 10.1021/bi971763a; Walter J, 2001, CURR OPIN NEUROBIOL, V11, P585, DOI 10.1016/S0959-4388(00)00253-1; Walter J, 1997, P NATL ACAD SCI USA, V94, P5349, DOI 10.1073/pnas.94.10.5349; Walter J, 1999, P NATL ACAD SCI USA, V96, P1391, DOI 10.1073/pnas.96.4.1391; Walter J, 1996, MOL MED, V2, P673, DOI 10.1007/BF03401652; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Wolozin B, 1996, SCIENCE, V274, P1710, DOI 10.1126/science.274.5293.1710; Xia XF, 2001, P NATL ACAD SCI USA, V98, P10863, DOI 10.1073/pnas.191284198; Yankner BA, 1996, NEURON, V16, P921, DOI 10.1016/S0896-6273(00)80115-4; Yoo AS, 2000, NEURON, V27, P561, DOI 10.1016/S0896-6273(00)00066-0; Younkin SG, 1998, J PHYSIOLOGY-PARIS, V92, P289, DOI 10.1016/S0928-4257(98)80035-1; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009; Zhang ZH, 1998, NATURE, V395, P698, DOI 10.1038/27208; Zhang ZH, 2000, NAT CELL BIOL, V2, P463, DOI 10.1038/35017108	63	55	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 16	2004	279	3					1585	1593		10.1074/jbc.M306653200	http://dx.doi.org/10.1074/jbc.M306653200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	762WT	14576165	hybrid, Green Published			2022-12-27	WOS:000188005700004
J	Monaghan, AS; Benton, DCH; Bahia, PK; Hosseini, R; Shah, YA; Haylett, DG; Moss, GWJ				Monaghan, AS; Benton, DCH; Bahia, PK; Hosseini, R; Shah, YA; Haylett, DG; Moss, GWJ			The SK3 subunit of small conductance Ca2+-activated K+ channels interacts with both SK1 and SK2 subunits in a heterologous expression system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIPPOCAMPAL PYRAMIDAL NEURONS; ACTIVATED POTASSIUM CURRENTS; HEK-293 CELLS; RAT SK1; APAMIN; SUBTYPES; BRAIN; SCHIZOPHRENIA; POLYPEPTIDES; SUBFAMILY	The aim of this study was to determine whether functional heteromeric channels can be formed by co-assembly of rat SK3 (rSK3) potassium channel subunits with either SK1 or SK2 subunits. First, to determine whether rSK3 could co-assemble with rSK2 we created rSK3VK (an SK3 mutant insensitive to block by UCL 1848). When rSK3VK was co-expressed with rSK2 the resulting currents had an intermediate sensitivity to UCL 1848 (IC50 of similar to5 nM compared with 120 pM for rSK2 and >300 nM for rSK3VK), suggesting that rSK3 and rSK2 can form functional heteromeric channels. To detect co-assembly of SK3 with SK1, we initially used a dominant negative construct of the human SK1 subunit (hSK1YP). hSK1YP dramatically reduced the SK3 current, supporting the idea that SK3 and SK1 subunits also interact. To determine whether these assemblies were functional we created rSK3VF, an rSK3 mutant with an enhanced affinity for tetraethylammonium chloride (TEA) (IC50 of 0.3 mM). Co-transfection of rSK3VF and hSK1 produced currents with a sensitivity to TEA not different from that of hSK1 alone (IC50 similar to15 mM). These results suggest that hSK1 does not produce functional cell-surface assemblies with SK3. Antibody-staining experiments suggested that hSK1 may reduce the number of functional SK3 subunits reaching the cell surface. Additional experiments showed that co-expression of the rat SK1 gene with SK3 also dramatically suppressed SK current. The pharmacology of the residual current was consistent with that of homomeric SK3 assemblies. These results demonstrate interactions that cause changes in protein trafficking, cell surface expression, and channel pharmacology and strongly suggest heteromeric assembly of SK3 with the other SK channel subunits.	UCL, Dept Pharmacol, London WC1E 6BT, England	University of London; University College London	Moss, GWJ (corresponding author), UCL, Dept Pharmacol, Gower St, London WC1E 6BT, England.	g.moss@ucl.ac.uk						Benton DCH, 2003, J PHYSIOL-LONDON, V553, P13, DOI 10.1113/jphysiol.2003.054551; Benton DCH, 1999, BRIT J PHARMACOL, V128; Bowden SEH, 2001, J NEUROSCI, V21, DOI 10.1523/JNEUROSCI.21-20-j0006.2001; Castellano A, 1997, J NEUROSCI, V17, P4652; Chandy KG, 1998, MOL PSYCHIATR, V3, P32, DOI 10.1038/sj.mp.4000353; Chen JQ, 2000, J MED CHEM, V43, P3478, DOI 10.1021/jm000904v; Deutsch C, 2002, ANNU REV PHYSIOL, V64, P19, DOI 10.1146/annurev.physiol.64.081501.155934; Dunn PM, 1996, BRIT J PHARMACOL, V117, P35, DOI 10.1111/j.1476-5381.1996.tb15151.x; Faber ESL, 2002, J NEUROSCI, V22, P1618, DOI 10.1523/JNEUROSCI.22-05-01618.2002; Grunnet M, 2001, PFLUG ARCH EUR J PHY, V441, P544, DOI 10.1007/s004240000447; HEGINBOTHAM L, 1992, NEURON, V8, P483, DOI 10.1016/0896-6273(92)90276-J; Hosseini R, 2001, J PHYSIOL-LONDON, V535, P323, DOI 10.1111/j.1469-7793.2001.00323.x; Hugnot JP, 1996, EMBO J, V15, P3322, DOI 10.1002/j.1460-2075.1996.tb00697.x; Ishii TM, 1997, J BIOL CHEM, V272, P23195, DOI 10.1074/jbc.272.37.23195; Joiner WJ, 1997, P NATL ACAD SCI USA, V94, P11013, DOI 10.1073/pnas.94.20.11013; Kohler M, 1996, SCIENCE, V273, P1709, DOI 10.1126/science.273.5282.1709; Ma D, 2002, CURR OPIN NEUROBIOL, V12, P287, DOI 10.1016/S0959-4388(02)00319-7; Ma DK, 2001, SCIENCE, V291, P316, DOI 10.1126/science.291.5502.316; Manganas LN, 2000, J BIOL CHEM, V275, P29685, DOI 10.1074/jbc.M005010200; MARTELL AE, 1974, CRITICAL STABILITY C, P199; Miller MJ, 2001, J BIOL CHEM, V276, P27753, DOI 10.1074/jbc.C100221200; Sah P, 2002, PROG NEUROBIOL, V66, P345, DOI 10.1016/S0301-0082(02)00004-7; Sailer CA, 2002, J NEUROSCI, V22, P9698; Shah M, 2000, BRIT J PHARMACOL, V129, P627, DOI 10.1038/sj.bjp.0703111; Stocker M, 1999, P NATL ACAD SCI USA, V96, P4662, DOI 10.1073/pnas.96.8.4662; Stocker M, 2000, MOL CELL NEUROSCI, V15, P476, DOI 10.1006/mcne.2000.0842; Stocker M, 1999, J NEUROCHEM, V72, P1725, DOI 10.1046/j.1471-4159.1999.721725.x; Strobaek D, 2000, BRIT J PHARMACOL, V129, P991, DOI 10.1038/sj.bjp.0703120; WADSWORTH JDF, 1994, J BIOL CHEM, V269, P18053; Wadsworth JDF, 1996, BIOCHEMISTRY-US, V35, P7917, DOI 10.1021/bi9602371; Wadsworth JDF, 1997, ARCH BIOCHEM BIOPHYS, V346, P151, DOI 10.1006/abbi.1997.0280	31	72	73	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 9	2004	279	2					1003	1009		10.1074/jbc.M308070200	http://dx.doi.org/10.1074/jbc.M308070200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	759DJ	14559917	hybrid			2022-12-27	WOS:000187722800023
J	Lim, JW; Kim, H; Kim, KH				Lim, JW; Kim, H; Kim, KH			The Ku antigen-recombination signal-binding protein J kappa complex binds to the nuclear factor-kappa B p50 promoter and acts as a positive regulator of p50 expression in human gastric cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPSTEIN-BARR-VIRUS; TRANSCRIPTION FACTOR COMPLEX; DNA END-BINDING; RBP-J-KAPPA; MESSENGER-RNA; CYCLOOXYGENASE-2 EXPRESSION; GENE-EXPRESSION; IN-VIVO; SUBUNIT; PROLIFERATION	The p50 subunit of NF-kappaB is a transcription factor that regulates the expression of a variety of genes. Previously, we showed that the expression of Ku antigen, a DNA repair protein, is mediated by NF-kappaB in gastric cancer AGS cells (Lim, J.W., Kim, H., and Kim, K. H. (2002) J. Biol. Chem. 277, 46093-46100). In this study, we report that the inhibition of Ku activity reduced both p50 expression and nuclear NF-kappaB activity in AGS cells. A co-immunoprecipitation experiment demonstrated that Ku antigen interacted with recombination signal-binding protein Jkappa (RBP-Jkappa), a DNA-binding protein. Ku antigen, RBP-Jkappa, and p50 were found to bind to the DNA region containing the kappaB element in the p50 promoter. Supershift and competition experiments demonstrated that Ku antigen and RBP-Jkappa bound sequence-specifically to downstream elements of kappaB at GCTTC and TGGGGG. mRNA expression and de novo synthesis of p50 were inhibited in cells transfected with the mutant gene expression constructs for IkappaBalpha, Ku80, and RBP-Jkappa. A reporter assay demonstrated that p50 transcription was positively mediated by NF-kappaB, Ku antigen, and RBP-Jkappa and that the binding elements for these proteins were required for optimal p50 expression. The interaction of Ku antigen with RBP-Jkappa and NF-kappaB p50 may act as a positive regulator of p50 expression in gastric cancer AGS cells.	Yonsei Univ, Coll Med, Dept Pharmacol, Seoul 120752, South Korea; Yonsei Univ, Coll Med, Inst Gastroenterol, Brain Korea Project Med Sci 21, Seoul 120752, South Korea	Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System	Kim, H (corresponding author), Yonsei Univ, Coll Med, Dept Pharmacol, 134 Shinchon Dong, Seoul 120752, South Korea.	kim626@yumc.yonsei.ac.kr		Kim, Hyeyoung/0000-0002-7019-917X				Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Battu S, 1998, ANTICANCER RES, V18, P3579; Budunova IV, 1999, ONCOGENE, V18, P7423, DOI 10.1038/sj.onc.1203104; Cary RB, 1998, NUCLEIC ACIDS RES, V26, P974, DOI 10.1093/nar/26.4.974; Dynan WS, 1998, NUCLEIC ACIDS RES, V26, P1551, DOI 10.1093/nar/26.7.1551; Erickson BA, 1999, J SURG RES, V81, P101, DOI 10.1006/jsre.1998.5511; Fennewald SM, 2002, J VIROL, V76, P1154, DOI 10.1128/JVI.76.3.1154-1162.2002; Giampuzzi M, 2000, J BIOL CHEM, V275, P36341, DOI 10.1074/jbc.M003362200; Gu YS, 1997, IMMUNITY, V7, P653, DOI 10.1016/S1074-7613(00)80386-6; Honjo T, 1996, GENES CELLS, V1, P1, DOI 10.1046/j.1365-2443.1996.10010.x; HSIEH JJD, 1995, SCIENCE, V268, P560, DOI 10.1126/science.7725102; Inoue M, 1998, JPN J CANCER RES, V89, P53, DOI 10.1111/j.1349-7006.1998.tb00479.x; Iso T, 2002, J BIOL CHEM, V277, P6598, DOI 10.1074/jbc.M110495200; Jeanson L, 2002, J BIOL CHEM, V277, P4918, DOI 10.1074/jbc.M110830200; Kannabiran C, 1997, MOL CELL BIOL, V17, P1, DOI 10.1128/MCB.17.1.1; Kao HY, 1998, GENE DEV, V12, P2269, DOI 10.1101/gad.12.15.2269; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; Kim SH, 2000, LEUKEMIA RES, V24, P917, DOI 10.1016/S0145-2126(00)00061-8; KNUTH MW, 1990, J BIOL CHEM, V265, P17911; Krauer KG, 1998, VIROLOGY, V252, P418, DOI 10.1006/viro.1998.9441; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; Li G, 2002, P NATL ACAD SCI USA, V99, P832, DOI 10.1073/pnas.022649699; Lim JW, 2002, J BIOL CHEM, V277, P46093, DOI 10.1074/jbc.M206603200; Lim JW, 2001, LAB INVEST, V81, P349, DOI 10.1038/labinvest.3780243; LING PD, 1994, J VIROL, V68, P5375, DOI 10.1128/JVI.68.9.5375-5383.1994; Marangoni E, 2000, NUCLEIC ACIDS RES, V28, P4778, DOI 10.1093/nar/28.23.4778; MEYER R, 1991, P NATL ACAD SCI USA, V88, P966, DOI 10.1073/pnas.88.3.966; MIMORI T, 1986, J BIOL CHEM, V261, P375; MOROZOV VE, 1994, J BIOL CHEM, V269, P16684; MUKHOPADHYAY T, 1995, ONCOGENE, V11, P999; NAKAJIMAIIJIMA S, 1985, P NATL ACAD SCI USA, V82, P6133, DOI 10.1073/pnas.82.18.6133; Osipovich O, 1999, BIOCHEM BIOPH RES CO, V261, P802, DOI 10.1006/bbrc.1999.1118; Oswald F, 2002, EMBO J, V21, P5417, DOI 10.1093/emboj/cdf549; Oswald F, 1998, MOL CELL BIOL, V18, P2077, DOI 10.1128/MCB.18.4.2077; PAYA CV, 1992, P NATL ACAD SCI USA, V89, P7826, DOI 10.1073/pnas.89.16.7826; Pedley J, 1998, MELANOMA RES, V8, P471, DOI 10.1097/00008390-199812000-00001; Sadji Z, 2000, CELL SIGNAL, V12, P745, DOI 10.1016/S0898-6568(00)00126-1; Sawaoka H, 1998, AM J PHYSIOL-GASTR L, V274, pG1061, DOI 10.1152/ajpgi.1998.274.6.G1061; Schooley K, 2003, BIOCHEM J, V369, P331, DOI 10.1042/BJ20020253; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Soubeyrand S, 2001, P NATL ACAD SCI USA, V98, P9605, DOI 10.1073/pnas.171211398; TAN XD, 1994, BBA-LIPID LIPID MET, V1215, P157, DOI 10.1016/0005-2760(94)90105-8; TEN RM, 1992, EMBO J, V11, P195, DOI 10.1002/j.1460-2075.1992.tb05042.x; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; TUN T, 1994, NUCLEIC ACIDS RES, V22, P965, DOI 10.1093/nar/22.6.965; Um JH, 2001, ONCOGENE, V20, P6048, DOI 10.1038/sj.onc.1204732; Warriar N, 1996, J BIOL CHEM, V271, P18662, DOI 10.1074/jbc.271.31.18662; Willis DM, 2002, J BIOL CHEM, V277, P37280, DOI 10.1074/jbc.M206482200; Wu XT, 1996, MOL CELL BIOL, V16, P5186; Zhang Ming-sheng, 2002, Ai Zheng, V21, P1226	51	15	16	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 2	2004	279	1					231	237		10.1074/jbc.M308609200	http://dx.doi.org/10.1074/jbc.M308609200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	757GU	14570916	hybrid			2022-12-27	WOS:000187555300028
J	Lou, HQ; Duan, ZH; Huo, XF; Huang, L				Lou, HQ; Duan, ZH; Huo, XF; Huang, L			Modulation of hyperthermophilic DNA polymerase activity by archaeal chromatin proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARCHAEBACTERIUM SULFOLOBUS-ACIDOCALDARIUS; BINDING PROTEINS; MICROSEQUENCE ANALYSIS; IN-VITRO; SOLFATARICUS; SSO7D; SAC7D; SEQUENCE; EXONUCLEASE; SHIBATAE	Sulfolobus synthesizes a large quantity of highly conserved 7-kDa DNA-binding proteins suspected to be involved in chromosomal organization. The effect of the 7-kDa proteins on the polymerization and 3'-5' exonuclease activities of a family B DNA polymerase ( polB1) from the hyperthermophilic archaeon Sulfolobus solfataricus was investigated. polB1 degraded both single-stranded DNA and double-stranded DNA at similar rates in vitro at temperatures of physiological relevance. The 7-kDa proteins were capable of significantly inhibiting the excision and enhancing the extension of matched template primers by the polymerase. However, the proteins did not protect single-stranded DNA from cleavage by polB1. In addition, the 7-kDa proteins did not affect the proofreading ability of polB1 and were not inhibitory to the excision of mismatched primers by the polymerase. The dNTP concentrations required for the effective inhibition of the 3'-5' exonuclease activity of polB1 were lowered from similar to1 mM in the absence of the 7-kDa proteins to similar to50 muM in the presence of the proteins at 65 degreesC. Our data suggest that the 7-kDa chromatin proteins serve to modulate the extension and excision activities of the hyperthermophilic DNA polymerase, reducing the cost of proofreading by the enzyme at high temperature.	Chinese Acad Sci, Inst Microbiol, State Key Lab Microbial Resources, Beijing 100080, Peoples R China	Chinese Academy of Sciences; Institute of Microbiology, CAS	Huang, L (corresponding author), Chinese Acad Sci, Inst Microbiol, State Key Lab Microbial Resources, Beijing 100080, Peoples R China.		Lou, Huiqiang/B-6287-2012	Lou, Huiqiang/0000-0003-4465-6186				Agback P, 1998, NAT STRUCT BIOL, V5, P579, DOI 10.1038/836; BAUMANN H, 1994, NAT STRUCT BIOL, V1, P808, DOI 10.1038/nsb1194-808; Bohlke K, 2002, EXTREMOPHILES, V6, P1, DOI 10.1007/s007920100222; BROCK TD, 1972, ARCH MIKROBIOL, V84, P54, DOI 10.1007/BF00408082; Chen XL, 2002, SCI CHINA SER C, V45, P583, DOI 10.1007/BF02879746; CHOLI T, 1988, BIOCHIM BIOPHYS ACTA, V950, P193, DOI 10.1016/0167-4781(88)90011-5; CHOLI T, 1988, J BIOL CHEM, V263, P7087; COWART M, 1989, BIOCHEMISTRY-US, V28, P1975, DOI 10.1021/bi00431a004; DAWSON JM, 1984, ANAL BIOCHEM, V140, P391, DOI 10.1016/0003-2697(84)90183-0; De Felice M, 1999, J MOL BIOL, V291, P47, DOI 10.1006/jmbi.1999.2939; Dijk J., 1986, BACTERIAL CHROMATIN, P185; EDMONDSON SP, 1995, BIOCHEMISTRY-US, V34, P13289, DOI 10.1021/bi00041a004; Edmondson SP, 2001, METHOD ENZYMOL, V334, P129; Fiorentino G, 2003, J BACTERIOL, V185, P3926, DOI 10.1128/JB.185.13.3926-3934.2003; Gao YG, 1998, NAT STRUCT BIOL, V5, P782, DOI 10.1038/1822; GROTE M, 1986, BIOCHIM BIOPHYS ACTA, V873, P405, DOI 10.1016/0167-4838(86)90090-7; Guagliardi A, 1997, J MOL BIOL, V267, P841, DOI 10.1006/jmbi.1996.0873; Kahler M, 2000, J BACTERIOL, V182, P655, DOI 10.1128/JB.182.3.655-663.2000; Kelman Z, 1999, J BIOL CHEM, V274, P28751, DOI 10.1074/jbc.274.40.28751; KIMURA M, 1984, FEBS LETT, V176, P176, DOI 10.1016/0014-5793(84)80935-7; KONG HM, 1993, J BIOL CHEM, V268, P1965; Kornberg A., 1992, DNA REPLICATION; KUNKEL TA, 1988, CELL, V53, P837, DOI 10.1016/S0092-8674(88)90189-4; Kvaratskhelia M, 2002, J BIOL CHEM, V277, P2992, DOI 10.1074/jbc.M109496200; Lopez-Garcia P, 1998, NUCLEIC ACIDS RES, V26, P2322, DOI 10.1093/nar/26.10.2322; Lundback T, 1998, J MOL BIOL, V276, P775, DOI 10.1006/jmbi.1997.1558; Mai VQ, 1998, J BACTERIOL, V180, P2560, DOI 10.1128/JB.180.9.2560-2563.1998; MCAFEE JG, 1995, BIOCHEMISTRY-US, V34, P10063, DOI 10.1021/bi00031a031; McAfee JG, 1996, BIOCHEMISTRY-US, V35, P4034, DOI 10.1021/bi952555q; Napoli A, 2002, NUCLEIC ACIDS RES, V30, P2656, DOI 10.1093/nar/gkf377; Perler FB, 1996, ADV PROTEIN CHEM, V48, P377; PISANI FM, 1992, NUCLEIC ACIDS RES, V20, P2711, DOI 10.1093/nar/20.11.2711; Robinson H, 1998, NATURE, V392, P202, DOI 10.1038/32455; Sandman K, 1998, CELL MOL LIFE SCI, V54, P1350, DOI 10.1007/s000180050259; She Q, 2001, P NATL ACAD SCI USA, V98, P7835, DOI 10.1073/pnas.141222098; TRAUT TW, 1994, MOL CELL BIOCHEM, V140, P1, DOI 10.1007/BF00928361	36	17	18	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	2004	279	1					127	132		10.1074/jbc.M309860200	http://dx.doi.org/10.1074/jbc.M309860200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	757GU	14563841	hybrid			2022-12-27	WOS:000187555300016
J	Lee, SR; Wong, JMY; Collins, K				Lee, SR; Wong, JMY; Collins, K			Human telomerase reverse transcriptase motifs required for elongation of a telomeric substrate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEINS; CATALYTIC SUBUNIT; IMMORTAL CELLS; RNA; ENZYME; PROCESSIVITY; COMPONENT; SEQUENCE; DOMAINS; SITE	The reverse transcriptase telomerase copies an internal RNA template to synthesize telomeric simple-sequence repeats. In the cellular context, telomerase must elongate its few intended substrates (authentic chromosome ends) without spurious activity on other potential substrates (chromosome ends created by damage, repair, or recombination). Many mechanisms have been proposed to account for the biological substrate specificity of telomerase, with most models focusing on protein-protein interactions between telomerase and telomeric chromatin. Telomerase activity assays testing the elongation of model oligonucleotide substrates have revealed that in addition to hybridization with the RNA template, optimal DNA substrates also engage telomerase protein-based interaction sites. The physiological significance of these non-template interaction sites has not been established. We used in vivo reconstitution to assemble telomerase enzymes with variant telomerase reverse transcriptase proteins. Several telomerase enzyme variants retained a wild-type level of catalytic function in vitro when assayed using an artificial sequence substrate but exhibited reduced activity on a more physiological telomeric-sequence substrate. Telomerases that demonstrated this defect in telomeric substrate usage in vitro also failed to support telomere length maintenance in vivo. Our findings suggest that non-template interactions of the telomerase ribonucleoprotein with telomeric DNA play a critical role in supporting telomerase function on its appropriate cellular substrates.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Collins, K (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 16 Barker Hall, Berkeley, CA 94720 USA.	kcollins@socrates.berkeley.edu	Wong, Judy/AAG-1868-2021	Wong, Judy/0000-0001-5572-4143; Lee, Suzanne/0000-0003-1608-2576				Armbruster BN, 2003, MOL CELL BIOL, V23, P3237, DOI 10.1128/MCB.23.9.3237-3246.2003; Armbruster BN, 2001, MOL CELL BIOL, V21, P7775, DOI 10.1128/MCB.21.22.7775-7786.2001; Banik SSR, 2002, MOL CELL BIOL, V22, P6234, DOI 10.1128/MCB.22.17.6234-6246.2002; Beattie TL, 2000, MOL BIOL CELL, V11, P3329, DOI 10.1091/mbc.11.10.3329; COHN M, 1995, SCIENCE, V269, P396, DOI 10.1126/science.7618104; Collins K, 1999, ANNU REV BIOCHEM, V68, P187, DOI 10.1146/annurev.biochem.68.1.187; COLLINS K, 1993, GENE DEV, V7, P1364, DOI 10.1101/gad.7.7b.1364; Collins K, 1998, P NATL ACAD SCI USA, V95, P8485, DOI 10.1073/pnas.95.15.8485; Counter CM, 1998, P NATL ACAD SCI USA, V95, P14723, DOI 10.1073/pnas.95.25.14723; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; Evans SK, 1999, SCIENCE, V286, P117, DOI 10.1126/science.286.5437.117; Ford LP, 2002, ONCOGENE, V21, P580, DOI 10.1038/sj.onc.1205086; Ford LP, 2000, MOL CELL BIOL, V20, P9084, DOI 10.1128/MCB.20.23.9084-9091.2000; Friedman KL, 1999, GENE DEV, V13, P2863, DOI 10.1101/gad.13.21.2863; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; Hammond PW, 1998, BIOCHEMISTRY-US, V37, P5162, DOI 10.1021/bi972988o; Hammond PW, 1997, MOL CELL BIOL, V17, P296, DOI 10.1128/MCB.17.1.296; Hardy CD, 2001, J BIOL CHEM, V276, P4863, DOI 10.1074/jbc.M005158200; Harrington L, 2003, CANCER LETT, V194, P139, DOI 10.1016/S0304-3835(02)00701-2; Kelleher C, 2002, TRENDS BIOCHEM SCI, V27, P572, DOI 10.1016/S0968-0004(02)02206-5; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; LEE MS, 1993, MOL CELL BIOL, V13, P6586, DOI 10.1128/MCB.13.10.6586; Lingner J, 1997, P NATL ACAD SCI USA, V94, P11190, DOI 10.1073/pnas.94.21.11190; Masutomi K, 2003, CELL, V114, P241, DOI 10.1016/S0092-8674(03)00550-6; McEachern MJ, 2000, ANNU REV GENET, V34, P331, DOI 10.1146/annurev.genet.34.1.331; Mitchell JR, 1999, MOL CELL BIOL, V19, P567; MORIN GB, 1991, NATURE, V353, P454, DOI 10.1038/353454a0; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; Singh SM, 2003, P NATL ACAD SCI USA, V100, P5718, DOI 10.1073/pnas.1036868100; Szatmari I, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.2.e3; Wallweber G, 2003, BIOCHEMISTRY-US, V42, P589, DOI 10.1021/bi026914a; Wang H, 1997, EMBO J, V16, P866, DOI 10.1093/emboj/16.4.866; Wong JMY, 2002, NAT CELL BIOL, V4, P731, DOI 10.1038/ncb846; Xia JQ, 2000, MOL CELL BIOL, V20, P5196, DOI 10.1128/MCB.20.14.5196-5207.2000; YU GL, 1990, NATURE, V344, P126, DOI 10.1038/344126a0	35	33	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52531	52536		10.1074/jbc.M311359200	http://dx.doi.org/10.1074/jbc.M311359200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14565961	hybrid			2022-12-27	WOS:000187480700069
J	Mahabeleshwar, GH; Kundu, GC				Mahabeleshwar, GH; Kundu, GC			Tyrosine kinase p56(lck) regulates cell motility and nuclear factor kappa B-mediated secretion of urokinase type plasminogen activator through tyrosine phosphorylation of I kappa B alpha following hypoxia/reoxygenation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; PROMATRIX METALLOPROTEINASE-2; SIGNAL-TRANSDUCTION; TUMOR HYPOXIA; METASTASIS; PATHWAYS; P56LCK; GROWTH; LCK; MICROENVIRONMENT	Nuclear factor kappaB (NFkappaB) plays major role in regulating cellular responses as a result of environmental injuries. The molecular mechanism(s) by which hypoxia/reoxygenation (H/R) regulates p56(lck)-dependent activation of NFkappaB through tyrosine phosphorylation of IkappaBalpha and modulates the expression of downstream genes that are involved in cell migration in human breast cancer cells are not well defined. In this paper, we investigated the involvement of protein-tyrosine kinase p56(lck) in the redox-regulated activation of NFkappaB following H/R in highly invasive (MDA-MB-231) and low invasive (MCF-7) breast cancer cells. We demonstrated that H/R induces tyrosine phosphorylation of p56(lck), nuclear translocation of NFkappaB, NFkappaB-DNA binding, and transactivation of NFkappaB through tyrosine phosphorylation of IkappaBalpha. Transfection of these cells with wild type Lck but not with mutant Lck F394 followed by H/R induces the tyrosine phosphorylation of inhibitor of nuclear factor kappaB (IkappaBalpha) and transcriptional activation of NFkappaB, and these are inhibited by Lck inhibitors. In vitro kinase assay demonstrated that immunoprecipitated p56(lck) but not Lyn or Fyn directly phosphorylate IkappaBalpha in presence of H/R. Pervanadate, H2O2, and H/R induce the interaction between Lck and tyrosine-phosphorylated IkappaBalpha, and this interaction is inhibited by Src homology 2 domain inhibitory peptide, suggesting that tyrosine-phosphorylated IkappaBalpha interacts with Src homology 2 domain of Lck. Luciferase reporter gene assay indicated that Lck induces NFkappaB-dependent urokinase type plasminogen activator (uPA) promoter activity in presence of H/R. Furthermore, H/R stimulates the cell motility through secretion of uPA. To our knowledge, this is the first report that p56(lck) in presence of H/R regulates NFkappaB activation, uPA secretion, and cell motility through tyrosine phosphorylation of IkappaBalpha and further demonstrates an important redox-regulated pathway for NFkappaB activation following H/R injury that is independent of IkappaB kinase/IkappaBalpha-mediated signaling pathways.	Natl Ctr Cell Sci, Pune 411007, Maharashtra, India	Department of Biotechnology (DBT) India; National Centre for Cell Science, Pune (NCCS)	Kundu, GC (corresponding author), Natl Ctr Cell Sci, NCCS Complex, Pune 411007, Maharashtra, India.	gopalkundu@hotmail.com	Kundu, Gopal C./ABA-9897-2020					ABRAHAM KM, 1991, P NATL ACAD SCI USA, V88, P3977, DOI 10.1073/pnas.88.9.3977; ABRAHAM N, 1990, MOL CELL BIOL, V10, P5197, DOI 10.1128/MCB.10.10.5197; Abu-Amer Y, 1998, J BIOL CHEM, V273, P29417, DOI 10.1074/jbc.273.45.29417; ALLEN JM, 1992, MOL CELL BIOL, V12, P2758, DOI 10.1128/MCB.12.6.2758; AMREIN KE, 1988, P NATL ACAD SCI USA, V85, P4247, DOI 10.1073/pnas.85.12.4247; Amundadottir LT, 1998, ONCOGENE, V16, P737, DOI 10.1038/sj.onc.1201829; Andreasen PA, 2000, CELL MOL LIFE SCI, V57, P25, DOI 10.1007/s000180050497; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Beraud C, 1999, P NATL ACAD SCI USA, V96, P429, DOI 10.1073/pnas.96.2.429; BERGMAN M, 1992, EMBO J, V11, P2919, DOI 10.1002/j.1460-2075.1992.tb05361.x; BOULET I, 1987, BIOCHEM BIOPH RES CO, V149, P56, DOI 10.1016/0006-291X(87)91604-4; Canty TG, 1999, CIRCULATION, V100, P361; CASNELLIE JE, 1982, J BIOL CHEM, V257, P3877; Dachs GU, 2000, EUR J CANCER, V36, P1649, DOI 10.1016/S0959-8049(00)00159-3; Das R, 2003, J BIOL CHEM, V278, P28593, DOI 10.1074/jbc.M303445200; Fan CG, 2003, J BIOL CHEM, V278, P2072, DOI 10.1074/jbc.M206718200; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; HARDWICK JS, 1995, P NATL ACAD SCI USA, V92, P4527, DOI 10.1073/pnas.92.10.4527; Hockel M, 1999, CANCER RES, V59, P4525; Hockel M, 2001, JNCI-J NATL CANCER I, V93, P266, DOI 10.1093/jnci/93.4.266; Imbert V, 1996, J INFLAMM, V46, P65; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; KARNITZ L, 1992, MOL CELL BIOL, V12, P4521, DOI 10.1128/MCB.12.10.4521; Koong AC, 2000, CANCER RES, V60, P883; KOSTER A, 1991, ANTICANCER RES, V11, P193; Livolsi A, 2001, EUR J BIOCHEM, V268, P1508, DOI 10.1046/j.1432-1327.2001.02028.x; Mahabeleshwar GH, 2003, J BIOL CHEM, V278, P6209, DOI 10.1074/jbc.M208905200; MARTH JD, 1988, MOL CELL BIOL, V8, P540, DOI 10.1128/MCB.8.2.540; MIYAMOTO S, 1995, ADV CANCER RES, V66, P255, DOI 10.1016/S0065-230X(08)60257-2; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; NAKAMURA K, 1993, ONCOGENE, V8, P3133; Nordsmark M, 2001, BRIT J CANCER, V84, P1070, DOI 10.1054/bjoc.2001.1728; Nordsmark M, 2000, RADIOTHER ONCOL, V57, P39, DOI 10.1016/S0167-8140(00)00223-1; Philip S, 2001, J BIOL CHEM, V276, P44926, DOI 10.1074/jbc.M103334200; Philip S, 2003, J BIOL CHEM, V278, P14487, DOI 10.1074/jbc.M207309200; Reuning U, 1998, INT J ONCOL, V13, P893; Rofstad EK, 2000, INT J RADIAT BIOL, V76, P589, DOI 10.1080/095530000138259; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; Sundfor K, 1998, BRIT J CANCER, V78, P822, DOI 10.1038/bjc.1998.586; Vaupel P, 1998, ADV EXP MED BIOL, V454, P591; VAUPEL P, 1989, CANCER RES, V49, P6449; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; VORONOVA AF, 1984, MOL CELL BIOL, V4, P2705, DOI 10.1128/MCB.4.12.2705; Yurchak LK, 1996, J BIOL CHEM, V271, P12549, DOI 10.1074/jbc.271.21.12549	47	43	46	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52598	52612		10.1074/jbc.M308941200	http://dx.doi.org/10.1074/jbc.M308941200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14534291	hybrid			2022-12-27	WOS:000187480700078
J	Parthasarathy, S; Eaazhisai, K; Balaram, H; Balaram, P; Murthy, MRN				Parthasarathy, S; Eaazhisai, K; Balaram, H; Balaram, P; Murthy, MRN			Structure of Plasmodium falciparum triose-phosphate isomerase-2-phosphoglycerate complex at 1.1-angstrom resolution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRYPANOSOMAL TRIOSEPHOSPHATE ISOMERASE; ANISOTROPIC DISPLACEMENT PARAMETERS; LIGAND-BOUND STATE; SITE LOOP MOTION; ACTIVE-SITE; RADIATION-DAMAGE; CRYSTAL-STRUCTURE; CATALYTIC LOOP; PHOSPHORYLATED PYRIDINES; SYNCHROTRON-RADIATION	Triose-phosphate isomerase, a key enzyme of the glycolytic pathway, catalyzes the isomerization of dihydroxy acetone phosphate and glyceraldehyde 3-phosphate. In this communication we report the crystal structure of Plasmodium falciparum triose-phosphate isomerase complexed to the inhibitor 2-phosphoglycerate at 1.1-Angstrom resolution. The crystallographic asymmetric unit contains a dimeric molecule. The inhibitor bound to one of the subunits in which the flexible catalytic loop 6 is in the open conformation has been cleaved into two fragments presumably due to radiation damage. The cleavage products have been tentatively identified as 2-oxoglycerate and meta-phosphate. The intact 2-phosphoglycerate bound to the active site of the other subunit has been observed in two different orientations. The active site loop in this subunit is in both open and "closed" conformations, although the open form is predominant. Concomitant with the loop closure, Phe-96, Leu-167, and residues 208-211 (YGGS) are also observed in dual conformations in the B-subunit. Detailed comparison of the active-site geometry in the present case to the Saccharomyces cerevisiae triose-phosphate isomerase-dihydroxy acetone phosphate and Leishmania mexicana triose-phosphate isomerase-phosphoglycolate complexes, which have also been determined at atomic resolution, shows that certain interactions are common to the three structures, although 2-phosphoglycerate is neither a substrate nor a transition state analogue.	Indian Inst Sci, Mol Biophys Unit, Bangalore 560012, Karnataka, India; Jawaharlal Nehru Ctr Adv Sci Res, Mol Biol & Genet Unit, Bangalore 560064, Karnataka, India	Indian Institute of Science (IISC) - Bangalore; Department of Science & Technology (India); Jawaharlal Nehru Center for Advanced Scientific Research (JNCASR)	Murthy, MRN (corresponding author), Indian Inst Sci, Mol Biophys Unit, Bangalore 560012, Karnataka, India.		Kandiah, Eaazhisai/D-2354-2010; Balaram, P./GOG-8417-2022	Kandiah, Eaazhisai/0000-0002-9877-7621				ALBERY WJ, 1976, BIOCHEMISTRY-US, V15, P5627, DOI 10.1021/bi00670a031; ALBERY WJ, 1976, BIOCHEMISTRY-US, V15, P5588, DOI 10.1021/bi00670a025; Aqvist J, 1996, J BIOL CHEM, V271, P10010, DOI 10.1074/jbc.271.17.10010; BASH PA, 1991, BIOCHEMISTRY-US, V30, P5826, DOI 10.1021/bi00238a003; BOURNE N, 1984, J AM CHEM SOC, V106, P7591, DOI 10.1021/ja00336a046; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Burmeister WP, 2000, ACTA CRYSTALLOGR D, V56, P328, DOI 10.1107/S0907444999016261; BUTCHER WW, 1955, J AM CHEM SOC, V77, P2420, DOI 10.1021/ja01614a018; CLELAND WW, 1994, SCIENCE, V264, P1887, DOI 10.1126/science.8009219; Cui Q, 2001, J AM CHEM SOC, V123, P2284, DOI 10.1021/ja002886c; DAVENPORT RC, 1991, BIOCHEMISTRY-US, V30, P5821, DOI 10.1021/bi00238a002; Derreumaux P, 1998, BIOPHYS J, V74, P72, DOI 10.1016/S0006-3495(98)77768-9; Desamero R, 2003, BIOCHEMISTRY-US, V42, P2941, DOI 10.1021/bi026994i; Harris TK, 1998, BIOCHEMISTRY-US, V37, P16828, DOI 10.1021/bi982089f; HEDMAN B, 1985, P NATL ACAD SCI USA, V82, P7604, DOI 10.1073/pnas.82.22.7604; HERLIHY JM, 1976, BIOCHEMISTRY-US, V15, P5601, DOI 10.1021/bi00670a026; HERSCHLAG D, 1990, BIOCHEMISTRY-US, V29, P5172, DOI 10.1021/bi00473a025; Jogl G, 2003, P NATL ACAD SCI USA, V100, P50, DOI 10.1073/pnas.0233793100; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JOSEPH D, 1990, SCIENCE, V249, P1425, DOI 10.1126/science.2402636; JOSEPHMCCARTHY D, 1994, BIOCHEMISTRY-US, V33, P2815, DOI 10.1021/bi00176a010; KNOWLES JR, 1991, NATURE, V350, P121, DOI 10.1038/350121a0; KOMIVES EA, 1991, BIOCHEMISTRY-US, V30, P3011, DOI 10.1021/bi00226a005; KUMAMOTO J, 1955, J AM CHEM SOC, V77, P2515, DOI 10.1021/ja01614a047; Kursula I, 2003, J BIOL CHEM, V278, P9544, DOI 10.1074/jbc.M211389200; LASKOWSKI RA, 1993, J MOL BIOL, V231, P1049, DOI 10.1006/jmbi.1993.1351; Leiros HKS, 2001, ACTA CRYSTALLOGR D, V57, P488, DOI 10.1107/S0907444901000646; LOLIS E, 1990, BIOCHEMISTRY-US, V29, P6619, DOI 10.1021/bi00480a010; LOLIS E, 1990, BIOCHEMISTRY-US, V29, P6609, DOI 10.1021/bi00480a009; Matsui Y, 2002, J MOL BIOL, V324, P469, DOI 10.1016/S0022-2836(02)01110-5; Merritt EA, 1999, ACTA CRYSTALLOGR D, V55, P1109, DOI 10.1107/S0907444999003789; Merritt EA, 1999, ACTA CRYSTALLOGR D, V55, P1997, DOI 10.1107/S0907444999011853; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Navaza J, 1997, METHOD ENZYMOL, V276, P581, DOI 10.1016/S0076-6879(97)76079-8; NOBLE MEM, 1991, PROTEINS, V10, P50, DOI 10.1002/prot.340100106; NOBLE MEM, 1991, J MED CHEM, V34, P2709, DOI 10.1021/jm00113a007; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Parthasarathy S, 2002, ACTA CRYSTALLOGR D, V58, P1992, DOI 10.1107/S0907444902015433; Parthasarathy S, 2002, BIOCHEMISTRY-US, V41, P13178, DOI 10.1021/bi025783a; POMPLIANO DL, 1990, BIOCHEMISTRY-US, V29, P3186, DOI 10.1021/bi00465a005; RANIE J, 1993, MOL BIOCHEM PARASIT, V61, P159, DOI 10.1016/0166-6851(93)90062-3; Ravelli RBG, 2002, J SYNCHROTRON RADIAT, V9, P355, DOI 10.1107/S0909049502014541; Ravelli RBG, 2000, STRUCTURE, V8, P315, DOI 10.1016/S0969-2126(00)00109-X; Rozovsky S, 2001, J MOL BIOL, V310, P259, DOI 10.1006/jmbi.2001.4672; Rozovsky S, 2001, J MOL BIOL, V310, P271, DOI 10.1006/jmbi.2001.4673; SAMPSON NS, 1992, BIOCHEMISTRY-US, V31, P8482, DOI 10.1021/bi00151a014; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; SKOOG MT, 1984, J AM CHEM SOC, V106, P7597, DOI 10.1021/ja00336a047; Velanker SS, 1997, STRUCTURE, V5, P751, DOI 10.1016/S0969-2126(97)00230-X; WADE RC, 1994, NAT STRUCT BIOL, V1, P65, DOI 10.1038/nsb0194-65; WADE RC, 1993, BIOPHYS J, V64, P9, DOI 10.1016/S0006-3495(93)81335-3; Weik M, 2000, P NATL ACAD SCI USA, V97, P623, DOI 10.1073/pnas.97.2.623; WIERENGA RK, 1991, J MOL BIOL, V220, P995, DOI 10.1016/0022-2836(91)90368-G; WILLIAMS JC, 1995, BIOCHEMISTRY-US, V34, P8309, DOI 10.1021/bi00026a012	54	22	23	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52461	52470		10.1074/jbc.M308525200	http://dx.doi.org/10.1074/jbc.M308525200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14563846	hybrid, Green Accepted			2022-12-27	WOS:000187480700060
J	Sun, QM; Zachariah, S; Chaudhary, PM				Sun, QM; Zachariah, S; Chaudhary, PM			The human herpes virus 8-encoded viral FLICE-inhibitory protein induces cellular transformation via NF-kappa B activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOMA-ASSOCIATED HERPESVIRUS; DNA-SEQUENCES; COUPLED RECEPTOR; APOPTOSIS; DEATH; HUMAN-HERPESVIRUS-8; PROLIFERATION; TRANSCRIPTION; EXPRESSION; PATHWAY	Infection with human herpes virus 8 (HHV8) has been associated with Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease. HHV8 encodes for a viral FLICE-inhibitory protein (vFLIP), designated K13, which resembles the prodomain of caspase-8 in structure and has been shown to protect cells against death receptor-induced apoptosis in vitro and in vivo. In this report, we present evidence that HHV8 vFLIP also possesses the unique ability of transforming Rat-1 and Balb/3T3 fibroblast cells, which is not shared by other vFLIPs. Rat-1 cells expressing HHV8 vFLIP form colonies in soft agar and form tumors in nude mice. The transforming ability of HHV8 vFLIP is associated with the activation of the NF-kappaB pathway and is blocked by molecular and chemical inhibitors of this pathway. Our results suggest that vFLIP K13 has activity beyond its role as an inhibitor of death receptor signaling and may play a causative role in the pathogenesis of HHV8-associated malignancies. Furthermore, inhibitors of the NF-kappaB pathway may have a role in the treatment of malignancies linked to HHV8 infection.	Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Div Hematol Oncol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Chaudhary, PM (corresponding author), Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	preet.chaudhary@utsouthwestern.edu	Chaudhary, Preet/E-1970-2018		NCI NIH HHS [1R01 CA85177] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA085177] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams J, 2000, ONCOGENE, V19, P6687, DOI 10.1038/sj.onc.1204088; Amati B, 1998, FRONT BIOSCI, V3, pd250, DOI [10.2741/a239, DOI 10.2741/A239]; An JB, 2003, ONCOGENE, V22, P3371, DOI 10.1038/sj.onc.1206407; Arvanitakis L, 1997, NATURE, V385, P347, DOI 10.1038/385347a0; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Bais C, 1998, NATURE, V391, P86, DOI 10.1038/34193; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bertin J, 1997, P NATL ACAD SCI USA, V94, P1172, DOI 10.1073/pnas.94.4.1172; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chaudhary PM, 2000, ONCOGENE, V19, P4451, DOI 10.1038/sj.onc.1203812; Chaudhary PM, 1999, ONCOGENE, V18, P5738, DOI 10.1038/sj.onc.1202976; Djerbi M, 1999, J EXP MED, V190, P1025, DOI 10.1084/jem.190.7.1025; Estrov Z, 1999, BLOOD, V94, P2844, DOI 10.1182/blood.V94.8.2844.420k43_2844_2853; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; EVAN G, 1994, PHILOS T R SOC B, V345, P269, DOI 10.1098/rstb.1994.0105; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Field N, 2003, J CELL SCI, V116, P3721, DOI 10.1242/jcs.00691; Gessain A, 1996, BLOOD, V87, P414; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Grisham MB, 1999, METHOD ENZYMOL, V300, P345; Hu SM, 1997, J BIOL CHEM, V272, P9621; Keifer JA, 2001, J BIOL CHEM, V276, P22382, DOI 10.1074/jbc.M100938200; Keller SA, 2000, BLOOD, V96, P2537; Liu L, 2002, J BIOL CHEM, V277, P13745, DOI 10.1074/jbc.M110480200; Luppi M, 1996, BLOOD, V87, P3903, DOI 10.1182/blood.V87.9.3903.bloodjournal8793903; Matta H, 2002, CANCER BIOL THER, V1, P652, DOI 10.4161/cbt.315; MAYO MW, 2000, BIOCHIM BIOPHYS ACTA, V1470, P55; Mosialos G, 1997, SEMIN CANCER BIOL, V8, P121, DOI 10.1006/scbi.1997.0063; Prakash O, 2002, JNCI-J NATL CANCER I, V94, P926; Prendergast GC, 1999, ONCOGENE, V18, P2967, DOI 10.1038/sj.onc.1202727; Rainbow L, 1997, J VIROL, V71, P5915, DOI 10.1128/JVI.71.8.5915-5921.1997; Roussel RR, 2000, ARCH BIOCHEM BIOPHYS, V377, P204, DOI 10.1006/abbi.2000.1770; Sarid R, 1998, J VIROL, V72, P1005, DOI 10.1128/JVI.72.2.1005-1012.1998; Schulz TF, 1998, J GEN VIROL, V79, P1573, DOI 10.1099/0022-1317-79-7-1573; SOULIER J, 1995, BLOOD, V86, P1276, DOI 10.1182/blood.V86.4.1276.bloodjournal8641276; Sturzl M, 1999, J NATL CANCER I, V91, P1725, DOI 10.1093/jnci/91.20.1725; Sun Q, 2003, BLOOD, V101, P1956, DOI 10.1182/blood-2002-07-2072; Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0; VAN AD, 1996, SCIENCE, V274, P787	40	91	97	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52437	52445		10.1074/jbc.M304199200	http://dx.doi.org/10.1074/jbc.M304199200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14563855	hybrid			2022-12-27	WOS:000187480700057
J	Atkinson, PGP; Coope, HJ; Rowe, M; Ley, SC				Atkinson, PGP; Coope, HJ; Rowe, M; Ley, SC			Latent membrane protein 1 of Epstein-Barr virus stimulates processing of NF-kappa B2 p100 to p52	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; MEMBRANE-PROTEIN 1; IKK-ALPHA; LYMPHOCYTE TRANSFORMATION; ACTIVATED CD40; KINASE ALPHA; MICE LACKING; C-TERMINUS; IN-VIVO; LMP1	Recent studies have identified a limited number of cellular receptors that can stimulate an alternative NF-kappaB activation pathway that depends upon the inducible processing of NF-kappaB2 p100 to p52. Here it is shown that the latent membrane protein (LMP)-1 of Epstein-Barr virus can trigger this signaling pathway in both B cells and epithelial cells. LMP1-induced p100 processing, which is mediated by the proteasome and is dependent upon de novo protein synthesis, results in the nuclear translocation of p52.RelB dimers. Previous studies have established that LMP1 also stimulates the canonical NF-kappaB-signaling pathway that triggers phosphorylation and degradation of IkappaBalpha. Interestingly, LMP1 activation of these two NF-kappaB pathways is shown here to require distinct regions of the LMP1 C-terminal cytoplasmic tail. Thus, C-terminal-activating region 1 is required for maximal triggering of p100 processing but is largely dispensable for stimulation of IkappaBalpha phosphorylation. In contrast, C-terminal-activating region 2 is critical for maximal LMP1 triggering of IkappaBalpha phosphorylation and up-regulation of p100 levels but does not contribute to activation of p100 processing. Because p100 deletion mutants that constitutively produce p52 oncogenically transform fibroblasts in vitro, it is likely that stimulation of p100 processing by LMP1 will play an important role in its transforming function.	Natl Inst Med Res, Div Immune Cell Biol, London NW7 1AA, England; Cardiff Univ, Sect Infect & Immun, Cardiff CF4 4XX, S Glam, Wales	MRC National Institute for Medical Research; Cardiff University	Ley, SC (corresponding author), Natl Inst Med Res, Div Immune Cell Biol, Mill Hill, London NW7 1AA, England.	sley@nimr.mrc.ac.uk	Rowe, Martin/B-2880-2009	Rowe, Martin/0000-0003-4139-7326				ALKALAY I, 1995, MOL CELL BIOL, V15, P1294; Beinke S, 2002, J BIOL CHEM, V277, P24162, DOI 10.1074/jbc.M201576200; Borza CM, 2002, NAT MED, V8, P594, DOI 10.1038/nm0602-594; Bren GD, 2001, ONCOGENE, V20, P7722, DOI 10.1038/sj.onc.1204868; Brennan P, 2001, J BIOL CHEM, V276, P1195, DOI 10.1074/jbc.M005461200; BURKLY L, 1995, NATURE, V373, P531, DOI 10.1038/373531a0; Caamano JH, 1998, J EXP MED, V187, P185, DOI 10.1084/jem.187.2.185; Cahir-McFarland ED, 2000, P NATL ACAD SCI USA, V97, P6055, DOI 10.1073/pnas.100119497; Chu ZL, 1998, J BIOL CHEM, V273, P15891, DOI 10.1074/jbc.273.26.15891; Ciana P, 1997, ONCOGENE, V14, P1805, DOI 10.1038/sj.onc.1201015; Claudio E, 2002, NAT IMMUNOL, V3, P958, DOI 10.1038/ni842; Coope HJ, 2002, EMBO J, V21, P5375, DOI 10.1093/emboj/cdf542; Courtois G, 1997, MOL CELL BIOL, V17, P1441, DOI 10.1128/MCB.17.3.1441; Dejardin E, 2002, IMMUNITY, V17, P525, DOI 10.1016/S1074-7613(02)00423-5; Devergne O, 1996, MOL CELL BIOL, V16, P7098; Eliopoulos AG, 2001, SEMIN CANCER BIOL, V11, P435, DOI 10.1006/scbi.2001.0410; FINKE J, 1987, J VIROL, V61, P3870, DOI 10.1128/JVI.61.12.3870-3878.1987; Floettmann JE, 1997, ONCOGENE, V15, P1851, DOI 10.1038/sj.onc.1201359; Floettmann JE, 1996, VIROLOGY, V223, P29, DOI 10.1006/viro.1996.0452; Floettmann JL, 1998, ONCOGENE, V17, P2383, DOI 10.1038/sj.onc.1202144; Franzoso G, 1998, J EXP MED, V187, P147, DOI 10.1084/jem.187.2.147; Fruehling S, 1996, J VIROL, V70, P6216, DOI 10.1128/JVI.70.9.6216-6226.1996; Geleziunas R, 1998, MOL CELL BIOL, V18, P5157, DOI 10.1128/MCB.18.9.5157; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Hatzivassiliou E, 2002, FRONT BIOSCI, V7, pD319, DOI 10.2741/hatziva; He ZM, 2000, CANCER RES, V60, P1845; Henriquez NV, 1999, J IMMUNOL, V162, P3298; Heusch M, 1999, ONCOGENE, V18, P6201, DOI 10.1038/sj.onc.1203022; HUEN DS, 1995, ONCOGENE, V10, P549; Izumi KM, 1997, P NATL ACAD SCI USA, V94, P1447, DOI 10.1073/pnas.94.4.1447; Izumi KM, 1997, P NATL ACAD SCI USA, V94, P12592, DOI 10.1073/pnas.94.23.12592; JEFFERIES WA, 1985, J EXP MED, V162, P117, DOI 10.1084/jem.162.1.117; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kayagaki N, 2002, IMMUNITY, V17, P515, DOI 10.1016/S1074-7613(02)00425-9; Kaye KM, 1999, J VIROL, V73, P10525, DOI 10.1128/JVI.73.12.10525-10530.1999; KAYE KM, 1995, J VIROL, V69, P675, DOI 10.1128/JVI.69.2.675-683.1995; KAYE KM, 1993, P NATL ACAD SCI USA, V90, P9150, DOI 10.1073/pnas.90.19.9150; Kieser A, 1999, EMBO J, V18, P2511, DOI 10.1093/emboj/18.9.2511; Kilger E, 1998, EMBO J, V17, P1700, DOI 10.1093/emboj/17.6.1700; Kulwichit W, 1998, P NATL ACAD SCI USA, V95, P11963, DOI 10.1073/pnas.95.20.11963; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Lin X, 1998, MOL CELL BIOL, V18, P5899, DOI 10.1128/MCB.18.10.5899; Mattia E, 1997, ONCOGENE, V15, P489, DOI 10.1038/sj.onc.1201183; MITCHELL T, 1995, J VIROL, V69, P2968, DOI 10.1128/JVI.69.5.2968-2976.1995; Mosialos G, 2001, CYTOKINE GROWTH F R, V12, P259, DOI 10.1016/S1359-6101(00)00035-6; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; Nitsche F, 1997, J VIROL, V71, P6619, DOI 10.1128/JVI.71.9.6619-6628.1997; PAINE E, 1995, J VIROL, V69, P4572, DOI 10.1128/JVI.69.7.4572-4576.1995; Pomerantz JL, 2002, MOL CELL, V10, P693, DOI 10.1016/S1097-2765(02)00697-4; RICKINSON AB, 1996, FIELDS VIROLOGY, P2397; Roff M, 1996, J BIOL CHEM, V271, P7844, DOI 10.1074/jbc.271.13.7844; ROWE M, 1986, INT J CANCER, V37, P367, DOI 10.1002/ijc.2910370307; ROWE M, 1987, J GEN VIROL, V68, P1575, DOI 10.1099/0022-1317-68-6-1575; Salmeron A, 2001, J BIOL CHEM, V276, P22215, DOI 10.1074/jbc.M101754200; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; Snapper CM, 1996, J EXP MED, V184, P1537, DOI 10.1084/jem.184.4.1537; Solan NJ, 2002, J BIOL CHEM, V277, P1405, DOI 10.1074/jbc.M109619200; SUN SC, 1994, P NATL ACAD SCI USA, V91, P1346, DOI 10.1073/pnas.91.4.1346; Sylla BS, 1998, P NATL ACAD SCI USA, V95, P10106, DOI 10.1073/pnas.95.17.10106; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; Thorley-Lawson DA, 2001, NAT REV IMMUNOL, V1, P75, DOI 10.1038/35095584; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; WEIH F, 1995, CELL, V80, P331, DOI 10.1016/0092-8674(95)90416-6; Xiao GT, 2001, MOL CELL, V7, P401, DOI 10.1016/S1097-2765(01)00187-3; Xiao GT, 2001, EMBO J, V20, P6805, DOI 10.1093/emboj/20.23.6805; YOUNG L, 1989, NEW ENGL J MED, V321, P1080, DOI 10.1056/NEJM198910193211604; ZimberStrobl U, 1996, EMBO J, V15, P7070, DOI 10.1002/j.1460-2075.1996.tb01098.x	69	66	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51134	51142		10.1074/jbc.M304771200	http://dx.doi.org/10.1074/jbc.M304771200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14532284	hybrid			2022-12-27	WOS:000187206300038
J	Bodding, M; Fecher-Trost, C; Flockerzi, V				Bodding, M; Fecher-Trost, C; Flockerzi, V			Store-operated Ca2+ current and TRPV6 channels in lymph node prostate cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED CALCIUM-CHANNEL; CATION CHANNEL; EPITHELIAL-CELLS; PORE PROPERTIES; T-LYMPHOCYTES; MAST-CELLS; CAT1; EXPRESSION; APOPTOSIS; DEPLETION	The contribution of endogenous and recombinant transient receptor potential vanilloid type 6 ( TRPV6) channels to Ca2+ entry across the plasma membrane was studied in the human lymph node prostate cancer cell line ( LNCaP). LNCaP cells do express the TRPV6 gene, and Ca2+ entry currents in these cells were detected after active and passive Ca2+ store depletion by intracellular application of inositol 1,4,5- trisphosphate, Ca2+ chelators, and the sarcoplasmic/ endoplasmic reticulum Ca2+ -ATPase inhibitor thapsigargin. This store- operated Ca2+ current ( I-SOC) had biophysical properties similar to those of the Ca2+ release- activated Ca2+ current ( I-CRAC) in rat basophilic leukemia cells such as the activation mechanism, inward rectification, and Ca2+ selectivity. These properties are also shared by the Ca2+- sensing Ca2+ current ( I-TRPV6) recorded after heterologous expression of TRPV6 cDNA in human embryonic kidney and rat basophilic leukemia cells ( Bodding, M., Wissenbach, U., Flockerzi, V. ( 2002) J. Biol. Chem. 277, 36656 - 36664). TRPV6 cDNA transfection of LNCaP cells restored recombinant I-TRPV6, which can be distinguished from I-SOC by the mechanism of activation, the voltage dependence of monovalent currents in the absence of external divalent cations, and the changes in Ca2+ current densities due to different membrane potentials. In addition, I-SOC was not affected by antiandrogen or 1,25- dihydroxyvitamin D-3 treatment of LNCaP cells, which up- regulates TRPV6 gene expression, or by androgen treatment, which has the opposite effect. Therefore, native channels responsible for I-SOC are different from those for recombinant I-TRPV6 and do not appear to be affected if one of their assumed subunits, TRPV6, is up- or down- regulated, suggesting a rather rigid subunit composition in vivo.	Univ Saarland, Med Fak, D-66421 Homburg, Germany	Saarland University	Bodding, M (corresponding author), Univ Saarland, Med Fak, D-66421 Homburg, Germany.							Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Bodding M, 2002, J BIOL CHEM, V277, P36656, DOI 10.1074/jbc.M202822200; Cui J, 2002, J BIOL CHEM, V277, P47175, DOI 10.1074/jbc.M205870200; Fixemer T, 2003, ONCOGENE, V22, P7858, DOI 10.1038/sj.onc.1206895; Gutierrez AA, 1999, J PHYSIOL-LONDON, V517, P95, DOI 10.1111/j.1469-7793.1999.0095z.x; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HARDIE RC, 1993, TRENDS NEUROSCI, V16, P371, DOI 10.1016/0166-2236(93)90095-4; HESS P, 1984, NATURE, V309, P453, DOI 10.1038/309453a0; Hirnet D, 2003, CELL CALCIUM, V33, P509, DOI 10.1016/S0143-4160(03)00066-6; Hoenderop JGJ, 2003, EMBO J, V22, P776, DOI 10.1093/emboj/cdg080; Hoenderop JGJ, 2001, J AM SOC NEPHROL, V12, P1342, DOI 10.1681/ASN.V1271342; HOTH M, 1993, J PHYSIOL-LONDON, V465, P359, DOI 10.1113/jphysiol.1993.sp019681; LEWIS RS, 1989, CELL REGUL, V1, P99, DOI 10.1091/mbc.1.1.99; Montell C, 2002, CELL, V108, P595, DOI 10.1016/S0092-8674(02)00670-0; Peng JB, 2001, BIOCHEM BIOPH RES CO, V282, P729, DOI 10.1006/bbrc.2001.4638; Peng JB, 1999, J BIOL CHEM, V274, P22739, DOI 10.1074/jbc.274.32.22739; Putney Jr JW, 1997, CAPACITATIVE CALCIUM; RIPPLE MO, 1995, CANCER RES, V55, P4234; Schindl R, 2002, J BIOL CHEM, V277, P26950, DOI 10.1074/jbc.M203700200; Skryma R, 2000, J PHYSIOL-LONDON, V527, P71, DOI 10.1111/j.1469-7793.2000.00071.x; Vanden Abeele F, 2003, CELL CALCIUM, V33, P357, DOI 10.1016/S0143-4160(03)00049-6; Vanden Abeele F, 2003, J BIOL CHEM, V278, P15381, DOI 10.1074/jbc.M212106200; Voets T, 2003, J GEN PHYSIOL, V121, P245, DOI 10.1085/jgp.20028752; Voets T, 2001, J BIOL CHEM, V276, P47767, DOI 10.1074/jbc.C100607200; Wertz IE, 2000, J BIOL CHEM, V275, P11470, DOI 10.1074/jbc.275.15.11470; Wissenbach U, 2001, J BIOL CHEM, V276, P19461, DOI 10.1074/jbc.M009895200; Wood R J, 2001, BMC Physiol, V1, P11, DOI 10.1186/1472-6793-1-11; Yue LX, 2001, NATURE, V410, P705, DOI 10.1038/35070596; ZWEIFACH A, 1993, P NATL ACAD SCI USA, V90, P6295, DOI 10.1073/pnas.90.13.6295	29	43	49	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					50872	50879		10.1074/jbc.M308800200	http://dx.doi.org/10.1074/jbc.M308800200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14534305	hybrid			2022-12-27	WOS:000187206300006
J	Gregory, MA; Qi, Y; Hann, SR				Gregory, MA; Qi, Y; Hann, SR			Phosphorylation by glycogen synthase kinase-3 controls c-Myc proteolysis and subnuclear localization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPHOMA CELL-LINES; N-TERMINAL DOMAIN; BURKITTS-LYMPHOMA; TRANSACTIVATION DOMAIN; INDUCED APOPTOSIS; NUCLEAR COLOCALIZATION; MOUSE PLASMACYTOMAS; PROTEIN STABILITY; IN-VIVO; V-MYC	The c-Myc protein is a transcription factor that is a central regulator of cell growth and proliferation. Thr-58 is a major phosphorylation site in c-Myc and is a mutational hotspot in Burkitt's and other aggressive human lymphomas, indicating that Thr-58 phosphorylation restricts the oncogenic potential of c-Myc. Mutation of Thr-58 is also associated with increased c-Myc protein stability. Here we show that inhibition of glycogen synthase kinase-3 (GSK-3) activity with lithium increases c-Myc stability and inhibits phosphorylation of c-Myc specifically at Thr-58 in vivo. Conversely, overexpression of GSK-3alpha or GSK-3beta enhances Thr-58 phosphorylation and ubiquitination of c-Myc. Together, these observations suggest that phosphorylation of Thr-58 mediated by GSK-3 facilitates c-Myc rapid proteolysis by the ubiquitin pathway. Furthermore, we demonstrate that GSK-3 binds c-Myc in vivo and in vitro and that GSK-3 colocalizes with c-Myc in the nucleus, strongly arguing that GSK-3 is the c-Myc Thr-58 kinase. We found that c-MycS, which lacks the N-terminal 100 amino acids of c-Myc, is unable to bind GSK-3; however, mutation of Ser-62, the priming phosphorylation site necessary for Thr-58 phosphorylation, does not disrupt GSK-3 binding. Finally, we show that Thr-58 phosphorylation alters the subnuclear localization of c-Myc, enhancing its localization to discrete nuclear bodies together with GSK-3.	Vanderbilt Univ, Sch Med, Dept Cell & Dev Biol, Nashville, TN 37232 USA	Vanderbilt University	Hann, SR (corresponding author), Vanderbilt Univ, Sch Med, Dept Cell & Dev Biol, 1161 21st Ave S,MCN B-2323, Nashville, TN 37232 USA.				NCI NIH HHS [R01 CA47399] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047399] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBERT T, 1994, ONCOGENE, V9, P759; Axelson H, 1995, EUR J CANCER, V31A, P2099, DOI 10.1016/0959-8049(95)00449-1; Bahram F, 2000, BLOOD, V95, P2104, DOI 10.1182/blood.V95.6.2104; BHATIA K, 1993, NAT GENET, V5, P56, DOI 10.1038/ng0993-56; Chang DW, 2000, MOL CELL BIOL, V20, P4309, DOI 10.1128/MCB.20.12.4309-4319.2000; Claassen GF, 1999, ONCOGENE, V18, P2925, DOI 10.1038/sj.onc.1202747; CLARK HM, 1994, CANCER RES, V54, P3383; Conzen SD, 2000, MOL CELL BIOL, V20, P6008, DOI 10.1128/MCB.20.16.6008-6018.2000; Dajani R, 2001, CELL, V105, P721, DOI 10.1016/S0092-8674(01)00374-9; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Facchini LM, 1998, FASEB J, V12, P633, DOI 10.1096/fasebj.12.9.633; FUJIMURO M, 1994, FEBS LETT, V349, P173, DOI 10.1016/0014-5793(94)00647-4; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Gregory MA, 2000, MOL CELL BIOL, V20, P2423, DOI 10.1128/MCB.20.7.2423-2435.2000; HANN SR, 1983, CELL, V34, P789, DOI 10.1016/0092-8674(83)90535-4; HANN SR, 1994, GENE DEV, V8, P2441, DOI 10.1101/gad.8.20.2441; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; HENRIKSSON M, 1992, EXP CELL RES, V203, P383, DOI 10.1016/0014-4827(92)90012-W; HENRIKSSON M, 1993, ONCOGENE, V8, P3199; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kim SY, 2003, MOL CELL, V11, P1177, DOI 10.1016/S1097-2765(03)00173-4; KOSKINEN PJ, 1991, J VIROL, V65, P842, DOI 10.1128/JVI.65.2.842-851.1991; LUTTERBACH B, 1994, MOL CELL BIOL, V14, P5510, DOI 10.1128/MCB.14.8.5510; Lutterbach B, 1999, J CELL BIOCHEM, V72, P483, DOI 10.1002/(SICI)1097-4644(19990315)72:4<483::AID-JCB4>3.0.CO;2-I; Manoukian AS, 2002, ADV CANCER RES, V84, P203, DOI 10.1016/S0065-230X(02)84007-6; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Niklinski J, 2000, MOL CELL BIOL, V20, P5276, DOI 10.1128/MCB.20.14.5276-5284.2000; Oster SK, 2002, ADV CANCER RES, V84, P81, DOI 10.1016/S0065-230X(02)84004-0; Peukert K, 1997, EMBO J, V16, P5672, DOI 10.1093/emboj/16.18.5672; PULVERER BJ, 1994, ONCOGENE, V9, P59; RABBITTS TH, 1983, NATURE, V306, P760, DOI 10.1038/306760a0; Rossig L, 2002, J BIOL CHEM, V277, P9684, DOI 10.1074/jbc.M106157200; Sachdev S, 2001, GENE DEV, V15, P3088, DOI 10.1101/gad.944801; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; SPECTOR DL, 1987, ONCOGENE, V1, P5; Spotts GD, 1997, MOL CELL BIOL, V17, P1459, DOI 10.1128/MCB.17.3.1459; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; ter Haar E, 2001, NAT STRUCT BIOL, V8, P593, DOI 10.1038/89624; WOODGETT JR, 2001, SCI STKE, pRE12; YANO T, 1993, ONCOGENE, V8, P2741; Yin XY, 2001, ONCOGENE, V20, P4650, DOI 10.1038/sj.onc.1204606; You ZB, 2002, J CELL BIOL, V157, P429, DOI 10.1083/jcb.200201110	47	320	329	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51606	51612		10.1074/jbc.M310722200	http://dx.doi.org/10.1074/jbc.M310722200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14563837	hybrid			2022-12-27	WOS:000187206300094
J	Kang, HT; Ju, JW; Cho, JW; Hwang, ES				Kang, HT; Ju, JW; Cho, JW; Hwang, ES			Down-regulation of Sp1 activity through modulation of O-glycosylation by treatment with a low glucose mimetic, 2-deoxyglucose	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-PAPILLOMAVIRUS TYPE-16; BETA-N-ACETYLGLUCOSAMINIDASE; TRANSCRIPTION FACTOR SP1; INDUCED APOPTOSIS; CELL-LINE; RETINOBLASTOMA PROTEIN; LINKED GLYCOSYLATION; CYTOPLASMIC PROTEINS; SIGNAL-TRANSDUCTION; ELECTRON-TRANSPORT	2-Deoxyglucose (2-DG), a nonmetabolizable glucose analogue, blocks glycolysis at the phosphohexose isomerase step and has been frequently used as a glucose starvation mimetic in studies of a wide variety of physiological dysfunctions. However, the effect of 2-DG on protein glycosylation and related signal pathways has not been investigated in depth. In HeLa, an HPV18-positive cervical carcinoma line, 2-DG treatment down-regulates human papillomavirus early gene transcription. This down-regulation was also achieved by low glucose supply or hypoxia, suggesting that this is a response commonly modulated by cellular glucose or energy level. We investigated how 2-DG and low glucose affect transcriptional activity. Human papillomavirus gene transcription was only marginally affected by the inhibition of ATP synthesis or the supplementation of pyruvate to 2-DG-treated cells, suggesting that poor ATP generation is involved only to a limited extent. 2-DG treatment also inhibited activation of p21 WAF1 promoter, which is controlled by p53 and/or Sp1. In a reporter assay using p21 WAF1 promoter constructs, 2-DG exerted a strong inhibitory effect on Sp1 activity. DNA binding activity of Sp1 in 2-DG-treated HeLa cells was intact, whereas it was severely impaired in cells incubated in a low glucose medium or in hypoxic condition. Unexpectedly, Sp1 was heavily modified with GlcNAc in 2-DG-treated cells, which is at least partially attributed to the inhibitory effect of 2-DG on N-acetyl-beta-D-glucosaminidase activity. Our results suggest that 2-DG, like low glucose or hypoxic condition, down-regulates Sp1 activity, but through hyper-GlcNAcylation instead of hypo-GlcNAcylation.	Univ Seoul, Dept Life Sci, Seoul 130743, South Korea; Yonsei Univ, Dept Biol, Seoul 120749, South Korea; Yonsei Univ, Prot Network Res Ctr, Seoul 120749, South Korea	University of Seoul; Yonsei University; Yonsei University	Cho, JW (corresponding author), 90 Jeonnongdong, Seoul 130743, South Korea.	chojw311@yonsei.ac.kr; eshwang@uos.ac.kr		Ju, Jung-Won/0000-0001-5248-6995				Bargonetti J, 1997, CELL MOL BIOL, V43, P935; Bialik S, 1999, CIRC RES, V85, P403, DOI 10.1161/01.RES.85.5.403; Biggs JR, 1996, J BIOL CHEM, V271, P901, DOI 10.1074/jbc.271.2.901; Blackburn RV, 1999, FREE RADICAL BIO MED, V26, P419, DOI 10.1016/S0891-5849(98)00217-2; Boehmelt G, 2000, EMBO J, V19, P5092, DOI 10.1093/emboj/19.19.5092; Bouwman P, 2002, MOL CELL ENDOCRINOL, V195, P27, DOI 10.1016/S0303-7207(02)00221-6; Boyer SN, 1996, CANCER RES, V56, P4620; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; CAY O, 1992, CANCER RES, V52, P5794; Comer FI, 2000, J BIOL CHEM, V275, P29179, DOI 10.1074/jbc.R000010200; DAWSON TL, 1993, AM J PHYSIOL, V264, pC961, DOI 10.1152/ajpcell.1993.264.4.C961; Discher DJ, 1998, J BIOL CHEM, V273, P26087, DOI 10.1074/jbc.273.40.26087; DONG DLY, 1994, J BIOL CHEM, V269, P19321; Dwarkanath BS, 2001, INT J RADIAT ONCOL, V50, P1051, DOI 10.1016/S0360-3016(01)01534-6; DYNAN WS, 1985, P NATL ACAD SCI USA, V82, P4915, DOI 10.1073/pnas.82.15.4915; Gao Y, 2001, J BIOL CHEM, V276, P9838, DOI 10.1074/jbc.M010420200; GLOSS B, 1990, J VIROL, V64, P5577, DOI 10.1128/JVI.64.11.5577-5584.1990; Goda N, 2003, MOL CELL BIOL, V23, P359, DOI 10.1128/MCB.23.1.359-369.2003; Griffith LS, 1999, EUR J BIOCHEM, V262, P824, DOI 10.1046/j.1432-1327.1999.00439.x; Haltiwanger RS, 1998, J BIOL CHEM, V273, P3611, DOI 10.1074/jbc.273.6.3611; HALTIWANGER RS, 1992, J BIOL CHEM, V267, P9005; Han I, 1997, MOL CELL BIOL, V17, P2550, DOI 10.1128/MCB.17.5.2550; Hanover JA, 1999, ARCH BIOCHEM BIOPHYS, V362, P38, DOI 10.1006/abbi.1998.1016; Hart GW, 1997, ANNU REV BIOCHEM, V66, P315, DOI 10.1146/annurev.biochem.66.1.315; Hawkins M, 1997, J CLIN INVEST, V99, P2173, DOI 10.1172/JCI119390; Healy DA, 2002, CLIN SCI, V103, P179, DOI 10.1042/cs1030179; Hermfisse U, 1996, BIOCHEM BIOPH RES CO, V225, P997, DOI 10.1006/bbrc.1996.1284; HOPPESEYLER F, 1993, J GEN VIROL, V74, P281, DOI 10.1099/0022-1317-74-2-281; HWANG ES, 1993, J VIROL, V67, P3720, DOI 10.1128/JVI.67.7.3720-3729.1993; Hwang ES, 1996, ONCOGENE, V12, P795; Hwang SG, 2002, J BIOL CHEM, V277, P2923, DOI 10.1074/jbc.M109113200; Ishiji Takaoki, 2000, Journal of Dermatology (Tokyo), V27, P73; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; Jeon JH, 2002, EXP MOL MED, V34, P496, DOI 10.1038/emm.2002.69; JONES KA, 1985, NATURE, V317, P179, DOI 10.1038/317179a0; KADONAGA JT, 1988, SCIENCE, V242, P1566, DOI 10.1126/science.3059495; KERN KA, 1987, SURGERY, V102, P380; Koutsodontis G, 2001, J BIOL CHEM, V276, P29116, DOI 10.1074/jbc.M104130200; Lane MA, 1998, J ANTI-AGING MED, V1, P327, DOI [10.1089/rej.1.1998.1.327, DOI 10.1089/REJ.1.1998.1.327]; Lee AS, 2001, TRENDS BIOCHEM SCI, V26, P504, DOI 10.1016/S0968-0004(01)01908-9; Lee YJ, 1997, J CELL SCI, V110, P681; Li WY, 1998, INVEST OPHTH VIS SCI, V39, P1535; Little Edward, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P1; Liu HP, 2002, BIOCHEM PHARMACOL, V64, P1745, DOI 10.1016/S0006-2952(02)01456-9; Maehama T, 1998, INT J CANCER, V76, P639, DOI 10.1002/(SICI)1097-0215(19980529)76:5<639::AID-IJC5>3.0.CO;2-R; Malhotra R, 1999, J BIOL CHEM, V274, P12567, DOI 10.1074/jbc.274.18.12567; McClain DA, 2002, J DIABETES COMPLICAT, V16, P72, DOI 10.1016/S1056-8727(01)00188-X; Merker MP, 2002, AM J PHYSIOL-LUNG C, V282, pL36, DOI 10.1152/ajplung.00283.2001; Mese H, 2001, ANTICANCER RES, V21, P1029; Miller CC, 2002, NUTR NEUROSCI, V5, P359, DOI 10.1080/1028415021000033839; MOBERG KH, 1992, ONCOGENE, V7, P411; Munoz-Pinedo C, 2003, J BIOL CHEM, V278, P12759, DOI 10.1074/jbc.M212392200; Nakano K, 1997, J BIOL CHEM, V272, P22199, DOI 10.1074/jbc.272.35.22199; Netzker R, 1997, EUR J BIOCHEM, V245, P174, DOI 10.1111/j.1432-1033.1997.00174.x; Roos MD, 1998, P ASSOC AM PHYSICIAN, V110, P422; Schafer D, 1997, FEBS LETT, V417, P325, DOI 10.1016/S0014-5793(97)01314-8; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHLAKE T, 1994, BIOCHEMISTRY-US, V33, P4197, DOI 10.1021/bi00180a012; SCHULZEOSTHOFF K, 1993, EMBO J, V12, P3095, DOI 10.1002/j.1460-2075.1993.tb05978.x; Schwoebel ED, 2002, J CELL BIOL, V157, P963, DOI 10.1083/jcb.200111077; SNOW CM, 1987, J CELL BIOL, V104, P1143, DOI 10.1083/jcb.104.5.1143; SOLS A, 1954, J BIOL CHEM, V210, P581; Spiro RG, 2002, GLYCOBIOLOGY, V12, p43R, DOI 10.1093/glycob/12.4.43R; SUTHERLAND RM, 1988, SCIENCE, V240, P177, DOI 10.1126/science.2451290; TOWER DB, 1958, J NEUROCHEM, V3, P185, DOI 10.1111/j.1471-4159.1958.tb12625.x; Van den Steen P, 1998, CRIT REV BIOCHEM MOL, V33, P151; Welch WJ, 1990, STRESS PROTEINS BIOL, P223; Wells L, 2001, SCIENCE, V291, P2376, DOI 10.1126/science.1058714; Yang XY, 2001, P NATL ACAD SCI USA, V98, P6611, DOI 10.1073/pnas.111099998	70	52	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51223	51231		10.1074/jbc.M307332200	http://dx.doi.org/10.1074/jbc.M307332200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14532290	hybrid			2022-12-27	WOS:000187206300048
J	Chang, HJ; Shi, R; Rehse, P; Lin, SX				Chang, HJ; Shi, R; Rehse, P; Lin, SX			Identifying androsterone (ADT) as a cognate substrate for human dehydroepiandrosterone sulfotransferase (DHEA-ST) important for steroid homeostasis - Structure of the enzyme-ADT complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-LIVER; HYDROXYSTEROID SULFOTRANSFERASE; CRYSTAL-STRUCTURE; RAT-LIVER; PURIFICATION; PROTEIN; IDENTIFICATION; EXPRESSION; 17-BETA-HYDROXYSTEROID-DEHYDROGENASE; STEREOSPECIFICITY	In steroid biosynthesis, human dehydroepiandrosterone sulfotransferase (DHEA-ST) in the adrenals has been reported to catalyze the transfer of the sulfonate group from 3'-phosphoadenosine-5'-phosphosulfate to dehydroepiandrosterone (DHEA). DHEA and its sulfate play roles as steroid precursors; however, the role of the enzyme in the catabolism of androgens is poorly understood. Androsterone sulfate is clinically recognized as one of the major androgen metabolites found in urine. Here it is demonstrated that this enzyme recognizes androsterone (ADT) as a cognate substrate with similar kinetics but a 2-fold specificity and stronger substrate inhibition than DHEA. The structure of human DHEA-ST in complex with ADT has been solved at 2.7 Angstrom resolution, confirming ADT recognition. Structural analysis has revealed the binding mode of ADT differs from that of DHEA, despite the similarity of the overall structure between the ADT and the DHEA binary complexes. Our results identify that this human enzyme is an ADT sulfotransferase as well as a DHEA sulfotransferase, implying an important role in steroid homeostasis for the adrenals and liver.	CHU Laval, Res Ctr, CIHR Grp Oncol, St Foy, PQ G1V 4G2, Canada; CHU Laval, Res Ctr, Mol Endocrinol Lab, St Foy, PQ G1V 4G2, Canada; Univ Laval, St Foy, PQ G1V 4G2, Canada	Laval University; Laval University; Laval University	Lin, SX (corresponding author), CHU Laval, Res Ctr, CIHR Grp Oncol, 2705 Laurier Blvd, St Foy, PQ G1V 4G2, Canada.	sxlin@crchul.ulaval.ca		Lin, Sheng-Xiang/0000-0001-9149-375X				ADAMS JB, 1979, BIOCHIM BIOPHYS ACTA, V567, P144, DOI 10.1016/0005-2744(79)90181-5; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chang HJ, 2001, J STEROID BIOCHEM, V77, P159, DOI 10.1016/S0960-0760(01)00048-6; COMER KA, 1992, MOL PHARMACOL, V41, P645; CORNISHBOWDEN A, 1995, ANAL ENZYME KINETIC, P118; de la Torre R, 2001, ANAL BIOCHEM, V289, P116, DOI 10.1006/abio.2000.4918; DICKERMAN Z, 1984, J CLIN ENDOCR METAB, V59, P1031, DOI 10.1210/jcem-59-6-1031; DRISCOLL WJ, 1993, J BIOL CHEM, V268, P23496; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FALANY CN, 1989, BIOCHEM J, V260, P641, DOI 10.1042/bj2600641; Falany CN, 1997, FASEB J, V11, P206, DOI 10.1096/fasebj.11.4.9068609; Gangloff A, 2001, BIOCHEM J, V356, P269, DOI 10.1042/0264-6021:3560269; GOEBELSMANN U, 1971, ACTA ENDOCRINOL-COP, V66, P679, DOI 10.1530/acta.0.0660679; Harris M, 2001, ACTA CRYSTALLOGR D, V57, P1201, DOI 10.1107/S0907444901007697; Javitt NB, 2001, ENDOCRINOLOGY, V142, P2978, DOI 10.1210/en.142.7.2978; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LuuThe V, 1996, J ENDOCRINOL, V150, pS87; LUUTHE V, 1995, DNA CELL BIOL, V14, P511, DOI 10.1089/dna.1995.14.511; MARCUS CJ, 1980, ANAL BIOCHEM, V107, P296, DOI 10.1016/0003-2697(80)90386-3; MILGROUM E, 1990, STEROID HORMONES, P398; OTTERNESS DM, 1992, MOL PHARMACOL, V41, P865; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Park BC, 1999, J BIOL CHEM, V274, P21562, DOI 10.1074/jbc.274.31.21562; Pedersen LC, 2000, FEBS LETT, V475, P61, DOI 10.1016/S0014-5793(00)01479-4; PEREZPAL.G, 1968, J CLIN ENDOCR METAB, V28, P19, DOI 10.1210/jcem-28-1-19; Rehse PH, 2002, BIOCHEM J, V364, P165, DOI 10.1042/bj3640165; SERONFERRE M, 1978, J CLIN ENDOCR METAB, V47, P603, DOI 10.1210/jcem-47-3-603; Strott CA, 1996, ENDOCR REV, V17, P670, DOI 10.1210/er.17.6.670; SUGIYAMA Y, 1984, BIOCHEM J, V224, P947, DOI 10.1042/bj2240947; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; WHITTEMORE RM, 1985, BIOCHEMISTRY-US, V24, P2477, DOI 10.1021/bi00331a013; Zhang HP, 1998, J BIOL CHEM, V273, P10888, DOI 10.1074/jbc.273.18.10888; Zhorov BS, 2000, PROTEINS, V38, P414, DOI 10.1002/(SICI)1097-0134(20000301)38:4<414::AID-PROT7>3.0.CO;2-X; Zhou M, 2001, ACTA CRYSTALLOGR D, V57, P1630, DOI 10.1107/S0907444901010964; ZWICKER H, 1993, J CLIN ENDOCR METAB, V76, P112, DOI 10.1210/jc.76.1.112	37	45	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	2004	279	4					2689	2696		10.1074/jbc.M310446200	http://dx.doi.org/10.1074/jbc.M310446200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	764MU	14573603	hybrid			2022-12-27	WOS:000188211300045
J	Goerges, AL; Nugent, MA				Goerges, AL; Nugent, MA			pH regulates vascular endothelial growth factor binding to fibronectin - A mechanism for control of extracellular matrix storage and release	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SULFATE PROTEOGLYCAN EXPRESSION; CELL-SURFACE; FACTOR VEGF; GENE-EXPRESSION; BREAST-CANCER; TUMOR PH; ANGIOGENESIS; HYPOXIA; GLYPICAN-1; RECEPTORS	Hypoxia is one of the major signals that induces angiogenesis. Hypoxic conditions lead to reduced extracellular pH. Vascular endothelial growth factor (VEGF) binding to endothelial cells and the extracellular matrix (ECM) increases at acidic pH (7.0-5.5). These interactions are dependent on heparan sulfate proteoglycans, but do not depend on the presence of VEGF receptors. Here we report that VEGF(165) and VEGF(121) binding to fibronectin also increased at acidic pH, and that these interactions are further enhanced by the addition of heparin. These results reveal that the accepted non-heparin-binding isoform of VEGF (VEGF(121)) is converted into a heparin-binding growth factor under acidic conditions. Interestingly, we did not observe increased binding of VEGF to collagen type I at acidic pH in the presence or absence of heparin, indicating that this effect is not a general property of all heparin-binding ECM proteins. The high level of VEGF binding at acidic pH was also rapidly reversed as demonstrated by increased rates of VEGF dissociation from fibronectin and fibronectin-heparin matrices as the pH was raised. The VEGF released from fibronectin retained its ability to stimulate the activation of extracellular-regulated kinase 1/2 in endothelial cells. These results suggest that VEGF may be stored in the extracellular matrix via interactions with fibronectin and heparan sulfate in tissues that are in need of vascularization so that it can aid in directing the dynamic process of growth and migration of new blood vessels.	Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA	Boston University	Nugent, MA (corresponding author), Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA.	nugent@biochem.bumc.bu.edu		Nugent, Matthew/0000-0002-8630-4712	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056200] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 56200] Funding Source: Medline; NIA NIH HHS [AG 00115] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ARIHIRO K, 1993, ACTA PATHOL JAPON, V43, P758; Burbridge M F, 1999, Angiogenesis, V3, P281, DOI 10.1023/A:1009092511894; Carmeliet P, 1999, NATURE, V401, P657, DOI 10.1038/44304; DAVID L, 1994, CANCER, V73, P518, DOI 10.1002/1097-0142(19940201)73:3<518::AID-CNCR2820730305>3.0.CO;2-T; Detmar M, 1997, J INVEST DERMATOL, V108, P263, DOI 10.1111/1523-1747.ep12286453; Dowd CJ, 1999, J BIOL CHEM, V274, P5236, DOI 10.1074/jbc.274.8.5236; Fairbrother WJ, 1998, STRUCT FOLD DES, V6, P637, DOI 10.1016/S0969-2126(98)00065-3; Folkman J, 1991, Princess Takamatsu Symp, V22, P339; Forsten KE, 2001, J CELL PHYSIOL, V189, P356, DOI 10.1002/jcp.10033; Gaus G, 2002, ACTA HISTOCHEM, V104, P51, DOI 10.1078/0065-1281-00631; Gengrinovitch S, 1999, J BIOL CHEM, V274, P10816, DOI 10.1074/jbc.274.16.10816; GITAYGOREN H, 1992, J BIOL CHEM, V267, P6093; Goerges AL, 2003, J BIOL CHEM, V278, P19518, DOI 10.1074/jbc.M211208200; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Hegele A, 2003, UROL RES, V30, P363, DOI 10.1007/s00240-002-0280-3; Ioachim E, 2002, EUR J CANCER, V38, P2362, DOI 10.1016/S0959-8049(02)00210-1; Iozzo RV, 2001, J CLIN INVEST, V108, P349, DOI 10.1172/JCI13738; Kerbel RS, 2000, CARCINOGENESIS, V21, P505, DOI 10.1093/carcin/21.3.505; Kleeff J, 1998, J CLIN INVEST, V102, P1662, DOI 10.1172/JCI4105; Li J, 2003, MICROSC RES TECHNIQ, V60, P107, DOI 10.1002/jemt.10249; LIU YX, 1995, CIRC RES, V77, P638, DOI 10.1161/01.RES.77.3.638; Matsuda K, 2001, CANCER RES, V61, P5562; Maxwell PH, 2002, SEMIN CELL DEV BIOL, V13, P29, DOI 10.1006/scdb.2001.0287; Nackaerts K, 1997, INT J CANCER, V74, P335, DOI 10.1002/(SICI)1097-0215(19970620)74:3<335::AID-IJC18>3.3.CO;2-4; PARK JE, 1993, MOL BIOL CELL, V4, P1317, DOI 10.1091/mbc.4.12.1317; RAPRAEGER A, 1986, J CELL BIOL, V103, P2683, DOI 10.1083/jcb.103.6.2683; Richardson TP, 2001, J CELL SCI, V114, P1613; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Robinson CJ, 2001, J CELL SCI, V114, P853; Roskams T, 1998, J PATHOL, V185, P290, DOI 10.1002/(SICI)1096-9896(199807)185:3<290::AID-PATH91>3.0.CO;2-I; SAUNDERS S, 1988, J CELL BIOL, V106, P423, DOI 10.1083/jcb.106.2.423; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Tonnesen MG, 2000, J INVEST DERM SYMP P, V5, P40, DOI 10.1046/j.1087-0024.2000.00014.x; TUDER RM, 1995, J CLIN INVEST, V95, P1798, DOI 10.1172/JCI117858; Tumova S, 2000, J BIOL CHEM, V275, P9410, DOI 10.1074/jbc.275.13.9410; Veikkola T, 2000, CANCER RES, V60, P203; Wijelath ES, 2002, CIRC RES, V91, P25, DOI 10.1161/01.RES.0000026420.22406.79; WIKEHOOLEY JL, 1984, RADIOTHER ONCOL, V2, P343, DOI 10.1016/S0167-8140(84)80077-8; WIKEHOOLEY JL, 1984, EUR J CANCER CLIN ON, V20, P619, DOI 10.1016/0277-5379(84)90006-3; Xu L, 2002, J BIOL CHEM, V277, P11368, DOI 10.1074/jbc.M108347200	41	74	77	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 16	2004	279	3					2307	2315		10.1074/jbc.M308482200	http://dx.doi.org/10.1074/jbc.M308482200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	762WT	14570917	hybrid			2022-12-27	WOS:000188005700088
J	Guterman, A; Glickman, MH				Guterman, A; Glickman, MH			Complementary roles for Rpn11 and Ubp6 in deubiquitination and proteolysis by the proteasome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							26S PROTEASOME; REGULATORY PARTICLE; SACCHAROMYCES-CEREVISIAE; TERMINAL HYDROLASE; UBIQUITIN-ALDEHYDE; CYSTEINE PROTEASES; PROTEIN BREAKDOWN; COP9 SIGNALOSOME; DEGRADATION; COMPLEX	Substrates destined for degradation by the 26 S proteasome are labeled with polyubiquitin chains. These chains can be dismantled by deubiquitinating enzymes (DUBs). A number of reports have identified different DUBs that can hydrolyze ubiquitin from substrates bound to the proteasome. We measured deubiquitination by both isolated lid and base-core particle subcomplexes, suggesting that at least two different DUBs are intrinsic components of 26 S proteasome holoenzymes. In agreement, we find that highly purified proteasomes contain both Rpn11 and Ubp6, situated within the lid and base subcomplexes, respectively. To study their relative contributions, we purified proteasomes from a mutant in the putative metalloprotease domain of Rpn11 and from a ubp6 null. Interestingly, in both preparations we observed slower deubiquitination rates, suggesting that Rpn11 and Ubp6 serve complementary roles. In accord, the double mutant is synthetically lethal. In contrast to WT proteasomes, proteasomes lacking the lid subcomplex or those purified from the rpn11 mutant are less sensitive to metal chelators, supporting the prediction that Rpn11 may be a metalloprotein. Treatment of proteasomes with ubiquitin-aldehyde or with cysteine modifiers also inhibited deubiquitination but simultaneously promoted degradation of a monoubiquitinated substrate along with the ubiquitin tag. Degradation is unique to 26 S proteasome holoenzymes; we could not detect degradation of a ubiquitinated protein by "lidless" proteasomes, although they were competent for deubiquitination. The fascinating observation that a single ubiquitin moiety is sufficient for targeting an otherwise stable substrate to proteasomes exposes how rapid deubiquitination of poorly ubiquitinated substrates may counteract degradation.	Technion Israel Inst Technol, Dept Biol, IL-32000 Haifa, Israel; Technion Israel Inst Technol, Inst Catalysis Sci & Technol, IL-32000 Haifa, Israel	Technion Israel Institute of Technology; Technion Israel Institute of Technology	Glickman, MH (corresponding author), Technion Israel Inst Technol, Dept Biol, IL-32000 Haifa, Israel.	glickman@tx.technion.ac.il		Glickman, Michael/0000-0002-1222-8104				Amerik AY, 2000, BIOL CHEM, V381, P981, DOI 10.1515/BC.2000.121; Baek KH, 2003, EXP MOL MED, V35, P1; Bajorek M, 2003, CURR BIOL, V13, P1140, DOI 10.1016/S0960-9822(03)00417-2; Balakirev MY, 2003, EMBO REP, V4, P517, DOI 10.1038/sj.embor.embor824; Benaroudj N, 2003, MOL CELL, V11, P69, DOI 10.1016/S1097-2765(02)00775-X; Berndt C, 2002, CURR BIOL, V12, pR815, DOI 10.1016/S0960-9822(02)01317-9; Borodovsky A, 2001, EMBO J, V20, P5187, DOI 10.1093/emboj/20.18.5187; Breitschopf K, 1998, EMBO J, V17, P5964, DOI 10.1093/emboj/17.20.5964; Chen L, 2002, MOL CELL BIOL, V22, P4902, DOI 10.1128/MCB.22.13.4902-4913.2002; Cope GA, 2002, SCIENCE, V298, P608, DOI 10.1126/science.1075901; Dantuma NP, 2000, NAT BIOTECHNOL, V18, P538, DOI 10.1038/75406; Di Fiore PP, 2003, NAT REV MOL CELL BIO, V4, P491, DOI 10.1038/nrm1124; Elsasser S, 2002, NAT CELL BIOL, V4, P725, DOI 10.1038/ncb845; Evans PC, 2003, J BIOL CHEM, V278, P23180, DOI 10.1074/jbc.M301863200; EYTAN E, 1989, P NATL ACAD SCI USA, V86, P7751, DOI 10.1073/pnas.86.20.7751; EYTAN E, 1993, J BIOL CHEM, V268, P4668; Finley D, 1998, TRENDS BIOCHEM SCI, V23, P244, DOI 10.1016/S0968-0004(98)01222-5; Fu HY, 2001, EMBO J, V20, P7096, DOI 10.1093/emboj/20.24.7096; Gan-Erdene T, 2003, J BIOL CHEM, V278, P28892, DOI 10.1074/jbc.M302890200; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Glickman MH, 1998, MOL CELL BIOL, V18, P3149, DOI 10.1128/MCB.18.6.3149; Glickman MH, 1998, CELL, V94, P615, DOI 10.1016/S0092-8674(00)81603-7; Glickman MH, 2002, CURR TOP MICROBIOL, V268, P43; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Glickman MH, 2000, SEMIN CELL DEV BIOL, V11, P149, DOI 10.1006/scdb.2000.0161; GLICKMAN MH, 2001, CURRENT PROTOCOLS PR, V24; Groisman R, 2003, CELL, V113, P357, DOI 10.1016/S0092-8674(03)00316-7; Groll M, 2000, NAT STRUCT BIOL, V7, P1062, DOI 10.1038/80992; GUTERMAN A, 2004, IN PRESS CURR PROTEI; HAAS A, 1990, J BIOL CHEM, V265, P21664; HADARI T, 1992, J BIOL CHEM, V267, P719; Hartmann-Petersen R, 2003, FEBS LETT, V535, P77, DOI 10.1016/S0014-5793(02)03874-7; HERSHKO A, 1985, BIOCHEM BIOPH RES CO, V128, P1079, DOI 10.1016/0006-291X(85)91050-2; HERSHKO A, 1980, P NATL ACAD SCI-BIOL, V77, P1783, DOI 10.1073/pnas.77.4.1783; HERSHKO A, 1987, P NATL ACAD SCI USA, V84, P1829, DOI 10.1073/pnas.84.7.1829; Holzl H, 2000, J CELL BIOL, V150, P119, DOI 10.1083/jcb.150.1.119; Hu M, 2002, CELL, V111, P1041, DOI 10.1016/S0092-8674(02)01199-6; JOHNSON ES, 1992, EMBO J, V11, P497, DOI 10.1002/j.1460-2075.1992.tb05080.x; JOHNSON ES, 1995, J BIOL CHEM, V270, P17442, DOI 10.1074/jbc.270.29.17442; Johnston SC, 1999, EMBO J, V18, P3877, DOI 10.1093/emboj/18.14.3877; Kim JH, 2003, J BIOCHEM, V134, P9, DOI 10.1093/jb/mvg107; Lam YA, 2002, NATURE, V416, P763, DOI 10.1038/416763a; Lam YA, 1997, J BIOL CHEM, V272, P28438, DOI 10.1074/jbc.272.45.28438; Lam YA, 1997, NATURE, V385, P737, DOI 10.1038/385737a0; Layfield R, 1999, ANAL BIOCHEM, V274, P40, DOI 10.1006/abio.1999.4234; Lee Jae Il, 1998, Biol Proced Online, V1, P92, DOI 10.1251/bpo11; Leggett DS, 2002, MOL CELL, V10, P495, DOI 10.1016/S1097-2765(02)00638-X; Li TW, 2000, BIOCHEM BIOPH RES CO, V272, P270, DOI 10.1006/bbrc.2000.2767; Linghu B, 2002, EUKARYOT CELL, V1, P491, DOI 10.1128/EC.1.3.491-494.2002; Liu CW, 2003, SCIENCE, V299, P408, DOI 10.1126/science.1079293; Lundgren J, 2003, MOL CELL BIOL, V23, P5320, DOI 10.1128/MCB.23.15.5320-5330.2003; Makarova KS, 2000, TRENDS BIOCHEM SCI, V25, P50, DOI 10.1016/S0968-0004(99)01530-3; Maytal-Kivity V, 2002, EMBO REP, V3, P1215, DOI 10.1093/embo-reports/kvf235; Maytal-Kivity V, 2003, INT J BIOCHEM CELL B, V35, P706, DOI 10.1016/S1357-2725(02)00378-3; Maytal-Kivity V, 2002, BMC BIOCHEM, V3, DOI 10.1186/1471-2091-3-28; Mendoza HM, 2003, J BIOL CHEM, V278, P25637, DOI 10.1074/jbc.M212948200; Navon A, 2001, MOL CELL, V8, P1339, DOI 10.1016/S1097-2765(01)00407-5; Papa FR, 1999, MOL BIOL CELL, V10, P741, DOI 10.1091/mbc.10.3.741; PICKART CM, 1986, J BIOL CHEM, V261, P210; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Raasi S, 2003, J BIOL CHEM, V278, P8951, DOI 10.1074/jbc.M212841200; Rinaldi T, 1998, MOL BIOL CELL, V9, P2917, DOI 10.1091/mbc.9.10.2917; Rinaldi T, 2002, GENE, V286, P43, DOI 10.1016/S0378-1119(01)00799-5; Saeki Y, 2002, BIOCHEM BIOPH RES CO, V296, P813, DOI 10.1016/S0006-291X(02)02002-8; Scheel H, 2003, HUM MOL GENET, V12, P2845, DOI 10.1093/hmg/ddg297; Seeger M, 2003, J BIOL CHEM, V278, P16791, DOI 10.1074/jbc.M208281200; SHAEFFER JR, 1995, BIOCHEMISTRY-US, V34, P4015, DOI 10.1021/bi00012a020; Shaeffer JR, 1996, BIOCHEMISTRY-US, V35, P10886, DOI 10.1021/bi9530705; Thrower JS, 2000, EMBO J, V19, P94, DOI 10.1093/emboj/19.1.94; Tran HJTT, 2003, BIOCHEMISTRY-US, V42, P11460, DOI 10.1021/bi035033g; vanNocker S, 1996, MOL CELL BIOL, V16, P6020; Verma R, 2002, SCIENCE, V298, P611, DOI 10.1126/science.1075898; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015; Weber-Ban EU, 1999, NATURE, V401, P90, DOI 10.1038/43481; Wee S, 2002, BMC GENET, V3, DOI 10.1186/1471-2156-3-15; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Wilkinson KD, 2000, SEMIN CELL DEV BIOL, V11, P141, DOI 10.1006/scdb.2000.0164; Wilkinson KD, 2003, NATURE, V424, P738, DOI 10.1038/424738a; Wing SS, 2003, INT J BIOCHEM CELL B, V35, P590, DOI 10.1016/S1357-2725(02)00392-8; Yao TT, 2002, NATURE, V419, P403, DOI 10.1038/nature01071; Zhang MS, 2003, EMBO J, V22, P1488, DOI 10.1093/emboj/cdg158; Zwickl P, 2000, CURR OPIN STRUC BIOL, V10, P242, DOI 10.1016/S0959-440X(00)00075-0	82	119	125	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 16	2004	279	3					1729	1738		10.1074/jbc.M307050200	http://dx.doi.org/10.1074/jbc.M307050200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	762WT	14581483	hybrid			2022-12-27	WOS:000188005700022
J	Higuchi, T; Orita, T; Nakanishi, S; Katsuya, K; Watanabe, H; Yamasaki, Y; Waga, I; Nanayama, T; Yamamoto, Y; Munger, W; Sun, HW; Falk, RJ; Jennette, JC; Alcorta, DA; Li, HP; Yamamoto, T; Saito, Y; Nakamura, M				Higuchi, T; Orita, T; Nakanishi, S; Katsuya, K; Watanabe, H; Yamasaki, Y; Waga, I; Nanayama, T; Yamamoto, Y; Munger, W; Sun, HW; Falk, RJ; Jennette, JC; Alcorta, DA; Li, HP; Yamamoto, T; Saito, Y; Nakamura, M			Molecular cloning, genomic structure, and expression analysis of MUC20, a novel mucin protein, up-regulated in injured kidney	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE-RENAL-FAILURE; CARCINOMA-ASSOCIATED ANTIGEN; MEMBRANE-ASSOCIATED MUCIN; GROWTH-FACTOR RECEPTOR; CELL-ADHESION; L-SELECTIN; GENETIC-POLYMORPHISM; SEQUENCE SIMILARITY; IGA NEPHROPATHY; CANCER ANTIGEN	Immunoglobulin A nephropathy (IgAN) is the most common primary glomerulonephritis in the world. Here, we identify a cDNA encoding a novel mucin protein, shown previously to be up-regulated in IgAN patients, from a human kidney cDNA library. This protein contains a mucin tandem repeat of 19 amino acids consisting of many threonine, serine, and proline residues and likely to be extensively O-glycosylated; thus, this gene was classified in the mucin family and named MUC20. The human MUC20 gene contains at least four exons and is localized close to MUC4 on chromosome 3q29. We found variations in repeat numbers in the mucin tandem domain, suggesting polymorphism of this region. Northern blot and reverse transcription-PCR analyses revealed that human MUC20 mRNA was expressed most highly in kidney and moderately in placenta, colon, lung, prostate, and liver. Immunohistochemical analysis of human kidney revealed that MUC20 protein was localized in the proximal tubules. Immunoblotting analysis of MUC20 proteins produced in Madin-Darby canine kidney and HEK293 cells indicated the localization of MUC20 protein in a membrane fraction and extensive posttranslational modification. Immunoelectron microscopy of MUC20-producing Madin-Darby canine kidney cells demonstrated that MUC20 protein was localized on the plasma membrane. Expression of MUC20 mRNA in a human kidney cell line was up-regulated by tumor necrosis factor-alpha, phorbol 12-myristate 13-acetate, or lipopolysaccharide. Two species of MUC20 mRNA ( hMUC20-L and hMUC20-S), resulting from alternative transcription, were identified in human tissue, whereas only one variant was observed in mouse tissues. Mouse MUC20 mRNA was expressed in the epithelial cells of proximal tubules, and the expression increased dramatically with the progression of lupus nephritis in the kidney of MRL/MpJ-lpr/lpr mice. Moreover, the expression of mouse MUC20 was augmented in renal tissues acutely injured by cisplatin or unilateral ureteral obstruction. These characteristics suggest that the production of MUC20 is correlated with development and progression of IgAN and other renal injuries.	Japan Tobacco Inc, Pharmaceut Frontier Res Labs, Cent Pharmaceut Res Inst, Kanagawa 2360004, Japan; Japan Tobacco Inc, Cent Pharmaceut Res Inst, Takatsuki, Oosaka 5691125, Japan; Gene Log Inc, Gaithersburg, MD 20878 USA; Univ N Carolina, Dept Med, Div Nephrol & Hypertens, Chapel Hill, NC 27599 USA; Niigata Univ, Fac Med, Inst Nephrol, Niigata 9518510, Japan	Japan Tobacco Inc.; Japan Tobacco Inc.; University of North Carolina; University of North Carolina Chapel Hill; Niigata University	Nakamura, M (corresponding author), Japan Tobacco Inc, Pharmaceut Frontier Res Labs, Cent Pharmaceut Res Inst, Kanagawa 2360004, Japan.	motonao.nakamura@ims.jti.co.jp	Nakanishi, Setsuko/G-5871-2015	Nakanishi, Setsuko/0000-0003-4909-2113; Jennette, John Charles/0000-0002-8081-6565				ALDRIDGE J, 1984, AM J HUM GENET, V36, P546; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ANDREWS BS, 1978, J EXP MED, V148, P1198, DOI 10.1084/jem.148.5.1198; ARIAS EB, 1994, BIOL REPROD, V51, P685, DOI 10.1095/biolreprod51.4.685; BAUMHUETER S, 1993, SCIENCE, V262, P436, DOI 10.1126/science.7692600; BERG EL, 1993, NATURE, V366, P695, DOI 10.1038/366695a0; Biesbrock AR, 1997, GLYCOCONJUGATE J, V14, P415, DOI 10.1023/A:1018587031814; BLUMENKRANTZ N, 1973, ANAL BIOCHEM, V55, P288, DOI 10.1016/0003-2697(73)90316-3; BOBEK LA, 1993, J BIOL CHEM, V268, P20563; *BOEHR MANNH, 1992, BOEHR MANNH TECHN B; Carvalho F, 1997, GLYCOCONJUGATE J, V14, P107, DOI 10.1023/A:1018573201347; COHEN PL, 1991, ANNU REV IMMUNOL, V9, P243, DOI 10.1146/annurev.iy.09.040191.001331; Desseyn JL, 1997, J BIOL CHEM, V272, P3168, DOI 10.1074/jbc.272.6.3168; Dohrmann CE, 1999, MECH DEVELOP, V84, P147, DOI 10.1016/S0925-4773(99)00055-6; DUPERAT VG, 1995, BIOCHEM J, V305, P211, DOI 10.1042/bj3050211; Fujita K, 1999, BRIT J CANCER, V80, P301, DOI 10.1038/sj.bjc.6690355; GENDLER SJ, 1990, J BIOL CHEM, V265, P15286; GIARD DJ, 1973, J NATL CANCER I, V51, P1417, DOI 10.1093/jnci/51.5.1417; Groenink J, 1996, ANTON LEEUW INT J G, V70, P79, DOI 10.1007/BF00393572; Gum JR, 2002, BIOCHEM BIOPH RES CO, V291, P466, DOI 10.1006/bbrc.2002.6475; GUM JR, 1994, J BIOL CHEM, V269, P2440; Ichimura T, 1998, J BIOL CHEM, V273, P4135, DOI 10.1074/jbc.273.7.4135; KAWAIDA K, 1994, P NATL ACAD SCI USA, V91, P4357, DOI 10.1073/pnas.91.10.4357; Kirkbride HJ, 2001, EUR J HUM GENET, V9, P347, DOI 10.1038/sj.ejhg.5200642; LAN MS, 1990, J BIOL CHEM, V265, P15294; LASKY LA, 1992, CELL, V69, P927, DOI 10.1016/0092-8674(92)90612-G; LEHMANN JM, 1989, P NATL ACAD SCI USA, V86, P9891, DOI 10.1073/pnas.86.24.9891; Leroy X, 2002, HISTOPATHOLOGY, V40, P450, DOI 10.1046/j.1365-2559.2002.01408.x; Li YQ, 1998, MOL CELL BIOL, V18, P7216, DOI 10.1128/MCB.18.12.7216; Li YQ, 2001, J BIOL CHEM, V276, P35239, DOI 10.1074/jbc.C100359200; Lillehoj EP, 2001, AM J PHYSIOL-LUNG C, V280, pL181, DOI 10.1152/ajplung.2001.280.1.L181; Liu B, 1999, ARCH BIOCHEM BIOPHYS, V364, P286, DOI 10.1006/abbi.1999.1141; Meerzaman D, 2001, AM J PHYSIOL-LUNG C, V281, pL86, DOI 10.1152/ajplung.2001.281.1.L86; Moniaux N, 1999, BIOCHEM J, V338, P325, DOI 10.1042/0264-6021:3380325; Nakamura M, 1998, RECEPTOR CHANNEL, V5, P255; NORGARD KE, 1993, J BIOL CHEM, V268, P12764; Pallesen LT, 2002, EUR J BIOCHEM, V269, P2755, DOI 10.1046/j.1432-1033.2002.02949.x; PANDEY P, 1995, CANCER RES, V55, P4000; Pigny P, 1996, GENOMICS, V38, P340, DOI 10.1006/geno.1996.0637; Prashar Y, 1999, METHOD ENZYMOL, V303, P258; Quin RJ, 2000, INT J CANCER, V87, P499, DOI 10.1002/1097-0215(20000815)87:4<499::AID-IJC6>3.0.CO;2-9; SAKO D, 1993, CELL, V75, P1179, DOI 10.1016/0092-8674(93)90327-M; Sambrook J. F., 1985, MOL CLONING LAB MANU; Schroeder JA, 2001, J BIOL CHEM, V276, P13057, DOI 10.1074/jbc.M011248200; SHANKAR V, 1994, BIOCHEM J, V300, P295, DOI 10.1042/bj3000295; Sheridan AM, 2000, CURR OPIN NEPHROL HY, V9, P427, DOI 10.1097/00041552-200007000-00015; Tashiro K, 1998, NEPHRON, V79, P21, DOI 10.1159/000044986; Thadhani R, 1996, NEW ENGL J MED, V334, P1448, DOI 10.1056/NEJM199605303342207; THEOFILOPOULOS AN, 1985, ADV IMMUNOL, V37, P269, DOI 10.1016/S0065-2776(08)60342-9; TORIBARA NW, 1993, J BIOL CHEM, V268, P5879; Vinall LE, 2000, AM J RESP CELL MOL, V23, P678, DOI 10.1165/ajrcmb.23.5.4176; Waga I, 2003, KIDNEY INT, V64, P1253, DOI 10.1046/j.1523-1755.2003.00220.x; Williams SJ, 1999, BIOCHEM BIOPH RES CO, V261, P83, DOI 10.1006/bbrc.1999.1001; Williams SJ, 1999, CANCER RES, V59, P4083; Williams SJ, 2001, J BIOL CHEM, V276, P18327, DOI 10.1074/jbc.M008850200; Yamamoto M, 1997, J BIOL CHEM, V272, P12492, DOI 10.1074/jbc.272.19.12492; Yang JW, 2002, J AM SOC NEPHROL, V13, P2464, DOI 10.1097/01.ASN.0000031827.16102.C1; Yin BWT, 2001, J BIOL CHEM, V276, P27371, DOI 10.1074/jbc.M103554200	58	114	126	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 16	2004	279	3					1968	1979		10.1074/jbc.M304558200	http://dx.doi.org/10.1074/jbc.M304558200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	762WT	14565953	hybrid, Green Published			2022-12-27	WOS:000188005700051
J	Lee, S; Helfman, DM				Lee, S; Helfman, DM			Cytoplasmic p21(Cip1) is involved in ras-induced inhibition of the ROCK/LIMK/cofilin pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHO-ASSOCIATED KINASE; BREAST-CANCER; CELL-TRANSFORMATION; P21 WAF1/CIP1/SDI1; ACTIN CYTOSKELETON; PROTEIN STABILITY; CDK INHIBITORS; GROWTH-FACTOR; LIM-KINASE; PHOSPHORYLATION	Accumulating evidence suggests that p21(Cip1) located in the cytoplasm might play a role in promoting transformation and tumor progression. Here we show that oncogenic H-RasV12 contributes to the loss of actin stress fibers by inducing cytoplasmic localization of p21(Cip1), which uncouples Rho-GTP from stress fiber formation by inhibiting Rho kinase (ROCK). Concomitant with the loss of stress fibers in Ras-transformed cells, there is a decrease in the phosphorylation level of cofilin, which is indicative of a compromised ROCK/LIMK/ cofilin pathway. Inhibition of MEK in Ras-transformed NIH3T3 results in restoration of actin stress fibers accompanied by a loss of cytoplasmic p21(Cip1), and increased phosphorylation of cofilin. Ectopic expression of cytoplasmic but not nuclear p21(Cip1) in Ras-transformed cells was effective in preventing stress fibers from being restored upon MEK inhibition and inhibited phosphorylation of cofilin. p21(Cip1) was also found to form a complex with ROCK in Ras-transformed cells in vivo. Furthermore, inhibition of the PI 3-kinase pathway resulted in loss of p21(Cip1) expression accompanied by restoration of phosphocofilin, which was not accompanied by stress fiber formation. These results suggest that restoration of cofilin phosphorylation in Ras- transformed cells is necessary but not sufficient for stress fiber formation. Our findings define a novel mechanism for coupling cytoplasmic p21(Cip1) to the control of actin polymerization by compromising the Rho/ ROCK/ LIMK/ cofilin pathway by oncogenic Ras. These studies suggest that localization of p21(Cip1) to the cytoplasm in transformed cells contributes to pathways that favor not only cell proliferation, but also cell motility thereby contributing to invasion and metastasis.	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; SUNY Stony Brook, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA	Cold Spring Harbor Laboratory; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Helfman, DM (corresponding author), Cold Spring Harbor Lab, 1 Bungtown Rd, Cold Spring Harbor, NY 11724 USA.	helfman@cshl.edu	Helfman, David M./C-2058-2011					Alpan RS, 1996, CELL GROWTH DIFFER, V7, P893; Amano M, 2000, EXP CELL RES, V261, P44, DOI 10.1006/excr.2000.5046; Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; Asada M, 1999, EMBO J, V18, P1223, DOI 10.1093/emboj/18.5.1223; Bamburg JR, 1999, TRENDS CELL BIOL, V9, P364, DOI 10.1016/S0962-8924(99)01619-0; Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; BenZeev A, 1997, CURR OPIN CELL BIOL, V9, P99, DOI 10.1016/S0955-0674(97)80158-5; Biankin AV, 2001, CANCER RES, V61, P8830; BONDY GP, 1985, CANCER RES, V45, P6005; Chen JC, 2003, J BIOL CHEM, V278, P2807, DOI 10.1074/jbc.M207943200; Coleman ML, 2003, EMBO J, V22, P2036, DOI 10.1093/emboj/cdg189; Coqueret O, 2003, TRENDS CELL BIOL, V13, P65, DOI 10.1016/S0962-8924(02)00043-0; FOX PL, 1994, ONCOGENE, V9, P3519; Gartel AL, 2000, ONCOGENE, V19, P961, DOI 10.1038/sj.onc.1203411; Gulli MP, 2001, GENE DEV, V15, P365, DOI 10.1101/gad.876901; HARPER JW, 1993, CELL, V75, P805; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; JUNG JM, 1995, ONCOGENE, V11, P2021; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; Korkolopoulou P, 2000, APPL IMMUNOHISTO M M, V8, P285, DOI 10.1097/00022744-200012000-00005; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Li Y, 2002, J BIOL CHEM, V277, P11352, DOI 10.1074/jbc.M109062200; Liang J, 2002, NAT MED, V8, P1153, DOI 10.1038/nm761; LIANG J, 2003, CELL CYCLE, V2, pA48; Maekawa M, 1999, SCIENCE, V285, P895, DOI 10.1126/science.285.5429.895; Manes T, 2003, J CELL BIOL, V161, P817, DOI 10.1083/jcb.200212172; McAllister SS, 2003, MOL CELL BIOL, V23, P216, DOI 10.1128/MCB.23.1.216-228.2003; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; Ohashi K, 2000, J BIOL CHEM, V275, P3577, DOI 10.1074/jbc.275.5.3577; Orend G, 1998, ONCOGENE, V16, P2575, DOI 10.1038/sj.onc.1201791; Pawlak G, 2002, MOL BIOL CELL, V13, P336, DOI 10.1091/mbc.01-02-0302; Pawlak G, 2001, CURR OPIN GENET DEV, V11, P41, DOI 10.1016/S0959-437X(00)00154-4; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Roninson IB, 2002, CANCER LETT, V179, P1, DOI 10.1016/S0304-3835(01)00847-3; Rossig L, 2002, J BIOL CHEM, V277, P9684, DOI 10.1074/jbc.M106157200; Sahai E, 2001, EMBO J, V20, P755, DOI 10.1093/emboj/20.4.755; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shin I, 2002, NAT MED, V8, P1145, DOI 10.1038/nm759; Sinibaldi D, 2000, ONCOGENE, V19, P5419, DOI 10.1038/sj.onc.1203947; Tanaka H, 2002, J CELL BIOL, V158, P321, DOI 10.1083/jcb.200202071; Viglietto G, 2002, NAT MED, V8, P1136, DOI 10.1038/nm762; Weiss RH, 2003, CANCER LETT, V189, P39, DOI 10.1016/S0304-3835(02)00495-0; Winston J, 1996, J BIOL CHEM, V271, P11253, DOI 10.1074/jbc.271.19.11253; Winters ZE, 2001, EUR J CANCER, V37, P2405, DOI 10.1016/S0959-8049(01)00327-6; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; YAMASHIRO S, 1991, NATURE, V349, P169, DOI 10.1038/349169a0; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032; Zondag GCM, 2000, J CELL BIOL, V149, P775, DOI 10.1083/jcb.149.4.775	51	133	140	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 16	2004	279	3					1885	1891		10.1074/jbc.M306968200	http://dx.doi.org/10.1074/jbc.M306968200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	762WT	14559914	Green Accepted, hybrid			2022-12-27	WOS:000188005700041
J	Price, PA; Williamson, MK; Nguyen, TMT; Than, TN				Price, PA; Williamson, MK; Nguyen, TMT; Than, TN			Serum levels of the fetuin-mineral complex correlate with artery calcification in the rat	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX GLA PROTEIN; INHIBIT BONE-RESORPTION; CORTICAL BONE; VITAMIN-D; IN-VITRO; GLYCOPROTEIN; CALCIUM; OSTEOPROTEGERIN; CARTILAGE; PHOSPHATE	The present studies were carried out to evaluate the possible association between the presence of the fetuinmineral complex in serum and vitamin D-induced artery calcification. The first experiment shows that there is a fetuin-mineral complex in the blood of rats in which extensive calcification of the artery media has been induced by treatment with vitamin D for 96 h, and that there is no detectable fetuin-mineral complex in the blood of rats in which artery calcification has been inhibited by concurrent treatment with ibandronate or osteoprotegerin. The second experiment shows that the timing of vitamin D-induced artery calcification correlates with the timing of the maximal increase in serum fetuin-mineral complex levels. Whereas both results indicate that serum levels of the fetuin-mineral complex are indeed associated with vitamin D-induced artery calcification, the biochemical basis for this association is presently unclear. One possibility is that high levels of the fetuin-mineral complex cause defects in the ability of fetuin to prevent the growth of the mineral component, which then seeds artery calcification. Another possibility is that the fetuin-mineral complex is the downstream product of a pathway that begins with the true causative agent, and that the serum level of the fetuinmineral complex is a marker for the activity of this agent in blood. An unexpected finding of the present studies is that vitamin D-induced artery calcification is also correlated with a 65 to 75% reduction in serum fetuin, a reduction that appears to be caused by the clearance of the fetuin-mineral complex from serum.	Univ Calif San Diego, Dept Biol, Div Biol, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Price, PA (corresponding author), Univ Calif San Diego, Dept Biol, Div Biol, 0368, La Jolla, CA 92093 USA.	pprice@ucsd.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058090] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 58090] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alagao FC, 2000, J BONE MINER RES, V15, pS208; ASHTON BA, 1976, CALC TISS RES, V22, P27; ASHTON BA, 1974, EUR J BIOCHEM, V45, P525, DOI 10.1111/j.1432-1033.1974.tb03577.x; BROWN WM, 1992, BIOESSAYS, V14, P749, DOI 10.1002/bies.950141105; Bucay N, 1998, GENE DEV, V12, P1260, DOI 10.1101/gad.12.9.1260; CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033; Gorski JP, 2000, BONE, V27, P103, DOI 10.1016/S8756-3282(00)00295-7; Hanken J., 1981, Functional Photography, V16, P22; JahnenDechent W, 1997, J BIOL CHEM, V272, P31496, DOI 10.1074/jbc.272.50.31496; Ketteler M, 2003, LANCET, V361, P827, DOI 10.1016/S0140-6736(03)12710-9; Luo GB, 1997, NATURE, V386, P78, DOI 10.1038/386078a0; MIZUNO M, 1991, BONE MINER, V13, P1, DOI 10.1016/0169-6009(91)90046-3; Munroe PB, 1999, NAT GENET, V21, P142, DOI 10.1038/5102; OHNISHI T, 1991, J BIOL CHEM, V266, P14636; OTAWARA Y, 1986, J BIOL CHEM, V261, P828; Pedersen KO, 1944, NATURE, V154, P575, DOI 10.1038/154575a0; Price PA, 2003, J BIOL CHEM, V278, P22153, DOI 10.1074/jbc.M300739200; Price PA, 2003, J BIOL CHEM, V278, P22144, DOI 10.1074/jbc.M300744200; Price PA, 1998, ARTERIOSCL THROM VAS, V18, P1400, DOI 10.1161/01.ATV.18.9.1400; Price PA, 2002, CALCIFIED TISSUE INT, V71, P356, DOI 10.1007/s00223-002-1006-9; Price PA, 2002, J BONE MINER RES, V17, P1171, DOI 10.1359/jbmr.2002.17.7.1171; Price PA, 2001, J NUTR, V131, P2910, DOI 10.1093/jn/131.11.2910; Price PA, 2002, CIRC RES, V91, P547, DOI 10.1161/01.RES.0000033987.22436.50; Price PA, 2001, ARTERIOSCL THROM VAS, V21, P817, DOI 10.1161/01.ATV.21.5.817; Price PA, 2000, ARTERIOSCL THROM VAS, V20, P317, DOI 10.1161/01.ATV.20.2.317; Price PA, 2001, ARTERIOSCL THROM VAS, V21, P1610, DOI 10.1161/hq1001.097102; Price PA, 2002, J BIOL CHEM, V277, P3926, DOI 10.1074/jbc.M106366200; QUELCH KJ, 1984, CALCIFIED TISSUE INT, V36, P545, DOI 10.1007/BF02405363; Rosa-Molinar E, 1999, BRAIN RES PROTOC, V4, P115, DOI 10.1016/S1385-299X(99)00007-0; Schafer C, 2003, J CLIN INVEST, V112, P357, DOI 10.1172/JCI17202; Schinke T, 1996, J BIOL CHEM, V271, P20789, DOI 10.1074/jbc.271.34.20789; Selye H., 1962, CALCIPHYLAXIS, P48; Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092-8674(00)80209-3; WENDEL M, 1993, MATRIX, V13, P331, DOI 10.1016/S0934-8832(11)80029-6	34	98	104	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 16	2004	279	3					1594	1600		10.1074/jbc.M305199200	http://dx.doi.org/10.1074/jbc.M305199200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	762WT	14578360	hybrid			2022-12-27	WOS:000188005700005
J	Jorgensen, SB; Viollet, B; Andreelli, F; Frosig, C; Birk, JB; Schjerling, P; Vaulont, S; Richter, EA; Wojtaszewski, JFP				Jorgensen, SB; Viollet, B; Andreelli, F; Frosig, C; Birk, JB; Schjerling, P; Vaulont, S; Richter, EA; Wojtaszewski, JFP			Knockout of the alpha(2) but not alpha(1) 5 '-AMP-activated protein kinase isoform abolishes 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside- but not contraction-induced glucose uptake in skeletal muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYL-COA CARBOXYLASE; 5-AMINOIMIDAZOLE-4-CARBOXAMIDE RIBONUCLEOSIDE; GLYCOGEN-SYNTHASE; MAMMALIAN TARGET; INSULIN ACTION; RAT MUSCLE; ACTIVATION; TRANSPORT; EXERCISE; MICE	We investigated the importance of the two catalytic alpha-isoforms of the 5'-AMP-activated protein kinase (AMPK) in 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside ( AICAR) and contraction-induced glucose uptake in skeletal muscle. Incubated soleus and EDL muscle from whole-body alpha(2)- or alpha(1)-AMPK knockout (KO) and wild type (WT) mice were incubated with 2.0 mM AICAR or electrically stimulated to contraction. Both AICAR and contraction increased 2DG uptake in WT muscles. KO of alpha(2), but not alpha(1), abolished AICAR-induced glucose uptake, whereas neither KO affected contraction-induced glucose uptake. AICAR and contraction increased alpha(2)- and alpha(1)-AMPK activity in wild type (WT) muscles. During AICAR stimulation, the remaining AMPK activity in KO muscles increased to the same level as in WT. During contraction, the remaining AMPK activity in alpha(2)-KO muscles was elevated by 100% probably explained by a 2-3-fold increase in alpha(1)-protein. In alpha(1)-KO muscles, alpha(2)-AMPK activity increased to similar levels as in WT. Both interventions increased total AMPK activity, as expressed by AMPK-P and ACCbeta-P, in WT muscles. During AICAR stimulation, this was dramatically reduced in alpha(2)-KO but not in alpha1-KO, whereas during contraction, both measurements were essentially similar to WT in both KO-muscles. The results show that alpha(2)-AMPK is the main donor of basal and AICAR-stimulated AMPK activity and is responsible for AICAR-induced glucose uptake. In contrast, during contraction, the two alpha-isoforms seem to substitute for each other in terms of activity, which may explain the normal glucose uptake despite the lack of either alpha(2)- or alpha(1)-AMPK. Alternatively, neither alpha-isoform of AMPK is involved in contraction-induced muscle glucose uptake.	Univ Copenhagen, Dept Human Physiol, Inst Exercise & Sport Sci, Copenhagen Muscle Res Ctr, DK-2100 Copenhagen, Denmark; Univ Paris 05, Dept Genet Dev & Mol Pathol, CNRS, INSERM,Inst Cochin, F-75014 Paris, France; Rigshosp, Copenhagen Muscle Res Ctr, Dept Mol Muscle Biol, Sect 9312, DK-2100 Copenhagen, Denmark	University of Copenhagen; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Rigshospitalet; University of Copenhagen	Jorgensen, SB (corresponding author), Univ Copenhagen, Dept Human Physiol, Inst Exercise & Sport Sci, Copenhagen Muscle Res Ctr, 13 Univ Pk, DK-2100 Copenhagen, Denmark.		Birk, Jesper B/D-3523-2015; Wojtaszewski, Jørgen FP/P-6583-2014; Schjerling, Peter/F-6194-2011; Viollet, Benoit/O-6927-2017; Viollet, Benoit/N-2397-2019; Vaulont, Sophie/O-6732-2017; Richter, Erik A./Y-8131-2019; Frøsig, Christian/A-3750-2015	Birk, Jesper B/0000-0001-9775-4789; Wojtaszewski, Jørgen FP/0000-0001-9785-6830; Schjerling, Peter/0000-0001-7138-3211; Viollet, Benoit/0000-0002-0121-0224; Viollet, Benoit/0000-0002-0121-0224; Richter, Erik A./0000-0002-6850-3056; Frøsig, Christian/0000-0001-9302-9328; wojtaszewski, jorgen/0000-0001-8185-3408				Al-Khalili L, 2003, CELL MOL LIFE SCI, V60, P991, DOI 10.1007/s00018-003-3001-3; Bergeron R, 1999, AM J PHYSIOL-ENDOC M, V276, pE938, DOI 10.1152/ajpendo.1999.276.5.E938; Bolster DR, 2002, J BIOL CHEM, V277, P23977, DOI 10.1074/jbc.C200171200; Buhl ES, 2002, DIABETES, V51, P2199, DOI 10.2337/diabetes.51.7.2199; CARLING D, 1989, BIOCHIM BIOPHYS ACTA, V1012, P81, DOI 10.1016/0167-4889(89)90014-1; Cheung PCF, 2000, BIOCHEM J, V346, P659, DOI 10.1042/0264-6021:3460659; CORTON JM, 1995, EUR J BIOCHEM, V229, P558, DOI 10.1111/j.1432-1033.1995.0558k.x; CORTON JM, 1994, CURR BIOL, V4, P315, DOI 10.1016/S0960-9822(00)00070-1; Derave W, 2000, DIABETES, V49, P1281, DOI 10.2337/diabetes.49.8.1281; Derave W, 1999, AM J PHYSIOL-ENDOC M, V277, pE1103, DOI 10.1152/ajpendo.1999.277.6.E1103; Fiedler M, 2001, DIABETOLOGIA, V44, P2180, DOI 10.1007/s001250100027; Fisher JS, 2002, AM J PHYSIOL-ENDOC M, V282, pE18, DOI 10.1152/ajpendo.2002.282.1.E18; Fryer LGD, 2002, J BIOL CHEM, V277, P25226, DOI 10.1074/jbc.M202489200; Fujii N, 2000, BIOCHEM BIOPH RES CO, V273, P1150, DOI 10.1006/bbrc.2000.3073; Halseth AE, 2002, BIOCHEM BIOPH RES CO, V294, P798, DOI 10.1016/S0006-291X(02)00557-0; Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821; Hardie DG, 1999, BIOCHEM J, V338, P717, DOI 10.1042/0264-6021:3380717; Hawley SA, 2002, DIABETES, V51, P2420, DOI 10.2337/diabetes.51.8.2420; Hayashi T, 2000, DIABETES, V49, P527, DOI 10.2337/diabetes.49.4.527; Hayashi T, 1998, DIABETES, V47, P1369, DOI 10.2337/diabetes.47.8.1369; HESPEL P, 1990, J PHYSIOL-LONDON, V427, P347, DOI 10.1113/jphysiol.1990.sp018175; Holmes BF, 1999, J APPL PHYSIOL, V87, P1990, DOI 10.1152/jappl.1999.87.5.1990; Horman S, 2002, CURR BIOL, V12, P1419, DOI 10.1016/S0960-9822(02)01077-1; HUTBER CA, 1997, AM J PHYSIOL, V272, pF262; Ihlemann J, 2000, AM J PHYSIOL-ENDOC M, V279, pE862, DOI 10.1152/ajpendo.2000.279.4.E862; Ihlemann J, 1999, AM J PHYSIOL-ENDOC M, V277, pE208, DOI 10.1152/ajpendo.1999.277.2.E208; Itani SI, 2003, DIABETES, V52, P1635, DOI 10.2337/diabetes.52.7.1635; Kimura N, 2003, GENES CELLS, V8, P65, DOI 10.1046/j.1365-2443.2003.00615.x; Kurth-Kraczek EJ, 1999, DIABETES, V48, P1667, DOI 10.2337/diabetes.48.8.1667; Lowry O. H., 1972, FLEXIBLE SYSTEM ENZY, P1; Merrill GF, 1997, AM J PHYSIOL-ENDOC M, V273, pE1107, DOI 10.1152/ajpendo.1997.273.6.E1107; MOORE F, 1991, EUR J BIOCHEM, V199, P691, DOI 10.1111/j.1432-1033.1991.tb16172.x; Mu J, 2001, MOL CELL, V7, P1085, DOI 10.1016/S1097-2765(01)00251-9; Mu J, 2003, BIOCHEM SOC T, V31, P236, DOI 10.1042/bst0310236; Musi N, 2002, DIABETES, V51, P2074, DOI 10.2337/diabetes.51.7.2074; PLOUG T, 1993, AM J PHYSIOL, V264, pE270, DOI 10.1152/ajpendo.1993.264.2.E270; Ponticos M, 1998, EMBO J, V17, P1688, DOI 10.1093/emboj/17.6.1688; RICHTER EA, 1989, J APPL PHYSIOL, V66, P876; Song XM, 2002, DIABETOLOGIA, V45, P56, DOI 10.1007/s125-002-8245-8; Stapleton D, 1996, J BIOL CHEM, V271, P611, DOI 10.1074/jbc.271.2.611; Stapleton D, 1997, FEBS LETT, V409, P452, DOI 10.1016/S0014-5793(97)00569-3; Vallet VS, 1997, J BIOL CHEM, V272, P21944, DOI 10.1074/jbc.272.35.21944; Vallet VS, 1998, J BIOL CHEM, V273, P20175, DOI 10.1074/jbc.273.32.20175; Vavvas D, 1997, J BIOL CHEM, V272, P13255, DOI 10.1074/jbc.272.20.13255; Viollet B, 2003, J CLIN INVEST, V111, P91, DOI 10.1172/JCI200316567; Winder WW, 2000, J APPL PHYSIOL, V88, P2219, DOI 10.1152/jappl.2000.88.6.2219; Winder WW, 1996, AM J PHYSIOL-ENDOC M, V270, pE299, DOI 10.1152/ajpendo.1996.270.2.E299; Wojtaszewski JFP, 2002, DIABETES, V51, P284, DOI 10.2337/diabetes.51.2.284; Wojtaszewski JFP, 2000, J PHYSIOL-LONDON, V528, P221, DOI 10.1111/j.1469-7793.2000.t01-1-00221.x; Wojtaszewski JFP, 2002, BIOCHEM BIOPH RES CO, V298, P309, DOI 10.1016/S0006-291X(02)02465-8; Woods A, 1996, FEBS LETT, V397, P347, DOI 10.1016/S0014-5793(96)01209-4	51	451	464	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 9	2004	279	2					1070	1079		10.1074/jbc.M306205200	http://dx.doi.org/10.1074/jbc.M306205200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	759DJ	14573616	hybrid			2022-12-27	WOS:000187722800030
J	Orchiston, EA; Bennett, D; Leslie, NR; Clarke, RG; Winward, L; Downes, CP; Safrany, ST				Orchiston, EA; Bennett, D; Leslie, NR; Clarke, RG; Winward, L; Downes, CP; Safrany, ST			PTEN M-CBR3, a versatile and selective regulator of inositol 1,3,4,5,6-pentakisphosphate (Ins(1,3,4,5,6)P-5) - Evidence for Ins(1,3,4,5,6)P-5 as a proliferative signal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; PLECKSTRIN HOMOLOGY DOMAINS; CELL-CYCLE PROGRESSION; TUMOR-SUPPRESSOR PTEN; HIGH-AFFINITY BINDING; PHOSPHATASE-ACTIVITY; PHOSPHOINOSITIDE 3-KINASE; GLIOBLASTOMA CELLS; LIPID PHOSPHATASE; RECEPTOR	The PTEN ( phosphatase and tensin homologue deleted on chromosome 10) tumor suppressor is a phosphatidylinositol 3,4,5-trisphosphate (PtdInsP(3)) 3-phosphatase that plays a crucial role in regulating many cellular processes by antagonizing the phosphoinositide 3-kinase signaling pathway. Although able to metabolize soluble inositol phosphates in vitro, the question of their significance as physiological substrates is unresolved. We show that inositol phosphates are not regulated by wild type PTEN, but that a synthetic mutant, PTEN M-CBR3, previously thought to be inactive toward inositides, can selectively regulate inositol 1,3,4,5,6-pentakisphosphate (Ins(1,3,4,5,6) P-5). Transfection of U87-MG cells with PTEN M-CBR3 lowered Ins(1,3,4,5,6) P-5 levels by 60% without detectable effect on PtdInsP(3). Although PTEN M-CBR3 is a 3-phosphatase, levels of myo-inositol 1,4,5,6-tetrakisphosphate were not increased, whereas myo-inositol 1,3,4,6-tetrakisphospate levels increased by 80%. We have used PTEN M-CBR3 to study the physiological function of Ins(1,3,4,5,6) P-5 and have found that Ins(1,3,4,5,6) P-5 does not modulate PKB phosphorylation, nor does it regulate clathrin-mediated epidermal growth factor receptor internalization. By contrast, PTEN M-CBR3 expression, and the subsequent lowering of Ins(1,3,4,5,6) P-5, are associated with reduced anchorage-independent colony formation and anchorage-dependent proliferation in U87-MG cells. Our results, together with previously published data, suggest that Ins(1,3,4,5,6) P-5 has a role in proliferation.	Univ Dundee, Fac Life Sci, Div Cell Signalling, Dundee DD1 5EH, Scotland; Univ Dundee, Fac Life Sci, Div Cell Biol & Immunol, Dundee DD1 5EH, Scotland	University of Dundee; University of Dundee	Safrany, ST (corresponding author), Univ Dundee, Fac Life Sci, Div Cell Signalling, MSI WTB Complex,Dow St, Dundee DD1 5EH, Scotland.	s.t.safrany@dundee.ac.uk	Safrany, Stephen/AAX-3332-2020; Leslie, Nicholas/D-2699-2009	Safrany, Stephen/0000-0002-9592-4112; LESLIE, Nicholas/0000-0001-5131-0541				BATTY IH, 1994, BIOCHEM J, V297, P529, DOI 10.1042/bj2970529; Caffrey JJ, 2001, FEBS LETT, V499, P6, DOI 10.1016/S0014-5793(01)02500-5; Cheney IW, 1998, CANCER RES, V58, P2331; Cheyney IW, 1999, CANCER RES, V59, P2318; Chi HB, 2000, MOL CELL BIOL, V20, P6496, DOI 10.1128/MCB.20.17.6496-6507.2000; Frech M, 1997, J BIOL CHEM, V272, P8474, DOI 10.1074/jbc.272.13.8474; FRENCH PJ, 1991, P ROY SOC B-BIOL SCI, V245, P193, DOI 10.1098/rspb.1991.0109; Furnari FB, 1998, CANCER RES, V58, P5002; Georgescu MM, 1999, P NATL ACAD SCI USA, V96, P10182, DOI 10.1073/pnas.96.18.10182; Georgescu MM, 2000, CANCER RES, V60, P7033; Gimm O, 2000, AM J PATHOL, V156, P1693, DOI 10.1016/S0002-9440(10)65040-7; GUSE AH, 1993, J BIOL CHEM, V268, P7129; Kavran JM, 1998, J BIOL CHEM, V273, P30497, DOI 10.1074/jbc.273.46.30497; Lee JO, 1999, CELL, V99, P323, DOI 10.1016/S0092-8674(00)81663-3; Leslie NR, 2001, BIOCHEM J, V357, P427, DOI 10.1042/0264-6021:3570427; Leslie NR, 2000, BIOCHEM J, V346, P827, DOI 10.1042/0264-6021:3460827; Leslie NR, 2002, CELL SIGNAL, V14, P285, DOI 10.1016/S0898-6568(01)00234-0; Li DM, 1998, P NATL ACAD SCI USA, V95, P15406, DOI 10.1073/pnas.95.26.15406; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; McConnachie G, 2003, BIOCHEM J, V371, P947, DOI 10.1042/BJ20021848; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Perren A, 2000, AM J PATHOL, V157, P1097, DOI 10.1016/S0002-9440(10)64624-X; Reynolds SD, 1996, EXP CELL RES, V226, P197, DOI 10.1006/excr.1996.0219; Rohrschneider LR, 2000, GENE DEV, V14, P505; SASAKAWA N, 1994, MOL PHARMACOL, V46, P380; Shen XT, 2003, SCIENCE, V299, P112, DOI 10.1126/science.1078068; Sorkina T, 2002, J BIOL CHEM, V277, P27433, DOI 10.1074/jbc.M201595200; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Sun H, 1999, P NATL ACAD SCI USA, V96, P6199, DOI 10.1073/pnas.96.11.6199; Takeuchi H, 1997, BBA-MOL CELL RES, V1359, P275, DOI 10.1016/S0167-4889(97)00109-2; Tang XW, 2002, J BIOL CHEM, V277, P338, DOI 10.1074/jbc.M108927200; Torres J, 2001, J BIOL CHEM, V276, P993, DOI 10.1074/jbc.M009134200; Vazquez F, 2000, MOL CELL BIOL, V20, P5010, DOI 10.1128/MCB.20.14.5010-5018.2000; Walker SM, 2001, BIOCHEM J, V360, P277, DOI 10.1042/0264-6021:3600277; Williams MR, 2000, CURR BIOL, V10, P439, DOI 10.1016/S0960-9822(00)00441-3; Wu Y, 2001, J BIOL CHEM, V276, P21745, DOI 10.1074/jbc.M101480200; YE WL, 1995, J BIOL CHEM, V270, P1564, DOI 10.1074/jbc.270.4.1564	37	27	29	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 9	2004	279	2					1116	1122		10.1074/jbc.M310933200	http://dx.doi.org/10.1074/jbc.M310933200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	759DJ	14561749	hybrid			2022-12-27	WOS:000187722800035
J	Drenan, RM; Liu, XY; Bertram, PG; Zheng, XFS				Drenan, RM; Liu, XY; Bertram, PG; Zheng, XFS			FKBP12-rapamycin-associated protein or mammalian target of rapamycin (FRAP/mTOR) localization in the endoplasmic reticulum and the Golgi	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PIK-RELATED KINASES; TOR; PATHWAY; RAPTOR; COMPLEX; DOMAIN	FKBP12-rapamycin-associated protein ( FRAP) or mammalian target of rapamycin ( mTOR) and its effector proteins form a critical signaling pathway that regulates eukaryotic cell growth and proliferation. Although the protein components in this pathway have begun to be identified, little is known about their subcellular localization or the physiological significance of their localization. By immunofluorescence, we find that both endogenous and recombinant FRAP/mTOR proteins show localization predominantly in the endoplasmic reticulum ( ER) and the Golgi apparatus. Consistent with this finding, FRAP/mTOR is cofractionated with calnexin, an ER marker protein. Biochemical characterization suggests that FRAP/mTOR is a peripheral ER/Golgi protein with tight membrane association. Finally, we have identified domains of FRAP/mTOR which may mediate its association with the ER and the Golgi apparatus.	Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Mol Cell Biol Grad Program, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Zheng, XFS (corresponding author), Washington Univ, Sch Med, Dept Pathol & Immunol, 660 S Euclid Ave, St Louis, MO 63110 USA.	zheng@pathology.wustl.edu			NCI NIH HHS [R01CA77668, R01CA099004] Funding Source: Medline; NIGMS NIH HHS [R01GM62817] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077668, R01CA099004] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062817] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDRADE MA, 1995, NAT GENET, V11, P115, DOI 10.1038/ng1095-115; BOSSINI R, 2000, TRENDS BIOCHEM SCI, V25, P225; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; CHEN J, 1995, P NATL ACAD SCI USA, V92, P4947, DOI 10.1073/pnas.92.11.4947; Chiu VK, 2002, NAT CELL BIOL, V4, P343, DOI 10.1038/ncb783; Choi JH, 2002, EMBO REP, V3, P988, DOI 10.1093/embo-reports/kvf197; Choi JW, 1996, SCIENCE, V273, P239, DOI 10.1126/science.273.5272.239; Dennis PB, 2001, SCIENCE, V294, P1102, DOI 10.1126/science.1063518; Dennis PB, 1999, CURR OPIN GENET DEV, V9, P49, DOI 10.1016/S0959-437X(99)80007-0; Desai BN, 2002, P NATL ACAD SCI USA, V99, P4319, DOI 10.1073/pnas.261702698; Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4; Huang Shile, 2002, Curr Opin Investig Drugs, V3, P295; HUNTER T, 1995, CELL, V83, P1, DOI 10.1016/0092-8674(95)90225-2; KEITH CT, 1995, SCIENCE, V270, P50, DOI 10.1126/science.270.5233.50; Kim DH, 2003, MOL CELL, V11, P895, DOI 10.1016/S1097-2765(03)00114-X; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; Kim JE, 2000, P NATL ACAD SCI USA, V97, P14340, DOI 10.1073/pnas.011511898; Kuruvilla FG, 1999, CHEM BIOL, V6, pR129, DOI 10.1016/S1074-5521(99)80070-2; Marx SO, 2001, CIRCULATION, V104, P852, DOI 10.1161/01.CIR.104.8.852; McDaniel ML, 2002, DIABETES, V51, P2877, DOI 10.2337/diabetes.51.10.2877; Pahl HL, 1999, PHYSIOL REV, V79, P683, DOI 10.1152/physrev.1999.79.3.683; Perry J, 2003, CELL, V112, P151, DOI 10.1016/S0092-8674(03)00033-3; Powers T, 1999, MOL BIOL CELL, V10, P987, DOI 10.1091/mbc.10.4.987; Raught B, 2001, P NATL ACAD SCI USA, V98, P7037, DOI 10.1073/pnas.121145898; Rohde J, 2001, J BIOL CHEM, V276, P9583, DOI 10.1074/jbc.R000034200; Sabatini DM, 1999, SCIENCE, V284, P1161, DOI 10.1126/science.284.5417.1161; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; SEHGAL SN, 1995, THER DRUG MONIT, V17, P660, DOI 10.1097/00007691-199512000-00019; STAN R, 1994, J BIOL CHEM, V269, P32027; Tsang CK, 2003, EMBO J, V22, P6045, DOI 10.1093/emboj/cdg578; Wedaman KP, 2003, MOL BIOL CELL, V14, P1204, DOI 10.1091/mbc.E02-09-0609; Zaragoza D, 1998, MOL CELL BIOL, V18, P4463, DOI 10.1128/MCB.18.8.4463; Zhang XW, 2002, J BIOL CHEM, V277, P28127, DOI 10.1074/jbc.M202625200; ZHENG XF, 1995, CELL, V82, P121, DOI 10.1016/0092-8674(95)90058-6	34	126	134	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 2	2004	279	1					772	778		10.1074/jbc.M305912200	http://dx.doi.org/10.1074/jbc.M305912200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	757GU	14578359	hybrid			2022-12-27	WOS:000187555300092
J	Kamiya, T; Maeshima, M				Kamiya, T; Maeshima, M			Residues in internal repeats of the rice cation/H+ exchanger are involved in the transport and selection of cations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOLEMMAL NA+-CA2+ EXCHANGER; CA2+/H+ ANTIPORTER; SACCHAROMYCES-CEREVISIAE; STRUCTURAL DETERMINANTS; H+/CA2+ ANTIPORTER; NA+/CA2+ EXCHANGER; REENTRANT LOOP; SUBUNIT VPH1P; ARABIDOPSIS; YEAST	In plants, the cation/H+ exchanger (CAX) translocates Ca2+ and other metal ions into vacuoles using the H+ gradient formed by H+-ATPase and H+-pyrophosphatase. Such exchangers carrying 11 transmembrane domains (TMs) have been isolated from plants, yeast, and bacteria. In this study, multiple sequence alignment of several CAXs revealed the presence of highly conserved 36-residue regions between TM3 and TM4 and between TM8 and TM9. These two repetitive motifs are designated repeats c-1 and c-2. Using site-directed mutagenesis, we generated 31 mutations in the repeats of the Oryza sativa CAX, which translocates Ca2+ and Mn2+. Mutant exchangers were expressed in a Saccharomyces cerevisiae strain that is sensitive to Ca2+ and Mn2+ because of the absence of vacuolar Ca2+-ATPase and the Ca2+/H+ exchanger. Mutant exchangers were classified into six classes according to their tolerance for Ca2+ and Mn2+. For example, the class III mutants had no tolerance for either ion, and the class IV mutants had tolerance only for Ca2+. The biochemical function of each residue was estimated. We investigated the membrane topology of the repeats using a method combining cysteine mutagenesis and sulfhydryl reagents. Our results suggest that repeat c-1 re- enters the membrane from the vacuolar luminal side and forms a solution-accessible region. Furthermore, several residues in repeats c-1 and c-2 were found to be conserved in animal Na+/Ca2+ exchangers. Finally, we suggest that these reentrant repeats may form a vestibule or filter for cation selection.	Nagoya Univ, Grad Sch Bioagr Sci, Lab Cell Dynam, Nagoya, Aichi 4648601, Japan	Nagoya University	Maeshima, M (corresponding author), Nagoya Univ, Grad Sch Bioagr Sci, Lab Cell Dynam, Nagoya, Aichi 4648601, Japan.		Maeshima, Masayoshi/D-3073-2013; Kamiya, Takehiro/AAU-1703-2020	Maeshima, Masayoshi/0000-0002-1611-5481; Kamiya, Takehiro/0000-0003-3790-7119				Cunningham KW, 1996, MOL CELL BIOL, V16, P2226; Dutzler R, 2002, NATURE, V415, P287, DOI 10.1038/415287a; Hirschi K, 2001, TRENDS PLANT SCI, V6, P100, DOI 10.1016/S1360-1385(00)01863-X; Hirschi KD, 2000, PLANT PHYSIOL, V124, P125, DOI 10.1104/pp.124.1.125; Hirschi KD, 1996, P NATL ACAD SCI USA, V93, P8782, DOI 10.1073/pnas.93.16.8782; Iwamoto T, 2000, J BIOL CHEM, V275, P38571, DOI 10.1074/jbc.M003788200; Iwamoto T, 1999, FEBS LETT, V446, P264, DOI 10.1016/S0014-5793(99)00218-5; Kirsch RD, 1998, NUCLEIC ACIDS RES, V26, P1848, DOI 10.1093/nar/26.7.1848; Kwon SI, 1999, MOL CELLS, V9, P625; Leng XH, 1996, J BIOL CHEM, V271, P22487, DOI 10.1074/jbc.271.37.22487; Leng XH, 1999, J BIOL CHEM, V274, P14655, DOI 10.1074/jbc.274.21.14655; Maeshima M, 2001, ANNU REV PLANT PHYS, V52, P469, DOI 10.1146/annurev.arplant.52.1.469; Murata K, 2000, NATURE, V407, P599, DOI 10.1038/35036519; Nakanishi Y, 2001, J BIOL CHEM, V276, P7654, DOI 10.1074/jbc.M009743200; Nicoll DA, 1999, J BIOL CHEM, V274, P910, DOI 10.1074/jbc.274.2.910; Nicoll DA, 1996, J BIOL CHEM, V271, P13385, DOI 10.1074/jbc.271.23.13385; Pittman JK, 2002, J BIOL CHEM, V277, P26452, DOI 10.1074/jbc.M202563200; Pittman JK, 2002, PLANT PHYSIOL, V130, P1054, DOI 10.1104/pp.008193; Pittman JK, 2001, PLANT PHYSIOL, V127, P1020, DOI 10.1104/pp.010409; Qiu ZY, 2001, J BIOL CHEM, V276, P194, DOI 10.1074/jbc.M005571200; Rogner M, 1996, TRENDS BIOCHEM SCI, V21, P44, DOI 10.1016/0968-0004(96)80862-0; Sanders D, 1999, PLANT CELL, V11, P691, DOI 10.1105/tpc.11.4.691; SCHUMAKER KS, 1990, PLANT PHYSIOL, V92, P340, DOI 10.1104/pp.92.2.340; Schwarz EM, 1997, P NATL ACAD SCI USA, V94, P10249, DOI 10.1073/pnas.94.19.10249; Shigaki T, 2003, J BIOL CHEM, V278, P6610, DOI 10.1074/jbc.M209952200; Shigaki T, 2001, J BIOL CHEM, V276, P43152, DOI 10.1074/jbc.M106637200; Slotboom DJ, 1999, P NATL ACAD SCI USA, V96, P14282, DOI 10.1073/pnas.96.25.14282; Sze H, 2000, ANNU REV PLANT PHYS, V51, P433, DOI 10.1146/annurev.arplant.51.1.433; Sze H, 1999, PLANT CELL, V11, P677, DOI 10.1105/tpc.11.4.677; Tamura N, 2001, J BIOL CHEM, V276, P20330, DOI 10.1074/jbc.M007993200; TANAKA K, 1990, MOL CELL BIOL, V10, P4303, DOI 10.1128/MCB.10.8.4303; Ueoka-Nakanishi H, 1999, EUR J BIOCHEM, V262, P417, DOI 10.1046/j.1432-1327.1999.00377.x; Ueoka-Nakanishi H, 2000, EUR J BIOCHEM, V267, P3090, DOI 10.1046/j.1432-1033.2000.01343.x; Wakabayashi S, 2000, J BIOL CHEM, V275, P7942, DOI 10.1074/jbc.275.11.7942	34	69	81	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	2004	279	1					812	819		10.1074/jbc.M309726200	http://dx.doi.org/10.1074/jbc.M309726200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	757GU	14561741	hybrid			2022-12-27	WOS:000187555300097
J	Swaminath, G; Xiang, Y; Lee, TW; Steenhuis, J; Parnot, C; Kobilka, BK				Swaminath, G; Xiang, Y; Lee, TW; Steenhuis, J; Parnot, C; Kobilka, BK			Sequential binding of agonists to the beta(2) adrenoceptor - Kinetic evidence for intermediate conformational states	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA(2) ADRENERGIC-RECEPTOR; PROTEIN-COUPLED RECEPTOR; LIGHT-DEPENDENT CHANGES; HUMAN BETA-2-ADRENERGIC RECEPTOR; CONSTITUTIVE ACTIVATION; TRANSMEMBRANE SEGMENT-6; STRUCTURAL INSTABILITY; CYTOPLASMIC DOMAINS; RHODOPSIN; SITE	The beta(2) adrenoreceptor (beta(2)AR) is a prototypical G protein-coupled receptor (GPCR) activated by catecholamines. Agonist activation of GPCRs leads to sequential interactions with heterotrimeric G proteins, which activate cellular signaling cascades, and with GPCR kinases and arrestins, which attenuate GPCR-mediated signaling. We used fluorescence spectroscopy to monitor catecholamine-induced conformational changes in purified beta(2)AR. Here we show that upon catecholamine binding, beta(2)ARs undergo transitions to two kinetically distinguishable conformational states. Using a panel of chemically related catechol derivatives, we identified the specific chemical groups on the agonist responsible for the rapid and slow conformational changes in the receptor. The conformational changes observed in our biophysical assay were correlated with biologic responses in cellular assays. Dopamine, which induces only a rapid conformational change, is efficient at activating G(s) but not receptor internalization. In contrast, norepinephrine and epinephrine, which induce both rapid and slow conformational changes, are efficient at activating G(s) and receptor internalization. These results support a mechanistic model for GPCR activation where contacts between the receptor and structural determinants of the agonist stabilize a succession of conformational states with distinct cellular functions.	Stanford Univ, Dept Cellular & Mol Physiol, Stanford, CA 94305 USA	Stanford University	Kobilka, BK (corresponding author), Stanford Univ, Dept Cellular & Mol Physiol, Stanford, CA 94305 USA.			Kobilka, Brian/0000-0001-5958-3990; Parnot, Charles/0000-0002-7346-5883				Altenbach C, 1999, BIOCHEMISTRY-US, V38, P7931, DOI 10.1021/bi9900121; Altenbach C, 1999, BIOCHEMISTRY-US, V38, P7945, DOI 10.1021/bi990014l; Altenbach C, 2001, BIOCHEMISTRY-US, V40, P15493, DOI 10.1021/bi011545o; Dunham TD, 1999, J BIOL CHEM, V274, P1683, DOI 10.1074/jbc.274.3.1683; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; Gether U, 1997, EMBO J, V16, P6737, DOI 10.1093/emboj/16.22.6737; Gether U, 1997, J BIOL CHEM, V272, P2587, DOI 10.1074/jbc.272.5.2587; Ghanouni P, 2001, P NATL ACAD SCI USA, V98, P5997, DOI 10.1073/pnas.101126198; Ghanouni P, 2001, J BIOL CHEM, V276, P24433, DOI 10.1074/jbc.C100162200; Javitch JA, 1997, J BIOL CHEM, V272, P18546, DOI 10.1074/jbc.272.30.18546; Jensen AD, 2001, J BIOL CHEM, V276, P9279, DOI 10.1074/jbc.M004871200; Ji TH, 1998, J BIOL CHEM, V273, P17299, DOI 10.1074/jbc.273.28.17299; Keith DE, 1996, J BIOL CHEM, V271, P19021, DOI 10.1074/jbc.271.32.19021; Kenakin T, 2001, FASEB J, V15, P598, DOI 10.1096/fj.00-0438rev; Kenakin T, 2003, TRENDS PHARMACOL SCI, V24, P346, DOI 10.1016/S0165-6147(03)00167-6; KOBILKA BK, 1990, J BIOL CHEM, V265, P7610; KOBILKA BK, 1995, ANAL BIOCHEM, V231, P269, DOI 10.1006/abio.1995.1533; LEFKOWITZ RJ, 1993, TRENDS PHARMACOL SCI, V14, P303, DOI 10.1016/0165-6147(93)90048-O; Liapakis G, 2000, J BIOL CHEM, V275, P37779, DOI 10.1074/jbc.M002092200; LIGGETT SB, 1991, J BIOL CHEM, V266, P4816; Lin SW, 1996, BIOCHEMISTRY-US, V35, P11149, DOI 10.1021/bi960858u; Luttrell LM, 2002, J CELL SCI, V115, P455; Neumann L, 2002, CHEMBIOCHEM, V3, P993, DOI 10.1002/1439-7633(20021004)3:10<993::AID-CBIC993>3.0.CO;2-Y; ODOWD BF, 1988, J BIOL CHEM, V263, P15985; Palanche T, 2001, J BIOL CHEM, V276, P34853, DOI 10.1074/jbc.M104363200; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Parnot C, 2002, TRENDS ENDOCRIN MET, V13, P336, DOI 10.1016/S1043-2760(02)00628-8; Rasmussen SGF, 1999, MOL PHARMACOL, V56, P175, DOI 10.1124/mol.56.1.175; Sheikh SP, 1999, J BIOL CHEM, V274, P17033, DOI 10.1074/jbc.274.24.17033; STRADER CD, 1989, FASEB J, V3, P1825, DOI 10.1096/fasebj.3.7.2541037; Swaminath G, 2003, J BIOL CHEM, V278, P352, DOI 10.1074/jbc.M206424200; Ward SDC, 2002, J BIOL CHEM, V277, P2247, DOI 10.1074/jbc.M107647200; Weiss JM, 1996, J THEOR BIOL, V181, P381, DOI 10.1006/jtbi.1996.0139; Wieland K, 1996, P NATL ACAD SCI USA, V93, P9276, DOI 10.1073/pnas.93.17.9276	34	287	300	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	2004	279	1					686	691		10.1074/jbc.M310888200	http://dx.doi.org/10.1074/jbc.M310888200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	757GU	14559905	hybrid			2022-12-27	WOS:000187555300082
J	Nguyen, DG; Booth, A; Gould, SJ; Hildreth, JEK				Nguyen, DG; Booth, A; Gould, SJ; Hildreth, JEK			Evidence that HIV budding in primary macrophages occurs through the exosome release pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; LIPID RAFT MICRODOMAINS; CELL-DERIVED EXOSOMES; MONOCLONAL-ANTIBODIES; MEMBRANE CHOLESTEROL; EPITHELIAL-CELLS; HUMAN-MONOCYTES; B-LYMPHOCYTES; HOST-CELLS; IN-VIVO	Lipid rafts are specialized regions of cell membranes enriched in cholesterol and sphingolipids that are involved in immune activation and signaling. Studies in T-cells indicate that these membrane domains serve as sites for release of human immunodeficiency virus (HIV). By budding through lipid rafts in T-cells, HIV selectively incorporates raft markers and excludes non-raft proteins. This process has been well studied in T-cells, but it is unknown whether lipid rafts serve as budding sites for HIV in macrophages. Recently, we proposed a new model of retroviral biogenesis called the Trojan exosome hypothesis (Gould, S. J., Booth, A., and Hildreth, J. E. K. (2003) Proc. Natl. Acad. Sci. U. S. A. 100, 10592-10597). This model proposes that retroviruses co-opt the existing cellular machinery for exosomal release. Here, we performed the first test designed to differentiate between the lipid raft hypothesis of retroviral biogenesis and the Trojan exosome hypothesis. Using macrophages, we examined the relative abundance of several host proteins on the cell surface, in lipid rafts, and on both HIV particles and exosomes derived from these cells. Our results show significant differences in the abundance of host proteins on the cell surface and in HIV. Moreover, our data demonstrate discordance in the abundance of some proteins in lipid rafts and in HIV. Finally, our data reveal a strong concordance between the host cell protein profile of exosomes and that of HIV. These results strongly support the Trojan exosome hypothesis and its prediction that retroviral budding represents exploitation of a pre-existing cellular pathway of intercellular vesicle trafficking.	Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA	Johns Hopkins University	Hildreth, JEK (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Physiol Bldg,Rm 320A,725 N Wolfe St, Baltimore, MD 21205 USA.			Nguyen, Deborah/0000-0002-1694-0617				Andre F, 2002, VACCINE, V20, pA28, DOI 10.1016/S0264-410X(02)00384-5; AZORSA DO, 1991, BLOOD, V78, P280; Bavari S, 2002, J EXP MED, V195, P593, DOI 10.1084/jem.20011500; Bess JW, 1997, VIROLOGY, V230, P134, DOI 10.1006/viro.1997.8499; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Campbell SM, 2001, J CLIN VIROL, V22, P217, DOI 10.1016/S1386-6532(01)00193-7; Canki M, 2000, AIDS RES HUM RETROV, V16, P453, DOI 10.1089/088922200309115; Conaldi PG, 1998, J CLIN INVEST, V102, P2041, DOI 10.1172/JCI3480; Douek DC, 2002, NATURE, V417, P95, DOI 10.1038/417095a; Escola JM, 1998, J BIOL CHEM, V273, P20121, DOI 10.1074/jbc.273.32.20121; Esser MT, 2001, J VIROL, V75, P6173, DOI 10.1128/JVI.75.13.6173-6182.2001; Fazeley F, 1997, ARCH VIROL, V142, P2237, DOI 10.1007/s007050050238; Flaherty MT, 1998, AIDS RES HUM RETROV, V14, P163, DOI 10.1089/aid.1998.14.163; Frank I, 1996, AIDS, V10, P1611, DOI 10.1097/00002030-199612000-00004; Garrus JE, 2001, CELL, V107, P55, DOI 10.1016/S0092-8674(01)00506-2; Gousset K, 2002, J CELL PHYSIOL, V190, P117, DOI 10.1002/jcp.10039; Graham DRM, 2003, J VIROL, V77, P8237, DOI 10.1128/JVI.77.15.8237-8248.2003; GUO MML, 1995, AIDS RES HUM RETROV, V11, P1007, DOI 10.1089/aid.1995.11.1007; Guyader M, 2002, J VIROL, V76, P10356, DOI 10.1128/JVI.76.20.10356-10364.2002; Hildreth JEK, 1999, HYBRIDOMA, V18, P437, DOI 10.1089/hyb.1999.18.437; HOUSSET C, 1993, J HEPATOL, V19, P252, DOI 10.1016/S0168-8278(05)80579-3; Hwang IY, 2003, P NATL ACAD SCI USA, V100, P6670, DOI 10.1073/pnas.1131852100; IKEUCHI K, 1990, J VIROL, V64, P4226, DOI 10.1128/JVI.64.9.4226-4231.1990; Ilangumaran S, 1996, ANAL BIOCHEM, V235, P49, DOI 10.1006/abio.1996.0090; Lawn SD, 2000, J VIROL, V74, P139, DOI 10.1128/JVI.74.1.139-145.2000; LI QG, 1995, J ACQ IMMUN DEF SYND, V9, P103; Liao ZH, 2001, AIDS RES HUM RETROV, V17, P1009, DOI 10.1089/088922201300343690; Liao ZH, 2003, AIDS RES HUM RETROV, V19, P675, DOI 10.1089/088922203322280900; MANE SM, 1989, ARCH BIOCHEM BIOPHYS, V268, P360, DOI 10.1016/0003-9861(89)90597-3; Manie SN, 2000, J VIROL, V74, P305, DOI 10.1128/JVI.74.1.305-311.2000; Meltzer M S, 1992, Curr Top Microbiol Immunol, V181, P239; Nguyen DH, 2000, J VIROL, V74, P3264, DOI 10.1128/JVI.74.7.3264-3272.2000; ORENSTEIN JM, 1988, J VIROL, V62, P2578, DOI 10.1128/JVI.62.8.2578-2586.1988; ORENTAS RJ, 1992, J LEUKOCYTE BIOL, V51, P199, DOI 10.1002/jlb.51.3.199; Pelchen-Matthews A, 2003, J CELL BIOL, V162, P443, DOI 10.1083/jcb.200304008; Peters BS, 2001, VACCINE, V20, P688, DOI 10.1016/S0264-410X(01)00394-2; Pinto LA, 1998, BLOOD, V92, P3346, DOI 10.1182/blood.V92.9.3346.421k40_3346_3354; Raposo G, 1996, J EXP MED, V183, P1161, DOI 10.1084/jem.183.3.1161; Raposo G, 2002, TRAFFIC, V3, P718, DOI 10.1034/j.1600-0854.2002.31004.x; Raulin J, 2002, PROG LIPID RES, V41, P27, DOI 10.1016/S0163-7827(01)00019-4; Rodgers W, 1996, J CELL BIOL, V135, P1515, DOI 10.1083/jcb.135.6.1515; Saifuddin M, 1997, J GEN VIROL, V78, P1907, DOI 10.1099/0022-1317-78-8-1907; Schartz NEC, 2002, CURR OPIN MOL THER, V4, P372; Schubert U, 1996, FEBS LETT, V398, P12, DOI 10.1016/S0014-5793(96)01146-5; SEDWICK CE, 2002, SCI STKE; Spruth M, 1999, AIDS RES HUM RETROV, V15, P533, DOI 10.1089/088922299311051; Stoorvogel W, 2002, TRAFFIC, V3, P321, DOI 10.1034/j.1600-0854.2002.30502.x; Strack B, 2000, P NATL ACAD SCI USA, V97, P13063, DOI 10.1073/pnas.97.24.13063; Thery C, 2002, NAT REV IMMUNOL, V2, P569, DOI 10.1038/nri855; UGOLINI V, 1980, P NATL ACAD SCI-BIOL, V77, P6764, DOI 10.1073/pnas.77.11.6764; Viard M, 2002, J VIROL, V76, P11584, DOI 10.1128/JVI.76.22.11584-11595.2002; Wubbolts R, 2003, J BIOL CHEM, V278, P10963, DOI 10.1074/jbc.M207550200; Zitvogel L, 1998, NAT MED, V4, P594, DOI 10.1038/nm0598-594	55	252	263	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52347	52354		10.1074/jbc.M309009200	http://dx.doi.org/10.1074/jbc.M309009200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14561735	hybrid			2022-12-27	WOS:000187480700045
J	Oram, JF; Wolfbauer, G; Vaughan, AM; Tang, CR; Albers, JJ				Oram, JF; Wolfbauer, G; Vaughan, AM; Tang, CR; Albers, JJ			Phospholipid transfer protein interacts with and stabilizes ATP-binding cassette transporter A1 and enhances cholesterol efflux from cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; APOLIPOPROTEIN-MEDIATED REMOVAL; AMPHIPATHIC HELICAL PEPTIDES; MESSENGER-RNA LEVELS; CELLULAR CHOLESTEROL; TANGIER-DISEASE; ABCA1; GENE; MUTATIONS; RECEPTOR	Phospholipid lipid transfer protein (PLTP) is ubiquitously expressed in animal tissues and plays multiple roles in lipoprotein metabolism, but the function of peripheral PLTP is still poorly understood. Here we show that one of its possible functions is to transport cholesterol and phospholipids from cells to lipoprotein particles by a process involving PLTP interactions with cellular ATP-binding cassette transporter A1 (ABCA1). When ABCA1 was induced in murine macrophages or ABCA1-transfected baby hamster kidney cells, PLTP gained the ability to promote cholesterol and phospholipid efflux from cells. Although PLTP alone had lipid efflux activity, its maximum activity was observed in the presence of high density lipoprotein particles. Pulse-chase studies showed that the interaction of PLTP with ABCA1-expressing cells played a role in promoting lipid efflux. Overexpression of ABCA1 dramatically increased binding of both PLTP and apoA-I to common sites on the cell surface. Both PLTP and apoA-I were covalently cross-linked to ABCA1, each protein blocked cross-linking of the other, and both PLTP and apoA-I stabilized ABCA1 protein. These results are consistent with PLTP and apoA-I binding to ABCA1 at the same or closely related sites. Thus, PLTP mimics apolipoproteins in removing cellular lipids by the ABCA1 pathway, except that PLTP acts more as an intermediary in the transfer of cellular lipids to lipoprotein particles.	Univ Washington, Dept Med, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Albers, JJ (corresponding author), Univ Washington, Dept Med, Box 356426, Seattle, WA 98195 USA.	jja@u.washington.edu			NHLBI NIH HHS [HL55362, HL30086, HL18645] Funding Source: Medline; NIDDK NIH HHS [DK02456] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL018645, P01HL030086, R01HL055362] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBERS JJ, 1995, BBA-LIPID LIPID MET, V1258, P27, DOI 10.1016/0005-2760(95)00091-P; Arakawa R, 2002, J BIOL CHEM, V277, P22426, DOI 10.1074/jbc.M202996200; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Bortnick AE, 2000, J BIOL CHEM, V275, P28634, DOI 10.1074/jbc.M003407200; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Cao GQ, 2002, J BIOL CHEM, V277, P39561, DOI 10.1074/jbc.M207187200; Chambenoit O, 2001, J BIOL CHEM, V276, P9955, DOI 10.1074/jbc.M010265200; Cheung MC, 1996, BBA-LIPID LIPID MET, V1303, P103, DOI 10.1016/0005-2760(96)00082-3; DAY JR, 1994, J BIOL CHEM, V269, P9388; Fitzgerald ML, 2002, J BIOL CHEM, V277, P33178, DOI 10.1074/jbc.M204996200; FRANCIS GA, 1995, J CLIN INVEST, V96, P78, DOI 10.1172/JCI118082; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; Haghpassand M, 2001, J CLIN INVEST, V108, P1315, DOI 10.1172/JCI200112810; Hailman E, 1996, J BIOL CHEM, V271, P12172, DOI 10.1074/jbc.271.21.12172; Huuskonen J, 1999, J LIPID RES, V40, P1123; Huuskonen J, 2000, CURR OPIN LIPIDOL, V11, P285, DOI 10.1097/00041433-200006000-00009; JAUHIAINEN M, 1993, J BIOL CHEM, V268, P4032; JIANG XC, 1995, J BIOL CHEM, V270, P17133, DOI 10.1074/jbc.270.29.17133; Jiang XC, 1999, J CLIN INVEST, V103, P907, DOI 10.1172/JCI5578; Jiang XC, 2001, NAT MED, V7, P847, DOI 10.1038/89977; Jiang XC, 1996, J CLIN INVEST, V98, P2373, DOI 10.1172/JCI119050; Laffitte BA, 2003, MOL CELL BIOL, V23, P2182, DOI 10.1128/MCB.23.6.2182-2191.2003; Lawn RM, 1999, J CLIN INVEST, V104, pR25, DOI 10.1172/JCI8119; Mak PA, 2002, J LIPID RES, V43, P2037, DOI 10.1194/jlr.C200014-JLR200; Mendez AJ, 1997, BBA-LIPID LIPID MET, V1346, P285, DOI 10.1016/S0005-2760(97)00031-3; MENDEZ AJ, 1994, J CLIN INVEST, V94, P1698, DOI 10.1172/JCI117515; MENDEZ AJ, 1991, J BIOL CHEM, V266, P10104; O'Brien KD, 2003, CIRCULATION, V108, P270, DOI 10.1161/01.CIR.0000079163.97653.CD; Oram JF, 2000, J BIOL CHEM, V275, P34508, DOI 10.1074/jbc.M006738200; Oram JF, 1999, J LIPID RES, V40, P1769; Oram JF, 2003, ARTERIOSCL THROM VAS, V23, P720, DOI 10.1161/01.ATV.0000054662.44688.9A; Oram JF, 1996, J LIPID RES, V37, P2473; Remaley AT, 2003, J LIPID RES, V44, P828, DOI 10.1194/jlr.M200475-JLR200; Rothblat GH, 1999, J LIPID RES, V40, P781; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; Smith JD, 1996, J BIOL CHEM, V271, P30647, DOI 10.1074/jbc.271.48.30647; TU AY, 1993, J BIOL CHEM, V268, P23098; van Haperen R, 2002, J BIOL CHEM, V277, P48938, DOI 10.1074/jbc.M209128200; van Tol A, 2002, CURR OPIN LIPIDOL, V13, P135, DOI 10.1097/00041433-200204000-00004; Vaughan AM, 2003, J LIPID RES, V44, P1373, DOI 10.1194/jlr.M300078-JLR200; Wang N, 2000, J BIOL CHEM, V275, P33053, DOI 10.1074/jbc.M005438200; Wang N, 2003, J CLIN INVEST, V111, P99, DOI 10.1172/JCI200316808; Wang XJ, 2002, J BIOL CHEM, V277, P15697, DOI 10.1074/jbc.M112068200; Wolfbauer G, 1999, BBA-MOL CELL BIOL L, V1439, P65, DOI 10.1016/S1388-1981(99)00077-3; YANCEY PG, 1995, BIOCHEMISTRY-US, V34, P7955, DOI 10.1021/bi00024a021	45	127	131	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52379	52385		10.1074/jbc.M310695200	http://dx.doi.org/10.1074/jbc.M310695200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14559902	hybrid			2022-12-27	WOS:000187480700049
J	Lundgren, S; Gojkovic, Z; Piskur, J; Dobritzsch, D				Lundgren, S; Gojkovic, Z; Piskur, J; Dobritzsch, D			Yeast beta-alanine synthase shares a structural scaffold and origin with dizinc-dependent exopeptidases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID AMIDOHYDROLASE; CRYSTAL-STRUCTURE; AMINOPEPTIDASE; ENZYME; 5-FLUOROURACIL; PYRIMIDINES; REPLACEMENT; DEGRADATION; REFINEMENT; CATABOLISM	beta-Alanine synthase (betaAS) is the final enzyme of the reductive pyrimidine catabolic pathway, which is responsible for the breakdown of pyrimidine bases, including several anticancer drugs. In eukaryotes, betaASs belong to two subfamilies, which exhibit a low degree of sequence similarity. We determined the structure of betaAS from Saccharomyces kluyveri to a resolution of 2.7 Angstrom. The subunit of the homodimeric enzyme consists of two domains: a larger catalytic domain with a dizinc metal center, which represents the active site of betaAS, and a smaller domain mediating the majority of the intersubunit contacts. Both domains exhibit a mixed alpha/beta-topology. Surprisingly, the observed high structural homology to a family of dizinc-dependent exopeptidases suggests that these two enzyme groups have a common origin. Alterations in the ligand composition of the metal-binding site can be explained as adjustments to the catalysis of a different reaction, the hydrolysis of an N-carbamyl bond by betaAS compared with the hydrolysis of a peptide bond by exopeptidases. In contrast, there is no resemblance to the three-dimensional structure of the functionally closely related N-carbamyl-D-amino acid amidohydrolases. Based on comparative structural analysis and observed deviations in the backbone conformations of the eight copies of the subunit in the asymmetric unit, we suggest that conformational changes occur during each catalytic cycle.	Karolinska Inst, Dept Med Biochem & Biophys, Div Mol Struct Biol, S-17177 Stockholm, Sweden; Tech Univ Denmark, BioCentrum DTU, DK-2800 Lyngby, Denmark	Karolinska Institutet; Technical University of Denmark	Dobritzsch, D (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, Div Mol Struct Biol, Tomtebodavagen 6, S-17177 Stockholm, Sweden.	Doreen.Dobritzsch@mbb.ki.se	Dobritzsch, Doreen/H-7334-2018					BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Biagini A, 2001, COMP BIOCHEM PHYS B, V128, P469, DOI 10.1016/S1096-4959(00)00341-9; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Christianson DW, 1996, ACCOUNTS CHEM RES, V29, P331, DOI 10.1021/ar9501232; Cowtan KD, 1996, ACTA CRYSTALLOGR D, V52, P43, DOI 10.1107/S090744499500761X; CRONAN JE, 1982, J BACTERIOL, V149, P916, DOI 10.1128/JB.149.3.916-922.1982; De Paola CC, 1999, BIOCHEMISTRY-US, V38, P9048, DOI 10.1021/bi9900572; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Dobritzsch D, 2003, ACTA CRYSTALLOGR D, V59, P1267, DOI 10.1107/S0907444903009120; ENNA SJ, 1983, INT REV NEUROBIOL, V24, P181, DOI 10.1016/S0074-7742(08)60222-6; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Gilboa R, 2001, PROTEINS, V44, P490, DOI 10.1002/prot.1115; Gojkovic Z, 2001, GENETICS, V158, P999; Gojkovic Z, 1998, ADV EXP MED BIOL, V431, P475; Hakansson K, 2002, EUR J BIOCHEM, V269, P443, DOI 10.1046/j.0014-2956.2001.02665.x; HEGGIE GD, 1987, CANCER RES, V47, P2203; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Jozic D, 2002, STRUCTURE, V10, P1097, DOI 10.1016/S0969-2126(02)00805-5; Kissinger CR, 1999, ACTA CRYSTALLOGR D, V55, P484, DOI 10.1107/S0907444998012517; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KVALNESKRICK KL, 1993, J BIOL CHEM, V268, P5686; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lipscomb WN, 1996, CHEM REV, V96, P2375, DOI 10.1021/cr950042j; Lu GG, 2000, J APPL CRYSTALLOGR, V33, P176, DOI 10.1107/S0021889899012339; MATTHEWS MM, 1987, J BIOL CHEM, V262, P7232; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MILANO G, 1994, ANTICANCER RES, V14, P2295; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nakai T, 2000, STRUCTURE, V8, P729, DOI 10.1016/S0969-2126(00)00160-X; RAWLINGS ND, 1995, METHOD ENZYMOL, V248, P183; Rowsell S, 1997, STRUCTURE, V5, P337, DOI 10.1016/S0969-2126(97)00191-3; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Traut TW, 1996, PROG NUCLEIC ACID RE, V53, P1, DOI 10.1016/S0079-6603(08)60142-7; vanGennip AH, 1997, J INHERIT METAB DIS, V20, P203, DOI 10.1023/A:1005356806329; Walsh TA, 2001, PLANT PHYSIOL, V125, P1001, DOI 10.1104/pp.125.2.1001; Wang DS, 2003, INT J NEUROSCI, V113, P293, DOI 10.1080/00207450390162092; Wang WC, 2001, J MOL BIOL, V306, P251, DOI 10.1006/jmbi.2000.4380; WASTERNACK C, 1980, PHARMACOL THERAPEUT, V8, P629, DOI 10.1016/0163-7258(80)90079-0; WILLIAMSON JM, 1979, J BIOL CHEM, V254, P8074	40	39	39	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51851	51862		10.1074/jbc.M308674200	http://dx.doi.org/10.1074/jbc.M308674200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14534321	hybrid			2022-12-27	WOS:000187206300121
J	Zhou, YP; Marlen, K; Palma, JF; Schweitzer, A; Reilly, L; Gregoire, FM; Xu, GG; Blume, JE; Johnson, JD				Zhou, YP; Marlen, K; Palma, JF; Schweitzer, A; Reilly, L; Gregoire, FM; Xu, GG; Blume, JE; Johnson, JD			Overexpression of repressive cAMP response element modulators in high glucose and fatty acid-treated rat islets - A common mechanism for glucose toxicity and lipotoxicity?	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC BETA-CELLS; INSULIN GENE-TRANSCRIPTION; CHRONIC HYPERGLYCEMIA; DIABETES-MELLITUS; ELEVATED GLUCOSE; DYSFUNCTION; EXPRESSION; SECRETION; DECREASE; EXPOSURE	The hyperlipidemia and hyperglycemia of the diabetic state accelerate beta-cell dysfunction, yet the mechanisms are not fully defined. We used rat islet-specific oligonucleotide arrays (Metabolex Rat Islet Genechips) to identify genes that are coordinately regulated by high glucose and free fatty acids (FFA). Exposure of rat islets to FFA (125 muM for 2 days) or glucose (27 mM for 4 days) reduced glucose-stimulated insulin secretion by 70 +/- 5 and 40 +/- 4%, respectively, relative to control-cultured islets. These treatments also substantially reduced the insulin content of the islets. Islet Genechips analysis revealed that the mRNA levels of cAMP response element modulator (CREM)-17X and inducible cAMP early repressor were significantly increased in both 27 mM glucose- and FFA-treated islets. Removing FFA or high glucose from the culture medium restored glucose- stimulated insulin secretion and the mRNA levels of the two CREM repressors to normal. Northern blot analysis revealed a 5-fold increase in the abundance of CREM-17X mRNA and a concomitant 50% reduction in the insulin mRNA in FFA-treated islets. Transient transfection of the insulin-secreting betaHC9 cells with CREM-17X suppressed rat insulin promoter activity by nearly 50%. Overexpression of CREM-17X in intact islets via adenovirus infection decreased islet insulin mRNA levels and insulin content and resulted in a significant decrease in glucose- or KCl-induced insulin secretion. Taken together, these data suggest that up-regulation of CREM repressors by either FFA or high glucose exacerbates beta-cell failure in type 2 diabetes by suppressing insulin gene transcription.	Metabolex Inc, Dept Insulin Secret Gen, Hayward, CA 94545 USA		Zhou, YP (corresponding author), Merck Res Labs, Rahway, NJ 07065 USA.			Blume, John/0000-0003-3026-953X				Bell GI, 2001, NATURE, V414, P788, DOI 10.1038/414788a; Bjorklund A, 1999, DIABETES, V48, P1409, DOI 10.2337/diabetes.48.7.1409; Edlund H, 2002, NAT REV GENET, V3, P524, DOI 10.1038/nrg841; Gremlich S, 1997, J BIOL CHEM, V272, P30261, DOI 10.1074/jbc.272.48.30261; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hoorens A, 1996, J CLIN INVEST, V98, P1568, DOI 10.1172/JCI118950; Inada A, 1998, BIOCHEM BIOPH RES CO, V253, P712, DOI 10.1006/bbrc.1998.9833; Inada A, 1999, J BIOL CHEM, V274, P21095, DOI 10.1074/jbc.274.30.21095; Jonas JC, 1999, J BIOL CHEM, V274, P14112, DOI 10.1074/jbc.274.20.14112; Juhl CB, 2003, J CLIN ENDOCR METAB, V88, P3794, DOI 10.1210/jc.2002-021181; LACY PE, 1967, DIABETES, V16, P35, DOI 10.2337/diab.16.1.35; LEAHY JL, 1992, DIABETES CARE, V15, P442, DOI 10.2337/diacare.15.3.442; Liang Y, 1996, AM J PHYSIOL-ENDOC M, V270, pE846, DOI 10.1152/ajpendo.1996.270.5.E846; Ling ZD, 1996, DIABETES, V45, P1774, DOI 10.2337/diabetes.45.12.1774; Liu YQ, 1998, DIABETES, V47, P1889, DOI 10.2337/diabetes.47.12.1889; Marshak S, 1999, DIABETES, V48, P1230, DOI 10.2337/diabetes.48.6.1230; Melloul D, 2002, DIABETOLOGIA, V45, P309, DOI 10.1007/s00125-001-0728-y; Porte D, 2001, DIABETES, V50, pS160, DOI 10.2337/diabetes.50.2007.S160; Roduit R, 2000, J BIOL CHEM, V275, P35799, DOI 10.1074/jbc.M006001200; Seufert J, 1998, J CLIN INVEST, V101, P2528, DOI 10.1172/JCI2401; STURIS J, 1994, AM J PHYSIOL, V267, pE250, DOI 10.1152/ajpendo.1994.267.2.E250; TOKUYAMA Y, 1995, DIABETES, V44, P1447, DOI 10.2337/diabetes.44.12.1447; TURNER RC, 1995, DIABETES, V44, P1249; UNGER RH, 1995, DIABETES, V44, P863, DOI 10.2337/diabetes.44.8.863; WALKER WH, 1994, P NATL ACAD SCI USA, V91, P12423, DOI 10.1073/pnas.91.26.12423; ZHOU YP, 1994, J CLIN INVEST, V93, P870, DOI 10.1172/JCI117042; Zhou YP, 1996, DIABETES, V45, P580, DOI 10.2337/diabetes.45.5.580	28	54	70	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51316	51323		10.1074/jbc.M307972200	http://dx.doi.org/10.1074/jbc.M307972200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14534319	hybrid			2022-12-27	WOS:000187206300059
J	Chen, YW; Allen, MD; Veprintsev, DB; Lowe, J; Bycroft, M				Chen, YW; Allen, MD; Veprintsev, DB; Lowe, J; Bycroft, M			The structure of the AXH domain of spinocerebellar ataxin-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOBLASTOMA TUMOR-SUPPRESSOR; RNA-BINDING DOMAIN; CRYSTAL-STRUCTURE; TRANSCRIPTIONAL REPRESSOR; PROTEIN; IDENTIFICATION; INTERACTS; HBP1; RECOGNITION; EXPRESSION	Spinocerebellar ataxia type 1 is a late-onset neurodegenerative disease caused by the expansion of a CAG triplet repeat in the SCA1 gene. This results in the lengthening of a polyglutamine tract in the gene product ataxin-1. This produces a toxic gain of function that results in specific neuronal death. A region in ataxin-1, the AXH domain, exhibits significant sequence similarity to the transcription factor HBP1. This region of the protein has been implicated in RNA binding and self-association. We have determined the crystal structure of the AXH domain of ataxin-1. The AXH domain is dimeric and contains an OB-fold, a structural motif found in many oligonucleotide-binding proteins, supporting its proposed role in RNA binding. By structure comparison with other proteins that contain an OB-fold, a putative RNA-binding site has been identified. We also identified a cluster of charged surface residues that are well conserved among AXH domains. These residues may constitute a second ligand-binding surface, suggesting that all AXH domains interact with a common yet unidentified partner.	Univ Cambridge, MRC Ctr, Ctr Prot Engn, Cambridge CB2 2QH, England; Univ Cambridge, MRC Ctr, Mol Biol Lab, Cambridge CB2 2QH, England	MRC Laboratory Molecular Biology; University of Cambridge; MRC Laboratory Molecular Biology; University of Cambridge	Bycroft, M (corresponding author), Univ Cambridge, MRC Ctr, Ctr Prot Engn, Hills Rd, Cambridge CB2 2QH, England.	mb10031@cus.cam.ac.uk	Löwe, Jan/B-3882-2011; Chen, Yu Wai/AAJ-8037-2020; Bycroft, Mark/D-9446-2017; Veprintsev, Dmitry B/H-2228-2012; Löwe, Jan/X-6998-2019	Chen, Yu Wai/0000-0001-7833-7533; Veprintsev, Dmitry B/0000-0002-3583-5409; Bycroft, Mark/0000-0002-0673-2216; Lowe, Jan/0000-0002-5218-6615				Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; Agrawal V, 2001, BMC Struct Biol, V1, P5, DOI 10.1186/1472-6807-1-5; Andersen AA, 2003, CURR OPIN CELL BIOL, V15, P281, DOI 10.1016/S0955-0674(03)00041-3; Arcus V, 2002, CURR OPIN STRUC BIOL, V12, P794, DOI 10.1016/S0959-440X(02)00392-5; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Battiste JL, 2000, MOL CELL, V5, P109, DOI 10.1016/S1097-2765(00)80407-4; Bogden CE, 1999, MOL CELL, V3, P487, DOI 10.1016/S1097-2765(00)80476-1; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Burright EN, 1997, HUM MOL GENET, V6, P513, DOI 10.1093/hmg/6.4.513; Bycroft M, 1997, CELL, V88, P235, DOI 10.1016/S0092-8674(00)81844-9; Chen HK, 2003, CELL, V113, P457, DOI 10.1016/S0092-8674(03)00349-0; de Chiara C, 2003, FEBS LETT, V551, P107, DOI 10.1016/S0014-5793(03)00818-4; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Deo RC, 2002, CELL, V108, P71, DOI 10.1016/S0092-8674(01)00632-8; Fernandez-Funez P, 2000, NATURE, V408, P101, DOI 10.1038/35040584; Glaser F, 2003, BIOINFORMATICS, V19, P163, DOI 10.1093/bioinformatics/19.1.163; Hong S, 2002, MOL CELL NEUROSCI, V20, P298, DOI 10.1006/mcne.2002.1103; Hong SG, 2003, BBA-MOL BASIS DIS, V1638, P35, DOI 10.1016/S0925-4439(03)00038-3; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kim HY, 2001, EMBO J, V20, P295, DOI 10.1093/emboj/20.1.295; Koshy B, 1996, HUM MOL GENET, V5, P1311, DOI 10.1093/hmg/5.9.1311; La Spada AR, 2003, NEURON, V38, P681, DOI 10.1016/S0896-6273(03)00328-3; Lamers MH, 2000, NATURE, V407, P711, DOI 10.1038/35037523; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lavender P, 1997, ONCOGENE, V14, P2721, DOI 10.1038/sj.onc.1201243; Lee JO, 1998, NATURE, V391, P859, DOI 10.1038/36038; LESLIE AG, 1992, JNT CCP4 ESF EACMB N, V26; Lin KM, 2001, LEUKEMIA, V15, P601, DOI 10.1038/sj.leu.2402071; Lin X, 2000, NAT NEUROSCI, V3, P157, DOI 10.1038/72101; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; Minor DL, 1996, NATURE, V380, P730, DOI 10.1038/380730a0; Miroux B, 1996, J MOL BIOL, V260, P289, DOI 10.1006/jmbi.1996.0399; MURZIN AG, 1993, EMBO J, V12, P861, DOI 10.1002/j.1460-2075.1993.tb05726.x; Nakagawa A, 1999, EMBO J, V18, P1459, DOI 10.1093/emboj/18.6.1459; Neuwald AF, 1998, J MOL MED, V76, P3, DOI 10.1007/s109-1998-8098-0; Orr HT, 2001, HUM MOL GENET, V10, P2307, DOI 10.1093/hmg/10.20.2307; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Sampson EM, 2001, EMBO J, V20, P4500, DOI 10.1093/emboj/20.16.4500; Shibata H, 2000, HUM MOL GENET, V9, P1303, DOI 10.1093/hmg/9.9.1303; Skinner PJ, 1997, NATURE, V389, P971, DOI 10.1038/40153; Tan S, 1998, NATURE, V391, P660, DOI 10.1038/35563; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Tevosian SG, 1997, GENE DEV, V11, P383, DOI 10.1101/gad.11.3.383; TURK D, 1996, P 1996 M INT UN CRYS; TURK D, 1992, THESIS TU MUNICH MUN; van den Ent F, 1999, STRUCTURE, V7, P1181, DOI 10.1016/S0969-2126(00)80052-0; Yue S, 2001, HUM MOL GENET, V10, P25, DOI 10.1093/hmg/10.1.25	48	46	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	2004	279	5					3758	3765		10.1074/jbc.M309817200	http://dx.doi.org/10.1074/jbc.M309817200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	766MF	14583607	hybrid			2022-12-27	WOS:000188379600077
J	Lisman, Q; Pomorski, T; Vogelzangs, C; Urli-Stam, D; van Delwijnen, WD; Holthuis, JCM				Lisman, Q; Pomorski, T; Vogelzangs, C; Urli-Stam, D; van Delwijnen, WD; Holthuis, JCM			Protein sorting in the late Golgi of Saccharomyces cerevisiae does not require mannosylated sphingolipids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL PHOSPHORYLCERAMIDE SYNTHASE; EPITHELIAL-CELLS; SECRETORY VESICLES; PLASMA-MEMBRANE; ENDOPLASMIC-RETICULUM; ANCHORED PROTEINS; YEAST; TRANSPORT; SURFACE; TRAFFICKING	Glycosphingolipids are widely viewed as integral components of the Golgi-based machinery by which membrane proteins are targeted to compartments of the endosomal/lysosomal system and to the surface domains of polarized cells. The yeast Saccharomyces cerevisiae creates glycosphingolipids by transferring mannose to the head group of inositol phosphorylceramide (IPC), yielding mannosyl-IPC (MIPC). Addition of an extra phosphoinositol group onto MIPC generates mannosyldi-IPC (M(IP)(2)C), the final and most abundant sphingo-lipid in yeast. Mannosylation of IPC is partially dependent on CSG1, a gene encoding a putative sphingolipid-mannosyltransferase. Here we show that open reading frame YBR161w, renamed CSH1, is functionally homologous to CSG1 and that deletion of both genes abolishes MIPC and M(IP)(2)C synthesis without affecting protein mannosylation. Csg1p and Csh1p are closely related polytopic membrane proteins that co-localize with IPC synthase in the medial-Golgi. Loss of Csg1p and Csh1p has no effect on clathrin- or AP-3 adaptor-mediated protein transport from the Golgi to the vacuole. Moreover, segregation of the periplasmic enzyme invertase, the plasma membrane ATPase Pma1p and the glycosylphosphatidylinositol-anchored protein Gas1p into distinct classes of secretory vesicles occurs independently of Csg1p and Csh1p. Our results indicate that protein sorting in the late Golgi of yeast does not require production of mannosylated sphingolipids.	Univ Utrecht, Fac Chem, Dept Membrane Enzymol, Ctr Biomembranes & Lipid Enzymol, NL-3584 CH Utrecht, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Cell Biol & Histol, NL-11085 AZ Amsterdam, Netherlands; Humboldt Univ, Inst Biol, D-10115 Berlin, Germany	Utrecht University; University of Amsterdam; Humboldt University of Berlin	Holthuis, JCM (corresponding author), Univ Utrecht, Fac Chem, Dept Membrane Enzymol, Ctr Biomembranes & Lipid Enzymol, HR Kruytgebouw N605,Padualaan 8, NL-3584 CH Utrecht, Netherlands.		Pomorski, Thomas Günther/G-4804-2014; Holthuis, Joost/AAL-9157-2020	Pomorski, Thomas Günther/0000-0002-4889-0829; Holthuis, Joost/0000-0001-8912-1586				Bagnat M, 2000, P NATL ACAD SCI USA, V97, P3254, DOI 10.1073/pnas.060034697; Bagnat M, 2001, MOL BIOL CELL, V12, P4129, DOI 10.1091/mbc.12.12.4129; BEELER T, 1994, J BIOL CHEM, V269, P7279; Beeler TJ, 1997, MOL GEN GENET, V255, P570, DOI 10.1007/s004380050530; BONNER WM, 1978, ANAL BIOCHEM, V89, P247, DOI 10.1016/0003-2697(78)90747-9; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Burd CG, 1998, SEMIN CELL DEV BIOL, V9, P527, DOI 10.1006/scdb.1998.0255; Cowles CR, 1997, EMBO J, V16, P2769, DOI 10.1093/emboj/16.10.2769; David D, 1998, J CELL BIOL, V143, P1167, DOI 10.1083/jcb.143.5.1167; Dean N, 1997, J BIOL CHEM, V272, P31908, DOI 10.1074/jbc.272.50.31908; Dickson RC, 1999, BBA-MOL CELL BIOL L, V1438, P305, DOI 10.1016/S1388-1981(99)00068-2; ELBLE R, 1992, BIOTECHNIQUES, V13, P18; Gurunathan S, 2002, EMBO J, V21, P602, DOI 10.1093/emboj/21.4.602; Haak D, 1997, J BIOL CHEM, V272, P29704, DOI 10.1074/jbc.272.47.29704; Hallstrom TC, 2001, J BIOL CHEM, V276, P23674, DOI 10.1074/jbc.M101568200; HARSAY E, 1995, J CELL BIOL, V131, P297, DOI 10.1083/jcb.131.2.297; Harsay E, 2002, J CELL BIOL, V156, P271, DOI 10.1083/jcb.200109077; HECHTBERGER P, 1994, EUR J BIOCHEM, V225, P641, DOI 10.1111/j.1432-1033.1994.00641.x; Holthuis JCM, 1998, MOL BIOL CELL, V9, P3383, DOI 10.1091/mbc.9.12.3383; Holthuis JCM, 1998, EMBO J, V17, P113, DOI 10.1093/emboj/17.1.113; Jungmann J, 1999, J BIOL CHEM, V274, P6579, DOI 10.1074/jbc.274.10.6579; Keller P, 1997, J CELL SCI, V110, P3001; Ledesma MD, 1998, P NATL ACAD SCI USA, V95, P3966, DOI 10.1073/pnas.95.7.3966; Levine TP, 2000, MOL BIOL CELL, V11, P2267, DOI 10.1091/mbc.11.7.2267; Martin-Belmonte F, 2000, J BIOL CHEM, V275, P41074, DOI 10.1074/jbc.M005429200; MAYS RW, 1995, J CELL BIOL, V130, P1105, DOI 10.1083/jcb.130.5.1105; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; Merrill Jr A. H., 1996, BIOCH LIPIDS LIPOPRO, P309; Mostov KE, 2000, CURR OPIN CELL BIOL, V12, P483, DOI 10.1016/S0955-0674(00)00120-4; Musch A, 1996, J CELL BIOL, V133, P543, DOI 10.1083/jcb.133.3.543; Nagiec MM, 1997, J BIOL CHEM, V272, P9809, DOI 10.1074/jbc.272.15.9809; NAKAYAMA K, 1992, EMBO J, V11, P2511, DOI 10.1002/j.1460-2075.1992.tb05316.x; PATTON JL, 1991, J BACTERIOL, V173, P3101, DOI 10.1128/JB.173.10.3101-3108.1991; PUOTI A, 1991, J CELL BIOL, V113, P515, DOI 10.1083/jcb.113.3.515; Rayner JC, 1998, J BIOL CHEM, V273, P26836, DOI 10.1074/jbc.273.41.26836; SAUER B, 1987, MOL CELL BIOL, V7, P2087, DOI 10.1128/MCB.7.6.2087; Schmidt K, 2001, J BIOL CHEM, V276, P14315, DOI 10.1074/jbc.M006221200; SIKORSKI RS, 1989, GENETICS, V122, P19; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SIMONS K, 1988, BIOCHEMISTRY-US, V27, P6197, DOI 10.1021/bi00417a001; Skrzypek M, 1997, J BACTERIOL, V179, P1513, DOI 10.1128/jb.179.5.1513-1520.1997; Sprong H, 2001, J CELL BIOL, V155, P369, DOI 10.1083/jcb.200106104; STACK JH, 1995, J CELL BIOL, V129, P321, DOI 10.1083/jcb.129.2.321; Stepp JD, 1997, J CELL BIOL, V139, P1761, DOI 10.1083/jcb.139.7.1761; Tanida I, 1996, FEBS LETT, V379, P38, DOI 10.1016/0014-5793(95)01478-0; TerBush DR, 1996, EMBO J, V15, P6483, DOI 10.1002/j.1460-2075.1996.tb01039.x; Uemura S, 2003, J BIOL CHEM, V278, P45049, DOI 10.1074/jbc.M305498200; VAN MEER G, 1987, J CELL BIOL, V105, P1623, DOI 10.1083/jcb.105.4.1623; Wach A, 1997, YEAST, V13, P1065, DOI 10.1002/(SICI)1097-0061(19970915)13:11<1065::AID-YEA159>3.3.CO;2-B; Wiggins CAR, 1998, P NATL ACAD SCI USA, V95, P7945, DOI 10.1073/pnas.95.14.7945; Yoshimori T, 1996, J CELL BIOL, V133, P247, DOI 10.1083/jcb.133.2.247; ZIEGLER FD, 1988, J BIOL CHEM, V263, P6986; Ziman M, 1996, MOL BIOL CELL, V7, P1909, DOI 10.1091/mbc.7.12.1909	54	25	27	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 9	2004	279	2					1020	1029		10.1074/jbc.M306119200	http://dx.doi.org/10.1074/jbc.M306119200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	759DJ	14583628	hybrid			2022-12-27	WOS:000187722800025
J	Uchida, N; Hoshino, S; Katada, T				Uchida, N; Hoshino, S; Katada, T			Identification of a human cytoplasmic poly(A) nuclease complex stimulated by poly(A)-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA DEADENYLATION; TRANSLATION INITIATION; BINDING-PROTEIN; POLY(A)-SPECIFIC RIBONUCLEASE; TRANSCRIPTION FACTOR; CAP STRUCTURE; YEAST; TAIL; GENE; CCR4	The poly( A) tail shortening in mRNA, called deadenylation, is the first rate-limiting step in eukaryotic mRNA turnover, and the polyadenylate-binding protein ( PABP) appears to be involved in the regulation of this step. However, the precise role of PABP remains largely unknown in higher eukaryotes. Here we identified and characterized a human PABP-dependent poly( A) nuclease (hPAN) complex consisting of catalytic hPan2 and regulatory hPan3 subunits. hPan2 has intrinsically a 3' to 5' exoribonuclease activity and requires Mg2+ for the enzyme activity. On the other hand, hPan3 interacts with PABP to simulate hPan2 nuclease activity. Interestingly, the hPAN nuclease complex has a higher substrate specificity to poly( A) RNA upon its association with PABP. Consistent with the roles of hPan2 and hPan3 in mRNA decay, the two subunits exhibit cytoplasmic co-localization. Thus, the human PAN complex is a poly(A)-specific exoribonuclease that is stimulated by PABP in the cytoplasm.	Univ Tokyo, Dept Physiol Chem, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan	University of Tokyo	Hoshino, S (corresponding author), Univ Tokyo, Dept Physiol Chem, Grad Sch Pharmaceut Sci, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	hoshino@mol.f.u-tokyo.ac.jp		Uchida, Naoyuki/0000-0002-4123-6154; Hoshino, Shinichi/0000-0001-6135-7896				Baggs JE, 2003, CURR BIOL, V13, P189, DOI 10.1016/S0960-9822(03)00014-9; BEELMAN CA, 1995, CELL, V81, P179, DOI 10.1016/0092-8674(95)90326-7; Boeck R, 1996, J BIOL CHEM, V271, P432, DOI 10.1074/jbc.271.1.432; Brown CE, 1996, MOL CELL BIOL, V16, P5744; CAPONIGRO G, 1995, GENE DEV, V9, P2421, DOI 10.1101/gad.9.19.2421; Chekanova JA, 2001, CURR BIOL, V11, P1207, DOI 10.1016/S0960-9822(01)00371-2; CHEN CYA, 1995, MOL CELL BIOL, V15, P5777; Chen JJ, 2002, EMBO J, V21, P1414, DOI 10.1093/emboj/21.6.1414; Daugeron MC, 2001, NUCLEIC ACIDS RES, V29, P2448, DOI 10.1093/nar/29.12.2448; DECKER CJ, 1993, GENE DEV, V7, P1632, DOI 10.1101/gad.7.8.1632; Dehlin E, 2000, EMBO J, V19, P1079, DOI 10.1093/emboj/19.5.1079; Dunckley T, 1999, EMBO J, V18, P5411, DOI 10.1093/emboj/18.19.5411; Dupressoir A, 1999, J BIOL CHEM, V274, P31068, DOI 10.1074/jbc.274.43.31068; Ford LP, 1999, GENE DEV, V13, P188, DOI 10.1101/gad.13.2.188; GALLIE DR, 1991, GENE DEV, V5, P2108, DOI 10.1101/gad.5.11.2108; Gao M, 2000, MOL CELL, V5, P479, DOI 10.1016/S1097-2765(00)80442-6; Gao M, 2001, EMBO J, V20, P1134, DOI 10.1093/emboj/20.5.1134; GORLACH M, 1994, EXP CELL RES, V211, P400, DOI 10.1006/excr.1994.1104; Green CB, 1996, P NATL ACAD SCI USA, V93, P14884, DOI 10.1073/pnas.93.25.14884; Hammet A, 2002, J BIOL CHEM, V277, P22469, DOI 10.1074/jbc.M202473200; Hoshino S, 1999, J BIOL CHEM, V274, P16677, DOI 10.1074/jbc.274.24.16677; IIZUKA N, 1994, MOL CELL BIOL, V14, P7322, DOI 10.1128/MCB.14.11.7322; Imataka H, 1998, EMBO J, V17, P7480, DOI 10.1093/emboj/17.24.7480; Jacobson A., 1996, TRANSLATIONAL CONTRO, P451; Korner CG, 1997, J BIOL CHEM, V272, P10448; Korner CG, 1998, EMBO J, V17, P5427, DOI 10.1093/emboj/17.18.5427; Kuhn U, 2003, J BIOL CHEM, V278, P16916, DOI 10.1074/jbc.M209886200; LaGrandeur TE, 1998, EMBO J, V17, P1487, DOI 10.1093/emboj/17.5.1487; LOWELL JE, 1992, GENE DEV, V6, P2088, DOI 10.1101/gad.6.11.2088; Lykke-Andersen J, 2002, MOL CELL BIOL, V22, P8114, DOI 10.1128/MCB.22.23.8114-8121.2002; Martinez J, 2001, J BIOL CHEM, V276, P27923, DOI 10.1074/jbc.M102270200; Martinez J, 2000, J BIOL CHEM, V275, P24222, DOI 10.1074/jbc.M001705200; Meyer S, 2002, BIOCHEMISTRY-US, V41, P6082, DOI 10.1021/bi0160866; MUHLRAD D, 1995, MOL CELL BIOL, V15, P2145; Preiss T, 1998, NATURE, V392, P516, DOI 10.1038/33192; Sachs A, 2000, COLD SPRING HARBOR M, V39, P447; SACHS AB, 1992, CELL, V70, P961, DOI 10.1016/0092-8674(92)90246-9; SACHS AB, 1989, CELL, V58, P857, DOI 10.1016/0092-8674(89)90938-0; Sonenberg N, 2003, CURR OPIN STRUC BIOL, V13, P56, DOI 10.1016/S0959-440X(03)00009-5; Tarun SZ, 1996, EMBO J, V15, P7168, DOI 10.1002/j.1460-2075.1996.tb01108.x; TARUN SZ, 1995, GENE DEV, V9, P2997, DOI 10.1101/gad.9.23.2997; Tucker M, 2000, ANNU REV BIOCHEM, V69, P571, DOI 10.1146/annurev.biochem.69.1.571; Tucker M, 2002, EMBO J, V21, P1427, DOI 10.1093/emboj/21.6.1427; Tucker M, 2001, CELL, V104, P377, DOI 10.1016/S0092-8674(01)00225-2; Uchida N, 2002, J BIOL CHEM, V277, P50286, DOI 10.1074/jbc.M203029200; van Dijk E, 2002, EMBO J, V21, P6915, DOI 10.1093/emboj/cdf678; Viswanathan P, 2003, J BIOL CHEM, V278, P14949, DOI 10.1074/jbc.M211794200; Wang Y, 2001, BMC Dev Biol, V1, P9, DOI 10.1186/1471-213X-1-9; Wang ZR, 2002, P NATL ACAD SCI USA, V99, P12663, DOI 10.1073/pnas.192445599; Wang ZR, 2001, CELL, V107, P751, DOI 10.1016/S0092-8674(01)00592-X; Welch EM, 2000, COLD SPRING HARBOR M, V39, P467; Wells SE, 1998, MOL CELL, V2, P135, DOI 10.1016/S1097-2765(00)80122-7; Wilusz CJ, 2001, RNA, V7, P1416; Zuo YH, 2001, NUCLEIC ACIDS RES, V29, P1017, DOI 10.1093/nar/29.5.1017	54	102	105	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 9	2004	279	2					1383	1391		10.1074/jbc.M309125200	http://dx.doi.org/10.1074/jbc.M309125200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	759DJ	14583602	hybrid			2022-12-27	WOS:000187722800067
J	Williams, RS; Chasman, DI; Hau, DD; Hui, B; Lau, AY; Glover, JNM				Williams, RS; Chasman, DI; Hau, DD; Hui, B; Lau, AY; Glover, JNM			Detection of protein folding defects caused by BRCA1-BRCT truncation and missense mutations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANCER SUSCEPTIBILITY GENE; POLYMERASE-II HOLOENZYME; BREAST-CANCER; OVARIAN-CANCER; TRANSCRIPTIONAL ACTIVATION; TERMINAL DOMAIN; BRCT DOMAINS; COMMON BRCA1; CELL-CYCLE; DNA-REPAIR	Most cancer-associated BRCA1 mutations identified to date result in the premature translational termination of the protein, highlighting a crucial role for the C-terminal, BRCT repeat region in mediating BRCA1 tumor suppressor function. However, the molecular and genetic effects of missense mutations that map to the BRCT region remain largely unknown. Using a protease-based assay, we directly assessed the sensitivity of the folding of the BRCT domain to an extensive set of truncation and single amino acid substitutions derived from breast cancer screening programs. The protein can tolerate truncations of up to 8 amino acids, but further deletion results in drastic BRCT folding defects. This molecular phenotype can be correlated with an increased susceptibility to disease. A cross-validated computational assessment of the BRCT mutation data base suggests that as much as half of all BRCT missense mutations contribute to BRCA1 loss of function and disease through protein-destabilizing effects. The coupled use of proteolytic methods and computational predictive methods to detect mutant BRCA1 conformations at the protein level will augment the efficacy of current BRCA1 screening protocols, especially in the absence of clinical data that can be used to discriminate deleterious BRCT missense mutations from benign polymorphisms.	Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada; Brigham & Womens Hosp, Div Prevent Med, Boston, MA 02215 USA; Variagen Nuvelo Inc, Cambridge, MA 02139 USA	University of Alberta; Harvard University; Brigham & Women's Hospital	Glover, JNM (corresponding author), Univ Alberta, Dept Biochem, 437 Med Sci Bldg, Edmonton, AB T6G 2H7, Canada.		Williams, R Scott/A-6059-2015	Williams, R Scott/0000-0002-4610-8397; Lau, Albert/0000-0002-0967-7558				Anderson SE, 1998, NAT GENET, V19, P254, DOI 10.1038/930; Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Bullock AN, 2001, NAT REV CANCER, V1, P68, DOI 10.1038/35094077; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; Cantor SB, 2001, CELL, V105, P149, DOI 10.1016/S0092-8674(01)00304-X; Carvalho MA, 2002, CANCER BIOL THER, V1, P502, DOI 10.4161/cbt.1.5.165; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chasman D, 2001, J MOL BIOL, V307, P683, DOI 10.1006/jmbi.2001.4510; Chen KS, 1996, CARCINOGENESIS, V17, P1561, DOI 10.1093/carcin/17.8.1561; Couch FJ, 1996, HUM MUTAT, V8, P8, DOI 10.1002/humu.1380080102; Deffenbaugh AM, 2002, GENET TEST, V6, P119, DOI 10.1089/10906570260199375; Ekblad CMS, 2002, J MOL BIOL, V320, P431, DOI 10.1016/S0022-2836(02)00478-3; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; FRIEDMAN LS, 1994, NAT GENET, V8, P399, DOI 10.1038/ng1294-399; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; Haile DT, 1999, J BIOL CHEM, V274, P2113, DOI 10.1074/jbc.274.4.2113; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Hayes F, 2000, CANCER RES, V60, P2411; Henikoff S, 1999, BIOINFORMATICS, V15, P471, DOI 10.1093/bioinformatics/15.6.471; HORTON RM, 1993, METHOD ENZYMOL, V217, P270; Huyton T, 2000, MUTAT RES-DNA REPAIR, V460, P319, DOI 10.1016/S0921-8777(00)00034-3; IMOTO T, 1986, J MOL BIOL, V190, P647, DOI 10.1016/0022-2836(86)90250-0; Joo WS, 2002, GENE DEV, V16, P583, DOI 10.1101/gad.959202; Joukov V, 2001, P NATL ACAD SCI USA, V98, P12078, DOI 10.1073/pnas.211427098; Li S, 1999, J BIOL CHEM, V274, P11334, DOI 10.1074/jbc.274.16.11334; Ludwig T, 2001, GENE DEV, V15, P1188, DOI 10.1101/gad.879201; MARKIEWICZ P, 1994, J MOL BIOL, V240, P421, DOI 10.1006/jmbi.1994.1458; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Monteiro ANA, 2000, TRENDS BIOCHEM SCI, V25, P469, DOI 10.1016/S0968-0004(00)01632-7; Monteiro ANA, 1997, AM J HUM GENET, V61, P761, DOI 10.1086/515515; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Nathanson KN, 2001, NAT MED, V7, P552, DOI 10.1038/87876; Pedersen JS, 2002, J MOL BIOL, V323, P115, DOI 10.1016/S0022-2836(02)00891-4; PetrijBosch A, 1997, NAT GENET, V17, P341, DOI 10.1038/ng1197-341; Ramensky V, 2002, NUCLEIC ACIDS RES, V30, P3894, DOI 10.1093/nar/gkf493; RENNELL D, 1991, J MOL BIOL, V222, P67, DOI 10.1016/0022-2836(91)90738-R; Saunders CT, 2002, J MOL BIOL, V322, P891, DOI 10.1016/S0022-2836(02)00813-6; Scully R, 2000, NATURE, V408, P429, DOI 10.1038/35044000; Scully R, 1999, MOL CELL, V4, P1093, DOI 10.1016/S1097-2765(00)80238-5; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; SHARAN SK, 1995, HUM MOL GENET, V4, P2275, DOI 10.1093/hmg/4.12.2275; SHATTUCKEIDENS D, 1995, JAMA-J AM MED ASSOC, V273, P535, DOI 10.1001/jama.273.7.535; Shen DJ, 1999, ONCOL RES, V11, P63; Sieber V, 1998, NAT BIOTECHNOL, V16, P955, DOI 10.1038/nbt1098-955; Sjolander K, 1996, COMPUT APPL BIOSCI, V12, P327; SODEOKA M, 1993, BIOORG MED CHEM LETT, V3, P1089, DOI 10.1016/S0960-894X(00)80293-0; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Vallon-Christersson J, 2001, HUM MOL GENET, V10, P353, DOI 10.1093/hmg/10.4.353; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; VOSSEN R, 1999, CURRENT PROTOCOLS HU; Wang L, 1998, PROTEIN SCI, V7, P2460, DOI 10.1002/pro.5560071124; Williams RS, 2003, J BIOL CHEM, V278, P2630, DOI 10.1074/jbc.M210019200; Williams RS, 2001, NAT STRUCT BIOL, V8, P838, DOI 10.1038/nsb1001-838; Worley T, 2002, CANCER BIOL THER, V1, P497, DOI 10.4161/cbt.1.5.164; Yarden RI, 1999, P NATL ACAD SCI USA, V96, P4983, DOI 10.1073/pnas.96.9.4983; Yu X, 1998, J BIOL CHEM, V273, P25388, DOI 10.1074/jbc.273.39.25388; Zhang XD, 1998, EMBO J, V17, P6404, DOI 10.1093/emboj/17.21.6404	58	102	106	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					53007	53016		10.1074/jbc.M310182200	http://dx.doi.org/10.1074/jbc.M310182200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14534301	hybrid			2022-12-27	WOS:000187480700124
J	Greene, MD; Frasch, WD				Greene, MD; Frasch, WD			Interactions among gamma R268, gamma Q269, and the beta subunit catch loop of Escherichia coli F-1-ATPase are important for catalytic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP SYNTHASE; F1-ATPASE; MUTAGENESIS; RESOLUTION; MECHANISM; ROTATION; ENZYMES; ENERGY	Removal of the ability to form a salt bridge or hydrogen bonds between the beta subunit catch loop (betaY297-D305) and the gamma subunit of Escherichia coli F1Fo-ATP synthase significantly altered the ability of the enzyme to hydrolyze ATP and the bacteria to grow via oxidative phosphorylation. Residues betaT304, betaD305, betaD302, gammaQ269, and gammaR268 were found to be very important for ATP hydrolysis catalyzed by soluble F-1-ATPase, and the latter four residues were also very important for oxidative phosphorylation. The greatest effects on catalytic activity were observed by the substitution of side chains that contribute to the shortest and/or multiple H-bonds as well as the salt bridge. Residue betaD305 would not tolerate substitution with Val or Ser and had extremely low activity as betaD305E, suggesting that this residue is particularly important for synthesis and hydrolysis activity. These results provide evidence that tight winding of the gamma subunit coiled-coil is important to the rate-limiting step in ATP hydrolysis and are consistent with an escapement mechanism for ATP synthesis in which alphabetagamma intersubunit interactions provide a means to make substrate binding a prerequisite of proton gradient-driven gamma subunit rotation.	Arizona State Univ, Sch Life Sci, Ctr Study Early Events Photosynth, Tempe, AZ 85287 USA	Arizona State University; Arizona State University-Tempe	Frasch, WD (corresponding author), Arizona State Univ, Sch Life Sci, Ctr Study Early Events Photosynth, Tempe, AZ 85287 USA.				NIGMS NIH HHS [GM50202, R01 GM050202] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050202] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; AlShawi MK, 1997, J BIOL CHEM, V272, P2300; ALSHAWI MK, 1988, J BIOL CHEM, V263, P19640; Braig K, 2000, STRUCTURE, V8, P567, DOI 10.1016/S0969-2126(00)00145-3; Chen W, 2001, BIOCHEMISTRY-US, V40, P7729, DOI 10.1021/bi0105779; Frasch WD, 2000, BBA-BIOENERGETICS, V1458, P310, DOI 10.1016/S0005-2728(00)00083-9; KATO Y, 1995, BBA-BIOENERGETICS, V1231, P275, DOI 10.1016/0005-2728(95)00087-Y; Menz RI, 2001, CELL, V106, P331, DOI 10.1016/S0092-8674(01)00452-4; NAKAMOTO RK, 1995, J BIOL CHEM, V270, P14042, DOI 10.1074/jbc.270.23.14042; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Sambrook J., 2002, MOL CLONING LAB MANU; WISE JG, 1990, J BIOL CHEM, V265, P10403; Yasuda R, 2001, NATURE, V410, P898, DOI 10.1038/35073513; Zhou YT, 1997, P NATL ACAD SCI USA, V94, P10583, DOI 10.1073/pnas.94.20.10583	14	30	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51594	51598		10.1074/jbc.M309948200	http://dx.doi.org/10.1074/jbc.M309948200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14532272	hybrid			2022-12-27	WOS:000187206300092
J	Hu, GH; Tsai, AL; Quiocho, FA				Hu, GH; Tsai, AL; Quiocho, FA			Insertion of an N7-methylguanine mRNA cap between two coplanar aromatic residues of a cap-binding protein is fast and selective for a positively charged cap	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VACCINIA VIRUS; POLY(A) POLYMERASE; STRUCTURAL BASIS; RECOGNITION; EIF4E	The N7-methylated guanosine (m(7)G) cap structure, which is found at the 5' ends of mature eukaryotic mRNAs, is critical to a myriad of biological processes. The twenty structures of complexes of cap nucleosides and nucleotides and methylated bases with the vaccinia virus VP39, a cap-specific RNA 2'-O-methyltransferase, which we have determined previously, have revealed the atomic basis of cap binding. The precise insertion and tight fitting of the m(7)Gua moiety of the cap between two parallel aromatic residues that are spaced only 6.8 Angstrom apart governs the high specificity of binding. Here we report the investigation of the reaction mechanism of VP39 with three capped ligands (m(7)G, m(7)GpppG, and m(7)GpppGA(3)) by fluorescence stopped-flow technique. Cap binding is a simple one-step mechanism with very fast association rate constant (similar to 10(7) M-1 s(-1)). Moreover, the pH dependence on the association rate constant of m(7)G binding indicates that only the positively charged keto tautomer of the cap is recognized and bound. The association and dissociation rate constants and affinity constants of the three ligands do not vary greatly, demonstrating that binding is achieved almost entirely by the interactions of m(7)Gua with two aromatic residues in a cation-pi sandwich.	Baylor Coll Med, Grad Program Struct & Computat Biol & Mol Biophys, Houston, TX 77030 USA; Baylor Coll Med, Howard Hughes Med Inst, Houston, TX 77030 USA; Baylor Coll Med, Verna & Marrs McLean Dept Biochem & Mol Biol, Houston, TX 77030 USA; Univ Texas, Sch Med, Div Hematol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute; Baylor College of Medicine; University of Texas System	Quiocho, FA (corresponding author), Baylor Coll Med, Grad Program Struct & Computat Biol & Mol Biophys, Houston, TX 77030 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056818] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM56818, GM-44911] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARBOSA E, 1978, J BIOL CHEM, V253, P7692; Blachut-Okrasinska E, 2000, EUR BIOPHYS J BIOPHY, V29, P487, DOI 10.1007/s002490000096; CARBERRY SE, 1989, BIOCHEMISTRY-US, V28, P8078, DOI 10.1021/bi00446a017; Dougherty DA, 1996, SCIENCE, V271, P163, DOI 10.1126/science.271.5246.163; GERSHON PD, 1991, CELL, V66, P1269, DOI 10.1016/0092-8674(91)90048-4; GLENNON RA, 1993, CHEM NUCLEOSIDES NUC, V2, P1; Hodel AE, 1998, MOL CELL, V1, P443, DOI 10.1016/S1097-2765(00)80044-1; Hodel AE, 1997, NAT STRUCT BIOL, V4, P350, DOI 10.1038/nsb0597-350; Hu GH, 1999, P NATL ACAD SCI USA, V96, P7149, DOI 10.1073/pnas.96.13.7149; Hu GH, 2002, BIOCHEMISTRY-US, V41, P7677, DOI 10.1021/bi0201926; JENCKS WP, 1981, P NATL ACAD SCI-BIOL, V78, P4046, DOI 10.1073/pnas.78.7.4046; Lockless SW, 1998, BIOCHEMISTRY-US, V37, P8564, DOI 10.1021/bi980178m; Marcotrigiano J, 1997, CELL, V89, P951, DOI 10.1016/S0092-8674(00)80280-9; Matsuo H, 1997, NAT STRUCT BIOL, V4, P717, DOI 10.1038/nsb0997-717; Quiocho FA, 2000, CURR OPIN STRUC BIOL, V10, P78, DOI 10.1016/S0959-440X(99)00053-6; RHOADS RE, 1983, BIOCHEMISTRY-US, V22, P6084, DOI 10.1021/bi00295a007; SCHNIERLE BS, 1992, P NATL ACAD SCI USA, V89, P2897, DOI 10.1073/pnas.89.7.2897	17	17	17	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51515	51520		10.1074/jbc.M307654200	http://dx.doi.org/10.1074/jbc.M307654200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14573618	hybrid			2022-12-27	WOS:000187206300082
J	Luo, JS; Benovic, JL				Luo, JS; Benovic, JL			G protein-coupled receptor kinase interaction with Hsp90 mediates kinase maturation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; NITRIC-OXIDE SYNTHASE; DEPENDENT PHOSPHORYLATION; SELECTIVE REGULATION; PROTEASOME PATHWAY; TYROSINE KINASE; BETA-GAMMA; RGS DOMAIN; 2 GRK2; C-SRC	G protein- coupled receptor kinase 2 ( GRK2) is a serine/ threonine- specific protein kinase that mediates agonist- dependent phosphorylation of numerous G protein-coupled receptors. In an effort to identify proteins that regulate GRK2 function, we searched for interacting proteins by immunoprecipitation of endogenous GRK2 from HL60 cells. Subsequent analysis by gel electrophoresis and mass spectrometry revealed that GRK2 associates with heat shock protein 90 ( Hsp90). GRK2 interaction with Hsp90 was confirmed by co- immunoprecipitation and was effectively disrupted by geldanamycin, an Hsp90- specific inhibitor. Interestingly, geldanamycin treatment of HL60 cells decreased the expression of endogenous GRK2 in a dose- and time- dependent manner, and metabolic labeling demonstrated that geldanamycin rapidly accelerated the degradation of newly synthesized GRK2. The use of various protease inhibitors suggested that GRK2 degradation induced by geldanamycin was predominantly through the proteasome pathway. To test whether Hsp90 plays a general role in regulating GRK maturation, additional GRKs were studied by transient expression in COS- 1 cells and subsequent treatment with geldanamycin. These studies demonstrate that GRK3, GRK5, and GRK6 are also stabilized by interaction with Hsp90. Taken together, our work revealed that GRK interaction with heat shock proteins plays an important role in regulating GRK maturation.	Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA	Jefferson University	Benovic, JL (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA.				NIGMS NIH HHS [GM44944] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044944] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		An WG, 2000, CELL GROWTH DIFFER, V11, P355; Basso AD, 2002, J BIOL CHEM, V277, P39858, DOI 10.1074/jbc.M206322200; Buchner J, 1999, TRENDS BIOCHEM SCI, V24, P136, DOI 10.1016/S0968-0004(99)01373-0; Busconi L, 2000, J BIOL CHEM, V275, P1565, DOI 10.1074/jbc.275.3.1565; Carman CV, 2000, J BIOL CHEM, V275, P10443, DOI 10.1074/jbc.275.14.10443; Carman CV, 1999, J BIOL CHEM, V274, P8858, DOI 10.1074/jbc.274.13.8858; Carman CV, 1998, J BIOL CHEM, V273, P20308, DOI 10.1074/jbc.273.32.20308; Carman CV, 1999, J BIOL CHEM, V274, P34483, DOI 10.1074/jbc.274.48.34483; Cong M, 2001, J BIOL CHEM, V276, P15192, DOI 10.1074/jbc.M009130200; Csermely P, 1998, PHARMACOL THERAPEUT, V79, P129, DOI 10.1016/S0163-7258(98)00013-8; Elorza A, 2000, MOL PHARMACOL, V57, P778, DOI 10.1124/mol.57.4.778; Fontana J, 2002, CIRC RES, V90, P866, DOI 10.1161/01.RES.0000016837.26733.BE; Freeman JLR, 1998, J BIOL CHEM, V273, P20653, DOI 10.1074/jbc.273.32.20653; Fujita N, 2002, J BIOL CHEM, V277, P10346, DOI 10.1074/jbc.M106736200; Garcia-Cardena G, 1998, NATURE, V392, P821, DOI 10.1038/33934; Grammatikakis N, 2002, J BIOL CHEM, V277, P8312, DOI 10.1074/jbc.M109200200; Gros R, 1999, CLIN PHARMACOL THER, V65, P545, DOI 10.1016/S0009-9236(99)70074-3; Gros R, 1997, J CLIN INVEST, V99, P2087, DOI 10.1172/JCI119381; Hartson SD, 1996, BIOCHEMISTRY-US, V35, P13451, DOI 10.1021/bi961332c; Iacovelli L, 1999, FASEB J, V13, P1; Imai J, 2000, MOL CELL BIOL, V20, P9262, DOI 10.1128/MCB.20.24.9262-9270.2000; KIM CM, 1993, RECEPTOR, V3, P39; Kohout TA, 2003, MOL PHARMACOL, V63, P9, DOI 10.1124/mol.63.1.9; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; Loudon RP, 1996, BLOOD, V88, P4547, DOI 10.1182/blood.V88.12.4547.bloodjournal88124547; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; Meyer P, 2003, MOL CELL, V11, P647, DOI 10.1016/S1097-2765(03)00065-0; Mitch WE, 1996, NEW ENGL J MED, V335, P1897, DOI 10.1056/NEJM199612193352507; Miyata Y, 2001, J BIOL CHEM, V276, P21841, DOI 10.1074/jbc.M010944200; Oppermann M, 1996, P NATL ACAD SCI USA, V93, P7649, DOI 10.1073/pnas.93.15.7649; Pai KS, 2001, J BIOL CHEM, V276, P32642, DOI 10.1074/jbc.M104212200; Passarino G, 2003, HUM MUTAT, V21, DOI 10.1002/humu.9141; Penela P, 1998, J BIOL CHEM, V273, P35238, DOI 10.1074/jbc.273.52.35238; Penela P, 2001, EMBO J, V20, P5129, DOI 10.1093/emboj/20.18.5129; Penn RB, 2000, TRENDS CARDIOVAS MED, V10, P81, DOI 10.1016/S1050-1738(00)00053-0; Perry SJ, 2002, TRENDS CELL BIOL, V12, P130, DOI 10.1016/S0962-8924(01)02239-5; Pitcher JA, 1999, J BIOL CHEM, V274, P34531, DOI 10.1074/jbc.274.49.34531; Pitcher JA, 1998, J BIOL CHEM, V273, P12316, DOI 10.1074/jbc.273.20.12316; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; Prasad SVN, 2001, J BIOL CHEM, V276, P18953, DOI 10.1074/jbc.M102376200; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Premont RT, 1998, P NATL ACAD SCI USA, V95, P14082, DOI 10.1073/pnas.95.24.14082; Sallese M, 2000, MOL PHARMACOL, V57, P826, DOI 10.1124/mol.57.4.826; Sarnago S, 1999, J BIOL CHEM, V274, P34411, DOI 10.1074/jbc.274.48.34411; Sato S, 2000, P NATL ACAD SCI USA, V97, P10832, DOI 10.1073/pnas.170276797; Schulte TW, 1997, BIOCHEM BIOPH RES CO, V239, P655, DOI 10.1006/bbrc.1997.7527; Shiina T, 2001, J BIOL CHEM, V276, P33019, DOI 10.1074/jbc.M100140200; Stancato LF, 1997, J BIOL CHEM, V272, P4013, DOI 10.1074/jbc.272.7.4013; Stepanova L, 1996, GENE DEV, V10, P1491, DOI 10.1101/gad.10.12.1491; UNGERER M, 1993, CIRCULATION, V87, P454, DOI 10.1161/01.CIR.87.2.454; Usui K, 2000, INT J MOL MED, V5, P335; Waheed AA, 2002, J BIOL CHEM, V277, P32409, DOI 10.1074/jbc.C200383200; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; Winstel R, 1996, P NATL ACAD SCI USA, V93, P2105, DOI 10.1073/pnas.93.5.2105; Xu Y, 1999, P NATL ACAD SCI USA, V96, P109, DOI 10.1073/pnas.96.1.109; XU Y, 1993, P NATL ACAD SCI USA, V90, P7074, DOI 10.1073/pnas.90.15.7074; Young JC, 2001, J CELL BIOL, V154, P267, DOI 10.1083/jcb.200104079	58	41	41	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					50908	50914		10.1074/jbc.M307637200	http://dx.doi.org/10.1074/jbc.M307637200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14557268	hybrid			2022-12-27	WOS:000187206300011
J	Mandelboim, M; Barth, S; Biton, M; Liang, XH; Michaeli, S				Mandelboim, M; Barth, S; Biton, M; Liang, XH; Michaeli, S			Silencing of Sm proteins in Trypanosoma brucei by RNA interference captured a novel cytoplasmic intermediate in spliced leader RNA biogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL NUCLEAR RIBONUCLEOPROTEINS; CAP 4 FORMATION; MUTATIONAL ANALYSIS; MESSENGER-RNA; U-SNRNA; RIBOSOMAL-RNA; LA PROTEIN; SL RNA; TRANS; GENE	In Trypanosoma brucei the small nuclear (sn) RNAs U1, U2, U4, and U5, as well as the spliced leader (SL) RNA, bind the seven Sm canonical proteins carrying the consensus Sm motif. To determine the function of these proteins in snRNA and SL RNA biogenesis, two of the Sm core proteins, SmE and SmD1, were silenced by RNAi. Surprisingly, whereas the level of all snRNAs, including U1, U2, U4, and U5 was reduced during silencing, the level of SL RNA was dramatically elevated, but the levels of U6 and spliced leader-associated RNA (SLA1) remained unchanged. The SL RNA that had accumulated in silenced cells lacked modification at the cap4 nucleotide but harbored modifications at the cap1 and cap2 nucleotides and carried the characteristic psi. This SL RNA possessed a longer tail and had accumulated in the cytoplasm in 10 and 50 S particles that were found by in situ hybridization to be present in "speckles." We propose a model for SL RNA biogenesis involving a cytoplasmic phase and suggest that the trypanosome-specific "cap4" nucleotides function as a signal for export and import of SL RNA out and into the nucleus. The SL RNA biogenesis pathway differs from that of U sn ribonucleoproteins (RNPs) in that it is the only RNA that binds Sm proteins that were stabilized under Sm depletion in a novel RNP, which we termed SL RNP-C.	Bar Ilan Univ, Fac Life Sci, IL-52900 Ramat Gan, Israel	Bar Ilan University	Michaeli, S (corresponding author), Bar Ilan Univ, Fac Life Sci, IL-52900 Ramat Gan, Israel.		Michaeli, Shulamit/AAC-8255-2022	Biton, Moshe/0000-0001-8330-1674				AGABIAN N, 1990, CELL, V61, P1157, DOI 10.1016/0092-8674(90)90674-4; BAKIN A, 1993, BIOCHEMISTRY-US, V32, P9754, DOI 10.1021/bi00088a030; BANGS JD, 1992, J BIOL CHEM, V267, P9805; Bell M, 1999, NUCLEIC ACIDS RES, V27, P3986, DOI 10.1093/nar/27.20.3986; Bell M, 2000, GENE, V247, P77, DOI 10.1016/S0378-1119(00)00118-9; Brahms H, 2000, J BIOL CHEM, V275, P17122, DOI 10.1074/jbc.M000300200; BROWN JD, 1994, EMBO J, V13, P4390, DOI 10.1002/j.1460-2075.1994.tb06759.x; BRUZIK JP, 1988, NATURE, V335, P559, DOI 10.1038/335559a0; Campbell DA, 2000, PARASITOL TODAY, V16, P78, DOI 10.1016/S0169-4758(99)01545-8; Chen YL, 2003, MOL BIOCHEM PARASIT, V126, P275, DOI 10.1016/S0166-6851(02)00276-1; COOPER M, 1995, EMBO J, V14, P2066, DOI 10.1002/j.1460-2075.1995.tb07198.x; Darzacq X, 2002, EMBO J, V21, P2746, DOI 10.1093/emboj/21.11.2746; Dungan JM, 1996, EMBO J, V15, P4016, DOI 10.1002/j.1460-2075.1996.tb00775.x; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; FREISTADT MS, 1988, J BIOL CHEM, V263, P15071; Ganot P, 1999, MOL CELL BIOL, V19, P6906; Goncharov I, 1999, J BIOL CHEM, V274, P12217, DOI 10.1074/jbc.274.18.12217; HAMM J, 1990, CELL, V63, P109, DOI 10.1016/0092-8674(90)90292-M; Huber J, 1998, EMBO J, V17, P4114, DOI 10.1093/emboj/17.14.4114; IZAURRALDE E, 1995, NATURE, V376, P709, DOI 10.1038/376709a0; Liang XH, 2003, EUKARYOT CELL, V2, P830, DOI 10.1128/EC.2.5.830-840.2003; Liang XH, 2002, RNA, V8, P237, DOI 10.1017/S1355838202018290; Liu L, 2003, J BIOL CHEM, V278, P18271, DOI 10.1074/jbc.M209215200; Liu L, 2002, J BIOL CHEM, V277, P47348, DOI 10.1074/jbc.M207736200; Liu Q, 1997, CELL, V90, P1013, DOI 10.1016/S0092-8674(00)80367-0; Lucke S, 1996, EMBO J, V15, P4380, DOI 10.1002/j.1460-2075.1996.tb00811.x; LYGEROU Z, 1994, GENE DEV, V8, P1423, DOI 10.1101/gad.8.12.1423; Mair G, 2000, J BIOL CHEM, V275, P28994, DOI 10.1074/jbc.M004193200; Mair G, 2000, RNA, V6, P163, DOI 10.1017/S135583820099229X; Mandelboim M, 2002, J BIOL CHEM, V277, P35210, DOI 10.1074/jbc.M201910200; MATTAJ IW, 1986, CELL, V46, P905, DOI 10.1016/0092-8674(86)90072-3; Mayes AE, 1999, EMBO J, V18, P4321, DOI 10.1093/emboj/18.15.4321; MCNALLY KP, 1992, MOL CELL BIOL, V12, P4844, DOI 10.1128/MCB.12.11.4844; MICHAELI S, 1990, J BIOL CHEM, V265, P10582; MOTTRAM J, 1989, MOL CELL BIOL, V9, P1212, DOI 10.1128/MCB.9.3.1212; NAKAAR V, 1995, PARASITOL TODAY, V11, P225, DOI 10.1016/0169-4758(95)80085-9; Ohno M, 2000, CELL, V101, P187, DOI 10.1016/S0092-8674(00)80829-6; Palacios I, 1997, EMBO J, V16, P6783, DOI 10.1093/emboj/16.22.6783; PALFI Z, 1992, J BIOL CHEM, V267, P20159; PALFI Z, 1994, J BIOL CHEM, V269, P30620; Palfi Z, 2000, P NATL ACAD SCI USA, V97, P8967, DOI 10.1073/pnas.150236097; PALFI Z, 1991, P NATL ACAD SCI USA, V88, P9097, DOI 10.1073/pnas.88.20.9097; Pannone BK, 1998, EMBO J, V17, P7442, DOI 10.1093/emboj/17.24.7442; Pellizzoni L, 2002, SCIENCE, V298, P1775, DOI 10.1126/science.1074962; PERRY KL, 1987, P NATL ACAD SCI USA, V84, P8190, DOI 10.1073/pnas.84.23.8190; Raker VA, 1996, EMBO J, V15, P2256, DOI 10.1002/j.1460-2075.1996.tb00579.x; RYMOND BC, 1993, P NATL ACAD SCI USA, V90, P848, DOI 10.1073/pnas.90.3.848; Seipelt RL, 1999, NUCLEIC ACIDS RES, V27, P587, DOI 10.1093/nar/27.2.587; SOGIN ML, 1986, P NATL ACAD SCI USA, V83, P1383, DOI 10.1073/pnas.83.5.1383; Sturm NR, 1999, J BIOL CHEM, V274, P19361, DOI 10.1074/jbc.274.27.19361; Sturm NR, 1999, MOL CELL BIOL, V19, P1595; THOMASHOW LS, 1983, CELL, V32, P35, DOI 10.1016/0092-8674(83)90494-4; TSCHUDI C, 1990, CELL, V61, P459, DOI 10.1016/0092-8674(90)90527-L; ULLU E, 1991, P NATL ACAD SCI USA, V88, P10074, DOI 10.1073/pnas.88.22.10074; Wang ZF, 2001, EMBO J, V20, P4674, DOI 10.1093/emboj/20.17.4674; Will CL, 2001, CURR OPIN CELL BIOL, V13, P290, DOI 10.1016/S0955-0674(00)00211-8; Wolin SL, 2002, ANNU REV BIOCHEM, V71, P375, DOI 10.1146/annurev.biochem.71.090501.150003; Xu YX, 1997, P NATL ACAD SCI USA, V94, P8473, DOI 10.1073/pnas.94.16.8473; Zeiner GM, 2003, EUKARYOT CELL, V2, P222, DOI 10.1128/EC.2.2.222-230.2003; Zhao XL, 2002, RNA, V8, P1515, DOI 10.1017/S1355838202022537	60	58	60	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51469	51478		10.1074/jbc.M308997200	http://dx.doi.org/10.1074/jbc.M308997200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14532264	hybrid			2022-12-27	WOS:000187206300077
J	Park, HI; Jin, YH; Hurst, DR; Monroe, CA; Lee, S; Schwartz, MA; Sang, QXA				Park, HI; Jin, YH; Hurst, DR; Monroe, CA; Lee, S; Schwartz, MA; Sang, QXA			The intermediate S1 ' pocket of the endometase/matrilysin-2 active site revealed by enzyme inhibition kinetic studies, protein sequence analyses, and homology modeling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MACROPHAGE ELASTASE MMP-12; X-RAY-STRUCTURE; CRYSTAL-STRUCTURE; CATALYTIC DOMAIN; METALLOPROTEINASE INHIBITORS; MATRIX METALLOPROTEINASE-26; SUBSTRATE-SPECIFICITY; TISSUE INHIBITOR; SWISS-MODEL; COLLAGENASE	Human matrix metalloproteinase-26 (MMP-26/ endometase/ matrilysin-2) is a newly identified MMP and its structure has not been reported. The enzyme active site S-1' pocket in MMPs is a well defined substrate P-1' amino acid residue-binding site with variable depth. To explore MMP-26 active site structure-activity, a series of new potent mercaptosulfide MMP inhibitors (MMPIs) with Leu or homophenylalanine (Homophe) side chains at the P-1' site were selected. The Homephe side chain is designed to probe deep S-1' pocket MMPs. These inhibitors were tested against MMP-26 and several MMPs with known x-ray crystal structures to distinguish shallow, intermediate, and deep S-1' pocket characteristics. MMP-26 has an inhibition profile most similar to those of MMPs with intermediate S-1' pockets. Investigations with hydroxamate MMPIs, including those designed for deep pocket MMPs, also indicated the presence of an intermediate pocket. Protein sequence analysis and homology modeling further verified that MMP-26 has an intermediate S-1' pocket formed by Leu-204, His-208, and Tyr-230. Moreover, residue 233 may influence the depth of an MMP S-1' pocket. The residue at the equivalent position of MMP-26 residue 233 is hydrophilic in intermediate-pocket MMPs (e.g. MMP-2, -8, and -9) and hydrophobic in deep-pocket MMPs (e.g. MMP-3, - 12, and - 14). MMP-26 contains a His-233 that renders the S-1' pocket to an intermediate size. This study suggests that MMPIs, protein sequence analyses, and molecular modeling are useful tools to understand structure-activity relationships and provides new insight for rational inhibitor design that may distinguish MMPs with deep versus intermediate S-1' pockets.	Florida State Univ, Dept Chem & Biochem, Tallahassee, FL 32306 USA; Florida State Univ, Inst Mol Biophys, Tallahassee, FL 32306 USA	State University System of Florida; Florida State University; State University System of Florida; Florida State University	Sang, QXA (corresponding author), Florida State Univ, Dept Chem & Biochem, Chem Res Bldg DLC,Rm 203, Tallahassee, FL 32306 USA.	sang@chem.fsu.edu	Hurst, Douglas R/B-7341-2009	Hurst, Douglas/0000-0002-1296-2210	NCI NIH HHS [CA78646] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA078646] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arighi CN, 1998, BIOCHEMISTRY-US, V37, P16802, DOI 10.1021/bi981827x; Bode W, 1999, CELL MOL LIFE SCI, V55, P639, DOI 10.1007/s000180050320; BODE W, 1994, EMBO J, V13, P1263, DOI 10.1002/j.1460-2075.1994.tb06378.x; Bohacek R, 1996, J AM CHEM SOC, V118, P8231, DOI 10.1021/ja950818y; Brinckerhoff CE, 2002, NAT REV MOL CELL BIO, V3, P207, DOI 10.1038/nrm763; BROWNER MF, 1995, BIOCHEMISTRY-US, V34, P6602, DOI 10.1021/bi00020a004; CHANG G, 1989, J AM CHEM SOC, V111, P4379, DOI 10.1021/ja00194a035; Copeland R. A., 2004, ENZYMES PRACTICAL IN; Coussens LM, 2002, SCIENCE, V295, P2387, DOI 10.1126/science.1067100; de Coignac AB, 2000, EUR J BIOCHEM, V267, P3323; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; Fernandez-Catalan C, 1998, EMBO J, V17, P5238, DOI 10.1093/emboj/17.17.5238; GALARDY RE, 1994, ANN NY ACAD SCI, V732, P315, DOI 10.1111/j.1749-6632.1994.tb24746.x; GOOLEY PR, 1994, NAT STRUCT BIOL, V1, P111, DOI 10.1038/nsb0294-111; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HURST DR, 2003, BIOCHEM J, DOI DOI 10.1015/BJ20031067; Jin YH, 2002, TETRAHEDRON LETT, V43, P7319, DOI 10.1016/S0040-4039(02)01750-1; KNIGHT CG, 1992, FEBS LETT, V296, P263, DOI 10.1016/0014-5793(92)80300-6; Lang R, 2001, J MOL BIOL, V312, P731, DOI 10.1006/jmbi.2001.4954; LOVEJOY B, 1994, SCIENCE, V263, P375, DOI 10.1126/science.8278810; MacPherson LJ, 1997, J MED CHEM, V40, P2525, DOI 10.1021/jm960871c; Marchenko GN, 2002, BIOCHEM J, V363, P253, DOI 10.1042/0264-6021:3630253; Marchenko GN, 2001, BIOCHEM J, V356, P705, DOI 10.1042/0264-6021:3560705; Matter H, 1999, J MED CHEM, V42, P1908, DOI 10.1021/jm980631s; Morgunova E, 2002, P NATL ACAD SCI USA, V99, P7414, DOI 10.1073/pnas.102185399; MORRISON JF, 1969, BIOCHIM BIOPHYS ACTA, V185, P269, DOI 10.1016/0005-2744(69)90420-3; Mucha A, 1998, J BIOL CHEM, V273, P2763, DOI 10.1074/jbc.273.5.2763; NAGASE H, 1994, J BIOL CHEM, V269, P20952; Nagase H, 2000, CANC DRUG DISC DEV, P39; Nar H, 2001, J MOL BIOL, V312, P743, DOI 10.1006/jmbi.2001.4953; NETZELARNETT S, 1993, BIOCHEMISTRY-US, V32, P6427, DOI 10.1021/bi00076a016; Overall CM, 2002, MOL BIOTECHNOL, V22, P51, DOI 10.1385/MB:22:1:051; Overall CM, 2002, NAT REV CANCER, V2, P657, DOI 10.1038/nrc884; Park HI, 2000, J BIOL CHEM, V275, P20540, DOI 10.1074/jbc.M002349200; Park HI, 2002, J BIOL CHEM, V277, P35168, DOI 10.1074/jbc.M205071200; Pavlovsky AG, 1999, PROTEIN SCI, V8, P1455, DOI 10.1110/ps.8.7.1455; PEITSCH MC, 1995, BIO-TECHNOL, V13, P658, DOI 10.1038/nbt0795-658; Peitsch MC, 1996, BIOCHEM SOC T, V24, P274, DOI 10.1042/bst0240274; RIDDLES PW, 1979, ANAL BIOCHEM, V94, P75, DOI 10.1016/0003-2697(79)90792-9; Rowsell S, 2002, J MOL BIOL, V319, P173, DOI 10.1016/S0022-2836(02)00262-0; SANG QX, 1995, BBA-PROTEIN STRUCT M, V1251, P99, DOI 10.1016/0167-4838(95)00086-A; Sang QXA, 2000, BIOCHEM BIOPH RES CO, V274, P780, DOI 10.1006/bbrc.2000.3212; Sang QXA, 1996, J PROTEIN CHEM, V15, P243, DOI 10.1007/BF01887112; SCHWARTZ MA, 1995, Patent No. 5455262; SPURLINO JC, 1994, PROTEINS, V19, P98, DOI 10.1002/prot.340190203; STAMS T, 1994, NAT STRUCT BIOL, V1, P119, DOI 10.1038/nsb0294-119; Uria JA, 2000, CANCER RES, V60, P4745; Zhao YG, 2003, J BIOL CHEM, V278, P15056, DOI 10.1074/jbc.M210975200; ZHAO YG, 2003, IN PRESS CANC RES	50	49	49	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51646	51653		10.1074/jbc.M310109200	http://dx.doi.org/10.1074/jbc.M310109200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14532275	hybrid			2022-12-27	WOS:000187206300099
J	Woelfle, J; Chia, DJ; Rotwein, P				Woelfle, J; Chia, DJ; Rotwein, P			Mechanisms of growth hormone (GH) action - Identification of conserved Stat5 binding sites that mediate GH-induced insulin-like growth factor-I gene activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATES GROWTH; RAPID CHANGES; TRANSCRIPTION; PROTEINS; TRANSACTIVATION; RECRUITMENT; COFACTOR; ROLES; SERUM; VIVO	Many of the actions of growth hormone (GH) on somatic growth and tissue maintenance are mediated by insulin-like growth factor-I (IGF-I), a secreted protein whose gene expression is rapidly and potently induced by GH by unknown mechanisms. Recent studies implicating Stat5a and Stat5b in the growth response to GH in mice and observations linking Stat5b to control of IGF-I gene transcription in rats have prompted the current investigations into the molecular determinants of a putative regulatory network extending from GH through Stat5b to IGF-I. Here we characterize as critical components of this hormone-activated transcriptional pathway two adjacent Stat5 binding sites in the second intron of the rat IGF-I gene located within a conserved region previously found to undergo acute and reversible changes in chromatin structure after in vivo GH treatment. As assessed by chromatin immunoprecipitation assays, GH rapidly induced binding of Stat5 to this DNA segment in the liver of GH-deficient rats, just prior to the onset of transcription from both major and minor IGF-I gene promoters. Biochemical reconstitution experiments showed that the two intronic Stat5 DNA elements were able to bind Stat5b in vitro after GH treatment could transmit GH- and Stat5b-dependent transcriptional responsiveness to the major IGF-I promoter and to a minimal neutral gene promoter and were required for full stimulation of reporter gene activity by GH. Taken together, these results identify an intronic enhancer as a key mediator of GH- induced IGF-I gene transcription working through Stat5b and provide new insight into the molecular architecture of this transcriptional pathway.	Oregon Hlth & Sci Univ, Div Mol Med, Dept Med, Portland, OR 97239 USA; Oregon Hlth & Sci Univ, Div Endocrinol, Dept Pediat, Portland, OR 97239 USA	Oregon Health & Science University; Oregon Health & Science University	Rotwein, P (corresponding author), Oregon Hlth & Sci Univ, Div Mol Med, Dept Med, 3181 SW Sam Jackson Pk Rd,Mail Code HTC3, Portland, OR 97239 USA.	rotweinp@ohsu.edu	Woellfe, joachim F/E-9406-2014; Rotwein, Peter/R-5783-2019	, Joachim/0000-0002-9132-6174; Rotwein, Peter/0000-0002-9505-1817	NIDDK NIH HHS [R01 DK063073] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK063073] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adamo ML., 1995, DIABETES REV, V3, P2; BERRY SA, 1994, MOL ENDOCRINOL, V8, P1714, DOI 10.1210/me.8.12.1714; BICHELL DP, 1992, MOL ENDOCRINOL, V6, P1899, DOI 10.1210/me.6.11.1899; Boulikas Teni, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P117; DAUGHADAY WH, 1989, ENDOCR REV, V10, P68, DOI 10.1210/edrv-10-1-68; DERCOLE AJ, 1984, P NATL ACAD SCI-BIOL, V81, P935, DOI 10.1073/pnas.81.3.935; Ehret GB, 2001, J BIOL CHEM, V276, P6675, DOI 10.1074/jbc.M001748200; GRONOWSKI AM, 1994, J BIOL CHEM, V269, P7874; GRONOWSKI AM, 1995, ENDOCRINOLOGY, V136, P4741, DOI 10.1210/en.136.11.4741; GULER HP, 1988, P NATL ACAD SCI USA, V85, P4889, DOI 10.1073/pnas.85.13.4889; Herrington J, 2001, TRENDS ENDOCRIN MET, V12, P252, DOI 10.1016/S1043-2760(01)00423-4; Horvath CM, 2000, TRENDS BIOCHEM SCI, V25, P496, DOI 10.1016/S0968-0004(00)01624-8; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; Kaspar BK, 2003, SCIENCE, V301, P839, DOI 10.1126/science.1086137; Le Roith D, 2001, ENDOCR REV, V22, P53, DOI 10.1210/er.22.1.53; Peng B, 2002, MOL ENDOCRINOL, V16, P2019, DOI 10.1210/me.2002-0108; Pfitzner E, 1998, MOL ENDOCRINOL, V12, P1582, DOI 10.1210/mend.12.10.0180; Pollak M, 2000, GROWTH HORM IGF RES, V10, P21, DOI 10.1016/S1096-6374(00)80005-2; Rascle A, 2003, MOL CELL BIOL, V23, P4162, DOI 10.1128/MCB.23.12.4162-4173.2003; ROTWEIN P, 1997, J ANIM SCI, V75, P11; Rotwein Peter, 1999, V17, P19; SALMON WD, 1957, J LAB CLIN MED, V49, P825; SCHOENLE E, 1982, NATURE, V296, P252, DOI 10.1038/296252a0; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; Thomas MJ, 1996, J BIOL CHEM, V271, P21835, DOI 10.1074/jbc.271.36.21835; Udy GB, 1997, P NATL ACAD SCI USA, V94, P7239, DOI 10.1073/pnas.94.14.7239; Woelfle J, 2003, J BIOL CHEM, V278, P22696, DOI 10.1074/jbc.M301362200; Xu M, 2003, EMBO J, V22, P893, DOI 10.1093/emboj/cdg094; Yakar S, 2002, J CLIN INVEST, V110, P771, DOI 10.1172/JCI200215463; Ye SK, 2001, IMMUNITY, V15, P813, DOI 10.1016/S1074-7613(01)00230-8; Zhu MH, 1999, CELL, V96, P121, DOI 10.1016/S0092-8674(00)80965-4	33	151	154	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51261	51266		10.1074/jbc.M309486200	http://dx.doi.org/10.1074/jbc.M309486200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14532269	hybrid			2022-12-27	WOS:000187206300052
J	Zhang, R; Xu, YQ; Ekman, N; Wu, ZH; Wu, J; Alitalo, K; Min, W				Zhang, R; Xu, YQ; Ekman, N; Wu, ZH; Wu, J; Alitalo, K; Min, W			Etk/Bmx transactivates vascular endothelial growth factor 2 and recruits phosphatidylinositol 3-kinase to mediate the tumor necrosis factor-induced angiogenic pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR-2; NITRIC-OXIDE SYNTHASE; TYROSINE KINASE ETK; KAPPA-B; ACTIVATION; VEGF; FAMILY; ALPHA; EXPRESSION; INHIBITOR	Tumor necrosis factor (TNF), via its receptor 2 (TNFR2), induces Etk (or Bmx) activation and Etk-dependent endothelial cell (EC) migration and tube formation. Because TNF receptor 2 lacks an intrinsic kinase activity, we examined the kinase(s) mediating TNF-induced Etk activation. TNF induces a coordinated phosphorylation of vascular endothelial growth factor (VEGF) receptor 2 (VEGFR2) and Etk, which is blocked by VEGFR2-specific inhibitors. In response to TNF, Etk and VEGFR2 form a complex resulting in a reciprocal activation between the two kinases. Subsequently, the downstream phosphatidylinositol 3-kinase (PI3K)-Akt signaling (but not signaling through phospholipase C-gamma) was initiated and directly led to TNF-induced EC migration, which was significantly inhibited by VEGFR2-, PI3K-, or Akt-specific inhibitors. Phosphorylation of VEGFR2 at Tyr-801 and Tyr-1175, the critical sites for VEGF-induced PI3K-Akt signaling, was not involved in TNF-mediated Akt activation. However, TNF induces phosphorylation of Etk at Tyr-566, directly mediating the recruitment of the p85 subunit of PI3K. Furthermore, TNF- but not VEGF-induced activation of VEGFR2, Akt, and EC migration are blunted in EC genetically deficient with Etk. Taken together, our data demonstrated that TNF induces transactivation between Etk and VEGFR2, and Etk directly activates PI3K- Akt angiogenic signaling independent of VEGF-induced VEGFR2- PI3K- Akt signaling pathway.	Yale Univ, Boyer Ctr Mol Med, Interdept Program Vasc Biol & Transplantat, Sch Med, New Haven, CT 06510 USA; Univ Helsinki, FIN-00014 Helsinki, Finland; Univ Rochester, Rochester, NY 14534 USA; Cell Signaling Technol Inc, Beverly, MA 01915 USA	Yale University; University of Helsinki; University of Rochester	Min, W (corresponding author), Yale Univ, Boyer Ctr Mol Med, Interdept Program Vasc Biol & Transplantat, Sch Med, 295 Congress Ave, New Haven, CT 06510 USA.	wang.min@yale.edu	Alitalo, Kari K/J-5013-2014	Alitalo, Kari K/0000-0002-7331-0902	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065978] Funding Source: NIH RePORTER; NHLBI NIH HHS [1R01HL65978-01] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alavi A, 2003, SCIENCE, V301, P94, DOI 10.1126/science.1082015; Andreotti AH, 1997, NATURE, V385, P93, DOI 10.1038/385093a0; Arras M, 1998, J CLIN INVEST, V101, P40, DOI 10.1172/JCI119877; Autiero M, 2003, NAT MED, V9, P936, DOI 10.1038/nm884; Bagheri-Yarmand R, 2001, J BIOL CHEM, V276, P29403, DOI 10.1074/jbc.M103129200; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Chau CH, 2002, ONCOGENE, V21, P8817, DOI 10.1038/sj.onc.1206032; Chen RY, 2001, NAT CELL BIOL, V3, P439, DOI 10.1038/35074500; Cheng N, 2001, J BIOL CHEM, V276, P13771, DOI 10.1074/jbc.M009147200; Dayanir V, 2001, J BIOL CHEM, V276, P17686, DOI 10.1074/jbc.M009128200; Dimmeler S, 2000, FEBS LETT, V477, P258, DOI 10.1016/S0014-5793(00)01657-4; Dougher M, 1999, ONCOGENE, V18, P1619, DOI 10.1038/sj.onc.1202478; Ekman N, 1997, CIRCULATION, V96, P1729, DOI 10.1161/01.CIR.96.6.1729; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; FRATERSCHRODER M, 1987, P NATL ACAD SCI USA, V84, P5277, DOI 10.1073/pnas.84.15.5277; Gille H, 2000, EMBO J, V19, P4064, DOI 10.1093/emboj/19.15.4064; Giraudo E, 1998, J BIOL CHEM, V273, P22128, DOI 10.1074/jbc.273.34.22128; Guo DQ, 2000, J BIOL CHEM, V275, P11216, DOI 10.1074/jbc.275.15.11216; IruelaArispe ML, 1997, THROMB HAEMOSTASIS, V78, P672; Jin ZG, 2003, CIRC RES, V93, P354, DOI 10.1161/01.RES.0000089257.94002.96; KEFFER J, 1991, EMBO J, V10, P4025, DOI 10.1002/j.1460-2075.1991.tb04978.x; Kim O, 2002, J BIOL CHEM, V277, P30066, DOI 10.1074/jbc.M201713200; Kiosses WB, 2002, CIRC RES, V90, P697, DOI 10.1161/01.RES.0000014227.76102.5D; Koch AE, 1998, ARTHRITIS RHEUM-US, V41, P951, DOI 10.1002/1529-0131(199806)41:6<951::AID-ART2>3.0.CO;2-D; Kureishi Y, 2000, NAT MED, V6, P1004, DOI 10.1038/79510; Lee MJ, 1999, CELL, V99, P301, DOI 10.1016/S0092-8674(00)81661-X; Lee WS, 1998, CIRC RES, V82, P845; LEIBOVICH SJ, 1987, NATURE, V329, P630, DOI 10.1038/329630a0; Li J, 2000, NAT MED, V6, P49, DOI 10.1038/71527; Liu YM, 2001, J CLIN INVEST, V107, P917, DOI 10.1172/JCI11947; Maceyka M, 2002, BBA-MOL CELL BIOL L, V1585, P193, DOI 10.1016/S1388-1981(02)00341-4; Madge LA, 2000, J BIOL CHEM, V275, P15458, DOI 10.1074/jbc.M001237200; Mano H, 1999, CYTOKINE GROWTH F R, V10, P267, DOI 10.1016/S1359-6101(99)00019-2; Mao JH, 1998, EMBO J, V17, P5638, DOI 10.1093/emboj/17.19.5638; MATSUMOTO T, 2001, SCI STKE; Meyer RD, 2003, J BIOL CHEM, V278, P16347, DOI 10.1074/jbc.M300259200; Pan S, 2002, MOL CELL BIOL, V22, P7512, DOI 10.1128/MCB.22.21.7512-7523.2002; Qi JH, 2001, EXP CELL RES, V263, P173, DOI 10.1006/excr.2000.5102; Qiu Y, 1998, P NATL ACAD SCI USA, V95, P3644, DOI 10.1073/pnas.95.7.3644; Qiu Y, 2000, ONCOGENE, V19, P5651, DOI 10.1038/sj.onc.1203958; Rajantie I, 2001, MOL CELL BIOL, V21, P4647, DOI 10.1128/MCB.21.14.4647-4655.2001; Ristimaki A, 1998, J BIOL CHEM, V273, P8413, DOI 10.1074/jbc.273.14.8413; SARMA V, 1992, J IMMUNOL, V148, P3302; Takahashi T, 2001, EMBO J, V20, P2768, DOI 10.1093/emboj/20.11.2768; TakahashiTezuka M, 1997, ONCOGENE, V14, P2273, DOI 10.1038/sj.onc.1201071; TAMAGNONE L, 1994, ONCOGENE, V9, P3683; Tanimoto T, 2002, J BIOL CHEM, V277, P42997, DOI 10.1074/jbc.M204764200; Tsai YT, 2000, MOL CELL BIOL, V20, P2043, DOI 10.1128/MCB.20.6.2043-2054.2000; Walsh DA, 1999, RHEUMATOLOGY, V38, P103, DOI 10.1093/rheumatology/38.2.103; Wu LW, 2000, J BIOL CHEM, V275, P5096, DOI 10.1074/jbc.275.7.5096	50	119	129	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51267	51276		10.1074/jbc.M310678200	http://dx.doi.org/10.1074/jbc.M310678200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14532277	hybrid			2022-12-27	WOS:000187206300053
J	Beltrami, E; Plescia, J; Wilkinson, JC; Duckett, CS; Altieri, DC				Beltrami, E; Plescia, J; Wilkinson, JC; Duckett, CS; Altieri, DC			Acute ablation of survivin uncovers p53-dependent mitotic checkpoint functions and control of mitochondrial apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILD-TYPE P53; SPINDLE CHECKPOINT; COLORECTAL-CANCER; RNA INTERFERENCE; CELL-CYCLE; AURORA-B; PROTEIN; GENE; MITOSIS; CYTOKINESIS	Survivin is a member of the Inhibitor of Apoptosis gene family that has been implicated in cell division and suppression of apoptosis. Here, we show that preferential ablation of the nuclear pool of survivin by RNA interference produces a mitotic arrest followed by re-entry into the cell cycle and polyploidy. Survivin ablation causes multiple centrosomal defects, aberrant multipolar spindle formation, and chromatin missegregation, and these phenotypes are exacerbated by loss of the cell cycle regulator, p21(Waf1/Cip1) in p21(-/-) cells. The mitotic checkpoint activated by loss of survivin is mediated by induction of p53 and associated with increased expression of its downstream target, p21(Waf1/Cip1). Accordingly, p53(-/-) cells exhibit reduced mitotic arrest and enhanced polyploidy upon survivin ablation as compared with their p53(+/+) counterparts. Partial reduction of the cytosolic pool of survivin by RNA interference sensitizes cells to ultraviolet B-mediated apoptosis and results in enhanced caspase-9 proteolytic cleavage, whereas complete ablation of cytosolic survivin causes loss of mitochondrial membrane potential and spontaneous apoptosis. These data demonstrate that survivin has separable checkpoint functions at multiple phases of mitosis and in the control of mitochondrial-dependent apoptosis.	Univ Massachusetts, Sch Med, Dept Canc Biol, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Ctr Canc, Worcester, MA 01605 USA; Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Altieri, DC (corresponding author), Univ Massachusetts, Sch Med, Dept Canc Biol, LRB428,364 Plantat St, Worcester, MA 01605 USA.	dario.altieri@umassmed.edu	beltrami, elena/AAE-9937-2021	Duckett, Colin/0000-0001-9413-2263	NATIONAL CANCER INSTITUTE [R01CA090917, R01CA078810, T32CA009676] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL054131, R01HL054131] Funding Source: NIH RePORTER; NCI NIH HHS [CA 90917, T32 CA 09676, CA 78810] Funding Source: Medline; NHLBI NIH HHS [HL 54131] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Altieri DC, 2003, NAT REV CANCER, V3, P46, DOI 10.1038/nrc968; Ambrosini G, 1998, J BIOL CHEM, V273, P11177, DOI 10.1074/jbc.273.18.11177; Blanc-Brude OP, 2003, CLIN CANCER RES, V9, P2683; Carvalho A, 2003, J CELL SCI, V116, P2987, DOI 10.1242/jcs.00612; Chan TA, 2000, GENE DEV, V14, P1584; Eckley DM, 1997, J CELL BIOL, V136, P1169, DOI 10.1083/jcb.136.6.1169; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Fortugno P, 2002, J CELL SCI, V115, P575; Fraser AG, 1999, CURR BIOL, V9, P292, DOI 10.1016/S0960-9822(99)80137-7; Giodini A, 2002, CANCER RES, V62, P2462; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; Jiang XY, 2001, J CELL BIOCHEM, V83, P342, DOI 10.1002/jcb.1228; Kallio MJ, 2002, CURR BIOL, V12, P900, DOI 10.1016/S0960-9822(02)00887-4; Kim PJ, 2003, LANCET, V362, P205, DOI 10.1016/S0140-6736(03)13910-4; Lanni JS, 1998, MOL CELL BIOL, V18, P1055, DOI 10.1128/MCB.18.2.1055; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Lens SMA, 2003, EMBO J, V22, P2934, DOI 10.1093/emboj/cdg307; Li FZ, 1999, NAT CELL BIOL, V1, P461, DOI 10.1038/70242; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Mahotka C, 1999, CANCER RES, V59, P6097; Mantel C, 1999, BLOOD, V93, P1390, DOI 10.1182/blood.V93.4.1390.404k25_1390_1398; Marusawa H, 2003, EMBO J, V22, P2729, DOI 10.1093/emboj/cdg263; McDonald ER, 2001, ANN MED, V33, P113, DOI 10.3109/07853890109002066; McKay TR, 2003, ONCOGENE, V22, P3539, DOI 10.1038/sj.onc.1206417; Mesri M, 2001, J CLIN INVEST, V108, P981, DOI 10.1172/JCI12983; Mirza A, 2002, ONCOGENE, V21, P2613, DOI 10.1038/sj.onc.1205353; Mollinari C, 2003, DEV CELL, V5, P295, DOI 10.1016/S1534-5807(03)00205-3; Murata-Hori M, 2002, CURR BIOL, V12, P894, DOI 10.1016/S0960-9822(02)00848-5; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Silke J, 2001, J CELL SCI, V114, P1821; Sommer KW, 2003, ONCOGENE, V22, P4266, DOI 10.1038/sj.onc.1206509; Speliotes EK, 2000, MOL CELL, V6, P211, DOI 10.1016/S1097-2765(00)00023-X; Tarapore P, 2001, ONCOGENE, V20, P3173, DOI 10.1038/sj.onc.1204424; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; Terada Y, 1998, EMBO J, V17, P667, DOI 10.1093/emboj/17.3.667; Uren AG, 2000, CURR BIOL, V10, P1319, DOI 10.1016/S0960-9822(00)00769-7; Verdecia MA, 2000, NAT STRUCT BIOL, V7, P602; Wang HW, 2002, EMBO J, V21, P2602, DOI 10.1093/emboj/21.11.2602; Wang XD, 2001, GENE DEV, V15, P2922; Wheatley SP, 2001, CURR BIOL, V11, P886, DOI 10.1016/S0960-9822(01)00238-X; Williams NS, 2003, CLIN CANCER RES, V9, P931; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	45	112	124	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 16	2004	279	3					2077	2084		10.1074/jbc.M309479200	http://dx.doi.org/10.1074/jbc.M309479200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	762WT	14581472	hybrid			2022-12-27	WOS:000188005700063
J	Taneja, N; Davis, M; Choy, JS; Beckett, MA; Singh, R; Kron, SJ; Weichselbaum, RR				Taneja, N; Davis, M; Choy, JS; Beckett, MA; Singh, R; Kron, SJ; Weichselbaum, RR			Histone H2AX phosphorylation as a predictor of radiosensitivity and target for radiotherapy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRAND BREAKS; DNA-DAMAGE CHECKPOINT; HUMAN-TUMOR-CELLS; IONIZING-RADIATION; GENOMIC INSTABILITY; CHROMATIN DYNAMICS; EARLY PARTICIPANT; REPAIR FACTORS; NECK-CANCER; THERAPY	Based on the role of phosphorylation of the histone H2A variant H2AX in recruitment of DNA repair and checkpoint proteins to the sites of DNA damage, we have investigated gammaH2AX as a reporter of tumor radiosensitivity and a potential target to enhance the effectiveness of radiation therapy. Clinically relevant ionizing radiation (IR) doses induced similar patterns of gammaH2AX focus formation or immunoreactivity in radiosensitive and radioresistant human tumor cell lines and xenografted tumors. However, radiosensitive tumor cells and xenografts retained gammaH2AX for a greater duration than radioresistant cells and tumors. These results suggest that persistence of gammaH2AX after IR may predict tumor response to radiotherapy. We synthesized peptide mimics of the H2AX carboxyl-terminal tail to test whether antagonizing H2AX function affects tumor cell survival following IR. The peptides did not alter the viability of unirradiated tumor cells, but both blocked induction of gammaH2AX foci by IR and enhanced cell death in irradiated radioresistant tumor cells. These results suggest that H2AX is a potential molecular target to enhance the effects of radiotherapy.	Univ Chicago, Ctr Mol Oncol, Chicago, IL 60637 USA; Univ Chicago, Dept Radiat & Cellular Oncol, Chicago, IL 60637 USA; Univ Chicago, Dept Mol Genet & Cell Biol, Chicago, IL 60637 USA	University of Chicago; University of Chicago; University of Chicago	Weichselbaum, RR (corresponding author), Univ Chicago, Ctr Mol Oncol, 924 E 57th St, Chicago, IL 60637 USA.	rrw@rover.bsd.uchicago.edu		Kron, Stephen/0000-0003-1518-2436; Choy, John/0000-0001-9196-3280				Abdollahi A, 2003, CANCER RES, V63, P3755; Banath JP, 2003, CANCER RES, V63, P4347; Bassing CH, 2002, P NATL ACAD SCI USA, V99, P8173, DOI 10.1073/pnas.122228699; BUDACH W, 1993, J NATL CANCER I, V85, P988, DOI 10.1093/jnci/85.12.988; Burma S, 2001, J BIOL CHEM, V276, P42462, DOI 10.1074/jbc.C100466200; Carbone R, 2002, ONCOGENE, V21, P1633, DOI 10.1038/sj.onc.1205227; Celeste A, 2003, NAT CELL BIOL, V5, P675, DOI 10.1038/ncb1004; Celeste A, 2002, SCIENCE, V296, P922, DOI 10.1126/science.1069398; Chapman JD, 2003, INT J RADIAT BIOL, V79, P71, DOI 10.1080/0955300021000038653; Chmura SJ, 2001, SEMIN RADIAT ONCOL, V11, P338, DOI 10.1053/srao.2001.26019; D'Amico AV, 2000, JAMA-J AM MED ASSOC, V284, P1280, DOI 10.1001/jama.284.10.1280; Eberharter A, 2002, EMBO REP, V3, P224, DOI 10.1093/embo-reports/kvf053; Fernandez-Capetillo O, 2002, NAT CELL BIOL, V4, P993, DOI 10.1038/ncb884; Fischle W, 2003, CURR OPIN CELL BIOL, V15, P172, DOI 10.1016/S0955-0674(03)00013-9; Furuta T, 2003, J BIOL CHEM, V278, P20303, DOI 10.1074/jbc.M300198200; Gellert M, 2002, ANNU REV BIOCHEM, V71, P101, DOI 10.1146/annurev.biochem.71.090501.150203; Goldberg M, 2003, NATURE, V421, P952, DOI 10.1038/nature01445; GORLACH A, 1994, ADV EXP MED BIOL, V345, P343; Green CM, 2002, EMBO REP, V3, P28, DOI 10.1093/embo-reports/kvf005; Guha C, 2000, GENE THER, V7, P852, DOI 10.1038/sj.gt.3301174; Hansen LT, 2003, LUNG CANCER-J IASLC, V40, P157, DOI 10.1016/S0169-5002(03)00026-6; Harari PM, 2003, SEMIN RADIAT ONCOL, V13, P3, DOI 10.1053/srao.2003.50001; Hasan S, 2002, J MOL MED, V80, P463, DOI 10.1007/s00109-002-0341-7; Hunter N, 2001, NAT GENET, V27, P236, DOI 10.1038/85781; KAIGHN ME, 1981, P NATL ACAD SCI-BIOL, V78, P5673, DOI 10.1073/pnas.78.9.5673; Kobayashi J, 2002, CURR BIOL, V12, P1846, DOI 10.1016/S0960-9822(02)01259-9; LIU VF, 1995, STEM CELLS, V13, P117; Martinez-Lopez W, 2001, CHROMOSOME RES, V9, P69, DOI 10.1023/A:1026747801728; Mauceri HJ, 1998, NATURE, V394, P287, DOI 10.1038/28412; Meyn RE, 1996, CANCER METAST REV, V15, P119, DOI 10.1007/BF00049491; Milas L, 2003, HEAD NECK-J SCI SPEC, V25, P152, DOI 10.1002/hed.10232; Morris MC, 2001, NAT BIOTECHNOL, V19, P1173, DOI 10.1038/nbt1201-1173; MUNDT AJ, 2000, CANC MED, P465; Mundt AJ, 2003, HOLLAND FREI CANC ME, P585; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Peng AM, 2003, J BIOL CHEM, V278, P8873, DOI 10.1074/jbc.C300001200; Redon C, 2002, CURR OPIN GENET DEV, V12, P162, DOI 10.1016/S0959-437X(02)00282-4; Robson T, 2000, INT J RADIAT BIOL, V76, P617, DOI 10.1080/095530000138277; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Roninson IB, 2001, DRUG RESIST UPDATE, V4, P303, DOI 10.1054/drup.2001.0213; SANKARANARAYANAN K, 1990, GENET RES, V56, P267, DOI 10.1017/S0016672300035370; Sartor CI, 2003, SEMIN RADIAT ONCOL, V13, P22, DOI 10.1053/srao.2003.50003; Schultz LB, 2000, J CELL BIOL, V151, P1381, DOI 10.1083/jcb.151.7.1381; Sedelnikova OA, 2003, CANCER BIOL THER, V2, P233; Sedelnikova OA, 2002, RADIAT RES, V158, P486, DOI 10.1667/0033-7587(2002)158[0486:QDOIID]2.0.CO;2; Shang YL, 2003, J BIOL CHEM, V278, P6323, DOI 10.1074/jbc.M210749200; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Smerdon MJ, 1999, PROG NUCLEIC ACID RE, V62, P227; SPELLMAN JE, 1995, J SURG RES, V58, P165, DOI 10.1006/jsre.1995.1026; Stewart GS, 2003, NATURE, V421, P961, DOI 10.1038/nature01446; Suit H, 2002, INT J RADIAT ONCOL, V53, P798, DOI 10.1016/S0360-3016(02)02851-1; Vaupel P, 2003, ADV EXP MED BIOL, V510, P45; Vokes EE, 1999, SEMIN RADIAT ONCOL, V9, P70; Ward IM, 2003, J BIOL CHEM, V278, P19579, DOI 10.1074/jbc.C300117200; Webb S, 2000, Lancet Oncol, V1, P30, DOI 10.1016/S1470-2045(00)00110-8; Weichselbaum R R, 1995, Cancer J Sci Am, V1, P28; WEICHSELBAUM RR, 1986, P NATL ACAD SCI USA, V83, P2684, DOI 10.1073/pnas.83.8.2684; Wolffe A. P., 1999, CHROMATIN STRUCTURE	59	231	239	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 16	2004	279	3					2273	2280		10.1074/jbc.M310030200	http://dx.doi.org/10.1074/jbc.M310030200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	762WT	14561744	hybrid			2022-12-27	WOS:000188005700084
J	Ventura, A; Maccarana, M; Raker, VA; Pelicci, PG				Ventura, A; Maccarana, M; Raker, VA; Pelicci, PG			A cryptic targeting signal induces isoform-specific localization of p46Shc to mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOTYROSINE-BINDING DOMAIN; KINASE-C-DELTA; OXIDATIVE STRESS; ENDOPLASMIC-RETICULUM; TYROSINE KINASE; SHC PROTEINS; PHOSPHORYLATION; PATHWAY; ACTIVATION; MEMBRANES	The human Src homology and collagen (Shc) gene encodes three protein isoforms of 46, 52, and 66 kDa that belong to a family of molecular adapters involved in several signal transduction pathways. Recently, the 66-kDa isoform has been shown to play a central role in controlling reactive oxygen species metabolism and life span in mammals. Despite the large amount of information available on the biology and biochemistry of Shc proteins, very little is known regarding the regulation of their subcellular localization. Here we demonstrate the specific and selective localization of p46Shc to the mitochondrial matrix. Through deletion mapping experiments, we show that targeting of p46Shc to mitochondria is mediated by its first 32 amino acids, which behave as a bona fide mitochondrial targeting sequence. We further demonstrate that the N-terminal location of the signal peptide is critical for its function. This accounts for the observation that p52Shc and p66Shc, containing the same sequence but more internally located, display a remarkably different subcellular localization. These findings indicate that p46Shc may exert a nonredundant biological function in signal transduction pathways involving mitochondria.	European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy; MIT, Ctr Canc Res, Cambridge, MA 02139 USA; FIRC Inst Mol Oncol, I-20131 Milan, Italy	IRCCS European Institute of Oncology (IEO); Massachusetts Institute of Technology (MIT); IFOM - FIRC Institute of Molecular Oncology	Ventura, A (corresponding author), MIT, Ctr Canc Res, 40 Ames St, Cambridge, MA 01239 USA.	aventura@mit.edu	maccarana, marco/AAB-4764-2021; Pelicci, Pier Giuseppe/AAL-6572-2020; Ventura, Andrea/F-1789-2011	Maccarana, Marco/0000-0003-3549-8921; Ventura, Andrea/0000-0003-4320-9907				Corso M, 2001, PLACENTA, V22, P432, DOI 10.1053/plac.2001.0672; Faisal A, 2002, J BIOL CHEM, V277, P30144, DOI 10.1074/jbc.M203229200; Farooq A, 2003, STRUCTURE, V11, P905, DOI 10.1016/S0969-2126(03)00134-5; Fradkov AF, 2000, FEBS LETT, V479, P127, DOI 10.1016/S0014-5793(00)01895-0; FUJIKI Y, 1982, J CELL BIOL, V93, P103, DOI 10.1083/jcb.93.1.103; HABIB T, 1994, J BIOL CHEM, V269, P25243; HORWICH AL, 1986, CELL, V44, P451, DOI 10.1016/0092-8674(86)90466-6; Huang LJS, 1999, J CELL BIOL, V145, P951, DOI 10.1083/jcb.145.5.951; Ito Y, 2001, CELL DEATH DIFFER, V8, P794, DOI 10.1038/sj.cdd.4400886; Kharbanda S, 2000, J BIOL CHEM, V275, P322, DOI 10.1074/jbc.275.1.322; Kumar S, 2001, J BIOL CHEM, V276, P17281, DOI 10.1074/jbc.M101414200; Lai KMV, 2000, GENE DEV, V14, P1132; LANFRANCONE L, 1995, ONCOGENE, V10, P907; Li LW, 1999, MOL CELL BIOL, V19, P8547; Lotti LV, 1996, MOL CELL BIOL, V16, P1946; Majumder PK, 2001, CELL GROWTH DIFFER, V12, P465; Migliaccio E, 1997, EMBO J, V16, P706, DOI 10.1093/emboj/16.4.706; Migliaccio E, 1999, NATURE, V402, P309, DOI 10.1038/46311; Okada S, 1997, J BIOL CHEM, V272, P28042, DOI 10.1074/jbc.272.44.28042; OKADA S, 1995, J BIOL CHEM, V270, P20737, DOI 10.1074/jbc.270.35.20737; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; Pfanner N, 2002, CURR OPIN CELL BIOL, V14, P400, DOI 10.1016/S0955-0674(02)00355-1; Ravichandran KS, 2001, ONCOGENE, V20, P6322, DOI 10.1038/sj.onc.1204776; Ravichandran KS, 1997, MOL CELL BIOL, V17, P5540, DOI 10.1128/MCB.17.9.5540; Robin MA, 2002, J BIOL CHEM, V277, P40583, DOI 10.1074/jbc.M203292200; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SALCINI AE, 1994, ONCOGENE, V9, P2827; Sato K, 2002, J BIOL CHEM, V277, P29568, DOI 10.1074/jbc.M203179200; TECHNIKOVADOBROVA Z, 1993, FEBS LETT, V322, P51, DOI 10.1016/0014-5793(93)81109-D; Trinei M, 2002, ONCOGENE, V21, P3872, DOI 10.1038/sj.onc.1205513; Ventura A, 2002, J BIOL CHEM, V277, P22370, DOI 10.1074/jbc.M200280200; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; Yuryev A, 2000, MOL CELL BIOL, V20, P4870, DOI 10.1128/MCB.20.13.4870-4878.2000; ZHOU MM, 1995, NATURE, V378, P584, DOI 10.1038/378584a0	34	49	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 16	2004	279	3					2299	2306		10.1074/jbc.M307655200	http://dx.doi.org/10.1074/jbc.M307655200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	762WT	14573619	hybrid			2022-12-27	WOS:000188005700087
J	Thompson, J; Hess, S; Pikis, A				Thompson, J; Hess, S; Pikis, A			Genes malh and pagl of Clostridium acetobutylicum ATCC 824 encode NAD(+)- and Mn2+-dependent phospho-alpha-glucosidase(s)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID-SEQUENCE SIMILARITIES; ALPHA-GLUCOSIDASE AGLA; GLUCOSYL-D-FRUCTOSES; BACILLUS-SUBTILIS; ESCHERICHIA-COLI; FUSOBACTERIUM-MORTIFERUM; KLEBSIELLA-PNEUMONIAE; GLYCOSYL HYDROLASES; FAMILY 4; PHOSPHOTRANSFERASE SYSTEM	The genome of Clostridium acetobutylicum 824 contains two genes encoding NAD(+), Mn2+, and dithiothreitol-dependent phospho-alpha-glucosidases that can be assigned to family 4 of the glycosylhydrolase superfamily. The two genes, designated malh ((mal) under bar tose 6-phosphate (h) under bar ydrolase) and pagl ((p) under bar hospho-(&alpha;-gl) under bar ucosidase), respectively, reside in separate operons that also encode proteins of the phosphoenolpyruvate-dependent: sugar phosphotransferase system. C. acetobutylicum grows on a variety of alpha-linked glucosides, including maltose, methyl-alpha-D-glucoside, and the five isomers of sucrose. In the presence of the requisite cofactors, extracts of these cells readily hydrolyzed the chromogenic substrate p-nitrophenyl-alpha-D-glucopyranoside 6-phosphate, but whether hydrolysis reflected expression of enzymes encoded by the malh or pagl genes was not discernible by spectrophotometric analysis or polyacrylamide gel electrophoresis. Resolution of this question required the cloning of the malh and pagl genes, and subsequent high expression, purification, and characterization of maltose-6'-phosphate hydrolase (MalH) and phospho-alpha-glucosidase (PagL), respectively. MalH and PagL exhibit 50% residue identity, and in solution are tetramers comprising similar sized (similar to50 kDa) subunits. The two proteins cross-react with polyclonal rabbit antibody against phospho-alpha-glucosidase from Fusobacterium mortiferum. Purified MalH and PagL cleaved p-nitrophenyl-alpha-D-glucopyranoside 6-phosphate with comparable efficiency, but only MalH catalyzed the hydrolysis of disaccharide 6'-phosphates formed via the phosphoenolpyruvate-dependent: sugar phosphotransferase system. Importantly, analysis of the proteome of C. acetobutylicum 824 by electrospray ionization-mass spectrometry confirmed expression of MalH during growth on many alpha-glucosides tested. Site-directed changes C169S and D170N yielded full-length, but catalytically inactive MalH. Of the two putative operons, our findings suggest that only proteins encoded by the mal operon participate in the dissimilation of maltose and related O-alpha-linked glucosides by C. acetobutylicum 824.	NIDCR, Microbial Biochem & Genet Unit, Oral Infect & Immun Branch, NIH, Bethesda, MD 20892 USA; NIDDK, Proteom & Mass Spectrometry Facil, Bioorgan Chem Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Thompson, J (corresponding author), NIDCR, Microbial Biochem & Genet Unit, Oral Infect & Immun Branch, NIH, Bldg 30,Rm 528,Convent Dr,MSC-4350, Bethesda, MD 20892 USA.		Hess, Sonja/K-4842-2013; PIKIS, ANDREAS/AFU-1192-2022	Hess, Sonja/0000-0002-5904-9816; 	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000341] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000341] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK070004] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bouma CL, 1997, J BACTERIOL, V179, P4129, DOI 10.1128/jb.179.13.4129-4137.1997; BURSTEIN C, 1971, BIOCHIM BIOPHYS ACTA, V230, P52, DOI 10.1016/0304-4165(71)90053-5; Dahl MK, 1997, FEMS MICROBIOL LETT, V148, P233, DOI 10.1016/S0378-1097(97)00039-6; DAVIES G, 1995, STRUCTURE, V3, P853, DOI 10.1016/S0969-2126(01)00220-9; Durre P, 1998, APPL MICROBIOL BIOT, V49, P639, DOI 10.1007/s002530051226; Hamada S, 2002, PURE APPL CHEM, V74, P1293, DOI 10.1351/pac200274071293; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; HENRISSAT B, 1993, BIOCHEM J, V293, P781, DOI 10.1042/bj2930781; JONES DT, 1995, FEMS MICROBIOL REV, V17, P223, DOI 10.1016/0168-6445(95)00010-A; LICHTENTHALER FW, 1990, J CHEM SOC PERK T 2, P1489, DOI 10.1039/p29900001489; Lodge JA, 2003, J BIOL CHEM, V278, P19151, DOI 10.1074/jbc.M211626200; LOESCHE WJ, 1986, MICROBIOL REV, V50, P353, DOI 10.1128/MMBR.50.4.353-380.1986; MEADOW ND, 1990, ANNU REV BIOCHEM, V59, P497, DOI 10.1146/annurev.biochem.59.1.497; MITCHELL WJ, 1995, FEMS MICROBIOL REV, V17, P317, DOI 10.1016/0168-6445(95)00013-3; Mitchell WJ, 1998, ADV MICROB PHYSIOL, V39, P31; MONOT F, 1982, APPL ENVIRON MICROB, V44, P1318, DOI 10.1128/AEM.44.6.1318-1324.1982; Moynihan PJ, 1998, J DENT, V26, P209, DOI 10.1016/S0300-5712(97)00010-9; NAGAO Y, 1988, BIOCHEM BIOPH RES CO, V151, P236, DOI 10.1016/0006-291X(88)90584-0; Newbrun E, 1989, CARIOLOGY, V3rd; Nolling J, 2001, J BACTERIOL, V183, P4823, DOI 10.1128/JB.183.16.4823-4838.2001; OOSHIMA T, 1990, CARIES RES, V24, P48, DOI 10.1159/000261238; OOSHIMA T, 1991, CARIES RES, V25, P277, DOI 10.1159/000261376; Peltroche-Llacsahuanga H, 2001, J DENT RES, V80, P378, DOI 10.1177/00220345010800011401; Pikis A, 2002, MICROBIOL-SGM, V148, P843, DOI 10.1099/00221287-148-3-843; POSTMA PW, 1993, MICROBIOL REV, V57, P543, DOI 10.1128/MMBR.57.3.543-594.1993; Raasch C, 2002, FEBS LETT, V517, P267, DOI 10.1016/S0014-5793(02)02641-8; Raasch C, 2000, EXTREMOPHILES, V4, P189, DOI 10.1007/PL00010711; REIZER J, 1988, CRC CR REV MICROBIOL, V15, P297, DOI 10.3109/10408418809104461; Rye CS, 2000, CURR OPIN CHEM BIOL, V4, P573, DOI 10.1016/S1367-5931(00)00135-6; SCHMITT R, 1966, BIOCHEM BIOPH RES CO, V22, P473, DOI 10.1016/0006-291X(66)90297-X; SUTRINA SL, 1990, J BIOL CHEM, V265, P18581; Tangney M, 2001, J IND MICROBIOL BIOT, V27, P298, DOI 10.1038/sj.jim.7000125; Tangney M, 2000, J MOL MICROB BIOTECH, V2, P71; Thompson J, 1999, J BACTERIOL, V181, P7339, DOI 10.1128/JB.181.23.7339-7345.1999; Thompson J, 1998, J BIOL CHEM, V273, P27347, DOI 10.1074/jbc.273.42.27347; Thompson J, 2002, J BIOL CHEM, V277, P34310, DOI 10.1074/jbc.M206397200; Thompson J, 2001, J BIOL CHEM, V276, P37415, DOI 10.1074/jbc.M106504200; THOMPSON J, 1995, J BACTERIOL, V177, P2505, DOI 10.1128/jb.177.9.2505-2512.1995; Thompson J, 2001, CARBOHYD RES, V331, P149, DOI 10.1016/S0008-6215(01)00028-3; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Yamamoto H, 2001, J BACTERIOL, V183, P5110, DOI 10.1128/JB.183.17.5110-5121.2001	41	23	26	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 9	2004	279	2					1553	1561		10.1074/jbc.M310733200	http://dx.doi.org/10.1074/jbc.M310733200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	759DJ	14570887	hybrid			2022-12-27	WOS:000187722800088
J	Decher, N; Pirard, B; Bundis, F; Peukert, S; Baringhaus, KH; Busch, AE; Steinmeyer, K; Sanguinetti, MC				Decher, N; Pirard, B; Bundis, F; Peukert, S; Baringhaus, KH; Busch, AE; Steinmeyer, K; Sanguinetti, MC			Molecular basis for Kv1.5 channel block - Conservation of drug binding sites among voltage-gated K+ channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIAC POTASSIUM CHANNEL; RECEPTOR-SITE; ATRIAL-FIBRILLATION; CALCIUM-CHANNELS; HUMAN HEART; DETERMINANTS; PORE; INACTIVATION; DOMAIN; HERG	Kv1.5 channels conduct the ultrarapid delayed rectifier current (I-Kur) that contributes to action potential repolarization of human atrial myocytes. Block of these channels has been proposed as a treatment for atrial arrhythmias. Here we report a novel and potent inhibitor of Kv1.5 potassium channels, N-benzyl-N-pyridin-3-yl-methyl-2-(toluene-4-sulfonylamino)-benzamide hydrochloride (S0100176), which exhibits features consistent with preferential block of the open state. The IC50 of S0100176 for Kv1.5 expressed in Xenopus oocytes was 0.7 muM. Ala-scanning mutagenesis within the pore helix and the S6 segment, regions that form the walls of the central cavity, was combined with voltage clamp analysis to identify point mutations that altered drug affinity. This approach identified Thr-479, Thr-480, Val-505, Ile-508, and Val-512 as the most important residues for block by S0100176. Mutations of these key residues to Ala or other amino acids caused marked changes in the IC50 of S0100176 (p<0.01). For example, the IC50 of S0100176 increased 362-fold for T480A, 26-fold for V505A, 150-fold for I508A, and 99-fold for V512A. We used modeling to dock S0100176 into the inner cavity of a Kv1.5 pore homology model that was generated based on the crystal structure of KcsA. The docking predicted that the five residues identified by the Ala scan were positioned less than 4.5 angstrom from the compound. Based on the homology models, the positions of the five amino acids identified to interact with S0100176 face toward the central cavity and overlap with putative binding sites for other blockers and voltage-gated potassium channels.	Univ Utah, Dept Physiol, Eccles Inst Human Genet, Salt Lake City, UT 84112 USA; Aventis Pharma Deutschland GmbH, D-65926 Frankfurt, Germany	Utah System of Higher Education; University of Utah; Sanofi-Aventis	Decher, N (corresponding author), Univ Utah, Dept Physiol, Eccles Inst Human Genet, 15 N 2030 E,Rm 4220, Salt Lake City, UT 84112 USA.	Niels.decher@hmbg.utah.edu	Sanguinetti, Michael/AAN-2615-2020; Decher, Niels/AAF-5002-2020		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055236] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL55236] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Baukrowitz T, 1996, P NATL ACAD SCI USA, V93, P13357, DOI 10.1073/pnas.93.23.13357; Caballero R, 2002, CARDIOVASC RES, V56, P104, DOI 10.1016/S0008-6363(02)00509-6; Chen J, 2002, P NATL ACAD SCI USA, V99, P12461, DOI 10.1073/pnas.192367299; CHOI KL, 1993, NEURON, V10, P533, DOI 10.1016/0896-6273(93)90340-W; COBBE SM, 1994, PACE, V17, P1005, DOI 10.1111/j.1540-8159.1994.tb01453.x; Decher N, 2001, FEBS LETT, V492, P84, DOI 10.1016/S0014-5793(01)02222-0; del Camino D, 2000, NATURE, V403, P321, DOI 10.1038/35002099; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; FEDIDA D, 1993, CIRC RES, V73, P210, DOI 10.1161/01.RES.73.1.210; Franqueza L, 1997, CIRC RES, V81, P1053; Hanner M, 2001, BIOCHEMISTRY-US, V40, P11687, DOI 10.1021/bi0111698; HOCKERMAN GH, 1995, J BIOL CHEM, V270, P22119, DOI 10.1074/jbc.270.38.22119; Hockerman GH, 1997, P NATL ACAD SCI USA, V94, P14906, DOI 10.1073/pnas.94.26.14906; Jiang YX, 2003, NATURE, V423, P33, DOI 10.1038/nature01580; Jiang YX, 2002, NATURE, V417, P523, DOI 10.1038/417523a; Kamiya K, 2001, MOL PHARMACOL, V60, P244, DOI 10.1124/mol.60.2.244; Lees-Miller JP, 2000, MOL PHARMACOL, V57, P367; Li GR, 1996, CIRC RES, V78, P689, DOI 10.1161/01.RES.78.4.689; McMartin C, 1997, J COMPUT AID MOL DES, V11, P333, DOI 10.1023/A:1007907728892; Mitcheson JS, 2000, P NATL ACAD SCI USA, V97, P12329, DOI 10.1073/pnas.210244497; Peterson BZ, 1997, J BIOL CHEM, V272, P18752, DOI 10.1074/jbc.272.30.18752; Peukert S, 2003, J MED CHEM, V46, P486, DOI 10.1021/jm0210461; Ragsdale DS, 1996, P NATL ACAD SCI USA, V93, P9270, DOI 10.1073/pnas.93.17.9270; Sanchez-Chapula JA, 2002, J BIOL CHEM, V277, P23587, DOI 10.1074/jbc.M200448200; Seebohm G, 2003, MOL PHARMACOL, V64, P70, DOI 10.1124/mol.64.1.70; SNYDERS DJ, 1992, MOL PHARMACOL, V41, P322; SNYDERS DJ, 1995, CIRC RES, V77, P575, DOI 10.1161/01.RES.77.3.575; SNYDERS DJ, 1993, J GEN PHYSIOL, V101, P513, DOI 10.1085/jgp.101.4.513; STUHMER W, 1992, METHOD ENZYMOL, V207, P319; Thompson J, 2003, J GEN PHYSIOL, V122, P239, DOI 10.1085/jgp.200308848; VALENZUELA C, 1995, BIOPHYS J, V69, P418, DOI 10.1016/S0006-3495(95)79914-3; Villmann C, 1997, J NEUROSCI, V17, P7634, DOI 10.1523/jneurosci.17-20-07634.1997; WANG ZG, 1992, CIRC RES, V71, P271, DOI 10.1161/01.RES.71.2.271; WANG ZG, 1993, CIRC RES, V73, P1061, DOI 10.1161/01.RES.73.6.1061; YELLEN G, 1991, SCIENCE, V251, P939, DOI 10.1126/science.2000494; Yeola SW, 1996, CIRC RES, V78, P1105, DOI 10.1161/01.RES.78.6.1105; YOOL AJ, 1995, BIOPHYS J, V68, P448, DOI 10.1016/S0006-3495(95)80206-7; ZHON M, 2001, NATURE, V411, P657; Zhou M, 2001, NATURE, V411, P657, DOI 10.1038/35079500	39	101	113	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 2	2004	279	1					394	400		10.1074/jbc.M307411200	http://dx.doi.org/10.1074/jbc.M307411200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	757GU	14578345	hybrid			2022-12-27	WOS:000187555300047
J	Haynes, LP; Tepikin, AV; Burgoyne, RD				Haynes, LP; Tepikin, AV; Burgoyne, RD			Calcium-binding protein 1 is an inhibitor of agonist-evoked, inositol 1,4,5-trisphosphate-mediated calcium signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENAL CHROMAFFIN CELLS; PC12 CELLS; CA2+-BINDING PROTEINS; ENDOPLASMIC-RETICULUM; CA2+ OSCILLATIONS; CALMODULIN; EXOCYTOSIS; SENSOR; TRANSDUCTION; EXPRESSION	Intracellular calcium signals are responsible for initiating a spectrum of physiological responses. The caldendrins/ calcium-binding proteins (CaBPs) represent mammal-specific members of the CaM superfamily. CaBPs display a restricted pattern of expression in neuronal/retinal tissues, suggesting a specialized role in Ca2+ signaling in these cell types. Recently, it was reported that a splice variant of CaBP1 functionally interacts with inositol 1,4,5-trisphosphate (InsP(3)) receptors to elicit channel activation in the absence of InsP(3) (Yang, J., McBride, S., Mak, D.- O. D., Vardi, N., Palczewski, K., Haeseleer, F., and Foskett, J. K. (2002) Proc. Natl. Acad. Sci. U. S. A. 99, 7711 - 7716). These data indicate a new mode of InsP3 receptor modulation and hence control of intracellular Ca2+ concentration ([Ca2+](i)) in neuronal tissues. We have analyzed the biochemistry of the long form splice variant of CaBP1 (L-CaBP1) and show that, in vitro, a recombinant form of the protein is able to bind Ca2+ with high affinity and undergo a conformational change. We also describe the localization of endogenous and overexpressed L-CaBP1 in the model neuroendocrine PC12 cell system, where it was associated with the plasma membrane and Golgi complex in a myristoylation-dependent manner. Furthermore, we show that overexpressed L-CaBP1 is able to substantially suppress rises in [Ca2+](i) in response to physiological agonists acting on purinergic receptors and that this inhibition is due in large part to blockade of release from intracellular Ca2+ stores. The related protein neuronal calcium sensor-1 was without effect on the [Ca2+](i) responses to agonist stimulation. Measurement of [ Ca2+] within the ER of permeabilized PC12 cells demonstrated that L-CaBP1 directly inhibited InsP(3)-mediated Ca2+ release. Expression of L-CaBP1 also inhibited histamine-induced [Ca2+](i) oscillations in HeLa cells. Together, these data suggest that L-CaBP1 is able to specifically regulate InsP(3) receptor-mediated alterations in [Ca2+](i) during agonist stimulation.	Univ Liverpool, Physiol Lab, Liverpool L69 3BX, Merseyside, England	University of Liverpool	Burgoyne, RD (corresponding author), Univ Liverpool, Physiol Lab, Crown St, Liverpool L69 3BX, Merseyside, England.	burgoyne@liverpool.ac.uk	Burgoyne, Robert/C-6706-2008; Burgoyne, Robert D/P-6641-2019	Burgoyne, Robert/0000-0002-9219-0387; Burgoyne, Robert D/0000-0002-9219-0387; Tepikin, Alexei/0000-0002-8172-7513				Ashby MC, 2002, PHYSIOL REV, V82, P701, DOI 10.1152/physrev.00006.2002; BARRY VA, 1994, J CELL SCI, V107, P451; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Berridge MJ, 1998, NEURON, V21, P13, DOI 10.1016/S0896-6273(00)80510-3; Bito H, 1997, CURR OPIN NEUROBIOL, V7, P419, DOI 10.1016/S0959-4388(97)80072-4; Bourne Y, 2001, J BIOL CHEM, V276, P11949, DOI 10.1074/jbc.M009373200; Burgoyne RD, 2003, BBA-MOL CELL RES, V1641, P137, DOI 10.1016/S0167-4889(03)00089-2; Burgoyne RD, 1998, BIOESSAYS, V20, P328, DOI 10.1002/(SICI)1521-1878(199804)20:4<328::AID-BIES9>3.0.CO;2-L; Burgoyne RD, 2001, BIOCHEM J, V353, P1; BURGOYNE RD, 1995, TRENDS NEUROSCI, V18, P191, DOI 10.1016/0166-2236(95)93900-I; Carafoli E, 2002, P NATL ACAD SCI USA, V99, P1115, DOI 10.1073/pnas.032427999; Chin D, 2000, TRENDS CELL BIOL, V10, P322, DOI 10.1016/S0962-8924(00)01800-6; COLLINS F, 1991, J NEUROSCI, V11, P2582; COX JA, 1994, J BIOL CHEM, V269, P32807; Fisher RJ, 1999, PFLUG ARCH EUR J PHY, V437, P754, DOI 10.1007/s004240050842; Graham ME, 1997, MOL BIOL CELL, V8, P431, DOI 10.1091/mbc.8.3.431; Haeseleer F, 2000, J BIOL CHEM, V275, P1247, DOI 10.1074/jbc.275.2.1247; Haynes LP, 1999, BIOCHEM J, V342, P707, DOI 10.1042/0264-6021:3420707; Ikura M, 1996, TRENDS BIOCHEM SCI, V21, P14, DOI 10.1016/0968-0004(96)80879-6; Johenning FW, 2002, J NEUROSCI, V22, P5344; Kasri NN, 2003, J BIOL CHEM, V278, P27548, DOI 10.1074/jbc.M302026200; KATER SB, 1991, J NEUROSCI, V11, P891; Koizumi S, 2002, J BIOL CHEM, V277, P30315, DOI 10.1074/jbc.M201132200; Landwehr M, 2003, FEBS LETT, V547, P189, DOI 10.1016/S0014-5793(03)00713-0; Laube G, 2002, MOL CELL NEUROSCI, V19, P459, DOI 10.1006/mcne.2001.1078; Lee A, 2002, NAT NEUROSCI, V5, P210, DOI 10.1038/nn805; McFerran BW, 1999, J BIOL CHEM, V274, P30258, DOI 10.1074/jbc.274.42.30258; McFerran BW, 1998, J BIOL CHEM, V273, P22768, DOI 10.1074/jbc.273.35.22768; Meldolesi J, 2001, PROG NEUROBIOL, V65, P309, DOI 10.1016/S0301-0082(01)00004-1; NEF S, 1995, J RECEPT SIGNAL TR R, V15, P365, DOI 10.3109/10799899509045227; O'Callaghan DW, 2003, J CELL SCI, V116, P4833, DOI 10.1242/jcs.00803; O'Callaghan DW, 2002, J BIOL CHEM, V277, P14227, DOI 10.1074/jbc.M111750200; Park MK, 2000, EMBO J, V19, P5729, DOI 10.1093/emboj/19.21.5729; Pinton P, 1998, EMBO J, V17, P5298, DOI 10.1093/emboj/17.18.5298; Rajebhosale M, 2003, J BIOL CHEM, V278, P6075, DOI 10.1074/jbc.M204702200; RODERICK HL, 2003, J PHYSL LOND P, V547, pPC36; SAUVE R, 1991, CELL CALCIUM, V12, P165, DOI 10.1016/0143-4160(91)90018-A; Seidenbecher CI, 2002, ADV EXP MED BIOL, V514, P451; Seidenbecher CI, 1998, J BIOL CHEM, V273, P21324, DOI 10.1074/jbc.273.33.21324; SKELTON NJ, 1994, NAT STRUCT BIOL, V1, P239, DOI 10.1038/nsb0494-239; THORN P, 1995, J PHYSIOL-LONDON, V482, P275, DOI 10.1113/jphysiol.1995.sp020516; WOJCIKIEWICZ RJH, 1995, J BIOL CHEM, V270, P11678, DOI 10.1074/jbc.270.19.11678; Yang J, 2002, P NATL ACAD SCI USA, V99, P7711, DOI 10.1073/pnas.102006299; Zucker RS, 1999, CURR OPIN NEUROBIOL, V9, P305, DOI 10.1016/S0959-4388(99)80045-2	46	99	103	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 2	2004	279	1					547	555		10.1074/jbc.M309617200	http://dx.doi.org/10.1074/jbc.M309617200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	757GU	14570872	hybrid			2022-12-27	WOS:000187555300066
J	Kikuchi, M; Hatano, N; Yokota, S; Shimozawa, N; Imanaka, T; Taniguchi, H				Kikuchi, M; Hatano, N; Yokota, S; Shimozawa, N; Imanaka, T; Taniguchi, H			Proteomic analysis of rat liver peroxisome - Presence of peroxisome-specific isozyme of Lon protease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP-DEPENDENT PROTEASE; MASS-SPECTROMETRY; IN-VITRO; GENE; PROTEINS; IDENTIFICATION; DEHYDROGENASE; CELLS; LOCALIZATION; BACTERIAL	Subcellular proteomics, which includes isolation of subcellular components prior to a proteomic analysis, is advantageous not only in characterizing large macromolecular complexes such as organelles but also in elucidating mechanisms of protein transport and organelle biosynthesis. Because of the high sensitivity achieved by the present proteomics technology, the purity of samples to be analyzed is important for the interpretation of the results obtained. In the present study, peroxisomes isolated from rat liver by usual cell fractionation were further purified by immunoisolation using a specific antibody raised against a peroxisomal membrane protein, PMP70. The isolated peroxisomes were analyzed by SDS-PAGE combined with liquid chromatography/mass spectrometry. Altogether 34 known peroxisomal proteins were identified in addition to several mitochondrial and microsomal proteins. Some of the latter may reside in the peroxisomes as well. Analysis of membrane fractions identified all known peroxins except for Pex7. Two new peroxisomal proteins of unknown function were of high abundance. One is a bi-functional protein consisting of an aminoglycoside phosphotransferase-domain and an acyl-CoA dehydrogenase domain. The other is a newly identified peroxisome-specific isoform of Lon protease, an ATP-dependent protease with chaperone-like activity. The peroxisomal localization of the protein was confirmed by immunological techniques. The peroxisome-type Lon protease, which is distinct from the mitochondrial isoform, may play an important role in the peroxisomal biogenesis.	RIKEN, Harima Inst Spring 8, Sayo, Hyogo 6795148, Japan; Yamanashi Med Univ, Yamanashi 4093898, Japan; Gifu Univ, Sch Med, Gifu 5008705, Japan; Toyama Med & Pharmaceut Univ, Fac Pharmaceut Sci, Toyama 9300194, Japan; Univ Tokushima, Inst Enzyme Res, Tokushima 7708503, Japan	RIKEN; University of Yamanashi; Gifu University; University of Toyama; Tokushima University	Taniguchi, H (corresponding author), RIKEN, Harima Inst Spring 8, 1-1-1 Kouto, Sayo, Hyogo 6795148, Japan.		Hatano, Naoya/F-6147-2011	Imanaka, Tsuneo/0000-0003-4677-1356; Shimozawa, Nobuyuki/0000-0003-3040-5458				Adam Z, 2001, PLANT PHYSIOL, V125, P1912, DOI 10.1104/pp.125.4.1912; Alfonzo JD, 1998, J BIOL CHEM, V273, P30003, DOI 10.1074/jbc.273.45.30003; Andersen JS, 2002, CURR BIOL, V12, P1, DOI 10.1016/S0960-9822(01)00650-9; Barakat S, 1998, PLANT MOL BIOL, V37, P141, DOI 10.1023/A:1005912831051; Bell AW, 2001, J BIOL CHEM, V276, P5152, DOI 10.1074/jbc.M006143200; FOWLER S, 1976, J CELL BIOL, V71, P535, DOI 10.1083/jcb.71.2.535; GOLDBERG AL, 1994, METHOD ENZYMOL, V244, P350; GOLDBERG AL, 1992, EUR J BIOCHEM, V203, P9, DOI 10.1111/j.1432-1033.1992.tb19822.x; Gygi SP, 1999, NAT BIOTECHNOL, V17, P994, DOI 10.1038/13690; Hanson BJ, 2001, ELECTROPHORESIS, V22, P950, DOI 10.1002/1522-2683()22:5<950::AID-ELPS950>3.0.CO;2-D; Helledie T, 2002, J BIOL CHEM, V277, P26821, DOI 10.1074/jbc.M111295200; Imanaka T, 1996, J BIOL CHEM, V271, P3706; IMANAKA T, 1991, BIOCHIM BIOPHYS ACTA, V1062, P264, DOI 10.1016/0005-2736(91)90401-S; Jung E, 2000, ELECTROPHORESIS, V21, P3369, DOI 10.1002/1522-2683(20001001)21:16<3369::AID-ELPS3369>3.0.CO;2-7; Konishi H, 2001, P NATL ACAD SCI USA, V98, P6587, DOI 10.1073/pnas.111158798; LAZAROW PB, 1976, P NATL ACAD SCI USA, V73, P2043, DOI 10.1073/pnas.73.6.2043; MIYAUCHI K, 1991, J BIOL CHEM, V266, P19536; Mohan KVK, 2002, J VIROL, V76, P2543, DOI 10.1128/JVI.76.5.2543-2547.2002; Mozdy AD, 2000, J CELL BIOL, V151, P367, DOI 10.1083/jcb.151.2.367; O'Donovan C, 2001, TRENDS BIOTECHNOL, V19, P178, DOI 10.1016/S0167-7799(01)01598-0; Pandey A, 2000, NATURE, V405, P837, DOI 10.1038/35015709; Sarria R, 1998, PLANT CELL, V10, P1217, DOI 10.1105/tpc.10.7.1217; Shevchenko A, 1996, P NATL ACAD SCI USA, V93, P14440, DOI 10.1073/pnas.93.25.14440; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Shimozawa N, 2003, AM J MED GENET A, V120A, P40, DOI 10.1002/ajmg.a.20030; SHIMOZAWA N, 1992, SCIENCE, V255, P1132, DOI 10.1126/science.1546315; SUZUKI CK, 1994, SCIENCE, V264, P273, DOI 10.1126/science.8146662; Suzuki Y, 1997, AM J HUM GENET, V61, P1153, DOI 10.1086/301599; TANIGUCHI H, 1994, J BIOL CHEM, V269, P22481; VANDYCK L, 1994, J BIOL CHEM, V269, P238; WANG N, 1993, P NATL ACAD SCI USA, V90, P11247, DOI 10.1073/pnas.90.23.11247; Washburn MP, 2001, NAT BIOTECHNOL, V19, P242, DOI 10.1038/85686; Wu CC, 2003, NAT BIOTECHNOL, V21, P262, DOI 10.1038/nbt0303-262; Yoshihara T, 2001, J HISTOCHEM CYTOCHEM, V49, P1123, DOI 10.1177/002215540104900906	34	208	216	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	2004	279	1					421	428		10.1074/jbc.M305623200	http://dx.doi.org/10.1074/jbc.M305623200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	757GU	14561759	hybrid			2022-12-27	WOS:000187555300051
J	Nourse, A; Trabi, M; Daly, NL; Craik, DJ				Nourse, A; Trabi, M; Daly, NL; Craik, DJ			A comparison of the self-association behavior of the plant cyclotides kalata B1 and kalata B2 via analytical ultracentrifugation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIZE-DISTRIBUTION ANALYSIS; MACROCYCLIC PEPTIDES; STRUCTURAL MOTIF; KNOTTED PROTEINS; LAMM EQUATION; DRUG DESIGN; SEDIMENTATION; MACROMOLECULES; SYSTEMS; SOLUTES	The recently discovered cyclotides kalata B1 and kalata B2 are miniproteins containing a head-to-tail cyclized backbone and a cystine knot motif, in which disulfide bonds and the connecting backbone segments form a ring that is penetrated by the third disulfide bond. This arrangement renders the cyclotides extremely stable against thermal and enzymatic decay, making them a possible template onto which functionalities can be grafted. We have compared the hydrodynamic properties of two prototypic cyclotides, kalata B1 and kalata B2, using analytical ultracentrifugation techniques. Direct evidence for oligomerization of kalata B2 was shown by sedimentation velocity experiments in which a method for determining size distribution of polydisperse molecules in solution was employed. The shape of the oligomers appears to be spherical. Both sedimentation velocity and equilibrium experiments indicate that in phosphate buffer kalata B1 exists mainly as a monomer, even at millimolar concentrations. In contrast, at 1.6 mM, kalata B2 exists as an equilibrium mixture of monomer (30%), tetramer (42%), octamer (25%), and possibly a small proportion of higher oligomers. The results from the sedimentation equilibrium experiments show that this self-association is concentration dependent and reversible. We link our findings to the three-dimensional structures of both cyclotides, and propose two putative interaction interfaces on opposite sides of the kalata B2 molecule, one involving a hydrophobic interaction with the Phe(6), and the second involving a charge-charge interaction with the Asp(25) residue. An understanding of the factors affecting solution aggregation is of vital importance for future pharmaceutical application of these molecules.	Univ Queensland, Inst Mol Biosci, Australian Res Council Special Res Ctr Funct & Ap, Brisbane, Qld, Australia	University of Queensland	Craik, DJ (corresponding author), Univ Queensland, Inst Mol Biosci, Australian Res Council Special Res Ctr Funct & Ap, Brisbane, Qld, Australia.		Trabi, Manuela/E-7150-2012; Craik, David/B-1695-2010; Daly, Norelle L/D-4302-2013	Craik, David/0000-0003-0007-6796; Daly, Norelle L/0000-0002-4697-6602; Nourse, Amanda/0000-0003-4595-5321				ANSEVIN AT, 1970, ANAL BIOCHEM, V34, P237, DOI 10.1016/0003-2697(70)90103-X; Bokesch HR, 2001, J NAT PROD, V64, P249, DOI 10.1021/np000372l; CLAVERIE JM, 1976, BIOPOLYMERS, V15, P843, DOI 10.1002/bip.1976.360150504; COX DJ, 1969, ARCH BIOCHEM BIOPHYS, V129, P106, DOI 10.1016/0003-9861(69)90157-X; Craik DJ, 1999, J MOL BIOL, V294, P1327, DOI 10.1006/jmbi.1999.3383; Craik DJ, 2001, TOXICON, V39, P1809, DOI 10.1016/S0041-0101(01)00129-5; Craik DJ, 2001, TOXICON, V39, P43, DOI 10.1016/S0041-0101(00)00160-4; Craik DJ, 2002, CURR OPIN DRUG DI DE, V5, P251; GRAN L, 1973, LLOYDIA, V36, P174; GUSTAFSON KR, 1994, J AM CHEM SOC, V116, P9337, DOI 10.1021/ja00099a064; Jennings C, 2001, P NATL ACAD SCI USA, V98, P10614, DOI 10.1073/pnas.191366898; KUNTZ ID, 1971, J AM CHEM SOC, V93, P516, DOI 10.1021/ja00731a037; Lamm O., 1929, ARK MAT ASTR FYS, V21B, P1; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; Laue TM, 1999, ANNU REV BIOPH BIOM, V28, P75, DOI 10.1146/annurev.biophys.28.1.75; Lebowitz J, 2002, PROTEIN SCI, V11, P2067, DOI 10.1110/ps.0207702; Lindholm P, 2002, MOL CANCER THER, V1, P365; McRorie D. K., 1993, SELF ASS SYSTEMS ANA; Minton AP, 2001, J BIOL CHEM, V276, P10577, DOI 10.1074/jbc.R100005200; Ofran Y, 2003, J MOL BIOL, V325, P377, DOI 10.1016/S0022-2836(02)01223-8; Rivas G, 1999, METHODS, V19, P194, DOI 10.1006/meth.1999.0851; Rosengren KJ, 2003, J BIOL CHEM, V278, P8606, DOI 10.1074/jbc.M211147200; SAETHER O, 1995, BIOCHEMISTRY-US, V34, P4147, DOI 10.1021/bi00013a002; Schuck P, 1998, BIOPHYS J, V75, P1503, DOI 10.1016/S0006-3495(98)74069-X; Schuck P, 2002, BIOPHYS J, V82, P1096, DOI 10.1016/S0006-3495(02)75469-6; Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0; Tam JP, 1999, P NATL ACAD SCI USA, V96, P8913, DOI 10.1073/pnas.96.16.8913; Trabi M, 2002, TRENDS BIOCHEM SCI, V27, P132, DOI 10.1016/S0968-0004(02)02057-1; Wibbenmeyer JA, 1999, J BIOL CHEM, V274, P26838, DOI 10.1074/jbc.274.38.26838; WITHERUP KM, 1994, J NAT PRODUCTS, V57, P1619, DOI 10.1021/np50114a002; ZIMMERMAN SB, 1993, ANNU REV BIOPH BIOM, V22, P27, DOI 10.1146/annurev.bb.22.060193.000331	31	57	58	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	2004	279	1					562	570		10.1074/jbc.M306826200	http://dx.doi.org/10.1074/jbc.M306826200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	757GU	14561762	hybrid			2022-12-27	WOS:000187555300068
J	Chernova, TA; Allen, KD; Wesoloski, LM; Shanks, JR; Chernoff, YO; Wilkinson, KD				Chernova, TA; Allen, KD; Wesoloski, LM; Shanks, JR; Chernoff, YO; Wilkinson, KD			Pleiotropic effects of Ubp6 loss on drug sensitivities and yeast prion are due to depletion of the free ubiquitin pool	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOA4 DEUBIQUITINATING ENZYME; SACCHAROMYCES-CEREVISIAE; DNA-REPAIR; REGULATORY PARTICLE; NUCLEAR-PROTEIN; 26S PROTEASOME; POLYUBIQUITIN; DEGRADATION; LOCALIZATION; RESISTANCE	Mutation of the mouse Usp14 gene, encoding the homolog of yeast deubiquitinating enzyme Ubp6, causes ataxia. Here we show that deletion of the UBP6 gene in Saccharomyces cerevisiae causes sensitivity to a broad range of toxic compounds and antagonizes phenotypic expression and de novo induction of the yeast prion [PSI+], a functionally defective self-perpetuating isoform of the translation termination factor Sup35. Conversely, overexpression of ubiquitin (Ub) increases phenotypic expression and induction of [PSI+] in the wild type cells and suppresses all tested ubp6Delta defects, indicating that they are primarily due to depletion of cellular Ub levels. Several lines of evidence suggest that Ubp6 functions on the proteasome. First, Ub levels in the ubp6Delta cells can be partly restored by proteasome inhibitors, suggesting that deletion of Ubp6 decreases Ub levels by increasing proteasome-dependent degradation of Ub. Second, fluorescence microscopy analysis shows that Ubp6-GFP fusion protein is localized to the nucleus of yeast cell, as are most proteasomes. Third, the N-terminal Ub-like domain, although it is not required for nuclear localization of Ubp6, targets Ubp6 to the proteasome and cannot be functionally replaced by Ub. The human ortholog of Ubp6, USP14, probably plays a similar role in higher eukaryotes, since it fully compensates for ubp6Delta defects and binds to the yeast proteasome. These data link the Ub system to prion expression and propagation and have broad implications for other neuronal inclusion body diseases.	Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA; Georgia Inst Technol, Sch Biol, Atlanta, GA 30332 USA; Georgia Inst Technol, Inst Bioengn & Biosci, Atlanta, GA 30332 USA	Emory University; University System of Georgia; Georgia Institute of Technology; University System of Georgia; Georgia Institute of Technology	Wilkinson, KD (corresponding author), Emory Univ, Sch Med, Dept Biochem, 4017 Rollins Res Bldg,1510 Clifton Rd, Atlanta, GA 30322 USA.	genekdw@emory.edu	Chernoff, Yury O/J-2833-2014; Chernova, Tatiana/AAR-5007-2020	Chernova, Tatiana/0000-0003-1966-0159; Chernoff, Yury/0000-0002-8934-9051; Allen, Kim D/0000-0001-9774-5014	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030308, R01GM058763] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM030308, R01GM58763, R01GM30308, R01GM23120] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amerik AY, 2000, BIOL CHEM, V381, P981, DOI 10.1515/BC.2000.121; Amerik AY, 1997, EMBO J, V16, P4826; ARNASON T, 1994, MOL CELL BIOL, V14, P7876, DOI 10.1128/MCB.14.12.7876; Ausubel FM, 1988, MOL REPROD DEV; Bailleul PA, 1999, GENETICS, V153, P81; Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; Borodovsky A, 2001, EMBO J, V20, P5187, DOI 10.1093/emboj/20.18.5187; CHEN P, 1993, CELL, V74, P357, DOI 10.1016/0092-8674(93)90426-Q; CHEN P, 1995, EMBO J, V14, P2620, DOI 10.1002/j.1460-2075.1995.tb07260.x; Chernoff YO, 2000, MOL MICROBIOL, V35, P865, DOI 10.1046/j.1365-2958.2000.01761.x; Chernoff YO, 1999, MOL CELL BIOL, V19, P8103; Chernoff YO, 2002, METHOD ENZYMOL, V351, P499; CHERNOFF YO, 1995, SCIENCE, V268, P880, DOI 10.1126/science.7754373; Chernoff YO, 2001, MUTAT RES-REV MUTAT, V488, P39, DOI 10.1016/S1383-5742(00)00060-0; Ciechanover A, 2003, BIOCHEM SOC T, V31, P474, DOI 10.1042/BST0310474; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Derkatch IL, 1996, GENETICS, V144, P1375; Dubiel W, 1999, CURR BIOL, V9, pR554, DOI 10.1016/S0960-9822(99)80353-4; Elsasser S, 2002, NAT CELL BIOL, V4, P725, DOI 10.1038/ncb845; Finley D, 1998, TRENDS BIOCHEM SCI, V23, P244, DOI 10.1016/S0968-0004(98)01222-5; Finley D, 2002, NAT CELL BIOL, V4, pE121, DOI 10.1038/ncb0502-e121; FINLEY D, 1994, MOL CELL BIOL, V14, P5501, DOI 10.1128/MCB.14.8.5501; Fleming JA, 2002, P NATL ACAD SCI USA, V99, P1461, DOI 10.1073/pnas.032516399; Funakoshi M, 2002, P NATL ACAD SCI USA, V99, P745, DOI 10.1073/pnas.012585199; Glickman MH, 1998, MOL CELL BIOL, V18, P3149, DOI 10.1128/MCB.18.6.3149; Glickman MH, 1998, CELL, V94, P615, DOI 10.1016/S0092-8674(00)81603-7; GUERMAN A, 2003, YEAST S, V20, pS139; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hochstrasser M, 1999, PHILOS T ROY SOC B, V354, P1513, DOI 10.1098/rstb.1999.0495; Holzl H, 2000, J CELL BIOL, V150, P119, DOI 10.1083/jcb.150.1.119; Jones AL, 2000, P NATL ACAD SCI USA, V97, P3224, DOI 10.1073/pnas.050432997; JUNGMANN J, 1993, NATURE, V361, P369, DOI 10.1038/361369a0; Keeven J, 2002, CURR GENET, V41, P11, DOI 10.1007/s00294-002-0274-2; KENWARD N, 1994, J NEUROCHEM, V62, P1870; Koegl M, 1999, CELL, V96, P635, DOI 10.1016/S0092-8674(00)80574-7; Lam YA, 1997, NATURE, V385, P737, DOI 10.1038/385737a0; Lambertson D, 2003, CURR GENET, V42, P199, DOI 10.1007/s00294-002-0350-7; Lee JC, 2003, IMMUNOL REV, V193, P39, DOI 10.1034/j.1600-065X.2003.00043.x; Leggett DS, 2002, MOL CELL, V10, P495, DOI 10.1016/S1097-2765(02)00638-X; Li TW, 2000, BIOCHEM BIOPH RES CO, V272, P270, DOI 10.1006/bbrc.2000.2767; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Mastrandrea LD, 1999, J BIOL CHEM, V274, P27299, DOI 10.1074/jbc.274.38.27299; MAYER AN, 1989, BIOCHEMISTRY-US, V28, P166, DOI 10.1021/bi00427a024; Mayer RJ, 2003, DRUG NEWS PERSPECT, V16, P103, DOI 10.1358/dnp.2003.16.2.829327; Maytal-Kivity V, 2002, BMC BIOCHEM, V3, DOI 10.1186/1471-2091-3-28; McDonald HB, 1997, J CELL BIOL, V137, P539, DOI 10.1083/jcb.137.3.539; Miller RJ, 2003, TRENDS PHARMACOL SCI, V24, P18, DOI 10.1016/S0165-6147(02)00011-1; Newnam GP, 1999, MOL CELL BIOL, V19, P1325; Papa FR, 1999, MOL BIOL CELL, V10, P741, DOI 10.1091/mbc.10.3.741; PAPA FR, 1993, NATURE, V366, P313, DOI 10.1038/366313a0; Pickart CM, 1997, FASEB J, V11, P1055, DOI 10.1096/fasebj.11.13.9367341; Russell SJ, 1999, J BIOL CHEM, V274, P21943, DOI 10.1074/jbc.274.31.21943; Schauber C, 1998, NATURE, V391, P715, DOI 10.1038/35661; Schnell JD, 2003, J BIOL CHEM, V278, P35857, DOI 10.1074/jbc.R300018200; Sherman F., 1986, METHODS YEAST GENETI; SPENCE J, 1995, MOL CELL BIOL, V15, P1265; Spence J, 2000, CELL, V102, P67, DOI 10.1016/S0092-8674(00)00011-8; Swaminathan S, 1999, MOL BIOL CELL, V10, P2583, DOI 10.1091/mbc.10.8.2583; Tran PB, 1999, TRENDS NEUROSCI, V22, P194, DOI 10.1016/S0166-2236(99)01409-5; Verma R, 2002, SCIENCE, V298, P611, DOI 10.1126/science.1075898; Verma R, 2000, MOL BIOL CELL, V11, P3425, DOI 10.1091/mbc.11.10.3425; WATKINS JF, 1993, MOL CELL BIOL, V13, P7757, DOI 10.1128/MCB.13.12.7757; Wilkinson CRM, 1998, EMBO J, V17, P6465, DOI 10.1093/emboj/17.22.6465; Wilkinson KD, 1997, FASEB J, V11, P1245, DOI 10.1096/fasebj.11.14.9409543; WILKINSON KD, 1986, BIOCHEMISTRY-US, V25, P6644, DOI 10.1021/bi00369a047; Wilson SM, 2002, NAT GENET, V32, P420, DOI 10.1038/ng1006; Wyndham AM, 1999, PROTEIN SCI, V8, P1268, DOI 10.1110/ps.8.6.1268; Yao TT, 2002, NATURE, V419, P403, DOI 10.1038/nature01071; Yedidia Y, 2001, EMBO J, V20, P5383, DOI 10.1093/emboj/20.19.5383; Yin LM, 2000, BIOCHEMISTRY-US, V39, P10001, DOI 10.1021/bi0007019	70	94	95	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52102	52115		10.1074/jbc.M310283200	http://dx.doi.org/10.1074/jbc.M310283200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14559899	hybrid			2022-12-27	WOS:000187480700017
J	Li, JH; Feltzer, RE; Dawson, KL; Hudson, EA; Clark, BJ				Li, JH; Feltzer, RE; Dawson, KL; Hudson, EA; Clark, BJ			Janus kinase 2 and calcium are required for angiotensin II-dependent activation of steroidogenic acute regulatory protein transcription in H295R human adrenocortical cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENAL GLOMERULOSA CELLS; ATRIAL-NATRIURETIC-PEPTIDE; SRC TYROSINE KINASE; ALDOSTERONE PRODUCTION; CA2+-REGULATED EXPRESSION; DIFFERENTIAL REGULATION; AT(1) RECEPTOR; CA2+; GENE; INFLUX	Angiotensin II- and K+-stimulated aldosterone production in the adrenocortical glomerulosa cells requires induction of the steroidogenic acute regulatory protein (StAR). While both agents activate Ca2+ signaling, the mechanisms leading to aldosterone synthesis are distinct, and the angiotensin II response cannot be mimicked by K+. We previously reported that StAR mRNA levels and promoter-reporter gene activity in transiently transfected H295R human adrenocortical cells were stimulated by angiotensin II but not by K+ treatment. The current study focused on identifying signaling pathways activated by angiotensin II that contribute to StAR transcriptional activation. We show that the angiotensin II-stimulated transcriptional activation of StAR was dependent upon influx of external calcium and requires protein kinase C activation. Furthermore we describe for the first time that the Janus tyrosine kinase family member, JAK2, was activated by angiotensin II treatment of H295R cells. Treatment of the cells with AG490, a selective inhibitor of JAK2, blocked JAK2 activation and StAR reporter gene activity and inhibited steroid production. Taken together these studies describe a novel pathway controlling StAR expression and steroidogenesis in adrenocortical cells.	Univ Louisville, Sch Med, Dept Biochem & Mol Biol, Louisville, KY 40292 USA	University of Louisville	Clark, BJ (corresponding author), Univ Louisville, Sch Med, Dept Biochem & Mol Biol, Louisville, KY 40292 USA.			Clark, Barbara/0000-0003-1558-1904				Ali MS, 1997, J BIOL CHEM, V272, P23382, DOI 10.1074/jbc.272.37.23382; Aptel HB, 1999, J ENDOCRINOL, V163, P131, DOI 10.1677/joe.0.1630131; BIRD IM, 1993, ENDOCRINOLOGY, V133, P1555, DOI 10.1210/en.133.4.1555; Bird IM, 1998, J CLIN ENDOCR METAB, V83, P1592, DOI 10.1210/jc.83.5.1592; BIRD IM, 1995, ENDOCRINOLOGY, V136, P5677, DOI 10.1210/en.136.12.5677; BODART V, 1995, J STEROID BIOCHEM, V54, P55, DOI 10.1016/0960-0760(95)00077-D; Bootman MD, 2002, CURR BIOL, V12, pR563, DOI 10.1016/S0960-9822(02)01055-2; Burnay MM, 1998, BIOCHEM J, V330, P21, DOI 10.1042/bj3300021; BURNAY MM, 1994, ENDOCRINOLOGY, V135, P751, DOI 10.1210/en.135.2.751; Cherradi N, 1998, MOL ENDOCRINOL, V12, P962, DOI 10.1210/me.12.7.962; Cherradi N, 1998, ENDOCR RES, V24, P355, DOI 10.3109/07435809809032615; Clark BJ, 1999, ENDOCRINOLOGY, V140, P4390, DOI 10.1210/en.140.10.4390; Clark BJ, 1995, MOL CELL ENDOCRINOL, V115, P215, DOI 10.1016/0303-7207(95)03683-0; Clyne CD, 1997, MOL ENDOCRINOL, V11, P638, DOI 10.1210/me.11.5.638; Condon JC, 2002, ENDOCRINOLOGY, V143, P3651, DOI 10.1210/en.2001-211359; Denner K, 1996, MOL CELL ENDOCRINOL, V121, P87, DOI 10.1016/0303-7207(96)03853-1; ELLIOTT ME, 1984, BIOCHEM PHARMACOL, V33, P1519, DOI 10.1016/0006-2952(84)90422-2; ELLIOTT ME, 1993, ENDOCRINOLOGY, V133, P1669, DOI 10.1210/en.133.4.1669; ELY JA, 1991, J BIOL CHEM, V266, P18635; Frank GD, 2002, MOL ENDOCRINOL, V16, P367, DOI 10.1210/me.16.2.367; Gyles SL, 2001, J BIOL CHEM, V276, P34888, DOI 10.1074/jbc.M102063200; HAJNOCZKY G, 1991, ENDOCRINOLOGY, V128, P2639, DOI 10.1210/endo-128-5-2639; Kim YC, 1997, STEROIDS, V62, P10, DOI 10.1016/S0039-128X(96)00153-5; LeHoux JG, 1998, J MOL ENDOCRINOL, V20, P183, DOI 10.1677/jme.0.0200183; LeHoux JG, 2001, J BIOL CHEM, V276, P8021, DOI 10.1074/jbc.M009495200; LIN D, 1995, SCIENCE, V267, P1828, DOI 10.1126/science.7892608; Lotshaw DP, 2001, MOL CELL ENDOCRINOL, V175, P157, DOI 10.1016/S0303-7207(01)00384-7; Marrero MB, 1996, CELL SIGNAL, V8, P21, DOI 10.1016/0898-6568(95)02016-0; MARRERO MB, 1995, NATURE, V375, P247, DOI 10.1038/375247a0; Marrero MB, 1997, J BIOL CHEM, V272, P24684, DOI 10.1074/jbc.272.39.24684; McNeill H, 1998, ENDOCR RES, V24, P373, DOI 10.3109/07435809809032617; MERRITT JE, 1990, BIOCHEM J, V271, P515, DOI 10.1042/bj2710515; Miller WL, 1997, J MOL ENDOCRINOL, V19, P227, DOI 10.1677/jme.0.0190227; Moore RK, 2001, BIOCHEM BIOPH RES CO, V289, P796, DOI 10.1006/bbrc.2001.6052; Natarajan R, 2002, ENDOCRINE, V18, P295, DOI 10.1385/ENDO:18:3:295; Parekh AB, 2003, J PHYSIOL-LONDON, V547, P333, DOI 10.1113/jphysiol.2002.034140; Penner R, 1993, Curr Opin Neurobiol, V3, P368, DOI 10.1016/0959-4388(93)90130-Q; Pezzi V, 1997, ENDOCRINOLOGY, V138, P835, DOI 10.1210/en.138.2.835; Pezzi V, 1996, J STEROID BIOCHEM, V58, P417, DOI 10.1016/0960-0760(96)00052-0; PYTHON CP, 1995, BIOCHEM J, V305, P569, DOI 10.1042/bj3050569; Rossier M F, 2000, Vitam Horm, V60, P229, DOI 10.1016/S0083-6729(00)60021-3; ROSSIER MF, 1993, BIOCHEM J, V296, P309, DOI 10.1042/bj2960309; Seger R, 2001, J BIOL CHEM, V276, P13957, DOI 10.1074/jbc.M006852200; Sewer MB, 2003, J BIOL CHEM, V278, P8106, DOI 10.1074/jbc.M210264200; Sewer MB, 2002, ENDOCRINOLOGY, V143, P1769, DOI 10.1210/en.143.5.1769; SIMPSON ER, 1988, ANNU REV PHYSIOL, V50, P427, DOI 10.1146/annurev.ph.50.030188.002235; Sirianni R, 2003, J MOL ENDOCRINOL, V30, P287, DOI 10.1677/jme.0.0300287; Sirianni R, 2001, J MOL ENDOCRINOL, V26, P207, DOI 10.1677/jme.0.0260207; Smith RD, 1999, ENDOCRINOLOGY, V140, P1385, DOI 10.1210/en.140.3.1385; SPAT A, 1989, J ENDOCRINOL, V122, P361, DOI 10.1677/joe.0.1220361; SPAT A, 1988, J STEROID BIOCHEM, V29, P443, DOI 10.1016/0022-4731(88)90256-7; Stocco DM, 1996, ENDOCR REV, V17, P221, DOI 10.1210/er.17.3.221; Stocco DM, 1999, VITAM HORM, V55, P399; Tian Y, 1998, ENDOCRINOLOGY, V139, P1801, DOI 10.1210/en.139.4.1801; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; Watanabe G, 1996, J BIOL CHEM, V271, P22570, DOI 10.1074/jbc.271.37.22570	56	33	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52355	52362		10.1074/jbc.M305232200	http://dx.doi.org/10.1074/jbc.M305232200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14565954	hybrid			2022-12-27	WOS:000187480700046
J	Rodriguez, M; Yu, XC; Chen, JJ; Songyang, Z				Rodriguez, M; Yu, XC; Chen, JJ; Songyang, Z			Phosphopeptide binding specificities of BRCA1 COOH-terminal (BRCT) domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-LIGASE-III; REPAIR PROTEIN XRCC1; DOUBLE-STRAND BREAKS; INTERACT IN-VIVO; DAMAGE CHECKPOINT; CONSERVED DOMAINS; CANCER; MDC1; GENE; NFBD1/KIAA0170	Protein phosphorylation by protein kinases may generate docking sites for other proteins. It thus allows the assembly of signaling complexes in response to kinase activation. Several protein domains that bind phosphoserine or phosphothreonine residues have been identified, including the 14-3-3, PIN1, FHA, KIX, WD-40 domain, and polo box (Yaffe, M. B., and Elia, A. E. (2001) Curr. Opin. Cell Biol. 13, 131-138; Elia, A. E., Cantley, L. C., and Yaffe, M. B. (2003) Science 299, 1228-1231). The BRCA1 COOH-terminal (BRCT) domains are protein modules found in many proteins that regulate DNA damage responses (Koonin, E. V., Altschul, S. F., and Bork, P. (1996) Nat. Genet. 13, 266-268). Whether BRCT domains can mediate phosphorylation-dependent interactions has not been systematically investigated. We report here that the BRCT domains also recognize phosphopeptides. Oriented peptide library analysis indicated that the BRCT domains from BRCA1, MDC1, BARD1, and DNA Ligase IV preferred distinct phosphoserine-containing peptides. In addition, the interaction between BRCA1 and the BRCT binding motif of BACH1 was required for BACH1 checkpoint activity. Furthermore, BRCT domains of the yeast DNA repair protein Rad9 could bind phosphopeptides, suggesting that the BRCT domains represent a class of ancient phosphopeptide-binding modules. Potential targets of BRCT domains were identified through data base search. Structural analysis of BRCA1 BRCT repeats also predicted conserved residues that may form the phosphopeptide-binding pocket. Thus, the BRCT repeats are a new family of phosphopeptide-binding domains in DNA damage responses.	Baylor Coll Med, Verna & Marrs McLean Dept Biochem & Mol Biol, Houston, TX 77030 USA; Mayo Clin & Mayo Fdn, Dept Oncol, Rochester, MN 55905 USA	Baylor College of Medicine; Mayo Clinic	Songyang, Z (corresponding author), Baylor Coll Med, Verna & Marrs McLean Dept Biochem & Mol Biol, 1 Baylor Plaza, Houston, TX 77030 USA.	songyang@bcm.tmc.edu			NIGMS NIH HHS [GM569209] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aravind L, 1999, NUCLEIC ACIDS RES, V27, P1223, DOI 10.1093/nar/27.5.1223; Arver B, 2000, SEMIN CANCER BIOL, V10, P271, DOI 10.1006/scbi.2000.0325; Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; CALDECOTT KW, 1994, MOL CELL BIOL, V14, P68, DOI 10.1128/MCB.14.1.68; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; Cantor SB, 2001, CELL, V105, P149, DOI 10.1016/S0092-8674(01)00304-X; Chai YL, 1999, ONCOGENE, V18, P263, DOI 10.1038/sj.onc.1202323; Durocher D, 2000, MOL CELL, V6, P1169, DOI 10.1016/S1097-2765(00)00114-3; Frank R, 2002, J IMMUNOL METHODS, V267, P13, DOI 10.1016/S0022-1759(02)00137-0; Goldberg M, 2003, NATURE, V421, P952, DOI 10.1038/nature01445; Joo WS, 2002, GENE DEV, V16, P583, DOI 10.1101/gad.959202; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Koonin EV, 1996, NAT GENET, V13, P266, DOI 10.1038/ng0796-266; Krishnan VV, 2001, BIOCHEMISTRY-US, V40, P13158, DOI 10.1021/bi010979g; Liu K, 2003, MOL CELL BIOL, V23, P3287, DOI 10.1128/MCB.23.9.3287-3304.2003; Lou ZK, 2003, NATURE, V421, P957, DOI 10.1038/nature01447; Ozaki T, 2000, DNA CELL BIOL, V19, P475, DOI 10.1089/10445490050128403; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Peng AM, 2003, J BIOL CHEM, V278, P8873, DOI 10.1074/jbc.C300001200; Pierce AJ, 2001, TRENDS CELL BIOL, V11, pS52, DOI 10.1016/S0962-8924(01)02149-3; Rittinger K, 1999, MOL CELL, V4, P153, DOI 10.1016/S1097-2765(00)80363-9; Rosen EM, 2003, J CELL PHYSIOL, V196, P19, DOI 10.1002/jcp.10257; Shiloh Y, 2001, CURR OPIN GENET DEV, V11, P71, DOI 10.1016/S0959-437X(00)00159-3; Stewart GS, 2003, NATURE, V421, P961, DOI 10.1038/nature01446; Taylor RM, 1998, CURR BIOL, V8, P877, DOI 10.1016/S0960-9822(07)00350-8; Thai TH, 1998, HUM MOL GENET, V7, P195, DOI 10.1093/hmg/7.2.195; Timson DJ, 2000, MUTAT RES-DNA REPAIR, V460, P301, DOI 10.1016/S0921-8777(00)00033-1; Tomkinson AE, 1997, BIOESSAYS, V19, P893, DOI 10.1002/bies.950191009; WEINERT TA, 1990, MOL CELL BIOL, V10, P6554, DOI 10.1128/MCB.10.12.6554; Williams RS, 2001, NAT STRUCT BIOL, V8, P838, DOI 10.1038/nsb1001-838; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Xu XZ, 2003, J BIOL CHEM, V278, P8795, DOI 10.1074/jbc.M211392200; Yaffe MB, 2001, CURR OPIN CELL BIOL, V13, P131, DOI 10.1016/S0955-0674(00)00189-7; Yamane K, 1999, ONCOGENE, V18, P5194, DOI 10.1038/sj.onc.1202922; Yu X, 1998, J BIOL CHEM, V273, P25388, DOI 10.1074/jbc.273.39.25388; Yu XC, 2003, SCIENCE, V302, P639, DOI 10.1126/science.1088753; Zhang XD, 1998, EMBO J, V17, P6404, DOI 10.1093/emboj/17.21.6404; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; Zhou SY, 1999, PROG BIOPHYS MOL BIO, V71, P359, DOI 10.1016/S0079-6107(98)00045-5	39	190	191	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52914	52918		10.1074/jbc.C300407200	http://dx.doi.org/10.1074/jbc.C300407200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14578343	hybrid			2022-12-27	WOS:000187480700113
J	Fukuhara, A; Shimizu, K; Kawakatsu, T; Fukuhara, T; Takai, Y				Fukuhara, A; Shimizu, K; Kawakatsu, T; Fukuhara, T; Takai, Y			Involvement of nectin-activated Cdc42 small G protein in organization of adherens and tight junctions in Madin-Darby canine kidney cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							E-CADHERIN; RHO-GTPASES; PHOSPHATIDYLINOSITOL 3-KINASE; TRANS-INTERACTIONS; ADHESION; RAC; AFADIN; MOLECULES; POLARITY; DOMAIN	Nectins, Ca2+-independent immunoglobulin-like cell-cell adhesion molecules, trans-interact and form cell-cell adhesion, which increases the velocities of the formation of the E-cadherin-based adherens junctions (AJs) and the claudin-based tight junctions ( TJs) in Madin-Darby canine kidney (MDCK) cells. The trans-interactions of nectins furthermore induce activation of Cdc42 and Rac small G proteins, but the roles of these small G proteins activated in this way remain unknown. We examined here the role and the mode of action of Cdc42 in the organization of AJs and TJs in MDCK cells. We first made the NWASP-Cdc42 and Rac interactive binding ( CRIB) domain, an inhibitor of activated Cdc42, fused to the Ki-Ras CAAX motif (NWASP-CRIB-CAAX; where A is aliphatic amino acid), which was targeted to the cell-cell adhesion sites. We then found that overexpression of NWASP-CRIB-CAAX reduced the velocities of the formation of AJs and TJs. Conversely, overexpression of a constitutively active mutant of Cdc42 ( V12Cdc42) increased their velocities, and the inhibitory effect of NWASP-CRIB-CAAX was suppressed by co-expression with V12Cdc42. The inhibitory effect of NWASP-CRIB-CAAX on the formation of AJs and TJs was suppressed by co-expression of nectin-1 of which trans-interaction activated endogenous Cdc42. Moreover, the formation of the claudin-based TJs required a greater amount of activated Cdc42 than that of the E-cadherin-based AJs. These results indicate that the Cdc42 activated by the trans-interactions of nectins is involved in the organization of AJs and TJs in different mechanisms in MDCK cells.	Osaka Univ, Dept Mol Biol & Biochem, Grad Sch Med, Fac Med, Osaka 5650871, Japan	Osaka University	Takai, Y (corresponding author), Osaka Univ, Dept Mol Biol & Biochem, Grad Sch Med, Fac Med, Osaka 5650871, Japan.	ytakai@molbio.med.osaka-u.ac.jp	Fukuhara, Atsunori/A-9601-2018	Fukuhara, Atsunori/0000-0002-6289-3778				Betson M, 2002, J BIOL CHEM, V277, P36962, DOI 10.1074/jbc.M207358200; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Braga VMM, 1999, MOL BIOL CELL, V10, P9, DOI 10.1091/mbc.10.1.9; Braga VMM, 1997, J CELL BIOL, V137, P1421, DOI 10.1083/jcb.137.6.1421; Braga VMM, 2002, CURR OPIN CELL BIOL, V14, P546, DOI 10.1016/S0955-0674(02)00373-3; Ehrlich JS, 2002, DEV CELL, V3, P259, DOI 10.1016/S1534-5807(02)00216-2; Etienne-Manneville S, 2003, CURR OPIN CELL BIOL, V15, P67, DOI 10.1016/S0955-0674(02)00005-4; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; FARQUHAR MG, 1963, J CELL BIOL, V17, P375, DOI 10.1083/jcb.17.2.375; Fukuhara A, 2002, ONCOGENE, V21, P7642, DOI 10.1038/sj.onc.1205875; Garrard SM, 2003, EMBO J, V22, P1125, DOI 10.1093/emboj/cdg110; GEORGOPOULOS C, 1989, TRENDS GENET, V5, P319, DOI 10.1016/0168-9525(89)90118-2; Goodwin M, 2003, J BIOL CHEM, V278, P20533, DOI 10.1074/jbc.M213171200; GUMBINER B, 1988, J CELL BIOL, V107, P1575, DOI 10.1083/jcb.107.4.1575; Gumbiner BM, 2000, J CELL BIOL, V148, P399, DOI 10.1083/jcb.148.3.399; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Honda T, 2003, BIOCHEM BIOPH RES CO, V306, P104, DOI 10.1016/S0006-291X(03)00919-7; Honda T, 2003, GENES CELLS, V8, P481, DOI 10.1046/j.1365-2443.2003.00649.x; Honda T, 2003, GENES CELLS, V8, P51, DOI 10.1046/j.1365-2443.2003.00616.x; Jou TS, 1998, J CELL BIOL, V142, P85, DOI 10.1083/jcb.142.1.85; Kawakatsu T, 2002, J BIOL CHEM, V277, P50749, DOI 10.1074/jbc.M209846200; Kodama A, 1999, ONCOGENE, V18, P3996, DOI 10.1038/sj.onc.1202773; Kovacs EM, 2002, J BIOL CHEM, V277, P6708, DOI 10.1074/jbc.M109640200; Kroschewski R, 1999, NAT CELL BIOL, V1, P8, DOI 10.1038/8977; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leung SM, 2000, MOL BIOL CELL, V11, P2131, DOI 10.1091/mbc.11.6.2131; Magee T, 1999, CELL, V98, P9, DOI 10.1016/S0092-8674(00)80601-7; Mandai K, 1997, J CELL BIOL, V139, P517, DOI 10.1083/jcb.139.2.517; Miki H, 1998, NATURE, V391, P93, DOI 10.1038/34208; Nakagawa M, 2001, J CELL SCI, V114, P1829; Noren NK, 2001, J BIOL CHEM, V276, P33305, DOI 10.1074/jbc.C100306200; Ohno S, 2001, CURR OPIN CELL BIOL, V13, P641, DOI 10.1016/S0955-0674(00)00264-7; Rojas R, 2001, MOL BIOL CELL, V12, P2257, DOI 10.1091/mbc.12.8.2257; Sakisaka T, 1999, ONCOGENE, V18, P1609, DOI 10.1038/sj.onc.1202451; Takahashi K, 1999, J CELL BIOL, V145, P539, DOI 10.1083/jcb.145.3.539; Takai Y, 2003, CANCER SCI, V94, P655, DOI 10.1111/j.1349-7006.2003.tb01499.x; Takai Y, 2003, J CELL SCI, V116, P17, DOI 10.1242/jcs.00167; Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047; TAKEICHI M, 1988, DEVELOPMENT, V102, P639; Takenawa T, 2001, J CELL SCI, V114, P1801; Tsukita S, 1999, TRENDS CELL BIOL, V9, P268, DOI 10.1016/S0962-8924(99)01578-0; Van Aelst L, 2002, GENE DEV, V16, P1032, DOI 10.1101/gad.978802; Yamamoto Y, 2002, ONCOGENE, V21, P2545, DOI 10.1038/sj.onc.1205335; Yap AS, 2003, J CELL BIOL, V160, P11, DOI 10.1083/jcb.200208156; Yasuda T, 2000, GENES CELLS, V5, P583, DOI 10.1046/j.1365-2443.2000.00349.x	46	66	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51885	51893		10.1074/jbc.M308015200	http://dx.doi.org/10.1074/jbc.M308015200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14530286	hybrid			2022-12-27	WOS:000187206300124
J	Sato, S; Tomomori-Sato, C; Banks, CAS; Parmely, TJ; Sorokina, I; Brower, CS; Conaway, RC; Conaway, JW				Sato, S; Tomomori-Sato, C; Banks, CAS; Parmely, TJ; Sorokina, I; Brower, CS; Conaway, RC; Conaway, JW			A mammalian homolog of Drosophila melanogaster transcriptional coactivator intersex is a subunit of the mammalian mediator complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; DOUBLESEX PROTEINS; NUCLEAR RECEPTORS; YEAST; ACTIVATION; ENHANCER; PATHWAYS	The multiprotein Mediator complex is a coactivator required for transcriptional activation of RNA polymerase II transcribed genes by DNA binding transcription factors. We previously partially purified a Med8-containing Mediator complex from rat liver nuclei (Brower, C. S., Sato, S., Tomomori-Sato, C., Kamura, T., Pause, A., Stearman, R., Klausner, R. D., Malik, S., Lane, W. S., Sorokina, I., Roeder, R. G., Conaway, J. W., and Conaway, R. C. ( 2002) Proc. Natl. Acad. Sci. U. S. A. 99, 10353 - 10358). Analysis of proteins present in the most highly enriched Mediator fractions by tandem mass spectrometry led to the identification of several new mammalian Mediator subunits, as well as several potential Mediator subunits. Here we identify one of these proteins, encoded by the previously uncharacterized AK000411 open reading frame, as a new subunit of the mammalian Mediator complex. The AK000411 protein, which we designate hIntersex ( human Intersex), shares significant sequence similarity with the Drosophila melanogaster intersex protein, which has functional properties expected of a transcriptional coactivator specific for the Drosophila doublesex transactivator. In addition, we show that hIntersex assembles into a subcomplex with Mediator subunits p28b and TRFP. Taken together, our findings identify a new subunit of the mammalian Mediator and shed new light on the architecture of the mammalian Mediator complex.	Stowers Inst Med Res, Kansas City, MO 64110 USA; CALTECH, Div Biol, Pasadena, CA 91125 USA; Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, Kansas City, KS 66160 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA	Stowers Institute for Medical Research; California Institute of Technology; University of Kansas; University of Kansas Medical Center; University of Oklahoma System; University of Oklahoma Health Sciences Center	Conaway, JW (corresponding author), Stowers Inst Med Res, 1000 E 50th St, Kansas City, MO 64110 USA.			Banks, Charles/0000-0002-0404-2940; Tomomori-Sato, Chieri/0000-0002-2543-293X; Sorokina, Irina/0000-0003-1531-1832; Conaway, Joan/0000-0002-2786-0663	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM041628] Funding Source: NIH RePORTER; NIGMS NIH HHS [R37 GM41628] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baker BS, 2001, CELL, V105, P13, DOI 10.1016/S0092-8674(01)00293-8; Boube M, 2002, CELL, V110, P143, DOI 10.1016/S0092-8674(02)00830-9; Brower CS, 2002, P NATL ACAD SCI USA, V99, P10353, DOI 10.1073/pnas.162424199; BURTIS KC, 1991, EMBO J, V10, P2577, DOI 10.1002/j.1460-2075.1991.tb07798.x; Cline TW, 1996, ANNU REV GENET, V30, P637, DOI 10.1146/annurev.genet.30.1.637; COSCHIGANO KT, 1993, GENE DEV, V7, P42, DOI 10.1101/gad.7.1.42; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Garrett-Engele CM, 2002, DEVELOPMENT, V129, P4661; Hodgkin J, 2002, GENE DEV, V16, P2322, DOI 10.1101/gad.1025502; Ito M, 1999, MOL CELL, V3, P361, DOI 10.1016/S1097-2765(00)80463-3; Jiang YW, 1998, P NATL ACAD SCI USA, V95, P8538, DOI 10.1073/pnas.95.15.8538; Kang JS, 2001, J BIOL CHEM, V276, P42003, DOI 10.1074/jbc.M105961200; Malik S, 2000, MOL CELL, V5, P753, DOI 10.1016/S1097-2765(00)80254-3; Myers LC, 2000, ANNU REV BIOCHEM, V69, P729, DOI 10.1146/annurev.biochem.69.1.729; Naar AM, 1999, NATURE, V398, P828, DOI 10.1038/19789; Rachez C, 1999, NATURE, V398, P824, DOI 10.1038/19783; Ryu SJ, 1999, NATURE, V397, P446, DOI 10.1038/17141; Sato S, 2003, J BIOL CHEM, V278, P15123, DOI 10.1074/jbc.C300054200; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304	19	41	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					49671	49674		10.1074/jbc.C300444200	http://dx.doi.org/10.1074/jbc.C300444200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	14576168	Green Accepted, hybrid			2022-12-27	WOS:000187068200004
J	Selvaraj, A; Prywes, R				Selvaraj, A; Prywes, R			Megakaryoblastic leukemia-1/2, a transcriptional co-activator of serum response factor, is required for skeletal myogenic differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE DIFFERENTIATION; TRANSLATIONAL CONTROL; CELL-PROLIFERATION; GENE-EXPRESSION; PROMOTER ELEMENTS; REGULATORY ROLE; GROWTH-FACTORS; CASEIN KINASE; ACTIN; ACTIVATION	Serum response factor (SRF) is required for the expression of a wide variety of muscle-specific genes that are expressed upon differentiation and is thus required for both striated and smooth muscle differentiation in addition to its role in regulating growth factor-inducible genes. A heart and smooth muscle-specific SRF co-activator, myocardin, has been shown to be required for cardiac development and smooth muscle differentiation. However, no such co-factors of SRF have been identified in the skeletal myogenic differentiation program. Myocardin and the related transcription factor megakaryoblastic leukemia-1 (MKL1/MAL/MRTF-A) can strongly potentiate the activity of SRF. Here we report the cloning of the third member of the myocardin/MKL family in humans, MKL2. MKL2 binds to and activates SRF similar to myocardin and MKL1. To determine the role of these factors in skeletal myogenic differentiation we used a dominant negative MKL2 to show that the MKL family of proteins is required for skeletal myogenic differentiation. Expression of the dominant negative protein in C2C12 skeletal myoblasts blocked the differentiation-induced expression of the SRF target genes skeletal alpha-actin and alpha-myosin heavy chain and blocked differentiation of the myoblasts to myotubes in vitro. C2C12 cells express both MKL1 and MKL2, but not myocardin, implicating MKL1 and/or MKL2 in the requirement for skeletal myogenic differentiation. MKL1 was predominantly cytoplasmic in C2C12 cells, with a small amount in the nucleus, however, no movement of MKL1 to the nucleus was observed upon differentiation.	Columbia Univ, Dept Biol Sci, New York, NY 10027 USA	Columbia University	Prywes, R (corresponding author), Columbia Univ, Dept Biol Sci, Fairchild 813B,MC 2420,1212 Amsterdam Ave, New York, NY 10027 USA.	mrp6@columbia.edu			NCI NIH HHS [CA 50329] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050329] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arai A, 2002, J BIOL CHEM, V277, P24453, DOI 10.1074/jbc.M202216200; Aravind L, 2000, TRENDS BIOCHEM SCI, V25, P112, DOI 10.1016/S0968-0004(99)01537-6; BOXER LM, 1989, MOL CELL BIOL, V9, P515, DOI 10.1128/MCB.9.2.515; Buckingham M, 2003, J ANAT, V202, P59, DOI 10.1046/j.1469-7580.2003.00139.x; Cen B, 2003, MOL CELL BIOL, V23, P6597, DOI 10.1128/MCB.23.18.6597-6608.2003; Chang DF, 2003, DEV CELL, V4, P107, DOI 10.1016/S1534-5807(02)00396-9; Chang PS, 2001, J BIOL CHEM, V276, P17206, DOI 10.1074/jbc.M010983200; Chen F, 2002, CELL, V110, P713, DOI 10.1016/S0092-8674(02)00932-7; Chen JY, 2002, J MOL CELL CARDIOL, V34, P1345, DOI 10.1006/jmcc.2002.2086; Chen X, 1999, MOL CELL BIOL, V19, P4695; Chen X, 2002, J BIOL CHEM, V277, P13045, DOI 10.1074/jbc.M110636200; CHOW KL, 1990, MOL CELL BIOL, V10, P528, DOI 10.1128/MCB.10.2.528; Clarke N, 1998, MOL CELL BIOL, V18, P1065, DOI 10.1128/MCB.18.2.1065; COX RD, 1992, DEV BIOL, V149, P228, DOI 10.1016/0012-1606(92)90279-P; Du KL, 2003, MOL CELL BIOL, V23, P2425, DOI 10.1128/MCB.23.7.2425-2437.2003; GAUTHIERROUVIERE C, 1991, EMBO J, V10, P2921, DOI 10.1002/j.1460-2075.1991.tb07842.x; Gupta M, 2001, J BIOL CHEM, V276, P10413, DOI 10.1074/jbc.M008625200; HAN TH, 1995, MOL CELL BIOL, V15, P2907; Herring BP, 2001, J BIOL CHEM, V276, P14482, DOI 10.1074/jbc.M011585200; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; JANSSENTIMMEN U, 1989, GENE, V80, P325, DOI 10.1016/0378-1119(89)90296-5; JOHANSEN FE, 1995, BBA-REV CANCER, V1242, P1, DOI 10.1016/0304-419X(94)00014-S; Kireeva ML, 1996, MOL CELL BIOL, V16, P1326; LASSAR AB, 1994, CURR OPIN CELL BIOL, V6, P788, DOI 10.1016/0955-0674(94)90046-9; Lu J, 2001, DEV BIOL, V240, P404, DOI 10.1006/dbio.2001.0403; Ma ZG, 2001, NAT GENET, V28, P220, DOI 10.1038/90054; Mack CP, 2001, J BIOL CHEM, V276, P341, DOI 10.1074/jbc.M005505200; MANAK JR, 1993, ONCOGENE, V8, P703; MCGREW LL, 1990, EMBO J, V9, P3743, DOI 10.1002/j.1460-2075.1990.tb07587.x; Meech R, 2003, J BIOL CHEM, V278, P8269, DOI 10.1074/jbc.M207617200; Mendez R, 2001, NAT REV MOL CELL BIO, V2, P521, DOI 10.1038/35080081; Mercher T, 2001, P NATL ACAD SCI USA, V98, P5776, DOI 10.1073/pnas.101001498; Miralles F, 2003, CELL, V113, P329, DOI 10.1016/S0092-8674(03)00278-2; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Nakamura M, 2001, J BIOL CHEM, V276, P18313, DOI 10.1074/jbc.M101127200; Nikolaev AY, 2003, CELL, V112, P29, DOI 10.1016/S0092-8674(02)01255-2; Pesole G, 1999, TRENDS GENET, V15, P378, DOI 10.1016/S0168-9525(99)01795-3; PRYWES R, 1988, P NATL ACAD SCI USA, V85, P7206, DOI 10.1073/pnas.85.19.7206; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; Sampath D, 2001, ENDOCRINOLOGY, V142, P2540, DOI 10.1210/en.142.6.2540; Sasazuki T, 2002, J BIOL CHEM, V277, P28853, DOI 10.1074/jbc.M203190200; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Sepulveda JL, 2002, J BIOL CHEM, V277, P25775, DOI 10.1074/jbc.M203122200; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; SHIMIZU RT, 1995, J BIOL CHEM, V270, P7631, DOI 10.1074/jbc.270.13.7631; SKARNES WC, 1992, GENE DEV, V6, P903, DOI 10.1101/gad.6.6.903; Sotiropoulos A, 1999, CELL, V98, P159, DOI 10.1016/S0092-8674(00)81011-9; Soulez M, 1996, MOL CELL BIOL, V16, P6065; TAKEDA S, 1992, J BIOL CHEM, V267, P16957; TAYLOR M, 1989, DEVELOPMENT, V106, P67; Thuerauf DJ, 1998, J BIOL CHEM, V273, P20636, DOI 10.1074/jbc.273.32.20636; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; VANDROMME M, 1992, J CELL BIOL, V118, P1489, DOI 10.1083/jcb.118.6.1489; VASSALLI JD, 1995, CURR BIOL, V5, P476, DOI 10.1016/S0960-9822(95)00095-9; Wang DZ, 2002, P NATL ACAD SCI USA, V99, P14855, DOI 10.1073/pnas.222561499; Wang DZ, 2001, CELL, V105, P851, DOI 10.1016/S0092-8674(01)00404-4; Wang Y, 2000, ONCOGENE, V19, P1379, DOI 10.1038/sj.onc.1203443; Wei L, 2000, AM J PHYSIOL-HEART C, V278, pH1736, DOI 10.1152/ajpheart.2000.278.6.H1736; Wei L, 1998, J BIOL CHEM, V273, P30287, DOI 10.1074/jbc.273.46.30287; WILLIAMS GT, 1993, MOL CELL BIOL, V13, P6124, DOI 10.1128/MCB.13.10.6124; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; Yordy JS, 2000, ONCOGENE, V19, P6503, DOI 10.1038/sj.onc.1204036; Yoshida T, 2003, CIRC RES, V92, P856, DOI 10.1161/01.RES.0000068405.49081.09; Zilberman A, 1998, CIRC RES, V82, P566, DOI 10.1161/01.RES.82.5.566	64	111	117	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					41977	41987		10.1074/jbc.M305679200	http://dx.doi.org/10.1074/jbc.M305679200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	14565952	hybrid			2022-12-27	WOS:000185989500053
J	Nakadai, T; Shimada, M; Shima, D; Handa, H; Tamura, TA				Nakadai, T; Shimada, M; Shima, D; Handa, H; Tamura, TA			Specific interaction with transcription factor IIA and localization of the mammalian TATA-binding protein-like protein (TLP/TRF2/TLF)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; TBP-LIKE PROTEIN; YEAST TFIIA/TBP/DNA COMPLEX; CELL-CYCLE PROGRESSION; ACTIVATED TRANSCRIPTION; CRYSTAL-STRUCTURE; GENE-EXPRESSION; DNA-BINDING; IN-VIVO; PREINITIATION COMPLEX	TBP-like protein (TLP) is structurally similar to the TATA-binding protein (TBP) and is thought to have a transcriptional regulation function. Although TLP has been found to form a complex with transcription factor IIA (TFIIA), the in vivo functions of TFIIA for TLP are not clear. In this study, we analyzed the interaction between TLP and TFIIA. We determined the biophysical properties for the interaction of TLP with TFIIA. Dissociation constants of TFIIA versus TLP and TFIIA versus TBP were 1.5 and 10 nM, respectively. Moreover, the dissociation rate constant of TLP and TFIIA (1.2x10(-4)/M.s was significantly lower than that of TBP (2.1x10(-3)/M.s). These results indicate that TLP has a higher affinity to TFIIA than does TBP and that the TLP-TFIIA complex is much more stable than is the TBP-TFIIA complex. We found that TLP forms a dimer and a trimer and that these multimerizations are inhibited by TFIIA. Moreover, TLP mutimers were more stable than a TBP dimer. We determined the amounts of TLPs in the nucleus and cytoplasm of NIH3T3 cells and found that the molecular number of TLP in the nucleus was only 4% of that in the cytoplasm. Immunostaining of cells also revealed cytoplasmic localization of TLP. We established cells that stably express mutant TLP lacking TFIIA binding ability and identified the amino acids of TLP required for TFIIA binding (Ala-32, Leu-33, Asn-37, Arg-52, Lys-53, Lys-78, and Arg-86). Interestingly, the level of TFIIA binding defective mutant TLPs in the nucleus was much higher than that of the wild-type TLP and TFIIA-interactable mutant TLPs. Immunostaining analyses showed consistent results. These results suggest that the TFIIA binding ability of TLP is required for characteristic cytoplasmic localization of TLP. TFIIA may regulate the intracellular molecular state and the function of TLP through its property of binding to TLP.	Chiba Univ, Fac Sci, Dept Biol, Inage Ku, Chiba 2638522, Japan; Tokyo Inst Technol, Grad Sch Biosci & Biotechnol, Yokohama, Kanagawa 2268501, Japan	Chiba University; Tokyo Institute of Technology	Tamura, TA (corresponding author), Chiba Univ, Fac Sci, Dept Biol, Inage Ku, 1-33 Yayoicho, Chiba 2638522, Japan.	ttamura@faculty.chiba-u.jp						Bryant GO, 1996, GENE DEV, V10, P2491, DOI 10.1101/gad.10.19.2491; Clemens KE, 1996, MOL CELL BIOL, V16, P4656; Coleman RA, 1997, P NATL ACAD SCI USA, V94, P7221, DOI 10.1073/pnas.94.14.7221; COLEMAN RA, 1995, J BIOL CHEM, V270, P13842, DOI 10.1074/jbc.270.23.13842; CORDEN J, 1980, SCIENCE, V209, P1406, DOI 10.1126/science.6251548; CROWLEY TE, 1993, NATURE, V361, P557, DOI 10.1038/361557a0; Damania B, 1998, MOL CELL BIOL, V18, P3926, DOI 10.1128/MCB.18.7.3926; Dantonel JC, 2000, MOL CELL, V6, P715, DOI 10.1016/S1097-2765(00)00069-1; Dantonel JC, 1999, TRENDS BIOCHEM SCI, V24, P335, DOI 10.1016/S0968-0004(99)01436-X; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; Emami KH, 1997, GENE DEV, V11, P3007, DOI 10.1101/gad.11.22.3007; Geiger JH, 1996, SCIENCE, V272, P830, DOI 10.1126/science.272.5263.830; Hansen SK, 1997, CELL, V91, P71, DOI 10.1016/S0092-8674(01)80010-6; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; Hochheimer A, 2002, NATURE, V420, P439, DOI 10.1038/nature01167; Holmes MC, 2000, SCIENCE, V288, P867, DOI 10.1126/science.288.5467.867; Jackson-Fisher AJ, 1999, MOL CELL, V3, P717, DOI 10.1016/S1097-2765(01)80004-6; Kaltenbach L, 2000, MOL CELL, V6, P705, DOI 10.1016/S1097-2765(00)00068-X; KANG JJ, 1995, MOL CELL BIOL, V15, P1234; KATO K, 1994, NUCLEIC ACIDS RES, V22, P1179, DOI 10.1093/nar/22.7.1179; KIM TK, 1995, J BIOL CHEM, V270, P10976, DOI 10.1074/jbc.270.18.10976; Kimura H, 1999, MOL CELL BIOL, V19, P5383; KOBAYASHI N, 1995, MOL CELL BIOL, V15, P6465; Lee TI, 1998, GENE DEV, V12, P1398, DOI 10.1101/gad.12.10.1398; Li FQ, 1997, GENES CELLS, V2, P143, DOI 10.1046/j.1365-2443.1997.1090306.x; Lieberman PM, 1997, MOL CELL BIOL, V17, P6624, DOI 10.1128/MCB.17.11.6624; MA DM, 1993, GENE DEV, V7, P2246, DOI 10.1101/gad.7.11.2246; Martianov I, 2001, MOL CELL, V7, P509, DOI 10.1016/S1097-2765(01)00198-8; Martianov I, 2002, DEVELOPMENT, V129, P945; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; Moore PA, 1999, MOL CELL BIOL, V19, P7610; Morimoto RI, 2002, CELL, V110, P281, DOI 10.1016/S0092-8674(02)00860-7; Muller F, 2001, CURR BIOL, V11, P282, DOI 10.1016/S0960-9822(01)00076-8; Nakadai T, 1999, J CELL SCI, V112, P1353; Nakai A, 2000, J BIOL CHEM, V275, P34665, DOI 10.1074/jbc.M005302200; NIKOLOV DB, 1992, NATURE, V360, P40, DOI 10.1038/360040a0; Ohbayashi T, 1999, BIOCHEM BIOPH RES CO, V255, P137, DOI 10.1006/bbrc.1999.0159; Ohbayashi T, 2001, BIOCHEM BIOPH RES CO, V285, P616, DOI 10.1006/bbrc.2001.5217; Ohbayashi T, 1999, NUCLEIC ACIDS RES, V27, P750, DOI 10.1093/nar/27.3.750; OHBYASHI T, 2003, NUCLEIC ACIDS RES, V31, P1; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; Ozer J, 1996, J BIOL CHEM, V271, P11182, DOI 10.1074/jbc.271.19.11182; Ozer J, 1998, MOL CELL BIOL, V18, P2559, DOI 10.1128/MCB.18.5.2559; Rabenstein MD, 1999, P NATL ACAD SCI USA, V96, P4791, DOI 10.1073/pnas.96.9.4791; Ranish JA, 1999, GENE DEV, V13, P49, DOI 10.1101/gad.13.1.49; Roberts CW, 1996, CELL, V86, P495; ROUX P, 1990, CELL, V63, P341, DOI 10.1016/0092-8674(90)90167-D; Shima D, 2003, GENES CELLS, V8, P215, DOI 10.1046/j.1365-2443.2003.00627.x; Shimada M, 1999, NUCLEIC ACIDS RES, V27, P3146, DOI 10.1093/nar/27.15.3146; Shimada M, 2003, MOL CELL BIOL, V23, P4107, DOI 10.1128/MCB.23.12.4107-4120.2003; STARGELL LA, 1995, SCIENCE, V269, P75, DOI 10.1126/science.7604282; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Taggart AKP, 1996, SCIENCE, V272, P1331, DOI 10.1126/science.272.5266.1331; Takada S, 2000, CELL, V101, P459, DOI 10.1016/S0092-8674(00)80857-0; Tan S, 1996, NATURE, V381, P127, DOI 10.1038/381127a0; Tang H, 1996, P NATL ACAD SCI USA, V93, P1119, DOI 10.1073/pnas.93.3.1119; Teichmann M, 1999, P NATL ACAD SCI USA, V96, P13720, DOI 10.1073/pnas.96.24.13720; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Veenstra GJC, 2000, SCIENCE, V290, P2312, DOI 10.1126/science.290.5500.2312; Weideman CA, 1997, J MOL BIOL, V271, P61, DOI 10.1006/jmbi.1997.1152; Zhang D, 2001, SCIENCE, V292, P1153, DOI 10.1126/science.1059188	61	30	33	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7447	7455		10.1074/jbc.M305412200	http://dx.doi.org/10.1074/jbc.M305412200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14570910	hybrid			2022-12-27	WOS:000189103300011
J	Westerberg, R; Tvrdik, P; Unden, AB; Mansson, JE; Norlen, L; Jakobsson, A; Holleran, WH; Elias, PM; Asadi, A; Flodby, P; Toftgard, R; Capecchi, MR; Jacobsson, A				Westerberg, R; Tvrdik, P; Unden, AB; Mansson, JE; Norlen, L; Jakobsson, A; Holleran, WH; Elias, PM; Asadi, A; Flodby, P; Toftgard, R; Capecchi, MR; Jacobsson, A			Role for ELOVL3 and fatty acid chain length in development of hair and skin function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRATUM-CORNEUM; SEBACEOUS GLANDS; STEM-CELLS; GENE FAMILY; MOUSE; ELONGATION; MICE; ASEBIA; LIPIDS; IDENTIFICATION	Very little is known about the in vivo regulation of mammalian fatty acid chain elongation enzymes as well as the role of specific fatty acid chain length in cellular responses and developmental processes. Here, we report that the Elovl3 gene product, which belongs to a highly conserved family of microsomal enzymes involved in the formation of very long chain fatty acids, revealed a distinct expression in the skin that was restricted to the sebaceous glands and the epithelial cells of the hair follicles. By disruption of the Elovl3 gene by homologous recombination in mouse, we show that ELOVL3 participates in the formation of specific neutral lipids that are necessary for the function of the skin. The Elovl3- ablated mice displayed a sparse hair coat, the pilosebaceous system was hyperplastic, and the hair lipid content was disturbed with exceptionally high levels of eicosenoic acid ( 20: 1). This was most prominent within the triglyceride fraction where fatty acids longer than 20 carbon atoms were almost undetectable. A functional consequence of this is that Elovl3- ablated mice exhibited a severe defect in water repulsion and increased trans- epidermal water loss.	Stockholm Univ, Wenner Gren Inst, Arrhenius Labs F3, SE-10691 Stockholm, Sweden; Karolinska Inst, NOVUM, Ctr Nutr & Toxicol, SE-14157 Huddinge, Sweden; Sahlgrens Univ Hosp, Dept Clin Neurosci, SE-43180 Molndal, Sweden; Karolinska Inst, Dept Med Biochem & Biophys, SE-17177 Stockholm, Sweden; Vet Affairs Med Ctr, Dept Dermatol, San Francisco, CA 94121 USA; Univ Utah, Howard Hughes Med Inst, Salt Lake City, UT 84112 USA	Stockholm University; Karolinska Institutet; Sahlgrenska University Hospital; Karolinska Institutet; US Department of Veterans Affairs; Veterans Health Administration (VHA); Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah	Jacobsson, A (corresponding author), Stockholm Univ, Wenner Gren Inst, Arrhenius Labs F3, SE-10691 Stockholm, Sweden.	anders.jacobsson@wgi.su.se	Tvrdik, Petr/AAK-4398-2021	Tvrdik, Petr/0000-0002-8750-9672	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR039448] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR39448] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BROWN WR, 1989, J INVEST DERMATOL, V92, P126; Chen HC, 2002, J CLIN INVEST, V109, P175, DOI 10.1172/JCI0213880; CINTI DL, 1992, PROG LIPID RES, V31, P1, DOI 10.1016/0163-7827(92)90014-A; CONIGLIO JG, 1994, PROG LIPID RES, V33, P387, DOI 10.1016/0163-7827(94)90024-8; David D, 1998, J CELL BIOL, V143, P1167, DOI 10.1083/jcb.143.5.1167; DOWNING DT, 1968, J CHROMATOGR, V38, P91, DOI 10.1016/0021-9673(68)85011-3; Fluhr JW, 2003, J INVEST DERMATOL, V120, P728, DOI 10.1046/j.1523-1747.2003.12134.x; GATES AH, 1965, SCIENCE, V148, P1471, DOI 10.1126/science.148.3676.1471; GOSSLER A, 1986, P NATL ACAD SCI USA, V83, P9065, DOI 10.1073/pnas.83.23.9065; Herron BJ, 1999, MAMM GENOME, V10, P864, DOI 10.1007/s003359901105; HOU SYE, 1991, J INVEST DERMATOL, V96, P215, DOI 10.1111/1523-1747.ep12461361; JOSEFOWICZ WJ, 1978, GENET RES, V31, P53, DOI 10.1017/S0016672300017791; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; Leonard AE, 2000, BIOCHEM J, V350, P765, DOI 10.1042/0264-6021:3500765; MADISON KC, 1987, J INVEST DERMATOL, V88, P714, DOI 10.1111/1523-1747.ep12470386; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; Matsuzaka T, 2002, J LIPID RES, V43, P911; Miyazaki M, 2000, J BIOL CHEM, V275, P30132, DOI 10.1074/jbc.M005488200; Moon YA, 2003, J BIOL CHEM, V278, P7335, DOI 10.1074/jbc.M211684200; Moon YA, 2001, J BIOL CHEM, V276, P45358, DOI 10.1074/jbc.M108413200; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; Nilsson M, 2000, P NATL ACAD SCI USA, V97, P3438, DOI 10.1073/pnas.050467397; Oh CS, 1997, J BIOL CHEM, V272, P17376, DOI 10.1074/jbc.272.28.17376; PINNAGODA J, 1990, CONTACT DERMATITIS, V22, P164, DOI 10.1111/j.1600-0536.1990.tb01553.x; POULOS A, 1995, LIPIDS, V30, P1, DOI 10.1007/BF02537036; SMITH S, 1994, FASEB J, V8, P1248, DOI 10.1096/fasebj.8.15.8001737; STEWART ME, 1991, ADV LIPID RES, V24, P263; Sundberg JP, 2000, AM J PATHOL, V156, P2067, DOI 10.1016/S0002-9440(10)65078-X; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; Tvrdik P, 2000, J CELL BIOL, V149, P707, DOI 10.1083/jcb.149.3.707; Tvrdik P, 1999, J BIOL CHEM, V274, P26387, DOI 10.1074/jbc.274.37.26387; Tvrdik P, 1997, J BIOL CHEM, V272, P31738, DOI 10.1074/jbc.272.50.31738; Uchida Y, 2000, J LIPID RES, V41, P2071; WILLIAMS D, 1994, DEV BIOL, V165, P469, DOI 10.1006/dbio.1994.1268; Zhang K, 2001, NAT GENET, V27, P89, DOI 10.1038/83817; Zheng Y, 1999, NAT GENET, V23, P268, DOI 10.1038/15446	36	133	142	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5621	5629		10.1074/jbc.M310529200	http://dx.doi.org/10.1074/jbc.M310529200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14581464	hybrid			2022-12-27	WOS:000188776500072
J	Kumagai, M; Makioka, A; Takeuchi, T; Nozaki, T				Kumagai, M; Makioka, A; Takeuchi, T; Nozaki, T			Molecular cloning and characterization of a protein farnesyltransferase from the enteric protozoan parasite Entamoeba histolytica	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAS; FARNESYL; GENES; TRANSFERASE; IDENTIFICATION; PRENYLATION; INHIBITION; MECHANISM; SUBUNIT; BINDING	Genes encoding alpha- and beta-subunits of a putative protein farnesyltransferase (FT) from the enteric protozoan parasite Entamoeba histolytica were obtained and their biochemical properties were characterized. Deduced amino acid sequences of the alpha- and beta-subunit of E. histolytica FT (EhFT) were 298- and 375-residues long with a molecular mass of 35.6 and 42.6 kDa, and a pI of 5.43 and 5.65, respectively. They showed 24% to 36% identity to and shared common signature domains and repeats with those from other organisms. Recombinant alpha- and beta-subunits, co-expressed in Escherichia coli, formed a heterodimer and showed activity to transfer farnesyl using farnesylpyrophosphate as a donor to human H-Ras possessing a C-terminal CVLS, but not a mutant H-Ras possessing CVLL. Among a number of small GTPases that belong to the Ras superfamily from this parasite, we identified EhRas4, which possesses CVVA at the C terminus, as a sole farnesyl acceptor for EhFT. This is in contrast to mammalian FT, which utilizes a variety of small GTPases that possess a C-terminal CaaX motif, where X is serine, methionine, glutamine, cysteine, or alanine. EhFT also showed remarkable resistance against a variety of known inhibitors of mammalian FT. These results suggest that remarkable biochemical differences in binding to substrates and inhibitors exist between amebic and mammalian FTs, which highlights this enzyme as a novel target for the development of new chemotherapeutics against amebiasis.	Natl Inst Infect Dis, Dept Parasitol, Shinjuku Ku, Tokyo 1628640, Japan; Jikei Univ, Sch Med, Dept Trop Med, Minato Ku, Tokyo 1058461, Japan; Keio Univ, Sch Med, Dept Trop Med & Parasitol, Shinjuku Ku, Tokyo 1608582, Japan; Japan Sci & Technol Agcy, Precursory Res Embryon Sci & Technol, Tokyo 1900012, Japan	National Institute of Infectious Diseases (NIID); Jikei University; Keio University; Japan Science & Technology Agency (JST)	Nozaki, T (corresponding author), Natl Inst Infect Dis, Dept Parasitol, Shinjuku Ku, 1-23-1 Toyama, Tokyo 1628640, Japan.	nozaki@nih.go.jp						[Anonymous], 1997, B WORLD HEALTH ORGAN, V75, P291; ARMSTRONG SA, 1995, J BIOL CHEM, V270, P7864, DOI 10.1074/jbc.270.14.7864; BOGUSKI MS, 1992, NEW BIOL, V4, P408; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DIAMOND LS, 1978, T ROY SOC TROP MED H, V72, P431, DOI 10.1016/0035-9203(78)90144-X; DIAMOND LS, 1972, J VIROL, V9, P326, DOI 10.1128/JVI.9.2.326-341.1972; Dunten P, 1998, BIOCHEMISTRY-US, V37, P7907, DOI 10.1021/bi980531o; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; Gelb MH, 2003, MOL BIOCHEM PARASIT, V126, P155, DOI 10.1016/S0166-6851(02)00282-7; Ghosh SK, 1997, INFECT IMMUN, V65, P4243, DOI 10.1128/IAI.65.10.4243-4249.1997; GIBBS JB, 1991, CELL, V65, P1, DOI 10.1016/0092-8674(91)90352-Y; GIBBS JB, 1993, J BIOL CHEM, V268, P7617; Guillen N, 1997, Arch Med Res, V28 Spec No, P129; Guillen N, 1998, J CELL SCI, V111, P1729; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; JAMES GL, 1995, J BIOL CHEM, V270, P6221, DOI 10.1074/jbc.270.11.6221; Juarez P, 2000, ARCH MED RES, V31, pS157, DOI 10.1016/S0188-4409(00)00111-9; Kral AM, 1997, J BIOL CHEM, V272, P27319, DOI 10.1074/jbc.272.43.27319; LERNER EC, 1995, J BIOL CHEM, V270, P26802, DOI 10.1074/jbc.270.45.26802; LOHIA A, 1993, MOL BIOCHEM PARASIT, V58, P177, DOI 10.1016/0166-6851(93)90104-6; Lohia A, 1996, GENE, V173, P205, DOI 10.1016/0378-1119(96)00232-6; MANNE V, 1995, DRUG DEVELOP RES, V34, P121, DOI 10.1002/ddr.430340205; MANNE V, 1984, P NATL ACAD SCI-BIOL, V81, P6953, DOI 10.1073/pnas.81.22.6953; Micali E, 2001, BIOCHEMISTRY-US, V40, P12254, DOI 10.1021/bi011133f; MOORES SL, 1991, J BIOL CHEM, V266, P14603; Nepomuceno-Silva JL, 2001, J BIOL CHEM, V276, P29711, DOI 10.1074/jbc.M102920200; Nozaki T, 1998, MOL BIOCHEM PARASIT, V97, P33, DOI 10.1016/S0166-6851(98)00129-7; OMER CA, 1995, METHOD ENZYMOL, V250, P3; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; Park HW, 1997, SCIENCE, V275, P1800, DOI 10.1126/science.275.5307.1800; POMPLIANO DL, 1992, BIOCHEMISTRY-US, V31, P3800, DOI 10.1021/bi00130a010; REDDY EP, 1982, NATURE, V300, P149, DOI 10.1038/300149a0; Rodriguez MA, 2000, MOL BIOCHEM PARASIT, V108, P199, DOI 10.1016/S0166-6851(00)00216-4; Saito-Nakano Y, 2001, MOL BIOCHEM PARASIT, V116, P219, DOI 10.1016/S0166-6851(01)00318-8; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SAMBROOK J, 1989, MOL CLONING LAB MANU, V18, P47; Shen PS, 1996, EXP PARASITOL, V82, P65, DOI 10.1006/expr.1996.0008; SHEN PS, 1994, MOL BIOCHEM PARASIT, V64, P111, DOI 10.1016/0166-6851(94)90139-2; TABIN CJ, 1982, NATURE, V300, P143, DOI 10.1038/300143a0; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; TAPAROWSKY E, 1982, NATURE, V300, P762, DOI 10.1038/300762a0; Temesvari LA, 1999, MOL BIOCHEM PARASIT, V103, P225, DOI 10.1016/S0166-6851(99)00133-4; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; VANDERPYL D, 1992, J ANTIBIOT, V45, P1802; Yokoyama K, 1997, MOL BIOCHEM PARASIT, V87, P61, DOI 10.1016/S0166-6851(97)00043-1; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325	50	23	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 16	2004	279	3					2316	2323		10.1074/jbc.M311478200	http://dx.doi.org/10.1074/jbc.M311478200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	762WT	14583615	hybrid			2022-12-27	WOS:000188005700089
J	Adams, CA; Kar, SR; Hopper, JE; Fried, MG				Adams, CA; Kar, SR; Hopper, JE; Fried, MG			Self-association of the amino-terminal domain of the yeast TATA-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; RESOLUTION REFINED STRUCTURE; TRANSCRIPTION FACTOR SL1; CRYSTAL-STRUCTURE; GENE-EXPRESSION; TFIID COMPLEX; MINOR-GROOVE; DNA CONTACTS; CORE DOMAIN; HUMAN TBP	The amino-terminal domain of yeast TATA-binding protein has been proposed to play a crucial role in the self-association mechanism(s) of the full-length protein. Here we tested the ability of this domain to self-associate under a variety of solution conditions. Escherichia coli two-hybrid assays, in vitro pull-down assays, and in vitro cross-linking provided qualitative evidence for a limited and specific self-association. Sedimentation equilibrium analysis using purified protein was consistent with a monomer-dimer equilibrium with an apparent dissociation constant of similar to8.4 muM. Higher stoichiometry associations remain possible but could not be detected by any of these methods. These results demonstrate that the minimal structure necessary for aminoterminal domain self-association must be present even in the absence of carboxyl-terminal domain structures. On the basis of these results we propose that aminoterminal domain structures contribute to the oligomerization interface of the full-length yeast TATA-binding protein.	Penn State Univ, Dept Biochem & Mol Biol, Coll Med, Hershey, PA 17033 USA; Penn State Univ, Dept Cell & Mol Physiol, Coll Med, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Fried, MG (corresponding author), Penn State Univ, Dept Biochem & Mol Biol, Coll Med, 500 Univ Dr, Hershey, PA 17033 USA.							Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; Campbell KM, 2000, BIOCHEMISTRY-US, V39, P2633, DOI 10.1021/bi9922998; CHASMAN DI, 1993, P NATL ACAD SCI USA, V90, P8174, DOI 10.1073/pnas.90.17.8174; Colbert T, 1998, MOL CELL BIOL, V18, P1682, DOI 10.1128/MCB.18.3.1682; Coleman RA, 1997, P NATL ACAD SCI USA, V94, P7221, DOI 10.1073/pnas.94.14.7221; COLEMAN RA, 1995, J BIOL CHEM, V270, P13842, DOI 10.1074/jbc.270.23.13842; COMAI L, 1994, SCIENCE, V266, P1966, DOI 10.1126/science.7801123; Daugherty MA, 2000, BIOCHEMISTRY-US, V39, P4869, DOI 10.1021/bi992423n; Daugherty MA, 1999, J MOL BIOL, V285, P1389, DOI 10.1006/jmbi.1998.2427; Dove SL, 1998, COLD SPRING HARB SYM, V63, P173, DOI 10.1101/sqb.1998.63.173; Dove SL, 1997, NATURE, V386, P627, DOI 10.1038/386627a0; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; Hidalgo P, 2001, GENE DEV, V15, P1007, DOI 10.1101/gad.873901; HORIKOSHI M, 1990, CELL, V61, P1171, DOI 10.1016/0092-8674(90)90681-4; Jackson-Fisher AJ, 1999, MOL CELL, V3, P717, DOI 10.1016/S1097-2765(01)80004-6; KATO K, 1994, NUCLEIC ACIDS RES, V22, P1179, DOI 10.1093/nar/22.7.1179; Khrapunov S, 2002, BIOCHEMISTRY-US, V41, P9559, DOI 10.1021/bi0255773; KIM JL, 1994, NAT STRUCT BIOL, V1, P638, DOI 10.1038/nsb0994-638; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; Laue TM, 1995, METHOD ENZYMOL, V259, P427; LEE DK, 1992, MOL CELL BIOL, V12, P5189, DOI 10.1128/MCB.12.11.5189; Lee TI, 1998, GENE DEV, V12, P1398, DOI 10.1101/gad.12.10.1398; LESCURE A, 1994, EMBO J, V13, P1166, DOI 10.1002/j.1460-2075.1994.tb06366.x; Leurent C, 2002, EMBO J, V21, P3424, DOI 10.1093/emboj/cdf342; LIEBERMAN PM, 1991, MOL CELL BIOL, V11, P63, DOI 10.1128/MCB.11.1.63; LU T, 1993, ANAL BIOCHEM, V213, P318, DOI 10.1006/abio.1993.1427; McRorie D. K., 1993, SELF ASS SYSTEMS ANA; Mittal V, 1997, SCIENCE, V275, P1136, DOI 10.1126/science.275.5303.1136; NIKOLOV DB, 1994, NAT STRUCT BIOL, V1, P621, DOI 10.1038/nsb0994-621; NIKOLOV DB, 1995, NATURE, V377, P119, DOI 10.1038/377119a0; NIKOLOV DB, 1992, NATURE, V360, P40, DOI 10.1038/360040a0; Oberleithner H, 1996, PFLUG ARCH EUR J PHY, V432, P839, DOI 10.1007/s004240050206; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; Parkhurst KM, 1996, BIOCHEMISTRY-US, V35, P7459, DOI 10.1021/bi9530301; Pemberton LF, 1999, J CELL BIOL, V145, P1407, DOI 10.1083/jcb.145.7.1407; PEREZHOWARD GM, 1995, BIOCHEMISTRY-US, V34, P8005, DOI 10.1021/bi00025a006; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; PETRI V, 1995, BIOCHEMISTRY-US, V34, P9977, DOI 10.1021/bi00031a020; PUGH BF, 1992, J BIOL CHEM, V267, P679; Rashidzadeh H, 2003, BIOCHEMISTRY-US, V42, P3655, DOI 10.1021/bi027203f; RUDLOFF U, 1994, P NATL ACAD SCI USA, V91, P8229, DOI 10.1073/pnas.91.17.8229; Sambrook J., 2002, MOL CLONING LAB MANU; SEIPEL K, 1993, NUCLEIC ACIDS RES, V21, P5609, DOI 10.1093/nar/21.24.5609; Taggart AKP, 1996, SCIENCE, V272, P1331, DOI 10.1126/science.272.5266.1331; Tora L, 2002, GENE DEV, V16, P673, DOI 10.1101/gad.976402; ZAWEL L, 1995, ANNU REV BIOCHEM, V64, P533; ZHOU Q, 1995, MOL CELL BIOL, V15, P534, DOI 10.1128/MCB.15.1.534	50	6	6	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 9	2004	279	2					1376	1382		10.1074/jbc.M307867200	http://dx.doi.org/10.1074/jbc.M307867200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	759DJ	14534318	hybrid			2022-12-27	WOS:000187722800066
J	Figueiredo, L; Klunker, D; Ang, D; Naylor, DJ; Kerner, MJ; Georgopoulos, C; Hartl, FU; Hayer-Hartl, M				Figueiredo, L; Klunker, D; Ang, D; Naylor, DJ; Kerner, MJ; Georgopoulos, C; Hartl, FU; Hayer-Hartl, M			Functional characterization of an archaeal GroEL/GroES chaperonin system - Significance of substrate encapsulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI GROEL; GROUP-II CHAPERONINS; MOLECULAR CHAPERONES; CRYSTAL-STRUCTURE; METHANOSARCINA-MAZEI; ATP HYDROLYSIS; IN-VIVO; PROTEIN; BACTERIOPHAGE-T4; BINDING	In all three kingdoms of life chaperonins assist the folding of a range of newly synthesized proteins. As shown recently, Archaea of the genus Methanosarcina contain both group I (GroEL/GroES) and group II ( thermosome) chaperonins in the cytosol. Here we report on a detailed functional analysis of the archaeal GroEL/ GroES system of Methanosarcina mazei ( Mm) in comparison to its bacterial counterpart from Escherichia coli (Ec). We find that the groESgroEL operon of M. mazei is unable to functionally replace groESgroEL in E. coli. However, the MmGroES protein can largely complement a mutant EcGroES protein in vivo. The ATPase rate of MmGroEL is very low and the dissociation of MmGroES from MmGroEL is 15 times slower than for the EcGroEL/ GroES system. This slow ATPase cycle results in a prolonged enclosure time for model substrate proteins, such as rhodanese, in the MmGroEL: GroES folding cage before their release into the medium. Interestingly, optimal functionality of MmGroEL/GroES and its ability to encapsulate larger proteins, such as malate dehydrogenase, requires the presence of ammonium sulfate in vitro. In the absence of ammonium sulfate, malate dehydrogenase fails to be encapsulated by GroES and rather cycles on and off the GroEL trans ring in a non-productive reaction. These results indicate that the archaeal GroEL/ GroES system has preserved the basic encapsulation mechanism of bacterial GroEL and suggest that it has adjusted the length of its reaction cycle to the slower growth rates of Archaea. Additionally, the release of only the folded protein from the GroEL/ GroES cage may prevent adverse interactions of the GroEL substrates with the thermosome, which is not normally located within the same compartment.	Max Planck Inst Biochem, Dept Cellular Biochem, D-82152 Martinsried, Germany; Ctr Med Univ Geneva, Ctr Biochim Med, CH-1211 Geneva, Switzerland	Max Planck Society; University of Geneva	Hartl, FU (corresponding author), Max Planck Inst Biochem, Dept Cellular Biochem, Klopferspitz 18A, D-82152 Martinsried, Germany.		Hartl, F. Ulrich/Y-8206-2019; Hayer-Hartl, Manajit/V-8078-2017	Hayer-Hartl, Manajit/0000-0001-8213-6742				Andra S, 1998, EUR J BIOCHEM, V255, P93, DOI 10.1046/j.1432-1327.1998.2550093.x; Ang D, 2001, J BIOL CHEM, V276, P8720, DOI 10.1074/jbc.M008477200; Archibald JM, 1999, CURR BIOL, V9, P1053, DOI 10.1016/S0960-9822(99)80457-6; Boisvert DC, 1996, NAT STRUCT BIOL, V3, P170, DOI 10.1038/nsb0296-170; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; BRAIG K, 1995, NAT STRUCT BIOL, V2, P1083, DOI 10.1038/nsb1295-1083; Brinker A, 2001, CELL, V107, P223, DOI 10.1016/S0092-8674(01)00517-7; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Chaudhuri TK, 2001, CELL, V107, P235, DOI 10.1016/S0092-8674(01)00523-2; Deppenmeier U, 2002, J MOL MICROB BIOTECH, V4, P453; Farr GW, 2003, EMBO J, V22, P3220, DOI 10.1093/emboj/cdg313; FAYET O, 1989, J BACTERIOL, V171, P1379, DOI 10.1128/JB.171.3.1379-1385.1989; Frydman J, 2001, ANNU REV BIOCHEM, V70, P603, DOI 10.1146/annurev.biochem.70.1.603; Furutani M, 1998, J BIOL CHEM, V273, P28399, DOI 10.1074/jbc.273.43.28399; Galagan JE, 2002, GENOME RES, V12, P532, DOI 10.1101/gr.223902; Geissler S, 1998, EMBO J, V17, P952, DOI 10.1093/emboj/17.4.952; Gutsche I, 1999, J MOL BIOL, V293, P295, DOI 10.1006/jmbi.1999.3008; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; Hayer-Hartl M, 2000, METH MOL B, V140, P127; HAYERHARTL MK, 1995, SCIENCE, V269, P836, DOI 10.1126/science.7638601; HayerHartl MK, 1996, EMBO J, V15, P6111, DOI 10.1002/j.1460-2075.1996.tb00999.x; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HORWICH AL, 1993, PHILOS T R SOC B, V339, P313, DOI 10.1098/rstb.1993.0030; Hunt JF, 1996, NATURE, V379, P37, DOI 10.1038/379037a0; KAGAWA Y, 1995, BIOCHEM BIOPH RES CO, V214, P730, DOI 10.1006/bbrc.1995.2346; Kelley WL, 1997, P NATL ACAD SCI USA, V94, P3679, DOI 10.1073/pnas.94.8.3679; Keppel F, 2002, EMBO REP, V3, P893, DOI 10.1093/embo-reports/kvf176; KIM S, 1994, TRENDS BIOCHEM SCI, V19, P543, DOI 10.1016/0968-0004(94)90058-2; Klein G, 2001, GENETICS, V158, P507; Klunker D, 2003, J BIOL CHEM, V278, P33256, DOI 10.1074/jbc.M302018200; Kowalski JM, 1998, SYST APPL MICROBIOL, V21, P173, DOI 10.1016/S0723-2020(98)80021-0; Kusmierczyk AR, 2000, J BIOL CHEM, V275, P33504, DOI 10.1074/jbc.M006256200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDRY SJ, 1993, NATURE, V364, P255, DOI 10.1038/364255a0; Landry SJ, 1996, P NATL ACAD SCI USA, V93, P11622, DOI 10.1073/pnas.93.21.11622; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; Leroux MR, 1999, EMBO J, V18, P6730, DOI 10.1093/emboj/18.23.6730; Leroux MR, 2001, ADV APPL MICROBIOL, V50, P219, DOI 10.1016/S0065-2164(01)50007-6; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; Meyer AS, 2003, CELL, V113, P369, DOI 10.1016/S0092-8674(03)00307-6; MINOR DL, 1994, NATURE, V367, P660, DOI 10.1038/367660a0; MINOR DL, 1994, NATURE, V371, P264, DOI 10.1038/371264a0; Minuth T, 1998, EUR J BIOCHEM, V258, P837, DOI 10.1046/j.1432-1327.1998.2580837.x; Nieba L, 1997, ANAL BIOCHEM, V252, P217, DOI 10.1006/abio.1997.2326; PERALTA D, 1994, FEBS LETT, V339, P45, DOI 10.1016/0014-5793(94)80381-1; Richardson A, 1999, J BIOL CHEM, V274, P52, DOI 10.1074/jbc.274.1.52; Richardson A, 2001, J BIOL CHEM, V276, P4981, DOI 10.1074/jbc.M008628200; Saibil H, 2000, CURR OPIN STRUC BIOL, V10, P251, DOI 10.1016/S0959-440X(00)00074-9; Siegers K, 2003, EMBO J, V22, P5230, DOI 10.1093/emboj/cdg483; Siegers K, 1999, EMBO J, V18, P75, DOI 10.1093/emboj/18.1.75; Sigler PB, 1998, ANNU REV BIOCHEM, V67, P581, DOI 10.1146/annurev.biochem.67.1.581; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VACHEREAU A, 1989, ANAL BIOCHEM, V179, P206, DOI 10.1016/0003-2697(89)90227-3; Vainberg IE, 1998, CELL, V93, P863, DOI 10.1016/S0092-8674(00)81446-4; VANDERVIES SM, 1994, NATURE, V368, P654, DOI 10.1038/368654a0; VIITANEN PV, 1991, BIOCHEMISTRY-US, V30, P9716, DOI 10.1021/bi00104a021; WALDMANN T, 1995, EUR J BIOCHEM, V227, P848, DOI 10.1111/j.1432-1033.1995.tb20210.x; WEISSMAN JS, 1994, CELL, V78, P693, DOI 10.1016/0092-8674(94)90533-9; Weissman JS, 1996, CELL, V84, P481, DOI 10.1016/S0092-8674(00)81293-3; Willison Keith R., 1996, P107, DOI 10.1016/B978-012237455-5/50006-3; Willison KR, 1994, BIOL HEAT SHOCK PROT, P299; Xu ZH, 1997, NATURE, V388, P741, DOI 10.1038/41944; ZEILSTRARYALLS J, 1993, J BACTERIOL, V175, P1134, DOI 10.1128/JB.175.4.1134-1143.1993	66	23	23	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 9	2004	279	2					1090	1099		10.1074/jbc.M310914200	http://dx.doi.org/10.1074/jbc.M310914200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	759DJ	14576149	hybrid			2022-12-27	WOS:000187722800032
J	Hill, JM; Morisawa, G; Kim, T; Huang, T; Wei, Y; Wei, YF; Werner, MH				Hill, JM; Morisawa, G; Kim, T; Huang, T; Wei, Y; Wei, YF; Werner, MH			Identification of an expanded binding surface on the FADD death domain responsible for interaction with CD95/Fas	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR RECEPTOR-1; NMR STRUCTURE; CELL-DEATH; MUTATIONAL ANALYSIS; SIGNALING COMPLEX; CRYSTAL-STRUCTURE; STRUCTURAL BASIS; EFFECTOR DOMAIN; FAS; APOPTOSIS	The initiation of programmed cell death at CD95 (Fas, Apo-1) is achieved by forming a death-inducing signaling complex (DISC) at the cytoplasmic membrane surface. Assembly of the DISC has been proposed to occur via homotypic interactions between the death domain (DD) of FADD and the cytoplasmic domain of CD95. Previous analysis of the FADD/CD95 interaction led to the identification of a putative CD95 binding surface within FADD DD formed by alpha helices 2 and 3. More detailed analysis of the CD95/FADD DD interaction now demonstrates that a bimodal surface exists in the FADD DD for interaction with CD95. An expansive surface on one side of the domain is composed of elements in alpha helices 1, 2, 3, 5, and 6. This major surface is common to many proteins harboring this motif, whether or not they are associated with programmed cell death. A secondary surface resides on the opposite face of the domain and involves residues in helices 3 and 4. The major surface is topologically similar to the protein interaction surface identified in Drosophila Tube DD and the death effector domain of hamster PEA-15, two physiologically unrelated proteins which interact with structurally unrelated binding partners. These results demonstrate the presence of a structurally conserved surface within the DD which can mediate protein recognition with homo- and heterotypic binding partners, whereas a second surface may be responsible for stabilizing the higher order complex in the DISC.	Rockefeller Univ, Lab Mol Biophys, New York, NY 10021 USA	Rockefeller University	Werner, MH (corresponding author), Rockefeller Univ, Lab Mol Biophys, 1230 York Ave,Box 42, New York, NY 10021 USA.		Wei, Yufeng/H-2733-2019; Hill, Justine M/C-5781-2009	Wei, Yufeng/0000-0001-6608-8488; 				Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bang S, 2000, J BIOL CHEM, V275, P36217, DOI 10.1074/jbc.M006620200; Berglund H, 2000, J MOL BIOL, V302, P171, DOI 10.1006/jmbi.2000.4011; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Eberstadt M, 1998, NATURE, V392, P941, DOI 10.1038/31972; Fesik SW, 2000, CELL, V103, P273, DOI 10.1016/S0092-8674(00)00119-7; Garvey TL, 2002, J VIROL, V76, P697, DOI 10.1128/JVI.76.2.697-706.2002; HARBURY PB, 1994, NATURE, V371, P80, DOI 10.1038/371080a0; Hill JM, 2002, EMBO J, V21, P6494, DOI 10.1093/emboj/cdf641; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Huang BH, 1996, NATURE, V384, P638, DOI 10.1038/384638a0; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JAATTELA M, 1995, ONCOGENE, V10, P2297; Jeong EJ, 1999, J BIOL CHEM, V274, P16337, DOI 10.1074/jbc.274.23.16337; Kischkel FC, 2001, J BIOL CHEM, V276, P46639, DOI 10.1074/jbc.M105102200; Liepinsh E, 1997, EMBO J, V16, P4999, DOI 10.1093/emboj/16.16.4999; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; OEHM A, 1992, J BIOL CHEM, V267, P10709; Park A, 1996, J BIOL CHEM, V271, P9858, DOI 10.1074/jbc.271.16.9858; Qin HX, 1999, NATURE, V399, P549, DOI 10.1038/21124; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Siegel RM, 1998, J CELL BIOL, V141, P1243, DOI 10.1083/jcb.141.5.1243; Sukits SF, 2001, J MOL BIOL, V310, P895, DOI 10.1006/jmbi.2001.4790; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; Telliez JB, 2000, J MOL BIOL, V300, P1323, DOI 10.1006/jmbi.2000.3899; Vaughn DE, 1999, J MOL BIOL, V293, P439, DOI 10.1006/jmbi.1999.3177; Wang L, 2001, P NATL ACAD SCI USA, V98, P13884, DOI 10.1073/pnas.241358198; Weber CH, 2001, FEBS LETT, V492, P171, DOI 10.1016/S0014-5793(01)02162-7; Xiao T, 1999, CELL, V99, P545, DOI 10.1016/S0092-8674(00)81542-1	32	37	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 9	2004	279	2					1474	1481		10.1074/jbc.M304996200	http://dx.doi.org/10.1074/jbc.M304996200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	759DJ	14573612	hybrid			2022-12-27	WOS:000187722800078
J	Korovkina, VP; Brainard, AM; Ismail, P; Schmidt, TJ; England, SK				Korovkina, VP; Brainard, AM; Ismail, P; Schmidt, TJ; England, SK			Estradiol binding to maxi-K channels induces their down-regulation via proteasomal degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE REPLACEMENT THERAPY; ESTROGEN-RECEPTOR; NITRIC-OXIDE; SMOOTH-MUSCLE; RELAXATION; PROGESTIN; DISEASE; WOMEN; TRIAL; RISK	Estrogens exert their biological action via both genomic and non-genomic mechanisms. Proteins different from classical estradiol receptors are believed to mediate the latter effects. Here we demonstrate that the maxi-K channel functions as an estrogen-binding protein in transfected HEK293 cells. Whole-cell maxi-K channel currents and protein expression were attenuated by exposure to either 17alpha- or 17beta-estradiol. This effect was dose-dependent for 17beta-estradiol at concentrations ranging from 10 nM to 1 muM, while 17alpha-estradiol inhibited channel expression only at 1 muM. These effects were mediated by direct low affinity binding of estradiol to the maxi-K channel but not to its accessory beta1-subunit, as revealed by cell membrane estradiol binding assays. However, specific binding of estradiol to the channel was facilitated by the presence of the beta1 subunit. Addition of MG-132, a blocker of proteasomal degradation, stabilized channel expression. These data suggest that channel down-regulation is mediated by estrogen-induced proteasomal degradation, similar to the pathway used for estrogen receptor degradation. Membrane expression of endogenous maxi-K channels in cultured vascular smooth muscle cells was also attenuated by prolonged exposure to 17alpha- and 17beta-estradiol. Thus our studies demonstrate that estrogen binds to maxi-K channels and may directly regulate channel expression and function. These results will have important implications in understanding estradiol-induced effects in multiple tissues including vascular smooth muscle.	Univ Iowa, Dept Physiol & Biophys, Carver Coll Med, Iowa City, IA 52242 USA	University of Iowa	England, SK (corresponding author), Univ Iowa, Dept Physiol & Biophys, Carver Coll Med, 6-432 Bowen Sci Bldg, Iowa City, IA 52242 USA.	sarah-england@uiowa.edu		Schmidt, Thomas/0000-0002-6792-9426	PHS HHS [K0201371, R0137831] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Bao AM, 2003, EUR J ENDOCRINOL, V148, P227, DOI 10.1530/eje.0.1480227; Benkusky NA, 2000, J BIOL CHEM, V275, P27712; Brem AS, 1999, MOL GENET METAB, V67, P53, DOI 10.1006/mgme.1999.2812; Chen EY, 2002, BMC BIOCHEM, V3, DOI 10.1186/1471-2091-3-29; Darkow DJ, 1997, AM J PHYSIOL-HEART C, V272, pH2765, DOI 10.1152/ajpheart.1997.272.6.H2765; Dick GM, 2001, J BIOL CHEM, V276, P44835, DOI 10.1074/jbc.M106851200; Dimitropoulou C, 2001, HYPERTENSION, V37, P301, DOI 10.1161/01.HYP.37.2.301; Fergus DJ, 2003, PFLUG ARCH EUR J PHY, V445, P697, DOI 10.1007/s00424-002-0994-7; Gerhard-Herman M, 2000, Curr Cardiol Rep, V2, P288, DOI 10.1007/s11886-000-0083-5; Han GC, 1999, J CARDIOVASC PHARM, V34, P619, DOI 10.1097/00005344-199911000-00001; Ho KJ, 2002, ARTERIOSCL THROM VAS, V22, P1952, DOI 10.1161/01.ATV.0000041200.85946.4A; Hoibraaten E, 2000, THROMB HAEMOSTASIS, V84, P961; Hsia J, 2000, CIRCULATION, V102, P2228; Jiang B, 2002, MOL CELL BIOCHEM, V238, P69, DOI 10.1023/A:1019907104763; Joswig M, 1999, EXP CLIN ENDOCR DIAB, V107, P477, DOI 10.1055/s-0029-1232556; Kiechl S, 1999, ARTERIOSCL THROM VAS, V19, P1484, DOI 10.1161/01.ATV.19.6.1484; Kirk CJ, 2003, COMP BIOCHEM PHYS A, V135, P1, DOI 10.1016/S1095-6433(02)00366-5; Knopp RH, 2002, AM J CARDIOL, V89, p28E; Lin HL, 2002, J PHARMACOL EXP THER, V301, P160, DOI 10.1124/jpet.301.1.160; Miura H, 1999, CIRCULATION, V99, P3132, DOI 10.1161/01.CIR.99.24.3132; Pedram A, 2002, J BIOL CHEM, V277, P50768, DOI 10.1074/jbc.M210106200; Preisler-Mashek MT, 2002, AM J PHYSIOL-ENDOC M, V282, pE891, DOI 10.1152/ajpendo.00353.2001; Russell KS, 2000, P NATL ACAD SCI USA, V97, P5930, DOI 10.1073/pnas.97.11.5930; Shumaker SA, 2003, JAMA-J AM MED ASSOC, V289, P2651, DOI 10.1001/jama.289.20.2651; SLAUGHTER RS, 1987, BIOCHIM BIOPHYS ACTA, V904, P92, DOI 10.1016/0005-2736(87)90090-3; Tolbert T, 2001, AM J HYPERTENS, V14, p186S, DOI 10.1016/S0895-7061(01)02087-8; Toran-Allerand CD, 2002, J NEUROSCI, V22, P8391; Tschugguel W, 2003, J CLIN ENDOCR METAB, V88, P2281, DOI 10.1210/jc.2002-021165; Valverde MA, 1999, SCIENCE, V285, P1929, DOI 10.1126/science.285.5435.1929; Wallace AD, 2001, J BIOL CHEM, V276, P42714, DOI 10.1074/jbc.M106033200; Wellman GC, 2002, STROKE, V33, P802, DOI 10.1161/hs0302.104089; Wellman GC, 1996, CIRC RES, V79, P1024, DOI 10.1161/01.RES.79.5.1024; White RE, 2002, CARDIOVASC RES, V53, P650, DOI 10.1016/S0008-6363(01)00428-X	33	39	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 9	2004	279	2					1217	1223		10.1074/jbc.M309158200	http://dx.doi.org/10.1074/jbc.M309158200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	759DJ	14555652	hybrid			2022-12-27	WOS:000187722800047
J	Reiss, U; Oskouian, B; Zhou, JH; Gupta, V; Sooriyakumaran, P; Kelly, S; Wang, E; Merrill, AH; Saba, JD				Reiss, U; Oskouian, B; Zhou, JH; Gupta, V; Sooriyakumaran, P; Kelly, S; Wang, E; Merrill, AH; Saba, JD			Sphingosine-phosphate lyase enhances stress-induced ceramide generation and apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THIN-LAYER-CHROMATOGRAPHY; PRIMARY CULTURED NEURONS; LONG-CHAIN BASES; SPHINGOSINE-1-PHOSPHATE LYASE; SPHINGOLIPID BIOSYNTHESIS; FUNCTIONAL EXPRESSION; CHROMOSOME 10Q; HEAT-STRESS; 1-PHOSPHATE; CANCER	Sphingosine-1-phosphate lyase is a widely expressed enzyme that catalyzes the essentially irreversible cleavage of the signaling molecule sphingosine 1-phosphate. To investigate whether sphingosine-1-phosphate lyase influences mammalian cell fate decisions, a recombinant human sphingosine-1-phosphate lyase fused to green fluorescent protein was expressed in HEK293 cells. The recombinant enzyme was active, localized to the endoplasmic reticulum, and reduced baseline sphingosine and sphingosine 1-phosphate levels. Stable overexpression led to diminished viability under stress, which was attributed to an increase in apoptosis and was reversible in a dose-dependent manner by exogenous sphingosine 1-phosphate. In contrast to sphingosine 1-phosphate, the products of the lyase reaction had no effect on apoptosis. Lyase enzymatic activity was required to potentiate apoptosis, because cells expressing a catalytically inactive enzyme behaved like controls. Stress increased the amounts of long- and very long- chain ceramides in HEK293 cells, and this was enhanced in cells overexpressing wild type but not catalytically inactive lyase. The ceramide increases appeared to be required for apoptosis, because inhibition of ceramide synthase with fumonisin B-1 decreased apoptosis in lyase-overexpressing cells. Thus, sphingosine-1-phosphate lyase overexpression in HEK293 cells decreases sphingosine and sphingosine 1-phosphate amounts but elevates stress-induced ceramide generation and apoptosis. This identifies sphingosine-1-phosphate lyase as a dual modulator of sphingosine 1-phosphate and ceramide metabolism as well as a regulator of cell fate decisions and, hence, a potential target for diseases with an imbalance in these biomodulators, such as cancer.	Childrens Hosp Oakland, Res Inst, Oakland, CA 94609 USA; Georgia Inst Technol, Sch Biol, Atlanta, GA 30332 USA	Children's Hospital Oakland Research Institute; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Benioff Children's Hospital Oakland; University System of Georgia; Georgia Institute of Technology	Saba, JD (corresponding author), Childrens Hosp Oakland, Res Inst, 5700 Martin Luther King Jr Way, Oakland, CA 94609 USA.	jsaba@chori.org		Merrill, Alfred/0000-0002-6673-968X	NATIONAL CANCER INSTITUTE [R01CA077528] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007951] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM066954, R01GM046368] Funding Source: NIH RePORTER; NCI NIH HHS [1R01CA77528] Funding Source: Medline; NHLBI NIH HHS [5-T32-HL07951-03] Funding Source: Medline; NIGMS NIH HHS [1R01GM066954, 5R01GM046368] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAUMANN WJ, 1969, J LIPID RES, V10, P132; Birchwood CJ, 2001, J BIOL CHEM, V276, P11712, DOI 10.1074/jbc.M010221200; Bockmuhl U, 2000, LARYNGO RHINO OTOL, V79, P81; COLICELLI J, 1989, P NATL ACAD SCI USA, V86, P3599, DOI 10.1073/pnas.86.10.3599; Dobrosotskaya IY, 2002, SCIENCE, V296, P879, DOI 10.1126/science.1071124; Goetzl EJ, 1999, J IMMUNOL, V162, P2049; Gottlieb D, 1999, Mol Cell Biol Res Commun, V1, P66, DOI 10.1006/mcbr.1999.0109; Grote E, 2000, MOL BIOL CELL, V11, P4051, DOI 10.1091/mbc.11.12.4051; Herr DR, 2003, DEVELOPMENT, V130, P2443, DOI 10.1242/dev.00456; Ichimura K, 1998, GENE CHROMOSOME CANC, V22, P9, DOI 10.1002/(SICI)1098-2264(199805)22:1<9::AID-GCC2>3.0.CO;2-1; JENKINS RB, 1990, CANCER-AM CANCER SOC, V66, P1213, DOI 10.1002/1097-0142(19900915)66:6<1213::AID-CNCR2820660622>3.0.CO;2-9; Johnson KR, 2003, J BIOL CHEM, V278, P34541, DOI 10.1074/jbc.M301741200; JOSSART GH, 1995, SURGERY, V118, P1018, DOI 10.1016/S0039-6060(05)80108-4; Kihara A, 2003, J BIOL CHEM, V278, P14578, DOI 10.1074/jbc.M211416200; Kluk MJ, 2002, BBA-MOL CELL BIOL L, V1582, P72, DOI 10.1016/S1388-1981(02)00139-7; KOZAK M, 1991, J BIOL CHEM, V266, P19867; Kroesen BJ, 2003, J BIOL CHEM, V278, P14723, DOI 10.1074/jbc.M210756200; Kwon YG, 2001, J BIOL CHEM, V276, P10627, DOI 10.1074/jbc.M011449200; Lacombe L, 1996, INT J CANCER, V69, P110, DOI 10.1002/(SICI)1097-0215(19960422)69:2<110::AID-IJC7>3.0.CO;2-3; Le Stunff H, 2002, BBA-MOL CELL BIOL L, V1582, P8, DOI 10.1016/S1388-1981(02)00132-4; Li GC, 2001, DEVELOPMENT, V128, P3473; Maceyka M, 2002, BBA-MOL CELL BIOL L, V1585, P193, DOI 10.1016/S1388-1981(02)00341-4; Mandala SM, 2000, P NATL ACAD SCI USA, V97, P7859, DOI 10.1073/pnas.120146897; Mandala SM, 2001, PROSTAG OTH LIPID M, V64, P143, DOI 10.1016/S0090-6980(01)00111-3; Mao CG, 1999, BIOCHEM J, V342, P667, DOI 10.1042/0264-6021:3420667; Mendel J, 2003, J BIOL CHEM, V278, P22341, DOI 10.1074/jbc.M302857200; MORITA R, 1991, CANCER RES, V51, P5817; Olivera A, 1999, J CELL BIOL, V147, P545, DOI 10.1083/jcb.147.3.545; Osawa Y, 2001, J IMMUNOL, V167, P173, DOI 10.4049/jimmunol.167.1.173; Payne SG, 2002, FEBS LETT, V531, P54, DOI 10.1016/S0014-5793(02)03480-4; Perry David K, 2003, Cancer Treat Res, V115, P345; Petersen I, 2000, BRAIN PATHOL, V10, P395; Petersen S, 1998, BRIT J CANCER, V77, P270, DOI 10.1038/bjc.1998.43; Petersen S, 2000, BRIT J CANCER, V82, P65; Pyne S, 2002, BBA-MOL CELL BIOL L, V1582, P121, DOI 10.1016/S1388-1981(02)00146-4; Radin NS, 2003, BIOORGAN MED CHEM, V11, P2123, DOI 10.1016/S0968-0896(02)00609-0; Ramstedt B, 1999, EUR J BIOCHEM, V266, P997, DOI 10.1046/j.1432-1327.1999.00938.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHEN WPV, 1990, CANCER GENET CYTOGEN, V45, P207, DOI 10.1016/0165-4608(90)90084-N; SKIPSKI VP, 1964, BIOCHEM J, V90, P374, DOI 10.1042/bj0900374; Skrzypek MS, 1999, J BACTERIOL, V181, P1134, DOI 10.1128/JB.181.4.1134-1140.1999; Spiegel S, 2002, LEUKEMIA, V16, P1596, DOI 10.1038/sj.leu.2402611; STECK PA, 1995, GENE CHROMOSOME CANC, V12, P255; Sullards MC, 2000, METHOD ENZYMOL, V312, P32; Szymanska J, 1998, GENE CHROMOSOME CANC, V23, P213, DOI 10.1002/(SICI)1098-2264(199811)23:3<213::AID-GCC2>3.0.CO;2-4; Tilly JL, 2002, BBA-MOL CELL BIOL L, V1585, P135, DOI 10.1016/S1388-1981(02)00333-5; Van Veldhoven PP, 2000, BBA-MOL CELL BIOL L, V1487, P128, DOI 10.1016/S1388-1981(00)00079-2; Van Veldhoven PP, 2000, METHOD ENZYMOL, V311, P244; VANECHTEN G, 1990, J BIOL CHEM, V265, P9333; vanEchtenDeckert G, 1997, J BIOL CHEM, V272, P15825, DOI 10.1074/jbc.272.25.15825; VANVELDHOVEN PP, 1991, J BIOL CHEM, V266, P12502; Yang ZQ, 2000, JPN J CANCER RES, V91, P156, DOI 10.1111/j.1349-7006.2000.tb00927.x; Zhou JH, 1998, BIOCHEM BIOPH RES CO, V242, P502, DOI 10.1006/bbrc.1997.7993	53	126	133	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 9	2004	279	2					1281	1290		10.1074/jbc.M309646200	http://dx.doi.org/10.1074/jbc.M309646200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	759DJ	14570870	hybrid			2022-12-27	WOS:000187722800054
J	Shin, D; Park, C				Shin, D; Park, C			N-terminal extension of canine glutamine synthetase created by splicing alters its enzymatic property	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; HUMAN BRAIN; PROTEIN; EXPRESSION; PURIFICATION; TRANSLATION; SULFOXIMINE; BINDING; BOVINE	It was found that an extra exon exists in the first intron of glutamine synthetase gene, generated by means of alternative splicing ( Shin, D., Park, S., and Park, C. (2003) Biochem. J. 374, 175 - 184). Inclusion of this exon decreased the translation of glutamine synthetase (GS) in human, dog, and mouse. When translated in vitro with the canine GS transcript containing the exon, we obtained two different species of GS enzymes. Besides the known 45-kDa protein, the extended form of GS was identified with additional 40 amino acids on its N-terminal end. An upstream ATG in the extra exon served as a translation initiator for the long form of GS. When the long transcript was translated in vivo in animal cells, only the long GS was expressed. On the other hand, the long GS is less predominant relative to the short one in canine tissues including brain and liver. Subcellular fractionation of canine brain revealed that the long GS is present in all cellular compartments as is the short one, which is consistent with fluorescence microscopy data obtained with green fluorescent protein fused to GS. The short (SGS) and long (LGS) forms of canine GS were purified in Escherichia coli and shown to have similar K-m values for L-glutamate and hydroxylamine. However, the K-m values for ATP were slightly altered, 1.3 and 1.9 mM for the short and long GSs, respectively. The K(i)s for L-methionine-S-sulfoximine (MSOX), a highly potent ATP-dependent inactivator of GS, were considerably different such that the values are 0.067 and 0.124 mM for the short and long forms, respectively. When the intrinsic fluorescences of tryptophans were monitored upon bindings of chloride and metal ions without any effect on the oligomeric state, the pattern of quenching in LGS was significantly different from that of SGS. Taken together, the N-terminal extension in the long isoform of GS induces a conformational change of core enzyme, leading to a change in affinity to its substrates as well as in the effector-induced conformational alterations.	Korea Adv Inst Sci & Technol, Dept Biol Sci, Ctr Behav Genet, Natl Creat Res Initiat, Taejon 305701, South Korea	Korea Advanced Institute of Science & Technology (KAIST)	Park, C (corresponding author), Korea Adv Inst Sci & Technol, Dept Biol Sci, Ctr Behav Genet, Natl Creat Res Initiat, Taejon 305701, South Korea.	ckpark@kaist.ac.kr	Park, Chankyu/C-1936-2011					Boksha IS, 2000, J NEUROCHEM, V75, P2574, DOI 10.1046/j.1471-4159.2000.0752574.x; Boksha IS, 2002, BIOCHEMISTRY-MOSCOW+, V67, P1012, DOI 10.1023/A:1020574003027; CAMPBELL JW, 1992, MOL BIOL EVOL, V9, P787; CARLSSON M, 1990, TRENDS NEUROSCI, V13, P272, DOI 10.1016/0166-2236(90)90108-M; Eisenberg D, 2000, BBA-PROTEIN STRUCT M, V1477, P122, DOI 10.1016/S0167-4838(99)00270-8; Gorovits R, 1997, P NATL ACAD SCI USA, V94, P7024, DOI 10.1073/pnas.94.13.7024; GRIFFITH OW, 1978, J BIOL CHEM, V253, P2333; GUNNERSEN D, 1992, P NATL ACAD SCI USA, V89, P11949, DOI 10.1073/pnas.89.24.11949; HASCHEMEYER RH, 1968, T NEW YORK ACAD SCI, V30, P875, DOI 10.1111/j.2164-0947.1968.tb02531.x; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; Kim KS, 1998, MOL PHYLOGENET EVOL, V10, P210, DOI 10.1006/mpev.1998.0513; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1989, MOL CELL BIOL, V9, P5073, DOI 10.1128/MCB.9.11.5073; LAUD PR, 1994, J MOL EVOL, V39, P93; Lie-Venema H, 1998, PROG NUCLEIC ACID RE, V61, P243, DOI 10.1016/S0079-6603(08)60829-6; Listrom CD, 1997, BIOCHEM J, V328, P159; MAURIZI MR, 1987, BIOCHEMISTRY-US, V26, P5023, DOI 10.1021/bi00390a021; MAURIZI MR, 1986, ARCH BIOCHEM BIOPHYS, V246, P494, DOI 10.1016/0003-9861(86)90496-0; MEISTER A, 1985, METHOD ENZYMOL, V113, P185; MEISTER A, 1974, ENZYMES, V10, P699; Morris DR, 2000, MOL CELL BIOL, V20, P8635, DOI 10.1128/MCB.20.23.8635-8642.2000; Oyama R, 2000, BBA-PROTEIN STRUCT M, V1479, P91, DOI 10.1016/S0167-4838(00)00057-1; Robinson SR, 2000, NEUROCHEM INT, V36, P471, DOI 10.1016/S0197-0186(99)00150-3; ROQUEMORE EP, 1994, METHOD ENZYMOL, V230, P443; Sambrook J., 2001, MOL CLONING LAB MANU; Santoro JC, 2001, ANAL BIOCHEM, V289, P18, DOI 10.1006/abio.2000.4911; Shin D, 2003, BIOCHEM J, V374, P175, DOI 10.1042/BJ20030132; Takeda A, 2003, BRAIN RES REV, V41, P79, DOI 10.1016/S0165-0173(02)00234-5; Uhlmann-Schiffler H, 2002, J BIOL CHEM, V277, P1066, DOI 10.1074/jbc.M107535200; Wang YM, 1996, GENOMICS, V37, P195, DOI 10.1006/geno.1996.0542	30	13	13	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 9	2004	279	2					1184	1190		10.1074/jbc.M309940200	http://dx.doi.org/10.1074/jbc.M309940200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	759DJ	14583610	hybrid			2022-12-27	WOS:000187722800043
J	Bafunno, V; Giancaspero, TA; Brizio, C; Bufano, D; Passarella, S; Boles, E; Barile, M				Bafunno, V; Giancaspero, TA; Brizio, C; Bufano, D; Passarella, S; Boles, E; Barile, M			Riboflavin uptake and FAD synthesis in Saccharomyces cerevisiae mitochondria - Involvement of the Flx1p carrier in FAD export	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLAVIN ADENINE-DINUCLEOTIDE; RAT-LIVER; STRUCTURAL GENE; DEHYDROGENASE; FLAVOPROTEIN; TRANSPORT; CYCLE; FLAVINYLATION; TRANSCRIPTION; BIOSYNTHESIS	We have studied the functional steps by which Saccharomyces cerevisiae mitochondria can synthesize FAD from cytosolic riboflavin (Rf). Riboflavin uptake into mitochondria took place via a mechanism that is consistent with the existence of ( at least two) carrier systems. FAD was synthesized inside mitochondria by a mitochondrial FAD synthetase (EC 2.7.7.2), and it was exported into the cytosol via an export system that was inhibited by lumiflavin, and which was different from the riboflavin uptake system. To understand the role of the putative mitochondrial FAD carrier, Flx1p, in this pathway, an flx1Delta mutant strain was constructed. Coupled mitochondria isolated from flx1Delta mutant cells were compared with wild-type mitochondria with respect to the capability to take up Rf, to synthesize FAD from it, and to export FAD into the extramitochondrial phase. Mitochondria isolated from flx1Delta mutant cells specifically lost the ability to export FAD, but did not lose the ability to take up Rf, FAD, or FMN and to synthesize FAD from Rf. Hence, Flx1p is proposed to be the mitochondrial FAD export carrier. Moreover, deletion of the FLX1 gene resulted in a specific reduction of the activities of mitochondrial lipoamide dehydrogenase and succinate dehydrogenase, which are FAD-binding enzymes. For the flavoprotein subunit of succinate dehydrogenase we could demonstrate that this was not due to a changed level of mitochondrial FAD or to a change in the degree of flavinylation of the protein. Instead, the amount of the flavoprotein subunit of succinate dehydrogenase was strongly reduced, indicating an additional regulatory role for Flx1p in protein synthesis or degradation.	Univ Bari, Dipartmento Biochim & Biol Mol, I-70126 Bari, Italy; CNR, Ist Biomembrane & Bioenerget, I-70126 Bari, Italy; Univ Molise, Dipartimento Sci Anim Vegetali & Ambiente, I-86100 Campobasso, Italy; Goethe Univ Frankfurt, Inst Mikrobiol, D-60439 Frankfurt, Germany	Universita degli Studi di Bari Aldo Moro; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biomembrane e Bioenergetica (IBBE-CNR); University of Molise; Goethe University Frankfurt	Barile, M (corresponding author), Univ Bari, Dipartmento Biochim & Biol Mol, Via Orabona 4, I-70126 Bari, Italy.	m.barile@biologia.uniba.it	Barile, Maria/R-6171-2016	Barile, Maria/0000-0001-5025-551X; Giancaspero, Teresa Anna/0000-0002-3293-7426; Boles, Eckhard/0000-0002-5713-1883	Telethon [1205] Funding Source: Medline	Telethon(Fondazione Telethon)		Bacher A, 2001, VITAM HORM, V61, P1; Barile M, 1997, EUR J BIOCHEM, V249, P777, DOI 10.1111/j.1432-1033.1997.00777.x; BARILE M, 1993, ARCH BIOCHEM BIOPHYS, V305, P442, DOI 10.1006/abbi.1993.1444; Barile M, 2000, EUR J BIOCHEM, V267, P4888, DOI 10.1046/j.1432-1327.2000.01552.x; Boles E, 1998, J BACTERIOL, V180, P2875, DOI 10.1128/JB.180.11.2875-2882.1998; Boubekeur S, 2001, EUR J BIOCHEM, V268, P5057, DOI 10.1046/j.1432-1327.2001.02418.x; Brizio C, 2000, EUR J BIOCHEM, V267, P4346, DOI 10.1046/j.1432-1327.2000.01464.x; Brizio C, 2002, FEBS LETT, V522, P141, DOI 10.1016/S0014-5793(02)02927-7; Cicek G, 2002, CLIN EXP IMMUNOL, V128, P83, DOI 10.1046/j.1365-2249.2002.01816.x; DAUM G, 1982, J BIOL CHEM, V257, P3028; Dlugai S, 2001, FEBS LETT, V505, P389, DOI 10.1016/S0014-5793(01)02854-X; Forster C, 2001, APPL MICROBIOL BIOT, V55, P85, DOI 10.1007/s002530000483; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Guldener U, 1996, NUCLEIC ACIDS RES, V24, P2519, DOI 10.1093/nar/24.13.2519; King T.E., 1967, METHOD ENZYMOL, V10, P322, DOI DOI 10.1016/0076-6879(67)10061-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee JG, 2000, J BIOCHEM-TOKYO, V128, P1059, DOI 10.1093/oxfordjournals.jbchem.a022834; Lipton SA, 2002, CELL, V111, P147, DOI 10.1016/S0092-8674(02)01046-2; Lorenz MC, 1998, EMBO J, V17, P1236, DOI 10.1093/emboj/17.5.1236; Lowenstein JM, 1969, METHOD ENZYMOL, P3, DOI [10.1016/0076-6879(69)13005-0, DOI 10.1016/0076-6879(69)13005-0]; MCCORMICK DB, 1989, PHYSIOL REV, V69, P1170, DOI 10.1152/physrev.1989.69.4.1170; Mironov AS, 2002, CELL, V111, P747, DOI 10.1016/S0092-8674(02)01134-0; NAGAO M, 1992, J BIOL CHEM, V267, P17925; NEUBURGER M, 1982, ARCH BIOCHEM BIOPHYS, V217, P312, DOI 10.1016/0003-9861(82)90507-0; Ozcan S, 1998, EMBO J, V17, P2566, DOI 10.1093/emboj/17.9.2566; Pallotta ML, 1998, FEBS LETT, V428, P245, DOI 10.1016/S0014-5793(98)00544-4; Pallotta ML, 1999, FEBS LETT, V462, P313, DOI 10.1016/S0014-5793(99)01535-5; Pastore D, 2002, FEBS LETT, V516, P15, DOI 10.1016/S0014-5793(02)02454-7; Rinaldi T, 1998, MOL BIOL CELL, V9, P2917, DOI 10.1091/mbc.9.10.2917; Robinson KM, 1996, J BIOL CHEM, V271, P4055; Said HM, 2000, AM J PHYSIOL-CELL PH, V278, pC270, DOI 10.1152/ajpcell.2000.278.2.C270; SAID HM, 1995, BBA-BIOMEMBRANES, V1236, P244, DOI 10.1016/0005-2736(95)00054-7; Santos MA, 2000, J BIOL CHEM, V275, P28618, DOI 10.1074/jbc.M004621200; SCHNAITMAN C, 1968, J CELL BIOL, V38, P158, DOI 10.1083/jcb.38.1.158; Tu BP, 2002, MOL CELL, V10, P983, DOI 10.1016/S1097-2765(02)00696-2; Tzagoloff A, 1996, J BIOL CHEM, V271, P7392, DOI 10.1074/jbc.271.13.7392; VANURK H, 1989, BIOCHIM BIOPHYS ACTA, V992, P78, DOI 10.1016/0304-4165(89)90053-6; Vergani L, 1999, BRAIN, V122, P2401, DOI 10.1093/brain/122.12.2401; Vitreschak AG, 2002, NUCLEIC ACIDS RES, V30, P3141, DOI 10.1093/nar/gkf433; WADDELL WJ, 1956, J LAB CLIN MED, V48, P311; WU M, 1995, MOL CELL BIOL, V15, P264, DOI 10.1128/MCB.15.1.264	41	87	88	3	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 2	2004	279	1					95	102		10.1074/jbc.M308230200	http://dx.doi.org/10.1074/jbc.M308230200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	757GU	14555654	hybrid			2022-12-27	WOS:000187555300012
J	Coss, D; Jacobs, SBR; Bender, CE; Mellon, PL				Coss, D; Jacobs, SBR; Bender, CE; Mellon, PL			A novel AP-1 site is critical for maximal induction of the follicle-stimulating hormone beta gene by gonadotropin-releasing hormone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATING PROTEIN-1-BINDING SITES; PROTEIN-KINASE-C; FACTOR NF-Y; TRANSCRIPTIONAL ACTIVATION; ESTROUS-CYCLE; RECEPTOR GENE; SUBUNIT GENE; PHYSICAL INTERACTION; RIBONUCLEIC-ACIDS; BINDING-ELEMENT	Regulation of follicle-stimulating hormone (FSH) synthesis is a central point of convergence for signals controlling reproduction. The FSHbeta subunit is primarily regulated by gonadotropin-releasing hormone (GnRH), gonadal steroids, and activin. Here, we identify elements in the mouse FSHbeta promoter responsible for GnRH-mediated induction utilizing the LbetaT2 cell line that endogenously expresses FSH. The proximal 398 bp of the mouse FSHbeta promoter is sufficient for response to GnRH. This response localizes primarily to an AP-1 half-site (-72/-69) juxtaposed to a CCAAT box, which binds nuclear factor-Y. Both elements are required for AP-1 binding, creating a novel AP-1 site. Multimers of this site confer GnRH induction, and mutation or internal deletion of this site reduces GnRH induction by 35%. The same reduction was achieved using a dominant negative Fos protein. This is the only functional AP-1 site identified in the proximal 398 bp, since its mutation eliminates FSHbeta induction by c-Fos and c-Jun. GnRH regulation of the FSHbeta gene occurs through induction of multiple Fos and Jun isoforms, forming at least four different AP-1 molecules, all of which bind to this site. Mitogen-activated protein kinase activity is required for induction of FSHbeta and JunB protein. Finally, AP-1 interacts with nuclear factor-Y, which occupies its overlapping site in vivo.	Univ Calif San Diego, Dept Reprod Med, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Mellon, PL (corresponding author), Univ Calif San Diego, Dept Reprod Med, 9500 Gilman Dr, La Jolla, CA 92093 USA.			Coss, Djurdjica/0000-0003-0692-1612; Jacobs, Suzanne/0000-0002-8103-1700	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P50HD012303, U54HD012303] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [F32HD041301, R01HD020377, R37HD020377] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA023100] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007044] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA023100, P30 CA23100] Funding Source: Medline; NICHD NIH HHS [R37 HD020377, U54 HD012303-26, U54 HD012303-25A1S1, U54 HD012303, R01 HD020377, R37 HD20377, F32 HD41301, F32 HD041301-02, P50 HD012303, F32 HD041301-01, U54 HD012303-25A10011, R01 HD020377-23, F32 HD041301, U54 HD012303-260011, U54 HD12303] Funding Source: Medline; NIDDK NIH HHS [T32 DK07044, T32 DK007044, T32 DK07451] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alarid ET, 1996, DEVELOPMENT, V122, P3319; Andersen H, 2002, ONCOGENE, V21, P4843, DOI 10.1038/sj.onc.1205590; Bellorini M, 1997, NUCLEIC ACIDS RES, V25, P2174, DOI 10.1093/nar/25.11.2174; BUTCHER RL, 1974, ENDOCRINOLOGY, V94, P1704, DOI 10.1210/endo-94-6-1704; CESNJAJ M, 1994, ENDOCRINOLOGY, V135, P692, DOI 10.1210/en.135.2.692; Chen L, 1998, NATURE, V392, P42, DOI 10.1038/32100; Currie RA, 1998, J BIOL CHEM, V273, P1430, DOI 10.1074/jbc.273.3.1430; D'Alonzo RC, 2002, J BIOL CHEM, V277, P816, DOI 10.1074/jbc.M107082200; Dalkin AC, 2001, ENDOCRINOLOGY, V142, P139, DOI 10.1210/en.142.1.139; Faniello MC, 1999, J BIOL CHEM, V274, P7623, DOI 10.1074/jbc.274.12.7623; Farsetti A, 2001, ENDOCRINOLOGY, V142, P3380, DOI 10.1210/en.142.8.3380; Gilthorpe J, 2002, DEVELOPMENT, V129, P3887; GLOVER JNM, 1995, NATURE, V373, P257, DOI 10.1038/373257a0; Graham-Rowe D, 1999, NEW SCI, V162, P5; Huang HJ, 2001, ENDOCRINOLOGY, V142, P2260, DOI 10.1210/en.142.6.2260; Jacobs SBR, 2003, MOL ENDOCRINOL, V17, P1470, DOI 10.1210/me.2002-0286; Kaiser UB, 1997, ENDOCR REV, V18, P46, DOI 10.1210/er.18.1.46; Kim IS, 1996, MOL CELL BIOL, V16, P4003; Kumar TR, 1997, NAT GENET, V15, P201, DOI 10.1038/ng0297-201; Lewis KA, 2000, NATURE, V404, P411, DOI 10.1038/35006129; Liang FQ, 2001, J BIOL CHEM, V276, P1516, DOI 10.1074/jbc.M006350200; Liberati C, 1998, J BIOL CHEM, V273, P16880, DOI 10.1074/jbc.273.27.16880; Liberati NT, 1999, P NATL ACAD SCI USA, V96, P4844, DOI 10.1073/pnas.96.9.4844; Liu FJ, 2002, MOL ENDOCRINOL, V16, P419, DOI 10.1210/me.16.3.419; Mantovani R, 1999, GENE, V239, P15, DOI 10.1016/S0378-1119(99)00368-6; MASON AJ, 1986, SCIENCE, V234, P1366, DOI 10.1126/science.3024317; Norwitz ER, 2002, J BIOL CHEM, V277, P37469, DOI 10.1074/jbc.M206571200; Olive M, 1997, J BIOL CHEM, V272, P18586, DOI 10.1074/jbc.272.30.18586; ORTOLANO GA, 1988, ENDOCRINOLOGY, V123, P2946, DOI 10.1210/endo-123-6-2946; PADMANABHAN V, 1995, BIOL REPROD, V53, P263, DOI 10.1095/biolreprod53.2.263; Pernasetti F, 2001, ENDOCRINOLOGY, V142, P2284, DOI 10.1210/en.142.6.2284; PIERCE JG, 1981, ANNU REV BIOCHEM, V50, P465, DOI 10.1146/annurev.bi.50.070181.002341; RONCHI A, 1995, NUCLEIC ACIDS RES, V23, P4565, DOI 10.1093/nar/23.22.4565; Strahl BD, 1997, ENDOCRINOLOGY, V138, P2621, DOI 10.1210/en.138.6.2621; Strahl BD, 1998, ENDOCRINOLOGY, V139, P4455, DOI 10.1210/en.139.11.4455; SZABO E, 1994, CELL GROWTH DIFFER, V5, P439; Teyssier C, 2001, J BIOL CHEM, V276, P36361, DOI 10.1074/jbc.M101806200; Tremblay JJ, 1999, MOL CELL BIOL, V19, P2567; Ueda A, 1998, J BIOL CHEM, V273, P19339, DOI 10.1074/jbc.273.30.19339; VALE W, 1977, ANNU REV PHYSIOL, V39, P473, DOI 10.1146/annurev.ph.39.030177.002353; Vasilyev VV, 2002, ENDOCRINOLOGY, V143, P1651, DOI 10.1210/en.143.5.1651; WEISS J, 1995, ENDOCRINOLOGY, V136, P1885, DOI 10.1210/en.136.5.1885; Wingender E, 2000, NUCLEIC ACIDS RES, V28, P316, DOI 10.1093/nar/28.1.316; Xia Y, 2000, P NATL ACAD SCI USA, V97, P5243, DOI 10.1073/pnas.97.10.5243	44	110	115	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	2004	279	1					152	162		10.1074/jbc.M304697200	http://dx.doi.org/10.1074/jbc.M304697200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	757GU	14570911	Green Accepted, hybrid			2022-12-27	WOS:000187555300019
J	Mazurkiewicz, P; Poelarends, GJ; Driessen, AJM; Konings, WN				Mazurkiewicz, P; Poelarends, GJ; Driessen, AJM; Konings, WN			Facilitated drug influx by an energy-uncoupled secondary multidrug transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METAL-TETRACYCLINE/H+ ANTIPORTER; CONTROLLED GENE-EXPRESSION; TRANSMEMBRANE SEGMENT 2; ESCHERICHIA-COLI; LACTOSE PERMEASE; STREPTOCOCCUS-PNEUMONIAE; CONFORMATIONAL-CHANGES; SCANNING MUTAGENESIS; LACTOCOCCUS-LACTIS; CONFERS RESISTANCE	The majority of bacterial multidrug resistance transporters belong to the class of secondary transporters. LmrP is a proton/drug antiporter of Lactococcus lactis that extrudes positively charged lipophilic substrates from the inner leaflet of the membrane to the external medium. This study shows that LmrP is a true secondary transporter. In the absence of a proton motive force, LmrP facilitates downhill fluxes of ethidium in both directions. These fluxes are inhibited by other substrates of LmrP. The cysteine-reactive agent p-chloromercuribenzene sulfonate inhibits these fluxes in wild type LmrP but not in the cysteine-less LmrP C270A mutant. Cysteine mutagenesis of LmrP resulted in three mutants, D68C/C270A, D128C/C270A, and E327C/C270A, with an energy-uncoupled phenotype. Asp(68) is located in the conserved motif GXXX(D/E)(R/K) XGRK for the major facilitator superfamily of secondary transporters and was found to play an important role in energy coupling, whereas the negatively charged residues Asp(128) and Glu(327) have indirect effects on the transport process. L. lactis strains expressing these uncoupled mutants of LmrP show an increased rate of ethidium influx and an increased drug susceptibility compared with cells harboring an empty vector. The rate of influx in these mutants is enhanced by a transmembrane electrical potential, inside negative. These observations suggest a new strategy for eliminating drug-resistant microbial pathogens, i.e. the design and use of modulators of secondary multidrug resistance transporters that uncouple drug efflux from proton influx, thereby allowing transmembrane electrical potential-driven influx of cationic drugs.	Univ Groningen, Dept Microbiol, Groningen Biomol Sci & Biotechnol Inst, NL-9751 NN Haren, Netherlands	University of Groningen	Konings, WN (corresponding author), Univ Groningen, Dept Microbiol, Groningen Biomol Sci & Biotechnol Inst, Kerklaan 30, NL-9751 NN Haren, Netherlands.		Konings, Wilhelmus N./C-7063-2013; Driessen, Arnold J.M./D-1876-2012	Poelarends, Gerrit/0000-0002-6917-6368; Driessen, Arnold J.M./0000-0001-9258-9104				Abramson J, 2003, SCIENCE, V301, P610, DOI 10.1126/science.1088196; Appelbaum PC, 2002, CLIN INFECT DIS, V34, P1613, DOI 10.1086/340400; BENTLEY J, 1993, GENE, V127, P117, DOI 10.1016/0378-1119(93)90625-D; Bolhuis H, 1996, J BIOL CHEM, V271, P24123, DOI 10.1074/jbc.271.39.24123; BOLHUIS H, 1994, J BACTERIOL, V176, P6957, DOI 10.1128/JB.176.22.6957-6964.1994; BOLHUIS H, 1995, J BIOL CHEM, V270, P26092, DOI 10.1074/jbc.270.44.26092; Bradley SF, 2002, CLIN INFECT DIS, V34, P211, DOI 10.1086/338150; BROOKER RJ, 1989, J BIOL CHEM, V264, P8135; deRuyter PGGA, 1996, APPL ENVIRON MICROB, V62, P3662, DOI 10.1128/AEM.62.10.3662-3667.1996; Dye C, 2002, SCIENCE, V295, P2042, DOI 10.1126/science.1063814; Frillingos S, 1997, BIOCHEMISTRY-US, V36, P269, DOI 10.1021/bi9618629; Frillingos S, 1998, FASEB J, V12, P1281, DOI 10.1096/fasebj.12.13.1281; Gajic O, 2003, J BIOL CHEM, V278, P34291, DOI 10.1074/jbc.M211100200; Garau J, 2002, LANCET INFECT DIS, V2, P404, DOI 10.1016/S1473-3099(02)00316-X; Gill MJ, 1999, ANTIMICROB AGENTS CH, V43, P187, DOI 10.1128/AAC.43.1.187; Green AL, 2000, J BIOL CHEM, V275, P23240, DOI 10.1074/jbc.M909202199; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; Hsieh PC, 1998, P NATL ACAD SCI USA, V95, P6602, DOI 10.1073/pnas.95.12.6602; JESSENMARSHALL AE, 1995, J BIOL CHEM, V270, P16251, DOI 10.1074/jbc.270.27.16251; JessenMarshall AE, 1996, J BIOL CHEM, V271, P1400, DOI 10.1074/jbc.271.3.1400; KACZOROWSKI GJ, 1979, BIOCHEMISTRY-US, V18, P3691, DOI 10.1021/bi00584a009; Kuipers OP, 1998, J BIOTECHNOL, V64, P15, DOI 10.1016/S0168-1656(98)00100-X; Lebendiker M, 1996, J BIOL CHEM, V271, P21193, DOI 10.1074/jbc.271.35.21193; Mazurkiewicz P, 2002, J BIOL CHEM, V277, P26081, DOI 10.1074/jbc.M203141200; NEYFAKH AA, 1991, P NATL ACAD SCI USA, V88, P4781, DOI 10.1073/pnas.88.11.4781; PAULSEN IT, 1993, GENE, V124, P1, DOI 10.1016/0378-1119(93)90755-R; Putman M, 1999, BIOCHEMISTRY-US, V38, P13900, DOI 10.1021/bi991262k; Putman M, 1999, BIOCHEMISTRY-US, V38, P1002, DOI 10.1021/bi981863w; Putman M, 2001, MICROBIOL-SGM, V147, P2873, DOI 10.1099/00221287-147-10-2873; Sakamoto K, 2001, J BACTERIOL, V183, P5371, DOI 10.1128/JB.183.18.5371-5375.2001; Sambrook J., 2002, MOL CLONING LAB MANU; Severina II, 2001, IUBMB LIFE, V52, P321, DOI 10.1080/152165401317291183; Someya Y, 2000, J BIOL CHEM, V275, P210, DOI 10.1074/jbc.275.1.210; Venkatesan P, 2000, BIOCHEMISTRY-US, V39, P10649, DOI 10.1021/bi0004394; Wu JH, 1997, J MOL BIOL, V270, P285, DOI 10.1006/jmbi.1997.1099; YAMAGUCHI A, 1990, J BIOL CHEM, V265, P15525; YAMAGUCHI A, 1992, J BIOL CHEM, V267, P19155; Yerushalmi H, 2000, J BIOL CHEM, V275, P5264, DOI 10.1074/jbc.275.8.5264; YOSHIDA H, 1990, J BACTERIOL, V172, P6942, DOI 10.1128/jb.172.12.6942-6949.1990	39	26	27	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	2004	279	1					103	108		10.1074/jbc.M306579200	http://dx.doi.org/10.1074/jbc.M306579200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	757GU	14561761	Green Published, hybrid			2022-12-27	WOS:000187555300013
J	Popik, W; Alce, TM				Popik, W; Alce, TM			CD4 receptor localized to non-raft membrane microdomains supports HIV-1 entry - Identification of a novel raft localization marker in CD4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; MEK/ERK SIGNALING PATHWAY; PLASMA-MEMBRANE; LIPID RAFTS; DETERGENT-RESISTANT; T-LYMPHOCYTES; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE PHOSPHORYLATION; IMMUNOLOGICAL SYNAPSE; CYTOPLASMIC DOMAIN	Despite the preferential localization of CD4 to lipid rafts, the significance and role of these microdomains in HIV-1 entry is still controversial. The possibility that CD4, when localized to non-raft domains, might be able to support virus entry cannot be excluded. Because disintegration of rafts by extraction of cellular cholesterol with methyl-beta-cyclodextrin suffers from various adverse effects, we investigated molecular determinants controlling raft localization of the CD4 receptor. Extensive mutagenesis of the receptor showed that a raft-localizing marker, consisting of a short sequence of positively charged amino acid residues, RHRRR, was present in the membrane-proximal cytoplasmic domain of CD4. Substitution of the RHRRR sequence with alanine residues abolished raft localization of the CD4 mutant, RA5, as determined biochemically using solubilization in nonionic detergents and by confocal microscopy. The possible inhibitory effect of the introduced mutations on the adjacent CVRC palmitoylation site was ruled out because wild type (wt) CD4 and RA5, but not a palmitoylation-deficient mutant, were efficiently palmitoylated. Nonetheless, the RA5 mutant supported productive virus entry to levels equivalent to that of wild type ( wt) CD4. Sucrose gradient analysis of Triton X-100 virus lysates showed that Gag and envelope gp120 proteins accumulated in low buoyant, high-density fractions. This pattern was changed after virus incubation with cells. Whereas Gag proteins localized to lipid rafts in cells expressing wt CD4 and RA5, gp120 accumulated in rafts in cells expressing wt CD4 but not RA5. We propose that raft localization of CD4 is not required for virus entry, however, post-binding fusion/ entry steps may require lipid raft assembly.	Johns Hopkins Univ, Sch Med, Ctr Oncol, Baltimore, MD 21231 USA	Johns Hopkins University; Johns Hopkins Medicine	Popik, W (corresponding author), Johns Hopkins Univ, Sch Med, Ctr Oncol, 1650 Orleans St, Baltimore, MD 21231 USA.				NIAID NIH HHS [AI50461] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI050461, R21AI050461] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alfalah M, 2002, J BIOL CHEM, V277, P10683, DOI 10.1074/jbc.M109357200; Arcaro A, 2000, J IMMUNOL, V165, P2068, DOI 10.4049/jimmunol.165.4.2068; ARTHOS J, 1989, CELL, V57, P469, DOI 10.1016/0092-8674(89)90922-7; Arvan P, 2002, TRAFFIC, V3, P771, DOI 10.1034/j.1600-0854.2002.31102.x; Benting JH, 1999, J CELL BIOL, V146, P313, DOI 10.1083/jcb.146.2.313; Briand G, 1997, VIROLOGY, V228, P171, DOI 10.1006/viro.1996.8399; Briggs JAG, 2003, EMBO J, V22, P1707, DOI 10.1093/emboj/cdg143; CRISE B, 1992, J BIOL CHEM, V267, P13593; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; del Real G, 2002, J EXP MED, V196, P293, DOI 10.1084/jem.20020308; DIAMOND DC, 1990, P NATL ACAD SCI USA, V87, P5001, DOI 10.1073/pnas.87.13.5001; Excoffon KJDA, 2003, J VIROL, V77, P2559, DOI 10.1128/JVI.77.4.2559-2567.2003; FIELDS AP, 1988, NATURE, V333, P278, DOI 10.1038/333278a0; Foti M, 2002, P NATL ACAD SCI USA, V99, P2008, DOI 10.1073/pnas.042689099; Fragoso R, 2003, J IMMUNOL, V170, P913, DOI 10.4049/jimmunol.170.2.913; Francois F, 2003, J VIROL, V77, P2539, DOI 10.1128/JVI.77.4.2539-2549.2003; Gomez-Mouton C, 2001, P NATL ACAD SCI USA, V98, P9642, DOI 10.1073/pnas.171160298; Graham DRM, 2003, J VIROL, V77, P8237, DOI 10.1128/JVI.77.15.8237-8248.2003; Hammache D, 1999, J VIROL, V73, P5244, DOI 10.1128/JVI.73.6.5244-5248.1999; Hammache D, 1998, BIOCHEM BIOPH RES CO, V246, P117, DOI 10.1006/bbrc.1998.8531; Holdorf AD, 2002, NAT IMMUNOL, V3, P259, DOI 10.1038/ni761; Hug P, 2000, J VIROL, V74, P6377, DOI 10.1128/JVI.74.14.6377-6385.2000; JASIN M, 1991, J VIROL, V65, P440, DOI 10.1128/JVI.65.1.440-444.1991; Kozak SL, 2002, J VIROL, V76, P1802, DOI 10.1128/JVI.76.4.1802-1815.2002; Krummel MF, 2000, SCIENCE, V289, P1349, DOI 10.1126/science.289.5483.1349; Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405; Liang XQ, 2001, J BIOL CHEM, V276, P30987, DOI 10.1074/jbc.M104018200; Liao ZH, 2001, AIDS RES HUM RETROV, V17, P1009, DOI 10.1089/088922201300343690; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; Manes S, 2000, EMBO REP, V1, P190, DOI 10.1093/embo-reports/kvd025; Melkonian KA, 1999, J BIOL CHEM, V274, P3910, DOI 10.1074/jbc.274.6.3910; Moffett S, 2000, J BIOL CHEM, V275, P2191, DOI 10.1074/jbc.275.3.2191; Nguyen DH, 2002, BLOOD, V99, P4298, DOI 10.1182/blood-2001-11-0087; Nguyen DH, 2002, J IMMUNOL, V168, P4121, DOI 10.4049/jimmunol.168.8.4121; Parolini I, 1999, J BIOL CHEM, V274, P14176, DOI 10.1074/jbc.274.20.14176; Percherancier Y, 2003, J BIOL CHEM, V278, P3153, DOI 10.1074/jbc.M207371200; Pitcher C, 1999, MOL BIOL CELL, V10, P677, DOI 10.1091/mbc.10.3.677; Popik W, 1996, MOL CELL BIOL, V16, P6532; Popik W, 1998, J VIROL, V72, P6406, DOI 10.1128/JVI.72.8.6406-6413.1998; Popik W, 2000, J VIROL, V74, P2558, DOI 10.1128/JVI.74.6.2558-2566.2000; Popik W, 2002, J VIROL, V76, P4709, DOI 10.1128/JVI.76.10.4709-4722.2002; Prior IA, 2003, J CELL BIOL, V160, P165, DOI 10.1083/jcb.200209091; Roper K, 2000, NAT CELL BIOL, V2, P582, DOI 10.1038/35023524; SALGHETTI S, 1995, P NATL ACAD SCI USA, V92, P349, DOI 10.1073/pnas.92.2.349; Singer II, 2001, J VIROL, V75, P3779, DOI 10.1128/JVI.75.8.3779-3790.2001; Sorice M, 1997, J LIPID RES, V38, P969; Sorice M, 2001, FEBS LETT, V506, P55, DOI 10.1016/S0014-5793(01)02830-7; Sorice M, 2000, GLYCOCONJUGATE J, V17, P247, DOI 10.1023/A:1026501609699; Steffens CM, 2003, J VIROL, V77, P4985, DOI 10.1128/JVI.77.8.4985-4991.2003; Tomas EM, 2002, IMMUNOL LETT, V83, P143, DOI 10.1016/S0165-2478(02)00075-5; TREMBLAY M, 1994, EMBO J, V13, P774, DOI 10.1002/j.1460-2075.1994.tb06320.x; Trkola A, 1996, NATURE, V384, P184, DOI 10.1038/384184a0; Viard M, 2002, J VIROL, V76, P11584, DOI 10.1128/JVI.76.22.11584-11595.2002; Waarts BL, 2002, J BIOL CHEM, V277, P38141, DOI 10.1074/jbc.M206998200; Wang J, 2002, J MEMBRANE BIOL, V189, P35, DOI 10.1007/s00232-002-1002-z; Wu LJ, 1996, NATURE, V384, P179, DOI 10.1038/384179a0; Yonemura S, 1998, J CELL BIOL, V140, P885, DOI 10.1083/jcb.140.4.885; Zhang WG, 1998, IMMUNITY, V9, P239, DOI 10.1016/S1074-7613(00)80606-8	58	96	104	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	2004	279	1					704	712		10.1074/jbc.M306380200	http://dx.doi.org/10.1074/jbc.M306380200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	757GU	14570906	hybrid			2022-12-27	WOS:000187555300084
J	Edelstein, C; Pfaffinger, D; Hinman, J; Miller, E; Lipkind, G; Tsimikas, S; Bergmark, C; Getz, GS; Witztum, JL; Scanu, AM				Edelstein, C; Pfaffinger, D; Hinman, J; Miller, E; Lipkind, G; Tsimikas, S; Bergmark, C; Getz, GS; Witztum, JL; Scanu, AM			Lysine-phosphatidylcholine adducts in kringle V impart unique immunological and potential pro-inflammatory properties to human apolipoprotein(a)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; RHESUS-MONKEY LIPOPROTEIN(A); OXIDIZED PHOSPHOLIPIDS; MONOCLONAL AUTOANTIBODIES; HUMAN-PLASMA; ELASTASE; PROTEIN; CELLS; ATHEROSCLEROSIS; INTERLEUKIN-8	Lipoprotein(a), Lp(a), an athero-thrombotic risk factor, reacts with EO6, a natural monoclonal autoantibody that recognizes the phophorylcholine (PC) group of oxidized phosphatidylcholine (oxPtdPC) either as a lipid or linked by a Schiff base to lysine residues of peptides/proteins. Here we show that EO6 reacts with free apolipoprotein(a) apo(a), its C-terminal domain, F2 (but not the N-terminal F1), kringle V-containing fragments obtained by the enzymatic digestion of apo(a) and also kringle V-containing apo(a) recombinants. The evidence that kringle V is critical for EO6 reactivity is supported by the finding that apo(a) of rhesus monkeys lacking kringle V did not react with EO6. Based on the previously established EO6 specificity requirements, we hypothesized that all or some of the six lysines in human kringle V are involved in Schiff base linkage with oxPtdPC. To test this hypothesis, we made use of a recombinant lysine-containing apo( a) fragment, rIII, containing kringle V but not the protease domain. EO6 reacted with rIII before and after reduction to stabilize the Schiff base and also after extensive ethanol/ ether extraction that yielded no lipids. On the other hand, delipidation of the saponified product yielded an average of two mol of phospholipids/mol of protein consistent with direct analysis of inorganic phosphorous on the non-saponified rIII. Moreover, only two of the six theoretical free lysine amino groups per mol of rIII were unavailable to chemical modification by 2,4,6-trinitrobenzene sulfonic acid. Finally, rIII, like human apo(a), stimulated the production of interleukin 8 in THP-1 macrophages in culture. Together, our studies provide evidence that in human apo(a), kringle V is the site that reacts with EO6 via lysine-oxPtdPC adducts that may also be involved in the previously reported pro-inflammatory effect of apo(a) in cultured human macrophages.	Univ Chicago, Dept Med, Chicago, IL 60637 USA; Univ Chicago, Dept Biochem & Mol Biol, Chicago, IL 60637 USA; Univ Chicago, Dept Pathol, Chicago, IL 60637 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA	University of Chicago; University of Chicago; University of Chicago; University of California System; University of California San Diego	Scanu, AM (corresponding author), Univ Chicago, Dept Med, MC5041,5841 S Maryland Ave, Chicago, IL 60637 USA.				NHLBI NIH HHS [HL 69464, HL 63209, HL 63115, HL 56989] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL069464, R01HL063115, R01HL063209, P50HL056989] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARTLETT GR, 1959, J BIOL CHEM, V234, P466; Blencowe C, 1995, J BIOL CHEM, V270, P31151, DOI 10.1074/jbc.270.52.31151; Bonen DK, 1998, J LIPID RES, V39, P1629; EATON DL, 1987, P NATL ACAD SCI USA, V84, P3224, DOI 10.1073/pnas.84.10.3224; Edelstein C, 1996, J LIPID RES, V37, P1786; Edelstein C, 1995, BIOCHEMISTRY-US, V34, P16483, DOI 10.1021/bi00050a032; Edelstein C, 2001, ARTERIOSCL THROM VAS, V21, P641; Edelstein C, 1997, J BIOL CHEM, V272, P11079; FLESS GM, 1989, J LIPID RES, V30, P651; FLESS GM, 1986, J BIOL CHEM, V261, P8712; FLESS GM, 1994, BIOCHEMISTRY-US, V33, P13492, DOI 10.1021/bi00249a038; Friedman P, 2002, J BIOL CHEM, V277, P7010, DOI 10.1074/jbc.M108860200; Gillotte KL, 2000, J LIPID RES, V41, P824; Glass CK, 2001, CELL, V104, P503, DOI 10.1016/S0092-8674(01)00238-0; Hill BC, 2003, ARCH BIOCHEM BIOPHYS, V412, P186, DOI 10.1016/S0003-9861(03)00032-8; Hobbs HH, 1999, CURR OPIN LIPIDOL, V10, P225, DOI 10.1097/00041433-199906000-00005; Horkko S, 1999, J CLIN INVEST, V103, P117, DOI 10.1172/JCI4533; Klezovitch O, 2001, J BIOL CHEM, V276, P46864, DOI 10.1074/jbc.M107943200; KLEZOVITCH O, 1996, ATHEROSCL THROMB VAS; Mochalkin I, 1999, BIOCHEMISTRY-US, V38, P1990, DOI 10.1021/bi9820558; Palinski W, 1996, J CLIN INVEST, V98, P800, DOI 10.1172/JCI118853; SATTLER W, 1991, BIOCHIM BIOPHYS ACTA, V1081, P65, DOI 10.1016/0005-2760(91)90251-C; Scanu AM, 1997, J LIPID RES, V38, P2193; SCANU AM, 1993, J CLIN INVEST, V91, P283, DOI 10.1172/JCI116182; SCANU AM, 1995, BBA-LIPID LIPID MET, V1256, P1, DOI 10.1016/0005-2760(95)00012-2; Scanu Angelo M, 2003, Curr Atheroscler Rep, V5, P106, DOI 10.1007/s11883-003-0081-3; SCHUMAKER VN, 1986, METHOD ENZYMOL, V128, P155; TOMLINSON JE, 1989, J BIOL CHEM, V264, P5957; Tsimikas S, 2003, J AM COLL CARDIOL, V41, P360, DOI 10.1016/S0735-1097(02)02769-9; Walton KA, 2003, J BIOL CHEM, V278, P29661, DOI 10.1074/jbc.M300738200; Witztum JL, 2001, TRENDS CARDIOVAS MED, V11, P93, DOI 10.1016/S1050-1738(01)00111-6	31	103	110	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52841	52847		10.1074/jbc.M310425200	http://dx.doi.org/10.1074/jbc.M310425200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14557258	hybrid			2022-12-27	WOS:000187480700104
J	Taylor, ER; Dornan, ES; Boner, W; Connolly, JA; McNair, S; Kannouche, P; Lehmann, AR; Morgan, IM				Taylor, ER; Dornan, ES; Boner, W; Connolly, JA; McNair, S; Kannouche, P; Lehmann, AR; Morgan, IM			The fidelity of HPV16 E1/E2-mediated DNA replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-PAPILLOMAVIRUS TYPE-16; PIGMENTOSUM VARIANT CELLS; XERODERMA-PIGMENTOSUM; CERVICAL-CARCINOMA; POLYMERASE-ETA; TRANSIENT REPLICATION; SIMIAN VIRUS-40; SHUTTLE VECTOR; E2 PROTEIN; E1	Human papillomaviruses (HPV) are causative agents in a variety of human diseases; for example over 99% of cervical carcinomas contain HPV DNA sequences. Often in cervical carcinoma the HPV genome is integrated into the host genome resulting in unregulated expression of the viral transforming proteins E6 and E7. Therefore viral integration is a step toward HPV-induced carcinogenesis. Integration of the HPV genome could occur following double-strand DNA breaks that could arise during viral DNA replication. We investigated the fidelity of HPV 16 E1- and E2-mediated DNA replication of non-damaged and UVC-damaged templates in a variety of cell lines with different genetic backgrounds; C33a (derived from an HPV-negative cervical carcinoma), XP30RO (deficient in the by-pass polymerase eta (poleta)), XP30eta (expressing a restored wild-type poleta), XP12RO (nucleotide excision repair defective), and MRC5 (derived from a 14-week-old human fetus). The results demonstrate that the fidelity of E1- and E2-mediated DNA replication is reflective of the genetic background in which the assays are carried out. For example, restoring poleta to the XP30 cell line results in a 3-fold drop in the number of mutants obtained following replication of a UVC-damaged template. A relatively high percentage of the mutant-replicated molecules arise as a result of genetic rearrangement. This is the first time such studies have been carried out with an HPV replication system, and the results are discussed in the context of the HPV life cycle and what is known about HPV genomes in human cancers.	Univ Glasgow, Dept Vet Pathol, Inst Comparat Med, Glasgow G61 1QH, Lanark, Scotland; Univ Sussex, Genome Damage & Stabil Ctr, Brighton BN1 9RQ, E Sussex, England	University of Glasgow; University of Sussex	Morgan, IM (corresponding author), Univ Glasgow, Dept Vet Pathol, Inst Comparat Med, Garscube Estate,Bearsden Rd, Glasgow G61 1QH, Lanark, Scotland.							Berg M, 1997, J VIROL, V71, P3853, DOI 10.1128/JVI.71.5.3853-3863.1997; Berneburg M, 2001, ADV GENET, V43, P71, DOI 10.1016/S0065-2660(01)43004-5; Boner W, 2002, J BIOL CHEM, V277, P22297, DOI 10.1074/jbc.M202163200; BOURRE F, 1989, MUTAT RES, V220, P107, DOI 10.1016/0165-1110(89)90016-X; BOUVARD V, 1994, EMBO J, V13, P5451, DOI 10.1002/j.1460-2075.1994.tb06880.x; Chaudhuri B, 2001, P NATL ACAD SCI USA, V98, P10085, DOI 10.1073/pnas.181347998; CHOO KB, 1989, J VIROL, V63, P782, DOI 10.1128/JVI.63.2.782-789.1989; Cordonnier AM, 1999, MUTAT RES-DNA REPAIR, V435, P111, DOI 10.1016/S0921-8777(99)00047-6; DEAU MC, 1991, VIROLOGY, V184, P492, DOI 10.1016/0042-6822(91)90419-C; DELVECCHIO AM, 1992, J VIROL, V66, P5949, DOI 10.1128/JVI.66.10.5949-5958.1992; FANNING E, 1992, ANNU REV BIOCHEM, V61, P55; Hall WS, 1997, VIRUS RES, V51, P183, DOI 10.1016/S0168-1702(97)00095-6; HAM J, 1991, TRENDS BIOCHEM SCI, V16, P440, DOI 10.1016/0968-0004(91)90172-R; Hsiao T Y, 1990, J Formos Med Assoc, V89, P293; JAMES MR, 1989, MUTAT RES, V202, P169; JEON S, 1995, P NATL ACAD SCI USA, V92, P1654, DOI 10.1073/pnas.92.5.1654; Kalantari M, 2001, DIAGN MOL PATHOL, V10, P46, DOI 10.1097/00019606-200103000-00008; Kannouche P, 2001, GENE DEV, V15, P158, DOI 10.1101/gad.187501; KASHER MS, 1988, VIROLOGY, V165, P225, DOI 10.1016/0042-6822(88)90676-9; LAPORTA RF, 1982, P NATL ACAD SCI-BIOL, V79, P3393, DOI 10.1073/pnas.79.11.3393; Larson AA, 1996, CANCER RES, V56, P1426; Lee D, 1999, NATURE, V399, P487, DOI 10.1038/20966; MACGREGOR GR, 1987, MUTAT RES, V183, P273, DOI 10.1016/0167-8817(87)90010-1; MAHER VM, 1976, NATURE, V261, P593, DOI 10.1038/261593a0; Mannik A, 2002, J VIROL, V76, P5835, DOI 10.1128/JVI.76.11.5835-5845.2002; Mantovani F, 2001, ONCOGENE, V20, P7874, DOI 10.1038/sj.onc.1204869; Masterson PJ, 1998, J VIROL, V72, P7407, DOI 10.1128/JVI.72.9.7407-7419.1998; Masutani C, 2000, EMBO J, V19, P3100, DOI 10.1093/emboj/19.12.3100; Mellin H, 2002, INT J CANCER, V102, P152, DOI 10.1002/ijc.10669; Piirsoo M, 1996, EMBO J, V15, P1; Sakai H, 1996, J VIROL, V70, P1602, DOI 10.1128/JVI.70.3.1602-1611.1996; Sedman J, 1998, J VIROL, V72, P6893, DOI 10.1128/JVI.72.8.6893-6897.1998; SEIDMAN MM, 1987, P NATL ACAD SCI USA, V84, P4944, DOI 10.1073/pnas.84.14.4944; Stary A, 2003, J BIOL CHEM, V278, P18767, DOI 10.1074/jbc.M211838200; Titolo S, 1999, J VIROL, V73, P5282, DOI 10.1128/JVI.73.7.5282-5293.1999; USTAV M, 1991, EMBO J, V10, P449, DOI 10.1002/j.1460-2075.1991.tb07967.x; Vance KW, 1999, J BIOL CHEM, V274, P27839, DOI 10.1074/jbc.274.39.27839; zur Hausen H, 2002, NAT REV CANCER, V2, P342, DOI 10.1038/nrc798	38	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52223	52230		10.1074/jbc.M308779200	http://dx.doi.org/10.1074/jbc.M308779200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14559922	hybrid			2022-12-27	WOS:000187480700031
J	Yamakami, M; Yoshimori, T; Yokosawa, H				Yamakami, M; Yoshimori, T; Yokosawa, H			Tom1, a VHS domain-containing protein, interacts with tollip, ubiquitin, and clathrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRUCTURAL BASIS; BINDING; RECOGNITION; MOTIF; TRAFFICKING; EPS15; GGAS; HRS; ENDOCYTOSIS; COMPONENT	The gene for Tom1 was initially identified as a specific target of the oncogene v-myb. The Tom1 protein belongs to the VHS domain-containing protein family, and it has a GAT domain in a central part as well as an N-terminal VHS domain. VHS domain-containing proteins, including Hrs/Vps27, STAM, and GGA proteins, have been implicated in intracellular trafficking and sorting, but the role of Tom1 has not yet been elucidated. In this study, we found that Tom1 binds directly with ubiquitin chains and Tollip, which was initially isolated as a mediator of interleukin-1 signaling and has a capacity to bind ubiquitin chains. Gel filtration and subsequent Western blot analysis showed that endogenous Tom1 associates with Tollip to form a complex. In addition, Tom1 was found to be capable of binding to clathrin heavy chain through a typical clathrin-binding motif. Fluorescence microscopic analysis revealed that green fluorescent protein-Tom1 was localized predominantly in the cytoplasm, whereas its mutant with deletion of the clathrin-binding motif had a diffuse localization throughout the cell. Thus, we propose that a Tom1-Tollip complex functions as a factor that links polyubiquitinated proteins to clathrin.	Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Biochem, Sapporo, Hokkaido 0600812, Japan; Natl Inst Genet, Dept Cell Genet, Mishima, Shizuoka 4118540, Japan	Hokkaido University; Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan	Yokosawa, H (corresponding author), Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Biochem, Sapporo, Hokkaido 0600812, Japan.	yoko@pharm.hokudai.ac.jp	Kimura, Megumi/D-7475-2012					Aguilar RC, 2003, CURR OPIN CELL BIOL, V15, P184, DOI 10.1016/S0955-0674(03)00010-3; Bache KG, 2003, J BIOL CHEM, V278, P12513, DOI 10.1074/jbc.M210843200; Bilodeau PS, 2002, NAT CELL BIOL, V4, P534, DOI 10.1038/ncb815; Buchberger A, 2002, TRENDS CELL BIOL, V12, P216, DOI 10.1016/S0962-8924(02)02269-9; Burk O, 1997, EMBO J, V16, P1371, DOI 10.1093/emboj/16.6.1371; Burns K, 2000, NAT CELL BIOL, V2, P346, DOI 10.1038/35014038; Collins BM, 2003, DEV CELL, V4, P321, DOI 10.1016/S1534-5807(03)00037-6; Confalonieri S, 2002, FEBS LETT, V513, P24, DOI 10.1016/S0014-5793(01)03241-0; de Beer T, 1998, SCIENCE, V281, P1357, DOI 10.1126/science.281.5381.1357; Dell'Angelica EC, 2000, J CELL BIOL, V149, P81, DOI 10.1083/jcb.149.1.81; Donaldson KM, 2003, CURR BIOL, V13, P258, DOI 10.1016/S0960-9822(03)00043-5; FUJIMURO M, 1994, FEBS LETT, V349, P173, DOI 10.1016/0014-5793(94)00647-4; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; Hirst J, 2001, MOL BIOL CELL, V12, P3573, DOI 10.1091/mbc.12.11.3573; Hofmann K, 2001, TRENDS BIOCHEM SCI, V26, P347, DOI 10.1016/S0968-0004(01)01835-7; Katzmann DJ, 2002, NAT REV MOL CELL BIO, V3, P893, DOI 10.1038/nrm973; Kirchhausen T, 2000, ANNU REV BIOCHEM, V69, P699, DOI 10.1146/annurev.biochem.69.1.699; Kirchhausen T, 2002, NAT STRUCT BIOL, V9, P241, DOI 10.1038/nsb0402-241; Lafer EM, 2002, TRAFFIC, V3, P513, DOI 10.1034/j.1600-0854.2002.30801.x; Lohi O, 2002, FEBS LETT, V513, P19, DOI 10.1016/S0014-5793(01)03287-2; Lohi O, 1998, FEBS LETT, V440, P255, DOI 10.1016/S0014-5793(98)01401-X; Mao YX, 2000, CELL, V100, P447, DOI 10.1016/S0092-8674(00)80680-7; Misra S, 2002, NATURE, V415, P933, DOI 10.1038/415933a; Misra S, 2000, BIOCHEMISTRY-US, V39, P11282, DOI 10.1021/bi0013546; Mullins C, 2001, MOL CELL BIOL, V21, P7981, DOI 10.1128/MCB.21.23.7981-7994.2001; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Polo S, 2002, NATURE, V416, P451, DOI 10.1038/416451a; Puertollano R, 2001, CELL, V105, P93, DOI 10.1016/S0092-8674(01)00299-9; Raiborg C, 2002, NAT CELL BIOL, V4, P394, DOI 10.1038/ncb791; Raiborg C, 2001, EMBO J, V20, P5008, DOI 10.1093/emboj/20.17.5008; Robinson MS, 2001, CURR OPIN CELL BIOL, V13, P444, DOI 10.1016/S0955-0674(00)00235-0; Shiba T, 2003, NAT STRUCT BIOL, V10, P386, DOI 10.1038/nsb920; Shiba T, 2002, NATURE, V415, P937, DOI 10.1038/415937a; Shih SC, 2002, NAT CELL BIOL, V4, P389, DOI 10.1038/ncb790; Shih SC, 2003, EMBO J, V22, P1273, DOI 10.1093/emboj/cdg140; Sorkin A, 2002, NAT REV MOL CELL BIO, V3, P600, DOI 10.1038/nrm883; Suer S, 2003, P NATL ACAD SCI USA, V100, P4451, DOI 10.1073/pnas.0831133100; Tebar F, 1996, J BIOL CHEM, V271, P28727, DOI 10.1074/jbc.271.46.28727	38	106	106	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52865	52872		10.1074/jbc.M306740200	http://dx.doi.org/10.1074/jbc.M306740200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14563850	hybrid			2022-12-27	WOS:000187480700107
J	Litvinov, RI; Vilaire, G; Shuman, H; Bennett, JS; Weisel, JW				Litvinov, RI; Vilaire, G; Shuman, H; Bennett, JS; Weisel, JW			Quantitative analysis of platelet alpha(v)beta(3) binding to osteopontin using laser tweezers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-IIB-IIIA; ATOMIC-FORCE MICROSCOPY; ACTIVATION STATE; LIGAND-BINDING; ADHESION; RECEPTOR; CONFORMATION; AFFINITY; ALPHA-V-BETA-3; FIBRONECTIN	To determine whether platelet adhesion to surfaces coated with the matrix protein osteopontin requires an agonist-induced increase in the affinity of the integrin alpha(v)beta(3) for this ligand, we used laser tweezers to measure the rupture force between single alpha(v)beta(3) molecules on the platelet surface and osteopontin-coated beads. Virtually all platelets stimulated with 10 muM ADP bound strongly to osteopontin, producing rupture forces as great as 100 piconewtons (pN) with a peak at 45-50 pN. By contrast, 90% of unstimulated, resting non-reactive platelets bound weakly to osteopontin, with rupture forces rarely exceeding 30-35 pN. However, approximate to10% of unstimulated platelets, resting reactive platelets, exhibited rupture force distributions similar to stimulated platelets. Moreover, ADP stimulation resulted in a 12-fold increase in the probability of detecting rupture forces >30 pN compared with resting non-reactive platelets. Pre-incubating stimulated platelets with the inhibitory prostaglandin E-1, a cyclic RGD peptide, the monoclonal antibody abciximab, or the alpha(v)beta(3)-specific cyclic peptide XJ735 returned force histograms to those of non-reactive platelets. These experiments demonstrate that ADP stimulation increases the strength of the interaction between platelet alpha(v)beta(3) and osteopontin. Furthermore, they indicate that platelet adhesion to osteopontin-coated surfaces requires an agonist-induced exposure of alpha(v)beta(3)-binding sites for this ligand.	Univ Penn, Sch Med, Div Hematol Oncol, Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Cell & Dev Biol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Physiol, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Bennett, JS (corresponding author), Univ Penn, Sch Med, Div Hematol Oncol, Dept Med, 421 Curie Blvd,BRB 2-3,Rm 914, Philadelphia, PA 19104 USA.		Litvinov, Rustem/E-5291-2011	Litvinov, Rustem/0000-0003-0643-1496	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL030954, P01HL062250, R01HL057407] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL57407, HL30954, HL62250] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Allen S, 1999, BIOCHEM J, V341, P173, DOI 10.1042/0264-6021:3410173; Bach AC, 1996, J AM CHEM SOC, V118, P293, DOI 10.1021/ja953163+; Basani RB, 2001, J BIOL CHEM, V276, P13975, DOI 10.1074/jbc.M011511200; Bazzoni G, 1998, TRENDS BIOCHEM SCI, V23, P30, DOI 10.1016/S0968-0004(97)01141-9; Bennett JS, 1996, TRENDS CARDIOVAS MED, V6, P31, DOI 10.1016/1050-1738(95)00126-3; Bennett JS, 1997, J BIOL CHEM, V272, P8137, DOI 10.1074/jbc.272.13.8137; Boettiger D, 2001, J BIOL CHEM, V276, P31684, DOI 10.1074/jbc.M103997200; COLLER BS, 1991, BLOOD, V77, P75; COLLER BS, 1985, J CLIN INVEST, V76, P101, DOI 10.1172/JCI111931; Felding-Habermann B, 2001, P NATL ACAD SCI USA, V98, P1853, DOI 10.1073/pnas.98.4.1853; FILARDO EJ, 1994, J BIOL CHEM, V269, P4641; FITZGERALD LA, 1987, BIOCHEMISTRY-US, V26, P8158, DOI 10.1021/bi00399a021; Goldsmith HL, 2000, BIOPHYS J, V78, P1195, DOI 10.1016/S0006-3495(00)76677-X; Helluin O, 2000, J BIOL CHEM, V275, P18337, DOI 10.1074/jbc.M001529200; LAWLER J, 1989, BLOOD, V74, P2022; Lee I, 2001, SURF SCI, V491, P433, DOI 10.1016/S0039-6028(01)01309-7; Lehenkari PP, 1999, BIOCHEM BIOPH RES CO, V259, P645, DOI 10.1006/bbrc.1999.0827; Litvinov RI, 2002, P NATL ACAD SCI USA, V99, P7426, DOI 10.1073/pnas.112194999; LUB M, 1995, IMMUNOL TODAY, V16, P479, DOI 10.1016/0167-5699(95)80031-X; Pampori N, 1999, J BIOL CHEM, V274, P21609, DOI 10.1074/jbc.274.31.21609; Paul BZS, 2003, J THROMB HAEMOST, V1, P814, DOI 10.1046/j.1538-7836.2003.00099.x; Shattil SJ, 1998, BLOOD, V91, P2645, DOI 10.1182/blood.V91.8.2645.2645_2645_2657; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; Stewart M, 1996, J CELL BIOCHEM, V61, P554, DOI 10.1002/(SICI)1097-4644(19960616)61:4<554::AID-JCB8>3.0.CO;2-N; Stout AL, 2001, BIOPHYS J, V80, P2976, DOI 10.1016/S0006-3495(01)76263-7; Visscher K, 1998, METHOD ENZYMOL, V298, P460, DOI 10.1016/S0076-6879(98)98040-5; Weisel JW, 2003, CURR OPIN STRUC BIOL, V13, P227, DOI 10.1016/S0959-440X(03)00039-3; Willemsen OH, 1998, BIOPHYS J, V75, P2220, DOI 10.1016/S0006-3495(98)77666-0	28	21	21	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51285	51290		10.1074/jbc.M304581200	http://dx.doi.org/10.1074/jbc.M304581200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14534308	hybrid			2022-12-27	WOS:000187206300055
J	Xu, Y; Kelley, RI; Blanck, TJJ; Schlame, M				Xu, Y; Kelley, RI; Blanck, TJJ; Schlame, M			Remodeling of cardiolipin by phospholipid transacylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; LINKED CARDIOSKELETAL MYOPATHY; NEUTROPENIA BARTH-SYNDROME; BEEF-HEART MITOCHONDRIA; YEAST MITOCHONDRIA; CARRIER PROTEIN; MAMMALIAN-CELLS; ACID; DEFICIENCY; MEMBRANE	Mitochondrial cardiolipin (CL) contains unique fatty acid patterns, but it is not known how the characteristic molecular species of CL are formed. We found a novel reaction that transfers acyl groups from phosphatidylcholine or phosphatidylethanolamine to CL in mitochondria of rat liver and human lymphoblasts. Acyl transfer was stimulated by ADP, ATP, and ATPgammaS, but not by other nucleotides. Coenzyme A stimulated the reaction only in the absence of adenine nucleotides. Free fatty acids were not incorporated into CL under the same incubation condition. The transacylation required addition of exogenous CL or monolyso-CL, whereas dilyso-CL was not a substrate. Transacylase activity was decreased in lymphoblasts from patients with Barth syndrome (tafazzin deletion), and this was accompanied by drastic changes in the molecular composition of CL. In rat liver, where linoleic acid was the most abundant residue of CL, only linoleoyl groups were transferred into CL, but not oleoyl or arachidonoyl groups. We demonstrated complete remodeling of tetraoleoyl-CL to tetralinoleoyl-CL in rat liver mitochondria and identified the intermediates linoleoyl-trioleoyl-CL, dilinoleoyl-dioleoyl-CL, and trilinoleoyl-oleoyl-CL by high-performance liquid chromatography. The data suggest that CL is remodeled by acyl specific phospholipid transacylation and that tafazzin is an acyltransferase involved in this mechanism.	NYU, Sch Med, Dept Anesthesiol, New York, NY 10016 USA; Kennedy Krieger Inst, Div Metab, Baltimore, MD 21205 USA	New York University; Kennedy Krieger Institute	Schlame, M (corresponding author), NYU, Sch Med, Dept Anesthesiol, New York, NY 10016 USA.			Blanck, Thomas/0000-0002-9597-8567				Barth PG, 1999, J INHERIT METAB DIS, V22, P555, DOI 10.1023/A:1005568609936; BEYER K, 1985, BIOCHEMISTRY-US, V24, P3821, DOI 10.1021/bi00336a001; Beyer K, 1996, BIOCHEMISTRY-US, V35, P15784, DOI 10.1021/bi9610055; Bione S, 1996, NAT GENET, V12, P385, DOI 10.1038/ng0496-385; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; DAUM G, 1985, BIOCHIM BIOPHYS ACTA, V822, P1, DOI 10.1016/0304-4157(85)90002-4; Dowhan W, 1997, ANNU REV BIOCHEM, V66, P199, DOI 10.1146/annurev.biochem.66.1.199; Hostetler K. Y., 1982, PHOSPHOLIPIDS, V4, P215; HOSTETLER KY, 1975, BIOCHIM BIOPHYS ACTA, V380, P382, DOI 10.1016/0005-2760(75)90106-X; Jiang F, 2000, J BIOL CHEM, V275, P22387, DOI 10.1074/jbc.M909868199; Koshkin V, 2002, BIOCHEM J, V364, P317, DOI 10.1042/bj3640317; Koshkin V, 2000, BIOCHEM J, V347, P687, DOI 10.1042/0264-6021:3470687; Kraffe E, 2002, LIPIDS, V37, P507, DOI 10.1007/s11745-002-0925-z; LANDRISCINA C, 1976, LIPIDS, V11, P61, DOI 10.1007/BF02532585; Lange C, 2001, EMBO J, V20, P6591, DOI 10.1093/emboj/20.23.6591; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Ma BJ, 1999, J LIPID RES, V40, P1837; MACDONALD JIS, 1991, BIOCHIM BIOPHYS ACTA, V1084, P105, DOI 10.1016/0005-2760(91)90209-Z; Neuwald AF, 1997, CURR BIOL, V7, pR465; ROBINSON NC, 1993, J BIOENERG BIOMEMBR, V25, P153, DOI 10.1007/BF00762857; RUSTOW B, 1989, BIOCHIM BIOPHYS ACTA, V1002, P261, DOI 10.1016/0005-2760(89)90296-8; Schlame M, 2000, PROG LIPID RES, V39, P257, DOI 10.1016/S0163-7827(00)00005-9; Schlame M, 2003, J AM COLL CARDIOL, V42, P1994, DOI 10.1016/j.jacc.2003.06.015; Schlame M, 2001, THROMB HAEMOSTASIS, V86, P1475, DOI 10.1055/s-0037-1616751; SCHLAME M, 1990, BIOCHEM J, V272, P589, DOI 10.1042/bj2720589; SCHLAME M, 1991, EUR J BIOCHEM, V199, P459, DOI 10.1111/j.1432-1033.1991.tb16144.x; Schlame M, 2002, ANN NEUROL, V51, P634, DOI 10.1002/ana.10176; Schlame M, 1999, J LIPID RES, V40, P1585; Taylor WA, 2003, J BIOL CHEM, V278, P12716, DOI 10.1074/jbc.M210329200; Trounce I A, 1996, Methods Enzymol, V264, P484, DOI 10.1016/S0076-6879(96)64044-0; Valianpour F, 2002, J PEDIATR-US, V141, P729, DOI 10.1067/mpd.2002.129174; WOLFF RL, 1995, LIPIDS, V30, P893, DOI 10.1007/BF02537479; WOLFF RL, 1988, REPROD NUTR DEV, V28, P1489, DOI 10.1051/rnd:19880906; Yamashita A, 1997, J BIOCHEM-TOKYO, V122, P1; Zhang M, 2002, J BIOL CHEM, V277, P43553, DOI 10.1074/jbc.C200551200	35	162	165	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51380	51385		10.1074/jbc.M307382200	http://dx.doi.org/10.1074/jbc.M307382200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14551214	hybrid			2022-12-27	WOS:000187206300066
J	Silke, J; Kratina, T; Ekert, PG; Pakusch, M; Vaux, DL				Silke, J; Kratina, T; Ekert, PG; Pakusch, M; Vaux, DL			Unlike Diablo/smac, Grim promotes global ubiquitination and specific degradation of X chromosome-linked inhibitor of apoptosis (XIAP) and neither cause apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN LIGASE ACTIVITY; CELL-DEATH; DROSOPHILA-REAPER; DIAP1; HID; CASPASE-3; SURVIVAL; DOMAIN; MORGUE; GENE	Grim is a Drosophila inhibitor of apoptosis (IAP) antagonist that directly interferes with inhibition of caspases by IAPs. Expression of Grim, or removal of DIAP1, is sufficient to activate apoptosis in fly cells. Transient expression of Grim in mammalian cells induces apoptosis, arguing for the conservation of apoptotic pathways, but cytoplasmic expression of the mammalian LAP antagonist Diablo/smac does not. To understand why, we compared Grim and Diablo. Although they have the same LAP binding specificity, only Grim promoted XIAP ubiquitination and degradation. Grim also synergized with XIAP to promote an increase in total cellular ubiquitination, whereas Diablo antagonized this activity. Surprisingly, Grim-induced ubiquitination of XIAP did not require the IAP RING finger. Analysis of a Grim mutant that promoted XIAP degradation, but was not cytotoxic, suggests that Grim killing in transient assays is due to a combination of IAP depletion, blocking of LAP-mediated caspase inhibition, and at least one other unidentified function. Unlike transiently transfected cells, inducible mammalian cell lines can sustain continuous expression of Grim and selective degradation of XIAP without undergoing apoptosis, demonstrating that down-regulation and antagonism of IAPs is not sufficient to cause apoptosis of mammalian cells.	Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia; Royal Childrens Hosp, Murdoch Childrens Res Inst, Parkville, Vic 3052, Australia	Walter & Eliza Hall Institute; Murdoch Children's Research Institute; Royal Children's Hospital Melbourne	Silke, J (corresponding author), Walter & Eliza Hall Inst Med Res, 1G Royal Parade, Melbourne, Vic 3050, Australia.	silke@wehi.edu.au	Vaux, David L/C-7249-2013; Ekert, Paul G/C-7247-2013; Ekert, Paul/Q-1842-2015; Silke, John/B-7622-2008	Vaux, David L/0000-0003-2703-1651; Ekert, Paul G/0000-0002-2976-8617; Ekert, Paul/0000-0002-2976-8617; Silke, John/0000-0002-7611-5774				Chen P, 1996, GENE DEV, V10, P1773, DOI 10.1101/gad.10.14.1773; Claveria C, 2002, EMBO J, V21, P3327, DOI 10.1093/emboj/cdf354; Claveria C, 1998, EMBO J, V17, P7199, DOI 10.1093/emboj/17.24.7199; Dorstyn L, 2002, J CELL BIOL, V156, P1089, DOI 10.1083/jcb.200111107; Duan HJ, 1996, J BIOL CHEM, V271, P16720, DOI 10.1074/jbc.271.28.16720; Ekert PG, 1999, EMBO J, V18, P330, DOI 10.1093/emboj/18.2.330; Ekert PG, 2001, J CELL BIOL, V152, P483, DOI 10.1083/jcb.152.3.483; Goyal L, 2000, EMBO J, V19, P589, DOI 10.1093/emboj/19.4.589; Harlin H, 2001, MOL CELL BIOL, V21, P3604, DOI 10.1128/MCB.21.10.3604-3608.2001; Hays R, 2002, NAT CELL BIOL, V4, P425, DOI 10.1038/ncb794; Holley CL, 2002, NAT CELL BIOL, V4, P439, DOI 10.1038/ncb798; Huang HK, 2000, J BIOL CHEM, V275, P26661; Lisi S, 2000, GENETICS, V154, P669; Lisztwan J, 1998, EMBO J, V17, P368, DOI 10.1093/emboj/17.2.368; MacFarlane M, 2002, J BIOL CHEM, V277, P36611, DOI 10.1074/jbc.M200317200; McCarthy JV, 1998, J BIOL CHEM, V273, P24009, DOI 10.1074/jbc.273.37.24009; Rodriguez A, 2002, EMBO J, V21, P2189, DOI 10.1093/emboj/21.9.2189; Ryoo HD, 2002, NAT CELL BIOL, V4, P432, DOI 10.1038/ncb795; Silke J, 2002, J CELL BIOL, V157, P115, DOI 10.1083/jcb.200108085; Silke J, 2001, EMBO J, V20, P3114, DOI 10.1093/emboj/20.12.3114; Srinivasula SM, 2001, NATURE, V410, P112, DOI 10.1038/35065125; Suzuki Y, 2001, P NATL ACAD SCI USA, V98, P8662, DOI 10.1073/pnas.161506698; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Vucic D, 1998, MOL CELL BIOL, V18, P3300, DOI 10.1128/MCB.18.6.3300; Wang SL, 1999, CELL, V98, P453, DOI 10.1016/S0092-8674(00)81974-1; WHITE K, 1994, SCIENCE, V264, P677, DOI 10.1126/science.8171319; Wilson R, 2002, NAT CELL BIOL, V4, P445, DOI 10.1038/ncb799; Wing JP, 2002, NAT CELL BIOL, V4, P451, DOI 10.1038/ncb800; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; Yoo SJ, 2002, NAT CELL BIOL, V4, P416, DOI 10.1038/ncb793; Zimmermann KC, 2002, J CELL BIOL, V156, P1077, DOI 10.1083/jcb.20112068	31	31	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					4313	4321		10.1074/jbc.M305661200	http://dx.doi.org/10.1074/jbc.M305661200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14570909	hybrid			2022-12-27	WOS:000188554300049
J	Waditee, R; Hossain, GS; Tanaka, Y; Nakamura, T; Shikata, M; Takano, J; Takabe, T; Takabe, T				Waditee, R; Hossain, GS; Tanaka, Y; Nakamura, T; Shikata, M; Takano, J; Takabe, T; Takabe, T			Isolation and functional characterization of Ca2+/H+ antiporters from cyanobacteria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL TAIL; APHANOTHECE-HALOPHYTICA; NA+/H+ ANTIPORTER; ESCHERICHIA-COLI; H+/CA2+ ANTIPORTER; ARABIDOPSIS; CAX1; PROTEIN; ACCUMULATION; MEMBRANE	Genome sequences of cyanobacteria, Synechocystis sp. PCC 6803, Anabaena sp. PCC 7120, and Thermosynechococcus elongatus BP-1 revealed the presence of a single Ca2+/H+ antiporter in these organisms. Here, we isolated the putative Ca2+/H+ antiporter gene from Synechocystis sp. PCC 6803 (synCAX) as well as a homologous gene from a halotolerant cyanobacterium Aphanothece halophytica (apCAX). In contrast to plant vacuolar CAXs, the full-length apCAX and synCAX genes complemented the Ca2+-sensitive phenotype of an Escherichia coli mutant. ApCAX and SynCAX proteins catalyzed specifically the Ca2+/H+ exchange reaction at alkaline pH. Immunological analysis suggested their localization in plasma membranes. The Synechocystis sp. PCC 6803 cells disrupted of synCAX exhibited lower Ca2+ efflux activity and a salt-sensitive phenotype. Overexpression of ApCAX and SynCAX enhanced the salt tolerance of Synechococcus sp. PCC 7942 cells. Mutagenesis analyses indicate the importance of two conserved acidic amino acid residues, Glu-74 and Glu-324, in the transmembrane segments for the exchange activity. These results clearly indicate that cyanobacteria contain a Ca2+/H+ antiporter in their plasma membranes, which plays an important role for salt tolerance.	Meijo Univ, Res Inst, Tenpaku Ku, Nagoya, Aichi 4688502, Japan; Meijo Univ, Grad Sch Environm & Human Sci, Nagoya, Aichi 4688502, Japan; Niigata Univ Pharm & Appl Life Sci, Fac Pharm, Niigata 9502081, Japan; Shimadzu Co, Nakagyou Ku, Kyoto 6048511, Japan; Nagoya Univ, Grad Sch Agr Sci, Chikusa Ku, Nagoya, Aichi 4648601, Japan	Meijo University; Meijo University; Niigata University; Shimadzu Corporation; Nagoya University	Takabe, T (corresponding author), Meijo Univ, Res Inst, Tenpaku Ku, Nagoya, Aichi 4688502, Japan.	takabe@ccmfs.meijo-u.ac.jp	Hossain, Gazi Sakir/AAE-5391-2020					BLACKFORD S, 1990, J BIOL CHEM, V265, P9617; BROCKMAN RW, 1968, BIOCHEMISTRY-US, V7, P2554, DOI 10.1021/bi00847a016; Cheng NH, 2003, J BIOL CHEM, V278, P6503, DOI 10.1074/jbc.M210883200; Cheng NH, 2003, PLANT CELL, V15, P347, DOI 10.1105/tpc.007385; Cheng NH, 2002, PLANT PHYSIOL, V128, P1245, DOI 10.1104/pp.010857; Cunningham KW, 1996, MOL CELL BIOL, V16, P2226; DEMARSAC NT, 1988, METHOD ENZYMOL, V167, P318; Gaxiola RA, 2002, PLANT PHYSIOL, V129, P967, DOI 10.1104/pp.020009; Hamada A, 2001, PLANT PHYSIOL, V125, P437, DOI 10.1104/pp.125.1.437; Hibino T, 1999, PLANT MOL BIOL, V40, P409, DOI 10.1023/A:1006273124726; Hirschi KD, 2000, PLANT PHYSIOL, V124, P125, DOI 10.1104/pp.124.1.125; Hirschi KD, 1996, P NATL ACAD SCI USA, V93, P8782, DOI 10.1073/pnas.93.16.8782; HOFMANN K, 1992, COMPUT APPL BIOSCI, V8, P331; ISHITANI M, 1993, AUST J PLANT PHYSIOL, V20, P693, DOI 10.1071/PP9930693; IVEY DM, 1993, J BIOL CHEM, V268, P11296; Kaneko T, 2001, DNA RES, V8, P205, DOI 10.1093/dnares/8.5.205; KANEKO T, 1996, DNA RES, V30, P109; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lee BH, 1997, PLANT MOL BIOL, V35, P763, DOI 10.1023/A:1005867420619; Marin K, 2003, P NATL ACAD SCI USA, V100, P9061, DOI 10.1073/pnas.1532302100; Maser P, 2001, PLANT PHYSIOL, V126, P1646, DOI 10.1104/pp.126.4.1646; MURATA N, 1988, METHOD ENZYMOL, V167, P245; NAKAMURA T, 1995, BBA-BIOENERGETICS, V1230, P170, DOI 10.1016/0005-2728(95)00053-L; Nakamura Y, 2002, DNA RES, V9, P123, DOI 10.1093/dnares/9.4.123; Nazarenko LV, 2003, MICROBIOL-SGM, V149, P1147, DOI 10.1099/mic.0.26074-0; OHYAMA T, 1994, J BACTERIOL, V176, P4311, DOI 10.1128/jb.176.14.4311-4315.1994; Ono K, 2001, PLANT SCI, V160, P455, DOI 10.1016/S0168-9452(00)00412-X; Pittman JK, 2002, J BIOL CHEM, V277, P26452, DOI 10.1074/jbc.M202563200; Pittman JK, 2002, PLANT PHYSIOL, V130, P1054, DOI 10.1104/pp.008193; Pittman JK, 2001, PLANT PHYSIOL, V127, P1020, DOI 10.1104/pp.010409; Saaf A, 2001, J BIOL CHEM, V276, P18905, DOI 10.1074/jbc.M101716200; Shigaki T, 2001, J BIOL CHEM, V276, P43152, DOI 10.1074/jbc.M106637200; Sze H, 2000, ANNU REV PLANT PHYS, V51, P433, DOI 10.1146/annurev.arplant.51.1.433; Torrecilla I, 2000, PLANT PHYSIOL, V123, P161, DOI 10.1104/pp.123.1.161; TSUJIBO H, 1983, J BACTERIOL, V154, P854, DOI 10.1128/JB.154.2.854-858.1983; Ueoka-Nakanishi H, 1999, EUR J BIOCHEM, V262, P417, DOI 10.1046/j.1432-1327.1999.00377.x; Waditee R, 2002, P NATL ACAD SCI USA, V99, P4109, DOI 10.1073/pnas.052576899; Waditee R, 2002, J BIOL CHEM, V277, P18373, DOI 10.1074/jbc.M112012200; Waditee R, 2001, J BIOL CHEM, V276, P36931, DOI 10.1074/jbc.M103650200; Zhang HX, 2001, P NATL ACAD SCI USA, V98, P12832, DOI 10.1073/pnas.231476498	40	45	48	1	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					4330	4338		10.1074/jbc.M310282200	http://dx.doi.org/10.1074/jbc.M310282200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14559898	hybrid			2022-12-27	WOS:000188554300051
J	Jha, A; Agostinelli, NR; Mishra, SK; Keyel, PA; Hawryluk, MJ; Traub, LM				Jha, A; Agostinelli, NR; Mishra, SK; Keyel, PA; Hawryluk, MJ; Traub, LM			A novel AP-2 adaptor interaction motif initially identified in the long-splice isoform of synaptojanin 1, SJ170	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLATHRIN-MEDIATED ENDOCYTOSIS; SYNAPTIC VESICLE ENDOCYTOSIS; ACCESSORY PROTEIN RECRUITMENT; HIGH-AFFINITY BINDING; APPENDAGE DOMAIN; GAMMA-ADAPTIN; PLASMA-MEMBRANE; ALPHA-ADAPTIN; STRUCTURAL BASIS; TERMINAL DOMAIN	Phosphoinositides play a fundamental role in clathrin-coat assembly at the cell surface. Several endocytic components and accessory factors contain independently folded phosphoinositide-binding modules that facilitate, in part, membrane placement at the bud site. As the clathrin-coat assembly process progresses toward deeply invaginated buds, focally synthesized phosphoinositides are dephosphorylated, principally through the action of the phosphoinositide polyphosphatase synaptojanin 1. Failure to catabolize polyphosphoinositides retards the fission process and endocytic activity. The long-splice isoform of synaptojanin 1, termed SJ170, contains a carboxyl-terminal extension that harbors interaction motifs for engaging several components of the endocytic machinery. Here, we demonstrate that in addition to DPF and FXDXF sequences, the SJ170 carboxyl terminus contains a novel AP-2 binding sequence, the WXXF motif. The WXXF sequence engages the independently folded alpha-subunit appendage that projects off the heterotetrameric AP-2 adaptor core. The endocytic protein kinases AAK1 and GAK also contain functional WXX(FW) motifs in addition to two DPF repeats, whereas stonin 2 harbors three tandem WXXF repeats. Each of the discrete SJ170 adaptor-interaction motifs bind to appendages relatively weakly but, as tandemly arrayed within the SJ170 extension, can cooperate to bind bivalent AP-2 with good apparent affinity. These interactions likely contribute to the appropriate targeting of certain endocytic components to clathrin bud sites assembling at the cell surface.	Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Traub, LM (corresponding author), Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, 3500 Terrace St,S325BST, Pittsburgh, PA 15261 USA.	traub@pitt.edu	Mishra, Santosh/S-7516-2017	Mishra, Santosh/0000-0001-8616-2606; Traub, Linton/0000-0002-1303-0298	NIDDK NIH HHS [R01 DK 53249] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053249] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arai Y, 2002, BRAIN DEV-JPN, V24, P67, DOI 10.1016/S0387-7604(01)00405-3; Arneson LS, 1999, J BIOL CHEM, V274, P17794, DOI 10.1074/jbc.274.25.17794; Berdnik D, 2002, DEV CELL, V3, P221, DOI 10.1016/S1534-5807(02)00215-0; Brett TJ, 2002, STRUCTURE, V10, P797, DOI 10.1016/S0969-2126(02)00784-0; Brodin L, 2000, CURR OPIN NEUROBIOL, V10, P312, DOI 10.1016/S0959-4388(00)00097-0; Chen H, 1998, NATURE, V394, P793, DOI 10.1038/29555; Cheon MS, 2003, AMINO ACIDS, V24, P127, DOI 10.1007/s00726-002-0340-6; Collins BM, 2003, NAT STRUCT BIOL, V10, P607, DOI 10.1038/nsb955; Collins BM, 2002, CELL, V109, P523, DOI 10.1016/S0092-8674(02)00735-3; Conner SD, 2002, J CELL BIOL, V156, P921, DOI 10.1083/jcb.200108123; Cremona O, 1999, CELL, V99, P179, DOI 10.1016/S0092-8674(00)81649-9; Cremona O, 2000, CYTOGENET CELL GENET, V88, P89, DOI 10.1159/000015493; Drake MT, 2000, J BIOL CHEM, V275, P6479, DOI 10.1074/jbc.275.9.6479; Drake MT, 2001, J BIOL CHEM, V276, P28700, DOI 10.1074/jbc.M104226200; Ford MGJ, 2001, SCIENCE, V291, P1051, DOI 10.1126/science.291.5506.1051; Ford MGJ, 2002, NATURE, V419, P361, DOI 10.1038/nature01020; Gaidarov I, 1999, EMBO J, V18, P871, DOI 10.1093/emboj/18.4.871; Gaidarov I, 1999, J CELL BIOL, V146, P755, DOI 10.1083/jcb.146.4.755; Gaidarov I, 1996, J BIOL CHEM, V271, P20922, DOI 10.1074/jbc.271.34.20922; Greener T, 2000, J BIOL CHEM, V275, P1365, DOI 10.1074/jbc.275.2.1365; Guo SL, 1999, J BIOL CHEM, V274, P12990, DOI 10.1074/jbc.274.19.12990; Haffner C, 2000, CURR BIOL, V10, P471, DOI 10.1016/S0960-9822(00)00446-2; Harris TW, 2000, J CELL BIOL, V150, P589, DOI 10.1083/jcb.150.3.589; Hughes WE, 2000, BIOCHEM J, V350, P337, DOI 10.1042/0264-6021:3500337; Itoh T, 2001, SCIENCE, V291, P1047, DOI 10.1126/science.291.5506.1047; Jost M, 1998, CURR BIOL, V8, P1399, DOI 10.1016/S0960-9822(98)00022-0; Kalthoff C, 2002, J BIOL CHEM, V277, P8209, DOI 10.1074/jbc.M111587200; Kearns AE, 2001, J BIOL CHEM, V276, P42213, DOI 10.1074/jbc.M106163200; Kent HM, 2002, STRUCTURE, V10, P1139, DOI 10.1016/S0969-2126(02)00801-8; Kim WT, 2002, P NATL ACAD SCI USA, V99, P17143, DOI 10.1073/pnas.222657399; Lui WWY, 2003, MOL BIOL CELL, V14, P2385, DOI 10.1091/mbc.e02-11-0735; Malecz N, 2000, CURR BIOL, V10, P1383, DOI 10.1016/S0960-9822(00)00778-8; Martina JA, 2001, J CELL BIOL, V153, P1111, DOI 10.1083/jcb.153.5.1111; Mattera R, 2003, EMBO J, V22, P78, DOI 10.1093/emboj/cdg015; MAYCOX PR, 1992, J CELL BIOL, V118, P1379, DOI 10.1083/jcb.118.6.1379; McPherson PS, 1996, NATURE, V379, P353, DOI 10.1038/379353a0; Miller GJ, 2003, NAT STRUCT BIOL, V10, P599, DOI 10.1038/nsb953; Mills IG, 2003, J CELL BIOL, V160, P213, DOI 10.1083/jcb.200208023; Mishra SK, 2002, P NATL ACAD SCI USA, V99, P16099, DOI 10.1073/pnas.252630799; Mishra SK, 2002, EMBO J, V21, P4915, DOI 10.1093/emboj/cdf487; Mishra SK, 2001, J BIOL CHEM, V276, P46230, DOI 10.1074/jbc.M108177200; Morgan JR, 2000, J NEUROSCI, V20, P8667; Nemoto Y, 2001, J BIOL CHEM, V276, P41133, DOI 10.1074/jbc.M106404200; Nogi T, 2002, NAT STRUCT BIOL, V9, P527, DOI 10.1038/nsb808; NORRIS FA, 1995, J BIOL CHEM, V270, P214, DOI 10.1074/jbc.270.1.214; Olusanya O, 2001, CURR BIOL, V11, P896, DOI 10.1016/S0960-9822(01)00240-8; Owen DJ, 2000, EMBO J, V19, P4216, DOI 10.1093/emboj/19.16.4216; Owen DJ, 1999, CELL, V97, P805, DOI 10.1016/S0092-8674(00)80791-6; Padron D, 2003, J CELL BIOL, V162, P693, DOI 10.1083/jcb.200302051; Ramjaun AR, 1996, J BIOL CHEM, V271, P24856, DOI 10.1074/jbc.271.40.24856; Ricotta D, 2002, J CELL BIOL, V156, P791, DOI 10.1083/jcb.200111068; Ritter B, 2003, EMBO REP, V4, P1089, DOI 10.1038/sj.embor.7400004; Rusk N, 2003, CURR BIOL, V13, P659, DOI 10.1016/S0960-9822(03)00241-0; Saito T, 2001, MOL PSYCHIATR, V6, P387, DOI 10.1038/sj.mp.4000871; Santolini E, 2000, J CELL BIOL, V151, P1345, DOI 10.1083/jcb.151.6.1345; Scheele U, 2003, J BIOL CHEM, V278, P25357, DOI 10.1074/jbc.M303738200; Shupliakov O, 1997, SCIENCE, V276, P259, DOI 10.1126/science.276.5310.259; Slepnev VI, 2000, NAT REV NEUROSCI, V1, P161, DOI 10.1038/35044540; Stauffer TP, 1998, CURR BIOL, V8, P343, DOI 10.1016/S0960-9822(98)70135-6; Stefan CJ, 2002, MOL BIOL CELL, V13, P542, DOI 10.1091/mbc.01-10-0476; Traub LM, 1999, P NATL ACAD SCI USA, V96, P8907, DOI 10.1073/pnas.96.16.8907; Umeda A, 2000, EUR J CELL BIOL, V79, P336, DOI 10.1078/S0171-9335(04)70037-0; Varnai P, 1998, J CELL BIOL, V143, P501, DOI 10.1083/jcb.143.2.501; Walther K, 2001, EMBO REP, V2, P634, DOI 10.1093/embo-reports/kve134; Wendland B, 1999, EMBO J, V18, P4383, DOI 10.1093/emboj/18.16.4383; Wenk MR, 2001, NEURON, V32, P79, DOI 10.1016/S0896-6273(01)00456-1; Woscholski R, 1997, J BIOL CHEM, V272, P9625; YE WL, 1995, J BIOL CHEM, V270, P1564, DOI 10.1074/jbc.270.4.1564	68	44	46	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 16	2004	279	3					2281	2290		10.1074/jbc.M305644200	http://dx.doi.org/10.1074/jbc.M305644200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	762WT	14565955	hybrid			2022-12-27	WOS:000188005700085
J	Morel, E; Fouquet, S; Chateau, D; Yvernault, L; Frobert, Y; Pincon-Raymond, M; Chambaz, J; Pillot, T; Rousset, M				Morel, E; Fouquet, S; Chateau, D; Yvernault, L; Frobert, Y; Pincon-Raymond, M; Chambaz, J; Pillot, T; Rousset, M			The cellular prion protein PrPc is expressed in human enterocytes in cell-cell junctional domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPONGIFORM ENCEPHALOPATHY AGENTS; LAMININ RECEPTOR; SCRAPIE; MICE; MEMBRANE; SIGNAL; GUT; MECHANISM; TRANSPORT; INTERACTS	The physiological function of PrPc, the cellular isoform of prion protein, still remains unclear, although it has been established, in vitro or by using nerve cells, that it can homodimerize, bind copper, or interact with other proteins. Expression of PrPc was demonstrated as necessary for prion infection propagation. Considering the importance of the intestinal barrier in the process of oral prion infectivity, we have analyzed the expression of PrPc in enterocytes, which represent the major cell population of the intestinal epithelium. Our study, conducted both on normal human intestinal tissues and on the enterocytic cell line Caco-2/TC7, shows for the first time that PrPc is present in enterocytes. Interestingly, we found that this glycosylphosphatidylinositol-anchored glycoprotein was localized in cholesterol-dependent raft domains of the upper lateral membranes of enterocytes, beneath tight junctions, in cell-cell junctional domains. We observed that PrPc, E-cadherin, and Src co-localized in adherens junctions and that PrPc was co-immunoprecipitated with Src kinase but not with E-cadherin. Alteration of cell polarity after cholesterol depletion or loosening of the cell-cell junctions after EGTA treatment rapidly impaired membrane targeting of PrPc. Overall, our results point out the signaling of cell-cell contacts as a putative role for PrPc in epithelial cells.	Univ Paris 06, INSERM, U505, F-75006 Paris, France; CEA Saclay, Serv Pharmacol & Immunol, F-91191 Gif Sur Yvette, France; Fac Med Nancy, INSERM, EPI 0014, F-54500 Vandoeuvre Les Nancy, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; CEA; UDICE-French Research Universities; Universite Paris Saclay; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lorraine	Rousset, M (corresponding author), Univ Paris 06, INSERM, U505, 15 Rue Ecole Med, F-75006 Paris, France.		MOREL, Etienne/N-2194-2014; MOREL, Etienne L/F-4765-2010	MOREL, Etienne/0000-0002-4763-4954; MOREL, Etienne L/0000-0001-7340-1313				Beekes M, 2000, NEUROSCI LETT, V278, P181, DOI 10.1016/S0304-3940(99)00934-9; Bons N, 1999, P NATL ACAD SCI USA, V96, P4046, DOI 10.1073/pnas.96.7.4046; Booth C, 2000, J CLIN INVEST, V105, P1493, DOI 10.1172/JCI10229; Brockes JP, 1999, CURR OPIN NEUROBIOL, V9, P571, DOI 10.1016/S0959-4388(99)00016-1; Brown DR, 2002, J NEUROSCI RES, V67, P211, DOI 10.1002/jnr.10118; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; CHANTRET I, 1994, J CELL SCI, V107, P213; Ford MJ, 2002, NEUROSCIENCE, V113, P177, DOI 10.1016/S0306-4522(02)00155-0; Fournier JG, 1998, CELL TISSUE RES, V292, P77, DOI 10.1007/s004410051036; Frame MC, 2002, NAT REV MOL CELL BIO, V3, P233, DOI 10.1038/nrm779; Gauczynski S, 2001, EMBO J, V20, P5863, DOI 10.1093/emboj/20.21.5863; Gauczynski S, 2001, ADV PROTEIN CHEM, V57, P229; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Heppner FL, 2001, NAT MED, V7, P976, DOI 10.1038/nm0901-976; Hundt C, 2001, EMBO J, V20, P5876, DOI 10.1093/emboj/20.21.5876; Kerneis S, 1997, SCIENCE, V277, P949, DOI 10.1126/science.277.5328.949; Knaus KJ, 2001, NAT STRUCT BIOL, V8, P770, DOI 10.1038/nsb0901-770; Krasemann S, 1996, MOL MED, V2, P725, DOI 10.1007/BF03401656; Le Lay S, 2001, J BIOL CHEM, V276, P16904, DOI 10.1074/jbc.M010955200; Le TL, 1999, J CELL BIOL, V146, P219, DOI 10.1083/jcb.146.1.219; Lemaire-Vieille C, 2000, P NATL ACAD SCI USA, V97, P5422, DOI 10.1073/pnas.080081197; Maignien T, 1999, J GEN VIROL, V80, P3035, DOI 10.1099/0022-1317-80-11-3035; Martins VR, 2001, BRAZ J MED BIOL RES, V34, P585, DOI 10.1590/S0100-879X2001000500005; Meyer RK, 2000, J BIOL CHEM, V275, P38081, DOI 10.1074/jbc.M007114200; Mouillet-Richard S, 2000, SCIENCE, V289, P1925, DOI 10.1126/science.289.5486.1925; Naslavsky N, 1997, J BIOL CHEM, V272, P6324, DOI 10.1074/jbc.272.10.6324; Nicoletti C, 2000, GUT, V47, P735, DOI 10.1136/gut.47.5.735; Nusrat A, 2000, J CELL SCI, V113, P1771; Onori P, 2001, DIGEST DIS SCI, V46, P1095, DOI 10.1023/A:1010778532240; Pammer J, 2000, VIRCHOWS ARCH, V436, P466, DOI 10.1007/s004280050474; Philippova MP, 1998, FEBS LETT, V429, P207, DOI 10.1016/S0014-5793(98)00598-5; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Rieger R, 1997, NAT MED, V3, P1383, DOI 10.1038/nm1297-1383; Sarnataro D, 2002, TRAFFIC, V3, P810, DOI 10.1034/j.1600-0854.2002.31106.x; Schmitt-Ulms G, 2001, J MOL BIOL, V314, P1209, DOI 10.1006/jmbi.2000.5183; Shmakov AN, 2000, J PATHOL, V191, P318, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH640>3.0.CO;2-4; Shmakov AN, 2001, GUT, V48, P443, DOI 10.1136/gut.48.4.443; Spielhaupter C, 2001, J BIOL CHEM, V276, P44604, DOI 10.1074/jbc.M103289200; Thielen C, 2001, CELL TISSUE RES, V306, P49, DOI 10.1007/s004410100436; WEISSMANN C, 1994, ANN NY ACAD SCI, V724, P235, DOI 10.1111/j.1749-6632.1994.tb38913.x	41	50	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 9	2004	279	2					1499	1505		10.1074/jbc.M308578200	http://dx.doi.org/10.1074/jbc.M308578200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	759DJ	14576159	hybrid			2022-12-27	WOS:000187722800081
J	Rusinol, AE; Thewke, D; Liu, J; Freeman, N; Panini, SR; Sinensky, MS				Rusinol, AE; Thewke, D; Liu, J; Freeman, N; Panini, SR; Sinensky, MS			AKT/protein kinase B regulation of BCL family members during oxysterol-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; LOW-DENSITY-LIPOPROTEIN; CYTOCHROME-C RELEASE; CELL-DEATH; SERINE PHOSPHORYLATION; PHOSPHATIDYLINOSITOL 3-KINASE; SURVIVAL SIGNALS; BH3 DOMAIN; X-L; ACTIVATION	Cells of the vasculature, including macrophages, smooth muscle cells, and endothelial cells, exhibit apoptosis in culture upon treatment with oxidized low density lipoprotein, as do vascular cells of atherosclerotic plaque. Several lines of evidence support the hypothesis that the apoptotic component of oxidized low density lipoprotein is one or more oxysterols, which have been shown to induce apoptosis through the mitochondrial pathway. Activation of the mitochondrial pathway of apoptosis is regulated by members of the BCL family of proteins. In this study, we demonstrate that, in the murine macrophage-like cell line P388D1, oxysterols (25-hydroxycholesterol and 7-ketocholesterol) induced the degradation of the prosurvival protein kinase AKT ( protein kinase B). This led, in turn, to the activation of the BCL-2 homology-3 domain-only proteins BIM and BAD and down-regulation of the anti-apoptotic multi-BCL homology domain protein BCL-x(L). These responses would be expected to activate the pro-apoptotic multi-BCL homology domain proteins BAX and BAK, leading to the previously reported release of cytochrome c observed during oxysterol-induced apoptosis. Somewhat surprisingly, small interfering RNA knockdown of BAX resulted in a complete block of the induction of apoptosis by 25-hydroxycholesterol.	E Tennessee State Univ, James H Quillen Coll Med, Dept Biochem & Mol Biol, Johnson City, TN 37614 USA	East Tennessee State University	Sinensky, MS (corresponding author), E Tennessee State Univ, James H Quillen Coll Med, Dept Biochem & Mol Biol, POB 70581, Johnson City, TN 37614 USA.	sinensky@mail.etsu.edu						Agrawal S, 2002, MOL CELL BIOL, V22, P1981, DOI 10.1128/MCB.22.7.1981-1992.2002; AUPEIX K, 1995, IMMUNOBIOLOGY, V194, P415, DOI 10.1016/S0171-2985(11)80108-7; BANSAL N, 1991, FASEB J, V5, P211, DOI 10.1096/fasebj.5.2.2004665; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; CHISOLM GM, 1994, P NATL ACAD SCI USA, V91, P11452, DOI 10.1073/pnas.91.24.11452; CHRIST M, 1993, IMMUNOLOGY, V78, P455; Colles SM, 2001, TRENDS CARDIOVAS MED, V11, P131, DOI 10.1016/S1050-1738(01)00106-2; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEL PL, 1997, SCIENCE, V278, P687; Dijkers PF, 2002, J CELL BIOL, V156, P531, DOI 10.1083/jcb.200108084; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Feng B, 2003, NAT CELL BIOL, V5, P781, DOI 10.1038/ncb1035; Glasgow JN, 2001, NEUROCHEM RES, V26, P647, DOI 10.1023/A:1010987220034; Harada K, 1997, FEBS LETT, V411, P63, DOI 10.1016/S0014-5793(97)00662-5; Harada-Shiba M, 1998, J BIOL CHEM, V273, P9681, DOI 10.1074/jbc.273.16.9681; Hardwick SJ, 1996, J PATHOL, V179, P294; Hortelano S, 2000, J IMMUNOL, V165, P6525, DOI 10.4049/jimmunol.165.11.6525; Kaufmann SH, 2001, TRENDS CELL BIOL, V11, P526, DOI 10.1016/S0962-8924(01)02173-0; Kirito K, 2002, J BIOL CHEM, V277, P8329, DOI 10.1074/jbc.M109824200; Klumpp S, 2002, CURR OPIN PHARMACOL, V2, P458, DOI 10.1016/S1471-4892(02)00176-5; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Liu HT, 2001, J EXP MED, V194, P113, DOI 10.1084/jem.194.2.113; Lizard G, 1998, FASEB J, V12, P1651, DOI 10.1096/fasebj.12.15.1651; Martin D, 2002, J BIOL CHEM, V277, P42943, DOI 10.1074/jbc.M201070200; Martinet W, 2001, CURR OPIN LIPIDOL, V12, P535, DOI 10.1097/00041433-200110000-00009; Moreau C, 2003, J BIOL CHEM, V278, P19426, DOI 10.1074/jbc.M209472200; Mori N, 2002, BLOOD, V100, P1828, DOI 10.1182/blood-2002-01-0151; Muller K, 2001, ATHEROSCLEROSIS, V156, P133, DOI 10.1016/S0021-9150(00)00641-9; Nguyen H, 2001, J BIOL CHEM, V276, P33361, DOI 10.1074/jbc.M105070200; Nunez G, 1998, CURR OPIN NEUROBIOL, V8, P613, DOI 10.1016/S0959-4388(98)80089-5; Ozes ON, 1999, NATURE, V401, P82; Panini SR, 2001, CURR OPIN LIPIDOL, V12, P529, DOI 10.1097/00041433-200110000-00008; Panini SR, 2001, J LIPID RES, V42, P1678; Pastorino JG, 1999, J BIOL CHEM, V274, P19411, DOI 10.1074/jbc.274.27.19411; Rhee SH, 2003, J BIOL CHEM, V278, P22506, DOI 10.1074/jbc.M208633200; Rovin BH, 2002, KIDNEY INT, V61, P1293, DOI 10.1046/j.1523-1755.2002.00282.x; Rusinol AE, 2000, J BIOL CHEM, V275, P7296, DOI 10.1074/jbc.275.10.7296; Ruvolo PP, 2003, PHARMACOL RES, V47, P383, DOI 10.1016/S1043-6618(03)00050-1; Schroepfer GJ, 2000, PHYSIOL REV, V80, P361, DOI 10.1152/physrev.2000.80.1.361; Scorrano L, 2003, BIOCHEM BIOPH RES CO, V304, P437, DOI 10.1016/S0006-291X(03)00615-6; SEVANIAN A, 1995, J LIPID RES, V36, P1971; Shinohara H, 1999, J BIOL CHEM, V274, P12263, DOI 10.1074/jbc.274.18.12263; Song JH, 2002, MOL CELLS, V13, P322; Steinbrecher UP, 1999, BBA-MOL CELL BIOL L, V1436, P279, DOI 10.1016/S0005-2760(98)00127-1; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; Wang XD, 2001, GENE DEV, V15, P2922; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wintergerst ES, 2000, EUR J BIOCHEM, V267, P6050, DOI 10.1046/j.1432-1327.2000.01682.x; Witztum JL, 2001, TRENDS CARDIOVAS MED, V11, P93, DOI 10.1016/S1050-1738(01)00111-6; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Yang L, 2000, BIOCHEM BIOPH RES CO, V278, P557, DOI 10.1006/bbrc.2000.3855; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zha JP, 1997, J BIOL CHEM, V272, P24101, DOI 10.1074/jbc.272.39.24101	54	70	73	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 9	2004	279	2					1392	1399		10.1074/jbc.M308619200	http://dx.doi.org/10.1074/jbc.M308619200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	759DJ	14559920	hybrid, Green Published			2022-12-27	WOS:000187722800068
J	Raschperger, E; Engstrom, U; Pettersson, RF; Fuxe, J				Raschperger, E; Engstrom, U; Pettersson, RF; Fuxe, J			CLMP, a novel member of the CTX family and a new component of epithelial tight junctions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOVIRUS RECEPTOR EXPRESSION; METASTATIC COLON-CANCER; ADHESION MOLECULE; IMMUNOGLOBULIN SUPERFAMILY; CELL-ADHESION; DIFFERENTIAL BEHAVIOR; A33 ANTIGEN; PHASE-I; PROTEIN; COXSACKIEVIRUS	The CTX family is a growing group of type I transmembrane proteins within the immunoglobulin superfamily (IgSF). They localize to junctional complexes between endothelial and epithelial cells and seem to participate in cell-cell adhesion and transmigration of leukocytes. Here, we report the identification of a new member of the CTX family. This protein, which was designated CLMP (coxsackie- and adenovirus receptor-like membrane protein), is composed of 373 amino acids including an extracellular part containing a V- and a C2-type domain, a transmembrane region and a cytoplasmic tail. CLMP mRNA was detected in a variety of both human and mouse tissues and cell lines. The protein migrated with an M-r of around 48 on SDS-PAGE and was predominantly expressed in epithelial cells within different tissues. In cultured epithelial cells, CLMP was detected in areas of cell-cell contacts. When exogenously expressed in polarized MDCK cells, CLMP was restricted to the subapical area of the lateral cell surface, where it colocalized with the tight junction markers ZO-1 and occludin. Also endogenous CLMP showed association with tight junctions, as analyzed in polarized human CACO-2 cells. This suggested a role for CLMP in cell-cell adhesion and indeed, overexpressed CLMP induced aggregation of non-polarized CHO cells. Furthermore, CLMP-expressing MDCK cells showed significantly increased transepithelial resistance, indicating a role for CLMP in junctional barrier function. Thus, we conclude that CLMP is a novel cell-cell adhesion molecule and a new component of epithelial tight junctions. We also suggest, based on phylogenetic studies, that CLMP, CAR, ESAM, and BT-IgSF form a new group of proteins within the CTX family.	Ludwig Inst Canc Res, Stockholm Branch, SE-17177 Stockholm, Sweden; Ludwig Inst Canc Res, Uppsala Branch, SE-75124 Uppsala, Sweden	Ludwig Institute for Cancer Research; Ludwig Institute for Cancer Research	Fuxe, J (corresponding author), Ludwig Inst Canc Res, Stockholm Branch, Nobels V3, SE-17177 Stockholm, Sweden.	jfux@licr.ki.se	Fuxe, Jonas/T-4433-2017	Fuxe, Jonas/0000-0003-4576-9377				Ando-Akatsuka Y, 1999, J CELL PHYSIOL, V179, P115, DOI 10.1002/(SICI)1097-4652(199905)179:2<115::AID-JCP1>3.0.CO;2-T; Arrate MP, 2001, J BIOL CHEM, V276, P45826, DOI 10.1074/jbc.M105972200; Asakura T, 1999, GENES CELLS, V4, P573, DOI 10.1046/j.1365-2443.1999.00283.x; Aurrand-Lions M, 2001, BLOOD, V98, P3699, DOI 10.1182/blood.V98.13.3699; Aurrand-Lions MA, 2000, CURR TOP MICROBIOL, V251, P91; Barton ES, 2001, CELL, V104, P441, DOI 10.1016/S0092-8674(01)00231-8; Bazzoni G, 2000, J BIOL CHEM, V275, P30970, DOI 10.1074/jbc.M003946200; Bazzoni G, 2000, J BIOL CHEM, V275, P20520, DOI 10.1074/jbc.M905251199; Bergelson JM, 1997, SCIENCE, V275, P1320, DOI 10.1126/science.275.5304.1320; Carson SD, 1997, BIOCHEM BIOPH RES CO, V233, P325, DOI 10.1006/bbrc.1997.6449; Chretien I, 1996, EUR J IMMUNOL, V26, P780, DOI 10.1002/eji.1830260409; Chretien I, 1998, EUR J IMMUNOL, V28, P4094; Cohen CJ, 2001, P NATL ACAD SCI USA, V98, P15191, DOI 10.1073/pnas.261452898; COLLINS VP, 1983, INT REV EXP PATHOL, V24, P135; Conron M, 2001, AM J RESP CELL MOL, V25, P141, DOI 10.1165/ajrcmb.25.2.4327; Cunningham SA, 2000, J BIOL CHEM, V275, P34750, DOI 10.1074/jbc.M002718200; Cunningham SA, 2002, J BIOL CHEM, V277, P27589, DOI 10.1074/jbc.C200331200; Ebnet K, 2000, J BIOL CHEM, V275, P27979; Ebnet K, 2001, EMBO J, V20, P3738, DOI 10.1093/emboj/20.14.3738; Fanning AS, 1998, J BIOL CHEM, V273, P29745, DOI 10.1074/jbc.273.45.29745; FARQUHAR MG, 1963, J CELL BIOL, V17, P375, DOI 10.1083/jcb.17.2.375; Fechner H, 1999, GENE THER, V6, P1520, DOI 10.1038/sj.gt.3301030; FURUSE M, 1993, J CELL BIOL, V123, P1777, DOI 10.1083/jcb.123.6.1777; Fuxe J, 2003, INT J CANCER, V103, P723, DOI 10.1002/ijc.10891; Hamazaki Y, 2002, J BIOL CHEM, V277, P455, DOI 10.1074/jbc.M109005200; Heath JK, 1997, P NATL ACAD SCI USA, V94, P469, DOI 10.1073/pnas.94.2.469; Hirata K, 2001, J BIOL CHEM, V276, P16223, DOI 10.1074/jbc.M100630200; Honda T, 2000, MOL BRAIN RES, V77, P19, DOI 10.1016/S0169-328X(00)00036-X; HOWARTH AG, 1992, AM J PHYSIOL, V262, pC461, DOI 10.1152/ajpcell.1992.262.2.C461; Ito M, 2000, CIRC RES, V86, P275, DOI 10.1161/01.RES.86.3.275; Itoh M, 1997, J CELL BIOL, V138, P181, DOI 10.1083/jcb.138.1.181; Johnstone CN, 2000, AM J PHYSIOL-GASTR L, V279, pG500, DOI 10.1152/ajpgi.2000.279.3.G500; Katahira J, 1997, J CELL BIOL, V136, P1239, DOI 10.1083/jcb.136.6.1239; Liang TW, 2002, J IMMUNOL, V168, P1618, DOI 10.4049/jimmunol.168.4.1618; Liu Y, 2000, J CELL SCI, V113, P2363; Martin-Padura I, 1998, J CELL BIOL, V142, P117, DOI 10.1083/jcb.142.1.117; Muller WA, 2003, TRENDS IMMUNOL, V24, P327, DOI 10.1016/S1471-4906(03)00117-0; NOURRY C, 2003, SCI STKE, V179, P1; Okegawa T, 2000, CANCER RES, V60, P5031; Okegawa T, 2002, J UROLOGY, V167, P1836, DOI 10.1016/S0022-5347(05)65245-7; Palmeri D, 2000, J BIOL CHEM, V275, P19139, DOI 10.1074/jbc.M003189200; Philipson L, 2004, CURR TOP MICROBIOL, V273, P87; Roelvink PW, 1998, J VIROL, V72, P7909, DOI 10.1128/JVI.72.10.7909-7915.1998; Sachs MD, 2002, UROLOGY, V60, P531, DOI 10.1016/S0090-4295(02)01748-X; Saitou M, 2000, MOL BIOL CELL, V11, P4131, DOI 10.1091/mbc.11.12.4131; Santoso S, 2002, J EXP MED, V196, P679, DOI 10.1084/jem.20020267; Sollerbrant K, 2003, J BIOL CHEM, V278, P7439, DOI 10.1074/jbc.M205927200; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Sonoda N, 1999, J CELL BIOL, V147, P195, DOI 10.1083/jcb.147.1.195; Suzu S, 2002, BIOCHEM BIOPH RES CO, V296, P1215, DOI 10.1016/S0006-291X(02)02025-9; Tomko RP, 1997, P NATL ACAD SCI USA, V94, P3352, DOI 10.1073/pnas.94.7.3352; Tsukita S, 2001, NAT REV MOL CELL BIO, V2, P285, DOI 10.1038/35067088; Tsukita S, 1999, CURR OPIN CELL BIOL, V11, P628, DOI 10.1016/S0955-0674(99)00016-2; Walters RW, 2002, CELL, V110, P789, DOI 10.1016/S0092-8674(02)00912-1; WELT S, 1990, J CLIN ONCOL, V8, P1894, DOI 10.1200/JCO.1990.8.11.1894; WELT S, 1994, J CLIN ONCOL, V12, P1193, DOI 10.1200/JCO.1994.12.6.1193; Welt S, 1996, J CLIN ONCOL, V14, P1787, DOI 10.1200/JCO.1996.14.6.1787; Wirtz S, 1999, GUT, V44, P800, DOI 10.1136/gut.44.6.800; Wittchen ES, 1999, J BIOL CHEM, V274, P35179, DOI 10.1074/jbc.274.49.35179; YONEMURA S, 1995, J CELL SCI, V108, P127	60	80	87	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 2	2004	279	1					796	804		10.1074/jbc.M308249200	http://dx.doi.org/10.1074/jbc.M308249200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	757GU	14573622	hybrid			2022-12-27	WOS:000187555300095
J	Brock, DA; Ehrenman, K; Ammann, R; Tang, YT; Gomer, RH				Brock, DA; Ehrenman, K; Ammann, R; Tang, YT; Gomer, RH			Two components of a secreted cell number-counting factor bind to cells and have opposing effects on cAMP signal transduction in Dictyostelium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; ACTIVATED PROTEIN-KINASE; GROUP-SIZE; DEVELOPMENTAL REGULATION; HUMAN-MONOCYTES; DISCOIDEUM; RECEPTOR; EXPRESSION; MOTILITY; GENE	A secreted 450-kDa complex of proteins called counting factor (CF) is part of a negative feedback loop that regulates the size of the groups formed by developing Dictyostelium cells. Two components of CF are countin and CF50. Both recombinant countin and recombinant CF50 decrease group size in Dictyostelium. countin(-) cells have a decreased cAMP-stimulated cAMP pulse, whereas recombinant countin potentiates the cAMP pulse. We find that cf50(-) cells have an increased cAMP pulse, whereas recombinant CF50 decreases the cAMP pulse, suggesting that countin and CF50 have opposite effects on cAMP signal transduction. In addition, countin and CF50 have opposite effects on cAMP-stimulated Erk2 activation. However, like recombinant countin, recombinant CF50 increases cell motility. We previously found that cells bind recombinant countin with a Hill coefficient of similar to2, a K-H of 60 pM, and similar to53 sites/cell. We find here that cells also bind I-125-recombinant CF50, with a Hill coefficient of similar to2, a K-H of similar to15 ng/ml (490 pM), and similar to56 sites/cell. Countin and CF50 require each other's presence to affect group size, but the presence of countin is not necessary for CF50 to bind to cells, and CF50 is not necessary for countin to bind to cells. Our working hypothesis is that a signal transduction pathway activated by countin binding to cells modulates a signal transduction pathway activated by CF50 binding to cells and vice versa and that these two pathways can be distinguished by their effects on cAMP signal transduction.	Rice Univ, Howard Hughes Med Inst, Houston, TX 77005 USA; Rice Univ, Dept Biochem & Cell Biol, Houston, TX 77005 USA	Howard Hughes Medical Institute; Rice University; Rice University	Gomer, RH (corresponding author), Rice Univ, Howard Hughes Med Inst, MS-140,6100 S Main St, Houston, TX 77005 USA.	richard@bioc.rice.edu		Gomer, Richard/0000-0003-2361-4307				Bosgraaf L, 2002, EMBO J, V21, P4560, DOI 10.1093/emboj/cdf438; Brock DA, 1996, DEVELOPMENT, V122, P2569; Brock DA, 1999, GENE DEV, V13, P1960, DOI 10.1101/gad.13.15.1960; Brock DA, 2003, EUKARYOT CELL, V2, P788, DOI 10.1128/EC.2.4.788-797.2003; Brock DA, 2002, DEVELOPMENT, V129, P3657; BYRNE PV, 1989, LEUKEMIA RES, V13, P117, DOI 10.1016/0145-2126(89)90135-5; CARDELLI JA, 1993, ADV CELL MOL BIOL M, V1, P341; Chung CY, 2001, TRENDS BIOCHEM SCI, V26, P557, DOI 10.1016/S0968-0004(01)01934-X; Clay JL, 1995, DEV BIOL, V172, P665, DOI 10.1006/dbio.1995.8045; Conlon I, 1999, CELL, V96, P235, DOI 10.1016/S0092-8674(00)80563-2; COUKELL MB, 1986, DEV GENET, V6, P163; Day SJ, 2000, DEVELOPMENT, V127, P2977; ECKERT BS, 1977, J CELL BIOL, V72, P339, DOI 10.1083/jcb.72.2.339; ELLIOTT MJ, 1989, BLOOD, V74, P2349; Elson EL, 1999, BIOCHEM SOC SYMP, V65, P299; Gao T, 2002, J BIOL CHEM, V277, P32596, DOI 10.1074/jbc.M203075200; Giannopoulos A, 1997, J UROLOGY, V157, P79, DOI 10.1016/S0022-5347(01)65287-X; GOMER RH, 1986, J CELL BIOL, V103, P1999, DOI 10.1083/jcb.103.5.1999; Gomer RH, 2001, NAT REV MOL CELL BIO, V2, P48, DOI 10.1038/35048058; GORDON JA, 1991, METHOD ENZYMOL, V201, P477; HOHL HR, 1964, DEV BIOL, V9, P137, DOI 10.1016/0012-1606(64)90018-1; HOLTER W, 1987, J IMMUNOL, V138, P2917; JAIN R, 1994, J BIOL CHEM, V269, P9128; Jang W, 2002, J BIOL CHEM, V277, P39202, DOI 10.1074/jbc.M205635200; Kessin R.H., 2001, DICTYOSTELIUM EVOLUT; KLEIN P, 1987, J BIOL CHEM, V262, P358; KLEIN PS, 1988, SCIENCE, V241, P1467, DOI 10.1126/science.3047871; Knetsch MLW, 1996, EMBO J, V15, P3361, DOI 10.1002/j.1460-2075.1996.tb00701.x; KOPACHIK W, 1982, J EMBRYOL EXP MORPH, V68, P23; LIMBIRD LE, 1986, CELL SURFACE RECEPTO, P66; Loomis WF., 1975, DICTYOSTELIUM DISCOI; LOUIS JM, 1993, P NATL ACAD SCI USA, V90, P5969, DOI 10.1073/pnas.90.13.5969; Ma H, 1997, EMBO J, V16, P4317, DOI 10.1093/emboj/16.14.4317; Maeda M, 1996, J BIOL CHEM, V271, P3351; MANN SKO, 1988, DEV GENET, V9, P337, DOI 10.1002/dvg.1020090415; MANSTEIN DJ, 1993, SYM SOC EXP BIOL, V47, P375; NEWELL PC, 1992, BIOESSAYS, V14, P473, DOI 10.1002/bies.950140708; Newell PC, 1995, BIOSCIENCE REP, V15, P445, DOI 10.1007/BF01204348; Parente CA, 1998, CELL, V95, P81, DOI 10.1016/S0092-8674(00)81784-5; Potter CJ, 2001, CURR OPIN GENET DEV, V11, P279, DOI 10.1016/S0959-437X(00)00191-X; Roelofs J, 2001, EMBO J, V20, P4341, DOI 10.1093/emboj/20.16.4341; Roisin-Bouffay C, 2000, MOL CELL, V6, P953, DOI 10.1016/S1097-2765(05)00082-1; ROSS FM, 1981, J GEN MICROBIOL, V127, P339; Schenk PW, 1999, BIOCHEM BIOPH RES CO, V260, P504, DOI 10.1006/bbrc.1999.0862; Schenk PW, 2001, BIOCHEM BIOPH RES CO, V282, P765, DOI 10.1006/bbrc.2001.4649; SHAFFER BM, 1958, Q J MICROSC SCI, V98, P393; SIU CH, 1988, BIOCHIM BIOPHYS ACTA, V968, P283, DOI 10.1016/0167-4889(88)90019-5; Spann TP, 1996, P NATL ACAD SCI USA, V93, P5003, DOI 10.1073/pnas.93.10.5003; Su TT, 2000, IN VIVO, V14, P141; Tang L, 2002, P NATL ACAD SCI USA, V99, P1371, DOI 10.1073/pnas.022516099; Tang L, 2001, J BIOL CHEM, V276, P27663, DOI 10.1074/jbc.M102205200; VanHaastert PJM, 1996, J CELL BIOL, V134, P1543, DOI 10.1083/jcb.134.6.1543; VARNUM B, 1985, J CELL BIOL, V101, P1, DOI 10.1083/jcb.101.1.1; VERKERKEVANWIJK I, 1997, DICTYOSTELIUM MODEL, P145	54	18	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52262	52272		10.1074/jbc.M309101200	http://dx.doi.org/10.1074/jbc.M309101200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14557265	hybrid			2022-12-27	WOS:000187480700035
J	Fan, GF; Ballou, LM; Lin, RZ				Fan, GF; Ballou, LM; Lin, RZ			Phospholipase C-independent activation of glycogen synthase kinase-3 beta and C-terminal Src kinase by G alpha(q)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							G-ALPHA-Q; PROTEIN-TYROSINE KINASE; SMOOTH-MUSCLE-CELLS; TAU-PHOSPHORYLATION; PHOSPHATIDYLINOSITOL 3-KINASE; ALPHA(1A)-ADRENERGIC RECEPTOR; ALZHEIMERS-DISEASE; DUAL REGULATION; INSULIN; IDENTIFICATION	It is generally thought that activation of phospholipase Cbeta (PLCbeta) by Galpha(q) accounts for most of the effects of G(q)-coupled receptors. Here we describe a novel effect of Galpha(q) that is independent of the PLCbeta pathway. Expression of the constitutively active Galpha(q) mutant Galpha(q)(Q209L) promoted an increase in glycogen synthase kinase-3beta (GSK-3beta) activity that was associated with increased phosphorylation of Tyr(216) on GSK-3beta. Galpha(q)(Q209L)-AA, a mutant that cannot activate PLCbeta, also induced GSK-3beta activation and phosphorylation of Tyr(216). We speculate that the protein-tyrosine kinase Csk (C-terminal Src kinase), which is also activated by Galpha(q) (Q209L) and Galpha(q)(Q209L)-AA, acts upstream of GSK-3beta. Expression of Csk accentuated the activation of GSK-3beta by Galpha(q)(Q209L), whereas catalytically inactive Csk blocked GSK-3beta activation by Galpha(q)(Q209L). Recombinant Csk phosphorylated and activated GSK-3beta in vitro, and GSK-3beta coprecipitated with Csk from cell lysates. These results suggest that activation of Csk and GSK-3beta by Galpha(q) may contribute to the physiological and pathological effects of G(q)-coupled receptors.	SUNY Stony Brook, Dept Med, Div Hematol, Stony Brook, NY 11794 USA; Dept Vet Affairs Med Ctr, Northport, NY 11768 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Lin, RZ (corresponding author), SUNY Stony Brook, Dept Med, Div Hematol, Stony Brook, NY 11794 USA.		Lin, Richard/J-1754-2014	Lin, Richard/0000-0002-3473-7276	NIDDK NIH HHS [R01 DK62722] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK062722] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams JW, 2001, ONCOGENE, V20, P1626, DOI 10.1038/sj.onc.1204275; Adams JW, 1998, P NATL ACAD SCI USA, V95, P10140, DOI 10.1073/pnas.95.17.10140; Althoefer H, 1997, J BIOL CHEM, V272, P24380, DOI 10.1074/jbc.272.39.24380; Ballou LM, 2003, J BIOL CHEM, V278, P23472, DOI 10.1074/jbc.M212232200; Ballou LM, 2001, J BIOL CHEM, V276, P40910, DOI 10.1074/jbc.M103480200; Ballou LM, 2000, J BIOL CHEM, V275, P4803, DOI 10.1074/jbc.275.7.4803; Batty IH, 1996, BIOCHEM J, V317, P347, DOI 10.1042/bj3170347; Bhat RV, 2000, P NATL ACAD SCI USA, V97, P11074, DOI 10.1073/pnas.190297597; Bhat RV, 2002, NEUROSIGNALS, V11, P251, DOI 10.1159/000067423; Bommakanti RK, 2000, J BIOL CHEM, V275, P38870, DOI 10.1074/jbc.M007403200; BOUSCAREL B, 1988, BIOCHEM J, V251, P47, DOI 10.1042/bj2510047; Cohen P, 1999, PHILOS T R SOC B, V354, P485, DOI 10.1098/rstb.1999.0399; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Doble BW, 2003, J CELL SCI, V116, P1175, DOI 10.1242/jcs.00384; Elyaman W, 2002, EUR J NEUROSCI, V15, P651, DOI 10.1046/j.1460-9568.2002.01899.x; Folli F, 1997, J CLIN INVEST, V100, P2158, DOI 10.1172/JCI119752; Grassi G, 2003, J HYPERTENS, V21, P1761, DOI 10.1097/00004872-200309000-00027; Hartigan JA, 2001, BIOCHEM BIOPH RES CO, V284, P485, DOI 10.1006/bbrc.2001.4986; Hoeflich KP, 2000, NATURE, V406, P86, DOI 10.1038/35017574; Howes AL, 2003, J BIOL CHEM, V278, P40343, DOI 10.1074/jbc.M305964200; HUGHES K, 1993, EMBO J, V12, P803, DOI 10.1002/j.1460-2075.1993.tb05715.x; Jiang ZY, 1999, DIABETES, V48, P1120, DOI 10.2337/diabetes.48.5.1120; Kaidanovich Oksana, 2002, Expert Opin Ther Targets, V6, P555; Kanzaki M, 2000, J BIOL CHEM, V275, P7167, DOI 10.1074/jbc.275.10.7167; Kim L, 1999, CELL, V99, P399, DOI 10.1016/S0092-8674(00)81526-3; Kim L, 2002, DEV CELL, V3, P523, DOI 10.1016/S1534-5807(02)00269-1; Lesort M, 1999, J NEUROCHEM, V72, P576, DOI 10.1046/j.1471-4159.1999.0720576.x; Lithell HO, 1996, AM J HYPERTENS, V9, pS150, DOI 10.1016/0895-7061(96)00290-7; Lowry WE, 2002, DEV CELL, V2, P733, DOI 10.1016/S1534-5807(02)00175-2; Ma YC, 1998, P NATL ACAD SCI USA, V95, P12197, DOI 10.1073/pnas.95.21.12197; Medina R, 1996, J BIOL CHEM, V271, P24720, DOI 10.1074/jbc.271.40.24720; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; OKADA M, 1991, J BIOL CHEM, V266, P24249; Polakis P, 2000, GENE DEV, V14, P1837; Rhee SG, 2001, ANNU REV BIOCHEM, V70, P281, DOI 10.1146/annurev.biochem.70.1.281; ROSS EM, 1996, GOODMAN GILMANS PHAR, P29; Sayas CL, 1999, J BIOL CHEM, V274, P37046, DOI 10.1074/jbc.274.52.37046; Sayas CL, 2002, J NEUROSCI, V22, P6863; Shaw M, 1997, FEBS LETT, V416, P307, DOI 10.1016/S0014-5793(97)01235-0; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P9113, DOI 10.1073/pnas.87.23.9113; Velloso LA, 1996, P NATL ACAD SCI USA, V93, P12490, DOI 10.1073/pnas.93.22.12490; Venkatakrishnan G, 1996, J BIOL CHEM, V271, P5066	42	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52432	52436		10.1074/jbc.M310982200	http://dx.doi.org/10.1074/jbc.M310982200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14561750	hybrid			2022-12-27	WOS:000187480700056
J	Gui, Y; Zheng, XL				Gui, Y; Zheng, XL			Epidermal growth factor induction of phenotype-dependent cell cycle arrest in vascular smooth muscle cells is through the mitogen-activated protein kinase pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ATHEROSCLEROTIC PLAQUES; LASER-SCANNING CYTOMETRY; FACTOR RECEPTOR; EGF RECEPTOR; CARCINOMA-CELLS; CANCER-CELLS; PULSE-CHASE; IN-VITRO; INHIBITION; PROLIFERATION	The heterogeneity of vascular smooth muscle cells is well established in tissue culture, but their differential responses to growth factors are not completely defined. We wished to identify effects of epidermal growth factor (EGF) on vascular smooth muscle cells in distinct phenotypes, such as spindle and epithelioid. We found that the EGF receptors were abundant in epithelioid cells but not spindle cells. EGF treatment inhibited serum-independent DNA synthesis, which was absent in spindle cells, of epithelioid cells. Additionally, using a pulse-chase assay, we found that bromodeoxyuridine-labeled cells failed to re-enter the S phase in the presence of EGF. These EGF effects were abolished by either inhibiting the EGF receptor tyrosine kinase with AG1478 or inhibiting the mitogen-activated protein kinase pathway with PD98059. In response to treatment with EGF, the EGF receptor was phosphorylated, which was correlated with phosphorylation and activation of p42/44 mitogen-activated protein kinases. Inhibition of EGF receptor phosphorylation and mitogen-activated protein kinase activation resulted in a reversal of the EGF-induced inhibition of bromodeoxyuridine incorporation and cell cycle arrest. Subsequent studies revealed that the activation of the EGF receptor and the mitogen-activated protein kinase pathway in epithelioid cells induced expression of the cell cycle inhibitory protein p27(Kip1) but not p21(Cip1). Taken together, our data demonstrate that the EGF receptor is abundantly expressed in epithelioid vascular smooth muscle cells and that the activation of this receptor results in cell cycle arrest through activation of the mitogen-activated protein kinase pathway.	Univ Calgary, Fac Med, Dept Biochem & Mol Biol, Hlth Sci Ctr,Smooth Muscle Res Grp, Calgary, AB T2N 4N1, Canada	University of Calgary; University of Manitoba; Children's Hospital Research Institute of Manitoba	Zheng, XL (corresponding author), Univ Calgary, Fac Med, Dept Biochem & Mol Biol, Hlth Sci Ctr,Smooth Muscle Res Grp, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.			Zheng, Xi-Long/0000-0002-0889-1827				Akiyama M, 2002, CANCER LETT, V178, P187, DOI 10.1016/S0304-3835(01)00838-2; BARNES DW, 1982, J CELL BIOL, V93, P1, DOI 10.1083/jcb.93.1.1; BARNES DW, 1984, ADV EXP MED BIOL, V172, P49; BENDITT EP, 1973, P NATL ACAD SCI USA, V70, P1753, DOI 10.1073/pnas.70.6.1753; BERK BC, 1985, J CLIN INVEST, V75, P1083, DOI 10.1172/JCI111772; BLAES N, 1991, IN VITRO CELL DEV B, V27, P725; BochatonPiallat ML, 1996, ARTERIOSCL THROM VAS, V16, P815, DOI 10.1161/01.ATV.16.6.815; Bornfeldt KE, 1997, J CLIN INVEST, V100, P875, DOI 10.1172/JCI119603; BRAVO R, 1984, P NATL ACAD SCI-BIOL, V81, P4848, DOI 10.1073/pnas.81.15.4848; CHAMLEYCAMPBELL J, 1979, PHYSIOL REV, V59, P1, DOI 10.1152/physrev.1979.59.1.1; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; CRISSMAN HA, 1994, METHOD CELL BIOL, V41, P341; Darzynkiewicz Z, 1999, EXP CELL RES, V249, P1, DOI 10.1006/excr.1999.4477; Eguchi S, 1998, J BIOL CHEM, V273, P8890, DOI 10.1074/jbc.273.15.8890; EHLER E, 1995, CIRCULATION, V92, P3289, DOI 10.1161/01.CIR.92.11.3289; FAN Z, 1995, J CELL BIOL, V131, P235, DOI 10.1083/jcb.131.1.235; Frid MG, 1997, CIRC RES, V81, P940; Gibson S, 1999, J BIOL CHEM, V274, P17612, DOI 10.1074/jbc.274.25.17612; GRATZNER HG, 1982, SCIENCE, V218, P474, DOI 10.1126/science.7123245; Hao H, 2002, ARTERIOSCL THROM VAS, V22, P1093, DOI 10.1161/01.ATV.0000022407.91111.E4; Hao HY, 2003, ARTERIOSCL THROM VAS, V23, P1510, DOI 10.1161/01.ATV.0000090130.85752.ED; Harris RC, 2003, EXP CELL RES, V284, P2, DOI 10.1016/S0014-4827(02)00105-2; Higashikubo R, 1996, CELL PROLIFERAT, V29, P43, DOI 10.1111/j.1365-2184.1996.tb00093.x; Holifield B, 1996, J CLIN INVEST, V97, P814, DOI 10.1172/JCI118481; Ichiba M, 2002, J GASTROENTEROL, V37, P497, DOI 10.1007/s005350200077; Jorissen RN, 2003, EXP CELL RES, V284, P31, DOI 10.1016/S0014-4827(02)00098-8; Kamentsky LA, 1997, ACTA CYTOL, V41, P123, DOI 10.1159/000332315; Li SH, 2001, CIRC RES, V89, P517, DOI 10.1161/hh1801.097165; Marra DE, 2000, CIRCULATION, V102, P2124, DOI 10.1161/01.CIR.102.17.2124; MITSUMATA M, 1994, ARTERIOSCLER THROMB, V14, P1364, DOI 10.1161/01.ATV.14.8.1364; NEXO E, 1992, REGUL PEPTIDES, V42, P75, DOI 10.1016/0167-0115(92)90025-P; OKA Y, 1983, J CLIN INVEST, V72, P249, DOI 10.1172/JCI110964; ORLANDI A, 1994, ARTERIOSCLER THROMB, V14, P982, DOI 10.1161/01.ATV.14.6.982; PEARSON TA, 1978, AM J PATHOL, V93, P93; PRASAD KAN, 1991, EXP CELL RES, V195, P20, DOI 10.1016/0014-4827(91)90495-G; Pumiglia KM, 1997, P NATL ACAD SCI USA, V94, P448, DOI 10.1073/pnas.94.2.448; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Schlessinger J, 2002, CELL, V110, P669, DOI 10.1016/S0092-8674(02)00966-2; Sibilia M, 2000, CELL, V102, P211, DOI 10.1016/S0092-8674(00)00026-X; Tanner FC, 2000, CIRCULATION, V101, P2022, DOI 10.1161/01.CIR.101.17.2022; Tanner FC, 1998, CIRC RES, V82, P396, DOI 10.1161/01.RES.82.3.396; WALKER LN, 1986, P NATL ACAD SCI USA, V83, P7311, DOI 10.1073/pnas.83.19.7311; Xie W, 1997, ANTICANCER RES, V17, P2627; YAMAMOTO M, 1994, EXP CELL RES, V212, P62, DOI 10.1006/excr.1994.1118; Zheng XL, 2001, J BIOL CHEM, V276, P13822, DOI 10.1074/jbc.M011031200; Zheng XL, 1998, J PHARMACOL EXP THER, V285, P325	46	21	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					53017	53025		10.1074/jbc.M309640200	http://dx.doi.org/10.1074/jbc.M309640200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14551192	hybrid			2022-12-27	WOS:000187480700125
J	Villeneuve, C; Etienne, G; Abadie, V; Montrozier, H; Bordier, C; Laval, F; Daffe, M; Maridonneau-Parini, I; Astarie-Dequeker, C				Villeneuve, C; Etienne, G; Abadie, V; Montrozier, H; Bordier, C; Laval, F; Daffe, M; Maridonneau-Parini, I; Astarie-Dequeker, C			Surface-exposed glycopeptidolipids of Mycobacterium smegmatis specifically inhibit the phagocytosis of mycobacteria by human macrophages - Identification of a novel family of glycopeptidolipids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE HCK; NONTUBERCULOUS MYCOBACTERIA; HUMAN NEUTROPHILS; NONOPSONIC PHAGOCYTOSIS; AZUROPHIL GRANULES; TUBERCLE-BACILLI; TUBERCULOSIS; PATHOGENICITY; VIRULENT; SURVIVAL	Phagocytosis by macrophages represents the early step of the mycobacterial infection. It is governed both by the nature of the host receptors used and the ligands exposed on the bacteria. The outermost molecules of the nonpathogenic Mycobacterium smegmatis were extracted by a mechanical treatment and found to specifically and dose dependently inhibit the phagocytosis of both M. smegmatis and the opportunistic pathogen M. kansasii by human macrophages derived from monocytes. The inhibitory activity was attributed to surface lipids because it is extracted by chloroform and reduced by alkaline hydrolysis but not by protease treatment. Fractionation of surface lipids by adsorption chromatography indicated that the major inhibitory compounds consisted of phospholipids and glycopeptidolipids (GPLs). Mass spectrometry and nuclear magnetic resonance spectroscopy analyses, combined with chemical degradation methods, demonstrated the existence of a novel family of GPLs that consists of a core composed of the long-chain tripeptidyl amino-alcohol with a di-O-acetyl-6-deoxytalosyl unit substituting the allo-threoninyl residue and a 2-succinyl-3,4-di-O-CH3-rhamnosyl unit linked to the alaninol end of the molecules. These compounds, as well as diglycosylated GPLs at the alaninol end and de-O-acylated GPLs, but not the non-serovar-specific di-O-acetylated GPLs, inhibited the phagocytosis of M. smegmatis and M. avium by human macrophages at a few nanomolar concentration without affecting the rate of zymosan internalization. At micromolar concentrations, the native GPLs also inhibit the uptake of both M. tuberculosis and M. kansasii. De-O-acylation experiments established the critical roles of both the succinyl and acetyl substituents. Collectively, these data provide evidence that surface-exposed mycobacterial glycoconjugates are efficient competitors of the interaction between macrophages and mycobacteria and, as such, could represent pharmacological tools for the control of mycobacterial infections.	Univ Toulouse 3, CNRS, Inst Pharmacol & Biol Struct,UMR 5089, Dept Mecanismes Mol Infect Mycobacteriennes, F-31077 Toulouse, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Astarie-Dequeker, C (corresponding author), Univ Toulouse 3, CNRS, Inst Pharmacol & Biol Struct,UMR 5089, Dept Mecanismes Mol Infect Mycobacteriennes, 205 Route Narbonne, F-31077 Toulouse, France.	Catherine.Astarie-Dequeker@ipbs.fr	LAUZERAL-VIZCAINO, Françoise/W-8898-2019; Maridonneau-Parini, Isabelle/F-1985-2011	LAUZERAL-VIZCAINO, Françoise/0000-0002-9741-3252; Maridonneau-Parini, Isabelle/0000-0003-0189-0976; Astarie-Dequeker, Catherine/0000-0003-1801-8105				ARMSTRONG JA, 1975, J EXP MED, V142, P1, DOI 10.1084/jem.142.1.1; Astarie-Dequeker C, 2002, J CELL SCI, V115, P81; Astarie-Dequeker C, 1999, INFECT IMMUN, V67, P469, DOI 10.1128/IAI.67.2.469-477.1999; BERMUDEZ LE, 1991, INFECT IMMUN, V59, P1697, DOI 10.1128/IAI.59.5.1697-1702.1991; Billman-Jacobe H, 1999, MOL MICROBIOL, V33, P1244, DOI 10.1046/j.1365-2958.1999.01572.x; BLAKENEY AB, 1985, CARBOHYD RES, V140, P319, DOI 10.1016/0008-6215(85)85132-6; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Chatterjee D, 2001, CELL MOL LIFE SCI, V58, P2018, DOI 10.1007/PL00000834; Constant P, 2002, J BIOL CHEM, V277, P38148, DOI 10.1074/jbc.M206538200; Cougoule C, 2002, INFECT IMMUN, V70, P1591, DOI 10.1128/IAI.70.3.1591-1598.2002; Cywes C, 1997, INFECT IMMUN, V65, P4258, DOI 10.1128/IAI.65.10.4258-4266.1997; Daffe M., 1999, Tubercle and Lung Disease, V79, P153, DOI 10.1054/tuld.1998.0200; DAFFE M, 1983, BIOCHIM BIOPHYS ACTA, V751, P439, DOI 10.1016/0005-2760(83)90304-1; Daffe M, 1998, ADV MICROB PHYSIOL, V39, P131; Daffe M, 2000, GLYCOMICROBIOLOGY, P225, DOI DOI 10.1007/0-306-46821-2_8; DECHASTELLIER C, 1993, INFECT IMMUN, V61, P3775, DOI 10.1128/IAI.61.9.3775-3784.1993; DITTMER JC, 1964, J LIPID RES, V5, P126; Ehlers MRW, 1998, TRENDS MICROBIOL, V6, P328, DOI 10.1016/S0966-842X(98)01301-8; Etienne G, 2002, MICROBIOL-SGM, V148, P3089, DOI 10.1099/00221287-148-10-3089; Laval F, 2001, ANAL CHEM, V73, P4537, DOI 10.1021/ac0105181; Le Cabec V, 2000, INFECT IMMUN, V68, P4736, DOI 10.1128/IAI.68.8.4736-4745.2000; LEIGH JA, 1987, CELL, V51, P579, DOI 10.1016/0092-8674(87)90127-9; Lemassu A, 1996, MICROBIOL-UK, V142, P1513, DOI 10.1099/13500872-142-6-1513; LEMIEUX RU, 1955, CAN J CHEM, V33, P1701, DOI 10.1139/v55-208; Manabe YC, 2000, NAT MED, V6, P1327, DOI 10.1038/82139; MARIN LML, 1991, BIOCHEMISTRY-US, V30, P10536, DOI 10.1021/bi00107a024; Marras TK, 2002, CLIN CHEST MED, V23, P553, DOI 10.1016/S0272-5231(02)00019-9; McGarvey J, 2002, CLIN CHEST MED, V23, P569, DOI 10.1016/S0272-5231(02)00012-6; N'Diaye EN, 1998, J IMMUNOL, V161, P4983; Ojha AK, 2002, MICROBIOL-SGM, V148, P3039, DOI 10.1099/00221287-148-10-3039; OrtaloMagne A, 1996, MICROBIOL-UK, V142, P927, DOI 10.1099/00221287-142-4-927; ORTALOMAGNE A, 1995, MICROBIOL-UK, V141, P1609, DOI 10.1099/13500872-141-7-1609; OrtaloMagne A, 1996, J BACTERIOL, V178, P456, DOI 10.1128/jb.178.2.456-461.1996; Patterson JH, 2000, J BIOL CHEM, V275, P24900, DOI 10.1074/jbc.M000147200; Peyron P, 2000, J IMMUNOL, V165, P5186, DOI 10.4049/jimmunol.165.9.5186; POURSHAFIE M, 1993, CLIN EXP IMMUNOL, V93, P72; Raynaud C, 1998, MICROBIOL-SGM, V144, P577, DOI 10.1099/00221287-144-2-577; RUSSELL DG, 1995, CURR OPIN IMMUNOL, V7, P479, DOI 10.1016/0952-7915(95)80092-1; Russell DG, 2001, NAT REV MOL CELL BIO, V2, P569, DOI 10.1038/35085034; SCHLESINGER LS, 1993, J IMMUNOL, V150, P2920; SUT A, 1990, BIOCHEMISTRY-US, V29, P8498, DOI 10.1021/bi00488a042; VERGNE I, 1995, FEBS LETT, V375, P254, DOI 10.1016/0014-5793(95)01219-5; Vergne I, 1998, FRONT BIOSCI, V3, pd865; XU SM, 1994, J IMMUNOL, V153, P2568; Zimmerli S, 1996, AM J RESP CELL MOL, V15, P760, DOI 10.1165/ajrcmb.15.6.8969271	45	63	65	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51291	51300		10.1074/jbc.M306554200	http://dx.doi.org/10.1074/jbc.M306554200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14534313	hybrid			2022-12-27	WOS:000187206300056
J	Shitamukai, A; Hirata, D; Sonobe, S; Miyakawa, T				Shitamukai, A; Hirata, D; Sonobe, S; Miyakawa, T			Evidence for antagonistic regulation of cell growth by the calcineurin and high osmolarity glycerol pathways in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; VACUOLAR H+-ATPASE; OSMOTIC-STRESS; MORPHOGENESIS CHECKPOINT; PHOSPHATASE CALCINEURIN; TYROSINE PHOSPHATASES; TRANSCRIPTION FACTOR; RESPONSE PATHWAY; GENE-EXPRESSION; MAPK PATHWAYS	Because Ca2+ signaling of budding yeast, through the activation of calcineurin and the Mpk1/Slt2 mitogen-activated protein kinase cascade, performs redundant function(s) in the events essential for growth, the simultaneous deletion of both these pathways (Deltacnb1 Deltampk1) leads to lethality. A PTC4 cDNA that encodes a protein phosphatase belonging to the PP2C family was obtained as a high dosage suppressor of the lethality of Deltacnb1 Deltampk1 strain. Overexpression of PTC4 led to a decrease in the high osmolarity-induced Hog1 phosphorylation, and HOG1 deletion remarkably suppressed the synthetic lethality, indicating an antagonistic role of the high osmolarity glycerol (HOG) pathway and the Ca2+ signaling pathway in growth regulation. The calcineurin-Crz1 pathway was required for the down-regulation of the HOG pathway. Analysis of the time course of actin polarization, bud formation, and the onset of mitosis in synchronous cell cultures demonstrated that calcineurin negatively regulates actin polarization at the bud site, whereas the HOG pathway positively regulates bud formation at a later step after actin has polarized.	Hiroshima Univ, Grad Sch Adv Sci Matter, Dept Mol Biotechnol, Higashihiroshima 7398530, Japan	Hiroshima University	Miyakawa, T (corresponding author), Hiroshima Univ, Grad Sch Adv Sci Matter, Dept Mol Biotechnol, Higashihiroshima 7398530, Japan.	tmiyaka@hiroshima-u.ac.jp	Shitamukai, Atsunori/AAT-8802-2021; Shitamukai, Atsunori/C-6817-2014	Shitamukai, Atsunori/0000-0003-4216-927X; 				ADAMS AEM, 1991, METHOD ENZYMOL, V194, P729; ALBERTYN J, 1994, MOL CELL BIOL, V14, P4135, DOI 10.1128/MCB.14.6.4135; Alexander MR, 2001, MOL BIOL CELL, V12, P53, DOI 10.1091/mbc.12.1.53; BOOHER RN, 1993, EMBO J, V12, P3417, DOI 10.1002/j.1460-2075.1993.tb06016.x; BREWSTER JL, 1994, YEAST, V10, P425, DOI 10.1002/yea.320100402; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; CHANG HY, 1995, NATURE, V376, P686, DOI 10.1038/376686a0; Cheng AY, 1999, GENE DEV, V13, P2946, DOI 10.1101/gad.13.22.2946; Cruz MC, 2001, EMBO J, V20, P1020, DOI 10.1093/emboj/20.5.1020; Cunningham KW, 1996, MOL CELL BIOL, V16, P2226; CYERT MS, 1992, MOL CELL BIOL, V12, P3460, DOI 10.1128/MCB.12.8.3460; Denis V, 2002, J CELL BIOL, V156, P29, DOI 10.1083/jcb.200111004; FARCASANU IC, 1995, EUR J BIOCHEM, V232, P712, DOI 10.1111/j.1432-1033.1995.tb20865.x; Gaits F, 1997, J BIOL CHEM, V272, P17873, DOI 10.1074/jbc.272.28.17873; GARRETTENGELE P, 1995, MOL CELL BIOL, V15, P4103; Gustin MC, 1998, MICROBIOL MOL BIOL R, V62, P1264, DOI 10.1128/MMBR.62.4.1264-1300.1998; Jacoby T, 1997, J BIOL CHEM, V272, P17749, DOI 10.1074/jbc.272.28.17749; Lee BN, 1999, P NATL ACAD SCI USA, V96, P12679, DOI 10.1073/pnas.96.22.12679; Lim HW, 2001, J BIOL CHEM, V276, P15913, DOI 10.1074/jbc.M100452200; Ma XJ, 1996, GENE DEV, V10, P1327, DOI 10.1101/gad.10.11.1327; MAEDA T, 1994, NATURE, V369, P242, DOI 10.1038/369242a0; MAEDA T, 1995, SCIENCE, V269, P554, DOI 10.1126/science.7624781; Matheos DP, 1997, GENE DEV, V11, P3445, DOI 10.1101/gad.11.24.3445; MAZUR P, 1995, MOL CELL BIOL, V15, P5671; McMillan JN, 1998, J CELL BIOL, V142, P1487, DOI 10.1083/jcb.142.6.1487; MENDOZA I, 1994, J BIOL CHEM, V269, P8792; Mizunuma M, 1998, NATURE, V392, P303, DOI 10.1038/32695; NAKAMURA T, 1993, EMBO J, V12, P4063, DOI 10.1002/j.1460-2075.1993.tb06090.x; Nakamura T, 1996, MOL GEN GENET, V251, P211; O'Rourke SM, 1998, GENE DEV, V12, P2874, DOI 10.1101/gad.12.18.2874; Posas F, 1996, CELL, V86, P865, DOI 10.1016/S0092-8674(00)80162-2; Posas F, 1998, EMBO J, V17, P1385, DOI 10.1093/emboj/17.5.1385; Sagasti A, 2001, CELL, V105, P221, DOI 10.1016/S0092-8674(01)00313-0; Sakumoto NM, 1999, YEAST, V15, P1669, DOI 10.1002/(SICI)1097-0061(199911)15:15<1669::AID-YEA480>3.0.CO;2-6; Sia RAL, 1998, EMBO J, V17, P6678, DOI 10.1093/emboj/17.22.6678; Stathopoulos AM, 1997, GENE DEV, V11, P3432, DOI 10.1101/gad.11.24.3432; Takekawa M, 1998, EMBO J, V17, P4744, DOI 10.1093/emboj/17.16.4744; TANIDA I, 1995, J BIOL CHEM, V270, P10113, DOI 10.1074/jbc.270.17.10113; Uesono Y, 2002, J BIOL CHEM, V277, P13848, DOI 10.1074/jbc.M108848200; Warmka J, 2001, MOL CELL BIOL, V21, P51, DOI 10.1128/MCB.21.1.51-60.2001; Withee JL, 1997, MOL BIOL CELL, V8, P263, DOI 10.1091/mbc.8.2.263; Withee JL, 1998, GENETICS, V149, P865; WurglerMurphy SM, 1997, MOL CELL BIOL, V17, P1289, DOI 10.1128/MCB.17.3.1289	43	48	51	2	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	2004	279	5					3651	3661		10.1074/jbc.M306098200	http://dx.doi.org/10.1074/jbc.M306098200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	766MF	14583627	hybrid			2022-12-27	WOS:000188379600064
J	Cheng, NH; Pittman, JK; Zhu, JK; Hirschi, KD				Cheng, NH; Pittman, JK; Zhu, JK; Hirschi, KD			The protein kinase SOS2 activates the Arabidopsis H+/Ca2+ antiporter CAX1 to integrate calcium transport and salt tolerance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; ION HOMEOSTASIS; CALCINEURIN; STRESS; YEAST; IDENTIFICATION; EXCHANGER; DOMAIN; PLANTS	The regulation of ions within cells is an indispensable component of growth and adaptation. The plant SOS2 protein kinase and its associated Ca2+ sensor, SOS3, have been demonstrated to modulate the plasma membrane H+/ Na+ antiporter SOS1; however, how these regulators modulate Ca2+ levels within cells is poorly understood. Here we demonstrate that SOS2 regulates the vacuolar H+/Ca2+ antiporter CAX1. Using a yeast growth assay, co-expression of SOS2 specifically activated CAX1, whereas SOS3 did not. CAX1-like chimeric transporters were activated by SOS2 if the chimeric proteins contained the N terminus of CAX1. Vacuolar membranes from CAX1-expressing cells were made to be H+/Ca2+-competent by the addition of SOS2 protein in a dose-dependent manner. Using a yeast two-hybrid assay, SOS2 interacted with the N terminus of CAX1. In each of these yeast assays, the activation of CAX1 by SOS2 was SOS3-independent. In planta, the high level of expression of a deregulated version of CAX1 caused salt sensitivity. These findings suggest multiple functions for SOS2 and provide a mechanistic link between Ca2+ and Na+ homeostasis in plants.	Baylor Coll Med, USDA ARS, Childrens Nutr Res Ctr, Plant Physiol Grp, Houston, TX 77030 USA; Univ Arizona, Dept Plant Sci, Tucson, AZ 85721 USA; Baylor Coll Med, Dept Human & Mol Genet, Houston, TX 77030 USA; Texas A&M Univ, Vegetable & Fruit Improvement Ctr, College Stn, TX 77845 USA	Baylor College of Medicine; United States Department of Agriculture (USDA); University of Arizona; Baylor College of Medicine; Texas A&M University System; Texas A&M University College Station	Hirschi, KD (corresponding author), Baylor Coll Med, USDA ARS, Childrens Nutr Res Ctr, Plant Physiol Grp, 1100 Bates St, Houston, TX 77030 USA.	kendalh@bcm.tmc.edu	hirschi, kendal/GNP-0351-2022; Zhu, Jian-Kang/F-7658-2011	Zhu, Jian-Kang/0000-0001-5134-731X; Pittman, Jon/0000-0001-7197-1494				Bressan RA, 1998, TRENDS PLANT SCI, V3, P411, DOI 10.1016/S1360-1385(98)01331-4; Cheng NH, 2003, J BIOL CHEM, V278, P6503, DOI 10.1074/jbc.M210883200; Cheng NH, 2003, PLANT CELL, V15, P347, DOI 10.1105/tpc.007385; Cheng NH, 2002, PLANT PHYSIOL, V128, P1245, DOI 10.1104/pp.010857; Cunningham KW, 1996, MOL CELL BIOL, V16, P2226; CYERT MS, 1992, MOL CELL BIOL, V12, P3460, DOI 10.1128/MCB.12.8.3460; Gong DM, 2002, PLANT PHYSIOL, V130, P256, DOI 10.1104/pp.004507; Guo Y, 2001, PLANT CELL, V13, P1383, DOI 10.1105/tpc.13.6.1383; Halfter U, 2000, P NATL ACAD SCI USA, V97, P3735, DOI 10.1073/pnas.040577697; HARPER JW, 1993, CELL, V75, P805; Hirschi KD, 1996, P NATL ACAD SCI USA, V93, P8782, DOI 10.1073/pnas.93.16.8782; Hirschi KD, 1999, PLANT CELL, V11, P2113, DOI 10.1105/tpc.11.11.2113; Hrabak EM, 2003, PLANT PHYSIOL, V132, P666, DOI 10.1104/pp.102.011999; LAUCHLI A, 1990, CUR TOP PL, V4, P26; Liu JP, 2000, P NATL ACAD SCI USA, V97, P3730, DOI 10.1073/pnas.060034197; Liu JP, 1998, SCIENCE, V280, P1943, DOI 10.1126/science.280.5371.1943; Maser P, 2001, PLANT PHYSIOL, V126, P1646, DOI 10.1104/pp.126.4.1646; Matsumoto TK, 2002, J BIOL CHEM, V277, P33075, DOI 10.1074/jbc.M205037200; Mendoza I, 1996, J BIOL CHEM, V271, P23061, DOI 10.1074/jbc.271.38.23061; MENDOZA I, 1994, J BIOL CHEM, V269, P8792; Miseta A, 1999, FEBS LETT, V451, P132, DOI 10.1016/S0014-5793(99)00519-0; Nathan DF, 1999, P NATL ACAD SCI USA, V96, P1409, DOI 10.1073/pnas.96.4.1409; Pittman JK, 2002, J BIOL CHEM, V277, P26452, DOI 10.1074/jbc.M202563200; Pittman JK, 2001, PLANT PHYSIOL, V127, P1020, DOI 10.1104/pp.010409; Qiu QS, 2002, P NATL ACAD SCI USA, V99, P8436, DOI 10.1073/pnas.122224699; Quintero FJ, 2002, P NATL ACAD SCI USA, V99, P9061, DOI 10.1073/pnas.132092099; Sherman F., 1986, METHODS YEAST GENETI; Shigaki T, 2001, J BIOL CHEM, V276, P43152, DOI 10.1074/jbc.M106637200; Shigaki T, 2000, GENE, V257, P291, DOI 10.1016/S0378-1119(00)00390-5; Zhu JK, 2000, PLANT PHYSIOL, V124, P941, DOI 10.1104/pp.124.3.941; Zhu JK, 2001, TRENDS PLANT SCI, V6, P66, DOI 10.1016/S1360-1385(00)01838-0	31	179	202	0	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	2004	279	4					2922	2926		10.1074/jbc.M309084200	http://dx.doi.org/10.1074/jbc.M309084200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	764MU	14583601	hybrid			2022-12-27	WOS:000188211300072
J	Liu, TS; Castro, S; Brasier, AR; Jamaluddin, M; Garofalo, RP; Casola, A				Liu, TS; Castro, S; Brasier, AR; Jamaluddin, M; Garofalo, RP; Casola, A			Reactive oxygen species mediate virus-induced STAT activation - Role of tyrosine phosphatases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPIRATORY SYNCYTIAL VIRUS; FACTOR-I GENE; NF-KAPPA-B; EPITHELIAL-CELLS; TRANSCRIPTION FACTORS; OXIDATIVE STRESS; PROMOTER ACTIVITY; RESPONSE ELEMENT; INTERFERON; EXPRESSION	Respiratory syncytial virus (RSV) is the leading cause of epidemic respiratory tract illness in children in the United States and worldwide. RSV infection of airway epithelial cells induces formation of reactive oxygen species (ROS), whose production mediates the expression of cytokines and chemokines involved the immune/ inflammatory responses of the lung. In this study, we have investigated the role of ROS in RSV-induced signal transducers and activators of transcription ( STAT) activation and interferon regulatory factor (IRF) gene expression in human airway epithelial cells. Our results indicate that RSV replication induces IRF-1 and -7 gene transcription, a response abrogated by antioxidants. RSV infection induces binding of STAT to the IRF-1 gamma-interferon-activated sequence ( GAS) and IRF-7 interferon-stimulated responsive element ( ISRE). STAT1 and STAT3 bind IRF-1 GAS, whereas STAT1, STAT2, IRF-1, and IRF-9 bind IRF-7 ISRE. Antioxidant treatment blocks RSV-induced STAT binding to both the IRF-1 GAS and IRF-7 ISRE by inhibition of inducible STAT1 and STAT3 tyrosine phosphorylation, suggesting that RSV-induced ROS formation is required for STAT activation and IRF gene expression. Although protein tyrosine phosphorylation is necessary for RSV-induced STAT activation, Janus kinase and Src kinase activation do not mediate this effect. Instead, RSV infection inhibits intracellular tyrosine phosphatase activity, which is restored by antioxidant treatment. Pharmacological inhibition of tyrosine phosphatases induces STAT activation. Together, these results suggest that modulation of phosphatases could be an important mechanism of virus-induced STAT activation. Treatment of alveolar epithelial cells with the NAD(P) H oxidase inhibitor diphenylene iodonium abolishes RSV-induced STAT activation, indicating that NAD( P) H oxidase-produced ROS are required for downstream activation of the transcription factors IRF and STAT in virus-infected airway epithelial cells.	Univ Texas, Med Branch, Dept Pediat, Div Child Hlth Res Ctr, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Internal Med, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Microbiol & Immunol, Galveston, TX 77555 USA; Univ Texas, Med Branch, Sealy Ctr Mol Sci, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Casola, A (corresponding author), Univ Texas, Med Branch, Dept Pediat, Div Child Hlth Res Ctr, 301 Univ Blvd, Galveston, TX 77555 USA.	ancasola@utmb.edu	Garofalo, Roberto P./AAF-7385-2022; Garofalo, Roberto P./ABL-2322-2022	Brasier, Allan/0000-0002-5012-4090	NIAID NIH HHS [AI01763] Funding Source: Medline; NIEHS NIH HHS [P30ES0-6676] Funding Source: Medline; PHS HHS [T32-07254, P01-46004] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI001763] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006676] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Allen RG, 2000, FREE RADICAL BIO MED, V28, P463, DOI 10.1016/S0891-5849(99)00242-7; Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; Boehlk S, 2000, EUR J IMMUNOL, V30, P1102, DOI 10.1002/(SICI)1521-4141(200004)30:4<1102::AID-IMMU1102>3.0.CO;2-X; Casola A, 2001, J BIOL CHEM, V276, P19715, DOI 10.1074/jbc.M101526200; Casola A, 2001, J VIROL, V75, P6428, DOI 10.1128/JVI.75.14.6428-6439.2001; Casola A, 2000, J IMMUNOL, V164, P5944, DOI 10.4049/jimmunol.164.11.5944; Chaturvedi P, 1998, ONCOGENE, V16, P1749, DOI 10.1038/sj.onc.1201972; Denu JM, 1998, BIOCHEMISTRY-US, V37, P5633, DOI 10.1021/bi973035t; Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001; Duff JL, 1997, J INVEST DERMATOL, V108, P295, DOI 10.1111/1523-1747.ep12286465; Flory E, 2000, J BIOL CHEM, V275, P8307, DOI 10.1074/jbc.275.12.8307; Gabbita SP, 2000, ARCH BIOCHEM BIOPHYS, V376, P1, DOI 10.1006/abbi.1999.1685; Garofalo R, 1996, J VIROL, V70, P8773, DOI 10.1128/JVI.70.12.8773-8781.1996; Garofalo RP, 2000, AM J RESP CELL MOL, V23, P581, DOI 10.1165/ajrcmb.23.5.f204; Gong GZ, 2001, P NATL ACAD SCI USA, V98, P9599, DOI 10.1073/pnas.171311298; Hall C. B., 1995, PRINCIPLES PRACTICE, V4, P1501; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; HAQUE SJ, 1995, J BIOL CHEM, V270, P25709, DOI 10.1074/jbc.270.43.25709; HARADA H, 1994, MOL CELL BIOL, V14, P1500, DOI 10.1128/MCB.14.2.1500; HEFFETZ D, 1990, J BIOL CHEM, V265, P2896; Imada K, 2000, MOL IMMUNOL, V37, P1, DOI 10.1016/S0161-5890(00)00018-3; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; Lim CP, 2001, J BIOL CHEM, V276, P21004, DOI 10.1074/jbc.M007592200; Lu RQ, 2000, J BIOL CHEM, V275, P31805, DOI 10.1074/jbc.M005288200; Maziere C, 1999, FEBS LETT, V448, P49, DOI 10.1016/S0014-5793(99)00324-5; Maziere C, 2001, FREE RADICAL BIO MED, V31, P1334, DOI 10.1016/S0891-5849(01)00649-9; Meng TC, 2002, MOL CELL, V9, P387, DOI 10.1016/S1097-2765(02)00445-8; Moon SK, 2002, BBA-MOL CELL RES, V1590, P41, DOI 10.1016/S0167-4889(02)00196-9; NELSON PJ, 1993, J IMMUNOL, V151, P2601; Nguyen Hannah, 1997, Cytokine and Growth Factor Reviews, V8, P293, DOI 10.1016/S1359-6101(97)00019-1; PATEL JA, 1995, AM J RESP CELL MOL, V13, P602, DOI 10.1165/ajrcmb.13.5.7576697; Robinson KA, 1999, ARCH BIOCHEM BIOPHYS, V365, P211, DOI 10.1006/abbi.1999.1178; Ruuskanen O, 1993, Curr Probl Pediatr, V23, P50, DOI 10.1016/0045-9380(93)90003-U; Schieffer B, 2000, CIRC RES, V87, P1195, DOI 10.1161/01.RES.87.12.1195; Simon AR, 2000, SCIENCE, V290, P144, DOI 10.1126/science.290.5489.144; Simon AR, 1998, AM J PHYSIOL-CELL PH, V275, pC1640, DOI 10.1152/ajpcell.1998.275.6.C1640; SIMS SH, 1993, MOL CELL BIOL, V13, P690, DOI 10.1128/MCB.13.1.690; STEVENS AM, 1995, MOL ENDOCRINOL, V9, P513, DOI 10.1210/me.9.4.513; TOURKINE N, 1995, J BIOL CHEM, V270, P20952, DOI 10.1074/jbc.270.36.20952; UEBA O, 1978, ACTA MED OKAYAMA, V32, P265; Waris G, 2001, MOL CELL BIOL, V21, P7721, DOI 10.1128/MCB.21.22.7721-7730.2001; Zhang YH, 2003, J VIROL, V77, P5933, DOI 10.1128/JVI.77.10.5933-5947.2003	42	122	127	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	2004	279	4					2461	2469		10.1074/jbc.M307251200	http://dx.doi.org/10.1074/jbc.M307251200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	764MU	14578356	hybrid			2022-12-27	WOS:000188211300017
J	Dong, MQ; Pinon, DI; Cox, RF; Miller, LJ				Dong, MQ; Pinon, DI; Cox, RF; Miller, LJ			Importance of the amino terminus in secretin family G protein-coupled receptors - Intrinsic photoaffinity labeling establishes initial docking constraints for the calcitonin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COVALENT CROSS-LINKING; PARATHYROID-HORMONE; EXTRACELLULAR DOMAIN; BINDING DOMAIN; CHOLECYSTOKININ RECEPTOR; AGONIST-BINDING; MOLECULAR PHARMACOLOGY; SPATIAL APPROXIMATION; DIRECT IDENTIFICATION; CHIMERIC RECEPTORS	The calcitonin receptor is a member of the class B family of G protein-coupled receptors, closely related to secretin and parathyroid hormone receptors. Although mechanisms of ligand binding have been directly explored for those receptors, current knowledge of the molecular basis of calcitonin binding to its receptor is based only on receptor mutagenesis. In this work we have utilized the more direct approach of photoaffinity labeling to explore spatial approximations between distinct residues within calcitonin and its receptor. For this we have developed two human calcitonin analogues incorporating a photolabile p-benzoyl-L-phenylalanine residue in the mid-region and carboxyl-terminal half of the peptide in positions 16 and 26, respectively. Both probes specifically bound to the human calcitonin receptor with high affinity and were potent stimulants of cAMP accumulation in calcitonin receptor-bearing human embryonic kidney 293 cells. They covalently labeled the calcitonin receptor in a saturable and specific manner. Further purification, deglycosylation, specific chemical and enzymatic cleavage, and sequencing of labeled wild type and mutant calcitonin receptors identified the sites of labeling for the position 16 and 26 probes as receptor residues Phe(137) and Thr(30), respectively. Both were within the extracellular amino terminus of the calcitonin receptor, with the former adjacent to the first transmembrane segment and the latter within the distal amino-terminal tail of the receptor. These data are consistent with affinity labeling of other members of the class B G protein-coupled receptors using analogous probes and may suggest a common ligand binding mechanism for this family.	Mayo Clin Scottsdale, Dept Mol Pharmacol & Expt Therapeut, Scottsdale, AZ 85259 USA; GlaxoSmithKline, Res Triangle Pk, NC 27709 USA	Mayo Clinic; Mayo Clinic Phoenix; GlaxoSmithKline	Dong, MQ (corresponding author), Mayo Clin Scottsdale, Dept Mol Pharmacol & Expt Therapeut, Johnson Res Bldg,13400 E Shea Blvd, Scottsdale, AZ 85259 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046577] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK46577] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams AE, 1998, MOL ENDOCRINOL, V12, P1673, DOI 10.1210/me.12.11.1673; Asmann YW, 2000, MOL PHARMACOL, V58, P911, DOI 10.1124/mol.58.5.911; Bazarsuren A, 2002, BIOPHYS CHEM, V96, P305, DOI 10.1016/S0301-4622(02)00023-6; Behar V, 2000, J BIOL CHEM, V275, P9, DOI 10.1074/jbc.275.1.9; Bergwitz C, 1996, J BIOL CHEM, V271, P26469, DOI 10.1074/jbc.271.43.26469; BOUIZAR Z, 1986, EUR J BIOCHEM, V155, P141, DOI 10.1111/j.1432-1033.1986.tb09469.x; CAO YJ, 1995, BIOCHEM BIOPH RES CO, V212, P673, DOI 10.1006/bbrc.1995.2021; Chorev M, 2002, RECEPTOR CHANNEL, V8, P219, DOI 10.1080/10606820213685; Coulie B, 2001, J BIOL CHEM, V276, P35518, DOI 10.1074/jbc.M104489200; Ding XQ, 2001, J BIOL CHEM, V276, P4236, DOI 10.1074/jbc.M003798200; Dong MQ, 2000, J BIOL CHEM, V275, P26032, DOI 10.1074/jbc.M000612200; Dong MQ, 2003, J BIOL CHEM, V278, P48300, DOI 10.1074/jbc.M309166200; Dong MQ, 1999, J BIOL CHEM, V274, P19161, DOI 10.1074/jbc.274.27.19161; Dong MQ, 2002, REGUL PEPTIDES, V109, P181, DOI 10.1016/S0167-0115(02)00202-1; Dong MQ, 2002, MOL ENDOCRINOL, V16, P2490, DOI 10.1210/me.2002-0111; Dong MQ, 2002, RECEPTOR CHANNEL, V8, P189, DOI 10.1080/10606820213686; Dong MQ, 1999, J BIOL CHEM, V274, P903, DOI 10.1074/jbc.274.2.903; DSANTOS CS, 1988, ENDOCRINOLOGY, V123, P1483, DOI 10.1210/endo-123-3-1483; FEYEN JHM, 1992, BIOCHEM BIOPH RES CO, V187, P8, DOI 10.1016/S0006-291X(05)81450-0; Ganguli SC, 1998, J PHARMACOL EXP THER, V286, P593; Gensure RC, 2001, J BIOL CHEM, V276, P42692, DOI 10.1074/jbc.M106215200; Gensure RC, 2001, J BIOL CHEM, V276, P28650, DOI 10.1074/jbc.M100717200; Gourlet P, 1996, EUR J BIOCHEM, V239, P349, DOI 10.1111/j.1432-1033.1996.0349u.x; Gourlet P, 1996, PEPTIDES, V17, P825, DOI 10.1016/0196-9781(96)00107-6; Grauschopf U, 2000, BIOCHEMISTRY-US, V39, P8878, DOI 10.1021/bi0001426; Greenberg Z, 2000, BIOCHEMISTRY-US, V39, P8142, DOI 10.1021/bi000195n; Hadac EM, 1998, J BIOL CHEM, V273, P12988, DOI 10.1074/jbc.273.21.12988; Hadac EM, 1996, PANCREAS, V13, P130, DOI 10.1097/00006676-199608000-00003; Holtmann MH, 1996, J BIOL CHEM, V271, P14944, DOI 10.1074/jbc.271.25.14944; HOLTMANN MH, 1995, J BIOL CHEM, V270, P14394, DOI 10.1074/jbc.270.24.14394; Ji ZS, 1997, J BIOL CHEM, V272, P24393, DOI 10.1074/jbc.272.39.24393; JUPPNER H, 1994, ENDOCRINOLOGY, V134, P879, DOI 10.1210/en.134.2.879; KAISER ET, 1984, SCIENCE, V223, P249, DOI 10.1126/science.6322295; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mannstadt M, 1998, J BIOL CHEM, V273, P16890, DOI 10.1074/jbc.273.27.16890; MOSELEY JM, 1987, PHARMACOL THERAPEUT, V34, P51, DOI 10.1016/0163-7258(87)90091-X; MOSELEY JM, 1982, J BIOL CHEM, V257, P5846; MOSELEY JM, 1986, J BONE MINER RES, V1, P293; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; Pantaloni C, 1996, J BIOL CHEM, V271, P22146, DOI 10.1074/jbc.271.36.22146; PEARSON RK, 1987, J BIOL CHEM, V262, P13850; Perrin MH, 2001, J BIOL CHEM, V276, P31528, DOI 10.1074/jbc.M101838200; Pondel M, 2000, INT J EXP PATHOL, V81, P405, DOI 10.1046/j.1365-2613.2000.00176.x; POWERS SP, 1988, INT J PEPT PROT RES, V31, P429; Pozvek G, 1997, MOL PHARMACOL, V51, P658, DOI 10.1124/mol.51.4.658; Purdue BW, 2002, RECEPTOR CHANNEL, V8, P243, DOI 10.1080/10606820213681; Quiza M, 1997, ENDOCRINOLOGY, V138, P530, DOI 10.1210/en.138.2.530; RITTEL W, 1976, EXPERIENTIA, V32, P246, DOI 10.1007/BF01937791; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sexton PM, 1999, CURR MED CHEM, V6, P1067; Stroop SD, 1996, ENDOCRINOLOGY, V137, P4752, DOI 10.1210/en.137.11.4752; STROOP SD, 1995, BIOCHEMISTRY-US, V34, P1050, DOI 10.1021/bi00003a040; Suva LJ, 1997, J PHARMACOL EXP THER, V283, P876; Tan YV, 2003, J BIOL CHEM, V278, P36531, DOI 10.1074/jbc.M304770200; VILARDAGA JP, 1995, BIOCHEM BIOPH RES CO, V211, P885, DOI 10.1006/bbrc.1995.1895; Zang MW, 2003, MOL PHARMACOL, V63, P993, DOI 10.1124/mol.63.5.993; Zhou AT, 1997, P NATL ACAD SCI USA, V94, P3644, DOI 10.1073/pnas.94.8.3644	57	43	44	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 9	2004	279	2					1167	1175		10.1074/jbc.M305719200	http://dx.doi.org/10.1074/jbc.M305719200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	759DJ	14583624	hybrid			2022-12-27	WOS:000187722800041
J	Buu, LM; Jang, LT; Lee, FJS				Buu, LM; Jang, LT; Lee, FJS			The yeast RNA-binding protein Rbp1p modifies the stability of mitochondrial porin mRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AU-RICH ELEMENT; 3' UNTRANSLATED REGION; 3'-UNTRANSLATED REGION; SACCHAROMYCES-CEREVISIAE; IN-VIVO; RECOGNITION MOTIFS; TRANSLATION INITIATION; FUNCTIONAL INTERACTION; ECTOPIC EXPRESSION; HUR	The Saccharomyces cerevisiae RNA-binding protein Rbp1p was initially identified as a negative growth regulator; however, its function is still obscure. Here, we show that Rbp1p in cells is associated with structures that sediment at 10,000 as well as 100,000 x g. It appears microscopically as punctate signals partially localized to the perinuclear region. Over-expression of Rbp1p in yeast resulted in growth defects on nonfermentable carbon sources, suggesting a function for Rbp1p in mitochondrial biogenesis. Absence of Rbp1p increased the level of mitochondrial porin, whereas over-expression of Rbp1p, but not an N-terminally truncated form, decreased porin levels. Over-expression of Rbp1p also decreased the level of mitochondrial porin mRNA by enhancing its degradation, an effect that was dependent on all three of the Rbp1p RNA recognition motifs. In cells, the porin mRNA is associated with Rbp1p . RNP ( ribonucleoprotein) complexes. In vitro binding assays showed that Rbp1p most likely interacts with a (C/G) U-rich element in the porin mRNA 3'-UTR. Based on these observations, we infer that Rbp1p has a role in negatively regulating mitochondrial porin expression post-transcriptionally.	Natl Taiwan Univ, Coll Med, Inst Mol Med, Taipei 100, Taiwan; Natl Taiwan Univ, Natl Taiwan Univ Hosp, Dept Med Res, Taipei 100, Taiwan	National Taiwan University; National Taiwan University; National Taiwan University Hospital	Lee, FJS (corresponding author), Natl Taiwan Univ, Coll Med, Inst Mol Med, 7 Chung Shan S Rd, Taipei 100, Taiwan.			LEE, FANG-JEN/0000-0002-2167-2426				Abe R, 1996, NUCLEIC ACIDS RES, V24, P4895, DOI 10.1093/nar/24.24.4895; ADAM SA, 1986, MOL CELL BIOL, V6, P2932, DOI 10.1128/MCB.6.8.2932; Akamatsu W, 1999, P NATL ACAD SCI USA, V96, P9885, DOI 10.1073/pnas.96.17.9885; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; Balmer LA, 2001, MOL CELL BIOL, V21, P2070, DOI 10.1128/MCB.21.6.2070-2084.2001; BOTHWELL ALM, 1991, J BIOL CHEM, V266, P24657; Brennan CM, 2000, J CELL BIOL, V151, P1, DOI 10.1083/jcb.151.1.1; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; Carpousis AJ, 1999, TRENDS GENET, V15, P24, DOI 10.1016/S0168-9525(98)01627-8; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Chkheidze AN, 1999, MOL CELL BIOL, V19, P4572; Chung SM, 1996, J BIOL CHEM, V271, P11518, DOI 10.1074/jbc.271.19.11518; Corral-Debrinski M, 2000, MOL CELL BIOL, V20, P7881, DOI 10.1128/MCB.20.21.7881-7892.2000; Cunningham KS, 2000, P NATL ACAD SCI USA, V97, P12498, DOI 10.1073/pnas.220425497; Czyzyk-Krzeska MF, 1999, BLOOD, V93, P2111, DOI 10.1182/blood.V93.6.2111.406k24_2111_2120; DAVID CS, 1999, MOL CELL BIOL, V19, P5247; Dean JLE, 2001, MOL CELL BIOL, V21, P721, DOI 10.1128/MCB.21.3.721-730.2001; Del Gato-Konczak F, 2000, MOL CELL BIOL, V20, P6287, DOI 10.1128/MCB.20.17.6287-6299.2000; Dember LM, 1996, J BIOL CHEM, V271, P2783, DOI 10.1074/jbc.271.5.2783; Fan XHC, 1998, EMBO J, V17, P3448, DOI 10.1093/emboj/17.12.3448; Forch P, 2000, MOL CELL, V6, P1089, DOI 10.1016/S1097-2765(00)00107-6; Frey S, 2001, J BIOL CHEM, V276, P15905, DOI 10.1074/jbc.M009430200; FUJIKI M, 1993, J BIOL CHEM, V268, P1914; Gallie DR, 1998, GENE, V216, P1, DOI 10.1016/S0378-1119(98)00318-7; Gao FB, 1996, J CELL SCI, V109, P579; GOOD PJ, 1995, P NATL ACAD SCI USA, V92, P4557, DOI 10.1073/pnas.92.10.4557; Gueydan C, 1999, J BIOL CHEM, V274, P2322, DOI 10.1074/jbc.274.4.2322; Huang CF, 1999, J BIOL CHEM, V274, P3819, DOI 10.1074/jbc.274.6.3819; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Jain RG, 1997, MOL CELL BIOL, V17, P954, DOI 10.1128/MCB.17.2.954; Kaiser C., 1994, METHODS YEAST GENETI; KAWAKAMI A, 1992, P NATL ACAD SCI USA, V89, P8681, DOI 10.1073/pnas.89.18.8681; Kedersha NL, 1999, J CELL BIOL, V147, P1431, DOI 10.1083/jcb.147.7.1431; Kessler SH, 1998, MOL CELL BIOL, V18, P51, DOI 10.1128/MCB.18.1.51; Koushika SP, 1996, CURR BIOL, V6, P1634, DOI 10.1016/S0960-9822(02)70787-2; Lasa M, 2000, MOL CELL BIOL, V20, P4265, DOI 10.1128/MCB.20.12.4265-4274.2000; Lee FJS, 1997, J BIOL CHEM, V272, P30998, DOI 10.1074/jbc.272.49.30998; LEE FJS, 1993, J BIOL CHEM, V268, P15080; LEVINE TD, 1993, MOL CELL BIOL, V13, P3494, DOI 10.1128/MCB.13.6.3494; Levy NS, 1998, J BIOL CHEM, V273, P6417, DOI 10.1074/jbc.273.11.6417; Lithgow T, 1997, TRENDS BIOCHEM SCI, V22, P110, DOI 10.1016/S0968-0004(97)01007-4; Ma WJ, 1997, NUCLEIC ACIDS RES, V25, P3564, DOI 10.1093/nar/25.18.3564; Malter JS, 2001, J NEUROSCI RES, V66, P311, DOI 10.1002/jnr.10021; Maquat LE, 2001, CELL, V104, P173, DOI 10.1016/S0092-8674(01)00202-1; MIGNONE F, GENOME BIOL, V3; Mitchell P, 2000, CURR OPIN GENET DEV, V10, P193, DOI 10.1016/S0959-437X(00)00063-0; MUHLRAD D, 1995, MOL CELL BIOL, V15, P2145; Myszka DG, 1998, ANAL BIOCHEM, V265, P326, DOI 10.1006/abio.1998.2937; NEUPERT W, 1997, ANNU REV BIOCHEM, V66, P683; Niranjanakumari S, 2002, METHODS, V26, P182, DOI 10.1016/S1046-2023(02)00021-X; Park SM, 2000, MOL CELL BIOL, V20, P4765, DOI 10.1128/MCB.20.13.4765-4772.2000; Paulsen IT, 1998, FEBS LETT, V430, P116, DOI 10.1016/S0014-5793(98)00629-2; Peng SSY, 1998, EMBO J, V17, P3461, DOI 10.1093/emboj/17.12.3461; Piecyk M, 2000, EMBO J, V19, P4154, DOI 10.1093/emboj/19.15.4154; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; Rodriguez-Pascual F, 2000, J BIOL CHEM, V275, P26040, DOI 10.1074/jbc.M910460199; Sambrook J., 2002, MOL CLONING LAB MANU; Schatz G, 1996, J BIOL CHEM, V271, P31763, DOI 10.1074/jbc.271.50.31763; Sela-Brown A, 2000, J BIOL CHEM, V275, P7424, DOI 10.1074/jbc.275.10.7424; Shyu AB, 2000, CELL, V102, P135, DOI 10.1016/S0092-8674(00)00018-0; Siomi H, 1997, CURR OPIN GENET DEV, V7, P345, DOI 10.1016/S0959-437X(97)80148-7; Siomi MC, 1996, MOL CELL BIOL, V16, P3825; TIAN QS, 1991, CELL, V67, P629, DOI 10.1016/0092-8674(91)90536-8; Tillmar L, 2002, J BIOL CHEM, V277, P1099, DOI 10.1074/jbc.M108340200; Toba G, 2002, J CELL SCI, V115, P2413; VERNET T, 1987, GENE, V52, P225, DOI 10.1016/0378-1119(87)90049-7; Wang WG, 2000, EMBO J, V19, P2340, DOI 10.1093/emboj/19.10.2340; WEISS IM, 1995, MOL CELL BIOL, V15, P2457; Wilhelm JE, 2000, J CELL BIOL, V148, P427, DOI 10.1083/jcb.148.3.427; Yeap BB, 2002, J BIOL CHEM, V277, P27183, DOI 10.1074/jbc.M202883200	70	11	11	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	2004	279	1					453	462		10.1074/jbc.M309278200	http://dx.doi.org/10.1074/jbc.M309278200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	757GU	14570877	hybrid			2022-12-27	WOS:000187555300055
J	Hu, XL; Chen, YX; Farooqui, M; Thomas, MC; Chiang, CM; Wei, LN				Hu, XL; Chen, YX; Farooqui, M; Thomas, MC; Chiang, CM; Wei, LN			Suppressive effect of receptor-interacting protein 140 on coregulator binding to retinoic acid receptor complexes, histone-modifying enzyme activity, and gene activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR RECEPTORS; TRANSCRIPTIONAL ACTIVATION; MOLECULAR INTERACTION; ORDERED RECRUITMENT; ESTROGEN-RECEPTOR; RNA-POLYMERASE; CHROMATIN; RIP140; COACTIVATORS; P/CAF	Gene induction by retinoic acid (RA) is suppressed by overexpression of receptor-interacting protein 140 (RIP140). RIP140-mediated suppression was reversed most effectively by overexpressing the coactivator p300/CREB-binding protein-associated factor (P/CAF). Immunoprecipitation demonstrated coexistence of holoreceptors complexed with RIP140 or P/CAF. Chromatin immunoprecipitation revealed rapid RA-enhanced recruitment of RIP140, but delayed P/CAF recruitment, to an RA-targeted promoter in COS-1 cells supplemented with RIP140. In RA-induced P19 cells, endogenous RIP140 was rapidly (within 4 h) and significantly recruited to both the RARbeta2 and TR2 genes, whereas the peak of endogenous P/CAF recruitment occurred much later (48 h) and to a lesser degree. Consistent with these observations, significant histone acetylation of endogenous RA receptor (RAR) targets was only observed 48 h following RA treatment. In vitro experiments confirmed RA-induced transcription from a chromatin template, which was reduced by adding RIP140. This study presents evidence for coexistence of multiple RAR-coregulator complexes and a preferential RA-induced recruitment of RIP140 to endogenous RAR-targeted promoters after short term RA treatment, which correlates with suppressed induction of RA-regulated gene expression in the presence of RIP140.	Univ Minnesota, Sch Med, Dept Pharmacol, Minneapolis, MN 55455 USA; Case Western Reserve Univ, Dept Biochem, Cleveland, OH 44106 USA	University of Minnesota System; University of Minnesota Twin Cities; Case Western Reserve University	Wei, LN (corresponding author), Univ Minnesota, Sch Med, Dept Pharmacol, 6-120 Jackson Hall,321 Church St SE, Minneapolis, MN 55455 USA.	weixx009@tc.umn.edu		Thomas, Merlin/0000-0003-0694-8743; Farooqui, Mariya/0000-0002-2136-8694	NATIONAL CANCER INSTITUTE [R01CA081017] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060521, R01DK054733] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059643] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [P50DA011806, R01DA011190, K02DA013926] Funding Source: NIH RePORTER; NCI NIH HHS [CA81017] Funding Source: Medline; NIDA NIH HHS [DA11806, K02 DA13926, DA11190] Funding Source: Medline; NIDDK NIH HHS [DK54733, DK60521] Funding Source: Medline; NIGMS NIH HHS [GM59643] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Benkirane M, 1998, J BIOL CHEM, V273, P24898, DOI 10.1074/jbc.273.38.24898; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Chen YX, 2002, MOL ENDOCRINOL, V16, P2528, DOI 10.1210/me.2002-0124; Chuang FM, 1997, MOL ENDOCRINOL, V11, P1332, DOI 10.1210/me.11.9.1332; Collingwood TN, 1999, J MOL ENDOCRINOL, V23, P255, DOI 10.1677/jme.0.0230255; Cosma MP, 1999, CELL, V97, P299, DOI 10.1016/S0092-8674(00)80740-0; Dilworth FJ, 2001, ONCOGENE, V20, P3047, DOI 10.1038/sj.onc.1204329; Farooqui M, 2003, BIOCHEMISTRY-US, V42, P971, DOI 10.1021/bi020497k; Freedman LP, 1999, TRENDS ENDOCRIN MET, V10, P403, DOI 10.1016/S1043-2760(99)00208-8; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Hermanson O, 2002, TRENDS ENDOCRIN MET, V13, P55, DOI 10.1016/S1043-2760(01)00527-6; Hou SY, 2000, MOL CELL BIOL, V20, P113, DOI 10.1128/MCB.20.1.113-125.2000; Itoh S, 2000, NUCLEIC ACIDS RES, V28, P4291, DOI 10.1093/nar/28.21.4291; KAMAKAKA RT, 1993, GENE DEV, V7, P1779, DOI 10.1101/gad.7.9.1779; Kerley JS, 2001, BIOCHEM BIOPH RES CO, V285, P969, DOI 10.1006/bbrc.2001.5274; Kraus WL, 2002, EUR J BIOCHEM, V269, P2275, DOI 10.1046/j.1432-1033.2002.02889.x; Lannoy VJ, 2000, J BIOL CHEM, V275, P22098, DOI 10.1074/jbc.M000855200; Lee CH, 1999, J BIOL CHEM, V274, P31320, DOI 10.1074/jbc.274.44.31320; Lee CH, 1999, BIOCHEMISTRY-US, V38, P8820, DOI 10.1021/bi9903547; Lee CH, 1998, MOL CELL BIOL, V18, P6745, DOI 10.1128/MCB.18.11.6745; LHorset F, 1996, MOL CELL BIOL, V16, P6029; Litt MD, 2001, SCIENCE, V293, P2453, DOI 10.1126/science.1064413; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; Miyata KS, 1998, MOL CELL ENDOCRINOL, V146, P69; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; Owen-Hughes T, 1999, METH MOL B, V119, P319; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Sharma D, 2002, P NATL ACAD SCI USA, V99, P7934, DOI 10.1073/pnas.122004799; Sheppard KA, 1999, MOL CELL BIOL, V19, P6367; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Subramaniam N, 1999, J BIOL CHEM, V274, P18121, DOI 10.1074/jbc.274.25.18121; Turner BM, 2000, BIOESSAYS, V22, P836, DOI 10.1002/1521-1878(200009)22:9<836::AID-BIES9>3.0.CO;2-X; Wei LN, 2001, J BIOL CHEM, V276, P16107, DOI 10.1074/jbc.M010185200; Wei LN, 2000, J BIOL CHEM, V275, P40782, DOI 10.1074/jbc.M004821200; Wu SY, 1999, J BIOL CHEM, V274, P23480, DOI 10.1074/jbc.274.33.23480; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0	39	27	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 2	2004	279	1					319	325		10.1074/jbc.M307621200	http://dx.doi.org/10.1074/jbc.M307621200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	757GU	14581481	hybrid			2022-12-27	WOS:000187555300039
J	Cleland, WW				Cleland, WW			The use of isotope effects to determine enzyme mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P-NITROPHENYL ACETATE; CATALYZED REACTIONS; MALIC ENZYME; CHEMICAL MECHANISM; TRANSITION-STATE; ACYL TRANSFER; ALCOHOL-DEHYDROGENASE; FORMATE DEHYDROGENASE; KINETIC MECHANISM; INITIAL VELOCITY		Univ Wisconsin, Dept Biochem, Inst Enzyme Res, Madison, WI 53726 USA	University of Wisconsin System; University of Wisconsin Madison	Cleland, WW (corresponding author), Univ Wisconsin, Dept Biochem, Inst Enzyme Res, Madison, WI 53726 USA.							AINSLIE GR, 1972, J BIOL CHEM, V247, P946; BALINSKY D, 1971, BIOCHEMISTRY-US, V10, P1947; BLANCHARD JS, 1980, BIOCHEMISTRY-US, V19, P4506, DOI 10.1021/bi00560a019; BLANCHARD JS, 1980, BIOCHEMISTRY-US, V19, P3543, DOI 10.1021/bi00556a020; Cleland W W, 1980, Methods Enzymol, V64, P104; Cleland WW, 1995, FASEB J, V9, P1585, DOI 10.1096/fasebj.9.15.8529838; CLELAND WW, 1982, CRC CR REV BIOCH MOL, V13, P385; CLELAND WW, 1963, BIOCHIM BIOPHYS ACTA, V67, P104, DOI 10.1016/0926-6569(63)90211-6; CLELAND WW, 1963, BIOCHIM BIOPHYS ACTA, V67, P188; CLELAND WW, 1963, BIOCHIM BIOPHYS ACTA, V67, P173, DOI 10.1016/0926-6569(63)90226-8; CLELAND WW, 1977, ISOTOPE EFFECTS ENZY, P280; COOK PF, 1981, BIOCHEMISTRY-US, V20, P1805, DOI 10.1021/bi00510a015; COOK PF, 1981, BIOCHEMISTRY-US, V20, P1797, DOI 10.1021/bi00510a014; COOK PF, 1981, BIOCHEMISTRY-US, V20, P1790, DOI 10.1021/bi00510a013; COOK PF, 1980, BIOCHEMISTRY-US, V19, P4853, DOI 10.1021/bi00562a023; Edens WA, 1997, BIOCHEMISTRY-US, V36, P1141, DOI 10.1021/bi962128s; GARCES E, 1969, BIOCHEMISTRY-US, V8, P633, DOI 10.1021/bi00830a026; GRISSOM CB, 1985, BIOCHEMISTRY-US, V24, P944, DOI 10.1021/bi00325a020; GULBINSKY JS, 1968, BIOCHEMISTRY-US, V7, P566, DOI 10.1021/bi00842a009; HENGGE AC, 1994, J AM CHEM SOC, V116, P11256, DOI 10.1021/ja00104a007; HERMES JD, 1985, BIOCHEMISTRY-US, V24, P2959, DOI 10.1021/bi00333a023; HERMES JD, 1984, J AM CHEM SOC, V106, P7263, DOI 10.1021/ja00335a077; HERMES JD, 1982, BIOCHEMISTRY-US, V21, P5106, DOI 10.1021/bi00263a040; HERMES JD, 1984, BIOCHEMISTRY-US, V23, P6263, DOI 10.1021/bi00320a057; HERMES JD, 1984, BIOCHEMISTRY-US, V23, P5479, DOI 10.1021/bi00318a016; Hess RA, 1998, J AM CHEM SOC, V120, P2703, DOI 10.1021/ja973413h; Lee LV, 2000, BIOCHEMISTRY-US, V39, P4808, DOI 10.1021/bi992894+; MORRISON JF, 1966, J BIOL CHEM, V241, P673; NORTHROP DB, 1975, BIOCHEMISTRY-US, V14, P2644, DOI 10.1021/bi00683a013; OLEARY MH, 1979, J AM CHEM SOC, V101, P3300, DOI 10.1021/ja00506a027; PARMENTIER LE, 1992, BIOCHEMISTRY-US, V31, P6570, DOI 10.1021/bi00143a029; Reinhardt LA, 2003, J AM CHEM SOC, V125, P1244, DOI 10.1021/ja0286977; RENDINA AR, 1984, BIOCHEMISTRY-US, V23, P6257, DOI 10.1021/bi00320a056; Rishavy MA, 2000, BIOCHEMISTRY-US, V39, P7546, DOI 10.1021/bi000458d; SCHIMERLIK MI, 1977, BIOCHEMISTRY-US, V16, P571, DOI 10.1021/bi00623a002; SCHIMERLIK MI, 1975, BIOCHEMISTRY-US, V14, P5347, DOI 10.1021/bi00695a020; SWAIN CG, 1958, J AM CHEM SOC, V80, P5885, DOI 10.1021/ja01554a077; UHR ML, 1974, J BIOL CHEM, V249, P2920; Urbauer JL, 1998, BIOCHEMISTRY-US, V37, P18026, DOI 10.1021/bi981820f; WALDROP GL, 1992, BIOCHEMISTRY-US, V31, P6585, DOI 10.1021/bi00143a031; WEISS PM, 1991, BIOCHEMISTRY-US, V30, P5755, DOI 10.1021/bi00237a018; WEISS PM, 1987, BIOCHEMISTRY-US, V26, P7378, DOI 10.1021/bi00397a027	42	41	41	1	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					51975	51984		10.1074/jbc.X300005200	http://dx.doi.org/10.1074/jbc.X300005200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14583616	hybrid			2022-12-27	WOS:000187480700002
J	D'Addario, M; Arora, PD; Ellen, RP; McCulloch, CAG				D'Addario, M; Arora, PD; Ellen, RP; McCulloch, CAG			Regulation of tension-induced mechanotranscriptional signals by the microtubule network in fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE ACTIN; MECHANICAL FORCES; FOCAL ADHESIONS; TRANSCRIPTION FACTOR; CARDIAC FIBROBLASTS; GENE-EXPRESSION; PROTEIN-KINASE; FILAMIN-A; CYTOSKELETON; TRANSDUCTION	Mechanical loading of connective tissues induces the expression of extracellular matrix and cytoskeletal genes that are involved in matrix remodeling. These processes depend in part on force transmission through beta(1) integrins and actin filaments, but the role of microtubules in regulating mechanotranscriptional responses is not well defined. We assessed the involvement of microtubules in the mechanotranscriptional regulation of filamin A, an actin-cross-linking protein that protects cells against force-induced apoptosis by stabilizing cell membranes. Collagen-coated magnetite beads and magnetic fields were used to apply tensile forces to cultured fibroblasts at focal adhesions. Force enhanced recruitment of alpha-tubulin and the plus end microtubule-binding protein cytoplasmic linker protein-170 (CLIP-170) at focal adhesions. Immunoprecipitation studies demonstrated no direct binding of tubulin to actin or filamin A, but CLIP-170 interacted with tubulin, filamin A, and beta-actin. The association of CLIP-170 with beta-actin was enhanced by force. Force activated the p38 mitogen-activated protein kinase, increased filamin A expression, and induced the relocation of p38 and filamin A to focal adhesions. Disruption of microtubules with nocodazole, independent of force application, enhanced filamin A expression and Sp1-mediated filamin A promoter activity, while stabilization of microtubules with Taxol inhibited force induction of both filamin A mRNA and protein. We conclude that in response to tensile forces applied through beta(1) integrins and actin the microtubule network modulates mechanotranscriptional coupling of filamin A.	Univ Toronto, Fac Dent, Inst Dent Res, Canadian Inst Hlth Res Grp Matrix Dynam, Toronto, ON M5S 3E2, Canada	University of Toronto	McCulloch, CAG (corresponding author), Univ Toronto, Fac Dent, Inst Dent Res, Canadian Inst Hlth Res Grp Matrix Dynam, Rm 244,Fitzgerald Bldg,150 Coll St, Toronto, ON M5S 3E2, Canada.							Akhmanova A, 2001, CELL, V104, P923, DOI 10.1016/S0092-8674(01)00288-4; Arora PD, 1996, J BIOL CHEM, V271, P20516, DOI 10.1074/jbc.271.34.20516; Bershadsky A, 1996, CURR BIOL, V6, P1279, DOI 10.1016/S0960-9822(02)70714-8; Brivanlou AH, 2002, SCIENCE, V295, P813, DOI 10.1126/science.1066355; Chien S, 1998, HYPERTENSION, V31, P162, DOI 10.1161/01.HYP.31.1.162; Critchley DR, 2000, CURR OPIN CELL BIOL, V12, P133, DOI 10.1016/S0955-0674(99)00067-8; D'Addario M, 1999, FASEB J, V13, P2203, DOI 10.1096/fasebj.13.15.2203; D'Addario M, 2001, J BIOL CHEM, V276, P31969, DOI 10.1074/jbc.M102715200; D'Addario M, 2002, J BIOL CHEM, V277, P47541, DOI 10.1074/jbc.M207681200; DANOWSKI BA, 1989, J CELL SCI, V93, P255; FOJAS DB, 2001, EMBO J, V20, P5737; Glogauer M, 1997, J CELL SCI, V110, P11; GOELZ SE, 1985, BIOCHEM BIOPH RES CO, V130, P118, DOI 10.1016/0006-291X(85)90390-0; Goode BL, 2000, CURR OPIN CELL BIOL, V12, P63, DOI 10.1016/S0955-0674(99)00058-7; Gundersen GG, 2002, CURR BIOL, V12, pR645, DOI 10.1016/S0960-9822(02)01156-9; Hui MZ, 1997, J CELL PHYSIOL, V172, P323, DOI 10.1002/(SICI)1097-4652(199709)172:3<323::AID-JCP6>3.0.CO;2-Q; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; Kainulainen T, 2002, J BIOL CHEM, V277, P21998, DOI 10.1074/jbc.M200715200; KAPELLER R, 1995, J BIOL CHEM, V270, P25985, DOI 10.1074/jbc.270.43.25985; KAPELLER R, 1993, MOL CELL BIOL, V13, P6052, DOI 10.1128/MCB.13.10.6052; Kaverina I, 1998, J CELL BIOL, V142, P181, DOI 10.1083/jcb.142.1.181; Kaverina I, 1999, J CELL BIOL, V146, P1033, DOI 10.1083/jcb.146.5.1033; Kaverina I, 2002, J CELL SCI, V115, P2283; Komarova YA, 2002, J CELL SCI, V115, P3527; Krendel M, 2002, NAT CELL BIOL, V4, P294, DOI 10.1038/ncb773; Krylyshkina O, 2003, J CELL BIOL, V161, P853, DOI 10.1083/jcb.200301102; Ma W, 2001, J BIOL CHEM, V276, P13664, DOI 10.1074/jbc.M011157200; PENDER N, 1991, J CELL SCI, V100, P187; Perez F, 1999, CELL, V96, P517, DOI 10.1016/S0092-8674(00)80656-X; PLOPPER G, 1993, BIOCHEM BIOPH RES CO, V193, P571, DOI 10.1006/bbrc.1993.1662; PRESTRIDGE DS, 1995, J MOL BIOL, V249, P923, DOI 10.1006/jmbi.1995.0349; RESZKA AA, 1995, P NATL ACAD SCI USA, V92, P8881, DOI 10.1073/pnas.92.19.8881; Rodriguez OC, 2003, NAT CELL BIOL, V5, P599, DOI 10.1038/ncb0703-599; Shyy JYJ, 1997, CURR OPIN CELL BIOL, V9, P707, DOI 10.1016/S0955-0674(97)80125-1; Sider JR, 1999, J CELL SCI, V112, P1947; Stossel TP, 2001, NAT REV MOL CELL BIO, V2, P138, DOI 10.1038/35052082; Thompson C, 1996, J CELL SCI, V109, P2843; Tidball JG, 1999, J BIOL CHEM, V274, P33155, DOI 10.1074/jbc.274.46.33155; Wang J, 2001, TISSUE CELL, V33, P86, DOI 10.1054/tice.2000.0160; Wang J, 2000, AM J PHYSIOL-HEART C, V279, pH2776, DOI 10.1152/ajpheart.2000.279.6.H2776; Wang JX, 2002, J BIOL CHEM, V277, P22889, DOI 10.1074/jbc.M203130200; WATSON PA, 1991, FASEB J, V5, P2013, DOI 10.1096/fasebj.5.7.1707019; Wittmann T, 2003, J CELL BIOL, V161, P845, DOI 10.1083/jcb.200303082	43	30	32	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					53090	53097		10.1074/jbc.M309027200	http://dx.doi.org/10.1074/jbc.M309027200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14561736	hybrid			2022-12-27	WOS:000187480700133
J	Astrinidis, A; Senapedis, W; Coleman, TR; Henske, EP				Astrinidis, A; Senapedis, W; Coleman, TR; Henske, EP			Cell cycle-regulated phosphorylation of hamartin, the product of the tuberous sclerosis complex 1 gene, by cyclin-dependent kinase 1 cyclin B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR GENE; P70 S6 KINASE; TSC1 GENE; GROWTH; IDENTIFICATION; RHEB; ACTIVATION; TARGET; MTOR; MUTATIONS	Tuberous sclerosis complex is a tumor suppressor gene syndrome whose manifestations can include seizures, mental retardation, and benign tumors of the brain, skin, heart, and kidneys. Hamartin and tuberin, the products of the TSC1 and TSC2 genes, respectively, form a complex and inhibit signaling by the mammalian target of rapamycin. Here, we demonstrate that endogenous hamartin is threonine-phosphorylated during nocodazole-induced G(2)/M arrest and during the G(2)/M phase of a normal cell cycle. In vitro assays showed that cyclin-dependent kinase 1 phosphorylates hamartin at three sites, one of which (Thr(417)) is in the hamartin-tuberin interaction domain. Tuberin interacts with phosphohamartin, and tuberin expression attenuates the phosphorylation of exogenous hamartin. Hamartin with alanine mutations in the three cyclin-dependent kinase 1 phosphorylation sites increased the inhibition of p70S6 kinase by the hamartin-tuberin complex. These findings support a model in which phosphorylation of hamartin regulates the function of the hamartin-tuberin complex during the G(2)/M phase of the cell cycle.	Fox Chase Canc Ctr, Philadelphia, PA 19111 USA	Fox Chase Cancer Center	Henske, EP (corresponding author), Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA.	EP_Henske@fccc.edu	Astrinidis, Aristotelis/A-1396-2010; Astreinidis, Aristotelis/ABA-6715-2021; Astreinidis, Aristotelis/AAK-5137-2020	Astrinidis, Aristotelis/0000-0001-7098-1391	NIDDK NIH HHS [DK51052] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051052, R29DK051052] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Astrinidis A, 2002, ONCOGENE, V21, P8470, DOI 10.1038/sj.onc.1205962; Catania MG, 2001, J NEUROPATH EXP NEUR, V60, P711, DOI 10.1093/jnen/60.7.711; Dan HC, 2002, J BIOL CHEM, V277, P35364, DOI 10.1074/jbc.M205838200; Fingar DC, 2002, GENE DEV, V16, P1472, DOI 10.1101/gad.995802; Gao XS, 2002, NAT CELL BIOL, V4, P699, DOI 10.1038/ncb847; Garami A, 2003, MOL CELL, V11, P1457, DOI 10.1016/S1097-2765(03)00220-X; Goncharova EA, 2002, J BIOL CHEM, V277, P30958, DOI 10.1074/jbc.M202678200; Henry KW, 1998, J BIOL CHEM, V273, P20535, DOI 10.1074/jbc.273.32.20535; Hodges AK, 2001, HUM MOL GENET, V10, P2899, DOI 10.1093/hmg/10.25.2899; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Ito N, 1999, CELL, V96, P529, DOI 10.1016/S0092-8674(00)80657-1; Jaeschke A, 2002, J CELL BIOL, V159, P217, DOI 10.1083/jcb.jcb.200206108; Karbowniczek M, 2003, AM J PATHOL, V162, P491, DOI 10.1016/S0002-9440(10)63843-6; Kenerson HL, 2002, CANCER RES, V62, P5645; Khare L, 2002, J MED GENET, V39, P676, DOI 10.1136/jmg.39.9.676; KUMAGAI A, 1995, MOL BIOL CELL, V6, P199, DOI 10.1091/mbc.6.2.199; Kwiatkowski DJ, 2002, HUM MOL GENET, V11, P525, DOI 10.1093/hmg/11.5.525; Lamb RF, 2000, NAT CELL BIOL, V2, P281, DOI 10.1038/35010550; Li Y, 2003, J BIOL CHEM, V278, P13663, DOI 10.1074/jbc.M300862200; Liu MY, 2002, CANCER RES, V62, P6475; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; Marygold SJ, 2002, CURR BIOL, V12, pR785, DOI 10.1016/S0960-9822(02)01294-0; McManus EJ, 2002, NAT CELL BIOL, V4, pE214, DOI 10.1038/ncb0902-e214; Miloloza A, 2000, HUM MOL GENET, V9, P1721, DOI 10.1093/hmg/9.12.1721; Nellist M, 2002, J BIOL CHEM, V277, P39417, DOI 10.1074/jbc.M204802200; Nellist M, 2001, HUM MOL GENET, V10, P2889, DOI 10.1093/hmg/10.25.2889; NELLIST M, 1993, CELL, V75, P1305; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Ohi R, 1999, CURR OPIN CELL BIOL, V11, P267, DOI 10.1016/S0955-0674(99)80036-2; Papst PJ, 1998, J BIOL CHEM, V273, P15077, DOI 10.1074/jbc.273.24.15077; Plank TL, 1998, CANCER RES, V58, P4766; Potter CJ, 2001, CELL, V105, P357, DOI 10.1016/S0092-8674(01)00333-6; Radimerski T, 2002, GENE DEV, V16, P2627, DOI 10.1101/gad.239102; Saucedo LJ, 2003, NAT CELL BIOL, V5, P566, DOI 10.1038/ncb996; Shah OJ, 2003, J BIOL CHEM, V278, P16433, DOI 10.1074/jbc.M300435200; Shumway SD, 2003, J BIOL CHEM, V278, P2089, DOI 10.1074/jbc.C200499200; Soucek T, 1997, J BIOL CHEM, V272, P29301, DOI 10.1074/jbc.272.46.29301; Stocker H, 2003, NAT CELL BIOL, V5, P559, DOI 10.1038/ncb995; Tapon N, 2001, CELL, V105, P345, DOI 10.1016/S0092-8674(01)00332-4; van Slegtenhorst M, 1998, HUM MOL GENET, V7, P1053, DOI 10.1093/hmg/7.6.1053; vanSlegtenhorst M, 1997, SCIENCE, V277, P805, DOI 10.1126/science.277.5327.805; WIENECKE R, 1995, J BIOL CHEM, V270, P16409, DOI 10.1074/jbc.270.27.16409; Xiao GH, 1997, J BIOL CHEM, V272, P6097, DOI 10.1074/jbc.272.10.6097; Zhang Y, 2003, NAT CELL BIOL, V5, P578, DOI 10.1038/ncb999; ZHOU SY, 1994, CURR BIOL, V4, P973, DOI 10.1016/S0960-9822(00)00221-9	45	64	66	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51372	51379		10.1074/jbc.M303956200	http://dx.doi.org/10.1074/jbc.M303956200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14551205	hybrid			2022-12-27	WOS:000187206300065
J	Davie, EW				Davie, EW			JBC Centennial 1905-2005 - 100 years of biochemistry and molecular biology - A brief historical review of the waterfall/cascade of blood coagulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							PLASMA THROMBOPLASTIN ANTECEDENT; THROMBIN-CATALYZED ACTIVATION; GAMMA-CARBOXYGLUTAMIC ACID; RECOMBINANT FACTOR VIIA; ENDOTHELIAL-CELL COFACTOR; TISSUE FACTOR; VITAMIN-K; HAGEMAN FACTOR; PROTEIN-C; FACTOR-IX		Univ Washington, Dept Biochem, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Davie, EW (corresponding author), Univ Washington, Dept Biochem, Seattle, WA 98195 USA.	ewd@u.washington.edu						AGGELER PM, 1952, P SOC EXP BIOL MED, V79, P692; AHMED SS, 2002, J THROMB HAEMOST, V1, P48; Aldouri M, 2002, PATHOPHYSIOL HAEMO T, V32, P41, DOI 10.1159/000057301; ALEXANDER B, 1951, J CLIN INVEST, V30, P596, DOI 10.1172/JCI102477; BACH R, 1986, BIOCHEMISTRY-US, V25, P4007, DOI 10.1021/bi00362a005; BACH R, 1981, J BIOL CHEM, V256, P8324; Banner DW, 1996, NATURE, V380, P41, DOI 10.1038/380041a0; Baugh RJ, 1998, J BIOL CHEM, V273, P4378, DOI 10.1074/jbc.273.8.4378; BERG P, 1955, J AM CHEM SOC, V77, P3163, DOI 10.1021/ja01616a090; BERGSAGEL DE, 1956, BRIT J HAEMATOL, V2, P113, DOI 10.1111/j.1365-2141.1956.tb06820.x; BIGGS R, 1952, BMJ-BRIT MED J, V2, P113; Bode W, 1997, THROMB HAEMOSTASIS, V78, P501; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; BROZE GJ, 1982, J CLIN INVEST, V70, P526, DOI 10.1172/JCI110644; BROZE GJ, 1985, J BIOL CHEM, V260, P917; BROZE GJ, 1990, BIOCHEMISTRY-US, V29, P7539, DOI 10.1021/bi00485a001; Chargaff E, 1944, J BIOL CHEM, V156, P161; CHEN R, 1971, BIOCHEMISTRY-US, V10, P4486, DOI 10.1021/bi00800a021; Collen D, 1999, THROMB HAEMOSTASIS, V82, P259; COLMAN RW, 1975, J CLIN INVEST, V56, P1650, DOI 10.1172/JCI108247; Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229; CUNNINGHAM LW, 1953, DISCUSS FARADAY SOC, P58; DALBEY RE, 1992, TRENDS BIOCHEM SCI, V17, P474, DOI 10.1016/0968-0004(92)90492-R; Dam H, 1935, NATURE, V135, P652, DOI 10.1038/135652b0; Danilos J, 2003, OBSTET GYNECOL, V101, P1172, DOI 10.1016/S0029-7844(03)00349-1; DAVIE EW, 1956, ARCH BIOCHEM BIOPHYS, V65, P21, DOI 10.1016/0003-9861(56)90173-4; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; DAVIE EW, 1964, SCIENCE, V145, P1310, DOI 10.1126/science.145.3638.1310; DAVIE EW, 1955, J BIOL CHEM, V212, P515; DEMOSS JA, 1956, P NATL ACAD SCI USA, V42, P325, DOI 10.1073/pnas.42.6.325; DISCIPIO RG, 1979, BIOCHEMISTRY-US, V18, P899, DOI 10.1021/bi00572a026; DISCIPIO RG, 1977, BIOCHEMISTRY-US, V16, P4189; Doolittle RF, 2003, J THROMB HAEMOST, V1, P1559, DOI 10.1046/j.1538-7836.2003.00278.x; EATON D, 1986, BIOCHEMISTRY-US, V25, P505, DOI 10.1021/bi00350a035; ESMON CT, 1981, P NATL ACAD SCI-BIOL, V78, P2249, DOI 10.1073/pnas.78.4.2249; FAIR DS, 1987, J BIOL CHEM, V262, P11692; FUJIKAWA K, 1974, BIOCHEMISTRY-US, V13, P5290, DOI 10.1021/bi00723a006; Furie B, 1999, BLOOD, V93, P1798, DOI 10.1182/blood.V93.6.1798.406k22_1798_1808; GAILANI D, 1991, SCIENCE, V253, P909, DOI 10.1126/science.1652157; Giannelli F, 1998, NUCLEIC ACIDS RES, V26, P265, DOI 10.1093/nar/26.1.265; Graham JB, 2003, J THROMB HAEMOST, V1, P871, DOI 10.1046/j.1538-7836.2003.00259.x; HAGEN FS, 1986, P NATL ACAD SCI USA, V83, P2412, DOI 10.1073/pnas.83.8.2412; HARDISTY RM, 1959, BRIT J HAEMATOL, V5, P203, DOI 10.1111/j.1365-2141.1959.tb04026.x; Harpel P C, 1976, Prog Hemost Thromb, V3, P145; Harrison S, 1998, SEMIN HEMATOL, V35, P4; HATHAWAY WE, 1965, BLOOD-J HEMATOL, V26, P521, DOI 10.1182/blood.V26.5.521.521; HEDNER U, 1983, J CLIN INVEST, V71, P1836, DOI 10.1172/JCI110939; HILZ H, 1955, P NATL ACAD SCI USA, V41, P880, DOI 10.1073/pnas.41.11.880; HOAGLAND MB, 1956, J BIOL CHEM, V218, P345; HOUGIE C, 1967, THROMB DIATH HAEMOST, V18, P211, DOI 10.1055/s-0038-1655030; HOUGIE C, 1957, J CLIN INVEST, V36, P485, DOI 10.1172/JCI103446; Howell WH, 1912, AM J PHYSIOL, V31, P1; ICHINOSE A, 1954, HEMOSTASIS HTROMBOSI; JONES ME, 1955, J AM CHEM SOC, V77, P819, DOI 10.1021/ja01608a101; Jurlander B, 2001, SEMIN THROMB HEMOST, V27, P373, DOI 10.1055/s-2001-16890; Kennedy EP, 2001, J BIOL CHEM, V276, P42619, DOI 10.1074/jbc.R100051200; KINGDON HS, 1964, BIOCHEMISTRY-US, V3, P166, DOI 10.1021/bi00890a005; KINGDON HS, 1958, P NATL ACAD SCI USA, V44, P757, DOI 10.1073/pnas.44.8.757; Kirkitadze MD, 2001, IMMUNOL REV, V180, P146, DOI 10.1034/j.1600-065X.2001.1800113.x; KISIEL W, 1977, BIOCHEMISTRY-US, V16, P5824, DOI 10.1021/bi00645a029; KISIEL W, 1976, BIOCHEMISTRY-US, V15, P4901, DOI 10.1021/bi00667a023; KURACHI K, 1976, BIOCHEMISTRY-US, V15, P373, DOI 10.1021/bi00647a021; LAKI K, 1948, SCIENCE, V108, P280, DOI 10.1126/science.108.2802.280; LUNDBLAD RL, 1964, BIOCHEMISTRY-US, V3, P1720, DOI 10.1021/bi00899a022; Lusher J, 1998, BLOOD COAGUL FIBRIN, V9, P119, DOI 10.1097/00001721-199803000-00002; MACFARLANE RG, 1964, NATURE, V202, P498, DOI 10.1038/202498a0; Madrazo J, 2001, P NATL ACAD SCI USA, V98, P11967, DOI 10.1073/pnas.211439798; MAGNUSSO.S, 1974, FEBS LETT, V44, P189, DOI 10.1016/0014-5793(74)80723-4; MARLAR RA, 1982, BLOOD, V60, P1353; Massie RK., 2011, NICHOLAS ALEXANDRA, P1967; MORAWITZ P, 1958, CHEM BLOOD COAGULATI, P1; Mosesson MW, 2001, ANN NY ACAD SCI, V936, P11; NAITO K, 1991, J BIOL CHEM, V266, P7353; NELSESTUEN GL, 1974, J BIOL CHEM, V249, P6347; Nelsestuen GL, 2000, VITAM HORM, V58, P355, DOI 10.1016/S0083-6729(00)58031-5; NEMERSON Y, 1995, THROMB HAEMOSTASIS, V74, P180; NEMERSON Y, 1970, BIOCHEMISTRY-US, V9, P5100, DOI 10.1021/bi00828a009; NEMERSON Y, 1988, BLOOD, V71, P1; NESHEIM ME, 1979, J BIOL CHEM, V254, P1326; OSTERUD B, 1977, P NATL ACAD SCI USA, V74, P5260, DOI 10.1073/pnas.74.12.5260; OSTERUD B, 1972, BIOCHEMISTRY-US, V11, P2853; OSTERUD B, 1970, BIOCHEMISTRY-US, V9, P1854; OWEN WG, 1981, J BIOL CHEM, V256, P5532; Owren PA, 1947, ACTA MED SCAND, V194, P521; Park P, 2003, NEUROSURGERY, V53, P34, DOI 10.1227/01.NEU.0000068830.54968.A8; Patek AJ, 1936, J CLIN INVEST, V15, P531, DOI 10.1172/JCI100806; Patek AJ, 1937, J CLIN INVEST, V16, P113, DOI 10.1172/JCI100829; PETERSON EA, 1956, J AM CHEM SOC, V78, P751, DOI 10.1021/ja01585a016; Pike ACW, 1999, P NATL ACAD SCI USA, V96, P8925, DOI 10.1073/pnas.96.16.8925; RAPAPORT SI, 1963, BLOOD, V21, P221, DOI 10.1182/blood.V21.2.221.221; RATNOFF OD, 1962, BIOCHEMISTRY-US, V1, P967, DOI 10.1021/bi00912a005; RATNOFF OD, 1955, J CLIN INVEST, V34, P602, DOI 10.1172/JCI103109; RATNOFF OD, 1962, BIOCHEMISTRY-US, V1, P677, DOI 10.1021/bi00910a022; RATNOFF OD, 1958, AM J MED, V25, P160, DOI 10.1016/0002-9343(58)90023-8; RATNOFF OD, 1961, J CLIN INVEST, V40, P803, DOI 10.1172/JCI104314; Robbins KC, 1944, AM J PHYSIOL, V142, P0581, DOI 10.1152/ajplegacy.1944.142.4.581; ROBBINS PW, 1957, J BIOL CHEM, V229, P837; Roberts HR, 1998, HAEMOPHILIA, V4, P331, DOI 10.1046/j.1365-2516.1998.440331.x; Roberts HR, 2003, BRIT J HAEMATOL, V122, P180, DOI 10.1046/j.1365-2141.2003.04459.x; ROSENBERG RD, 1984, J CLIN INVEST, V74, P1, DOI 10.1172/JCI111389; ROSENBERG RD, 1979, CHEM PHYSL HUMAN PLA, P353; ROSENTHAL RL, 1953, P SOC EXP BIOL MED, V82, P171; ROVERY M, 1952, BIOCHIM BIOPHYS ACTA, V9, P702, DOI 10.1016/0006-3002(52)90234-5; SAITO H, 1975, J CLIN INVEST, V55, P1082, DOI 10.1172/JCI108009; SAKAI T, 1989, J BIOL CHEM, V264, P9980; SANDERS NL, 1985, BLOOD, V66, P204; SANGER F, 1988, ANNU REV BIOCHEM, V57, P1, DOI 10.1146/annurev.bi.57.070188.000245; SCHIFFMAN S, 1977, BLOOD, V49, P935; SCHULMAN I, 1952, BLOOD, V7, P794, DOI 10.1182/blood.V7.8.794.794; SEEGERS WH, 1955, AM J CLIN PATHOL, V25, P983; Selkoe D, 2003, ANNU REV NEUROSCI, V26, P565, DOI 10.1146/annurev.neuro.26.041002.131334; SOULIER JP, 1958, REV FR ETUD CLIN BIO, V3, P263; Steiner DF, 1998, CURR OPIN CHEM BIOL, V2, P31, DOI 10.1016/S1367-5931(98)80033-1; STENFLO J, 1974, P NATL ACAD SCI USA, V71, P2730, DOI 10.1073/pnas.71.7.2730; STENFLO J, 1974, J BIOL CHEM, V249, P5527; Stroud RM, 1999, CURR OPIN STRUC BIOL, V9, P754, DOI 10.1016/S0959-440X(99)00040-8; Sunnerhagen M, 1996, HAEMOSTASIS, V26, P45; Tobias Joseph D, 2003, Pediatr Crit Care Med, V4, P49, DOI 10.1097/00130478-200301000-00009; VALLEE BL, 1995, NEUROCHEM INT, V27, P23, DOI 10.1016/0197-0186(94)00165-Q; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; VALLEE BL, 1992, FARADAY DISCUSS, V93, P47, DOI 10.1039/fd9929300047; VEHAR GA, 1987, ANN NY ACAD SCI, V509, P82, DOI 10.1111/j.1749-6632.1987.tb30986.x; VEHAR GA, 1980, BIOCHEMISTRY-US, V19, P401, DOI 10.1021/bi00544a001; WALKER FJ, 1980, J BIOL CHEM, V255, P5521; WEBSTER LT, 1960, J BIOL CHEM, V236, P91; WEBSTER ME, 1976, KININS PHARMACODYNAM, P285; Wilkinson KD, 2000, SEMIN CELL DEV BIOL, V11, P141, DOI 10.1006/scdb.2000.0164; WILLIAMS WJ, 1966, J BIOL CHEM, V241, P1847; WOOD H. G., 1941, JOUR BIOL CHEM, V139, P377; WOOD HG, 1985, ANNU REV BIOCHEM, V54, P1; Wood HG, 1936, BIOCHEM J, V30, P48, DOI 10.1042/bj0300048; WUEPPER KD, 1973, J EXP MED, V138, P1345, DOI 10.1084/jem.138.6.1345	133	90	105	2	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					50819	50832		10.1074/jbc.X300009200	http://dx.doi.org/10.1074/jbc.X300009200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14570883	hybrid			2022-12-27	WOS:000187206300001
J	Spahr, H; Khorosjutina, O; Baraznenok, V; Linder, T; Samuelsen, CO; Hermand, D; Makela, TP; Holmberg, S; Gustafsson, CM				Spahr, H; Khorosjutina, O; Baraznenok, V; Linder, T; Samuelsen, CO; Hermand, D; Makela, TP; Holmberg, S; Gustafsson, CM			Mediator influences Schizosaccharomyces pombe RNA polymerase II-dependent transcription in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CDK-ACTIVATING KINASE; SACCHAROMYCES-CEREVISIAE; FACTOR TFIIH; STATIONARY-PHASE; FISSION YEAST; SUBUNITS; COMPLEX; PURIFICATION; HOLOENZYME; PROTEINS	The fission yeast Schizosaccharomyces pombe has proved an important model system for cross-species comparative studies of many fundamental processes in the eukaryotic cell, such as cell cycle control and DNA replication. The RNA polymerase II transcription machinery is, however, still relatively poorly understood in S. pombe, partially due to the absence of a reconstituted in vitro transcription system. We have now purified S. pombe RNA polymerase II and its general initiation factors TFIIB, TFIIF, TFIIE, and TFIIH to near homogeneity. These factors enable RNA polymerase II to initiate transcription from the S. pombe alcohol dehydrogenase promoter (adh1p) when combined with Saccharomyces cerevisiae TATA-binding protein. We use our reconstituted system to examine effects of Mediator on basal transcription in vitro. S. pombe Mediator exists in two distinct forms, a free form, which contains the spSrb8, spTrap240, spSrb10, and spSrb11 subunits, and a smaller form, which lacks these four subunits and associates with RNA polymerase II to form a holoenzyme. We find that spSrb8/spTrap240/spSrb10/spSrb11 containing Mediator repress basal transcription, whereas Mediator lacking these subunits has a stimulatory effect on transcription. Our findings thus demonstrate that the spSrb8/spTrap240/spSrb10/spSrb11 sub-complex governs the ability of Mediator to stimulate or repress basal transcription in vitro.	Karolinska Inst, Novum, Dept Med Nutr, SE-14186 Huddinge, Sweden; Inst Mol Biol, Dept Genet, DK-1353 Copenhagen K, Denmark; Fac Univ Notre Dame Paix, Lab Genet Mol GEMO, B-5000 Namur, Belgium; Univ Helsinki, Haartman Inst, FIN-00014 Helsinki, Finland; Univ Helsinki, Bioctr Helsinki, FIN-00014 Helsinki, Finland	Karolinska Institutet; University of Namur; University of Helsinki; University of Helsinki	Gustafsson, CM (corresponding author), Karolinska Inst, Novum, Dept Med Nutr, SE-14186 Huddinge, Sweden.		Holmberg, Steen/N-1128-2014; makela, tomi/B-3734-2009; Linder, Tomas/B-2492-2009; Linder, Tomas/AAN-3433-2020	Holmberg, Steen/0000-0002-0262-3207; makela, tomi/0000-0002-4869-8044; Linder, Tomas/0000-0001-5365-0494; Linder, Tomas/0000-0001-5365-0494; Gustafsson, Claes/0000-0003-3531-8468				Alfa C., 1993, EXPT FISSION YEAST; Borggrefe T, 2002, J BIOL CHEM, V277, P44202, DOI 10.1074/jbc.M207195200; BURATOWSKI S, 1988, NATURE, V334, P37, DOI 10.1038/334037a0; Cairns BR, 1996, MOL CELL BIOL, V16, P3308; Chang YW, 2001, GENETICS, V157, P17; Cramer Patrick, 2001, Science (Washington D C), V292, P1863, DOI 10.1126/science.1059493; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; FLANAGAN PM, 1992, P NATL ACAD SCI USA, V89, P7659, DOI 10.1073/pnas.89.16.7659; GOODRICH JA, 1994, CELL, V77, P145, DOI 10.1016/0092-8674(94)90242-9; Hengartner CJ, 1998, MOL CELL, V2, P43, DOI 10.1016/S1097-2765(00)80112-4; HENRY NL, 1994, GENE DEV, V8, P2868, DOI 10.1101/gad.8.23.2868; Herman PK, 2002, CURR OPIN MICROBIOL, V5, P602, DOI 10.1016/S1369-5274(02)00377-6; Hermand D, 2001, EMBO J, V20, P82, DOI 10.1093/emboj/20.1.82; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; Kimura M, 1997, J BIOL CHEM, V272, P25851, DOI 10.1074/jbc.272.41.25851; Kotova I, 2001, EUR J BIOCHEM, V268, P4527, DOI 10.1046/j.1432-1327.2001.02378.x; LIAO SM, 1995, NATURE, V374, P193, DOI 10.1038/374193a0; Mittler G, 2001, EMBO REP, V2, P808, DOI 10.1093/embo-reports/kve186; MURRAY JM, 1992, NUCLEIC ACIDS RES, V20, P2673, DOI 10.1093/nar/20.11.2673; PARVIN JD, 1993, CELL, V73, P533, DOI 10.1016/0092-8674(93)90140-L; Sakurai H, 1999, MOL CELL BIOL, V19, P7511; Samuelsen CO, 2003, P NATL ACAD SCI USA, V100, P6422, DOI 10.1073/pnas.1030497100; SAYRE MH, 1992, J BIOL CHEM, V267, P23383; SERIZAWA H, 1995, NATURE, V374, P280, DOI 10.1038/374280a0; SHIEKHATTAR R, 1995, NATURE, V374, P283, DOI 10.1038/374283a0; Shpakovski GV, 2000, J MOL BIOL, V295, P1119, DOI 10.1006/jmbi.1999.3399; Spahr H, 2000, J BIOL CHEM, V275, P1351, DOI 10.1074/jbc.275.2.1351; Spahr H, 2001, P NATL ACAD SCI USA, V98, P11985, DOI 10.1073/pnas.211253898; Svejstrup JQ, 1996, TRENDS BIOCHEM SCI, V21, P346, DOI 10.1016/0968-0004(96)10046-3; Tasto JJ, 2001, YEAST, V18, P657, DOI 10.1002/yea.713; THOMPSON CM, 1995, P NATL ACAD SCI USA, V92, P4587, DOI 10.1073/pnas.92.10.4587; Woychik NA, 2002, CELL, V108, P453, DOI 10.1016/S0092-8674(02)00646-3	33	32	35	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51301	51306		10.1074/jbc.M306750200	http://dx.doi.org/10.1074/jbc.M306750200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14534314	hybrid			2022-12-27	WOS:000187206300057
J	Faisal, A; Kleiner, S; Nagamine, Y				Faisal, A; Kleiner, S; Nagamine, Y			Non-redundant role of Shc in Erk activation by cytoskeletal reorganization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; ADAPTER PROTEIN SHC; GENE-EXPRESSION; SIGNALING PATHWAY; TYROSINE KINASES; GRB2 BINDING; RAS PATHWAY; N-SHC; SRC; RECEPTOR	We have shown previously that cytoskeletal reorganization (CSR) induced by pharmacological reagents such as colchicine or cytochalasins can up-regulate the urokinase-type plasminogen activator (uPA) gene via the Ras/Erk signaling pathway. In this present study using the small interfering RNA technique, we have found that ShcA adapter proteins play a rather active role in CSR-induced Erk activation, contrary to their mostly redundant role in other signaling pathways, e.g. growth factor-induced Erk activation, where Grb2 can bind directly to the receptor tyrosine kinase and activate Erk in the absence of ShcA. ShcA knockdown abolished CSR-induced activation of both Erk and the uPA promoter. Expression of small interfering RNA-escaping silent mutants of p52 or p46 but not p66 ShcA isoform efficiently rescued CSR-induced Erk activation. Moreover, we have shown that phosphorylation of either Tyr-239/Tyr-240 or Tyr-313 in p52(ShcA) can mediate CSR-induced Erk activation equally well. In a quest for molecules upstream of ShcA in this signaling, we found that CSR-induced ShcA tyrosine phosphorylation, its association with Grb2, Erk activation, and uPA gene expression were all dependent on Rho kinase, p38 mitogen-activated protein kinase, and Src. In summary, we have found a novel, non-redundant role for ShcA in contrast to its redundant role in many other signaling pathways.	Friedrich Miescher Inst Biomed Res, CH-4058 Basel, Switzerland	Friedrich Miescher Institute for Biomedical Research	Nagamine, Y (corresponding author), Friedrich Miescher Inst Biomed Res, Maulbeerstr 66, CH-4058 Basel, Switzerland.	nagamine@fmi.ch	Faisal, Amir/AAE-8992-2020	Faisal, Amir/0000-0002-7376-8286				AGGELER J, 1984, J CELL BIOL, V98, P1662, DOI 10.1083/jcb.98.5.1662; ARVIDSSON AK, 1994, MOL CELL BIOL, V14, P6715, DOI 10.1128/MCB.14.10.6715; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; Besser D, 1995, ONCOGENE, V11, P2383; Blake RA, 2000, MOL CELL BIOL, V20, P9018, DOI 10.1128/MCB.20.23.9018-9027.2000; Bonfini L, 1996, TRENDS BIOCHEM SCI, V21, P257, DOI 10.1016/S0968-0004(96)10033-5; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; Dankort D, 2001, J BIOL CHEM, V276, P38921, DOI 10.1074/jbc.M106239200; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Faisal A, 2002, J BIOL CHEM, V277, P30144, DOI 10.1074/jbc.M203229200; Fuchs E, 2001, GENE DEV, V15, P1, DOI 10.1101/gad.861501; Gotoh N, 1996, EMBO J, V15, P6197, DOI 10.1002/j.1460-2075.1996.tb01008.x; GRAUSPORTA D, 1995, MOL CELL BIOL, V15, P1182; Guren TK, 2003, J CELL PHYSIOL, V196, P113, DOI 10.1002/jcp.10282; HOFSTETTER P, 1987, MOL CELL BIOL, V7, P4535, DOI 10.1128/MCB.7.12.4535; Irigoyen JP, 1997, J BIOL CHEM, V272, P1904, DOI 10.1074/jbc.272.3.1904; Irigoyen JP, 1999, BIOCHEM BIOPH RES CO, V262, P666, DOI 10.1006/bbrc.1999.1202; Ishihara H, 1998, BIOCHEM BIOPH RES CO, V252, P139, DOI 10.1006/bbrc.1998.9621; Kisielow M, 2002, BIOCHEM J, V363, P1, DOI 10.1042/0264-6021:3630001; Kojima T, 2001, BIOCHEM BIOPH RES CO, V284, P1039, DOI 10.1006/bbrc.2001.5080; Lai KMV, 2000, GENE DEV, V14, P1132; Lambert CA, 2001, MATRIX BIOL, V20, P397, DOI 10.1016/S0945-053X(01)00156-1; Lock P, 1998, EMBO J, V17, P4346, DOI 10.1093/emboj/17.15.4346; Luzi L, 2000, CURR OPIN GENET DEV, V10, P668, DOI 10.1016/S0959-437X(00)00146-5; Migliaccio E, 1997, EMBO J, V16, P706, DOI 10.1093/emboj/16.4.706; Migliaccio E, 1999, NATURE, V402, P309, DOI 10.1038/46311; Nakamura T, 1996, ONCOGENE, V13, P1111; Nakamura T, 1998, J BIOL CHEM, V273, P6960, DOI 10.1074/jbc.273.12.6960; Nakamura T, 2002, ONCOGENE, V21, P22, DOI 10.1038/sj.onc.1205019; OBryan JP, 1996, P NATL ACAD SCI USA, V93, P2729, DOI 10.1073/pnas.93.7.2729; Okada S, 1997, J BIOL CHEM, V272, P28042, DOI 10.1074/jbc.272.44.28042; Pelicci G, 1996, ONCOGENE, V13, P633; PELICCI G, 1995, ONCOGENE, V11, P899; Ravichandran KS, 2001, ONCOGENE, V20, P6322, DOI 10.1038/sj.onc.1204776; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; Sakai R, 2000, NEURON, V28, P819, DOI 10.1016/S0896-6273(00)00156-2; Samarakoon R, 2003, J CELL PHYSIOL, V195, P411, DOI 10.1002/jcp.10247; Samarakoon R, 2002, J CELL SCI, V115, P3093; Saucier C, 2002, ONCOGENE, V21, P1800, DOI 10.1038/sj.onc.1205261; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Schlaepfer DD, 1998, MOL CELL BIOL, V18, P2571, DOI 10.1128/MCB.18.5.2571; SCHLAEPFER DD, 1994, NATURE, V372, P786; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Schmid-Alliana A, 1998, J BIOL CHEM, V273, P3394, DOI 10.1074/jbc.273.6.3394; Subbaramaiah K, 2000, J BIOL CHEM, V275, P14838, DOI 10.1074/jbc.275.20.14838; vanderGeer P, 1996, CURR BIOL, V6, P1435, DOI 10.1016/S0960-9822(96)00748-8; Varedi M, 1997, J CELL PHYSIOL, V172, P192, DOI 10.1002/(SICI)1097-4652(199708)172:2<192::AID-JCP6>3.0.CO;2-J; Walk SF, 1998, EUR J IMMUNOL, V28, P2265, DOI 10.1002/(SICI)1521-4141(199808)28:08<2265::AID-IMMU2265>3.0.CO;2-P; Wang TH, 1998, J BIOL CHEM, V273, P4928, DOI 10.1074/jbc.273.9.4928; Yujiri T, 1999, J BIOL CHEM, V274, P12605, DOI 10.1074/jbc.274.18.12605; ZAMBETTI G, 1991, EXP CELL RES, V192, P93, DOI 10.1016/0014-4827(91)90162-N; Zhang L, 2002, NAT IMMUNOL, V3, P749, DOI 10.1038/ni820	54	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	2004	279	5					3202	3211		10.1074/jbc.M310010200	http://dx.doi.org/10.1074/jbc.M310010200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	766MF	14576154	hybrid			2022-12-27	WOS:000188379600010
J	Bauer, JA; Bennett, EM; Begley, TP; Ealick, SE				Bauer, JA; Bennett, EM; Begley, TP; Ealick, SE			Three-dimensional structure of YaaE from Bacillus subtilis, a glutaminase implicated in pyridoxal-5 '-phosphate biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCEROL PHOSPHATE SYNTHASE; SACCHAROMYCES-CEREVISIAE; CRYSTAL-STRUCTURE; VITAMIN-B-6; PYRIDOXINE; GENE; SYNTHETASE; RESISTANCE; PROGRAM; BARREL	The structure of YaaE from Bacillus subtilis was determined at 2.5-Angstrom resolution. YaaE is a member of the triad glutamine aminotransferase family and functions in a recently identified alternate pathway for the biosynthesis of vitamin B-6. Proposed active residues include conserved Cys-79, His-170, and Glu-172. YaaE shows similarity to HisH, a glutaminase involved in histidine biosynthesis. YaaD associates with YaaE. A homology model of this protein was constructed. YaaD is predicted to be a (beta/alpha)(8) barrel on the basis of sequence comparisons. The predicted active site includes highly conserved residues 211-216 and 233-235. Finally, a homology model of a putative YaaD-YaaE complex was prepared using the structure of HisH-F as a model. This model predicts that the ammonia molecule generated by YaaE is channeled through the center of the YaaD barrel to the putative YaaD active site.	Cornell Univ, Dept Chem & Biol Chem, Ithaca, NY 14853 USA	Cornell University	Ealick, SE (corresponding author), Cornell Univ, Dept Chem & Biol Chem, Ithaca, NY 14853 USA.	see3@cornell.edu	Begley, Tadhg/B-5801-2015		NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR015301] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK044083, R01DK044083] Funding Source: NIH RePORTER	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMURO N, 1985, J BIOL CHEM, V260, P4844; Antelmann H, 1997, ELECTROPHORESIS, V18, P1451, DOI 10.1002/elps.1150180820; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bean LE, 2001, GENETICS, V157, P1067; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Braun EL, 1996, J BACTERIOL, V178, P6865, DOI 10.1128/jb.178.23.6865-6872.1996; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cane DE, 2003, CHIMIA, V57, P75; Chaudhuri BN, 2001, STRUCTURE, V9, P987, DOI 10.1016/S0969-2126(01)00661-X; CHRISTOPHER JA, 1998, SPOCK; Douangamath A, 2002, STRUCTURE, V10, P185, DOI 10.1016/S0969-2126(02)00702-5; Drewke C, 2001, VITAM HORM, V61, P121; Ehrenshaft M, 1999, CURR GENET, V34, P478, DOI 10.1007/s002940050423; Ehrenshaft M, 2001, J BACTERIOL, V183, P3383, DOI 10.1128/JB.183.11.3383-3390.2001; EVANS L, 1993, ELECT J DIFFERENTIAL, V3, P1; FUGE EK, 1994, J BACTERIOL, V176, P5802, DOI 10.1128/JB.176.18.5802-5813.1994; Holm L, 1998, NUCLEIC ACIDS RES, V26, P316, DOI 10.1093/nar/26.1.316; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Jorgensen WL, 1996, J AM CHEM SOC, V118, P11225, DOI 10.1021/ja9621760; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LESLIE AGW, 1997, MOSFLM VERSION 6 2 2; MARTIN AC, 1998, PROFIT VERSION 1 8; MARTIRENOM MA, 2002, CURRENT PROTOCOLS PR; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Mittenhuber G, 2001, J MOL MICROB BIOTECH, V3, P1; MOHAMADI F, 1990, J COMPUT CHEM, V11, P440, DOI 10.1002/jcc.540110405; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; Osmani AH, 1999, J BIOL CHEM, V274, P23565, DOI 10.1074/jbc.274.33.23565; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Padilla PA, 1998, J BACTERIOL, V180, P5718, DOI 10.1128/JB.180.21.5718-5726.1998; Qiu D, 1997, J PHYS CHEM A, V101, P3005, DOI 10.1021/jp961992r; Sakai A, 2002, J BIOSCI BIOENG, V93, P309, DOI 10.1263/jbb.93.309; Sakai A, 2001, J BIOSCI BIOENG, V91, P147, DOI 10.1263/jbb.91.147; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Spraggon G, 2001, P NATL ACAD SCI USA, V98, P6021, DOI 10.1073/pnas.111150298; TAZUYA K, 1995, BBA-GEN SUBJECTS, V1244, P113, DOI 10.1016/0304-4165(94)00205-C; Tesmer JG, 1996, NAT STRUCT BIOL, V3, P74, DOI 10.1038/nsb0196-74; Thoden JB, 1998, BIOCHEMISTRY-US, V37, P8825, DOI 10.1021/bi9807761; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Zeidler J, 2003, J ORG CHEM, V68, P3486, DOI 10.1021/jo020730k; Zeidler J, 2002, J AM CHEM SOC, V124, P4542, DOI 10.1021/ja012708z	44	39	46	0	10	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	2004	279	4					2704	2711		10.1074/jbc.M310311200	http://dx.doi.org/10.1074/jbc.M310311200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	764MU	14585832	hybrid			2022-12-27	WOS:000188211300047
J	Sade, H; Krishna, S; Sarin, A				Sade, H; Krishna, S; Sarin, A			The anti-apoptotic effect of Notch-1 requires p56(lck)-dependent, Akt/PKB-mediated signaling in T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE; FACTOR RECEPTOR; DEATH; ACTIVATION; SURVIVAL; BINDING; KINASE; TRANSFORMATION; LOCALIZATION; HOMEOSTASIS	The Notch family of transmembrane receptors have been implicated in a variety of cellular decisions in different cell types. Here we investigate the mechanism underlying Notch-1-mediated anti-apoptotic function in T cells using model cell lines as the experimental system. Ectopic expression of the intracellular domain of Notch1/activated Notch (AcN1) increases expression of antiapoptotic proteins of the inhibitors of apoptosis (IAP) family, the Bcl-2 family, and the FLICE-like inhibitor protein (FLIP) and inhibits death triggered by multiple stimuli that activate intrinsic or extrinsic pathways of apoptosis in human and murine T cell lines. Numb inhibited the AcN1-dependent induction of anti-apoptotic proteins and anti-apoptotic function. Using pharmacological inhibitors and dominant-negative approaches, we describe a functional role for phosphatidylinositol 3-kinase (PI3K)-dependent activation of the serine-threonine kinase Akt/PKB in the regulation of AcN1-mediated anti-apoptotic function and the expression of FLIP and IAP family proteins. Using a cell line deficient for the T cell-specific, Src family protein, the tyrosine kinase p56(lck) and by reconstitution approaches we demonstrate that p56lck is required for the Notch-1-mediated activation of Akt/PKB function. Furthermore, the Src tyrosine kinase inhibitor, PP2, abrogated ectopically expressed AcN1-mediated anti-apoptotic function and phosphorylation of p56(lck). We present evidence that endogenous Notch-1 associates with p56(lck) and PI3K but that Akt/PKB does not co-immunoprecipitate with the Notch1.p56(lck).PI3K complex. Finally, we demonstrate that the Notch1.p56(lck).PI3K complex is present in primary T cells that have been activated in vitro and sustained in culture with the cytokine interleukin-2.	Univ Agr Sci Bangalore, Natl Ctr Biol Sci, Bangalore 560065, Karnataka, India	Tata Institute of Fundamental Research (TIFR); National Centre for Biological Sciences (NCBS); University of Agricultural Sciences Bangalore	Sarin, A (corresponding author), Univ Agr Sci Bangalore, Natl Ctr Biol Sci, GKVK Campus,New Bellary Rd, Bangalore 560065, Karnataka, India.	sarina@ncbs.res.in						Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Aster JC, 1997, J BIOL CHEM, V272, P11336; Boehme SA, 1996, J IMMUNOL, V156, P4075; Carmena A, 2002, DEV BIOL, V244, P226, DOI 10.1006/dbio.2002.0606; Ceponis PJM, 2000, J BIOL CHEM, V275, P29132, DOI 10.1074/jbc.M003516200; Chen WS, 2001, GENE DEV, V15, P2203, DOI 10.1101/gad.913901; Cuevas B, 1999, J BIOL CHEM, V274, P27583, DOI 10.1074/jbc.274.39.27583; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Deftos ML, 1998, IMMUNITY, V9, P777, DOI 10.1016/S1074-7613(00)80643-3; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Goldrath AW, 1999, NATURE, V402, P255, DOI 10.1038/35005508; Gottlieb E, 2000, MOL CELL BIOL, V20, P5680, DOI 10.1128/MCB.20.15.5680-5689.2000; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Izon DJ, 2002, CURR OPIN IMMUNOL, V14, P192, DOI 10.1016/S0952-7915(02)00321-7; Jehn BM, 1999, J IMMUNOL, V162, P635; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Lodolce JP, 1998, IMMUNITY, V9, P669, DOI 10.1016/S1074-7613(00)80664-0; Luo B, 1997, MOL CELL BIOL, V17, P6057, DOI 10.1128/MCB.17.10.6057; Nair P, 2003, J VIROL, V77, P7106, DOI 10.1128/JVI.77.12.7106-7112.2003; PAGES F, 1994, NATURE, V369, P327, DOI 10.1038/369327a0; Perez OD, 2002, IMMUNITY, V16, P51, DOI 10.1016/S1074-7613(02)00266-2; Plas DR, 2002, NAT IMMUNOL, V3, P515, DOI 10.1038/ni0602-515; RAAB M, 1995, P NATL ACAD SCI USA, V92, P8891, DOI 10.1073/pnas.92.19.8891; Radtke F, 2002, IMMUNOL REV, V187, P65, DOI 10.1034/j.1600-065X.2002.18706.x; Rangarajan A, 2001, VIROLOGY, V286, P23, DOI 10.1006/viro.2001.0867; Robey E, 1996, CELL, V87, P483, DOI 10.1016/S0092-8674(00)81368-9; Sade H, 2003, EUR J IMMUNOL, V33, P913, DOI 10.1002/eji.200323782; SARIN A, 1993, J EXP MED, V178, P1693, DOI 10.1084/jem.178.5.1693; Sarin A, 1996, J EXP MED, V184, P2445, DOI 10.1084/jem.184.6.2445; Schmitt TM, 2002, IMMUNITY, V17, P749, DOI 10.1016/S1074-7613(02)00474-0; Seddon B, 2000, SCIENCE, V290, P127, DOI 10.1126/science.290.5489.127; Sohn SJ, 2001, J IMMUNOL, V166, P2209, DOI 10.4049/jimmunol.166.4.2209; Sprent J, 2002, ANNU REV IMMUNOL, V20, P551, DOI 10.1146/annurev.immunol.20.100101.151926; Van Parijs L, 1998, SCIENCE, V280, P243; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; Washburn T, 1997, CELL, V88, P833, DOI 10.1016/S0092-8674(00)81929-7; Yang YL, 1997, BLOOD, V89, P550, DOI 10.1182/blood.V89.2.550; YANO H, 1993, J BIOL CHEM, V268, P25846; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; Zhong WM, 1996, NEURON, V17, P43, DOI 10.1016/S0896-6273(00)80279-2	43	207	219	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	2004	279	4					2937	2944		10.1074/jbc.M309924200	http://dx.doi.org/10.1074/jbc.M309924200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	764MU	14583609	hybrid			2022-12-27	WOS:000188211300074
J	Gallagher, ED; Gutowski, S; Sternweis, PC; Cobb, MH				Gallagher, ED; Gutowski, S; Sternweis, PC; Cobb, MH			RhoA binds to the amino terminus of MEKK1 and regulates its kinase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; NF-KAPPA-B; SERINE THREONINE KINASE; GENE DISRUPTION; PUTATIVE TARGET; CELL-MIGRATION; RAC GTPASES; DOMAIN; INTERACTS; PATHWAYS	MEKK1 is a mitogen-activated protein kinase kinase kinase (MAP3K) that can regulate the c-Jun amino-terminal kinase (JNK) MAP kinase cascade. MEKK1 is comprised of a kinase domain and a long amino-terminal regulatory domain. This amino-terminal domain has a scaffold function in that it can assemble modules of the JNK and ERK MAP kinase cascades. Recently, we have demonstrated that MEKK1 binds to p115 Rho GTPase-activating protein, which has GTPase-activating protein activity toward RhoA. Thus, we tested whether Rho GTPases interact with the regulatory domain of MEKK1. RhoA, but not Rac or Cdc42, binds to a site in the amino-terminal one-third of MEKK1, which includes its PHD domain. The interaction is prevented by mutation of the essential cysteine in the MEKK1 PHD domain. Rho-GTP stimulates the kinase activity of full-length MEKK1 as much as 10-fold toward MEK4 but does not appear to be ubiquitinated by MEKK1 under conditions that result in modification of ERK2. In summary, we have characterized a novel point at which Rho GTPases impinge upon the regulation and function of MEKK1.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Cobb, MH (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	mcobb@mednet.swmed.edu		Cobb, Melanie/0000-0003-0833-5473	NIGMS NIH HHS [GM 56498, GM 31954] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031954, R01GM056498] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; Blank JL, 1996, J BIOL CHEM, V271, P5361, DOI 10.1074/jbc.271.10.5361; Bonvin C, 2002, CELL SIGNAL, V14, P123, DOI 10.1016/S0898-6568(01)00219-4; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; Chadee DN, 2002, MOL CELL BIOL, V22, P737, DOI 10.1128/MCB.22.3.737-749.2002; CHOI KY, 1994, CELL, V78, P499; Christerson LB, 2002, J CELL PHYSIOL, V192, P200, DOI 10.1002/jcp.10125; Christerson LB, 1999, CELL MOTIL CYTOSKEL, V43, P186, DOI 10.1002/(SICI)1097-0169(1999)43:3<186::AID-CM2>3.0.CO;2-1; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Fanger GR, 1998, J BIOL CHEM, V273, P3476, DOI 10.1074/jbc.273.6.3476; Fanger GR, 1997, EMBO J, V16, P4961, DOI 10.1093/emboj/16.16.4961; FROST JA, 1998, J BIOL CHEM, V273, P28253; Fujisawa K, 1996, J BIOL CHEM, V271, P23022, DOI 10.1074/jbc.271.38.23022; Gallagher ED, 2002, J BIOL CHEM, V277, P45785, DOI 10.1074/jbc.M207702200; Gerwins P, 1997, J BIOL CHEM, V272, P8288, DOI 10.1074/jbc.272.13.8288; Karandikar M, 2000, J BIOL CHEM, V275, P40120, DOI 10.1074/jbc.M005926200; Karin M, 1998, P NATL ACAD SCI USA, V95, P9067, DOI 10.1073/pnas.95.16.9067; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Leung T, 1996, MOL CELL BIOL, V16, P5313; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Lu ZM, 2002, MOL CELL, V9, P945, DOI 10.1016/S1097-2765(02)00519-1; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARCUS S, 1994, P NATL ACAD SCI USA, V91, P7762, DOI 10.1073/pnas.91.16.7762; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; PRINTEN JA, 1994, GENETICS, V138, P609; Reid T, 1996, J BIOL CHEM, V271, P13556, DOI 10.1074/jbc.271.23.13556; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RUSSELL M, 1995, J BIOL CHEM, V270, P11757, DOI 10.1074/jbc.270.20.11757; Sambrook J., 2002, MOL CLONING LAB MANU; SCHLESINGER TK, 2002, J BIOL CHEM; Sotiropoulos A, 1999, CELL, V98, P159, DOI 10.1016/S0092-8674(00)81011-9; Su YC, 1997, EMBO J, V16, P1279, DOI 10.1093/emboj/16.6.1279; Vincent S, 1997, MOL CELL BIOL, V17, P2247, DOI 10.1128/MCB.17.4.2247; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Xia Y, 1998, GENE DEV, V12, P3369, DOI 10.1101/gad.12.21.3369; Xia Y, 2000, P NATL ACAD SCI USA, V97, P5243, DOI 10.1073/pnas.97.10.5243; Xu BE, 2000, J BIOL CHEM, V275, P16795, DOI 10.1074/jbc.275.22.16795; XU SC, 1995, P NATL ACAD SCI USA, V92, P6808, DOI 10.1073/pnas.92.15.6808; Xu SC, 1996, P NATL ACAD SCI USA, V93, P5291, DOI 10.1073/pnas.93.11.5291; Xu SC, 1997, J BIOL CHEM, V272, P32056, DOI 10.1074/jbc.272.51.32056; Yin MJ, 1998, CELL, V93, P875, DOI 10.1016/S0092-8674(00)81447-6; Yujiri T, 2000, P NATL ACAD SCI USA, V97, P7272, DOI 10.1073/pnas.130176697; Yujiri T, 1999, J BIOL CHEM, V274, P12605, DOI 10.1074/jbc.274.18.12605; Yujiri T, 1998, SCIENCE, V282, P1911, DOI 10.1126/science.282.5395.1911	48	59	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 16	2004	279	3					1872	1877		10.1074/jbc.M309525200	http://dx.doi.org/10.1074/jbc.M309525200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	762WT	14581471	hybrid			2022-12-27	WOS:000188005700039
J	Schrantz, N; Correia, JD; Fowler, B; Ge, QY; Sun, ZJ; Bokoch, GM				Schrantz, N; Correia, JD; Fowler, B; Ge, QY; Sun, ZJ; Bokoch, GM			Mechanism of p21-activated kinase 6-mediated inhibition of androgen receptor signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PROSTATE-CANCER; RNA-POLYMERASE-III; PHOSPHORYLATION SITES; GROWTH-FACTOR; PROTEIN; IDENTIFICATION; ACTIVATION; COACTIVATOR; BINDING; ACTIN	PAK6 was first identified as an androgen receptor (AR)-interacting protein able to inhibit AR-mediated transcriptional responses. PAK6 is a serine/threonine kinase belonging to the p21-activated kinase (PAK) family implicated in actin reorganization and cell motility, gene transcription, apoptosis, and cell transformation. We investigated the biochemical basis for inhibition of AR signaling by PAK6. We compared the kinase activity of PAK6 with two other well characterized members of the PAK family, PAK1 and PAK4. Like PAK4, PAK6 possesses a constitutive basal kinase activity that, unlike PAK1, is not modulated by the binding of active Rac or Cdc42 GTPases. In order to test the involvement of PAK6 kinase activity in suppression of AR-mediated transcription, we generated kinase-dead (K436A) and kinase-active (S531N) mutants of PAK6. We show that PAK6 kinase activity is required for effective PAK6-induced repression of AR signaling. Suppression does not depend upon GTPase binding to PAK6 and is not mimicked by the closely related PAK1 and PAK4 isoforms. Kinase-dependent inhibition by PAK6 extended to the enhanced AR-mediated transcription seen in the presence of coactivating molecules and to the action of AR coinhibitors. Active PAK6 inhibited nuclear translocation of the stimulated AR, suggesting a possible mechanism for inhibition of AR responsiveness. Finally, we observe that autophosphorylated, active PAK6 protein is differently expressed among prostate cancer cell lines. Modulation of PAK6 activity may be responsible for regulation of AR signaling in various forms of prostate cancer.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Stanford Univ, Sch Med, Dept Surg & Genet, Stanford, CA 94305 USA; Cell Signaling Technol Inc, Beverly, MA 01915 USA	Scripps Research Institute; Scripps Research Institute; Stanford University	Bokoch, GM (corresponding author), Scripps Res Inst, Dept Immunol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	bokoch@scripps.edu			NCI NIH HHS [R01 CA087767, R01 CA070297] Funding Source: Medline; NIDDK NIH HHS [R01 DK061002] Funding Source: Medline; NIGMS NIH HHS [GM 39434] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039434] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abo A, 1998, EMBO J, V17, P6527, DOI 10.1093/emboj/17.22.6527; Bagrodia S, 1999, TRENDS CELL BIOL, V9, P350, DOI 10.1016/S0962-8924(99)01618-9; Brady ME, 1999, J BIOL CHEM, V274, P17599, DOI 10.1074/jbc.274.25.17599; Briand JF, 2001, MOL CELL BIOL, V21, P6056, DOI 10.1128/MCB.21.17.6056-6065.2001; Cao GW, 2001, CANCER GENE THER, V8, P497, DOI 10.1038/sj.cgt.7700333; Cau J, 2001, J CELL BIOL, V155, P1029, DOI 10.1083/jcb.200104123; CULIG Z, 1994, CANCER RES, V54, P5474; Dan I, 2001, TRENDS CELL BIOL, V11, P220, DOI 10.1016/S0962-8924(01)01980-8; DENNER LA, 1990, J BIOL CHEM, V265, P16548; DERUITER PE, 1995, MOL CELL ENDOCRINOL, V110, pR1, DOI 10.1016/0303-7207(95)03534-E; Dotzlaw H, 2002, MOL ENDOCRINOL, V16, P661, DOI 10.1210/me.16.4.661; Fu MF, 2000, J BIOL CHEM, V275, P20853, DOI 10.1074/jbc.M000660200; Fujimoto N, 1999, J BIOL CHEM, V274, P8316, DOI 10.1074/jbc.274.12.8316; Gatti A, 1999, J BIOL CHEM, V274, P8022, DOI 10.1074/jbc.274.12.8022; Gioeli D, 2002, J BIOL CHEM, V277, P29304, DOI 10.1074/jbc.M204131200; HALACHMI S, 1994, SCIENCE, V264, P1455, DOI 10.1126/science.8197458; Hanstein B, 1996, P NATL ACAD SCI USA, V93, P11540, DOI 10.1073/pnas.93.21.11540; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; Jaffer ZM, 2002, INT J BIOCHEM CELL B, V34, P713, DOI 10.1016/S1357-2725(01)00158-3; Jenster G, 1999, SEMIN ONCOL, V26, P407; JENSTER G, 1991, MOL ENDOCRINOL, V5, P1396, DOI 10.1210/mend-5-10-1396; Knaus UG, 1998, INT J BIOCHEM CELL B, V30, P857, DOI 10.1016/S1357-2725(98)00059-4; Lee SR, 2002, MOL ENDOCRINOL, V16, P85, DOI 10.1210/me.16.1.85; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Nazareth LV, 1996, J BIOL CHEM, V271, P19900, DOI 10.1074/jbc.271.33.19900; OHARANEMOTO Y, 1988, J STEROID BIOCHEM, V31, P295; Pandey A, 2002, ONCOGENE, V21, P3939, DOI 10.1038/sj.onc.1205478; Puto LA, 2003, J BIOL CHEM, V278, P9388, DOI 10.1074/jbc.M208414200; QUIGLEY CA, 1995, ENDOCR REV, V16, P271, DOI 10.1210/er.16.3.271; SANCHEZ ER, 1990, J BIOL CHEM, V265, P22067; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; Voutsina A, 1999, NUCLEIC ACIDS RES, V27, P1047, DOI 10.1093/nar/27.4.1047; Wang RA, 2002, EMBO J, V21, P5437, DOI 10.1093/emboj/cdf543; Wang X, 2002, J BIOL CHEM, V277, P15426, DOI 10.1074/jbc.M111218200; Yang F, 2001, J BIOL CHEM, V276, P15345, DOI 10.1074/jbc.M010311200; Yang FJ, 2002, J BIOL CHEM, V277, P11336, DOI 10.1074/jbc.M111962200; Yu JS, 1998, BIOCHEM J, V334, P121, DOI 10.1042/bj3340121; Zenke FT, 1999, J BIOL CHEM, V274, P32565, DOI 10.1074/jbc.274.46.32565; Zhau HYE, 1996, P NATL ACAD SCI USA, V93, P15152, DOI 10.1073/pnas.93.26.15152; ZHOU ZX, 1995, MOL ENDOCRINOL, V9, P605, DOI 10.1210/me.9.5.605; ZHOU ZX, 1994, J BIOL CHEM, V269, P13115	42	74	82	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 16	2004	279	3					1922	1931		10.1074/jbc.M311145200	http://dx.doi.org/10.1074/jbc.M311145200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	762WT	14573606	hybrid			2022-12-27	WOS:000188005700046
J	Uchino, M; Sakai, N; Kashiwagi, K; Shirai, Y; Shinohara, Y; Hirose, K; Iino, M; Yamamura, T; Saito, N				Uchino, M; Sakai, N; Kashiwagi, K; Shirai, Y; Shinohara, Y; Hirose, K; Iino, M; Yamamura, T; Saito, N			Isoform-specific phosphorylation of metabotropic glutamate receptor 5 by protein kinase C (PKC) blocks Ca2+ oscillation and oscillatory translocation of Ca2+-dependent PKC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GREEN FLUORESCENT PROTEIN; GLUTAMATE RECEPTORS; CALCIUM OSCILLATIONS; INOSITOL 1,4,5-TRISPHOSPHATE; SIGNAL TRANSDUCTION; LIVING CELLS; ACTIVATION; SUBSTRATE; FAMILY; EXPRESSION	Prolonged activation of metabotropic glutamate receptor 5a (mGluR5a) causes synchronized oscillations in intracellular calcium, inositol 1,4,5-trisphosphate production, and protein kinase C (PKC) activation. Additionally, mGluR5 stimulation elicited cyclical translocations of myristoylated alanine-rich protein kinase C substrate, which were opposite to that of gammaPKC (i.e. from plasma membrane to cytosol) and dependent on PKC activity, indicating that myristoylated alanine-rich protein kinase C substrate is repetitively phosphorylated by oscillating gammaPKC on the plasma membrane. Mutation of mGluR5 Thr(840) to aspartate abolished the oscillation of gammaPKC, but the mutation to alanine (T840A) did not. Cotransfection of gammaPKC with betaIIPKC, another Ca2+-dependent PKC, resulted in synchronous oscillatory translocation of both classical PKCs. In contrast, cotransfection of deltaPKC, a Ca2+-independent PKC, abolished the oscillations of both gammaPKC and inositol 1,4,5-trisphosphate. Regulation of the oscillations was dependent on deltaPKC kinase activity but not on gammaPKC. Furthermore, the T840A-mGluR5-mediated oscillations were not blocked by the deltaPKC overexpression. These results revealed that activation of mGluR5 causes translocation of both gammaPKC and deltaPKC to the plasma membrane. deltaPKC, but not gammaPKC, phosphorylates mGluR5 Thr(840), leading to the blockade of both Ca2+ oscillations and gammaPKC cycling. This subtype-specific targeting proposes the molecular basis of the multiple functions of PKC.	Kobe Univ, Biosignal Res Ctr, Mol Pharmacol Lab, Kobe, Hyogo 6578501, Japan; Hyogo Med Univ, Dept Surg 2, Nishinomiya, Hyogo 6638501, Japan; Kyoto Univ, Fac Med, Dept Biol Sci, Kyoto 6068501, Japan; Univ Tokyo, Grad Sch Med, Dept Pharmacol, Tokyo 1130033, Japan	Kobe University; Hyogo College of Medicine; University of Hyogo; Kyoto University; University of Tokyo	Saito, N (corresponding author), 1-1 Rokkodai Cho,Nada Ku, Kobe, Hyogo 6578501, Japan.	naosaito@kobe-u.ac.jp	Shirai, Yasuhito/O-3255-2018					ADEREM A, 1992, CELL, V71, P713, DOI 10.1016/0092-8674(92)90546-O; ADEREM AA, 1988, NATURE, V332, P362, DOI 10.1038/332362a0; Babwah AV, 2003, J BIOL CHEM, V278, P5419, DOI 10.1074/jbc.M211053200; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BLACKSHEAR PJ, 1993, J BIOL CHEM, V268, P1501; Codazzi F, 2001, CURR BIOL, V11, P1089, DOI 10.1016/S0960-9822(01)00326-8; Dale LB, 2001, J BIOL CHEM, V276, P35900, DOI 10.1074/jbc.M103847200; Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; GEORGE DJ, 1992, J BIOL CHEM, V267, P24879; GU XN, 1995, NATURE, V375, P784, DOI 10.1038/375784a0; HAJNOCZKY G, 1995, CELL, V82, P41; Hirose K, 1999, SCIENCE, V284, P1527, DOI 10.1126/science.284.5419.1527; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; Irie N, 2002, BIOCHEM BIOPH RES CO, V298, P738, DOI 10.1016/S0006-291X(02)02531-7; Kajimoto T, 2001, MOL CELL BIOL, V21, P1769, DOI 10.1128/MCB.21.5.1769-1783.2001; Kashiwagi K, 2002, J BIOL CHEM, V277, P18037, DOI 10.1074/jbc.M111761200; Kawabata S, 1998, J BIOL CHEM, V273, P17381, DOI 10.1074/jbc.273.28.17381; Kawabata S, 1996, NATURE, V383, P89, DOI 10.1038/383089a0; KLIGMAN D, 1986, J NEUROCHEM, V47, P298; Nakahara K, 1997, J NEUROCHEM, V69, P1467; NAKANISHI S, 1994, ANNU REV BIOPH BIOM, V23, P319, DOI 10.1146/annurev.bb.23.060194.001535; Nash MS, 2002, J BIOL CHEM, V277, P35947, DOI 10.1074/jbc.M205622200; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; Oancea E, 1998, CELL, V95, P307, DOI 10.1016/S0092-8674(00)81763-8; Oancea E, 1998, J CELL BIOL, V140, P485, DOI 10.1083/jcb.140.3.485; Ohmori S, 2000, J BIOL CHEM, V275, P26449, DOI 10.1074/jbc.M003588200; Ohmori S, 1998, MOL CELL BIOL, V18, P5263, DOI 10.1128/MCB.18.9.5263; ONO Y, 1989, P NATL ACAD SCI USA, V86, P4868, DOI 10.1073/pnas.86.13.4868; ONO Y, 1988, J BIOL CHEM, V263, P6927; OSADA S, 1992, MOL CELL BIOL, V12, P3930, DOI 10.1128/MCB.12.9.3930; Sakai N, 1997, J CELL BIOL, V139, P1465, DOI 10.1083/jcb.139.6.1465; Shirai Y, 2000, J CELL SCI, V113, P1335; Shirai Y, 1998, J CELL BIOL, V143, P511, DOI 10.1083/jcb.143.2.511	38	32	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 16	2004	279	3					2254	2261		10.1074/jbc.M309894200	http://dx.doi.org/10.1074/jbc.M309894200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	762WT	14561742	hybrid			2022-12-27	WOS:000188005700082
J	Dalal, S; Kosa, JL; Sweasy, JB				Dalal, S; Kosa, JL; Sweasy, JB			The D246V mutant of DNA polymerase beta misincorporates nucleotides - Evidence for a role for the flexible loop in DNA positioning within the active site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE-EXCISION-REPAIR; REVERSE-TRANSCRIPTASE; CRYSTAL-STRUCTURES; MUTATOR MUTANT; FIDELITY; MECHANISM; OVEREXPRESSION; INSTABILITY; SPECIFICITY; MUTATIONS	DNA polymerase beta, a member of the X family of DNA polymerases, is known to be involved in base excision repair. A key to determining the biochemical properties of this DNA polymerase is structure-function studies of site-specific mutants that result in substitution of particular amino acids at critical sites. In a previous genetic screen, we identified three 3'-azido-2',3'-dideoxythymidine 5'-triphosphate-resistant mutants, namely E249K, D246V, and R253M, of polymerase beta in the flexible loop of the palm domain. In this work, we perform an extensive kinetic analysis to investigate the role of the D246V mutant on polymerase fidelity. We find that D246V misincorporates T opposite template bases G and C. The mechanistic basis of misincorporation appears to be altered DNA positioning within the active site. We provide evidence that the fidelity of D246V is greatly affected by the base that is 5' of the templating base. We propose that the Asp residue at position 246 helps to maintain the proper positioning of the DNA within the polymerase active site and maintains the fidelity of polymerase beta. Altogether, the results suggest that the flexible loop domain of polymerase beta plays a major role in its fidelity.	Yale Univ, Sch Med, Dept Therapeut Radiol & Genet, New Haven, CT 06520 USA; MIT, Cambridge, MA 02139 USA	Yale University; Massachusetts Institute of Technology (MIT)	Sweasy, JB (corresponding author), Yale Univ, Sch Med, Dept Therapeut Radiol & Genet, 333 Cedar St,POB 208040, New Haven, CT 06520 USA.	joann.sweasy@yale.edu			NATIONAL CANCER INSTITUTE [R01CA080830] Funding Source: NIH RePORTER; NCI NIH HHS [CA80830, R01 CA080830] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Beard WA, 1996, J BIOL CHEM, V271, P12141, DOI 10.1074/jbc.271.21.12141; Berg BJV, 2001, J BIOL CHEM, V276, P3408, DOI 10.1074/jbc.M002884200; Bhattacharyya N, 1999, DNA CELL BIOL, V18, P549, DOI 10.1089/104454999315097; Bouayadi K, 1997, CANCER RES, V57, P110; Canitrot Y, 1998, P NATL ACAD SCI USA, V95, P12586, DOI 10.1073/pnas.95.21.12586; Canitrot Y, 2000, FASEB J, V14, P1765, DOI 10.1096/fj.99-1063com; Chagovetz AM, 1997, J BIOL CHEM, V272, P27501, DOI 10.1074/jbc.272.44.27501; CHEN MS, 1993, BIOCHEMISTRY-US, V32, P6002, DOI 10.1021/bi00074a011; Dong Ziming, 2002, Zhonghua Yi Xue Za Zhi, V82, P899; JOHNSON KA, 1993, ANNU REV BIOCHEM, V62, P685, DOI 10.1146/annurev.bi.62.070193.003345; KATI WM, 1992, J BIOL CHEM, V267, P25988; Kennard O., 1987, NUCL ACIDS MOL BIOL, V1, P25; Kokoska RJ, 2002, J BIOL CHEM, V277, P19633, DOI 10.1074/jbc.M202021200; Kosa JL, 1999, J BIOL CHEM, V274, P3851, DOI 10.1074/jbc.274.6.3851; Kosa JL, 1999, J BIOL CHEM, V274, P35866, DOI 10.1074/jbc.274.50.35866; Li SX, 1999, BIOCHEMISTRY-US, V38, P4800, DOI 10.1021/bi9827058; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; LOEB LA, 1974, CANCER RES, V34, P2311; Osheroff WP, 1999, J BIOL CHEM, V274, P20749, DOI 10.1074/jbc.274.30.20749; Pelletier H, 1996, BIOCHEMISTRY-US, V35, P12742, DOI 10.1021/bi952955d; Plug AW, 1997, P NATL ACAD SCI USA, V94, P1327, DOI 10.1073/pnas.94.4.1327; Potapova O, 2002, J BIOL CHEM, V277, P28157, DOI 10.1074/jbc.M202607200; Sawaya MR, 1997, BIOCHEMISTRY-US, V36, P11205, DOI 10.1021/bi9703812; SEEBERG E, 1995, TRENDS BIOCHEM SCI, V20, P391, DOI 10.1016/S0968-0004(00)89086-6; Shah AM, 2001, J BIOL CHEM, V276, P10824, DOI 10.1074/jbc.M008680200; SINGHAL RK, 1993, J BIOL CHEM, V268, P15906; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; Srivastava DK, 1999, CARCINOGENESIS, V20, P1049, DOI 10.1093/carcin/20.6.1049; Srivastava DK, 1998, J BIOL CHEM, V273, P21203, DOI 10.1074/jbc.273.33.21203; Steitz TA, 1998, NATURE, V391, P231, DOI 10.1038/34542; TANTILLO C, 1994, J MOL BIOL, V243, P369, DOI 10.1006/jmbi.1994.1665; WANG LM, 1992, CANCER RES, V52, P4824; Washington SL, 1997, P NATL ACAD SCI USA, V94, P1321, DOI 10.1073/pnas.94.4.1321; Werneburg BG, 1996, BIOCHEMISTRY-US, V35, P7041, DOI 10.1021/bi9527202; Wilson SH, 2000, NAT STRUCT BIOL, V7, P176	35	27	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 2	2004	279	1					577	584		10.1074/jbc.M309607200	http://dx.doi.org/10.1074/jbc.M309607200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	757GU	14563842	hybrid			2022-12-27	WOS:000187555300070
J	Lutz, EP; Kako, Y; Yagyu, H; Heeren, J; Marks, S; Wright, T; Melford, K; Ben-Zeev, O; Radner, H; Merkel, M; Bensadoun, A; Wong, H; Goldberg, IJ				Lutz, EP; Kako, Y; Yagyu, H; Heeren, J; Marks, S; Wright, T; Melford, K; Ben-Zeev, O; Radner, H; Merkel, M; Bensadoun, A; Wong, H; Goldberg, IJ			Mice expressing only covalent dimeric heparin binding-deficient lipoprotein lipase - Muscles inefficiently secrete dimeric enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODY; TRANSGENIC MICE; SULFATE; TISSUES; INVOLVEMENT; SITE	Lipoprotein lipase (LpL) hydrolyzes triglycerides of circulating lipoproteins while bound as homodimers to endothelial cell surface heparan sulfate proteoglycans. This primarily occurs in the capillary beds of muscle and adipose tissue. By creating a mouse line that expresses covalent dimers of heparin-binding deficient LpL (hLpL(HBM-Dimer)) in muscle, we confirmed in vivo that linking two LpL monomers in a head to tail configuration creates a functional LpL. The hLpL(HBM-Dimer) transgene produced abundant activity and protein in muscle, and the LpL was the expected size of a dimer (similar to110 kDa). Unlike the heparin-binding mutant monomer, hLpL(HBM-Dimer) had the same stability as nonmutated LpL. The hLpL(HBM-Dimer) transgene prevented the neonatal demise of LpL knockout mice; however, these mice were hypertriglyceridemic. Postheparin plasma LpL activity was lower than expected with the robust expression in muscle and was no longer covalently linked. Studies in transfected cells showed that Chinese hamster lung cells, but not COS cells, also degraded tandem repeated LpL into monomers. Thus, although muscle can synthesize tethered, dimeric LpL, efficient production of this enzyme leading to secretion, and physiological function appears to favor secretion of a noncovalent dimer composed of monomeric subunits.	Columbia Univ, Dept Med, New York, NY 10032 USA; Univ Hamburg, Hosp Eppendorf, Dept Med, D-20246 Hamburg, Germany; Univ Hamburg, Hosp Eppendorf, Dept Med Biochem & Mol Biol, D-20246 Hamburg, Germany; Cornell Univ, Div Nutr Sci, Ithaca, NY 14853 USA; Univ Calif Los Angeles, W Los Angeles Vet Affairs Med Ctr, Dept Med, Lipid Res Lab, Los Angeles, CA 90073 USA; Univ Mainz, Inst Pathol, D-55101 Mainz, Germany	Columbia University; University of Hamburg; University of Hamburg; Cornell University; University of California System; University of California Los Angeles; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; West Los Angeles VA Medical Center; Johannes Gutenberg University of Mainz	Goldberg, IJ (corresponding author), Columbia Univ, Dept Med, 630 W 168th St, New York, NY 10032 USA.			Merkel, Martin/0000-0002-2850-5110	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL014990, R01HL045095, P01HL028481, R37HL045095] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL028481, HL45095, HL014990] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ben-Zeev O, 1999, METH MOL B, V109, P257; Ben-Zeev O, 2002, J BIOL CHEM, V277, P10727, DOI 10.1074/jbc.M108128200; BENAVRAM CM, 1986, P NATL ACAD SCI USA, V83, P4185, DOI 10.1073/pnas.83.12.4185; Bergo M, 1996, BIOCHEM J, V313, P893, DOI 10.1042/bj3130893; Chang SF, 1998, J LIPID RES, V39, P2350; GOLDBERG IJ, 1986, BIOCHIM BIOPHYS ACTA, V878, P168, DOI 10.1016/0005-2760(86)90143-8; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; Hocquette JF, 1998, COMP BIOCHEM PHYS B, V121, P201, DOI 10.1016/S0305-0491(98)10090-1; Kako Y, 1999, J LIPID RES, V40, P2185; LevakFrank S, 1997, J BIOL CHEM, V272, P17182, DOI 10.1074/jbc.272.27.17182; LEVAKFRANK S, 1995, J CLIN INVEST, V96, P976, DOI 10.1172/JCI118145; Lookene A, 1996, BIOCHEMISTRY-US, V35, P12155, DOI 10.1021/bi960008e; Lutz EP, 2001, J CLIN INVEST, V107, P1183, DOI 10.1172/JCI11774; Merkel M, 2002, J LIPID RES, V43, P1997, DOI 10.1194/jlr.R200015-JLR200; PETERSON J, 1992, J LIPID RES, V33, P1165; Sendak RA, 1998, J LIPID RES, V39, P1310; SHIMADA K, 1981, J CLIN INVEST, V68, P995, DOI 10.1172/JCI110354; Vlodavsky I, 1996, CANCER METAST REV, V15, P177, DOI 10.1007/BF00437470; WALLINDER L, 1984, BIOCHIM BIOPHYS ACTA, V795, P513, DOI 10.1016/0005-2760(84)90181-4; Wong H, 1997, P NATL ACAD SCI USA, V94, P5594, DOI 10.1073/pnas.94.11.5594; ZECHNER R, 1990, BIOCHIM BIOPHYS ACTA, V1044, P20, DOI 10.1016/0005-2760(90)90213-H	21	4	4	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	2004	279	1					238	244		10.1074/jbc.M310559200	http://dx.doi.org/10.1074/jbc.M310559200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	757GU	14570890	hybrid			2022-12-27	WOS:000187555300029
J	Yoon, J; Oh, B; Kim, K; Park, J; Han, D; Kim, KK; Cha, SS; Lee, D; Kim, Y				Yoon, J; Oh, B; Kim, K; Park, J; Han, D; Kim, KK; Cha, SS; Lee, D; Kim, Y			A bound water molecule is crucial in initiating autocatalytic precursor activation in an N-terminal hydrolase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							7-AMINOCEPHALOSPORANIC ACID ACYLASE; ACTIVE-SITE RESIDUES; CEPHALOSPORIN ACYLASE; GLUTARYL-7-AMINOCEPHALOSPORANIC ACID; LYSOSOMAL ASPARTYLGLUCOSAMINIDASE; AUTOPROTEOLYTIC ACTIVATION; STRUCTURAL CLASSIFICATION; 20S PROTEASOME; MECHANISM; SUBUNIT	Cephalosporin acylase is a member of the N-terminal hydrolase family, which is activated from an inactive precursor by autoproteolytic processing to generate a new N-terminal nucleophile Ser or Thr. The gene structure of the precursor cephalosporin acylases generally consists of a signal peptide that is followed by an alpha-subunit, a spacer sequence, and a beta-subunit. The cephalosporin acylase precursor is post-translationally modified into an active heterodimeric enzyme with alpha- and beta-subunits, first by intramolecular cleavage and, second, by intermolecular cleavage. Intramolecular autocatalytic proteolysis is initiated by nucleophilic attack of the residue Ser-1beta onto the adjacent scissile carbonyl carbon. This study determined the precursor structure after disabling the intramolecular cleavage. This study also provides experimental evidence showing that a conserved water molecule plays an important role in assisting the polarization of the OG atom of Ser-1beta to generate a strong nucleophile and to direct the OG atom of the Ser-1beta to a target carbonyl carbon. Intramolecular proteolysis is disabled as a result of a mutation of the residues causing conformational distortion to the active site. This is because distortion affects the existence of the catalytically crucial water at the proper position. This study provides the first evidence showing that a bound water molecule plays a critical role in initiating intramolecular cleavage in the post-translational modification of the precursor enzyme.	Seoul Natl Univ, Coll Med, Div Mol Gen Med, Seoul 110799, South Korea; Sungkyunkwan Univ, Sch Med, SBRI, Ctr Mol Med,Dept Mol Cell Biol, Suwon 440746, South Korea; Pohang Accelerator Lab, Beamline Div, Pohang 790784, Kyungbuk, South Korea; Seoul Natl Univ, Coll Med, Dept Clin Pathol, Seoul 110799, South Korea; Seoul Natl Univ, Coll Med, Canc Res Inst, Seoul 110799, South Korea	Seoul National University (SNU); Samsung; Sungkyunkwan University (SKKU); Pohang University of Science & Technology (POSTECH); Seoul National University (SNU); Seoul National University (SNU)	Kim, Y (corresponding author), Seoul Natl Univ, Coll Med, Div Mol Gen Med, 28 Yongon Dong, Seoul 110799, South Korea.		Kim, Youngsoo/D-6046-2012; Lee, Dong soon/E-5079-2012; Cha, Sun Shin/B-7370-2009; Han, Dohyun/AAU-7871-2020	Han, Dohyun/0000-0002-0841-1598; Cha, Sun-Shin/0000-0002-0913-8706				BRANNIGAN JA, 1995, NATURE, V378, P416, DOI 10.1038/378416a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Ditzel L, 1998, J MOL BIOL, V279, P1187, DOI 10.1006/jmbi.1998.1818; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; Guan C, 1998, J BIOL CHEM, V273, P9695, DOI 10.1074/jbc.273.16.9695; IKONEN E, 1993, EMBO J, V12, P295, DOI 10.1002/j.1460-2075.1993.tb05656.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kim DW, 1999, J MICROBIOL, V37, P200; Kim S, 2001, J BIOL CHEM, V276, P48376, DOI 10.1074/jbc.M109603200; Kim Y, 2002, J BIOL CHEM, V277, P2823, DOI 10.1074/jbc.M108888200; Kim Y, 2001, CHEM BIOL, V8, P1253, DOI 10.1016/S1074-5521(01)00092-8; Kim Y, 2000, STRUCTURE, V8, P1059, DOI 10.1016/S0969-2126(00)00505-0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kwon TH, 2000, J STRUCT BIOL, V131, P79, DOI 10.1006/jsbi.2000.4256; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lee YS, 1998, J BACTERIOL, V180, P4576, DOI 10.1128/JB.180.17.4576-4582.1998; Lee YS, 2000, J BIOL CHEM, V275, P39200, DOI 10.1074/jbc.M002504200; Li Y, 1999, EUR J BIOCHEM, V262, P713, DOI 10.1046/j.1432-1327.1999.00417.x; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Murzin AG, 1996, CURR OPIN STRUC BIOL, V6, P386, DOI 10.1016/S0959-440X(96)80059-5; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Saarela J, 1998, J BIOL CHEM, V273, P25320, DOI 10.1074/jbc.273.39.25320; Schmidtke G, 1996, EMBO J, V15, P6887, DOI 10.1002/j.1460-2075.1996.tb01081.x; Tikkanen R, 1996, EMBO J, V15, P2954, DOI 10.1002/j.1460-2075.1996.tb00658.x; Xu QA, 1999, CELL, V98, P651, DOI 10.1016/S0092-8674(00)80052-5	27	20	20	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	2004	279	1					341	347		10.1074/jbc.M309281200	http://dx.doi.org/10.1074/jbc.M309281200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	757GU	14534294	hybrid			2022-12-27	WOS:000187555300041
J	Bagnato, C; Igal, RA				Bagnato, C; Igal, RA			Overexpression of diacylglycerol acyltransferase-1 reduces phospholipid synthesis, proliferation, and invasiveness in simian virus 40-transformed human lung fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; LOW-DENSITY LIPOPROTEIN; FATTY-ACIDS; PHOSPHATIDYLCHOLINE SYNTHESIS; PLASMA-MEMBRANE; METABOLIC-FATE; TRIACYLGLYCEROL; CELLS; RAS; HEPATOCYTES	Diacylglycerol (DAG) is a versatile molecule that participates as substrate in the synthesis of structural and energetic lipids, and acts as the physiological signal that activates protein kinase C. Diacylglycerol acyltransferase (DGAT), the last committed enzyme in triacylglycerol synthesis, could potentially regulate the content and use of both signaling and glycerolipid substrate DAG by converting it into triacylglycerol. To test this hypothesis, we stably overexpressed the DGAT1 mouse gene in human lung SV40-transformed fibroblasts (DGAT cells), which contains high levels of DAG. DGAT cells exhibited a 3.9-fold higher DGAT activity and a 3.2-fold increase in triacylglycerol content, whereas DAG and phosphatidylcholine decreased by 70 and 20%, respectively, compared with empty vector-transfected SV40 cells (Control cells). Both acylation and de novo synthesis of phosphatidylcholine, phosphatidylethanolamine, and sphingomyelin were reduced by 30-40% in DGAT cells compared with controls, suggesting that DGAT used substrates for triacylglycerol synthesis that had originally been destined to produce phospholipids. The incorporation of [C-14]DAG and [C-14]fatty acids released from plasma membrane by additions of either phospholipase C or phospholipase A(2) into triacylglycerol was increased by 6.2- and 2.8-fold, respectively, in DGAT cells compared with control cells, indicating that DGAT can attenuate signaling lipids. Finally, DGAT overexpression reversed the neoplastic phenotype because it dramatically reduced the cell growth rate and suppressed the anchorage-independent growth of the SV40 cells. These results strongly support the view that DGAT participates in the regulation of membrane lipid synthesis and lipid signaling, thereby playing an important role in modulating cell growth properties.	Natl Univ La Plata, Fac Ciencias Med, CONICET, Inst Invest Bioquim La Plata, RA-1900 La Plata, Argentina	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); National University of La Plata	Igal, RA (corresponding author), Natl Univ La Plata, Fac Ciencias Med, CONICET, Inst Invest Bioquim La Plata, Calles 60 & 120, RA-1900 La Plata, Argentina.	aigal@atlas.med.unlp.edu.ar			FIC NIH HHS [TW00981] Funding Source: Medline	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		Araki W, 1997, P NATL ACAD SCI USA, V94, P11946, DOI 10.1073/pnas.94.22.11946; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Cao JS, 2003, J BIOL CHEM, V278, P13860, DOI 10.1074/jbc.M300139200; Cases S, 1998, P NATL ACAD SCI USA, V95, P13018, DOI 10.1073/pnas.95.22.13018; Cases S, 2001, J BIOL CHEM, V276, P38870, DOI 10.1074/jbc.M106219200; Chuang M, 1998, BBA-LIPID LIPID MET, V1390, P149, DOI 10.1016/S0005-2760(97)00173-2; Cnop M, 2001, DIABETES, V50, P1771, DOI 10.2337/diabetes.50.8.1771; COLEMAN RA, 1992, METHOD ENZYMOL, V209, P134; DIAZLAVIADA I, 1990, EMBO J, V9, P3907, DOI 10.1002/j.1460-2075.1990.tb07611.x; FLORINCHRISTENSEN J, 1992, J BIOL CHEM, V267, P14783; Igal RA, 2001, J LIPID RES, V42, P88; Igal RA, 2001, J BIOL CHEM, V276, P42205, DOI 10.1074/jbc.M103386200; Igal RA, 1996, J BIOL CHEM, V271, P16644, DOI 10.1074/jbc.271.28.16644; JACKOWSKI S, 1994, J BIOL CHEM, V269, P3858; Jackowski S, 2000, BBA-MOL CELL BIOL L, V1483, P301, DOI 10.1016/S1388-1981(99)00203-6; JOHANSEN T, 1994, MOL CELL BIOL, V14, P646, DOI 10.1128/MCB.14.1.646; Katan M, 1998, BBA-MOL CELL BIOL L, V1436, P5, DOI 10.1016/S0005-2760(98)00125-8; Kelpe CL, 2002, ENDOCRINOLOGY, V143, P3326, DOI 10.1210/en.2002-220402; KUHAJDA FP, 1994, P NATL ACAD SCI USA, V91, P6379, DOI 10.1073/pnas.91.14.6379; LARRODERA P, 1990, CELL, V61, P1113, DOI 10.1016/0092-8674(90)90074-O; Listenberger LL, 2003, P NATL ACAD SCI USA, V100, P3077, DOI 10.1073/pnas.0630588100; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Luberto C, 1998, J BIOL CHEM, V273, P14550, DOI 10.1074/jbc.273.23.14550; Luberto C, 2000, J BIOL CHEM, V275, P14760, DOI 10.1074/jbc.275.19.14760; Martin A, 1997, ONCOGENE, V14, P1571, DOI 10.1038/sj.onc.1200987; MERRILL AH, 1982, J LIPID RES, V23, P1368; Miquel K, 1998, J BIOL CHEM, V273, P26179, DOI 10.1074/jbc.273.40.26179; Nakashima S, 2002, J BIOCHEM, V132, P669, DOI 10.1093/oxfordjournals.jbchem.a003272; Owen MR, 1997, BIOCHEM J, V323, P17, DOI 10.1042/bj3230017; PREISS J, 1986, J BIOL CHEM, V261, P8597; Schaider H, 1998, ANTICANCER RES, V18, P995; STALS HK, 1994, FEBS LETT, V343, P99, DOI 10.1016/0014-5793(94)80615-2; TEEGARDEN D, 1990, J BIOL CHEM, V265, P6042; Topham MK, 1998, NATURE, V394, P697, DOI 10.1038/29337; Topham MK, 2001, J CELL BIOL, V152, P1135, DOI 10.1083/jcb.152.6.1135; Unger RH, 1999, P NATL ACAD SCI USA, V96, P2327, DOI 10.1073/pnas.96.5.2327; VANBLITTERSWIJK WJ, 1991, J BIOL CHEM, V266, P10337; VANDERBEND RL, 1994, J BIOL CHEM, V269, P4098; Wakelam MJO, 1998, BBA-MOL CELL BIOL L, V1436, P117, DOI 10.1016/S0005-2760(98)00123-4; WALKEY CJ, 1994, J BIOL CHEM, V269, P5742; Wang XY, 1999, EXP CELL RES, V250, P253, DOI 10.1006/excr.1999.4529; WIGGINS D, 1992, BIOCHEM J, V284, P457, DOI 10.1042/bj2840457; Wolins NE, 2001, J BIOL CHEM, V276, P5101, DOI 10.1074/jbc.M006775200	43	54	60	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52203	52211		10.1074/jbc.M305760200	http://dx.doi.org/10.1074/jbc.M305760200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14557275	hybrid			2022-12-27	WOS:000187480700029
J	Fernandez, N; Renedo, M; Alonso, S; Crespo, MS				Fernandez, N; Renedo, M; Alonso, S; Crespo, MS			Release of arachidonic acid by stimulation of opsonic receptors in human monocytes - The Fc gamma R and the complement receptor 3 pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING LECTIN SITE; PLATELET-ACTIVATING-FACTOR; BETA-GLUCAN RECEPTOR; CR3 CD11B/CD18; DENDRITIC CELLS; IMMUNE-COMPLEXES; ARTHUS REACTION; PROTEIN-KINASE; CROSS-LINKING; DECTIN-1	The role of the opsonic receptors FcgammaR and CR3 on the release of arachidonic acid (AA) by human monocytes was studied using IgG-ovalbumin (OVA) equivalence immune complexes (IC), anti-OVA IgG bound to OVA-coupled latex beads, and C3bi-bound IC. Release of AA was produced by IC and latex-OVA beads bound to IgG, whereas binding of C3bi to IC inhibited the ability of IC to release AA. In contrast, coating of zymosan particles with C3bi enhanced AA release as compared with that produced by non-coated particles. Masking of C3bi on C3bi-bound IC by incubation with anti-C3 IgG resulted in the recovery of their ability to release AA, thereby suggesting that binding of C3b by IC reduces their flogogenic effects, whereas opsonization of microbial walls by complement may enhance their proinflammatory potential. The binding/uptake of opsonized zymosan particles was inhibited by anti-CR3 Ab and C3bi-bound IC, but not by beta-glucan, mannan, and anti-Toll-like receptor 2 Ab. These findings show that cooperative engagement of CR3 on both the lectin-like site involved in beta-glucan binding and the I-domain involved in C3bi binding, as it can be observed in the innate immune response, produces AA release, whereas the unique interaction of C3bi-bound IC with the I-domain of CR3, as it may occur in the adaptive immune response, diverts the IC lattice from a productive interaction with FcgammaR linked to AA release.	CSIC, Inst Mol Biol & Genet, Fac Med, Valladolid 47005, Spain; Hosp Clin Univ, Unidad Invest, Valladolid 47005, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-UVA - Instituto de Biologia y Genetica Molecular (IBGM); Universidad de la Laguna	Crespo, MS (corresponding author), CSIC, Inst Mol Biol & Genet, Fac Med, Valladolid 47005, Spain.	mscres@ibgm.uva.es	Fernández, Nieves/N-5426-2018	Fernández, Nieves/0000-0002-9141-3956				ALCOLEA JM, 1987, COMPLEMENT INFLAMMAT, V4, P21, DOI 10.1159/000463004; Alonso A, 1996, EUR J IMMUNOL, V26, P2165, DOI 10.1002/eji.1830260931; Banki Z, 2003, J IMMUNOL, V170, P3963, DOI 10.4049/jimmunol.170.8.3963; Brown GD, 2002, J EXP MED, V196, P407, DOI 10.1084/jem.20020470; Brown GD, 2003, J EXP MED, V197, P1119, DOI 10.1084/jem.20021890; Choi IW, 2003, J EXP MED, V198, P145, DOI 10.1084/jem.20022129; Daeron M, 1997, ANNU REV IMMUNOL, V15, P203, DOI 10.1146/annurev.immunol.15.1.203; EDEN A, 1973, CELL IMMUNOL, V7, P459, DOI 10.1016/0008-8749(73)90210-4; Fernandez N, 2002, EUR J IMMUNOL, V32, P383, DOI 10.1002/1521-4141(200202)32:2<383::AID-IMMU383>3.0.CO;2-9; Fernandez N, 2002, J IMMUNOL, V169, P3321, DOI 10.4049/jimmunol.169.6.3321; Gantner BN, 2003, J EXP MED, V197, P1107, DOI 10.1084/jem.20021787; Grewal S, 2002, J CELL SCI, V115, P4533, DOI 10.1242/jcs.00146; Hanasaki K, 1999, J BIOL CHEM, V274, P34203, DOI 10.1074/jbc.274.48.34203; Hazan-Halevy I, 2000, J BIOL CHEM, V275, P12416, DOI 10.1074/jbc.275.17.12416; Hazenbos WLW, 1996, IMMUNITY, V5, P181, DOI 10.1016/S1074-7613(00)80494-X; HIRASAWA N, 1995, J IMMUNOL, V154, P5391; ISENMAN DE, 1981, BIOCHEMISTRY-US, V20, P4458, DOI 10.1021/bi00518a034; Le Cabec V, 2000, INFECT IMMUN, V68, P4736, DOI 10.1128/IAI.68.8.4736-4745.2000; Le Cabec V, 2002, J IMMUNOL, V169, P2003, DOI 10.4049/jimmunol.169.4.2003; MARSH CB, 1995, J IMMUNOL, V155, P3161; Marth T, 1997, J EXP MED, V185, P1987, DOI 10.1084/jem.185.11.1987; MILLER GW, 1975, P NATL ACAD SCI USA, V72, P418, DOI 10.1073/pnas.72.2.418; MORGAN BP, 1991, IMMUNOL TODAY, V12, P301, DOI 10.1016/0167-5699(91)90003-C; PASSLICK B, 1989, BLOOD, V74, P2527, DOI 10.1182/blood.V74.7.2527.2527; Pickering MC, 2002, NAT GENET, V31, P424, DOI 10.1038/ng912; Ravetch JV, 2001, ANNU REV IMMUNOL, V19, P275, DOI 10.1146/annurev.immunol.19.1.275; Regnault A, 1999, J EXP MED, V189, P371, DOI 10.1084/jem.189.2.371; Romani L, 2002, TRENDS MICROBIOL, V10, P508, DOI 10.1016/S0966-842X(02)02460-5; Sabroe I, 2003, J IMMUNOL, V171, P1630, DOI 10.4049/jimmunol.171.4.1630; STANDIFORD TJ, 1995, J IMMUNOL, V155, P1515; STEIL AA, 1995, BRIT J PHARMACOL, V114, P895, DOI 10.1111/j.1476-5381.1995.tb13288.x; SYLVESTRE DL, 1994, SCIENCE, V265, P1095, DOI 10.1126/science.8066448; Taborda CP, 2002, IMMUNITY, V16, P791, DOI 10.1016/S1074-7613(02)00328-X; TAKAHASHI M, 1978, J CLIN INVEST, V62, P349, DOI 10.1172/JCI109135; TAKATA Y, 1984, J IMMUNOL, V132, P2531; Taylor PR, 2002, J IMMUNOL, V169, P3876, DOI 10.4049/jimmunol.169.7.3876; Thornton BP, 1996, J IMMUNOL, V156, P1235; Underhill DM, 1999, NATURE, V401, P811, DOI 10.1038/44605; Vidarte L, 2001, J BIOL CHEM, V276, P38217; Vivanco F, 1999, MOL IMMUNOL, V36, P843, DOI 10.1016/S0161-5890(99)00105-4; Xia Y, 1999, J IMMUNOL, V162, P7285; Xia Y, 1999, J IMMUNOL, V162, P2281; Zelle-Rieser C, 2002, FEBS LETT, V511, P123, DOI 10.1016/S0014-5793(01)03326-9	43	23	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52179	52187		10.1074/jbc.M310905200	http://dx.doi.org/10.1074/jbc.M310905200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14532278	hybrid			2022-12-27	WOS:000187480700026
J	Fu, T; Kozarsky, KF; Borensztajn, J				Fu, T; Kozarsky, KF; Borensztajn, J			Overexpression of SR-BI by adenoviral vector reverses the fibrate-induced hypercholesterolemia of apolipoprotein E-deficient mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; SCAVENGER RECEPTOR; HDL RECEPTOR; CHOLESTEROL; ATHEROSCLEROSIS; EXPRESSION; CLEARANCE; PROTEIN	The hypercholesterolemia characteristic of apolipoprotein (apoE)-deficient mice fed on a regular chow diet is caused by the abnormal accumulation of apoB-48-carrying remnants of chylomicrons and very low density lipoproteins in the plasma. Treatment of apoE-deficient mice with ciprofibrate or other peroxisome proliferator-activated receptor alpha agonists severely aggravates their hypercholesterolemia by interfering with one or more mechanisms of remnant removal from the circulation that do not require mediation by apoE (Fu, T., Kashireddy, P., and Borensztajn, J. (2003) Biochem. J. 373, 941-947). In the present investigation we report that ciprofibrate treatment causes the down-regulation of hepatic scavenger receptor class B, type I (SR-BI) protein expression in the livers of apoE-deficient mice. On cessation of the treatment SR-BI expression returns to its pretreatment levels, coinciding with a reversal of the hypercholesterolemia to base-line concentrations. Restoration of SR-BI expression in ciprofibrate-treated apoE-deficient mice by recombinant adenoviral gene transfer abolishes the ciprofibrate-induced over accumulation of apoB-48-carrying remnants in the plasma. We also report that remnants isolated from the plasma of ciprofibrate-treated apoE-deficient mice bind to murine SR-BI expressed in stably transfected cultured cells. These observations suggest that, in addition to its well established role as high density lipoprotein receptor, SR-BI can also function as a remnant receptor responsible for the clearance of remnants from the circulation of apoE-deficient mice.	Northwestern Univ, Dept Pathol, Feinberg Sch Med, Chicago, IL 60611 USA; GlaxoSmithKline, Dept Prot Agents & Human Gene Therapy, King Of Prussia, PA 19406 USA	Northwestern University; Feinberg School of Medicine; GlaxoSmithKline	Borensztajn, J (corresponding author), Northwestern Univ, Dept Pathol, Feinberg Sch Med, 303 E Chicago Ave, Chicago, IL 60611 USA.	jbb@northwestern.edu						Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; Cooper AD, 1997, J LIPID RES, V38, P2173; Crawford SE, 1999, J LIPID RES, V40, P797; Fluiter K, 1997, BIOCHEM J, V326, P515, DOI 10.1042/bj3260515; Fu T, 2003, BIOCHEM J, V373, P941, DOI 10.1042/BJ20030105; Havel RJ, 1998, ATHEROSCLEROSIS, V141, pS1; Kozarsky KF, 2000, ARTERIOSCL THROM VAS, V20, P721, DOI 10.1161/01.ATV.20.3.721; Kozarsky KF, 1997, NATURE, V387, P414, DOI 10.1038/387414a0; Krieger M, 2001, J CLIN INVEST, V108, P793, DOI 10.1172/JCI200114011; Mardones P, 2003, J BIOL CHEM, V278, P7884, DOI 10.1074/jbc.M211627200; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; Reddy JK, 1996, ANN NY ACAD SCI, V804, P176, DOI 10.1111/j.1749-6632.1996.tb18616.x; Rigotti A, 1997, P NATL ACAD SCI USA, V94, P12610, DOI 10.1073/pnas.94.23.12610; RIGOTTI A, 1995, J BIOL CHEM, V270, P16221, DOI 10.1074/jbc.270.27.16221; Silver DL, 2001, J BIOL CHEM, V276, P25287, DOI 10.1074/jbc.M101726200; STAELS B, 1992, J LIPID RES, V33, P727; Ueda Y, 1999, J BIOL CHEM, V274, P7165, DOI 10.1074/jbc.274.11.7165; Wang N, 1998, J BIOL CHEM, V273, P32920, DOI 10.1074/jbc.273.49.32920; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543	19	43	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52559	52563		10.1074/jbc.M310892200	http://dx.doi.org/10.1074/jbc.M310892200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14570884	hybrid			2022-12-27	WOS:000187480700073
J	Zambonelli, C; Casali, M; Roberts, MF				Zambonelli, C; Casali, M; Roberts, MF			Mutagenesis of putative catalytic and regulatory residues of Streptomyces chromofuscus phospholipase D differentially modifies phosphatase and phosphodiesterase activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PURPLE ACID-PHOSPHATASE; C-TERMINAL DOMAINS; ALKALINE-PHOSPHATASE; CRYSTAL-STRUCTURE; INTERFACIAL BINDING; MUTATIONAL ANALYSIS; BACILLUS-SUBTILIS; ESCHERICHIA-COLI; GENE FAMILY; D DEFINES	Phospholipase D from Streptomyces chromofuscus (scPLD) is a member of the diverse family of metallo-phosphodiesterase/phosphatase enzymes that also includes purple acid phosphatases, protein phosphatases, and nucleotide phosphodiesterases. Whereas iron is an essential cofactor for scPLD activity, Mn2+ is also found in the enzyme. A third metal ion, Ca2+, has been shown to enhance scPLD catalytic activity although it is not an essential cofactor. Sequence alignment of scPLD with known phosphodiesterases and phosphatases requiring metal ions suggested that His-212, Glu-213, and Asp-389 could be involved in Mn2+ binding. H212A, E213A, and D389A were prepared to test this hypothesis. These three mutant enzymes and wild type scPLD show similar metal content but considerably different catalytic properties, suggesting different roles for each residue. His-212 appears involved in binding the phosphate group of substrates, whereas Glu-213 acts as a ligand for Ca2+. D389A showed a greatly reduced phosphodiesterase activity but almost unaltered ability to hydrolyze the phosphate group in p-nitrophenyl phosphate suggesting it had a critical role in aligning groups at the active site to control phosphodiesterase versus phosphatase activities. We propose a model for substrate and cofactor binding to the catalytic site of scPLD based on these results and on sequence alignment to purple acid phosphatases of known structure.	Boston Coll, Merkert Chem Ctr, Chestnut Hill, MA 02467 USA	Boston College	Roberts, MF (corresponding author), Boston Coll, Merkert Chem Ctr, Chestnut Hill, MA 02467 USA.	mary.roberts@bc.edu			NIGMS NIH HHS [GM 26762] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026762] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Copeland R. A., 2004, ENZYMES PRACTICAL IN; Dong GA, 1999, BBA-PROTEIN STRUCT M, V1430, P234, DOI 10.1016/S0167-4838(99)00005-9; Eder S, 1996, MICROBIOL-SGM, V142, P2041, DOI 10.1099/13500872-142-8-2041; Eibl H, 1981, Methods Enzymol, V72, P632; Exton JH, 2002, FEBS LETT, V531, P58, DOI 10.1016/S0014-5793(02)03405-1; Gijsbers R, 2001, J BIOL CHEM, V276, P1361, DOI 10.1074/jbc.M007552200; GRIFFITH JP, 1995, CELL, V82, P507, DOI 10.1016/0092-8674(95)90439-5; Guddat LW, 1999, STRUCT FOLD DES, V7, P757, DOI 10.1016/S0969-2126(99)80100-2; HAMMOND SM, 1995, J BIOL CHEM, V270, P29640; Holtz KM, 1999, FEBS LETT, V462, P7, DOI 10.1016/S0014-5793(99)01448-9; KIM EE, 1991, J MOL BIOL, V218, P449, DOI 10.1016/0022-2836(91)90724-K; KISSINGER CR, 1995, NATURE, V378, P641, DOI 10.1038/378641a0; Klabunde T, 1996, J MOL BIOL, V259, P737, DOI 10.1006/jmbi.1996.0354; KOONIN EV, 1994, PROTEIN SCI, V3, P356; LAGOCKI JW, 1976, J BIOL CHEM, V251, P6001; Leiros I, 2000, STRUCTURE, V8, P655, DOI 10.1016/S0969-2126(00)00150-7; Lindqvist Y, 1999, J MOL BIOL, V291, P135, DOI 10.1006/jmbi.1999.2962; Liscovitch M, 2000, BIOCHEM J, V345, P401, DOI 10.1042/0264-6021:3450401; O'Brien PJ, 2001, BIOCHEMISTRY-US, V40, P5691, DOI 10.1021/bi0028892; Oh MK, 2003, BBA-PROTEINS PROTEOM, V1649, P146, DOI 10.1016/S1570-9639(03)00166-3; Qin CB, 2002, PLANT PHYSIOL, V128, P1057, DOI 10.1104/pp.010928; Rusnak F, 2000, PHYSIOL REV, V80, P1483, DOI 10.1152/physrev.2000.80.4.1483; SOWADSKI JM, 1985, J MOL BIOL, V186, P417, DOI 10.1016/0022-2836(85)90115-9; Stec B, 2000, J MOL BIOL, V299, P1303, DOI 10.1006/jmbi.2000.3799; Stieglitz K, 1999, J BIOL CHEM, V274, P35367, DOI 10.1074/jbc.274.50.35367; STRATER N, 1995, SCIENCE, V268, P1489, DOI 10.1126/science.7770774; Sung TC, 1997, EMBO J, V16, P4519, DOI 10.1093/emboj/16.15.4519; Todd MJ, 2001, ANAL BIOCHEM, V296, P179, DOI 10.1006/abio.2001.5218; Uppenberg J, 1999, J MOL BIOL, V290, P201, DOI 10.1006/jmbi.1999.2896; VINCENT JB, 1990, FEBS LETT, V263, P265, DOI 10.1016/0014-5793(90)81389-6; Vogel A., 2001, HDB METALLOPROTEINS, V2, P752; Wang XM, 2002, PHYSIOL PLANTARUM, V115, P331, DOI 10.1034/j.1399-3054.2002.1150301.x; Widlanski TS, 1997, CHEM BIOL, V4, P489, DOI 10.1016/S1074-5521(97)90319-7; WIELOCH T, 1982, J BIOL CHEM, V257, P1523; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; Xie Z, 2000, J BIOL CHEM, V275, P24962, DOI 10.1074/jbc.M909745199; Xie Z, 1998, J BIOL CHEM, V273, P34679, DOI 10.1074/jbc.273.52.34679; YAMANE K, 1978, J BACTERIOL, V134, P108, DOI 10.1128/JB.134.1.108-114.1978; Yang HY, 2003, PROTEIN SCI, V12, P2087, DOI 10.1110/ps.03192503; Yang HY, 2002, PROTEIN SCI, V11, P2958, DOI 10.1110/ps.0225302; YANG SF, 1967, J BIOL CHEM, V242, P477; Zambonelli C, 2003, J BIOL CHEM, V278, P13706, DOI 10.1074/jbc.M210363200; Zhang J, 1996, BIOCHEMISTRY-US, V35, P6276, DOI 10.1021/bi952954l; ZHUO SQ, 1994, J BIOL CHEM, V269, P26234	44	15	17	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52282	52289		10.1074/jbc.M310252200	http://dx.doi.org/10.1074/jbc.M310252200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14557260	hybrid			2022-12-27	WOS:000187480700037
J	Murakami, S; Tamura, N; Saito, A; Hirata, T; Yamaguchi, A				Murakami, S; Tamura, N; Saito, A; Hirata, T; Yamaguchi, A			Extramembrane central pore of multidrug exporter AcrB in Escherichia coli plays an important role in drug transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRAM-NEGATIVE BACTERIA; SITE-SPECIFIC MUTAGENESIS; LARGE PERIPLASMIC LOOPS; PSEUDOMONAS-AERUGINOSA; EFFLUX PUMPS; SUBSTRATE-SPECIFICITY; PHENOTYPIC SELECTION; MEMBRANE TOPOLOGY; CRYSTAL-STRUCTURE; PROTEIN	We previously reported the crystal structure of the major multidrug exporter AcrB in Escherichia coli (Murakami, S., Nakashima, R., Yamashita, E., and Yamaguchi, A. (2002) Nature 419, 587-593). The extramembrane headpiece of the AcrB trimer contains a central pore composed of three alpha-helices. Each pore helix belongs to a different monomer. In this study, we constructed cysteine-scanning mutants as to the residues comprising the pore helix. Of the 21 mutants (D99C to P119C), 5 (D101C, V105C, N109C, Q112C, and P116C) showed significantly reduced drug resistance and drug-exporting activity. These residues are localized on one side of the pore helix, i.e. on the wall of the pore. These observations strongly indicate the important role of this pore in the drug transport process. A N-ethylmaleimide binding experiment revealed that the pore is in the closed state, and the thickness of the permeability barrier in the middle of the pore corresponds to 2.5 alpha-helical turns. Two mutants (V105C and Q112C), which showed the greatest loss of activity of all of the pore mutants, were detected in the form of disulfide cross-linking dimers under normal conditions, suggesting that a conformational change of the pore is indispensable during the transport process.	Osaka Univ, Inst Sci & Ind Res, Dept Cell Membrane Biol, Ibaraki, Osaka 5670047, Japan; Osaka Univ, Fac Pharmaceut Sci, Suita, Osaka 5650871, Japan; Japan Sci & Technol Corp, CREST, Osaka 5670047, Japan; Japan Sci & Technol Corp, PRESTO, Osaka 5670047, Japan	Osaka University; Osaka University; Japan Science & Technology Agency (JST); Japan Science & Technology Agency (JST)	Yamaguchi, A (corresponding author), Osaka Univ, Inst Sci & Ind Res, Dept Cell Membrane Biol, 8-1 Mihogaoka, Ibaraki, Osaka 5670047, Japan.	akihito@sanken.osaka-u.ac.jp	Murakami, Satoshi/E-8155-2015	Murakami, Satoshi/0000-0001-5553-7663				Andersen C, 2002, P NATL ACAD SCI USA, V99, P11103, DOI 10.1073/pnas.162039399; Eda S, 2003, J BIOL CHEM, V278, P2085, DOI 10.1074/jbc.C200661200; Elkins CA, 2002, J BACTERIOL, V184, P6490, DOI 10.1128/JB.184.23.6490-6499.2002; Fralick JA, 1996, J BACTERIOL, V178, P5803, DOI 10.1128/jb.178.19.5803-5805.1996; Fujihira E, 2002, J BIOCHEM, V131, P145, DOI 10.1093/oxfordjournals.jbchem.a003069; Germ M, 1999, BIOCHEM BIOPH RES CO, V261, P452, DOI 10.1006/bbrc.1999.1045; Kobayashi N, 2003, FEBS LETT, V546, P241, DOI 10.1016/S0014-5793(03)00579-9; Koronakis V, 2000, NATURE, V405, P914, DOI 10.1038/35016007; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Mao WM, 2002, MOL MICROBIOL, V46, P889, DOI 10.1046/j.1365-2958.2002.03223.x; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Morita Y, 1998, ANTIMICROB AGENTS CH, V42, P1778, DOI 10.1128/AAC.42.7.1778; Murakami S, 2002, NATURE, V419, P587, DOI 10.1038/nature01050; Murata T, 2002, BIOCHEM BIOPH RES CO, V299, P247, DOI 10.1016/S0006-291X(02)02626-8; Nikaido H, 1996, J BACTERIOL, V178, P5853, DOI 10.1128/jb.178.20.5853-5859.1996; Nikaido H, 2001, J MOL MICROB BIOTECH, V3, P215; Nishino K, 2001, J BACTERIOL, V183, P5803, DOI 10.1128/JB.183.20.5803-5812.2001; Poole K, 2001, J MOL MICROB BIOTECH, V3, P255; SAIER MH, 1994, MOL MICROBIOL, V11, P841, DOI 10.1111/j.1365-2958.1994.tb00362.x; Srikumar R, 1998, ANTIMICROB AGENTS CH, V42, P65, DOI 10.1128/AAC.42.1.65; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8765; Tikhonova EB, 2002, J BACTERIOL, V184, P6499, DOI 10.1128/JB.184.23.6499-6507.2002; YAMAMOTO T, 1981, J BACTERIOL, V145, P808, DOI 10.1128/JB.145.2.808-813.1981; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; Zgurskaya HI, 1999, P NATL ACAD SCI USA, V96, P7190, DOI 10.1073/pnas.96.13.7190	28	54	64	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	2004	279	5					3743	3748		10.1074/jbc.M308893200	http://dx.doi.org/10.1074/jbc.M308893200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	766MF	14576158	hybrid			2022-12-27	WOS:000188379600075
J	Zoidl, G; Bruzzone, R; Weickert, S; Kremer, M; Zoidl, C; Mitropoulou, G; Srinivas, M; Spray, DC; Dermietzel, R				Zoidl, G; Bruzzone, R; Weickert, S; Kremer, M; Zoidl, C; Mitropoulou, G; Srinivas, M; Spray, DC; Dermietzel, R			Molecular cloning and functional expression of zfCx52.6 - A novel connexin with hemichannel-forming properties expressed in horizontal cells of the zebrafish retina	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAP-JUNCTION CHANNELS; AII AMACRINE CELLS; MAMMALIAN RETINA; NEURONAL CONNEXIN36; DOPAMINERGIC MODULATION; ELECTRICAL SYNAPSES; GENE CONNEXIN36; SKATE RETINA; CYCLIC-AMP; PROTEIN	Gap junction-mediated electrical coupling contributes to synchronous oscillatory activities of neurons, and considerable progress has been made in defining the molecular composition of gap junction channels. In particular, cloning and functional expression of gap junction proteins (connexins (Cx)) from zebrafish retina have shown that this part of the brain possesses a high degree of connexin diversity that may account for differential functional properties of electrical synapses. Here, we report the cloning and functional characterization of a new connexin, designated zebrafish Cx52.6 (zfCx52.6). This connexin shows little similarity to known connexins from fish and higher vertebrates. By combining in situ hybridization with Laser Capture Microdissection and RT-PCR, we found that this novel fish connexin is expressed in horizontal cells in the inner nuclear layer of the retina. Functional expression of zfCx52.6 in neuroblastoma cells and Xenopus oocytes led to functional gap junctional channels and, in single oocytes, induced large non-junctional membrane currents indicative of the formation of hemichannels, which were inhibited in reversible fashion by raising extracellular Ca2+ concentrations.	Ruhr Univ Bochum, Dept Neuroanat & Mol Brain Res, D-44801 Bochum, Germany; Inst Pasteur, Dept Neurosci, F-75015 Paris, France; Interdisciplinary Ctr Neurosci IZN, Dept Clin Neurobiol, D-69120 Heidelberg, Germany; Yeshiva Univ Albert Einstein Coll Med, Dept Neurosci, Rose F Kennedy Ctr, Bronx, NY 10461 USA	Ruhr University Bochum; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Ruprecht Karls University Heidelberg; Yeshiva University; Albert Einstein College of Medicine	Dermietzel, R (corresponding author), Ruhr Univ Bochum, Dept Neuroanat & Mol Brain Res, Univ St 150, D-44801 Bochum, Germany.	rolf.dermietzel@ruhr-uni-bochum.de	Bruzzone, Roberto/C-4719-2009; Bruzzone, Roberto/G-9355-2017	Bruzzone, Roberto/0000-0003-4373-1447; Bruzzone, Roberto/0000-0003-4373-1447; Spray, David/0000-0001-8368-5073	NIMH NIH HHS [MH65495] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH065495] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Al-Ubaidi MR, 2000, J NEUROSCI RES, V59, P813, DOI 10.1002/(SICI)1097-4547(20000315)59:6<813::AID-JNR14>3.3.CO;2-R; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BARRIO LC, 1991, P NATL ACAD SCI USA, V88, P8410, DOI 10.1073/pnas.88.19.8410; Becker D, 1998, CELL BIOL INT, V22, P781, DOI 10.1006/cbir.1998.0390; BENNETT MVL, 1991, NEURON, V6, P305, DOI 10.1016/0896-6273(91)90241-Q; BRUZZONE R, 1993, MOL BIOL CELL, V4, P7, DOI 10.1091/mbc.4.1.7; Bruzzone R, 1996, EUR J BIOCHEM, V238, P1, DOI 10.1111/j.1432-1033.1996.0001q.x; Castro C, 1999, J NEUROSCI, V19, P3752; Condorelli DF, 1998, EUR J NEUROSCI, V10, P1202, DOI 10.1046/j.1460-9568.1998.00163.x; Deans MR, 2002, NEURON, V36, P703, DOI 10.1016/S0896-6273(02)01046-2; Dermietzel R, 2000, J NEUROSCI, V20, P8331, DOI 10.1523/JNEUROSCI.20-22-08331.2000; DERMIETZEL R, 1993, TRENDS NEUROSCI, V16, P186, DOI 10.1016/0166-2236(93)90151-B; DEVRIES SH, 1992, J PHYSIOL-LONDON, V445, P201, DOI 10.1113/jphysiol.1992.sp018920; DEVRIES SH, 1989, J PHYSIOL-LONDON, V414, P351, DOI 10.1113/jphysiol.1989.sp017692; Feigenspan A, 2001, J NEUROSCI, V21, P230, DOI 10.1523/JNEUROSCI.21-01-00230.2001; Galarreta M, 1999, NATURE, V402, P72, DOI 10.1038/47029; Gibson JR, 1999, NATURE, V402, P75, DOI 10.1038/47035; Gillen C, 1996, EUR J NEUROSCI, V8, P405, DOI 10.1111/j.1460-9568.1996.tb01223.x; Guldenagel M, 2001, J NEUROSCI, V21, P6036, DOI 10.1523/JNEUROSCI.21-16-06036.2001; HAEFLIGER JA, 1992, J BIOL CHEM, V267, P2057; HAMPSON ECGM, 1994, P ROY SOC B-BIOL SCI, V255, P67, DOI 10.1098/rspb.1994.0010; HAMPSON ECGM, 1992, J NEUROSCI, V12, P4911; Harris AL, 2001, Q REV BIOPHYS, V34, P325, DOI 10.1017/S0033583501003705; HENNEMANN H, 1992, J CELL BIOL, V117, P1299, DOI 10.1083/jcb.117.6.1299; Hopperstad MG, 2000, BIOPHYS J, V79, P1954, DOI 10.1016/S0006-3495(00)76444-7; Hormuzdi SG, 2001, NEURON, V31, P487, DOI 10.1016/S0896-6273(01)00387-7; JANSSENBIENHOLD U, 1993, EUR J NEUROSCI, V5, P584, DOI 10.1111/j.1460-9568.1993.tb00524.x; Kamermans M, 2001, SCIENCE, V292, P1178, DOI 10.1126/science.1060101; KIMMEL CB, 1995, DEV DYNAM, V203, P253, DOI 10.1002/aja.1002030302; LASATER EM, 1987, P NATL ACAD SCI USA, V84, P7319, DOI 10.1073/pnas.84.20.7319; Li HY, 1996, J CELL BIOL, V134, P1019, DOI 10.1083/jcb.134.4.1019; Lu CB, 1999, VISUAL NEUROSCI, V16, P811, DOI 10.1017/S0952523899165015; Masai I, 2000, NEURON, V27, P251, DOI 10.1016/S0896-6273(00)00034-9; MCMAHON DG, 1994, J NEUROSCI, V14, P1722, DOI 10.1523/JNEUROSCI.14-03-01722.1994; Meier C, 2002, HISTOCHEM CELL BIOL, V117, P461, DOI 10.1007/s00418-002-0417-z; Mergia E, 2003, CELL SIGNAL, V15, P189, DOI 10.1016/S0898-6568(02)00078-5; METHFESSEL C, 1986, PFLUG ARCH EUR J PHY, V407, P577, DOI 10.1007/BF00582635; MILKS LC, 1988, EMBO J, V7, P2967, DOI 10.1002/j.1460-2075.1988.tb03159.x; MILLS SL, 1995, NATURE, V377, P734, DOI 10.1038/377734a0; MIYACHI EI, 1989, J PHYSIOL-LONDON, V419, P213, DOI 10.1113/jphysiol.1989.sp017870; Mueller T, 2003, DEV BRAIN RES, V140, P137, DOI 10.1016/S0165-3806(02)00583-7; NITROPOULOU G, 2003, J NEUROSCI RES, V15, P147; O'Brien J, 1998, J NEUROSCI, V18, P7625; OBrien J, 1996, MOL BIOL CELL, V7, P233, DOI 10.1091/mbc.7.2.233; OLMSTED JB, 1970, P NATL ACAD SCI USA, V65, P129, DOI 10.1073/pnas.65.1.129; PEREDA AE, 1995, J NEUROSCI, V15, P5943; PICCOLINO M, 1982, P NATL ACAD SCI-BIOL, V79, P3671, DOI 10.1073/pnas.79.11.3671; QIAN HH, 1992, J GEN PHYSIOL, V100, P457, DOI 10.1085/jgp.100.3.457; Quist AP, 2000, J CELL BIOL, V148, P1063, DOI 10.1083/jcb.148.5.1063; Scheer N, 2001, DEVELOPMENT, V128, P1099; Sohl G, 1998, FEBS LETT, V428, P27, DOI 10.1016/S0014-5793(98)00479-7; Sohl G, 2000, BRAIN RES REV, V32, P138, DOI 10.1016/S0165-0173(99)00074-0; SPRAY DC, 1981, J GEN PHYSIOL, V77, P77, DOI 10.1085/jgp.77.1.77; SWENSON KI, 1989, CELL, V57, P145, DOI 10.1016/0092-8674(89)90180-3; Taylor JS, 2003, GENOME RES, V13, P382, DOI 10.1101/gr.640303; Van de Peer Yves, 2003, Journal of Structural and Functional Genomics, V3, P65, DOI 10.1023/A:1022652814749; VANEY DI, 1994, PROG RETIN EYE RES, V13, P301, DOI 10.1016/1350-9462(94)90014-0; VANEY DI, 1993, P ROY SOC B-BIOL SCI, V252, P93, DOI 10.1098/rspb.1993.0051; VANEY DI, 1991, NEUROSCI LETT, V125, P187, DOI 10.1016/0304-3940(91)90024-N; Vaney DI, 1998, J NEUROSCI, V18, P10594; VANEY DI, 1996, GAP JUNCTIONS NERVOU, P79; Veruki ML, 2002, J NEUROSCI, V22, P10558; Veruki ML, 2002, NEURON, V33, P935, DOI 10.1016/S0896-6273(02)00609-8; Vetter ML, 2001, SEMIN CELL DEV BIOL, V12, P491, DOI 10.1006/scdb.2001.0273; WAGNER TL, 1998, VISUAL NEUROSCI, V15, P1173; WEILER R, 1996, GAP JUNCTIONS NERVOU, P103; White TW, 1999, EUR J NEUROSCI, V11, P1883, DOI 10.1046/j.1460-9568.1999.00607.x; White TW, 2000, BRAIN RES REV, V32, P130, DOI 10.1016/S0165-0173(99)00072-7; WILDERS R, 1992, BIOPHYS J, V63, P942, DOI 10.1016/S0006-3495(92)81664-8; Willecke K, 2002, BIOL CHEM, V383, P725, DOI 10.1515/BC.2002.076; Yeager M, 1998, CURR OPIN STRUC BIOL, V8, P517, DOI 10.1016/S0959-440X(98)80131-0; Zoidl G, 2002, CELL TISSUE RES, V310, P137, DOI 10.1007/s00441-002-0632-x; Zoidl G, 2002, J NEUROSCI RES, V69, P448, DOI 10.1002/jnr.10284	73	44	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	2004	279	4					2913	2921		10.1074/jbc.M304850200	http://dx.doi.org/10.1074/jbc.M304850200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	764MU	14583621	hybrid			2022-12-27	WOS:000188211300071
J	Fukuhara, N; Fernandez, E; Ebert, J; Conti, E; Svergun, D				Fukuhara, N; Fernandez, E; Ebert, J; Conti, E; Svergun, D			Conformational variability of nucleo-cytoplasmic transport factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR EXPORT RECEPTOR; SMALL-ANGLE SCATTERING; IMPORTIN-ALPHA; BIOLOGICAL MACROMOLECULES; BETA; PROTEINS; IDENTIFICATION; RESOLUTION; DOMAIN; CSE1P	The transport of macromolecules between the nucleus and cytoplasm of eukaryotic cells is largely mediated by a single family of transport factors, the karyopherin or importin beta-like family. Structural and biochemical evidence suggests conformational flexibility of these modular HEAT-repeat proteins is crucial for their regulation. Here we use small angle x-ray scattering to assess the extent of conformational variation within a set of nuclear import and export factors. The study reveals that importin beta, transportin, and the exportin Xpo-t share a similar S-like superhelical conformation in their unbound state. There are no obvious differences in the overall structures that might generally distinguish nuclear export from nuclear import mediators. Two other members of the family, the exportins Cse1 and Xpo1, possess a significantly more globular conformation, indicating that the extended S-like architecture is not a hallmark of all karyopherins. Binding of RanGTP/cargo to importin beta, transportin, and Xpo-t triggers distinct conformational responses, suggesting that even closely related karyopherins employ different mechanisms of conformational regulation and that cargo and nuclear pore-interacting surfaces of the different receptors may be unique.	European Mol Biol Lab, D-69117 Heidelberg, Germany; DESY, European Mol Biol Lab, D-22603 Hamburg, Germany; Russian Acad Sci, Inst Crystallog, Moscow 117333, Russia	European Molecular Biology Laboratory (EMBL); European Molecular Biology Laboratory (EMBL); Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY); Russian Academy of Sciences; FSRC Crystallography & Photonics RAS	Conti, E (corresponding author), European Mol Biol Lab, Meyerhofstr 1, D-69117 Heidelberg, Germany.	conti@embl-heidelberg.de		Svergun, Dmitri/0000-0003-0830-5696; Conti, Elena/0000-0003-1254-5588				Andrade MA, 2001, J MOL BIOL, V309, P1, DOI 10.1006/jmbi.2001.4624; Arts GJ, 1998, CURR BIOL, V8, P305, DOI 10.1016/S0960-9822(98)70130-7; BOULIN CJ, 1988, NUCL INSTRUM METH A, V269, P312, DOI 10.1016/0168-9002(88)90895-9; Chook YM, 1999, NATURE, V399, P230, DOI 10.1038/20375; Chook YM, 2002, BIOCHEMISTRY-US, V41, P6955, DOI 10.1021/bi012122p; Cingolani G, 2000, FEBS LETT, V484, P291, DOI 10.1016/S0014-5793(00)02154-2; Cingolani G, 2002, MOL CELL, V10, P1345, DOI 10.1016/S1097-2765(02)00727-X; Cingolani G, 1999, NATURE, V399, P221, DOI 10.1038/20367; Conti E, 2001, CURR OPIN CELL BIOL, V13, P310, DOI 10.1016/S0955-0674(00)00213-1; Conti Elena, 2002, Results Probl Cell Differ, V35, P93; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Gorlich D, 1997, J CELL BIOL, V138, P65, DOI 10.1083/jcb.138.1.65; Hellmuth K, 1998, MOL CELL BIOL, V18, P6374, DOI 10.1128/MCB.18.11.6374; Jakel S, 1998, EMBO J, V17, P4491, DOI 10.1093/emboj/17.15.4491; Konarev PV, 2003, J APPL CRYSTALLOGR, V36, P1277, DOI 10.1107/S0021889803012779; Kozin MB, 2001, J APPL CRYSTALLOGR, V34, P33, DOI 10.1107/S0021889800014126; Kunzler M, 1998, FEBS LETT, V433, P185, DOI 10.1016/S0014-5793(98)00892-8; Kutay U, 1998, MOL CELL, V1, P359, DOI 10.1016/S1097-2765(00)80036-2; Kutay U, 1997, CELL, V90, P1061, DOI 10.1016/S0092-8674(00)80372-4; Macara IG, 2001, MICROBIOL MOL BIOL R, V65, P570, DOI 10.1128/MMBR.65.4.570-594.2001; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; Maurer P, 2001, MOL BIOL CELL, V12, P539, DOI 10.1091/mbc.12.3.539; Nakielny S, 1999, CELL, V99, P677, DOI 10.1016/S0092-8674(00)81666-9; Pemberton LF, 1998, CURR OPIN CELL BIOL, V10, P392, DOI 10.1016/S0955-0674(98)80016-1; Pollard VW, 1996, CELL, V86, P985, DOI 10.1016/S0092-8674(00)80173-7; Solsbacher J, 1998, MOL CELL BIOL, V18, P6805, DOI 10.1128/MCB.18.11.6805; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; Strom AC, 2001, GENOME BIOL, V2; Svergun D, 1995, J APPL CRYSTALLOGR, V28, P768, DOI 10.1107/S0021889895007047; Svergun DI, 1999, BIOPHYS J, V76, P2879, DOI 10.1016/S0006-3495(99)77443-6; SVERGUN DI, 1992, J APPL CRYSTALLOGR, V25, P495, DOI 10.1107/S0021889892001663; Svergun DI, 2002, CURR OPIN STRUC BIOL, V12, P654, DOI 10.1016/S0959-440X(02)00363-9; SVERGUN DI, 1993, J APPL CRYSTALLOGR, V26, P258, DOI 10.1107/S0021889892011828; Svergun DI, 2001, BIOPHYS J, V80, P2946, DOI 10.1016/S0006-3495(01)76260-1; Vetter IR, 1999, CELL, V97, P635, DOI 10.1016/S0092-8674(00)80774-6; Volkov VV, 2003, J APPL CRYSTALLOGR, V36, P860, DOI 10.1107/S0021889803000268	38	64	64	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 16	2004	279	3					2176	2181		10.1074/jbc.M309112200	http://dx.doi.org/10.1074/jbc.M309112200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	762WT	14561738	hybrid			2022-12-27	WOS:000188005700074
J	Yamasaki, K; Daiho, T; Danko, S; Suzuki, H				Yamasaki, K; Daiho, T; Danko, S; Suzuki, H			Multiple and distinct effects of mutations of Tyr(122), Glu(123), Arg(324), and Arg(334) involved in interactions between the top part of second and fourth transmembrane helices in sarcoplasmic reticulum Ca2+-ATPase - Changes in cytoplasmic domain organization during isometric transition of phosphoenzyme intermediate and subsequent Ca2+ release	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL CONSEQUENCES; AMINO-ACIDS; CONFORMATIONAL TRANSITION; ADENOSINE-TRIPHOSPHATE; CALCIUM-PUMP; COS-1 CELLS; A-DOMAIN; CA-2+-ATPASE; TRANSPORT; HYDROLYSIS	We explored, by mutational substitutions and kinetic analysis, possible roles of the four residues involved in the hydrogen-bonding or ionic interactions found in the Ca2+-bound structure of sarcoplasmic reticulum Ca2+-ATPase, Tyr(122)-Arg(324), and Glu(123)-Arg(334) at the top part of second transmembrane helix (M2) connected to the A domain and fourth transmembrane helix (M4) in the P domain. The observed substitution effects indicated that Glu(123), Arg(334), and Tyr(122) contributed to the rapid transition between the Ca2+-unbound and bound states of the unphosphorylated enzyme. Results further showed the more profound inhibitory effects of the substitutions in the M4/P domain (Arg(324) and Arg(334)) upon the isomeric transition of phosphorylated intermediate (EP) (loss of ADP sensitivity) and those in M2/A domain (Tyr(122) and Glu(123)) upon the subsequent processing and hydrolysis of EP. The observed distinct effects suggest that the interactions seen in the Ca2+-bound structure are not functionally important but indicate that Arg(334) with its positive charge and Tyr(122) with its aromatic ring are critically important for the above distinct steps. On the basis of the available structural information, the results strongly suggest that Arg(334) moves downward and forms new interactions with M2 (likely Asn(111)); it thus contributes to the inclination of the M4/P domain toward the M2/A domain, which is crucial for the appropriate gathering between the P domain and the largely rotated A domain to cause the loss of ADP sensitivity. On the other hand, Tyr(122) most likely functions in the subsequent Ca2+-releasing step to produce hydrophobic interactions at the A-P domain interface formed upon their gathering and thus to produce the Ca2+-released form of EP. During the Ca2+-transport cycle, the four residues seem to change interaction partners and thus contribute to the coordinated movements of the cytoplasmic and transmembrane domains.	Asahikawa Med Coll, Dept Biochem, Asahikawa, Hokkaido 0788510, Japan	Asahikawa Medical College	Suzuki, H (corresponding author), Asahikawa Med Coll, Dept Biochem, Asahikawa, Hokkaido 0788510, Japan.	hisuzuki@asahikawa-med.ac.jp						ANDERSEN JP, 1989, J BIOL CHEM, V264, P21018; CLARKE DM, 1989, J BIOL CHEM, V264, P11246; CLARKE DM, 1990, J BIOL CHEM, V265, P22223; CLARKE DM, 1990, J BIOL CHEM, V265, P14088; Daiho T, 1999, J BIOL CHEM, V274, P23910, DOI 10.1074/jbc.274.34.23910; Daiho T, 2003, J BIOL CHEM, V278, P39197, DOI 10.1074/jbc.M305200200; Daiho T, 1999, FEBS LETT, V444, P54, DOI 10.1016/S0014-5793(99)00027-7; Danko S, 2001, FEBS LETT, V505, P129, DOI 10.1016/S0014-5793(01)02801-0; Danko S, 2001, FEBS LETT, V489, P277, DOI 10.1016/S0014-5793(01)02111-1; DEMEIS L, 1980, BIOCHEMISTRY-US, V19, P4252, DOI 10.1021/bi00559a017; EBASHI S, 1962, J CELL BIOL, V14, P389, DOI 10.1083/jcb.14.3.389; HASSELBACH W, 1961, BIOCHEM Z, V333, P518; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; IMAMURA Y, 1989, J BIOCHEM-TOKYO, V105, P775, DOI 10.1093/oxfordjournals.jbchem.a122743; INESI G, 1988, METHOD ENZYMOL, V157, P154; Juul B, 2000, INT CONGR SER, V1207, P233; KANAZAWA T, 1970, J BIOCHEM-TOKYO, V67, P693, DOI 10.1093/oxfordjournals.jbchem.a129297; Kato S, 2003, J BIOL CHEM, V278, P9624, DOI 10.1074/jbc.M208861200; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; LEMAIRE M, 1990, J BIOL CHEM, V265, P1111; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Ma HL, 2003, J BIOL CHEM, V278, P28938, DOI 10.1074/jbc.M304120200; MacLennan DH, 1997, J BIOL CHEM, V272, P28815, DOI 10.1074/jbc.272.46.28815; MARUYAMA K, 1988, P NATL ACAD SCI USA, V85, P3314, DOI 10.1073/pnas.85.10.3314; Moller JV, 2002, J BIOL CHEM, V277, P38647, DOI 10.1074/jbc.M204603200; MOLLER M, 1986, ADV PINEAL RES, V1, P51; Patchornik G, 2000, P NATL ACAD SCI USA, V97, P11954, DOI 10.1073/pnas.220332897; PICK U, 1982, J BIOL CHEM, V257, P6120; Rice WJ, 1996, J BIOL CHEM, V271, P31412, DOI 10.1074/jbc.271.49.31412; SHIGEKAWA M, 1978, J BIOL CHEM, V253, P1451; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; VILSEN B, 1991, J BIOL CHEM, V266, P16157; VILSEN B, 1991, J BIOL CHEM, V266, P18839; VILSEN B, 1989, J BIOL CHEM, V264, P21024; WEBER K, 1969, J BIOL CHEM, V244, P4406; ZHANG Z, 1995, J BIOL CHEM, V270, P16283	37	34	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 16	2004	279	3					2202	2210		10.1074/jbc.M309398200	http://dx.doi.org/10.1074/jbc.M309398200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	762WT	14578351	hybrid			2022-12-27	WOS:000188005700077
J	Basu, NK; Ciotti, M; Hwang, MS; Kole, L; Mitra, PS; Cho, JW; Owens, IS				Basu, NK; Ciotti, M; Hwang, MS; Kole, L; Mitra, PS; Cho, JW; Owens, IS			Differential and special properties of the major human UGT1-encoded gastrointestinal UDP-glucuronosyltransferases enhance potential to control chemical uptake	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BILIRUBIN; GLUCURONIDATION; EXPRESSION; CURCUMIN; PHENOL; LIVER; COLON; IDENTIFICATION; TRANSFERASE; CLONING	UDP- glucuronosyltransferase (UGT) isozymes detoxify metabolites, drugs, toxins, and environmental chemicals via conjugation to glucuronic acid. Based on the extended UGT1 locus combined with Northern blot analysis and in situ hybridization, we determined the distribution of UGT1A1 and UGT1A7 through UGT1A10 mRNAs and found them for the first time segmentally distributed in the mucosal epithelia layer of the gastrointestinal tract. Biochemically, recombinant isozymes exhibited pH optima of 5.5, 6.4, 7.6, 8.5, and/or a broad pH range, and activities were found to be unaffected or progressively inhibited by increasing substrate concentrations after attaining V-max for certain chemicals. Under different optimal conditions, all exhibited wide substrate selections for dietary and environmentally associated chemicals. Evidence also suggests tandem effects of isozymes in the time for completion of reactions when comparing short- and long-term incubations. Moreover, treatment of colon cells with certain diet-associated constituents, curcumin and nordihydroguaiaretic acid, reversibly targets UGTs causing inhibition without affecting protein levels; there is no direct inhibition of control UGT using curcumin as substrate in the in vitro assay. In summary, we demonstrate that UGTs are located in gastrointestinal mucosa, have vast overlapping activities under differential optimal conditions, and exhibit marked sensitivity to certain dietary substrates/constituents, representing a first comprehensive study of critical properties concerning glucuronidating isozymes in alimentary tissues. Additionally, the highly dynamic, complex, and variable properties necessarily impact absorption of ingested chemicals and therapeutic drugs.	NICHD, Heritable Disorders Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Owens, IS (corresponding author), NICHD, Heritable Disorders Branch, NIH, Bldg 10,Rm 9S-241, Bethesda, MD 20892 USA.	owens@helix.nih.gov			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD008751] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD008751] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Basu NK, 2003, BIOCHEM BIOPH RES CO, V303, P98, DOI 10.1016/S0006-291X(03)00241-9; BOCK KW, 1993, BIOCHEM PHARMACOL, V45, P1809, DOI 10.1016/0006-2952(93)90437-2; Bock KW, 2002, BIOCHEM PHARMACOL, V63, P1683, DOI 10.1016/S0006-2952(02)00921-8; BROWN JP, 1980, MUTAT RES, V75, P243, DOI 10.1016/0165-1110(80)90029-9; Cheng ZQ, 1998, ARCH BIOCHEM BIOPHYS, V356, P301, DOI 10.1006/abbi.1998.0781; Ciotti M, 1997, PHARMACOGENETICS, V7, P485, DOI 10.1097/00008571-199712000-00007; Ciotti M, 1999, BIOCHEM BIOPH RES CO, V260, P199, DOI 10.1006/bbrc.1999.0453; Ciotti M, 1996, BIOCHEMISTRY-US, V35, P10119, DOI 10.1021/bi960584a; CIOTTI M, 1995, J BIOL CHEM, V270, P3284, DOI 10.1074/jbc.270.7.3284; Court MH, 2001, J PHARMACOL EXP THER, V299, P998; Cox R. I., 1978, Effects of poisonous plants on livestock., P451; DEMORAIS SMF, 1989, HEPATOLOGY, V10, P163, DOI 10.1002/hep.1840100207; Edwards DJ, 1996, DRUG METAB DISPOS, V24, P1287; FOX CH, 1993, CURRENT PROTOCOLS IM; Gong QH, 2001, PHARMACOGENETICS, V11, P357, DOI 10.1097/00008571-200106000-00011; GUGLER R, 1975, EUR J CLIN PHARMACOL, V9, P229, DOI 10.1007/BF00614022; GUPTA E, 1994, CANCER RES, V54, P3723; HOENSCH HP, 1981, HEPATO-GASTROENTEROL, V28, P221; Jee SH, 1998, J INVEST DERMATOL, V111, P656, DOI 10.1046/j.1523-1747.1998.00352.x; KELLIS JT, 1984, SCIENCE, V225, P1032, DOI 10.1126/science.6474163; Kuhnau J, 1976, World Rev Nutr Diet, V24, P117; LEVIN W, 1976, P NATL ACAD SCI USA, V73, P243, DOI 10.1073/pnas.73.1.243; Mojarrabi B, 1998, BIOCHEM BIOPH RES CO, V247, P704, DOI 10.1006/bbrc.1998.8843; Naught LE, 2001, ARCH BIOCHEM BIOPHYS, V396, P111, DOI 10.1006/abbi.2001.2618; Pan MH, 1999, DRUG METAB DISPOS, V27, P486; Pereira MA, 1996, CARCINOGENESIS, V17, P1305, DOI 10.1093/carcin/17.6.1305; RITTER JK, 1993, J BIOL CHEM, V268, P23573; RITTER JK, 1991, J BIOL CHEM, V266, P1043; Seawright Alan A., 1995, Natural Toxins, V3, P227, DOI 10.1002/nt.2620030411; Sharma RA, 2001, CLIN CANCER RES, V7, P1452; Strassburg CP, 1998, J BIOL CHEM, V273, P8719, DOI 10.1074/jbc.273.15.8719; Strassburg CP, 2000, J BIOL CHEM, V275, P36164, DOI 10.1074/jbc.M002180200; URAGUCHI K, 1972, FOOD COSMET TOXICOL, V10, P193, DOI 10.1016/S0015-6264(72)80197-4; WOOSTER R, 1991, BIOCHEM J, V278, P465, DOI 10.1042/bj2780465	34	68	78	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 9	2004	279	2					1429	1441		10.1074/jbc.M306439200	http://dx.doi.org/10.1074/jbc.M306439200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	759DJ	14557274	hybrid			2022-12-27	WOS:000187722800073
J	Grechez-Cassiau, A; Panda, S; Lacoche, S; Teboul, M; Azmi, S; Laudet, V; Hogenesch, JB; Taneja, R; Delaunay, F				Grechez-Cassiau, A; Panda, S; Lacoche, S; Teboul, M; Azmi, S; Laudet, V; Hogenesch, JB; Taneja, R; Delaunay, F			The transcriptional repressor STRA13 regulates a subset of peripheral circadian outputs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; MOUSE-LIVER; SERUM-FREE; E-BOX; CLOCK; PROTEIN; DEC1; MECHANISM; PACEMAKER; RECEPTOR	Central and peripheral mammalian circadian clocks regulate a variety of behavioral and physiological processes through the rhythmic transcription of hundreds of clock-controlled genes. The circadian expression of many transcriptional regulators suggests that a major part of this circadian gene network is indirectly regulated by clock genes. Here we show that the basic helix-loop-helix transcriptional repressor Stra13 is rhythmically expressed in mouse peripheral organs. The circadian transcription of Stra13 is mediated by a response element recognized by the CLOCK-BMAL1 heterodimer and located in the proximal promoter region. CLOCK-BMAL1-dependent activation of Stra13 is strongly repressed by CRY1 and also by STRA13 itself. To determine putative Stra13 output genes, we performed microarray analyses of differential gene expression in the liver between wild type and Stra13(-/-) mice and identified 42 target genes including a subset of 20 previously known as clock-controlled genes. Importantly, we demonstrate that circadian gene expression of the serum protein insulin-like growth factor-binding protein 1 and of the NKG2D receptor ligand retinoic acid early transcript was suppressed in Stra13(-/-) mice. These biochemical and genetic data establish a role for the basic helix-loop-helix repressor STRA13 as a circadian output regulator in the periphery.	Univ Nice Sophia Antipolis, CNRS, UMR 6078, F-06230 Villefranche Sur Mer, France; Novartis Res Fdn, Genom Inst, San Diego, CA 92121 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Mt Sinai Sch Med, Brookdale Dept Mol Cell & Dev Biol, New York, NY 10029 USA; Ecole Normale Super Lyon, CNRS, UMR 5665, F-69364 Lyon, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; Novartis; Scripps Research Institute; Icahn School of Medicine at Mount Sinai; Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON)	Delaunay, F (corresponding author), Univ Nice Sophia Antipolis, CNRS, UMR 6078, 284 Chemin Lazaret, F-06230 Villefranche Sur Mer, France.	delaunay@obs-vlfr.fr	Taneja, Reshma/F-9658-2014; Panda, Satchidananda/J-6891-2012	Taneja, Reshma/0000-0002-2151-2094; Reshma, Taneja/0000-0001-6214-6177; Delaunay, Franck/0000-0003-4927-1701; Teboul, Michele/0000-0002-3418-4384				Akhtar RA, 2002, CURR BIOL, V12, P540, DOI 10.1016/S0960-9822(02)00759-5; Azmi S, 2003, J BIOL CHEM, V278, P20098, DOI 10.1074/jbc.M210427200; Balsalobre A, 2000, SCIENCE, V289, P2344, DOI 10.1126/science.289.5488.2344; Balsalobre A, 1998, CELL, V93, P929, DOI 10.1016/S0092-8674(00)81199-X; Baxter RC, 2000, AM J PHYSIOL-ENDOC M, V278, pE967, DOI 10.1152/ajpendo.2000.278.6.E967; Bek MJ, 2003, FASEB J, V17, P682, DOI 10.1096/fj.02-0250fje; Boudjelal M, 1997, GENE DEV, V11, P2052, DOI 10.1101/gad.11.16.2052; Bunger MK, 2000, CELL, V103, P1009, DOI 10.1016/S0092-8674(00)00205-1; Ceriani MF, 2002, J NEUROSCI, V22, P9305, DOI 10.1523/jneurosci.22-21-09305.2002; Cerwenka A, 2000, IMMUNITY, V12, P721, DOI 10.1016/S1074-7613(00)80222-8; Damiola F, 2000, GENE DEV, V14, P2950, DOI 10.1101/gad.183500; Delaunay F, 2002, TRENDS GENET, V18, P595, DOI 10.1016/S0168-9525(02)02794-4; Diefenbach A, 2002, IMMUNOL REV, V188, P9, DOI 10.1034/j.1600-065X.2002.18802.x; Fraser DJ, 2003, J BIOL CHEM, V278, P39392, DOI 10.1074/jbc.M306148200; Gekakis N, 1998, SCIENCE, V280, P1564, DOI 10.1126/science.280.5369.1564; Grundschober C, 2001, J BIOL CHEM, V276, P46751, DOI 10.1074/jbc.M107499200; Haus E, 1999, CHRONOBIOL INT, V16, P581, DOI 10.3109/07420529908998730; Heuck C, 1999, PEDIATR RES, V45, P733, DOI 10.1203/00006450-199905010-00021; Honma S, 2002, NATURE, V419, P841, DOI 10.1038/nature01123; Hsieh CS, 2002, J IMMUNOL, V168, P2618, DOI 10.4049/jimmunol.168.6.2618; Ikeda M, 1997, BIOCHEM BIOPH RES CO, V233, P258, DOI 10.1006/bbrc.1997.6371; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Jin XW, 1999, CELL, V96, P57, DOI 10.1016/S0092-8674(00)80959-9; King DP, 1997, CELL, V89, P641, DOI 10.1016/S0092-8674(00)80245-7; Kornmann B, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.11.e51; Kume K, 1999, CELL, V98, P193, DOI 10.1016/S0092-8674(00)81014-4; Lavery DJ, 1999, MOL CELL BIOL, V19, P6488; LAVERY DJ, 1993, GENE DEV, V7, P1871, DOI 10.1101/gad.7.10.1871; Li YX, 2003, J BIOL CHEM, V278, P16899, DOI 10.1074/jbc.M300596200; Matsuo T, 2003, SCIENCE, V302, P255, DOI 10.1126/science.1086271; McDonald MJ, 2001, CELL, V107, P567, DOI 10.1016/S0092-8674(01)00545-1; McNamara P, 2001, CELL, V105, P877, DOI 10.1016/S0092-8674(01)00401-9; Munoz E, 2002, J BIOL CHEM, V277, P36009, DOI 10.1074/jbc.M203909200; Panda S, 2002, CELL, V109, P307, DOI 10.1016/S0092-8674(02)00722-5; Panda S, 2002, NATURE, V417, P329, DOI 10.1038/417329a; Preitner N, 2002, CELL, V110, P251, DOI 10.1016/S0092-8674(02)00825-5; Reppert SM, 2002, NATURE, V418, P935, DOI 10.1038/nature00965; Ripperger JA, 2000, GENE DEV, V14, P679; Ryter SW, 2000, FREE RADICAL BIO MED, V28, P289, DOI 10.1016/S0891-5849(99)00223-3; SHAPIRO DJ, 1969, BIOCHEM BIOPH RES CO, V37, P867, DOI 10.1016/0006-291X(69)90972-3; Shen M, 2001, EUR J CELL BIOL, V80, P329, DOI 10.1078/0171-9335-00167; Skjaerbaek C, 2000, CLIN ENDOCRINOL, V52, P25, DOI 10.1046/j.1365-2265.2000.00876.x; Storch KF, 2002, NATURE, V417, P78, DOI 10.1038/nature744; Sun H, 2000, P NATL ACAD SCI USA, V97, P4058, DOI 10.1073/pnas.070526297; Sun H, 2001, NAT IMMUNOL, V2, P1040, DOI 10.1038/ni721; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Ueda HR, 2002, NATURE, V418, P534, DOI 10.1038/nature00906; Wykoff CC, 2000, ONCOGENE, V19, P6297, DOI 10.1038/sj.onc.1204012; Yagita K, 2000, GENE DEV, V14, P1353; Zawel L, 2002, P NATL ACAD SCI USA, V99, P2848, DOI 10.1073/pnas.261714999	50	66	68	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 9	2004	279	2					1141	1150		10.1074/jbc.M305369200	http://dx.doi.org/10.1074/jbc.M305369200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	759DJ	14581485	hybrid, Green Published			2022-12-27	WOS:000187722800038
J	Hug, BA; Ahmed, N; Robbins, JA; Lazar, MA				Hug, BA; Ahmed, N; Robbins, JA; Lazar, MA			A chromatin immunoprecipitation screen reveals protein kinase C beta as a direct RUNX1 target gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYELOID-LEUKEMIA CELLS; NECROSIS-FACTOR-ALPHA; ESTER-INDUCED DIFFERENTIATION; TRANSCRIPTION FACTORS; MYELOGENOUS LEUKEMIA; INDUCED APOPTOSIS; BINDING-SITES; BONE-MARROW; EXPRESSION; ACTIVATION	RUNX1 (also known as AML1) is a DNA-binding transcription factor that functions as a tumor suppressor and developmental determinant in hematopoietic cells. Target promoters have been identified primarily through the use of differential expression strategies and candidate gene approaches but not biochemical screens. Using a chromatin immunoprecipitation screen, we identified protein kinase Cbeta as a direct RUNX1 target gene and demonstrate that endogenous RUNX1 binds the chromatinized protein kinase Cbeta promoter of U937 cells. A phylogenetically conserved RUNX1-binding site within the PKCbeta promoter binds RUNX1 in electrophoretic mobility shift analyses and confers RUNX1 responsiveness on a heterologous promoter. Changes in RUNX1 activity affect endogenous protein kinase Cbeta expression, and a dominant-negative form of RUNX1 protects U937 cells from apoptotic stimuli previously shown to be dependent on protein kinase Cbeta. This protection can be reversed by the ectopic expression of protein kinase Cbeta. Together these findings demonstrate that protein kinase Cbeta is a direct, downstream target of RUNX1 and links RUNX1 to a myeloid apoptotic pathway.	Univ Penn, Sch Med, Dept Med, Div Endocrinol Diabet & Metab,CRB 615, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Med, Div Endocrinol Diabet & Metab,CRB 611, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Penn Diabet Ctr, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Hug, BA (corresponding author), Univ Penn, Sch Med, Dept Med, Div Endocrinol Diabet & Metab,CRB 615, 415 Curie Blvd, Philadelphia, PA 19104 USA.		Lazar, Mitchell A/AAF-3738-2019	Robbins, Jonathan/0000-0001-9690-4976				Britos-Bray M, 1998, BLOOD, V92, P4344, DOI 10.1182/blood.V92.11.4344.423a01_4344_4352; Burel SA, 2001, MOL CELL BIOL, V21, P5577, DOI 10.1128/MCB.21.16.5577-5590.2001; Bushweller JH, 2000, SEMIN CELL DEV BIOL, V11, P377, DOI 10.1006/scdb.2000.0182; Cameron ER, 2003, BLOOD CELL MOL DIS, V30, P194, DOI 10.1016/S1079-9796(03)00031-7; Halle JP, 1997, MOL CELL BIOL, V17, P4220, DOI 10.1128/MCB.17.8.4220; HASS R, 1993, CELL GROWTH DIFFER, V4, P657; HOMMA Y, 1986, P NATL ACAD SCI USA, V83, P7316, DOI 10.1073/pnas.83.19.7316; Hug BA, 2002, CANCER RES, V62, P2906; Ito Y, 2001, CELL DEATH DIFFER, V8, P794, DOI 10.1038/sj.cdd.4400886; Laouar A, 1999, J BIOL CHEM, V274, P23526, DOI 10.1074/jbc.274.33.23526; Laouar A, 2001, MOL CARCINOGEN, V32, P195, DOI 10.1002/mc.10012; Li JY, 1999, NAT GENET, V23, P348, DOI 10.1038/15531; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Lund AH, 2002, CANCER CELL, V1, P213, DOI 10.1016/S1535-6108(02)00049-1; Lutterbach B, 2000, GENE, V245, P223, DOI 10.1016/S0378-1119(00)00014-7; MACFARLANE DE, 1994, J BIOL CHEM, V269, P4327; Matsushita H, 1999, BRIT J CANCER, V79, P1325, DOI 10.1038/sj.bjc.6690214; Meinhardt G, 2000, EUR J CELL BIOL, V79, P824, DOI 10.1078/0171-9335-00100; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092-8674(00)80260-3; OBEID LM, 1992, J BIOL CHEM, V267, P20804; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; Otto F, 2003, J CELL BIOCHEM, V89, P9, DOI 10.1002/jcb.10491; Otto F, 2002, HUM MUTAT, V19, P209, DOI 10.1002/humu.10043; Pandey P, 2000, ONCOGENE, V19, P3941, DOI 10.1038/sj.onc.1203751; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Pear WS, 1998, BLOOD, V92, P3780, DOI 10.1182/blood.V92.10.3780.422k15_3780_3792; Perry C, 2002, LEUKEMIA RES, V26, P221, DOI 10.1016/S0145-2126(01)00128-X; Phelps DE, 1996, J BIOL CHEM, V271, P7978, DOI 10.1074/jbc.271.14.7978; Shimada H, 2000, BLOOD, V96, P655; Song WJ, 1999, NAT GENET, V23, P166, DOI 10.1038/13793; Stewart M, 1997, P NATL ACAD SCI USA, V94, P8646, DOI 10.1073/pnas.94.16.8646; Takada Y, 1999, J BIOL CHEM, V274, P28286, DOI 10.1074/jbc.274.40.28286; TANAKA T, 1995, EMBO J, V14, P341, DOI 10.1002/j.1460-2075.1995.tb07008.x; Tanaka Tomoyuki, 1997, Leukemia (Basingstoke), V11, P299; Tenen DG, 1997, BLOOD, V90, P489, DOI 10.1182/blood.V90.2.489.489_489_519; Vaillant F, 2002, J IMMUNOL, V169, P2866, DOI 10.4049/jimmunol.169.6.2866; Weinmann AS, 2002, GENE DEV, V16, P235, DOI 10.1101/gad.943102; Weinmann AS, 2001, MOL CELL BIOL, V21, P6820, DOI 10.1128/MCB.21.20.6820-6832.2001; Weinmann AS, 2002, METHODS, V26, P37, DOI 10.1016/S1046-2023(02)00006-3; Wells J, 2002, METHODS, V26, P48, DOI 10.1016/S1046-2023(02)00007-5; Wotton S, 2002, CANCER RES, V62, P7181; Yeoh EJ, 2002, CANCER CELL, V1, P133, DOI 10.1016/S1535-6108(02)00032-6	43	42	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 9	2004	279	2					825	830		10.1074/jbc.M309524200	http://dx.doi.org/10.1074/jbc.M309524200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	759DJ	14561740	hybrid			2022-12-27	WOS:000187722800003
J	Korfali, N; Ruchaud, S; Loegering, D; Bernard, D; Dingwall, C; Kaufmann, SH; Earnshaw, WC				Korfali, N; Ruchaud, S; Loegering, D; Bernard, D; Dingwall, C; Kaufmann, SH; Earnshaw, WC			Caspase-7 gene disruption reveals an involvement of the enzyme during the early stages of apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-C-DELTA; CELL-DEATH; CHROMATIN CONDENSATION; POLY(ADP-RIBOSE) POLYMERASE; PHOSPHATIDYLSERINE EXPOSURE; DNA FRAGMENTATION; FODRIN CLEAVAGE; ENDONUCLEASE-G; IN-VITRO; B-CELLS	Caspases play a key role during apoptotic execution. In an attempt to elucidate the specific role of caspase-7 we generated a chicken DT40 cell line in which both alleles of the gene were disrupted. Viability assays showed that caspase-7(-/-) clones are more resistant to the common apoptosis-inducing drugs etoposide and staurosporine. Caspase-7(-/-) cells show a delay in phosphatidylserine externalization and DNA fragmentation as well as cleavage of the caspase substrates poly(ADP-ribose) polymerase 1 and lamins B1 and B2. Caspase affinity labeling and activity assays indicated that deficient cells exhibit a delay in caspase activation compared with wild type DT40 cells, providing an explanation for the differences in apoptotic execution between caspase-7 null and wild type DT40 cells. These results strongly suggest that caspase-7 is involved earlier than other effector caspases in the apoptotic execution process in DT40 B lymphocytes.	Univ Edinburgh, Inst Cell & Mol Biol, Wellcome Trust Ctr Cell Biol, Edinburgh EH9 3JR, Midlothian, Scotland; Mayo Clin, Div Oncol Res, Rochester, MN 55905 USA; Univ Paris 07, Unite Format Rech Biol & Sci Nat, Magistere Genet, F-75005 Paris, France; GlaxoSmithKline, Neurol Ctr Excellence Drug Discovery, Harlow CM19 5AW, Essex, England	University of Edinburgh; Mayo Clinic; UDICE-French Research Universities; Universite Paris Cite; GlaxoSmithKline	Earnshaw, WC (corresponding author), Univ Edinburgh, Inst Cell & Mol Biol, Wellcome Trust Ctr Cell Biol, Swann Bldg,Mayfield Rd, Edinburgh EH9 3JR, Midlothian, Scotland.		Earnshaw, William/AAY-7438-2020; Ruchaud, Sandrine/AAJ-2179-2021	Earnshaw, William/0000-0002-7191-0621; Kaufmann, Scott/0000-0002-4900-7145	NATIONAL CANCER INSTITUTE [R01CA069008] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA069008, R01 CA69008] Funding Source: Medline; Wellcome Trust [073915] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Wellcome Trust(Wellcome TrustEuropean Commission)		Allsopp TE, 2000, CELL DEATH DIFFER, V7, P984, DOI 10.1038/sj.cdd.4400733; Bergeron L, 1998, GENE DEV, V12, P1304, DOI 10.1101/gad.12.9.1304; Bourdon JC, 2002, J CELL BIOL, V158, P235, DOI 10.1083/jcb.200203006; Bras A, 1999, FASEB J, V13, P931, DOI 10.1096/fasebj.13.8.931; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; BUERSTEDDE JM, 1991, CELL, V67, P179, DOI 10.1016/0092-8674(91)90581-I; Coelho D, 2000, BRIT J CANCER, V83, P642, DOI 10.1054/bjoc.2000.1322; Creagh EM, 2001, BIOCHEM SOC T, V29, P696, DOI 10.1042/0300-5127:0290696; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Faleiro L, 1997, EMBO J, V16, P2271, DOI 10.1093/emboj/16.9.2271; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P2737; Ferraro-Peyret C, 2002, J IMMUNOL, V169, P4805, DOI 10.4049/jimmunol.169.9.4805; Germain M, 1999, J BIOL CHEM, V274, P28379, DOI 10.1074/jbc.274.40.28379; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; Halenbeck R, 1998, CURR BIOL, V8, P537, DOI 10.1016/S0960-9822(98)79298-X; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Janicke RU, 1998, J BIOL CHEM, V273, P15540, DOI 10.1074/jbc.273.25.15540; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KOOPMAN G, 1994, BLOOD, V84, P1415, DOI 10.1182/blood.V84.5.1415.1415; Kottke TJ, 2002, J BIOL CHEM, V277, P804, DOI 10.1074/jbc.M108419200; Kottke TJ, 1999, J BIOL CHEM, V274, P15927, DOI 10.1074/jbc.274.22.15927; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; Lane JD, 2001, J CELL BIOL, V153, P1415, DOI 10.1083/jcb.153.7.1415; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; LAZEBNIK YA, 1993, J CELL BIOL, V123, P7, DOI 10.1083/jcb.123.1.7; Le DA, 2002, P NATL ACAD SCI USA, V99, P15188, DOI 10.1073/pnas.232473399; Le XF, 2001, ONCOGENE, V20, P8258, DOI 10.1038/sj.onc.1205039; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Marsden VS, 2002, NATURE, V419, P634, DOI 10.1038/nature01101; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; Martin SJ, 1996, J BIOL CHEM, V271, P28753, DOI 10.1074/jbc.271.46.28753; Martins LM, 1997, J BIOL CHEM, V272, P7421, DOI 10.1074/jbc.272.11.7421; Mc Gee MM, 2002, FEBS LETT, V515, P66, DOI 10.1016/S0014-5793(02)02440-7; McIlroy D, 1999, ONCOGENE, V18, P4401, DOI 10.1038/sj.onc.1202868; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Nitta T, 2001, EXP CELL RES, V265, P174, DOI 10.1006/excr.2001.5177; Parrish J, 2001, NATURE, V412, P90, DOI 10.1038/35083608; Rao RV, 2001, J BIOL CHEM, V276, P33869, DOI 10.1074/jbc.M102225200; Riedl SJ, 2001, P NATL ACAD SCI USA, V98, P14790, DOI 10.1073/pnas.221580098; Rodriguez J, 1999, GENE DEV, V13, P3179, DOI 10.1101/gad.13.24.3179; Ruchaud S, 2002, EMBO J, V21, P1967, DOI 10.1093/emboj/21.8.1967; Ruiz-Vela A, 1999, EMBO J, V18, P4988, DOI 10.1093/emboj/18.18.4988; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Samejima K, 2001, J BIOL CHEM, V276, P45427, DOI 10.1074/jbc.M108844200; Slee EA, 1999, CELL DEATH DIFFER, V6, P1067, DOI 10.1038/sj.cdd.4400601; Slee EA, 2001, J BIOL CHEM, V276, P7320, DOI 10.1074/jbc.M008363200; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Talanian RV, 1997, J BIOL CHEM, V272, P9677; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Vanags DM, 1996, J BIOL CHEM, V271, P31075, DOI 10.1074/jbc.271.49.31075; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; WOOD ER, 1990, J CELL BIOL, V111, P2839, DOI 10.1083/jcb.111.6.2839; Wyllie A H, 1980, Int Rev Cytol, V68, P251; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; Zheng TS, 2000, NAT MED, V6, P1241, DOI 10.1038/81343; Zheng TS, 1999, CELL DEATH DIFFER, V6, P1043, DOI 10.1038/sj.cdd.4400593; Zhivotovsky B, 1999, CELL DEATH DIFFER, V6, P644, DOI 10.1038/sj.cdd.4400536	63	32	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 9	2004	279	2					1030	1039		10.1074/jbc.M306277200	http://dx.doi.org/10.1074/jbc.M306277200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	759DJ	14583630	hybrid			2022-12-27	WOS:000187722800026
J	Mistry, P; Deacon, K; Mistry, S; Blank, J; Patel, R				Mistry, P; Deacon, K; Mistry, S; Blank, J; Patel, R			NF-kappa B promotes survival during mitotic cell cycle arrest	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PACLITAXEL-INDUCED APOPTOSIS; ALPHA-INDUCED APOPTOSIS; PROTEIN-KINASE-C; GENE-EXPRESSION; T-LYMPHOCYTES; IKK-ALPHA; FACTOR REQUIRES; MICE LACKING; HELA-CELLS; FAS-LIGAND	By activating the mitotic checkpoint, anti-microtubule drugs such as nocodazole cause mammalian cells to arrest in mitosis and then undergo apoptosis. Microtubule depolymerization is rapid and results in the activation of the transcription factor NF-kappaB and induction of NF-kappaB-dependent gene expression. However, the functional consequence of NF-kappaB activation has remained unclear. Evidence has accumulated to suggest that NF-kappaB transcriptional activity is required to suppress apoptosis. In the present study, we confirm and extend previous findings that microtubule depolymerization leads to the rapid activation of NF-kappaB and test the hypothesis that the induction of NF-kappaB regulates cell survival during mitotic cell cycle arrest in order to define its role. Using a range of functional assays, we have shown that microtubule depolymerization correlates with the activation of IKKalpha and IKKbeta; the phosphorylation, ubiquitination, and degradation of IkappaBalpha; the translocation of native p65 (RelA) into the nucleus; and increased NF-kappaB transcriptional activity. By inhibiting either the activation of the IKKs or the degradation of IkappaBalpha, we find that the level of apoptosis is significantly increased in the mitotically arrested cells. Inhibition of NF-kappaB signaling in the nonmitotic cells did not affect their survival. We establish that although NF-kappaB is activated rapidly in response to microtubule depolymerization, its cell survival function is not required until mitotic cell cycle arrest, when the mitotic checkpoint is activated and apoptosis is triggered. We conclude that NF-kappaB may regulate the transcription of one or more antiapoptotic proteins that may regulate cell survival during mitotic cell cycle arrest.	Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England; Univ Leicester, Dept Cell Physiol & Pharmacol, Leicester LE1 7RH, Leics, England	University of Leicester; University of Leicester	Patel, R (corresponding author), Univ Leicester, Dept Biochem, Univ Rd, Leicester LE1 7RH, Leics, England.							Aggarwal BB, 2000, BIOCHEM PHARMACOL, V60, P1033, DOI 10.1016/S0006-2952(00)00393-2; Anest V, 2003, NATURE, V423, P659, DOI 10.1038/nature01648; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Bui NT, 2001, J CELL BIOL, V152, P753, DOI 10.1083/jcb.152.4.753; Chaudhary PM, 2000, ONCOGENE, V19, P4451, DOI 10.1038/sj.onc.1203812; Chen F, 2001, AM J PATHOL, V159, P387, DOI 10.1016/S0002-9440(10)61708-7; Cohen L, 1998, NATURE, V395, P292, DOI 10.1038/26254; Crepieux P, 1997, MOL CELL BIOL, V17, P7375, DOI 10.1128/MCB.17.12.7375; Das KC, 1997, J BIOL CHEM, V272, P14914, DOI 10.1074/jbc.272.23.14914; De Smaele E, 2001, NATURE, V414, P308, DOI 10.1038/35104560; Deacon K, 2003, MOL BIOL CELL, V14, P2071, DOI 10.1091/mbc.e02-10-0653; FINCO TS, 1995, IMMUNITY, V3, P263, DOI 10.1016/1074-7613(95)90112-4; Goto H, 1999, J BIOL CHEM, V274, P25543, DOI 10.1074/jbc.274.36.25543; Gottesfeld JM, 1997, TRENDS BIOCHEM SCI, V22, P197, DOI 10.1016/S0968-0004(97)01045-1; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Huang Y, 2002, MOL PHARMACOL, V61, P105, DOI 10.1124/mol.61.1.105; Huang Y, 2000, CANCER RES, V60, P4426; HWANG S, 1995, CANCER BIOCHEM BIOPH, V14, P265; Jordan MA, 1996, CANCER RES, V56, P816; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; Kasibhatla S, 1999, J BIOL CHEM, V274, P987, DOI 10.1074/jbc.274.2.987; Khoshnan A, 2000, J IMMUNOL, V165, P1743, DOI 10.4049/jimmunol.165.4.1743; Kisselev AF, 2001, CHEM BIOL, V8, P739, DOI 10.1016/S1074-5521(01)00056-4; Kwan R, 2001, MOL CELL BIOL, V21, P7183, DOI 10.1128/MCB.21.21.7183-7190.2001; Lee FS, 1998, P NATL ACAD SCI USA, V95, P9319, DOI 10.1073/pnas.95.16.9319; Leers MPG, 1999, J PATHOL, V187, P567, DOI 10.1002/(SICI)1096-9896(199904)187:5<567::AID-PATH288>3.0.CO;2-J; Li QT, 1999, GENE DEV, V13, P1322, DOI 10.1101/gad.13.10.1322; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; May MJ, 2000, SCIENCE, V289, P1550, DOI 10.1126/science.289.5484.1550; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Micheau O, 2001, MOL CELL BIOL, V21, P5299, DOI 10.1128/MCB.21.16.5299-5305.2001; Moscat J, 2003, EMBO REP, V4, P31, DOI 10.1038/sj.embor.embor704; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; Nemoto S, 1998, MOL CELL BIOL, V18, P7336, DOI 10.1128/MCB.18.12.7336; Oyaizu H, 2001, ONCOL REP, V8, P825; Oyaizu H, 1999, Mol Cell Biol Res Commun, V2, P36, DOI 10.1006/mcbr.1999.0146; Ozes ON, 1999, NATURE, V401, P82; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Patel R, 1999, J BIOL CHEM, V274, P7958, DOI 10.1074/jbc.274.12.7958; Patel R, 1998, J CELL SCI, V111, P2247; Roff M, 1996, J BIOL CHEM, V271, P7844, DOI 10.1074/jbc.271.13.7844; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; ROSETTE C, 1995, J CELL BIOL, V128, P1111, DOI 10.1083/jcb.128.6.1111; Ross J, 1997, BIOESSAYS, V19, P527, DOI 10.1002/bies.950190612; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Scatena CD, 1998, J BIOL CHEM, V273, P30777, DOI 10.1074/jbc.273.46.30777; Sorger PK, 1997, CURR OPIN CELL BIOL, V9, P807, DOI 10.1016/S0955-0674(97)80081-6; Stehlik C, 1998, J EXP MED, V188, P211, DOI 10.1084/jem.188.1.211; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; Tang GL, 2001, NATURE, V414, P313, DOI 10.1038/35104568; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; von Haefen C, 2003, ONCOGENE, V22, P2236, DOI 10.1038/sj.onc.1206280; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; WOODS CM, 1995, MOL MED, V1, P506, DOI 10.1007/BF03401588; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Wu MX, 1998, SCIENCE, V281, P998, DOI 10.1126/science.281.5379.998; Yamamoto Y, 2003, NATURE, V423, P655, DOI 10.1038/nature01576; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yujiri T, 1998, SCIENCE, V282, P1911, DOI 10.1126/science.282.5395.1911; Zhao Q, 1999, J BIOL CHEM, V274, P8355, DOI 10.1074/jbc.274.13.8355; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382	63	46	47	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 9	2004	279	2					1482	1490		10.1074/jbc.M310413200	http://dx.doi.org/10.1074/jbc.M310413200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	759DJ	14581467	hybrid			2022-12-27	WOS:000187722800079
J	Todorov, VT; Volkl, S; Muller, M; Bohla, A; Klar, J; Kunz-Schughart, LA; Hehlgans, T; Kurtz, A				Todorov, VT; Volkl, S; Muller, M; Bohla, A; Klar, J; Kunz-Schughart, LA; Hehlgans, T; Kurtz, A			Tumor necrosis factor-alpha activates NF kappa B to inhibit renin transcription by targeting cAMP-responsive element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-TRANSCRIPTION; JUXTAGLOMERULAR CELLS; TRANSGENIC MICE; LEUCINE ZIPPER; EXPRESSION; BINDING; PROTEINS; PROMOTER; RECEPTOR; FAMILY	Tumor necrosis factor-alpha (TNFalpha) is known to inhibit renin gene expression in juxtaglomerular cells, which are the main source of renin in vivo. In the present study we aimed to characterize the intracellular mechanisms of TNFalpha signaling to renin gene in the mouse juxtaglomerular cell line As4.1. TNFalpha was found to activate NFkappaB, which is one of the principal intracellular mediators of TNFalpha signal transduction. Constitutive activation of NFkappaB suppressed renin gene transcription, but NFkappaB appeared not to target the NFkappaB binding sites in the renin promoter. Thus, NFkappaB, but not the canonical NFkappaB binding sequences in the renin promoter, seemed to be involved in the suppression of renin transcription by TNFalpha. Deletion/mutation analysis revealed that the effect of TNFalpha on renin gene is transmitted by a cAMP-responsive element (CRE) located at -2697 to -2690. Mobility shift/supershift assays evidenced for the presence of NFkappaB proteins in the complex that binds to mouse renin CRE. Our results strongly suggest that NFkappaB mediates the effect of TNFalpha on renin transcription targeting a CRE in the mouse renin promoter.	Univ Regensburg, Inst Physiol, D-93040 Regensburg, Germany; Univ Regensburg, Inst Pathol, D-93040 Regensburg, Germany; Univ Regensburg, Dept Immunol, D-93040 Regensburg, Germany	University of Regensburg; University of Regensburg; University of Regensburg	Todorov, VT (corresponding author), Univ Regensburg, Inst Physiol, D-93040 Regensburg, Germany.		Bohla, Alexander/J-1537-2012	Bohla, Alexander/0000-0001-9610-5138; Volkl, Simon/0000-0003-2193-3048; Todorov, Vladimir/0000-0002-7011-8130				Bader M, 2000, J MOL MED, V78, P130, DOI 10.1007/s001090000089; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Baumann H, 2000, J BIOL CHEM, V275, P22014, DOI 10.1074/jbc.M002830200; BIENKOWSKI RS, 1995, MOL BIOL COLLAGEN MA, P77; Brasier AR, 2000, MOL CELL BIOCHEM, V212, P155, DOI 10.1023/A:1007133710837; BUSCH SJ, 1990, TRENDS GENET, V6, P36, DOI 10.1016/0168-9525(90)90071-D; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; DOBRZANSKI P, 1994, EMBO J, V13, P4608, DOI 10.1002/j.1460-2075.1994.tb06782.x; Dorffel Y, 1999, HYPERTENSION, V34, P113, DOI 10.1161/01.HYP.34.1.113; Fuchs S, 2003, J HYPERTENS, V21, P327, DOI 10.1097/00004872-200302000-00024; Gallois C, 1998, J BIOL CHEM, V273, P23183, DOI 10.1074/jbc.273.36.23183; Gires O, 2001, CANCER, V92, P620, DOI 10.1002/1097-0142(20010801)92:3<620::AID-CNCR1362>3.0.CO;2-F; Glenn CL, 2000, HUM MOL GENET, V9, P1943, DOI 10.1093/hmg/9.13.1943; HACKENTHAL E, 1990, PHYSIOL REV, V70, P1067, DOI 10.1152/physrev.1990.70.4.1067; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; Hottiger MO, 1998, EMBO J, V17, P3124, DOI 10.1093/emboj/17.11.3124; Jensen BL, 1996, AM J PHYSIOL-RENAL, V271, pF659, DOI 10.1152/ajprenal.1996.271.3.F659; Johns DG, 2001, J HYPERTENS, V19, P63, DOI 10.1097/00004872-200101000-00009; Jones CA, 2000, PHYSIOL GENOMICS, V4, P75, DOI 10.1152/physiolgenomics.2000.4.1.75; JONES CA, 1990, MOL ENDOCRINOL, V4, P375, DOI 10.1210/mend-4-3-375; Kapadia SR, 1997, CIRC RES, V81, P187, DOI 10.1161/01.RES.81.2.187; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Ke S, 2001, J BIOL CHEM, V276, P39638, DOI 10.1074/jbc.M106286200; Klar J, 2002, PFLUG ARCH EUR J PHY, V444, P335, DOI 10.1007/s00424-002-0818-9; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; La Ferla K, 2002, FASEB J, V16, P1811, DOI 10.1096/fj.02-0168fje; LALLI E, 1994, J BIOL CHEM, V269, P17359; Liu XB, 2003, CIRC RES, V92, P1033, DOI 10.1161/01.RES.0000071355.82009.43; MATTHIAS P, 1989, NUCLEIC ACIDS RES, V17, P6418, DOI 10.1093/nar/17.15.6418; MCDONNELL PC, 1992, ONCOGENE, V7, P163; Mendez-Pertuz M, 2003, EMBO J, V22, P3102, DOI 10.1093/emboj/cdg295; Muller MWH, 2002, PFLUG ARCH EUR J PHY, V444, P499, DOI 10.1007/s00424-002-0835-8; Pan L, 2001, J BIOL CHEM, V276, P45530, DOI 10.1074/jbc.M103010200; Petrovic N, 1996, J BIOL CHEM, V271, P22499, DOI 10.1074/jbc.271.37.22499; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SIGMUND CD, 1990, J BIOL CHEM, V265, P19916; SIGMUND CD, 1990, BIOCHEM BIOPH RES CO, V170, P344, DOI 10.1016/0006-291X(90)91280-6; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; Todorov V, 2002, AM J PHYSIOL-REG I, V283, pR1046, DOI 10.1152/ajpregu.00142.2002; Todorov V, 2001, KIDNEY BLOOD PRESS R, V24, P75, DOI 10.1159/000054210; VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.iy.10.040192.002211; Vo N, 2001, J BIOL CHEM, V276, P13505, DOI 10.1074/jbc.R000025200; Wagner C, 1998, CURR OPIN NEPHROL HY, V7, P437, DOI 10.1097/00041552-199807000-00015; Wagner C, 1998, KIDNEY INT, V54, P78; WEIH F, 1994, ONCOGENE, V9, P3289; Whiteside ST, 1997, SEMIN CANCER BIOL, V8, P75, DOI 10.1006/scbi.1997.0058; Wilson SH, 2001, BIOCHEM BIOPH RES CO, V286, P968, DOI 10.1006/bbrc.2001.5485; Ying LH, 1997, J BIOL CHEM, V272, P2412; ZIFF EB, 1990, TRENDS GENET, V6, P69, DOI 10.1016/0168-9525(90)90081-G	51	42	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 9	2004	279	2					1458	1467		10.1074/jbc.M308697200	http://dx.doi.org/10.1074/jbc.M308697200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	759DJ	14563845	hybrid			2022-12-27	WOS:000187722800076
J	Paitel, E; Sunyach, C; da Costa, CA; Bourdon, JC; Vincent, B; Checler, F				Paitel, E; Sunyach, C; da Costa, CA; Bourdon, JC; Vincent, B; Checler, F			Primary cultured neurons devoid of cellular prion display lower responsiveness to Staurosporine through the control of p53 at both transcriptional and post-transcriptional levels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILD-TYPE; PARKINSONS-DISEASE; APOPTOTIC STIMULI; MOLECULAR-BIOLOGY; PROTEIN; SCRAPIE; PRP; ACTIVATION; BINDING; CELLS	We assessed the contribution of the cellular prion protein (PrPc) in the control of neuronal apoptosis by examining cell death in both human cells and murine primary cultured neurons. We first confirmed our previous finding that staurosporine-induced caspase activation is increased by PrPc overexpression in HEK293 cells. We show here that this phenotype is fully dependent on p53 and that the control of p53 activity by PrPc occurs at both transcriptional and post-transcriptional levels in human cells. Of most interest, we demonstrate that neuronal endogenous PrPc also controls a p53-dependent pro-apoptotic phenotype. Thus, DNA fragmentation and TUNEL ( terminal deoxynucleotidyltransferase- mediated dUTP nick end-labeling)-positive cells were lower in primary cultured neurons derived from Zrch-1 mice embryos in which PrPc has been abrogated than in wildtype neurons. PrPc knock-out neurons also displayed drastically diminished caspase-3-like activity and immunoreactivity together with reduced p53 expression and transcriptional activity, a phenotype complemented in part by PrPc transfection. Interestingly, p53 expression was also reduced in the brain of adult Prnp(-/-) mice. Neuronal PrPc likely controls p53 at a post-transcriptional level because the deletion of cellular prion protein is accompanied by a higher Mdm2-like immunoreactivity and reduced phosphorylated p38 MAPK expression. We therefore propose that the physiological function of endogenous cellular prion could be to regulate p53-dependent caspase-3-mediated neuronal cell death. This phenotype likely occurs through upregulation of p53 promoter transactivation as well as downstream by controlling p53 stability via Mdm2 expression.	CNRS, UMR 6097, Inst Pharmacol Mol & Cellulaire, F-06560 Valbonne, France; Ninewells Hosp & Med Sch, Dundee DD1 9SY, Scotland	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; University of Dundee	Checler, F (corresponding author), CNRS, UMR 6097, Inst Pharmacol Mol & Cellulaire, 660 Route Lucioles, F-06560 Valbonne, France.	checler@ipmc.cnrs.fr	JC, Bourdon/A-4439-2008; da Costa, Cristine Alves/G-8075-2011; Checler, Frederic/C-1241-2009	JC, Bourdon/0000-0003-4623-9386; da Costa, Cristine Alves/0000-0002-7777-005X; Checler, Frederic/0000-0003-2098-1750; Vincent, Bruno/0000-0003-3876-2118				Aguzzi A, 2001, NAT REV MOL CELL BIO, V2, P118, DOI 10.1038/35052063; Aguzzi A, 2001, NAT MED, V7, P289, DOI 10.1038/85423; Bounhar Y, 2001, J BIOL CHEM, V276, P39145, DOI 10.1074/jbc.C100443200; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brandner S, 1996, NATURE, V379, P339, DOI 10.1038/379339a0; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; Bykov VJN, 2002, NAT MED, V8, P282, DOI 10.1038/nm0302-282; Checler F, 2002, TRENDS NEUROSCI, V25, P616, DOI 10.1016/S0166-2236(02)02263-4; Chesebro B, 1999, NEURON, V24, P503, DOI 10.1016/S0896-6273(00)81105-8; Chiarini LB, 2002, EMBO J, V21, P3317, DOI 10.1093/emboj/cdf324; da Costa CA, 2000, J BIOL CHEM, V275, P24065, DOI 10.1074/jbc.M002413200; da Costa CA, 2002, J BIOL CHEM, V277, P50980, DOI 10.1074/jbc.M207825200; da Costa CA, 2002, P NATL ACAD SCI USA, V99, P4043, DOI 10.1073/pnas.062059899; Demart S, 1999, BIOCHEM BIOPH RES CO, V265, P652, DOI 10.1006/bbrc.1999.1730; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Ghetti B, 1996, BRAIN PATHOL, V6, P127, DOI 10.1111/j.1750-3639.1996.tb00796.x; GINSBERG D, 1990, ONCOGENE, V5, P1285; Hur K, 2002, MECH AGEING DEV, V123, P1637, DOI 10.1016/S0047-6374(02)00099-4; Jamieson E, 2001, NEUROREPORT, V12, P3567, DOI 10.1097/00001756-200111160-00039; Kuwahara C, 1999, NATURE, V400, P225, DOI 10.1038/22241; Ma JY, 2002, SCIENCE, V298, P1781, DOI 10.1126/science.1073725; MACLEOD K, 1995, GENE DEV, V15, P935; Mallucci GR, 2002, EMBO J, V21, P202, DOI 10.1093/emboj/21.3.202; MARTINS VR, 2002, NEUROCHEM INT, V1223, P1; Milhavet O, 2002, BRAIN RES REV, V38, P328, DOI 10.1016/S0165-0173(01)00150-3; Paitel E, 2003, J BIOL CHEM, V278, P10061, DOI 10.1074/jbc.M211580200; Paitel E, 2002, J NEUROCHEM, V83, P1208, DOI 10.1046/j.1471-4159.2002.01234.x; Prusiner SB, 1996, TRENDS BIOCHEM SCI, V21, P482, DOI 10.1016/S0968-0004(96)10063-3; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Schatzl HM, 1997, J VIROL, V71, P8821; Siso S, 2002, ACTA NEUROPATHOL, V103, P615, DOI 10.1007/s00401-001-0512-6; Vincent B, 1996, J NEUROSCI, V16, P5049; Weissmann C, 2002, ACTA NEUROBIOL EXP, V62, P153; WESTAWAY D, 1994, CELL, V76, P117, DOI 10.1016/0092-8674(94)90177-5; Yin YL, 2002, NAT CELL BIOL, V4, P462, DOI 10.1038/ncb801; Zhu YH, 2002, J BIOL CHEM, V277, P22909, DOI 10.1074/jbc.M200042200	38	55	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	2004	279	1					612	618		10.1074/jbc.M310453200	http://dx.doi.org/10.1074/jbc.M310453200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	757GU	14570892	hybrid			2022-12-27	WOS:000187555300074
J	Taimi, M; Helvig, C; Wisniewski, J; Ramshaw, H; White, J; Amad, M; Korczak, B; Petkovich, M				Taimi, M; Helvig, C; Wisniewski, J; Ramshaw, H; White, J; Amad, M; Korczak, B; Petkovich, M			A novel human cytochrome P450, CYP26C1, involved in metabolism of 9-cis and all-trans isomers of retinoic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINALDEHYDE DEHYDROGENASE; ALDEHYDE DEHYDROGENASE; ALCOHOL-DEHYDROGENASE; VENTRAL RETINA; EXPRESSION; IDENTIFICATION; CLONING; ENZYME; PROMOTER; DOMAINS	Retinoids are potent regulators of cell proliferation, cell differentiation, and morphogenesis and are important therapeutic agents in oncology and dermatology. The gene regulatory activity of endogenous retinoids is effected primarily by retinoic acid isomers ( all-trans and 9-cis) that are synthesized from retinaldehyde precursors in a broad range of tissues and act as ligands for nuclear retinoic acid receptors. The catabolism of all-trans-retinoic acid (atRA) is an important mechanism of controlling RA levels in cell and tissues. We have previously identified two cytochrome P450s, P450RAI-1 and P450RAI-2 ( herein named CYP26A1 and CYP26B1), which were shown to be responsible for catabolism of atRA both in the embryo and the adult. In this report, we describe the identification, molecular cloning, and substrate characterization of a third member of the CYP26 family, named CYP26C1. Transiently transfected cells expressing CYP26C1 convert atRA to polar water-soluble metabolites similar to those generated by CYP26A1 and - B1. Competition studies with all-trans, 13-cis, and 9-cis isomers of retinoic acid demonstrated that atRA was the preferred substrate for CYP26C1. Although CYP26C1 shares extensive sequence similarity with CYP26A1 and CYP26B1, its catalytic activity appears distinct from those of other CYP26 family members. Specifically, CYP26C1 can also recognize and metabolize 9-cis-RA and is much less sensitive than the other CYP26 family members to the inhibitory effects of ketoconazole. CYP26C1 is not widely expressed in the adult but is inducible by RA in HPK1a, transformed human keratinocyte cell lines. This third CYP26 member may play a specific role in catabolizing both all-trans and 9-cis isomers of RA.	Cytochroma Inc, Markham, ON L3R 8E4, Canada; Queens Univ, Canc Res Labs, Kingston, ON K7L 3N6, Canada	Queens University - Canada	Korczak, B (corresponding author), Cytochroma Inc, 330 Cochrane Dr, Markham, ON L3R 8E4, Canada.	bozena@cytochroma.com						Abu-Abed S, 2001, GENE DEV, V15, P226, DOI 10.1101/gad.855001; Abu-Abed S, 2002, MECH DEVELOP, V110, P173, DOI 10.1016/S0925-4773(01)00572-X; ACHKAR CC, 1994, DRUG METAB DISPOS, V22, P451; Ang HL, 1996, J BIOL CHEM, V271, P9526, DOI 10.1074/jbc.271.16.9526; Bhat PV, 1995, GENE, V166, P303, DOI 10.1016/0378-1119(96)81752-5; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Chawla A, 2001, SCIENCE, V294, P1866, DOI 10.1126/science.294.5548.1866; Chithalen JV, 2002, J LIPID RES, V43, P1133, DOI 10.1194/jlr.M100343-JLR200; DRAGER UC, 1995, ADV EXP MED BIOL, V372, P185; Duester G, 1998, J NUTR, V128, p459S, DOI 10.1093/jn/128.2.459S; Li HX, 2000, MECH DEVELOP, V95, P283, DOI 10.1016/S0925-4773(00)00352-X; Loudig O, 2000, MOL ENDOCRINOL, V14, P1483, DOI 10.1210/me.14.9.1483; MacLean G, 2001, MECH DEVELOP, V107, P195, DOI 10.1016/S0925-4773(01)00463-4; Maden M, 1999, BIOESSAYS, V21, P809, DOI 10.1002/(SICI)1521-1878(199910)21:10<809::AID-BIES2>3.0.CO;2-0; Maden M, 1998, DEVELOPMENT, V125, P4133; Marill J, 2003, CURR DRUG METAB, V4, P1, DOI 10.2174/1389200033336900; MENDELSOHN C, 1991, DEVELOPMENT, V113, P723; Mic FA, 2000, MECH DEVELOP, V97, P227, DOI 10.1016/S0925-4773(00)00434-2; Montplaisir V, 2002, J BIOL CHEM, V277, P17486, DOI 10.1074/jbc.M112445200; Napoli JL, 1996, FASEB J, V10, P993, DOI 10.1096/fasebj.10.9.8801182; Niederreither K, 2002, NAT GENET, V31, P84, DOI 10.1038/ng876; Niederreither K, 2000, DEVELOPMENT, V127, P75; Niederreither K, 1997, MECH DEVELOP, V62, P67, DOI 10.1016/S0925-4773(96)00653-3; Njar VCO, 2002, MINI-REV MED CHEM, V2, P261, DOI 10.2174/1389557023406223; REDFERN CPF, 1993, FEBS LETT, V321, P163, DOI 10.1016/0014-5793(93)80100-9; Ross SA, 2000, PHYSIOL REV, V80, P1021, DOI 10.1152/physrev.2000.80.3.1021; ROSSANT J, 1991, GENE DEV, V5, P1333, DOI 10.1101/gad.5.8.1333; Samokyszyn VM, 2000, J BIOL CHEM, V275, P6908, DOI 10.1074/jbc.275.10.6908; Suzuki R, 2000, MECH DEVELOP, V98, P37, DOI 10.1016/S0925-4773(00)00450-0; Swindell EC, 1999, DEV BIOL, V216, P282, DOI 10.1006/dbio.1999.9487; Tahayato A, 2003, GENE EXPR PATTERNS, V3, P449, DOI 10.1016/S1567-133X(03)00066-8; Vermot J, 2000, ENDOCRINOLOGY, V141, P3638, DOI 10.1210/en.141.10.3638; Vogel S, 2001, J BIOL CHEM, V276, P1353, DOI 10.1074/jbc.M005118200; White JA, 1998, GENOMICS, V48, P270, DOI 10.1006/geno.1997.5157; White JA, 1997, J BIOL CHEM, V272, P18538, DOI 10.1074/jbc.272.30.18538; White JA, 1996, J BIOL CHEM, V271, P29922, DOI 10.1074/jbc.271.47.29922; White JA, 2000, P NATL ACAD SCI USA, V97, P6403, DOI 10.1073/pnas.120161397; Zouboulis CC, 2001, SKIN PHARMACOL APPL, V14, P303, DOI 10.1159/000056361	38	164	173	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 2	2004	279	1					77	85		10.1074/jbc.M308337200	http://dx.doi.org/10.1074/jbc.M308337200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	757GU	14532297	hybrid			2022-12-27	WOS:000187555300010
J	Tang, CH; Grimm, EA				Tang, CH; Grimm, EA			Depletion of endogenous nitric oxide enhances cisplatin-induced apoptosis in a p53-dependent manner in melanoma cell lines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILD-TYPE P53; TUMOR-SUPPRESSOR PROTEIN; SYNTHASE EXPRESSION; MALIGNANT-MELANOMA; S-NITROSOTHIOLS; CYCLE ARREST; CANCER CELLS; MCF-7 CELLS; DNA-DAMAGE; BLACK-BOX	The expression of inducible nitric-oxide synthase in melanoma tumor cells was recently shown to correlate strongly with poor patient survival after combination biochemotherapy (p<0.001). Furthermore, evidence suggests that nitric oxide, a reaction product of nitric-oxide synthase, exhibits antiapoptotic activity in melanoma cells. We therefore hypothesized that nitric oxide antagonizes chemotherapy-induced apoptosis. Whether nitric oxide is capable of regulating cell growth and apoptotic responses to cisplatin treatment in melanoma cell lines was evaluated. We demonstrate herein that depletion of endogenously produced nitric oxide can inhibit melanoma proliferation and promote apoptosis. Moreover, our data indicate that the depletion of nitric oxide leads to changes in cell cycle regulation and enhances cisplatin-induced apoptosis in melanoma cells. Strikingly, we observed that the depletion of nitric oxide inhibits cisplatin-induced wild type p53 accumulation and p21(Waf1/Cip1/Sdi1) expression in melanoma cells. When cisplatin-induced p53 binding to the p21(Waf1/Cip1/Sdi1) promoter was examined, it was found that nitric oxide depletion significantly reduced the presence of p53-DNA complexes after cisplatin treatment. Furthermore, dominant negative inhibition of p53 activity enhanced cisplatin-induced apoptosis. Together, these data strongly suggest that endogenously produced nitric oxide is required for cisplatin-induced p53 activation and p21(Waf1/Cip1/Sdi1) expression, which can regulate melanoma sensitivity to cisplatin.	Univ Texas, MD Anderson Canc Ctr, Grad Sch Biomed Sci, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Bioimmunotherapy, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Grimm, EA (corresponding author), Univ Texas, MD Anderson Canc Ctr, Grad Sch Biomed Sci, 1515 Holcombe Blvd, Houston, TX 77030 USA.				NCI NIH HHS [R01 CA90282] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA090282] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alderton WK, 2001, BIOCHEM J, V357, P593, DOI 10.1042/0264-6021:3570593; Ambs S, 1997, FASEB J, V11, P443, DOI 10.1096/fasebj.11.6.9194524; Bae I, 1996, CANCER RES, V56, P840; Bargonetti J, 2002, CURR OPIN ONCOL, V14, P86, DOI 10.1097/00001622-200201000-00015; BASSETSEGUIN N, 1994, J INVEST DERMATOL, V103, P102; Bogdan C, 2001, NAT IMMUNOL, V2, P907, DOI 10.1038/ni1001-907; Brune B, 1999, CELL DEATH DIFFER, V6, P969, DOI 10.1038/sj.cdd.4400582; Calmels S, 1997, CANCER RES, V57, P3365; Caruccio L, 1999, J IMMUNOL METHODS, V230, P1, DOI 10.1016/S0022-1759(99)00100-3; Chazotte-Aubert L, 2000, BIOCHEM BIOPH RES CO, V267, P609, DOI 10.1006/bbrc.1999.2003; Chazotte-Aubert L, 2001, BIOCHEM BIOPH RES CO, V281, P766, DOI 10.1006/bbrc.2001.4423; Chin L, 1998, GENE DEV, V12, P3467, DOI 10.1101/gad.12.22.3467; Cillari E, 1998, Adv Dent Res, V12, P126; DOYLE MP, 1981, J INORG BIOCHEM, V14, P351, DOI 10.1016/S0162-0134(00)80291-3; Ekmekcioglu S, 2000, CLIN CANCER RES, V6, P4768; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Espey MG, 2002, P NATL ACAD SCI USA, V99, P11127, DOI 10.1073/pnas.152157599; Forrester K, 1996, P NATL ACAD SCI USA, V93, P2442, DOI 10.1073/pnas.93.6.2442; Fukunaga-Takenaka R, 2003, BIOCHEM BIOPH RES CO, V308, P966, DOI 10.1016/S0006-291X(03)01516-X; Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319; Giustarini D, 2003, CLIN CHIM ACTA, V330, P85, DOI 10.1016/S0009-8981(03)00046-9; Gorospe M, 1997, ONCOGENE, V14, P929, DOI 10.1038/sj.onc.1200897; HARPER JW, 1993, CELL, V75, P805; Ishida A, 1997, J BIOL CHEM, V272, P10050; Ivanova K, 2001, J INVEST DERMATOL, V116, P409, DOI 10.1046/j.1523-1747.2001.01255.x; Jaffrey SR, 2001, NAT CELL BIOL, V3, P193, DOI 10.1038/35055104; Janssen YMW, 1998, AM J PHYSIOL-LUNG C, V275, pL1100, DOI 10.1152/ajplung.1998.275.6.L1100; Joshi M, 1996, MELANOMA RES, V6, P121, DOI 10.1097/00008390-199604000-00006; Kim PKM, 2001, INT IMMUNOPHARMACOL, V1, P1421, DOI 10.1016/S1567-5769(01)00088-1; Kokunai T, 2001, J NEURO-ONCOL, V51, P111, DOI 10.1023/A:1010645205169; Kolb JP, 2000, LEUKEMIA, V14, P1685, DOI 10.1038/sj.leu.2401896; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; Li JR, 1999, CELL DEATH DIFFER, V6, P952, DOI 10.1038/sj.cdd.4400579; Li JR, 1997, BIOCHEM BIOPH RES CO, V240, P419, DOI 10.1006/bbrc.1997.7672; Liu LM, 1999, CELL DEATH DIFFER, V6, P937, DOI 10.1038/sj.cdd.4400578; MacMillan-Crow LA, 2000, ARCH BIOCHEM BIOPHYS, V377, P350, DOI 10.1006/abbi.2000.1799; MAEDA H, 1994, J LEUKOCYTE BIOL, V56, P588, DOI 10.1002/jlb.56.5.588; Mahyar-Roemer M, 2001, ONCOGENE, V20, P3387, DOI 10.1038/sj.onc.1204440; Martinez LA, 2002, CARCINOGENESIS, V23, P1289, DOI 10.1093/carcin/23.8.1289; Massi D, 2001, J PATHOL, V194, P194, DOI 10.1002/1096-9896(200106)194:2<194::AID-PATH851>3.0.CO;2-S; McGill G, 1999, J CLIN INVEST, V104, P223, DOI 10.1172/JCI7861; Meyskens FL, 2001, FREE RADICAL BIO MED, V31, P799, DOI 10.1016/S0891-5849(01)00650-5; Mortensen K, 1999, J BIOL CHEM, V274, P37679, DOI 10.1074/jbc.274.53.37679; Nakaya N, 2000, ONCOGENE, V19, P6369, DOI 10.1038/sj.onc.1204100; Patel T, 1996, FASEB J, V10, P587, DOI 10.1096/fasebj.10.5.8621058; Pfeiffer S, 1997, FREE RADICAL BIO MED, V22, P787, DOI 10.1016/S0891-5849(96)00407-8; POREMBA C, 1995, ONCOL RES, V7, P331; PRYOR WA, 1995, AM J PHYSIOL, V268, P699; Rafikova O, 2002, P NATL ACAD SCI USA, V99, P5913, DOI 10.1073/pnas.092048999; Robinson EK, 1998, ANN SURG ONCOL, V5, P342, DOI 10.1007/BF02303498; Roninson IB, 2002, CANCER LETT, V179, P1, DOI 10.1016/S0304-3835(01)00847-3; Rossig L, 1999, J BIOL CHEM, V274, P6823, DOI 10.1074/jbc.274.11.6823; Ruan SB, 1999, CLIN CANCER RES, V5, P197; Salvucci O, 2001, CANCER RES, V61, P318; Satyamoorthy K, 2001, TRENDS MOL MED, V7, P191, DOI 10.1016/S1471-4914(01)02013-5; Satyamoorthy K, 2000, CELL GROWTH DIFFER, V11, P467; Schonhoff CM, 2002, BIOCHEMISTRY-US, V41, P13570, DOI 10.1021/bi026262q; Suschek CV, 1999, J BIOL CHEM, V274, P6130, DOI 10.1074/jbc.274.10.6130; Trotter MJ, 1997, J CUTAN PATHOL, V24, P265, DOI 10.1111/j.1600-0560.1997.tb00790.x; VIDAL MJ, 1995, MELANOMA RES, V5, P243, DOI 10.1097/00008390-199508000-00006; Wink DA, 1998, CARCINOGENESIS, V19, P711, DOI 10.1093/carcin/19.5.711; Xu WM, 2002, CELL RES, V12, P311, DOI 10.1038/sj.cr.7290133; Xu WM, 2000, NAT CELL BIOL, V2, P339, DOI 10.1038/35014028	63	82	87	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	2004	279	1					288	298		10.1074/jbc.M310821200	http://dx.doi.org/10.1074/jbc.M310821200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	757GU	14576150	hybrid			2022-12-27	WOS:000187555300036
J	Wei, YD; Shen, WY; Dauk, M; Wang, F; Selvaraj, G; Zou, JT				Wei, YD; Shen, WY; Dauk, M; Wang, F; Selvaraj, G; Zou, JT			Targeted gene disruption of glycerol-3-phosphate dehydrogenase in Colletotrichum gloeosporioides reveals evidence that glycerol is a significant transferred nutrient from host plant to fungal pathogen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							F-SP MALVAE; INFECTION; METABOLISM; TURGOR; HAUSTORIA; TRANSFORMATION; 3-PHOSPHATE; PENETRATION; PATHWAYS; GLUCOSE	Unidirectional transfer of nutrients from plant host to pathogen represents a most revealing aspect of the parasitic lifestyle of plant pathogens. Whereas much effort has been focused on sugars and amino acids, the identification of other significant metabolites is equally important for comprehensive characterization of metabolic interactions between plants and biotrophic fungal pathogens. Employing a strategy of targeted gene disruption, we generated a mutant strain (gpdhDelta) defective in glycerol-3-phosphate dehydrogenase in a hemibiotrophic plant pathogen, Colletotrichum gloeosporioides f. sp. malvae. The gpdhDelta strain had severe defects in carbon utilization as it could use neither glucose nor amino acids for sustained growth. Although the mutant mycelia were able to grow on potato dextrose agar medium, they displayed arrhythmicity in growth and failure to conidiate. The metabolic defect of gpdhDelta could be entirely ameliorated by glycerol in chemically defined minimal medium. Furthermore, glycerol was the one and only metabolite that could restore rhythmic growth and conidiation of gpdhDelta. Despite the profound defects in carbon source utilization, in planta the gpdhDelta strain exhibited normal pathogenicity, proceeded normally in its life cycle, and produced abundant conidia. Analysis of plant tissues at the peripheral zone of fungal infection sites revealed a time-dependent reduction in glycerol content. This study provides strong evidence for a role of glycerol as a significant transferred metabolite from plant to fungal pathogen.	Univ Saskatchewan, Dept Biol, Saskatoon, SK S7N 5E2, Canada; Natl Res Council Canada, Inst Plant Biotechnol, Saskatoon, SK S7N OW9, Canada	University of Saskatchewan; National Research Council Canada	Wei, YD (corresponding author), Univ Saskatchewan, Dept Biol, Saskatoon, SK S7N 5E2, Canada.	yangdou.wei@usask.ca; jitao.zou@nrc-cnrc.gc.ca						AGRIOS GN, 1997, PLANT PATHOLOGY; Brisson D, 2001, BIOESSAYS, V23, P534, DOI 10.1002/bies.1073; deJong JC, 1997, NATURE, V389, P244, DOI 10.1038/38418; Dixon KP, 1999, PLANT CELL, V11, P2045, DOI 10.1105/tpc.11.10.2045; Eto K, 1999, SCIENCE, V283, P981, DOI 10.1126/science.283.5404.981; Fillinger S, 2001, MOL MICROBIOL, V39, P145, DOI 10.1046/j.1365-2958.2001.02223.x; FOCH J, 1957, J BIOL CHEM, V226, P497; GANCEDO C, 1968, EUR J BIOCHEM, V5, P165, DOI 10.1111/j.1432-1033.1968.tb00353.x; GERBER DW, 1988, PLANT SCI, V56, P31, DOI 10.1016/0168-9452(88)90182-3; Hahn M, 1997, MOL PLANT MICROBE IN, V10, P438, DOI 10.1094/MPMI.1997.10.4.438; HOWARD RJ, 1991, P NATL ACAD SCI USA, V88, P11281, DOI 10.1073/pnas.88.24.11281; JELITTO T, 1992, PLANTA, V188, P238, DOI 10.1007/BF00216819; Lang G., 1984, METHOD ENZYMAT AN, VVI, P525; Larsson C, 1998, YEAST, V14, P347, DOI 10.1002/(SICI)1097-0061(19980315)14:4<347::AID-YEA226>3.0.CO;2-9; MANNERS JM, 1982, NEW PHYTOL, V91, P221, DOI 10.1111/j.1469-8137.1982.tb03308.x; MARTIN TJ, 1978, PHYSIOL PLANT PATHOL, V13, P1, DOI 10.1016/0048-4059(78)90070-X; Mendgen K, 1996, ANNU REV PHYTOPATHOL, V34, P367, DOI 10.1146/annurev.phyto.34.1.367; MENDGEN K, 1981, PHYTOPATHOLOGY, V71, P983, DOI 10.1094/Phyto-71-983; Mendgen K, 2002, TRENDS PLANT SCI, V7, P352, DOI 10.1016/S1360-1385(02)02297-5; MENDGEN K, 1979, ARCH MICROBIOL, V123, P129, DOI 10.1007/BF00446811; MENDGEN K, 1988, PLANTA, V174, P283, DOI 10.1007/BF00394782; Moore DD, 1995, GLOB MOB SURV; MORBIDONI HR, 1995, J BACTERIOL, V177, P5899, DOI 10.1128/jb.177.20.5899-5905.1995; Owen OE, 2002, J BIOL CHEM, V277, P30409, DOI 10.1074/jbc.R200006200; Parniske M, 2000, CURR OPIN PLANT BIOL, V3, P320, DOI 10.1016/S1369-5266(00)00088-1; Pfeffer PE, 1999, PLANT PHYSIOL, V120, P587, DOI 10.1104/pp.120.2.587; PUNT PJ, 1992, METHOD ENZYMOL, V216, P447; REDMAN RS, 1994, EXP MYCOL, V18, P230, DOI 10.1006/emyc.1994.1023; Rivers RL, 1997, J BIOL CHEM, V272, P16256, DOI 10.1074/jbc.272.26.16256; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; STABLES RC, 1958, CONTRB BOYCE THOMPSO, V19, P349; Staples RC, 2001, TRENDS PLANT SCI, V6, P496, DOI 10.1016/S1360-1385(01)02126-4; Sutton PN, 1999, PLANTA, V208, P426, DOI 10.1007/s004250050578; Thines E, 2000, PLANT CELL, V12, P1703, DOI 10.1105/tpc.12.9.1703; Thordal-Christensen H, 2003, CURR OPIN PLANT BIOL, V6, P351, DOI 10.1016/S1369-5266(03)00063-3; TOM GD, 1978, ARCH MICROBIOL, V117, P259, DOI 10.1007/BF00738544; Voegele RT, 2001, P NATL ACAD SCI USA, V98, P8133, DOI 10.1073/pnas.131186798; Wei YD, 1997, MYCOL RES, V101, P357, DOI 10.1017/S0953756296002651; Wei YD, 2002, MICROBIOL-SGM, V148, P2149, DOI 10.1099/00221287-148-7-2149; Wei YD, 2001, PLANT PHYSIOL BIOCH, V39, P841, DOI 10.1016/S0981-9428(01)01308-0; Wilkins Thea A., 1996, P21; YELTON MM, 1984, P NATL ACAD SCI-BIOL, V81, P1470, DOI 10.1073/pnas.81.5.1470; Zardoya R, 2002, P NATL ACAD SCI USA, V99, P14893, DOI 10.1073/pnas.192573799; Zheng ZF, 2001, J BIOL CHEM, V276, P41710, DOI 10.1074/jbc.M104749200	44	47	53	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 2	2004	279	1					429	435		10.1074/jbc.M308363200	http://dx.doi.org/10.1074/jbc.M308363200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	757GU	14563847	hybrid			2022-12-27	WOS:000187555300052
J	Arlander, SJH; Eapen, AK; Vroman, BT; McDonald, RJ; Toft, DO; Karnitz, LM				Arlander, SJH; Eapen, AK; Vroman, BT; McDonald, RJ; Toft, DO; Karnitz, LM			Hsp90 inhibition depletes Chk1 and sensitizes tumor cells to replication stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-PHASE CHECKPOINT; DNA-DAMAGE; HUMAN CDC25A; RADIOSENSITIZING AGENT; ANSAMYCINS CAUSES; TERMINAL DOMAIN; G2 CHECKPOINT; LUNG-CANCER; HUMAN RAD9; CYCLIN-E	DNA damage and replication stress activate the Chk1 signaling pathway, which blocks S phase progression, stabilizes stalled replication forks, and participates in G(2) arrest. In this study, we show that Chk1 interacts with Hsp90, a molecular chaperone that participates in the folding, assembly, maturation, and stabilization of specific proteins known as clients. Consistent with Chk1 being an Hsp90 client, we also found that Chk1 but not Chk2 is destabilized in cells treated with the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG). 17-AAG-mediated Chk1 loss blocked the ability of Chk1 to target Cdc25A for proteolytic destruction, demonstrating that the Chk1 signaling pathway was disrupted in the 17-AAG-treated cells. Finally, 17-AAG-mediated disruption of Chk1 activation dramatically sensitized various tumor cells to gemcitabine, an S phase-active chemotherapeutic agent. Collectively, our studies identify Chk1 as a novel Hsp90 client and suggest that pharmacologic inhibition of Hsp90 may sensitize tumor cells to chemotherapeutic agents by disrupting Chk1 function during replication stress.	Mayo Clin & Mayo Fdn, Div Dev Oncol Res, Rochester, MN 55905 USA; Mayo Clin & Mayo Grad Sch Med, Dept Mol Pharmacol & Expt Therapeut, Rochester, MN 55901 USA; Mayo Clin & Mayo Grad Sch Med, Dept Biochem & Mol Biol, Rochester, MN 55901 USA; Mayo Clin & Mayo Fdn, Div Radiat Oncol, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic	Karnitz, LM (corresponding author), Mayo Clin & Mayo Fdn, Div Dev Oncol Res, Guggenheim 13,200 1st St SW, Rochester, MN 55905 USA.	karnitz.larry@mayo.edu						Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Barent RL, 1998, MOL ENDOCRINOL, V12, P342, DOI 10.1210/me.12.3.342; Basso AD, 2002, J BIOL CHEM, V277, P39858, DOI 10.1074/jbc.M206322200; Basso AD, 2002, ONCOGENE, V21, P1159, DOI 10.1038/sj.onc.1205184; Blagosklonny MV, 2002, LEUKEMIA, V16, P455, DOI 10.1038/sj.leu.2402415; Blomberg I, 1999, MOL CELL BIOL, V19, P6183; Burtelow MA, 2000, J BIOL CHEM, V275, P26343, DOI 10.1074/jbc.M001244200; Busby EC, 2000, CANCER RES, V60, P2108; Byrd JC, 2001, EXP HEMATOL, V29, P703, DOI 10.1016/S0301-472X(01)00649-X; Dimitrova DS, 2000, NAT CELL BIOL, V2, P686, DOI 10.1038/35036309; Feijoo C, 2001, J CELL BIOL, V154, P913, DOI 10.1083/jcb.200104099; Fujita N, 2002, J BIOL CHEM, V277, P10346, DOI 10.1074/jbc.M106736200; Fuse E, 1998, CANCER RES, V58, P3248; Gescher A, 2000, CRIT REV ONCOL HEMAT, V34, P127, DOI 10.1016/S1040-8428(00)00058-5; Grammatikakis N, 1999, MOL CELL BIOL, V19, P1661; Graves PR, 2000, J BIOL CHEM, V275, P5600, DOI 10.1074/jbc.275.8.5600; Grenert JP, 1997, J BIOL CHEM, V272, P23843, DOI 10.1074/jbc.272.38.23843; Guo N, 2002, CELL GROWTH DIFFER, V13, P77; Hassepass I, 2003, J BIOL CHEM, V278, P29824, DOI 10.1074/jbc.M302704200; Heffernan TP, 2002, MOL CELL BIOL, V22, P8552, DOI 10.1128/MCB.22.24.8552-8561.2002; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; Hostein I, 2001, CANCER RES, V61, P4003; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; Kaneko Y, 1999, ONCOGENE, V18, P3673, DOI 10.1038/sj.onc.1202706; Kaye SB, 1998, BRIT J CANCER, V78, P1, DOI 10.1038/bjc.1998.747; Liu QH, 2000, GENE DEV, V14, P1448; Luo Y, 2001, ANTICANCER RES, V21, P23; Lupardus PJ, 2002, GENE DEV, V16, P2327, DOI 10.1101/gad.1013502; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; Maloney A, 2002, EXPERT OPIN BIOL TH, V2, P3, DOI 10.1517/14712598.2.1.3; Melo J, 2002, CURR OPIN CELL BIOL, V14, P237, DOI 10.1016/S0955-0674(02)00312-5; Munster PN, 2001, CANCER RES, V61, P2945; Naumann U, 1997, Recent Results Cancer Res, V143, P237; Neckers L, 2002, TRENDS MOL MED, V8, pS55, DOI 10.1016/S1471-4914(02)02316-X; Neve RM, 2001, ANN ONCOL, V12, P9, DOI 10.1023/A:1011199404516; Nimmanapalli R, 2001, CANCER RES, V61, P1799; Noble S, 1997, DRUGS, V54, P447, DOI 10.2165/00003495-199754030-00009; Pearl LH, 2002, ADV PROTEIN CHEM, V59, P157; Playle LC, 2002, BRIT J CANCER, V87, P352, DOI 10.1038/sj.bjc.6600492; Pratt WB, 2003, EXP BIOL MED, V228, P111, DOI 10.1177/153537020322800201; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; Raitano A. B., 1997, BIOCHIM BIOPHYS ACTA, V1333, P201, DOI 10.1016/S0304-419X(97)00023-1; Rhind N, 2000, J CELL SCI, V113, P3889; Roe SM, 1999, J MED CHEM, V42, P260, DOI 10.1021/jm980403y; Roos-Mattjus P, 2003, J BIOL CHEM, V278, P24428, DOI 10.1074/jbc.M301544200; Sampath D, 2002, MOL PHARMACOL, V62, P680, DOI 10.1124/mol.62.3.680; Sarkaria JN, 1999, CANCER RES, V59, P4375; Sato S, 2000, P NATL ACAD SCI USA, V97, P10832, DOI 10.1073/pnas.170276797; Sausville EA, 2001, J CLIN ONCOL, V19, P2319, DOI 10.1200/JCO.2001.19.8.2319; Schulte TW, 1998, CELL STRESS CHAPERON, V3, P100, DOI 10.1379/1466-1268(1998)003<0100:ARBTTN>2.3.CO;2; Sexl V, 1999, ONCOGENE, V18, P573, DOI 10.1038/sj.onc.1202362; Shi Z, 2001, CANCER RES, V61, P1065; Shimuta K, 2002, EMBO J, V21, P3694, DOI 10.1093/emboj/cdf357; SMITH DF, 1995, MOL CELL BIOL, V15, P6804; Sorensen CS, 2003, CANCER CELL, V3, P247, DOI 10.1016/S1535-6108(03)00048-5; Srethapakdi M, 2000, CANCER RES, V60, P3940; Sutor SL, 1999, J BIOL CHEM, V274, P7002, DOI 10.1074/jbc.274.11.7002; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Volkmer E, 1999, J BIOL CHEM, V274, P567, DOI 10.1074/jbc.274.2.567; Walter J, 2000, MOL CELL, V5, P617, DOI 10.1016/S1097-2765(00)80241-5; Ward IM, 2001, J BIOL CHEM, V276, P47755, DOI 10.1074/jbc.C100587200; Weiss RS, 2000, GENE DEV, V14, P1886; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; Xiao HH, 2002, RADIAT RES, V158, P84, DOI 10.1667/0033-7587(2002)158[0084:HUPSCW]2.0.CO;2; Xiao Z, 2003, J BIOL CHEM, V278, P21767, DOI 10.1074/jbc.M300229200; You ZZ, 2002, J BIOL CHEM, V277, P27088, DOI 10.1074/jbc.M204120200; Zachos G, 2003, EMBO J, V22, P713, DOI 10.1093/emboj/cdg060; Zhao H, 2002, P NATL ACAD SCI USA, V99, P14795, DOI 10.1073/pnas.182557299; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001; Zhao S, 2000, NATURE, V405, P473, DOI 10.1038/35013083; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zou L, 2002, GENE DEV, V16, P198, DOI 10.1101/gad.950302; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	73	151	158	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52572	52577		10.1074/jbc.M309054200	http://dx.doi.org/10.1074/jbc.M309054200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14570880	hybrid			2022-12-27	WOS:000187480700075
J	Hong, YJ; Stanley, P				Hong, YJ; Stanley, P			Lec3 Chinese hamster ovary mutants lack UDP-N-acetylglucosamine 2-epimerase activity because of mutations in the epimerase domain of the Gne gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYLNEURAMINIC ACID BIOSYNTHESIS; BIFUNCTIONAL ENZYME CATALYZES; FIRST 2 STEPS; SIALIC-ACID; 2-EPIMERASE/N-ACETYLMANNOSAMINE KINASE; UDP-N-ACETYLGLUCOSAMINE-2-EPIMERASE/N-ACETYLMANNOSAMINE KINASE; GLYCOSYLATION MUTANTS; GLCNAC 2-EPIMERASE; MOLECULAR-CLONING; POLYSIALIC ACID	Lec3 Chinese hamster ovary (CHO) cell glycosylation mutants have a defect in sialic acid biosynthesis that is shown here to be reflected most sensitively in reduced polysialic acid (PSA) on neural cell adhesion molecules. To identify the genetic origin of the phenotype, genes encoding different factors required for sialic acid biosynthesis were transfected into Lec3 cells. Only a Gne cDNA encoding UDP-GlcNAc 2-epimerase: ManNAc kinase rescued PSA synthesis. In an in vitro UDP-GlcNAc 2-epimerase assay, Lec3 cells had no detectable UDP-GlcNAc 2-epimerase activity, and Lec3 cells grown in serum-free medium were essentially devoid of sialic acid on glycoproteins. The Lec3 phenotype was rescued by exogenously added N-acetylmannosamine or mannosamine but not by the same concentrations of N-acetylglucosamine, glucosamine, glucose, or mannose. Sequencing of CHO Gne cDNAs identified a nonsense (E35stop) and a missense (G135E) mutation, respectively, in two independent Lec3 mutants. The G135E Lec3 mutant transfected with a rat Gne cDNA had restored in vitro UDP-GlcNAc 2-epimerase activity and cell surface PSA expression. Both Lec3 mutants were similarly rescued with a CHO Gne cDNA and with CHO Gne encoding the known kinase-deficient D413K mutation. However, cDNAs encoding the known epimerase-deficient mutation H132A or the new Lec3 G135E Gne mutation did not rescue the Lec3 phenotype. The G135E Gne missense mutation is a novel mechanism for inactivating UDP-GlcNAc 2-epimerase activity. Lec3 mutants with no UDP-GlcNAc 2-epimerase activity represent sensitive hosts for characterizing disease-causing mutations in the human GNE gene that give rise to sialuria, hereditary inclusion body myopathy, and Nonaka myopathy.	Yeshiva Univ Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Stanley, P (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Cell Biol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.			Stanley, Pamela/0000-0001-5704-3747	PHS HHS [P01 13330, R01 36434] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Alexander DA, 2002, J VIROL, V76, P11265, DOI 10.1128/JVI.76.22.11265-11272.2002; Angata T, 2002, CHEM REV, V102, P439, DOI 10.1021/cr000407m; Argov Z, 2003, NEUROLOGY, V60, P1519, DOI 10.1212/01.WNL.0000061617.71839.42; Chigorno V, 1996, J BIOL CHEM, V271, P21738, DOI 10.1074/jbc.271.36.21738; DEUTSCHER SL, 1984, CELL, V39, P295, DOI 10.1016/0092-8674(84)90007-2; Durbec P, 2001, MOL NEUROBIOL, V24, P53; Eckhardt M, 1998, J BIOL CHEM, V273, P20189, DOI 10.1074/jbc.273.32.20189; ECKHARDT M, 1995, NATURE, V373, P715, DOI 10.1038/373715a0; Eckhardt M, 1996, P NATL ACAD SCI USA, V93, P7572, DOI 10.1073/pnas.93.15.7572; Effertz K, 1999, J BIOL CHEM, V274, P28771, DOI 10.1074/jbc.274.40.28771; Eisenberg I, 2001, NAT GENET, V29, P83, DOI 10.1038/ng718; Eisenberg Iris, 2003, Hum Mutat, V21, P99, DOI 10.1002/humu.9100; FROSCH M, 1985, P NATL ACAD SCI USA, V82, P1194, DOI 10.1073/pnas.82.4.1194; HAYRINEN J, 1995, J INFECT DIS, V171, P1481, DOI 10.1093/infdis/171.6.1481; Hinderlich S, 1997, J BIOL CHEM, V272, P24313, DOI 10.1074/jbc.272.39.24313; Hinderlich S, 2000, EUR J BIOCHEM, V267, P3301, DOI 10.1046/j.1432-1327.2000.01360.x; Hinderlich S, 2001, BIOL CHEM, V382, P291, DOI 10.1515/BC.2001.036; Hong YJ, 2002, EMBO J, V21, P5047, DOI 10.1093/emboj/cdf508; Horstkorte R, 2000, FEBS LETT, V470, P315, DOI 10.1016/S0014-5793(00)01331-4; Kayashima T, 2002, J HUM GENET, V47, P77, DOI 10.1007/s100380200004; Keppler OT, 1999, SCIENCE, V284, P1372, DOI 10.1126/science.284.5418.1372; KNIEP B, 1990, ANAL BIOCHEM, V188, P5, DOI 10.1016/0003-2697(90)90519-F; KOJIMA N, 1995, FEBS LETT, V360, P1, DOI 10.1016/0014-5793(95)00059-I; Kojima N, 1998, J BIOCHEM-TOKYO, V124, P726, DOI 10.1093/oxfordjournals.jbchem.a022173; Kuge O, 1997, J BIOL CHEM, V272, P19133, DOI 10.1074/jbc.272.31.19133; Lawrence SM, 2000, J BIOL CHEM, V275, P17869, DOI 10.1074/jbc.M000217200; Luchansky SJ, 2003, J BIOL CHEM, V278, P8035, DOI 10.1074/jbc.M212127200; Matrosovich M, 2003, REV MED VIROL, V13, P85, DOI 10.1002/rmv.372; MENDLA K, 1988, BIOCHEM J, V250, P261, DOI 10.1042/bj2500261; Munster AK, 1998, P NATL ACAD SCI USA, V95, P9140, DOI 10.1073/pnas.95.16.9140; Patnaik SK, 2000, ARCH BIOCHEM BIOPHYS, V375, P322, DOI 10.1006/abbi.1999.1693; Potvin B, 1995, J BIOL CHEM, V270, P30415, DOI 10.1074/jbc.270.51.30415; ROBERTSON MA, 1978, CELL, V13, P515, DOI 10.1016/0092-8674(78)90325-2; Schachner M, 1997, CURR OPIN CELL BIOL, V9, P627, DOI 10.1016/S0955-0674(97)80115-9; Schwarzkopf M, 2002, P NATL ACAD SCI USA, V99, P5267, DOI 10.1073/pnas.072066199; Seppala R, 1999, AM J HUM GENET, V64, P1563, DOI 10.1086/302411; STANLEY P, 1981, MOL CELL BIOL, V1, P687, DOI 10.1128/MCB.1.8.687; STANLEY P, 1975, SOMAT CELL GENET, V1, P3, DOI 10.1007/BF01538729; STANLEY P, 1980, J CELL BIOL, V85, P60, DOI 10.1083/jcb.85.1.60; STANLEY P, 1987, TRENDS GENET, V3, P77, DOI 10.1016/0168-9525(87)90180-6; Stasche R, 1997, J BIOL CHEM, V272, P24319, DOI 10.1074/jbc.272.39.24319; Tong HH, 2002, ACTA OTO-LARYNGOL, V122, P413, DOI 10.1080/00016480260000111; TROY FA, 1992, GLYCOBIOLOGY, V2, P5, DOI 10.1093/glycob/2.1.5; Vestweber D, 1999, PHYSIOL REV, V79, P181, DOI 10.1152/physrev.1999.79.1.181; Yarema KJ, 2001, NAT BIOTECHNOL, V19, P553, DOI 10.1038/89305; Zhang AM, 1999, J BIOL CHEM, V274, P10439, DOI 10.1074/jbc.274.15.10439	46	33	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					53045	53054		10.1074/jbc.M309967200	http://dx.doi.org/10.1074/jbc.M309967200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14561743	hybrid			2022-12-27	WOS:000187480700128
J	Knappe, S; Wu, F; Masikat, MR; Morser, J; Wu, QY				Knappe, S; Wu, F; Masikat, MR; Morser, J; Wu, QY			Functional analysis of the transmembrane domain and activation cleavage of human corin - Design and characterization of a soluble corin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROATRIAL NATRIURETIC PEPTIDE; SURFACE PROTEOLYTIC-ENZYMES; SERINE-PROTEASE; PLASMINOGEN-ACTIVATOR; BLOOD-COAGULATION; HUMAN-LIVER; HEPSIN; TRYPSIN; CLONING; CANCER	Corin is a cardiac transmembrane serine protease. In cell-based studies, corin converted pro-atrial natriuretic peptide (pro-ANP) to mature ANP, suggesting that corin is potentially the pro-ANP convertase. In this study, we evaluated the importance of the transmembrane domain and activation cleavage in human corin. We showed that a soluble corin that consists of only the extracellular domain was capable of processing recombinant human pro-ANP in cell-based assays. In contrast, a mutation at the conserved activation cleavage site, R801A, abolished the function of corin, demonstrating that the activation cleavage is essential for corin activity. These results allowed us to design, express, and purify a mutant soluble corin, EKsolCorin, that contains an enterokinase recognition sequence at the activation cleavage site. Purified EKsolCorin was activated by enterokinase in a dose-dependent manner. Activated EKsolCorin had hydrolytic activity toward peptide substrates with a preference for Arg and Lys residues in the P-1 position. This activity of EKsolCorin was inhibited by trypsin-like serine protease inhibitors but not inhibitors of chymotrypsin-like, cysteine-, or metallo-proteases. In pro-ANP processing assays, purified active EKsolCorin converted recombinant human pro-ANP to biologically active ANP in a highly sequence-specific manner. The pro-ANP processing activity of EKsolCorin was not inhibited by human plasma. Together, our data indicate that the transmembrane domain is not necessary for the biological activity of corin but may be a mechanism to localize corin at specific sites, whereas the proteolytic cleavage at the activation site is an essential step in controlling the activity of corin.	Berlex Biosci, Dept Cardiovasc Res, Richmond, CA 94804 USA		Wu, QY (corresponding author), Berlex Biosci, Dept Cardiovasc Res, 2600 Hilltop Dr, Richmond, CA 94804 USA.			Wu, Qingyu/0000-0003-0561-9315				Cal S, 2003, P NATL ACAD SCI USA, V100, P9185, DOI 10.1073/pnas.1633392100; Chen HH, 1998, J CARDIOVASC PHARM, V32, pS22; Cho EG, 2001, J BIOL CHEM, V276, P44581, DOI 10.1074/jbc.M107059200; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; Hooper JD, 2000, EUR J BIOCHEM, V267, P6931, DOI 10.1046/j.1432-1327.2000.01806.x; Hooper JD, 2001, J BIOL CHEM, V276, P857, DOI 10.1074/jbc.R000020200; Hooper JD, 2003, BIOCHEM J, V373, P689, DOI 10.1042/BJ20030390; KAZAMA Y, 1995, J BIOL CHEM, V270, P66, DOI 10.1074/jbc.270.1.66; Kim DR, 2001, BBA-GENE STRUCT EXPR, V1518, P204, DOI 10.1016/S0167-4781(01)00184-1; KITAMOTO Y, 1994, P NATL ACAD SCI USA, V91, P7588, DOI 10.1073/pnas.91.16.7588; KOLLER KJ, 1992, CIRCULATION, V86, P1081, DOI 10.1161/01.CIR.86.4.1081; KRAUT J, 1977, ANNU REV BIOCHEM, V46, P331, DOI 10.1146/annurev.bi.46.070177.001555; KURACHI K, 1994, METHOD ENZYMOL, V244, P100; Lang JC, 2001, BRIT J CANCER, V84, P237, DOI 10.1054/bjoc.2000.1586; Levin ER, 1998, NEW ENGL J MED, V339, P321; LEYTUS SP, 1988, BIOCHEMISTRY-US, V27, P1067, DOI 10.1021/bi00403a032; Lin CY, 1999, J BIOL CHEM, V274, P18231, DOI 10.1074/jbc.274.26.18231; Lin CY, 1997, J BIOL CHEM, V272, P9147; Lu DS, 1997, J BIOL CHEM, V272, P31293, DOI 10.1074/jbc.272.50.31293; Lu DS, 1999, J MOL BIOL, V292, P361, DOI 10.1006/jmbi.1999.3089; MADISON EL, 1993, SCIENCE, V262, P419, DOI 10.1126/science.8211162; MANN KG, 1990, BLOOD, V76, P1; Netzel-Arnett S, 2003, CANCER METAST REV, V22, P237, DOI 10.1023/A:1023003616848; NEURATH H, 1984, SCIENCE, V224, P350, DOI 10.1126/science.6369538; PaoloniGiacobino A, 1997, GENOMICS, V44, P309, DOI 10.1006/geno.1997.4845; Scott HS, 2001, NAT GENET, V27, P59, DOI 10.1038/83768; Stein B, 1998, AM HEART J, V135, P914, DOI 10.1016/S0002-8703(98)70054-7; STROUD RM, 1974, SCI AM, V231, P74, DOI 10.1038/scientificamerican0774-74; Stubbs MT, 1998, BIOL CHEM, V379, P95; Szabo R, 2003, THROMB HAEMOSTASIS, V90, P185, DOI 10.1160/TH03-02-0071; Takeuchi T, 2000, J BIOL CHEM, V275, P26333, DOI 10.1074/jbc.M002941200; Takeuchi T, 1999, P NATL ACAD SCI USA, V96, P11054, DOI 10.1073/pnas.96.20.11054; Velasco G, 2002, J BIOL CHEM, V277, P37637, DOI 10.1074/jbc.M203007200; Wallrapp C, 2000, CANCER RES, V60, P2602; Wilkins MR, 1997, LANCET, V349, P1307, DOI 10.1016/S0140-6736(96)07424-7; Wu CL, 2003, J BIOL CHEM, V278, P25847, DOI 10.1074/jbc.M301223200; Wu F, 2002, J BIOL CHEM, V277, P16900, DOI 10.1074/jbc.M201503200; WU Q, 2001, FRONTIERS BIOSCIENCE, V6, P192; Wu QY, 2003, CURR TOP DEV BIOL, V54, P167, DOI 10.1016/S0070-2153(03)54009-1; Yamaguchi N, 2002, J BIOL CHEM, V277, P6806, DOI 10.1074/jbc.M103645200; Yamaoka K, 1998, J BIOL CHEM, V273, P11895, DOI 10.1074/jbc.273.19.11895; Yan W, 1999, J BIOL CHEM, V274, P14926, DOI 10.1074/jbc.274.21.14926; Yan W, 2000, P NATL ACAD SCI USA, V97, P8525, DOI 10.1073/pnas.150149097; Zhukov A, 1997, BBA-PROTEIN STRUCT M, V1337, P85, DOI 10.1016/S0167-4838(96)00152-5	45	95	99	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52363	52370		10.1074/jbc.M309991200	http://dx.doi.org/10.1074/jbc.M309991200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14559895	hybrid			2022-12-27	WOS:000187480700047
J	Pfeiffer, K; Gohil, V; Stuart, RA; Hunte, C; Brandt, U; Greenberg, ML; Schagger, H				Pfeiffer, K; Gohil, V; Stuart, RA; Hunte, C; Brandt, U; Greenberg, ML; Schagger, H			Cardiolipin stabilizes respiratory chain supercomplexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C-OXIDASE; OXIDATIVE-PHOSPHORYLATION ENZYMES; BLUE NATIVE ELECTROPHORESIS; BOVINE HEART; SACCHAROMYCES-CEREVISIAE; CARRIER PROTEIN; BC(1) COMPLEX; ATP SYNTHASE; NUCLEAR GENE; YEAST	Cardiolipin stabilized supercomplexes of Saccharomyces cerevisiae respiratory chain complexes III and IV (ubiquinol: cytochrome c oxidoreductase and cytochrome c oxidase, respectively), but was not essential for their formation in the inner mitochondrial membrane because they were found also in a cardiolipin-deficient strain. Reconstitution with cardiolipin largely restored wild-type stability. The putative interface of complexes III and IV comprises transmembrane helices of cytochromes b and c(1) and tightly bound cardiolipin. Subunits Rip1p, Qcr6p, Qcr9p, Qcr10p, Cox8p, Cox12p, and Cox13p and cytochrome c were not essential for the assembly of supercomplexes; and in the absence of Qcr6p, the formation of supercomplexes was even promoted. An additional marked effect of cardiolipin concerns cytochrome c oxidase. We show that a cardiolipin-deficient strain harbored almost inactive resting cytochrome c oxidase in the membrane. Transition to the fully active pulsed state occurred on a minute time scale.	Univ Frankfurt Klinikum, Zentrum Biol Chem, D-60590 Frankfurt, Germany; Wayne State Univ, Dept Biol Sci, Detroit, MI 48202 USA; Marquette Univ, Dept Biol, Milwaukee, WI 53051 USA; Max Planck Inst Biophys, D-60439 Frankfurt, Germany	Goethe University Frankfurt; Goethe University Frankfurt Hospital; Wayne State University; Marquette University; Max Planck Society	Schagger, H (corresponding author), Univ Frankfurt Klinikum, Zentrum Biol Chem, Theodor Stern Kai 7,Haus 25B, D-60590 Frankfurt, Germany.	schagger@zbc.kgu.de	Brandt, Ulrich/C-4406-2008; Brandt, Ulrich/GLV-1242-2022; Hunte, Carola/E-4071-2015	Brandt, Ulrich/0000-0003-1869-6811; Brandt, Ulrich/0000-0003-1869-6811; Hunte, Carola/0000-0002-0826-3986; Gohil, Vishal/0000-0002-9920-2563	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062263] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL62263] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arnold I, 1998, EMBO J, V17, P7170, DOI 10.1093/emboj/17.24.7170; BERRY EA, 1985, J BIOL CHEM, V260, P2458; Beyer K, 1996, BIOCHEMISTRY-US, V35, P15784, DOI 10.1021/bi9610055; Boumans H, 1998, J BIOL CHEM, V273, P4872, DOI 10.1074/jbc.273.9.4872; BRANDT U, 1994, J BIOL CHEM, V269, P12947; Chang SC, 1998, J BIOL CHEM, V273, P14933, DOI 10.1074/jbc.273.24.14933; Cruciat CM, 2000, J BIOL CHEM, V275, P18093, DOI 10.1074/jbc.M001901200; DREES M, 1988, BIOCHEMISTRY-US, V27, P8584, DOI 10.1021/bi00423a012; EBLE KS, 1990, J BIOL CHEM, V265, P19434; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; FOLCH J, 1957, J BIOL CHEM, V226, P497; Follmann K, 1998, BIOCHEM MOL BIOL INT, V45, P1047; Fyfe PK, 2001, TRENDS BIOCHEM SCI, V26, P106, DOI 10.1016/S0968-0004(00)01746-1; Gomez B, 1999, BIOCHEMISTRY-US, V38, P9031, DOI 10.1021/bi990603r; HALESTRAP AP, 1989, BIOCHIM BIOPHYS ACTA, V973, P355, DOI 10.1016/S0005-2728(89)80378-0; HAYERHARTL M, 1992, EUR J BIOCHEM, V209, P423, DOI 10.1111/j.1432-1033.1992.tb17305.x; HOCH FL, 1992, BIOCHIM BIOPHYS ACTA, V1113, P71, DOI 10.1016/0304-4157(92)90035-9; Hunte C, 2000, STRUCTURE, V8, P669, DOI 10.1016/S0969-2126(00)00152-0; Jiang F, 1997, MOL MICROBIOL, V26, P481, DOI 10.1046/j.1365-2958.1997.5841950.x; Jiang F, 2000, J BIOL CHEM, V275, P22387, DOI 10.1074/jbc.M909868199; Koshkin V, 2002, BIOCHEM J, V364, P317, DOI 10.1042/bj3640317; Koshkin V, 2000, BIOCHEM J, V347, P687, DOI 10.1042/0264-6021:3470687; LAIRD DM, 1986, J BIOL CHEM, V261, P4851; LAMARCHE AEP, 1992, J BIOL CHEM, V267, P22473; Lange C, 2001, EMBO J, V20, P6591, DOI 10.1093/emboj/20.23.6591; LECOCQ J, 1964, BIOCHEMISTRY-US, V3, P976, DOI 10.1021/bi00895a023; LERAY C, 1987, J CHROMATOGR-BIOMED, V420, P411, DOI 10.1016/0378-4347(87)80198-6; McAuley KE, 1999, P NATL ACAD SCI USA, V96, P14706, DOI 10.1073/pnas.96.26.14706; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Mizushima T, 1999, ACTA CRYSTALLOGR A S, V55; Moody AJ, 1996, BBA-BIOENERGETICS, V1276, P6; Ostrander DB, 2001, J BIOL CHEM, V276, P38061; Palsdottir H, 2003, J BIOL CHEM, V278, P31303, DOI 10.1074/jbc.M302195200; Paumard P, 2002, EMBO J, V21, P221, DOI 10.1093/emboj/21.3.221; PHILLIPS JD, 1993, J BIOL CHEM, V268, P11727; ROBINSON NC, 1990, BIOCHEMISTRY-US, V29, P8962, DOI 10.1021/bi00490a012; ROTHSTEIN RJ, 1980, GENETICS, V94, P871; RYTOMAA M, 1994, J BIOL CHEM, V269, P1770; Schagger H, 2002, BBA-BIOENERGETICS, V1555, P154, DOI 10.1016/S0005-2728(02)00271-2; SCHAGGER H, 1990, EUR J BIOCHEM, V190, P123, DOI 10.1111/j.1432-1033.1990.tb15554.x; SCHAGGER H, 1995, ELECTROPHORESIS, V16, P763, DOI 10.1002/elps.11501601125; Schagger H, 2000, EMBO J, V19, P1777, DOI 10.1093/emboj/19.8.1777; SCHAGGER H, 1994, ANAL BIOCHEM, V217, P220, DOI 10.1006/abio.1994.1112; Schlame M, 2000, PROG LIPID RES, V39, P257, DOI 10.1016/S0163-7827(00)00005-9; SCHMITT ME, 1990, J BIOL CHEM, V265, P17005; Sedlak E, 1999, BIOCHEMISTRY-US, V38, P14966, DOI 10.1021/bi9914053; Tomasetig L, 2002, BBA-BIOENERGETICS, V1556, P133, DOI 10.1016/S0005-2728(02)00344-4; Tuller G, 1998, FEBS LETT, V421, P15, DOI 10.1016/S0014-5793(97)01525-1; Vreken P, 2000, BIOCHEM BIOPH RES CO, V279, P378, DOI 10.1006/bbrc.2000.3952; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; WILSON MT, 1981, P NATL ACAD SCI-BIOL, V78, P7115, DOI 10.1073/pnas.78.11.7115; YU CA, 1980, BIOCHEMISTRY-US, V19, P5715, DOI 10.1021/bi00566a008; Zerbetto E, 1997, ELECTROPHORESIS, V18, P2059, DOI 10.1002/elps.1150181131; Zhang M, 2002, J BIOL CHEM, V277, P43553, DOI 10.1074/jbc.C200551200	54	603	613	3	45	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52873	52880		10.1074/jbc.M308366200	http://dx.doi.org/10.1074/jbc.M308366200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14561769	hybrid			2022-12-27	WOS:000187480700108
J	Sargueil, B; Hampel, KJ; Lambert, D; Burke, JM				Sargueil, B; Hampel, KJ; Lambert, D; Burke, JM			In vitro selection of second site revertants analysis of the hairpin ribozyme active site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERTIARY STRUCTURE; STRUCTURAL BASIS; MECHANISM; DOMAIN; LOOP; HAMMERHEAD; SECONDARY; DYNAMICS; CLEAVAGE; KINETICS	We have used in vitro genetics to evaluate the function and interactions of the conserved base G8 in the hairpin ribozyme catalytic RNA. Second site revertant selection for a G8X mutant, where X is any of the other three natural nucleobases, yielded a family of second site suppressors of the G8U mutant, but not of G8C or G8A, indicating that only G and U can be tolerated at position 8 of the ribozyme. This result is consistent with recent observations that point to the functional importance of G8 N-1 in the chemistry of catalysis by this ribozyme reaction. Suppression of the G8U mutation was observed when changes were made directly across loop A from the mutated base at substrate position +2 or positions +2 and +3 in combination. The same changes made in the context of the natural G8 sequence resulted in a very large drop in activity. Thus, the G8U mutation results in a change in specificity of the ribozyme from 5'-N down arrow GUC-3' to 5'-N down arrow GCU-3'. The results presented imply that G8 interacts directly with U + 2 during catalysis. We propose that this interaction favors the correct positioning of the catalytic determinants of G8. The implications for the folding of the ribozyme and the catalytic mechanism are discussed.	CNRS, Ctr Genet Mol, F-91190 Gif Sur Yvette, France; Univ Vermont, Dept Microbiol & Mol Genet, Markey Ctr Mol Genet, Burlington, VT 05405 USA	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; University of Vermont	Sargueil, B (corresponding author), CNRS, Ctr Genet Mol, Ave Terrasse, F-91190 Gif Sur Yvette, France.	sargueil@cgm.cnrs-gif.fr	, John/AAB-5945-2021	sargueil, bruno/0000-0003-4483-355X				ANDERSON P, 1994, NUCLEIC ACIDS RES, V22, P1096, DOI 10.1093/nar/22.6.1096; BERZALHERRANZ A, 1992, GENE DEV, V6, P129, DOI 10.1101/gad.6.1.129; BERZALHERRANZ A, 1993, EMBO J, V12, P2567, DOI 10.1002/j.1460-2075.1993.tb05912.x; BURKE JM, 1994, NUCL ACIDS MOL BIOL, V8, P105; BUTCHER SE, 1994, J MOL BIOL, V244, P52, DOI 10.1006/jmbi.1994.1703; BUTCHER SE, 1995, J BIOL CHEM, V270, P29648; Butcher SE, 1999, NAT STRUCT BIOL, V6, P212; BUZAYAN JM, 1986, NUCLEIC ACIDS RES, V14, P9729, DOI 10.1093/nar/14.24.9729; Cai ZP, 1996, BIOCHEMISTRY-US, V35, P6026, DOI 10.1021/bi952985g; Earnshaw DJ, 1997, J MOL BIOL, V274, P197, DOI 10.1006/jmbi.1997.1405; Esteban JA, 1998, P NATL ACAD SCI USA, V95, P6091, DOI 10.1073/pnas.95.11.6091; Esteban JA, 1997, J BIOL CHEM, V272, P13629, DOI 10.1074/jbc.272.21.13629; Fedor MJ, 2000, J MOL BIOL, V297, P269, DOI 10.1006/jmbi.2000.3560; FEDOR MJ, 1990, P NATL ACAD SCI USA, V87, P1668, DOI 10.1073/pnas.87.5.1668; GREEN R, 1991, Methods (Orlando), V2, P75, DOI 10.1016/S1046-2023(05)80127-6; HAMPEL A, 1989, BIOCHEMISTRY-US, V28, P4929, DOI 10.1021/bi00438a002; Hampel A, 1997, CHEM BIOL, V4, P513, DOI 10.1016/S1074-5521(97)90323-9; Hampel KJ, 2001, BIOCHEMISTRY-US, V40, P3723, DOI 10.1021/bi0028385; JOSEPH S, 1993, J BIOL CHEM, V268, P24515; Komatsu Y, 1999, NUCLEIC ACIDS RES, V27, P4314, DOI 10.1093/nar/27.22.4314; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lebruska LL, 2002, CHEM BIOL, V9, P465, DOI 10.1016/S1074-5521(02)00130-8; Major F, 2001, CURR OPIN STRUC BIOL, V11, P282, DOI 10.1016/S0959-440X(00)00203-7; MAJOR F, 1991, SCIENCE, V253, P1255, DOI 10.1126/science.1716375; MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; Murray JB, 1998, CHEM BIOL, V5, P587, DOI 10.1016/S1074-5521(98)90116-8; Nesbitt S, 1997, CHEM BIOL, V4, P619, DOI 10.1016/S1074-5521(97)90247-7; PEARLMAN DA, 1995, COMPUT PHYS COMMUN, V91, P1, DOI 10.1016/0010-4655(95)00041-D; Pinard R, 1999, BIOCHEMISTRY-US, V38, P16035, DOI 10.1021/bi992024s; Pinard R, 2001, EMBO J, V20, P6434, DOI 10.1093/emboj/20.22.6434; PYLE AM, 1994, BIOCHEMISTRY-US, V33, P2716, DOI 10.1021/bi00175a047; Rupert PB, 2002, SCIENCE, V298, P1421, DOI 10.1126/science.1076093; Rupert PB, 2001, NATURE, V410, P780, DOI 10.1038/35071009; Ryder SP, 1999, J MOL BIOL, V291, P295, DOI 10.1006/jmbi.1999.2959; SARGUEIL B, 1995, BIOCHEMISTRY-US, V34, P7739, DOI 10.1021/bi00023a021; Sargueil B, 1997, Methods Mol Biol, V74, P289; Sargueil B, 2000, J BIOL CHEM, V275, P32157, DOI 10.1074/jbc.M005591200; Shippy R, 1998, BIOCHEMISTRY-US, V37, P564, DOI 10.1021/bi9721288; Walter F, 1998, BIOCHEMISTRY-US, V37, P14195, DOI 10.1021/bi981513+; Walter NG, 1997, RNA, V3, P392; Walter NG, 1998, EMBO J, V17, P2378, DOI 10.1093/emboj/17.8.2378; Walter NG, 1999, NAT STRUCT BIOL, V6, P544; Walter NG, 2001, BIOCHEMISTRY-US, V40, P2580, DOI 10.1021/bi001609f; Wilson TJ, 2002, RNA, V8, P587, DOI 10.1017/S1355838202020514; Wilson TJ, 2001, BIOCHEMISTRY-US, V40, P2291, DOI 10.1021/bi002644p; Young KJ, 1997, NUCLEIC ACIDS RES, V25, P3760, DOI 10.1093/nar/25.19.3760; Zhuang XW, 2002, SCIENCE, V296, P1473, DOI 10.1126/science.1069013	47	10	10	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52783	52791		10.1074/jbc.M306703200	http://dx.doi.org/10.1074/jbc.M306703200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14555657	hybrid			2022-12-27	WOS:000187480700097
J	Tsuboi, T; Xavier, GD; Leclerc, I; Rutter, GA				Tsuboi, T; Xavier, GD; Leclerc, I; Rutter, GA			5 '-AMP-activated protein kinase controls insulin-containing secretory vesicle dynamics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC BETA-CELLS; EVANESCENT-WAVE MICROSCOPY; SENSITIVE POTASSIUM CHANNELS; GREEN FLUORESCENT PROTEIN; ACETYL-COA CARBOXYLASE; GENE-EXPRESSION; DEPENDENT EXOCYTOSIS; CHROMAFFIN CELLS; CYTOPLASMIC CA2+; ENERGY-CHARGE	Changes in 5'-AMP-activated protein kinase (AMPK) activity have recently been implicated in the control of insulin secretion by glucose (da Silva Xavier, G., Leclerc, I., Varadi, A., Tsuboi, T., Moule, S. K., and Rutter, G. A. (2003) Biochem. J. 371, 761 - 774). Here, we examine the possibility that activation of AMPK may regulate distal steps in insulin secretion, including vesicle movement and fusion with the plasma membrane. Vesicle dynamics were imaged in single pancreatic MIN6 beta-cells expressing lumen-targeted pH-insensitive yellow fluorescent protein, neuropeptide Y. Venus, or monomeric red fluorescent protein by total internal reflection fluorescence and Nipkow disc confocal microscopy. Overexpression of a truncated, constitutively active form of AMPK (AMPKalpha1, 1 - 312, T172D; AMPK CA), inhibited glucose-stimulated (30 versus 3.0 mM) vesicle movements, and decreased the number of vesicles docked or fusing at the plasma membrane, while having no effect on the kinetics of individual secretory events. Expression of the activated form of AMPK also prevented dispersal of the cortical actin network at high glucose concentrations. Monitored in permeabilized cells, where the effects of AMPK CA on glucose metabolism and ATP synthesis were bypassed, AMPK CA inhibited Ca2+ and ATP-induced insulin secretion, and decreased ATP-dependent vesicle movements. These findings suggest that components of the vesicle transport network, including vesicle-associated motor proteins, may be targets of AMPK in beta-cells, dephosphorylation of which is required for vesicle mobilization at elevated glucose concentrations.	Univ Bristol, Sch Med Sci, Dept Biochem, Bristol BS8 1TD, Avon, England; Univ Bristol, Henry Wellcome Labs Integrated Cell Signalling, Bristol BS8 1TD, Avon, England	University of Bristol; University of Bristol	Rutter, GA (corresponding author), Univ Bristol, Sch Med Sci, Dept Biochem, Univ Walk, Bristol BS8 1TD, Avon, England.		TSUBOI, Takashi/AAD-7976-2019	TSUBOI, Takashi/0000-0001-8290-2021; Leclerc, Isabelle/0000-0003-0044-7921; Rutter, Guy/0000-0001-6360-0343; da Silva Xavier, Gabriela/0000-0002-0678-012X	Diabetes UK [13/0004672] Funding Source: Medline	Diabetes UK(Diabetes UK)		Aguilar-Bryan L, 1999, ENDOCR REV, V20, P101, DOI 10.1210/er.20.2.101; Ainscow EK, 2000, DIABETES, V49, P1149, DOI 10.2337/diabetes.49.7.1149; Ainscow EK, 2001, BIOCHEM J, V353, P175, DOI 10.1042/0264-6021:3530175; Aizawa T, 1998, TRENDS PHARMACOL SCI, V19, P496, DOI 10.1016/S0165-6147(98)01273-5; AXELROD D, 1981, J CELL BIOL, V89, P141, DOI 10.1083/jcb.89.1.141; Bruun TZ, 2000, EUR J PHARMACOL, V403, P221, DOI 10.1016/S0014-2999(00)00602-6; Bryan J, 1997, CURR OPIN CELL BIOL, V9, P553, DOI 10.1016/S0955-0674(97)80033-6; Bubb MR, 2000, J BIOL CHEM, V275, P5163, DOI 10.1074/jbc.275.7.5163; Burgoyne RD, 2003, PHYSIOL REV, V83, P581, DOI 10.1152/physrev.00031.2002; Campbell RE, 2002, P NATL ACAD SCI USA, V99, P7877, DOI 10.1073/pnas.082243699; CARLING D, 1987, FEBS LETT, V223, P217, DOI 10.1016/0014-5793(87)80292-2; Detimary P, 1998, BIOCHEM J, V333, P269, DOI 10.1042/bj3330269; Eliasson L, 1997, J PHYSIOL-LONDON, V503, P399, DOI 10.1111/j.1469-7793.1997.399bh.x; Eto K, 2002, DIABETES, V51, pS414, DOI 10.2337/diabetes.51.2007.S414; GILON P, 1992, J BIOL CHEM, V267, P20713; Grodsky G M, 1969, Acta Diabetol Lat, V6 Suppl 1, P554; Hardie DG, 2003, FEBS LETT, V546, P113, DOI 10.1016/S0014-5793(03)00560-X; Hardie DG, 2001, BIOESSAYS, V23, P1112, DOI 10.1002/bies.10009; Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821; Henquin JC, 2000, DIABETES, V49, P1751, DOI 10.2337/diabetes.49.11.1751; HENQUIN JC, 1984, EXPERIENTIA, V40, P1043, DOI 10.1007/BF01971450; HOLZ RW, 1989, J BIOL CHEM, V264, P5412; Jahn R, 2003, CELL, V112, P519, DOI 10.1016/S0092-8674(03)00112-0; Kemp BE, 2003, BIOCHEM SOC T, V31, P162; Kennedy HJ, 1999, J BIOL CHEM, V274, P13281, DOI 10.1074/jbc.274.19.13281; KOMATSU M, 1995, P NATL ACAD SCI USA, V92, P10728, DOI 10.1073/pnas.92.23.10728; KUSUMI A, 1993, BIOPHYS J, V65, P2021, DOI 10.1016/S0006-3495(93)81253-0; Lang JC, 1997, EMBO J, V16, P5837, DOI 10.1093/emboj/16.19.5837; Lang T, 2000, BIOPHYS J, V78, P2863, DOI 10.1016/S0006-3495(00)76828-7; Leclerc I, 1998, FEBS LETT, V431, P180, DOI 10.1016/S0014-5793(98)00745-5; LI GD, 1994, MOL BIOL CELL, V5, P1199, DOI 10.1091/mbc.5.11.1199; MIYAZAKI JI, 1990, ENDOCRINOLOGY, V127, P126, DOI 10.1210/endo-127-1-126; MUNDAY MR, 1991, BIOCHEM J, V280, P733, DOI 10.1042/bj2800733; Nagai T, 2002, NAT BIOTECHNOL, V20, P87, DOI 10.1038/nbt0102-87; NELSON TY, 1985, J CLIN INVEST, V75, P1015, DOI 10.1172/JCI111762; Pinton P, 2002, J BIOL CHEM, V277, P37702, DOI 10.1074/jbc.M204478200; Pouli AE, 1998, BIOCHEM J, V331, P669, DOI 10.1042/bj3310669; Pouli AE, 1998, BIOCHEM J, V333, P193, DOI 10.1042/bj3330193; PRENTKI M, 1992, J BIOL CHEM, V267, P5802; Qian H, 1991, BIOPHYS J, V60, P910, DOI 10.1016/S0006-3495(91)82125-7; Rorsman P, 2000, NEWS PHYSIOL SCI, V15, P72; Rutter GA, 2003, BIOCHEM J, V375, P1, DOI 10.1042/BJ20030048; RUTTER GA, 1988, BIOCHEM J, V252, P181, DOI 10.1042/bj2520181; Rutter Guy A., 2001, Molecular Aspects of Medicine, V22, P247, DOI 10.1016/S0098-2997(01)00013-9; Safayhi H, 1997, MOL ENDOCRINOL, V11, P619, DOI 10.1210/me.11.5.619; Salt IP, 1998, BIOCHEM J, V335, P533, DOI 10.1042/bj3350533; STAPLETON D, 1994, J BIOL CHEM, V269, P29343; Stein SC, 2000, BIOCHEM J, V345, P437, DOI 10.1042/0264-6021:3450437; Steyer JA, 1999, BIOPHYS J, V76, P2262, DOI 10.1016/S0006-3495(99)77382-0; Terakawa S, 2001, PROC SPIE, V4597, P121, DOI 10.1117/12.446647; TERAKAWA S, 1997, BIOIMAGES, V5, P24; Thurmond DC, 2003, MOL ENDOCRINOL, V17, P732, DOI 10.1210/me.2002-0333; Tokunaga M, 1997, BIOCHEM BIOPH RES CO, V231, P566, DOI 10.1006/bbrc.1997.6144; Toomre D, 2001, TRENDS CELL BIOL, V11, P298, DOI 10.1016/S0962-8924(01)02027-X; Tsuboi T, 2000, CURR BIOL, V10, P1307, DOI 10.1016/S0960-9822(00)00756-9; Tsuboi T, 2003, CURR BIOL, V13, P563, DOI 10.1016/S0960-9822(03)00176-3; Tsuboi T, 2002, BIOPHYS J, V83, P172, DOI 10.1016/S0006-3495(02)75159-X; Tsuboi T, 2002, J BIOL CHEM, V277, P15957, DOI 10.1074/jbc.C200051200; Varadi A, 2002, J CELL SCI, V115, P4177, DOI 10.1242/jcs.00083; VITALE ML, 1995, NEURON, V14, P353, DOI 10.1016/0896-6273(95)90291-0; Wilson JR, 1999, DIABETES, V48, P2383, DOI 10.2337/diabetes.48.12.2383; Woods A, 2000, MOL CELL BIOL, V20, P6704, DOI 10.1128/MCB.20.18.6704-6711.2000; Xavier GD, 2003, BIOCHEM J, V371, P761; Xavier GD, 2000, P NATL ACAD SCI USA, V97, P4023, DOI 10.1073/pnas.97.8.4023; YEH LA, 1980, J BIOL CHEM, V255, P2308	65	88	94	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52042	52051		10.1074/jbc.M307800200	http://dx.doi.org/10.1074/jbc.M307800200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14532293	hybrid			2022-12-27	WOS:000187480700010
J	Hoshi, H; Nakagawa, H; Nishiguchi, S; Iwata, K; Niikura, K; Monde, K; Nishimura, SI				Hoshi, H; Nakagawa, H; Nishiguchi, S; Iwata, K; Niikura, K; Monde, K; Nishimura, SI			An engineered hyaluronan synthase - Characterization of recombinant human hyaluronan synthase 2 expressed in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFERENTIATED TERATOCARCINOMA CELLS; PASTEURELLA-MULTOCIDA; MOLECULAR-CLONING; STREPTOCOCCUS-PYOGENES; IN-VITRO; PROTEIN; ACID; CDNA; IDENTIFICATION; GENE	The Class I hyaluronan synthase ( HAS) is a unique glycosyltransferase synthesizing hyaluronan ( HA), a polysaccharide composed of GlcUA and GlcNAc, by using one catalytic domain that elongates two different monosaccharides. As for the synthetic mechanism, there are two alternative manners for the sugar elongation process. Some bacterial HASs add new sugars to the non-reducing end of the acceptor to grow polymers. On the other hand, some vertebrate enzymes seem to transfer sugars to the reducing end. Expression of vertebrate HASs as active and soluble proteins will accelerate further precise insight into mechanisms of sugar elongation reactions by natural HASs. Since large scale production of HA polymers and oligomers would become powerful tools both for basic studies and new biotechnology to create functional carbohydrates in medicinal purposes, advent of an efficient method for the expression of HASs in Escherichia coli is strongly expected. Here we communicate the first success of the production of recombinant human HAS2 proteins composed of only the catalytic region in E. coli as the active form. It was demonstrated that an engineered HAS2 expressed in E. coli exhibited significant activity to synthesize a mixture of HAS oligomers from 8-mer (HA8) to 16-mer (HA16). Engineered HAS2 prepared herein elongated sugars from exogenous tetrasaccharide to form polymers with a direction to the non-reducing end. According to the present results, large scale production of engineered recombinant HASs is to be performed using E. coli that will provide practical and economic advantages in manufacturing enzymes for use in the synthesis of various oligomeric HA molecules and their industrial applications.	Hokkaido Univ, Grad Sch Sci, Div Biol Sci,Frontier Res Ctr Postgenom Sci & Tech, Lab Biomacromol Chem,Kita Ku, Sapporo, Hokkaido 0010021, Japan; Hokkaido Univ, Japan Bioind Assoc, Sapporo Lab Glycocluster Project, Sapporo, Hokkaido 0010021, Japan; Natl Inst Adv Ind Sci & Technol Res AIST, Res Ctr Glycosci, Glycochemosynth Team, Sapporo, Hokkaido 0628517, Japan	Hokkaido University; Hokkaido University; National Institute of Advanced Industrial Science & Technology (AIST)	Nishimura, SI (corresponding author), Hokkaido Univ, Grad Sch Sci, Div Biol Sci,Frontier Res Ctr Postgenom Sci & Tech, Lab Biomacromol Chem,Kita Ku, N21,W11, Sapporo, Hokkaido 0010021, Japan.	shin@glyco.sci.hokudai.ac.jp	Nishimura, Shinichiro/F-5277-2011; Monde, Kenji/F-5286-2011	Monde, Kenji/0000-0002-1424-1054				Asplund T, 1998, BBA-GEN SUBJECTS, V1380, P377, DOI 10.1016/S0304-4165(98)00010-5; DeAngelis PL, 1999, CELL MOL LIFE SCI, V56, P670, DOI 10.1007/s000180050461; DeAngelis PL, 1998, J BIOL CHEM, V273, P8454, DOI 10.1074/jbc.273.14.8454; Deangelis PL, 2003, J BIOL CHEM, V278, P35199, DOI 10.1074/jbc.M306431200; DeAngelis PL, 1999, J BIOL CHEM, V274, P26557, DOI 10.1074/jbc.274.37.26557; DEANGELIS PL, 1993, J BIOL CHEM, V268, P19181; DeAngelis PL, 1996, J BIOL CHEM, V271, P23657, DOI 10.1074/jbc.271.39.23657; DeAngelis PL, 1996, BIOCHEMISTRY-US, V35, P9768, DOI 10.1021/bi960154k; GRUNDMANN U, 1990, NUCLEIC ACIDS RES, V18, P667, DOI 10.1093/nar/18.3.667; Heldermon C, 2001, J BIOL CHEM, V276, P2037, DOI 10.1074/jbc.M002276200; Itano N, 1999, J BIOL CHEM, V274, P25085, DOI 10.1074/jbc.274.35.25085; Itano N, 1996, J BIOL CHEM, V271, P9875, DOI 10.1074/jbc.271.17.9875; Jing W, 2000, GLYCOBIOLOGY, V10, P883, DOI 10.1093/glycob/10.9.883; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Nickel V, 1998, J BIOL CHEM, V273, P23668, DOI 10.1074/jbc.273.37.23668; Nishimura S, 1997, J AM CHEM SOC, V119, P10555, DOI 10.1021/ja971786c; Nishimura S, 2001, CURR OPIN CHEM BIOL, V5, P325, DOI 10.1016/S1367-5931(00)00209-X; Ohno S, 2001, BBA-GENE STRUCT EXPR, V1520, P71, DOI 10.1016/S0167-4781(01)00256-1; PREHM P, 1983, BIOCHEM J, V211, P181, DOI 10.1042/bj2110181; PREHM P, 1983, BIOCHEM J, V211, P191, DOI 10.1042/bj2110191; Pummill PE, 2001, J BIOL CHEM, V276, P39832, DOI 10.1074/jbc.M105489200; Shyjan AM, 1996, J BIOL CHEM, V271, P23395, DOI 10.1074/jbc.271.38.23395; Spicer AP, 1998, J BIOL CHEM, V273, P1923, DOI 10.1074/jbc.273.4.1923; Spicer AP, 1997, J BIOL CHEM, V272, P8957; STOOLMILLER AC, 1969, J BIOL CHEM, V244, P236; TAYLOR KA, 1992, ANAL BIOCHEM, V201, P190, DOI 10.1016/0003-2697(92)90194-C; Tlapak-Simmons VL, 1998, J BIOL CHEM, V273, P26100, DOI 10.1074/jbc.273.40.26100; Tlapak-Simmons VL, 1999, J BIOL CHEM, V274, P4239, DOI 10.1074/jbc.274.7.4239; Toda A, 2002, ADV SYNTH CATAL, V344, P61; UEJIMA T, 1992, CANCER RES, V52, P6158; Watanabe K, 1996, J BIOL CHEM, V271, P22945, DOI 10.1074/jbc.271.38.22945; Weigel PH, 1997, J BIOL CHEM, V272, P13997, DOI 10.1074/jbc.272.22.13997; Yanagidani S, 1997, J BIOCHEM-TOKYO, V121, P626; Yoshida M, 2000, J BIOL CHEM, V275, P497, DOI 10.1074/jbc.275.1.497	34	15	16	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	2004	279	4					2341	2349		10.1074/jbc.M305723200	http://dx.doi.org/10.1074/jbc.M305723200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	764MU	14583625	hybrid			2022-12-27	WOS:000188211300004
J	Inoue, Y; Yu, AM; Inoue, J; Gonzalez, FJ				Inoue, Y; Yu, AM; Inoue, J; Gonzalez, FJ			Hepatocyte nuclear factor 4 alpha is a central regulator of bile acid conjugation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL-COA SYNTHETASE; N-ACYLTRANSFERASE; MOLECULAR-CLONING; SALT TRANSPORTERS; GENE-EXPRESSION; HNF4-ALPHA; PROMOTER; LIGASE	Hepatocyte nuclear factor 4alpha (HNF4alpha) has an important role in regulating the expression of liver-specific genes. Because bile acids are produced from cholesterol in liver and many enzymes involved in their biosynthesis are preferentially expressed in liver, the role of HNF4alpha in the regulation of bile acid production was examined. In mice, unconjugated bile acids are conjugated with taurine by the liver-specific enzymes, bile acid-CoA ligase and bile acid-CoA: amino acid N-acyl-transferase ( BAT). Mice lacking hepatic HNF4alpha expression exhibited markedly decreased expression of the very long chain acyl-CoA synthase-related gene ( VLACSR), a mouse candidate for bile acid-CoA ligase, and BAT. This was associated with markedly elevated levels of unconjugated and glycine-conjugated bile acids in gallbladder. HNF4alpha was found to bind directly to the mouse VLACSR and BAT gene promoters, and the promoter activities were dependent on HNF4alpha-binding sites and HNF4alpha expression. In conclusion, HNF4alpha plays a central role in bile acid conjugation by direct regulation of VLACSR and BAT in vivo.	NCI, Lab Metab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Gonzalez, FJ (corresponding author), NCI, Lab Metab, Ctr Canc Res, NIH, 9000 Rockville Pike,Bldg 37,Rm 3106, Bethesda, MD 20892 USA.	fjgonz@helix.nih.gov	Inoue, Yusuke/O-6207-2018	Inoue, Yusuke/0000-0002-9710-7482; Yu, Aiming/0000-0003-1441-4012				[Anonymous], 2001, NUCL RECEPTORS GENET; Bahar RJ, 1999, GASTROENTEROL CLIN N, V28, P27, DOI 10.1016/S0889-8553(05)70042-X; Berger J, 1998, BIOCHEM BIOPH RES CO, V247, P255, DOI 10.1006/bbrc.1998.8770; Bjorkhem I, 2001, CURR OPIN LIPIDOL, V12, P97, DOI 10.1097/00041433-200104000-00002; CAPOCACCIA L, 1981, DIGEST DIS SCI, V26, P513, DOI 10.1007/BF01308099; Carlton VEH, 2003, NAT GENET, V34, P91, DOI 10.1038/ng1147; Chiang JYL, 2002, ENDOCR REV, V23, P443, DOI 10.1210/er.2000-0035; Falany CN, 2002, J LIPID RES, V43, P2062, DOI 10.1194/jlr.M200260-JLR200; FALANY CN, 1994, J BIOL CHEM, V269, P19375; Falany CN, 1997, J LIPID RES, V38, P1139; FURUTANI M, 1995, BIOCHEM J, V311, P203, DOI 10.1042/bj3110203; Garuti R, 2002, GENE, V283, P133, DOI 10.1016/S0378-1119(01)00874-5; Hayhurst GP, 2001, MOL CELL BIOL, V21, P1393, DOI 10.1128/MCB.21.4.1393-1403.2001; Inoue Y, 2002, J BIOL CHEM, V277, P25257, DOI 10.1074/jbc.M203126200; Kardassis D, 2002, BIOCHEMISTRY-US, V41, P1217, DOI 10.1021/bi015618f; Meier PJ, 2002, ANNU REV PHYSIOL, V64, P635, DOI 10.1146/annurev.physiol.64.082201.100300; Parviz F, 2003, NAT GENET, V34, P292, DOI 10.1038/ng1175; Pircher PC, 2003, J BIOL CHEM, V278, P27703, DOI 10.1074/jbc.M302128200; Russell DW, 2003, ANNU REV BIOCHEM, V72, P137, DOI 10.1146/annurev.biochem.72.121801.161712; Schrem H, 2002, PHARMACOL REV, V54, P129, DOI 10.1124/pr.54.1.129; St-Pierre MV, 2001, J EXP BIOL, V204, P1673; Steinberg SJ, 2000, J BIOL CHEM, V275, P15605, DOI 10.1074/jbc.C000015200; Tirona RG, 2003, NAT MED, V9, P220, DOI 10.1038/nm815; Trauner M, 2003, PHYSIOL REV, V83, P633, DOI 10.1152/physrev.00027.2002; Vlahcevic ZR, 1999, GASTROENTEROL CLIN N, V28, P1, DOI 10.1016/S0889-8553(05)70041-8; Wang DQH, 1999, AM J PHYSIOL-GASTR L, V276, pG751, DOI 10.1152/ajpgi.1999.276.3.G751	26	73	74	3	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	2004	279	4					2480	2489		10.1074/jbc.M311015200	http://dx.doi.org/10.1074/jbc.M311015200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	764MU	14583614	hybrid			2022-12-27	WOS:000188211300019
J	Schmidt, PM; Schramm, M; Schroder, H; Wunder, F; Stasch, JP				Schmidt, PM; Schramm, M; Schroder, H; Wunder, F; Stasch, JP			Identification of residues crucially involved in the binding of the heme moiety of soluble guanylate cyclase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE; INDEPENDENT ACTIVATION; NOBEL LECTURE; YC-1; SITE; 1H-<1,2,4>OXADIAZOLO<4,3-A>QUINOXALIN-1-ONE; STIMULATOR; INHIBITION; HEMOGLOBIN; DISCOVERY	Soluble guanylate cyclase (sGC), a heterodimeric hemeprotein, is the only receptor for the biological messenger nitric oxide (NO) identified to date and is intimately involved in various signal transduction pathways. By using the recently discovered NO- and heme-independent sGC activator BAY 58-2667 and a novel cGMP reporter cell, we could distinguish between heme-containing and heme-free sGC in an intact cellular system. Using these novel tools, we identified the invariant amino acids tyrosine 135 and arginine 139 of the beta(1)-subunit as crucially important for both the binding of the heme moiety and the activation of sGC by BAY 58-2667. The heme is displaced by BAY 58-2667 due to a competition between the carboxylic groups of this compound and the heme propionic acids for the identified residues tyrosine 135 and arginine 139. This displacement results in the release of the axial heme ligand histidine 105 and to the observed activation of sGC. Based on these findings we postulate a signal transmission triad composed of histidine 105, tyrosine 135, and arginine 139 responsible for the enzyme activation by this compound and probably also for transducing changes in heme status and porphyrin geometry upon NO binding into alterations of sGC catalytic activity.	Bayer AG, Inst Cardiovasc Res, D-42096 Wuppertal, Germany; Univ Halle Wittenberg, Sch Pharm, D-06120 Halle Saale, Germany	Bayer AG; Martin Luther University Halle Wittenberg	Stasch, JP (corresponding author), Bayer AG, Inst Cardiovasc Res, Aprather Weg 18A, D-42096 Wuppertal, Germany.	Johannes-Peter.Stasch.JS@bayer-ag.de	Schmidt, Peter/V-3882-2019	Schmidt, Peter/0000-0003-1340-9086; Wunder, Frank/0000-0002-1311-2357				Alayash AI, 1998, ARCH BIOCHEM BIOPHYS, V349, P65, DOI 10.1006/abbi.1997.0449; Alayash AI, 1999, NAT BIOTECHNOL, V17, P545, DOI 10.1038/9849; ALONSOALIJA C, 2001, Patent No. 11978; Becker EM, 1999, NITRIC OXIDE-BIOL CH, V3, P55, DOI 10.1006/niox.1999.0207; Contzen J, 1999, BIOCHEMISTRY-US, V38, P16253, DOI 10.1021/bi991759u; Foerster J, 1996, EUR J BIOCHEM, V240, P380, DOI 10.1111/j.1432-1033.1996.0380h.x; Friebe A, 1996, EMBO J, V15, P6863, DOI 10.1002/j.1460-2075.1996.tb01078.x; Friebe A, 1998, MOL PHARMACOL, V53, P123, DOI 10.1124/mol.53.1.123; Furchgott RF, 1999, ANGEW CHEM INT EDIT, V38, P1870, DOI 10.1002/(SICI)1521-3773(19990712)38:13/14<1870::AID-ANIE1870>3.0.CO;2-8; GARTHWAITE J, 1995, MOL PHARMACOL, V48, P184; Gong WM, 2000, BIOCHEMISTRY-US, V39, P3955, DOI 10.1021/bi992346w; HEBBEL RP, 1988, P NATL ACAD SCI USA, V85, P237, DOI 10.1073/pnas.85.1.237; HOBBS A, 2000, EMERGING THER TARGET, V4, P735, DOI DOI 10.1517/14728222.4.6.735; Hobbs AJ, 2002, BRIT J PHARMACOL, V136, P637, DOI 10.1038/sj.bjp.0704779; Hoenicka M, 1999, J MOL MED-JMM, V77, P14, DOI 10.1007/s001090050292; IGNARRO LJ, 1984, J BIOL CHEM, V259, P6201; IGNARRO LJ, 1982, P NATL ACAD SCI-BIOL, V79, P2870, DOI 10.1073/pnas.79.9.2870; Ignarro LJ, 1999, ANGEW CHEM INT EDIT, V38, P1882, DOI 10.1002/(SICI)1521-3773(19990712)38:13/14<1882::AID-ANIE1882>3.0.CO;2-V; Iyer LM, 2003, BMC GENOMICS, V4, DOI 10.1186/1471-2164-4-5; KO FN, 1994, BLOOD, V84, P4226, DOI 10.1182/blood.V84.12.4226.bloodjournal84124226; Kosarikov DN, 2001, J INORG BIOCHEM, V87, P267, DOI 10.1016/S0162-0134(01)00387-7; MARLETTA MA, 2003, BMC M 1 INT C CGMP N, V1, pOP20; Martin E, 2001, P NATL ACAD SCI USA, V98, P12938, DOI 10.1073/pnas.231486198; Mayer B, 2001, TRENDS PHARMACOL SCI, V22, P546, DOI 10.1016/S0165-6147(00)01889-7; Megson IL, 2002, EXPERT OPIN INV DRUG, V11, P587; MONCADA S, 1991, PHARMACOL REV, V43, P109; Mulsch A, 1997, BRIT J PHARMACOL, V120, P681, DOI 10.1038/sj.bjp.0700982; Murad F, 1999, ANGEW CHEM INT EDIT, V38, P1857, DOI 10.1002/(SICI)1521-3773(19990712)38:13/14<1856::AID-ANIE1856>3.0.CO;2-D; Napoli C, 2003, ANNU REV PHARMACOL, V43, P97, DOI 10.1146/annurev.pharmtox.43.100901.140226; Popovic DM, 2001, J AM CHEM SOC, V123, P6040, DOI 10.1021/ja003878z; Schelvis JPM, 1998, BIOCHEMISTRY-US, V37, P16289, DOI 10.1021/bi981547h; Schmidt P, 2003, PROTEIN EXPRES PURIF, V31, P42, DOI 10.1016/S1046-5928(03)00142-6; Schmidt P, 2003, EUR J PHARMACOL, V468, P167, DOI 10.1016/S0014-2999(03)01674-1; Schrammel A, 1996, MOL PHARMACOL, V50, P1; Stasch JP, 2002, BRIT J PHARMACOL, V136, P773, DOI 10.1038/sj.bjp.0704778; Stasch JP, 2001, NATURE, V410, P212, DOI 10.1038/35065611; Stasch JP, 2002, BRIT J PHARMACOL, V135, P333, DOI 10.1038/sj.bjp.0704484; Stone JR, 1996, BIOCHEMISTRY-US, V35, P3258, DOI 10.1021/bi952386+; Straub A, 2001, BIOORG MED CHEM LETT, V11, P781, DOI 10.1016/S0960-894X(01)00073-7; WEDEL B, 1994, P NATL ACAD SCI USA, V91, P2592, DOI 10.1073/pnas.91.7.2592; WU CC, 1995, BRIT J PHARMACOL, V116, P1973, DOI 10.1111/j.1476-5381.1995.tb16400.x; WUNDER F, 2003, BMC M 1 INT C CGMP S, V1, P59; Zhao Y, 1998, BIOCHEMISTRY-US, V37, P4502, DOI 10.1021/bi972686m; Zhao YD, 2000, BIOCHEMISTRY-US, V39, P10848, DOI 10.1021/bi9929296	44	136	145	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	2004	279	4					3025	3032		10.1074/jbc.M310141200	http://dx.doi.org/10.1074/jbc.M310141200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	764MU	14570894	hybrid			2022-12-27	WOS:000188211300083
J	Vincent, F; Yates, D; Garman, E; Davies, GJ; Brannigan, JA				Vincent, F; Yates, D; Garman, E; Davies, GJ; Brannigan, JA			The three-dimensional structure of the N-acetylglucosamine-6-phosphate deacetylase, NagA, from Bacillus subtilis - A member of the urease superfamily	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYLGLUCOSAMINE 6-PHOSPHATE DEACETYLASE; HUMAN GRANZYME-A; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; N-ACETYLGLUCOSAMINE; ENZYME; ESTERASE; INSIGHTS; REVEALS; AMIDOHYDROLASES	The enzyme N-acetylglucosamine-6-phosphate deacetylase, NagA, catalyzes the hydrolysis of the N-acetyl group of GlcNAc-6-P to yield glucosamine 6-phosphate and acetate, the first committed step in the biosynthetic pathway to amino-sugar-nucleotides. It is classified into carbohydrate esterase family CE-9 ( see afmb.cnrsmrs. fr/CAZY/). Here we report the cloning, expression, and three-dimensional structure ( Protein Data Bank code 1un7) determination by x-ray crystallography of the Bacillus subtilis NagA at a resolution of 2.0 Angstrom. The structure presents two domains, a (beta/alpha)(8) barrel enclosing the active center and a small beta barrel domain. The structure is dimeric, and the substrate phosphate coordination at the active center is provided by an Arg/His pair contributed from the second molecule of the dimer. Both the overall structure and the active center bear a striking similarity to the urease superfamily with two metals involved in substrate binding and catalysis. PIXE (Proton-Induced x-ray Emission) data show that iron is the predominant metal in the purified protein. We propose a catalytic mechanism involving proton donation to the leaving group by aspartate, nucleophilic attack by an Fe-bridged hydroxide, and stabilization of the carbonyl oxygen by one of the two Fe atoms of the pair. We believe that this is the first sugar deacetylase to utilize this fold and catalytic mechanism.	Univ York, Dept Chem, Struct Biol Lab, York YO10 5YW, N Yorkshire, England; Univ Oxford, Dept Biochem, Lab Mol Biophys, Oxford OX1 3QU, England	University of York - UK; University of Oxford	Davies, GJ (corresponding author), Univ York, Dept Chem, Struct Biol Lab, York YO10 5YW, N Yorkshire, England.	davies@ysbl.york.ac.uk	Davies, Gideon J/A-9042-2011; Vincent, Florence/F-7137-2016	Davies, Gideon J/0000-0002-7343-776X; vincent, Florence/0000-0002-8564-4184; Garman, Elspeth/0000-0001-8329-5665				Alice AF, 2003, MICROBIOL-SGM, V149, P1687, DOI 10.1099/mic.0.26231-0; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bell JK, 2003, NAT STRUCT BIOL, V10, P527, DOI 10.1038/nsb944; Benini S, 1999, STRUCTURE, V7, P205, DOI 10.1016/S0969-2126(99)80026-4; Benini S, 2001, J BIOL INORG CHEM, V6, P778, DOI 10.1007/s007750100254; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Burling FT, 2003, ACTA CRYSTALLOGR D, V59, P73, DOI [10.1107/S0907444902018929, 10.1107/s0907444902018929]; Coggins BE, 2003, NAT STRUCT BIOL, V10, P645, DOI 10.1038/nsb948; Cooper BF, 1997, PROTEIN SCI, V6, P1031, DOI 10.1002/pro.5560060509; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Ferreira FM, 2000, ACTA CRYSTALLOGR D, V56, P670, DOI 10.1107/S0907444900003668; Garman E, 1999, STRUCT FOLD DES, V7, pR291, DOI 10.1016/S0969-2126(00)88335-5; Ghosh D, 2001, J BIOL CHEM, V276, P11159, DOI 10.1074/jbc.M008831200; GRIME GW, 1991, NUCL INSTRUM METH B, V54, P52, DOI 10.1016/0168-583X(91)95490-5; Hink-Schauer C, 2003, NAT STRUCT BIOL, V10, P535, DOI 10.1038/nsb945; HOLM L, 1995, TRENDS BIOCHEM SCI, V20, P478, DOI 10.1016/S0968-0004(00)89105-7; Holm L, 1997, PROTEINS, V28, P72, DOI 10.1002/(SICI)1097-0134(199705)28:1<72::AID-PROT7>3.0.CO;2-L; Ireton GC, 2002, J MOL BIOL, V315, P687, DOI 10.1006/jmbi.2001.5277; Jenkins J, 2001, J MOL BIOL, V305, P951, DOI 10.1006/jmbi.2000.4324; Johansson S. A. E., 1995, PARTICLE INDUCED XRA; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Karplus PA, 1997, ACCOUNTS CHEM RES, V30, P330, DOI 10.1021/ar960022j; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Liaw SH, 2003, J BIOL CHEM, V278, P4957, DOI 10.1074/jbc.M210795200; Mao C, 1997, STRUCTURE, V5, P1373, DOI 10.1016/S0969-2126(97)00287-6; May O, 1998, BIOL CHEM, V379, P743; Molgaard A, 2000, STRUCTURE, V8, P373, DOI 10.1016/S0969-2126(00)00118-0; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Nitanai Y, 2002, J MOL BIOL, V321, P177, DOI 10.1016/S0022-2836(02)00632-0; Oldfield TJ, 2001, ACTA CRYSTALLOGR D, V57, P82, DOI 10.1107/S0907444900014098; Oliva G, 1995, STRUCTURE, V3, P1323, DOI 10.1016/S0969-2126(01)00270-2; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Park JT, 2001, J BACTERIOL, V183, P3842, DOI 10.1128/JB.183.13.3842-3847.2001; Pearson MA, 2000, BIOCHEMISTRY-US, V39, P8575, DOI 10.1021/bi000613o; Perrakis A, 2001, ACTA CRYSTALLOGR D, V57, P1445, DOI 10.1107/S0907444901014007; Prates JAM, 2001, STRUCTURE, V9, P1183, DOI 10.1016/S0969-2126(01)00684-0; RAMAKRISHNAN C, 1965, BIOPHYS J, V5, P909, DOI 10.1016/S0006-3495(65)86759-5; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Ronning DR, 2000, NAT STRUCT BIOL, V7, P141; Souza JM, 1997, ARCH BIOCHEM BIOPHYS, V340, P338, DOI 10.1006/abbi.1997.9780; Thoden JB, 2003, BIOCHEMISTRY-US, V42, P4874, DOI 10.1021/bi034233p; Vincent F, 2003, J MOL BIOL, V330, P593, DOI 10.1016/S0022-2836(03)00632-6; Wang ZM, 1998, BIOCHEMISTRY-US, V37, P8314, DOI 10.1021/bi980324o; White R J, 1975, Methods Enzymol, V41, P497; Whittington DA, 2003, P NATL ACAD SCI USA, V100, P8146, DOI 10.1073/pnas.1432990100; Yamano N, 1996, BIOSCI BIOTECH BIOCH, V60, P1320, DOI 10.1271/bbb.60.1320	50	56	59	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	2004	279	4					2809	2816		10.1074/jbc.M310165200	http://dx.doi.org/10.1074/jbc.M310165200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	764MU	14557261	Green Published, hybrid			2022-12-27	WOS:000188211300059
J	Fotiadis, D; Qian, P; Philippsen, A; Bullough, PA; Engel, A; Hunter, CN				Fotiadis, D; Qian, P; Philippsen, A; Bullough, PA; Engel, A; Hunter, CN			Structural analysis of the reaction center light-harvesting complex I photosynthetic core complex of Rhodospirillum rubrum using atomic force microscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHODOBACTER-SPHAEROIDES R-26; PUFX PROTEIN; RHODOPSEUDOMONAS-VIRIDIS; ANGSTROM RESOLUTION; TRYPTOPHAN RESIDUES; ANTENNA COMPLEX; ENERGY-TRANSFER; LH2; SUBUNITS; MEMBRANE	The bacterium Rhodospirillum rubrum contains a simple photosynthetic system, in which the reaction center ( RC) receives energy from the light-harvesting (LH1) complex. We have used high-resolution atomic force microscopy (AFM) to image two-dimensional crystals of the RC-LH1 complex of R. rubrum. The AFM topographs show that the RC-LH1 complex is similar to 94 Angstrom in height, the RC-H subunit protrudes from the cytoplasmic face of the membrane by 40 Angstrom, and it sits 21 Angstrom above the highest point of the surrounding LH1 ring. In contrast, the RC on the periplasmic side is at a lower level than LH1, which protrudes from the membrane by 12 Angstrom. The RC-LH1 complex can adopt an irregular shape in regions of uneven packing forces in the crystal; this reflects a likely flexibility in the natural membrane, which might be functionally important by allowing the export of quinol formed as a result of RC photochemistry. Nanodissection of the RC by the AFM tip removes the RC-H subunit and reveals the underlying RC-L and -M subunits. LH1 complexes completely lacking the RC were also found, providing ideal conditions for imaging both rings of LH1 polypeptides for the first time by AFM. In addition, we demonstrate the ellipticity of the LH1 ring at the cytoplasmic and periplasmic sides of the membrane, in both the presence and absence of the RC. These AFM measurements have been reconciled with previous electron microscopy and NMR data to produce a model of the RC-LH1 complex.	Univ Sheffield, Krebs Inst, Dept Mol Biol & Biotechnol, Sheffield S10 2TN, S Yorkshire, England; Univ Basel, Biozentrum, ME Muller Inst Struct Biol, CH-4056 Basel, Switzerland	University of Sheffield; University of Basel	Hunter, CN (corresponding author), Univ Sheffield, Krebs Inst, Dept Mol Biol & Biotechnol, Sheffield S10 2TN, S Yorkshire, England.	c.n.hunter@sheffield.ac.uk	Qian, Pu/GZM-2400-2022	Bullough, Per/0000-0001-8147-1127				ALLEN JP, 1987, P NATL ACAD SCI USA, V84, P6162, DOI 10.1073/pnas.84.17.6162; ARNOUX B, 1989, FEBS LETT, V258, P47, DOI 10.1016/0014-5793(89)81612-6; BARZ WP, 1995, BIOCHEMISTRY-US, V34, P15248, DOI 10.1021/bi00046a033; BARZ WP, 1995, BIOCHEMISTRY-US, V34, P15235, DOI 10.1021/bi00046a032; BEEKMAN LMP, 1994, BIOCHEMISTRY-US, V33, P3143, DOI 10.1021/bi00177a001; BINNIG G, 1986, PHYS REV LETT, V56, P930, DOI 10.1103/PhysRevLett.56.930; BRUNISHOLZ RA, 1984, H-S Z PHYSIOL CHEM, V365, P689, DOI 10.1515/bchm2.1984.365.2.689; Conroy MJ, 2000, J MOL BIOL, V298, P83, DOI 10.1006/jmbi.2000.3649; de Planque MRR, 2003, BIOCHEMISTRY-US, V42, P5341, DOI 10.1021/bi027000r; DEISENHOFER J, 1985, NATURE, V318, P618, DOI 10.1038/318618a0; Engel A, 2000, NAT STRUCT BIOL, V7, P715, DOI 10.1038/78929; Fotiadis D, 2000, J MOL BIOL, V300, P779, DOI 10.1006/jmbi.2000.3920; Fotiadis D, 1998, J MOL BIOL, V283, P83, DOI 10.1006/jmbi.1998.2097; Freer A, 1996, STRUCTURE, V4, P449, DOI 10.1016/S0969-2126(96)00050-0; Gerken U, 2003, BIOCHEMISTRY-US, V42, P10354, DOI 10.1021/bi034969m; HALL RL, 1978, PHOTOCHEM PHOTOBIOL, V28, P273, DOI 10.1111/j.1751-1097.1978.tb07708.x; HUNTER CN, 1989, TRENDS BIOCHEM SCI, V14, P72; Jamieson SJ, 2002, EMBO J, V21, P3927, DOI 10.1093/emboj/cdf410; JAP BK, 1992, ULTRAMICROSCOPY, V46, P45, DOI 10.1016/0304-3991(92)90007-7; KARRASCH S, 1995, EMBO J, V14, P631, DOI 10.1002/j.1460-2075.1995.tb07041.x; Katona G, 2003, J MOL BIOL, V331, P681, DOI 10.1016/S0022-2836(03)00751-4; LILBURN TG, 1992, BIOCHIM BIOPHYS ACTA, V1100, P160; MONSHOUWER R, 1995, CHEM PHYS LETT, V246, P341, DOI 10.1016/0009-2614(95)01104-H; OLSEN JD, 1994, P NATL ACAD SCI USA, V91, P7124, DOI 10.1073/pnas.91.15.7124; Olsen JD, 1997, BIOCHEMISTRY-US, V36, P12625, DOI 10.1021/bi9710481; Pugh RJ, 1998, BBA-BIOENERGETICS, V1366, P301, DOI 10.1016/S0005-2728(98)00131-5; Qian P, 2003, J BIOL CHEM, V278, P23678, DOI 10.1074/jbc.M302753200; SCHABERT FA, 1995, SCIENCE, V268, P92, DOI 10.1126/science.7701347; Scheuring S, 2003, P NATL ACAD SCI USA, V100, P1690, DOI 10.1073/pnas.0437992100; Scheuring S, 2003, J MOL BIOL, V325, P569, DOI 10.1016/S0022-2836(02)01241-X; Scheuring S, 2001, EMBO J, V20, P3029, DOI 10.1093/emboj/20.12.3029; SCHIFFER M, 1992, PROTEIN ENG, V5, P213, DOI 10.1093/protein/5.3.213; Sundstrom V, 1999, J PHYS CHEM B, V103, P2327, DOI 10.1021/jp983722+; T Forster, 1965, MODERN QUANTUM CHEMI, VIII, P93; VISSCHER KJ, 1989, PHOTOSYNTH RES, V22, P211, DOI 10.1007/BF00048300; YEATES TO, 1988, P NATL ACAD SCI USA, V85, P7993, DOI 10.1073/pnas.85.21.7993	36	125	135	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 16	2004	279	3					2063	2068		10.1074/jbc.M310382200	http://dx.doi.org/10.1074/jbc.M310382200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	762WT	14578348	hybrid			2022-12-27	WOS:000188005700061
J	Watanabe, H; Shimizu, T; Nishihira, J; Abe, R; Nakayama, T; Taniguchi, M; Sabe, H; Ishibashi, T; Shimizu, H				Watanabe, H; Shimizu, T; Nishihira, J; Abe, R; Nakayama, T; Taniguchi, M; Sabe, H; Ishibashi, T; Shimizu, H			Ultraviolet A-induced production of matrix metalloproteinase-1 is mediated by macrophage migration inhibitory factor (MIF) in human dermal fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; IMMUNOHISTOCHEMICAL LOCALIZATION; CELL-GROWTH; RAT-BRAIN; IN-VITRO; EXPRESSION; COLLAGENASE; CYTOKINE; SKIN; GENE	Matrix metalloproteinases ( MMPs) are thought to be responsible for dermal photoaging in human skin. In the present study, we evaluated the involvement of macrophage migration inhibitory factor (MIF) in MMP-1 expression under ultraviolet A (UVA) irradiation in cultured human dermal fibroblasts. UVA ( 20 J/cm(2)) up-regulates MIF production, and UVA-induced MMP-1 mRNA production is inhibited by an anti-MIF antibody. MIF ( 100 ng/ml) was shown to induce MMP-1 in cultured human dermal fibroblasts. We found that MIF ( 100 ng/ml) enhanced MMP-1 activity in cultured fibroblasts assessed by zymography. Moreover, we observed that fibroblasts obtained from MIF-deficient mice were much less sensitive to UVA regarding MMP-13 expression than those from wild-type BALB/c mice. Furthermore, after UVA irradiation ( 10 J/cm(2)), dermal fibroblasts of MIF-deficient mice produced significantly decreased levels of MMP-13 compared with fibroblasts of wild-type mice. Next we investigated the signal transduction pathway of MIF. The up-regulation of MMP-1 mRNA by MIF stimulation was found to be inhibited by a PKC inhibitor (GF109203X), a Src-family tyrosine kinase inhibitor ( herbimycin A), a tyrosine kinase inhibitor ( genistein), a PKA inhibitor (H89), a MEK inhibitor (PD98089), and a JNK inhibitor (SP600125). In contrast, the p38 inhibitor (SB203580) was found to have little effect on expression of MMP-1 mRNA. We found that PKC-pan, PKCalpha/betaII, PKCdelta (Thr505), PKCdelta (Ser(643)), Raf, and MAPK were phosphorylated by MIF. Moreover, we demonstrated that phosphorylation of PKCalpha/betaII and MAPK in response to MIF was suppressed by genistein, and herbimycin A as well as by transfection of the plasmid of C-terminal Src kinase. The DNA binding activity of AP-1 was significantly up-regulated 2 h after MIF stimulation. Taken together, these results suggest that MIF is involved in the up-regulation of UVA-induced MMP-1 in dermal fibroblasts through PKC-, PKA-, Src family tyrosine kinase, MAPK-,c-Jun-, and AP-1-dependent pathways.	Hokkaido Univ, Grad Sch Med, Dept Dermatol, Kita Ku, Sapporo, Hokkaido 0608638, Japan; Hokkaido Univ, Grad Sch Med, Dept Mol Biochem, Kita Ku, Sapporo, Hokkaido 0608638, Japan; Chiba Univ, Grad Sch Med, Dept Med Immunol, Chuo Ku, Chiba 2608670, Japan; Chiba Univ, Grad Sch Med, Dept Mol Immunol, Chuo Ku, Chiba 2608670, Japan; RIKEN, Res Ctr Allergy & Immunol, Lab Immune Regulat, Yokohama, Kanagawa 2300045, Japan; Osaka Biosci Inst, Dept Mol Biol, Osaka 5650874, Japan	Hokkaido University; Hokkaido University; Chiba University; Chiba University; RIKEN	Shimizu, H (corresponding author), Hokkaido Univ, Grad Sch Med, Dept Dermatol, Kita Ku, Sapporo, Hokkaido 0608638, Japan.	shimizu@med.hokudai.ac.jp	Shimizu, Hiroshi/A-5193-2012; Sabe, Hisataka/GPF-4385-2022; Abe, Riichiro/A-5450-2012; Nakayama, Toshinori/E-1067-2017; Sabe, Hisataka/A-4066-2012	Nakayama, Toshinori/0000-0002-1434-2007; Shimizu, Tadamichi/0000-0002-3231-0279				Adachi O, 1998, IMMUNITY, V9, P143, DOI 10.1016/S1074-7613(00)80596-8; Alexander JP, 2001, INVEST OPHTH VIS SCI, V42, P2831; Bacher M, 1998, MOL MED, V4, P217, DOI 10.1007/BF03401919; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; BLOOM BR, 1966, SCIENCE, V153, P80, DOI 10.1126/science.153.3731.80; Bonny C, 2001, DIABETES, V50, P77, DOI 10.2337/diabetes.50.1.77; Brauchle M, 2000, EXP CELL RES, V258, P135, DOI 10.1006/excr.2000.4913; Brenneisen P, 1996, PHOTOCHEM PHOTOBIOL, V64, P877, DOI 10.1111/j.1751-1097.1996.tb01851.x; Bucala R, 1996, FASEB J, V10, P1607, DOI 10.1096/fasebj.10.14.9002552; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; Choi SW, 1998, J DERMATOL SCI, V18, P54; CHURCHILL WH, 1975, J IMMUNOL, V115, P781; DAVID JR, 1966, P NATL ACAD SCI USA, V56, P72, DOI 10.1073/pnas.56.1.72; Fisher GJ, 1997, NEW ENGL J MED, V337, P1419, DOI 10.1056/NEJM199711133372003; Herrmann G, 1993, Exp Dermatol, V2, P92, DOI 10.1111/j.1600-0625.1993.tb00015.x; Honma N, 2000, IMMUNOLOGY, V100, P84, DOI 10.1046/j.1365-2567.2000.00011.x; Imamura K, 1996, BIOCHEM MOL BIOL INT, V40, P1233; Kawaguchi Y, 1996, ARCH DERMATOL RES, V288, P39, DOI 10.1007/BF02505041; Lan HY, 1996, AM J PATHOL, V149, P1119; Lan HY, 1998, TRANSPLANTATION, V66, P1465, DOI 10.1097/00007890-199812150-00009; NATHAN CF, 1971, J EXP MED, V133, P1356, DOI 10.1084/jem.133.6.1356; Nishibori M, 1996, NEUROSCI LETT, V213, P193; Nishihira J, 2000, J INTERF CYTOK RES, V20, P751, DOI 10.1089/10799900050151012; Nishihira J, 1998, INT J MOL MED, V2, P17; NISHIHIRA J, 1995, BBA-PROTEIN STRUCT M, V1247, P159, DOI 10.1016/0167-4838(94)00215-3; NISHINO T, 1995, MOL MED, V1, P781, DOI 10.1007/BF03401892; Ohnishi Y, 2000, ARCH DERMATOL RES, V292, P27, DOI 10.1007/PL00007457; Onodera S, 2000, J BIOL CHEM, V275, P444, DOI 10.1074/jbc.275.1.444; Rutter JL, 1997, J CELL BIOCHEM, V66, P322, DOI 10.1002/(SICI)1097-4644(19970901)66:3<322::AID-JCB5>3.3.CO;2-D; SABE H, 1994, P NATL ACAD SCI USA, V91, P3984, DOI 10.1073/pnas.91.9.3984; Shimizu T, 1997, BIOCHEM BIOPH RES CO, V240, P173, DOI 10.1006/bbrc.1997.7633; Shimizu T, 1996, FEBS LETT, V381, P199, DOI 10.1016/0014-5793(96)00120-2; Suzuki T, 1999, BRAIN RES, V816, P457, DOI 10.1016/S0006-8993(98)01179-2; Takahashi N, 1998, MOL MED, V4, P707, DOI 10.1007/BF03401765; Tesch GH, 1998, J AM SOC NEPHROL, V9, P417; WLASCHEK M, 1994, PHOTOCHEM PHOTOBIOL, V59, P550, DOI 10.1111/j.1751-1097.1994.tb02982.x; Wlaschek M, 1997, FEBS LETT, V413, P239, DOI 10.1016/S0014-5793(97)00919-8; Yu WH, 2001, ANAL BIOCHEM, V293, P38, DOI 10.1006/abio.2001.5099	38	77	77	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 16	2004	279	3					1676	1683		10.1074/jbc.M303650200	http://dx.doi.org/10.1074/jbc.M303650200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	762WT	14581488	hybrid			2022-12-27	WOS:000188005700016
J	Zhang, LB; Fogg, DK; Waisman, DM				Zhang, LB; Fogg, DK; Waisman, DM			RNA interference-mediated silencing of the S100A10 gene attenuates plasmin generation and invasiveness of Colo 222 colorectal cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANNEXIN II TETRAMER; DOUBLE-STRANDED-RNA; MESSENGER-RNA; ALPHA-ENOLASE; CYTOKERATIN 8; P11 SUBUNIT; T-PA; BINDING; UROKINASE; PROTEIN	S100A10 is a key plasminogen receptor of the extracellular cell surface that is overexpressed in many cancer cells. Typically, S100A10 is thought to be anchored to the plasma membrane via the phospholipid-binding sites of its binding partner, annexin A2. Here, using the potent and highly sequence-specific mechanism of RNA interference (RNAi), we have stably silenced the expression of the S100A10 gene in colorectal (CCL-222) cancer cells. We show that siRNA expression mediated by the pSUPER vector causes efficient, stable, and specific down-regulation of S100A10 gene expression. The siRNA-mediated down-regulation of S100A10 gene expression resulted in a major decrease in the appearance of extracellular S100A10 protein and correlated with a 45% loss of plasminogen binding, a 65% loss in cellular plasmin generation and a complete loss in plasminogen-dependent cellular invasiveness. We also observed that the CCL-222 cells do not express annexin A2 on their extracellular surface. Thus, the data show that annexin A2 is not required by S100A10 for its association with the plasma membrane, for its colocalization with uPAR, or for its binding and activation of plasminogen.	Univ Calgary, Fac Med, Dept Biochem & Mol Biol, Canc Biol Res Grp, Calgary, AB T2N 4N1, Canada; Univ Calgary, Dept Oncol, Calgary, AB T2N 4N1, Canada	University of Calgary; University of Calgary	Waisman, DM (corresponding author), Univ Calgary, Fac Med, Dept Biochem & Mol Biol, Canc Biol Res Grp, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	waisman@ucalgary.ca		Waisman, David/0000-0002-5097-9662; Zhang, Libo/0000-0001-7072-4408				Agami R, 2002, CURR OPIN CHEM BIOL, V6, P829, DOI 10.1016/S1367-5931(02)00378-2; Baglioni C, 1983, Interferon, V5, P23; Balch C, 1997, EXP CELL RES, V237, P259, DOI 10.1006/excr.1997.3817; Blasi F, 2002, NAT REV MOL CELL BIO, V3, P932, DOI 10.1038/nrm977; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Choi KS, 2003, FASEB J, V17, P235, DOI 10.1096/fj.02-0697com; Choi KS, 2003, MOL B INT U, P218; CLARKE PA, 1995, RNA, V1, P7; Cottrell TR, 2003, TRENDS MICROBIOL, V11, P37, DOI 10.1016/S0966-842X(02)00004-5; Donato R., 1999, Cell Calcium, V26, P85, DOI 10.1054/ceca.1999.0079; Donato R, 2001, INT J BIOCHEM CELL B, V33, P637, DOI 10.1016/S1357-2725(01)00046-2; Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Falcone DJ, 2001, BLOOD, V97, P777, DOI 10.1182/blood.V97.3.777; Felez J, 1998, FIBRINOLYSIS PROTEOL, V12, P183, DOI 10.1016/S0268-9499(98)80012-X; Filipenko NR, 2003, MOL B INT U, P127; Fire A, 1999, TRENDS GENET, V15, P358, DOI 10.1016/S0168-9525(99)01818-1; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Fitzpatrick SL, 2000, BIOCHEMISTRY-US, V39, P1021, DOI 10.1021/bi991411z; Fogg DK, 2002, BIOCHEMISTRY-US, V41, P4953, DOI 10.1021/bi012045y; Gerke V, 2002, PHYSIOL REV, V82, P331, DOI 10.1152/physrev.00030.2001; Gil J, 2000, APOPTOSIS, V5, P107, DOI 10.1023/A:1009664109241; Girard C, 2002, EMBO J, V21, P4439, DOI 10.1093/emboj/cdf469; Hammond SM, 2000, NATURE, V404, P293, DOI 10.1038/35005107; Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a; HARDER T, 1993, J CELL SCI, V104, P1109; Hawley SB, 2001, J BIOL CHEM, V276, P179, DOI 10.1074/jbc.M004919200; HEMBROUGH TA, 1995, J CELL SCI, V108, P1071; Hembrough TA, 1996, J BIOL CHEM, V271, P25684, DOI 10.1074/jbc.271.41.25684; Kang HM, 1997, BIOCHEMISTRY-US, V36, P2041, DOI 10.1021/bi962569b; Kang HM, 1999, TRENDS CARDIOVAS MED, V9, P92, DOI 10.1016/S1050-1738(99)00012-2; Kassam G, 1998, BIOCHEMISTRY-US, V37, P16958, DOI 10.1021/bi981713l; Kassam G, 1998, J BIOL CHEM, V273, P4790, DOI 10.1074/jbc.273.8.4790; Kennerdell JR, 2000, NAT BIOTECHNOL, V18, P896, DOI 10.1038/78531; Kim SH, 2002, AUDIOL NEURO-OTOL, V7, P348, DOI 10.1159/000066159; Kjoller L, 2002, BIOL CHEM, V383, P5, DOI 10.1515/BC.2002.002; Kralovich KR, 1998, J PROTEIN CHEM, V17, P845, DOI 10.1023/A:1020738620817; Ma JX, 2000, J BIOL CHEM, V275, P12806, DOI 10.1074/jbc.275.17.12806; MacLeod TJ, 2003, J BIOL CHEM, V278, P25577, DOI 10.1074/jbc.M301017200; MILES LA, 1991, BIOCHEMISTRY-US, V30, P1682, DOI 10.1021/bi00220a034; Mondino Anna, 1999, Thrombosis and Haemostasis, V82, P19; NAMIRANIAN S, 1995, BIOCHEM J, V309, P977, DOI 10.1042/bj3090977; Okuse K, 2002, NATURE, V417, P653, DOI 10.1038/nature00781; Pancholi V, 2001, CELL MOL LIFE SCI, V58, P902, DOI 10.1007/PL00000910; Ploug M, 2003, CURR PHARM DESIGN, V9, P1499, DOI 10.2174/1381612033454630; PLOW EF, 1986, J CELL BIOL, V103, P2411, DOI 10.1083/jcb.103.6.2411; Preissner KT, 2000, CURR OPIN CELL BIOL, V12, P621, DOI 10.1016/S0955-0674(00)00141-1; REDLITZ A, 1995, BAILLIERE CLIN HAEM, V8, P313, DOI 10.1016/S0950-3536(05)80270-7; Seaton BA, 1998, BIOMETALS, V11, P399, DOI 10.1023/A:1009205925714; Sidenius N, 2003, CANCER METAST REV, V22, P205, DOI 10.1023/A:1023099415940; Siever DA, 1997, INT J BIOCHEM CELL B, V29, P1219, DOI 10.1016/S1357-2725(97)00057-5; Sioud Mouldy, 2001, Current Molecular Medicine (Hilversum), V1, P575, DOI 10.2174/1566524013363366; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; STEPHENS RW, 1989, J CELL BIOL, V108, P1987, DOI 10.1083/jcb.108.5.1987; Timmons L, 1998, NATURE, V395, P854, DOI 10.1038/27579; TRESSLER RJ, 1993, J CELL BIOCHEM, V53, P265, DOI 10.1002/jcb.240530311; Voorhoeve PM, 2003, TRENDS BIOTECHNOL, V21, P2, DOI 10.1016/S0167-7799(02)00002-1; Wu T, 1997, J BIOL CHEM, V272, P17145, DOI 10.1074/jbc.272.27.17145; Yang D, 2000, CURR BIOL, V10, P1191, DOI 10.1016/S0960-9822(00)00732-6; YEATMAN TJ, 1993, CLIN EXP METASTAS, V11, P37, DOI 10.1007/BF00880064; Zamore PD, 2000, CELL, V101, P25, DOI 10.1016/S0092-8674(00)80620-0; Zobiack N, 2001, FEBS LETT, V500, P137, DOI 10.1016/S0014-5793(01)02604-7	63	87	96	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 16	2004	279	3					2053	2062		10.1074/jbc.M310357200	http://dx.doi.org/10.1074/jbc.M310357200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	762WT	14570893	hybrid			2022-12-27	WOS:000188005700060
J	Lee, KW; Liu, BR; Ma, LQ; Li, HJ; Bang, P; Koeffler, HP; Cohen, P				Lee, KW; Liu, BR; Ma, LQ; Li, HJ; Bang, P; Koeffler, HP; Cohen, P			Cellular internalization of insulin-like growth factor binding protein-3 - Distinct endocytic pathways facilitate re-uptake and nuclear localization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED APOPTOSIS; LIPID RAFTS; FACTOR-I; CAVEOLAE; RECEPTOR; CELLS; TRANSFERRIN; CANCER; FIBROBLASTS; SURVIVAL	Insulin-like growth factor binding protein-3 (IGFBP-3) is well established as a growth-inhibitory, apoptosis-inducing secreted molecule that acts via insulin-like growth factor (IGF)-independent as well as IGF-dependent pathways. Nuclear localization of IGFBP-3 has been observed and nuclear binding partners for IGFBP-3 demonstrated. However, little is known about the mechanism of IGFBP-3 internalization. We hypothesized that IGFBP-3 is first secreted then taken up again into cells and that its internalization could occur via binding to transferrin or caveolin. Incubation of cells with an IGFBP-3-neutralizing antibody demonstrated that nuclear translocation of endogenous IGFBP-3 requires IGFBP-3 secretion and re-uptake. Nuclear localization of exogenously added IGFBP-3 was rapid, occurring within 15 min, inhibited by co-incubation and extracellular sequestration with IGF-I, and dependent on the transferrin-binding C-terminal peptide region of IGFBP-3. Co-immunoprecipitation assays confirmed that IGFBP-3 binds transferrin but not directly to the transferrin receptor (TfR1); however, transferrin binds TfR1 and a ternary complex is formed. Specific binding to caveolin scaffolding docking sequence was confirmed utilizing radiolabeled IGFBP-3. Blocking TfR1-mediated endocytosis prevents both endogenous and exogenous IGFBP-3 re-uptake and inhibitors of caveolae formation also retard IGFBP-3 nuclear entry. Co-treatment with anti-transferrin receptor antibody and cholesterol depletion agents completely abolished endogenous and exogenous IGFBP-3 uptake. Suppression of IGFBP-3 internalization by TfR1 blockade inhibited IGFBP-3-induced apoptosis. Together, these data indicate that the actions of IGFBP-3 are mediated by internalization via distinct endocytic pathways.	Univ Calif Los Angeles, Mattel Childrens Hosp, David Geffen Sch Med, Div Pediat Endocrinol, Los Angeles, CA 90095 USA; Karolinska Inst, Astrid Lindgren Childrens Hosp, Dept Woman & Child Hlth, Pediat Endocrinol Unit, S-17177 Stockholm, Sweden; Univ Calif Los Angeles, Cedars Sinai Med Ctr, Sch Med, Dept Med, Los Angeles, CA 90048 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Karolinska Institutet; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Cohen, P (corresponding author), Univ Calif Los Angeles, Mattel Childrens Hosp, David Geffen Sch Med, Div Pediat Endocrinol, 10833 Le Conte Ave,MDCC 22-315, Los Angeles, CA 90095 USA.				NATIONAL CANCER INSTITUTE [U01CA084128, R01CA100938] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040203] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG020954] Funding Source: NIH RePORTER; NCI NIH HHS [CA 84128, CA100938] Funding Source: Medline; NIAID NIH HHS [AI40203] Funding Source: Medline; NIA NIH HHS [AG20954] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Baxter Robert C., 1995, Progress in Growth Factor Research, V6, P215, DOI 10.1016/0955-2235(95)00004-6; BOOTH BA, 1995, GROWTH REGULAT, V5, P1; Brodsky FM, 2001, ANNU REV CELL DEV BI, V17, P517, DOI 10.1146/annurev.cellbio.17.1.517; Butt AJ, 2000, J BIOL CHEM, V275, P39174, DOI 10.1074/jbc.M908888199; COHEN P, 1993, MOL ENDOCRINOL, V7, P380, DOI 10.1210/me.7.3.380; Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451; Couet J, 1997, J BIOL CHEM, V272, P6525, DOI 10.1074/jbc.272.10.6525; Craft N, 1999, NAT MED, V5, P280, DOI 10.1038/6495; DEJONG G, 1990, CLIN CHIM ACTA, V190, P1, DOI 10.1016/0009-8981(90)90278-Z; Di Guglielmo GM, 2003, NAT CELL BIOL, V5, P410, DOI 10.1038/ncb975; DIGUGLIELMO GM, 1994, EMBO J, V13, P4269, DOI 10.1002/j.1460-2075.1994.tb06747.x; Firth SM, 2002, ENDOCR REV, V23, P824, DOI 10.1210/er.2001-0033; Firth SM, 1998, J BIOL CHEM, V273, P2631, DOI 10.1074/jbc.273.5.2631; Franklin SL, 2003, J CLIN ENDOCR METAB, V88, P900, DOI 10.1210/jc.2002-020472; Galbiati F, 2001, CELL, V106, P403, DOI 10.1016/S0092-8674(01)00472-X; GRUENBERG J, 1995, CURR OPIN CELL BIOL, V7, P552, DOI 10.1016/0955-0674(95)80013-1; Haugh JM, 1999, J BIOL CHEM, V274, P34350, DOI 10.1074/jbc.274.48.34350; Incardona JP, 2002, CURR BIOL, V12, P983, DOI 10.1016/S0960-9822(02)00895-3; INGERMANN AR, 2000, GROWTH HORM IGF RES, V10, P27; Jaques G, 1997, ENDOCRINOLOGY, V138, P1767, DOI 10.1210/en.138.4.1767; Joshee N, 2002, HUM GENE THER, V13, P1991, DOI 10.1089/10430340260355392; Kawabata H, 2000, J BIOL CHEM, V275, P16618, DOI 10.1074/jbc.M908846199; Lamaze C, 2001, MOL CELL, V7, P661, DOI 10.1016/S1097-2765(01)00212-X; Lee KW, 2002, J ENDOCRINOL, V175, P33, DOI 10.1677/joe.0.1750033; Lesnikov V, 2001, EXP HEMATOL, V29, P477, DOI 10.1016/S0301-472X(00)00687-1; Li WL, 1997, ENDOCRINOLOGY, V138, P1763, DOI 10.1210/en.138.4.1763; Liu BR, 2000, J BIOL CHEM, V275, P33607, DOI 10.1074/jbc.M002547200; MARTIN JL, 1992, ENDOCRINOLOGY, V131, P1703, DOI 10.1210/en.131.4.1703; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; Mineo C, 1999, J BIOL CHEM, V274, P30636, DOI 10.1074/jbc.274.43.30636; Mukherjee S, 1997, PHYSIOL REV, V77, P759, DOI 10.1152/physrev.1997.77.3.759; Neufeld EB, 1996, J BIOL CHEM, V271, P21604, DOI 10.1074/jbc.271.35.21604; PALADE GE, 1953, J APPL PHYS, V24, P1424; RADULESCU RT, 1994, TRENDS BIOCHEM SCI, V19, P278, DOI 10.1016/0968-0004(94)90004-3; Rajah R, 1997, J BIOL CHEM, V272, P12181, DOI 10.1074/jbc.272.18.12181; Rajah R, 2002, CELL GROWTH DIFFER, V13, P163; Rastellini C, 2001, TRANSPLANT P, V33, P518, DOI 10.1016/S0041-1345(00)02118-7; Razani B, 2002, PHARMACOL REV, V54, P431, DOI 10.1124/pr.54.3.431; Ricort JM, 2002, J BIOL CHEM, V277, P19448, DOI 10.1074/jbc.M200439200; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; SANDVIG K, 1989, J CELL BIOL, V108, P1331, DOI 10.1083/jcb.108.4.1331; Schedlich LJ, 2002, MICROSC RES TECHNIQ, V59, P12, DOI 10.1002/jemt.10173; Schedlich LJ, 2000, J BIOL CHEM, V275, P23462, DOI 10.1074/jbc.M002208200; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; Shigematsu S, 2003, J BIOL CHEM, V278, P10683, DOI 10.1074/jbc.M208563200; Shin JS, 2001, MICROBES INFECT, V3, P755, DOI 10.1016/S1286-4579(01)01423-X; Sieczkarski SB, 2002, J VIROL, V76, P10455, DOI 10.1128/JVI.76.20.10455-10464.2002; Storch S, 2001, FEBS LETT, V509, P395, DOI 10.1016/S0014-5793(01)03204-5; Torgersen ML, 2001, J CELL SCI, V114, P3737; Vainio S, 2002, EMBO REP, V3, P95, DOI 10.1093/embo-reports/kvf010; Weinzimer SA, 2001, J CLIN ENDOCR METAB, V86, P1806, DOI 10.1210/jc.86.4.1806; Wraight CJ, 1998, J INVEST DERMATOL, V111, P239, DOI 10.1046/j.1523-1747.1998.00258.x; YAMADA E, 1955, J BIOPHYS BIOCHEM CY, V1, P445, DOI 10.1083/jcb.1.5.445; Zhang YZ, 2000, J NEUROSCI, V20, P5671, DOI 10.1523/JNEUROSCI.20-15-05671.2000	55	118	119	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	2004	279	1					469	476		10.1074/jbc.M307316200	http://dx.doi.org/10.1074/jbc.M307316200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	757GU	14576164	hybrid			2022-12-27	WOS:000187555300057
J	Shearer, AG; Hampton, RY				Shearer, AG; Hampton, RY			Structural control of endoplasmic reticulum-associated degradation - Effect of chemical chaperones on 3-hydroxy-3-methylglutaryl-CoA reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HMG-COA REDUCTASE; UBIQUITIN LIGASE; REGULATED DEGRADATION; MEMBRANE-PROTEIN; QUALITY-CONTROL; ER DEGRADATION; IN-VIVO; PROTEOLYSIS; PHENOTYPE; REQUIRES	The endoplasmic reticulum (ER) quality control pathway destroys misfolded and unassembled proteins in the ER. Most substrates of this ER-associated degradation (ERAD) pathway are constitutively targeted for destruction through recognition of poorly understood structural hallmarks of misfolding. However, the normal yeast ER membrane protein 3-hydroxy-3-methylglutaryl-CoA reductase (Hmg2p) undergoes ERAD that is physiologically regulated by sterol pathway signals. We have proposed that Hmg2p ERAD occurs by a regulated transition to an ERAD quality control substrate. Consistent with this, we had previously shown that Hmg2p is strongly stabilized by chemical chaperones such as glycerol, which stabilize misfolded proteins. To understand the features of Hmg2p that permit regulated ERAD, we have thoroughly characterized the effects of chemical chaperones on Hmg2p. These agents caused a reversible, immediate, direct change in Hmg2p degradation consistent with an effect on Hmg2p structure. We devised an in vitro limited proteolysis assay of Hmg2p in its native membranes. In vitro, chemical chaperones caused a dramatic, rapid change in Hmg2p structure to a less accessible form. As in the living cell, the in vitro action of chemical chaperones was highly specific for Hmg2p and completely reversible. To evaluate the physiological relevance of this model behavior, we used the limited proteolysis assay to examine the effects of changing in vivo degradation signals on Hmg2p structure. We found that changes similar to those observed with chemical chaperones were brought about by alteration of natural degradation signal. Thus, Hmg2p can undergo significant, reversible structural changes that are relevant to the physiological control of Hmg2p ERAD. These findings support the idea that Hmg2p regulation is brought about by regulated alteration of folding state. Considering the ubiquitous nature of quality control pathways in biology, it may be that this strategy of regulation is widespread.	Univ Calif San Diego, Div Biol Sci, Sect Cell & Mol Biol, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Hampton, RY (corresponding author), Univ Calif San Diego, Div Biol Sci, Sect Cell & Mol Biol, La Jolla, CA 92093 USA.	rhampton@ucsd.edu			NIGMS NIH HHS [3 T32 GM07240-25S1, GM51996-06] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM051996] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bays NW, 2001, NAT CELL BIOL, V3, P24, DOI 10.1038/35050524; Bordallo J, 1998, MOL BIOL CELL, V9, P209, DOI 10.1091/mbc.9.1.209; Braun S, 2002, EMBO J, V21, P615, DOI 10.1093/emboj/21.4.615; Brown CR, 1996, CELL STRESS CHAPERON, V1, P117, DOI 10.1379/1466-1268(1996)001<0117:CCCTMP>2.3.CO;2; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; Courtenay ES, 2000, BIOCHEMISTRY-US, V39, P4455, DOI 10.1021/bi992887l; Cronin SR, 2000, J CELL BIOL, V148, P915, DOI 10.1083/jcb.148.5.915; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; DESHAIES RJ, 1995, EMBO J, V14, P303, DOI 10.1002/j.1460-2075.1995.tb07004.x; FELDHEIM D, 1992, MOL CELL BIOL, V12, P3288, DOI 10.1128/MCB.12.7.3288; Friedlander R, 2000, NAT CELL BIOL, V2, P379, DOI 10.1038/35017001; Gardner R, 1998, MOL BIOL CELL, V9, P2611, DOI 10.1091/mbc.9.9.2611; Gardner RG, 2001, MOL CELL BIOL, V21, P4276, DOI 10.1128/MCB.21.13.4276-4291.2001; Gardner RG, 2000, J CELL BIOL, V151, P69, DOI 10.1083/jcb.151.1.69; Gardner RG, 1999, EMBO J, V18, P5994, DOI 10.1093/emboj/18.21.5994; Gardner RG, 1999, J BIOL CHEM, V274, P31671, DOI 10.1074/jbc.274.44.31671; GERHART JC, 1968, BIOCHEMISTRY-US, V7, P538, DOI 10.1021/bi00842a600; GOEBL MG, 1988, SCIENCE, V241, P1331, DOI 10.1126/science.2842867; Hampton RY, 2002, ANNU REV CELL DEV BI, V18, P345, DOI 10.1146/annurev.cellbio.18.032002.131219; Hampton RY, 1997, P NATL ACAD SCI USA, V94, P12944, DOI 10.1073/pnas.94.24.12944; Hampton RY, 2002, CURR OPIN CELL BIOL, V14, P476, DOI 10.1016/S0955-0674(02)00358-7; HAMPTON RY, 1994, J CELL BIOL, V125, P299, DOI 10.1083/jcb.125.2.299; Hiller MM, 1996, SCIENCE, V273, P1725, DOI 10.1126/science.273.5282.1725; Niwa J, 2002, J BIOL CHEM, V277, P36793, DOI 10.1074/jbc.M206559200; Pickart CM, 2001, MOL CELL, V8, P499, DOI 10.1016/S1097-2765(01)00347-1; Qu BH, 1996, J BIOL CHEM, V271, P7261, DOI 10.1074/jbc.271.13.7261; Sakamoto KM, 2002, MOL GENET METAB, V77, P44, DOI 10.1016/S1096-7192(02)00146-4; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Sato S, 1996, J BIOL CHEM, V271, P635, DOI 10.1074/jbc.271.2.635; Swanson R, 2001, GENE DEV, V15, P2660, DOI 10.1101/gad.933301; Welch WJ, 1996, CELL STRESS CHAPERON, V1, P109, DOI 10.1379/1466-1268(1996)001<0109:IOMACC>2.3.CO;2; Wilhovsky S, 2000, MOL BIOL CELL, V11, P1697, DOI 10.1091/mbc.11.5.1697; Zhang F, 1998, NAT STRUCT BIOL, V5, P180, DOI 10.1038/nsb0398-180; Zhou ZF, 1999, J BIOL CHEM, V274, P31123, DOI 10.1074/jbc.274.44.31123	35	44	46	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 2	2004	279	1					188	196		10.1074/jbc.M307734200	http://dx.doi.org/10.1074/jbc.M307734200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	757GU	14570925	hybrid, Green Submitted			2022-12-27	WOS:000187555300023
J	Uyemura, SA; Luo, SH; Vieira, M; Moreno, SNJ; Docampo, R				Uyemura, SA; Luo, SH; Vieira, M; Moreno, SNJ; Docampo, R			Oxidative phosphorylation and rotenone-insensitive malate- and NADH-quinone oxidoreductases in Plasmodium yoelii yoelii mitochondria in situ	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; CITRIC-ACID CYCLE; SACCHAROMYCES-CEREVISIAE; UNCOUPLING PROTEIN; MALARIAL PARASITE; ESCHERICHIA-COLI; GENOME SEQUENCE; CA2+ TRANSPORT; DEHYDROGENASE; FALCIPARUM	Respiration, membrane potential, and oxidative phosphorylation of mitochondria of Plasmodium yoelii yoelii trophozoites were assayed in situ after permeabilization with digitonin. ADP induced an oligomycin-sensitive transition from resting to phosphorylating respiration in the presence of oxidizable substrates. A functional respiratory chain was demonstrated. In addition, the ability of the parasite to oxidize exogenous NADH, as well as the insensitivity of respiration to rotenone and its sensitivity to flavone, suggested the presence of an alternative NADH-quinone (NADH-Q) oxidoreductase. Rotenone-insensitive respiration and membrane potential generation in the presence of malate suggested the presence of a malate-quinone oxidoreductase. These results are in agreement with the presence of genes in P. yoelii encoding for proteins with homology to NADH-Q oxidoreductases of bacteria, plant, fungi, and protozoa and malate-quinone oxidoreductases of bacteria. The complete inhibition of respiration by antimycin A and cyanide excluded the presence of an alternative oxidase as described in other parasites. An uncoupling effect of fatty acids was partly reversed by bovine serum albumin and GTP but was unaffected by carboxyatractyloside. These results provide the first biochemical evidence of the presence of an alternative NADH-Q oxidoreductase and a malate-quinone oxidoreductase and confirm the operation of oxidative phosphorylation in malaria parasites.	Univ Illinois, Coll Vet Med, Dept Pathobiol, Mol Parasitol Lab, Urbana, IL 61802 USA; Univ Illinois, Ctr Zoonoses Res, Urbana, IL 61802 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Docampo, R (corresponding author), Univ Illinois, Coll Vet Med, Dept Pathobiol, Mol Parasitol Lab, 2001 S Lincoln Ave, Urbana, IL 61802 USA.	rodoc@uiuc.edu	Uyemura, Sergio/B-4656-2011	Uyemura, Sergio/0000-0001-5505-9817				AKERMAN KEO, 1976, FEBS LETT, V68, P191, DOI 10.1016/0014-5793(76)80434-6; BEACH DH, 1977, J PARASITOL, V63, P62, DOI 10.2307/3280105; BEAVIS AD, 1992, J BIOL CHEM, V267, P3079; Carlton JM, 2002, NATURE, V419, P512, DOI 10.1038/nature01099; COHN DV, 1958, J BIOL CHEM, V233, P299; DEVRIES S, 1988, EUR J BIOCHEM, V176, P377; DIVO AA, 1985, J PROTOZOOL, V32, P442, DOI 10.1111/j.1550-7408.1985.tb04041.x; DLUZEWSKI AR, 1984, T ROY SOC TROP MED H, V78, P622, DOI 10.1016/0035-9203(84)90221-9; Felsenstein J., 2005, PHYLIP PHYLOGENY INF, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; FRY M, 1992, BIOCHEM PHARMACOL, V43, P1545, DOI 10.1016/0006-2952(92)90213-3; Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097; HOLZ GG, 1977, B WORLD HEALTH ORGAN, V55, P237; HOLZ GG, 1977, J PROTOZOOL, V24, P566, DOI 10.1111/j.1550-7408.1977.tb01017.x; HOMEWOOD CA, 1976, ANN TROP MED PARASIT, V70, P249, DOI 10.1080/00034983.1976.11687119; Jarmuszkiewicz W, 2002, FEBS LETT, V532, P459, DOI 10.1016/S0014-5793(02)03734-1; Jarmuszkiewicz W, 1999, J BIOL CHEM, V274, P23198, DOI 10.1074/jbc.274.33.23198; Jezek P, 1998, BBA-BIOENERGETICS, V1365, P319, DOI 10.1016/S0005-2728(98)00084-X; Kather B, 2000, J BACTERIOL, V182, P3204, DOI 10.1128/JB.182.11.3204-3209.2000; Kerscher SJ, 2000, BBA-BIOENERGETICS, V1459, P274, DOI 10.1016/S0005-2728(00)00162-6; Kitajima-Ihara T, 1998, FEBS LETT, V421, P37, DOI 10.1016/S0014-5793(97)01533-0; Kretzschmar U, 2002, MICROBIOL-SGM, V148, P3839, DOI 10.1099/00221287-148-12-3839; LENAZ G, 1995, FEBS LETT, V366, P119, DOI 10.1016/0014-5793(95)00508-7; Molenaar D, 1998, EUR J BIOCHEM, V254, P395, DOI 10.1046/j.1432-1327.1998.2540395.x; MONS B, 1990, BLOOD CELLS, V16, P299; Pich MM, 1996, FEBS LETT, V380, P176, DOI 10.1016/0014-5793(96)00037-3; RAVANEL P, 1990, PHYTOCHEMISTRY, V29, P441, DOI 10.1016/0031-9422(90)85093-U; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Sensi SL, 2003, P NATL ACAD SCI USA, V100, P6157, DOI 10.1073/pnas.1031598100; Skulachev VP, 1998, BBA-BIOENERGETICS, V1363, P100, DOI 10.1016/S0005-2728(97)00091-1; Smith IF, 2003, J NEUROCHEM, V85, P1109, DOI 10.1046/j.1471-4159.2003.01785.x; Srivastava IK, 1999, ANTIMICROB AGENTS CH, V43, P1334, DOI 10.1128/AAC.43.6.1334; Srivastava IK, 1997, J BIOL CHEM, V272, P3961, DOI 10.1074/jbc.272.7.3961; TETTER ME, 1969, BIOCHIM BIOPHYS ACTA, V172, P331, DOI 10.1016/0005-2728(69)90076-0; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Uyemura SA, 2000, J BIOL CHEM, V275, P9709, DOI 10.1074/jbc.275.13.9709; Vaidya Akhil B., 1998, P355; van der Rest ME, 2000, J BACTERIOL, V182, P6892, DOI 10.1128/JB.182.24.6892-6899.2000; VERCESI AE, 1991, J BIOL CHEM, V266, P14431; VERCESI AE, 1993, J BIOL CHEM, V268, P8564; Vercesi AE, 1998, J BIOL CHEM, V273, P31040, DOI 10.1074/jbc.273.47.31040; VERCESI AE, 1992, MOL BIOCHEM PARASIT, V56, P251, DOI 10.1016/0166-6851(92)90174-I; VERCESI AE, 1992, BIOCHEM J, V284, P463, DOI 10.1042/bj2840463; VIENS P, 1971, CAN J MICROBIOL, V17, P257, DOI 10.1139/m71-043; WALLACE WR, 1966, AM J TROP MED HYG, V15, P811, DOI 10.4269/ajtmh.1966.15.811; Yagi T, 1998, BBA-BIOENERGETICS, V1364, P125, DOI 10.1016/S0005-2728(98)00023-1	46	75	78	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 2	2004	279	1					385	393		10.1074/jbc.M307264200	http://dx.doi.org/10.1074/jbc.M307264200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	757GU	14561763	hybrid			2022-12-27	WOS:000187555300046
J	Yamamoto, K; Sonoda, M; Inokuchi, J; Shirasawa, S; Sasazuki, T				Yamamoto, K; Sonoda, M; Inokuchi, J; Shirasawa, S; Sasazuki, T			Polycomb group suppressor of zeste 12 links heterochromatin protein 1 alpha and enhancer of zeste 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSITION-EFFECT VARIEGATION; HISTONE METHYLTRANSFERASE ACTIVITY; HP1 PROTEINS; DROSOPHILA-MELANOGASTER; GROUP GENE; LYSINE 9; CHROMATIN; H3; METHYLATION; DOMAIN	Drosophila suppressor of zeste 12 (Su(z)12) is a Polycomb group (PcG) transcriptional repressor and is present in E(z)-ESC, a multiprotein complex with methylation activity specific for lysine 9 and 27 of histone H3. Although PcG- and heterochromatin-mediated gene silencing have been considered distinct, mutant flies of Su( z) 12 showed not only homeotic transformation but also position effect variegation. We now report that the mammalian SU(Z)12 directly interacts with heterochromatin protein 1alpha (HP1alpha) and PcG enhancer of zeste 2 (EZH2), the mammalian counterpart of E( z), in vitro and in vivo. Two distinct domains in SU( Z) 12 are involved in these interactions, the region between the zinc finger motif and the VEFS ((V) under bar RN2-(E) under bar MF2-(F) under bar IS2-(S) under baru(z)12) box for HP1alpha (amino acid residues 479-536) and the VEFS box for EZH2 (amino acid residues 600-639), which are not mutually exclusive. Interestingly this region of the VEFS box has been shown to be critical for the phenotype of the Su(z) 12 mutant fly. In addition SU(Z) 12 represses transcription activity in the presence of HP1alpha in a reporter assay. These results provide a molecular explanation for the functional link of these epigenetic silencing processes mediated by Su(z)12.	Kyushu Univ, Dept Mol Genet, Med Inst Bioregulat, Div Mol Populat Genet,Higashi Ku, Fukuoka 8128582, Japan; Kyushu Univ, Ctr Excellence Program Lifestyle Related Dis, Higashi Ku, Fukuoka 8128582, Japan; Int Med Ctr Japan, Dept Pathol, Shinjuku Ku, Tokyo 1628655, Japan; Int Med Ctr Japan, Res Inst, Shinjuku Ku, Tokyo 1628655, Japan	Kyushu University; Kyushu University; National Center for Global Health & Medicine - Japan; National Center for Global Health & Medicine - Japan	Yamamoto, K (corresponding author), Kyushu Univ, Dept Mol Genet, Med Inst Bioregulat, Div Mol Populat Genet,Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.		Inokuchi, Jin-ichi/AAW-9964-2020; Inokuchi, Junichi/AAO-3297-2020	Inokuchi, Jin-ichi/0000-0002-0703-5746; Inokuchi, Junichi/0000-0002-6791-905X				Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Birve A, 2001, DEVELOPMENT, V128, P3371; Brasher SV, 2000, EMBO J, V19, P1587, DOI 10.1093/emboj/19.7.1587; Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997; Czermin B, 2002, CELL, V111, P185, DOI 10.1016/S0092-8674(02)00975-3; Delattre M, 2000, J CELL SCI, V113, P4253; Eissenberg JC, 2000, CURR OPIN GENET DEV, V10, P204, DOI 10.1016/S0959-437X(00)00058-7; Elgin SCR, 1996, CURR OPIN GENET DEV, V6, P193, DOI 10.1016/S0959-437X(96)80050-5; Francis NJ, 2001, NAT REV MOL CELL BIO, V2, P409, DOI 10.1038/35073039; Henikoff S., 2000, BIOCHIM BIOPHYS ACTA, V1470, P01; Hwang KK, 2001, P NATL ACAD SCI USA, V98, P11423, DOI 10.1073/pnas.211303598; Kuzmichev A, 2002, GENE DEV, V16, P2893, DOI 10.1101/gad.1035902; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Laible G, 1997, EMBO J, V16, P3219, DOI 10.1093/emboj/16.11.3219; LeDouarin B, 1996, EMBO J, V15, P6701, DOI 10.1002/j.1460-2075.1996.tb01060.x; Muller J, 2002, CELL, V111, P197, DOI 10.1016/S0092-8674(02)00976-5; Murzina N, 1999, MOL CELL, V4, P529, DOI 10.1016/S1097-2765(00)80204-X; Nielsen AL, 1999, EMBO J, V18, P6385, DOI 10.1093/emboj/18.22.6385; Nielsen AL, 2001, MOL CELL, V7, P729, DOI 10.1016/S1097-2765(01)00218-0; Nielsen AL, 2002, EMBO J, V21, P5797, DOI 10.1093/emboj/cdf560; Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620; O'Carroll D, 2001, MOL CELL BIOL, V21, P4330, DOI 10.1128/MCB.21.13.4330-4336.2001; Peters AHFM, 2001, CELL, V107, P323, DOI 10.1016/S0092-8674(01)00542-6; Raaphorst FM, 2001, J IMMUNOL, V166, P5925, DOI 10.4049/jimmunol.166.10.5925; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Remboutsika E, 1999, J CELL SCI, V112, P1671; REUTER G, 1981, MOL GEN GENET, V182, P516, DOI 10.1007/BF00293947; Richards EJ, 2002, CELL, V108, P489, DOI 10.1016/S0092-8674(02)00644-X; Seeler JS, 1998, P NATL ACAD SCI USA, V95, P7316, DOI 10.1073/pnas.95.13.7316; Sewalt RGAB, 2002, MOL CELL BIOL, V22, P5539, DOI 10.1128/MCB.22.15.5539-5553.2002; Simon JA, 2002, CURR OPIN GENET DEV, V12, P210, DOI 10.1016/S0959-437X(02)00288-5; SINCLAIR DAR, 1989, MOL GEN GENET, V216, P328, DOI 10.1007/BF00334372; Smothers JF, 2000, CURR BIOL, V10, P27, DOI 10.1016/S0960-9822(99)00260-2; Tie F, 2003, MOL CELL BIOL, V23, P3352, DOI 10.1128/MCB.23.9.3352-3362.2003; TORA L, 1989, CELL, V59, P447; Vassallo MF, 2002, P NATL ACAD SCI USA, V99, P5919, DOI 10.1073/pnas.092025499; Yamamoto K, 2003, BIOCHEM BIOPH RES CO, V301, P287, DOI 10.1016/S0006-291X(02)03021-8; Ye QA, 1997, J BIOL CHEM, V272, P14983, DOI 10.1074/jbc.272.23.14983	38	58	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	2004	279	1					401	406		10.1074/jbc.M307344200	http://dx.doi.org/10.1074/jbc.M307344200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	757GU	14570930	hybrid			2022-12-27	WOS:000187555300048
J	Fedor-Chaiken, M; Meigs, TE; Kaplan, DD; Brackenbury, R				Fedor-Chaiken, M; Meigs, TE; Kaplan, DD; Brackenbury, R			Two regions of cadherin cytoplasmic domains are involved in suppressing motility of a mammary carcinoma cell line	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER CELLS; RHO-FAMILY GTPASES; BETA-CATENIN; N-CADHERIN; P120 CATENIN; ADHESION COMPLEX; IN-VIVO; EXPRESSION; METASTASIS; MIGRATION	E-cadherin has been termed an "invasion suppressor," yet the mechanism of this suppression is not known. In contrast, several reports indicate N-cadherin does not suppress but, rather, promotes cell motility and invasion. Here, by characterizing a series of chimeric cadherins we defined a previously uncharacterized region consisting of the transmembrane domain and an adjacent portion of the cytoplasmic segment that is responsible for the difference in ability of E- and N-cadherin to suppress movement of mammary carcinoma cells, as quantified from time-lapse video recordings. A mutation in this region enabled N-cadherin to suppress motility, indicating that both E- and N-cadherin can suppress, but the activity of N-cadherin is latent, presumably repressed by binding of a specific inhibitor. To define regions common to E- and N-cadherin that are required for suppression, we analyzed a series of deletion mutants. We found that suppression of movement requires E-cadherin amino acids 699-710. Strikingly, beta-catenin binding is not sufficient for and p120ctn is not involved in suppression of these mammary carcinoma cells. Furthermore, the comparable region of N-cadherin can substitute for this required region in E-cadherin and is required for suppression by the mutant form of N-cadherin that is capable of suppressing. Variations in expression of factors that bind to the two regions we have identified may explain previously observed differences in response of tumor cells to cadherins.	Univ Cincinnati, Coll Med, Dept Cell Biol Neurobiol & Anat, Vontz Ctr Mol Studies, Cincinnati, OH 45267 USA; Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA	University System of Ohio; University of Cincinnati; Duke University	Fedor-Chaiken, M (corresponding author), Univ Cincinnati, Coll Med, Dept Cell Biol Neurobiol & Anat, Vontz Ctr Mol Studies, 3125 Eden Ave, Cincinnati, OH 45267 USA.			Brackenbury, Robert/0000-0002-1332-4018; Kaplan, Daniel/0000-0001-8297-560X	NATIONAL CANCER INSTITUTE [R21CA091159] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R55AR044713, R01AR044713] Funding Source: NIH RePORTER; NCI NIH HHS [CA91159] Funding Source: Medline; NIAMS NIH HHS [AR44713] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Anastasiadis PZ, 2000, NAT CELL BIOL, V2, P637, DOI 10.1038/35023588; BRACKENBURY R, 1977, J BIOL CHEM, V252, P6835; BRACKENBURY R, 1981, P NATL ACAD SCI-BIOL, V78, P387, DOI 10.1073/pnas.78.1.387; Brady-Kalnay SM, 1998, J CELL BIOL, V141, P287, DOI 10.1083/jcb.141.1.287; Chen HY, 1997, J CELL SCI, V110, P345; CHEN WC, 1991, J CELL BIOL, V114, P319, DOI 10.1083/jcb.114.2.319; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; Grosheva I, 2001, J CELL SCI, V114, P695; Gumbiner BM, 2000, J CELL BIOL, V148, P399, DOI 10.1083/jcb.148.3.399; Hazan RB, 2000, J CELL BIOL, V148, P779, DOI 10.1083/jcb.148.4.779; Horikawa K, 2001, J CELL BIOL, V155, P1297, DOI 10.1083/jcb.200108156; Iijima M, 2002, CELL, V109, P599, DOI 10.1016/S0092-8674(02)00745-6; Kaplan DD, 2001, J BIOL CHEM, V276, P44037, DOI 10.1074/jbc.M106121200; Kashima T, 2003, INT J CANCER, V104, P147, DOI 10.1002/ijc.10931; Kinch M S, 1997, Cell Adhes Commun, V4, P425, DOI 10.3109/15419069709004459; KINCH MS, 1995, BIOCHEM SOC T, V23, P446, DOI 10.1042/bst0230446; KNUDSEN KA, 1995, J CELL BIOL, V130, P67, DOI 10.1083/jcb.130.1.67; Li Z, 2003, CELL, V114, P215, DOI 10.1016/S0092-8674(03)00559-2; Lilien J, 2002, DEV DYNAM, V224, P18, DOI 10.1002/dvdy.10087; Meigs TE, 2002, J BIOL CHEM, V277, P24594, DOI 10.1074/jbc.M201984200; MIYATANI S, 1989, SCIENCE, V245, P631, DOI 10.1126/science.2762814; Muller T, 1999, J BIOL CHEM, V274, P10173, DOI 10.1074/jbc.274.15.10173; Muller T, 2002, EXP CELL RES, V280, P119, DOI 10.1006/excr.2002.5630; NAGAFUCHI A, 1988, EMBO J, V7, P3679, DOI 10.1002/j.1460-2075.1988.tb03249.x; NAGAFUCHI A, 1989, CELL REGUL, V1, P37, DOI 10.1091/mbc.1.1.37; Nieman MT, 1999, J CELL BIOL, V147, P631, DOI 10.1083/jcb.147.3.631; Nollet F, 1999, Mol Cell Biol Res Commun, V2, P77, DOI 10.1006/mcbr.1999.0155; Noren NK, 2000, J CELL BIOL, V150, P567, DOI 10.1083/jcb.150.3.567; NOSE A, 1988, CELL, V54, P993, DOI 10.1016/0092-8674(88)90114-6; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; Ozawa M, 2003, J BIOL CHEM, V278, P46014, DOI 10.1074/jbc.M307778200; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; Provost E, 1999, CURR OPIN CELL BIOL, V11, P567, DOI 10.1016/S0955-0674(99)00015-0; SOMMERS CL, 1994, CANCER RES, V54, P3544; Suyama K, 2002, CANCER CELL, V2, P301, DOI 10.1016/S1535-6108(02)00150-2; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Thoreson MA, 2000, J CELL BIOL, V148, P189, DOI 10.1083/jcb.148.1.189; Van Aken E, 2001, VIRCHOWS ARCH, V439, P725, DOI 10.1007/S004280100516; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; Wong AST, 2003, J CELL BIOL, V161, P1191, DOI 10.1083/jcb.200212033; Xu G, 2002, J BIOL CHEM, V277, P49989, DOI 10.1074/jbc.M206454200; Xu YR, 1999, J CELL BIOCHEM, V75, P264; Xu YR, 1997, J BIOL CHEM, V272, P13463, DOI 10.1074/jbc.272.21.13463; Yap AS, 1998, J CELL BIOL, V141, P779, DOI 10.1083/jcb.141.3.779	45	14	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52371	52378		10.1074/jbc.M310576200	http://dx.doi.org/10.1074/jbc.M310576200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14559901	hybrid			2022-12-27	WOS:000187480700048
J	Knights, CD; Liu, YG; Appella, E; Kulesz-Martin, M				Knights, CD; Liu, YG; Appella, E; Kulesz-Martin, M			Defective p53 post-translational modification required for wild type p53 inactivation in malignant epithelial cells with mdm2 gene amplification	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALTERNATIVELY SPLICED P53; TUMOR-SUPPRESSOR PROTEIN; MOUSE EPIDERMAL-CELLS; DNA-BINDING; IN-VITRO; PHOSPHORYLATION; ACETYLATION; DAMAGE; ACTIVATION; KINASE	Mdm2 gene amplification occurs in benign and chemotherapy-responsive malignant tumors with wtp53 genes as well as in breast and epithelial cancers. Mdm2 amplification in benign tumors suggests that it is not sufficient for p53 inactivation in cancer, implying that other defects in the p53 pathway are required for malignancy. We investigated mechanisms of wtp53 protein inactivation in malignant conversion of epithelial cells by comparing clonally related initiated cells with their derivative cancerous cells that have mdm2 amplification. Deficiencies in p53 accumulation and activities in response to DNA damage were not due simply to Mdm2 destabilization of p53 protein, but to continued association of DNA-bound p53 with Mdm2 protein and lack of binding and acetylation by p300 protein. The aberrant interactions were not because of mdm2 amplification alone, because DNA-bound p53 protein from initiated cells failed to bind ectopically expressed Mdm2 or endogenous overexpressed Mdm2 from cancerous cells. Phosphorylations of endogenous p53 at Ser(18), -23, or -37 were insufficient to dissociate Mdm2, because each was induced by UV in cancerous cells. Interestingly, phospho-mimic p53-T21E did dissociate the Mdm2 protein from DNA-bound p53 and recovered p300 binding and p21 induction in the cancerous cells. Thus wtp53 in malignant cells with mdm2 amplification can be inactivated by continued association of DNA-bound p53 protein with Mdm2 and failure of p300 binding and acetylation, coupled with a defect in p53 phosphorylation at Thr(21). These findings suggest therapeutic strategies that address both p53/Mdm2 interaction and associated p53 protein defects in human tumors that have amplified mdm2 genes.	Oregon Hlth Sci Univ, Dept Dermatol, Portland, OR 97239 USA; SUNY Buffalo, Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Buffalo, NY 14263 USA; SUNY Buffalo, Roswell Pk Canc Inst, Program Biochem, Buffalo, NY 14263 USA; NCI, Cell Biol Lab, Div Basic Sci, NIH, Bethesda, MD 20892 USA	Oregon Health & Science University; Roswell Park Cancer Institute; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Roswell Park Cancer Institute; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Kulesz-Martin, M (corresponding author), Oregon Hlth Sci Univ, Dept Dermatol, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.				NCI NIH HHS [CA69533, CA31101] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA031101, P30CA069533] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; BAKER SJ, 1990, CANCER RES, V50, P7717; Barcia R, 2002, ARCH BIOCHEM BIOPHYS, V399, P1, DOI 10.1006/abbi.2001.2746; Barlev NA, 2001, MOL CELL, V8, P1243, DOI 10.1016/S1097-2765(01)00414-2; Bean LJH, 2002, J BIOL CHEM, V277, P1864, DOI 10.1074/jbc.M108881200; BURNS PA, 1991, ONCOGENE, V6, P2363; Chehab NH, 1999, P NATL ACAD SCI USA, V96, P13777, DOI 10.1073/pnas.96.24.13777; Craig AL, 1999, BIOCHEM J, V342, P133, DOI 10.1042/0264-6021:3420133; Dumaz N, 1999, EMBO J, V18, P7002, DOI 10.1093/emboj/18.24.7002; Dumaz N, 1999, FEBS LETT, V463, P312, DOI 10.1016/S0014-5793(99)01647-6; Ferguson WS, 2001, CANCER INVEST, V19, P292, DOI 10.1081/CNV-100102557; Freedman DA, 1999, CANCER RES, V59, P1; Ganguli G, 2000, EMBO J, V19, P5135, DOI 10.1093/emboj/19.19.5135; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; Grossman SR, 2003, SCIENCE, V300, P342, DOI 10.1126/science.1080386; Grossman SR, 2001, EUR J BIOCHEM, V268, P2773, DOI 10.1046/j.1432-1327.2001.02226.x; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Haapajarvi T, 1999, EXP CELL RES, V248, P272, DOI 10.1006/excr.1999.4403; Hainaut P, 1998, NUCLEIC ACIDS RES, V26, P205, DOI 10.1093/nar/26.1.205; HAN KA, 1992, CANCER RES, V52, P749; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Ito A, 2001, EMBO J, V20, P1331, DOI 10.1093/emboj/20.6.1331; Ito A, 2002, EMBO J, V21, P6236, DOI 10.1093/emboj/cdf616; Jabbur JR, 2002, CANCER BIOL THER, V1, P277, DOI 10.4161/cbt.81; Jabbur JR, 2002, ONCOGENE, V21, P7100, DOI 10.1038/sj.onc.1205856; Jin YT, 2002, J BIOL CHEM, V277, P30838, DOI 10.1074/jbc.M204078200; Kaku S, 2001, NUCLEIC ACIDS RES, V29, P1989, DOI 10.1093/nar/29.9.1989; Kar S, 2002, J BIOL CHEM, V277, P15579, DOI 10.1074/jbc.M106915200; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Kobet E, 2000, P NATL ACAD SCI USA, V97, P12547, DOI 10.1073/pnas.97.23.12547; KULESZMARTIN M, 1986, CARCINOGENESIS, V7, P1425, DOI 10.1093/carcin/7.9.1425; KULESZMARTIN M, 1985, CARCINOGENESIS, V6, P1245, DOI 10.1093/carcin/6.9.1245; KULESZMARTIN MF, 1988, CARCINOGENESIS, V9, P171, DOI 10.1093/carcin/9.1.171; KULESZMARTIN MF, 1994, MOL CELL BIOL, V14, P1698, DOI 10.1128/MCB.14.3.1698; Lai ZH, 2000, ARCH BIOCHEM BIOPHYS, V381, P278, DOI 10.1006/abbi.2000.1998; Lambert PF, 1998, J BIOL CHEM, V273, P33048, DOI 10.1074/jbc.273.49.33048; Li MY, 2002, J BIOL CHEM, V277, P50607, DOI 10.1074/jbc.C200578200; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; Liu L, 1999, MOL CELL BIOL, V19, P1202; Liu YG, 2001, CANCER RES, V61, P5402; Lopez-Borges S, 2000, ONCOGENE, V19, P3656, DOI 10.1038/sj.onc.1203709; MCKAY RDG, 1981, J MOL BIOL, V145, P471, DOI 10.1016/0022-2836(81)90540-4; Momand J, 1997, J CELL BIOCHEM, V64, P343; Momand J, 1998, NUCLEIC ACIDS RES, V26, P3453, DOI 10.1093/nar/26.15.3453; RUGGERI B, 1991, CANCER RES, V51, P6615; Sakaguchi K, 2000, J BIOL CHEM, V275, P9278, DOI 10.1074/jbc.275.13.9278; Schon O, 2002, J MOL BIOL, V323, P491, DOI 10.1016/S0022-2836(02)00852-5; Unger T, 1999, EMBO J, V18, P1805, DOI 10.1093/emboj/18.7.1805; Wadgaonkar R, 1999, J BIOL CHEM, V274, P13760, DOI 10.1074/jbc.274.20.13760; Wu Y, 1997, P NATL ACAD SCI USA, V94, P8982, DOI 10.1073/pnas.94.17.8982; WU Y, 1994, EMBO J, V13, P4823, DOI 10.1002/j.1460-2075.1994.tb06808.x; Wu ZQ, 2002, MOL CELL BIOL, V22, P2441, DOI 10.1128/MCB.22.8.2441-2449.2002; ZAUBERMAN A, 1993, EMBO J, V12, P2799, DOI 10.1002/j.1460-2075.1993.tb05941.x	54	21	23	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52890	52900		10.1074/jbc.M300279200	http://dx.doi.org/10.1074/jbc.M300279200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14555661	hybrid			2022-12-27	WOS:000187480700110
J	Matta, H; Sun, QM; Moses, G; Chaudhary, PM				Matta, H; Sun, QM; Moses, G; Chaudhary, PM			Molecular genetic analysis of human herpes virus 8-encoded viral FLICE inhibitory protein-induced NF-kappa B activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEVERE LIVER DEGENERATION; NUCLEAR-FACTOR; MICE LACKING; PROTEASOME INHIBITOR; DEFICIENT MICE; IKK-ALPHA; T-CELLS; KINASE; LYMPHOTOXIN; RECEPTOR	The human herpes virus 8 (HHV8)-encoded viral FLICE inhibitory protein (vFLIP), also known as K13, is known to activate the NF-kappaB pathway, a property not shared by other vFLIPs. Previous studies have demonstrated that HHV8 vFLIP K13 interacts with several cellular signaling proteins involved in NF-kappaB activation, such as receptor-interacting protein, NF-kappaB-inducing kinase, IkappaB kinase (IKK) 1, IKK2, and NF-kappaB essential modulator (NEMO). In this report we have used cell lines deficient in the above proteins to investigate the mechanism of NF-kappaB activation via HHV8 vFLIP K13. We demonstrate that receptor-interacting protein and NF-kappaB-inducing kinase are dispensable for vFLIP K13-induced NF-kappaB DNA binding and transcriptional activation. On the other hand, vFLIP K13-induced NF-kappaB DNA binding activity is significantly reduced, although not absent, in cells deficient in IKK1, IKK2, and NEMO. Furthermore, vFLIP K13-induced NF-kappaB transcriptional activity is only weakly present in IKK1-deficient cells and almost completely absent in those deficient in IKK2 and NEMO. HHV8 vFLIP K13-induced NF-kappaB activation in IKK1- and IKK2-deficient fibroblasts could be rescued by wild type but not by the kinase-inactive mutants of IKK1 and IKK2, respectively. Consistent with the above results, vFLIP K13-induced NF-kappaB activation could be effectively blocked by chemical inhibitors of the kinase activity of IKK1 and IKK2. Thus, a cooperative interaction of all three subunits of the IKK complex is required for maximal NF-kappaB activation via HHV8 vFLIP K13. Selective inhibitors of the IKK1 kinase activity may have a role in the treatment of disorders caused by abnormal NF-kappaB activation by HHV8 vFLIP K13.	Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Div Hematol Oncol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Chaudhary, PM (corresponding author), Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	preet.chaudhary@utsouthwestern.edu	Chaudhary, Preet/E-1970-2018		NATIONAL CANCER INSTITUTE [R01CA085177] Funding Source: NIH RePORTER; NCI NIH HHS [CA85177] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		An JB, 2003, ONCOGENE, V22, P3371, DOI 10.1038/sj.onc.1206407; Anest V, 2003, NATURE, V423, P659, DOI 10.1038/nature01648; Bertin J, 1997, P NATL ACAD SCI USA, V94, P1172, DOI 10.1073/pnas.94.4.1172; Cannon M, 2003, J VIROL, V77, P57, DOI 10.1128/JVI.77.1.57-67.2003; Chaudhary PM, 1999, ONCOGENE, V18, P5738, DOI 10.1038/sj.onc.1202976; Claudio E, 2002, NAT IMMUNOL, V3, P958, DOI 10.1038/ni842; Coope HJ, 2002, EMBO J, V21, P5375, DOI 10.1093/emboj/cdf542; Cory AH, 2002, ANTICANCER RES, V22, P3805; Dourmishev LA, 2003, MICROBIOL MOL BIOL R, V67, P175, DOI 10.1128/MMBR.67.2.175-212.2003; Estrov Z, 1999, BLOOD, V94, P2844, DOI 10.1182/blood.V94.8.2844.420k43_2844_2853; Field N, 2003, J CELL SCI, V116, P3721, DOI 10.1242/jcs.00691; Garg A, 2002, LEUKEMIA, V16, P1053, DOI 10.1038/sj.leu.2402482; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Hu SM, 1997, J BIOL CHEM, V272, P9621; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Kapahi P, 2000, J BIOL CHEM, V275, P36062, DOI 10.1074/jbc.M007204200; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; Li QT, 2000, GENE DEV, V14, P1729; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Liu L, 2002, J BIOL CHEM, V277, P13745, DOI 10.1074/jbc.M110480200; Makris C, 2000, MOL CELL, V5, P969, DOI 10.1016/S1097-2765(00)80262-2; Mitsiades N, 2003, BLOOD, V101, P2377, DOI 10.1182/blood-2002-06-1768; Mordmuller B, 2003, EMBO REP, V4, P82, DOI 10.1038/embor710; Muller JR, 2003, J BIOL CHEM, V278, P12006, DOI 10.1074/jbc.M210768200; Pati S, 2003, J VIROL, V77, P5759, DOI 10.1128/JVI.77.10.5759-5773.2003; Rainbow L, 1997, J VIROL, V71, P5915, DOI 10.1128/JVI.71.8.5915-5921.1997; Roussel RR, 2000, ARCH BIOCHEM BIOPHYS, V377, P204, DOI 10.1006/abbi.2000.1770; Rudolph D, 2000, GENE DEV, V14, P854; Sarid R, 1998, J VIROL, V72, P1005, DOI 10.1128/JVI.72.2.1005-1012.1998; Schmidt-Supprian M, 2000, MOL CELL, V5, P981, DOI 10.1016/S1097-2765(00)80263-4; Schulz TF, 1998, J GEN VIROL, V79, P1573, DOI 10.1099/0022-1317-79-7-1573; Sinha SK, 2002, J BIOL CHEM, V277, P44953, DOI 10.1074/jbc.M207923200; Smith C, 2001, J IMMUNOL, V167, P5895, DOI 10.4049/jimmunol.167.10.5895; Sturzl M, 1999, J NATL CANCER I, V91, P1725, DOI 10.1093/jnci/91.20.1725; Sun R, 1999, J VIROL, V73, P2232, DOI 10.1128/JVI.73.3.2232-2242.1999; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0; Ting AT, 1996, EMBO J, V15, P6189, DOI 10.1002/j.1460-2075.1996.tb01007.x; Verma SC, 2003, FEMS MICROBIOL LETT, V222, P155, DOI 10.1016/S0378-1097(03)00261-1; Xiao GT, 2001, EMBO J, V20, P6805, DOI 10.1093/emboj/20.23.6805; Yamamoto Y, 2003, NATURE, V423, P655, DOI 10.1038/nature01576; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yilmaz ZB, 2003, EMBO J, V22, P121, DOI 10.1093/emboj/cdg004; Yin L, 2001, SCIENCE, V291, P2162, DOI 10.1126/science.1058453; Yin MJ, 1998, NATURE, V396, P77, DOI 10.1038/23948; Zingarelli B, 2003, CRIT CARE MED, V31, pS105, DOI 10.1097/00003246-200301001-00015	48	43	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52406	52411		10.1074/jbc.M307308200	http://dx.doi.org/10.1074/jbc.M307308200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14561765	hybrid			2022-12-27	WOS:000187480700053
J	Barbieri, CE; Barton, CE; Pietenpol, JA				Barbieri, CE; Barton, CE; Pietenpol, JA			Delta Np63 alpha expression is regulated by the phosphoinositide 3-kinase pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SQUAMOUS-CELL CARCINOMA; KERATINOCYTE STEM-CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; P63 EXPRESSION; P53 HOMOLOG; SIGNALING PATHWAYS; DOWN-REGULATION; DIFFERENTIATION; PROTEIN; CANCER	p63 is a homologue of p53 that functions to maintain progenitor cell populations in stratified epithelia. DeltaNp63alpha is overexpressed in epithelial cancers and has been shown to have oncogenic properties. We have previously reported that inhibition of epidermal growth factor receptor signaling results in a decrease in DeltaNp63alpha expression. Here, we demonstrate DeltaNp63alpha is a target of the phosphoinositide-3-kinase (PI3K) pathway downstream of the epidermal growth factor receptor. Treatment of keratinocytes with epidermal growth factor results in an increase in DeltaNp63alpha expression at the mRNA level, which is abrogated by inhibition of PI3K but not mitogen-activated protein kinase signaling. Small interfering RNA-mediated knockdown of the p110beta catalytic subunit of PI3K results in a decrease in DeltaNp63alpha protein levels in keratinocytes. The results presented herein suggest that regulation of DeltaNp63alpha expression by the PI3K pathway plays a critical role in the survival and proliferative capacity of squamous epithelia.	Vanderbilt Univ, Med Ctr, Dept Biochem, Ctr Mol Toxicol,Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA	Vanderbilt University	Pietenpol, JA (corresponding author), Vanderbilt Univ, Med Ctr, Dept Biochem, Ctr Mol Toxicol,Vanderbilt Ingram Canc Ctr, 652 PRB, Nashville, TN 37232 USA.			Barton, Christopher/0000-0002-4882-6026; Barbieri, Christopher/0000-0002-0381-1947	NATIONAL CANCER INSTITUTE [T32CA009385, P30CA068485, R01CA070856] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R41GM073407] Funding Source: NIH RePORTER; NCI NIH HHS [CA68485, CA009385, CA70856] Funding Source: Medline; NIEHS NIH HHS [ES00267] Funding Source: Medline; NIGMS NIH HHS [GM73407] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ali IU, 1999, JNCI-J NATL CANCER I, V91, P1922, DOI 10.1093/jnci/91.22.1922; Bakkers J, 2002, DEV CELL, V2, P617, DOI 10.1016/S1534-5807(02)00163-6; Bamberger C, 2002, J INVEST DERMATOL, V118, P133, DOI 10.1046/j.0022-202x.2001.01649.x; Bamberger C, 2001, FEBS LETT, V501, P121, DOI 10.1016/S0014-5793(01)02643-6; BELLACOSA A, 1995, INT J CANCER, V64, P280, DOI 10.1002/ijc.2910640412; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Chen XB, 1999, MOL MED TODAY, V5, P387, DOI 10.1016/S1357-4310(99)01545-2; Cheng JQ, 1996, P NATL ACAD SCI USA, V93, P3636, DOI 10.1073/pnas.93.8.3636; Choi HR, 2002, HUM PATHOL, V33, P158, DOI 10.1053/hupa.2002.30722; Czauderna F, 2003, NUCLEIC ACIDS RES, V31, P670, DOI 10.1093/nar/gkg141; Dellavalle RP, 2001, J DERMATOL SCI, V27, P82, DOI 10.1016/S0923-1811(01)00105-0; Di Como CJ, 2002, CLIN CANCER RES, V8, P494; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Flatt PM, 1998, CELL GROWTH DIFFER, V9, P535; Flatt PM, 2000, MOL CELL BIOL, V20, P4210, DOI 10.1128/MCB.20.12.4210-4223.2000; Ghioni P, 2002, MOL CELL BIOL, V22, P8659, DOI 10.1128/MCB.22.24.8659-8668.2002; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Glass DJ, 2003, NAT CELL BIOL, V5, P87, DOI 10.1038/ncb0203-87; Hibi K, 2000, P NATL ACAD SCI USA, V97, P5462, DOI 10.1073/pnas.97.10.5462; Hu H, 2002, INT J CANCER, V102, P580, DOI 10.1002/ijc.10739; Kaur P, 2000, J INVEST DERMATOL, V114, P413, DOI 10.1046/j.1523-1747.2000.00884.x; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; King KE, 2003, ONCOGENE, V22, P3635, DOI 10.1038/sj.onc.1206536; King WG, 1997, MOL CELL BIOL, V17, P4406, DOI 10.1128/MCB.17.8.4406; Lee H, 2002, DEV CELL, V2, P607, DOI 10.1016/S1534-5807(02)00166-1; Liefer KM, 2000, CANCER RES, V60, P4016; Massion PP, 2002, CANCER RES, V62, P3636; Matheny KE, 2003, LARYNGOSCOPE, V113, P936, DOI 10.1097/00005537-200306000-00004; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Nguyen BP, 2000, J BIOL CHEM, V275, P31896, DOI 10.1074/jbc.M006379200; Nylander K, 2000, INT J CANCER, V87, P368, DOI 10.1002/1097-0215(20000801)87:3<368::AID-IJC9>3.3.CO;2-A; Okkenhaug K, 2003, NAT REV IMMUNOL, V3, P317, DOI 10.1038/nri1056; Park BJ, 2000, CANCER RES, V60, P3370; Parsa R, 1999, J INVEST DERMATOL, V113, P1099, DOI 10.1046/j.1523-1747.1999.00780.x; Patapoutian A, 2001, CURR OPIN NEUROBIOL, V11, P272, DOI 10.1016/S0959-4388(00)00208-7; Pellegrini G, 2001, P NATL ACAD SCI USA, V98, P3156, DOI 10.1073/pnas.061032098; Saltiel AR, 2002, TRENDS CELL BIOL, V12, P65, DOI 10.1016/S0962-8924(01)02207-3; Sauer H, 2000, FEBS LETT, V476, P218, DOI 10.1016/S0014-5793(00)01747-6; Sayama K, 2002, J BIOL CHEM, V277, P40390, DOI 10.1074/jbc.M112423200; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Vojtek AB, 2003, MOL CELL BIOL, V23, P4417, DOI 10.1128/MCB.23.13.4417-4427.2003; Wang QD, 2001, GASTROENTEROLOGY, V120, P1381, DOI 10.1053/gast.2001.24044; Wang TY, 2001, HUM PATHOL, V32, P479, DOI 10.1053/hupa.2001.24324; Westfall MD, 2003, MOL CELL BIOL, V23, P2264, DOI 10.1128/MCB.23.7.2264-2276.2003; Woenckhaus J, 2002, J PATHOL, V198, P335, DOI 10.1002/path.1207; Worsham MJ, 2003, ARCH OTOLARYNGOL, V129, P702, DOI 10.1001/archotol.129.7.702; Wu CY, 2001, J CELL BIOL, V155, P505, DOI 10.1083/jcb.200108077; Yang A, 2000, NAT REV MOL CELL BIO, V1, P199, DOI 10.1038/35043127; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073	53	69	73	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51408	51414		10.1074/jbc.M309943200	http://dx.doi.org/10.1074/jbc.M309943200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14555649	hybrid			2022-12-27	WOS:000187206300069
J	Hay, E; Lemonnier, J; Fromigue, O; Guenou, H; Marie, PJ				Hay, E; Lemonnier, J; Fromigue, O; Guenou, H; Marie, PJ			Bone morphogenetic protein receptor IB signaling mediates apoptosis independently of differentiation in osteoblastic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; ALKALINE-PHOSPHATASE; GENE-EXPRESSION; SMAD; BMP-2; INDUCTION; KINASE; ROLES; DEATH; REQUIREMENT	Bone morphogenetic protein-2 (BMP-2) is an important regulator of osteoblast differentiation. However, the regulation of osteoblast apoptosis by BMP signaling remains poorly understood. Here we examined the role of type I BMP receptor (BMP-RI) in osteoblast apoptosis promoted by BMP-2. Despite undetectable BMP-RIB expression in OHS4 cells, BMP-2 or BMP-2 overexpression increased osteoblast differentiation similarly as in SaOS2 cells which express BMP-RIB, as shown by alkaline phosphatase and CBFA1/RUNX2 expression. In contrast to SaOS2 cells, however, BMP-2 or BMP-2 overexpression did not increase caspase-9 and caspases-3, -6, and -7 activity and DNA fragmentation in OHS4 cells. Consistently, BMP-2 increased protein kinase C (PKC) activity, and PKC inhibition suppressed BMP-2-induced caspase activity in SaOS2 but not in OHS4 cells that lack BMP-RIB. A dominant negative BMP-RIB inhibited BMP-2-induced caspase activity, whereas wild-type BMP-RIB promoted caspase activity induced by BMP-2 in SaOS2 and MC3T3-E1 cells. Wild-type BMP-RIB rescued the apoptotic response to BMP-2, and a constitutively active BMP-RIB restored the apoptotic signal in OHS4 cells, supporting an essential role for BMP-RIB in osteoblast apoptosis. We also assessed whether BMP-2-induced apoptosis occurred independently of osteoblast differentiation. General inhibition of caspases did not abolish BMP-2-induced alkaline phosphatase and CBFA1/RUNX2 expression in SaOS2 cells. Furthermore, broad caspases inhibition increased matrix mineralization but did not reverse the BMP-2 effect on mineralization in MC3T3-E1 cells. These results indicate that BMP2-induced apoptosis was mediated by BMP-RIB in osteoblasts and occurred independently of BMP-2-induced osteoblast differentiation, which provides additional insights into the dual mechanism of BMP-2 action on osteoblast fate.	Lariboisiere Hosp, CNRS, INSERM, U349,Lab Osteoblast Biol & Pathol, F-75475 Paris 10, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Marie, PJ (corresponding author), Lariboisiere Hosp, CNRS, INSERM, U349,Lab Osteoblast Biol & Pathol, F-75475 Paris 10, France.	pierre.marie@larib.inserm.fr	Fromigue, Olivia/B-8225-2013; Guenou, Hind/Q-3811-2018	Fromigue, Olivia/0000-0002-3050-6155; Hay, Eric/0000-0002-0131-9983; Guenou, Hind/0000-0003-3906-2519				Akiyama S, 1997, EXP CELL RES, V235, P362, DOI 10.1006/excr.1997.3680; Aoki H, 2001, J CELL SCI, V114, P1483; Canalis E, 2003, ENDOCR REV, V24, P218, DOI 10.1210/er.2002-0023; Chen D, 1998, J CELL BIOL, V142, P295, DOI 10.1083/jcb.142.1.295; Chen D, 1997, CALCIFIED TISSUE INT, V60, P283, DOI 10.1007/s002239900230; CHEN SJ, 1993, BIOCHEMISTRY-US, V32, P1032, DOI 10.1021/bi00055a006; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Drissi H, 1997, J BONE MINER RES, V12, P1805, DOI 10.1359/jbmr.1997.12.11.1805; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Ebisawa T, 1999, J CELL SCI, V112, P3519; FOURNIER B, 1991, J CELL BIOL, V114, P577, DOI 10.1083/jcb.114.3.577; Fromigue O, 1998, J CELL BIOCHEM, V68, P411, DOI 10.1002/(SICI)1097-4644(19980315)68:4<411::AID-JCB2>3.3.CO;2-C; Fujii M, 1999, MOL BIOL CELL, V10, P3801, DOI 10.1091/mbc.10.11.3801; Ghosh-Choudhury N, 2002, J BIOL CHEM, V277, P33361, DOI 10.1074/jbc.M205053200; Guha U, 2002, DEV BIOL, V249, P108, DOI 10.1006/dbio.2002.0752; HARRIS SE, 1994, J BONE MINER RES, V9, P855; Hay E, 1999, J CELL BIOCHEM, V72, P81, DOI 10.1002/(SICI)1097-4644(19990101)72:1<81::AID-JCB9>3.0.CO;2-N; Hay E, 2001, J BIOL CHEM, V276, P29028, DOI 10.1074/jbc.M011265200; Hay E, 2000, J CELL PHYSIOL, V183, P117, DOI 10.1002/(SICI)1097-4652(200004)183:1<117::AID-JCP14>3.0.CO;2-#; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hoffmann A, 2001, CRIT REV EUKAR GENE, V11, P23; Hogan BLM, 1996, CURR OPIN GENET DEV, V6, P432, DOI 10.1016/S0959-437X(96)80064-5; ISHIDOU Y, 1995, J BONE MINER RES, V10, P1651; Jilka RL, 1998, J BONE MINER RES, V13, P793, DOI 10.1359/jbmr.1998.13.5.793; KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755; Lai CF, 2002, J BIOL CHEM, V277, P15514, DOI 10.1074/jbc.M200794200; Lecanda F, 1997, J CELL BIOCHEM, V67, P386, DOI 10.1002/(SICI)1097-4644(19971201)67:3<386::AID-JCB10>3.3.CO;2-5; Lee KS, 2002, ONCOGENE, V21, P7156, DOI 10.1038/sj.onc.1205937; Luppen CA, 2003, J BIOL CHEM, V278, P44995, DOI 10.1074/jbc.M306730200; Luppen CA, 2003, J BONE MINER RES, V18, P1186, DOI 10.1359/jbmr.2003.18.7.1186; Lynch MP, 1998, J CELL BIOCHEM, V68, P31; Macias D, 1997, DEVELOPMENT, V124, P1109; Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115; Marie PJ, 2002, HISTOL HISTOPATHOL, V17, P877, DOI 10.14670/HH-17.877; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Miyazono K, 1999, BONE, V25, P91, DOI 10.1016/S8756-3282(99)00113-1; Miyazono K, 2001, J CELL PHYSIOL, V187, P265, DOI 10.1002/jcp.1080; Moses HL, 1996, CURR OPIN GENET DEV, V6, P581, DOI 10.1016/S0959-437X(96)80087-6; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Namiki M, 1997, J BIOL CHEM, V272, P22046, DOI 10.1074/jbc.272.35.22046; Panchision DM, 2001, GENE DEV, V15, P2094, DOI 10.1101/gad.894701; Pronk GJ, 1996, SCIENCE, V271, P808, DOI 10.1126/science.271.5250.808; QUARLES LD, 1992, J BONE MINER RES, V7, P683; Rodan G A, 1982, Prog Clin Biol Res, V110 Pt B, P249; ROSENZWEIG BL, 1995, P NATL ACAD SCI USA, V92, P7632, DOI 10.1073/pnas.92.17.7632; Skillington J, 2002, J CELL BIOL, V159, P135, DOI 10.1083/jcb.200204060; TENDIJKE P, 1994, J BIOL CHEM, V269, P16985; Wozney JM, 1998, CLIN ORTHOP RELAT R, P26; Wrana JL, 2000, CELL, V100, P189, DOI 10.1016/S0092-8674(00)81556-1; Xiao GZ, 1998, J BIOL CHEM, V273, P32988, DOI 10.1074/jbc.273.49.32988; Yamaguchi A, 2000, ENDOCR REV, V21, P393, DOI 10.1210/er.21.4.393; Yokouchi Y, 1996, DEVELOPMENT, V122, P3725; Zhang ZY, 2000, DEV BIOL, V220, P154, DOI 10.1006/dbio.2000.9637; Zhao M, 2002, J CELL BIOL, V157, P1049, DOI 10.1083/jcb.200109012; Zou HY, 1996, SCIENCE, V272, P738, DOI 10.1126/science.272.5262.738; Zou HY, 1997, GENE DEV, V11, P2191, DOI 10.1101/gad.11.17.2191	56	41	44	2	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 16	2004	279	3					1650	1658		10.1074/jbc.M300969200	http://dx.doi.org/10.1074/jbc.M300969200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	762WT	14576167	hybrid			2022-12-27	WOS:000188005700013
J	Oestergaard, VH; Bjergbaek, L; Skouboe, C; Giangiacomo, L; Knudsen, BR; Andersen, AH				Oestergaard, VH; Bjergbaek, L; Skouboe, C; Giangiacomo, L; Knudsen, BR; Andersen, AH			The transducer domain is important for clamp operation in human DNA topoisomerase II alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; DROSOPHILA-MELANOGASTER; CRYSTAL-STRUCTURE; ONE ATP; MECHANISM; TRANSPORT; PROTEIN; ENZYME; SITE; RELIGATION	DNA topoisomerase II is a multidomain homodimeric enzyme that changes DNA topology by coupling ATP hydrolysis to the transport of one DNA helix through a transient double-stranded break in another. The process requires dramatic conformational changes including closure of an ATP-operated clamp, which is comprised of two N-terminal domains from each protomer. The most N-terminal domain contains the ATP-binding site and is directly involved in clamp closure, undergoing dimerization upon ATP binding. The second domain, the transducer domain, forms the walls of the N-terminal clamp and connects the clamp to the enzyme core. Although structurally conserved, it is unclear whether the transducer domain is involved in clamp mechanism. We have purified and characterized a human topoisomerase IIalpha enzyme with a two-amino acid insertion at position 408 in the transducer domain. The enzyme retains both ATPase and DNA cleavage activities. However, the insertion, which is situated far from the N-terminal dimerization area, severely disrupts the function of the N-terminal clamp. The clamp-deficient enzyme is catalytically inactive and lacks most aspects of interdomain communication. Surprisingly, it seems to have retained the intersubunit communication, allowing it to bind ATP cooperatively in the presence of DNA. The results show that even distal parts of the transducer domain are important for the dynamics of the N-terminal clamp and furthermore indicate that stable clamp closure is not required for cooperative binding of ATP.	Univ Aarhus, Dept Mol Biol, DK-8000 Aarhus C, Denmark	Aarhus University	Andersen, AH (corresponding author), Univ Aarhus, Dept Mol Biol, CF Mollers Alle,Bldg 130, DK-8000 Aarhus C, Denmark.	aha@mb.au.dk	Bjergbæk, Lotte/AAW-6302-2021; Oestergaard, Vibe Hallundbæk/B-7254-2015; Andersen, Anni/O-1162-2017	Oestergaard, Vibe Hallundbæk/0000-0002-1633-0560; Bjergbaek, Lotte/0000-0002-8233-3356				ANDERSEN AH, 1991, J BIOL CHEM, V266, P9203; Baird CL, 1999, P NATL ACAD SCI USA, V96, P13685, DOI 10.1073/pnas.96.24.13685; Ban C, 1998, CELL, V95, P541, DOI 10.1016/S0092-8674(00)81621-9; Berger JM, 1996, NATURE, V379, P225, DOI 10.1038/379225a0; Berger JM, 1998, P NATL ACAD SCI USA, V95, P7876, DOI 10.1073/pnas.95.14.7876; Biersack H, 1996, P NATL ACAD SCI USA, V93, P8288, DOI 10.1073/pnas.93.16.8288; Bjergbaek L, 2000, J BIOL CHEM, V275, P13041, DOI 10.1074/jbc.275.17.13041; Burden DA, 1998, BBA-GENE STRUCT EXPR, V1400, P139, DOI 10.1016/S0167-4781(98)00132-8; CLASSEN S, 2003, P NATL ACAD SCI US; Corbett KD, 2003, EMBO J, V22, P151, DOI 10.1093/emboj/cdg008; CRENSHAW DG, 1993, J BIOL CHEM, V268, P21335; DeLano W, 2002, PYMOL 0 99; Fass D, 1999, NAT STRUCT BIOL, V6, P322; GOCKE E, 1983, NUCLEIC ACIDS RES, V11, P7661, DOI 10.1093/nar/11.22.7661; Harkins TT, 1998, BIOCHEMISTRY-US, V37, P7299, DOI 10.1021/bi9729108; Hu T, 1998, J BIOL CHEM, V273, P9586, DOI 10.1074/jbc.273.16.9586; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Jensen S, 1996, MOL CELL BIOL, V16, P3866; Lamour V, 2002, J BIOL CHEM, V277, P18947, DOI 10.1074/jbc.M111740200; LINDSLEY JE, 1993, J BIOL CHEM, V268, P8096; Mao Y, 1999, BIOCHEMISTRY-US, V38, P10793, DOI 10.1021/bi9909804; Morris SNK, 1999, J BIOL CHEM, V274, P3446, DOI 10.1074/jbc.274.6.3446; OSHEROFF N, 1986, J BIOL CHEM, V261, P9944; OSHEROFF N, 1983, J BIOL CHEM, V258, P9536; REECE RJ, 1989, J BIOL CHEM, V264, P19648; ROBINSON MJ, 1990, BIOCHEMISTRY-US, V29, P2511, DOI 10.1021/bi00462a012; ROCA J, 1994, CELL, V77, P609, DOI 10.1016/0092-8674(94)90222-4; ROCA J, 1992, CELL, V71, P833, DOI 10.1016/0092-8674(92)90558-T; SHIOZAKI K, 1991, MOL CELL BIOL, V11, P6093, DOI 10.1128/MCB.11.12.6093; Skouboe C, 2003, J BIOL CHEM, V278, P5768, DOI 10.1074/jbc.M210332200; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; WATT PM, 1994, BIOCHEM J, V303, P681, DOI 10.1042/bj3030681; WIGLEY DB, 1991, NATURE, V351, P624, DOI 10.1038/351624a0; WORLAND ST, 1989, J BIOL CHEM, V264, P4412	34	24	25	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 16	2004	279	3					1684	1691		10.1074/jbc.M309624200	http://dx.doi.org/10.1074/jbc.M309624200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	762WT	14583603	hybrid			2022-12-27	WOS:000188005700017
J	Ma, CL; Kotaria, R; Mayor, JA; Eriks, LR; Dean, AM; Walters, DE; Kaplan, RS				Ma, CL; Kotaria, R; Mayor, JA; Eriks, LR; Dean, AM; Walters, DE; Kaplan, RS			The mitochondrial citrate transport protein - Probing the secondary structure of transmembrane domain III, identification of residues that likely comprise a portion of the citrate transport pathway, and development of a model for the putative TMDIII-TMDIII ' interface	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHANNEL-LINING RESIDUES; DOPAMINE D2 RECEPTOR; RAT-LIVER; TRICARBOXYLATE CARRIER; GXXXG MOTIF; YEAST; PURIFICATION; BINDING; ACCESSIBILITY; EXPRESSION	The mitochondrial citrate transport protein (CTP) has been investigated by mutating 28 consecutive residues within transmembrane domain III (TMDIII), one at a time, to cysteine. A cysteine-less CTP that retains wildtype functional properties, served as the starting template. The single Cys CTP mutants were abundantly expressed in Escherichia coli, isolated, and functionally reconstituted in a liposomal system. The accessibility of each single Cys mutant to two methanethiosulfonate reagents was evaluated by determining the rate constants for inhibition of CTP function. These rate constants varied by over five orders of magnitude. With two independent data sets we observed peaks and troughs in the rate constant data at identical amino acid positions and a periodicity of 4 was observed from residues 123-137. Based on the pattern of accessibility we conclude that residues 123-137 exist as an alpha-helix. Although less certain, a combination of the rate constant data and the specific activity data with the single Cys mutants suggests that the alpha-helical secondary structure may extend to residue 113. Furthermore, the rate constant data define water-accessible and water-inaccessible faces of the helix. We infer that the water-accessible face comprises a portion of the substrate translocation pathway through the CTP, whereas the water-inaccessible surface faces the lipid bilayer. Finally, based on a combination of the CTP inhibition rate constant data and the existence of significant sequence identity with a transmembrane segment within glycophorin A that forms a portion of its dimer interface, a model for a putative CTP TMDIII-TMDIII' dimer interface has been developed.	Finch Univ Hlth Sci Chicago Med Sch, Dept Biochem & Mol Biol, N Chicago, IL 60064 USA; Gortner Labs 240, Biol Proc Technol Inst, St Paul, MN 55108 USA	Chicago Medical School	Kaplan, RS (corresponding author), Finch Univ Hlth Sci Chicago Med Sch, Dept Biochem & Mol Biol, 3333 Green Bay Rd, N Chicago, IL 60064 USA.	kaplanr@finchcms.edu	Mayor, June/AAP-1544-2021; Walters, D. Eric/C-9626-2010	Walters, D. Eric/0000-0002-1513-3522	NIGMS NIH HHS [GM-54642] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054642] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKABAS MH, 1994, NEURON, V13, P919, DOI 10.1016/0896-6273(94)90257-7; AKABAS MH, 1994, J BIOL CHEM, V269, P14865; AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; BISACCIA F, 1990, BIOCHIM BIOPHYS ACTA, V1019, P250, DOI 10.1016/0005-2728(90)90201-E; BISACCIA F, 1989, BIOCHIM BIOPHYS ACTA, V977, P171, DOI 10.1016/S0005-2728(89)80068-4; Briggs C, 1999, BIOCHEMISTRY-US, V38, P5096, DOI 10.1021/bi982945n; BRUNENGR.H, 1973, FEBS LETT, V36, P130, DOI 10.1016/0014-5793(73)80353-9; Cheung M, 1996, BIOPHYS J, V70, P2688, DOI 10.1016/S0006-3495(96)79838-7; CONOVER TE, 1987, TRENDS BIOCHEM SCI, V12, P88, DOI 10.1016/0968-0004(87)90042-9; ENDEMANN G, 1982, J BIOL CHEM, V257, P3434; Fleming KG, 2001, P NATL ACAD SCI USA, V98, P14340, DOI 10.1073/pnas.251367498; Fu DY, 1996, BIOCHEMISTRY-US, V35, P11278, DOI 10.1021/bi960928x; Holmgren M, 1996, NEUROPHARMACOLOGY, V35, P797, DOI 10.1016/0028-3908(96)00129-3; JAVITCH JA, 1995, NEURON, V14, P825, DOI 10.1016/0896-6273(95)90226-0; Kaplan RS, 2000, BIOCHEMISTRY-US, V39, P9157, DOI 10.1021/bi000433e; KAPLAN RS, 1985, ANAL BIOCHEM, V150, P97, DOI 10.1016/0003-2697(85)90445-2; Kaplan RS, 2000, J BIOL CHEM, V275, P12009, DOI 10.1074/jbc.275.16.12009; KAPLAN RS, 1993, J BIOL CHEM, V268, P13682; KAPLAN RS, 1990, J BIOL CHEM, V265, P13379; KAPLAN RS, 1995, J BIOL CHEM, V270, P4108, DOI 10.1074/jbc.270.8.4108; Kotaria R, 1999, J BIOENERG BIOMEMBR, V31, P543, DOI 10.1023/A:1005460810527; KURZ LL, 1995, BIOPHYS J, V68, P900, DOI 10.1016/S0006-3495(95)80266-3; Liu Y, 2002, GENOME BIOL, V3; MacKenzie KR, 1997, SCIENCE, V276, P131, DOI 10.1126/science.276.5309.131; Muller V, 1996, BIOCHEMISTRY-US, V35, P16132, DOI 10.1021/bi960667r; PALMIERI F, 1972, EUR J BIOCHEM, V26, P587, DOI 10.1111/j.1432-1033.1972.tb01801.x; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; ROBERTS DD, 1986, BIOCHEMISTRY-US, V25, P5595, DOI 10.1021/bi00367a038; Russ WP, 2000, J MOL BIOL, V296, P911, DOI 10.1006/jmbi.1999.3489; Senes A, 2000, J MOL BIOL, V296, P921, DOI 10.1006/jmbi.1999.3488; Walters DE, 2000, J MOL MODEL, V6, P587, DOI 10.1007/s0089400060587; WATSON JA, 1970, J BIOL CHEM, V245, P5993; WEINER SJ, 1986, J COMPUT CHEM, V7, P230, DOI 10.1002/jcc.540070216; Winkler E, 1997, BIOCHEMISTRY-US, V36, P148, DOI 10.1021/bi962178x; Xu Y, 2000, J BIOL CHEM, V275, P7117, DOI 10.1074/jbc.275.10.7117; XU Y, 1995, BIOCHEM BIOPH RES CO, V207, P783, DOI 10.1006/bbrc.1995.1255	37	22	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 9	2004	279	2					1533	1540		10.1074/jbc.M310866200	http://dx.doi.org/10.1074/jbc.M310866200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	759DJ	14561747	hybrid			2022-12-27	WOS:000187722800085
J	Albenne, C; Skov, LK; Mirza, O; Gajhede, M; Feller, G; D'Amico, S; Andre, G; Potocki-Veronese, G; van der Veen, BA; Monsan, P; Remaud-Simeon, M				Albenne, C; Skov, LK; Mirza, O; Gajhede, M; Feller, G; D'Amico, S; Andre, G; Potocki-Veronese, G; van der Veen, BA; Monsan, P; Remaud-Simeon, M			Molecular basis of the amylose-like polymer formation catalyzed by Neisseria polysaccharea amylosucrase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE GENOME SEQUENCE; ACTIVE-SITE; GLYCOGEN; SUCROSE; OLIGOSACCHARIDE; MECHANISM; ENZYME; ACID	Amylosucrase from Neisseria polysaccharea is a remarkable transglucosidase from family 13 of the glycosidehydrolases that synthesizes an insoluble amylose-like polymer from sucrose in the absence of any primer. Amylosucrase shares strong structural similarities with alpha-amylases. Exactly how this enzyme catalyzes the formation of alpha-1,4-glucan and which structural features are involved in this unique functionality existing in family 13 are important questions still not fully answered. Here, we provide evidence that amylosucrase initializes polymer formation by releasing, through sucrose hydrolysis, a glucose molecule that is subsequently used as the first acceptor molecule. Maltooligosaccharides of increasing size were produced and successively elongated at their nonreducing ends until they reached a critical size and concentration, causing precipitation. The ability of amylosucrase to bind and to elongate maltooligosaccharides is notably due to the presence of key residues at the OB1 acceptor binding site that contribute strongly to the guidance ( Arg(415), subsite +4) and the correct positioning (Asp(394) and Arg(446), subsite +1) of acceptor molecules. On the other hand, Arg(226) (subsites +2/+3) limits the binding of maltooligosaccharides, resulting in the accumulation of small products (G to G3) in the medium. A remarkable mutant (R226A), activated by the products it forms, was generated. It yields twice as much insoluble glucan as the wild-type enzyme and leads to the production of lower quantities of by-products.	Inst Natl Sci Appl, Ctr Bioingn Gilbert Durand, CNRS, UMR 5504,INRA,UMR 792, F-31077 Toulouse 4, France; Danish Univ Pharmaceut Sci, Dept Med Chem, DK-2100 Copenhagen, Denmark; Univ Liege, Inst Chem B6, Biochem Lab, B-4000 Liege, Belgium; INRA, UPCM, F-44316 Nantes 03, France	Centre National de la Recherche Scientifique (CNRS); CNRS - Institute for Engineering & Systems Sciences (INSIS); INRAE; Universite de Toulouse; Universite Federale Toulouse Midi-Pyrenees (ComUE); Institut National des Sciences Appliquees de Toulouse; University of Copenhagen; University of Liege; INRAE	Remaud-Simeon, M (corresponding author), Inst Natl Sci Appl, Ctr Bioingn Gilbert Durand, CNRS, UMR 5504,INRA,UMR 792, F-31077 Toulouse 4, France.	remaud@insa-tlse.fr	Veronese, Gabrielle/GTF-3473-2022	Gajhede, Michael/0000-0001-9864-2287; ALBENNE, Cecile/0000-0001-9856-9745; Mirza, Osman Asghar/0000-0001-9435-0690				Albenne C, 2002, FEBS LETT, V527, P67, DOI 10.1016/S0014-5793(02)03168-X; Albenne C, 2002, BIOLOGIA, V57, P119; Becker M, 2002, BIOTECHNOL PROGR, V18, P964, DOI 10.1021/bp020013b; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; da Silva ACR, 2002, NATURE, V417, P459, DOI 10.1038/417459a; DAVIES G, 1995, STRUCTURE, V3, P853, DOI 10.1016/S0969-2126(01)00220-9; Davies GJ, 1997, BIOCHEM J, V321, P557, DOI 10.1042/bj3210557; de Montalk GP, 2000, FEMS MICROBIOL LETT, V186, P103; de Montalk GP, 2000, FEBS LETT, V471, P219, DOI 10.1016/S0014-5793(00)01406-X; De Montalk GP, 1999, J BACTERIOL, V181, P375; Glockner FO, 2003, P NATL ACAD SCI USA, V100, P8298, DOI 10.1073/pnas.1431443100; HEHRE EJ, 1949, J BIOL CHEM, V177, P267; KOSHLAND DE, 1953, BIOL REV, V28, P416, DOI 10.1111/j.1469-185X.1953.tb01386.x; MacGregor EA, 1996, FEBS LETT, V378, P263, DOI 10.1016/0014-5793(95)01428-4; MACKENZIE CR, 1978, CAN J MICROBIOL, V24, P357, DOI 10.1139/m78-060; Mirza O, 2001, BIOCHEMISTRY-US, V40, P9032, DOI 10.1021/bi010706l; MOOSER G, 1991, J BIOL CHEM, V266, P8916; Mooser G., 1992, ENZYMES, P187; Nierman WC, 2001, P NATL ACAD SCI USA, V98, P4136, DOI 10.1073/pnas.061029298; PREISS J, 1973, ANN NY ACAD SCI, V210, P265, DOI 10.1111/j.1749-6632.1973.tb47578.x; Remaud-Simeon M, 2000, J MOL CATAL B-ENZYM, V10, P117, DOI 10.1016/S1381-1177(00)00119-3; RIOU JY, 1983, ANN INST PASTEUR MIC, VB134, P257, DOI 10.1016/S0769-2609(83)80038-6; ROBYT JF, 1974, ARCH BIOCHEM BIOPHYS, V165, P634, DOI 10.1016/0003-9861(74)90291-4; Sarcabal P, 2000, FEBS LETT, V474, P33, DOI 10.1016/S0014-5793(00)01567-2; Skov LK, 2002, J BIOL CHEM, V277, P47741, DOI 10.1074/jbc.M207860200; Skov LK, 2001, J BIOL CHEM, V276, P25273, DOI 10.1074/jbc.M010998200; SVENSSON B, 1994, PLANT MOL BIOL, V25, P141, DOI 10.1007/BF00023233; Uitdehaag JCM, 1999, NAT STRUCT BIOL, V6, P432, DOI 10.1038/8235; White O, 1999, SCIENCE, V286, P1571, DOI 10.1126/science.286.5444.1571	29	87	94	1	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 2	2004	279	1					726	734		10.1074/jbc.M309891200	http://dx.doi.org/10.1074/jbc.M309891200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	757GU	14570882	Green Published, hybrid			2022-12-27	WOS:000187555300087
J	Deval, J; White, KL; Miller, MD; Parkin, NT; Courcambeck, J; Halfon, P; Selmi, B; Boretto, J; Canard, B				Deval, J; White, KL; Miller, MD; Parkin, NT; Courcambeck, J; Halfon, P; Selmi, B; Boretto, J; Canard, B			Mechanistic basis for reduced viral and enzymatic fitness of HIV-1 reverse transcriptase containing both K65R and M184V mutations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; ANTIRETROVIRAL-EXPERIENCED PATIENTS; REPLICATION CAPACITY; PRIMER UNBLOCKING; DRUG-RESISTANCE; DNA-SYNTHESIS; TENOFOVIR DF; LAMIVUDINE; NUCLEOTIDE; THERAPY	HIV-1 drug resistance mutations are often inversely correlated with viral fitness, which remains poorly described at the molecular level. Some resistance mutations can also suppress resistance caused by other resistance mutations. We report the molecular mechanisms by which a virus resistant to lamivudine with the M184V reverse transcriptase mutation shows increased susceptibility to tenofovir and can suppress the effects of the tenofovir resistance mutation K65R. Additionally, we report how the decreased viral replication capacity of resistant viruses is directly linked to their decreased ability to use natural nucleotide substrates and that combination of the K65R and M184V resistance mutations leads to greater decreases in viral replication capacity. All together, these results define at the molecular level how nucleoside-resistant viruses can be driven to reduced viral fitness.	CNRS, UMR 6098, F-13288 Marseille 09, France; Univ Aix Marseille 1, ESIL, F-13288 Marseille, France; Univ Aix Marseille 2, ESIL, F-13288 Marseille 09, France; Gilead Sci Inc, Foster City, CA 94404 USA; ViroLog Inc, San Francisco, CA USA; Genosci, Marseille, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; Gilead Sciences	Canard, B (corresponding author), CNRS, UMR 6098, Campus Luminy, F-13288 Marseille 09, France.		Parkin, Neil/P-2724-2019	Canard, Bruno/0000-0003-4924-1991				Arion D, 1998, BIOCHEMISTRY-US, V37, P15908, DOI 10.1021/bi981200e; Back NKT, 1996, EMBO J, V15, P4040, DOI 10.1002/j.1460-2075.1996.tb00777.x; Berkhout B, 1999, DRUG RESIST UPDATE, V2, P69, DOI 10.1054/drup.1998.0067; Boretto J, 2001, ANAL BIOCHEM, V292, P139, DOI 10.1006/abio.2001.5045; Boyer PL, 2002, J VIROL, V76, P3248, DOI 10.1128/JVI.76.7.3248-3256.2002; De Clercq E, 2001, J CLIN VIROL, V22, P73, DOI 10.1016/S1386-6532(01)00167-6; Deeks SG, 2001, NEW ENGL J MED, V344, P472, DOI 10.1056/NEJM200102153440702; Deval J, 2002, J BIOL CHEM, V277, P42097, DOI 10.1074/jbc.M206725200; Diallo K, 2003, J VIROL, V77, P8621, DOI 10.1128/JVI.77.16.8621-8632.2003; Essink BBO, 1997, NUCLEIC ACIDS RES, V25, P3212, DOI 10.1093/nar/25.16.3212; Feng JY, 1999, BIOCHEMISTRY-US, V38, P9440, DOI 10.1021/bi990709m; Frost SDW, 2000, J VIROL, V74, P6262, DOI 10.1128/JVI.74.14.6262-6268.2000; GAO WY, 1993, P NATL ACAD SCI USA, V90, P8925, DOI 10.1073/pnas.90.19.8925; GAO WY, 1994, J BIOL CHEM, V269, P12633; Garcia-Lerma JG, 2000, J VIROL, V74, P9339, DOI 10.1128/JVI.74.20.9339-9346.2000; Gotte M, 2000, J VIROL, V74, P3579, DOI 10.1128/JVI.74.8.3579-3585.2000; GU ZX, 1994, ANTIMICROB AGENTS CH, V38, P275, DOI 10.1128/AAC.38.2.275; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; Krebs R, 1997, BIOCHEMISTRY-US, V36, P10292, DOI 10.1021/bi970512z; LARDER B, 1992, REVERSE TRANSCRIPTAS, P205; Maeda Y, 1998, J INFECT DIS, V177, P1207, DOI 10.1086/515282; Margot NA, 2002, AIDS, V16, P1227, DOI 10.1097/00002030-200206140-00004; MCCOLL D, 2002, 6 INT C DRUG THER HI; Menendez-Arias L, 2002, TRENDS PHARMACOL SCI, V23, P381, DOI 10.1016/S0165-6147(02)02054-0; Meyer PR, 2003, J VIROL, V77, P3871, DOI 10.1128/JVI.77.6.3871-3877.2003; Meyer PR, 1999, MOL CELL, V4, P35, DOI 10.1016/S1097-2765(00)80185-9; MILLER MD, 2002, 6 INT C DRUG THER HI; Miller V, 1998, J INFECT DIS, V177, P1521, DOI 10.1086/515304; Miller V, 2001, ANTIVIR THER, V6, P25; PARIKH U, 2003, ANTIVIR THER, pS152; PEPE G, 1985, J THEOR BIOL, V115, P571, DOI 10.1016/S0022-5193(85)80141-7; Pepe G, 2002, EUR J MED CHEM, V37, P865, DOI 10.1016/S0223-5234(02)01371-5; PEPE G, 1990, STUD PHYS THEO CHEM, V71, P93; Petrella Marco, 2002, AIDS Reviews, V4, P224; Petropoulos CJ, 2000, ANTIMICROB AGENTS CH, V44, P920, DOI 10.1128/AAC.44.4.920-928.2000; Quinones-Mateu ME, 2002, DRUG RESIST UPDATE, V5, P224, DOI 10.1016/S1368-7646(02)00123-1; Roy B, 1999, ANAL BIOCHEM, V269, P403, DOI 10.1006/abio.1999.4051; Sarafianos SG, 1999, P NATL ACAD SCI USA, V96, P10027, DOI 10.1073/pnas.96.18.10027; Schinazi R.F., 2000, INT ANTIVIRAL NEWS, V8, P65; Schooley RT, 2002, AIDS, V16, P1257, DOI 10.1097/00002030-200206140-00008; Selmi B, 2003, ANTIVIR THER, V8, P143; Selmi B, 2001, J BIOL CHEM, V276, P48466, DOI 10.1074/jbc.M107003200; Sharma PL, 1999, J VIROL, V73, P8448, DOI 10.1128/JVI.73.10.8448-8456.1999; Sufka SA, 2003, J INFECT DIS, V187, P1027, DOI 10.1086/368359; TERAI C, 1991, EXP CELL RES, V193, P375, DOI 10.1016/0014-4827(91)90110-G; Wainberg MA, 1999, ANTIVIR THER, V4, P87; White KL, 2002, ANTIMICROB AGENTS CH, V46, P3437, DOI 10.1128/AAC.46.11.3437-3446.2002; ZHANG D, 1994, ANTIMICROB AGENTS CH, V38, P282, DOI 10.1128/AAC.38.2.282	48	128	135	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	2004	279	1					509	516		10.1074/jbc.M308806200	http://dx.doi.org/10.1074/jbc.M308806200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	757GU	14551187	hybrid			2022-12-27	WOS:000187555300061
J	Mata, NL; Moghrabi, WN; Lee, JS; Bui, TV; Radu, RA; Horwitz, J; Travis, GH				Mata, NL; Moghrabi, WN; Lee, JS; Bui, TV; Radu, RA; Horwitz, J; Travis, GH			Rpe65 is a retinyl ester binding protein that presents insoluble substrate to the isomerase in retinal pigment epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLY(ETHYLENE GLYCOL)-MEDIATED FUSION; VITAMIN-A; VISUAL CYCLE; UNILAMELLAR VESICLES; RPE65-DEFICIENT MICE; MEMBRANE-RECEPTOR; BETA-CAROTENE; IDENTIFICATION; RETINOIDS; EYE	Photon capture by a rhodopsin pigment molecule induces 11-cis to all-trans isomerization of its retinaldehyde chromophore. To restore light sensitivity, the all-trans-retinaldehyde must be chemically re-isomerized by an enzyme pathway called the visual cycle. Rpe65, an abundant protein in retinal pigment epithelial (RPE) cells and a homolog of beta-carotene dioxygenase, appears to play a role in this pathway. Rpe65(-/-) knockout mice massively accumulate all-trans-retinyl esters but lack 11-cis-retinoids and rhodopsin visual pigment in their retinas. Mutations in the human RPE65 gene cause a severe recessive blinding disease called Leber's congenital amaurosis. The function of Rpe65, however, is unknown. Here we show that Rpe65 specifically binds all-trans-retinyl palmitate but not 11-cis-retinyl palmitate by a spectral-shift assay, by co-elution during gel filtration, and by co-immunoprecipitation. Using a novel fluorescent resonance energy transfer ( FRET) binding assay in liposomes, we demonstrate that Rpe65 extracts all-trans-retinyl esters from phospholipid membranes. Assays of isomerase activity reveal that Rpe65 strongly stimulates the enzymatic conversion of all-trans-retinyl palmitate to 11-cis-retinol in microsomes from bovine RPE cells. Moreover, we show that addition of Rpe65 to membranes from rpe65(-/-) mice, which possess no detectable isomerase activity, restores isomerase activity to wild-type levels. Rpe65 by itself, however, has no intrinsic isomerase activity. These observations suggest that Rpe65 presents retinyl esters as substrate to the isomerase for synthesis of visual chromophore. This proposed function explains the phenotype in mice and humans lacking Rpe65.	Univ Calif Los Angeles, Sch Med, Jules Stein Eye Inst, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Travis, GH (corresponding author), Univ Calif Los Angeles, Sch Med, Jules Stein Eye Inst, 100 Stein Plaza Rm BH-667, Los Angeles, CA 90095 USA.		Radu, Roxana A./K-8924-2019; Travis, Gabriel Harvey/AIF-1062-2022	Travis, Gabriel Harvey/0000-0003-4020-9493; Radu, Roxana/0000-0002-5064-6403				BAVIK CO, 1991, J BIOL CHEM, V266, P14978; BAVIK CO, 1992, J BIOL CHEM, V267, P23035; BERNSTEIN PS, 1986, BIOCHEMISTRY-US, V25, P6473, DOI 10.1021/bi00369a020; Bhattacharya SK, 2002, FASEB J, V16, pA14; BOK D, 1984, INVEST OPHTH VIS SCI, V25, P877; BRIDGES CDB, 1976, EXP EYE RES, V22, P435, DOI 10.1016/0014-4835(76)90182-2; BRIDGES CDB, 1982, METHOD ENZYMOL, V81, P463; Crabb JW, 1998, PROTEIN SCI, V7, P746, DOI 10.1002/pro.5560070324; DEIGNER PS, 1989, SCIENCE, V244, P968, DOI 10.1126/science.2727688; Ekesten B, 2001, VISION RES, V41, P2425, DOI 10.1016/S0042-6989(01)00140-7; Evans KO, 2002, BIOCHEMISTRY-US, V41, P1241, DOI 10.1021/bi011508x; FUTTERMAN S, 1964, J BIOL CHEM, V239, P81; Garwin GG, 2000, METHOD ENZYMOL, V316, P313; Gollapalli DR, 2003, BIOCHEMISTRY-US, V42, P5809, DOI 10.1021/bi0341004; Grimm C, 2000, NAT GENET, V25, P63, DOI 10.1038/75614; Gu SM, 1997, NAT GENET, V17, P194, DOI 10.1038/ng1097-194; Haque ME, 2001, BIOCHEMISTRY-US, V40, P14243, DOI 10.1021/bi011308l; Haque ME, 2001, BIOCHEMISTRY-US, V40, P4340, DOI 10.1021/bi002030k; HO MTP, 1989, J BIOL CHEM, V264, P17759; Jahng WJ, 2003, BIOCHEMISTRY-US, V42, P6159, DOI 10.1021/bi034002i; LENTZ BR, 1987, BIOCHEMISTRY-US, V26, P5389, DOI 10.1021/bi00391a026; LEVY D, 1990, BIOCHIM BIOPHYS ACTA, V1025, P179, DOI 10.1016/0005-2736(90)90096-7; Ma JX, 1998, BBA-GENE STRUCT EXPR, V1443, P255, DOI 10.1016/S0167-4781(98)00221-8; Malinin VS, 2001, BIOCHEMISTRY-US, V40, P8292, DOI 10.1021/bi010570r; Marlhens F, 1997, NAT GENET, V17, P139, DOI 10.1038/ng1097-139; Mata NL, 2002, NEURON, V36, P69, DOI 10.1016/S0896-6273(02)00912-1; MAYER LD, 1986, BIOCHIM BIOPHYS ACTA, V858, P161, DOI 10.1016/0005-2736(86)90302-0; Menon AK, 2000, CURR BIOL, V10, P241, DOI 10.1016/S0960-9822(00)00356-0; Moiseyev G, 2003, BIOCHEMISTRY-US, V42, P2229, DOI 10.1021/bi026911y; Narfstrom K, 2003, INVEST OPHTH VIS SCI, V44, P1663, DOI 10.1167/iovs.02-0595; Newcomer ME, 2000, BBA-PROTEIN STRUCT M, V1482, P57, DOI 10.1016/S0167-4838(00)00150-3; NICOTRA CMA, 1994, MOL CELL BIOCHEM, V132, P45, DOI 10.1007/BF00925674; POOLE RK, 1987, SPECTROPHOTOMETRY SP, P23; Qtaishat NM, 2003, INVEST OPHTH VIS SCI, V44, P1435, DOI 10.1167/iovs.02-0679; RANDO RR, 1982, BIOCHEM BIOPH RES CO, V104, P430, DOI 10.1016/0006-291X(82)90655-6; RANDO RR, 1983, J AM CHEM SOC, V105, P2879, DOI 10.1021/ja00347a058; Redmond TM, 1998, NAT GENET, V20, P344, DOI 10.1038/3813; REDMOND TM, 1985, BIOCHEMISTRY-US, V24, P787, DOI 10.1021/bi00324a038; Redmond TM, 2001, J BIOL CHEM, V276, P6560, DOI 10.1074/jbc.M009030200; RODRIGUEZ KA, 1989, AM J PHYSIOL, V256, pR255, DOI 10.1152/ajpregu.1989.256.1.R255; Ruiz A, 1999, J BIOL CHEM, V274, P3834, DOI 10.1074/jbc.274.6.3834; SAARI JC, 1987, J BIOL CHEM, V262, P7618; Simon A, 1999, J CELL SCI, V112, P549; Thomas RM, 2002, BIOCHEMISTRY-US, V41, P1591, DOI 10.1021/bi011555p; TREHAN A, 1990, BIOCHEMISTRY-US, V29, P309, DOI 10.1021/bi00454a001; Tsilou E, 1997, ARCH BIOCHEM BIOPHYS, V346, P21, DOI 10.1006/abbi.1997.0276; Van Hooser JP, 2000, P NATL ACAD SCI USA, V97, P8623, DOI 10.1073/pnas.150236297; von Lintig J, 2000, J BIOL CHEM, V275, P11915, DOI 10.1074/jbc.275.16.11915; Yan WM, 2001, GENOMICS, V72, P193, DOI 10.1006/geno.2000.6476; Znoiko SL, 2002, INVEST OPHTH VIS SCI, V43, P1604	50	103	106	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	2004	279	1					635	643		10.1074/jbc.M310042200	http://dx.doi.org/10.1074/jbc.M310042200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	757GU	14532273	hybrid			2022-12-27	WOS:000187555300077
J	Walchli, S; Espanel, X; Harrenga, A; Rossi, M; Cesareni, G; van Huijsduijnen, RH				Walchli, S; Espanel, X; Harrenga, A; Rossi, M; Cesareni, G; van Huijsduijnen, RH			Probing protein-tyrosine phosphatase substrate specificity using a phosphotyrosine-containing phage library	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDE LIBRARIES; INSULIN-RECEPTOR; TRAPPING MUTANTS; STRUCTURAL BASIS; PTP-PEST; 1B; INHIBITOR; IDENTIFICATION; GENE; DEPHOSPHORYLATION	Protein tyrosine phosphatases (PTPs) play important, highly dynamic roles in signaling. Currently about 90 different PTP genes have been described. The enzymes are highly regulated at all levels of expression, and it is becoming increasingly clear that substrate specificity of the PTP catalytic domains proper contributes considerably to PTP functionality. To investigate PTP substrate selectivity, we have set up a procedure to generate phage libraries that presents randomized, phosphotyrosine-containing peptides. Phages that expressed suitable substrates were selected by immobilized, substrate-trapping GST-PTP fusion proteins. After multiple rounds of selection, positive clones were confirmed by SPOT analysis, dephosphorylation by wild-type enzyme, and K-m determinations. We have identified distinct consensus substrate motifs for PTP1B, Sap-1, PTP-beta, SHP1, and SHP2. Our results confirm substrate specificity for individual PTPs at the peptide level. Such consensus sequences may be useful both for identifying potential PTP substrates and for the development of peptidomimetic inhibitors.	Serono Pharmaceut Res Inst, CH-1228 Geneva, Switzerland		van Huijsduijnen, RH (corresponding author), Serono Pharmaceut Res Inst, CH-1228 Geneva, Switzerland.		Rossi, Mario/E-7666-2012; Hooft van Huijsduijnen, Rob/B-3653-2009	Rossi, Mario/0000-0001-6349-8895; Walchli, Sebastien/0000-0001-5869-1746; Hooft van Huijsduijnen, Rob/0000-0002-2261-9424				Andersen JN, 2001, MOL CELL BIOL, V21, P7117, DOI 10.1128/MCB.21.21.7117-7136.2001; Asante-Appiah E, 2001, J BIOL CHEM, V276, P26036, DOI 10.1074/jbc.M011697200; Burshtyn DN, 1997, J BIOL CHEM, V272, P13066, DOI 10.1074/jbc.272.20.13066; Cheng A, 2002, DEV CELL, V2, P497, DOI 10.1016/S1534-5807(02)00149-1; Cochrane D, 2000, J MOL BIOL, V297, P89, DOI 10.1006/jmbi.2000.3561; Cote JF, 1998, BIOCHEMISTRY-US, V37, P13128, DOI 10.1021/bi981259l; Deng SJ, 2001, COMB CHEM HIGH T SCR, V4, P525; Dente L, 1997, J MOL BIOL, V269, P694, DOI 10.1006/jmbi.1997.1073; Elchebly M, 1999, SCIENCE, V283, P1544, DOI 10.1126/science.283.5407.1544; Espanel X, 2003, J BIOL CHEM, V278, P15162, DOI 10.1074/jbc.M211887200; Espanel X, 2002, PROTEIN SCI, V11, P2326, DOI 10.1110/ps.0213402; Espanel X, 2001, ENDOCRINE, V15, P19, DOI 10.1385/ENDO:15:1:019; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; Garton AJ, 1996, MOL CELL BIOL, V16, P6408; Goldstein BJ, 1998, MOL CELL BIOCHEM, V182, P91, DOI 10.1023/A:1006812218502; Hooft van Huijsduijnen Rob, 2002, Expert Opin Ther Targets, V6, P637; Huyer G, 1998, ANAL BIOCHEM, V258, P19, DOI 10.1006/abio.1997.2541; KAY BK, 1996, PHAGE DISPLAY PEPTID, P1; Klaman LD, 2000, MOL CELL BIOL, V20, P5479, DOI 10.1128/MCB.20.15.5479-5489.2000; Kole HK, 1996, J BIOL CHEM, V271, P14302, DOI 10.1074/jbc.271.24.14302; Morinville A, 1998, TRENDS PHARMACOL SCI, V19, P452, DOI 10.1016/S0165-6147(98)01257-7; Myers MP, 2001, J BIOL CHEM, V276, P47771, DOI 10.1074/jbc.C100583200; Pellegrini MC, 1998, BIOCHEMISTRY-US, V37, P15598, DOI 10.1021/bi981427+; Persson C, 2002, FEBS LETT, V517, P27, DOI 10.1016/S0014-5793(02)02570-X; Salmeen A, 2000, MOL CELL, V6, P1401, DOI 10.1016/S1097-2765(00)00137-4; Sarmiento M, 2000, BIOCHEMISTRY-US, V39, P8171, DOI 10.1021/bi000319w; Schmitz R, 1996, J MOL BIOL, V260, P664, DOI 10.1006/jmbi.1996.0429; Sun JP, 2003, J BIOL CHEM, V278, P12406, DOI 10.1074/jbc.M212491200; van Huijsduijnen RH, 1998, GENE, V225, P1; van Huijsduijnen RH, 2002, DRUG DISCOV TODAY, V7, P1013, DOI 10.1016/S1359-6446(02)02438-8; Vetter SW, 2000, J BIOL CHEM, V275, P2265, DOI 10.1074/jbc.275.4.2265; Walchli S, 2000, GENE, V253, P137, DOI 10.1016/S0378-1119(00)00275-4; Walchli S, 2000, J BIOL CHEM, V275, P9792, DOI 10.1074/jbc.275.13.9792; Yang J, 2000, J BIOL CHEM, V275, P4066, DOI 10.1074/jbc.275.6.4066; Zabolotny JM, 2002, DEV CELL, V2, P489, DOI 10.1016/S1534-5807(02)00148-X; Zhang YL, 2000, J BIOL CHEM, V275, P34205, DOI 10.1074/jbc.M004490200; ZHANG ZY, 1993, ANAL BIOCHEM, V211, P7, DOI 10.1006/abio.1993.1224; Zhang ZY, 2001, CURR OPIN CHEM BIOL, V5, P416, DOI 10.1016/S1367-5931(00)00223-4; Zhang ZY, 2002, ANNU REV PHARMACOL, V42, P209, DOI 10.1146/annurev.pharmtox.42.083001.144616	39	38	40	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	2004	279	1					311	318		10.1074/jbc.M307617200	http://dx.doi.org/10.1074/jbc.M307617200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	757GU	14578355	hybrid			2022-12-27	WOS:000187555300038
J	Mandal, D; Baudin-Creuza, V; Bhattacharyya, A; Pathak, S; Delaunay, J; Kundu, M; Basu, J				Mandal, D; Baudin-Creuza, V; Bhattacharyya, A; Pathak, S; Delaunay, J; Kundu, M; Basu, J			Caspase 3-mediated proteolysis of the N-terminal cytoplasmic domain of the human erythroid anion exchanger 1 (band 3)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RED-BLOOD-CELLS; MEMBRANE PROTEIN; PHOSPHATIDYLSERINE EXTERNALIZATION; 3-ANKYRIN INTERACTION; BIOCHEMICAL PATHWAYS; ICE/CED-3 PROTEASE; MEDIATED CLEAVAGE; PLASMA-MEMBRANE; APOPTOSIS; ASSOCIATION	The N-terminal cytoplasmic domain of the anion exchanger 1 (AE1 or band 3) of the human erythrocyte associates with peripheral membrane proteins to regulate membrane-cytoskeleton interactions, with glycolytic enzymes such as glyceraldehyde-3-phosphate dehydrogenase and aldolase, with the protein-tyrosine kinase p72(syk), with hemoglobin and with hemichromes. We have demonstrated that the N-terminal cytoplasmic domain of band 3 (CDB3) is a substrate of the apoptosis executioner caspase 3 (1). CDB3 has two non-conventional caspase 3 cleavage sites, TATD(45) and EQGD(205) (2). In vitro treatment of recombinant CDB3 with caspase 3 generated two fragments, which could be blocked by pretreatment with the caspase 3 inhibitor Z-DEVD-fmk (3). Recombinant CDB3 in which the caspase 3 cleavage sites Asp(45) and Asp(205) were mutated, was resistant to proteolysis (4). Proteolytically derived fragments cross-reactive with polyclonal anti-band 3 antibody appeared with simultaneous cleavage of poly (ADP-ribose) polymerase and procaspase 3 in staurosporine (STS)-treated HEK293 cells transiently transfected with CDB3 (5). In vivo cleavage of CDB3 could be blocked by pretreatment of cells with Z-DEVD-fmk or in cells transfected with mutant CDB3 (D45A, D205A) (6). Co-transfection experiments showed that STS-mediated cleavage of CDB3 diminished its interaction with the N-terminal domain of protein 4.2, confirming that such cleavage interferes with the interaction of CDB3 with cytoskeletal proteins (7). Active caspase 3 was observed in aged red cells but not in young cells. This red cell caspase 3 could cleave band 3 present in inside-out vesicles prepared from young erythrocytes arguing in favor of a physiological role of caspase 3 in aged erythrocytes.	Bose Inst, Dept Chem, Kolkata 700009, W Bengal, India; INSERM, U473, F-94276 Le Kremlin Bicetre, France	Department of Science & Technology (India); Bose Institute; Institut National de la Sante et de la Recherche Medicale (Inserm)	Basu, J (corresponding author), Bose Inst, Dept Chem, 93-1 Acharya,Prafalla Chandra Rd, Kolkata 700009, W Bengal, India.	joyoti@vsnl.com	Bhattacharyya, Asima/J-7423-2012; mandal, debabrata/AAF-6690-2019; BAUDIN-CREUZA, Véronique/K-7309-2017; PATHAK, SHRESH/I-6938-2012	Bhattacharyya, Asima/0000-0001-7292-6644; BAUDIN-CREUZA, Véronique/0000-0003-1032-3236; PATHAK, SHRESH/0000-0001-5275-1816				Affar EB, 2001, J BIOL CHEM, V276, P2935, DOI 10.1074/jbc.M007269200; An XL, 1996, J BIOL CHEM, V271, P33187, DOI 10.1074/jbc.271.52.33187; APPELL KC, 1981, J BIOL CHEM, V256, P1104; BENNETT V, 1980, J BIOL CHEM, V255, P6424; BENNETT V, 1983, METHOD ENZYMOL, V96, P313; Berg CP, 2001, CELL DEATH DIFFER, V8, P1197, DOI 10.1038/sj.cdd.4400905; Bhattacharyya R, 1999, BIOCHEM J, V340, P505, DOI 10.1042/0264-6021:3400505; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Casey JR, 1998, BIOCHEM CELL BIOL, V76, P709, DOI 10.1139/bcb-76-5-709; Chang HY, 2000, MICROBIOL MOL BIOL R, V64, P821, DOI 10.1128/MMBR.64.4.821-846.2000; COHEN CM, 1993, SEMIN HEMATOL, V30, P119; Corsi D, 1999, EUR J BIOCHEM, V261, P775, DOI 10.1046/j.1432-1327.1999.00336.x; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Fadok VA, 2001, CELL DEATH DIFFER, V8, P582, DOI 10.1038/sj.cdd.4400856; Flygare J, 2000, EUR J BIOCHEM, V267, P5977, DOI 10.1046/j.1432-1327.2000.01675.x; Golan DE, 1996, BIOPHYS J, V70, P1534, DOI 10.1016/S0006-3495(96)79717-5; HARRISON ML, 1994, J BIOL CHEM, V269, P955; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Houde C, 2003, J BIOL CHEM, V278, P16929, DOI 10.1074/jbc.M301842200; JACOBSON MD, 1994, EMBO J, V13, P1899, DOI 10.1002/j.1460-2075.1994.tb06459.x; JENKINS JD, 1984, J BIOL CHEM, V259, P9374; KORSGREN C, 1986, J BIOL CHEM, V261, P5536; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; Lee A, 2001, J BIOL CHEM, V276, P20735, DOI 10.1074/jbc.M009723200; LOW PS, 1986, BIOCHIM BIOPHYS ACTA, V864, P145, DOI 10.1016/0304-4157(86)90009-2; LOW PS, 1991, BLOOD, V77, P1581; LUTZ HU, 1992, BIOCHIM BIOPHYS ACTA, V1116, P1, DOI 10.1016/0304-4165(92)90120-J; LUTZ HU, 1979, J BIOL CHEM, V254, P1177; Mandal D, 2002, FEBS LETT, V513, P184, DOI 10.1016/S0014-5793(02)02294-9; Martin SJ, 1996, J BIOL CHEM, V271, P28753, DOI 10.1074/jbc.271.46.28753; MURTHY SNP, 1981, J BIOL CHEM, V256, P1203; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Paszty K, 2002, J BIOL CHEM, V277, P6822, DOI 10.1074/jbc.M109548200; ROGALSKI AA, 1989, J BIOL CHEM, V264, P6438; RYBICKI AC, 1993, BLOOD, V81, P2155; SALHANY JM, 1989, J BIOL CHEM, V264, P1399; Samejima K, 1999, J BIOL CHEM, V274, P4335, DOI 10.1074/jbc.274.7.4335; SCHULZEOSTHOFF K, 1994, J CELL BIOL, V127, P15, DOI 10.1083/jcb.127.1.15; Stennicke HR, 2000, BIOCHEM J, V350, P563, DOI 10.1042/0264-6021:3500563; Stroh C, 1998, CELL DEATH DIFFER, V5, P997, DOI 10.1038/sj.cdd.4400451; Takahashi A, 1996, P NATL ACAD SCI USA, V93, P8395, DOI 10.1073/pnas.93.16.8395; WALDER JA, 1984, J BIOL CHEM, V259, P238; Wang KKW, 1998, J BIOL CHEM, V273, P22490, DOI 10.1074/jbc.273.35.22490; WAUGH SM, 1985, BIOCHEMISTRY-US, V24, P34, DOI 10.1021/bi00322a006; Wolf BB, 1999, J BIOL CHEM, V274, P20049, DOI 10.1074/jbc.274.29.20049; Zhang DC, 2000, BLOOD, V96, P2925; Zhivotovsky B, 1997, BIOCHEM BIOPH RES CO, V230, P481, DOI 10.1006/bbrc.1996.6016	49	96	110	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52551	52558		10.1074/jbc.M306914200	http://dx.doi.org/10.1074/jbc.M306914200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14570914	hybrid			2022-12-27	WOS:000187480700072
J	O'Neil, RH; Lilien, RH; Donald, BR; Stroud, RM; Anderson, AC				O'Neil, RH; Lilien, RH; Donald, BR; Stroud, RM; Anderson, AC			Phylogenetic classification of protozoa based on the structure of the linker domain in the bifunctional enzyme, dihydrofolate reductase-thymidylate synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; ANTIFOLATE RESISTANCE; TERNARY COMPLEX; EUKARYOTES; REVEALS; TOMUDEX; BINDING; GENE	We have determined the crystal structure of dihydrofolate reductase-thymidylate synthase (DHFR-TS) from Cryptosporidium hominis, revealing a unique linker domain containing an 11-residue alpha-helix that has extensive interactions with the opposite DHFR-TS monomer of the homodimeric enzyme. Analysis of the structure of DHFR-TS from C. hominis and of previously solved structures of DHFR-TS from Plasmodium falciparum and Leishmania major reveals that the linker domain primarily controls the relative orientation of the DHFR and TS domains. Using the tertiary structure of the linker domains, we have been able to place a number of protozoa in two distinct and dissimilar structural families corresponding to two evolutionary families and provide the first structural evidence validating the use of DHFR-TS as a tool of phylogenetic classification. Furthermore, the structure of C. hominis DHFR-TS calls into question surface electrostatic channeling as the universal means of dihydrofolate transport between TS and DHFR in the bifunctional enzyme.	Dartmouth Coll, Dept Chem, Burke Labs, Hanover, NH 03755 USA; Dartmouth Coll, Dept Comp Sci, Hanover, NH 03755 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA	Dartmouth College; Dartmouth College; University of California System; University of California San Francisco	Anderson, AC (corresponding author), Dartmouth Coll, Dept Chem, Burke Labs, 6128, Hanover, NH 03755 USA.	Amy.C.Anderson@Dartmouth.edu			NCI NIH HHS [CA63081] Funding Source: Medline; NIGMS NIH HHS [GM067542, GM65982] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA063081] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067542, R01GM065982] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agarwal PK, 2002, P NATL ACAD SCI USA, V99, P2794, DOI 10.1073/pnas.052005999; Almog R, 2001, PROTEIN SCI, V10, P988, DOI 10.1110/ps.47601; Anderson AC, 2001, CHEM BIOL, V8, P445, DOI 10.1016/S1074-5521(01)00023-0; Anderson AC, 2000, J MOL BIOL, V297, P645, DOI 10.1006/jmbi.2000.3544; Atreya CE, 2003, J BIOL CHEM, V278, P28901, DOI 10.1074/jbc.M212689200; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baldauf SL, 2000, SCIENCE, V290, P972, DOI 10.1126/science.290.5493.972; BOLIN JT, 1982, J BIOL CHEM, V257, P13650; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CARRERAS CW, 1995, ANNU REV BIOCHEM, V64, P721, DOI 10.1146/annurev.bi.64.070195.003445; CHAMPNESS JN, 1994, STRUCTURE, V2, P915, DOI 10.1016/S0969-2126(94)00093-X; CHEN JT, 1987, BIOCHEMISTRY-US, V26, P4093, DOI 10.1021/bi00387a053; Cody V, 1999, BIOCHEMISTRY-US, V38, P4303, DOI 10.1021/bi982728m; CODY V, 1992, ANTI-CANCER DRUG DES, V7, P483; Elcock AH, 1997, BIOCHEMISTRY-US, V36, P16049, DOI 10.1021/bi971709u; Elcock AH, 1996, J MOL BIOL, V262, P370, DOI 10.1006/jmbi.1996.0520; KNIGHTON DR, 1994, NAT STRUCT BIOL, V1, P186, DOI 10.1038/nsb0394-186; KNOLL AH, 1992, SCIENCE, V256, P622, DOI 10.1126/science.1585174; Li RB, 2000, J MOL BIOL, V295, P307, DOI 10.1006/jmbi.1999.3328; Liang PH, 1998, BIOCHEMISTRY-US, V37, P12195, DOI 10.1021/bi9803168; MONTFORT WR, 1990, BIOCHEMISTRY-US, V29, P6964, DOI 10.1021/bi00482a004; OEFNER C, 1988, EUR J BIOCHEM, V174, P377, DOI 10.1111/j.1432-1033.1988.tb14108.x; OTWINOWSKI Z, 1993, DENZO SCALEPACK; Sayre PH, 2001, J MOL BIOL, V313, P813, DOI 10.1006/jmbi.2001.5074; Sogin ML, 1997, CURR OPIN GENET DEV, V7, P792, DOI 10.1016/S0959-437X(97)80042-1; Sotelo-Mundo RR, 1999, BIOCHEMISTRY-US, V38, P1087, DOI 10.1021/bi981881d; Stechmann A, 2002, SCIENCE, V297, P89, DOI 10.1126/science.1071196; STROUD RM, 1994, NAT STRUCT BIOL, V1, P131, DOI 10.1038/nsb0394-131; Trujillo M, 1996, BIOCHEMISTRY-US, V35, P6366, DOI 10.1021/bi952923q; Van de Peer Y, 1997, J MOL EVOL, V45, P619, DOI 10.1007/PL00006266; Vasquez JR, 1996, MOL BIOCHEM PARASIT, V79, P153, DOI 10.1016/0166-6851(96)02647-3; Watney JB, 2003, J AM CHEM SOC, V125, P3745, DOI 10.1021/ja028487u; Yuvaniyama J, 2003, NAT STRUCT BIOL, V10, P357, DOI 10.1038/nsb921	33	60	62	0	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52980	52987		10.1074/jbc.M310328200	http://dx.doi.org/10.1074/jbc.M310328200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14555647	hybrid			2022-12-27	WOS:000187480700121
J	Chan, FKM; Shisler, J; Bixby, JG; Felices, M; Zheng, LX; Appel, M; Orenstein, J; Moss, B; Lenardo, MJ				Chan, FKM; Shisler, J; Bixby, JG; Felices, M; Zheng, LX; Appel, M; Orenstein, J; Moss, B; Lenardo, MJ			A role for tumor necrosis factor receptor-2 and receptor-interacting protein in programmed necrosis and antiviral responses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEATH DOMAIN KINASE; NF-KAPPA-B; CELL-DEATH; TNF RECEPTORS; FACTOR-ALPHA; RIP; APOPTOSIS; INNATE; REQUIREMENT; PATHWAY	Members of the tumor necrosis factor (TNF) receptor (TNFR) superfamily are potent regulators of apoptosis, a process that is important for the maintenance of immune homeostasis. Recent evidence suggests that TNFR-1 and Fas and TRAIL receptors can also trigger an alternative form of cell death that is morphologically distinct from apoptosis. Because distinct molecular components including the serine/threonine protein kinase receptor-interacting protein ( RIP) are required, we have referred to this alternative form of cell death as "programmed necrosis." We show that TNFR-2 signaling can potentiate programmed necrosis via TNFR-1. When cells were pre-stimulated through TNFR-2 prior to subsequent activation of TNFR-1, enhanced cell death and recruitment of RIP to the TNFR-1 complex were observed. However, TNF-induced programmed necrosis was normally inhibited by caspase-8 cleavage of RIP. To ascertain the physiological significance of RIP and programmed necrosis, we infected Jurkat cells with vaccinia virus (VV) and found that VV-infected cells underwent programmed necrosis in response to TNF, but deficiency of RIP rescued the infected cells from TNF-induced cytotoxicity. Moreover, TNFR-2(-/-) mice exhibited reduced inflammation in the liver and defective viral clearance during VV infection. Interestingly, death effector domain-containing proteins such as MC159, E8, K13, and cellular FLIP, but not the apoptosis inhibitors Bcl-x(L), p35, and XIAP, potently suppressed programmed necrosis. Thus, TNF-induced programmed necrosis is facilitated by TNFR-2 signaling and caspase inhibition and may play a role in controlling viral infection.	Univ Massachusetts, Sch Med, Dept Pathol, Worcester, MA 01655 USA; NIAID, Immunol Lab, NIH, Bethesda, MD 20892 USA; NIAID, Viral Dis Lab, NIH, Bethesda, MD 20892 USA; Univ Massachusetts, Sch Med, Div Diabet, Worcester, MA 01655 USA; George Washington Univ, Dept Pathol, Washington, DC 20037 USA	University of Massachusetts System; University of Massachusetts Worcester; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Massachusetts System; University of Massachusetts Worcester; George Washington University	Chan, FKM (corresponding author), Univ Massachusetts, Sch Med, Dept Pathol, Rm S2-125,55 Lake Ave N, Worcester, MA 01655 USA.	francis.chan@umassmed.edu	Chan, Francis Ka-Ming/E-9647-2014; Chan, Francis/ABB-1895-2021	Chan, Francis Ka-Ming/0000-0002-4803-8353; Shisler, Joanna/0000-0003-4833-1557; Moss, Bernard/0000-0002-2154-8564	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000539, ZIAAI000539] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK032520] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK32520] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Benedict CA, 2002, NAT IMMUNOL, V3, P1013, DOI 10.1038/ni1102-1013; Chan FKM, 2000, IMMUNITY, V13, P419, DOI 10.1016/S1074-7613(00)00041-8; Chan FKM, 2000, EUR J IMMUNOL, V30, P652; Chan FKM, 2000, SCIENCE, V288, P2351, DOI 10.1126/science.288.5475.2351; Chaudhary PM, 1999, ONCOGENE, V18, P5738, DOI 10.1038/sj.onc.1202976; Chin AI, 2002, NATURE, V416, P190, DOI 10.1038/416190a; Cusson N, 2002, J EXP MED, V196, P15, DOI 10.1084/jem.20011470; Elzey BD, 2001, J IMMUNOL, V167, P3049, DOI 10.4049/jimmunol.167.6.3049; Herbein G, 2000, P SOC EXP BIOL MED, V223, P241, DOI 10.1046/j.1525-1373.2000.22335.x; Holler N, 2000, NAT IMMUNOL, V1, P489, DOI 10.1038/82732; Hornef MW, 2002, NAT IMMUNOL, V3, P1033, DOI 10.1038/ni1102-1033; Jaattela M, 2003, NAT IMMUNOL, V4, P416, DOI 10.1038/ni0503-416; Joza N, 2001, NATURE, V410, P549, DOI 10.1038/35069004; Juo P, 1999, CELL GROWTH DIFFER, V10, P797; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; Khwaja A, 1999, J BIOL CHEM, V274, P36817, DOI 10.1074/jbc.274.51.36817; Kobayashi K, 2002, NATURE, V416, P194, DOI 10.1038/416194a; Legler DF, 2003, IMMUNITY, V18, P655, DOI 10.1016/S1074-7613(03)00092-X; Lewis J, 2000, J BIOL CHEM, V275, P10519, DOI 10.1074/jbc.275.14.10519; Li M, 2000, J VIROL, V74, P7470, DOI 10.1128/JVI.74.16.7470-7477.2000; Lin Y, 1999, GENE DEV, V13, P2514, DOI 10.1101/gad.13.19.2514; Matzinger P, 2002, SCIENCE, V296, P301, DOI 10.1126/science.1071059; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; Pimentel-Muinos FX, 1999, IMMUNITY, V11, P783, DOI 10.1016/S1074-7613(00)80152-1; Shisler JL, 2001, SEMIN IMMUNOL, V13, P67, DOI 10.1006/smim.2000.0297; Siegel RM, 1998, J CELL BIOL, V141, P1243, DOI 10.1083/jcb.141.5.1243; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; Ting AT, 1996, EMBO J, V15, P6189, DOI 10.1002/j.1460-2075.1996.tb01007.x; Wajant H, 2001, INT J BIOCHEM CELL B, V33, P19, DOI 10.1016/S1357-2725(00)00064-9; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; Weiss T, 1997, J IMMUNOL, V158, P2398; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797	33	332	347	2	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51613	51621		10.1074/jbc.M305633200	http://dx.doi.org/10.1074/jbc.M305633200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14532286	hybrid			2022-12-27	WOS:000187206300095
J	Imai, Y; Soda, M; Murakami, T; Shoji, M; Abe, K; Takahashi, R				Imai, Y; Soda, M; Murakami, T; Shoji, M; Abe, K; Takahashi, R			A product of the human gene adjacent to parkin is a component of Lewy bodies and suppresses pael receptor-induced cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-PROTEIN LIGASE; ALPHA-SYNUCLEIN; DISEASE; IDENTIFICATION; CHAPERONIN; MUTATION; TUBULIN; COMPLEX; STRESS	Parkin, a RING-type ubiquitin ligase, is the product of the gene responsible for autosomal recessive juvenile parkinsonism. A reverse strand gene located upstream of the parkin gene in the human genome has been identified. The gene product, termed Glup/PACRG, forms a large molecular chaperone complex containing heat shock proteins 70 and 90 and chaperonin components. Glup suppressed cell death induced by accumulation of unfolded Pael receptor (Pael-R), a substrate of Parkin. On the other hand, Glup facilitated the formation of inclusions consisting of Pael-R, molecular chaperones, protein degradation molecules, and Glup itself, when proteasome is inhibited. Glup knockdown attenuated the formation of Pael-R inclusions, which resulted in the promotion of cell death with extensive vacuolization. Moreover, Glup turned out to be a component of Lewy bodies in Parkinson's disease cases. These data suggest that Glup may play an important role in the formation of Lewy bodies and protection of dopaminergic neurons against Parkinson's disease.	RIKEN, Lab Motor Syst Neurodegenerat, Brain Sci Inst, Saitama 3510198, Japan; Okayama Univ, Dept Neurol, Grad Sch Med & Dent, Okayama 7008558, Japan	RIKEN; Okayama University	Takahashi, R (corresponding author), RIKEN, Lab Motor Syst Neurodegenerat, Brain Sci Inst, Saitama 3510198, Japan.	ryosuke@brain.riken.go.jp	Imai, Yuzuru/AAA-6472-2019	Imai, Yuzuru/0000-0003-2924-5231; Shoji, Mikio/0000-0003-1027-1712				Asakawa S, 2001, BIOCHEM BIOPH RES CO, V286, P863, DOI 10.1006/bbrc.2001.5490; Auluck PK, 2002, SCIENCE, V295, P865, DOI 10.1126/science.1067389; Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; Campbell RE, 2002, P NATL ACAD SCI USA, V99, P7877, DOI 10.1073/pnas.082243699; CHEN XY, 1994, P NATL ACAD SCI USA, V91, P9111, DOI 10.1073/pnas.91.19.9111; Chung KKK, 2001, NAT MED, V7, P1144, DOI 10.1038/nm1001-1144; GAO YJ, 1992, CELL, V69, P1043, DOI 10.1016/0092-8674(92)90622-J; Goldberg MS, 2000, NAT CELL BIOL, V2, pE115, DOI 10.1038/35017124; Imai Y, 2000, J BIOL CHEM, V275, P35661, DOI 10.1074/jbc.C000447200; Imai Y, 2001, CELL, V105, P891, DOI 10.1016/S0092-8674(01)00407-X; Imai Y, 2002, MOL CELL, V10, P55, DOI 10.1016/S1097-2765(02)00583-X; Junn E, 2002, J BIOL CHEM, V277, P47870, DOI 10.1074/jbc.M203159200; Kim S, 2002, NAT CELL BIOL, V4, P826, DOI 10.1038/ncb863; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; McNaught KSP, 2002, EUR J NEUROSCI, V16, P2136, DOI 10.1046/j.1460-9568.2002.02301.x; Mizuno Y, 1998, J NEUROCHEM, V71, P893; Nagai T, 2002, NAT BIOTECHNOL, V20, P87, DOI 10.1038/nbt0102-87; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Schlossmacher MG, 2002, AM J PATHOL, V160, P1655, DOI 10.1016/S0002-9440(10)61113-3; Sharon R, 2001, P NATL ACAD SCI USA, V98, P9110, DOI 10.1073/pnas.171300598; Shimohata T, 2000, NAT GENET, V26, P29, DOI 10.1038/79139; Shimura H, 2000, NAT GENET, V25, P302, DOI 10.1038/77060; Shimura H, 1999, ANN NEUROL, V45, P668, DOI 10.1002/1531-8249(199905)45:5<668::AID-ANA19>3.0.CO;2-Z; STERNLICHT H, 1993, P NATL ACAD SCI USA, V90, P9422, DOI 10.1073/pnas.90.20.9422; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; Trojanowski JQ, 1998, CELL DEATH DIFFER, V5, P832, DOI 10.1038/sj.cdd.4400432; West A, 2001, J NEUROCHEM, V78, P1146, DOI 10.1046/j.1471-4159.2001.00512.x; West AB, 2003, J MOL BIOL, V326, P11, DOI 10.1016/S0022-2836(02)01376-1; YAFFE MB, 1992, NATURE, V358, P245, DOI 10.1038/358245a0; Zhang Y, 2000, P NATL ACAD SCI USA, V97, P13354, DOI 10.1073/pnas.240347797	31	57	74	2	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51901	51910		10.1074/jbc.M309655200	http://dx.doi.org/10.1074/jbc.M309655200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14532270	hybrid			2022-12-27	WOS:000187206300126
J	Lee, JH; Yang, ES; Park, JW				Lee, JH; Yang, ES; Park, JW			Inactivation of NADP(+)-dependent isocitrate dehydrogenase by peroxynitrite - Implications for cytotoxicity and alcohol-induced liver injury	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURONAL NITRIC-OXIDE; SUPEROXIDE-DISMUTASE; HYDROGEN-PEROXIDE; GLUTATHIONE-PEROXIDASE; CATALYZED OXIDATION; TYROSINE NITRATION; ANTIOXIDANT ENZYME; RADICAL PRODUCTION; N-ETHYLMALEIMIDE; ESCHERICHIA-COLI	Recently, we demonstrated that the control of cytosolic and mitochondrial redox balance and oxidative damage is one of the primary functions of NADP(+)-dependent isocitrate dehydrogenase (ICDH) by supplying NADPH for antioxidant systems. We investigated whether the ICDH would be a vulnerable target of peroxynitrite anion (ONOO-) as a purified enzyme, in intact cells, and in liver mitochondria from ethanol-fed rats. Synthetic peroxynitrite and 3-morpholinosydnomine N-ethylcarbamide (SIN-1), a peroxynitrite-generating compound, inactivated ICDH in a dose- and time-dependent manner. The inactivation of ICDH by peroxynitrite or SIN-1 was reversed by dithiothreitol. Loss of enzyme activity was associated with the depletion of the thiol groups in protein. Immunoblotting analysis of peroxynitrite-modified ICDH indicates that S-nitrosylation of cysteine and nitration of tyrosine residues are the predominant modifications. Using electrospray ionization mass spectrometry (ESI-MS) with tryptic digestion of protein, we found that peroxynitrite forms S-nitrosothiol adducts on Cys(305) and Cys(387) of ICDH. Nitration of Tyr(280) was also identified, however, this modification did not significantly affect the activity of ICDH. These results indicate that S-nitrosylation of cysteine residues on ICDH is a mechanism involving the inactivation of ICDH by peroxynitrite. The structural alterations of modified enzyme were indicated by the changes in protease susceptibility and binding of the hydrophobic probe 8-anilino-1-napthalene sulfonic acid. When U937 cells were incubated with 100 muM SIN-1 bolus, a significant decrease in both cytosolic and mitochondrial ICDH activities were observed. Using immunoprecipitation and ESI-MS, we were also able to isolate and positively identify S-nitrosylated and nitrated mitochondrial ICDH from SIN-1-treated U937 cells as well as liver from ethanol-fed rats. Inactivation of ICDH resulted in the pro-oxidant state of cells reflected by an increased level of intracellular reactive oxygen species, a decrease in the ratio of [NADPH]/[NADPH + NADP(+)], and a decrease in the efficiency of reduced glutathione turnover. The per-oxynitrite-mediated damage to ICDH may result in the perturbation of the cellular antioxidant defense mechanisms and subsequently lead to a pro-oxidant condition.	Kyungpook Natl Univ, Coll Nat Sci, Dept Biochem, Taegu 702701, South Korea	Kyungpook National University	Park, JW (corresponding author), Kyungpook Natl Univ, Coll Nat Sci, Dept Biochem, Taegu 702701, South Korea.							Akerboom T P, 1981, Methods Enzymol, V77, P373; ANDERSON ME, 1985, METHOD ENZYMOL, V113, P548; Arai M, 1999, J BIOL CHEM, V274, P4924, DOI 10.1074/jbc.274.8.4924; Araki M, 1999, J BIOL CHEM, V274, P2271, DOI 10.1074/jbc.274.4.2271; Baraona E, 2002, ALCOHOL CLIN EXP RES, V26, P883, DOI 10.1111/j.1530-0277.2002.tb02618.x; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BECKMAN JS, 1993, NATURE, V364, P584, DOI 10.1038/364584a0; BECKMAN JS, 1994, METHOD ENZYMOL, V233, P229; BECKMAN JS, 1993, BIOCHEM SOC T, V21, P330, DOI 10.1042/bst0210330; Berlett BS, 1996, P NATL ACAD SCI USA, V93, P1776, DOI 10.1073/pnas.93.5.1776; CARRERAS MC, 1994, FEBS LETT, V341, P65, DOI 10.1016/0014-5793(94)80241-6; CHAE HZ, 1994, J BIOL CHEM, V269, P27670; CHURCH FC, 1985, ANAL BIOCHEM, V146, P343, DOI 10.1016/0003-2697(85)90549-4; CROW JP, 1995, BIOCHEMISTRY-US, V34, P3544, DOI 10.1021/bi00011a008; FATANIA HR, 1993, FEBS LETT, V322, P245, DOI 10.1016/0014-5793(93)81579-O; Frears ER, 1996, FEBS LETT, V381, P21, DOI 10.1016/0014-5793(96)00065-8; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; HAUSLADEN A, 1994, J BIOL CHEM, V269, P29405; HOGG N, 1992, BIOCHEM J, V281, P419, DOI 10.1042/bj2810419; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; Houston M, 1998, ARCH BIOCHEM BIOPHYS, V355, P1, DOI 10.1006/abbi.1998.0675; Huhmer AFR, 1996, CHEM RES TOXICOL, V9, P484, DOI 10.1021/tx950152l; Ischiropoulos H, 1998, ARCH BIOCHEM BIOPHYS, V356, P1, DOI 10.1006/abbi.1998.0755; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P446, DOI 10.1016/0003-9861(92)90433-W; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P431, DOI 10.1016/0003-9861(92)90431-U; Jaeschke H, 2002, TOXICOL SCI, V65, P166, DOI 10.1093/toxsci/65.2.166; JIANG ZY, 1992, ANAL BIOCHEM, V202, P384, DOI 10.1016/0003-2697(92)90122-N; Jo SH, 2001, J BIOL CHEM, V276, P16168, DOI 10.1074/jbc.M010120200; Kang SW, 1998, J BIOL CHEM, V273, P6297, DOI 10.1074/jbc.273.11.6297; KLETZIEN RF, 1994, FASEB J, V8, P174, DOI 10.1096/fasebj.8.2.8119488; Knoops B, 1999, J BIOL CHEM, V274, P30451, DOI 10.1074/jbc.274.43.30451; Konorev EA, 1998, FEBS LETT, V427, P171, DOI 10.1016/S0014-5793(98)00413-X; KOOY NW, 1994, ARCH BIOCHEM BIOPHYS, V310, P352, DOI 10.1006/abbi.1994.1178; KOPPENOL WH, 1992, CHEM RES TOXICOL, V5, P834, DOI 10.1021/tx00030a017; KOSHLAND DE, 1985, CURR TOP CELL REGUL, V27, P13; KWON SJ, 1994, BIOCHEM BIOPH RES CO, V201, P8, DOI 10.1006/bbrc.1994.1662; Lee SM, 2002, FREE RADICAL BIO MED, V32, P1185, DOI 10.1016/S0891-5849(02)00815-8; Li YB, 1998, J BIOL CHEM, V273, P2015, DOI 10.1074/jbc.273.4.2015; LOVERDE AW, 1973, J NEUROCHEM, V20, P441, DOI 10.1111/j.1471-4159.1973.tb12143.x; MacMillanCrow LA, 1996, P NATL ACAD SCI USA, V93, P11853, DOI 10.1073/pnas.93.21.11853; MARKLUND S, 1974, European Journal of Biochemistry, V47, P469, DOI 10.1111/j.1432-1033.1974.tb03714.x; Oh-Hashi K, 2001, FREE RADICAL BIO MED, V30, P213, DOI 10.1016/S0891-5849(00)00461-5; PADJAMA S, 1993, BIOCHEM BIOPH RES CO, V195, P539; Padmaja S, 1998, ARCH BIOCHEM BIOPHYS, V349, P1, DOI 10.1006/abbi.1997.0407; PANDOLFI PP, 1995, EMBO J, V14, P5209, DOI 10.1002/j.1460-2075.1995.tb00205.x; PRYOR WA, 1995, AM J PHYSIOL, V268, P699; Przedborski S, 1996, P NATL ACAD SCI USA, V93, P4565, DOI 10.1073/pnas.93.10.4565; RADI R, 1991, J BIOL CHEM, V266, P4244; RUBBO H, 1994, ARCH BIOCHEM BIOPHYS, V308, P96, DOI 10.1006/abbi.1994.1014; Salvemini F, 1999, J BIOL CHEM, V274, P2750, DOI 10.1074/jbc.274.5.2750; Savvides SN, 2002, J BIOL CHEM, V277, P2779, DOI 10.1074/jbc.M108190200; SCHWARZ MA, 1994, J BIOL CHEM, V269, P15238; SCOTT MD, 1991, BLOOD, V77, P2059; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMYTH GE, 1992, ARCH BIOCHEM BIOPHYS, V293, P356, DOI 10.1016/0003-9861(92)90406-M; SMYTH GE, 1991, J BIOL CHEM, V266, P14918; Souza JM, 1998, ARCH BIOCHEM BIOPHYS, V360, P187, DOI 10.1006/abbi.1998.0932; STADTMAN ER, 1990, FREE RADICAL BIO MED, V9, P315, DOI 10.1016/0891-5849(90)90006-5; Stamler JS, 1998, NAT STRUCT BIOL, V5, P247, DOI 10.1038/nsb0498-247; Sun LJ, 1999, J BIOL CHEM, V274, P17334, DOI 10.1074/jbc.274.24.17334; SZWEDA LI, 1993, ARCH BIOCHEM BIOPHYS, V301, P391, DOI 10.1006/abbi.1993.1161; Tsukamoto H, 2001, FASEB J, V15, P1335, DOI 10.1096/fj.00-0650rev; Uppu RM, 1996, ANAL BIOCHEM, V236, P242, DOI 10.1006/abio.1996.0162; VEECH RL, 1969, BIOCHEM J, V115, P609, DOI 10.1042/bj1150609a; Wang PH, 1996, J BIOL CHEM, V271, P29223, DOI 10.1074/jbc.271.46.29223; WATABE S, 1995, BIOCHEM BIOPH RES CO, V213, P1010, DOI 10.1006/bbrc.1995.2229; White AR, 1999, J NEUROCHEM, V72, P2092, DOI 10.1046/j.1471-4159.1999.0722092.x; ZEREZ CR, 1987, ANAL BIOCHEM, V164, P367, DOI 10.1016/0003-2697(87)90506-9	68	107	110	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51360	51371		10.1074/jbc.M302332200	http://dx.doi.org/10.1074/jbc.M302332200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14551203	hybrid			2022-12-27	WOS:000187206300064
J	Bianchini, EP; Pike, RN; Le Bonniec, BF				Bianchini, EP; Pike, RN; Le Bonniec, BF			The elusive role of the potential factor X cation-binding exosite-1 in substrate and inhibitor interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR VA BINDING; PLASMINOGEN-ACTIVATOR INHIBITOR-1; BLOOD-COAGULATION FACTOR; FACTOR PATHWAY INHIBITOR; AMINO-ACID-RESIDUES; MACROMOLECULAR SUBSTRATE; HEPARIN-BINDING; TISSUE FACTOR; FACTOR IXA; PROTHROMBINASE COMPLEX	number of studies suggest that blood-clotting factor X (FX) uses secondary site(s) to interact (as a substrate) with its activators. Numerous pieces of evidence also imply that, within prothrombinase (as an enzyme), activated FX (FXa) uses exosite(s) for cofactor Va and/or prothrombin recognition. Similarly, FXa exosite(s) seem to govern interaction with inhibitors. An obvious difference between FXa and thrombin resides within a region called exosite-1: positively charged in thrombin and clearly of opposite polarity in FXa. To investigate the role of this potential cation-binding exosite, we prepared a series of mutants within loops 34-40 and 70-80 of FX. Overall, the mutations induced relatively subtle, non-synergistic modulation. The potential exosite was dispensable for FX activation and is unlikely to constitute a critical region for factor Va binding, albeit it is clearly important for prothrombin activation. Our data also implicate loop 34-40 of FXa in the interaction with the tissue factor pathway inhibitor, in prevention of plasminogen activator inhibitor-1 binding, and in tempering inhibition by heparin-activated antithrombin. Compared with FX, mutants with reduced electrostatic potential potentiated thrombin production in FX-depleted plasma, whereas mutants with inverted electrostatic potential impeded clotting. Despite the definite consequences observed, disruption of the potential cation-binding exosite of FX had rather weak effects, far from what would be expected if this region was as crucial as in thrombin.	Univ Paris 05, Fac Pharm, INSERM, U428, F-75270 Paris 06, France; Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic 3800, Australia	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Monash University	Le Bonniec, BF (corresponding author), Univ Paris 05, Fac Pharm, INSERM, U428, 4 Av Observ, F-75270 Paris 06, France.	lebonnie@infobiogen.fr	Le Bonniec, Bernard/ABA-1366-2020; Le Bonniec, Bernard/S-5756-2016	Le Bonniec, Bernard/0000-0002-8432-7363; Le Bonniec, Bernard/0000-0002-8432-7363; Pike, Robert/0000-0002-2083-0269; BIANCHINI, Elsa/0000-0002-1370-5312				Anderson PJ, 2000, J BIOL CHEM, V275, P16435, DOI 10.1074/jbc.M001255200; ARNI RK, 1993, BIOCHEMISTRY-US, V32, P4727, DOI 10.1021/bi00069a006; Bajaj SP, 1999, THROMB HAEMOSTASIS, V82, P218; Banner DW, 1996, NATURE, V380, P41, DOI 10.1038/380041a0; Betz A, 1998, J BIOL CHEM, V273, P10709, DOI 10.1074/jbc.273.17.10709; Bianchini EP, 2002, J BIOL CHEM, V277, P20527, DOI 10.1074/jbc.M201139200; Bode W, 1997, THROMB HAEMOSTASIS, V78, P501; Boskovic DS, 2000, J BIOL CHEM, V275, P38561, DOI 10.1074/jbc.M006637200; Braud S, 2002, BIOCHEMISTRY-US, V41, P8478, DOI 10.1021/bi016069g; Burgering MJM, 1997, J MOL BIOL, V269, P395, DOI 10.1006/jmbi.1997.1029; Camire RM, 2000, BIOCHEMISTRY-US, V39, P14322, DOI 10.1021/bi001074q; Chen L, 2003, J BIOL CHEM, V278, P27564, DOI 10.1074/jbc.M302707200; Chuang YJ, 2001, J BIOL CHEM, V276, P14961, DOI 10.1074/jbc.M011550200; Dekker RJ, 1999, J MOL BIOL, V293, P613, DOI 10.1006/jmbi.1999.3178; Dennis MS, 2000, NATURE, V404, P465, DOI 10.1038/35006574; Dharmawardana KR, 1998, BIOCHEMISTRY-US, V37, P13143, DOI 10.1021/bi9812165; Dickinson CD, 1996, P NATL ACAD SCI USA, V93, P14379, DOI 10.1073/pnas.93.25.14379; Djie MZ, 1996, BIOCHEMISTRY-US, V35, P11461, DOI 10.1021/bi952717i; DRAPIER JC, 1979, BIOCHIMIE, V61, P463, DOI 10.1016/S0300-9084(79)80202-3; Fuentes-Prior P, 2000, NATURE, V404, P518, DOI 10.1038/35006683; HORREVOETS AJG, 1993, J BIOL CHEM, V268, P779; Huntington JA, 1996, BIOCHEMISTRY-US, V35, P8495, DOI 10.1021/bi9604643; JONES DH, 1990, BIOTECHNIQUES, V8, P178; Kalafatis M, 2002, BIOCHEMISTRY-US, V41, P12715, DOI 10.1021/bi026208+; Kolkman JA, 1999, J BIOL CHEM, V274, P29087, DOI 10.1074/jbc.274.41.29087; KOSOW DP, 1974, THROMB RES, V4, P219, DOI 10.1016/0049-3848(74)90087-5; Krishnaswamy S, 1997, BIOCHEMISTRY-US, V36, P12080, DOI 10.1021/bi970979+; LAUDANO AP, 1980, BIOCHEMISTRY-US, V19, P1013, DOI 10.1021/bi00546a028; LEBONNIEC BF, 1992, J BIOL CHEM, V267, P6970; LEBONNIEC BF, 1993, J BIOL CHEM, V268, P19055; LEBONNIEC BF, 1991, J BIOL CHEM, V266, P13796; MADISON EL, 1990, P NATL ACAD SCI USA, V87, P3530, DOI 10.1073/pnas.87.9.3530; MADISON EL, 1989, NATURE, V339, P721, DOI 10.1038/339721a0; Manithody C, 2002, BIOCHEMISTRY-US, V41, P6780, DOI 10.1021/bi0255367; Mathur A, 1997, J BIOL CHEM, V272, P23418, DOI 10.1074/jbc.272.37.23418; Mine S, 2002, BIOCHEMISTRY-US, V41, P78, DOI 10.1021/bi011299g; Myles T, 1998, J BIOL CHEM, V273, P31203, DOI 10.1074/jbc.273.47.31203; Olson ST, 2002, TRENDS CARDIOVAS MED, V12, P331, DOI 10.1016/S1050-1738(02)00183-4; OLSON ST, 1993, METHOD ENZYMOL, V222, P525; Picard V, 1999, J BIOL CHEM, V274, P4586, DOI 10.1074/jbc.274.8.4586; Quinsey NS, 2002, J BIOL CHEM, V277, P15971, DOI 10.1074/jbc.M108131200; Rezaie AR, 2000, BIOCHEMISTRY-US, V39, P12083, DOI 10.1021/bi0011126; Rezaie AR, 2000, J BIOL CHEM, V275, P3320, DOI 10.1074/jbc.275.5.3320; REZAIE AR, 1994, J BIOL CHEM, V269, P21495; Rezaie AR, 2001, BBA-GEN SUBJECTS, V1528, P167, DOI 10.1016/S0304-4165(01)00189-1; Rijkers DTS, 1998, THROMB RES, V89, P161, DOI 10.1016/S0049-3848(97)00312-5; Rudolph AE, 2000, BIOCHEMISTRY-US, V39, P2861, DOI 10.1021/bi992379b; Rudolph AE, 2001, J BIOL CHEM, V276, P5123, DOI 10.1074/jbc.M006961200; Sabharwal AK, 1997, J BIOL CHEM, V272, P22037, DOI 10.1074/jbc.272.35.22037; SHEEHAN JP, 1994, P NATL ACAD SCI USA, V91, P5518, DOI 10.1073/pnas.91.12.5518; Shobe J, 1999, J BIOL CHEM, V274, P24171, DOI 10.1074/jbc.274.34.24171; Stanley TB, 1999, J BIOL CHEM, V274, P16940, DOI 10.1074/jbc.274.24.16940; STONE SR, 1986, BIOCHEMISTRY-US, V25, P4622, DOI 10.1021/bi00364a025; Wilkens M, 2002, J BIOL CHEM, V277, P9366, DOI 10.1074/jbc.M110848200; Williams J W, 1979, Methods Enzymol, V63, P437; WU QY, 1991, P NATL ACAD SCI USA, V88, P6775, DOI 10.1073/pnas.88.15.6775; Yang LK, 2002, J BIOL CHEM, V277, P50756, DOI 10.1074/jbc.M208485200	57	15	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	2004	279	5					3671	3679		10.1074/jbc.M309691200	http://dx.doi.org/10.1074/jbc.M309691200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	766MF	14583605	hybrid			2022-12-27	WOS:000188379600066
J	Gera, JF; Mellinghoff, IK; Shi, YJ; Rettig, MB; Tran, C; Hsu, JH; Sawyers, CL; Lichtenstein, AK				Gera, JF; Mellinghoff, IK; Shi, YJ; Rettig, MB; Tran, C; Hsu, JH; Sawyers, CL; Lichtenstein, AK			AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EIF2-ALPHA KINASE GCN2; TRANSLATION INITIATION; MESSENGER-RNA; SIGNALING PATHWAY; CELL-SURVIVAL; CANCER-CELLS; TOR; IRES; GROWTH; HYPOTHESIS	Prior work demonstrates that AKT activity regulates sensitivity of cells to G(1) arrest induced by mammalian target of rapamycin (mTOR) inhibitors such as rapamycin and CCI-779. To investigate this, a novel high-throughput microarray polysome analysis was performed to identify genes whose mRNA translational efficiency was differentially affected following mTOR inhibition. The analysis also allowed the assessment of steady-state transcript levels. We identified two transcripts, cyclin D1 and c-myc, which exhibited differential expression in an AKT-dependent manner: High levels of activated AKT resulted in rapamycin-induced down-regulation of expression, whereas low levels resulted in up-regulation of expression. To ectopically express these proteins we exploited the finding that the p27(kip1) mRNA was efficiently translated in the face of mTOR inhibition irrespective of AKT activity. Thus, the p27(kip1) 5'-untranslated region was fused to the cyclin D1 and c-myc coding regions and these constructs were expressed in cells. In transfected cells, expression of cyclin D1 or c-myc was not decreased by rapamycin. Most importantly, this completely converted sensitive cells to a phenotype resistant to G(1) arrest. Furthermore, the AKT-dependent differential expression patterns of these two genes was also observed in a mouse xenograft model following in vivo treatment with CCI-779. These results identify two critical downstream molecular targets whose expression is regulated by AKT activity and whose down-regulation is required for rapamycin/CCI-779 sensitivity.	Univ Calif Los Angeles, Med Ctr, W Los Angeles Vet Adm, Dept Med,Div Hematol & Oncol, Los Angeles, CA 90073 USA; Univ Calif Los Angeles, Sch Med, Jonsson Comprehens Canc Ctr, Howard Hughes Med Inst,Mol Biol Inst, Los Angeles, CA 90073 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; Howard Hughes Medical Institute; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Gera, JF (corresponding author), Univ Calif Los Angeles, Med Ctr, W Los Angeles Vet Adm, Dept Med,Div Hematol & Oncol, Los Angeles, CA 90073 USA.	gera@ucla.edu	Tran, Canh-Dung/D-4442-2011; Sawyers, Charles/G-5327-2016	Tran, Canh-Dung/0000-0002-1011-4226; Gera, Joseph/0000-0002-2908-6894	NATIONAL CANCER INSTITUTE [R01CA096920] Funding Source: NIH RePORTER; NCI NIH HHS [CA096920] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abraham RT, 2002, CELL, V111, P9, DOI 10.1016/S0092-8674(02)01009-7; Avruch J, 2001, Prog Mol Subcell Biol, V26, P115; Bacus SS, 2002, ONCOGENE, V21, P3532, DOI 10.1038/sj.onc.1205438; Barbet NC, 1996, MOL BIOL CELL, V7, P25, DOI 10.1091/mbc.7.1.25; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; Cheng JQ, 1996, P NATL ACAD SCI USA, V93, P3636, DOI 10.1073/pnas.93.8.3636; Cherkasova VA, 2003, GENE DEV, V17, P859, DOI 10.1101/gad.1069003; Dennis PB, 2001, SCIENCE, V294, P1102, DOI 10.1126/science.1063518; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; Grolleau A, 2002, J BIOL CHEM, V277, P22175, DOI 10.1074/jbc.M202014200; Hardwick JS, 1999, P NATL ACAD SCI USA, V96, P14866, DOI 10.1073/pnas.96.26.14866; Hashemolhosseini S, 1998, J BIOL CHEM, V273, P14424, DOI 10.1074/jbc.273.23.14424; Hosoi H, 1998, MOL PHARMACOL, V54, P815, DOI 10.1124/mol.54.5.815; Hsu JH, 2001, BLOOD, V98, P2853, DOI 10.1182/blood.V98.9.2853; Jacinto E, 2003, NAT REV MOL CELL BIO, V4, P117, DOI 10.1038/nrm1018; KNUDSEN S, 2002, BIOL GUIDE ANAL DNA, P43; KORTH MJ, 1997, MRNA METABOLISM POST, P265; Kubota H, 2003, J BIOL CHEM, V278, P20457, DOI 10.1074/jbc.C300133200; Kullmann M, 2002, GENE DEV, V16, P3087, DOI 10.1101/gad.248902; Le Quesne JPC, 2001, J MOL BIOL, V310, P111, DOI 10.1006/jmbi.2001.4745; Mauro VP, 2002, P NATL ACAD SCI USA, V99, P12031, DOI 10.1073/pnas.192442499; Miskimins WK, 2001, MOL CELL BIOL, V21, P4960, DOI 10.1128/MCB.21.15.4960-4967.2001; Nelsen CJ, 2003, J BIOL CHEM, V278, P3656, DOI 10.1074/jbc.M209374200; Neshat MS, 2001, P NATL ACAD SCI USA, V98, P10314, DOI 10.1073/pnas.171076798; Pap M, 2002, MOL CELL BIOL, V22, P578, DOI 10.1128/MCB.22.2.578-586.2002; Peng T, 2002, MOL CELL BIOL, V22, P5575, DOI 10.1128/MCB.22.15.5575-5584.2002; Powers T, 1999, MOL BIOL CELL, V10, P987, DOI 10.1091/mbc.10.4.987; Richter, 1997, ANAL MRNA FORMATION, P305, DOI 10.1016/B978-012587545-5/50017-3; Rousseau D, 1996, P NATL ACAD SCI USA, V93, P1065, DOI 10.1073/pnas.93.3.1065; Sonenberg N, 1996, TRANSLATIONAL CONTRO, P245; Stoneley M, 2000, NUCLEIC ACIDS RES, V28, P687, DOI 10.1093/nar/28.3.687; Stoneley M, 1998, ONCOGENE, V16, P423, DOI 10.1038/sj.onc.1201763; Thomas G, 1997, CURR OPIN CELL BIOL, V9, P782, DOI 10.1016/S0955-0674(97)80078-6; Vagner S, 2001, EMBO REP, V2, P893, DOI 10.1093/embo-reports/kve208; Xu FH, 1998, BLOOD, V92, P241, DOI 10.1182/blood.V92.1.241.413k28_241_251; Zong Q, 1999, P NATL ACAD SCI USA, V96, P10632, DOI 10.1073/pnas.96.19.10632	36	284	296	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 23	2004	279	4					2737	2746		10.1074/jbc.M309999200	http://dx.doi.org/10.1074/jbc.M309999200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	764MU	14576155	hybrid			2022-12-27	WOS:000188211300051
J	Hartmann, H; Bongers, A; Decker, H				Hartmann, H; Bongers, A; Decker, H			Small-angle X-ray scattering-based three-dimensional reconstruction of the immunogen KLH1 reveals different oxygen-dependent conformations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KEYHOLE-LIMPET HEMOCYANIN; FUNCTIONAL UNIT; GASTROPOD HEMOCYANIN; NEUTRON-SCATTERING; RESOLUTION; SUBUNIT; SERA; REACTIVITY; STATES	For decades the respiratory protein keyhole limpet hemocyanin (KLH1) from the marine gastropod Megathura crenulata has been used widely as a potent immunostimulant, useful hapten carrier, and valuable agent in the treatment of bladder carcinoma. Although much information on the immunological properties of KLH1 is available, biochemical and structural data are still incomplete. Small-angle x-ray scattering revealed the existence of two conformations, an oxy state being slightly more compact than the deoxy state. Based on small-angle scattering curves, a newly developed Monte Carlo algorithm delivered a surface representation of proteins. The massive changes of the surfaces of reconstructed didecameric KLH1 molecules are explained as a twist of the two non-covalently associated decameric half-molecules. Upon oxygenation, the KLH1 molecule becomes longer and skinnier. This study provides the first real evidence how a molluscan hemocyanin changes conformation during an allosteric transition.	Univ Mainz, Inst Mol Biophys, D-55128 Mainz, Germany	Johannes Gutenberg University of Mainz	Hartmann, H (corresponding author), Univ Mainz, Inst Mol Biophys, Jakob Welder Weg 26, D-55128 Mainz, Germany.	hartmann@biophysik.biologie.uni-mainz.de; decker@biophysik.biologie.uni-mainz.de						Berzofsky J., 1984, FUNDAMENTAL IMMUNOLO, P595; Chacon P, 1998, BIOPHYS J, V74, P2760, DOI 10.1016/S0006-3495(98)77984-6; CRUMPTON MJ, 1974, ANTIGENS, P1; Cuff ME, 1998, J MOL BIOL, V278, P855, DOI 10.1006/jmbi.1998.1647; DECKER H, 1990, J MOL BIOL, V211, P281, DOI 10.1016/0022-2836(90)90027-J; ELLERTON HD, 1983, PROG BIOPHYS MOL BIO, V41, P143, DOI 10.1016/0079-6107(83)90028-7; Feigin L.A., 1987, STRUCTURE ANAL SMALL; Glatter O., 1982, SMALL ANGLE XRAY SCA; HARRIS JR, 1995, MICRON, V26, P201; Harris JR, 1999, MICRON, V30, P597, DOI 10.1016/S0968-4328(99)00036-0; Hartmann H, 2001, EUR BIOPHYS J BIOPHY, V30, P471, DOI 10.1007/s002490100169; HARTMANN H, 2004, IN PRESS METHODS ENZ; HAUBOLD HG, 1989, REV SCI INSTRUM, V60, P1943, DOI 10.1063/1.1140895; Henderson SJ, 1996, BIOPHYS J, V70, P1618, DOI 10.1016/S0006-3495(96)79725-4; JurincicWinkler CD, 1996, ANTICANCER RES, V16, P2105; Kantelhardt SR, 2002, BIOCHEM J, V366, P217, DOI 10.1042/BJ20011678; LAMM DL, 1993, J UROLOGY, V149, P648, DOI 10.1016/S0022-5347(17)36172-4; Lieb B, 2001, P NATL ACAD SCI USA, V98, P4546, DOI 10.1073/pnas.071049998; Livingston P, 1997, CANCER IMMUNOL IMMUN, V43, P324, DOI 10.1007/s002620050340; MAGNUS KA, 1994, PROTEINS, V19, P302, DOI 10.1002/prot.340190405; MARKL J, 1991, NATURWISSENSCHAFTEN, V78, P30, DOI 10.1007/BF01134040; Meissner U, 2000, J MOL BIOL, V298, P21, DOI 10.1006/jmbi.2000.3631; MELLEMA JE, 1972, NATURE, V239, P146, DOI 10.1038/239146a0; METROPOLIS N, 1953, J CHEM PHYS, V21, P1087, DOI 10.1063/1.1699114; Miller KI, 1998, J MOL BIOL, V278, P827, DOI 10.1006/jmbi.1998.1648; Orlova EV, 1997, J MOL BIOL, V271, P417, DOI 10.1006/jmbi.1997.1182; Perbandt M, 2003, BIOCHEMISTRY-US, V42, P6341, DOI 10.1021/bi020672x; SENOZAN NM, 1989, COMP BIOCHEM PHYS A, V94, P195, DOI 10.1016/0300-9629(89)90534-3; Sohngen SM, 1997, EUR J BIOCHEM, V248, P602, DOI 10.1111/j.1432-1033.1997.00602.x; Stoeva S, 1999, BBA-PROTEIN STRUCT M, V1435, P94, DOI 10.1016/S0167-4838(99)00198-3; Svergun DI, 1999, BIOPHYS J, V76, P2879, DOI 10.1016/S0006-3495(99)77443-6; SVERGUN DI, 1994, J MOL BIOL, V240, P78, DOI 10.1006/jmbi.1994.1419; Swerdlow RD, 1996, COMP BIOCHEM PHYS B, V113, P537, DOI 10.1016/0305-0491(95)02091-8; VANDRIEL R, 1974, J MOL BIOL, V89, P103; vanHolde KE, 1995, ADV PROTEIN CHEM, V47, P1, DOI 10.1016/S0065-3233(08)60545-8; VANKUIK JA, 1985, J BIOL CHEM, V260, P3984; WIRGUIN I, 1995, CANCER IMMUNOL IMMUN, V40, P307, DOI 10.1007/BF01519630	37	19	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	2004	279	4					2841	2845		10.1074/jbc.M308959200	http://dx.doi.org/10.1074/jbc.M308959200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	764MU	14573592	hybrid			2022-12-27	WOS:000188211300063
J	Karring, H; Mathu, SGJ; van Duin, J; Clark, BFC; Kraal, B; Knudsen, CR				Karring, H; Mathu, SGJ; van Duin, J; Clark, BFC; Kraal, B; Knudsen, CR			Q beta-phage resistance by deletion of the coiled-coil motif in elongation factor Ts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-Q-BETA; RIBONUCLEIC-ACID REPLICASE; EF-TU; RNA REPLICATION; HOST FACTOR; POLYMERASE; MUTANT; GENE; RECONSTITUTION; RENATURATION	Elongation factor Ts (EF-Ts) is the guanine-nucleotide exchange factor of elongation factor Tu (EF-Tu), which promotes the binding of aminoacyl-tRNA to the mRNA-programmed ribosome in prokaryotes. The EF-Tu.EF-Ts complex, one of the EF-Tu complexes during protein synthesis, is also a component of RNA-dependent RNA polymerases like the polymerase from coliphage Qbeta. The present study shows that the Escherichia coli mutant GRd.tsf lacking the coiled-coil motif of EF-Ts is completely resistant to phage Qbeta and that Qbeta-polymerase complex formation is not observed. GRd.tsf is the first E. coli mutant ever described that is unable to form a Qbeta-polymerase complex while still maintaining an almost normal growth behavior. The phage resistance correlates with an observed instability of the mutant EF-Tu.EF-Ts complex in the presence of guanine nucleotides. Thus, the mutant EF-Tu.EF-Ts is the first EF-Tu.EF-Ts complex ever described that is completely inactive in the Qbeta-polymerase complex despite its almost full activity in protein synthesis. We propose that the role of EF-Ts in the Qbeta-polymerase complex is to control and trap EF-Tu in a stable conformation with affinity for RNA templates while unable to bind aminoacyl-tRNA.	Aarhus Univ, Dept Mol Biol, DK-8000 Aarhus C, Denmark; Leiden Univ, Leiden Inst Chem, Dept Biochem, NL-2300 RA Leiden, Netherlands	Aarhus University; Leiden University; Leiden University - Excl LUMC	Knudsen, CR (corresponding author), Aarhus Univ, Dept Mol Biol, Gustav Wieds Vej 10C, DK-8000 Aarhus C, Denmark.	crk@imsb.au.dk		Knudsen, Charlotte/0000-0003-2356-4821; Karring, Henrik/0000-0002-4672-1503				AMANN E, 1988, GENE, V69, P301, DOI 10.1016/0378-1119(88)90440-4; ARMSTRONGMAJOR J, 1985, BIOCHIM BIOPHYS ACTA, V824, P140, DOI 10.1016/0167-4781(85)90090-9; BARRERA I, 1993, J MOL BIOL, V232, P512, DOI 10.1006/jmbi.1993.1407; Bjornsson A, 1998, METH MOL B, V77, P75; BLUMENTHAL T, 1972, P NATL ACAD SCI USA, V69, P1313, DOI 10.1073/pnas.69.5.1313; BLUMENTHAL T, 1976, BIOCHEMISTRY-US, V15, P422, DOI 10.1021/bi00647a028; BLUMENTHAL T, 1979, ANNU REV BIOCHEM, V48, P525, DOI 10.1146/annurev.bi.48.070179.002521; BONI IV, 1991, NUCLEIC ACIDS RES, V19, P155, DOI 10.1093/nar/19.1.155; Brown D, 1996, P NATL ACAD SCI USA, V93, P11558, DOI 10.1073/pnas.93.21.11558; BROWN D, 1995, BIOCHEMISTRY-US, V34, P14765, DOI 10.1021/bi00045a018; Brown L, 1997, J BACTERIOL, V179, P656, DOI 10.1128/jb.179.3.656-662.1997; BROWN S, 1976, J BIOL CHEM, V251, P2749; BROWN S, 1976, P NATL ACAD SCI USA, V73, P1131, DOI 10.1073/pnas.73.4.1131; Caldas TD, 1998, J BIOL CHEM, V273, P11478, DOI 10.1074/jbc.273.19.11478; EGGEN K, 1967, BIOCHEM BIOPH RES CO, V28, P587, DOI 10.1016/0006-291X(67)90354-3; Franze de Fernandez M T, 1972, J Biol Chem, V247, P824; FRANZE MT, 1968, NATURE, V219, P588, DOI 10.1038/219588a0; GARWES D, 1969, BIOCHIM BIOPHYS ACTA, V186, P166, DOI 10.1016/0005-2787(69)90499-7; HARUNA I, 1965, SCIENCE, V150, P884, DOI 10.1126/science.150.3698.884; HORI K, 1967, P NATL ACAD SCI USA, V57, P1790, DOI 10.1073/pnas.57.6.1790; HORIUCHI K, 1971, VIROLOGY, V45, P429, DOI 10.1016/0042-6822(71)90343-6; KAMEN R, 1972, EUR J BIOCHEM, V31, P44, DOI 10.1111/j.1432-1033.1972.tb02498.x; KAMEN R, 1970, NATURE, V228, P527, DOI 10.1038/228527a0; KARNIK S, 1983, EMBO J, V2, P1521, DOI 10.1002/j.1460-2075.1983.tb01617.x; Karring H, 2003, EUR J BIOCHEM, V270, P4294, DOI 10.1046/j.1432-1033.2003.03822.x; Karring H, 2002, BBA-PROTEINS PROTEOM, V1601, P172, DOI 10.1016/S1570-9639(02)00460-0; Kawashima T, 1996, NATURE, V379, P511, DOI 10.1038/379511a0; KNUDSEN CR, 1992, BIOCHEM INT, V28, P353; KONDO M, 1970, NATURE, V228, P525, DOI 10.1038/228525a0; Krab IM, 1998, BBA-GENE STRUCT EXPR, V1443, P1, DOI 10.1016/S0167-4781(98)00169-9; Krab IM, 2001, BIOCHEMISTRY-US, V40, P8531, DOI 10.1021/bi0104930; KUWANO M, 1972, J BACTERIOL, V112, P1150, DOI 10.1128/JB.112.3.1150-1156.1972; KUWANO M, 1973, NATURE-NEW BIOL, V244, P107, DOI 10.1038/newbio244107a0; LANDERS TA, 1974, J BIOL CHEM, V249, P5801; MANDAL NC, 1977, P NATL ACAD SCI USA, V74, P1657, DOI 10.1073/pnas.74.4.1657; Mathu SGJ, 2003, J CHROMATOGR B, V786, P279, DOI 10.1016/S1570-0232(02)00811-5; Miller DL, 1977, MOL MECH PROTEIN BIO, P323; MILLS DR, 1990, J VIROL, V64, P3872, DOI 10.1128/JVI.64.8.3872-3881.1990; MOODY MD, 1994, BIOCHEMISTRY-US, V33, P13836, DOI 10.1021/bi00250a038; Muffler A, 1996, GENE DEV, V10, P1143, DOI 10.1101/gad.10.9.1143; Nesper M, 1998, EUR J BIOCHEM, V255, P81, DOI 10.1046/j.1432-1327.1998.2550081.x; Neuhard J., 1987, ESCHERICHIA COLI SAL; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Schuppli D, 1997, P NATL ACAD SCI USA, V94, P10239, DOI 10.1073/pnas.94.19.10239; SHAKLEE PN, 1988, VIROLOGY, V163, P209, DOI 10.1016/0042-6822(88)90250-4; Su Q, 1997, VIROLOGY, V227, P211, DOI 10.1006/viro.1996.8302; TANIGUCHI T, 1978, NATURE, V274, P223, DOI 10.1038/274223a0; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; VANDIEIJEN G, 1975, J MOL BIOL, V93, P351, DOI 10.1016/0022-2836(75)90282-X; Wang Y, 1997, NAT STRUCT BIOL, V4, P650, DOI 10.1038/nsb0897-650; WEINER AM, 1971, NATURE-NEW BIOL, V234, P206, DOI 10.1038/newbio234206a0; WEISSMANN C, 1974, FEBS LETT, V43, pS10	52	15	15	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 16	2004	279	3					1878	1884		10.1074/jbc.M306605200	http://dx.doi.org/10.1074/jbc.M306605200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	762WT	14583631	hybrid			2022-12-27	WOS:000188005700040
J	Kesty, NC; Kuehn, MJ				Kesty, NC; Kuehn, MJ			Incorporation of heterologous outer membrane and periplasmic proteins into Escherichia coli outer membrane vesicles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GREEN FLUORESCENT PROTEIN; HEAT-LABILE ENTEROTOXIN; GENERAL SECRETORY PATHWAY; GRAM-NEGATIVE BACTERIA; IN-VITRO; ACTINOBACILLUS-ACTINOMYCETEMCOMITANS; PSEUDOMONAS-AERUGINOSA; SHIGA TOXIN; CELLS; RELEASE	Gram-negative bacteria shed outer membrane vesicles composed of outer membrane and periplasmic components. Since vesicles from pathogenic bacteria contain virulence factors and have been shown to interact with eukaryotic cells, it has been proposed that vesicles behave as delivery vehicles. We wanted to determine whether heterologously expressed proteins would be incorporated into the membrane and lumen of vesicles and whether these altered vesicles would associate with host cells. Ail, an outer membrane adhesin/invasin from Yersinia enterocolitica, was detected in purified outer membrane and in vesicles from Escherichia coli strains DH5alpha, HB101, and MC4100 transformed with plasmid-encoded Ail. In vesicle-host cell co-incubation assays we found that vesicles containing Ail were internalized by eukaryotic cells, unlike vesicles without Ail. To determine whether lumenal vesicle contents could be modified and delivered to host cells, we used periplasmically expressed green fluorescent protein (GFP). GFP fused with the Tat signal sequence was secreted into the periplasm via the twin arginine transporter ( Tat) in both the laboratory E. coli strain DH5alpha and the pathogenic enterotoxigenic E. coli ATCC strain 43886. Pronase-resistant fluorescence was detectable in vesicles from Tat-GFP-transformed strains, demonstrating that GFP was inside intact vesicles. Inclusion of GFP cargo increased vesicle density but did not result in morphological changes in vesicles. These studies are the first to demonstrate the incorporation of heterologously expressed outer membrane and periplasmic proteins into bacterial vesicles.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Duke University	Kuehn, MJ (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Box 3711, Durham, NC 27710 USA.	meta.kuehn@duke.edu	Kuehn, Meta/AAL-2950-2021	Kuehn, Meta/0000-0003-0519-3019	NIAID NIH HHS [R03 AI054606] Funding Source: Medline; NIGMS NIH HHS [R01 GM066140] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R03AI054606] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM066140] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Beermann C, 2000, CELL IMMUNOL, V201, P124, DOI 10.1006/cimm.2000.1640; Bernadac A, 1998, J BACTERIOL, V180, P4872, DOI 10.1128/JB.180.18.4872-4878.1998; Beveridge TJ, 1999, J BACTERIOL, V181, P4725, DOI 10.1128/JB.181.16.4725-4733.1999; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; Demuth DR, 2003, CELL MICROBIOL, V5, P111, DOI 10.1046/j.1462-5822.2003.00259.x; DEVOE IW, 1973, J EXP MED, V138, P1156, DOI 10.1084/jem.138.5.1156; Feilmeier BJ, 2000, J BACTERIOL, V182, P4068, DOI 10.1128/JB.182.14.4068-4076.2000; Fiocca R, 1999, J PATHOL, V188, P220, DOI 10.1002/(SICI)1096-9896(199906)188:2<220::AID-PATH307>3.0.CO;2-C; HOEKSTRA D, 1976, BIOCHIM BIOPHYS ACTA, V455, P889, DOI 10.1016/0005-2736(76)90058-4; Horstman AL, 2000, J BIOL CHEM, V275, P12489, DOI 10.1074/jbc.275.17.12489; Horstman AL, 2002, J BIOL CHEM, V277, P32538, DOI 10.1074/jbc.M203740200; JOBLING MG, 1990, NUCLEIC ACIDS RES, V18, P5315, DOI 10.1093/nar/18.17.5315; Kadurugamuwa JL, 1998, ANTIMICROB AGENTS CH, V42, P1476, DOI 10.1128/AAC.42.6.1476; Kadurugamuwa JL, 1996, J BACTERIOL, V178, P2767, DOI 10.1128/jb.178.10.2767-2774.1996; KADURUGAMUWA JL, 1995, J BACTERIOL, V177, P3998, DOI 10.1128/jb.177.14.3998-4008.1995; Kato S, 2002, MICROB PATHOGENESIS, V32, P1, DOI 10.1006/mpat.2001.0474; Keenan J, 2000, FEMS MICROBIOL LETT, V182, P259, DOI 10.1111/j.1574-6968.2000.tb08905.x; Kolling GL, 1999, APPL ENVIRON MICROB, V65, P1843; Li ZS, 1998, J BACTERIOL, V180, P5478, DOI 10.1128/JB.180.20.5478-5483.1998; Lory S, 1998, CURR OPIN MICROBIOL, V1, P27, DOI 10.1016/S1369-5274(98)80139-2; MILLER VL, 1988, INFECT IMMUN, V56, P1242, DOI 10.1128/IAI.56.5.1242-1248.1988; MUGOPSTELTEN D, 1978, BIOCHIM BIOPHYS ACTA, V508, P287, DOI 10.1016/0005-2736(78)90331-0; NIKAIDO H, 1994, METHOD ENZYMOL, V235, P225; Pelham HRB, 1996, CELL STRUCT FUNCT, V21, P413, DOI 10.1247/csf.21.413; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; Sambrook J., 1989, MOL CLONING, pA1; Santini CL, 2001, J BIOL CHEM, V276, P8159, DOI 10.1074/jbc.C000833200; Sargent F, 2001, EUR J BIOCHEM, V268, P3361, DOI 10.1046/j.1432-1327.2001.02263.x; Scott ME, 2001, P NATL ACAD SCI USA, V98, P13978, DOI 10.1073/pnas.241411198; SHOBERG RJ, 1993, INFECT IMMUN, V61, P3892, DOI 10.1128/IAI.61.9.3892-3900.1993; Stanley NR, 2001, J BACTERIOL, V183, P139, DOI 10.1128/JB.183.1.139-144.2001; Stoorvogel W, 2002, TRAFFIC, V3, P321, DOI 10.1034/j.1600-0854.2002.30502.x; Tauschek M, 2002, P NATL ACAD SCI USA, V99, P7066, DOI 10.1073/pnas.092152899; Thery C, 2002, NAT REV IMMUNOL, V2, P569, DOI 10.1038/nri855; Thomas JD, 2001, MOL MICROBIOL, V39, P47, DOI 10.1046/j.1365-2958.2001.02253.x; WAI SN, 1995, MICROBIOL IMMUNOL, V39, P451, DOI 10.1111/j.1348-0421.1995.tb02228.x; Wai SN, 2003, CELL, V115, P25, DOI 10.1016/S0092-8674(03)00754-2; Yahr TL, 2001, EMBO J, V20, P2472, DOI 10.1093/emboj/20.10.2472; Yokoyama K, 2000, FEMS MICROBIOL LETT, V192, P139, DOI 10.1016/S0378-1097(00)00424-9	39	146	157	3	40	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 16	2004	279	3					2069	2076		10.1074/jbc.M307628200	http://dx.doi.org/10.1074/jbc.M307628200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	762WT	14578354	Green Accepted, hybrid			2022-12-27	WOS:000188005700062
J	Murthy, V; Han, SY; Beauchamp, RL; Smith, N; Haddad, LA; Ito, N; Ramesh, V				Murthy, V; Han, SY; Beauchamp, RL; Smith, N; Haddad, LA; Ito, N; Ramesh, V			Pam and its ortholog highwire interact with and may negatively regulate the TSC1 center dot TSC2 complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUBEROUS SCLEROSIS GENE; TUMOR-SUPPRESSOR PROTEINS; CELL-GROWTH; DEVELOPMENTAL EXPRESSION; 3-KINASE/AKT PATHWAY; EMBRYONIC LETHALITY; MAMMALIAN TARGET; SYNAPTIC GROWTH; TSC2 MUTATION; C-ELEGANS	Tuberous Sclerosis Complex (TSC) is an autosomal dominant disorder associated with mutations in TSC1, which codes for hamartin, or TSC2, which codes for tuberin. The brain is one of the most severely affected organs, and CNS lesions include cortical tubers and subependymal giant cell astrocytomas, resulting in mental retardation and seizures. Tuberin and hamartin function together as a complex in mammals and Drosophila. We report here the association of Pam, a protein identified as an interactor of Myc, with the tuberin-hamartin complex in the brain. The C terminus of Pam containing the RING zinc finger motif binds to tuberin. Pam is expressed in embryonic and adult brain as well as in cultured neurons. Pam has two forms in the rat CNS, an similar to 450-kDa form expressed in early embryonic stages and an similar to 350-kDa form observed in the postnatal period. In cortical neurons, Pam co-localizes with tuberin and hamartin in neurites and growth cones. Although Pam function(s) are yet to be defined, the highly conserved Pam homologs, HIW ( Drosophila) and RPM-1 ( Caenorhabditis elegans), are neuron-specific proteins that regulate synaptic growth. Here we show that HIW can genetically interact with the Tsc1.Tsc2 complex in Drosophila and could negatively regulate Tsc1.Tsc2 activity. Based on genetic studies, HIW has been implicated in ubiquitination, possibly functioning as an E3 ubiquitin ligase through the RING zinc finger domain. Therefore, we hypothesize that Pam, through its interaction with tuberin, could regulate the ubiquitination and proteasomal degradation of the tuberin-hamartin complex particularly in the CNS.	Massachusetts Gen Hosp, Mol Neurogenet Unit, Charlestown, MA 02129 USA	Harvard University; Massachusetts General Hospital	Ramesh, V (corresponding author), Massachusetts Gen Hosp, Mol Neurogenet Unit, Bldg 149,13th St,Rm 6222, Charlestown, MA 02129 USA.		Haddad, Luciana A/D-8002-2012	Haddad, Luciana A/0000-0003-1043-8981	NINDS NIH HHS [NS41917, NS24279] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS041917, P01NS024279] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Brent R, 1997, ANNU REV GENET, V31, P663, DOI 10.1146/annurev.genet.31.1.663; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Dan HC, 2002, J BIOL CHEM, V277, P35364, DOI 10.1074/jbc.M205838200; DiAntonio A, 2001, NATURE, V412, P449, DOI 10.1038/35086595; Ganoth D, 2001, NAT CELL BIOL, V3, P321, DOI 10.1038/35060126; Gao XS, 2002, NAT CELL BIOL, V4, P699, DOI 10.1038/ncb847; Gao XS, 2001, GENE DEV, V15, P1383, DOI 10.1101/gad.901101; Garami A, 2003, MOL CELL, V11, P1457, DOI 10.1016/S1097-2765(03)00220-X; GOMEZ M, 1999, TUBEROUS SCLEROSI CO; Goncharova EA, 2002, J BIOL CHEM, V277, P30958, DOI 10.1074/jbc.M202678200; Gottlieb TM, 2002, ONCOGENE, V21, P1299, DOI 10.1038/sj.onc.1205181; Guo QB, 1998, P NATL ACAD SCI USA, V95, P9172, DOI 10.1073/pnas.95.16.9172; Haddad LA, 2002, J BIOL CHEM, V277, P44180, DOI 10.1074/jbc.M207211200; Henry KW, 1998, J BIOL CHEM, V273, P20535, DOI 10.1074/jbc.273.32.20535; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Ito N, 1999, CELL, V96, P529, DOI 10.1016/S0092-8674(00)80657-1; Jaeschke A, 2002, J CELL BIOL, V159, P217, DOI 10.1083/jcb.jcb.200206108; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Kenerson HL, 2002, CANCER RES, V62, P5645; Kobayashi T, 1999, CANCER RES, V59, P1206; Kobayashi T, 2001, P NATL ACAD SCI USA, V98, P8762, DOI 10.1073/pnas.151033798; Kwiatkowski DJ, 2002, HUM MOL GENET, V11, P525, DOI 10.1093/hmg/11.5.525; Lin HK, 2002, EMBO J, V21, P4037, DOI 10.1093/emboj/cdf406; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; Murthy A, 1998, J BIOL CHEM, V273, P1273, DOI 10.1074/jbc.273.3.1273; Murthy V, 2001, ACTA NEUROPATHOL, V101, P202; Nellist M, 1999, J BIOL CHEM, V274, P35647, DOI 10.1074/jbc.274.50.35647; NELLIST M, 1993, CELL, V75, P1305; Niida Y, 2001, AM J HUM GENET, V69, P493, DOI 10.1086/321972; Noonan DJ, 2002, ARCH BIOCHEM BIOPHYS, V398, P132, DOI 10.1006/abbi.2001.2682; Onda H, 1999, J CLIN INVEST, V104, P687, DOI 10.1172/JCI7319; Plas DR, 2003, J BIOL CHEM, V278, P12361, DOI 10.1074/jbc.M213069200; Potter CJ, 2001, CELL, V105, P357, DOI 10.1016/S0092-8674(01)00333-6; Potter CJ, 2002, NAT CELL BIOL, V4, P658, DOI 10.1038/ncb840; Schaefer AM, 2000, NEURON, V26, P345, DOI 10.1016/S0896-6273(00)81168-X; Scholich K, 2001, J BIOL CHEM, V276, P47583, DOI 10.1074/jbc.M107816200; Stocker H, 2003, NAT CELL BIOL, V5, P559, DOI 10.1038/ncb995; Tapon N, 2001, CELL, V105, P345, DOI 10.1016/S0092-8674(01)00332-4; Tee AR, 2002, P NATL ACAD SCI USA, V99, P13571, DOI 10.1073/pnas.202476899; vanSlegtenhorst M, 1997, SCIENCE, V277, P805, DOI 10.1126/science.277.5327.805; Wan HI, 2000, NEURON, V26, P313, DOI 10.1016/S0896-6273(00)81166-6; Yang HT, 2002, DEV BRAIN RES, V136, P35, DOI 10.1016/S0165-3806(02)00311-5; Zhang Y, 2003, NAT CELL BIOL, V5, P578, DOI 10.1038/ncb999; Zhen M, 2000, NEURON, V26, P331, DOI 10.1016/S0896-6273(00)81167-8; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973	45	68	70	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 9	2004	279	2					1351	1358		10.1074/jbc.M310208200	http://dx.doi.org/10.1074/jbc.M310208200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	759DJ	14559897	hybrid			2022-12-27	WOS:000187722800063
J	Rosales, JL; Lee, BC; Modarressi, M; Sarker, KP; Lee, KY; Jeong, YG; Oko, R; Lee, KY				Rosales, JL; Lee, BC; Modarressi, M; Sarker, KP; Lee, KY; Jeong, YG; Oko, R; Lee, KY			Outer dense fibers serve as a functional target for Cdk5 center dot p35 in the developing sperm tail	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASE-5; NEURONAL CDC2-LIKE KINASE; PROTEIN-KINASE; BOVINE BRAIN; MOLECULAR-CLONING; PERINUCLEAR THECA; MAMMALIAN SPERM; RAT SPERMATOZOA; CDK5 ACTIVATOR; NERVOUS-SYSTEM	Cdk5 is ubiquitously expressed in all tissues, but its activators, p35 and p39, are principally found in brain, and Cdk5 activity has mostly been associated with brain development, particularly neuronal differentiation and migration. Here we show that the p35 transcript and protein are also present in the testis, and an active Cdk5 . p35 complex exists in this tissue as well. Cdk5 and p35 are prominently observed in elongating spermatid tails, particularly over the tail outer dense fibers (ODF). The appearance of Cdk5 . p35 proceeds from the proximal to the distal end of elongating spermatids, coinciding with the proximal to distal assembly of ODF along the length of the tail axoneme. Incidentally, increased Cdk5 . p35 activity is observed in isolated elongating spermatids and at a time when elongating spermatids appear in the developing testis, suggesting a role for Cdk5 . p35 in spermiogenesis. The presence of Cdk5 and p35 in ODF isolated from rat sperm tails implies a strong association among these proteins. In vitro ODF phosphorylation by Cdk5 . p35 and decreased in vivo sperm tail ODF phosphorylation in p35-deficient mice indicate that Cdk5 . p35 is an integral component of ODF and that ODF is a functional Cdk5 . p35 target in the testis. Our results demonstrate for the first time that Cdk5 . p35 may participate in the regulation of sperm tail development via a mechanism involving ODF phosphorylation. Apparently, as in brain development, Cdk5 . p35 plays a part in testis development.	Univ Calgary, Fac Med, Dept Cell Biol & Anat, Canc Biol Res Grp, Calgary, AB T2N 4N1, Canada; Univ Calgary, Neurosci Res Grp, Dept Cell Biol & Anat, Calgary, AB T2N 4N1, Canada; Queens Univ, Dept Anat & Cell Biol, Kingston, ON K7L 3N6, Canada	University of Calgary; University of Calgary; Queens University - Canada	Lee, KY (corresponding author), Univ Calgary, Fac Med, Dept Cell Biol & Anat, Canc Biol Res Grp, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	kylee@ucalgary.ca	Modarressi, Mohammad Hossein/AAL-8377-2020	Modarressi, Mohammad hossein/0000-0003-2763-1964; Rosales, Jesusa/0000-0002-2543-3801				BALTZ JM, 1990, BIOL REPROD, V43, P485, DOI 10.1095/biolreprod43.3.485; Bibb JA, 2001, NATURE, V410, P376, DOI 10.1038/35066591; Chae T, 1997, NEURON, V18, P29, DOI 10.1016/S0896-6273(01)80044-1; CHAUDHRY PS, 1995, CELL MOTIL CYTOSKEL, V32, P65, DOI 10.1002/cm.970320108; Chen F, 1999, EXP CELL RES, V249, P422, DOI 10.1006/excr.1999.4522; CLERMONT Y, 1990, ANAT RECORD, V227, P447, DOI 10.1002/ar.1092270408; Connell-Crowley L, 2000, CURR BIOL, V10, P599, DOI 10.1016/S0960-9822(00)00487-5; de Rouvroit CL, 2001, MECH DEVELOP, V105, P47, DOI 10.1016/S0925-4773(01)00396-3; FAWCETT DW, 1975, DEV BIOL, V44, P394, DOI 10.1016/0012-1606(75)90411-X; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; Feng YY, 2001, NAT REV NEUROSCI, V2, P408, DOI 10.1038/35077559; Gao CY, 1997, DEV GENET, V20, P267; Grootegoed JA, 2000, BEST PRACT RES CL EN, V14, P331, DOI 10.1053/beem.2000.0083; GROOTEGOED JA, 1977, BIOCHEM J, V168, P23, DOI 10.1042/bj1680023; Hasegawa M, 1997, J BIOL CHEM, V272, P33118, DOI 10.1074/jbc.272.52.33118; HIGGY NA, 1995, DEV GENET, V16, P190, DOI 10.1002/dvg.1020160211; INO H, 1994, BRAIN RES, V661, P196, DOI 10.1016/0006-8993(94)91197-5; ISHIGURO K, 1994, FEBS LETT, V342, P203, DOI 10.1016/0014-5793(94)80501-6; Kesavapany S, 2001, EUR J NEUROSCI, V13, P241, DOI 10.1046/j.1460-9568.2001.01376.x; Kim YH, 1999, J REPROD FERTIL, V116, P345, DOI 10.1530/jrf.0.1160345; Lazaro JB, 1997, J CELL SCI, V110, P1251; Lee KY, 1997, BRAIN RES, V773, P197, DOI 10.1016/S0006-8993(97)00508-8; Lee KY, 1996, J BIOL CHEM, V271, P1538, DOI 10.1074/jbc.271.3.1538; Lindemann CB, 1996, CELL MOTIL CYTOSKEL, V34, P258, DOI 10.1002/(SICI)1097-0169(1996)34:4<258::AID-CM1>3.0.CO;2-4; Maricich SM, 2001, NEURON, V31, P175, DOI 10.1016/S0896-6273(01)00370-1; MIYAJIMA M, 1995, NEUROREPORT, V6, P1130, DOI 10.1097/00001756-199505300-00014; MORALES CR, 1994, MOL REPROD DEV, V37, P229, DOI 10.1002/mrd.1080370215; Musa FRM, 2000, J ANDROL, V21, P392; NagDas SK, 2002, BIOL REPROD, V67, P1058, DOI 10.1095/biolreprod67.4.1058; Niethammer M, 2000, NEURON, V28, P697, DOI 10.1016/S0896-6273(00)00147-1; Nikolic M, 1996, GENE DEV, V10, P816, DOI 10.1101/gad.10.7.816; Nikolic M, 1998, NATURE, V395, P194, DOI 10.1038/26034; Ohshima T, 1999, J NEUROSCI, V19, P6017, DOI 10.1523/JNEUROSCI.19-14-06017.1999; Ohshima T, 1996, P NATL ACAD SCI USA, V93, P11173, DOI 10.1073/pnas.93.20.11173; Oko R, 1998, ANDROLOGIA, V30, P193; OKO R, 1988, BIOL REPROD, V39, P169, DOI 10.1095/biolreprod39.1.169; Oko R., 1990, P3; OKO R, 2001, ANDROLOGY 21ST CENTU; Paglini G, 1998, J NEUROSCI, V18, P9858; Petersen C, 2002, MOL REPROD DEV, V61, P102, DOI 10.1002/mrd.1136; Qi Z, 1998, FEBS LETT, V423, P227, DOI 10.1016/S0014-5793(98)00096-9; Reiner O, 2000, NEURON, V28, P633, DOI 10.1016/S0896-6273(00)00142-2; Rosales JL, 2000, J CELL BIOCHEM, V78, P151, DOI 10.1002/(SICI)1097-4644(20000701)78:1<151::AID-JCB14>3.0.CO;2-L; Russell L. D., 1990, HISTOLOGICAL HISTOPA; RUSSELL LD, 1991, AM J ANAT, V192, P97, DOI 10.1002/aja.1001920202; Sasaki S, 2000, NEURON, V28, P681, DOI 10.1016/S0896-6273(00)00146-X; Shao XP, 1997, J BIOL CHEM, V272, P6105, DOI 10.1074/jbc.272.10.6105; Sutovsky P, 2003, MICROSC RES TECHNIQ, V61, P362, DOI 10.1002/jemt.10350; Tovich PR, 2003, J BIOL CHEM, V278, P32431, DOI 10.1074/jbc.M303786200; TSAI LH, 1993, DEVELOPMENT, V119, P1029; VERA JC, 1984, J BIOL CHEM, V259, P5970; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H	52	32	32	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 9	2004	279	2					1224	1232		10.1074/jbc.M310867200	http://dx.doi.org/10.1074/jbc.M310867200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	759DJ	14581463	hybrid			2022-12-27	WOS:000187722800048
J	Turnbull, JJ; Nakajima, J; Welford, RWD; Yamazaki, M; Saito, K; Schofield, CJ				Turnbull, JJ; Nakajima, J; Welford, RWD; Yamazaki, M; Saito, K; Schofield, CJ			Mechanistic studies on three 2-oxoglutarate-dependent oxygenases of flavonoid biosynthesis - Anthocyanidin synthase, flavonol synthase, and flavanone 3 beta-hydroxylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCYRRHIZA-ECHINATA L.; PETUNIA-HYBRIDA; CYTOCHROME-P450 CDNA; ARABIDOPSIS-THALIANA; MOLECULAR-CLONING; ESCHERICHIA-COLI; OXIDATIVE DEMETHYLATION; FUNCTIONAL EXPRESSION; DEPENDENT DIOXYGENASE; CLAVAMINATE SYNTHASE	Anthocyanidin synthase (ANS), flavonol synthase (FLS), and flavanone 3beta-hydroxylase (FHT) are involved in the biosynthesis of flavonoids in plants and are all members of the family of 2-oxoglutarate- and ferrous iron-dependent oxygenases. ANS, FLS, and FHT are closely related by sequence and catalyze oxidation of the flavonoid "C ring"; they have been shown to have overlapping substrate and product selectivities. In the initial steps of catalysis, 2-oxoglutarate and dioxygen are thought to react at the ferrous iron center producing succinate, carbon dioxide, and a reactive ferryl intermediate, the latter of which can then affect oxidation of the flavonoid substrate. Here we describe work on ANS, FLS, and FHT utilizing several different substrates carried out in O-18(2)/(OH2)-O-16, O-16(2)/(OH2)-O-18, and O-18(2)/(OH2)-O-18 atmospheres. In the O-18(2)/(OH2)-O-16 atmosphere close to complete incorporation of a single O-18 label was observed in the dihydroflavonol products (e.g. (2R, 3R)-trans-dihydrokaempferol) from incubations of flavanones (e.g. (2S)naringenin) with FHT, ANS, and FLS. This and other evidence supports the intermediacy of a reactive oxidizing species, the oxygen of which does not exchange with that of water. In the case of products formed by oxidation of flavonoid substrates with a C-3 hydroxyl group (e.g. (2R, 3R)-trans-dihydroquercetin), the results imply that oxygen exchange can occur at a stage subsequent to initial oxidation of the C-ring, probably via an enzyme-bound C-3 ketone/3,3-gem-diol intermediate.	Dyson Perrins Lab, Oxford OX1 3QY, England; Oxford Ctr Mol Sci, Oxford OX1 3QY, England; Chiba Univ, Grad Sch Pharmaceut Sci, Dept Mol Biol & Biotechnol, Inage Ku, Chiba, Japan	University of Oxford; University of Oxford; Chiba University	Saito, K (corresponding author), Dyson Perrins Lab, S Parks Rd, Oxford OX1 3QY, England.	ksaito@p.chiba-u.ac.jp; christopher.schofield@chem.ox.ac.uk	Saito, Kazuki/D-2670-2009; Yamazaki, Mami/A-9050-2010	Saito, Kazuki/0000-0001-6310-5342; Yamazaki, Mami/0000-0001-6157-5287; Schofield, Christopher/0000-0002-0290-6565	Biotechnology and Biological Sciences Research Council [B18672] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Akashi T, 1999, PLANT PHYSIOL, V121, P821, DOI 10.1104/pp.121.3.821; Akashi T, 1998, BIOCHEM BIOPH RES CO, V251, P67, DOI 10.1006/bbrc.1998.9414; Akashi T, 1998, FEBS LETT, V431, P287, DOI 10.1016/S0014-5793(98)00781-9; Akashi T, 1999, PLANT CELL PHYSIOL, V40, P1182, DOI 10.1093/oxfordjournals.pcp.a029505; Anzellotti D, 2000, ARCH BIOCHEM BIOPHYS, V382, P161, DOI 10.1006/abbi.2000.2002; ARAVIND L, 2001, GENOME BIOL; BALDWIN JE, 1993, TETRAHEDRON, V49, P7499, DOI 10.1016/S0040-4020(01)87226-4; Bohm B. A., 1998, INTRO FLAVONOIDS; BRITSCH L, 1990, ARCH BIOCHEM BIOPHYS, V282, P152, DOI 10.1016/0003-9861(90)90099-K; BRITSCH L, 1990, ARCH BIOCHEM BIOPHYS, V276, P348, DOI 10.1016/0003-9861(90)90731-D; BRITSCH L, 1986, EUR J BIOCHEM, V156, P569, DOI 10.1111/j.1432-1033.1986.tb09616.x; BRITSCH L, 1981, Z NATURFORSCH C, V36, P742; BRITSCH L, 1992, J BIOL CHEM, V267, P5380; Falnes PO, 2002, NATURE, V419, P178, DOI 10.1038/nature01048; Ferrer JL, 1999, NAT STRUCT BIOL, V6, P775, DOI 10.1038/11553; FORKMANN G, 1984, PLANTA, V161, P261, DOI 10.1007/BF00982923; Harborne JB, 2000, PHYTOCHEMISTRY, V55, P481, DOI 10.1016/S0031-9422(00)00235-1; Heller W., 1993, FLAVONOIDS ADV RES 1, P499; HELLER W, 1988, FLAVONOIDS, P400; Hewitson KS, 2002, J BIOL CHEM, V277, P26351, DOI 10.1074/jbc.C200273200; HOLME E, 1971, J BIOL CHEM, V246, P3314; HOLME E, 1982, BIOCHEM BIOPH RES CO, V107, P518, DOI 10.1016/0006-291X(82)91522-4; HOLTON TA, 1993, PLANT J, V4, P1003, DOI 10.1046/j.1365-313X.1993.04061003.x; HSU CA, 1981, J BIOL CHEM, V256, P6098; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jez JM, 2000, NAT STRUCT BIOL, V7, P786, DOI 10.1038/79025; Jez JM, 2000, J BIOL CHEM, V275, P39640, DOI 10.1074/jbc.M008569200; KIEHLMANN E, 1995, J NAT PRODUCTS, V58, P450, DOI 10.1021/np50117a018; KIKUCHI Y, 1983, BIOCHEM J, V213, P507, DOI 10.1042/bj2130507; Latunde-Dada AO, 2001, J BIOL CHEM, V276, P1688, DOI 10.1074/jbc.M006277200; Lloyd MD, 1999, TETRAHEDRON, V55, P10201, DOI 10.1016/S0040-4020(99)00547-5; Lukacin R, 2000, ARCH BIOCHEM BIOPHYS, V375, P364, DOI 10.1006/abbi.1999.1676; Lukacin R, 2003, PHYTOCHEMISTRY, V62, P287, DOI 10.1016/S0031-9422(02)00567-8; Martens S, 2003, FEBS LETT, V544, P93, DOI 10.1016/S0014-5793(03)00479-4; Martens S, 2001, PHYTOCHEMISTRY, V58, P43, DOI 10.1016/S0031-9422(01)00191-1; McNeill LA, 2002, BIOORG MED CHEM LETT, V12, P1547, DOI 10.1016/S0960-894X(02)00219-6; Mehn MP, 2003, J AM CHEM SOC, V125, P7828, DOI 10.1021/ja028867f; MYLLYLA R, 1984, J BIOL CHEM, V259, P5403; Nakajima J, 2001, J BIOL CHEM, V276, P25797, DOI 10.1074/jbc.M100744200; Nakanishi K., 1999, COMPREHENSIVE NATURA, V1, P713; Prescott AG, 2002, PHYTOCHEMISTRY, V60, P589, DOI 10.1016/S0031-9422(02)00155-3; Prescott AG, 2000, NAT PROD REP, V17, P367, DOI 10.1039/a902197c; Price JC, 2003, BIOCHEMISTRY-US, V42, P7497, DOI 10.1021/bi030011f; ROBINSON R., 1936, Nature, London, V137, P172, DOI 10.1038/137172a0; Rohde JU, 2003, SCIENCE, V299, P1037, DOI 10.1126/science.299.5609.1037; Ryle MJ, 2002, CURR OPIN CHEM BIOL, V6, P193, DOI 10.1016/S1367-5931(02)00302-2; SABOURIN PJ, 1982, J BIOL CHEM, V257, P7460; Saito K, 1999, PLANT J, V17, P181, DOI 10.1046/j.1365-313X.1999.00365.x; Saito K, 2002, NEW PHYTOL, V155, P9, DOI 10.1046/j.1469-8137.2002.00440.x; Schofield CJ, 1999, CURR OPIN STRUC BIOL, V9, P722, DOI 10.1016/S0959-440X(99)00036-6; Scott-Moncrieff R, 1936, J GENET, V32, P117, DOI 10.1007/BF02982506; Springob K, 2003, NAT PROD REP, V20, P288, DOI 10.1039/b109542k; STAFFORD HA, 1985, PHYTOCHEMISTRY, V24, P333; THORNBURG LD, 1993, BIOCHEMISTRY-US, V32, P14023, DOI 10.1021/bi00213a036; Trewick SC, 2002, NATURE, V419, P174, DOI 10.1038/nature00908; Turnbull JJ, 2003, BIOORG MED CHEM LETT, V13, P3853, DOI 10.1016/S0960-894X(03)00711-X; Turnbull JJ, 2001, ACTA CRYSTALLOGR D, V57, P425, DOI 10.1107/S0907444900019818; Turnbull JJ, 2000, CHEM COMMUN, P2473, DOI 10.1039/b007594i; Welford RWD, 2003, J BIOL CHEM, V278, P10157, DOI 10.1074/jbc.M211058200; Welford RWD, 2001, CHEM COMMUN, P1828, DOI 10.1039/b105576n; Wilmouth RC, 2002, STRUCTURE, V10, P93, DOI 10.1016/S0969-2126(01)00695-5; Wilson WJ, 2002, BIOCHEM BIOPH RES CO, V293, P446, DOI 10.1016/S0006-291X(02)00244-9; Wu M, 2000, BIOORG CHEM, V28, P261; Zhang ZH, 2000, NAT STRUCT BIOL, V7, P127; Zhou J, 2001, J AM CHEM SOC, V123, P7388, DOI 10.1021/ja004025+	66	142	162	3	63	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 9	2004	279	2					1206	1216		10.1074/jbc.M309228200	http://dx.doi.org/10.1074/jbc.M309228200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	759DJ	14570878	hybrid			2022-12-27	WOS:000187722800046
J	Gross, R; Pisa, R; Sanger, M; Lancaster, CRD; Simon, J				Gross, R; Pisa, R; Sanger, M; Lancaster, CRD; Simon, J			Characterization of the menaquinone reduction site in the diheme cytochrome b membrane anchor of Wolinella succinogenes NiFe-hydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUMARATE REDUCTASE; FORMATE DEHYDROGENASE; ELECTRON-TRANSPORT; NITRATE REDUCTASE; REDOX LOOP; VIBRIO-SUCCINOGENES; BACILLUS-SUBTILIS; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; FORCE GENERATION	The majority of bacterial membrane- bound NiFe-hydrogenases and formate dehydrogenases have homologous membrane- integral cytochrome b subunits. The prototypic NiFe-hydrogenase of Wolinella succinogenes (HydABC complex) catalyzes H-2 oxidation by menaquinone during anaerobic respiration and contains a membrane-integral cytochrome b subunit (HydC) that carries the menaquinone reduction site. Using the crystal structure of the homologous FdnI subunit of Escherichia coli formate dehydrogenase-N as a model, the HydC protein was modified to examine residues thought to be involved in menaquinone binding. Variant HydABC complexes were produced in W. succinogenes, and several conserved HydC residues were identified that are essential for growth with H-2 as electron donor and for quinone reduction by H-2. Modification of HydC with a C-terminal Strep-tag II enabled one-step purification of the HydABC complex by Strep-Tactin affinity chromatography. The tagged HydC, separated from HydAB by isoelectric focusing, was shown to contain 1.9 mol of heme b/mol of HydC demonstrating that HydC ligates both heme b groups. The four histidine residues predicted as axial heme b ligands were individually replaced by alanine in Strep-tagged HydC. Replacement of either histidine ligand of the heme b group proximal to HydAB led to HydABC preparations that contained only one heme b group. This remaining heme b could be completely reduced by quinone supporting the view that the menaquinone reduction site is located near the distal heme b group. The results indicate that both heme b groups are involved in electron transport and that the architecture of the menaquinone reduction site near the cytoplasmic side of the membrane is similar to that proposed for E. coli FdnI.	Univ Frankfurt, Inst Mikrobiol, D-60439 Frankfurt, Germany; Max Planck Inst Biophys, D-60439 Frankfurt, Germany	Goethe University Frankfurt; Max Planck Society	Simon, J (corresponding author), Univ Frankfurt, Inst Mikrobiol, Marie Curie Str 9, D-60439 Frankfurt, Germany.		Simon, Jörg/F-2355-2016; Lancaster, C. Roy/E-4313-2010	Simon, Jörg/0000-0003-0214-3745; Lancaster, C. Roy D./0000-0002-2814-0051				BERKS BC, 1995, MOL MICROBIOL, V15, P319, DOI 10.1111/j.1365-2958.1995.tb02246.x; Bertero MG, 2003, NAT STRUCT BIOL, V10, P681, DOI 10.1038/nsb969; Biel S, 2002, EUR J BIOCHEM, V269, P1974, DOI 10.1046/j.1432-1033.2002.02842.x; Blasco F, 2001, CELL MOL LIFE SCI, V58, P179, DOI 10.1007/PL00000846; BODE C, 1968, Z KLIN CHEM KLIN BIO, V6, P418; BRONDER M, 1982, ARCH MICROBIOL, V131, P213; DROSS F, 1992, EUR J BIOCHEM, V206, P93, DOI 10.1111/j.1432-1033.1992.tb16905.x; GEISLER V, 1994, BBA-BIOENERGETICS, V1184, P219, DOI 10.1016/0005-2728(94)90226-7; Gross R, 1999, ARCH MICROBIOL, V172, P227, DOI 10.1007/s002030050764; Gross R, 1998, MOL MICROBIOL, V30, P639, DOI 10.1046/j.1365-2958.1998.01100.x; Gross R, 1998, ARCH MICROBIOL, V170, P50, DOI 10.1007/s002030050614; Hederstedt L, 2002, BBA-BIOENERGETICS, V1553, P74, DOI 10.1016/S0005-2728(01)00231-6; Hunte C, 2003, FEBS LETT, V545, P39, DOI 10.1016/S0014-5793(03)00391-0; JONES RW, 1980, FEMS MICROBIOL LETT, V8, P167, DOI 10.1111/j.1574-6968.1980.tb05072.x; Jormakka M, 2003, FEBS LETT, V545, P25, DOI 10.1016/S0014-5793(03)00389-2; Jormakka M, 2002, SCIENCE, V295, P1863, DOI 10.1126/science.1068186; KLIMMEK O, 2004, IN PRESS RESP ARCHAE; KROGER A, 1976, EUR J BIOCHEM, V69, P497, DOI 10.1111/j.1432-1033.1976.tb10934.x; Kroger A, 2002, BBA-BIOENERGETICS, V1553, P23, DOI 10.1016/S0005-2728(01)00234-1; KROGER A, 1980, BIOCHIM BIOPHYS ACTA, V589, P118, DOI 10.1016/0005-2728(80)90136-X; Kroger A., 1994, PRACTICAL GUIDE MEMB, V2, P141; Lancaster CRD, 2000, P NATL ACAD SCI USA, V97, P13051, DOI 10.1073/pnas.220425797; Lancaster CRD, 1999, NATURE, V402, P377, DOI 10.1038/46483; Lancaster CRD, 2002, BBA-BIOENERGETICS, V1553, P84, DOI 10.1016/S0005-2728(01)00230-4; Lancaster CRD, 2002, BBA-BIOMEMBRANES, V1565, P215, DOI 10.1016/S0005-2736(02)00571-0; Lenger R, 1997, EUR J BIOCHEM, V246, P646, DOI 10.1111/j.1432-1033.1997.t01-2-00646.x; LORENZEN JP, 1993, ARCH MICROBIOL, V159, P477, DOI 10.1007/BF00288597; Meek L, 2000, J BACTERIOL, V182, P3429, DOI 10.1128/JB.182.12.3429-3436.2000; Mulrooney SB, 2003, FEMS MICROBIOL REV, V27, P239, DOI 10.1016/S0168-6445(03)00042-1; Parkhill J, 2000, NATURE, V403, P665, DOI 10.1038/35001088; Richardson D, 2002, SCIENCE, V295, P1842, DOI 10.1126/science.1070366; Richardson DJ, 2001, CELL MOL LIFE SCI, V58, P165, DOI 10.1007/PL00000845; Rothery RA, 2001, J MOL MICROB BIOTECH, V3, P273; Sambrook J., 2002, MOL CLONING LAB MANU; Schnorpfeil M, 2001, EUR J BIOCHEM, V268, P3069, DOI 10.1046/j.1432-1327.2001.02202.x; Simon J, 2000, MOL MICROBIOL, V35, P686, DOI 10.1046/j.1365-2958.2000.01742.x; Simon J, 2002, FEMS MICROBIOL REV, V26, P285, DOI 10.1111/j.1574-6976.2002.tb00616.x; Simon J, 1998, EUR J BIOCHEM, V251, P418, DOI 10.1046/j.1432-1327.1998.2510418.x; Simon J, 2003, MOL MICROBIOL, V49, P69, DOI 10.1046/j.1365-2958.2003.03544.x; Stanley NR, 2002, MOL MICROBIOL, V43, P1005, DOI 10.1046/j.1365-2958.2002.02797.x; UNDEN G, 1986, METHOD ENZYMOL, V126, P387; Vignais PM, 2001, FEMS MICROBIOL REV, V25, P455, DOI 10.1111/j.1574-6976.2001.tb00587.x; Wittershagen A, 1997, SPECTROCHIM ACTA B, V52, P1033, DOI 10.1016/S0584-8547(96)01639-4; Xia D, 1997, SCIENCE, V277, P60, DOI 10.1126/science.277.5322.60	44	41	42	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	2004	279	1					274	281		10.1074/jbc.M310610200	http://dx.doi.org/10.1074/jbc.M310610200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	757GU	14576151	hybrid			2022-12-27	WOS:000187555300034
J	Ong, CK; Ng, CY; Leong, C; Ng, CP; Foo, KT; Tan, PH; Huynh, H				Ong, CK; Ng, CY; Leong, C; Ng, CP; Foo, KT; Tan, PH; Huynh, H			Genomic structure of human OKL38 gene and its differential expression in kidney carcinogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							1ST INTRON; HEPATOCELLULAR-CARCINOMA; CA REPEAT; CANCER; REGION; HETEROZYGOSITY; IDENTIFICATION; POLYMORPHISM; DELETION; BINDING	We previously demonstrated the growth inhibitory property of OKL38 and its possible roles in mammary carcinogenesis. To further understand the regulation and roles of OKL38 in tumorigenesis we proceeded to clone and characterize the human OKL38 gene and three of its variants with transcripts of 1.9, 2.2, and 2.4 kb. The human OKL38 gene spans similar to 18 kb and contains 8 exons and 7 introns with exon size ranging from 92 to 1270 bp. RT-PCR and sequence analysis suggest that different transcripts were arrived through differential promoter usage and alternate splicing. Multiple Tissue Expression array (MTE) and Multiple Tissue Northern blot (MTN) indicated that OKL38 was ubiquitously expressed in all tissues with high expression in liver, kidney, and testis. The cancer profiling array (CPA) of paired normal/tumor cDNA showed that OKL38 mRNA was down-regulated in 70% ( 14 of 20) of kidney tumors. Western analysis revealed that the OKL38 protein was undetectable in 78% ( 7 of 9 pairs) of kidney tumor tissues. Immunohistological analysis showed that 64% ( 14 of 22) of kidney tumors were either lost or underexpressed OKL38 protein compared with the adjacent normal tissue. A transfection study using OKL38-eGFP recombinant construct showed that overexpression of the 52 kDa OKL38 protein in A498 cells resulted in growth inhibition and cell death. This study demonstrates the complex genomic structure of the OKL38 gene and its growth inhibitory and cytotoxic properties. Our data suggest the potential use of OKL38 in diagnosis, prognosis, and/or treatment of kidney cancer.	Natl Canc Ctr, Div Cellular & Mol Res, Mol Endocrinol Lab, Singapore 169610, Singapore; Singapore Gen Hosp, Dept Urol, Singapore 169608, Singapore; Singapore Gen Hosp, Dept Pathol, Singapore 169608, Singapore	National Cancer Centre Singapore (NCCS); Singapore General Hospital; Singapore General Hospital	Huynh, H (corresponding author), Natl Canc Ctr, Div Cellular & Mol Res, Mol Endocrinol Lab, Singapore 169610, Singapore.	cmrhth@nccs.com		Ong, Choon Kiat/0000-0001-6402-4288				Awad M, 1999, HUM IMMUNOL, V60, P343, DOI 10.1016/S0198-8859(98)00133-5; BELLDEGRUN A, 1998, CAMPBELLS UROLOGY, V3, P2283; Burke TW, 1997, GENE DEV, V11, P3020, DOI 10.1101/gad.11.22.3020; Finkel T, 2000, FEBS LETT, V476, P52, DOI 10.1016/S0014-5793(00)01669-0; Fiskerstrand CE, 1999, NEUROSCI LETT, V263, P141, DOI 10.1016/S0304-3940(99)00127-5; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Halliwell B, 1999, FREE RADICAL RES, V31, P261, DOI 10.1080/10715769900300841; Han HJ, 1998, J HUM GENET, V43, P212, DOI 10.1007/s100380050074; HOLMGREN A, 1998, OXIDATIVE STRESS CAN, P229; Hui JY, 2003, NAT STRUCT BIOL, V10, P33, DOI 10.1038/nsb875; Huynh H, 2002, CELL GROWTH DIFFER, V13, P115; Huynh H, 2001, ENDOCRINOLOGY, V142, P3607, DOI 10.1210/en.142.8.3607; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; Kawakami M, 1999, INT J ONCOL, V15, P715; Kosteas T, 1997, HUM GENET, V100, P441, DOI 10.1007/s004390050530; Kozak M, 2002, MAMM GENOME, V13, P401, DOI 10.1007/s00335-002-4002-5; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Latil A, 1997, CANCER RES, V57, P1058; Mateu E, 1999, HUM HERED, V49, P15, DOI 10.1159/000022834; Mejean A, 2003, J UROLOGY, V169, P821, DOI 10.1097/01.ju.0000051378.14270.2a; NIELSEN H, 1998, P 6 INT C INT SYST M; Osborne S A, 2001, BMC Genomics, V2, P10, DOI 10.1186/1471-2164-2-10; Rhee SG, 1999, EXP MOL MED, V31, P53, DOI 10.1038/emm.1999.9; Sato M, 1998, GENE CHROMOSOME CANC, V22, P1; Sheu JC, 1999, BRIT J CANCER, V80, P468, DOI 10.1038/sj.bjc.6690380; Sies H, 1999, FREE RADICAL BIO MED, V27, P916, DOI 10.1016/S0891-5849(99)00177-X; Smith ND, 2003, J UROLOGY, V169, P1219, DOI 10.1097/01.ju.0000056085.58221.80; Toyooka KO, 2001, CANCER RES, V61, P4556; Vogelzang NJ, 1998, LANCET, V352, P1691, DOI 10.1016/S0140-6736(98)01041-1; Williams C. H. J, 1992, CHEM BIOCH FLAVOENZY, P121	30	30	32	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 2	2004	279	1					743	754		10.1074/jbc.M308668200	http://dx.doi.org/10.1074/jbc.M308668200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	757GU	14570898	hybrid			2022-12-27	WOS:000187555300089
J	Otto, M; Hawlisch, H; Monk, PN; Muller, M; Klos, A; Karp, CL; Kohl, J				Otto, M; Hawlisch, H; Monk, PN; Muller, M; Klos, A; Karp, CL; Kohl, J			C5a mutants are potent antagonists of the C5a receptor (CD88) and of C5L2 - Position 69 is the locus that determines agonism or antagonism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISCHEMIA-REPERFUSION INJURY; SITE-DIRECTED MUTAGENESIS; AFFINITY BINDING-SITES; MAST-CELLS; CHEMOATTRACTANT RECEPTOR; FUNCTIONAL-RESPONSES; EPITHELIAL-CELLS; DENDRITIC CELLS; PHAGE LIBRARIES; HUMAN BASOPHILS	The anaphylatoxin C5a exerts a plethora of biologic activities critical in the pathogenesis of systemic inflammatory diseases. Recently, we reported on a C5a mutant, jun/fos-A8, as a potent antagonist for the human and mouse C5a receptor (CD88). Addressing the molecular mechanism accounting for CD88 receptor antagonism by site-directed mutagenesis, we found that a positively charged amino acid at position 69 is crucial. Replacements by either hydrophobic or negatively charged amino acids switched the CD88 antagonist jun/fos-A8 to a CD88 agonist. In addition to CD88, the seven-transmembrane receptor C5L2 has recently been found to provide high affinity binding sites for C5a and its desarginated form, C5adesArg(74). A jun/fos-A8 mutant in which the jun/ fos moieties and amino acids at positions 71 - 73 were deleted, A8(Delta71-73), blocked C5a and C5adesArg(74) binding to CD88 and C5L2. In contrast, the cyclic C5a C-terminal analog peptide AcF-[OP-D-ChaWR] inhibited binding of the two anaphylatoxins to CD88 but not to C5L2, suggesting that the C5a core segment is important for high affinity binding to C5L2. Both receptors are coexpressed on human monocytes and the human mast cell line HMC-1; however, C5L2 expression on monocytes is weaker as compared with HMC-1 cells and highly variable. In contrast, no C5L2 expression was found on human neutrophils. A8(Delta71-73) is the first antagonist that blocks C5a and C5adesArg(74) binding to both C5a receptors, CD88 and C5L2, making it a valuable tool for studying C5L2 functions and for blocking the biological activities of C5a and C5adesArg(74) in mice and humans.	Childrens Hosp Res Fdn, Div Mol Immunol, MLC 7021, Cincinnati, OH 45229 USA; Hannover Med Sch, Inst Med Microbiol, D-30625 Hannover, Germany; Univ Sheffield, Sch Med, Dept Neurol, Sheffield S10 2RX, S Yorkshire, England	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University System of Ohio; University of Cincinnati; Hannover Medical School; University of Sheffield	Kohl, J (corresponding author), Childrens Hosp Res Fdn, Div Mol Immunol, MLC 7021, Cincinnati, OH 45229 USA.	Joerg.Koehl@chmcc.org	Monk, Peter/C-6155-2008; Koehl, Joerg/C-8531-2011	Monk, Peter/0000-0003-4637-3059; Koehl, Joerg/0000-0003-1121-3178; Karp, Christopher/0000-0002-0832-2659				Arumugam TV, 2003, KIDNEY INT, V63, P134, DOI 10.1046/j.1523-1755.2003.00737.x; Baumann U, 2000, J IMMUNOL, V164, P1065, DOI 10.4049/jimmunol.164.2.1065; Baumann U, 2001, J IMMUNOL, V167, P1022, DOI 10.4049/jimmunol.167.2.1022; Bock D, 1997, EUR J IMMUNOL, V27, P1522, DOI 10.1002/eji.1830270631; BOULAY F, 1991, BIOCHEMISTRY-US, V30, P2993, DOI 10.1021/bi00226a002; Bozic CR, 1996, SCIENCE, V273, P1722, DOI 10.1126/science.273.5282.1722; BUBECK P, 1994, EUR J BIOCHEM, V219, P897, DOI 10.1111/j.1432-1033.1994.tb18571.x; Cain SA, 2001, BIOCHEMISTRY-US, V40, P14047, DOI 10.1021/bi011055w; Cain SA, 2002, J BIOL CHEM, V277, P7165, DOI 10.1074/jbc.C100714200; Campbell WD, 2002, MICROBIOL IMMUNOL, V46, P131, DOI 10.1111/j.1348-0421.2002.tb02669.x; Crass T, 1999, J BIOL CHEM, V274, P8367, DOI 10.1074/jbc.274.13.8367; Crass T, 1999, BIOCHEMISTRY-US, V38, P9712, DOI 10.1021/bi990139q; de Vries B, 2003, J IMMUNOL, V170, P3883, DOI 10.4049/jimmunol.170.7.3883; Drouin SM, 2001, J IMMUNOL, V166, P2025, DOI 10.4049/jimmunol.166.3.2025; Eglite S, 2000, J IMMUNOL, V165, P2183, DOI 10.4049/jimmunol.165.4.2183; EMBER JA, 1992, J IMMUNOL, V148, P3165; EMBER JA, 1998, HUMAN COMPLEMENT SYS, P241; Fayyazi A, 2000, IMMUNOLOGY, V99, P38, DOI 10.1046/j.1365-2567.2000.00911.x; FUREDER W, 1995, J IMMUNOL, V155, P3152; Gasque P, 2002, MOL NEUROBIOL, V25, P1, DOI 10.1385/MN:25:1:001; GERARD NP, 1991, NATURE, V349, P614, DOI 10.1038/349614a0; HAVILAND DL, 1995, J IMMUNOL, V154, P1861; Heller T, 1999, J IMMUNOL, V163, P985; Hennecke M, 1998, EUR J BIOCHEM, V252, P36, DOI 10.1046/j.1432-1327.1998.2520036.x; Hennecke M, 1997, GENE, V184, P263, DOI 10.1016/S0378-1119(96)00611-7; Ji H, 2002, IMMUNITY, V16, P157, DOI 10.1016/S1074-7613(02)00275-3; Kalant D, 2003, J BIOL CHEM, V278, P11123, DOI 10.1074/jbc.M206169200; Karp CL, 1996, SCIENCE, V273, P228, DOI 10.1126/science.273.5272.228; Karp CL, 2000, NAT IMMUNOL, V1, P221, DOI 10.1038/79759; Kiener HP, 1998, ARTHRITIS RHEUM-US, V41, P233, DOI 10.1002/1529-0131(199802)41:2<233::AID-ART7>3.0.CO;2-V; Klco JM, 2003, J BIOL CHEM, V278, P35345, DOI 10.1074/jbc.M305606200; KLOS A, 1988, J IMMUNOL METHODS, V111, P241, DOI 10.1016/0022-1759(88)90133-0; KOHL J, 1993, EUR J IMMUNOL, V23, P646, DOI 10.1002/eji.1830230311; KONTEATIS ZD, 1994, J IMMUNOL, V153, P4200; LANZA TJ, 1992, J MED CHEM, V35, P252, DOI 10.1021/jm00080a008; Laudes IJ, 2002, J IMMUNOL, V169, P5962, DOI 10.4049/jimmunol.169.10.5962; Lee DK, 2001, MOL BRAIN RES, V86, P13, DOI 10.1016/S0169-328X(00)00242-4; Marinissen MJ, 2001, TRENDS PHARMACOL SCI, V22, P368, DOI 10.1016/S0165-6147(00)01678-3; Mastellos D, 2001, J IMMUNOL, V166, P2479, DOI 10.4049/jimmunol.166.4.2479; Mellado M, 2001, ANNU REV IMMUNOL, V19, P397, DOI 10.1146/annurev.immunol.19.1.397; MOLLISON KW, 1989, P NATL ACAD SCI USA, V86, P292, DOI 10.1073/pnas.86.1.292; MORGAN EL, 1993, J IMMUNOL, V151, P377; Mukherjee P, 2001, J NEUROCHEM, V77, P43, DOI 10.1046/j.1471-4159.2001.00167.x; Ohno M, 2000, MOL IMMUNOL, V37, P407, DOI 10.1016/S0161-5890(00)00067-5; Okinaga S, 2003, BIOCHEMISTRY-US, V42, P9406, DOI 10.1021/bi034489v; OPPERMANN M, 1993, J IMMUNOL, V151, P3785; OR YS, 1992, J MED CHEM, V35, P402, DOI 10.1021/jm00080a030; Paczkowski NJ, 1999, BRIT J PHARMACOL, V128, P1461, DOI 10.1038/sj.bjp.0702938; Pellas TC, 1998, J IMMUNOL, V160, P5616; Pellas TC, 1999, CURR PHARM DESIGN, V5, P737; Perianayagam MC, 2002, KIDNEY INT, V61, P456, DOI 10.1046/j.1523-1755.2002.00139.x; Raffetseder U, 1996, EUR J BIOCHEM, V235, P82, DOI 10.1111/j.1432-1033.1996.00082.x; Reiman R, 2002, EUR J IMMUNOL, V32, P1157, DOI 10.1002/1521-4141(200204)32:4<1157::AID-IMMU1157>3.3.CO;2-D; Soruri A, 2003, J IMMUNOL, V170, P3306, DOI 10.4049/jimmunol.170.6.3306; Strachan AJ, 2000, J IMMUNOL, V164, P6560, DOI 10.4049/jimmunol.164.12.6560; SUCKAU D, 1990, P NATL ACAD SCI USA, V87, P9848, DOI 10.1073/pnas.87.24.9848; Sumichika H, 2002, J BIOL CHEM, V277, P49403, DOI 10.1074/jbc.M209672200; TOTH MJ, 1994, PROTEIN SCI, V3, P1159, DOI 10.1002/pro.5560030802; Tsuji RF, 2000, J IMMUNOL, V165, P1588, DOI 10.4049/jimmunol.165.3.1588; Werfel T, 1996, SCAND J IMMUNOL, V44, P30, DOI 10.1046/j.1365-3083.1996.d01-272.x; Wittamer V, 2003, J EXP MED, V198, P977, DOI 10.1084/jem.20030382; Wong AK, 1998, J MED CHEM, V41, P3417, DOI 10.1021/jm9800651; Zahedi R, 2000, CLIN EXP IMMUNOL, V121, P226, DOI 10.1046/j.1365-2249.2000.01249.x	63	67	72	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 2	2004	279	1					142	151		10.1074/jbc.M310078200	http://dx.doi.org/10.1074/jbc.M310078200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	757GU	14570896	hybrid			2022-12-27	WOS:000187555300018
J	Cheng, ZJ; Harikumar, KG; Holicky, EL; Miller, LJ				Cheng, ZJ; Harikumar, KG; Holicky, EL; Miller, LJ			Heterodimerization of type A and B cholecystokinin receptors enhance signaling and promote cell growth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CCK-A; FUNCTIONAL EXPRESSION; MOLECULAR-CLONING; GASTRIN; DIMERIZATION; PROLIFERATION; COEXPRESSION; PANCREAS; BINDING; LIGAND	Dimerization of several G protein-coupled receptors has recently been described, but little is known about its clinical and functional relevance. Cholecystokinin (CCK) and gastrin are structurally related gastrointestinal and neuronal peptides whose functions are mediated by two structurally related receptors in this superfamily, the type A and B CCK receptors. We previously demonstrated spontaneous homodimerization of type A CCK receptors and the dissociation of those complexes by agonist occupation (Cheng, Z. J., and Miller, L. J. (2001) J. Biol. Chem. 276, 48040-48047). Here, for the first time, we also demonstrate spontaneous homodimerization of type B CCK receptors, as well as heterodimerization of that receptor with the type A CCK receptor. Unlike type A CCK receptor dimers, the homodimerization of type B CCK receptors was not affected by ligand occupation. However, although heterodimers of type A and B CCK receptors bound natural agonists normally, they exhibited unusual functional and regulatory characteristics. Such complexes demonstrated enhanced agonist-stimulated cellular signaling and delayed agonist-induced receptor internalization. As a likely consequence, agonist-stimulated cell growth was markedly enhanced in cells simultaneously expressing both of these receptors. Our results provide the first evidence that heterodimerization of G protein-coupled receptors can form a more "powerful" signaling unit, which has potential clinical significance in promoting cell growth.	Mayo Clin Scottsdale, Ctr Canc, Scottsdale, AZ 85259 USA; Mayo Clin Scottsdale, Dept Mol Pharmacol & Expt Therapeut, Scottsdale, AZ 85259 USA	Mayo Clinic; Mayo Clinic Phoenix; Mayo Clinic; Mayo Clinic Phoenix	Miller, LJ (corresponding author), Mayo Clin Scottsdale, Ctr Canc, 13400 E Shea Blvd, Scottsdale, AZ 85259 USA.	miller@mayo.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032878, R37DK032878] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AbdAlla S, 2001, NAT MED, V7, P1003, DOI 10.1038/nm0901-1003; Akagi K, 1999, BBA-MOL CELL RES, V1452, P243, DOI 10.1016/S0167-4889(99)00137-8; Angers S, 2000, P NATL ACAD SCI USA, V97, P3684, DOI 10.1073/pnas.060590697; BALDWIN GS, 1995, J GASTROEN HEPATOL, V10, P215, DOI 10.1111/j.1440-1746.1995.tb01083.x; Bouvier M, 2001, NAT REV NEUROSCI, V2, P274, DOI 10.1038/35067575; Cheng ZJ, 2001, J BIOL CHEM, V276, P48040, DOI 10.1074/jbc.M105668200; Clerc P, 2002, GASTROENTEROLOGY, V122, P428, DOI 10.1053/gast.2002.30984; Cvejic S, 1997, J BIOL CHEM, V272, P26959, DOI 10.1074/jbc.272.43.26959; Darrow JW, 1998, BIOORG MED CHEM LETT, V8, P3127, DOI 10.1016/S0960-894X(98)00548-4; Desbois C, 1998, LIFE SCI, V63, P2059; Ding WQ, 2002, CANCER RES, V62, P947; Ding XQ, 2001, PEPTIDES, V22, P1223, DOI 10.1016/S0196-9781(01)00445-4; Ding XQ, 2001, J BIOL CHEM, V276, P4236, DOI 10.1074/jbc.M003798200; Gines S, 2000, P NATL ACAD SCI USA, V97, P8606, DOI 10.1073/pnas.150241097; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hebert TE, 1996, J BIOL CHEM, V271, P16384, DOI 10.1074/jbc.271.27.16384; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; Jordan BA, 1999, NATURE, V399, P697, DOI 10.1038/21441; KOPIN AS, 1992, P NATL ACAD SCI USA, V89, P3605, DOI 10.1073/pnas.89.8.3605; Kroeger KM, 2001, J BIOL CHEM, V276, P12736, DOI 10.1074/jbc.M011311200; Kuner R, 1999, SCIENCE, V283, P74, DOI 10.1126/science.283.5398.74; MAGGIO R, 1993, P NATL ACAD SCI USA, V90, P3103, DOI 10.1073/pnas.90.7.3103; MAGGIO R, 1993, FEBS LETT, V319, P195, DOI 10.1016/0014-5793(93)80066-4; Miller LJ, 1996, GASTROENTEROLOGY, V111, P1767, DOI 10.1016/S0016-5085(96)70045-8; Monnot C, 1996, J BIOL CHEM, V271, P1507, DOI 10.1074/jbc.271.3.1507; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; Nishimori I, 1999, PANCREAS, V19, P109, DOI 10.1097/00006676-199908000-00001; Ohlsson B, 1998, INT J PANCREATOL, V24, P211; Pfeiffer M, 2001, J BIOL CHEM, V276, P14027, DOI 10.1074/jbc.M006084200; Rocheville M, 2000, J BIOL CHEM, V275, P7862, DOI 10.1074/jbc.275.11.7862; ROETTGER BF, 1995, J CELL BIOL, V128, P1029, DOI 10.1083/jcb.128.6.1029; Rozengurt E, 2001, ANNU REV PHYSIOL, V63, P49, DOI 10.1146/annurev.physiol.63.1.49; SETHI T, 1992, CANCER RES, V52, P6031; SEVA C, 1990, DIGESTION, V46, P166, DOI 10.1159/000200381; Todisco A, 1997, AM J PHYSIOL-GASTR L, V273, pG891, DOI 10.1152/ajpgi.1997.273.4.G891; ULRICH CD, 1993, BIOCHEM BIOPH RES CO, V193, P204, DOI 10.1006/bbrc.1993.1610; WANK SA, 1994, ANN NY ACAD SCI, V713, P49, DOI 10.1111/j.1749-6632.1994.tb44052.x; Weinberg DS, 1997, J CLIN INVEST, V100, P597, DOI 10.1172/JCI119570; White JH, 1998, NATURE, V396, P679, DOI 10.1038/25354; Williams CL, 1997, PEPTIDES, V18, P409, DOI 10.1016/S0196-9781(96)00341-5; WOODRUFF GN, 1991, NEUROPEPTIDES, V19, P45, DOI 10.1016/0143-4179(91)90082-T; Zeng FY, 1999, J BIOL CHEM, V274, P19487, DOI 10.1074/jbc.274.27.19487	42	57	61	0	4	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52972	52979		10.1074/jbc.M310090200	http://dx.doi.org/10.1074/jbc.M310090200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14534299	hybrid			2022-12-27	WOS:000187480700120
J	Lim, CS; Kim, SH; Jung, JG; Kim, JK; Song, WK				Lim, CS; Kim, SH; Jung, JG; Kim, JK; Song, WK			Regulation of SPIN90 phosphorylation and interaction with Nck by ERK and cell adhesion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; SIGNAL-TRANSDUCTION; ADAPTER PROTEIN; GROWTH-FACTOR; SH3 DOMAINS; 90 KDA; ACTIVATION; TYROSINE; BINDING; PROLINE	SPIN90 is a widely expressed Nck-binding protein that contains one Src homology 3 (SH3) domain, three Pro-rich motifs, and a serine/threonine-rich region, and is known to participate in sarcomere assembly during cardiac myocyte differentiation. We used in vitro binding assays and yeast two-hybrid screening analysis to identify Nck, betaPIX, Wiscott-Aldrich syndrome protein (WASP), and ERK1 as SPIN90-binding proteins. It appears that betaPIX, WASP, and SPIN90 form a complex that interacts with Nck in a manner dependent upon cell adhesion to extracellular matrix. The betaPIX . WASP . SPIN90 . Nck interaction was abolished in suspended and cytochalasin D-treated cells, but was recovered when cells were replated on fibronectin-coated dishes. The SPIN90 . betaPIX . WASP complex was stable, even in suspended cells, suggesting SPIN90 serves as an adaptor molecule to recruit other proteins to Nck at focal adhesions. In addition, we found that overexpression of the SPIN90 SH3 domain or Pro-rich region, respectively, abolished SPIN90 . Nck and SPIN90 . betaPIX interactions, resulting in detachment of cells from extracellular matrix. SPIN90 was phosphorylated by ERK1, which was, itself, activated by cell adhesion and platelet-derived growth factor. Such phosphorylation of SPIN90 likely promotes the interaction of the SPIN90 . betaPIX . WASP complex and Nck. It thus appears that the interaction of the betaPIX . WASP . SPIN90 complex with Nck is crucial for stable cell adhesion and can be dynamically modulated by SPIN90 phosphorylation that is dependent on cell adhesion and ERK activation.	Kwangju Inst Sci & Technol, Dept Life Sci, Gwangju 500712, South Korea; Changwon Natl Univ, Dept Microbiol, Chang Won 641773, South Korea	Gwangju Institute of Science & Technology (GIST); Changwon National University	Song, WK (corresponding author), Kwangju Inst Sci & Technol, Dept Life Sci, 1 Oryong Dong, Gwangju 500712, South Korea.	wksong@kjist.ac.kr	Kim, Sung Hyun/AAI-8554-2020	Jung, Jin/0000-0002-4296-4786; Kim, Sung Hyun/0000-0002-3166-9941				ALEXANDROPOULOS K, 1995, P NATL ACAD SCI USA, V92, P3110, DOI 10.1073/pnas.92.8.3110; Aplin AE, 1998, PHARMACOL REV, V50, P197; BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; Bagrodia S, 1999, TRENDS CELL BIOL, V9, P350, DOI 10.1016/S0962-8924(99)01618-9; Bagrodia S, 1999, J BIOL CHEM, V274, P22393, DOI 10.1074/jbc.274.32.22393; Bi EF, 1999, CURR BIOL, V9, pR160, DOI 10.1016/S0960-9822(99)80102-X; Bokoch GM, 1996, J BIOL CHEM, V271, P25746, DOI 10.1074/jbc.271.42.25746; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; Buday L, 2002, CELL SIGNAL, V14, P723, DOI 10.1016/S0898-6568(02)00027-X; Chang F, 2003, LEUKEMIA, V17, P1263, DOI 10.1038/sj.leu.2402945; CHOU MM, 1995, J BIOL CHEM, V270, P7359, DOI 10.1074/jbc.270.13.7359; Daniels RH, 1999, TRENDS BIOCHEM SCI, V24, P350, DOI 10.1016/S0968-0004(99)01442-5; Daniels RH, 1998, EMBO J, V17, P754, DOI 10.1093/emboj/17.3.754; DAVIS RJ, 1995, MOL REPROD DEV, V42, P459, DOI 10.1002/mrd.1080420414; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Fincham VJ, 2000, EMBO J, V19, P2911, DOI 10.1093/emboj/19.12.2911; Frodin M, 1999, MOL CELL ENDOCRINOL, V151, P65, DOI 10.1016/S0303-7207(99)00061-1; Fukuoka M, 2001, J CELL BIOL, V152, P471, DOI 10.1083/jcb.152.3.471; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Hannigan GE, 1997, J MOL MED, V75, P35, DOI 10.1007/s001090050084; Howe AK, 2002, CURR OPIN GENET DEV, V12, P30, DOI 10.1016/S0959-437X(01)00260-X; HU QJ, 1995, MOL CELL BIOL, V15, P1169; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; Kim YY, 1999, CELL ADHES COMMUN, V7, P85, DOI 10.3109/15419069909034393; Knaus UG, 1998, INT J BIOCHEM CELL B, V30, P857, DOI 10.1016/S1357-2725(98)00059-4; Lee SH, 2001, J BIOL CHEM, V276, P25066, DOI 10.1074/jbc.M010892200; Leopoldt D, 2000, J CELL PHYSIOL, V183, P208, DOI 10.1002/(SICI)1097-4652(200005)183:2<208::AID-JCP7>3.0.CO;2-5; LI W, 1992, MOL CELL BIOL, V12, P5824, DOI 10.1128/MCB.12.12.5824; Lim CS, 2001, J BIOL CHEM, V276, P12871, DOI 10.1074/jbc.M009411200; MORTON CJ, 1994, CURR BIOL, V4, P615, DOI 10.1016/S0960-9822(00)00134-2; PERALDI P, 1993, ENDOCRINOLOGY, V132, P2578, DOI 10.1210/en.132.6.2578; Porter JC, 1998, TRENDS CELL BIOL, V8, P390, DOI 10.1016/S0962-8924(98)01344-0; Quilliam LA, 1996, J BIOL CHEM, V271, P28772, DOI 10.1074/jbc.271.46.28772; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RIVEROLEZCANO OM, 1995, MOL CELL BIOL, V15, P5725; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; SEGER R, 1991, P NATL ACAD SCI USA, V88, P6142, DOI 10.1073/pnas.88.14.6142; Smith JM, 1999, J BIOL CHEM, V274, P27956, DOI 10.1074/jbc.274.39.27956; Su YC, 1997, EMBO J, V16, P1279, DOI 10.1093/emboj/16.6.1279; Vidal M, 2001, CRIT REV ONCOL HEMAT, V40, P175, DOI 10.1016/S1040-8428(01)00142-1; WANG JK, 1994, MOL CELL BIOL, V14, P181, DOI 10.1128/MCB.14.1.181; Wunderlich L, 1999, CELL SIGNAL, V11, P25, DOI 10.1016/S0898-6568(98)00027-8; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0	46	24	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52116	52123		10.1074/jbc.M310974200	http://dx.doi.org/10.1074/jbc.M310974200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14559906	hybrid			2022-12-27	WOS:000187480700018
J	Opatowsky, Y; Chomsky-Hecht, O; Kang, MG; Campbell, KP; Hirsch, JA				Opatowsky, Y; Chomsky-Hecht, O; Kang, MG; Campbell, KP; Hirsch, JA			The voltage-dependent calcium channel beta subunit contains two stable interacting domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+ CHANNEL; SKELETAL-MUSCLE; ALPHA(1A) SUBUNIT; NEURAL NETWORKS; PROTEIN; INACTIVATION; PROTEOLYSIS; ASSOCIATION; EXPRESSION; ACTIVATION	Voltage-dependent calcium channels selectively enable Ca2+ ion movement through cellular membranes. These multiprotein complexes are involved in a wide spectrum of biological processes such as signal transduction and cellular homeostasis. alpha(1) is the membrane pore-forming subunit, whereas beta is an intracellular subunit that binds to alpha(1), facilitating and modulating channel function. We have expressed, purified, and characterized recombinant beta(3) and beta(2a) using both biochemical and biophysical methods, including electrophysiology, to better understand the beta family's protein structural and functional correlates. Our results indicate that the beta protein is composed of two distinct domains that associate with one another in a stable manner. The data also suggest that the polypeptide regions outside these domains are not structured when beta is not in complex with the channel. In addition, the beta structural core, comprised of just these two domains without other sequences, binds tightly to the alpha interaction domain (AID) motif, a sequence derived from the alpha(1) subunit and the principal anchor site of beta. Domain II is responsible for this binding, but domain I enhances it.	Tel Aviv Univ, Fac Life Sci, Dept Biochem, IL-69978 Ramat Aviv, Israel; Univ Iowa, Carver Coll Med, Howard Hughes Med Inst, Dept Physiol & Biophys, Iowa City, IA 52242 USA	Tel Aviv University; Howard Hughes Medical Institute; University of Iowa	Hirsch, JA (corresponding author), Tel Aviv Univ, Fac Life Sci, Dept Biochem, Sherman Bldg,Rm 621, IL-69978 Ramat Aviv, Israel.	jhirsch@post.tau.ac.il	Hirsch, Joel/AAC-8000-2021; Tuluc, Petronel/C-2527-2011	Hirsch, Joel/0000-0001-7544-8668; Campbell, Kevin/0000-0003-2066-5889; Kang, Myoung-Goo/0000-0003-2649-219X				AUSIO J, 1987, BIOCHEMISTRY-US, V26, P975, DOI 10.1021/bi00378a001; Bers DR, 1999, CARDIOVASC RES, V42, P339, DOI 10.1016/S0008-6363(99)00038-3; Bichet D, 2000, NEURON, V25, P177, DOI 10.1016/S0896-6273(00)80881-8; Birnbaumer L, 1998, J BIOENERG BIOMEMBR, V30, P357, DOI 10.1023/A:1021989622656; BOHM G, 1992, PROTEIN ENG, V5, P191, DOI 10.1093/protein/5.3.191; Brice NL, 1997, EUR J NEUROSCI, V9, P749, DOI 10.1111/j.1460-9568.1997.tb01423.x; Canti C, 1999, J NEUROSCI, V19, P6855, DOI 10.1523/JNEUROSCI.19-16-06855.1999; Catterall WA, 1996, J BIOENERG BIOMEMBR, V28, P219, DOI 10.1007/BF02110697; DEWAARD M, 1994, NEURON, V13, P495, DOI 10.1016/0896-6273(94)90363-8; Finkbeiner S, 1998, J NEUROBIOL, V37, P171, DOI 10.1002/(SICI)1097-4695(199810)37:1<171::AID-NEU13>3.0.CO;2-H; Hanlon MR, 1999, FEBS LETT, V445, P366, DOI 10.1016/S0014-5793(99)00156-8; Hubbard SJ, 1998, PROTEIN ENG, V11, P349, DOI 10.1093/protein/11.5.349; Hubbard SJ, 1998, BBA-PROTEIN STRUCT M, V1382, P191, DOI 10.1016/S0167-4838(97)00175-1; Kang MG, 2001, J BIOL CHEM, V276, P32917, DOI 10.1074/jbc.M100787200; Kapust RB, 1999, PROTEIN SCI, V8, P1668, DOI 10.1110/ps.8.8.1668; LACERDA AE, 1991, NATURE, V352, P527, DOI 10.1038/352527a0; LEUNG AT, 1988, J BIOL CHEM, V263, P994; Nakai J, 1998, J BIOL CHEM, V273, P24983, DOI 10.1074/jbc.273.39.24983; PRAGNELL M, 1994, NATURE, V368, P67, DOI 10.1038/368067a0; Pupko T, 2002, BIOINFORMATICS, V18, P1116, DOI 10.1093/bioinformatics/18.8.1116; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; Romero P, 2001, PROTEINS, V42, P38, DOI 10.1002/1097-0134(20010101)42:1<38::AID-PROT50>3.0.CO;2-3; Rost B, 1996, METHOD ENZYMOL, V266, P525; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SINGER D, 1991, SCIENCE, V253, P1553, DOI 10.1126/science.1716787; Stephens GJ, 2000, J PHYSIOL-LONDON, V525, P377, DOI 10.1111/j.1469-7793.2000.t01-1-00377.x; TAKAHASHI M, 1987, BIOCHEMISTRY-US, V26, P5518, DOI 10.1021/bi00391a046; Tareilus E, 1997, P NATL ACAD SCI USA, V94, P1703, DOI 10.1073/pnas.94.5.1703; VARADI G, 1991, NATURE, V352, P159, DOI 10.1038/352159a0; Walker D, 1998, TRENDS NEUROSCI, V21, P148, DOI 10.1016/S0166-2236(97)01200-9; Walker D, 1999, J BIOL CHEM, V274, P12383, DOI 10.1074/jbc.274.18.12383; Walker D, 1998, J BIOL CHEM, V273, P2361, DOI 10.1074/jbc.273.4.2361; WITCHER DR, 1995, J BIOL CHEM, V270, P18088, DOI 10.1074/jbc.270.30.18088; Yamaguchi H, 1998, J BIOL CHEM, V273, P19348, DOI 10.1074/jbc.273.30.19348; [No title captured]	35	66	68	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52323	52332		10.1074/jbc.M303564200	http://dx.doi.org/10.1074/jbc.M303564200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14559910	Green Submitted, hybrid			2022-12-27	WOS:000187480700042
J	Valentin, FO; Field, MC; Tippins, JR				Valentin, FO; Field, MC; Tippins, JR			The mechanism of oxidative stress stabilization of the thromboxane receptor in COS-7 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNFOLDED-PROTEIN RESPONSE; ENDOPLASMIC-RETICULUM; PLASMA-MEMBRANE; N-GLYCOSYLATION; A(2) RECEPTOR; ISOPROSTANE; DISEASE; RAT; EXPRESSION; HEART	The 8-iso-prostaglandin F-2alpha, a prostanoid produced in vivo by cyclooxygenase-independent free-radical-catalyzed lipid peroxidation, acts as a partial agonist on the thromboxane receptor (TXA(2)R) and is a potent vasoconstrictor in the oxidatively stressed isolated perfused rat heart. We hypothesized that the response in the isolated heart may be due to augmentation of TXA(2)R density, which may be initiated by the presence of oxidative radicals. Previous studies have shown that TXA(2)R density is increased during atherosclerosis on both the medial and intimal smooth muscle layers in human coronary arteries. Here we describe the effect of oxidative stress on TXA(2)R. The thromboxane A(2) receptor beta isoform (TXA(2)Rbeta) was transiently expressed in COS-7 cells. Immunofluorescence suggested that the presence of H2O2 increased translocation of TXA(2)Rbeta from the endoplasmic reticulum (ER) to the Golgi complex. H2O2 treatment also increased binding of a TXA(2)R antagonist ([H-3] SQ29548) to membranes. Degradation kinetics of TXA(2)Rbeta following cycloheximide treatment, a protein synthesis inhibitor, suggested not only that TXA(2)Rbeta is a short-lived protein predominantly localized to the ER but also that TXA(2)Rbeta degradation is modulated in the presence of H2O2. Our results indicate that oxidative stress induces maturation and stabilization of the TXA(2)Rbeta protein probably by intracellular translocation. Importantly, these observations also suggest that TXA(2)Rbeta levels are modulated by ER-associated degradation and controlled by the efficiency of transport to post-ER compartments. Stabilization of the TXA(2)Rbeta by translocation from a degradative compartment, i.e. the ER, can account for the augmentation of receptor density observed in vivo.	Univ London Imperial Coll Sci Technol & Med, Dept Biol Sci, London SW7 2AZ, England; Univ London Imperial Coll Sci Technol & Med, Wellcome Trust Labs Mol Parasitol, London SW7 2AZ, England	Imperial College London; Imperial College London	Tippins, JR (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Biol Sci, Exhibit Rd, London SW7 2AZ, England.	j.tippins@imperial.ac.uk	Field, Mark/AAD-6455-2021	Field, Mark/0000-0002-4866-2885				Audoly LP, 2000, CIRCULATION, V101, P2833, DOI 10.1161/01.CIR.101.24.2833; BECKER KP, 1998, BIOCHIM BIOPHYS ACTA, V27, P109; Benedetti C, 2000, BIOCHEM BIOPH RES CO, V278, P530, DOI 10.1006/bbrc.2000.3838; Boer U, 2000, BIOCHEM J, V350, P839, DOI 10.1042/0264-6021:3500839; Chapman R, 1998, ANNU REV CELL DEV BI, V14, P459, DOI 10.1146/annurev.cellbio.14.1.459; Chiang N, 1998, ARCH BIOCHEM BIOPHYS, V352, P207, DOI 10.1006/abbi.1998.0620; DONALDSON JG, 1990, J CELL BIOL, V111, P2295, DOI 10.1083/jcb.111.6.2295; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; FITZGERALD GA, 1987, FASEB J, V46, P154; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Halaban R, 2001, J BIOL CHEM, V276, P11933, DOI 10.1074/jbc.M008703200; HIRATA M, 1991, NATURE, V349, P617, DOI 10.1038/349617a0; John GW, 1997, BRIT J PHARMACOL, V122, P899, DOI 10.1038/sj.bjp.0701441; Kamekura I, 1999, J CARDIOVASC PHARM, V33, P836, DOI 10.1097/00005344-199906000-00002; Katugampola SD, 2002, CLIN SCI, V103, p171S, DOI 10.1042/CS103S171S; Katugampola SD, 2001, BRIT J PHARMACOL, V134, P1385, DOI 10.1038/sj.bjp.0704416; KOPITO RR, 1999, PHYSIOL REV, V79, P167; Kromer BM, 1999, BRIT J PHARMACOL, V126, P1171, DOI 10.1038/sj.bjp.0702433; Kromer BM, 1996, BRIT J PHARMACOL, V119, P1276, DOI 10.1111/j.1476-5381.1996.tb16033.x; Mehrabi MR, 1999, CARDIOVASC RES, V43, P492; MODESTI PA, 1995, AM HEART J, V129, P873, DOI 10.1016/0002-8703(95)90106-X; MORINELLI TA, 1994, J BIOL CHEM, V269, P5693; MORROW JD, 1990, ANAL BIOCHEM, V184, P1, DOI 10.1016/0003-2697(90)90002-Q; Narumiya S, 1999, PHYSIOL REV, V79, P1193, DOI 10.1152/physrev.1999.79.4.1193; RAYCHOWDHURY MK, 1994, J BIOL CHEM, V269, P19256; RICKWOOD D, 1982, ANAL BIOCHEM, V123, P23, DOI 10.1016/0003-2697(82)90618-2; Sato N, 2000, NAT CELL BIOL, V2, P863, DOI 10.1038/35046500; Shang J, 2002, GLYCOBIOLOGY, V12, P307, DOI 10.1093/glycob/12.5.307; SMRCKA AV, 1993, J BIOL CHEM, V268, P9667; SOUSA M, 1995, EMBO J, V14, P4196, DOI 10.1002/j.1460-2075.1995.tb00093.x; SUN DQ, 1994, CIRCULATION, V89, P793, DOI 10.1161/01.CIR.89.2.793; YATSUNAMI K, 1990, BIOCHIM BIOPHYS ACTA, V1051, P94, DOI 10.1016/0167-4889(90)90178-G; YOSHIMURA A, 1990, P NATL ACAD SCI USA, V87, P4139, DOI 10.1073/pnas.87.11.4139	33	40	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					8316	8324		10.1074/jbc.M306761200	http://dx.doi.org/10.1074/jbc.M306761200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14583632	hybrid			2022-12-27	WOS:000189103300113
J	Wong, GW; Yasuda, S; Morokawa, N; Li, LX; Stevens, RL				Wong, GW; Yasuda, S; Morokawa, N; Li, LX; Stevens, RL			Mouse chromosome 17A3.3 contains 13 genes that encode functional tryptic-like serine proteases with distinct tissue and cell expression patterns	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE MAST-CELL; SUBSTRATE-SPECIFICITY; COMPLEMENTARY-DNA; MESSENGER-RNA; TRYPTASES; CLONING; PROTEIN; FAMILY; MEMBER; DIFFERENTIATION	Probing of the mouse EST data base at GenBank(TM) with known tryptase cDNAs resulted in the identification of undiscovered serine protease transcripts whose genes reside at a 1.5-Mb complex on mouse chromosome 17A3.3. Mouse tryptase-5 (mT5), tryptase-6 (mT6), and mast cell protease-11 (mMCP-11) are new members of this serine protease superfamily whose amino acid sequences are 36 - 54% identical to each other and to their other 10 family members. The 13 functional mouse proteases can be subdivided into two subgroups based on conserved features in their propeptides. Of the three new serine proteases, mT6 is most widely expressed in tissues. mT5 is preferentially expressed in smooth muscle, whereas mMCP-11 is preferentially expressed in the spleen and bone marrow. In contrast to mT5 and mT6, mMCP-11 is also expressed in mast cells. Although mT6 and mMCP-11 are constitutively secreted when expressed in mammalian and insect cells, mT5 remains membrane-associated. The fact that recombinant mT5, mT6, and mMCP-11 possess non-identical expression patterns and substrate specificities suggests that each protease has a unique function in vivo. Of the 13 functional mouse tryptase genes identified at the complex, 12 have orthologs that reside in the syntenic region of human chromosome 16p13.3. The establishment of these ortholog pairs helps clarify the evolutionary relationship of the serine protease locus in the two species. This information provides a useful framework for the functional analysis of each protease using gene targeting and other molecular approaches.	Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Stevens, RL (corresponding author), Brigham & Womens Hosp, Dept Med, Smith Bldg,Rm 616B,1 Jimmy Fund Way, Boston, MA 02115 USA.	rstevens@rics.bwh.harvard.edu	Yasuda, Shinsuke/A-4369-2012	Wong, G. William/0000-0002-5286-6506	NHLBI NIH HHS [HL-63284, HL-36110] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036110, R01HL063284] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Badge RM, 2000, HUM MOL GENET, V9, P1239, DOI 10.1093/hmg/9.8.1239; BENYON RC, 1991, INT ARCH ALLER A IMM, V94, P218, DOI 10.1159/000235364; Bhagwandin VJ, 2003, J BIOL CHEM, V278, P3363, DOI 10.1074/jbc.M209353200; CAMPANELLI D, 1990, J CLIN INVEST, V85, P904, DOI 10.1172/JCI114518; Caughey GH, 2000, J IMMUNOL, V164, P6566, DOI 10.4049/jimmunol.164.12.6566; Chen C, 2003, BIOCHEM J, V374, P97, DOI 10.1042/BJ20030242; Chertov O, 1997, J EXP MED, V186, P739, DOI 10.1084/jem.186.5.739; CROMLISH JA, 1987, J BIOL CHEM, V262, P1363; EKLUND KK, 1993, J IMMUNOL, V151, P4266; GHILDYAL N, 1994, J IMMUNOL, V153, P2624; GHILDYAL N, 1993, J IMMUNOL, V151, P3206; GURISH MF, 1992, J EXP MED, V175, P1003, DOI 10.1084/jem.175.4.1003; Hallgren J, 2000, BIOCHEMISTRY-US, V39, P13068, DOI 10.1021/bi000973b; Harris JL, 2001, J BIOL CHEM, V276, P34941, DOI 10.1074/jbc.M102997200; Honda A, 2002, J BIOL CHEM, V277, P16976, DOI 10.1074/jbc.M112470200; Hooper JD, 1999, CANCER RES, V59, P3199; Huang C, 2000, J BIOL CHEM, V275, P351, DOI 10.1074/jbc.275.1.351; Huang CF, 1997, J BIOL CHEM, V272, P31885, DOI 10.1074/jbc.272.50.31885; Huang CF, 1998, J IMMUNOL, V160, P1910; Huang CF, 1999, J BIOL CHEM, V274, P19670, DOI 10.1074/jbc.274.28.19670; Huang CF, 2001, J BIOL CHEM, V276, P26276, DOI 10.1074/jbc.M102356200; Inoue M, 1998, BIOCHEM BIOPH RES CO, V252, P307, DOI 10.1006/bbrc.1998.9645; JOHNSON DA, 1992, PROTEIN SCI, V1, P370; MCNEIL HP, 1992, P NATL ACAD SCI USA, V89, P11174, DOI 10.1073/pnas.89.23.11174; Mekori YA, 1999, J ALLERGY CLIN IMMUN, V104, P517, DOI 10.1016/S0091-6749(99)70316-7; MILLER JS, 1990, J CLIN INVEST, V86, P864, DOI 10.1172/JCI114786; MILLER JS, 1989, J CLIN INVEST, V84, P1188, DOI 10.1172/JCI114284; MORGAN JG, 1991, J IMMUNOL, V147, P3210; O'Sullivan CM, 2001, REPRODUCTION, V122, P235, DOI 10.1530/rep.0.1220235; O'Sullivan CM, 2001, REPRODUCTION, V122, P61, DOI 10.1530/rep.0.1220061; Ochi H, 1999, J EXP MED, V190, P267, DOI 10.1084/jem.190.2.267; Oh SW, 2002, J IMMUNOL, V168, P1992, DOI 10.4049/jimmunol.168.4.1992; Pallaoro M, 1999, J BIOL CHEM, V274, P3355, DOI 10.1074/jbc.274.6.3355; PEREIRA HA, 1995, J LEUKOCYTE BIOL, V57, P805, DOI 10.1002/jlb.57.6.805; Pereira PJB, 1998, NATURE, V392, P306, DOI 10.1038/32703; RAZIN E, 1984, J IMMUNOL, V132, P1479; REYNOLDS DS, 1991, J BIOL CHEM, V266, P3847; Scarman AL, 2001, EUR J BIOCHEM, V268, P1250, DOI 10.1046/j.1432-1327.2001.01986.x; Shaw-Smith CJ, 2000, BBA-GENE STRUCT EXPR, V1490, P131, DOI 10.1016/S0167-4781(99)00226-2; VANDERSLICE P, 1990, P NATL ACAD SCI USA, V87, P3811, DOI 10.1073/pnas.87.10.3811; Wang HW, 2002, J IMMUNOL, V169, P5145, DOI 10.4049/jimmunol.169.9.5145; WILLIAMS EB, 1989, J BIOL CHEM, V264, P7536; Wong GW, 2001, J BIOL CHEM, V276, P49169, DOI 10.1074/jbc.M108677200; Wong GW, 2002, J BIOL CHEM, V277, P41906, DOI 10.1074/jbc.M205868200; Wong GW, 2001, J BIOL CHEM, V276, P20648, DOI 10.1074/jbc.M010422200; Wong UW, 1999, J BIOL CHEM, V274, P30784, DOI 10.1074/jbc.274.43.30784; Xia ZN, 1996, J BIOL CHEM, V271, P8747, DOI 10.1074/jbc.271.15.8747; Yasuda S, 2003, FASEB J, V17, pC12	48	59	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	2004	279	4					2438	2452		10.1074/jbc.M308209200	http://dx.doi.org/10.1074/jbc.M308209200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	764MU	14583634	hybrid			2022-12-27	WOS:000188211300015
J	Galleguillos, D; Vecchiola, A; Fuentealba, JA; Ojeda, V; Alvarez, K; Gomez, A; Andres, ME				Galleguillos, D; Vecchiola, A; Fuentealba, JA; Ojeda, V; Alvarez, K; Gomez, A; Andres, ME			PIAS gamma represses the transcriptional activation induced by the nuclear receptor Nurr1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NGFI-B; TYROSINE-HYDROXYLASE; ANDROGEN RECEPTOR; SUBSTANTIA-NIGRA; GENE ACTIVATION; IDENTIFICATION; EXPRESSION; MOTIF; SUMO; HETERODIMERIZATION	Nurr1 is a transcription factor essential for the development of ventral dopaminergic neurons. In search for regulatory mechanisms of Nurr1 function, we identified the SUMO ( small ubiquitin-like modifier)-E3 ubiquitin-protein isopeptide ligase, PIASgamma, as an interaction partner of Nurr1. Overexpressed PIASgamma and Nurr1 co-localize in the nuclei of transfected cells, and their interaction is demonstrated through co-immunoprecipitation and glutathione S-transferase pulldown assays. Co-expression of PIASgamma with Nurr1 results in a potent repression of Nurr1-dependent transcriptional activation of an artificial NGFI-B response element (NBRE) reporter as well as of a reporter driven by the native tyrosine hydroxylase promoter. We identified two consensus sumoylation sites in Nurr1. The substitution of lysine 91 by arginine in one SUMO site enhanced the transcriptional activity of Nurr1, whereas the substitution of lysine 577 by arginine in the second SUMO site decreased transcriptional activity of Nurr1. Interestingly, PIASgamma-induced repression of Nurr1 activity does not require the two sumoylation sites, because each mutant is repressed as efficiently as the wild type Nurr1. In addition, the mutations do not alter Nurr1 nuclear localization. Finally, we provide evidence that Nurr1 and PIASgamma co-exist in several nuclei of the rodent central nervous system by demonstrating the co-expression of Nurr1 protein and PIASgamma mRNA in the same cells. In conclusion, our studies identified PIASgamma as a transcriptional co-regulator of Nurr1 and suggest that this interaction may have a physiological role in regulating the expression of Nurr1 target genes.	Pontificia Univ Catolica Chile, Fac Ciencias Biol, Dept Biol Celular & Mol, Santiago, Chile	Pontificia Universidad Catolica de Chile	Andres, ME (corresponding author), Pontificia Univ Catolica Chile, Fac Ciencias Biol, Dept Biol Celular & Mol, Alameda 340,POB 114-D, Santiago, Chile.	mandres@bio.puc.cl	Fuentealba, Jose Antonio/AAF-6897-2020	Fuentealba-Evans, Jose/0000-0003-0775-0675; Galleguillos, Danny/0000-0001-6987-9322; Alvarez, Karin/0000-0001-5349-0267				Andres ME, 1996, J NEUROSCI RES, V46, P375, DOI 10.1002/(SICI)1097-4547(19961101)46:3<375::AID-JNR11>3.3.CO;2-W; Andres ME, 1999, P NATL ACAD SCI USA, V96, P9873, DOI 10.1073/pnas.96.17.9873; Bonifati V, 2003, SCIENCE, V299, P256, DOI 10.1126/science.1077209; Castillo SO, 1998, MOL CELL NEUROSCI, V11, P36, DOI 10.1006/mcne.1998.0673; Castro DS, 1999, J BIOL CHEM, V274, P37483, DOI 10.1074/jbc.274.52.37483; Chauchereau A, 2003, J BIOL CHEM, V278, P12335, DOI 10.1074/jbc.M207148200; Cookson MR, 2003, NEURON, V37, P7, DOI 10.1016/S0896-6273(02)01166-2; Dodou E, 1997, MOL CELL BIOL, V17, P1848, DOI 10.1128/MCB.17.4.1848; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; Giguere V, 1999, ENDOCR REV, V20, P689, DOI 10.1210/er.20.5.689; Grimes JA, 2000, J BIOL CHEM, V275, P9461, DOI 10.1074/jbc.275.13.9461; Gross M, 2001, ONCOGENE, V20, P3880, DOI 10.1038/sj.onc.1204489; Hagerty T, 2001, J NEUROCHEM, V76, P825, DOI 10.1046/j.1471-4159.2001.00072.x; Iniguez-Lluhi JA, 2000, MOL CELL BIOL, V20, P6040, DOI 10.1128/MCB.20.16.6040-6050.2000; Iwawaki T, 2000, BIOCHEM BIOPH RES CO, V274, P590, DOI 10.1006/bbrc.2000.3204; Johnson ES, 2001, CELL, V106, P735, DOI 10.1016/S0092-8674(01)00491-3; Kim KI, 2002, J CELL PHYSIOL, V191, P257, DOI 10.1002/jcp.10100; Kotaja N, 2000, MOL ENDOCRINOL, V14, P1986, DOI 10.1210/me.14.12.1986; LAW SW, 1992, MOL ENDOCRINOL, V6, P2129, DOI 10.1210/me.6.12.2129; Liu B, 1998, P NATL ACAD SCI USA, V95, P10626, DOI 10.1073/pnas.95.18.10626; Liu B, 2001, P NATL ACAD SCI USA, V98, P3203, DOI 10.1073/pnas.051489598; Long JY, 2003, P NATL ACAD SCI USA, V100, P9791, DOI 10.1073/pnas.1733973100; Maira M, 2003, MOL CELL BIOL, V23, P763, DOI 10.1128/MCB.23.3.763-776.2003; Maira M, 1999, MOL CELL BIOL, V19, P7549; Nishida T, 2002, J BIOL CHEM, V277, P41311, DOI 10.1074/jbc.M206741200; Ojeda V, 2003, J NEUROSCI RES, V73, P686, DOI 10.1002/jnr.10705; Paulsen RE, 1995, J MOL NEUROSCI, V6, P249, DOI 10.1007/BF02736784; PERLMANN T, 1995, GENE DEV, V9, P769, DOI 10.1101/gad.9.7.769; Poukka H, 2000, P NATL ACAD SCI USA, V97, P14145, DOI 10.1073/pnas.97.26.14145; Rodriguez MS, 2001, J BIOL CHEM, V276, P12654, DOI 10.1074/jbc.M009476200; Sacchetti P, 2001, J NEUROCHEM, V76, P1565, DOI 10.1046/j.1471-4159.2001.00181.x; Sacchetti P, 1999, MOL BRAIN RES, V74, P167, DOI 10.1016/S0169-328X(99)00275-2; Sachdev S, 2001, GENE DEV, V15, P3088, DOI 10.1101/gad.944801; Sakurada K, 1999, DEVELOPMENT, V126, P4017; Saucedo-Cardenas O, 1998, P NATL ACAD SCI USA, V95, P4013, DOI 10.1073/pnas.95.7.4013; Schimmel JJ, 1999, MOL BRAIN RES, V74, P1, DOI 10.1016/S0169-328X(99)00234-X; Schmidt D, 2002, P NATL ACAD SCI USA, V99, P2872, DOI 10.1073/pnas.052559499; Sohn YC, 2001, J BIOL CHEM, V276, P43734, DOI 10.1074/jbc.M107208200; Subramanian L, 2003, J BIOL CHEM, V278, P9134, DOI 10.1074/jbc.M210440200; Takahashi Y, 2001, J BIOL CHEM, V276, P48973, DOI 10.1074/jbc.M109295200; TapiaRamirez J, 1997, P NATL ACAD SCI USA, V94, P1177, DOI 10.1073/pnas.94.4.1177; Wang ZL, 2003, NATURE, V423, P555, DOI 10.1038/nature01645; Wansa KDSA, 2002, J BIOL CHEM, V277, P33001, DOI 10.1074/jbc.M203572200; WILSON TE, 1991, SCIENCE, V252, P1296, DOI 10.1126/science.1925541; Zetterstrom RH, 1996, MOL ENDOCRINOL, V10, P1656, DOI 10.1210/me.10.12.1656; Zetterstrom RH, 1997, SCIENCE, V276, P248, DOI 10.1126/science.276.5310.248	46	54	56	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 16	2004	279	3					2005	2011		10.1074/jbc.M308113200	http://dx.doi.org/10.1074/jbc.M308113200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	762WT	14559918	hybrid			2022-12-27	WOS:000188005700054
J	Matsunaga, M; Jaehning, JA				Matsunaga, M; Jaehning, JA			A mutation in the yeast mitochondrial core RNA polymerase, Rpo41, confers defects in both specificity factor interaction and promoter utilization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTORS B1; OPEN COMPLEX-FORMATION; SACCHAROMYCES-CEREVISIAE; T7 LYSOZYME; STRUCTURAL BASIS; RIBOSOMAL-RNA; ELONGATION COMPLEX; BACTERIOPHAGE T3; GENE-EXPRESSION; SIGMA-FACTORS	The yeast mitochondrial RNA polymerase ( RNAP) is composed of the core RNAP, Rpo41, and the mitochondrial transcription factor, Mtf1. Both are required for mitochondrial transcription, but how the two proteins interact to create a functional, promoter-selective holoenzyme is still unknown. Rpo41 is similar to the single polypeptide bacteriophage T7RNAP, which does not require additional factors for promoter-selective initiation but whose activity is modulated during infection by association with T7 lysozyme. In this study we used the co-crystal structure of T7RNAP and T7 lysozyme as a model to define a potential Mtf1 interaction surface on Rpo41, making site-directed mutations in Rpo41 at positions predicted to reside at the same location as the T7RNAP/T7 lysozyme interface. We identified Rpo41 mutant E1224A as having reduced interactions with Mtf1 in a two-hybrid assay and a temperature-sensitive petite phenotype in vivo. Although the E1224A mutant has full activity in a non-selective in vitro transcription assay, it is temperature-sensitive for selective transcription from linear DNA templates containing the 14S rRNA, COX2, and tRNAcys mitochondrial promoters. The tRNAcys promoter defect can be rescued by template supercoiling but not by addition of a dinucleotide primer. The fact that mutation of Rpo41 results in selective transcription defects indicates that the core RNAP, like T7RNAP, plays an important role in promoter utilization.	Univ Colorado, Hlth Sci Ctr, Dept Biochem & Mol Genet, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Program Mol Biol, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Jaehning, JA (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Biochem & Mol Genet, B121,4200 E 9th Ave, Denver, CO 80262 USA.	Judith.Jaehning@UCHSC.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036692] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 36692] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		[Anonymous], 1991, Methods Enzymol, V194, P1; ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; Bates PA, 2001, PROTEINS, P39; Bates PA, 1999, PROTEINS, P47; BISWAS TK, 1986, P NATL ACAD SCI USA, V83, P270, DOI 10.1073/pnas.83.2.270; BISWAS TK, 1990, P NATL ACAD SCI USA, V87, P9338, DOI 10.1073/pnas.87.23.9338; BISWAS TK, 1990, J BIOL CHEM, V265, P19053; Biswas TK, 1998, GENE, V212, P305, DOI 10.1016/S0378-1119(98)00133-4; Brieba LG, 2001, BIOCHEMISTRY-US, V40, P3882, DOI 10.1021/bi002716c; Burgess RR, 2001, CURR OPIN MICROBIOL, V4, P126, DOI 10.1016/S1369-5274(00)00177-6; CAMERON VL, 1989, J BIOL CHEM, V264, P13391; Campbell EA, 2002, MOL CELL, V9, P527, DOI 10.1016/S1097-2765(02)00470-7; Cermakian N, 1997, J MOL EVOL, V45, P671, DOI 10.1007/PL00006271; Cermakian N, 1996, NUCLEIC ACIDS RES, V24, P648, DOI 10.1093/nar/24.4.648; Cheetham GMT, 1999, NATURE, V399, P80, DOI 10.1038/19999; CHENG XD, 1994, P NATL ACAD SCI USA, V91, P4034, DOI 10.1073/pnas.91.9.4034; Cliften PF, 1997, GENE DEV, V11, P2897, DOI 10.1101/gad.11.21.2897; Cliften PF, 2000, MOL CELL BIOL, V20, P7013, DOI 10.1128/MCB.20.18.7013-7023.2000; Contreras-Moreira B, 2002, BIOINFORMATICS, V18, P1141, DOI 10.1093/bioinformatics/18.8.1141; COSTANZO MC, 1990, ANNU REV GENET, V24, P91; DEHASETH PL, 1995, MOL MICROBIOL, V16, P817, DOI 10.1111/j.1365-2958.1995.tb02309.x; Falkenberg M, 2002, NAT GENET, V31, P289, DOI 10.1038/ng909; Fischer D, 1999, PROTEINS, P209; Gaal T, 1997, SCIENCE, V278, P2092, DOI 10.1126/science.278.5346.2092; Gardner LP, 1997, BIOCHEMISTRY-US, V36, P2908, DOI 10.1021/bi962397i; GREENLEAF AL, 1986, P NATL ACAD SCI USA, V83, P3391, DOI 10.1073/pnas.83.10.3391; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Helmann JD, 1999, BIOCHEMISTRY-US, V38, P5959, DOI 10.1021/bi990206g; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; Huang JB, 1999, J MOL BIOL, V293, P457, DOI 10.1006/jmbi.1999.3135; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JAEHNING JA, 1993, MOL MICROBIOL, V8, P1, DOI 10.1111/j.1365-2958.1993.tb01197.x; JANG SH, 1991, J BIOL CHEM, V266, P22671; Jeruzalmi D, 1998, EMBO J, V17, P4101, DOI 10.1093/emboj/17.14.4101; JOHO KE, 1990, J MOL BIOL, V215, P31, DOI 10.1016/S0022-2836(05)80092-0; JORGENSEN ED, 1991, J BIOL CHEM, V266, P645; Karlok MA, 2002, J BIOL CHEM, V277, P28143, DOI 10.1074/jbc.M204123200; KELLEY LA, 1999, RECOMB 99 P 3 ANN C, P218; KLEMENT JF, 1990, J MOL BIOL, V215, P21, DOI 10.1016/S0022-2836(05)80091-9; Kumar A, 1997, BIOCHEMISTRY-US, V36, P13954, DOI 10.1021/bi971432y; Kuzmine I, 2003, J BIOL CHEM, V278, P2819, DOI 10.1074/jbc.M208405200; LISOWSKY T, 1988, MOL GEN GENET, V214, P218, DOI 10.1007/BF00337714; Ma KY, 2002, J BIOL CHEM, V277, P43206, DOI 10.1074/jbc.M206658200; MANGUS DA, 1994, J BIOL CHEM, V269, P26568; MASTERS BS, 1987, CELL, V51, P89, DOI 10.1016/0092-8674(87)90013-4; MCALLISTER WT, 1993, CELL MOL BIOL RES, V39, P385; MCALLISTER WT, 1978, P NATL ACAD SCI USA, V75, P804, DOI 10.1073/pnas.75.2.804; MCCLURE WR, 1980, P NATL ACAD SCI-BIOL, V77, P5634, DOI 10.1073/pnas.77.10.5634; MOFFATT BA, 1987, CELL, V49, P221, DOI 10.1016/0092-8674(87)90563-0; MOOKHTIAR KA, 1991, BIOCHEMISTRY-US, V30, P6305, DOI 10.1021/bi00239a032; Murakami KS, 2002, SCIENCE, V296, P1285, DOI 10.1126/science.1069595; OSINGA KA, 1982, NUCLEIC ACIDS RES, V10, P7993, DOI 10.1093/nar/10.24.7993; Rantanen A, 2003, MAMM GENOME, V14, P1, DOI 10.1007/s00335-002-2218-z; RASKIN CA, 1992, J MOL BIOL, V228, P506, DOI 10.1016/0022-2836(92)90838-B; Schubot FD, 2001, PROTEIN SCI, V10, P1980, DOI 10.1110/ps.11201; Seidel-Rogol BL, 2003, NAT GENET, V33, P23, DOI 10.1038/ng1064; SHADEL GS, 1995, MOL CELL BIOL, V15, P2101; Stano NM, 2002, J MOL BIOL, V315, P1009, DOI 10.1006/jmbi.2001.5313; Taanman JW, 1999, BBA-BIOENERGETICS, V1410, P103, DOI 10.1016/S0005-2728(98)00161-3; Tahirov TH, 2002, NATURE, V420, P43, DOI 10.1038/nature01129; Temiakov D, 2000, P NATL ACAD SCI USA, V97, P14109, DOI 10.1073/pnas.250473197; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TZAGOLOFF A, 1986, ANNU REV BIOCHEM, V55, P249, DOI 10.1146/annurev.bi.55.070186.001341; Villemain J, 1998, J MOL BIOL, V281, P793, DOI 10.1006/jmbi.1998.1989; WETTSTEINEDWARDS J, 1986, J BIOL CHEM, V261, P2905; WINKLEY CS, 1985, J BIOL CHEM, V260, P4214; Yin YW, 2002, SCIENCE, V298, P1387, DOI 10.1126/science.1077464; Young BA, 2002, CELL, V109, P417, DOI 10.1016/S0092-8674(02)00752-3; Zhang X, 1997, J MOL BIOL, V269, P10, DOI 10.1006/jmbi.1997.1016	70	16	16	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 16	2004	279	3					2012	2019		10.1074/jbc.M307819200	http://dx.doi.org/10.1074/jbc.M307819200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	762WT	14570924	hybrid			2022-12-27	WOS:000188005700055
J	Ogawa, D; Shikata, K; Honke, K; Sato, S; Matsuda, M; Nagase, R; Tone, A; Okada, S; Usui, H; Wada, J; Miyasaka, M; Kawashima, H; Suzuki, Y; Suzuki, T; Taniguchi, N; Hirahara, Y; Tadano-Aritomi, K; Ishizuka, I; Tedder, TF; Makino, H				Ogawa, D; Shikata, K; Honke, K; Sato, S; Matsuda, M; Nagase, R; Tone, A; Okada, S; Usui, H; Wada, J; Miyasaka, M; Kawashima, H; Suzuki, Y; Suzuki, T; Taniguchi, N; Hirahara, Y; Tadano-Aritomi, K; Ishizuka, I; Tedder, TF; Makino, H			Cerebroside sulfotransferase deficiency ameliorates L-selectin-dependent monocyte infiltration in the kidney after ureteral obstruction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPHOCYTE HOMING RECEPTOR; LEUKOCYTE ADHESION MOLECULE; ACUTE-RENAL-FAILURE; P-SELECTIN; LIGANDS; SULFOGLYCOLIPIDS; OLIGOSACCHARIDES; MACROPHAGES; GLYCOLIPIDS; EXPRESSION	Mononuclear cells infiltrating the interstitium are involved in renal tubulointerstitial injury. The unilateral ureteral obstruction (UUO) is an established experimental model of renal interstitial inflammation. In our previous study, we postulated that L-selectin on monocytes is involved in their infiltration into the interstitium by UUO and that a sulfated glycolipid, sulfatide, is the physiological L-selectin ligand in the kidney. Here we tested the above hypothesis using sulfatide-and L-selectin-deficient mice. Sulfatide-deficient mice were generated by gene targeting of the cerebroside sulfotransferase (Cst) gene. Although the L-selectin-IgG chimera protein specifically bound to sulfatide fraction in acidic lipids from wild-type kidney, it did not show such binding in fractions of Cst(-/-) mice kidney, indicating that sulfatide is the major L-selectin-binding glycolipid in the kidney. The distribution of L-selectin ligand in wildtype mice changed after UUO; sulfatide was relocated from the distal tubules to the peritubular capillaries where monocytes infiltrate, suggesting that sulfatide relocated to the endothelium after UUO interacted with L-selectin on monocytes. In contrast, L-selectin ligand was not detected in Cst(-/-) mice irrespective of UUO treatment. Compared with wild-type mice, Cst(-/-) mice showed a considerable reduction in the number of monocytes/macrophages that infiltrated the interstitium after UUO. The number of monocytes/macrophages was also reduced to a similar extent in L-selectin(-/-) mice. Our results suggest that sulfatide is a major L-selectin-binding molecule in the kidney and that the interaction between L-selectin and sulfatide plays a critical role in monocyte infiltration into the kidney interstitium.	Okayama Univ, Grad Sch Med & Dent, Dept Med & Clin Sci, Okayama 7008558, Japan; Kochi Med Sch, Dept Mol Genet, Kochi 7838505, Japan; Kanazawa Univ, Grad Sch Med Sci, Dept Dermatol, Kanazawa, Ishikawa 9208641, Japan; Osaka Univ, Grad Sch Med, Lab Mol & Cellular Recognit, Suita, Osaka 5650871, Japan; Univ Shizuoka, Sch Pharmaceut Sci, Dept Biochem, Shizuoka 4228526, Japan; CREST, Shizuoka 4228526, Japan; Osaka Univ, Grad Sch Med, Dept Biochem, CREST, Suita, Osaka 5650871, Japan; Osaka Med Ctr Maternal & Child Hlth, Res Inst, Dept Mol Med, Osaka 5441101, Japan; Teikyo Univ, Sch Med, Dept Biochem, Tokyo 1738605, Japan; Duke Univ, Med Ctr, Dept Immunol, Durham, NC 27710 USA	Okayama University; Kochi University; Kanazawa University; Osaka University; University of Shizuoka; Japan Science & Technology Agency (JST); Japan Science & Technology Agency (JST); Osaka University; Teikyo University; Duke University	Shikata, K (corresponding author), Okayama Univ, Grad Sch Med & Dent, Dept Med & Clin Sci, 2-5-1 Shikata Cho, Okayama 7008558, Japan.	shikata@md.okayama-u.ac.jp	Taniguchi, Naoyuki/A-7086-2016; WADA, Jun/B-2023-2011; Taniguchi, Naoyuki/I-4182-2014	WADA, Jun/0000-0003-1468-5170; Taniguchi, Naoyuki/0000-0001-5889-5968; Yasuo, Suzuki/0000-0003-3518-5642				Aliprantis AO, 1996, IMMUNOL TODAY, V17, P573, DOI 10.1016/S0167-5699(96)10071-2; ALON R, 1995, J IMMUNOL, V154, P5356; ARBONES ML, 1994, IMMUNITY, V1, P247, DOI 10.1016/1074-7613(94)90076-0; ARUFFO A, 1991, CELL, V67, P35, DOI 10.1016/0092-8674(91)90570-O; BEVILACQUA MP, 1993, J CLIN INVEST, V91, P379, DOI 10.1172/JCI116210; Borsig L, 2002, P NATL ACAD SCI USA, V99, P2193, DOI 10.1073/pnas.261704098; DIAMOND JR, 1995, AM J KIDNEY DIS, V26, P133, DOI 10.1016/0272-6386(95)90166-3; DZIUKAS LJ, 1982, LAB INVEST, V47, P185; GALLATIN WM, 1983, NATURE, V304, P30, DOI 10.1038/304030a0; GREEN PJ, 1992, BIOCHEM BIOPH RES CO, V188, P244, DOI 10.1016/0006-291X(92)92376-9; GREEN PJ, 1995, GLYCOBIOLOGY, V5, P29, DOI 10.1093/glycob/5.1.29; Hickey MJ, 2000, J IMMUNOL, V165, P7164, DOI 10.4049/jimmunol.165.12.7164; Hirata K, 1998, DIABETOLOGIA, V41, P185, DOI 10.1007/s001250050888; Honke K, 1997, J BIOL CHEM, V272, P4864, DOI 10.1074/jbc.272.8.4864; Honke K, 2002, P NATL ACAD SCI USA, V99, P4227, DOI 10.1073/pnas.032068299; IMAI Y, 1990, J CELL BIOL, V111, P1225, DOI 10.1083/jcb.111.3.1225; IMAI Y, 1993, NATURE, V361, P555; Ishibashi T, 2002, J NEUROSCI, V22, P6507; Ishizuka I, 1997, PROG LIPID RES, V36, P245, DOI 10.1016/S0163-7827(97)00011-8; Kawashima H, 2003, J BIOL CHEM, V278, P13069, DOI 10.1074/jbc.M212244200; Kirveskari J, 2000, J AM SOC NEPHROL, V11, P2358, DOI 10.1681/ASN.V11122358; Lange-Sperandio B, 2002, KIDNEY INT, V61, P516, DOI 10.1046/j.1523-1755.2002.00162.x; LASKY LA, 1989, CELL, V56, P1045, DOI 10.1016/0092-8674(89)90637-5; Li YF, 1999, FEBS LETT, V444, P201, DOI 10.1016/S0014-5793(99)00046-0; MULLIGAN MS, 1995, INT IMMUNOL, V7, P1107, DOI 10.1093/intimm/7.7.1107; Naruse T, 2002, KIDNEY INT, V62, P94, DOI 10.1046/j.1523-1755.2002.00419.x; NEEDHAM LK, 1993, P NATL ACAD SCI USA, V90, P1359, DOI 10.1073/pnas.90.4.1359; NELSON RM, 1993, BLOOD, V82, P3253; Nikolic-Paterson DJ, 2001, NEPHROL DIAL TRANSPL, V16, P3, DOI 10.1093/ndt/16.suppl_5.3; NORGARDSUMNICHT KE, 1993, SCIENCE, V261, P480, DOI 10.1126/science.7687382; SAITO T, 1990, KIDNEY INT, V37, P1076, DOI 10.1038/ki.1990.88; SCHREINER GF, 1988, KIDNEY INT, V34, P487, DOI 10.1038/ki.1988.207; Shikata K, 1999, J PATHOL, V188, P93, DOI 10.1002/(SICI)1096-9896(199905)188:1<93::AID-PATH305>3.0.CO;2-#; SIEGELMAN MH, 1989, SCIENCE, V243, P1165, DOI 10.1126/science.2646713; Singbartl K, 2000, FASEB J, V14, P48, DOI 10.1096/fasebj.14.1.48; Singbartl K, 2000, CRIT CARE MED, V28, P2507, DOI 10.1097/00003246-200007000-00053; SUZUKI Y, 1991, J BIOCHEM-TOKYO, V109, P354; SUZUKI Y, 1993, BIOCHEM BIOPH RES CO, V190, P426, DOI 10.1006/bbrc.1993.1065; Tadano-Aritomi K, 2000, J LIPID RES, V41, P1237; TAKI T, 1994, ANAL BIOCHEM, V221, P312, DOI 10.1006/abio.1994.1418; TAMATANI T, 1993, J IMMUNOL, V150, P1735	41	36	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 16	2004	279	3					2085	2090		10.1074/jbc.M305809200	http://dx.doi.org/10.1074/jbc.M305809200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	762WT	14583626	hybrid			2022-12-27	WOS:000188005700064
J	Rinehart, J; Horn, EK; Wei, D; Soll, D; Schneider, A				Rinehart, J; Horn, EK; Wei, D; Soll, D; Schneider, A			Non-canonical eukaryotic glutaminyl- and glutamyl-tRNA synthetases form mitochondrial aminoacyl-tRNA in Trypanosoma brucei	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; SACCHAROMYCES-CEREVISIAE; LEISHMANIA-TARENTOLAE; GENE-EXPRESSION; COMPLEX; IMPORT; INTERFERENCE; PROTEIN; AMIDOTRANSFERASE; BIOSYNTHESIS	Glutaminyl-tRNA synthetase is thought to be absent from organelles. Instead, Gln-tRNA is formed via the transamidation pathway, the other route to this essential compound in protein biosynthesis. However, it was previously shown that glutaminyl-tRNA synthetase activity is present in Leishmania mitochondria. This work identifies genes encoding glutaminyl- and glutamyl-tRNA synthetase in the closely related organism Trypanosoma brucei. Down-regulation of their respective gene products by RNA interference showed that (i) they are essential for the growth of insect stage T. brucei and (ii) they are responsible for essentially all of the glutaminyl- and glutamyl-tRNA synthetase activity detected in both the cytosol and the mitochondria. In vitro aminoacylation experiments with the recombinant T. brucei enzymes and total tRNA confirmed the identity of the two aminoacyl-tRNA synthetases. Interestingly, T. brucei uses the same eukaryotic-type glutaminyl- tRNA synthetase to form mitochondrial and cytosolic Gln-tRNA. The formation of Glu-tRNA in mitochondria and the cytoplasm is catalyzed by a single eukaryotic-type discriminating glutamyl-tRNA synthetase. T. brucei, similar to Leishmania, imports all of its mitochondrial tRNAs from the cytosol. The use of these two eukaryotic-type enzymes in mitochondria may therefore reflect an adaptation to the situation in which the cytosol and mitochondria use the same set of tRNAs.	Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; Yale Univ, Dept Chem, New Haven, CT 06520 USA; Univ Fribourg, Dept Biol Zool, CH-1700 Fribourg, Switzerland	Yale University; Yale University; University of Fribourg	Schneider, A (corresponding author), Yale Univ, Dept Mol Biophys & Biochem, POB 208114,266 Whitney Ave, New Haven, CT 06520 USA.	andre.schneider@unifr.ch			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022854, R37GM022854] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM22854] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahel I, 2002, J BIOL CHEM, V277, P34743, DOI 10.1074/jbc.M206928200; Beverley S M, 1993, Methods Mol Biol, V21, P333; Bochud-Allemann N, 2002, J BIOL CHEM, V277, P32849, DOI 10.1074/jbc.M205776200; Bridge AJ, 2003, NAT GENET, V34, P263, DOI 10.1038/ng1173; CERINI C, 1991, EMBO J, V10, P4267, DOI 10.1002/j.1460-2075.1991.tb05005.x; CHATTON B, 1988, J BIOL CHEM, V263, P52; Coppin JF, 2003, PARASITOL RES, V89, P113, DOI 10.1007/s00436-002-0643-2; Curnow AW, 1998, P NATL ACAD SCI USA, V95, P12838, DOI 10.1073/pnas.95.22.12838; Curnow AW, 1997, P NATL ACAD SCI USA, V94, P11819, DOI 10.1073/pnas.94.22.11819; Galani K, 2001, EMBO J, V20, P6889, DOI 10.1093/emboj/20.23.6889; HARRIS ME, 1990, J BIOL CHEM, V265, P11368; Kim JY, 2002, P NATL ACAD SCI USA, V99, P7912, DOI 10.1073/pnas.122110199; Kim T, 2000, J BIOL CHEM, V275, P21768, DOI 10.1074/jbc.M002404200; LAMOUR V, 1994, P NATL ACAD SCI USA, V91, P8670, DOI 10.1073/pnas.91.18.8670; LAPOINTE J, 1986, J BACTERIOL, V165, P88, DOI 10.1128/jb.165.1.88-93.1986; LUDMERER SW, 1993, J BIOL CHEM, V268, P5519; LYE LF, 1993, MOL BIOCHEM PARASIT, V58, P233, DOI 10.1016/0166-6851(93)90045-Y; Nabholz CE, 1997, P NATL ACAD SCI USA, V94, P7903, DOI 10.1073/pnas.94.15.7903; NATSOULIS G, 1986, CELL, V46, P235, DOI 10.1016/0092-8674(86)90740-3; Ngo H, 1998, P NATL ACAD SCI USA, V95, P14687, DOI 10.1073/pnas.95.25.14687; Quevillon S, 1999, J MOL BIOL, V285, P183, DOI 10.1006/jmbi.1998.2316; Robinson KA, 2003, MOL BIOCHEM PARASIT, V128, P217, DOI 10.1016/S0166-6851(03)00079-3; Rusconi CP, 1996, EMBO J, V15, P3286, DOI 10.1002/j.1460-2075.1996.tb00693.x; Schneider A, 2001, INT J PARASITOL, V31, P1403, DOI 10.1016/S0020-7519(01)00296-X; Schneider A, 2000, TRENDS CELL BIOL, V10, P509, DOI 10.1016/S0962-8924(00)01854-7; Schneider A, 2001, TRENDS GENET, V17, P557, DOI 10.1016/S0168-9525(01)02439-8; SCHON A, 1986, NATURE, V322, P281, DOI 10.1038/322281a0; Shi HF, 2000, RNA, V6, P1069, DOI 10.1017/S1355838200000297; Sledz CA, 2003, NAT CELL BIOL, V5, P834, DOI 10.1038/ncb1038; Small I, 1998, PLANT MOL BIOL, V38, P265, DOI 10.1023/A:1006081903354; STOSCHECK CM, 1987, ANAL BIOCHEM, V160, P301, DOI 10.1016/0003-2697(87)90051-0; SUYAMA Y, 1976, GENETICS BIOGENESIS, P763; Tan THP, 2002, MOL CELL BIOL, V22, P3707, DOI 10.1128/MCB.22.11.3707-3716.2002; Tumbula DL, 2000, NATURE, V407, P106, DOI 10.1038/35024120; Tumbula-Hansen D, 2002, J BIOL CHEM, V277, P37184, DOI 10.1074/jbc.M204767200; Wang ZF, 2000, J BIOL CHEM, V275, P40174, DOI 10.1074/jbc.M008405200	36	32	32	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 9	2004	279	2					1161	1166		10.1074/jbc.M310100200	http://dx.doi.org/10.1074/jbc.M310100200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	759DJ	14563839	Green Published, hybrid			2022-12-27	WOS:000187722800040
J	Samino, Y; Lopez, D; Guil, S; de Leon, P; Del Val, M				Samino, Y; Lopez, D; Guil, S; de Leon, P; Del Val, M			An endogenous HIV envelope-derived peptide without the terminal NH3+ group anchor is physiologically presented by major histocompatibility complex class I molecules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; CYTOTOXIC-T-CELLS; PROCESSED VIRAL PEPTIDES; ANTIGEN PRESENTATION; 3-DIMENSIONAL STRUCTURE; ENDOPLASMIC-RETICULUM; LYMPHOCYTE EPITOPES; TYPE-1 INFECTION; IMMUNE-RESPONSES; BINDING-SITE	Cytotoxic T lymphocytes (CTL) recognize viral peptidic antigens presented by major histocompatibility complex (MHC) class I molecules on the surface of infected cells. The CTL response is critical in clearance and prevention of HIV infection. Yet, there are no descriptions of physiological peptides derived from the viral envelope protein. In the few reports on endogenous MHC class I viral peptidic ligands from HIV internal proteins, definitive positive identification by mass spectrometry is lacking. The HIV-1 envelope glycoprotein gp160 induces a strong specific CTL response restricted by several human and murine MHC class I molecules, including H-2D(d). Previous analyses showed that this response can be optimally mimicked with the synthetic decameric peptide (318)RGPGRAFVTI(327). We aim to identify the endogenous natural peptides mediating the response to this epitope. Our data indicate the presence of, at least, two peptidic species of different length and sharing the same antigenic core, which are associated with the D-d presenting molecule in infected cells. One species is at least, probably, the optimal decapeptide. The second species, identified by mass spectrometry for the first time in HIV, is, unexpectedly, a nonamer, which lacks the correctly positioned N-terminal group to bind to Dd. And yet, it is present in similar amounts and, notably, is equally antigenic. Thus, the physiological set of HIV-derived MHC class I ligands is richer and different than expected from studies with synthetic peptides. This may help raise the plasticity and thus the effectiveness of the immune response against the viral infection. These data have implications for HIV vaccine development.	Inst Salud Carlos III, Ctr Nacl Microbiol, E-28220 Madrid, Spain	Instituto de Salud Carlos III; Centro Nacional de Microbiologa (CNM)	Del Val, M (corresponding author), Inst Salud Carlos III, Ctr Nacl Microbiol, Ctra Pozuelo,Km 2, E-28220 Madrid, Spain.	mdval@isciii.es	Del Val, Margarita/E-4769-2010; López, Daniel/I-2632-2014	Del Val, Margarita/0000-0001-6769-4279; López, Daniel/0000-0003-0268-5878; de Leon, Patricia/0000-0003-2518-2245				ABASTADO JP, 1987, J EXP MED, V166, P327, DOI 10.1084/jem.166.2.327; Achour A, 1998, IMMUNITY, V9, P199, DOI 10.1016/S1074-7613(00)80602-0; BERGMANN C, 1993, EUR J IMMUNOL, V23, P2777, DOI 10.1002/eji.1830231109; BERGMANN CC, 1994, J IMMUNOL, V152, P5603; Borrow P, 1997, NAT MED, V3, P205, DOI 10.1038/nm0297-205; BORROW P, 1994, J VIROL, V68, P6103, DOI 10.1128/JVI.68.9.6103-6110.1994; BOUVIER M, 1994, SCIENCE, V265, P398, DOI 10.1126/science.8023162; CAO YZ, 1995, NEW ENGL J MED, V332, P201, DOI 10.1056/NEJM199501263320401; CARBONE FR, 1990, J EXP MED, V171, P377, DOI 10.1084/jem.171.2.377; Carrington M, 1999, SCIENCE, V283, P1748, DOI 10.1126/science.283.5408.1748; CHAKRABARTI S, 1986, NATURE, V320, P535, DOI 10.1038/320535a0; Chen WS, 2000, IMMUNITY, V12, P83, DOI 10.1016/S1074-7613(00)80161-2; COLLINS EJ, 1994, NATURE, V371, P626, DOI 10.1038/371626a0; CORR M, 1993, J EXP MED, V178, P1877, DOI 10.1084/jem.178.6.1877; DEL VM, 1991, CELL, V66, P1145; Del-Val M, 2002, MOL IMMUNOL, V39, P235, DOI 10.1016/S0161-5890(02)00104-9; DELVAL M, 1988, J VIROL, V62, P3965, DOI 10.1128/JVI.62.11.3965-3972.1988; FALK K, 1991, J EXP MED, V174, P425, DOI 10.1084/jem.174.2.425; Flyer DC, 2002, INFECT IMMUN, V70, P2926, DOI 10.1128/IAI.70.6.2926-2932.2002; FRUMENTO G, 1993, CELL IMMUNOL, V152, P623, DOI 10.1006/cimm.1993.1318; Gil-Torregrosa BC, 2000, TRAFFIC, V1, P641, DOI 10.1034/j.1600-0854.2000.010808.x; Goulder PJR, 1997, NAT MED, V3, P212, DOI 10.1038/nm0297-212; Haynes BF, 1996, SCIENCE, V271, P324, DOI 10.1126/science.271.5247.324; Herr W, 1999, P NATL ACAD SCI USA, V96, P12033, DOI 10.1073/pnas.96.21.12033; Hogan CM, 2001, ANN INTERN MED, V134, P761, DOI 10.7326/0003-4819-134-9_Part_1-200105010-00013; Kaslow RA, 1996, NAT MED, V2, P405, DOI 10.1038/nm0496-405; Knuehl C, 2001, J IMMUNOL, V167, P1515, DOI 10.4049/jimmunol.167.3.1515; KORBER BTM, 2001, THEORETICAL BIOL BIO; KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994; KOZLOWSKI S, 1992, J EXP MED, V175, P1417, DOI 10.1084/jem.175.6.1417; KULKARNI AB, 1993, J VIROL, V67, P4086, DOI 10.1128/JVI.67.7.4086-4092.1993; Li HM, 1998, J MOL BIOL, V283, P179, DOI 10.1006/jmbi.1998.2091; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; Lopez D, 2000, J IMMUNOL, V164, P5070, DOI 10.4049/jimmunol.164.10.5070; Lopez D, 2001, J IMMUNOL, V167, P4238, DOI 10.4049/jimmunol.167.8.4238; Lucchiari-Hartz M, 2000, J EXP MED, V191, P239, DOI 10.1084/jem.191.2.239; McMichael AJ, 1997, ANNU REV IMMUNOL, V15, P271, DOI 10.1146/annurev.immunol.15.1.271; Montoya M, 1999, J IMMUNOL, V163, P1914; NEEFJES J, 1995, EUR J IMMUNOL, V25, P1133, DOI 10.1002/eji.1830250444; NEISIG A, 1995, J IMMUNOL, V154, P1273; OZATO K, 1982, TRANSPLANTATION, V34, P113, DOI 10.1097/00007890-198209000-00001; Paz P, 1999, IMMUNITY, V11, P241, DOI 10.1016/S1074-7613(00)80099-0; ROTZSCHKE O, 1990, NATURE, V348, P252, DOI 10.1038/348252a0; SALTER RD, 1986, EMBO J, V5, P943, DOI 10.1002/j.1460-2075.1986.tb04307.x; Schmitz JE, 1999, SCIENCE, V283, P857, DOI 10.1126/science.283.5403.857; Serwold T, 2001, NAT IMMUNOL, V2, P644, DOI 10.1038/89800; Serwold T, 2002, NATURE, V419, P480, DOI 10.1038/nature01074; SHIRAI M, 1992, J IMMUNOL, V148, P1657; Shirai M, 1996, J IMMUNOL, V157, P4399; Stryhn A, 2000, EUR J IMMUNOL, V30, P3089, DOI 10.1002/1521-4141(200011)30:11<3089::AID-IMMU3089>3.0.CO;2-5; TAKAHASHI H, 1988, P NATL ACAD SCI USA, V85, P3105, DOI 10.1073/pnas.85.9.3105; TAKESHITA T, 1995, J IMMUNOL, V154, P1973; TAYLOR PM, 1987, IMMUNOGENETICS, V26, P267, DOI 10.1007/BF00346521; Tomiyama H, 2000, EUR J IMMUNOL, V30, P2521, DOI 10.1002/1521-4141(200009)30:9<2521::AID-IMMU2521>3.0.CO;2-Q; TOWNSEND ARM, 1986, CELL, V44, P959, DOI 10.1016/0092-8674(86)90019-X; TSOMIDES TJ, 1994, J EXP MED, V180, P1283, DOI 10.1084/jem.180.4.1283; Yague J, 2001, J BIOL CHEM, V276, P43699, DOI 10.1074/jbc.M105981200; York IA, 2002, NAT IMMUNOL, V3, P1177, DOI 10.1038/ni860; Yusim K, 2002, J VIROL, V76, P8757, DOI 10.1128/JVI.76.17.8757-8768.2002	59	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 9	2004	279	2					1151	1160		10.1074/jbc.M305343200	http://dx.doi.org/10.1074/jbc.M305343200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	759DJ	14583622	hybrid, Green Published			2022-12-27	WOS:000187722800039
J	Takeuchi, K; Ito, F				Takeuchi, K; Ito, F			Suppression of adriamycin-induced apoptosis by sustained activation of the phosphatidylinositol-3 '-OH kinase-Akt pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCYTE-GROWTH-FACTOR; FORKHEAD TRANSCRIPTION FACTOR; PROTEIN-TYROSINE KINASES; SCATTER FACTOR-RECEPTOR; DNA-DAMAGING AGENTS; PHOSPHOLIPASE-C-II; CELL-SURVIVAL; EGF-RECEPTOR; PHOSPHOINOSITIDE 3-KINASE; EPITHELIAL-CELLS	The mechanisms by which growth factors trigger signal transduction pathways leading to protection against apoptosis are of great interest. In this study, we investigated the effect of hepatocyte growth factor (HGF/SF) and epidermal growth factor (EGF) on adriamycin (ADR)-induced apoptosis. Treatment of human epithelial MKN74 cells with ADR, a DNA topoisomerase IIalpha inhibitor, caused apoptosis. However, cells pretreated with HGF/SF, but not those pretreated with EGF, were resistant to this apoptosis. The protective effect of HGF/SF against the ADR-induced apoptosis was abolished in the presence of either LY294002, an inhibitor of phosphatidylinositol-3'-OH kinase (PI3-K) or 1L-6-hydroxymethyl-chiro-inositol 2-(R)-2-O-methyl-3-O-octadecylcarbonate, an inhibitor of Akt, thus implicating the activation of PI3-K-Akt signaling in the antiapoptotic action of HGF/SF. Immunoblotting analysis revealed that HGF/SF stimulated the sustained phosphorylation of Akt for several hours but that EGF stimulated the phosphorylation only transiently. Furthermore, ADR-induced activation of caspase-9, a downstream molecule of Akt, was inhibited for at least 24 h after HGF/SF stimulation, but it was not affected by EGF stimulation. Cell-surface biotin-labeling analysis showed that the HGF/SF receptor remained on the cell surface until at least 30 min after HGF/SF addition but that the EGF receptor level on the cell surface was attenuated at an earlier time after EGF addition. These results indicate that HGF/SF, but not EGF, transmitted protective signals against ADR-induced apoptosis by causing sustained activation of the PI3-K-Akt signaling pathway. Furthermore, the difference in antiapoptotic capacity between HGF/SF and EGF is explained, at least in part, by the delayed down-regulation of the HGF/SF receptor.	Setsunan Univ, Fac Pharmaceut Sci, Dept Biochem, Osaka 5730101, Japan	Setsunan University	Ito, F (corresponding author), Setsunan Univ, Fac Pharmaceut Sci, Dept Biochem, Osaka 5730101, Japan.			Ito, Fumiaki/0000-0002-4129-4899				Bardelli A, 1997, ONCOGENE, V15, P3103, DOI 10.1038/sj.onc.1201561; BJORGE JD, 1990, P NATL ACAD SCI USA, V87, P3816, DOI 10.1073/pnas.87.10.3816; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Bowers DC, 2000, CANCER RES, V60, P4277; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; CHATANI Y, 1992, BIOCHEM BIOPH RES CO, V185, P860, DOI 10.1016/0006-291X(92)91706-V; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEL PL, 1997, SCIENCE, V278, P687; Fabregat I, 1996, FEBS LETT, V384, P14, DOI 10.1016/0014-5793(96)00266-9; Fan SJ, 2000, ONCOGENE, V19, P2212, DOI 10.1038/sj.onc.1203566; FAN SJ, 1994, CANCER RES, V54, P5824; Fan SJ, 1998, ONCOGENE, V17, P131, DOI 10.1038/sj.onc.1201943; Fan SJ, 2001, MOL CELL BIOL, V21, P4968, DOI 10.1128/MCB.21.15.4968-4984.2001; Friedlander RM, 1996, J EXP MED, V184, P717, DOI 10.1084/jem.184.2.717; Gamen S, 2000, EXP CELL RES, V258, P223, DOI 10.1006/excr.2000.4924; Gao M, 2001, J BIOL CHEM, V276, P47257, DOI 10.1074/jbc.M106791200; GEIER A, 1994, IN VITRO CELL DEV-AN, V30A, P867; Gibson EM, 2002, CANCER RES, V62, P488; GOHDA E, 1988, J CLIN INVEST, V81, P414, DOI 10.1172/JCI113334; GRAZIANI A, 1993, J BIOL CHEM, V268, P9165; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; HERRMANN M, 1994, NUCLEIC ACIDS RES, V22, P5506, DOI 10.1093/nar/22.24.5506; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Kennedy SG, 1999, MOL CELL BIOL, V19, P5800; Khwaja A, 1998, J BIOL CHEM, V273, P18793, DOI 10.1074/jbc.273.30.18793; Kulik G, 1998, MOL CELL BIOL, V18, P6711, DOI 10.1128/MCB.18.11.6711; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MERLO GR, 1995, J CELL BIOL, V128, P1185, DOI 10.1083/jcb.128.6.1185; Minshall C, 1996, J IMMUNOL, V156, P939; Mitsiades CS, 2002, ONCOGENE, V21, P5673, DOI 10.1038/sj.onc.1205664; MIYAZAWA K, 1989, BIOCHEM BIOPH RES CO, V163, P967, DOI 10.1016/0006-291X(89)92316-4; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; Nagamine K, 1996, EUR J BIOCHEM, V236, P476, DOI 10.1111/j.1432-1033.1996.t01-1-00476.x; NAKAMURA T, 1987, FEBS LETT, V224, P311, DOI 10.1016/0014-5793(87)80475-1; NISHIBE S, 1989, J BIOL CHEM, V264, P10335; PONZETTO C, 1993, MOL CELL BIOL, V13, P4600, DOI 10.1128/MCB.13.8.4600; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; RESNICOFF M, 1995, CANCER RES, V55, P2463; ROSSOMANDO AJ, 1989, P NATL ACAD SCI USA, V86, P6940, DOI 10.1073/pnas.86.18.6940; RUFFJAMISON S, 1993, J BIOL CHEM, V268, P7610; SCHECHTER RL, 1992, BIOCHEM CELL BIOL, V70, P349, DOI 10.1139/o92-054; Soltoff SP, 1996, J BIOL CHEM, V271, P563, DOI 10.1074/jbc.271.1.563; STRAIN AJ, 1991, J CLIN INVEST, V87, P1853, DOI 10.1172/JCI115207; TAKANO H, 1992, ANTI-CANCER DRUG, V3, P323, DOI 10.1097/00001813-199208000-00002; Takeuchi K, 2001, J BIOL CHEM, V276, P26077, DOI 10.1074/jbc.M102704200; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; Tanimura S, 1998, ONCOGENE, V17, P57, DOI 10.1038/sj.onc.1201905; Thien CBF, 2001, NAT REV MOL CELL BIO, V2, P294, DOI 10.1038/35067100; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145; WEIDNER KM, 1991, P NATL ACAD SCI USA, V88, P7001, DOI 10.1073/pnas.88.16.7001; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xiao GH, 2001, P NATL ACAD SCI USA, V98, P247, DOI 10.1073/pnas.011532898; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Yao R, 1996, ONCOGENE, V13, P343; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; ZARNEGAR R, 1989, CANCER RES, V49, P3314; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhou HL, 2000, J CELL BIOL, V151, P483, DOI 10.1083/jcb.151.3.483	70	27	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 9	2004	279	2					892	900		10.1074/jbc.M306615200	http://dx.doi.org/10.1074/jbc.M306615200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	759DJ	14570904	hybrid			2022-12-27	WOS:000187722800011
J	Williams, DC; Cai, ML; Clore, GM				Williams, DC; Cai, ML; Clore, GM			Molecular basis for synergistic transcriptional activation by Oct1 and Sox2 revealed from the solution structure of the 42-kDa Oct1 center dot Sox2 center dot Hoxb1-DNA ternary transcription factor complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHORYL TRANSFER COMPLEX; LIQUID-CRYSTALLINE PHASE; NMR STRUCTURES; DIPOLAR COUPLINGS; BIOLOGICAL MACROMOLECULES; PROTEIN COMPLEXES; CROSS-VALIDATION; DNA COMPLEXES; MEAN FORCE; DOMAIN	The Oct and Sox transcription factors control many different aspects of neural development and embryogenesis, often binding to adjacent sites on DNA, and interacting with one another through their DNA binding domains to regulate transcription synergistically. Oct proteins contain two DNA binding domains (POUS and POUHD) connected by a flexible linker, which interact with DNA in a bipartite manner. Residual dipolar coupling measurements on the binary Oct1.DNA complex reveal that the two domains are characterized by distinct alignment tensors in both phage pf1 and polyethylene glycol/hexanol liquid crystalline media. We show that this difference is due to a fast microscopic dissociation/association process involving alternative binding modes for the weaker binding POUS domain in the binary complex. Upon binding of Sox2 to an adjacent site in the Hoxb1 regulatory element, all components of the ternary Oct1.Sox2.DNA complex share a single alignment tensor. Thus ternary complex formation increases the site-specific affinity of Oct1 for DNA by effectively locking the POUS domain in a single orientation on the DNA. The solution NMR structure of the ternary 42 kDa Oct1.Sox2.Hoxb1.DNA complex, determined by novel procedures based on orientational restraints from dipolar couplings and conjoined rigid body/torsion angle dynamics, reveals that Sox2 and POUS interact through a predominantly hydrophobic interface, surrounded by a ring of electrostatic interactions. These observations suggest a mechanism of combinatorial control involving direct protein-protein interactions on the DNA whereby Oct1 in conjunction with a co-interacting transcription factor provide cell-specific transcription regulation.	NIDDK, Chem Phys Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Clore, GM (corresponding author), NIDDK, Chem Phys Lab, NIH, Bldg 5,Rm B1-301, Bethesda, MD 20892 USA.	mariusc@intra.niddk.nih.gov	Clore, G. Marius/A-3511-2008; Clore, G Marius/L-2546-2018	Clore, G. Marius/0000-0003-3809-1027; Clore, G Marius/0000-0003-3809-1027	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK029023, Z01DK029023] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ambrosetti DC, 2000, J BIOL CHEM, V275, P23387, DOI 10.1074/jbc.M000932200; Bax A, 2001, METHOD ENZYMOL, V339, P127, DOI 10.1016/S0076-6879(01)39313-8; BAX A, 1994, METHOD ENZYMOL, V239, P79; Braddock DT, 2002, NATURE, V415, P1051, DOI 10.1038/4151051a; Braddock DT, 2001, J AM CHEM SOC, V123, P8634, DOI 10.1021/ja016234f; CANTOR CR, 1980, BIOPHYSICAL CHEM 3, P979; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; Chasman D, 1999, GENE DEV, V13, P2650, DOI 10.1101/gad.13.20.2650; Clore GM, 2000, P NATL ACAD SCI USA, V97, P9021, DOI 10.1073/pnas.97.16.9021; Clore GM, 1999, J AM CHEM SOC, V121, P9008, DOI 10.1021/ja991789k; Clore GM, 2003, J AM CHEM SOC, V125, P1518, DOI 10.1021/ja028383j; Clore GM, 1998, TRENDS BIOTECHNOL, V16, P22, DOI 10.1016/S0167-7799(97)01135-9; Clore GM, 1998, J AM CHEM SOC, V120, P10571, DOI 10.1021/ja982592f; Cornilescu G, 2002, J BIOL CHEM, V277, P42289, DOI 10.1074/jbc.M207314200; Dailey L, 2001, J CELL PHYSIOL, V186, P315, DOI 10.1002/1097-4652(2001)9999:9999<000::AID-JCP1046>3.0.CO;2-Y; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Di Rocco G, 2001, J BIOL CHEM, V276, P20506, DOI 10.1074/jbc.M011175200; GARRETT DS, 1991, J MAGN RESON, V95, P214, DOI 10.1016/0022-2364(91)90341-P; Gaufo OO, 2000, DEVELOPMENT, V127, P5343; GORENSTEIN DG, 1994, CHEM REV, V94, P1315, DOI 10.1021/cr00029a007; Goto NK, 1999, J BIOMOL NMR, V13, P369, DOI 10.1023/A:1008393201236; Hansen MR, 2000, METHOD ENZYMOL, V317, P220; Hovde S, 2002, GENE DEV, V16, P2772, DOI 10.1101/gad.1021002; Huang K, 2000, EMBO J, V19, P2615, DOI 10.1093/emboj/19.11.2615; Kamachi Y, 2000, TRENDS GENET, V16, P182, DOI 10.1016/S0168-9525(99)01955-1; Klemm JD, 1996, GENE DEV, V10, P27, DOI 10.1101/gad.10.1.27; KLEMM JD, 1994, CELL, V77, P21, DOI 10.1016/0092-8674(94)90231-3; Kuszewski J, 2001, J AM CHEM SOC, V123, P3903, DOI 10.1021/ja010033u; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Levine M, 2003, NATURE, V424, P147, DOI 10.1038/nature01763; Murphy EC, 2001, J MOL BIOL, V312, P481, DOI 10.1006/jmbi.2001.4977; Nishimoto M, 1999, MOL CELL BIOL, V19, P5453; Ottiger M, 1998, J AM CHEM SOC, V120, P12334, DOI 10.1021/ja9826791; Pervushin K, 1997, P NATL ACAD SCI USA, V94, P12366, DOI 10.1073/pnas.94.23.12366; PTASHNE M, 2002, GENES SIGNALS; Remenyi A, 2003, GENE DEV, V17, P2048, DOI 10.1101/gad.269303; Remenyi A, 2001, MOL CELL, V8, P569, DOI 10.1016/S1097-2765(01)00336-7; Ruckert M, 2000, J AM CHEM SOC, V122, P7793, DOI 10.1021/ja001068h; Sauter P, 1998, MOL CELL BIOL, V18, P7397, DOI 10.1128/MCB.18.12.7397; Scaffidi P, 2001, J BIOL CHEM, V276, P47296, DOI 10.1074/jbc.M107619200; Schwieters CD, 2002, J BIOMOL NMR, V23, P221, DOI 10.1023/A:1019875223132; Schwieters CD, 2003, J MAGN RESON, V160, P65, DOI 10.1016/S1090-7807(02)00014-9; Schwieters CD, 2001, J MAGN RESON, V152, P288, DOI 10.1006/jmre.2001.2413; Schwieters CD, 2001, J MAGN RESON, V149, P239, DOI 10.1006/jmre.2001.2300; Tugarinov V, 2002, J AM CHEM SOC, V124, P10025, DOI 10.1021/ja0205636; Wang GS, 2000, EMBO J, V19, P5635, DOI 10.1093/emboj/19.21.5635; Wolberger C, 1999, ANNU REV BIOPH BIOM, V28, P29, DOI 10.1146/annurev.biophys.28.1.29; Yang DW, 1999, J BIOMOL NMR, V14, P333, DOI 10.1023/A:1008314803561; Zweckstetter M, 2000, J AM CHEM SOC, V122, P3791, DOI 10.1021/ja0000908; Zweckstetter M, 2002, J BIOMOL NMR, V23, P127, DOI 10.1023/A:1016316415261	50	123	125	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 9	2004	279	2					1449	1457		10.1074/jbc.M309790200	http://dx.doi.org/10.1074/jbc.M309790200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	759DJ	14559893	hybrid			2022-12-27	WOS:000187722800075
J	Bourne, Y; Roig-Zamboni, V; Barre, A; Peumans, WJ; Astoul, CH; Van Damme, EJM; Rouge, P				Bourne, Y; Roig-Zamboni, V; Barre, A; Peumans, WJ; Astoul, CH; Van Damme, EJM; Rouge, P			The crystal structure of the Calystegia sepium agglutinin reveals a novel quaternary arrangement of lectin subunits with a beta-prism fold	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JACALIN-RELATED LECTINS; MANNOSE-BINDING LECTIN; MOLECULAR-CLONING; CARBOHYDRATE-RECOGNITION; PLANT LECTIN; REFINEMENT; PROTEINS; ASSOCIATION; RESOLUTION; SEQUENCE	The high number of quaternary structures observed for lectins highlights the important role of these oligomeric assemblies during carbohydrate recognition events. Although a large diversity in the mode of association of lectin subunits is frequently observed, the oligomeric assemblies of plant lectins display small variations within a single family. The crystal structure of the mannose-binding jacalin-related lectin from Calystegia sepium (Calsepa) has been determined at 1.37-Angstrom resolution. Calsepa exhibits the same beta-prism fold as identified previously for other members of the family, but the shape and the hydrophobic character of its carbohydrate- binding site is unlike that of other members, consistent with surface plasmon resonance analysis showing a preference for methylated sugars. Calsepa reveals a novel dimeric assembly markedly dissimilar to those described earlier for Heltuba and jacalin but mimics the canonical 12-stranded beta-sandwich dimer found in legume lectins. The present structure exemplifies the adaptability of the beta-prism building block in the evolution of plant lectins and highlights the biological role of these quaternary structures for carbohydrate recognition.	CNRS, UMR 6098, AFMB CNRS, F-13402 Marseille 20, France; UPS, CNRS, UMR 5546, F-31326 Castanet Tolosan, France; Univ Ghent, Dept Mol Biotechnol, B-9000 Ghent, Belgium	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Ghent University	Bourne, Y (corresponding author), CNRS, UMR 6098, AFMB CNRS, F-13402 Marseille 20, France.	yves@afmb.cnrs-mrs.fr	Van Damme, Els J/B-4410-2015; Bourne, Yves/AAC-4635-2022; Van Damme, Els/U-3904-2019; Rouge, Pierre/T-2059-2019	Bourne, Yves/0000-0003-3850-0548; Van Damme, Els/0000-0001-9848-766X; Barre, annick/0000-0002-1360-8491; SANCHEZ, Corinne/0000-0003-3895-0194				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Barre A, 1996, PLANT PHYSIOL, V112, P1531, DOI 10.1104/pp.112.4.1531; Barre A, 2001, BIOCHIMIE, V83, P645, DOI 10.1016/S0300-9084(01)01315-3; Bourne Y, 1999, STRUCTURE, V7, P1473, DOI 10.1016/S0969-2126(00)88338-0; BOURNE Y, 1990, J MOL BIOL, V214, P571, DOI 10.1016/0022-2836(90)90199-V; EINSPAHR H, 1986, J BIOL CHEM, V261, P6518; GILSON MK, 1987, NATURE, V330, P84, DOI 10.1038/330084a0; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; HUI Y, 1993, J BIOL CHEM, V268, P5905; Jeyaprakash AA, 2002, J MOL BIOL, V321, P637, DOI 10.1016/S0022-2836(02)00674-5; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lee X, 1998, J BIOL CHEM, V273, P6312, DOI 10.1074/jbc.273.11.6312; LORIS R, 1993, BIOCHEMISTRY-US, V32, P8772, DOI 10.1021/bi00085a007; Loris R, 1998, BBA-PROTEIN STRUCT M, V1383, P9, DOI 10.1016/S0167-4838(97)00182-9; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Peumans WJ, 2000, FEBS LETT, V477, P186, DOI 10.1016/S0014-5793(00)01801-9; Peumans WJ, 1997, GLYCOCONJUGATE J, V14, P259, DOI 10.1023/A:1018502107707; Peumans WJ, 2000, PLANTA, V211, P546, DOI 10.1007/s004250000307; Prabu MM, 1999, PROTEINS, V35, P58, DOI 10.1002/(SICI)1097-0134(19990401)35:1<58::AID-PROT6>3.0.CO;2-A; RINI JM, 1995, ANNU REV BIOPH BIOM, V24, P551, DOI 10.1146/annurev.biophys.24.1.551; Romero A, 1997, NAT STRUCT BIOL, V4, P783, DOI 10.1038/nsb1097-783; Rosa JC, 1999, PROTEIN SCI, V8, P13; ROUSSEL A, 1989, TURBO FRODO SILICON; RUTENBER E, 1991, PROTEINS, V10, P260, DOI 10.1002/prot.340100310; Sankaranarayanan R, 1996, NAT STRUCT BIOL, V3, P596, DOI 10.1038/nsb0796-596; Sreerama N, 1999, PROTEIN SCI, V8, P370; STURA EA, 1999, PROTEIN CRYSTALLIZAT, P113; Tateno H, 2003, J BIOL CHEM, V278, P10891, DOI 10.1074/jbc.M211840200; Van Damme EJM, 1999, EUR J BIOCHEM, V259, P135, DOI 10.1046/j.1432-1327.1999.00013.x; Van Damme EJM, 2001, CRIT REV PLANT SCI, V20, P395, DOI 10.1080/713608299; VanDamme EJM, 1996, FEBS LETT, V397, P352, DOI 10.1016/S0014-5793(96)01211-2; Zhang WL, 2000, PLANTA, V210, P970, DOI 10.1007/s004250050705	37	50	52	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 2	2004	279	1					527	533		10.1074/jbc.M308218200	http://dx.doi.org/10.1074/jbc.M308218200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	757GU	14561768	hybrid			2022-12-27	WOS:000187555300063
J	Li, XY; Chen, HN; Epstein, PN				Li, XY; Chen, HN; Epstein, PN			Metallothionein protects islets from hypoxia and extends islet graft survival by scavenging most kinds of reactive oxygen species	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED OXIDATIVE STRESS; PANCREATIC-ISLETS; NITRIC-OXIDE; SUPEROXIDE-DISMUTASE; ANTIOXIDANT ENZYMES; RINM5F CELLS; BETA-CELLS; PRIMARY NONFUNCTION; INSULIN-SECRETION; GENE-TRANSFER	Islet transplantation is a promising therapy for Type 1 diabetes, but many attempts have failed due to early graft hypoxia or immune rejection, which generate reactive oxygen species (ROS). In the current study, we determined that transgenic overexpression of the antioxidant metallothionein (MT) in pancreatic beta cells provided broad resistance to oxidative stress by scavenging most kinds of ROS including H2O2, peroxynitrite radical released from streptozotocin, 3-morpholinosydnonimine (SIN-1), and superoxide radical produced by xanthine/ xanthine oxidase. MT also reduced nitric oxide-induced beta cell death. A direct test of hypoxia/reperfusion sensitivity was made by exposing FVB and MT islets to hypoxia (1% O-2). MT markedly reduced ROS production and improved islet cell survival. Because MT protected beta cells from a broad spectrum of ROS and from hypoxia, we considered it to be an ideal candidate for improving islet transplantation. We first tested syngeneic transplantation by implanting islets under the kidney capsule of the same strain, FVB mice, thereby eliminating the immune rejection component. Under these conditions, MT islets maintained much greater insulin content than control islets. Allotransplantation was then tested. MT transgenic and normal FVB islets were implanted under the kidney capsule of BALB/c mice that were previously treated with streptozotocin to induce diabetes. We found that MT islets extended the duration of euglycemia 2-fold longer than nontransgenic islets. The benefit of MT was due to protection from ROS since nitrotyrosine staining, an indicator of free radical damage, was much lower in MT grafts than in FVB grafts. The time course of protection suggested that the major mode of MT action may have been protection from hypoxia or hypoxia/reperfusion. These data demonstrate that treatment with a broad spectrum antioxidant protects islets from ROS damage such as that produced during the early phase of islet transplantation.	Univ Louisville, Dept Pharmacol & Toxicol, Sch Med, Louisville, KY 40202 USA; Univ Louisville, Dept Pediat, Sch Med, Louisville, KY 40202 USA	University of Louisville; University of Louisville	Epstein, PN (corresponding author), Univ Louisville, Dept Pharmacol & Toxicol, Sch Med, Louisville, KY 40202 USA.			Epstein, Paul/0000-0002-7006-8954	NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR017702] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058100] Funding Source: NIH RePORTER; NCRR NIH HHS [P20 RR017702] Funding Source: Medline; NIDDK NIH HHS [R01-DK52309, R01-DK58100] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		APPELS B, 1989, J IMMUNOL, V142, P3803; Arita S, 2000, TRANSPLANT P, V32, P1667, DOI 10.1016/S0041-1345(00)01424-X; Bertera S, 2003, DIABETES, V52, P387, DOI 10.2337/diabetes.52.2.387; Biarnes M, 2002, DIABETES, V51, P66, DOI 10.2337/diabetes.51.1.66; BRENNER HH, 1993, AUTOIMMUNITY, V15, P93, DOI 10.3109/08916939309043883; Byth HA, 2001, PHYTOCHEM ANALYSIS, V12, P340, DOI 10.1002/pca.595; Cai L, 2000, J BIOL CHEM, V275, P38957, DOI 10.1074/jbc.C000593200; Carlsson PO, 2000, TRANSPLANTATION, V69, P761; Carlsson PO, 2001, DIABETES, V50, P489, DOI 10.2337/diabetes.50.3.489; Chen HN, 2001, DIABETES, V50, P2040, DOI 10.2337/diabetes.50.9.2040; Davalli AM, 1996, DIABETES, V45, P1161, DOI 10.2337/diabetes.45.9.1161; Duranteau J, 1998, J BIOL CHEM, V273, P11619, DOI 10.1074/jbc.273.19.11619; EIZIRIK DL, 1994, P NATL ACAD SCI USA, V91, P9253, DOI 10.1073/pnas.91.20.9253; Gembal M, 1993, Endokrynol Pol, V44, P147; Gonzalez RJ, 2001, TOXICOL IN VITRO, V15, P257, DOI 10.1016/S0887-2333(01)00014-5; GOTOH M, 1985, TRANSPLANTATION, V40, P437, DOI 10.1097/00007890-198510000-00018; Hadjivassiliou V, 1998, NITRIC OXIDE-BIOL CH, V2, P429, DOI 10.1006/niox.1998.0203; Hussain S, 1996, NEUROCHEM INT, V29, P145, DOI 10.1016/0197-0186(95)00114-X; JANSSON L, 1995, J CLIN INVEST, V96, P721, DOI 10.1172/JCI118115; Karsten V, 2001, TRANSPL P, V33, P575, DOI 10.1016/S0041-1345(00)02148-5; KENNEDY MC, 1993, BIOCHEM BIOPH RES CO, V196, P632, DOI 10.1006/bbrc.1993.2296; Ketchum RJ, 2000, CELL TRANSPLANT, V9, P453, DOI 10.1177/096368970000900402; KRONCKE KD, 1993, DIABETOLOGIA, V36, P17, DOI 10.1007/BF00399088; Kumari MVR, 1998, FREE RADICAL RES, V29, P93, DOI 10.1080/10715769800300111; LAND W, 1994, TRANSPLANTATION, V57, P211, DOI 10.1097/00007890-199401001-00010; Lenzen S, 1996, FREE RADICAL BIO MED, V20, P463, DOI 10.1016/0891-5849(96)02051-5; Li CY, 2002, AM J PHYSIOL-CELL PH, V282, pC227, DOI 10.1152/ajpcell.00112.2001; Lortz S, 2000, DIABETES, V49, P1123, DOI 10.2337/diabetes.49.7.1123; MALAISSE WJ, 1982, P NATL ACAD SCI-BIOL, V79, P927, DOI 10.1073/pnas.79.3.927; Marquet R L, 1994, Transpl Int, V7 Suppl 1, pS660; MENDOLA J, 1989, DIABETES, V38, P379, DOI 10.2337/diabetes.38.3.379; MENGER MD, 1992, J CLIN INVEST, V90, P1361, DOI 10.1172/JCI116002; Miura T, 1997, LIFE SCI, V60, P301; MONTANA E, 1993, J CLIN INVEST, V91, P780, DOI 10.1172/JCI116297; Moritz W, 2002, FASEB J, V16, P745, DOI 10.1096/fj.01-0403fje; NAKAO N, 1994, P NATL ACAD SCI USA, V91, P12408, DOI 10.1073/pnas.91.26.12408; Ohly P, 2000, DIABETOLOGIA, V43, P1020, DOI 10.1007/s001250050009; PETROWSKY H, 1995, TRANSPLANT P, V27, P729; Ryan EA, 2002, DIABETES, V51, P2148, DOI 10.2337/diabetes.51.7.2148; Stevens RB, 1996, TRANSPLANTATION, V61, P1740, DOI 10.1097/00007890-199606270-00014; SuarezPinzon WL, 1997, DIABETES, V46, P907, DOI 10.2337/diabetes.46.5.907; Tajiri Y, 1999, PANCREAS, V18, P274, DOI 10.1097/00006676-199904000-00009; THORNALLEY PJ, 1985, BIOCHIM BIOPHYS ACTA, V827, P36, DOI 10.1016/0167-4838(85)90098-6; Tiedge M, 1999, DIABETOLOGIA, V42, P849, DOI 10.1007/s001250051237; Tiedge M, 1998, DIABETES, V47, P1578, DOI 10.2337/diabetes.47.10.1578; UCHIGATA Y, 1982, J BIOL CHEM, V257, P6084; Vajkoczy P, 1997, AM J PATHOL, V150, P1487; WEIR GC, 1990, DIABETES, V39, P401, DOI 10.2337/diabetes.39.4.401; White SA, 2001, DIABETIC MED, V18, P78, DOI 10.1046/j.1464-5491.2001.00465.x; Winter DT, 2002, TRANSPL P, V34, P2366, DOI 10.1016/S0041-1345(02)03273-6; Xu B, 1999, FREE RADICAL BIO MED, V27, P830, DOI 10.1016/S0891-5849(99)00130-6; YANG YP, 1994, LIFE SCI, V55, P43, DOI 10.1016/0024-3205(94)90080-9; Ye G, 2003, DIABETES, V52, P777, DOI 10.2337/diabetes.52.3.777; ZHANG H, 1995, DIABETOLOGIA, V38, P635, DOI 10.1007/BF00401832	54	126	128	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	2004	279	1					765	771		10.1074/jbc.M307907200	http://dx.doi.org/10.1074/jbc.M307907200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	757GU	14576162	hybrid			2022-12-27	WOS:000187555300091
J	Romanelli, RG; Barni, T; Maggi, M; Luconi, M; Failli, P; Pezzatini, A; Pelo, E; Torricelli, F; Crescioli, C; Ferruzzi, P; Salerno, R; Marini, M; Rotella, CM; Vannelli, GB				Romanelli, RG; Barni, T; Maggi, M; Luconi, M; Failli, P; Pezzatini, A; Pelo, E; Torricelli, F; Crescioli, C; Ferruzzi, P; Salerno, R; Marini, M; Rotella, CM; Vannelli, GB			Expression and function of gonadotropin-releasing hormone (GnRH) receptor in human olfactory GnRH-secreting neurons - An autocrine GnRH loop underlies neuronal migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAYS; LUTEINIZING-HORMONE; KALLMANN-SYNDROME; HYPOGONADOTROPIC HYPOGONADISM; HYPOTHALAMIC NEURONS; GENE-EXPRESSION; LHRH NEURONS; PROGENITOR CELLS; MESSENGER-RNA; CANCER CELLS	Olfactory neurons and gonadotropin-releasing hormone ( GnRH) neurons share a common origin during organogenesis. Kallmann's syndrome, clinically characterized by anosmia and hypogonadotropic hypogonadism, is due to an abnormality in the migration of olfactory and GnRH neurons. We recently characterized the human FNC-B4 cell line, which retains properties present in vivo in both olfactory and GnRH neurons. In this study, we found that FNC-B4 neurons expressed GnRH receptor and responded to GnRH with time- and dose-dependent increases in GnRH gene expression and protein release ( up to 5-fold). In addition, GnRH and its analogs stimulated cAMP production and calcium mobilization, although at different biological thresholds (nanomolar for cAMP and micromolar concentrations for calcium). We also observed that GnRH triggered axon growth, actin cytoskeleton remodeling, and a dose-dependent increase in migration ( up to 3-4-fold), whereas it down-regulated nestin expression. All these effects were blocked by a specific GnRH receptor antagonist, cetrorelix. We suggest that GnRH, secreted by olfactory neuroblasts, acts in an autocrine pattern to promote differentiation and migration of those cells that diverge from the olfactory sensory lineage and are committed to becoming GnRH neurons.	Univ Florence, Sch Med, Dept Anat Histol & Forens Med, I-50134 Florence, Italy; Univ Florence, Sch Med, Dept Clin Physiopathol, I-50134 Florence, Italy; Univ Florence, Sch Med, Dept Endocrinol, I-50134 Florence, Italy; Univ Florence, Sch Med, Androl Unit, I-50134 Florence, Italy; Univ Florence, Sch Med, Genet Unit, I-50134 Florence, Italy; Univ Florence, Sch Med, Dept Internal Med, I-50134 Florence, Italy; Univ Florence, Sch Med, Dept Preclin & Clin Pharmacol, I-50134 Florence, Italy; Univ Catanzaro, Dept Expt & Clin Med, I-88100 Catanzaro, Italy	University of Florence; University of Florence; University of Florence; University of Florence; University of Florence; University of Florence; University of Florence; Magna Graecia University of Catanzaro	Vannelli, GB (corresponding author), Univ Florence, Sch Med, Dept Anat Histol & Forens Med, Vle Morgagni 85, I-50134 Florence, Italy.		Maggi, Mario/AAB-8284-2019; Luconi, Michaela/W-9522-2019; ROMANELLI, Roberto Giulio/K-4406-2018	Luconi, Michaela/0000-0001-5186-064X; Failli, Paola/0000-0003-3879-9068; BARNI, Tullio/0000-0002-9044-4929; MAGGI, Mario/0000-0003-3267-4221; ROMANELLI, Roberto Giulio/0000-0001-9219-8189				Allen MP, 2002, MOL CELL BIOL, V22, P599, DOI 10.1128/MCB.22.2.599-613.2002; Allen MP, 2000, J BIOL CHEM, V275, P39662, DOI 10.1074/jbc.M007097200; AUBERT ML, 1985, ENDOCRINOLOGY, V116, P1565, DOI 10.1210/endo-116-4-1565; Barni T, 1999, J CLIN ENDOCR METAB, V84, P4266, DOI 10.1210/jc.84.11.4266; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CALOF AL, 1989, NEURON, V3, P115, DOI 10.1016/0896-6273(89)90120-7; Carlier MF, 2003, BIOESSAYS, V25, P336, DOI 10.1002/bies.10257; Carloni V, 1997, GASTROENTEROLOGY, V112, P522, DOI 10.1053/gast.1997.v112.pm9024306; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; Dode C, 2003, NAT GENET, V33, P463, DOI 10.1038/ng1122; Florio P, 2000, EUR J ENDOCRINOL, V143, P133, DOI 10.1530/eje.0.1430133; Giacobini P, 2002, ENDOCRINOLOGY, V143, P3306, DOI 10.1210/en.2002-220146; GRAZIADEI PP, 1973, TISSUE CELL, V5, P113, DOI 10.1016/S0040-8166(73)80010-2; Grundker C, 2001, ENDOCRINOLOGY, V142, P2369, DOI 10.1210/en.142.6.2369; Imai A, 1996, J CLIN ENDOCR METAB, V81, P3249, DOI 10.1210/jc.81.9.3249; KARANDE AA, 1995, MOL CELL ENDOCRINOL, V114, P51, DOI 10.1016/0303-7207(95)03641-J; Kim KH, 1999, BRAIN RES, V826, P220, DOI 10.1016/S0006-8993(99)01271-8; Kramer PR, 2000, DEV BIOL, V227, P343, DOI 10.1006/dbio.2000.9896; Kramer PR, 2000, GENE DEV, V14, P1824; Krsmanovic LZ, 1999, ENDOCRINOLOGY, V140, P1423, DOI 10.1210/en.140.3.1423; KRSMANOVIC LZ, 1991, P NATL ACAD SCI USA, V88, P11124, DOI 10.1073/pnas.88.24.11124; Krsmanovic LZ, 2003, P NATL ACAD SCI USA, V100, P2969, DOI 10.1073/pnas.0535708100; KRSMANOVIC LZ, 1993, P NATL ACAD SCI USA, V90, P3908, DOI 10.1073/pnas.90.9.3908; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; Limonta P, 1999, ENDOCRINOLOGY, V140, P5250, DOI 10.1210/en.140.11.5250; Lin XW, 1999, ENDOCRINOLOGY, V140, P358, DOI 10.1210/en.140.1.358; MacColl G, 2002, TRENDS ENDOCRIN MET, V13, P112, DOI 10.1016/S1043-2760(01)00545-8; MacConell LA, 1999, NEUROENDOCRINOLOGY, V70, P246, DOI 10.1159/000054483; Maggi M, 2000, J CLIN ENDOCR METAB, V85, P1658, DOI 10.1210/jc.85.4.1658; Maggi R, 2000, ENDOCRINOLOGY, V141, P2105, DOI 10.1210/en.141.6.2105; MELLON PL, 1990, NEURON, V5, P1, DOI 10.1016/0896-6273(90)90028-E; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; Nachtigall LB, 1997, NEW ENGL J MED, V336, P410, DOI 10.1056/NEJM199702063360604; Neves SR, 2002, SCIENCE, V296, P1636, DOI 10.1126/science.1071550; Nunes MC, 2003, NAT MED, V9, P439, DOI 10.1038/nm837; Oliveira LMB, 2001, J CLIN ENDOCR METAB, V86, P1532, DOI 10.1210/jc.86.4.1532; PERI A, 1995, J CLIN INVEST, V96, P343, DOI 10.1172/JCI118040; PINZANI M, 1992, J CLIN INVEST, V90, P642, DOI 10.1172/JCI115905; Quinton R, 1997, J CLIN ENDOCR METAB, V82, P309, DOI 10.1210/jc.82.1.309; Quinton R, 1999, CLIN ENDOCRINOL, V50, P481; RADOVICK S, 1991, P NATL ACAD SCI USA, V88, P3402, DOI 10.1073/pnas.88.8.3402; RUGARLI EI, 1993, NAT GENET, V4, P19, DOI 10.1038/ng0593-19; SALISBURY RL, 1982, NEUROENDOCRINOLOGY, V35, P265, DOI 10.1159/000123392; Schwanzel-Fukuda M, 2002, PROG BRAIN RES, V141, P59; SCHWANZELFUKUDA M, 1989, MOL BRAIN RES, V6, P311, DOI 10.1016/0169-328X(89)90076-4; SCHWANZELFUKUDA M, 1989, NATURE, V338, P161, DOI 10.1038/338161a0; Sealfon SC, 1997, ENDOCR REV, V18, P180, DOI 10.1210/er.18.2.180; Seminara SB, 2000, J ENDOCRINOL INVEST, V23, P560, DOI 10.1007/BF03343776; Simonian SX, 2001, NEUROENDOCRINOLOGY, V73, P149, DOI 10.1159/000054631; SLOB AK, 1980, J ENDOCRINOL, V87, P81, DOI 10.1677/joe.0.0870081; Soussi-Yanicostas N, 2002, CELL, V109, P217, DOI 10.1016/S0092-8674(02)00713-4; Stanislaus D, 1998, BIOL REPROD, V59, P579, DOI 10.1095/biolreprod59.3.579; STOJILKOVIC SS, 1994, ENDOCR REV, V15, P462, DOI 10.1210/er.15.4.462; VANNELLI GB, 1995, J NEUROSCI, V15, P4382; WETSEL WC, 1995, CELL MOL NEUROBIOL, V15, P43, DOI 10.1007/BF02069558; WRAY S, 1989, P NATL ACAD SCI USA, V86, P8132, DOI 10.1073/pnas.86.20.8132; Wray S, 2001, J NEUROENDOCRINOL, V13, P3, DOI 10.1046/j.1365-2826.2001.00609.x	57	53	53	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	2004	279	1					117	126		10.1074/jbc.M307955200	http://dx.doi.org/10.1074/jbc.M307955200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	757GU	14565958	hybrid			2022-12-27	WOS:000187555300015
J	Shah, BH; Farshori, MP; Catt, KJ				Shah, BH; Farshori, MP; Catt, KJ			Neuropeptide-induced transactivation of a neuronal epidermal growth factor receptor is mediated by metalloprotease-dependent formation of heparin-binding epidermal growth factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GONADOTROPIN-RELEASING-HORMONE; PROTEIN-COUPLED RECEPTORS; SMOOTH-MUSCLE-CELLS; KINASE-C-DELTA; ANGIOTENSIN-II; EGF RECEPTOR; MATRIX METALLOPROTEINASES; TYROSINE KINASES; NERVOUS-SYSTEM; ERK ACTIVATION	Numerous external stimuli, including G protein-coupled receptor agonists, cytokines, growth factors, and steroids activate mitogen-activated protein kinases (MAPKs) through phosphorylation of the epidermal growth factor receptor (EGF-R). In immortalized hypothalamic neurons (GT1-7 cells), agonist binding to the gonadotropin-releasing hormone receptor (GnRH-R) causes phosphorylation of MAPKs that is mediated by protein kinase C (PKC)-dependent transactivation of the EGF-R. An analysis of the mechanisms involved in this process showed that GnRH stimulation of GT1-7 cells causes release/shedding of the soluble ligand, heparin binding epidermal growth factor (HB-EGF), as a consequence of metalloprotease activation. GnRH-induced phosphorylation of the EGF-R and, subsequently, of Shc, ERK1/2, and its dependent protein, p90(RSK-1) (p90 ribosomal S6 kinase 1 or RSK-1), was abolished by metalloprotease inhibition. Similarly, blockade of the effect of HB-EGF with the selective inhibitor CRM197 or a neutralizing antibody attenuated signals generated by GnRH and phorbol 12-myristate 13-acetate, but not those stimulated by EGF. In contrast, phosphorylation of the EGF-R, Shc, and ERK1/2 by EGF and HB-EGF was independent of PKC and metalloprotease activity. The signaling characteristics of HB-EGF closely resembled those of GnRH and EGF in terms of the phosphorylation of EGF-R, Shc, ERK1/2, and RSK-1 as well as the nuclear translocation of RSK-1. However, neither the selective Src kinase inhibitor PP2 nor the overexpression of negative regulatory Src kinase and dominant negative Pyk2 had any effect on HB-EGF-induced responses. In contrast to GT1-7 cells, human embryonic kidney 293 cells expressing the GnRH-R did not exhibit metalloprotease induction and EGF-R transactivation during GnRH stimulation. These data indicate that the GnRH-induced transactivation of the EGF-R and the subsequent ERK1/2 phosphorylation result from ectodomain shedding of HB-EGF through PKC-dependent activation of metalloprotease(s) in neuronal GT1-7 cells.	NICHD, Endocrinol & Reprod Res Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Catt, KJ (corresponding author), NICHD, Endocrinol & Reprod Res Branch, NIH, Bldg 49,Rm 6A36, Bethesda, MD 20892 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000184] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000184] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ARMIENTO JD, 2002, TRENDS CARDIOVAS MED, V12, P97; Asakura M, 2002, NAT MED, V8, P35, DOI 10.1038/nm0102-35; Bakke LJ, 2002, BIOL REPROD, V66, P1627, DOI 10.1095/biolreprod66.6.1627; Benard O, 2001, J BIOL CHEM, V276, P4554, DOI 10.1074/jbc.M006995200; CARPENTER G, 2000, SCI STKE; Cussac D, 2002, J BIOL CHEM, V277, P19882, DOI 10.1074/jbc.M110142200; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Eguchi S, 2001, J BIOL CHEM, V276, P7957, DOI 10.1074/jbc.M008570200; Frank GD, 2003, MOL CELL BIOL, V23, P1581, DOI 10.1128/MCB.23.5.1581-1589.2003; Gallet C, 2003, BIOCHEM J, V371, P733, DOI 10.1042/BJ20021030; Goto T, 1999, J ENDOCRINOL, V161, P393, DOI 10.1677/joe.0.1610393; Grewal JS, 2001, J BIOL CHEM, V276, P27335, DOI 10.1074/jbc.M103578200; Grosse R, 2000, J BIOL CHEM, V275, P12251, DOI 10.1074/jbc.275.16.12251; Gschwind A, 2001, ONCOGENE, V20, P1594, DOI 10.1038/sj.onc.1204192; Hartung HP, 2000, J NEUROIMMUNOL, V107, P140, DOI 10.1016/S0165-5728(00)00225-3; Izumi Y, 1998, EMBO J, V17, P7260, DOI 10.1093/emboj/17.24.7260; Jin KL, 2002, J NEUROSCI, V22, P5365; Jones SM, 2002, AM J PHYSIOL-CELL PH, V282, pC420, DOI 10.1152/ajpcell.00253.2001; Jorissen RN, 2003, EXP CELL RES, V284, P31, DOI 10.1016/S0014-4827(02)00098-8; Kim HE, 2000, J CLIN INVEST, V106, P857, DOI 10.1172/JCI8040; Kornblum HI, 1999, EUR J NEUROSCI, V11, P3236, DOI 10.1046/j.1460-9568.1999.00744.x; Kraus S, 2003, J BIOL CHEM, V278, P32618, DOI 10.1074/jbc.M303886200; Kraus S, 2001, ARCH MED RES, V32, P499, DOI 10.1016/S0188-4409(01)00331-9; Krsmanovic LZ, 2003, P NATL ACAD SCI USA, V100, P2969, DOI 10.1073/pnas.0535708100; Krsmanovic LZ, 2001, MOL ENDOCRINOL, V15, P429, DOI 10.1210/me.15.3.429; Lowes VL, 2002, NEUROSIGNALS, V11, P5, DOI 10.1159/000057317; Luttrell LM, 2002, CAN J PHYSIOL PHARM, V80, P375, DOI 10.1139/Y02-045; Marinissen MJ, 2001, TRENDS PHARMACOL SCI, V22, P368, DOI 10.1016/S0165-6147(00)01678-3; MATRISIAN LM, 1990, TRENDS GENET, V6, P121, DOI 10.1016/0168-9525(90)90126-Q; Murasawa S, 1998, CIRC RES, V82, P1338, DOI 10.1161/01.RES.82.12.1338; Naor Z, 2000, TRENDS ENDOCRIN MET, V11, P91, DOI 10.1016/S1043-2760(99)00232-5; Nath D, 2001, J CELL SCI, V114, P1213; Pierce KL, 2002, NAT REV MOL CELL BIO, V3, P639, DOI 10.1038/nrm908; Pierce KL, 2001, J BIOL CHEM, V276, P23155, DOI 10.1074/jbc.M101303200; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Rajagopalan S, 1996, J CLIN INVEST, V98, P2572, DOI 10.1172/JCI119076; Reynolds CM, 2002, HYPERTENSION, V39, P525, DOI 10.1161/hy0202.103076; Rosenberg GA, 2002, GLIA, V39, P279, DOI 10.1002/glia.10108; Saito S, 2002, BIOCHEM BIOPH RES CO, V294, P1023, DOI 10.1016/S0006-291X(02)00595-8; Saito Y, 2001, J MOL CELL CARDIOL, V33, P3, DOI 10.1006/jmcc.2000.1272; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Seals DF, 2003, GENE DEV, V17, P7, DOI 10.1101/gad.1039703; Shah BH, 2003, J BIOL CHEM, V278, P19118, DOI 10.1074/jbc.M212932200; Shah BH, 2003, J BIOL CHEM, V278, P2866, DOI 10.1074/jbc.m208783200; Shah BH, 2002, MOL PHARMACOL, V61, P343, DOI 10.1124/mol.61.2.343; Siwik DA, 2001, AM J PHYSIOL-CELL PH, V280, pC53, DOI 10.1152/ajpcell.2001.280.1.C53; Sorescu Dan, 2002, Congest Heart Fail, V8, P132, DOI 10.1111/j.1527-5299.2002.00717.x; Spinale FG, 2002, CIRC RES, V90, P520, DOI 10.1161/01.RES.0000013290.12884.A3; STOJILKOVIC SS, 1995, J NEUROENDOCRINOL, V7, P739, DOI 10.1111/j.1365-2826.1995.tb00711.x; Tanaka N, 1999, BRAIN RES, V827, P130, DOI 10.1016/S0006-8993(99)01319-0; Umata T, 2001, J BIOL CHEM, V276, P30475, DOI 10.1074/jbc.M103673200; Wang DM, 1999, J BIOL CHEM, V274, P24342, DOI 10.1074/jbc.274.34.24342; Yan YB, 2002, J CELL BIOL, V158, P221, DOI 10.1083/jcb.200112026; Zwick E, 1999, J BIOL CHEM, V274, P20989, DOI 10.1074/jbc.274.30.20989	54	38	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	2004	279	1					414	420		10.1074/jbc.M309083200	http://dx.doi.org/10.1074/jbc.M309083200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	757GU	14573593	hybrid			2022-12-27	WOS:000187555300050
J	Voets, T; Nilius, B; Hoefs, S; van der Kemp, AWCM; Droogmans, G; Bindels, RJM; Hoenderop, JGJ				Voets, T; Nilius, B; Hoefs, S; van der Kemp, AWCM; Droogmans, G; Bindels, RJM; Hoenderop, JGJ			TRPM6 forms the Mg2+ influx channel involved in intestinal and renal Mg2+ absorption	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL CA2+ CHANNEL; ION-CHANNEL; SECONDARY HYPOCALCEMIA; CATION CHANNEL; MIC CHANNELS; EXPRESSION; FAMILY; HYPOMAGNESEMIA; MECHANISM; TRANSPORT	Mg2+ is an essential ion involved in a multitude of physiological and biochemical processes and a major constituent of bone tissue. Mg2+ homeostasis in mammals depends on the equilibrium between intestinal Mg2+ absorption and renal Mg2+ excretion, but little is known about the molecular nature of the proteins involved in the transepithelial transport of Mg2+ in these organs. Recently, it was shown that patients with mutations in TRPM6, a member of the transient receptor potential family of cation channels, suffer from hypomagnesemia with secondary hypocalcemia (HSH) as a result of impaired renal and/or intestinal Mg2+ handling. Here, we show that TRPM6 is specifically localized along the apical membrane of the renal distal convoluted tubule and the brush-border membrane of the small intestine, epithelia particularly associated with active Mg2+ ( re) absorption. In kidney, parvalbumin and calbindin-D-28K, two divalent-binding proteins, are coexpressed with TRPM6 and might function as intracellular Mg2+ buffers in the distal convoluted tubule. Heterologous expression of wild-type TRPM6 but not TRPM6 mutants identified in HSH patients induces a Mg2+- and Ca2+-permeable cation channel tightly regulated by intracellular Mg2+ levels. The TRPM6-induced channel displays strong outward rectification, has a 5-fold higher affinity for Mg2+ than for Ca2+, and is blocked in a voltage-dependent manner by ruthenium red. Our data indicate that TRPM6 comprises all or part of the apical Mg2+ channel of Mg2+-absorbing epithelia.	Katholieke Univ Leuven, Dept Physiol, B-3000 Louvain, Belgium; Univ Med Ctr Nijmegen, Nijmegen Ctr Mol Life Sci, Dept Physiol, NL-6500 HB Nijmegen, Netherlands	KU Leuven; Radboud University Nijmegen	Voets, T (corresponding author), Katholieke Univ Leuven, Dept Physiol, Campus Gasthuisberg, B-3000 Louvain, Belgium.		Hoenderop, Joost G.J./H-8047-2014; Bindels, René JM/B-9824-2013; Voets, Thomas/E-2466-2012; Voets, Thomas/AAD-4389-2019	Hoenderop, Joost G.J./0000-0002-1816-8544; Bindels, René JM/0000-0003-1167-1339; Voets, Thomas/0000-0001-5526-5821; Voets, Thomas/0000-0001-5526-5821				Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Dai LJ, 2001, PHYSIOL REV, V81, P51, DOI 10.1152/physrev.2001.81.1.51; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hermosura MC, 2002, J PHYSIOL-LONDON, V539, P445, DOI 10.1113/jphysiol.2001.013361; HESS P, 1984, NATURE, V309, P453, DOI 10.1038/309453a0; Hille B., 2001, ION CHANNELS EXCITAB, V3rd Edn; Hoenderop JGJ, 2000, J AM SOC NEPHROL, V11, P1171, DOI 10.1681/ASN.V1171171; Hoenderop JGJ, 2003, EMBO J, V22, P776, DOI 10.1093/emboj/cdg080; Hoenderop JGJ, 2001, J PHYSIOL-LONDON, V537, P747; KAPLAN JH, 1988, P NATL ACAD SCI USA, V85, P6571, DOI 10.1073/pnas.85.17.6571; Kozak JA, 2002, J GEN PHYSIOL, V120, P221, DOI 10.1085/jgp.20028601; Monteilh-Zoller MK, 2003, J GEN PHYSIOL, V121, P49, DOI 10.1085/jgp.20028740; Montell C, 2002, CELL, V108, P595, DOI 10.1016/S0092-8674(02)00670-0; Nadler MJS, 2001, NATURE, V411, P590, DOI 10.1038/35079092; Nijenhuis T, 2003, KIDNEY INT, V64, P555, DOI 10.1046/j.1523-1755.2003.00128.x; Nilius B, 2001, BRIT J PHARMACOL, V134, P453, DOI 10.1038/sj.bjp.0704272; Obermuller N, 1995, AM J PHYSIOL-RENAL, V269, pF900, DOI 10.1152/ajprenal.1995.269.6.F900; Prakriya M, 2002, J GEN PHYSIOL, V119, P487, DOI 10.1085/jgp.20028551; Runnels LW, 2002, NAT CELL BIOL, V4, P329, DOI 10.1038/ncb781; Runnels LW, 2001, SCIENCE, V291, P1043, DOI 10.1126/science.1058519; Schlingmann KP, 2002, NAT GENET, V31, P166, DOI 10.1038/ng889; Strubing C, 2001, NEURON, V29, P645, DOI 10.1016/S0896-6273(01)00240-9; Trouet D, 1997, PFLUG ARCH EUR J PHY, V434, P632, DOI 10.1007/s004240050445; Walder RY, 2002, NAT GENET, V31, P171, DOI 10.1038/ng901; Yang W, 2002, PROTEINS, V47, P344, DOI 10.1002/prot.10093	25	433	448	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	2004	279	1					19	25		10.1074/jbc.M311201200	http://dx.doi.org/10.1074/jbc.M311201200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	757GU	14576148	Green Published, hybrid			2022-12-27	WOS:000187555300003
J	Han, J; Kori, R; Shui, JW; Chen, YR; Yao, ZB; Tan, TH				Han, J; Kori, R; Shui, JW; Chen, YR; Yao, ZB; Tan, TH			The SH3 domain-containing adaptor HIP-55 mediates c-Jun N-terminal kinase activation in T cell receptor signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEMATOPOIETIC PROGENITOR KINASE-1; LYMPHOCYTE ANTIGEN RECEPTORS; ACTIN-BINDING PROTEIN-1; TYROSINE PHOSPHORYLATION; CYTOSKELETON; TRANSDUCTION; APOPTOSIS; PATHWAY; HPK1; LAT	HIP-55 (hematopoietic progenitor kinase 1 (HPK1)-interacting protein of 55 kDa, also called SH3P7 and mAbp1) is a novel SH3 domain-containing protein. HIP-55 binds to actin filaments both in vitro and in vivo. HIP-55 activates HPK1 and c-Jun N-terminal kinase (JNK), which are two important lymphocyte signaling molecules. Until now, the regulation and function of HIP-55 in T cell receptor (TCR) signaling were unknown. We found that HIP-55 was recruited to glycolipid-enriched microdomains upon TCR stimulation, which indicates that HIP-55 is regulated by TCR signaling. HIP-55 interacted with ZAP-70, a critical protein-tyrosine kinase in TCR signaling, and this interaction was induced by TCR signaling. ZAP-70 phosphorylated HIP-55 at Tyr-334 and Tyr-344 in vitro and in vivo, and the HIP-55 mutant (Y334F/Y344F) was not tyrosine-phosphorylated in stimulated T cells. To study its function in T cell activation, HIP-55-deficient Jurkat T cells were established using the RNA interference approach. In the HIP-55-deficient cells, TCR ( but not UV)-stimulated JNK activation was decreased. Furthermore, the activation of HPK1, a known JNK upstream activator and HIP-55-interacting protein, was also decreased in the HIP-55-deficient cells. Our data reveal the regulation of HIP-55 during TCR signaling, and using a genetic approach, we demonstrate for the first time that HIP-55 plays a functional role in TCR signaling.	Baylor Coll Med, Dept Immunol, Houston, TX 77030 USA; Amgen Inc, Dept Biol, Boulder, CO 80301 USA	Baylor College of Medicine; Amgen	Tan, TH (corresponding author), Baylor Coll Med, Dept Immunol, M929,1 Baylor Plaza, Houston, TX 77030 USA.		Tan, Tse-Hua/ABD-7080-2021; Tan, Tse-Hua/E-3983-2010; Chen, Yi-Rong/CAH-7991-2022; Chen, Yi-Rong/E-3991-2010; Chen, Yi-Rong/CAF-2186-2022; Shui, Jr-Wen/Q-2617-2018	Tan, Tse-Hua/0000-0003-4969-3170; Tan, Tse-Hua/0000-0003-4969-3170; Chen, Yi-Rong/0000-0002-4307-3002; Chen, Yi-Rong/0000-0002-4307-3002; Chen, Yi-Rong/0000-0002-4307-3002; Shui, Jr-Wen/0000-0002-5243-3727; Han, Jin/0000-0003-0662-006X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042532] Funding Source: NIH RePORTER; NIAID NIH HHS [R01-AI42532] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Chen CY, 1998, SCIENCE, V280, P1945, DOI 10.1126/science.280.5371.1945; Chen Y. R., 1999, GENE THER MOL BIOL, V4, P83; Chen YR, 2000, INT J ONCOL, V16, P651; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; Chen YR, 2001, BIOCHEM BIOPH RES CO, V288, P981, DOI 10.1006/bbrc.2001.5862; Dong C, 1998, SCIENCE, V282, P2092, DOI 10.1126/science.282.5396.2092; Ensenat D, 1999, J BIOL CHEM, V274, P33945, DOI 10.1074/jbc.274.48.33945; Hu MCT, 1996, GENE DEV, V10, P2251, DOI 10.1101/gad.10.18.2251; Huang C, 1997, J BIOL CHEM, V272, P13911, DOI 10.1074/jbc.272.21.13911; Kane LP, 2000, CURR OPIN IMMUNOL, V12, P242, DOI 10.1016/S0952-7915(00)00083-2; Kessels MM, 2000, MOL BIOL CELL, V11, P393, DOI 10.1091/mbc.11.1.393; Kessels MM, 2001, J CELL BIOL, V153, P351, DOI 10.1083/jcb.153.2.351; Kiefer F, 1996, EMBO J, V15, P7013, DOI 10.1002/j.1460-2075.1996.tb01093.x; Larbolette O, 1999, MOL CELL BIOL, V19, P1539; Li W, 1996, SCIENCE, V271, P1272, DOI 10.1126/science.271.5253.1272; Ling P, 1999, MOL CELL BIOL, V19, P1359; Ling P, 2001, J BIOL CHEM, V276, P18908, DOI 10.1074/jbc.M101485200; Liou J, 2000, IMMUNITY, V12, P399, DOI 10.1016/S1074-7613(00)80192-2; Mise-Omata S, 2003, BIOCHEM BIOPH RES CO, V301, P704, DOI 10.1016/S0006-291X(02)02972-8; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; Wange RL, 1996, IMMUNITY, V5, P197, DOI 10.1016/S1074-7613(00)80315-5; YAMANASHI Y, 1993, P NATL ACAD SCI USA, V90, P3631, DOI 10.1073/pnas.90.8.3631; Yamanashi Y, 1997, J EXP MED, V185, P1387, DOI 10.1084/jem.185.7.1387; Yang DD, 1998, IMMUNITY, V9, P575, DOI 10.1016/S1074-7613(00)80640-8; Zhang WG, 2000, SEMIN IMMUNOL, V12, P35, DOI 10.1006/smim.2000.0205; Zhang WG, 1999, IMMUNITY, V10, P323, DOI 10.1016/S1074-7613(00)80032-1; Zhang WG, 1998, IMMUNITY, V9, P239, DOI 10.1016/S1074-7613(00)80606-8; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0	29	37	41	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52195	52202		10.1074/jbc.M305026200	http://dx.doi.org/10.1074/jbc.M305026200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14557276	hybrid			2022-12-27	WOS:000187480700028
J	Miller, LC; Swayne, LA; Chen, L; Feng, ZP; Wacker, JL; Muchowski, PJ; Zamponi, GW; Braun, JEA				Miller, LC; Swayne, LA; Chen, L; Feng, ZP; Wacker, JL; Muchowski, PJ; Zamponi, GW; Braun, JEA			Cysteine string protein (CSP) inhibition of N-type calcium channels is blocked by mutant huntingtin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR CHAPERONES; MOUSE MODEL; HEAT-SHOCK; DISEASE; POLYGLUTAMINE; PHOSPHORYLATION; AGGREGATION; MODULATION; EXOCYTOSIS; DROSOPHILA	Cysteine string protein (CSP), a 34-kDa molecular chaperone, is expressed on synaptic vesicles in neurons and on secretory vesicles in endocrine, neuroendocrine, and exocrine cells. CSP can be found in a complex with two other chaperones, the heat shock cognate protein Hsc70, and small glutamine-rich tetratricopeptide repeat domain protein (SGT). CSP function is vital in synaptic transmission; however, the precise nature of its role remains controversial. We have previously reported interactions of CSP with both heterotrimeric GTP-binding proteins ( G proteins) and N-type calcium channels. These associations give rise to a tonic G protein inhibition of the channels. Here we have examined the effects of huntingtin fragments (exon 1) with (huntingtin(exon1/exp)) and without (huntingtin(exon1/nonexp)) expanded polyglutamine ( polyQ) tracts on the CSP chaperone system. In vitro huntingtin(exon1/exp) sequestered CSP and blocked the association of CSP with G proteins. In contrast, huntingtin(exon1/nonexp) did not interact with CSP and did not alter the CSP/G protein association. Similarly, co-expression of huntingtin(exon1/exp) with CSP and N-type calcium channels eliminated CSP's tonic G protein inhibition of the channels, while coexpression of huntingtin(exon1/nonexp) did not alter the robust inhibition promoted by CSP. These results indicate that CSP's modulation of G protein inhibition of calcium channel activity is blocked in the presence of a huntingtin fragment with expanded polyglutamine tracts.	Univ Calgary, Dept Physiol & Biophys Cellular & Mol Neurobiol, Cellular & Mol Neurobiol Res Grp, Calgary, AB T2N 4N1, Canada; Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA	University of Calgary; University of Washington; University of Washington Seattle	Braun, JEA (corresponding author), Univ Calgary, Dept Physiol & Biophys Cellular & Mol Neurobiol, Cellular & Mol Neurobiol Res Grp, Calgary, AB T2N 4N1, Canada.	braunj@ucalgary.ca		Dansereau, Linda/0000-0002-0522-8309; Zamponi, Gerald W./0000-0002-0644-9066				Bibb JA, 2000, P NATL ACAD SCI USA, V97, P6809, DOI 10.1073/pnas.120166397; BRAUN JEA, 1995, NEUROPHARMACOLOGY, V34, P1361, DOI 10.1016/0028-3908(95)00114-L; Braun JEA, 1996, J BIOL CHEM, V271, P25989, DOI 10.1074/jbc.271.42.25989; Brown H, 1998, EMBO J, V17, P5048, DOI 10.1093/emboj/17.17.5048; Chamberlain LH, 1998, MOL BIOL CELL, V9, P2259, DOI 10.1091/mbc.9.8.2259; Chamberlain LH, 1997, BIOCHEM J, V322, P853, DOI 10.1042/bj3220853; Chamberlain LH, 1996, J BIOL CHEM, V271, P19514, DOI 10.1074/jbc.271.32.19514; Chamberlain LH, 2000, J NEUROCHEM, V74, P1781, DOI 10.1046/j.1471-4159.2000.0741781.x; Chen NS, 1999, J NEUROCHEM, V72, P1890, DOI 10.1046/j.1471-4159.1999.0721890.x; Chen S, 2002, J PHYSIOL-LONDON, V538, P383, DOI 10.1113/jphysiol.2001.013397; Chuang JZ, 2002, J BIOL CHEM, V277, P19831, DOI 10.1074/jbc.M109613200; Cribbs LL, 1998, CIRC RES, V83, P103, DOI 10.1161/01.RES.83.1.103; Dawson-Scully K, 2000, J NEUROSCI, V20, P6039, DOI 10.1523/JNEUROSCI.20-16-06039.2000; Evans GJO, 2002, BIOCHEM J, V364, P343, DOI 10.1042/BJ20020123; Evans GJO, 2001, J BIOL CHEM, V276, P47877, DOI 10.1074/jbc.M108186200; Graham ME, 2000, J NEUROSCI, V20, P1281; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; GUNDERSEN CB, 1992, NEURON, V9, P527, DOI 10.1016/0896-6273(92)90190-O; Hodgson JG, 1999, NEURON, V23, P181, DOI 10.1016/S0896-6273(00)80764-3; Jarvis SE, 2001, TRENDS PHARMACOL SCI, V22, P519, DOI 10.1016/S0165-6147(00)01800-9; Kazantsev A, 1999, P NATL ACAD SCI USA, V96, P11404, DOI 10.1073/pnas.96.20.11404; Ko J, 2001, BRAIN RES BULL, V56, P319, DOI 10.1016/S0361-9230(01)00599-8; Leveque C, 1998, J BIOL CHEM, V273, P13488, DOI 10.1074/jbc.273.22.13488; Lievens JC, 2002, MOL CELL NEUROSCI, V20, P638, DOI 10.1006/mcne.2002.1152; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; Magga JM, 2000, NEURON, V28, P195, DOI 10.1016/S0896-6273(00)00096-9; MASTROGIACOMO A, 1994, SCIENCE, V263, P981, DOI 10.1126/science.7906056; Miller LC, 2003, J CELL SCI, V116, P2967, DOI 10.1242/jcs.00595; Morales M, 1999, EUR J NEUROSCI, V11, P1818, DOI 10.1046/j.1460-9568.1999.00604.x; Morgan JR, 2001, NEURON, V32, P289, DOI 10.1016/S0896-6273(01)00467-6; Muchowski PJ, 2000, P NATL ACAD SCI USA, V97, P7841, DOI 10.1073/pnas.140202897; Muchowskil PJ, 2002, NEURON, V35, P9, DOI 10.1016/S0896-6273(02)00761-4; Nie ZP, 1999, J NEUROSCI, V19, P10270; Ohtsuka K, 2000, BRAIN RES BULL, V53, P141, DOI 10.1016/S0361-9230(00)00325-7; Panov AV, 2002, NAT NEUROSCI, V5, P731, DOI 10.1038/nn884; Ranjan R, 1998, J NEUROSCI, V18, P956; Sakahira H, 2002, P NATL ACAD SCI USA, V99, P16412, DOI 10.1073/pnas.182426899; Sakisaka T, 2002, EMBO J, V21, P6125, DOI 10.1093/emboj/cdf603; SILVER PA, 1993, CELL, V74, P5, DOI 10.1016/0092-8674(93)90287-Z; Spafford JD, 2003, CURR OPIN NEUROBIOL, V13, P308, DOI 10.1016/S0959-4388(03)00061-8; Stahl B, 1999, EUR J CELL BIOL, V78, P375, DOI 10.1016/S0171-9335(99)80079-X; Tang TS, 2003, NEURON, V39, P227, DOI 10.1016/S0896-6273(03)00366-0; Tobaben S, 2001, NEURON, V31, P987, DOI 10.1016/S0896-6273(01)00427-5; Tobin AJ, 2000, TRENDS CELL BIOL, V10, P531, DOI 10.1016/S0962-8924(00)01853-5; Umbach JA, 1998, J NEUROSCI, V18, P3233; Usdin MT, 1999, HUM MOL GENET, V8, P839, DOI 10.1093/hmg/8.5.839; VONSATTEL JP, 1985, J NEUROPATH EXP NEUR, V44, P559, DOI 10.1097/00005072-198511000-00003; Wu MN, 1999, NEURON, V23, P593, DOI 10.1016/S0896-6273(00)80811-9; Wyttenbach A, 2000, P NATL ACAD SCI USA, V97, P2898, DOI 10.1073/pnas.97.6.2898; Zeron MM, 2002, NEURON, V33, P849, DOI 10.1016/S0896-6273(02)00615-3; Zhang H, 1998, FEBS LETT, V437, P267, DOI 10.1016/S0014-5793(98)01233-2; Zhang H, 1999, J CELL SCI, V112, P1345; Zhang H, 2002, J BIOL CHEM, V277, P28948, DOI 10.1074/jbc.M111706200; Zhou H, 2001, J BIOL CHEM, V276, P48417, DOI 10.1074/jbc.M104140200; Zinsmaier KE, 2001, BIOCHEM PHARMACOL, V62, P1, DOI 10.1016/S0006-2952(01)00648-7; ZINSMAIER KE, 1994, SCIENCE, V263, P977, DOI 10.1126/science.8310297	56	36	36	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					53072	53081		10.1074/jbc.M306230200	http://dx.doi.org/10.1074/jbc.M306230200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14570907	hybrid			2022-12-27	WOS:000187480700131
J	Ali, MK; Bergson, C				Ali, MK; Bergson, C			Elevated intracellular calcium triggers recruitment of the receptor cross-talk accessory protein calcyon to the plasma membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED HIPPOCAMPAL-NEURONS; EVOKED DENDRITIC EXOCYTOSIS; DOPAMINE D1 RECEPTOR; KINASE-II; BETA(1)-ADRENERGIC RECEPTORS; REGULATED EXOCYTOSIS; SURFACE EXPRESSION; EPITHELIAL-CELLS; AMPA RECEPTORS; ACTIVATION	Calcyon is called a "cross-talk accessory protein" because the mechanism by which it enables the typically G(s)-linked D1 dopamine receptor to stimulate intracellular calcium release depends on a priming step involving heterologous G(q)-linked G-protein-coupled receptor activation. The details of how priming facilitates the D1R calcium response have yet to be precisely elucidated. The present work shows that calcyon is constitutively localized both in vesicular and plasma membrane compartments within HEK293 cells. In addition, surface biotinylation and luminescence assays revealed that priming stimulates a 2-fold increase in the levels of calcyon expressed on the cell surface and that subsequent D1R activation produces further accumulation of the protein in the plasma membrane. The effects of priming and D1R agonists were blocked by nocodazole implicating microtubules in the delivery of calcyon-containing vesicles to the cell surface. Accumulation of calcyon in the plasma membrane correlated well with increased intracellular calcium levels as thapsigargin mimicked, and 2-aminoethoxydiphenylborane abrogated, the effects of priming. KN-62, an inhibitor of calcium/calmodulin-dependent protein kinase II ( CaMKII) also blocked the effects of priming and D1R agonists. Furthermore, expression of constitutively active forms of the kinase bypassed the requirement for priming indicating that CaMKII is a key effector in the Ca2+ and microtubule-dependent delivery of calcyon to the cell surface.	Med Coll Georgia, Dept Pharmacol & Toxicol, Augusta, GA 30912 USA	University System of Georgia; Augusta University	Bergson, C (corresponding author), Med Coll Georgia, Dept Pharmacol & Toxicol, Augusta, GA 30912 USA.				NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH063271, P50MH044866] Funding Source: NIH RePORTER; NIMH NIH HHS [MH44866, R01 MH063271, MH63271] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Apodaca G, 2001, TRAFFIC, V2, P149, DOI 10.1034/j.1600-0854.2001.020301.x; Bermak JC, 2001, NAT CELL BIOL, V3, P492, DOI 10.1038/35074561; Bi GQ, 1997, J CELL BIOL, V138, P999, DOI 10.1083/jcb.138.5.999; Burgoyne RD, 1998, CELL CALCIUM, V24, P367, DOI 10.1016/S0143-4160(98)90060-4; Coorssen JR, 1996, EMBO J, V15, P3787, DOI 10.1002/j.1460-2075.1996.tb00752.x; Delmas P, 2002, NEURON, V34, P209, DOI 10.1016/S0896-6273(02)00641-4; Doctor RB, 2002, AM J PHYSIOL-CELL PH, V282, pC1042, DOI 10.1152/ajpcell.00367.2001; Easom RA, 1999, DIABETES, V48, P675, DOI 10.2337/diabetes.48.4.675; Fagni L, 2000, TRENDS NEUROSCI, V23, P80, DOI 10.1016/S0166-2236(99)01492-7; Fukuda M, 2003, J BIOL CHEM, V278, P3220, DOI 10.1074/jbc.M208323200; Geerlings A, 2001, J BIOL CHEM, V276, P17584, DOI 10.1074/jbc.M010602200; Gines S, 2000, P NATL ACAD SCI USA, V97, P8606, DOI 10.1073/pnas.150241097; Hayashi Y, 2000, SCIENCE, V287, P2262, DOI 10.1126/science.287.5461.2262; He JQ, 2002, BIOCHEM BIOPH RES CO, V297, P565, DOI 10.1016/S0006-291X(02)02259-3; Kim OJ, 2002, J NEUROSCI, V22, P5920; Kreitzer G, 2003, NAT CELL BIOL, V5, P126, DOI 10.1038/ncb917; Lan JY, 2001, J NEUROSCI, V21, P6058, DOI 10.1523/JNEUROSCI.21-16-06058.2001; Lee FJS, 2002, CELL, V111, P219, DOI 10.1016/S0092-8674(02)00962-5; Lezcano N, 2000, SCIENCE, V287, P1660, DOI 10.1126/science.287.5458.1660; Lezcano N, 2002, J NEUROPHYSIOL, V87, P2167, DOI 10.1152/jn.00541.2001; Maletic-Savatic M, 1998, J NEUROSCI, V18, P6814; Maletic-Savatic M, 1998, J NEUROSCI, V18, P6803; Missale C, 1998, PHYSIOL REV, V78, P189, DOI 10.1152/physrev.1998.78.1.189; Scott L, 2002, P NATL ACAD SCI USA, V99, P1661, DOI 10.1073/pnas.032654599; Shi SH, 1999, SCIENCE, V284, P1811, DOI 10.1126/science.284.5421.1811; Steiner P, 2002, J CELL BIOL, V157, P1197, DOI 10.1083/jcb.200202022; STEINHARDT RA, 1994, SCIENCE, V263, P390, DOI 10.1126/science.7904084; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; Tanimura A, 2000, J BIOL CHEM, V275, P27488; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Vickery RG, 1999, J CELL BIOL, V144, P31, DOI 10.1083/jcb.144.1.31; Wang XX, 2002, J NEUROSCI, V22, P931, DOI 10.1523/JNEUROSCI.22-03-00931.2002; Xiao B, 1998, NEURON, V21, P707, DOI 10.1016/S0896-6273(00)80588-7; Xu JG, 2003, J BIOL CHEM, V278, P10770, DOI 10.1074/jbc.M207968200; Yamamoto H, 2002, ARCH BIOCHEM BIOPHYS, V408, P255, DOI 10.1016/S0003-9861(02)00556-8; Yang EY, 1999, J BIOL CHEM, V274, P26199, DOI 10.1074/jbc.274.37.26199; Zelenin S, 2002, J COMP NEUROL, V446, P37, DOI 10.1002/cne.10198	37	21	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51654	51663		10.1074/jbc.M305803200	http://dx.doi.org/10.1074/jbc.M305803200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14534309	hybrid			2022-12-27	WOS:000187206300100
J	Murugappan, S; Tuluc, F; Dorsam, RT; Shankar, H; Kunapuli, SP				Murugappan, S; Tuluc, F; Dorsam, RT; Shankar, H; Kunapuli, SP			Differential role of protein kinase C delta isoform in agonist-induced dense granule secretion in human platelets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHORBOL ESTER; CALCIUM MOBILIZATION; PKC-DELTA; TYROSINE PHOSPHORYLATION; PHOSPHOLIPASE C-GAMMA-2; STIMULATED PLATELETS; FIBRINOGEN RECEPTOR; ALPHA-GRANULE; ACTIVATION; THROMBIN	Several platelet agonists, including thrombin, collagen, and thromboxane A(2), cause dense granule release independently of thromboxane generation. Because protein kinase C (PKC) isoforms are implicated in platelet secretion, we investigated the role of individual PKC isoforms in platelet dense granule release. PKCdelta was phosphorylated in a time-dependent manner that coincided with dense granule release in response to protease-activated receptor-activating peptides SFLLRN and AYPGKF in human platelets. Only agonists that caused platelet dense granule secretion activated PKCdelta. SFLLRN- or AYPGKF-induced dense granule release and PKCdelta phosphorylation occurred at the same respective agonist concentration. Furthermore, AYPGKF and SFLLRN- induced dense granule release was blocked by rottlerin, a PKCdelta selective inhibitor. In contrast, convulxin-induced dense granule secretion was potentiated by rottlerin but was abolished by Go6976, a classical PKC isoform inhibitor. However, SFLLRN- induced dense granule release was unaffected in the presence of Go6976. Finally, rottlerin did not affect SFLLRN- induced platelet aggregation, even in the presence of dimethyl-BAPTA, indicating that PKCdelta has no role in platelet fibrinogen receptor activation. We conclude that PKCdelta and the classical PKC isoforms play a differential role in platelet dense granule release mediated by protease-activated receptors and glycoprotein VI. Furthermore, PKCdelta plays a positive role in protease-activated receptor-mediated dense granule secretion, whereas it functions as a negative regulator downstream of glycoprotein VI signaling.	Temple Univ, Dept Physiol, Sch Med, Philadelphia, PA 19140 USA; Temple Univ, Dept Pharmacol, Sch Med, Philadelphia, PA 19140 USA; Temple Univ, Sol Sherry Thrombosis Res Ctr, Sch Med, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Kunapuli, SP (corresponding author), Temple Univ, Dept Physiol, Sch Med, Rm 224,OMS,3420 N Broad St, Philadelphia, PA 19140 USA.	spk@temple.edu	Tuluc, Petronel/C-2527-2011		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007777, R01HL060683, P01HL064943] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32 HL07777, HL60683, HL64943] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKKERMAN JWN, 1982, THROMB RES, V27, P59, DOI 10.1016/0049-3848(82)90278-X; BALDASSARE JJ, 1992, J BIOL CHEM, V267, P15585; Bornancin F, 1996, CURR BIOL, V6, P1114, DOI 10.1016/S0960-9822(02)70678-7; Bornancin F, 1997, J BIOL CHEM, V272, P3544, DOI 10.1074/jbc.272.6.3544; Brass LF, 1997, THROMB HAEMOSTASIS, V78, P581; Chung SH, 2000, J BIOL CHEM, V275, P25286, DOI 10.1074/jbc.M004204200; Covic L, 2000, BIOCHEMISTRY-US, V39, P5458, DOI 10.1021/bi9927078; CRABOS M, 1991, BIOCHEM BIOPH RES CO, V178, P878, DOI 10.1016/0006-291X(91)90973-B; Crosby D, 2003, J BIOL CHEM, V278, P24533, DOI 10.1074/jbc.M301847200; DANIEL JL, 1994, BIOCHEM J, V302, P617, DOI 10.1042/bj3020617; Deb DK, 2003, J IMMUNOL, V171, P267, DOI 10.4049/jimmunol.171.1.267; Dempsey EC, 2000, AM J PHYSIOL-LUNG C, V279, pL429, DOI 10.1152/ajplung.2000.279.3.L429; DONATO JL, 1994, BRAZ J MED BIOL RES, V27, P2163; Fabre JE, 1999, NAT MED, V5, P1199, DOI 10.1038/13522; Fujii T, 2000, J BIOL CHEM, V275, P7574, DOI 10.1074/jbc.275.11.7574; Gabbeta J, 1997, P NATL ACAD SCI USA, V94, P8750, DOI 10.1073/pnas.94.16.8750; GERRARD JM, 1989, BLOOD, V74, P2405; GRABAREK J, 1992, J BIOL CHEM, V267, P10011; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; Jain N, 1999, J BIOL CHEM, V274, P24392, DOI 10.1074/jbc.274.34.24392; Jin JG, 1998, P NATL ACAD SCI USA, V95, P8070, DOI 10.1073/pnas.95.14.8070; Jin JG, 1998, J BIOL CHEM, V273, P2030, DOI 10.1074/jbc.273.4.2030; KAIBUCHI K, 1983, J BIOL CHEM, V258, P6701; Kambhampati S, 2003, J BIOL CHEM, V278, P32544, DOI 10.1074/jbc.M301523200; Keranen LM, 1995, CURR BIOL, V5, P1394, DOI 10.1016/S0960-9822(95)00277-6; KHAN WA, 1993, J BIOL CHEM, V268, P5063; KILEY SC, 1990, MOL ENDOCRINOL, V4, P59, DOI 10.1210/mend-4-1-59; KNIGHT DE, 1984, EUR J BIOCHEM, V143, P437, DOI 10.1111/j.1432-1033.1984.tb08391.x; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Leon C, 1999, J CLIN INVEST, V104, P1731, DOI 10.1172/JCI8399; Li J, 2002, AM J PHYSIOL-GASTR L, V283, pG1197, DOI 10.1152/ajpgi.00177.2002; Mackay K, 2001, J MOL CELL CARDIOL, V33, P1301, DOI 10.1006/jmcc.2001.1400; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Mills DCB, 1996, THROMB HAEMOSTASIS, V76, P835; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; Offermanns S, 1997, NATURE, V389, P183, DOI 10.1038/38284; OZAWA K, 1993, J BIOL CHEM, V268, P2280; PACKHAM MA, 1994, CAN J PHYSIOL PHARM, V72, P278, DOI 10.1139/y94-043; Parekh D, 1999, J BIOL CHEM, V274, P34758, DOI 10.1074/jbc.274.49.34758; Parekh DB, 2000, EMBO J, V19, P496, DOI 10.1093/emboj/19.4.496; Paul BZS, 1999, J BIOL CHEM, V274, P29108, DOI 10.1074/jbc.274.41.29108; PULCINELLI FM, 1995, FEBS LETT, V364, P87, DOI 10.1016/0014-5793(95)00352-A; Quinton TM, 2002, BIOCHEM J, V368, P535, DOI 10.1042/BJ20020226; Rahman A, 2001, MOL CELL BIOL, V21, P5554, DOI 10.1128/MCB.21.16.5554-5565.2001; RAO AK, 1989, BLOOD, V74, P664; Rybin VO, 2003, J BIOL CHEM, V278, P14555, DOI 10.1074/jbc.M212644200; SHATTIL SJ, 1987, J BIOL CHEM, V262, P992; SHOJI M, 1986, BIOCHEM BIOPH RES CO, V135, P1144, DOI 10.1016/0006-291X(86)91047-8; SIESS W, 1988, BIOCHEM J, V255, P309; SMITH JB, 1993, BIOCHEM BIOPH RES CO, V191, P695, DOI 10.1006/bbrc.1993.1273; Tan MQ, 2003, J BIOL CHEM, V278, P2824, DOI 10.1074/jbc.M211523200; Uddin S, 2002, J BIOL CHEM, V277, P14408, DOI 10.1074/jbc.M109671200; WALKER TR, 1993, BIOCHEM J, V289, P277, DOI 10.1042/bj2890277; Wang DM, 2000, IMMUNITY, V13, P25, DOI 10.1016/S1074-7613(00)00005-4; WANG F, 1993, BIOCHEM BIOPH RES CO, V191, P240, DOI 10.1006/bbrc.1993.1208; Wang WJ, 1997, J BIOL CHEM, V272, P76; WATSON SP, 1988, BIOCHEM J, V249, P345, DOI 10.1042/bj2490345; WERNER MH, 1991, MOL PHARMACOL, V39, P547; WILKINSON SE, 1993, BIOCHEM J, V294, P335, DOI 10.1042/bj2940335; YAMADA K, 1987, BIOCHEM BIOPH RES CO, V144, P35, DOI 10.1016/S0006-291X(87)80471-0; YANEY GC, 2002, AM J PHYSIOL, pE880; Yoshioka A, 2001, J BIOL CHEM, V276, P39379, DOI 10.1074/jbc.M102933200; Zheng WH, 2000, J BIOL CHEM, V275, P13377, DOI 10.1074/jbc.275.18.13377	65	84	85	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	2004	279	4					2360	2367		10.1074/jbc.M306960200	http://dx.doi.org/10.1074/jbc.M306960200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	764MU	14578358	hybrid			2022-12-27	WOS:000188211300006
J	Edman, K; Royant, A; Larsson, G; Jacobson, F; Taylor, T; van der Spoel, D; Landau, EM; Pebay-Peyroula, E; Neutze, R				Edman, K; Royant, A; Larsson, G; Jacobson, F; Taylor, T; van der Spoel, D; Landau, EM; Pebay-Peyroula, E; Neutze, R			Deformation of helix C in the low temperature L-intermediate of bacteriorhodopsin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							PROTONATED SCHIFF-BASE; PROTEIN PHOTOCYCLE INTERMEDIATE; TIME-RESOLVED CRYSTALLOGRAPHY; 1.8 ANGSTROM RESOLUTION; LIPIDIC CUBIC PHASES; SENSORY RHODOPSIN-II; X-RAY-DIFFRACTION; STRUCTURAL-CHANGES; CONFORMATIONAL-CHANGES; RETINAL PROTEINS	X-ray and electron diffraction studies of specific reaction intermediates, or reaction intermediate analogues, have produced a consistent picture of the structural mechanism of light-driven proton pumping by bacteriorhodopsin. Of central importance within this picture is the structure of the L-intermediate, which follows the retinal all-trans to 13-cis photoisomerization step of the K-intermediate and sets the stage for the primary proton transfer event from the positively charged Schiff base to the negatively charged Asp-85. Here we report the structural changes in bacteriorhodopsin following red light illumination at 150 K. Single crystal microspectrophotometry showed that only the L-intermediate is populated in three-dimensional crystals under these conditions. The experimental difference Fourier electron density map and refined crystallographic structure were consistent with those previously presented (Royant, A., Edman, K., Ursby, T., Pebay-Peyroula, E., Landau, E. M., and Neutze, R. ( 2000) Nature 406, 645 - 648; Royant, A., Edman, K., Ursby, T., Pebay- Peyroula, E., Landau, E. M., and Neutze, R. ( 2001) Photochem. Photobiol. 74, 794 - 804). Based on the refined crystallographic structures, molecular dynamic simulations were used to examine the influence of the conformational change of the protein that is associated with the K-to-L transition on retinal dynamics. Implications regarding the structural mechanism for proton pumping by bacteriorhodopsin are discussed.	Univ Texas, Med Branch, Sealy Ctr Struct Biol, Membrane Prot Lab, Galveston, TX 77555 USA; Chalmers Univ Technol, Dept Chem & Biosci, S-40530 Gothenburg, Sweden; Univ Grenoble 1, CEA, CNRS, UMR 5075,Inst Biol Struct, F-38027 Grenoble 1, France; European Synchrotron Radiat Facil, F-38043 Grenoble, France; Stockholm Univ, Dept Biochem & Biophys, S-10691 Stockholm, Sweden; Swedish Univ Agr Sci, Dept Mol Biol, Ctr Biomed, S-75124 Uppsala, Sweden; Uppsala Univ, Dept Cell & Mol Biol, S-75124 Uppsala, Sweden; Univ Texas, Med Branch, Dept Physiol & Biophys, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; Chalmers University of Technology; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); European Synchrotron Radiation Facility (ESRF); Stockholm University; Swedish University of Agricultural Sciences; Uppsala University; University of Texas System; University of Texas Medical Branch Galveston	Landau, EM (corresponding author), Univ Texas, Med Branch, Sealy Ctr Struct Biol, Membrane Prot Lab, Galveston, TX 77555 USA.	emlandau@utmb.edu; pebay@godot.ibs.fr; neutze@molbiotech.chalmers.se	Neutze, Richard/A-7573-2010; van der Spoel, David/A-5471-2008; Royant, Antoine/G-3684-2012; van der Spoel, David/AAD-9820-2019	Neutze, Richard/0000-0003-0986-6153; van der Spoel, David/0000-0002-7659-8526; Royant, Antoine/0000-0002-1919-8649; van der Spoel, David/0000-0002-7659-8526				ALBECK A, 1992, J AM CHEM SOC, V114, P2400, DOI 10.1021/ja00033a015; Aqvist J, 2000, NATURE, V404, P881, DOI 10.1038/35009114; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Balashov SP, 1996, BIOPHYS J, V70, P473, DOI 10.1016/S0006-3495(96)79591-7; Balashov SP, 1997, BIOCHEMISTRY-US, V36, P8671, DOI 10.1021/bi970744y; Balashov SP, 2001, PHOTOCHEM PHOTOBIOL, V73, P453, DOI 10.1562/0031-8655(2001)073<0453:TASIOT>2.0.CO;2; BALASHOV SP, 1988, PHYSICOCHEMICAL BIOL, V8, P1; Baudry J, 2001, J PHYS CHEM B, V105, P905, DOI 10.1021/jp000898e; BECHER B, 1978, BIOCHEMISTRY-US, V17, P2293, DOI 10.1021/bi00605a006; Belrhali H, 1999, STRUCTURE, V7, P909, DOI 10.1016/S0969-2126(99)80118-X; Bourgeois D, 2002, J APPL CRYSTALLOGR, V35, P319, DOI 10.1107/S0021889802003837; BRAIMAN M, 1982, P NATL ACAD SCI-BIOL, V79, P403, DOI 10.1073/pnas.79.2.403; BRAIMAN MS, 1988, BIOCHEMISTRY-US, V27, P8516, DOI 10.1021/bi00423a002; Braiman MS, 1996, BIOPHYS J, V70, P939, DOI 10.1016/S0006-3495(96)79637-6; Brown LS, 1996, P NATL ACAD SCI USA, V93, P1731, DOI 10.1073/pnas.93.4.1731; BROWN LS, 1995, J BIOL CHEM, V270, P27122, DOI 10.1074/jbc.270.45.27122; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHANG CH, 1988, PHOTOCHEM PHOTOBIOL, V47, P261, DOI 10.1111/j.1751-1097.1988.tb02724.x; Chu K, 2000, NATURE, V403, P921, DOI 10.1038/35002641; DENCHER NA, 1989, P NATL ACAD SCI USA, V86, P7876, DOI 10.1073/pnas.86.20.7876; DOIG SJ, 1991, J PHYS CHEM-US, V95, P6372, DOI 10.1021/j100169a054; Edman K, 2002, STRUCTURE, V10, P473, DOI 10.1016/S0969-2126(02)00736-0; Edman K, 1999, NATURE, V401, P822, DOI 10.1038/44623; Essen LO, 2002, CURR OPIN STRUC BIOL, V12, P516, DOI 10.1016/S0959-440X(02)00356-1; Facciotti MT, 2001, BIOPHYS J, V81, P3442, DOI 10.1016/S0006-3495(01)75976-0; FRIEDMAN N, 1994, BIOCHEMISTRY-US, V33, P1971, DOI 10.1021/bi00174a001; Gai F, 1998, SCIENCE, V279, P1886, DOI 10.1126/science.279.5358.1886; GAT Y, 1993, J AM CHEM SOC, V115, P3772, DOI 10.1021/ja00062a052; Genick UK, 1998, NATURE, V392, P206, DOI 10.1038/32462; Genick UK, 1997, SCIENCE, V275, P1471, DOI 10.1126/science.275.5305.1471; Gergely C, 1997, J PHYS CHEM B, V101, P9390, DOI 10.1021/jp971381e; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HADFIELD A, 1993, J APPL CRYSTALLOGR, V26, P839, DOI 10.1107/S0021889893005552; Haupts U, 1997, BIOCHEMISTRY-US, V36, P2, DOI 10.1021/bi962014g; Hayashi S, 2002, BIOPHYS J, V83, P1281, DOI 10.1016/S0006-3495(02)73900-3; HEBERLE J, 1993, EMBO J, V12, P3721, DOI 10.1002/j.1460-2075.1993.tb06049.x; HENDERSON R, 1971, ACTA CRYSTALL B-STRU, VB 27, P1414, DOI 10.1107/S0567740871004060; Hendrickson FM, 1998, BIOPHYS J, V75, P1446, DOI 10.1016/S0006-3495(98)74063-9; Herzfeld J, 2000, BBA-BIOENERGETICS, V1460, P95, DOI 10.1016/S0005-2728(00)00132-8; HESSLING B, 1993, BIOPHYS J, V65, P1929, DOI 10.1016/S0006-3495(93)81264-5; Hu JGG, 1997, BIOCHEMISTRY-US, V36, P9316, DOI 10.1021/bi970416y; Kandori H, 2002, BIOCHEMISTRY-US, V41, P6026, DOI 10.1021/bi025585j; Kandori H, 2001, BIOCHEMISTRY-US, V40, P9238, DOI 10.1021/bi0103819; Kandori H, 2001, P NATL ACAD SCI USA, V98, P1571, DOI 10.1073/pnas.98.4.1571; KHORANA HG, 1993, P NATL ACAD SCI USA, V90, P1166, DOI 10.1073/pnas.90.4.1166; KOCH MHJ, 1991, EMBO J, V10, P521, DOI 10.1002/j.1460-2075.1991.tb07978.x; Kolbe M, 2000, SCIENCE, V288, P1390, DOI 10.1126/science.288.5470.1390; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Landau EM, 1996, P NATL ACAD SCI USA, V93, P14532, DOI 10.1073/pnas.93.25.14532; Lanyi JK, 2003, J MOL BIOL, V328, P439, DOI 10.1016/S0022-2836(03)00263-8; Lanyi JK, 2002, J MOL BIOL, V321, P727, DOI 10.1016/S0022-2836(02)00682-4; Lanyi JK, 2001, CURR OPIN STRUC BIOL, V11, P415, DOI 10.1016/S0959-440X(00)00226-8; Lanyi JK, 2000, J PHYS CHEM B, V104, P11441, DOI 10.1021/jp0023718; Lindahl E, 2001, J MOL MODEL, V7, P306, DOI 10.1007/s008940100045; Luecke H, 2000, BBA-BIOENERGETICS, V1460, P133, DOI 10.1016/S0005-2728(00)00135-3; Luecke H, 2001, SCIENCE, V293, P1499, DOI 10.1126/science.1062977; Luecke H, 2000, J MOL BIOL, V300, P1237, DOI 10.1006/jmbi.2000.3884; Luecke H, 1999, SCIENCE, V286, P255, DOI 10.1126/science.286.5438.255; Luecke H, 1998, SCIENCE, V280, P1934, DOI 10.1126/science.280.5371.1934; Luecke H, 1999, J MOL BIOL, V291, P899, DOI 10.1006/jmbi.1999.3027; MAEDA A, 1994, BIOCHEMISTRY-US, V33, P1713, DOI 10.1021/bi00173a013; Maeda A, 1997, J BIOCHEM-TOKYO, V121, P399; MARTI T, 1991, J BIOL CHEM, V266, P18674; Matsui Y, 2002, J MOL BIOL, V324, P469, DOI 10.1016/S0022-2836(02)01110-5; MCMASTER E, 1988, BIOCHEM BIOPH RES CO, V156, P86, DOI 10.1016/S0006-291X(88)80808-8; Murata K, 2000, BIOPHYS J, V79, P982, DOI 10.1016/S0006-3495(00)76352-1; NAKASAKO M, 1991, FEBS LETT, V292, P73, DOI 10.1016/0014-5793(91)80837-S; Neutze R, 2002, BBA-BIOMEMBRANES, V1565, P144, DOI 10.1016/S0005-2736(02)00566-7; Nollert P, 1998, BIOCHEM SOC T, V26, P709, DOI 10.1042/bst0260709; OESTERHELT D, 1992, J BIOENERG BIOMEMBR, V24, P181, DOI 10.1007/BF00762676; ORMOS P, 1991, P NATL ACAD SCI USA, V88, P473, DOI 10.1073/pnas.88.2.473; OTWINOWSKI Z, 1993, DATA COLLECTION PROC, P55; Perman B, 1998, SCIENCE, V279, P1946, DOI 10.1126/science.279.5358.1946; Petkova AT, 1999, BIOCHEMISTRY-US, V38, P1562, DOI 10.1021/bi981968z; Reat V, 1998, P NATL ACAD SCI USA, V95, P4970, DOI 10.1073/pnas.95.9.4970; REDINBO MR, 1993, ACTA CRYSTALLOGR D, V49, P375, DOI 10.1107/S090744499300294X; Ren Z, 2001, BIOCHEMISTRY-US, V40, P13788, DOI 10.1021/bi0107142; Rouhani S, 2001, J MOL BIOL, V313, P615, DOI 10.1006/jmbi.2001.5066; Royant A, 2000, NATURE, V406, P645, DOI 10.1038/35020599; Royant A, 2002, ACTA CRYSTALLOGR D, V58, P784, DOI 10.1107/S090744490200392X; Royant A, 2001, PHOTOCHEM PHOTOBIOL, V74, P794, DOI 10.1562/0031-8655(2001)074<0794:SCOBSL>2.0.CO;2; Royant A, 2001, P NATL ACAD SCI USA, V98, P10131, DOI 10.1073/pnas.181203898; Sass HJ, 2000, NATURE, V406, P649, DOI 10.1038/35020607; SCHLICHTING I, 1994, NATURE, V371, P808, DOI 10.1038/371808a0; Schneider TR, 2000, ACTA CRYSTALLOGR D, V56, P714, DOI 10.1107/S0907444900003723; Schobert B, 2002, J MOL BIOL, V321, P715, DOI 10.1016/S0022-2836(02)00681-2; Schotte F, 2003, SCIENCE, V300, P1944, DOI 10.1126/science.1078797; SCHWEIGER U, 1994, BIOCHEMISTRY-US, V33, P535, DOI 10.1021/bi00168a019; SHEVES M, 1986, P NATL ACAD SCI USA, V83, P3262, DOI 10.1073/pnas.83.10.3262; Srajer V, 1996, SCIENCE, V274, P1726, DOI 10.1126/science.274.5293.1726; Srajer V, 2001, BIOCHEMISTRY-US, V40, P13802, DOI 10.1021/bi010715u; Subramaniam S, 2000, NATURE, V406, P653, DOI 10.1038/35020614; Subramaniam S, 1999, J MOL BIOL, V287, P145, DOI 10.1006/jmbi.1999.2589; SUBRAMANIAM S, 1993, EMBO J, V12, P1; Tajkhorshid E, 1999, J PHYS CHEM B, V103, P5581, DOI 10.1021/jp983742b; TAKEI H, 1994, J BIOL CHEM, V269, P7387; Tittor J, 2002, J MOL BIOL, V319, P555, DOI 10.1016/S0022-2836(02)00307-8; van Gunsteren W, 1996, BIOMOLECULAR SIMULAT; VARO G, 1991, BIOCHEMISTRY-US, V30, P5008, DOI 10.1021/bi00234a024; Vonck J, 2000, EMBO J, V19, P2152, DOI 10.1093/emboj/19.10.2152; Yeates TO, 1997, METHOD ENZYMOL, V276, P344, DOI 10.1016/S0076-6879(97)76068-3; Zhang L, 1996, PROTEINS, V24, P433, DOI 10.1002/(SICI)1097-0134(199604)24:4<433::AID-PROT3>3.0.CO;2-F	103	66	67	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 16	2004	279	3					2147	2158		10.1074/jbc.M300709200	http://dx.doi.org/10.1074/jbc.M300709200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	762WT	14532280	hybrid			2022-12-27	WOS:000188005700071
J	Ge, HF; Yang, GQ; Huang, L; Motola, DL; Pourbahrami, T; Li, C				Ge, HF; Yang, GQ; Huang, L; Motola, DL; Pourbahrami, T; Li, C			Oligomerization and regulated proteolytic processing of angiopoietin-like protein 4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR; ADIPOCYTE; ENDOCRINE; GENE; METABOLISM; EXPRESSION; OXIDATION; MUSCLE	Angiopoietin-like protein 4 (Angptl4) is a recently identified circulating protein expressed primarily in adipose tissue and liver. Also known as peroxisome proliferator-activated receptor ( PPAR)-gamma angiopoietin-related, fasting induced adipose factor, and hepatic fibrinogen/angiopoietin-related protein, recombinant Angptl4 causes increase of plasma very low density lipoprotein levels by inhibition of lipoprotein lipase activity. Similar to angiopoietins and other angiopoietin-like proteins, Angptl4 contains an amino-terminal coiled-coil domain and a carboxyl-terminal fibrinogen-like domain. We report here that Angptl4 is evolutionarily conserved among several mammalian species and that full-length Angptl4 protein is an oligomer containing intermolecular disulfide bonds. Oligomerized Angptl4 undergoes proteolytic processing to release its carboxyl fibrinogen-like domain, which circulates as a monomer. Angptl4' s N-terminal coiled-coil domain mediates its oligomerization, which by itself is sufficient to form higher order oligomeric structure. Adenovirus-mediated overexpression of Angptl4 in 293 cells shows that conversion of full-length, oligomerized Angptl4 is mediated by a cell-associated protease activity induced by serum. These findings demonstrate a novel property of angiopoietin-like proteins and suggest that oligomerization and proteolytic processing of Angptl4 may regulate its biological activities in vivo.	Univ Texas, SW Med Ctr, Touchstone Ctr Diabet Res, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Li, C (corresponding author), 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	cai.li@utsouthwestern.edu			NIDDK NIH HHS [DK 60137] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060137] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahima RS, 2000, TRENDS ENDOCRIN MET, V11, P327, DOI 10.1016/S1043-2760(00)00301-5; Belanger AJ, 2002, J MOL CELL CARDIOL, V34, P765, DOI 10.1006/jmcc.2002.2021; Combs TP, 2003, DIABETES, V52, P268, DOI 10.2337/diabetes.52.2.268; Davis S, 2003, NAT STRUCT BIOL, V10, P38, DOI 10.1038/nsb880; Fruebis J, 2001, P NATL ACAD SCI USA, V98, P2005, DOI 10.1073/pnas.041591798; Fruhbeck G, 2001, AM J PHYSIOL-ENDOC M, V280, pE827, DOI 10.1152/ajpendo.2001.280.6.E827; Ge HF, 2002, J BIOL CHEM, V277, P45898, DOI 10.1074/jbc.M205825200; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Holm C, 2000, ANNU REV NUTR, V20, P365, DOI 10.1146/annurev.nutr.20.1.365; Huang L, 2001, J BIOL CHEM, V276, P6343, DOI 10.1074/jbc.M009795200; Inaba T, 2003, J BIOL CHEM, V278, P21344, DOI 10.1074/jbc.M213202200; Kaneda A, 2002, CANCER RES, V62, P6645; Kaplan R, 2003, J LIPID RES, V44, P136, DOI 10.1194/jlr.M200367-JLR200; Kersten S, 2000, J BIOL CHEM, V275, P28488, DOI 10.1074/jbc.M004029200; Kim I, 2000, BIOCHEM J, V346, P603, DOI 10.1042/0264-6021:3460603; Kim S, 2000, J NUTR, V130, p3110S; Koishi R, 2002, NAT GENET, V30, P151, DOI 10.1038/ng814; Le Jan S, 2003, AM J PATHOL, V162, P1521, DOI 10.1016/S0002-9440(10)64285-X; Pajvani UB, 2003, J BIOL CHEM, V278, P9073, DOI 10.1074/jbc.M207198200; SCHERER PE, 1995, J BIOL CHEM, V270, P26746, DOI 10.1074/jbc.270.45.26746; Shimamura M, 2003, BIOCHEM BIOPH RES CO, V301, P604, DOI 10.1016/S0006-291X(02)03058-9; Tomas E, 2002, P NATL ACAD SCI USA, V99, P16309, DOI 10.1073/pnas.222657499; Yoon JC, 2000, MOL CELL BIOL, V20, P5343, DOI 10.1128/MCB.20.14.5343-5349.2000; Yoshida K, 2002, J LIPID RES, V43, P1770, DOI 10.1194/jlr.C200010-JLR200	24	122	135	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 16	2004	279	3					2038	2045		10.1074/jbc.M307583200	http://dx.doi.org/10.1074/jbc.M307583200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	762WT	14570927	hybrid			2022-12-27	WOS:000188005700058
J	Dal Bosco, C; Lezhneva, L; Biehl, A; Leister, D; Strotmann, H; Wanner, G; Meurer, J				Dal Bosco, C; Lezhneva, L; Biehl, A; Leister, D; Strotmann, H; Wanner, G; Meurer, J			Inactivation of the chloroplast ATP synthase gamma subunit results in high non-photochemical fluorescence quenching and altered nuclear gene expression in Arabidopsis thaliana	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COUPLING FACTOR-I; CHLAMYDOMONAS-REINHARDTII; CHLOROPHYLL-FLUORESCENCE; PHOTOSYSTEM-II; ELECTRON-TRANSPORT; HEAT-STRESS; DELTA-PH; THYLAKOID MEMBRANES; ENERGY-CONVERSION; XANTHOPHYLL CYCLE	The nuclear atpC1 gene encoding the gamma subunit of the plastid ATP synthase has been inactivated by T-DNA insertion mutagenesis in Arabidopsis thaliana. In the seedling-lethal dpa1 ( deficiency of plastid ATP synthase 1) mutant, the absence of detectable amounts of the gamma subunit destabilizes the entire ATP synthase complex. The expression of a second gene copy, atpC2, is unaltered in dpa1 and is not sufficient to compensate for the lack of atpC1 expression. However, in vivo protein labeling analysis suggests that assembly of the ATP synthase alpha and beta subunits into the thylakoid membrane still occurs in dpa1. As a consequence of the destabilized ATP synthase complex, photophosphorylation is abolished even under reducing conditions. Further effects of the mutation include an increased light sensitivity of the plant and an altered photosystem II activity. At low light intensity, chlorophyll fluorescence induction kinetics is close to those found in wild type, but non-photochemical quenching strongly increases with increasing actinic light intensity resulting in steady state fluorescence levels of about 60% of the minimal dark fluorescence. Most fluorescence quenching relaxed within 3 min after dark incubation. Spectroscopic and biochemical studies have shown that a high proton gradient is responsible for most quenching. Thylakoids of illuminated dpa1 plants were swollen due to an increased proton accumulation in the lumen. Expression profiling of 3292 nuclear genes encoding mainly chloroplast proteins demonstrates that most organelle functions are down-regulated. On the contrary, the mRNA expression of some photosynthesis genes is significantly up-regulated, probably to compensate for the defect in dpa1.	Univ Munich, Dept Biol 1, D-80638 Munich, Germany; Max Planck Inst Zuchtungsforsch, Abt Ertragsphysiol & Pflanzenzuchtung, D-50829 Cologne, Germany; Univ Dusseldorf, D-40225 Dusseldorf, Germany	University of Munich; Max Planck Society; Heinrich Heine University Dusseldorf	Meurer, J (corresponding author), Univ Munich, Dept Biol 1, Menzingerstr 67, D-80638 Munich, Germany.	meurer@botanik.biologie.uni-muenchen.de	Leister, Dario/D-5587-2009; Meurer, Jörg/F-8479-2010	Leister, Dario/0000-0003-1897-8421; Meurer, Jörg/0000-0003-2973-9514; Dal Bosco, Cristina/0000-0002-0280-5369				Ackerman SH, 2002, BBA-BIOENERGETICS, V1555, P101, DOI 10.1016/S0005-2728(02)00262-1; ASADA K, 1996, ADV PHOTOSYNTHESIS P, V5, P123; AVRON M, 1960, BIOCHIM BIOPHYS ACTA, V40, P257, DOI 10.1016/0006-3002(60)91350-0; Bald D, 2001, J BIOL CHEM, V276, P39505, DOI 10.1074/jbc.C100436200; BILGER W, 1994, PLANTA, V193, P238, DOI 10.1007/BF00192536; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; Bondarava N, 2003, J BIOL CHEM, V278, P13554, DOI 10.1074/jbc.M212842200; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bukhov NG, 2000, PHOTOCHEM PHOTOBIOL, V72, P351, DOI 10.1562/0031-8655(2000)072&lt;0351:NROTIE&gt;2.0.CO;2; CAO J, 1990, BIOCHIM BIOPHYS ACTA, V1015, P180, DOI 10.1016/0005-2728(90)90018-Y; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; Dellaporta SL, 1983, PLANT MOL BIOL REP, V1, P19, DOI DOI 10.1007/BF02712670; DUCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964; FALK G, 1988, BIOCHEM J, V254, P109, DOI 10.1042/bj2540109; FELMANN KA, 1991, PLANT J, V1, P71; GABRYS H, 1994, PLANT PHYSIOL, V104, P769, DOI 10.1104/pp.104.2.769; Gilmore AM, 1999, CONCEPTS IN PHOTOBIOLOGY, P513; Govindjee, 2002, FUNCT PLANT BIOL, V29, P425, DOI 10.1071/PP01136; Groth G, 2001, J BIOL CHEM, V276, P1345, DOI 10.1074/jbc.M008015200; Groth G, 1999, PHYSIOL PLANTARUM, V106, P142, DOI 10.1034/j.1399-3054.1999.106120.x; Hadi MZ, 2002, PLANT CELL REP, V21, P130, DOI 10.1007/s00299-002-0473-9; HADIKUSUMO RG, 1988, BIOCHIM BIOPHYS ACTA, V933, P212, DOI 10.1016/0005-2728(88)90072-2; Havaux M, 1996, PHOTOSYNTH RES, V47, P85, DOI 10.1007/BF00017756; HEBER U, 1992, PLANT PHYSIOL, V100, P1621, DOI 10.1104/pp.100.4.1621; INOHARA N, 1991, J BIOL CHEM, V266, P7333; Jander G, 2002, PLANT PHYSIOL, V129, P440, DOI 10.1104/pp.003533; JUNESCH U, 1987, BIOCHIM BIOPHYS ACTA, V893, P275, DOI 10.1016/0005-2728(87)90049-1; Kanazawa A, 2002, P NATL ACAD SCI USA, V99, P12789, DOI 10.1073/pnas.182427499; Kaul S, 2000, NATURE, V408, P796, DOI 10.1038/35048692; KETCHAM SR, 1984, J BIOL CHEM, V259, P7286; KLIONSKY DJ, 1985, J BIOL CHEM, V260, P11207; Konno H, 2000, BIOCHEM J, V352, P783, DOI 10.1042/0264-6021:3520783; KOTHEN G, 1995, BBA-BIOENERGETICS, V1229, P208, DOI 10.1016/0005-2728(95)00005-4; KRAUSE GH, 1991, ANNU REV PLANT PHYS, V42, P313, DOI 10.1146/annurev.pp.42.060191.001525; Kurth J, 2002, PLANTA, V215, P101, DOI 10.1007/s00425-001-0719-8; Laskey R A, 1980, Methods Enzymol, V65, P363; Legen J, 2001, DNA RES, V8, P53, DOI 10.1093/dnares/8.2.53; LEMAIRE C, 1989, J BIOL CHEM, V264, P10235; Li XP, 2002, P NATL ACAD SCI USA, V99, P15222, DOI 10.1073/pnas.232447699; Li XP, 2000, NATURE, V403, P391, DOI 10.1038/35000131; Majeran W, 2001, PLANT PHYSIOL, V126, P421, DOI 10.1104/pp.126.1.421; Meurer J, 1996, PLANTA, V198, P385, DOI 10.1007/BF00620055; Meurer J, 2002, PLANT CELL, V14, P3255, DOI 10.1105/tpc.006809; Meurer J, 1998, EMBO J, V17, P5286, DOI 10.1093/emboj/17.18.5286; Meurer J, 1996, PLANT CELL, V8, P1193, DOI 10.1105/tpc.8.7.1193; Muller P, 2001, PLANT PHYSIOL, V125, P1558, DOI 10.1104/pp.125.4.1558; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; NALIN CM, 1984, J BIOL CHEM, V259, P7275; NELSON N, 1992, Current Opinion in Cell Biology, V4, P654, DOI 10.1016/0955-0674(92)90086-R; NISHIO JN, 1993, PLANT PHYSIOL, V101, P89, DOI 10.1104/pp.101.1.89; Nishio K, 2002, P NATL ACAD SCI USA, V99, P13448, DOI 10.1073/pnas.202149599; Niyogi KK, 1998, PLANT CELL, V10, P1121, DOI 10.1105/tpc.10.7.1121; Niyogi KK, 1997, PLANT CELL, V9, P1369, DOI 10.2307/3870388; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; ORT DR, 1992, ANNU REV PLANT PHYS, V43, P269, DOI 10.1146/annurev.pp.43.060192.001413; Reiss B, 1996, P NATL ACAD SCI USA, V93, P3094, DOI 10.1073/pnas.93.7.3094; Richly E, 2003, EMBO REP, V4, P491, DOI 10.1038/sj.embor.embor828; ROBERTSON D, 1990, MOL GEN GENET, V221, P155, DOI 10.1007/BF00261715; Rosenblum BB, 1997, NUCLEIC ACIDS RES, V25, P4500, DOI 10.1093/nar/25.22.4500; Ross SA, 1996, J BIOENERG BIOMEMBR, V28, P49; ROSS SA, 1995, J BIOL CHEM, V270, P9813, DOI 10.1074/jbc.270.17.9813; Sabbert D, 1996, NATURE, V381, P623, DOI 10.1038/381623a0; Sambrook J., 2002, MOL CLONING LAB MANU; Sanger F, 1992, Biotechnology, V24, P104; Sazanov LA, 1998, FEBS LETT, V429, P115, DOI 10.1016/S0014-5793(98)00573-0; Schwarz O, 1998, PHOTOSYNTH RES, V57, P287, DOI 10.1023/A:1006006907945; SELMANREIMER S, 1991, J BIOL CHEM, V266, P182; SMART EJ, 1991, MOL CELL BIOL, V11, P5053, DOI 10.1128/MCB.11.10.5053; STEINER JJ, 1995, NUCLEIC ACIDS RES, V23, P2569, DOI 10.1093/nar/23.13.2569-a; STROTMANN H, 1990, EUR J BIOCHEM, V193, P879, DOI 10.1111/j.1432-1033.1990.tb19412.x; STROTMANN H, 1977, BIOCHIM BIOPHYS ACTA, V460, P126, DOI 10.1016/0005-2728(77)90158-X; Strotmann H., 1998, MOL BIOL CHLOROPLAST, P477; Swiatek M, 2003, MOL GENET GENOMICS, V268, P699, DOI 10.1007/s00438-002-0791-1; VANKOOTEN O, 1990, PHOTOSYNTH RES, V25, P147, DOI 10.1007/BF00033156; Vision TJ, 2000, SCIENCE, V290, P2114, DOI 10.1126/science.290.5499.2114; WITT HT, 1979, BIOCHIM BIOPHYS ACTA, V505, P355, DOI 10.1016/0304-4173(79)90008-9; Wittwer CT, 1997, BIOTECHNIQUES, V22, P176, DOI 10.2144/97221pf02; Wollman FA, 1999, BBA-BIOENERGETICS, V1411, P21, DOI 10.1016/S0005-2728(99)00043-2; Yamane Y, 2000, PHOTOSYNTH RES, V63, P23, DOI 10.1023/A:1006350706802	79	71	129	2	46	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 9	2004	279	2					1060	1069		10.1074/jbc.M308435200	http://dx.doi.org/10.1074/jbc.M308435200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	759DJ	14576160	hybrid			2022-12-27	WOS:000187722800029
J	Pang, H; Bartlam, M; Zeng, QH; Miyatake, H; Hisano, T; Miki, K; Wong, LL; Gao, GF; Rao, ZH				Pang, H; Bartlam, M; Zeng, QH; Miyatake, H; Hisano, T; Miki, K; Wong, LL; Gao, GF; Rao, ZH			Crystal structure of human pirin - An iron-binding nuclear protein and transcription cofactor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; HIF-ALPHA; METALS; COMPLEX; DOMAIN; BCL-3	Pirin is a newly identified nuclear protein that interacts with the oncoprotein B-cell lymphoma 3-encoded (Bcl-3) and nuclear factor I (NFI). The crystal structure of human Pirin at 2.1-Angstrom resolution shows it to be a member of the functionally diverse cupin superfamily. The structure comprises two beta-barrel domains, with an Fe(II) cofactor bound within the cavity of the N-terminal domain. These findings suggest an enzymatic role for Pirin, most likely in biological redox reactions involving oxygen, and provide compelling evidence that Pirin requires the participation of the metal ion for its interaction with Bcl-3 to co-regulate the NF-kappaB transcription pathway and the interaction with NFI in DNA replication. Substitution of iron by heavy metals thus provides a novel pathway for these metals to directly influence gene transcription. The structure suggests an interesting new role of iron in biology and that Pirin may be involved in novel mechanisms of gene regulation.	Tsinghua Univ, Struct Biol Lab, Beijing 100084, Peoples R China; Chinese Acad Sci, Natl Lab Biomacromol, Inst Biophys, Sch Life Sci & Engn, Beijing 100084, Peoples R China; RIKEN, Theoret Struct Biol Lab, Harima Inst, Hyogo 6795148, Japan; Univ Oxford, Inorgan Chem Lab, Dept Chem, Oxford OX1 3QR, England; Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Med, Oxford OX3 9DU, England	Tsinghua University; Chinese Academy of Sciences; Institute of Biophysics, CAS; RIKEN; University of Oxford; University of Oxford	Rao, ZH (corresponding author), Tsinghua Univ, Struct Biol Lab, Beijing 100084, Peoples R China.	raozh@xtal.tsinghua.edu.cn	Gao, George Fu/ABD-5229-2021; Rao, Zihe/HCH-6944-2022	Bartlam, Mark/0000-0001-5173-5080				Adachi M, 2001, J MOL BIOL, V305, P291, DOI 10.1006/jmbi.2000.4310; Anand R, 2002, BIOCHEMISTRY-US, V41, P7659, DOI 10.1021/bi0200965; Bergman AC, 1999, CELL MOL LIFE SCI, V55, P467, DOI 10.1007/s000180050303; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bundy DL, 1997, J BIOL CHEM, V272, P33132, DOI 10.1074/jbc.272.52.33132; Chen F, 2002, ENVIRON HEALTH PERSP, V110, P807, DOI 10.1289/ehp.02110s5807; Cleasby A, 1996, NAT STRUCT BIOL, V3, P470, DOI 10.1038/nsb0596-470; Dechend R, 1999, ONCOGENE, V18, P3316, DOI 10.1038/sj.onc.1202717; DeMoor JM, 2000, CELL MOL BIOL, V46, P367; Dunwell JM, 2001, TRENDS BIOCHEM SCI, V26, P740, DOI 10.1016/S0968-0004(01)01981-8; Fujita M, 1999, J BIOL CHEM, V274, P25927, DOI 10.1074/jbc.274.36.25927; Fusetti F, 2002, STRUCTURE, V10, P259, DOI 10.1016/S0969-2126(02)00704-9; Hewitson KS, 2002, J BIOL CHEM, V277, P26351, DOI 10.1074/jbc.C200273200; Holm L, 1998, NUCLEIC ACIDS RES, V26, P316, DOI 10.1093/nar/26.1.316; Huxford T, 1998, CELL, V95, P759, DOI 10.1016/S0092-8674(00)81699-2; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jacobs MD, 1998, CELL, V95, P749, DOI 10.1016/S0092-8674(00)81698-0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; LANE BG, 1993, J BIOL CHEM, V268, P12239; LENARDO M, 1994, IMMUNOL TODAY, V15, P145, DOI 10.1016/0167-5699(94)90308-5; Liang R, 2001, ANN CLIN LAB SCI, V31, P91; Makarova KS, 2002, TRENDS BIOCHEM SCI, V27, P384, DOI 10.1016/S0968-0004(02)02140-0; Michel F, 2001, EMBO J, V20, P6180, DOI 10.1093/emboj/20.22.6180; Mitchell TC, 2001, NAT IMMUNOL, V2, P397, DOI 10.1038/87692; Molkentin JD, 2000, J BIOL CHEM, V275, P38949, DOI 10.1074/jbc.R000029200; Moont G, 1999, PROTEINS, V35, P364, DOI 10.1002/(SICI)1097-0134(19990515)35:3<364::AID-PROT11>3.0.CO;2-4; MULLER CW, 1995, NATURE, V373, P311, DOI 10.1038/373311a0; OHALLORAN TV, 1993, SCIENCE, V261, P715, DOI 10.1126/science.8342038; Orzaez D, 2001, PLANT MOL BIOL, V46, P459, DOI 10.1023/A:1010618515051; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Pochapsky TC, 2002, NAT STRUCT BIOL, V9, P966, DOI 10.1038/nsb863; Richard M, 1999, BLOOD, V93, P4318, DOI 10.1182/blood.V93.12.4318.412k09_4318_4327; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; Schwarz EM, 1997, GENE DEV, V11, P187, DOI 10.1101/gad.11.2.187; Soisson SM, 1997, SCIENCE, V276, P421, DOI 10.1126/science.276.5311.421; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Wendler WMF, 1997, J BIOL CHEM, V272, P8482, DOI 10.1074/jbc.272.13.8482; Zhang ZH, 2000, NAT STRUCT BIOL, V7, P127	41	82	110	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 9	2004	279	2					1491	1498		10.1074/jbc.M310022200	http://dx.doi.org/10.1074/jbc.M310022200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	759DJ	14573596	hybrid			2022-12-27	WOS:000187722800080
J	Shalabi, A; Zamudio, F; Wu, XY; Scaloni, A; Possani, LD; Villereal, ML				Shalabi, A; Zamudio, F; Wu, XY; Scaloni, A; Possani, LD; Villereal, ML			Tetrapandins, a new class of scorpion toxins that specifically inhibit store-operated calcium entry in human embryonic kidney-293 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2-AMINOETHOXYDIPHENYL BORATE 2-APB; CA2+ ENTRY; INTRACELLULAR CALCIUM; RECEPTOR; CHANNELS; PATHWAYS; OSCILLATIONS; MECHANISMS; CURRENTS; RELEASE	Venoms from 14 snakes and four scorpions were screened for inhibitory activities toward store-operated Ca2+ entry (SOCE) in human embryonic kidney-293 cells. An inhibitory activity was found in venom from the African scorpion Pandinus imperator. The active agent of this venom was purified by gel filtration and reverse-phase high pressure liquid chromatography methods. Sequence information on the purified fraction, by automatic Edman degradation and mass spectrometry analysis, identified the activity as being contained in two tetrapeptides, which we have named tetrapandins. We demonstrate that synthesized tetrapandins have inhibitory activity for SOCE in human embryonic kidney-293 cells while having no effect on either thapsigarginor carbachol-stimulated release of Ca2+ stores. These toxins should be extremely useful in future studies to determine downstream events regulated by SOCE as well as to determine whether multiple pathways exist for thapsigargin-stimulated Ca2+ entry.	Univ Chicago, Dept Neurobiol Pharmacol & Physiol, Chicago, IL 60637 USA; Univ Nacl Autonoma Mexico, Inst Biotechnol, Dept Mol Med & Bioproc, Cuernavaca 62210, Morelos, Mexico; CNR, Ist Sistema Prod Anim Ambiente Mediterraneo, Proteom & Mass Spectrometry Lab, I-80147 Naples, Italy	University of Chicago; Universidad Nacional Autonoma de Mexico; Consiglio Nazionale delle Ricerche (CNR); Istituto Per Il Sistema Produzione Animale In Ambiente Mediterraneo (ISPAAM-CNR)	Villereal, ML (corresponding author), Univ Chicago, Dept Neurobiol Pharmacol & Physiol, 947 E 58th St, Chicago, IL 60637 USA.	mitch@drugs.bsd.uchicago.edu	Possani, Lourival D/J-2397-2013	Scaloni, Andrea/0000-0001-9362-8515	NIGMS NIH HHS [GM-54500] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alessandro R, 1996, IN VIVO, V10, P153; Barritt GJ, 1999, BIOCHEM J, V337, P153, DOI 10.1042/0264-6021:3370153; Bilmen JG, 2002, EUR J BIOCHEM, V269, P3678, DOI 10.1046/j.1432-1033.2002.03060.x; Bootman MD, 2002, CURR BIOL, V12, pR563, DOI 10.1016/S0960-9822(02)01055-2; Bootman MD, 2002, FASEB J, V16, DOI 10.1096/fj.02-0037rev; Braun FJ, 2003, MOL PHARMACOL, V63, P1304, DOI 10.1124/mol.63.6.1304; CARBONE E, 1982, NATURE, V296, P90, DOI 10.1038/296090a0; Chinopoulos C, 2003, J BIOL CHEM, V278, P27382, DOI 10.1074/jbc.M303808200; Conde R, 2000, FEBS LETT, V471, P165, DOI 10.1016/S0014-5793(00)01384-3; de la Rosa LA, 2001, CELL SIGNAL, V13, P711, DOI 10.1016/S0898-6568(01)00200-5; Dietl P, 1996, CELL CALCIUM, V20, P11, DOI 10.1016/S0143-4160(96)90046-9; FASOLATO C, 1994, TRENDS PHARMACOL SCI, V15, P77, DOI 10.1016/0165-6147(94)90282-8; Harks EGA, 2003, FASEB J, V17, P941, DOI 10.1096/fj.02-0786fje; Hong S. J., 1994, Journal of Biomedical Science, V1, P172, DOI 10.1007/BF02253347; HONG SJ, 1994, EUR J PHARMACOL, V265, P35, DOI 10.1016/0014-2999(94)90220-8; HUPE DJ, 1991, J BIOL CHEM, V266, P10136; Jenkins RE, 2001, PROTEOMICS, V1, P1092, DOI 10.1002/1615-9861(200109)1:9<1092::AID-PROT1092>3.0.CO;2-S; KAO CY, 1966, PHARMACOL REV, V18, P997; KEITH RA, 1989, BRIT J PHARMACOL, V98, P767, DOI 10.1111/j.1476-5381.1989.tb14604.x; KWAN CY, 1990, J BIOL CHEM, V265, P678; Luo D, 2001, J BIOL CHEM, V276, P5613, DOI 10.1074/jbc.M007524200; Ma HT, 2000, SCIENCE, V287, P1647, DOI 10.1126/science.287.5458.1647; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; OLIVERA BM, 1991, ANN NY ACAD SCI, V635, P114, DOI 10.1111/j.1749-6632.1991.tb36486.x; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; Peppiatt CM, 2003, CELL CALCIUM, V34, P97, DOI 10.1016/S0143-4160(03)00026-5; Possani LD, 1999, EUR J BIOCHEM, V264, P287, DOI 10.1046/j.1432-1327.1999.00625.x; Possani LD, 2000, BIOCHIMIE, V82, P861, DOI 10.1016/S0300-9084(00)01167-6; Possani Lourival D., 1999, Perspectives in Drug Discovery and Design, V15-16, P15, DOI 10.1023/A:1017062613503; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; Putney JW, 2001, J CELL SCI, V114, P2223; SCHILLING WP, 1989, J BIOL CHEM, V264, P12838; SCHWARZ G, 1994, CELL CALCIUM, V15, P45, DOI 10.1016/0143-4160(94)90103-1; SOERGEL DG, 1992, MOL PHARMACOL, V41, P487; Valdivia HH, 1998, TRENDS CARDIOVAS MED, V8, P111, DOI 10.1016/S1050-1738(97)00138-2; Wang Y, 2002, CELL CALCIUM, V32, P209, DOI 10.1016/S0143416002001562; Wu XY, 2000, AM J PHYSIOL-CELL PH, V278, pC526, DOI 10.1152/ajpcell.2000.278.3.C526; Wu XY, 2002, J BIOL CHEM, V277, P13597, DOI 10.1074/jbc.M110881200; Zamudio FZ, 1997, J BIOL CHEM, V272, P11886, DOI 10.1074/jbc.272.18.11886; Zitt C, 2002, PROG NEUROBIOL, V66, P243, DOI 10.1016/S0301-0082(02)00002-3	40	9	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 9	2004	279	2					1040	1049		10.1074/jbc.M308234200	http://dx.doi.org/10.1074/jbc.M308234200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	759DJ	14583617	hybrid			2022-12-27	WOS:000187722800027
J	Fotin-Mleczek, M; Henkler, F; Hausser, A; Glauner, H; Samel, D; Graness, A; Scheurich, P; Mauri, D; Wajant, H				Fotin-Mleczek, M; Henkler, F; Hausser, A; Glauner, H; Samel, D; Graness, A; Scheurich, P; Mauri, D; Wajant, H			Tumor necrosis factor receptor-associated factor (TRAF) 1 regulates CD40-induced TRAF2-mediated NF-kappa B activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-PROTEIN LIGASE; TERMINAL KINASE; FACTOR FAMILY; FACTOR TNF; TARGETED DISRUPTION; CYTOPLASMIC DOMAIN; INDUCED APOPTOSIS; GENE-EXPRESSION; BINDING-SITES; HUMAN TRAF2	To investigate CD40 signaling complex formation in living cells, we used green fluorescent protein (GFP)tagged CD40 signaling intermediates and confocal life imaging. The majority of cytoplasmic TRAF2-GFP and, to a lesser extent, TRAF3-GFP, but not TRAF1-GFP or TRAF4-GFP, translocated into CD40 signaling complexes within a few minutes after CD40 triggering with the CD40 ligand. The inhibitor of apoptosis proteins cIAP1 and cIAP2 were also recruited by TRAF2 to sites of CD40 signaling. An excess of TRAF2 allowed recruitment of TRAF1-GFP to sites of CD40 signaling, whereas an excess of TRAF1 abrogated the interaction of TRAF2 and CD40. Overexpression of TRAF1, however, had no effect on the interaction of TRADD and TRAF2, known to be important for tumor necrosis factor receptor 1 (TNF-R1)-mediated NF-kappaB activation. Accordingly, TRAF1 inhibited CD40-dependent but not TNF-R1-dependent NF-kappaB activation. Moreover, down-regulation of TRAF1 with small interfering RNAs enhanced CD40/ CD40 ligand-induced NF-kappaB activation but showed no effect on TNF signaling. Because of the trimeric organization of TRAF proteins, we propose that the stoichiometry of TRAF1-TRAF2 heteromeric complexes (( TRAF2)(2)-TRAF1 versus TRAF2-(TRAF1)(2)) determines their capability to mediate CD40 signaling but has no major effect on TNF signaling.	Univ Wurzburg, Dept Mol Internal Med, D-97070 Wurzburg, Germany; Univ Stuttgart, Inst Cell Biol & Immunol, D-70569 Stuttgart, Germany; Apotech Biochem Ltd, CH-1066 Epalinges, Switzerland	University of Wurzburg; University of Stuttgart	Wajant, H (corresponding author), Univ Wurzburg, Dept Mol Internal Med, Roentgenring 11, D-97070 Wurzburg, Germany.		Hausser, Angelika/AAC-4531-2021; Wajant, Harald/A-3020-2017	Wajant, Harald/0000-0002-2005-3949				Ahonen CL, 2002, NAT IMMUNOL, V3, P451, DOI 10.1038/ni792; Alam A, 1999, J EXP MED, V190, P1879, DOI 10.1084/jem.190.12.1879; Arron JR, 2002, J EXP MED, V196, P923, DOI 10.1084/jem.20020774; Baud V, 1999, GENE DEV, V13, P1297, DOI 10.1101/gad.13.10.1297; Boucher LM, 1997, BIOCHEM BIOPH RES CO, V233, P592, DOI 10.1006/bbrc.1997.6509; Carpentier I, 1999, FEBS LETT, V460, P246, DOI 10.1016/S0014-5793(99)01356-3; CHENG GH, 1995, SCIENCE, V267, P1494, DOI 10.1126/science.7533327; Devin A, 2001, MOL CELL BIOL, V21, P3986, DOI 10.1128/MCB.21.12.3986-3994.2001; Fotin-Mleczek M, 2002, J CELL SCI, V115, P2757; Grammer AC, 1998, J IMMUNOL, V161, P1183; Hanissian SH, 1997, IMMUNITY, V6, P379, DOI 10.1016/S1074-7613(00)80281-2; Henkler F, 2003, J BIOL CHEM, V278, P29216, DOI 10.1074/jbc.M211090200; Heyninck K, 1999, J CELL BIOL, V145, P1471, DOI 10.1083/jcb.145.7.1471; Hostager BS, 2000, J BIOL CHEM, V275, P15392, DOI 10.1074/jbc.M909520199; HU HM, 1994, J BIOL CHEM, V269, P30069; Huang HK, 2000, J BIOL CHEM, V275, P26661; Inada H, 2001, J CELL BIOL, V155, P415, DOI 10.1083/jcb.200103078; Irmler M, 2000, FEBS LETT, V468, P129, DOI 10.1016/S0014-5793(00)01206-0; Ishida T, 1996, J BIOL CHEM, V271, P28745, DOI 10.1074/jbc.271.46.28745; Ishida T, 1996, P NATL ACAD SCI USA, V93, P9437, DOI 10.1073/pnas.93.18.9437; Jabara HH, 2002, IMMUNITY, V17, P265, DOI 10.1016/S1074-7613(02)00394-1; Jabara HH, 1998, BLOOD, V92, P2435, DOI 10.1182/blood.V92.7.2435.2435_2435_2440; Karras JG, 1997, J IMMUNOL, V159, P4350; Kashiwada M, 1998, J EXP MED, V187, P237, DOI 10.1084/jem.187.2.237; Kennedy NJ, 1999, J EXP MED, V190, P1891, DOI 10.1084/jem.190.12.1891; Leo E, 1999, J BIOL CHEM, V274, P22414, DOI 10.1074/jbc.274.32.22414; Leo E, 2001, J BIOL CHEM, V276, P8087, DOI 10.1074/jbc.M009450200; Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015; Mack A, 2002, EUR J IMMUNOL, V32, P1986, DOI 10.1002/1521-4141(200207)32:7<1986::AID-IMMU1986>3.0.CO;2-#; McWhirter SM, 1999, P NATL ACAD SCI USA, V96, P8408, DOI 10.1073/pnas.96.15.8408; Morgan M, 2002, J CELL BIOL, V157, P975, DOI 10.1083/jcb.200204039; Nakano H, 1999, P NATL ACAD SCI USA, V96, P9803, DOI 10.1073/pnas.96.17.9803; Nguyen LT, 1999, IMMUNITY, V11, P379, DOI 10.1016/S1074-7613(00)80113-2; Ni CZ, 2000, P NATL ACAD SCI USA, V97, P10395, DOI 10.1073/pnas.97.19.10395; Park YC, 1999, NATURE, V398, P533, DOI 10.1038/19110; Pullen SS, 1999, BIOCHEMISTRY-US, V38, P10168, DOI 10.1021/bi9909905; Pullen SS, 1998, BIOCHEMISTRY-US, V37, P11836, DOI 10.1021/bi981067q; Revy P, 1999, J IMMUNOL, V163, P787; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; SATO T, 1995, FEBS LETT, V358, P113, DOI 10.1016/0014-5793(94)01406-Q; Schonbeck U, 2001, CELL MOL LIFE SCI, V58, P4, DOI 10.1007/PL00000776; Schwenzer R, 1999, J BIOL CHEM, V274, P19368, DOI 10.1074/jbc.274.27.19368; Shu HB, 1996, P NATL ACAD SCI USA, V93, P13973, DOI 10.1073/pnas.93.24.13973; Siegmund D, 2002, MOL MED, V8, P725, DOI 10.1007/BF03402036; Siemienski K, 1997, GENE, V195, P35, DOI 10.1016/S0378-1119(97)00147-9; Tsitsikov EN, 2001, IMMUNITY, V15, P647, DOI 10.1016/S1074-7613(01)00207-2; Tsukamoto N, 1999, P NATL ACAD SCI USA, V96, P1234, DOI 10.1073/pnas.96.4.1234; Vidalain PO, 2000, EMBO J, V19, P3304, DOI 10.1093/emboj/19.13.3304; Wajant H, 2001, CELL SIGNAL, V13, P389, DOI 10.1016/S0898-6568(01)00160-7; Wajant H, 2001, INT J BIOCHEM CELL B, V33, P19, DOI 10.1016/S1357-2725(00)00064-9; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Xu Y, 1996, IMMUNITY, V5, P407, DOI 10.1016/S1074-7613(00)80497-5; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874	53	87	91	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	2004	279	1					677	685		10.1074/jbc.M310969200	http://dx.doi.org/10.1074/jbc.M310969200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	757GU	14557256	hybrid			2022-12-27	WOS:000187555300081
J	Kim, YC; Yakunin, AF; Kuznetsova, E; Xu, XH; Pennycooke, M; Gu, J; Cheung, F; Proudfoot, M; Arrowsmith, CH; Joachimiak, A; Edwards, AM; Christendat, D				Kim, YC; Yakunin, AF; Kuznetsova, E; Xu, XH; Pennycooke, M; Gu, J; Cheung, F; Proudfoot, M; Arrowsmith, CH; Joachimiak, A; Edwards, AM; Christendat, D			Structure- and function-based characterization of a new phosphoglycolate phosphatase from Thermoplasma acidophilum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; PHOSPHOSERINE PHOSPHATASE; ANGSTROM RESOLUTION; CATALYTIC DOMAIN; ENZYME; DEHALOGENASE; INTERMEDIATE; HYDROLASE; PATHWAY; FOLD	The protein TA0175 has a large number of sequence homologues, most of which are annotated as unknown and a few as belonging to the haloacid dehalogenase superfamily, but has no known biological function. Using a combination of amino acid sequence analysis, three-dimensional crystal structure information, and kinetic analysis, we have characterized TA0175 as phosphoglycolate phosphatase from Thermoplasma acidophilum. The crystal structure of TA0175 revealed two distinct domains, a larger core domain and a smaller cap domain. The large domain is composed of a centrally located five-stranded parallel beta-sheet with strand order S10, S9, S8, S1, S2 and a small beta-hairpin, strands S3 and S4. This central sheet is flanked by a set of three alpha-helices on one side and two helices on the other. The smaller domain is composed of an open faced beta-sandwich represented by three antiparallel beta-strands, S5, S6, and S7, flanked by two oppositely oriented alpha-helices, H3 and H4. The topology of the large domain is conserved; however, structural variation is observed in the smaller domain among the different functional classes of the haloacid dehalogenase superfamily. Enzymatic assays on TA0175 revealed that this enzyme catalyzed the dephosphorylation of phosphoglycolate in vitro with similar kinetic properties seen for eukaryotic phosphoglycolate phosphatase. Activation by divalent cations, especially Mg2+, and competitive inhibition behavior with Cl- ions are similar between TA0175 and phosphoglycolate phosphatase. The experimental evidence presented for TA0175 is indicative of phosphoglycolate phosphatase.	Univ Toronto, Dept Bot, Toronto, ON M5S 3B2, Canada; Argonne Natl Lab, Struct Biol Ctr, Argonne, IL 60439 USA; Univ Toronto, Banting & Best Dept Med Res, Toronto, ON M5G 1L6, Canada; Clin Genom Ctr Preteom, Toronto, ON M5G 1L7, Canada	University of Toronto; United States Department of Energy (DOE); Argonne National Laboratory; University of Toronto	Edwards, AM (corresponding author), Univ Toronto, Dept Bot, 25 Willcocks St, Toronto, ON M5S 3B2, Canada.	aled.edwards@utoronto.ca	Yakunin, Alexander/J-1519-2014	Edwards, Aled/0000-0002-4782-6016; Yakunin, Alexander/0000-0003-0813-6490; Kim, Youngchang/0000-0002-1610-4889; Arrowsmith, Cheryl/0000-0002-4971-3250	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM062414] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM62414-01, P50 GM062414, P50 GM062414-01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aravind L, 1998, TRENDS BIOCHEM SCI, V23, P127, DOI 10.1016/S0968-0004(98)01189-X; BAYKOV AA, 1988, ANAL BIOCHEM, V171, P266, DOI 10.1016/0003-2697(88)90484-8; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cho HS, 2000, J MOL BIOL, V297, P543, DOI 10.1006/jmbi.2000.3595; Christendat D, 2000, J BIOL CHEM, V275, P24608, DOI 10.1074/jbc.C000238200; CHRISTOPHER JA, 1998, SPOCK; Collet JF, 1999, J BIOL CHEM, V274, P33985, DOI 10.1074/jbc.274.48.33985; Collet JF, 1998, J BIOL CHEM, V273, P14107, DOI 10.1074/jbc.273.23.14107; Hisano T, 1996, J BIOL CHEM, V271, P20322, DOI 10.1074/jbc.271.34.20322; HUSIC HD, 1984, ARCH BIOCHEM BIOPHYS, V229, P64, DOI 10.1016/0003-9861(84)90130-9; Inamdar KV, 2002, J BIOL CHEM, V277, P27162, DOI 10.1074/jbc.M204688200; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUO CH, 1982, EXP CELL RES, V142, P141, DOI 10.1016/0014-4827(82)90418-9; Lyngstadaas A, 1999, BBA-GEN SUBJECTS, V1472, P376, DOI 10.1016/S0304-4165(99)00146-4; Mamedov TG, 2001, J BIOL CHEM, V276, P45573, DOI 10.1074/jbc.M103882200; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Morais MC, 2000, BIOCHEMISTRY-US, V39, P10385, DOI 10.1021/bi001171j; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Parsons JF, 2002, PROTEINS, V46, P393, DOI 10.1002/prot.10057; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Regni C, 2002, STRUCTURE, V10, P269, DOI 10.1016/S0969-2126(02)00705-0; ROSE ZB, 1981, ARCH BIOCHEM BIOPHYS, V208, P602, DOI 10.1016/0003-9861(81)90549-X; SEAL SN, 1987, J BIOL CHEM, V262, P13496; Thompson PR, 2001, P NATL ACAD SCI USA, V98, P8170, DOI 10.1073/pnas.161273998; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Wang WR, 2001, STRUCTURE, V9, P65, DOI 10.1016/S0969-2126(00)00558-X; Wang WR, 2002, J MOL BIOL, V319, P421, DOI 10.1016/S0022-2836(02)00324-8; WEST AH, 1995, J MOL BIOL, V250, P276, DOI 10.1006/jmbi.1995.0376	29	42	44	2	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 2	2004	279	1					517	526		10.1074/jbc.M306054200	http://dx.doi.org/10.1074/jbc.M306054200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	757GU	14555659	Green Accepted, hybrid			2022-12-27	WOS:000187555300062
J	She, YM; Seifers, DL; Haber, S; Ens, W; Standing, KG				She, YM; Seifers, DL; Haber, S; Ens, W; Standing, KG			Characterization of the agent of "high plains disease" - Mass spectrometry determines the sequence of the disease-specific protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOSAIC-VIRUS; WHEAT; MAIZE; CORN; TRANSMISSION; BLAST	The "32-kDa" protein specifically associated with high plains disease was characterized by time-of-flight mass spectrometry, after the agent had been isolated in pure culture by "vascular puncture inoculation," a novel mechanical means of transmission. Two isolates from different geographic locations each consisted of a mixture of subpopulations that were highly homologous to an amino acid sequence derived from a nucleotide sequence (U60141) deposited in GenBank(TM) by the Nebraska group as " the probable N-protein of high plains virus." However, the U60141 sequence was found to be incomplete; de novo sequencing of peptides produced by proteolytic digestions of the 32-kDa band from an SDS-PAGE separation showed that an additional 18 amino acid residues were present at the N terminus. BLAST ( basic local alignment search tool) examination of the sequence showed no significant homology with any protein in the databases, indicating that the infectious agent of high plains disease is likely a member of a hitherto unclassified virus group.	Univ Manitoba, Dept Phys & Astron, Winnipeg, MB R3T 2N2, Canada; Hosp Sick Children, Toronto, ON M5G 1X8, Canada; Kansas State Univ, Agr Res Ctr, Hays, KS 67601 USA; Agr & Agri Food Canada, Cereal Res Ctr, Winnipeg, MB R3T 2M9, Canada	University of Manitoba; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Kansas State University; Agriculture & Agri Food Canada	Standing, KG (corresponding author), Univ Manitoba, Dept Phys & Astron, Winnipeg, MB R3T 2N2, Canada.	standin@cc.umanitoba.ca	Standing, Kenneth/E-2416-2011	She, Yi-Min/0000-0002-0571-4630	NIGMS NIH HHS [GM59240] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059240] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahn KK, 1998, J SUBMICR CYTOL PATH, V30, P563; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Jardine D. J., 1994, Phytopathology, V84, P1117; Jensen SG, 1996, PLANT DIS, V80, P1387, DOI 10.1094/PD-80-1387; Jensen Stanley G., 1994, Phytopathology, V84, P1158; Keough T, 1999, P NATL ACAD SCI USA, V96, P7131, DOI 10.1073/pnas.96.13.7131; Loboda AV, 2000, RAPID COMMUN MASS SP, V14, P1047, DOI 10.1002/1097-0231(20000630)14:12<1047::AID-RCM990>3.0.CO;2-E; LOUIE R, 1995, PHYTOPATHOLOGY, V85, P139, DOI 10.1094/Phyto-85-139; Louie R., 1996, Phytopathology, V86, pS1; Marcon A, 1999, CROP SCI, V39, P1171, DOI 10.2135/cropsci1999.0011183X003900040037x; Seifers Dallas L, 1998, Plant Dis, V82, P875, DOI 10.1094/PDIS.1998.82.8.875; Seifers DL, 1997, PLANT DIS, V81, P1161, DOI 10.1094/PDIS.1997.81.10.1161; Seifers DL, 2002, PLANT DIS, V86, P138, DOI 10.1094/PDIS.2002.86.2.138; Seifers DL, 2000, PHYTOPATHOLOGY, V90, P505, DOI 10.1094/PHYTO.2000.90.5.505; She YM, 2002, ANAL BIOCHEM, V310, P137, DOI 10.1016/S0003-2697(02)00321-4; She YM, 2001, J BIOL CHEM, V276, P20039, DOI 10.1074/jbc.M100189200; Shevchenko A, 2001, ANAL CHEM, V73, P1917, DOI 10.1021/ac0013709	17	13	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 2	2004	279	1					488	494		10.1074/jbc.M308506200	http://dx.doi.org/10.1074/jbc.M308506200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	757GU	14561770	hybrid			2022-12-27	WOS:000187555300059
J	Shiraishi, K; Kato, S; Han, SY; Liu, W; Otsuka, K; Sakayori, M; Ishida, T; Takeda, M; Kanamaru, R; Ohuchi, N; Ishioka, C				Shiraishi, K; Kato, S; Han, SY; Liu, W; Otsuka, K; Sakayori, M; Ishida, T; Takeda, M; Kanamaru, R; Ohuchi, N; Ishioka, C			Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST FUNCTIONAL ASSAY; PROLYL ISOMERASE PIN1; WILD-TYPE; CELL-LINE; APOPTOTIC FUNCTION; HUMAN CANCERS; MUTANT; PROTEINS; GENE; TRANSCRIPTION	Temperature-sensitive (ts) mutations have been used as a genetic and molecular tool to study the functions of many gene products. Each ts mutant protein may contain a temperature-dependent intramolecular mechanism such as ts conformational change. To identify key ts structural elements controlling the protein function, we screened ts p53 mutants from a comprehensive mutation library consisting of 2,314 p53 missense mutations for their sequence-specific transactivity through p53-binding sequences in Saccharomyces cerevisiae. We isolated 142 ts p53 mutants, including 131 unreported ts mutants. These mutants clustered in beta-strands in the DNA-binding domain, particularly in one of the two beta-sheets of the protein, and 15 residues (Thr(155), Arg(158), Met(160), Ala(161), Val(172), His(214), Ser(215), Pro(223), Thr(231), Thr(253), Ile(254), Thr(256), Ser(269), Glu(271), and Glu(285)) were ts hot spots. Among the 142 mutants, 54 were examined further in human osteosarcoma Saos-2 cells, and it was confirmed that 89% of the mutants were also ts in mammalian cells. The ts mutants represented distinct ts transactivities for the p53 binding sequences and a distinct epitope expression pattern for conformation-specific anti-p53 antibodies. These results indicated that the intramolecular beta-sheet in the core DNA-binding domain of p53 was a key structural element controlling the protein function and provided a clue for finding a molecular mechanism that enables the rescue of the mutant p53 function.	Tohoku Univ, Inst Dev Aging & Canc, Dept Clin Oncol, Aoba Ku, Sendai, Miyagi 9808575, Japan; Tohoku Univ, Sch Med, Div Surg Oncol, Sendai, Miyagi 9808574, Japan	Tohoku University; Tohoku University	Ishioka, C (corresponding author), Tohoku Univ, Inst Dev Aging & Canc, Dept Clin Oncol, Aoba Ku, 4-1 Seiryo Machi, Sendai, Miyagi 9808575, Japan.	chikashi@idac.tohoku.ac.jp	Kato, Shunsuke/F-7607-2014	Ishioka, Chikashi/0000-0002-3023-1227				Ashcroft M, 1999, MOL CELL BIOL, V19, P1751; Barlev NA, 2001, MOL CELL, V8, P1243, DOI 10.1016/S1097-2765(01)00414-2; Campomenosi P, 2001, ONCOGENE, V20, P3573, DOI 10.1038/sj.onc.1204468; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; DI CC, 1998, ONCOGENE, V16, P2527; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001; Hall PA, 1996, J PATHOL, V180, P1; HARRIS CC, 1993, NEW ENGL J MED, V329, P1318, DOI 10.1056/NEJM199310283291807; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Ikeda J, 2001, INT J CANCER, V94, P35, DOI 10.1002/ijc.1431; Jia LQ, 1997, MOL CARCINOGEN, V19, P243, DOI 10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kato S, 2003, P NATL ACAD SCI USA, V100, P8424, DOI 10.1073/pnas.1431692100; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kobayashi D, 2001, JPN J CANCER RES, V92, P475, DOI 10.1111/j.1349-7006.2001.tb01118.x; Kokontis JM, 2001, ONCOGENE, V20, P659, DOI 10.1038/sj.onc.1204139; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Maurici D, 2001, ONCOGENE, V20, P3533, DOI 10.1038/sj.onc.1204428; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; North S, 2002, MOL CARCINOGEN, V33, P181, DOI 10.1002/mc.10038; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Ponchel F, 1998, BRIT J CANCER, V77, P1555, DOI 10.1038/bjc.1998.256; ROLLEY N, 1995, ONCOGENE, V11, P763; Ryan KM, 1998, MOL CELL BIOL, V18, P3692, DOI 10.1128/MCB.18.7.3692; Samuels-Lev Y, 2001, MOL CELL, V8, P781, DOI 10.1016/S1097-2765(01)00367-7; Shimada A, 1999, CANCER RES, V59, P2781; Siddik ZH, 1998, CANCER RES, V58, P698; Soussi T, 2000, HUM MUTAT, V15, P105, DOI 10.1002/(SICI)1098-1004(200001)15:1<105::AID-HUMU19>3.0.CO;2-G; SOUSSI T, 1990, ONCOGENE, V5, P945; Tsuiki H, 2001, ONCOGENE, V20, P420, DOI 10.1038/sj.onc.1204126; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; Wang YL, 2000, TRENDS BIOCHEM SCI, V25, P300, DOI 10.1016/S0968-0004(00)01561-9; Zacchi P, 2002, NATURE, V419, P853, DOI 10.1038/nature01120; Zhan MC, 2001, CANCER, V92, P1556, DOI 10.1002/1097-0142(20010915)92:6<1556::AID-CNCR1482>3.0.CO;2-S; ZHANG W, 1994, EMBO J, V13, P2535, DOI 10.1002/j.1460-2075.1994.tb06543.x; Zheng HW, 2002, NATURE, V419, P849, DOI 10.1038/nature01116	41	71	72	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 2	2004	279	1					348	355		10.1074/jbc.M310815200	http://dx.doi.org/10.1074/jbc.M310815200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	757GU	14559903	hybrid			2022-12-27	WOS:000187555300042
J	Koo, BH; Kim, DS				Koo, BH; Kim, DS			Factor Xa induces mitogenesis of vascular smooth muscle cells via autocrine production of epiregulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; COAGULATION-FACTOR XA; FACTOR RECEPTOR; TISSUE FACTOR; IN-VITRO; THROMBIN; PROTEIN; ACTIVATION; EXPRESSION; POTENT	Factor Xa has been reported to elicit smooth muscle cell proliferation via autocrine release of platelet-derived growth factor. However, this study has shown that factor Xa-induced mitogenesis of rat aortic smooth muscle cell is independent of platelet-derived growth factor. We also could not observe any platelet-derived growth factor isoforms in the cultured medium of factor Xa-stimulated cells. Our finding that the cultured medium of factor Xa-stimulated cells strongly induces rat aortic smooth muscle cell mitogenesis in the absence of factor Xa activity led us to explore the existence of a novel autocrine pathway. The autocrine growth factor was purified from the cultured medium and was identified to be epiregulin. Recombinant epiregulin was also able to induce the mitogenesis. The secretion of epiregulin from factor Xa-stimulated rat aortic smooth muscle cell required mRNA expression and protein synthesis of the growth factor. The mitogenic effect of factor Xa on rat aortic smooth muscle cell was significantly reduced by anti-epiregulin antibody or by antisense oligodeoxynucleotide to epiregulin. Several lines of experimental evidence clearly indicate that the autocrine production of epiregulin, an epidermal growth factor-related ligand, is induced in the factor Xa-stimulated mitogenic process of rat aortic smooth muscle cell.	Yonsei Univ, Coll Sci, Dept Biochem, Seoul 120749, South Korea	Yonsei University	Kim, DS (corresponding author), Yonsei Univ, Coll Sci, Dept Biochem, Seoul 120749, South Korea.	dskim@yonsei.ac.kr						Bachhuber BG, 1997, J VASC RES, V34, P41, DOI 10.1159/000159200; BARSHAVIT R, 1990, CELL REGUL, V1, P453, DOI 10.1091/mbc.1.6.453; BARSHAVIT R, 1992, AM J RESP CELL MOL, V6, P123, DOI 10.1165/ajrcmb/6.2.123; Blanc-Brude OP, 2001, AM J PHYSIOL-CELL PH, V281, pC681, DOI 10.1152/ajpcell.2001.281.2.C681; Bono F, 2000, ARTERIOSCL THROM VAS, V20, pE107, DOI 10.1161/01.ATV.20.11.e107; Bono F, 1997, J CELL PHYSIOL, V172, P36, DOI 10.1002/(SICI)1097-4652(199707)172:1<36::AID-JCP4>3.0.CO;2-E; Bretschneider E, 2000, THROMB HAEMOSTASIS, V84, P499; Camerer E, 2000, P NATL ACAD SCI USA, V97, P5255, DOI 10.1073/pnas.97.10.5255; Carmeliet P, 1998, INT J BIOCHEM CELL B, V30, P661, DOI 10.1016/S1357-2725(97)00121-0; CHAMLEYCAMPBELL J, 1979, PHYSIOL REV, V59, P1, DOI 10.1152/physrev.1979.59.1.1; CHOHISY DR, 1990, J BIOL CHEM, V265, P7729; Draper BK, 2003, J CELL BIOCHEM, V89, P1126, DOI 10.1002/jcb.10584; GASIC GP, 1992, P NATL ACAD SCI USA, V89, P2317, DOI 10.1073/pnas.89.6.2317; HERBERT JM, 1992, FEBS LETT, V301, P155, DOI 10.1016/0014-5793(92)81237-G; Herbert JM, 1998, J CLIN INVEST, V101, P993, DOI 10.1172/JCI1833; Igura T, 1996, ARTERIOSCL THROM VAS, V16, P1524, DOI 10.1161/01.ATV.16.12.1524; INOUE S, 1993, ARTERIOSCLER THROMB, V13, P1859, DOI 10.1161/01.ATV.13.12.1859; Jiang B, 1996, SURGERY, V120, P427, DOI 10.1016/S0039-6060(96)80319-9; KAHAN C, 1992, J BIOL CHEM, V267, P13369; Kamath L, 2001, CANCER RES, V61, P5933; Ko FN, 1996, J CLIN INVEST, V98, P1493, DOI 10.1172/JCI118938; Komurasaki T, 1997, ONCOGENE, V15, P2841, DOI 10.1038/sj.onc.1201458; Koo BH, 2002, FEBS LETT, V523, P85, DOI 10.1016/S0014-5793(02)02948-4; KOVALENKO M, 1994, CANCER RES, V54, P6106; Li ZH, 1995, EXP MOL PATHOL, V63, P77, DOI 10.1006/exmp.1995.1032; LUSCHER TF, 1994, CORONARY ARTERY GRAF, P42; MAJESKY MW, 1991, J CLIN INVEST, V88, P904, DOI 10.1172/JCI115393; MARMUR JD, 1993, J CLIN INVEST, V91, P2253, DOI 10.1172/JCI116452; MCNAMARA CA, 1993, J CLIN INVEST, V91, P94, DOI 10.1172/JCI116206; NAKANO T, 1993, J BIOL CHEM, V268, P22941; NALDINI A, 1993, CELL IMMUNOL, V147, P367, DOI 10.1006/cimm.1993.1076; Papapetropoulos A, 1998, P NATL ACAD SCI USA, V95, P4738, DOI 10.1073/pnas.95.8.4738; Riewald M, 2001, BLOOD, V97, P3109, DOI 10.1182/blood.V97.10.3109; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Senden NHM, 1998, J IMMUNOL, V161, P4318; Shelly M, 1998, J BIOL CHEM, V273, P10496, DOI 10.1074/jbc.273.17.10496; Shirakata Y, 2000, J BIOL CHEM, V275, P5748, DOI 10.1074/jbc.275.8.5748; STOUFFER GA, 1993, AM J PHYSIOL, V265, pC806, DOI 10.1152/ajpcell.1993.265.3.C806; Taylor DS, 1999, P NATL ACAD SCI USA, V96, P1633, DOI 10.1073/pnas.96.4.1633; Toyoda H, 1995, FEBS LETT, V377, P403, DOI 10.1016/0014-5793(95)01403-9; TOYODA H, 1995, J BIOL CHEM, V270, P7495, DOI 10.1074/jbc.270.13.7495; WEISS RH, 1993, J BIOL CHEM, V268, P5724; Zhu ZW, 2000, BIOCHEM BIOPH RES CO, V273, P1019, DOI 10.1006/bbrc.2000.3033	44	22	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52578	52586		10.1074/jbc.M310007200	http://dx.doi.org/10.1074/jbc.M310007200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14570897	hybrid			2022-12-27	WOS:000187480700076
J	Lo, RKH; Cheung, H; Wong, YH				Lo, RKH; Cheung, H; Wong, YH			Constitutively active G alpha(16) stimulates STAT3 via a c-Src/JAK- and ERK-dependent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR SMOOTH-MUSCLE; PROTEIN-COUPLED RECEPTORS; EPIDERMAL-GROWTH-FACTOR; GTPASE-DEFICIENT G-ALPHA(16); SRC TYROSINE KINASE; N-TERMINAL KINASE; SERINE PHOSPHORYLATION; ALPHA-SUBUNIT; MEDIATED ACTIVATION; SIGNALING PATHWAY	The hematopoietic-specific Galpha(16) protein has recently been shown to mediate receptor-induced activation of the signal transducer and activator of transcription 3 (STAT3). In the present study, we have delineated the mechanism by which Galpha(16) stimulates STAT3 in human embryonic kidney 293 cells. A constitutively active Galpha(16) mutant, Galpha(16)QL, stimulated STAT3-dependent luciferase activity as well as the phosphorylation of STAT3 at both Tyr(705) and Ser(727). Galpha(16)QL-induced STAT3 activation was enhanced by overexpression of extracellular signal-regulated kinase 1 (ERK1), but was inhibited by U0126, a Raf-1 inhibitor, and coexpression of the dominant negative mutants of Ras and Rac1. Inhibition of phospholipase Cbeta, protein kinase C, and calmodulin-dependent kinase II by their respective inhibitors also suppressed Galpha(16)QL-induced STAT3 activation. The involvement of tyrosine kinases such as c-Src and Janus kinase 2 and 3 (JAK2 and JAK3) in Galpha(16)QL-induced activation of STAT3 was illustrated by the combined use of selective inhibitors and dominant negative mutants. In contrast, c-Jun N-terminal kinase, p38 MAPK, RhoA, Cdc42, phosphatidylinositol 3-kinase, and the epidermal growth factor receptor did not appear to be required. Similar observations were obtained with human erythroleukemia cells, where STAT3 phosphorylation was stimulated by C5a in a PTX-insensitive manner. Collectively, these results highlight the important regulatory roles of the Ras/Raf/MEK/ERK and c-Src/JAK pathways on the stimulation of STAT3 by activated Galpha(16). Demonstration of the involvement of different kinases in Galpha(16)QL-induced STAT3 activation supports the involvement of multiple signaling pathways in the regulation of transcription by G proteins.	Hong Kong Univ Sci & Technol, Dept Biochem, Kowloon, Hong Kong, Peoples R China; Hong Kong Univ Sci & Technol, Mol Neurosci Ctr, Kowloon, Hong Kong, Peoples R China; Hong Kong Univ Sci & Technol, Biotechnol Res Inst, Kowloon, Hong Kong, Peoples R China	Hong Kong University of Science & Technology; Hong Kong University of Science & Technology; Hong Kong University of Science & Technology	Wong, YH (corresponding author), Hong Kong Univ Sci & Technol, Dept Biochem, Clear Water Bay, Kowloon, Hong Kong, Peoples R China.			Wong, Yung Hou/0000-0002-0123-7697				Abe J, 1999, J BIOL CHEM, V274, P21003, DOI 10.1074/jbc.274.30.21003; AKITA Y, 1990, BIOCHEM BIOPH RES CO, V172, P184, DOI 10.1016/S0006-291X(05)80191-3; Akita Y, 2002, J BIOCHEM, V132, P847, DOI 10.1093/oxfordjournals.jbchem.a003296; AMATRUDA TT, 1991, P NATL ACAD SCI USA, V88, P5587, DOI 10.1073/pnas.88.13.5587; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Buggy JJ, 1998, BIOCHEM J, V331, P211, DOI 10.1042/bj3310211; Buitrago CG, 2003, J BIOL CHEM, V278, P2199, DOI 10.1074/jbc.M205732200; Cao XM, 1996, MOL CELL BIOL, V16, P1595; Chan ASL, 2002, CELL SIGNAL, V14, P249, DOI 10.1016/S0898-6568(01)00240-6; Choe ES, 2001, NEUROSCI LETT, V313, P129, DOI 10.1016/S0304-3940(01)02258-3; Chung JK, 1997, MOL CELL BIOL, V17, P6508, DOI 10.1128/MCB.17.11.6508; Cirri P, 1997, BIOCHEM BIOPH RES CO, V239, P493, DOI 10.1006/bbrc.1997.7493; Corre I, 1999, ONCOGENE, V18, P6335, DOI 10.1038/sj.onc.1203010; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; GASQUE P, 1995, J IMMUNOL, V155, P4882; Ginnan R, 2002, AM J PHYSIOL-CELL PH, V282, pC754, DOI 10.1152/ajpcell.00335.2001; Heasley LE, 1996, MOL CELL BIOL, V16, P648; Ho MKC, 1999, J NEUROCHEM, V73, P2101; Kam AYF, 2003, J NEUROCHEM, V84, P503, DOI 10.1046/j.1471-4159.2003.01535.x; Kraus S, 2001, ARCH MED RES, V32, P499, DOI 10.1016/S0188-4409(01)00331-9; Liang HY, 1999, J BIOL CHEM, V274, P19846, DOI 10.1074/jbc.274.28.19846; Lim CP, 1999, J BIOL CHEM, V274, P31055, DOI 10.1074/jbc.274.43.31055; Lim CP, 2001, J BIOL CHEM, V276, P21004, DOI 10.1074/jbc.M007592200; Lippert E, 1997, FEBS LETT, V417, P292, DOI 10.1016/S0014-5793(97)01308-2; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; Lowes VL, 2002, NEUROSIGNALS, V11, P5, DOI 10.1159/000057317; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; Ma YC, 2000, CELL, V102, P635, DOI 10.1016/S0092-8674(00)00086-6; Marrero MB, 1997, J BIOL CHEM, V272, P24684, DOI 10.1074/jbc.272.39.24684; Marty C, 2003, MOL CELL BIOL, V23, P3847, DOI 10.1128/MCB.23.11.3847-3858.2003; Mody SM, 2000, MOL PHARMACOL, V57, P13; OFFERMANNS S, 1995, J BIOL CHEM, V270, P15175, DOI 10.1074/jbc.270.25.15175; PACE AM, 1991, P NATL ACAD SCI USA, V88, P7031, DOI 10.1073/pnas.88.16.7031; Pelletier S, 2003, MOL CELL BIOL, V23, P1316, DOI 10.1128/MCB.23.4.1316-1333.2003; Piiper A, 2003, J BIOL CHEM, V278, P7065, DOI 10.1074/jbc.M211234200; QIAN NX, 1994, J BIOL CHEM, V269, P17417; Ram PT, 2000, SCIENCE, V287, P142, DOI 10.1126/science.287.5450.142; Ram PT, 2001, ONCOGENE, V20, P1601, DOI 10.1038/sj.onc.1204186; Sasaguri T, 2000, BIOCHEM BIOPH RES CO, V268, P25, DOI 10.1006/bbrc.1999.2066; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; Shah BH, 2003, J BIOL CHEM, V278, P2866, DOI 10.1074/jbc.m208783200; Simon AR, 2000, SCIENCE, V290, P144, DOI 10.1126/science.290.5489.144; Turkson J, 1999, MOL CELL BIOL, V19, P7519; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; Vila-Coro AJ, 1999, FASEB J, V13, P1699, DOI 10.1096/fasebj.13.13.1699; Ward AC, 2000, BLOOD, V95, P19; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Woo CH, 2002, J BIOL CHEM, V277, P8572, DOI 10.1074/jbc.M104766200; Wu EHT, 2003, BIOCHEM BIOPH RES CO, V303, P920, DOI 10.1016/S0006-291X(03)00451-0; Yang CM, 2003, J BIOMED SCI, V10, P208, DOI 10.1159/000068713; Yang M, 2001, J IMMUNOL, V166, P6885, DOI 10.4049/jimmunol.166.11.6885; Zhang Y, 2000, J BIOL CHEM, V275, P24935, DOI 10.1074/jbc.M002383200; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	56	83	86	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52154	52165		10.1074/jbc.M307299200	http://dx.doi.org/10.1074/jbc.M307299200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14551213	hybrid			2022-12-27	WOS:000187480700023
J	Nicholas, RA; Krings, S; Tomberg, J; Nicola, G; Davies, C				Nicholas, RA; Krings, S; Tomberg, J; Nicola, G; Davies, C			Crystal structure of wild-type penicillin-binding protein 5 from Escherichia coli - Implications for deacylation of the acyl-enzyme complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PENICILLIN-BINDING PROTEIN-5; D-ALANINE CARBOXYPEPTIDASE; SITE-DIRECTED MUTAGENESIS; BETA-LACTAMASE; SPECIFICITY; MECHANISM; MUTANT; PURIFICATION; INHIBITOR; PROGRAM	Penicillin-binding protein 5 (PBP 5) of Escherichia coli functions as a D-alanine carboxypeptidase (CPase), cleaving D-alanine from the C terminus of cell wall peptides. Like all PBPs, PBP 5 forms a covalent acyl-enzyme complex with beta-lactam antibiotics; however, PBP 5 is distinguished by its high rate of deacylation of the acyl-enzyme complex (t(1/2) approximate to 10 min). A Gly(105) --> Asp mutation in PBP 5 markedly impairs deacylation with only minor effects on acylation, and abolishes CPase activity. We have determined the three-dimensional structure of a soluble form of wild-type PBP 5 at 1.85-Angstrom resolution and have also refined the structure of the G105D mutant form of PBP 5 to 1.9-Angstrom resolution. Comparison of the two structures reveals that the major effect of the mutation is to disorder a loop comprising residues 74-90 that sits atop the SXN motif of the active site. Deletion of the 74-90 loop in wild-type PBP 5 markedly diminished the deacylation rate of penicillin G with a minimal impact on acylation, and abolished CPase activity. These effects were very similar to those observed in the G105D mutant, reinforcing the idea that this mutation causes disordering of the 74-90 loop. Mutation of two consecutive serines within this loop, which hydrogen bond to Ser(110) and Asn(112) in the SXN motif, had marked effects on CPase activity, but not beta-lactam antibiotic binding or hydrolysis. These data suggest a direct role for the SXN motif in deacylation of the acyl-enzyme complex and imply that the functioning of this motif is modulated by the 74-90 loop.	Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA; Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA	University of North Carolina; University of North Carolina Chapel Hill; Medical University of South Carolina	Nicholas, RA (corresponding author), Univ N Carolina, Dept Pharmacol, CB 7365 Mary Ellen Jones Bldg, Chapel Hill, NC 27599 USA.	nicholas@med.unc.edu; davies@musc.edu			NIAID NIH HHS [AI36901] Funding Source: Medline; NIGMS NIH HHS [R01 GM066861, GM66861] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI036901] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM066861] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADACHI H, 1991, J BIOL CHEM, V266, P3186; AMANUMA H, 1980, J BIOL CHEM, V255, P1173; AMANUMA H, 1984, J BIOL CHEM, V259, P1294; [Anonymous], 1992, CHEM B LACTAMS; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BEGG KJ, 1995, J BACTERIOL, V177, P6211, DOI 10.1128/jb.177.21.6211-6222.1995; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; Davies C, 2001, J BIOL CHEM, V276, P616, DOI 10.1074/jbc.M004471200; Dubus A, 1996, PROTEINS, V25, P473, DOI 10.1002/prot.7; GHUYSEN JM, 1991, ANNU REV MICROBIOL, V45, P37, DOI 10.1146/annurev.mi.45.100191.000345; Guillaume G, 1997, J BIOL CHEM, V272, P5438, DOI 10.1074/jbc.272.9.5438; Gutheil WG, 1998, ANAL BIOCHEM, V259, P62, DOI 10.1006/abio.1998.2642; Gutheil WG, 2000, ANAL BIOCHEM, V287, P196, DOI 10.1006/abio.2000.4835; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JORIS B, 1988, BIOCHEM J, V250, P313, DOI 10.1042/bj2500313; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lewis ER, 1997, P NATL ACAD SCI USA, V94, P443, DOI 10.1073/pnas.94.2.443; MALHOTRA KT, 1992, J BIOL CHEM, V267, P11386; MATSUHASHI M, 1978, P NATL ACAD SCI USA, V75, P2631, DOI 10.1073/pnas.75.6.2631; MATSUHASHI M, 1979, J BACTERIOL, V137, P644, DOI 10.1128/JB.137.1.644-647.1979; McDonough MA, 2002, J MOL BIOL, V322, P111, DOI 10.1016/S0022-2836(02)00742-8; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Nelson DE, 2000, J BACTERIOL, V182, P1714, DOI 10.1128/JB.182.6.1714-1721.2000; NICHOLAS RA, 1988, J BIOL CHEM, V263, P2034; OEFNER C, 1990, NATURE, V343, P284, DOI 10.1038/343284a0; Pflugrath JW, 1999, ACTA CRYSTALLOGR D, V55, P1718, DOI 10.1107/S090744499900935X; Silvaggi NR, 2003, BIOCHEMISTRY-US, V42, P1199, DOI 10.1021/bi0268955; SMITH JB, 1984, FEBS LETT, V165, P185, DOI 10.1016/0014-5793(84)80166-0; Stefanova ME, 2002, BBA-PROTEIN STRUCT M, V1597, P292, DOI 10.1016/S0167-4838(02)00311-4; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TIPPER DJ, 1965, P NATL ACAD SCI USA, V54, P1133, DOI 10.1073/pnas.54.4.1133; WAXMAN DJ, 1980, J BIOL CHEM, V255, P3964; WISE EM, 1965, P NATL ACAD SCI USA, V54, P75, DOI 10.1073/pnas.54.1.75	37	77	78	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52826	52833		10.1074/jbc.M310177200	http://dx.doi.org/10.1074/jbc.M310177200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14555648	hybrid			2022-12-27	WOS:000187480700102
J	Peters, H; Nefedov, M; Sarsero, J; Pitt, J; Fowler, KJ; Gazeas, S; Kahler, SG; Ioannou, PA				Peters, H; Nefedov, M; Sarsero, J; Pitt, J; Fowler, KJ; Gazeas, S; Kahler, SG; Ioannou, PA			A knock-out mouse model for methylmalonic aciduria resulting in neonatal lethality	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROPIONYL-COA CARBOXYLASE; TANDEM MASS-SPECTROMETRY; INBORN-ERRORS; METABOLISM; ACIDEMIA; TRANSPLANTATION; HYPERGLYCINEMIA; ACIDOSIS; MUTASE; LOCUS	Methylmalonic aciduria is a human autosomal recessive disorder of organic acid metabolism resulting from a functional defect in the activity of the enzyme methylmalonyl-CoA mutase. Based upon the homology of the human mutase locus with the mouse locus, we have chosen to disrupt the mouse mutase locus within the critical CoA binding domain using gene-targeting techniques to create a mouse model of methylmalonic aciduria. The phenotype of homozygous knock-out mice (mut(-/-)) is one of early neonatal lethality. Mice appear phenotypically normal at birth and are indistinguishable from littermates. By 15 h of age, they develop reduced movement and suckle less. This is followed by the development of abnormal breathing, and all of the mice with a null phenotype die by 24 h of age. Urinary levels of methylmalonic and methylcitric acids are grossly increased. Measurement of acylcarnitines in blood shows elevation of propionylcarnitine with no change in the levels of acetylcarnitine and free carnitine. Incorporation of [C-14] propionate in primary fibroblast cultures from mut(-/-) mice is reduced to approximately 6% of normal level, whereas there is no detectable synthesis of mut mRNA in the liver. This is the first mouse model that recapitulates the key phenotypic features of mut(0) methylmalonic aciduria.	Royal Childrens Hosp, Murdoch Childrens Res Inst, CAGT Res Grp, Parkville, Vic 3052, Australia; Univ Melbourne, Royal Childrens Hosp, Dept Pediat, Melbourne, Vic, Australia	Murdoch Children's Research Institute; Royal Children's Hospital Melbourne; Royal Children's Hospital Melbourne; University of Melbourne	Ioannou, PA (corresponding author), Royal Childrens Hosp, Murdoch Childrens Res Inst, CAGT Res Grp, Flemington Rd, Parkville, Vic 3052, Australia.		peters, heidi/GWD-0358-2022	Peters, Heidi/0000-0001-7189-5874				Bradley A, 1987, TERATOCARCINOMAS EMB, P113; Chace DH, 2001, CLIN CHEM, V47, P2040; Chakrapani A, 2002, J PEDIATR-US, V140, P261, DOI 10.1067/mpd.2002.121698; CHILDS B, 1961, PEDIATRICS, V27, P522; GLASGOW AM, 1976, PEDIATR RES, V10, P683, DOI 10.1203/00006450-197610070-00010; Kolvraa S, 1980, J Inherit Metab Dis, V3, P63, DOI 10.1007/BF02312526; Kushnir MM, 2000, J CHROMATOGR B, V741, P231, DOI 10.1016/S0378-4347(00)00079-7; LEDLEY FD, 1988, AM J HUM GENET, V42, P839; Leonard JV, 2001, J INHERIT METAB DIS, V24, P309, DOI 10.1023/A:1010395724012; MATSUI SM, 1983, NEW ENGL J MED, V308, P857, DOI 10.1056/NEJM198304143081501; Miyazaki T, 2001, J BIOL CHEM, V276, P35995, DOI 10.1074/jbc.M105467200; NHAM SU, 1990, GENOMICS, V44, P33; OBERHOLZ.VG, 1967, ARCH DIS CHILD, V42, P492, DOI 10.1136/adc.42.225.492; Rashed MS, 1997, CLIN CHEM, V43, P1129; STOKKE O, 1967, SCAND J CLIN LAB INV, V20, P313, DOI 10.3109/00365516709076961; Vadolas J, 2002, BLOOD, V100, P4209, DOI 10.1182/blood-2001-12-0365; WADLINGTON WB, 1975, J PEDIATR-US, V86, P707, DOI 10.1016/S0022-3476(75)80354-4; WALTER JH, 1989, EUR J PEDIATR, V148, P344, DOI 10.1007/BF00444131; WENDEL U, 1991, PEDIATR RES, V29, P403, DOI 10.1203/00006450-199104000-00015; Wilcken B, 2003, NEW ENGL J MED, V348, P2304, DOI 10.1056/NEJMoa025225; WILKEMEYER MF, 1990, BIOCHEM J, V271, P449, DOI 10.1042/bj2710449; WILLARD HF, 1976, HUM GENET, V34, P277, DOI 10.1007/BF00295291	22	52	54	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52909	52913		10.1074/jbc.M310533200	http://dx.doi.org/10.1074/jbc.M310533200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14555645	hybrid			2022-12-27	WOS:000187480700112
J	Tu, YP; Nayak, SK; Woodson, J; Ross, EM				Tu, YP; Nayak, SK; Woodson, J; Ross, EM			Phosphorylation-regulated inhibition of the G(z) GTPase-activating protein activity of RGS proteins by synapsin I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE-STRING PROTEIN; HETEROTRIMERIC G-PROTEINS; SIGNALING RGS; SITES; ASSOCIATION; G-ALPHA(Z); KINASES; DOMAINS; BINDING; SWITCH	Synapsins are neuronal proteins that bind and cluster synaptic vesicles in the presynaptic space, presumably by anchoring to actin filaments, but specific regulatory functions of the synapsins are unknown. We found that a sub-population of brain synapsin Ia, a splice variant of one of three synapsin isoforms, inhibits the GTPase-activating protein (GAP) activity of several RGS proteins. Inhibition is highly selective for Galpha(z), a member of the G(i) family that is found in neurons, platelets, adrenal chromaffin cells, and a few other neurosecretory cells. G(z) has been indirectly implicated in the regulation of secretion. Synapsin Ia constitutes a major fraction of the total GAP-inhibitory activity in brain, and its inhibitory activity is absent from the brains of synapsin I-/-/II-/- mice. Inhibition depends on the cationic D/E domain of synapsin. Phosphorylation of synapsin Ia at serine 9 by either cyclic AMP-dependent protein kinase or p21-activated protein kinase (PAK1) attenuates its potency as a GAP inhibitor more than 7-fold. Synapsin can thus act as a phosphorylation-modulated mediator of feedback regulation of G(z) signaling by the synaptic machinery.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Ross, EM (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	ross@utsw.swmed.edu			NIGMS NIH HHS [GM30355] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030355, R01GM030355] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ammer H, 2002, J NEUROCHEM, V83, P818, DOI 10.1046/j.1471-4159.2002.01188.x; BAHLER M, 1987, NATURE, V326, P704, DOI 10.1038/326704a0; Barker SA, 2001, GENOMICS, V78, P223, DOI 10.1006/geno.2001.6659; BERSTEIN G, 1992, CELL, V70, P411, DOI 10.1016/0092-8674(92)90165-9; Buchner E, 1997, TRENDS NEUROSCI, V20, P223, DOI 10.1016/S0166-2236(96)10082-5; CASEY PJ, 1990, J BIOL CHEM, V265, P2383; Chamberlain LH, 1998, BIOCHEM J, V335, P205, DOI 10.1042/bj3350205; Chi P, 2003, NEURON, V38, P69, DOI 10.1016/S0896-6273(03)00151-X; Cole RN, 1999, J NEUROCHEM, V73, P418, DOI 10.1046/j.1471-4159.1999.0730418.x; CZERNIK AJ, 1987, P NATL ACAD SCI USA, V84, P7518, DOI 10.1073/pnas.84.21.7518; Dan I, 2001, TRENDS CELL BIOL, V11, P220, DOI 10.1016/S0962-8924(01)01980-8; De Vries L, 2000, ANNU REV PHARMACOL, V40, P235, DOI 10.1146/annurev.pharmtox.40.1.235; Esser L, 1998, EMBO J, V17, P977, DOI 10.1093/emboj/17.4.977; Fan XM, 2000, J BIOL CHEM, V275, P32129, DOI 10.1074/jbc.M004577200; Ferreira A, 2002, CELL MOL LIFE SCI, V59, P589, DOI 10.1007/s00018-002-8451-5; Fields TA, 1997, BIOCHEM J, V321, P561, DOI 10.1042/bj3210561; Hendry IA, 2000, BRAIN RES, V870, P10, DOI 10.1016/S0006-8993(00)02387-8; Hilfiker S, 1999, PHILOS T ROY SOC B, V354, P269, DOI 10.1098/rstb.1999.0378; HINTON DR, 1990, J NEUROSCI, V10, P2763; Ho MKC, 2001, ONCOGENE, V20, P1615, DOI 10.1038/sj.onc.1204190; Hollinger S, 2002, PHARMACOL REV, V54, P527, DOI 10.1124/pr.54.3.527; Hosaka M, 1999, J BIOL CHEM, V274, P16747, DOI 10.1074/jbc.274.24.16747; Hosaka M, 1999, NEURON, V24, P377, DOI 10.1016/S0896-6273(00)80851-X; Jovanovic JN, 2001, J NEUROSCI, V21, P7944, DOI 10.1523/JNEUROSCI.21-20-07944.2001; Kao HT, 2002, NAT NEUROSCI, V5, P431, DOI 10.1038/nn840; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI L, 1995, P NATL ACAD SCI USA, V92, P9235, DOI 10.1073/pnas.92.20.9235; Magga JM, 2000, NEURON, V28, P195, DOI 10.1016/S0896-6273(00)00096-9; Meng JW, 2002, J BIOL CHEM, V277, P43417, DOI 10.1074/jbc.M204074200; Meng JW, 1999, J BIOL CHEM, V274, P36663, DOI 10.1074/jbc.274.51.36663; PIERIBONE VA, 1995, NATURE, V375, P493, DOI 10.1038/375493a0; ROSAHL TW, 1995, NATURE, V375, P488, DOI 10.1038/375488a0; ROSAHL TW, 1993, CELL, V75, P661, DOI 10.1016/0092-8674(93)90487-B; Ross EM, 2000, ANNU REV BIOCHEM, V69, P795, DOI 10.1146/annurev.biochem.69.1.795; Ross EM, 1999, CRC METH SIG TRANS, P123; Ryan TA, 1996, J CELL BIOL, V134, P1219, DOI 10.1083/jcb.134.5.1219; Sakurada K, 2002, J BIOL CHEM, V277, P45473, DOI 10.1074/jbc.M206673200; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; Serres F, 2000, J NEUROSCI, V20, P3095, DOI 10.1523/JNEUROSCI.20-09-03095.2000; SUDHOF TC, 1989, SCIENCE, V245, P1474, DOI 10.1126/science.2506642; Tu YP, 2001, J BIOL CHEM, V276, P20160, DOI 10.1074/jbc.M101599200; Wang J, 1997, J BIOL CHEM, V272, P5732, DOI 10.1074/jbc.272.9.5732; Wang J, 1999, J BIOL CHEM, V274, P31641, DOI 10.1074/jbc.274.44.31641; Wang J, 1998, J BIOL CHEM, V273, P26014, DOI 10.1074/jbc.273.40.26014; Yang J, 2000, P NATL ACAD SCI USA, V97, P9984, DOI 10.1073/pnas.180194597	45	14	15	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52273	52281		10.1074/jbc.M309626200	http://dx.doi.org/10.1074/jbc.M309626200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14557263	hybrid			2022-12-27	WOS:000187480700036
J	Yin, MJ; Shao, LH; Voehringer, D; Smeal, T; Jallal, B				Yin, MJ; Shao, LH; Voehringer, D; Smeal, T; Jallal, B			The serine/threonine kinase Nek6 is required for cell cycle progression through mitosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NIMA PROTEIN-KINASE; ASPERGILLUS-NIDULANS; VERTEBRATE CELLS; MAMMALIAN-CELLS; CANCER CELLS; PHOSPHORYLATION; REGULATOR; FAMILY; TAXOL; SPECIFICITY	The Aspergillus nidulans protein NIMA ((n) under bar ever (i) under barn (m) under bar itosis, gene (A) under bar) is a protein kinase required for the initiation of mitosis, whereas its inactivation is necessary for mitotic exit. Here, we demonstrate that human NIMA-related kinase 6 (Nek6) is required for mitotic progression of human cells. Nek6 is phosphorylated and activated during M phase. Inhibition of Nek6 function by either overexpression of an inactive Nek6 mutant or elimination of endogenous Nek6 by siRNA arrests cells in M phase and triggers apoptosis. Time-lapse recording of the cell cycle progression of cells expressing kinase-inactive Nek6 reveals mitotic arrest at the metaphase stage prior to cells entering apoptosis. In contrast to NIMA and the closely related mammalian Nek2 kinase, which regulate centrosome function and separation, our data demonstrate an important function for Nek6 during mitosis and suggest that Nek6 kinase is required for metaphase-anaphase transition.	SUGEN Inc, San Francisco, CA 94080 USA	Pfizer	Yin, MJ (corresponding author), 10724 Sci Ctr Dr, San Diego, CA 92121 USA.							Abrieu A, 2001, CELL, V106, P83, DOI 10.1016/S0092-8674(01)00410-X; Belham C, 2001, CURR BIOL, V11, P1155, DOI 10.1016/S0960-9822(01)00369-4; Blagosklonny MV, 1997, CANCER RES, V57, P130; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fry AM, 1998, EMBO J, V17, P470, DOI 10.1093/emboj/17.2.470; Guadagno TM, 1996, CELL, V84, P73, DOI 10.1016/S0092-8674(00)80994-0; Haldar S, 1996, CANCER RES, V56, P1253; Holland PM, 2002, J BIOL CHEM, V277, P16229, DOI 10.1074/jbc.M108662200; Hoyt MA, 2001, J CELL BIOL, V154, P909, DOI 10.1083/jcb.200108010; Kanda T, 1998, CURR BIOL, V8, P377, DOI 10.1016/S0960-9822(98)70156-3; LANDAU NR, 1992, J VIROL, V66, P5110, DOI 10.1128/JVI.66.8.5110-5113.1992; Lee S, 2002, CANCER RES, V62, P5703; LETWIN K, 1992, EMBO J, V11, P3521, DOI 10.1002/j.1460-2075.1992.tb05435.x; Lizcano JM, 2002, J BIOL CHEM, V277, P27839, DOI 10.1074/jbc.M202042200; Lu K P, 1995, Prog Cell Cycle Res, V1, P187; LU KP, 1995, CELL, V81, P413, DOI 10.1016/0092-8674(95)90394-1; Musacchio A, 2002, NAT REV MOL CELL BIO, V3, P731, DOI 10.1038/nrm929; OCONNELL MJ, 1994, EMBO J, V13, P4926, DOI 10.1002/j.1460-2075.1994.tb06820.x; OSMANI AH, 1991, CELL, V67, P283, DOI 10.1016/0092-8674(91)90180-7; OSMANI SA, 1987, J CELL BIOL, V104, P1495, DOI 10.1083/jcb.104.6.1495; PU RT, 1995, EMBO J, V14, P995, DOI 10.1002/j.1460-2075.1995.tb07080.x; Roig J, 2002, GENE DEV, V16, P1640, DOI 10.1101/gad.972202; ROWINSKY EK, 1995, NEW ENGL J MED, V332, P1004, DOI 10.1056/NEJM199504133321507; Upadhya P, 2000, P NATL ACAD SCI USA, V97, P217, DOI 10.1073/pnas.97.1.217; YE XS, 1995, EMBO J, V14, P986, DOI 10.1002/j.1460-2075.1995.tb07079.x	26	80	88	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52454	52460		10.1074/jbc.M308080200	http://dx.doi.org/10.1074/jbc.M308080200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14563848	hybrid			2022-12-27	WOS:000187480700059
J	Lin, HK; Hu, YC; Yang, L; Altuwaijri, S; Chen, YT; Kang, HY; Chang, CS				Lin, HK; Hu, YC; Yang, L; Altuwaijri, S; Chen, YT; Kang, HY; Chang, CS			Suppression versus induction of androgen receptor functions by the phosphatidylinositol 3-kinase/Akt pathway in prostate cancer LNCaP cells with different passage numbers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH; APOPTOSIS; SURVIVAL; LIGASE; MDM2; PHOSPHORYLATION; PROGRESSION; P53; E3	The phosphatidylinositol 3- kinase ( PI3K)/ Akt pathway controls several important biological functions, such as cell growth regulation, apoptosis, and migration. However, the way in which PI3K/ Akt controls androgen receptor ( AR)- mediated prostate cancer cell growth remains unclear and controversial. Here, we demonstrate that the PI3K/ Akt pathway regulates AR activity in a cell passage number- dependent manner. Specifically, PI3K/ Akt pathway can suppress AR activity in androgen- dependent LNCaP cells with low passage numbers. In contrast, it can also enhance AR activity in LNCaP cells with high passage numbers. Furthermore, we also demonstrate that insulin- like growth factor- 1 can activate the PI3K/ Akt pathway that results in the phosphorylation of AR at Ser(210) and Ser(790). The consequence of these events may then change the stability of AR protein. Together, our results demonstrate that the PI3K/ Akt pathway may have distinct mechanisms to modulate AR functions in various stages of prostate cancer cells and that a combined therapy of antiandrogens and anti- PI3K/ Akt inhibitors may be worth considering as a future therapeutic approach to battle prostate cancer.	Univ Rochester, Med Ctr, Dept Pathol, George Whipple Lab Canc Res, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Dept Urol, George Whipple Lab Canc Res, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Dept Radiat Oncol, George Whipple Lab Canc Res, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Ctr Canc, Rochester, NY 14642 USA; Chang Gung Univ, Ctr Menopause & Reprod Med Res, Kaohsiung 833, Taiwan	University of Rochester; University of Rochester; University of Rochester; University of Rochester; Chang Gung University	Chang, CS (corresponding author), Univ Rochester, Med Ctr, Dept Pathol, George Whipple Lab Canc Res, Rochester, NY 14642 USA.		Hu, Yueh-Chiang/AAX-2370-2020; Kang, Hong-Yo/W-9031-2019	Kang, Hong-Yo/0000-0003-0626-5037; Hu, Yueh-Chiang/0000-0002-7992-0525; Chang, Chawnshang/0000-0001-8510-3516	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060905] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK60905] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Carson JP, 1999, CANCER RES, V59, P1449; Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Gioeli D, 2002, J BIOL CHEM, V277, P29304, DOI 10.1074/jbc.M204131200; Graff JR, 2000, J BIOL CHEM, V275, P24500, DOI 10.1074/jbc.M003145200; Heinlein CA, 2002, ENDOCR REV, V23, P175, DOI 10.1210/er.23.2.175; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Hu YC, 2002, J BIOL CHEM, V277, P33571, DOI 10.1074/jbc.M203531200; Li PF, 2001, J BIOL CHEM, V276, P20444, DOI 10.1074/jbc.M010226200; Lin HK, 2002, EMBO J, V21, P4037, DOI 10.1093/emboj/cdf406; Lin HK, 2001, P NATL ACAD SCI USA, V98, P7200, DOI 10.1073/pnas.121173298; Murillo H, 2001, ENDOCRINOLOGY, V142, P4795, DOI 10.1210/en.142.11.4795; Poukka H, 2000, J CELL SCI, V113, P2991; Sheflin L, 2000, BIOCHEM BIOPH RES CO, V276, P144, DOI 10.1006/bbrc.2000.3424; THOMPSON J, 2002, END SOC 84 ANN M SAN, P526; Wen Y, 2000, CANCER RES, V60, P6841; Yeh SY, 2000, P NATL ACAD SCI USA, V97, P11256, DOI 10.1073/pnas.190353897	18	151	156	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					50902	50907		10.1074/jbc.M300676200	http://dx.doi.org/10.1074/jbc.M300676200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14555644	hybrid			2022-12-27	WOS:000187206300010
J	Newberry, EP; Xie, Y; Kennedy, S; Han, XL; Buhman, KK; Luo, JY; Gross, RW; Davidson, NO				Newberry, EP; Xie, Y; Kennedy, S; Han, XL; Buhman, KK; Luo, JY; Gross, RW; Davidson, NO			Decreased hepatic triglyceride accumulation and altered fatty acid uptake in mice with deletion of the liver fatty acid-binding protein gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BIOLOGICAL SAMPLES; TRANSPORT PROTEIN; MASS-SPECTROMETRY; LIPID EXTRACTS; PPAR-ALPHA; EXPRESSION; CHOLESTEROL; OXIDATION; METABOLISM; MECHANISMS	Liver fatty acid-binding protein (L-Fabp) is an abundant cytosolic lipid-binding protein with broad substrate specificity, expressed in mammalian enterocytes and hepatocytes. We have generated mice with a targeted deletion of the endogenous L-Fabp gene and have characterized their response to alterations in hepatic fatty acid flux following prolonged fasting. Chow-fed L-Fabp(-/-) mice were indistinguishable from wild-type littermates with regard to growth, serum and tissue lipid profiles, and fatty acid distribution within hepatic complex lipid species. In response to 48-h fasting, however, wild-type mice demonstrated a similar to 10-fold increase in hepatic triglyceride content while L-Fabp(-/-) mice demonstrated only a 2-fold increase. Hepatic VLDL secretion was decreased in L-Fabp(-/-) mice suggesting that the decreased accumulation of hepatic triglyceride was not the result of increased secretion. Fatty acid oxidation, as inferred from serum beta-hydroxybutyrate levels, was increased in response to fasting, although the increase in L-Fabp(-/-) mice was significantly reduced in comparison to wild-type controls, despite comparable induction of PPARalpha target genes. Studies in primary hepatocytes revealed indistinguishable initial rates of oleate uptake, but longer intervals revealed reduced rates of uptake in fasted L-Fabp(-/-) mice. Oleate incorporation into cellular triglyceride and diacylglycerol was reduced in L-Fabp(-/-) mice although incorporation into phospholipid and cholesterol ester was no different than wild-type controls. These data point to an inducible defect in fatty acid utilization in fasted L-Fabp(-/-) mice that involves targeting of substrate for use in triglyceride metabolism.	Washington Univ, Sch Med, Dept Internal Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Davidson, NO (corresponding author), Washington Univ, Sch Med, Dept Internal Med, St Louis, MO 63110 USA.		Buhman, Kimberly/AAV-3111-2021	Buhman, Kimberly/0000-0002-3784-1028	NHLBI NIH HHS [P01 HL-57278, HL-38180] Funding Source: Medline; NIDDK NIH HHS [DK-P30-56341, DK-P30-52574, DK-56260] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038180, R37HL038180, P01HL057278] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056260, P30DK056341, P30DK052574] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CARR TP, 1993, CLIN BIOCHEM, V26, P39, DOI 10.1016/0009-9120(93)90015-X; DIETRICH A, 1995, J LIPID RES, V36, P1745; Fuchs M, 2001, J BIOL CHEM, V276, P48058, DOI 10.1074/jbc.M106732200; GORDON JI, 1985, J BIOL CHEM, V260, P1995; Han XL, 2001, ANAL BIOCHEM, V295, P88, DOI 10.1006/abio.2001.5178; Han XL, 2003, J LIPID RES, V44, P1071, DOI 10.1194/jlr.R300004-JLR200; Hashimoto T, 2000, J BIOL CHEM, V275, P28918, DOI 10.1074/jbc.M910350199; HAUNERLAND N, 1984, H-S Z PHYSIOL CHEM, V365, P365, DOI 10.1515/bchm2.1984.365.1.365; Hertzel AV, 2000, TRENDS ENDOCRIN MET, V11, P175; Lawrence JW, 2000, J LIPID RES, V41, P1390; Le May C, 2000, FEBS LETT, V475, P163, DOI 10.1016/S0014-5793(00)01648-3; Leone TC, 1999, P NATL ACAD SCI USA, V96, P7473, DOI 10.1073/pnas.96.13.7473; Linden D, 2002, J BIOL CHEM, V277, P23044, DOI 10.1074/jbc.M110416200; Martin GG, 2003, J BIOL CHEM, V278, P21429, DOI 10.1074/jbc.M300287200; Maugeais C, 2000, J LIPID RES, V41, P1673; NEMECZ G, 1991, ARCH BIOCHEM BIOPHYS, V286, P300, DOI 10.1016/0003-9861(91)90044-J; NEMECZ G, 1991, J BIOL CHEM, V266, P17180; Norris AW, 2002, J LIPID RES, V43, P646; SCHAFFER JE, 1994, CELL, V79, P427, DOI 10.1016/0092-8674(94)90252-6; Seedorf U, 1998, GENE DEV, V12, P1189, DOI 10.1101/gad.12.8.1189; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; Stahl A, 1999, MOL CELL, V4, P299, DOI 10.1016/S1097-2765(00)80332-9; Storch J, 2002, MOL CELL BIOCHEM, V239, P25, DOI 10.1023/A:1020546321508; Storch J, 2000, BBA-MOL CELL BIOL L, V1486, P28, DOI 10.1016/S1388-1981(00)00046-9; Thompson J, 1997, J BIOL CHEM, V272, P7140, DOI 10.1074/jbc.272.11.7140; Thumser AEA, 2000, J LIPID RES, V41, P647; VANDENBERGHE G, 1991, J INHERIT METAB DIS, V14, P407, DOI 10.1007/BF01797914; Vassileva G, 2000, FASEB J, V14, P2040, DOI 10.1096/fj.99-0959com; Wolfrum C, 1999, BBA-MOL CELL BIOL L, V1437, P194, DOI 10.1016/S1388-1981(99)00008-6; Wolfrum C, 1999, J LIPID RES, V40, P708; Wolfrum C, 2001, P NATL ACAD SCI USA, V98, P2323, DOI 10.1073/pnas.051619898	31	221	237	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51664	51672		10.1074/jbc.M309377200	http://dx.doi.org/10.1074/jbc.M309377200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14534295	hybrid			2022-12-27	WOS:000187206300101
J	Pickett, JS; Bowers, KE; Fierke, CA				Pickett, JS; Bowers, KE; Fierke, CA			Mutagenesis studies of protein farnesyltransferase implicate aspartate beta 352 as a magnesium ligand	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-LEVEL EXPRESSION; CRYSTAL-STRUCTURE; ISOPRENOID BIOSYNTHESIS; ANGSTROM RESOLUTION; SUBSTRATE-BINDING; GERANYLGERANYLTRANSFERASE; ENZYME; YEAST; TRANSFERASE; SUBUNIT	Protein farnesyltransferase (FTase) catalyzes the addition of a farnesyl chain onto the sulfur of a C-terminal cysteine of a protein substrate. Magnesium ions enhance farnesylation catalyzed by FTase by several hundredfold, with a K-Mg value of 4 mM. The magnesium ion is proposed to coordinate the diphosphate leaving group of farnesyldiphosphate (FPP) to stabilize the developing charge in the farnesylation transition state. Here we further investigate the magnesium binding site using mutagenesis and biochemical studies. Free FPP binds Mg2+ with a K-d of 120 muM. The 10-fold weaker affinity for Mg2+ observed for the FTase.FPP.peptide ternary complex is probably caused by the positive charges in the diphosphate binding pocket of FTase. Furthermore, mutation of aspartate beta352 to alanine (Dbeta352A) or lysine (Dbeta352K) in FTase drastically alters the Mg2+ dependence of FTase catalysis without dramatically affecting the rate constant of farnesylation minus magnesium or the binding affinity of either substrate. In Dbeta352A FTase, the K-Mg increases 28-fold to 110 +/- 30 mM, and the farnesylation rate constant at saturating Mg2+ decreases 27-fold to 0.30 +/- 0.05 s(-1). Substitution of a lysine for Asp-beta352 removes the magnesium activation of farnesylation catalyzed by FTase but does not significantly enhance the rate constant for farnesylation in the absence of Mg2+. In wild type FTase, Mg2+ can be replaced by Mn2+ with a 2-fold lower K-Mn (2 mM). These results suggest both that Mg2+ coordinates the side chain carboxylate of Asp-beta352 and that the role of magnesium in the reaction includes positioning the FPP prior to catalysis.	Univ Michigan, Dept Chem, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Fierke, CA (corresponding author), 930 N Univ Ave, Ann Arbor, MI 48109 USA.				NATIONAL CANCER INSTITUTE [F32CA084757] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040602, R29GM040602] Funding Source: NIH RePORTER; NCI NIH HHS [F32 CA84757] Funding Source: Medline; NIGMS NIH HHS [GM40602, GM08597] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLACK CB, 1994, COORDIN CHEM REV, V135, P165, DOI 10.1016/0010-8545(94)80068-5; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; Cowan J. A., 1995, P1; Cowan JA, 2002, BIOMETALS, V15, P225, DOI 10.1023/A:1016022730880; Cox AD, 2001, DRUGS, V61, P723, DOI 10.2165/00003495-200161060-00002; Dai Q, 1998, J BIOL CHEM, V273, P15030, DOI 10.1074/jbc.273.24.15030; DAWSON RMC, 1986, DATA BIOCH RES, P414; DOLENCE JM, 1995, P NATL ACAD SCI USA, V92, P5008, DOI 10.1073/pnas.92.11.5008; Dolence JM, 1997, BIOCHEMISTRY-US, V36, P9246, DOI 10.1021/bi970039p; Dunten P, 1998, BIOCHEMISTRY-US, V37, P7907, DOI 10.1021/bi980531o; Figueroa C, 2001, J BIOL CHEM, V276, P28219, DOI 10.1074/jbc.M101763200; FINEGOLD AA, 1991, P NATL ACAD SCI USA, V88, P4448, DOI 10.1073/pnas.88.10.4448; FURFINE ES, 1995, BIOCHEMISTRY-US, V34, P6857, DOI 10.1021/bi00020a032; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; Hightower KE, 1998, BIOCHEMISTRY-US, V37, P15555, DOI 10.1021/bi981525v; Huang CC, 2000, BIOCHEMISTRY-US, V39, P2593, DOI 10.1021/bi992356x; Huang CC, 1997, J BIOL CHEM, V272, P20; Kemp LE, 2002, P NATL ACAD SCI USA, V99, P6591, DOI 10.1073/pnas.102679799; Legler PM, 2002, BIOCHEMISTRY-US, V41, P10834, DOI 10.1021/bi020362e; Lesburg CA, 1997, SCIENCE, V277, P1820, DOI 10.1126/science.277.5333.1820; Long SB, 2000, STRUCTURE, V8, P209, DOI 10.1016/S0969-2126(00)00096-4; Long SB, 1998, BIOCHEMISTRY-US, V37, P9612, DOI 10.1021/bi980708e; Long SB, 2002, NATURE, V419, P645, DOI 10.1038/nature00986; Long SB, 2001, P NATL ACAD SCI USA, V98, P12948, DOI 10.1073/pnas.241407898; MOOMAW JF, 1992, J BIOL CHEM, V267, P17438; Otto JC, 1999, J BIOL CHEM, V274, P8379, DOI 10.1074/jbc.274.13.8379; Park HW, 1997, SCIENCE, V275, P1800, DOI 10.1126/science.275.5307.1800; Pickett JS, 2003, BIOCHEMISTRY-US, V42, P9741, DOI 10.1021/bi0346852; POPOVYCH O, 1960, SPECTROCHIM ACTA, V16, P49, DOI 10.1016/0371-1951(60)80070-7; REISS Y, 1992, J BIOL CHEM, V267, P6403; Rellick LM, 1997, BIOPOLYMERS, V42, P191, DOI 10.1002/(SICI)1097-0282(199708)42:2<191::AID-BIP8>3.0.CO;2-I; RIDDLES PW, 1979, ANAL BIOCHEM, V94, P75, DOI 10.1016/0003-2697(79)90792-9; Rozema DB, 1999, BIOCHEMISTRY-US, V38, P13138, DOI 10.1021/bi990794y; Saderholm MJ, 2000, BIOCHEMISTRY-US, V39, P12398, DOI 10.1021/bi0011781; SCHAFER WR, 1989, SCIENCE, V245, P379, DOI 10.1126/science.2569235; SEABRA MC, 1991, CELL, V65, P429, DOI 10.1016/0092-8674(91)90460-G; SEABRA MC, 1992, J BIOL CHEM, V267, P14497; Sebti SM, 2001, CANC DRUG DISC DEV, V8, P197; SOROKA K, 1987, ANAL CHEM, V59, P629, DOI 10.1021/ac00131a019; Starks CM, 1997, SCIENCE, V277, P1815, DOI 10.1126/science.277.5333.1815; Strickland CL, 1998, BIOCHEMISTRY-US, V37, P16601, DOI 10.1021/bi981197z; Tamanoi F, 2001, CELL MOL LIFE SCI, V58, P1636, DOI 10.1007/PL00000802; Tesmer JJG, 1999, SCIENCE, V285, P756, DOI 10.1126/science.285.5428.756; Wendt KU, 1998, STRUCTURE, V6, P127, DOI 10.1016/S0969-2126(98)00015-X; Witter DJ, 1996, BIOCHEMISTRY-US, V35, P10454, DOI 10.1021/bi960500y; Wu Z, 1999, PROTEIN ENG, V12, P341, DOI 10.1093/protein/12.4.341; YOKOYAMA K, 1991, P NATL ACAD SCI USA, V88, P5302, DOI 10.1073/pnas.88.12.5302; YOKOYAMA K, 1993, J BIOL CHEM, V268, P4055; Zhang FL, 1996, BIOCHEM J, V320, P925, DOI 10.1042/bj3200925; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325; Zimmerman KK, 1998, PROTEIN EXPRES PURIF, V14, P395, DOI 10.1006/prep.1998.0979	51	35	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51243	51250		10.1074/jbc.M309226200	http://dx.doi.org/10.1074/jbc.M309226200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14532266	hybrid			2022-12-27	WOS:000187206300050
J	Wang, RW; Zhang, L; Bolstad, J; Diao, N; Brown, C; Ruest, L; Welch, W; Williams, AJ; Chen, SRW				Wang, RW; Zhang, L; Bolstad, J; Diao, N; Brown, C; Ruest, L; Welch, W; Williams, AJ; Chen, SRW			Residue Gln(4863) within a predicted transmembrane sequence of the Ca2+ release channel (ryanodine receptor) is critical for ryanodine interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE SARCOPLASMIC-RETICULUM; PORE-FORMING SEGMENT; CENTRAL CORE DISEASE; SKELETAL-MUSCLE; MALIGNANT HYPERTHERMIA; H-3 RYANODINE; CA2+-RELEASE CHANNEL; PROVIDES INSIGHTS; FUNCTIONAL-STATE; CARDIAC-MUSCLE	Despite the pivotal role of ryanodine in ryanodine receptor (RyR) research, the molecular basis of ryanodine-RyR interaction remains largely undefined. We investigated the role of the proposed transmembrane helix TM10 in ryanodine interaction and channel function. Each amino acid residue within the TM10 sequence, (4844)IIFDITFFFFVIVILLAIIQGLII(4867), of the mouse RyR2 was mutated to either alanine or glycine. Mutants were expressed in human embryonic kidney 293 cells, and their properties were assessed. Mutations D4847A, F4850A, F4851A, L4858A, L4859A, and I4866A severely curtailed the release of intracellular Ca2+ in human embryonic kidney 293 cells in response to extracellular caffeine and diminished [H-3] ryanodine binding to cell lysates. Mutations F4846A, T4849A, I4855A, V4856A, and Q4863A eliminated or markedly reduced [H-3] ryanodine binding, but cells expressing these mutants responded to extracellular caffeine by releasing stored Ca2+. Interestingly these two groups of mutants, each with similar properties, are largely located on opposite sides of the predicted TM10 helix. Single channel analyses revealed that mutation Q4863A dramatically altered the kinetics and apparent affinity of ryanodine interaction with single RyR2 channels and abolished the effect of ryanodol, an analogue of ryanodine, whereas the single channel conductance of the Q4863A mutant and its responses to caffeine, ATP, and Mg2+ were comparable to those of the wild type channels. Furthermore the effect of ryanodine on single Q4863A mutant channels was influenced by the transmembrane holding potential. Together these results suggest that the TM10 sequence and in particular the Q4863 residue constitute an important determinant of ryanodine interaction.	Univ Calgary, Dept Physiol & Biophys, Cardiovasc Res Grp, Calgary, AB T2N 4N1, Canada; Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada; Univ Sherbrooke, Dept Chem, Sherbrooke, PQ J1K 2R1, Canada; Univ Nevada, Sch Med, Dept Biochem, Reno, NV 89557 USA; Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London SW3 6LY, England	University of Calgary; University of Calgary; University of Sherbrooke; Nevada System of Higher Education (NSHE); University of Nevada Reno; Imperial College London	Chen, SRW (corresponding author), Univ Calgary, Dept Physiol & Biophys, Cardiovasc Res Grp, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.			Williams, Alan/0000-0002-3770-8761				Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Bhat MB, 1997, BIOPHYS J, V73, P1329, DOI 10.1016/S0006-3495(97)78166-9; CALLAWAY C, 1994, J BIOL CHEM, V269, P15876; Chen SRW, 2002, BIOPHYS J, V82, P2436, DOI 10.1016/S0006-3495(02)75587-2; CHU A, 1990, MOL PHARMACOL, V37, P735; CORONADO R, 1994, AM J PHYSIOL, V266, pC1485, DOI 10.1152/ajpcell.1994.266.6.C1485; Dirksen RT, 2002, TRENDS CARDIOVAS MED, V12, P189, DOI 10.1016/S1050-1738(02)00163-9; Du GG, 1998, J BIOL CHEM, V273, P33259, DOI 10.1074/jbc.273.50.33259; Du GG, 2001, J BIOL CHEM, V276, P31760, DOI 10.1074/jbc.M102751200; Fill M, 2002, PHYSIOL REV, V82, P893, DOI 10.1152/physrev.00013.2002; FranziniArmstrong C, 1997, PHYSIOL REV, V77, P699, DOI 10.1152/physrev.1997.77.3.699; Gao L, 2000, BIOPHYS J, V79, P828, DOI 10.1016/S0006-3495(00)76339-9; HAWKES MJ, 1992, J BIOL CHEM, V267, P6702; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOLMBERG SRM, 1990, BIOCHIM BIOPHYS ACTA, V1022, P187, DOI 10.1016/0005-2736(90)90113-3; Li P, 2001, J GEN PHYSIOL, V118, P33, DOI 10.1085/jgp.118.1.33; Loke J, 1998, AM J MED, V104, P470, DOI 10.1016/S0002-9343(98)00108-9; Marks AR, 2002, J CELL PHYSIOL, V190, P1, DOI 10.1002/jcp.10031; Masumiya H, 2001, J BIOL CHEM, V276, P39727, DOI 10.1074/jbc.M106557200; Masumiya H, 2003, J BIOL CHEM, V278, P3786, DOI 10.1074/jbc.M210962200; MCGREW SG, 1989, BIOCHEMISTRY-US, V28, P1686, DOI 10.1021/bi00430a039; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; Mickelson JR, 1996, PHYSIOL REV, V76, P537, DOI 10.1152/physrev.1996.76.2.537; OGAWA Y, 1994, CRIT REV BIOCHEM MOL, V29, P229, DOI 10.3109/10409239409083482; Orlova EV, 1996, NAT STRUCT BIOL, V3, P547, DOI 10.1038/nsb0696-547; PESSAH IN, 1991, MOL PHARMACOL, V39, P679; Sambrook J., 2002, MOL CLONING LAB MANU; Scoote M, 2002, CARDIOVASC RES, V56, P359, DOI 10.1016/S0008-6363(02)00574-6; Sutko JL, 1997, PHARMACOL REV, V49, P53; Tanna B, 1998, J GEN PHYSIOL, V112, P55, DOI 10.1085/jgp.112.1.55; Tanna B, 2000, J GEN PHYSIOL, V116, P1, DOI 10.1085/jgp.116.1.1; Tanna B, 2003, J GEN PHYSIOL, V121, P551, DOI 10.1085/jgp.200208753; Tinker A, 1996, BIOPHYS J, V70, P2110, DOI 10.1016/S0006-3495(96)79777-1; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Wang RW, 2003, BIOPHYS J, V84, p427A; Williams AJ, 2001, Q REV BIOPHYS, V34, P61, DOI 10.1017/S0033583501003675; WITCHER DR, 1994, J BIOL CHEM, V269, P13076; Zhao MC, 1999, J BIOL CHEM, V274, P25971, DOI 10.1074/jbc.274.37.25971; ZORZATO F, 1990, J BIOL CHEM, V265, P2244	39	36	37	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51557	51565		10.1074/jbc.M306788200	http://dx.doi.org/10.1074/jbc.M306788200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14557272	hybrid			2022-12-27	WOS:000187206300088
J	Kozjak, V; Wiedemann, N; Milenkovic, D; Lohaus, C; Meyer, HE; Guiard, B; Meisinger, C; Pfanner, N				Kozjak, V; Wiedemann, N; Milenkovic, D; Lohaus, C; Meyer, HE; Guiard, B; Meisinger, C; Pfanner, N			An essential role of Sam50 in the protein sorting and assembly machinery of the mitochondrial outer membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMPORT CHANNEL; TOM COMPLEX; PREPROTEIN TRANSLOCASE; BIOGENESIS; PORE; COMPONENT; RECEPTORS; BETA; ORIGIN	The preprotein translocase of the outer mitochondrial membrane ( TOM complex) contains one essential subunit, the channel Tom40. The assembly pathway of the precursor of Tom40 involves the TOM complex and the sorting and assembly machinery (SAM complex) with the non-essential subunit Mas37. We have identified Sam50, the second essential protein of the mitochondrial outer membrane. Sam50 contains a beta-barrel domain conserved from bacteria to man and is a subunit of the SAM complex. Yeast mutants of Sam50 are defective in the assembly pathways of Tom40 and the abundant outer membrane protein porin, while the import of matrix proteins is not affected. Thus the protein sorting and assembly machinery of the mitochondrial outer membrane involves an essential, conserved protein.	Univ Freiburg, Inst Biochem & Mol Biol, D-79104 Freiburg, Germany; Univ Freiburg, Fak Biol, D-79104 Freiburg, Germany; Ruhr Univ Bochum, Med Proteom Ctr, D-44780 Bochum, Germany; Univ Paris 06, Ctr Genet Mol, CNRS, Lab Propre, F-91190 Gif Sur Yvette, France	University of Freiburg; University of Freiburg; Ruhr University Bochum; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Saclay	Pfanner, N (corresponding author), Univ Freiburg, Inst Biochem & Mol Biol, Hermann Herder Str 7, D-79104 Freiburg, Germany.	Nikolaus.Pfanner@biochemie.uni-freiburg.de	Meisinger, Chris/J-1110-2014; Pfanner, Nikolaus/AAV-7878-2021; Kozjak-Pavlovic, Vera/E-1494-2013	Meisinger, Chris/0000-0002-8326-3548; Kozjak-Pavlovic, Vera/0000-0001-9658-7018; Wiedemann, Nils/0000-0001-8305-6728				Ahting U, 2001, J CELL BIOL, V153, P1151, DOI 10.1083/jcb.153.6.1151; BAKER KP, 1990, NATURE, V348, P605, DOI 10.1038/348605a0; BlachlyDyson E, 1997, MOL CELL BIOL, V17, P5727, DOI 10.1128/MCB.17.10.5727; Bolter B, 1998, P NATL ACAD SCI USA, V95, P15831, DOI 10.1073/pnas.95.26.15831; Endo T, 2003, J CELL SCI, V116, P3259, DOI 10.1242/jcs.00667; Gabriel K, 2003, EMBO J, V22, P2380, DOI 10.1093/emboj/cdg229; Gabriel K, 2001, TRENDS BIOCHEM SCI, V26, P36, DOI 10.1016/S0968-0004(00)01684-4; Geissler A, 2002, CELL, V111, P507, DOI 10.1016/S0092-8674(02)01073-5; Genevrois S, 2003, EMBO J, V22, P1780, DOI 10.1093/emboj/cdg174; GRATZER S, 1995, J CELL BIOL, V129, P25, DOI 10.1083/jcb.129.1.25; Herrmann JM, 2000, CURR OPIN MICROBIOL, V3, P210, DOI 10.1016/S1369-5274(00)00077-1; Hill K, 1998, NATURE, V395, P516, DOI 10.1038/26780; Jensen RE, 2001, NAT STRUCT BIOL, V8, P1008, DOI 10.1038/nsb1201-1008; Kaur H, 2003, PROTEIN SCI, V12, P627, DOI 10.1110/ps.0228903; KEIL P, 1993, J BIOL CHEM, V268, P19177; Knop M, 1999, YEAST, V15, P963, DOI 10.1002/(SICI)1097-0061(199907)15:10B<963::AID-YEA399>3.0.CO;2-W; Koehler CM, 2000, FEBS LETT, V476, P27, DOI 10.1016/S0014-5793(00)01664-1; Krimmer T, 2001, J CELL BIOL, V152, P289, DOI 10.1083/jcb.152.2.289; Mannella CA, 1996, J BIOENERG BIOMEMBR, V28, P163, DOI 10.1007/BF02110647; Matouschek A, 2001, NAT STRUCT BIOL, V8, P284, DOI 10.1038/86140; Meisinger C, 2001, MOL CELL BIOL, V21, P2337, DOI 10.1128/MCB.21.7.2337-2348.2001; Mihara K, 2003, NATURE, V424, P505, DOI 10.1038/424505a; Model K, 2001, NAT STRUCT BIOL, V8, P361, DOI 10.1038/86253; Rapaport D, 1999, J CELL BIOL, V146, P321, DOI 10.1083/jcb.146.2.321; Rapaport D, 2002, TRENDS BIOCHEM SCI, V27, P191, DOI 10.1016/S0968-0004(02)02065-0; Rapaport D, 2001, MOL BIOL CELL, V12, P1189, DOI 10.1091/mbc.12.5.1189; Reumann S, 1999, P NATL ACAD SCI USA, V96, P784, DOI 10.1073/pnas.96.2.784; Suzuki H, 2000, J BIOL CHEM, V275, P37930, DOI 10.1074/jbc.M006558200; Taylor RD, 2003, J BIOL CHEM, V278, P765, DOI 10.1074/jbc.M208083200; Truscott KN, 2003, CURR BIOL, V13, pR326, DOI 10.1016/S0960-9822(03)00239-2; Truscott KN, 2002, MOL CELL BIOL, V22, P7780, DOI 10.1128/MCB.22.22.7780-7789.2002; van Wilpe S, 1999, NATURE, V401, P485, DOI 10.1038/46802; Voulhoux R, 2003, SCIENCE, V299, P262, DOI 10.1126/science.1078973; Wiedemann N, 2003, NATURE, V424, P565, DOI 10.1038/nature01753	34	256	262	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					48520	48523		10.1074/jbc.C300442200	http://dx.doi.org/10.1074/jbc.C300442200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	14570913	hybrid			2022-12-27	WOS:000186829000002
J	Harrod, AC; Yang, XF; Junker, M; Reitzer, L				Harrod, AC; Yang, XF; Junker, M; Reitzer, L			Evidence for a second interaction between the regulatory amino-terminal and central output domains of the response regulator NtrC (nitrogen regulator I) in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENHANCER-BINDING-PROTEIN; TRANSCRIPTIONAL ACTIVATION; RECEIVER DOMAIN; RNA-POLYMERASE; DNA-BINDING; CORRELATION SPECTROSCOPY; SALMONELLA-TYPHIMURIUM; SIGNAL-TRANSDUCTION; MOLECULAR MACHINE; ENTERIC BACTERIA	Nitrogen limitation in Escherichia coli activates about 100 genes. Their expression requires the response regulator NtrC ( also called nitrogen regulator I or NRI). Phosphorylation of the amino-terminal domain (NTD) of NtrC activates the neighboring central domain and leads to transcriptional activation from promoters that require sigma(54)-containing RNA polymerase. The NTD has five beta strands alternating with five alpha helices. Phosphorylation of aspartate 54 has been shown to reposition alpha helix 3 to beta strand 5 (the "3445 face") within the NTD. To further study the interactions between the amino-terminal and central domains, we isolated strains with alterations in the NTD that were able to grow on a poor nitrogen source in the absence of phosphorylation by the cognate sensor kinase. We identified strains with alterations located in the 3445 face and alpha helix 5. Both types of alterations stimulated central domain activities. The alpha helix 5 alterations differed from those in the 3445 face. They did not cause a large scale conformational change in the NTD, which is not necessary for transcriptional activation in these mutants. Yeast two-hybrid analysis indicated that substitutions in both alpha helix 5 and the 3445 face diminish the interaction between the NTD and the central domain. Our results suggest that alpha helix 5 of the NTD, in addition to the 3445 face, interacts with the central domain. We present a model of interdomain signal transduction that proposes different functions for alpha helix 5 and the 3445 face.	Univ Texas, Dept Mol & Cell Biol, Richardson, TX 75083 USA	University of Texas System; University of Texas Dallas	Reitzer, L (corresponding author), Univ Texas, Dept Mol & Cell Biol, POB 830688, Richardson, TX 75083 USA.	reitzer@utdallas.edu	Yang, X. Frank/F-3266-2010; Reitzer, Larry/A-2510-2016	Reitzer, Larry/0000-0002-4406-6090; Harrod, Albert/0000-0002-5035-5286	NIGMS NIH HHS [GM47965] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047965] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allen MP, 2001, J BACTERIOL, V183, P2204, DOI 10.1128/JB.183.7.2204-2211.2001; Atkinson MR, 2002, J BACTERIOL, V184, P5358, DOI 10.1128/JB.184.19.5358-5363.2002; AUSTIN S, 1992, EMBO J, V11, P2219, DOI 10.1002/j.1460-2075.1992.tb05281.x; Buckler DR, 2002, STRUCTURE, V10, P153, DOI 10.1016/S0969-2126(01)00706-7; CHEN P, 1995, J BACTERIOL, V177, P2490, DOI 10.1128/jb.177.9.2490-2496.1995; Djordjevic S, 1998, J STRUCT BIOL, V124, P189, DOI 10.1006/jsbi.1998.4034; Djordjevic S, 1998, P NATL ACAD SCI USA, V95, P1381, DOI 10.1073/pnas.95.4.1381; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FLASHNER Y, 1995, J MOL BIOL, V249, P700, DOI 10.1006/jmbi.1995.0330; GU BH, 1994, MOL MICROBIOL, V13, P51, DOI 10.1111/j.1365-2958.1994.tb00401.x; HANNIG EM, 1988, MOL CELL BIOL, V8, P4808, DOI 10.1128/MCB.8.11.4808; HUALA E, 1992, J BACTERIOL, V174, P1428, DOI 10.1128/jb.174.4.1428-1431.1992; HUNT TP, 1985, P NATL ACAD SCI USA, V82, P8453, DOI 10.1073/pnas.82.24.8453; Hwang I, 1999, P NATL ACAD SCI USA, V96, P4880, DOI 10.1073/pnas.96.9.4880; Ikeda TP, 1996, J MOL BIOL, V259, P589, DOI 10.1006/jmbi.1996.0342; KEENER J, 1988, P NATL ACAD SCI USA, V85, P4976, DOI 10.1073/pnas.85.14.4976; Kern D, 1999, NATURE, V402, P894, DOI 10.1038/47273; Kiupakis AK, 2002, J BACTERIOL, V184, P2940, DOI 10.1128/JB.184.11.2940-2950.2002; KLOSE KE, 1993, J MOL BIOL, V232, P67, DOI 10.1006/jmbi.1993.1370; KLOSE KE, 1994, J MOL BIOL, V241, P233, DOI 10.1006/jmbi.1994.1492; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lee JH, 2000, J BACTERIOL, V182, P5188, DOI 10.1128/JB.182.18.5188-5195.2000; Leung DW, 1989, TECHNIQUE, V1, P11; LOWRY OH, 1972, FLEXIBLE SYSTEM ENZY, P147; Lu CD, 1999, J BACTERIOL, V181, P1934, DOI 10.1128/JB.181.6.1934-1938.1999; LUKAT GS, 1992, P NATL ACAD SCI USA, V89, P718, DOI 10.1073/pnas.89.2.718; Magasanik B., 1996, ESCHERICHIA COLI SAL, P1344; Miller J. H, 1972, EXPT MOL GENETICS; MOORE JB, 1993, J BACTERIOL, V175, P2692, DOI 10.1128/JB.175.9.2692-2701.1993; MORETT E, 1993, J BACTERIOL, V175, P6067, DOI 10.1128/JB.175.19.6067-6074.1993; NINFA AJ, 1987, CELL, V50, P1039, DOI 10.1016/0092-8674(87)90170-X; NINFA AJ, 1986, P NATL ACAD SCI USA, V83, P5909, DOI 10.1073/pnas.83.16.5909; Ninfa AJ, 1995, 2 COMPONENT SIGNAL T, P67; Nohaile M, 1997, J MOL BIOL, V273, P299, DOI 10.1006/jmbi.1997.1296; POPHAM DL, 1989, SCIENCE, V243, P629, DOI 10.1126/science.2563595; PORTER SC, 1993, GENE DEV, V7, P2258, DOI 10.1101/gad.7.11.2258; Porter SC, 1995, 2 COMPONENT SIGNAL T, P147; Reitzer L, 2001, MICROBIOL MOL BIOL R, V65, P422, DOI 10.1128/MMBR.65.3.422-444.2001; Reitzer L.J., 1996, ESCHERICHIA COLI SAL, P391; REITZER LJ, 1989, J BACTERIOL, V171, P5512, DOI 10.1128/jb.171.10.5512-5522.1989; REITZER LJ, 1986, CELL, V45, P785, DOI 10.1016/0092-8674(86)90553-2; Rippe K, 2000, BIOCHEMISTRY-US, V39, P2131, DOI 10.1021/bi9922190; Rippe K, 1998, J MOL BIOL, V278, P915, DOI 10.1006/jmbi.1998.1746; Rippe K, 1997, J MOL BIOL, V270, P125, DOI 10.1006/jmbi.1997.1079; Rombel I, 1998, COLD SPRING HARB SYM, V63, P157, DOI 10.1101/sqb.1998.63.157; ROTHSTEIN DM, 1980, P NATL ACAD SCI-BIOL, V77, P7372, DOI 10.1073/pnas.77.12.7372; SANDERS DA, 1992, J BACTERIOL, V174, P5117, DOI 10.1128/JB.174.15.5117-5122.1992; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SCHNEIDER BL, 1991, J BACTERIOL, V173, P6355, DOI 10.1128/jb.173.20.6355-6363.1991; Sevenich FW, 1998, NUCLEIC ACIDS RES, V26, P1373, DOI 10.1093/nar/26.6.1373; SHIAU SP, 1993, J BACTERIOL, V175, P190, DOI 10.1128/JB.175.1.190-199.1993; Shukla D, 1998, J BIOL CHEM, V273, P23993, DOI 10.1074/jbc.273.37.23993; Stock AM, 2000, ANNU REV BIOCHEM, V69, P183, DOI 10.1146/annurev.biochem.69.1.183; STOCK AM, 1993, BIOCHEMISTRY-US, V32, P13375, DOI 10.1021/bi00212a001; Volkman BF, 2001, SCIENCE, V291, P2429, DOI 10.1126/science.291.5512.2429; VOLKMAN BF, 1995, BIOCHEMISTRY-US, V34, P1413, DOI 10.1021/bi00004a036; WEDEL A, 1990, SCIENCE, V248, P486, DOI 10.1126/science.1970441; WEDEL A, 1995, GENE DEV, V9, P2042, DOI 10.1101/gad.9.16.2042; WEISS DS, 1991, CELL, V67, P155, DOI 10.1016/0092-8674(91)90579-N; WEISS V, 1992, P NATL ACAD SCI USA, V89, P5088, DOI 10.1073/pnas.89.11.5088; WEISS V, 1988, P NATL ACAD SCI USA, V85, P8919, DOI 10.1073/pnas.85.23.8919; Wyman C, 1997, SCIENCE, V275, P1658, DOI 10.1126/science.275.5306.1658; Yan D, 1999, P NATL ACAD SCI USA, V96, P14789, DOI 10.1073/pnas.96.26.14789; ZHANG OW, 1994, J BIOMOL NMR, V4, P845, DOI 10.1007/BF00398413; Zimmer DP, 2000, P NATL ACAD SCI USA, V97, P14674, DOI 10.1073/pnas.97.26.14674	65	5	5	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	2004	279	4					2350	2359		10.1074/jbc.M306181200	http://dx.doi.org/10.1074/jbc.M306181200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	764MU	14563853	hybrid			2022-12-27	WOS:000188211300005
J	Davidson, L; Pawson, AJ; Millar, RP; Maudsley, S				Davidson, L; Pawson, AJ; Millar, RP; Maudsley, S			Cytoskeletal reorganization dependence of signaling by the gonadotropin-releasing hormone receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; PROTEIN-COUPLED RECEPTORS; TYROSINE PHOSPHORYLATION; MAP KINASE; INTEGRIN ENGAGEMENT; MEDIATED ACTIVATION; TRANSFORMED-CELLS; GROWTH-FACTOR; C-SRC; TRANSDUCTION	Activation of classical G protein-coupled receptors (GPCRs) like the mammalian gonadotropin-releasing hormone receptor (GnRHR) typically stimulates heterotrimeric G protein molecules that subsequently activate downstream effectors. Receptor activation of heterotrimeric G protein pathways primarily controls intermediary cell metabolism by elevation or diminution of soluble cytoplasmic second messenger molecules. We have demonstrated here that stimulation of the GnRHR also results in a dramatic change in both cell adhesion and superstructural morphology. Gonadotropin-releasing hormone ( GnRH) receptor activation rapidly increases the capacity of HEK293 cells expressing the GnRHR to remain matrix-adherent in the face of fluid insults. Coinciding with this profound elevation in matrix adherence, we demonstrated a GnRH-induced alteration in both cell morphology and the de novo generation of polymerized actin structures. GnRH induction of cytoskeletal remodeling was correlated with significant increases in the tyrosine phosphorylation status of a series of cytoskeletal associated proteins, e. g. focal adhesion kinase (FAK), c-Src, and microtubule-associated protein kinase ( MAPK or ERK1/2). The activation of the distal downstream effector ERK1/2 was demonstrated to be sensitive to the disrupters of cytoskeletal rearrangement, cytochalasin D and latrunculin B. In addition to the sensitivity of ERKs to cytoskeletal integrity, GnRH-induced FAK and c-Src kinase activation were sensitive to these agents and the fibronectin-integrin antagonistic RGDS peptide. Activation of ERK was dependent on its protein-protein assembly with FAK and c-Src at focal adhesion complexes. Induction of the cell remodeling event leading to this signaling complex assembly occurred primarily via GnRHR activation of the monomeric G protein Rac but not RhoA. These findings demonstrated a clear divergence of GnRHR signaling via the Rac monomeric G protein focal adhesion signaling complex assembly and cytoskeletal remodeling independent of the classical heterotrimeric G protein-controlled phospholipase C-beta pathway.	Royal Edinburgh Infirm, MRC, Human Reprod Sci Unit, Edinburgh EH16 4SB, Midlothian, Scotland	Royal Infirmary of Edinburgh	Maudsley, S (corresponding author), Royal Edinburgh Infirm, MRC, Human Reprod Sci Unit, Univ Edinburgh Chancellors Bldg,49 Little France, Edinburgh EH16 4SB, Midlothian, Scotland.	s.maudsley@hrsu.mrc.ac.uk	Maudsley, Stuart/Q-4782-2019; Millar, Robert P/A-4853-2012; Maudsley, Stuart/AAV-9929-2021; Pawson, Adam J/Q-5678-2016	Maudsley, Stuart/0000-0002-1868-184X; Pawson, Adam J/0000-0003-2280-845X; Millar, Robert P/0000-0003-3606-2708	Medical Research Council [MC_U127685842, U.1276.00.005.00002.01 (85842)] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		ALI IU, 1977, CELL, V11, P115, DOI 10.1016/0092-8674(77)90322-1; ANDERSON L, 1995, ENDOCRINOLOGY, V136, P5228, DOI 10.1210/en.136.11.5228; BERG KA, 1994, MOL PHARMACOL, V46, P477; Brakebusch C, 2002, J CLIN INVEST, V109, P999, DOI 10.1172/JCI200215468; Cary LA, 1998, J CELL BIOL, V140, P211, DOI 10.1083/jcb.140.1.211; CHOI KY, 1994, CELL, V78, P499; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; DeFea KA, 2000, P NATL ACAD SCI USA, V97, P11086, DOI 10.1073/pnas.190276697; Del Pozo MA, 2002, NAT CELL BIOL, V4, P232, DOI 10.1038/ncb759; Della Rocca GJ, 1999, J BIOL CHEM, V274, P13978, DOI 10.1074/jbc.274.20.13978; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; Eliceiri BP, 2002, J CELL BIOL, V157, P149, DOI 10.1083/jcb.200109079; Etienne-Manneville S, 2003, NATURE, V421, P753, DOI 10.1038/nature01423; Etienne-Manneville S, 2001, CELL, V106, P489, DOI 10.1016/S0092-8674(01)00471-8; Fincham VJ, 2000, EMBO J, V19, P2911, DOI 10.1093/emboj/19.12.2911; FUKUMOTO Y, 1990, ONCOGENE, V5, P1321; Guo XG, 2003, J BIOL CHEM, V278, P13207, DOI 10.1074/jbc.M208896200; Hall A, 2000, PHILOS T R SOC B, V355, P965, DOI 10.1098/rstb.2000.0632; Higgs HN, 1999, J BIOL CHEM, V274, P32531, DOI 10.1074/jbc.274.46.32531; HIRAOKA K, 1992, BIOCHEM BIOPH RES CO, V182, P921, DOI 10.1016/0006-291X(92)91820-G; HORDIJK PL, 1994, J BIOL CHEM, V269, P645; Igishi T, 1999, J BIOL CHEM, V274, P30738, DOI 10.1074/jbc.274.43.30738; Kraus S, 2001, ARCH MED RES, V32, P499, DOI 10.1016/S0188-4409(01)00331-9; Krsmanovic LZ, 2003, P NATL ACAD SCI USA, V100, P2969, DOI 10.1073/pnas.0535708100; LEE EYH, 1984, J CELL BIOL, V98, P146, DOI 10.1083/jcb.98.1.146; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Levi NL, 1998, MOL ENDOCRINOL, V12, P815, DOI 10.1210/me.12.6.815; Luttrell LM, 2003, J MOL ENDOCRINOL, V30, P117, DOI 10.1677/jme.0.0300117; Luttrell LM, 1997, J BIOL CHEM, V272, P31648, DOI 10.1074/jbc.272.50.31648; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; MAHER PA, 1985, P NATL ACAD SCI USA, V82, P6576, DOI 10.1073/pnas.82.19.6576; Marinissen MJ, 2001, TRENDS PHARMACOL SCI, V22, P368, DOI 10.1016/S0165-6147(00)01678-3; MAUDSLEY S, 2001, 83 ANN M END SOC DEN, P508; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; Millar RP, 2003, TRENDS ENDOCRIN MET, V14, P35, DOI 10.1016/S1043-2760(02)00016-4; Miranti CK, 2002, NAT CELL BIOL, V4, pE83, DOI 10.1038/ncb0402-e83; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; Ott TR, 2002, MOL ENDOCRINOL, V16, P1079, DOI 10.1210/me.16.5.1079; Parsons JT, 1997, CURR OPIN CELL BIOL, V9, P187, DOI 10.1016/S0955-0674(97)80062-2; PTASZNIK A, 1995, J BIOL CHEM, V270, P19969, DOI 10.1074/jbc.270.34.19969; RodriguezFernandez JL, 1996, J BIOL CHEM, V271, P27895, DOI 10.1074/jbc.271.44.27895; ROHRSCHNEIDER LR, 1980, P NATL ACAD SCI-BIOL, V77, P3514, DOI 10.1073/pnas.77.6.3514; Sanui T, 2003, BLOOD, V102, P2948, DOI 10.1182/blood-2003-01-0173; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; Schlaepfer DD, 1997, J BIOL CHEM, V272, P13189, DOI 10.1074/jbc.272.20.13189; Short SM, 2000, J BIOL CHEM, V275, P12970, DOI 10.1074/jbc.275.17.12970; Slack BE, 1998, P NATL ACAD SCI USA, V95, P7281, DOI 10.1073/pnas.95.13.7281; TAMKUN JW, 1986, CELL, V46, P271, DOI 10.1016/0092-8674(86)90744-0; Turner CE, 2000, NAT CELL BIOL, V2, pE231, DOI 10.1038/35046659; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; YAMADA KM, 1976, P NATL ACAD SCI USA, V73, P1217, DOI 10.1073/pnas.73.4.1217; Yujiri T, 2003, J BIOL CHEM, V278, P3846, DOI 10.1074/jbc.M206087200; Zhao JH, 1998, J CELL BIOL, V143, P1997, DOI 10.1083/jcb.143.7.1997	56	67	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 16	2004	279	3					1980	1993		10.1074/jbc.M309827200	http://dx.doi.org/10.1074/jbc.M309827200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	762WT	14559894	hybrid			2022-12-27	WOS:000188005700052
J	Kobori, N; Waymire, JC; Haycock, JW; Clifton, GL; Dash, PK				Kobori, N; Waymire, JC; Haycock, JW; Clifton, GL; Dash, PK			Enhancement of tyrosine hydroxylase phosphorylation and activity by glial cell line-derived neurotrophic factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC PHOSPHORYLATION; PHOSPHATIDYLINOSITOL 3-KINASE; DIRECTED MUTAGENESIS; DOPAMINERGIC-NEURONS; C-RET; GDNF; DIFFERENTIATION; SERINE-40; NEUROBLASTOMA; BIOSYNTHESIS	Although glial cell-line derived neurotrophic factor (GDNF) acts as a potent survival factor for dopaminergic neurons, it is not known whether GDNF can directly alter dopamine synthesis. Tyrosine hydroxylase (TH) is the rate-limiting enzyme for dopamine biosynthesis, and its activity is regulated by phosphorylation on three seryl residues: Ser-19, Ser-31, and Ser-40. Using a TH-expressing human neuroblastoma cell line and rat primary mesencephalic neuron cultures, the present study examined whether GDNF alters the phosphorylation of TH and whether these changes are accompanied by increased enzymatic activity. Exposure to GDNF did not alter the TH protein level in either neuroblastoma cells or in primary neurons. However, significant increases in the phosphorylation of Ser-31 and Ser-40 were detected within minutes of GDNF application in both cell types. Enhanced Ser-31 and Ser-40 phosphorylation was associated with increased TH activity but not dopamine synthesis in neuroblastoma cells, possibly because of the absence of L-aromatic amino acid decarboxylase activity in these cells. In contrast, increased phosphorylation of Ser-31 and Ser-40 was found to enhance dopamine synthesis in primary neurons. Pharmacological experiments show that Erk and protein kinase A phosphorylate Ser-31 and Ser-40, respectively, and that their inhibition blocked both TH phosphorylation and activity. Our results indicate that, in addition to its role as a survival factor for dopaminergic neurons, GDNF can directly increase dopamine synthesis.	Univ Texas, Sch Med, Dept Neurobiol & Anat, Houston, TX 77255 USA; Univ Texas, Sch Med, Vivian L Smith Ctr Neurol Res, Houston, TX 77255 USA; Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, New Orleans, LA 70119 USA	University of Texas System; University of Texas System; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans	Dash, PK (corresponding author), Univ Texas, Sch Med, Dept Neurobiol & Anat, POB 20708, Houston, TX 77255 USA.	p.dash@uth.tmc.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035457] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 35457] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Airaksinen MS, 1999, MOL CELL NEUROSCI, V13, P313, DOI 10.1006/mcne.1999.0754; Bauer M, 2002, J NEUROCHEM, V82, P1300, DOI 10.1046/j.1471-4159.2002.01074.x; Beck KD, 1996, NEURON, V16, P665, DOI 10.1016/S0896-6273(00)80085-9; BECK KD, 1995, NATURE, V373, P339, DOI 10.1038/373339a0; Besset V, 2000, J BIOL CHEM, V275, P39159, DOI 10.1074/jbc.M006908200; BUNONE G, 1995, EXP CELL RES, V217, P92, DOI 10.1006/excr.1995.1067; Cooper DMF, 2003, BIOCHEM SOC T, V31, P912; DAUBNER SC, 1992, J BIOL CHEM, V267, P12639; Fitzpatrick PF, 1999, ANNU REV BIOCHEM, V68, P355, DOI 10.1146/annurev.biochem.68.1.355; Gash DM, 1996, NATURE, V380, P252, DOI 10.1038/380252a0; GRIMA B, 1987, NATURE, V326, P707, DOI 10.1038/326707a0; Harada K, 1996, J NEUROCHEM, V67, P629; Hayashi H, 2000, ONCOGENE, V19, P4469, DOI 10.1038/sj.onc.1203799; Haycock JW, 2002, J NEUROSCI METH, V116, P29, DOI 10.1016/S0165-0270(02)00025-0; HAYCOCK JW, 1992, P NATL ACAD SCI USA, V89, P2365, DOI 10.1073/pnas.89.6.2365; IKEDA H, 1994, NEUROCHEM RES, V19, P1487, DOI 10.1007/BF00968995; Kearns CM, 1997, J NEUROSCI, V17, P7111; LEVINE RA, 1984, ANAL BIOCHEM, V143, P205, DOI 10.1016/0003-2697(84)90577-3; Lew JY, 1999, MOL PHARMACOL, V55, P202, DOI 10.1124/mol.55.2.202; Lindgren N, 2001, EUR J NEUROSCI, V13, P773, DOI 10.1046/j.0953-816x.2000.01443.x; Lu X, 1997, J COMP NEUROL, V388, P484; Mason I, 2000, Pharm Acta Helv, V74, P261, DOI 10.1016/S0031-6865(99)00048-5; McCulloch RI, 2001, BIOCHEMISTRY-US, V40, P7273, DOI 10.1021/bi010546d; Melillo RM, 2001, ONCOGENE, V20, P209, DOI 10.1038/sj.onc.1204049; Nutt JG, 2003, NEUROLOGY, V60, P69, DOI 10.1212/WNL.60.1.69; Paratcha G, 2001, NEURON, V29, P171, DOI 10.1016/S0896-6273(01)00188-X; Pothos EN, 1998, J NEUROSCI, V18, P4106; ROSS RA, 1981, CELL MOL NEUROBIOL, V1, P301, DOI 10.1007/BF00710685; SAADAT S, 1988, J NEUROCHEM, V51, P572, DOI 10.1111/j.1471-4159.1988.tb01077.x; Saarma M, 2001, TRENDS NEUROSCI, V24, P427, DOI 10.1016/S0166-2236(00)01864-6; Salvatore MF, 2001, J NEUROCHEM, V79, P349, DOI 10.1046/j.1471-4159.2001.00593.x; SUTHERLAND C, 1993, EUR J BIOCHEM, V217, P715, DOI 10.1111/j.1432-1033.1993.tb18297.x; Tansey MG, 2000, NEURON, V25, P611, DOI 10.1016/S0896-6273(00)81064-8; WAYMIRE JC, 1978, J NEUROCHEM, V31, P693, DOI 10.1111/j.1471-4159.1978.tb07842.x; Winkler C, 1996, J NEUROSCI, V16, P7206; WU J, 1992, J BIOL CHEM, V267, P25754	36	35	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 16	2004	279	3					2182	2191		10.1074/jbc.M310734200	http://dx.doi.org/10.1074/jbc.M310734200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	762WT	14570886	hybrid			2022-12-27	WOS:000188005700075
J	Nishitai, G; Shimizu, N; Negishi, T; Kishimoto, H; Nakagawa, K; Kitagawa, D; Watanabe, T; Momose, H; Ohata, S; Tanemura, S; Asaka, S; Kubota, J; Saito, R; Yoshida, H; Mak, TW; Wada, T; Penninger, JM; Azuma, N; Nishina, H; Katada, T				Nishitai, G; Shimizu, N; Negishi, T; Kishimoto, H; Nakagawa, K; Kitagawa, D; Watanabe, T; Momose, H; Ohata, S; Tanemura, S; Asaka, S; Kubota, J; Saito, R; Yoshida, H; Mak, TW; Wada, T; Penninger, JM; Azuma, N; Nishina, H; Katada, T			Stress induces mitochondria-mediated apoptosis independent of SAPK/JNK activation in embryonic stem cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE SAPK/JNK; N-TERMINAL KINASE; SYNERGISTIC ACTIVATION; SIGNAL-TRANSDUCTION; JNK; SEK1; PHOSPHORYLATION; PROLIFERATION; RECEPTOR; LACKING	SAPK/JNK, which belongs to the family of mitogen-activated protein kinase ( MAPK), is activated by many types of cellular stresses or extracellular signals and is involved in embryonic development, immune responses, and cell survival or apoptosis. However, the physiological roles of SAPK/JNK in the signaling of stress-induced apoptosis are still controversial. To evaluate the precise function, SAPK/JNK-inactivated mouse embryonic stem (ES) cells were generated by disrupting genes of the MAPK activators, SEK1 and MKK7. Although SAPK/JNK activation by various stresses was completely abolished in sek1(-/-) mkk7(-/-) ES cells, apoptotic responses including DNA fragmentation and caspase 3 activation still occurred normally, which displays a sharp contrast to apaf1(-/-) ES cells exhibiting profound defects in the mitochondria-dependent apoptosis. These normal apoptotic responses without SAPK/JNK activation were also observed in fibroblasts derived from sek1(-/-) mkk7(-/-) ES cells. Instead, interleukin-1beta (IL-1beta)- induced IL-6 gene expression was greatly suppressed in sek1(-/-) mkk7(-/-) fibroblasts. These results clearly show that SAPK/JNK activation is responsible for the inflammatory cytokine-induced gene expression but not essentially required for the mitochondria-dependent apoptosis at least in ES or fibroblast-like cells, which are prototypes of all cell lineages.	Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Physiol Chem, Bunkyo Ku, Tokyo 1130033, Japan; Saga Med Sch, Dept Biomol Sci, Saga 8498501, Japan; Univ Turin, Univ Hlth Network, Dept Med Biophys, Toronto, ON M5G 2C1, Canada; Univ Turin, Univ Hlth Network, Dept Immunol, Toronto, ON M5G 2C1, Canada; Natl Ctr Child Hlth & Dev, Dept Ophthalmol, Setagaya Ku, Tokyo 1578535, Japan	University of Tokyo; Saga University; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Turin; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Turin; National Center for Child Health & Development - Japan	Nishina, H (corresponding author), Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Physiol Chem, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	nishina@mol.f.u-tokyo.ac.jp	Ohata, Shinya/S-2320-2018; Penninger, Josef M/I-6860-2013	Ohata, Shinya/0000-0003-4333-4433; Penninger, Josef M/0000-0002-8194-3777				Aoki H, 2002, J BIOL CHEM, V277, P10244, DOI 10.1074/jbc.M112355200; Beere HM, 2000, NAT CELL BIOL, V2, P469, DOI 10.1038/35019501; Bruey JM, 2000, NAT CELL BIOL, V2, P645, DOI 10.1038/35023595; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chauhan D, 2003, J BIOL CHEM, V278, P17593, DOI 10.1074/jbc.C300076200; Conze D, 2002, J EXP MED, V195, P811, DOI 10.1084/jem.20011508; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Ganiatsas S, 1998, P NATL ACAD SCI USA, V95, P6881, DOI 10.1073/pnas.95.12.6881; Holtmann H, 2001, J BIOL CHEM, V276, P3508, DOI 10.1074/jbc.M004376200; KANEGAE Y, 1995, NUCLEIC ACIDS RES, V23, P3816, DOI 10.1093/nar/23.19.3816; Kishimoto H, 2003, J BIOL CHEM, V278, P16595, DOI 10.1074/jbc.M213182200; Kitagawa D, 2002, J BIOL CHEM, V277, P366, DOI 10.1074/jbc.M107110200; Krause A, 1998, J BIOL CHEM, V273, P23681, DOI 10.1074/jbc.273.37.23681; Kuan CY, 1999, NEURON, V22, P667, DOI 10.1016/S0896-6273(00)80727-8; Lawler S, 1998, CURR BIOL, V8, P1387, DOI 10.1016/S0960-9822(98)00019-0; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Lin A, 2003, BIOESSAYS, V25, P17, DOI 10.1002/bies.10204; Manning AM, 2003, NAT REV DRUG DISCOV, V2, P554, DOI 10.1038/nrd1132; Nishina H, 1997, NATURE, V385, P350, DOI 10.1038/385350a0; Nishina H, 1997, J EXP MED, V186, P941, DOI 10.1084/jem.186.6.941; Nishina H, 1999, DEVELOPMENT, V126, P505; Orrenius S, 2003, NAT REV MOL CELL BIO, V4, P552, DOI 10.1038/nrm1150; Putcha GV, 2003, NEURON, V38, P899, DOI 10.1016/S0896-6273(03)00355-6; Sabapathy K, 1999, MECH DEVELOP, V89, P115, DOI 10.1016/S0925-4773(99)00213-0; Saleh A, 2000, NAT CELL BIOL, V2, P476, DOI 10.1038/35019510; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Tournier C, 2001, GENE DEV, V15, P1419, DOI 10.1101/gad.888501; Wada T, 2001, J BIOL CHEM, V276, P30892, DOI 10.1074/jbc.M011780200; Watanabe T, 2002, DEV BIOL, V250, P332, DOI 10.1006/dbio.2002.0781; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X	32	23	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 16	2004	279	3					1621	1626		10.1074/jbc.M310335200	http://dx.doi.org/10.1074/jbc.M310335200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	762WT	14585831	hybrid			2022-12-27	WOS:000188005700009
J	Shin, EY; Woo, KN; Lee, CS; Koo, SH; Kim, YG; Kim, WJ; Bae, CD; Chang, SI; Kim, EG				Shin, EY; Woo, KN; Lee, CS; Koo, SH; Kim, YG; Kim, WJ; Bae, CD; Chang, SI; Kim, EG			Basic fibroblast growth factor stimulates activation of Rac1 through a p85 beta PIX phosphorylation-dependent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCHANGE FACTORS; PHAGOCYTE NADPH OXIDASE; GTP-BINDING PROTEINS; DBL HOMOLOGY DOMAIN; RHO-GTPASES; PHOSPHOINOSITIDE 3-KINASE; GUANOSINE TRIPHOSPHATASES; TYROSINE PHOSPHORYLATION; BIOLOGICAL-ACTIVITY; KINASE	In a previous study (Shin, E. Y., Shin, K. S., Lee, C. S., Woo, K. N., Quan, S. H., Soung, N. K., Kim, Y. G., Cha, C. I., Kim, S. R., Park, D., Bokoch, G. M., and Kim, E. G. ( 2002) J. Biol. Chem. 277, 44417 - 44430) we reported that phosphorylation of p85 betaPIX, a guanine nucleotide exchange factor (GEF) for Rac1/Cdc42, is a signal for translocation of the PIX complex to neuronal growth cones and is associated with basic fibroblast growth factor (bFGF)induced neurite outgrowth. However, the issue of whether p85 betaPIX phosphorylation affects GEF activity on Rac1/Cdc42 is yet to be explored. Here we show that Rac1 activation occurs in a p85 betaPIX phosphorylation-dependent manner. A GST-PBD binding assay reveals that Rac1 is activated in a dose- and time-dependent manner in PC12 cells in response to bFGF. Inhibition of ERK or PAK2, the kinases upstream of p85 betaPIX in the bFGF signaling, prevents Rac1 activation, suggesting that phosphorylation of p85 betaPIX functions upstream of Rac1 activation. To directly address this issue, transfection studies with wild-type and mutant p85 betaPIX (S525A/ T526A, a non-phosphorylatable form) were performed. Expression of mutant PIX markedly inhibits both bFGF- and nerve growth factor (NGF)- induced activation of Rac1, indicating that phosphorylation of p85 betaPIX is responsible for activation of this G protein. Both wildtype and mutant p85 betaPIX displaying negative GEF activity (L238R/L239S) are similarly recruited to growth cones, suggesting that Rac1 activation is not essential for translocation of the PIX complex (PAK2-p85 betaPIX-Rac1). However, expression of mutant p85 betaPIX (L238R/ L239S) results in retraction of the pre-existing neurites. Our results provide evidence that bFGF- and NGF-induced phosphorylation of p85 betaPIX mediates Rac1 activation, which in turn regulates cytoskeletal reorganization at growth cones, but not translocation of the PIX complex.	Chungbuk Natl Univ, Med Res Inst, Coll Med, Dept Biochem, Cheongju 361763, South Korea; Chungbuk Natl Univ, Biotechnol Res Inst, Cheongju 361763, South Korea; Chungbuk Natl Univ, Med Res Inst, Coll Med, Dept Neurosurg, Cheongju 361763, South Korea; Chungbuk Natl Univ, Med Res Inst, Coll Med, Dept Urol, Cheongju 361763, South Korea; Chungbuk Natl Univ, Coll Nat Sci, Dept Biochem, Cheongju 361763, South Korea; Sungkyunkwan Univ, Sch Med, Dept Mol Cell Biol, Suwon 440746, South Korea	Chungbuk National University; Chungbuk National University; Chungbuk National University; Chungbuk National University; Chungbuk National University; Sungkyunkwan University (SKKU)	Kim, EG (corresponding author), Chungbuk Natl Univ, Med Res Inst, Coll Med, Dept Biochem, San 48, Cheongju 361763, South Korea.	egkim@med.chungbuk.ac.kr	Chang, Soo-Ik/K-4079-2013	Chang, Soo-Ik/0000-0002-5620-0867				Abassi YA, 2002, EMBO J, V21, P4571, DOI 10.1093/emboj/cdf446; Aghazadeh B, 2000, CELL, V102, P625, DOI 10.1016/S0092-8674(00)00085-4; Aghazadeh B, 1998, NAT STRUCT BIOL, V5, P1098, DOI 10.1038/4209; Ago T, 1999, J BIOL CHEM, V274, P33644, DOI 10.1074/jbc.274.47.33644; AltunGultekin ZF, 1996, J NEUROSCI RES, V44, P308, DOI 10.1002/(SICI)1097-4547(19960515)44:4<308::AID-JNR2>3.0.CO;2-G; Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; Bagrodia S, 1998, J BIOL CHEM, V273, P23633, DOI 10.1074/jbc.273.37.23633; Bagrodia S, 1999, J BIOL CHEM, V274, P22393, DOI 10.1074/jbc.274.32.22393; Brown MC, 2002, MOL BIOL CELL, V13, P1550, DOI 10.1091/mbc.02-02-0015; Brugnera E, 2002, NAT CELL BIOL, V4, P574, DOI 10.1038/ncb824; Buchanan FG, 2000, J BIOL CHEM, V275, P9742, DOI 10.1074/jbc.275.13.9742; del Pozo MA, 2000, EMBO J, V19, P2008, DOI 10.1093/emboj/19.9.2008; Di Cesare A, 2000, NAT CELL BIOL, V2, P521, DOI 10.1038/35019561; Dinauer MC, 2003, CURR OPIN HEMATOL, V10, P8, DOI 10.1097/00062752-200301000-00003; Gianni D, 2003, J BIOL CHEM, V278, P9290, DOI 10.1074/jbc.M211899200; GULBINS E, 1993, SCIENCE, V260, P822, DOI 10.1126/science.8484124; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HALL A, 1993, PHILOS T ROY SOC B, V340, P267, DOI 10.1098/rstb.1993.0067; Han JW, 1997, MOL CELL BIOL, V17, P1346, DOI 10.1128/MCB.17.3.1346; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; Hoffman GR, 2002, FEBS LETT, V513, P85, DOI 10.1016/S0014-5793(01)03310-5; Huang J, 1999, J BIOL CHEM, V274, P19731, DOI 10.1074/jbc.274.28.19731; Kanazawa H, 2002, J BIOL CHEM, V277, P20026, DOI 10.1074/jbc.M109218200; KATZAV S, 1991, MOL CELL BIOL, V11, P1912, DOI 10.1128/MCB.11.4.1912; Kim S, 2001, J BIOL CHEM, V276, P10581, DOI 10.1074/jbc.C000806200; Koh CG, 2001, J CELL SCI, V114, P4239; KOTANI K, 1994, EMBO J, V13, P2313, DOI 10.1002/j.1460-2075.1994.tb06515.x; Lopez-Lago M, 2000, MOL CELL BIOL, V20, P1678, DOI 10.1128/MCB.20.5.1678-1691.2000; Luo LQ, 2000, NAT REV NEUROSCI, V1, P173, DOI 10.1038/35044547; Manabe R, 2002, J CELL SCI, V115, P1497; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; NOBES CD, 1995, J CELL SCI, V108, P225; Price MO, 2002, J BIOL CHEM, V277, P19220, DOI 10.1074/jbc.M200061200; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Robbe K, 2003, J BIOL CHEM, V278, P4756, DOI 10.1074/jbc.M210412200; RON D, 1989, ONCOGENE, V4, P1067; Royal I, 2000, MOL BIOL CELL, V11, P1709, DOI 10.1091/mbc.11.5.1709; Schmidt A, 2002, GENE DEV, V16, P1587, DOI 10.1101/gad.1003302; Shin EY, 2002, J BIOL CHEM, V277, P44417, DOI 10.1074/jbc.M203754200; Sterpetti P, 1999, MOL CELL BIOL, V19, P1334; Tong JF, 2003, J BIOL CHEM, V278, P6111, DOI 10.1074/jbc.M208972200; Turner CE, 1999, J CELL BIOL, V145, P851, DOI 10.1083/jcb.145.4.851; vanLeeuwen FN, 1995, ONCOGENE, V11, P2215; Wells CD, 2001, J BIOL CHEM, V276, P28897, DOI 10.1074/jbc.M102913200; WENNSTROM S, 1994, CURR BIOL, V4, P385, DOI 10.1016/S0960-9822(00)00087-7; Whitehead IP, 1997, BIOCHIM BIOPHYS ACTA, V1332, P1; Yang FC, 2001, P NATL ACAD SCI USA, V98, P5614, DOI 10.1073/pnas.101546898; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; Yoshii S, 1999, ONCOGENE, V18, P5680, DOI 10.1038/sj.onc.1202936; Zheng Y, 2001, TRENDS BIOCHEM SCI, V26, P724, DOI 10.1016/S0968-0004(01)01973-9	51	45	46	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 16	2004	279	3					1994	2004		10.1074/jbc.M307330200	http://dx.doi.org/10.1074/jbc.M307330200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	762WT	14557270	hybrid			2022-12-27	WOS:000188005700053
J	Anderson, HDI; Rahmutula, D; Gardner, DG				Anderson, HDI; Rahmutula, D; Gardner, DG			Tumor necrosis factor-alpha inhibits endothelial nitric-oxide synthase gene promoter activity in bovine aortic endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I-KAPPA-B; TNF-ALPHA; MESSENGER-RNA; KINASE-ALPHA; SUPEROXIDE GENERATION; INSULIN-RESISTANCE; IKK-ALPHA; EXPRESSION; DYSFUNCTION; ACTIVATION	Tumor necrosis factor-alpha (TNF-alpha) has been shown to reduce endothelial nitric-oxide synthase (eNOS) gene expression through post-transcriptional regulation of mRNA stability. The current study documented an independent effect of the cytokine on the eNOS gene promoter. TNF-alpha effected a time- and dose-dependent reduction in activity of a transiently transfected human -1197 eNOS-luciferase reporter. This reduction was inhibited by co-transfection of dominant negative IKKbeta as well as a nonphosphorylatable constitutively suppressive mutant of IkappaB implying involvement of the NFkappaB cascade in the inhibitory effect. The locus of the TNF-alpha-dependent inhibition was traced to two Sp1-binding sites positioned between -109 and -95 and -81 and -67 relative to the transcription start site. Electrophoretic mobility shift analysis and immunoperturbation studies showed evidence for Sp1 and Sp3 binding to each element. TNF-alpha treatment had no effect on the binding pattern to the downstream (-81 to -67) site but did suppress association of Sp1 and Sp3 to the upstream (-109 to -95) site. Collectively, these data indicate that TNF-alpha exerts transcriptional, as well as post-transcriptional, effects on eNOS gene expression and suggest a potential mechanism to account for the endothelial dysfunction that accompanies disorders such as diabetes mellitus and heart failure.	Univ Calif San Francisco, Ctr Diabet, HSW 1109, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, HSW 1109, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Gardner, DG (corresponding author), Univ Calif San Francisco, Ctr Diabet, HSW 1109, San Francisco, CA 94143 USA.	handerson@sbrc.ca; gardner@itsa.ucsf.edu		Anderson, Hope/0000-0001-6570-6678	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045637] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK063720] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL45637] Funding Source: Medline; NIDDK NIH HHS [P30 DK63720] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agnoletti L, 1999, CIRCULATION, V100, P1983, DOI 10.1161/01.CIR.100.19.1983; Alonso J, 1997, MOL CELL BIOL, V17, P5719, DOI 10.1128/MCB.17.10.5719; Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; Beauparlant P, 1996, J VIROL, V70, P5777, DOI 10.1128/JVI.70.9.5777-5785.1996; Boden G, 2003, EXP CLIN ENDOCR DIAB, V111, P121, DOI 10.1055/s-2003-39781; Bonnard M, 2000, EMBO J, V19, P4976, DOI 10.1093/emboj/19.18.4976; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; Chakravarthy U, 1998, DIABETES, V47, P945, DOI 10.2337/diabetes.47.6.945; Channon KM, 2002, J PHYSIOL PHARMACOL, V53, P515; Che WY, 2002, CIRC RES, V90, P1222, DOI 10.1161/01.RES.0000021127.83364.7D; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Corda S, 2001, AM J RESP CELL MOL, V24, P762, DOI 10.1165/ajrcmb.24.6.4228; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Ding YX, 2000, AM J PHYSIOL-ENDOC M, V279, pE11, DOI 10.1152/ajpendo.2000.279.1.E11; Fichtlscherer S, 2001, CIRCULATION, V104, P3023, DOI 10.1161/hc5001.101749; FURCHGOTT RF, 1987, BLOOD VESSELS, V24, P145; GARG UC, 1989, J CLIN INVEST, V83, P1774, DOI 10.1172/JCI114081; GRIFFITH TM, 1987, NATURE, V329, P442, DOI 10.1038/329442a0; Harrison DG, 1997, J CLIN INVEST, V100, P2153, DOI 10.1172/JCI119751; Hink U, 2001, CIRC RES, V88, pE14; Hirano F, 1998, MOL CELL BIOL, V18, P1266, DOI 10.1128/MCB.18.3.1266; Hotamisligil GS, 1999, J INTERN MED, V245, P621, DOI 10.1046/j.1365-2796.1999.00490.x; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; JOHNSON A, 1994, AM J PHYSIOL, V267, pL318, DOI 10.1152/ajplung.1994.267.3.L318; Karantzoulis-Fegaras F, 1999, J BIOL CHEM, V274, P3076, DOI 10.1074/jbc.274.5.3076; Karin M, 2000, SEMIN IMMUNOL, V12, P85, DOI 10.1006/smim.2000.0210; Karin M., 1999, SCI SIGNAL TRANSDUCT, V5, P1; Krasinski K, 2001, CIRCULATION, V104, P1754, DOI 10.1161/hc4001.098046; Kuang PP, 2002, AM J PHYSIOL-CELL PH, V283, pC58, DOI 10.1152/ajpcell.00314.2001; KUBES P, 1991, P NATL ACAD SCI USA, V88, P4651, DOI 10.1073/pnas.88.11.4651; Kuboki K, 2000, CIRCULATION, V101, P676, DOI 10.1161/01.CIR.101.6.676; Landmesser U, 2003, J CLIN INVEST, V111, P1201, DOI 10.1172/JCI200314172; LEVINE B, 1990, NEW ENGL J MED, V323, P236, DOI 10.1056/NEJM199007263230405; Li J, 1998, J BIOL CHEM, V273, P30736, DOI 10.1074/jbc.273.46.30736; Liang FQ, 1999, J CLIN INVEST, V104, P1603, DOI 10.1172/JCI7362; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Meininger CJ, 2000, BIOCHEM J, V349, P353, DOI 10.1042/0264-6021:3490353; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Mercurio F, 1999, MOL CELL BIOL, V19, P1526; MICHEL T, 1992, J CARDIOVASC PHARM, V20, pS45, DOI 10.1097/00005344-199204002-00014; MOHAMED F, 1995, ARTERIOSCL THROM VAS, V15, P52, DOI 10.1161/01.ATV.15.1.52; Mohamed-Ali V, 1998, INT J OBESITY, V22, P1145, DOI 10.1038/sj.ijo.0800770; Muzaffar S, 2003, THORAX, V58, P598, DOI 10.1136/thorax.58.7.598; NADAUD S, 1994, BIOCHEM BIOPH RES CO, V198, P1027, DOI 10.1006/bbrc.1994.1146; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; Pfeiffer A, 1997, HORM METAB RES, V29, P111, DOI 10.1055/s-2007-979001; RADI R, 1991, J BIOL CHEM, V266, P4244; Rizzoni D, 2001, CIRCULATION, V103, P1238; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Shinozaki K, 2000, CIRC RES, V87, P566, DOI 10.1161/01.RES.87.7.566; Steppan CM, 2001, NATURE, V409, P307, DOI 10.1038/35053000; Tanaka H, 1996, ARTERIOSCL THROM VAS, V16, P12, DOI 10.1161/01.ATV.16.1.12; Tickerhoof MM, 2003, AM J PHYSIOL-HEART C, V285, pH2694, DOI 10.1152/ajpheart.00394.2003; Tojima Y, 2000, NATURE, V404, P778, DOI 10.1038/35008109; Vasquez-Vivar J, 1998, P NATL ACAD SCI USA, V95, P9220, DOI 10.1073/pnas.95.16.9220; Vaziri ND, 1999, HYPERTENSION, V34, P1237, DOI 10.1161/01.HYP.34.6.1237; Wagner AH, 2002, BRIT J PHARMACOL, V136, P143, DOI 10.1038/sj.bjp.0704678; Wajant H, 2003, CELL DEATH DIFFER, V10, P45, DOI 10.1038/sj.cdd.4401189; WANG P, 1994, AM J PHYSIOL, V266, pH2535, DOI 10.1152/ajpheart.1994.266.6.H2535; Wen JK, 2000, BIOCHEMISTRY-MOSCOW+, V65, P1376, DOI 10.1023/A:1002848705637; Winkler G, 1999, DIABETIC MED, V16, P207, DOI 10.1046/j.1464-5491.1999.00052.x; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Xia Y, 1998, J BIOL CHEM, V273, P25804, DOI 10.1074/jbc.273.40.25804; Yang JH, 2001, NAT IMMUNOL, V2, P620, DOI 10.1038/89769; Ye Q, 2003, HYPERTENSION, V41, P675, DOI 10.1161/01.HYP.0000047204.72286.34; YOSHIZUMI M, 1993, CIRC RES, V73, P205, DOI 10.1161/01.RES.73.1.205; Young ME, 1998, BIOCHEM J, V329, P73; Zandi E, 1998, SCIENCE, V281, P1360, DOI 10.1126/science.281.5381.1360; Zhang DX, 2002, AM J PHYSIOL-HEART C, V283, pH1785, DOI 10.1152/ajpheart.00318.2002; Zhang JL, 1997, RES COMMUN MOL PATH, V96, P71; Zhao Q, 1999, J BIOL CHEM, V274, P8355, DOI 10.1074/jbc.274.13.8355	72	135	139	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 9	2004	279	2					963	969		10.1074/jbc.M309552200	http://dx.doi.org/10.1074/jbc.M309552200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	759DJ	14581470	hybrid			2022-12-27	WOS:000187722800019
J	Frick, DN; Rypma, RS; Lam, AMI; Gu, BH				Frick, DN; Rypma, RS; Lam, AMI; Gu, BH			The nonstructural protein 3 protease/helicase requires an intact protease domain to unwind duplex RNA efficiently	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATITIS-C VIRUS; HELICASES DISPLACE STREPTAVIDIN; CELL-CULTURE ADAPTATION; ESCHERICHIA-COLI UVRD; NS3 PROTEIN; CRYSTAL-STRUCTURE; NUCLEOSIDE TRIPHOSPHATASE; ENZYMATIC-ACTIVITIES; KINETIC-ANALYSIS; DNA HELICASE	The nonstructural 3 (NS3) protein encoded by the hepatitis C virus possesses both an N-terminal serine protease activity and a C-terminal 3'-5' helicase activity. This study examines the effects of the protease on the helicase by comparing the enzymatic properties of the full-length NS3 protein with truncated versions in which the protease is either deleted or replaced by a polyhistidine (His tag) or a glutathione S-transferase fusion protein (GST tag). When the NS3 protein lacks the protease domain it unwinds RNA more slowly and does not unwind RNA in the presence of excess nucleic acid that acts as an enzyme trap. Some but not all of the RNA helicase activity can be restored by adding a His tag or GST tag to the N terminus of the truncated helicase, suggesting that the effects of the protease are both specific and nonspecific. Similar but smaller effects are also seen in DNA helicase and translocation assays. While translocating on RNA ( or DNA) the full-length protein hydrolyzes ATP more slowly than the truncated protein, suggesting that the protease allows for more efficient ATP usage. Binding assays reveal that the full-length protein assembles on single-stranded DNA as a higher order oligomer than the truncated fragment, and the binding appears to be more cooperative. The data suggest that hepatitis C virus RNA helicase, and therefore viral replication, could be influenced by the rotations of the protease domain which likely occur during polyprotein processing.	New York Med Coll, Dept Biochem & Mol Biol, Valhalla, NY 10595 USA; Jefferson Ctr Biomed Res, Dept Biochem & Mol Biol, Doylestown, PA 18901 USA	New York Medical College; Jefferson University	Frick, DN (corresponding author), New York Med Coll, Dept Biochem & Mol Biol, Valhalla, NY 10595 USA.	David_Frick@NYMC.edu		Frick, David/0000-0002-2434-7223	NIAID NIH HHS [R01 AI052395-01A1, R01 AI052395-03, R01 AI052395, AI052395, R01 AI052395-02] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI052395] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ali JA, 1997, SCIENCE, V275, P377, DOI 10.1126/science.275.5298.377; Banerjee R, 2001, J VIROL, V75, P1708, DOI 10.1128/JVI.75.4.1708-1721.2001; Blight KJ, 2002, J VIROL, V76, P13001, DOI 10.1128/JVI.76.24.13001-13014.2002; Bukh J, 2002, P NATL ACAD SCI USA, V99, P14416, DOI 10.1073/pnas.212532699; Chao L, 1999, J VIROL, V73, P8798, DOI 10.1128/JVI.73.10.8798-8807.1999; Cho HS, 1998, J BIOL CHEM, V273, P15045, DOI 10.1074/jbc.273.24.15045; Du MX, 2002, BIOCHEM J, V363, P147, DOI 10.1042/0264-6021:3630147; DUBENDORFF JW, 1991, J MOL BIOL, V219, P45, DOI 10.1016/0022-2836(91)90856-2; Flajolet M, 2000, GENE, V242, P369, DOI 10.1016/S0378-1119(99)00511-9; FRICK DN, 2003, IN PRESS CURR ORG CH, V7; Gallinari P, 1999, BIOCHEMISTRY-US, V38, P5620, DOI 10.1021/bi982892+; Gallinari P, 1998, J VIROL, V72, P6758, DOI 10.1128/JVI.72.8.6758-6769.1998; Gibrat JF, 1996, CURR OPIN STRUC BIOL, V6, P377, DOI 10.1016/S0959-440X(96)80058-3; Grobler JA, 2003, J BIOL CHEM, V278, P16741, DOI 10.1074/jbc.M212602200; Gu BH, 2003, J VIROL, V77, P5352, DOI 10.1128/JVI.77.9.5352-5359.2003; Gwack Y, 1997, EUR J BIOCHEM, V250, P47, DOI 10.1111/j.1432-1033.1997.00047.x; Heilek GM, 1997, J VIROL, V71, P6264, DOI 10.1128/JVI.71.8.6264-6266.1997; Howe AYM, 1999, PROTEIN SCI, V8, P1332, DOI 10.1110/ps.8.6.1332; JIN L, 1995, ARCH BIOCHEM BIOPHYS, V323, P47, DOI 10.1006/abbi.1995.0008; Khu YL, 2001, J VIROL, V75, P205, DOI 10.1128/JVI.75.1.205-214.2001; Kim DW, 1997, VIRUS RES, V49, P17, DOI 10.1016/S0168-1702(97)01452-4; Kim JL, 1998, STRUCTURE, V6, P89, DOI 10.1016/S0969-2126(98)00010-0; Kolykhalov AA, 2000, J VIROL, V74, P2046, DOI 10.1128/JVI.74.4.2046-2051.2000; Lam AMI, 2003, J BIOL CHEM, V278, P44514, DOI 10.1074/jbc.M306444200; Lam AMI, 2003, J VIROL, V77, P3950, DOI 10.1128/JVI.77.7.3950-3961.2003; Levin MK, 1999, J BIOL CHEM, V274, P31839, DOI 10.1074/jbc.274.45.31839; Levin MK, 2003, J BIOL CHEM, V278, P23311, DOI 10.1074/jbc.M301283200; Levin MK, 2002, J BIOL CHEM, V277, P29377, DOI 10.1074/jbc.M112315200; Locatelli GA, 2002, BIOCHEMISTRY-US, V41, P10332, DOI 10.1021/bi026082g; Lohmann V, 2001, J VIROL, V75, P1437, DOI 10.1128/JVI.75.3.1437-1449.2001; Maluf NK, 2003, J MOL BIOL, V325, P913, DOI 10.1016/S0022-2836(02)01277-9; Morris PD, 1999, BIOCHEMISTRY-US, V38, P5164, DOI 10.1021/bi9822269; Morris PD, 2002, BIOCHEMISTRY-US, V41, P2372, DOI 10.1021/bi012058b; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; Pang PS, 2002, EMBO J, V21, P1168, DOI 10.1093/emboj/21.5.1168; Paolini C, 2000, J GEN VIROL, V81, P1335, DOI 10.1099/0022-1317-81-5-1335; Piccininni S, 2002, J BIOL CHEM, V277, P45670, DOI 10.1074/jbc.M204124200; Porter DJT, 1998, J BIOL CHEM, V273, P18906, DOI 10.1074/jbc.273.30.18906; Preugschat F, 2000, BIOCHEMISTRY-US, V39, P5174, DOI 10.1021/bi9923860; Preugschat F, 1996, J BIOL CHEM, V271, P24449, DOI 10.1074/jbc.271.40.24449; Sali DL, 1998, BIOCHEMISTRY-US, V37, P3392, DOI 10.1021/bi972010r; Silverman E, 2003, GENE, V312, P1, DOI 10.1016/S0378-1119(03)00626-7; SUZICH JA, 1993, J VIROL, V67, P6152, DOI 10.1128/JVI.67.10.6152-6158.1993; Tan SL, 2002, NAT REV DRUG DISCOV, V1, P867, DOI 10.1038/nrd937; WONG I, 1992, SCIENCE, V256, P350, DOI 10.1126/science.256.5055.350; Yanagi M, 1997, P NATL ACAD SCI USA, V94, P8738, DOI 10.1073/pnas.94.16.8738; Yao NH, 1999, STRUCTURE, V7, P1353, DOI 10.1016/S0969-2126(00)80025-8; Yao NH, 1997, NAT STRUCT BIOL, V4, P463, DOI 10.1038/nsb0697-463	48	87	91	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 9	2004	279	2					1269	1280		10.1074/jbc.M310630200	http://dx.doi.org/10.1074/jbc.M310630200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	759DJ	14585830	Green Accepted, hybrid			2022-12-27	WOS:000187722800053
J	Gwizdek, C; Ossareh-Nazari, B; Brownawell, AM; Evers, S; Macara, IG; Dargemont, C				Gwizdek, C; Ossareh-Nazari, B; Brownawell, AM; Evers, S; Macara, IG; Dargemont, C			Minihelix-containing RNAs mediate exportin-5-dependent nuclear export of the double-stranded RNA-binding protein ILF3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL-CHARACTERIZATION; MOLECULAR-BASIS; KINASE; DOMAIN; IDENTIFICATION; TRANSPORT; ROLES; PHOSPHOPROTEINS; TRANSLATION; EXPRESSION	The karyopherin-related nuclear transport factor exportin-5 preferentially recognizes and transports RNAs containing minihelix motif, a structural cis-acting export element that comprises a double-stranded stem (>14 nucleotides) with a base-paired 5' end and a 3-8-nucleotide protruding 3' end. This structural motif is present in various small cellular and viral polymerase III transcripts such as the adenovirus VA1 RNA ( VA1). Here we show that the double-stranded RNA-binding protein, ILF3 ((i) under bar nter (l) under bar eukin enhancer (b) under bar inding factor (3) under bar) preferentially binds minihelix motif. Gel retardation assays and glutathione S-transferase pull-down experiments revealed that ILF3, exportin-5, RanGTP, and VA1 RNA assembled in a quaternary complex in which the RNA moiety bridges the interaction between ILF3 and exportin-5. Formation of this complex is facilitated by the ability of both exportin-5 and ILF3 to mutually increase their apparent affinity for VA1 RNA. Using microinjection in the nucleus of HeLa cells and transfection experiments, we show here that formation of the cooperative RanGTP-dependent RNA/ILF3/exportin-5 complex promotes the co-transport of VA1 and ILF3 from the nucleus to the cytoplasm. Exportin-5 thus appears as the first example of a nuclear export receptor that mediates RNA export but also promotes transport of proteinaceous cargo through appropriate and specific RNA adaptors.	Univ Paris 06, Inst Jacques Monod, CNRS, Unite Mixte Rech 7592, F-75251 Paris 05, France; Univ Paris 07, Inst Jacques Monod, CNRS, Unite Mixte Rech 7592, F-75251 Paris 05, France; Univ Virginia, Ctr Cell Signaling, Charlottesville, VA 22908 USA; Hoffmann La Roche AG, PRPN G, CH-4070 Basel, Switzerland	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; University of Virginia; Roche Holding	Dargemont, C (corresponding author), Univ Paris 06, Inst Jacques Monod, CNRS, Unite Mixte Rech 7592, 2 Pl Jussieu,Tour 43, F-75251 Paris 05, France.	dargemont@ijm.jussieu.fr						Bass BL, 1997, TRENDS BIOCHEM SCI, V22, P157, DOI 10.1016/S0968-0004(97)01035-9; BOELENS WC, 1995, RNA, V1, P273; Brownawell AM, 2002, J CELL BIOL, V156, P53, DOI 10.1083/jcb.200110082; BYCROFT M, 1995, FEBS LETT, V362, P333, DOI 10.1016/0014-5793(95)00181-8; Calado A, 2002, EMBO J, V21, P6216, DOI 10.1093/emboj/cdf620; Doyle M, 2003, J CELL BIOL, V161, P309, DOI 10.1083/jcb.200301034; Duchange N, 2000, GENE, V261, P345, DOI 10.1016/S0378-1119(00)00495-9; Fountoulakis M, 1997, ANAL BIOCHEM, V250, P153, DOI 10.1006/abio.1997.2213; Gorlich D, 1998, EMBO J, V17, P2721, DOI 10.1093/emboj/17.10.2721; Gwizdek C, 2003, J BIOL CHEM, V278, P5505, DOI 10.1074/jbc.C200668200; Gwizdek C, 2001, J BIOL CHEM, V276, P25910, DOI 10.1074/jbc.M100493200; Keegan LP, 2001, NAT REV GENET, V2, P869, DOI 10.1038/35098584; KHARRAT A, 1995, EMBO J, V14, P3572, DOI 10.1002/j.1460-2075.1995.tb07363.x; Langland JO, 1999, BIOCHEMISTRY-US, V38, P6361, DOI 10.1021/bi982410u; Liao HJ, 1998, P NATL ACAD SCI USA, V95, P8514, DOI 10.1073/pnas.95.15.8514; Liu Y, 2000, P NATL ACAD SCI USA, V97, P12541, DOI 10.1073/pnas.97.23.12541; Maraia RJ, 2001, J CELL BIOL, V153, pF13, DOI 10.1083/jcb.153.4.F13; Marcoulatos P, 1998, J INTERF CYTOK RES, V18, P351, DOI 10.1089/jir.1998.18.351; MATHEWS MB, 1991, J VIROL, V65, P5657, DOI 10.1128/JVI.65.11.5657-5662.1991; MatsumotoTaniura N, 1996, MOL BIOL CELL, V7, P1455, DOI 10.1091/mbc.7.9.1455; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; Micklem DR, 2000, EMBO J, V19, P1366, DOI 10.1093/emboj/19.6.1366; Mourelatos Z, 2002, GENE DEV, V16, P720, DOI 10.1101/gad.974702; Nanduri S, 2000, EMBO J, V19, P5567, DOI 10.1093/emboj/19.20.5567; Nanduri S, 1998, EMBO J, V17, P5458, DOI 10.1093/emboj/17.18.5458; Nemergut ME, 2000, J CELL BIOL, V149, P835, DOI 10.1083/jcb.149.4.835; Ossareh-Nazari B, 2001, TRAFFIC, V2, P684, DOI 10.1034/j.1600-0854.2001.21002.x; Patel RC, 1999, J BIOL CHEM, V274, P20432, DOI 10.1074/jbc.274.29.20432; Reichman TW, 2002, MOL CELL BIOL, V22, P343, DOI 10.1128/MCB.22.1.343-356.2002; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; Ryter JM, 1998, EMBO J, V17, P7505, DOI 10.1093/emboj/17.24.7505; Saunders LR, 2001, J BIOL CHEM, V276, P32300, DOI 10.1074/jbc.M104207200; SCHMEDT C, 1995, J MOL BIOL, V249, P29, DOI 10.1006/jmbi.1995.0278; Simons FHM, 1996, RNA, V2, P264; Smith AE, 2002, SCIENCE, V295, P488, DOI 10.1126/science.1064732; Spanggord RJ, 2002, BIOCHEMISTRY-US, V41, P4511, DOI 10.1021/bi0120594; Tian B, 2001, J BIOL CHEM, V276, P9936, DOI 10.1074/jbc.M007328200; Zhang HD, 2002, EMBO J, V21, P5875, DOI 10.1093/emboj/cdf582	39	68	76	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 9	2004	279	2					884	891		10.1074/jbc.M306808200	http://dx.doi.org/10.1074/jbc.M306808200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	759DJ	14570900	Green Published, hybrid			2022-12-27	WOS:000187722800010
J	Niv, MY; Rubin, H; Cohen, J; Tsirulnikov, L; Licht, T; Peretzman-Shemer, A; Cna'an, E; Tartakovsky, A; Stein, I; Albeck, S; Weinstein, I; Goldenberg-Furmanov, M; Tobi, D; Cohen, E; Laster, M; Ben-Sasson, SA; Reuveni, H				Niv, MY; Rubin, H; Cohen, J; Tsirulnikov, L; Licht, T; Peretzman-Shemer, A; Cna'an, E; Tartakovsky, A; Stein, I; Albeck, S; Weinstein, I; Goldenberg-Furmanov, M; Tobi, D; Cohen, E; Laster, M; Ben-Sasson, SA; Reuveni, H			Sequence-based design of kinase inhibitors applicable for therapeutics and target identification	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; HUMAN PROSTATE-CANCER; CRYSTAL-STRUCTURE; STRUCTURAL BASIS; SUBSTRATE RECOGNITION; PEPTIDE INHIBITORS; CELL-CYCLE; SRC FAMILY; C-KIT; CATALYTIC SUBUNIT	A platform for specifically modulating kinase-dependent signaling using peptides derived from the catalytic domain of the kinase is presented. This technology, termed KinAce(TM), utilizes the canonical structure of protein kinases. The targeted regions ( subdomain V and subdomains IX and X) are analyzed and their sequence, three-dimensional structure, and involvement in protein-protein interaction are highlighted. Short myristoylated peptides were derived from the target regions of the tyrosine kinases c-Kit and Lyn and the serine/threonine kinases 3-phosphoinositide-dependent kinase-1 (PDK1) and Akt/protein kinase B (PKB). For each kinase an active designer peptide is shown to selectively inhibit the signaling of the kinase from which it is derived, and to inhibit cancer cell proliferation in the micromolar range. This technology emerges as an applicable tool for deriving sequence-based selective inhibitors for a broad range of protein kinases as hits that may be further developed into drugs. Moreover, it enables identification of novel kinase targets for selected therapeutic indications as demonstrated in the KinScreen application.	Keryx Biopharmaceut, IL-93420 Jerusalem, Israel; Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Expt Med & Canc Res, Jerusalem, Israel	Hebrew University of Jerusalem	Reuveni, H (corresponding author), Keryx Biopharmaceut, 15 Yad Haruzim St, IL-93420 Jerusalem, Israel.	hadas@keryx.com	Niv, Masha/AAL-1123-2020; Tobi, Dror/V-5384-2019; Niv, Masha Y/E-3148-2010	Tobi, Dror/0000-0002-1125-2751; licht, tamar/0000-0003-2333-1665; Niv, Masha/0000-0001-8275-8795				Adachi T, 1999, J IMMUNOL, V162, P1496; Adachi T, 1999, J IMMUNOL, V163, P939; Akamine P, 2003, J MOL BIOL, V327, P159, DOI 10.1016/S0022-2836(02)01446-8; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Alfaro-Lopez J, 1998, J MED CHEM, V41, P2252, DOI 10.1021/jm9707885; Allard P, 1997, MOL CELL ENDOCRINOL, V126, P25, DOI 10.1016/S0303-7207(96)03966-4; ATFI A, 1994, J BIOL CHEM, V269, P30688; Avdeef Alex, 2001, Current Topics in Medicinal Chemistry, V1, P277, DOI 10.2174/1568026013395100; Ball KL, 1997, CURR BIOL, V7, P71, DOI 10.1016/S0960-9822(06)00029-7; Bastola DR, 2002, MOL CELL BIOCHEM, V236, P75, DOI 10.1023/A:1016191913274; Batkin M, 1999, FEBS LETT, V452, P395, DOI 10.1016/S0014-5793(99)00500-1; BELLACOSA A, 1995, INT J CANCER, V64, P280, DOI 10.1002/ijc.2910640412; BENSASSON S, 2001, Patent No. 6174993; Blum G, 2000, BIOCHEMISTRY-US, V39, P15705, DOI 10.1021/bi001516y; Blume-Jensen P, 1998, CURR BIOL, V8, P779, DOI 10.1016/S0960-9822(98)70302-1; BLUMEJENSEN P, 1991, EMBO J, V10, P4121, DOI 10.1002/j.1460-2075.1991.tb04989.x; BLUMEJENSEN P, 1994, J BIOL CHEM, V269, P21793; Boissan M, 2000, J LEUKOCYTE BIOL, V67, P135, DOI 10.1002/jlb.67.2.135; BOLEN JB, 1992, FASEB J, V6, P3403, DOI 10.1096/fasebj.6.15.1281458; Bonny C, 2001, DIABETES, V50, P77, DOI 10.2337/diabetes.50.1.77; Brazil DP, 2002, CELL, V111, P293, DOI 10.1016/S0092-8674(02)01083-8; Brinckerhoff LH, 1999, INT J CANCER, V83, P326, DOI 10.1002/(SICI)1097-0215(19991029)83:3<326::AID-IJC7>3.0.CO;2-X; Brotherton DH, 1998, NATURE, V395, P244, DOI 10.1038/26164; Brown NR, 1999, NAT CELL BIOL, V1, P438, DOI 10.1038/15674; Burgering BMT, 2002, TRENDS BIOCHEM SCI, V27, P352, DOI 10.1016/S0968-0004(02)02113-8; Camenisch GP, 1998, PHARMACEUT RES, V15, P1174, DOI 10.1023/A:1011975404789; Chan VWF, 1997, IMMUNITY, V7, P69, DOI 10.1016/S1074-7613(00)80511-7; Chang CI, 2002, MOL CELL, V9, P1241, DOI 10.1016/S1097-2765(02)00525-7; Dasgupta P, 2000, LIFE SCI, V66, P1557, DOI 10.1016/S0024-3205(00)00476-8; DesboisMouthon C, 1996, METABOLISM, V45, P1493, DOI 10.1016/S0026-0495(96)90178-X; EICHHOLTZ T, 1993, J BIOL CHEM, V268, P1982; Engh RA, 2002, PHARMACOL THERAPEUT, V93, P99, DOI 10.1016/S0163-7258(02)00180-8; Fabbro D, 2002, PHARMACOL THERAPEUT, V93, P79, DOI 10.1016/S0163-7258(02)00179-1; Favelyukis S, 2001, NAT STRUCT BIOL, V8, P1058, DOI 10.1038/nsb721; FLEIG UN, 1992, MOL CELL BIOL, V12, P2295, DOI 10.1128/MCB.12.5.2295; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Fujimoto M, 2000, IMMUNITY, V13, P47, DOI 10.1016/S1074-7613(00)00007-8; GALLAGHER PJ, 1993, J BIOL CHEM, V268, P26578; Gaul BS, 2000, J BIOL CHEM, V275, P16174, DOI 10.1074/jbc.M909044199; Goldberg J, 1996, CELL, V84, P875, DOI 10.1016/S0092-8674(00)81066-1; GOLDENBERGFURMA.M, 2003, IN PRESS CANC RES; Graff JR, 2000, J BIOL CHEM, V275, P24500, DOI 10.1074/jbc.M003145200; Hardie G, 1995, PROTEIN KINASE FACTS, V2; HERRING BP, 1992, J BIOL CHEM, V267, P25945; HU SH, 1994, NATURE, V369, P581, DOI 10.1038/369581a0; HUANG CYF, 1995, J BIOL CHEM, V270, P7183, DOI 10.1074/jbc.270.13.7183; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; Jackson JG, 2000, ONCOGENE, V19, P4574, DOI 10.1038/sj.onc.1203825; JONES DT, 1992, COMPUT APPL BIOSCI, V8, P275, DOI 10.1093/bioinformatics/8.3.275; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; Karni R, 2003, FEBS LETT, V537, P47, DOI 10.1016/S0014-5793(03)00069-3; Kelemen BR, 2002, J BIOL CHEM, V277, P8741, DOI 10.1074/jbc.M108459200; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; Kobe B, 1996, EMBO J, V15, P6810, DOI 10.1002/j.1460-2075.1996.tb01072.x; Kroner C, 2000, J BIOL CHEM, V275, P27790, DOI 10.1074/jbc.M000540200; KRUEGER JK, 1995, J BIOL CHEM, V270, P16848, DOI 10.1074/jbc.270.28.16848; Lauta VM, 2000, FUNDAM CLIN PHARM, V14, P425, DOI 10.1111/j.1472-8206.2000.tb00425.x; Lei M, 2000, CELL, V102, P387, DOI 10.1016/S0092-8674(00)00043-X; Licht T, 2003, BLOOD, V102, P2099, DOI 10.1182/blood-2002-12-3634; Linnekin D, 1999, INT J BIOCHEM CELL B, V31, P1053, DOI 10.1016/S1357-2725(99)00078-3; Lou Q, 1997, CANCER RES, V57, P1877; Lowe ED, 1997, EMBO J, V16, P6646, DOI 10.1093/emboj/16.22.6646; Mayans O, 1998, NATURE, V395, P863, DOI 10.1038/27603; Nakatani K, 1999, J BIOL CHEM, V274, P21528, DOI 10.1074/jbc.274.31.21528; Nichols A, 2000, J BIOL CHEM, V275, P24613, DOI 10.1074/jbc.M001515200; NICOSIA RF, 1990, LAB INVEST, V63, P115; NISSANOV J, 1995, LAB INVEST, V73, P734; Paradis S, 1999, GENE DEV, V13, P1438, DOI 10.1101/gad.13.11.1438; Parang K, 2002, PHARMACOL THERAPEUT, V93, P145, DOI 10.1016/S0163-7258(02)00184-5; Parang K, 2001, NAT STRUCT BIOL, V8, P37; Ramdas L, 1999, J PEPT RES, V53, P569, DOI 10.1034/j.1399-3011.1999.00063.x; Robinson FL, 2002, J BIOL CHEM, V277, P14844, DOI 10.1074/jbc.M107776200; Sawyer TK, 2002, MINI-REV MED CHEM, V2, P475, DOI 10.2174/1389557023405765; Scott JW, 2002, J MOL BIOL, V317, P309, DOI 10.1006/jmbi.2001.5316; Shaltiel S, 1998, P NATL ACAD SCI USA, V95, P484, DOI 10.1073/pnas.95.2.484; Shewchuk LM, 2000, STRUCTURE, V8, P1105, DOI 10.1016/S0969-2126(00)00516-5; Stambolic V, 1999, ONCOGENE, V18, P6094, DOI 10.1038/sj.onc.1203126; STROM SC, 1982, METHOD ENZYMOL, V82, P544; Sumitomo M, 2000, J CLIN INVEST, V106, P1399, DOI 10.1172/JCI10536; Takahashi Y, 1997, DIABETOLOGIA, V40, P412, DOI 10.1007/s001250050695; Tanoue T, 2001, EMBO J, V20, P466, DOI 10.1093/emboj/20.3.466; Testa JR, 2001, P NATL ACAD SCI USA, V98, P10983, DOI 10.1073/pnas.211430998; Till JH, 1999, J BIOL CHEM, V274, P4995, DOI 10.1074/jbc.274.8.4995; Traxler P, 2003, EXPERT OPIN THER TAR, V7, P215, DOI 10.1517/14728222.7.2.215; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Varadarajan S, 1999, BRAIN RES BULL, V50, P133, DOI 10.1016/S0361-9230(99)00093-3; WEN W, 1994, J BIOL CHEM, V269, P8423; Wettergren A, 1998, REGUL PEPTIDES, V77, P83, DOI 10.1016/S0167-0115(98)00044-5; Whang YE, 1998, P NATL ACAD SCI USA, V95, P5246, DOI 10.1073/pnas.95.9.5246; Wick K. L. R., 2001, Current Drug Targets - Immune Endocrine and Metabolic Disorders, V1, P209; Yakymovych I, 2002, BIOCHEMISTRY-US, V41, P11000, DOI 10.1021/bi025936u; Yang J, 2002, NAT STRUCT BIOL, V9, P940, DOI 10.1038/nsb870; Yoganathan N, 2002, PHARMACOL THERAPEUT, V93, P233, DOI 10.1016/S0163-7258(02)00192-4; Yokoyama N, 1999, FEBS LETT, V456, P403, DOI 10.1016/S0014-5793(99)00992-8; Zaliani A, 1998, PROTEIN ENG, V11, P803, DOI 10.1093/protein/11.9.803; Zeng X, 2002, CANCER RES, V62, P3538; Zhang W, 2000, CANCER RES, V60, P6757; Zhang XH, 2002, J BIOL CHEM, V277, P45276, DOI 10.1074/jbc.M208063200; Zheleva DI, 2002, J PEPT RES, V60, P257, DOI 10.1034/j.1399-3011.2002.21014.x	99	42	46	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 9	2004	279	2					1242	1255		10.1074/jbc.M306723200	http://dx.doi.org/10.1074/jbc.M306723200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	759DJ	14570903	hybrid			2022-12-27	WOS:000187722800050
J	Ashe, M; Lil, PPA; Dees, E; Price, KL; Bader, D				Ashe, M; Lil, PPA; Dees, E; Price, KL; Bader, D			LEK1 is a potential inhibitor of pocket protein-mediated cellular processes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOBLASTOMA GENE FAMILY; DNA-SYNTHESIS; DIFFERENTIATION; E2F; BINDING; RB; ACTIVATION; GROWTH; CELLS; IDENTIFICATION	LEK1, a member of the LEK family of proteins, is ubiquitously expressed in developing murine tissues. Our current studies are aimed at identifying the role of LEK1 during cell growth and differentiation. Little is known about the function of LEK proteins. Recent studies in our laboratory have focused on the characterization of the LEK1 atypical Rb-binding domain that is conserved among all LEK proteins. Our findings suggest that LEK1 potentially functions as a universal regulator of pocket protein activity. Pocket proteins exhibit distinct expression patterns during development and function to regulate cell cycle, apoptosis, and tissue-specific gene expression. We show that LEK1 interacts with all three pocket proteins, p107, p130, and pRb. Additionally, this interaction occurs specifically between the LEK1 Rb-binding motif and the "pocket domain" of Rb proteins responsible for Rb association with other targets. Analyses of the effects of disruption of LEK1 protein expression by morpholino oligomers demonstrate that LEK1 depletion decreases cell proliferation, disrupts cell cycle progression, and induces apoptosis. Given its expression in developing cells, its association with pocket proteins, and its effects on proliferation, cell cycle, and viability of cells, we suggest that LEK1 functions in a similar manner to phosphorylation to disrupt association of Rb proteins with appropriate binding targets. Thus, the LEK1/Rb interaction serves to retain cells in a pre-differentiative, actively proliferative state despite the presence of Rb proteins during development. Our data suggest that LEK1 is unique among LEK family members in that it specifically functions during murine development to regulate the activity of Rb proteins during cell division and proliferation. Furthermore, we discuss the distinct possibility that a yet unidentified splice variant of the closely related human CENP-F, serves a similar function to LEK1 in humans.	Vanderbilt Univ, Stahlman Cardiovasc Res Labs, Program Dev Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Div Cardiovasc Med, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Bader, D (corresponding author), Vanderbilt Univ, Stahlman Cardiovasc Res Labs, Program Dev Biol, 221 Kirkland Hall, Nashville, TN 37232 USA.							Aznar S, 2001, PROG NUCLEIC ACID RE, V67, P193, DOI 10.1016/S0079-6603(01)67029-6; Bhat UG, 1999, P NATL ACAD SCI USA, V96, P7859, DOI 10.1073/pnas.96.14.7859; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; DOBBELSTEIN M, 1992, ONCOGENE, V7, P837; Garriga J, 1998, BIOCHEM J, V333, P645, DOI 10.1042/bj3330645; Goodwin RL, 1999, J BIOL CHEM, V274, P18597, DOI 10.1074/jbc.274.26.18597; HAGEMEIER C, 1993, NUCLEIC ACIDS RES, V21, P4998, DOI 10.1093/nar/21.22.4998; Hu NP, 1997, CANCER RES, V57, P4123; Jiang Z, 1997, ONCOGENE, V14, P1789, DOI 10.1038/sj.onc.1201014; Knudsen ES, 1997, MOL CELL BIOL, V17, P5771, DOI 10.1128/MCB.17.10.5771; LIAO H, 1995, J CELL BIOL, V130, P507, DOI 10.1083/jcb.130.3.507; Lin SCJ, 1996, SEMIN CANCER BIOL, V7, P279, DOI 10.1006/scbi.1996.0036; Lipinski MM, 1999, ONCOGENE, V18, P7873, DOI 10.1038/sj.onc.1203244; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; Morris EJ, 2001, J NEUROSCI, V21, P5017, DOI 10.1523/JNEUROSCI.21-14-05017.2001; NEVINS JR, 1992, NATURE, V358, P375, DOI 10.1038/358375a0; OZAKI T, 1994, ONCOGENE, V9, P2649; Pabon-Pena LM, 2000, J BIOL CHEM, V275, P21453, DOI 10.1074/jbc.M000518200; Paggi MG, 1996, J CELL BIOCHEM, V62, P418; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; SCHNEIDER JW, 1994, SCIENCE, V264, P1467, DOI 10.1126/science.8197461; Sellers WR, 1998, GENE DEV, V12, P95, DOI 10.1101/gad.12.1.95; Soonpaa MH, 1996, AM J PHYSIOL-HEART C, V271, pH2183; Wei Y, 1996, DEVELOPMENT, V122, P2779; YEE AS, 1998, FRONT BIOSCI, V3, P532; Yin F, 2001, BIOCHEM BIOPH RES CO, V286, P916, DOI 10.1006/bbrc.2001.5491; ZHU XL, 1995, J BIOL CHEM, V270, P19545, DOI 10.1074/jbc.270.33.19545	28	29	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	2004	279	1					664	676		10.1074/jbc.M308810200	http://dx.doi.org/10.1074/jbc.M308810200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	757GU	14555653	hybrid			2022-12-27	WOS:000187555300080
J	Belyaev, ND; Wood, IC; Bruce, AW; Street, M; Trinh, JB; Buckley, NJ				Belyaev, ND; Wood, IC; Bruce, AW; Street, M; Trinh, JB; Buckley, NJ			Distinct RE-1 silencing transcription factor-containing complexes interact with different target genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYLCHOLINE-RECEPTOR GENE; HISTONE DEACETYLASE COMPLEX; NEURAL-SPECIFIC EXPRESSION; SODIUM-CHANNEL GENE; NEURONAL GENES; IN-VIVO; CROSS-LINKING; SYNAPSIN-I; ELEMENT; REPRESSION	Establishment of neuronal identity requires co-ordinated expression of specific batteries of genes. These programs of gene expression are executed by activation of neuron-specific genes in neuronal cells and their repression in non-neuronal cells. Such co-ordinate regulation requires that individual activators and repressors regulate transcription from specific subsets of their potential target genes, yet we know little of the mechanisms that underlie this selective process. The RE-1 silencing transcription factor ( REST) is a repressor that is proposed to silence transcription of numerous neuron-specific genes in non-neuronal cells via recruitment of two independent histone deacetylase ( HDAC)-containing co-repressor complexes. However, in vivo, REST appears to be an obligate silencer for only a minority of RE-1-bearing genes. Here we examine the interaction of REST, Co-REST, Sin3A, HDAC1, and HDAC2 with two archetypical endogenous target genes, the M4 muscarinic receptor and the sodium type II channel (NaV1.2) genes. We find that these genes are present in distinct chromosomal domains. The NaV1.2 gene is actively transcribed but repressed by REST independently of histone deacetylation or DNA methylation and does not co-localize with epigenetic markers of silence, including dimethylation of H3K9 and HP1. In contrast, the M4 gene is maintained in a silent state independently of REST and co-localizes with dimethylated H3K9 and HP1alpha and HP1gamma, characteristic of silenced or senescent euchromatic DNA. This contrasts with the coordinate REST-dependent regulation of this locus reported previously. Taken together, we infer that distinct repressor complexes and mechanisms are operative at particular loci even in cell lines derived from a common embryological origin.	Univ Leeds, Sch Biochem & Mol Biol, Leeds LS2 9JT, W Yorkshire, England; Univ Leeds, Sch Biomed Sci, Leeds LS2 9JT, W Yorkshire, England	University of Leeds; University of Leeds	Buckley, NJ (corresponding author), Univ Leeds, Sch Biochem & Mol Biol, Leeds LS2 9JT, W Yorkshire, England.		Buckley, Noel J/B-9675-2012; Bruce, Alexander W/H-4235-2014; Wood, Ian/AAK-9423-2021	Buckley, Noel J/0000-0003-1152-0653; Bruce, Alexander W/0000-0003-4297-4412; Wood, Ian/0000-0003-1886-2533				Andres ME, 1999, P NATL ACAD SCI USA, V96, P9873, DOI 10.1073/pnas.96.17.9873; ARCHER TK, 1992, SCIENCE, V255, P1573, DOI 10.1126/science.1347958; Armisen R, 2002, J NEUROSCI, V22, P8347; Ballas N, 2001, NEURON, V31, P353, DOI 10.1016/S0896-6273(01)00371-3; Battaglioli E, 2002, J BIOL CHEM, V277, P41038, DOI 10.1074/jbc.M205691200; Bessis A, 1997, P NATL ACAD SCI USA, V94, P5906, DOI 10.1073/pnas.94.11.5906; Braun H, 2001, NUCLEIC ACIDS RES, V29, P4994, DOI 10.1093/nar/29.24.4994; Brene S, 2000, EUR J NEUROSCI, V12, P1525, DOI 10.1046/j.1460-9568.2000.00040.x; Chen ZF, 1998, NAT GENET, V20, P136, DOI 10.1038/2431; CHONG JHA, 1995, CELL, V80, P949, DOI 10.1016/0092-8674(95)90298-8; Fryer CJ, 1998, NATURE, V393, P88, DOI 10.1038/30032; Galasinski SC, 2002, J BIOL CHEM, V277, P19618, DOI 10.1074/jbc.M201174200; Grimes JA, 2000, J BIOL CHEM, V275, P9461, DOI 10.1074/jbc.275.13.9461; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hakimi MA, 2002, P NATL ACAD SCI USA, V99, P7420, DOI 10.1073/pnas.112008599; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; Huang YF, 1999, NAT NEUROSCI, V2, P867, DOI 10.1038/13165; Jepsen K, 2000, CELL, V102, P753, DOI 10.1016/S0092-8674(00)00064-7; Kallunki P, 1997, J CELL BIOL, V138, P1343, DOI 10.1083/jcb.138.6.1343; KRANER SD, 1992, NEURON, V9, P37, DOI 10.1016/0896-6273(92)90218-3; Kuo MH, 1999, METHODS, V19, P425, DOI 10.1006/meth.1999.0879; Kuwahara K, 2001, MOL CELL BIOL, V21, P2085, DOI 10.1128/MCB.21.6.2085-2097.2001; Lachner M, 2003, J CELL SCI, V116, P2117, DOI 10.1242/jcs.00493; LI LA, 1993, P NATL ACAD SCI USA, V90, P1460, DOI 10.1073/pnas.90.4.1460; Lonnerberg P, 1996, J BIOL CHEM, V271, P33358, DOI 10.1074/jbc.271.52.33358; Lu JR, 2000, P NATL ACAD SCI USA, V97, P4070, DOI 10.1073/pnas.080064097; Lunyak VV, 2002, SCIENCE, V298, P1747, DOI 10.1126/science.1076469; Mieda M, 1997, J BIOL CHEM, V272, P5854, DOI 10.1074/jbc.272.9.5854; MORI N, 1992, NEURON, V9, P45, DOI 10.1016/0896-6273(92)90219-4; Muhr J, 2001, CELL, V104, P861, DOI 10.1016/S0092-8674(01)00283-5; Myers SJ, 1998, J NEUROSCI, V18, P6723; Naruse Y, 1999, P NATL ACAD SCI USA, V96, P13691, DOI 10.1073/pnas.96.24.13691; Ohtsuka T, 1999, EMBO J, V18, P2196, DOI 10.1093/emboj/18.8.2196; Orlando V, 1997, METHODS, V11, P205, DOI 10.1006/meth.1996.0407; Roopra A, 2000, MOL CELL BIOL, V20, P2147, DOI 10.1128/MCB.20.6.2147-2157.2000; Schoch S, 1996, J BIOL CHEM, V271, P3317, DOI 10.1074/jbc.271.6.3317; SCHOENHERR CJ, 1995, SCIENCE, V267, P1360, DOI 10.1126/science.7871435; Schoenherr CJ, 1996, P NATL ACAD SCI USA, V93, P9881, DOI 10.1073/pnas.93.18.9881; Seth KA, 2001, J BIOL CHEM, V276, P13917, DOI 10.1074/jbc.M007745200; Soutoglou E, 2000, MOL CELL, V5, P745, DOI 10.1016/S1097-2765(00)80253-1; Ulleras E, 2001, EXP CELL RES, V270, P188, DOI 10.1006/excr.2001.5338; Vries RGJ, 2001, EMBO J, V20, P6095, DOI 10.1093/emboj/20.21.6095; Wood IC, 1999, BIOCHEM J, V340, P475, DOI 10.1042/0264-6021:3400475; Wood IC, 1996, J BIOL CHEM, V271, P14221, DOI 10.1074/jbc.271.24.14221; Wood IC, 2003, J MOL BIOL, V334, P863, DOI 10.1016/j.jmb.2003.10.017; You A, 2001, P NATL ACAD SCI USA, V98, P1454, DOI 10.1073/pnas.98.4.1454; Zhang HS, 2000, CELL, V101, P79, DOI 10.1016/S0092-8674(00)80625-X	47	60	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	2004	279	1					556	561		10.1074/jbc.M310353200	http://dx.doi.org/10.1074/jbc.M310353200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	757GU	14561745	hybrid			2022-12-27	WOS:000187555300067
J	Onnerfjord, P; Heathfield, TF; Heinegard, D				Onnerfjord, P; Heathfield, TF; Heinegard, D			Identification of tyrosine sulfation in extracellular leucine-rich repeat proteins using mass spectrometry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN IB-ALPHA; VON-WILLEBRAND-FACTOR; RECESSIVE CHONDRODYSPLASIA PUNCTATA; HIGH-AFFINITY BINDING; ARYLSULFATASE-E; HIV-1 ENTRY; P-SELECTIN; POSTTRANSLATIONAL MODIFICATIONS; THROMBIN BINDING; MATRIX PROTEINS	Multiple and variable tyrosine sulfation in extracellular class II leucine-rich repeat proteins/proteoglycans were characterized by mass spectrometry. The sulfogroup on tyrosine is labile and is released from peptides under normal mass spectrometric conditions. Thus, special approaches must be considered in order to identify this modification. By using a combination of mass spectrometry studies operating in negative and positive ion mode, tyrosine sulfation could be identified. In positive mode, the peptides normally appeared non-sulfated, whereas in negative mode a mixture of sulfated and non-sulfated species was observed. A combination of peptides released by different proteinases was used to obtain details on the locations of sulfate groups. Multiple tyrosine sulfates were observed in the N-terminal region of fibromodulin ( up to 9 sites), osteoadherin ( up to 6 sites), and lumican ( 2 sites). Osteoadherin contains two additional sulfated tyrosine residues close to its C terminus. We also identified an error in the published sequence of bovine fibromodulin, resulting in the replacement of Thr(37) by Tyr(37)-Gly(38), thus increasing its homology with its human counterpart.	Lund Univ, Dept Cell & Mol Biol, Sect Connect Tissue Biol, S-22184 Lund, Sweden	Lund University	Heinegard, D (corresponding author), Lund Univ, Dept Cell & Mol Biol, Sect Connect Tissue Biol, BMC C12, S-22184 Lund, Sweden.		Onnerfjord, Patrik/R-3131-2019	Onnerfjord, Patrik/0000-0002-2345-2937				AXELSSON I, 1975, BIOCHEM J, V145, P491, DOI 10.1042/bj1450491; Bannert N, 2001, J EXP MED, V194, P1661, DOI 10.1084/jem.194.11.1661; Bernimoulin MP, 2003, J BIOL CHEM, V278, P37, DOI 10.1074/jbc.M204360200; Brunetti-Pierri N, 2003, AM J MED GENET A, V117A, P164, DOI 10.1002/ajmg.a.10950; Bundgaard JR, 1997, J BIOL CHEM, V272, P21700, DOI 10.1074/jbc.272.35.21700; Costagliola S, 2002, EMBO J, V21, P504, DOI 10.1093/emboj/21.4.504; Dahl HHM, 1999, MOL GENET METAB, V68, P503, DOI 10.1006/mgme.1999.2935; Daniele A, 1998, AM J HUM GENET, V62, P562, DOI 10.1086/301746; DONG JF, 1994, BIOCHEMISTRY-US, V33, P13946, DOI 10.1021/bi00250a050; Dong JF, 1999, BLOOD, V94, p441A; Dong JF, 2001, J BIOL CHEM, V276, P16690, DOI 10.1074/jbc.M101035200; ECAROTCHARRIER B, 1989, J BIOL CHEM, V264, P20049; Farzan M, 2000, J BIOL CHEM, V275, P33516, DOI 10.1074/jbc.M007228200; Farzan M, 1999, CELL, V96, P667, DOI 10.1016/S0092-8674(00)80577-2; Farzan M, 2002, J BIOL CHEM, V277, P29484, DOI 10.1074/jbc.M203361200; Farzan M, 2001, J EXP MED, V193, P1059, DOI 10.1084/jem.193.9.1059; Fong AM, 2002, J BIOL CHEM, V277, P19418, DOI 10.1074/jbc.M201396200; FUNDERBURGH JL, 1990, J BIOL CHEM, V265, P8297; HEINEGARD D, 1986, J BIOL CHEM, V261, P3866; Horton WA, 1995, EUR J HUM GENET, V3, P357; HUTTNER WB, 1987, TRENDS BIOCHEM SCI, V12, P361, DOI 10.1016/0968-0004(87)90166-6; HUTTNER WB, 1984, METHOD ENZYMOL, V107, P200; Landon, 1977, Methods Enzymol, V47, P145; Leppanen A, 1999, J BIOL CHEM, V274, P24838, DOI 10.1074/jbc.274.35.24838; Leppanen A, 2000, J BIOL CHEM, V275, P39569, DOI 10.1074/jbc.M005005200; LEYTE A, 1991, J BIOL CHEM, V266, P740; MARCHESE P, 1995, J BIOL CHEM, V270, P9571, DOI 10.1074/jbc.270.16.9571; MARCUS F, 1985, INT J PEPT PROT RES, V25, P542; Meh DA, 2001, THROMB HAEMOSTASIS, V85, P470; Monigatti F, 2002, BIOINFORMATICS, V18, P769, DOI 10.1093/bioinformatics/18.5.769; Nemeth-Cawley JF, 2002, J MASS SPECTROM, V37, P270, DOI 10.1002/jms.281; NIEHRS C, 1994, CHEM-BIOL INTERACT, V92, P257, DOI 10.1016/0009-2797(94)90068-X; Nlend MC, 1999, BIOCHEM BIOPH RES CO, V262, P193, DOI 10.1006/bbrc.1999.1173; Ouyang YB, 2002, J BIOL CHEM, V277, P23781, DOI 10.1074/jbc.M202420200; Parenti G, 1997, CURR OPIN GENET DEV, V7, P386, DOI 10.1016/S0959-437X(97)80153-0; Parenti G, 1997, AM J MED GENET, V73, P139, DOI 10.1002/(SICI)1096-8628(19971212)73:2<139::AID-AJMG7>3.0.CO;2-P; Preobrazhensky AA, 2000, J IMMUNOL, V165, P5295, DOI 10.4049/jimmunol.165.9.5295; Schuerenbeg M, 2000, ANAL CHEM, V72, P3436, DOI 10.1021/ac000092a; Seibert C, 2002, P NATL ACAD SCI USA, V99, P11031, DOI 10.1073/pnas.172380899; Severs JC, 1999, RAPID COMMUN MASS SP, V13, P1016, DOI 10.1002/(SICI)1097-0231(19990615)13:11<1016::AID-RCM599>3.0.CO;2-5; Sheffield LJ, 1997, AM J HUM GENET, V61, pA27; Steen H, 2001, ANAL CHEM, V73, P1440, DOI 10.1021/ac001318c; Suiko M, 1996, BIOSCI BIOTECH BIOCH, V60, P137, DOI 10.1271/bbb.60.137; Tait AS, 2002, BLOOD, V99, P4422, DOI 10.1182/blood.V99.12.4422; TALBO G, 1994, TECHNIQUES IN PROTEIN CHEMISTRY V, P105; TALBO G, 1993, RAPID COMMUN MASS SP, V7, P201, DOI 10.1002/rcm.1290070307; Venot N, 2002, BIOCHEM BIOPH RES CO, V298, P193, DOI 10.1016/S0006-291X(02)02425-7; Wendel M, 1998, J CELL BIOL, V141, P839, DOI 10.1083/jcb.141.3.839; WILKINS PP, 1995, J BIOL CHEM, V270, P22677, DOI 10.1074/jbc.270.39.22677; Wolfender JL, 1999, J MASS SPECTROM, V34, P447, DOI 10.1002/(SICI)1096-9888(199904)34:4<447::AID-JMS801>3.3.CO;2-T; YAGAMI T, 1995, RAPID COMMUN MASS SP, V9, P1335, DOI 10.1002/rcm.1290091403; Zaia J, 2001, BIOCHEMISTRY-US, V40, P12983, DOI 10.1021/bi010887r	52	97	109	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	2004	279	1					26	33		10.1074/jbc.M308689200	http://dx.doi.org/10.1074/jbc.M308689200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	757GU	14551184	hybrid			2022-12-27	WOS:000187555300004
J	Park, PW; Foster, TJ; Nishi, E; Duncan, SJ; Klagsbrun, M; Chen, Y				Park, PW; Foster, TJ; Nishi, E; Duncan, SJ; Klagsbrun, M; Chen, Y			Activation of syndecan-1 ectodomain shedding by Staphylococcus aureus alpha-toxin and beta-toxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; GROWTH-FACTOR; CONVERTING-ENZYME; FACTOR RECEPTOR; SECRETASE CLEAVAGE; GAMMA-TOXIN; VIRULENCE; CERAMIDE; EGF; INTERLEUKIN-6	Exploitation of host components by microbes to promote their survival in the hostile host environment has been a recurring theme in recent years. Available data indicate that bacterial pathogens activate ectodomain shedding of host cell surface molecules to enhance their virulence. We reported previously that several major bacterial pathogens activate ectodomain shedding of syndecan-1, the major heparan sulfate proteoglycan of epithelial cells. Here we define the molecular basis of how Staphylococcus aureus activates syndecan-1 shedding. We screened mutant S. aureus strains devoid of various toxin and protease genes and found that only strains lacking both alpha-toxin and beta-toxin genes do not stimulate shedding. Mutations in the agr global regulatory locus, which positively regulates expression of alpha- and beta-toxins and other exoproteins, also abrogated the capacity to stimulate syndecan-1 shedding. Furthermore, purified S. aureus alpha- and beta-toxins, but not enterotoxin A and toxic shock syndrome toxin-1, rapidly potentiated shedding in a concentration-dependent manner. These results establish that S. aureus activates syndecan- 1 ectodomain shedding via its two virulence factors, alpha- and beta-toxins. Toxin-activated shedding was also selectively inhibited by antagonists of the host cell shedding mechanism, indicating that alpha- and beta-toxins shed syndecan- 1 ectodomains through stimulation of the host cell's shedding machinery. Interestingly, beta-toxin, but not alpha-toxin, also enhanced ectodomain shedding of syndecan- 4 and heparin-binding epidermal growth factor. Because shedding of these ectodomains has been implicated in promoting bacterial pathogenesis, activation of ectodomain shedding by alpha-toxin and beta-toxin may be a previously unknown virulence mechanism of S. aureus.	Baylor Coll Med, Infect Dis Sect, Houston, TX 77030 USA; Baylor Coll Med, Dept Med, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA; Baylor Coll Med, Biol Inflammat Ctr, Houston, TX 77030 USA; Univ Dublin Trinity Coll, Dept Microbiol, Moyne Inst Prevent Med, Dublin 2, Ireland; Kyoto Univ, Grad Sch Med, Horizontal Med Res Org, Mol Pathol Unit, Kyoto, Japan; Harvard Univ, Childrens Hosp, Sch Med, Dept Surg Res, Boston, MA 02115 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Trinity College Dublin; Kyoto University; Harvard University; Boston Children's Hospital; Harvard Medical School	Park, PW (corresponding author), Baylor Coll Med, Infect Dis Sect, 1 Baylor Plaza,Rm N1319, Houston, TX 77030 USA.	pwpark@bcm.tmc.edu	Nishi, Eiichiro/A-8246-2019	Nishi, Eiichiro/0000-0002-8188-8026; Park, Pyong Woo/0000-0002-7979-4979	NHLBI NIH HHS [HL69050, R01 HL069050] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL069050] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Althoff K, 2000, EUR J BIOCHEM, V267, P2624, DOI 10.1046/j.1432-1327.2000.01278.x; Arribas J, 2002, CHEM REV, V102, P4627, DOI 10.1021/cr010202t; Arvidson S, 2000, GRAM-POSITIVE PATHOGENS, P379; Asakura M, 2002, NAT MED, V8, P35, DOI 10.1038/nm0102-35; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Bohach GA, 2000, GRAM-POSITIVE PATHOGENS, P367; Bolen JB, 1997, ANNU REV IMMUNOL, V15, P371, DOI 10.1146/annurev.immunol.15.1.371; Brou C, 2000, MOL CELL, V5, P207, DOI 10.1016/S1097-2765(00)80417-7; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; Elenius K, 1997, EMBO J, V16, P1268, DOI 10.1093/emboj/16.6.1268; Fan HZ, 1999, EMBO J, V18, P6962, DOI 10.1093/emboj/18.24.6962; Fan HZ, 2003, J BIOL CHEM, V278, P18617, DOI 10.1074/jbc.M300331200; Fitzgerald ML, 2000, J CELL BIOL, V148, P811, DOI 10.1083/jcb.148.4.811; Gechtman Z, 1999, J BIOL CHEM, V274, P28828, DOI 10.1074/jbc.274.40.28828; Grassme H, 2003, NAT MED, V9, P322, DOI 10.1038/nm823; Gutwein P, 2000, J BIOL CHEM, V275, P15490, DOI 10.1074/jbc.275.20.15490; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; Haro H, 2000, J CLIN INVEST, V105, P143, DOI 10.1172/JCI7091; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; Izumi Y, 1998, EMBO J, V17, P7260, DOI 10.1093/emboj/17.24.7260; Kajita M, 2001, J CELL BIOL, V153, P893, DOI 10.1083/jcb.153.5.893; Kinnunen T, 1998, J BIOL CHEM, V273, P10702, DOI 10.1074/jbc.273.17.10702; Lemjabbar H, 2002, NAT MED, V8, P41, DOI 10.1038/nm0102-41; Li QL, 2002, CELL, V111, P635, DOI 10.1016/S0092-8674(02)01079-6; Mattsson E, 1996, INFECT IMMUN, V64, P4351, DOI 10.1128/IAI.64.10.4351-4355.1996; McAleese FM, 2001, J BIOL CHEM, V276, P29969, DOI 10.1074/jbc.M102389200; MCGEEHAN GM, 1994, NATURE, V370, P558, DOI 10.1038/370558a0; Merlos-Suarez A, 2001, J BIOL CHEM, V276, P48510, DOI 10.1074/jbc.M103488200; MOHLER KM, 1994, NATURE, V370, P218, DOI 10.1038/370218a0; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; Nilsson IM, 1999, INFECT IMMUN, V67, P1045, DOI 10.1128/IAI.67.3.1045-1049.1999; NISHI E, 2003, ENCY HORMONES, V2, P235; NOVICK R, 1967, VIROLOGY, V33, P155, DOI 10.1016/0042-6822(67)90105-5; Novick RP, 2003, MOL MICROBIOL, V48, P1429, DOI 10.1046/j.1365-2958.2003.03526.x; NOVICK RP, 1993, EMBO J, V12, P3967, DOI 10.1002/j.1460-2075.1993.tb06074.x; OREILLY M, 1986, MICROB PATHOGENESIS, V1, P125, DOI 10.1016/0882-4010(86)90015-X; Ott VL, 1998, J BIOL CHEM, V273, P35291, DOI 10.1074/jbc.273.52.35291; Park PW, 2000, J BIOL CHEM, V275, P29923, DOI 10.1074/jbc.R000008200; Park PW, 2001, NATURE, V411, P98, DOI 10.1038/35075100; Park PW, 2000, J BIOL CHEM, V275, P3057, DOI 10.1074/jbc.275.5.3057; PATEL AH, 1987, INFECT IMMUN, V55, P3103, DOI 10.1128/IAI.55.12.3103-3110.1987; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; Powell WC, 1999, CURR BIOL, V9, P1441, DOI 10.1016/S0960-9822(00)80113-X; Puglielli L, 2003, J BIOL CHEM, V278, P19777, DOI 10.1074/jbc.M300466200; Rose F, 2002, AM J PHYSIOL-LUNG C, V282, pL207, DOI 10.1152/ajplung.00156.2001; ROSEJOHN S, 1994, BIOCHEM J, V300, P281, DOI 10.1042/bj3000281; Schlondorff J, 1999, J CELL SCI, V112, P3603; SHEAGREN JN, 1984, NEW ENGL J MED, V310, P1437, DOI 10.1056/NEJM198405313102206; SHEAGREN JN, 1984, NEW ENGL J MED, V310, P1368, DOI 10.1056/NEJM198405243102107; Shi M, 2001, J IMMUNOL, V167, P123, DOI 10.4049/jimmunol.167.1.123; Song LZ, 1996, SCIENCE, V274, P1859, DOI 10.1126/science.274.5294.1859; Sunnarborg SW, 2002, J BIOL CHEM, V277, P12838, DOI 10.1074/jbc.M112050200; Supersac G, 1998, MICROB PATHOGENESIS, V24, P241, DOI 10.1006/mpat.1997.0192; Suzuki M, 1997, J BIOL CHEM, V272, P31730, DOI 10.1074/jbc.272.50.31730; Tokumaru S, 2000, J CELL BIOL, V151, P209, DOI 10.1083/jcb.151.2.209; Valeva A, 1997, P NATL ACAD SCI USA, V94, P11607, DOI 10.1073/pnas.94.21.11607; Vandana S, 1997, J BIOL CHEM, V272, P24858, DOI 10.1074/jbc.272.40.24858; Vollmer P, 1996, INFECT IMMUN, V64, P3646, DOI 10.1128/IAI.64.9.3646-3651.1996; Walev I, 2000, J LEUKOCYTE BIOL, V68, P865; Walev I, 1996, P NATL ACAD SCI USA, V93, P7882, DOI 10.1073/pnas.93.15.7882; Zako M, 2003, J BIOL CHEM, V278, P13561, DOI 10.1074/jbc.M209658200	61	84	97	2	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 2	2004	279	1					251	258		10.1074/jbc.M308537200	http://dx.doi.org/10.1074/jbc.M308537200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	757GU	14573623	hybrid			2022-12-27	WOS:000187555300031
J	Rothem, L; Stark, M; Kaufman, Y; Mayo, L; Assaraf, YG				Rothem, L; Stark, M; Kaufman, Y; Mayo, L; Assaraf, YG			Reduced folate carrier gene silencing in multiple antifolate-resistant tumor cell lines is due to a simultaneous loss of function of multiple transcription factors but not promoter methylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHOTREXATE RESISTANCE; CHROMOSOMAL-PROTEIN; MEMBRANE-TRANSPORT; BINDING-PROTEINS; IN-VIVO; LEUKEMIA; EXPRESSION; MECHANISM; SP1; IDENTIFICATION	The human reduced folate carrier (hRFC) is the major uptake route for antifolates used in cancer chemotherapy. Here we explored the molecular basis for the decrease or loss of hRFC gene expression in seventeen tumor cell lines with resistance to multiple antifolates due to impaired antifolate transport. We studied the role of various cis-acting elements including CRE/AP-1-like element and GC-box in hRFC promoters A and B, respectively, as well as AP-2, Mzf-1 and E-box that are contained within or near four tandemly repeated sequences upstream of promoter A. Decreased or abolished binding either to [P-32] GC-box, Mzf-1, AP-1, E-box, or CRE oligonucleotides was detected in similar to50-80% of antifolate-resistant cell lines. Strikingly, similar to80% of the cell lines displayed a simultaneously decreased binding to three or more of these hRFC promoter elements, whereas normal AP-2 binding was retained. The possible contribution of promoter methylation to hRFC gene silencing was also explored. None of the antifolate-resistant cell lines, except for MDA-MB-231 cells, showed hRFC promoter methylation; consistently, MDA-MB-231 was the only cell line that retained binding to all six cis-acting elements. Western blot analysis demonstrated decreased expression of transcriptional activators (pCREB-1, pATF-1, USF-1, c-Fos, c-Jun, Sp1, and Sp3) and/or increased expression of repressors (short Sp3 isoforms), whereas normal AP2alpha levels were retained. Transient expression of the relevant transcription factors restored, at least partially, both promoter binding and hRFC gene expression. This is the first report that transcriptional silencing of the hRFC gene in multiple tumor cell lines with resistance to various novel antifolates is a result of a simultaneous loss of function of multiple transcription factors but not promoter methylation.	Technion Israel Inst Technol, Dept Biol, IL-32000 Haifa, Israel	Technion Israel Institute of Technology	Assaraf, YG (corresponding author), Technion Israel Inst Technol, Dept Biol, IL-32000 Haifa, Israel.	assaraf@tx.technion.ac.il	m, Lior/AGK-3671-2022; Stark, Michal/AFL-9651-2022; Stark, Michal/AAH-1763-2022	m, Lior/0000-0002-1296-6692; Stark, Michal/0000-0002-4712-7696; Stark, Michal/0000-0002-4712-7696; Assaraf, Yehuda G./0000-0001-6692-8221				Armstrong SA, 1997, J BIOL CHEM, V272, P13489, DOI 10.1074/jbc.272.21.13489; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; Boritzki TJ, 1996, INVEST NEW DRUG, V14, P295, DOI 10.1007/BF00194533; Bouwman P, 2002, MOL CELL ENDOCRINOL, V195, P27, DOI 10.1016/S0303-7207(02)00221-6; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Braun H, 2001, NUCLEIC ACIDS RES, V29, P4994, DOI 10.1093/nar/29.24.4994; Byers PH, 2002, J CLIN INVEST, V109, P3, DOI 10.1172/JCI14841; Davey C, 1997, J MOL BIOL, V267, P276, DOI 10.1006/jmbi.1997.0899; DEGRAW JI, 1986, J MED CHEM, V29, P1056, DOI 10.1021/jm00156a026; Ding BC, 2001, BIOCHEM PHARMACOL, V61, P665; Drori S, 2000, J BIOL CHEM, V275, P30855, DOI 10.1074/jbc.M003988200; Gong MK, 1997, BLOOD, V89, P2494, DOI 10.1182/blood.V89.7.2494; Gorlick R, 1997, BLOOD, V89, P1013, DOI 10.1182/blood.V89.3.1013; Guo W, 1999, CLIN CANCER RES, V5, P621; Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538; Ifergan I, 2003, CANCER-AM CANCER SOC, V98, P1958, DOI 10.1002/cncr.11741; JACKMAN AL, 1991, CANCER RES, V51, P5579; Jackman AL, 1997, CLIN CANCER RES, V3, P911; Jansen G, 1998, J BIOL CHEM, V273, P30189, DOI 10.1074/jbc.273.46.30189; Jansen G, 1998, DRUG RESIST UPDATE, V1, P211, DOI 10.1016/S1368-7646(98)80042-3; LEWIS JD, 1992, CELL, V69, P905, DOI 10.1016/0092-8674(92)90610-O; Liani E, 2003, INT J CANCER, V103, P587, DOI 10.1002/ijc.10829; Maquat LE, 2002, CURR BIOL, V12, pR196, DOI 10.1016/S0960-9822(02)00747-9; MATHERLY LH, 1995, BLOOD, V85, P500; Matherly LH, 2003, VITAM HORM, V66, P403, DOI 10.1016/S0083-6729(03)01012-4; MEEHAN RR, 1989, CELL, V58, P499, DOI 10.1016/0092-8674(89)90430-3; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Ng HH, 2000, MOL CELL BIOL, V20, P1394, DOI 10.1128/MCB.20.4.1394-1406.2000; OHLSSON H, 1986, CELL, V45, P35, DOI 10.1016/0092-8674(86)90535-0; RHEE MS, 1994, MOL PHARMACOL, V45, P783; Roos MD, 1997, MOL CELL BIOL, V17, P6472, DOI 10.1128/MCB.17.11.6472; Rothem L, 2003, J BIOL CHEM, V278, P8935, DOI 10.1074/jbc.M209578200; Rothem L, 2002, BIOCHEM J, V367, P741, DOI 10.1042/BJ20020801; Rots MG, 2000, LEUKEMIA, V14, P2166, DOI 10.1038/sj.leu.2401943; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Sharif KA, 1998, BIOCHEM PHARMACOL, V55, P1683, DOI 10.1016/S0006-2952(98)00039-2; Shih C, 1997, CANCER RES, V57, P1116; Stokstad ELR, 1990, FOLIC ACID METABOLIS, P1; TATE PH, 1993, CURR OPIN GENET DEV, V3, P226, DOI 10.1016/0959-437X(93)90027-M; Whetstine JR, 2002, J BIOL CHEM, V277, P43873, DOI 10.1074/jbc.M208296200; Whetstine JR, 2002, BIOCHEM J, V367, P629, DOI 10.1042/BJ20020512; Whetstine JR, 2001, J BIOL CHEM, V276, P6350, DOI 10.1074/jbc.M008074200; Wong SC, 1999, J BIOL CHEM, V274, P10388, DOI 10.1074/jbc.274.15.10388; Worm J, 2001, J BIOL CHEM, V276, P39990, DOI 10.1074/jbc.M103181200; Yang R, 2003, CLIN CANCER RES, V9, P837; Yang XY, 2002, CELL, V110, P69, DOI 10.1016/S0092-8674(02)00810-3; Yang XY, 2001, P NATL ACAD SCI USA, V98, P6611, DOI 10.1073/pnas.111099998; Zhu QW, 2000, BIOCHEM BIOPH RES CO, V271, P100, DOI 10.1006/bbrc.2000.2586	48	39	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 2	2004	279	1					374	384		10.1074/jbc.M309092200	http://dx.doi.org/10.1074/jbc.M309092200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	757GU	14551190	hybrid			2022-12-27	WOS:000187555300045
J	Slatter, DA; Avery, NC; Bailey, AJ				Slatter, DA; Avery, NC; Bailey, AJ			Identification of a new cross-link and unique histidine adduct from bovine serum albumin incubated with malondialdehyde	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; LIPID-DERIVED MALONDIALDEHYDE; GLYCATION END-PRODUCTS; IMMUNOCHEMICAL DETECTION; MAILLARD REACTION; OXIDATIVE STRESS; LYSINE RESIDUES; IN-VITRO; COLLAGEN; PROTEIN	Malondialdehyde, acetaldehyde, acrolein, and 4-hydroxynonenal are all products of fatty acid oxidation found in the fatty streaks of atherosclerotic arteries due to a lack of antioxidants and an increase in glycation products. Previously identified cross-links derived from these molecules have nearly always required more than one molecule of each type, although this is physiologically less likely than a reaction involving a single molecule. Here we provide indirect but strong evidence for a malondialdehyde-derived cross-link requiring just one malondialdehyde molecule to link arginine and lysine, giving 2-ornithinyl-4-methyl( 1epsilon-lysyl) 1,3-imidazole following a 4-day incubation of albumin with 8 mM malondialdehyde. This cross-link was identified as its partial degradation product N-epsilon-(2-carboxyl, 2- aminoethane)-N-epsilon-methanoyl-lysine by NMR and mass spectrometry. Analysis of plasma from treated diabetic patients revealed that one patient levels had as high as 0.46%, 0.67% of their lysine/ arginine residues modified by this cross-link, although others had lower levels. Alkaline hydrolysis of serum albumin also revealed two acid-labile malondialdehyde adducts of histidine in significant quantities, the isomers 4- and 2- ethylidene-histidine. These constituted up to 0.93% of the histidines in treated diabetic patients. Although collagen is readily cross-linked by malondialdehyde, none of these particular products could be found in incubations of collagen with malondialdehyde.	Univ Bristol, Div Mol & Cellular Biol, Collagen Res Grp, Bristol BS40 5DS, Avon, England	University of Bristol	Slatter, DA (corresponding author), Univ Cambridge, Dept Biochem, Bldg O,Downing Site, Cambridge CB2 1QW, England.		Slatter, David/AAW-6938-2021; Slatter, David/AAV-5771-2020					Al-Abed Y, 1999, P NATL ACAD SCI USA, V96, P2385, DOI 10.1073/pnas.96.5.2385; Baynes JW, 2000, FREE RADICAL BIO MED, V28, P1708, DOI 10.1016/S0891-5849(00)00228-8; Biemel KM, 2002, J BIOL CHEM, V277, P24907, DOI 10.1074/jbc.M202681200; Cohn JA, 1996, ARCH BIOCHEM BIOPHYS, V328, P158, DOI 10.1006/abbi.1996.0156; Decker EA, 2001, J AGR FOOD CHEM, V49, P511, DOI 10.1021/jf0010533; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; Frye EB, 1998, J BIOL CHEM, V273, P18714, DOI 10.1074/jbc.273.30.18714; Furuhata A, 2002, J BIOL CHEM, V277, P27919, DOI 10.1074/jbc.M202794200; GOMEZSANCHEZ A, 1992, CARBOHYD RES, V229, P307, DOI 10.1016/S0008-6215(00)90577-9; HICKS M, 1988, BIOCHEM BIOPH RES CO, V151, P649, DOI 10.1016/S0006-291X(88)80330-9; Hipkiss AR, 2002, NEUROBIOL AGING, V23, P645, DOI 10.1016/S0197-4580(02)00006-4; Ichihashi K, 2001, J BIOL CHEM, V276, P23903, DOI 10.1074/jbc.M101947200; LIGHT ND, 1982, METHOD ENZYMOL, V82, P360; Mooradian AD, 2001, NUTRITION, V17, P619, DOI 10.1016/S0899-9007(01)00580-9; Nagai R, 2000, DIABETES, V49, P1714, DOI 10.2337/diabetes.49.10.1714; Price DL, 2001, J BIOL CHEM, V276, P48967, DOI 10.1074/jbc.M108196200; QUINN PJ, 1992, MOL ASPECTS MED, V13, P379, DOI 10.1016/0098-2997(92)90006-L; Requena JR, 1997, BIOCHEM J, V322, P317, DOI 10.1042/bj3220317; SELL DR, 1989, J BIOL CHEM, V264, P21597; Sims TJ, 2000, METH MOL B, V139, P11; SIU GM, 1982, LIPIDS, V17, P349, DOI 10.1007/BF02535193; Slatter DA, 1998, FEBS LETT, V421, P180, DOI 10.1016/S0014-5793(97)01554-8; Slatter DA, 1999, J BIOL CHEM, V274, P19661, DOI 10.1074/jbc.274.28.19661; Slatter DA, 2000, DIABETOLOGIA, V43, P550, DOI 10.1007/s001250051342; SUMMERFIELD FW, 1978, BIOCHEM BIOPH RES CO, V82, P547, DOI 10.1016/0006-291X(78)90909-9; TSAI L, 1995, FREE RADICAL BIO MED, V19, P39, DOI 10.1016/0891-5849(95)00009-M; Tuma DJ, 2001, CHEM RES TOXICOL, V14, P822, DOI 10.1021/tx000222a; Uchida K, 1998, J BIOL CHEM, V273, P16058, DOI 10.1074/jbc.273.26.16058; UCHIDA K, 1994, BIOCHEMISTRY-US, V33, P12487, DOI 10.1021/bi00207a016; VANREYK DM, 1995, FREE RADICAL RES, V23, P533, DOI 10.3109/10715769509065274; WAUTIER JL, 1994, P NATL ACAD SCI USA, V91, P7742, DOI 10.1073/pnas.91.16.7742; Xu GH, 2000, CHEM RES TOXICOL, V13, P406, DOI 10.1021/tx990200s; Yamada S, 2001, J LIPID RES, V42, P1187; YAMAUCHI M, 1987, J BIOL CHEM, V262, P11428	34	48	54	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	2004	279	1					61	69		10.1074/jbc.M310608200	http://dx.doi.org/10.1074/jbc.M310608200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	757GU	14570889	hybrid			2022-12-27	WOS:000187555300008
J	Swindle, CS; Kim, HG; Klug, CA				Swindle, CS; Kim, HG; Klug, CA			Mutation of CpGs in the murine stem cell virus retroviral vector long terminal repeat represses silencing in embryonic stem cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DE-NOVO METHYLATION; MOLONEY LEUKEMIA-VIRUS; HISTONE DEACETYLASE; GENE-EXPRESSION; TRANSCRIPTIONAL REPRESSION; DENOVO METHYLATION; DNA METHYLATION; CARCINOMA-CELLS; R REGION; MECHANISMS	Although DNA methylation and transcriptional repression are generally associated, a causal role for DNA methylation in silencing of retroviral vectors has not been established. The newer generation murine stem cell virus retroviral vector (MSCV) lacks many of the repressive cis-acting DNA sequences identified in Moloney murine leukemia virus but remains sensitive to transcriptional silencing in various cell types. To determine the contribution of cytosine methylation to MSCV silencing, we mutated CpG dinucleotides located in the MSCV long terminal repeat (LTR) that are clustered in the U3 region and directly spanning the transcription start site in the R region. Effects of the CpG mutations on MSCV silencing were assessed in murine embryonic stem cells. An analysis of numerous clonal proviral integrants showed that mutation of CpGs in both clusters eliminated proviral integrants that were completely silenced. Variegated expression was shown to represent a substantial component of intraclonal silencing and was independent of the presence of CpGs in the LTR. Treatment of transduced cells with 5-azadeoxycytidine delayed establishment of the silenced state but had only a modest effect on expression of some proviral integrants at late times post-transduction. These results are direct evidence for a causal contribution of DNA methylation in the LTR to MSCV silencing and define the promoter region CpGs as a repressive element in embryonic stem cells. Furthermore, distinct mechanisms are suggested for establishment and maintenance of the silenced proviral state.	Univ Alabama, Dept Microbiol, Div Dev & Clin Immunol, WTI 387, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Klug, CA (corresponding author), Univ Alabama, Dept Microbiol, Div Dev & Clin Immunol, WTI 387, 1824 6th Ave S, Birmingham, AL 35294 USA.				NIAID NIH HHS [T32 AI007051, AIT3207051] Funding Source: Medline; NIDDK NIH HHS [R01DK54766] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007051] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054766] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anderson MT, 1996, P NATL ACAD SCI USA, V93, P8508, DOI 10.1073/pnas.93.16.8508; CHALLITA PM, 1994, P NATL ACAD SCI USA, V91, P2567, DOI 10.1073/pnas.91.7.2567; Cherry SR, 2000, MOL CELL BIOL, V20, P7419, DOI 10.1128/MCB.20.20.7419-7426.2000; CLARK SJ, 1995, NAT GENET, V10, P20, DOI 10.1038/ng0595-20; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; Cupelli L, 1998, J VIROL, V72, P7807, DOI 10.1128/JVI.72.10.7807-7814.1998; Curradi M, 2002, MOL CELL BIOL, V22, P3157, DOI 10.1128/MCB.22.9.3157-3173.2002; de Guzman CG, 2002, MOL CELL BIOL, V22, P5506, DOI 10.1128/MCB.22.15.5506-5517.2002; DRANOFF G, 1993, P NATL ACAD SCI USA, V90, P3539, DOI 10.1073/pnas.90.8.3539; GAUTSCH JW, 1983, NATURE, V301, P32, DOI 10.1038/301032a0; HAWLEY RG, 1994, GENE THER, V1, P136; HOEBEN RC, 1991, J VIROL, V65, P904, DOI 10.1128/JVI.65.2.904-912.1991; Hu-Li J, 2001, IMMUNITY, V14, P1, DOI 10.1016/S1074-7613(01)00084-X; JAHNER D, 1982, NATURE, V298, P623, DOI 10.1038/298623a0; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; KESHET I, 1985, P NATL ACAD SCI USA, V82, P2560, DOI 10.1073/pnas.82.9.2560; Klug CA, 2000, BLOOD, V96, P894, DOI 10.1182/blood.V96.3.894.015k35_894_901; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Li Z, 2002, LEUKEMIA, V16, P1655, DOI 10.1038/sj.leu.2402619; Lorincz MC, 2002, MOL CELL BIOL, V22, P7572, DOI 10.1128/MCB.22.21.7572-7580.2002; Lorincz MC, 2000, MOL CELL BIOL, V20, P842, DOI 10.1128/MCB.20.3.842-850.2000; Lorincz MC, 2001, MOL CELL BIOL, V21, P7913, DOI 10.1128/MCB.21.23.7913-7922.2001; Marshall E, 2002, SCIENCE, V298, P34, DOI 10.1126/science.298.5591.34; Milot E, 1996, CELL, V87, P105, DOI 10.1016/S0092-8674(00)81327-6; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; NIWA O, 1983, CELL, V32, P1105, DOI 10.1016/0092-8674(83)90294-5; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Osborne CS, 1999, J VIROL, V73, P5490, DOI 10.1128/JVI.73.7.5490-5496.1999; Pannell D, 2000, EMBO J, V19, P5884, DOI 10.1093/emboj/19.21.5884; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Richards EJ, 2002, CELL, V108, P489, DOI 10.1016/S0092-8674(02)00644-X; STEWART CL, 1982, P NATL ACAD SCI-BIOL, V79, P4098, DOI 10.1073/pnas.79.13.4098; Swindle CS, 2002, J HEMATOTH STEM CELL, V11, P449, DOI 10.1089/15258160260090915; Trubetskoy AM, 1999, J VIROL, V73, P3477, DOI 10.1128/JVI.73.4.3477-3483.1999; TSUKIYAMA T, 1989, MOL CELL BIOL, V9, P4670, DOI 10.1128/MCB.9.11.4670; Yang WM, 1997, J BIOL CHEM, V272, P28001, DOI 10.1074/jbc.272.44.28001	37	59	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	2004	279	1					34	41		10.1074/jbc.M309128200	http://dx.doi.org/10.1074/jbc.M309128200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	757GU	14559924	hybrid			2022-12-27	WOS:000187555300005
J	Defenbaugh, DA; Nakai, H				Defenbaugh, DA; Nakai, H			A context-dependent ClpX recognition determinant located at the C terminus of phage Mu repressor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TEMPERATURE-SENSITIVE MUTATIONS; BACTERIOPHAGE-MU; ESCHERICHIA-COLI; DEGRADATION MACHINE; DNA-BINDING; SECONDARY STRUCTURE; BETA-SHEET; F-PLASMID; 10SA RNA; PROTEIN	The bacteriophage Mu immunity repressor is a conformationally sensitive sensor that can be interconverted between forms resistant to and sensitive to degradation by ClpXP protease. Protease-sensitive repressor molecules with an altered C-terminal sequence promote rapid degradation of the wild-type repressor by inducing its C-terminal end to become exposed. Here we determined that the last 5 C-terminal residues (CTD5) of the wild-type repressor contain the motif required for recognition by the ClpX molecular chaperone, a motif that is strongly dependent upon the context in which it is presented. Although attachment of the 11-residue ssrA degradation tag to the C terminus of green fluorescent protein (GFP) promoted its rapid degradation by ClpXP, attachment of 5-27 C-terminal residues of the repressor failed to promote degradation. Disordered peptides derived from 41 and 35 C-terminal residues of CcdA (CcdA41) and thioredoxin (TrxA35), respectively, activated CTD5 when placed as linkers between GFP and repressor C-terminal sequences. However, when the entire thioredoxin sequence was included as a linker to promote an ordered configuration of the TrxA35 peptide, the resulting substrate was not degraded. In addition, a hybrid tag, in which CTD5 replaced the 3-residue recognition motif of the ssrA tag, was inactive when attached directly to GFP but active when attached through the CcdA41 peptide. Thus, CTD5 is sufficient to act as a recognition motif but has requirements for its presentation not shared by the ssrA tag. We suggest that activation of CTD5 may require presentation on a disordered or flexible domain that confers ligand flexibility.	Georgetown Univ, Sch Med, Dept Biochem & Mol Biol, Med Ctr, Washington, DC 20057 USA	Georgetown University	Nakai, H (corresponding author), Georgetown Univ, Sch Med, Dept Biochem & Mol Biol, Med Ctr, POB 571455, Washington, DC 20057 USA.				NATIONAL CANCER INSTITUTE [P30CA051008] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058265] Funding Source: NIH RePORTER; NCI NIH HHS [P30CA51008] Funding Source: Medline; NIGMS NIH HHS [GM58265] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alazard R, 1998, EUR J BIOCHEM, V252, P408, DOI 10.1046/j.1432-1327.1998.2520408.x; Burton RE, 2001, EMBO J, V20, P3092, DOI 10.1093/emboj/20.12.3092; Chaffotte AF, 1997, BIOCHEMISTRY-US, V36, P16040, DOI 10.1021/bi9708500; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; De Angelis DA, 1998, P NATL ACAD SCI USA, V95, P12312, DOI 10.1073/pnas.95.21.12312; Felden B, 1997, RNA, V3, P89; Flynn JM, 2003, MOL CELL, V11, P671, DOI 10.1016/S1097-2765(03)00060-1; Flynn JM, 2001, P NATL ACAD SCI USA, V98, P10584, DOI 10.1073/pnas.191375298; GEUSKENS V, 1992, EMBO J, V11, P5121, DOI 10.1002/j.1460-2075.1992.tb05619.x; GEUSKENS V, 1991, J BACTERIOL, V173, P6578, DOI 10.1128/jb.173.20.6578-6585.1991; Gonciarz-Swiatek M, 1999, J BIOL CHEM, V274, P13999, DOI 10.1074/jbc.274.20.13999; Hauer JA, 1999, BIOCHEMISTRY-US, V38, P6774, DOI 10.1021/bi983074k; HOLMGREN A, 1975, P NATL ACAD SCI USA, V72, P2305, DOI 10.1073/pnas.72.6.2305; Hoskins JR, 2002, P NATL ACAD SCI USA, V99, P11037, DOI 10.1073/pnas.172378899; JAFFE A, 1985, J BACTERIOL, V163, P841; Jones JM, 1998, J BIOL CHEM, V273, P459, DOI 10.1074/jbc.273.1.459; Jorgensen CI, 1998, MOL MICROBIOL, V27, P41, DOI 10.1046/j.1365-2958.1998.00655.x; KATTI SK, 1990, J MOL BIOL, V212, P167, DOI 10.1016/0022-2836(90)90313-B; Keiler KC, 1996, SCIENCE, V271, P990, DOI 10.1126/science.271.5251.990; Kenniston JA, 2003, CELL, V114, P511, DOI 10.1016/S0092-8674(03)00612-3; KOMINE Y, 1994, P NATL ACAD SCI USA, V91, P9223, DOI 10.1073/pnas.91.20.9223; KRAUSE HM, 1983, NUCLEIC ACIDS RES, V11, P5483, DOI 10.1093/nar/11.16.5483; KRAUSE HM, 1986, J BIOL CHEM, V261, P3744; Kriwacki RW, 1996, P NATL ACAD SCI USA, V93, P11504, DOI 10.1073/pnas.93.21.11504; Kruklitis R, 1996, EMBO J, V15, P935, DOI 10.1002/j.1460-2075.1996.tb00428.x; Kumar S, 2002, BIOCHEMISTRY-US, V41, P5359, DOI 10.1021/bi012154c; Laachouch JE, 1996, EMBO J, V15, P437, DOI 10.1002/j.1460-2075.1996.tb00374.x; Lamrani S, 1999, MOL MICROBIOL, V32, P327, DOI 10.1046/j.1365-2958.1999.01352.x; Lee C, 2001, MOL CELL, V7, P627, DOI 10.1016/S1097-2765(01)00209-X; LEUNG PC, 1989, NATURE, V338, P656, DOI 10.1038/338656a0; Levchenko I, 2000, SCIENCE, V289, P2354, DOI 10.1126/science.289.5488.2354; Levchenko I, 1997, CELL, V91, P939, DOI 10.1016/S0092-8674(00)80485-7; Levchenko I, 1997, GENE DEV, V11, P1561, DOI 10.1101/gad.11.12.1561; Marshall-Batty KR, 2003, J BIOL CHEM, V278, P1612, DOI 10.1074/jbc.M209352200; MHAMMEDIALAOUI A, 1994, MOL MICROBIOL, V11, P1109, DOI 10.1111/j.1365-2958.1994.tb00387.x; MIZUUCHI M, 1989, CELL, V58, P399, DOI 10.1016/0092-8674(89)90854-4; Mukhopadhyay B, 2003, MOL MICROBIOL, V47, P171, DOI 10.1046/j.1365-2958.2003.03286.x; Neher SB, 2003, GENE DEV, V17, P1084, DOI 10.1101/gad.1078003; O'Handley D, 2002, J MOL BIOL, V322, P311, DOI 10.1016/S0022-2836(02)00755-6; OGURA T, 1983, P NATL ACAD SCI-BIOL, V80, P4784, DOI 10.1073/pnas.80.15.4784; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; Rai SS, 2001, J MOL BIOL, V312, P311, DOI 10.1006/jmbi.2001.4957; Ranquet C, 2001, P NATL ACAD SCI USA, V98, P10220, DOI 10.1073/pnas.171620598; REUTIMANN H, 1981, J BIOL CHEM, V256, P6796; REUTIMANN H, 1983, BIOPOLYMERS, V22, P107, DOI 10.1002/bip.360220117; Rousseau P, 1996, J BIOL CHEM, V271, P9739, DOI 10.1074/jbc.271.16.9739; Symonds N., 1987, PHAGE MU; Tasayco ML, 2000, BIOCHEMISTRY-US, V39, P10613, DOI 10.1021/bi000761e; TASAYCO ML, 1995, PROTEINS, V22, P41, DOI 10.1002/prot.340220106; TOUSSAINT A, 1994, GENETICA, V93, P27, DOI 10.1007/BF01435237; VAJDA S, 1994, BIOCHEMISTRY-US, V33, P13977, DOI 10.1021/bi00251a004; VANMELDEREN L, 1994, MOL MICROBIOL, V11, P1151; VanMelderen L, 1996, J BIOL CHEM, V271, P27730, DOI 10.1074/jbc.271.44.27730; VOGEL JL, 1991, J BACTERIOL, V173, P6568, DOI 10.1128/jb.173.20.6568-6577.1991; Vogel JL, 1996, GENETICS, V142, P661; Wah DA, 2002, CHEM BIOL, V9, P1237, DOI 10.1016/S1074-5521(02)00268-5; Weber-Ban EU, 1999, NATURE, V401, P90, DOI 10.1038/43481; Welty DJ, 1997, J MOL BIOL, V272, P31, DOI 10.1006/jmbi.1997.1193; Williams KP, 1996, RNA, V2, P1306	59	5	5	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52333	52339		10.1074/jbc.M308724200	http://dx.doi.org/10.1074/jbc.M308724200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14559921	hybrid			2022-12-27	WOS:000187480700043
J	Guo, HB; Lee, I; Kamar, M; Pierce, M				Guo, HB; Lee, I; Kamar, M; Pierce, M			N-acetylglucosaminyltransferase V expression levels regulate cadherin-associated homotypic cell-cell adhesion and intracellular signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINE-LINKED OLIGOSACCHARIDES; BETA-1-6 BRANCHED OLIGOSACCHARIDES; GROWTH-FACTOR RECEPTOR; TYROSINE PHOSPHORYLATION; CANCER-CELLS; HUMAN-BREAST; HOMOPHILIC ADHESION; CONTACT FORMATION; ALPHA-CATENIN; METASTASIS	A common glycan alteration in transformed cells and human tumors is the highly elevated levels of N-linked beta(1,6)glycans caused by increased transcription of N-acetylglucosaminyltransferase V (GnT-V). Here, we define the involvement of GnT-V in modulation of homotypic cell-cell adhesion in human fibrosarcoma HT1080 and mouse NIH3T3 cells. Increased GnT-V expression resulted in a significant decrease in the rates of calcium-dependent cell-cell adhesion. Reduced cell-cell adhesion was blocked by function-blocking antibody against N-cadherin and abrogated by pre-treatment of cells with swainsonine, demonstrating the involvement of N-cadherin in the cell-cell adhesion and that changes in N-linked beta(1,6)glycan expression are responsible for the reduction in rates of adhesion, although this reduction could be mediated by the altered N-linked glycosylation of glycoproteins other than N-cadherin. Overexpression of GnT-V had no effect on the levels of cell surface expression of N-cadherin; however, it did cause a marked enhancement of both beta(1,6) branching and poly-N-acetyllactosamine expression on N-cadherin. GnT-V overexpression resulted in decreased N-cadherin clustering on the cell surface induced by anti-N-cadherin antibody and affected the outside-in signal transduction pathway of ERK mediated by N-cadherin. Overexpression of GnT-V sensitized stimulation of tyrosine phosphorylation of catenins by growth factors and expression of v-src, which is consistent with its reduction of cell-cell adhesion. In vitro, GnT-V-overexpressing cells showed increased motility concomitant with increased phosphorylation of catenins. Moreover, GnT-V-deficient embryo fibroblasts from GnT-V homozygous null mice (GnT-V-/-) express N-cadherin and showed significantly increased levels of N-cadherin-based cell-cell adhesion compared with those from GnT-V+/- mice. These levels of adhesion were inhibited significantly by transient expression of GnT-V, confirming the hypothesis that levels of GnT-V can regulate cadherin-associated homotypic cell-cell adhesion. Aberrant N-linked beta(1,6) branching that occurs during oncogenesis can, therefore, lessen cell-cell adhesion, contributing to increased cellular motility and invasiveness.	Univ Georgia, Dept Biochem & Mol Biol, Athens, GA 30602 USA; Univ Georgia, Complex Carbohydrate Res Ctr, Athens, GA 30602 USA	University System of Georgia; University of Georgia; University System of Georgia; University of Georgia	Pierce, M (corresponding author), Univ Georgia, Dept Biochem & Mol Biol, Life Sci Bldg,B-314, Athens, GA 30602 USA.			Lee, Intaek/0000-0003-1084-674X	NCI NIH HHS [R01CA64462] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA064462] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABBONDANZO SJ, 1993, METHOD ENZYMOL, V225, P803; Adams CL, 1996, J CELL BIOL, V135, P1899, DOI 10.1083/jcb.135.6.1899; Anastasiadis PZ, 2000, J CELL SCI, V113, P1319; Betson M, 2002, J BIOL CHEM, V277, P36962, DOI 10.1074/jbc.M207358200; Braga VMM, 1997, J CELL BIOL, V137, P1421, DOI 10.1083/jcb.137.6.1421; Chothia C, 1997, ANNU REV BIOCHEM, V66, P823, DOI 10.1146/annurev.biochem.66.1.823; Conacci-Sorrell M, 2002, J CLIN INVEST, V109, P987, DOI 10.1172/JCI200215429; CUMMINGS RD, 1982, J BIOL CHEM, V257, P1230; Daniel JM, 1997, BIOESSAYS, V19, P883, DOI 10.1002/bies.950191008; DEMETRIOU M, 1995, J CELL BIOL, V130, P383, DOI 10.1083/jcb.130.2.383; DENNIS JW, 1989, CANCER RES, V49, P945; FERNANDES B, 1991, CANCER RES, V51, P718; Granovsky M, 2000, NAT MED, V6, P306; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Guo HB, 2002, CANCER RES, V62, P6837; Guo HB, 2001, J CANCER RES CLIN, V127, P231, DOI 10.1007/s004320000186; Guo X, 2002, AM J PHYSIOL-CELL PH, V283, pC722, DOI 10.1152/ajpcell.00054.2002; Hajra KM, 2002, GENE CHROMOSOME CANC, V34, P255, DOI 10.1002/gcc.10083; Hakomori S, 2002, P NATL ACAD SCI USA, V99, P10231, DOI 10.1073/pnas.172380699; Hazan RB, 1998, J BIOL CHEM, V273, P9078, DOI 10.1074/jbc.273.15.9078; Hazan RB, 2000, J CELL BIOL, V148, P779, DOI 10.1083/jcb.148.4.779; HIRANO S, 1992, CELL, V70, P293, DOI 10.1016/0092-8674(92)90103-J; Hirohashi S, 1998, AM J PATHOL, V153, P333, DOI 10.1016/S0002-9440(10)65575-7; Irby RB, 2002, CANCER RES, V62, P2669; JIANG WG, 1995, CANCER RES, V55, P5043; Kashima T, 2003, INT J CANCER, V104, P147, DOI 10.1002/ijc.10931; Kim SH, 2000, J BIOL CHEM, V275, P36999, DOI 10.1074/jbc.M003430200; Kitada T, 2001, J BIOL CHEM, V276, P475, DOI 10.1074/jbc.M006689200; Koch AW, 1999, CURR OPIN STRUC BIOL, V9, P275, DOI 10.1016/S0959-440X(99)80038-4; LEAVESLEY DI, 1993, J CELL BIOL, V121, P163, DOI 10.1083/jcb.121.1.163; Li G, 2001, CANCER RES, V61, P3819; Lilien J, 2002, DEV DYNAM, V224, P18, DOI 10.1002/dvdy.10087; Mareel M, 2003, PHYSIOL REV, V83, P337, DOI 10.1152/physrev.00024.2002; Moloney DJ, 2000, NATURE, V406, P369, DOI 10.1038/35019000; Muller T, 1999, J BIOL CHEM, V274, P10173, DOI 10.1074/jbc.274.15.10173; Nakagawa M, 2001, J CELL SCI, V114, P1829; Nieman MT, 1999, J CELL BIOL, V147, P631, DOI 10.1083/jcb.147.3.631; Noren NK, 2001, J BIOL CHEM, V276, P33305, DOI 10.1074/jbc.C100306200; Ohkubo T, 1999, J BIOL CHEM, V274, P21409, DOI 10.1074/jbc.274.30.21409; Ozawa M, 2001, J CELL SCI, V114, P503; Pece S, 2000, J BIOL CHEM, V275, P41227, DOI 10.1074/jbc.M006578200; PRZYBYLO M, 2002, IN PRESS CANC CELL I, V2; SANCHEZMATEOS P, 1993, J IMMUNOL, V151, P3817; Seberger PJ, 1999, GLYCOBIOLOGY, V9, P235, DOI 10.1093/glycob/9.3.235; Seelentag WKF, 1998, CANCER RES, V58, P5559; Shan WS, 1999, BIOPHYS CHEM, V82, P157, DOI 10.1016/S0301-4622(99)00115-5; Shirane K, 1999, BIOCHEM BIOPH RES CO, V265, P434, DOI 10.1006/bbrc.1999.1684; Skinner MA, 2001, J BIOL CHEM, V276, P48451, DOI 10.1074/jbc.M103569200; Suyama K, 2002, CANCER CELL, V2, P301, DOI 10.1016/S1535-6108(02)00150-2; Takahashi K, 1997, ONCOGENE, V15, P71, DOI 10.1038/sj.onc.1201160; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; Takeichi M, 1993, CURR OPIN CELL BIOL, V5, P806, DOI 10.1016/0955-0674(93)90029-P; Thoreson MA, 2000, J CELL BIOL, V148, P189, DOI 10.1083/jcb.148.1.189; Tran NL, 2002, J BIOL CHEM, V277, P32905, DOI 10.1074/jbc.M200300200; Weiss EE, 1998, J CELL BIOL, V141, P755, DOI 10.1083/jcb.141.3.755; Yagi T, 2000, GENE DEV, V14, P1169; Yamamoto H, 2000, CANCER RES, V60, P134; Yao M, 1998, J CANCER RES CLIN, V124, P27, DOI 10.1007/s004320050129; Yap AS, 1997, CURR BIOL, V7, P308, DOI 10.1016/S0960-9822(06)00154-0; Yoshida A, 2001, DEV CELL, V1, P717, DOI 10.1016/S1534-5807(01)00070-3; Yoshimura M, 1996, J BIOL CHEM, V271, P13811, DOI 10.1074/jbc.271.23.13811	61	127	132	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52412	52424		10.1074/jbc.M308837200	http://dx.doi.org/10.1074/jbc.M308837200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14561752	hybrid			2022-12-27	WOS:000187480700054
J	Nofer, JR; Feuerborn, R; Levkau, B; Sokoll, A; Seedorf, U; Assmann, G				Nofer, JR; Feuerborn, R; Levkau, B; Sokoll, A; Seedorf, U; Assmann, G			Involvement of Cdc42 signaling in apoA-I-induced cholesterol efflux	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEINS; HUMAN SKIN FIBROBLASTS; CASSETTE TRANSPORTER 1; PROTEIN-KINASE-C; TANGIER-DISEASE; INTRACELLULAR CHOLESTEROL; CELLS; ACTIVATION; GTPASES; ABCA1	Cholesterol efflux, an important mechanism by which high density lipoproteins (HDL) protect against atherosclerosis, is initiated by docking of apolipoprotein A-I (apoA-I), a major HDL protein, to specific binding sites followed by activation of ATP-binding cassette transporter A1 (ABCA1) and translocation of cholesterol from intracellular compartments to the exofacial monolayer of the plasma membrane where it is accessible to HDL. In this report, we investigated potential signal transduction pathways that may link apoA-I binding to cholesterol translocation to the plasma membrane and cholesterol efflux. By using pull-down assays we found that apoA-I substantially increased the amount of activated Cdc42, Rac1, and Rho in human fibroblasts. Moreover, apoA-I induced actin polymerization, which is known to be controlled by Rho family G proteins. Inhibition of Cdc42 and Rac1 with Clostridium difficile toxin B inhibited apoA-I-induced cholesterol efflux, whereas inhibition of Rho with Clostridium botulinum C3-exoenzyme exerted opposite effects. Adenoviral expression of a Cdc42(T17N) dominant negative mutant substantially reduced apoA-I-induced cholesterol efflux, whereas dominant negative Rac1( T17N) had no effect. We further found that two downstream effectors of Cdc42/Rac1 signaling, c-Jun N-terminal kinase (JNK) and p38 mitogen-activated protein kinase ( p38 MAPK), are activated by apoA-I. Pharmacological inhibition of JNK but not p38 MAPK decreased apoA-I-induced cholesterol efflux, whereas anisomycin and hydrogen peroxide, two direct JNK activators, could partially substitute for apoA-I in its ability to induce cholesterol efflux. These results for the first time demonstrate activation of Rho family G proteins and stress kinases by apoA-I and implicate the involvement of Cdc42 and JNK in the apoA-I-induced cholesterol efflux.	Univ Munster, Inst Klin Chem & Lab Med, D-48129 Munster, Germany; Univ Munster, Inst Arterioskleroseforsch, D-48149 Munster, Germany	University of Munster; University of Munster	Nofer, JR (corresponding author), Univ Munster, Inst Klin Chem & Lab Med, Albert Schweizer Str 33, D-48129 Munster, Germany.	nofer@uni-muenster.de	Levkau, Bodo/N-9144-2017	Seedorf, Udo/0000-0003-4652-5358				Assmann G, 2003, ANNU REV MED, V54, P321, DOI 10.1146/annurev.med.54.101601.152409; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DARBON JM, 1986, J BIOL CHEM, V261, P8002; Deeg MA, 1997, ARTERIOSCL THROM VAS, V17, P1667, DOI 10.1161/01.ATV.17.9.1667; DEVRIESSMITS AMM, 1995, METHOD ENZYMOL, V255, P156; Diederich W, 2001, ATHEROSCLEROSIS, V159, P313, DOI 10.1016/S0021-9150(01)00518-4; DOWNWARD J, 1995, METHOD ENZYMOL, V255, P110; Erickson JW, 1996, J BIOL CHEM, V271, P26850, DOI 10.1074/jbc.271.43.26850; Fielding CJ, 2001, BBA-MOL CELL BIOL L, V1533, P175, DOI 10.1016/S1388-1981(01)00162-7; Fielding PE, 1996, BIOCHEMISTRY-US, V35, P14932, DOI 10.1021/bi9613382; Garver WS, 1997, ARTERIOSCL THROM VAS, V17, P2698, DOI 10.1161/01.ATV.17.11.2698; HA KS, 1993, J CELL BIOL, V123, P1789, DOI 10.1083/jcb.123.6.1789; Hall PF, 1995, J STEROID BIOCHEM, V55, P601, DOI 10.1016/0960-0760(95)00211-1; Hirano K, 2000, FEBS LETT, V484, P275, DOI 10.1016/S0014-5793(00)02171-2; Jaffer ZM, 2002, INT J BIOCHEM CELL B, V34, P713, DOI 10.1016/S1357-2725(01)00158-3; Kimura T, 2001, J BIOL CHEM, V276, P31780, DOI 10.1074/jbc.M104353200; Lin GR, 2002, BIOCHEM BIOPH RES CO, V291, P727, DOI 10.1006/bbrc.2002.6505; MENDEZ AJ, 1995, J BIOL CHEM, V270, P5891, DOI 10.1074/jbc.270.11.5891; MENDEZ AJ, 1991, J BIOL CHEM, V266, P10104; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Neufeld EB, 2001, J BIOL CHEM, V276, P27584, DOI 10.1074/jbc.M103264200; Nofer JR, 2001, J BIOL CHEM, V276, P34480, DOI 10.1074/jbc.M103782200; Nofer JR, 2001, THROMB HAEMOSTASIS, V85, P730; Nofer JR, 2000, BIOCHEMISTRY-US, V39, P15199, DOI 10.1021/bi001162a; Oram JF, 2000, J BIOL CHEM, V275, P34508, DOI 10.1074/jbc.M006738200; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; Sander EE, 1999, J CELL BIOL, V147, P1009, DOI 10.1083/jcb.147.5.1009; TABAS I, 1994, J BIOL CHEM, V269, P22547; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; THERET N, 1990, BIOCHEM BIOPH RES CO, V173, P1361, DOI 10.1016/S0006-291X(05)80938-6; Tsukamoto K, 2002, ARTERIOSCL THROM VAS, V22, P1899, DOI 10.1161/01.ATV.0000036080.42391.33; Tsukamoto K, 2001, BIOCHEM BIOPH RES CO, V287, P757, DOI 10.1006/bbrc.2001.5575; von Eckardstein A, 2001, ARTERIOSCL THROM VAS, V21, P13, DOI 10.1161/01.ATV.21.1.13; von Eckardstein A, 2000, CURR OPIN CARDIOL, V15, P348, DOI 10.1097/00001573-200009000-00007; WALTER M, 1995, ARTERIOSCL THROM VAS, V15, P1975, DOI 10.1161/01.ATV.15.11.1975; Wang N, 2001, J BIOL CHEM, V276, P23742, DOI 10.1074/jbc.M102348200; Wu WJ, 2000, NATURE, V405, P800, DOI 10.1038/35015585	41	55	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					53055	53062		10.1074/jbc.M305673200	http://dx.doi.org/10.1074/jbc.M305673200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14563854	hybrid			2022-12-27	WOS:000187480700129
J	Rambaratsingh, RA; Stone, JC; Blumberg, PM; Lorenzo, PS				Rambaratsingh, RA; Stone, JC; Blumberg, PM; Lorenzo, PS			RasGRP1 represents a novel non-protein kinase C phorbol ester signaling pathway in mouse epidermal keratinocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKIN TUMOR PROMOTION; PROTEIN-KINASE; EXCHANGE FACTOR; DIFFERENTIATION MARKERS; RAS ACTIVATION; DIACYLGLYCEROL; CELLS; CALCIUM; EXPRESSION; INDUCTION	The mouse skin model of carcinogenesis has been instrumental in our appreciation of the multistage nature of carcinogenesis. In this system, tumor promotion is a critical step in the generation of tumors and is usually achieved by treatment with the phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA). Although it is generally assumed that protein kinase C (PKC) is the sole receptor for TPA in this system, we sought to evaluate whether non-PKC pathways could also contribute to the effects of phorbol esters in skin. We documented expression of the high affinity non-PKC phorbol ester receptor and Ras activator RasGRP1 in mouse primary keratinocytes. Overexpression of RasGRP1 in keratinocytes increased the level of active GTP-loaded Ras. TPA treatment further elevated this Ras activation in a PKC-independent manner and induced the translocation and down-regulation of RasGRP1. Overexpression of RasGRP1 in keratinocytes also caused apoptosis. Finally, induction of keratinocyte differentiation by elevation of extracellular calcium suppressed expression of endogenous RasGRP1, whereas overexpression of RasGRP1 inhibited expression of the differentiation markers keratins 1 and 10 induced by high calcium in the medium. Taken together, our results demonstrate that RasGRP1 is an additional diacylglycerol/phorbol ester receptor in epidermal keratinocytes and suggest that activation of this novel receptor may contribute to some of the phorbol ester- and Ras-mediated effects in mouse epidermis.	Univ Hawaii, Canc Res Ctr Hawaii, Nat Prod Program, Honolulu, HI 96813 USA; Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada; NCI, Cellular Carcinogenesis & Tumor Promot Lab, NIH, Bethesda, MD 20892 USA	Cancer Research Center of Hawaii; University of Hawaii System; University of Alberta; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Lorenzo, PS (corresponding author), Univ Hawaii, Canc Res Ctr Hawaii, Nat Prod Program, Rm 315,1236 Lauhala St, Honolulu, HI 96813 USA.				NATIONAL CANCER INSTITUTE [Z01BC005270, R55CA096841] Funding Source: NIH RePORTER; NCI NIH HHS [R55-CA96841-01, R55 CA096841-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHMED S, 1993, J BIOL CHEM, V268, P10709; Betz A, 1998, NEURON, V21, P123, DOI 10.1016/S0896-6273(00)80520-6; Bivona TG, 2003, NATURE, V424, P694, DOI 10.1038/nature01806; Boutwell R K, 1974, CRC Crit Rev Toxicol, V2, P419; CACACE AM, 1993, ONCOGENE, V8, P2095; Caloca MJ, 1999, P NATL ACAD SCI USA, V96, P11854, DOI 10.1073/pnas.96.21.11854; Caloca MJ, 2003, J BIOL CHEM, V278, P33465, DOI 10.1074/jbc.M302807200; CHENG C, 1990, MOL CARCINOGEN, V3, P363, DOI 10.1002/mc.2940030608; Chiu VK, 2002, NAT CELL BIOL, V4, P343, DOI 10.1038/ncb783; Clyde-Smith J, 2000, J BIOL CHEM, V275, P32260, DOI 10.1074/jbc.M006087200; Dajee M, 2002, ONCOGENE, V21, P1527, DOI 10.1038/sj.onc.1205287; DENNING MF, 1995, CELL GROWTH DIFFER, V6, P149; Dhillon AS, 2002, EMBO J, V21, P64, DOI 10.1093/emboj/21.1.64; DIGIOVANNI J, 1992, PHARMACOL THERAPEUT, V54, P63, DOI 10.1016/0163-7258(92)90051-Z; DLUGOSZ AA, 1993, J CELL BIOL, V120, P217, DOI 10.1083/jcb.120.1.217; Dower NA, 2000, NAT IMMUNOL, V1, P317, DOI 10.1038/79766; Ebinu JO, 1998, SCIENCE, V280, P1082, DOI 10.1126/science.280.5366.1082; HENNINGS H, 1987, J INVEST DERMATOL, V88, P60, DOI 10.1111/1523-1747.ep12465014; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; Karen J, 1999, CANCER RES, V59, P474; Kawasaki H, 1998, P NATL ACAD SCI USA, V95, P13278, DOI 10.1073/pnas.95.22.13278; Kim R, 2003, J VIROL, V77, P2056, DOI 10.1128/JVI.77.3.2056-2062.2003; Li LW, 1999, MOL CELL BIOL, V19, P8547; Lin AW, 2001, P NATL ACAD SCI USA, V98, P5025, DOI 10.1073/pnas.091100298; Lorenzo PS, 2000, MOL PHARMACOL, V57, P840; Lorenzo PS, 2001, CANCER RES, V61, P943; Marks F, 1995, MUTAT RES-FUND MOL M, V333, P161, DOI 10.1016/0027-5107(95)00142-5; Mason CS, 1999, EMBO J, V18, P2137, DOI 10.1093/emboj/18.8.2137; Perletti GP, 1996, ONCOGENE, V12, P847; Puente LG, 2000, J IMMUNOL, V165, P6865, DOI 10.4049/jimmunol.165.12.6865; Reddig PJ, 1999, CANCER RES, V59, P5710; Reddig PJ, 2000, CANCER RES, V60, P595; Reuther GW, 2002, J BIOL CHEM, V277, P30508, DOI 10.1074/jbc.M111330200; Roper E, 2001, EMBO REP, V2, P145, DOI 10.1093/embo-reports/kve020; Sanjuan MA, 2003, J IMMUNOL, V170, P2877, DOI 10.4049/jimmunol.170.6.2877; Suzuki T, 2002, NAT GENET, V32, P166, DOI 10.1038/ng949; Szaniawska B, 1996, CANCER LETT, V107, P205, DOI 10.1016/0304-3835(96)04369-8; Tarutani M, 2003, CANCER RES, V63, P319; Teixeira C, 2003, BLOOD, V102, P1414, DOI 10.1182/blood-2002-11-3621; Tognon CE, 1998, MOL CELL BIOL, V18, P6995, DOI 10.1128/MCB.18.12.6995; Topham MK, 2001, J CELL BIOL, V152, P1135, DOI 10.1083/jcb.152.6.1135; Wang HQ, 1999, J CELL SCI, V112, P3497; Yamashita S, 2000, J BIOL CHEM, V275, P25488, DOI 10.1074/jbc.M003414200; YUAN SX, 1995, CANCER RES, V55, P3456; YUSPA SH, 1980, BIOCHEM BIOPH RES CO, V97, P700, DOI 10.1016/0006-291X(80)90321-6; YUSPA SH, 1986, CARCINOGENESIS, V7, P949, DOI 10.1093/carcin/7.6.949; YUSPA SH, 1992, PROG CLIN BIOL RES, V376, P103; YUSPA SH, 1981, J SUPRAMOL STR CELL, V17, P245, DOI 10.1002/jsscb.380170306; YUSPA SH, 1983, CARCINOGENESIS, V4, P1413, DOI 10.1093/carcin/4.11.1413	49	34	37	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52792	52801		10.1074/jbc.M308240200	http://dx.doi.org/10.1074/jbc.M308240200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14532295	hybrid			2022-12-27	WOS:000187480700098
J	Tisdale, EJ				Tisdale, EJ			Rab2 interacts directly with atypical protein kinase C (aPKC) iota/lambda and inhibits aPKC iota/lambda-dependent glyceraldehyde-3-phosphate dehydrogenase phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL SPECIFICITY; ENDOPLASMIC-RETICULUM; BINDING-PROTEINS; IN-VITRO; MEMBRANE; TRANSPORT; DOMAIN; TRANSFORMATION; LOCALIZATION; EFFECTOR	Atypical protein kinase C iota/lambda (PKCiota/lambda) is essential for protein transport in the early secretory pathway. The small GTPase Rab2 selectively recruits the kinase to (v) under bar esicular (t) under bar ubular (c) under bar lusters (VTCs) where PKCiota/lambda phosphorylates glyceraldehyde-3-phosphate dehydrogenase (GAPDH). VTCs are composed of small vesicles and tubules and serve as transport intermediates that shuttle cargo from the endoplasmic reticulum to the Golgi complex. These structures are the first site of segregation of the anterograde and retrograde pathways. When Rab2 binds to a VTC subcompartment, the subsequent recruitment of PKCiota/lambda and soluble components, including COPI (coatomer and ADP-ribosylation factor), results in the release of retrograde-directed vesicles. Because Rab2 stimulates PKCiota/lambda membrane association in a dose-dependent manner, we investigated whether the two proteins physically interact. Using a combination of in vivo and in vitro assays, we found that Rab2 interacts directly with PKCiota/lambda and that this interaction occurs through the Rab2 amino terminus (residues 1-19) and the PKCiota/lambda regulatory domain. A mutant lacking the PKCiota/lambda binding domain (Rab2N'Delta19) was functionally characterized. In contrast to Rab2, Rab2N'Delta19 failed to recruit PKCiota/lambda to normal rat kidney microsomes in a quantitative binding assay. To determine whether Rab2 modulates the ability of PKCiota/lambda to phosphorylate GAPDH, an in vitro kinase assay was supplemented with Rab2 or Rab2N'Delta19. Rab2 inhibited PKCiota/lambda-dependent GAPDH phosphorylation, whereas no effect was observed when the assay was performed with the amino-terminal truncation mutant. These results suggest that a downstream effector recruited to the VTC stimulates PKCiota/lambda-mediated GAPDH phosphorylation by alleviating the inhibition imposed by Rab2-PKCiota/lambda interaction.	Wayne State Univ, Sch Med, Dept Pharmacol, Detroit, MI 48201 USA	Wayne State University	Tisdale, EJ (corresponding author), Wayne State Univ, Sch Med, Dept Pharmacol, 6374 Scott Hall,540 E Canfield Ave, Detroit, MI 48201 USA.	etisdale@med.wayne.edu						ARIDOR M, 1995, J CELL BIOL, V131, P875, DOI 10.1083/jcb.131.4.875; BALCH WE, 1994, CELL, V76, P841, DOI 10.1016/0092-8674(94)90359-X; BERRA E, 1993, CELL, V74, P555, DOI 10.1016/0092-8674(93)80056-K; BORDIER C, 1981, J BIOL CHEM, V256, P1604; CHAPLINE C, 1993, J BIOL CHEM, V268, P6858; Chapline C, 1998, J BIOL CHEM, V273, P19482, DOI 10.1074/jbc.273.31.19482; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DiazMeco MT, 1996, MOL CELL BIOL, V16, P105; DIAZMECO MT, 1994, J BIOL CHEM, V269, P31706; Etienne-Manneville S, 2003, CURR OPIN CELL BIOL, V15, P67, DOI 10.1016/S0955-0674(02)00005-4; Feig LA, 1999, NAT CELL BIOL, V1, pE25, DOI 10.1038/10018; Hammer JA, 2002, CURR OPIN CELL BIOL, V14, P69, DOI 10.1016/S0955-0674(01)00296-4; HYATT SL, 1994, BIOCHEMISTRY-US, V33, P1223, DOI 10.1021/bi00171a023; Jaken S, 2000, BIOESSAYS, V22, P245, DOI 10.1002/(SICI)1521-1878(200003)22:3<245::AID-BIES6>3.0.CO;2-X; Li GP, 2001, BIOCHEM J, V355, P681, DOI 10.1042/bj3550681; Martinez O, 1998, BBA-MOL CELL RES, V1404, P101, DOI 10.1016/S0167-4889(98)00050-0; Moscat J, 2000, EMBO REP, V1, P399, DOI 10.1093/embo-reports/kvd098; Ostermeier C, 1999, CELL, V96, P363, DOI 10.1016/S0092-8674(00)80549-8; PELHAM HRB, 1995, CURR OPIN CELL BIOL, V7, P530, DOI 10.1016/0955-0674(95)80010-7; Pereira-Leal JB, 2000, J MOL BIOL, V301, P1077, DOI 10.1006/jmbi.2000.4010; Sanchez P, 1998, MOL CELL BIOL, V18, P3069, DOI 10.1128/MCB.18.5.3069; Simonsen A, 1998, NATURE, V394, P494, DOI 10.1038/28879; STEELEMORTIMER O, 1994, EMBO J, V13, P34, DOI 10.1002/j.1460-2075.1994.tb06232.x; STENMARK H, 1994, EMBO J, V13, P575, DOI 10.1002/j.1460-2075.1994.tb06295.x; Tisdale EJ, 1999, MOL BIOL CELL, V10, P1837, DOI 10.1091/mbc.10.6.1837; Tisdale EJ, 2000, TRAFFIC, V1, P702, DOI 10.1034/j.1600-0854.2000.010903.x; Tisdale EJ, 1996, J BIOL CHEM, V271, P29372, DOI 10.1074/jbc.271.46.29372; Tisdale EJ, 2002, J BIOL CHEM, V277, P3334, DOI 10.1074/jbc.M109744200; Tisdale EJ, 2003, J BIOL CHEM, V278, P38015, DOI 10.1074/jbc.M305381200; Tisdale EJ, 1997, J CELL BIOL, V137, P581, DOI 10.1083/jcb.137.3.581; Tisdale EJ, 2001, J BIOL CHEM, V276, P2480, DOI 10.1074/jbc.M007567200; Tisdale EJ, 1998, J BIOL CHEM, V273, P17269, DOI 10.1074/jbc.273.27.17269; Wang Y, 1997, NATURE, V388, P593, DOI 10.1038/41580; Waters MG, 1999, CURR OPIN CELL BIOL, V11, P453, DOI 10.1016/S0955-0674(99)80065-9; Wooten MW, 1999, J NEUROSCI RES, V58, P607, DOI 10.1002/(SICI)1097-4547(19991201)58:5<607::AID-JNR1>3.0.CO;2-M; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055	37	44	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52524	52530		10.1074/jbc.M309343200	http://dx.doi.org/10.1074/jbc.M309343200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14570876	hybrid			2022-12-27	WOS:000187480700068
J	Forsberg, LS; Noel, KD; Box, J; Carlson, RW				Forsberg, LS; Noel, KD; Box, J; Carlson, RW			Genetic locus and structural characterization of the biochemical defect in the O-antigenic polysaccharide of the symbiotically deficient Rhizobium etli mutant, CE166 - Replacement of N-acetylquinovosamine with its hexosyl-4-ulose precursor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPSULAR POLYSACCHARIDE; PSEUDOMONAS-AERUGINOSA; GENOME SEQUENCE; LIPOPOLYSACCHARIDE; LEGUMINOSARUM; BIOSYNTHESIS; PHASEOLI; REDUCTASES; BACTERIA; REGION	The O-antigen polysaccharide (OPS) of Rhizobium etli CE3 lipopolysaccharide (LPS) is linked to the core oligosaccharide via an N-acetylquinovosaminosyl (QuiNAc) residue. A mutant of CE3, CE166, produces LPS with reduced amounts of OPS, and a suppressed mutant, CE166alpha, produces LPS with nearly normal OPS levels. Both mutants are deficient in QuiNAc production. Characterization of OPS from CE166 and CE166alpha showed that QuiNAc was replaced by its 4-keto derivative, 2-acetamido-2,6-dideoxyhexosyl-4-ulose. The identity of this residue was determined by NMR and mass spectrometry, and by gas chromatography-mass spectrometry analysis of its 2-acetamido-4-deutero-2,6-dideoxyhexosyl derivatives produced by reduction of the 4-keto group using borodeuteride. Mass spectrometric and methylation analyses showed that the 2-acetamido-2,6-dideoxyhexosyl-4-ulosyl residue was 3-linked and attached to the core-region external Kdo III residue of the LPS, the same position as that of QuiNAc in the CE3 LPS. DNA sequencing revealed that the transposon insertion in strain CE166 was located in an open reading frame whose predicted translation product, LpsQ, falls within a large family of predicted open reading frames, which includes biochemically characterized members that are sugar epimerases and/or reductases. A hypothesis to be tested in future work is that lpsQ encodes UDP-2-acetamido-2,6-dideoxyhexosyl-4-ulose reductase, the second step in the synthesis of UDP-QuiNAc from UDP-GlcNAc.	Univ Georgia, Complex Carbohydrate Res Ctr, Athens, GA 30602 USA; Marquette Univ, Dept Biol Sci, Milwaukee, WI 53233 USA	University System of Georgia; University of Georgia; Marquette University	Carlson, RW (corresponding author), Univ Georgia, Complex Carbohydrate Res Ctr, Athens, GA 30602 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039583] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM39583] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andersson SGE, 1998, NATURE, V396, P133, DOI 10.1038/24094; Belanger M, 1999, MICROBIOL-UK, V145, P3505, DOI 10.1099/00221287-145-12-3505; BERINGER JE, 1974, J GEN MICROBIOL, V84, P188; BHAT UR, 1991, CARBOHYD RES, V220, P219, DOI 10.1016/0008-6215(91)80020-N; Capela D, 2001, P NATL ACAD SCI USA, V98, P9877, DOI 10.1073/pnas.161294398; CARLSON RW, 1978, PLANT PHYSIOL, V62, P912, DOI 10.1104/pp.62.6.912; CARLSON RW, 1987, J BACTERIOL, V169, P4923, DOI 10.1128/jb.169.11.4923-4928.1987; CAVA JR, 1990, MOL GEN GENET, V221, P125, DOI 10.1007/BF00280377; CAVA JR, 1989, J BACTERIOL, V171, P8, DOI 10.1128/jb.171.1.8-15.1989; CAVA JR, 1988, THESIS MARQUETTE U M; Creuzenet C, 2000, J BIOL CHEM, V275, P34873, DOI 10.1074/jbc.M006369200; Creuzenet C, 2002, J BIOL CHEM, V277, P26769, DOI 10.1074/jbc.M202882200; Creuzenet C, 2001, MOL MICROBIOL, V41, P1295, DOI 10.1046/j.1365-2958.2001.02589.x; DelVecchio VG, 2002, P NATL ACAD SCI USA, V99, P443, DOI 10.1073/pnas.221575398; Dombrecht B, 2001, MOL PLANT MICROBE IN, V14, P426, DOI 10.1094/MPMI.2001.14.3.426; Duelli DM, 2001, J BACTERIOL, V183, P6054, DOI 10.1128/JB.183.20.6054-6064.2001; FINAN TM, 1986, J BACTERIOL, V167, P66, DOI 10.1128/jb.167.1.66-72.1986; Forsberg LS, 1998, J BIOL CHEM, V273, P2747, DOI 10.1074/jbc.273.5.2747; Forsberg LS, 2000, J BIOL CHEM, V275, P18851, DOI 10.1074/jbc.M001090200; HRABAK EM, 1981, J BACTERIOL, V148, P697, DOI 10.1128/JB.148.2.697-711.1981; JANSSON PE, 1985, CARBOHYD RES, V140, P101, DOI 10.1016/0008-6215(85)85053-9; JORNVALL H, 1995, BIOCHEMISTRY-US, V34, P6003, DOI 10.1021/bi00018a001; Kaneko T, 2000, DNA RES, V7, P331, DOI 10.1093/dnares/7.6.331; Kaneko T, 2002, DNA RES, V9, P189, DOI 10.1093/dnares/9.6.189; KANNENBERG EL, 1998, RHIZOBIACEAE MOL BIO; Kneidinger B, 2003, BIOCHEM J, V371, P989, DOI 10.1042/BJ20030099; MacLean LL, 2003, EUR J BIOCHEM, V270, P3440, DOI 10.1046/j.1432-1033.2003.03736.x; NOEL KD, 1986, J BACTERIOL, V168, P1392, DOI 10.1128/jb.168.3.1392-1401.1986; Noel KD, 2000, J BACTERIOL, V182, P5317, DOI 10.1128/JB.182.19.5317-5324.2000; Rocchetta HL, 1999, MICROBIOL MOL BIOL R, V63, P523, DOI 10.1128/MMBR.63.3.523-553.1999; Rosano C, 2000, J MOL BIOL, V303, P77, DOI 10.1006/jmbi.2000.4106; Sadovskaya I, 1998, EUR J BIOCHEM, V253, P319, DOI 10.1046/j.1432-1327.1998.2530319.x; SHERWOOD MT, 1970, J GEN MICROBIOL, V71, P351; TAO H, 1992, J BACTERIOL, V174, P2222, DOI 10.1128/JB.174.7.2222-2229.1992; Thoden JB, 1996, BIOCHEMISTRY-US, V35, P2557, DOI 10.1021/bi952715y; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; YORK WS, 1985, CARBOHYD RES, V138, P109, DOI 10.1016/0008-6215(85)85228-9; York WS, 1985, METHOD ENZYMOL, P3, DOI DOI 10.1016/0076-6879(86)18062-1	38	30	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51347	51359		10.1074/jbc.M309016200	http://dx.doi.org/10.1074/jbc.M309016200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14551189	Green Submitted, hybrid			2022-12-27	WOS:000187206300063
J	Sulistijo, ES; Jaszewski, TM; MacKenzie, KR				Sulistijo, ES; Jaszewski, TM; MacKenzie, KR			Sequence-specific dimerization of the transmembrane domain of the "BH3-only" protein BNIP3 in membranes and detergent	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BCL-X-L; PROGRAMMED CELL-DEATH; TERMINAL HYDROPHOBIC REGION; GLYCOPHORIN-A DIMERIZATION; PRO-APOPTOTIC ACTIVITY; HUMAN INSULIN-RECEPTOR; BH3 DOMAIN; ALPHA-HELICES; GXXXG MOTIF; MITOCHONDRIAL-MEMBRANE	Mitochondria-mediated apoptosis is regulated by proteins of the Bcl-2 superfamily, most of which contain a C-terminal hydrophobic domain that plays a role in membrane targeting. Experiments with BNIP3 have implicated the transmembrane (TM) domain in its proapoptotic function, homodimerization, and interactions with Bcl-2 and Bcl-x(L). We show that the BNIP3 TM domain self-associates strongly in Escherichia coli cell membranes and causes reversible dimerization of a soluble protein in the detergent SDS when expressed as an in-frame fusion. Limited mutational analysis identifies specific residues that are critical for BNIP3 TM self-association in membranes, and these residues are also important for dimerization in SDS micelles, suggesting that the self-association observed in membranes is preserved in detergent. The effects of sequence changes at positions Ala(176) and Gly(180) suggest that the BNIP3 TM domain associates using a variant of the GXXXG motif previously shown to be important in the dimerization of glycophorin A. The importance of residue His(173) in BNIP3 TM domain dimerization indicates that polar residues, which have been implicated in self-association of model TM peptides, can act in concert with the AXXXG motif to stabilize TM domain interactions. Our results demonstrate that the hydrophobic C-terminal TM domain of the pro-apoptotic BNIP3 protein dimerizes tightly in lipidic environments, and that this association has a strong sequence dependence but is independent of the identity of flanking regions. Thus, the transmembrane domain represents another region of the Bcl-2 superfamily of proteins that is capable of mediating strong and specific protein-protein interactions.	Rice Univ, Dept Biochem & Cell Biol, Houston, TX 77005 USA	Rice University	MacKenzie, KR (corresponding author), Rice Univ, Dept Biochem & Cell Biol, 6100 Main St, Houston, TX 77005 USA.				NIGMS NIH HHS [R01 GM067850] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; Antonsson B, 2001, J BIOL CHEM, V276, P11615, DOI 10.1074/jbc.M010810200; ARKIN IT, 1994, EMBO J, V13, P4757, DOI 10.1002/j.1460-2075.1994.tb06801.x; Blakey D, 2002, BIOCHEM J, V364, P527, DOI 10.1042/BJ20011761; Bouillet P, 2002, J CELL SCI, V115, P1567; Bowen ME, 2002, BIOCHEMISTRY-US, V41, P15861, DOI 10.1021/bi0269411; BOYD JM, 1994, CELL, V79, P341, DOI 10.1016/0092-8674(94)90202-X; Brosig B, 1998, PROTEIN SCI, V7, P1052; Bruick RK, 2000, P NATL ACAD SCI USA, V97, P9082, DOI 10.1073/pnas.97.16.9082; Chen G, 1997, J EXP MED, V186, P1975, DOI 10.1084/jem.186.12.1975; Chen G, 1999, J BIOL CHEM, V274, P7, DOI 10.1074/jbc.274.1.7; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; Choma C, 2000, NAT STRUCT BIOL, V7, P161; Cizeau J, 2000, ONCOGENE, V19, P5453, DOI 10.1038/sj.onc.1203929; Cornea RL, 1997, BIOCHEMISTRY-US, V36, P2960, DOI 10.1021/bi961955q; Dawson JP, 2002, J MOL BIOL, V316, P799, DOI 10.1006/jmbi.2001.5353; Degterev A, 2001, NAT CELL BIOL, V3, P173, DOI 10.1038/35055085; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; Fisher LE, 1999, J MOL BIOL, V293, P639, DOI 10.1006/jmbi.1999.3126; Fleming KG, 1997, J MOL BIOL, V272, P266, DOI 10.1006/jmbi.1997.1236; FUJII J, 1989, J BIOL CHEM, V264, P12950; Gratkowski H, 2001, P NATL ACAD SCI USA, V98, P880, DOI 10.1073/pnas.98.3.880; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Guo K, 2001, CELL DEATH DIFFER, V8, P367, DOI 10.1038/sj.cdd.4400810; Hegde R, 1998, J BIOL CHEM, V273, P7783, DOI 10.1074/jbc.273.14.7783; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; IMAGAWA T, 1986, J BIOCHEM-TOKYO, V99, P41, DOI 10.1093/oxfordjournals.jbchem.a135478; Imazu T, 1999, ONCOGENE, V18, P4523, DOI 10.1038/sj.onc.1202722; Inohara N, 1997, EMBO J, V16, P1686, DOI 10.1093/emboj/16.7.1686; Knudson CM, 1997, NAT GENET, V16, P358, DOI 10.1038/ng0897-358; Kubasiak LA, 2002, P NATL ACAD SCI USA, V99, P12825, DOI 10.1073/pnas.202474099; Lamy L, 2003, J BIOL CHEM, V278, P23915, DOI 10.1074/jbc.M301869200; Langosch D, 1996, J MOL BIOL, V263, P525, DOI 10.1006/jmbi.1996.0595; LEMMON MA, 1992, J BIOL CHEM, V267, P7683; LEMMON MA, 1994, NAT STRUCT BIOL, V1, P157, DOI 10.1038/nsb0394-157; LEMMON MA, 1992, BIOCHEMISTRY-US, V31, P12719, DOI 10.1021/bi00166a002; MacKenzie KR, 1998, P NATL ACAD SCI USA, V95, P3583, DOI 10.1073/pnas.95.7.3583; MacKenzie KR, 1997, SCIENCE, V276, P131, DOI 10.1126/science.276.5309.131; Mcclain MS, 2003, J BIOL CHEM, V278, P12101, DOI 10.1074/jbc.M212595200; McClain MS, 2001, INFECT IMMUN, V69, P1181, DOI 10.1128/IAI.69.2.1181-1184.2001; Mendrola JM, 2002, J BIOL CHEM, V277, P4704, DOI 10.1074/jbc.M108681200; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Nouraini S, 2000, MOL CELL BIOL, V20, P1604, DOI 10.1128/MCB.20.5.1604-1615.2000; Ohi N, 1999, CELL DEATH DIFFER, V6, P314, DOI 10.1038/sj.cdd.4400493; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Puthalakath H, 2002, CELL DEATH DIFFER, V9, P505, DOI 10.1038/sj.cdd.4400998; Ray R, 2000, J BIOL CHEM, V275, P1439, DOI 10.1074/jbc.275.2.1439; Russ WP, 1999, P NATL ACAD SCI USA, V96, P863, DOI 10.1073/pnas.96.3.863; Russ WP, 2000, J MOL BIOL, V296, P911, DOI 10.1006/jmbi.1999.3489; Saito M, 2000, NAT CELL BIOL, V2, P553, DOI 10.1038/35019596; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; Senes A, 2000, J MOL BIOL, V296, P921, DOI 10.1006/jmbi.1999.3488; Shaw W V, 1975, Methods Enzymol, V43, P737; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; Tan KO, 2001, J BIOL CHEM, V276, P2802, DOI 10.1074/jbc.M008955200; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; Vande Velde C, 2000, MOL CELL BIOL, V20, P5454, DOI 10.1128/MCB.20.15.5454-5468.2000; Vieira Helena L. A., 2002, Oncogene, V21, P1963, DOI 10.1038/sj.onc.1205270; Voulhoux R, 2003, SCIENCE, V299, P262, DOI 10.1126/science.1078973; Wang JL, 2000, P NATL ACAD SCI USA, V97, P7124, DOI 10.1073/pnas.97.13.7124; Wang JL, 2000, CANCER RES, V60, P1498; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Wang K, 1998, MOL CELL BIOL, V18, P6083, DOI 10.1128/MCB.18.10.6083; Watanabe Y, 2002, J PROTEIN CHEM, V21, P169, DOI 10.1023/A:1015372600277; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Yasuda M, 1998, J BIOL CHEM, V273, P12415, DOI 10.1074/jbc.273.20.12415; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Zha JP, 1997, J BIOL CHEM, V272, P24101, DOI 10.1074/jbc.272.39.24101; Zhou FX, 2001, P NATL ACAD SCI USA, V98, P2250, DOI 10.1073/pnas.041593698; Zhou FX, 2000, NAT STRUCT BIOL, V7, P154	71	86	87	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51950	51956		10.1074/jbc.M308429200	http://dx.doi.org/10.1074/jbc.M308429200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14532263	hybrid			2022-12-27	WOS:000187206300131
J	Takahashi, S; Inatome, R; Hotta, A; Qingyu, Q; Hackenmiller, R; Simon, MC; Yamamura, H; Yanagi, S				Takahashi, S; Inatome, R; Hotta, A; Qingyu, Q; Hackenmiller, R; Simon, MC; Yamamura, H; Yanagi, S			Role for Fes/Fps tyrosine kinase in microtubule nucleation through its Fes/CIP4 homology domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-FES; PROTEIN; GENE; ACTIVATION; FPS/FES; NEURONS; CELLS; MICE	We have previously demonstrated that Fes/Fps (Fes) tyrosine kinase is involved in Semaphorin3A-mediated signaling. Here we report a role for Fes tyrosine kinase in microtubule dynamics. A fibrous formation of Fes was observed in a kinase-dependent manner, which associated with microtubules and functionally correlated with microtubule bundling. Microtubule regeneration assays revealed that Fes aggregates colocalized with gamma-tubulin at microtubule nucleation sites in a Fes/CIP4 homology (FCH) domain-dependent manner and that expression of FCH domain-deleted Fes mutants blocked normal centrosome formation. In support of these observations, mouse embryonic fibroblasts derived from Fes-deficient mice displayed an aberrant structure of nucleation and centrosome with unbundling and disoriented filaments of microtubules. Our findings suggest that Fes plays a critical role in microtubule dynamics including microtubule nucleation and bundling through its FCH domain.	Kobe Univ, Grad Sch Med, Dept Genome Sci, Div Proteom,Chuo Ku, Kobe, Hyogo 6500017, Japan; Oregon Hlth Sci Univ, Dept Cell & Dev Biol, Portland, OR 97201 USA; Univ Penn, Sch Med, Howard Hughes Med Inst, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Abramson Family Canc Res Inst, Dept Canc Biol, Philadelphia, PA 19104 USA; JST, PRESTO, Kawaguchi, Saitama, Japan	Kobe University; Oregon Health & Science University; Howard Hughes Medical Institute; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Japan Science & Technology Agency (JST)	Yanagi, S (corresponding author), Kobe Univ, Grad Sch Med, Dept Genome Sci, Div Proteom,Chuo Ku, Kobe, Hyogo 6500017, Japan.		Simon, Celeste/AAG-3941-2021; Yanagi, Shigeru/AAU-9513-2020	Yanagi, Shigeru/0000-0002-1392-8663				Aspenstrom P, 1997, CURR BIOL, V7, P479, DOI 10.1016/S0960-9822(06)00219-3; BRANDT R, 1994, CELL MOTIL CYTOSKEL, V28, P143, DOI 10.1002/cm.970280206; Craig AWB, 1999, J BIOL CHEM, V274, P19934, DOI 10.1074/jbc.274.28.19934; Fukata Y, 2002, NAT CELL BIOL, V4, P583, DOI 10.1038/ncb825; Greer P, 2002, NAT REV MOL CELL BIO, V3, P278, DOI 10.1038/nrm783; Hackenmiller R, 2000, IMMUNITY, V13, P397, DOI 10.1016/S1074-7613(00)00039-X; Hackenmiller R, 2002, DEV BIOL, V245, P255, DOI 10.1006/dbio.2002.0643; Haigh J, 1996, CELL GROWTH DIFFER, V7, P931; HANAFUSA T, 1980, P NATL ACAD SCI-BIOL, V77, P3009, DOI 10.1073/pnas.77.5.3009; HJERMSTAD SJ, 1993, ONCOGENE, V8, P2283; Inagaki N, 2001, NAT NEUROSCI, V4, P781, DOI 10.1038/90476; Inatome R, 2000, J BIOL CHEM, V275, P27291; Mitsui N, 2002, EMBO J, V21, P3274, DOI 10.1093/emboj/cdf328; Read RD, 1997, J BIOL CHEM, V272, P18498, DOI 10.1074/jbc.272.29.18498; Takahashi S, 2003, GENES CELLS, V8, P81, DOI 10.1046/j.1365-2443.2003.00617.x; Tian L, 2000, J BIOL CHEM, V275, P7854, DOI 10.1074/jbc.275.11.7854; YEE SP, 1989, P NATL ACAD SCI USA, V86, P5873, DOI 10.1073/pnas.86.15.5873	17	33	34	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					49129	49133		10.1074/jbc.C300289200	http://dx.doi.org/10.1074/jbc.C300289200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	14551201	hybrid			2022-12-27	WOS:000186829000076
J	Moldoveanu, T; Jia, ZC; Davies, PL				Moldoveanu, T; Jia, ZC; Davies, PL			Calpain activation by cooperative Ca2+ binding at two non-EF-hand sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GIRDLE MUSCULAR-DYSTROPHY; SMALL-SUBUNIT GENE; SEX DETERMINATION; CRYSTAL-STRUCTURE; ACTIVE-SITE; CALCIUM; CLEAVAGE; PROTEIN; FAMILY; DOMAIN	The active site residues in calpain are mis-aligned in the apo, Ca2+-free form. Alignment for catalysis requires binding of Ca2+ to two non-EF-hand sites, one in each of the core domains I and II. Using domain swap constructs between the protease cores of the mu and m isoforms (which have different Ca2+ requirements) and structural and biochemical characterization of site-directed mutants, we have deduced the order of Ca2+ binding and the basis of the cooperativity between the two sites. Ca2+ binds first to the partially preformed site in domain I. Knockout of this site through D106A substitution eliminates binding to this domain as shown by the crystal structure of D106A muI-II. However, at elevated Ca2+ concentrations this mutant still forms the double salt bridge that links the two Ca2+ sites and becomes nearly as active as muI-II. Elimination of the bridge in E333A muI-II has a more drastic effect on enzyme action, especially at low Ca2+ concentrations. Domain II Ca2+ binding appears essential, because Ca2+-coordinating side-chain mutants E302R and D333A have severely impaired muI-II activation and activity. The introduction of mutations into the whole heterodimeric enzyme that eliminate the salt bridge or Ca2+ binding to domain II produce similar phenotypes, suggesting that the protease core Ca2+ switch is crucial and cannot be overridden by Ca2+ binding to other domains.	Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada; Queens Univ, Prot Engn Network Ctr Excellence, Kingston, ON K7L 3N6, Canada	Queens University - Canada; Queens University - Canada	Davies, PL (corresponding author), Queens Univ, Dept Biochem, Botterell Hall, Kingston, ON K7L 3N6, Canada.	daviesp@post.queensu.ca	Moldoveanu, Tudor/N-8173-2018	Moldoveanu, Tudor/0000-0003-0791-318X				Arthur JSC, 2000, MOL CELL BIOL, V20, P4474, DOI 10.1128/MCB.20.12.4474-4481.2000; ARTHUR JSC, 1995, FEBS LETT, V368, P397, DOI 10.1016/0014-5793(95)00691-2; Barnes TM, 1996, EMBO J, V15, P4477, DOI 10.1002/j.1460-2075.1996.tb00825.x; BERTI PJ, 1995, J MOL BIOL, V246, P273, DOI 10.1006/jmbi.1994.0083; Brewer JM, 1999, BIOTECHNOL APPL BIOC, V30, P173; Cohen GH, 1997, J APPL CRYSTALLOGR, V30, P1160, DOI 10.1107/S0021889897006729; Cox EA, 1998, MICROSC RES TECHNIQ, V43, P412, DOI 10.1002/(SICI)1097-0029(19981201)43:5<412::AID-JEMT7>3.0.CO;2-F; Dutt P, 2000, BIOCHEM J, V348, P37, DOI 10.1042/0264-6021:3480037; Dutt P, 2002, BIOCHEM J, V367, P263, DOI 10.1042/BJ20020485; Glading A, 2002, TRENDS CELL BIOL, V12, P46, DOI 10.1016/S0962-8924(01)02179-1; Hosfield CM, 1999, EMBO J, V18, P6880, DOI 10.1093/emboj/18.24.6880; Hosfield CM, 2001, J BIOL CHEM, V276, P7404, DOI 10.1074/jbc.M007352200; Huang YH, 2001, TRENDS MOL MED, V7, P355, DOI 10.1016/S1471-4914(01)02049-4; Jia ZC, 2001, BIOPHYS J, V80, P2590, DOI 10.1016/S0006-3495(01)76229-7; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; Lee KS, 1997, ANN NY ACAD SCI, V825, P95, DOI 10.1111/j.1749-6632.1997.tb48419.x; Lee MS, 2000, NATURE, V405, P360, DOI 10.1038/35012636; Lid SE, 2002, P NATL ACAD SCI USA, V99, P5460, DOI 10.1073/pnas.042098799; Maki M, 1997, BIOCHEM J, V328, P718; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Moldoveanu T, 2003, NAT STRUCT BIOL, V10, P371, DOI 10.1038/nsb917; Moldoveanu T, 2002, CELL, V108, P649, DOI 10.1016/S0092-8674(02)00659-1; Nixon RA, 2000, ANN NY ACAD SCI, V924, P117; Ort T, 2001, EMBO J, V20, P4013, DOI 10.1093/emboj/20.15.4013; Richard I, 1997, AM J HUM GENET, V60, P1128; RICHARD I, 1995, CELL, V81, P27, DOI 10.1016/0092-8674(95)90368-2; Rizo J, 1998, J BIOL CHEM, V273, P15879, DOI 10.1074/jbc.273.26.15879; Santella L, 1998, CELL CALCIUM, V23, P123, DOI 10.1016/S0143-4160(98)90110-5; Sokol SB, 2000, GENE DEV, V14, P901; Sorimachi H, 2001, J BIOCHEM-TOKYO, V129, P653, DOI 10.1093/oxfordjournals.jbchem.a002903; Strobl S, 2000, P NATL ACAD SCI USA, V97, P588, DOI 10.1073/pnas.97.2.588; Tompa P, 2001, BIOCHEM BIOPH RES CO, V280, P1333, DOI 10.1006/bbrc.2001.4279; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; WANG KKW, 1994, TRENDS PHARMACOL SCI, V15, P412, DOI 10.1016/0165-6147(94)90090-6; Zimmerman UJP, 2000, IUBMB LIFE, V50, P63	37	48	48	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					6106	6114		10.1074/jbc.M310460200	http://dx.doi.org/10.1074/jbc.M310460200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14581465	hybrid			2022-12-27	WOS:000188776500126
J	Huys, I; Olamendi-Portugal, T; Garcia-Gomez, BI; Vandenberghe, I; Van Beeumen, J; Dyason, K; Clynen, E; Zhu, SY; van der Walt, J; Possani, LD; Tytgat, J				Huys, I; Olamendi-Portugal, T; Garcia-Gomez, BI; Vandenberghe, I; Van Beeumen, J; Dyason, K; Clynen, E; Zhu, SY; van der Walt, J; Possani, LD; Tytgat, J			A subfamily of acidic alpha-K+ toxins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BUTHUS-MARTENSII KARSCH; POTASSIUM CHANNEL; CRYSTAL-STRUCTURE; SCORPION TOXINS; BLOCKING PEPTIDE; MAXI-K; CHARYBDOTOXIN; PURIFICATION; VENOM; NEUROTOXINS	Three homologous acidic peptides have been isolated from the venom of three different Parabuthus scorpion species, P. transvaalicus, P. villosus, and P. granulatus. Analysis of the primary sequences reveals that they structurally belong to subfamily 11 of short chain alpha-K+-blocking peptides ( Tytgat, J., Chandy, K. G., Garcia, M. L., Gutman, G. A., Martin-Eauclaire, M. F., van der Walt, J. J., and Possani, L. D. ( 1999) Trends Pharmacol. Sci. 20, 444 - 447). These toxins are 36 - 37 amino acids in length and have six aligned cysteine residues, but they differ substantially from the other alpha-K+ toxins because of the absence of the critical Lys(27) and their total overall negative charge. Parabutoxin 1 (PBTx1), which has been expressed by recombinant methods, has been submitted to functional characterization. Despite the lack of the Lys27, this toxin blocks several Kv1-type channels heterologously expressed in Xenopus oocytes but with low affinities ( micromolar range). Because a relationship between the biological activity and the acidic residue substitutions may exist, we set out to elucidate the relative impact of the acidic character of the toxin and the lack of the critical Lys27 on the weak activity of PBTx1 toward Kv1 channels. To achieve this, a specific mutant named rPBTx1 T24F/V26K was made recombinantly and fully characterized on Kv1-type channels heterologously expressed in Xenopus oocytes. Analysis of rPBTx1 T24F/V26K displaying an affinity toward Kv1.2 and Kv1.3 channels in the nanomolar range shows the importance of the functional dyad above the acidic character of this toxin.	Katholieke Univ Leuven, Toxicol Lab, B-3000 Louvain, Belgium; Inst Biotechnol, Dept Mol Med & Bioproc, Cuernavaca, Morelos, Mexico; Univ Ghent, Lab Prot Biochem & Prot Engn, B-9000 Ghent, Belgium; Potchefstroom Univ Christian Higher Educ, Dept Physiol, ZA-2520 Potchefstroom, South Africa; Katholieke Univ Leuven, Lab Dev Physiol & Mol Biol, B-3000 Louvain, Belgium	KU Leuven; Ghent University; North West University - South Africa; KU Leuven	Tytgat, J (corresponding author), Katholieke Univ Leuven, Toxicol Lab, E Van Evenstr 4, B-3000 Louvain, Belgium.	Jan.Tytgat@pharm.kuleuven.ac.be	Possani, Lourival D/J-2397-2013; Tytgat, Jan/F-1560-2010; Huys, Isabelle/M-8673-2016	Tytgat, Jan/0000-0003-1778-6022				AIYAR J, 1995, NEURON, V15, P1169, DOI 10.1016/0896-6273(95)90104-3; ARMSTRONG CM, 1974, J GEN PHYSIOL, V63, P533, DOI 10.1085/jgp.63.5.533; Batista CVF, 2002, BBA-PROTEINS PROTEOM, V1601, P123, DOI 10.1016/S1570-9639(02)00458-2; Becerril B, 1996, BIOCHEM J, V313, P753, DOI 10.1042/bj3130753; BEDNAREK MA, 1994, BIOCHEM BIOPH RES CO, V198, P619, DOI 10.1006/bbrc.1994.1090; BONTEMS F, 1991, SCIENCE, V254, P1521, DOI 10.1126/science.1720574; Buisine E, 1997, J PEPT RES, V49, P545; Corona M, 2001, TOXICON, V39, P1893, DOI 10.1016/S0041-0101(01)00174-X; Dauplais M, 1997, J BIOL CHEM, V272, P4302, DOI 10.1074/jbc.272.7.4302; ESCOBAR L, 1993, BIOCHEMISTRY-US, V32, P6982, DOI 10.1021/bi00078a024; Fu W, 2002, BIOPHYS J, V83, P2370, DOI 10.1016/S0006-3495(02)75251-X; Garcia M L, 1997, Adv Pharmacol, V39, P425, DOI 10.1016/S1054-3589(08)60078-2; GARCIA ML, 1994, BIOCHEMISTRY-US, V33, P6834, DOI 10.1021/bi00188a012; GIMENEZGALLEGO G, 1988, P NATL ACAD SCI USA, V85, P3329, DOI 10.1073/pnas.85.10.3329; GOLDSTEIN SAN, 1994, NEURON, V12, P1377, DOI 10.1016/0896-6273(94)90452-9; Goudet C, 2002, TOXICON, V40, P1239, DOI 10.1016/S0041-0101(02)00142-3; Grishin E, 1999, EUR J BIOCHEM, V264, P276, DOI 10.1046/j.1432-1327.1999.00622.x; Huys I, 2002, EUR J BIOCHEM, V269, P1854, DOI 10.1046/j.1432-1033.2002.02833.x; HUYS I, 2003, EUR J NEUROSCI; Li HM, 1996, J MOL BIOL, V261, P415, DOI 10.1006/jmbi.1996.0473; Li HM, 1996, SCI CHINA SER C, V39, P373; Luo MJ, 1997, TOXICON, V35, P723, DOI 10.1016/S0041-0101(96)00146-8; MACKINNON R, 1989, SCIENCE, V245, P1382, DOI 10.1126/science.2476850; Mansuelle Pascal, 1992, Natural Toxins, V1, P61, DOI 10.1002/nt.2620010112; MARTIN MF, 1986, TOXICON, V24, P1131, DOI 10.1016/0041-0101(86)90139-X; Mullmann TJ, 1999, BIOCHEMISTRY-US, V38, P2395, DOI 10.1021/bi982040+; Olamendi-Portugal T, 2002, BIOCHEM BIOPH RES CO, V299, P562, DOI 10.1016/S0006-291X(02)02706-7; PARK CS, 1992, BIOCHEMISTRY-US, V31, P7749, DOI 10.1021/bi00149a002; PARK CS, 1992, NEURON, V9, P307, DOI 10.1016/0896-6273(92)90169-E; Peter M, 2001, J MEMBRANE BIOL, V179, P13, DOI 10.1007/s002320010033; Pimenta AMC, 2003, BIOCHEM BIOPH RES CO, V301, P1086, DOI 10.1016/S0006-291X(03)00082-2; Possani LD, 1999, EUR J BIOCHEM, V264, P287, DOI 10.1046/j.1432-1327.1999.00625.x; Ranganathan R, 1996, NEURON, V16, P131, DOI 10.1016/S0896-6273(00)80030-6; Rauer H, 2000, J BIOL CHEM, V275, P1201, DOI 10.1074/jbc.275.2.1201; RomiLebrun R, 1997, EUR J BIOCHEM, V245, P457, DOI 10.1111/j.1432-1033.1997.00457.x; Savarin P, 1998, BIOCHEMISTRY-US, V37, P5407, DOI 10.1021/bi9730341; Schroeder N, 2002, FEBS LETT, V527, P298, DOI 10.1016/S0014-5793(02)03256-8; Smith LA, 1997, BIOCHEMISTRY-US, V36, P7690, DOI 10.1021/bi963105g; Tsetlin V, 1999, EUR J BIOCHEM, V264, P281, DOI 10.1046/j.1432-1327.1999.00623.x; Tytgat J, 1999, TRENDS PHARMACOL SCI, V20, P444, DOI 10.1016/S0165-6147(99)01398-X; Tytgat J, 1998, BIOPHYS J, V74, pA229; Tytgat J, 1998, FEBS LETT, V441, P387, DOI 10.1016/S0014-5793(98)01589-0; Wang DC, 1999, J NAT TOXINS, V8, P309; Wei A, 1996, NEUROPHARMACOLOGY, V35, P805, DOI 10.1016/0028-3908(96)00126-8; WILSON AC, 1977, ANNU REV BIOCHEM, V46, P573, DOI 10.1146/annurev.bi.46.070177.003041	45	21	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	2004	279	4					2781	2789		10.1074/jbc.M311029200	http://dx.doi.org/10.1074/jbc.M311029200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	764MU	14561751	hybrid			2022-12-27	WOS:000188211300056
J	Kutateladze, TG; Capelluto, DGS; Ferguson, CG; Cheever, ML; Kutateladze, AG; Prestwich, GD; Overduin, M				Kutateladze, TG; Capelluto, DGS; Ferguson, CG; Cheever, ML; Kutateladze, AG; Prestwich, GD; Overduin, M			Multivalent mechanism of membrane insertion by the FYVE domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM DODECYL-SULFATE; PLECKSTRIN HOMOLOGY DOMAINS; PHOSPHATIDYLINOSITOL 3-PHOSPHATE; PHOSPHOLIPID-BINDING; CRYSTAL-STRUCTURE; C2 DOMAIN; LIPID-BILAYERS; PROTEIN; NMR; MICELLES	Targeting of a wide variety of proteins to membranes involves specific recognition of phospholipid head groups and insertion into lipid bilayers. For example, proteins that contain FYVE domains are recruited to endosomes through interaction with phosphatidylinositol 3-phosphate (PtdIns(3)P). However, the structural mechanism of membrane docking and insertion by this domain remains unclear. Here, the depth and angle of micelle insertion and the lipid binding properties of the FYVE domain of early endosome antigen 1 are estimated by NMR spectroscopy. Spin label probes incorporated into micelles identify a hydrophobic protuberance that inserts into the micelle core and is surrounded by interfacially active polar residues. A novel proxyl PtdIns(3)P derivative is developed to map the position of the phosphoinositide acyl chains, which are found to align with the membrane insertion element. Dual engagement of the FYVE domain with PtdIns(3)P and dodecylphosphocholine micelles yields a 6-fold enhancement of affinity. The additional interaction of phosphatidylserine with a conserved basic site of the protein further amplifies the micelle binding affinity and dramatically alters the angle of insertion. Thus, the FYVE domain is targeted to endosomes through the synergistic action of stereospecific PtdIns(3)P head group ligation, hydrophobic insertion and electrostatic interactions with acidic phospholipids.	Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Program Mol Biol, Denver, CO 80262 USA; Echelon Biosci Inc, Salt Lake City, UT 84108 USA; Univ Denver, Dept Chem & Biochem, Denver, CO 80210 USA; Univ Utah, Dept Med Chem, Salt Lake City, UT 84108 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Denver; Utah System of Higher Education; University of Utah	Kutateladze, TG (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80262 USA.	Tatiana.Kutateladze@UCHSC.edu	Overduin, Michael/AAG-3632-2020; Ferguson, Colin/AAY-2524-2021	Overduin, Michael/0000-0002-3114-6585; Ferguson, Colin/0000-0002-9021-4533; Kutateladze, Tatiana/0000-0001-7375-6990	Wellcome Trust [071684] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALTIERI AS, 1995, J AM CHEM SOC, V117, P7566, DOI 10.1021/ja00133a039; Bhatnagar RS, 1997, TRENDS CELL BIOL, V7, P14, DOI 10.1016/S0962-8924(97)10044-7; Burd CG, 1998, MOL CELL, V2, P157, DOI 10.1016/S1097-2765(00)80125-2; Chapman ER, 1998, J BIOL CHEM, V273, P13995, DOI 10.1074/jbc.273.22.13995; Cheever ML, 2001, NAT CELL BIOL, V3, P613, DOI 10.1038/35083000; Chen J, 1998, J ORG CHEM, V63, P6511, DOI 10.1021/jo980501r; Diraviyam K, 2003, J MOL BIOL, V328, P721, DOI 10.1016/S0022-2836(03)00325-5; Dumas JJ, 2001, MOL CELL, V8, P947, DOI 10.1016/S1097-2765(01)00385-9; Ford MGJ, 2002, NATURE, V419, P361, DOI 10.1038/nature01020; Frazier AA, 2002, BIOCHEMISTRY-US, V41, P6282, DOI 10.1021/bi0160821; Gaullier JM, 2000, J BIOL CHEM, V275, P24595, DOI 10.1074/jbc.M906554199; Gaullier JM, 1998, NATURE, V394, P432, DOI 10.1038/28767; Gillooly DJ, 2000, EMBO J, V19, P4577, DOI 10.1093/emboj/19.17.4577; Grzesiek S, 1996, BIOCHEMISTRY-US, V35, P10256, DOI 10.1021/bi9611164; HENRY GD, 1994, METHOD ENZYMOL, V239, P515; IKURA M, 1990, J MAGN RESON, V86, P204, DOI 10.1016/0022-2364(90)90227-Z; Jarvet J, 1997, BIOCHEMISTRY-US, V36, P8153, DOI 10.1021/bi970193b; Johnson RP, 1998, BIOCHEMISTRY-US, V37, P10211, DOI 10.1021/bi9727242; Karathanassis D, 2002, EMBO J, V21, P5057, DOI 10.1093/emboj/cdf519; Kobayashi T, 1998, NATURE, V392, P193, DOI 10.1038/32440; Kohout SC, 2003, BIOCHEMISTRY-US, V42, P1254, DOI 10.1021/bi026596f; Kutateladze T, 2001, SCIENCE, V291, P1793, DOI 10.1126/science.291.5509.1793; Kutateladze TG, 1999, MOL CELL, V3, P805, DOI 10.1016/S1097-2765(01)80013-7; KUTATELADZE TG, 2003, HDB METALLOPROTEINS, V3; LAUTERWEIN J, 1979, BIOCHIM BIOPHYS ACTA, V556, P244, DOI 10.1016/0005-2736(79)90046-4; Lee EY, 2002, SCIENCE, V297, P1193, DOI 10.1126/science.1071362; Lemmon MA, 2000, BIOCHEM J, V350, P1, DOI 10.1042/0264-6021:3500001; Lemmon MA, 2002, FEBS LETT, V513, P71, DOI 10.1016/S0014-5793(01)03243-4; Mao YX, 2000, CELL, V100, P447, DOI 10.1016/S0092-8674(00)80680-7; MARION D, 1989, J AM CHEM SOC, V111, P1515, DOI 10.1021/ja00186a066; Misra S, 1999, CELL, V97, P657, DOI 10.1016/S0092-8674(00)80776-X; Murray D, 1997, STRUCTURE, V5, P985, DOI 10.1016/S0969-2126(97)00251-7; Overduin M, 2001, Mol Interv, V1, P150; PAPAVOINE CHM, 1994, BIOCHEMISTRY-US, V33, P12990, DOI 10.1021/bi00248a007; Patki V, 1998, NATURE, V394, P433, DOI 10.1038/28771; Perisic O, 1999, J BIOL CHEM, V274, P14979, DOI 10.1074/jbc.274.21.14979; Perisic O, 1998, J BIOL CHEM, V273, P1596, DOI 10.1074/jbc.273.3.1596; Prestwich GD, 1996, ACCOUNTS CHEM RES, V29, P503, DOI 10.1021/ar960136v; Rauch ME, 2002, J BIOL CHEM, V277, P14068, DOI 10.1074/jbc.M109572200; Ridley SH, 2001, J CELL SCI, V114, P3991; Sankaran VG, 2001, BIOCHEMISTRY-US, V40, P8581, DOI 10.1021/bi010425d; Sbrissa D, 2002, J BIOL CHEM, V277, P6073, DOI 10.1074/jbc.M110194200; Seelig A, 2000, J BIOL CHEM, V275, P17954, DOI 10.1074/jbc.M002264200; Singh SM, 2003, PROTEIN SCI, V12, P1934, DOI 10.1110/ps.0358803; Stahelin RV, 2003, J BIOL CHEM, V278, P14469, DOI 10.1074/jbc.M212579200; Stahelin RV, 2003, J BIOL CHEM, V278, P28993, DOI 10.1074/jbc.M302865200; Stahelin RV, 2002, J BIOL CHEM, V277, P26379, DOI 10.1074/jbc.M201106200; Stolt PC, 2003, STRUCTURE, V11, P569, DOI 10.1016/S0969-2126(03)00068-6; Tochtrop GP, 2002, P NATL ACAD SCI USA, V99, P1847, DOI 10.1073/pnas.012379199; vandenHooven HW, 1996, EUR J BIOCHEM, V235, P394, DOI 10.1111/j.1432-1033.1996.00394.x; Zimmermann P, 2002, MOL CELL, V9, P1215, DOI 10.1016/S1097-2765(02)00549-X; Zwahlen C, 1997, J AM CHEM SOC, V119, P6711, DOI 10.1021/ja970224q	52	76	80	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 23	2004	279	4					3050	3057		10.1074/jbc.M309007200	http://dx.doi.org/10.1074/jbc.M309007200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	764MU	14578346	hybrid			2022-12-27	WOS:000188211300086
J	Lu, D; Zhang, HF; Ludwig, D; Persaud, A; Jimenez, X; Burtrum, D; Balderes, P; Liu, ML; Bohlen, P; Witte, L; Zhu, ZP				Lu, D; Zhang, HF; Ludwig, D; Persaud, A; Jimenez, X; Burtrum, D; Balderes, P; Liu, ML; Bohlen, P; Witte, L; Zhu, ZP			Simultaneous blockade of both the epidermal growth factor receptor and the insulin-like growth factor receptor signaling pathways in cancer cells with a fully human recombinant bispecific antibody	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-I RECEPTOR; BREAST-CANCER; ESCHERICHIA-COLI; EFFICIENT ROUTE; EGF RECEPTOR; IGF-I; THERAPY; CHEMOTHERAPY; FRAGMENTS; DESIGN	Both the epidermal growth factor receptor ( EGFR) and the insulin-like growth factor receptor (IGFR) have been implicated in the tumorigenesis of a variety of human cancers. Effective tumor inhibition has been achieved both experimentally and clinically with a number of strategies that antagonize either receptor activity. Here we constructed and produced two fully human recombinant bispecific antibodies (BsAb) that target both EGFR and IGFR, using two neutralizing human antibodies originally isolated from a phage display library. The BsAb not only retained the antigen binding capacity of each of the parent antibodies, but also were capable of binding to both targets simultaneously as demonstrated by a cross-linking enzyme-linked immunosorbent assay. Furthermore, the BsAb effectively blocked both ligands, EGF and IGF, from binding to their respective receptors, and inhibited tumor cell proliferation as potently as a combination of both the parent antibodies. More importantly, the BsAb were able to completely block activation of several major signal transduction molecules, including Akt and p44/p42 MAP kinases, by both EGF and IGF, whereas each individual parent antibody was only effective in inhibiting those signal molecules activated by the relevant single growth factor. The BsAb molecules retained good antigen binding activity after incubation with mouse serum at 37 degreesC for up to 6 days. Taken together, our results underscore the benefits of simultaneous targeting multiple growth factor receptor pathways for more efficacious cancer treatment. This report describes the first time use of a recombinant BsAb for targeting two tumor-associated molecules on either a single or adjacent tumor cells for enhanced antitumor activity.	ImClone Syst Inc, Dept Antibody Technol, New York, NY 10014 USA; ImClone Syst Inc, Dept Mol & Cell Biol, New York, NY 10014 USA; ImClone Syst Inc, Dept Prot Chem, New York, NY 10014 USA	Eli Lilly; Eli Lilly; Eli Lilly	Zhu, ZP (corresponding author), ImClone Syst Inc, Dept Antibody Technol, 180 Varick St, New York, NY 10014 USA.	Zhenping@imclone.com	Shao, Zongping/AAY-8177-2020; Liu, Meilin/E-5782-2010	Liu, Meilin/0000-0002-6188-2372				Alt M, 1999, FEBS LETT, V454, P90, DOI 10.1016/S0014-5793(99)00782-6; Arteaga C, 2003, SEMIN ONCOL, V30, P3, DOI 10.1016/S0093-7754(03)00185-4; Arteaga CL, 2002, SEMIN ONCOL, V29, P3, DOI 10.1053/sonc.2002.35642; Baselga J, 2001, ONCOLOGY-BASEL, V61, P14, DOI 10.1159/000055397; Baserga R, 1999, EXP CELL RES, V253, P1, DOI 10.1006/excr.1999.4667; BEBBINGTON CR, 1992, BIO-TECHNOL, V10, P169, DOI 10.1038/nbt0292-169; Benini S, 2001, CLIN CANCER RES, V7, P1790; Boylan M, 1998, ANN ONCOL, V9, P205, DOI 10.1023/A:1008241804078; BURTRUM D, 2003, IN PRESS CANC RES; Carter P, 1995, J Hematother, V4, P463, DOI 10.1089/scd.1.1995.4.463; Carter P, 2001, J IMMUNOL METHODS, V248, P7, DOI 10.1016/S0022-1759(00)00339-2; Chakravarti A, 2002, CANCER RES, V62, P200; Cheson Bruce, 2002, Curr Opin Investig Drugs, V3, P165; Clark AS, 2002, MOL CANCER THER, V1, P707; Cohen MH, 2003, ONCOLOGIST, V8, P303, DOI 10.1634/theoncologist.8-4-303; Coloma MJ, 1997, NAT BIOTECHNOL, V15, P159, DOI 10.1038/nbt0297-159; CUNNINGHAM D, 2003, P AM SOC CLIN ONCOL, V22; Czuczman MS, 1999, J CLIN ONCOL, V17, P268, DOI 10.1200/JCO.1999.17.1.268; de Haard HJ, 1999, J BIOL CHEM, V274, P18218, DOI 10.1074/jbc.274.26.18218; Glennie MJ, 2000, IMMUNOL TODAY, V21, P403, DOI 10.1016/S0167-5699(00)01669-8; Gooch JL, 1999, BREAST CANCER RES TR, V56, P1, DOI 10.1023/A:1006208721167; Grillo-Lopez Antonio J, 2002, Expert Rev Anticancer Ther, V2, P485, DOI 10.1586/14737140.2.5.485; Grunwald V, 2003, ADV EXP MED BIOL, V532, P235; HOLLIGER P, 1993, P NATL ACAD SCI USA, V90, P6444, DOI 10.1073/pnas.90.14.6444; Khalil Mazen Y, 2003, Expert Rev Anticancer Ther, V3, P367, DOI 10.1586/14737140.3.3.367; Laird AD, 2003, EXPERT OPIN INV DRUG, V12, P51, DOI 10.1517/eoid.12.1.51.21253; Lee CT, 1996, CANCER RES, V56, P3038; Lu D, 2003, J BIOL CHEM, V278, P43496, DOI 10.1074/jbc.M307742200; Lu D, 2003, J IMMUNOL METHODS, V279, P219, DOI 10.1016/S0022-1759(03)00251-5; Lu D, 2002, J IMMUNOL METHODS, V267, P213, DOI 10.1016/S0022-1759(02)00148-5; Lu D, 2002, INT J CANCER, V97, P393, DOI 10.1002/ijc.1634; Lu D, 2001, CANCER RES, V61, P7002; Lu YH, 2001, JNCI-J NATL CANCER I, V93, P1852, DOI 10.1093/jnci/93.24.1852; Manegold C, 2003, ADV EXP MED BIOL, V532, P247; Mendelsohn J, 2003, CANCER IMMUNOL IMMUN, V52, P342, DOI 10.1007/s00262-002-0354-7; Mendelsohn J, 2003, J CLIN ONCOL, V21, P2787, DOI 10.1200/JCO.2003.01.504; Merchant AM, 1998, NAT BIOTECHNOL, V16, P677, DOI 10.1038/nbt0798-677; O'Connor R, 2000, BIOCHEM SOC T, V28, P47, DOI 10.1042/bst0280047; PACK P, 1992, BIOCHEMISTRY-US, V31, P1579, DOI 10.1021/bi00121a001; Perer ES, 2000, J SURG RES, V94, P1, DOI 10.1006/jsre.2000.5923; Pluckthun A, 1997, IMMUNOTECHNOLOGY, V3, P83, DOI 10.1016/S1380-2933(97)00067-5; Reinmuth N, 2002, CLIN CANCER RES, V8, P3259; Ross JS, 2003, AM J CLIN PATHOL, V119, P472, DOI 10.1309/Y6LPC0LR726L9DX9; RUBIN R, 1995, LAB INVEST, V73, P311; Sachdev D, 2003, CANCER RES, V63, P627; Saltz L, 2001, P AN M AM SOC CLIN, V20, P7; Segal DM, 2001, J IMMUNOL METHODS, V248, P1, DOI 10.1016/S0022-1759(00)00338-0; Sievers EL, 2001, CURR OPIN ONCOL, V13, P522, DOI 10.1097/00001622-200111000-00016; Todorovska A, 2001, J IMMUNOL METHODS, V248, P47, DOI 10.1016/S0022-1759(00)00342-2; Turner BC, 1997, CANCER RES, V57, P3079; van Spriel AB, 2000, IMMUNOL TODAY, V21, P391, DOI 10.1016/S0167-5699(00)01659-5; vandenBerg HW, 1996, BRIT J CANCER, V73, P477, DOI 10.1038/bjc.1996.84; Waksal HW, 1999, CANCER METAST REV, V18, P427, DOI 10.1023/A:1006302101468; Wang YL, 2002, CURR CANCER DRUG TAR, V2, P191, DOI 10.2174/1568009023333863; Weiner LM, 1997, CANCER IMMUNOL IMMUN, V45, P190, DOI 10.1007/s002620050430; Wells A, 1999, INT J BIOCHEM CELL B, V31, P637, DOI 10.1016/S1357-2725(99)00015-1; Werner H, 1997, CRIT REV ONCOGENESIS, V8, P71, DOI 10.1615/CritRevOncog.v8.i1.40; Yarden Y, 2001, EUR J CANCER, V37, pS3; ZHU ZP, 1995, INT J CANCER, V62, P319, DOI 10.1002/ijc.2910620315; Zhu ZP, 1996, BIO-TECHNOL, V14, P192, DOI 10.1038/nbt0296-192; Zia F, 1996, J CELL BIOCHEM, P269; Zuo Z, 2000, PROTEIN ENG, V13, P361, DOI 10.1093/protein/13.5.361	62	115	190	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	2004	279	4					2856	2865		10.1074/jbc.M310132200	http://dx.doi.org/10.1074/jbc.M310132200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	764MU	14576153	hybrid			2022-12-27	WOS:000188211300065
J	Ghannam, G; Takeda, A; Camarata, T; Moore, MA; Viale, A; Yaseen, NR				Ghannam, G; Takeda, A; Camarata, T; Moore, MA; Viale, A; Yaseen, NR			The oncogene Nup98-HOXA9 induces gene transcription in myeloid cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							NUCLEAR-PORE COMPLEX; HEMATOPOIETIC LINEAGE COMMITMENT; GLUCOCORTICOID-INDUCIBLE KINASE; ACUTE MYELOGENOUS LEUKEMIA; ACTIVATED PROTEIN-KINASE; BMX TYROSINE KINASE; GROWTH-FACTOR PCDGF; HOX HOMEOBOX GENES; LYMPHOID-TISSUE; MALT LYMPHOMA	The nucleoporin Nup98 gene is frequently rearranged in acute myelogenous leukemia (AML). In most cases this results in fusion of the N terminus of Nup98 to the DNA binding domain of a homeodomain transcription factor. The prototype of these fusions, Nup98-HOXA9, is associated with human AML and induces AML in mouse models. To understand the mechanisms by which Nup98-HOXA9 causes AML, we expressed it in myeloid cells and identified its target genes using high density oligonucleotide microarrays. The analysis was performed in triplicate and was confirmed by quantitative real time PCR. Of the 102 Nup98-HOXA9 target genes identified, 92 were up-regulated, and only 10 were down-regulated, suggesting a transcriptional activation function. A similar analysis of wild-type HOXA9 revealed 13 target genes, 12 of which were up-regulated, and 1 was down-regulated. In contrast, wild-type Nup98 had no effect on gene expression, demonstrating that the HOXA9 DNA binding domain is required for gene regulation. Co-transfection experiments using a luciferase reporter linked to the promoter of one of the Nup98-HOXA9 target genes confirmed up-regulation at the transcriptional level by Nup98-HOXA9 but not by either HOXA9 or Nup98. These data indicate that Nup98-HOXA9 is an aberrant transcription factor whose activity depends on the HOXA9 DNA binding domain but has a stronger and wider transcriptional effect than HOXA9. Several of the genes regulated by Nup98-HOXA9 are associated with increased cell proliferation and survival as well as drug metabolism, providing insights into the pathogenesis and epidemiology of Nup98-HOXA9-induced AML.	Northwestern Univ, Feinberg Sch Med, Dept Pathol, Chicago, IL 60611 USA; Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Program Mol Pharmacol, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Dept Mol Biol & Expt Therapeut, New York, NY 10021 USA	Northwestern University; Feinberg School of Medicine; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Yaseen, NR (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Pathol, 303 E Chicago Ave,Ward 6-116, Chicago, IL 60611 USA.	n-yaseen@northwestern.edu		Camarata, Troy/0000-0002-7628-2716; Yaseen, Nabeel/0000-0001-6902-5116	NCI NIH HHS [K22 CA93873] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K22CA093873] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahmad F, 2000, J IMMUNOL, V164, P4678, DOI 10.4049/jimmunol.164.9.4678; Ahmad M, 2000, CELL SIGNAL, V12, P541, DOI 10.1016/S0898-6568(00)00093-0; Akagi T, 1999, ONCOGENE, V18, P5785, DOI 10.1038/sj.onc.1203018; Alberts B., 2002, MOL BIOL CELL, V4th, P1157; Allman D, 2002, IMMUNOL REV, V187, P75, DOI 10.1034/j.1600-065X.2002.18707.x; Bachi A, 2000, RNA, V6, P136, DOI 10.1017/S1355838200991994; Bagheri-Yarmand R, 2001, J BIOL CHEM, V276, P29403, DOI 10.1074/jbc.M103129200; Balemans W, 2002, DEV BIOL, V250, P231, DOI 10.1006/dbio.2002.0779; Bi WZ, 1999, DEV BIOL, V211, P255, DOI 10.1006/dbio.1999.9307; Bijl J, 1996, BLOOD, V87, P1737, DOI 10.1182/blood.V87.5.1737.bloodjournal8751737; Bijl JJ, 1997, AM J PATHOL, V151, P1067; Bijl JJ, 1998, LEUKEMIA, V12, P1724, DOI 10.1038/sj.leu.2401106; Bijl JJ, 1997, BLOOD, V90, P4116, DOI 10.1182/blood.V90.10.4116; Blevins MB, 2003, J BIOL CHEM, V278, P20979, DOI 10.1074/jbc.M302061200; Brunet A, 2001, MOL CELL BIOL, V21, P952, DOI 10.1128/MCB.21.3.952-965.2001; Burel SA, 2001, MOL CELL BIOL, V21, P5577, DOI 10.1128/MCB.21.16.5577-5590.2001; Buse P, 1999, J BIOL CHEM, V274, P7253, DOI 10.1074/jbc.274.11.7253; Calvo KR, 2002, ONCOGENE, V21, P4247, DOI 10.1038/sj.onc.1205516; Calvo KR, 2000, MOL CELL BIOL, V20, P3274, DOI 10.1128/MCB.20.9.3274-3285.2000; Chau CH, 2002, ONCOGENE, V21, P8817, DOI 10.1038/sj.onc.1206032; Chiba S, 1998, INT J HEMATOL, V68, P343; Chou FC, 2001, DRUG METAB DISPOS, V29, P1205; Chung EJ, 2002, MOL CELLS, V14, P382; Corbett AH, 1997, MICROBIOL MOL BIOL R, V61, P193, DOI 10.1128/.61.2.193-211.1997; Coso OA, 1997, J BIOL CHEM, V272, P20691, DOI 10.1074/jbc.272.33.20691; Cowling RT, 2000, J LEUKOCYTE BIOL, V67, P240, DOI 10.1002/jlb.67.2.240; Dash AB, 2002, P NATL ACAD SCI USA, V99, P7622, DOI 10.1073/pnas.102583199; Degen WGJ, 1996, INT J CANCER, V65, P460, DOI 10.1002/(SICI)1097-0215(19960208)65:4<460::AID-IJC12>3.3.CO;2-B; Delmolino LM, 1997, J CELL PHYSIOL, V173, P371; Dierlamm J, 1999, BLOOD, V93, P3601, DOI 10.1182/blood.V93.11.3601; Donald CD, 2001, ANTICANCER RES, V21, P3739; Drabkin H, 2002, LEUKEMIA, V16, P186, DOI 10.1038/sj.leu.2402354; Dunwoodie SL, 2002, DEVELOPMENT, V129, P1795; EDMONDSON DG, 1994, DEVELOPMENT, V120, P1251; Felix CA, 1998, P NATL ACAD SCI USA, V95, P13176, DOI 10.1073/pnas.95.22.13176; Ferrando AA, 2003, BLOOD, V102, P262, DOI 10.1182/blood-2002-10-3221; Fontoura BMA, 2000, J BIOL CHEM, V275, P31289, DOI 10.1074/jbc.M004651200; Fontoura BMA, 2001, P NATL ACAD SCI USA, V98, P3208, DOI 10.1073/pnas.061014698; Fuchs O, 2002, BLOOD CELL MOL DIS, V28, P221, DOI 10.1006/bcmd.2002.0487; Fujino T, 2002, BLOOD, V99, P1428, DOI 10.1182/blood.V99.4.1428; Fuller JF, 1999, BLOOD, V93, P3391, DOI 10.1182/blood.V93.10.3391.410k26_3391_3400; Gamper N, 2002, PFLUG ARCH EUR J PHY, V443, P625, DOI 10.1007/s00424-001-0741-5; Giampaolo A, 2002, LEUKEMIA, V16, P1293, DOI 10.1038/sj.leu.2402532; Griffis ER, 2002, MOL BIOL CELL, V13, P1282, DOI 10.1091/mbc.01-11-0538; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; Hartmann W, 2000, AM J PATHOL, V157, P1393, DOI 10.1016/S0002-9440(10)64652-4; Hayashi M, 2001, J BIOL CHEM, V276, P8631, DOI 10.1074/jbc.C000838200; He ZH, 2003, NAT MED, V9, P225, DOI 10.1038/nm816; Hiratsuka M, 2002, EUR J CLIN PHARMACOL, V58, P417, DOI 10.1007/s00228-002-0499-5; Hussong JW, 2000, BLOOD, V95, P309; Hustert E, 2001, PHARMACOGENETICS, V11, P773, DOI 10.1097/00008571-200112000-00005; Ito Y, 2001, PANCREAS, V23, P246, DOI 10.1097/00006676-200110000-00004; Jaju RJ, 2001, BLOOD, V98, P1264, DOI 10.1182/blood.V98.4.1264; Janardan SK, 1996, PHARMACOGENETICS, V6, P379, DOI 10.1097/00008571-199610000-00001; Janulis M, 2001, MOL CELL BIOL, V21, P2235, DOI 10.1128/MCB.21.6.2235-2247.2001; Jones MB, 2003, GYNECOL ONCOL, V88, pS136, DOI 10.1006/gyno.2002.6704; Kappen C, 2000, AM J HEMATOL, V65, P111, DOI 10.1002/1096-8652(200010)65:2<111::AID-AJH4>3.0.CO;2-Z; Kasper LH, 1999, MOL CELL BIOL, V19, P764; Kato Y, 1997, EMBO J, V16, P7054, DOI 10.1093/emboj/16.23.7054; Kaukonen J, 1996, BRIT J HAEMATOL, V94, P455; Koch I, 2002, DRUG METAB DISPOS, V30, P1108, DOI 10.1124/dmd.30.10.1108; KOEFFLER HP, 1980, BLOOD, V56, P344; KRAEMER D, 1994, P NATL ACAD SCI USA, V91, P1519, DOI 10.1073/pnas.91.4.1519; Kroon E, 2001, EMBO J, V20, P350, DOI 10.1093/emboj/20.3.350; La Starza R, 2003, GENE CHROMOSOME CANC, V36, P420, DOI 10.1002/gcc.10182; Lahortiga I, 2003, CANCER RES, V63, P3079; Lam DH, 2001, LEUKEMIA, V15, P1689, DOI 10.1038/sj.leu.2402269; Lamba JK, 2002, ADV DRUG DELIVER REV, V54, P1271, DOI 10.1016/S0169-409X(02)00066-2; Lawrence HJ, 1996, STEM CELLS, V14, P281, DOI 10.1002/stem.140281; Lawrence HJ, 1999, LEUKEMIA, V13, P1993, DOI 10.1038/sj.leu.2401578; LEIFER D, 1993, P NATL ACAD SCI USA, V90, P1546, DOI 10.1073/pnas.90.4.1546; Leimeister C, 2000, DEV BIOL, V227, P91, DOI 10.1006/dbio.2000.9884; Leimeister C, 1999, MECH DEVELOP, V85, P173, DOI 10.1016/S0925-4773(99)00080-5; Leong MLL, 2003, J BIOL CHEM, V278, P5871, DOI 10.1074/jbc.M211649200; Liau LM, 2000, CANCER RES, V60, P1353; Line A, 2002, BRIT J CANCER, V86, P1824, DOI 10.1038/sj.bjc.6600321; Liu CH, 2001, J BIOL CHEM, V276, P18563, DOI 10.1074/jbc.M010787200; Lu RQ, 2000, P NATL ACAD SCI USA, V97, P3993, DOI 10.1073/pnas.97.8.3993; Lu RQ, 2001, P NATL ACAD SCI USA, V98, P142, DOI 10.1073/pnas.011525198; Lucas PC, 2001, J BIOL CHEM, V276, P19012, DOI 10.1074/jbc.M009984200; Maier MM, 2000, BIOCHEM BIOPH RES CO, V275, P652, DOI 10.1006/bbrc.2000.3354; MANS DRA, 1990, BRIT J CANCER, V62, P54, DOI 10.1038/bjc.1990.228; Markert JM, 2001, PHYSIOL GENOMICS, V5, P21, DOI 10.1152/physiolgenomics.2001.5.1.21; Matsubayashi H, 2003, CLIN CANCER RES, V9, P1446; McAllister-Lucas LM, 2001, J BIOL CHEM, V276, P30589, DOI 10.1074/jbc.M103824200; Mikosz CA, 2001, J BIOL CHEM, V276, P16649, DOI 10.1074/jbc.M010842200; Mizuno H, 2001, GENES CELLS, V6, P261, DOI 10.1046/j.1365-2443.2001.00418.x; Moon E, 2002, CLIN CANCER RES, V8, P589; Morgan JA, 1999, CANCER RES, V59, P6205; Nagai F, 2002, BIOL PHARM BULL, V25, P383, DOI 10.1248/bpb.25.383; Noura S, 2001, INT J ONCOL, V19, P39; Ohnishi K, 1998, LEUKEMIA LYMPHOMA, V31, P599, DOI 10.3109/10428199809057620; Okamoto S, 2000, P NATL ACAD SCI USA, V97, P7561, DOI 10.1073/pnas.130502697; Okamoto S, 2002, P NATL ACAD SCI USA, V99, P3974, DOI 10.1073/pnas.022036399; Onichtchouk D, 1999, NATURE, V401, P480, DOI 10.1038/46794; Owens BM, 2002, STEM CELLS, V20, P364, DOI 10.1634/stemcells.20-5-364; Pan S, 2002, MOL CELL BIOL, V22, P7512, DOI 10.1128/MCB.22.21.7512-7523.2002; Panagopoulos L, 2003, GENE CHROMOSOME CANC, V36, P107, DOI 10.1002/gcc.10139; Payne KJ, 2002, IMMUNOL REV, V187, P48, DOI 10.1034/j.1600-065X.2002.18705.x; Pineault N, 2003, BLOOD, V101, P4529, DOI 10.1182/blood-2002-08-2484; Porter CM, 2002, J IMMUNOL, V168, P4936, DOI 10.4049/jimmunol.168.10.4936; POWERS MA, 1995, J CELL BIOL, V128, P721, DOI 10.1083/jcb.128.5.721; Powers MA, 1997, J CELL BIOL, V136, P241, DOI 10.1083/jcb.136.2.241; Radtke F, 2002, IMMUNOL REV, V187, P65, DOI 10.1034/j.1600-065X.2002.18706.x; RADU A, 1995, CELL, V81, P215, DOI 10.1016/0092-8674(95)90331-3; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; RELLING MV, 1994, MOL PHARMACOL, V45, P352; Rosati R, 2002, BLOOD, V99, P3857, DOI 10.1182/blood.V99.10.3857; Sanchez-Izquierdo D, 2003, BLOOD, V101, P4539, DOI 10.1182/blood-2002-10-3236; Scandura JM, 2002, ONCOGENE, V21, P3422, DOI 10.1038/sj.onc.1205315; Shen WF, 1999, MOL CELL BIOL, V19, P3051; Shen WF, 1997, MOL CELL BIOL, V17, P6448, DOI 10.1128/MCB.17.11.6448; Steidl C, 2000, GENOMICS, V66, P195, DOI 10.1006/geno.2000.6200; Stoffler D, 1999, CURR OPIN CELL BIOL, V11, P391, DOI 10.1016/S0955-0674(99)80055-6; Streubel B, 2003, BLOOD, V101, P2335, DOI 10.1182/blood-2002-09-2963; SUTHERLAND JA, 1986, J BIOL RESP MODIF, V5, P250; Suzuki A, 2002, BRIT J HAEMATOL, V116, P170, DOI 10.1046/j.1365-2141.2002.03246.x; TAETLE R, 1993, CANCER RES, V53, P3386; Taketani T, 2002, CANCER RES, V62, P4571; Taketani T, 2002, GENE CHROMOSOME CANC, V34, P437, DOI 10.1002/gcc.10077; Taketani T, 2002, CANCER RES, V62, P33; TAMAGNONE L, 1994, ONCOGENE, V9, P3683; TESSIER N, 1988, BLOOD, V72, P159; Thun MJ, 2002, JNCI-J NATL CANCER I, V94, P252, DOI 10.1093/jnci/94.4.252; Tsai YT, 2000, MOL CELL BIOL, V20, P2043, DOI 10.1128/MCB.20.6.2043-2054.2000; Tschan MP, 1999, BRIT J HAEMATOL, V106, P644, DOI 10.1046/j.1365-2141.1999.01617.x; Tsujimoto H, 1999, MOL CARCINOGEN, V26, P298, DOI 10.1002/(SICI)1098-2744(199912)26:4<298::AID-MC8>3.0.CO;2-M; Uren AG, 2000, MOL CELL, V6, P961, DOI 10.1016/S1097-2765(05)00086-9; Vadiveloo PK, 1999, J LEUKOCYTE BIOL, V66, P579, DOI 10.1002/jlb.66.4.579; VANMAANEN JMS, 1987, CANCER RES, V47, P4658; Vereninov AA, 2001, CELL PHYSIOL BIOCHEM, V11, P19, DOI 10.1159/000047788; Wang XS, 2001, J BIOL CHEM, V276, P26559, DOI 10.1074/jbc.M101083200; WEBSTER MK, 1993, MOL CELL BIOL, V13, P2031, DOI 10.1128/MCB.13.4.2031; WEBSTER MK, 1993, J BIOL CHEM, V268, P11482; Weil D, 1997, BLOOD, V90, P4332, DOI 10.1182/blood.V90.11.4332.4332_4332_4340; Williams CS, 1999, ONCOGENE, V18, P7908, DOI 10.1038/sj.onc.1203286; Xu SQ, 1998, J BIOL CHEM, V273, P20078, DOI 10.1074/jbc.273.32.20078; Xu XM, 1997, J BIOL CHEM, V272, P6943, DOI 10.1074/jbc.272.11.6943; Xue LY, 1999, ONCOGENE, V18, P3391, DOI 10.1038/sj.onc.1202687; Yaseen NR, 1997, P NATL ACAD SCI USA, V94, P4451, DOI 10.1073/pnas.94.9.4451; Zhang HD, 1998, P NATL ACAD SCI USA, V95, P14202, DOI 10.1073/pnas.95.24.14202; Zimmermann F, 1997, BLOOD, V89, P2723, DOI 10.1182/blood.V89.8.2723	142	65	67	2	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 9	2004	279	2					866	875		10.1074/jbc.M307280200	http://dx.doi.org/10.1074/jbc.M307280200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	759DJ	14561764	hybrid			2022-12-27	WOS:000187722800008
J	Joerger, AC; Allen, MD; Fersht, AR				Joerger, AC; Allen, MD; Fersht, AR			Crystal structure of a superstable mutant of human p53 core domain - Insights into the mechanism of rescuing oncogenic mutations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING DOMAIN; CANCER; PROTEIN	Most of the cancer-associated mutations in the tumor suppressor p53 map to its DNA-binding core domain. Many of them inactivate p53 by decreasing its thermodynamic stability. We have previously designed the superstable quadruple mutant M133L/V203A/N239Y/N268D containing the second-site suppressor mutations N239Y and N268D, which specifically restore activity and stability in several oncogenic mutants. Here we present the x-ray structure of this quadruple mutant at 1.9 Angstrom resolution, which was solved in a new crystal form in the absence of DNA. This structure reveals that the four point mutations cause only small local structural changes, whereas the overall structure of the central beta-sandwich and the DNA-binding surface is conserved. The suppressor mutation N268D results in an altered hydrogen bond pattern connecting strands S1 and S10, thus bridging the two sheets of the beta-sandwich scaffold in an energetically more favorable way. The second suppressor mutation N239Y, which is located in close proximity to the DNA-binding surface in loop L3, seems to reduce the plasticity of the structure in large parts of loop L3 as indicated by decreased crystallographic temperature factors. The same is observed for residues in the vicinity of the N268D substitution. This increase in rigidity provides the structural basis for the increase in thermostability and an understanding how N268D and N239Y rescue some of the common cancer mutants.	Univ Cambridge, Chem Lab, Cambridge CB2 2QH, England; MRC Ctr, Cambridge Ctr Prot Engn, Cambridge CB2 2QH, England	University of Cambridge; MRC Laboratory Molecular Biology; University of Cambridge	Fersht, AR (corresponding author), Univ Cambridge, Chem Lab, Hilld Rd, Cambridge CB2 2QH, England.	arf25@cam.ac.uk	Fersht, Alan R/B-2189-2008	Joerger, Andreas/0000-0002-1232-0138				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bargonetti J, 2002, CURR OPIN ONCOL, V14, P86, DOI 10.1097/00001622-200201000-00015; Brachmann RK, 1998, EMBO J, V17, P1847, DOI 10.1093/emboj/17.7.1847; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bullock AN, 2000, ONCOGENE, V19, P1245, DOI 10.1038/sj.onc.1203434; Bullock AN, 1997, P NATL ACAD SCI USA, V94, P14338, DOI 10.1073/pnas.94.26.14338; Bykov VJN, 2002, NAT MED, V8, P282, DOI 10.1038/nm0302-282; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Friedler A, 2002, P NATL ACAD SCI USA, V99, P937, DOI 10.1073/pnas.241629998; Hainaut P, 2000, ADV CANCER RES, V77, P81; KASTAN MB, 1991, CANCER RES, V51, P6304; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LESLIE AGW, 1992, JOINT CCP4 ESF EACMB, V26; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Nikolova PV, 2000, EMBO J, V19, P370, DOI 10.1093/emboj/19.3.370; Nikolova PV, 1998, P NATL ACAD SCI USA, V95, P14675, DOI 10.1073/pnas.95.25.14675; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; PRIVES C, 1994, CELL, V78, P543, DOI 10.1016/0092-8674(94)90519-3; TURK D, 1992, THESIS TU MUNCHEN MU; Wong KB, 1999, P NATL ACAD SCI USA, V96, P8438, DOI 10.1073/pnas.96.15.8438; Wray JW, 1999, J MOL BIOL, V292, P1111, DOI 10.1006/jmbi.1999.3102; ZHANG W, 1994, EMBO J, V13, P2535, DOI 10.1002/j.1460-2075.1994.tb06543.x; Zhao KH, 2001, J BIOL CHEM, V276, P12120, DOI 10.1074/jbc.M011644200	26	129	136	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 9	2004	279	2					1291	1296		10.1074/jbc.M309732200	http://dx.doi.org/10.1074/jbc.M309732200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	759DJ	14534297	hybrid			2022-12-27	WOS:000187722800055
J	Skurk, C; Maatz, H; Kim, HS; Yang, J; Abid, MR; Aird, WC; Walsh, K				Skurk, C; Maatz, H; Kim, HS; Yang, J; Abid, MR; Aird, WC; Walsh, K			The Akt-regulated forkhead transcription factor FOXO3a controls endothelial cell viability through modulation of the caspase-8 inhibitor FLIP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAS LIGAND; OXIDIZED LDL; C-FLIP; DOWN-REGULATION; GROWTH-FACTOR; FACTOR AFX; APOPTOSIS; EXPRESSION; PROTEIN; DEATH	FLICE-inhibitory protein (FLIP) is a homolog of caspase-8 that lacks catalytic activity and has been shown to be important in protecting endothelial cells from apoptosis. The serine/threonine kinase Akt/PKB was recently reported to promote FLIP expression in endothelial and tumor cells. Here we examined the role of the forkhead transcription factor FOXO3a, a downstream target of Akt, in controlling FLIP regulation in endothelial cells. FOXO3a nuclear translocation was regulated by Akt in human umbilical vein endothelial cells. Transduction of a nonphosphorylatable, constitutively active mutant of FOXO3a (TM-FOXO3a) led to the down-regulation of FLIP levels. Transduction with TM-FOXO3a also increased caspase-8 activity and promoted apoptosis in endothelial cells. Conversely, transduction of a dominant-negative mutant of FOXO3a up-regulated FLIP levels and protected endothelial cells from apoptosis under serum deprivation conditions. Restoration of intracellular FLIP blocked caspase-8 activation and inhibited apoptosis in TM-FOXO3a-transduced cells. These data suggest that FOXO3a is a downstream target of Akt in endothelial cells that can promote apoptosis via FLIP down-regulation and activation of the extrinsic apoptotic pathway.	Boston Univ, Sch Med, Whitaker Cardiovasc Inst, Boston, MA 02118 USA; Seoul Natl Univ Hosp, Dept Internal Med, Seoul 110744, South Korea; Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA	Boston University; Seoul National University (SNU); Seoul National University Hospital; Harvard University; Beth Israel Deaconess Medical Center	Walsh, K (corresponding author), Boston Univ, Sch Med, Whitaker Cardiovasc Inst, 715 Albany St,W611, Boston, MA 02118 USA.	kxwalsh@bu.edu	Kim, Hyo Soo/J-2753-2012		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL072108, R56HL072108] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040197] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R37AG015052, R03AG017291, R01AG015052] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL72108] Funding Source: Medline; NIAMS NIH HHS [AR40197] Funding Source: Medline; NIA NIH HHS [AG15052, AG17291] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Anderson MJ, 1998, GENOMICS, V47, P187, DOI 10.1006/geno.1997.5122; Aoudjit F, 2001, J CELL BIOL, V152, P633, DOI 10.1083/jcb.152.3.633; Bourguignon C, 1998, DEVELOPMENT, V125, P4889; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Chavakis E, 2001, CIRCULATION, V103, P2102; CHIANG PS, 2002, SCIENCE, V296, P530; Dijkers PF, 2002, J CELL BIOL, V156, P531, DOI 10.1083/jcb.200108084; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Freyaldenhoven BS, 1997, ONCOGENE, V15, P483, DOI 10.1038/sj.onc.1201189; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Fujio Y, 1999, J BIOL CHEM, V274, P16349, DOI 10.1074/jbc.274.23.16349; Fujio Y, 1999, MOL CELL BIOL, V19, P5073; Hahne M, 1996, SCIENCE, V274, P1363, DOI 10.1126/science.274.5291.1363; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Imanishi T, 2000, AM J PATHOL, V156, P125, DOI 10.1016/S0002-9440(10)64712-8; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Kim HS, 2002, J BIOL CHEM, V277, P41888, DOI 10.1074/jbc.M206657200; Kureishi Y, 2000, NAT MED, V6, P1004, DOI 10.1038/79510; LaVallee TM, 2003, CANCER RES, V63, P468; Mano T, 2000, HUM GENE THER, V11, P1625, DOI 10.1089/10430340050111287; Modur V, 2002, J BIOL CHEM, V277, P47928, DOI 10.1074/jbc.M207509200; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Nemoto S, 2002, SCIENCE, V295, P2450, DOI 10.1126/science.1069004; Panka DJ, 2001, J BIOL CHEM, V276, P6893, DOI 10.1074/jbc.C000569200; Perlman H, 2002, J RHEUMATOL, V29, P1593; Ramaswamy S, 2002, CANCER CELL, V2, P81, DOI 10.1016/S1535-6108(02)00086-7; Rena G, 1999, J BIOL CHEM, V274, P17179, DOI 10.1074/jbc.274.24.17179; RICHARDSON BC, 1994, EUR J IMMUNOL, V24, P2640, DOI 10.1002/eji.1830241111; Sata M, 1998, J BIOL CHEM, V273, P33103, DOI 10.1074/jbc.273.50.33103; Sata M, 1998, J CLIN INVEST, V102, P1682, DOI 10.1172/JCI3531; Sata M, 1998, NAT MED, V4, P415, DOI 10.1038/nm0498-415; Sata M, 1998, P NATL ACAD SCI USA, V95, P1213, DOI 10.1073/pnas.95.3.1213; Sata M, 2000, ARTERIOSCL THROM VAS, V20, P309, DOI 10.1161/01.ATV.20.2.309; Scaffidi C, 1999, J BIOL CHEM, V274, P1541, DOI 10.1074/jbc.274.3.1541; Scheid MP, 2001, NAT REV MOL CELL BIO, V2, P760, DOI 10.1038/35096067; Schmidt M, 2002, MOL CELL BIOL, V22, P7842, DOI 10.1128/MCB.22.22.7842-7852.2002; Shiojima I, 2002, CIRC RES, V90, P1243, DOI 10.1161/01.RES.0000022200.71892.9F; Smith RC, 1997, GENE DEV, V11, P1674, DOI 10.1101/gad.11.13.1674; Stupack DG, 2001, J CELL BIOL, V155, P459, DOI 10.1083/jcb.200106070; Suhara T, 2002, MOL CELL BIOL, V22, P680, DOI 10.1128/MCB.22.2.680-691.2002; Suhara T, 2001, CIRC RES, V89, P13, DOI 10.1161/hh1301.092506; Takaishi H, 1999, P NATL ACAD SCI USA, V96, P11836, DOI 10.1073/pnas.96.21.11836; Tan PB, 1998, CELL, V93, P569, DOI 10.1016/S0092-8674(00)81186-1; Tang TTL, 2002, J BIOL CHEM, V277, P14255, DOI 10.1074/jbc.M110901200; Tran H, 2002, SCIENCE, V296, P530, DOI 10.1126/science.1068712; Volpert OV, 2002, NAT MED, V8, P349, DOI 10.1038/nm0402-349; Walsh K, 2000, CIRC RES, V87, P184, DOI 10.1161/01.RES.87.3.184; Wang JCW, 2000, J BIOL CHEM, V275, P18418, DOI 10.1074/jbc.M910211199; Yang J, 2003, J BIOL CHEM, V278, P15185, DOI 10.1074/jbc.M211707200; Yao J, 2001, MOL CELL BIOL, V21, P1962, DOI 10.1128/MCB.21.6.1962-1972.2001	52	216	222	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 9	2004	279	2					1513	1525		10.1074/jbc.M304736200	http://dx.doi.org/10.1074/jbc.M304736200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	759DJ	14551207	hybrid			2022-12-27	WOS:000187722800083
J	West, JM; Tsuruta, H; Kantrowitz, ER				West, JM; Tsuruta, H; Kantrowitz, ER			A fluorescent probe-labeled Escherichia coli aspartate transcarbamoylase that monitors the allosteric conformational state	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							QUATERNARY-STRUCTURE TRANSITION; PYRENE EXCIMER FLUORESCENCE; PHOSPHONACETYL-L-ASPARTATE; RAY SOLUTION SCATTERING; BISUBSTRATE ANALOG; HETEROTROPIC INTERACTIONS; CRYSTAL-STRUCTURES; EFFECTOR BINDING; CARBAMOYLTRANSFERASE; PROTEIN	A new system has been developed capable of monitoring conformational changes of the 240s loop of aspartate transcarbamoylase, which are tightly correlated with the quaternary structural transition, with high sensitivity in solution. Pyrene, a fluorescent probe, was conjugated to residue 241 in the 240s loop of aspartate transcarbamoylase to monitor changes in conformation by fluorescence spectroscopy. Pyrene maleimide was conjugated to a cysteine residue on the 240s loop of a previously constructed double catalytic chain mutant version of the enzyme, C47A/A241C. The pyrene-labeled enzyme undergoes the normal T to R structural transition, as demonstrated by small-angle x-ray scattering. Like the wild-type enzyme, the pyrene-labeled enzyme exhibits cooperativity toward aspartate, and is activated by ATP and inhibited by CTP at subsaturating concentrations of aspartate. The binding of the bisubstrate analogue N-(phosphonoacetyl)-L-aspartate (PALA), or the aspartate analogue succinate, in the presence of saturating carbamoyl phosphate, to the pyrene-labeled enzyme caused a sigmoidal change in the fluorescence emission. Saturation with ATP and CTP ( in the presence of either subsaturating amounts of PALA or succinate and carbamoyl phosphate) caused a hyperbolic increase and decrease, respectively, in the fluorescence emission. The half-saturation values from the fluorescence saturation curves and kinetic saturation curves were, within error, identical. Fluorescence and small-angle x-ray scattering stopped-flow experiments, using aspartate and carbamoyl phosphate, confirm that the change in excimer fluorescence and the quaternary structure change correlate. These results in conjunction with previous studies suggest that the allosteric transition involves both global and local conformational changes and that the heterotropic effect of the nucleotides may be exerted through local conformational changes in the active site by directly influencing the conformation of the 240s loop.	Boston Coll, Merkert Chem Ctr, Dept Chem, Chestnut Hill, MA 02467 USA; Stanford Linear Accelerator Ctr, Stanford Synchrotron Radiat Lab, Menlo Pk, CA 94025 USA	Boston College; Stanford University; United States Department of Energy (DOE); SLAC National Accelerator Laboratory	Kantrowitz, ER (corresponding author), Boston Coll, Merkert Chem Ctr, Dept Chem, Chestnut Hill, MA 02467 USA.				NCRR NIH HHS [P41RR01209] Funding Source: Medline; NIGMS NIH HHS [GM26237] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001209] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026237] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Birks J., 1970, PHOTOPHYSICS AROMATI, DOI DOI 10.1002/BBPC.19700741223; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHANGEUX JP, 1968, BIOCHEMISTRY-US, V7, P531, DOI 10.1021/bi00842a007; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P680; ELLMAN GL, 1958, ARCH BIOCHEM BIOPHYS, V74, P443, DOI 10.1016/0003-9861(58)90014-6; Endrizzi JA, 2000, P NATL ACAD SCI USA, V97, P5077, DOI 10.1073/pnas.090087197; FETLER L, 1995, J MOL BIOL, V251, P243, DOI 10.1006/jmbi.1995.0432; FETLER L, 1995, BIOCHEMISTRY-US, V34, P15654, DOI 10.1021/bi00048a008; Fetler L, 2001, BIOCHEMISTRY-US, V40, P8773, DOI 10.1021/bi0029494; GERHART JC, 1968, BIOCHEMISTRY-US, V7, P538, DOI 10.1021/bi00842a600; GERHART JC, 1967, J BIOL CHEM, V242, P2886; GERHART JC, 1965, BIOCHEMISTRY-US, V4, P1054, DOI 10.1021/bi00882a012; GERHART JC, 1962, J BIOL CHEM, V237, P891; GOUAUX JE, 1990, BIOCHEMISTRY-US, V29, P7702, DOI 10.1021/bi00485a020; HERVE G, 1985, J MOL BIOL, V185, P189, DOI 10.1016/0022-2836(85)90190-1; HONZATKO RB, 1982, J MOL BIOL, V160, P219, DOI 10.1016/0022-2836(82)90175-9; HONZATKO RB, 1982, P NATL ACAD SCI-BIOL, V79, P7171, DOI 10.1073/pnas.79.23.7171; HOWLETT GJ, 1977, BIOCHEMISTRY-US, V16, P5091, DOI 10.1021/bi00642a023; HSUANYU Y, 1989, BIOCHIM BIOPHYS ACTA, V995, P54, DOI 10.1016/0167-4838(89)90232-X; Jin L, 1999, PROTEINS, V37, P729, DOI 10.1002/(SICI)1097-0134(19991201)37:4<729::AID-PROT21>3.0.CO;2-F; KANTROWITZ ER, 1988, SCIENCE, V241, P669, DOI 10.1126/science.3041592; KANTROWITZ ER, 1990, TRENDS BIOCHEM SCI, V15, P53, DOI 10.1016/0968-0004(90)90176-C; KE HM, 1988, J MOL BIOL, V204, P725, DOI 10.1016/0022-2836(88)90365-8; KE HM, 1984, P NATL ACAD SCI USA, V81, P4027; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRAUSE KL, 1987, J MOL BIOL, V193, P527, DOI 10.1016/0022-2836(87)90265-8; LADJIMI MM, 1985, J MOL BIOL, V186, P715, DOI 10.1016/0022-2836(85)90391-2; LADJIMI MM, 1988, BIOCHEMISTRY-US, V27, P276, DOI 10.1021/bi00401a042; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lehrer S S, 1995, Subcell Biochem, V24, P115; Lehrer SS, 1997, METHOD ENZYMOL, V278, P286; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; MOODY MF, 1979, J MOL BIOL, V133, P517, DOI 10.1016/0022-2836(79)90405-4; NEWTON CJ, 1990, P NATL ACAD SCI USA, V87, P2309, DOI 10.1073/pnas.87.6.2309; NOWLAN SF, 1985, J BIOL CHEM, V260, P4712; ORNSTEIN L, 1964, ANN NY ACAD SCI, V121, P321, DOI 10.1111/j.1749-6632.1964.tb14207.x; PASTRALANDIS SC, 1981, ANAL BIOCHEM, V118, P358, DOI 10.1016/0003-2697(81)90594-7; PASTRALANDIS SC, 1978, J BIOL CHEM, V253, P4624; Sakash JB, 2000, J BIOL CHEM, V275, P752, DOI 10.1074/jbc.275.2.752; SCHACHMAN HK, 1988, J BIOL CHEM, V263, P18583; SILVER RS, 1983, J MOL BIOL, V168, P729, DOI 10.1016/S0022-2836(83)80072-2; STEVENS RC, 1990, BIOCHEMISTRY-US, V29, P7691, DOI 10.1021/bi00485a019; STEVENS RC, 1992, P NATL ACAD SCI USA, V89, P5281, DOI 10.1073/pnas.89.12.5281; Svergun DI, 1997, PROTEINS, V27, P110; TAUC P, 1982, J MOL BIOL, V155, P155, DOI 10.1016/0022-2836(82)90442-9; TSURUTA H, 1990, FEBS LETT, V263, P66, DOI 10.1016/0014-5793(90)80706-O; Tsuruta H, 1998, PROTEINS, V31, P383, DOI 10.1002/(SICI)1097-0134(19980601)31:4<383::AID-PROT5>3.3.CO;2-O; West JM, 2003, J AM CHEM SOC, V125, P9924, DOI 10.1021/ja0360440; West JM, 2002, J BIOL CHEM, V277, P47300, DOI 10.1074/jbc.M209913200; WILD JR, 1989, P NATL ACAD SCI USA, V86, P46, DOI 10.1073/pnas.86.1.46	51	19	19	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 9	2004	279	2					945	951		10.1074/jbc.M304018200	http://dx.doi.org/10.1074/jbc.M304018200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	759DJ	14581486	hybrid			2022-12-27	WOS:000187722800017
J	Yoo, JH; Cheong, MS; Park, CY; Moon, BC; Kim, MC; Kang, YH; Park, HC; Choi, MS; Lee, JH; Jung, WY; Yoon, HW; Chung, WS; Lim, CO; Lee, SY; Cho, MJ				Yoo, JH; Cheong, MS; Park, CY; Moon, BC; Kim, MC; Kang, YH; Park, HC; Choi, MS; Lee, JH; Jung, WY; Yoon, HW; Chung, WS; Lim, CO; Lee, SY; Cho, MJ			Regulation of the dual specificity protein phosphatase, DsPTP1, through interactions with calmodulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE; TARGET RECOGNITION; BINDING PROTEINS; GENE FAMILY; MOLECULAR CHARACTERIZATION; TYROSINE PHOSPHATASES; CATALYTIC SUBUNIT; CRYSTAL-STRUCTURE; PLANT-CELLS; GUARD-CELLS	Reversible phosphorylation is a key mechanism for the control of intercellular events in eukaryotic cells. In animal cells, Ca2+/CaM-dependent protein phosphorylation and dephosphorylation are implicated in the regulation of a number of cellular processes. However, little is known on the functions of Ca2+/CaM-dependent protein kinases and phosphatases in Ca2+ signaling in plants. From an Arabidopsis expression library, we isolated cDNA encoding a dual specificity protein phosphatase 1, which is capable of hydrolyzing both phosphoserine/threonine and phosphotyrosine residues of the substrates. Using a gel overlay assay, we identified two Ca2+-dependent CaM binding domains (CaMBDI in the N terminus and CaMBDII in the C terminus). Specific binding of CaM to two CaMBD was confirmed by site-directed mutagenesis, a gel mobility shift assay, and a competition assay using a Ca2+/CaM-dependent enzyme. At increasing concentrations of CaM, the biochemical activity of dual specificity protein phosphatase 1 on the p-nitrophenyl phosphate (pNPP) substrate was increased, whereas activity on the phosphotyrosine of myelin basic protein (MBP) was inhibited. Our results collectively indicate that calmodulin differentially regulates the activity of protein phosphatase, dependent on the substrate. Based on these findings, we propose that the Ca2+ signaling pathway is mediated by CaM cross-talks with a protein phosphorylation signal pathway in plants via protein dephosphorylation.	Gyeongsang Natl Univ, Plant Mol Biol & Biotechnol Res Ctr, Div Appl Life Sci, Program BK21, Jinju 660701, South Korea	Gyeongsang National University	Cho, MJ (corresponding author), Gyeongsang Natl Univ, Plant Mol Biol & Biotechnol Res Ctr, Div Appl Life Sci, Program BK21, Jinju 660701, South Korea.	mjcho@nongae.gsnu.ac.kr	Cho, Moo Je/F-1649-2010; Park, Chan Young/F-5696-2010	Park, Chan Young/0000-0002-5183-3665; Jung, WonYong/0000-0002-1751-8418				ALESSI DR, 1995, CURR BIOL, V5, P283, DOI 10.1016/S0960-9822(95)00059-5; ALLEN GJ, 1995, PLANT CELL, V7, P1473; Aramburu J, 2000, CURR TOP CELL REGUL, V36, P237; Barford D, 1996, TRENDS BIOCHEM SCI, V21, P407, DOI 10.1016/S0968-0004(96)10060-8; BUSH DS, 1995, ANNU REV PLANT PHYS, V46, P95, DOI 10.1146/annurev.pp.46.060195.000523; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; Cheng SH, 2002, PLANT PHYSIOL, V129, P469, DOI 10.1104/pp.005645; Chou IT, 1997, PLANT MOL BIOL, V35, P873, DOI 10.1023/A:1005930024796; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COHEN P, 1992, TRENDS BIOCHEM SCI, V17, P408, DOI 10.1016/0968-0004(92)90010-7; Cohen PTW, 1997, TRENDS BIOCHEM SCI, V22, P245, DOI 10.1016/S0968-0004(97)01060-8; CRIVICI A, 1995, ANNU REV BIOPH BIOM, V24, P85, DOI 10.1146/annurev.bb.24.060195.000505; Das AK, 1996, EMBO J, V15, P6798, DOI 10.1002/j.1460-2075.1996.tb01071.x; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; Dombradi V, 2002, EMBO REP, V3, P120, DOI 10.1093/embo-reports/kvf034; EGLOFF MP, 1995, J MOL BIOL, V254, P942, DOI 10.1006/jmbi.1995.0667; ERICKSONVIITANEN S, 1987, METHOD ENZYMOL, V139, P455; Evans DRH, 1998, NATURE, V394, P23, DOI 10.1038/27782; Fauman EB, 1996, TRENDS BIOCHEM SCI, V21, P413, DOI 10.1016/S0968-0004(96)10059-1; Galat A, 2000, EUR J BIOCHEM, V267, P4945, DOI 10.1046/j.1432-1327.2000.01509.x; GOLDBERG J, 1995, NATURE, V376, P745, DOI 10.1038/376745a0; GRIFFITH JP, 1995, CELL, V82, P507, DOI 10.1016/0092-8674(95)90439-5; Gupta R, 1998, PLANT J, V16, P581, DOI 10.1046/j.1365-313x.1998.00327.x; Hoeflich KP, 2002, CELL, V108, P739, DOI 10.1016/S0092-8674(02)00682-7; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Kao YL, 2000, BIOCHEM BIOPH RES CO, V267, P201, DOI 10.1006/bbrc.1999.1896; Kerk D, 2002, PLANT PHYSIOL, V129, P908, DOI 10.1104/pp.004002; Kim MC, 2002, NATURE, V416, P447, DOI 10.1038/416447a; KLEE CB, 1991, NEUROCHEM RES, V16, P1059, DOI 10.1007/BF00965851; KNIGHT MR, 1991, NATURE, V352, P524, DOI 10.1038/352524a0; Kudla J, 1999, P NATL ACAD SCI USA, V96, P4718, DOI 10.1073/pnas.96.8.4718; Kutuzov MA, 2001, BIOCHEM BIOPH RES CO, V289, P634, DOI 10.1006/bbrc.2001.6020; Laser H, 2000, P NATL ACAD SCI USA, V97, P13732, DOI 10.1073/pnas.250400997; LEE SH, 1995, J BIOL CHEM, V270, P21806, DOI 10.1074/jbc.270.37.21806; Lee SH, 1999, BBA-PROTEIN STRUCT M, V1433, P56, DOI 10.1016/S0167-4838(99)00149-1; Lee SJ, 2001, NEURON, V32, P1097, DOI 10.1016/S0896-6273(01)00538-4; Liang L, 2000, J BIOL CHEM, V275, P30075, DOI 10.1074/jbc.M004843200; LOHSE DL, 1995, STRUCTURE, V3, P987, DOI 10.1016/S0969-2126(01)00234-9; LUAN S, 1993, P NATL ACAD SCI USA, V90, P2202, DOI 10.1073/pnas.90.6.2202; McAinsh MR, 1998, TRENDS PLANT SCI, V3, P32, DOI 10.1016/S1360-1385(97)01150-3; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; Meskiene I, 1998, P NATL ACAD SCI USA, V95, P1938, DOI 10.1073/pnas.95.4.1938; Mulligan RM, 1997, P NATL ACAD SCI USA, V94, P2793, DOI 10.1073/pnas.94.7.2793; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; Osawa M, 1999, NAT STRUCT BIOL, V6, P819; Pardo JM, 1998, P NATL ACAD SCI USA, V95, P9681, DOI 10.1073/pnas.95.16.9681; PRICE AH, 1994, PLANT CELL, V6, P1301, DOI 10.1105/tpc.6.9.1301; Reddy ASN, 2000, BIOCHEM BIOPH RES CO, V279, P762, DOI 10.1006/bbrc.2000.4032; Reddy ASN, 2001, PLANT SCI, V160, P381, DOI 10.1016/S0168-9452(00)00386-1; Reddy VS, 2002, J BIOL CHEM, V277, P9840, DOI 10.1074/jbc.M111626200; Rhoads AR, 1997, FASEB J, V11, P331, DOI 10.1096/fasebj.11.5.9141499; Rusnak F, 2000, PHYSIOL REV, V80, P1483, DOI 10.1152/physrev.2000.80.4.1483; Sanders D, 2002, PLANT CELL, V14, pS401, DOI 10.1105/tpc.002899; Sanders D, 1999, PLANT CELL, V11, P691, DOI 10.1105/tpc.11.4.691; Schenk PW, 1999, BBA-MOL CELL RES, V1449, P1, DOI 10.1016/S0167-4889(98)00178-5; SHIOZAKI K, 1995, EMBO J, V14, P492, DOI 10.1002/j.1460-2075.1995.tb07025.x; Smith RD, 1996, ANNU REV PLANT PHYS, V47, P101, DOI 10.1146/annurev.arplant.47.1.101; Snedden WA, 2001, NEW PHYTOL, V151, P35, DOI 10.1046/j.1469-8137.2001.00154.x; Stagljar I, 1998, P NATL ACAD SCI USA, V95, P5187, DOI 10.1073/pnas.95.9.5187; Trewavas AJ, 1998, CURR OPIN PLANT BIOL, V1, P428, DOI 10.1016/S1369-5266(98)80268-9; Ulm R, 2001, GENE DEV, V15, P699, DOI 10.1101/gad.192601; Varshavsky A, 1996, P NATL ACAD SCI USA, V93, P12142, DOI 10.1073/pnas.93.22.12142; WALTON KM, 1993, ANNU REV BIOCHEM, V62, P101; WurglerMurphy SM, 1997, TRENDS BIOCHEM SCI, V22, P172, DOI 10.1016/S0968-0004(97)01036-0; Xu Q, 1998, PLANT CELL, V10, P849, DOI 10.1105/tpc.10.5.849; Xu Q, 1998, PLANT J, V15, P511, DOI 10.1046/j.1365-313X.1998.00232.x; Yang T, 2002, P NATL ACAD SCI USA, V99, P4097, DOI 10.1073/pnas.052564899; Zielinski RE, 1998, ANNU REV PLANT PHYS, V49, P697, DOI 10.1146/annurev.arplant.49.1.697	68	29	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 9	2004	279	2					848	858		10.1074/jbc.M310709200	http://dx.doi.org/10.1074/jbc.M310709200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	759DJ	14570888	hybrid			2022-12-27	WOS:000187722800006
J	Bailey, D; O'Hare, P				Bailey, D; O'Hare, P			Characterization of the localization and proteolytic activity of the SUMO-specific protease, SENP1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-LIKE PROTEINS; E3 LIGASE; TRANSCRIPTIONAL ACTIVATION; CONJUGATION; IDENTIFICATION; BINDING; PML; P53; ISOPEPTIDASE; PATHWAY	Modification of proteins by small ubiquitin-like modifier ( SUMO) plays an important role in the function, compartmentalization, and stability of target proteins, contributing to the regulation of diverse processes. SUMO-1 modification can be regulated not only at the level of conjugation; it may also be reversed by a class of proteases known as the SUMO-specific proteases. However, current understanding of the regulation, specificity, and function of these proteases remains limited. In this study, we characterize aspects of the compartmentalization and proteolytic activity of the mammalian SUMO-specific protease, SENP1, providing insight into its function and regulation. We demonstrate the presence of a single nonconsensus nuclear localization signal within the N terminus of the protein, the mutation of which results in pronounced cytoplasmic accumulation in contrast to the nuclear accumulation of the parental protein. In addition, we observe that the N terminus of the protein may be essential for the correct regulation of the protease, since expression of the core domain alone results in limited expression and loss of SUMO-1, indicative of constitutive catalytic activity. Consistent with the prediction that the protease is a member of the cysteine family of proteases, we mutated a key cysteine residue and observed that expression of this catalytic mutant had a dominant negative phenotype, resulting in the accumulation of high molecular weight SUMO-1 conjugates. Furthermore, we demonstrate that SENP1 may itself be a target for SUMO-1 modification occurring at a nonconsensus site. Finally, we demonstrate that SENP1 localization is influenced by expression and localization of SUMO-1-conjugated target proteins within the cell.	Marie Curie Res Inst, Surrey RH8 OTL, England		O'Hare, P (corresponding author), Marie Curie Res Inst, Surrey RH8 OTL, England.	P.OHare@mcri.ac.uk		O'Hare, Peter/0000-0003-4508-5602				Bailey D, 2002, J GEN VIROL, V83, P2951, DOI 10.1099/0022-1317-83-12-2951; BATCHELOR AH, 1992, J VIROL, V66, P3573, DOI 10.1128/JVI.66.6.3573-3582.1992; Best JL, 2002, MOL CELL, V10, P843, DOI 10.1016/S1097-2765(02)00699-8; Cokol M, 2000, EMBO REP, V1, P411, DOI 10.1093/embo-reports/kvd092; Desterro JMP, 1997, FEBS LETT, V417, P297, DOI 10.1016/S0014-5793(97)01305-7; Desterro JMP, 1999, J BIOL CHEM, V274, P10618, DOI 10.1074/jbc.274.15.10618; FRANGIONI JV, 1993, J CELL SCI, V105, P481; Gong LM, 2000, J BIOL CHEM, V275, P3355, DOI 10.1074/jbc.275.5.3355; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; Hang J, 2002, J BIOL CHEM, V277, P19961, DOI 10.1074/jbc.M201799200; Hay RT, 1999, PHILOS T R SOC B, V354, P1601, DOI 10.1098/rstb.1999.0504; Hochstrasser M, 2000, NAT CELL BIOL, V2, pE153, DOI 10.1038/35019643; Hochstrasser M, 2001, CELL, V107, P5, DOI 10.1016/S0092-8674(01)00519-0; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; Johnson ES, 2001, CELL, V106, P735, DOI 10.1016/S0092-8674(01)00491-3; Kadoya T, 2002, MOL CELL BIOL, V22, P3803, DOI 10.1128/MCB.22.11.3803-3819.2002; Kahyo T, 2001, MOL CELL, V8, P713, DOI 10.1016/S1097-2765(01)00349-5; Kamitani T, 1998, J BIOL CHEM, V273, P3117, DOI 10.1074/jbc.273.6.3117; Kamitani T, 1998, J BIOL CHEM, V273, P26675, DOI 10.1074/jbc.273.41.26675; Kim KI, 2000, J BIOL CHEM, V275, P14102, DOI 10.1074/jbc.275.19.14102; Kirsh O, 2002, EMBO J, V21, P2682, DOI 10.1093/emboj/21.11.2682; Li MY, 2002, NATURE, V416, P648, DOI 10.1038/nature737; Li SJ, 2000, MOL CELL BIOL, V20, P2367, DOI 10.1128/MCB.20.7.2367-2377.2000; Li SJ, 2003, J CELL BIOL, V160, P1069, DOI 10.1083/jcb.200212052; Li SJ, 1999, NATURE, V398, P246, DOI 10.1038/18457; Matunis MJ, 2002, MOL CELL, V10, P441, DOI 10.1016/S1097-2765(02)00653-6; MAUL GG, 1994, J GEN VIROL, V75, P1223, DOI 10.1099/0022-1317-75-6-1223; Mossessova E, 2000, MOL CELL, V5, P865, DOI 10.1016/S1097-2765(00)80326-3; Muller S, 2000, J BIOL CHEM, V275, P13321, DOI 10.1074/jbc.275.18.13321; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; Nagase T, 1998, DNA Res, V5, P277, DOI 10.1093/dnares/5.5.277; Nishida T, 2000, EUR J BIOCHEM, V267, P6423, DOI 10.1046/j.1432-1327.2000.01729.x; O'Rourke D, 1998, J GEN VIROL, V79, P537, DOI 10.1099/0022-1317-79-3-537; Pichler A, 2002, CELL, V108, P109, DOI 10.1016/S0092-8674(01)00633-X; Pickart CM, 2001, MOL CELL, V8, P499, DOI 10.1016/S1097-2765(01)00347-1; Rodriguez MS, 2001, J BIOL CHEM, V276, P12654, DOI 10.1074/jbc.M009476200; Sachdev S, 2001, GENE DEV, V15, P3088, DOI 10.1101/gad.944801; Sampson DA, 2001, J BIOL CHEM, V276, P21664, DOI 10.1074/jbc.M100006200; Schwarz SE, 1998, P NATL ACAD SCI USA, V95, P560, DOI 10.1073/pnas.95.2.560; Schwienhorst I, 2000, MOL GEN GENET, V263, P771, DOI 10.1007/s004380000254; Stade K, 2002, J BIOL CHEM, V277, P49554, DOI 10.1074/jbc.M207991200; Suzuki T, 1999, J BIOL CHEM, V274, P31131, DOI 10.1074/jbc.274.44.31131; Tatham MH, 2001, J BIOL CHEM, V276, P35368, DOI 10.1074/jbc.M104214200; Taylor DL, 2002, J CELL SCI, V115, P1113; Verger A, 2003, EMBO REP, V4, P137, DOI 10.1038/sj.embor.embor738; Wu XY, 2001, J BIOL CHEM, V276, P24177, DOI 10.1074/jbc.M100412200; Yeh ETH, 2000, GENE, V248, P1, DOI 10.1016/S0378-1119(00)00139-6; Zhang H, 2002, MOL CELL BIOL, V22, P6498, DOI 10.1128/MCB.22.18.6498-6508.2002	48	147	159	2	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 2	2004	279	1					692	703		10.1074/jbc.M306195200	http://dx.doi.org/10.1074/jbc.M306195200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	757GU	14563852	hybrid			2022-12-27	WOS:000187555300083
J	Hakanpaa, J; Paananen, A; Askolin, S; Nakari-Setala, T; Parkkinen, T; Penttila, M; Linder, MB; Rouvinen, J				Hakanpaa, J; Paananen, A; Askolin, S; Nakari-Setala, T; Parkkinen, T; Penttila, M; Linder, MB; Rouvinen, J			Atomic resolution structure of the HFBII hydrophobin, a self-assembling amphiphile	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRICHODERMA-REESEI; FUNGAL BIOLOGY; SC3	Hydrophobins are proteins specific to filamentous fungi. Hydrophobins have several important roles in fungal physiology, for example, adhesion, formation of protective surface coatings, and the reduction of the surface tension of water, which allows growth of aerial structures. Hydrophobins show remarkable biophysical properties, for example, they are the most powerful surface-active proteins known. To this point the molecular basis of the function of this group of proteins has been largely unknown. We have now determined the crystal structure of the hydrophobin HFBII from Trichoderma reesei at 1.0 Angstrom resolution. HFBII has a novel, compact single domain structure containing one alpha-helix and four antiparallel beta-strands that completely envelop two disulfide bridges. The protein surface is mainly hydrophilic, but two beta-hairpin loops contain several conserved aliphatic side chains that form a flat hydrophobic patch that makes the molecule amphiphilic. The amphiphilicity of the HFBII molecule is expected to be a source for surface activity, and we suggest that the behavior of this surfactant is greatly enhanced by the self-assembly that is favored by the combination of size and rigidity. This mechanism of function is supported by atomic force micrographs that show highly ordered arrays of HFBII at the air water interface. The data presented show that much of the current views on structure function relations in hydrophobins must be re-evaluated.	Univ Joensuu, Dept Chem, FIN-80101 Joensuu, Finland; VTT Biotechnol, Espoo 02044, Finland	University of Eastern Finland; VTT Technical Research Center Finland	Rouvinen, J (corresponding author), Univ Joensuu, Dept Chem, POB 111, FIN-80101 Joensuu, Finland.	juha.rouvinen@joensuu.fi	Linder, Markus/N-8043-2019; Penttilä, Merja E/A-4710-2013; Linder, Markus B/E-5879-2011; Hakanpää, Johanna M/A-6958-2011	Linder, Markus/0000-0002-7271-6441; Linder, Markus B/0000-0002-7271-6441; Hakanpää, Johanna M/0000-0003-0110-1439; Parkkinen, Tarja/0000-0002-2348-0508; Penttila, Merja/0000-0002-6929-1032; Rouvinen, Juha/0000-0003-1843-5718; Kallio, Johanna/0000-0001-7330-8928				Bailey MJ, 2002, APPL MICROBIOL BIOT, V58, P721, DOI 10.1007/s00253-002-0966-z; BRANDEN C, 1998, INTRO PROTEIN STRUCT, P31; Collen A, 2002, BBA-GEN SUBJECTS, V1569, P139, DOI 10.1016/S0304-4165(01)00244-6; de Vocht ML, 2000, J BIOL CHEM, V275, P28428, DOI 10.1074/jbc.M000691200; de Vocht ML, 1998, BIOPHYS J, V74, P2059, DOI 10.1016/S0006-3495(98)77912-3; De Vocht ML, 2002, PROTEIN SCI, V11, P1199, DOI 10.1110/ps.4540102; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; Foadi J, 2000, ACTA CRYSTALLOGR D, V56, P1137, DOI 10.1107/S090744490000932X; GEDDE UW, 1995, POLYM PHYSICS; Gow NA., 1995, GROWING FUNGUS, DOI [10.1007/978-0-585-27576-5, DOI 10.1007/978-0-585-27576-5]; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Jonsson B., 1998, IEEE ELECTR INSUL M, V14, P42, DOI [10.1109/MEI.1998.714652, DOI 10.1109/MEI.1998.714652]; KLEEMOLA T, 2002, P EUR BREW CONV 2001, P127; Lehn JM, 2002, SCIENCE, V295, P2400, DOI 10.1126/science.1071063; Linder M, 2002, PROTEIN SCI, V11, P2257, DOI 10.1110/ps.0207902; Linder M, 2001, BIOMACROMOLECULES, V2, P511, DOI 10.1021/bm0001493; Mackay JP, 2001, STRUCTURE, V9, P83, DOI 10.1016/S0969-2126(00)00559-1; NakariSetala T, 1996, EUR J BIOCHEM, V235, P248, DOI 10.1111/j.1432-1033.1996.00248.x; NakariSetala T, 1997, EUR J BIOCHEM, V248, P415, DOI 10.1111/j.1432-1033.1997.00415.x; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Paananen A, 2003, BIOCHEMISTRY-US, V42, P5253, DOI 10.1021/bi034031t; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Ritva S, 2003, J APPL CRYSTALLOGR, V36, P499, DOI 10.1107/S0021889803000578; Scholtmeijer K, 2002, APPL ENVIRON MICROB, V68, P1367, DOI 10.1128/AEM.68.3.1367-1373.2002; Scholtmeijer K, 2001, APPL MICROBIOL BIOT, V56, P1, DOI 10.1007/s002530100632; Talbot NJ, 1997, CURR BIOL, V7, pR78, DOI 10.1016/S0960-9822(06)00041-8; Talbot NJ, 1999, NATURE, V398, P295, DOI 10.1038/18575; Torkkeli M, 2002, BIOPHYS J, V83, P2240, DOI 10.1016/S0006-3495(02)73984-2; Tucker SL, 2001, ANNU REV PHYTOPATHOL, V39, P385, DOI 10.1146/annurev.phyto.39.1.385; WESSELS JGH, 1994, ANNU REV PHYTOPATHOL, V32, P413, DOI 10.1146/annurev.py.32.090194.002213; Wosten HAB, 2000, BBA-REV BIOMEMBRANES, V1469, P79, DOI 10.1016/S0304-4157(00)00002-2; Wosten HAB, 1999, CURR BIOL, V9, P85, DOI 10.1016/S0960-9822(99)80019-0; WOSTEN HAB, 1993, PLANT CELL, V5, P1567; YAGUCHI M, 1993, DUTCH ELM DISEASE RESEARCH, P152; Zangi R, 2002, BIOPHYS J, V83, P112, DOI 10.1016/S0006-3495(02)75153-9	35	198	209	0	44	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 2	2004	279	1					534	539		10.1074/jbc.M309650200	http://dx.doi.org/10.1074/jbc.M309650200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	757GU	14555650	hybrid			2022-12-27	WOS:000187555300064
J	Huang, QQ; Fisher, SA; Brozovich, FV				Huang, QQ; Fisher, SA; Brozovich, FV			Unzipping the role of myosin light chain phosphatase in smooth muscle cell relaxation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE I-ALPHA; SIGNAL-TRANSDUCTION; TARGETING SUBUNIT; NITRIC-OXIDE; CYCLIC-GMP; CGMP; PHOSPHORYLATION; ISOFORMS; EXPRESSION; TELOKIN	Recently, it has been hypothesized that myosin light chain (MLC) phosphatase is activated by cGMP-dependent protein kinase (PKG) via a leucine zipper-leucine zipper (LZ-LZ) interaction through the C-terminal LZ in the myosin-binding subunit (MBS) of MLC phosphatase and the N-terminal LZ of PKG (Surks, H. K., Mochizuki, N., Kasai, Y., Georgescu, S. P., Tang, K. M., Ito, M., Lincoln, T. M., and Mendelsohn, M. E. ( 1999) Science 286, 1583 - 1587). Alternative splicing of a 3'-exon produces a LZ(+) or LZ(-) MBS, and the sensitivity to cGMP-mediated smooth muscle relaxation correlates with the relative expression of LZ(+)/LZ(-) MBS isoforms (Khatri, J. J., Joyce, K. M., Brozovich, F. V., and Fisher, S. A. ( 2001) J. Biol. Chem. 276, 37250 - 37257). In the present study, we determined the effect of LZ(+)/LZ(-) MBS isoforms on cGMP-induced MLC20 dephosphorylation. Four avian smooth muscle MBS-recombinant adenoviruses were prepared and transfected into cultured embryonic chicken gizzard smooth muscle cells. The expressed exogenous MBS isoforms were shown to replace the endogenous isoform in the MLC phosphatase holoenzyme. The interaction of type I PKG (PKGI) with the MBS did not depend on the presence of cGMP or the MBS LZ. However, direct activation of PKGI by 8-bromo-cGMP produced a dose-dependent decrease in MLC20 phosphorylation ( p < 0.05) only in smooth muscle cells expressing a LZ(+) MBS. These results suggest that the activation of MLC phosphatase by PKGI requires a LZ(+) MBS, but the binding of PKGI to the MBS is not mediated by a LZ- LZ interaction. Thus, the relative expression of LZ(+)/LZ(-) MBS isoforms could explain differences in tissue sensitivity to NO-mediated vasodilatation.	Case Western Reserve Univ, Dept Physiol & Biophys, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Med Cardiol, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University	Brozovich, FV (corresponding author), Case Western Reserve Univ, Dept Physiol, 10900 Euclid Ave, Cleveland, OH 44106 USA.	fxb9@cwru.edu	fisher, steven/G-2630-2010		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066171, R01HL064137, R01HL069894] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL64137, HL69894, HL66171] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALEXANDER DC, 1987, METHOD ENZYMOL, V154, P41; Alioua A, 1998, J BIOL CHEM, V273, P32950, DOI 10.1074/jbc.273.49.32950; Chiche JD, 1998, J BIOL CHEM, V273, P34263, DOI 10.1074/jbc.273.51.34263; Dirksen WP, 2000, AM J PHYSIOL-CELL PH, V278, pC589, DOI 10.1152/ajpcell.2000.278.3.C589; Dostmann WRG, 2000, P NATL ACAD SCI USA, V97, P14772, DOI 10.1073/pnas.97.26.14772; Etter EF, 2001, J BIOL CHEM, V276, P34681, DOI 10.1074/jbc.M104737200; Fukao M, 1999, J BIOL CHEM, V274, P10927, DOI 10.1074/jbc.274.16.10927; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; GONG MC, 1992, J BIOL CHEM, V267, P14662; Hartshorne DJ, 1998, J MUSCLE RES CELL M, V19, P325, DOI 10.1023/A:1005385302064; HARTSHORNE DJ, 1987, PHYSL GASTROINTESTIN, P432; Hayashi K, 1998, J BIOL CHEM, V273, P28860, DOI 10.1074/jbc.273.44.28860; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Huang QQ, 1999, J BIOL CHEM, V274, P35095, DOI 10.1074/jbc.274.49.35095; Jin JP, 1996, BIOCHEM CELL BIOL, V74, P187, DOI 10.1139/o96-019; Kashiwada K, 1997, J BIOL CHEM, V272, P15396, DOI 10.1074/jbc.272.24.15396; Khatri JJ, 2001, J BIOL CHEM, V276, P37250, DOI 10.1074/jbc.M105275200; Langsetmo K, 2001, J BIOL CHEM, V276, P34318, DOI 10.1074/jbc.M103255200; Lee MR, 1997, J BIOL CHEM, V272, P5063, DOI 10.1074/jbc.272.8.5063; LINCOLN TM, 1989, PHARMACOL THERAPEUT, V41, P479, DOI 10.1016/0163-7258(89)90127-7; Lincoln TM, 2001, J APPL PHYSIOL, V91, P1421, DOI 10.1152/jappl.2001.91.3.1421; MacDonald JA, 2000, FEBS LETT, V479, P83, DOI 10.1016/S0014-5793(00)01884-6; Rembold CM, 2000, J PHYSIOL-LONDON, V524, P865, DOI 10.1111/j.1469-7793.2000.00865.x; Richards CT, 2002, J BIOL CHEM, V277, P4422, DOI 10.1074/jbc.M111047200; SCHMIDT HHHW, 1993, BIOCHIM BIOPHYS ACTA, V1178, P153, DOI 10.1016/0167-4889(93)90006-B; SHIMIZU H, 1994, J BIOL CHEM, V269, P30407; Somlyo A P, 1999, Rev Physiol Biochem Pharmacol, V134, P201; SOMLYO AP, 1994, NATURE, V372, P231, DOI 10.1038/372231a0; Surks HK, 1999, SCIENCE, V286, P1583, DOI 10.1126/science.286.5444.1583; Walker LA, 2001, J BIOL CHEM, V276, P24519, DOI 10.1074/jbc.M103560200; Wu XQ, 1998, J BIOL CHEM, V273, P11362, DOI 10.1074/jbc.273.18.11362	31	67	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 2	2004	279	1					597	603		10.1074/jbc.M308496200	http://dx.doi.org/10.1074/jbc.M308496200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	757GU	14530290	hybrid			2022-12-27	WOS:000187555300072
J	Rao, RV; Poksay, KS; Castro-Obregon, S; Schilling, B; Row, RH; del Rio, G; Gibson, BW; Ellerby, HM; Bredesen, DE				Rao, RV; Poksay, KS; Castro-Obregon, S; Schilling, B; Row, RH; del Rio, G; Gibson, BW; Ellerby, HM; Bredesen, DE			Molecular components of a cell death pathway activated by endoplasmic reticulum stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOSIDE DIPHOSPHATE KINASE; APOPTOSIS-INDUCING PROTEIN; CYTOCHROME-C RELEASE; OXIDATIVE STRESS; ASIALOGLYCOPROTEIN RECEPTOR; MEDIATED APOPTOSIS; PROMOTE APOPTOSIS; ATP BINDING; BREFELDIN-A; CASPASE-12	Alterations in Ca2+ homeostasis and accumulation of misfolded proteins in the endoplasmic reticulum (ER) cause ER stress that ultimately leads to programmed cell death. Recent studies have shown that ER stress triggers programmed cell death via an alternative intrinsic pathway of apoptosis that, unlike the intrinsic pathway described previously, is independent of Apaf-1 and cytochrome c. In the present work, we have used a set of complementary approaches, including two-dimensional gel electrophoresis coupled with matrix- assisted laser desorption ionization-time-of-flight mass spectrometry and nano-liquid chromatography-electrospray ionization mass spectrometry with tandem mass spectrometry, RNA interference, co-immunoprecipitation, immunodepletion of candidate proteins, and reconstitution studies, to identify mediators of the ER stress-induced cell death pathway. Our data identify two molecules, valosin-containing protein and apoptosis-linked gene-2 (ALG-2), that appear to play a role in mediating ER stress-induced cell death.	Buck Inst Age Res, Novato, CA 94945 USA; Univ Calif San Francisco, San Francisco, CA 94143 USA	Buck Institute for Research on Aging; University of California System; University of California San Francisco	Ellerby, HM (corresponding author), Buck Inst Age Res, 8001 Redwood Blvd, Novato, CA 94945 USA.	mellerby@buckinstitute.org; dbredesen@buckinstitute.org	Castro-Obregon, Susana/AAE-5105-2020	Castro-Obregon, Susana/0000-0003-0549-5690	NATIONAL CANCER INSTITUTE [R01CA084262] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033376] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG012282] Funding Source: NIH RePORTER; NCI NIH HHS [CA84262] Funding Source: Medline; NIA NIH HHS [AG12282] Funding Source: Medline; NINDS NIH HHS [NS33376] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adams JM, 2001, TRENDS BIOCHEM SCI, V26, P61, DOI 10.1016/S0968-0004(00)01740-0; Beresford PJ, 2001, J BIOL CHEM, V276, P43285, DOI 10.1074/jbc.M108137200; Bitko V, 2001, J CELL BIOCHEM, V80, P441, DOI 10.1002/1097-4644(20010301)80:3<441::AID-JCB170>3.0.CO;2-C; Breckenridge DG, 2002, P NATL ACAD SCI USA, V99, P4331, DOI 10.1073/pnas.072088099; Brewster JL, 2000, GENESIS, V26, P271, DOI 10.1002/(SICI)1526-968X(200004)26:4<271::AID-GENE90>3.0.CO;2-E; Castro-Obregon S, 2002, CELL DEATH DIFFER, V9, P807, DOI 10.1038/sj.cdd.4401035; Chua BT, 2000, J BIOL CHEM, V275, P5131, DOI 10.1074/jbc.275.7.5131; Dalal S, 2001, CELL, V104, P5, DOI 10.1016/S0092-8674(01)00186-6; Drexler HCA, 2000, FASEB J, V14, P65, DOI 10.1096/fasebj.14.1.65; Drexler HCA, 1997, P NATL ACAD SCI USA, V94, P855, DOI 10.1073/pnas.94.3.855; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Ellerby HM, 1997, J NEUROSCI, V17, P6165; Field HI, 2002, PROTEOMICS, V2, P36, DOI 10.1002/1615-9861(200201)2:1<36::AID-PROT36>3.0.CO;2-W; Fischer H, 2002, BIOCHEM BIOPH RES CO, V293, P722, DOI 10.1016/S0006-291X(02)00289-9; FUKUCHI T, 1994, BBA-PROTEIN STRUCT M, V1205, P113, DOI 10.1016/0167-4838(94)90099-X; Germain M, 2002, J BIOL CHEM, V277, P18053, DOI 10.1074/jbc.M201235200; GERMAIN M, 2003, SCI STKE; Guo H, 1998, EXP CELL RES, V245, P57, DOI 10.1006/excr.1998.4235; Harding HP, 2002, ANNU REV CELL DEV BI, V18, P575, DOI 10.1146/annurev.cellbio.18.011402.160624; Hirabayashi M, 2001, CELL DEATH DIFFER, V8, P977, DOI 10.1038/sj.cdd.4400907; Hong NA, 2000, DEV BIOL, V220, P76, DOI 10.1006/dbio.2000.9615; Hoppe J, 2002, EUR J CELL BIOL, V81, P567, DOI 10.1078/0171-9335-00276; Jung SK, 2000, J IMMUNOL, V165, P1491, DOI 10.4049/jimmunol.165.3.1491; Jung YS, 2001, BIOCHEM BIOPH RES CO, V288, P420, DOI 10.1006/bbrc.2001.5769; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kilic M, 2002, CELL DEATH DIFFER, V9, P125, DOI 10.1038/sj/cdd/4400968; Kobayashi T, 2002, J BIOL CHEM, V277, P47358, DOI 10.1074/jbc.M207783200; Kouroku Y, 2002, HUM MOL GENET, V11, P1505, DOI 10.1093/hmg/11.13.1505; Kuznetsov G, 1997, J BIOL CHEM, V272, P3057, DOI 10.1074/jbc.272.5.3057; Lacana E, 1997, J IMMUNOL, V158, P5129; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu H, 1997, J BIOL CHEM, V272, P21751, DOI 10.1074/jbc.272.35.21751; LOCKSHIN RA, 1964, J INSECT PHYSIOL, V10, P643, DOI 10.1016/0022-1910(64)90034-4; LODISH HF, 1992, J BIOL CHEM, V267, P12753; Lord JM, 2002, CURR BIOL, V12, pR182, DOI 10.1016/S0960-9822(02)00738-8; Mathiasen IS, 2002, J BIOL CHEM, V277, P30738, DOI 10.1074/jbc.M201558200; Matsuzawa A, 2002, ANTIOXID REDOX SIGN, V4, P415, DOI 10.1089/15230860260196218; McCormick TS, 1997, J BIOL CHEM, V272, P6087, DOI 10.1074/jbc.272.9.6087; Miramar MD, 2001, J BIOL CHEM, V276, P16391, DOI 10.1074/jbc.M010498200; Morishima N, 2002, J BIOL CHEM, V277, P34287, DOI 10.1074/jbc.M204973200; Murakawa M, 2001, CELL DEATH DIFFER, V8, P298, DOI 10.1038/sj.cdd.4400811; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Nakagawa T, 2000, J CELL BIOL, V150, P887, DOI 10.1083/jcb.150.4.887; Negroni A, 2000, CELL DEATH DIFFER, V7, P843, DOI 10.1038/sj.cdd.4400720; Nehls S, 2000, NAT CELL BIOL, V2, P288, DOI 10.1038/35010558; Ng FWH, 1997, J CELL BIOL, V139, P327, DOI 10.1083/jcb.139.2.327; Nishitoh H, 2002, GENE DEV, V16, P1345, DOI 10.1101/gad.992302; Nutt LK, 2002, J BIOL CHEM, V277, P20301, DOI 10.1074/jbc.M201604200; Nutt LK, 2002, J BIOL CHEM, V277, P9219, DOI 10.1074/jbc.M106817200; Obermoeller LM, 1998, J BIOL CHEM, V273, P22374, DOI 10.1074/jbc.273.35.22374; Oubrahim H, 2002, J BIOL CHEM, V277, P20135, DOI 10.1074/jbc.C200226200; Ozawa K, 1999, J BIOL CHEM, V274, P6397, DOI 10.1074/jbc.274.10.6397; Rao RV, 2002, FEBS LETT, V514, P122, DOI 10.1016/S0014-5793(02)02289-5; Rao RV, 2002, J BIOL CHEM, V277, P21836, DOI 10.1074/jbc.M202726200; Rao RV, 2001, J BIOL CHEM, V276, P33869, DOI 10.1074/jbc.M102225200; Reddy RK, 2003, J BIOL CHEM, V278, P20915, DOI 10.1074/jbc.M212328200; Rowe T, 1997, NATURE, V388, P20, DOI 10.1038/40269; Rudner J, 2002, APOPTOSIS, V7, P441, DOI 10.1023/A:1020087108926; Saleh A, 1999, J BIOL CHEM, V274, P17941, DOI 10.1074/jbc.274.25.17941; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Scorrano L, 2003, SCIENCE, V300, P135, DOI 10.1126/science.1081208; Shao RG, 1996, EXP CELL RES, V227, P190, DOI 10.1006/excr.1996.0266; SHIMADA N, 1993, J BIOL CHEM, V268, P2583; Sperandio S, 2000, P NATL ACAD SCI USA, V97, P14376, DOI 10.1073/pnas.97.26.14376; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Tanaka S, 2000, J BIOL CHEM, V275, P10388, DOI 10.1074/jbc.275.14.10388; Thomenius MJ, 2003, J BIOL CHEM, V278, P6243, DOI 10.1074/jbc.M208878200; URANO T, 1992, FEBS LETT, V309, P358, DOI 10.1016/0014-5793(92)80807-S; Vale RD, 2000, J CELL BIOL, V150, pF13, DOI 10.1083/jcb.150.1.F13; Vito P, 1999, J BIOL CHEM, V274, P1533, DOI 10.1074/jbc.274.3.1533; Vito P, 1996, SCIENCE, V271, P521, DOI 10.1126/science.271.5248.521; Wang Q, 2003, BIOCHEM BIOPH RES CO, V300, P253, DOI 10.1016/S0006-291X(02)02840-1; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; WIKSTROM L, 1993, J BIOL CHEM, V268, P14412; Wolf BB, 1999, BLOOD, V94, P1683, DOI 10.1182/blood.V94.5.1683.417k37_1683_1692; Wu DY, 1999, DEVELOPMENT, V126, P2021; Yu ZF, 1999, EXP NEUROL, V155, P302, DOI 10.1006/exnr.1998.7002; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797; Zong WX, 2003, J CELL BIOL, V162, P59, DOI 10.1083/jcb.200302084; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	82	129	137	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 2	2004	279	1					177	187		10.1074/jbc.M304490200	http://dx.doi.org/10.1074/jbc.M304490200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	757GU	14561754	hybrid			2022-12-27	WOS:000187555300022
J	Coulonval, K; Bockstaele, L; Paternot, S; Roger, PP				Coulonval, K; Bockstaele, L; Paternot, S; Roger, PP			Phosphorylations of cyclin-dependent kinase 2 revisited using two-dimensional gel electrophoresis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT-KINASE; CDK-ACTIVATING KINASE; IMMOBILIZED PH GRADIENTS; THYROID EPITHELIAL-CELLS; DNA-REPLICATION; SUBCELLULAR-LOCALIZATION; RETINOBLASTOMA PROTEIN; S-PHASE; HUMAN FIBROBLASTS; COMPLEX	To control the G(1)/S transition and the progression through the S phase, the activation of the cyclin-dependent kinase (CDK) 2 involves the binding of cyclin E then cyclin A, the activating Thr-160 phosphorylation within the T-loop by CDK-activating kinase (CAK), inhibitory phosphorylations within the ATP binding region at Tyr-15 and Thr-14, dephosphorylation of these sites by cdc25A, and release from Cip/Kip family (p27(kip1) and p21(cip1)) CDK inhibitors. To re-assess the precise relationship between the different phosphorylations of CDK2, and the influence of cyclins and CDK inhibitors upon them, we introduce here the use of the high resolution power of two-dimensional gel electrophoresis, combined to Tyr-15- or Thr-160-phosphospecific antibodies. The relative proportions of the potentially active forms of CDK2 ( phosphorylated at Thr-160 but not Tyr-15) and inactive forms (non-phosphorylated, phosphorylated only at Tyr-15, or at both Tyr-15 and Thr-160), and their respective association with cyclin E, cyclin A, p21, and p27, were demonstrated during the mitogenic stimulation of normal human fibroblasts. Novel observations modify the current model of the sequential CDK2 activation process: (i) Tyr-15 phosphorylation induced by serum was not restricted to cyclin-bound CDK2; (ii) Thr-160 phosphorylation engaged the entirety of Tyr-15- phosphorylated CDK2 associated not only with a cyclin but also with p27 and p21, suggesting that Cip/ Kip proteins do not prevent CDK2 activity by impairing its phosphorylation by CAK; (iii) the potentially active CDK2 phosphorylated at Thr-160 but not Tyr-15 represented a tiny fraction of total CDK2 and a minor fraction of cyclin A-bound CDK2, underscoring the rate-limiting role of Tyr-15 dephosphorylation by cdc25A.	Free Univ Brussels, Inst Interdisciplinary Res, B-1070 Brussels, Belgium; Free Univ Brussels, Fac Med, Dept Prot Chem, B-1070 Brussels, Belgium	Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Libre de Bruxelles; Vrije Universiteit Brussel	Roger, PP (corresponding author), ULB, IRIBHM, Campus Erasme,Bldg C,808 Route lennik, B-1070 Brussels, Belgium.	proger@ulb.ac.be		Roger, Pierre/0000-0002-5812-1783				APRELIKOVA O, 1995, J BIOL CHEM, V270, P18195, DOI 10.1074/jbc.270.31.18195; Baldin V, 1997, BIOCHEM BIOPH RES CO, V236, P130, DOI 10.1006/bbrc.1997.6913; Baptist M, 1996, J CELL PHYSIOL, V166, P256; BAPTIST M, 1995, EXP CELL RES, V221, P160, DOI 10.1006/excr.1995.1363; Bartek J, 2001, CURR OPIN CELL BIOL, V13, P738, DOI 10.1016/S0955-0674(00)00280-5; Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; BJELLQVIST B, 1993, ELECTROPHORESIS, V14, P1023, DOI 10.1002/elps.11501401163; Blomberg I, 1999, MOL CELL BIOL, V19, P6183; Bresnahan WA, 1996, CELL GROWTH DIFFER, V7, P1283; Cai K, 1998, P NATL ACAD SCI USA, V95, P12254, DOI 10.1073/pnas.95.21.12254; CARDOSO MC, 1993, CELL, V74, P979, DOI 10.1016/0092-8674(93)90721-2; Coverley D, 2002, NAT CELL BIOL, V4, P523, DOI 10.1038/ncb813; DULIC V, 1993, P NATL ACAD SCI USA, V90, P11034, DOI 10.1073/pnas.90.23.11034; Ekholm SV, 2000, CURR OPIN CELL BIOL, V12, P676, DOI 10.1016/S0955-0674(00)00151-4; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Farkas T, 2002, J BIOL CHEM, V277, P26741, DOI 10.1074/jbc.M200381200; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; Frouin I, 2002, EMBO J, V21, P2485, DOI 10.1093/emboj/21.10.2485; GIANAZZA E, 1995, J CHROMATOGR A, V705, P67, DOI 10.1016/0021-9673(94)01251-9; Gorg A, 2000, ELECTROPHORESIS, V21, P1037, DOI 10.1002/(SICI)1522-2683(20000401)21:6<1037::AID-ELPS1037>3.0.CO;2-V; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; Hagopian JC, 2001, J BIOL CHEM, V276, P275, DOI 10.1074/jbc.M007337200; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; Hengst L, 1998, GENE DEV, V12, P3882, DOI 10.1101/gad.12.24.3882; Higashi H, 1996, EUR J BIOCHEM, V237, P460, DOI 10.1111/j.1432-1033.1996.0460k.x; HOFFMANN I, 1994, J CELL SCI, P75; Ishimi Y, 2001, J BIOL CHEM, V276, P34428, DOI 10.1074/jbc.M104480200; Jallepalli PV, 1997, CURR OPIN CELL BIOL, V9, P358, DOI 10.1016/S0955-0674(97)80008-7; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; Kaldis P, 1998, MOL BIOL CELL, V9, P2545, DOI 10.1091/mbc.9.9.2545; Kaneko Y, 1999, ONCOGENE, V18, P3673, DOI 10.1038/sj.onc.1202706; Kawasaki H, 2001, EMBO J, V20, P4618, DOI 10.1093/emboj/20.16.4618; Kelly BL, 1998, P NATL ACAD SCI USA, V95, P2535, DOI 10.1073/pnas.95.5.2535; Lents NH, 2002, J BIOL CHEM, V277, P47469, DOI 10.1074/jbc.M207425200; Lew DJ, 1996, CURR OPIN CELL BIOL, V8, P795, DOI 10.1016/S0955-0674(96)80080-9; LI Y, 1994, ONCOGENE, V9, P2261; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; Mailand N, 2002, EMBO J, V21, P5911, DOI 10.1093/emboj/cdf567; MATSUOKA M, 1994, MOL CELL BIOL, V14, P7265, DOI 10.1128/MCB.14.11.7265; Morisaki H, 1999, EXP CELL RES, V253, P503, DOI 10.1006/excr.1999.4698; Morris MC, 2002, J BIOL CHEM, V277, P23847, DOI 10.1074/jbc.M107890200; Nagahara H, 1999, P NATL ACAD SCI USA, V96, P14961, DOI 10.1073/pnas.96.26.14961; Nilsson I, 2000, Prog Cell Cycle Res, V4, P107; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; PARKER LL, 1991, EMBO J, V10, P1255, DOI 10.1002/j.1460-2075.1991.tb08067.x; Pavletich NP, 1999, J MOL BIOL, V287, P821, DOI 10.1006/jmbi.1999.2640; Petersen BO, 1999, EMBO J, V18, P396, DOI 10.1093/emboj/18.2.396; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POON RYC, 1995, SCIENCE, V270, P90, DOI 10.1126/science.270.5233.90; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; Saha P, 1997, MOL CELL BIOL, V17, P4338, DOI 10.1128/MCB.17.8.4338; Saha P, 1998, MOL CELL BIOL, V18, P2758, DOI 10.1128/MCB.18.5.2758; SEBASTIAN B, 1993, P NATL ACAD SCI USA, V90, P3521, DOI 10.1073/pnas.90.8.3521; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SILLERO A, 1989, ANAL BIOCHEM, V179, P319, DOI 10.1016/0003-2697(89)90136-X; SOBCZAKTHEPOT J, 1993, EXP CELL RES, V206, P43, DOI 10.1006/excr.1993.1118; SOLOMON MJ, 1994, TRENDS BIOCHEM SCI, V19, P496, DOI 10.1016/0968-0004(94)90137-6; Sorensen CS, 2003, CANCER CELL, V3, P247, DOI 10.1016/S1535-6108(03)00048-5; Stein GH, 1999, MOL CELL BIOL, V19, P2109; Stevenson LM, 2002, BIOCHEMISTRY-US, V41, P8528, DOI 10.1021/bi025812h; TASSAN JP, 1994, J CELL BIOL, V127, P467, DOI 10.1083/jcb.127.2.467; Tsakraklides V, 2002, J BIOL CHEM, V277, P33482, DOI 10.1074/jbc.M205537200; Ukomadu C, 2003, J BIOL CHEM, V278, P4840, DOI 10.1074/jbc.M208658200; Vaziri C, 2003, MOL CELL, V11, P997, DOI 10.1016/S1097-2765(03)00099-6; WATANABE N, 1995, EMBO J, V14, P1878, DOI 10.1002/j.1460-2075.1995.tb07180.x; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Xu X, 1999, BIOCHEMISTRY-US, V38, P8713; Zarkowska T, 1997, J BIOL CHEM, V272, P12738, DOI 10.1074/jbc.272.19.12738; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; Zhao H, 2002, P NATL ACAD SCI USA, V99, P14795, DOI 10.1073/pnas.182557299; Zhao JY, 2000, GENE DEV, V14, P2283, DOI 10.1101/gad.827700	73	46	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52052	52060		10.1074/jbc.M307012200	http://dx.doi.org/10.1074/jbc.M307012200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14551212	hybrid			2022-12-27	WOS:000187480700011
J	Dostanic, I; Lorenz, JN; Schultz, JEJ; Grupp, IL; Neumann, JC; Wani, MA; Lingrel, JB				Dostanic, I; Lorenz, JN; Schultz, JEJ; Grupp, IL; Neumann, JC; Wani, MA; Lingrel, JB			The alpha 2 isoform of Na,K-ATPase mediates ouabain-induced cardiac inotropy in mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; NA+/K+-ATPASE COMPLEXES; BETA-SUBUNIT STRUCTURE; RAT-HEART; DIGITALIS; NA+,K+-ATPASE; GLYCOSIDES; DEPENDENCE; CALCIUM; MUSCLE	Inhibition of Na,K-ATPase activity by cardiac glycosides is believed to be the major mechanism by which this class of drugs increases heart contractility. However, direct evidence demonstrating this is lacking. Furthermore it is unknown which specific alpha isoform of Na,K-ATPase is responsible for the effect of cardiac glycosides. Several studies also suggest that cardiac glycosides, such as ouabain, function by mechanisms other than inhibition of the Na,K-ATPase. To determine whether Na,K-ATPase, specifically the alpha2 Na,K-ATPase isozyme, mediates ouabain-induced cardiac inotropy, we developed animals expressing a ouabain-insensitive alpha2 isoform of the Na,K-ATPase using Cre-Lox technology and analyzed cardiac contractility after administration of ouabain. The homozygous knock-in animals were born in normal Mendelian ratio and developed normally to adulthood. Analysis of their cardiovascular function demonstrated normal heart function. Cardiac contractility analysis in isolated hearts and in intact animals demonstrated that ouabain-induced cardiac inotropy occurred in hearts from wild type but not from the targeted animals. These results clearly demonstrate that the Na,K-ATPase and specifically the alpha2 Na, K-ATPase isozyme mediates ouabain-induced cardiac contractility in mice.	Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Cellular & Mol Physiol, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Pharmacol & Cell Biophys, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Lingrel, JB (corresponding author), Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA.	jerry.lingrel@uc.edu			NHLBI NIH HHS [R01 HL28573, R01 HL66062] Funding Source: Medline; NIDDK NIH HHS [R01 DK57552] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066062, R01HL028573] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK057552] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKERA T, 1977, PHARMACOL REV, V29, P187; BRODY TM, 1977, FED PROC, V36, P2219; EAKLE KA, 1994, J BIOL CHEM, V269, P6550; EAKLE KA, 1995, J BIOL CHEM, V270, P13937, DOI 10.1074/jbc.270.23.13937; FUJINO M, 1992, ADV EXP MED BIOL, V311, P449; GRUPP I, 1985, J PHYSIOL-LONDON, V360, P149, DOI 10.1113/jphysiol.1985.sp015609; GRUPP IL, 1993, AM J PHYSIOL, V265, pH1401, DOI 10.1152/ajpheart.1993.265.4.H1401; HAMLYN JM, 1989, J BIOL CHEM, V264, P7395; He SW, 2001, AM J PHYSIOL-REG I, V281, pR917, DOI 10.1152/ajpregu.2001.281.3.R917; Hickerson T W, 1988, Prog Clin Biol Res, V258, P223; ISBERG G, 1984, CARDIAC GLYCOSIDE RE, P56; James PF, 1999, MOL CELL, V3, P555, DOI 10.1016/S1097-2765(00)80349-4; JEWELL EA, 1991, J BIOL CHEM, V266, P16925; Kang WK, 2002, J PHARMACOL EXP THER, V302, P577, DOI 10.1124/jpet.302.2.577; Kometiani P, 2001, AM J PHYSIOL-HEART C, V280, pH1415, DOI 10.1152/ajpheart.2001.280.3.H1415; LEE CO, 1985, AM J PHYSIOL, V249, pC367, DOI 10.1152/ajpcell.1985.249.5.C367; LEVI AJ, 1994, PROG BIOPHYS MOL BIO, V62, P1, DOI 10.1016/0079-6107(94)90005-1; LINGREL JB, 1990, PROG NUCLEIC ACID RE, V38, P37; LINGREL JB, 1994, J BIOL CHEM, V269, P19659; MAIXENT JM, 1987, J BIOL CHEM, V262, P6842; MCDONOUGH AA, 1990, FASEB J, V4, P1598, DOI 10.1096/fasebj.4.6.2156741; MCGARRY SJ, 1993, BRIT J PHARMACOL, V108, P1043, DOI 10.1111/j.1476-5381.1993.tb13503.x; Moseley AE, 2003, J BIOL CHEM, V278, P5317, DOI 10.1074/jbc.M211315200; NUNEZDURAN H, 1988, AM J PHYSIOL, V255, pC479, DOI 10.1152/ajpcell.1988.255.4.C479; PRICE EM, 1988, BIOCHEMISTRY-US, V27, P8400, DOI 10.1021/bi00422a016; PRICE EM, 1990, J BIOL CHEM, V265, P6638; Sagawa T, 2002, AM J PHYSIOL-HEART C, V282, pH1118, DOI 10.1152/ajpheart.00700.2001; Schoner W, 2002, EUR J BIOCHEM, V269, P2440, DOI 10.1046/j.1432-1033.2002.02911.x; Schwartz A, 2001, CARDIOVASC RES, V51, P9, DOI 10.1016/S0008-6363(01)00336-4; SHAMRAJ OI, 1994, P NATL ACAD SCI USA, V91, P12952, DOI 10.1073/pnas.91.26.12952; SHULL GE, 1998, BIOCHEMISTRY-US, V25, P8125; SWEADNER KJ, 1989, BIOCHIM BIOPHYS ACTA, V988, P185, DOI 10.1016/0304-4157(89)90019-1; Woo AL, 2000, J BIOL CHEM, V275, P20693, DOI 10.1074/jbc.M002323200	33	95	98	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					53026	53034		10.1074/jbc.M308547200	http://dx.doi.org/10.1074/jbc.M308547200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14559919	hybrid			2022-12-27	WOS:000187480700126
J	Kim, MS; Kim, SS; Jung, ST; Park, JY; Yoo, HW; Ko, J; Csiszar, K; Choi, SY; Kim, Y				Kim, MS; Kim, SS; Jung, ST; Park, JY; Yoo, HW; Ko, J; Csiszar, K; Choi, SY; Kim, Y			Expression and purification of enzymatically active forms of the human lysyl oxidase-like protein 4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE-RICH DOMAIN; LIVER FIBROSIS; GENE; CLONING; MATURATION; ISOENZYME; BINDING; ACID	The lysyl oxidase-like protein 4 (LOXL4) is the latest member of the emerging family of lysyl oxidases, several of which were shown to function as copper-dependent amine oxidases catalyzing lysine-derived cross-links in extracellular matrix proteins. LOXL4 contains four scavenger receptor cysteine-rich domains in addition to the characteristic domains of the LOX family, including the copper-binding domain, the cytokine receptor-like domain, and the residues of the lysyl-tyrosyl quinone cofactor. In an effort to assess its amine oxidase activity, we expressed LOXL4 as recombinant forms attached with hexa-histidine residues at the carboxyl terminus by using an Escherichia coli expression system. The recombinant proteins were purified with nickel-chelating affinity chromatography and converted into enzymatically active forms by stepwise dialysis. The purified LOXL4 proteins showed beta-aminopropionitrile-inhibitable activity of 0.022 - 0.032 units/mg toward a nonpeptidyl substrate, benzylamine. These results indicate that LOXL4, with the four scavenger receptor cysteine rich domains, may also function as an active amine oxidase. Availability of the pure and active forms of LOXL4 will be significantly helpful in functional studies related to substrate specificity and crystal structure of this amine oxidase, which should provide significant insights into functional differences within the LOX family members.	Univ Ulsan, Coll Med, Asan Med Ctr, GEnome Res Ctr Birth Defects & Genet Dis, Seoul 138736, South Korea; Univ Ulsan, Coll Med, Asan Med Ctr, Asan Inst Life Sci, Seoul 138736, South Korea; Univ Hawaii, John A Burns Sch Med, Cardiovasc Res Ctr, Honolulu, HI 96822 USA; Korea Univ, Sch Life Sci & Biotechnol, Seoul 136701, South Korea	University of Ulsan; Asan Medical Center; University of Ulsan; Asan Medical Center; University of Hawaii System; Korea University	Kim, Y (corresponding author), Univ Ulsan, Coll Med, Asan Med Ctr, GEnome Res Ctr Birth Defects & Genet Dis, Seoul 138736, South Korea.		Jung, Sang Taek/AAJ-9729-2021					Asuncion L, 2001, MATRIX BIOL, V20, P487, DOI 10.1016/S0945-053X(01)00161-5; Bodian DL, 1997, BIOCHEMISTRY-US, V36, P2637, DOI 10.1021/bi962560+; Borel A, 2001, J BIOL CHEM, V276, P48944, DOI 10.1074/jbc.M109499200; CRONSHAW AD, 1995, BIOCHEM J, V306, P279, DOI 10.1042/bj3060279; Decitre M, 1998, LAB INVEST, V78, P143; Di Donato A, 1997, FEBS LETT, V419, P63, DOI 10.1016/S0014-5793(97)01420-8; Hohenester E, 1999, NAT STRUCT BIOL, V6, P228, DOI 10.1038/6669; Ito H, 2001, J BIOL CHEM, V276, P24023, DOI 10.1074/jbc.M100861200; Jonasson P, 2002, BIOTECHNOL APPL BIOC, V35, P91, DOI 10.1042/BA20010099; Jourdan-Le Saux C, 1999, J BIOL CHEM, V274, P12939; KAGAN HM, 1986, J CELL BIOL, V103, P1121, DOI 10.1083/jcb.103.3.1121; KAGAN HM, 1991, AM J RESP CELL MOL, V5, P206, DOI 10.1165/ajrcmb/5.3.206; KAGAN HM, 1981, ARTERIOSCLEROSIS, V1, P287, DOI 10.1161/01.ATV.1.4.287; Kim YH, 1999, J CELL BIOCHEM, V72, P181, DOI 10.1002/(SICI)1097-4644(19990201)72:2<181::AID-JCB3>3.0.CO;2-D; KIM YH, 1995, J BIOL CHEM, V270, P7176, DOI 10.1074/jbc.270.13.7176; Li WD, 2000, J CELL BIOCHEM, V78, P550, DOI 10.1002/1097-4644(20000915)78:4<550::AID-JCB4>3.3.CO;2-#; Maki JM, 2001, BIOCHEM J, V355, P381, DOI 10.1042/0264-6021:3550381; Maki JM, 2001, MATRIX BIOL, V20, P493, DOI 10.1016/S0945-053X(01)00157-3; RicardBlum S, 1996, GASTROENTEROLOGY, V111, P172, DOI 10.1053/gast.1996.v111.pm8698196; Sasaki T, 1998, EMBO J, V17, P1606, DOI 10.1093/emboj/17.6.1606; Sharma R, 1997, BIOSCIENCE REP, V17, P409, DOI 10.1023/A:1027361418200; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Tang CL, 2001, J BIOL CHEM, V276, P30575, DOI 10.1074/jbc.C100138200; Wang SX, 1996, SCIENCE, V273, P1078, DOI 10.1126/science.273.5278.1078	24	46	53	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52071	52074		10.1074/jbc.M308856200	http://dx.doi.org/10.1074/jbc.M308856200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14551188	hybrid			2022-12-27	WOS:000187480700013
J	Mitkova, AV; Khopde, SM; Biswas, SB				Mitkova, AV; Khopde, SM; Biswas, SB			Mechanism and stoichiometry of interaction of DnaG primase with DnaB helicase of Escherichia coli in RNA primer synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COORDINATED LEADING-STRAND; OKAZAKI FRAGMENT SIZE; REPLICATION FORK; NUCLEOTIDE-BINDING; GENE-PRODUCT; FUNCTIONAL INTERACTION; ENZYMATIC REPLICATION; CHROMOSOMAL ORIGIN; ATP HYDROLYSIS; PROTEIN	Initiation and synthesis of RNA primers in the lagging strand of the replication fork in Escherichia coli requires the replicative DnaB helicase and the DNA primase, the DnaG gene product. In addition, the physical interaction between these two replication enzymes appears to play a role in the initiation of chromosomal DNA replication. In vitro, DnaB helicase stimulates primase to synthesize primers on single-stranded (ss) oligonucleotide templates. Earlier studies hypothesized that multiple primase molecules interact with each DnaB hexamer and single-stranded DNA. We have examined this hypothesis and determined the exact stoichiometry of primase to DnaB hexamer. We have also demonstrated that ssDNA binding activity of the DnaB helicase is necessary for directing the primase to the initiator trinucleotide and synthesis of 11-20-nucleotide long primers. Although, association of these two enzymes determines the extent and rate of synthesis of the RNA primers in vitro, direct evidence of the formation of primase-DnaB complex has remained elusive in E. coli due to the transient nature of their interaction. Therefore, we stabilized this complex using a chemical crosslinker and carried out a stoichiometric analysis of this complex by gel filtration. This allowed us to demonstrate that the primase-helicase complex of E. coli is comprised of three molecules of primase bound to one DnaB hexamer. Fluorescence anisotropy studies of the interaction of DnaB with primase, labeled with the fluorescent probe Ru(bipy)(3), and Scatchard analysis further supported this conclusion. The addition of DnaC protein, leading to the formation of the DnaB-DnaC complex, to the simple priming system resulted in the synthesis of shorter primers. Therefore, interactions of the DnaB-primase complex with other replication factors might be critical for determining the physiological length of the RNA primers in vivo and the overall kinetics of primer synthesis.	Univ Med & Dent New Jersey, Sch Osteopath Med, Dept Mol Biol, Stratford, NJ 08084 USA	Rowan University; Rowan University School of Osteopathic Medicine; Rutgers State University New Brunswick; Rutgers State University Medical Center	Biswas, SB (corresponding author), Univ Med & Dent New Jersey, Sch Osteopath Med, Dept Mol Biol, Stratford, NJ 08084 USA.	biswassb@umdnj.edu						Ackermann M, 2001, J BIOL CHEM, V276, P39926, DOI 10.1074/jbc.M104248200; ARAI K, 1981, J BIOL CHEM, V256, P5247; Arezi B, 2000, TRENDS BIOCHEM SCI, V25, P572, DOI 10.1016/S0968-0004(00)01680-7; Barcena M, 2001, EMBO J, V20, P1462, DOI 10.1093/emboj/20.6.1462; BERNSTEIN JA, 1989, J BIOL CHEM, V264, P13066; Bhattacharyya S, 2000, BIOCHEMISTRY-US, V39, P745, DOI 10.1021/bi991555d; Bird LE, 2000, BIOCHEMISTRY-US, V39, P171, DOI 10.1021/bi9918801; BISWAS EE, 1986, BIOCHEMISTRY-US, V25, P7368, DOI 10.1021/bi00371a019; Biswas EE, 1999, BIOCHEMISTRY-US, V38, P10919, DOI 10.1021/bi990048t; BISWAS SB, 1987, J BIOL CHEM, V262, P7831; BOUCHE JP, 1975, J BIOL CHEM, V250, P5995; BRAMHILL D, 1988, CELL, V52, P743, DOI 10.1016/0092-8674(88)90412-6; BUJALOWSKI W, 1994, BIOCHEMISTRY-US, V33, P4682, DOI 10.1021/bi00181a028; Chang P, 2000, J BIOL CHEM, V275, P26187, DOI 10.1074/jbc.M001800200; CONAWAY RC, 1982, P NATL ACAD SCI-BIOL, V79, P2523, DOI 10.1073/pnas.79.8.2523; denBlaauwen T, 1997, FEBS LETT, V416, P35, DOI 10.1016/S0014-5793(97)01142-3; Donate LE, 2000, J MOL BIOL, V303, P383, DOI 10.1006/jmbi.2000.4132; Fiorentini P, 1997, MOL CELL BIOL, V17, P2764, DOI 10.1128/MCB.17.5.2764; Flowers S, 2003, BIOCHEMISTRY-US, V42, P1910, DOI 10.1021/bi025992v; FULLER RS, 1983, P NATL ACAD SCI-BIOL, V80, P5817, DOI 10.1073/pnas.80.19.5817; FUNNELL BE, 1986, J BIOL CHEM, V261, P5616; FUNNELL BE, 1987, J BIOL CHEM, V262, P10327; Goodman MF, 2000, TRENDS BIOCHEM SCI, V25, P189, DOI 10.1016/S0968-0004(00)01564-4; Goodman MF, 2002, ANNU REV BIOCHEM, V71, P17, DOI 10.1146/annurev.biochem.71.083101.124707; Hiasa H, 1999, J BIOL CHEM, V274, P27244, DOI 10.1074/jbc.274.38.27244; Johnson SK, 2000, BIOCHEMISTRY-US, V39, P736, DOI 10.1021/bi991554l; Kaguni JM, 1997, MOL CELLS, V7, P145; KASPRZAK AA, 1988, BIOCHEMISTRY-US, V27, P8050, DOI 10.1021/bi00421a012; Khopde S, 2002, BIOCHEMISTRY-US, V41, P14820, DOI 10.1021/bi026711m; KITANI T, 1985, J MOL BIOL, V184, P45, DOI 10.1016/0022-2836(85)90042-7; KOBORI JA, 1982, J BIOL CHEM, V257, P13763; Konieczny I, 1997, P NATL ACAD SCI USA, V94, P14378, DOI 10.1073/pnas.94.26.14378; KORNBERG A, 1992, DNA REPLICATION, P275; LOHMAN TM, 1981, J MOL BIOL, V152, P67, DOI 10.1016/0022-2836(81)90096-6; Lu YB, 1996, P NATL ACAD SCI USA, V93, P12902, DOI 10.1073/pnas.93.23.12902; Ludlam AV, 2001, J BIOL CHEM, V276, P27345, DOI 10.1074/jbc.M101940200; MARIANS KJ, 1992, ANNU REV BIOCHEM, V61, P673, DOI 10.1146/annurev.bi.61.070192.003325; MARSZALEK J, 1994, J BIOL CHEM, V269, P4883; MATSON SW, 1991, PROG NUCLEIC ACID RE, V40, P289; Matson SW, 2003, NAT STRUCT BIOL, V10, P499, DOI 10.1038/nsb0703-499; MCMACKEN R, 1977, P NATL ACAD SCI USA, V74, P4190, DOI 10.1073/pnas.74.10.4190; MESSER W, 1996, ESCHERICHIA COLI SAL, V2, P1579; NAKAYAMA N, 1984, J BIOL CHEM, V259, P88; NAKAYAMA N, 1984, J BIOL CHEM, V259, P97; OGAWA T, 1980, ANNU REV BIOCHEM, V49, P421, DOI 10.1146/annurev.bi.49.070180.002225; Ramirez-Aguilar KA, 2002, BIOCHEMISTRY-US, V41, P14569, DOI 10.1021/bi026680v; REHAKRANTZ LJ, 1978, J BIOL CHEM, V253, P4051; SANMARTIN MC, 1995, J STRUCT BIOL, V114, P167, DOI 10.1006/jsbi.1995.1016; Stephens KM, 1997, J BIOL CHEM, V272, P28800, DOI 10.1074/jbc.272.45.28800; Swart JR, 1995, BIOCHEMISTRY-US, V34, P16097, DOI 10.1021/bi00049a025; Tougu K, 1996, J BIOL CHEM, V271, P21391, DOI 10.1074/jbc.271.35.21391; TOUGU K, 1994, J BIOL CHEM, V269, P4675; VANDERENDE A, 1985, P NATL ACAD SCI USA, V82, P3954; Vanloock MS, 2001, J MOL BIOL, V311, P951, DOI 10.1006/jmbi.2001.4932; WICKNER S, 1975, P NATL ACAD SCI USA, V72, P921, DOI 10.1073/pnas.72.3.921; WU CA, 1992, J BIOL CHEM, V267, P4030; YODA K, 1991, MOL GEN GENET, V227, P1, DOI 10.1007/BF00260698; ZECHNER EL, 1992, J BIOL CHEM, V267, P4045; Zhu Q, 2001, P NATL ACAD SCI USA, V98, P9766, DOI 10.1073/pnas.171579898	59	56	59	2	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52253	52261		10.1074/jbc.M308956200	http://dx.doi.org/10.1074/jbc.M308956200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14557266	hybrid			2022-12-27	WOS:000187480700034
J	Poulin, F; Brueschke, A; Sonenberg, N				Poulin, F; Brueschke, A; Sonenberg, N			Gene fusion and overlapping reading frames in the mammalian genes for 4E-BP3 and MASK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAP-DEPENDENT TRANSLATION; 4E-BINDING PROTEIN-1; INITIATION; PHOSPHORYLATION; INHIBITOR; BINDING; CLEAVAGE; KINASE	4E-BP3 is a member of the eukaryotic initiation factor (eIF) 4F-binding protein family of translational repressors. eIF4E-binding proteins (4E-BPs) inhibit translation initiation by sequestering eIF4E, the cap-binding protein, from eIF4G thus preventing ribosome recruitment to the mRNA. Previous analysis of 4E-BP3 expression uncovered an 8.5-kb mRNA variant of unknown origin. To study this splice variant, we determined the structure of the genomic locus encoding human 4E-BP3 (EIF4EBP3). EIF4EBP3 is located on human chromosome 5q31.3 and comprises three exons (A, B, and C) and two introns. Exon B contains the region of the open reading frame responsible for eIF4E binding. GenBank(TM) searches revealed multiple expressed sequence tags originating from the alternative splicing of exon B with unidentified upstream exons. Further studies revealed that the 8.5-kb transcript arises from the fusion of EIF4EBP3 with the mammalian homologue of Drosophila MASK ( multiple ankyrin repeats, single KH domain), which is crucial for photoreceptor differentiation, cell survival, and proliferation. Surprisingly, the open reading frame of the MASK-BP3 transcript is different from that of 4E-BP3, which indicates that exon B is translated using an alternative reading frame. A gene fusion similar to that of MASK and EIF4EBP3 has been reported only once in mammals for the UEV1-Kua transcript. The use of an alternative reading frame is also very rare, having been described for two loci, INK4a/ARF and XLalphas/ALEX. The simultaneous exploitation of both mechanisms underscores the flexibility of mammalian genomes and has important implications for the functional analysis of 4E-BP3 and MASK. Interestingly, both eIF4E and MASK are downstream effectors of the Ras/MAPK pathway, which provides a rationale for the MASK-BP3 fusion in mammals.	McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; McGill Univ, McGill Canc Ctr, Montreal, PQ H3G 1Y6, Canada	McGill University; McGill University	Sonenberg, N (corresponding author), McGill Univ, Dept Biochem, 3655 Promenade Sir William Osler,Rm 807, Montreal, PQ H3G 1Y6, Canada.	nahum.sonenberg@mcgill.ca						Beretta L, 1996, J VIROL, V70, P8993, DOI 10.1128/JVI.70.12.8993-8996.1996; Enright AJ, 1999, NATURE, V402, P86, DOI 10.1038/47056; Enright AJ, 2001, GENOME BIOL, V2; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Gingras AC, 2001, GENE DEV, V15, P2852; Gingras AC, 1999, GENE DEV, V13, P1422, DOI 10.1101/gad.13.11.1422; Gingras AC, 1998, GENE DEV, V12, P502, DOI 10.1101/gad.12.4.502; HAGHIGHAT A, 1995, EMBO J, V14, P5701, DOI 10.1002/j.1460-2075.1995.tb00257.x; Horoszewicz J S, 1980, Prog Clin Biol Res, V37, P115; Kleijn M, 2002, FEBS LETT, V532, P319, DOI 10.1016/S0014-5793(02)03694-3; Klemke M, 2001, EMBO J, V20, P3849, DOI 10.1093/emboj/20.14.3849; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; Marcotrigiano J, 1999, MOL CELL, V3, P707, DOI 10.1016/S1097-2765(01)80003-4; Marcotte EM, 1999, SCIENCE, V285, P751, DOI 10.1126/science.285.5428.751; Mathews MB, 2000, COLD SPRING HARBOR M, V39, P1; Moran JV, 1999, SCIENCE, V283, P1530, DOI 10.1126/science.283.5407.1530; Ohlmann T, 1997, EMBO J, V16, P844, DOI 10.1093/emboj/16.4.844; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Poulin F, 2003, MOL B INT U, P280; Poulin F, 1998, J BIOL CHEM, V273, P14002, DOI 10.1074/jbc.273.22.14002; QUELLE DE, 1995, CELL, V83, P993; Raught B, 2000, COLD SPRING HARBOR M, V39, P245; Raught B, 1999, INT J BIOCHEM CELL B, V31, P43, DOI 10.1016/S1357-2725(98)00131-9; Schalm SS, 2002, CURR BIOL, V12, P632, DOI 10.1016/S0960-9822(02)00762-5; SHATKIN AJ, 1985, CELL, V40, P223, DOI 10.1016/0092-8674(85)90132-1; Smith RK, 2002, DEVELOPMENT, V129, P71; Tee AR, 2002, MOL CELL BIOL, V22, P1674, DOI 10.1128/MCB.22.6.1674-1683.2002; Thomson TM, 2000, GENOME RES, V10, P1743, DOI 10.1101/gr.GR-1405R; Tsukiyama-Kohara K, 2001, NAT MED, V7, P1128, DOI 10.1038/nm1001-1128; TsukiyamaKohara K, 1996, GENOMICS, V38, P353, DOI 10.1006/geno.1996.0638; Wang XM, 2003, MOL CELL BIOL, V23, P1546, DOI 10.1128/MCB.23.5.1546-1557.2003	32	47	49	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52290	52297		10.1074/jbc.M310761200	http://dx.doi.org/10.1074/jbc.M310761200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14557257	Green Published, hybrid			2022-12-27	WOS:000187480700038
J	Wajapeyee, N; Somasundaram, K				Wajapeyee, N; Somasundaram, K			Cell cycle arrest and apoptosis induction by activator protein 2 alpha (AP-2 alpha) and the role of p53 and p21(WAF1/CIP1) in AP-2 alpha-mediated growth inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR AP-2; DNA-BINDING; TUMOR-GROWTH; DOWN-REGULATION; GENE; EXPRESSION; ACTIVATION; CLONING; TRANSACTIVATION; IDENTIFICATION	Activator protein 2alpha (AP-2alpha) is a sequence-specific DNA-binding transcription factor implicated in differentiation and transformation. In this study, we have made a replication-deficient recombinant adenovirus that expresses functional AP-2alpha (Ad-AP2). Cells infected with Ad-AP2 expressed induced levels of AP-2alpha protein, which bound to DNA in a sequence-specific manner and activated the AP-2-specific reporter 3X-AP2. Expression of AP-2alpha from Ad-AP2 inhibited cellular DNA synthesis and induced apoptosis. Ad-AP2 infection resulted in efficient inhibition of growth of cancer cells of six different types. In addition, prior expression of AP-2alpha increased the chemosensitivity of H460, a lung carcinoma cell line, to adriamycin (2.5-fold) and cisplatin (5-fold). Furthermore, the growth inhibition by AP-2alpha was found to be less efficient in the absence of p53 or p21, which correlated with reduced apoptosis in p53 null cells and lack of DNA synthesis inhibition in p21(WAF1/CIP1) null cells by AP-2alpha, respectively. These results suggest that AP-2alpha inhibits the growth of cells by inducing cell cycle arrest and apoptosis and that the use of AP-2alpha should be explored as a therapeutic strategy either alone or in combination with chemotherapy.	Indian Inst Sci, Dept Microbiol & Cell Biol, Bangalore 560012, Karnataka, India	Indian Institute of Science (IISC) - Bangalore	Somasundaram, K (corresponding author), Indian Inst Sci, Dept Microbiol & Cell Biol, Bangalore 560012, Karnataka, India.	skumar@mcbl.iisc.ernet.in	Wajapeyee, Narendra/F-3011-2012					Bar-Eli M, 2001, PIGM CELL RES, V14, P78, DOI 10.1034/j.1600-0749.2001.140202.x; Bar-Eli M, 1999, CANCER METAST REV, V18, P377, DOI 10.1023/A:1006377309524; Blagosklonny MV, 1996, INT J CANCER, V67, P386, DOI 10.1002/(SICI)1097-0215(19960729)67:3<386::AID-IJC13>3.0.CO;2-6; BOSHER JM, 1995, P NATL ACAD SCI USA, V92, P744, DOI 10.1073/pnas.92.3.744; Bosher JM, 1996, ONCOGENE, V13, P1701; BUETTNER R, 1993, MOL CELL BIOL, V13, P4174, DOI 10.1128/MCB.13.7.4174; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; BYRNE C, 1994, DEVELOPMENT, V120, P2369; CARMICHAEL J, 1987, CANCER RES, V47, P936; Chazaud C, 1996, MECH DEVELOP, V54, P83, DOI 10.1016/0925-4773(95)00463-7; Das S, 2003, J BIOL CHEM, V278, P18313, DOI 10.1074/jbc.M211704200; DAS S, 2003, IN PRESS ONCOGENE; DECLERCK YA, 1994, GENE, V139, P185, DOI 10.1016/0378-1119(94)90753-6; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FINI ME, 1994, J BIOL CHEM, V269, P28620; GAUBATZ S, 1995, EMBO J, V14, P1508, DOI 10.1002/j.1460-2075.1995.tb07137.x; Gee JMW, 1999, J PATHOL, V189, P514, DOI 10.1002/(SICI)1096-9896(199912)189:4<514::AID-PATH463>3.0.CO;2-9; Gershenwald JE, 2001, ONCOGENE, V20, P3363, DOI 10.1038/sj.onc.1204450; Gille J, 1997, EMBO J, V16, P750, DOI 10.1093/emboj/16.4.750; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hennig G, 1996, J BIOL CHEM, V271, P595, DOI 10.1074/jbc.271.1.595; Huang S, 1998, EMBO J, V17, P4358, DOI 10.1093/emboj/17.15.4358; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; Jean D, 1998, J BIOL CHEM, V273, P16501, DOI 10.1074/jbc.273.26.16501; KANNAN F, 1994, GENE DEV, V8, P1258, DOI 10.1101/gad.8.11.1258; Karjalainen JM, 1998, J CLIN ONCOL, V16, P3584, DOI 10.1200/JCO.1998.16.11.3584; McPherson LA, 1999, NUCLEIC ACIDS RES, V27, P4040, DOI 10.1093/nar/27.20.4040; McPherson LA, 1997, P NATL ACAD SCI USA, V94, P4342, DOI 10.1073/pnas.94.9.4342; McPherson LA, 2002, J BIOL CHEM, V277, P45028, DOI 10.1074/jbc.M208924200; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; Mohibullah N, 1999, NUCLEIC ACIDS RES, V27, P2760, DOI 10.1093/nar/27.13.2760; MOSER M, 1995, DEVELOPMENT, V121, P2779; Ropponen KM, 2001, J CLIN PATHOL, V54, P533, DOI 10.1136/jcp.54.7.533; Ropponen KM, 1999, BRIT J CANCER, V81, P133, DOI 10.1038/sj.bjc.6690662; Roth Jack A, 2003, Methods Mol Biol, V223, P577; Schorle H, 1996, NATURE, V381, P235, DOI 10.1038/381235a0; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Somasundaram K, 1999, ONCOGENE, V18, P6605, DOI 10.1038/sj.onc.1203284; Somasundaram K, 1996, P NATL ACAD SCI USA, V93, P3088, DOI 10.1073/pnas.93.7.3088; Somasundaram K, 1997, ONCOGENE, V14, P1047, DOI 10.1038/sj.onc.1201002; Somasundaram Kumaravel, 2003, Methods Mol Biol, V223, P101; WALDMAN T, 1995, CANCER RES, V55, P5187; WILLIAMS T, 1991, SCIENCE, V251, P1067, DOI 10.1126/science.1998122; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78; Zhang J, 2003, DEV BIOL, V256, P127, DOI 10.1016/S0012-1606(02)00119-7; Zhang JA, 1996, NATURE, V381, P238, DOI 10.1038/381238a0; Zhao F, 2001, J BIOL CHEM, V276, P40755, DOI 10.1074/jbc.M106284200; ZUTTER MM, 1994, J BIOL CHEM, V269, P463	50	82	88	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52093	52101		10.1074/jbc.M305624200	http://dx.doi.org/10.1074/jbc.M305624200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14551210	hybrid			2022-12-27	WOS:000187480700016
J	Feigelson, SW; Grabovsky, V; Shamri, R; Levy, S; Alon, R				Feigelson, SW; Grabovsky, V; Shamri, R; Levy, S; Alon, R			The CD81 tetraspanin facilitates instantaneous leukocyte VLA-4 adhesion strengthening to vascular cell adhesion molecule 1 (VCAM-1) under shear flow	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; INTEGRIN ACTIVATION; T-CELLS; ALPHA-4 INTEGRIN; MAJOR CD9; BINDING; LFA-1; SUPERFAMILY; COMPLEXES; LIGAND	Leukocyte integrins must rapidly strengthen their binding to target endothelial sites to arrest rolling adhesions under physiological shear flow. We demonstrate that the integrin-associated tetraspanin, CD81, regulates VLA-4 and VLA-5 adhesion strengthening in monocytes and primary murine B cells. CD81 strengthens multivalent VLA-4 contacts within subsecond integrin occupancy without altering intrinsic adhesive properties to low density ligand. CD81 facilitates both VLA-4-mediated leukocyte rolling and arrest on VCAM-1 under shear flow as well as VLA-5-dependent adhesion to fibronectin during short stationary contacts. CD81 also augments VLA-4 avidity enhancement induced by either chemokine-stimulated G(i) proteins or by protein kinase C activation, although it is not required for Gi protein or protein kinase C signaling activities. In contrast to other proadhesive integrin-associated proteins, CD81-promoted integrin adhesiveness does not require its own ligand occupancy or ligation. These results provide the first demonstration of an integrin-associated trans-membranal protein that facilitates instantaneous multivalent integrin occupancy events that promote leukocyte adhesion to an endothelial ligand under shear flow.	Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel; Stanford Univ, Dept Oncol, Stanford, CA 94305 USA	Weizmann Institute of Science; Stanford University	Alon, R (corresponding author), Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel.		ALON, RONEN/GRX-6987-2022	Alon, Ronen/0000-0001-9161-6369				ALON R, 1995, J CELL BIOL, V128, P1243, DOI 10.1083/jcb.128.6.1243; Alon R, 2002, SEMIN IMMUNOL, V14, P93, DOI 10.1006/smim.2001.0346; BAKER BW, 1992, NUCLEIC ACIDS RES, V20, P5234, DOI 10.1093/nar/20.19.5234; BARGATZE RF, 1993, J EXP MED, V178, P367, DOI 10.1084/jem.178.1.367; BEHR S, 1995, J EXP MED, V182, P1191, DOI 10.1084/jem.182.5.1191; Berditchevski F, 1997, J BIOL CHEM, V272, P2595, DOI 10.1074/jbc.272.5.2595; Berditchevski F, 1996, MOL BIOL CELL, V7, P193, DOI 10.1091/mbc.7.2.193; BERLIN C, 1995, CELL, V80, P413, DOI 10.1016/0092-8674(95)90491-3; Besson A, 2002, J BIOL CHEM, V277, P22073, DOI 10.1074/jbc.M111644200; Boucheix C, 2001, CELL MOL LIFE SCI, V58, P1189, DOI 10.1007/PL00000933; Charrin S, 2001, J BIOL CHEM, V276, P14329, DOI 10.1074/jbc.M011297200; Constantin G, 2000, IMMUNITY, V13, P759, DOI 10.1016/S1074-7613(00)00074-1; Deng J, 2000, J IMMUNOL, V165, P5054, DOI 10.4049/jimmunol.165.9.5054; Dwir O, 2000, J BIOL CHEM, V275, P18682, DOI 10.1074/jbc.M001103200; Feigelson S, 2001, J BIOL CHEM, V276, P13891, DOI 10.1074/jbc.M004939200; Fenczik CA, 1997, NATURE, V390, P81, DOI 10.1038/36349; Ganju RK, 1998, J BIOL CHEM, V273, P23169, DOI 10.1074/jbc.273.36.23169; Grabovsky V, 2000, J EXP MED, V192, P495, DOI 10.1084/jem.192.4.495; Hemler ME, 2001, J CELL BIOL, V155, P1103, DOI 10.1083/jcb.200108061; Hemler ME, 1998, CURR OPIN CELL BIOL, V10, P578, DOI 10.1016/S0955-0674(98)80032-X; Henderson RB, 2001, J EXP MED, V194, P219, DOI 10.1084/jem.194.2.219; JAKUBOWSKI A, 1995, CELL ADHES COMMUN, V3, P131, DOI 10.3109/15419069509081282; Jirousek MR, 1996, J MED CHEM, V39, P2664, DOI 10.1021/jm950588y; KAMATA T, 1995, BIOCHEM J, V305, P945, DOI 10.1042/bj3050945; KASSNER PD, 1995, MOL BIOL CELL, V6, P661, DOI 10.1091/mbc.6.6.661; KOLESNIKOVA TV, 2002, FASEB C ADV TETR RES; Kucik DF, 1996, J CLIN INVEST, V97, P2139, DOI 10.1172/JCI118651; Lammerding J, 2003, P NATL ACAD SCI USA, V100, P7616, DOI 10.1073/pnas.1337546100; LI JX, 1992, CELL, V70, P791, DOI 10.1016/0092-8674(92)90312-Z; Lin KC, 1999, J MED CHEM, V42, P920, DOI 10.1021/jm980673g; LITCHFIELD DW, 1986, BIOCHEM BIOPH RES CO, V134, P1276, DOI 10.1016/0006-291X(86)90388-8; Liu L, 2002, J BIOL CHEM, V277, P40893, DOI 10.1074/jbc.M206208200; Lub M, 1997, MOL BIOL CELL, V8, P341, DOI 10.1091/mbc.8.2.341; Maecker HT, 1997, J EXP MED, V185, P1505, DOI 10.1084/jem.185.8.1505; Maecker HT, 1997, FASEB J, V11, P428, DOI 10.1096/fasebj.11.6.9194523; Mannion BA, 1996, J IMMUNOL, V157, P2039; Porter JC, 1998, TRENDS CELL BIOL, V8, P390, DOI 10.1016/S0962-8924(98)01344-0; RON D, 1995, J BIOL CHEM, V270, P24180, DOI 10.1074/jbc.270.41.24180; RUBINSTEIN E, 1994, EUR J IMMUNOL, V24, P3005, DOI 10.1002/eji.1830241213; Sebzda E, 2002, NAT IMMUNOL, V3, P251, DOI 10.1038/ni765; Serru V, 1999, BIOCHEM J, V340, P103, DOI 10.1042/0264-6021:3400103; Shibagaki N, 1999, EUR J IMMUNOL, V29, P4081, DOI 10.1002/(SICI)1521-4141(199912)29:12<4081::AID-IMMU4081>3.3.CO;2-9; Shimaoka M, 2003, CELL, V112, P99, DOI 10.1016/S0092-8674(02)01257-6; Sigal A, 2000, J IMMUNOL, V165, P442, DOI 10.4049/jimmunol.165.1.442; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Stipp CS, 2001, J BIOL CHEM, V276, P40545, DOI 10.1074/jbc.M107338200; Stipp CS, 2001, J BIOL CHEM, V276, P4853, DOI 10.1074/jbc.M009859200; Takagi J, 2002, CELL, V110, P599, DOI 10.1016/S0092-8674(02)00935-2; Ticchioni M, 2001, FASEB J, V15, P341, DOI 10.1096/fj.99-0833com; Todd SC, 1996, J EXP MED, V184, P2055, DOI 10.1084/jem.184.5.2055; VanCompernolle SE, 2001, EUR J IMMUNOL, V31, P823, DOI 10.1002/1521-4141(200103)31:3<823::AID-IMMU823>3.3.CO;2-4; Xiong JP, 2002, SCIENCE, V296, P151, DOI 10.1126/science.1069040; YAUCH RL, 1997, J EXP MED, V186, P1; Yue LL, 1999, J CELL PHYSIOL, V181, P355, DOI 10.1002/(SICI)1097-4652(199911)181:2<355::AID-JCP17>3.0.CO;2-B; Zhang XA, 2001, J BIOL CHEM, V276, P25005, DOI 10.1074/jbc.M102156200; Zhou XM, 2000, J BIOL CHEM, V275, P20217, DOI 10.1074/jbc.M909129199; Zhou XM, 2001, J BIOL CHEM, V276, P44762, DOI 10.1074/jbc.M104029200	57	78	81	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51203	51212		10.1074/jbc.M303601200	http://dx.doi.org/10.1074/jbc.M303601200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14532283	hybrid			2022-12-27	WOS:000187206300046
J	Hoshiya, Y; Gupta, V; Kawakubo, H; Brachtel, E; Carey, JL; Sasur, L; Scott, A; Donahoe, PK; Maheswaran, S				Hoshiya, Y; Gupta, V; Kawakubo, H; Brachtel, E; Carey, JL; Sasur, L; Scott, A; Donahoe, PK; Maheswaran, S			Mullerian inhibiting substance promotes interferon gamma-induced gene expression and apoptosis in breast cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATORY FACTOR-I; BILIARY GLYCOPROTEIN CD66A; KAPPA-B; ADHESION MOLECULE; TRANSCRIPTIONAL ACTIVATION; EPITHELIAL-CELLS; IL-12/PULSE IL-2; IRF FAMILY; IFN-GAMMA; LONG ARM	This report demonstrates that in addition to interferons and cytokines, members of the TGFbeta superfamily such as Mullerian inhibiting substance (MIS) and activin A also regulate IRF-1 expression. MIS induced IRF-1 expression in the mammary glands of mice in vivo and in breast cancer cells in vitro and stimulation of IRF-1 by MIS was dependent on activation of the NFkappaB pathway. In the rat mammary gland, IRF-1 expression gradually decreased during pregnancy and lactation but increased at involution. In breast cancer, the IRF-1 protein was absent in 13% of tumors tested compared with matched normal glands. Consistent with its growth suppressive activity, expression of IRF-1 in breast cancer cells induced apoptosis. Treatment of breast cancer cells with MIS and interferon gamma (IFN-gamma) co-stimulated IRF-1 and CEACAM1 expression and synergistic induction of CEACAM1 by a combination of MIS and IFN-gamma was impaired by antisense IRF-1 expression. Furthermore, a combination of IFN-gamma and MIS inhibited the growth of breast cancer cells to a greater extent than either one alone. Both reagents alone significantly decreased the fraction of cells in the S-phase of the cell cycle, an effect not enhanced when they were used in combination. However, MIS promoted IFN-gamma-induced apoptosis demonstrating a functional interaction between these two classes of signaling molecules in regulation of breast cancer cell growth.	Massachusetts Gen Hosp, Pediat Surg Res Labs, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Maheswaran, S (corresponding author), Massachusetts Gen Hosp, Pediat Surg Res Labs, WRN 1024,55 Fruit St, Boston, MA 02114 USA.	maheswaran@helix.mgh.harvard.edu	Madore, Laura/AAE-9127-2020		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD032112] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA089138, R01CA017393] Funding Source: NIH RePORTER; NCI NIH HHS [CA17393, CA89138-01A1] Funding Source: Medline; NICHD NIH HHS [HD32112] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Blanco JCG, 2000, J EXP MED, V191, P2131, DOI 10.1084/jem.191.12.2131; Borden EC, 2000, SEMIN CANCER BIOL, V10, P125, DOI 10.1006/scbi.2000.0315; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Brunda MJ, 1996, CANCER CHEMOTH PHARM, V38, pS16, DOI 10.1007/s002800051031; BRUNDA MJ, 1995, J IMMUNOTHER, V17, P71, DOI 10.1097/00002371-199502000-00001; Brunda MJ, 1996, ANN NY ACAD SCI, V795, P266, DOI 10.1111/j.1749-6632.1996.tb52676.x; Chapman RS, 2000, ONCOGENE, V19, P6386, DOI 10.1038/sj.onc.1204016; Chen CJ, 1996, J BIOL CHEM, V271, P28181, DOI 10.1074/jbc.271.45.28181; CHEUNG PH, 1993, J BIOL CHEM, V268, P6139; Cifaldi L, 2001, CANCER RES, V61, P2809; Doherty GM, 2001, ANN SURG, V233, P623, DOI 10.1097/00000658-200105000-00005; Eklund EA, 1998, J BIOL CHEM, V273, P13957, DOI 10.1074/jbc.273.22.13957; Gollob JA, 2000, CLIN CANCER RES, V6, P1678; GUSTAFSON ML, 1992, NEW ENGL J MED, V326, P466, DOI 10.1056/NEJM199202133260707; Ha TU, 2000, J BIOL CHEM, V275, P37101, DOI 10.1074/jbc.M005701200; HABIF DV, 1995, CANCER INVEST, V13, P165, DOI 10.3109/07357909509011686; Hadden JW, 1999, INT J IMMUNOPHARMACO, V21, P79, DOI 10.1016/S0192-0561(98)00077-0; Haus Olga, 2000, Archivum Immunologiae et Therapiae Experimentalis, V48, P95; HOSHIYA Y, 2003, MOL CELL ENDOCRINOL; HSIEH JT, 1995, CANCER RES, V55, P190; Huang J, 1998, ANTICANCER RES, V18, P3203; Huang J, 1999, J CELL SCI, V112, P4193; Kalvakolanu DV, 2000, HISTOL HISTOPATHOL, V15, P523, DOI 10.14670/HH-15.523; Kirchhoff S, 1999, ONCOGENE, V18, P3725, DOI 10.1038/sj.onc.1202704; KURIAN MS, 1995, CLIN CANCER RES, V1, P343; Luo WP, 1999, CANCER GENE THER, V6, P313, DOI 10.1038/sj.cgt.7700055; Luo WP, 1997, ONCOGENE, V14, P1697, DOI 10.1038/sj.onc.1200999; Marecki S, 2001, J IMMUNOL, V166, P6829, DOI 10.4049/jimmunol.166.11.6829; MARTIN E, 1994, J EXP MED, V180, P977, DOI 10.1084/jem.180.3.977; Miyazaki M, 1998, BIOCHEM BIOPH RES CO, V246, P873, DOI 10.1006/bbrc.1998.8712; Nozawa H, 1998, INT J CANCER, V77, P522, DOI 10.1002/(SICI)1097-0215(19980812)77:4<522::AID-IJC8>3.0.CO;2-W; Ogasawara K, 1998, NATURE, V391, P700, DOI 10.1038/35636; Ogasawara S, 1996, GASTROENTEROLOGY, V110, P52, DOI 10.1053/gast.1996.v110.pm8536888; Ohmori Y, 1997, J BIOL CHEM, V272, P14899, DOI 10.1074/jbc.272.23.14899; OZZELLO L, 1990, BREAST CANCER RES TR, V16, P89, DOI 10.1007/BF01809292; RAGIN RC, 1992, PROTEIN EXPRES PURIF, V3, P236, DOI 10.1016/1046-5928(92)90020-W; Riethdorf L, 1997, J HISTOCHEM CYTOCHEM, V45, P957, DOI 10.1177/002215549704500705; Romeo G, 2002, J INTERF CYTOK RES, V22, P39, DOI 10.1089/107999002753452647; Ruiz-Ruiz C, 2000, CANCER RES, V60, P5673; Segev DL, 2000, J BIOL CHEM, V275, P28371, DOI 10.1074/jbc.M004554200; Segev DL, 2001, J BIOL CHEM, V276, P26799, DOI 10.1074/jbc.M103092200; SIMS SH, 1993, MOL CELL BIOL, V13, P690, DOI 10.1128/MCB.13.1.690; SOULE HD, 1990, CANCER RES, V50, P6075; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; STRANDER H, 1986, ADV CANCER RES, V46, pR9; Tamura G, 1996, CANCER RES, V56, P612; Tanaka N, 2000, SEMIN CANCER BIOL, V10, P73, DOI 10.1006/scbi.2000.0310; Taniguchi T, 2002, CURR OPIN IMMUNOL, V14, P111, DOI 10.1016/S0952-7915(01)00305-3; Taniguchi T, 2001, ANNU REV IMMUNOL, V19, P623, DOI 10.1146/annurev.immunol.19.1.623; TANIGUCHI T, 1997, BIOCHIM BIOPHYS ACTA, V1333, P9; Teixeira J, 2001, ENDOCR REV, V22, P657, DOI 10.1210/er.22.5.657; Tendler DS, 2001, CANCER RES, V61, P3682; THOMPSON J, 1992, GENOMICS, V12, P761, DOI 10.1016/0888-7543(92)90307-E; THOMPSON NL, 1994, PATHOBIOLOGY, V62, P209, DOI 10.1159/000163912; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; WADLER S, 1990, CANCER RES, V50, P3473; Wigginton JM, 2001, J IMMUNOL, V166, P1156, DOI 10.4049/jimmunol.166.2.1156; Wigginton JM, 2001, J CLIN INVEST, V108, P51; WILLMAN CL, 1993, SCIENCE, V259, P968, DOI 10.1126/science.8438156; Zhu W, 2002, J BIOL CHEM, V277, P35787, DOI 10.1074/jbc.C200346200	60	25	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51703	51712		10.1074/jbc.M307626200	http://dx.doi.org/10.1074/jbc.M307626200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14532292	hybrid			2022-12-27	WOS:000187206300105
J	Wietek, C; Miggin, SM; Jefferies, CA; O'Neill, LAJ				Wietek, C; Miggin, SM; Jefferies, CA; O'Neill, LAJ			Interferon regulatory factor-3-mediated activation of the interferon-sensitive response element by toll-like receptor (TLR) 4 but not TLR3 requires the p65 subunit of NF-kappa B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; IFN-BETA; SIGNALING PATHWAYS; ADAPTER MOLECULE; GENE-EXPRESSION; TRANSCRIPTIONAL ACTIVATION; ANTIVIRAL RESPONSE; VIRUS-INFECTION; IN-VIVO; FACTOR-3	Interferon regulatory factor ( IRF) 3 is a transcription factor that binds the interferon- sensitive response element ( ISRE) and is activated by Toll- like receptor 3 ( TLR3) and TLR4. We have found that a dominant negative form of I kappa B kinase 2 and a mutant form of I kappa B, which acts as a super- repressor of NF- kappa B, blocked activation of the ISRE by the TLR4 ligand lipopolysaccharide but not the TLR3 ligand poly( I- C). TLR4 failed to activate the ISRE in mouse embryonic fibroblasts bearing a targeted deletion of p65, whereas the response to TLR3 in these cells was normal. The p65 subunit of NF- kappa B was detected in the lipopolysaccharide- activated but not poly( I- C)- activated ISRE- binding complex. Finally, p65 promoted transactivation of gene expression by IRF- 3. These results therefore indicate that IRF- 3-mediated activation of the ISRE by TLR4 but not TLR3 requires the p65 subunit of NF- kappa B.	Trinity Coll Dublin, Dept Biochem, Dublin, Ireland	Trinity College Dublin	Wietek, C (corresponding author), Trinity Coll Dublin, Dept Biochem, Dublin, Ireland.		Jefferies, Caroline/AAI-1543-2021	Jefferies, Caroline/0000-0002-8879-6722; Miggin, Sinead/0000-0002-3421-3552; O'Neill, Luke/0000-0002-4333-2748				Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; BIN LH, 2003, J BIOL CHEM, V28, P28; Bluyssen Hans A. R., 1996, Cytokine and Growth Factor Reviews, V7, P11, DOI 10.1016/1359-6101(96)00005-6; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Doyle SE, 2003, J IMMUNOL, V170, P3565, DOI 10.4049/jimmunol.170.7.3565; Doyle SE, 2002, IMMUNITY, V17, P251, DOI 10.1016/S1074-7613(02)00390-4; DUNNE A, 2003, SCI STKE; Fitzgerald KA, 2003, NAT IMMUNOL, V4, P491, DOI 10.1038/ni921; Fitzgerald KA, 2001, NATURE, V413, P78, DOI 10.1038/35092578; Fitzgerald KA, 2003, J EXP MED, V198, P1043, DOI 10.1084/jem.20031023; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; Hiroi M, 2003, J BIOL CHEM, V278, P651, DOI 10.1074/jbc.M204544200; Hoebe K, 2003, NATURE, V424, P743, DOI 10.1038/nature01889; Horng T, 2002, NATURE, V420, P329, DOI 10.1038/nature01180; Horng T, 2001, NAT IMMUNOL, V2, P835, DOI 10.1038/ni0901-835; Hoshino K, 2002, INT IMMUNOL, V14, P1225, DOI 10.1093/intimm/dxf089; Hottiger MO, 1998, EMBO J, V17, P3124, DOI 10.1093/emboj/17.11.3124; Huang Q, 2001, SCIENCE, V294, P870, DOI 10.1126/science.294.5543.870; Kawai T, 2001, J IMMUNOL, V167, P5887, DOI 10.4049/jimmunol.167.10.5887; Kim T, 2000, J BIOL CHEM, V275, P16910, DOI 10.1074/jbc.M000524200; KRAVCHENKO VV, 2003, J BIOL CHEM, V6, P6; Lin CH, 2001, MOL CELL, V8, P581, DOI 10.1016/S1097-2765(01)00333-1; Lin RT, 1999, MOL CELL BIOL, V19, P2465; Navarro L, 1999, J BIOL CHEM, V274, P35535, DOI 10.1074/jbc.274.50.35535; Oshiumi H, 2003, NAT IMMUNOL, V4, P161, DOI 10.1038/ni886; OSHIUMI H, 2003, J BIOL CHEM; Peters KL, 2002, P NATL ACAD SCI USA, V99, P6322, DOI 10.1073/pnas.092133199; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Rock FL, 1998, P NATL ACAD SCI USA, V95, P588, DOI 10.1073/pnas.95.2.588; Schafer SL, 1998, J BIOL CHEM, V273, P2714, DOI 10.1074/jbc.273.5.2714; Servant MJ, 2003, J BIOL CHEM, V278, P9441, DOI 10.1074/jbc.M209851200; Servant MJ, 2002, BIOCHEM PHARMACOL, V64, P985, DOI 10.1016/S0006-2952(02)01165-6; Servant MJ, 2001, J BIOL CHEM, V276, P355, DOI 10.1074/jbc.M007790200; Sharma S, 2003, SCIENCE, V300, P1148, DOI 10.1126/science.1081315; Shinobu N, 2002, FEBS LETT, V517, P251, DOI 10.1016/S0014-5793(02)02636-4; Suhara W, 2000, J BIOCHEM-TOKYO, V128, P301, DOI 10.1093/oxfordjournals.jbchem.a022753; Suhara W, 2002, J BIOL CHEM, V277, P22304, DOI 10.1074/jbc.M200192200; Toshchakov V, 2002, NAT IMMUNOL, V3, P392, DOI 10.1038/ni774; Wathelet MG, 1998, MOL CELL, V1, P507, DOI 10.1016/S1097-2765(00)80051-9; Yamaguchi S, 1999, J MOL ENDOCRINOL, V22, P81, DOI 10.1677/jme.0.0220081; Yamamoto M, 2002, NATURE, V420, P324, DOI 10.1038/nature01182; Yamamoto M, 2003, SCIENCE, V301, P640, DOI 10.1126/science.1087262; Yamamoto M, 2002, J IMMUNOL, V169, P6668, DOI 10.4049/jimmunol.169.12.6668; Yoneyama M, 1998, EMBO J, V17, P1087, DOI 10.1093/emboj/17.4.1087	44	98	101	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					50923	50931		10.1074/jbc.M308135200	http://dx.doi.org/10.1074/jbc.M308135200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14557267	hybrid, Green Accepted, Green Published			2022-12-27	WOS:000187206300013
J	Fairlie, WD; Uboldi, AD; McCoubrie, JE; Wang, CXC; Lee, EF; Yao, SG; De Souza, DP; Mifsud, S; Metcalf, D; Nicola, NA; Norton, RS; Baca, M				Fairlie, WD; Uboldi, AD; McCoubrie, JE; Wang, CXC; Lee, EF; Yao, SG; De Souza, DP; Mifsud, S; Metcalf, D; Nicola, NA; Norton, RS; Baca, M			Affinity maturation of leukemia inhibitory factor and conversion to potent antagonists of signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CILIARY NEUROTROPHIC FACTOR; INTERLEUKIN-6 RECEPTOR ANTAGONIST; IMMUNOGLOBULIN-LIKE DOMAIN; MONOVALENT PHAGE DISPLAY; ONCOSTATIN-M; FACTOR LIF; HEMATOPOIETIC-CELLS; BACKBONE DYNAMICS; ESCHERICHIA-COLI; BINDING PEPTIDES	Leukemia inhibitory factor (LIF)-induced cell signaling occurs following sequential binding to the LIF receptor alpha-chain (LIFR), then to the gp130 co-receptor used by all members of the interleukin-6 family of cytokines. By monovalently displaying human LIF on the surface of M13 phage and randomizing clusters of residues in regions predicted to be important for human LIFR binding, we have identified mutations, which lead to significant increases in affinity for binding to LIFR. Six libraries were constructed in which regions of 4 - 6 amino acids were randomized then panned against LIFR. Mutations identified in three distinct clusters, residues 53 - 57, 102 - 103, and 150 - 155, gave rise to proteins with significantly increased affinity for binding to both human and mouse LIFR. Combining the mutations for each of these regions further increased the affinity, such that the best mutants bound to human LIFR with > 1000-fold higher affinity than wild-type human LIF. NMR analysis indicated that the mutations did not alter the overall structure of the molecule relative to the native protein, although some local changes occurred in the vicinity of the substituted residues. Despite increases in LIFR binding affinity, these mutants did not show any increase in activity as agonists of LIF-induced proliferation of Ba/F3 cells expressing human LIFR and gp130 compared with wild-type LIF. Incorporation of two additional mutations ( Q29A and G124R), which were found to abrogate cell signaling, led to the generation of highly potent antagonists of both human and murine LIF-induced bioactivity.	Walter & Eliza Hall Inst Med Res, Parkville, Vic 3050, Australia; Cooperat Res Ctr Cellular Growth Factors, Parkville, Vic 3050, Australia	Walter & Eliza Hall Institute	Baca, M (corresponding author), Walter & Eliza Hall Inst Med Res, 1G Royal Parade, Parkville, Vic 3050, Australia.	baca@wehi.edu.au	Yao, Shenggen/ABH-9989-2020; Lee, Erinna/N-1523-2015; Nicola, Nicos/D-2989-2011; Yao, Shenggen/AAE-1602-2019; De Souza, David P/O-9800-2016; Fairlie, Walter/M-8401-2015	Yao, Shenggen/0000-0002-7137-9615; Lee, Erinna/0000-0003-1255-9808; Nicola, Nicos/0000-0003-1054-7889; De Souza, David P/0000-0002-7225-2632; Fairlie, Walter/0000-0002-2498-1160; Mifsud, Sandra/0000-0002-1010-292X; Norton, Raymond/0000-0001-8893-0584				Ballinger MD, 1998, J BIOL CHEM, V273, P11675, DOI 10.1074/jbc.273.19.11675; BARTELS C, 1995, J BIOMOL NMR, V6, P1, DOI 10.1007/BF00417486; Bitard J, 2003, J BIOL CHEM, V278, P16253, DOI 10.1074/jbc.M207193200; BRAKENHOFF JPJ, 1994, J BIOL CHEM, V269, P86; Bravo J, 2000, EMBO J, V19, P2399, DOI 10.1093/emboj/19.11.2399; Cai LQ, 2000, CYTOKINE, V12, P1676, DOI 10.1006/cyto.2000.0758; DiMarco A, 1996, P NATL ACAD SCI USA, V93, P9247, DOI 10.1073/pnas.93.17.9247; EHLERS M, 1995, J BIOL CHEM, V270, P8158, DOI 10.1074/jbc.270.14.8158; Fairlie WD, 2002, PROTEIN EXPRES PURIF, V26, P171; Fairlie WD, 2003, BIOCHEMISTRY-US, V42, P13193, DOI 10.1021/bi035303v; Farmer BT, 1996, NAT STRUCT BIOL, V3, P995, DOI 10.1038/nsb1296-995; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; GEARING DP, 1994, P NATL ACAD SCI USA, V91, P1119, DOI 10.1073/pnas.91.3.1119; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GEARING DP, 1989, BIO-TECHNOL, V7, P1157; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; HILTON DJ, 1992, TRENDS BIOCHEM SCI, V17, P72, DOI 10.1016/0968-0004(92)90505-4; Hinds MG, 1998, J BIOL CHEM, V273, P13738, DOI 10.1074/jbc.273.22.13738; Hinds MG, 1997, J BIOMOL NMR, V9, P113, DOI 10.1023/A:1018636018243; Hudson KR, 1996, J BIOL CHEM, V271, P11971, DOI 10.1074/jbc.271.20.11971; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; LAYTON MJ, 1992, P NATL ACAD SCI USA, V89, P8616, DOI 10.1073/pnas.89.18.8616; LAYTON MJ, 1994, J BIOL CHEM, V269, P29891; LOWMAN HB, 1993, J MOL BIOL, V234, P564, DOI 10.1006/jmbi.1993.1612; METCALF D, 1988, LEUKEMIA, V2, P216; Mitchell MH, 2002, BIOL REPROD, V67, P460, DOI 10.1095/biolreprod67.2.460; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; OWCZAREK CM, 1993, EMBO J, V12, P3487, DOI 10.1002/j.1460-2075.1993.tb06023.x; Pearce KH, 1999, BIOCHEMISTRY-US, V38, P81, DOI 10.1021/bi9817008; Plun-Favreau H, 2003, J BIOL CHEM, V278, P27169, DOI 10.1074/jbc.M303168200; SAVINO R, 1994, EMBO J, V13, P5863, DOI 10.1002/j.1460-2075.1994.tb06931.x; Sidhu SS, 2000, METHOD ENZYMOL, V328, P333, DOI 10.1016/S0076-6879(00)28406-1; Simpson RJ, 1997, PROTEIN SCI, V6, P929, DOI 10.1002/pro.5560060501; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Sporeno E, 1996, BLOOD, V87, P4510, DOI 10.1182/blood.V87.11.4510.bloodjournal87114510; STEWART CL, 1992, NATURE, V359, P76, DOI 10.1038/359076a0; Vernallis AB, 1997, J BIOL CHEM, V272, P26947, DOI 10.1074/jbc.272.43.26947; WELLS JA, 1990, BIOCHEMISTRY-US, V29, P8509, DOI 10.1021/bi00489a001; WISHART DS, 1995, J BIOMOL NMR, V6, P135, DOI 10.1007/BF00211777; WISHART DS, 1994, METHOD ENZYMOL, V239, P363; Yao SG, 2000, PROTEIN SCI, V9, P671; Yue ZP, 2000, BIOL REPROD, V63, P508, DOI 10.1095/biolreprod63.2.508; Zhang JG, 1997, BIOCHEM J, V325, P693, DOI 10.1042/bj3250693; Zhang Y, 1998, J BIOL CHEM, V273, P34370, DOI 10.1074/jbc.273.51.34370	44	29	31	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 16	2004	279	3					2125	2134		10.1074/jbc.M310103200	http://dx.doi.org/10.1074/jbc.M310103200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	762WT	14585833	hybrid			2022-12-27	WOS:000188005700069
J	Cameron, SJ; Abe, J; Malik, S; Che, WY; Yang, J				Cameron, SJ; Abe, J; Malik, S; Che, WY; Yang, J			Differential role of MEK5 alpha and MEK5 beta in BMK1/ERK5 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; PROTEIN-KINASE-C; CELL-PROLIFERATION; SIGNAL-TRANSDUCTION; TYROSINE KINASES; GENE-EXPRESSION; ERK5; PATHWAY; MEK5; SURVIVAL	Big mitogen-activated protein kinase 1/extracellular-regulated kinase 5 (BMK1/ERK5) is regulated sequentially by a series of upstream MAP kinase kinases ( MEKs) in a signaling cascade. MEKs activate their downstream MAPK by phosphorylation of threonine and tyrosine in the T-X-Y motif. MEK5 is the upstream BMK1 kinase and exists as naturally occurring splice variants, MEK5alpha and MEK5beta. The full-length MEK5 (MEK5alpha) is 89 amino acids longer than MEK5beta at the N terminus, but the precise functional difference between the two splice variants is not known. Dual phosphorylation site mutation of MEK5alpha (Ser-311-->Asp and Thr-315-->Asp; MEK5alpha(S311D/T315D)) activated BMK1, but the corresponding dual phosphorylation sites mutant of MEK5beta could not induce BMK1 kinase activation or nuclear translocation. Furthermore, MEK5beta inhibited epidermal growth factor-induced BMK1 activation and MEK5alpha( S311D/T315D)-induced MEF2 transcriptional activity. Both MEK5alpha and MEK5beta individually co-immunoprecipitated with BMK1, but the presence of MEK5beta prevented association of MEK5alpha with BMK1 suggesting a mechanistic basis for the dominant-negative behavior of MEK5alpha on BMK1 activation. The ratio of MEK5alpha to MEK5beta expression was higher in cancer cell lines, and overexpression of MEK5beta-inhibited serum-induced DNA synthesis. These data suggest that alternative splicing of MEK5alpha and MEK5beta may play a critical role in BMK1 activation and subsequent cell proliferation.	Columbia Univ Coll Phys & Surg, Dept Anesthesiol, New York, NY 10032 USA; Univ Rochester, Med Ctr, Dept Pharmacol Physiol, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Cardiovasc Res Ctr, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Dept Anesthesiol, Rochester, NY 14642 USA	Columbia University; University of Rochester; University of Rochester; University of Rochester	Yang, J (corresponding author), Columbia Univ Coll Phys & Surg, Dept Anesthesiol, P&S,630 W 168th St, New York, NY 10032 USA.				NHLBI NIH HHS [R01 HL66919-02] Funding Source: Medline; NIDA NIH HHS [T32 DA007232] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066919] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [T32DA007232] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Abe J, 1996, J BIOL CHEM, V271, P16586, DOI 10.1074/jbc.271.28.16586; Cameron SJ, 2003, J BIOL CHEM, V278, P18682, DOI 10.1074/jbc.M213283200; Diaz-Meco MT, 2001, MOL CELL BIOL, V21, P1218, DOI 10.1128/MCB.21.4.1218-1227.2001; Dong F, 2001, J BIOL CHEM, V276, P10811, DOI 10.1074/jbc.M008748200; English JM, 1999, J BIOL CHEM, V274, P31588, DOI 10.1074/jbc.274.44.31588; ENGLISH JM, 1995, J BIOL CHEM, V270, P28897, DOI 10.1074/jbc.270.48.28897; Esparis-Ogando A, 2002, MOL CELL BIOL, V22, P270, DOI 10.1128/MCB.22.1.270-285.2002; Gutkind J.S, 2000, SCI STKE; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; Kamakura S, 1999, J BIOL CHEM, V274, P26563, DOI 10.1074/jbc.274.37.26563; Kasler HG, 2000, MOL CELL BIOL, V20, P8382, DOI 10.1128/MCB.20.22.8382-8389.2000; Kato Y, 1997, EMBO J, V16, P7054, DOI 10.1093/emboj/16.23.7054; Kato Y, 1998, NATURE, V395, P713, DOI 10.1038/27234; Luo HL, 2002, ARTERIOSCL THROM VAS, V22, P394, DOI 10.1161/hq0302.105343; Marinissen MJ, 1999, MOL CELL BIOL, V19, P4289; Mehta PB, 2003, ONCOGENE, V22, P1381, DOI 10.1038/sj.onc.1206154; Mody N, 2003, BIOCHEM J, V372, P567, DOI 10.1042/BJ20030193; Mody N, 2001, FEBS LETT, V502, P21, DOI 10.1016/S0014-5793(01)02651-5; Nicol RL, 2001, EMBO J, V20, P2757, DOI 10.1093/emboj/20.11.2757; Pearson G, 2001, J BIOL CHEM, V276, P7927, DOI 10.1074/jbc.M009764200; Ponting CP, 2002, TRENDS BIOCHEM SCI, V27, P10, DOI 10.1016/S0968-0004(01)02006-0; Regan CP, 2002, P NATL ACAD SCI USA, V99, P9248, DOI 10.1073/pnas.142293999; Sohn SJ, 2002, J BIOL CHEM, V277, P43344, DOI 10.1074/jbc.M207573200; Sun WY, 2001, J BIOL CHEM, V276, P5093, DOI 10.1074/jbc.M003719200; Suzaki Y, 2002, J BIOL CHEM, V277, P9614, DOI 10.1074/jbc.M111790200; Watson FL, 2001, NAT NEUROSCI, V4, P981, DOI 10.1038/nn720; Weldon CB, 2002, SURGERY, V132, P293, DOI 10.1067/msy.2002.125389; Yan C, 2001, J BIOL CHEM, V276, P10870, DOI 10.1074/jbc.M009286200; Zhao M, 2002, ARCH BIOCHEM BIOPHYS, V400, P199, DOI 10.1016/S0003-9861(02)00028-0; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665	30	35	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 9	2004	279	2					1506	1512		10.1074/jbc.M308755200	http://dx.doi.org/10.1074/jbc.M308755200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	759DJ	14583600	hybrid			2022-12-27	WOS:000187722800082
J	Claveria, C; Martinez, C; Torres, M				Claveria, C; Martinez, C; Torres, M			A Bax/Bak-independent mitochondrial death pathway triggered by Drosophila Grim GH3 domain in mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BCL-2 FAMILY-MEMBERS; REAPER-INDUCED APOPTOSIS; CYTOCHROME-C; CASPASE ACTIVATION; INDUCE APOPTOSIS; PROAPOPTOTIC BAX; BH3 DOMAIN; PROTEINS; HID; INHIBITOR	Grim encodes a protein required for programmed cell death in Drosophila, whose proapoptotic activity is conserved in mammalian cells. Two proapoptotic domains are relevant for Grim killing function; the N-terminal region, which induces apoptosis by disrupting inhibitor of apoptosis protein (IAP) blockage of caspase activity, and the internal GH3 domain, which triggers a mitochondrial pathway. We explored the role of these two domains in heterologous killing of mammalian cells by Grim. The GH3 domain is essential for Grim proapoptotic activity in mouse cells, whereas the N-terminal domain is dispensable. The GH3 domain is required and sufficient for Grim targeting to mitochondria and for cytochrome c release in a caspase-and N-terminal-independent, IAP-insensitive manner. These Grim GH3 activities do not require Bax or Bak function, revealing GH3 activity as the first proapoptotic stimulus able to trigger the mitochondrial death pathway in mammalian cells in the absence of multidomain proapoptotic Bcl-2 proteins.	Univ Autonoma Madrid, Dept Immunol & Oncol, Ctr Nacl Biotecnol, CSIC, E-28049 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)	Torres, M (corresponding author), Univ Autonoma Madrid, Dept Immunol & Oncol, Ctr Nacl Biotecnol, CSIC, E-28049 Madrid, Spain.		Torres, Miguel/A-7388-2013; Torres, Miguel/CAG-0003-2022	Torres, Miguel/0000-0003-0906-4767; Torres, Miguel/0000-0003-0906-4767				Abrams JM, 1999, TRENDS CELL BIOL, V9, P435, DOI 10.1016/S0962-8924(99)01646-3; Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; Aravind L, 2001, SCIENCE, V291, P1279, DOI 10.1126/science.291.5507.1279; Bergmann A, 1998, CELL, V95, P331, DOI 10.1016/S0092-8674(00)81765-1; Brachmann CB, 2000, CURR BIOL, V10, P547, DOI 10.1016/S0960-9822(00)00474-7; Brodsky MH, 2000, CELL, V101, P103, DOI 10.1016/S0092-8674(00)80627-3; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; Chen P, 1996, J BIOL CHEM, V271, P25735, DOI 10.1074/jbc.271.42.25735; Chen P, 1996, GENE DEV, V10, P1773, DOI 10.1101/gad.10.14.1773; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Chou JJ, 1999, CELL, V96, P615, DOI 10.1016/S0092-8674(00)80572-3; Christich A, 2002, CURR BIOL, V12, P137, DOI 10.1016/S0960-9822(01)00658-3; Claveria C, 2002, EMBO J, V21, P3327, DOI 10.1093/emboj/cdf354; Claveria C, 1998, EMBO J, V17, P7199, DOI 10.1093/emboj/17.24.7199; Colussi PA, 2000, J CELL BIOL, V148, P703, DOI 10.1083/jcb.148.4.703; Dorstyn L, 2002, J CELL BIOL, V156, P1089, DOI 10.1083/jcb.200111107; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Evans EK, 1997, EMBO J, V16, P7372, DOI 10.1093/emboj/16.24.7372; Goyal L, 2000, EMBO J, V19, P589, DOI 10.1093/emboj/19.4.589; Green DR, 2000, CELL, V102, P1, DOI 10.1016/S0092-8674(00)00003-9; GRETHER ME, 1995, GENE DEV, V9, P1694, DOI 10.1101/gad.9.14.1694; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Haining WN, 1999, P NATL ACAD SCI USA, V96, P4936, DOI 10.1073/pnas.96.9.4936; Hsu YT, 1997, J BIOL CHEM, V272, P13829, DOI 10.1074/jbc.272.21.13829; Igaki T, 2000, P NATL ACAD SCI USA, V97, P662, DOI 10.1073/pnas.97.2.662; Juin P, 2002, MOL CELL BIOL, V22, P6158, DOI 10.1128/MCB.22.17.6158-6169.2002; Kandasamy K, 2003, CANCER RES, V63, P1712; Kelekar A, 1998, TRENDS CELL BIOL, V8, P324, DOI 10.1016/S0962-8924(98)01321-X; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Kurada P, 1998, CELL, V95, P319, DOI 10.1016/S0092-8674(00)81764-X; Lei K, 2002, MOL CELL BIOL, V22, P4929, DOI 10.1128/MCB.22.13.4929-4942.2002; Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2; Lisi S, 2000, GENETICS, V154, P669; McCall K, 1997, TRENDS GENET, V13, P222, DOI 10.1016/S0168-9525(97)01126-8; McCarthy JV, 1998, J BIOL CHEM, V273, P24009, DOI 10.1074/jbc.273.37.24009; McDonnell JM, 1999, CELL, V96, P625, DOI 10.1016/S0092-8674(00)80573-5; Metzstein MM, 1998, TRENDS GENET, V14, P410, DOI 10.1016/S0168-9525(98)01573-X; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Okada H, 2002, MOL CELL BIOL, V22, P3509, DOI 10.1128/MCB.22.10.3509-3517.2002; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; Rodriguez A, 1999, NAT CELL BIOL, V1, P272, DOI 10.1038/12984; Schlesinger PH, 1997, P NATL ACAD SCI USA, V94, P11357, DOI 10.1073/pnas.94.21.11357; Srinivasula SM, 2002, CURR BIOL, V12, P125, DOI 10.1016/S0960-9822(01)00657-1; Varkey J, 1999, J CELL BIOL, V144, P701, DOI 10.1083/jcb.144.4.701; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Vucic D, 1997, P NATL ACAD SCI USA, V94, P10183, DOI 10.1073/pnas.94.19.10183; Vucic D, 1998, MOL CELL BIOL, V18, P3300, DOI 10.1128/MCB.18.6.3300; Wang SL, 1999, CELL, V98, P453, DOI 10.1016/S0092-8674(00)81974-1; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; WHITE K, 1994, SCIENCE, V264, P677, DOI 10.1126/science.8171319; Wing JP, 2002, CURR BIOL, V12, P131, DOI 10.1016/S0960-9822(01)00664-9; Wing JP, 1998, CELL DEATH DIFFER, V5, P930, DOI 10.1038/sj.cdd.4400423; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Zhang H, 2000, J BIOL CHEM, V275, P27303; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601	56	25	27	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 9	2004	279	2					1368	1375		10.1074/jbc.M309819200	http://dx.doi.org/10.1074/jbc.M309819200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	759DJ	14551193	hybrid			2022-12-27	WOS:000187722800065
J	Madani, S; Hichami, A; Charkaoui-Malki, M; Khan, NA				Madani, S; Hichami, A; Charkaoui-Malki, M; Khan, NA			Diacylglycerols containing omega 3 and omega 6 fatty acids bind to RasGRP and modulate MAP kinase activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-RELEASING PROTEIN; AORTIC ENDOTHELIAL-CELLS; HUMAN T-CELLS; PHOSPHOLIPASE-D; EXCHANGE FACTOR; PHORBOL ESTERS; EICOSAPENTAENOIC ACID; ACYL-CHAIN; IDENTIFICATION; GTPASE	We elucidated the effects of different diacylglycerols (DAGs), i.e. 1-stearoyl-2-arachidonoyl-sn-glycerol ( SAG), 1-stearoyl-2-docosahexaenoyl-sn-glycerol (SDG), and 1-stearoyl-2-eicosapentaenoyl-sn-glycerol (SEG), on [H-3] PDBu binding to RasGRP. The competition studies with these DAGs on [H-3] PDBu binding to RasGRP revealed different K-i values for these DAG molecular species. Furthermore, we transfected human Jurkat T cells by a plasmid containing RasGRP and assessed the implication of endogenous DAGs on activation of MAP kinases ERK1/ERK2, induced by phorbol-12-myristate-13-acetate (PMA). In control cells, GF109203X, a protein kinase C inhibitor, inhibited ERK1/ERK2 activation. However, this agent curtailed but failed to completely diminish ERK1/ERK2 phosphorylation in RasGRP-overexpressing cells, though calphostin C, a DAG binding inhibitor, suppressed the phosphorylation of MAP kinases in these cells. In cells incubated with arachidonic acid (AA), docosahexaenoic acid (DHA), and eicosapentaenoic acid (EPA), PMA induced the production of endogenous DAGs containing these fatty acids, respectively: DAG-AA, DAG-DHA, and DAG-EPA. The inhibition of production of DAG-AA and DAG-DHA significantly inhibited MAP kinase activation in RasGRP overexpressing, but not in control, cells. Our study demonstrates that three DAG molecular species bind to RasGRP, but only DAG-AA and DAG-DHA participate in the modulation of RasGRP-mediated activation of MAP kinases in Jurkat T cells.	Univ Bourgogne, Fac Sci, Unite Propre Rech Enseignement Super Lipides & Nu, Equipe Accueil 2422, F-21000 Dijon, France; Univ Bourgogne, Fac Sci, Biol Cellulaire & Mol Lab, Equipe Accueil 2422, F-21000 Dijon, France	Universite de Bourgogne; Universite de Bourgogne	Khan, NA (corresponding author), Univ Bourgogne, Fac Sci, Unite Propre Rech Enseignement Super Lipides & Nu, Equipe Accueil 2422, 6 Blvd Gabriel, F-21000 Dijon, France.	naim.khan@u-bourgogne.fr	Cherkaoui-Malki, Mustapha/B-2412-2012	Cherkaoui-Malki, Mustapha/0000-0001-5010-739X; hichami, aziz/0000-0003-4331-5152				ALBRIGHT CF, 1993, EMBO J, V12, P339, DOI 10.1002/j.1460-2075.1993.tb05662.x; AMARAL MC, 1993, IMMUNOLOGY, V79, P24; Bechoua S, 1998, J LIPID RES, V39, P873; BOKOCH GM, 1993, FASEB J, V7, P750, DOI 10.1096/fasebj.7.9.8330683; Bordoni A, 1992, Cardiologia, V37, P631; Bradshaw CD, 1996, IMMUNOL LETT, V53, P69, DOI 10.1016/S0165-2478(96)02614-4; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; Denys A, 2001, J LIPID RES, V42, P2015; Ebinu JO, 1998, SCIENCE, V280, P1082, DOI 10.1126/science.280.5366.1082; Ebinu JO, 2000, BLOOD, V95, P3199; FLENGER JH, 1994, J BIOL CHEM, V269, P2550; HA KS, 1993, J BIOL CHEM, V268, P10534; Harbige LS, 1998, P NUTR SOC, V57, P555, DOI 10.1079/PNS19980081; Khan NA, 1999, BIOCHEM J, V344, P199, DOI 10.1042/0264-6021:3440199; KHAN NA, 2002, RT RES DEV LIPIDS, V6, P65; Kuroki T, 1998, BIOCHEM BIOPH RES CO, V247, P473, DOI 10.1006/bbrc.1998.8814; LEACH KL, 1991, J BIOL CHEM, V266, P3215; Lorenzo PS, 2000, MOL PHARMACOL, V57, P840; Lorenzo PS, 2001, CANCER RES, V61, P943; Madani S, 2001, FASEB J, V15, P2595, DOI 10.1096/fj.01-0753int; Marais R, 1998, SCIENCE, V280, P109, DOI 10.1126/science.280.5360.109; Marignani PA, 1996, J NUTR, V126, P2738; Marignani PA, 1996, BIOCHEM BIOPH RES CO, V225, P469, DOI 10.1006/bbrc.1996.1196; Pettitt TR, 1997, J BIOL CHEM, V272, P17354, DOI 10.1074/jbc.272.28.17354; Pierret P, 2001, NEUROSCIENCE, V108, P381, DOI 10.1016/S0306-4522(01)00429-8; Pierret P, 2000, J NEUROCYTOL, V29, P485, DOI 10.1023/A:1007245728751; PREISS J, 1986, J BIOL CHEM, V261, P8597; Rebhun JF, 2000, J BIOL CHEM, V275, P34901, DOI 10.1074/jbc.M005327200; Rebhun JF, 2000, J BIOL CHEM, V275, P13406, DOI 10.1074/jbc.C000085200; Reuther GW, 2002, J BIOL CHEM, V277, P30508, DOI 10.1074/jbc.M111330200; Rong SB, 2002, J MED CHEM, V45, P853, DOI 10.1021/jm010422z; SEBALDT RJ, 1992, BIOCHEM J, V284, P367, DOI 10.1042/bj2840367; SHARKEY NA, 1985, CANCER RES, V45, P19; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; Tognon CE, 1998, MOL CELL BIOL, V18, P6995, DOI 10.1128/MCB.18.12.6995; Yang Y, 2002, J BIOL CHEM, V277, P25756, DOI 10.1074/jbc.M202575200	36	37	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 9	2004	279	2					1176	1183		10.1074/jbc.M306252200	http://dx.doi.org/10.1074/jbc.M306252200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	759DJ	14583629	hybrid			2022-12-27	WOS:000187722800042
J	Ouchi, N; Kobayashi, H; Kihara, S; Kumada, M; Sato, K; Inoue, T; Funahashi, T; Walsh, K				Ouchi, N; Kobayashi, H; Kihara, S; Kumada, M; Sato, K; Inoue, T; Funahashi, T; Walsh, K			Adiponectin stimulates angiogenesis by promoting cross-talk between AMP-activated protein kinase and Akt signaling in endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID OXIDATION; ADIPOSE-SPECIFIC PROTEIN; ACETYL-COA CARBOXYLASE; NITRIC-OXIDE; GROWTH-FACTOR; INSULIN-RESISTANCE; PLASMA-PROTEIN; GLUCOSE-TRANSPORT; GLOBULAR DOMAIN; VISCERAL FAT	Adiponectin is an adipocyte-specific adipocytokine with anti-atherogenic and anti-diabetic properties. Here, we investigated whether adiponectin regulates angiogenic processes in vitro and in vivo. Adiponectin stimulated the differentiation of human umbilical vein endothelium cells (HUVECs) into capillary-like structures in vitro and functioned as a chemoattractant in migration assays. Adiponectin promoted the phosphorylation of AMP-activated protein kinase ( AMPK), protein kinase Akt/protein kinase B, and endothelial nitric oxide synthesis ( eNOS) in HUVECs. Transduction with either dominant-negative AMPK or dominant-negative Akt abolished adiponectin-induced eNOS phosphorylation as well as adiponectin-stimulated HUVEC migration and differentiation. Dominant-negative AMPK also inhibited adiponectin-induced Akt phosphorylation, suggesting that AMPK is upstream of Akt. Dominant-negative Akt or the phosphatidylinositol 3-kinase inhibitor LY294002 blocked adiponectin-stimulated Akt and eNOS phosphorylation, migration, and differentiation without altering AMPK phosphorylation. Finally, adiponectin stimulated blood vessel growth in vivo in mouse Matrigel plug implantation and rabbit corneal models of angiogenesis. These data indicate that adiponectin can function to stimulate the new blood vessel growth by promoting cross-talk between AMP-activated protein kinase and Akt signaling within endothelial cells.	Boston Univ, Sch Med, Whitaker Cardiovasc Inst, Boston, MA 02118 USA; Osaka Univ, Dept Internal Med & Mol Sci, Grad Sch Med, Osaka 5650871, Japan; Sankyo Co Ltd, Pharmacol & Mol Biol Res Labs, Shinagawa Ku, Tokyo 1408710, Japan	Boston University; Osaka University; Daiichi Sankyo Company Limited	Walsh, K (corresponding author), Boston Univ, Sch Med, Whitaker Cardiovasc Inst, 715 Albany St,W611, Boston, MA 02118 USA.		OUCHI, Noriyuki/I-7306-2014		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD023681] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040197] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG015052, R01AG017241, R37AG015052] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01 AR040197, AR40197] Funding Source: Medline; NIA NIH HHS [AG15052, R01 AG015052, R37 AG015052, AG17241, R01 AG017241] Funding Source: Medline; NICHD NIH HHS [HD23681, P01 HD023681] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Arita Y, 2002, CIRCULATION, V105, P2893, DOI 10.1161/01.CIR.0000018622.84402.FF; Arita Y, 1999, BIOCHEM BIOPH RES CO, V257, P79, DOI 10.1006/bbrc.1999.0255; Carmeliet P, 2003, NAT MED, V9, P653, DOI 10.1038/nm0603-653; Chen H, 2003, J BIOL CHEM, V278, P45021, DOI 10.1074/jbc.M307878200; Chen ZP, 1999, FEBS LETT, V443, P285, DOI 10.1016/S0014-5793(98)01705-0; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Ferrara N, 1999, NAT MED, V5, P1359, DOI 10.1038/70928; Fruebis J, 2001, P NATL ACAD SCI USA, V98, P2005, DOI 10.1073/pnas.041591798; Fujio Y, 1999, J BIOL CHEM, V274, P16349, DOI 10.1074/jbc.274.23.16349; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; Hotta K, 2000, ARTERIOSCL THROM VAS, V20, P1595, DOI 10.1161/01.ATV.20.6.1595; Jakobsen SN, 2001, J BIOL CHEM, V276, P46912, DOI 10.1074/jbc.C100483200; Janiak P, 2002, CARDIOVASC RES, V56, P293, DOI 10.1016/S0008-6363(02)00538-2; Kim I, 2000, CIRC RES, V86, P24, DOI 10.1161/01.RES.86.1.24; Kishida K, 2003, BIOCHEM BIOPH RES CO, V306, P286, DOI 10.1016/S0006-291X(03)00940-9; Kovacic S, 2003, J BIOL CHEM, V278, P39422, DOI 10.1074/jbc.M305371200; KUDO N, 1995, J BIOL CHEM, V270, P17513, DOI 10.1074/jbc.270.29.17513; Kumada M, 2003, ARTERIOSCL THROM VAS, V23, P85, DOI 10.1161/01.ATV.0000048856.22331.50; Kureishi Y, 2000, NAT MED, V6, P1004, DOI 10.1038/79510; Luo ZY, 2000, J CLIN INVEST, V106, P493, DOI 10.1172/JCI9419; Maeda K, 1996, BIOCHEM BIOPH RES CO, V221, P286, DOI 10.1006/bbrc.1996.0587; Maeda N, 2002, NAT MED, V8, P731, DOI 10.1038/nm724; Matsuda M, 2002, J BIOL CHEM, V277, P37487, DOI 10.1074/jbc.M206083200; Milan G, 2002, OBES RES, V10, P1095, DOI 10.1038/oby.2002.149; Morales-Ruiz M, 2000, CIRC RES, V86, P892, DOI 10.1161/01.RES.86.8.892; Morrow VA, 2003, J BIOL CHEM, V278, P31629, DOI 10.1074/jbc.M212831200; Mu J, 2001, MOL CELL, V7, P1085, DOI 10.1016/S1097-2765(01)00251-9; Nagata D, 2003, J BIOL CHEM, V278, P31000, DOI 10.1074/jbc.M300643200; Okamoto Y, 2002, CIRCULATION, V106, P2767, DOI 10.1161/01.CIR.0000042707.50032.19; Ouchi N, 2003, CURR OPIN LIPIDOL, V14, P561, DOI 10.1097/00041433-200312000-00003; Ouchi N, 2001, CIRCULATION, V103, P1057, DOI 10.1161/01.CIR.103.8.1057; Ouchi N, 1999, CIRCULATION, V100, P2473, DOI 10.1161/01.CIR.100.25.2473; Pajvani UB, 2003, J BIOL CHEM, V278, P9073, DOI 10.1074/jbc.M207198200; Phillips G D, 1994, In Vivo, V8, P961; Rivard A, 1999, AM J PATHOL, V154, P355, DOI 10.1016/S0002-9440(10)65282-0; Schaper W, 1999, CIRCULATION, V99, P2224, DOI 10.1161/01.CIR.99.17.2224; Shimomura I, 1996, NAT MED, V2, P800, DOI 10.1038/nm0796-800; Shiojima I, 2002, CIRC RES, V90, P1243, DOI 10.1161/01.RES.0000022200.71892.9F; Tomas E, 2002, P NATL ACAD SCI USA, V99, P16309, DOI 10.1073/pnas.222657499; Trayhurn P, 2001, P NUTR SOC, V60, P329, DOI 10.1079/PNS200194; Vita JA, 2002, CIRCULATION, V106, P164, DOI 10.1161/01.CIR.0000023452.26135.34; Waltenberger J, 2001, CARDIOVASC RES, V49, P554, DOI 10.1016/S0008-6363(00)00228-5; Wu XD, 2003, DIABETES, V52, P1355, DOI 10.2337/diabetes.52.6.1355; Yamauchi T, 2003, NATURE, V423, P762, DOI 10.1038/nature01705; Yamauchi T, 2002, NAT MED, V8, P1288, DOI 10.1038/nm788; Yamauchi T, 2001, NAT MED, V7, P941, DOI 10.1038/90984; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0; ZICHE M, 1994, J CLIN INVEST, V94, P2036, DOI 10.1172/JCI117557	49	618	672	2	42	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 9	2004	279	2					1304	1309		10.1074/jbc.M310389200	http://dx.doi.org/10.1074/jbc.M310389200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	759DJ	14557259	hybrid, Green Accepted			2022-12-27	WOS:000187722800057
J	Padmanabhan, B; Adachi, N; Kataoka, K; Horikoshi, M				Padmanabhan, B; Adachi, N; Kataoka, K; Horikoshi, M			Crystal structure of the homolog of the oncoprotein gankyrin, an interactor of Rb and CDK4/6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT KINASE CDK6; ANKYRIN-REPEAT; CYCLIN-D; PROTEIN; MOLSCRIPT; DOMAIN	The oncoprotein gankyrin plays a central role in tumorigenesis and cell proliferation. Gankyrin interacts with the retinoblastoma tumor suppressor (Rb) and cyclin-dependent kinase 4/6 (CDK4/6), increases phosphorylation at specific residues of Rb by CDK4/6 in vivo, and promotes tumorigenesis. The phosphorylation of Rb by CDK4/6 leads to the deregulation of the cell cycle during G(1)/S transition. Although how phosphorylation occurs on Rb has been studied extensively, the mechanism of site-specific phosphorylation of Rb remains unclear due to a lack of information on the structural arrangement of Rb and CDK4/6. Here, we have determined and refined to 2.3-Angstrom resolution the crystal structure of a gankyrin homolog, the non-ATPase subunit 6 (Nas6p) of the proteasome from yeast. The crystal structure reveals that Nas6p contains seven ankyrin repeats. The number of the repeats is different from that predicted from the primary structure. Nas6p also possesses an unusual curved structure with two acidic regions at the N- and C-terminal regions separated by one basic region, suggesting that it has at least two functional surfaces. The tertiary structure of Nas6p, together with the previous biochemical studies, indicates that the CDK4/6 and Rb binding surfaces of gankyrin are located at the N- and C-terminal regions, respectively, and face the same side of gankyrin. These observations suggest that gankyrin brings Rb and CDK4/6 together through gankyrin-Rb and gankyrin-CDK4/6 interactions and determines the relative positioning of the substrate ( Rb) and the enzyme (CDK4/6). Our findings provide mechanistic insight into site-specific phosphorylation of Rb caused by CDK4/6.	Japan Sci & Technol Corp, Horikoshi Gene Selector Project, Exploratory Res Adv Technol, Tsukuba, Ibaraki 3002635, Japan; Univ Tokyo, Dev Biol Lab, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan	Japan Science & Technology Agency (JST); University of Tokyo	Horikoshi, M (corresponding author), Japan Sci & Technol Corp, Horikoshi Gene Selector Project, Exploratory Res Adv Technol, 5-9-6 Tokodai, Tsukuba, Ibaraki 3002635, Japan.	horikosh@iam.u-tokyo.ac.jp						Adachi N, 2002, ACTA CRYSTALLOGR D, V58, P859, DOI 10.1107/S0907444902004808; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brotherton DH, 1998, NATURE, V395, P244, DOI 10.1038/26164; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; Higashitsuji H, 2000, NAT MED, V6, P96, DOI 10.1038/71600; Hori T, 1998, GENE, V216, P113, DOI 10.1016/S0378-1119(98)00309-6; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; IKEDA MA, 1993, MOL CELL BIOL, V13, P7029, DOI 10.1128/MCB.13.11.7029; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lee JO, 1998, NATURE, V391, P859, DOI 10.1038/36038; Michel F, 2001, EMBO J, V20, P6180, DOI 10.1093/emboj/20.22.6180; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Rossmann MG, 1999, ACTA CRYSTALLOGR D, V55, P1631, DOI 10.1107/S0907444999008379; Russo AA, 1998, NATURE, V395, P237, DOI 10.1038/26155; Sedgwick SG, 1999, TRENDS BIOCHEM SCI, V24, P311, DOI 10.1016/S0968-0004(99)01426-7; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; WU EW, 1993, J VIROL, V67, P2402, DOI 10.1128/JVI.67.4.2402-2407.1993	24	21	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 9	2004	279	2					1546	1552		10.1074/jbc.M310266200	http://dx.doi.org/10.1074/jbc.M310266200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	759DJ	14583612	hybrid			2022-12-27	WOS:000187722800087
J	Papageorgiou, AC; Baker, MD; McLeod, JD; Goda, SK; Manzotti, CN; Sansom, DM; Tranter, HS; Acharya, KR				Papageorgiou, AC; Baker, MD; McLeod, JD; Goda, SK; Manzotti, CN; Sansom, DM; Tranter, HS; Acharya, KR			Identification of a secondary zinc-binding site in staphylococcal enterotoxin C2 - Implications for superantigen recognition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-II; STREPTOCOCCAL PYROGENIC EXOTOXIN; T-CELL-RECEPTOR; CRYSTAL-STRUCTURE; STRUCTURAL BASIS; MOLECULES; REVEALS; STIMULATION; ACTIVATION; COMPLEXES	The previously determined crystal structure of the superantigen staphylococcal enterotoxin C2 (SEC2) showed binding of a single zinc ion located between the N- and C-terminal domains (Papageorgiou, A. C., Acharya, K. R., Shapiro, R., Passalacqua, E. F., Brehm, R. D., and Tranter, H. S. (1995) Structure 3, 769 - 779). Here we present the crystal structure of SEC2 determined to 2.0 Angstrom resolution in the presence of additional zinc. The structure revealed the presence of a secondary zinc-binding site close to the major histocompatibility complex (MHC)-binding site of the toxin and some 28 Angstrom away from the primary zinc-binding site of the toxin found in previous studies. T cell stimulation assays showed that varying the concentration of zinc ions present affected the activity of the toxin and we observed that high zinc concentrations considerably inhibited T cell responses. This indicates that SEC2 may have multiple modes of interaction with the immune system that are dependent on serum zinc levels. The potential role of the secondary zinc-binding site and that of the primary one in the formation of the TCR.SEC2.MHC complex are considered, and the possibility that zinc may regulate the activity of SEC2 as a toxin facilitating different T cell responses is discussed.	Univ Bath, Dept Biol & Biochem, Bath BA2 7AY, Avon, England; Hlth Protect Agcy, Ctr Appl Microbiol Res, Salisbury SP4 0JG, Wilts, England; Univ Birmingham, Div Immun & Infect, Sch Med, Birmingham B15 2TT, W Midlands, England	University of Bath; Health Protection Agency; University of Birmingham	Acharya, KR (corresponding author), Univ Bath, Dept Biol & Biochem, Bath BA2 7AY, Avon, England.	K.R.Acharya@bath.ac.uk	Papageorgiou, Anastassios C./AAL-5274-2020; Baker, Matthew/B-4850-2011; Goda, Sayed K/AAU-9078-2020; Goda, Sayed/Q-8251-2019	Papageorgiou, Anastassios C./0000-0002-7980-1120; Baker, Matthew/0000-0001-6950-204X; Sansom, David/0000-0001-6506-3115; Acharya, K. Ravi/0000-0002-3009-4058; Manzotti, Claire/0000-0001-5894-5435				ACHARYA KR, 1994, NATURE, V367, P94, DOI 10.1038/367094a0; Al-Daccak R, 1998, J IMMUNOL, V160, P225; BLACKMAN M, 1990, SCIENCE, V248, P1335, DOI 10.1126/science.1972592; BLOMSTERHAUTAMAA DA, 1988, METHOD ENZYMOL, V165, P37; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chi YI, 2002, J BIOL CHEM, V277, P22839, DOI 10.1074/jbc.M201932200; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Fields BA, 1996, NATURE, V384, P188, DOI 10.1038/384188a0; HERMAN A, 1991, ANNU REV IMMUNOL, V9, P745, DOI 10.1146/annurev.iy.09.040191.003525; JARDETZKY TS, 1994, NATURE, V368, P711, DOI 10.1038/368711a0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lavoie PM, 2001, J IMMUNOL, V166, P7229, DOI 10.4049/jimmunol.166.12.7229; Li PL, 1997, J EXP MED, V186, P375, DOI 10.1084/jem.186.3.375; Li YL, 2001, IMMUNITY, V14, P93, DOI 10.1016/S1074-7613(01)00092-9; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; OTWINOWSKI Z, 1993, SCALEPACK SOFTWARE S; OTWINOWSKI Z, 1993, DENZO OSCILLATION DA; Papageorgiou AC, 1999, EMBO J, V18, P9, DOI 10.1093/emboj/18.1.9; PAPAGEORGIOU AC, 1995, STRUCTURE, V3, P769, DOI 10.1016/S0969-2126(01)00212-X; Papageorgiou AC, 2000, TRENDS MICROBIOL, V8, P369, DOI 10.1016/S0966-842X(00)01793-5; Papageorgiou AC, 1997, STRUCTURE, V5, P991, DOI 10.1016/S0969-2126(97)00252-9; Papageorgiou AC, 1998, J MOL BIOL, V277, P61, DOI 10.1006/jmbi.1997.1577; PASSALACQUA EF, 1993, J MOL BIOL, V233, P170, DOI 10.1006/jmbi.1993.1493; Petersson K, 2001, EMBO J, V20, P3306, DOI 10.1093/emboj/20.13.3306; SANSOM DM, 1993, IMMUNOLOGY, V80, P242; SCHAD EM, 1995, EMBO J, V14, P3292, DOI 10.1002/j.1460-2075.1995.tb07336.x; Schad EM, 1997, J MOL BIOL, V269, P270, DOI 10.1006/jmbi.1997.1023; SETH A, 1994, NATURE, V369, P324, DOI 10.1038/369324a0; Sundstrom M, 1996, EMBO J, V15, P6832, DOI 10.1002/j.1460-2075.1996.tb01074.x; SWAMINATHAN S, 1995, NAT STRUCT BIOL, V2, P680, DOI 10.1038/nsb0895-680; Tiedemann RE, 1995, P NATL ACAD SCI USA, V92, P12156, DOI 10.1073/pnas.92.26.12156; TODD J, 1978, LANCET, V2, P1116; Tripp TJ, 2003, INFECT IMMUN, V71, P1548, DOI 10.1128/IAI.71.3.1548-1550.2003; ULRICH RG, 1995, NAT STRUCT BIOL, V2, P554, DOI 10.1038/nsb0795-554; Wen R, 1996, J EXP MED, V183, P1083, DOI 10.1084/jem.183.3.1083	38	12	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 9	2004	279	2					1297	1303		10.1074/jbc.M307333200	http://dx.doi.org/10.1074/jbc.M307333200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	759DJ	14559915	hybrid, Green Accepted			2022-12-27	WOS:000187722800056
J	Cavallone, D; Malagolini, N; Monti, A; Wu, XR; Serafini-Cessi, F				Cavallone, D; Malagolini, N; Monti, A; Wu, XR; Serafini-Cessi, F			Variation of high mannose chains of Tamm-Horsfall glycoprotein confers differential binding to type 1-fimbriated Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER KIDNEY-CELLS; UROTHELIAL DIFFERENTIATION; URINARY GLYCOPROTEIN; STRUCTURAL-ANALYSIS; UROPLAKIN-III; IDENTIFICATION; PROTEIN; BOVINE; UROMODULIN; ADHESION	Tamm-Horsfall glycoprotein (THP), the most abundant protein in mammalian urine, has been implicated in defending the urinary tract against infections by type 1-fimbriated Escherichia coli. Recent experimental evidence indicates that the defensive capability of THP relies on its single high mannose chain, which binds to E. coli FimH lectin and competes with mannosylated uroplakin receptors on the bladder surface. Here we describe several major differences, on both structural and functional levels, between human THP (hTHP) and pig THP (pTHP). pTHP contains a much higher proportion (47%) of Man(5)GlcNAc(2) than does hTHP (8%). FimH-expressing E. coli adhere to monomeric pTHP at an approximately 3-fold higher level than to monomeric hTHP. This suggests that the shorter high mannose chain ( Man5GlcNAc2) is a much better binder for FimH than the longer chains (Man(6-7)GlcNAc(2)) and that pTHP is a more potent urinary defense factor than hTHP. In addition, unlike hTHP whose polyantennary glycans are exclusively capped by sialic acid and sulfate groups, those of pTHP are also terminated by Galalpha1,3Gal epitope. This is consistent with the fact that the outer medulla of pig kidney expresses the alpha1,3-galactosyltransferase, which is completely absent in human kidney. Finally, pTHP is more resistant to leukocyte elastase hydrolysis than hTHP, thus explaining why pTHP is much less prone to urinary degradation than hTHP. These results demonstrate for the first time that the species variations of the glycomoiety of THP can lead to the differential binding of THP to type 1-fimbriated E. coli and that the differences in high mannose processing may reflect species-specific adaptation of urinary defenses against E. coli infections.	Univ Bologna, Dept Expt Pathol, I-40126 Bologna, Italy; NYU, Sch Med, Dept Urol, New York, NY 10016 USA; NYU, Sch Med, Dept Microbiol, New York, NY 10016 USA	University of Bologna; New York University; New York University	Serafini-Cessi, F (corresponding author), Univ Bologna, Dept Expt Pathol, Via S Giacomo 14, I-40126 Bologna, Italy.		Cavallone, Daniela/AAB-2660-2019	Cavallone, Daniela/0000-0001-6718-9571; Wu, Xue-Ru/0000-0001-6058-6291	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056903] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK056903, DK56903] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABBONDANZA A, 1980, BIOCHEM J, V187, P525, DOI 10.1042/bj1870525; BEACHEY EH, 1981, J INFECT DIS, V143, P325, DOI 10.1093/infdis/143.3.325; BLOOMFIELD FJ, 1977, BIOCHEM J, V164, P41, DOI 10.1042/bj1640041; Cavallone D, 2002, CLIN BIOCHEM, V35, P405, DOI 10.1016/S0009-9120(02)00329-6; Cavallone D, 2001, BIOCHEM BIOPH RES CO, V280, P110, DOI 10.1006/bbrc.2000.4090; DALLOLIO F, 1988, CARBOHYD RES, V178, P327, DOI 10.1016/0008-6215(88)80123-X; DAWNAY A, 1980, BIOCHEM J, V185, P679, DOI 10.1042/bj1850679; de Brito BG, 1999, VET MICROBIOL, V65, P123, DOI 10.1016/S0378-1135(98)00277-6; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; DUNSTAN DR, 1974, PROC R SOC SER B-BIO, V186, P297, DOI 10.1098/rspb.1974.0051; FIRON N, 1984, INFECT IMMUN, V43, P1088, DOI 10.1128/IAI.43.3.1088-1090.1984; FLETCHER AP, 1970, BIOCHEM J, V120, P417, DOI 10.1042/bj1200417; FUKUOKA SI, 1992, P NATL ACAD SCI USA, V89, P1189, DOI 10.1073/pnas.89.4.1189; GALILI U, 1987, P NATL ACAD SCI USA, V84, P1369, DOI 10.1073/pnas.84.5.1369; GRANT AMS, 1973, CLIN SCI, V44, P163, DOI 10.1042/cs0440163; HARD K, 1992, EUR J BIOCHEM, V209, P895, DOI 10.1111/j.1432-1033.1992.tb17362.x; HULL RA, 1981, INFECT IMMUN, V33, P933, DOI 10.1128/IAI.33.3.933-938.1981; Jovine L, 2002, NAT CELL BIOL, V4, P457, DOI 10.1038/ncb802; JOZIASSE DH, 1989, J BIOL CHEM, V264, P14290; Kachar B, 1999, J MOL BIOL, V285, P595, DOI 10.1006/jmbi.1998.2304; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KOSS LG, 1969, LAB INVEST, V21, P154; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MALAGOLINI N, 1994, GLYCOCONJUGATE J, V11, P89, DOI 10.1007/BF00731148; Malagolini N, 2000, BBA-GEN SUBJECTS, V1475, P231, DOI 10.1016/S0304-4165(00)00073-8; Mulvey MA, 1998, SCIENCE, V282, P1494, DOI 10.1126/science.282.5393.1494; Mulvey MA, 2002, CELL MICROBIOL, V4, P257, DOI 10.1046/j.1462-5822.2002.00193.x; NEESER JR, 1986, INFECT IMMUN, V52, P428, DOI 10.1128/IAI.52.2.428-436.1986; OHANLEY P, 1985, J CLIN INVEST, V75, P347, DOI 10.1172/JCI111707; Pak J, 2001, J BIOL CHEM, V276, P9924, DOI 10.1074/jbc.M008610200; PENNICA D, 1987, SCIENCE, V236, P83, DOI 10.1126/science.3453112; PRASADAN K, 1995, BBA-GENE STRUCT EXPR, V1260, P328, DOI 10.1016/0167-4781(94)00240-4; Serafini-Cessi F, 2003, AM J KIDNEY DIS, V42, P658, DOI 10.1016/S0272-6386(03)00829-1; SERAFINICESSI F, 1993, BIOCHEM BIOPH RES CO, V194, P784, DOI 10.1006/bbrc.1993.1890; SERAFINICESSI F, 1984, BIOSCIENCE REP, V4, P269, DOI 10.1007/BF01119663; SERAFINICESSI F, 1983, BIOCHEM J, V215, P483, DOI 10.1042/bj2150483; SERAFINICESSI F, 1989, J IMMUNOL METHODS, V120, P185, DOI 10.1016/0022-1759(89)90241-X; SHARON N, 1987, FEBS LETT, V217, P145, DOI 10.1016/0014-5793(87)80654-3; Sherblom A P, 1993, Methods Mol Biol, V14, P143; Smilovich D, 1998, GLYCOBIOLOGY, V8, P841, DOI 10.1093/glycob/8.8.841; SOKURENKO EV, 1995, J BACTERIOL, V177, P3680, DOI 10.1128/jb.177.13.3680-3686.1995; Sokurenko EV, 1998, P NATL ACAD SCI USA, V95, P8922, DOI 10.1073/pnas.95.15.8922; STEVENSON FK, 1971, BIOCHIM BIOPHYS ACTA, V236, P59, DOI 10.1016/0005-2795(71)90149-8; STROMBERG N, 1990, EMBO J, V9, P2001, DOI 10.1002/j.1460-2075.1990.tb08328.x; TAMM I, 1950, P SOC EXP BIOL MED, V74, P108, DOI 10.3181/00379727-74-17825; van Rooijen JJM, 1999, GLYCOBIOLOGY, V9, P21, DOI 10.1093/glycob/9.1.21; Van Rooijen JJM, 1998, EUR J BIOCHEM, V256, P471, DOI 10.1046/j.1432-1327.1998.2560471.x; WALZ T, 1995, J MOL BIOL, V248, P887, DOI 10.1006/jmbi.1995.0269; WOOD C, 1979, ARCH BIOCHEM BIOPHYS, V198, P1, DOI 10.1016/0003-9861(79)90389-8; WU, 1996, P NATL ACAD SCI USA, V93, P9630; WU XR, 1993, J CELL SCI, V106, P31; WU XR, 1994, J BIOL CHEM, V269, P13716; WU XR, 1990, J BIOL CHEM, V265, P19170; Yu Heron, 1994, Gene Expression, V4, P63	54	30	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	2004	279	1					216	222		10.1074/jbc.M308821200	http://dx.doi.org/10.1074/jbc.M308821200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	757GU	14570881	hybrid			2022-12-27	WOS:000187555300026
J	Kendrick, TS; Lipscombe, RJ; Rausch, O; Nicholson, SE; Layton, JE; Goldie-Cregan, LC; Bogoyevitch, MA				Kendrick, TS; Lipscombe, RJ; Rausch, O; Nicholson, SE; Layton, JE; Goldie-Cregan, LC; Bogoyevitch, MA			Contribution of the membrane-distal tyrosine in intracellular signaling by the granulocyte colony-stimulating factor receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							G-CSF RECEPTOR; ACTIVATED PROTEIN-KINASE; EPIDERMAL-GROWTH-FACTOR; SH2 DOMAINS; PHOSPHORYLATED PEPTIDES; DIFFERENTIATION SIGNALS; TRANSCRIPTION FACTOR; RAPID ACTIVATION; B-LYMPHOCYTES; BINDING	We have evaluated the contribution of intracellular tyrosine residues of the granulocyte colony-stimulating factor receptor (GCSF-R) to its signaling and cellular outcomes. We began with stable BaF3 cell lines overexpressing wild-type or mutant GCSF-Rs. When all four intracellular tyrosines of the GCSF-R were replaced with phenylalanine (FFFF GCSF-R), cell proliferation and survival were compromised. Replacement of only the membrane-distal tyrosine (YYYF GCSF-R) also showed reduced survival following a GCSF withdrawal/replacement protocol, suggesting a role for this tyrosine. Proliferation by FFFY GCSF-R cells was attenuated by similar to70%. In evaluating the biochemical steps involved in signaling, we then showed that the membrane-distal tyrosine was necessary and sufficient for c-JunN-terminal kinase (JNK) activation. With the use of a cell-permeable JNK-inhibitory peptide, JNK was implicated in the proliferation of the FFFY GCSF-R mutant. To further define the events linking the membrane-distal tyrosine and JNK activation, the Src homology 2 domains of Shc, Grb2, and 3BP2 were shown to bind the full-length GCSF-R and a phosphopeptide encompassing the membrane-distal tyrosine. When binding to variant phosphopeptides based on this membrane-distal tyrosine was tested, altering the amino acids immediately following the phosphotyrosine could selectively abolish the interaction with Shc or Grb2, or the binding to both Grb2 and 3BP2. When these changes were introduced into the full-length GCSF-R and new cell lines created, only the mutant that did not interact with Grb2 and 3BP2 did not activate JNK. Our results suggest that direct binding of Shc by the GCSF-R is not essential for JNK activation.	Univ Western Australia, Sch Biomed & Chem Sci, Cell Signaling Lab, Crawley, WA 6009, Australia; Univ Western Australia, Prot Facil, Crawley, WA 6009, Australia; Inst Canc Res, Chester Beatty Labs, London SW3 6JB, England; Ludwig Inst Canc Res, Melbourne Tumour Biol Branch, Melbourne, Vic 3050, Australia; Western Australian Inst Med Res, Perth, WA 6000, Australia	University of Western Australia; University of Western Australia; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Ludwig Institute for Cancer Research; University of Western Australia	Bogoyevitch, MA (corresponding author), Univ Western Australia, Sch Biomed & Chem Sci, Cell Signaling Lab, 35 Stirling Hwy, Crawley, WA 6009, Australia.	marieb@cyllene.uwa.edu.au		, Sandra/0000-0002-1314-2134; Bogoyevitch, Marie/0000-0001-9745-3716				Adachi M, 1996, CELL, V85, P15; Akbarzadeh S, 2002, BLOOD, V99, P879, DOI 10.1182/blood.V99.3.879; Barr RK, 2002, J BIOL CHEM, V277, P10987, DOI 10.1074/jbc.M107565200; BASHEY A, 1994, BLOOD, V83, P949, DOI 10.1182/blood.V83.4.949.bloodjournal834949; Bouillie S, 1999, J IMMUNOL, V162, P136; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chakraborty A, 1999, BLOOD, V93, P15, DOI 10.1182/blood.V93.1.15.401a46_15_24; Chay KO, 2002, J BIOL CHEM, V277, P14521, DOI 10.1074/jbc.M111639200; COREY SJ, 1994, P NATL ACAD SCI USA, V91, P4683, DOI 10.1073/pnas.91.11.4683; de Koning JP, 1998, BLOOD, V91, P1924, DOI 10.1182/blood.V91.6.1924.1924_1924_1933; Deckert M, 1998, IMMUNITY, V9, P595, DOI 10.1016/S1074-7613(00)80657-3; deKoning JP, 1996, BLOOD, V87, P132; DEMETRI GD, 1991, BLOOD, V78, P2791; Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188; DONG F, 1993, MOL CELL BIOL, V13, P7774, DOI 10.1128/MCB.13.12.7774; Dunn C, 2002, CELL SIGNAL, V14, P585, DOI 10.1016/S0898-6568(01)00275-3; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FELDER S, 1993, MOL CELL BIOL, V13, P1449, DOI 10.1128/MCB.13.3.1449; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; FUKUNAGA R, 1990, P NATL ACAD SCI USA, V87, P8702, DOI 10.1073/pnas.87.22.8702; FUKUNAGA R, 1993, CELL, V74, P1079, DOI 10.1016/0092-8674(93)90729-A; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Hashimoto A, 1999, J BIOL CHEM, V274, P20139, DOI 10.1074/jbc.274.29.20139; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Hunter MG, 1998, J IMMUNOL, V160, P4979; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LADBURY JE, 1995, P NATL ACAD SCI USA, V92, P3199, DOI 10.1073/pnas.92.8.3199; LAW CL, 1994, J BIOL CHEM, V269, P12310; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Ng DCH, 2000, J BIOL CHEM, V275, P40856, DOI 10.1074/jbc.M004639200; Nicholson SE, 1996, J BIOL CHEM, V271, P26947, DOI 10.1074/jbc.271.43.26947; NICHOLSON SE, 1994, P NATL ACAD SCI USA, V91, P2985, DOI 10.1073/pnas.91.8.2985; Nieba L, 1996, ANAL BIOCHEM, V234, P155, DOI 10.1006/abio.1996.0067; PAN CX, 1993, J BIOL CHEM, V268, P25818; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PAYNE G, 1993, P NATL ACAD SCI USA, V90, P4902, DOI 10.1073/pnas.90.11.4902; Pomerance M, 1998, J BIOL CHEM, V273, P24301, DOI 10.1074/jbc.273.38.24301; Rausch O, 1997, MOL CELL BIOL, V17, P1170, DOI 10.1128/MCB.17.3.1170; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; Schwarze SR, 2000, TRENDS CELL BIOL, V10, P290, DOI 10.1016/S0962-8924(00)01771-2; Smith A, 1997, CURR BIOL, V7, P893, DOI 10.1016/S0960-9822(06)00380-0; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; Thoren PEG, 2000, FEBS LETT, V482, P265, DOI 10.1016/S0014-5793(00)02072-X; TIAN SS, 1994, BLOOD, V84, P1760; Ward AC, 1998, BIOCHEM BIOPH RES CO, V251, P117, DOI 10.1006/bbrc.1998.9441; Ward AC, 1999, J BIOL CHEM, V274, P14956, DOI 10.1074/jbc.274.21.14956; Ward AC, 1999, BLOOD, V93, P113, DOI 10.1182/blood.V93.1.113.401k33_113_124; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Williams EJ, 1997, J BIOL CHEM, V272, P22349, DOI 10.1074/jbc.272.35.22349; YOSHIKAWA A, 1995, EMBO J, V14, P5288, DOI 10.1002/j.1460-2075.1995.tb00213.x; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	55	16	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 2	2004	279	1					326	340		10.1074/jbc.M310144200	http://dx.doi.org/10.1074/jbc.M310144200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	757GU	14557262	hybrid			2022-12-27	WOS:000187555300040
J	Mizuno, K; Hayashi, T; Peyton, DH; Bachinger, HP				Mizuno, K; Hayashi, T; Peyton, DH; Bachinger, HP			The peptides acetyl-(Gly-3(S)Hyp-4(R)Hyp)(10)-NH2 and acetyl-(Gly-Pro-3(S)Hyp)(10)-NH2 do not form a collagen triple helix	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASEMENT-MEMBRANE COLLAGEN; INDUCED STABILIZATION; PROLYL 3-HYDROXYLASE; 3-HYDROXYPROLINE; STABILITY; POSITION; CHAIN; WATER; CIS	Hydroxylation of proline residues in the Yaa position of the Gly-Xaa-Yaa repeated sequence to 4(R)-hydroxyproline is essential for the formation of the collagen triple helix. A small number of 3(S)-hydroyxyproline residues are present in most collagens in the Xaa position. Neither the structural nor a biological role is known for 3(S)-hydroxyproline. To characterize the structural role of 3(S)-hydroxyproline, the peptide Ac-(Gly-3(S)Hyp4(R)Hyp)(10)-NH2 was synthesized and analyzed by circular dichroism spectroscopy, analytical ultracentrifugation, and H-1 nuclear magnetic resonance spectroscopy. At 4degreesC in water the circular dichroism spectrum indicates that this peptide was in a polyproline-II-like secondary structure with a positive peak at 225 nm similar to Ac-(Gly-Pro4(R)Hyp)(10)-NH2. The positive peak at 225 nm almost linearly decreases with increasing temperature to 95degreesC without an obvious transition. Although the peptide Ac(Gly-Pro-4(R)Hyp)(10)-NH2 forms a trimer at 10degreesC, sedimentation equilibrium experiments indicate that Ac-(Gly3(S)Hyp-4(R)Hyp)(10)-NH2 is a monomer in water at 7degreesC. To study the role of 3(S)-hydroxyproline in the Yaa position, we synthesized Ac-(Gly-Pro-3(S)Hyp)(10)-NH2. This peptide also does not form a triple helix in water. H-1 Nuclear magnetic resonance spectroscopy data (including line widths and nuclear Overhauser effects) are entirely consistent, with neither Ac-(Gly-3(S)Hyp-4( R)Hyp)(10)-NH2 nor Ac-(Gly-Pro-3( S)Hyp)(10)-NH2 forming a triple helix in water. Therefore 3(S)-hydroxyproline destabilizes the collagen triple helix in either position. In contrast, when 3(S)-hydroxyproline is inserted as a guest in the highly stable-Gly-Pro-4(R)Hyp-repeated host sequence, Ac-(Gly-Pro-4(R)Hyp)(3)-Gly-3(S)Hyp-4(R)Hyp-(Gly-Pro-4(R)Hyp)(4)-Gly-Gly-NH2 forms as stable a trimer (T-m=49.6degreesC) as Ac-( Gly-Pro-4(R)Hyp)(8)-Gly-Gly-NH2 (T-m=48.9degreesC). Given that Ac-( Gly-Pro- 4(R)Hyp)(3)-Gly-4(R)Hyp-Pro-(Gly-Pro4(R)Hyp)(4)-Gly-Gly-NH2 forms a triple helix nearly as stable as the above two peptides (T-m=45.0degreesC) and the knowledge that Ac-(Gly-4(R)Hyp-Pro)(10)-NH2 does not form a triple helix, we conclude that the host environment dominates the structure of host-guest peptides and that these peptides are not necessarily accurate predictors of triple helical stability.	Shriners Hosp Children, Res Dept, Portland, OR 97239 USA; Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97239 USA; Portland State Univ, Dept Chem, Portland, OR 97201 USA; Kitasato Univ, Grad Sch Med Sci, Dept Mol Morphol, Sagamihara, Kanagawa 2288555, Japan	Oregon Health & Science University; Portland State University; Kitasato University	Bachinger, HP (corresponding author), Shriners Hosp Children, Res Dept, 3101 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.	hpb@shcc.org	Mizuno, Kazunori/AAY-7613-2021	Mizuno, Kazunori/0000-0003-3354-6264; Peyton, David/0000-0001-5828-055X				Ackerman MS, 1999, J BIOL CHEM, V274, P7668, DOI 10.1074/jbc.274.12.7668; Adachi E, 1997, INT REV CYTOL, V173, P73; BALACCO G, 1994, J CHEM INF COMP SCI, V34, P1235, DOI 10.1021/ci00022a003; Balacco Giuseppe, 2000, Molecular Biology Today, V1, P23; Bann JG, 2000, J BIOL CHEM, V275, P24466, DOI 10.1074/jbc.M003336200; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BELLON G, 1984, ANAL BIOCHEM, V137, P151, DOI 10.1016/0003-2697(84)90362-2; Bos KJ, 1999, MATRIX BIOL, V18, P149, DOI 10.1016/S0945-053X(99)00015-3; Boudko S, 2002, J MOL BIOL, V317, P459, DOI 10.1006/jmbi.2002.5439; BURGESON RE, 1976, P NATL ACAD SCI USA, V73, P2579, DOI 10.1073/pnas.73.8.2579; Cavanagh J., 1996, PROTEIN NMR SPECTROS; CHUNG E, 1976, BIOCHEM BIOPH RES CO, V71, P1167, DOI 10.1016/0006-291X(76)90776-2; Crouch E, 2001, ANNU REV PHYSIOL, V63, P521, DOI 10.1146/annurev.physiol.63.1.521; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; EBEHARDT ES, 1996, J AM CHEM SOC, V118, P5437; ENGEL J, 1977, BIOPOLYMERS, V16, P601, DOI 10.1002/bip.1977.360160310; Frank S, 2003, J BIOL CHEM, V278, P7747, DOI 10.1074/jbc.C200698200; Frank S, 2001, J MOL BIOL, V308, P1081, DOI 10.1006/jmbi.2001.4644; GAILL F, 1995, J MOL BIOL, V246, P284, DOI 10.1006/jmbi.1994.0084; GAY S, 1979, ARCH BIOCHEM BIOPHYS, V198, P370, DOI 10.1016/0003-9861(79)90509-5; GRYDER RM, 1975, J BIOL CHEM, V250, P2470; Holmgren SK, 1998, NATURE, V392, P666, DOI 10.1038/33573; Improta R, 2002, J AM CHEM SOC, V124, P7857, DOI 10.1021/ja020187p; INOUYE K, 1976, BIOCHIM BIOPHYS ACTA, V420, P133, DOI 10.1016/0005-2795(76)90352-4; INOUYE K, 1982, ARCH BIOCHEM BIOPHYS, V219, P198, DOI 10.1016/0003-9861(82)90149-7; Jenkins CL, 2003, J AM CHEM SOC, V125, P6422, DOI 10.1021/ja034015j; Jenkins CL, 2002, NAT PROD REP, V19, P49, DOI 10.1039/a903001h; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Kefalides N A, 1973, Int Rev Connect Tissue Res, V6, P63; Kivirikko KI, 1998, MATRIX BIOL, V16, P357, DOI 10.1016/S0945-053X(98)90009-9; Kivirikko KI, 1998, MATRIX BIOL, V16, P355, DOI 10.1016/S0945-053X(98)90008-7; KLEINMAN HK, 1982, BIOCHEMISTRY-US, V21, P6188, DOI 10.1021/bi00267a025; KRESINA TF, 1979, BIOCHEMISTRY-US, V18, P3089, DOI 10.1021/bi00581a028; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; MILLER EJ, 1967, J BIOL CHEM, V242, P5481; MILLER EJ, 1971, BIOCHEMISTRY-US, V10, P1652, DOI 10.1021/bi00785a024; Mizuno K, 2003, J BIOL CHEM, V278, P32373, DOI 10.1074/jbc.M304741200; Persikov AV, 2000, BIOCHEMISTRY-US, V39, P14960, DOI 10.1021/bi001560d; PRIVALOV PL, 1982, ADV PROTEIN CHEM, V35, P1, DOI 10.1016/S0065-3233(08)60468-4; REXRODT FW, 1973, EUR J BIOCHEM, V38, P384, DOI 10.1111/j.1432-1033.1973.tb03071.x; RHODES RK, 1978, BIOCHEMISTRY-US, V17, P3442, DOI 10.1021/bi00610a003; RHODES RK, 1979, J BIOL CHEM, V254, P2084; RISTELI J, 1978, ANAL BIOCHEM, V84, P423, DOI 10.1016/0003-2697(78)90060-X; RISTELI J, 1977, EUR J BIOCHEM, V73, P485, DOI 10.1111/j.1432-1033.1977.tb11341.x; SAGE H, 1979, J BIOL CHEM, V254, P9893; Tenner AJ, 1999, CURR OPIN IMMUNOL, V11, P34, DOI 10.1016/S0952-7915(99)80007-7; Vitagliano L, 2001, PROTEIN SCI, V10, P2627, DOI 10.1110/ps.ps.26601a; Vitagliano L, 2001, BIOPOLYMERS, V58, P459, DOI 10.1002/1097-0282(20010415)58:5<459::AID-BIP1021>3.0.CO;2-V; WIJFFELS GL, 1994, BIOCHEM J, V299, P781, DOI 10.1042/bj2990781; WOLFF JS, 1966, FED PROC, V25, P862; WOLFF JS, 1966, J BIOL CHEM, V241, P1300; YURCHENCO PD, 1987, J CELL BIOL, V105, P2559, DOI 10.1083/jcb.105.6.2559	52	27	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 2	2004	279	1					282	287		10.1074/jbc.M308181200	http://dx.doi.org/10.1074/jbc.M308181200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	757GU	14576161	hybrid			2022-12-27	WOS:000187555300035
J	Bougie, I; Bisaillon, M				Bougie, I; Bisaillon, M			Initial binding of the broad spectrum antiviral nucleoside ribavirin to the hepatitis C virus RNA polymerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; NUCLEOTIDE-BINDING; KINETIC MECHANISM; DNA; COMBINATION; VIRAZOLE; INTERFERON-ALPHA-2B; CONFORMATIONS; METABOLISM; THERAPY	Ribavirin is a broad spectrum antiviral nucleoside that displays activity against a variety of RNA and DNA viruses. Ribavirin is currently used in combination with interferon-alpha for the treatment of hepatitis C virus (HCV) infection and was recently shown to be directly incorporated by the HCV RNA polymerase into RNA products. This capacity ultimately leads to increased mutation rates and drastically reduces the viral fitness. As a first step toward elucidating the nature of the specific interaction between ribavirin and the HCV polymerase, we have utilized fluorescence spectroscopy to monitor precisely the binding of ribavirin triphosphate (RTP) to the viral polymerase. This spectroscopic approach allowed us to clearly separate the RTP binding activity from the concomitant catalytic steps. We report here the first detailed study of the binding kinetics and thermodynamic parameters involved in the interaction between RTP and an RNA polymerase. We demonstrate that RTP binds to the same active site as nucleotides. Furthermore, we provide evidence that the HCV polymerase cannot only bind to RTP but also to nonphosphorylated ribavirin, albeit with less affinity. By using various combinations of template-primers, we also demonstrate that base pairing is not involved in the initial binding of RTP to the HCV polymerase. Based on the results of circular dichroism and denaturation studies, we show that the RNA polymerase undergoes subtle conformational changes upon the binding of RTP, although the interaction does not significantly modify the stability of the protein. Finally, although metal ions are required for catalytic activity, they are not required for the initial binding of RTP to the polymerase. Such quantitative analyses are of primary importance for the rational design of new ribavirin analogues of potential therapeutic value and provide crucial insights on the interaction between RTP and the HCV RNA polymerase.	Univ Sherbrooke, Fac Med, Dept Biochim, Sherbrooke, PQ J1H 5N4, Canada	University of Sherbrooke	Bisaillon, M (corresponding author), Univ Sherbrooke, Fac Med, Dept Biochim, 3001 12E Ave, Sherbrooke, PQ J1H 5N4, Canada.	Martin.Bisaillon@USherbrooke.ca						Ago H, 1999, STRUCTURE, V7, P1417, DOI 10.1016/S0969-2126(00)80031-3; ALTER HJ, 1995, BLOOD, V85, P1681, DOI 10.1182/blood.V85.7.1681.bloodjournal8571681; Bougie I, 2003, J BIOL CHEM, V278, P3868, DOI 10.1074/jbc.M209785200; Bressanelli S, 1999, P NATL ACAD SCI USA, V96, P13034, DOI 10.1073/pnas.96.23.13034; Bressanelli S, 2002, J VIROL, V76, P3482, DOI 10.1128/JVI.76.7.3482-3492.2002; Cameron CE, 2001, CURR OPIN INFECT DIS, V14, P757, DOI 10.1097/00001432-200112000-00015; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; Crotty S, 2000, NAT MED, V6, P1375, DOI 10.1038/82191; Crotty S, 2001, P NATL ACAD SCI USA, V98, P6895, DOI 10.1073/pnas.111085598; Davis GL, 1998, NEW ENGL J MED, V339, P1493, DOI 10.1056/NEJM199811193392102; DECLERCQ E, 1993, ADV VIRUS RES, V42, P1, DOI 10.1016/S0065-3527(08)60082-2; Doublie S, 1999, STRUCTURE, V7, pR31, DOI 10.1016/S0969-2126(99)80017-3; EFTINK MR, 1976, BIOCHEMISTRY-US, V15, P672, DOI 10.1021/bi00648a035; ERIKSSON B, 1977, ANTIMICROB AGENTS CH, V11, P946, DOI 10.1128/AAC.11.6.946; Fang SH, 2000, J HEPATOL, V33, P791, DOI 10.1016/S0168-8278(00)80312-8; FERNANDEZLARSSON R, 1990, MOL PHARMACOL, V38, P766; FERRIN LJ, 1986, BIOCHEMISTRY-US, V25, P5131, DOI 10.1021/bi00366a023; Flowers S, 2003, BIOCHEMISTRY-US, V42, P1910, DOI 10.1021/bi025992v; Fried MW, 2002, NEW ENGL J MED, V347, P975, DOI 10.1056/NEJMoa020047; HOUGHTON M, 1996, VIROLOGY, P1035; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; HUGGINS JW, 1991, J INFECT DIS, V164, P1119, DOI 10.1093/infdis/164.6.1119; KOCHHAR DM, 1980, TOXICOL APPL PHARM, V52, P99, DOI 10.1016/0041-008X(80)90252-5; KUCHTA RD, 1987, BIOCHEMISTRY-US, V26, P8410, DOI 10.1021/bi00399a057; KUCHTA RD, 1988, BIOCHEMISTRY-US, V27, P6716, DOI 10.1021/bi00418a012; Lanford RE, 2003, J VIROL, V77, P1092, DOI 10.1128/JVI.77.2.1092-1104.2003; Lau JYN, 2002, HEPATOLOGY, V35, P1002, DOI 10.1053/jhep.2002.32672; Lauer GM, 2001, NEW ENGL J MED, V345, P41, DOI 10.1056/NEJM200107053450107; Lesburg CA, 1999, NAT STRUCT BIOL, V6, P937; Maag D, 2001, J BIOL CHEM, V276, P46094, DOI 10.1074/jbc.C100349200; McHutchison JG, 1998, NEW ENGL J MED, V339, P1485, DOI 10.1056/NEJM199811193392101; MILLER JP, 1977, ANN NY ACAD SCI, V284, P211, DOI 10.1111/j.1749-6632.1977.tb21953.x; MULLER WEG, 1977, BIOCHEM PHARMACOL, V26, P1071, DOI 10.1016/0006-2952(77)90246-5; Ng KKS, 2002, J BIOL CHEM, V277, P1381, DOI 10.1074/jbc.M109261200; PAGE T, 1990, INT J BIOCHEM, V22, P379, DOI 10.1016/0020-711X(90)90140-X; PAN JY, 1995, J BIOL CHEM, V270, P24204, DOI 10.1074/jbc.270.41.24204; PRUSINER P, 1973, NATURE-NEW BIOL, V244, P116, DOI 10.1038/newbio244116a0; Ranjith-Kumar CT, 2002, J VIROL, V76, P12513, DOI 10.1128/JVI.76.24.12513-12525.2002; Saab S, 1999, J CLIN GASTROENTEROL, V28, P289, DOI 10.1097/00004836-199906000-00001; SAITO I, 1990, P NATL ACAD SCI USA, V87, P6547, DOI 10.1073/pnas.87.17.6547; Sarbah SA, 2000, J CLIN GASTROENTEROL, V30, P125, DOI 10.1097/00004836-200003000-00005; SIDWELL RW, 1972, SCIENCE, V177, P705, DOI 10.1126/science.177.4050.705; STREETER DG, 1973, P NATL ACAD SCI USA, V70, P1174, DOI 10.1073/pnas.70.4.1174; Zhou TQ, 1997, J BIOL CHEM, V272, P19731, DOI 10.1074/jbc.272.32.19731; Zuckerman E, 2001, BLOOD, V97, P1555, DOI 10.1182/blood.V97.6.1555	45	32	34	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52471	52478		10.1074/jbc.M308917200	http://dx.doi.org/10.1074/jbc.M308917200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14563844	hybrid			2022-12-27	WOS:000187480700061
J	Moraitis, AN; Giguere, V				Moraitis, AN; Giguere, V			The co-repressor hairless protects ROR alpha orphan nuclear receptor from proteasome-mediated degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; RETINOID-X-RECEPTOR; GLUCOCORTICOID RECEPTOR; 26S PROTEASOME; IN-VIVO; TRANSCRIPTIONAL ACTIVATION; DEPENDENT ACTIVATION; DEFICIENT MICE; RAY-STRUCTURE; HUMAN HOMOLOG	RORalpha is a constitutively active orphan nuclear receptor essential for cerebellar development and is previously shown to regulate genes involved in both myogenesis and adipogenesis. The transcriptional activity of RORalpha is dependent on the presence of a ubiquitous ligand and can be abolished by interaction with Hairless (Hr), a ligand-oblivious nuclear receptor co-repressor. In this study, we first demonstrate that RORalpha is a short-lived protein and that treatment with the MG-132 proteasome inhibitor results in the accumulation of ubiquitin-conjugated receptor and inhibition of transcription. These data show that RORalpha transcriptional activity and degradation are intrinsically linked. In addition, the introduction of inactivation mutations in the ligand-binding pocket and co-regulator-binding surface of RORalpha significantly increases protein stability, indicating that ligand and/or co-regulator binding perpetuates RORalpha degradation. Strikingly, expression of the co-repressor Hr results in the stabilization of RORalpha because of an inhibition of proteasome-mediated degradation of the receptor. Stabilization of RORalpha by Hr requires intact nuclear receptor recognition LXXLL motifs within Hr. Interestingly, the co-repressor nuclear receptor co-repressor (NCoR) has no effect on RORalpha protein turnover. This study shows that stabilization of RORalpha is an essential component of Hr-mediated repression and suggests a molecular mechanism to achieve transcriptional repression by a liganded receptor-co-repressor complex.	McGill Univ, Ctr Hlth, Mol Oncol Grp, Montreal, PQ H3A 1A1, Canada; McGill Univ, Dept Biochem, Montreal, PQ H3A 1A1, Canada; McGill Univ, Dept Med, Montreal, PQ H3A 1A1, Canada; McGill Univ, Dept Oncol, Montreal, PQ H3A 1A1, Canada	McGill University; McGill University; McGill University; McGill University	Giguere, V (corresponding author), McGill Univ, Ctr Hlth, Mol Oncol Grp, Rm H5-21,687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.			Giguere, Vincent/0000-0001-9567-3694				Atkins GB, 1999, MOL ENDOCRINOL, V13, P1550, DOI 10.1210/me.13.9.1550; Baumann CT, 2001, MOL ENDOCRINOL, V15, P485, DOI 10.1210/me.15.4.485; Boudjelal M, 2000, CANCER RES, V60, P2247; Chang C, 2001, J BIOL CHEM, V276, P30956, DOI 10.1074/jbc.M102254200; Conaway RC, 2002, SCIENCE, V296, P1254, DOI 10.1126/science.1067466; Dace A, 2000, P NATL ACAD SCI USA, V97, P8985, DOI 10.1073/pnas.160257997; Dennis AP, 2001, FRONT BIOSCI, V6, pD954, DOI 10.2741/Dennis; Dussault I, 1997, MOL CELL BIOL, V17, P1860, DOI 10.1128/MCB.17.4.1860; Dussault I, 1998, MECH DEVELOP, V70, P147, DOI 10.1016/S0925-4773(97)00187-1; FORMAN BM, 1994, MOL ENDOCRINOL, V8, P1253, DOI 10.1210/me.8.9.1253; GIGUERE V, 1995, MOL CELL BIOL, V15, P2517; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Gonzalez F, 2002, SCIENCE, V296, P548, DOI 10.1126/science.1069490; Gottlicher M, 1996, STEROIDS, V61, P257, DOI 10.1016/0039-128X(96)00032-3; Grossman SR, 2003, SCIENCE, V300, P342, DOI 10.1126/science.1080386; Hamilton BA, 1996, NATURE, V379, P736, DOI 10.1038/379736a0; Harding HP, 1997, MOL ENDOCRINOL, V11, P1737, DOI 10.1210/me.11.11.1737; Hauser S, 2000, J BIOL CHEM, V275, P18527, DOI 10.1074/jbc.M001297200; Hofmann F, 1996, GENE DEV, V10, P2949, DOI 10.1101/gad.10.23.2949; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Hsieh JC, 2003, J BIOL CHEM, V278, P38665, DOI 10.1074/jbc.M304886200; Imhof MO, 1996, MOL CELL BIOL, V16, P2594; Jarvis CI, 2002, MOL CELL ENDOCRINOL, V186, P1, DOI 10.1016/S0303-7207(01)00668-2; Jetten AM, 2002, CELL DEATH DIFFER, V9, P1167, DOI 10.1038/sj.cdd.4401085; Kallen JA, 2002, STRUCTURE, V10, P1697, DOI 10.1016/S0969-2126(02)00912-7; Kopf E, 2000, J BIOL CHEM, V275, P33280, DOI 10.1074/jbc.M002840200; Lau P, 1999, NUCLEIC ACIDS RES, V27, P411, DOI 10.1093/nar/27.2.411; Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4; LEE JW, 1995, NATURE, V374, P91, DOI 10.1038/374091a0; Li XY, 1999, MOL ENDOCRINOL, V13, P1686, DOI 10.1210/me.13.10.1686; Lonard DM, 2000, MOL CELL, V5, P939, DOI 10.1016/S1097-2765(00)80259-2; Masuyama H, 2002, ENDOCRINOLOGY, V143, P55, DOI 10.1210/en.143.1.55; MELCHER K, 1995, MOL CELL BIOL, V15, P2839; Molinari E, 1999, EMBO J, V18, P6439, DOI 10.1093/emboj/18.22.6439; Moraitis AN, 2002, MOL CELL BIOL, V22, P6831, DOI 10.1128/MCB.22.19.6831-6841.2002; Muratani M, 2003, NAT REV MOL CELL BIO, V4, P192, DOI 10.1038/nrm1049; Nawaz Z, 1999, MOL CELL BIOL, V19, P1182; Nomura Y, 1999, BIOCHEM BIOPH RES CO, V260, P729, DOI 10.1006/bbrc.1999.0969; Ottosen S, 2002, SCIENCE, V296, P479, DOI 10.1126/science.1071270; Potter GB, 2001, GENE DEV, V15, P2687, DOI 10.1101/gad.916701; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; Reid G, 2002, CELL MOL LIFE SCI, V59, P821, DOI 10.1007/s00018-002-8470-2; Reid G, 2003, MOL CELL, V11, P695, DOI 10.1016/S1097-2765(03)00090-X; RETNAKARAN R, 1994, MOL ENDOCRINOL, V8, P1234, DOI 10.1210/me.8.9.1234; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Rubin DM, 1997, MOL BIOL REP, V24, P17; Salghetti SE, 2001, SCIENCE, V293, P1651, DOI 10.1126/science.1062079; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; Salghetti SE, 2000, P NATL ACAD SCI USA, V97, P3118, DOI 10.1073/pnas.050007597; Stehlin C, 2001, EMBO J, V20, P5822, DOI 10.1093/emboj/20.21.5822; Steinmayr M, 1998, P NATL ACAD SCI USA, V95, P3960, DOI 10.1073/pnas.95.7.3960; Syvala H, 1996, J STEROID BIOCHEM, V58, P517, DOI 10.1016/0960-0760(96)00073-8; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015; VONBAUR E, 1996, EMBO J, V15, P110; Wallace AD, 2001, J BIOL CHEM, V276, P42714, DOI 10.1074/jbc.M106033200; Zhang JS, 1998, GENE DEV, V12, P1775, DOI 10.1101/gad.12.12.1775; Zhu J, 1999, P NATL ACAD SCI USA, V96, P14807, DOI 10.1073/pnas.96.26.14807; Zilfou JT, 2001, MOL CELL BIOL, V21, P3974, DOI 10.1128/MCB.21.12.3974-3985.2001	59	30	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52511	52518		10.1074/jbc.M308152200	http://dx.doi.org/10.1074/jbc.M308152200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14570920	hybrid			2022-12-27	WOS:000187480700066
J	von Kobbe, C; Thoma, NH; Czyzewski, BK; Pavletich, NP; Bohr, VA				von Kobbe, C; Thoma, NH; Czyzewski, BK; Pavletich, NP; Bohr, VA			Werner syndrome protein contains three structure-specific DNA binding domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOM-SYNDROME PROTEINS; RECQ FAMILY HELICASES; SYNDROME GENE-PRODUCT; WRN PROTEIN; IN-VITRO; EXONUCLEASE; REPLICATION; INTERACTS; COMPLEX; DAMAGE	Werner syndrome (WS) is a premature aging syndrome caused by mutations in the WS gene (WRN) and a deficiency in the function of the Werner protein (WRN). WRN is a multifunctional nuclear protein that catalyzes three DNA-dependent reactions: a 3'-5'-exonuclease, an ATPase, and a 3'-5'-helicase. Deficiency in WRN results in a cellular phenotype of genomic instability. The biochemical characteristics of WRN and the cellular phenotype of WRN mutants suggest that WRN plays an important role in DNA metabolic pathways such as recombination, transcription, replication, and repair. The catalytic activities of WRN have been extensively studied and are fairly well understood. However, much less is known about the domain-specific interactions between WRN and its DNA substrates. This study identifies and characterizes three distinct WRN DNA binding domains using recombinant truncated fragments of WRN and five DNA substrates (long forked duplex, blunt-ended duplex, single-stranded DNA, 5'-overhang duplex, and Holliday junction). Substrate-specific DNA binding activity was detected in three domains, one N-terminal and two different C-terminal WRN fragments (RecQ conserved domain and helicase RNase D conserved domain-containing domains). The substrate specificity of each DNA binding domain may indicate that each protein domain has a distinct biological function. The importance of these results is discussed with respect to proposed roles for WRN in distinct DNA metabolic pathways.	NIA, Lab Mol Gerontol, NIH, Baltimore, MD 21224 USA; Mem Sloan Kettering Canc Ctr, Struct Biol Program, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Howard Hughes Med Inst, New York, NY 10021 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Memorial Sloan Kettering Cancer Center; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center	Bohr, VA (corresponding author), NIA, Lab Mol Gerontol, NIH, 5600 Nathan Shock Dr, Baltimore, MD 21224 USA.		Bohr, Vilhelm/AAP-5931-2020	von Kobbe, Cayetano/0000-0003-3895-3790				Bernstein DA, 2003, EMBO J, V22, P4910, DOI 10.1093/emboj/cdg500; Bernstein DA, 2003, NUCLEIC ACIDS RES, V31, P2778, DOI 10.1093/nar/gkg376; Blander G, 2002, J BIOL CHEM, V277, P50934, DOI 10.1074/jbc.M210479200; Brosh RM, 2000, NUCLEIC ACIDS RES, V28, P2420, DOI 10.1093/nar/28.12.2420; Brosh RM, 2001, EMBO J, V20, P5791; Brosh RM, 1999, J BIOL CHEM, V274, P18341, DOI 10.1074/jbc.274.26.18341; CHENG RZ, 1990, MUTAT RES, V237, P259, DOI 10.1016/0921-8734(90)90008-F; Cooper MP, 2000, GENE DEV, V14, P907; Enomoto T, 2001, J BIOCHEM, V129, P501, DOI 10.1093/oxfordjournals.jbchem.a002883; Gray MD, 1997, NAT GENET, V17, P100, DOI 10.1038/ng0997-100; Harrigan JA, 2003, J BIOL CHEM, V278, P22686, DOI 10.1074/jbc.M213103200; Huang SR, 1998, NAT GENET, V20, P114, DOI 10.1038/2410; Imamura O, 2002, ONCOGENE, V21, P954, DOI 10.1038/sj.onc.1205143; Janscak P, 2003, J MOL BIOL, V330, P29, DOI 10.1016/S0022-2836(03)00534-5; Kamath-Loeb AS, 1998, J BIOL CHEM, V273, P34145, DOI 10.1074/jbc.273.51.34145; Karmakar P, 2002, J BIOL CHEM, V277, P18291, DOI 10.1074/jbc.M111523200; Karow JK, 2000, CURR OPIN GENET DEV, V10, P32, DOI 10.1016/S0959-437X(99)00039-8; Kawabe Y, 2000, J BIOL CHEM, V275, P20963, DOI 10.1074/jbc.C000273200; Lebel M, 1999, J BIOL CHEM, V274, P37795, DOI 10.1074/jbc.274.53.37795; Li JL, 2001, BIOCHEMISTRY-US, V40, P15194, DOI 10.1021/bi011067h; Liu Z, 1999, STRUCTURE, V7, P1557, DOI 10.1016/S0969-2126(00)88346-X; Machwe A, 2000, NUCLEIC ACIDS RES, V28, P2762, DOI 10.1093/nar/28.14.2762; Martin G M, 1978, Birth Defects Orig Artic Ser, V14, P5; Matsumoto T, 1997, NAT GENET, V16, P335, DOI 10.1038/ng0897-335; Mohaghegh P, 2001, NUCLEIC ACIDS RES, V29, P2843, DOI 10.1093/nar/29.13.2843; Moser MJ, 1999, HUM MUTAT, V13, P271, DOI 10.1002/(SICI)1098-1004(1999)13:4<271::AID-HUMU2>3.0.CO;2-Q; Opresko PL, 2003, CARCINOGENESIS, V24, P791, DOI 10.1093/carcin/bgg034; Opresko PL, 2002, J BIOL CHEM, V277, P41110, DOI 10.1074/jbc.M205396200; Opresko PL, 2001, J BIOL CHEM, V276, P44677, DOI 10.1074/jbc.M107548200; Orren DK, 1999, NUCLEIC ACIDS RES, V27, P3557, DOI 10.1093/nar/27.17.3557; Orren DK, 2002, BIOCHEMISTRY-US, V41, P13483, DOI 10.1021/bi0266986; Rodriguez-Lopez AM, 2002, AGING CELL, V1, P30, DOI 10.1046/j.1474-9728.2002.00002.x; Shen JC, 2000, NUCLEIC ACIDS RES, V28, P3260, DOI 10.1093/nar/28.17.3260; Spillare EA, 1999, GENE DEV, V13, P1355, DOI 10.1101/gad.13.11.1355; Szekely AM, 2000, P NATL ACAD SCI USA, V97, P11365, DOI 10.1073/pnas.97.21.11365; TAKEUCHI F, 1982, EXP GERONTOL, V17, P473, DOI 10.1016/S0531-5565(82)80009-0; von Kobbe C, 2003, MOL CELL BIOL, V23, P8601, DOI 10.1128/MCB.23.23.8601-8613.2003; von Kobbe C, 2002, J CELL SCI, V115, P3901, DOI 10.1242/jcs.00076; von Kobbe C, 2002, J BIOL CHEM, V277, P22035, DOI 10.1074/jbc.M200914200; Xue Y, 2002, BIOCHEMISTRY-US, V41, P2901, DOI 10.1021/bi0157161; Yamagata K, 1998, P NATL ACAD SCI USA, V95, P8733, DOI 10.1073/pnas.95.15.8733; Yang Q, 2002, J BIOL CHEM, V277, P31980, DOI 10.1074/jbc.M204111200; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	43	103	104	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52997	53006		10.1074/jbc.M308338200	http://dx.doi.org/10.1074/jbc.M308338200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14534320	hybrid			2022-12-27	WOS:000187480700123
J	Romano, D; Magalon, K; Ciampini, A; Talet, C; Enjalbert, A; Gerard, C				Romano, D; Magalon, K; Ciampini, A; Talet, C; Enjalbert, A; Gerard, C			Differential involvement of the Ras and Rap1 small GTPases in vasoactive intestinal and pituitary adenylyl cyclase activating polypeptides control of the prolactin gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-A; THYROTROPIN-RELEASING-HORMONE; EPIDERMAL-GROWTH-FACTOR; 3',5'-CYCLIC ADENOSINE-MONOPHOSPHATE; SIGNAL-TRANSDUCTION PATHWAYS; PROMOTER ACTIVITY; MAP KINASE; RESPONSIVE ELEMENT; FACTOR-RECEPTOR; CELL-GROWTH	In pituitary cells, transcriptional regulation of the prolactin (PRL) gene and prolactin secretion are controlled by multiple transduction pathways through the activation of G protein coupled receptors and receptor tyrosine kinases. In the somatolactotrope GH4C1 cell line, we have previously identified crosstalk between the MAPKinase cascade ERK1/2 and the cAMP/protein kinase A pathway after the activation of the VPAC2 receptor by vasoactive intestinal polypeptide (VIP) or pituitary adenylyl cyclase-activating polypeptide (PACAP38). In the present study, we focus on the involvement of the GTPases Ras and Rap1 as downstream components of signal transmission initiated by activation of the VPAC2 receptor. By using pull-down experiments, we show that VIP and PACAP38 preferentially activate Rap1, whereas thyrotropin releasing hormone (TRH) and epidermal growth factor (EGF) mainly activate Ras GTPase. Experiments involving the expression of the dominant-negative mutants of Ras and Rap1 signaling (RasN17 or Rap1N17) indicate that both GTPases Ras and Rap1 are recruited for the ERK activation by VIP and PACAP38, whereas Rap1 is poorly involved in TRH or EGF-induced ERK activation. The use of U0126, a selective inhibitor of MAPKinase kinase, provides evidence that MAPKinase contributes to the regulation of the PRL gene. Moreover, cotransfection of RasN17 or Rap1N17 with the PRL proximal promoter luciferase reporter construct indicates that Rap1 may be responsible for VIP/PACAP-induced activation of the PRL promoter. Interestingly, Ras would be involved as a negative regulator of VIP/PACAP-induced PRL gene activation, in contrast to its stimulatory role in the regulation of the PRL promoter by TRH and EGF.	Fac Med Nord, Inst Federat Rech Jean Roche, UMR 6544, F-13916 Marseille 20, France	UDICE-French Research Universities; Aix-Marseille Universite	Gerard, C (corresponding author), Fac Med Nord, Inst Federat Rech Jean Roche, UMR 6544, F-13916 Marseille 20, France.			GERARD, corinne/0000-0001-8748-9010				Augustijn KD, 2002, P NATL ACAD SCI USA, V99, P12657, DOI 10.1073/pnas.192693499; Bos JL, 1998, EMBO J, V17, P6776, DOI 10.1093/emboj/17.23.6776; Bos JL, 2001, NAT REV MOL CELL BIO, V2, P369, DOI 10.1038/35073073; Bouschet T, 2003, J BIOL CHEM, V278, P4778, DOI 10.1074/jbc.M204652200; Busca R, 2000, EMBO J, V19, P2900, DOI 10.1093/emboj/19.12.2900; Cass LA, 2000, ONCOGENE, V19, P924, DOI 10.1038/sj.onc.1203393; Castillo AI, 1998, ONCOGENE, V16, P1981, DOI 10.1038/sj.onc.1200204; Ciullo I, 2001, ONCOGENE, V20, P1186, DOI 10.1038/sj.onc.1204219; Coleman DT, 1996, ENDOCRINOLOGY, V137, P1276, DOI 10.1210/en.137.4.1276; CONRAD KE, 1994, MOL CELL BIOL, V14, P1553, DOI 10.1128/MCB.14.3.1553; CONRAD KE, 1992, ONCOGENE, V7, P1279; Day RN, 1998, J BIOL CHEM, V273, P31909, DOI 10.1074/jbc.273.48.31909; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; Diamond SE, 1999, MOL ENDOCRINOL, V13, P228, DOI 10.1210/me.13.2.228; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; GOURDJI D, 1979, FEBS LETT, V104, P165, DOI 10.1016/0014-5793(79)81107-2; Grewal SS, 2000, J BIOL CHEM, V275, P34433, DOI 10.1074/jbc.M004728200; Herrmann C, 1996, J BIOL CHEM, V271, P6794, DOI 10.1074/jbc.271.12.6794; HOWARD PW, 1995, J BIOL CHEM, V270, P20930, DOI 10.1074/jbc.270.36.20930; Iacovelli L, 2001, MOL PHARMACOL, V60, P924, DOI 10.1124/mol.60.5.924; Jacob KK, 1998, J BIOL CHEM, V273, P4800, DOI 10.1074/jbc.273.8.4800; Jacob KK, 1999, MOL CELL ENDOCRINOL, V152, P137, DOI 10.1016/S0303-7207(99)00043-X; Kanasaki H, 2002, BIOL REPROD, V67, P107, DOI 10.1095/biolreprod67.1.107; Kao SC, 2001, J BIOL CHEM, V276, P18169, DOI 10.1074/jbc.M008870200; KATO Y, 1978, ENDOCRINOLOGY, V103, P554, DOI 10.1210/endo-103-2-554; Kievit P, 2001, MOL ENDOCRINOL, V15, P614, DOI 10.1210/me.15.4.614; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; Le Pechon-Vallee C, 2000, NEUROENDOCRINOLOGY, V72, P46, DOI 10.1159/000054570; LIANG J, 1992, MOL ENDOCRINOL, V6, P885, DOI 10.1210/me.6.6.885; LIN CJ, 1992, NATURE, V360, P765, DOI 10.1038/360765a0; MELOCHE S, 1992, MOL BIOL CELL, V3, P63, DOI 10.1091/mbc.3.1.63; OHMICHI M, 1994, J BIOL CHEM, V269, P3783; Okada S, 1998, EMBO J, V17, P2554, DOI 10.1093/emboj/17.9.2554; Pellegrini-Bouiller I, 1999, J CLIN ENDOCR METAB, V84, P2212, DOI 10.1210/jc.84.6.2212; PICKETT CA, 1994, P NATL ACAD SCI USA, V91, P8612, DOI 10.1073/pnas.91.18.8612; PICKETT CA, 1995, MOL CELL BIOL, V15, P6777; RAWLINGS SR, 1995, ENDOCRINOLOGY, V136, P2088, DOI 10.1210/en.136.5.2088; Rawlings SR, 1996, ENDOCR REV, V17, P4, DOI 10.1210/er.17.1.4; Ray D, 1997, ENDOCR REV, V18, P206, DOI 10.1210/er.18.2.206; Ribeiro-Neto F, 2002, P NATL ACAD SCI USA, V99, P5418, DOI 10.1073/pnas.082122499; RUVKUN G, 1992, NATURE, V360, P711, DOI 10.1038/360711a0; Schmitt JM, 2000, J BIOL CHEM, V275, P25342, DOI 10.1074/jbc.M003213200; Schmitt JM, 2002, J BIOL CHEM, V277, P43024, DOI 10.1074/jbc.M204006200; Schweppe RE, 2001, NUCLEIC ACIDS RES, V29, P1251, DOI 10.1093/nar/29.5.1251; Stork PJS, 2002, TRENDS CELL BIOL, V12, P258, DOI 10.1016/S0962-8924(02)02294-8; Suzuki S, 1999, ENDOCRINOLOGY, V140, P2850, DOI 10.1210/en.140.6.2850; Tsygankova OM, 2001, MOL CELL BIOL, V21, P1921, DOI 10.1128/MCB.21.6.1921-1929.2001; vanBiesen T, 1996, ENDOCR REV, V17, P698, DOI 10.1210/er.17.6.698; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Wang YH, 1999, MOL ENDOCRINOL, V13, P1094, DOI 10.1210/me.13.7.1094; Wang YH, 2000, MOL ENDOCRINOL, V14, P1328, DOI 10.1210/me.14.9.1328; Wolthuis RMF, 1997, EMBO J, V16, P6748, DOI 10.1093/emboj/16.22.6748; Yonehara T, 2001, ENDOCRINOLOGY, V142, P2811, DOI 10.1210/en.142.7.2811	54	34	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51386	51394		10.1074/jbc.M308372200	http://dx.doi.org/10.1074/jbc.M308372200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14551200	hybrid			2022-12-27	WOS:000187206300067
J	Baker, MA; Lane, DJR; Ly, JD; De Pinto, V; Lawen, A				Baker, MA; Lane, DJR; Ly, JD; De Pinto, V; Lawen, A			VDAC1 is a transplasma membrane NADH-ferricyanide reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT ANION CHANNEL; MITOCHONDRIAL OUTER-MEMBRANE; HUMAN B-LYMPHOCYTES; PLASMA-MEMBRANE; HUMAN PORIN; POLYACRYLAMIDE GELS; LARGE-CONDUCTANCE; MAMMALIAN-CELLS; CYTOCHROME-C; PURIFICATION	Porin isoform 1 or VDAC (voltage-dependent anion-selective channel) 1 is the predominant protein in the outer mitochondrial membrane. We demonstrated previously that a plasma membrane NADH-ferricyanide reductase activity becomes up-regulated upon mitochondrial perturbation, and therefore suggested that it functions as a cellular redox sensor. VDAC1 is known to be expressed in the plasma membrane; however, its function there remained a mystery. Here we show that VDAC1, when expressed in the plasma membrane, functions as a NADH-ferricyanide reductase. VDAC1 preparations purified from both plasma membrane and mitochondria fractions exhibit NADH-ferricyanide reductase activity, which can be immunoprecipitated with poly- and monoclonal antibodies directed against VDAC(1). Transfecting cells with pl-VDAC1-GFP, which carries an N-terminal signal peptide, directs VDAC1 to the plasma membrane, as shown by confocal microscopy and FAGS analysis, and significantly increases the plasma membrane NADH-ferricyanide reductase activity of the transfected cells. This novel enzymatic activity of the well known VDAC1 molecule may provide an explanation for its role in the plasma membrane. Our data suggest that a major function of VDAC1 in the plasma membrane is that of a NADH(-ferricyanide) reductase that may be involved in the maintenance of cellular redox homeostasis.	Monash Univ, Sch Biomed Sci, Dept Biochem & Mol Biol, Melbourne, Vic 3800, Australia; Univ Catania, Dipartimento Sci Chim, Biochem & Mol Biol Lab, I-95125 Catania, Italy	Monash University; University of Catania	Lawen, A (corresponding author), Monash Univ, Sch Biomed Sci, Dept Biochem & Mol Biol, Bldg 13D,100 Wellington Rd, Melbourne, Vic 3800, Australia.	alfons.lawen@med.monash.edu.au	Lawen, Alfons/A-6598-2008; De Pinto, Vito/AAC-2634-2019	Lawen, Alfons/0000-0001-6553-9945; De Pinto, Vito/0000-0001-5513-2906; Lane, Darius/0000-0001-8725-6903				BABEL D, 1991, BIOL CHEM H-S, V372, P1027, DOI 10.1515/bchm3.1991.372.2.1027; Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; Bahamonde MI, 2003, J BIOL CHEM, V278, P33284, DOI 10.1074/jbc.M302814200; Baker MA, 2000, ANTIOXID REDOX SIGN, V2, P197, DOI 10.1089/ars.2000.2.2-197; Bathori G, 1999, J BIOL CHEM, V274, P29607, DOI 10.1074/jbc.274.42.29607; BlachlyDyson E, 1997, MOL CELL BIOL, V17, P5727, DOI 10.1128/MCB.17.10.5727; BLATZ AL, 1983, BIOPHYS J, V43, P237, DOI 10.1016/S0006-3495(83)84344-6; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; Buettner R, 2000, P NATL ACAD SCI USA, V97, P3201, DOI 10.1073/pnas.060242297; Bulliard C, 1997, BIOCHEM J, V324, P555, DOI 10.1042/bj3240555; Casadio R, 2002, FEBS LETT, V520, P1, DOI 10.1016/S0014-5793(02)02758-8; COLE T, 1992, BIOL CHEM H-S, V373, P891, DOI 10.1515/bchm3.1992.373.2.891; DEPINTO V, 1989, EUR J BIOCHEM, V183, P179; DEPINTO V, 1987, BIOCHIM BIOPHYS ACTA, V905, P499, DOI 10.1016/0005-2736(87)90480-9; DERMIETZEL R, 1994, P NATL ACAD SCI USA, V91, P499, DOI 10.1073/pnas.91.2.499; ENOCH HG, 1976, J BIOL CHEM, V251, P5095; Gonzalez-Gronow M, 2003, J BIOL CHEM, V278, P27312, DOI 10.1074/jbc.M303172200; GREBING C, 1984, J BIOENERG BIOMEMBR, V16, P517, DOI 10.1007/BF00743243; Grubb DR, 2001, ONCOGENE, V20, P4085, DOI 10.1038/sj.onc.1204545; JAKOB C, 1995, FEBS LETT, V368, P5, DOI 10.1016/0014-5793(95)00465-L; JALONEN T, 1989, ACTA PHYSIOL SCAND, V136, P611, DOI 10.1111/j.1748-1716.1989.tb08709.x; Kim C, 2002, J BIOL CHEM, V277, P16441, DOI 10.1074/jbc.M112311200; KONIG U, 1991, BIOL CHEM H-S, V372, P565, DOI 10.1515/bchm3.1991.372.2.565; Krimmer T, 2001, J CELL BIOL, V152, P289, DOI 10.1083/jcb.152.2.289; LARM JA, 1994, J BIOL CHEM, V269, P30097; Lee AC, 1996, J BIOL CHEM, V271, P26724, DOI 10.1074/jbc.271.43.26724; LEE AC, 1994, J BIOL CHEM, V269, P30974; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; LIU MY, 1992, J BIOENERG BIOMEMBR, V24, P41, DOI 10.1007/BF00769529; Ly JD, 2003, REDOX REP, V8, P3, DOI 10.1179/135100003125001198; MARTINUS RD, 1993, BIOCHEM MOL BIOL INT, V31, P997; McKie AT, 2001, SCIENCE, V291, P1755, DOI 10.1126/science.1057206; MOLLER W, 1985, FEBS LETT, V186, P1, DOI 10.1016/0014-5793(85)81326-0; Morre DM, 2000, J CHROMATOGR B, V743, P377, DOI 10.1016/S0378-4347(00)00058-X; NAVAS P, 1986, BIOCHEM BIOPH RES CO, V135, P110, DOI 10.1016/0006-291X(86)90949-6; NESTERENKO MV, 1994, J BIOCHEM BIOPH METH, V28, P239, DOI 10.1016/0165-022X(94)90020-5; Pavlov EV, 2001, J CELL BIOL, V155, P725, DOI 10.1083/jcb.200107057; PEKARTHY JM, 1972, J BIOL CHEM, V247, P1767; Sampson MJ, 1997, J BIOL CHEM, V272, P18966, DOI 10.1074/jbc.272.30.18966; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Song JM, 1996, J BIOENERG BIOMEMBR, V28, P153, DOI 10.1007/BF02110646; SORGATO MC, 1993, CRIT REV BIOCHEM MOL, V28, P127; THINNES FP, 1992, J BIOENERG BIOMEMBR, V24, P71, DOI 10.1007/BF00769533; THINNES FP, 1989, BIOL CHEM H-S, V370, P1253; Thinnes FP, 2000, MOL GENET METAB, V69, P240, DOI 10.1006/mgme.2000.2968; Vaillant F, 1996, J BIOENERG BIOMEMBR, V28, P531, DOI 10.1007/BF02110443; Van Duijn MM, 1998, J BIOL CHEM, V273, P13415, DOI 10.1074/jbc.273.22.13415; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; WINKELBACH H, 1994, BIOCHEM MED METAB B, V52, P120, DOI 10.1006/bmmb.1994.1042; Yu WH, 1996, J BIOENERG BIOMEMBR, V28, P93, DOI 10.1007/BF02110638; YU WH, 1995, J BIOL CHEM, V270, P13998, DOI 10.1074/jbc.270.23.13998; ZIZI M, 1994, J BIOL CHEM, V269, P1614; Zizi M, 1998, BIOPHYS J, V75, P704, DOI 10.1016/S0006-3495(98)77560-5	54	138	142	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					4811	4819		10.1074/jbc.M311020200	http://dx.doi.org/10.1074/jbc.M311020200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14573604	hybrid			2022-12-27	WOS:000188554300106
J	Baek, KH; Kim, MS; Kim, YS; Shin, JM; Choi, HK				Baek, KH; Kim, MS; Kim, YS; Shin, JM; Choi, HK			DUB-1A, a novel deubiquitinating enzyme subfamily member, is polyubiquitinated and cytokine-inducible in B-lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEUBIQUITYLATING ENZYME; PROTEIN-DEGRADATION; 26S PROTEASOMES; UBIQUITINATION; GENE; COMPLEX; SYSTEM; FAMILY	Recently, we isolated the Dub-2A gene, which encodes a novel murine deubiquitinating enzyme subfamily member, from a bacterial artificial chromosome library clone by PCR amplification with degenerate PCR primers for the Dub-2 cDNA (Baek, K.- H., Mondoux, M. A., Jaster, R., Fire-Levin E., and D'Andrea, A. D. ( 2001) Blood 98, 636 - 642). In this study, we analyzed two more clones from the library to isolate genes encoding other deubiquitinating enzymes. Dub-1A, which encodes the shortest member of the DUB subfamily of deubiquitinating enzymes so far, has been identified in both clones and characterized. Sequence analysis showed that Dub-1A encodes a 468-amino acid protein that has a molecular mass of similar to 51 kDa and that contains a putative catalytic domain (Cys, His, and Asp) conserved among DUB proteins. The amino acid sequence of DUB-1A is 84.5, 84.7, and 85.3% identical to those of DUB-1, DUB-2, and DUB-2A, respectively. Reverse transcription-PCR revealed that Dub-1A is expressed not only in B-lymphocytes in response to interleukin-3 stimulation, but also in T-lymphocytes, brain, heart, liver, lung, kidney, ovary, and spleen. This suggests that Dub-1A may play essential roles in each of these organs. In vivo and in vitro deubiquitinating enzyme assays showed that DUB-1A has functional deubiquitinating activity and that the 5'-flanking sequence of Dub-1A has a functional enhancer domain as shown in Dub-1 and Dub-2A. Interestingly, immunoblot analysis revealed that DUB-1A is polyubiquitinated, indicating that it is degraded through proteasome-mediated degradation. In the absence of JAK2, Dub-1A was expressed at a lower level. This suggests that DUB-1A functions downstream of JAK2 kinase in the interleukin-3 signaling pathway.	Pochom CHA Univ, CHA Gen Hosp, Cell & Gene Therapy Res Inst, Seoul 135081, South Korea; Pochom CHA Univ, CHA Gen Hosp, Grad Sch Life Sci & Biotechnol, Seoul 135081, South Korea	Pochon Cha University; Pochon Cha University	Baek, KH (corresponding author), Pochom CHA Univ, CHA Gen Hosp, Cell & Gene Therapy Res Inst, 605 Yeoksam 1 Dong, Seoul 135081, South Korea.	baek@cha.ac.kr		Baek, Kwang-Hyun/0000-0001-7662-7190				Baek KH, 2003, EXP MOL MED, V35, P1; Baek KH, 2001, BLOOD, V98, P636, DOI 10.1182/blood.V98.3.636; Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; Ben-Neriah Y, 2002, NAT IMMUNOL, V3, P20, DOI 10.1038/ni0102-20; Borodovsky A, 2002, CHEM BIOL, V9, P1149, DOI 10.1016/S1074-5521(02)00248-X; Cadavid ALM, 2000, DEVELOPMENT, V127, P1727; Chung CH, 1999, BIOCHEM BIOPH RES CO, V266, P633, DOI 10.1006/bbrc.1999.1880; Ciechanover A, 2000, BIOESSAYS, V22, P442, DOI 10.1002/(SICI)1521-1878(200005)22:5<442::AID-BIES6>3.0.CO;2-Q; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; D'Andrea A, 1998, CRIT REV BIOCHEM MOL, V33, P337, DOI 10.1080/10409239891204251; Evans PC, 2003, J BIOL CHEM, V278, P23180, DOI 10.1074/jbc.M301863200; Gewies A, 2003, CANCER RES, V63, P682; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Hochstrasser M, 1996, CELL, V84, P813, DOI 10.1016/S0092-8674(00)81058-2; Holzl H, 2000, J CELL BIOL, V150, P119, DOI 10.1083/jcb.150.1.119; Hu M, 2002, CELL, V111, P1041, DOI 10.1016/S0092-8674(02)01199-6; Jaster R, 1997, MOL CELL BIOL, V17, P3364, DOI 10.1128/MCB.17.6.3364; Jaster R, 1999, BBA-GENE STRUCT EXPR, V1446, P308, DOI 10.1016/S0167-4781(99)00095-0; Koegl M, 1999, CELL, V96, P635, DOI 10.1016/S0092-8674(00)80574-7; Layfield R, 2001, NEUROPATH APPL NEURO, V27, P171, DOI 10.1046/j.1365-2990.2001.00335.x; Lee JH, 2001, AM J HEMATOL, V67, P270, DOI 10.1002/ajh.1130; Leggett DS, 2002, MOL CELL, V10, P495, DOI 10.1016/S1097-2765(02)00638-X; Migone TS, 2001, BLOOD, V98, P1935, DOI 10.1182/blood.V98.6.1935; Moazed D, 1996, CELL, V86, P667, DOI 10.1016/S0092-8674(00)80139-7; Pantaleon M, 2001, MECH DEVELOP, V109, P151, DOI 10.1016/S0925-4773(01)00551-2; PAPA FR, 1993, NATURE, V366, P313, DOI 10.1038/366313a0; Park KC, 2002, P NATL ACAD SCI USA, V99, P9733, DOI 10.1073/pnas.152011799; Varshavsky A, 1997, TRENDS BIOCHEM SCI, V22, P383, DOI 10.1016/S0968-0004(97)01122-5; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Wilkinson KD, 2000, SEMIN CELL DEV BIOL, V11, P141, DOI 10.1006/scdb.2000.0164; Wilkinson KD, 1997, FASEB J, V11, P1245, DOI 10.1096/fasebj.11.14.9409543; Zhu Y, 1996, P NATL ACAD SCI USA, V93, P3275, DOI 10.1073/pnas.93.8.3275; Zhu YA, 1997, J BIOL CHEM, V272, P51	34	42	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 23	2004	279	4					2368	2376		10.1074/jbc.M304774200	http://dx.doi.org/10.1074/jbc.M304774200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	764MU	14583620	hybrid			2022-12-27	WOS:000188211300007
J	Sandberg, EM; Ma, XY; VonDerLinden, D; Godeny, MD; Sayeski, PP				Sandberg, EM; Ma, XY; VonDerLinden, D; Godeny, MD; Sayeski, PP			Jak2 tyrosine kinase mediates angiotensin II-dependent inactivation of ERK2 via induction of mitogen-activated protein kinase phosphatase 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; EGF RECEPTOR TRANSACTIVATION; SMOOTH-MUSCLE-CELLS; MAP KINASE; AT(1) RECEPTOR; NUCLEAR TRANSLOCATION; LYSOPHOSPHATIDIC ACID; SIGNAL TRANSDUCER; COUPLED RECEPTORS; PHOSPHORYLATION	Previous work has shown that inhibition of Jak2 via the pharmacological compound AG490 blocks the angiotensin II (Ang II)-dependent activation of ERK2, thereby suggesting an essential role of Jak2 in ERK activation. However, recent studies have thrown into question the specificity of AG490 and therefore the role of Jak2 in ERK activation. To address this, we reconstituted an Ang II signaling system in a Jak2 -/- cell line and measured the ability of Ang II to activate ERK2 in these cells. Controls for this study were the same cells expressing Jak2 via the addition of a Jak2 expression plasmid. In the cells expressing Jak2, Ang II induced a marked increase in ERK2 activity as measured by Western blot analysis and in vitro kinase assays. ERK2 activity returned to basal levels within 30 min. However, in the cells lacking Jak2, Ang II treatment resulted in ERK2 activation that did not return to basal levels until 120 min after ligand addition. Analysis of phosphatase gene expression revealed that Ang II induced mitogen-activated protein kinase phosphatase 1 (MKP-1) expression in cells expressing Jak2 but failed to induce MKP-1 expression in cells lacking Jak2. Therefore, our results suggest that Jak2 is not required for Ang II-induced ERK2 activation. Rather Jak2 is required for Ang II-induced ERK2 inactivation via induction of MKP-1 gene expression.	Univ Florida, Coll Med, Dept Physiol & Funct Genom, Gainesville, FL 32610 USA	State University System of Florida; University of Florida	Sayeski, PP (corresponding author), Univ Florida, Coll Med, Dept Physiol & Funct Genom, POB 100274, Gainesville, FL 32610 USA.	psayeski@phys.med.ufl.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067277] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K01DK060471] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL 67277] Funding Source: Medline; NIDDK NIH HHS [K01 DK 60471] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adachi T, 2002, J CELL PHYSIOL, V192, P151, DOI 10.1002/jcp.10124; Agell N, 2002, CELL SIGNAL, V14, P649, DOI 10.1016/S0898-6568(02)00007-4; Ali MS, 2000, J BIOL CHEM, V275, P15586, DOI 10.1074/jbc.M908931199; Ali MS, 1997, J BIOL CHEM, V272, P23382, DOI 10.1074/jbc.272.37.23382; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; Ausubel F.A., 1997, CURRENT PROTOCOLS MO, DOI DOI 10.1.4; Brondello JM, 1999, SCIENCE, V286, P2514, DOI 10.1126/science.286.5449.2514; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; De Vos J, 2000, BRIT J HAEMATOL, V109, P823, DOI 10.1046/j.1365-2141.2000.02127.x; Gschwind A, 2002, CANCER RES, V62, P6329; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; Kleinberger-Doron N, 1998, EXP CELL RES, V241, P340, DOI 10.1006/excr.1998.4061; Kohlhuber F, 1997, MOL CELL BIOL, V17, P695, DOI 10.1128/MCB.17.2.695; KOSAKO H, 1992, EMBO J, V11, P2903, DOI 10.1002/j.1460-2075.1992.tb05359.x; LEDUC I, 1995, J BIOL CHEM, V270, P4401, DOI 10.1074/jbc.270.9.4401; MARRERO MB, 1995, NATURE, V375, P247, DOI 10.1038/375247a0; Marrero MB, 1997, J BIOL CHEM, V272, P24684, DOI 10.1074/jbc.272.39.24684; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Oda Y, 1999, CAN J PHYSIOL PHARM, V77, P606, DOI 10.1139/cjpp-77-8-606; Oppermann M, 1996, J BIOL CHEM, V271, P13266, DOI 10.1074/jbc.271.22.13266; OSHEROV N, 1993, J BIOL CHEM, V268, P11134; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Ruchatz H, 2003, EXP HEMATOL, V31, P309, DOI 10.1016/S0301-472X(03)00007-9; Salazar EP, 2003, J CELL PHYSIOL, V194, P314, DOI 10.1002/jcp.10204; Sano H, 2001, J IMMUNOL, V166, P3515, DOI 10.4049/jimmunol.166.5.3515; Sayeski PP, 1999, J BIOL CHEM, V274, P33131, DOI 10.1074/jbc.274.46.33131; Sayeski PP, 2001, J BIOL CHEM, V276, P10556, DOI 10.1074/jbc.M008856200; Sayeski PP, 1998, CIRC RES, V82, P1279, DOI 10.1161/01.RES.82.12.1279; Takahashi T, 1997, J BIOL CHEM, V272, P16018, DOI 10.1074/jbc.272.25.16018; Voisin L, 2002, AM J PHYSIOL-CELL PH, V283, pC446, DOI 10.1152/ajpcell.00261.2001; WANG XY, 1995, J BIOL CHEM, V270, P27999; Winston LA, 1995, J BIOL CHEM, V270, P30837, DOI 10.1074/jbc.270.52.30837; WU J, 1993, P NATL ACAD SCI USA, V90, P173, DOI 10.1073/pnas.90.1.173; Xia K, 1996, P NATL ACAD SCI USA, V93, P11681, DOI 10.1073/pnas.93.21.11681; Zhen XC, 2002, MOL PHARMACOL, V62, P1356, DOI 10.1124/mol.62.6.1356; Zhong M, 2003, ENDOCRINOLOGY, V144, P2947, DOI 10.1210/en.2002-221039; ZUHUANG H, 1994, J BIOL CHEM, V269, P21411	38	28	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 16	2004	279	3					1956	1967		10.1074/jbc.M303540200	http://dx.doi.org/10.1074/jbc.M303540200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	762WT	14551204	hybrid			2022-12-27	WOS:000188005700050
J	Chauhan, S; Kunz, S; Davis, K; Roberts, J; Martin, G; Demetriou, MC; Sroka, TC; Cress, AE; Miesfeld, RL				Chauhan, S; Kunz, S; Davis, K; Roberts, J; Martin, G; Demetriou, MC; Sroka, TC; Cress, AE; Miesfeld, RL			Androgen control of cell proliferation and cytoskeletal reorganization in human fibrosarcoma cells - Role of RhoB signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; PROSTATE CARCINOMA-CELLS; TRANSCRIPTIONAL ACTIVATION; FIBRONECTIN BIOSYNTHESIS; MOLECULAR-CLONING; STEROID-HORMONES; EPITHELIAL-CELLS; BINDING PROTEINS; FAMILY GTPASES; MESSENGER-RNA	We recently generated an HT-1080-derived cell line called HT-AR1 that responds to dihydrotestosterone (DHT) treatment by undergoing cell growth arrest in association with cytoskeletal reorganization and induction of neuroendocrine-like cell differentiation. In this report, we show that DHT induces a dose-dependent increase in G(0)/G(1) growth-arrested cells using physiological levels of hormone. The arrested cells increase in cell size and contain a dramatic redistribution of desmoplakin, keratin 5, and chromogranin A proteins. DHT-induced cytoskeletal changes were also apparent from time lapse video microscopy that showed that androgen treatment resulted in the rapid appearance of neuronal-like membrane extensions. Expression profiling analysis using RNA isolated from DHT-treated HT-AR1 cells revealed that androgen receptor activation leads to the coordinate expression of numerous cell signaling genes including RhoB, PTGF-beta, caveolin-2, Egr-1, myosin 1B, and EHM2. Because RhoB has been shown to have a role in tumor suppression and neuronal differentiation in other cell types, we investigated RhoB signaling functions in the HT-AR1 steroid response. We found that steroid induction of RhoB was DHT-specific and that newly synthesized RhoB protein was post-translationally modified and localized to endocytic vesicles. Moreover, treatment with a farnesyl transferase inhibitor reduced DHT-dependent growth arrest, suggesting that prenylated RhoB might function to inhibit HT-AR1 cell proliferation. This was directly shown by transfecting HT-AR1 cells with RhoB coding sequences containing activating or dominant negative mutations.	Univ Arizona, Dept Biochem & Mol Biophys, Tucson, AZ 85721 USA; Univ Arizona, Dept Mol & Cellular Biol, Tucson, AZ 85721 USA; Univ Arizona, Dept Cell Biol & Anat, Tucson, AZ 85721 USA; Univ Arizona, Arizona Canc Ctr, Tucson, AZ 85721 USA	University of Arizona; University of Arizona; University of Arizona; Arizona Center Cancer Care; University of Arizona	Miesfeld, RL (corresponding author), Univ Arizona, Dept Biochem & Mol Biophys, Tucson, AZ 85721 USA.	RLM@u.arizona.edu	Cress, Anne/V-6527-2019	Cress, Anne/0000-0001-6194-0061	NATIONAL CANCER INSTITUTE [P01CA056666, R01CA075152, P30CA023074] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA075152, P01 CA 56666, P01 CA056666, P30 CA023074-27, CA 23074, P30 CA023074, P01 CA056666-090002, R01 CA075152-08, CA 75152] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adamson ED, 2002, TUMOR BIOL, V23, P93, DOI 10.1159/000059711; Adnane J, 2002, CLIN CANCER RES, V8, P2225; Adnane J, 2002, J BIOL CHEM, V277, P8500, DOI 10.1074/jbc.M104367200; Amler LC, 2000, CANCER RES, V60, P6134; Baek SJ, 2001, J BIOL CHEM, V276, P33384, DOI 10.1074/jbc.M101814200; BEMENT WM, 1994, P NATL ACAD SCI USA, V91, P6549, DOI 10.1073/pnas.91.14.6549; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Bjornstrom L, 2002, MOL ENDOCRINOL, V16, P2202, DOI 10.1210/me.2002-0072; Bootcov MR, 1997, P NATL ACAD SCI USA, V94, P11514, DOI 10.1073/pnas.94.21.11514; Brenner KA, 2000, ONCOGENE, V19, P3156, DOI 10.1038/sj.onc.1203626; Bulens F, 1997, J BIOL CHEM, V272, P663; Castoria G, 2003, J CELL BIOL, V161, P547, DOI 10.1083/jcb.200211099; Chapman MS, 1996, MOL ENDOCRINOL, V10, P967, DOI 10.1210/me.10.8.967; Chauhan S, 2003, BIOCHEM BIOPH RES CO, V310, P421, DOI 10.1016/j.bbrc.2003.08.147; Chauhan S, 2003, J STEROID BIOCHEM, V84, P441, DOI 10.1016/S0960-0760(03)00065-7; Chen Z, 2000, J BIOL CHEM, V275, P17974, DOI 10.1074/jbc.C000145200; Cheung J, 2000, MOL ENDOCRINOL, V14, P939, DOI 10.1210/me.14.7.939; Davidson EH, 2002, DEV BIOL, V246, P162, DOI 10.1006/dbio.2002.0635; Davidson EH, 2002, SCIENCE, V295, P1669, DOI 10.1126/science.1069883; Davis TL, 2001, J BIOL CHEM, V276, P26099, DOI 10.1074/jbc.M102811200; DEAN DC, 1988, J CELL BIOL, V106, P2159, DOI 10.1083/jcb.106.6.2159; Ellis S, 2000, TRENDS CELL BIOL, V10, P85, DOI 10.1016/S0962-8924(99)01710-9; Engel ME, 1998, J BIOL CHEM, V273, P9921, DOI 10.1074/jbc.273.16.9921; Fritz G, 2001, J BIOL CHEM, V276, P3115, DOI 10.1074/jbc.M005058200; FRITZ G, 1995, J BIOL CHEM, V270, P25172, DOI 10.1074/jbc.270.42.25172; Fritz G, 2001, NUCLEIC ACIDS RES, V29, P792, DOI 10.1093/nar/29.3.792; Gampel A, 1999, CURR BIOL, V9, P955, DOI 10.1016/S0960-9822(99)80422-9; Haluska P, 2002, EUR J CANCER, V38, P1685, DOI 10.1016/S0959-8049(02)00166-1; Heinlein CA, 2002, MOL ENDOCRINOL, V16, P2181, DOI 10.1210/me.2002-0070; Hoover KB, 2002, DEV GENES EVOL, V212, P230, DOI 10.1007/s00427-002-0231-6; JONES JCR, 1985, J CELL BIOL, V101, P506, DOI 10.1083/jcb.101.2.506; Kampa M, 2002, FASEB J, V16, P1429, DOI 10.1096/fj.02-0131fje; Khan J, 1999, P NATL ACAD SCI USA, V96, P13264, DOI 10.1073/pnas.96.23.13264; Kinoshita Y, 2003, CANCER RES, V63, P3546; Kondoh N, 2002, IN VITRO CELL DEV-AN, V38, P111; Laplante I, 2001, DEV BRAIN RES, V129, P157, DOI 10.1016/S0165-3806(01)00197-3; LEE SL, 1995, J BIOL CHEM, V270, P9971, DOI 10.1074/jbc.270.17.9971; Liu AX, 2001, MOL CELL BIOL, V21, P6906, DOI 10.1128/MCB.21.20.6906-6912.2001; Liu JP, 1998, DEVELOPMENT, V125, P5055; Lokeshwar VB, 1996, CANCER RES, V56, P651; Losel R, 2003, NAT REV MOL CELL BIO, V4, P46, DOI 10.1038/nrm1009; Losel RM, 2003, PHYSIOL REV, V83, P965, DOI 10.1152/physrev.00003.2003; Mattingly RR, 2002, J PHARMACOL EXP THER, V303, P74, DOI 10.1124/jpet.102.036061; MEDCALF RL, 1986, EMBO J, V5, P2217, DOI 10.1002/j.1460-2075.1986.tb04487.x; Michaelson D, 2001, J CELL BIOL, V152, P111, DOI 10.1083/jcb.152.1.111; Morley SD, 1996, MOL ENDOCRINOL, V10, P585, DOI 10.1210/me.10.5.585; Muller JM, 2002, EMBO J, V21, P736, DOI 10.1093/emboj/21.4.736; Nelson PS, 2002, P NATL ACAD SCI USA, V99, P11890, DOI 10.1073/pnas.182376299; Olenik C, 1999, MOL BRAIN RES, V70, P9, DOI 10.1016/S0169-328X(99)00121-7; OLIVER N, 1983, CELL, V33, P287, DOI 10.1016/0092-8674(83)90357-4; Papakonstanti EA, 2003, MOL ENDOCRINOL, V17, P870, DOI 10.1210/me.2002-0253; Paralkar VM, 1998, J BIOL CHEM, V273, P13760, DOI 10.1074/jbc.273.22.13760; Perlman WR, 2003, J COMP NEUROL, V455, P513, DOI 10.1002/cne.10510; Peterziel H, 1999, ONCOGENE, V18, P6322, DOI 10.1038/sj.onc.1203032; Price LS, 2001, SEMIN CANCER BIOL, V11, P167, DOI 10.1006/scbi.2000.0367; RASHEED S, 1974, CANCER, V33, P1027, DOI 10.1002/1097-0142(197404)33:4<1027::AID-CNCR2820330419>3.0.CO;2-Z; Raychowdhury R, 2002, MOL ENDOCRINOL, V16, P2802, DOI 10.1210/me.2001-0292; Razani B, 2002, MOL CELL BIOL, V22, P2329, DOI 10.1128/MCB.22.7.2329-2344.2002; RUNDLETT SE, 1995, MOL CELL ENDOCRINOL, V109, P1, DOI 10.1016/0303-7207(95)03477-O; Scherer PE, 1996, P NATL ACAD SCI USA, V93, P131, DOI 10.1073/pnas.93.1.131; Schiene-Fischer C, 2001, FEBS LETT, V495, P1, DOI 10.1016/S0014-5793(01)02326-2; Schwarze SR, 2002, J BIOL CHEM, V277, P14877, DOI 10.1074/jbc.M200373200; Shimizu K, 2000, GENOMICS, V65, P113, DOI 10.1006/geno.2000.6154; Simerly RB, 2002, ANNU REV NEUROSCI, V25, P507, DOI 10.1146/annurev.neuro.25.112701.142745; Simoncini T, 2003, EUR J ENDOCRINOL, V148, P281, DOI 10.1530/eje.0.1480281; Speck O, 2003, NATURE, V421, P83, DOI 10.1038/nature01295; Strelau J, 2000, ADV RES NEURODEGENER, V8, P273; Svaren J, 2000, J BIOL CHEM, V275, P38524, DOI 10.1074/jbc.M005220200; Takahashi K, 1997, J BIOL CHEM, V272, P23371, DOI 10.1074/jbc.272.37.23371; Tate CG, 2003, BBA-BIOMEMBRANES, V1610, P141, DOI 10.1016/S0005-2736(02)00719-8; Thiel G, 2002, J CELL PHYSIOL, V193, P287, DOI 10.1002/jcp.10178; Thodeti CK, 2002, BIOCHEM J, V365, P157, DOI 10.1042/BJ20020248; Tran NL, 1999, AM J PATHOL, V155, P787, DOI 10.1016/S0002-9440(10)65177-2; Webb GC, 2000, P NATL ACAD SCI USA, V97, P5773, DOI 10.1073/pnas.100126597; Whitacre DC, 2001, ENDOCRINE, V15, P111, DOI 10.1385/ENDO:15:1:111; Wing MR, 2003, J BIOL CHEM, V278, P41253, DOI 10.1074/jbc.M306904200; Xing RH, 1997, CANCER RES, V57, P3585; Yang SZ, 2003, J BIOL CHEM, V278, P39906, DOI 10.1074/jbc.M307250200; YokoyamaKobayashi M, 1997, J BIOCHEM-TOKYO, V122, P622; Yonemura S, 2002, J CELL SCI, V115, P2569	80	17	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 9	2004	279	2					937	944		10.1074/jbc.M311325200	http://dx.doi.org/10.1074/jbc.M311325200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	759DJ	14576147	Green Accepted, hybrid			2022-12-27	WOS:000187722800016
J	Li, GQ; Xiang, Y; Sabapathy, K; Silverman, RH				Li, GQ; Xiang, Y; Sabapathy, K; Silverman, RH			An apoptotic signaling pathway in the interferon antiviral response mediated by RNase L and c-Jun NH2-terminal kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; RIBOTOXIC STRESS-RESPONSE; ACTIVATED PROTEIN-KINASE; N-TERMINAL KINASE; 2-5A-DEPENDENT RNASE; RIBONUCLEASE-L; VIRUS; EXPRESSION; ENZYME; BCL-2	Cellular stress responses induced during viral infections are critical to the health and survival of organisms. In higher vertebrates, interferons (IFNs) mediate the innate antiviral response in part through the action of RNase L, a uniquely regulated enzyme. RNase L is activated by 5'-phosphorylated, 2'-5' oligoadenylates (2 5A) produced from IFN-inducible and double stranded RNA-dependent synthetases. We show that viral activation of the c-Jun NH2-terminal kinases (JNK) family of MAP kinases and viral induction of apoptosis are both deficient in mouse cells lacking RNase L. Also, JNK phosphorylation in response to 2-5A was greatly reduced in RNase L-/- mouse cells. In addition, 2 - 5A treatment of the human ovarian carcinoma cell line, Hey1b, resulted in specific ribosomal RNA cleavage products coinciding with JNK activation. Furthermore, suppression of JNK activity with the chemical inhibitor, SP600125, prevented apoptosis induced by 2 - 5A. In contrast, inhibition of alternative MAP kinases, p38 and ERK, failed to prevent 2-5A-mediated apoptosis. Short interfering RNA to JNK1/JNK2 mRNAs resulted in JNK ablation while also suppressing 2-5A-mediated apoptosis. Moreover, Jnk1(-/-) Jnk2(-/-) cells were highly resistant to the apoptotic effects of IFN and 2 - 5A. These findings suggest that JNK and RNase L function in an integrated signaling pathway during the IFN response that leads to elimination of virus-infected cells through apoptosis.	Cleveland Clin Fdn, Lerner Res Inst, Dept Canc Biol, Cleveland, OH 44195 USA; Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA; Natl Canc Ctr, Div Cellular & Mol Res, Mol Carcinogenesis Lab, Singapore 169610, Singapore	Cleveland Clinic Foundation; Case Western Reserve University; National Cancer Centre Singapore (NCCS)	Silverman, RH (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Canc Biol, NB40,9500 Euclid Ave, Cleveland, OH 44195 USA.	silverr@ccf.org			NATIONAL CANCER INSTITUTE [R01CA044059] Funding Source: NIH RePORTER; NCI NIH HHS [CA44059] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Bain J, 2003, BIOCHEM J, V371, P199, DOI 10.1042/BJ20021535; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Carpten J, 2002, NAT GENET, V30, P181, DOI 10.1038/ng823; Castelli JC, 1997, J EXP MED, V186, P967, DOI 10.1084/jem.186.6.967; Chu WM, 1999, IMMUNITY, V11, P721, DOI 10.1016/S1074-7613(00)80146-6; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; DiazGuerra M, 1997, VIROLOGY, V236, P354, DOI 10.1006/viro.1997.8719; DiazGuerra M, 1997, VIROLOGY, V227, P220, DOI 10.1006/viro.1996.8294; DONG BH, 1995, J BIOL CHEM, V270, P4133, DOI 10.1074/jbc.270.8.4133; Dong BH, 2001, RNA, V7, P361, DOI 10.1017/S1355838201002230; GANGEMI JD, 1989, J INTERFERON RES, V9, P227, DOI 10.1089/jir.1989.9.227; Hess P, 2002, NAT GENET, V32, P201, DOI 10.1038/ng946; Iordanov Mihail S., 2000, Molecular Cell Biology Research Communications, V4, P122, DOI 10.1006/mcbr.2000.0266; Iordanov MS, 1999, J BIOL CHEM, V274, P25801, DOI 10.1074/jbc.274.36.25801; Iordanov MS, 2000, MOL CELL BIOL, V20, P617, DOI 10.1128/MCB.20.2.617-627.2000; Iordanov MS, 1998, J BIOL CHEM, V273, P15794, DOI 10.1074/jbc.273.25.15794; Iordanov MS, 1997, MOL CELL BIOL, V17, P3373, DOI 10.1128/MCB.17.6.3373; Ito T, 1997, J BIOL CHEM, V272, P11671, DOI 10.1074/jbc.272.18.11671; KERR IM, 1978, P NATL ACAD SCI USA, V75, P256, DOI 10.1073/pnas.75.1.256; Kuan CY, 1999, NEURON, V22, P667, DOI 10.1016/S0896-6273(00)80727-8; Le Roy F, 2001, J BIOL CHEM, V276, P48473, DOI 10.1074/jbc.M107482200; Lei K, 2002, MOL CELL BIOL, V22, P4929, DOI 10.1128/MCB.22.13.4929-4942.2002; Leitner WW, 2003, NAT MED, V9, P33, DOI 10.1038/nm813; Liu Y, 1997, J BIOL CHEM, V272, P4419, DOI 10.1074/jbc.272.7.4419; Ludwig S, 2001, J BIOL CHEM, V276, P10990, DOI 10.1074/jbc.M009902200; Maundrell K, 1997, J BIOL CHEM, V272, P25238, DOI 10.1074/jbc.272.40.25238; McLean TI, 1999, J VIROL, V73, P8415, DOI 10.1128/JVI.73.10.8415-8426.1999; NOLANSORDEN NL, 1990, ANAL BIOCHEM, V184, P298, DOI 10.1016/0003-2697(90)90684-2; Peters KL, 2002, P NATL ACAD SCI USA, V99, P6322, DOI 10.1073/pnas.092133199; Putcha GV, 2001, NEURON, V29, P615, DOI 10.1016/S0896-6273(01)00238-0; RICE AP, 1984, J VIROL, V50, P220, DOI 10.1128/JVI.50.1.220-228.1984; Rusch L, 2001, METHOD ENZYMOL, V342, P10, DOI 10.1016/S0076-6879(01)42531-6; Rusch L, 2000, J INTERF CYTOK RES, V20, P1091, DOI 10.1089/107999000750053762; Sabapathy K, 1999, MECH DEVELOP, V89, P115, DOI 10.1016/S0925-4773(99)00213-0; Sabapathy K, 2001, J EXP MED, V193, P317, DOI 10.1084/jem.193.3.317; Sabapathy K, 1999, CURR BIOL, V9, P116, DOI 10.1016/S0960-9822(99)80065-7; Silverman RH, 2002, VIRAL IMMUNOL, V15, P77, DOI 10.1089/088282402317340242; Silverman RH, 2003, BIOCHEMISTRY-US, V42, P1805, DOI 10.1021/bi027147i; Sledz CA, 2003, NAT CELL BIOL, V5, P834, DOI 10.1038/ncb1038; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Ventura JJ, 2003, MOL CELL BIOL, V23, P2871, DOI 10.1128/MCB.23.8.2871-2882.2003; Weston CR, 2002, CURR OPIN GENET DEV, V12, P14, DOI 10.1016/S0959-437X(01)00258-1; Whitfield J, 2001, NEURON, V29, P629, DOI 10.1016/S0896-6273(01)00239-2; Williams B R, 2001, Sci STKE, V2001, pre2, DOI 10.1126/stke.2001.89.re2; Xiang Y, 2002, J VIROL, V76, P5251, DOI 10.1128/JVI.76.10.5251-5259.2002; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; ZHOU AM, 1993, CELL, V72, P753, DOI 10.1016/0092-8674(93)90403-D; Zhou AM, 1997, EMBO J, V16, P6355, DOI 10.1093/emboj/16.21.6355	49	109	111	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 9	2004	279	2					1123	1131		10.1074/jbc.M305893200	http://dx.doi.org/10.1074/jbc.M305893200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	759DJ	14570908	hybrid			2022-12-27	WOS:000187722800036
J	Li, YZ; Sassano, A; Majchrzak, B; Deb, DK; Levy, DE; Gaestel, M; Nebreda, AR; Fish, EN; Platanias, LC				Li, YZ; Sassano, A; Majchrzak, B; Deb, DK; Levy, DE; Gaestel, M; Nebreda, AR; Fish, EN; Platanias, LC			Role of p38 alpha map kinase in Type I interferon signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; MEDIATES TYROSINE PHOSPHORYLATION; STAT1 SERINE PHOSPHORYLATION; CRKL ADAPTER PROTEIN; EARLY GENE INDUCTION; TRANSCRIPTIONAL ACTIVATION; JAK-STAT; PHOSPHATIDYLINOSITOL 3-KINASE; ALPHA; PATHWAY	Multiple signaling pathways are activated during engagement of the Type I interferon (IFN) receptor to mediate biological responses, including the Jak-Stat and Rac1/p38 Map kinase signaling cascades. In the present study we sought to determine the functional relevance of the p38alpha isoform in IFN signaling, using cells from mouse embryos with targeted disruption of the p38alpha gene. Our data demonstrate that p38alpha activation is essential for Type I IFN-dependent transcriptional regulation via ISRE or GAS elements. On the other hand, the function of p38alpha is not required for IFN-dependent Ser(727) or Tyr(701) phosphorylation of Stat1 and does not impact on the formation of ISGF3 or SIF nuclear binding complexes. In efforts to identify downstream effectors of p38 that may mediate IFN-dependent transcriptional responses, we found that IFNalpha activates the kinase Msk1, a known regulator of histone phosphorylation and chromatin remodeling. In other studies, we demonstrate that Type I IFN-dependent activation of the kinases MapKapK-2 and MapKapK-3 is defective in the absence of p38alpha, while Type I IFN-dependent antiviral properties are decreased in cells with targeted disruption of the MapKapK-2 gene. Altogether, our data establish that the p38alpha Map kinase pathway regulates activation of downstream effectors that participate in the induction of IFN-dependent gene transcription, to mediate IFN-responses.	Northwestern Univ, Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Div Hematol Oncol, Chicago, IL 60611 USA; Lakeside Vet Adm Med Ctr, Chicago, IL 60611 USA; Univ Hlth Network, Toronto Res Inst, Div Cell & Mol Biol, Toronto, ON M5S 3E2, Canada; Univ Toronto, Dept Immunol, Toronto, ON M5S 3E2, Canada; Univ Chicago, Ben May Canc Inst, Chicago, IL 60637 USA; NYU, Sch Med, Dept Pathol, New York, NY 10016 USA; Hannover Med Sch, Inst Biochem, D-30625 Hannover, Germany; European Mol Biol Lab, D-69117 Heidelberg, Germany	Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Robert H. Lurie Comprehensive Cancer Center; Northwestern University; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Chicago; New York University; Hannover Medical School; European Molecular Biology Laboratory (EMBL)	Platanias, LC (corresponding author), Northwestern Univ, Sch Med, Robert H Lurie Comprehens Canc Ctr, 710 N Fairbanks St,Olson 8250, Chicago, IL 60611 USA.		Gaestel, Matthias/A-6560-2013; Nebreda, Angel Rodriguez/R-9594-2019; Levy, David/AAG-6202-2019; Levy, David/GPS-4945-2022	Gaestel, Matthias/0000-0002-4944-4652; Levy, David/0000-0002-7320-7788; 	NCI NIH HHS [CA94079, CA77816] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA094079, R01CA077816] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aaronson DS, 2002, SCIENCE, V296, P1653, DOI 10.1126/science.1071545; Adams RH, 2000, MOL CELL, V6, P109, DOI 10.1016/S1097-2765(00)00012-5; Ahmad S, 1997, J BIOL CHEM, V272, P29991, DOI 10.1074/jbc.272.48.29991; Allen M, 2000, J EXP MED, V191, P859, DOI 10.1084/jem.191.5.859; Alsayed Y, 2000, J IMMUNOL, V164, P1800, DOI 10.4049/jimmunol.164.4.1800; Burfoot MS, 1997, J BIOL CHEM, V272, P24183, DOI 10.1074/jbc.272.39.24183; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chatterjee-Kishore M, 2000, TRENDS CELL BIOL, V10, P106, DOI 10.1016/S0962-8924(99)01709-2; Chen HW, 1999, CELL, V98, P675, DOI 10.1016/S0092-8674(00)80054-9; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; Dong C, 2002, ANNU REV IMMUNOL, V20, P55, DOI 10.1146/annurev.immunol.20.091301.131133; Doualla-Bell F, 2001, ENDOCRINOLOGY, V142, P5107, DOI 10.1210/en.142.12.5107; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; Fish EN, 1999, J BIOL CHEM, V274, P571, DOI 10.1074/jbc.274.2.571; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; Fukunaga R, 1997, EMBO J, V16, P1921, DOI 10.1093/emboj/16.8.1921; Goh KC, 1999, EMBO J, V18, P5601, DOI 10.1093/emboj/18.20.5601; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; Jiang Y, 1997, J BIOL CHEM, V272, P30122, DOI 10.1074/jbc.272.48.30122; Kambhampati S, 2003, J BIOL CHEM, V278, P32544, DOI 10.1074/jbc.M301523200; Khanna-Gupta A, 2003, BLOOD, V101, P3460, DOI 10.1182/blood-2002-09-2767; Kotenko SV, 2000, ONCOGENE, V19, P2557, DOI 10.1038/sj.onc.1203524; Kotlyarov A, 1999, NAT CELL BIOL, V1, P94, DOI 10.1038/10061; Kovarik P, 2001, EMBO J, V20, P91, DOI 10.1093/emboj/20.1.91; Kumar S, 1997, BIOCHEM BIOPH RES CO, V235, P533, DOI 10.1006/bbrc.1997.6849; Lekmine F, 2003, J BIOL CHEM, V278, P27772, DOI 10.1074/jbc.M301364200; Lekmine F, 2002, BIOCHEM BIOPH RES CO, V291, P744, DOI 10.1006/bbrc.2002.6516; Mayer IA, 2001, J BIOL CHEM, V276, P28570, DOI 10.1074/jbc.M011685200; McLaughlin MM, 1996, J BIOL CHEM, V271, P8488, DOI 10.1074/jbc.271.14.8488; Morley SJ, 2003, CELL SIGNAL, V15, P741, DOI 10.1016/S0898-6568(03)00008-1; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; Platanias LC, 2003, BLOOD, V101, P4667, DOI 10.1182/blood-2002-12-3647; Platanias LC, 1999, EXP HEMATOL, V27, P1583, DOI 10.1016/S0301-472X(99)00109-5; Platanias LC, 1996, J BIOL CHEM, V271, P278, DOI 10.1074/jbc.271.1.278; Platanias LC, 2003, PHARMACOL THERAPEUT, V98, P129, DOI 10.1016/S0163-7258(03)00016-0; Ramsauer K, 2002, P NATL ACAD SCI USA, V99, P12859, DOI 10.1073/pnas.192264999; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Schafer C, 1998, J BIOL CHEM, V273, P24173, DOI 10.1074/jbc.273.37.24173; Soloaga A, 2003, EMBO J, V22, P2788, DOI 10.1093/emboj/cdg273; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Thomson S, 1999, SEMIN CELL DEV BIOL, V10, P205, DOI 10.1006/scdb.1999.0302; Thomson S, 2001, MOL CELL, V8, P1231, DOI 10.1016/S1097-2765(01)00404-X; THONPSON S, 1999, EMBO J, V18, P4779; Tschopp C., 2000, Molecular Cell Biology Research Communications, V3, P205, DOI 10.1006/mcbr.2000.0217; Uddin S, 2000, J BIOL CHEM, V275, P27634; Uddin S, 1997, J IMMUNOL, V158, P2390; Uddin S, 1999, J BIOL CHEM, V274, P30127, DOI 10.1074/jbc.274.42.30127; UDDIN S, 1995, J BIOL CHEM, V270, P15938, DOI 10.1074/jbc.270.27.15938; Uddin S, 1997, BLOOD, V90, P2574; Verma A, 2002, LEUKEMIA LYMPHOMA, V43, P703, DOI 10.1080/10428190290016782; Verma A, 2002, J BIOL CHEM, V277, P7726, DOI 10.1074/jbc.M106640200; Verma A, 2002, J IMMUNOL, V168, P5984, DOI 10.4049/jimmunol.168.12.5984; Wang XM, 1998, J BIOL CHEM, V273, P9373, DOI 10.1074/jbc.273.16.9373; Wang YB, 1998, J BIOL CHEM, V273, P2161, DOI 10.1074/jbc.273.4.2161; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; WEN Z, 1995, CELL, V28, P241; Wilk-Blaszczak MA, 1998, J NEUROSCI, V18, P112; Zhang JJ, 1998, EMBO J, V17, P6963, DOI 10.1093/emboj/17.23.6963; Zhu XJ, 1997, MOL CELL BIOL, V17, P6618, DOI 10.1128/MCB.17.11.6618	64	95	98	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 9	2004	279	2					970	979		10.1074/jbc.M309927200	http://dx.doi.org/10.1074/jbc.M309927200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	759DJ	14578350	hybrid			2022-12-27	WOS:000187722800020
J	Koc, A; Wheeler, LJ; Mathews, CK; Merrill, GF				Koc, A; Wheeler, LJ; Mathews, CK; Merrill, GF			Hydroxyurea arrests DNA replication by a mechanism that preserves basal dNTP pools	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEOXYRIBONUCLEOSIDE TRIPHOSPHATE POOLS; MOUSE EMBRYO CELLS; RIBONUCLEOTIDE REDUCTASE; SACCHAROMYCES-CEREVISIAE; EXCISION-REPAIR; SYNTHESIS GENES; ACID SYNTHESIS; YEAST; CYCLE; INHIBITION	The relationship between dNTP levels and DNA synthesis was investigated using alpha factor-synchronized yeast treated with the ribonucleotide reductase inhibitor hydroxyurea (HU). Although HU blocked DNA synthesis and prevented the dNTP pool expansion that normally occurs at G(1)/S, it did not exhaust the levels of any of the four dNTPs, which dropped to about 80% of G(1) levels. When dbf4 yeast that are ts for replication initiation were allowed to preaccumulate dNTPs at 37 degreesC before being released to 25 degreesC in the presence of HU, they synthesized 0.3 genome equivalents of DNA and then arrested as dNTPs approached sub-G(1) levels. Accumulation of dNTPs at G(1)/S was not a prerequisite for replication initiation, since dbf4 cells incubated in HU at 25 degreesC were able to replicate when subsequently switched to 37 degreesC in the absence of HU. The replication arrest mechanism was not dependent on the Mec1/ Rad53 pathway, since checkpoint-deficient rad53 cells also failed to exhaust basal dNTPs when incubated in HU. The persistence of basal dNTP levels in HU-arrested cells and partial bypass of the arrest in cells that had preaccumulated dNTPs suggest that cells have a mechanism for arresting DNA chain elongation when dNTP levels are not maintained above a critical threshold.	Oregon State Univ, Dept Biochem & Biophys, Corvallis, OR 97331 USA; Oregon State Univ, Genet Program, Corvallis, OR 97331 USA	Oregon State University; Oregon State University	Merrill, GF (corresponding author), Oregon State Univ, Dept Biochem & Biophys, Corvallis, OR 97331 USA.		KOÇ, AHMET/ABI-3322-2020	KOÇ, AHMET/0000-0003-3484-2137	NCI NIH HHS [CA82633] Funding Source: Medline; NIEHS NIH HHS [P30 ES00210] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA082633] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000210] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ADAMS RLP, 1967, J BIOL CHEM, V242, P1314; ADAMS RLP, 1971, BIOCHIM BIOPHYS ACTA, V240, P455, DOI 10.1016/0005-2787(71)90702-7; BJURSELL KG, 1972, EUR J BIOCHEM, V29, P348, DOI 10.1111/j.1432-1033.1972.tb01995.x; Bundy R, 1999, AM J PHYSIOL-HEART C, V277, pH1799, DOI 10.1152/ajpheart.1999.277.5.H1799; Chabes A, 2003, CELL, V112, P391, DOI 10.1016/S0092-8674(03)00075-8; DAY RS, 1993, MUTAT RES, V293, P215, DOI 10.1016/0921-8777(93)90072-O; ELLEDGE SJ, 1993, BIOESSAYS, V15, P333, DOI 10.1002/bies.950150507; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; ERIKSSON S, 1987, EXP CELL RES, V168, P79, DOI 10.1016/0014-4827(87)90417-4; EXINGER F, 1992, CURR GENET, V22, P9, DOI 10.1007/BF00351735; Gandhi V, 1998, J CLIN ONCOL, V16, P2321, DOI 10.1200/JCO.1998.16.7.2321; HARTWELL LH, 1976, J MOL BIOL, V104, P803, DOI 10.1016/0022-2836(76)90183-2; HEREFORD LM, 1974, J MOL BIOL, V84, P445, DOI 10.1016/0022-2836(74)90451-3; Jorgensen P, 2002, SCIENCE, V297, P395, DOI 10.1126/science.1070850; Koc A, 2003, J BIOL CHEM, V278, P9345, DOI 10.1074/jbc.M213013200; KOHALMI SE, 1991, J MOL BIOL, V220, P933, DOI 10.1016/0022-2836(91)90364-C; LAGERGREN J, 1987, BIOCHEM PHARMACOL, V36, P2985, DOI 10.1016/0006-2952(87)90213-9; Larsson C, 1997, J BACTERIOL, V179, P7243, DOI 10.1128/jb.179.23.7243-7250.1997; LEEDS JM, 1985, MOL CELL BIOL, V5, P3443, DOI 10.1128/MCB.5.12.3443; Lengronne A, 2001, NUCLEIC ACIDS RES, V29, P1433, DOI 10.1093/nar/29.7.1433; LOWNDES NF, 1991, NATURE, V350, P247, DOI 10.1038/350247a0; MCINTOSH EM, 1993, CURR GENET, V24, P185, DOI 10.1007/BF00351790; MCINTOSH EM, 1991, MOL CELL BIOL, V11, P329, DOI 10.1128/MCB.11.1.329; MERRILL GF, 1992, BIOESSAYS, V14, P823, DOI 10.1002/bies.950141206; MULLER EGD, 1994, J BIOL CHEM, V269, P24466; NORDENSKJOLD BA, 1970, J BIOL CHEM, V245, P5360; NORTH TW, 1980, J BIOL CHEM, V255, P6640; Raghuraman MK, 2001, SCIENCE, V294, P115, DOI 10.1126/science.294.5540.115; Santocanale C, 1998, NATURE, V395, P615, DOI 10.1038/27001; Sclafani RA, 2000, J CELL SCI, V113, P2111; SKOOG L, 1974, J BIOL CHEM, V249, P6434; SKOOG L, 1971, EUR J BIOCHEM, V19, P81, DOI 10.1111/j.1432-1033.1971.tb01290.x; SLABAUGH MB, 1991, J VIROL, V65, P2290, DOI 10.1128/JVI.65.5.2290-2298.1991; SLATER ML, 1973, J BACTERIOL, V113, P263, DOI 10.1128/JB.113.1.263-270.1973; SNYDER RD, 1984, MUTAT RES, V131, P163, DOI 10.1016/0167-8817(84)90057-9; SNYDER RD, 1988, MUTAT RES, V200, P193, DOI 10.1016/0027-5107(88)90082-6; TYRSTED G, 1982, BIOCHEM PHARMACOL, V31, P3107, DOI 10.1016/0006-2952(82)90087-9; WALLIS JW, 1989, CELL, V58, P409, DOI 10.1016/0092-8674(89)90855-6; Yao RJ, 2003, P NATL ACAD SCI USA, V100, P6628, DOI 10.1073/pnas.1131932100; Zhao XL, 2001, EMBO J, V20, P3544, DOI 10.1093/emboj/20.13.3544; Zhao XL, 1998, MOL CELL, V2, P329, DOI 10.1016/S1097-2765(00)80277-4; Zhao XL, 2002, P NATL ACAD SCI USA, V99, P3746, DOI 10.1073/pnas.062502299	42	247	255	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	2004	279	1					223	230		10.1074/jbc.M303952200	http://dx.doi.org/10.1074/jbc.M303952200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	757GU	14573610	hybrid			2022-12-27	WOS:000187555300027
J	Singh, B; Charkowicz, D; Mascarenhas, D				Singh, B; Charkowicz, D; Mascarenhas, D			Insulin-like growth factor-independent effects mediated by a C-terminal metal-binding domain of insulin-like growth factor binding protein-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; NITRIC-OXIDE SYNTHASE; TYROSINE PHOSPHORYLATION; OXIDATIVE STRESS; EARLY ENDOSOMES; ACIDIC PH; FACTOR-I; TRANSFERRIN; RECEPTOR; CAVEOLAE	Insulin-like growth factors (IGFs) play a central role in the integration of proliferative and survival responses of most mammalian cell types. IGF-binding protein-3 (IGFBP-3) influences IGF action directly as a carrier of IGFs but also modulates these actions indirectly via independent mechanisms involving interactions with plasma, extracellular matrix and cell surface molecules, conditional proteolysis, cellular uptake, and nuclear transport. Here we demonstrate that a short C-terminal metal-binding domain (MBD) of IGFBP-3 mediates binding to metals. MBD epitopes, sequestered in the intact molecule, are unmasked by incubation in the presence of ferrous ( but not ferric or zinc) ions. An isolated 14-mer MBD peptide triggered apoptotic effects in stressed HEK293 cells as effectively as IGFBP-3. The MBD, which encompasses a nuclear localization sequence and an adjacent putative caveolin-binding sequence, mobilizes rapid cellular uptake and nuclear localization of unrelated proteins such as green fluorescent protein and streptavidin-horseradish peroxidase conjugate. Metal ions stimulate MBD-mediated cellular/nuclear uptake in vivo. Cross-linking studies showed a direct physical interaction of MBD with integrins alpha(v) and beta(1), caveolin-1, and transferrin receptor. MBD-mediated protein mobilization and pro-apoptotic effects are inhibited by nystatin but not chlorpromazine, suggesting an involvement of caveolar-mediated endocytosis. However, MBD effects are inhibited by antibodies to transferrin receptor or integrins. These results are discussed with particular reference to the cell target specificity of IGFBP-3 in disease processes such as cancer and atherosclerosis.	Protigen Inc, Sunnyvale, CA 94085 USA		Mascarenhas, D (corresponding author), Protigen Inc, 525 Del Rey Ave,Ste B, Sunnyvale, CA 94085 USA.	desmond@protigen.com						Abou-Seif MAM, 2001, CLIN CHEM LAB MED, V39, P618, DOI 10.1515/CCLM.2001.099; Balagopalakrishna C, 1999, J LIPID RES, V40, P1347; Baron W, 2003, CURR BIOL, V13, P151, DOI 10.1016/S0960-9822(02)01437-9; Baumrucker CR, 2003, DOMEST ANIM ENDOCRIN, V24, P287, DOI 10.1016/S0739-7240(03)00014-6; Besler HT, 2002, NUTR NEUROSCI, V5, P215, DOI 10.1080/10284150290029205; Campbell L, 2001, ADV DRUG DELIVER REV, V49, P325, DOI 10.1016/S0169-409X(01)00145-4; Campbell PG, 1999, J BIOL CHEM, V274, P30215, DOI 10.1074/jbc.274.42.30215; Campbell PG, 1998, AM J PHYSIOL-ENDOC M, V275, pE321, DOI 10.1152/ajpendo.1998.275.2.E321; Chamberlain LH, 2002, J BIOL CHEM, V277, P49750, DOI 10.1074/jbc.M206936200; Clemmons DR, 2003, ENDOCRINOLOGY, V144, P1664, DOI 10.1210/en.2002-221102; Couet J, 2001, ADV DRUG DELIVER REV, V49, P223, DOI 10.1016/S0169-409X(01)00139-9; DAVIS RJ, 1987, J BIOL CHEM, V262, P13126; Durham SK, 1999, HORM METAB RES, V31, P216, DOI 10.1055/s-2007-978722; Eliceiri BP, 2000, CANCER J, V6, pS245; Eliceiri BP, 2001, CURR OPIN CELL BIOL, V13, P563, DOI 10.1016/S0955-0674(00)00252-0; Everson WV, 2001, TRENDS CARDIOVAS MED, V11, P246, DOI 10.1016/S1050-1738(01)00119-0; Fielding CJ, 2000, BBA-MOL CELL BIOL L, V1529, P210, DOI 10.1016/S1388-1981(00)00150-5; Firth SM, 2002, ENDOCR REV, V23, P824, DOI 10.1210/er.2001-0033; Fowler CA, 2000, INT J CANCER, V88, P448, DOI 10.1002/1097-0215(20001101)88:3<448::AID-IJC18>3.3.CO;2-M; Fowlkes JL, 1996, J BIOL CHEM, V271, P14676, DOI 10.1074/jbc.271.25.14676; Gagescu R, 2000, MOL BIOL CELL, V11, P2775, DOI 10.1091/mbc.11.8.2775; Gui YT, 2001, J CLIN ENDOCR METAB, V86, P2104, DOI 10.1210/jc.86.5.2104; Gustavsson J, 1999, FASEB J, V13, P1961, DOI 10.1096/fasebj.13.14.1961; Hogg N, 2002, IMMUNOL REV, V186, P164, DOI 10.1034/j.1600-065X.2002.18614.x; Hood JD, 2002, SCIENCE, V296, P2404, DOI 10.1126/science.1070200; Jikimoto T, 2002, MOL IMMUNOL, V38, P765, DOI 10.1016/S0161-5890(01)00113-4; Kontush A, 1999, ATHEROSCLEROSIS, V144, P117, DOI 10.1016/S0021-9150(99)00044-1; LAMB DJ, 1994, FEBS LETT, V352, P15, DOI 10.1016/0014-5793(94)00903-1; Leake DS, 1997, ATHEROSCLEROSIS, V129, P149, DOI 10.1016/S0021-9150(96)06035-2; Leal SM, 1997, J BIOL CHEM, V272, P20572, DOI 10.1074/jbc.272.33.20572; Li E, 2001, J VIROL, V75, P5405, DOI 10.1128/JVI.75.11.5405-5409.2001; Liu B, 2003, GROWTH HORM IGF RES, V13, P89, DOI 10.1016/S1096-6374(03)00007-8; Liu BR, 2000, J BIOL CHEM, V275, P33607, DOI 10.1074/jbc.M002547200; Maggi D, 2002, BIOCHEM BIOPH RES CO, V295, P1085, DOI 10.1016/S0006-291X(02)00809-4; Nakamura H, 1996, INT IMMUNOL, V8, P603, DOI 10.1093/intimm/8.4.603; Nimnual AS, 2003, NAT CELL BIOL, V5, P236, DOI 10.1038/ncb938; Oteiza PI, 1997, NEUROCHEM RES, V22, P535, DOI 10.1023/A:1027384432715; Rajah R, 1997, J BIOL CHEM, V272, P12181, DOI 10.1074/jbc.272.18.12181; Razani B, 2001, J BIOL CHEM, V276, P38121; RIFICI VA, 1994, ATHEROSCLEROSIS, V107, P99, DOI 10.1016/0021-9150(94)90145-7; Roberts M, 2001, CURR BIOL, V11, P1392, DOI 10.1016/S0960-9822(01)00442-0; Schedlich LJ, 2000, J BIOL CHEM, V275, P23462, DOI 10.1074/jbc.M002208200; Schubert W, 2002, J BIOL CHEM, V277, P40091, DOI 10.1074/jbc.M205948200; Sharma DK, 2003, J BIOL CHEM, V278, P7564, DOI 10.1074/jbc.M210457200; Smith RM, 1998, CELL SIGNAL, V10, P355, DOI 10.1016/S0898-6568(97)00170-8; SOMMER A, 1993, GROWTH REGULAT, V3, P46; Stubbs M, 2000, MOL MED TODAY, V6, P15, DOI 10.1016/S1357-4310(99)01615-9; Trischler M, 1999, J CELL SCI, V112, P4773; Uittenbogaard A, 2000, J BIOL CHEM, V275, P11278, DOI 10.1074/jbc.275.15.11278; Weinzimer SA, 2001, J CLIN ENDOCR METAB, V86, P1806, DOI 10.1210/jc.86.4.1806; Wouters EFM, 2002, CHEST, V121, p127S, DOI 10.1378/chest.121.5_suppl.127S; Wu HB, 2000, J CELL BIOCHEM, V77, P288, DOI 10.1002/(SICI)1097-4644(20000501)77:2<288::AID-JCB11>3.0.CO;2-J; Zhang Y, 1998, PROTEIN EXPRES PURIF, V12, P159, DOI 10.1006/prep.1997.0834	53	48	53	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 2	2004	279	1					477	487		10.1074/jbc.M307322200	http://dx.doi.org/10.1074/jbc.M307322200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	757GU	14576163	hybrid			2022-12-27	WOS:000187555300058
J	Hendrickx, N; Volanti, C; Moens, U; Seternes, OM; de Witte, P; Vandenheede, JR; Piette, J; Agostinis, P				Hendrickx, N; Volanti, C; Moens, U; Seternes, OM; de Witte, P; Vandenheede, JR; Piette, J; Agostinis, P			Up-regulation of cyclooxygenase-2 and apoptosis resistance by p38 MAPK in hypericin-mediated photodynamic therapy of human cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; NF-KAPPA-B; MESSENGER-RNA STABILITY; CYTOCHROME-C; POSTTRANSCRIPTIONAL CONTROL; SIGNALING PATHWAYS; PROSTAGLANDIN E-2; BCL-2 EXPRESSION; OXIDATIVE STRESS; HELA-CELLS	Photodynamic Therapy (PDT) is an approved anticancer therapy that kills cancer cells by the photochemical generation of reactive oxygen species following absorption of visible light by a photosensitizer, which selectively accumulates in tumors. We report that hypericin-mediated PDT of human cancer cells leads to up-regulation of the inducible cyclooxygenase-2 (COX-2) enzyme and the subsequent release of PGE(2). Dissection of the signaling pathways involved revealed that the selective activation of p38 MAPK alpha and beta mediate COX-2 up-regulation at the protein and messenger levels. The p38 MAPK inhibitor, PD169316, abrogated COX-2 expression in PDT-treated cells, whereas overexpression of the drug-resistant PD169316-insensitive p38 MAPK alpha and beta isoforms restored COX-2 levels in the presence of the kinase inhibitor. Transcriptional regulation by nuclear factor-kappaB was not involved in COX-2 up-regulation by PDT. The half-life of the COX-2 messenger was drastically shortened by p38 MAPK inhibition in transcriptionally arrested cells, suggesting that p38 MAPK mainly acts by stabilizing the COX-2 transcript. Overexpression of WT-p38 MAPK increased cellular resistance to PDT-induced apoptosis, and inhibiting this pathway exacerbated cell death and prevented PGE2 secretion. Hence, the combination of PDT with pyridinyl imidazole inhibitors of p38 MAPK may improve the therapeutic efficacy of PDT by blocking COX-2 up-regulation, which contributes to tumor growth by the release of growth- and pro-angiogenic factors, as well as by sensitizing cancer cells to apoptosis.	Catholic Univ Louvain, Div Biochem, B-3000 Louvain, Belgium; Catholic Univ Louvain, Lab Pharmaceut Biol & Phytopharmacol, B-3000 Louvain, Belgium; Univ Liege, Inst Pathol B23, Lab Virol & Immunol, B-4000 Liege, Belgium; Univ Tromso, Inst Med Biol, Mol Genet Sect, Dept Biochem, N-9037 Tromso, Norway	Universite Catholique Louvain; Universite Catholique Louvain; University of Liege; UiT The Arctic University of Tromso	Agostinis, P (corresponding author), Catholic Univ Louvain, Div Biochem, Campus Gasthuisberg,Herestr 49, B-3000 Louvain, Belgium.		Seternes, Ole Morten/M-9520-2019; Agostinis, Patrizia/AAO-2468-2020; Agostinis, Patrizia/ABI-1177-2020	Seternes, Ole Morten/0000-0001-8537-3612; Agostinis, Patrizia/0000-0003-1314-2115; de Witte, Peter/0000-0002-9989-9567				Agostinis P, 2002, INT J BIOCHEM CELL B, V34, P221, DOI 10.1016/S1357-2725(01)00126-1; Assefa Z, 1999, J BIOL CHEM, V274, P8788, DOI 10.1074/jbc.274.13.8788; Cao Y, 2002, J CELL PHYSIOL, V190, P279, DOI 10.1002/jcp.10068; Chen B, 2002, INT J CANCER, V98, P284, DOI 10.1002/ijc.10175; D'Hallewin MA, 2000, J UROLOGY, V164, P349, DOI 10.1016/S0022-5347(05)67357-0; Dixon DA, 2000, J BIOL CHEM, V275, P11750, DOI 10.1074/jbc.275.16.11750; Dougherty TJ, 1998, JNCI-J NATL CANCER I, V90, P889, DOI 10.1093/jnci/90.12.889; Eyers PA, 1999, FEBS LETT, V451, P191, DOI 10.1016/S0014-5793(99)00552-9; Faour WH, 2001, J BIOL CHEM, V276, P31720, DOI 10.1074/jbc.M104036200; Ferrario A, 2002, CANCER RES, V62, P3956; Granville DJ, 2000, BLOOD, V95, P256; Gugliucci A, 2002, J BIOL CHEM, V277, P31789, DOI 10.1074/jbc.M204450200; Gupta AK, 2001, CANCER RES, V61, P4278; Han JA, 2002, EMBO J, V21, P5635, DOI 10.1093/emboj/cdf591; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; Kamuhabwa AAR, 2003, INT J CANCER, V107, P460, DOI 10.1002/ijc.11396; Korus M, 2002, ONCOGENE, V21, P4601, DOI 10.1038/sj.onc.1205678; Kumagai T, 2002, ARCH BIOCHEM BIOPHYS, V397, P240, DOI 10.1006/abbi.2001.2601; Lasa M, 2000, MOL CELL BIOL, V20, P4265, DOI 10.1128/MCB.20.12.4265-4274.2000; Lasa M, 2001, MOL CELL BIOL, V21, P771, DOI 10.1128/MCB.21.3.771-780.2001; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Liu XH, 1998, CANCER RES, V58, P4245; Madrid LV, 2001, J BIOL CHEM, V276, P18934, DOI 10.1074/jbc.M101103200; Matroule JY, 1999, J BIOL CHEM, V274, P2988, DOI 10.1074/jbc.274.5.2988; Newton R, 1997, BIOCHEM BIOPH RES CO, V234, P85, DOI 10.1006/bbrc.1997.6586; Oleinick NL, 2002, PHOTOCH PHOTOBIO SCI, V1, P1, DOI 10.1039/b108586g; Rousseau S, 2002, EMBO J, V21, P6505, DOI 10.1093/emboj/cdf639; Schoonbroodt S, 2000, BIOCHEM PHARMACOL, V60, P1075, DOI 10.1016/S0006-2952(00)00371-3; Sheng HM, 1998, CANCER RES, V58, P362; Shirahama T, 2001, CANCER, V92, P188, DOI 10.1002/1097-0142(20010701)92:1<188::AID-CNCR1308>3.0.CO;2-W; Silverman N, 2001, GENE DEV, V15, P2321, DOI 10.1101/gad.909001; Slee EA, 1999, CELL DEATH DIFFER, V6, P1067, DOI 10.1038/sj.cdd.4400601; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; Subbaramaiah K, 2003, J BIOL CHEM, V278, P37637, DOI 10.1074/jbc.M301481200; Sun YJ, 2002, CANCER RES, V62, P6323; Vantieghem A, 2002, J BIOL CHEM, V277, P37718, DOI 10.1074/jbc.M204348200; Vantieghem A, 2001, PHOTOCHEM PHOTOBIOL, V74, P133, DOI 10.1562/0031-8655(2001)074&lt;0133:DPMCCR&gt;2.0.CO;2; Vantieghem A, 1998, FEBS LETT, V440, P19, DOI 10.1016/S0014-5793(98)01416-1; Volanti C, 2002, PHOTOCHEM PHOTOBIOL, V75, P36, DOI 10.1562/0031-8655(2002)075<0036:IOOSIN>2.0.CO;2; Williams CS, 1999, ONCOGENE, V18, P7908, DOI 10.1038/sj.onc.1203286; Wong TW, 2003, CANCER RES, V63, P3812; Young PR, 1997, J BIOL CHEM, V272, P12116, DOI 10.1074/jbc.272.18.12116	42	108	117	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52231	52239		10.1074/jbc.M307591200	http://dx.doi.org/10.1074/jbc.M307591200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14557269	hybrid, Green Published			2022-12-27	WOS:000187480700032
J	Henning, D; So, RB; Jin, RY; Lau, LF; Valdez, BC				Henning, D; So, RB; Jin, RY; Lau, LF; Valdez, BC			Silencing of RNA helicase II/Gu alpha inhibits mammalian ribosomal RNA production	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOLAR PROTEIN BOP1; CELL-CYCLE; PROTEOMIC ANALYSIS; INTERFERENCE; LOCALIZATION; BIOGENESIS; DISRUPTION; EXPRESSION; SEQUENCES; ROLES	The intricate production of ribosomal RNA is well defined in yeast, but its complexity in higher organisms is barely understood. We recently showed that down-regulation of nucleolar protein RNA helicase II/Gualpha (RH-II/Gualpha or DDX21) in Xenopus oocytes inhibited processing of 20 S rRNA to 18 S and contributed to degradation of 28 S rRNA (Yang, H., Zhou, J., Ochs, R. L., Henning, D., Jin, R., and Valdez, B. C. (2003) J. Biol. Chem. 278, 38847-38859). Since no nucleolar RNA helicase has been functionally characterized in mammalian cells, we used short interfering RNA to search for functions for RH-II/Gualpha and its paralogue RH-II/Gualpha in rRNA production. Silencing of RH-II/Gualpha by more than 80% in HeLa cells resulted in an almost 80% inhibition of 18 and 28 S rRNA production. This inhibition could be reversed by exogenous expression of wild type RH-II/Gualpha. A helicase-deficient mutant form having ATPase activity was able to rescue the production of 28 S but not 18 S rRNA. A phenotype exhibiting inhibition of 18 S and 28 S rRNA production was also observed when the paralogue RH-II/Gualpha was overexpressed. Both down-regulation of RH-II/Gualpha and overexpression of RH-II/Gualpha slowed cell proliferation. The opposite effects of the two paralogues suggest antagonistic functions.	Baylor Coll Med, Dept Pharmacol, Houston, TX 77030 USA; Univ Illinois, Coll Med, Dept Mol Genet, Chicago, IL 60607 USA	Baylor College of Medicine; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Valdez, BC (corresponding author), Baylor Coll Med, Dept Pharmacol, 1 Baylor Plaza, Houston, TX 77030 USA.	bvaldez@bcm.tmc.edu		Lau, Lester/0000-0002-4364-2914	NATIONAL CANCER INSTITUTE [R01CA095627] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052341] Funding Source: NIH RePORTER; NCI NIH HHS [CA95627] Funding Source: Medline; NIDDK NIH HHS [DK52341] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Andersen JS, 2002, CURR BIOL, V12, P1, DOI 10.1016/S0960-9822(01)00650-9; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; FLORESROZAS H, 1993, J BIOL CHEM, V268, P21372; FULLERPACE FV, 1993, EMBO J, V12, P3619, DOI 10.1002/j.1460-2075.1993.tb06035.x; Ginisty H, 1998, EMBO J, V17, P1476, DOI 10.1093/emboj/17.5.1476; Harnpicharnchai P, 2001, MOL CELL, V8, P505, DOI 10.1016/S1097-2765(01)00344-6; Hayano T, 2003, J BIOL CHEM, V278, P34309, DOI 10.1074/jbc.M304304200; Jankowsky E, 2001, SCIENCE, V291, P121, DOI 10.1126/science.291.5501.121; JIN L, 1995, ARCH BIOCHEM BIOPHYS, V323, P47, DOI 10.1006/abbi.1995.0008; Leary DJ, 2001, FEBS LETT, V509, P145, DOI 10.1016/S0014-5793(01)03143-X; LEE CG, 1993, J BIOL CHEM, V268, P16822; Lee MS, 1996, GENE DEV, V10, P1233, DOI 10.1101/gad.10.10.1233; LEE WC, 1992, MOL CELL BIOL, V12, P3865, DOI 10.1128/MCB.12.9.3865; McManus MT, 2002, NAT REV GENET, V3, P737, DOI 10.1038/nrg908; Meier UT, 2003, NAT GENET, V33, P116, DOI 10.1038/ng0203-116; Olson MOJ, 2002, INT REV CYTOL, V219, P199; Paddison PJ, 2002, CANCER CELL, V2, P17, DOI 10.1016/S1535-6108(02)00092-2; Paule M. R., 1996, RIBOSOMAL RNA STRUCT, P395; PAUSE A, 1992, EMBO J, V11, P2643, DOI 10.1002/j.1460-2075.1992.tb05330.x; Pederson T, 1998, NUCLEIC ACIDS RES, V26, P3871, DOI 10.1093/nar/26.17.3871; Pestov DG, 2001, MOL CELL BIOL, V21, P4246, DOI 10.1128/MCB.21.13.4246-4255.2001; PESTOV DG, 1994, P NATL ACAD SCI USA, V91, P12549, DOI 10.1073/pnas.91.26.12549; Rossler OG, 2001, NUCLEIC ACIDS RES, V29, P2088, DOI 10.1093/nar/29.10.2088; Ruggero D, 2003, SCIENCE, V299, P259, DOI 10.1126/science.1079447; SAVINO R, 1990, EMBO J, V9, P2299, DOI 10.1002/j.1460-2075.1990.tb07401.x; SCHEFFNER M, 1989, CELL, V57, P955, DOI 10.1016/0092-8674(89)90334-6; Scherl A, 2002, MOL BIOL CELL, V13, P4100, DOI 10.1091/mbc.E02-05-0271; Schwer B, 1998, EMBO J, V17, P2086, DOI 10.1093/emboj/17.7.2086; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Shaw PJ, 1995, ANNU REV CELL DEV BI, V11, P93, DOI 10.1146/annurev.cb.11.110195.000521; SHUMAN S, 1993, J BIOL CHEM, V268, P11798; SOLLNERWEBB B, 1996, RIBOSOMAL RNA STRUCT, P469; Strezoska Z, 2002, J BIOL CHEM, V277, P29617, DOI 10.1074/jbc.M204381200; Strezoska Z, 2000, MOL CELL BIOL, V20, P5516, DOI 10.1128/MCB.20.15.5516-5528.2000; Sugimoto M, 2003, MOL CELL, V11, P415, DOI 10.1016/S1097-2765(03)00057-1; Valdez BC, 2000, GENOMICS, V66, P184, DOI 10.1006/geno.2000.6209; Valdez BC, 1995, MOL IMMUNOL, V32, P1207, DOI 10.1016/0161-5890(95)00093-3; Valdez BC, 2002, EXP CELL RES, V276, P249, DOI 10.1006/excr.2002.5538; Valdez BC, 2002, GENE, V284, P53, DOI 10.1016/S0378-1119(01)00888-5; Valdez BC, 1996, NUCLEIC ACIDS RES, V24, P1220, DOI 10.1093/nar/24.7.1220; Valdez BC, 1997, EUR J BIOCHEM, V250, P800, DOI 10.1111/j.1432-1033.1997.00800.x; Venema J, 1999, ANNU REV GENET, V33, P261, DOI 10.1146/annurev.genet.33.1.261; Visintin R, 2000, CURR OPIN CELL BIOL, V12, P372, DOI 10.1016/S0955-0674(00)00102-2; Wang C, 2002, MOL CELL BIOL, V22, P8457, DOI 10.1128/MCB.22.24.8457-8466.2002; Warner JR, 2001, CELL, V107, P133, DOI 10.1016/S0092-8674(01)00531-1; Westermarck J, 2002, EMBO J, V21, P451, DOI 10.1093/emboj/21.3.451; Yanagida M, 2001, PROTEOMICS, V1, P1390, DOI 10.1002/1615-9861(200111)1:11<1390::AID-PROT1390>3.0.CO;2-Z; Yang HS, 2003, J BIOL CHEM, V278, P38847, DOI 10.1074/jbc.M302258200; Zhang SS, 1997, J BIOL CHEM, V272, P11487; Zhao Y, 2003, MOL CELL BIOL, V23, P699, DOI 10.1128/MCB.23.2.699-707.2003	50	62	65	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52307	52314		10.1074/jbc.M310846200	http://dx.doi.org/10.1074/jbc.M310846200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14559904	hybrid			2022-12-27	WOS:000187480700040
J	Lau, PP; Chan, L				Lau, PP; Chan, L			Involvement of a chaperone regulator, Bcl2-associated athanogene-4, in apolipoprotein B mRNA editing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOBEC-1 COMPLEMENTATION FACTOR; BINDING-PROTEIN; MOLECULAR-CLONING; DEATH DOMAINS; GRY-RBP; BAG-1; CYTIDINE; COMPLEX; HSC70; IDENTIFICATION	Apobec-1 is the catalytic subunit of a multicomponent editosome complex that mediates apolipoprotein B (apoB) mRNA editing. We isolated a novel apobec-1-interacting protein by yeast two-hybrid cloning and identified the protein as BAG-4. BAG-4, a chaperone-regulating protein, also known as SODD (silencer of death domains), is a member of the BAG family of proteins. In this report, we found that apobec-1 is localized in the perinucleolar compartment in HepG2 cells and rat liver MCR-RH7777 cells. BAG-4 binds to apobec-1 via its N-terminal region independent of the BAG domain. It is ubiquitously expressed with predominant occurrence in human pancreas, heart, brain, and placenta. Immunoprecipitation experiments confirmed that BAG-4 interacts with Hsc70/Hsp90 in HepG2 cells. BAG-4 tagged with green fluorescent protein (GFP) or FLAG was localized both in cytoplasm of mouse BNLCL.2 liver cells and human liver hepatoma HepG2 cells. After heat shock, GFP-BAG-4 co-localizes with Hsc70 in the nucleus in HepG2 cells, whereas GFP-BAG-4 mutants lacking the BAG domain remain perinuclear. BAG-4 has no effects on apoB mRNA editing in vitro. However, unlike other apobec-1 complementation factors studied to date, antisense knockdown of BAG-4 in BNLCL.2 cells and in MCR-RH7777 cells increases rather than decreases endogenous apoB mRNA editing. Overexpression of BAG-4 in MCR-RH7777 cells also suppresses apoB mRNA editing. ApoB-48 production also increases with antisense BAG-4 expression in MCR-RH7777 cells. We previously showed that apoB mRNA editing is an intranuclear event (Lau, P. P., Xiong, W. J., Zhu, H. J., Chen, S. H., and Chan, L. ( 1991) J. Biol. Chem. 266, 20550-20554). Thus, BAG-4 overexpression down-regulates apoB mRNA editing by shuttling apobec-1 from the intranuclear perinucleolar compartment to the cytoplasm. We propose that BAG-4 functions as a negative regulator for apobec-1-mediated apoB mRNA editing through its ability to suppress the Hsp/Hsc70 chaperone activity and thereby editosome formation and, as a consequence, prevents nuclear localization of the apobec-1 editosome.	Baylor Coll Med, Dept Med, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Chan, L (corresponding author), Baylor Coll Med, Dept Med, Houston, TX 77030 USA.				NHLBI NIH HHS [HL-56668] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056668] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anant S, 2001, J BIOL CHEM, V276, P47338, DOI 10.1074/jbc.M104911200; Antoku K, 2001, BIOCHEM BIOPH RES CO, V286, P1003, DOI 10.1006/bbrc.2001.5512; Bimston D, 1998, EMBO J, V17, P6871, DOI 10.1093/emboj/17.23.6871; Blanc V, 2001, J BIOL CHEM, V276, P46386, DOI 10.1074/jbc.M107654200; Blanc V, 2001, J BIOL CHEM, V276, P10272, DOI 10.1074/jbc.M006435200; CHAN L, 2000, RECENT PROG HORM RES, V55; Chester A, 2003, EMBO J, V22, P3971, DOI 10.1093/emboj/cdg369; Demand J, 1998, MOL CELL BIOL, V18, P2023, DOI 10.1128/MCB.18.4.2023; Doong H, 2002, CANCER LETT, V188, P25, DOI 10.1016/S0304-3835(02)00456-1; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; HEOHFELD J, 1997, EMBO J, V16, P6209; Huang S, 2000, J STRUCT BIOL, V129, P233, DOI 10.1006/jsbi.2000.4247; Huang S, 1998, J CELL BIOL, V143, P35, DOI 10.1083/jcb.143.1.35; Jiang YP, 1999, SCIENCE, V283, P543, DOI 10.1126/science.283.5401.543; Kaminski A, 1998, RNA, V4, P626, DOI 10.1017/S1355838298971898; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; King FW, 2001, EMBO J, V20, P6297, DOI 10.1093/emboj/20.22.6297; LAU PP, 1994, P NATL ACAD SCI USA, V91, P8522, DOI 10.1073/pnas.91.18.8522; LAU PP, 1991, J BIOL CHEM, V266, P20550; Lau PP, 1997, J BIOL CHEM, V272, P1452, DOI 10.1074/jbc.272.3.1452; Lau PP, 2001, BIOCHEM BIOPH RES CO, V282, P977, DOI 10.1006/bbrc.2001.4679; Lau PP, 2001, J BIOL CHEM, V276, P46445, DOI 10.1074/jbc.M109215200; Lellek H, 2000, J BIOL CHEM, V275, P19848, DOI 10.1074/jbc.M001786200; Liao Q, 2001, FEBS LETT, V503, P151, DOI 10.1016/S0014-5793(01)02728-4; Mehta A, 2000, MOL CELL BIOL, V20, P1846, DOI 10.1128/MCB.20.5.1846-1854.2000; Minami Y, 1996, J BIOL CHEM, V271, P19617, DOI 10.1074/jbc.271.32.19617; Sondermann H, 2001, SCIENCE, V291, P1553, DOI 10.1126/science.1057268; Sowden MP, 2002, J CELL SCI, V115, P1027; Takayama S, 1999, J BIOL CHEM, V274, P781, DOI 10.1074/jbc.274.2.781; TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092-8674(95)90410-7; Terada K, 2000, J BIOL CHEM, V275, P24728, DOI 10.1074/jbc.M002021200; Yang Y, 2001, EXP CELL RES, V267, P153, DOI 10.1006/excr.2001.5255; Yang Y, 2000, J BIOL CHEM, V275, P22663, DOI 10.1074/jbc.M910406199; Zylicz M, 2001, EMBO J, V20, P4634, DOI 10.1093/emboj/20.17.4634	34	18	18	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52988	52996		10.1074/jbc.M310153200	http://dx.doi.org/10.1074/jbc.M310153200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14559896	hybrid			2022-12-27	WOS:000187480700122
J	MacDonald, PE; Wang, XL; Xia, FZ; El-kholy, W; Targonsky, ED; Tsushima, RG; Wheeler, MB				MacDonald, PE; Wang, XL; Xia, FZ; El-kholy, W; Targonsky, ED; Tsushima, RG; Wheeler, MB			Antagonism of rat beta-cell voltage-dependent K+ currents by exendin 4 requires dual activation of the cAMP/protein kinase A and phosphatidylinositol 3-kinase signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+-INDUCED CA2+ RELEASE; GLUCAGON-LIKE PEPTIDES; PROTEIN-KINASE; INSULIN-SECRETION; POTASSIUM CHANNELS; 3T3-L1 ADIPOCYTES; GROWTH-FACTOR; ADRENERGIC MODULATION; SELECTIVE-INHIBITION; PANCREATIC-ISLETS	Antagonism of voltage-dependent K+(Kv) currents in pancreatic beta-cells may contribute to the ability of glucagon-like peptide-1 (GLP-1) to stimulate insulin secretion. The mechanism and signaling pathway regulating these currents in rat beta-cells were investigated using the GLP-1 receptor agonist exendin 4. Inhibition of Kv currents resulted from a 20-mV leftward shift in the voltage dependence of steady-state inactivation. Blocking cAMP or protein kinase A (PKA) signaling (Rp-cAMP and H-89, respectively) prevented the inhibition of currents by exendin 4. However, direct activation of this pathway alone by intracellular dialysis of cAMP or the PKA catalytic subunit (cPKA) could not inhibit currents, implicating a role for alternative signaling pathways. A number of phosphorylation sites associated with phosphatidylinositol 3 (PI3)-kinase activation were upregulated in GLP-1-treated MIN6 insulinoma cells, and the PI3 kinase inhibitor wortmannin could prevent antagonism of beta-cell currents by exendin 4. Antagonists of Src family kinases (PP1) and the epidermal growth factor (EGF) receptor (AG1478) also prevented current inhibition by exendin 4, demonstrating a role for Src kinase-mediated trans-activation of the EGF tyrosine kinase receptor. Accordingly, the EGF receptor agonist betacellulin could replicate the effects of exendin 4 in the presence of elevated intracellular cAMP. Downstream, the PKCzeta pseudosubstrate inhibitor could prevent current inhibition by exendin 4. Therefore, antagonism of beta-cell Kv currents by GLP-1 receptor activation requires both cAMP/PKA and PI3 kinase/PKCzeta signaling via trans-activation of the EGF receptor. This represents a novel dual pathway for the control of Kv currents by G protein-coupled receptors.	Univ Toronto, Dept Physiol, Toronto, ON M1H 1E6, Canada; Univ Toronto, Dept Med, Toronto, ON M1H 1E6, Canada	University of Toronto; University of Toronto	Wheeler, MB (corresponding author), Univ Toronto, Dept Physiol, 1 Kings Coll Circle,Rm 3352, Toronto, ON M5S 1A8, Canada.	michael.wheeler@utoronto.ca	MacDonald, Patrick/A-4154-2008	MacDonald, Patrick/0000-0002-5439-6288; Wheeler, Michael B./0000-0002-7480-7267				ATWATER I, 1979, J PHYSIOL-LONDON, V288, P561; Boland LM, 1999, AM J PHYSIOL-CELL PH, V277, pC100, DOI 10.1152/ajpcell.1999.277.1.C100; Bondeva T, 1998, SCIENCE, V282, P293, DOI 10.1126/science.282.5387.293; Buteau J, 1999, DIABETOLOGIA, V42, P856, DOI 10.1007/s001250051238; Buteau J, 2003, DIABETES, V52, P124, DOI 10.2337/diabetes.52.1.124; Buteau J, 2001, DIABETES, V50, P2237, DOI 10.2337/diabetes.50.10.2237; CHOQUET D, 1987, SCIENCE, V235, P1211, DOI 10.1126/science.2434998; Drucker DJ, 2001, ENDOCRINOLOGY, V142, P521, DOI 10.1210/en.142.2.521; Drucker DJ, 2002, GASTROENTEROLOGY, V122, P531, DOI 10.1053/gast.2002.31068; EDWARDS G, 1995, DIABETES RES CLIN PR, V28, pS57, DOI 10.1016/0168-8227(95)01080-W; Egan JM, 2003, AM J PHYSIOL-ENDOC M, V284, pE1072, DOI 10.1152/ajpendo.00315.2002; El-Kholy W, 2003, FASEB J, V17, P720, DOI 10.1096/fj.02-0802fje; Gomez E, 2002, J BIOL CHEM, V277, P48146, DOI 10.1074/jbc.M209165200; Gong JP, 1999, SCIENCE, V285, P1565, DOI 10.1126/science.285.5433.1565; Gopel S, 1999, J PHYSIOL-LONDON, V521, P717, DOI 10.1111/j.1469-7793.1999.00717.x; HENQUIN JC, 1977, BIOCHEM BIOPH RES CO, V77, P551, DOI 10.1016/S0006-291X(77)80014-4; Hui HX, 2003, ENDOCRINOLOGY, V144, P1444, DOI 10.1210/en.2002-220897; Huotari MA, 1998, ENDOCRINOLOGY, V139, P1494, DOI 10.1210/en.139.4.1494; Inoue G, 1998, J BIOL CHEM, V273, P11548, DOI 10.1074/jbc.273.19.11548; Inukai I, 2001, FEBS LETT, V490, P32, DOI 10.1016/S0014-5793(01)02132-9; Kang GX, 2003, J BIOL CHEM, V278, P8279, DOI 10.1074/jbc.M211682200; Kang GX, 2001, J PHYSIOL-LONDON, V536, P375, DOI 10.1111/j.1469-7793.2001.0375c.xd; Kashima Y, 2001, J BIOL CHEM, V276, P46046, DOI 10.1074/jbc.M108378200; Krasilnikov MA, 2000, BIOCHEMISTRY-MOSCOW+, V65, P59; Light PE, 2002, MOL ENDOCRINOL, V16, P2135, DOI 10.1210/me.2002-0084; Lin Tai-An, 1994, Journal of Biological Chemistry, V269, P21255; Liu Y, 1999, CHEM BIOL, V6, P671, DOI 10.1016/S1074-5521(99)80118-5; Lou XL, 2003, J PHYSIOL-LONDON, V548, P191, DOI 10.1113/jphysiol.2002.034405; MacDonald PE, 2003, DIABETOLOGIA, V46, P1046, DOI 10.1007/s00125-003-1159-8; MacDonald PE, 2003, J PHYSIOL-LONDON, V546, P647, DOI 10.1113/jphysiol.2002.035709; MacDonald PE, 2002, DIABETES, V51, pS434, DOI 10.2337/diabetes.51.2007.S434; MacDonald PE, 2002, DIABETES, V51, pS443, DOI 10.2337/diabetes.51.2007.S443; MacDonald PE, 2002, J BIOL CHEM, V277, P44938, DOI 10.1074/jbc.M205532200; MacDonald PE, 2001, MOL ENDOCRINOL, V15, P1423, DOI 10.1210/me.15.8.1423; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; MURRAY KT, 1994, CIRC RES, V75, P999, DOI 10.1161/01.RES.75.6.999; Ricort JM, 1996, EUR J BIOCHEM, V239, P17, DOI 10.1111/j.1432-1033.1996.0017u.x; ROBINSON LJ, 1993, J BIOL CHEM, V268, P26422; Roe MW, 1996, J BIOL CHEM, V271, P32241, DOI 10.1074/jbc.271.50.32241; Salapatek AMF, 1999, MOL ENDOCRINOL, V13, P1305, DOI 10.1210/me.13.8.1305; Schwartzberg PL, 1998, ONCOGENE, V17, P1463, DOI 10.1038/sj.onc.1202176; SOLIVEN B, 1990, J MEMBRANE BIOL, V117, P263, DOI 10.1007/BF01868456; Su JP, 2001, PFLUG ARCH EUR J PHY, V442, P49, DOI 10.1007/s004240000508; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Trumper K, 2000, ANN NY ACAD SCI, V921, P242; WALSH KB, 1988, SCIENCE, V242, P67, DOI 10.1126/science.2845575; WALSH KB, 1989, J GEN PHYSIOL, V93, P841, DOI 10.1085/jgp.93.5.841; Wymann MP, 1998, BBA-MOL CELL BIOL L, V1436, P127, DOI 10.1016/S0005-2760(98)00139-8; Zhang CY, 2001, CELL, V105, P745, DOI 10.1016/S0092-8674(01)00378-6; Zhou J, 2002, J CELL PHYSIOL, V192, P304, DOI 10.1002/jcp.10143; ZUNKLER BJ, 1988, PFLUG ARCH EUR J PHY, V411, P613, DOI 10.1007/BF00580856	51	86	88	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52446	52453		10.1074/jbc.M307612200	http://dx.doi.org/10.1074/jbc.M307612200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14565957	hybrid			2022-12-27	WOS:000187480700058
J	Martin, D; Tawadros, T; Meylan, L; Abderrahmani, A; Condorelli, DF; Waeber, G; Haefliger, JA				Martin, D; Tawadros, T; Meylan, L; Abderrahmani, A; Condorelli, DF; Waeber, G; Haefliger, JA			Critical role of the transcriptional repressor neuron-restrictive silencer factor in the specific control of connexin36 in insulin-producing cell lines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC BETA-CELLS; SCAFFOLD PROTEIN IB1/JIP-1; CYTOKINE-INDUCED APOPTOSIS; SODIUM-CHANNEL GENE; HISTONE DEACETYLASE; TARGET GENES; FACTOR REST; RAT-BRAIN; REGULATORY ELEMENTS; PROMOTER SEQUENCE	Connexin36 (Cx36) is specifically expressed in neurons and in pancreatic beta-cells. Cx36 functions as a critical regulator of insulin secretion and content in beta-cells. In order to identify the molecular mechanisms that control the beta-cell expression of Cx36, we initiated the characterization of the human 5' regulatory region of the CX36 gene. A 2043-bp fragment of the human CX36 promoter was identified from a human BAC library and fused to a luciferase reporter gene. This promoter region was sufficient to confer specific expression to the reporter gene in insulin-secreting cell lines. Within this 5' regulatory region, a putative neuron-restrictive silencer element conserved between rodent and human species was recognized and binds the neuron-restrictive silencing factor (NRSF/REST). This factor is not expressed in insulin-secreting cells and neurons; it functions as a potent repressor through the recruitment of histone deacetylase to the promoter of neuronal genes. The NRSF-mediated repression of Cx36 in HeLa cells was abolished by trichostatin A, confirming the functional importance of histone deacetylase activity. Ectopic expression, by viral gene transfer, of NRSF/REST in different insulin-secreting beta-cell lines induced a marked reduction in Cx36 mRNA and protein content. Moreover, mutations in the Cx36 neuron-restrictive silencer element relieved the low transcriptional activity of the human CX36 promoter observed in HeLa cells and in INS-1 cells expressing NRSF/REST. The data showed that cx36 gene expression in insulin-producing beta-cell lines is strictly controlled by the transcriptional repressor NRSF/REST indicating that Cx36 participates to the neuronal phenotype of the pancreatic beta-cells.	Univ Hosp, Dept Internal Med, Lab Mol Biol 19 135S, Lausanne 1011, Switzerland; Univ Catania, Dept Chem Sci, I-95125 Catania, Italy	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Catania	Haefliger, JA (corresponding author), Univ Hosp, Dept Internal Med, Lab Mol Biol 19 135S, Lausanne 1011, Switzerland.		Condorelli, Daniele Filippo/AAS-1810-2021; Abderrahmani, Amar/O-3124-2017	Condorelli, Daniele Filippo/0000-0002-0311-5386; Abderrahmani, Amar/0000-0003-0752-0343; Haefliger, Jacques-Antoine/0000-0003-2732-1667; Waeber, Gerard/0000-0003-4193-788X	Telethon [E.1283] Funding Source: Medline	Telethon(Fondazione Telethon)		Abderrahmani A, 2001, MOL CELL BIOL, V21, P7256, DOI 10.1128/MCB.21.21.7256-7267.2001; ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; Atouf F, 1997, J BIOL CHEM, V272, P1929, DOI 10.1074/jbc.272.3.1929; Ballas N, 2001, NEURON, V31, P353, DOI 10.1016/S0896-6273(01)00371-3; Belluardo N, 1999, J NEUROSCI RES, V57, P740, DOI 10.1002/(SICI)1097-4547(19990901)57:5<740::AID-JNR16>3.0.CO;2-Z; Belluardo N, 2000, BRAIN RES, V865, P121, DOI 10.1016/S0006-8993(00)02300-3; Bondurand N, 2001, HUM MOL GENET, V10, P2783, DOI 10.1093/hmg/10.24.2783; Bonny C, 2000, J BIOL CHEM, V275, P16466, DOI 10.1074/jbc.M908297199; Bonny C, 1998, J BIOL CHEM, V273, P1843, DOI 10.1074/jbc.273.4.1843; Bruzzone R, 1996, BIOESSAYS, V18, P709, DOI 10.1002/bies.950180906; Bruzzone R, 1996, EUR J BIOCHEM, V238, P1, DOI 10.1111/j.1432-1033.1996.0001q.x; Calabrese A, 2003, DIABETES, V52, P417, DOI 10.2337/diabetes.52.2.417; Calabrese A, 2001, CELL COMMUN ADHES, V8, P387, DOI 10.3109/15419060109080759; Carystinos GD, 2003, MOL PHARMACOL, V63, P821, DOI 10.1124/mol.63.4.821; Caton D, 2003, J CELL SCI, V116, P2285, DOI 10.1242/jcs.00442; Chen ZF, 1998, NAT GENET, V20, P136, DOI 10.1038/2431; CHIN LS, 1994, J BIOL CHEM, V269, P18507; CHONG JHA, 1995, CELL, V80, P949, DOI 10.1016/0092-8674(95)90298-8; Condorelli DF, 1998, EUR J NEUROSCI, V10, P1202, DOI 10.1046/j.1460-9568.1998.00163.x; Condorelli DF, 2000, BRAIN RES REV, V32, P72, DOI 10.1016/S0165-0173(99)00068-5; DECAMILLI P, 1990, ANNU REV PHYSIOL, V52, P625, DOI 10.1146/annurev.ph.52.030190.003205; Duval N, 2002, J CELL SCI, V115, P3241; Fernandez-Cobo M, 2001, J CELL BIOCHEM, V81, P514, DOI 10.1002/1097-4644(20010601)81:3<514::AID-JCB1065>3.0.CO;2-J; Geimonen E, 1996, J BIOL CHEM, V271, P23667, DOI 10.1074/jbc.271.39.23667; Grimes JA, 2000, J BIOL CHEM, V275, P9461, DOI 10.1074/jbc.275.13.9461; Haefliger JA, 2003, J CELL SCI, V116, P1463, DOI 10.1242/jcs.00356; Haefliger JA, 2002, EXP CELL RES, V274, P216, DOI 10.1006/excr.2001.5465; Haefliger JA, 2001, KIDNEY INT, V60, P190, DOI 10.1046/j.1523-1755.2001.00786.x; Helbecque N, 2003, MOL PSYCHIATR, V8, P413, DOI 10.1038/sj.mp.4001344; Huang YF, 1999, NAT NEUROSCI, V2, P867, DOI 10.1038/13165; Kallunki P, 1998, P NATL ACAD SCI USA, V95, P3233, DOI 10.1073/pnas.95.6.3233; Kasahara H, 2001, J CLIN INVEST, V108, P189, DOI 10.1172/JCI200112694; KRANER SD, 1992, NEURON, V9, P37, DOI 10.1016/0896-6273(92)90218-3; Kuhnel F, 2000, J BIOL CHEM, V275, P6421, DOI 10.1074/jbc.275.9.6421; Le Gurun S, 2003, J BIOL CHEM, V278, P37690, DOI 10.1074/jbc.M212382200; Lietz M, 2003, EUR J BIOCHEM, V270, P2, DOI 10.1046/j.1432-1033.2003.03360.x; MIYAZAKI JI, 1990, ENDOCRINOLOGY, V127, P126, DOI 10.1210/endo-127-1-126; MORI N, 1992, NEURON, V9, P45, DOI 10.1016/0896-6273(92)90219-4; Morsi AS, 2003, TOXICOL IN VITRO, V17, P191, DOI 10.1016/S0887-2333(03)00003-1; Myers SJ, 1998, J NEUROSCI, V18, P6723; Naruse Y, 1999, P NATL ACAD SCI USA, V96, P13691, DOI 10.1073/pnas.96.24.13691; Nishimura E, 1996, NEUROSCI LETT, V211, P101, DOI 10.1016/0304-3940(96)12722-1; Rash JE, 2001, CELL COMMUN ADHES, V8, P315, DOI 10.3109/15419060109080745; Rash JE, 2001, J NEUROSCI, V21, P1983, DOI 10.1523/JNEUROSCI.21-06-01983.2001; Rash JE, 2000, P NATL ACAD SCI USA, V97, P7573, DOI 10.1073/pnas.97.13.7573; Richard G, 2000, EXP DERMATOL, V9, P77, DOI 10.1034/j.1600-0625.2000.009002077.x; Roopra A, 2000, MOL CELL BIOL, V20, P2147, DOI 10.1128/MCB.20.6.2147-2157.2000; SCHAACK J, 1995, J VIROL, V69, P3920, DOI 10.1128/JVI.69.6.3920-3923.1995; SCHOENHERR CJ, 1995, SCIENCE, V267, P1360, DOI 10.1126/science.7871435; Schoenherr CJ, 1996, P NATL ACAD SCI USA, V93, P9881, DOI 10.1073/pnas.93.18.9881; Serre-Beinier V, 2000, DIABETES, V49, P727, DOI 10.2337/diabetes.49.5.727; Spray DC, 1998, CIRC RES, V83, P679, DOI 10.1161/01.RES.83.6.679; Stock A, 2000, BIOL CHEM, V381, P973, DOI 10.1515/BC.2000.120; TapiaRamirez J, 1997, P NATL ACAD SCI USA, V94, P1177, DOI 10.1073/pnas.94.4.1177; Tawadros T, 2002, J CELL SCI, V115, P385; Teunissen BEJ, 2002, BIOCHEM BIOPH RES CO, V292, P71, DOI 10.1006/bbrc.2002.6621; Thiel G, 1998, J BIOL CHEM, V273, P26891, DOI 10.1074/jbc.273.41.26891; THOMASREETZ A, 1993, P NATL ACAD SCI USA, V90, P5317, DOI 10.1073/pnas.90.11.5317; Timmusk T, 1999, J BIOL CHEM, V274, P1078; Tu ZJ, 2001, MOL REPROD DEV, V59, P17, DOI 10.1002/mrd.1002; VOZZI C, 1995, J CELL BIOL, V131, P1561, DOI 10.1083/jcb.131.6.1561; Waeber G, 2000, NAT GENET, V24, P291, DOI 10.1038/73523; WHITE TW, 1995, KIDNEY INT, V48, P1148, DOI 10.1038/ki.1995.398; Willecke K, 2002, BIOL CHEM, V383, P725, DOI 10.1515/BC.2002.076; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174	65	55	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					53082	53089		10.1074/jbc.M306861200	http://dx.doi.org/10.1074/jbc.M306861200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14565956	hybrid			2022-12-27	WOS:000187480700132
J	Shivakrupa, R; Radha, V; Sudhakar, C; Swarup, G				Shivakrupa, R; Radha, V; Sudhakar, C; Swarup, G			Physical and functional interaction between Hck tyrosine kinase and guanine nucleotide exchange factor C3G results in apoptosis, which is independent of C3G catalytic domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SH3 DOMAIN; CELL-ADHESION; GENE HCK; R-RAS; PROTEIN; ACTIVATION; CRK; RAP1; PHOSPHORYLATION; IDENTIFICATION	The hematopoietic cell kinase Hck is a Src family tyrosine kinase expressed in cells of myelomonocytic lineage, B lymphocytes, and embryonic stem cells. To study its role in signaling pathways we used the Hck-SH3 domain in protein interaction cloning and identified C3G, the guanine nucleotide exchange factor for Rap1 and R-Ras, as a protein that associated with Hck. This interaction was direct and was mediated partly through the proline-rich region of C3G. C3G could be co-immunoprecipitated with Hck from Cos-1 cells transfected with Hck and C3G. C3G was phosphorylated on tyrosine 504 in cells when coexpressed with Hck but not with a catalytically inactive mutant of Hck. Phosphorylation of endogenous C3G at Tyr-504 was increased by treatment of human myelomonocytic THP-1 cells with mercuric chloride, which is known to activate Hck tyrosine kinase specifically. Coexpression of Hck with C3G induced a high level of apoptosis in many cell lines by 30 - 42 h of transfection. Induction of apoptosis was not dependent on Tyr-504 phosphorylation or the catalytic domain of C3G but required the catalytic activity of Hck. Using dominant negative constructs of caspases we found that caspase-1, - 8, and - 9 are involved in this apoptotic pathway. These results suggest that C3G and Hck interact physically and functionally in vivo to activate kinase-dependent and caspase-mediated apoptosis, which is independent of catalytic domain of C3G.	Ctr Cellular & Mol Biol, Hyderabad 500007, Andhra Pradesh, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Centre for Cellular & Molecular Biology (CCMB)	Swarup, G (corresponding author), Ctr Cellular & Mol Biol, Hyderabad 500007, Andhra Pradesh, India.			Swarup, Ghanshyam/0000-0002-8098-0509				Al-Ramadi BK, 1998, P NATL ACAD SCI USA, V95, P12498, DOI 10.1073/pnas.95.21.12498; Briggs SD, 1997, J BIOL CHEM, V272, P17899, DOI 10.1074/jbc.272.29.17899; BRIGGS SD, 1995, J BIOL CHEM, V270, P14718, DOI 10.1074/jbc.270.24.14718; Choi KS, 2001, J VIROL, V75, P1949, DOI 10.1128/JVI.75.4.1949-1957.2001; Cory GOC, 2002, J BIOL CHEM, V277, P45115, DOI 10.1074/jbc.M203346200; de Jong R, 1998, ONCOGENE, V17, P2805, DOI 10.1038/sj.onc.1202207; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; English BK, 1997, J LEUKOCYTE BIOL, V62, P859, DOI 10.1002/jlb.62.6.859; ENGLISH BK, 1993, J EXP MED, V178, P1017, DOI 10.1084/jem.178.3.1017; ERPEL T, 1995, CURR OPIN CELL BIOL, V7, P176, DOI 10.1016/0955-0674(95)80025-5; Gaozza E, 1997, ONCOGENE, V15, P3127, DOI 10.1038/sj.onc.1201575; GHAZIZADEH S, 1994, J BIOL CHEM, V269, P8878; Gotoh T, 1997, J BIOL CHEM, V272, P18602, DOI 10.1074/jbc.272.30.18602; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; Gouri BSV, 1997, INDIAN J BIOCHEM BIO, V34, P29; Guerrero C, 1998, ONCOGENE, V16, P613, DOI 10.1038/sj.onc.1201569; Gupta S, 2002, FEBS LETT, V532, P61, DOI 10.1016/S0014-5793(02)03628-1; Howlett CJ, 1999, BIOCHEM BIOPH RES CO, V257, P129, DOI 10.1006/bbrc.1999.0427; Ichiba T, 1999, J BIOL CHEM, V274, P14376, DOI 10.1074/jbc.274.20.14376; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Kamatkar S, 1996, J BIOL CHEM, V271, P26755, DOI 10.1074/jbc.271.43.26755; KNUDSEN BS, 1994, J BIOL CHEM, V269, P32781; Lerner EC, 2002, NAT STRUCT BIOL, V9, P365, DOI 10.1038/nsb782; Ling L, 2003, J BIOL CHEM, V278, P27301, DOI 10.1074/jbc.M302516200; LINNEKIN D, 1994, BLOOD, V84, P94, DOI 10.1182/blood.V84.1.94.bloodjournal84194; LOCK P, 1991, MOL CELL BIOL, V11, P4363, DOI 10.1128/MCB.11.9.4363; Mochizuki N, 2000, J BIOL CHEM, V275, P12667, DOI 10.1074/jbc.275.17.12667; Ohba Y, 2000, MOL CELL BIOL, V20, P6074, DOI 10.1128/MCB.20.16.6074-6083.2000; Ohba Y, 2001, EMBO J, V20, P3333, DOI 10.1093/emboj/20.13.3333; Poghosyan Z, 2002, J BIOL CHEM, V277, P4999, DOI 10.1074/jbc.M107430200; QUINTRELL N, 1987, MOL CELL BIOL, V7, P2267, DOI 10.1128/MCB.7.6.2267; Radha V, 1999, FEBS LETT, V453, P308, DOI 10.1016/S0014-5793(99)00734-6; Radha V, 2002, APOPTOSIS, V7, P195, DOI 10.1023/A:1015370512425; Robbins SM, 2000, EUR J BIOCHEM, V267, P7201, DOI 10.1046/j.1432-1327.2000.01830.x; Schreiner SJ, 2002, J BIOL CHEM, V277, P45680, DOI 10.1074/jbc.M204255200; Scott MP, 2002, J BIOL CHEM, V277, P28238, DOI 10.1074/jbc.M202783200; Seol DW, 1999, J BIOL CHEM, V274, P2072, DOI 10.1074/jbc.274.4.2072; Shivakrupa, 1999, DNA CELL BIOL, V18, P701, DOI 10.1089/104454999314980; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Songyang Zhou, 1995, Trends in Biochemical Sciences, V20, P470, DOI 10.1016/S0968-0004(00)89103-3; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; Tanaka S, 1997, P NATL ACAD SCI USA, V94, P2356, DOI 10.1073/pnas.94.6.2356; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Voss AK, 2003, DEVELOPMENT, V130, P355, DOI 10.1242/dev.00217; Wang JY, 1996, J EXP MED, V184, P831, DOI 10.1084/jem.184.3.831; Wang JYJ, 2000, ONCOGENE, V19, P5643, DOI 10.1038/sj.onc.1203878; Warmuth M, 1997, J BIOL CHEM, V272, P33260, DOI 10.1074/jbc.272.52.33260; Yousefi S, 1996, J EXP MED, V183, P1407, DOI 10.1084/jem.183.4.1407; Zhai B, 2001, BIOCHEM BIOPH RES CO, V286, P61, DOI 10.1006/bbrc.2001.5348; ZIEGLER SF, 1987, MOL CELL BIOL, V7, P2276, DOI 10.1128/MCB.7.6.2276; ZIEGLER SF, 1989, MOL CELL BIOL, V9, P2724, DOI 10.1128/MCB.9.6.2724	52	55	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52188	52194		10.1074/jbc.M310656200	http://dx.doi.org/10.1074/jbc.M310656200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14551197	hybrid			2022-12-27	WOS:000187480700027
J	Liang, HB; VanValkenburgh, C; Chen, XM; Mullins, C; Van Kaer, L; Green, N; Fang, H				Liang, HB; VanValkenburgh, C; Chen, XM; Mullins, C; Van Kaer, L; Green, N; Fang, H			Genetic complementation in yeast reveals functional similarities between the catalytic Subunits of mammalian signal peptidase complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; SACCHAROMYCES-CEREVISIAE; CRYSTAL-STRUCTURE; SHUTTLE VECTORS; CLEAVAGE SITES; SEC11 PROTEIN; SEQUENCE; CONTAINS; IDENTIFICATION; PURIFICATION	Type I signal peptidases ( SPs) comprise a family of structurally related enzymes that cleave signal peptides from precursor proteins following their transport out of the cytoplasmic space in eukaryotic and prokaryotic cells. One such enzyme, the mitochondrial inner membrane peptidase, has two catalytic subunits, which recognize distinct cleavage site motifs in their signal peptide substrates. The only other known type I SP with two catalytic subunits is the signal peptidase complex ( SPC) in the mammalian endoplasmic reticulum. Here, we tested the hypothesis that, as with inner membrane peptidase catalytic subunits, SPC catalytic subunits exhibit nonoverlapping substrate specificity. We constructed two yeast strains without endogenous SP, one expressing canine SPC18 and the other expressing a truncation of canine SPC21 ( SPC21DeltaN), which lacks 24 N- terminal residues that prevent expression of SPC21 in yeast. By monitoring a variety of soluble and membrane- bound substrates, we find that, in contrast to the tested hypothesis, SPC catalytic subunits exhibit overlapping substrate specificity. SPC18 and SPC21DeltaN do, however, cleave some substrates with different efficiencies, although no pattern for this behavior could be discerned. In light of the functional similarities between SPC proteins, we developed a membrane protein fragmentation assay to monitor the position of the catalytic sites relative to the surface of the endoplasmic reticulum membrane. Using this assay, our results suggest that the active sites of SPC18 and SPC21DeltaN are located 4 - 11 Angstrom above the membrane surface. These data, thus, support a model that SPC18 and SPC21 are functionally and structurally similar to each other.	Vanderbilt Univ, Sch Med, Dept Microbiol & Immunol, Nashville, TN 37232 USA	Vanderbilt University	Fang, H (corresponding author), Vanderbilt Univ, Sch Med, Dept Microbiol & Immunol, 221 Kirkland Hall, Nashville, TN 37232 USA.	hong.fang@vanderbilt.edu	Van Kaer, Luc/H-1033-2015	Van Kaer, Luc/0000-0001-5275-2309				BENNETZEN JL, 1982, J BIOL CHEM, V257, P3018; BOHNI PC, 1988, J CELL BIOL, V106, P1035, DOI 10.1083/jcb.106.4.1035; Chen XM, 2001, J BIOL CHEM, V276, P2411, DOI 10.1074/jbc.M007723200; Chen XM, 1999, J BIOL CHEM, V274, P37750, DOI 10.1074/jbc.274.53.37750; Chou KC, 2001, PROTEIN ENG, V14, P75, DOI 10.1093/protein/14.2.75; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; EVANS EA, 1986, P NATL ACAD SCI USA, V83, P581, DOI 10.1073/pnas.83.3.581; Fang H, 1997, J BIOL CHEM, V272, P13152, DOI 10.1074/jbc.272.20.13152; GREEN N, 1992, J CELL BIOL, V116, P597, DOI 10.1083/jcb.116.3.597; GREENBURG G, 1989, J BIOL CHEM, V264, P15762; HOPP TP, 1988, BIO-TECHNOL, V6, P1204, DOI 10.1038/nbt1088-1204; JAIN RG, 1994, J BIOL CHEM, V269, P16305; Jan PS, 2000, MOL GEN GENET, V263, P483, DOI 10.1007/s004380051192; KURJAN J, 1982, CELL, V30, P933, DOI 10.1016/0092-8674(82)90298-7; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Luo WT, 2003, J BIOL CHEM, V278, P4943, DOI 10.1074/jbc.M210916200; McLauchlan J, 2002, EMBO J, V21, P3980, DOI 10.1093/emboj/cdf414; Meyer HA, 1997, J BIOL CHEM, V272, P13159, DOI 10.1074/jbc.272.20.13159; MULLINS C, 1995, J BIOL CHEM, V270, P17139, DOI 10.1074/jbc.270.29.17139; MULLINS C, 1996, J BIOL CHEM, V271, P29092; Ng DTW, 1996, J CELL BIOL, V134, P269, DOI 10.1083/jcb.134.2.269; NILSSON I, 1993, J BIOL CHEM, V268, P5798; NUNNARI J, 1993, SCIENCE, V262, P1997, DOI 10.1126/science.8266095; Paetzel M, 2002, CHEM REV, V102, P4549, DOI 10.1021/cr010166y; Paetzel M, 2002, J BIOL CHEM, V277, P9512, DOI 10.1074/jbc.M110983200; Paetzel M, 1998, NATURE, V396, P186, DOI 10.1038/24196; PERLMAN D, 1983, J MOL BIOL, V167, P391, DOI 10.1016/S0022-2836(83)80341-6; PRATJE E, 1986, EMBO J, V5, P1313, DOI 10.1002/j.1460-2075.1986.tb04361.x; Rayner JC, 1998, J BIOL CHEM, V273, P26836, DOI 10.1074/jbc.273.41.26836; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; Rothe C, 1998, EUR J BIOCHEM, V252, P16, DOI 10.1046/j.1432-1327.1998.2520016.x; SHELNESS GS, 1990, J BIOL CHEM, V265, P9512; SHELNESS GS, 1993, J BIOL CHEM, V268, P5201; SIKORSKI RS, 1989, GENETICS, V122, P19; SIKORSKI RS, 1991, METHOD ENZYMOL, V194, P302; TAUSSIG R, 1983, NUCLEIC ACIDS RES, V11, P1943, DOI 10.1093/nar/11.6.1943; VanValkenburgh C, 1999, J BIOL CHEM, V274, P11519, DOI 10.1074/jbc.274.17.11519; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; VONHEIJNE G, 1990, J MEMBRANE BIOL, V115, P195, DOI 10.1007/BF01868635; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; YADEAU JT, 1991, P NATL ACAD SCI USA, V88, P517, DOI 10.1073/pnas.88.2.517; YUK MH, 1993, J CELL BIOL, V123, P1735, DOI 10.1083/jcb.123.6.1735	42	15	19	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					50932	50939		10.1074/jbc.M307542200	http://dx.doi.org/10.1074/jbc.M307542200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14559916	hybrid			2022-12-27	WOS:000187206300014
J	Pasta, SY; Raman, B; Ramakrishna, T; Rao, CM				Pasta, SY; Raman, B; Ramakrishna, T; Rao, CM			Role of the conserved SRLFDQFFG region of alpha-crystallin, a small heat shock protein - Effect on oligomeric size, subunit exchange, and chaperone-like activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECONDARY STRUCTURE PREDICTION; DESMIN-RELATED MYOPATHY; MOLTEN-GLOBULE STATE; C-TERMINAL EXTENSION; AMINO-ACID-SEQUENCE; B-CRYSTALLIN; A-CRYSTALLIN; MOLECULAR CHAPERONE; QUATERNARY STRUCTURE; INTERMOLECULAR EXCHANGE	Small heat shock proteins (sHsps) are necessary for several cellular functions and in stress tolerance. Most sHsps are oligomers; intersubunit interactions leading to changes in oligomeric structure and exposure of specific regions may modulate their functioning. Many sHsps, including alphaA- and alphaB-crystallin, contain a well conserved SRLFDQFFG sequence motif in the N-terminal region. Sequence-based prediction shows that it exhibits helical propensity with amphipathic character, suggesting that it plays a critical role in the structure and function of alpha-crystallins. In order to investigate the role of this motif in the structure and function of sHsps, we have made constructs deleting this sequence from alphaA- and alphaB-crystallin, overexpressed, purified, and studied these engineered proteins. Circular dichroism spectroscopic studies show changes in tertiary and secondary structure on deletion of the sequence. Glycerol density gradient centrifugation and dynamic light scattering studies show that the multimeric size of the mutant proteins is significantly reduced, indicating a role for this motif in higher order organization of the subunits. Both deletion mutants exhibit similar oligomeric size and increased chaperone-like activity. Urea-induced denaturation study shows that the SRLFDQFFG sequence contributes significantly to the structural stability. Fluorescence resonance energy transfer studies show that the rate of exchange of the subunits in the alphaAdel-crystallin oligomer is higher compared with that in the alphaA-crystallin oligomer, suggesting that this region contributes to the oligomer dynamics in addition to the higher order assembly and structural stability. Thus, our study shows that the SRLFDQFFG sequence is one of the critical motifs in structure-function regulation of alphaA- and alphaB-crystallin.	Ctr Cellular & Mol Biol, Hyderabad 500007, Andhra Pradesh, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Centre for Cellular & Molecular Biology (CCMB)	Rao, CM (corresponding author), Ctr Cellular & Mol Biol, Hyderabad 500007, Andhra Pradesh, India.	mohan@ccmb.res.in						Andley UP, 2002, J BIOL CHEM, V277, P10178, DOI 10.1074/jbc.M109211200; Baldi P, 1999, BIOINFORMATICS, V15, P937, DOI 10.1093/bioinformatics/15.11.937; Berengian AR, 1997, BIOCHEMISTRY-US, V36, P9951, DOI 10.1021/bi9712347; BHAT SP, 1989, BIOCHEM BIOPH RES CO, V158, P319, DOI 10.1016/S0006-291X(89)80215-3; BHAT SP, 1991, EUR J BIOCHEM, V202, P775, DOI 10.1111/j.1432-1033.1991.tb16432.x; Bloemendal H, 1981, MOL CELLULAR BIOL EY, P1; Bova MP, 2000, J BIOL CHEM, V275, P1035, DOI 10.1074/jbc.275.2.1035; Bova MP, 2002, J BIOL CHEM, V277, P38468, DOI 10.1074/jbc.M205594200; Bova MP, 1999, P NATL ACAD SCI USA, V96, P6137, DOI 10.1073/pnas.96.11.6137; Bova MP, 1997, J BIOL CHEM, V272, P29511, DOI 10.1074/jbc.272.47.29511; BRUNSCHIER R, 1993, J BIOL CHEM, V268, P2767; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; Clark JI, 2000, CURR OPIN STRUC BIOL, V10, P52, DOI 10.1016/S0959-440X(99)00048-2; DAS KP, 1995, FEBS LETT, V369, P321, DOI 10.1016/0014-5793(95)00775-5; Das KP, 1996, J BIOL CHEM, V271, P10449, DOI 10.1074/jbc.271.18.10449; DASGUPTA S, 1992, EXP EYE RES, V54, P461, DOI 10.1016/0014-4835(92)90058-Z; Datta SA, 1999, J BIOL CHEM, V274, P34773, DOI 10.1074/jbc.274.49.34773; DATTA SA, 2000, THESIS JAWAHARLAL NE; de Jong WW, 1998, INT J BIOL MACROMOL, V22, P151, DOI 10.1016/S0141-8130(98)00013-0; Feil IK, 2001, J BIOL CHEM, V276, P12024, DOI 10.1074/jbc.M010856200; Fischer D, 1999, PROTEINS, P209; Garnier J, 1996, METHOD ENZYMOL, V266, P540; Goenka S, 2001, BIOCHEM J, V359, P547, DOI 10.1042/0264-6021:3590547; Gu LX, 2002, J MOL BIOL, V319, P517, DOI 10.1016/S0022-2836(02)00311-X; HANSEN JE, 1994, J BIOL CHEM, V269, P6286; Hess J F, 1998, Mol Vis, V4, P29; Hook DWA, 1997, EUR J BIOCHEM, V247, P380, DOI 10.1111/j.1432-1033.1997.00380.x; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; INGOLIA TD, 1982, P NATL ACAD SCI-BIOL, V79, P2360, DOI 10.1073/pnas.79.7.2360; Ito K, 2001, J BIOL CHEM, V276, P5346, DOI 10.1074/jbc.M009004200; KATO K, 1991, BIOCHIM BIOPHYS ACTA, V1080, P173, DOI 10.1016/0167-4838(91)90146-Q; KLEMENZ R, 1991, P NATL ACAD SCI USA, V88, P3652, DOI 10.1073/pnas.88.9.3652; KNELLER DG, 1990, J MOL BIOL, V214, P171, DOI 10.1016/0022-2836(90)90154-E; Kumar LVS, 1999, J BIOL CHEM, V274, P24137, DOI 10.1074/jbc.274.34.24137; Lambert H, 1999, J BIOL CHEM, V274, P9378, DOI 10.1074/jbc.274.14.9378; Leung SM, 1996, CELL STRESS CHAPERON, V1, P78, DOI 10.1379/1466-1268(1996)001<0078:TAOTBH>2.3.CO;2; LEVIN JM, 1986, FEBS LETT, V205, P303, DOI 10.1016/0014-5793(86)80917-6; LI LK, 1974, EXP EYE RES, V19, P49, DOI 10.1016/0014-4835(74)90071-2; LIANG JN, 1982, BIOCHEMISTRY-US, V21, P1847, DOI 10.1021/bi00537a022; Litt M, 1998, HUM MOL GENET, V7, P471, DOI 10.1093/hmg/7.3.471; Marini I, 2000, J BIOL CHEM, V275, P32559, DOI 10.1074/jbc.M006133200; Martin JL, 1997, CIRCULATION, V96, P4343; McGuffin LJ, 2000, BIOINFORMATICS, V16, P404, DOI 10.1093/bioinformatics/16.4.404; MERCK KB, 1992, BIOCHIM BIOPHYS ACTA, V1130, P267, DOI 10.1016/0167-4781(92)90439-7; MUSCI G, 1985, BIOCHEMISTRY-US, V24, P2034, DOI 10.1021/bi00329a035; Narberhaus F, 2002, MICROBIOL MOL BIOL R, V66, P64, DOI 10.1128/MMBR.66.1.64-93.2002; NISHIKAWA K, 1986, BIOCHIM BIOPHYS ACTA, V871, P45, DOI 10.1016/0167-4838(86)90131-7; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; Pasta SY, 2002, J BIOL CHEM, V277, P45821, DOI 10.1074/jbc.M206499200; QUAXJEUKEN Y, 1985, P NATL ACAD SCI USA, V82, P5819, DOI 10.1073/pnas.82.17.5819; Raghava GPS, 2000, BIOTECHNIQUES, V29, P108, DOI 10.2144/00291bc02; Rajaraman K, 1996, J BIOL CHEM, V271, P27595, DOI 10.1074/jbc.271.44.27595; Rajaraman K, 1998, BIOCHEM BIOPH RES CO, V249, P917, DOI 10.1006/bbrc.1998.9242; Rajaraman K, 2001, FEBS LETT, V497, P118, DOI 10.1016/S0014-5793(01)02451-6; Raman B, 1997, J BIOL CHEM, V272, P23559, DOI 10.1074/jbc.272.38.23559; RAMAN B, 1995, FEBS LETT, V365, P133, DOI 10.1016/0014-5793(95)00440-K; RAMAN B, 1994, J BIOL CHEM, V269, P27264; Smith JB, 1996, EXP EYE RES, V63, P125, DOI 10.1006/exer.1996.0100; Smulders RHPH, 1996, J BIOL CHEM, V271, P29060, DOI 10.1074/jbc.271.46.29060; Sun TX, 1998, FEBS LETT, V430, P401, DOI 10.1016/S0014-5793(98)00707-8; Sun TX, 1997, J BIOL CHEM, V272, P6220, DOI 10.1074/jbc.272.10.6220; Sun TX, 1998, J BIOL CHEM, V273, P286, DOI 10.1074/jbc.273.1.286; SWEET RM, 1986, BIOPOLYMERS, V25, P1565, DOI 10.1002/bip.360250813; van Montfort RLM, 2001, NAT STRUCT BIOL, V8, P1025, DOI 10.1038/nsb722; VANDENOETELAAR PJM, 1990, BIOCHEMISTRY-US, V29, P3488, DOI 10.1021/bi00466a010; Vicart P, 1998, NAT GENET, V20, P92, DOI 10.1038/1765; Yonehara M, 1996, J BIOL CHEM, V271, P2641, DOI 10.1074/jbc.271.5.2641	67	71	71	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51159	51166		10.1074/jbc.M307523200	http://dx.doi.org/10.1074/jbc.M307523200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14532291	hybrid			2022-12-27	WOS:000187206300041
J	Stange, M; Xu, L; Balshaw, D; Yamaguchi, N; Meissner, G				Stange, M; Xu, L; Balshaw, D; Yamaguchi, N; Meissner, G			Characterization of recombinant skeletal muscle (Ser-2843) and cardiac muscle (Ser-2809) ryanodine receptor phosphorylation mutants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-RELEASE CHANNEL; DEPENDENT PROTEIN-KINASE; JUNCTIONAL SARCOPLASMIC-RETICULUM; HEART-FAILURE; DEFECTIVE REGULATION; ADENINE-NUCLEOTIDE; CALMODULIN; FKBP12.6; MODULATION; BINDING	Phosphorylation of the skeletal muscle (RyR1) and cardiac muscle (RyR2) ryanodine receptors has been reported to modulate channel activity. Abnormally high phosphorylation levels ( hyperphosphorylation) at Ser-2843 in RyR1 and Ser-2809 in RyR2 and dissociation of FK506-binding proteins from the receptors have been implicated as one of the causes of altered calcium homeostasis observed during human heart failure. Using site-directed mutagenesis, we prepared recombinant RyR1 and RyR2 mutant receptors mimicking constitutively phosphorylated and dephosphorylated channels carrying a Ser/Asp (RyR1-S2843D and RyR2-S2809D) and Ser/ Ala (RyR1-S2843A and RyR2-S2809A) substitution, respectively. Following transient expression in human embryonic kidney 293 cells, the effects of Ca2+, Mg2+, and ATP on channel function were determined using single channel and [H-3] ryanodine binding measurements. In both assays, neither the skeletal nor cardiac mutants showed significant differences compared with wild type. Similarly essentially identical caffeine responses were observed in Ca2+ imaging measurements. Co-immunoprecipitation and Western blot analysis showed comparable binding of FK506-binding proteins to wild type and mutant receptors. Finally metabolic labeling experiments showed that the cardiac ryanodine receptor was phosphorylated at additional sites. Taken together, the results did not support the view that phosphorylation of a single site (RyR1-Ser-2843 and RyR2-Ser-2809) substantially changes RyR1 and RyR2 channel function.	Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Cell & Mol Physiol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Meissner, G (corresponding author), Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA.				NHLBI NIH HHS [HL27430, HL73051] Funding Source: Medline; NIAMS NIH HHS [AR18687] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL027430, R01HL073051] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR018687, R01AR018687] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Balshaw DM, 2001, J BIOL CHEM, V276, P20144, DOI 10.1074/jbc.M010771200; Bandyopadhyay A, 2000, BIOCHEM J, V352, P61, DOI 10.1042/0264-6021:3520061; Bayer KU, 1998, EMBO J, V17, P5598, DOI 10.1093/emboj/17.19.5598; BRILLANTES AMB, 1994, CELL, V77, P513, DOI 10.1016/0092-8674(94)90214-3; CHU A, 1990, BIOCHEMISTRY-US, V29, P5899, DOI 10.1021/bi00477a003; DAMIANI E, 1995, BIOCHEM BIOPH RES CO, V209, P457, DOI 10.1006/bbrc.1995.1524; Dulhunty AF, 2001, BIOPHYS J, V81, P3240, DOI 10.1016/S0006-3495(01)75959-0; FABIATO A, 1983, AM J PHYSIOL, V245, P1; Fessenden JD, 2000, BIOPHYS J, V79, P2509, DOI 10.1016/S0006-3495(00)76492-7; Fill M, 2002, PHYSIOL REV, V82, P893, DOI 10.1152/physrev.00013.2002; Franzini-Armstrong C, 1999, BIOPHYS J, V77, P1528, DOI 10.1016/S0006-3495(99)77000-1; FranziniArmstrong C, 1997, PHYSIOL REV, V77, P699, DOI 10.1152/physrev.1997.77.3.699; Gaburjakova M, 2001, J BIOL CHEM, V276, P16931, DOI 10.1074/jbc.M100856200; Gao L, 1997, FEBS LETT, V412, P223, DOI 10.1016/S0014-5793(97)00781-3; GUO W, 1994, J BIOL CHEM, V269, P28359; HAIN J, 1994, BIOPHYS J, V67, P1823, DOI 10.1016/S0006-3495(94)80664-2; HAIN J, 1995, J BIOL CHEM, V270, P2074, DOI 10.1074/jbc.270.5.2074; HOHENEGGER M, 1993, BIOCHEM J, V296, P303, DOI 10.1042/bj2960303; Jiang MT, 2002, CIRC RES, V91, P1015, DOI 10.1161/01.RES.0000043663.08689.05; Li YX, 2002, CIRC RES, V90, P309, DOI 10.1161/hh0302.105660; Lokuta AJ, 1997, J BIOL CHEM, V272, P25333, DOI 10.1074/jbc.272.40.25333; LOKUTA AJ, 1995, J PHYSIOL-LONDON, V487, P609, DOI 10.1113/jphysiol.1995.sp020904; Marx SO, 2000, CELL, V101, P365, DOI 10.1016/S0092-8674(00)80847-8; Marx SO, 1998, SCIENCE, V281, P818, DOI 10.1126/science.281.5378.818; Marx SO, 2001, CIRC RES, V88, P1151, DOI 10.1161/hh1101.091268; MEISSNER G, 1984, J BIOL CHEM, V259, P2365; Meissner G, 2002, FRONT BIOSCI, V7, pD2072, DOI 10.2741/meissner; MEISSNER G, 1987, J BIOL CHEM, V262, P3065; NAKAI J, 1990, FEBS LETT, V271, P169, DOI 10.1016/0014-5793(90)80399-4; Narayanan N, 1997, BASIC RES CARDIOL, V92, P25, DOI 10.1007/BF00794065; Reiken S, 2003, J CELL BIOL, V160, P919, DOI 10.1083/jcb.200211012; RIOS E, 1991, PHYSIOL REV, V71, P849, DOI 10.1152/physrev.1991.71.3.849; Rodriguez P, 2003, J BIOL CHEM, V278, P38593, DOI 10.1074/jbc.C301180200; SCHOENMAKERS TJM, 1992, BIOTECHNIQUES, V12, P870; Simmerman HKB, 1998, PHYSIOL REV, V78, P921, DOI 10.1152/physrev.1998.78.4.921; Stange M, 2001, BIOPHYS J, V81, P1419, DOI 10.1016/S0006-3495(01)75797-9; SUKO J, 1993, BIOCHIM BIOPHYS ACTA, V1175, P193, DOI 10.1016/0167-4889(93)90023-I; Sutko JL, 1997, PHARMACOL REV, V49, P53; Szegedi C, 1999, BIOCHEM J, V337, P19, DOI 10.1042/0264-6021:3370019; Temsah RM, 2000, J PHARMACOL EXP THER, V293, P15; Timerman AP, 1996, J BIOL CHEM, V271, P20385, DOI 10.1074/jbc.271.34.20385; Uehara A, 2002, PFLUG ARCH EUR J PHY, V444, P202, DOI 10.1007/s00424-002-0791-3; VALDIVIA HH, 1995, SCIENCE, V267, P1997, DOI 10.1126/science.7701323; Ward CW, 2003, FASEB J, V17, P1517, DOI 10.1096/fj.02-1083fje; Wehrens XHT, 2003, CELL, V113, P829, DOI 10.1016/S0092-8674(03)00434-3; WITCHER DR, 1991, J BIOL CHEM, V266, P11144; Yano M, 2000, CIRCULATION, V102, P2131, DOI 10.1161/01.CIR.102.17.2131; Zhang T, 2003, CIRC RES, V92, P912, DOI 10.1161/01.RES.0000069686.31472.C5	48	133	136	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51693	51702		10.1074/jbc.M310406200	http://dx.doi.org/10.1074/jbc.M310406200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14532276	Green Published, hybrid			2022-12-27	WOS:000187206300104
J	Wang, F; Metcalf, T; van der Wel, H; West, CM				Wang, F; Metcalf, T; van der Wel, H; West, CM			Initiation of mucin-type O-glycosylation in Dictyostelium is homologous to the corresponding step in animals and is important for spore coat function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYL-D-GALACTOSAMINE; POLYPEPTIDE N-ACETYLGALACTOSAMINYLTRANSFERASES; TRYPANOSOMA-CRUZI; CELL-ADHESION; CAENORHABDITIS-ELEGANS; COMPLEX GLYCOSYLATION; EXTRACELLULAR-MATRIX; GLCNAC-TRANSFERASE; BIOLOGICAL ROLES; CDNA CLONING	Like animal cells, many unicellular eukaryotes modify mucin-like domains of secretory proteins with multiple O-linked glycans. Unlike animal mucin-type glycans, those of some microbial eukaryotes are initiated by alpha-linked GlcNAc rather than alpha-GalNAc. Based on sequence similarity to a recently cloned soluble polypeptide hydroxyproline GlcNAc-transferase that modifies Skp1 in the cytoplasm of the social ameba Dictyostelium, we have identified an enzyme, polypeptide alpha-N-acetyl-glucosaminyltransferase (pp alpha-GlcNAc-T2), that attaches GlcNAc to numerous secretory proteins in this organism. Unlike the Skp1 GlcNAc-transferase, pp alpha-GlcNAc-T2 is predicted to be a type 2 transmembrane protein. A highly purified, soluble, recombinant fragment of pp alpha-GlcNAc-T2 efficiently transfers GlcNAc from UDP-GlcNAc to synthetic peptides corresponding to mucin-like domains in two proteins that traverse the secretory pathway. pp alpha-GlcNAc-T2 is required for addition of GlcNAc to peptides in cell extracts and to the proteins in vivo. Mass spectrometry and Edman degradation analyses show that pp alpha-GlcNAc-T2 attaches GlcNAc in alpha-linkage to the Thr residues of all the synthetic mucin repeats. pp alpha-GlcNAc-T2 is encoded by the previously described modB locus defined by chemical mutagenesis, based on sequence analysis and complementation studies. This finding establishes that the many phenotypes of modB mutants, including a permeability defect in the spore coat, can now be ascribed to defects in mucin-type O-glycosylation. A comparison of the sequences of pp alpha-GlcNAc-T2 and the animal pp alpha-GalNAc-transferases reveals an ancient common ancestry indicating that, despite the different N-acetylhexosamines involved, the enzymes share a common mechanism of action.	Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73104 USA; Univ Florida, Coll Med, Dept Anat & Cell Biol, Gainesville, FL 32610 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center; State University System of Florida; University of Florida	West, CM (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, 940 Stanton L Young Blvd,BMSB 853, Oklahoma City, OK 73104 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037539] Funding Source: NIH RePORTER; NCRR NIH HHS [P41-RR80605] Funding Source: Medline; NIGMS NIH HHS [R01-GM37539] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Acosta-Serrano A, 2001, MOL BIOCHEM PARASIT, V114, P143, DOI 10.1016/S0166-6851(01)00245-6; APARICIO JG, 1990, J CELL BIOCHEM, V42, P255, DOI 10.1002/jcb.240420408; Bowers-Morrow VM, 2002, CELL BIOL INT, V26, P951, DOI 10.1006/cbir.2002.0947; CHAMPION A, 1991, J GEN MICROBIOL, V137, P2431, DOI 10.1099/00221287-137-10-2431; CHOU TY, 1995, J BIOL CHEM, V270, P18961, DOI 10.1074/jbc.270.32.18961; Colley KJ, 1997, GLYCOBIOLOGY, V7, P1, DOI 10.1093/glycob/7.1.1-b; Coltart DM, 2002, J AM CHEM SOC, V124, P9833, DOI 10.1021/ja020208f; CREAN EV, 1979, J BACTERIOL, V140, P188, DOI 10.1128/JB.140.1.188-196.1979; Dekker J, 2002, TRENDS BIOCHEM SCI, V27, P126, DOI 10.1016/S0968-0004(01)02052-7; Fukuda M, 2002, BBA-GEN SUBJECTS, V1573, P394, DOI 10.1016/S0304-4165(02)00409-9; Gerken TA, 1997, J BIOL CHEM, V272, P9709; GERKEN TA, 1997, TECHNIQUES GLYCOBIOL, P247; Hagen FK, 1998, J BIOL CHEM, V273, P8268, DOI 10.1074/jbc.273.14.8268; HOHMANN HP, 1987, EMBO J, V6, P3663, DOI 10.1002/j.1460-2075.1987.tb02699.x; HOULE J, 1989, P NATL ACAD SCI USA, V86, P3679; Jung E, 1998, EUR J BIOCHEM, V253, P517, DOI 10.1046/j.1432-1327.1998.2530517.x; Jung E, 1997, BIOCHEMISTRY-US, V36, P4034, DOI 10.1021/bi9617825; Kapitonov D, 1999, GLYCOBIOLOGY, V9, P961, DOI 10.1093/glycob/9.10.961; Li GC, 2000, MICROBIOL-SGM, V146, P2219, DOI 10.1099/00221287-146-9-2219; Loomes KM, 1999, EUR J BIOCHEM, V266, P105, DOI 10.1046/j.1432-1327.1999.00824.x; LOOMIS WF, 1985, DEV BIOL, V109, P111, DOI 10.1016/0012-1606(85)90351-3; Metcalf T, 2003, MICROBIOL-SGM, V149, P305, DOI 10.1099/mic.0.25984-0; Morgado-Diaz JA, 2001, PARASITOLOGY, V123, P33, DOI 10.1017/S0031182001007946; MURRAY BA, 1984, MOL CELL BIOL, V4, P514, DOI 10.1128/MCB.4.3.514; Perez-Vilar J, 1999, J BIOL CHEM, V274, P31751, DOI 10.1074/jbc.274.45.31751; Previato JO, 1998, J BIOL CHEM, V273, P14982, DOI 10.1074/jbc.273.24.14982; RAMALINGAM R, 1992, J BACTERIOL, V174, P7834, DOI 10.1128/JB.174.23.7834-7837.1992; ROTH J, 1994, P NATL ACAD SCI USA, V91, P8935, DOI 10.1073/pnas.91.19.8935; Schwientek T, 2002, J BIOL CHEM, V277, P22623, DOI 10.1074/jbc.M202684200; Shah-Mahoney N, 1997, GENE, V203, P33, DOI 10.1016/S0378-1119(97)00487-3; STROUS GJ, 1992, CRIT REV BIOCHEM MOL, V27, P57, DOI 10.3109/10409239209082559; TAKEMOTO K, 1985, J CELL SCI, V77, P93; Ten Hagen KG, 2003, GLYCOBIOLOGY, V13, p1R, DOI 10.1093/glycob/cwg007; Teng-umnuay P, 1999, J BIOL CHEM, V274, P36392, DOI 10.1074/jbc.274.51.36392; TI ZC, 1995, DEV BIOL, V168, P332; van der Wel H, 2002, J BIOL CHEM, V277, P46328, DOI 10.1074/jbc.M208024200; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; West CM, 2002, GLYCOBIOLOGY, V12, p17R, DOI 10.1093/glycob/12.2.17R; WEST CM, 1988, EXP CELL RES, V175, P26, DOI 10.1016/0014-4827(88)90252-2; West CM, 2003, CELL MOL LIFE SCI, V60, P229, DOI 10.1007/s000180300018; West CM, 2003, INT REV CYTOL, V222, P237; West CM, 2002, EUKARYOT CELL, V1, P281, DOI 10.1128/EC.1.2.281-292.2002; WEST CM, 1986, MOL CELL BIOCHEM, V72, P121; WEST CM, 1985, J BIOL CHEM, V260, P13801; Wilkins MR, 1995, EXPERIENTIA, V51, P1189, DOI 10.1007/BF01944736; Wojczyk BS, 2003, MOL BIOCHEM PARASIT, V131, P93, DOI 10.1016/S0166-6851(03)00196-8; Zachara NE, 1996, EUR J BIOCHEM, V238, P511, DOI 10.1111/j.1432-1033.1996.0511z.x; Zachara NE, 2000, METH MOL B, V125, P121; Zhang YY, 1999, J CELL SCI, V112, P4367	49	22	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51395	51407		10.1074/jbc.M308756200	http://dx.doi.org/10.1074/jbc.M308756200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14551185	hybrid			2022-12-27	WOS:000187206300068
J	Worley, JR; Baugh, MD; Hughes, DA; Edwards, DR; Hogan, A; Sampson, MJ; Gavrilovic, J				Worley, JR; Baugh, MD; Hughes, DA; Edwards, DR; Hogan, A; Sampson, MJ; Gavrilovic, J			Metalloproteinase expression in PMA-stimulated THP-1 cells - Effects of peroxisome proliferator-activated receptor-gamma (PPAR gamma) agonists and 9-cis-retinoic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; SMOOTH-MUSCLE-CELLS; MACROPHAGE-GENE-EXPRESSION; 9-CIS RETINOIC ACID; N-3 FATTY-ACIDS; TNF-ALPHA; MATRIX-METALLOPROTEINASE; EXTRACELLULAR-MATRIX; GROWTH-FACTOR; IN-VITRO	The PPARgamma agonists, thiazolidinediones (TZDs), have anti-inflammatory properties as well as increasing insulin sensitivity. This has widened their therapeutic scope to treat inflammatory diseases such as atherosclerosis in addition to Type 2 Diabetes. TZDs are known to reduce monocyte/macrophage expression of Matrix metalloproteinase (MMP)-9, which is implicated in atherosclerotic plaque destabilization. This study aims to identify other metalloproteinase genes of the ADAM (A Disintegin And Metalloproteinase) and ADAMTS families that are regulated by PPARgamma or RXR agonists, which are potentially important in type 2 diabetes and/or related atherosclerosis. The synthetic PPARgamma agonist, GW7845, and the natural agonist 15d-PGJ(2), suppressed PMA stimulated MMP-9 in human monocyte-like cells (THP-1) only in the presence of 9-cis-retinoic acid. Quantitative Real-Time PCR showed that this reduction was regulated at the mRNA level. Expression of ADAMs 8, 9, and 17 were increased, and ADAM15 was decreased by stimulation of THP-1 with PMA, although these ADAMs were not regulated by PPARgamma or RXR agonists. PMA-induced ADAM28 expression was further enhanced by the addition of 9-cis-retinoic acid. ADAMTS4, implicated in rheumatoid arthritis, was expressed in THP-1 cells, and significantly increased after 24 h of PMA stimulation. ADAMTS4 expression was suppressed by both PPARgamma and RXR agonists and was undetectable when the agonists were combined. Pretreatment of THP-1 cells with the PPARgamma antagonist, GW9662, suggests that PPARgamma plays subtly different roles in the regulation of MMP-9, ADAMTS4 and ADAM28 gene expression. These results indicate that PPARgamma and RXR agonists have complex effects on monocyte metalloproteinase expression, which may have implications for therapeutic strategies.	Univ E Anglia, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England; Norfolk & Norwich Hosp NHS Trust, Bertram Diabet Res Unit, Norwich NR4 7UY, Norfolk, England; Inst Food Res, Norwich NR4 7UA, Norfolk, England	University of East Anglia; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Quadram Institute; University of East Anglia	Gavrilovic, J (corresponding author), Univ E Anglia, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England.	j.gavrilovic@uea.ac.uk	Edwards, Dylan R/B-4734-2009; Hughes, Derralynn/J-8012-2013; Gavrilovic, Jelena/J-7754-2013	Edwards, Dylan R/0000-0002-3292-2064; Hughes, Derralynn/0000-0003-4531-9173; Gavrilovic, Jelena/0000-0002-5312-1784				Benbow U, 1997, MATRIX BIOL, V15, P519, DOI 10.1016/S0945-053X(97)90026-3; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Blobel CP, 2000, CURR OPIN CELL BIOL, V12, P606, DOI 10.1016/S0955-0674(00)00139-3; Bridges LC, 2002, J BIOL CHEM, V277, P3784, DOI 10.1074/jbc.M109538200; Calder PC, 2001, CURR OPIN CLIN NUTR, V4, P115, DOI 10.1097/00075197-200103000-00006; Camejo G, 2002, ATHEROSCLEROSIS SUPP, V3, P3, DOI 10.1016/S1567-5688(01)00005-8; Chawla A, 2001, NAT MED, V7, P48, DOI 10.1038/83336; Curtis CL, 2002, ARTHRITIS RHEUM, V46, P1544, DOI 10.1002/art.10305; Curtis CL, 2000, J BIOL CHEM, V275, P721, DOI 10.1074/jbc.275.2.721; Doedens JR, 2000, J BIOL CHEM, V275, P14598, DOI 10.1074/jbc.275.19.14598; Eberhardt W, 2002, J BIOL CHEM, V277, P33518, DOI 10.1074/jbc.M202008200; Evanko SP, 1999, ARTERIOSCL THROM VAS, V19, P1004, DOI 10.1161/01.ATV.19.4.1004; Evanko SP, 1998, AM J PATHOL, V152, P533; Fernandez-Real JM, 2002, AM J PHYSIOL-ENDOC M, V282, pE952, DOI 10.1152/ajpendo.00444.2001; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Fukuda K, 1997, ARTERIOSCL THROM VAS, V17, P1962, DOI 10.1161/01.ATV.17.10.1962; Galis ZS, 2002, CIRC RES, V90, P251, DOI 10.1161/res.90.3.251; GIENI RS, 1995, J IMMUNOL METHODS, V187, P85, DOI 10.1016/0022-1759(95)00170-F; Giuffre L, 1997, J CELL BIOL, V136, P945, DOI 10.1083/jcb.136.4.945; Halpert I, 1996, P NATL ACAD SCI USA, V93, P9748, DOI 10.1073/pnas.93.18.9748; Han S, 2002, IMMUNOLOGY, V106, P53, DOI 10.1046/j.1365-2567.2002.01404.x; Hayashi S, 1996, BIOCHEM BIOPH RES CO, V224, P574, DOI 10.1006/bbrc.1996.1066; Herren B, 1997, FASEB J, V11, P173, DOI 10.1096/fasebj.11.2.9039960; Herren B, 2002, NEWS PHYSIOL SCI, V17, P73, DOI 10.1152/nips.01373.2001; Higuchi Y, 2002, PATHOBIOLOGY, V70, P47, DOI 10.1159/000066003; Hunter JG, 2001, J BIOL CHEM, V276, P38297; Izumi Y, 1998, EMBO J, V17, P7260, DOI 10.1093/emboj/17.24.7260; Ji JD, 2001, J AUTOIMMUN, V17, P215, DOI 10.1006/jaut.2001.0542; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; Kintscher U, 2000, EUR J PHARMACOL, V401, P259, DOI 10.1016/S0014-2999(00)00461-1; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; Kolodgie FD, 2002, ARTERIOSCL THROM VAS, V22, P1642, DOI 10.1161/01.ATV.0000034021.92658.4C; Koshy PJT, 2002, ARTHRITIS RHEUM, V46, P961, DOI 10.1002/art.10212; LECA G, 1995, J IMMUNOL, V154, P1069; Leesnitzer LM, 2002, BIOCHEMISTRY-US, V41, P6640, DOI 10.1021/bi0159581; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Li AC, 2000, J CLIN INVEST, V106, P523, DOI 10.1172/JCI10370; Marx N, 1998, CIRC RES, V83, P1097, DOI 10.1161/01.RES.83.11.1097; Marx N, 1998, AM J PATHOL, V153, P17, DOI 10.1016/S0002-9440(10)65540-X; Meier CA, 2002, CYTOKINE, V18, P320, DOI 10.1006/cyto.2002.1945; Moller DE, 2000, TRENDS ENDOCRIN MET, V11, P212, DOI 10.1016/S1043-2760(00)00272-1; Morimoto Y, 1997, LIFE SCI, V61, P795, DOI 10.1016/S0024-3205(97)00561-4; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; Mukherjee R, 1997, J BIOL CHEM, V272, P8071, DOI 10.1074/jbc.272.12.8071; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; Olsson U, 1999, DIABETES, V48, P616, DOI 10.2337/diabetes.48.3.616; Palakurthi SS, 2001, CANCER RES, V61, P6213; PAN LY, 1995, J CELL BIOCHEM, V57, P575, DOI 10.1002/jcb.240570402; Patel L, 2002, BIOCHEM BIOPH RES CO, V290, P707, DOI 10.1006/bbrc.2001.6263; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; Primakoff P, 2000, TRENDS GENET, V16, P83, DOI 10.1016/S0168-9525(99)01926-5; RAAB G, 1997, BIOCHIM BIOPHYS ACTA, V1333, P179; Ricote M, 1998, P NATL ACAD SCI USA, V95, P7614, DOI 10.1073/pnas.95.13.7614; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Roberts CM, 1999, J BIOL CHEM, V274, P29251, DOI 10.1074/jbc.274.41.29251; Sabatini M, 2002, OSTEOARTHR CARTILAGE, V10, P673, DOI 10.1053/joca.2002.0827; Sandy JD, 2001, J BIOL CHEM, V276, P13372, DOI 10.1074/jbc.M009737200; Schlomann U, 2002, J BIOL CHEM, V277, P48210, DOI 10.1074/jbc.M203355200; Shu H, 2000, BIOCHEM BIOPH RES CO, V267, P345, DOI 10.1006/bbrc.1999.1968; Suh N, 1999, CANCER RES, V59, P5671; Tang BL, 2001, INT J BIOCHEM CELL B, V33, P33, DOI 10.1016/S1357-2725(00)00061-3; Thieringer R, 2000, J IMMUNOL, V164, P1046, DOI 10.4049/jimmunol.164.2.1046; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; Uysal KT, 1997, NATURE, V389, P610, DOI 10.1038/39335; Williams KJ, 2001, CURR OPIN LIPIDOL, V12, P477, DOI 10.1097/00041433-200110000-00002; Zhu LY, 1998, BIOCHEM BIOPH RES CO, V251, P842, DOI 10.1006/bbrc.1998.9567	67	76	79	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51340	51346		10.1074/jbc.M310865200	http://dx.doi.org/10.1074/jbc.M310865200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14534304	hybrid			2022-12-27	WOS:000187206300062
